token,label
Molecular,O
mechanism,O
of,O
the,O
schedule,O
-,O
dependent,O
synergistic,O
interaction,O
in,O
EGFR,B-GP
-,O
mutant,O
non,B-DS
-,I-DS
small,I-DS
cell,I-DS
lung,I-DS
cancer,I-DS
cell,O
lines,O
treated,O
with,O
paclitaxel,O
and,O
gefitinib,O
Background,O
Chemotherapy,O
combined,O
concurrently,O
with,O
TKIs,O
produced,O
a,O
negative,O
interaction,O
and,O
failed,O
to,O
improve,O
survival,O
when,O
compared,O
with,O
chemotherapy,O
or,O
TKIs,O
alone,O
in,O
the,O
treatment,O
of,O
non,B-DS
-,I-DS
small,I-DS
cell,I-DS
lung,I-DS
cancer,I-DS
(,O
NSCLC,B-DS
).,O
The,O
present,O
study,O
investigated,O
the,O
sequence,O
-,O
dependent,O
interaction,O
between,O
paclitaxel,O
and,O
gefitinib,O
and,O
clarified,O
the,O
underlying,O
mechanism,O
.,O
Methods,O
The,O
effects,O
on,O
cell,O
proliferation,O
",",O
EGFR,B-GP
signaling,O
pathway,O
",",O
and,O
TGFα,B-GP
expression,O
were,O
evaluated,O
in,O
a,O
panel,O
of,O
human,B-OG
NSCLC,B-DS
cell,O
lines,O
harboring,O
EGFR,B-GP
mutations,O
with,O
three,O
different,O
combination,O
sequences,O
:,O
sequential,O
treatment,O
with,O
paclitaxel,O
followed,O
by,O
gefitinib,O
(,O
T,O
→,O
G,O
"),",O
sequential,O
treatment,O
with,O
gefitinib,O
followed,O
by,O
paclitaxel,O
(,O
G,O
→,O
T,O
"),",O
or,O
concomitant,O
treatment,O
(,O
T,O
+,O
G,O
).,O
Results,O
The,O
sequence,O
-,O
dependent,O
anti,O
-,O
proliferative,O
effects,O
differed,O
between,O
EGFR,B-GP
-,O
TKI,O
-,O
sensitive,O
and,O
-,O
resistant,O
cell,O
lines,O
carrying,O
EGFR,B-GP
mutations,O
.,O
A,O
synergistic,O
anti,O
-,O
proliferative,O
activity,O
was,O
obtained,O
with,O
paclitaxel,O
treatment,O
followed,O
by,O
gefitinib,O
in,O
all,O
cell,O
lines,O
",",O
with,O
mean,O
CI,O
values,O
of,O
0,O
.,O
63,O
in,O
Hcc827,O
",",O
0,O
.,O
54,O
in,O
PC,O
-,O
9,O
",",O
0,O
.,O
81,O
in,O
PC,O
-,O
9,O
/,O
GR,O
",",O
and,O
0,O
.,O
77,O
in,O
H1650,O
cells,O
for,O
the,O
T,O
→,O
G,O
sequence,O
.,O
The,O
mean,O
CI,O
values,O
for,O
the,O
G,O
→,O
T,O
sequence,O
were,O
1,O
.,O
29,O
in,O
Hcc827,O
",",O
1,O
.,O
16,O
in,O
PC,O
-,O
9,O
",",O
1,O
.,O
52,O
in,O
PC,O
-,O
9,O
/,O
GR,O
",",O
and,O
1,O
.,O
5,O
in,O
H1650,O
cells,O
.,O
The,O
mean,O
CI,O
values,O
for,O
T,O
+,O
G,O
concomitant,O
treatment,O
were,O
0,O
.,O
88,O
in,O
Hcc827,O
",",O
0,O
.,O
91,O
in,O
PC,O
-,O
9,O
",",O
1,O
.,O
05,O
in,O
PC,O
-,O
9,O
/,O
GR,O
",",O
and,O
1,O
.,O
18,O
in,O
H1650,O
cells,O
.,O
Paclitaxel,O
produced,O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
EGFR,B-GP
phosphorylation,O
.,O
Paclitaxel,O
significantly,O
increased,O
EGFR,B-GP
phosphorylation,O
compared,O
with,O
that,O
in,O
untreated,O
controls,O
(,O
mean,O
differences,O
:,O
+,O
50,O
%,O
in,O
Hcc827,O
",",O
+,O
56,O
%,O
in,O
PC,O
-,O
9,O
",",O
+,O
39,O
%,O
in,O
PC,O
-,O
9,O
/,O
GR,O
",",O
and,O
+,O
69,O
%,O
in,O
H1650,O
cells,O
;,O
p,O
<,O
0,O
.,O
05,O
).,O
The,O
T,O
→,O
G,O
sequence,O
produced,O
significantly,O
greater,O
inhibition,O
of,O
EGFR,B-GP
phosphorylation,O
compared,O
with,O
the,O
opposite,O
sequence,O
(,O
mean,O
differences,O
:,O
-,O
58,O
%,O
in,O
Hcc827,O
",",O
-,O
38,O
%,O
in,O
PC,O
-,O
9,O
",",O
-,O
35,O
%,O
in,O
PC,O
-,O
9,O
/,O
GR,O
",",O
and,O
-,O
30,O
%,O
in,O
H1650,O
cells,O
;,O
p,O
<,O
0,O
.,O
05,O
).,O
Addition,O
of,O
a,O
neutralizing,O
anti,O
-,O
TGFα,B-GP
antibody,B-GP
abolished,O
paclitaxel,O
-,O
induced,O
activation,O
of,O
the,O
EGFR,B-GP
pathway,O
in,O
PC,O
-,O
9,O
and,O
H1650,O
cells,O
.,O
Sequence,O
-,O
dependent,O
TGFα,B-GP
expression,O
and,O
release,O
are,O
responsible,O
for,O
the,O
sequence,O
-,O
dependent,O
EGFR,B-GP
pathway,O
modulation,O
.,O
Conclusion,O
The,O
data,O
suggest,O
that,O
the,O
sequence,O
of,O
paclitaxel,O
followed,O
by,O
gefitinib,O
is,O
an,O
appropriate,O
treatment,O
combination,O
for,O
NSCLC,B-DS
cell,O
lines,O
harboring,O
EGFR,B-GP
mutations,O
.,O
Our,O
results,O
provide,O
molecular,O
evidence,O
to,O
support,O
clinical,O
treatment,O
strategies,O
for,O
patients,O
with,O
lung,B-DS
cancer,I-DS
.,O
Background,O
Despite,O
recent,O
advances,O
in,O
early,O
diagnosis,O
and,O
treatment,O
",",O
non,B-DS
-,I-DS
small,I-DS
cell,I-DS
lung,I-DS
cancer,I-DS
(,O
NSCLC,B-DS
),O
is,O
still,O
a,O
disease,O
with,O
a,O
poor,O
prognosis,O
.,O
Platinum,O
-,O
based,O
doublet,O
chemotherapy,O
is,O
the,O
mainstay,O
of,O
treatment,O
for,O
advanced,O
NSCLC,B-DS
with,O
good,O
performance,O
status,O
[,O
1,O
",",O
2,O
].,O
Current,O
data,O
suggest,O
that,O
NSCLC,B-DS
chemotherapy,O
has,O
reached,O
a,O
therapeutic,O
plateau,O
[,O
3,O
",",O
4,O
].,O
Gefitinib,O
and,O
erlotinib,O
are,O
orally,O
active,O
",",O
reversible,O
Her,B-GP
-,I-GP
1,I-GP
/,O
epidermal,B-GP
growth,I-GP
factor,I-GP
receptor,I-GP
tyrosine,B-GP
kinase,I-GP
inhibitors,O
(,O
EGFR,B-GP
-,O
TKIs,O
).,O
In,O
2004,O
",",O
researchers,O
found,O
that,O
EGFR,B-GP
-,O
activating,O
mutations,O
correlated,O
with,O
clinical,O
responses,O
[,O
5,O
-,O
7,O
].,O
The,O
Iressa,O
Pan,O
-,O
Asia,O
Study,O
(,O
IPASS,O
),O
trial,O
indicated,O
that,O
gefitinib,O
was,O
superior,O
to,O
carboplatin,O
plus,O
paclitaxel,O
as,O
an,O
initial,O
treatment,O
for,O
patients,O
with,O
advanced,O
NSCLC,B-DS
harboring,O
an,O
EGFR,B-GP
mutation,O
[,O
8,O
].,O
The,O
finding,O
was,O
further,O
supported,O
by,O
two,O
randomized,O
studies,O
(,O
the,O
WJTOG3405,O
and,O
NEJ,O
002,O
trials,O
),O
that,O
consistently,O
reported,O
a,O
high,O
tumor,B-DS
response,O
rate,O
and,O
progression,O
-,O
free,O
survival,O
(,O
PFS,O
),O
in,O
patients,O
with,O
an,O
EGFR,B-GP
mutation,O
[,O
9,O
",",O
10,O
].,O
The,O
EGFR,B-GP
mutation,O
rate,O
was,O
higher,O
in,O
Asian,O
than,O
in,O
western,O
patients,O
",",O
explaining,O
the,O
higher,O
response,O
rate,O
in,O
East,O
Asian,O
patients,O
[,O
11,O
].,O
Based,O
on,O
these,O
studies,O
",",O
an,O
EGFR,B-GP
mutation,O
is,O
currently,O
the,O
only,O
established,O
predictive,O
factor,O
for,O
EGFR,B-GP
-,O
TKIs,O
.,O
An,O
increasingly,O
interesting,O
area,O
of,O
clinical,O
research,O
is,O
the,O
development,O
of,O
rationale,O
combinations,O
of,O
cytotoxic,O
drugs,O
with,O
molecularly,O
targeted,O
therapies,O
to,O
increase,O
the,O
therapeutic,O
potential,O
by,O
blocking,O
cancer,B-DS
cell,O
survival,O
mechanisms,O
.,O
Recently,O
",",O
we,O
have,O
shown,O
that,O
the,O
sequence,O
of,O
paclitaxel,O
followed,O
by,O
gefitinib,O
improves,O
the,O
antiproliferative,O
effect,O
compared,O
with,O
other,O
sequences,O
and,O
produced,O
a,O
synergistic,O
effect,O
.,O
We,O
also,O
found,O
the,O
sequence,O
-,O
dependent,O
modulation,O
of,O
EGFR,B-GP
phosphorylation,O
plays,O
a,O
role,O
in,O
this,O
sequence,O
-,O
dependent,O
antiproliferative,O
effect,O
[,O
12,O
].,O
However,O
",",O
we,O
did,O
not,O
focus,O
on,O
cell,O
lines,O
with,O
mutant,O
EGFR,B-GP
and,O
the,O
exact,O
mechanism,O
underlying,O
the,O
modulation,O
of,O
EGFR,B-GP
phosphorylation,O
remains,O
to,O
be,O
determined,O
.,O
While,O
other,O
studies,O
indicated,O
that,O
TGFα,B-GP
release,O
is,O
responsible,O
for,O
EGFR,B-GP
activation,O
induced,O
by,O
radiotherapy,O
[,O
13,O
",",O
14,O
"],",O
we,O
hypothesized,O
that,O
TGFα,B-GP
might,O
play,O
a,O
role,O
in,O
the,O
sequence,O
-,O
dependent,O
antiproliferative,O
effect,O
.,O
Thus,O
",",O
the,O
present,O
study,O
was,O
performed,O
in,O
NSCLC,B-DS
cell,O
lines,O
harboring,O
EGFR,B-GP
-,O
activating,O
mutations,O
to,O
investigate,O
the,O
synergistic,O
interaction,O
between,O
paclitaxel,O
and,O
gefitinib,O
",",O
and,O
to,O
determine,O
the,O
underlying,O
mechanism,O
(,O
s,O
).,O
We,O
found,O
that,O
sequence,O
-,O
dependent,O
TGFα,B-GP
expression,O
and,O
release,O
were,O
responsible,O
for,O
the,O
sequence,O
-,O
dependent,O
EGFR,B-GP
pathway,O
modulation,O
and,O
sequence,O
-,O
dependent,O
antiproliferative,O
effect,O
.,O
Materials,O
and,O
methods,O
Drugs,O
and,O
chemicals,O
Pure,O
gefitinib,O
",",O
kindly,O
provided,O
by,O
AstraZeneca,O
(,O
London,O
",",O
UK,O
"),",O
was,O
dissolved,O
in,O
dimethyl,O
sulfoxide,O
(,O
DMSO,O
),O
as,O
a,O
20,O
mM,O
stock,O
solution,O
.,O
Paclitaxel,O
was,O
purchased,O
from,O
Sigma,O
(,O
St,O
.,O
Louis,O
",",O
MO,O
",",O
USA,O
),O
and,O
was,O
dissolved,O
in,O
DMSO,O
as,O
a,O
1,O
mM,O
stock,O
solution,O
.,O
Both,O
drugs,O
were,O
diluted,O
with,O
culture,O
medium,O
before,O
use,O
.,O
Primary,O
antibodies,B-GP
:,O
anti,O
-,O
pY1068,O
EGFR,B-GP
(,O
phosphotyrosine,O
-,O
specific,O
EGFR,B-GP
antibody,B-GP
),O
and,O
anti,O
-,O
β,B-GP
-,I-GP
actin,I-GP
were,O
purchased,O
from,O
Cell,O
Signaling,O
Technology,O
(,O
Danvers,O
",",O
MA,O
",",O
USA,O
"),",O
anti,O
-,O
EGFR,B-GP
was,O
purchased,O
from,O
Santa,O
Cruz,O
Biotechnology,O
(,O
Santa,O
Cruz,O
",",O
CA,O
",",O
USA,O
"),",O
and,O
anti,O
-,O
TGFα,B-GP
antibody,B-GP
[,O
189,O
-,O
2130,O
.,O
1,O
],O
was,O
purchased,O
from,O
Abcam,O
(,O
Cambridge,O
",",O
MA,O
",",O
USA,O
).,O
Cell,O
lines,O
The,O
human,B-OG
lung,B-DS
adenocarcinoma,I-DS
cell,O
lines,O
PC,O
-,O
9,O
",",O
Hcc827,O
",",O
and,O
H1650,O
were,O
kindly,O
provided,O
by,O
Dr,O
.,O
Tony,O
Mok,O
(,O
Chinese,O
University,O
of,O
Hong,O
Kong,O
).,O
These,O
cell,O
lines,O
have,O
been,O
extensively,O
characterized,O
.,O
PC,O
-,O
9,O
is,O
derived,O
from,O
a,O
patient,O
with,O
adenocarcinoma,B-DS
",",O
harboring,O
an,O
EGFR,B-GP
exon,O
19,O
in,O
-,O
frame,O
deletion,O
[,O
E746,O
-,O
A750,O
],O
that,O
is,O
highly,O
sensitive,O
to,O
EGFR,B-GP
-,O
TKIs,O
[,O
15,O
"],",O
Hcc827,O
is,O
derived,O
from,O
lung,B-DS
adenocarcinomas,I-DS
harboring,O
an,O
EGFR,B-GP
exon,O
19,O
in,O
-,O
frame,O
deletion,O
that,O
is,O
highly,O
sensitive,O
to,O
EGFR,B-GP
-,O
TKIs,O
[,O
16,O
].,O
H1650,O
carries,O
an,O
EGFR,B-GP
exon,O
19,O
in,O
-,O
frame,O
deletion,O
mutation,O
and,O
is,O
resistant,O
to,O
EGFR,B-GP
-,O
TKIs,O
.,O
Martin,O
et,O
al,O
.,O
reported,O
the,O
homozygous,O
deletion,O
of,O
PTEN,B-GP
in,O
H1650,O
cells,O
",",O
which,O
activated,O
EGFR,B-GP
and,O
contributed,O
to,O
erlotinib,O
resistance,O
[,O
17,O
].,O
PC,O
-,O
9,O
/,O
GR,O
is,O
a,O
gefitinib,O
-,O
acquired,O
resistant,O
cell,O
line,O
that,O
was,O
established,O
by,O
chronic,O
exposure,O
of,O
PC,O
-,O
9,O
cells,O
to,O
medium,O
with,O
increasing,O
concentrations,O
of,O
gefitinib,O
.,O
Briefly,O
",",O
PC,O
-,O
9,O
cells,O
were,O
exposed,O
to,O
10,O
nmol,O
/,O
L,O
of,O
gefitinib,O
in,O
medium,O
containing,O
10,O
%,O
fetal,O
bovine,O
serum,O
",",O
and,O
the,O
concentration,O
was,O
increased,O
in,O
a,O
stepwised,O
manner,O
.,O
Cells,O
that,O
were,O
able,O
to,O
grow,O
in,O
1,O
μmol,O
/,O
L,O
gefitinib,O
were,O
obtained,O
6,O
month,O
after,O
initial,O
expose,O
.,O
The,O
decreased,O
sensitivity,O
did,O
not,O
recover,O
even,O
the,O
cells,O
were,O
kept,O
in,O
culture,O
for,O
>,O
4,O
month,O
without,O
gefitinib,O
.,O
These,O
cells,O
were,O
grown,O
in,O
RPMI,O
1640,O
medium,O
supplemented,O
with,O
10,O
%,O
fetal,O
bovine,O
serum,O
(,O
FBS,O
"),",O
penicillin,O
(,O
100,O
UI,O
/,O
ml,O
"),",O
and,O
streptomycin,O
(,O
100,O
μg,O
/,O
ml,O
),O
at,O
37,O
°,O
C,O
in,O
a,O
humidified,O
atmosphere,O
with,O
5,O
%,O
CO2,O
and,O
harvested,O
with,O
trypsin,B-GP
-,O
EDTA,O
when,O
the,O
cells,O
were,O
in,O
exponential,O
growth,O
.,O
Sequencing,O
of,O
EGFR,B-GP
gene,O
The,O
exons,O
encoding,O
the,O
intracellular,O
domain,O
of,O
EGFR,B-GP
were,O
amplified,O
from,O
genomic,O
DNA,O
and,O
directly,O
sequenced,O
.,O
To,O
further,O
characterize,O
additional,O
mutation,O
",",O
we,O
amplified,O
the,O
EGFR,B-GP
exon,O
19,O
to,O
20,O
from,O
PC,O
-,O
9,O
or,O
PC,O
-,O
9,O
/,O
GR,O
cDNA,O
",",O
and,O
the,O
PCR,O
products,O
were,O
subcloned,O
into,O
plasmid,O
vector,O
",",O
then,O
inserts,O
were,O
isolated,O
and,O
sequenced,O
.,O
Treatment,O
regimens,O
Cell,O
viability,O
was,O
determined,O
using,O
the,O
MTT,O
(,O
3,O
-(,O
4,O
",",O
5,O
-,O
dimethylthiazol,O
-,O
2,O
-,O
yl,O
)-,O
2,O
",",O
5,O
-,O
diphenyltetrazolium,O
bromide,O
),O
assay,O
",",O
according,O
to,O
the,O
method,O
of,O
Mosmann,O
and,O
Carmichael,O
[,O
18,O
",",O
19,O
].,O
To,O
evaluate,O
the,O
antiproliferative,O
effects,O
of,O
combined,O
treatment,O
",",O
cells,O
were,O
treated,O
with,O
three,O
different,O
sequences,O
:,O
I,O
",",O
pretreated,O
with,O
paclitaxel,O
for,O
24,O
h,O
",",O
aspirated,O
and,O
washed,O
once,O
with,O
phosphate,O
-,O
buffered,O
saline,O
(,O
PBS,O
"),",O
followed,O
by,O
gefitinib,O
for,O
48,O
h,O
;,O
II,O
",",O
pretreated,O
with,O
gefitinib,O
for,O
48,O
h,O
",",O
aspirated,O
and,O
washed,O
once,O
with,O
PBS,O
",",O
followed,O
by,O
paclitaxel,O
for,O
24,O
h,O
;,O
III,O
",",O
treated,O
concomitantly,O
with,O
paclitaxel,O
plus,O
gefitinib,O
for,O
48,O
h,O
",",O
and,O
then,O
incubated,O
in,O
drug,O
-,O
free,O
medium,O
for,O
24,O
h,O
.,O
The,O
different,O
drug,O
doses,O
were,O
combined,O
using,O
constant,O
ratios,O
of,O
the,O
IC50,O
values,O
",",O
calculated,O
from,O
previous,O
cytotoxicity,O
tests,O
.,O
Thus,O
",",O
we,O
used,O
0,O
.,O
125,O
",",O
0,O
.,O
25,O
",",O
0,O
.,O
5,O
",",O
1,O
",",O
2,O
",",O
and,O
4,O
times,O
the,O
IC50,O
dose,O
in,O
paclitaxel,O
and,O
gefitinib,O
combination,O
doses,O
to,O
calculate,O
the,O
CI,O
value,O
.,O
The,O
results,O
of,O
sequential,O
treatment,O
with,O
paclitaxel,O
and,O
gefitinib,O
were,O
analyzed,O
according,O
to,O
the,O
method,O
of,O
Chou,O
and,O
Talaly,O
[,O
20,O
].,O
The,O
resulting,O
combination,O
index,O
(,O
CI,O
),O
represented,O
a,O
quantitative,O
measure,O
of,O
the,O
degree,O
of,O
interaction,O
between,O
different,O
drugs,O
",",O
with,O
CI,O
>,O
1,O
.,O
1,O
",",O
CI,O
=,O
0,O
.,O
9,O
-,O
1,O
.,O
1,O
",",O
and,O
CI,O
<,O
0,O
.,O
9,O
indicating,O
antagonistic,O
",",O
additive,O
",",O
and,O
synergistic,O
effects,O
",",O
respectively,O
.,O
The,O
CI,O
value,O
was,O
calculated,O
using,O
the,O
CompuSyn,O
software,O
(,O
ComboSyn,O
",",O
Inc,O
".,",O
Paramus,O
",",O
NJ,O
",",O
USA,O
).,O
Western,O
blot,O
analysis,O
Cells,O
were,O
seeded,O
at,O
1,O
×,O
105,O
per,O
plate,O
on,O
10,O
-,O
cm,O
plates,O
and,O
left,O
to,O
settle,O
overnight,O
.,O
Cells,O
were,O
then,O
treated,O
by,O
adding,O
fresh,O
medium,O
containing,O
drugs,O
for,O
the,O
desired,O
times,O
.,O
Soluble,O
protein,O
was,O
extracted,O
with,O
the,O
addition,O
of,O
RIPA,O
lysis,O
solution,O
.,O
Lysates,O
were,O
cleared,O
by,O
centrifugation,O
(,O
12000,O
rpm,O
",",O
4,O
°,O
C,O
",",O
15,O
min,O
"),",O
and,O
soluble,O
protein,O
extracts,O
were,O
stored,O
frozen,O
at,O
-,O
80,O
°,O
C,O
.,O
Protein,O
concentrations,O
were,O
quantitated,O
using,O
the,O
bicinchoninic,O
acid,O
assay,O
[,O
21,O
].,O
Total,O
cell,O
extracts,O
(,O
30,O
μg,O
of,O
protein,O
/,O
well,O
),O
were,O
resolved,O
on,O
8,O
-,O
10,O
%,O
acrylamide,O
Tris,O
-,O
acetate,O
gels,O
",",O
and,O
then,O
proteins,O
were,O
transferred,O
to,O
a,O
polyvinylidene,O
fluoride,O
(,O
PVDF,O
),O
membrane,O
",",O
blocked,O
for,O
1,O
h,O
at,O
room,O
temperature,O
in,O
5,O
%,O
w,O
/,O
v,O
non,O
-,O
fat,O
milk,O
diluted,O
in,O
Tris,O
-,O
buffered,O
saline,O
Tween,O
20,O
(,O
TBST,O
"),",O
and,O
finally,O
incubated,O
with,O
appropriate,O
primary,O
antibodies,B-GP
under,O
the,O
conditions,O
recommended,O
by,O
the,O
manufacturers,O
.,O
The,O
blots,O
were,O
then,O
washed,O
with,O
TBST,O
for,O
30,O
min,O
and,O
incubated,O
with,O
horseradish,B-OG
peroxidase,B-GP
-,O
conjugated,O
secondary,O
antibody,B-GP
at,O
room,O
temperature,O
for,O
1,O
h,O
.,O
Antibody,B-GP
binding,O
was,O
detected,O
using,O
an,O
enhanced,O
chemiluminescence,O
system,O
(,O
Santa,O
Cruz,O
",",O
CA,O
",",O
USA,O
).,O
To,O
quantify,O
protein,O
levels,O
",",O
films,O
were,O
scanned,O
and,O
analyzed,O
with,O
the,O
Labworks,O
software,O
(,O
World,O
BioHazTec,O
Corp,O
",",O
NM,O
",",O
USA,O
).,O
The,O
relative,O
protein,O
levels,O
were,O
counted,O
using,O
a,O
comparison,O
with,O
the,O
untreated,O
control,O
.,O
Real,O
-,O
time,O
polymerase,B-GP
chain,O
reaction,O
(,O
PCR,O
),O
To,O
compare,O
the,O
possible,O
influence,O
of,O
TGFα,B-GP
gene,O
expression,O
on,O
the,O
sequence,O
-,O
dependent,O
synergistic,O
effect,O
between,O
paclitaxel,O
and,O
gefitinib,O
",",O
we,O
used,O
PC,O
-,O
9,O
cells,O
to,O
analyze,O
the,O
sequential,O
modulation,O
of,O
TGFα,B-GP
expression,O
.,O
The,O
primer,O
and,O
probe,O
design,O
",",O
total,O
RNA,O
isolation,O
",",O
cDNA,O
synthesis,O
",",O
and,O
quantification,O
standards,O
for,O
real,O
-,O
time,O
PCR,O
were,O
performed,O
as,O
described,O
previously,O
[,O
22,O
",",O
23,O
].,O
Total,O
RNA,O
was,O
isolated,O
using,O
the,O
Trizol,O
reagent,O
(,O
Invitrogen,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
protocol,O
.,O
The,O
integrity,O
of,O
the,O
total,O
RNA,O
was,O
examined,O
by,O
1,O
%,O
agarose,O
gel,O
electrophoresis,O
",",O
the,O
quantity,O
was,O
determined,O
based,O
on,O
the,O
absorbance,O
at,O
260,O
nm,O
(,O
A260,O
"),",O
and,O
the,O
purity,O
was,O
analyzed,O
based,O
on,O
the,O
absorbance,O
ratio,O
at,O
260,O
and,O
280,O
nm,O
.,O
For,O
pure,O
RNA,O
the,O
ratio,O
of,O
A260,O
/,O
280,O
is,O
~,O
2,O
.,O
0,O
(,O
A260,O
/,O
280,O
;,O
Amersham,O
Biosciences,O
GeneQuant,O
",",O
Pittsburgh,O
",",O
PA,O
",",O
USA,O
).,O
cDNA,O
was,O
synthesized,O
from,O
total,O
RNA,O
(,O
1,O
μg,O
),O
using,O
AMV,B-OG
reverse,B-GP
transcriptase,I-GP
XL,O
(,O
Takara,O
Bio,O
",",O
Inc,O
".,",O
Shiga,O
",",O
Japan,O
).,O
β,B-GP
-,I-GP
actin,I-GP
served,O
as,O
an,O
internal,O
control,O
.,O
To,O
create,O
real,O
-,O
time,O
PCR,O
standards,O
",",O
TGFα,B-GP
and,O
β,B-GP
-,I-GP
actin,I-GP
were,O
amplified,O
using,O
reverse,B-GP
transcriptase,I-GP
-,O
PCR,O
and,O
specific,O
primers,O
.,O
The,O
amplicons,O
were,O
cloned,O
into,O
the,O
pMD18,O
-,O
T,O
vector,O
(,O
Takara,O
),O
and,O
the,O
sequence,O
was,O
confirmed,O
by,O
sequencing,O
.,O
The,O
purified,O
recombinant,O
DNA,O
was,O
quantified,O
and,O
then,O
serially,O
diluted,O
in,O
ultra,O
-,O
pure,O
water,O
to,O
a,O
final,O
concentration,O
ranging,O
from,O
107,O
to,O
101,O
copies,O
/,O
μL,O
.,O
For,O
quantification,O
standards,O
",",O
we,O
used,O
1,O
-,O
μL,O
aliquots,O
of,O
10,O
-,O
fold,O
serial,O
dilutions,O
of,O
plasmid,O
DNA,O
.,O
A,O
new,O
standard,O
curve,O
was,O
run,O
for,O
each,O
real,O
-,O
time,O
PCR,O
",",O
and,O
each,O
test,O
run,O
included,O
a,O
control,O
containing,O
non,O
-,O
target,O
DNA,O
.,O
The,O
amount,O
of,O
TGFα,B-GP
mRNA,O
was,O
normalized,O
to,O
the,O
expression,O
values,O
of,O
the,O
housekeeping,B-GP
gene,I-GP
β,B-GP
-,I-GP
actin,I-GP
.,O
TGFα,B-GP
enzyme,O
-,O
linked,O
immunosorbent,O
assay,O
(,O
ELISA,O
),O
Medium,O
was,O
harvested,O
from,O
cells,O
grown,O
on,O
6,O
-,O
well,O
dishes,O
.,O
Samples,O
were,O
processed,O
using,O
the,O
human,B-OG
TGFα,B-GP
quantikine,O
ELISA,O
kit,O
(,O
R,O
&,O
D,O
systems,O
",",O
Inc,O
".,",O
Minneapolis,O
",",O
MN,O
",",O
USA,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
Statistics,O
Results,O
are,O
presented,O
as,O
the,O
mean,O
±,O
standard,O
error,O
(,O
SE,O
),O
of,O
at,O
least,O
three,O
experiments,O
.,O
Statistical,O
comparisons,O
of,O
sequence,O
-,O
dependent,O
effects,O
were,O
conducted,O
by,O
student,O
',O
s,O
t,O
tests,O
.,O
Statistics,O
and,O
graphs,O
were,O
generated,O
using,O
the,O
GraphPad,O
Prism,O
software,O
(,O
ver,O
.,O
5,O
.,O
00,O
for,O
windows,O
",",O
GraphPad,O
Software,O
Inc,O
",",O
CA,O
",",O
USA,O
).,O
Results,O
The,O
potential,O
mechanisms,O
for,O
gefitinib,O
resistance,O
in,O
PC,O
-,O
9,O
/,O
GR,O
cells,O
The,O
gefitinib,O
-,O
acquired,O
resistant,O
PC,O
-,O
9,O
/,O
GR,O
cells,O
were,O
obtained,O
6,O
months,O
after,O
initial,O
exposure,O
.,O
These,O
cells,O
were,O
100,O
-,O
fold,O
more,O
resistant,O
than,O
parental,O
cells,O
(,O
Table,O
-,O
1,O
).,O
Additional,O
mutations,O
were,O
not,O
detected,O
by,O
direct,O
sequencing,O
.,O
The,O
PCR,O
product,O
of,O
PC,O
-,O
9,O
and,O
PC,O
-,O
9,O
/,O
GR,O
were,O
subcloned,O
into,O
a,O
plasmid,O
vector,O
",",O
then,O
the,O
inserts,O
were,O
randomly,O
selected,O
and,O
sequenced,O
.,O
Among,O
the,O
20,O
sequences,O
from,O
PC,O
-,O
9,O
/,O
GR,O
",",O
we,O
found,O
6,O
sequences,O
were,O
wild,O
-,O
type,O
",",O
11,O
had,O
only,O
the,O
15,O
-,O
bp,O
deletion,O
",",O
and,O
3,O
had,O
both,O
the,O
15,O
-,O
bp,O
deletion,O
and,O
T790M,O
mutation,O
.,O
These,O
T790M,O
mutation,O
seemed,O
to,O
be,O
the,O
cause,O
of,O
gefitinib,O
resistance,O
.,O
Of,O
10,O
colones,O
isolated,O
from,O
PC,O
-,O
9,O
",",O
4,O
had,O
no,O
mutation,O
",",O
and,O
the,O
others,O
had,O
the,O
15,O
-,O
bp,O
deletion,O
(,O
Figure,O
1,O
).,O
PC,O
-,O
9,O
/,O
GR,O
exon,O
20,O
sequence,O
.,O
A,O
.,O
Wild,O
type,O
by,O
direct,O
sequencing,O
.,O
B,O
.,O
3,O
of,O
20,O
clones,O
had,O
ACG,O
>,O
ATG,O
T790M,O
mutation,O
by,O
clone,O
sequencing,O
.,O
C,O
.,O
17,O
of,O
20,O
clones,O
were,O
wild,O
type,O
Sequence,O
-,O
dependent,O
antiproliferative,O
effects,O
differed,O
between,O
EGFR,B-GP
-,O
TKI,O
-,O
sensitive,O
and,O
EGFR,B-GP
-,O
TKI,O
-,O
resistant,O
NSCLC,B-DS
cell,O
lines,O
To,O
evaluate,O
the,O
antiproliferative,O
effects,O
of,O
paclitaxel,O
and,O
gefitinib,O
treatment,O
",",O
we,O
performed,O
a,O
series,O
of,O
MTT,O
cell,O
growth,O
assays,O
.,O
Treatment,O
with,O
gefitinib,O
alone,O
for,O
72,O
h,O
resulted,O
in,O
a,O
dose,O
-,O
dependent,O
inhibition,O
of,O
cancer,B-DS
cell,O
growth,O
.,O
Table,O
1,O
summarizes,O
the,O
IC50,O
of,O
these,O
two,O
drugs,O
.,O
PC,O
-,O
9,O
and,O
Hcc827,O
were,O
highly,O
sensitive,O
to,O
gefitinib,O
",",O
while,O
H1650,O
exhibited,O
primary,O
resistance,O
and,O
PC,O
-,O
9,O
/,O
GR,O
showed,O
acquired,O
resistance,O
to,O
gefitinib,O
.,O
All,O
of,O
these,O
cell,O
lines,O
demonstrated,O
similar,O
sensitivities,O
to,O
paclitaxel,O
.,O
We,O
evaluated,O
the,O
growth,O
inhibition,O
effect,O
on,O
Hcc827,O
",",O
PC,O
-,O
9,O
",",O
PC,O
-,O
9,O
/,O
GR,O
",",O
and,O
H1650,O
of,O
three,O
different,O
sequences,O
of,O
combined,O
paclitaxel,O
and,O
gefitinib,O
treatments,O
.,O
Figure,O
2a,O
shows,O
the,O
schema,O
for,O
in,O
vitro,O
sequential,O
treatment,O
between,O
paclitaxel,O
and,O
gefitinib,O
.,O
As,O
shown,O
in,O
Figure,O
2b,O
and,O
2c,O
",",O
the,O
antiproliferative,O
effects,O
between,O
paclitaxel,O
and,O
gefitinib,O
were,O
sequence,O
-,O
dependent,O
.,O
Although,O
the,O
differences,O
were,O
not,O
marked,O
",",O
the,O
sequence,O
of,O
paclitaxel,O
followed,O
by,O
gefitinib,O
was,O
most,O
efficacious,O
against,O
EGFR,B-GP
-,O
mutant,O
NSCLC,B-DS
cells,O
.,O
IC50,O
values,O
for,O
each,O
drug,O
were,O
calculated,O
by,O
performing,O
dose,O
response,O
experiments,O
with,O
gefitinib,O
and,O
paclitaxel,O
IC50,O
Hcc827,O
PC,O
-,O
9,O
PC,O
-,O
9,O
/,O
GR,O
H1650,O
Paclitaxel,O
2,O
.,O
27,O
±,O
0,O
.,O
15nM,O
2,O
.,O
33,O
±,O
0,O
.,O
47nM,O
2,O
.,O
59,O
±,O
0,O
.,O
62nM,O
3,O
.,O
29,O
±,O
0,O
.,O
35nM,O
Gefitinib,O
16,O
±,O
1,O
.,O
12nM,O
19,O
±,O
2nM,O
2,O
.,O
1,O
±,O
0,O
.,O
39,O
μM,O
9,O
.,O
37,O
±,O
0,O
.,O
52,O
μM,O
The,O
antiproliferative,O
effect,O
with,O
paclitaxel,O
and,O
gefitinib,O
is,O
sequence,O
-,O
dependent,O
.,O
A,O
.,O
Schema,O
of,O
sequential,O
treatment,O
.,O
B,O
and,O
C,O
.,O
The,O
sequence,O
of,O
paclitaxel,O
followed,O
by,O
gefitinib,O
produced,O
the,O
most,O
potent,O
antiproliferative,O
effect,O
in,O
PC,O
-,O
9,O
and,O
Hcc827,O
cells,O
.,O
T,O
→,O
G,O
",",O
paclitaxel,O
followed,O
by,O
gefitinib,O
.,O
G,O
→,O
T,O
",",O
gefitinib,O
followed,O
by,O
paclitaxel,O
.,O
T,O
+,O
G,O
",",O
concomitant,O
paclitaxel,O
and,O
gefitinib,O
.,O
T,O
",",O
paclitaxel,O
alone,O
for,O
72,O
h,O
.,O
G,O
",",O
gefitinib,O
alone,O
for,O
72,O
h,O
.,O
The,O
calculation,O
of,O
CI,O
values,O
revealed,O
that,O
the,O
sequence,O
of,O
paclitaxel,O
followed,O
by,O
gefitinib,O
produced,O
synergistic,O
effects,O
.,O
In,O
Hcc827,O
and,O
PC,O
-,O
9,O
cell,O
lines,O
",",O
which,O
were,O
highly,O
sensitive,O
to,O
EGFR,B-GP
-,O
TKIs,O
",",O
the,O
sequence,O
of,O
paclitaxel,O
followed,O
by,O
gefitinib,O
resulted,O
in,O
synergistic,O
effects,O
",",O
with,O
mean,O
CI,O
values,O
of,O
0,O
.,O
63,O
in,O
Hcc827,O
",",O
0,O
.,O
54,O
in,O
PC,O
-,O
9,O
.,O
Concomitant,O
administration,O
of,O
the,O
drugs,O
resulted,O
in,O
both,O
synergistic,O
and,O
additive,O
effects,O
",",O
with,O
mean,O
CI,O
values,O
of,O
0,O
.,O
88,O
in,O
Hcc827,O
",",O
0,O
.,O
91,O
in,O
PC,O
-,O
9,O
.,O
The,O
gefitinib,O
followed,O
by,O
paclitaxel,O
sequence,O
resulted,O
in,O
an,O
additive,O
and,O
antagonistic,O
interaction,O
with,O
mean,O
CI,O
values,O
of,O
1,O
.,O
29,O
in,O
Hcc827,O
",",O
1,O
.,O
16,O
in,O
PC,O
-,O
9,O
(,O
Figure,O
3a,O
",",O
b,O
).,O
In,O
the,O
PC,O
-,O
9,O
/,O
GR,O
cell,O
line,O
",",O
which,O
exhibited,O
acquired,O
resistance,O
to,O
EGFR,B-GP
-,O
TKIs,O
",",O
the,O
sequence,O
of,O
paclitaxel,O
followed,O
by,O
gefitinib,O
resulted,O
in,O
a,O
synergistic,O
and,O
additive,O
interaction,O
with,O
increasing,O
drug,O
concentrations,O
(,O
mean,O
CI,O
",",O
0,O
.,O
81,O
).,O
In,O
contrast,O
",",O
the,O
sequence,O
of,O
gefitinib,O
followed,O
by,O
paclitaxel,O
resulted,O
in,O
an,O
antagonistic,O
effect,O
(,O
mean,O
CI,O
",",O
1,O
.,O
52,O
).,O
Concomitant,O
treatment,O
with,O
the,O
two,O
drugs,O
resulted,O
in,O
additive,O
and,O
antagonistic,O
effects,O
(,O
mean,O
CI,O
",",O
1,O
.,O
05,O
)(,O
Figure,O
3c,O
).,O
In,O
the,O
H1650,O
cell,O
line,O
",",O
a,O
synergistic,O
and,O
additive,O
growth,O
inhibition,O
effect,O
was,O
found,O
with,O
the,O
sequence,O
of,O
paclitaxel,O
followed,O
by,O
gefitinib,O
(,O
mean,O
CI,O
",",O
0,O
.,O
77,O
).,O
In,O
contrast,O
",",O
the,O
sequence,O
of,O
gefitinib,O
followed,O
by,O
paclitaxel,O
resulted,O
in,O
an,O
antagonistic,O
interaction,O
(,O
mean,O
CI,O
",",O
1,O
.,O
5,O
).,O
Simultaneous,O
administration,O
of,O
the,O
two,O
drugs,O
resulted,O
in,O
an,O
additive,O
and,O
antagonistic,O
interaction,O
(,O
mean,O
CI,O
",",O
1,O
.,O
18,O
)(,O
Figure,O
3d,O
).,O
Each,O
experiment,O
was,O
repeated,O
in,O
triplicate,O
.,O
Synergism,O
of,O
sequence,O
-,O
dependent,O
cytotoxicity,O
between,O
paclitaxel,O
and,O
gefitinib,O
.,O
Points,O
",",O
mean,O
values,O
of,O
three,O
different,O
experiments,O
.,O
○,O
T,O
→,O
G,O
",",O
paclitaxel,O
followed,O
by,O
gefitinib,O
.,O
□,O
G,O
→,O
T,O
",",O
gefitinib,O
followed,O
by,O
paclitaxel,O
.,O
△,O
T,O
+,O
G,O
",",O
concomitant,O
paclitaxel,O
and,O
gefitinib,O
.,O
The,O
sequence,O
T,O
→,O
G,O
produced,O
the,O
most,O
potent,O
cytotoxic,O
growth,O
inhibition,O
.,O
The,O
T,O
→,O
G,O
sequence,O
resulted,O
in,O
a,O
synergistic,O
effect,O
.,O
Sequence,O
-,O
dependent,O
modulation,O
of,O
the,O
EGFR,B-GP
signaling,O
pathway,O
To,O
gain,O
insight,O
into,O
the,O
mechanisms,O
involved,O
regulating,O
the,O
interaction,O
between,O
paclitaxel,O
and,O
gefitinib,O
",",O
we,O
examed,O
the,O
effect,O
of,O
paclitaxel,O
on,O
EGFR,B-GP
phosphorylation,O
.,O
In,O
cell,O
lines,O
of,O
PC,O
-,O
9,O
and,O
H1650,O
",",O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
pEGFR,O
levels,O
were,O
observed,O
24,O
hous,O
after,O
1,O
",",O
2,O
and,O
3,O
fold,O
IC50,O
dose,O
of,O
paclitaxel,O
exposure,O
(,O
Figure,O
4,O
).,O
Because,O
EGFR,B-GP
-,O
TKIs,O
specifically,O
target,O
the,O
tyrosine,B-GP
kinase,I-GP
activity,O
of,O
EGFR,B-GP
",",O
we,O
analyzed,O
the,O
sequence,O
-,O
dependent,O
modulation,O
of,O
the,O
EGFR,B-GP
signaling,O
pathway,O
using,O
an,O
IC50,O
dose,O
of,O
paclitaxel,O
plus,O
gefitinib,O
combination,O
.,O
As,O
shown,O
in,O
Figure,O
5,O
",",O
gefitinib,O
significantly,O
inhibited,O
EGFR,B-GP
phosphorylation,O
(,O
p,O
<,O
0,O
.,O
01,O
).,O
When,O
Hcc827,O
",",O
PC,O
-,O
9,O
",",O
PC,O
-,O
9,O
/,O
GR,O
and,O
H1650,O
cell,O
lines,O
were,O
exposed,O
to,O
paclitaxel,O
alone,O
",",O
phosphorylated,O
EGFR,B-GP
(,O
pEGFR,O
),O
levels,O
increased,O
significantly,O
after,O
paclitaxel,O
exposure,O
for,O
24,O
h,O
than,O
that,O
in,O
untreated,O
control,O
(,O
mean,O
difference,O
",",O
+,O
50,O
%,O
in,O
Hcc827,O
",",O
+,O
56,O
%,O
in,O
PC,O
-,O
9,O
",",O
+,O
39,O
%,O
in,O
PC,O
-,O
9,O
/,O
GR,O
and,O
+,O
69,O
%,O
in,O
H1650,O
cells,O
respectively,O
",",O
p,O
<,O
0,O
.,O
05,O
).,O
The,O
increase,O
in,O
pEGFR,O
induced,O
by,O
paclitaxel,O
was,O
blocked,O
by,O
adding,O
gefitinib,O
.,O
In,O
the,O
reverse,O
sequence,O
",",O
gefitinib,O
treatment,O
for,O
48,O
h,O
significantly,O
inhibited,O
pEGFR,O
levels,O
",",O
compared,O
with,O
the,O
untreated,O
control,O
level,O
of,O
pEGFR,O
",",O
and,O
subsequent,O
paclitaxel,O
exposure,O
for,O
24,O
h,O
enhanced,O
pEGFR,O
levels,O
.,O
The,O
paclitaxel,O
followed,O
by,O
gefitinib,O
sequence,O
produced,O
significantly,O
greater,O
pEGFR,O
inhibition,O
than,O
did,O
the,O
reverse,O
sequence,O
(,O
mean,O
difference,O
",",O
-,O
58,O
%,O
in,O
Hcc827,O
",",O
-,O
38,O
%,O
in,O
PC,O
-,O
9,O
",",O
-,O
35,O
%,O
in,O
PC,O
-,O
9,O
/,O
GR,O
and,O
-,O
30,O
%,O
in,O
H1650,O
respectively,O
",",O
p,O
<,O
0,O
.,O
05,O
).,O
Effect,O
of,O
paclitaxel,O
on,O
EGFR,B-GP
phosphorylation,O
.,O
PC,O
-,O
9,O
and,O
H1650,O
cells,O
were,O
exposed,O
to,O
1,O
",",O
2,O
and,O
3,O
fold,O
IC50,O
dose,O
paclitaxel,O
for,O
24,O
h,O
.,O
A,O
dose,O
-,O
dependent,O
increase,O
in,O
EGFR,B-GP
phosphorylation,O
levels,O
were,O
observed,O
.,O
Sequential,O
modulation,O
of,O
EGFR,B-GP
phosphorylation,O
.,O
Cells,O
were,O
exposed,O
to,O
the,O
IC50,O
dose,O
of,O
gefitinib,O
and,O
paclitaxel,O
using,O
different,O
sequences,O
.,O
*,O
Paclitaxel,O
significantly,O
activated,O
the,O
EGFR,B-GP
pathway,O
compared,O
with,O
control,O
after,O
paclitaxel,O
exposure,O
for,O
24,O
h,O
(,O
p,O
<,O
0,O
.,O
05,O
).,O
#,O
p,O
<,O
0,O
.,O
05,O
.,O
The,O
phosphorylated,O
EGFR,B-GP
(,O
p,O
-,O
EGFR,B-GP
),O
level,O
after,O
treatment,O
with,O
paclitaxel,O
followed,O
by,O
gefitinib,O
was,O
lower,O
than,O
that,O
for,O
gefitinib,O
followed,O
by,O
paclitaxel,O
.,O
These,O
data,O
suggest,O
that,O
paclitaxel,O
may,O
also,O
have,O
a,O
self,O
-,O
limiting,O
effect,O
on,O
its,O
toxicity,O
",",O
via,O
activation,O
of,O
the,O
EGFR,B-GP
tyrosine,B-GP
kinase,I-GP
phosphorylation,O
",",O
leading,O
to,O
increased,O
proliferation,O
and,O
survival,O
of,O
paclitaxel,O
-,O
mediated,O
cytotoxicity,O
.,O
The,O
increase,O
in,O
pEGFR,O
can,O
be,O
blocked,O
by,O
adding,O
gefitinib,O
",",O
which,O
produces,O
a,O
synergistic,O
effect,O
.,O
In,O
the,O
reverse,O
sequence,O
",",O
however,O
",",O
the,O
sequence,O
of,O
gefitinib,O
followed,O
by,O
paclitaxel,O
interferes,O
with,O
the,O
inhibition,O
of,O
pEGFR,O
by,O
gefitinib,O
.,O
Paclitaxel,O
-,O
induced,O
primary,O
activation,O
of,O
EGFR,B-GP
is,O
blocked,O
by,O
a,O
neutralizing,O
antibody,B-GP
to,O
TGFα,B-GP
Several,O
studies,O
have,O
demonstrated,O
that,O
chemotherapy,O
activates,O
EGFR,B-GP
phosphorylation,O
[,O
24,O
].,O
Multiple,O
mechanisms,O
allow,O
for,O
EGFR,B-GP
activation,O
and,O
persistent,O
tumor,B-DS
cell,O
proliferation,O
",",O
including,O
activating,O
mutations,O
",",O
receptor,O
amplification,O
",",O
and,O
ligand,O
up,O
-,O
regulation,O
[,O
25,O
",",O
26,O
].,O
Other,O
studies,O
have,O
found,O
that,O
radiation,O
causes,O
release,O
of,O
TGFα,B-GP
",",O
which,O
is,O
responsible,O
for,O
activation,O
of,O
the,O
EGFR,B-GP
signaling,O
pathway,O
[,O
13,O
].,O
We,O
next,O
examined,O
whether,O
activation,O
of,O
the,O
EGFR,B-GP
signaling,O
pathway,O
induced,O
by,O
paclitaxel,O
is,O
dependent,O
on,O
TGFα,B-GP
.,O
Paclitaxel,O
caused,O
EGFR,B-GP
activation,O
in,O
PC,O
-,O
9,O
and,O
H1650,O
cells,O
after,O
a,O
12,O
-,O
h,O
exposure,O
and,O
lasted,O
for,O
48,O
h,O
.,O
Addition,O
of,O
a,O
neutralizing,O
antibody,B-GP
to,O
TGFα,B-GP
reduced,O
the,O
activation,O
of,O
EGFR,B-GP
(,O
Figure,O
6,O
).,O
These,O
data,O
demonstrated,O
that,O
paclitaxel,O
-,O
induced,O
EGFR,B-GP
activation,O
was,O
dependent,O
on,O
the,O
function,O
of,O
TGFα,B-GP
.,O
Paclitaxel,O
-,O
induced,O
activation,O
of,O
EGFR,B-GP
is,O
blocked,O
by,O
adding,O
neutralizing,O
TGFα,B-GP
antibody,B-GP
.,O
The,O
dose,O
of,O
paclitaxel,O
is,O
2,O
-,O
fold,O
IC50,O
.,O
The,O
dose,O
of,O
TGFα,B-GP
antibody,B-GP
is,O
0,O
.,O
15,O
μg,O
/,O
mL,O
A,O
.,O
PC,O
-,O
9,O
B,O
.,O
H1650,O
TGFα,B-GP
is,O
a,O
cognate,O
ligand,O
for,O
EGFR,B-GP
",",O
mediate,O
tyrosine,O
phosphorylation,O
of,O
the,O
receptor,O
.,O
We,O
then,O
determine,O
the,O
growth,O
inhibition,O
effect,O
of,O
an,O
anti,O
-,O
TGFα,B-GP
antibody,B-GP
.,O
PC,O
-,O
9,O
and,O
H1650,O
cells,O
were,O
grow,O
into,O
the,O
medium,O
containing,O
increasing,O
concentration,O
of,O
anti,O
-,O
TGFα,B-GP
antibody,B-GP
for,O
72,O
hours,O
.,O
The,O
antibody,B-GP
show,O
a,O
modest,O
growth,O
inhibition,O
effect,O
",",O
inhibited,O
the,O
growth,O
of,O
PC,O
-,O
9,O
and,O
H1650,O
by,O
about,O
30,O
%,O
at,O
500,O
ng,O
/,O
ml,O
(,O
Figure,O
7,O
).,O
Growth,O
inhibition,O
of,O
PC,O
-,O
9,O
and,O
H1650,O
by,O
an,O
anti,O
-,O
TGFα,B-GP
.,O
antibody,B-GP
.,O
PC,O
-,O
9,O
and,O
H1650,O
cells,O
were,O
grow,O
into,O
a,O
96,O
well,O
plate,O
.,O
The,O
following,O
day,O
",",O
the,O
cells,O
were,O
incubated,O
with,O
indicated,O
concentration,O
of,O
anti,O
-,O
TGFα,B-GP
antibody,B-GP
for,O
72,O
h,O
.,O
The,O
inhibition,O
ratio,O
were,O
determined,O
by,O
MTT,O
assay,O
.,O
Sequence,O
-,O
dependent,O
TGFα,B-GP
expression,O
and,O
release,O
are,O
responsible,O
for,O
the,O
sequence,O
-,O
dependent,O
EGFR,B-GP
pathway,O
modulation,O
To,O
further,O
evaluate,O
whether,O
sequential,O
modulation,O
of,O
the,O
EGFR,B-GP
pathway,O
is,O
due,O
to,O
the,O
release,O
of,O
TGFα,B-GP
",",O
PC,O
-,O
9,O
",",O
Hcc827,O
and,O
H1650,O
cells,O
were,O
treated,O
with,O
sequential,O
paclitaxel,O
and,O
gefitinib,O
as,O
indicated,O
in,O
the,O
treatment,O
schema,O
of,O
Figure,O
2a,O
.,O
Medium,O
was,O
subjected,O
to,O
ELISA,O
to,O
verify,O
soluble,O
TGFα,B-GP
levels,O
and,O
was,O
normalized,O
to,O
cell,O
numbers,O
.,O
As,O
shown,O
in,O
Figure,O
8a,O
",",O
paclitaxel,O
exposure,O
for,O
24,O
h,O
significantly,O
stimulated,O
TGFα,B-GP
release,O
.,O
Gefitinib,O
significantly,O
inhibited,O
the,O
release,O
of,O
TGFα,B-GP
(,O
p,O
<,O
0,O
.,O
05,O
).,O
The,O
paclitaxel,O
-,O
followed,O
-,O
by,O
-,O
gefitinib,O
sequence,O
resulted,O
in,O
a,O
significant,O
reduction,O
of,O
TGFα,B-GP
levels,O
",",O
compared,O
with,O
the,O
reverse,O
sequence,O
(,O
p,O
<,O
0,O
.,O
05,O
).,O
Sequential,O
modulation,O
of,O
TGFα,B-GP
release,O
and,O
expression,O
.,O
Cells,O
were,O
exposed,O
to,O
IC50,O
dose,O
of,O
paclitaxel,O
and,O
gefitinib,O
with,O
different,O
sequence,O
.,O
A,O
",",O
standard,O
enzyme,O
-,O
linked,O
immunosorbent,O
assay,O
analysis,O
of,O
soluble,O
TGFα,B-GP
levels,O
in,O
PC,O
-,O
9,O
",",O
Hcc827,O
and,O
H1650,O
cells,O
.,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
significantly,O
different,O
from,O
control,O
.,O
#,O
P,O
<,O
0,O
.,O
05,O
",",O
T,O
→,O
G,O
VS,O
G,O
→,O
T,O
.,O
B,O
",",O
reverse,O
transcription,O
-,O
polymerase,B-GP
chain,O
reaction,O
analysis,O
of,O
TGFα,B-GP
expression,O
.,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
significantly,O
different,O
from,O
control,O
.,O
#,O
P,O
<,O
0,O
.,O
05,O
",",O
T,O
→,O
G,O
vs,O
.,O
G,O
→,O
T,O
.,O
To,O
gain,O
further,O
insight,O
into,O
the,O
mechanisms,O
involved,O
in,O
regulating,O
the,O
interaction,O
between,O
paclitaxel,O
and,O
gefitinib,O
",",O
we,O
examined,O
changes,O
in,O
TGFα,B-GP
mRNA,O
expression,O
in,O
treated,O
PC,O
-,O
9,O
",",O
Hcc827,O
and,O
H1650,O
cells,O
.,O
Quantitative,O
PCR,O
analysis,O
of,O
TGFα,B-GP
mRNA,O
expression,O
levels,O
showed,O
that,O
in,O
comparison,O
with,O
the,O
respective,O
control,O
",",O
paclitaxel,O
significantly,O
increased,O
(,O
p,O
<,O
0,O
.,O
01,O
"),",O
while,O
gefitinib,O
significantly,O
decreased,O
TGFα,B-GP
mRNA,O
expression,O
(,O
p,O
<,O
0,O
.,O
05,O
).,O
The,O
paclitaxel,O
-,O
followed,O
-,O
by,O
-,O
gefitinib,O
sequence,O
significantly,O
decreased,O
TGFα,B-GP
mRNA,O
expression,O
",",O
compared,O
with,O
the,O
reverse,O
sequence,O
(,O
Figure,O
8b,O
;,O
p,O
<,O
0,O
.,O
05,O
).,O
Discussion,O
The,O
present,O
study,O
demonstrated,O
that,O
the,O
antiproliferative,O
effect,O
with,O
paclitaxel,O
and,O
gefitinib,O
is,O
sequence,O
-,O
dependent,O
in,O
EGFR,B-GP
-,O
mutant,O
NSCLC,B-DS
cells,O
.,O
We,O
found,O
that,O
the,O
sequence,O
of,O
paclitaxel,O
followed,O
by,O
gefitinib,O
produced,O
the,O
most,O
efficacious,O
antiproliferative,O
effect,O
.,O
Other,O
studies,O
have,O
demonstrated,O
sequence,O
-,O
dependent,O
interaction,O
between,O
EGFR,B-GP
-,O
TKIs,O
and,O
chemotherapy,O
in,O
human,B-OG
cancer,B-DS
cell,O
lines,O
[,O
27,O
].,O
These,O
studies,O
also,O
revealed,O
that,O
pretreatment,O
with,O
erlotinib,O
caused,O
G1,O
arrest,O
and,O
effectively,O
abrogated,O
the,O
activity,O
of,O
chemotherapy,O
",",O
resulting,O
in,O
decreased,O
cytotoxicity,O
and,O
decreased,O
apoptosis,O
[,O
28,O
-,O
30,O
].,O
Solit,O
et,O
al,O
.,O
reported,O
schedule,O
-,O
dependent,O
efficacy,O
in,O
an,O
NSCLC,B-DS
xenograft,O
model,O
with,O
paclitaxel,O
and,O
gefitinib,O
[,O
31,O
].,O
Our,O
study,O
was,O
novel,O
because,O
we,O
found,O
that,O
sequence,O
-,O
dependent,O
modulation,O
of,O
the,O
EGFR,B-GP
signaling,O
pathway,O
might,O
play,O
a,O
role,O
in,O
the,O
sequence,O
-,O
dependent,O
interaction,O
in,O
NSCLC,B-DS
cells,O
harboring,O
an,O
EGFR,B-GP
mutation,O
.,O
We,O
found,O
that,O
paclitaxel,O
-,O
induced,O
activation,O
of,O
EGFR,B-GP
was,O
dependent,O
on,O
the,O
function,O
of,O
TGFα,B-GP
.,O
Additionally,O
",",O
TGFα,B-GP
expression,O
and,O
release,O
were,O
sequence,O
-,O
dependent,O
",",O
which,O
may,O
responsible,O
for,O
the,O
sequence,O
-,O
dependent,O
interaction,O
between,O
paclitaxel,O
and,O
gefitinib,O
.,O
As,O
EGFR,B-GP
-,O
TKIs,O
gefitinib,O
and,O
erlotinib,O
are,O
active,O
in,O
patients,O
with,O
NSCLC,B-DS
harboring,O
EGFR,B-GP
mutations,O
",",O
combining,O
them,O
in,O
treatment,O
with,O
chemotherapy,O
was,O
deemed,O
promising,O
[,O
8,O
",",O
9,O
].,O
However,O
",",O
in,O
the,O
INTACT,O
-,O
1,O
",",O
INTACT,O
-,O
2,O
",",O
TALENT,O
",",O
and,O
TRIBUTE,O
clinical,O
trials,O
",",O
the,O
addition,O
of,O
gefitinib,O
or,O
erlotinib,O
to,O
first,O
-,O
line,O
chemotherapy,O
failed,O
to,O
improve,O
survival,O
[,O
32,O
-,O
35,O
].,O
In,O
a,O
phase,O
II,O
trial,O
of,O
CALGB,O
30406,O
",",O
the,O
concurrent,O
combination,O
of,O
paclitaxel,O
plus,O
carboplatin,O
with,O
erlotinib,O
showed,O
a,O
similar,O
efficacy,O
compared,O
with,O
erlotinib,O
alone,O
in,O
patients,O
with,O
advanced,O
lung,B-DS
adenocarcinoma,I-DS
[,O
36,O
].,O
Gandara,O
et,O
al,O
.,O
[,O
37,O
",",O
38,O
],O
proposed,O
two,O
hypotheses,O
that,O
seem,O
reasonable,O
to,O
explain,O
the,O
negative,O
results,O
.,O
First,O
",",O
patients,O
were,O
not,O
selected,O
based,O
on,O
a,O
predictive,O
response,O
marker,O
",",O
although,O
other,O
studies,O
have,O
reported,O
that,O
activating,O
mutations,O
in,O
the,O
EGFR,B-GP
tyrosine,B-GP
kinase,I-GP
domain,O
were,O
associated,O
with,O
a,O
dramatic,O
response,O
to,O
gefitinib,O
and,O
erlotinib,O
.,O
Second,O
",",O
potentiation,O
of,O
the,O
antagonistic,O
interaction,O
between,O
concurrent,O
EGFR,B-GP
-,O
TKI,O
and,O
chemotherapy,O
may,O
have,O
played,O
a,O
role,O
",",O
because,O
in,O
vitro,O
and,O
in,O
vivo,O
studies,O
of,O
administration,O
of,O
concurrent,O
EGFR,B-GP
-,O
TKI,O
and,O
chemotherapy,O
have,O
suggested,O
antagonism,O
.,O
Davies,O
et,O
al,O
.,O
[,O
39,O
],O
have,O
proposed,O
the,O
pharmacodynamic,O
separation,O
model,O
:,O
EGFR,B-GP
-,O
TKIs,O
primarily,O
cause,O
cell,O
cycle,O
arrest,O
and,O
accumulation,O
of,O
cells,O
in,O
G1,O
;,O
and,O
thus,O
",",O
when,O
administered,O
concurrently,O
with,O
chemotherapy,O
",",O
can,O
interfere,O
with,O
cell,O
cycle,O
-,O
specific,O
cytotoxicity,O
.,O
Our,O
previous,O
study,O
[,O
12,O
],O
and,O
other,O
study,O
[,O
30,O
],O
found,O
that,O
EGFR,B-GP
-,O
TKI,O
induces,O
G1,O
arrest,O
",",O
which,O
produced,O
a,O
negative,O
interaction,O
when,O
combined,O
concurrently,O
with,O
chemotherapy,O
or,O
followed,O
by,O
chemotherapy,O
.,O
Chemotherapy,O
has,O
been,O
shown,O
to,O
activate,O
multiple,O
signaling,O
pathways,O
[,O
40,O
],O
and,O
",",O
recently,O
",",O
to,O
activate,O
the,O
EGFR,B-GP
pathway,O
as,O
well,O
as,O
to,O
enhance,O
ubiquitination,O
and,O
degradation,O
[,O
41,O
",",O
42,O
].,O
The,O
intracellular,O
TK,B-GP
activity,O
of,O
EGFR,B-GP
is,O
increased,O
as,O
a,O
consequence,O
of,O
binding,O
of,O
various,O
cognate,O
ligands,O
",",O
including,O
EGF,B-GP
",",O
TGFα,B-GP
",",O
and,O
amphiregulin,B-GP
",",O
leading,O
to,O
homodimerization,O
of,O
two,O
EGFRs,B-GP
or,O
heterodimerization,O
of,O
EGFR,B-GP
with,O
other,O
family,O
members,O
[,O
43,O
].,O
Improper,O
activation,O
of,O
EGFR,B-GP
TK,B-GP
results,O
in,O
increased,O
malignant,O
cell,O
survival,O
",",O
proliferation,O
",",O
invasion,O
",",O
and,O
metastasis,O
[,O
44,O
",",O
45,O
].,O
Several,O
chemotherapy,O
drugs,O
were,O
found,O
to,O
activate,O
the,O
EGFR,B-GP
signaling,O
pathway,O
[,O
41,O
].,O
Radiation,O
has,O
also,O
been,O
demonstrated,O
to,O
activate,O
the,O
EGFR,B-GP
signaling,O
pathway,O
by,O
causing,O
the,O
release,O
of,O
TGFα,B-GP
",",O
which,O
is,O
responsible,O
for,O
secondary,O
activation,O
of,O
EGFR,B-GP
",",O
mitogen,B-GP
-,I-GP
activated,I-GP
protein,I-GP
kinase,I-GP
(,O
MAPK,B-GP
"),",O
and,O
Janus,B-GP
kinase,I-GP
(,O
JNK,B-GP
),O
pathways,O
[,O
13,O
].,O
In,O
the,O
present,O
study,O
",",O
neutralizing,O
TGFα,B-GP
abolished,O
the,O
paclitaxel,O
induced,O
-,O
activation,O
of,O
EGFR,B-GP
",",O
and,O
paclitaxel,O
may,O
stimulate,O
release,O
of,O
TGFα,B-GP
to,O
activate,O
the,O
EGFR,B-GP
pathway,O
.,O
Autocrine,O
loops,O
are,O
established,O
when,O
soluble,O
factors,O
secreted,O
by,O
cells,O
bind,O
to,O
and,O
stimulate,O
receptors,O
on,O
their,O
own,O
surfaces,O
[,O
46,O
].,O
TGFα,B-GP
is,O
a,O
cognate,O
ligand,O
for,O
EGFR,B-GP
and,O
can,O
establish,O
an,O
autocrine,O
loop,O
that,O
leads,O
to,O
receptor,O
hyperactivity,O
[,O
47,O
].,O
Ciardiello,O
",",O
et,O
al,O
.,O
found,O
that,O
a,O
TGFα,B-GP
-,O
EGFR,B-GP
autocrine,O
growth,O
pathway,O
is,O
active,O
in,O
cancer,B-DS
cell,O
lines,O
",",O
and,O
gefitinib,O
produced,O
a,O
dose,O
-,O
dependent,O
inhibition,O
of,O
the,O
secretion,O
of,O
TGFα,B-GP
[,O
48,O
].,O
Our,O
data,O
suggest,O
that,O
paclitaxel,O
may,O
exert,O
a,O
self,O
-,O
limiting,O
effect,O
on,O
its,O
ability,O
to,O
kill,O
and,O
reduce,O
the,O
proliferation,O
of,O
autocrine,O
-,O
regulated,O
tumor,B-DS
cells,O
",",O
potentially,O
by,O
increasing,O
both,O
the,O
rates,O
of,O
transcription,O
and,O
activation,O
of,O
TGFα,B-GP
.,O
Increased,O
expression,O
and,O
release,O
of,O
TGFα,B-GP
leads,O
to,O
both,O
increased,O
EGFR,B-GP
and,O
activation,O
of,O
the,O
downstream,O
signaling,O
pathway,O
",",O
which,O
",",O
in,O
turn,O
",",O
leads,O
to,O
both,O
increased,O
proliferation,O
of,O
tumor,B-DS
cells,O
as,O
well,O
as,O
other,O
enhanced,O
cytoprotective,O
responses,O
.,O
Increased,O
TGFα,B-GP
expression,O
and,O
release,O
can,O
be,O
blocked,O
by,O
subsequent,O
administration,O
of,O
gefitinib,O
",",O
which,O
can,O
block,O
TGFα,B-GP
-,O
triggered,O
EGFR,B-GP
signaling,O
pathway,O
activation,O
and,O
produce,O
a,O
synergistic,O
effect,O
.,O
In,O
contrast,O
",",O
initial,O
exposure,O
to,O
gefitinib,O
decreases,O
TGFα,B-GP
expression,O
and,O
release,O
",",O
and,O
subsequent,O
paclitaxel,O
treatment,O
enhances,O
TGFα,B-GP
expression,O
and,O
release,O
",",O
producing,O
an,O
antagonistic,O
effect,O
.,O
Cytotoxic,O
chemotherapy,O
treatment,O
for,O
patients,O
with,O
advanced,O
NSCLC,B-DS
has,O
reached,O
a,O
plateau,O
",",O
but,O
further,O
improvements,O
are,O
expected,O
with,O
the,O
integration,O
of,O
targeted,O
therapies,O
[,O
49,O
",",O
50,O
].,O
EGFR,B-GP
-,O
TKIs,O
treatment,O
concurrent,O
with,O
chemotherapy,O
failed,O
to,O
improve,O
survival,O
.,O
Alternative,O
schedules,O
of,O
TKI,O
administration,O
in,O
combination,O
with,O
chemotherapy,O
",",O
such,O
as,O
sequential,O
and,O
pulse,O
administration,O
",",O
are,O
under,O
investigation,O
.,O
In,O
the,O
Fast,O
-,O
Act,O
trial,O
",",O
a,O
randomized,O
phase,O
II,O
trial,O
of,O
sequential,O
erlotinib,O
and,O
chemotherapy,O
as,O
first,O
-,O
line,O
treatment,O
of,O
patients,O
with,O
advanced,O
NSCLC,B-DS
",",O
gemcitabine,O
plus,O
cisplatin,O
or,O
carboplatin,O
(,O
GC,O
),O
were,O
sequentially,O
followed,O
by,O
erlotinib,O
(,O
GC,O
-,O
E,O
),O
versus,O
GC,O
followed,O
by,O
a,O
placebo,O
(,O
GC,O
-,O
P,O
).,O
The,O
results,O
revealed,O
that,O
GC,O
-,O
E,O
significantly,O
improved,O
PFS,O
compared,O
with,O
GC,O
-,O
P,O
[,O
51,O
].,O
Based,O
on,O
these,O
results,O
",",O
Fast,O
-,O
Act,O
II,O
",",O
a,O
randomized,O
phase,O
III,O
trial,O
of,O
sequential,O
erlotinib,O
and,O
chemotherapy,O
",",O
is,O
underway,O
[,O
52,O
].,O
In,O
the,O
final,O
analysis,O
of,O
the,O
pivotal,O
IPASS,O
trial,O
",",O
although,O
there,O
is,O
significant,O
improvement,O
in,O
PFS,O
and,O
RR,O
for,O
patients,O
receiving,O
gefitinib,O
",",O
overall,O
survival,O
was,O
similar,O
for,O
gefitinib,O
and,O
carboplatin,O
/,O
paclitaxel,O
",",O
reported,O
Chin,O
-,O
Hsin,O
Yang,O
[,O
53,O
].,O
The,O
effect,O
of,O
the,O
initial,O
randomized,O
treatment,O
therapy,O
on,O
overall,O
survival,O
is,O
likely,O
to,O
have,O
been,O
confounded,O
by,O
subsequent,O
study,O
",",O
particulary,O
",",O
the,O
switching,O
of,O
patients,O
to,O
the,O
alternative,O
study,O
treatment,O
.,O
This,O
suggests,O
the,O
sequence,O
of,O
therapy,O
may,O
not,O
make,O
a,O
significant,O
impact,O
in,O
patients,O
with,O
mutant,O
EGFR,B-GP
",",O
as,O
long,O
as,O
such,O
patients,O
are,O
exposed,O
to,O
an,O
EGFR,B-GP
TKI,O
in,O
general,O
",",O
and,O
whether,O
it,O
is,O
given,O
first,O
-,O
line,O
or,O
later,O
translates,O
into,O
the,O
same,O
overall,O
survival,O
benefit,O
.,O
The,O
limitation,O
of,O
this,O
study,O
is,O
that,O
because,O
the,O
short,O
exposure,O
time,O
",",O
the,O
interaction,O
of,O
sequential,O
treatment,O
in,O
vitro,O
may,O
not,O
correlate,O
the,O
interaction,O
between,O
first,O
-,O
line,O
and,O
second,O
-,O
line,O
treatment,O
in,O
clinic,O
.,O
The,O
drug,O
interaction,O
patterns,O
observed,O
in,O
vitro,O
may,O
not,O
be,O
similar,O
to,O
those,O
observed,O
clinically,O
.,O
Because,O
the,O
culture,O
condition,O
can,O
perturb,O
cell,O
function,O
and,O
potentiate,O
drug,O
sensitivity,O
",",O
obtaining,O
good,O
correlations,O
can,O
be,O
problematic,O
.,O
Pharmacokinetics,O
",",O
pharmacodynamics,O
",",O
rescue,O
effects,O
and,O
toxicity,O
to,O
normal,O
cells,O
/,O
tissues,O
that,O
affect,O
drug,O
action,O
in,O
clinical,O
setting,O
are,O
not,O
considered,O
by,O
in,O
vitro,O
assays,O
.,O
Because,O
each,O
patient,O
has,O
a,O
unique,O
pharmacogenetic,O
makeup,O
",",O
correlating,O
in,O
vitro,O
and,O
clinical,O
results,O
is,O
often,O
not,O
a,O
straightforward,O
process,O
.,O
However,O
",",O
our,O
study,O
provided,O
a,O
rational,O
for,O
the,O
ongoing,O
clinical,O
investigation,O
of,O
sequential,O
treatment,O
of,O
NSCLC,B-DS
.,O
Conclusions,O
In,O
summary,O
",",O
our,O
studies,O
have,O
demonstrated,O
that,O
sequential,O
administrations,O
of,O
paclitaxel,O
followed,O
by,O
gefitinib,O
result,O
in,O
the,O
most,O
effective,O
cytotoxic,O
effects,O
in,O
NSCLC,B-DS
cell,O
lines,O
harboring,O
EGFR,B-GP
mutations,O
.,O
The,O
sequence,O
-,O
dependent,O
modulation,O
of,O
TGFα,B-GP
expression,O
and,O
release,O
might,O
be,O
responsible,O
for,O
the,O
synergistic,O
interaction,O
between,O
paclitaxel,O
and,O
gefitinib,O
.,O
Although,O
the,O
extrapolation,O
of,O
in,O
vitro,O
data,O
to,O
the,O
clinical,O
setting,O
should,O
be,O
considered,O
with,O
caution,O
",",O
these,O
results,O
may,O
have,O
implications,O
for,O
the,O
rational,O
development,O
of,O
chemotherapeutic,O
regimens,O
for,O
the,O
treatment,O
of,O
NSCLC,B-DS
.,O
Competing,O
interests,O
Yi,O
-,O
long,O
Wu,O
has,O
received,O
speaking,O
honoraria,O
from,O
AstraZeneca,O
",",O
Eli,O
lilly,O
",",O
F,O
.,O
Hoffmann,O
-,O
La,O
Roche,O
and,O
Pfizer,O
.,O
No,O
other,O
potential,O
conflict,O
of,O
interest,O
relevant,O
to,O
this,O
article,O
was,O
reported,O
.,O
Authors,O
',O
contributions,O
HC,O
designed,O
thses,O
experiments,O
",",O
performed,O
part,O
of,O
these,O
experiments,O
and,O
drafted,O
this,O
manuscript,O
.,O
YW,O
designed,O
these,O
experiments,O
",",O
analyzed,O
the,O
results,O
",",O
guided,O
these,O
experiments,O
and,O
revised,O
this,O
manuscript,O
.,O
SA,O
and,O
ZC,O
carried,O
out,O
RT,O
-,O
PCR,O
.,O
DS,O
and,O
YZ,O
carried,O
out,O
the,O
western,O
blot,O
",",O
XZ,O
analyzed,O
the,O
experiment,O
results,O
.,O
JS,O
carried,O
out,O
part,O
of,O
the,O
MTT,O
assays,O
.,O
All,O
authors,O
have,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
The,O
peripheral,O
olfactory,O
code,O
in,O
Drosophila,B-OG
larvae,O
contains,O
temporal,O
information,O
and,O
is,O
robust,O
over,O
multiple,O
timescales,O
Present,O
address,O
:,O
Laboratory,O
for,O
Dystonia,O
Research,O
",",O
University,O
of,O
Leuven,O
",",O
O,O
&,O
N,O
IV,O
Herestraat,O
49,O
",",O
PO,O
Box,O
602,O
",",O
3000,O
Leuven,O
",",O
Belgium,O
.,O
We,O
studied,O
the,O
electrophysiological,O
activity,O
of,O
two,O
classes,O
of,O
Drosophila,B-OG
melanogaster,I-OG
larval,O
olfactory,O
sensory,O
neurons,O
(,O
OSNs,O
"),",O
Or24a,B-GP
and,O
Or74a,B-GP
",",O
in,O
response,O
to,O
1,O
s,O
stimulation,O
with,O
butanol,O
",",O
octanol,O
",",O
2,O
-,O
heptanone,O
",",O
and,O
propyl,O
acetate,O
.,O
Each,O
odour,O
/,O
OSN,O
combination,O
produced,O
unique,O
responses,O
in,O
terms,O
of,O
spike,O
count,O
and,O
temporal,O
profile,O
.,O
We,O
used,O
a,O
classifier,O
algorithm,O
to,O
explore,O
the,O
information,O
content,O
of,O
OSN,O
activity,O
",",O
and,O
showed,O
that,O
as,O
well,O
as,O
spike,O
count,O
",",O
the,O
activity,O
of,O
these,O
OSNs,O
included,O
temporal,O
information,O
that,O
enabled,O
the,O
classifier,O
to,O
accurately,O
identify,O
odours,O
.,O
The,O
responses,O
of,O
OSNs,O
during,O
continuous,O
odour,O
exposure,O
(,O
5,O
and,O
20,O
min,O
),O
showed,O
that,O
both,O
types,O
of,O
neuron,O
continued,O
to,O
respond,O
",",O
with,O
no,O
complete,O
adaptation,O
",",O
and,O
with,O
no,O
change,O
to,O
their,O
ability,O
to,O
encode,O
temporal,O
information,O
.,O
Finally,O
",",O
we,O
exposed,O
larvae,O
to,O
octanol,O
for,O
3,O
days,O
and,O
found,O
only,O
minor,O
quantitative,O
changes,O
in,O
OSN,O
response,O
to,O
odours,O
",",O
indicating,O
that,O
the,O
larval,O
peripheral,O
code,O
is,O
robust,O
when,O
faced,O
with,O
long,O
-,O
term,O
exposure,O
to,O
odours,O
",",O
such,O
as,O
would,O
be,O
found,O
in,O
a,O
natural,O
context,O
.,O
Introduction,O
Peripheral,O
olfactory,O
coding,O
involves,O
responses,O
by,O
olfactory,O
sensory,O
neurons,O
(,O
OSNs,O
),O
as,O
part,O
of,O
a,O
combinatorial,O
code,O
;,O
in,O
general,O
",",O
each,O
OSN,O
class,O
responds,O
to,O
more,O
than,O
one,O
odour,O
",",O
and,O
each,O
odour,O
can,O
activate,O
more,O
than,O
one,O
class,O
of,O
OSN,O
[,O
1,O
].,O
The,O
electrophysiological,O
activity,O
of,O
individual,O
OSNs,O
during,O
odour,O
stimulation,O
can,O
be,O
broadly,O
classified,O
into,O
three,O
types,O
:,O
excitation,O
",",O
inhibition,O
",",O
and,O
no,O
change,O
from,O
spontaneous,O
firing,O
activity,O
",",O
with,O
excitatory,O
and,O
inhibitory,O
responses,O
showing,O
a,O
large,O
quantitative,O
range,O
",",O
depending,O
on,O
the,O
OSN,O
/,O
odour,O
combination,O
[,O
2,O
].,O
Spike,O
count,O
codes,O
provide,O
animals,B-OG
with,O
high,O
levels,O
of,O
information,O
",",O
enabling,O
representation,O
of,O
a,O
wide,O
variety,O
of,O
aspects,O
of,O
the,O
stimulus,O
.,O
As,O
a,O
result,O
",",O
most,O
studies,O
of,O
peripheral,O
olfactory,O
activity,O
(,O
e,O
.,O
g,O
.,O
[,O
2,O
]),O
have,O
focused,O
on,O
spike,O
count,O
to,O
describe,O
the,O
responses,O
of,O
different,O
OSN,O
/,O
odour,O
combinations,O
.,O
In,O
many,O
sensory,O
systems,O
",",O
the,O
temporal,O
pattern,O
of,O
spikes,O
within,O
a,O
time,O
window,O
contains,O
information,O
beyond,O
that,O
conveyed,O
by,O
spike,O
count,O
[,O
3,O
",",O
4,O
].,O
Most,O
explorations,O
of,O
temporal,O
coding,O
",",O
in,O
olfaction,O
and,O
in,O
other,O
sensory,O
modalities,O
",",O
have,O
focused,O
on,O
the,O
central,O
processing,O
of,O
stimuli,O
(,O
e,O
.,O
g,O
.,O
[,O
4,O
",",O
5,O
]).,O
Peripheral,O
OSNs,O
also,O
appear,O
to,O
show,O
temporal,O
coding,O
[,O
6,O
",",O
7,O
];,O
where,O
olfactory,O
stimuli,O
have,O
a,O
temporal,O
structure,O
",",O
OSNs,O
can,O
respond,O
to,O
these,O
temporal,O
features,O
[,O
8,O
].,O
In,O
adult,O
Drosophila,B-OG
",",O
different,O
OSN,O
/,O
odour,O
combinations,O
show,O
different,O
response,O
latencies,O
",",O
suggesting,O
that,O
temporal,O
coding,O
in,O
the,O
periphery,O
may,O
constitute,O
an,O
additional,O
coding,O
dimension,O
alongside,O
spike,O
count,O
[,O
9,O
",",O
10,O
].,O
Little,O
is,O
known,O
about,O
how,O
or,O
whether,O
the,O
informational,O
content,O
of,O
OSN,O
responses,O
changes,O
over,O
different,O
timescales,O
.,O
Most,O
electrophysiological,O
experiments,O
use,O
brief,O
periods,O
of,O
odour,O
stimulation,O
—,O
often,O
around,O
1,O
s,O
.,O
While,O
this,O
corresponds,O
to,O
one,O
aspect,O
of,O
real,O
-,O
life,O
olfaction,O
(,O
sniffing,O
",",O
or,O
moving,O
through,O
an,O
odour,O
plume,O
"),",O
animals,B-OG
can,O
also,O
be,O
immersed,O
in,O
odours,O
for,O
much,O
longer,O
periods,O
.,O
This,O
paper,O
explores,O
two,O
major,O
issues,O
in,O
peripheral,O
olfactory,O
coding,O
:,O
the,O
existence,O
and,O
significance,O
of,O
temporal,O
coding,O
",",O
and,O
the,O
consistency,O
of,O
peripheral,O
responses,O
over,O
different,O
timescales,O
.,O
We,O
studied,O
the,O
electrophysiological,O
responses,O
of,O
the,O
Drosophila,B-OG
melanogaster,I-OG
larva,O
",",O
which,O
possesses,O
only,O
21,O
pairs,O
of,O
unique,O
OSNs,O
housed,O
in,O
a,O
pair,O
of,O
sensilla,O
called,O
the,O
dorsal,O
organs,O
[,O
11,O
].,O
Using,O
the,O
Gal4,B-GP
-,O
UAS,O
system,O
",",O
it,O
is,O
possible,O
to,O
create,O
larvae,O
with,O
a,O
single,O
-,O
functional,O
pair,O
of,O
identified,O
OSNs,O
[,O
11,O
].,O
The,O
remaining,O
OSNs,O
are,O
non,O
-,O
responsive,O
",",O
producing,O
unmodulated,O
spontaneous,O
activity,O
",",O
while,O
the,O
electrophysiological,O
activity,O
of,O
single,O
-,O
functional,O
OSNs,O
appears,O
to,O
be,O
no,O
different,O
from,O
those,O
of,O
wild,O
-,O
type,O
OSNs,O
[,O
2,O
"],",O
enabling,O
individual,O
OSN,O
responses,O
to,O
be,O
examined,O
in,O
isolation,O
.,O
We,O
studied,O
the,O
responses,O
of,O
OSNs,O
expressing,O
Or24a,B-GP
and,O
Or74a,B-GP
olfactory,B-GP
receptors,I-GP
.,O
These,O
OSNs,O
were,O
chosen,O
because,O
they,O
respond,O
to,O
different,O
ranges,O
of,O
odours,O
and,O
because,O
Or24a,B-GP
is,O
more,O
broadly,O
tuned,O
than,O
Or74a,B-GP
—,O
but,O
with,O
some,O
overlap,O
[,O
12,O
].,O
We,O
explored,O
how,O
much,O
information,O
regarding,O
odour,O
identity,O
is,O
carried,O
by,O
a,O
single,O
OSN,O
and,O
then,O
investigated,O
whether,O
OSN,O
activity,O
is,O
maintained,O
during,O
stimulation,O
over,O
four,O
different,O
timescales,O
:,O
1,O
s,O
",",O
5,O
min,O
",",O
20,O
min,O
",",O
and,O
3,O
days,O
.,O
By,O
combining,O
electrophysiological,O
data,O
and,O
algorithmic,O
approaches,O
to,O
OSN,O
signal,O
content,O
",",O
we,O
revealed,O
the,O
existence,O
of,O
temporal,O
coding,O
and,O
its,O
maintenance,O
in,O
larval,O
OSNs,O
over,O
ecologically,O
significant,O
timescales,O
",",O
suggesting,O
that,O
this,O
phenomenon,O
is,O
of,O
significance,O
in,O
real,O
-,O
world,O
olfactory,O
processing,O
.,O
Material,O
and,O
methods,O
Drosophila,B-OG
stocks,O
Stocks,O
were,O
maintained,O
on,O
a,O
cornmeal,O
–,O
agar,O
–,O
glucose,O
medium,O
at,O
25,O
°,O
C,O
under,O
a,O
12,O
light,O
(,O
L,O
),O
:,O
12,O
dark,O
(,O
D,O
),O
cycle,O
.,O
Larvae,O
were,O
reared,O
under,O
the,O
same,O
conditions,O
on,O
a,O
yeast,B-OG
paste,O
.,O
Single,O
-,O
functional,O
OSN,O
lines,O
(,O
Or24a,B-GP
and,O
Or74a,B-GP
),O
were,O
created,O
according,O
to,O
the,O
protocols,O
outlined,O
in,O
[,O
11,O
],O
using,O
lines,O
kindly,O
supplied,O
by,O
Professor,O
Leslie,O
Vosshall,O
(,O
Rockefeller,O
University,O
).,O
Electrophysiological,O
recordings,O
Three,O
-,O
day,O
-,O
old,O
larvae,O
were,O
immobilized,O
with,O
Parafilm,O
on,O
a,O
moistened,O
matchstick,O
.,O
A,O
chloride,O
-,O
coated,O
silver,O
wire,O
reference,O
electrode,O
was,O
inserted,O
into,O
the,O
posterior,O
end,O
of,O
the,O
larva,O
.,O
Borosilicate,O
glass,O
capillary,O
microelectrodes,O
with,O
a,O
tip,O
diameter,O
of,O
less,O
than,O
1,O
µm,O
were,O
filled,O
with,O
Drosophila,B-OG
larval,O
ringer,O
solution,O
adjusted,O
to,O
pH,O
7,O
.,O
1,O
with,O
HCl,O
or,O
NaOH,O
[,O
13,O
].,O
The,O
tip,O
of,O
the,O
microelectrode,O
was,O
inserted,O
into,O
the,O
cuticle,O
at,O
the,O
base,O
of,O
the,O
dorsal,O
organ,O
.,O
Electrical,O
activity,O
was,O
acquired,O
using,O
a,O
Neurolog,O
system,O
(,O
Digitimer,O
).,O
The,O
differential,O
activity,O
from,O
the,O
reference,O
and,O
the,O
recording,O
electrodes,O
was,O
amplified,O
and,O
filtered,O
(,O
filter,O
unit,O
NL125,O
and,O
126,O
),O
and,O
directed,O
to,O
a,O
CED,O
micro,O
1401,O
mk,O
II,O
(,O
Cambridge,O
Electronic,O
Design,O
),O
analogue,O
to,O
digital,O
converter,O
at,O
a,O
sampling,O
rate,O
of,O
10,O
kHz,O
.,O
The,O
digital,O
signal,O
was,O
recorded,O
and,O
analysed,O
with,O
CED,O
Spike2,O
software,O
(,O
v,O
.,O
7,O
.,O
06,O
).,O
Spike,O
sorting,O
was,O
performed,O
off,O
-,O
line,O
using,O
Spike2,O
.,O
Each,O
recording,O
contained,O
the,O
activity,O
of,O
only,O
one,O
functional,O
OSN,O
.,O
The,O
activity,O
of,O
the,O
functional,O
OSN,O
was,O
extracted,O
on,O
the,O
basis,O
of,O
the,O
amplitude,O
and,O
waveform,O
of,O
the,O
spikes,O
and,O
its,O
responsiveness,O
to,O
odours,O
;,O
where,O
the,O
activity,O
of,O
other,O
OSNs,O
was,O
recorded,O
",",O
it,O
showed,O
unmodulated,O
spontaneous,O
activity,O
irrespective,O
of,O
stimulation,O
.,O
A,O
principal,O
component,O
analysis,O
verified,O
that,O
spikes,O
belonged,O
to,O
the,O
functional,O
OSN,O
[,O
2,O
].,O
Odour,O
stimulation,O
Odours,O
Butanol,O
",",O
octanol,O
",",O
2,O
-,O
heptanone,O
",",O
and,O
propyl,O
acetate,O
were,O
from,O
Sigma,O
-,O
Aldrich,O
and,O
of,O
the,O
highest,O
purity,O
available,O
and,O
were,O
mixed,O
with,O
distilled,O
water,O
to,O
a,O
final,O
concentration,O
of,O
2,O
%,O
in,O
25,O
ml,O
conical,O
flasks,O
.,O
Odour,O
delivery,O
system,O
A,O
continuous,O
stream,O
of,O
air,O
(,O
2,O
.,O
5,O
ml,O
s,O
−,O
1,O
),O
was,O
directed,O
through,O
a,O
flask,O
containing,O
distilled,O
water,O
and,O
was,O
switched,O
to,O
an,O
odorant,O
flask,O
for,O
the,O
appropriate,O
duration,O
before,O
being,O
returned,O
to,O
the,O
distilled,O
water,O
route,O
.,O
The,O
exit,O
of,O
the,O
delivery,O
system,O
was,O
0,O
.,O
5,O
cm,O
from,O
the,O
dorsal,O
organ,O
.,O
Repeated,O
stimuli,O
were,O
presented,O
with,O
a,O
30,O
s,O
inter,O
-,O
stimulus,O
interval,O
.,O
The,O
odour,O
delivery,O
system,O
used,O
polytetrafluoroethylene,O
tubing,O
",",O
and,O
odour,O
flasks,O
were,O
sealed,O
with,O
silicone,O
plugs,O
.,O
A,O
photo,O
-,O
ionization,O
detector,O
(,O
PID,O
),O
sensor,O
(,O
Alphasenses,O
),O
showed,O
that,O
odour,O
delivery,O
was,O
reliable,O
and,O
consistent,O
.,O
Continuous,O
odour,O
exposure,O
experiments,O
Continuous,O
exposure,O
to,O
octanol,O
took,O
place,O
for,O
periods,O
of,O
5,O
min,O
",",O
20,O
min,O
",",O
and,O
3,O
days,O
.,O
For,O
the,O
5,O
and,O
20,O
min,O
periods,O
",",O
larvae,O
were,O
exposed,O
to,O
a,O
continual,O
odour,O
flow,O
and,O
continuous,O
recordings,O
were,O
made,O
of,O
activity,O
from,O
the,O
relevant,O
OSN,O
.,O
For,O
the,O
3,O
-,O
day,O
exposure,O
experiment,O
",",O
20,O
µl,O
of,O
octanol,O
was,O
loaded,O
onto,O
a,O
filter,O
paper,O
placed,O
inside,O
a,O
0,O
.,O
5,O
µl,O
Eppendorf,O
tube,O
pierced,O
by,O
six,O
holes,O
and,O
fixed,O
to,O
the,O
lid,O
of,O
a,O
Petri,O
dish,O
",",O
the,O
bottom,O
of,O
which,O
was,O
covered,O
in,O
yeast,B-OG
paste,O
.,O
The,O
larvae,O
fed,O
on,O
the,O
paste,O
and,O
were,O
unable,O
to,O
come,O
into,O
direct,O
contact,O
with,O
the,O
odour,O
source,O
.,O
In,O
the,O
5,O
and,O
20,O
min,O
exposure,O
experiments,O
",",O
the,O
larva,O
was,O
stimulated,O
before,O
and,O
after,O
odour,O
exposure,O
in,O
the,O
sequence,O
:,O
octanol,O
",",O
2,O
-,O
heptanone,O
",",O
and,O
propyl,O
acetate,O
",",O
each,O
odour,O
for,O
1,O
s,O
and,O
repeated,O
five,O
times,O
.,O
Each,O
recording,O
started,O
and,O
finished,O
with,O
a,O
control,O
stimulus,O
(,O
distilled,O
water,O
).,O
For,O
3,O
-,O
day,O
exposure,O
",",O
the,O
sequence,O
octanol,O
",",O
2,O
-,O
heptanone,O
",",O
and,O
propyl,O
acetate,O
were,O
repeated,O
10,O
times,O
following,O
exposure,O
and,O
preparation,O
for,O
recording,O
.,O
Classifier,O
algorithm,O
Odour,O
decoding,O
Analyses,O
were,O
performed,O
using,O
MATLAB,O
(,O
MathWorks,O
).,O
A,O
peri,O
-,O
stimulus,O
time,O
histogram,O
-,O
(,O
PSTH,O
)-,O
classifier,O
[,O
14,O
],O
was,O
constructed,O
from,O
odour,O
-,O
evoked,O
spike,O
data,O
.,O
For,O
each,O
1,O
s,O
stimulation,O
trial,O
",",O
spike,O
times,O
within,O
a,O
time,O
window,O
of,O
a,O
given,O
duration,O
(,O
maximum,O
=,O
6,O
s,O
"),",O
starting,O
at,O
stimulus,O
onset,O
",",O
were,O
discretized,O
into,O
50,O
ms,O
bins,O
[,O
9,O
],O
to,O
form,O
a,O
response,O
vector,O
.,O
A,O
leave,O
-,O
one,O
-,O
out,O
cross,O
-,O
validation,O
approach,O
was,O
used,O
",",O
whereby,O
the,O
classifier,O
was,O
trained,O
using,O
data,O
from,O
all,O
trials,O
except,O
the,O
ith,O
one,O
(,O
training,O
set,O
),O
and,O
then,O
tested,O
on,O
trial,O
i,O
(,O
testing,O
set,O
).,O
A,O
template,O
response,O
vector,O
for,O
each,O
of,O
the,O
four,O
odours,O
was,O
obtained,O
by,O
averaging,O
the,O
response,O
vectors,O
for,O
that,O
odour,O
to,O
form,O
a,O
PSTH,O
.,O
For,O
each,O
trial,O
",",O
Euclidean,O
distances,O
between,O
the,O
test,O
response,O
vector,O
and,O
each,O
template,O
vector,O
were,O
computed,O
and,O
the,O
template,O
with,O
the,O
smallest,O
distance,O
was,O
selected,O
.,O
If,O
the,O
test,O
response,O
vector,O
was,O
equidistant,O
to,O
two,O
or,O
more,O
templates,O
",",O
a,O
random,O
selection,O
was,O
made,O
from,O
among,O
the,O
equidistant,O
templates,O
.,O
This,O
procedure,O
was,O
repeated,O
for,O
i,O
=,O
1,O
…,O
5,O
trials,O
and,O
",",O
for,O
each,O
odour,O
",",O
we,O
calculated,O
the,O
fraction,O
of,O
trials,O
on,O
which,O
it,O
was,O
decoded,O
correctly,O
.,O
To,O
assess,O
whether,O
the,O
decoding,O
performance,O
for,O
a,O
given,O
odour,O
was,O
statistically,O
significant,O
",",O
we,O
computed,O
the,O
distribution,O
of,O
performance,O
values,O
for,O
all,O
22,O
larvae,O
under,O
the,O
,O
hypothesis,O
that,O
the,O
OSN,O
was,O
firing,O
randomly,O
",",O
by,O
generating,O
surrogate,O
datasets,O
where,O
the,O
relationship,O
between,O
odour,O
and,O
response,O
was,O
randomized,O
.,O
One,O
-,O
tailed,O
t,O
-,O
tests,O
for,O
each,O
time,O
bin,O
were,O
run,O
with,O
the,O
Bonferroni,O
correction,O
.,O
In,O
a,O
variant,O
of,O
this,O
analysis,O
",",O
based,O
on,O
‘,O
sliding,O
windows,O
"',",O
decoding,O
performance,O
was,O
computed,O
for,O
responses,O
of,O
fixed,O
duration,O
(,O
200,O
ms,O
),O
from,O
various,O
start,O
times,O
.,O
Decoding,O
performance,O
was,O
then,O
calculated,O
as,O
a,O
function,O
of,O
the,O
start,O
time,O
.,O
Classifier,O
:,O
spike,O
count,O
To,O
assess,O
the,O
accuracy,O
of,O
decoding,O
based,O
only,O
on,O
spike,O
count,O
information,O
",",O
for,O
each,O
trial,O
–,O
odour,O
combination,O
",",O
the,O
elements,O
of,O
the,O
corresponding,O
response,O
vector,O
were,O
randomly,O
shuffled,O
.,O
This,O
destroyed,O
any,O
temporal,O
structure,O
of,O
the,O
spike,O
train,O
",",O
but,O
preserved,O
the,O
number,O
of,O
spikes,O
inside,O
the,O
response,O
time,O
window,O
.,O
The,O
decoding,O
procedure,O
was,O
then,O
repeated,O
using,O
these,O
shuffled,O
data,O
.,O
These,O
analyses,O
were,O
repeated,O
on,O
a,O
fixed,O
time,O
window,O
(,O
stimulus,O
delivery,O
period,O
"),",O
comparing,O
all,O
possible,O
pairs,O
of,O
odours,O
.,O
Statistical,O
analysis,O
Where,O
parametric,O
tests,O
were,O
used,O
",",O
data,O
distributions,O
were,O
first,O
checked,O
for,O
normality,O
.,O
Analyses,O
were,O
performed,O
with,O
GraphPad,O
",",O
XLSTAT,O
2012,O
",",O
or,O
SPSS,O
.,O
Results,O
Electrophysiological,O
responses,O
to,O
odour,O
stimuli,O
The,O
in,O
vivo,O
firing,O
activity,O
of,O
Or24a,B-GP
and,O
Or74a,B-GP
OSNs,O
(,O
n,O
=,O
22,O
for,O
each,O
),O
in,O
response,O
to,O
five,O
1,O
s,O
presentations,O
of,O
each,O
of,O
four,O
odours,O
—,O
octanol,O
",",O
butanol,O
",",O
2,O
-,O
heptanone,O
",",O
and,O
propyl,O
acetate,O
—,O
is,O
shown,O
in,O
figure,O
1,O
.,O
Most,O
OSN,O
/,O
odour,O
combinations,O
produced,O
a,O
unique,O
response,O
profile,O
(,O
strong,O
excitation,O
",",O
weak,O
excitation,O
",",O
or,O
inhibition,O
),O
that,O
outlasted,O
the,O
1,O
s,O
stimulus,O
presentation,O
.,O
The,O
peak,O
instantaneous,O
firing,O
rates,O
of,O
these,O
larval,O
OSNs,O
were,O
around,O
60,O
Hz,O
",",O
with,O
most,O
activity,O
less,O
than,O
40,O
Hz,O
.,O
Figure,O
1,O
.,O
Electrophysiological,O
responses,O
to,O
four,O
odours,O
shown,O
by,O
Or24a,B-GP
and,O
Or74a,B-GP
OSNs,O
.,O
Graphs,O
show,O
means,O
from,O
five,O
presentations,O
of,O
each,O
odour,O
in,O
22,O
larvae,O
;,O
firing,O
activity,O
(,O
in,O
hertz,O
),O
is,O
plotted,O
in,O
50,O
ms,O
bins,O
.,O
Grey,O
bars,O
indicate,O
1,O
s,O
stimulus,O
.,O
Error,O
bars,O
:,O
standard,O
error,O
(,O
s,O
.,O
e,O
.).,O
Each,O
panel,O
includes,O
a,O
typical,O
trace,O
(,O
green,O
),O
showing,O
the,O
electrophysiological,O
activity,O
of,O
a,O
single,O
OSN,O
of,O
that,O
class,O
;,O
some,O
of,O
these,O
traces,O
show,O
higher,O
levels,O
of,O
spontaneous,O
activity,O
than,O
those,O
that,O
appear,O
in,O
the,O
pooled,O
histograms,O
.,O
Mean,O
activity,O
in,O
hertz,O
(,O
with,O
s,O
.,O
d,O
.),O
of,O
OSN,O
/,O
odour,O
combinations,O
(,O
n,O
=,O
110,O
in,O
all,O
cases,O
),O
during,O
1,O
s,O
stimulation,O
:,O
Or24a,B-GP
/,O
octanol,O
=,O
2,O
.,O
85,O
(,O
2,O
.,O
32,O
"),",O
Or24a,B-GP
/,O
butanol,O
=,O
9,O
.,O
11,O
(,O
5,O
.,O
88,O
"),",O
Or24a,B-GP
/,O
2,O
-,O
heptanone,O
=,O
8,O
.,O
77,O
(,O
6,O
.,O
24,O
"),",O
Or24a,B-GP
/,O
propyl,O
acetate,O
=,O
46,O
.,O
95,O
(,O
16,O
.,O
84,O
"),",O
Or74a,B-GP
/,O
octanol,O
=,O
50,O
.,O
48,O
(,O
23,O
.,O
8,O
"),",O
Or74a,B-GP
/,O
butanol,O
=,O
48,O
.,O
81,O
(,O
24,O
.,O
1,O
"),",O
Or74a,B-GP
/,O
2,O
-,O
heptanone,O
=,O
18,O
.,O
28,O
(,O
15,O
.,O
4,O
"),",O
and,O
Or74a,B-GP
/,O
propyl,O
acetate,O
=,O
11,O
.,O
82,O
(,O
10,O
.,O
9,O
).,O
Mean,O
number,O
of,O
spikes,O
(,O
with,O
s,O
.,O
d,O
.),O
of,O
OSN,O
/,O
odour,O
combinations,O
(,O
n,O
=,O
110,O
in,O
all,O
cases,O
),O
over,O
6,O
s,O
of,O
experiment,O
(,O
1,O
s,O
stimulation,O
and,O
5,O
s,O
after,O
stimulus,O
offset,O
):,O
Or24a,B-GP
/,O
octanol,O
=,O
6,O
.,O
52,O
(,O
6,O
.,O
77,O
"),",O
Or24a,B-GP
/,O
butanol,O
=,O
27,O
.,O
90,O
(,O
12,O
.,O
74,O
"),",O
Or24a,B-GP
/,O
2,O
-,O
heptanone,O
=,O
23,O
.,O
23,O
(,O
12,O
.,O
91,O
"),",O
Or24a,B-GP
/,O
propyl,O
acetate,O
=,O
77,O
.,O
26,O
(,O
30,O
.,O
93,O
"),",O
Or74a,B-GP
/,O
octanol,O
=,O
109,O
.,O
92,O
(,O
55,O
.,O
77,O
"),",O
Or74a,B-GP
/,O
butanol,O
=,O
85,O
.,O
4,O
(,O
41,O
.,O
31,O
"),",O
Or74a,B-GP
/,O
2,O
-,O
heptanone,O
=,O
44,O
.,O
00,O
(,O
26,O
.,O
00,O
"),",O
and,O
Or74a,B-GP
/,O
propyl,O
acetate,O
=,O
29,O
.,O
20,O
(,O
20,O
.,O
40,O
).,O
Mean,O
spontaneous,O
activity,O
rates,O
(,O
with,O
s,O
.,O
e,O
.),O
in,O
the,O
second,O
before,O
stimulation,O
onset,O
:,O
Or24a,B-GP
/,O
octanol,O
=,O
7,O
.,O
5,O
(,O
0,O
.,O
5,O
"),",O
Or24a,B-GP
/,O
butanol,O
=,O
8,O
.,O
2,O
(,O
0,O
.,O
5,O
"),",O
Or24a,B-GP
/,O
2,O
-,O
heptanone,O
=,O
7,O
.,O
9,O
(,O
0,O
.,O
5,O
"),",O
Or24a,B-GP
/,O
propyl,O
acetate,O
=,O
7,O
.,O
9,O
(,O
0,O
.,O
5,O
"),",O
Or74a,B-GP
/,O
octanol,O
=,O
5,O
.,O
6,O
(,O
0,O
.,O
3,O
"),",O
Or74a,B-GP
/,O
butanol,O
=,O
5,O
.,O
9,O
(,O
0,O
.,O
3,O
"),",O
Or74a,B-GP
/,O
2,O
-,O
heptanone,O
=,O
5,O
.,O
9,O
(,O
0,O
.,O
3,O
"),",O
and,O
Or74a,B-GP
/,O
propyl,O
acetate,O
=,O
5,O
.,O
9,O
(,O
0,O
.,O
3,O
).,O
(,O
Online,O
version,O
in,O
colour,O
.),O
Peripheral,O
activity,O
contains,O
temporal,O
information,O
To,O
explore,O
whether,O
the,O
firing,O
responses,O
contain,O
enough,O
information,O
for,O
the,O
individual,O
OSNs,O
to,O
correctly,O
identify,O
each,O
of,O
the,O
four,O
odours,O
",",O
we,O
used,O
a,O
classifier,O
algorithm,O
implemented,O
in,O
MATLAB,O
that,O
was,O
trained,O
to,O
decode,O
odour,O
identity,O
using,O
the,O
raw,O
firing,O
data,O
.,O
The,O
task,O
of,O
the,O
classifier,O
algorithm,O
was,O
to,O
identify,O
which,O
of,O
the,O
four,O
odours,O
had,O
induced,O
the,O
pattern,O
of,O
individual,O
OSN,O
activity,O
on,O
a,O
given,O
trial,O
;,O
we,O
termed,O
this,O
as,O
a,O
forced,O
four,O
-,O
choice,O
‘,O
discrimination,O
’,O
task,O
.,O
For,O
Or24a,B-GP
neurons,O
",",O
two,O
of,O
the,O
four,O
odours,O
(,O
octanol,O
and,O
propyl,O
acetate,O
),O
were,O
reliably,O
identified,O
by,O
the,O
classifier,O
with,O
high,O
levels,O
of,O
performance,O
(,O
perfect,O
performance,O
=,O
1,O
.,O
0,O
",",O
observed,O
performance,O
=,O
0,O
.,O
95,O
for,O
both,O
octanol,O
and,O
propyl,O
acetate,O
;,O
see,O
figure,O
2,O
",",O
blue,O
lines,O
).,O
Significant,O
above,O
-,O
chance,O
levels,O
of,O
performance,O
(,O
black,O
lines,O
),O
were,O
reached,O
within,O
550,O
ms,O
of,O
stimulus,O
onset,O
for,O
octanol,O
and,O
150,O
ms,O
for,O
propyl,O
acetate,O
.,O
Average,O
across,O
-,O
larva,O
identification,O
performance,O
levels,O
for,O
butanol,O
and,O
2,O
-,O
heptanone,O
were,O
lower,O
",",O
but,O
still,O
significant,O
(,O
maxima,O
=,O
0,O
.,O
66,O
and,O
0,O
.,O
59,O
",",O
respectively,O
).,O
For,O
Or74a,B-GP
neurons,O
",",O
the,O
classifier,O
was,O
highly,O
effective,O
for,O
all,O
four,O
odours,O
;,O
significant,O
performance,O
was,O
reached,O
within,O
150,O
–,O
400,O
ms,O
of,O
stimulus,O
onset,O
and,O
maximum,O
performance,O
of,O
0,O
.,O
80,O
–,O
0,O
.,O
87,O
was,O
reached,O
.,O
For,O
both,O
OSN,O
classes,O
",",O
significant,O
performance,O
was,O
still,O
obtained,O
when,O
the,O
model,O
had,O
access,O
only,O
to,O
the,O
firing,O
activity,O
after,O
stimulus,O
offset,O
(,O
this,O
was,O
tested,O
using,O
a,O
200,O
ms,O
‘,O
sliding,O
window,O
’;,O
figure,O
3a,O
).,O
These,O
classifier,O
experiments,O
indicate,O
that,O
the,O
information,O
contained,O
in,O
peripheral,O
OSN,O
responses,O
is,O
sufficient,O
to,O
discriminate,O
odours,O
with,O
a,O
high,O
degree,O
of,O
accuracy,O
in,O
a,O
two,O
-,O
bit,O
classification,O
task,O
.,O
Figure,O
2,O
.,O
Classifier,O
decoding,O
performance,O
on,O
a,O
four,O
-,O
choice,O
discrimination,O
task,O
composed,O
of,O
responses,O
of,O
Or24a,B-GP
and,O
Or74a,B-GP
",",O
based,O
on,O
spike,O
count,O
code,O
(,O
green,O
),O
or,O
spike,O
pattern,O
code,O
(,O
blue,O
).,O
Black,O
:,O
performance,O
after,O
trial,O
–,O
odour,O
combination,O
shuffling,O
(,O
i,O
.,O
e,O
.,O
chance,O
level,O
).,O
Shaded,O
area,O
around,O
each,O
line,O
:,O
s,O
.,O
e,O
.,O
Heat,O
bars,O
under,O
each,O
graph,O
show,O
the,O
significance,O
of,O
comparisons,O
(,O
log10,O
p,O
-,O
values,O
).,O
Upper,O
heat,O
bar,O
",",O
comparisons,O
between,O
the,O
spike,O
pattern,O
curve,O
(,O
blue,O
),O
and,O
performance,O
after,O
trial,O
–,O
odour,O
combination,O
shuffling,O
(,O
green,O
);,O
lower,O
heat,O
bar,O
",",O
comparisons,O
for,O
each,O
phase,O
of,O
the,O
experiment,O
(,O
early,O
",",O
middle,O
",",O
and,O
late,O
",",O
see,O
text,O
).,O
Figure,O
3,O
.,O
Performance,O
of,O
classifier,O
using,O
spike,O
count,O
and,O
spike,O
pattern,O
.,O
(,O
a,O
),O
Average,O
performance,O
over,O
22,O
larvae,O
of,O
the,O
200,O
ms,O
sliding,O
window,O
classifier,O
model,O
(,O
blue,O
),O
faced,O
with,O
a,O
four,O
-,O
choice,O
discrimination,O
task,O
.,O
Black,O
:,O
performance,O
after,O
trial,O
–,O
odour,O
combination,O
shuffling,O
.,O
Shaded,O
area,O
around,O
curves,O
:,O
s,O
.,O
e,O
.,O
Heat,O
bars,O
under,O
each,O
graph,O
show,O
the,O
log10,O
p,O
-,O
values,O
of,O
bin,O
-,O
by,O
-,O
bin,O
comparisons,O
between,O
the,O
sliding,O
window,O
classifier,O
model,O
and,O
performance,O
after,O
trial,O
–,O
odour,O
combination,O
shuffling,O
.,O
(,O
b,O
),O
Decoding,O
performance,O
of,O
the,O
classifier,O
based,O
on,O
spike,O
count,O
code,O
(,O
left,O
),O
and,O
spike,O
pattern,O
code,O
(,O
right,O
),O
when,O
faced,O
with,O
a,O
two,O
-,O
choice,O
discrimination,O
task,O
.,O
The,O
colours,O
correspond,O
to,O
the,O
performance,O
of,O
the,O
model,O
in,O
discriminating,O
between,O
each,O
pair,O
of,O
odours,O
",",O
as,O
given,O
by,O
the,O
vertical,O
heat,O
map,O
.,O
To,O
test,O
for,O
the,O
contribution,O
of,O
temporal,O
information,O
to,O
the,O
code,O
",",O
we,O
randomly,O
shuffled,O
the,O
sequence,O
of,O
50,O
ms,O
response,O
time,O
bins,O
",",O
thus,O
keeping,O
the,O
number,O
of,O
spikes,O
for,O
each,O
trial,O
constant,O
(,O
i,O
.,O
e,O
.,O
‘,O
spike,O
count,O
’),O
but,O
destroying,O
any,O
information,O
in,O
the,O
temporal,O
structure,O
of,O
the,O
spike,O
train,O
(‘,O
spike,O
pattern,O
’;,O
figure,O
2,O
",",O
green,O
lines,O
).,O
If,O
there,O
is,O
no,O
temporal,O
information,O
in,O
the,O
activity,O
of,O
the,O
OSNs,O
",",O
but,O
only,O
spike,O
count,O
information,O
",",O
then,O
the,O
classifier,O
should,O
perform,O
equally,O
well,O
with,O
the,O
shuffled,O
dataset,O
as,O
with,O
the,O
original,O
data,O
.,O
After,O
training,O
the,O
classifier,O
on,O
these,O
time,O
-,O
shuffled,O
data,O
",",O
we,O
tested,O
for,O
significant,O
differences,O
in,O
discrimination,O
performance,O
between,O
the,O
spike,O
count,O
code,O
and,O
the,O
spike,O
pattern,O
code,O
in,O
three,O
ad,O
hoc,O
phases,O
of,O
the,O
OSN,O
response,O
(,O
early,O
=,O
0,O
–,O
400,O
ms,O
;,O
middle,O
=,O
450,O
ms,O
–,O
2,O
s,O
;,O
late,O
=,O
2,O
.,O
05,O
–,O
6,O
s,O
—,O
see,O
figure,O
2,O
",",O
bottom,O
panels,O
).,O
In,O
the,O
absence,O
of,O
information,O
from,O
the,O
temporal,O
pattern,O
",",O
spike,O
count,O
alone,O
yielded,O
significantly,O
lower,O
discrimination,O
performance,O
(,O
p,O
<,O
0,O
.,O
01,O
),O
in,O
at,O
least,O
one,O
phase,O
for,O
all,O
OSN,O
/,O
odour,O
combinations,O
",",O
with,O
the,O
exception,O
of,O
Or74a,B-GP
/,O
propyl,O
acetate,O
(,O
figure,O
2,O
and,O
electronic,O
supplementary,O
material,O
",",O
S1,O
).,O
Pairwise,O
comparisons,O
of,O
the,O
ability,O
of,O
the,O
classifier,O
to,O
reliably,O
identify,O
odours,O
reinforce,O
this,O
point,O
.,O
For,O
example,O
",",O
where,O
the,O
number,O
of,O
spikes,O
was,O
similar,O
(,O
e,O
.,O
g,O
.,O
Or74a,B-GP
/,O
butanol,O
and,O
Or74a,B-GP
/,O
octanol,O
—,O
see,O
legend,O
to,O
figure,O
1,O
"),",O
the,O
classifier,O
showed,O
a,O
greater,O
ability,O
to,O
reliably,O
identify,O
the,O
odour,O
when,O
temporal,O
information,O
was,O
included,O
than,O
when,O
spike,O
count,O
alone,O
was,O
taken,O
into,O
account,O
(,O
figures,O
2,O
and,O
3b,O
).,O
We,O
conclude,O
that,O
although,O
spike,O
count,O
alone,O
can,O
provide,O
sufficient,O
information,O
for,O
a,O
single,O
OSN,O
to,O
distinguish,O
some,O
odours,O
",",O
the,O
responses,O
contain,O
additional,O
temporal,O
information,O
—,O
spike,O
pattern,O
—,O
that,O
permits,O
substantially,O
more,O
reliable,O
and,O
more,O
rapid,O
odour,O
identification,O
.,O
Peripheral,O
coding,O
over,O
longer,O
timescales,O
Larvae,O
spend,O
virtually,O
their,O
whole,O
lives,O
in,O
food,O
",",O
with,O
their,O
OSNs,O
continuously,O
stimulated,O
by,O
food,O
odours,O
.,O
To,O
investigate,O
how,O
OSNs,O
adjust,O
to,O
longer,O
periods,O
of,O
exposure,O
to,O
an,O
odour,O
",",O
single,O
-,O
functional,O
Or24a,B-GP
and,O
Or74a,B-GP
larvae,O
were,O
exposed,O
for,O
5,O
min,O
to,O
octanol,O
",",O
2,O
-,O
heptanone,O
",",O
or,O
propyl,O
acetate,O
and,O
the,O
electrophysiological,O
activity,O
of,O
the,O
functional,O
OSN,O
during,O
this,O
period,O
was,O
recorded,O
(,O
figure,O
4a,O
).,O
We,O
focused,O
on,O
these,O
three,O
odours,O
",",O
because,O
they,O
represented,O
three,O
different,O
chemical,O
functional,O
groups,O
",",O
and,O
induced,O
a,O
range,O
of,O
responses,O
in,O
the,O
two,O
classes,O
of,O
OSN,O
.,O
For,O
the,O
sake,O
of,O
clarity,O
",",O
the,O
1,O
s,O
period,O
during,O
which,O
OSN,O
responses,O
were,O
tested,O
was,O
termed,O
‘,O
stimulation,O
"’,",O
while,O
longer,O
durations,O
were,O
termed,O
‘,O
exposure,O
’.,O
Figure,O
4,O
.,O
Electrophysiological,O
responses,O
during,O
and,O
after,O
5,O
min,O
stimulation,O
with,O
octanol,O
",",O
2,O
-,O
heptanone,O
",",O
and,O
propyl,O
acetate,O
.,O
(,O
a,O
),O
Firing,O
activity,O
of,O
Or24a,B-GP
and,O
Or74a,B-GP
OSNs,O
in,O
5,O
s,O
bins,O
(,O
grey,O
;,O
n,O
=,O
5,O
–,O
6,O
for,O
each,O
OSN,O
).,O
Also,O
shown,O
are,O
one,O
bin,O
before,O
and,O
10,O
bins,O
after,O
stimulation,O
(,O
white,O
).,O
(,O
b,O
),O
Activity,O
(,O
spike,O
count,O
),O
of,O
Or24a,B-GP
and,O
Or74a,B-GP
OSNs,O
before,O
(,O
grey,O
columns,O
),O
and,O
after,O
(,O
black,O
columns,O
),O
exposure,O
to,O
octanol,O
for,O
5,O
min,O
.,O
Activity,O
shown,O
:,O
1,O
s,O
stimulation,O
(‘,O
0,O
"’,",O
horizontal,O
bar,O
"),",O
1,O
s,O
before,O
(‘−,O
1,O
’),O
and,O
after,O
(‘+,O
1,O
’),O
stimulation,O
.,O
Significant,O
differences,O
between,O
before,O
-,O
and,O
after,O
-,O
exposure,O
values,O
for,O
−,O
1,O
",",O
0,O
",",O
and,O
+,O
1,O
are,O
given,O
by,O
asterisks,O
(,O
n,O
=,O
5,O
–,O
6,O
for,O
each,O
group,O
).,O
Four,O
of,O
the,O
six,O
OSN,O
/,O
odour,O
combinations,O
showed,O
a,O
significant,O
change,O
in,O
the,O
mean,O
firing,O
rate,O
over,O
the,O
full,O
5,O
min,O
-,O
exposure,O
period,O
compared,O
with,O
spontaneous,O
activity,O
(,O
p,O
<,O
0,O
.,O
0001,O
",",O
Kruskal,O
–,O
Wallis,O
test,O
with,O
Dunn,O
',O
s,O
post,O
hoc,O
comparison,O
).,O
The,O
two,O
non,O
-,O
significant,O
exceptions,O
were,O
Or24a,B-GP
/,O
2,O
-,O
heptanone,O
and,O
Or74a,B-GP
/,O
propyl,O
acetate,O
(,O
figure,O
4a,O
"),",O
both,O
of,O
which,O
also,O
showed,O
low,O
levels,O
of,O
response,O
to,O
a,O
1,O
s,O
stimulus,O
(,O
figure,O
1,O
).,O
Or24a,B-GP
was,O
strongly,O
inhibited,O
during,O
the,O
first,O
minute,O
of,O
exposure,O
to,O
octanol,O
(,O
0,O
spikes,O
s,O
−,O
1,O
);,O
it,O
then,O
recovered,O
to,O
2,O
spikes,O
s,O
−,O
1,O
but,O
still,O
showed,O
a,O
significant,O
reduction,O
in,O
activity,O
over,O
the,O
5,O
min,O
of,O
stimulation,O
(,O
p,O
<,O
0,O
.,O
0001,O
",",O
Kruskal,O
–,O
Wallis,O
test,O
).,O
The,O
remaining,O
three,O
OSN,O
/,O
odour,O
pairs,O
(,O
Or24a,B-GP
/,O
propyl,O
acetate,O
",",O
Or74a,B-GP
/,O
octanol,O
",",O
and,O
Or74a,B-GP
/,O
2,O
-,O
heptanone,O
),O
showed,O
significant,O
increases,O
in,O
the,O
firing,O
rate,O
for,O
the,O
full,O
5,O
min,O
exposure,O
",",O
with,O
two,O
OSN,O
/,O
odour,O
pairs,O
showing,O
significant,O
declines,O
in,O
the,O
level,O
of,O
activity,O
following,O
the,O
first,O
60,O
s,O
(,O
Or24a,B-GP
/,O
propyl,O
acetate,O
:,O
41,O
spikes,O
s,O
−,O
1,O
at,O
the,O
beginning,O
of,O
odour,O
exposure,O
and,O
only,O
20,O
spikes,O
s,O
−,O
1,O
after,O
60,O
s,O
",",O
p,O
=,O
0,O
.,O
019,O
",",O
Mann,O
–,O
Whitney,O
;,O
Or74a,B-GP
/,O
octanol,O
:,O
35,O
spikes,O
s,O
−,O
1,O
at,O
the,O
beginning,O
and,O
14,O
spikes,O
s,O
−,O
1,O
after,O
60,O
s,O
",",O
p,O
=,O
0,O
.,O
0001,O
",",O
Mann,O
–,O
Whitney,O
).,O
We,O
conclude,O
that,O
these,O
neurons,O
respond,O
continuously,O
during,O
long,O
periods,O
of,O
odour,O
exposure,O
(,O
minutes,O
),O
and,O
do,O
not,O
show,O
complete,O
adaptation,O
.,O
We,O
next,O
explored,O
whether,O
5,O
min,O
exposure,O
to,O
a,O
given,O
odour,O
altered,O
OSN,O
responses,O
to,O
subsequent,O
1,O
s,O
stimulation,O
with,O
that,O
same,O
odour,O
(,O
figure,O
4b,O
).,O
Or24a,B-GP
neurons,O
showed,O
a,O
significant,O
increase,O
in,O
their,O
response,O
to,O
1,O
s,O
propyl,O
acetate,O
following,O
5,O
min,O
exposure,O
to,O
propyl,O
acetate,O
(,O
mean,O
firing,O
rate,O
=,O
38,O
.,O
3,O
±,O
2,O
.,O
4,O
spikes,O
s,O
−,O
1,O
before,O
exposure,O
;,O
52,O
.,O
8,O
±,O
1,O
.,O
1,O
spikes,O
s,O
−,O
1,O
after,O
exposure,O
",",O
Mann,O
–,O
Whitney,O
U,O
-,O
test,O
",",O
p,O
≤,O
0,O
.,O
001,O
).,O
The,O
spontaneous,O
activity,O
of,O
Or24a,B-GP
OSNs,O
was,O
affected,O
by,O
5,O
min,O
exposure,O
to,O
2,O
-,O
heptanone,O
and,O
propyl,O
acetate,O
",",O
as,O
shown,O
by,O
significant,O
reductions,O
in,O
pre,O
-,O
stimulus,O
(‘−,O
1,O
’),O
firing,O
rates,O
following,O
exposure,O
.,O
A,O
small,O
but,O
significant,O
increase,O
in,O
the,O
low,O
level,O
of,O
firing,O
after,O
stimulus,O
offset,O
was,O
seen,O
after,O
exposure,O
to,O
2,O
-,O
heptanone,O
.,O
For,O
Or74a,B-GP
",",O
the,O
only,O
significant,O
change,O
in,O
activity,O
after,O
5,O
min,O
exposure,O
to,O
an,O
odour,O
was,O
seen,O
for,O
octanol,O
",",O
where,O
exposure,O
significantly,O
reduced,O
firing,O
rates,O
during,O
1,O
s,O
stimulation,O
(,O
Mann,O
–,O
Whitney,O
U,O
-,O
test,O
",",O
p,O
=,O
0,O
.,O
004,O
).,O
We,O
next,O
explored,O
the,O
specific,O
effects,O
of,O
octanol,O
on,O
OSN,O
activity,O
by,O
exposing,O
both,O
Or24a,B-GP
and,O
Or74a,B-GP
OSNs,O
to,O
octanol,O
for,O
20,O
min,O
while,O
recording,O
their,O
electrophysiological,O
activity,O
.,O
Both,O
OSN,O
classes,O
maintained,O
the,O
qualitative,O
response,O
they,O
showed,O
during,O
1,O
s,O
stimulation,O
–,O
inhibition,O
(,O
Or24a,B-GP
),O
or,O
significant,O
excitation,O
(,O
Or74a,B-GP
;,O
p,O
=,O
0,O
.,O
002,O
",",O
Kruskal,O
–,O
Wallis,O
test,O
followed,O
by,O
Dunn,O
',O
s,O
post,O
hoc,O
test,O
;,O
figure,O
5a,O
;,O
note,O
different,O
scales,O
on,O
the,O
y,O
-,O
axis,O
).,O
In,O
the,O
seconds,O
after,O
the,O
end,O
of,O
octanol,O
exposure,O
",",O
both,O
classes,O
of,O
neuron,O
returned,O
to,O
pre,O
-,O
exposure,O
spontaneous,O
firing,O
rates,O
.,O
Figure,O
5,O
.,O
Electrophysiological,O
responses,O
during,O
and,O
after,O
20,O
min,O
stimulation,O
with,O
octanol,O
.,O
(,O
a,O
),O
Electrophysiological,O
activity,O
of,O
Or24a,B-GP
and,O
Or74a,B-GP
OSNs,O
during,O
20,O
min,O
stimulation,O
with,O
octanol,O
",",O
in,O
10,O
s,O
bins,O
(,O
grey,O
;,O
n,O
=,O
5,O
for,O
Or24a,B-GP
",",O
n,O
=,O
6,O
for,O
Or74a,B-GP
).,O
Also,O
shown,O
are,O
one,O
bin,O
before,O
and,O
12,O
bins,O
after,O
stimulation,O
(,O
white,O
).,O
Note,O
different,O
y,O
scales,O
.,O
(,O
b,O
),O
Activity,O
of,O
Or24a,B-GP
and,O
Or74a,B-GP
OSNs,O
in,O
response,O
to,O
octanol,O
",",O
2,O
-,O
heptanone,O
",",O
and,O
propyl,O
acetate,O
",",O
before,O
(,O
grey,O
columns,O
),O
and,O
after,O
(,O
black,O
columns,O
),O
exposure,O
to,O
octanol,O
for,O
20,O
min,O
.,O
Activity,O
shown,O
:,O
1,O
s,O
stimulation,O
(‘,O
0,O
"’,",O
horizontal,O
bar,O
"),",O
1,O
s,O
before,O
(‘−,O
1,O
"’),",O
and,O
after,O
(‘+,O
1,O
’),O
stimulation,O
.,O
Significant,O
differences,O
between,O
before,O
-,O
and,O
after,O
-,O
exposure,O
values,O
for,O
−,O
1,O
",",O
0,O
",",O
and,O
+,O
1,O
are,O
given,O
by,O
asterisks,O
(,O
n,O
=,O
5,O
for,O
Or24a,B-GP
",",O
n,O
=,O
6,O
for,O
Or74a,B-GP
).,O
To,O
test,O
for,O
any,O
changes,O
in,O
the,O
responses,O
of,O
the,O
OSNs,O
following,O
the,O
20,O
min,O
period,O
of,O
exposure,O
to,O
octanol,O
",",O
we,O
stimulated,O
larvae,O
with,O
each,O
of,O
the,O
three,O
odours,O
in,O
separate,O
1,O
s,O
stimulation,O
periods,O
(,O
figure,O
5b,O
),O
both,O
before,O
and,O
after,O
octanol,O
exposure,O
.,O
The,O
significant,O
reduction,O
in,O
the,O
Or74a,B-GP
response,O
to,O
octanol,O
that,O
was,O
observed,O
following,O
5,O
min,O
exposure,O
was,O
also,O
seen,O
after,O
20,O
min,O
exposure,O
;,O
indeed,O
",",O
the,O
effect,O
continued,O
into,O
the,O
second,O
after,O
the,O
stimulus,O
offset,O
.,O
Both,O
OSN,O
classes,O
showed,O
significant,O
cross,O
-,O
adaption,O
following,O
20,O
min,O
exposure,O
to,O
octanol,O
:,O
Or24a,B-GP
showed,O
small,O
but,O
significant,O
increases,O
in,O
firing,O
during,O
1,O
s,O
stimulation,O
with,O
2,O
-,O
heptanone,O
and,O
propyl,O
acetate,O
",",O
while,O
Or74a,B-GP
showed,O
significant,O
reductions,O
in,O
the,O
firing,O
rate,O
in,O
response,O
to,O
2,O
-,O
heptanone,O
",",O
during,O
1,O
s,O
stimulation,O
and,O
in,O
the,O
second,O
after,O
the,O
stimulus,O
offset,O
.,O
We,O
used,O
the,O
PSTH,O
classifier,O
to,O
explore,O
the,O
performance,O
of,O
Or74a,B-GP
neurons,O
in,O
a,O
forced,O
three,O
-,O
choice,O
‘,O
discrimination,O
’,O
task,O
(,O
octanol,O
",",O
2,O
-,O
heptanone,O
",",O
propyl,O
acetate,O
),O
following,O
5,O
and,O
20,O
min,O
pre,O
-,O
exposure,O
to,O
octanol,O
.,O
Two,O
-,O
tailed,O
t,O
-,O
tests,O
showed,O
that,O
the,O
discrimination,O
performance,O
of,O
Or74a,B-GP
neurons,O
was,O
not,O
significantly,O
different,O
before,O
and,O
after,O
exposure,O
to,O
octanol,O
for,O
either,O
5,O
or,O
20,O
min,O
(,O
electronic,O
supplementary,O
material,O
",",O
S2,O
).,O
We,O
conclude,O
that,O
any,O
change,O
in,O
response,O
to,O
1,O
s,O
odour,O
stimulation,O
in,O
this,O
class,O
of,O
OSN,O
following,O
octanol,O
exposure,O
does,O
not,O
affect,O
its,O
ability,O
to,O
discriminate,O
the,O
three,O
odours,O
tested,O
",",O
and,O
in,O
particular,O
it,O
did,O
not,O
affect,O
the,O
ability,O
of,O
these,O
OSNs,O
to,O
encode,O
temporal,O
information,O
relating,O
to,O
stimulus,O
identity,O
.,O
Finally,O
",",O
we,O
extended,O
odour,O
exposure,O
time,O
to,O
the,O
upper,O
limit,O
possible,O
in,O
this,O
short,O
-,O
lived,O
stage,O
of,O
the,O
fly,B-OG
',O
s,O
life,O
cycle,O
.,O
We,O
reared,O
Or24a,B-GP
and,O
Or74a,B-GP
larvae,O
in,O
the,O
presence,O
of,O
an,O
octanol,O
odour,O
source,O
for,O
3,O
days,O
",",O
and,O
then,O
measured,O
their,O
electrophysiological,O
responses,O
to,O
a,O
1,O
s,O
stimulus,O
of,O
octanol,O
",",O
2,O
-,O
heptanone,O
",",O
or,O
propyl,O
acetate,O
when,O
compared,O
with,O
age,O
-,O
matched,O
single,O
-,O
functional,O
OSN,O
larvae,O
that,O
had,O
not,O
been,O
exposed,O
to,O
octanol,O
(,O
figure,O
6,O
).,O
The,O
results,O
were,O
similar,O
to,O
those,O
seen,O
after,O
5,O
and,O
20,O
min,O
octanol,O
exposure,O
.,O
There,O
was,O
a,O
significant,O
reduction,O
in,O
the,O
strong,O
response,O
to,O
octanol,O
in,O
Or74a,B-GP
OSNs,O
compared,O
with,O
control,O
",",O
non,O
-,O
exposed,O
",",O
age,O
-,O
matched,O
OSNs,O
",",O
which,O
was,O
seen,O
both,O
in,O
the,O
1,O
s,O
stimulation,O
and,O
in,O
the,O
second,O
following,O
stimulus,O
offset,O
(,O
Mann,O
–,O
Whitney,O
U,O
-,O
test,O
",",O
p,O
=,O
0,O
.,O
009,O
and,O
<,O
0,O
.,O
001,O
",",O
respectively,O
).,O
However,O
",",O
even,O
after,O
3,O
days,O
of,O
exposure,O
",",O
these,O
Or74a,B-GP
OSNs,O
were,O
still,O
showing,O
a,O
firing,O
rate,O
of,O
about,O
60,O
Hz,O
during,O
stimulation,O
.,O
Some,O
cross,O
-,O
adaptation,O
was,O
seen,O
",",O
in,O
the,O
shape,O
of,O
a,O
significant,O
decline,O
in,O
the,O
activity,O
of,O
Or74a,B-GP
OSNs,O
in,O
response,O
to,O
1,O
s,O
stimulation,O
with,O
propyl,O
acetate,O
(,O
Mann,O
–,O
Whitney,O
U,O
-,O
test,O
",",O
p,O
=,O
0,O
.,O
007,O
),O
and,O
a,O
significant,O
decline,O
in,O
the,O
response,O
to,O
2,O
-,O
heptanone,O
in,O
the,O
second,O
after,O
stimulus,O
offset,O
(,O
Mann,O
–,O
Whitney,O
U,O
-,O
test,O
",",O
p,O
=,O
0,O
.,O
043,O
).,O
Although,O
there,O
were,O
significant,O
reductions,O
in,O
the,O
pre,O
-,O
stimulus,O
spontaneous,O
activity,O
of,O
the,O
Or24a,B-GP
OSN,O
",",O
this,O
was,O
only,O
seen,O
with,O
octanol,O
;,O
in,O
all,O
cases,O
",",O
these,O
neurons,O
showed,O
very,O
low,O
spontaneous,O
activity,O
(‘−,O
1,O
’,O
column,O
).,O
In,O
no,O
case,O
was,O
anything,O
approaching,O
full,O
response,O
adaptation,O
seen,O
",",O
indicating,O
that,O
even,O
on,O
this,O
ecologically,O
relevant,O
timescale,O
",",O
the,O
peripheral,O
olfactory,O
code,O
remains,O
intact,O
despite,O
long,O
-,O
term,O
odour,O
exposure,O
.,O
Figure,O
6,O
.,O
Electrophysiological,O
responses,O
to,O
odours,O
after,O
3,O
days,O
exposure,O
to,O
octanol,O
.,O
Activity,O
of,O
Or24a,B-GP
and,O
Or74a,B-GP
OSNs,O
in,O
response,O
to,O
octanol,O
",",O
2,O
-,O
heptanone,O
",",O
and,O
propyl,O
acetate,O
",",O
following,O
exposure,O
to,O
octanol,O
(,O
black,O
columns,O
).,O
Age,O
-,O
matched,O
larvae,O
(,O
grey,O
columns,O
),O
were,O
not,O
exposed,O
to,O
octanol,O
.,O
Activity,O
shown,O
:,O
1,O
s,O
stimulation,O
(‘,O
0,O
"’,",O
horizontal,O
bar,O
"),",O
1,O
s,O
before,O
(‘−,O
1,O
"’),",O
and,O
after,O
(‘+,O
1,O
’),O
stimulation,O
.,O
Significant,O
differences,O
between,O
control,O
and,O
experimental,O
groups,O
are,O
given,O
by,O
asterisks,O
(,O
n,O
(,O
control,O
),O
=,O
10,O
and,O
n,O
(,O
octanol,O
),O
=,O
9,O
for,O
Or24a,B-GP
;,O
n,O
(,O
control,O
),O
=,O
8,O
and,O
n,O
(,O
octanol,O
),O
=,O
11,O
for,O
Or74a,B-GP
).,O
Discussion,O
Our,O
results,O
show,O
that,O
the,O
peripheral,O
olfactory,O
code,O
in,O
Drosophila,B-OG
larvae,O
contains,O
both,O
spike,O
count,O
and,O
temporal,O
information,O
that,O
can,O
be,O
used,O
to,O
identify,O
odours,O
",",O
and,O
that,O
the,O
temporal,O
component,O
increases,O
the,O
speed,O
and,O
accuracy,O
of,O
odour,O
discrimination,O
.,O
Furthermore,O
",",O
we,O
show,O
that,O
the,O
code,O
is,O
robust,O
in,O
response,O
to,O
continuous,O
stimulation,O
with,O
an,O
odour,O
—,O
even,O
over,O
a,O
period,O
of,O
days,O
.,O
It,O
appears,O
that,O
in,O
Drosophila,B-OG
larvae,O
the,O
peripheral,O
olfactory,O
code,O
is,O
based,O
on,O
a,O
combinatorial,O
code,O
consisting,O
of,O
the,O
activity,O
of,O
single,O
OSNs,O
.,O
In,O
the,O
adult,O
fly,B-OG
antenna,O
",",O
OSNs,O
are,O
found,O
in,O
groups,O
of,O
two,O
or,O
three,O
cells,O
",",O
housed,O
in,O
hair,O
-,O
like,O
sensilla,O
;,O
if,O
one,O
OSN,O
shows,O
a,O
sustained,O
response,O
",",O
non,O
-,O
synaptic,O
inhibition,O
can,O
occur,O
in,O
the,O
other,O
neuron,O
[,O
15,O
].,O
We,O
have,O
previously,O
found,O
no,O
evidence,O
for,O
either,O
synaptic,O
or,O
ephaptic,O
interactions,O
between,O
larval,O
OSNs,O
[,O
2,O
].,O
In,O
agreement,O
with,O
previous,O
studies,O
(,O
e,O
.,O
g,O
.,O
[,O
2,O
",",O
12,O
"]),",O
we,O
found,O
that,O
OSN,O
response,O
dynamics,O
is,O
odour,O
-,O
and,O
OR,O
-,O
dependent,O
.,O
Although,O
it,O
is,O
possible,O
that,O
the,O
activity,O
of,O
these,O
genetically,O
manipulated,O
OSNs,O
differ,O
from,O
that,O
of,O
their,O
wild,O
-,O
type,O
equivalents,O
",",O
there,O
is,O
no,O
evidence,O
for,O
this,O
[,O
2,O
].,O
Firing,O
responses,O
were,O
maintained,O
even,O
during,O
long,O
exposure,O
periods,O
(,O
5,O
and,O
20,O
min,O
)—,O
the,O
overall,O
response,O
of,O
an,O
OSN,O
to,O
a,O
given,O
odour,O
did,O
not,O
vary,O
as,O
a,O
function,O
of,O
stimulus,O
duration,O
.,O
Electrophysiological,O
studies,O
of,O
Drosophila,B-OG
olfaction,O
have,O
used,O
0,O
.,O
5,O
or,O
1,O
s,O
odour,O
presentations,O
(,O
e,O
.,O
g,O
.,O
[,O
2,O
",",O
12,O
]).,O
Our,O
findings,O
suggest,O
that,O
in,O
larvae,O
such,O
stimuli,O
yield,O
electrophysiological,O
responses,O
that,O
do,O
not,O
differ,O
qualitatively,O
from,O
those,O
seen,O
over,O
longer,O
",",O
more,O
ecologically,O
relevant,O
timescales,O
.,O
Many,O
OSN,O
responses,O
showed,O
a,O
second,O
peak,O
at,O
or,O
shortly,O
after,O
stimulus,O
offset,O
(,O
figure,O
1,O
);,O
this,O
may,O
represent,O
an,O
‘,O
off,O
’,O
response,O
.,O
The,O
fact,O
that,O
it,O
was,O
seen,O
in,O
both,O
OSNs,O
and,O
for,O
all,O
four,O
odours,O
(,O
though,O
not,O
in,O
all,O
OSN,O
/,O
odour,O
combinations,O
),O
suggests,O
this,O
may,O
be,O
a,O
fundamental,O
feature,O
of,O
odour,O
coding,O
in,O
these,O
neurons,O
.,O
Our,O
classifier,O
analysis,O
of,O
the,O
electrophysiological,O
activity,O
of,O
identified,O
OSNs,O
indicates,O
that,O
the,O
peripheral,O
olfactory,O
code,O
contains,O
not,O
only,O
spike,O
count,O
information,O
but,O
also,O
temporal,O
information,O
—,O
spike,O
pattern,O
—,O
that,O
represents,O
specific,O
aspects,O
of,O
the,O
olfactory,O
stimulus,O
.,O
This,O
reinforces,O
the,O
growing,O
conviction,O
that,O
in,O
a,O
range,O
of,O
organisms,O
peripheral,O
olfactory,O
codes,O
include,O
temporal,O
information,O
[,O
6,O
].,O
The,O
time,O
taken,O
for,O
the,O
classifier,O
to,O
reach,O
an,O
odour,O
identification,O
performance,O
that,O
was,O
close,O
to,O
100,O
%,O
was,O
at,O
most,O
a,O
few,O
100,O
ms,O
;,O
after,O
this,O
time,O
",",O
discrimination,O
capacity,O
remained,O
high,O
.,O
The,O
sliding,O
window,O
analysis,O
suggested,O
that,O
OSN,O
activity,O
contains,O
an,O
odour,O
-,O
specific,O
signature,O
for,O
the,O
entire,O
stimulus,O
duration,O
",",O
and,O
even,O
for,O
some,O
time,O
after,O
stimulus,O
offset,O
.,O
Odour,O
discrimination,O
based,O
on,O
response,O
temporal,O
structure,O
is,O
therefore,O
robust,O
over,O
time,O
.,O
If,O
the,O
larval,O
nervous,O
system,O
fails,O
to,O
identify,O
an,O
odour,O
immediately,O
after,O
stimulus,O
onset,O
",",O
it,O
can,O
still,O
exploit,O
the,O
sustained,O
response,O
to,O
make,O
its,O
choice,O
again,O
",",O
reducing,O
the,O
chance,O
of,O
making,O
mistakes,O
.,O
Temporal,O
coding,O
requires,O
that,O
(,O
i,O
),O
neurons,O
convey,O
stimulus,O
information,O
via,O
spike,O
patterns,O
beyond,O
that,O
available,O
from,O
spike,O
count,O
and,O
(,O
ii,O
),O
differences,O
in,O
spike,O
pattern,O
can,O
modulate,O
an,O
animal,B-OG
',O
s,O
decisions,O
even,O
in,O
the,O
absence,O
of,O
a,O
difference,O
in,O
spike,O
count,O
[,O
16,O
].,O
We,O
suggest,O
that,O
temporal,O
information,O
in,O
the,O
peripheral,O
olfactory,O
code,O
may,O
be,O
exploited,O
by,O
Drosophila,B-OG
larvae,O
to,O
make,O
decisions,O
about,O
behavioural,O
outputs,O
.,O
This,O
has,O
yet,O
to,O
be,O
demonstrated,O
in,O
any,O
animal,B-OG
.,O
Although,O
there,O
were,O
some,O
significant,O
changes,O
in,O
the,O
firing,O
rates,O
of,O
OSNs,O
following,O
prolonged,O
exposure,O
to,O
an,O
odour,O
",",O
in,O
no,O
case,O
did,O
we,O
observe,O
complete,O
adaptation,O
—,O
indeed,O
",",O
in,O
the,O
case,O
of,O
Or24a,B-GP
",",O
5,O
min,O
exposure,O
to,O
propyl,O
acetate,O
significantly,O
increased,O
the,O
response,O
to,O
that,O
odour,O
(,O
figure,O
4b,O
).,O
In,O
general,O
",",O
the,O
responses,O
of,O
these,O
two,O
classes,O
of,O
OSNs,O
were,O
robust,O
",",O
in,O
that,O
they,O
retained,O
much,O
of,O
the,O
spike,O
count,O
and,O
spike,O
pattern,O
responses,O
that,O
characterized,O
the,O
responses,O
of,O
control,O
OSNs,O
.,O
This,O
finding,O
may,O
have,O
its,O
roots,O
in,O
the,O
ecology,O
of,O
this,O
species,O
;,O
Drosophila,B-OG
eggs,O
are,O
deposited,O
on,O
a,O
food,O
source,O
(,O
vegetable,O
matter,O
that,O
is,O
beginning,O
to,O
decay,O
),O
by,O
females,O
",",O
and,O
under,O
laboratory,O
conditions,O
larvae,O
remain,O
on,O
that,O
food,O
source,O
",",O
continually,O
bathed,O
in,O
food,O
odours,O
.,O
In,O
adult,O
flies,B-OG
",",O
continuous,O
early,O
exposure,O
to,O
odours,O
causes,O
significant,O
plasticity,O
in,O
both,O
peripheral,O
and,O
central,O
structures,O
",",O
perhaps,O
indicating,O
a,O
role,O
for,O
experience,O
in,O
the,O
peripheral,O
code,O
in,O
this,O
species,O
[,O
17,O
].,O
Such,O
effects,O
may,O
occur,O
in,O
larvae,O
",",O
although,O
testing,O
this,O
hypothesis,O
would,O
be,O
challenging,O
because,O
rearing,O
larvae,O
requires,O
continuous,O
exposure,O
to,O
food,O
and,O
its,O
accompanying,O
odours,O
.,O
Significant,O
examples,O
of,O
cross,O
-,O
adaptation,O
were,O
seen,O
for,O
both,O
OSN,O
classes,O
following,O
exposure,O
to,O
octanol,O
for,O
20,O
min,O
(,O
figure,O
5b,O
).,O
The,O
two,O
stimuli,O
involved,O
—,O
octanol,O
and,O
2,O
-,O
heptanone,O
—,O
must,O
share,O
some,O
characteristic,O
that,O
is,O
not,O
present,O
in,O
propyl,O
acetate,O
(,O
for,O
which,O
no,O
cross,O
-,O
adaptation,O
was,O
found,O
"),",O
and,O
which,O
is,O
responsible,O
for,O
such,O
effects,O
.,O
Further,O
interpretation,O
is,O
difficult,O
because,O
the,O
way,O
that,O
odours,O
bind,O
to,O
the,O
receptor,O
molecule,O
is,O
not,O
known,O
",",O
nor,O
do,O
we,O
fully,O
understand,O
the,O
biochemistry,O
of,O
olfactory,B-GP
receptor,I-GP
function,O
.,O
The,O
ability,O
of,O
larvae,O
to,O
largely,O
maintain,O
their,O
OSN,O
responses,O
despite,O
long,O
-,O
term,O
exposure,O
suggests,O
that,O
there,O
must,O
be,O
substantial,O
enzymatic,O
activity,O
in,O
and,O
around,O
the,O
larval,O
OSN,O
membrane,O
.,O
Putative,O
odorant,O
degrading,O
enzymes,O
have,O
been,O
found,O
in,O
adult,O
Drosophila,B-OG
[,O
18,O
];,O
the,O
role,O
of,O
such,O
enzymes,O
has,O
not,O
yet,O
been,O
studied,O
in,O
larvae,O
.,O
We,O
conclude,O
that,O
",",O
at,O
both,O
experimental,O
and,O
ecologically,O
relevant,O
timescales,O
",",O
the,O
peripheral,O
olfactory,O
code,O
in,O
Drosophila,B-OG
larvae,O
contains,O
temporal,O
information,O
.,O
The,O
code,O
is,O
robust,O
in,O
that,O
the,O
structure,O
of,O
odour,O
-,O
specific,O
OSN,O
responses,O
is,O
largely,O
retained,O
irrespective,O
of,O
experience,O
.,O
The,O
next,O
challenge,O
will,O
be,O
to,O
demonstrate,O
the,O
behavioural,O
significance,O
of,O
temporal,O
information,O
in,O
the,O
peripheral,O
code,O
.,O
Supplementary,O
Material,O
Supplementary,O
electronic,O
information,O
Prediction,O
of,O
cassava,B-OG
protein,O
interactome,O
based,O
on,O
interolog,O
method,O
Cassava,B-OG
is,O
a,O
starchy,O
root,O
crop,O
whose,O
role,O
in,O
food,O
security,O
becomes,O
more,O
significant,O
nowadays,O
.,O
Together,O
with,O
the,O
industrial,O
uses,O
for,O
versatile,O
purposes,O
",",O
demand,O
for,O
cassava,B-OG
starch,O
is,O
continuously,O
growing,O
.,O
However,O
",",O
in,O
-,O
depth,O
study,O
to,O
uncover,O
the,O
mystery,O
of,O
cellular,O
regulation,O
",",O
especially,O
the,O
interaction,O
between,O
proteins,O
",",O
is,O
lacking,O
.,O
To,O
reduce,O
the,O
knowledge,O
gap,O
in,O
protein,O
-,O
protein,O
interaction,O
(,O
PPI,O
"),",O
genome,O
-,O
scale,O
PPI,O
network,O
of,O
cassava,B-OG
was,O
constructed,O
using,O
interolog,O
-,O
based,O
method,O
(,O
MePPI,O
-,O
In,O
",",O
available,O
at,O
http,O
://,O
bml,O
.,O
sbi,O
.,O
kmutt,O
.,O
ac,O
.,O
th,O
/,O
ppi,O
).,O
The,O
network,O
was,O
constructed,O
from,O
the,O
information,O
of,O
seven,O
template,O
plants,B-OG
.,O
The,O
MePPI,O
-,O
In,O
included,O
90,O
",",O
173,O
interactions,O
from,O
7,O
",",O
209,O
proteins,O
.,O
At,O
least,O
",",O
39,O
percent,O
of,O
the,O
total,O
predictions,O
were,O
found,O
with,O
supports,O
from,O
gene,O
/,O
protein,O
expression,O
data,O
",",O
while,O
further,O
co,O
-,O
expression,O
analysis,O
yielded,O
16,O
highly,O
promising,O
PPIs,O
.,O
In,O
addition,O
",",O
domain,O
-,O
domain,O
interaction,O
information,O
was,O
employed,O
to,O
increase,O
reliability,O
of,O
the,O
network,O
and,O
guide,O
the,O
search,O
for,O
more,O
groups,O
of,O
promising,O
PPIs,O
.,O
Moreover,O
",",O
the,O
topology,O
and,O
functional,O
content,O
of,O
MePPI,O
-,O
In,O
was,O
similar,O
to,O
the,O
networks,O
of,O
Arabidopsis,B-OG
and,O
rice,B-OG
.,O
The,O
potential,O
contribution,O
of,O
MePPI,O
-,O
In,O
for,O
various,O
applications,O
",",O
such,O
as,O
protein,O
-,O
complex,O
formation,O
and,O
prediction,O
of,O
protein,O
function,O
",",O
was,O
discussed,O
and,O
exemplified,O
.,O
The,O
insights,O
provided,O
by,O
our,O
MePPI,O
-,O
In,O
would,O
hopefully,O
enable,O
us,O
to,O
pursue,O
precise,O
trait,O
improvement,O
in,O
cassava,B-OG
.,O
Introduction,O
Proteins,O
are,O
macromolecules,O
that,O
play,O
crucial,O
roles,O
in,O
a,O
range,O
of,O
biological,O
processes,O
in,O
cells,O
.,O
They,O
do,O
not,O
only,O
act,O
as,O
catalysts,O
but,O
are,O
also,O
involved,O
in,O
intracellular,O
regulatory,O
processes,O
",",O
e,O
.,O
g,O
.,O
signal,O
transduction,O
and,O
transcriptional,O
regulation1,O
.,O
Although,O
specific,O
function,O
is,O
assigned,O
to,O
each,O
protein,O
",",O
too,O
often,O
",",O
we,O
see,O
that,O
the,O
protein,O
remains,O
inactive,O
in,O
the,O
cellular,O
matrix,O
.,O
This,O
is,O
because,O
the,O
protein,O
needs,O
to,O
go,O
through,O
some,O
modification,O
processes,O
",",O
such,O
as,O
protein,O
dimerization,O
and,O
complex,O
formation,O
via,O
protein,O
binding,O
.,O
Cooperation,O
between,O
proteins,O
",",O
called,O
protein,O
-,O
protein,O
interaction,O
(,O
PPI,O
"),",O
allows,O
cells,O
to,O
dynamically,O
modulate,O
when,O
proteins,O
and,O
their,O
counterparts,O
are,O
turned,O
on,O
to,O
play,O
roles,O
in,O
particular,O
cellular,O
processes,O
.,O
Since,O
these,O
interactions,O
are,O
highly,O
dependent,O
on,O
prevailing,O
conditions,O
of,O
exposure,O
",",O
the,O
PPI,O
is,O
considered,O
a,O
type,O
of,O
biological,O
language,O
utilized,O
to,O
synchronize,O
cellular,O
regulation,O
",",O
especially,O
at,O
post,O
-,O
translational,O
level,O
.,O
Due,O
to,O
the,O
immense,O
impact,O
of,O
PPIs,O
on,O
the,O
regulation,O
of,O
cellular,O
processes,O
",",O
great,O
attempts,O
have,O
been,O
devoted,O
to,O
capture,O
the,O
interactions,O
between,O
proteins,O
as,O
well,O
as,O
investigate,O
their,O
consequences,O
.,O
Earlier,O
",",O
availability,O
of,O
experimental,O
techniques,O
",",O
such,O
as,O
affinity,O
chromatography,O
",",O
immunoprecipitation,O
and,O
chemical,O
crosslinking,O
",",O
only,O
allowed,O
for,O
investigation,O
of,O
interaction,O
of,O
one,O
",",O
or,O
maximally,O
",",O
a,O
few,O
protein,O
pair,O
at,O
once2,O
.,O
Nowadays,O
",",O
large,O
-,O
scale,O
detection,O
of,O
PPIs,O
at,O
genome,O
-,O
wide,O
level,O
has,O
been,O
made,O
possible,O
through,O
yeast,B-OG
two,O
-,O
hybrid,O
(,O
Y2H,O
"),",O
or,O
affinity,O
purification,O
coupled,O
with,O
mass,O
spectrometry,O
(,O
AP,O
-,O
MS,O
),O
3,O
–,O
5,O
.,O
With,O
these,O
techniques,O
",",O
however,O
",",O
it,O
still,O
seems,O
impossible,O
to,O
acquire,O
knowledge,O
in,O
protein,O
science,O
at,O
the,O
rate,O
that,O
is,O
fast,O
enough,O
to,O
catch,O
up,O
with,O
the,O
big,O
data,O
currently,O
available,O
in,O
post,O
-,O
genomic,O
era,O
.,O
Computational,O
inference,O
technique,O
is,O
an,O
alternative,O
method,O
that,O
can,O
be,O
used,O
to,O
identify,O
the,O
interactions,O
between,O
proteins,O
.,O
This,O
technique,O
is,O
based,O
on,O
the,O
hypothesis,O
that,O
the,O
function,O
of,O
proteins,O
",",O
and,O
also,O
the,O
interaction,O
among,O
them,O
are,O
conserved,O
across,O
their,O
evolutionary,O
lineage,O
.,O
By,O
incorporating,O
various,O
types,O
of,O
data,O
",",O
such,O
as,O
amino,O
acid,O
sequences,O
",",O
functional,O
domains,O
",",O
folding,O
structure,O
and,O
co,O
-,O
evolution,O
of,O
interacting,O
sites,O
",",O
successes,O
in,O
PPI,O
conjecture,O
in,O
a,O
wide,O
range,O
of,O
organisms,O
have,O
been,O
reported6,O
–,O
9,O
.,O
The,O
information,O
acquired,O
from,O
PPI,O
prediction,O
has,O
helped,O
expand,O
the,O
understanding,O
of,O
the,O
regulation,O
at,O
protein,O
level,O
",",O
such,O
as,O
PPI,O
-,O
based,O
mechanism,O
of,O
signal,O
transduction,O
process,O
",",O
and,O
molecular,O
interaction,O
underlying,O
host,O
-,O
pathogen,O
relationship10,O
–,O
12,O
.,O
Recently,O
",",O
in,O
an,O
effort,O
to,O
move,O
beyond,O
the,O
available,O
PPI,O
data,O
",",O
sophisticated,O
computational,O
methods,O
",",O
such,O
as,O
machine,O
learning13,O
",",O
14,O
",",O
Bayesian,O
network15,O
",",O
16,O
",",O
physical,O
docking17,O
and,O
correlated,O
mutation18,O
",",O
have,O
been,O
introduced,O
.,O
To,O
approach,O
genome,O
-,O
wide,O
prediction,O
",",O
machine,O
learning,O
based,O
methods,O
are,O
of,O
wide,O
interest,O
.,O
Series,O
of,O
effective,O
algorithms,O
have,O
continuously,O
been,O
developed,O
in,O
an,O
attempt,O
to,O
incorporate,O
multiple,O
genomic,O
/,O
proteomic,O
features,O
into,O
a,O
framework,O
of,O
PPI,O
prediction19,O
–,O
22,O
.,O
These,O
algorithmic,O
methods,O
predict,O
PPI,O
from,O
amino,O
acid,O
sequences,O
and,O
their,O
collective,O
information,O
",",O
for,O
instance,O
evolutionary,O
background,O
.,O
Some,O
examples,O
include,O
support,O
vector,O
machine,O
(,O
SVM,O
),O
13,O
",",O
14,O
",",O
23,O
",",O
rotation,O
forest,O
and,O
decision,O
tree24,O
",",O
25,O
",",O
Bayesian,O
classification15,O
",",O
16,O
",",O
Naïve,O
Bayes26,O
",",O
relevance,O
vector,O
machine,O
(,O
RVM,O
),O
27,O
",",O
28,O
and,O
weighted,O
sparse,O
representation,O
(,O
WSRC,O
),O
29,O
",",O
30,O
.,O
These,O
computational,O
algorithms,O
have,O
contributed,O
immensely,O
to,O
the,O
study,O
of,O
PPI,O
in,O
a,O
broad,O
range,O
of,O
organisms,O
",",O
from,O
bacteria16,B-OG
to,O
humans31,B-OG
.,O
Nonetheless,O
",",O
the,O
performance,O
of,O
the,O
machine,O
learning,O
based,O
-,O
methods,O
depends,O
enormously,O
on,O
the,O
numbers,O
and,O
quality,O
of,O
the,O
employed,O
data,O
",",O
especially,O
the,O
model,O
-,O
training,O
information,O
which,O
are,O
in,O
general,O
related,O
to,O
experimentally,O
measured,O
data,O
.,O
Application,O
of,O
such,O
methods,O
in,O
non,O
-,O
model,O
organisms,O
",",O
which,O
always,O
lack,O
data,O
",",O
are,O
quite,O
challenging,O
.,O
To,O
closely,O
investigate,O
the,O
interaction,O
of,O
a,O
protein,O
set,O
",",O
computational,O
methods,O
that,O
include,O
information,O
on,O
protein,O
structure,O
into,O
prediction,O
regime,O
",",O
such,O
as,O
Struct2Net32,O
and,O
physical,O
docking17,O
are,O
proposed,O
.,O
In,O
plants,B-OG
",",O
earlier,O
studies,O
of,O
PPI,O
were,O
limited,O
to,O
only,O
a,O
few,O
species,O
.,O
The,O
current,O
PPI,O
information,O
of,O
plants,B-OG
",",O
especially,O
cassava,B-OG
",",O
has,O
constrained,O
choices,O
of,O
predictive,O
methods,O
.,O
Not,O
only,O
the,O
number,O
of,O
data,O
is,O
small,O
",",O
but,O
only,O
few,O
experimental,O
evidences,O
are,O
available,O
.,O
The,O
computational,O
prediction,O
methods,O
such,O
as,O
classification,O
",",O
machine,O
learning,O
and,O
statistical,O
inference,O
were,O
considered,O
not,O
suitable,O
",",O
and,O
sometimes,O
not,O
applicable,O
",",O
for,O
the,O
status,O
of,O
data,O
resource,O
.,O
A,O
simple,O
computational,O
technique,O
called,O
interolog,O
",",O
which,O
relies,O
on,O
existing,O
data,O
",",O
is,O
often,O
adopted,O
for,O
PPI,O
prediction,O
under,O
this,O
restriction,O
.,O
The,O
interolog,O
method,O
is,O
inspired,O
by,O
the,O
hypothesis,O
that,O
the,O
function,O
of,O
protein,O
is,O
retained,O
and,O
passed,O
through,O
their,O
orthologs,O
in,O
evolution,O
-,O
related,O
organisms,O
.,O
The,O
method,O
",",O
basically,O
",",O
infers,O
PPI,O
information,O
from,O
other,O
well,O
-,O
studied,O
species,O
by,O
orthology,O
-,O
based,O
deduction,O
.,O
Most,O
of,O
PPI,O
networks,O
in,O
plants,B-OG
were,O
basically,O
developed,O
based,O
on,O
the,O
interolog,O
method,O
",",O
for,O
example,O
Arabidopsis6,O
",",O
rice33,O
and,O
tomato34,O
.,O
The,O
first,O
plant,B-OG
PPI,O
network,O
constructed,O
by,O
interolog,O
-,O
based,O
method,O
was,O
reported,O
in,O
2007,O
",",O
describing,O
19,O
",",O
979,O
interactions,O
of,O
3,O
",",O
617,O
Arabidopsis,B-OG
proteins35,O
.,O
Since,O
the,O
first,O
publication,O
was,O
released,O
",",O
accuracy,O
of,O
the,O
interolog,O
-,O
based,O
PPI,O
network,O
has,O
greatly,O
been,O
improved,O
by,O
integrating,O
various,O
sources,O
of,O
information,O
",",O
from,O
both,O
predictive,O
studies,O
and,O
experimental,O
measurements36,O
–,O
38,O
.,O
Presently,O
",",O
the,O
PPI,O
research,O
of,O
plant,B-OG
species,O
has,O
been,O
expanded,O
from,O
model,O
plants,B-OG
",",O
e,O
.,O
g,O
.,O
Arabidopsis6,O
",",O
35,O
–,O
39,O
and,O
rice9,O
",",O
33,O
",",O
40,O
",",O
to,O
economic,O
crops,O
",",O
e,O
.,O
g,O
tomato34,O
",",O
maize41,O
and,O
sweet,B-OG
orange42,I-OG
.,O
The,O
previous,O
research,O
works,O
are,O
the,O
good,O
evidences,O
of,O
the,O
appropriateness,O
of,O
such,O
method,O
for,O
PPI,O
inference,O
in,O
plants,B-OG
.,O
Cassava,B-OG
(,O
Manihot,B-OG
esculenta,I-OG
Crantz,O
),O
is,O
an,O
important,O
crop,O
of,O
the,O
world,O
",",O
since,O
its,O
roots,O
feed,O
at,O
least,O
800,O
million,O
people43,O
.,O
Cassava,B-OG
yield,O
improvement,O
is,O
thus,O
",",O
a,O
major,O
research,O
topic,O
ultimately,O
aiming,O
to,O
guarantee,O
food,O
sufficiency,O
for,O
growing,O
population,O
.,O
To,O
date,O
",",O
the,O
advent,O
of,O
high,O
-,O
throughput,O
technology,O
has,O
improved,O
our,O
understanding,O
of,O
various,O
aspects,O
of,O
cassava,B-OG
",",O
especially,O
root,O
development44,O
",",O
45,O
and,O
starch,O
biosynthesis46,O
–,O
48,O
.,O
However,O
",",O
the,O
information,O
at,O
protein,O
level,O
",",O
which,O
drives,O
the,O
physiology,O
of,O
cassava,B-OG
",",O
is,O
still,O
a,O
mystery,O
.,O
Several,O
reports,O
on,O
protein,O
expression,O
exist,O
under,O
the,O
conditions,O
of,O
interest49,O
–,O
59,O
",",O
but,O
they,O
do,O
not,O
provide,O
further,O
information,O
on,O
PPIs,O
that,O
might,O
relate,O
to,O
post,O
-,O
translational,O
or,O
protein,O
-,O
level,O
regulation,O
.,O
Here,O
",",O
by,O
employing,O
interolog,O
approach,O
",",O
we,O
propose,O
the,O
first,O
genome,O
-,O
scale,O
protein,O
-,O
protein,O
interaction,O
network,O
of,O
cassava,B-OG
(,O
MePPI,O
-,O
In,O
"),",O
using,O
available,O
PPI,O
data,O
and,O
information,O
from,O
a,O
variety,O
of,O
plant,B-OG
species,O
.,O
Our,O
MePPI,O
-,O
In,O
contains,O
90,O
",",O
173,O
interactions,O
interconnecting,O
7,O
",",O
209,O
cassava,B-OG
proteins,O
(,O
approximately,O
21,O
percent,O
of,O
all,O
proteins,O
in,O
the,O
whole,O
genome,O
).,O
These,O
interactions,O
were,O
partially,O
supported,O
by,O
protein,O
/,O
gene,O
expression,O
and,O
domain,O
-,O
domain,O
interaction,O
data,O
.,O
The,O
resulting,O
PPI,O
network,O
provided,O
the,O
landscape,O
of,O
possible,O
interactions,O
that,O
might,O
help,O
fill,O
the,O
knowledge,O
-,O
gap,O
on,O
post,O
-,O
translational,O
regulation,O
in,O
cassava,B-OG
as,O
exemplified,O
in,O
the,O
last,O
section,O
.,O
Methods,O
Construction,O
of,O
cassava,B-OG
PPI,O
network,O
using,O
interolog,O
-,O
based,O
method,O
The,O
interolog,O
method,O
is,O
generally,O
based,O
on,O
the,O
inference,O
of,O
PPI,O
information,O
known,O
to,O
exist,O
in,O
other,O
organisms,O
.,O
In,O
this,O
study,O
",",O
plant,B-OG
species,O
",",O
whose,O
PPI,O
information,O
was,O
employed,O
for,O
inference,O
",",O
were,O
selected,O
based,O
on,O
one,O
of,O
these,O
criteria,O
;,O
(,O
1,O
),O
having,O
a,O
closed,O
evolution,O
with,O
cassava,B-OG
(,O
i,O
.,O
e,O
.,O
Ricinus,B-OG
communis,I-OG
(,O
castor,B-OG
bean,I-OG
"),",O
Populus,B-OG
trichocarpa,I-OG
(,O
poplar,B-OG
),O
and,O
Glycine,B-OG
max,I-OG
(,O
soybean,B-OG
")),",O
(,O
2,O
),O
being,O
recognized,O
as,O
a,O
starch,O
-,O
storing,O
plant,B-OG
(,O
i,O
.,O
e,O
.,O
Solanum,B-OG
tuberosum,I-OG
(,O
potato,B-OG
"),",O
Zea,B-OG
mays,I-OG
(,O
maize,B-OG
),O
and,O
Oryza,B-OG
sativa,I-OG
(,O
rice,B-OG
")),",O
or,O
(,O
3,O
),O
having,O
abundant,O
PPI,O
information,O
(,O
i,O
.,O
e,O
.,O
Arabidopsis,B-OG
thaliana,I-OG
).,O
The,O
protein,O
information,O
of,O
these,O
template,O
plants,B-OG
was,O
obtained,O
from,O
Phytozome,O
V960,O
and,O
Uniprot61,O
databases,O
",",O
and,O
the,O
protein,O
interaction,O
information,O
was,O
collected,O
from,O
seven,O
databases,O
;,O
IntAct62,O
",",O
MINT63,O
",",O
AtPIN36,O
",",O
AtPID37,O
",",O
PAIR38,O
",",O
APID39,O
",",O
and,O
PRIN9,O
(,O
Fig,O
.,O
1a,O
).,O
To,O
find,O
protein,O
orthologs,O
in,O
cassava,B-OG
",",O
we,O
performed,O
BLASTp,O
search,O
against,O
the,O
cassava,B-OG
genome,O
sequence,O
.,O
The,O
cassava,B-OG
orthologous,O
proteins,O
were,O
identified,O
if,O
the,O
identity,O
percentage,O
≥,O
60,O
",",O
coverage,O
percentage,O
≥,O
80,O
and,O
e,O
-,O
value,O
≤,O
10,O
−,O
10,O
.,O
To,O
be,O
able,O
to,O
infer,O
interaction,O
that,O
originally,O
exists,O
in,O
one,O
of,O
the,O
plant,B-OG
templates,O
to,O
cassava,B-OG
",",O
orthologous,O
proteins,O
interconnected,O
by,O
such,O
interaction,O
must,O
be,O
identified,O
in,O
cassava,B-OG
.,O
The,O
cassava,B-OG
PPI,O
network,O
",",O
MePPI,O
-,O
In,O
",",O
was,O
then,O
visualized,O
using,O
Cytoscape,O
software64,O
.,O
Figure,O
1Overall,O
methodology,O
of,O
PPI,O
prediction,O
in,O
cassava,B-OG
consisting,O
of,O
three,O
parts,O
:,O
(,O
a,O
),O
Construction,O
of,O
protein,O
-,O
protein,O
interaction,O
network,O
of,O
cassava,B-OG
using,O
interolog,O
-,O
based,O
approach,O
(,O
MePPI,O
-,O
In,O
"),",O
(,O
b,O
),O
Validation,O
of,O
the,O
PPIs,O
proposed,O
in,O
MePPI,O
-,O
In,O
using,O
protein,O
/,O
gene,O
expression,O
or,O
domain,O
-,O
domain,O
interaction,O
(,O
DDI,O
),O
evidence,O
",",O
and,O
(,O
c,O
),O
Characterization,O
of,O
MePPI,O
-,O
In,O
based,O
on,O
three,O
aspects,O
–,O
network,O
topology,O
",",O
functional,O
contents,O
and,O
biological,O
inference,O
.,O
Validation,O
of,O
MePPI,O
-,O
In,O
based,O
on,O
expression,O
data,O
Protein,O
and,O
gene,O
expression,O
data,O
were,O
exploited,O
in,O
this,O
prediction,O
framework,O
to,O
directly,O
indicate,O
if,O
the,O
proteins,O
",",O
or,O
products,O
of,O
genes,O
",",O
exist,O
in,O
real,O
cassava,B-OG
system,O
.,O
Afterwards,O
",",O
the,O
proteins,O
were,O
considered,O
available,O
for,O
the,O
interactions,O
among,O
them,O
to,O
occur,O
.,O
To,O
perform,O
this,O
",",O
we,O
utilized,O
seven,O
sets,O
of,O
protein,O
expression,O
data,O
(,O
Li,O
et,O
al,O
.,O
50,O
",",O
Mitprasat,O
et,O
al,O
.,O
51,O
",",O
Naconsie,O
et,O
al,O
.,O
52,O
",",O
Otiwi,O
et,O
al,O
.,O
53,O
",",O
Sheffield,O
et,O
al,O
.,O
56,O
",",O
Vanderschuren,O
et,O
al,O
.,O
57,O
and,O
Zhao,O
et,O
al,O
.,O
59,O
"),",O
and,O
four,O
sets,O
of,O
gene,O
expression,O
data,O
(,O
Yang,O
et,O
al,O
.,O
45,O
",",O
Li,O
et,O
al,O
.,O
65,O
",",O
An,O
et,O
al,O
.,O
66,O
and,O
Utsumi,O
et,O
al,O
.,O
67,O
).,O
For,O
the,O
gene,O
expression,O
data,O
",",O
it,O
is,O
important,O
to,O
note,O
that,O
only,O
highly,O
expressed,O
genes,O
that,O
showed,O
expression,O
level,O
above,O
the,O
80th,O
percentile,O
rank,O
were,O
used,O
.,O
In,O
MePPI,O
-,O
In,O
",",O
the,O
nodes,O
(,O
proteins,O
),O
were,O
highlighted,O
as,O
blue,O
color,O
",",O
if,O
their,O
expression,O
information,O
was,O
available,O
",",O
as,O
shown,O
in,O
Fig,O
.,O
2,O
.,O
Figure,O
2Cassava,O
protein,O
-,O
protein,O
interaction,O
network,O
(,O
MePPI,O
-,O
In,O
),O
derived,O
by,O
the,O
interolog,O
-,O
based,O
method,O
.,O
The,O
network,O
contained,O
90,O
",",O
173,O
interactions,O
(,O
edges,O
),O
interconnecting,O
7,O
",",O
209,O
proteins,O
(,O
nodes,O
).,O
Different,O
colors,O
were,O
given,O
to,O
both,O
edges,O
and,O
nodes,O
.,O
The,O
black,O
edges,O
represent,O
PPIs,O
with,O
DDI,O
or,O
co,O
-,O
expression,O
support,O
",",O
while,O
the,O
grey,O
ones,O
represent,O
those,O
with,O
no,O
supporting,O
data,O
.,O
Blue,O
color,O
nodes,O
represent,O
proteins,O
with,O
supporting,O
expression,O
data45,O
",",O
50,O
–,O
53,O
",",O
56,O
",",O
57,O
",",O
59,O
",",O
65,O
–,O
67,O
",",O
while,O
the,O
orange,O
ones,O
have,O
no,O
expression,O
support,O
.,O
(,O
All,O
information,O
is,O
publicly,O
available,O
at,O
http,O
://,O
bml,O
.,O
sbi,O
.,O
kmutt,O
.,O
ac,O
.,O
th,O
/,O
ppi,O
).,O
From,O
eleven,O
datasets,O
mentioned,O
above,O
",",O
only,O
the,O
time,O
-,O
series,O
datasets,O
of,O
Naconsie,O
et,O
al,O
.,O
52,O
",",O
Yang,O
et,O
al,O
.,O
45,O
",",O
Li,O
et,O
al,O
.,O
65,O
and,O
An,O
et,O
al,O
.,O
66,O
were,O
employed,O
to,O
investigate,O
the,O
correlation,O
of,O
the,O
expression,O
profiles,O
for,O
interacting,O
protein,O
pair,O
.,O
This,O
was,O
based,O
on,O
the,O
hypothesis,O
that,O
the,O
genes,O
/,O
proteins,O
with,O
co,O
-,O
expression,O
profile,O
would,O
have,O
greater,O
probability,O
to,O
interact,O
than,O
uncorrelated,O
ones,O
.,O
Herein,O
",",O
the,O
expression,O
profiles,O
of,O
the,O
highly,O
expressed,O
genes,O
were,O
determined,O
based,O
on,O
Pearson,O
’,O
s,O
correlation,O
(,O
Pearson,O
correlation,O
coefficient,O
score,O
(,O
PCC,O
)),O
68,O
",",O
and,O
co,O
-,O
expression,O
of,O
a,O
protein,O
pair,O
in,O
MePPI,O
-,O
In,O
was,O
suggested,O
at,O
PCC,O
>,O
0,O
.,O
9,O
and,O
p,O
-,O
value,O
<,O
0,O
.,O
1,O
.,O
Validation,O
of,O
MePPI,O
-,O
In,O
based,O
on,O
domain,O
-,O
domain,O
interaction,O
(,O
DDI,O
),O
data,O
Since,O
proteins,O
always,O
interact,O
via,O
specific,O
domains,O
",",O
the,O
reliability,O
of,O
predicted,O
PPIs,O
could,O
be,O
determined,O
using,O
information,O
on,O
domain,O
-,O
domain,O
interaction,O
(,O
DDI,O
).,O
In,O
this,O
work,O
",",O
the,O
domain,O
information,O
of,O
all,O
proteins,O
in,O
the,O
cassava,B-OG
PPI,O
network,O
was,O
obtained,O
from,O
Pfam,O
database69,O
and,O
the,O
interactions,O
between,O
protein,O
domains,O
were,O
collected,O
from,O
iPfam,O
database70,O
(,O
Fig,O
.,O
1b,O
).,O
From,O
the,O
original,O
MePPI,O
-,O
In,O
",",O
different,O
colors,O
were,O
given,O
to,O
the,O
interactions,O
(,O
edges,O
),O
with,O
or,O
without,O
supporting,O
DDI,O
information,O
as,O
shown,O
in,O
Fig,O
.,O
2,O
.,O
Scoring,O
the,O
confidence,O
of,O
the,O
MePPI,O
-,O
In,O
The,O
confidence,O
of,O
predicted,O
PPIs,O
in,O
MePPI,O
-,O
In,O
was,O
determined,O
based,O
on,O
the,O
consistency,O
of,O
the,O
results,O
inferred,O
by,O
two,O
methods,O
:,O
interolog,O
and,O
domain,O
-,O
domain,O
interaction,O
analyses,O
.,O
Each,O
predicted,O
interaction,O
was,O
given,O
the,O
level,O
of,O
confidence,O
",",O
in,O
terms,O
of,O
confidence,O
value,O
(,O
CV,O
).,O
The,O
confidence,O
value,O
(,O
CV,O
),O
score,O
was,O
defined,O
as,O
a,O
product,O
of,O
the,O
confidence,O
values,O
from,O
interolog,O
(,O
CV,O
interolog,O
),O
and,O
DDI,O
(,O
CV,O
DDI,O
),O
(,O
Equation,O
1,O
).,O
Since,O
our,O
interolog,O
-,O
based,O
PPI,O
prediction,O
was,O
derived,O
from,O
the,O
evidence,O
in,O
plant,B-OG
templates,O
",",O
the,O
CV,O
interolog,O
was,O
formulated,O
to,O
represent,O
the,O
confidence,O
of,O
the,O
prediction,O
",",O
based,O
upon,O
the,O
number,O
of,O
species,O
from,O
which,O
the,O
interaction,O
was,O
inferred,O
.,O
Additionally,O
",",O
this,O
score,O
was,O
also,O
weighted,O
by,O
the,O
method,O
employed,O
to,O
identify,O
the,O
interactions,O
in,O
the,O
source,O
organism,O
",",O
computational,O
prediction,O
or,O
experimental,O
measurements,O
(,O
Equation,O
2,O
).,O
The,O
CV,O
DDI,O
indicated,O
the,O
confidence,O
of,O
prediction,O
based,O
on,O
domain,O
-,O
domain,O
interactions,O
",",O
in,O
which,O
the,O
number,O
of,O
interacting,O
domains,O
between,O
a,O
predicted,O
protein,O
pair,O
was,O
taken,O
into,O
account,O
(,O
Equation,O
3,O
).,O
The,O
formulas,O
were,O
as,O
follows,O
:,O
1,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
}$$,O
CV,O
=,O
C,O
{,O
V,O
},O
_,O
{,O
interolog,O
}\,O
times,O
C,O
{,O
V,O
},O
_,O
{,O
DDI,O
}$$\,O
end,O
{,O
document,O
},O
CV,O
=,O
CVinterolog,O
×,O
CVDDI,O
2,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
}$$,O
C,O
{,O
V,O
},O
_,O
{,O
interolog,O
}=\,O
frac,O
{{\,O
sum,O
},O
_,O
{,O
i,O
=,O
1,O
}^{,O
N,O
}{,O
S,O
},O
_,O
{,O
i,O
}{,O
M,O
},O
_,O
{,O
i,O
}}{,O
N,O
}$$\,O
end,O
{,O
document,O
},O
CVinterolog,O
=∑,O
i,O
=,O
1NSiMiN,O
3,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
}$$,O
C,O
{,O
V,O
},O
_,O
{,O
DDI,O
}=,O
dD,O
$$\,O
end,O
{,O
document,O
},O
CVDDI,O
=,O
dDwhere,O
S,O
∈,O
{,O
0,O
",",O
1,O
},O
is,O
the,O
existence,O
factor,O
",",O
indicating,O
the,O
presence,O
of,O
an,O
orthologous,O
protein,O
pair,O
in,O
cassava,B-OG
genome,O
.,O
In,O
this,O
study,O
",",O
S,O
is,O
always,O
equal,O
to,O
1,O
because,O
orthologous,O
protein,O
pairs,O
need,O
to,O
be,O
identified,O
prior,O
to,O
being,O
incorporated,O
in,O
the,O
MePPI,O
-,O
In,O
.,O
M,O
refers,O
to,O
the,O
reliability,O
of,O
the,O
method,O
by,O
which,O
the,O
interactions,O
were,O
identified,O
:,O
0,O
.,O
5,O
for,O
computational,O
prediction,O
",",O
and,O
1,O
for,O
experimental,O
measurement,O
.,O
N,O
∈,O
{,O
1,O
",",O
2,O
",",O
"…,",O
7,O
},O
is,O
the,O
number,O
of,O
species,O
from,O
which,O
the,O
protein,O
-,O
protein,O
interactions,O
in,O
cassava,B-OG
were,O
inferred,O
.,O
D,O
=,O
[,O
0,O
",",O
1,O
],O
refers,O
to,O
domain,O
enrichment,O
",",O
which,O
is,O
the,O
ratio,O
of,O
the,O
reported,O
DDI,O
pairs,O
to,O
all,O
interactions,O
possibly,O
happening,O
among,O
domains,O
in,O
a,O
protein,O
pair,O
.,O
For,O
example,O
",",O
D,O
calculated,O
for,O
three,O
and,O
four,O
domain,O
-,O
containing,O
proteins,O
that,O
interact,O
via,O
two,O
DDIs,O
is,O
equal,O
to,O
2,O
/(,O
3,O
×,O
4,O
).,O
To,O
compensate,O
the,O
probability,O
bias,O
in,O
calculation,O
of,O
D,O
for,O
the,O
studied,O
protein,O
pairs,O
that,O
contain,O
only,O
one,O
domain,O
",",O
the,O
correction,O
factor,O
(,O
d,O
),O
=,O
0,O
.,O
5,O
was,O
used,O
.,O
Otherwise,O
",",O
d,O
was,O
set,O
to,O
1,O
.,O
Analysis,O
of,O
topology,O
and,O
functional,O
content,O
of,O
MePPI,O
-,O
In,O
The,O
MePPI,O
-,O
In,O
network,O
was,O
characterized,O
in,O
terms,O
of,O
topology,O
and,O
biological,O
function,O
relevance,O
(,O
Fig,O
.,O
1c,O
).,O
The,O
topology,O
of,O
the,O
network,O
was,O
analyzed,O
using,O
network,O
analysis,O
tools,O
in,O
Cytoscape64,O
.,O
The,O
topological,O
characteristics,O
of,O
MePPI,O
-,O
In,O
were,O
then,O
compared,O
with,O
those,O
of,O
the,O
cassava,B-OG
random,O
network,O
(,O
simulated,O
by,O
Cytoscape,O
containing,O
the,O
same,O
number,O
of,O
nodes,O
and,O
average,O
number,O
of,O
edges,O
as,O
MePPI,O
-,O
In,O
"),",O
Arabidopsis36,O
and,O
rice9,O
PPI,O
networks,O
.,O
Biological,O
function,O
of,O
the,O
proteins,O
in,O
MePPI,O
-,O
In,O
was,O
examined,O
through,O
AgriGO71,O
",",O
from,O
which,O
GO,O
enrichment,O
analysis,O
was,O
determined,O
using,O
REVIGO72,O
.,O
The,O
results,O
were,O
illustrated,O
in,O
scatterplot,O
graph,O
and,O
compared,O
with,O
the,O
GO,O
enrichment,O
of,O
proteins,O
in,O
Arabidopsis36,O
and,O
rice9,O
PPI,O
networks,O
.,O
Results,O
and,O
Discussion,O
Protein,O
-,O
protein,O
interaction,O
network,O
of,O
cassava,B-OG
The,O
interaction,O
between,O
proteins,O
is,O
a,O
transient,O
phenomenon,O
that,O
allows,O
cells,O
to,O
be,O
regulated,O
at,O
post,O
-,O
translational,O
level,O
.,O
Since,O
experimental,O
investigation,O
of,O
PPIs,O
is,O
difficult,O
and,O
requires,O
huge,O
effort,O
",",O
prediction,O
of,O
protein,O
interactions,O
through,O
computational,O
techniques,O
has,O
",",O
thus,O
",",O
widely,O
been,O
accepted73,O
",",O
74,O
.,O
In,O
this,O
study,O
",",O
interolog,O
-,O
based,O
method,O
was,O
utilized,O
to,O
construct,O
a,O
genome,O
-,O
scale,O
PPI,O
network,O
of,O
cassava,B-OG
.,O
Upon,O
the,O
homology,O
-,O
based,O
principle,O
of,O
this,O
method,O
",",O
seven,O
plant,B-OG
species,O
were,O
selected,O
as,O
templates,O
",",O
based,O
on,O
one,O
of,O
the,O
three,O
criteria,O
(,O
the,O
model,O
plant,B-OG
",",O
Arabidopsis,B-OG
",",O
has,O
abundant,O
PPI,O
information,O
;,O
potato,B-OG
",",O
rice,B-OG
and,O
maize,B-OG
are,O
starch,O
-,O
storing,O
crops,O
;,O
castor,B-OG
bean,I-OG
",",O
poplar,B-OG
and,O
soybean,B-OG
are,O
closely,O
related,O
to,O
cassava,B-OG
).,O
According,O
to,O
PPI,O
information,O
from,O
various,O
databases,O
(,O
Fig,O
.,O
1a,O
"),",O
Arabidopsis,B-OG
has,O
the,O
most,O
abundant,O
PPI,O
information,O
(,O
235,O
",",O
215,O
interactions,O
of,O
17,O
",",O
962,O
proteins,O
),O
followed,O
by,O
rice,B-OG
(,O
76,O
",",O
829,O
interactions,O
of,O
5,O
",",O
219,O
proteins,O
"),",O
potato,B-OG
(,O
42,O
interactions,O
of,O
48,O
proteins,O
"),",O
maize,B-OG
(,O
25,O
interactions,O
of,O
29,O
proteins,O
"),",O
soybean,B-OG
(,O
10,O
interactions,O
of,O
12,O
proteins,O
"),",O
castor,B-OG
bean,I-OG
(,O
10,O
interactions,O
of,O
10,O
proteins,O
"),",O
and,O
poplar,B-OG
(,O
8,O
interactions,O
of,O
10,O
proteins,O
),O
(,O
Table,O
1,O
).,O
To,O
infer,O
PPI,O
information,O
for,O
cassava,B-OG
from,O
each,O
template,O
plant,B-OG
",",O
BLASTp,O
search,O
of,O
the,O
cassava,B-OG
genome,O
sequence,O
database,O
was,O
carried,O
out,O
.,O
The,O
cassava,B-OG
orthologous,O
proteins,O
that,O
showed,O
identity,O
percentage,O
≥,O
60,O
",",O
coverage,O
percentage,O
≥,O
80,O
and,O
e,O
-,O
value,O
≤,O
10,O
−,O
10,O
were,O
identified,O
.,O
If,O
these,O
orthologous,O
proteins,O
matched,O
the,O
proteins,O
of,O
template,O
plants,B-OG
that,O
had,O
previously,O
been,O
identified,O
to,O
have,O
protein,O
-,O
protein,O
interaction,O
",",O
such,O
interactions,O
were,O
regarded,O
as,O
orthologous,O
PPIs,O
in,O
cassava,B-OG
.,O
Based,O
on,O
the,O
results,O
obtained,O
",",O
majority,O
of,O
the,O
inferred,O
PPIs,O
were,O
from,O
Arabidopsis,B-OG
(,O
90,O
",",O
069,O
interactions,O
),O
followed,O
by,O
rice,B-OG
(,O
212,O
interactions,O
"),",O
potato,B-OG
(,O
19,O
interactions,O
"),",O
soybean,B-OG
(,O
7,O
interactions,O
"),",O
maize,B-OG
and,O
poplar,B-OG
(,O
5,O
interactions,O
each,O
),O
and,O
castor,B-OG
bean,I-OG
(,O
2,O
interactions,O
),O
(,O
Table,O
1,O
).,O
Table,O
1Protein,O
-,O
protein,O
interactions,O
in,O
plant,B-OG
templates,O
and,O
MePPI,O
-,O
In,O
.,O
PlantsGenome,O
Information60,O
PPI,O
InformationMePPI,O
-,O
InNumber,O
of,O
genesNumber,O
of,O
proteinsNumber,O
of,O
PPIsNumber,O
of,O
proteinsSourcesInfered,O
PPIs,O
in,O
cassavaOrthologs,O
in,O
casssavaArabidopsis27,O
",",O
41635,O
",",O
386235,O
",",O
21517,O
",",O
962ref,O
.,O
36,O
–,O
ref,O
.,O
39,O
90,O
",",O
0697,O
",",O
193ref,O
.,O
62,O
–,O
ref,O
.,O
63,O
Rice55,O
",",O
986154,O
",",O
31076,O
",",O
8295,O
",",O
219ref,O
.,O
9,O
",",O
ref,O
.,O
62,O
21284Potato35,B-OG
",",O
11959,O
",",O
6994248ref,O
.,O
62,O
1915Maize32,O
",",O
54088,O
",",O
3832529ref,O
.,O
62,O
58Soybean54,B-OG
",",O
17583,O
",",O
7951012ref,O
.,O
62,O
77Poplar41,B-OG
",",O
33583,O
",",O
796810ref,O
.,O
62,O
57Castorbean25,B-OG
",",O
87831,O
",",O
5761010ref,O
.,O
62,O
2290,O
",",O
1737,O
",",O
209,O
The,O
resulting,O
interolog,O
-,O
based,O
PPI,O
network,O
of,O
cassava,B-OG
",",O
or,O
MePPI,O
-,O
In,O
",",O
is,O
comprised,O
of,O
90,O
",",O
173,O
interactions,O
interconnecting,O
7,O
",",O
209,O
proteins,O
",",O
which,O
accounted,O
for,O
c,O
.,O
a,O
.,O
21,O
percent,O
of,O
proteins,O
in,O
the,O
whole,O
genome,O
(,O
Fig,O
.,O
S1,O
).,O
The,O
overall,O
predicted,O
PPIs,O
are,O
available,O
at,O
http,O
://,O
bml,O
.,O
sbi,O
.,O
kmutt,O
.,O
ac,O
.,O
th,O
/,O
ppi,O
.,O
Figure,O
2,O
illustrates,O
the,O
overview,O
of,O
MePPI,O
-,O
In,O
within,O
which,O
subnetwork,O
demonstrated,O
partial,O
set,O
of,O
protein,O
interaction,O
",",O
metabolism,O
and,O
sub,O
-,O
metabolism,O
with,O
specific,O
group,O
of,O
proteins,O
of,O
interest,O
.,O
It,O
is,O
important,O
to,O
note,O
here,O
that,O
different,O
colors,O
were,O
given,O
to,O
both,O
interactions,O
(,O
edges,O
),O
and,O
proteins,O
(,O
nodes,O
),O
to,O
indicate,O
whether,O
their,O
existence,O
could,O
be,O
supported,O
by,O
other,O
evidences,O
.,O
Edge,O
colors,O
represented,O
interactions,O
from,O
interolog,O
-,O
based,O
method,O
with,O
or,O
without,O
co,O
-,O
expression,O
or,O
DDI,O
support,O
(,O
black,O
or,O
grey,O
"),",O
while,O
node,O
colors,O
denoted,O
the,O
proteins,O
with,O
or,O
without,O
expression,O
data,O
(,O
blue,O
or,O
orange,O
),O
(,O
see,O
more,O
details,O
in,O
the,O
Supporting,O
the,O
interactions,O
section,O
below,O
).,O
Approximately,O
99,O
percent,O
of,O
the,O
PPIs,O
in,O
MePPI,O
-,O
In,O
were,O
inferred,O
from,O
Arabidopsis,B-OG
and,O
rice,B-OG
.,O
,O
of,O
the,O
interactions,O
included,O
in,O
our,O
network,O
was,O
presented,O
in,O
all,O
seven,O
template,O
plants,B-OG
.,O
These,O
results,O
implied,O
that,O
availability,O
of,O
data,O
was,O
the,O
main,O
limitation,O
in,O
inference,O
-,O
based,O
PPI,O
network,O
construction,O
.,O
To,O
improve,O
the,O
confidence,O
of,O
the,O
network,O
derived,O
originally,O
from,O
interolog,O
-,O
based,O
prediction,O
method,O
",",O
other,O
available,O
types,O
of,O
data,O
",",O
such,O
as,O
expression,O
or,O
domain,O
-,O
domain,O
interaction,O
",",O
could,O
be,O
incorporated,O
in,O
the,O
newly,O
constructed,O
MePPI,O
-,O
In,O
.,O
Supporting,O
the,O
interactions,O
of,O
proteins,O
with,O
expression,O
data,O
Our,O
MePPI,O
-,O
In,O
was,O
constructed,O
using,O
interolog,O
-,O
based,O
method,O
",",O
which,O
could,O
only,O
project,O
the,O
known,O
PPIs,O
in,O
other,O
plants,B-OG
to,O
cassava,B-OG
.,O
Accordingly,O
",",O
it,O
might,O
be,O
helpful,O
if,O
collective,O
information,O
could,O
be,O
incorporated,O
to,O
support,O
the,O
occurrence,O
of,O
such,O
predictions,O
in,O
cassava,B-OG
.,O
In,O
this,O
study,O
",",O
expression,O
of,O
the,O
proteins,O
included,O
in,O
MePPI,O
-,O
In,O
was,O
examined,O
using,O
information,O
from,O
seven,O
protein,O
expression50,O
–,O
53,O
",",O
56,O
",",O
57,O
",",O
59,O
and,O
four,O
gene,O
expression,O
datasets45,O
",",O
65,O
–,O
67,O
.,O
Subsequently,O
",",O
co,O
-,O
expression,O
of,O
each,O
interacting,O
protein,O
pair,O
was,O
also,O
determined,O
.,O
This,O
was,O
based,O
on,O
the,O
fact,O
that,O
interaction,O
between,O
two,O
proteins,O
occurs,O
only,O
if,O
both,O
proteins,O
are,O
presented,O
at,O
the,O
same,O
time,O
.,O
From,O
eleven,O
expression,O
datasets,O
exploited,O
here,O
",",O
4,O
",",O
698,O
proteins,O
expression,O
were,O
detected,O
",",O
from,O
the,O
total,O
number,O
of,O
7,O
",",O
209,O
proteins,O
in,O
MePPI,O
-,O
In,O
",",O
(,O
Fig,O
.,O
3a,O
",",O
Table,O
S1,O
).,O
Accordingly,O
",",O
different,O
colors,O
were,O
given,O
to,O
nodes,O
(,O
or,O
proteins,O
),O
shown,O
in,O
Fig,O
.,O
2,O
.,O
The,O
blue,O
color,O
nodes,O
highlighted,O
the,O
proteins,O
with,O
supporting,O
expression,O
data,O
",",O
while,O
the,O
orange,O
ones,O
had,O
no,O
supporting,O
expression,O
data,O
.,O
Since,O
expression,O
of,O
the,O
proteins,O
from,O
eleven,O
expression,O
datasets,O
indicated,O
their,O
presence,O
in,O
cassava,B-OG
",",O
these,O
proteins,O
were,O
then,O
considered,O
available,O
for,O
the,O
interactions,O
among,O
them,O
to,O
occur,O
.,O
From,O
the,O
total,O
of,O
90,O
",",O
173,O
interactions,O
in,O
MePPI,O
-,O
In,O
",",O
35,O
",",O
146,O
interactions,O
(,O
or,O
39,O
percent,O
),O
were,O
observed,O
to,O
connect,O
the,O
proteins,O
with,O
supporting,O
expression,O
data,O
.,O
Figure,O
3MePPI,O
-,O
In,O
with,O
supporting,O
expression,O
evidence,O
.,O
(,O
a,O
),O
Overview,O
of,O
the,O
number,O
of,O
proteins,O
in,O
MePPI,O
-,O
In,O
and,O
expression,O
information45,O
",",O
50,O
–,O
53,O
",",O
56,O
",",O
57,O
",",O
59,O
",",O
65,O
–,O
67,O
.,O
The,O
numbers,O
in,O
parenthesis,O
represented,O
the,O
total,O
number,O
of,O
genes,O
or,O
proteins,O
in,O
each,O
cohort,O
.,O
(,O
b,O
),O
The,O
list,O
of,O
PPIs,O
between,O
proteins,O
with,O
co,O
-,O
expression,O
profiles,O
derived,O
from,O
time,O
-,O
series,O
expression,O
datasets,O
of,O
Yang,O
et,O
al,O
.,O
45,O
(,O
cassava,B-OG
fibrous,O
",",O
intermediate,O
and,O
storage,O
roots,O
at,O
4,O
months,O
"),",O
Li,O
et,O
al,O
.,O
65,O
(,O
cassava,B-OG
leaves,O
",",O
stems,O
and,O
roots,O
harvested,O
at,O
2nd,O
",",O
4th,O
",",O
7th,O
and,O
10th,O
month,O
"),",O
An,O
et,O
al,O
.,O
66,O
(,O
cassava,B-OG
apical,O
shoots,O
subjected,O
to,O
cold,O
at,O
7,O
°,O
C,O
for,O
0,O
",",O
4,O
and,O
9,O
h,O
),O
and,O
Naconsie,O
et,O
al,O
.,O
52,O
(,O
cassava,B-OG
storage,O
roots,O
harvested,O
at,O
3rd,O
",",O
6th,O
",",O
9th,O
and,O
12th,O
months,O
).,O
The,O
resulting,O
interactions,O
were,O
classified,O
into,O
three,O
groups,O
based,O
on,O
the,O
number,O
of,O
proteins,O
and,O
their,O
topologies,O
.,O
Each,O
protein,O
was,O
presented,O
as,O
a,O
circle,O
in,O
the,O
color,O
that,O
corresponds,O
to,O
the,O
graph,O
of,O
its,O
expression,O
profile,O
(,O
see,O
more,O
information,O
in,O
Table,O
S2,O
).,O
Among,O
the,O
eleven,O
expression,O
datasets,O
",",O
the,O
time,O
-,O
series,O
datasets,O
of,O
Naconsie,O
et,O
al,O
.,O
52,O
",",O
Yang,O
et,O
al,O
.,O
45,O
",",O
Li,O
et,O
al,O
.,O
65,O
and,O
An,O
et,O
al,O
.,O
66,O
were,O
utilized,O
to,O
observe,O
the,O
correlation,O
of,O
expression,O
between,O
two,O
proteins,O
(,O
Pearson,O
correlation,O
coefficient,O
score,O
(,O
PCC,O
),O
>,O
0,O
.,O
9,O
and,O
p,O
-,O
value,O
<,O
0,O
.,O
1,O
).,O
From,O
the,O
results,O
obtained,O
",",O
there,O
were,O
16,O
interactions,O
that,O
were,O
identified,O
to,O
interconnect,O
the,O
proteins,O
with,O
co,O
-,O
expression,O
pattern,O
(,O
Table,O
S2,O
).,O
We,O
further,O
classified,O
these,O
PPIs,O
into,O
three,O
groups,O
based,O
on,O
the,O
number,O
of,O
protein,O
members,O
and,O
the,O
types,O
of,O
interactions,O
(,O
Fig,O
.,O
3b,O
).,O
First,O
",",O
the,O
heterodimeric,O
interactions,O
represented,O
interactions,O
between,O
two,O
proteins,O
",",O
for,O
example,O
",",O
an,O
interaction,O
between,O
methionine,B-GP
adenosyltransferase,I-GP
3,I-GP
(,O
M3,B-GP
),O
and,O
small,B-GP
ubiquitin,I-GP
-,I-GP
like,I-GP
modifier,I-GP
1,I-GP
(,O
SUMO1,B-GP
).,O
The,O
second,O
group,O
represented,O
linear,O
multimeric,O
interactions,O
",",O
which,O
probably,O
exhibited,O
the,O
sequential,O
functional,O
relationship,O
between,O
proteins,O
.,O
The,O
third,O
was,O
circular,O
multimeric,O
interactions,O
.,O
The,O
interactions,O
between,O
nucleolar,B-GP
complex,I-GP
protein,I-GP
2,I-GP
(,O
NOC2P,B-GP
"),",O
ribosomal,B-GP
RNA,I-GP
processing,I-GP
brix,I-GP
domain,I-GP
protein,I-GP
(,O
RRB,B-GP
),O
and,O
pescadillo,B-GP
-,I-GP
like,I-GP
protein,I-GP
(,O
PES,B-GP
),O
potentially,O
suggested,O
functional,O
relationship,O
of,O
these,O
proteins,O
in,O
rRNA,O
processing,O
and,O
cell,O
proliferation,O
control75,O
.,O
Supporting,O
the,O
interaction,O
of,O
proteins,O
with,O
DDI,O
data,O
From,O
our,O
MePPI,O
-,O
In,O
",",O
reliability,O
of,O
each,O
PPI,O
was,O
determined,O
by,O
incorporating,O
the,O
information,O
on,O
domain,O
-,O
domain,O
interaction,O
(,O
DDI,O
).,O
This,O
was,O
based,O
upon,O
the,O
observation,O
that,O
the,O
proteins,O
usually,O
interact,O
via,O
specific,O
domains,O
.,O
In,O
this,O
work,O
",",O
the,O
domain,O
information,O
of,O
proteins,O
in,O
MePPI,O
-,O
In,O
were,O
obtained,O
from,O
Pfam,O
database69,O
and,O
the,O
interactions,O
between,O
protein,O
domains,O
were,O
from,O
iPfam,O
database70,O
(,O
Fig,O
.,O
1b,O
).,O
From,O
the,O
total,O
number,O
of,O
proteins,O
proposed,O
in,O
MePPI,O
-,O
In,O
",",O
only,O
4,O
",",O
963,O
proteins,O
(,O
or,O
69,O
percent,O
),O
were,O
identified,O
to,O
have,O
at,O
least,O
one,O
domain,O
.,O
From,O
these,O
numbers,O
",",O
only,O
1,O
",",O
981,O
proteins,O
(,O
or,O
27,O
percent,O
of,O
the,O
proteins,O
proposed,O
in,O
MePPI,O
-,O
In,O
or,O
40,O
percent,O
of,O
the,O
proteins,O
with,O
domain,O
information,O
),O
were,O
indicated,O
",",O
by,O
iPfam,O
",",O
to,O
interact,O
via,O
specific,O
domains,O
.,O
Accordingly,O
",",O
only,O
6,O
",",O
826,O
from,O
90,O
",",O
173,O
interactions,O
(~,O
seven,O
percent,O
),O
could,O
be,O
confirmed,O
through,O
DDI,O
information,O
.,O
Even,O
with,O
Pfam,O
and,O
iPfam,O
",",O
the,O
largest,O
universal,O
repositories,O
of,O
protein,O
domain,O
information,O
",",O
only,O
a,O
small,O
fraction,O
of,O
interactions,O
initially,O
proposed,O
in,O
MePPI,O
-,O
In,O
were,O
identified,O
to,O
have,O
supporting,O
DDI,O
information,O
.,O
However,O
",",O
this,O
did,O
not,O
mean,O
that,O
the,O
DDI,O
information,O
could,O
not,O
provide,O
any,O
insight,O
into,O
the,O
confidence,O
level,O
of,O
PPIs,O
obtained,O
from,O
interolog,O
-,O
based,O
prediction,O
method,O
.,O
Ranking,O
the,O
confidence,O
of,O
PPIs,O
in,O
MePPI,O
-,O
In,O
based,O
on,O
DDI,O
data,O
In,O
this,O
study,O
",",O
the,O
confidence,O
of,O
the,O
predicted,O
PPIs,O
in,O
MePPI,O
-,O
In,O
was,O
classified,O
into,O
two,O
groups,O
.,O
The,O
PPIs,O
with,O
high,O
confidence,O
level,O
(,O
High,O
(,O
H,O
"),",O
Table,O
2,O
),O
represented,O
those,O
with,O
supporting,O
domain,O
information,O
(,O
6,O
",",O
826,O
PPIs,O
).,O
The,O
other,O
class,O
which,O
exhibited,O
basal,O
confidence,O
level,O
(,O
Basal,O
(,O
B,O
"),",O
Table,O
2,O
),O
included,O
the,O
remaining,O
interactions,O
in,O
MePPI,O
-,O
In,O
(,O
83,O
",",O
347,O
PPIs,O
).,O
Emphases,O
on,O
the,O
class,O
of,O
high,O
confidence,O
level,O
",",O
confidence,O
value,O
(,O
CV,O
),O
scores,O
",",O
for,O
the,O
6,O
",",O
826,O
PPIs,O
",",O
were,O
determined,O
and,O
classified,O
into,O
three,O
sub,O
-,O
groups,O
",",O
based,O
on,O
the,O
percentile,O
rank,O
of,O
the,O
CV,O
scores,O
(,O
see,O
Methods,O
).,O
The,O
CV,O
score,O
basically,O
ranges,O
from,O
0,O
to,O
1,O
",",O
from,O
the,O
lowest,O
to,O
the,O
highest,O
level,O
of,O
confidence,O
.,O
However,O
",",O
the,O
distribution,O
of,O
CV,O
scores,O
was,O
observed,O
to,O
be,O
positively,O
skewed,O
",",O
meaning,O
that,O
majority,O
of,O
the,O
PPIs,O
had,O
the,O
CV,O
score,O
≤,O
0,O
.,O
5,O
.,O
This,O
was,O
because,O
most,O
of,O
the,O
PPIs,O
in,O
MePPI,O
-,O
In,O
were,O
obtained,O
from,O
computational,O
prediction,O
",",O
not,O
experimental,O
measurements,O
.,O
Accordingly,O
",",O
the,O
factor,O
M,O
for,O
the,O
calculation,O
of,O
CV,O
interolog,O
was,O
set,O
at,O
0,O
.,O
5,O
.,O
Also,O
",",O
in,O
most,O
cases,O
",",O
the,O
correction,O
factor,O
d,O
for,O
the,O
calculation,O
of,O
CV,O
DDI,O
was,O
set,O
at,O
0,O
.,O
5,O
to,O
represent,O
the,O
DDIs,O
between,O
proteins,O
with,O
only,O
one,O
domain,O
.,O
The,O
small,O
values,O
of,O
both,O
CV,O
interolog,O
and,O
CV,O
DDI,O
only,O
allowed,O
a,O
maximum,O
final,O
CV,O
scores,O
of,O
0,O
.,O
5,O
.,O
Accordingly,O
",",O
percentile,O
calculation,O
was,O
employed,O
to,O
further,O
classify,O
these,O
high,O
confidence,O
PPIs,O
into,O
three,O
sub,O
-,O
classes,O
:,O
H1,O
(,O
percentile,O
of,O
CV,O
score,O
>,O
80,O
"),",O
H2,O
(,O
percentile,O
of,O
CV,O
score,O
:,O
50,O
–,O
80,O
),O
and,O
H3,O
(,O
percentile,O
of,O
CV,O
score,O
<,O
50,O
),O
(,O
Table,O
2,O
).,O
Table,O
2Classification,O
of,O
predicted,O
PPIs,O
based,O
on,O
the,O
confidence,O
level,O
.,O
Confidence,O
levelRange,O
of,O
confidence,O
value,O
(,O
CV,O
),O
NumberPPIsProteinsTotal,O
MePPI,O
-,O
In,O
——,O
90,O
",",O
1737,O
",",O
209Interolog,O
",",O
no,O
DDI,O
informationBasal,O
(,O
B,O
)—,O
83,O
",",O
3475,O
",",O
228Interolog,O
",",O
DDI,O
-,O
heterodimerHigh,O
(,O
H,O
)[,O
0,O
.,O
00,O
",",O
1,O
.,O
00,O
],O
6,O
",",O
8261,O
",",O
981Percentile,O
of,O
CV,O
score,O
:,O
>,O
80H1,O
[,O
0,O
.,O
14,O
",",O
1,O
.,O
00,O
],O
1,O
",",O
184733Percentile,O
of,O
CV,O
score,O
:,O
50,O
–,O
80H2,O
[,O
0,O
.,O
12,O
",",O
0,O
.,O
14,O
),O
3,O
",",O
8591,O
",",O
439Percentile,O
of,O
CV,O
score,O
:,O
<,O
50H3,O
[,O
0,O
.,O
01,O
",",O
0,O
.,O
12,O
),O
1,O
",",O
783855,O
As,O
mentioned,O
above,O
",",O
the,O
current,O
knowledge,O
of,O
protein,O
domain,O
and,O
DDI,O
information,O
can,O
support,O
only,O
up,O
to,O
seven,O
percent,O
of,O
the,O
overall,O
interactions,O
in,O
MePPI,O
-,O
In,O
.,O
However,O
",",O
the,O
confidence,O
level,O
obtained,O
",",O
along,O
with,O
the,O
PPIs,O
",",O
herein,O
",",O
should,O
help,O
contrast,O
the,O
reliability,O
of,O
each,O
prediction,O
for,O
further,O
investigation,O
by,O
experimental,O
approaches,O
.,O
Characteristics,O
of,O
the,O
MePPI,O
-,O
In,O
Network,O
The,O
MePPI,O
-,O
In,O
proposed,O
in,O
this,O
study,O
is,O
the,O
first,O
genome,O
-,O
wide,O
protein,O
-,O
protein,O
interaction,O
network,O
of,O
cassava,B-OG
consisting,O
of,O
90,O
",",O
173,O
interactions,O
and,O
7,O
",",O
209,O
proteins,O
.,O
Here,O
",",O
characteristics,O
of,O
the,O
MePPI,O
-,O
In,O
were,O
described,O
in,O
terms,O
of,O
the,O
global,O
network,O
topology,O
and,O
the,O
functional,O
coverage,O
.,O
At,O
last,O
",",O
we,O
discussed,O
how,O
MePPI,O
-,O
In,O
might,O
be,O
used,O
to,O
infer,O
biological,O
regulatory,O
processes,O
.,O
Some,O
of,O
these,O
applications,O
include,O
(,O
1,O
),O
identification,O
of,O
a,O
hub,O
protein,O
in,O
the,O
interactome,O
cascade,O
",",O
(,O
2,O
),O
functional,O
identification,O
of,O
unknown,O
protein,O
",",O
(,O
3,O
),O
inference,O
of,O
protein,O
complex,O
formation,O
",",O
and,O
(,O
4,O
),O
study,O
of,O
protein,O
connections,O
in,O
metabolic,O
pathway,O
as,O
well,O
as,O
connection,O
of,O
various,O
metabolic,O
pathways,O
via,O
protein,O
-,O
protein,O
interactions,O
.,O
These,O
examples,O
showed,O
the,O
contribution,O
of,O
MePPI,O
-,O
In,O
in,O
envisaging,O
cellular,O
communication,O
via,O
crosstalk,O
at,O
protein,O
level,O
.,O
MePPI,O
-,O
In,O
performs,O
as,O
a,O
biological,O
network,O
A,O
protein,O
-,O
protein,O
interaction,O
network,O
",",O
such,O
as,O
MePPI,O
-,O
In,O
",",O
is,O
generally,O
constructed,O
from,O
available,O
proteome,O
and,O
interactome,O
data,O
of,O
reference,O
species,O
and,O
the,O
studied,O
organism,O
itself,O
.,O
The,O
MePPI,O
-,O
In,O
proposed,O
here,O
included,O
knowledge,O
of,O
PPIs,O
from,O
both,O
cassava,B-OG
and,O
other,O
plants,B-OG
.,O
The,O
constructed,O
network,O
contained,O
a,O
large,O
number,O
of,O
possible,O
interacting,O
protein,O
pairs,O
;,O
nonetheless,O
",",O
it,O
was,O
impossible,O
to,O
determine,O
the,O
exact,O
coverage,O
of,O
the,O
network,O
constituents,O
of,O
the,O
overall,O
PPIs,O
that,O
exist,O
in,O
real,O
living,O
cells,O
.,O
The,O
ill,O
-,O
defined,O
network,O
boundary,O
did,O
not,O
allow,O
assessment,O
of,O
its,O
representativeness,O
in,O
the,O
cellular,O
PPI,O
matrix,O
.,O
In,O
this,O
circumstance,O
",",O
network,O
topology,O
was,O
employed,O
",",O
at,O
least,O
as,O
an,O
alternative,O
",",O
to,O
suggest,O
the,O
plausibility,O
of,O
the,O
proposed,O
network,O
as,O
if,O
it,O
possesses,O
the,O
properties,O
of,O
common,O
biological,O
network,O
system76,O
.,O
To,O
investigate,O
topology,O
of,O
MePPI,O
-,O
In,O
",",O
the,O
key,O
global,O
network,O
properties,O
",",O
including,O
node,O
degree,O
distribution,O
",",O
average,O
path,O
length,O
(,O
L,O
),O
and,O
clustering,O
coefficient,O
(,O
C,O
i,O
"),",O
were,O
determined,O
according,O
to,O
graphical,O
analysis,O
method76,O
.,O
The,O
MePPI,O
-,O
In,O
exhibited,O
the,O
biological,O
network,O
characteristics,O
based,O
upon,O
the,O
two,O
supporting,O
properties,O
;,O
scale,O
-,O
free,O
and,O
small,O
world,O
.,O
First,O
",",O
the,O
connectivity,O
(,O
k,O
),O
of,O
the,O
proteins,O
in,O
MePPI,O
-,O
In,O
followed,O
a,O
power,O
-,O
law,O
distribution,O
",",O
P,O
(,O
k,O
)~,O
k,O
−,O
γ,O
.,O
The,O
MePPI,O
-,O
In,O
exhibited,O
scale,O
-,O
free,O
property,O
and,O
showed,O
an,O
explicit,O
deviation,O
from,O
a,O
random,O
network,O
",",O
in,O
which,O
most,O
proteins,O
had,O
relatively,O
the,O
same,O
numbers,O
of,O
interactions,O
as,O
shown,O
in,O
the,O
relationship,O
between,O
degree,O
and,O
number,O
of,O
nodes,O
(,O
Fig,O
.,O
4,O
).,O
In,O
MePPI,O
-,O
In,O
",",O
most,O
proteins,O
have,O
only,O
a,O
few,O
interactions,O
and,O
only,O
a,O
few,O
proteins,O
",",O
called,O
hub,O
proteins,O
",",O
have,O
a,O
large,O
number,O
of,O
interactions,O
.,O
The,O
scale,O
-,O
free,O
property,O
is,O
not,O
only,O
observed,O
in,O
MePPI,O
-,O
In,O
",",O
but,O
also,O
occurs,O
in,O
other,O
types,O
of,O
biological,O
networks76,O
",",O
such,O
as,O
metabolic,O
network,O
",",O
and,O
gene,O
regulatory,O
network77,O
.,O
MePPI,O
-,O
In,O
was,O
analyzed,O
and,O
compared,O
with,O
the,O
PPI,O
networks,O
of,O
Arabidopsis36,O
and,O
rice9,O
.,O
Figure,O
4,O
described,O
the,O
various,O
features,O
of,O
these,O
PPI,O
networks,O
",",O
including,O
network,O
diameter,O
",",O
average,O
path,O
length,O
and,O
clustering,O
coefficient,O
.,O
Although,O
these,O
PPI,O
networks,O
contained,O
different,O
numbers,O
of,O
interactions,O
and,O
proteins,O
",",O
all,O
of,O
them,O
followed,O
a,O
power,O
law,O
distribution,O
",",O
a,O
common,O
behavior,O
of,O
biological,O
networks,O
in,O
living,O
organisms,O
.,O
Figure,O
4The,O
global,O
network,O
properties,O
of,O
protein,O
-,O
protein,O
interaction,O
networks,O
in,O
cassava,B-OG
",",O
Arabidopsis,B-OG
and,O
rice,B-OG
.,O
Second,O
",",O
the,O
MePPI,O
-,O
In,O
possessed,O
a,O
small,O
-,O
world,O
structure,O
.,O
According,O
to,O
the,O
definition,O
given,O
by,O
Watz,O
and,O
Strogatz78,O
",",O
the,O
average,O
path,O
length,O
of,O
a,O
small,O
-,O
world,O
network,O
must,O
be,O
relatively,O
greater,O
than,O
average,O
path,O
length,O
(,O
L,O
),O
of,O
random,O
network,O
",",O
while,O
the,O
clustering,O
coefficient,O
(,O
C,O
i,O
),O
of,O
small,O
world,O
network,O
is,O
relatively,O
much,O
higher,O
than,O
C,O
i,O
of,O
random,O
network,O
(,O
L,O
small,O
world,O
≥,O
L,O
random,O
but,O
C,O
i,O
small,O
world,O
≫,O
C,O
i,O
random,O
).,O
The,O
average,O
path,O
length,O
(,O
average,O
of,O
shortest,O
paths,O
between,O
all,O
possible,O
pairs,O
of,O
proteins,O
in,O
the,O
network,O
),O
value,O
of,O
MePPI,O
-,O
In,O
was,O
3,O
.,O
53,O
",",O
slightly,O
greater,O
than,O
that,O
of,O
the,O
random,O
network,O
with,O
the,O
same,O
number,O
of,O
nodes,O
and,O
average,O
number,O
of,O
edges,O
per,O
node,O
(,O
3,O
.,O
04,O
).,O
Moreover,O
",",O
the,O
much,O
higher,O
clustering,O
coeffiecient,O
of,O
MePPI,O
-,O
In,O
",",O
when,O
comparing,O
with,O
random,O
network,O
shown,O
in,O
Fig,O
.,O
4,O
",",O
also,O
supported,O
the,O
small,O
world,O
property,O
of,O
our,O
network,O
.,O
This,O
property,O
of,O
MePPI,O
-,O
In,O
is,O
considered,O
beneficial,O
",",O
since,O
it,O
can,O
protect,O
cassava,B-OG
from,O
any,O
perturbation,O
caused,O
by,O
endogenous,O
and,O
exogenous,O
stimuli,O
.,O
In,O
conclusion,O
",",O
based,O
on,O
the,O
two,O
network,O
properties,O
mentioned,O
above,O
",",O
MePPI,O
-,O
In,O
exhibits,O
a,O
well,O
-,O
presented,O
biological,O
network,O
behavior,O
.,O
It,O
is,O
thus,O
presumed,O
that,O
the,O
MePPI,O
-,O
In,O
contains,O
sufficient,O
information,O
",",O
hence,O
",",O
could,O
be,O
utilized,O
as,O
the,O
model,O
PPI,O
network,O
in,O
cassava,B-OG
.,O
Functional,O
content,O
of,O
MePPI,O
-,O
In,O
Besides,O
the,O
network,O
topology,O
",",O
functional,O
content,O
of,O
proteins,O
in,O
MePPI,O
-,O
In,O
was,O
determined,O
to,O
demonstrate,O
some,O
PPI,O
-,O
based,O
regulation,O
in,O
cassava,B-OG
.,O
The,O
functional,O
coverage,O
of,O
proteins,O
in,O
the,O
network,O
was,O
examined,O
by,O
GO,O
analysis,O
.,O
The,O
results,O
were,O
presented,O
based,O
on,O
three,O
classes,O
of,O
gene,O
ontology79,O
",",O
biological,O
process,O
",",O
molecular,O
function,O
and,O
cellular,O
component,O
.,O
In,O
addition,O
to,O
the,O
basic,O
GO,O
terms,O
",",O
GO,O
enrichment,O
of,O
proteins,O
in,O
MePPI,O
-,O
In,O
was,O
examined,O
and,O
the,O
results,O
were,O
presented,O
in,O
scatterplot,O
(,O
Fig,O
.,O
5,O
).,O
The,O
node,O
color,O
showed,O
degree,O
of,O
enrichment,O
ranging,O
from,O
low,O
(,O
red,O
),O
to,O
high,O
(,O
blue,O
"),",O
while,O
the,O
node,O
size,O
represented,O
the,O
frequency,O
of,O
proteins,O
in,O
each,O
functional,O
group,O
.,O
According,O
to,O
the,O
scatterplot,O
of,O
MePPI,O
-,O
In,O
",",O
a,O
large,O
number,O
of,O
proteins,O
",",O
in,O
‘,O
biological,O
process,O
’,O
class,O
",",O
were,O
identified,O
to,O
be,O
related,O
to,O
cellular,O
and,O
metabolic,O
processes,O
.,O
These,O
corresponded,O
to,O
the,O
result,O
in,O
the,O
‘,O
molecular,O
function,O
’,O
class,O
",",O
in,O
which,O
a,O
large,O
number,O
of,O
the,O
proteins,O
were,O
observed,O
to,O
have,O
catalytic,O
activity,O
or,O
binding,O
capacity,O
",",O
probably,O
acting,O
as,O
enzymes,O
in,O
metabolic,O
pathways,O
and,O
transcription,B-GP
factors,I-GP
in,O
cellular,O
regulatory,O
processes,O
.,O
For,O
the,O
last,O
class,O
of,O
gene,O
ontology,O
or,O
the,O
‘,O
cellular,O
component,O
"’,",O
our,O
results,O
provided,O
no,O
information,O
on,O
specific,O
compartments,O
of,O
the,O
cell,O
where,O
the,O
PPIs,O
tend,O
to,O
occur,O
.,O
Figure,O
5Comparison,O
of,O
the,O
functional,O
content,O
of,O
MePPI,O
-,O
In,O
and,O
the,O
PPI,O
networks,O
of,O
Arabidopsis,B-OG
and,O
rice,B-OG
.,O
The,O
scatterplots,O
were,O
derived,O
based,O
on,O
GO,O
enrichment,O
analysis,O
.,O
The,O
node,O
color,O
showed,O
degree,O
of,O
enrichment,O
ranging,O
from,O
low,O
(,O
red,O
),O
to,O
high,O
(,O
blue,O
"),",O
while,O
the,O
node,O
size,O
represented,O
the,O
frequency,O
of,O
the,O
proteins,O
in,O
each,O
functional,O
group,O
.,O
By,O
comparing,O
MePPI,O
-,O
In,O
with,O
the,O
Arabidopsis,B-OG
and,O
rice,B-OG
PPI,O
networks,O
",",O
some,O
similarities,O
of,O
the,O
functional,O
content,O
of,O
the,O
proteins,O
were,O
observed,O
(,O
Fig,O
.,O
5,O
).,O
These,O
included,O
the,O
proteins,O
that,O
function,O
in,O
cellular,O
processes,O
and,O
cellular,O
metabolism,O
",",O
and,O
possess,O
catalytic,O
or,O
binding,O
capacity,O
.,O
The,O
functional,O
content,O
of,O
MePPI,O
-,O
In,O
was,O
observed,O
to,O
be,O
more,O
closely,O
related,O
to,O
Arabidopsis,B-OG
than,O
to,O
rice,B-OG
.,O
These,O
differences,O
probably,O
reflect,O
the,O
different,O
nature,O
of,O
the,O
plants,B-OG
as,O
cassava,B-OG
and,O
Arabidopsis,B-OG
are,O
dicots,B-OG
",",O
while,O
rice,B-OG
is,O
a,O
monocot80,B-OG
",",O
81,O
.,O
Inference,O
of,O
biological,O
regulation,O
from,O
MePPI,O
-,O
In,O
The,O
involvement,O
of,O
protein,O
-,O
protein,O
interaction,O
in,O
mediating,O
cellular,O
regulation,O
has,O
been,O
reported,O
in,O
several,O
studies82,O
–,O
84,O
.,O
These,O
studies,O
demonstrated,O
key,O
roles,O
of,O
PPIs,O
in,O
post,O
-,O
translational,O
regulation,O
that,O
governs,O
biological,O
processes,O
in,O
cells,O
.,O
In,O
similar,O
manner,O
",",O
we,O
propose,O
possible,O
post,O
-,O
translational,O
regulation,O
in,O
cassava,B-OG
using,O
the,O
information,O
acquired,O
from,O
MePPI,O
-,O
In,O
.,O
Genome,O
-,O
scale,O
network,O
enabled,O
us,O
to,O
access,O
the,O
extensive,O
cooperation,O
of,O
PPIs,O
underlying,O
specific,O
cellular,O
regulatory,O
process,O
",",O
beyond,O
the,O
explanation,O
at,O
an,O
associative,O
protein,O
pair,O
.,O
As,O
the,O
first,O
global,O
protein,O
interaction,O
network,O
in,O
cassava,B-OG
",",O
our,O
MePPI,O
-,O
In,O
was,O
able,O
to,O
illustrate,O
the,O
complexity,O
of,O
cellular,O
regulation,O
in,O
cassava,B-OG
",",O
from,O
the,O
highly,O
elaborate,O
topology,O
of,O
the,O
network,O
(,O
Fig,O
.,O
2,O
).,O
Moreover,O
",",O
our,O
cassava,B-OG
PPI,O
network,O
(,O
MePPI,O
-,O
In,O
),O
has,O
brought,O
various,O
insights,O
.,O
First,O
",",O
it,O
helps,O
in,O
identifying,O
the,O
most,O
important,O
protein,O
whose,O
significance,O
is,O
reflected,O
by,O
its,O
number,O
of,O
interactions,O
with,O
diverse,O
partner,O
proteins,O
(,O
denoted,O
as,O
high,O
node,O
degree,O
in,O
Fig,O
.,O
2,O
).,O
Regarding,O
the,O
MePPI,O
-,O
In,O
",",O
heat,B-GP
shock,I-GP
protein,I-GP
90,I-GP
.,I-GP
1,I-GP
(,O
HSP90,B-GP
.,I-GP
1,I-GP
;,O
cassava4,O
.,O
1_002708m,O
),O
showed,O
the,O
highest,O
(,O
620,O
),O
number,O
of,O
connections,O
(,O
Fig,O
.,O
6,O
).,O
HSP90,B-GP
.,I-GP
1,I-GP
was,O
recognized,O
as,O
a,O
communication,O
hub,O
because,O
it,O
interacts,O
with,O
various,O
types,O
of,O
proteins,O
including,O
transcription,B-GP
factors,I-GP
",",O
signaling,O
proteins,O
",",O
structural,B-GP
proteins,I-GP
and,O
enzymatic,O
proteins,O
(,O
Fig,O
.,O
6,O
).,O
HSP90,B-GP
.,I-GP
1,I-GP
was,O
reported,O
to,O
play,O
roles,O
in,O
various,O
biological,O
processes,O
",",O
including,O
protein,O
folding,O
",",O
intracellular,O
transport,O
",",O
protein,O
degradation,O
and,O
cell,O
signaling85,O
",",O
86,O
",",O
which,O
agrees,O
with,O
our,O
finding,O
.,O
Similar,O
to,O
cassava,B-OG
",",O
Arabidopsis,B-OG
and,O
rice,B-OG
also,O
use,O
heat,B-GP
shock,I-GP
protein,I-GP
as,O
the,O
center,O
of,O
communication,O
",",O
but,O
the,O
hub,O
protein,O
in,O
these,O
two,O
plants,B-OG
was,O
heat,B-GP
shock,I-GP
protein,I-GP
70,I-GP
(,O
HSP70,B-GP
),O
33,O
",",O
36,O
.,O
In,O
MePPI,O
-,O
In,O
",",O
the,O
HSP70,B-GP
is,O
one,O
of,O
the,O
proteins,O
with,O
many,O
connections,O
(,O
following,O
only,O
HPS90,B-GP
.,I-GP
1,I-GP
).,O
However,O
",",O
partner,O
proteins,O
that,O
interact,O
with,O
cassava,B-OG
HSP70,B-GP
are,O
different,O
from,O
those,O
that,O
interact,O
with,O
Arabidopsis,B-OG
and,O
rice,B-OG
HSP70,B-GP
.,O
These,O
results,O
suggested,O
that,O
cassava,B-OG
",",O
Arabidopsis,B-OG
and,O
rice,B-OG
may,O
use,O
these,O
core,O
proteins,O
to,O
respond,O
to,O
stress,O
",",O
but,O
how,O
these,O
plants,B-OG
react,O
are,O
different,O
since,O
they,O
use,O
different,O
mechanisms,O
through,O
different,O
protein,O
activities,O
.,O
Figure,O
6Interaction,O
of,O
the,O
cassava,B-OG
heat,B-GP
shock,I-GP
protein,I-GP
90,I-GP
.,I-GP
1,I-GP
(,O
HSP90,B-GP
.,I-GP
1,I-GP
;,O
cassava4,O
.,O
1_002708m,O
),O
and,O
its,O
partner,O
proteins,O
in,O
MePPI,O
-,O
In,O
.,O
The,O
nodes,O
represent,O
the,O
proteins,O
;,O
blue,O
for,O
proteins,O
with,O
supporting,O
expression,O
data45,O
",",O
50,O
–,O
53,O
",",O
56,O
",",O
57,O
",",O
59,O
",",O
65,O
–,O
67,O
and,O
orange,O
for,O
proteins,O
with,O
no,O
supporting,O
data,O
.,O
The,O
edges,O
represent,O
interactions,O
between,O
HSP90,B-GP
.,I-GP
1,I-GP
and,O
its,O
partners,O
.,O
Second,O
",",O
the,O
MePPI,O
-,O
In,O
might,O
be,O
used,O
to,O
identify,O
functions,O
of,O
unknown,O
proteins,O
in,O
similar,O
manner,O
to,O
Sharan,O
et,O
al,O
.,O
87,O
.,O
Proteins,O
involved,O
in,O
same,O
metabolic,O
pathway,O
usually,O
interact,O
to,O
carry,O
out,O
a,O
specific,O
task,O
required,O
by,O
cells,O
.,O
From,O
MePPI,O
-,O
In,O
",",O
the,O
unknown,O
protein,O
",",O
cassava4,O
.,O
1_011746m,O
",",O
was,O
observed,O
to,O
interact,O
with,O
five,O
proteins,O
;,O
cassava4,O
.,O
1_032607m,O
(,O
basic,B-GP
leucine,I-GP
zipper,I-GP
transcription,I-GP
factor,I-GP
protein,I-GP
(,O
bZIP,B-GP
")),",O
cassava4,O
.,O
1_007074m,O
(,O
TGACG,B-GP
motif,I-GP
-,I-GP
binding,I-GP
factor,I-GP
6,I-GP
"),",O
cassava4,O
.,O
1_015896m,O
(,O
response,B-GP
regulator,I-GP
5,I-GP
"),",O
cassava4,O
.,O
1_023865m,O
(,O
response,B-GP
regulator,I-GP
6,I-GP
"),",O
and,O
cassava4,O
.,O
1_022288m,O
(,O
response,B-GP
regulator,I-GP
9,I-GP
"),",O
all,O
of,O
which,O
are,O
transcription,O
factors88,O
",",O
89,O
(,O
Fig,O
.,O
7,O
).,O
Based,O
on,O
its,O
interaction,O
with,O
transcription,B-GP
factors,I-GP
",",O
the,O
unknown,O
protein,O
might,O
act,O
as,O
another,O
component,O
in,O
this,O
transcriptional,O
regulation,O
cascade,O
.,O
Figure,O
7Interaction,O
of,O
an,O
unknown,O
protein,O
(,O
cassava4,O
.,O
1_011746m,O
),O
with,O
partner,O
proteins,O
with,O
known,O
function,O
.,O
The,O
nodes,O
represent,O
the,O
proteins,O
;,O
blue,O
for,O
proteins,O
with,O
supporting,O
expression,O
data45,O
",",O
50,O
–,O
53,O
",",O
56,O
",",O
57,O
",",O
59,O
",",O
65,O
–,O
67,O
and,O
orange,O
for,O
proteins,O
with,O
no,O
supporting,O
data,O
.,O
The,O
edges,O
represent,O
interactions,O
between,O
the,O
unknown,O
protein,O
and,O
its,O
partners,O
.,O
Third,O
",",O
the,O
network,O
could,O
be,O
used,O
to,O
investigate,O
the,O
possibility,O
of,O
proteins,O
to,O
form,O
complexes,O
",",O
as,O
in,O
vivo,O
proteins,O
often,O
work,O
together,O
by,O
forming,O
protein,O
complex,O
.,O
From,O
MePPI,O
-,O
In,O
",",O
interaction,O
between,O
ubiquitin,B-GP
-,I-GP
conjugating,I-GP
protein,I-GP
(,O
E2,B-GP
;,O
cassava4,O
.,O
1_017321m,O
),O
and,O
ubiquitin,B-GP
ligase,I-GP
proteins,O
(,O
E3,B-GP
;,O
cassava4,O
.,O
1_000004m,O
and,O
cassava4,O
.,O
1_002295m,O
),O
was,O
observed,O
with,O
high,O
interaction,O
confidence,O
(,O
Fig,O
.,O
8,O
).,O
This,O
finding,O
agreed,O
well,O
with,O
the,O
results,O
from,O
previous,O
study,O
which,O
reported,O
that,O
during,O
ubiquitination,O
process,O
",",O
ubiquitin,B-GP
-,I-GP
conjugating,I-GP
proteins,I-GP
form,O
complexes,O
with,O
ubiquitin,B-GP
ligase,I-GP
proteins,O
prior,O
to,O
binding,O
to,O
target,O
proteins90,O
.,O
In,O
addition,O
to,O
the,O
proteins,O
that,O
are,O
known,O
to,O
form,O
complexes,O
",",O
our,O
network,O
also,O
indicated,O
additional,O
protein,O
components,O
that,O
might,O
form,O
complex,O
with,O
the,O
ubiquitin,B-GP
-,I-GP
conjugating,I-GP
protein,I-GP
(,O
Fig,O
.,O
8,O
).,O
These,O
included,O
the,O
F,B-GP
-,I-GP
box,I-GP
family,I-GP
proteins,I-GP
",",O
which,O
were,O
reported,O
to,O
mediate,O
ubiquitination,O
during,O
protein,O
degradation91,O
",",O
and,O
galactose,B-GP
oxidase,I-GP
/,O
kelch,B-GP
repeat,I-GP
superfamily,I-GP
proteins,I-GP
",",O
which,O
functions,O
as,O
substrate,O
-,O
specific,O
adapter,B-GP
proteins,I-GP
in,O
ubiquitin,B-GP
ligase,I-GP
binding92,O
.,O
Figure,O
8Protein,O
complex,O
of,O
the,O
cassava,B-OG
ubiquitin,B-GP
-,I-GP
conjugating,I-GP
protein,I-GP
(,O
cassava4,O
.,O
1_017321m,O
).,O
The,O
nodes,O
represent,O
the,O
proteins,O
;,O
ubiquitin,B-GP
-,I-GP
conjugating,I-GP
protein,I-GP
(,O
yellow,O
);,O
ubiquitin,B-GP
ligases,I-GP
(,O
green,O
);,O
F,B-GP
-,I-GP
box,I-GP
family,I-GP
proteins,I-GP
(,O
purple,O
);,O
galactose,B-GP
oxidase,I-GP
/,O
kelch,B-GP
repeat,I-GP
superfamily,I-GP
proteins,I-GP
(,O
pink,O
);,O
other,O
proteins,O
(,O
orange,O
).,O
The,O
edges,O
represent,O
PPIs,O
:,O
black,O
–,O
PPIs,O
with,O
DDI,O
or,O
co,O
-,O
expression,O
support,O
",",O
and,O
grey,O
for,O
–,O
PPIs,O
with,O
no,O
supporting,O
data,O
.,O
Fourth,O
",",O
the,O
network,O
could,O
be,O
used,O
to,O
gain,O
knowledge,O
on,O
a,O
particular,O
metabolic,O
pathway,O
.,O
As,O
the,O
value,O
of,O
cassava,B-OG
mainly,O
relies,O
on,O
its,O
capacity,O
to,O
synthesize,O
and,O
store,O
starch,O
",",O
our,O
MePPI,O
-,O
In,O
might,O
provide,O
some,O
insight,O
related,O
to,O
the,O
biosynthesis,O
of,O
starch,O
in,O
cassava,B-OG
.,O
Herein,O
",",O
all,O
proteins,O
involved,O
in,O
the,O
CO2,O
fixation,O
pathway,O
(,O
Calvin,O
cycle,O
"),",O
sucrose,O
biosynthesis,O
pathway,O
and,O
starch,O
biosynthesis,O
pathway,O
(,O
defined,O
as,O
starch,O
proteins,O
),O
47,O
as,O
well,O
as,O
their,O
partners,O
",",O
were,O
presented,O
in,O
the,O
form,O
of,O
starch,O
sub,O
-,O
network,O
(,O
Fig,O
.,O
9,O
).,O
According,O
to,O
Fig,O
.,O
9,O
",",O
starch,O
proteins,O
interact,O
not,O
only,O
with,O
starch,O
proteins,O
",",O
but,O
with,O
other,O
proteins,O
such,O
as,O
signaling,O
proteins,O
",",O
regulatory,B-GP
proteins,I-GP
",",O
and,O
proteins,O
in,O
other,O
metabolic,O
pathways,O
.,O
These,O
results,O
suggested,O
that,O
starch,O
metabolism,O
was,O
tightly,O
regulated,O
.,O
Since,O
starch,O
proteins,O
connected,O
to,O
proteins,O
in,O
other,O
metabolic,O
processes,O
",",O
its,O
perturbations,O
could,O
eventually,O
affect,O
whole,O
organism,O
.,O
This,O
might,O
be,O
the,O
reason,O
why,O
unexpected,O
pleiotropic,O
effects,O
were,O
often,O
observed,O
",",O
even,O
though,O
the,O
mutants,O
in,O
question,O
had,O
already,O
been,O
proven,O
to,O
lack,O
only,O
a,O
single,O
starch,O
gene,O
.,O
Figure,O
9Cassava,O
starch,O
sub,O
-,O
network,O
.,O
The,O
nodes,O
represent,O
starch,O
proteins,O
(,O
green,O
),O
and,O
their,O
first,O
neighbors,O
(,O
orange,O
).,O
The,O
edges,O
represent,O
interactions,O
between,O
proteins,O
;,O
black,O
for,O
PPIs,O
with,O
DDI,O
or,O
co,O
-,O
expression,O
supporting,O
data,O
",",O
and,O
grey,O
for,O
PPIs,O
with,O
no,O
supporting,O
information,O
.,O
Within,O
the,O
starch,O
sub,O
-,O
network,O
",",O
the,O
arrows,O
indicated,O
where,O
the,O
starch,B-GP
synthases,I-GP
(,O
SS1,B-GP
",",O
SS2,B-GP
",",O
SS3,B-GP
",",O
SS4,B-GP
"),",O
starch,B-GP
branching,I-GP
enzymes,I-GP
(,O
SBE2,B-GP
.,I-GP
1,I-GP
",",O
SBE2,B-GP
.,I-GP
2,I-GP
"),",O
isoamylase,B-GP
(,O
ISA3,B-GP
),O
and,O
ADP,B-GP
glucose,I-GP
pyrophosphorylase,I-GP
in,O
large,O
and,O
small,O
subunit,O
(,O
APL1,B-GP
",",O
APS1,B-GP
),O
resided,O
.,O
Conclusions,O
The,O
study,O
of,O
protein,O
-,O
protein,O
interaction,O
allows,O
us,O
to,O
envisage,O
potential,O
post,O
-,O
translational,O
regulation,O
that,O
mediates,O
the,O
cellular,O
processes,O
in,O
cassava,B-OG
.,O
Our,O
MePPI,O
-,O
In,O
is,O
the,O
first,O
genome,O
-,O
scale,O
protein,O
-,O
protein,O
interaction,O
network,O
of,O
cassava,B-OG
",",O
consisting,O
of,O
90,O
",",O
173,O
interactions,O
and,O
7,O
",",O
209,O
proteins,O
.,O
The,O
MePPI,O
-,O
In,O
was,O
constructed,O
from,O
extensive,O
PPI,O
data,O
of,O
seven,O
plants,B-OG
(,O
i,O
.,O
e,O
.,O
Arabidopsis,B-OG
",",O
rice,B-OG
",",O
potato,B-OG
",",O
maize,B-OG
",",O
castor,B-OG
bean,I-OG
",",O
soybean,B-OG
",",O
and,O
poplar,B-OG
),O
using,O
interolog,O
-,O
based,O
method,O
.,O
The,O
MePPI,O
-,O
In,O
contained,O
the,O
largest,O
number,O
of,O
PPIs,O
in,O
cassava,B-OG
",",O
which,O
are,O
involved,O
in,O
many,O
biological,O
processes,O
especially,O
cellular,O
process,O
",",O
and,O
metabolism,O
.,O
Moreover,O
",",O
confidence,O
value,O
(,O
CV,O
),O
was,O
calculated,O
to,O
rank,O
the,O
reliability,O
of,O
the,O
prediction,O
",",O
which,O
is,O
beneficial,O
for,O
the,O
discovery,O
of,O
promising,O
PPI,O
for,O
further,O
investigation,O
.,O
The,O
biological,O
insights,O
gained,O
from,O
the,O
MePPI,O
-,O
In,O
network,O
",",O
hopefully,O
",",O
fill,O
a,O
part,O
of,O
the,O
current,O
gap,O
of,O
knowledge,O
on,O
cassava,B-OG
proteins,O
and,O
their,O
function,O
.,O
Electronic,O
supplementary,O
material,O
Supplement,O
Figure,O
S1,O
Supplement,O
Table,O
S1,O
Supplement,O
Table,O
S2,O
Electronic,O
supplementary,O
material,O
Supplementary,O
information,O
accompanies,O
this,O
paper,O
at,O
10,O
.,O
1038,O
/,O
s41598,O
-,O
017,O
-,O
17633,O
-,O
2,O
.,O
Publisher,O
',O
s,O
note,O
:,O
Springer,O
Nature,O
remains,O
neutral,O
with,O
regard,O
to,O
jurisdictional,O
claims,O
in,O
published,O
maps,O
and,O
institutional,O
affiliations,O
.,O
Activation,O
of,O
the,O
Interferon,B-GP
Pathway,O
is,O
Dependent,O
Upon,O
Autoantibodies,B-GP
in,O
African,O
-,O
American,O
SLE,B-DS
Patients,O
",",O
but,O
Not,O
in,O
European,O
-,O
American,O
SLE,B-DS
Patients,O
Edited,O
by,O
:,O
Fabrizio,O
Mattei,O
",",O
Istituto,O
Superiore,O
di,O
Sanità,O
",",O
Italy,O
Reviewed,O
by,O
:,O
Dalil,O
Hannani,O
",",O
Institut,O
de,O
Cancérologie,O
Gustave,O
Roussy,O
–,O
INSERM,O
U1015,O
",",O
France,O
;,O
Kamil,O
R,O
.,O
Kranc,O
",",O
University,O
of,O
Edinburgh,O
",",O
UK,O
This,O
article,O
was,O
submitted,O
to,O
Molecular,O
Innate,O
Immunity,O
",",O
a,O
section,O
of,O
the,O
journal,O
Frontiers,O
in,O
Immunology,O
.,O
Background,O
:,O
In,O
systemic,B-DS
lupus,I-DS
erythematosus,I-DS
(,O
SLE,B-DS
"),",O
antibodies,B-GP
directed,O
at,O
RNA,B-GP
-,I-GP
binding,I-GP
proteins,I-GP
(,O
anti,O
-,O
RBP,B-GP
),O
are,O
associated,O
with,O
high,O
serum,O
type,B-GP
I,I-GP
interferon,I-GP
(,O
IFN,B-GP
"),",O
which,O
plays,O
an,O
important,O
role,O
in,O
SLE,B-DS
pathogenesis,O
.,O
African,O
-,O
Americans,O
(,O
AA,O
),O
are,O
more,O
likely,O
to,O
develop,O
SLE,B-DS
",",O
and,O
SLE,B-DS
is,O
also,O
more,O
severe,O
in,O
this,O
population,O
.,O
We,O
hypothesized,O
that,O
peripheral,O
blood,O
gene,O
expression,O
patterns,O
would,O
differ,O
between,O
AA,O
and,O
European,O
-,O
American,O
(,O
EA,O
),O
SLE,B-DS
patients,O
",",O
and,O
between,O
those,O
with,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
and,O
those,O
who,O
lack,O
these,O
antibodies,B-GP
.,O
Methods,O
:,O
Whole,O
blood,O
RNA,O
from,O
33,O
female,O
SLE,B-DS
patients,O
and,O
16,O
matched,O
female,O
controls,O
from,O
AA,O
and,O
EA,O
ancestral,O
backgrounds,O
was,O
analyzed,O
on,O
Affymetrix,O
Gene,O
1,O
.,O
0,O
ST,O
gene,O
expression,O
arrays,O
.,O
Ingenuity,O
Pathway,O
Analysis,O
was,O
used,O
to,O
compare,O
the,O
top,O
differentially,O
expressed,O
canonical,O
pathways,O
amongst,O
the,O
sample,O
groups,O
.,O
An,O
independent,O
cohort,O
of,O
116,O
SLE,B-DS
patients,O
was,O
used,O
to,O
replicate,O
findings,O
using,O
quantitative,O
real,O
-,O
time,O
PCR,O
(,O
qPCR,O
).,O
Results,O
:,O
Both,O
AA,O
and,O
EA,O
patients,O
with,O
positive,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
showed,O
over,O
-,O
expression,O
of,O
similar,O
IFN,B-GP
-,O
related,O
canonical,O
pathways,O
",",O
such,O
as,O
IFN,B-GP
Signaling,O
(,O
P,O
=,O
1,O
.,O
3,O
×,O
10,O
−,O
7,O
and,O
6,O
.,O
3,O
×,O
10,O
−,O
11,O
in,O
AA,O
vs,O
.,O
EA,O
respectively,O
"),",O
Antigen,O
Presenting,O
Pathway,O
(,O
P,O
=,O
1,O
.,O
8,O
×,O
10,O
−,O
5,O
and,O
2,O
.,O
5,O
×,O
10,O
−,O
6,O
"),",O
and,O
a,O
number,O
of,O
pattern,B-GP
recognition,I-GP
receptor,I-GP
pathways,O
.,O
In,O
anti,O
-,O
RBP,B-GP
negative,O
(,O
RBP,B-GP
−),O
patients,O
",",O
EA,O
subjects,O
demonstrated,O
similar,O
IFN,B-GP
-,O
related,O
pathway,O
activation,O
",",O
whereas,O
no,O
IFN,B-GP
-,O
related,O
pathways,O
were,O
detected,O
in,O
RBP,B-GP
−,O
AA,O
patients,O
.,O
qPCR,O
validation,O
confirmed,O
similar,O
results,O
.,O
Conclusion,O
:,O
Our,O
data,O
show,O
that,O
IFN,B-GP
-,O
induced,O
gene,O
expression,O
is,O
completely,O
dependent,O
on,O
the,O
presence,O
of,O
autoantibodies,B-GP
in,O
AA,O
SLE,B-DS
patients,O
but,O
not,O
in,O
EA,O
patients,O
.,O
This,O
molecular,O
heterogeneity,O
suggests,O
differences,O
in,O
IFN,B-GP
-,O
pathway,O
activation,O
between,O
ancestral,O
backgrounds,O
in,O
SLE,B-DS
.,O
This,O
heterogeneity,O
may,O
be,O
clinically,O
important,O
",",O
as,O
therapeutics,O
targeting,O
this,O
pathway,O
are,O
being,O
developed,O
.,O
Introduction,O
Systemic,B-DS
lupus,I-DS
erythematosus,I-DS
(,O
SLE,B-DS
),O
is,O
a,O
heterogeneous,O
disease,O
characterized,O
by,O
complex,O
genetic,O
contributions,O
and,O
activation,O
of,O
a,O
number,O
of,O
immune,O
system,O
pathways,O
(,O
1,O
–,O
3,O
).,O
Recent,O
advances,O
in,O
human,B-OG
genetic,O
studies,O
have,O
helped,O
us,O
better,O
understand,O
the,O
immunopathogenesis,O
of,O
the,O
disorder,O
(,O
4,O
",",O
5,O
).,O
Multiple,O
candidate,O
gene,O
association,O
studies,O
and,O
genome,O
wide,O
association,O
studies,O
have,O
led,O
to,O
discovery,O
of,O
more,O
than,O
30,O
susceptibility,O
loci,O
throughout,O
the,O
whole,O
genome,O
",",O
most,O
of,O
which,O
are,O
involved,O
in,O
three,O
main,O
pathways,O
in,O
lupus,B-DS
pathogenesis,O
:,O
abnormal,O
clearance,O
of,O
nuclear,O
debris,O
and,O
immune,O
complexes,O
",",O
over,O
-,O
activation,O
of,O
innate,O
immune,O
system,O
through,O
Toll,B-GP
-,I-GP
like,I-GP
receptor,I-GP
(,O
TLR,B-GP
),O
and,O
type,B-GP
I,I-GP
interferon,I-GP
(,O
IFN,B-GP
),O
signaling,O
",",O
and,O
aberrant,O
adaptive,O
immune,O
response,O
through,O
B,O
and,O
T,O
cell,O
signaling,O
(,O
6,O
",",O
7,O
).,O
Moreover,O
",",O
gene,O
expression,O
microarray,O
studies,O
have,O
been,O
instrumental,O
in,O
defining,O
important,O
aspects,O
of,O
the,O
complex,O
immunological,O
pathogenesis,O
in,O
human,B-OG
subjects,O
(,O
8,O
",",O
9,O
).,O
Several,O
gene,O
expression,O
analyses,O
in,O
SLE,B-DS
have,O
found,O
up,O
-,O
regulation,O
of,O
IFN,B-GP
-,O
inducible,O
genes,O
(,O
IFIGs,B-GP
),O
in,O
more,O
than,O
50,O
%,O
of,O
patients,O
(,O
10,O
–,O
13,O
"),",O
and,O
others,O
have,O
shown,O
differential,O
expression,O
of,O
genes,O
involved,O
in,O
several,O
pathways,O
including,O
inflammation,O
",",O
apoptosis,O
",",O
DNA,O
repair,O
",",O
and,O
T,O
cell,O
activation,O
(,O
12,O
",",O
14,O
–,O
17,O
).,O
Interferon,B-GP
-,I-GP
α,I-GP
is,O
a,O
pleiotropic,O
type,B-GP
I,I-GP
IFN,I-GP
which,O
plays,O
a,O
key,O
pathogenic,O
role,O
in,O
lupus,B-DS
development,O
(,O
18,O
).,O
It,O
is,O
an,O
anti,O
-,O
viral,O
cytokine,B-GP
which,O
is,O
regulated,O
by,O
endosomal,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
(,O
PRRs,B-GP
),O
such,O
as,O
TLRs,B-GP
or,O
cytosolic,O
PRRs,B-GP
like,O
RIG,B-GP
-,I-GP
I,I-GP
like,I-GP
receptors,I-GP
(,O
RLRs,B-GP
),O
(,O
18,O
",",O
19,O
).,O
It,O
has,O
the,O
potential,O
to,O
break,O
self,O
-,O
tolerance,O
by,O
inducing,O
dendritic,O
cell,O
differentiation,O
which,O
in,O
turn,O
leads,O
to,O
activation,O
of,O
autoreactive,O
T,O
and,O
B,O
cells,O
",",O
thus,O
linking,O
innate,O
and,O
adaptive,O
immune,O
systems,O
(,O
20,O
",",O
21,O
).,O
IFN,B-GP
-,I-GP
α,I-GP
is,O
a,O
heritable,O
risk,O
factor,O
in,O
SLE,B-DS
(,O
22,O
",",O
23,O
),O
and,O
some,O
people,O
who,O
have,O
received,O
recombinant,O
human,B-OG
IFN,B-GP
-,I-GP
α,I-GP
as,O
a,O
treatment,O
for,O
viral,O
hepatitis,B-DS
C,I-DS
or,O
malignancy,O
have,O
developed,O
de,O
novo,O
SLE,B-DS
which,O
resolves,O
upon,O
discontinuation,O
of,O
the,O
IFN,B-GP
-,I-GP
α,I-GP
treatment,O
(,O
24,O
).,O
These,O
data,O
strongly,O
support,O
a,O
causal,O
role,O
for,O
IFN,B-GP
-,I-GP
α,I-GP
in,O
SLE,B-DS
pathogenesis,O
.,O
Increased,O
activity,O
of,O
IFN,B-GP
-,I-GP
α,I-GP
has,O
been,O
associated,O
with,O
presence,O
of,O
various,O
SLE,B-DS
-,O
associated,O
autoantibodies,B-GP
",",O
both,O
anti,O
-,O
double,O
-,O
stranded,O
DNA,O
(,O
anti,O
-,O
dsDNA,O
),O
and,O
anti,O
-,O
RNA,B-GP
-,I-GP
binding,I-GP
protein,I-GP
(,O
anti,O
-,O
RBP,B-GP
),O
antibodies,B-GP
along,O
with,O
different,O
organ,O
involvement,O
such,O
as,O
hematologic,O
",",O
renal,O
",",O
and,O
central,O
nervous,O
systems,O
(,O
10,O
",",O
25,O
",",O
26,O
).,O
However,O
",",O
longitudinal,O
studies,O
have,O
not,O
confirmed,O
the,O
association,O
between,O
increases,O
in,O
IFIG,B-GP
expression,O
and,O
disease,O
flare,O
(,O
27,O
",",O
28,O
).,O
It,O
seems,O
that,O
patients,O
with,O
high,O
IFN,B-GP
-,I-GP
α,I-GP
have,O
more,O
severe,O
disease,O
and,O
a,O
higher,O
rate,O
of,O
flare,O
on,O
average,O
",",O
but,O
the,O
changes,O
in,O
IFN,B-GP
-,I-GP
α,I-GP
levels,O
in,O
circulation,O
do,O
not,O
correlate,O
closely,O
or,O
quantitatively,O
with,O
changes,O
in,O
measures,O
of,O
disease,O
activity,O
over,O
time,O
.,O
Systemic,B-DS
lupus,I-DS
erythematosus,I-DS
is,O
both,O
more,O
prevalent,O
and,O
more,O
severe,O
in,O
African,O
-,O
American,O
(,O
AA,O
),O
populations,O
than,O
in,O
European,O
-,O
American,O
(,O
EA,O
),O
populations,O
",",O
and,O
disease,O
manifestations,O
are,O
variable,O
amongst,O
different,O
ancestral,O
backgrounds,O
(,O
29,O
–,O
32,O
).,O
AA,O
and,O
Hispanic,O
-,O
American,O
(,O
HA,O
),O
patients,O
are,O
likely,O
to,O
have,O
more,O
active,O
SLE,B-DS
",",O
with,O
an,O
earlier,O
age,O
at,O
onset,O
",",O
than,O
EA,O
patients,O
(,O
31,O
",",O
32,O
).,O
Anti,O
-,O
ribonucleoprotein,B-GP
(,O
anti,O
-,O
RNP,B-GP
),O
and,O
anti,O
-,O
Smith,B-GP
(,O
anti,O
-,O
Sm,B-GP
),O
antibodies,B-GP
are,O
more,O
prevalent,O
in,O
AA,O
patients,O
than,O
in,O
EA,O
and,O
HA,O
(,O
30,O
",",O
32,O
"),",O
and,O
a,O
number,O
of,O
genetic,O
variants,O
are,O
associated,O
with,O
autoantibody,B-GP
profiles,O
in,O
different,O
ancestral,O
groups,O
(,O
33,O
",",O
34,O
).,O
Moreover,O
",",O
compared,O
to,O
EA,O
patients,O
",",O
HA,O
",",O
and,O
AA,O
patients,O
have,O
a,O
higher,O
incidence,O
of,O
SLE,B-DS
-,O
related,O
renal,B-DS
disease,I-DS
",",O
associated,O
with,O
anti,O
-,O
dsDNA,O
and,O
anti,O
-,O
RNP,B-GP
antibodies,B-GP
(,O
31,O
",",O
35,O
).,O
Additionally,O
",",O
some,O
of,O
the,O
genetic,O
factors,O
associated,O
with,O
SLE,B-DS
are,O
not,O
shared,O
between,O
AA,O
and,O
EA,O
patients,O
(,O
36,O
–,O
39,O
).,O
These,O
data,O
all,O
support,O
the,O
idea,O
that,O
molecular,O
and,O
biological,O
differences,O
should,O
exist,O
in,O
SLE,B-DS
patients,O
of,O
different,O
ancestral,O
backgrounds,O
.,O
We,O
have,O
shown,O
that,O
overall,O
serum,O
IFN,B-GP
-,I-GP
α,I-GP
activity,O
is,O
higher,O
in,O
SLE,B-DS
patients,O
of,O
non,O
-,O
European,O
ancestry,O
as,O
compared,O
to,O
European,O
ancestry,O
",",O
either,O
directly,O
or,O
indirectly,O
through,O
an,O
increased,O
prevalence,O
of,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
(,O
40,O
",",O
41,O
).,O
In,O
this,O
study,O
",",O
we,O
compare,O
peripheral,O
blood,O
gene,O
expression,O
between,O
AA,O
and,O
EA,O
SLE,B-DS
patients,O
taking,O
into,O
account,O
the,O
differences,O
in,O
autoantibody,B-GP
profile,O
",",O
and,O
we,O
find,O
a,O
striking,O
difference,O
in,O
the,O
activation,O
of,O
the,O
IFN,B-GP
pathway,O
between,O
the,O
two,O
groups,O
.,O
Materials,O
and,O
Methods,O
Patients,O
",",O
samples,O
",",O
and,O
data,O
collection,O
Serum,O
samples,O
were,O
obtained,O
from,O
149,O
female,O
SLE,B-DS
patients,O
from,O
the,O
University,O
of,O
Chicago,O
Medical,O
Center,O
(,O
UCMC,O
),O
(,O
n,O
=,O
119,O
),O
and,O
NorthShore,O
University,O
Health,O
System,O
(,O
n,O
=,O
30,O
).,O
All,O
cases,O
fulfilled,O
the,O
American,O
College,O
of,O
Rheumatology,O
criteria,O
for,O
the,O
diagnosis,O
of,O
SLE,B-DS
(,O
1,O
",",O
42,O
"),",O
and,O
the,O
data,O
regarding,O
the,O
presence,O
or,O
absence,O
of,O
these,O
criteria,O
as,O
well,O
as,O
of,O
SLE,B-DS
-,O
associated,O
autoantibodies,B-GP
[,O
anti,O
-,O
nuclear,O
antibodies,B-GP
(,O
ANA,O
"),",O
and,O
anti,O
-,O
Ro,B-GP
",",O
anti,O
-,O
La,B-GP
",",O
anti,O
-,O
Sm,B-GP
",",O
anti,O
-,O
RNP,B-GP
",",O
and,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
],O
were,O
available,O
for,O
all,O
patients,O
.,O
Forty,O
-,O
nine,O
unrelated,O
females,O
who,O
were,O
screened,O
by,O
medical,O
record,O
review,O
for,O
the,O
absence,O
of,O
autoimmune,B-DS
disease,I-DS
were,O
used,O
as,O
controls,O
.,O
They,O
were,O
of,O
similar,O
age,O
(,O
P,O
=,O
0,O
.,O
21,O
),O
as,O
the,O
SLE,B-DS
cases,O
.,O
All,O
subjects,O
provided,O
informed,O
consent,O
",",O
and,O
the,O
study,O
was,O
approved,O
by,O
the,O
institutional,O
review,O
boards,O
at,O
the,O
Mayo,O
Clinic,O
and,O
University,O
of,O
Chicago,O
.,O
Detection,O
of,O
autoantibodies,B-GP
Antibodies,B-GP
to,O
Ro,B-GP
",",O
La,B-GP
",",O
Sm,B-GP
",",O
and,O
RNP,B-GP
for,O
all,O
samples,O
were,O
measured,O
by,O
ELISA,O
methods,O
(,O
INOVA,O
Diagnostics,O
",",O
San,O
Diego,O
",",O
CA,O
",",O
USA,O
),O
at,O
UCMC,O
at,O
the,O
time,O
of,O
serum,O
and,O
RNA,O
sampling,O
",",O
and,O
standard,O
clinical,O
laboratory,O
cutoff,O
points,O
were,O
used,O
to,O
categorize,O
them,O
as,O
positive,O
or,O
negative,O
.,O
Anti,O
-,O
dsDNA,O
antibodies,B-GP
were,O
measured,O
using,O
Crithidia,B-OG
luciliae,I-OG
immunofluorescence,O
at,O
UCMC,O
",",O
and,O
detectable,O
fluorescence,O
was,O
considered,O
positive,O
.,O
Gene,O
expression,O
analysis,O
Thirty,O
-,O
three,O
SLE,B-DS
cases,O
and,O
16,O
age,O
-,O
matched,O
controls,O
were,O
selected,O
for,O
microarray,O
gene,O
expression,O
analysis,O
.,O
The,O
cases,O
were,O
subdivided,O
into,O
AA,O
and,O
EA,O
patients,O
",",O
and,O
those,O
with,O
positive,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
and,O
those,O
without,O
as,O
described,O
in,O
Table,O
1,O
.,O
Whole,O
blood,O
from,O
the,O
subjects,O
was,O
collected,O
in,O
PAX,O
gene,O
tubes,O
(,O
Qiagen,O
"),",O
and,O
RNA,O
was,O
purified,O
in,O
spin,O
columns,O
per,O
manufacture,O
recommendations,O
.,O
The,O
RNA,O
was,O
analyzed,O
on,O
Affymetrix,O
Gene,O
1,O
.,O
0,O
ST,O
gene,O
expression,O
arrays,O
",",O
which,O
were,O
run,O
in,O
the,O
University,O
of,O
Chicago,O
Microarray,O
Core,O
facility,O
.,O
These,O
intensity,O
data,O
were,O
normalized,O
through,O
Affymetrix,O
Expression,O
Console,O
software,O
.,O
Data,O
from,O
the,O
microarray,O
experiment,O
have,O
been,O
deposited,O
in,O
the,O
GEO,O
database,O
",",O
accession,O
number,O
GSE50635,O
.,O
Samples,O
and,O
data,O
collection,O
for,O
microarray,O
analysis,O
*.,O
SLE,B-DS
cases,O
**,O
Non,O
-,O
autoimmune,O
controls,O
RBP,B-GP
+,O
RBP,B-GP
−,O
European,O
-,O
American,O
Female,O
8,O
8,O
8,O
African,O
-,O
American,O
Female,O
9,O
8,O
8,O
*,O
There,O
was,O
no,O
difference,O
in,O
age,O
amongst,O
the,O
groups,O
.,O
**,O
All,O
SLE,B-DS
cases,O
fulfilled,O
the,O
ACR,O
criteria,O
for,O
SLE,B-DS
.,O
Anti,O
-,O
RBP,B-GP
(,O
anti,O
-,O
Ro,B-GP
",",O
anti,O
-,O
La,B-GP
",",O
anti,O
-,O
Sm,B-GP
",",O
and,O
anti,O
-,O
RNP,B-GP
),O
antibodies,B-GP
were,O
measured,O
by,O
ELISA,O
",",O
and,O
anti,O
-,O
dsDNA,O
antibody,B-GP
levels,O
were,O
measured,O
using,O
Crithidia,B-OG
luciliae,I-OG
immunofluorescence,O
.,O
RBP,B-GP
"+,",O
anti,O
-,O
RNA,B-GP
-,I-GP
binding,I-GP
-,I-GP
protein,I-GP
(,O
RBP,B-GP
),O
antibody,B-GP
positive,O
;,O
RBP,B-GP
"−,",O
RBP,B-GP
antibody,B-GP
negative,O
.,O
Quantitative,O
real,O
-,O
time,O
PCR,O
(,O
qPCR,O
),O
was,O
used,O
to,O
validate,O
the,O
hypotheses,O
generated,O
from,O
the,O
microarray,O
data,O
with,O
an,O
independent,O
replication,O
cohort,O
.,O
The,O
RNA,O
of,O
whole,O
blood,O
from,O
60,O
AA,O
SLE,B-DS
patients,O
",",O
47,O
anti,O
-,O
RBP,B-GP
antibody,B-GP
positive,O
(,O
RBP,B-GP
"+),",O
and,O
13,O
anti,O
-,O
RBP,B-GP
antibody,B-GP
negative,O
(,O
RBP,B-GP
"−),",O
and,O
56,O
EA,O
SLE,B-DS
patients,O
",",O
21,O
RBP,B-GP
+,O
and,O
24,O
RBP,B-GP
−,O
along,O
with,O
25,O
AA,O
and,O
8,O
EA,O
controls,O
was,O
purified,O
using,O
Qiagen,O
RNeasy,O
kit,O
.,O
cDNA,O
was,O
synthesized,O
from,O
total,O
mRNA,O
",",O
and,O
qPCR,O
was,O
used,O
to,O
measure,O
relative,O
transcript,O
expression,O
using,O
SYBR,O
Green,O
dye,O
on,O
an,O
ABI,O
7900HT,O
thermal,O
cycler,O
.,O
Statistical,O
analysis,O
For,O
each,O
ancestry,O
",",O
the,O
anti,O
-,O
RBP,B-GP
antibody,B-GP
status,O
was,O
used,O
as,O
a,O
dichotomous,O
variable,O
",",O
and,O
each,O
subgroup,O
was,O
compared,O
to,O
respective,O
controls,O
from,O
the,O
same,O
ancestral,O
background,O
.,O
Following,O
normalization,O
",",O
the,O
mean,O
microarray,O
gene,O
expression,O
values,O
along,O
with,O
standard,O
deviations,O
were,O
calculated,O
for,O
each,O
subgroup,O
and,O
used,O
to,O
calculate,O
the,O
fold,O
changes,O
between,O
subjects,O
and,O
controls,O
.,O
Values,O
were,O
compared,O
between,O
the,O
groups,O
using,O
the,O
two,O
-,O
tailed,O
Student,O
’,O
s,O
unpaired,O
t,O
-,O
test,O
.,O
Similar,O
comparisons,O
were,O
made,O
with,O
the,O
qPCR,O
data,O
",",O
but,O
this,O
time,O
",",O
all,O
group,O
results,O
were,O
expressed,O
in,O
medians,O
and,O
compared,O
using,O
Mann,O
–,O
Whitney,O
tests,O
as,O
they,O
did,O
not,O
follow,O
Gaussian,O
distributions,O
.,O
For,O
both,O
microarray,O
and,O
qPCR,O
analyses,O
",",O
P,O
values,O
less,O
than,O
0,O
.,O
05,O
were,O
considered,O
significant,O
.,O
Canonical,O
pathway,O
analysis,O
From,O
the,O
microarray,O
data,O
",",O
the,O
differentially,O
expressed,O
genes,O
with,O
a,O
cutoff,O
P,O
value,O
of,O
0,O
.,O
05,O
along,O
with,O
their,O
respective,O
fold,O
changes,O
were,O
analyzed,O
further,O
through,O
Ingenuity,O
Pathway,O
Analysis,O
(,O
IPA,O
),O
(,O
Ingenuity,O
®,O
Systems,O
",",O
www,O
.,O
ingenuity,O
.,O
com,O
),O
to,O
compare,O
the,O
top,O
canonical,O
pathways,O
amongst,O
the,O
sample,O
groups,O
(,O
Table,O
1,O
).,O
The,O
IPA,O
canonical,O
pathway,O
analysis,O
identified,O
the,O
pathways,O
from,O
the,O
IPA,O
Knowledge,O
Base,O
that,O
were,O
most,O
significant,O
to,O
the,O
data,O
set,O
.,O
The,O
significance,O
of,O
the,O
association,O
between,O
the,O
data,O
set,O
and,O
the,O
canonical,O
pathway,O
was,O
measured,O
in,O
two,O
ways,O
:,O
(,O
1,O
),O
A,O
ratio,O
of,O
the,O
number,O
of,O
molecules,O
from,O
the,O
data,O
set,O
that,O
map,O
to,O
the,O
pathway,O
divided,O
by,O
the,O
total,O
number,O
of,O
molecules,O
that,O
map,O
to,O
the,O
canonical,O
pathway,O
was,O
displayed,O
.,O
(,O
2,O
),O
Fisher,O
’,O
s,O
exact,O
test,O
was,O
used,O
to,O
calculate,O
a,O
P,O
value,O
determining,O
the,O
probability,O
that,O
the,O
association,O
between,O
the,O
genes,O
in,O
the,O
dataset,O
and,O
the,O
canonical,O
pathway,O
was,O
explained,O
by,O
chance,O
alone,O
.,O
Results,O
Demographics,O
and,O
presence,O
of,O
ANA,O
and,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
The,O
average,O
age,O
of,O
all,O
subjects,O
included,O
in,O
the,O
microarray,O
portion,O
of,O
the,O
study,O
was,O
43,O
.,O
5,O
±,O
10,O
.,O
6,O
years,O
.,O
When,O
the,O
subjects,O
and,O
controls,O
were,O
divided,O
into,O
subgroups,O
according,O
to,O
ancestry,O
and,O
the,O
presence,O
of,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
(,O
Table,O
1,O
"),",O
there,O
was,O
no,O
statistical,O
difference,O
in,O
age,O
amongst,O
the,O
subgroups,O
including,O
controls,O
.,O
There,O
was,O
lower,O
prevalence,O
in,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
in,O
RBP,B-GP
−,O
AA,O
patients,O
(,O
77,O
%,O
of,O
RBP,B-GP
+,O
vs,O
.,O
31,O
%,O
of,O
RBP,B-GP
−,O
had,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
",",O
P,O
=,O
0,O
.,O
005,O
).,O
In,O
EA,O
subjects,O
",",O
this,O
difference,O
was,O
much,O
less,O
pronounced,O
",",O
and,O
was,O
not,O
statistically,O
significant,O
(,O
66,O
%,O
of,O
RBP,B-GP
+,O
vs,O
.,O
54,O
%,O
of,O
RBP,B-GP
−,O
had,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
",",O
P,O
=,O
0,O
.,O
4,O
).,O
This,O
is,O
in,O
concordance,O
with,O
our,O
previous,O
large,O
-,O
scale,O
analyses,O
in,O
SLE,B-DS
",",O
in,O
which,O
we,O
have,O
also,O
found,O
that,O
anti,O
-,O
RBP,B-GP
and,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
are,O
more,O
correlated,O
in,O
AA,O
as,O
compared,O
to,O
EA,O
SLE,B-DS
patients,O
(,O
40,O
).,O
All,O
subjects,O
were,O
female,O
and,O
all,O
tested,O
positive,O
for,O
ANA,O
.,O
IFN,B-GP
-,O
related,O
canonical,O
pathway,O
activation,O
in,O
AA,O
vs,O
.,O
EA,O
SLE,B-DS
patients,O
Top,O
10,O
canonical,O
pathways,O
from,O
each,O
subgroup,O
are,O
shown,O
in,O
Table,O
2,O
.,O
Many,O
immune,O
system,O
associated,O
pathways,O
were,O
associated,O
with,O
the,O
cases,O
",",O
and,O
similar,O
to,O
previous,O
studies,O
",",O
type,B-GP
I,I-GP
IFN,I-GP
-,O
related,O
pathways,O
were,O
the,O
most,O
differentially,O
expressed,O
when,O
comparing,O
cases,O
vs,O
.,O
controls,O
except,O
in,O
RBP,B-GP
−,O
AA,O
group,O
.,O
We,O
examined,O
in,O
greater,O
detail,O
the,O
six,O
canonical,O
pathways,O
which,O
were,O
type,B-GP
I,I-GP
IFN,I-GP
-,O
related,O
across,O
patients,O
from,O
the,O
two,O
different,O
ancestral,O
backgrounds,O
studied,O
.,O
As,O
shown,O
in,O
Table,O
3,O
",",O
the,O
microarray,O
analysis,O
of,O
all,O
SLE,B-DS
cases,O
vs,O
.,O
controls,O
demonstrated,O
all,O
six,O
IFN,B-GP
-,O
related,O
canonical,O
pathways,O
significantly,O
involved,O
.,O
The,O
same,O
pattern,O
was,O
also,O
observed,O
for,O
all,O
EA,O
cases,O
vs,O
.,O
controls,O
.,O
However,O
",",O
to,O
our,O
surprise,O
",",O
the,O
associations,O
between,O
the,O
IFN,B-GP
-,O
related,O
canonical,O
pathways,O
and,O
AA,O
SLE,B-DS
cases,O
were,O
not,O
as,O
strong,O
as,O
only,O
three,O
out,O
of,O
six,O
pathways,O
were,O
found,O
to,O
be,O
significant,O
.,O
This,O
is,O
despite,O
that,O
fact,O
that,O
high,O
circulating,O
levels,O
of,O
type,B-GP
I,I-GP
IFN,I-GP
are,O
more,O
common,O
in,O
AA,O
SLE,B-DS
patients,O
(,O
40,O
).,O
Top,O
10,O
canonical,O
pathways,O
from,O
each,O
subgroup,O
vs,O
.,O
matching,O
controls,O
through,O
IPA,O
from,O
microarray,O
data,O
.,O
All,O
cases,O
All,O
EA,O
All,O
AA,O
EA,O
RBP,B-GP
+,O
EA,O
RBP,B-GP
−,O
AA,O
RBP,B-GP
+,O
AA,O
RBP,B-GP
−,O
EIF2,B-GP
signaling,O
Interferon,B-GP
signaling,O
EIF2,B-GP
signaling,O
Interferon,B-GP
signaling,O
Antigen,O
presentation,O
pathway,O
EIF2,B-GP
signaling,O
Regulation,O
of,O
IL,B-GP
-,I-GP
2,I-GP
expression,O
in,O
activated,O
and,O
anergic,O
T,O
lymphocytes,O
Interferon,B-GP
signaling,O
Antigen,O
presentation,O
pathway,O
Activation,O
of,O
IRF,B-GP
by,O
cytosolic,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
Activation,O
of,O
IRF,B-GP
by,O
cytosolic,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
OX40,B-GP
signaling,O
pathway,O
Regulation,O
of,O
eIF4,B-GP
and,O
p70S6K,B-GP
signaling,O
Glucocorticoid,B-GP
receptor,I-GP
signaling,O
Antigen,O
presentation,O
pathway,O
Role,O
of,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
in,O
recognition,O
of,O
bacteria,B-OG
and,O
viruses,B-OG
Angiopoietin,B-GP
signaling,O
Antigen,O
presentation,O
pathway,O
Autoimmune,B-DS
thyroid,I-DS
disease,I-DS
signaling,O
mTOR,B-GP
signaling,O
CD28,B-GP
signaling,O
in,O
T,O
helper,O
cells,O
Activation,O
of,O
IRF,B-GP
by,O
cytosolic,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
Retinoic,O
acid,O
mediated,O
apoptosis,O
signaling,O
Regulation,O
of,O
eIF4,B-GP
and,O
p70S6K,B-GP
signaling,O
Role,O
of,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
in,O
recognition,O
of,O
bacteria,B-OG
and,O
viruses,B-OG
Allograft,O
rejection,O
signaling,O
Activation,O
of,O
IRF,B-GP
by,O
cytosolic,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
T,B-GP
cell,I-GP
receptor,I-GP
signaling,O
IL,B-GP
-,I-GP
12,I-GP
signaling,O
and,O
production,O
in,O
macrophages,O
Activation,O
of,O
IRF,B-GP
by,O
cytosolic,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
Hypoxia,O
signaling,O
in,O
the,O
cardiovascular,O
system,O
IL,B-GP
-,I-GP
15,I-GP
production,O
Interferon,B-GP
signaling,O
Interferon,B-GP
signaling,O
Glycosphingolipid,O
biosynthesis,O
-,O
globoseries,O
mTOR,B-GP
signaling,O
Graft,B-DS
-,I-DS
vs,I-DS
.-,I-DS
host,I-DS
disease,I-DS
signaling,O
Role,O
of,O
RIG1,B-GP
-,I-GP
like,I-GP
receptors,I-GP
in,O
antiviral,O
innate,O
immunity,O
Retinoic,O
acid,O
mediated,O
apoptosis,O
signaling,O
Graft,B-DS
-,I-DS
vs,I-DS
.-,I-DS
host,I-DS
disease,I-DS
signaling,O
Apoptosis,O
signaling,O
Biosynthesis,O
of,O
steroids,O
Role,O
of,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
in,O
recognition,O
of,O
bacteria,B-OG
and,O
viruses,B-OG
Dendritic,O
cell,O
maturation,O
mTOR,B-GP
signaling,O
Role,O
of,O
RIG1,B-GP
-,I-GP
like,I-GP
receptors,I-GP
in,O
antiviral,O
innate,O
immunity,O
Cytotoxic,O
T,O
lymphocyte,O
-,O
mediated,O
apoptosis,O
of,O
target,O
cells,O
Colorectal,B-DS
cancer,I-DS
metastasis,O
signaling,O
April,B-GP
mediated,O
signaling,O
TNFR2,B-GP
signaling,O
IL,B-GP
-,I-GP
15,I-GP
production,O
Hereditary,B-DS
breast,I-DS
cancer,I-DS
signaling,O
Communication,O
between,O
innate,O
and,O
adaptive,O
immune,O
cells,O
Crosstalk,O
between,O
dendritic,O
cells,O
and,O
natural,O
killer,O
cells,O
TNFR2,B-GP
signaling,O
Reelin,B-GP
signaling,O
in,O
neurons,O
Production,O
of,O
nitric,O
oxide,O
and,O
reactive,O
oxygen,O
species,O
in,O
macrophages,O
Autoimmune,B-DS
thyroid,I-DS
disease,I-DS
signaling,O
Role,O
of,O
PI3K,B-GP
/,O
AKT,B-GP
signaling,O
in,O
the,O
pathogenesis,O
of,O
influenza,B-DS
Dendritic,O
Cell,O
maturation,O
Type,B-DS
I,I-DS
diabetes,I-DS
mellitus,I-DS
signaling,O
IL,B-GP
-,I-GP
8,I-GP
signaling,O
Glycosphingolipid,O
biosynthesis,O
–,O
neolactoseries,O
IL,B-GP
-,I-GP
15,I-GP
production,O
Communication,O
between,O
innate,O
and,O
adaptive,O
immune,O
cells,O
TNFR2,B-GP
signaling,O
Starch,O
and,O
sucrose,O
metabolism,O
Dendritic,O
cell,O
maturation,O
P2Y,B-GP
purigenic,I-GP
receptor,I-GP
signaling,O
pathway,O
Mitotic,O
roles,O
of,O
polo,B-GP
-,I-GP
like,I-GP
kinase,I-GP
IPA,O
",",O
ingenuity,O
pathway,O
analysis,O
;,O
EA,O
",",O
European,O
-,O
American,O
;,O
AA,O
",",O
African,O
-,O
American,O
;,O
RBP,B-GP
"+,",O
anti,O
-,O
RNA,B-GP
-,I-GP
binding,I-GP
-,I-GP
protein,I-GP
(,O
RBP,B-GP
),O
antibody,B-GP
positive,O
;,O
RBP,B-GP
"−,",O
RBP,B-GP
antibody,B-GP
negative,O
;,O
eIF2,B-GP
",",O
eukaryotic,B-GP
initiation,I-GP
factor,I-GP
2,I-GP
;,O
IRF,B-GP
",",O
interferon,B-GP
-,I-GP
regulatory,I-GP
factor,I-GP
;,O
mTOR,B-GP
",",O
mammalian,B-GP
target,I-GP
of,I-GP
rapamycin,I-GP
;,O
TNFR2,B-GP
",",O
tumor,B-GP
necrosis,I-GP
factor,I-GP
receptor,I-GP
2,I-GP
;,O
eIF4,B-GP
",",O
eukaryotic,B-GP
initiation,I-GP
factor,I-GP
4,I-GP
;,O
RIG1,B-GP
",",O
retinoic,B-GP
acid,I-GP
-,I-GP
inducible,I-GP
gene,I-GP
1,I-GP
;,O
PI3K,B-GP
",",O
phosphatidylinositol,B-GP
3,I-GP
-,I-GP
kinase,I-GP
;,O
OX40,B-GP
=,O
CD134,O
.,O
P,O
values,O
for,O
IPA,O
IFN,B-GP
-,O
related,O
canonical,O
pathways,O
from,O
microarray,O
data,O
.,O
All,O
SLE,B-DS
cases,O
(,O
n,O
=,O
33,O
),O
EA,O
SLE,B-DS
cases,O
(,O
n,O
=,O
16,O
),O
AA,O
SLE,B-DS
cases,O
(,O
n,O
=,O
17,O
),O
Interferon,B-GP
signaling,O
1,O
.,O
53,O
×,O
10,O
−,O
10,O
6,O
.,O
55,O
×,O
10,O
−,O
12,O
0,O
.,O
29,O
Activation,O
of,O
IRF,B-GP
by,O
cytosolic,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
6,O
.,O
14,O
×,O
10,O
−,O
5,O
2,O
.,O
74,O
×,O
10,O
−,O
5,O
8,O
.,O
46,O
×,O
10,O
−,O
5,O
Role,O
of,O
RIG1,B-GP
-,I-GP
like,I-GP
receptors,I-GP
in,O
antiviral,O
innate,O
immunity,O
1,O
.,O
63,O
×,O
10,O
−,O
4,O
5,O
.,O
85,O
×,O
10,O
−,O
7,O
0,O
.,O
044,O
Role,O
of,O
PKR,B-GP
in,O
interferon,B-GP
induction,O
and,O
antiviral,O
response,O
0,O
.,O
020,O
0,O
.,O
038,O
0,O
.,O
091,O
Role,O
of,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
in,O
recognition,O
of,O
bacteria,B-OG
and,O
viruses,B-OG
0,O
.,O
0097,O
0,O
.,O
0064,O
0,O
.,O
0011,O
Communication,O
between,O
innate,O
and,O
adaptive,O
immune,O
cells,O
0,O
.,O
0098,O
0,O
.,O
0013,O
Not,O
listed,O
IPA,O
",",O
ingenuity,O
pathway,O
analysis,O
;,O
IFN,B-GP
",",O
interferon,B-GP
;,O
SLE,B-DS
",",O
systemic,B-DS
lupus,I-DS
erythematosus,I-DS
;,O
EA,O
",",O
European,O
-,O
American,O
;,O
AA,O
",",O
African,O
-,O
American,O
;,O
IRF,B-GP
",",O
interferon,B-GP
-,I-GP
regulatory,I-GP
factor,I-GP
;,O
RIG1,B-GP
",",O
retinoic,B-GP
acid,I-GP
-,I-GP
inducible,I-GP
gene,I-GP
1,I-GP
;,O
and,O
PKR,B-GP
",",O
protein,B-GP
kinase,I-GP
R,I-GP
.,O
IFN,B-GP
-,O
related,O
canonical,O
pathway,O
activation,O
is,O
not,O
seen,O
in,O
RBP,B-GP
−,O
AA,O
patients,O
To,O
explore,O
this,O
further,O
",",O
we,O
looked,O
at,O
the,O
associations,O
between,O
IFN,B-GP
-,O
related,O
canonical,O
pathways,O
within,O
SLE,B-DS
patient,O
subgroups,O
stratified,O
by,O
both,O
ancestry,O
and,O
the,O
presence,O
or,O
absence,O
of,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
.,O
As,O
shown,O
in,O
Table,O
4,O
",",O
all,O
six,O
type,B-GP
I,I-GP
IFN,I-GP
-,O
related,O
pathways,O
were,O
activated,O
in,O
both,O
AA,O
and,O
EA,O
RBP,B-GP
+,O
patients,O
.,O
The,O
key,O
pathway,O
difference,O
was,O
found,O
between,O
AA,O
and,O
EA,O
patients,O
who,O
were,O
RBP,B-GP
−.,O
RBP,B-GP
−,O
EA,O
patients,O
demonstrated,O
activation,O
of,O
all,O
six,O
IFN,B-GP
-,O
related,O
canonical,O
pathways,O
",",O
whereas,O
not,O
a,O
single,O
type,B-GP
I,I-GP
IFN,I-GP
pathway,O
was,O
significantly,O
involved,O
in,O
the,O
RBP,B-GP
−,O
AA,O
patients,O
.,O
P,O
values,O
from,O
IPA,O
IFN,B-GP
-,O
related,O
canonical,O
pathways,O
from,O
microarray,O
data,O
.,O
EA,O
RBP,B-GP
+,O
EA,O
RBP,B-GP
−,O
AA,O
RBP,B-GP
+,O
AA,O
RBP,B-GP
−,O
Interferon,B-GP
signaling,O
5,O
.,O
8,O
×,O
10,O
−,O
11,O
10,O
.,O
6,O
×,O
10,O
−,O
5,O
1,O
.,O
3,O
×,O
10,O
−,O
7,O
0,O
.,O
063,O
Activation,O
of,O
IRF,B-GP
by,O
cytosolic,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
1,O
.,O
1,O
×,O
10,O
−,O
6,O
0,O
.,O
016,O
2,O
.,O
86,O
×,O
10,O
−,O
8,O
0,O
.,O
25,O
Role,O
of,O
RIG1,B-GP
-,I-GP
like,I-GP
receptors,I-GP
in,O
antiviral,O
innate,O
immunity,O
2,O
.,O
0,O
×,O
10,O
−,O
5,O
0,O
.,O
030,O
0,O
.,O
0014,O
Not,O
listed,O
Role,O
of,O
PKR,B-GP
in,O
interferon,B-GP
induction,O
and,O
antiviral,O
response,O
0,O
.,O
0073,O
0,O
.,O
042,O
9,O
.,O
0,O
×,O
10,O
−,O
4,O
Not,O
listed,O
Role,O
of,O
pattern,B-GP
recognition,I-GP
receptors,I-GP
in,O
recognition,O
of,O
bacteria,B-OG
and,O
viruses,B-OG
1,O
.,O
8,O
×,O
10,O
−,O
4,O
0,O
.,O
028,O
5,O
.,O
8,O
×,O
10,O
−,O
4,O
0,O
.,O
31,O
Communication,O
between,O
innate,O
and,O
adaptive,O
immune,O
cells,O
0,O
.,O
0043,O
0,O
.,O
0064,O
0,O
.,O
023,O
Not,O
listed,O
IPA,O
",",O
ingenuity,O
pathway,O
analysis,O
;,O
IFN,B-GP
",",O
interferon,B-GP
;,O
EA,O
",",O
European,O
–,O
American,O
;,O
AA,O
",",O
African,O
-,O
American,O
;,O
RBP,B-GP
"+,",O
anti,O
-,O
RNA,B-GP
-,I-GP
binding,I-GP
-,I-GP
protein,I-GP
(,O
RBP,B-GP
),O
antibody,B-GP
positive,O
;,O
RBP,B-GP
"−,",O
RBP,B-GP
antibody,B-GP
negative,O
;,O
IRF,B-GP
",",O
interferon,B-GP
-,I-GP
regulatory,I-GP
factor,I-GP
;,O
RIG1,B-GP
",",O
retinoic,B-GP
acid,I-GP
-,I-GP
inducible,I-GP
gene,I-GP
1,I-GP
;,O
and,O
PKR,B-GP
",",O
protein,B-GP
kinase,I-GP
R,I-GP
.,O
IFN,B-GP
-,O
induced,O
gene,O
expression,O
pathway,O
diagrams,O
in,O
AA,O
vs,O
.,O
EA,O
patients,O
In,O
Figure,O
1,O
",",O
we,O
show,O
pathway,O
diagrams,O
generated,O
in,O
IPA,O
software,O
of,O
the,O
type,O
I,O
and,O
type,B-GP
II,I-GP
IFN,I-GP
pathways,O
",",O
with,O
genes,O
that,O
were,O
up,O
-,O
regulated,O
in,O
cases,O
vs,O
.,O
controls,O
shaded,O
red,O
.,O
It,O
is,O
striking,O
that,O
none,O
of,O
the,O
genes,O
illustrated,O
downstream,O
of,O
the,O
type,O
I,O
and,O
type,B-GP
II,I-GP
IFN,I-GP
receptors,I-GP
are,O
up,O
-,O
regulated,O
in,O
the,O
RBP,B-GP
−,O
AA,O
patients,O
",",O
while,O
in,O
the,O
RBP,B-GP
−,O
EA,O
patients,O
",",O
many,O
IFN,B-GP
-,O
induced,O
genes,O
are,O
over,O
-,O
expressed,O
.,O
It,O
is,O
also,O
interesting,O
that,O
STAT1,B-GP
over,O
-,O
expression,O
is,O
observed,O
in,O
the,O
RBP,B-GP
+,O
subjects,O
regardless,O
of,O
ancestral,O
background,O
",",O
and,O
this,O
is,O
not,O
observed,O
in,O
the,O
RBP,B-GP
−,O
patients,O
from,O
either,O
ancestral,O
background,O
.,O
Pathway,O
diagram,O
illustrating,O
the,O
type,O
I,O
and,O
type,B-GP
II,I-GP
IFN,I-GP
pathways,O
in,O
SLE,B-DS
patient,O
subsets,O
.,O
Genes,O
which,O
are,O
up,O
-,O
regulated,O
are,O
shaded,O
red,O
",",O
with,O
increasingly,O
dark,O
red,O
shading,O
indicating,O
a,O
greater,O
degree,O
of,O
over,O
-,O
expression,O
in,O
cases,O
as,O
compared,O
to,O
controls,O
of,O
the,O
same,O
ancestral,O
background,O
.,O
AA,O
",",O
African,O
-,O
American,O
;,O
EA,O
",",O
European,O
-,O
American,O
;,O
RBP,B-GP
"+,",O
anti,O
-,O
RNA,B-GP
-,I-GP
binding,I-GP
-,I-GP
protein,I-GP
(,O
RBP,B-GP
),O
antibody,B-GP
positive,O
;,O
and,O
RBP,B-GP
"−,",O
RBP,B-GP
antibody,B-GP
negative,O
.,O
Pictures,O
generated,O
using,O
Ingenuity,O
Pathway,O
Analysis,O
software,O
.,O
Replication,O
study,O
confirms,O
the,O
dependence,O
of,O
IFN,B-GP
-,O
induced,O
gene,O
expression,O
upon,O
presence,O
of,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
in,O
AA,O
patients,O
",",O
but,O
not,O
EA,O
patients,O
Three,O
IFIGs,B-GP
(,O
IFIT1,B-GP
",",O
MX1,B-GP
",",O
and,O
PKR,B-GP
),O
were,O
selected,O
for,O
qPCR,O
analysis,O
to,O
replicate,O
the,O
microarray,O
observation,O
with,O
regards,O
to,O
the,O
association,O
between,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
and,O
IFN,B-GP
-,O
related,O
gene,O
expression,O
across,O
different,O
ancestral,O
backgrounds,O
.,O
These,O
genes,O
were,O
quantified,O
in,O
whole,O
blood,O
mRNA,O
from,O
an,O
independent,O
cohort,O
of,O
116,O
SLE,B-DS
patients,O
and,O
33,O
controls,O
.,O
As,O
shown,O
in,O
Figure,O
2,O
",",O
the,O
pattern,O
observed,O
mirrors,O
the,O
microarray,O
data,O
.,O
All,O
three,O
genes,O
were,O
up,O
-,O
regulated,O
in,O
both,O
EA,O
and,O
AA,O
RBP,B-GP
+,O
patients,O
.,O
In,O
the,O
RBP,B-GP
−,O
patients,O
",",O
there,O
is,O
essentially,O
no,O
increase,O
in,O
IFN,B-GP
-,O
induced,O
gene,O
expression,O
in,O
AA,O
patients,O
",",O
while,O
the,O
expression,O
of,O
these,O
genes,O
",",O
in,O
particular,O
PKR,B-GP
",",O
is,O
increased,O
in,O
the,O
RBP,B-GP
−,O
EA,O
SLE,B-DS
patients,O
.,O
Because,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
have,O
been,O
associated,O
with,O
high,O
IFN,B-GP
-,I-GP
α,I-GP
(,O
25,O
",",O
26,O
"),",O
it,O
is,O
important,O
to,O
determine,O
whether,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
are,O
contributing,O
to,O
the,O
induction,O
of,O
IFN,B-GP
-,O
induced,O
gene,O
expression,O
we,O
observe,O
in,O
our,O
RBP,B-GP
−,O
EA,O
patients,O
.,O
As,O
noted,O
above,O
",",O
the,O
RBP,B-GP
−,O
EA,O
subjects,O
were,O
more,O
likely,O
to,O
have,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
than,O
the,O
RBP,B-GP
−,O
AA,O
subjects,O
.,O
When,O
we,O
looked,O
at,O
the,O
RBP,B-GP
negative,O
patients,O
in,O
the,O
qPCR,O
replication,O
cohorts,O
with,O
regard,O
to,O
presence,O
or,O
absence,O
of,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
",",O
there,O
was,O
no,O
significant,O
difference,O
in,O
IFIT1,B-GP
",",O
MX1,B-GP
",",O
or,O
PKR,B-GP
over,O
-,O
expression,O
in,O
the,O
AA,O
subjects,O
.,O
In,O
RBP,B-GP
−,O
EA,O
patients,O
",",O
however,O
",",O
over,O
-,O
expression,O
of,O
IFN,B-GP
-,O
induced,O
genes,O
(,O
IFIT1,B-GP
and,O
PKR,B-GP
),O
was,O
observed,O
in,O
the,O
anti,O
-,O
dsDNA,O
antibody,B-GP
positive,O
patients,O
but,O
not,O
in,O
the,O
anti,O
-,O
dsDNA,O
antibody,B-GP
negative,O
group,O
(,O
Figure,O
3,O
).,O
Thus,O
",",O
in,O
RBP,B-GP
−,O
EA,O
subjects,O
",",O
the,O
anti,O
-,O
dsDNA,O
antibody,B-GP
status,O
did,O
have,O
an,O
effect,O
on,O
expression,O
of,O
IFIGs,B-GP
",",O
and,O
thus,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
are,O
contributing,O
to,O
the,O
IFN,B-GP
-,O
induced,O
gene,O
expression,O
in,O
this,O
group,O
.,O
Strikingly,O
",",O
anti,O
-,O
dsDNA,O
antibodies,B-GP
had,O
no,O
impact,O
upon,O
IFN,B-GP
-,O
induced,O
gene,O
expression,O
in,O
the,O
RBP,B-GP
−,O
AA,O
group,O
.,O
This,O
was,O
somewhat,O
unexpected,O
and,O
reinforces,O
the,O
idea,O
of,O
RBP,B-GP
antibody,B-GP
dependence,O
in,O
the,O
AA,O
ancestral,O
background,O
.,O
Type,B-GP
I,I-GP
IFN,I-GP
-,O
induced,O
gene,O
expression,O
in,O
SLE,B-DS
patient,O
subgroups,O
and,O
controls,O
.,O
Expression,O
of,O
three,O
genes,O
(,O
IFIT1,B-GP
",",O
MX1,B-GP
",",O
and,O
PKR,B-GP
),O
are,O
shown,O
in,O
both,O
patients,O
with,O
anti,O
-,O
RNA,B-GP
-,I-GP
binding,I-GP
protein,I-GP
antibodies,B-GP
(,O
RBP,B-GP
"+),",O
and,O
those,O
who,O
lack,O
those,O
antibodies,B-GP
(,O
RBP,B-GP
−).,O
Central,O
tendency,O
shown,O
is,O
a,O
median,O
",",O
with,O
error,O
bars,O
representing,O
the,O
interquartile,O
range,O
.,O
P,O
values,O
generated,O
by,O
Mann,O
–,O
Whitney,O
U,O
test,O
.,O
Type,B-GP
I,I-GP
IFN,I-GP
-,O
induced,O
gene,O
expression,O
in,O
RBP,B-GP
–,O
SLE,B-DS
patient,O
subgroups,O
and,O
controls,O
in,O
regards,O
to,O
of,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
.,O
Expression,O
of,O
three,O
genes,O
(,O
IFIT1,B-GP
",",O
MX1,B-GP
",",O
and,O
PKR,B-GP
),O
are,O
shown,O
in,O
both,O
patients,O
with,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
(,O
DNA,O
"+),",O
and,O
those,O
who,O
lack,O
those,O
antibodies,B-GP
(,O
DNA,O
−).,O
Central,O
tendency,O
shown,O
is,O
a,O
median,O
",",O
with,O
error,O
bars,O
representing,O
the,O
interquartile,O
range,O
.,O
P,O
values,O
generated,O
by,O
Mann,O
–,O
Whitney,O
U,O
test,O
.,O
Discussion,O
To,O
our,O
knowledge,O
",",O
this,O
was,O
the,O
first,O
study,O
to,O
show,O
differential,O
gene,O
expression,O
patterns,O
in,O
various,O
subgroups,O
of,O
SLE,B-DS
patients,O
stratified,O
by,O
ancestral,O
background,O
and,O
presence,O
or,O
absence,O
of,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
.,O
Through,O
microarray,O
whole,O
genome,O
expression,O
with,O
pathway,O
analysis,O
followed,O
by,O
independent,O
qPCR,O
validation,O
",",O
we,O
demonstrated,O
that,O
activation,O
of,O
IFN,B-GP
-,O
related,O
pathways,O
depended,O
on,O
presence,O
of,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
in,O
AA,O
patients,O
",",O
but,O
not,O
in,O
EA,O
patients,O
.,O
The,O
results,O
also,O
support,O
the,O
model,O
suggested,O
by,O
our,O
previous,O
study,O
in,O
which,O
African,O
ancestry,O
increases,O
the,O
likelihood,O
of,O
SLE,B-DS
-,O
associated,O
autoantibody,B-GP
formation,O
",",O
leading,O
to,O
higher,O
IFN,B-GP
-,I-GP
α,I-GP
activity,O
(,O
41,O
).,O
In,O
the,O
present,O
study,O
",",O
we,O
observe,O
a,O
similar,O
dependence,O
of,O
IFN,B-GP
-,O
induced,O
gene,O
expression,O
upon,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
in,O
AA,O
patients,O
",",O
and,O
this,O
is,O
not,O
shared,O
with,O
the,O
EA,O
patients,O
",",O
and,O
this,O
novel,O
observation,O
should,O
be,O
confirmed,O
in,O
larger,O
cohorts,O
.,O
Autoantibody,B-GP
immune,O
complexes,O
present,O
in,O
SLE,B-DS
patients,O
have,O
been,O
implicated,O
as,O
major,O
endogenous,O
IFN,B-GP
-,O
inducers,O
",",O
likely,O
via,O
the,O
endosomal,O
TLR,B-GP
and,O
IFN,B-GP
regulatory,I-GP
factor,I-GP
pathways,O
(,O
43,O
–,O
45,O
).,O
Our,O
data,O
would,O
suggest,O
that,O
the,O
classical,O
activation,O
of,O
IFN,B-GP
-,O
related,O
pathways,O
observed,O
in,O
SLE,B-DS
patients,O
is,O
highly,O
dependent,O
upon,O
anti,O
-,O
RBP,B-GP
antibodies,B-GP
in,O
AA,O
SLE,B-DS
patients,O
",",O
and,O
this,O
dependence,O
is,O
not,O
shared,O
by,O
EA,O
SLE,B-DS
patients,O
.,O
The,O
additional,O
IFN,B-GP
-,O
pathway,O
activation,O
observed,O
in,O
EA,O
subjects,O
is,O
partly,O
due,O
to,O
the,O
presence,O
of,O
anti,O
-,O
dsDNA,O
antibodies,B-GP
.,O
As,O
shown,O
in,O
Figure,O
3,O
there,O
are,O
a,O
number,O
of,O
anti,O
-,O
dsDNA,O
and,O
anti,O
-,O
RBP,B-GP
negative,O
EA,O
patients,O
that,O
show,O
over,O
-,O
expression,O
of,O
IFN,B-GP
-,O
induced,O
genes,O
",",O
while,O
in,O
AA,O
SLE,B-DS
patients,O
lacking,O
RBP,B-GP
antibodies,B-GP
",",O
IFN,B-GP
-,O
induced,O
gene,O
expression,O
resembles,O
the,O
AA,O
control,O
population,O
.,O
This,O
heterogeneity,O
in,O
the,O
dependence,O
of,O
IFN,B-GP
-,O
related,O
pathways,O
on,O
autoantibody,B-GP
profile,O
may,O
reflect,O
differential,O
activation,O
of,O
the,O
TLR,B-GP
pathway,O
is,O
SLE,B-DS
patients,O
of,O
different,O
ancestral,O
backgrounds,O
.,O
Anti,O
-,O
RBP,B-GP
antibodies,B-GP
would,O
be,O
expected,O
to,O
activate,O
the,O
RNA,O
-,O
sensing,O
TLRs,B-GP
",",O
while,O
anti,O
-,O
dsDNA,O
antibody,B-GP
immune,O
complexes,O
would,O
be,O
expected,O
to,O
activate,O
TLR,B-GP
9,I-GP
.,O
Genetic,O
variations,O
in,O
the,O
TLR,B-GP
pathway,O
genes,O
such,O
as,O
IRF5,B-GP
and,O
IRF7,B-GP
have,O
been,O
associated,O
with,O
risk,O
of,O
SLE,B-DS
",",O
and,O
with,O
gain,O
of,O
function,O
within,O
the,O
type,B-GP
I,I-GP
IFN,I-GP
pathway,O
(,O
46,O
",",O
47,O
).,O
In,O
our,O
previous,O
study,O
looking,O
at,O
genetic,O
variation,O
at,O
the,O
IRF7,B-GP
/,O
PHRF1,B-GP
locus,O
",",O
we,O
observed,O
two,O
different,O
high,O
IFN,B-GP
genetic,O
effects,O
in,O
AA,O
subjects,O
",",O
while,O
we,O
saw,O
only,O
one,O
in,O
EA,O
subjects,O
(,O
46,O
).,O
This,O
example,O
demonstrates,O
genetic,O
diversity,O
between,O
world,O
populations,O
in,O
the,O
TLR,B-GP
/,O
IRF,B-GP
system,O
",",O
and,O
could,O
support,O
the,O
idea,O
that,O
this,O
pathway,O
may,O
more,O
prominent,O
in,O
AA,O
subjects,O
and,O
help,O
to,O
explain,O
the,O
findings,O
we,O
report,O
here,O
.,O
Additionally,O
",",O
many,O
of,O
the,O
genetic,O
polymorphisms,O
we,O
have,O
discovered,O
that,O
are,O
associated,O
with,O
increased,O
type,B-GP
I,I-GP
IFN,I-GP
in,O
SLE,B-DS
patients,O
differ,O
between,O
ancestral,O
backgrounds,O
(,O
34,O
",",O
48,O
"),",O
and,O
this,O
would,O
also,O
support,O
the,O
idea,O
that,O
the,O
pathway,O
will,O
be,O
more,O
or,O
less,O
prominent,O
in,O
different,O
ancestral,O
backgrounds,O
.,O
There,O
were,O
EA,O
SLE,B-DS
patients,O
that,O
had,O
increased,O
expression,O
of,O
IFN,B-GP
-,O
induced,O
genes,O
who,O
did,O
not,O
have,O
either,O
anti,O
-,O
RBP,B-GP
or,O
anti,O
-,O
dsDNA,O
autoantibodies,B-GP
.,O
These,O
data,O
suggest,O
that,O
IFN,B-GP
-,O
related,O
pathways,O
may,O
be,O
activated,O
through,O
different,O
mechanisms,O
in,O
this,O
ancestral,O
background,O
.,O
All,O
patients,O
in,O
our,O
study,O
had,O
ANA,O
",",O
and,O
it,O
may,O
be,O
that,O
other,O
nuclear,B-GP
antigen,I-GP
/,O
autoantibody,B-GP
complexes,O
could,O
have,O
triggered,O
the,O
TLR,B-GP
/,O
RLR,B-GP
system,O
leading,O
to,O
IFN,B-GP
-,O
pathway,O
activation,O
in,O
these,O
subjects,O
.,O
It,O
is,O
also,O
possible,O
that,O
other,O
molecules,O
such,O
as,O
HMGB1,B-GP
",",O
which,O
can,O
bind,O
with,O
immune,O
complexes,O
",",O
may,O
be,O
activating,O
an,O
inflammatory,O
cascade,O
in,O
plasmacytoid,O
dendritic,O
cells,O
resulting,O
in,O
activation,O
of,O
IFN,B-GP
pathways,O
(,O
49,O
).,O
Another,O
possibility,O
is,O
that,O
there,O
is,O
an,O
increased,O
sensitivity,O
to,O
IFN,B-GP
signaling,O
or,O
a,O
downstream,O
activator,O
of,O
IFN,B-GP
-,O
induced,O
gene,O
expression,O
in,O
these,O
patients,O
.,O
We,O
have,O
observed,O
some,O
SLE,B-DS
patients,O
in,O
previous,O
studies,O
that,O
have,O
high,O
IFN,B-GP
-,O
induced,O
gene,O
activity,O
in,O
their,O
PBMC,O
with,O
essentially,O
normal,O
circulating,O
type,B-GP
I,I-GP
IFN,I-GP
activity,O
from,O
the,O
same,O
sample,O
(,O
50,O
",",O
51,O
).,O
This,O
surprising,O
diversity,O
in,O
IFN,B-GP
-,O
pathway,O
activation,O
between,O
different,O
SLE,B-DS
patient,O
subgroups,O
is,O
relevant,O
to,O
clinical,O
care,O
",",O
as,O
therapeutics,O
directed,O
at,O
IFN,B-GP
or,O
IFN,B-GP
-,O
related,O
pathways,O
are,O
being,O
actively,O
developed,O
(,O
52,O
).,O
It,O
seems,O
likely,O
that,O
these,O
IFN,B-GP
-,O
pathway,O
targeting,O
therapeutics,O
will,O
be,O
characterized,O
by,O
heterogeneity,O
in,O
treatment,O
response,O
",",O
and,O
our,O
results,O
may,O
suggest,O
some,O
groups,O
that,O
are,O
likely,O
to,O
be,O
better,O
responders,O
that,O
could,O
be,O
predicted,O
without,O
having,O
to,O
run,O
a,O
gene,O
expression,O
chip,O
prior,O
to,O
therapy,O
.,O
The,O
RBP,B-GP
−,O
AA,O
group,O
is,O
very,O
interesting,O
in,O
this,O
regard,O
",",O
as,O
it,O
seems,O
that,O
this,O
patient,O
group,O
may,O
represent,O
a,O
distinct,O
subset,O
of,O
SLE,B-DS
patients,O
which,O
is,O
not,O
as,O
IFN,B-GP
-,O
dependent,O
as,O
other,O
groups,O
of,O
SLE,B-DS
patients,O
.,O
This,O
may,O
represent,O
a,O
significant,O
difference,O
in,O
disease,O
pathogenesis,O
",",O
which,O
could,O
be,O
important,O
in,O
planning,O
targeted,O
therapies,O
.,O
Conclusion,O
Systemic,B-DS
lupus,I-DS
erythematosus,I-DS
is,O
a,O
heterogeneous,O
disease,O
with,O
differences,O
in,O
disease,O
incidence,O
",",O
clinical,O
manifestations,O
",",O
serological,O
findings,O
",",O
and,O
genetic,O
risk,O
factors,O
between,O
ancestral,O
backgrounds,O
(,O
7,O
",",O
29,O
–,O
32,O
",",O
36,O
–,O
39,O
).,O
Perhaps,O
it,O
is,O
not,O
very,O
surprising,O
to,O
find,O
heterogeneity,O
in,O
the,O
activation,O
of,O
molecular,O
pathways,O
between,O
ancestral,O
groups,O
",",O
and,O
it,O
seems,O
likely,O
that,O
different,O
pathogenic,O
factors,O
will,O
be,O
relevant,O
in,O
RBP,B-GP
−,O
AA,O
patients,O
as,O
compared,O
to,O
the,O
RBP,B-GP
+,O
SLE,B-DS
patients,O
.,O
SLE,B-DS
is,O
a,O
complex,O
autoimmune,B-DS
disease,I-DS
",",O
and,O
understanding,O
heterogeneity,O
in,O
the,O
molecular,O
pathogenesis,O
in,O
lupus,B-DS
will,O
be,O
crucial,O
in,O
informing,O
therapeutic,O
and,O
diagnostic,O
strategies,O
.,O
This,O
study,O
demonstrates,O
the,O
relevance,O
of,O
careful,O
patient,O
characterization,O
and,O
including,O
patients,O
from,O
more,O
than,O
one,O
ancestral,O
background,O
in,O
biological,O
studies,O
of,O
SLE,B-DS
.,O
Author,O
’,O
s,O
Contributions,O
Kichul,O
Ko,O
participated,O
in,O
the,O
design,O
of,O
the,O
study,O
and,O
its,O
coordination,O
",",O
screened,O
for,O
cases,O
and,O
controls,O
",",O
lead,O
the,O
statistical,O
analysis,O
",",O
and,O
drafted,O
the,O
manuscript,O
.,O
Yelena,O
Koldobskaya,O
helped,O
screen,O
for,O
cases,O
and,O
controls,O
",",O
and,O
collected,O
microarray,O
data,O
.,O
Elizabeth,O
Rosenzweig,O
helped,O
generate,O
qPCR,O
data,O
.,O
Timothy,O
B,O
.,O
Niewold,O
was,O
the,O
senior,O
scientist,O
overseeing,O
the,O
study,O
and,O
helped,O
with,O
study,O
design,O
",",O
statistical,O
analysis,O
",",O
and,O
manuscript,O
drafting,O
.,O
Conflict,O
of,O
Interest,O
Statement,O
The,O
authors,O
declare,O
that,O
the,O
research,O
was,O
conducted,O
in,O
the,O
absence,O
of,O
any,O
commercial,O
or,O
financial,O
relationships,O
that,O
could,O
be,O
construed,O
as,O
a,O
potential,O
conflict,O
of,O
interest,O
.,O
IFN,B-GP
-,I-GP
γ,I-GP
Stimulates,O
Autophagy,O
-,O
Mediated,O
Clearance,O
of,O
Burkholderia,B-OG
cenocepacia,I-OG
in,O
Human,B-OG
Cystic,B-DS
Fibrosis,I-DS
Macrophages,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
KA,O
AOA,O
BTK,O
.,O
Performed,O
the,O
experiments,O
:,O
KA,O
MFT,O
BTK,O
.,O
Analyzed,O
the,O
data,O
:,O
KA,O
MFT,O
AOA,O
BTK,O
.,O
Contributed,O
reagents,O
/,O
materials,O
/,O
analysis,O
tools,O
:,O
AOA,O
BTK,O
.,O
Wrote,O
the,O
paper,O
:,O
KA,O
BTK,O
.,O
Burkholderia,B-OG
cenocepacia,I-OG
is,O
a,O
virulent,O
pathogen,O
that,O
causes,O
significant,O
morbidity,O
and,O
mortality,O
in,O
patients,O
with,O
cystic,B-DS
fibrosis,I-DS
(,O
CF,B-DS
"),",O
survives,O
intracellularly,O
in,O
macrophages,O
",",O
and,O
uniquely,O
causes,O
systemic,B-DS
infections,I-DS
in,O
CF,B-DS
.,O
Autophagy,O
is,O
a,O
physiologic,O
process,O
that,O
involves,O
engulfing,O
non,O
-,O
functional,O
organelles,O
and,O
proteins,O
and,O
delivering,O
them,O
for,O
lysosomal,O
degradation,O
",",O
but,O
also,O
plays,O
a,O
role,O
in,O
eliminating,O
intracellular,O
pathogens,O
",",O
including,O
B,B-OG
.,I-OG
cenocepacia,I-OG
.,O
Autophagy,O
is,O
defective,O
in,O
CF,B-DS
but,O
can,O
be,O
stimulated,O
in,O
murine,O
CF,B-DS
models,O
leading,O
to,O
increased,O
clearance,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
",",O
but,O
little,O
is,O
known,O
about,O
autophagy,O
stimulation,O
in,O
human,B-OG
CF,B-DS
macrophages,O
.,O
IFN,B-GP
-,I-GP
γ,I-GP
activates,O
macrophages,O
and,O
increases,O
antigen,O
presentation,O
while,O
also,O
inducing,O
autophagy,O
in,O
macrophages,O
.,O
We,O
therefore,O
",",O
hypothesized,O
that,O
treatment,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
would,O
increase,O
autophagy,O
and,O
macrophage,O
activation,O
in,O
patients,O
with,O
CF,B-DS
.,O
Peripheral,O
blood,O
monocyte,O
derived,O
macrophages,O
(,O
MDMs,O
),O
were,O
obtained,O
from,O
CF,B-DS
and,O
non,O
-,O
CF,B-DS
donors,O
and,O
subsequently,O
infected,O
with,O
B,B-OG
.,I-OG
cenocepacia,I-OG
.,O
Basal,O
serum,O
levels,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
were,O
similar,O
between,O
CF,B-DS
and,O
non,O
-,O
CF,B-DS
patients,O
",",O
however,O
after,O
B,B-DS
.,I-DS
cenocepacia,I-DS
infection,I-DS
there,O
is,O
deficient,O
IFN,B-GP
-,I-GP
γ,I-GP
production,O
in,O
CF,B-DS
MDMs,O
.,O
IFN,B-GP
-,I-GP
γ,I-GP
treated,O
CF,B-DS
MDMs,O
demonstrate,O
increased,O
co,O
-,O
localization,O
with,O
the,O
autophagy,O
molecule,O
p62,B-GP
",",O
increased,O
autophagosome,O
formation,O
",",O
and,O
increased,O
trafficking,O
to,O
lysosomes,O
compared,O
to,O
untreated,O
CF,B-DS
MDMs,O
.,O
Electron,O
microscopy,O
confirmed,O
IFN,B-GP
-,I-GP
γ,I-GP
promotes,O
double,O
membrane,O
vacuole,O
formation,O
around,O
bacteria,B-OG
in,O
CF,B-DS
MDMs,O
",",O
while,O
only,O
single,O
membrane,O
vacuoles,O
form,O
in,O
untreated,O
CF,B-DS
cells,O
.,O
Bacterial,O
burden,O
is,O
significantly,O
reduced,O
in,O
autophagy,O
stimulated,O
CF,B-DS
MDMs,O
",",O
comparable,O
to,O
non,O
-,O
CF,B-DS
levels,O
.,O
IL,B-GP
-,I-GP
1β,I-GP
production,O
is,O
decreased,O
in,O
CF,B-DS
MDMs,O
after,O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
.,O
Together,O
",",O
these,O
results,O
demonstrate,O
that,O
IFN,B-GP
-,I-GP
γ,I-GP
promotes,O
autophagy,O
-,O
mediated,O
clearance,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
human,B-OG
CF,B-DS
macrophages,O
.,O
Introduction,O
Cystic,B-DS
fibrosis,I-DS
(,O
CF,B-DS
),O
is,O
an,O
inherited,O
",",O
life,O
-,O
limiting,O
disease,O
that,O
causes,O
multi,O
-,O
organ,O
dysfunction,O
characterized,O
by,O
progressive,O
respiratory,B-DS
infections,I-DS
with,O
inspissated,O
mucous,O
[,O
1,O
"],",O
[,O
2,O
].,O
Patients,O
with,O
CF,B-DS
can,O
be,O
infected,O
by,O
a,O
variety,O
of,O
pathogens,O
",",O
including,O
the,O
rapidly,O
transmissible,O
Burkholderia,B-OG
cenocepacia,I-OG
[,O
3,O
]–[,O
6,O
].,O
B,B-OG
.,I-OG
cenocepacia,I-OG
is,O
a,O
unique,O
CF,B-DS
pathogen,O
that,O
causes,O
either,O
a,O
distinct,O
clinical,O
phenotype,O
of,O
systemic,O
fatal,O
septicemia,B-DS
or,O
hastened,O
chronic,O
respiratory,O
deterioration,O
with,O
diminished,O
long,O
term,O
survival,O
[,O
7,O
"],",O
[,O
8,O
].,O
Therapeutic,O
options,O
are,O
severely,O
limited,O
due,O
to,O
multi,O
-,O
drug,O
resistance,O
and,O
near,O
universal,O
exclusion,O
from,O
lung,O
transplant,O
eligibility,O
due,O
to,O
poor,O
post,O
-,O
transplant,O
survival,O
in,O
chronically,O
infected,O
patients,O
[,O
9,O
]–[,O
13,O
].,O
Macrophages,O
are,O
a,O
first,O
-,O
line,O
defense,O
against,O
pathogens,O
including,O
B,B-OG
.,I-OG
cenocepacia,I-OG
.,O
The,O
vital,O
role,O
of,O
macrophages,O
in,O
CF,B-DS
pathogen,O
interactions,O
",",O
in,O
addition,O
to,O
airway,O
epithelial,O
cells,O
",",O
has,O
been,O
highlighted,O
by,O
several,O
groups,O
[,O
14,O
]–[,O
19,O
].,O
Bacteria,B-OG
survive,O
in,O
CF,B-DS
macrophages,O
despite,O
successful,O
phagocytosis,O
due,O
to,O
links,O
between,O
CF,B-GP
transmembrane,I-GP
conductance,I-GP
regulator,I-GP
(,O
CFTR,B-GP
),O
dysfunction,O
and,O
impaired,O
phagolysosomal,O
killing,O
[,O
17,O
"],",O
[,O
20,O
"],",O
[,O
21,O
].,O
B,B-OG
.,I-OG
cenocepacia,I-OG
is,O
also,O
specifically,O
able,O
to,O
evade,O
degradation,O
in,O
CF,B-DS
macrophages,O
leading,O
to,O
severe,O
and,O
persistent,O
inflammation,O
[,O
19,O
"],",O
[,O
22,O
"],",O
[,O
23,O
].,O
Additionally,O
",",O
in,O
model,O
systems,O
B,B-OG
.,I-OG
cenocepacia,I-OG
replicates,O
inside,O
of,O
macrophages,O
prior,O
to,O
dissemination,O
[,O
24,O
].,O
In,O
conjunction,O
with,O
macrophage,O
defects,O
",",O
CF,B-DS
leads,O
to,O
deficient,O
autophagy,O
through,O
inflammatory,O
mediated,O
cross,O
-,O
linking,O
of,O
the,O
essential,O
beclin,B-GP
-,I-GP
1,I-GP
autophagy,O
initiator,O
interactome,O
[,O
25,O
].,O
Autophagy,O
is,O
a,O
physiologic,O
process,O
that,O
normally,O
augments,O
innate,O
responses,O
to,O
intraphagosomal,O
pathogens,O
and,O
may,O
relate,O
to,O
macrophage,O
clearance,O
defects,O
.,O
Deficient,O
autophagy,O
prevents,O
destruction,O
of,O
engulfed,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
murine,O
CF,B-DS
macrophages,O
[,O
22,O
"],",O
[,O
26,O
].,O
Autophagy,O
stimulation,O
by,O
rapamycin,O
reduces,O
murine,O
CF,B-DS
bacterial,O
burden,O
and,O
inflammation,O
[,O
22,O
].,O
Autophagy,O
stimulation,O
with,O
rapamycin,O
also,O
enhances,O
clearance,O
of,O
other,O
major,O
CF,B-DS
pathogens,O
such,O
as,O
Pseudomonas,B-OG
aeruginosa,I-OG
[,O
27,O
],O
and,O
Staphylococcus,O
aureus,O
[,O
28,O
"],",O
but,O
autophagy,O
has,O
not,O
been,O
studied,O
in,O
human,B-OG
CF,B-DS
macrophages,O
.,O
Restoration,O
of,O
functional,O
autophagy,O
with,O
an,O
anti,O
-,O
inflammatory,O
peptide,O
",",O
IDR,O
-,O
1018,O
",",O
decreases,O
inflammation,O
in,O
CF,B-DS
cells,O
[,O
29,O
"],",O
and,O
may,O
globally,O
alleviate,O
CF,B-DS
symptoms,O
by,O
releasing,O
sequestered,O
essential,O
autophagy,O
molecules,O
",",O
such,O
as,O
the,O
autophagy,O
adaptor,O
molecule,O
P62,B-GP
/,O
SQSTM1,B-GP
(,O
p62,B-GP
)[,O
30,O
].,O
Relief,O
of,O
sequestered,O
autophagy,O
molecules,O
enabled,O
protein,O
aggregate,O
clearance,O
and,O
improved,O
CFTR,B-GP
trafficking,O
",",O
lending,O
benefits,O
of,O
autophagy,O
-,O
stimulated,O
pathogen,O
clearance,O
[,O
25,O
].,O
Although,O
rapamycin,O
was,O
effective,O
in,O
murine,O
CF,B-DS
studies,O
",",O
systemic,O
side,O
effects,O
of,O
rapamycin,O
in,O
CF,B-DS
[,O
31,O
],O
and,O
increased,O
development,O
of,O
interstitial,B-DS
lung,I-DS
disease,I-DS
[,O
32,O
],O
prevent,O
clinical,O
trials,O
.,O
Additionally,O
",",O
autophagy,O
stimulation,O
by,O
immununologics,O
",",O
such,O
as,O
rapamycin,O
",",O
raises,O
questions,O
how,O
this,O
would,O
affect,O
other,O
microorganisms,B-OG
in,O
the,O
lungs,O
of,O
CF,B-DS
patients,O
.,O
Alternatively,O
",",O
IFN,B-GP
-,I-GP
γ,I-GP
has,O
been,O
shown,O
to,O
increase,O
macrophage,O
clearance,O
of,O
apoptotic,O
cells,O
in,O
chronic,B-DS
granulomatous,I-DS
disease,I-DS
(,O
CGD,B-DS
),O
[,O
33,O
"],",O
and,O
is,O
used,O
prophylactically,O
in,O
CGD,B-DS
patients,O
to,O
prevent,O
acquisition,O
of,O
severe,O
infections,B-DS
such,O
as,O
Burkholderia,B-OG
species,O
[,O
34,O
"],",O
[,O
35,O
].,O
CGD,B-DS
",",O
the,O
only,O
other,O
known,O
clinical,O
disease,O
commonly,O
affected,O
by,O
Burkholderia,B-OG
species,O
",",O
also,O
has,O
known,O
phagocytic,O
killing,O
defects,O
[,O
36,O
"],",O
[,O
37,O
],O
and,O
was,O
recently,O
shown,O
to,O
have,O
deficient,O
autophagic,O
responses,O
to,O
B,B-OG
.,I-OG
cenocepacia,I-OG
[,O
38,O
].,O
Furthermore,O
",",O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
enhances,O
the,O
autophagy,O
response,O
in,O
macrophages,O
derived,O
from,O
non,O
-,O
CGD,B-DS
patients,O
resulting,O
in,O
clearance,O
of,O
pathogens,O
that,O
evade,O
typical,O
phagocytic,O
degradation,O
[,O
39,O
].,O
IFN,B-GP
-,I-GP
γ,I-GP
therapy,O
is,O
well,O
tolerated,O
in,O
CGD,B-DS
patients,O
who,O
have,O
altered,O
immune,O
functions,O
and,O
polymicrobial,B-DS
infections,I-DS
similar,O
to,O
CF,B-DS
[,O
34,O
"],",O
[,O
40,O
].,O
Although,O
a,O
trial,O
of,O
inhaled,O
IFN,B-GP
-,I-GP
γ,I-GP
in,O
CF,B-DS
patients,O
with,O
mild,O
to,O
moderate,O
disease,O
did,O
not,O
prove,O
effective,O
in,O
altering,O
lung,O
function,O
[,O
41,O
"],",O
IFN,B-GP
-,I-GP
γ,I-GP
has,O
never,O
been,O
studied,O
systemically,O
in,O
CF,B-DS
",",O
or,O
specifically,O
in,O
B,B-OG
.,I-OG
cenocepacia,I-OG
infected,O
patients,O
",",O
who,O
may,O
require,O
more,O
than,O
local,O
lung,O
treatment,O
.,O
We,O
hypothesize,O
that,O
due,O
to,O
known,O
defects,O
in,O
CF,B-DS
macrophage,O
autophagy,O
",",O
IFN,B-GP
-,I-GP
γ,I-GP
will,O
reduce,O
B,B-OG
.,I-OG
cenocepacia,I-OG
burden,O
in,O
human,B-OG
CF,B-DS
macrophages,O
through,O
more,O
effective,O
killing,O
and,O
enhanced,O
autophagy,O
that,O
degrade,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
nascent,O
vacuoles,O
.,O
Materials,O
and,O
Methods,O
Bacterial,O
Strains,O
and,O
Culture,O
Burkholderia,B-OG
cenocepacia,I-OG
strain,I-OG
k56,I-OG
-,I-OG
2,I-OG
is,O
a,O
clinical,O
isolate,O
of,O
the,O
ET12,O
lineage,O
originally,O
isolated,O
from,O
a,O
CF,B-DS
patient,O
’,O
s,O
sputum,O
.,O
The,O
strain,O
was,O
tagged,O
dsRED,O
and,O
grown,O
in,O
Luria,O
-,O
Bertani,O
(,O
LB,O
),O
broth,O
at,O
37,O
°,O
C,O
overnight,O
with,O
high,O
amplitude,O
shaking,O
.,O
The,O
B,B-OG
.,I-OG
cenocepacia,I-OG
MHK1,I-OG
strain,O
is,O
derived,O
from,O
k56,O
-,O
2,O
and,O
has,O
a,O
mutation,O
in,O
an,O
antibiotic,B-GP
efflux,I-GP
pump,I-GP
that,O
confers,O
gentamicin,O
sensitivity,O
",",O
but,O
does,O
not,O
alter,O
the,O
trafficking,O
of,O
the,O
mutant,O
in,O
macrophages,O
[,O
42,O
].,O
For,O
colony,O
forming,O
unit,O
(,O
CFU,O
),O
analysis,O
",",O
50,O
µg,O
/,O
ml,O
gentamicin,O
(,O
Invitrogen,O
",",O
3564,O
),O
was,O
added,O
for,O
0,O
.,O
5,O
hours,O
as,O
described,O
previously,O
[,O
43,O
].,O
To,O
enumerate,O
intracellular,O
bacteria,B-OG
",",O
infected,O
macrophages,O
were,O
lysed,O
with,O
ice,O
-,O
cold,O
PBS,O
(,O
Invitrogen,O
",",O
14190,O
),O
at,O
designated,O
times,O
.,O
Extracellular,O
bacteria,B-OG
were,O
enumerated,O
directly,O
from,O
cell,O
supernatants,O
during,O
macrophage,O
viability,O
assays,O
.,O
Recovered,O
bacteria,B-OG
were,O
quantified,O
by,O
plating,O
serial,O
dilutions,O
on,O
LB,O
agar,O
plates,O
and,O
counting,O
colonies,O
using,O
the,O
Acolyte,O
Colony,O
Counter,O
",",O
5710,O
/,O
SYN,O
.,O
Human,B-OG
Monocyte,O
-,O
Derived,O
Macrophages,O
(,O
MDMs,O
),O
–,O
Ethics,O
Statement,O
Human,B-OG
subjects,O
underwent,O
written,O
informed,O
consent,O
for,O
blood,O
donation,O
at,O
the,O
Nationwide,O
Children,O
’,O
s,O
Hospital,O
as,O
approved,O
by,O
the,O
Institutional,O
Review,O
Board,O
of,O
Nationwide,O
Children,O
’,O
s,O
Hospital,O
.,O
Written,O
consent,O
from,O
legal,O
guardians,O
of,O
minors,O
was,O
obtained,O
as,O
well,O
as,O
written,O
assent,O
from,O
minors,O
aged,O
9,O
to,O
17,O
years,O
.,O
Blood,O
was,O
drawn,O
in,O
heparinized,O
tubes,O
.,O
Exclusion,O
criteria,O
included,O
history,O
of,O
B,B-OG
.,I-OG
cepacia,I-OG
complex,I-OG
culture,O
positivity,O
",",O
chronic,B-DS
immunosuppression,I-DS
",",O
CFTR,B-GP
modulator,O
use,O
",",O
and,O
history,O
of,O
transplantation,O
.,O
Chronic,O
azithromycin,O
was,O
the,O
only,O
immunomodulatory,O
medicine,O
taken,O
by,O
some,O
subjects,O
during,O
the,O
study,O
period,O
.,O
Peripheral,O
blood,O
mononuclear,O
cells,O
(,O
PBMCs,O
),O
were,O
isolated,O
from,O
27,O
CF,B-DS
and,O
27,O
non,O
-,O
CF,B-DS
healthy,O
controls,O
.,O
Monocytes,O
were,O
separated,O
using,O
a,O
Ficol,O
gradient,O
via,O
Lymphocyte,O
Separation,O
Medium,O
(,O
Corning,O
",",O
25,O
-,O
072,O
-,O
CV,O
).,O
Isolated,O
monocytes,O
were,O
re,O
-,O
suspended,O
in,O
RPMI,O
(,O
Gibco,O
",",O
22400,O
-,O
089,O
),O
and,O
10,O
%,O
human,B-OG
AB,O
serum,O
(,O
Lonza,O
",",O
14,O
-,O
490E,O
),O
to,O
a,O
concentration,O
of,O
2,O
×,O
106,O
cells,O
/,O
mL,O
and,O
incubated,O
for,O
5,O
days,O
at,O
37,O
°,O
C,O
to,O
derive,O
macrophages,O
.,O
Macrophages,O
were,O
then,O
infected,O
with,O
B,B-OG
.,I-OG
cenocepacia,I-OG
strain,I-OG
k56,I-OG
-,I-OG
2,I-OG
at,O
a,O
multiplicity,O
of,O
infection,B-DS
(,O
MOI,O
),O
ranging,O
from,O
2,O
–,O
10,O
over,O
the,O
stated,O
times,O
.,O
Reagents,O
IFN,B-GP
-,I-GP
γ,I-GP
(,O
eBioscience,O
",",O
14,O
-,O
8319,O
-,O
80,O
),O
was,O
used,O
at,O
a,O
concentration,O
of,O
200,O
ηg,O
/,O
ml,O
based,O
upon,O
effectiveness,O
in,O
trial,O
experiments,O
.,O
Rapamycin,O
(,O
LC,O
laboratories,O
",",O
AY,O
-,O
22989,O
),O
was,O
added,O
to,O
the,O
cells,O
at,O
a,O
concentration,O
of,O
25,O
µg,O
/,O
ml,O
.,O
Treatments,O
were,O
added,O
1,O
hour,O
post,O
infection,B-DS
and,O
the,O
cells,O
were,O
allowed,O
to,O
incubate,O
for,O
2,O
",",O
4,O
",",O
and,O
24hours,O
before,O
obtaining,O
results,O
.,O
Two,O
mM,O
3,O
-,O
methyladenine,O
(,O
3MA,O
",",O
M9281,O
),O
and,O
10,O
nM,O
Bafilomycin,O
(,O
Sigma,O
-,O
Aldrich,O
",",O
B1793,O
),O
were,O
added,O
one,O
hour,O
prior,O
to,O
infection,B-DS
in,O
inhibitor,O
experiments,O
.,O
Immunoblotting,O
Macrophage,O
supernatants,O
were,O
removed,O
post,O
treatment,O
and,O
the,O
cells,O
were,O
washed,O
twice,O
with,O
phosphate,O
buffered,O
saline,O
(,O
PBS,O
).,O
The,O
cells,O
were,O
lysed,O
in,O
lysis,O
buffer,O
and,O
primed,O
with,O
a,O
protease,B-GP
inhibitor,O
(,O
Roche,O
Applied,O
Science,O
",",O
10,O
-,O
519,O
-,O
978,O
-,O
001,O
).,O
Then,O
",",O
30,O
ug,O
of,O
protein,O
was,O
separated,O
by,O
SDS,O
-,O
PAGE,O
and,O
transferred,O
onto,O
polyvinylidene,O
difluoride,O
(,O
PVDF,O
),O
membranes,O
.,O
Membranes,O
were,O
immunoblotted,O
for,O
LC3,B-GP
(,O
Sigma,O
-,O
Aldrich,O
",",O
L8918,O
"),",O
p62,B-GP
(,O
Sigma,O
-,O
Aldrich,O
",",O
P0067,O
"),",O
beclin,B-GP
-,I-GP
1,I-GP
(,O
Abcam,O
",",O
ab51031,O
"),",O
actin,B-GP
(,O
Abcam,O
",",O
ab8226,O
-,O
100,O
"),",O
IFNGR1,B-GP
(,O
Abcam,O
",",O
ab61179,O
"),",O
IFNGRbeta,B-GP
(,O
Abcam,O
",",O
ab84524,O
"),",O
and,O
calreticulin,B-GP
(,O
Stressgen,O
",",O
#,O
SPA,O
-,O
600,O
).,O
Protein,O
bands,O
were,O
detected,O
with,O
HRP,B-GP
-,O
conjugated,O
secondary,O
antibodies,B-GP
visualized,O
using,O
enhanced,O
chemiluminescent,O
(,O
ECL,O
),O
reagents,O
(,O
Life,O
Sciences,O
",",O
RPN2106,O
).,O
Enzyme,O
-,O
Linked,O
Immunosorbent,O
Assay,O
(,O
ELISA,O
),O
MDM,O
culture,O
supernatants,O
were,O
clarified,O
and,O
stored,O
at,O
−,O
20,O
°,O
C,O
until,O
assayed,O
for,O
cytokine,B-GP
content,O
.,O
MDMs,O
were,O
infected,O
for,O
4,O
and,O
24,O
hours,O
with,O
k56,O
-,O
2,O
.,O
The,O
quantification,O
of,O
IL,B-GP
-,I-GP
1β,I-GP
",",O
IFN,B-GP
-,I-GP
γ,I-GP
",",O
and,O
IL,B-GP
-,I-GP
10,I-GP
in,O
supernatants,O
was,O
determined,O
by,O
sandwich,O
ELISA,O
following,O
the,O
manufacturer,O
’,O
s,O
protocol,O
(,O
R,O
&,O
D,O
system,O
Inc,O
",",O
DY285,O
),O
as,O
previously,O
described,O
[,O
43,O
].,O
Cytotoxicity,O
MDMs,O
were,O
infected,O
with,O
k56,O
-,O
2,O
for,O
4,O
and,O
24hours,O
and,O
the,O
culture,O
supernatants,O
were,O
collected,O
and,O
centrifuged,O
.,O
Histone,B-GP
-,O
associated,O
DNA,O
fragments,O
were,O
detected,O
using,O
a,O
cytotoxicity,O
detection,O
photometric,O
assay,O
kit,O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
protocol,O
(,O
Roche,O
Applied,O
Science,O
",",O
11,O
644,O
793,O
001,O
).,O
All,O
experiments,O
were,O
performed,O
in,O
at,O
least,O
triplicate,O
.,O
Additionally,O
",",O
macrophage,O
viability,O
was,O
assessed,O
via,O
naphthol,O
staining,O
.,O
MDMs,O
were,O
plated,O
in,O
24,O
-,O
well,O
plates,O
",",O
infected,O
for,O
1,O
h,O
",",O
then,O
treated,O
for,O
24,O
h,O
.,O
Cells,O
were,O
washed,O
and,O
treated,O
with,O
1,O
%,O
Cetavlon,O
in,O
0,O
.,O
1,O
M,O
citric,O
acid,O
with,O
0,O
.,O
05,O
%,O
Napthol,O
blue,O
black,O
(,O
Sigma,O
-,O
Aldrich,O
"),",O
pH,O
2,O
.,O
2,O
",",O
for,O
15,O
min,O
at,O
room,O
temperature,O
.,O
Stained,O
nuclei,O
were,O
enumerated,O
on,O
a,O
haemacytometer,O
using,O
phase,O
-,O
contrast,O
microscopy,O
.,O
Confocal,O
Microscopy,O
Confocal,O
microscopy,O
sample,O
were,O
analyzed,O
with,O
an,O
Olympus,O
FV10i,O
Spectral,O
Confocal,O
microscope,O
.,O
Two,O
million,O
MDMs,O
were,O
cultured,O
on,O
12,O
mm,O
glass,O
cover,O
slips,O
in,O
24,O
-,O
well,O
tissue,O
culture,O
plates,O
and,O
infected,O
synchronously,O
with,O
k56,O
-,O
2,O
at,O
an,O
MOI,O
of,O
2,O
or,O
10,O
.,O
Nuclei,O
were,O
stained,O
with,O
the,O
nucleic,O
acid,O
dye,O
4,O
"′,",O
6,O
′-,O
diamino,O
-,O
2,O
-,O
phenylindole,O
(,O
DAPI,O
),O
blue,O
for,O
imaging,O
.,O
LC3,B-GP
stained,O
green,O
with,O
a,O
cleaved,O
LC3,B-GP
antibody,B-GP
detection,O
(,O
Abgent,O
",",O
AP1805a,O
).,O
Lysosomes,O
were,O
stained,O
green,O
with,O
Lysotracker,O
Green,O
(,O
Invitrogen,O
",",O
L7526,O
).,O
p62,B-GP
was,O
detected,O
with,O
a,O
green,O
fluorescent,O
ligand,O
(,O
BD,O
Bioscience,O
",",O
610832,O
).,O
At,O
least,O
one,O
hundred,O
macrophages,O
were,O
scored,O
for,O
each,O
condition,O
with,O
scoring,O
verified,O
by,O
independent,O
study,O
members,O
.,O
All,O
experiments,O
were,O
performed,O
in,O
at,O
least,O
triplicate,O
.,O
Transmission,O
Electron,O
Microscopy,O
TEM,O
Images,O
were,O
obtained,O
using,O
a,O
FEI,O
Technai,O
G2,O
Spirit,O
transmission,O
electron,O
microscope,O
(,O
FEI,O
",",O
USA,O
"),",O
Macrofire,O
(,O
Optronics,O
),O
digital,O
camera,O
and,O
AMT,O
image,O
capture,O
Software,O
with,O
assistance,O
from,O
the,O
Campus,O
Microscopy,O
and,O
Imaging,O
Facility,O
(,O
CMIF,O
),O
at,O
The,O
Ohio,O
State,O
University,O
.,O
MDMs,O
were,O
isolated,O
and,O
infected,O
with,O
k56,O
-,O
2,O
at,O
an,O
MOI,O
of,O
10,O
for,O
1,O
hour,O
prior,O
to,O
24,O
hour,O
experimental,O
treatments,O
.,O
Cells,O
were,O
cultured,O
on,O
Permanox,O
(,O
Lab,O
-,O
Tek,O
),O
chamber,O
slides,O
and,O
fixed,O
with,O
2,O
.,O
5,O
%,O
gluteraldehyde,O
in,O
0,O
.,O
1,O
M,O
phosphate,O
buffer,O
with,O
0,O
.,O
1,O
M,O
sucrose,O
.,O
Slides,O
were,O
post,O
fixed,O
with,O
1,O
%,O
osmium,O
tetroxide,O
in,O
phosphate,O
buffer,O
then,O
en,O
bloc,O
stained,O
with,O
2,O
%,O
uranyl,O
acetate,O
in,O
10,O
%,O
ethanol,O
",",O
dehydrated,O
in,O
a,O
graded,O
series,O
of,O
ethanols,O
and,O
embedded,O
in,O
Eponate,O
12,O
epoxy,O
resin,O
(,O
Ted,O
Pella,O
Inc,O
".,",O
USA,O
).,O
Ultrathin,O
sections,O
were,O
cut,O
on,O
a,O
Leica,O
EM,O
UC6,O
ultra,O
microtome,O
(,O
Leica,O
microsystems,O
",",O
Germany,O
"),",O
collected,O
on,O
copper,O
grids,O
",",O
and,O
then,O
stained,O
with,O
lead,O
citrate,O
and,O
uranyl,O
acetate,O
.,O
Statistical,O
Analysis,O
Statistical,O
analysis,O
was,O
performed,O
using,O
GraphPad,O
Prism,O
software,O
(,O
version,O
6,O
.,O
0,O
).,O
Statistical,O
significance,O
was,O
determined,O
with,O
a,O
two,O
-,O
tailed,O
p,O
<,O
0,O
.,O
05,O
.,O
Mann,O
-,O
Whitney,O
was,O
used,O
for,O
non,O
-,O
parametric,O
measurements,O
",",O
and,O
ANOVA,O
was,O
used,O
where,O
appropriate,O
.,O
Results,O
Patient,O
Demographics,O
Subject,O
demographics,O
are,O
described,O
in,O
Table,O
1,O
.,O
CF,B-DS
and,O
non,O
-,O
CF,B-DS
subjects,O
were,O
similar,O
in,O
terms,O
of,O
ethnicity,O
(,O
100,O
%,O
Caucasian,O
),O
and,O
mean,O
age,O
(,O
30,O
.,O
4,O
±,O
11,O
.,O
5,O
years,O
vs,O
.,O
33,O
.,O
5,O
±,O
9,O
.,O
2,O
years,O
",",O
p,O
=,O
0,O
.,O
53,O
).,O
Subjects,O
with,O
CF,B-DS
had,O
a,O
mean,O
forced,O
expiratory,O
volume,O
in,O
one,O
second,O
(,O
FEV1,O
),O
%,O
predicted,O
of,O
57,O
.,O
1,O
"%,",O
indicative,O
of,O
moderately,O
severe,O
lung,O
function,O
at,O
the,O
time,O
of,O
sampling,O
.,O
81,O
%,O
of,O
CF,B-DS
patients,O
had,O
chronic,O
respiratory,O
cultures,O
positive,O
for,O
P,B-OG
.,I-OG
aeruginosa,I-OG
",",O
and,O
48,O
%,O
had,O
methicillin,B-OG
resistant,I-OG
S,I-OG
.,I-OG
aureus,I-OG
(,O
MRSA,B-OG
).,O
Importantly,O
",",O
48,O
%,O
of,O
subjects,O
were,O
on,O
chronic,O
azithromycin,O
prophylaxis,O
",",O
and,O
this,O
treatment,O
was,O
not,O
noted,O
to,O
influence,O
the,O
experiments,O
below,O
.,O
Azithromycin,O
has,O
been,O
show,O
to,O
block,O
autophagy,O
in,O
CF,B-DS
macrophages,O
in,O
vitro,O
[,O
44,O
"],",O
but,O
CF,B-DS
Patient,O
Registry,O
data,O
does,O
not,O
support,O
an,O
increased,O
risk,O
of,O
mycobacterial,B-DS
infections,I-DS
for,O
those,O
on,O
chronic,O
azithromycin,O
as,O
proposed,O
in,O
the,O
study,O
by,O
Renna,O
and,O
colleagues,O
[,O
45,O
].,O
Cell,O
cultures,O
in,O
our,O
experiments,O
were,O
not,O
further,O
treated,O
with,O
azithromycin,O
.,O
Patient,O
Demographics,O
.,O
non,O
CF,B-DS
patients,O
(,O
n,O
=,O
27,O
),O
CF,B-DS
patients,O
(,O
n,O
=,O
27,O
),O
Mean,O
age,O
(,O
years,O
±,O
st,O
.,O
dev,O
.),O
33,O
.,O
5,O
±,O
9,O
.,O
2,O
30,O
.,O
4,O
±,O
11,O
.,O
5,O
Males,O
30,O
%,O
59,O
%,O
Caucasian,O
100,O
%,O
100,O
%,O
Mean,O
FEV1,O
(%,O
predicted,O
),O
N,O
/,O
A,O
57,O
.,O
1,O
±,O
21,O
.,O
4,O
Pseudomonas,O
colonization,O
N,O
/,O
A,O
81,O
%,O
MRSA,B-OG
colonization,O
N,O
/,O
A,O
48,O
%,O
IFN,B-GP
-,I-GP
γ,I-GP
Production,O
is,O
Reduced,O
in,O
CF,B-DS
PBMCs,O
IFN,B-GP
-,I-GP
γ,I-GP
effectively,O
stimulates,O
autophagic,O
responses,O
in,O
macrophages,O
[,O
46,O
"],",O
[,O
47,O
].,O
However,O
",",O
CF,B-DS
cells,O
insufficiently,O
produce,O
IFN,B-GP
-,I-GP
γ,I-GP
in,O
response,O
to,O
another,O
pathogen,O
",",O
P,B-OG
.,I-OG
aeruginosa,I-OG
[,O
48,O
].,O
To,O
determine,O
if,O
IFN,B-GP
-,I-GP
γ,I-GP
is,O
differentially,O
produced,O
in,O
CF,B-DS
in,O
response,O
to,O
B,B-OG
.,I-OG
cenocepacia,I-OG
",",O
IFN,B-GP
-,I-GP
γ,I-GP
was,O
measured,O
in,O
the,O
serum,O
of,O
CF,B-DS
and,O
non,O
-,O
CF,B-DS
subjects,O
prior,O
to,O
macrophage,O
isolation,O
and,O
in,O
PBMC,O
culture,O
supernatants,O
with,O
and,O
without,O
24,O
hour,O
B,B-DS
.,I-DS
cenocepacia,I-DS
infection,I-DS
.,O
Mean,O
serum,O
levels,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
were,O
non,O
-,O
significantly,O
lower,O
in,O
CF,B-DS
versus,O
non,O
-,O
CF,B-DS
subjects,O
(,O
56,O
.,O
6,O
±,O
6,O
.,O
6,O
vs,O
.,O
78,O
.,O
9,O
±,O
10,O
.,O
4,O
",",O
p,O
=,O
0,O
.,O
08,O
",",O
Figure,O
1A,O
).,O
Infected,O
non,O
-,O
CF,B-DS
PBMC,O
supernatants,O
displayed,O
significantly,O
higher,O
IFN,B-GP
-,I-GP
γ,I-GP
levels,O
compared,O
to,O
uninfected,O
",",O
whereas,O
there,O
was,O
no,O
change,O
in,O
IFN,B-GP
-,I-GP
γ,I-GP
production,O
between,O
uninfected,O
and,O
infected,O
CF,B-DS
PBMCs,O
(,O
Figure,O
1B,O
).,O
Uninfected,O
CF,B-DS
and,O
non,O
-,O
CF,B-DS
PBMC,O
IFN,B-GP
-,I-GP
γ,I-GP
levels,O
were,O
both,O
slightly,O
higher,O
than,O
serum,O
levels,O
.,O
There,O
was,O
no,O
difference,O
in,O
IFN,B-GP
-,I-GP
γ,I-GP
production,O
between,O
CF,B-DS
patients,O
on,O
azithromycin,O
therapy,O
and,O
those,O
not,O
(,O
figure,O
S1A,O
).,O
Additionally,O
",",O
there,O
was,O
no,O
difference,O
in,O
IFN,B-GP
-,I-GP
γ,I-GP
receptor,I-GP
expression,O
during,O
infection,B-DS
between,O
IFN,B-GP
-,I-GP
γ,I-GP
treated,O
and,O
non,O
-,O
treated,O
MDMs,O
as,O
measured,O
by,O
immunoblotting,O
(,O
Figures,O
1C,O
",",O
1D,O
).,O
Our,O
results,O
are,O
consistent,O
with,O
studies,O
from,O
P,B-OG
.,I-OG
aeruginosa,I-OG
[,O
48,O
"],",O
suggesting,O
a,O
defective,O
host,O
CF,B-DS
IFN,B-GP
-,I-GP
γ,I-GP
response,O
to,O
multiple,O
pathogens,O
in,O
CF,B-DS
.,O
IFN,B-GP
-,I-GP
γ,I-GP
is,O
deficiently,O
produced,O
in,O
CF,B-DS
PBMCs,O
in,O
response,O
to,O
B,B-OG
.,I-OG
cenocepacia,I-OG
.,O
1A,O
),O
IFN,B-GP
-,I-GP
γ,I-GP
levels,O
from,O
the,O
serum,O
of,O
14,O
non,O
-,O
CF,B-DS
and,O
14,O
CF,B-DS
patients,O
at,O
the,O
time,O
of,O
blood,O
donation,O
",",O
p,O
=,O
0,O
.,O
056,O
",",O
n,O
=,O
14,O
subjects,O
for,O
each,O
condition,O
",",O
Mann,O
-,O
Whitney,O
testing,O
.,O
1B,O
),O
IFN,B-GP
-,I-GP
γ,I-GP
production,O
from,O
PBMC,O
24,O
hour,O
cell,O
supernatants,O
from,O
CF,B-DS
and,O
non,O
-,O
CF,B-DS
patients,O
.,O
NT,O
represents,O
uninfected,O
cells,O
",",O
and,O
k56,O
were,O
infected,O
with,O
B,B-OG
.,I-OG
cenocepacia,I-OG
k56,I-OG
-,I-OG
2,I-OG
.,O
n,O
=,O
8,O
subjects,O
for,O
NT,O
and,O
10,O
subjects,O
k56,O
",",O
Mann,O
-,O
Whitney,O
testing,O
.,O
1C,O
),O
Immunoblot,O
for,O
IFN,B-GP
-,I-GP
receptor,I-GP
1,I-GP
from,O
cell,O
lysates,O
of,O
MDMs,O
infected,O
with,O
k56,O
-,O
2,O
+/−,O
treatment,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
.,O
1D,O
),O
Immunoblot,O
for,O
IFN,B-GP
-,I-GP
receptor,I-GP
β,I-GP
from,O
cell,O
lysates,O
of,O
MDMs,O
infected,O
with,O
k56,O
-,O
2,O
+/−,O
treatment,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
.,O
IFN,B-GP
-,I-GP
γ,I-GP
Increases,O
B,B-OG
.,I-OG
cenocepacia,I-OG
Co,O
-,O
localization,O
with,O
p62,B-GP
p62,B-GP
is,O
an,O
essential,O
intracellular,O
protein,O
that,O
targets,O
cargo,O
for,O
autophagy,O
as,O
well,O
as,O
regulates,O
signaling,O
pathways,O
involved,O
in,O
cell,O
survival,O
and,O
/,O
or,O
death,O
[,O
49,O
].,O
This,O
docking,O
molecule,O
is,O
required,O
for,O
targeting,O
B,B-OG
.,I-OG
cenocepacia,I-OG
to,O
autophagosomes,O
in,O
a,O
murine,O
model,O
[,O
26,O
"],",O
however,O
its,O
mechanism,O
of,O
action,O
in,O
human,B-OG
cells,O
infected,O
with,O
B,B-OG
.,I-OG
cenocepacia,I-OG
is,O
unknown,O
.,O
Using,O
confocal,O
microscopy,O
",",O
we,O
investigated,O
how,O
p62,B-GP
targets,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
human,B-OG
CF,B-DS
macrophages,O
by,O
examining,O
MDMs,O
for,O
co,O
-,O
localization,O
of,O
bacteria,B-OG
with,O
p62,B-GP
after,O
a,O
24,O
hour,O
infection,B-DS
.,O
MDMs,O
were,O
stimulated,O
with,O
rapamycin,O
or,O
IFN,B-GP
-,I-GP
γ,I-GP
for,O
the,O
duration,O
of,O
infection,B-DS
.,O
Untreated,O
CF,B-DS
macrophages,O
demonstrated,O
significantly,O
less,O
median,O
co,O
-,O
localization,O
with,O
p62,B-GP
compared,O
to,O
non,O
-,O
CF,B-DS
macrophages,O
(,O
16,O
.,O
8,O
%,O
(,O
10,O
.,O
1,O
–,O
19,O
.,O
1,O
),O
vs,O
.,O
37,O
.,O
0,O
%,O
(,O
34,O
.,O
9,O
–,O
40,O
.,O
0,O
"),",O
p,O
=,O
0,O
.,O
016,O
",",O
Figures,O
2A,O
",",O
B,O
).,O
IFN,B-GP
-,I-GP
γ,I-GP
or,O
rapamycin,O
treatment,O
significantly,O
increased,O
median,O
bacterial,O
co,O
-,O
localization,O
with,O
p62,B-GP
in,O
CF,B-DS
human,B-OG
MDMs,O
(,O
CF,B-DS
IFN,B-GP
-,I-GP
γ,I-GP
32,O
.,O
7,O
%,O
(,O
25,O
.,O
2,O
–,O
33,O
.,O
4,O
"),",O
p,O
=,O
0,O
.,O
006,O
",",O
CF,B-DS
rapamycin,O
26,O
.,O
3,O
%,O
(,O
22,O
.,O
4,O
–,O
47,O
.,O
4,O
"),",O
p,O
=,O
0,O
.,O
008,O
",",O
Figures,O
2A,O
",",O
B,O
),O
nearing,O
non,O
-,O
CF,B-DS
levels,O
.,O
p62,B-GP
levels,O
detected,O
by,O
western,O
blotting,O
are,O
increased,O
in,O
uninfected,O
and,O
infected,O
CF,B-DS
MDMs,O
compared,O
to,O
non,O
-,O
CF,B-DS
MDMs,O
(,O
Figure,O
2C,O
).,O
Twenty,O
-,O
four,O
hour,O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
of,O
non,O
-,O
CF,B-DS
and,O
CF,B-DS
MDMs,O
resulted,O
in,O
a,O
decrement,O
in,O
p62,B-GP
accumulation,O
(,O
Figure,O
2C,O
).,O
To,O
ensure,O
that,O
initiation,O
of,O
the,O
beclin,B-GP
-,I-GP
1,I-GP
interactome,O
was,O
not,O
influencing,O
p62,B-GP
expression,O
",",O
beclin,B-GP
-,I-GP
1,I-GP
was,O
measured,O
via,O
immunoblotting,O
and,O
confocal,O
microscopy,O
after,O
24,O
hour,O
infection,B-DS
.,O
There,O
was,O
no,O
difference,O
in,O
beclin,B-GP
-,I-GP
1,I-GP
levels,O
between,O
CF,B-DS
and,O
non,O
CF,B-DS
MDMs,O
(,O
Figure,O
2C,O
",",O
confocal,O
not,O
shown,O
).,O
Altogether,O
",",O
this,O
data,O
suggested,O
that,O
p62,B-GP
is,O
either,O
sequestered,O
or,O
inefficiently,O
utilized,O
by,O
human,B-OG
CF,B-DS
MDMs,O
",",O
and,O
IFN,B-GP
-,I-GP
γ,I-GP
can,O
alleviate,O
this,O
undesirable,O
phenotype,O
in,O
CF,B-DS
cells,O
.,O
IFN,B-GP
-,I-GP
γ,I-GP
increases,O
B,B-OG
.,I-OG
cenocepacia,I-OG
co,O
-,O
localization,O
with,O
p62,B-GP
and,O
decreases,O
p62,B-GP
accumulation,O
in,O
CF,B-DS
.,O
2A,O
),O
Confocal,O
microscopy,O
for,O
non,O
-,O
CF,B-DS
and,O
CF,B-DS
macrophages,O
infected,O
with,O
m,O
-,O
RFP,B-GP
expressing,O
k56,O
-,O
2,O
.,O
IFN,B-GP
-,I-GP
y,I-GP
or,O
rapamycin,O
treatment,O
was,O
administered,O
after,O
1,O
hour,O
of,O
infection,B-DS
for,O
a,O
24,O
hour,O
treatment,O
period,O
.,O
p62,B-GP
is,O
stained,O
green,O
",",O
and,O
macrophage,O
nuclei,O
are,O
stained,O
blue,O
with,O
DAPI,O
.,O
Co,O
-,O
localization,O
of,O
bacteria,B-OG
with,O
p62,B-GP
is,O
noted,O
in,O
yellow,O
in,O
the,O
bottom,O
panel,O
.,O
2B,O
),O
The,O
percentage,O
of,O
bacterial,O
co,O
-,O
localization,O
with,O
p62,B-GP
was,O
scored,O
for,O
over,O
100,O
macrophages,O
per,O
condition,O
",",O
n,O
=,O
5,O
subjects,O
per,O
condition,O
",",O
Mann,O
-,O
Whitney,O
testing,O
.,O
2C,O
),O
Immunoblot,O
for,O
non,O
-,O
CF,B-DS
and,O
CF,B-DS
macrophages,O
demonstrating,O
p62,B-GP
accumulation,O
in,O
CF,B-DS
with,O
reduction,O
during,O
IFN,B-GP
-,I-GP
y,I-GP
therapy,O
",",O
representative,O
of,O
5,O
subjects,O
.,O
Immunoblot,O
of,O
beclin,B-GP
-,I-GP
1,I-GP
levels,O
for,O
non,O
-,O
CF,B-DS
and,O
CF,B-DS
macrophages,O
from,O
cell,O
lysates,O
of,O
control,O
(,O
NT,O
),O
and,O
MDMs,O
infected,O
with,O
k56,O
-,O
2,O
+/−,O
treatment,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
",",O
n,O
=,O
4,O
.,O
Autophagic,O
Flux,O
is,O
Enhanced,O
by,O
IFN,B-GP
-,I-GP
γ,I-GP
in,O
CF,B-DS
MDMs,O
Autophagic,O
flux,O
is,O
deficient,O
in,O
CF,B-DS
cells,O
[,O
25,O
"],",O
[,O
30,O
].,O
Microtubule,B-GP
-,I-GP
associated,I-GP
proteins,I-GP
1A,I-GP
/,I-GP
1B,I-GP
light,I-GP
chain,I-GP
3A,I-GP
(,O
LC3,B-GP
),O
can,O
be,O
monitored,O
to,O
assess,O
autophagosome,O
formation,O
and,O
flux,O
.,O
During,O
the,O
autophagic,O
process,O
",",O
cytosolic,O
LC3,B-GP
(,O
LC3,B-GP
-,I-GP
I,I-GP
),O
is,O
conjugated,O
to,O
phosphatidylethanolamine,O
to,O
form,O
LC3,B-GP
-,I-GP
II,I-GP
",",O
which,O
is,O
then,O
recruited,O
to,O
the,O
autophagosomal,O
membrane,O
.,O
We,O
analyzed,O
LC3,B-GP
concentrations,O
by,O
immunoblotting,O
to,O
monitor,O
the,O
conversion,O
of,O
LC3,B-GP
-,I-GP
I,I-GP
to,O
LC3,B-GP
-,I-GP
II,I-GP
",",O
as,O
well,O
as,O
depletion,O
/,O
accumulation,O
of,O
the,O
proteins,O
to,O
assist,O
in,O
determination,O
of,O
turnover,O
of,O
proteins,O
.,O
During,O
basal,O
",",O
uninfected,O
conditions,O
(,O
NT,O
"),",O
CF,B-DS
macrophages,O
demonstrated,O
persistence,O
of,O
increased,O
LC3,B-GP
-,I-GP
1,I-GP
over,O
24,O
hours,O
compared,O
to,O
non,O
CF,B-DS
as,O
evidence,O
by,O
high,O
proportion,O
of,O
LC31,B-GP
relative,O
to,O
total,O
LC3,B-GP
(,O
Figures,O
3A,O
",",O
3B,O
).,O
Infection,B-DS
with,O
k56,O
-,O
2,O
leads,O
to,O
persistently,O
elevated,O
LC3,B-GP
-,I-GP
1,I-GP
levels,O
in,O
CF,B-DS
by,O
24,O
hours,O
compared,O
to,O
non,O
CF,B-DS
",",O
but,O
to,O
a,O
lesser,O
extent,O
than,O
basal,O
conditions,O
(,O
Figure,O
3B,O
).,O
LC31,B-GP
levels,O
are,O
seen,O
to,O
decrease,O
in,O
CF,B-DS
similar,O
to,O
non,O
CF,B-DS
levels,O
by,O
24,O
hours,O
with,O
the,O
use,O
of,O
either,O
IFN,B-GP
-,I-GP
γ,I-GP
or,O
rapamycin,O
(,O
Figure,O
3B,O
).,O
Specific,O
autophagy,O
inhibitors,O
were,O
used,O
to,O
monitor,O
treatment,O
effects,O
.,O
The,O
addition,O
of,O
bafilomycin,O
to,O
inhibit,O
autophagolysosomal,O
fusion,O
via,O
inhibiting,O
vacuolar,B-GP
H,I-GP
+,I-GP
ATPase,I-GP
(,O
V,B-GP
-,I-GP
ATPase,I-GP
),O
caused,O
an,O
increase,O
in,O
LC3,B-GP
-,I-GP
1,I-GP
in,O
CF,B-DS
at,O
4,O
and,O
24,O
hours,O
(,O
Figures,O
3A,O
",",O
3B,O
"),",O
reversing,O
the,O
effects,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
.,O
The,O
addition,O
of,O
3,O
-,O
methyladenine,O
(,O
3,O
-,O
MA,O
),O
to,O
block,O
autophagosome,O
formation,O
via,O
inhibiting,O
type,B-GP
III,I-GP
Phosphatidylinositol,I-GP
3,I-GP
-,I-GP
kinases,I-GP
had,O
a,O
similar,O
",",O
but,O
lesser,O
effect,O
in,O
CF,B-DS
on,O
LC3,B-GP
conversion,O
compared,O
to,O
bafilomycin,O
.,O
Combining,O
data,O
from,O
4,O
and,O
24,O
hour,O
time,O
points,O
suggests,O
a,O
deficit,O
in,O
autophagic,O
flux,O
in,O
CF,B-DS
macrophages,O
",",O
with,O
enhancement,O
through,O
autophagy,O
stimulators,O
such,O
as,O
IFN,B-GP
-,I-GP
γ,I-GP
that,O
are,O
increasing,O
autophagosome,O
formation,O
.,O
Autophagic,O
flux,O
is,O
decreased,O
in,O
CF,B-DS
.,O
3A,O
),O
Representative,O
immunoblot,O
of,O
4,O
hour,O
treatment,O
protein,O
lysates,O
for,O
LC3,B-GP
-,I-GP
1,I-GP
and,O
LC3,B-GP
-,I-GP
2,I-GP
from,O
non,O
-,O
CF,B-DS
and,O
CF,B-DS
macrophages,O
",",O
with,O
corresponding,O
summed,O
band,O
densitometries,O
normalized,O
to,O
loading,O
control,O
.,O
All,O
lanes,O
are,O
marked,O
with,O
a,O
“+”,O
if,O
the,O
corresponding,O
treatments,O
were,O
added,O
:,O
B,B-DS
.,I-DS
cenocepacia,I-DS
infection,I-DS
(,O
k56,O
-,O
2,O
"),",O
autophagy,O
stimulators,O
(,O
IFN,B-GP
-,I-GP
y,I-GP
",",O
Rapamycin,O
),O
and,O
autophagy,O
inhibitors,O
(,O
Bafilomycin,O
",",O
3,O
-,O
MA,O
).,O
Inhibitors,O
were,O
added,O
one,O
hour,O
prior,O
to,O
infection,B-DS
.,O
Autophagy,O
stimulators,O
were,O
added,O
one,O
hour,O
after,O
infection,B-DS
for,O
a,O
total,O
of,O
4,O
hours,O
of,O
treatment,O
.,O
Data,O
is,O
representative,O
of,O
3,O
independent,O
experiments,O
.,O
3B,O
),O
Representative,O
immunoblot,O
of,O
24,O
hour,O
treatment,O
protein,O
lysates,O
for,O
LC3,B-GP
-,I-GP
1,I-GP
and,O
LC3,B-GP
-,I-GP
2,I-GP
from,O
non,O
-,O
CF,B-DS
and,O
CF,B-DS
macrophages,O
with,O
corresponding,O
summed,O
band,O
densitometries,O
normalized,O
to,O
loading,O
control,O
.,O
All,O
lanes,O
are,O
marked,O
with,O
a,O
“+”,O
if,O
the,O
corresponding,O
treatments,O
were,O
added,O
:,O
B,B-DS
.,I-DS
cenocepacia,I-DS
infection,I-DS
(,O
k56,O
-,O
2,O
"),",O
autophagy,O
stimulators,O
(,O
IFN,B-GP
-,I-GP
y,I-GP
",",O
Rapamycin,O
),O
and,O
autophagy,O
inhibitors,O
(,O
Bafilomycin,O
",",O
3,O
-,O
MA,O
).,O
Inhibitors,O
were,O
added,O
one,O
hour,O
prior,O
to,O
infection,B-DS
.,O
Autophagy,O
stimulators,O
were,O
added,O
one,O
hour,O
after,O
infection,B-DS
for,O
a,O
total,O
of,O
24,O
hours,O
of,O
treatment,O
.,O
Data,O
is,O
representative,O
of,O
3,O
independent,O
experiments,O
.,O
Autophagy,O
Stimulation,O
Increases,O
Bacterial,O
Clearance,O
in,O
CF,B-DS
B,B-DS
.,I-DS
cenocepacia,I-DS
infection,I-DS
causes,O
increased,O
bacterial,O
burden,O
in,O
human,B-OG
and,O
murine,O
CF,B-DS
cells,O
",",O
indicating,O
an,O
innate,O
defect,O
in,O
clearing,O
the,O
pathogen,O
in,O
CF,B-DS
[,O
19,O
"],",O
[,O
22,O
].,O
Persistent,O
bacterial,O
loads,O
can,O
lead,O
to,O
systemic,O
involvement,O
and,O
/,O
or,O
heightened,O
inflammation,O
.,O
Because,O
autophagy,O
regulates,O
pathogen,O
clearance,O
",",O
we,O
stimulated,O
autophagy,O
in,O
MDMs,O
with,O
IFN,B-GP
-,I-GP
y,I-GP
or,O
rapamycin,O
for,O
4,O
and,O
24,O
hours,O
and,O
assessed,O
bacterial,O
clearance,O
by,O
confocal,O
microscopy,O
and,O
CFU,O
.,O
Twenty,O
-,O
four,O
hours,O
is,O
an,O
expected,O
clinical,O
dosing,O
regimen,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
",",O
and,O
4,O
hours,O
was,O
chosen,O
to,O
ensure,O
sufficient,O
autophagosome,O
formation,O
",",O
as,O
murine,O
studies,O
have,O
shown,O
that,O
even,O
in,O
wild,O
type,O
macrophages,O
B,B-OG
.,I-OG
cenocepacia,I-OG
requires,O
at,O
least,O
2,O
hours,O
to,O
traffic,O
to,O
autophagosomes,O
.,O
There,O
is,O
no,O
difference,O
in,O
bacterial,O
counts,O
at,O
2,O
hours,O
(,O
figure,O
S2,O
).,O
At,O
4,O
hours,O
of,O
treatment,O
",",O
there,O
were,O
significantly,O
higher,O
bacterial,O
counts,O
in,O
both,O
autophagy,O
-,O
stimulated,O
and,O
unstimulated,O
CF,B-DS
macrophages,O
compared,O
to,O
non,O
-,O
CF,B-DS
macrophages,O
(,O
Figures,O
4A,O
).,O
However,O
",",O
CF,B-DS
macrophages,O
treated,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
for,O
4,O
hours,O
had,O
a,O
higher,O
proportion,O
of,O
bacterial,O
co,O
-,O
localized,O
with,O
autophagosomes,O
as,O
marked,O
by,O
LC3,B-GP
compared,O
to,O
untreated,O
CF,B-DS
macrophages,O
(,O
Figure,O
4A,O
).,O
A,O
24,O
hour,O
treatment,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
or,O
rapamycin,O
markedly,O
reduced,O
bacterial,O
counts,O
in,O
the,O
CF,B-DS
macrophages,O
compared,O
to,O
untreated,O
CF,B-DS
macrophages,O
(,O
Figures,O
4B,O
",",O
4C,O
",",O
4E,O
).,O
These,O
reductions,O
mirror,O
bacterial,O
levels,O
in,O
non,O
-,O
CF,B-DS
macrophages,O
.,O
There,O
was,O
no,O
difference,O
in,O
bacterial,O
counts,O
between,O
CF,B-DS
patients,O
on,O
azithromycin,O
therapy,O
and,O
those,O
not,O
(,O
Supplemental,O
Figure,O
1B,O
).,O
24,O
hour,O
extracellular,O
bacterial,O
counts,O
were,O
not,O
reduced,O
(,O
Figure,O
S2,O
).,O
There,O
is,O
a,O
sustained,O
increase,O
in,O
the,O
co,O
-,O
localization,O
of,O
bacteria,B-OG
with,O
LC3,B-GP
after,O
24,O
hours,O
of,O
autophagy,O
stimulation,O
in,O
CF,B-DS
macrophages,O
compared,O
to,O
untreated,O
CF,B-DS
macrophages,O
(,O
p,O
=,O
0,O
.,O
02,O
",",O
Figures,O
4B,O
",",O
4D,O
).,O
Electron,O
microscopy,O
confirmed,O
these,O
confocal,O
findings,O
.,O
Untreated,O
non,O
-,O
CF,B-DS
macrophages,O
contained,O
double,O
membrane,O
vacuoles,O
surrounding,O
B,B-OG
.,I-OG
cenocepacia,I-OG
",",O
indicative,O
of,O
autophagosome,O
formation,O
(,O
Figure,O
5A,O
).,O
Untreated,O
CF,B-DS
macrophages,O
displayed,O
only,O
single,O
membrane,O
bound,O
vacuoles,O
(,O
5C,O
"),",O
but,O
when,O
stimulated,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
",",O
CF,B-DS
macrophages,O
displayed,O
double,O
membrane,O
vacuoles,O
similar,O
to,O
the,O
non,O
-,O
CF,B-DS
(,O
5D,O
).,O
This,O
observation,O
suggests,O
autophagosome,O
formation,O
is,O
stimulated,O
upon,O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
in,O
the,O
CF,B-DS
MDMs,O
.,O
Additionally,O
",",O
IFN,B-GP
-,I-GP
γ,I-GP
had,O
no,O
direct,O
effects,O
on,O
bacterial,O
growth,O
when,O
added,O
to,O
bacteria,B-OG
in,O
media,O
devoid,O
of,O
MDMs,O
",",O
with,O
no,O
difference,O
in,O
bacterial,O
growth,O
over,O
24,O
hours,O
between,O
media,O
with,O
k56,O
-,O
2,O
alone,O
",",O
and,O
media,O
with,O
k56,O
-,O
2,O
plus,O
IFN,B-GP
-,I-GP
γ,I-GP
(,O
Figure,O
S3,O
).,O
In,O
summation,O
",",O
these,O
results,O
indicate,O
that,O
IFN,B-GP
-,I-GP
γ,I-GP
effectively,O
stimulates,O
early,O
autophagic,O
targeting,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
to,O
autophagosomes,O
",",O
thus,O
allowing,O
enhanced,O
clearance,O
after,O
24,O
hours,O
.,O
IFN,B-GP
-,I-GP
γ,I-GP
increases,O
autophagosome,O
formation,O
.,O
4A,O
),O
Confocal,O
microscopy,O
for,O
non,O
-,O
CF,B-DS
and,O
CF,B-DS
macrophages,O
infected,O
with,O
m,O
-,O
RFP,B-GP
expressing,O
k56,O
-,O
2,O
.,O
IFN,B-GP
-,I-GP
y,I-GP
treatment,O
was,O
administered,O
after,O
1,O
hour,O
of,O
infection,B-DS
for,O
a,O
4,O
hour,O
treatment,O
period,O
.,O
LC3,B-GP
is,O
stained,O
green,O
",",O
and,O
macrophage,O
nuclei,O
are,O
stained,O
blue,O
with,O
DAPI,O
.,O
Co,O
-,O
localization,O
of,O
bacteria,B-OG
with,O
LC3,B-GP
is,O
noted,O
in,O
yellow,O
in,O
the,O
bottom,O
panel,O
as,O
noted,O
by,O
white,O
arrows,O
.,O
4B,O
),O
24,O
hour,O
IFN,B-GP
-,I-GP
γ,I-GP
and,O
rapamycin,O
treatments,O
similar,O
to,O
4A,O
.,O
4C,O
),O
Summary,O
of,O
scored,O
bacteria,B-OG
per,O
100,O
macrophages,O
from,O
individual,O
subjects,O
for,O
the,O
confocal,O
microscopy,O
experiments,O
from,O
4B,O
",",O
n,O
=,O
17,O
subjects,O
",",O
with,O
2,O
replicates,O
per,O
subject,O
",",O
unpaired,O
t,O
-,O
test,O
.,O
4D,O
),O
The,O
percentage,O
of,O
bacterial,O
co,O
-,O
localization,O
with,O
LC3,B-GP
was,O
scored,O
for,O
over,O
100,O
macrophages,O
per,O
condition,O
from,O
4B,O
",",O
n,O
=,O
17,O
subjects,O
",",O
with,O
2,O
replicates,O
per,O
subject,O
",",O
unpaired,O
t,O
-,O
test,O
.,O
4E,O
),O
CFU,O
counts,O
for,O
non,O
-,O
CF,B-DS
and,O
CF,B-DS
macrophages,O
infected,O
with,O
MHK1,O
for,O
24,O
hours,O
(,O
n,O
=,O
6,O
).,O
IFN,B-GP
-,I-GP
γ,I-GP
stimulates,O
double,O
-,O
membrane,O
autophagosome,O
formation,O
.,O
5A,O
),O
Electron,O
microscopy,O
of,O
non,O
-,O
CF,B-DS
macrophage,O
infected,O
with,O
k56,O
-,O
2,O
only,O
for,O
24,O
hours,O
.,O
White,O
arrow,O
indicates,O
double,O
membrane,O
formation,O
indicative,O
of,O
autophagosomes,O
.,O
5B,O
),O
EM,O
of,O
non,O
-,O
CF,B-DS
macrophage,O
treated,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
for,O
24,O
hours,O
.,O
5C,O
),O
EM,O
of,O
CF,B-DS
macrophage,O
infected,O
with,O
k56,O
-,O
2,O
only,O
.,O
Black,O
arrow,O
indicates,O
single,O
membrane,O
vacuole,O
.,O
5D,O
),O
EM,O
of,O
CF,B-DS
macrophage,O
treated,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
for,O
24,O
hours,O
.,O
White,O
arrow,O
indicates,O
double,O
membrane,O
formation,O
.,O
Pictures,O
are,O
marked,O
with,O
500,O
nm,O
marker,O
.,O
Lysosome,O
Targeting,O
is,O
Increased,O
in,O
Autophagy,O
Stimulated,O
CF,B-DS
MDMs,O
Rapamycin,O
increases,O
lysosomal,O
degradation,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
CF,B-DS
murine,O
macrophages,O
by,O
promoting,O
phagosome,O
-,O
lysosome,O
fusion,O
via,O
autophagy,O
[,O
22,O
].,O
Human,B-OG
CF,B-DS
macrophages,O
also,O
demonstrate,O
decreased,O
co,O
-,O
localization,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
with,O
lysosomes,O
[,O
19,O
].,O
We,O
examined,O
the,O
extent,O
to,O
which,O
IFN,B-GP
-,I-GP
γ,I-GP
enhances,O
autophagosome,O
fusion,O
with,O
lysosomes,O
by,O
infecting,O
human,B-OG
MDMs,O
with,O
B,B-OG
.,I-OG
cenocepacia,I-OG
for,O
1,O
hour,O
and,O
then,O
treating,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
for,O
2,O
and,O
24,O
hours,O
.,O
We,O
then,O
scored,O
co,O
-,O
localization,O
of,O
a,O
fluorescent,O
lysotracker,O
with,O
bacteria,B-OG
using,O
confocal,O
microscopy,O
.,O
After,O
2,O
hours,O
of,O
infection,B-DS
",",O
untreated,O
CF,B-DS
macrophages,O
exhibited,O
very,O
little,O
co,O
-,O
localization,O
of,O
bacteria,B-OG
with,O
lysosomes,O
(,O
11,O
.,O
5,O
±,O
3,O
.,O
2,O
"%,",O
Figures,O
6A,O
",",O
B,O
),O
compared,O
to,O
non,O
-,O
CF,B-DS
macrophages,O
(,O
29,O
.,O
9,O
±,O
8,O
.,O
5,O
"%,",O
Figures,O
6A,O
",",O
B,O
).,O
However,O
",",O
CF,B-DS
macrophages,O
treated,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
demonstrate,O
increased,O
lysosomal,O
co,O
-,O
localization,O
of,O
bacteria,B-OG
(,O
26,O
.,O
5,O
±.,O
5,O
"%,",O
p,O
<,O
0,O
.,O
0001,O
",",O
Figures,O
6A,O
",",O
B,O
).,O
After,O
24,O
hours,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
therapy,O
CF,B-DS
macrophages,O
demonstrated,O
a,O
sustained,O
lysosomal,O
co,O
-,O
localization,O
of,O
remaining,O
bacteria,B-OG
",",O
similar,O
to,O
what,O
was,O
observed,O
in,O
non,O
-,O
CF,B-DS
macrophages,O
(,O
34,O
.,O
8,O
±,O
5,O
.,O
4,O
%,O
vs,O
.,O
37,O
.,O
0,O
±,O
9,O
.,O
5,O
"%,",O
p,O
=,O
0,O
.,O
5,O
",",O
Figures,O
6C,O
",",O
D,O
).,O
Untreated,O
CF,B-DS
macrophages,O
have,O
significantly,O
less,O
lysosomal,O
co,O
-,O
localization,O
compared,O
to,O
treated,O
CF,B-DS
macrophages,O
at,O
24,O
hours,O
.,O
(,O
25,O
.,O
1,O
±,O
9,O
.,O
4,O
"%,",O
p,O
=,O
0,O
.,O
038,O
",",O
Figures,O
6C,O
",",O
D,O
).,O
Together,O
",",O
the,O
results,O
demonstrate,O
delayed,O
lysosomal,O
targeting,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
CF,B-DS
MDMs,O
.,O
Combined,O
with,O
prior,O
results,O
",",O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
increases,O
autophagosome,O
formation,O
in,O
CF,B-DS
macrophages,O
",",O
enhancing,O
lysosomal,O
targeting,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
.,O
Lysosomal,O
co,O
-,O
localization,O
is,O
increased,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
in,O
CF,B-DS
.,O
6A,O
),O
Confocal,O
microscopy,O
for,O
non,O
-,O
CF,B-DS
and,O
CF,B-DS
macrophages,O
infected,O
with,O
k56,O
-,O
2,O
.,O
Macrophages,O
were,O
labeled,O
with,O
green,O
lysotracker,O
and,O
bacterial,O
co,O
-,O
localization,O
to,O
lysosomes,O
was,O
measured,O
after,O
a,O
2,O
hour,O
infection,B-DS
.,O
Macrophage,O
nuclei,O
are,O
stained,O
blue,O
with,O
DAPI,O
.,O
Co,O
-,O
localization,O
of,O
bacteria,B-OG
with,O
lysotracker,O
is,O
noted,O
in,O
yellow,O
by,O
white,O
arrows,O
.,O
6B,O
),O
Quantitative,O
scoring,O
of,O
%,O
bacterial,O
co,O
-,O
localization,O
with,O
lysosomes,O
from,O
6A,O
",",O
n,O
=,O
8,O
subjects,O
",",O
Mann,O
-,O
Whitney,O
testing,O
.,O
6C,O
),O
24,O
hour,O
k56,O
-,O
2,O
infection,B-DS
with,O
lysotracker,O
staining,O
.,O
6D,O
),O
Bacterial,O
co,O
-,O
localization,O
with,O
lysotracker,O
quantitative,O
scoring,O
for,O
5C,O
",",O
n,O
=,O
8,O
subjects,O
",",O
Mann,O
-,O
Whitney,O
testing,O
.,O
IL,B-GP
-,I-GP
1β,I-GP
Production,O
is,O
Decreased,O
with,O
Autophagy,O
Stimulation,O
CF,B-DS
macrophages,O
excessively,O
produce,O
the,O
pro,B-GP
-,I-GP
inflammatory,I-GP
cytokine,I-GP
IL,B-GP
-,I-GP
1β,I-GP
in,O
response,O
to,O
B,B-DS
.,I-DS
cenocepacia,I-DS
infection,I-DS
[,O
19,O
"],",O
[,O
50,O
].,O
Human,B-OG
bronchial,O
epithelial,O
cells,O
do,O
not,O
produce,O
IL,B-GP
-,I-GP
1β,I-GP
in,O
response,O
to,O
B,B-OG
.,I-OG
cenocepacia,I-OG
[,O
51,O
].,O
During,O
B,B-DS
.,I-DS
cenocepacia,I-DS
infection,I-DS
pyrin,B-GP
inflammasome,B-GP
activation,O
results,O
in,O
IL,B-GP
-,I-GP
1β,I-GP
release,O
from,O
mononuclear,O
cells,O
[,O
52,O
].,O
Therefore,O
",",O
we,O
measured,O
IL,B-GP
-,I-GP
1β,I-GP
production,O
in,O
human,B-OG
CF,B-DS
macrophages,O
after,O
autophagy,O
stimulation,O
as,O
a,O
primary,O
source,O
of,O
excess,O
inflammatory,B-GP
cytokine,I-GP
production,O
during,O
infection,B-DS
.,O
MDMs,O
were,O
infected,O
with,O
B,B-OG
.,I-OG
cenocepacia,I-OG
and,O
treated,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
or,O
rapamycin,O
for,O
4,O
and,O
24,O
hours,O
and,O
cell,O
supernatants,O
were,O
examined,O
by,O
ELISA,O
for,O
IL,B-GP
-,I-GP
1β,I-GP
production,O
.,O
After,O
4,O
hours,O
of,O
autophagy,O
stimulation,O
",",O
IL,B-GP
-,I-GP
1β,I-GP
levels,O
were,O
similar,O
between,O
treated,O
and,O
untreated,O
CF,B-DS
macrophages,O
",",O
but,O
CF,B-DS
macrophages,O
had,O
significantly,O
more,O
IL,B-GP
-,I-GP
1β,I-GP
than,O
non,O
-,O
CF,B-DS
macrophages,O
(,O
p,O
=,O
0,O
.,O
0012,O
",",O
Figure,O
7A,O
).,O
However,O
",",O
in,O
CF,B-DS
macrophages,O
treated,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
",",O
IL,B-GP
-,I-GP
1β,I-GP
levels,O
diminished,O
by,O
24,O
hours,O
of,O
treatment,O
(,O
p,O
=,O
0,O
.,O
045,O
"),",O
while,O
untreated,O
CF,B-DS
macrophages,O
infected,O
with,O
B,B-OG
.,I-OG
cenocepacia,I-OG
perpetuate,O
elevated,O
IL,B-GP
-,I-GP
1β,I-GP
production,O
(,O
Figure,O
7B,O
).,O
There,O
was,O
no,O
difference,O
in,O
IL,B-GP
-,I-GP
1β,I-GP
production,O
between,O
CF,B-DS
patients,O
on,O
azithromycin,O
therapy,O
and,O
those,O
not,O
(,O
figure,O
S1C,O
).,O
IL,B-GP
-,I-GP
10,I-GP
was,O
also,O
measured,O
as,O
it,O
can,O
directly,O
impair,O
IFN,B-GP
-,I-GP
γ,I-GP
signaling,O
pathways,O
and,O
its,O
production,O
can,O
correlate,O
with,O
inflammatory,B-GP
cytokines,I-GP
such,O
as,O
IL,B-GP
-,I-GP
1β,I-GP
.,O
There,O
was,O
no,O
difference,O
in,O
IL,B-GP
-,I-GP
10,I-GP
production,O
in,O
24,O
hour,O
supernatants,O
between,O
uninfected,O
",",O
infected,O
",",O
and,O
IFN,B-GP
-,I-GP
γ,I-GP
treated,O
CF,B-DS
and,O
non,O
-,O
CF,B-DS
macrophages,O
(,O
Figure,O
7C,O
).,O
These,O
results,O
demonstrate,O
autophagy,O
induction,O
plays,O
a,O
role,O
in,O
reducing,O
IL,B-GP
-,I-GP
1β,I-GP
production,O
in,O
macrophage,O
responses,O
to,O
B,B-OG
.,I-OG
cenocepacia,I-OG
.,O
IL,B-GP
-,I-GP
1β,I-GP
is,O
decreased,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
in,O
CF,B-DS
.,O
IL,B-GP
-,I-GP
1β,I-GP
levels,O
in,O
macrophage,O
supernatants,O
after,O
infection,B-DS
with,O
k56,O
-,O
2,O
and,O
either,O
a,O
4,O
hour,O
treatment,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
or,O
a,O
control,O
diluent,O
(,O
7A,O
),O
or,O
a,O
24,O
hour,O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
(,O
7B,O
"),",O
n,O
=,O
7,O
subjects,O
",",O
Mann,O
-,O
Whitney,O
analysis,O
.,O
7C,O
),O
IL,B-GP
-,I-GP
10,I-GP
levels,O
in,O
macrophage,O
supernatants,O
after,O
infection,B-DS
with,O
k56,O
-,O
2,O
and,O
a,O
24,O
hour,O
treatment,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
or,O
a,O
control,O
diluent,O
",",O
n,O
=,O
7,O
subjects,O
",",O
Mann,O
-,O
Whitney,O
analysis,O
.,O
Significant,O
differences,O
are,O
noted,O
.,O
Cell,O
Death,O
is,O
Decreased,O
by,O
IFN,B-GP
-,I-GP
γ,I-GP
Treatment,O
during,O
B,B-DS
.,I-DS
cenocepacia,I-DS
Infection,I-DS
B,B-OG
.,I-OG
cenocepacia,I-OG
promotes,O
increased,O
cell,O
death,O
in,O
human,B-OG
CF,B-DS
macrophages,O
[,O
19,O
].,O
Autophagy,O
has,O
an,O
interconnected,O
role,O
with,O
apoptosis,O
and,O
necrosis,O
in,O
the,O
regulation,O
of,O
cell,O
death,O
[,O
53,O
].,O
We,O
examined,O
MDMs,O
for,O
LDH,B-GP
release,O
at,O
4,O
and,O
24,O
hours,O
after,O
infection,B-DS
to,O
assess,O
cell,O
death,O
as,O
a,O
result,O
of,O
autophagy,O
stimulation,O
in,O
CF,B-DS
macrophages,O
infected,O
with,O
B,B-OG
.,I-OG
cenocepacia,I-OG
.,O
After,O
4,O
hours,O
of,O
infection,B-DS
IFN,B-GP
-,I-GP
γ,I-GP
treated,O
CF,B-DS
MDMs,O
trended,O
towards,O
higher,O
cell,O
death,O
compared,O
to,O
untreated,O
CF,B-DS
MDMs,O
(,O
Figure,O
8A,O
).,O
All,O
CF,B-DS
macrophages,O
had,O
higher,O
cell,O
death,O
than,O
non,O
-,O
CF,B-DS
macrophages,O
(,O
Figure,O
8A,O
).,O
After,O
24,O
of,O
infection,B-DS
CF,B-DS
macrophages,O
remained,O
with,O
slightly,O
higher,O
cell,O
death,O
than,O
non,O
-,O
CF,B-DS
",",O
except,O
for,O
IFN,B-GP
-,I-GP
γ,I-GP
treated,O
CF,B-DS
MDMs,O
.,O
There,O
was,O
also,O
no,O
difference,O
among,O
autophagy,O
stimulated,O
CF,B-DS
macrophages,O
compared,O
to,O
un,O
-,O
stimulated,O
CF,B-DS
macrophages,O
(,O
Figures,O
8B,O
).,O
Macrophage,O
viability,O
was,O
additionally,O
assessed,O
at,O
24,O
hours,O
of,O
infection,B-DS
via,O
a,O
naphthol,O
blue,O
/,O
black,O
assay,O
.,O
At,O
24,O
hours,O
there,O
was,O
no,O
difference,O
in,O
macrophage,O
viability,O
between,O
CF,B-DS
and,O
non,O
CF,B-DS
macrophage,O
(,O
Figure,O
8C,O
).,O
Macrophage,O
viability,O
was,O
not,O
decreased,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
(,O
Figure,O
8c,O
).,O
Taken,O
together,O
",",O
this,O
data,O
suggests,O
that,O
autophagic,O
clearance,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
CF,B-DS
macrophages,O
decreases,O
cell,O
death,O
in,O
a,O
human,B-OG
model,O
after,O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
.,O
Cell,O
death,O
is,O
decreased,O
with,O
autophagy,O
stimulation,O
in,O
CF,B-DS
.,O
Percent,O
LDH,B-GP
release,O
from,O
MDM,O
supernatants,O
treated,O
with,O
autophagy,O
stimulators,O
IFN,B-GP
-,I-GP
γ,I-GP
or,O
Rapamycin,O
for,O
4,O
hours,O
(,O
8A,O
),O
or,O
24,O
hours,O
(,O
8B,O
"),",O
n,O
=,O
at,O
least,O
6,O
subjects,O
per,O
condition,O
",",O
Mann,O
-,O
Whitney,O
testing,O
.,O
8c,O
),O
Percent,O
of,O
macrophages,O
deemed,O
viable,O
per,O
naphthol,O
staining,O
after,O
a,O
24,O
hour,O
infection,B-DS
",",O
n,O
=,O
2,O
.,O
Discussion,O
The,O
discovery,O
of,O
new,O
therapeutic,O
classes,O
or,O
novel,O
utilization,O
of,O
existing,O
therapeutics,O
is,O
imperative,O
for,O
CF,B-DS
patients,O
infected,O
with,O
B,B-OG
.,I-OG
cenocepacia,I-OG
due,O
to,O
its,O
devastating,O
impact,O
on,O
morbidity,O
and,O
mortality,O
.,O
Here,O
",",O
we,O
demonstrate,O
the,O
effectiveness,O
of,O
autophagy,O
stimulation,O
as,O
a,O
therapeutic,O
class,O
",",O
specifically,O
IFN,B-GP
-,I-GP
γ,I-GP
in,O
clearing,O
B,B-OG
.,I-OG
cenocepacia,I-OG
from,O
human,B-OG
CF,B-DS
macrophages,O
.,O
This,O
is,O
a,O
crucial,O
finding,O
considering,O
the,O
mounting,O
evidence,O
for,O
CFTR,B-GP
dysfunction,O
in,O
monocyte,O
-,O
pathogen,O
interactions,O
in,O
CF,B-DS
[,O
54,O
"],",O
as,O
well,O
as,O
the,O
ability,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
to,O
replicate,O
within,O
macrophages,O
[,O
24,O
"],",O
[,O
55,O
].,O
By,O
improving,O
the,O
clearance,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
from,O
macrophages,O
",",O
we,O
can,O
minimize,O
the,O
chances,O
of,O
overwhelming,O
bacteremia,B-DS
as,O
well,O
as,O
reduce,O
continued,O
pro,O
-,O
inflammatory,O
signaling,O
.,O
Our,O
work,O
is,O
aligned,O
well,O
with,O
a,O
recent,O
study,O
from,O
Al,O
-,O
Khodor,O
and,O
colleagues,O
in,O
CGD,B-DS
macrophages,O
[,O
38,O
"],",O
and,O
importantly,O
demonstrates,O
the,O
effectiveness,O
of,O
a,O
post,O
infection,B-DS
therapeutic,O
intervention,O
.,O
Autophagy,O
stimulation,O
also,O
holds,O
the,O
promise,O
of,O
clearing,O
other,O
pathogens,O
in,O
CF,B-DS
besides,O
B,B-OG
.,I-OG
cenocepacia,I-OG
[,O
27,O
"],",O
[,O
28,O
"],",O
[,O
56,O
"],",O
as,O
well,O
as,O
facilitating,O
CFTR,B-GP
trafficking,O
[,O
30,O
].,O
IFN,B-GP
-,I-GP
γ,I-GP
has,O
numerous,O
signaling,O
effects,O
in,O
the,O
body,O
including,O
host,O
defense,O
",",O
autoimmunity,O
",",O
inflammatory,O
responses,O
",",O
and,O
is,O
a,O
major,O
activator,O
of,O
macrophages,O
[,O
57,O
].,O
Importantly,O
",",O
we,O
found,O
deficient,O
production,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
with,O
adequate,O
receptor,O
expression,O
in,O
CF,B-DS
PBMCs,O
in,O
response,O
to,O
B,B-OG
.,I-OG
cenocepacia,I-OG
compared,O
to,O
non,O
-,O
CF,B-DS
PBMCs,O
",",O
suggesting,O
a,O
natural,O
defect,O
in,O
CF,B-DS
macrophage,O
priming,O
/,O
pathogen,O
response,O
.,O
This,O
was,O
in,O
contrast,O
to,O
our,O
previous,O
work,O
with,O
the,O
J2315,O
strain,O
[,O
19,O
"],",O
however,O
our,O
previous,O
study,O
may,O
have,O
been,O
affected,O
by,O
the,O
different,O
strain,O
as,O
well,O
as,O
negligible,O
baseline,O
IFN,B-GP
-,I-GP
γ,I-GP
from,O
pure,O
macrophage,O
cultures,O
.,O
IFN,B-GP
-,I-GP
γ,I-GP
has,O
been,O
previously,O
studied,O
in,O
CF,B-DS
as,O
an,O
inhalational,O
therapy,O
in,O
patients,O
without,O
Burkholderia,B-DS
infections,I-DS
",",O
demonstrating,O
no,O
significant,O
effects,O
on,O
lung,O
function,O
",",O
sputum,O
bacterial,O
density,O
",",O
or,O
inflammatory,O
sputum,O
markers,O
[,O
41,O
].,O
However,O
",",O
in,O
that,O
study,O
only,O
2,O
of,O
the,O
48,O
treated,O
patients,O
had,O
detected,O
serum,O
IFN,B-GP
-,I-GP
γ,I-GP
levels,O
",",O
and,O
they,O
did,O
not,O
measure,O
lower,O
airway,O
IFN,B-GP
-,I-GP
γ,I-GP
levels,O
to,O
monitor,O
deposition,O
efficacy,O
.,O
Furthermore,O
",",O
the,O
effective,O
aerosol,O
deposition,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
is,O
low,O
in,O
several,O
non,O
-,O
CF,B-DS
studies,O
",",O
which,O
questions,O
the,O
efficacy,O
of,O
the,O
aforementioned,O
CF,B-DS
study,O
as,O
alveolar,O
macrophages,O
would,O
not,O
be,O
affected,O
by,O
upper,O
airway,O
deposition,O
.,O
A,O
2004,O
study,O
of,O
aerosolized,O
IFN,B-GP
-,I-GP
γ,I-GP
in,O
TB,B-DS
patients,O
demonstrated,O
greater,O
upper,O
airway,O
deposition,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
than,O
lower,O
airway,O
",",O
with,O
a,O
mean,O
lower,O
airway,O
deposition,O
of,O
only,O
35,O
.,O
8,O
µg,O
of,O
a,O
500,O
ug,O
dose,O
[,O
58,O
].,O
Recent,O
studies,O
in,O
patients,O
with,O
idiopathic,B-DS
pulmonary,I-DS
fibrosis,I-DS
demonstrated,O
only,O
65,O
%,O
lower,O
airway,O
deposition,O
using,O
a,O
Philips,O
Respironics,O
I,O
-,O
neb,O
[,O
59,O
].,O
Based,O
on,O
the,O
sputum,O
density,O
of,O
CF,B-DS
patients,O
it,O
is,O
reasonable,O
to,O
assume,O
that,O
nebulized,O
concentrations,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
would,O
be,O
even,O
lower,O
in,O
CF,B-DS
patients,O
’,O
lower,O
airways,O
",",O
necessitating,O
systemic,O
IFN,B-GP
-,I-GP
γ,I-GP
use,O
in,O
situations,O
such,O
as,O
B,B-DS
.,I-DS
cenocepacia,I-DS
septicemia,I-DS
or,O
worsening,O
patient,O
progression,O
until,O
improved,O
aerosol,O
deposition,O
can,O
be,O
achieved,O
.,O
Prior,O
studies,O
in,O
CF,B-DS
murine,O
models,O
of,O
P,B-DS
.,I-DS
aeruginosa,I-DS
infection,I-DS
effectively,O
utilized,O
IFN,B-GP
-,I-GP
γ,I-GP
as,O
a,O
systemic,O
therapy,O
[,O
60,O
"],",O
and,O
patients,O
with,O
CGD,B-DS
inject,O
IFN,B-GP
-,I-GP
γ,I-GP
subcutaneously,O
to,O
prevent,O
infections,B-DS
with,O
species,O
including,O
Burkholderia,B-OG
[,O
34,O
].,O
Known,O
side,O
effects,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
administration,O
are,O
fever,O
",",O
headaches,O
",",O
myalgias,O
",",O
fatigue,O
",",O
irritability,O
",",O
and,O
flulike,B-DS
syndromes,I-DS
",",O
but,O
overall,O
it,O
has,O
been,O
safely,O
used,O
in,O
CGD,B-DS
[,O
61,O
].,O
The,O
effects,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
on,O
the,O
total,O
CF,B-DS
microbiome,O
still,O
remain,O
to,O
be,O
characterized,O
",",O
but,O
on,O
individual,O
pathogens,O
such,O
as,O
B,B-OG
.,I-OG
cenocepacia,I-OG
and,O
P,B-OG
.,I-OG
aeruginosa,I-OG
",",O
there,O
is,O
a,O
demonstrable,O
benefit,O
on,O
bacterial,O
clearance,O
.,O
Autophagy,O
stimulation,O
is,O
also,O
known,O
to,O
reduce,O
inflammasome,B-GP
mediated,O
IL,B-GP
-,I-GP
1β,I-GP
production,O
[,O
62,O
],O
and,O
attenuates,O
hyperinflammatory,O
responses,O
from,O
CF,B-DS
cells,O
[,O
29,O
],O
independent,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
.,O
We,O
demonstrated,O
that,O
IFN,B-GP
-,I-GP
γ,I-GP
was,O
effective,O
in,O
reducing,O
the,O
exaggerated,O
IL,B-GP
-,I-GP
1β,I-GP
production,O
that,O
is,O
observed,O
in,O
response,O
to,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
CF,B-DS
macrophages,O
.,O
This,O
result,O
was,O
not,O
unexpected,O
given,O
the,O
possibility,O
of,O
inflammasome,B-GP
dependent,O
IFN,B-GP
-,I-GP
γ,I-GP
signaling,O
[,O
63,O
"],",O
as,O
well,O
as,O
the,O
observed,O
reduction,O
in,O
bacteria,B-OG
with,O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
in,O
the,O
CF,B-DS
macrophages,O
.,O
Therefore,O
",",O
our,O
results,O
suggest,O
the,O
reductions,O
in,O
IL,B-GP
-,I-GP
1β,I-GP
are,O
likely,O
due,O
to,O
both,O
the,O
reduced,O
burden,O
observed,O
and,O
dampened,O
inflammasome,B-GP
activation,O
.,O
IL,B-GP
-,I-GP
10,I-GP
was,O
unchanged,O
with,O
treatment,O
",",O
but,O
was,O
not,O
significantly,O
different,O
between,O
CF,B-DS
and,O
non,O
CF,B-DS
prior,O
to,O
treatment,O
",",O
and,O
therefore,O
not,O
likely,O
to,O
be,O
reduced,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
therapy,O
.,O
Importantly,O
",",O
IL,B-GP
-,I-GP
10,I-GP
was,O
not,O
significantly,O
overproduced,O
in,O
response,O
to,O
therapy,O
.,O
In,O
addition,O
to,O
reductions,O
in,O
bacteria,B-OG
and,O
inflammatory,B-GP
cytokines,I-GP
",",O
autophagy,O
stimulation,O
was,O
effective,O
in,O
increasing,O
autophagosome,O
formation,O
and,O
trafficking,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
to,O
lysosomes,O
.,O
B,B-OG
.,I-OG
cenocepacia,I-OG
-,O
containing,O
vacuoles,O
have,O
been,O
shown,O
to,O
have,O
prolonged,O
arrest,O
phases,O
[,O
64,O
"],",O
and,O
the,O
ability,O
to,O
correctly,O
utilize,O
otherwise,O
sequestered,O
autophagic,O
machinery,O
may,O
be,O
key,O
in,O
overcoming,O
this,O
delay,O
.,O
Electron,O
microscopy,O
confirmed,O
the,O
presence,O
of,O
single,O
membrane,O
vacuoles,O
containing,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
untreated,O
CF,B-DS
macrophages,O
that,O
were,O
effectively,O
converted,O
to,O
double,O
membrane,O
autophagosomes,O
upon,O
IFN,B-GP
-,I-GP
γ,I-GP
stimulation,O
.,O
This,O
process,O
was,O
marked,O
by,O
decreased,O
p62,B-GP
accumulation,O
and,O
decreased,O
LC3,B-GP
-,I-GP
I,I-GP
accumulation,O
",",O
suggesting,O
effective,O
autophagic,O
flux,O
",",O
allowing,O
for,O
early,O
autophagolysosomal,O
fusion,O
and,O
subsequent,O
bacterial,O
clearance,O
.,O
This,O
study,O
is,O
limited,O
by,O
the,O
use,O
of,O
a,O
single,O
pathogen,O
model,O
",",O
which,O
was,O
necessary,O
to,O
accurately,O
follow,O
B,B-OG
.,I-OG
cenocepacia,I-OG
trafficking,O
as,O
well,O
as,O
cytokine,B-GP
production,O
.,O
Future,O
studies,O
will,O
examine,O
multi,O
-,O
pathogen,O
models,O
to,O
examine,O
more,O
closely,O
effects,O
on,O
pathogen,O
interactions,O
.,O
Further,O
work,O
is,O
also,O
needed,O
in,O
vivo,O
to,O
determine,O
the,O
benefits,O
in,O
human,B-OG
subjects,O
.,O
B,B-OG
.,I-OG
cenocepacia,I-OG
also,O
possesses,O
several,O
quorum,O
sensing,O
systems,O
that,O
may,O
affect,O
its,O
activity,O
in,O
humans,B-OG
and,O
during,O
a,O
24,O
hour,O
infection,B-DS
model,O
[,O
65,O
]–[,O
67,O
].,O
This,O
will,O
be,O
important,O
to,O
consider,O
in,O
future,O
multi,O
-,O
pathogen,O
studies,O
.,O
Additionally,O
",",O
we,O
tried,O
to,O
overcome,O
inherent,O
human,B-OG
subject,O
differences,O
in,O
cell,O
signaling,O
and,O
baseline,O
medications,O
through,O
the,O
use,O
of,O
multiple,O
subjects,O
.,O
Importantly,O
",",O
we,O
did,O
not,O
see,O
differences,O
in,O
B,B-OG
.,I-OG
cenocepacia,I-OG
clearance,O
by,O
CF,B-DS
patients,O
chronically,O
on,O
azithromycin,O
",",O
but,O
samples,O
did,O
not,O
receive,O
further,O
supplementation,O
with,O
azithromycin,O
during,O
any,O
of,O
the,O
experiments,O
.,O
In,O
summary,O
",",O
CF,B-DS
macrophages,O
have,O
a,O
deficient,O
IFN,B-GP
-,I-GP
γ,I-GP
response,O
to,O
B,B-OG
.,I-OG
cenocepacia,I-OG
",",O
ineffective,O
utilization,O
of,O
the,O
autophagy,O
cargo,O
molecule,O
p62,B-GP
",",O
decreased,O
autophagosome,O
formation,O
",",O
and,O
delayed,O
lysosomal,O
uptake,O
.,O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
increased,O
autophagy,O
mediated,O
clearance,O
of,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
human,B-OG
CF,B-DS
macrophages,O
via,O
increased,O
autophagosome,O
formation,O
and,O
lysosomal,O
trafficking,O
",",O
and,O
was,O
associated,O
with,O
decreased,O
inflammatory,B-GP
cytokine,I-GP
production,O
.,O
The,O
use,O
of,O
IFN,B-GP
-,I-GP
γ,I-GP
or,O
autophagy,O
stimulating,O
drugs,O
is,O
promising,O
for,O
treating,O
life,O
-,O
threatening,O
or,O
chronic,B-DS
infections,I-DS
from,O
B,B-OG
.,I-OG
cenocepacia,I-OG
in,O
patients,O
with,O
CF,B-DS
",",O
but,O
further,O
study,O
is,O
needed,O
to,O
determine,O
their,O
efficacy,O
outside,O
of,O
cell,O
culture,O
models,O
.,O
Supporting,O
Information,O
Chronic,O
azithromycin,O
use,O
has,O
no,O
effect,O
on,O
CF,B-DS
MDMs,O
.,O
S1A,O
),O
Serum,O
(,O
n,O
=,O
7,O
),O
and,O
infected,O
PBMC,O
(,O
k56,O
",",O
n,O
=,O
5,O
),O
IFN,B-GP
-,I-GP
γ,I-GP
levels,O
from,O
CF,B-DS
and,O
non,O
-,O
CF,B-DS
patients,O
separated,O
by,O
patients,O
with,O
(+,O
azithromycin,O
),O
and,O
without,O
chronic,O
azithromycin,O
prophylaxis,O
.,O
S1B,O
),O
Summary,O
of,O
scored,O
bacteria,B-OG
per,O
100,O
macrophages,O
from,O
individual,O
subjects,O
for,O
the,O
confocal,O
microscopy,O
experiments,O
from,O
4B,O
and,O
separated,O
by,O
patients,O
with,O
(+,O
azithromycin,O
),O
and,O
without,O
chronic,O
azithromycin,O
prophylaxis,O
.,O
S1C,O
),O
IL,B-GP
-,I-GP
1β,I-GP
levels,O
in,O
macrophage,O
supernatants,O
after,O
infection,B-DS
with,O
k56,O
-,O
2,O
and,O
either,O
a,O
24,O
hour,O
treatment,O
with,O
IFN,B-GP
-,I-GP
γ,I-GP
or,O
a,O
control,O
diluent,O
and,O
separated,O
by,O
patients,O
with,O
(+,O
azithromycin,O
),O
and,O
without,O
chronic,O
azithromycin,O
prophylaxis,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
No,O
difference,O
in,O
2,O
hour,O
or,O
supernatant,O
CFUs,O
.,O
CFU,O
counts,O
for,O
non,O
-,O
CF,B-DS
and,O
CF,B-DS
macrophages,O
infected,O
with,O
MHK1,O
for,O
2,O
(,O
n,O
=,O
3,O
),O
and,O
24,O
hour,O
supernatants,O
(,O
n,O
=,O
3,O
),O
with,O
or,O
without,O
IFN,B-GP
-,I-GP
γ,I-GP
treatment,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
IFN,B-GP
-,I-GP
γ,I-GP
has,O
no,O
effect,O
on,O
bacterial,O
growth,O
in,O
media,O
devoid,O
of,O
MDMs,O
.,O
Optical,O
density,O
(,O
OD,O
),O
of,O
bacteria,B-OG
cultured,O
in,O
LB,O
broth,O
alone,O
(,O
k56,O
-,O
2,O
),O
versus,O
LB,O
+,O
IFN,B-GP
-,I-GP
γ,I-GP
(,O
IFN,B-GP
-,I-GP
γ,I-GP
),O
was,O
compared,O
over,O
24,O
hours,O
during,O
normal,O
growth,O
conditions,O
at,O
37,O
°,O
with,O
high,O
amplitude,O
shaking,O
.,O
Inset,O
shows,O
negligible,O
difference,O
at,O
24,O
hours,O
in,O
OD,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
First,O
report,O
of,O
Toxoplasma,B-OG
gondii,I-OG
in,O
camels,B-OG
(,O
Camelus,B-OG
dromedarius,I-OG
),O
in,O
Ethiopia,O
:,O
bioassay,O
and,O
seroepidemiological,O
investigation,O
Background,O
Toxoplasmosis,B-DS
is,O
a,O
major,O
public,O
health,O
concern,O
in,O
many,O
countries,O
of,O
the,O
world,O
.,O
A,O
cross,O
-,O
sectional,O
and,O
follow,O
up,O
experimental,O
study,O
designs,O
were,O
used,O
for,O
seroepidemiological,O
and,O
bioassay,O
studies,O
",",O
respectively,O
from,O
November,O
2012,O
to,O
April,O
2013,O
.,O
The,O
objectives,O
were,O
to,O
estimate,O
the,O
seroprevalence,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
",",O
to,O
assess,O
risk,O
factors,O
and,O
to,O
isolate,O
the,O
parasite,O
from,O
camels,B-OG
in,O
the,O
Fentale,O
district,O
",",O
Ethiopia,O
.,O
A,O
direct,O
agglutination,O
test,O
(,O
DAT,O
),O
and,O
indirect,O
enzyme,O
linked,O
immunosorbent,O
assay,O
(,O
ELISA,O
),O
kits,O
were,O
used,O
to,O
test,O
camel,B-OG
sera,O
.,O
Hearts,O
and,O
tongues,O
(,O
each,O
25,O
g,O
),O
from,O
31,O
seropositive,O
camels,B-OG
were,O
bioassayed,O
in,O
mice,B-OG
.,O
Associations,O
between,O
seroprevalence,O
and,O
potential,O
risk,O
factors,O
(,O
collected,O
using,O
a,O
questionnaire,O
survey,O
),O
were,O
analyzed,O
using,O
logistic,O
regression,O
.,O
Results,O
An,O
overall,O
T,B-OG
.,I-OG
gondii,I-OG
prevalence,O
of,O
49,O
.,O
62,O
%,O
(,O
220,O
/,O
455,O
),O
by,O
DAT,O
and,O
40,O
.,O
49,O
%,O
(,O
179,O
/,O
451,O
),O
by,O
indirect,O
ELISA,O
test,O
were,O
detected,O
.,O
Herd,O
level,O
seroprevalence,O
of,O
96,O
.,O
77,O
%,O
(,O
30,O
/,O
31,O
),O
(,O
95,O
%,O
CI,O
:,O
83,O
.,O
30,O
–,O
99,O
.,O
92,O
),O
by,O
DAT,O
was,O
recorded,O
and,O
it,O
was,O
significantly,O
higher,O
in,O
areas,O
where,O
wild,O
felids,B-OG
are,O
present,O
(,O
P,O
=,O
0,O
.,O
038,O
).,O
Multivariable,O
logistic,O
regression,O
showed,O
that,O
the,O
likelihood,O
of,O
acquiring,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
was,O
significantly,O
higher,O
in,O
camels,B-OG
in,O
the,O
Ilala,O
pastoral,O
association,O
[,O
PA,O
],O
(,O
82,O
.,O
26,O
%),O
(,O
Adjusted,O
Odds,O
ratio,O
[,O
aOR,O
],O
=,O
10,O
.,O
8,O
;,O
P,O
<,O
0,O
.,O
001,O
),O
than,O
camels,B-OG
in,O
the,O
Galcha,O
PA,O
(,O
31,O
.,O
43,O
"%),",O
in,O
camels,B-OG
of,O
≥,O
8,O
years,O
old,O
(,O
56,O
.,O
52,O
%;,O
aOR,O
=,O
1,O
.,O
88,O
;,O
P,O
=,O
0,O
",",O
033,O
),O
than,O
camels,B-OG
of,O
≤,O
4,O
years,O
old,O
(,O
34,O
.,O
26,O
%),O
and,O
in,O
areas,O
where,O
domestic,O
cats,B-OG
are,O
present,O
(,O
aOR,O
=,O
4,O
.,O
16,O
;,O
P,O
=,O
0,O
.,O
006,O
).,O
All,O
camel,B-OG
owners,O
were,O
uneducated,O
",",O
handle,O
aborted,O
fetus,O
with,O
bare,O
hands,O
",",O
and,O
drink,O
raw,O
camel,B-OG
milk,O
.,O
DAT,O
and,O
ELISA,O
tests,O
had,O
moderate,O
agreement,O
(,O
Kappa,O
=,O
0,O
.,O
41,O
).,O
Viable,O
T,B-OG
.,I-OG
gondii,I-OG
were,O
isolated,O
from,O
16,O
.,O
13,O
%,O
(,O
5,O
/,O
31,O
),O
of,O
DAT,O
positive,O
camels,B-OG
.,O
One,O
DAT,O
positive,O
but,O
ELISA,O
negative,O
camel,B-OG
sample,O
gave,O
a,O
cyst,B-DS
positive,O
result,O
.,O
Conclusions,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
of,O
camels,B-OG
in,O
the,O
study,O
district,O
is,O
widespread,O
.,O
Age,O
",",O
presence,O
of,O
domestic,O
cats,B-OG
and,O
study,O
PA,O
are,O
independent,O
predictors,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
seropositivity,O
.,O
Isolation,O
of,O
viable,O
parasites,O
from,O
edible,O
tissues,O
of,O
camels,B-OG
and,O
the,O
very,O
poor,O
knowledge,O
of,O
pastoralists,O
about,O
toxoplasmosis,B-DS
suggest,O
the,O
need,O
for,O
prevention,O
of,O
toxoplasmosis,B-DS
through,O
bio,O
-,O
security,O
measures,O
",",O
education,O
and,O
further,O
investigation,O
to,O
unravel,O
the,O
impact,O
of,O
camel,B-OG
toxoplasmosis,B-DS
deserves,O
consideration,O
.,O
Electronic,O
supplementary,O
material,O
The,O
online,O
version,O
of,O
this,O
article,O
(,O
doi,O
:,O
10,O
.,O
1186,O
/,O
s12917,O
-,O
014,O
-,O
0222,O
-,O
7,O
),O
contains,O
supplementary,O
material,O
",",O
which,O
is,O
available,O
to,O
authorized,O
users,O
.,O
Background,O
A,O
population,O
over,O
2,O
.,O
3,O
million,O
camels,B-OG
is,O
estimated,O
in,O
Ethiopia,O
[,O
1,O
"],",O
which,O
is,O
considered,O
the,O
third,O
largest,O
camel,B-OG
populated,O
country,O
in,O
the,O
world,O
.,O
All,O
camels,B-OG
in,O
Ethiopia,O
are,O
owned,O
by,O
pastoralists,O
[,O
2,O
].,O
Camels,B-OG
play,O
a,O
central,O
role,O
in,O
the,O
livelihood,O
of,O
pastoralists,O
through,O
provision,O
of,O
milk,O
",",O
meat,O
",",O
and,O
draught,O
power,O
and,O
they,O
also,O
determine,O
their,O
wealth,O
and,O
social,O
status,O
[,O
3,O
].,O
Despite,O
their,O
social,O
",",O
ecological,O
and,O
economic,O
importance,O
in,O
Ethiopia,O
",",O
until,O
recently,O
they,O
were,O
neglected,O
by,O
researchers,O
and,O
development,O
planners,O
and,O
as,O
a,O
result,O
little,O
is,O
known,O
about,O
productivity,O
and,O
health,O
problems,O
in,O
camels,B-OG
compared,O
to,O
other,O
livestock,O
[,O
4,O
",",O
5,O
].,O
Camels,B-OG
suffer,O
from,O
various,O
parasitic,B-DS
diseases,I-DS
",",O
including,O
toxoplasmosis,B-DS
",",O
which,O
have,O
public,O
health,O
and,O
economic,O
importance,O
[,O
6,O
].,O
Toxoplasmosis,B-DS
is,O
caused,O
by,O
an,O
intracellular,O
Apicomplexa,B-OG
protozoan,O
",",O
T,B-OG
.,I-OG
gondii,I-OG
",",O
found,O
worldwide,O
and,O
in,O
an,O
exceptionally,O
broad,O
host,O
range,O
on,O
earth,O
[,O
7,O
].,O
Camels,B-OG
acquire,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
through,O
ingestion,O
or,O
inhalation,O
of,O
sporulated,O
oocysts,O
that,O
are,O
shed,O
by,O
cats,B-OG
or,O
wild,O
felids,B-OG
in,O
the,O
environment,O
[,O
8,O
].,O
The,O
prevalence,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
in,O
camels,B-OG
varies,O
widely,O
depending,O
on,O
the,O
localities,O
of,O
the,O
world,O
[,O
9,O
"],",O
ranging,O
from,O
3,O
.,O
12,O
%,O
in,O
Iran,O
[,O
10,O
],O
to,O
90,O
.,O
90,O
%,O
in,O
Turkey,O
[,O
11,O
].,O
T,B-OG
.,I-OG
gondii,I-OG
infects,O
one,O
-,O
third,O
of,O
the,O
world,O
human,B-OG
population,O
.,O
The,O
infection,B-DS
can,O
be,O
life,O
threatening,O
during,O
pregnancy,O
and,O
in,O
immunocompromised,O
individuals,O
[,O
12,O
",",O
13,O
].,O
The,O
disease,O
is,O
a,O
major,O
public,O
health,O
concern,O
in,O
many,O
countries,O
of,O
the,O
world,O
[,O
14,O
].,O
In,O
USA,O
",",O
it,O
is,O
the,O
third,O
leading,O
cause,O
of,O
death,O
from,O
foodborne,O
diseases,O
[,O
12,O
].,O
Humans,B-OG
become,O
infected,O
with,O
T,B-OG
.,I-OG
gondii,I-OG
mostly,O
by,O
ingesting,O
raw,O
or,O
undercooked,O
meat,O
of,O
infected,O
animals,B-OG
or,O
by,O
ingesting,O
food,O
or,O
water,O
contaminated,O
with,O
oocysts,O
[,O
13,O
],O
and,O
the,O
parasite,O
can,O
be,O
transmitted,O
to,O
the,O
fetus,O
by,O
the,O
passage,O
of,O
tachyzoites,O
through,O
the,O
placenta,O
[,O
15,O
].,O
The,O
presence,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
in,O
milk,O
[,O
10,O
],O
and,O
edible,O
tissues,O
[,O
16,O
],O
of,O
carrier,O
camels,B-OG
indicate,O
the,O
possibility,O
of,O
transmission,O
to,O
humans,B-OG
;,O
particularly,O
in,O
pastoral,O
communities,O
in,O
which,O
raw,O
milk,O
",",O
and,O
to,O
some,O
extent,O
raw,O
meat,O
",",O
can,O
be,O
frequently,O
consumed,O
[,O
17,O
].,O
Recent,O
reports,O
from,O
Ethiopia,O
indicate,O
high,O
seroprevalence,O
of,O
toxoplasmosis,B-DS
in,O
women,B-OG
of,O
child,O
-,O
bearing,O
age,O
ranging,O
from,O
70,O
.,O
29,O
to,O
87,O
.,O
4,O
%,O
[,O
18,O
-,O
20,O
].,O
Studies,O
done,O
in,O
different,O
parts,O
of,O
Ethiopia,O
over,O
the,O
last,O
24,O
years,O
indicated,O
high,O
seroprevalence,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
in,O
sheep,B-OG
[,O
21,O
-,O
23,O
"],",O
goats,B-OG
[,O
21,O
",",O
22,O
",",O
24,O
",",O
25,O
"],",O
cattle,B-OG
[,O
21,O
"],",O
chicken,B-OG
[,O
26,O
],O
and,O
cats,B-OG
[,O
27,O
].,O
However,O
",",O
there,O
is,O
no,O
single,O
report,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
in,O
Ethiopian,O
camels,B-OG
so,O
far,O
.,O
Although,O
DAT,O
and,O
ELISA,O
tests,O
have,O
been,O
widely,O
used,O
for,O
detection,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
in,O
epidemiological,O
studies,O
",",O
there,O
are,O
no,O
reports,O
on,O
the,O
comparative,O
evaluation,O
of,O
the,O
diagnostic,O
capability,O
of,O
these,O
diagnostic,O
tests,O
in,O
naturally,O
infected,O
camels,B-OG
.,O
This,O
report,O
compares,O
serodiagnostic,O
methods,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
in,O
camels,B-OG
using,O
commercial,O
kits,O
(,O
DAT,O
and,O
ELISA,O
"),",O
and,O
isolation,O
of,O
the,O
parasite,O
from,O
edible,O
camel,B-OG
tissues,O
",",O
to,O
estimate,O
the,O
seroprevalence,O
of,O
toxoplasmosis,B-DS
in,O
camels,B-OG
.,O
The,O
role,O
of,O
the,O
identified,O
risk,O
factors,O
on,O
the,O
parasite,O
transmission,O
is,O
also,O
discussed,O
.,O
Methods,O
Study,O
area,O
and,O
study,O
animals,B-OG
The,O
study,O
was,O
conducted,O
in,O
the,O
Fentale,O
district,O
(,O
39,O
.,O
93,O
°,O
E,O
to,O
39,O
°,O
56,O
’,O
0,O
”,O
E,O
longitude,O
and,O
8,O
.,O
975o,O
N,O
to,O
8,O
.,O
58,O
’,O
30,O
”,O
N,O
latitude,O
),O
which,O
is,O
located,O
in,O
the,O
East,O
Shewa,O
Zone,O
of,O
Oromia,O
Regional,O
State,O
",",O
Ethiopia,O
(,O
Figure,O
1,O
),O
at,O
190,O
Kms,O
East,O
of,O
Addis,O
Ababa,O
.,O
It,O
lies,O
at,O
an,O
altitude,O
range,O
of,O
955,O
-,O
2007,O
meters,O
above,O
sea,O
level,O
",",O
and,O
has,O
an,O
annual,O
rainfall,O
ranging,O
from,O
560,O
millimeter,O
(,O
mm,O
),O
to,O
630,O
mm,O
and,O
mean,O
temperature,O
ranging,O
from,O
29,O
°,O
C,O
to,O
38,O
°,O
C,O
.,O
The,O
vegetation,O
comprises,O
mix,O
of,O
acacia,B-OG
trees,I-OG
",",O
bushes,B-OG
and,O
shrubs,B-OG
that,O
are,O
common,O
to,O
the,O
lowland,O
areas,O
of,O
Ethiopia,O
.,O
With,O
its,O
arid,O
and,O
semi,O
-,O
arid,O
climate,O
",",O
pastoral,O
and,O
agro,O
-,O
pastoral,O
production,O
systems,O
predominate,O
in,O
the,O
area,O
.,O
The,O
district,O
is,O
estimated,O
to,O
possess,O
48,O
",",O
078,O
camels,B-OG
found,O
in,O
eighteen,O
pastoral,O
associations,O
(,O
PAs,O
).,O
Pastoral,O
and,O
agro,O
-,O
pastoral,O
production,O
systems,O
are,O
practiced,O
in,O
11,O
and,O
7,O
PAs,O
",",O
respectively,O
[,O
28,O
].,O
Figure,O
1Map,O
of,O
the,O
Fentale,O
district,O
showing,O
sampled,O
pastoral,O
associations,O
(,O
PAs,O
),O
(,O
adapted,O
from,O
https,O
://,O
www,O
.,O
google,O
.,O
com,O
.,O
et,O
/,O
search,O
?,O
q,O
=,O
Ethiopia,O
+,O
map,O
&,O
btnG,O
=&,O
tbm,O
=,O
isch,O
&,O
gws_rd,O
=,O
ssl,O
).,O
The,O
study,O
population,O
consisted,O
of,O
camels,B-OG
of,O
different,O
age,O
groups,O
in,O
selected,O
PAs,O
of,O
the,O
district,O
managed,O
under,O
the,O
two,O
production,O
systems,O
.,O
The,O
camels,B-OG
of,O
both,O
sex,O
groups,O
were,O
classified,O
by,O
age,O
into,O
three,O
categories,O
(≤,O
4,O
years,O
",",O
4,O
-,O
8,O
years,O
and,O
>,O
8,O
years,O
),O
[,O
29,O
].,O
Ages,O
of,O
camels,B-OG
were,O
recorded,O
based,O
on,O
information,O
from,O
the,O
owners,O
and,O
also,O
estimated,O
according,O
to,O
their,O
dentations,O
[,O
30,O
].,O
Study,O
design,O
",",O
sample,O
size,O
determination,O
and,O
sampling,O
method,O
Cross,O
-,O
sectional,O
and,O
follow,O
up,O
experimental,O
study,O
designs,O
were,O
used,O
for,O
seroepidemiological,O
and,O
bioassay,O
studies,O
",",O
respectively,O
from,O
November,O
2012,O
to,O
April,O
2013,O
.,O
Out,O
of,O
18,O
PAs,O
",",O
a,O
total,O
of,O
6,O
PAs,O
(,O
pastoral,O
=,O
3,O
",",O
agro,O
-,O
pastoral,O
=,O
3,O
),O
were,O
chosen,O
conveniently,O
based,O
on,O
accessibility,O
of,O
the,O
PAs,O
.,O
Camel,B-OG
herds,O
in,O
each,O
of,O
the,O
selected,O
PAs,O
were,O
stratified,O
by,O
herd,O
size,O
into,O
three,O
:,O
small,O
(,O
1,O
-,O
9,O
"),",O
medium,O
(,O
10,O
-,O
19,O
),O
and,O
large,O
(≥,O
20,O
),O
camels,B-OG
[,O
31,O
].,O
Out,O
of,O
58,O
camel,B-OG
herds,O
found,O
in,O
the,O
selected,O
study,O
PAs,O
(,O
n,O
=,O
6,O
"),",O
31,O
herds,O
were,O
randomly,O
selected,O
using,O
the,O
lottery,O
method,O
.,O
Then,O
",",O
all,O
camels,B-OG
in,O
selected,O
herds,O
were,O
used,O
to,O
collect,O
blood,O
samples,O
.,O
Since,O
there,O
has,O
been,O
no,O
previous,O
study,O
on,O
camel,B-OG
toxoplasmosis,B-DS
in,O
Ethiopia,O
",",O
50,O
%,O
expected,O
prevalence,O
(,O
P,O
),O
and,O
95,O
%,O
confidence,O
interval,O
(,O
Z,O
=,O
1,O
.,O
96,O
),O
with,O
a,O
5,O
%,O
desired,O
absolute,O
precision,O
(,O
d,O
),O
was,O
considered,O
to,O
arrive,O
at,O
the,O
required,O
sample,O
size,O
(,O
n,O
=,O
384,O
),O
for,O
the,O
seroepidemiological,O
study,O
using,O
the,O
formula,O
:,O
n,O
=,O
P,O
(,O
1,O
-,O
P,O
),O
Z2,O
/,O
d2,O
),O
[,O
32,O
].,O
Additionally,O
",",O
purposive,O
sampling,O
of,O
blood,O
from,O
70,O
camels,B-OG
was,O
considered,O
for,O
sample,O
selection,O
by,O
serology,O
in,O
order,O
to,O
use,O
their,O
heart,O
and,O
tongue,O
for,O
bioassay,O
.,O
Sample,O
collection,O
and,O
transportation,O
Blood,O
samples,O
for,O
serum,O
separation,O
were,O
collected,O
from,O
the,O
jugular,O
vein,O
of,O
apparently,O
healthy,O
camels,B-OG
using,O
labeled,O
plain,O
vacutainer,O
tubes,O
following,O
proper,O
physical,O
restraining,O
.,O
For,O
the,O
bioassay,O
",",O
heart,O
",",O
tongue,O
and,O
blood,O
sample,O
of,O
purposively,O
selected,O
70,O
camels,B-OG
",",O
originating,O
from,O
Fentale,O
district,O
but,O
slaughtered,O
at,O
Akaki,O
abattoir,O
near,O
Addis,O
Ababa,O
",",O
were,O
collected,O
.,O
The,O
collected,O
samples,O
were,O
kept,O
in,O
an,O
icebox,O
containing,O
ice,O
packs,O
and,O
immediately,O
transported,O
to,O
the,O
Ethio,O
-,O
Belgium,O
post,O
-,O
graduate,O
research,O
laboratory,O
",",O
College,O
of,O
Veterinary,O
Medicine,O
and,O
Agriculture,O
",",O
Debre,O
Zeit,O
",",O
Ethiopia,O
for,O
serological,O
testing,O
and,O
isolation,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
.,O
Sera,O
were,O
separated,O
by,O
centrifugation,O
at,O
3200,O
rpm,O
for,O
10,O
minutes,O
",",O
decanted,O
into,O
cryovials,O
and,O
stored,O
at,O
-,O
20,O
°,O
C,O
until,O
used,O
for,O
serological,O
assay,O
.,O
Heart,O
and,O
tongue,O
samples,O
were,O
kept,O
at,O
+,O
4,O
°,O
C,O
for,O
1,O
-,O
3,O
days,O
until,O
serological,O
results,O
were,O
known,O
.,O
Questionnaire,O
survey,O
A,O
close,O
-,O
ended,O
questionnaire,O
was,O
designed,O
and,O
self,O
-,O
administered,O
to,O
collect,O
data,O
about,O
the,O
potential,O
risk,O
factors,O
for,O
camels,B-OG
to,O
acquire,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
.,O
Awareness,O
of,O
camel,B-OG
owners,O
about,O
toxoplasmosis,B-DS
including,O
the,O
habits,O
of,O
consumption,O
of,O
raw,O
camel,B-OG
meat,O
and,O
milk,O
was,O
also,O
documented,O
.,O
The,O
questions,O
in,O
the,O
questionnaire,O
included,O
sex,O
(,O
male,O
",",O
female,O
"),",O
age,O
(≤,O
4,O
years,O
",",O
4,O
-,O
8,O
years,O
and,O
>,O
8,O
years,O
"),",O
production,O
system,O
(,O
pastoral,O
/,O
agropastoral,O
"),",O
presence,O
of,O
cats,B-OG
(,O
yes,O
/,O
no,O
"),",O
presence,O
of,O
wild,O
felids,B-OG
(,O
yes,O
/,O
no,O
"),",O
source,O
of,O
drinking,O
water,O
(,O
tap,O
",",O
stagnant,O
:,O
[,O
lake,O
",",O
pond,O
and,O
well,O
"],",O
river,O
",",O
mixed,O
[,O
river,O
and,O
stagnant,O
]),O
and,O
herd,O
size,O
(,O
small,O
:,O
1,O
-,O
9,O
",",O
medium,O
:,O
10,O
-,O
19,O
",",O
large,O
:,O
≥,O
20,O
camels,B-OG
),O
[,O
31,O
].,O
Information,O
about,O
history,O
of,O
abortion,O
(,O
yes,O
/,O
no,O
"),",O
way,O
of,O
handling,O
aborted,O
fetus,O
(,O
wearing,O
gloves,O
",",O
without,O
wearing,O
glove,O
",",O
washing,O
hand,O
after,O
handling,O
",",O
without,O
washing,O
hand,O
after,O
handling,O
),O
and,O
method,O
of,O
disposal,O
of,O
aborted,O
fetus,O
(,O
giving,O
to,O
cat,B-OG
",",O
throwing,O
along,O
the,O
way,O
",",O
burying,O
),O
were,O
recorded,O
.,O
Moreover,O
",",O
camel,B-OG
owners,O
consumption,O
habits,O
of,O
camel,B-OG
meat,O
(,O
cooking,O
",",O
without,O
cooking,O
",",O
both,O
),O
and,O
raw,O
milk,O
consumption,O
(,O
yes,O
/,O
no,O
"),",O
educational,O
level,O
(,O
uneducated,O
",",O
primary,O
school,O
",",O
secondary,O
school,O
",",O
tertiary,O
/,O
university,O
),O
and,O
awareness,O
about,O
:,O
toxoplasmosis,B-DS
(,O
yes,O
/,O
no,O
"),",O
role,O
of,O
cat,B-OG
to,O
transmit,O
diseases,O
to,O
owner,O
(,O
yes,O
/,O
no,O
"),",O
role,O
of,O
cat,B-OG
to,O
transmit,O
diseases,O
to,O
camel,B-OG
(,O
yes,O
/,O
no,O
),O
and,O
camel,B-OG
migration,O
(,O
yes,O
/,O
no,O
),O
and,O
routes,O
of,O
migration,O
were,O
also,O
gathered,O
.,O
Laboratory,O
investigation,O
Direct,O
agglutination,O
test,O
(,O
DAT,O
),O
All,O
sera,O
samples,O
collected,O
were,O
examined,O
for,O
the,O
presence,O
of,O
antibodies,B-GP
(,O
IgG,B-GP
),O
against,O
T,B-OG
.,I-OG
gondii,I-OG
by,O
the,O
direct,O
agglutination,O
test,O
(,O
Toxo,O
screen,O
DA,O
",",O
biomerieux,O
"®,",O
France,O
),O
following,O
the,O
protocol,O
of,O
the,O
manufacturer,O
.,O
The,O
kit,O
was,O
claimed,O
by,O
the,O
manufacturer,O
to,O
have,O
sensitivity,O
and,O
specificity,O
of,O
96,O
.,O
22,O
%,O
and,O
98,O
.,O
80,O
"%,",O
respectively,O
.,O
Sera,O
were,O
assayed,O
at,O
a,O
screening,O
dilution,O
of,O
1,O
:,O
40,O
and,O
1,O
:,O
4000,O
.,O
A,O
titer,O
of,O
1,O
:,O
40,O
or,O
1,O
:,O
4000,O
or,O
both,O
was,O
considered,O
indicative,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
exposure,O
.,O
Sedimentation,O
of,O
antigen,O
at,O
the,O
bottom,O
of,O
the,O
well,O
and,O
clear,O
agglutination,O
above,O
half,O
of,O
the,O
well,O
at,O
either,O
dilution,O
were,O
recorded,O
as,O
negative,O
and,O
positive,O
results,O
respectively,O
.,O
DAT,O
positive,O
samples,O
were,O
titrated,O
to,O
know,O
the,O
endpoint,O
titer,O
.,O
Positive,O
and,O
negative,O
controls,O
were,O
included,O
in,O
each,O
test,O
.,O
Indirect,O
enzyme,O
linked,O
immunosorbent,O
assay,O
(,O
ELISA,O
),O
A,O
total,O
of,O
451,O
(,O
381,O
from,O
field,O
and,O
70,O
from,O
abattoir,O
),O
sera,O
were,O
tested,O
for,O
T,B-OG
.,I-OG
gondii,I-OG
IgG,B-GP
antibodies,I-GP
by,O
the,O
indirect,O
ELISA,O
kit,O
(,O
ID,O
VET,O
Innovative,O
Diagnostic,O
",",O
ID,O
Screen,O
"®,",O
Montpellier,O
",",O
France,O
),O
following,O
the,O
manufacturer,O
’,O
s,O
instructions,O
.,O
The,O
wells,O
of,O
the,O
kit,O
are,O
coated,O
with,O
T,B-OG
.,I-OG
gondii,I-OG
P30,B-GP
(,O
SAG1,B-GP
),O
surface,O
antigen,O
.,O
The,O
kit,O
uses,O
non,O
-,O
species,O
specific,O
protein,O
conjugate,O
that,O
is,O
used,O
in,O
several,O
animal,B-OG
species,O
.,O
For,O
interpretation,O
of,O
the,O
result,O
S,O
/,O
P,O
%,O
was,O
calculated,O
as,O
:,O
S,O
/,O
P,O
%,O
=,O
(,O
optical,O
density,O
[,O
OD,O
],O
450,O
value,O
of,O
the,O
sample,O
–,O
OD,O
450,O
value,O
of,O
the,O
negative,O
control,O
)/(,O
mean,O
OD,O
450,O
value,O
of,O
the,O
positive,O
control,O
–,O
OD,O
450,O
value,O
of,O
the,O
negative,O
control,O
),O
×,O
100,O
.,O
Any,O
sample,O
with,O
S,O
/,O
P,O
%,O
≤,O
40,O
"%,",O
40,O
%,O
-,O
50,O
%,O
and,O
≥,O
50,O
%,O
were,O
considered,O
as,O
negative,O
",",O
doubtful,O
and,O
positive,O
",",O
respectively,O
.,O
With,O
this,O
cut,O
-,O
off,O
the,O
manufacturer,O
claims,O
the,O
test,O
to,O
have,O
more,O
than,O
99,O
%,O
specificity,O
and,O
sensitivity,O
.,O
The,O
test,O
was,O
considered,O
valid,O
if,O
the,O
mean,O
OD,O
value,O
of,O
the,O
positive,O
control,O
(,O
ODPC,O
),O
is,O
greater,O
than,O
0,O
.,O
350,O
(,O
ODPC,O
>,O
0,O
.,O
350,O
),O
and,O
the,O
ratio,O
of,O
the,O
mean,O
OD,O
value,O
of,O
the,O
positive,O
and,O
negative,O
controls,O
(,O
ODPC,O
and,O
ODNC,O
),O
is,O
greater,O
than,O
3,O
.,O
5,O
(,O
ODPC,O
/,O
ODNC,O
>,O
3,O
.,O
5,O
).,O
The,O
doubtful,O
sera,O
were,O
retested,O
.,O
Bioassay,O
Heart,O
and,O
tongue,O
tissue,O
samples,O
(,O
pooled,O
weight,O
50,O
g,O
),O
from,O
DAT,O
positive,O
camels,B-OG
(,O
n,O
=,O
31,O
),O
slaughtered,O
at,O
Akaki,O
abattoir,O
",",O
were,O
processed,O
for,O
isolation,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
as,O
described,O
previously,O
[,O
13,O
].,O
Briefly,O
",",O
each,O
sample,O
was,O
cut,O
into,O
small,O
pieces,O
",",O
homogenized,O
in,O
a,O
blender,O
for,O
30,O
seconds,O
",",O
followed,O
by,O
soaking,O
in,O
125,O
ml,O
of,O
saline,O
solution,O
for,O
another,O
30,O
seconds,O
(,O
0,O
.,O
14,O
M,O
sodium,O
chloride,O
).,O
After,O
homogenization,O
250,O
ml,O
of,O
pepsin,B-GP
solution,O
(,O
Merck,O
KG,O
.,O
A,O
",",O
Darmstadt,O
",",O
Germany,O
),O
was,O
added,O
(,O
pH,O
=,O
1,O
.,O
1,O
–,O
1,O
.,O
2,O
),O
and,O
incubated,O
at,O
37,O
°,O
C,O
for,O
1,O
h,O
.,O
The,O
homogenate,O
was,O
filtered,O
through,O
two,O
layers,O
of,O
gauze,O
and,O
centrifuged,O
at,O
3200,O
rpm,O
for,O
10,O
minutes,O
.,O
The,O
supernatant,O
was,O
discarded,O
and,O
to,O
the,O
sediment,O
15,O
to,O
20,O
ml,O
of,O
1,O
.,O
2,O
%,O
sodium,O
bicarbonate,O
(,O
pH,O
=,O
8,O
.,O
3,O
),O
was,O
added,O
and,O
centrifuged,O
at,O
3200,O
rpm,O
for,O
10,O
min,O
.,O
The,O
supernatant,O
was,O
discarded,O
and,O
the,O
sediment,O
was,O
re,O
-,O
suspended,O
in,O
5,O
to,O
10,O
ml,O
of,O
antibiotic,O
saline,O
solution,O
(,O
1000,O
U,O
/,O
ml,O
penicillin,O
and,O
100,O
μg,O
of,O
streptomycin,O
/,O
ml,O
of,O
saline,O
solution,O
).,O
The,O
suspension,O
was,O
inoculated,O
intraperitoneally,O
(,O
1,O
ml,O
per,O
mouse,B-OG
),O
into,O
five,O
apparently,O
healthy,O
T,B-OG
.,I-OG
gondii,I-OG
seronegative,O
female,O
Swiss,B-OG
-,I-OG
Albino,I-OG
mice,I-OG
(,O
National,O
Veterinary,O
Institute,O
",",O
Debre,O
Zeit,O
),O
per,O
sample,O
(,O
weighting,O
25,O
–,O
35,O
g,O
),O
as,O
described,O
by,O
Dubey,O
[,O
13,O
].,O
Bioassays,O
were,O
performed,O
within,O
1,O
-,O
3,O
days,O
of,O
the,O
slaughter,O
of,O
the,O
camels,B-OG
.,O
Separate,O
knives,O
",",O
cutting,O
boards,O
",",O
gloves,O
",",O
plastic,O
cups,O
/,O
falcon,O
tubes,O
",",O
and,O
plastic,O
bags,O
for,O
blending,O
and,O
pepsin,B-GP
digestion,O
were,O
used,O
for,O
each,O
sample,O
to,O
avoid,O
contamination,O
among,O
samples,O
.,O
Tissue,O
homogenate,O
kept,O
in,O
6,O
falcon,O
tubes,O
(,O
50,O
ml,O
),O
were,O
centrifuged,O
in,O
2,O
steps,O
;,O
the,O
first,O
and,O
second,O
batch,O
in,O
4,O
and,O
2,O
floating,O
buckets,O
of,O
the,O
centrifuge,O
.,O
Approximately,O
110,O
-,O
140,O
minutes,O
elapsed,O
from,O
the,O
time,O
the,O
tissue,O
was,O
homogenized,O
in,O
saline,O
to,O
the,O
time,O
the,O
material,O
was,O
pulled,O
into,O
syringes,O
for,O
mouse,B-OG
inoculation,O
.,O
The,O
inoculated,O
mice,B-OG
were,O
observed,O
daily,O
for,O
illness,O
for,O
60,O
days,O
and,O
information,O
on,O
number,O
of,O
survivors,O
",",O
dead,O
",",O
day,O
of,O
death,O
",",O
symptoms,O
",",O
and,O
weight,O
(,O
initial,O
and,O
final,O
),O
were,O
recorded,O
.,O
The,O
mice,B-OG
were,O
fed,O
with,O
pelleted,O
feed,O
and,O
municipal,O
chlorinated,O
water,O
ad,O
-,O
libitum,O
.,O
T,B-OG
.,I-OG
gondii,I-OG
isolate,O
was,O
considered,O
as,O
virulent,O
if,O
100,O
%,O
mortality,O
of,O
mouse,B-OG
was,O
observed,O
within,O
four,O
weeks,O
of,O
infection,B-DS
[,O
33,O
].,O
Surviving,O
mice,B-OG
were,O
bled,O
on,O
day,O
60,O
after,O
anesthetizing,O
with,O
di,O
-,O
ethyl,O
ether,O
(,O
Biolab,O
laboratories,O
ltd,O
",",O
Israel,O
).,O
Brains,O
of,O
all,O
mice,B-OG
were,O
removed,O
by,O
sagittal,O
dissection,O
and,O
then,O
examined,O
for,O
tissue,O
cysts,B-DS
.,O
The,O
inoculated,O
mice,B-OG
were,O
considered,O
infected,O
with,O
T,B-OG
.,I-OG
gondii,I-OG
when,O
tissue,O
cysts,B-DS
were,O
found,O
in,O
brain,O
tissues,O
and,O
/,O
or,O
the,O
sera,O
of,O
mice,B-OG
react,O
positively,O
for,O
the,O
commercial,O
DAT,O
.,O
The,O
brain,O
was,O
homogenized,O
in,O
1,O
ml,O
phosphate,O
buffer,O
saline,O
(,O
PBS,O
),O
by,O
using,O
a,O
mortar,O
and,O
pestle,O
.,O
The,O
numbers,O
of,O
cysts,B-DS
in,O
five,O
aliquots,O
of,O
each,O
10,O
μl,O
were,O
counted,O
under,O
microscope,O
with,O
a,O
10,O
×,O
and,O
40,O
×,O
objective,O
lens,O
and,O
summed,O
.,O
The,O
total,O
number,O
of,O
cysts,B-DS
in,O
the,O
brain,O
of,O
each,O
mouse,B-OG
was,O
determined,O
by,O
multiplying,O
the,O
number,O
of,O
cysts,B-DS
in,O
the,O
50,O
μl,O
sample,O
examined,O
with,O
the,O
dilution,O
factor,O
[,O
34,O
].,O
Data,O
management,O
and,O
analyses,O
The,O
data,O
generated,O
from,O
field,O
and,O
laboratory,O
investigations,O
were,O
entered,O
and,O
coded,O
using,O
Microsoft,O
Excel,O
®,O
2007,O
and,O
analyzed,O
using,O
STATA,O
version,O
11,O
.,O
0,O
for,O
Windows,O
(,O
Stata,O
Corp,O
.,O
College,O
Station,O
",",O
TX,O
",",O
USA,O
).,O
Descriptive,O
statistic,O
was,O
used,O
to,O
summarize,O
the,O
data,O
.,O
The,O
information,O
from,O
the,O
questionnaire,O
survey,O
was,O
used,O
to,O
define,O
explanatory,O
variables,O
to,O
be,O
tested,O
in,O
a,O
logistic,O
regression,O
model,O
",",O
for,O
any,O
assessment,O
of,O
association,O
between,O
the,O
serological,O
status,O
of,O
the,O
camels,B-OG
(,O
dependent,O
variable,O
),O
and,O
the,O
risk,O
factors,O
(,O
independent,O
variables,O
).,O
Initially,O
",",O
all,O
risk,O
factors,O
were,O
individually,O
screened,O
by,O
cross,O
-,O
tabulation,O
for,O
association,O
with,O
the,O
likelihood,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
using,O
Chi,O
-,O
squared,O
analysis,O
.,O
Non,O
-,O
collinear,O
variables,O
",",O
with,O
P,O
-,O
value,O
<,O
0,O
.,O
25,O
in,O
the,O
univariable,O
analysis,O
",",O
were,O
entered,O
into,O
the,O
multivariable,O
logistic,O
regression,O
model,O
.,O
During,O
the,O
analyses,O
the,O
clustering,O
nature,O
of,O
the,O
outcome,O
within,O
a,O
herd,O
was,O
considered,O
by,O
including,O
herd,O
as,O
a,O
clustering,O
variable,O
.,O
This,O
enabled,O
us,O
to,O
use,O
a,O
clustered,O
sandwich,O
estimator,O
i,O
.,O
e,O
".,",O
robust,O
standard,O
error,O
rather,O
than,O
the,O
standard,O
error,O
of,O
the,O
parameters,O
estimated,O
using,O
maximum,O
likelihood,O
method,O
.,O
The,O
results,O
of,O
the,O
logistic,O
regression,O
for,O
each,O
variable,O
were,O
expressed,O
as,O
P,O
-,O
value,O
and,O
odds,O
ratio,O
(,O
OR,O
),O
with,O
95,O
%,O
confidence,O
intervals,O
to,O
measure,O
the,O
strength,O
of,O
associations,O
.,O
The,O
seroprevalence,O
results,O
of,O
DAT,O
and,O
ELISA,O
tests,O
were,O
compared,O
using,O
the,O
Chi,O
-,O
squared,O
test,O
and,O
their,O
concordance,O
was,O
determined,O
by,O
calculating,O
the,O
Kappa,O
index,O
.,O
Using,O
DAT,O
as,O
a,O
reference,O
test,O
",",O
the,O
diagnostic,O
sensitivity,O
(,O
Se,O
"),",O
specificity,O
(,O
Sp,O
"),",O
positive,O
predictive,O
value,O
(,O
PPV,O
),O
and,O
negative,O
predictive,O
value,O
(,O
NPV,O
),O
of,O
ELISA,O
were,O
calculated,O
and,O
interpreted,O
following,O
the,O
recommendations,O
of,O
Dohoo,O
et,O
al,O
.,O
[,O
35,O
].,O
A,O
student,O
t,O
-,O
test,O
was,O
employed,O
to,O
assess,O
the,O
mean,O
weight,O
difference,O
between,O
seropositive,O
and,O
seronegative,O
mice,B-OG
.,O
Differences,O
were,O
considered,O
significant,O
when,O
P,O
≤,O
0,O
.,O
05,O
.,O
Ethical,O
considerations,O
This,O
research,O
project,O
was,O
approved,O
by,O
the,O
animal,B-OG
ethical,O
committee,O
of,O
the,O
College,O
of,O
Veterinary,O
Medicine,O
and,O
Agriculture,O
",",O
Addis,O
Ababa,O
University,O
.,O
All,O
efforts,O
were,O
made,O
to,O
minimize,O
animal,B-OG
suffering,O
during,O
the,O
course,O
of,O
the,O
study,O
.,O
Informed,O
written,O
consents,O
were,O
obtained,O
from,O
all,O
camel,B-OG
owners,O
who,O
participated,O
in,O
the,O
study,O
.,O
Results,O
Animal,B-OG
level,O
seroprevalence,O
An,O
overall,O
T,B-OG
.,I-OG
gondii,I-OG
prevalence,O
of,O
49,O
.,O
62,O
%,O
(,O
220,O
/,O
455,O
),O
by,O
DAT,O
and,O
40,O
.,O
49,O
%,O
(,O
179,O
/,O
451,O
),O
by,O
indirect,O
ELISA,O
test,O
were,O
detected,O
.,O
Out,O
of,O
the,O
218,O
DAT,O
positive,O
sera,O
",",O
16,O
(,O
7,O
.,O
34,O
%),O
were,O
negative,O
at,O
1,O
:,O
40,O
dilution,O
but,O
positive,O
at,O
1,O
:,O
4000,O
dilution,O
.,O
The,O
serum,O
samples,O
collected,O
from,O
the,O
abattoir,O
were,O
excluded,O
from,O
risk,O
factor,O
assessment,O
because,O
of,O
missing,O
information,O
for,O
most,O
variables,O
.,O
A,O
statistically,O
significant,O
difference,O
in,O
seroprevalence,O
was,O
observed,O
between,O
studied,O
PAs,O
with,O
the,O
highest,O
and,O
lowest,O
seroprevalence,O
recorded,O
from,O
Ilala,O
(,O
82,O
.,O
26,O
%),O
and,O
Galcha,O
(,O
31,O
.,O
43,O
%),O
PAs,O
",",O
respectively,O
(,O
P,O
=,O
0,O
.,O
0001,O
).,O
The,O
seroprevalence,O
was,O
also,O
significantly,O
different,O
between,O
age,O
groups,O
(,O
P,O
=,O
0,O
.,O
002,O
"),",O
herd,O
sizes,O
(,O
P,O
=,O
0,O
.,O
011,O
),O
and,O
history,O
of,O
abortion,O
(,O
P,O
=,O
0,O
.,O
003,O
).,O
However,O
",",O
there,O
was,O
no,O
statistically,O
significant,O
difference,O
in,O
seroprevalence,O
between,O
males,O
and,O
females,O
(,O
P,O
=,O
0,O
.,O
757,O
),O
and,O
pastoral,O
and,O
agro,O
-,O
pastoral,O
production,O
systems,O
(,O
P,O
=,O
0,O
.,O
683,O
;,O
Table,O
1,O
).,O
Using,O
ELISA,O
",",O
the,O
PA,O
(,O
P,O
=,O
0,O
.,O
003,O
),O
and,O
history,O
of,O
abortion,O
(,O
P,O
=,O
0,O
.,O
038,O
),O
were,O
significantly,O
associated,O
with,O
seropositivity,O
(,O
see,O
Additional,O
file,O
1,O
:,O
Table,O
S1,O
).,O
Of,O
the,O
seropositive,O
samples,O
73,O
.,O
8,O
%,O
(,O
138,O
/,O
187,O
),O
had,O
DAT,O
end,O
titer,O
of,O
≥,O
6000,O
.,O
The,O
DAT,O
end,O
titer,O
of,O
the,O
seropositive,O
camels,B-OG
(,O
n,O
=,O
187,O
),O
is,O
shown,O
in,O
Figure,O
2,O
.,O
Table,O
1,O
T,B-OG
.,I-OG
gondii,I-OG
seroprevalence,O
in,O
camels,B-OG
of,O
the,O
Fentale,O
district,O
",",O
stratified,O
by,O
explanatory,O
variables,O
as,O
detected,O
by,O
DAT,O
Variable,O
Categories,O
No,O
.,O
tested,O
No,O
.,O
positive,O
%,O
seroprevalence,O
Chi,O
-,O
square,O
P,O
-,O
value,O
PAGalcha351131,O
.,O
4338,O
.,O
8441,O
<,O
0,O
.,O
001,O
Tuttuti2118640,O
.,O
76Saraweba381744,O
.,O
74Garafafate10550,O
.,O
00Turo291758,O
.,O
62Ilala625182,O
.,O
26Total38518748,O
.,O
34SexFemale20910047,O
.,O
850,O
.,O
09610,O
.,O
757Male1768749,O
.,O
43Age,O
≤,O
4,O
yrs1083734,O
.,O
2612,O
.,O
61900,O
.,O
002,O
4,O
-,O
8,O
yrs1859852,O
.,O
97,O
>,O
8,O
yrs925256,O
.,O
52PsPastoral30814848,O
.,O
050,O
.,O
16640,O
.,O
683Agro,O
-,O
pastoral773950,O
.,O
65HsSmall853945,O
.,O
889,O
.,O
06750,O
.,O
011,O
Medium1739856,O
.,O
65Large1275039,O
.,O
37AbortionNo1989045,O
.,O
458,O
.,O
62840,O
.,O
003,O
Yes111090,O
.,O
91StillbirthNo2079847,O
.,O
342,O
.,O
20110,O
.,O
138Yes22100,O
.,O
00NNMNo100,O
.,O
000,O
.,O
92180,O
.,O
337Yes20810048,O
.,O
08PA,O
=,O
pastoral,O
association,O
",",O
Hs,O
=,O
herd,O
size,O
",",O
Ps,O
=,O
production,O
system,O
",",O
NNM,O
=,O
neonatal,O
mortality,O
",",O
P,O
-,O
values,O
of,O
statistically,O
significant,O
variables,O
were,O
highlighted,O
in,O
bold,O
;,O
No,O
.,O
=,O
number,O
.,O
Figure,O
2,O
DAT,O
end,O
titer,O
of,O
seropositive,O
camels,B-OG
(,O
n,O
=,O
183,O
).,O
Herd,O
level,O
seroprevalence,O
Out,O
of,O
31,O
camel,B-OG
herds,O
examined,O
",",O
30,O
(,O
96,O
.,O
77,O
%),O
(,O
95,O
%,O
CI,O
:,O
83,O
.,O
30,O
–,O
99,O
.,O
92,O
),O
and,O
29,O
(,O
93,O
.,O
55,O
%),O
(,O
95,O
%,O
CI,O
:,O
78,O
.,O
58,O
–,O
99,O
.,O
21,O
),O
herds,O
were,O
seropositive,O
by,O
the,O
DAT,O
and,O
ELISA,O
test,O
",",O
respectively,O
(,O
i,O
.,O
e,O
".,",O
contain,O
at,O
least,O
one,O
seropositive,O
camel,B-OG
).,O
Using,O
DAT,O
",",O
herd,O
level,O
seroprevalence,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
was,O
not,O
significantly,O
associated,O
with,O
PAs,O
(,O
P,O
=,O
0,O
.,O
372,O
"),",O
production,O
system,O
(,O
P,O
=,O
0,O
.,O
170,O
"),",O
herd,O
size,O
(,O
P,O
=,O
0,O
.,O
576,O
"),",O
history,O
of,O
abortion,O
(,O
P,O
=,O
0,O
.,O
549,O
),O
and,O
presence,O
of,O
domestic,O
cats,B-OG
(,O
P,O
=,O
0,O
.,O
549,O
).,O
However,O
",",O
there,O
was,O
significant,O
association,O
between,O
herd,O
seroprevalence,O
and,O
presence,O
of,O
wild,O
felids,B-OG
(,O
P,O
=,O
0,O
.,O
038,O
;,O
Table,O
2,O
).,O
Using,O
ELISA,O
",",O
herd,O
level,O
seroprevalence,O
was,O
not,O
associated,O
with,O
the,O
studied,O
variables,O
except,O
neonatal,O
mortality,O
(,O
see,O
Additional,O
file,O
1,O
:,O
Table,O
S2,O
).,O
Table,O
2,O
Herd,O
level,O
seroprevalence,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
in,O
camels,B-OG
of,O
the,O
Fentale,O
district,O
as,O
detected,O
by,O
DAT,O
Variable,O
Categories,O
No,O
.,O
tested,O
No,O
.,O
positive,O
%,O
seroprevalence,O
Chi,O
-,O
square,O
P,O
-,O
value,O
PAGalcha441005,O
.,O
37330,O
.,O
372Tuttuti1111100Saraweba5480Garafafate22100Turo44100Ilala55100PsPastoral20201001,O
.,O
87880,O
.,O
170Agro,O
-,O
pastoral111090,O
.,O
91HsSmall151493,O
.,O
331,O
.,O
0220,O
.,O
576Medium1111100Large55100AbortionYes881000,O
.,O
35940,O
.,O
549No232195,O
.,O
65StillbirthYes331000,O
.,O
11070,O
.,O
739No282796,O
.,O
43NNMYes221000,O
.,O
07130,O
.,O
790No292896,O
.,O
55CatYes881000,O
.,O
35940,O
.,O
549No232295,O
.,O
65WfYes25251004,O
.,O
30560,O
.,O
038,O
No6583,O
.,O
33RiverYes2929100,O
--,O
PA,O
=,O
pastoral,O
association,O
",",O
Hs,O
=,O
herd,O
size,O
",",O
Ps,O
=,O
production,O
system,O
",",O
Wf,O
=,O
presence,O
of,O
wild,O
felids,B-OG
",",O
NNM,O
=,O
neonatal,O
mortality,O
",",O
No,O
.,O
=,O
number,O
.,O
Risk,O
factors,O
for,O
T,B-OG
.,I-OG
gondii,I-OG
seropositivity,O
Univariable,O
logistic,O
regression,O
analysis,O
Epidemiological,O
risk,O
factors,O
for,O
acquiring,O
T,B-OG
.,I-OG
gondii,I-OG
between,O
DAT,O
seroreactive,O
and,O
nonreactive,O
camels,B-OG
were,O
compared,O
using,O
univariable,O
logistic,O
regression,O
analysis,O
.,O
During,O
the,O
statistical,O
analysis,O
the,O
first,O
level,O
/,O
category,O
(,O
with,O
lowest,O
seroprevalence,O
),O
of,O
each,O
independent,O
variable,O
was,O
used,O
as,O
the,O
reference,O
category,O
.,O
The,O
results,O
showed,O
that,O
sex,O
",",O
herd,O
size,O
and,O
production,O
system,O
had,O
no,O
significant,O
association,O
with,O
T,B-OG
.,I-OG
gondii,I-OG
seropositivity,O
of,O
the,O
camels,B-OG
(,O
P,O
>,O
0,O
.,O
05,O
),O
while,O
study,O
area,O
",",O
age,O
",",O
history,O
of,O
abortion,O
",",O
presence,O
of,O
domestic,O
cats,B-OG
and,O
presence,O
of,O
wild,O
felids,B-OG
were,O
found,O
to,O
be,O
significantly,O
associated,O
with,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
(,O
P,O
<,O
0,O
.,O
05,O
),O
(,O
Table,O
3,O
).,O
Table,O
3,O
Animal,B-OG
level,O
Logistic,O
regression,O
analysis,O
of,O
predictors,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
in,O
Camels,B-OG
as,O
detected,O
by,O
DAT,O
Variable,O
Category,O
No,O
.,O
of,O
positive,O
/,O
tested,O
(%),O
Univariable,O
Multivariable,O
OR,O
(,O
95,O
%,O
CI,O
),O
P,O
OR,O
(,O
95,O
%,O
CI,O
),O
P,O
PAGalcha11,O
/,O
35,O
(,O
31,O
.,O
43,O
),O
11,O
-,O
Tuttuti86,O
/,O
211,O
(,O
40,O
.,O
75,O
),O
1,O
.,O
5,O
(,O
0,O
.,O
58,O
-,O
3,O
.,O
88,O
),O
0,O
.,O
4021,O
.,O
55,O
(,O
0,O
.,O
60,O
-,O
3,O
.,O
99,O
),O
0,O
.,O
367Saraweba17,O
/,O
38,O
(,O
44,O
.,O
74,O
),O
1,O
.,O
77,O
(,O
0,O
.,O
45,O
-,O
6,O
.,O
97,O
),O
0,O
.,O
4171,O
.,O
5,O
(,O
0,O
.,O
63,O
-,O
3,O
.,O
58,O
),O
0,O
.,O
357Garafafate5,O
/,O
10,O
(,O
50,O
),O
2,O
.,O
18,O
(,O
0,O
.,O
87,O
-,O
5,O
.,O
45,O
),O
0,O
.,O
0950,O
.,O
6,O
3,O
(,O
0,O
.,O
17,O
-,O
2,O
.,O
33,O
),O
0,O
.,O
487Turo17,O
/,O
29,O
(,O
58,O
.,O
62,O
),O
3,O
.,O
1,O
(.,O
77,O
-,O
12,O
.,O
34,O
),O
0,O
.,O
1101,O
.,O
06,O
(.,O
23,O
-,O
4,O
.,O
94,O
),O
0,O
.,O
940Ilala51,O
/,O
62,O
(,O
82,O
.,O
26,O
),O
10,O
.,O
11,O
(,O
4,O
.,O
3,O
-,O
24,O
.,O
21,O
)<,O
0,O
.,O
001,O
10,O
.,O
8,O
(,O
4,O
.,O
83,O
-,O
24,O
.,O
17,O
)<,O
0,O
.,O
001,O
SexFemale100,O
/,O
209,O
(,O
47,O
.,O
85,O
),O
1Male87,O
/,O
176,O
(,O
49,O
.,O
43,O
),O
1,O
.,O
06,O
(,O
0,O
.,O
70,O
-,O
1,O
.,O
62,O
),O
0,O
.,O
767Age,O
≤,O
4,O
yrs37,O
/,O
108,O
(,O
34,O
.,O
26,O
),O
11,O
-,O
4,O
-,O
8,O
yrs98,O
/,O
185,O
(,O
52,O
.,O
97,O
),O
2,O
.,O
16,O
(,O
1,O
.,O
28,O
-,O
3,O
.,O
64,O
),O
0,O
.,O
004,O
1,O
.,O
73,O
(,O
0,O
.,O
99,O
-,O
3,O
.,O
02,O
),O
0,O
.,O
053,O
>,O
8,O
yrs52,O
/,O
92,O
(,O
56,O
.,O
52,O
),O
2,O
.,O
49,O
(,O
1,O
.,O
34,O
-,O
4,O
.,O
65,O
),O
0,O
.,O
004,O
1,O
.,O
88,O
(,O
1,O
.,O
05,O
-,O
3,O
.,O
37,O
),O
0,O
.,O
033,O
Ps1,O
Pastoral148,O
/,O
308,O
(,O
48,O
.,O
05,O
),O
1Agro,O
-,O
pastoral39,O
/,O
77,O
(,O
50,O
.,O
65,O
),O
1,O
.,O
12,O
(,O
0,O
.,O
46,O
-,O
2,O
.,O
64,O
),O
0,O
.,O
814CatNo173,O
/,O
305,O
(,O
43,O
.,O
28,O
),O
11,O
-,O
Yes55,O
/,O
80,O
(,O
68,O
.,O
75,O
),O
2,O
.,O
88,O
(,O
1,O
.,O
28,O
-,O
6,O
.,O
47,O
),O
0,O
.,O
010,O
4,O
.,O
16,O
(,O
1,O
.,O
49,O
-,O
11,O
.,O
61,O
),O
0,O
.,O
006,O
Wf2,O
No18,O
/,O
80,O
(,O
22,O
.,O
5,O
),O
11,O
-,O
Yes169,O
/,O
305,O
(,O
55,O
.,O
41,O
),O
4,O
.,O
28,O
(,O
2,O
.,O
40,O
-,O
7,O
.,O
63,O
),O
<,O
0,O
.,O
001,O
2,O
.,O
04,O
(,O
0,O
.,O
86,O
-,O
4,O
.,O
83,O
),O
0,O
.,O
104AbortionNo90,O
/,O
198,O
(,O
45,O
.,O
45,O
),O
11,O
-,O
Yes10,O
/,O
11,O
(,O
90,O
.,O
91,O
),O
12,O
.,O
0,O
(,O
1,O
.,O
25,O
-,O
114,O
.,O
96,O
),O
0,O
.,O
031,O
9,O
.,O
23,O
(,O
0,O
.,O
8,O
-,O
107,O
.,O
05,O
),O
0,O
.,O
075Hs3,O
Small39,O
/,O
85,O
(,O
45,O
.,O
88,O
),O
1Medium98,O
/,O
173,O
(,O
56,O
.,O
65,O
),O
1,O
.,O
54,O
(,O
0,O
.,O
59,O
-,O
4,O
.,O
01,O
),O
0,O
.,O
376Large50,O
/,O
127,O
(,O
39,O
.,O
37,O
),O
0,O
.,O
76,O
(,O
0,O
.,O
26,O
-,O
2,O
.,O
29,O
),O
0,O
.,O
633,O
1Production,O
system,O
",",O
2Wild,O
felids,B-OG
",",O
3Herd,O
size,O
.,O
Multivariable,O
logistic,O
regression,O
analysis,O
Stillbirth,O
and,O
neonatal,O
mortality,O
were,O
not,O
included,O
in,O
the,O
multivariable,O
model,O
due,O
to,O
collinearity,O
with,O
abortion,O
.,O
Five,O
variables,O
(,O
study,O
area,O
[,O
PAs,O
"],",O
age,O
",",O
abortion,O
",",O
exposure,O
to,O
domestic,O
and,O
wild,O
cats,B-OG
),O
that,O
presented,O
P,O
-,O
value,O
<,O
0,O
.,O
25,O
in,O
the,O
univariable,O
analysis,O
",",O
were,O
subjected,O
to,O
the,O
multivariable,O
regression,O
model,O
.,O
The,O
analysis,O
showed,O
a,O
significant,O
association,O
between,O
T,B-OG
.,I-OG
gondii,I-OG
seropositivity,O
and,O
study,O
area,O
(,O
PAs,O
),O
(,O
P,O
=,O
0,O
.,O
0001,O
"),",O
age,O
(,O
P,O
=,O
0,O
.,O
033,O
),O
and,O
the,O
presence,O
of,O
domestic,O
cats,B-OG
(,O
P,O
=,O
0,O
.,O
006,O
;,O
Table,O
3,O
).,O
The,O
results,O
of,O
the,O
logistic,O
regression,O
analysis,O
based,O
on,O
the,O
results,O
of,O
the,O
ELISA,O
were,O
presented,O
as,O
Additional,O
file,O
1,O
:,O
Table,O
S3,O
).,O
Camel,B-OG
owners,O
food,O
habit,O
and,O
awareness,O
about,O
toxoplasmosis,B-DS
All,O
(,O
100,O
%),O
camel,B-OG
owners,O
who,O
responded,O
to,O
the,O
questionnaire,O
survey,O
were,O
uneducated,O
pastoralists,O
",",O
had,O
no,O
awareness,O
about,O
T,B-OG
.,I-OG
gondii,I-OG
",",O
toxoplasmosis,B-DS
and,O
its,O
transmission,O
to,O
humans,B-OG
through,O
raw,O
meat,O
and,O
raw,O
milk,O
consumption,O
.,O
Camel,B-OG
meat,O
consumption,O
habit,O
showed,O
that,O
67,O
.,O
7,O
%,O
consume,O
cooked,O
meat,O
and,O
the,O
rest,O
(,O
32,O
.,O
3,O
%),O
consume,O
either,O
cooked,O
or,O
uncooked,O
meat,O
.,O
All,O
respondents,O
(,O
100,O
%),O
consume,O
raw,O
camel,B-OG
milk,O
",",O
handle,O
aborted,O
fetus,O
with,O
bare,O
hands,O
(,O
no,O
protection,O
),O
and,O
don,O
’,O
t,O
wash,O
their,O
hands,O
after,O
handling,O
aborted,O
fetus,O
.,O
Furthermore,O
",",O
none,O
of,O
the,O
camel,B-OG
owners,O
bury,O
or,O
burn,O
aborted,O
materials,O
;,O
rather,O
they,O
simply,O
dispose,O
of,O
by,O
throwing,O
it,O
in,O
the,O
field,O
.,O
Comparison,O
of,O
seroprevalence,O
results,O
of,O
DAT,O
and,O
ELISA,O
tests,O
Overall,O
",",O
the,O
451,O
serum,O
samples,O
were,O
tested,O
by,O
both,O
DAT,O
and,O
ELISA,O
kits,O
for,O
comparison,O
.,O
A,O
total,O
agreement,O
between,O
the,O
two,O
tests,O
was,O
obtained,O
on,O
132,O
positive,O
samples,O
(,O
29,O
.,O
27,O
%),O
and,O
186,O
(,O
41,O
.,O
24,O
%),O
negative,O
samples,O
.,O
But,O
86,O
sera,O
were,O
positive,O
only,O
by,O
DAT,O
test,O
and,O
47,O
sera,O
were,O
positive,O
only,O
by,O
ELISA,O
test,O
.,O
Comparison,O
of,O
the,O
two,O
test,O
results,O
indicated,O
that,O
seropositivity,O
differed,O
significantly,O
between,O
the,O
two,O
kits,O
(,O
χ2,O
=,O
76,O
.,O
714,O
",",O
P,O
<,O
0,O
.,O
001,O
).,O
However,O
",",O
Kappa,O
analysis,O
demonstrated,O
that,O
the,O
two,O
tests,O
had,O
a,O
moderate,O
agreement,O
in,O
detecting,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
in,O
camels,B-OG
(,O
70,O
.,O
51,O
%,O
agreement,O
",",O
Kappa,O
=,O
0,O
.,O
41,O
;,O
P,O
<,O
0,O
.,O
0001,O
).,O
By,O
considering,O
DAT,O
as,O
a,O
reference,O
test,O
",",O
the,O
sensitivity,O
",",O
specificity,O
",",O
and,O
positive,O
and,O
negative,O
predictive,O
values,O
of,O
ELISA,O
was,O
calculated,O
as,O
60,O
.,O
55,O
"%,",O
79,O
.,O
83,O
"%,",O
and,O
73,O
.,O
74,O
%,O
and,O
68,O
.,O
38,O
"%,",O
respectively,O
.,O
Bioassay,O
Of,O
the,O
70,O
camel,B-OG
sera,O
from,O
the,O
abattoir,O
",",O
33,O
(,O
47,O
.,O
1,O
%),O
(,O
95,O
%,O
CI,O
:,O
35,O
.,O
09,O
-,O
59,O
.,O
45,O
),O
and,O
29,O
(,O
41,O
.,O
43,O
%),O
(,O
95,O
%,O
CI,O
:,O
29,O
.,O
77,O
-,O
53,O
.,O
83,O
),O
were,O
IgG,B-GP
seropositive,O
using,O
DAT,O
and,O
ELISA,O
",",O
respectively,O
.,O
Viable,O
T,B-OG
.,I-OG
gondii,I-OG
cysts,B-DS
were,O
isolated,O
from,O
5,O
of,O
31,O
DAT,O
seropositive,O
bioassayed,O
camels,B-OG
(,O
16,O
.,O
13,O
%).,O
Out,O
of,O
the,O
31,O
DAT,O
positive,O
sera,O
",",O
22,O
were,O
positive,O
for,O
ELISA,O
and,O
one,O
ELISA,O
negative,O
camel,B-OG
sample,O
gave,O
a,O
cyst,B-DS
positive,O
result,O
.,O
For,O
two,O
seropositive,O
camel,B-OG
samples,O
",",O
isolation,O
of,O
the,O
parasite,O
was,O
not,O
possible,O
because,O
of,O
the,O
death,O
of,O
all,O
of,O
the,O
inoculated,O
mice,B-OG
within,O
a,O
day,O
of,O
inoculation,O
.,O
On,O
day,O
60,O
post,O
-,O
inoculation,O
",",O
out,O
of,O
108,O
mice,B-OG
that,O
survived,O
",",O
22,O
(,O
20,O
.,O
4,O
%),O
were,O
seropositive,O
for,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
(,O
i,O
.,O
e,O
".,",O
out,O
of,O
31,O
camel,B-OG
samples,O
",",O
10,O
(,O
32,O
.,O
3,O
%),O
gave,O
a,O
seropositive,O
result,O
on,O
mice,B-OG
).,O
Viable,O
cysts,B-DS
were,O
isolated,O
in,O
mice,B-OG
from,O
5,O
tissue,O
samples,O
from,O
the,O
camels,B-OG
(,O
on,O
5,O
seropositive,O
and,O
1,O
seronegative,O
mice,B-OG
),O
(,O
Table,O
4,O
).,O
It,O
was,O
not,O
possible,O
to,O
detect,O
cysts,B-DS
from,O
17,O
of,O
the,O
seropositive,O
mice,B-OG
.,O
Eleven,O
out,O
of,O
108,O
survived,O
mice,B-OG
showed,O
loss,O
of,O
weight,O
(,O
10,O
.,O
2,O
"%),",O
of,O
which,O
9,O
and,O
2,O
mice,B-OG
were,O
seropositive,O
and,O
seronegative,O
",",O
respectively,O
",",O
i,O
.,O
e,O
".,",O
40,O
.,O
9,O
%,O
(,O
9,O
/,O
22,O
),O
of,O
seropositive,O
and,O
2,O
.,O
3,O
%,O
(,O
2,O
/,O
86,O
),O
of,O
seronegative,O
mice,B-OG
showed,O
loss,O
of,O
weight,O
.,O
The,O
mean,O
weight,O
change,O
between,O
seropositive,O
(,O
infected,O
",",O
mean,O
=,O
0,O
.,O
25,O
g,O
±,O
6,O
.,O
58,O
),O
and,O
seronegative,O
(,O
non,O
-,O
infected,O
",",O
mean,O
=,O
5,O
.,O
55,O
g,O
±,O
3,O
.,O
41,O
),O
mice,B-OG
was,O
significantly,O
different,O
(,O
P,O
<,O
0,O
.,O
0001,O
).,O
The,O
mean,O
cyst,B-DS
count,O
per,O
mouse,B-OG
brain,O
was,O
46,O
.,O
5,O
(,O
range,O
:,O
28,O
–,O
88,O
).,O
One,O
mouse,B-OG
that,O
showed,O
neurological,O
signs,O
(,O
hind,O
quarter,O
paralysis,O
",",O
torticollis,O
),O
and,O
tachypnoea,O
on,O
day,O
20,O
post,O
-,O
inoculation,O
became,O
cyst,B-DS
negative,O
but,O
seropositive,O
.,O
Table,O
4,O
Isolation,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
from,O
naturally,O
infected,O
seropositive,O
camels,B-OG
of,O
East,O
Shewa,O
Zones,O
",",O
Central,O
Ethiopia,O
Camel,B-OG
no,O
.,O
Sex,O
Age,O
group,O
DAT,O
screening,O
Mice,B-OG
with,O
cyst,B-DS
/,O
examined,O
(,O
n,O
),O
Mice,B-OG
seropositive,O
/,O
examined,O
(,O
n,O
),O
Days,O
of,O
mice,B-OG
death,O
PI,O
(,O
no,O
.,O
of,O
mice,B-OG
dead,O
),O
H1M,O
≥,O
8,O
Yrs1,O
/,O
400,O
/,O
50,O
/,O
5H2M,O
≥,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
50,O
/,O
5H4M4,O
-,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40001,O
/,O
50,O
/,O
5H6M,O
≥,O
8,O
Yrs1,O
/,O
400,O
/,O
30,O
/,O
31,O
(,O
1,O
"),",O
2,O
(,O
1,O
),O
H9M,O
≥,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40002,O
/,O
55,O
/,O
5H11M4,O
-,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
40,O
/,O
41,O
(,O
3,O
),O
H15F,O
≥,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
30,O
/,O
32,O
(,O
3,O
),O
H19M,O
≥,O
8,O
Yrs1,O
/,O
401,O
/,O
51,O
/,O
5H20M,O
≥,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40001,O
/,O
55,O
/,O
5H23M,O
≤,O
4,O
Yrs1,O
/,O
40000,O
/,O
31,O
/,O
32,O
(,O
2,O
),O
H25M,O
≥,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40001,O
/,O
33,O
/,O
32,O
(,O
2,O
),O
H28F,O
≤,O
4,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
43,O
/,O
41,O
(,O
2,O
),O
H30F,O
≥,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
11,O
/,O
14,O
(,O
1,O
),O
H33,O
",",O
H43F,O
≥,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
50,O
/,O
5H39M,O
≥,O
8,O
Yrs1,O
/,O
40000,O
/,O
50,O
/,O
5H44F4,O
-,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
51,O
/,O
5H45F4,O
-,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
41,O
/,O
41,O
(,O
1,O
),O
H55F,O
≤,O
4,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
30,O
/,O
31,O
(,O
2,O
),O
H56,O
",",O
H60,O
",",O
H65F4,O
-,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
50,O
/,O
5H63F4,O
-,O
8,O
Yrs1,O
/,O
40000,O
/,O
50,O
/,O
5H59M4,O
-,O
8,O
Yrs1,O
/,O
40000,O
/,O
40,O
/,O
42,O
(,O
2,O
),O
H61,O
",",O
H64F4,O
-,O
8,O
Yrs1,O
/,O
40000,O
/,O
40,O
/,O
42,O
(,O
1,O
"),",O
2,O
(,O
1,O
),O
H62F4,O
-,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
40,O
/,O
41,O
(,O
1,O
),O
H66F,O
≤,O
4,O
Yrs1,O
/,O
40000,O
/,O
51,O
/,O
5H67F,O
≥,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
40,O
/,O
42,O
(,O
1,O
),O
H68M4,O
-,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
30,O
/,O
31,O
(,O
2,O
"),",O
1,O
(,O
3,O
),O
H69F,O
≥,O
8,O
Yrs1,O
/,O
40,O
&,O
1,O
/,O
40000,O
/,O
10,O
/,O
14,O
(,O
1,O
),O
Discussion,O
Overall,O
seroprevalence,O
We,O
report,O
for,O
the,O
first,O
time,O
evidence,O
for,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
and,O
its,O
seroprevalence,O
",",O
risk,O
factors,O
and,O
bioassay,O
results,O
in,O
Ethiopian,O
camels,B-OG
.,O
An,O
estimated,O
overall,O
seroprevalence,O
of,O
49,O
.,O
623,O
%,O
by,O
DAT,O
and,O
40,O
.,O
49,O
%,O
by,O
ELISA,O
tests,O
were,O
detected,O
.,O
Seventy,O
-,O
four,O
percent,O
of,O
seropositive,O
camels,B-OG
(,O
from,O
field,O
samples,O
),O
had,O
DAT,O
end,O
titer,O
of,O
≥,O
6000,O
.,O
This,O
might,O
indicate,O
actively,O
circulating,O
",",O
recently,O
acquired,O
or,O
recrudescence,O
of,O
previously,O
acquired,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
in,O
camels,B-OG
of,O
the,O
study,O
area,O
due,O
to,O
climatic,O
stress,O
",",O
malnutrition,B-DS
and,O
prevalent,O
diseases,O
like,O
trypanosomosis,B-DS
[,O
36,O
],O
which,O
reduce,O
the,O
animals,B-OG
’,O
resistance,O
[,O
37,O
].,O
Moreover,O
",",O
the,O
seropositive,O
sera,O
that,O
became,O
negative,O
at,O
1,O
:,O
40,O
but,O
positive,O
at,O
1,O
:,O
4000,O
dilutions,O
(,O
7,O
.,O
34,O
"%,",O
16,O
/,O
218,O
),O
indicate,O
prozone,O
phenomenon,O
.,O
Presence,O
of,O
viable,O
T,B-OG
.,I-OG
gondii,I-OG
cysts,B-DS
in,O
16,O
.,O
13,O
%,O
(,O
5,O
/,O
31,O
),O
of,O
camels,B-OG
slaughtered,O
for,O
human,B-OG
consumption,O
is,O
definitive,O
diagnosis,O
of,O
natural,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
and,O
suggests,O
the,O
potential,O
transmission,O
of,O
toxoplasmosis,B-DS
to,O
humans,B-OG
through,O
consumption,O
of,O
raw,O
or,O
undercooked,O
camel,B-OG
meat,O
or,O
offal,O
such,O
as,O
the,O
liver,O
which,O
is,O
commonly,O
consumed,O
by,O
pastoralists,O
.,O
Considering,O
the,O
lower,O
human,B-OG
population,O
density,O
(,O
hence,O
possibly,O
lower,O
domestic,O
cat,B-OG
density,O
"),",O
the,O
arid,O
and,O
semi,O
-,O
arid,O
climate,O
of,O
the,O
Fentale,O
district,O
",",O
which,O
is,O
hostile,O
for,O
the,O
survival,O
of,O
oocysts,O
in,O
the,O
environment,O
",",O
and,O
the,O
browsing,O
habit,O
of,O
camel,B-OG
feeding,O
(,O
hence,O
lower,O
risk,O
of,O
acquiring,O
T,B-OG
.,I-OG
gondii,I-OG
oocysts,O
from,O
the,O
ground,O
"),",O
the,O
high,O
seroprevalence,O
found,O
in,O
the,O
present,O
study,O
was,O
not,O
to,O
our,O
expectation,O
.,O
Recently,O
",",O
a,O
relatively,O
lower,O
seroprevalence,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
in,O
goats,B-OG
(,O
15,O
.,O
37,O
%),O
[,O
25,O
],O
and,O
in,O
sheep,B-OG
(,O
13,O
.,O
36,O
%),O
[,O
23,O
],O
was,O
reported,O
from,O
the,O
same,O
district,O
.,O
However,O
",",O
the,O
high,O
seroprevalence,O
in,O
camels,B-OG
of,O
the,O
current,O
study,O
in,O
our,O
opinion,O
might,O
be,O
a,O
function,O
of,O
cumulative,O
effect,O
of,O
the,O
age,O
of,O
camels,B-OG
[,O
38,O
],O
related,O
to,O
absence,O
of,O
regular,O
culling,O
programs,O
.,O
Moreover,O
",",O
the,O
migration,O
of,O
camels,B-OG
to,O
midland,O
areas,O
in,O
search,O
of,O
feed,O
",",O
the,O
poor,O
veterinary,O
service,O
",",O
inadequate,O
attention,O
by,O
government,O
",",O
local,O
change,O
in,O
landownership,O
and,O
increased,O
farming,O
[,O
5,O
],O
-,O
which,O
necessitate,O
cat,B-OG
keeping,O
to,O
control,O
rodents,B-OG
",",O
might,O
have,O
additionally,O
contributed,O
to,O
the,O
high,O
prevalence,O
.,O
The,O
present,O
seroprevalence,O
(,O
48,O
.,O
34,O
%),O
is,O
in,O
close,O
agreement,O
with,O
the,O
51,O
.,O
3,O
%,O
and,O
46,O
%,O
-,O
54,O
.,O
2,O
%,O
seroprevalence,O
reported,O
from,O
Sudan,O
[,O
39,O
],O
and,O
Egypt,O
[,O
40,O
",",O
41,O
"],",O
respectively,O
.,O
As,O
compared,O
to,O
the,O
present,O
finding,O
",",O
much,O
higher,O
seroprevalence,O
has,O
been,O
reported,O
from,O
Turkey,O
(,O
90,O
.,O
9,O
%),O
and,O
Sudan,O
(,O
67,O
%),O
by,O
Utuk,O
et,O
al,O
.,O
[,O
11,O
],O
and,O
Elamin,O
et,O
al,O
.,O
[,O
8,O
"],",O
respectively,O
.,O
Lower,O
seroprevalence,O
was,O
recorded,O
earlier,O
from,O
Iran,O
3,O
.,O
12,O
%,O
[,O
10,O
"],",O
Saudi,O
Arabia,O
6,O
.,O
5,O
%,O
[,O
42,O
"],",O
16,O
%,O
[,O
43,O
"],",O
13,O
.,O
1,O
%,O
[,O
44,O
"],",O
Sudan,O
(,O
20,O
%),O
[,O
45,O
"],",O
United,O
Arab,O
Emirates,O
(,O
22,O
.,O
4,O
%),O
[,O
46,O
],O
and,O
Egypt,O
(,O
17,O
.,O
4,O
-,O
31,O
.,O
4,O
%),O
[,O
9,O
",",O
47,O
",",O
48,O
].,O
The,O
variation,O
in,O
seroprevalence,O
between,O
the,O
present,O
study,O
and,O
aforementioned,O
African,O
and,O
Arabian,O
countries,O
might,O
be,O
due,O
to,O
the,O
difference,O
in,O
density,O
of,O
cats,B-OG
and,O
wild,O
felids,B-OG
",",O
climatic,O
conditions,O
[,O
13,O
"],",O
farming,O
and,O
management,O
practices,O
[,O
49,O
"],",O
sample,O
size,O
[,O
45,O
"],",O
cut,O
-,O
off,O
values,O
and,O
sensitivity,O
difference,O
in,O
the,O
serological,O
tests,O
employed,O
[,O
13,O
",",O
42,O
].,O
Risk,O
factors,O
Assessment,O
of,O
the,O
association,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
seroprevalence,O
with,O
potential,O
risk,O
factors,O
was,O
made,O
with,O
the,O
aim,O
of,O
identifying,O
factors,O
relevant,O
for,O
prevention,O
of,O
the,O
disease,O
.,O
Accordingly,O
",",O
using,O
the,O
results,O
of,O
DAT,O
",",O
a,O
multivariable,O
logistic,O
regression,O
model,O
revealed,O
that,O
study,O
PA,O
(,O
P,O
=,O
0,O
.,O
001,O
"),",O
exposure,O
to,O
domestic,O
cats,B-OG
(,O
P,O
=,O
0,O
.,O
006,O
),O
and,O
age,O
of,O
the,O
camels,B-OG
(,O
P,O
=,O
0,O
.,O
033,O
),O
were,O
found,O
to,O
be,O
independent,O
predictors,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
seropositivity,O
.,O
On,O
the,O
other,O
hand,O
",",O
only,O
study,O
PA,O
(,O
P,O
=,O
0,O
.,O
006,O
),O
and,O
exposure,O
to,O
domestic,O
cats,B-OG
(,O
P,O
=,O
0,O
.,O
011,O
),O
were,O
found,O
to,O
be,O
independent,O
predictors,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
seropositivity,O
using,O
results,O
of,O
ELISA,O
(,O
see,O
Additional,O
file,O
1,O
).,O
This,O
suggests,O
that,O
DAT,O
is,O
a,O
more,O
preferred,O
test,O
for,O
assessing,O
the,O
risk,O
factors,O
in,O
camels,B-OG
than,O
ELISA,O
.,O
Camels,B-OG
from,O
Ilala,O
PA,O
(,O
82,O
.,O
26,O
%),O
are,O
10,O
.,O
8,O
times,O
more,O
likely,O
to,O
be,O
seropositive,O
than,O
camels,B-OG
of,O
Galcha,O
PA,O
(,O
31,O
.,O
43,O
%),O
[,O
P,O
<,O
0,O
.,O
001,O
].,O
The,O
observed,O
difference,O
in,O
seroprevalence,O
across,O
PAs,O
could,O
be,O
due,O
to,O
differences,O
in,O
the,O
age,O
of,O
camels,B-OG
sampled,O
[,O
50,O
"],",O
the,O
sample,O
size,O
[,O
44,O
"],",O
the,O
degree,O
of,O
environmental,O
contamination,O
[,O
13,O
],O
and,O
the,O
frequency,O
of,O
exposure,O
to,O
risk,O
factors,O
[,O
51,O
].,O
The,O
seroprevalence,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
was,O
higher,O
in,O
camels,B-OG
older,O
than,O
8,O
years,O
(,O
OR,O
=,O
2,O
.,O
49,O
",",O
95,O
%,O
CI,O
:,O
1,O
.,O
34,O
",",O
4,O
.,O
65,O
),O
as,O
compared,O
to,O
camels,B-OG
≤,O
4,O
years,O
old,O
.,O
Thus,O
",",O
the,O
probability,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
in,O
camels,B-OG
increases,O
as,O
the,O
age,O
of,O
the,O
animal,B-OG
increases,O
suggesting,O
postnatal,B-DS
infection,I-DS
.,O
The,O
high,O
seroprevalence,O
in,O
older,O
camels,B-OG
than,O
young,O
camels,B-OG
might,O
be,O
due,O
to,O
the,O
higher,O
likelihood,O
of,O
exposure,O
of,O
older,O
camels,B-OG
to,O
any,O
one,O
of,O
the,O
risk,O
factors,O
to,O
acquire,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
[,O
52,O
].,O
This,O
finding,O
is,O
in,O
harmony,O
with,O
the,O
studies,O
conducted,O
in,O
Saudi,O
Arabia,O
[,O
8,O
",",O
43,O
],O
who,O
reported,O
a,O
higher,O
seroprevalence,O
in,O
adult,O
than,O
young,O
camels,B-OG
.,O
The,O
univariable,O
logistic,O
regression,O
showed,O
that,O
the,O
odds,O
of,O
being,O
infected,O
by,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
was,O
higher,O
in,O
aborted,O
camels,B-OG
than,O
non,O
-,O
aborted,O
camels,B-OG
(,O
OR,O
=,O
12,O
",",O
95,O
%,O
CI,O
:,O
1,O
.,O
25,O
",",O
114,O
.,O
95,O
;,O
P,O
=,O
0,O
.,O
031,O
),O
and,O
in,O
areas,O
where,O
the,O
presence,O
of,O
wild,O
felids,B-OG
was,O
reported,O
(,O
OR,O
=,O
4,O
.,O
28,O
",",O
95,O
%,O
CI,O
:,O
2,O
.,O
40,O
",",O
7,O
.,O
63,O
;,O
P,O
<,O
0,O
.,O
001,O
),O
than,O
in,O
their,O
absence,O
.,O
However,O
",",O
these,O
variables,O
were,O
not,O
independent,O
predictors,O
of,O
seropositivity,O
in,O
the,O
final,O
logistic,O
regression,O
model,O
(,O
P,O
>,O
0,O
.,O
05,O
).,O
The,O
high,O
seroprevalence,O
in,O
aborted,O
camels,B-OG
is,O
consistent,O
with,O
biological,O
features,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
in,O
sheep,B-OG
",",O
goats,B-OG
and,O
pigs,B-OG
.,O
T,B-OG
.,I-OG
gondii,I-OG
has,O
been,O
reported,O
as,O
an,O
important,O
cause,O
of,O
abortion,O
in,O
Bacterian,B-OG
camels,I-OG
[,O
53,O
],O
and,O
in,O
zoo,O
camels,B-OG
in,O
USA,O
[,O
54,O
].,O
There,O
was,O
no,O
statistically,O
significant,O
sex,O
-,O
linked,O
difference,O
in,O
seroprevalence,O
between,O
male,O
(,O
49,O
.,O
43,O
%;,O
95,O
%,O
CI,O
:,O
42,O
.,O
0,O
",",O
56,O
.,O
86,O
),O
and,O
female,O
(,O
47,O
.,O
85,O
%;,O
95,O
%,O
CI,O
:,O
41,O
.,O
0,O
",",O
54,O
.,O
65,O
),O
camels,B-OG
.,O
This,O
is,O
consistent,O
with,O
studies,O
in,O
dromedaries,B-OG
of,O
Sudan,O
[,O
8,O
"],",O
Saudi,O
Arabia,O
[,O
43,O
],O
and,O
bactrian,B-OG
camels,I-OG
of,O
China,O
[,O
55,O
].,O
Bioassay,O
As,O
far,O
as,O
the,O
bioassay,O
result,O
is,O
concerned,O
",",O
tissue,O
cysts,B-DS
were,O
isolated,O
from,O
16,O
.,O
13,O
%,O
(,O
5,O
∕,O
31,O
),O
of,O
DAT,O
positive,O
camels,B-OG
.,O
Bradyzoite,O
tissue,O
cysts,B-DS
were,O
detected,O
by,O
microscopy,O
in,O
22,O
.,O
73,O
%,O
(,O
5,O
/,O
22,O
),O
of,O
DAT,O
positive,O
mice,B-OG
.,O
This,O
lower,O
rate,O
of,O
detection,O
of,O
cyst,B-DS
by,O
microscopy,O
might,O
be,O
due,O
to,O
the,O
low,O
number,O
of,O
cysts,B-DS
in,O
camel,B-OG
tissue,O
and,O
the,O
low,O
sensitivity,O
of,O
microscopy,O
[,O
13,O
].,O
Cyst,B-DS
count,O
has,O
also,O
been,O
reported,O
to,O
vary,O
depending,O
on,O
the,O
virulence,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
strain,O
and,O
number,O
of,O
passages,O
in,O
the,O
mice,B-OG
[,O
56,O
].,O
Previously,O
",",O
viable,O
tissue,O
cysts,B-DS
have,O
been,O
isolated,O
in,O
cats,B-OG
from,O
naturally,O
infected,O
camels,B-OG
in,O
Saudi,O
Arabia,O
[,O
16,O
].,O
It,O
has,O
also,O
been,O
reported,O
that,O
the,O
success,O
of,O
isolation,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
cysts,B-DS
as,O
well,O
as,O
the,O
number,O
of,O
tissue,O
cysts,B-DS
produced,O
vary,O
considerably,O
with,O
the,O
intermediate,O
hosts,O
",",O
being,O
higher,O
in,O
sheep,B-OG
",",O
goats,B-OG
and,O
pigs,B-OG
[,O
49,O
",",O
57,O
].,O
The,O
number,O
of,O
isolated,O
tissue,O
cysts,B-DS
ranged,O
from,O
25,O
to,O
88,O
per,O
brain,O
of,O
mice,B-OG
",",O
which,O
is,O
low,O
compared,O
to,O
the,O
number,O
of,O
cysts,B-DS
/,O
mouse,B-OG
brain,O
isolated,O
from,O
sheep,B-OG
and,O
goats,B-OG
of,O
the,O
same,O
district,O
(,O
Gebremedhin,O
et,O
al,O
".,",O
unpublished,O
).,O
More,O
sensitive,O
methods,O
like,O
PCR,O
might,O
detect,O
the,O
DNA,O
of,O
tissue,O
cysts,B-DS
in,O
the,O
brain,O
of,O
seropositive,O
mice,B-OG
presently,O
reported,O
perhaps,O
as,O
false,O
negative,O
due,O
to,O
the,O
small,O
volume,O
of,O
brain,O
homogenate,O
examined,O
(,O
50,O
μl,O
"),",O
lower,O
sensitivity,O
of,O
microscopy,O
and,O
the,O
possible,O
low,O
burden,O
of,O
viable,O
cysts,B-DS
in,O
tissue,O
of,O
camels,B-OG
[,O
13,O
].,O
Even,O
though,O
detection,O
of,O
brain,O
cysts,B-DS
was,O
not,O
possible,O
",",O
manifestations,O
of,O
tachypnoea,O
and,O
neurological,O
signs,O
by,O
a,O
mouse,B-OG
on,O
day,O
20,O
post,O
-,O
inoculation,O
might,O
indicate,O
the,O
more,O
virulent,O
nature,O
of,O
the,O
strain,O
[,O
13,O
].,O
The,O
death,O
of,O
mice,B-OG
in,O
less,O
than,O
3,O
days,O
following,O
i,O
.,O
p,O
.,O
inoculation,O
was,O
attributed,O
to,O
septic,B-DS
peritonitis,I-DS
that,O
resulted,O
from,O
bacterial,O
contamination,O
of,O
isolates,O
or,O
unintended,O
puncturing,O
of,O
the,O
intestine,O
or,O
other,O
vital,O
organs,O
[,O
34,O
].,O
Comparison,O
of,O
seroprevalence,O
results,O
of,O
DAT,O
and,O
ELISA,O
Comparison,O
of,O
the,O
diagnosis,O
of,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
of,O
camels,B-OG
by,O
DAT,O
and,O
ELISA,O
showed,O
moderate,O
agreement,O
(,O
Kappa,O
=,O
0,O
.,O
41,O
",",O
P,O
<,O
0,O
.,O
0001,O
).,O
We,O
think,O
that,O
the,O
discrepancies,O
between,O
the,O
results,O
of,O
DAT,O
and,O
ELISA,O
might,O
be,O
ascribed,O
to,O
the,O
difference,O
in,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
tests,O
in,O
camel,B-OG
.,O
DAT,O
is,O
more,O
sensitive,O
than,O
ELISA,O
which,O
is,O
in,O
accordance,O
with,O
findings,O
of,O
Dubey,O
[,O
58,O
],O
and,O
Shaapan,O
et,O
al,O
.,O
[,O
59,O
],O
who,O
reported,O
DAT,O
as,O
the,O
most,O
sensitive,O
test,O
among,O
all,O
serological,O
tests,O
.,O
It,O
has,O
also,O
been,O
reported,O
that,O
test,O
performances,O
may,O
vary,O
when,O
applied,O
on,O
different,O
animal,B-OG
species,O
[,O
60,O
].,O
For,O
example,O
",",O
as,O
opposed,O
to,O
our,O
finding,O
",",O
Zhu,O
et,O
al,O
.,O
[,O
61,O
],O
from,O
Beijing,O
",",O
China,O
",",O
reported,O
significantly,O
high,O
T,B-OG
.,I-OG
gondii,I-OG
seroprevalence,O
by,O
ELISA,O
(,O
34,O
.,O
7,O
%),O
as,O
compared,O
to,O
DAT,O
(,O
23,O
.,O
1,O
"%,",O
cut,O
-,O
off,O
:,O
1,O
:,O
25,O
),O
in,O
dogs,B-OG
(,O
high,O
degree,O
of,O
agreement,O
",",O
Kappa,O
=,O
0,O
.,O
644,O
"),",O
while,O
no,O
significant,O
difference,O
between,O
the,O
two,O
tests,O
was,O
reported,O
in,O
the,O
case,O
of,O
cats,B-OG
.,O
The,O
P30,B-GP
ELISA,O
test,O
we,O
used,O
in,O
the,O
current,O
study,O
employs,O
non,O
-,O
species,O
specific,O
conjugate,O
and,O
was,O
recommended,O
by,O
the,O
manufacturer,O
to,O
detect,O
anti,O
-,O
T,B-OG
.,I-OG
gondii,I-OG
antibodies,B-GP
in,O
ruminant,B-OG
",",O
cat,B-OG
or,O
pig,B-OG
sera,O
",",O
plasma,O
or,O
meat,O
juice,O
.,O
However,O
",",O
literature,O
with,O
regards,O
to,O
validation,O
of,O
this,O
kit,O
for,O
camels,B-OG
was,O
not,O
accessible,O
;,O
consequently,O
comparison,O
of,O
our,O
results,O
with,O
others,O
couldn,O
’,O
t,O
be,O
made,O
possible,O
.,O
Nevertheless,O
",",O
isolation,O
of,O
viable,O
cysts,B-DS
from,O
four,O
of,O
five,O
camels,B-OG
positive,O
by,O
ELISA,O
(,O
out,O
of,O
ten,O
camel,B-OG
tissues,O
positive,O
by,O
bioassay,O
using,O
DAT,O
",",O
seven,O
were,O
also,O
ELISA,O
positive,O
),O
coupled,O
with,O
the,O
relatively,O
higher,O
specificity,O
(,O
79,O
.,O
83,O
%),O
and,O
PPV,O
(,O
73,O
.,O
74,O
%),O
of,O
ELISA,O
in,O
the,O
present,O
study,O
",",O
suggests,O
the,O
usefulness,O
of,O
the,O
P30,B-GP
ELISA,O
test,O
in,O
epidemiological,O
studies,O
of,O
camel,B-OG
toxoplasmosis,B-DS
particularly,O
among,O
highly,O
disease,O
prevalent,O
populations,O
and,O
in,O
instances,O
of,O
abortion,O
storms,O
[,O
62,O
].,O
Although,O
in,O
the,O
present,O
study,O
DAT,O
is,O
more,O
sensitive,O
than,O
ELISA,O
",",O
the,O
subjective,O
nature,O
and,O
longer,O
waiting,O
time,O
before,O
reading,O
the,O
results,O
might,O
limit,O
widespread,O
and,O
large,O
scale,O
usage,O
of,O
DAT,O
for,O
epidemiological,O
studies,O
[,O
61,O
].,O
Camel,B-OG
owners,O
’,O
food,O
habit,O
and,O
awareness,O
about,O
toxoplasmosis,B-DS
From,O
the,O
questionnaire,O
data,O
it,O
was,O
evident,O
that,O
all,O
of,O
the,O
respondents,O
were,O
uneducated,O
and,O
have,O
a,O
very,O
poor,O
knowledge,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
and,O
its,O
mode,O
of,O
transmission,O
between,O
animals,B-OG
",",O
to,O
humans,B-OG
and,O
the,O
role,O
of,O
felids,B-OG
in,O
the,O
epidemiology,O
of,O
the,O
disease,O
.,O
The,O
lack,O
of,O
knowledge,O
about,O
the,O
disease,O
is,O
one,O
of,O
the,O
main,O
risk,O
factors,O
exposing,O
individuals,O
to,O
the,O
disease,O
",",O
as,O
all,O
of,O
them,O
drink,O
raw,O
camel,B-OG
milk,O
and,O
32,O
.,O
3,O
%,O
responded,O
that,O
they,O
eat,O
either,O
cooked,O
or,O
raw,O
camel,B-OG
meat,O
.,O
Human,B-OG
cases,O
of,O
toxoplasmosis,B-DS
have,O
previously,O
been,O
linked,O
directly,O
to,O
the,O
consumption,O
of,O
raw,O
goat,B-OG
’,O
s,O
milk,O
[,O
63,O
],O
and,O
camel,B-OG
milk,O
[,O
8,O
].,O
Recently,O
",",O
T,B-OG
.,I-OG
gondii,I-OG
tachyzoites,O
have,O
been,O
detected,O
from,O
milk,O
of,O
naturally,O
infected,O
camels,B-OG
in,O
Iran,O
using,O
ELISA,O
",",O
PCR,O
",",O
cell,O
culture,O
and,O
cat,B-OG
bioassay,O
[,O
10,O
],O
and,O
from,O
experimentally,O
infected,O
camels,B-OG
in,O
Sudan,O
[,O
64,O
].,O
The,O
high,O
seropositivity,O
and,O
moderately,O
high,O
rate,O
of,O
isolation,O
of,O
viable,O
tissue,O
cysts,B-DS
from,O
edible,O
organs,O
in,O
the,O
current,O
study,O
might,O
be,O
of,O
great,O
public,O
health,O
significance,O
.,O
This,O
is,O
due,O
to,O
the,O
deep,O
rooted,O
habit,O
of,O
consumption,O
of,O
raw,O
camel,B-OG
milk,O
",",O
offal,O
(,O
liver,O
),O
and,O
to,O
a,O
lesser,O
extent,O
",",O
meat,O
by,O
the,O
pastoral,O
communities,O
of,O
the,O
study,O
area,O
.,O
Moreover,O
",",O
the,O
absence,O
of,O
precautions,O
in,O
handling,O
aborted,O
materials,O
and,O
poor,O
knowledge,O
of,O
pastoralists,O
about,O
toxoplasmosis,B-DS
and,O
the,O
role,O
of,O
cats,B-OG
in,O
the,O
transmission,O
of,O
the,O
disease,O
are,O
additional,O
suggestive,O
evidences,O
for,O
the,O
spread,O
of,O
toxoplasmosis,B-DS
to,O
humans,B-OG
and,O
among,O
camels,B-OG
in,O
the,O
study,O
district,O
.,O
In,O
the,O
absence,O
of,O
a,O
vaccine,O
for,O
camels,B-OG
and,O
the,O
difficulty,O
in,O
changing,O
the,O
pastoral,O
extensive,O
livestock,O
management,O
system,O
to,O
intensive,O
management,O
to,O
reduce,O
the,O
prevalence,O
of,O
the,O
disease,O
",",O
prevention,O
of,O
the,O
disease,O
through,O
education,O
of,O
pastoralists,O
remains,O
a,O
better,O
alternative,O
and,O
perhaps,O
a,O
more,O
economically,O
feasible,O
option,O
to,O
combat,O
the,O
disease,O
.,O
The,O
limitations,O
of,O
the,O
current,O
study,O
include,O
interviewee,O
recall,O
bias,O
",",O
the,O
relatively,O
small,O
number,O
of,O
camels,B-OG
considered,O
for,O
bioassay,O
and,O
the,O
inability,O
to,O
genotype,O
the,O
isolates,O
due,O
to,O
a,O
shortage,O
of,O
resources,O
.,O
Further,O
studies,O
to,O
improve,O
the,O
sensitivity,O
and,O
specificity,O
of,O
ELISA,O
for,O
diagnosis,O
of,O
toxoplasmosis,B-DS
in,O
camels,B-OG
are,O
required,O
.,O
Conclusions,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
of,O
camels,B-OG
in,O
the,O
study,O
district,O
is,O
widespread,O
.,O
Age,O
",",O
presence,O
of,O
domestic,O
cats,B-OG
and,O
study,O
PA,O
are,O
independent,O
predictors,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
seropositivity,O
.,O
Isolation,O
of,O
viable,O
parasites,O
from,O
edible,O
tissues,O
of,O
camels,B-OG
and,O
the,O
very,O
poor,O
knowledge,O
of,O
pastoralists,O
about,O
toxoplasmosis,B-DS
",",O
suggest,O
that,O
people,O
are,O
at,O
a,O
higher,O
risk,O
of,O
acquiring,O
T,B-DS
.,I-DS
gondii,I-DS
infection,I-DS
.,O
Therefore,O
",",O
prevention,O
of,O
toxoplasmosis,B-DS
through,O
biosecurity,O
measures,O
",",O
education,O
of,O
pastoralists,O
about,O
the,O
identified,O
risks,O
and,O
further,O
investigation,O
to,O
unravel,O
the,O
economic,O
and,O
public,O
health,O
implications,O
of,O
the,O
high,O
prevalence,O
of,O
T,B-OG
.,I-OG
gondii,I-OG
in,O
the,O
area,O
deserves,O
consideration,O
.,O
containing,O
results,O
of,O
analysis,O
based,O
on,O
ELISA,O
for,O
animal,B-OG
level,O
seroprevalence,O
",",O
Table,O
S2,O
.,O
herd,O
level,O
seroprevalence,O
and,O
Table,O
S3,O
.,O
logistic,O
regression,O
analysis,O
of,O
predictors,O
of,O
seropositivity,O
.,O
Competing,O
interests,O
The,O
authors,O
declare,O
that,O
they,O
have,O
no,O
competing,O
interests,O
.,O
Authors,O
’,O
contribution,O
EZG,O
conceived,O
and,O
designed,O
the,O
proposal,O
",",O
participated,O
in,O
the,O
coordination,O
and,O
management,O
of,O
the,O
study,O
",",O
collected,O
",",O
tested,O
and,O
analyzed,O
the,O
data,O
and,O
drafted,O
the,O
article,O
.,O
HAY,O
participated,O
in,O
sample,O
collection,O
",",O
laboratory,O
testing,O
and,O
drafting,O
of,O
article,O
with,O
inputs,O
from,O
GT,O
",",O
GT,O
and,O
FD,O
.,O
TST,O
",",O
MV,O
and,O
V,O
di,O
M,O
participated,O
in,O
the,O
study,O
design,O
and,O
edition,O
of,O
article,O
.,O
All,O
authors,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
Characterization,O
of,O
microbial,O
community,O
structure,O
during,O
continuous,O
anaerobic,O
digestion,O
of,O
straw,O
and,O
cow,B-OG
manure,O
Funding,O
Information,O
We,O
acknowledge,O
MicroDrive,O
(,O
http,O
://,O
www,O
.,O
slu,O
.,O
se,O
/,O
microdrive,O
),O
and,O
The,O
Swedish,O
Energy,O
Agency,O
for,O
the,O
financial,O
support,O
.,O
This,O
work,O
was,O
also,O
funded,O
in,O
part,O
by,O
the,O
Research,O
Council,O
of,O
Norway,O
",",O
Grant,O
Numbers,O
190877,O
/,O
S60,O
and,O
203402,O
/,O
E20,O
.,O
Responses,O
of,O
bacterial,O
and,O
archaeal,O
communities,O
to,O
the,O
addition,O
of,O
straw,O
during,O
anaerobic,O
digestion,O
of,O
manure,O
at,O
different,O
temperatures,O
(,O
37,O
°,O
C,O
",",O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
),O
were,O
investigated,O
using,O
five,O
laboratory,O
-,O
scale,O
semi,O
-,O
continuous,O
stirred,O
tank,O
reactors,O
.,O
The,O
results,O
revealed,O
that,O
including,O
straw,O
as,O
co,O
-,O
substrate,O
decreased,O
the,O
species,O
richness,O
for,O
bacteria,B-OG
",",O
whereas,O
increasing,O
the,O
operating,O
temperature,O
decreased,O
the,O
species,O
richness,O
for,O
both,O
archaea,B-OG
and,O
bacteria,B-OG
",",O
and,O
also,O
the,O
evenness,O
of,O
the,O
bacteria,B-OG
.,O
Taxonomic,O
classifications,O
of,O
the,O
archaeal,O
community,O
showed,O
that,O
Methanobrevibacter,B-OG
dominated,O
in,O
the,O
manure,O
samples,O
",",O
while,O
Methanosarcina,B-OG
dominated,O
in,O
all,O
digesters,O
regardless,O
of,O
substrate,O
.,O
Increase,O
of,O
the,O
operating,O
temperature,O
to,O
52,O
°,O
C,O
led,O
to,O
increased,O
relative,O
abundance,O
of,O
Methanoculleus,B-OG
and,O
Methanobacterium,B-OG
.,O
Among,O
the,O
bacteria,B-OG
",",O
the,O
phyla,O
Firmicutes,B-OG
and,O
Bacteroidetes,B-OG
dominated,O
within,O
all,O
samples,O
.,O
Compared,O
with,O
manure,O
itself,O
",",O
digestion,O
of,O
manure,O
resulted,O
in,O
a,O
higher,O
abundance,O
of,O
an,O
uncultured,O
class,O
WWE1,O
and,O
lower,O
abundance,O
of,O
Bacilli,B-OG
.,O
Adding,O
straw,O
to,O
the,O
digesters,O
increased,O
the,O
level,O
of,O
Bacteroidia,B-OG
",",O
while,O
increasing,O
the,O
operating,O
temperature,O
decreased,O
the,O
level,O
of,O
this,O
class,O
and,O
instead,O
increased,O
the,O
relative,O
abundance,O
of,O
an,O
uncultured,O
genus,O
affiliated,O
to,O
order,O
MBA08,O
(,O
Clostridia,B-OG
).,O
A,O
considerable,O
fraction,O
of,O
bacterial,O
sequences,O
could,O
not,O
be,O
allocated,O
to,O
genus,O
level,O
",",O
indicating,O
that,O
novel,O
phylotypes,O
are,O
resident,O
in,O
these,O
communities,O
.,O
Introduction,O
In,O
recent,O
years,O
",",O
the,O
search,O
for,O
renewable,O
energy,O
resources,O
to,O
replace,O
fossil,O
fuels,O
has,O
received,O
increasing,O
attention,O
worldwide,O
.,O
Anaerobic,O
digestion,O
(,O
AD,O
),O
represents,O
a,O
highly,O
interesting,O
approach,O
in,O
this,O
regard,O
",",O
since,O
it,O
allows,O
various,O
organic,O
waste,O
materials,O
and,O
dedicated,O
energy,O
crops,O
to,O
be,O
converted,O
to,O
a,O
renewable,O
energy,O
carrier,O
(,O
biogas,O
"),",O
and,O
produces,O
a,O
nutrient,O
-,O
rich,O
residue,O
that,O
can,O
be,O
used,O
as,O
fertilizer,O
in,O
agriculture,O
(,O
Weiland,O
",",O
2010,O
;,O
Appels,O
et,O
al,O
".,",O
2011,O
;,O
Nkoa,O
",",O
2014,O
).,O
Among,O
various,O
possible,O
substrates,O
",",O
agricultural,O
residues,O
",",O
such,O
as,O
manure,O
and,O
straw,O
",",O
offer,O
great,O
potential,O
for,O
AD,O
(,O
Wang,O
et,O
al,O
".,",O
2009,O
;,O
Appels,O
et,O
al,O
".,",O
2011,O
;,O
Tsavkelova,O
and,O
Netrusov,O
",",O
2012,O
).,O
However,O
",",O
the,O
use,O
of,O
these,O
materials,O
for,O
biogas,O
production,O
is,O
still,O
somewhat,O
restricted,O
because,O
of,O
their,O
high,O
content,O
of,O
lignocellulose,O
",",O
which,O
is,O
difficult,O
to,O
degrade,O
due,O
to,O
its,O
intricate,O
structure,O
",",O
with,O
cellulose,O
fibres,O
tightly,O
linked,O
to,O
hemicellulose,O
and,O
lignin,O
(,O
Tsavkelova,O
and,O
Netrusov,O
",",O
2012,O
).,O
Consequently,O
",",O
lignocellulosic,O
materials,O
typically,O
result,O
in,O
slow,O
degradation,O
and,O
low,O
biogas,O
yields,O
(,O
Angelidaki,O
and,O
Ellegaard,O
",",O
2003,O
;,O
Hendriks,O
and,O
Zeeman,O
",",O
2009,O
;,O
Frigon,O
and,O
Guiot,O
",",O
2010,O
).,O
Moreover,O
",",O
using,O
straw,O
for,O
biogas,O
production,O
requires,O
co,O
-,O
digestion,O
with,O
a,O
nutrient,O
-,O
rich,O
material,O
",",O
as,O
straw,O
has,O
a,O
high,O
C,O
/,O
N,O
ratio,O
and,O
low,O
levels,O
of,O
trace,O
metals,O
(,O
Lehtomäki,O
et,O
al,O
".,",O
2007,O
;,O
Estevez,O
et,O
al,O
".,",O
2012,O
;,O
Risberg,O
et,O
al,O
".,",O
2013,O
).,O
The,O
biogas,O
potential,O
of,O
straw,O
can,O
be,O
improved,O
by,O
a,O
combination,O
of,O
different,O
measures,O
",",O
but,O
so,O
far,O
no,O
clear,O
and,O
generally,O
applicable,O
solution,O
has,O
been,O
identified,O
.,O
One,O
way,O
to,O
improve,O
the,O
digestibility,O
is,O
to,O
use,O
pretreatment,O
techniques,O
",",O
such,O
as,O
steam,O
explosion,O
",",O
but,O
such,O
strategies,O
increase,O
energy,O
consumption,O
",",O
possibly,O
threatening,O
the,O
economic,O
feasibility,O
of,O
the,O
process,O
(,O
Hendriks,O
and,O
Zeeman,O
",",O
2009,O
;,O
Frigon,O
and,O
Guiot,O
",",O
2010,O
;,O
Galbe,O
and,O
Zacchi,O
",",O
2012,O
).,O
Some,O
attempts,O
have,O
also,O
been,O
made,O
to,O
improve,O
the,O
degradation,O
efficiency,O
by,O
using,O
hydrolytic,B-GP
enzymes,I-GP
",",O
as,O
a,O
pretreatment,O
or,O
direct,O
additive,O
",",O
or,O
by,O
addition,O
of,O
specific,O
cellulose,B-OG
-,I-OG
degrading,I-OG
bacteria,I-OG
(,O
Parawira,O
",",O
2012,O
;,O
Peng,O
et,O
al,O
".,",O
2014,O
).,O
Although,O
not,O
providing,O
clear,O
answers,O
yet,O
",",O
these,O
studies,O
clearly,O
indicate,O
the,O
potential,O
for,O
improved,O
degradation,O
efficiency,O
through,O
increased,O
knowledge,O
of,O
cellulose,O
-,O
degrading,O
organisms,O
",",O
and,O
eventually,O
more,O
efficient,O
cellulose,O
conversion,O
.,O
The,O
formation,O
of,O
methane,O
proceeds,O
via,O
a,O
complex,O
process,O
involving,O
four,O
microbial,O
steps,O
:,O
hydrolysis,O
",",O
fermentation,O
",",O
acetogenesis,O
and,O
methanogenesis,O
(,O
Zinder,O
and,O
Koch,O
",",O
1984,O
;,O
Angelidaki,O
et,O
al,O
".,",O
2011,O
).,O
When,O
lignocellulose,O
-,O
rich,O
materials,O
",",O
such,O
as,O
straw,O
",",O
are,O
used,O
as,O
substrate,O
for,O
biogas,O
production,O
",",O
hydrolysis,O
of,O
cellulose,O
was,O
suggested,O
to,O
be,O
the,O
rate,O
-,O
limiting,O
step,O
(,O
Noike,O
et,O
al,O
".,",O
1985,O
;,O
Lynd,O
et,O
al,O
".,",O
2002,O
).,O
The,O
taxonomy,O
and,O
phylogeny,O
of,O
microbial,O
communities,O
within,O
the,O
AD,O
process,O
have,O
been,O
studied,O
by,O
various,O
culture,O
-,O
based,O
and,O
molecular,O
methods,O
",",O
including,O
construction,O
of,O
clone,O
libraries,O
and,O
sequencing,O
by,O
targeting,O
16S,O
rDNA,O
and,O
functional,O
genes,O
(,O
Klocke,O
et,O
al,O
".,",O
2008,O
;,O
Liu,O
et,O
al,O
".,",O
2009,O
;,O
Sun,O
et,O
al,O
".,",O
2013,O
;,O
Vanwonterghem,O
et,O
al,O
".,",O
2014,O
;,O
Ziganshina,O
et,O
al,O
".,",O
2014,O
).,O
In,O
addition,O
",",O
the,O
development,O
and,O
application,O
of,O
next,O
-,O
generation,O
sequencing,O
technologies,O
has,O
enabled,O
time,O
and,O
cost,O
-,O
efficient,O
studies,O
of,O
the,O
microbial,O
communities,O
in,O
various,O
biogas,O
processes,O
(,O
Werner,O
et,O
al,O
".,",O
2011,O
;,O
Sundberg,O
et,O
al,O
".,",O
2013,O
;,O
Ziganshin,O
et,O
al,O
".,",O
2013,O
;,O
Yang,O
et,O
al,O
".,",O
2014,O
).,O
The,O
microorganisms,B-OG
involved,O
in,O
the,O
hydrolysis,O
step,O
have,O
been,O
studied,O
in,O
ruminating,O
animals,B-OG
",",O
and,O
more,O
recently,O
also,O
in,O
the,O
biogas,O
process,O
.,O
In,O
the,O
rumen,O
of,O
cattle,B-OG
",",O
ubiquitous,O
detected,O
genera,O
include,O
Clostridium,B-OG
",",O
Bacteroides,B-OG
",",O
Succinivibrio,B-OG
",",O
Prevotella,B-OG
and,O
Ruminococcus,B-OG
(,O
Dowd,O
et,O
al,O
".,",O
2008,O
;,O
Callaway,O
et,O
al,O
".,",O
2010,O
).,O
Fibrobacter,B-OG
",",O
formerly,O
grouped,O
to,O
Bacteroides,B-OG
",",O
as,O
well,O
as,O
Ruminococcus,B-OG
and,O
uncultured,O
bacteria,B-OG
have,O
also,O
been,O
suggested,O
to,O
play,O
important,O
roles,O
in,O
cellulose,O
hydrolysis,O
in,O
the,O
rumen,O
(,O
Leschine,O
",",O
1995,O
;,O
Ransom,O
-,O
Jones,O
et,O
al,O
".,",O
2012,O
).,O
For,O
the,O
biogas,O
production,O
process,O
",",O
just,O
a,O
few,O
previous,O
studies,O
have,O
specifically,O
addressed,O
the,O
hydrolysis,O
step,O
.,O
In,O
a,O
recent,O
study,O
by,O
Lebuhn,O
and,O
colleagues,O
(,O
2014,O
"),",O
Firmicutes,B-OG
and,O
Bacteroidetes,B-OG
were,O
suggested,O
to,O
be,O
important,O
in,O
a,O
hydrolytic,O
/,O
acidogenic,O
digester,O
fed,O
with,O
dried,O
hay,O
and,O
straw,O
.,O
These,O
two,O
phyla,O
have,O
also,O
been,O
shown,O
to,O
be,O
important,O
during,O
batch,O
digestion,O
of,O
wheat,B-OG
straw,O
and,O
swine,B-OG
manure,O
(,O
Li,O
et,O
al,O
".,",O
2014,O
).,O
In,O
a,O
previous,O
study,O
",",O
we,O
investigated,O
the,O
cellulolytic,O
community,O
in,O
biogas,O
digesters,O
operating,O
at,O
different,O
temperatures,O
with,O
a,O
mixture,O
of,O
straw,O
and,O
manure,O
or,O
manure,O
alone,O
",",O
by,O
specifically,O
targeting,O
the,O
glycoside,B-GP
hydrolase,I-GP
families,O
5,O
and,O
48,O
(,O
Sun,O
et,O
al,O
".,",O
2013,O
).,O
In,O
that,O
study,O
",",O
all,O
sequenced,O
clones,O
belonged,O
to,O
the,O
phyla,O
Firmicutes,B-OG
and,O
Bacteroidetes,B-OG
.,O
However,O
",",O
the,O
entire,O
microbial,O
community,O
was,O
not,O
investigated,O
",",O
and,O
the,O
total,O
response,O
to,O
the,O
addition,O
of,O
straw,O
and,O
to,O
the,O
temperature,O
shifts,O
remains,O
unclear,O
.,O
To,O
gain,O
a,O
better,O
understanding,O
of,O
the,O
response,O
of,O
the,O
microbial,O
community,O
to,O
straw,O
-,O
rich,O
materials,O
",",O
in,O
the,O
present,O
study,O
the,O
same,O
laboratory,O
-,O
scale,O
semi,O
-,O
continuous,O
reactors,O
were,O
employed,O
for,O
extended,O
analysis,O
of,O
both,O
the,O
bacterial,O
and,O
archaeal,O
communities,O
by,O
means,O
of,O
454,O
-,O
pyrosequencing,O
.,O
More,O
specifically,O
",",O
the,O
aims,O
of,O
this,O
study,O
were,O
to,O
examine,O
(,O
i,O
),O
the,O
microbial,O
communities,O
using,O
manure,O
as,O
sole,O
substrate,O
",",O
(,O
ii,O
),O
the,O
microbial,O
response,O
caused,O
by,O
addition,O
of,O
straw,O
and,O
(,O
iii,O
),O
the,O
impact,O
of,O
different,O
operating,O
temperatures,O
.,O
Results,O
Ecological,O
index,O
of,O
archaeal,O
and,O
bacterial,O
community,O
Amplicon,O
pyrosequencing,O
of,O
25,O
samples,O
yielded,O
77,O
791,O
and,O
64,O
731,O
non,O
-,O
chimeric,O
reads,O
for,O
archaea,B-OG
and,O
bacteria,B-OG
respectively,O
.,O
The,O
number,O
of,O
operational,O
taxonomic,O
units,O
(,O
OTUs,O
),O
per,O
sample,O
ranged,O
from,O
12,O
to,O
25,O
for,O
archaea,B-OG
and,O
from,O
112,O
to,O
277,O
for,O
bacteria,B-OG
(,O
Table,O
1,O
).,O
The,O
phylogenetic,O
compositions,O
as,O
determined,O
by,O
principal,O
coordinate,O
analysis,O
(,O
PCoA,O
),O
of,O
unweighted,O
UniFrac,O
matrices,O
(,O
Fig,O
.,O
1,O
),O
for,O
the,O
archaeal,O
and,O
bacterial,O
communities,O
within,O
the,O
same,O
digester,O
at,O
multiple,O
sampling,O
points,O
over,O
time,O
were,O
similar,O
.,O
For,O
instance,O
",",O
the,O
four,O
sampling,O
points,O
of,O
the,O
parallel,O
digesters,O
RTcSS,O
(,O
reactors,O
operated,O
with,O
steam,O
-,O
exploded,O
straw,O
and,O
manure,O
at,O
37,O
°,O
C,O
",",O
Risberg,O
et,O
al,O
".,",O
2013,O
),O
were,O
clustered,O
closely,O
together,O
",",O
indicating,O
comparable,O
phylogenetic,O
structures,O
within,O
a,O
total,O
period,O
of,O
91,O
days,O
.,O
Moreover,O
",",O
the,O
communities,O
in,O
all,O
parallel,O
digesters,O
running,O
under,O
the,O
same,O
conditions,O
were,O
also,O
comparable,O
",",O
e,O
.,O
g,O
.,O
the,O
community,O
in,O
duplicate,O
reactors,O
running,O
with,O
steam,O
-,O
exploded,O
straw,O
and,O
manure,O
at,O
different,O
temperatures,O
(,O
R37SS,O
",",O
R44SS,O
and,O
R52SS,O
),O
was,O
also,O
similar,O
at,O
individual,O
time,O
points,O
.,O
The,O
estimated,O
richness,O
for,O
all,O
samples,O
analysed,O
at,O
all,O
sampling,O
points,O
based,O
on,O
the,O
Chao1,O
index,O
indicated,O
that,O
the,O
observed,O
phylotypes,O
covered,O
23,O
–,O
93,O
%,O
and,O
48,O
–,O
82,O
%,O
of,O
the,O
archaeal,O
and,O
bacterial,O
populations,O
respectively,O
(,O
Table,O
1,O
).,O
In,O
general,O
",",O
the,O
species,O
richness,O
expressed,O
as,O
the,O
number,O
of,O
observed,O
OTUs,O
decreased,O
as,O
the,O
operating,O
temperature,O
increased,O
for,O
both,O
bacteria,B-OG
and,O
archaea,B-OG
(,O
Table,O
1,O
and,O
Fig,O
.,O
S1,O
).,O
For,O
bacterial,O
reads,O
",",O
no,O
species,O
richness,O
difference,O
was,O
observed,O
between,O
manure,O
itself,O
and,O
the,O
digester,O
operated,O
with,O
manure,O
alone,O
(,O
RM,O
).,O
However,O
",",O
a,O
slightly,O
lower,O
bacterial,O
species,O
richness,O
was,O
observed,O
in,O
digesters,O
that,O
received,O
straw,O
in,O
the,O
substrate,O
(,O
digesters,O
RTcSS,O
and,O
R37SS,O
),O
than,O
that,O
operated,O
with,O
manure,O
alone,O
(,O
RM,O
),O
(,O
Welch,O
’,O
s,O
t,O
-,O
test,O
",",O
P,O
<,O
0,O
.,O
01,O
).,O
In,O
contrast,O
",",O
for,O
archaea,B-OG
",",O
no,O
clear,O
trend,O
in,O
species,O
richness,O
was,O
observed,O
when,O
comparing,O
the,O
manure,O
itself,O
and,O
the,O
mesophilic,O
digesters,O
operating,O
with,O
manure,O
",",O
alone,O
or,O
combined,O
with,O
straw,O
.,O
The,O
Simpson,O
diversity,O
index,O
ranged,O
from,O
0,O
.,O
53,O
to,O
0,O
.,O
78,O
for,O
archaea,B-OG
and,O
from,O
0,O
.,O
72,O
to,O
0,O
.,O
98,O
for,O
bacteria,B-OG
(,O
Table,O
1,O
).,O
For,O
the,O
bacterial,O
community,O
",",O
a,O
lower,O
Simpson,O
index,O
was,O
observed,O
during,O
the,O
increase,O
in,O
operating,O
temperature,O
",",O
suggesting,O
lower,O
community,O
evenness,O
in,O
these,O
digesters,O
(,O
R44SS,O
and,O
R52SS,O
",",O
digesters,O
processing,O
straw,O
and,O
manure,O
at,O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
).,O
Compared,O
with,O
the,O
bacterial,O
community,O
",",O
the,O
Simpson,O
index,O
was,O
generally,O
lower,O
for,O
the,O
archaeal,O
community,O
",",O
and,O
with,O
the,O
lowest,O
value,O
in,O
R44SS,O
compared,O
with,O
R37SS,O
and,O
R52SS,O
(,O
Welch,O
’,O
s,O
t,O
-,O
test,O
",",O
P,O
<,O
0,O
.,O
05,O
).,O
The,O
Shannon,O
diversity,O
index,O
varied,O
from,O
1,O
.,O
46,O
to,O
2,O
.,O
64,O
for,O
archaea,B-OG
and,O
from,O
3,O
.,O
45,O
to,O
6,O
.,O
36,O
for,O
bacteria,B-OG
(,O
Table,O
1,O
).,O
Within,O
the,O
bacterial,O
community,O
",",O
the,O
Shannon,O
index,O
was,O
comparably,O
lower,O
in,O
digesters,O
operating,O
with,O
straw,O
at,O
higher,O
temperatures,O
",",O
i,O
.,O
e,O
.,O
at,O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
compared,O
with,O
37,O
°,O
C,O
(,O
Welch,O
’,O
s,O
t,O
-,O
test,O
",",O
P,O
<,O
0,O
.,O
05,O
).,O
For,O
the,O
archaeal,O
community,O
",",O
a,O
lower,O
Shannon,O
diversity,O
index,O
was,O
observed,O
in,O
R44SS,O
compared,O
with,O
R37,O
/,O
TcSS,O
and,O
R52SS,O
(,O
Welch,O
’,O
s,O
t,O
-,O
test,O
",",O
P,O
<,O
0,O
.,O
05,O
"),",O
and,O
in,O
RM,O
compared,O
with,O
R37,O
/,O
TcSS,O
(,O
Welch,O
’,O
s,O
t,O
-,O
test,O
",",O
P,O
<,O
0,O
.,O
01,O
).,O
Summary,O
of,O
observed,O
OTUs,O
",",O
Chao1,O
",",O
Shannon,O
and,O
Simpson,O
index,O
in,O
manure,O
(,O
S1,O
and,O
S2,O
correspond,O
to,O
duplicate,O
samples,O
),O
and,O
in,O
laboratory,O
-,O
scale,O
digesters,O
processing,O
:,O
(,O
1,O
),O
manure,O
as,O
sole,O
substrate,O
(,O
RM,O
);,O
(,O
2,O
),O
stream,O
-,O
exploded,O
straw,O
and,O
manure,O
",",O
operating,O
constantly,O
at,O
37,O
°,O
C,O
(,O
RTcSS,O
);,O
and,O
(,O
3,O
),O
steam,O
-,O
exploded,O
straw,O
and,O
manure,O
",",O
operating,O
temperatures,O
37,O
°,O
C,O
",",O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
(,O
R37SS,O
",",O
R44SS,O
and,O
R52SS,O
"),",O
where,O
R1,O
and,O
R2,O
represent,O
parallel,O
digesters,O
Sample,O
Archaea,B-OG
Bacteria,B-OG
Chao1,O
OTUs,O
Shannon,O
Simpson,O
Chao1,O
OTUs,O
Shannon,O
Simpson,O
Manure,O
S1,O
22,O
20,O
2,O
.,O
081,O
0,O
.,O
648,O
358,O
270,O
6,O
.,O
361,O
0,O
.,O
971,O
Manure,O
S2,O
27,O
25,O
2,O
.,O
404,O
0,O
.,O
693,O
420,O
274,O
6,O
.,O
167,O
0,O
.,O
957,O
RM,O
Day,O
42,O
69,O
23,O
2,O
.,O
028,O
0,O
.,O
639,O
487,O
266,O
6,O
.,O
355,O
0,O
.,O
975,O
RM,O
Day,O
85,O
18,O
13,O
1,O
.,O
848,O
0,O
.,O
607,O
553,O
277,O
6,O
.,O
292,O
0,O
.,O
972,O
RM,O
Day,O
148,O
22,O
18,O
1,O
.,O
870,O
0,O
.,O
597,O
440,O
253,O
5,O
.,O
819,O
0,O
.,O
956,O
RTcSS,O
R1,O
Day,O
9,O
26,O
18,O
2,O
.,O
369,O
0,O
.,O
747,O
320,O
191,O
4,O
.,O
896,O
0,O
.,O
910,O
RTcSS,O
R2,O
Day,O
9,O
26,O
20,O
2,O
.,O
367,O
0,O
.,O
723,O
371,O
225,O
5,O
.,O
550,O
0,O
.,O
949,O
R37SS,O
R1,O
Day,O
9,O
20,O
17,O
2,O
.,O
271,O
0,O
.,O
736,O
398,O
209,O
5,O
.,O
221,O
0,O
.,O
932,O
R37SS,O
R2,O
Day,O
9,O
28,O
22,O
2,O
.,O
309,O
0,O
.,O
714,O
425,O
203,O
5,O
.,O
197,O
0,O
.,O
934,O
RTcSS,O
R1,O
Day,O
38,O
23,O
20,O
2,O
.,O
643,O
0,O
.,O
777,O
309,O
197,O
5,O
.,O
463,O
0,O
.,O
952,O
RTcSS,O
R2,O
Day,O
38,O
47,O
24,O
2,O
.,O
612,O
0,O
.,O
759,O
319,O
198,O
5,O
.,O
524,O
0,O
.,O
953,O
R37SS,O
R1,O
Day,O
38,O
22,O
20,O
2,O
.,O
295,O
0,O
.,O
737,O
325,O
212,O
5,O
.,O
377,O
0,O
.,O
936,O
R37SS,O
R2,O
Day,O
38,O
28,O
23,O
2,O
.,O
117,O
0,O
.,O
632,O
398,O
209,O
5,O
.,O
494,O
0,O
.,O
951,O
RTcSS,O
R1,O
Day,O
80,O
55,O
20,O
2,O
.,O
390,O
0,O
.,O
744,O
421,O
244,O
6,O
.,O
134,O
0,O
.,O
969,O
RTcSS,O
R2,O
Day,O
80,O
26,O
21,O
2,O
.,O
237,O
0,O
.,O
682,O
315,O
217,O
5,O
.,O
811,O
0,O
.,O
959,O
R37SS,O
R1,O
Day,O
80,O
21,O
18,O
1,O
.,O
740,O
0,O
.,O
533,O
374,O
229,O
5,O
.,O
688,O
0,O
.,O
950,O
R37SS,O
R2,O
Day,O
80,O
101,O
23,O
2,O
.,O
438,O
0,O
.,O
751,O
358,O
234,O
5,O
.,O
819,O
0,O
.,O
948,O
RTcSS,O
R1,O
Day,O
99,O
21,O
18,O
2,O
.,O
000,O
0,O
.,O
639,O
375,O
235,O
5,O
.,O
988,O
0,O
.,O
965,O
RTcSS,O
R2,O
Day,O
99,O
44,O
16,O
1,O
.,O
704,O
0,O
.,O
569,O
334,O
221,O
5,O
.,O
900,O
0,O
.,O
959,O
R37SS,O
R1,O
Day,O
99,O
32,O
22,O
2,O
.,O
530,O
0,O
.,O
736,O
321,O
232,O
6,O
.,O
064,O
0,O
.,O
968,O
R37SS,O
R2,O
Day,O
99,O
78,O
23,O
2,O
.,O
399,O
0,O
.,O
729,O
391,O
224,O
5,O
.,O
827,O
0,O
.,O
959,O
R44SS,O
R1,O
Day,O
224,O
21,O
14,O
1,O
.,O
618,O
0,O
.,O
594,O
191,O
156,O
5,O
.,O
015,O
0,O
.,O
923,O
R44SS,O
R2,O
Day,O
224,O
22,O
15,O
1,O
.,O
456,O
0,O
.,O
545,O
255,O
158,O
4,O
.,O
906,O
0,O
.,O
926,O
R52SS,O
R1,O
Day,O
402,O
13,O
12,O
2,O
.,O
150,O
0,O
.,O
718,O
149,O
112,O
3,O
.,O
446,O
0,O
.,O
717,O
R52SS,O
R2,O
Day,O
402,O
17,O
15,O
2,O
.,O
233,O
0,O
.,O
731,O
165,O
119,O
4,O
.,O
023,O
0,O
.,O
787,O
(,O
A,O
),O
Archaeal,O
and,O
(,O
B,O
),O
bacterial,O
phylogenetic,O
distances,O
between,O
samples,O
as,O
determined,O
by,O
unweighted,O
UniFrac,O
principal,O
coordinate,O
analysis,O
(,O
red,O
=,O
manure,O
;,O
blue,O
=,O
digester,O
RM,O
;,O
orange,O
=,O
digester,O
RTcSS,O
and,O
R37SS,O
;,O
green,O
=,O
digester,O
R44SS,O
;,O
purple,O
=,O
digester,O
R52SS,O
).,O
Comparative,O
analysis,O
of,O
archaeal,O
communities,O
across,O
samples,O
For,O
archaea,B-OG
",",O
the,O
OTU,O
table,O
was,O
randomly,O
subsampled,O
640,O
times,O
prior,O
to,O
downstream,O
analysis,O
.,O
It,O
was,O
possible,O
to,O
assign,O
more,O
than,O
99,O
.,O
6,O
%,O
of,O
the,O
sequences,O
at,O
the,O
phylum,O
level,O
",",O
among,O
which,O
more,O
than,O
98,O
.,O
1,O
%,O
belonged,O
to,O
the,O
phylum,O
Euryarchaeota,B-OG
(,O
mainly,O
the,O
classes,O
Methanomicrobia,B-OG
and,O
Methanobacteria,B-OG
).,O
The,O
rest,O
of,O
the,O
sequences,O
(<,O
1,O
.,O
9,O
%),O
were,O
represented,O
by,O
Crenarchaeota,B-OG
and,O
unclassified,O
sequences,O
.,O
For,O
each,O
sample,O
",",O
at,O
least,O
95,O
.,O
1,O
%,O
of,O
the,O
sequences,O
could,O
be,O
assigned,O
to,O
genus,O
level,O
(,O
Fig,O
.,O
2,O
).,O
Methanosarcina,B-OG
from,O
the,O
order,O
Methanosarcinales,B-OG
",",O
known,O
to,O
utilize,O
both,O
acetate,O
and,O
hydrogen,O
",",O
was,O
the,O
most,O
dominant,O
genus,O
in,O
digesters,O
RM,O
(,O
97,O
.,O
4,O
–,O
99,O
.,O
5,O
"%),",O
RTcSS,O
and,O
R37SS,O
(,O
90,O
.,O
3,O
–,O
98,O
.,O
8,O
"%),",O
R44SS,O
(,O
96,O
.,O
9,O
–,O
97,O
.,O
7,O
"%),",O
and,O
R52SS,O
(,O
74,O
.,O
1,O
–,O
77,O
.,O
1,O
"%),",O
while,O
this,O
genus,O
represented,O
only,O
1,O
.,O
3,O
%,O
and,O
6,O
.,O
4,O
%,O
of,O
the,O
reads,O
from,O
the,O
two,O
manure,O
samples,O
.,O
Sequences,O
belonging,O
to,O
the,O
acetoclastic,B-OG
methanogen,I-OG
",",O
Methanosaeta,B-OG
",",O
were,O
only,O
detected,O
in,O
two,O
samples,O
and,O
at,O
a,O
low,O
level,O
",",O
in,O
RM,O
on,O
day,O
42,O
(,O
1,O
.,O
1,O
%),O
and,O
in,O
RTcSS,O
R1,O
on,O
day,O
9,O
(,O
0,O
.,O
2,O
%).,O
For,O
hydrogenotrophic,B-OG
methanogens,I-OG
",",O
the,O
genus,O
Methanoculleus,B-OG
represented,O
less,O
than,O
0,O
.,O
3,O
%,O
in,O
all,O
digesters,O
operating,O
at,O
37,O
°,O
C,O
and,O
44,O
°,O
C,O
",",O
but,O
corresponded,O
to,O
6,O
.,O
9,O
–,O
11,O
.,O
9,O
%,O
in,O
R52SS,O
.,O
In,O
the,O
manure,O
samples,O
",",O
the,O
genus,O
Methanoculleus,B-OG
represented,O
less,O
than,O
0,O
.,O
4,O
%,O
of,O
the,O
community,O
;,O
instead,O
",",O
the,O
archaeal,O
community,O
was,O
dominated,O
by,O
Methanobrevibacter,B-OG
from,O
the,O
order,O
Methanobacteriales,B-OG
(,O
85,O
.,O
2,O
%,O
and,O
93,O
.,O
3,O
%).,O
However,O
",",O
the,O
levels,O
of,O
Methanobrevibacter,B-OG
were,O
low,O
in,O
all,O
digesters,O
(<,O
3,O
.,O
1,O
%).,O
In,O
addition,O
",",O
sequences,O
related,O
to,O
the,O
genus,O
Methanobacterium,B-OG
were,O
found,O
at,O
low,O
levels,O
in,O
the,O
low,O
-,O
medium,O
temperature,O
digesters,O
(,O
37,O
–,O
44,O
°,O
C,O
),O
and,O
in,O
the,O
manure,O
(<,O
2,O
.,O
5,O
"%),",O
but,O
were,O
more,O
abundant,O
at,O
the,O
higher,O
digestion,O
temperature,O
(,O
12,O
.,O
3,O
–,O
14,O
.,O
4,O
%,O
in,O
R52SS,O
).,O
Relative,O
abundance,O
of,O
archaea,B-OG
16S,O
rRNA,O
gene,O
at,O
the,O
genus,O
level,O
in,O
manure,O
(,O
S1,O
and,O
S2,O
correspond,O
to,O
duplicate,O
samples,O
),O
and,O
in,O
laboratory,O
-,O
scale,O
digesters,O
processing,O
:,O
(,O
1,O
),O
manure,O
as,O
sole,O
substrate,O
(,O
RM,O
);,O
(,O
2,O
),O
stream,O
-,O
exploded,O
straw,O
and,O
manure,O
",",O
operating,O
constantly,O
at,O
37,O
°,O
C,O
(,O
RTcSS,O
);,O
and,O
(,O
3,O
),O
steam,O
-,O
exploded,O
straw,O
and,O
manure,O
",",O
operating,O
temperatures,O
37,O
°,O
C,O
",",O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
(,O
R37SS,O
",",O
R44SS,O
and,O
R52SS,O
"),",O
where,O
R1,O
and,O
R2,O
represent,O
parallel,O
digesters,O
.,O
Comparative,O
analysis,O
of,O
bacterial,O
communities,O
across,O
samples,O
The,O
bacterial,O
OTU,O
table,O
was,O
rarefied,O
1700,O
times,O
according,O
to,O
the,O
sample,O
having,O
the,O
lowest,O
sequence,O
counts,O
.,O
It,O
was,O
possible,O
to,O
assign,O
at,O
least,O
97,O
.,O
2,O
%,O
of,O
the,O
sequence,O
reads,O
at,O
the,O
phylum,O
level,O
.,O
However,O
",",O
only,O
10,O
.,O
7,O
–,O
38,O
.,O
8,O
%,O
of,O
total,O
sequences,O
could,O
be,O
allocated,O
to,O
known,O
genus,O
(,O
Fig,O
.,O
S2,O
).,O
Firmicutes,B-OG
",",O
Bacteroidetes,B-OG
and,O
Cloacimonetes,B-OG
were,O
identified,O
as,O
the,O
three,O
most,O
dominant,O
phyla,O
within,O
the,O
bacterial,O
community,O
(,O
Fig,O
.,O
S3,O
).,O
In,O
addition,O
",",O
sequences,O
belonging,O
to,O
Acidobacteria,B-OG
",",O
Actinobacteria,B-OG
",",O
Chloroflexi,B-OG
",",O
Fibrobacteres,B-OG
",",O
Planctomycetes,B-OG
",",O
Proteobacteria,B-OG
",",O
Synergistetes,B-OG
",",O
Tenericutes,B-OG
",",O
Thermi,B-OG
and,O
Verrucomicrobia,B-OG
were,O
detected,O
in,O
some,O
of,O
the,O
samples,O
",",O
but,O
at,O
low,O
occurrence,O
(,O
below,O
3,O
.,O
3,O
%,O
for,O
each,O
sample,O
).,O
Firmicutes,B-OG
was,O
observed,O
in,O
all,O
digesters,O
as,O
well,O
as,O
in,O
the,O
manure,O
samples,O
",",O
with,O
the,O
highest,O
relative,O
abundance,O
in,O
the,O
digesters,O
operated,O
at,O
52,O
°,O
C,O
(,O
97,O
.,O
6,O
–,O
97,O
.,O
8,O
"%),",O
followed,O
by,O
the,O
digesters,O
operated,O
at,O
44,O
°,O
C,O
(,O
76,O
.,O
5,O
–,O
82,O
.,O
5,O
%).,O
In,O
the,O
remaining,O
samples,O
",",O
the,O
relative,O
abundance,O
of,O
sequences,O
belonging,O
to,O
this,O
phylum,O
was,O
56,O
.,O
8,O
–,O
74,O
.,O
1,O
%,O
(,O
manure,O
"),",O
45,O
.,O
9,O
–,O
50,O
.,O
4,O
%,O
(,O
RM,O
",",O
digester,O
operated,O
with,O
manure,O
alone,O
),O
and,O
32,O
.,O
6,O
–,O
49,O
.,O
5,O
%,O
(,O
R37SS,O
and,O
RTcSS,O
",",O
Fig,O
.,O
S3,O
).,O
Within,O
the,O
Firmicutes,B-OG
",",O
sequences,O
belonging,O
to,O
the,O
classes,O
Bacilli,B-OG
and,O
Clostridia,B-OG
dominated,O
(,O
Fig,O
.,O
3,O
).,O
The,O
class,O
Clostridia,B-OG
was,O
represented,O
in,O
similar,O
levels,O
in,O
the,O
digesters,O
operated,O
at,O
37,O
°,O
C,O
(,O
26,O
.,O
8,O
–,O
41,O
.,O
9,O
%),O
and,O
in,O
the,O
manure,O
samples,O
(,O
30,O
.,O
4,O
–,O
34,O
.,O
9,O
%).,O
However,O
",",O
in,O
line,O
with,O
the,O
increase,O
in,O
operating,O
temperature,O
",",O
the,O
relative,O
abundance,O
of,O
sequences,O
within,O
this,O
class,O
increased,O
and,O
was,O
66,O
.,O
8,O
–,O
77,O
.,O
2,O
%,O
and,O
92,O
.,O
4,O
–,O
93,O
.,O
8,O
%,O
in,O
R44SS,O
and,O
R52SS,O
respectively,O
.,O
Within,O
the,O
class,O
Clostridia,B-OG
",",O
sequences,O
belonging,O
to,O
the,O
order,O
Clostridiales,B-OG
and,O
to,O
the,O
uncultured,O
order,O
MBA08,O
were,O
found,O
to,O
be,O
dominant,O
(,O
Fig,O
.,O
4,O
).,O
Clostridiales,B-OG
was,O
present,O
in,O
manure,O
(,O
29,O
.,O
4,O
–,O
33,O
.,O
7,O
%),O
and,O
all,O
digesters,O
(,O
10,O
.,O
1,O
–,O
38,O
.,O
8,O
),O
with,O
the,O
lowest,O
relative,O
abundance,O
at,O
52,O
°,O
C,O
(,O
10,O
.,O
1,O
–,O
15,O
.,O
0,O
"%),",O
while,O
MBA08,O
was,O
not,O
detected,O
in,O
manure,O
but,O
in,O
all,O
digesters,O
(,O
1,O
.,O
9,O
–,O
74,O
.,O
4,O
%),O
with,O
the,O
highest,O
relative,O
abundance,O
at,O
52,O
°,O
C,O
(,O
67,O
.,O
1,O
–,O
74,O
.,O
4,O
%).,O
Within,O
the,O
order,O
Clostridiales,B-OG
",",O
the,O
families,O
Peptostreptococcaceae,B-OG
(,O
5,O
.,O
4,O
–,O
18,O
.,O
1,O
%),O
and,O
Clostridiaceae,B-OG
(,O
2,O
.,O
2,O
–,O
11,O
.,O
1,O
%),O
were,O
identified,O
as,O
the,O
major,O
groups,O
.,O
In,O
addition,O
",",O
Lachnospiraceae,B-OG
",",O
Ruminococcaceae,B-OG
",",O
Syntrophomonadaceae,B-OG
",",O
Peptococcaceae,B-OG
",",O
Catabacteriaceae,B-OG
",",O
Eubacteriaceae,B-OG
and,O
Veillonellaceae,B-OG
were,O
present,O
at,O
lower,O
levels,O
(,O
data,O
not,O
shown,O
).,O
Within,O
the,O
Clostridiaceae,B-OG
",",O
sequences,O
belonging,O
to,O
the,O
genera,O
Clostridium,B-OG
and,O
Sedimentibacter,B-OG
dominated,O
(,O
Fig,O
.,O
S2,O
).,O
Clostridium,B-OG
was,O
detected,O
in,O
all,O
sampling,O
points,O
(,O
0,O
.,O
7,O
–,O
4,O
.,O
4,O
%).,O
Sedimentibacter,B-OG
was,O
absent,O
in,O
R52SS,O
but,O
detected,O
in,O
the,O
other,O
samples,O
",",O
with,O
a,O
slightly,O
higher,O
level,O
in,O
digesters,O
receiving,O
straw,O
(,O
3,O
.,O
0,O
–,O
6,O
.,O
9,O
%).,O
For,O
the,O
class,O
Bacilli,B-OG
",",O
a,O
higher,O
relative,O
abundance,O
was,O
seen,O
in,O
the,O
manure,O
samples,O
(,O
23,O
.,O
5,O
–,O
36,O
.,O
2,O
%),O
than,O
in,O
all,O
digester,O
samples,O
(,O
2,O
.,O
3,O
–,O
8,O
.,O
6,O
"%,",O
Fig,O
.,O
3,O
).,O
The,O
orders,O
Lactobacillales,B-OG
and,O
Turicibacterales,B-OG
represented,O
the,O
major,O
fraction,O
of,O
sequences,O
within,O
this,O
class,O
in,O
all,O
samples,O
(,O
Fig,O
.,O
4,O
).,O
Lactobacillales,B-OG
had,O
a,O
higher,O
relative,O
abundance,O
in,O
manure,O
samples,O
compared,O
with,O
digester,O
samples,O
.,O
Relative,O
abundance,O
of,O
bacterial,O
16S,O
rRNA,O
gene,O
at,O
the,O
class,O
level,O
in,O
manure,O
(,O
S1,O
and,O
S2,O
correspond,O
to,O
duplicate,O
samples,O
),O
and,O
in,O
laboratory,O
-,O
scale,O
digesters,O
processing,O
:,O
(,O
1,O
),O
manure,O
as,O
sole,O
substrate,O
(,O
RM,O
);,O
(,O
2,O
),O
stream,O
-,O
exploded,O
straw,O
and,O
manure,O
",",O
operating,O
constantly,O
at,O
37,O
°,O
C,O
(,O
RTcSS,O
);,O
and,O
(,O
3,O
),O
steam,O
-,O
exploded,O
straw,O
and,O
manure,O
",",O
operating,O
temperatures,O
37,O
°,O
C,O
",",O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
(,O
R37SS,O
",",O
R44SS,O
and,O
R52SS,O
"),",O
where,O
R1,O
and,O
R2,O
represent,O
parallel,O
digesters,O
.,O
Relative,O
abundance,O
of,O
bacterial,O
16S,O
rRNA,O
gene,O
at,O
the,O
order,O
level,O
in,O
manure,O
(,O
S1,O
and,O
S2,O
correspond,O
to,O
duplicate,O
samples,O
),O
and,O
in,O
laboratory,O
-,O
scale,O
digesters,O
processing,O
:,O
(,O
1,O
),O
manure,O
as,O
sole,O
substrate,O
(,O
RM,O
);,O
(,O
2,O
),O
stream,O
-,O
exploded,O
straw,O
and,O
manure,O
",",O
operating,O
constantly,O
at,O
37,O
°,O
C,O
(,O
RTcSS,O
);,O
and,O
(,O
3,O
),O
steam,O
-,O
exploded,O
straw,O
and,O
manure,O
",",O
operating,O
temperatures,O
37,O
°,O
C,O
",",O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
(,O
R37SS,O
",",O
R44SS,O
and,O
R52SS,O
"),",O
where,O
R1,O
and,O
R2,O
represent,O
parallel,O
digesters,O
.,O
For,O
the,O
phylum,O
Bacteroidetes,B-OG
",",O
the,O
class,O
Bacteroidia,B-OG
represented,O
more,O
than,O
98,O
.,O
8,O
%,O
of,O
the,O
sequences,O
in,O
all,O
samples,O
(,O
Fig,O
.,O
3,O
).,O
However,O
",",O
at,O
the,O
genus,O
level,O
",",O
most,O
of,O
the,O
sequences,O
within,O
this,O
phylum,O
were,O
represented,O
by,O
uncultured,O
clones,O
.,O
The,O
relative,O
level,O
of,O
the,O
phylum,O
Bacteroidetes,B-OG
in,O
the,O
digester,O
operating,O
with,O
manure,O
was,O
similar,O
to,O
that,O
in,O
the,O
raw,O
manure,O
(,O
21,O
.,O
0,O
–,O
39,O
.,O
4,O
"%),",O
but,O
lower,O
than,O
that,O
in,O
the,O
digesters,O
co,O
-,O
digesting,O
straw,O
at,O
37,O
°,O
C,O
(,O
40,O
.,O
0,O
–,O
65,O
.,O
1,O
%).,O
In,O
contrast,O
to,O
the,O
response,O
to,O
straw,O
addition,O
",",O
the,O
relative,O
abundance,O
of,O
Bacteroidetes,B-OG
decreased,O
with,O
increased,O
operating,O
temperature,O
.,O
At,O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
",",O
Bacteroidetes,B-OG
represented,O
13,O
.,O
2,O
–,O
16,O
.,O
6,O
%,O
and,O
0,O
.,O
40,O
%,O
of,O
the,O
population,O
respectively,O
(,O
Fig,O
.,O
S3,O
).,O
The,O
candidate,O
phylum,O
Cloacimonetes,B-OG
was,O
present,O
at,O
levels,O
corresponding,O
to,O
less,O
than,O
0,O
.,O
2,O
%,O
in,O
the,O
manure,O
samples,O
",",O
but,O
at,O
higher,O
levels,O
in,O
digesters,O
operating,O
with,O
only,O
manure,O
(,O
6,O
.,O
0,O
–,O
14,O
.,O
5,O
%),O
(,O
Fig,O
.,O
S3,O
).,O
In,O
the,O
digesters,O
operating,O
with,O
straw,O
",",O
the,O
level,O
of,O
this,O
phylum,O
varied,O
from,O
0,O
.,O
30,O
%,O
to,O
10,O
.,O
3,O
%,O
during,O
operation,O
at,O
37,O
°,O
C,O
",",O
and,O
it,O
was,O
not,O
detected,O
at,O
all,O
in,O
digesters,O
operated,O
at,O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
.,O
Within,O
all,O
the,O
digesters,O
operated,O
at,O
37,O
°,O
C,O
",",O
sequences,O
belonging,O
to,O
the,O
uncultured,O
cluster,O
WWE1,O
(,O
at,O
class,O
level,O
),O
contributed,O
to,O
the,O
majority,O
of,O
this,O
phylum,O
(,O
Fig,O
.,O
3,O
).,O
Discussion,O
The,O
sequence,O
analysis,O
showed,O
that,O
the,O
microbial,O
community,O
structure,O
in,O
digesters,O
with,O
the,O
same,O
treatment,O
and,O
in,O
parallel,O
digesters,O
was,O
relatively,O
stable,O
and,O
similar,O
over,O
the,O
whole,O
operating,O
period,O
.,O
This,O
stability,O
indicates,O
that,O
the,O
differences,O
in,O
communities,O
observed,O
for,O
different,O
groups,O
of,O
digesters,O
in,O
the,O
present,O
study,O
were,O
caused,O
by,O
different,O
operating,O
conditions,O
(,O
i,O
.,O
e,O
.,O
temperature,O
",",O
substrate,O
),O
and,O
not,O
just,O
by,O
variations,O
due,O
to,O
time,O
.,O
For,O
archaea,B-OG
",",O
the,O
dominant,O
phylum,O
was,O
Euryarchaeota,B-OG
",",O
as,O
found,O
previously,O
in,O
other,O
pyrosequencing,O
studies,O
on,O
anaerobic,O
digesters,O
(,O
Cardinali,O
-,O
Rezende,O
et,O
al,O
".,",O
2009,O
;,O
Riviere,O
et,O
al,O
".,",O
2009,O
;,O
Ritari,O
et,O
al,O
".,",O
2012,O
;,O
Zakrzewski,O
et,O
al,O
".,",O
2012,O
).,O
For,O
bacteria,B-OG
",",O
Firmicutes,B-OG
and,O
Bacteroidetes,B-OG
have,O
been,O
repeatedly,O
identified,O
as,O
the,O
main,O
phyla,O
in,O
various,O
anaerobic,O
digesters,O
(,O
Klocke,O
et,O
al,O
".,",O
2007,O
;,O
Garcia,O
et,O
al,O
".,",O
2011,O
;,O
Jaenicke,O
et,O
al,O
".,",O
2011,O
;,O
Kampmann,O
et,O
al,O
".,",O
2012,O
;,O
St,O
-,O
Pierre,O
and,O
Wright,O
",",O
2014,O
;,O
Lucas,O
et,O
al,O
".,",O
2015,O
).,O
The,O
presence,O
of,O
large,O
proportions,O
of,O
unknown,O
sequences,O
at,O
the,O
genus,O
level,O
",",O
as,O
observed,O
here,O
",",O
has,O
also,O
been,O
reported,O
in,O
other,O
amplicon,O
sequencing,O
studies,O
(,O
Zakrzewski,O
et,O
al,O
".,",O
2012,O
;,O
Lu,O
et,O
al,O
".,",O
2013,O
;,O
Li,O
et,O
al,O
".,",O
2014,O
;,O
Smith,O
et,O
al,O
".,",O
2014,O
"),",O
as,O
well,O
as,O
during,O
construction,O
of,O
the,O
a,O
16S,O
rDNA,O
clone,O
library,O
(,O
Liu,O
et,O
al,O
".,",O
2009,O
).,O
It,O
is,O
clear,O
that,O
isolation,O
and,O
cultivation,O
of,O
uncultured,O
microorganisms,B-OG
would,O
provide,O
deeper,O
insights,O
into,O
their,O
function,O
in,O
the,O
AD,O
process,O
",",O
as,O
suggested,O
previously,O
(,O
Narihiro,O
and,O
Sekiguchi,O
",",O
2007,O
;,O
Curtis,O
et,O
al,O
".,",O
2013,O
).,O
Manure,O
versus,O
mesophilic,O
AD,O
of,O
manure,O
Manure,O
can,O
be,O
used,O
as,O
the,O
sole,O
substrate,O
during,O
AD,O
",",O
but,O
typically,O
results,O
in,O
low,O
biogas,O
yields,O
(,O
Mata,O
-,O
Alvarez,O
et,O
al,O
".,",O
2000,O
;,O
Angelidaki,O
and,O
Ellegaard,O
",",O
2003,O
).,O
Co,O
-,O
digestion,O
with,O
more,O
energy,O
-,O
rich,O
materials,O
can,O
result,O
in,O
higher,O
yields,O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
presence,O
of,O
manure,O
can,O
be,O
a,O
precondition,O
for,O
enabling,O
AD,O
of,O
materials,O
with,O
a,O
high,O
C,O
/,O
N,O
ratio,O
and,O
low,O
buffering,O
capacity,O
",",O
such,O
as,O
straw,O
(,O
Mata,O
-,O
Alvarez,O
et,O
al,O
".,",O
2014,O
).,O
Manure,O
contributes,O
nitrogen,O
",",O
trace,O
elements,O
and,O
buffering,O
components,O
",",O
and,O
thus,O
creates,O
more,O
suitable,O
conditions,O
for,O
the,O
growth,O
of,O
microbes,B-OG
",",O
including,O
methanogens,B-OG
",",O
in,O
the,O
AD,O
process,O
(,O
Mata,O
-,O
Alvarez,O
et,O
al,O
".,",O
2000,O
).,O
Possibly,O
",",O
effects,O
by,O
manure,O
could,O
also,O
be,O
caused,O
by,O
microbial,O
inoculation,O
.,O
It,O
is,O
well,O
known,O
that,O
the,O
rumen,O
has,O
high,O
cellulose,O
-,O
degrading,O
efficiency,O
and,O
the,O
bacteria,B-OG
involved,O
in,O
this,O
may,O
also,O
be,O
involved,O
in,O
degradation,O
in,O
the,O
AD,O
process,O
.,O
Methanogens,B-OG
active,O
in,O
the,O
rumen,O
may,O
also,O
contribute,O
to,O
methanogenesis,O
in,O
the,O
biogas,O
production,O
process,O
.,O
In,O
our,O
diversity,O
index,O
analysis,O
of,O
the,O
archaeal,O
and,O
bacterial,O
communities,O
",",O
no,O
difference,O
was,O
observed,O
between,O
the,O
manure,O
and,O
the,O
digester,O
operated,O
with,O
manure,O
(,O
Table,O
1,O
).,O
However,O
",",O
community,O
composition,O
analysis,O
revealed,O
a,O
clear,O
difference,O
between,O
the,O
digester,O
and,O
the,O
manure,O
for,O
both,O
archaea,B-OG
and,O
bacteria,B-OG
(,O
Figs,O
4,O
).,O
In,O
the,O
manure,O
samples,O
",",O
Methanobrevibacter,B-OG
from,O
the,O
order,O
Methanobacteriales,B-OG
was,O
the,O
most,O
dominant,O
archaeal,O
genus,O
(,O
85,O
.,O
2,O
%,O
and,O
93,O
.,O
3,O
"%),",O
showing,O
similarity,O
to,O
the,O
methanogenic,O
community,O
structure,O
in,O
the,O
rumen,O
of,O
cows,B-OG
(,O
Janssen,O
and,O
Kirs,O
",",O
2008,O
;,O
Danielsson,O
et,O
al,O
".,",O
2012,O
).,O
However,O
",",O
when,O
the,O
manure,O
was,O
used,O
as,O
substrate,O
for,O
biogas,O
production,O
",",O
the,O
number,O
of,O
sequences,O
affiliated,O
to,O
this,O
hydrogenotrophic,O
genus,O
represented,O
less,O
than,O
3,O
.,O
2,O
%,O
and,O
instead,O
the,O
Methanosarcina,B-OG
became,O
dominant,O
(>,O
97,O
%).,O
The,O
cause,O
of,O
the,O
decrease,O
in,O
relative,O
abundance,O
of,O
Methanobrevibacter,B-OG
is,O
not,O
clear,O
.,O
The,O
dominance,O
of,O
Methanosarcina,B-OG
is,O
",",O
however,O
",",O
in,O
line,O
with,O
previous,O
studies,O
of,O
manure,O
-,O
based,O
digesters,O
(,O
Karakashev,O
et,O
al,O
".,",O
2005,O
;,O
Demirel,O
and,O
Scherer,O
",",O
2008,O
;,O
Goberna,O
et,O
al,O
".,",O
2010,O
;,O
St,O
-,O
Pierre,O
and,O
Wright,O
",",O
2014,O
).,O
High,O
abundance,O
of,O
this,O
methanogen,B-OG
has,O
been,O
suggested,O
to,O
be,O
caused,O
by,O
its,O
relatively,O
high,O
growth,O
rate,O
and,O
ability,O
to,O
tolerate,O
conditions,O
inhibitory,O
to,O
other,O
methanogens,B-OG
",",O
such,O
as,O
presence,O
of,O
ammonia,O
(,O
De,O
Vrieze,O
et,O
al,O
".,",O
2012,O
).,O
However,O
",",O
the,O
digesters,O
investigated,O
in,O
this,O
study,O
had,O
low,O
levels,O
of,O
ammonia,O
",",O
and,O
similar,O
to,O
the,O
manure,O
(,O
Risberg,O
et,O
al,O
".,",O
2013,O
"),",O
thus,O
this,O
parameter,O
is,O
not,O
the,O
likely,O
cause,O
for,O
the,O
shift,O
in,O
the,O
methanogenic,O
community,O
.,O
Methanosarcina,B-OG
can,O
also,O
use,O
the,O
hydrogenotrophic,O
pathway,O
for,O
methanogenesis,O
",",O
unlike,O
the,O
other,O
acetotrophic,O
methanogen,B-OG
Methanosaeta,B-OG
",",O
and,O
this,O
might,O
also,O
enhance,O
its,O
competitive,O
ability,O
",",O
even,O
at,O
low,O
acetate,O
levels,O
as,O
prevailing,O
in,O
the,O
investigated,O
digesters,O
(,O
De,O
Vrieze,O
et,O
al,O
".,",O
2012,O
).,O
Another,O
possible,O
explanation,O
for,O
the,O
dominance,O
of,O
this,O
methanogen,B-OG
is,O
the,O
once,O
-,O
per,O
-,O
day,O
feeding,O
regime,O
",",O
which,O
has,O
been,O
reported,O
before,O
to,O
select,O
for,O
Methanosarcina,B-OG
rather,O
than,O
Methanosaeta,B-OG
(,O
Conklin,O
et,O
al,O
".,",O
2006,O
).,O
Analysis,O
of,O
the,O
bacterial,O
community,O
identified,O
Bacteroidetes,B-OG
(,O
21,O
.,O
0,O
–,O
39,O
.,O
4,O
%),O
and,O
Firmicutes,B-OG
(,O
45,O
.,O
9,O
–,O
74,O
.,O
1,O
%),O
as,O
the,O
major,O
phyla,O
in,O
both,O
the,O
manure,O
samples,O
and,O
the,O
digesters,O
operating,O
with,O
manure,O
(,O
Fig,O
.,O
S3,O
).,O
This,O
confirms,O
previous,O
findings,O
on,O
bacterial,O
populations,O
in,O
the,O
rumen,O
of,O
cows,B-OG
(,O
Kim,O
et,O
al,O
".,",O
2011,O
;,O
Danielsson,O
et,O
al,O
".,",O
2012,O
"),",O
manure,O
digesters,O
(,O
Kampmann,O
et,O
al,O
".,",O
2012,O
;,O
St,O
-,O
Pierre,O
and,O
Wright,O
",",O
2014,O
),O
and,O
other,O
biogas,O
digesters,O
(,O
Krause,O
et,O
al,O
".,",O
2008,O
;,O
Schlüter,O
et,O
al,O
".,",O
2008,O
;,O
Lee,O
et,O
al,O
".,",O
2012,O
;,O
Sundberg,O
et,O
al,O
".,",O
2013,O
;,O
Ziganshin,O
et,O
al,O
".,",O
2013,O
;,O
Li,O
et,O
al,O
".,",O
2014,O
).,O
However,O
",",O
as,O
for,O
the,O
archaeal,O
population,O
",",O
statistical,O
analysis,O
revealed,O
that,O
the,O
bacterial,O
community,O
in,O
the,O
digester,O
was,O
separated,O
from,O
the,O
manure,O
sample,O
(,O
Fig,O
.,O
1B,O
).,O
This,O
was,O
most,O
likely,O
caused,O
by,O
the,O
substantially,O
higher,O
amount,O
(,O
6,O
.,O
0,O
–,O
14,O
.,O
5,O
%),O
of,O
sequences,O
related,O
to,O
the,O
candidate,O
phylum,O
Cloacimonetes,B-OG
in,O
the,O
manure,O
digesters,O
than,O
in,O
the,O
manure,O
itself,O
.,O
Representatives,O
of,O
this,O
phylum,O
seem,O
not,O
to,O
be,O
specific,O
for,O
manure,O
as,O
they,O
have,O
been,O
detected,O
also,O
in,O
digesters,O
operating,O
with,O
other,O
substrates,O
(,O
Cardinali,O
-,O
Rezende,O
et,O
al,O
".,",O
2009,O
;,O
Sundberg,O
et,O
al,O
".,",O
2013,O
;,O
Li,O
et,O
al,O
".,",O
2014,O
),O
and,O
in,O
the,O
rumen,O
(,O
Piao,O
et,O
al,O
".,",O
2014,O
).,O
In,O
the,O
present,O
study,O
",",O
sequences,O
belonging,O
to,O
the,O
uncultured,O
WWE1,O
contributed,O
to,O
the,O
majority,O
of,O
the,O
candidate,O
phylum,O
Cloacimonetes,B-OG
(,O
Fig,O
.,O
3,O
).,O
This,O
uncultured,O
cluster,O
was,O
first,O
discovered,O
as,O
a,O
subdominant,O
group,O
(,O
up,O
to,O
10,O
%),O
in,O
an,O
anaerobic,O
sludge,O
digester,O
(,O
Chouari,O
et,O
al,O
".,",O
2005,O
"),",O
but,O
later,O
also,O
in,O
other,O
anaerobic,O
digesters,O
(,O
Riviere,O
et,O
al,O
".,",O
2009,O
;,O
Lucas,O
et,O
al,O
".,",O
2015,O
).,O
The,O
genome,O
of,O
one,O
species,O
from,O
this,O
phylum,O
",",O
namely,O
‘,O
Candidatus,B-OG
Cloacamonas,I-OG
acidaminovorans,I-OG
"’,",O
was,O
recovered,O
from,O
a,O
metagenomic,O
study,O
",",O
which,O
suggested,O
it,O
as,O
a,O
syntrophic,O
bacterium,B-OG
capable,O
of,O
degrading,O
propionate,O
and,O
amino,O
acids,O
(,O
Pelletier,O
et,O
al,O
".,",O
2008,O
).,O
In,O
a,O
recent,O
study,O
",",O
evidence,O
emerged,O
suggesting,O
that,O
this,O
group,O
of,O
bacteria,B-OG
also,O
is,O
involved,O
in,O
the,O
AD,O
of,O
cellulose,O
",",O
through,O
an,O
extracellular,O
cellulose,O
hydrolysis,O
process,O
and,O
/,O
or,O
in,O
the,O
fermentation,O
of,O
organic,O
substrates,O
originating,O
from,O
cellulose,O
(,O
Limam,O
et,O
al,O
".,",O
2014,O
).,O
Variation,O
in,O
the,O
bacterial,O
community,O
between,O
the,O
manure,O
and,O
the,O
digester,O
was,O
also,O
seen,O
at,O
different,O
taxonomic,O
levels,O
",",O
with,O
the,O
most,O
pronounced,O
difference,O
within,O
the,O
phylum,O
Firmicutes,B-OG
.,O
Here,O
",",O
a,O
significantly,O
higher,O
relative,O
abundance,O
of,O
sequences,O
belonging,O
to,O
the,O
order,O
of,O
Lactobacillales,B-OG
(,O
from,O
class,O
Bacilli,B-OG
),O
was,O
observed,O
in,O
the,O
manure,O
samples,O
than,O
in,O
the,O
manure,O
digester,O
.,O
The,O
relative,O
abundance,O
of,O
Clostridia,B-OG
was,O
rather,O
similar,O
in,O
all,O
digesters,O
",",O
which,O
resulted,O
in,O
a,O
higher,O
Clostridia,B-OG
/,O
Bacilli,B-OG
ratio,O
in,O
the,O
manure,O
digester,O
than,O
in,O
the,O
manure,O
itself,O
.,O
A,O
higher,O
level,O
of,O
Clostridia,B-OG
in,O
relation,O
to,O
Bacilli,B-OG
was,O
also,O
seen,O
in,O
a,O
previous,O
study,O
analysing,O
three,O
different,O
manure,O
digesters,O
(,O
St,O
-,O
Pierre,O
and,O
Wright,O
",",O
2014,O
).,O
The,O
cause,O
of,O
the,O
increase,O
in,O
Clostridia,B-OG
/,O
Bacilli,B-OG
ratio,O
in,O
the,O
digesters,O
relative,O
to,O
the,O
manure,O
is,O
not,O
clear,O
",",O
but,O
one,O
possible,O
explanation,O
is,O
that,O
the,O
availability,O
of,O
easily,O
fermentable,O
sugar,O
is,O
comparably,O
lower,O
in,O
the,O
anaerobic,O
digester,O
(,O
Walter,O
et,O
al,O
".,",O
2011,O
).,O
Microbial,O
response,O
caused,O
by,O
straw,O
As,O
described,O
in,O
our,O
previous,O
paper,O
",",O
adding,O
straw,O
(,O
steam,O
-,O
exploded,O
or,O
non,O
-,O
pretreated,O
),O
as,O
a,O
co,O
-,O
substrate,O
during,O
the,O
digestion,O
of,O
manure,O
did,O
not,O
impact,O
on,O
the,O
overall,O
process,O
stability,O
or,O
performance,O
(,O
gas,O
yield,O
and,O
degree,O
of,O
degradation,O
",",O
Risberg,O
et,O
al,O
".,",O
2013,O
);,O
however,O
",",O
a,O
response,O
was,O
obtained,O
for,O
the,O
microbial,O
community,O
.,O
For,O
archaea,B-OG
",",O
no,O
difference,O
was,O
observed,O
for,O
the,O
major,O
population,O
during,O
operation,O
at,O
37,O
°,O
C,O
with,O
manure,O
as,O
the,O
sole,O
substrate,O
or,O
with,O
a,O
mixture,O
of,O
manure,O
and,O
straw,O
.,O
Addition,O
of,O
straw,O
had,O
a,O
more,O
pronounced,O
effect,O
on,O
the,O
bacterial,O
community,O
",",O
for,O
example,O
reflected,O
in,O
a,O
significant,O
decrease,O
in,O
bacterial,O
species,O
richness,O
compared,O
with,O
digestion,O
of,O
manure,O
alone,O
(,O
Table,O
1,O
and,O
Fig,O
.,O
S1,O
).,O
A,O
similar,O
decrease,O
in,O
species,O
richness,O
was,O
observed,O
in,O
a,O
study,O
by,O
Li,O
and,O
colleagues,O
(,O
2014,O
"),",O
where,O
addition,O
of,O
straw,O
resulted,O
in,O
a,O
decrease,O
in,O
the,O
number,O
of,O
observed,O
species,O
and,O
in,O
the,O
Shannon,O
index,O
.,O
This,O
result,O
possibly,O
reflects,O
selection,O
and,O
enrichment,O
of,O
specialists,O
involved,O
in,O
degradation,O
of,O
the,O
straw,O
.,O
At,O
the,O
phylum,O
level,O
",",O
the,O
addition,O
of,O
straw,O
resulted,O
in,O
an,O
increase,O
in,O
the,O
relative,O
abundance,O
of,O
Bacteroidetes,B-OG
compared,O
with,O
the,O
digesters,O
processing,O
manure,O
alone,O
.,O
However,O
",",O
sequences,O
affiliated,O
with,O
Firmicutes,B-OG
were,O
at,O
similar,O
abundance,O
in,O
all,O
digesters,O
operated,O
at,O
37,O
°,O
C,O
.,O
This,O
result,O
was,O
somewhat,O
surprising,O
",",O
as,O
Firmicutes,B-OG
contains,O
many,O
isolated,O
cellulose,O
degraders,O
(,O
Lynd,O
et,O
al,O
".,",O
2002,O
"),",O
and,O
several,O
studies,O
in,O
biogas,O
digesters,O
have,O
suggested,O
representatives,O
of,O
this,O
phylum,O
",",O
particularly,O
belonging,O
to,O
the,O
order,O
Clostridiales,B-OG
",",O
to,O
be,O
key,O
players,O
for,O
degradation,O
of,O
cellulose,O
(,O
Krause,O
et,O
al,O
".,",O
2008,O
;,O
Hanreich,O
et,O
al,O
".,",O
2013,O
;,O
Li,O
et,O
al,O
".,",O
2013,O
;,O
Lu,O
et,O
al,O
".,",O
2013,O
;,O
Lebuhn,O
et,O
al,O
".,",O
2014,O
).,O
However,O
",",O
in,O
the,O
present,O
study,O
",",O
a,O
higher,O
abundance,O
of,O
Sedimentibacter,B-OG
was,O
observed,O
in,O
the,O
digesters,O
operating,O
with,O
straw,O
",",O
in,O
similarity,O
to,O
a,O
study,O
by,O
Li,O
and,O
colleagues,O
(,O
2014,O
).,O
However,O
",",O
this,O
is,O
not,O
necessarily,O
an,O
expected,O
change,O
",",O
as,O
the,O
two,O
species,O
isolated,O
and,O
characterized,O
from,O
this,O
genus,O
so,O
far,O
are,O
not,O
capable,O
of,O
utilizing,O
carbohydrates,O
(,O
Breitenstein,O
et,O
al,O
".,",O
2002,O
).,O
In,O
line,O
with,O
our,O
results,O
",",O
a,O
recent,O
metagenomic,O
study,O
also,O
found,O
an,O
increase,O
in,O
the,O
level,O
of,O
Bacteroidetes,B-OG
in,O
anaerobic,O
batch,O
fermentation,O
of,O
straw,O
and,O
hay,O
(,O
Hanreich,O
et,O
al,O
".,",O
2013,O
).,O
In,O
this,O
study,O
",",O
the,O
number,O
of,O
expressed,O
sugar,O
transporters,O
increased,O
simultaneously,O
with,O
the,O
level,O
of,O
Bacteroidetes,B-OG
",",O
which,O
was,O
assumed,O
to,O
be,O
responsible,O
for,O
degradation,O
of,O
polysaccharides,O
.,O
Representatives,O
of,O
the,O
phylum,O
Bacteroidetes,B-OG
have,O
been,O
shown,O
to,O
have,O
the,O
capacity,O
to,O
degrade,O
a,O
wide,O
variety,O
of,O
plant,O
polysaccharides,O
",",O
including,O
cellulose,O
(,O
Robert,O
et,O
al,O
".,",O
2007,O
;,O
Hatamoto,O
et,O
al,O
".,",O
2014,O
;,O
Naas,O
et,O
al,O
".,",O
2014,O
).,O
However,O
",",O
recent,O
studies,O
show,O
that,O
cellulose,O
conversion,O
in,O
Bacteroidetes,B-OG
needs,O
further,O
investigation,O
(,O
Naas,O
et,O
al,O
".,",O
2014,O
"),",O
and,O
thus,O
the,O
role,O
of,O
this,O
phylum,O
during,O
straw,O
degradation,O
remains,O
somewhat,O
unclear,O
.,O
The,O
straw,O
in,O
this,O
study,O
was,O
pretreated,O
by,O
steam,O
explosion,O
(,O
Risberg,O
et,O
al,O
".,",O
2013,O
).,O
This,O
treatment,O
disrupts,O
the,O
intricate,O
structure,O
of,O
lignocellulose,O
and,O
releases,O
more,O
simple,O
carbohydrates,O
",",O
possibly,O
explaining,O
the,O
increased,O
level,O
of,O
Bacteroidetes,B-OG
.,O
Impact,O
of,O
temperature,O
For,O
archaeal,O
and,O
bacterial,O
communities,O
",",O
the,O
species,O
richness,O
decreased,O
in,O
line,O
with,O
the,O
increase,O
in,O
process,O
temperature,O
.,O
Similarly,O
",",O
Sundberg,O
and,O
co,O
-,O
workers,O
(,O
2013,O
),O
observed,O
that,O
among,O
21,O
full,O
-,O
scale,O
biogas,O
digesters,O
",",O
thermophilic,O
co,O
-,O
digestion,O
plants,O
had,O
lower,O
microbial,O
richness,O
than,O
mesophilic,O
plants,O
.,O
A,O
similar,O
trend,O
was,O
also,O
observed,O
in,O
a,O
methanogenic,O
digester,O
processing,O
organic,O
household,O
waste,O
at,O
37,O
°,O
C,O
and,O
at,O
55,O
°,O
C,O
",",O
where,O
a,O
higher,O
species,O
richness,O
was,O
found,O
for,O
both,O
the,O
archaeal,O
and,O
bacterial,O
community,O
at,O
the,O
mesophilic,O
temperature,O
(,O
Levén,O
et,O
al,O
".,",O
2007,O
).,O
Interestingly,O
",",O
the,O
species,O
richness,O
of,O
the,O
archaea,B-OG
was,O
lowest,O
at,O
44,O
°,O
C,O
",",O
suggesting,O
that,O
an,O
increase,O
in,O
temperature,O
with,O
only,O
a,O
few,O
degrees,O
from,O
37,O
°,O
C,O
has,O
an,O
impact,O
on,O
the,O
diversity,O
of,O
this,O
community,O
.,O
This,O
result,O
was,O
in,O
line,O
with,O
a,O
previous,O
study,O
where,O
a,O
significant,O
decrease,O
in,O
species,O
richness,O
of,O
methanogens,B-OG
was,O
observed,O
after,O
an,O
increase,O
in,O
operational,O
temperature,O
from,O
37,O
°,O
C,O
to,O
42,O
°,O
C,O
in,O
lab,O
-,O
scale,O
digesters,O
processing,O
municipal,O
solid,O
waste,O
supplemented,O
with,O
albumin,B-GP
(,O
Westerholm,O
M,O
".,",O
Isaksson,O
S,O
".,",O
Müller,O
B,O
".,",O
and,O
Schnürer,O
A,O
".,",O
unpublished,O
).,O
Thus,O
",",O
it,O
is,O
apparent,O
that,O
temperature,O
is,O
a,O
strong,O
regulating,O
factor,O
for,O
the,O
microbial,O
community,O
in,O
the,O
biogas,O
process,O
",",O
and,O
an,O
increase,O
in,O
temperature,O
restricts,O
the,O
number,O
of,O
species,O
present,O
.,O
Notably,O
",",O
the,O
previously,O
published,O
operating,O
data,O
for,O
these,O
digesters,O
show,O
that,O
this,O
decrease,O
in,O
richness,O
of,O
both,O
bacteria,B-OG
and,O
archaea,B-OG
and,O
in,O
the,O
evenness,O
of,O
bacteria,B-OG
did,O
not,O
affect,O
the,O
overall,O
performance,O
of,O
the,O
digesters,O
(,O
Risberg,O
et,O
al,O
".,",O
2013,O
).,O
Moreover,O
",",O
in,O
the,O
study,O
by,O
Westerholm,O
et,O
al,O
.,O
(,O
unpublished,O
"),",O
the,O
increase,O
in,O
temperature,O
to,O
42,O
°,O
C,O
even,O
resulted,O
in,O
increased,O
methane,O
yields,O
compared,O
with,O
operation,O
at,O
37,O
°,O
C,O
",",O
in,O
spite,O
of,O
a,O
decreased,O
species,O
richness,O
of,O
methanogens,B-OG
.,O
For,O
the,O
archaeal,O
community,O
",",O
after,O
an,O
increase,O
in,O
operating,O
temperature,O
from,O
37,O
°,O
C,O
to,O
52,O
°,O
C,O
",",O
there,O
was,O
an,O
increase,O
in,O
the,O
relative,O
abundance,O
of,O
the,O
genera,O
Methanobacterium,B-OG
and,O
Methanoculleus,B-OG
",",O
from,O
the,O
order,O
Methanobacteriales,B-OG
and,O
Methanomicrobiales,B-OG
respectively,O
.,O
Similar,O
results,O
have,O
been,O
reported,O
for,O
a,O
laboratory,O
-,O
scale,O
biogas,O
digester,O
fed,O
with,O
only,O
cattle,B-OG
manure,O
during,O
a,O
temperature,O
shift,O
from,O
39,O
°,O
C,O
to,O
55,O
°,O
C,O
",",O
where,O
a,O
decrease,O
in,O
relative,O
abundance,O
of,O
Methanosarcina,B-OG
from,O
89,O
%,O
to,O
54,O
%,O
was,O
accompanied,O
by,O
an,O
increase,O
of,O
Methanoculleus,B-OG
spp,I-OG
.,O
(,O
Ziganshin,O
et,O
al,O
".,",O
2013,O
).,O
Moreover,O
",",O
a,O
sharp,O
increase,O
in,O
the,O
relative,O
abundance,O
of,O
hydrogenotrophic,B-OG
methanogens,I-OG
Methanobacterium,B-OG
",",O
Methanoculleus,B-OG
and,O
Methanothermobacter,B-OG
has,O
been,O
observed,O
in,O
biogas,O
digesters,O
co,O
-,O
digesting,O
cattle,B-OG
excreta,O
and,O
olive,O
mill,O
wastes,O
during,O
a,O
temperature,O
shift,O
from,O
37,O
°,O
C,O
to,O
55,O
°,O
C,O
",",O
likely,O
induced,O
by,O
an,O
increase,O
in,O
H2,O
partial,O
pressure,O
(,O
Goberna,O
et,O
al,O
".,",O
2010,O
).,O
For,O
the,O
bacterial,O
community,O
",",O
the,O
relative,O
abundance,O
of,O
Firmicutes,B-OG
increased,O
during,O
the,O
transition,O
to,O
the,O
thermophilic,O
temperature,O
.,O
This,O
increase,O
was,O
mainly,O
caused,O
by,O
a,O
higher,O
abundance,O
of,O
sequences,O
related,O
to,O
the,O
uncultured,O
order,O
MBA08,O
within,O
the,O
class,O
Clostridia,B-OG
.,O
Interestingly,O
",",O
this,O
order,O
was,O
represented,O
by,O
a,O
single,O
uncultured,O
genus,O
",",O
which,O
partially,O
explained,O
the,O
decreased,O
species,O
richness,O
and,O
evenness,O
of,O
the,O
bacterial,O
community,O
.,O
The,O
MBA08,O
cluster,O
was,O
first,O
discovered,O
in,O
a,O
thermophilic,O
laboratory,O
-,O
scale,O
digester,O
processing,O
municipal,O
solid,O
waste,O
(,O
Tang,O
et,O
al,O
".,",O
2004,O
),O
and,O
also,O
later,O
in,O
a,O
thermophilic,O
garbage,O
digester,O
(,O
Cheon,O
et,O
al,O
".,",O
2007,O
).,O
Thus,O
",",O
it,O
seems,O
reasonable,O
to,O
assume,O
that,O
this,O
cluster,O
contains,O
thermophilic,O
Clostridia,B-OG
.,O
In,O
our,O
previous,O
study,O
using,O
the,O
same,O
anaerobic,O
digesters,O
and,O
using,O
a,O
functional,O
gene,O
approach,O
for,O
community,O
analysis,O
",",O
we,O
also,O
found,O
that,O
the,O
major,O
response,O
to,O
the,O
temperature,O
rise,O
was,O
an,O
increase,O
in,O
the,O
relative,O
abundance,O
of,O
organisms,O
belonging,O
to,O
the,O
class,O
Clostridia,B-OG
(,O
Sun,O
et,O
al,O
".,",O
2013,O
).,O
In,O
contrast,O
to,O
Firmicutes,B-OG
",",O
the,O
relative,O
abundance,O
of,O
Bacteroidetes,B-OG
decreased,O
with,O
the,O
increase,O
in,O
operating,O
temperature,O
in,O
the,O
present,O
study,O
.,O
This,O
trend,O
was,O
also,O
seen,O
in,O
our,O
previous,O
study,O
(,O
Sun,O
et,O
al,O
".,",O
2013,O
),O
and,O
in,O
the,O
study,O
by,O
Ziganshin,O
and,O
colleagues,O
(,O
2013,O
"),",O
who,O
observed,O
a,O
decrease,O
in,O
sequences,O
related,O
to,O
this,O
phylum,O
during,O
a,O
temperature,O
shift,O
from,O
38,O
°,O
C,O
to,O
55,O
°,O
C,O
in,O
digesters,O
processing,O
cattle,B-OG
manure,O
and,O
agricultural,O
waste,O
.,O
Moreover,O
",",O
introduction,O
of,O
cellulose,O
into,O
a,O
thermophilic,O
sludge,O
digester,O
resulted,O
in,O
increased,O
abundance,O
of,O
Firmicutes,B-OG
and,O
decreased,O
abundance,O
of,O
Bacteroidetes,B-OG
(,O
Lu,O
et,O
al,O
".,",O
2013,O
).,O
In,O
addition,O
",",O
a,O
high,O
ratio,O
of,O
Firmicutes,B-OG
/,O
Bacteroidetes,B-OG
has,O
been,O
observed,O
in,O
different,O
digesters,O
operated,O
at,O
high,O
temperature,O
",",O
e,O
.,O
g,O
.,O
in,O
three,O
hydrolytic,O
/,O
acidogenic,O
horizontal,O
tubular,O
digesters,O
processing,O
dried,O
hay,O
and,O
straw,O
",",O
operating,O
at,O
38,O
°,O
C,O
",",O
45,O
°,O
C,O
and,O
55,O
°,O
C,O
(,O
Lebuhn,O
et,O
al,O
".,",O
2014,O
"),",O
in,O
two,O
digesters,O
treating,O
organic,O
household,O
waste,O
at,O
37,O
°,O
C,O
and,O
55,O
°,O
C,O
(,O
Levén,O
et,O
al,O
".,",O
2007,O
"),",O
and,O
in,O
a,O
thermophilic,O
reactor,O
operating,O
with,O
poultry,O
manure,O
(,O
Smith,O
et,O
al,O
".,",O
2014,O
).,O
Temperature,O
clearly,O
has,O
a,O
strong,O
effect,O
on,O
the,O
bacterial,O
community,O
in,O
a,O
biogas,O
digester,O
",",O
and,O
the,O
high,O
relative,O
abundance,O
of,O
Clostridia,B-OG
suggested,O
a,O
competitive,O
advantage,O
for,O
this,O
class,O
.,O
Conclusions,O
Comparing,O
sequencing,O
results,O
from,O
the,O
manure,O
used,O
as,O
substrate,O
and,O
the,O
digesters,O
operated,O
under,O
various,O
conditions,O
revealed,O
that,O
the,O
microbial,O
communities,O
in,O
the,O
digesters,O
were,O
likely,O
shaped,O
by,O
the,O
operating,O
conditions,O
.,O
For,O
archaea,B-OG
",",O
the,O
hydrogenotrophic,B-OG
methanogens,I-OG
present,O
in,O
the,O
manure,O
were,O
outcompeted,O
in,O
the,O
digester,O
environment,O
by,O
Methanosarcina,B-OG
",",O
which,O
can,O
utilize,O
both,O
hydrogen,O
and,O
acetate,O
.,O
For,O
bacteria,B-OG
",",O
the,O
relative,O
abundance,O
of,O
Bacilli,B-OG
was,O
higher,O
in,O
manure,O
",",O
while,O
an,O
uncultured,O
cluster,O
WWE1,O
affiliated,O
to,O
the,O
phylum,O
Cloacimonetes,B-OG
was,O
more,O
abundant,O
in,O
the,O
digester,O
operated,O
with,O
manure,O
alone,O
.,O
After,O
including,O
straw,O
for,O
co,O
-,O
digestion,O
with,O
manure,O
",",O
no,O
major,O
changes,O
were,O
observed,O
for,O
the,O
archaeal,O
community,O
.,O
However,O
",",O
for,O
bacteria,B-OG
",",O
the,O
abundance,O
of,O
Bacteroidia,B-OG
increased,O
",",O
suggesting,O
importance,O
of,O
this,O
group,O
.,O
Both,O
the,O
archaeal,O
and,O
bacterial,O
communities,O
responded,O
to,O
increased,O
operating,O
temperatures,O
.,O
For,O
archaea,B-OG
",",O
although,O
Methanosarcina,B-OG
was,O
the,O
most,O
dominant,O
genus,O
in,O
all,O
digester,O
samples,O
",",O
Methanoculleus,B-OG
and,O
Methanobacterium,B-OG
were,O
considerably,O
more,O
abundant,O
at,O
the,O
higher,O
temperatures,O
.,O
For,O
bacteria,B-OG
",",O
a,O
decrease,O
in,O
the,O
relative,O
abundance,O
of,O
Bacteroidia,B-OG
was,O
accompanied,O
by,O
an,O
increase,O
in,O
Clostridia,B-OG
.,O
A,O
considerable,O
fraction,O
of,O
bacterial,O
reads,O
could,O
not,O
be,O
allocated,O
to,O
genus,O
level,O
",",O
meaning,O
that,O
more,O
efforts,O
to,O
isolate,O
and,O
characterize,O
unknown,O
dominant,O
microbes,B-OG
in,O
anaerobic,O
digesters,O
are,O
needed,O
.,O
Such,O
efforts,O
could,O
provide,O
deeper,O
insights,O
into,O
microbial,O
function,O
in,O
the,O
AD,O
process,O
.,O
Experimental,O
procedures,O
Anaerobic,O
digesters,O
Samples,O
for,O
microbial,O
community,O
structure,O
analysis,O
were,O
taken,O
from,O
five,O
laboratory,O
-,O
scale,O
semi,O
-,O
continuous,O
stirred,O
tank,O
reactors,O
(,O
Dolly,O
",",O
Belach,O
Bioteknik,O
",",O
Stockholm,O
",",O
Sweden,O
),O
run,O
under,O
different,O
conditions,O
(,O
Risberg,O
et,O
al,O
".,",O
2013,O
).,O
In,O
addition,O
to,O
the,O
digester,O
samples,O
",",O
two,O
samples,O
were,O
taken,O
from,O
the,O
manure,O
used,O
as,O
substrate,O
for,O
the,O
digesters,O
.,O
A,O
detailed,O
description,O
of,O
the,O
digesters,O
",",O
the,O
chemical,O
composition,O
of,O
the,O
manure,O
and,O
the,O
process,O
performance,O
can,O
be,O
found,O
in,O
Risberg,O
and,O
colleagues,O
(,O
2013,O
).,O
In,O
this,O
study,O
",",O
the,O
phase,O
referred,O
to,O
as,O
‘,O
second,O
experimental,O
period,O
’,O
was,O
used,O
for,O
the,O
microbial,O
analysis,O
.,O
In,O
brief,O
",",O
five,O
set,O
-,O
ups,O
of,O
digesters,O
(,O
designated,O
RM,O
",",O
RTcSS,O
",",O
R37SS,O
",",O
R44SS,O
and,O
R52SS,O
),O
were,O
investigated,O
in,O
this,O
study,O
;,O
all,O
but,O
RM,O
operated,O
in,O
duplicate,O
.,O
All,O
digesters,O
had,O
the,O
same,O
hydraulic,O
retention,O
time,O
(,O
HRT,O
),O
of,O
25,O
days,O
",",O
and,O
the,O
organic,O
loading,O
rate,O
was,O
maintained,O
at,O
around,O
2,O
.,O
8,O
g,O
VS,O
l,O
−,O
l,O
day,O
−,O
l,O
.,O
The,O
inoculum,O
used,O
for,O
starting,O
up,O
the,O
AD,O
process,O
(,O
RTcSS,O
and,O
R37SS,O
),O
originated,O
from,O
the,O
digester,O
RLcSS,O
in,O
Risberg,O
and,O
colleagues,O
(,O
2013,O
"),",O
which,O
operated,O
at,O
similar,O
conditions,O
with,O
another,O
batch,O
of,O
manure,O
for,O
83,O
days,O
(,O
full,O
load,O
).,O
All,O
the,O
digesters,O
were,O
fed,O
6,O
days,O
a,O
week,O
and,O
had,O
stable,O
and,O
similar,O
performance,O
:,O
the,O
pH,O
was,O
7,O
.,O
5,O
–,O
8,O
.,O
1,O
",",O
the,O
ammonium,O
-,O
nitrogen,O
level,O
was,O
1,O
.,O
5,O
–,O
2,O
.,O
0,O
g,O
kg,O
−,O
1,O
wet,O
weight,O
(,O
1,O
.,O
2,O
g,O
kg,O
−,O
1,O
wet,O
weight,O
for,O
manure,O
itself,O
"),",O
no,O
accumulation,O
of,O
acids,O
occurred,O
during,O
the,O
whole,O
operating,O
period,O
",",O
and,O
the,O
specific,O
methane,O
yield,O
was,O
0,O
.,O
13,O
–,O
0,O
.,O
17,O
l,O
CH4,O
kg,O
−,O
1,O
VS,O
(,O
Risberg,O
et,O
al,O
".,",O
2013,O
).,O
Digester,O
RM,O
operated,O
with,O
cow,B-OG
manure,O
as,O
the,O
sole,O
substrate,O
at,O
37,O
°,O
C,O
",",O
while,O
two,O
parallel,O
digesters,O
RTcSS,O
operated,O
with,O
cow,B-OG
manure,O
supplemented,O
with,O
steam,O
-,O
exploded,O
straw,O
(,O
78,O
/,O
22,O
%,O
on,O
a,O
VS,O
basis,O
),O
at,O
37,O
°,O
C,O
during,O
the,O
whole,O
operating,O
period,O
.,O
Another,O
two,O
parallel,O
digesters,O
R37SS,O
were,O
fed,O
with,O
the,O
same,O
substrate,O
and,O
initially,O
operated,O
under,O
the,O
same,O
conditions,O
as,O
RTcSS,O
at,O
37,O
°,O
C,O
",",O
but,O
both,O
digesters,O
were,O
then,O
subjected,O
to,O
a,O
temperature,O
rise,O
to,O
44,O
°,O
C,O
and,O
further,O
to,O
52,O
°,O
C,O
.,O
After,O
around,O
three,O
HRTs,O
of,O
operation,O
at,O
the,O
corresponding,O
temperature,O
(,O
i,O
.,O
e,O
.,O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
"),",O
the,O
digesters,O
were,O
named,O
R44SS,O
and,O
R52SS,O
respectively,O
.,O
The,O
total,O
operating,O
time,O
of,O
the,O
digesters,O
was,O
402,O
days,O
.,O
DNA,O
extraction,O
For,O
digesters,O
RTcSS,O
and,O
R37SS,O
",",O
samples,O
were,O
withdrawn,O
on,O
days,O
9,O
",",O
38,O
",",O
80,O
and,O
99,O
of,O
operation,O
.,O
The,O
starting,O
point,O
for,O
this,O
experiment,O
was,O
set,O
to,O
the,O
day,O
when,O
the,O
digesters,O
had,O
been,O
in,O
operation,O
for,O
three,O
HRTs,O
at,O
full,O
load,O
.,O
For,O
digesters,O
R44SS,O
and,O
R52SS,O
",",O
samples,O
were,O
taken,O
after,O
operation,O
at,O
the,O
corresponding,O
temperature,O
(,O
44,O
°,O
C,O
and,O
52,O
°,O
C,O
",",O
respectively,O
),O
for,O
around,O
three,O
HRTs,O
",",O
i,O
.,O
e,O
.,O
on,O
days,O
224,O
and,O
402,O
.,O
For,O
digester,O
RM,O
",",O
samples,O
were,O
taken,O
on,O
days,O
42,O
",",O
85,O
and,O
148,O
.,O
A,O
20,O
ml,O
sample,O
was,O
withdrawn,O
from,O
each,O
digester,O
and,O
stored,O
at,O
−,O
20,O
°,O
C,O
until,O
analysis,O
.,O
Total,O
genomic,O
DNA,O
was,O
prepared,O
in,O
triplicate,O
using,O
the,O
FastDNA,O
Spin,O
Kit,O
for,O
Soil,O
(,O
MP,O
Biomedicals,O
",",O
Santa,O
Ana,O
",",O
CA,O
",",O
USA,O
).,O
Aliquots,O
of,O
200,O
μl,O
digester,O
sludge,O
were,O
used,O
for,O
extraction,O
following,O
the,O
manufacturer,O
’,O
s,O
protocol,O
",",O
and,O
60,O
μl,O
water,O
was,O
used,O
in,O
the,O
final,O
elution,O
of,O
DNA,O
.,O
The,O
concentrations,O
of,O
extracted,O
DNA,O
were,O
measured,O
using,O
the,O
Quant,O
-,O
iT,O
dsDNA,O
BR,O
Assay,O
Kit,O
(,O
Invitrogen,O
",",O
Life,O
Technologies,O
Europe,O
",",O
Stockholm,O
",",O
Sweden,O
).,O
454,O
-,O
pyrosequencing,O
Primers,O
targeting,O
the,O
bacterial,O
16S,O
rRNA,O
gene,O
integrated,O
with,O
454,O
Life,O
Sciences,O
adaptors,O
8F,O
(,O
5,O
′-,O
CCT,O
ATC,O
CCC,O
TGT,O
GTG,O
CCT,O
TGG,O
CAG,O
TCT,O
CAG,O
CAA,O
CAG,O
CTA,O
GAG,O
TTT,O
GAT,O
CCT,O
GG,O
-,O
3,O
′),O
and,O
515R,O
(,O
5,O
′-,O
CCA,O
TCT,O
CAT,O
CCC,O
TGC,O
GTG,O
TCT,O
CCG,O
ACT,O
CAG,O
NNN,O
NNN,O
NNT,O
TAC,O
CGC,O
GGC,O
TGC,O
T,O
-,O
3,O
′),O
were,O
used,O
for,O
amplification,O
from,O
genomic,O
DNA,O
by,O
polymerase,O
chain,O
reaction,O
(,O
PCR,O
),O
(,O
Stanley,O
et,O
al,O
".,",O
2013,O
).,O
For,O
archaea,B-OG
",",O
the,O
primers,O
340F,O
(,O
5,O
′-,O
CCT,O
ATC,O
CCC,O
TGT,O
GTG,O
CCT,O
TGG,O
CAG,O
TCT,O
CAG,O
CAA,O
AAG,O
CTC,O
CCT,O
AYG,O
GGG,O
YGC,O
ASC,O
AG,O
-,O
3,O
′),O
and,O
1,O
000R,O
(,O
5,O
′-,O
CCA,O
TCT,O
CAT,O
CCC,O
TGC,O
GTG,O
TCT,O
CCG,O
ACT,O
CAG,O
NNN,O
NNN,O
NNG,O
GCC,O
ATG,O
CAC,O
YWC,O
YTC,O
TC,O
-,O
3,O
′),O
were,O
used,O
for,O
amplification,O
(,O
Gantner,O
et,O
al,O
".,",O
2011,O
).,O
For,O
samples,O
from,O
RM,O
",",O
RTcSS,O
and,O
R37SS,O
",",O
the,O
PCR,O
amplification,O
was,O
performed,O
with,O
iProof,O
High,O
-,O
Fidelity,O
DNA,B-GP
Polymerase,I-GP
(,O
Bio,O
-,O
Rad,O
",",O
Hercules,O
",",O
CA,O
",",O
USA,O
).,O
For,O
samples,O
R44SS,O
and,O
R52SS,O
",",O
PCR,O
amplification,O
was,O
conducted,O
using,O
Maxima,O
Hot,O
Start,O
PCR,O
Master,O
Mix,O
(,O
Fermentas,O
",",O
Thermo,O
Fisher,O
Scientific,O
",",O
Hudson,O
",",O
NH,O
",",O
USA,O
),O
for,O
bacteria,B-OG
and,O
Bio,O
-,O
Rad,O
iQ,O
™,O
Supermix,O
(,O
Bio,O
-,O
Rad,O
),O
for,O
archaea,B-OG
.,O
Each,O
PCR,O
reaction,O
contained,O
12,O
.,O
5,O
μl,O
of,O
corresponding,O
reaction,O
mix,O
",",O
0,O
.,O
5,O
μM,O
of,O
each,O
primer,O
",",O
20,O
ng,O
of,O
DNA,O
template,O
and,O
9,O
.,O
5,O
μl,O
of,O
sterile,O
water,O
(,O
25,O
μl,O
final,O
volume,O
).,O
The,O
PCR,O
programmes,O
were,O
as,O
follows,O
:,O
initial,O
denaturation,O
at,O
98,O
°,O
C,O
for,O
3,O
min,O
",",O
30,O
cycles,O
(,O
35,O
cycles,O
for,O
archaea,B-OG
),O
of,O
denaturation,O
at,O
98,O
°,O
C,O
for,O
10,O
s,O
",",O
annealing,O
at,O
55,O
°,O
C,O
(,O
57,O
°,O
C,O
for,O
archaea,B-OG
),O
for,O
45,O
s,O
and,O
elongation,O
at,O
72,O
°,O
C,O
for,O
45,O
s,O
",",O
followed,O
by,O
a,O
final,O
extension,O
step,O
of,O
7,O
min,O
at,O
72,O
°,O
C,O
.,O
The,O
size,O
and,O
purity,O
of,O
amplicons,O
were,O
checked,O
by,O
electrophoresis,O
on,O
2,O
%,O
agarose,O
gel,O
.,O
Short,O
",",O
non,O
-,O
specific,O
amplification,O
products,O
were,O
removed,O
with,O
AMP,O
beads,O
(,O
AMPure,O
XP,O
",",O
Beckman,O
Coulter,O
Genomics,O
",",O
Danvers,O
",",O
MA,O
",",O
USA,O
),O
using,O
the,O
manufacturer,O
’,O
s,O
protocol,O
but,O
with,O
a,O
modified,O
bead,O
to,O
DNA,O
volume,O
ratio,O
of,O
0,O
.,O
7,O
:,O
1,O
.,O
The,O
concentrations,O
of,O
purified,O
products,O
were,O
measured,O
using,O
the,O
Quant,O
-,O
iT,O
dsDNA,O
BR,O
Assay,O
Kit,O
(,O
Invitrogen,O
).,O
All,O
PCR,O
products,O
were,O
pooled,O
in,O
equal,O
molar,O
amounts,O
and,O
further,O
checked,O
on,O
2,O
%,O
agarose,O
gel,O
.,O
The,O
mixed,O
pool,O
of,O
PCR,O
products,O
from,O
manure,O
samples,O
",",O
RM,O
",",O
RTcSS,O
and,O
R37SS,O
",",O
was,O
sequenced,O
at,O
Norwegian,O
Sequencing,O
Centre,O
in,O
Oslo,O
",",O
while,O
the,O
one,O
from,O
R44SS,O
and,O
R52SS,O
was,O
sequenced,O
at,O
the,O
Swedish,O
Institute,O
for,O
Infectious,O
Disease,O
Control,O
in,O
Solna,O
",",O
using,O
the,O
Roche,O
/,O
454,O
GS,O
Titanium,O
technology,O
platform,O
.,O
Sequences,O
have,O
been,O
deposited,O
in,O
the,O
National,O
Center,O
for,O
Biotechnology,O
Information,O
(,O
NCBI,O
),O
Sequence,O
Read,O
Archive,O
under,O
the,O
accession,O
number,O
SRP049689,O
.,O
16S,O
rRNA,O
gene,O
sequence,O
analysis,O
The,O
16S,O
rRNA,O
gene,O
sequences,O
were,O
processed,O
using,O
the,O
qiime,O
pipeline,O
(,O
Caporaso,O
et,O
al,O
".,",O
2010a,O
).,O
In,O
summary,O
",",O
the,O
dataset,O
was,O
first,O
quality,O
trimmed,O
by,O
removing,O
sequences,O
that,O
were,O
less,O
than,O
400,O
or,O
more,O
than,O
600,O
bp,O
in,O
length,O
",",O
contained,O
ambiguous,O
bases,O
",",O
had,O
a,O
mean,O
quality,O
score,O
<,O
25,O
",",O
contained,O
a,O
homopolymer,O
run,O
exceeding,O
6,O
bp,O
",",O
or,O
did,O
not,O
contain,O
a,O
primer,O
or,O
barcode,O
sequence,O
.,O
The,O
usearch,O
quality,O
filter,O
was,O
used,O
to,O
remove,O
chimera,O
sequences,O
(,O
Edgar,O
",",O
2010,O
).,O
The,O
OTUs,O
were,O
determined,O
using,O
uclust,O
at,O
a,O
threshold,O
of,O
97,O
%,O
(,O
Edgar,O
",",O
2010,O
).,O
Representative,O
sequences,O
were,O
selected,O
as,O
the,O
most,O
abundant,O
sequence,O
in,O
each,O
OTU,O
and,O
further,O
aligned,O
against,O
the,O
Greengenes,O
core,O
set,O
(,O
gg_13_8,O
),O
using,O
pynast,O
software,O
(,O
Caporaso,O
et,O
al,O
".,",O
2010b,O
;,O
McDonald,O
et,O
al,O
".,",O
2012,O
),O
and,O
a,O
minimum,O
identity,O
of,O
75,O
%.,O
Taxonomy,O
was,O
assigned,O
to,O
each,O
OTU,O
using,O
the,O
Ribosomal,O
Database,O
Project,O
classifier,O
(,O
Wang,O
et,O
al,O
".,",O
2007,O
),O
with,O
a,O
minimum,O
confidence,O
threshold,O
of,O
80,O
%.,O
The,O
alignment,O
was,O
filtered,O
to,O
remove,O
gaps,O
and,O
hypervariable,O
regions,O
using,O
a,O
Lane,O
mask,O
",",O
and,O
a,O
maximum,O
-,O
likelihood,O
tree,O
was,O
constructed,O
from,O
the,O
filtered,O
alignment,O
using,O
FastTree,O
(,O
Price,O
et,O
al,O
".,",O
2010,O
).,O
The,O
OTU,O
tables,O
were,O
rarefied,O
(,O
according,O
to,O
the,O
sample,O
containing,O
the,O
smallest,O
set,O
of,O
sequences,O
),O
to,O
equalize,O
sampling,O
depth,O
and,O
avoid,O
heterogeneity,O
(,O
i,O
.,O
e,O
.,O
avoid,O
bias,O
from,O
unequal,O
sampling,O
effort,O
).,O
From,O
the,O
OTU,O
tables,O
and,O
phylogenetic,O
trees,O
",",O
an,O
unweighted,O
UniFrac,O
distance,O
matrix,O
was,O
constructed,O
and,O
further,O
visualized,O
with,O
PCoA,O
(,O
Lozupone,O
and,O
Knight,O
",",O
2005,O
).,O
Rarefaction,O
curve,O
",",O
observed,O
species,O
",",O
chao1,O
(,O
Hill,O
et,O
al,O
".,",O
2003,O
"),",O
Shannon,O
(,O
Spellerberg,O
and,O
Fedor,O
",",O
2003,O
),O
and,O
Simpson,O
indices,O
(,O
Simpson,O
",",O
1949,O
),O
were,O
computed,O
by,O
qiime,O
alpha,O
diversity,O
analysis,O
script,O
(,O
Caporaso,O
et,O
al,O
".,",O
2010,O
).,O
An,O
investigation,O
into,O
corneal,O
enzymatic,O
resistance,O
following,O
epithelium,O
-,O
off,O
and,O
epithelium,O
-,O
on,O
corneal,O
cross,O
-,O
linking,O
protocols,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
corneal,O
enzymatic,O
resistance,O
following,O
epithelium,O
off,O
and,O
on,O
riboflavin,O
/,O
UVA,O
cross,O
-,O
linking,O
(,O
CXL,O
).,O
One,O
hundred,O
and,O
fourteen,O
porcine,O
eyes,O
were,O
divided,O
into,O
four,O
non,O
-,O
irradiated,O
control,O
groups,O
and,O
seven,O
CXL,O
groups,O
.,O
The,O
latter,O
comprised,O
;,O
(,O
i,O
),O
epithelium,O
-,O
off,O
",",O
0,O
.,O
1,O
%,O
iso,O
-,O
osmolar,O
riboflavin,O
",",O
9,O
mW,O
UVA,O
irradiation,O
for,O
10,O
min,O
",",O
(,O
ii,O
),O
disrupted,O
epithelium,O
",",O
0,O
.,O
1,O
%,O
hypo,O
-,O
osmolar,O
riboflavin,O
",",O
9,O
mW,O
UVA,O
for,O
10,O
min,O
",",O
(,O
iii,O
),O
epithelium,O
-,O
on,O
",",O
0,O
.,O
25,O
%,O
hypo,O
-,O
osmolar,O
riboflavin,O
with,O
0,O
.,O
01,O
%,O
benzylalkonium,O
chloride,O
(,O
BACS,O
"),",O
9,O
mW,O
UVA,O
for,O
10,O
min,O
",",O
(,O
iv,O
),O
epithelium,O
-,O
on,O
",",O
5,O
min,O
iontophoresis,O
at,O
0,O
.,O
1,O
mA,O
for,O
5,O
min,O
with,O
0,O
.,O
1,O
%,O
riboflavin,O
solution,O
",",O
9,O
mW,O
UVA,O
for,O
10,O
min,O
or,O
(,O
v,O
),O
12,O
.,O
5,O
min,O
",",O
(,O
vi,O
),O
epithelium,O
-,O
on,O
",",O
prolonged,O
iontophoresis,O
protocol,O
of,O
25,O
min,O
with,O
1,O
.,O
0,O
mA,O
for,O
5,O
min,O
and,O
0,O
.,O
5,O
mA,O
for,O
5,O
min,O
with,O
0,O
.,O
25,O
%,O
riboflavin,O
with,O
0,O
.,O
01,O
%,O
BACS,O
",",O
9,O
mW,O
UVA,O
for,O
10,O
min,O
or,O
(,O
vii,O
),O
12,O
.,O
5,O
min,O
.,O
Enzymatic,O
resistance,O
was,O
assessed,O
by,O
daily,O
measurement,O
of,O
a,O
corneal,O
button,O
placed,O
in,O
pepsin,B-GP
solution,O
and,O
measurement,O
of,O
corneal,O
button,O
dry,O
weight,O
after,O
11,O
days,O
of,O
digestion,O
.,O
This,O
study,O
revealed,O
that,O
the,O
enzymatic,O
resistance,O
was,O
greater,O
in,O
CXL,O
corneas,O
than,O
non,O
-,O
irradiated,O
corneas,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
Epithelium,O
-,O
off,O
CXL,O
showed,O
the,O
greatest,O
enzymatic,O
resistance,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
The,O
prolonged,O
iontophoresis,O
protocol,O
was,O
found,O
to,O
be,O
superior,O
to,O
all,O
other,O
trans,O
-,O
epithelial,O
protocols,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
A,O
25,O
%,O
increase,O
in,O
UVA,O
radiance,O
significantly,O
increased,O
corneal,O
enzymatic,O
resistance,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
In,O
conclusion,O
",",O
although,O
epithelium,O
-,O
on,O
CXL,O
appears,O
to,O
be,O
inferior,O
to,O
epithelium,O
-,O
off,O
CXL,O
in,O
terms,O
of,O
enzymatic,O
resistance,O
to,O
pepsin,B-GP
digestion,O
",",O
the,O
outcome,O
of,O
epithelium,O
-,O
on,O
CXL,O
may,O
be,O
significantly,O
improved,O
through,O
the,O
use,O
of,O
higher,O
concentrations,O
of,O
riboflavin,O
solution,O
",",O
a,O
longer,O
duration,O
of,O
iontophoresis,O
and,O
an,O
increase,O
in,O
UVA,O
radiance,O
.,O
Highlights,O
•,O
Epi,O
-,O
off,O
CXL,O
is,O
superior,O
to,O
epi,O
-,O
on,O
CXL,O
in,O
terms,O
of,O
enzymatic,O
resistance,O
.•,O
Epi,O
-,O
on,O
CXL,O
effectiveness,O
can,O
be,O
improved,O
by,O
using,O
a,O
prolonged,O
iontophoresis,O
protocol,O
.•,O
Higher,O
riboflavin,O
concentrations,O
and,O
increased,O
UVA,O
radiance,O
may,O
also,O
enhance,O
epi,O
-,O
on,O
CXL,O
.,O
Introduction,O
Over,O
the,O
past,O
decade,O
",",O
riboflavin,O
/,O
UVA,O
corneal,O
cross,O
-,O
linking,O
(,O
CXL,O
),O
has,O
become,O
an,O
established,O
treatment,O
to,O
halt,O
the,O
progression,O
of,O
keratoconus,B-DS
and,O
other,O
corneal,B-DS
ectasias,I-DS
.,O
Riboflavin,O
is,O
a,O
hydrophilic,O
molecule,O
",",O
with,O
a,O
molecular,O
weight,O
of,O
340,O
Da,O
",",O
while,O
",",O
the,O
corneal,O
epithelium,O
is,O
lipophyllic,O
",",O
with,O
a,O
decreasing,O
permeability,O
to,O
molecules,O
over,O
180,O
Da,O
(,O
Huang,O
et,O
al,O
".,",O
1989,O
).,O
Therefore,O
in,O
the,O
“,O
gold,O
-,O
standard,O
”,O
CXL,O
protocol,O
the,O
epithelium,O
is,O
removed,O
from,O
the,O
central,O
corneal,O
to,O
allow,O
adequate,O
stromal,O
absorption,O
of,O
riboflavin,O
prior,O
to,O
UVA,O
irradiation,O
.,O
Spoerl,O
et,O
al,O
.,O
confirmed,O
this,O
need,O
for,O
epithelial,O
removal,O
",",O
reporting,O
no,O
changes,O
in,O
corneal,O
biomechanics,O
when,O
CXL,O
was,O
performed,O
with,O
the,O
epithelium,O
intact,O
(,O
Spoerl,O
et,O
al,O
".,",O
1998,O
).,O
On,O
this,O
basis,O
",",O
the,O
epithelium,O
was,O
removed,O
in,O
the,O
first,O
published,O
clinical,O
studies,O
(,O
Caporossi,O
et,O
al,O
".,",O
2006,O
",",O
Gkika,O
et,O
al,O
".,",O
2011,O
",",O
O,O
',O
Brart,O
et,O
al,O
".,",O
2011,O
",",O
Richoz,O
et,O
al,O
".,",O
2013,O
",",O
Wittig,O
-,O
Silva,O
et,O
al,O
".,",O
2014,O
",",O
Wollensak,O
et,O
al,O
".,",O
2003,O
).,O
However,O
",",O
epithelial,O
debridement,O
is,O
associated,O
with,O
a,O
number,O
of,O
adverse,O
events,O
",",O
including,O
severe,O
ocular,O
pain,O
in,O
the,O
immediate,O
post,O
-,O
operative,O
period,O
",",O
delayed,O
visual,O
rehabilitation,O
and,O
the,O
risks,O
of,O
scarring,O
",",O
infectious,O
and,O
non,O
-,O
infectious,O
keratitis,B-DS
(,O
Koller,O
et,O
al,O
".,",O
2009,O
).,O
As,O
a,O
result,O
of,O
such,O
considerations,O
",",O
a,O
number,O
of,O
trans,O
-,O
epithelial,O
CXL,O
techniques,O
have,O
been,O
postulated,O
.,O
The,O
first,O
epithelium,O
-,O
on,O
CXL,O
(,O
epi,O
-,O
on,O
-,O
CXL,O
),O
protocols,O
included,O
the,O
use,O
of,O
multiple,O
topical,O
applications,O
of,O
tetracaine,O
1,O
%,O
to,O
disrupt,O
epithelial,O
tight,O
junctions,O
(,O
Boxer,O
Wachler,O
et,O
al,O
".,",O
2010,O
",",O
Chan,O
et,O
al,O
".,",O
2007,O
),O
and,O
partial,O
epithelial,O
debridement,O
in,O
a,O
grid,O
pattern,O
(,O
Rechichi,O
et,O
al,O
".,",O
2013,O
).,O
More,O
recently,O
",",O
novel,O
formulations,O
of,O
riboflavin,O
have,O
been,O
developed,O
to,O
facilitate,O
epi,O
-,O
on,O
-,O
CXL,O
.,O
Laboratory,O
studies,O
have,O
shown,O
that,O
riboflavin,O
preparations,O
in,O
which,O
trometamol,O
(,O
Tris,O
-,O
hydroxymethyl,O
-,O
aminometane,O
),O
and,O
sodium,O
ethylenediaminetetraacetic,O
acid,O
(,O
EDTA,O
),O
have,O
been,O
added,O
facilitate,O
stromal,O
absorption,O
when,O
used,O
in,O
conjunction,O
with,O
superficial,O
/,O
grid,O
pattern,O
epithelial,O
trauma,B-DS
(,O
Alhamad,O
et,O
al,O
".,",O
2012,O
).,O
Similarly,O
",",O
preparations,O
without,O
dextran,O
but,O
with,O
sodium,O
chloride,O
0,O
.,O
44,O
%,O
and,O
benzalkonium,O
chloride,O
(,O
BAC,O
),O
have,O
been,O
shown,O
to,O
facilitate,O
trans,O
-,O
epithelial,O
riboflavin,O
stromal,O
absorption,O
(,O
Kissner,O
et,O
al,O
".,",O
2010,O
",",O
Raiskup,O
et,O
al,O
".,",O
2012,O
).,O
Clinical,O
studies,O
with,O
such,O
formulations,O
have,O
demonstrated,O
equivocal,O
results,O
with,O
some,O
suggesting,O
similar,O
efficacy,O
to,O
epithelium,O
-,O
off,O
CXL,O
(,O
epi,O
-,O
off,O
-,O
CXL,O
),O
(,O
Filippello,O
et,O
al,O
".,",O
2012,O
",",O
Magli,O
et,O
al,O
".,",O
2013,O
"),",O
and,O
others,O
showing,O
less,O
pronounced,O
effects,O
(,O
Buzzonetti,O
and,O
Petrocelli,O
",",O
2012,O
",",O
Kocak,O
et,O
al,O
".,",O
2014,O
",",O
Koppen,O
et,O
al,O
".,",O
2012,O
",",O
Leccisotti,O
and,O
Islam,O
",",O
2010,O
).,O
As,O
riboflavin,O
is,O
negatively,O
charged,O
at,O
physiological,O
pH,O
and,O
soluble,O
in,O
water,O
",",O
iontophoresis,O
as,O
a,O
means,O
of,O
enhancing,O
trans,O
-,O
epithelial,O
absorption,O
has,O
also,O
been,O
postulated,O
.,O
In,O
vitro,O
studies,O
of,O
CXL,O
using,O
iontophoresis,O
-,O
assisted,O
delivery,O
(,O
Ion,O
-,O
CXL,O
),O
of,O
riboflavin,O
0,O
.,O
1,O
%,O
with,O
a,O
current,O
of,O
0,O
.,O
5,O
–,O
1,O
mA,O
for,O
5,O
–,O
10,O
min,O
have,O
been,O
encouraging,O
",",O
demonstrating,O
enhanced,O
trans,O
-,O
epithelial,O
riboflavin,O
absorption,O
and,O
corneal,O
tissue,O
biomechanics,O
(,O
Cassagne,O
et,O
al,O
".,",O
2016,O
",",O
Lombardo,O
et,O
al,O
".,",O
2014,O
",",O
Mastropasqua,O
et,O
al,O
".,",O
2014,O
",",O
Touboul,O
et,O
al,O
".,",O
2014,O
",",O
Vinciguerra,O
et,O
al,O
".,",O
2014a,O
).,O
Early,O
clinical,O
studies,O
have,O
reported,O
cessation,O
of,O
progression,O
and,O
improvements,O
in,O
keratometric,O
and,O
visual,O
parameters,O
(,O
Bikbova,O
and,O
Bikbov,O
",",O
2014,O
",",O
Buzzonetti,O
et,O
al,O
".,",O
2015,O
",",O
Vinciguerra,O
et,O
al,O
".,",O
2014b,O
).,O
In,O
addition,O
to,O
the,O
desire,O
to,O
keep,O
the,O
epithelium,O
intact,O
",",O
the,O
current,O
“,O
gold,O
-,O
standard,O
"”,",O
epi,O
-,O
off,O
-,O
CXL,O
protocol,O
",",O
involves,O
a,O
30,O
min,O
application,O
of,O
riboflavin,O
followed,O
by,O
a,O
30,O
min,O
irradiation,O
with,O
370,O
nm,O
UVA,O
light,O
",",O
with,O
an,O
intensity,O
of,O
3,O
mW,O
/,O
cm2,O
",",O
necessitating,O
in,O
excess,O
of,O
one,O
hour,O
treatment,O
time,O
.,O
In,O
an,O
attempt,O
to,O
reduce,O
treatment,O
times,O
",",O
the,O
use,O
of,O
accelerated,O
CXL,O
(,O
A,O
-,O
CXL,O
),O
procedures,O
using,O
the,O
same,O
energy,O
dose,O
but,O
higher,O
UVA,O
intensities,O
and,O
shorter,O
exposure,O
times,O
have,O
been,O
investigated,O
.,O
Published,O
clinical,O
studies,O
of,O
A,O
-,O
CXL,O
protocols,O
are,O
relatively,O
few,O
.,O
However,O
",",O
those,O
using,O
7,O
mW,O
for,O
15,O
min,O
or,O
9,O
mW,O
for,O
10,O
min,O
have,O
reported,O
improvements,O
in,O
corrected,O
distance,O
acuity,O
and,O
a,O
reduction,O
in,O
topographic,O
keratometry,O
at,O
up,O
to,O
46,O
months,O
follow,O
-,O
up,O
with,O
no,O
adverse,O
events,O
associated,O
with,O
the,O
high,O
fluences,O
used,O
(,O
Cinar,O
et,O
al,O
".,",O
2014,O
",",O
Cummings,O
et,O
al,O
".,",O
2016,O
",",O
Kanellopoulos,O
",",O
2012,O
",",O
Kymionis,O
et,O
al,O
".,",O
2014a,O
",",O
Shetty,O
et,O
al,O
".,",O
2015,O
).,O
More,O
recently,O
",",O
it,O
has,O
also,O
been,O
demonstrated,O
that,O
the,O
efficacy,O
of,O
A,O
-,O
CXL,O
may,O
be,O
further,O
improved,O
by,O
increasing,O
the,O
UVA,O
exposure,O
time,O
and,O
the,O
overall,O
cumulative,O
dosage,O
(,O
Aldahlawi,O
et,O
al,O
".,",O
2016,O
",",O
Kymionis,O
et,O
al,O
".,",O
2014b,O
",",O
Sherif,O
",",O
2014,O
).,O
Increased,O
resistance,O
of,O
the,O
corneal,O
stroma,O
to,O
enzymatic,O
digestion,O
following,O
standard,O
(,O
Hayes,O
et,O
al,O
".,",O
2013,O
",",O
Spoerl,O
et,O
al,O
".,",O
2004,O
),O
and,O
accelerated,O
(,O
Aldahlawi,O
et,O
al,O
".,",O
2015,O
),O
epi,O
-,O
off,O
-,O
CXL,O
has,O
been,O
demonstrated,O
by,O
a,O
number,O
of,O
investigators,O
.,O
It,O
is,O
likely,O
that,O
the,O
improved,O
enzymatic,O
resistance,O
is,O
an,O
important,O
factor,O
in,O
protection,O
against,O
disease,O
progression,O
",",O
since,O
an,O
increase,O
in,O
proteinase,B-GP
activity,O
and,O
a,O
reduction,O
in,O
proteinase,B-GP
inhibitor,O
activity,O
has,O
been,O
identified,O
in,O
keratoconic,O
corneas,O
(,O
Zhou,O
et,O
al,O
".,",O
1998,O
).,O
In,O
order,O
to,O
investigate,O
the,O
efficacy,O
of,O
a,O
number,O
of,O
different,O
epi,O
-,O
on,O
-,O
CXL,O
protocols,O
",",O
we,O
compared,O
the,O
enzymatic,O
resistance,O
of,O
corneal,O
tissue,O
cross,O
-,O
linked,O
using,O
epi,O
-,O
off,O
-,O
CXL,O
with,O
that,O
of,O
corneas,O
treated,O
with,O
partially,O
disrupted,O
-,O
epithelium,O
CXL,O
(,O
dis,O
-,O
CXL,O
"),",O
existing,O
epi,O
-,O
on,O
-,O
CXL,O
protocols,O
(,O
involving,O
different,O
riboflavin,O
formulations,O
and,O
modes,O
of,O
delivery,O
),O
and,O
a,O
prolonged,O
iontophoresis,O
CXL,O
protocol,O
with,O
0,O
.,O
25,O
%,O
riboflavin,O
(,O
TC,O
-,O
ion,O
-,O
CXL,O
),O
that,O
we,O
have,O
recently,O
developed,O
.,O
In,O
addition,O
to,O
this,O
we,O
examined,O
the,O
effect,O
of,O
increasing,O
the,O
cumulative,O
UVA,O
dosage,O
on,O
the,O
enzymatic,O
resistance,O
of,O
corneas,O
treated,O
with,O
iontophoresis,O
-,O
assisted,O
epi,O
-,O
on,O
-,O
CXL,O
.,O
Pepsin,B-GP
was,O
selected,O
as,O
the,O
enzyme,O
of,O
choice,O
for,O
this,O
study,O
in,O
favour,O
of,O
collagenase,B-GP
",",O
as,O
it,O
is,O
a,O
non,O
-,O
specific,O
endopeptidase,B-GP
that,O
can,O
break,O
down,O
both,O
collagen,B-GP
and,O
proteoglycan,O
core,B-GP
proteins,I-GP
",",O
both,O
of,O
which,O
are,O
believed,O
to,O
be,O
sites,O
of,O
riboflavin,O
/,O
UVA,O
induced,O
cross,O
-,O
links,O
(,O
Hayes,O
et,O
al,O
".,",O
2013,O
).,O
Porcine,O
eyes,O
were,O
used,O
as,O
",",O
unlike,O
human,B-OG
cadaver,O
eyes,O
and,O
rabbit,B-OG
eyes,O
which,O
are,O
of,O
limited,O
availability,O
in,O
the,O
UK,O
",",O
they,O
were,O
readily,O
available,O
in,O
the,O
fresh,O
state,O
and,O
in,O
the,O
large,O
numbers,O
required,O
for,O
this,O
study,O
.,O
However,O
",",O
due,O
to,O
the,O
porcine,O
cornea,O
having,O
a,O
thicker,O
epithelium,O
than,O
the,O
human,B-OG
cornea,O
",",O
the,O
results,O
presented,O
herein,O
should,O
be,O
regarded,O
as,O
a,O
conservative,O
assessment,O
of,O
the,O
effectiveness,O
of,O
trans,O
-,O
epithelial,O
CXL,O
.,O
Materials,O
and,O
methods,O
Specimen,O
preparation,O
A,O
total,O
of,O
one,O
hundred,O
and,O
fourteen,O
fresh,O
porcine,O
cadaver,O
eyes,O
with,O
clear,O
corneas,O
and,O
intact,O
epithelium,O
were,O
retrieved,O
from,O
a,O
local,O
European,O
Community,O
licensed,O
abattoir,O
within,O
6,O
–,O
8,O
h,O
of,O
death,O
.,O
Due,O
to,O
the,O
large,O
number,O
of,O
eyes,O
and,O
treatment,O
groups,O
involved,O
",",O
it,O
was,O
necessary,O
to,O
split,O
the,O
study,O
into,O
two,O
runs,O
.,O
Run,O
1,O
examined,O
the,O
effectiveness,O
of,O
dis,O
-,O
CXL,O
and,O
epi,O
-,O
on,O
-,O
CXL,O
protocols,O
at,O
increasing,O
corneal,O
enzymatic,O
resistance,O
to,O
digestion,O
with,O
pepsin,B-GP
",",O
whilst,O
run,O
2,O
examined,O
the,O
effect,O
on,O
enzymatic,O
resistance,O
of,O
increasing,O
the,O
UVA,O
dosage,O
by,O
25,O
%,O
from,O
5,O
.,O
4,O
J,O
/,O
cm2,O
to,O
6,O
.,O
75,O
J,O
/,O
cm2,O
during,O
iontophoretic,O
epi,O
-,O
on,O
-,O
CXL,O
.,O
In,O
both,O
runs,O
",",O
the,O
effectiveness,O
of,O
the,O
standard,O
epi,O
-,O
off,O
CXL,O
protocol,O
at,O
increasing,O
enzymatic,O
resistance,O
was,O
also,O
examined,O
for,O
comparative,O
purposes,O
.,O
The,O
11,O
treatment,O
groups,O
are,O
described,O
below,O
and,O
summarised,O
in,O
Table,O
1,O
.,O
Run,O
1,O
:,O
Each,O
treatment,O
group,O
consisted,O
of,O
six,O
eyes,O
.,O
i,O
),O
Epi,O
-,O
off,O
standard,O
protocol,O
(,O
Group,O
1,O
:,O
Epi,O
-,O
off,O
-,O
ribo,O
;,O
Group,O
2,O
:,O
Epi,O
-,O
off,O
-,O
CXL,O
),O
Complete,O
corneal,O
epithelial,O
debridement,O
was,O
performed,O
in,O
groups,O
1,O
and,O
2,O
using,O
a,O
single,O
edged,O
razor,O
blade,O
.,O
These,O
eyes,O
then,O
received,O
0,O
.,O
1,O
%,O
riboflavin,O
eye,O
drops,O
containing,O
20,O
%,O
dextran,O
T,O
-,O
500,O
solution,O
(,O
Mediocross,O
D,O
"®,",O
Peschke,O
Meditrade,O
",",O
Huenenberg,O
",",O
Switzerland,O
),O
every,O
5,O
min,O
for,O
30,O
min,O
.,O
The,O
central,O
9,O
mm,O
region,O
of,O
corneas,O
in,O
group,O
2,O
was,O
then,O
exposed,O
to,O
365,O
nm,O
UVA,O
light,O
with,O
a,O
fluence,O
of,O
CXL,O
9,O
mW,O
/,O
cm2,O
for,O
10,O
min,O
using,O
a,O
CCL,O
-,O
365,O
Vario,O
™,O
cross,O
-,O
linking,O
system,O
(,O
Peschkmed,O
",",O
Huenenberg,O
",",O
Switzerland,O
).,O
During,O
irradiation,O
",",O
riboflavin,O
was,O
re,O
-,O
applied,O
at,O
5,O
min,O
intervals,O
.,O
Group,O
1,O
served,O
as,O
a,O
non,O
-,O
irradiated,O
control,O
.,O
ii,O
),O
Epi,O
-,O
disrupted,O
protocol,O
(,O
Group,O
3,O
:,O
Dis,O
-,O
ribo,O
;,O
Group,O
4,O
:,O
Dis,O
-,O
CXL,O
),O
Partial,O
epithelial,O
disruption,O
was,O
performed,O
in,O
groups,O
3,O
and,O
4,O
",",O
by,O
making,O
64,O
full,O
-,O
thickness,O
epithelial,O
punctures,O
with,O
a,O
25,O
gauge,O
needle,O
in,O
an,O
8,O
×,O
8,O
grid,O
pattern,O
.,O
The,O
corneas,O
were,O
then,O
soaked,O
in,O
riboflavin,O
0,O
.,O
1,O
%,O
dextran,O
-,O
free,O
solution,O
(,O
Vitamin,O
B2,O
Streuli,O
",",O
Uznach,O
",",O
Switzerland,O
),O
for,O
30,O
min,O
and,O
rinsed,O
with,O
phosphate,O
-,O
buffered,O
saline,O
(,O
PBS,O
),O
for,O
5,O
min,O
.,O
Group,O
4,O
was,O
then,O
irradiated,O
with,O
9,O
mW,O
UVA,O
for,O
10,O
min,O
with,O
PBS,O
applied,O
at,O
5,O
min,O
intervals,O
to,O
keep,O
the,O
corneal,O
surface,O
moist,O
.,O
Group,O
3,O
served,O
as,O
a,O
non,O
-,O
irradiated,O
control,O
.,O
iii,O
),O
Epi,O
-,O
on,O
and,O
high,O
riboflavin,O
concentration,O
protocol,O
(,O
Group,O
5,O
:,O
Medio,O
-,O
ribo,O
;,O
Group,O
6,O
:,O
Medio,O
-,O
CXL,O
),O
Groups,O
5,O
and,O
6,O
received,O
0,O
.,O
25,O
%,O
riboflavin,O
with,O
1,O
.,O
2,O
%,O
hydroxypropylmethyl,O
cellulose,O
(,O
HPMC,O
),O
and,O
0,O
.,O
01,O
%,O
BAC,O
(,O
Mediocross,O
TE,O
"®,",O
Peschketrade,O
",",O
Huenenberg,O
",",O
Switzerland,O
),O
every,O
5,O
min,O
for,O
30,O
min,O
.,O
This,O
was,O
followed,O
by,O
a,O
5,O
min,O
rinse,O
with,O
PBS,O
.,O
Group,O
6,O
was,O
then,O
irradiated,O
with,O
9,O
mW,O
UVA,O
for,O
10,O
min,O
with,O
PBS,O
applied,O
at,O
5,O
min,O
intervals,O
.,O
Group,O
5,O
served,O
as,O
a,O
non,O
-,O
irradiated,O
control,O
.,O
iv,O
),O
Epi,O
-,O
on,O
",",O
high,O
riboflavin,O
concentration,O
and,O
prolonged,O
iontophoresis,O
(,O
St,O
.,O
Thomas,O
-,O
Cardiff,O
),O
protocol,O
(,O
Group,O
7,O
:,O
TC,O
-,O
ion,O
-,O
ribo,O
;,O
Group,O
8,O
:,O
TC,O
-,O
ion,O
-,O
CXL,O
),O
Groups,O
7,O
and,O
8,O
received,O
iontophoresis,O
assisted,O
delivery,O
of,O
0,O
.,O
25,O
%,O
riboflavin,O
with,O
1,O
.,O
2,O
%,O
HPMC,O
and,O
0,O
.,O
01,O
%,O
BAC,O
(,O
Mediocross,O
TE,O
"®,",O
Peschketrade,O
",",O
Huenenberg,O
",",O
Switzerland,O
),O
using,O
a,O
current,O
of,O
1,O
mA,O
for,O
5,O
min,O
.,O
The,O
corneas,O
were,O
then,O
soaked,O
with,O
this,O
riboflavin,O
solution,O
for,O
5,O
min,O
before,O
a,O
further,O
application,O
of,O
iontophoresis,O
with,O
a,O
power,O
of,O
0,O
.,O
5,O
mA,O
/,O
min,O
for,O
5,O
min,O
and,O
another,O
5,O
min,O
riboflavin,O
soak,O
.,O
The,O
iontophoresis,O
delivery,O
system,O
was,O
used,O
to,O
treat,O
ex,O
vivo,O
eyes,O
by,O
connecting,O
the,O
return,O
electrode,O
to,O
a,O
needle,O
inserted,O
into,O
the,O
vitreous,O
chamber,O
;,O
the,O
negative,O
electrode,O
was,O
a,O
steel,O
grid,O
contained,O
in,O
a,O
corneal,O
well,O
applicator,O
which,O
was,O
adhered,O
to,O
the,O
eye,O
by,O
means,O
of,O
a,O
vacuum,O
well,O
system,O
(,O
Fig,O
.,O
1,O
).,O
The,O
steel,O
grid,O
(,O
negative,O
electrode,O
),O
was,O
completely,O
covered,O
with,O
riboflavin,O
and,O
the,O
power,O
generator,O
set,O
to,O
the,O
desired,O
current,O
and,O
duration,O
.,O
The,O
steel,O
grid,O
remained,O
covered,O
with,O
riboflavin,O
solution,O
for,O
the,O
entire,O
procedure,O
.,O
After,O
treatment,O
the,O
applicator,O
was,O
removed,O
from,O
the,O
cornea,O
and,O
the,O
corneas,O
were,O
washed,O
with,O
PBS,O
for,O
5,O
min,O
.,O
Group,O
8,O
was,O
then,O
irradiated,O
with,O
9,O
mW,O
UVA,O
for,O
10min,O
with,O
PBS,O
applied,O
at,O
5,O
min,O
intervals,O
.,O
Group,O
7,O
served,O
as,O
a,O
non,O
-,O
irradiated,O
control,O
.,O
Run,O
2,O
:,O
Each,O
treatment,O
group,O
consisted,O
of,O
11,O
eyes,O
.,O
i,O
),O
Epi,O
-,O
off,O
standard,O
protocol,O
(,O
Group,O
1,O
:,O
Epi,O
-,O
off,O
-,O
ribo,O
;,O
Group,O
2,O
:,O
Epi,O
-,O
off,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
),O
Corneas,O
were,O
treated,O
as,O
described,O
for,O
groups,O
1,O
and,O
2,O
in,O
run,O
1,O
.,O
ii,O
),O
Epi,O
-,O
on,O
",",O
high,O
riboflavin,O
concentration,O
and,O
prolonged,O
iontophoresis,O
(,O
St,O
.,O
Thomas,O
-,O
Cardiff,O
),O
protocol,O
(,O
Group,O
8,O
:,O
TC,O
-,O
ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
;,O
Group,O
9,O
:,O
TC,O
-,O
ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
),O
Groups,O
8,O
and,O
9,O
received,O
iontophoresis,O
assisted,O
delivery,O
of,O
0,O
.,O
25,O
%,O
riboflavin,O
with,O
1,O
.,O
2,O
%,O
HPMC,O
and,O
0,O
.,O
01,O
%,O
BAC,O
(,O
Mediocross,O
TE,O
"®,",O
Peschketrade,O
",",O
Huenenberg,O
",",O
Switzerland,O
),O
using,O
a,O
current,O
of,O
1,O
mA,O
for,O
5min,O
.,O
The,O
corneas,O
were,O
then,O
soaked,O
with,O
this,O
riboflavin,O
solution,O
for,O
5,O
min,O
before,O
a,O
further,O
application,O
of,O
iontophoresis,O
with,O
a,O
power,O
of,O
0,O
.,O
5,O
mA,O
/,O
min,O
for,O
5,O
min,O
and,O
another,O
5,O
min,O
riboflavin,O
soak,O
.,O
Following,O
a,O
3,O
min,O
wash,O
with,O
PBS,O
",",O
the,O
corneas,O
in,O
Group,O
8,O
were,O
irradiated,O
with,O
9,O
mW,O
UVA,O
for,O
10,O
min,O
and,O
those,O
in,O
Group,O
9,O
were,O
irradiated,O
with,O
9,O
mW,O
UVA,O
for,O
12min,O
and,O
30,O
s,O
.,O
During,O
irradiation,O
",",O
PBS,O
was,O
applied,O
to,O
all,O
corneas,O
at,O
5,O
min,O
intervals,O
.,O
iii,O
),O
Epi,O
-,O
on,O
basic,O
iontophoresis,O
protocol,O
(,O
Group,O
10,O
:,O
Ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
;,O
Group,O
11,O
:,O
Ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
),O
Groups,O
10,O
and,O
11,O
underwent,O
iontophoresis,O
assisted,O
riboflavin,O
delivery,O
using,O
an,O
isotonic,O
0,O
.,O
1,O
%,O
riboflavin,O
solution,O
(,O
Vitamin,O
B2,O
),O
containing,O
1,O
.,O
0,O
%,O
HPMC,O
dextran,O
-,O
free,O
solution,O
(,O
Mediocross,O
M,O
"®,",O
Peschketrade,O
",",O
Huenenberg,O
",",O
Switzerland,O
),O
and,O
a,O
1,O
mA,O
current,O
(,O
Iontophoresis,O
device,O
",",O
Sooft,O
Italia,O
S,O
.,O
p,O
.,O
A,O
",",O
Italy,O
).,O
After,O
treatment,O
the,O
corneas,O
were,O
washed,O
with,O
PBS,O
for,O
3,O
min,O
.,O
Group,O
10,O
was,O
then,O
irradiated,O
with,O
9,O
mW,O
UVA,O
for,O
10min,O
and,O
group,O
11,O
was,O
irradiated,O
with,O
9,O
mW,O
UVA,O
for,O
12,O
min,O
and,O
30,O
s,O
.,O
During,O
irradiation,O
",",O
PBS,O
was,O
applied,O
to,O
all,O
corneas,O
at,O
5,O
min,O
intervals,O
.,O
Measurements,O
of,O
corneal,O
thickness,O
Using,O
a,O
Pachette2,O
™,O
Ultrasonic,O
Pachymeter,O
(,O
DGH,O
Technology,O
",",O
Exton,O
",",O
USA,O
"),",O
the,O
central,O
corneal,O
thickness,O
was,O
measured,O
in,O
all,O
eyes,O
prior,O
to,O
treatment,O
and,O
where,O
applicable,O
after,O
removal,O
of,O
the,O
epithelium,O
",",O
application,O
of,O
riboflavin,O
and,O
UVA,O
irradiation,O
.,O
Measurements,O
of,O
enzymatic,O
digestion,O
A,O
corneo,O
-,O
scleral,O
ring,O
was,O
dissected,O
from,O
each,O
eye,O
immediately,O
following,O
treatment,O
",",O
wrapped,O
tightly,O
in,O
Clingfilm,O
™,O
(,O
to,O
prevent,O
moisture,O
loss,O
),O
and,O
refrigerated,O
until,O
all,O
treatments,O
were,O
complete,O
.,O
An,O
8,O
mm,O
corneal,O
button,O
was,O
trephined,O
from,O
the,O
centre,O
of,O
each,O
cornea,O
using,O
a,O
disposable,O
skin,O
biopsy,O
punch,O
.,O
The,O
corneal,O
buttons,O
were,O
then,O
immersed,O
into,O
individual,O
plastic,O
tubes,O
",",O
each,O
containing,O
5,O
ml,O
of,O
pepsin,B-GP
solution,O
",",O
and,O
incubated,O
in,O
a,O
water,O
bath,O
at,O
a,O
temperature,O
of,O
23,O
°,O
C,O
.,O
The,O
pepsin,B-GP
solution,O
was,O
made,O
up,O
of,O
1,O
g,O
of,O
>,O
500,O
U,O
/,O
mg,O
pepsin,B-GP
from,O
porcine,O
gastric,O
mucosa,O
(,O
Sigma,O
-,O
Aldrich,O
",",O
Dorset,O
",",O
UK,O
),O
in,O
10,O
ml,O
0,O
.,O
1,O
M,O
HCL,O
at,O
pH,O
1,O
.,O
2,O
.,O
The,O
structural,O
integrity,O
of,O
the,O
most,O
anterior,O
layers,O
of,O
the,O
cornea,O
was,O
assessed,O
by,O
means,O
of,O
daily,O
measurements,O
of,O
corneal,O
button,O
diameter,O
.,O
The,O
measurements,O
",",O
which,O
were,O
made,O
using,O
an,O
electronic,O
digital,O
caliper,O
",",O
continued,O
until,O
the,O
specimen,O
could,O
no,O
longer,O
be,O
distinguished,O
from,O
the,O
surrounding,O
pepsin,B-GP
solution,O
.,O
At,O
this,O
point,O
the,O
tissue,O
was,O
considered,O
to,O
have,O
undergone,O
complete,O
digestion,O
.,O
As,O
an,O
additional,O
means,O
of,O
assessing,O
enzymatic,O
resistance,O
",",O
5,O
corneal,O
buttons,O
from,O
each,O
of,O
the,O
6,O
treatment,O
groups,O
in,O
run,O
2,O
were,O
removed,O
after,O
11,O
days,O
in,O
pepsin,B-GP
digest,O
solution,O
and,O
placed,O
in,O
a,O
60,O
°,O
C,O
oven,O
until,O
a,O
constant,O
dry,O
weight,O
was,O
obtained,O
.,O
The,O
dry,O
weight,O
of,O
the,O
tissue,O
represents,O
the,O
total,O
mass,O
of,O
undigested,O
tissue,O
and,O
can,O
therefore,O
be,O
used,O
as,O
an,O
indicator,O
of,O
the,O
effective,O
depth,O
of,O
cross,O
-,O
linking,O
.,O
Statistical,O
evaluation,O
Measurements,O
of,O
corneal,O
thickness,O
",",O
complete,O
digestion,O
time,O
and,O
tissue,O
dry,O
weight,O
were,O
statistically,O
analysed,O
using,O
a,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
),O
test,O
.,O
Post,O
hoc,O
Bonferroni,O
comparisons,O
were,O
used,O
to,O
isolate,O
significant,O
interactions,O
.,O
All,O
statistical,O
analyses,O
were,O
performed,O
with,O
the,O
Statistical,O
Package,O
for,O
the,O
Social,O
Sciences,O
(,O
IBM,O
SPSS,O
Statistics,O
20,O
",",O
New,O
York,O
",",O
USA,O
).,O
P,O
<,O
0,O
.,O
01,O
was,O
considered,O
significant,O
.,O
Data,O
were,O
presented,O
in,O
the,O
results,O
as,O
mean,O
±,O
standard,O
deviation,O
(,O
SD,O
).,O
Results,O
Corneal,O
thickness,O
Fig,O
.,O
2,O
shows,O
the,O
average,O
corneal,O
thickness,O
pre,O
-,O
treatment,O
",",O
post,O
-,O
riboflavin,O
application,O
and,O
post,O
-,O
irradiation,O
for,O
each,O
treatment,O
group,O
in,O
runs,O
1,O
and,O
2,O
.,O
Statistical,O
tests,O
revealed,O
that,O
corneas,O
treated,O
using,O
the,O
standard,O
",",O
epi,O
-,O
off,O
protocol,O
and,O
an,O
iso,O
-,O
osmolar,O
riboflavin,O
solution,O
(,O
groups,O
1,O
and,O
2,O
),O
were,O
significantly,O
thinner,O
than,O
the,O
corneas,O
in,O
all,O
other,O
groups,O
(,O
p,O
<,O
0,O
.,O
007,O
).,O
Qualitative,O
assessment,O
of,O
riboflavin,O
uptake,O
As,O
shown,O
in,O
Fig,O
.,O
3,O
",",O
the,O
distinctive,O
yellow,O
colouration,O
of,O
riboflavin,O
was,O
most,O
clearly,O
visible,O
in,O
the,O
epi,O
-,O
off,O
and,O
TC,O
-,O
ion,O
treated,O
corneas,O
.,O
Although,O
riboflavin,O
was,O
also,O
seen,O
in,O
corneas,O
from,O
other,O
treatment,O
groups,O
",",O
the,O
colour,O
was,O
notably,O
less,O
intense,O
.,O
Photographs,O
recorded,O
during,O
the,O
irradiation,O
process,O
in,O
run,O
2,O
showed,O
a,O
non,O
-,O
homogenous,O
distribution,O
of,O
riboflavin,O
in,O
Ion,O
-,O
CXL,O
treated,O
corneas,O
and,O
a,O
more,O
uniform,O
distribution,O
following,O
epi,O
-,O
off,O
CXL,O
and,O
TC,O
-,O
Ion,O
-,O
CXL,O
.,O
Pepsin,B-GP
digestion,O
of,O
corneal,O
buttons,O
Table,O
2,O
shows,O
the,O
number,O
of,O
days,O
required,O
for,O
complete,O
tissue,O
digestion,O
to,O
occur,O
in,O
each,O
irradiated,O
and,O
non,O
-,O
irradiated,O
treatment,O
group,O
.,O
Although,O
the,O
digestion,O
times,O
of,O
equivalent,O
non,O
-,O
irradiated,O
(,O
group,O
1,O
),O
and,O
cross,O
-,O
linked,O
treatment,O
groups,O
(,O
group,O
2,O
),O
were,O
seen,O
to,O
vary,O
slightly,O
between,O
runs,O
1,O
and,O
2,O
",",O
possibly,O
as,O
a,O
result,O
of,O
differences,O
in,O
the,O
breed,O
and,O
age,O
of,O
the,O
pig,B-OG
eyes,O
",",O
the,O
overall,O
trends,O
were,O
consistent,O
between,O
the,O
two,O
runs,O
.,O
For,O
this,O
reason,O
the,O
data,O
from,O
each,O
run,O
was,O
normalized,O
against,O
the,O
total,O
digestion,O
time,O
of,O
the,O
standard,O
epi,O
-,O
off,O
CXL,O
group,O
to,O
facilitate,O
comparison,O
between,O
the,O
two,O
runs,O
(,O
Fig,O
.,O
4,O
",",O
Fig,O
.,O
5,O
).,O
Fig,O
.,O
4,O
",",O
Fig,O
.,O
5,O
show,O
cumulative,O
measurements,O
of,O
corneal,O
disk,O
diameter,O
for,O
each,O
irradiated,O
and,O
non,O
-,O
irradiated,O
treatment,O
group,O
throughout,O
the,O
digestion,O
process,O
.,O
In,O
both,O
runs,O
1,O
and,O
2,O
",",O
the,O
cross,O
-,O
linked,O
groups,O
showed,O
a,O
significantly,O
greater,O
resistance,O
to,O
enzymatic,O
digestion,O
than,O
the,O
non,O
-,O
irradiated,O
groups,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
In,O
run,O
1,O
",",O
complete,O
digestion,O
of,O
all,O
non,O
-,O
irradiated,O
corneas,O
had,O
occurred,O
by,O
day,O
13,O
(,O
Table,O
2,O
).,O
At,O
the,O
same,O
time,O
point,O
(,O
normalized,O
digestion,O
time,O
of,O
0,O
.,O
33,O
"),",O
the,O
mean,O
diameter,O
of,O
the,O
epi,O
-,O
off,O
-,O
CXL,O
",",O
dis,O
-,O
CXL,O
",",O
medio,O
-,O
CXL,O
and,O
TC,O
-,O
ion,O
-,O
CXL,O
groups,O
had,O
only,O
decreased,O
by,O
39,O
"%,",O
62,O
"%,",O
74,O
"%,",O
and,O
40,O
%,O
respectively,O
(,O
Fig,O
.,O
4,O
).,O
No,O
significant,O
difference,O
was,O
found,O
between,O
the,O
non,O
-,O
irradiated,O
groups,O
in,O
terms,O
of,O
either,O
the,O
average,O
corneal,O
button,O
diameter,O
at,O
any,O
time,O
point,O
in,O
the,O
digestion,O
process,O
or,O
in,O
the,O
time,O
required,O
for,O
complete,O
digestion,O
to,O
occur,O
(,O
Fig,O
.,O
4,O
).,O
There,O
were,O
however,O
significant,O
differences,O
between,O
the,O
cross,O
-,O
linked,O
groups,O
in,O
term,O
of,O
the,O
time,O
taken,O
for,O
complete,O
digestion,O
to,O
occur,O
(,O
Fig,O
.,O
4,O
).,O
The,O
conventionally,O
treated,O
",",O
epi,O
-,O
off,O
-,O
CXL,O
corneas,O
(,O
group,O
2,O
),O
took,O
significantly,O
longer,O
to,O
digest,O
than,O
all,O
other,O
cross,O
-,O
linked,O
corneas,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
Although,O
less,O
resistant,O
to,O
enzyme,O
digestion,O
than,O
the,O
epi,O
-,O
off,O
-,O
CXL,O
corneas,O
",",O
the,O
TC,O
-,O
ion,O
-,O
CXL,O
treated,O
corneas,O
(,O
group,O
8,O
),O
took,O
significantly,O
longer,O
to,O
digest,O
than,O
corneas,O
treated,O
with,O
other,O
disrupted,O
epithelium,O
(,O
dis,O
-,O
CXL,O
),O
or,O
epi,O
-,O
on,O
-,O
CXL,O
protocols,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
In,O
run,O
2,O
",",O
the,O
non,O
-,O
irradiated,O
corneas,O
were,O
completely,O
digested,O
by,O
day,O
10,O
(,O
Table,O
2,O
).,O
At,O
this,O
same,O
time,O
point,O
",",O
which,O
corresponds,O
to,O
a,O
normalized,O
digestion,O
time,O
of,O
0,O
.,O
25,O
",",O
the,O
mean,O
diameter,O
of,O
corneas,O
in,O
the,O
epi,O
-,O
off,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
",",O
TC,O
-,O
ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
",",O
TC,O
-,O
ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
",",O
Ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
and,O
Ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
treatment,O
groups,O
had,O
reduced,O
by,O
21,O
.,O
4,O
"%,",O
16,O
.,O
2,O
"%,",O
13,O
.,O
4,O
"%,",O
26,O
.,O
7,O
%,O
and,O
19,O
.,O
4,O
%,O
respectively,O
(,O
Fig,O
.,O
5,O
).,O
Significant,O
differences,O
in,O
the,O
mean,O
disk,O
diameter,O
of,O
the,O
CXL,O
treatment,O
groups,O
were,O
only,O
apparent,O
after,O
24,O
days,O
of,O
digestion,O
(,O
corresponding,O
to,O
a,O
normalized,O
digestion,O
time,O
of,O
0,O
.,O
6,O
in,O
Fig,O
.,O
5,O
).,O
The,O
epi,O
-,O
off,O
-,O
CXL,O
group,O
(,O
group,O
2,O
),O
took,O
longer,O
to,O
undergo,O
complete,O
digestion,O
than,O
all,O
other,O
cross,O
-,O
linked,O
groups,O
(,O
p,O
<,O
0,O
.,O
0001,O
),O
but,O
corneas,O
treated,O
with,O
the,O
prolonged,O
",",O
high,O
riboflavin,O
concentration,O
",",O
iontophoresis,O
protocol,O
(,O
TC,O
-,O
ion,O
-,O
CXL,O
),O
were,O
found,O
to,O
persist,O
in,O
the,O
pepsin,B-GP
digest,O
solution,O
for,O
significantly,O
longer,O
than,O
those,O
treated,O
with,O
the,O
basic,O
Ion,O
-,O
CXL,O
protocol,O
(,O
Fig,O
.,O
5,O
).,O
In,O
both,O
the,O
Ion,O
-,O
CXL,O
and,O
TC,O
-,O
ion,O
-,O
CXL,O
treatment,O
groups,O
",",O
an,O
increase,O
in,O
UVA,O
radiance,O
from,O
5,O
.,O
4,O
J,O
/,O
cm2,O
to,O
6,O
.,O
75,O
J,O
/,O
cm2,O
resulted,O
in,O
a,O
significant,O
increase,O
in,O
the,O
time,O
required,O
for,O
complete,O
digestion,O
to,O
occur,O
(,O
P,O
<,O
0,O
.,O
0001,O
).,O
Undigested,O
tissue,O
mass,O
In,O
run,O
2,O
",",O
only,O
the,O
cross,O
-,O
linked,O
corneas,O
remained,O
after,O
11,O
days,O
in,O
pepsin,B-GP
digest,O
solution,O
(,O
Fig,O
.,O
6,O
).,O
At,O
this,O
time,O
point,O
",",O
the,O
average,O
stromal,O
dry,O
weight,O
of,O
the,O
epi,O
-,O
off,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
treated,O
corneas,O
(,O
group,O
2,O
),O
was,O
significantly,O
higher,O
than,O
that,O
of,O
all,O
other,O
treatment,O
groups,O
(,O
groups,O
8,O
",",O
10,O
",",O
11,O
",",O
P,O
<,O
0,O
.,O
0001,O
;,O
group,O
9,O
",",O
P,O
<,O
0,O
.,O
001,O
).,O
The,O
stromal,O
dry,O
weight,O
did,O
not,O
differ,O
significantly,O
between,O
the,O
Ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
and,O
Ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
treatment,O
groups,O
(,O
p,O
=,O
0,O
.,O
32,O
),O
or,O
between,O
the,O
TC,O
-,O
ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
and,O
TC,O
-,O
ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
groups,O
(,O
p,O
=,O
0,O
.,O
038,O
).,O
However,O
",",O
corneas,O
treated,O
with,O
the,O
TC,O
-,O
Ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
protocol,O
had,O
a,O
higher,O
stromal,O
dry,O
weight,O
than,O
corneas,O
treated,O
with,O
basic,O
ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
protocol,O
(,O
p,O
<,O
0,O
.,O
003,O
).,O
Discussion,O
Attaining,O
adequate,O
stromal,O
riboflavin,O
concentration,O
is,O
essential,O
for,O
CXL,O
.,O
Riboflavin,O
acts,O
as,O
a,O
photo,O
-,O
sensitizer,O
for,O
the,O
production,O
of,O
oxygen,O
free,O
radicals,O
",",O
which,O
drive,O
the,O
CXL,O
process,O
(,O
McCall,O
et,O
al,O
".,",O
2010,O
),O
and,O
as,O
a,O
result,O
insufficient,O
stromal,O
absorption,O
may,O
result,O
in,O
treatment,O
failure,O
(,O
Wollensak,O
et,O
al,O
".,",O
2003,O
",",O
Wollensak,O
and,O
Iomdina,O
",",O
2009,O
).,O
As,O
riboflavin,O
is,O
a,O
hydrophilic,O
molecule,O
which,O
cannot,O
penetrate,O
epithelial,O
cell,O
membranes,O
and,O
tight,O
junctions,O
",",O
the,O
first,O
riboflavin,O
/,O
UVA,O
CXL,O
protocols,O
required,O
complete,O
central,O
corneal,O
epithelial,O
debridement,O
prior,O
to,O
riboflavin,O
application,O
(,O
Spoerl,O
et,O
al,O
".,",O
1998,O
",",O
Wollensak,O
et,O
al,O
".,",O
2003,O
).,O
Although,O
epi,O
-,O
off,O
-,O
CXL,O
is,O
considered,O
to,O
be,O
the,O
gold,O
standard,O
procedure,O
",",O
with,O
multiple,O
prospective,O
and,O
randomized,O
controlled,O
studies,O
demonstrating,O
its,O
efficacy,O
in,O
terms,O
of,O
cessation,O
of,O
keratoconus,B-DS
progression,O
and,O
improvements,O
in,O
keratometric,O
and,O
visual,O
parameters,O
(,O
Caporossi,O
et,O
al,O
".,",O
2006,O
",",O
Gkika,O
et,O
al,O
".,",O
2011,O
",",O
O,O
',O
Brart,O
et,O
al,O
".,",O
2011,O
",",O
Richoz,O
et,O
al,O
".,",O
2013,O
",",O
Wittig,O
-,O
Silva,O
et,O
al,O
".,",O
2014,O
",",O
Wollensak,O
et,O
al,O
".,",O
2003,O
"),",O
new,O
methods,O
of,O
epi,O
-,O
on,O
-,O
CXL,O
have,O
been,O
postulated,O
to,O
remove,O
the,O
need,O
for,O
epithelial,O
debridement,O
",",O
thereby,O
alleviating,O
post,O
-,O
operative,O
pain,O
and,O
potential,O
risks,O
of,O
infection,B-DS
(,O
Koller,O
et,O
al,O
".,",O
2009,O
).,O
In,O
addition,O
",",O
to,O
reduce,O
the,O
long,O
treatment,O
times,O
associated,O
with,O
epi,O
-,O
off,O
-,O
CXL,O
with,O
3mw,O
/,O
cm2,O
UVA,O
irradiation,O
",",O
the,O
use,O
of,O
A,O
-,O
CXL,O
protocols,O
using,O
the,O
same,O
energy,O
dose,O
but,O
higher,O
UVA,O
intensities,O
and,O
shorter,O
exposure,O
times,O
have,O
been,O
advocated,O
.,O
In,O
order,O
to,O
evaluate,O
the,O
efficacy,O
of,O
such,O
differing,O
CXL,O
protocols,O
",",O
multiple,O
methodologies,O
",",O
including,O
extensiometry,O
(,O
Cassagne,O
et,O
al,O
".,",O
2016,O
",",O
Kissner,O
et,O
al,O
".,",O
2010,O
",",O
Vinciguerra,O
et,O
al,O
".,",O
2014a,O
",",O
Wollensak,O
and,O
Iomdina,O
",",O
2009,O
"),",O
shear,O
wave,O
elastography,O
(,O
Touboul,O
et,O
al,O
".,",O
2014,O
"),",O
Brillouin,O
microscopy,O
(,O
Scarcelli,O
et,O
al,O
".,",O
2013,O
),O
and,O
Scheimpflug,O
air,O
pulse,O
tonometry,O
(,O
Mastropasqua,O
et,O
al,O
".,",O
2014,O
),O
have,O
been,O
employed,O
.,O
However,O
each,O
of,O
these,O
methodologies,O
have,O
their,O
inherent,O
inaccuracies,O
and,O
as,O
yet,O
there,O
is,O
no,O
agreed,O
best,O
practice,O
for,O
assessing,O
biomechanical,O
changes,O
following,O
CXL,O
.,O
Although,O
the,O
precise,O
aetiology,O
of,O
keratoconus,B-DS
is,O
unknown,O
(,O
Davidson,O
et,O
al,O
".,",O
2014,O
"),",O
an,O
increased,O
activity,O
of,O
protease,B-GP
enzymes,O
and,O
reduced,O
activity,O
of,O
protease,B-GP
inhibitors,O
has,O
been,O
identified,O
(,O
Spoerl,O
et,O
al,O
".,",O
2004,O
"),",O
with,O
the,O
resultant,O
increase,O
in,O
stromal,O
protein,O
digestion,O
liable,O
to,O
be,O
a,O
factor,O
in,O
corneal,B-DS
thinning,I-DS
and,O
secondary,O
biomechanical,O
instability,O
(,O
Andreassen,O
et,O
al,O
".,",O
1980,O
).,O
Spoerl,O
et,O
al,O
.,O
(,O
2004,O
),O
reported,O
increased,O
resistance,O
of,O
stromal,O
tissue,O
to,O
enzymatic,O
digestion,O
following,O
epi,O
-,O
off,O
CXL,O
with,O
a,O
dose,O
response,O
related,O
to,O
the,O
intensity,O
of,O
UVA,O
irradiance,O
.,O
This,O
increased,O
resistance,O
to,O
protease,B-GP
digestion,O
following,O
CXL,O
has,O
been,O
replicated,O
by,O
others,O
(,O
Hayes,O
et,O
al,O
".,",O
2013,O
",",O
Aldahlawi,O
et,O
al,O
".,",O
2016,O
),O
and,O
is,O
thought,O
to,O
be,O
an,O
important,O
factor,O
in,O
preventing,O
disease,O
progression,O
.,O
In,O
this,O
study,O
we,O
utilized,O
enzymatic,O
resistance,O
to,O
pepsin,B-GP
digestion,O
to,O
evaluate,O
the,O
effects,O
of,O
epi,O
-,O
off,O
-,O
CXL,O
",",O
dis,O
-,O
CXL,O
and,O
epi,O
-,O
on,O
-,O
CXL,O
.,O
Although,O
minor,O
differences,O
in,O
the,O
rate,O
of,O
enzymatic,O
digestion,O
were,O
seen,O
between,O
similarly,O
treated,O
corneas,O
in,O
runs,O
1,O
and,O
2,O
",",O
possibly,O
due,O
to,O
variations,O
in,O
the,O
age,O
and,O
breed,O
of,O
the,O
pig,B-OG
eyes,O
in,O
different,O
batches,O
of,O
abattoir,O
tissue,O
",",O
each,O
run,O
showed,O
an,O
increased,O
resistance,O
in,O
all,O
of,O
the,O
cross,O
-,O
linked,O
groups,O
compared,O
to,O
their,O
non,O
-,O
irradiated,O
controls,O
.,O
However,O
",",O
in,O
accordance,O
with,O
the,O
findings,O
of,O
Wollensak,O
and,O
Iomdina,O
(,O
2009,O
"),",O
which,O
reported,O
corneal,O
stiffness,O
after,O
epi,O
-,O
on,O
-,O
CXL,O
to,O
be,O
only,O
one,O
fifth,O
of,O
that,O
seen,O
after,O
epi,O
-,O
off,O
-,O
CXL,O
(,O
indicating,O
a,O
reduced,O
crosslinking,O
effect,O
"),",O
we,O
found,O
enzymatic,O
resistance,O
to,O
be,O
significantly,O
greater,O
with,O
epi,O
-,O
off,O
-,O
CXL,O
than,O
with,O
dis,O
-,O
CXL,O
or,O
epi,O
-,O
on,O
-,O
CXL,O
.,O
Whilst,O
dis,O
-,O
CXL,O
showed,O
a,O
greater,O
resistance,O
to,O
digestion,O
than,O
the,O
non,O
-,O
irradiated,O
controls,O
",",O
it,O
was,O
not,O
as,O
effective,O
as,O
the,O
other,O
epi,O
-,O
on,O
-,O
CXL,O
protocols,O
tested,O
",",O
possibly,O
due,O
to,O
the,O
non,O
-,O
homogeneous,O
uptake,O
of,O
riboflavin,O
that,O
we,O
have,O
documented,O
previously,O
(,O
Alhamad,O
et,O
al,O
".,",O
2012,O
).,O
Such,O
observations,O
are,O
supported,O
by,O
a,O
recently,O
published,O
",",O
randomized,O
controlled,O
study,O
which,O
showed,O
better,O
corneal,O
flattening,O
with,O
epi,O
-,O
off,O
-,O
CXL,O
than,O
dis,O
-,O
CXL,O
",",O
although,O
interestingly,O
",",O
dis,O
-,O
CXL,O
resulted,O
in,O
better,O
improvement,O
of,O
corrected,O
distance,O
visual,O
acuity,O
at,O
6,O
months,O
(,O
Razmjoo,O
et,O
al,O
".,",O
2014,O
).,O
In,O
this,O
study,O
we,O
showed,O
that,O
corneas,O
cross,O
-,O
linked,O
using,O
Mediocross,O
TE,O
®,O
(,O
Medio,O
-,O
CXL,O
protocol,O
),O
showed,O
a,O
greater,O
resistance,O
to,O
enzymatic,O
digestion,O
than,O
non,O
-,O
irradiated,O
controls,O
and,O
dis,O
-,O
CXL,O
treated,O
corneas,O
.,O
However,O
",",O
the,O
enhanced,O
enzymatic,O
resistance,O
achieved,O
with,O
Medio,O
-,O
CXL,O
was,O
found,O
to,O
be,O
inferior,O
to,O
that,O
of,O
the,O
epi,O
-,O
off,O
and,O
ion,O
-,O
CXL,O
protocols,O
.,O
Mediocross,O
TE,O
®,O
is,O
a,O
hypo,O
-,O
osmolar,O
riboflavin,O
solution,O
that,O
contains,O
0,O
.,O
01,O
%,O
BAC,O
",",O
a,O
cationic,O
surfactant,O
that,O
can,O
disrupt,O
epithelial,O
tight,O
junctions,O
to,O
increase,O
corneal,O
permeability,O
to,O
riboflavin,O
(,O
Kissner,O
et,O
al,O
".,",O
2010,O
",",O
Raiskup,O
et,O
al,O
".,",O
2012,O
).,O
Laboratory,O
studies,O
have,O
shown,O
that,O
preparations,O
with,O
sodium,O
chloride,O
and,O
BAC,O
can,O
facilitate,O
riboflavin,O
transfer,O
through,O
an,O
intact,O
epithelium,O
albeit,O
in,O
a,O
reduced,O
concentration,O
compared,O
to,O
the,O
epi,O
-,O
off,O
-,O
CXL,O
(,O
Touboul,O
et,O
al,O
".,",O
2014,O
"),",O
and,O
with,O
significant,O
associated,O
superficial,O
epithelial,O
damage,O
(,O
Uematsu,O
et,O
al,O
".,",O
2007,O
).,O
Published,O
clinical,O
studies,O
using,O
enhanced,O
riboflavin,O
solutions,O
with,O
epithelial,O
penetration,O
enhancers,O
are,O
limited,O
and,O
have,O
produced,O
equivocal,O
results,O
.,O
Some,O
have,O
reported,O
similar,O
efficacy,O
to,O
epi,O
-,O
off,O
-,O
CXL,O
(,O
Filippello,O
et,O
al,O
".,",O
2012,O
",",O
Magli,O
et,O
al,O
".,",O
2013,O
"),",O
while,O
others,O
have,O
demonstrated,O
less,O
pronounced,O
effects,O
with,O
high,O
rates,O
of,O
treatment,O
failure,O
(,O
Buzzonetti,O
and,O
Petrocelli,O
",",O
2012,O
",",O
Kocak,O
et,O
al,O
".,",O
2014,O
",",O
Koppen,O
et,O
al,O
".,",O
2012,O
",",O
Leccisotti,O
and,O
Islam,O
",",O
2010,O
).,O
There,O
are,O
currently,O
only,O
three,O
published,O
randomized,O
",",O
controlled,O
trials,O
comparing,O
epi,O
-,O
off,O
and,O
epi,O
-,O
on,O
-,O
CXL,O
.,O
Two,O
of,O
the,O
studies,O
",",O
with,O
follow,O
-,O
up,O
times,O
of,O
up,O
to,O
12,O
months,O
",",O
reported,O
similar,O
outcomes,O
(,O
Nawaz,O
et,O
al,O
".,",O
2015,O
",",O
Rossi,O
et,O
al,O
".,",O
2015,O
).,O
However,O
",",O
the,O
third,O
study,O
",",O
showed,O
epi,O
-,O
on,O
-,O
CXL,O
to,O
be,O
safe,O
but,O
demonstrated,O
continued,O
progression,O
of,O
keratoconus,B-DS
in,O
23,O
%,O
of,O
cases,O
at,O
12,O
month,O
follow,O
-,O
up,O
(,O
Soeters,O
et,O
al,O
".,",O
2015,O
).,O
The,O
latter,O
result,O
is,O
consistent,O
with,O
the,O
less,O
pronounced,O
biomechanical,O
changes,O
observed,O
experimentally,O
following,O
epi,O
-,O
on,O
-,O
CXL,O
(,O
Wollensak,O
and,O
Iomdina,O
",",O
2009,O
).,O
As,O
riboflavin,O
is,O
negatively,O
charged,O
at,O
physiological,O
pH,O
and,O
soluble,O
in,O
water,O
",",O
the,O
use,O
of,O
iontophoresis,O
has,O
been,O
postulated,O
to,O
enhance,O
trans,O
-,O
epithelial,O
absorption,O
.,O
Commercially,O
recommended,O
protocols,O
for,O
iontophoresis,O
utilize,O
0,O
.,O
1,O
%,O
riboflavin,O
solution,O
and,O
electrical,O
currents,O
of,O
0,O
.,O
5,O
–,O
1,O
mA,O
for,O
5,O
–,O
10,O
min,O
.,O
Treatment,O
of,O
rabbit,B-OG
corneas,O
by,O
this,O
means,O
has,O
been,O
shown,O
to,O
reduce,O
the,O
stromal,O
riboflavin,O
uptake,O
achieved,O
with,O
epi,O
-,O
off,O
-,O
CXL,O
by,O
two,O
thirds,O
",",O
but,O
to,O
produce,O
a,O
similar,O
improvement,O
in,O
corneal,O
biomechanics,O
(,O
Cassagne,O
et,O
al,O
".,",O
2016,O
).,O
Studies,O
on,O
rabbit,B-OG
and,O
human,B-OG
cadaver,O
corneas,O
have,O
demonstrated,O
similar,O
findings,O
",",O
with,O
better,O
riboflavin,O
penetration,O
and,O
increased,O
elastometry,O
measurements,O
obtained,O
with,O
Ion,O
-,O
CXL,O
than,O
with,O
epi,O
-,O
on,O
-,O
CXL,O
(,O
using,O
Ricrolin,O
TE,O
),O
but,O
less,O
than,O
epi,O
-,O
off,O
-,O
CXL,O
(,O
Vinciguerra,O
et,O
al,O
".,",O
2014a,O
).,O
In,O
a,O
human,B-OG
donor,O
eye,O
model,O
",",O
Mastropasqua,O
et,O
al,O
.,O
demonstrated,O
a,O
corneal,O
stiffening,O
effect,O
following,O
Ion,O
-,O
CXL,O
(,O
Mastropasqua,O
et,O
al,O
".,",O
2014,O
"),",O
with,O
Lombardo,O
et,O
al,O
.,O
(,O
2014,O
),O
reporting,O
an,O
almost,O
comparable,O
effect,O
on,O
corneal,O
stiffness,O
to,O
that,O
with,O
epi,O
-,O
off,O
-,O
CXL,O
.,O
These,O
findings,O
have,O
been,O
confirmed,O
by,O
supersonic,O
shear,O
wave,O
elastography,O
(,O
Touboul,O
et,O
al,O
".,",O
2014,O
).,O
Furthermore,O
",",O
initial,O
clinical,O
studies,O
in,O
prospective,O
case,O
series,O
have,O
reported,O
cessation,O
of,O
keratoconus,B-DS
progression,O
with,O
up,O
to,O
15,O
month,O
follow,O
-,O
up,O
and,O
some,O
limited,O
improvements,O
in,O
keratometric,O
and,O
visual,O
parameters,O
(,O
Bikbova,O
and,O
Bikbov,O
",",O
2014,O
",",O
Buzzonetti,O
et,O
al,O
".,",O
2015,O
",",O
Vinciguerra,O
et,O
al,O
".,",O
2014b,O
).,O
However,O
",",O
the,O
relative,O
efficacy,O
of,O
this,O
technique,O
compared,O
to,O
epi,O
-,O
off,O
-,O
CXL,O
remains,O
to,O
be,O
determined,O
especially,O
over,O
longer,O
term,O
follow,O
-,O
up,O
.,O
Using,O
spectrophotometry,O
(,O
Hayes,O
et,O
al,O
".,",O
2015,O
),O
and,O
two,O
-,O
photon,O
fluorescence,O
microscopy,O
(,O
Gore,O
et,O
al,O
".,",O
2014,O
"),",O
we,O
have,O
found,O
that,O
stromal,O
riboflavin,O
absorption,O
in,O
epithelium,O
-,O
intact,O
corneas,O
can,O
be,O
improved,O
by,O
increasing,O
riboflavin,O
concentration,O
",",O
epithelial,O
contact,O
time,O
and,O
iontophoresis,O
dosage,O
.,O
Based,O
on,O
this,O
work,O
",",O
we,O
have,O
modified,O
the,O
basic,O
Sooft,O
italia,O
Ion,O
-,O
CXL,O
protocol,O
(,O
Sooft,O
italia,O
S,O
.,O
p,O
.,O
A,O
",",O
Motegiorgio,O
",",O
Italy,O
),O
and,O
developed,O
the,O
St,O
Thomas,O
',O
s,O
/,O
Cardiff,O
modified,O
iontophoresis,O
protocol,O
(,O
TC,O
-,O
ion,O
-,O
CXL,O
),O
which,O
uses,O
Mediocross,O
TE,O
®,O
as,O
the,O
iontophoretic,O
solution,O
instead,O
of,O
Ricrolin,O
"+®,",O
as,O
the,O
riboflavin,O
concentration,O
of,O
the,O
former,O
is,O
higher,O
(,O
0,O
.,O
25,O
%),O
and,O
the,O
use,O
of,O
the,O
cationic,O
surfactant,O
BAC,O
has,O
been,O
shown,O
with,O
percutaneous,O
treatment,O
to,O
have,O
synergistic,O
effect,O
with,O
iontophoresis,O
on,O
the,O
transport,O
of,O
anions,O
(,O
Fang,O
et,O
al,O
".,",O
1998,O
).,O
In,O
addition,O
to,O
using,O
this,O
formulation,O
",",O
the,O
modified,O
protocol,O
employed,O
a,O
riboflavin,O
-,O
epithelial,O
contact,O
period,O
of,O
5,O
min,O
after,O
iontophoresis,O
to,O
allow,O
time,O
for,O
the,O
sub,O
-,O
epithelial,O
iontophoretically,O
delivered,O
riboflavin,O
to,O
diffuse,O
homogeneously,O
into,O
the,O
stroma,O
",",O
as,O
well,O
as,O
an,O
increased,O
dosage,O
of,O
iontophoresis,O
with,O
a,O
second,O
treatment,O
5,O
min,O
after,O
the,O
first,O
.,O
Results,O
from,O
the,O
present,O
study,O
demonstrated,O
that,O
both,O
the,O
basic,O
Ion,O
-,O
CXL,O
and,O
modified,O
TC,O
-,O
ion,O
-,O
CXL,O
protocols,O
resulted,O
in,O
a,O
greater,O
resistance,O
to,O
enzymatic,O
digestion,O
than,O
all,O
other,O
dis,O
-,O
CXL,O
and,O
trans,O
-,O
epithelial,O
CXL,O
protocols,O
tested,O
.,O
Furthermore,O
",",O
as,O
we,O
have,O
demonstrated,O
previously,O
for,O
epi,O
-,O
off,O
CXL,O
treated,O
corneas,O
(,O
Aldahlawi,O
et,O
al,O
".,",O
2016,O
"),",O
we,O
have,O
now,O
shown,O
that,O
the,O
enzymatic,O
resistance,O
of,O
Ion,O
-,O
CXL,O
and,O
TC,O
-,O
ion,O
-,O
CXL,O
treated,O
corneas,O
can,O
also,O
be,O
enhanced,O
by,O
increasing,O
the,O
cumulative,O
energy,O
dose,O
and,O
allowing,O
additional,O
type,O
I,O
photochemical,O
cross,O
-,O
linking,O
to,O
occur,O
.,O
The,O
improvement,O
in,O
enzymatic,O
resistance,O
was,O
evidenced,O
by,O
the,O
Ion,O
-,O
CXL,O
and,O
TC,O
-,O
ion,O
-,O
CXL,O
corneas,O
treated,O
with,O
a,O
total,O
energy,O
dose,O
of,O
6,O
.,O
75,O
J,O
/,O
cm2,O
persisting,O
for,O
longer,O
in,O
enzyme,O
digest,O
solution,O
than,O
those,O
that,O
received,O
a,O
lower,O
energy,O
dose,O
of,O
5,O
.,O
4,O
J,O
/,O
cm2,O
.,O
The,O
absence,O
of,O
any,O
difference,O
in,O
their,O
dry,O
weights,O
after,O
11,O
days,O
of,O
digestion,O
is,O
likely,O
explained,O
by,O
the,O
fact,O
that,O
at,O
this,O
stage,O
of,O
the,O
digestion,O
process,O
",",O
the,O
rate,O
of,O
digestion,O
was,O
similar,O
for,O
both,O
the,O
high,O
and,O
low,O
energy,O
treatment,O
groups,O
and,O
significant,O
differences,O
in,O
average,O
corneal,O
disk,O
diameter,O
were,O
not,O
observed,O
until,O
day,O
24,O
.,O
The,O
enzymatic,O
resistance,O
achieved,O
with,O
the,O
TC,O
-,O
ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
protocol,O
was,O
closest,O
to,O
that,O
of,O
the,O
standard,O
epi,O
-,O
off,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
protocol,O
",",O
suggesting,O
that,O
this,O
technique,O
may,O
be,O
the,O
best,O
trans,O
-,O
epithelial,O
alternative,O
for,O
epi,O
-,O
off,O
-,O
CXL,O
.,O
Its,O
slightly,O
lower,O
efficacy,O
compared,O
to,O
epi,O
-,O
off,O
-,O
CXL,O
",",O
demonstrated,O
by,O
measurements,O
of,O
corneal,O
disk,O
diameter,O
and,O
tissue,O
dry,O
weight,O
",",O
may,O
be,O
due,O
to,O
a,O
reduced,O
riboflavin,O
stromal,O
absorption,O
or,O
due,O
to,O
other,O
factors,O
.,O
These,O
might,O
include,O
absorption,O
of,O
UVA,O
by,O
riboflavin,O
within,O
the,O
epithelium,O
",",O
resulting,O
in,O
shielding,O
of,O
the,O
underlying,O
stroma,O
and,O
a,O
reduced,O
UVA,O
dosage,O
to,O
the,O
stroma,O
",",O
although,O
this,O
is,O
unlikely,O
as,O
a,O
3,O
min,O
PBS,O
wash,O
of,O
the,O
ocular,O
surface,O
was,O
performed,O
before,O
UVA,O
exposure,O
.,O
Another,O
possible,O
cause,O
of,O
the,O
reduced,O
efficacy,O
might,O
be,O
the,O
oxygen,O
consumption,O
by,O
the,O
epithelium,O
itself,O
(,O
Harvitt,O
and,O
Bonanno,O
",",O
1998,O
"),",O
which,O
could,O
reduce,O
the,O
amount,O
of,O
oxygen,O
available,O
to,O
the,O
stroma,O
to,O
drive,O
the,O
CXL,O
process,O
(,O
McCall,O
et,O
al,O
".,",O
2010,O
).,O
Such,O
problems,O
may,O
be,O
overcome,O
by,O
additional,O
manipulation,O
of,O
the,O
UVA,O
dosage,O
",",O
in,O
terms,O
of,O
its,O
intensity,O
and,O
duration,O
and,O
/,O
or,O
by,O
increasing,O
oxygen,O
availability,O
and,O
require,O
further,O
investigation,O
.,O
One,O
further,O
explanation,O
may,O
be,O
the,O
limitation,O
of,O
our,O
porcine,O
model,O
.,O
As,O
the,O
porcine,O
cornea,O
has,O
a,O
much,O
thicker,O
corneal,O
epithelium,O
than,O
the,O
human,B-OG
cornea,O
(,O
90,O
μm,O
and,O
50,O
μm,O
respectively,O
"),",O
the,O
results,O
of,O
the,O
current,O
study,O
should,O
be,O
regarded,O
as,O
a,O
conservative,O
assessment,O
of,O
the,O
effectiveness,O
of,O
trans,O
-,O
epithelial,O
CXL,O
.,O
Unfortunately,O
",",O
human,B-OG
donor,O
corneas,O
are,O
unsuitable,O
for,O
examining,O
the,O
effects,O
of,O
CXL,O
on,O
enzymatic,O
resistance,O
due,O
to,O
the,O
fact,O
that,O
donors,O
are,O
typically,O
over,O
60,O
years,O
old,O
",",O
and,O
the,O
naturally,O
occurring,O
cross,O
-,O
links,O
which,O
increase,O
with,O
age,O
",",O
may,O
mask,O
the,O
effects,O
of,O
the,O
CXL,O
treatment,O
under,O
investigation,O
.,O
However,O
",",O
it,O
would,O
be,O
interesting,O
to,O
repeat,O
our,O
methodology,O
in,O
the,O
rabbit,B-OG
model,O
which,O
has,O
a,O
thinner,O
epithelium,O
(,O
40,O
μm,O
),O
and,O
is,O
closer,O
in,O
thickness,O
to,O
that,O
of,O
the,O
human,B-OG
cornea,O
.,O
Such,O
a,O
study,O
would,O
complement,O
our,O
current,O
findings,O
by,O
providing,O
a,O
more,O
liberal,O
estimate,O
of,O
the,O
effectiveness,O
of,O
trans,O
-,O
epithelial,O
cross,O
-,O
linking,O
.,O
This,O
study,O
",",O
which,O
shows,O
our,O
St,O
Thomas,O
'/,O
Cardiff,O
modified,O
iontophoresis,O
protocol,O
(,O
TC,O
-,O
ion,O
-,O
CXL,O
),O
to,O
be,O
more,O
effective,O
than,O
other,O
trans,O
-,O
epithelial,O
CXL,O
protocols,O
at,O
increasing,O
the,O
enzymatic,O
resistance,O
of,O
the,O
cornea,O
supports,O
the,O
concept,O
that,O
iontophoresis,O
-,O
assisted,O
CXL,O
may,O
",",O
with,O
modifications,O
in,O
terms,O
of,O
riboflavin,O
concentration,O
",",O
duration,O
of,O
iontophoretic,O
treatment,O
",",O
riboflavin,O
soak,O
-,O
time,O
and,O
UVA,O
energy,O
dose,O
",",O
be,O
an,O
effective,O
technique,O
to,O
prevent,O
the,O
progression,O
of,O
keratoconus,B-DS
and,O
avoid,O
the,O
postoperative,O
pain,O
associated,O
with,O
epithelial,O
debridement,O
.,O
Such,O
a,O
technique,O
is,O
envisaged,O
to,O
be,O
especially,O
useful,O
for,O
eyes,O
that,O
are,O
not,O
eligible,O
for,O
treatment,O
with,O
epi,O
-,O
off,O
-,O
CXL,O
due,O
to,O
minimum,O
corneal,O
thickness,O
values,O
less,O
than,O
400,O
μm,O
.,O
Further,O
laboratory,O
studies,O
to,O
optimize,O
this,O
protocol,O
and,O
randomized,O
",",O
prospective,O
clinical,O
studies,O
to,O
compare,O
its,O
efficacy,O
with,O
epi,O
-,O
off,O
CXL,O
are,O
indicated,O
and,O
are,O
currently,O
being,O
undertaken,O
(,O
O,O
',O
Brart,O
D,O
",",O
personal,O
communication,O
",",O
International,O
Standard,O
Randomized,O
Controlled,O
Trials,O
Number,O
:,O
04451470,O
).,O
Conflict,O
of,O
interest,O
The,O
authors,O
have,O
no,O
conflicts,O
of,O
interest,O
to,O
disclose,O
.,O
Iontophoresis,O
riboflavin,O
delivery,O
system,O
modified,O
for,O
use,O
in,O
ex,O
-,O
vivo,O
eyes,O
.,O
Corneal,O
thickness,O
measurements,O
are,O
shown,O
for,O
each,O
group,O
in,O
run,O
1,O
and,O
run,O
2,O
before,O
treatment,O
",",O
after,O
riboflavin,O
application,O
and,O
where,O
applicable,O
",",O
following,O
UVA,O
irradiation,O
.,O
*,O
In,O
groups,O
1,O
and,O
2,O
the,O
corneal,O
epithelium,O
(,O
measuring,O
∼,O
90,O
μm,O
in,O
thickness,O
),O
was,O
removed,O
as,O
part,O
of,O
the,O
riboflavin,O
application,O
process,O
.,O
Corneal,O
buttons,O
from,O
each,O
group,O
in,O
run,O
1,O
and,O
2,O
are,O
shown,O
immediately,O
post,O
-,O
treatment,O
.,O
The,O
characteristic,O
yellow,O
colour,O
of,O
riboflavin,O
can,O
be,O
seen,O
most,O
clearly,O
in,O
the,O
epithelium,O
-,O
removed,O
",",O
riboflavin,O
treated,O
corneas,O
(,O
epi,O
-,O
off,O
),O
and,O
in,O
the,O
corneas,O
that,O
received,O
riboflavin,O
via,O
the,O
St,O
Thomas,O
',O
s,O
/,O
Cardiff,O
modified,O
iontophoresis,O
protocol,O
(,O
TC,O
-,O
Ion,O
).,O
Photographs,O
recorded,O
during,O
the,O
irradiation,O
process,O
show,O
a,O
non,O
-,O
homogenous,O
distribution,O
of,O
riboflavin,O
in,O
corneas,O
treated,O
with,O
the,O
basic,O
iontophoresis,O
protocol,O
(,O
Ion,O
-,O
CXL,O
).,O
The,O
summed,O
diameter,O
of,O
all,O
corneal,O
disks,O
within,O
each,O
treatment,O
group,O
(,O
n,O
=,O
6,O
),O
are,O
shown,O
for,O
run,O
1,O
as,O
a,O
function,O
of,O
time,O
in,O
pepsin,B-GP
digest,O
solution,O
.,O
The,O
digestion,O
time,O
for,O
each,O
treatment,O
group,O
has,O
been,O
normalized,O
against,O
the,O
total,O
digestion,O
time,O
of,O
the,O
standard,O
epi,O
-,O
off,O
CXL,O
group,O
.,O
The,O
summed,O
diameter,O
of,O
all,O
corneal,O
disks,O
within,O
each,O
treatment,O
group,O
(,O
n,O
=,O
6,O
),O
are,O
shown,O
for,O
run,O
2,O
as,O
a,O
function,O
of,O
time,O
in,O
pepsin,B-GP
digest,O
solution,O
.,O
The,O
digestion,O
time,O
for,O
each,O
treatment,O
group,O
has,O
been,O
normalized,O
against,O
the,O
total,O
digestion,O
time,O
of,O
the,O
standard,O
epi,O
-,O
off,O
CXL,O
group,O
.,O
Corneal,O
button,O
dry,O
weight,O
after,O
11,O
days,O
of,O
digestion,O
.,O
Error,O
bars,O
show,O
standard,O
deviation,O
.,O
Treatment,O
groups,O
.,O
Group,O
Abbreviation,O
Epithelium,O
Riboflavin,O
formulation,O
Ionto,O
(,O
1,O
mA,O
),O
Ribo,O
soak,O
Ionto,O
(,O
0,O
.,O
5,O
mA,O
),O
Ribo,O
soak,O
Saline,O
rinse,O
9,O
mW,O
UVA,O
Applied,O
during,O
irradiation,O
(,O
1,O
),O
Epithelium,O
-,O
off,O
non,O
-,O
irradiated,O
control,O
Epi,O
-,O
off,O
-,O
ribo,O
Off,O
Mediocross,O
D,O
:,O
0,O
.,O
1,O
%,O
Riboflavin,O
",",O
20,O
%,O
dextran,O
–,O
30,O
min,O
–,O
–,O
–,O
–,O
–,O
(,O
2,O
),O
Epithelium,O
-,O
off,O
standard,O
CXL,O
Epi,O
-,O
off,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
Off,O
Mediocross,O
D,O
–,O
30,O
min,O
–,O
–,O
–,O
10,O
min,O
Mediocross,O
D,O
(,O
3,O
),O
Disrupted,O
epithelium,O
non,O
-,O
irradiated,O
control,O
Dis,O
-,O
ribo,O
Disrupted,O
Vitamin,O
B2,O
Streuli,O
:,O
0,O
.,O
1,O
%,O
riboflavin,O
",",O
saline,O
–,O
30,O
min,O
–,O
–,O
5,O
min,O
–,O
–,O
(,O
4,O
),O
Disrupted,O
epithelium,O
CXL,O
Dis,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
Disrupted,O
Vitamin,O
B2,O
Streuli,O
–,O
30,O
min,O
–,O
–,O
5,O
min,O
10,O
min,O
PBS,O
(,O
5,O
),O
Epithelium,O
intact,O
non,O
-,O
irradiated,O
control,O
Medio,O
-,O
ribo,O
On,O
Mediocross,O
TE,O
:,O
0,O
.,O
25,O
%,O
riboflavin,O
",",O
1,O
.,O
2,O
%,O
HPMC,O
",",O
0,O
.,O
01,O
%,O
BACS,O
",",O
Pi,O
-,O
water,O
–,O
30,O
min,O
–,O
–,O
5,O
min,O
–,O
–,O
(,O
6,O
),O
Epithelium,O
intact,O
high,O
riboflavin,O
concentration,O
CXL,O
Medio,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
On,O
Mediocross,O
TE,O
–,O
30,O
min,O
–,O
–,O
5,O
min,O
10,O
min,O
PBS,O
(,O
7,O
),O
Epithelium,O
intact,O
",",O
high,O
riboflavin,O
concentration,O
and,O
prolonged,O
iontophoresis,O
non,O
-,O
irradiated,O
control,O
TC,O
-,O
ion,O
-,O
ribo,O
On,O
Mediocross,O
TE,O
5,O
min,O
5,O
min,O
5,O
min,O
5,O
min,O
5,O
min,O
–,O
–,O
(,O
8,O
),O
Epithelium,O
intact,O
",",O
high,O
riboflavin,O
concentration,O
and,O
prolonged,O
iontophoresis,O
CXL,O
TC,O
-,O
ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
On,O
Mediocross,O
TE,O
5,O
min,O
5,O
min,O
5,O
min,O
5,O
min,O
5,O
min,O
10,O
min,O
PBS,O
(,O
9,O
),O
Epithelium,O
intact,O
",",O
high,O
riboflavin,O
concentration,O
",",O
prolonged,O
iontophoresis,O
and,O
high,O
UVA,O
energy,O
dose,O
CXL,O
TC,O
-,O
ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
On,O
Mediocross,O
TE,O
5,O
min,O
5,O
min,O
5,O
min,O
5,O
min,O
3,O
min,O
12,O
min,O
30,O
s,O
PBS,O
(,O
10,O
),O
Epithelium,O
intact,O
",",O
basic,O
iontophoresis,O
protocol,O
Ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
On,O
Mediocross,O
M,O
:,O
0,O
.,O
1,O
%,O
riboflavin,O
",",O
1,O
.,O
0,O
%,O
HPMC,O
5,O
min,O
–,O
–,O
–,O
3,O
min,O
10,O
min,O
PBS,O
(,O
11,O
),O
Epithelium,O
intact,O
",",O
basic,O
iontophoresis,O
protocol,O
with,O
high,O
UVA,O
energy,O
dose,O
Ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
On,O
Mediocross,O
M,O
5,O
min,O
–,O
–,O
–,O
3,O
min,O
12,O
min,O
30,O
s,O
PBS,O
Time,O
taken,O
for,O
the,O
complete,O
tissue,O
digestion,O
to,O
occur,O
.,O
Groups,O
Time,O
taken,O
for,O
complete,O
digestion,O
(,O
in,O
days,O
),O
Minimum,O
Maximum,O
Average,O
(±,O
SD,O
),O
RUN,O
1,O
(,O
1,O
),O
Epi,O
-,O
off,O
-,O
ribo,O
11,O
12,O
11,O
.,O
5,O
±,O
0,O
.,O
55,O
(,O
2,O
),O
Epi,O
-,O
off,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
39,O
40,O
39,O
.,O
5,O
±,O
0,O
.,O
55,O
(,O
3,O
),O
Dis,O
-,O
ribo,O
11,O
13,O
11,O
.,O
8,O
±,O
0,O
.,O
75,O
(,O
4,O
),O
Dis,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
15,O
16,O
15,O
.,O
6,O
±,O
0,O
.,O
52,O
(,O
5,O
),O
Medio,O
-,O
ribo,O
11,O
12,O
11,O
.,O
6,O
±,O
0,O
.,O
51,O
(,O
6,O
),O
Medio,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
14,O
15,O
14,O
.,O
6,O
±,O
0,O
.,O
52,O
(,O
7,O
),O
TC,O
-,O
ion,O
-,O
ribo,O
11,O
12,O
11,O
.,O
3,O
±,O
0,O
.,O
52,O
(,O
8,O
),O
TC,O
-,O
ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
32,O
33,O
32,O
.,O
2,O
±,O
0,O
.,O
41,O
RUN,O
2,O
(,O
1,O
),O
Epi,O
-,O
off,O
-,O
ribo,O
9,O
10,O
9,O
.,O
5,O
±,O
0,O
.,O
55,O
(,O
2,O
),O
Epi,O
-,O
off,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
43,O
44,O
43,O
.,O
5,O
±,O
0,O
.,O
55,O
(,O
8,O
),O
TC,O
-,O
ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
34,O
35,O
34,O
.,O
3,O
±,O
0,O
.,O
52,O
(,O
9,O
),O
TC,O
-,O
ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
41,O
42,O
41,O
.,O
7,O
±,O
0,O
.,O
52,O
(,O
10,O
),O
Ion,O
-,O
CXL,O
5,O
.,O
4,O
J,O
/,O
cm2,O
27,O
28,O
27,O
.,O
3,O
±,O
0,O
.,O
52,O
(,O
11,O
),O
Ion,O
-,O
CXL,O
6,O
.,O
75,O
J,O
/,O
cm2,O
34,O
35,O
34,O
.,O
5,O
±,O
0,O
.,O
55,O
Evaluation,O
of,O
current,O
prediction,O
models,O
for,O
Lynch,B-DS
syndrome,I-DS
:,O
updating,O
the,O
PREMM5,O
model,O
to,O
identify,O
PMS2,B-GP
mutation,O
carriers,O
Until,O
recently,O
",",O
no,O
prediction,O
models,O
for,O
Lynch,B-DS
syndrome,I-DS
(,O
LS,B-DS
),O
had,O
been,O
validated,O
for,O
PMS2,B-GP
mutation,O
carriers,O
.,O
We,O
aimed,O
to,O
evaluate,O
MMRpredict,O
and,O
PREMM5,O
in,O
a,O
clinical,O
cohort,O
and,O
for,O
PMS2,B-GP
mutation,O
carriers,O
specifically,O
.,O
In,O
a,O
retrospective,O
",",O
clinic,O
-,O
based,O
cohort,O
we,O
calculated,O
predictions,O
for,O
LS,B-DS
according,O
to,O
MMRpredict,O
and,O
PREMM5,O
.,O
The,O
area,O
under,O
the,O
operator,O
receiving,O
characteristic,O
curve,O
(,O
AUC,O
),O
was,O
compared,O
between,O
MMRpredict,O
and,O
PREMM5,O
for,O
LS,B-DS
patients,O
in,O
general,O
and,O
for,O
different,O
LS,B-DS
genes,O
specifically,O
.,O
Of,O
734,O
index,O
patients,O
",",O
83,O
(,O
11,O
%),O
were,O
diagnosed,O
with,O
LS,B-DS
;,O
23,O
MLH1,B-GP
",",O
17,O
MSH2,B-GP
",",O
31,O
MSH6,B-GP
and,O
12,O
PMS2,B-GP
mutation,O
carriers,O
.,O
Both,O
prediction,O
models,O
performed,O
well,O
for,O
MLH1,B-GP
and,O
MSH2,B-GP
(,O
AUC,O
0,O
.,O
80,O
and,O
0,O
.,O
83,O
for,O
PREMM5,O
and,O
0,O
.,O
79,O
for,O
MMRpredict,O
),O
and,O
fair,O
for,O
MSH6,B-GP
mutation,O
carriers,O
(,O
0,O
.,O
69,O
for,O
PREMM5,O
and,O
0,O
.,O
66,O
for,O
MMRpredict,O
).,O
MMRpredict,O
performed,O
fair,O
for,O
PMS2,B-GP
mutation,O
carriers,O
(,O
AUC,O
0,O
.,O
72,O
"),",O
while,O
PREMM5,O
failed,O
to,O
discriminate,O
PMS2,B-GP
mutation,O
carriers,O
from,O
non,O
-,O
mutation,O
carriers,O
(,O
AUC,O
0,O
.,O
51,O
).,O
The,O
only,O
statistically,O
significant,O
difference,O
between,O
PMS2,B-GP
mutation,O
carriers,O
and,O
non,O
-,O
mutation,O
carriers,O
was,O
proximal,O
location,O
of,O
colorectal,B-DS
cancer,I-DS
(,O
77,O
vs,O
.,O
28,O
"%,",O
p,O
<,O
0,O
.,O
001,O
).,O
Adding,O
location,O
of,O
colorectal,B-DS
cancer,I-DS
to,O
PREMM5,O
considerably,O
improved,O
the,O
models,O
performance,O
for,O
PMS2,B-GP
mutation,O
carriers,O
(,O
AUC,O
0,O
.,O
77,O
),O
and,O
overall,O
(,O
AUC,O
0,O
.,O
81,O
vs,O
.,O
0,O
.,O
72,O
).,O
We,O
validated,O
these,O
results,O
in,O
an,O
external,O
cohort,O
of,O
376,O
colorectal,B-DS
cancer,I-DS
patients,O
",",O
including,O
158,O
LS,B-DS
patients,O
.,O
MMRpredict,O
and,O
PREMM5,O
cannot,O
adequately,O
identify,O
PMS2,B-GP
mutation,O
carriers,O
.,O
Adding,O
location,O
of,O
colorectal,B-DS
cancer,I-DS
to,O
PREMM5,O
may,O
improve,O
the,O
performance,O
of,O
this,O
model,O
",",O
which,O
should,O
be,O
validated,O
in,O
larger,O
cohorts,O
.,O
Electronic,O
supplementary,O
material,O
The,O
online,O
version,O
of,O
this,O
article,O
(,O
doi,O
:,O
10,O
.,O
1007,O
/,O
s10689,O
-,O
017,O
-,O
0039,O
-,O
1,O
),O
contains,O
supplementary,O
material,O
",",O
which,O
is,O
available,O
to,O
authorized,O
users,O
.,O
Introduction,O
Lynch,B-DS
syndrome,I-DS
(,O
LS,B-DS
),O
is,O
a,O
hereditary,O
predisposition,O
to,O
colorectal,B-DS
cancer,I-DS
",",O
endometrial,B-DS
cancer,I-DS
and,O
other,O
extra,O
-,O
colonic,B-DS
cancers,I-DS
at,O
a,O
young,O
age,O
[,O
1,O
",",O
2,O
].,O
Morbidity,O
and,O
mortality,O
of,O
LS,B-DS
carriers,O
can,O
be,O
significantly,O
reduced,O
by,O
surveillance,O
programs,O
[,O
3,O
–,O
5,O
].,O
Therefore,O
identifying,O
LS,B-DS
carriers,O
is,O
of,O
great,O
importance,O
.,O
LS,B-DS
is,O
caused,O
by,O
a,O
germline,O
mutation,O
in,O
one,O
of,O
the,O
mismatch,O
repair,O
(,O
MMR,O
),O
genes,O
MLH1,B-GP
",",O
MSH2,B-GP
",",O
MSH6,B-GP
or,O
PMS2,B-GP
",",O
or,O
in,O
the,O
3,O
′,O
end,O
of,O
the,O
EPCAM,B-GP
gene,O
and,O
consequent,O
hypermethylation,O
of,O
the,O
MSH2,B-GP
promoter,O
region,O
[,O
6,O
–,O
10,O
].,O
As,O
a,O
result,O
",",O
tumours,B-DS
in,O
LS,B-DS
patients,O
are,O
characterized,O
by,O
microsatellite,O
instability,O
(,O
MSI,O
),O
and,O
by,O
loss,O
of,O
MMR,O
protein,O
expression,O
in,O
immunohistochemistry,O
(,O
IHC,O
),O
[,O
11,O
–,O
13,O
].,O
Analysis,O
of,O
MSI,O
and,O
IHC,O
",",O
combined,O
with,O
MLH1,B-GP
promoter,O
methylation,O
analysis,O
to,O
exclude,O
sporadic,O
MMR,O
deficient,O
tumours,B-DS
",",O
are,O
used,O
to,O
identify,O
patients,O
with,O
tumours,B-DS
likely,O
caused,O
by,O
LS,B-DS
[,O
13,O
].,O
A,O
definite,O
diagnosis,O
of,O
LS,B-DS
is,O
made,O
when,O
a,O
pathogenic,O
germline,O
mutation,O
is,O
found,O
.,O
The,O
revised,O
Bethesda,O
guidelines,O
were,O
based,O
on,O
a,O
set,O
of,O
diagnostic,O
criteria,O
to,O
select,O
patients,O
eligible,O
for,O
LS,B-DS
screening,O
in,O
tumour,B-DS
tissue,O
.,O
However,O
",",O
due,O
to,O
limited,O
sensitivity,O
",",O
many,O
LS,B-DS
patients,O
will,O
likely,O
be,O
missed,O
by,O
these,O
guidelines,O
[,O
14,O
–,O
17,O
].,O
Several,O
prediction,O
models,O
",",O
such,O
as,O
MMRpro,O
",",O
MMRpredict,O
and,O
PREMM5,O
have,O
also,O
been,O
developed,O
to,O
calculate,O
an,O
individual,O
’,O
s,O
probability,O
of,O
carrying,O
a,O
germline,O
MMR,O
mutation,O
[,O
18,O
–,O
20,O
].,O
These,O
models,O
could,O
aid,O
in,O
the,O
selection,O
of,O
patients,O
at,O
high,O
risk,O
of,O
having,O
LS,B-DS
",",O
for,O
tumour,B-DS
analysis,O
or,O
direct,O
germline,O
mutation,O
analysis,O
.,O
MMRpro,O
is,O
less,O
useful,O
in,O
clinical,O
practice,O
since,O
detailed,O
information,O
of,O
all,O
relatives,O
is,O
needed,O
as,O
input,O
for,O
the,O
model,O
[,O
19,O
].,O
However,O
",",O
MMRpredict,O
and,O
PREMM1,O
",",O
2,O
",",O
6,O
(,O
a,O
previous,O
version,O
of,O
the,O
newly,O
developed,O
PREMM5,O
model,O
),O
both,O
performed,O
well,O
in,O
previous,O
evaluations,O
[,O
21,O
–,O
27,O
].,O
An,O
advantage,O
of,O
PREMM5,O
is,O
that,O
it,O
can,O
also,O
be,O
used,O
for,O
individuals,O
with,O
extracolonic,O
malignancies,O
and,O
healthy,O
individuals,O
",",O
as,O
opposed,O
to,O
MMRpredict,O
",",O
which,O
can,O
only,O
be,O
used,O
for,O
CRC,B-DS
patients,O
.,O
Until,O
recently,O
",",O
all,O
prediction,O
models,O
for,O
LS,B-DS
were,O
developed,O
with,O
cohorts,O
of,O
patients,O
carrying,O
a,O
MLH1,B-GP
",",O
MSH2,B-GP
",",O
or,O
MSH6,B-GP
mutation,O
.,O
The,O
recently,O
published,O
PREMM5,O
model,O
is,O
the,O
only,O
model,O
that,O
included,O
PMS2,B-GP
mutation,O
carriers,O
in,O
its,O
development,O
.,O
In,O
this,O
study,O
we,O
aimed,O
to,O
evaluate,O
MMRpredict,O
and,O
PREMM5,O
in,O
a,O
clinical,O
cohort,O
and,O
for,O
PMS2,B-GP
mutation,O
carriers,O
specifically,O
.,O
Additionally,O
",",O
we,O
aimed,O
to,O
identify,O
clinical,O
features,O
useful,O
for,O
distinguishing,O
PMS2,B-GP
mutation,O
carriers,O
from,O
non,O
-,O
mutation,O
carriers,O
.,O
Methods,O
In,O
a,O
retrospective,O
",",O
clinic,O
-,O
based,O
cohort,O
we,O
assessed,O
the,O
performance,O
of,O
MMRpredict,O
and,O
PREMM5,O
in,O
predicting,O
LS,B-DS
mutations,O
in,O
general,O
and,O
for,O
MLH1,B-GP
",",O
MSH2,B-GP
",",O
MSH6,B-GP
and,O
PMS2,B-GP
mutations,O
specifically,O
.,O
Additionally,O
",",O
we,O
performed,O
a,O
univariate,O
analysis,O
to,O
identify,O
variables,O
that,O
can,O
distinguish,O
PMS2,B-GP
mutation,O
carriers,O
from,O
patients,O
with,O
no,O
MMR,O
mutation,O
.,O
Study,O
population,O
We,O
collected,O
data,O
for,O
all,O
families,O
that,O
were,O
referred,O
for,O
genetic,O
counselling,O
at,O
Erasmus,O
MC,O
",",O
Rotterdam,O
",",O
The,O
Netherlands,O
",",O
and,O
in,O
which,O
colorectal,B-DS
cancer,I-DS
was,O
analysed,O
for,O
MSI,O
and,O
/,O
or,O
IHC,O
between,O
2000,O
and,O
2010,O
.,O
Exclusion,O
criteria,O
were,O
:,O
failed,O
or,O
inconclusive,O
analysis,O
for,O
MSI,O
and,O
IHC,O
",",O
a,O
pathogenic,O
mutation,O
in,O
APC,B-GP
or,O
MUTYH,B-GP
",",O
a,O
variant,O
of,O
unknown,O
clinical,O
significance,O
in,O
one,O
of,O
the,O
MMR,O
genes,O
or,O
APC,B-GP
",",O
and,O
MSI,O
or,O
IHC,O
suspect,O
for,O
LS,B-DS
while,O
no,O
MMR,O
mutation,O
was,O
detected,O
.,O
To,O
increase,O
the,O
number,O
of,O
LS,B-DS
families,O
",",O
35,O
LS,B-DS
families,O
outside,O
our,O
cohort,O
",",O
diagnosed,O
after,O
2010,O
",",O
were,O
also,O
included,O
in,O
the,O
analysis,O
.,O
Analysis,O
of,O
MSI,O
and,O
IHC,O
MSI,O
analysis,O
was,O
carried,O
out,O
with,O
five,O
markers,O
for,O
MSI,O
as,O
described,O
previously,O
;,O
up,O
to,O
2007,O
the,O
Bethesda,O
panel,O
[,O
28,O
],O
was,O
used,O
and,O
from,O
2007,O
onwards,O
our,O
center,O
performs,O
Promega,O
pentaplex,O
MSI,O
analysis,O
[,O
29,O
].,O
IHC,O
for,O
MLH1,B-GP
",",O
MSH2,B-GP
",",O
MSH6,B-GP
and,O
PMS2,B-GP
protein,O
was,O
performed,O
as,O
described,O
previously,O
[,O
13,O
].,O
Tumours,B-DS
without,O
MSI,O
or,O
only,O
a,O
low,O
degree,O
of,O
MSI,O
and,O
with,O
all,O
MMR,O
proteins,O
present,O
",",O
were,O
considered,O
MMR,O
proficient,O
.,O
Tumours,B-DS
showing,O
a,O
high,O
degree,O
of,O
MSI,O
and,O
/,O
or,O
absence,O
of,O
one,O
or,O
more,O
MMR,O
proteins,O
",",O
were,O
considered,O
MMR,O
deficient,O
.,O
MLH1,B-GP
hypermethylation,O
analysis,O
was,O
performed,O
to,O
distinguish,O
between,O
sporadic,O
MMR,O
deficient,O
tumours,B-DS
and,O
MMR,O
deficient,O
tumours,B-DS
suspect,O
for,O
LS,B-DS
.,O
Germline,O
mutation,O
analysis,O
Patients,O
with,O
MMR,O
deficient,O
tumours,B-DS
suspect,O
for,O
LS,B-DS
underwent,O
germline,O
mutation,O
analysis,O
of,O
the,O
gene,O
indicated,O
by,O
IHC,O
.,O
Germline,O
mutation,O
analysis,O
of,O
MLH1,B-GP
",",O
MSH2,B-GP
and,O
MSH6,B-GP
was,O
performed,O
by,O
sequencing,O
and,O
multiplex,O
ligation,O
dependent,O
probe,O
amplification,O
analyses,O
.,O
PMS2,B-GP
mutation,O
analysis,O
was,O
performed,O
as,O
described,O
elsewhere,O
[,O
30,O
].,O
Family,O
classification,O
Tumour,B-DS
characteristics,O
",",O
age,O
at,O
diagnosis,O
",",O
results,O
of,O
molecular,O
diagnostics,O
and,O
germline,O
mutation,O
analysis,O
",",O
and,O
a,O
detailed,O
family,O
history,O
were,O
collected,O
from,O
medical,O
records,O
.,O
In,O
every,O
family,O
the,O
patient,O
in,O
whom,O
MSI,O
and,O
/,O
or,O
IHC,O
was,O
analysed,O
",",O
was,O
labelled,O
the,O
index,O
patient,O
.,O
If,O
more,O
than,O
one,O
family,O
member,O
was,O
screened,O
for,O
LS,B-DS
",",O
the,O
youngest,O
CRC,B-DS
patient,O
analysed,O
was,O
considered,O
the,O
index,O
patient,O
.,O
Index,O
patients,O
with,O
MMR,O
proficient,O
tumours,B-DS
or,O
sporadic,O
MMR,O
deficient,O
tumours,B-DS
",",O
were,O
labelled,O
non,O
-,O
mutation,O
carriers,O
.,O
Families,O
identified,O
with,O
a,O
pathogenic,O
MMR,O
mutation,O
were,O
labelled,O
LS,B-DS
families,O
.,O
Prediction,O
models,O
For,O
each,O
index,O
patient,O
the,O
probability,O
of,O
carrying,O
a,O
LS,B-DS
mutation,O
according,O
to,O
MMRpredict,O
and,O
PREMM5,O
was,O
calculated,O
as,O
previously,O
described,O
[,O
18,O
",",O
20,O
].,O
For,O
PREMM5,O
",",O
the,O
equation,O
was,O
slightly,O
different,O
from,O
the,O
published,O
equation,O
",",O
based,O
on,O
personal,O
communications,O
with,O
F,O
.,O
Kastrinos,O
.,O
See,O
Supplemental,O
Material,O
(,O
Appendix,O
1,O
),O
for,O
the,O
corrected,O
PREMM5,O
equation,O
.,O
Statistical,O
analysis,O
Data,O
were,O
analyzed,O
using,O
SPSS,O
statistical,O
software,O
version,O
21,O
.,O
0,O
.,O
Differences,O
between,O
mutation,O
carriers,O
and,O
non,O
-,O
mutation,O
carriers,O
were,O
compared,O
using,O
the,O
Chi,O
square,O
test,O
or,O
Fishers,O
’,O
exact,O
test,O
for,O
frequencies,O
",",O
and,O
by,O
using,O
the,O
Mann,O
Whitney,O
U,O
test,O
for,O
continuous,O
data,O
.,O
These,O
analysis,O
were,O
also,O
performed,O
to,O
compare,O
PMS2,B-GP
mutation,O
carriers,O
with,O
non,O
-,O
mutation,O
carriers,O
.,O
P,O
values,O
<,O
0,O
.,O
01,O
were,O
considered,O
statistically,O
significant,O
.,O
Receiver,O
operating,O
characteristic,O
curves,O
were,O
created,O
for,O
MMRpredict,O
and,O
PREMM5,O
by,O
plotting,O
the,O
true,O
positive,O
rate,O
(,O
sensitivity,O
),O
against,O
the,O
false,O
positive,O
rate,O
(,O
1,O
-,O
specificity,O
).,O
Performance,O
of,O
MMRpredict,O
and,O
PREMM5,O
was,O
evaluated,O
by,O
the,O
area,O
under,O
the,O
receiver,O
operating,O
characteristic,O
curve,O
(,O
AUC,O
).,O
We,O
compared,O
the,O
AUC,O
of,O
PREMM5,O
and,O
MMRpredict,O
for,O
LS,B-DS
patients,O
in,O
general,O
and,O
for,O
the,O
different,O
MMR,O
genes,O
specifically,O
.,O
Sensitivity,O
and,O
specificity,O
were,O
calculated,O
for,O
cut,O
-,O
offs,O
previously,O
indicated,O
by,O
the,O
developers,O
of,O
the,O
models,O
(,O
5,O
",",O
10,O
",",O
20,O
and,O
40,O
%).,O
These,O
values,O
were,O
compared,O
with,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
revised,O
Bethesda,O
guidelines,O
.,O
Model,O
updating,O
Location,O
of,O
CRC,B-DS
is,O
included,O
in,O
MMRpredict,O
",",O
but,O
not,O
in,O
the,O
PREMM5,O
model,O
.,O
To,O
update,O
the,O
PREMM5,O
model,O
",",O
we,O
used,O
a,O
previously,O
proposed,O
framework,O
to,O
update,O
multinomial,O
logistic,O
regression,O
models,O
[,O
31,O
].,O
We,O
extended,O
the,O
PREMM5,O
model,O
using,O
recalibration,O
and,O
extension,O
.,O
The,O
PREMM5,O
model,O
contains,O
four,O
linear,O
predictors,O
",",O
each,O
contributing,O
weights,O
to,O
the,O
probability,O
of,O
carrying,O
a,O
mutation,O
in,O
MLH1,B-GP
",",O
MSH2,B-GP
(,O
or,O
TACSTD1,B-GP
"),",O
MSH6,B-GP
and,O
PMS2,B-GP
.,O
The,O
coefficients,O
of,O
the,O
linear,O
predictors,O
were,O
constrained,O
such,O
that,O
the,O
linear,O
predictor,O
only,O
contributed,O
to,O
the,O
calculation,O
of,O
the,O
corresponding,O
mutation,O
.,O
Since,O
the,O
original,O
PREMM5,O
model,O
was,O
developed,O
on,O
a,O
population,O
with,O
no,O
MSH6,B-GP
mutation,O
carriers,O
with,O
two,O
or,O
more,O
CRCs,B-DS
",",O
we,O
developed,O
two,O
adaptations,O
of,O
the,O
PREMM5,O
model,O
.,O
First,O
we,O
recalibrated,O
the,O
PREMM5,O
model,O
and,O
re,O
-,O
estimated,O
the,O
coefficient,O
of,O
the,O
predictor,O
‘,O
Two,O
or,O
more,O
CRCs,B-DS
’,O
in,O
the,O
linear,O
predictor,O
for,O
MSH6,B-GP
.,O
In,O
the,O
second,O
adaptation,O
we,O
also,O
added,O
side,O
of,O
CRC,B-DS
as,O
an,O
additional,O
predictor,O
to,O
the,O
original,O
PREMM5,O
model,O
.,O
Discriminative,O
ability,O
of,O
the,O
prediction,O
models,O
was,O
quantified,O
using,O
the,O
AUC,O
.,O
Calculations,O
were,O
done,O
using,O
R,O
software,O
(,O
version,O
3,O
.,O
3,O
.,O
0,O
"),",O
with,O
estimation,O
of,O
the,O
coefficients,O
in,O
the,O
updated,O
PREMM5,O
model,O
using,O
the,O
VGAM,O
package,O
.,O
Validation,O
of,O
the,O
extended,O
PREMM5,O
model,O
For,O
external,O
validation,O
of,O
the,O
extended,O
PREMM5,O
model,O
",",O
we,O
used,O
a,O
cohort,O
of,O
376,O
CRC,B-DS
patients,O
.,O
Of,O
these,O
patients,O
",",O
218,O
were,O
patients,O
with,O
MMR,O
proficient,O
CRC,B-DS
",",O
that,O
where,O
analysed,O
in,O
the,O
Erasmus,O
Medical,O
Center,O
Rotterdam,O
outside,O
the,O
dates,O
of,O
our,O
initial,O
cohort,O
.,O
LS,B-DS
patients,O
(,O
n,O
=,O
158,O
),O
in,O
our,O
validation,O
cohort,O
were,O
CRC,B-DS
patients,O
from,O
Leiden,O
University,O
Medical,O
Center,O
in,O
whom,O
an,O
MMR,O
mutation,O
was,O
found,O
and,O
with,O
known,O
location,O
of,O
CRC,B-DS
.,O
For,O
all,O
patients,O
of,O
the,O
validation,O
cohort,O
we,O
calculated,O
the,O
probability,O
of,O
carrying,O
an,O
MMR,O
mutation,O
according,O
to,O
the,O
original,O
PREMM5,O
model,O
and,O
the,O
extended,O
model,O
.,O
The,O
performance,O
of,O
both,O
models,O
were,O
evaluated,O
by,O
comparing,O
the,O
AUC,O
.,O
Results,O
A,O
total,O
of,O
734,O
index,O
patients,O
were,O
included,O
in,O
the,O
study,O
;,O
346,O
(,O
47,O
%),O
were,O
male,O
and,O
mean,O
age,O
at,O
time,O
of,O
diagnosis,O
was,O
53,O
years,O
(±,O
13,O
years,O
).,O
Overall,O
",",O
569,O
(,O
78,O
%),O
patients,O
fulfilled,O
the,O
revised,O
Bethesda,O
guidelines,O
.,O
Of,O
the,O
734,O
index,O
patients,O
",",O
83,O
(,O
11,O
%),O
were,O
diagnosed,O
with,O
a,O
LS,B-DS
mutation,O
;,O
23,O
MLH1,B-GP
",",O
17,O
MSH2,B-GP
",",O
31,O
MSH6,B-GP
and,O
12,O
PMS2,B-GP
mutation,O
carriers,O
.,O
Patient,O
characteristics,O
Patient,O
characteristics,O
for,O
mutation,O
-,O
positive,O
and,O
mutation,O
-,O
negative,O
patients,O
are,O
shown,O
in,O
Table,O
1,O
.,O
Significantly,O
more,O
mutation,O
carriers,O
developed,O
multiple,O
CRCs,B-DS
(,O
21,O
vs,O
.,O
10,O
"%,",O
p,O
=,O
0,O
.,O
005,O
),O
and,O
multiple,O
LS,B-DS
-,O
associated,O
cancers,B-DS
in,O
general,O
(,O
13,O
vs,O
.,O
4,O
"%,",O
p,O
=,O
0,O
.,O
002,O
),O
than,O
non,O
-,O
mutation,O
-,O
carriers,O
.,O
CRC,B-DS
patients,O
carrying,O
an,O
MMR,O
mutation,O
had,O
a,O
younger,O
age,O
of,O
onset,O
(,O
49,O
vs,O
.,O
53,O
years,O
",",O
p,O
=,O
0,O
.,O
002,O
),O
and,O
more,O
often,O
had,O
proximal,O
CRCs,B-DS
(,O
64,O
vs,O
.,O
28,O
"%,",O
p,O
<,O
0,O
.,O
001,O
),O
than,O
non,O
-,O
mutation,O
carriers,O
.,O
Among,O
women,B-OG
",",O
the,O
frequency,O
of,O
EC,B-DS
was,O
higher,O
for,O
mutation,O
carriers,O
than,O
for,O
non,O
-,O
mutation,O
carriers,O
(,O
41,O
vs,O
.,O
3,O
"%,",O
p,O
<,O
0,O
.,O
001,O
).,O
In,O
the,O
mutation,O
positive,O
group,O
",",O
first,O
and,O
second,O
degree,O
relatives,O
developed,O
CRC,B-DS
at,O
a,O
younger,O
age,O
than,O
in,O
the,O
mutation,O
negative,O
group,O
(,O
50,O
vs,O
.,O
64,O
years,O
",",O
p,O
<,O
0,O
.,O
001,O
and,O
47,O
vs,O
.,O
62,O
years,O
",",O
p,O
=,O
0,O
.,O
008,O
).,O
First,O
degree,O
relatives,O
of,O
mutation,O
carriers,O
had,O
higher,O
rates,O
of,O
EC,B-DS
than,O
relatives,O
of,O
non,O
-,O
mutation,O
carriers,O
(,O
19,O
vs,O
.,O
5,O
"%,",O
p,O
<,O
0,O
.,O
001,O
).,O
Table,O
1Index,O
characteristics,O
and,O
family,O
history,O
by,O
mutation,O
status,O
(,O
n,O
=,O
734,O
),O
Mutation,O
negative,O
",",O
%,O
(,O
n,O
),O
Mutation,O
positive,O
",",O
%,O
(,O
n,O
),O
P,O
valuen65183Revised,O
Bethesda,O
guidelines76,O
%,O
(,O
494,O
),O
90,O
%,O
(,O
75,O
),O
0,O
.,O
003Index,O
characteristics,O
Male,O
gender47,O
%,O
(,O
305,O
),O
49,O
%,O
(,O
41,O
),O
0,O
.,O
66,O
CRC,B-DS
Age,O
CRC,B-DS
(,O
median,O
",",O
IQR,O
),O
53,O
years,O
[,O
45,O
–,O
62,O
],O
49,O
years,O
[,O
39,O
–,O
59,O
],O
0,O
.,O
002,O
Proximal,O
CRC28,O
%,O
(,O
185,O
),O
64,O
%,O
(,O
53,O
)<,O
0,O
.,O
001,O
≥,O
2,O
CRCs10,O
%,O
(,O
66,O
),O
21,O
%,O
(,O
17,O
),O
0,O
.,O
005,O
Endometrial,O
cancer3,O
%,O
(,O
11,O
),O
41,O
%,O
(,O
17,O
)<,O
0,O
.,O
001,O
Age,O
EC,B-DS
(,O
median,O
",",O
IQR,O
),O
55,O
years,O
[,O
50,O
–,O
75,O
],O
54,O
years,O
[,O
49,O
–,O
57,O
],O
0,O
.,O
18,O
Multiple,O
LS,B-DS
cancers4,O
%,O
(,O
27,O
),O
13,O
%,O
(,O
11,O
),O
0,O
.,O
002First,O
degree,O
relatives,O
CRC55,O
%,O
(,O
358,O
),O
51,O
%,O
(,O
42,O
),O
0,O
.,O
45,O
≥,O
2,O
FDRs,O
with,O
CRC16,O
%,O
(,O
107,O
),O
17,O
%,O
(,O
14,O
),O
0,O
.,O
92,O
Age,O
CRC,B-DS
(,O
median,O
",",O
IQR,O
),O
64,O
years,O
[,O
55,O
–,O
71,O
],O
50,O
years,O
[,O
43,O
–,O
57,O
]<,O
0,O
.,O
001,O
Endometrial,O
cancer5,O
%,O
(,O
35,O
),O
19,O
%,O
(,O
16,O
)<,O
0,O
.,O
001,O
≥,O
2,O
FDRs,O
with,O
EC0,O
.,O
6,O
%,O
(,O
4,O
),O
2,O
%,O
(,O
2,O
),O
0,O
.,O
14,O
Age,O
EC,B-DS
(,O
median,O
",",O
IQR,O
),O
55,O
years,O
[,O
50,O
–,O
64,O
],O
50,O
years,O
[,O
45,O
–,O
57,O
],O
0,O
.,O
25,O
Other,O
LS,B-DS
cancers22,O
%,O
(,O
142,O
),O
19,O
%,O
(,O
16,O
),O
0,O
.,O
60Second,O
degree,O
relatives,O
CRC33,O
%,O
(,O
212,O
),O
35,O
%,O
(,O
29,O
),O
0,O
.,O
66,O
≥,O
2,O
SDRs,O
with,O
CRC12,O
%,O
(,O
81,O
),O
12,O
%,O
(,O
10,O
),O
0,O
.,O
92,O
Age,O
CRC,B-DS
(,O
median,O
",",O
IQR,O
),O
62,O
years,O
[,O
50,O
–,O
74,O
],O
47,O
years,O
[,O
38,O
–,O
64,O
],O
0,O
.,O
008,O
Endometrial,O
cancer3,O
%,O
(,O
22,O
),O
7,O
%,O
(,O
6,O
),O
0,O
.,O
12,O
≥,O
2,O
SDRs,O
with,O
EC0,O
.,O
3,O
%,O
(,O
2,O
),O
2,O
%,O
(,O
2,O
),O
0,O
.,O
07,O
Age,O
EC,B-DS
(,O
median,O
",",O
IQR,O
),O
70,O
years,O
[,O
50,O
–,O
76,O
],O
49,O
years,O
[,O
44,O
–,O
51,O
],O
0,O
.,O
13,O
Other,O
LS,B-DS
cancers16,O
%,O
(,O
104,O
),O
18,O
%,O
(,O
15,O
),O
0,O
.,O
63,O
Discriminative,O
ability,O
of,O
prediction,O
models,O
Overall,O
",",O
PREMM5,O
predicted,O
higher,O
probabilities,O
of,O
carrying,O
a,O
LS,B-DS
mutation,O
than,O
MMRpredict,O
(,O
median,O
score,O
0,O
.,O
06,O
vs,O
.,O
0,O
.,O
03,O
",",O
Supplemental,O
Table,O
1,O
).,O
For,O
mutation,O
carriers,O
",",O
risk,O
scores,O
varied,O
from,O
0,O
.,O
02,O
to,O
0,O
.,O
99,O
for,O
PREMM5,O
and,O
from,O
0,O
.,O
002,O
to,O
0,O
.,O
99,O
for,O
MMRpredict,O
.,O
Both,O
prediction,O
models,O
could,O
fairly,O
discriminate,O
between,O
index,O
patients,O
with,O
and,O
without,O
an,O
MMR,O
mutation,O
.(,O
Fig,O
.,O
1,O
),O
PREMM5,O
and,O
MMRpredict,O
had,O
similar,O
overall,O
performance,O
(,O
AUC,O
0,O
.,O
72,O
[,O
95,O
%,O
CI,O
0,O
.,O
66,O
–,O
0,O
.,O
79,O
],O
vs,O
.,O
0,O
.,O
73,O
[,O
95,O
%,O
CI,O
0,O
.,O
66,O
–,O
0,O
.,O
79,O
]).,O
For,O
MLH1,B-GP
and,O
MSH2,B-GP
mutation,O
carriers,O
",",O
both,O
prediction,O
models,O
performed,O
well,O
",",O
with,O
AUC,O
of,O
0,O
.,O
80,O
[,O
95,O
%,O
CI,O
0,O
.,O
71,O
–,O
0,O
.,O
89,O
],O
and,O
0,O
.,O
83,O
[,O
95,O
%,O
CI,O
0,O
.,O
73,O
–,O
0,O
.,O
94,O
],O
for,O
PREMM5,O
and,O
AUC,O
of,O
0,O
.,O
79,O
[,O
95,O
%,O
CI,O
0,O
.,O
69,O
–,O
0,O
.,O
89,O
and,O
0,O
.,O
67,O
–,O
0,O
.,O
91,O
],O
for,O
MMRpredict,O
.,O
Both,O
models,O
had,O
a,O
fair,O
discriminative,O
power,O
for,O
MSH6,B-GP
mutation,O
carriers,O
(,O
AUC,O
of,O
0,O
.,O
69,O
[,O
95,O
%,O
CI,O
0,O
.,O
58,O
–,O
0,O
.,O
80,O
],O
for,O
PREMM5,O
and,O
AUC,O
of,O
0,O
.,O
66,O
[,O
95,O
%,O
CI,O
0,O
.,O
56,O
–,O
0,O
.,O
76,O
],O
for,O
MMRpredict,O
).,O
MMRpredict,O
still,O
had,O
fair,O
performance,O
for,O
PMS2,B-GP
mutation,O
carriers,O
(,O
AUC,O
of,O
0,O
.,O
72,O
[,O
95,O
%,O
CI,O
0,O
.,O
57,O
–,O
0,O
.,O
87,O
"]),",O
while,O
PREMM5,O
failed,O
to,O
discriminate,O
PMS2,B-GP
mutation,O
carriers,O
from,O
non,O
-,O
mutation,O
carriers,O
at,O
all,O
with,O
an,O
AUC,O
of,O
0,O
.,O
51,O
[,O
95,O
%,O
CI,O
0,O
.,O
35,O
–,O
0,O
.,O
66,O
].,O
Fig,O
.,O
1Performance,O
of,O
PREMM5,O
and,O
MMRpredict,O
in,O
a,O
clinical,O
setting,O
for,O
all,O
mutation,O
carriers,O
and,O
for,O
individual,O
MMR,O
mutations,O
Sensitivity,O
and,O
specificity,O
Using,O
a,O
cut,O
-,O
off,O
of,O
5,O
%,O
for,O
both,O
prediction,O
models,O
",",O
PREMM5,O
had,O
a,O
higher,O
sensitivity,O
than,O
MMRpredict,O
(,O
78,O
vs,O
.,O
70,O
%).,O
This,O
higher,O
sensitivity,O
came,O
at,O
the,O
expense,O
of,O
a,O
lower,O
specificity,O
(,O
46,O
vs,O
.,O
67,O
%).,O
For,O
PREMM5,O
",",O
using,O
a,O
cut,O
-,O
off,O
of,O
5,O
"%,",O
resulted,O
in,O
a,O
sensitivity,O
for,O
MLH1,B-GP
and,O
MSH2,B-GP
mutations,O
of,O
88,O
and,O
91,O
"%,",O
while,O
the,O
sensitivity,O
for,O
MSH6,B-GP
mutation,O
carriers,O
was,O
74,O
%,O
and,O
the,O
sensitivity,O
for,O
PMS2,B-GP
mutation,O
carriers,O
was,O
only,O
50,O
%.,O
For,O
MMRpredict,O
",",O
at,O
a,O
5,O
%,O
cut,O
-,O
off,O
sensitivity,O
for,O
MLH1,B-GP
and,O
MSH2,B-GP
mutation,O
carriers,O
were,O
74,O
and,O
77,O
"%,",O
while,O
sensitivity,O
for,O
PMS2,B-GP
as,O
well,O
as,O
MSH6,B-GP
mutation,O
carriers,O
were,O
65,O
and,O
67,O
%.,O
For,O
both,O
models,O
",",O
using,O
a,O
cut,O
-,O
off,O
of,O
≥,O
20,O
%,O
failed,O
to,O
identify,O
over,O
50,O
%,O
of,O
the,O
mutation,O
carriers,O
.,O
Sensitivity,O
of,O
the,O
revised,O
Bethesda,O
guidelines,O
decreased,O
from,O
96,O
%,O
for,O
MLH1,B-GP
mutation,O
carriers,O
to,O
83,O
%,O
for,O
PMS2,B-GP
mutation,O
carriers,O
(,O
Supplemental,O
Table,O
2,O
).,O
Overall,O
",",O
the,O
revised,O
Bethesda,O
guidelines,O
had,O
a,O
sensitivity,O
of,O
90,O
%,O
with,O
a,O
specificity,O
of,O
24,O
%.,O
In,O
order,O
to,O
reach,O
the,O
same,O
sensitivity,O
",",O
PREMM5,O
and,O
MMRpredict,O
had,O
a,O
similar,O
specificity,O
(,O
25,O
%).,O
PMS2,B-GP
mutation,O
carriers,O
versus,O
non,O
-,O
mutation,O
carriers,O
Mutation,O
carriers,O
differed,O
significantly,O
from,O
non,O
-,O
mutation,O
carriers,O
in,O
many,O
ways,O
(,O
Table,O
1,O
).,O
In,O
contrast,O
",",O
there,O
were,O
almost,O
no,O
significant,O
differences,O
between,O
PMS2,B-GP
mutation,O
carriers,O
and,O
non,O
-,O
mutation,O
carriers,O
.,O
Only,O
one,O
significant,O
difference,O
remained,O
;,O
PMS2,B-GP
mutation,O
carriers,O
more,O
often,O
had,O
proximal,O
CRC,B-DS
than,O
patients,O
without,O
an,O
MMR,O
mutation,O
(,O
83,O
vs,O
.,O
28,O
"%,",O
p,O
<,O
0,O
.,O
001,O
),O
(,O
Table,O
2,O
).,O
Table,O
2Index,O
characteristics,O
and,O
family,O
history,O
for,O
PMS2,B-GP
mutation,O
carriers,O
compared,O
with,O
non,O
-,O
mutation,O
carriersMutation,O
negative,O
",",O
%,O
(,O
n,O
),O
PMS2,B-GP
mutation,O
positive,O
",",O
%,O
(,O
n,O
),O
P,O
valuen65112Revised,O
Bethesda,O
guidelines76,O
%,O
(,O
494,O
),O
83,O
%,O
(,O
10,O
),O
0,O
.,O
74Index,O
characteristics,O
Male,O
gender47,O
%,O
(,O
305,O
),O
50,O
%,O
(,O
6,O
),O
0,O
.,O
83,O
CRC,B-DS
Age,O
CRC,B-DS
(,O
median,O
",",O
IQR,O
),O
53,O
years,O
[,O
45,O
–,O
62,O
],O
46,O
years,O
[,O
40,O
–,O
61,O
],O
0,O
.,O
21,O
Proximal,O
CRC28,O
%,O
(,O
185,O
),O
83,O
%,O
(,O
10,O
)<,O
0,O
.,O
001,O
≥,O
2,O
CRCs10,O
%,O
(,O
66,O
),O
8,O
%,O
(,O
1,O
),O
1,O
.,O
0,O
Endometrial,O
cancer3,O
%,O
(,O
11,O
),O
0,O
%,O
(,O
0,O
),O
1,O
.,O
0,O
Age,O
EC,B-DS
(,O
median,O
",",O
IQR,O
),O
55,O
years,O
[,O
50,O
–,O
75,O
],O
Multiple,O
LS,B-DS
cancers4,O
%,O
(,O
27,O
),O
0,O
%,O
(,O
0,O
),O
1,O
.,O
0First,O
degree,O
relatives,O
CRC55,O
%,O
(,O
358,O
),O
42,O
%,O
(,O
5,O
),O
0,O
.,O
36,O
≥,O
2,O
FDRs,O
with,O
CRC16,O
%,O
(,O
107,O
),O
8,O
%,O
(,O
1,O
),O
0,O
.,O
70,O
Age,O
CRC,B-DS
(,O
median,O
",",O
IQR,O
),O
64,O
years,O
[,O
55,O
–,O
71,O
],O
62,O
years,O
[,O
45,O
–,O
90,O
],O
0,O
.,O
68,O
Endometrial,O
cancer5,O
%,O
(,O
35,O
),O
17,O
%,O
(,O
2,O
),O
0,O
.,O
14,O
≥,O
2,O
FDRs,O
with,O
EC0,O
.,O
6,O
%,O
(,O
4,O
),O
8,O
%,O
(,O
1,O
),O
0,O
.,O
88,O
Age,O
EC,B-DS
(,O
median,O
",",O
IQR,O
),O
55,O
years,O
[,O
50,O
–,O
64,O
],O
37,O
years,O
[–],O
0,O
.,O
24,O
Other,O
LS,B-DS
cancers22,O
%,O
(,O
142,O
),O
8,O
%,O
(,O
1,O
),O
0,O
.,O
48Second,O
degree,O
relatives,O
CRC33,O
%,O
(,O
212,O
),O
17,O
%,O
(,O
2,O
),O
0,O
.,O
35,O
≥,O
2,O
SDRs,O
with,O
CRC12,O
%,O
(,O
81,O
),O
8,O
%,O
(,O
1,O
),O
1,O
.,O
0,O
Age,O
CRC,B-DS
(,O
median,O
",",O
IQR,O
),O
62,O
years,O
[,O
50,O
–,O
74,O
],O
39,O
years,O
[,O
39,O
–],O
0,O
.,O
12,O
Endometrial,O
cancer3,O
%,O
(,O
22,O
),O
8,O
%,O
(,O
1,O
),O
0,O
.,O
35,O
≥,O
2,O
SDRs,O
with,O
EC0,O
.,O
3,O
%,O
(,O
2,O
),O
8,O
%,O
(,O
1,O
),O
0,O
.,O
05,O
Age,O
EC,B-DS
(,O
median,O
",",O
IQR,O
),O
70,O
years,O
[,O
50,O
–,O
76,O
],O
49,O
years,O
[–],O
0,O
.,O
67,O
Other,O
LS,B-DS
cancers16,O
%,O
(,O
104,O
),O
17,O
%,O
(,O
2,O
),O
1,O
.,O
0,O
Improvement,O
of,O
the,O
PREMM5,O
model,O
Since,O
location,O
of,O
CRC,B-DS
was,O
the,O
only,O
significant,O
difference,O
between,O
PMS2,B-GP
mutation,O
carriers,O
and,O
non,O
-,O
mutation,O
carriers,O
",",O
we,O
incorporated,O
this,O
variable,O
in,O
the,O
PREMM5,O
model,O
",",O
aiming,O
to,O
improve,O
the,O
prediction,O
model,O
.,O
For,O
PMS2,B-GP
mutation,O
carriers,O
",",O
the,O
extended,O
PREMM5,O
model,O
had,O
considerably,O
better,O
predictions,O
than,O
the,O
original,O
PREMM55,O
model,O
(,O
AUC,O
0,O
.,O
77,O
[,O
95,O
%,O
CI,O
0,O
.,O
63,O
–,O
0,O
.,O
90,O
],O
vs,O
.,O
0,O
.,O
51,O
[,O
95,O
%,O
CI,O
0,O
.,O
35,O
–,O
0,O
.,O
66,O
]),O
(,O
Fig,O
.,O
2,O
).,O
At,O
a,O
5,O
%,O
cut,O
-,O
off,O
",",O
the,O
new,O
PREMM5,O
model,O
identified,O
5,O
/,O
6,O
PMS2,B-GP
mutation,O
carriers,O
that,O
would,O
have,O
been,O
missed,O
by,O
PREMM5,O
and,O
3,O
/,O
4,O
PMS2,B-GP
mutation,O
carriers,O
that,O
would,O
have,O
been,O
missed,O
by,O
MMRpredict,O
at,O
the,O
same,O
cut,O
-,O
off,O
.,O
Fig,O
.,O
2Performance,O
of,O
PREMM5,O
and,O
the,O
extended,O
PREMM5,O
model,O
in,O
a,O
clinical,O
setting,O
for,O
all,O
mutation,O
carriers,O
and,O
for,O
individual,O
MMR,O
mutations,O
Adding,O
tumour,B-DS
location,O
also,O
improved,O
the,O
performance,O
of,O
PREMM5,O
for,O
identifying,O
MLH1,B-GP
(,O
AUC,O
0,O
.,O
92,O
[,O
95,O
%,O
CI,O
0,O
.,O
88,O
–,O
0,O
.,O
97,O
],O
vs,O
.,O
0,O
.,O
80,O
[,O
95,O
%,O
CI,O
0,O
.,O
71,O
–,O
0,O
.,O
89,O
]),O
and,O
MSH6,B-GP
(,O
AUC,O
0,O
.,O
75,O
[,O
95,O
%,O
CI,O
0,O
.,O
65,O
–,O
0,O
.,O
84,O
],O
vs,O
.,O
0,O
.,O
69,O
[,O
95,O
%,O
CI,O
0,O
.,O
58,O
–,O
0,O
.,O
80,O
]),O
mutation,O
carriers,O
(,O
Fig,O
.,O
2,O
).,O
However,O
",",O
performance,O
for,O
MSH2,B-GP
mutation,O
carriers,O
slightly,O
decreased,O
(,O
AUC,O
0,O
.,O
80,O
[,O
95,O
%,O
CI,O
0,O
.,O
69,O
–,O
0,O
.,O
91,O
],O
vs,O
.,O
0,O
.,O
83,O
[,O
95,O
%,O
CI,O
0,O
.,O
73,O
–,O
0,O
.,O
94,O
]).,O
Overall,O
",",O
the,O
adjusted,O
PREMM5,O
model,O
performed,O
better,O
than,O
the,O
original,O
PREMM5,O
model,O
(,O
AUC,O
0,O
.,O
81,O
[,O
95,O
%,O
CI,O
0,O
.,O
76,O
–,O
0,O
.,O
86,O
],O
vs,O
.,O
0,O
.,O
72,O
[,O
95,O
%,O
CI,O
0,O
.,O
66,O
–,O
0,O
.,O
79,O
]),O
and,O
MMRpredict,O
(,O
AUC,O
0,O
.,O
81,O
vs,O
.,O
0,O
.,O
73,O
[,O
95,O
%,O
CI,O
0,O
.,O
66,O
–,O
0,O
.,O
79,O
]).,O
The,O
adjusted,O
prediction,O
model,O
can,O
be,O
found,O
as,O
supplemental,O
material,O
.,O
At,O
a,O
5,O
%,O
cut,O
-,O
off,O
",",O
sensitivity,O
of,O
the,O
extended,O
PREMM5,O
model,O
was,O
higher,O
than,O
the,O
sensitivity,O
of,O
the,O
original,O
PREMM5,O
model,O
(,O
92,O
vs,O
.,O
78,O
%),O
with,O
similar,O
specificity,O
(,O
45,O
vs,O
.,O
46,O
%).,O
Sensitivity,O
and,O
specificity,O
of,O
the,O
extended,O
PREMM5,O
model,O
at,O
a,O
5,O
%,O
cut,O
off,O
were,O
both,O
higher,O
than,O
those,O
of,O
the,O
revised,O
Bethesda,O
guidelines,O
(,O
sensitivity,O
92,O
vs,O
.,O
90,O
%,O
and,O
specificity,O
45,O
vs,O
.,O
24,O
%).,O
Validation,O
of,O
the,O
extended,O
PREMM5,O
model,O
In,O
our,O
validation,O
cohort,O
",",O
60,O
%,O
of,O
the,O
patients,O
were,O
male,O
and,O
median,O
age,O
was,O
55,O
years,O
(,O
IQR,O
45,O
–,O
63,O
years,O
).,O
The,O
cohort,O
included,O
31,O
MLH1,B-GP
",",O
26,O
MSH2,B-GP
",",O
28,O
MSH6,B-GP
and,O
73,O
PMS2,B-GP
mutation,O
carriers,O
.,O
Similar,O
to,O
the,O
results,O
in,O
the,O
initial,O
cohort,O
",",O
the,O
extended,O
PREMM5,O
model,O
had,O
better,O
predictions,O
than,O
the,O
original,O
PREMM5,O
model,O
for,O
PMS2,B-GP
mutation,O
carriers,O
(,O
AUC,O
0,O
.,O
90,O
[,O
95,O
%,O
CI,O
0,O
.,O
86,O
–,O
0,O
.,O
94,O
],O
vs,O
.,O
0,O
.,O
82,O
[,O
95,O
%,O
CI,O
0,O
.,O
76,O
–,O
0,O
.,O
87,O
]),O
and,O
overall,O
(,O
AUC,O
0,O
.,O
92,O
[,O
95,O
%,O
CI,O
0,O
.,O
89,O
–,O
0,O
.,O
95,O
],O
vs,O
.,O
0,O
.,O
87,O
[,O
95,O
%,O
CI,O
0,O
.,O
84,O
–,O
0,O
.,O
91,O
]).,O
Performance,O
for,O
MLH1,B-GP
",",O
MSH2,B-GP
and,O
MSH6,B-GP
mutation,O
carriers,O
was,O
also,O
slightly,O
better,O
for,O
the,O
extended,O
PREMM5,O
model,O
than,O
for,O
the,O
original,O
PREMM5,O
model,O
(,O
AUC,O
0,O
.,O
97,O
[,O
95,O
%,O
CI,O
0,O
.,O
94,O
–,O
1,O
.,O
00,O
],O
vs,O
.,O
0,O
.,O
95,O
[,O
95,O
%,O
CI,O
0,O
.,O
91,O
–,O
0,O
.,O
99,O
],O
for,O
MLH1,B-GP
",",O
0,O
.,O
97,O
[,O
95,O
%,O
CI,O
0,O
.,O
93,O
–,O
1,O
.,O
00,O
],O
vs,O
.,O
0,O
.,O
96,O
[,O
95,O
%,O
CI,O
0,O
.,O
92,O
–,O
0,O
.,O
99,O
],O
for,O
MSH2,B-GP
and,O
0,O
.,O
86,O
[,O
95,O
%,O
CI,O
0,O
.,O
97,O
–,O
0,O
.,O
93,O
],O
vs,O
.,O
0,O
.,O
85,O
[,O
95,O
%,O
CI,O
0,O
.,O
77,O
–,O
0,O
.,O
93,O
],O
for,O
MSH6,B-GP
mutation,O
carriers,O
).,O
Discussion,O
The,O
results,O
of,O
our,O
study,O
indicate,O
that,O
while,O
the,O
models,O
MMRpredict,O
and,O
PREMM5,O
can,O
adequately,O
predict,O
whether,O
an,O
individual,O
is,O
likely,O
to,O
have,O
Lynch,B-DS
syndrome,I-DS
",",O
they,O
fail,O
to,O
identify,O
PMS2,B-GP
mutation,O
carriers,O
.,O
The,O
performance,O
of,O
the,O
PREMM5,O
model,O
improved,O
considerably,O
by,O
adding,O
the,O
location,O
of,O
CRC,B-DS
to,O
the,O
model,O
.,O
In,O
our,O
clinical,O
cohort,O
of,O
734,O
CRC,B-DS
patients,O
as,O
well,O
as,O
in,O
a,O
validation,O
cohort,O
of,O
376,O
CRC,B-DS
patients,O
",",O
this,O
extended,O
PREMM5,O
model,O
not,O
only,O
identified,O
PMS2,B-GP
mutation,O
carriers,O
more,O
accurately,O
",",O
its,O
overall,O
performance,O
was,O
also,O
better,O
than,O
the,O
original,O
PREMM5,O
model,O
and,O
the,O
MMRpredict,O
model,O
.,O
Our,O
results,O
are,O
in,O
line,O
with,O
those,O
of,O
previous,O
studies,O
",",O
where,O
the,O
PREMM1,O
",",O
2,O
",",O
6,O
model,O
had,O
a,O
slightly,O
better,O
overall,O
performance,O
than,O
MMRpredict,O
[,O
22,O
",",O
32,O
",",O
33,O
].,O
The,O
first,O
PREMM,O
model,O
",",O
PREMM1,O
",",O
2,O
also,O
performed,O
better,O
than,O
MMRpredict,O
in,O
several,O
studies,O
[,O
23,O
",",O
24,O
"],",O
but,O
had,O
similar,O
[,O
25,O
",",O
26,O
],O
or,O
less,O
accurate,O
[,O
21,O
],O
predictions,O
in,O
other,O
studies,O
.,O
A,O
recent,O
meta,O
-,O
analysis,O
also,O
found,O
pooled,O
AUCs,O
to,O
be,O
higher,O
for,O
the,O
PREMM,O
model,O
than,O
for,O
MMRpredict,O
(,O
AUC,O
0,O
.,O
84,O
vs,O
.,O
0,O
.,O
81,O
),O
[,O
27,O
].,O
Although,O
PREMM5,O
had,O
better,O
overall,O
predictions,O
",",O
MMRpredict,O
had,O
a,O
better,O
performance,O
for,O
PMS2,B-GP
mutation,O
carriers,O
specifically,O
.,O
An,O
explanation,O
for,O
this,O
could,O
be,O
that,O
the,O
location,O
of,O
CRC,B-DS
is,O
incorporated,O
in,O
the,O
MMRpredict,O
model,O
but,O
not,O
in,O
the,O
PREMM5,O
model,O
.,O
Proximal,O
location,O
of,O
CRC,B-DS
is,O
a,O
known,O
predictor,O
for,O
Lynch,B-DS
syndrome,I-DS
and,O
in,O
our,O
cohort,O
was,O
the,O
only,O
significant,O
difference,O
between,O
PMS2,B-GP
mutation,O
carriers,O
and,O
non,O
-,O
mutation,O
carriers,O
.,O
After,O
adding,O
this,O
new,O
variable,O
to,O
the,O
existing,O
PREMM55,O
model,O
",",O
this,O
new,O
model,O
performed,O
better,O
than,O
MMRpredict,O
for,O
PMS2,B-GP
mutation,O
carriers,O
.,O
The,O
extended,O
PREMM55,O
model,O
also,O
performed,O
better,O
than,O
the,O
original,O
model,O
for,O
MLH1,B-GP
",",O
MSH2,B-GP
and,O
MSH6,B-GP
mutation,O
carriers,O
and,O
had,O
a,O
better,O
overall,O
performance,O
.,O
In,O
our,O
validation,O
cohort,O
",",O
all,O
AUCs,O
were,O
much,O
higher,O
than,O
in,O
our,O
original,O
cohort,O
",",O
including,O
those,O
for,O
PMS2,B-GP
mutation,O
carriers,O
.,O
Selection,O
of,O
patients,O
for,O
analysis,O
of,O
MSI,O
and,O
IHC,O
may,O
have,O
been,O
less,O
stringent,O
at,O
the,O
Erasmus,O
Medical,O
Center,O
Rotterdam,O
than,O
at,O
the,O
Leiden,O
University,O
Medical,O
Center,O
.,O
Therefore,O
",",O
mutation,O
carriers,O
in,O
our,O
validation,O
cohort,O
",",O
who,O
were,O
all,O
from,O
Leiden,O
University,O
Medical,O
Center,O
",",O
may,O
have,O
had,O
a,O
family,O
history,O
more,O
suspect,O
for,O
Lynch,B-DS
syndrome,I-DS
than,O
family,O
history,O
of,O
the,O
patients,O
in,O
our,O
original,O
cohort,O
.,O
This,O
could,O
explain,O
the,O
higher,O
AUCs,O
in,O
the,O
validation,O
cohort,O
.,O
However,O
",",O
in,O
both,O
cohorts,O
we,O
showed,O
that,O
the,O
extended,O
PREMM5,O
had,O
better,O
performance,O
.,O
Prediction,O
models,O
for,O
Lynch,B-DS
syndrome,I-DS
are,O
not,O
yet,O
regularly,O
used,O
in,O
current,O
clinical,O
practice,O
.,O
However,O
",",O
the,O
US,O
Multi,O
-,O
Society,O
Task,O
Force,O
on,O
Colorectal,B-DS
Cancer,I-DS
recommends,O
genetic,O
evaluation,O
if,O
an,O
individual,O
’,O
s,O
risk,O
of,O
carrying,O
an,O
MMR,O
gene,O
mutation,O
is,O
≥,O
5,O
%,O
according,O
to,O
one,O
of,O
the,O
prediction,O
models,O
MMRpro,O
",",O
MMRpredict,O
or,O
PREMM,O
[,O
34,O
].,O
The,O
American,O
guideline,O
recommends,O
that,O
all,O
CRC,B-DS
patients,O
undergo,O
routine,O
screening,O
for,O
LS,B-DS
by,O
analysis,O
of,O
MSI,O
and,O
IHC,O
[,O
34,O
"],",O
while,O
current,O
European,O
guidelines,O
recommend,O
such,O
routine,O
screening,O
in,O
at,O
least,O
all,O
CRC,B-DS
patients,O
up,O
to,O
70,O
years,O
of,O
age,O
[,O
35,O
].,O
A,O
recent,O
study,O
demonstrated,O
that,O
routine,O
screening,O
for,O
LS,B-DS
without,O
an,O
age,O
cut,O
-,O
off,O
is,O
not,O
cost,O
-,O
effective,O
[,O
36,O
].,O
A,O
strategy,O
using,O
prediction,O
models,O
might,O
lower,O
the,O
cost,O
of,O
screening,O
for,O
LS,B-DS
.,O
In,O
fact,O
",",O
two,O
cost,O
-,O
effectiveness,O
analyses,O
found,O
that,O
strategies,O
including,O
prediction,O
models,O
were,O
more,O
cost,O
-,O
effective,O
than,O
those,O
involving,O
direct,O
tumour,B-DS
testing,O
of,O
all,O
CRC,B-DS
patients,O
",",O
if,O
these,O
prediction,O
models,O
were,O
perfectly,O
implemented,O
[,O
36,O
",",O
37,O
].,O
Additionally,O
",",O
prediction,O
models,O
could,O
also,O
be,O
used,O
in,O
cases,O
where,O
no,O
tumour,B-DS
tissue,O
is,O
available,O
or,O
where,O
tumour,B-DS
tissue,O
analysis,O
failed,O
",",O
to,O
assess,O
whether,O
an,O
individual,O
should,O
be,O
analysed,O
for,O
a,O
germline,O
MMR,O
mutation,O
.,O
The,O
US,O
Multi,O
-,O
Society,O
Task,O
Force,O
on,O
Colorectal,B-DS
Cancer,I-DS
recommends,O
the,O
use,O
of,O
either,O
PREMM,O
",",O
MMRpredict,O
or,O
MMRpro,O
to,O
assess,O
the,O
probability,O
of,O
an,O
individual,O
carrying,O
an,O
MMR,O
mutation,O
[,O
34,O
].,O
Since,O
we,O
did,O
not,O
include,O
the,O
MMRpro,O
model,O
in,O
our,O
analysis,O
",",O
we,O
do,O
not,O
know,O
how,O
MMRpro,O
would,O
have,O
performed,O
in,O
our,O
cohort,O
.,O
However,O
",",O
MMRpro,O
is,O
less,O
useful,O
in,O
clinical,O
practice,O
since,O
extensive,O
family,O
data,O
is,O
needed,O
as,O
input,O
for,O
the,O
model,O
.,O
Collection,O
of,O
this,O
kind,O
of,O
data,O
is,O
very,O
time,O
consuming,O
and,O
therefore,O
not,O
suitable,O
in,O
clinical,O
practice,O
.,O
PREMM5,O
and,O
MMRpredict,O
are,O
web,O
-,O
based,O
models,O
that,O
are,O
easily,O
accessible,O
and,O
therefore,O
much,O
easier,O
to,O
use,O
.,O
Also,O
",",O
multiple,O
studies,O
—,O
including,O
the,O
recent,O
meta,O
-,O
analysis,O
—,O
have,O
shown,O
MMRpro,O
to,O
have,O
similar,O
accuracy,O
to,O
PREMM1,O
",",O
2,O
",",O
6,O
[,O
21,O
–,O
27,O
",",O
32,O
].,O
Both,O
PREMM5,O
and,O
MMRpredict,O
were,O
far,O
more,O
accurate,O
for,O
MLH1,B-GP
and,O
MSH2,B-GP
mutation,O
carriers,O
than,O
for,O
LS,B-DS
patients,O
carrying,O
a,O
mutation,O
in,O
MSH6,B-GP
or,O
PMS2,B-GP
.,O
This,O
finding,O
is,O
in,O
line,O
with,O
a,O
previous,O
study,O
that,O
showed,O
that,O
carriers,O
of,O
mutations,O
in,O
MSH6,B-GP
or,O
PMS2,B-GP
had,O
lower,O
risk,O
scores,O
than,O
carriers,O
of,O
a,O
mutation,O
in,O
MLH1,B-GP
or,O
MSH2,B-GP
[,O
21,O
].,O
In,O
our,O
study,O
",",O
discrimination,O
between,O
non,O
-,O
mutation,O
carriers,O
and,O
PMS2,B-GP
mutation,O
carriers,O
was,O
the,O
least,O
accurate,O
",",O
in,O
line,O
with,O
its,O
more,O
limited,O
penetrance,O
.,O
Around,O
15,O
%,O
of,O
all,O
Lynch,B-DS
syndrome,I-DS
cases,O
are,O
estimated,O
to,O
be,O
caused,O
by,O
PMS2,B-GP
mutations,O
[,O
38,O
].,O
In,O
our,O
cohort,O
",",O
14,O
%,O
(,O
12,O
/,O
83,O
),O
of,O
the,O
Lynch,B-DS
syndrome,I-DS
patients,O
were,O
PMS2,B-GP
mutation,O
carriers,O
.,O
To,O
our,O
knowledge,O
",",O
our,O
study,O
is,O
the,O
first,O
to,O
validate,O
LS,B-DS
prediction,O
models,O
for,O
PMS2,B-GP
mutation,O
carriers,O
specifically,O
since,O
the,O
development,O
of,O
the,O
PREMM5,O
model,O
.,O
At,O
a,O
5,O
%,O
cut,O
-,O
off,O
",",O
our,O
extended,O
PREMM5,O
model,O
was,O
able,O
to,O
detect,O
5,O
/,O
6,O
PMS2,B-GP
mutation,O
carriers,O
who,O
would,O
have,O
been,O
missed,O
by,O
the,O
original,O
PREMM5,O
model,O
at,O
the,O
same,O
cut,O
-,O
off,O
.,O
Identification,O
of,O
Lynch,B-DS
syndrome,I-DS
carriers,O
is,O
highly,O
important,O
",",O
since,O
this,O
allows,O
not,O
only,O
them,O
",",O
but,O
also,O
their,O
family,O
members,O
carrying,O
the,O
same,O
mutation,O
",",O
to,O
undergo,O
intensive,O
surveillance,O
in,O
order,O
to,O
prevent,O
the,O
development,O
of,O
cancer,B-DS
.,O
Our,O
new,O
model,O
would,O
also,O
identify,O
more,O
Lynch,B-DS
syndrome,I-DS
patients,O
overall,O
than,O
the,O
original,O
PREMM5,O
model,O
.,O
The,O
performance,O
of,O
prediction,O
models,O
can,O
differ,O
between,O
high,O
-,O
risk,O
settings,O
and,O
population,O
-,O
based,O
cohorts,O
.,O
Further,O
validation,O
studies,O
should,O
indicate,O
whether,O
our,O
results,O
can,O
be,O
generalized,O
to,O
settings,O
with,O
patients,O
at,O
low,O
to,O
median,O
risk,O
of,O
having,O
Lynch,B-DS
syndrome,I-DS
.,O
Since,O
patients,O
in,O
our,O
study,O
cohort,O
were,O
all,O
referred,O
for,O
genetic,O
counselling,O
",",O
family,O
histories,O
were,O
obtained,O
in,O
detail,O
and,O
in,O
many,O
cases,O
also,O
verified,O
by,O
medical,O
documents,O
.,O
In,O
other,O
settings,O
where,O
patients,O
are,O
at,O
lower,O
risk,O
of,O
having,O
Lynch,B-DS
syndrome,I-DS
",",O
family,O
history,O
is,O
not,O
verified,O
and,O
might,O
be,O
less,O
reliable,O
.,O
Therefore,O
",",O
prediction,O
models,O
should,O
also,O
be,O
validated,O
in,O
population,O
-,O
based,O
cohorts,O
.,O
However,O
",",O
in,O
a,O
meta,O
-,O
analysis,O
",",O
prediction,O
models,O
performed,O
better,O
in,O
population,O
-,O
based,O
cohorts,O
than,O
in,O
clinic,O
-,O
based,O
cohorts,O
[,O
27,O
].,O
It,O
is,O
not,O
known,O
whether,O
the,O
current,O
prediction,O
models,O
for,O
Lynch,B-DS
syndrome,I-DS
are,O
useful,O
in,O
non,O
-,O
Western,O
populations,O
.,O
In,O
a,O
recent,O
study,O
among,O
Korean,O
patients,O
",",O
PREMM1,O
",",O
2,O
",",O
6,O
was,O
more,O
accurate,O
than,O
MMRpro,O
and,O
MMRpredict,O
",",O
but,O
still,O
only,O
reached,O
an,O
AUC,O
of,O
0,O
.,O
71,O
[,O
32,O
].,O
There,O
was,O
no,O
association,O
between,O
tumour,B-DS
location,O
and,O
mutation,O
status,O
",",O
so,O
our,O
extended,O
PREMM5,O
model,O
might,O
not,O
improve,O
predictions,O
in,O
populations,O
of,O
non,O
-,O
Western,O
ethnicity,O
.,O
However,O
",",O
germline,O
analysis,O
for,O
PMS2,B-GP
was,O
not,O
performed,O
in,O
the,O
Korean,O
study,O
",",O
so,O
there,O
might,O
have,O
been,O
more,O
mutation,O
carriers,O
in,O
their,O
cohort,O
.,O
Another,O
non,O
-,O
Western,O
population,O
has,O
been,O
studied,O
by,O
Khan,O
et,O
al,O
".,",O
who,O
analysed,O
the,O
performance,O
of,O
prediction,O
models,O
in,O
15,O
African,O
American,O
patients,O
[,O
22,O
].,O
In,O
these,O
patients,O
",",O
MMRpredict,O
and,O
PREMM1,O
",",O
2,O
",",O
6,O
both,O
had,O
a,O
high,O
AUC,O
of,O
0,O
.,O
89,O
.,O
A,O
main,O
strength,O
of,O
our,O
study,O
was,O
the,O
large,O
cohort,O
",",O
which,O
consisted,O
of,O
more,O
than,O
700,O
index,O
patient,O
including,O
83,O
Lynch,B-DS
syndrome,I-DS
patients,O
.,O
Also,O
",",O
our,O
cohort,O
included,O
patients,O
with,O
MSH6,B-GP
and,O
PMS2,B-GP
mutations,O
.,O
Since,O
12,O
patients,O
were,O
identified,O
as,O
a,O
PMS2,B-GP
mutation,O
carrier,O
",",O
we,O
were,O
able,O
to,O
evaluate,O
the,O
prediction,O
models,O
for,O
each,O
MMR,O
mutation,O
specifically,O
",",O
admittedly,O
with,O
considerable,O
uncertainty,O
[,O
39,O
].,O
Furthermore,O
",",O
we,O
validated,O
the,O
extended,O
PREMM5,O
model,O
in,O
a,O
separate,O
cohort,O
of,O
376,O
patients,O
including,O
73,O
PMS2,B-GP
mutation,O
carriers,O
.,O
A,O
limitation,O
of,O
our,O
study,O
was,O
that,O
germline,O
mutation,O
analysis,O
was,O
not,O
done,O
for,O
all,O
index,O
patients,O
.,O
Patients,O
who,O
had,O
microsatellite,O
stable,O
tumours,B-DS
with,O
normal,O
IHC,O
were,O
assumed,O
to,O
be,O
non,O
-,O
mutation,O
carriers,O
.,O
However,O
",",O
some,O
of,O
these,O
patients,O
might,O
still,O
have,O
an,O
MMR,O
mutation,O
.,O
Also,O
",",O
the,O
sample,O
size,O
per,O
gene,O
was,O
still,O
relatively,O
small,O
and,O
it,O
is,O
unclear,O
whether,O
our,O
results,O
from,O
a,O
high,O
-,O
risk,O
population,O
apply,O
to,O
a,O
population,O
-,O
based,O
setting,O
.,O
In,O
conclusion,O
",",O
we,O
have,O
shown,O
that,O
although,O
MMRpredict,O
and,O
PREMM5,O
can,O
accurately,O
predict,O
an,O
individual,O
’,O
s,O
risk,O
of,O
carrying,O
a,O
causative,O
MMR,O
mutation,O
",",O
neither,O
model,O
is,O
able,O
to,O
identify,O
patients,O
with,O
PMS2,B-GP
mutations,O
.,O
Adding,O
the,O
location,O
of,O
CRC,B-DS
to,O
the,O
PREMM5,O
model,O
improves,O
the,O
performance,O
of,O
the,O
model,O
for,O
PMS2,B-GP
mutation,O
carriers,O
as,O
well,O
as,O
its,O
overall,O
performance,O
.,O
These,O
findings,O
should,O
be,O
validated,O
in,O
large,O
cohorts,O
from,O
population,O
-,O
based,O
settings,O
.,O
Electronic,O
supplementary,O
material,O
Below,O
is,O
the,O
link,O
to,O
the,O
electronic,O
supplementary,O
material,O
.,O
Supplementary,O
material,O
1,O
(,O
DOCX,O
14,O
KB,O
),O
Supplementary,O
material,O
2,O
(,O
DOCX,O
15,O
KB,O
),O
Supplementary,O
material,O
3,O
(,O
DOCX,O
19,O
KB,O
),O
Electronic,O
supplementary,O
material,O
The,O
online,O
version,O
of,O
this,O
article,O
(,O
doi,O
:,O
10,O
.,O
1007,O
/,O
s10689,O
-,O
017,O
-,O
0039,O
-,O
1,O
),O
contains,O
supplementary,O
material,O
",",O
which,O
is,O
available,O
to,O
authorized,O
users,O
.,O
Transgender,O
and,O
Gender,O
Nonconforming,O
in,O
Emergency,O
Departments,O
:,O
A,O
Qualitative,O
Report,O
of,O
Patient,O
Experiences,O
Abstract,O
Background,O
:,O
Individuals,O
who,O
have,O
a,O
transgender,O
or,O
gender,O
nonconforming,O
(,O
TGGNC,O
),O
experience,O
belong,O
to,O
a,O
marginalized,O
segment,O
of,O
the,O
U,O
.,O
S,O
.,O
population,O
",",O
and,O
healthcare,O
can,O
be,O
difficult,O
for,O
them,O
to,O
navigate,O
.,O
Although,O
emergency,O
departments,O
(,O
EDs,O
),O
traditionally,O
serve,O
as,O
healthcare,O
“,O
safety,O
nets,O
”,O
for,O
vulnerable,O
populations,O
",",O
quantitative,O
studies,O
outside,O
the,O
United,O
States,O
have,O
found,O
that,O
TGGNC,O
-,O
experienced,O
persons,O
tend,O
to,O
avoid,O
EDs,O
and,O
/,O
or,O
have,O
negative,O
experiences,O
.,O
This,O
qualitative,O
study,O
primarily,O
describes,O
the,O
ED,O
experiences,O
of,O
people,O
with,O
a,O
TGGNC,O
history,O
;,O
furthermore,O
",",O
the,O
study,O
explores,O
reasons,O
why,O
this,O
population,O
avoids,O
U,O
.,O
S,O
.,O
EDs,O
and,O
their,O
recommendations,O
for,O
improvements,O
to,O
ED,O
care,O
.,O
Methods,O
:,O
This,O
qualitative,O
study,O
used,O
data,O
about,O
TGGNC,O
-,O
historied,O
persons,O
',O
experiences,O
in,O
U,O
.,O
S,O
.,O
EDs,O
from,O
retrospective,O
",",O
anonymous,O
",",O
written,O
surveys,O
(,O
paper,O
or,O
web,O
based,O
).,O
National,O
data,O
collection,O
took,O
place,O
from,O
June,O
2012,O
through,O
December,O
2014,O
.,O
Participant,O
responses,O
(,O
n,O
=,O
240,O
),O
were,O
examined,O
using,O
thematic,O
analysis,O
.,O
Results,O
:,O
Using,O
a,O
framework,O
that,O
recognized,O
positive,O
and,O
negative,O
responses,O
",",O
the,O
themes,O
of,O
Self,O
-,O
Efficacy,O
and,O
Power,O
Inequity,O
surfaced,O
.,O
These,O
themes,O
exposed,O
the,O
tension,O
between,O
patients,O
with,O
TGGNC,O
experiences,O
and,O
clinicians,O
who,O
were,O
perceived,O
to,O
lack,O
training,O
in,O
this,O
area,O
",",O
resulting,O
in,O
negative,O
patient,O
experiences,O
.,O
When,O
practitioners,O
had,O
specific,O
training,O
about,O
this,O
population,O
",",O
participants,O
reported,O
positive,O
care,O
experiences,O
.,O
Conclusions,O
:,O
This,O
study,O
indicates,O
that,O
many,O
TGGNC,O
-,O
historied,O
persons,O
who,O
use,O
U,O
.,O
S,O
.,O
EDs,O
have,O
negative,O
experiences,O
",",O
largely,O
due,O
to,O
lack,O
of,O
provider,O
sensitivity,O
toward,O
and,O
training,O
about,O
this,O
patient,O
population,O
.,O
Data,O
from,O
this,O
investigation,O
suggest,O
that,O
training,O
of,O
U,O
.,O
S,O
.,O
ED,O
providers,O
and,O
institutional,O
support,O
would,O
help,O
improve,O
care,O
for,O
this,O
marginalized,O
group,O
.,O
Introduction,O
Gender,O
is,O
frequently,O
perceived,O
to,O
be,O
binary,O
and,O
correlative,O
to,O
anatomical,O
sex,O
",",O
but,O
this,O
is,O
not,O
the,O
case,O
for,O
all,O
.,O
1,O
",",O
2,O
Gender,O
is,O
an,O
internal,O
experience,O
and,O
relates,O
to,O
masculinity,O
",",O
femininity,O
",",O
and,O
their,O
various,O
combinations,O
;,O
it,O
can,O
be,O
demonstrated,O
through,O
body,O
language,O
",",O
clothing,O
",",O
voice,O
",",O
and,O
other,O
social,O
and,O
cultural,O
expressions,O
.,O
3,O
Those,O
with,O
a,O
transgender,O
or,O
gender,O
nonconforming,O
(,O
TGGNC,O
),O
life,O
experience,O
or,O
history,O
*,O
have,O
a,O
gender,O
identity,O
different,O
than,O
the,O
gender,O
assumed,O
at,O
birth,O
.,O
Individuals,O
with,O
TGGNC,O
life,O
experiences,O
are,O
among,O
the,O
most,O
marginalized,O
and,O
disenfranchised,O
people,O
in,O
the,O
United,O
States,O
:,O
They,O
disproportionately,O
experience,O
homelessness,O
",",O
underemployment,O
",",O
and,O
live,O
in,O
extreme,O
poverty,O
.,O
Furthermore,O
",",O
in,O
one,O
national,O
study,O
",",O
41,O
%,O
had,O
attempted,O
suicide,O
compared,O
to,O
the,O
general,O
population,O
',O
s,O
rate,O
of,O
less,O
than,O
2,O
%.,O
4,O
",",O
5,O
Unemployed,O
people,O
with,O
a,O
TGGNC,O
life,O
experience,O
are,O
more,O
likely,O
to,O
perform,O
work,O
in,O
the,O
“,O
underground,O
economy,O
”,O
(,O
e,O
.,O
g,O
".,",O
sex,O
work,O
or,O
selling,O
drugs,O
"),",O
be,O
incarcerated,O
",",O
or,O
use,O
alcohol,O
or,O
illicit,O
substances,O
to,O
cope,O
with,O
mistreatment,O
experienced,O
;,O
this,O
group,O
(,O
unemployed,O
with,O
a,O
TGGNC,O
history,O
),O
is,O
four,O
times,O
more,O
likely,O
to,O
be,O
HIV,B-OG
infected,O
.,O
4,O
And,O
in,O
a,O
2011,O
national,O
study,O
by,O
the,O
National,O
Center,O
for,O
Transgender,O
Equality,O
",",O
many,O
with,O
a,O
TGGNC,O
experience,O
had,O
survived,O
physical,O
(,O
61,O
%),O
and,O
sexual,O
(,O
64,O
%),O
assault,O
.,O
4,O
Multiple,O
studies,O
report,O
that,O
TGGNC,O
-,O
historied,O
people,O
frequently,O
avoid,O
accessing,O
necessary,O
healthcare,O
because,O
of,O
harassment,O
and,O
discrimination,O
in,O
healthcare,O
settings,O
.,O
4,O
",",O
6,O
–,O
14,O
Emergency,O
Departments,O
(,O
EDs,O
),O
are,O
the,O
de,O
facto,O
“,O
safety,O
net,O
”,O
of,O
the,O
U,O
.,O
S,O
.,O
healthcare,O
system,O
",",O
open,O
to,O
anyone,O
in,O
medical,O
need,O
",",O
at,O
any,O
time,O
.,O
15,O
The,O
Emergency,O
Medicine,O
Treatment,O
and,O
Active,O
Labor,O
Act,O
of,O
1986,O
was,O
enacted,O
to,O
prevent,O
clinicians,O
from,O
turning,O
away,O
those,O
who,O
lack,O
insurance,O
or,O
the,O
ability,O
to,O
pay,O
but,O
have,O
emergency,O
medical,O
conditions,O
.,O
16,O
This,O
has,O
resulted,O
in,O
EDs,O
being,O
a,O
setting,O
where,O
anyone,O
can,O
request,O
evaluation,O
and,O
treatment,O
.,O
Thus,O
EDs,O
",",O
which,O
serve,O
many,O
marginalized,O
populations,O
",",O
should,O
also,O
be,O
able,O
to,O
care,O
for,O
patients,O
with,O
a,O
TGGNC,O
history,O
",",O
who,O
are,O
clearly,O
among,O
the,O
nation,O
',O
s,O
most,O
vulnerable,O
.,O
While,O
92,O
%,O
of,O
general,O
ED,O
patients,O
in,O
the,O
United,O
States,O
report,O
being,O
satisfied,O
with,O
the,O
emergency,O
care,O
received,O
",",O
17,O
it,O
is,O
unknown,O
how,O
TGGNC,O
-,O
historied,O
persons,O
in,O
the,O
United,O
States,O
experience,O
the,O
nation,O
',O
s,O
EDs,O
",",O
which,O
should,O
be,O
accessible,O
to,O
this,O
vulnerable,O
population,O
",",O
as,O
it,O
is,O
for,O
others,O
.,O
This,O
investigation,O
explores,O
how,O
TGGNC,O
-,O
historied,O
persons,O
",",O
as,O
a,O
disenfranchised,O
group,O
",",O
experience,O
care,O
in,O
the,O
medical,O
safety,O
net,O
of,O
the,O
United,O
States,O
.,O
Materials,O
and,O
Methods,O
“,O
TG,O
in,O
the,O
ED,O
”,O
was,O
an,O
anonymous,O
",",O
retrospective,O
",",O
written,O
survey,O
accessible,O
in,O
English,O
and,O
Spanish,O
.,O
The,O
survey,O
was,O
available,O
online,O
via,O
SurveyMonkey,O
and,O
in,O
paper,O
form,O
.,O
Data,O
collection,O
started,O
in,O
June,O
2012,O
and,O
ended,O
in,O
December,O
2014,O
",",O
when,O
new,O
surveys,O
no,O
longer,O
revealed,O
new,O
themes,O
.,O
Eligible,O
participants,O
self,O
-,O
identified,O
as,O
having,O
a,O
TGGNC,O
life,O
experience,O
",",O
were,O
at,O
least,O
18,O
years,O
old,O
",",O
could,O
read,O
and,O
write,O
in,O
English,O
or,O
Spanish,O
",",O
and,O
wanted,O
",",O
needed,O
",",O
and,O
/,O
or,O
had,O
used,O
an,O
ED,O
in,O
the,O
United,O
States,O
.,O
A,O
convenience,O
sample,O
of,O
participants,O
was,O
recruited,O
from,O
across,O
the,O
United,O
States,O
via,O
community,O
and,O
health,O
centers,O
that,O
serve,O
lesbian,O
",",O
gay,O
",",O
bisexual,O
",",O
and,O
TGGNC,O
-,O
experienced,O
(,O
LGBT,O
),O
persons,O
;,O
Facebook,O
†;,O
a,O
2014,O
national,O
conference,O
on,O
transgender,O
health18,O
;,O
and,O
word,O
-,O
of,O
-,O
mouth,O
.,O
The,O
institutional,O
review,O
boards,O
of,O
both,O
The,O
Icahn,O
School,O
of,O
Medicine,O
at,O
Mount,O
Sinai,O
and,O
Columbia,O
University,O
in,O
New,O
York,O
City,O
approved,O
the,O
study,O
.,O
Written,O
and,O
verbal,O
consent,O
was,O
waived,O
to,O
protect,O
the,O
anonymity,O
of,O
participants,O
and,O
no,O
remuneration,O
was,O
provided,O
for,O
participation,O
.,O
The,O
survey,O
questions,O
were,O
drafted,O
based,O
on,O
the,O
existing,O
literature,O
and,O
refined,O
by,O
TGGNC,O
health,O
experts,O
",",O
including,O
persons,O
with,O
a,O
TGGNC,O
life,O
experience,O
and,O
those,O
providing,O
healthcare,O
to,O
this,O
population,O
for,O
at,O
least,O
10,O
years,O
.,O
Free,O
response,O
questions,O
were,O
posed,O
to,O
participants,O
about,O
experiences,O
in,O
the,O
ED,O
",",O
as,O
well,O
as,O
current,O
gender,O
identity,O
",",O
reasons,O
for,O
nonuse,O
of,O
the,O
ED,O
",",O
and,O
recommendations,O
for,O
ED,O
clinicians,O
to,O
improve,O
their,O
care,O
of,O
this,O
patient,O
population,O
.,O
As,O
data,O
were,O
being,O
collected,O
",",O
the,O
research,O
team,O
developed,O
a,O
simple,O
conceptual,O
framework,O
(,O
Fig,O
.,O
1,O
),O
based,O
on,O
social,O
cognitive,O
theory,O
(,O
SCT,O
),O
and,O
stigma,O
theory,O
.,O
These,O
public,O
health,O
theories,O
helped,O
guide,O
analysis,O
of,O
how,O
participants,O
experienced,O
ED,O
care,O
.,O
SCT,O
posits,O
that,O
behavior,O
is,O
influenced,O
by,O
environmental,O
and,O
personal,O
factors,O
",",O
as,O
well,O
as,O
the,O
behavior,O
itself,O
.,O
This,O
model,O
is,O
strongly,O
based,O
on,O
the,O
role,O
of,O
self,O
-,O
efficacy,O
(,O
an,O
individual,O
',O
s,O
belief,O
in,O
their,O
own,O
capacity,O
to,O
execute,O
behaviors,O
necessary,O
to,O
achieve,O
specific,O
goals,O
),O
in,O
behavior,O
change,O
.,O
19,O
Yet,O
",",O
SCT,O
alone,O
does,O
not,O
account,O
for,O
the,O
patient,O
–,O
provider,O
power,O
differential,O
and,O
its,O
effects,O
on,O
patient,O
experiences,O
.,O
Stigma,O
theory,O
rests,O
on,O
the,O
idea,O
that,O
all,O
social,O
relationships,O
occur,O
within,O
an,O
unequal,O
structure,O
",",O
in,O
which,O
some,O
groups,O
have,O
more,O
social,O
",",O
political,O
",",O
and,O
/,O
or,O
economic,O
power,O
than,O
others,O
;,O
and,O
that,O
traditional,O
power,O
holders,O
may,O
",",O
intentionally,O
or,O
unintentionally,O
",",O
use,O
stigma,O
and,O
discrimination,O
to,O
reinforce,O
existing,O
structural,O
inequities,O
to,O
assert,O
their,O
possession,O
of,O
power,O
.,O
20,O
Conceptual,O
framework,O
:,O
Social,O
cognitive,O
theory,O
and,O
stigma,O
theory,O
.,O
The,O
primary,O
survey,O
question,O
for,O
those,O
who,O
sought,O
emergency,O
medical,O
care,O
was,O
open,O
ended,O
:,O
“,O
Please,O
tell,O
us,O
about,O
your,O
experience,O
.”,O
To,O
examine,O
the,O
data,O
",",O
investigators,O
collaboratively,O
developed,O
labels,O
",",O
or,O
codes,O
",",O
to,O
apply,O
to,O
lines,O
of,O
text,O
such,O
that,O
similar,O
pieces,O
of,O
information,O
could,O
be,O
grouped,O
and,O
compared,O
.,O
The,O
codes,O
were,O
synthesized,O
into,O
one,O
codebook,O
",",O
with,O
rules,O
on,O
when,O
to,O
use,O
or,O
not,O
use,O
each,O
code,O
.,O
Two,O
expert,O
consultants,O
in,O
qualitative,O
analysis,O
",",O
acquainted,O
with,O
the,O
data,O
",",O
reviewed,O
the,O
codebook,O
and,O
then,O
with,O
the,O
team,O
coded,O
five,O
pages,O
of,O
data,O
to,O
determine,O
utility,O
of,O
codes,O
and,O
finalize,O
the,O
codebook,O
.,O
Codes,O
were,O
applied,O
to,O
the,O
data,O
using,O
NVivo,O
10,O
".‡,",O
21,O
To,O
classify,O
respondents,O
',O
reports,O
about,O
their,O
experiences,O
in,O
the,O
ED,O
",",O
the,O
principal,O
investigator,O
(,O
MCS,O
),O
first,O
examined,O
the,O
frequency,O
with,O
which,O
each,O
code,O
was,O
applied,O
",",O
then,O
all,O
text,O
that,O
fell,O
under,O
multiple,O
codes,O
.,O
Next,O
",",O
each,O
ED,O
experience,O
was,O
reviewed,O
for,O
all,O
codes,O
used,O
to,O
describe,O
the,O
experience,O
.,O
For,O
the,O
data,O
display,O
(,O
Table,O
1,O
"),",O
the,O
codes,O
were,O
then,O
grouped,O
according,O
to,O
SCT,O
-,O
influenced,O
categories,O
:,O
the,O
category,O
of,O
“,O
Provider,O
Behavior,O
”,O
included,O
the,O
codes,O
“,O
competency,O
",”",O
“,O
outed,O
",”",O
“,O
provider,O
discomfort,O
",”",O
and,O
“,O
confidentiality,O
.”,O
Under,O
“,O
Patient,O
–,O
Provider,O
Encounter,O
”,O
were,O
the,O
codes,O
“,O
respect,O
",”",O
“,O
gendered,O
",”",O
“,O
inappropriate,O
",”",O
and,O
“,O
perceived,O
medical,O
care,O
.”,O
“,O
Systems,O
Issues,O
”,O
included,O
“,O
institutional,O
practice,O
",”",O
and,O
the,O
category,O
of,O
“,O
Self,O
-,O
Efficacy,O
”,O
incorporated,O
“,O
fear,O
",”",O
“,O
disclosure,O
",”",O
and,O
“,O
self,O
-,O
efficacy,O
.”,O
An,O
experience,O
was,O
considered,O
“,O
negative,O
”,O
if,O
the,O
participant,O
expressed,O
discontent,O
with,O
medical,O
care,O
and,O
/,O
or,O
interactions,O
with,O
ED,O
personnel,O
.,O
When,O
participants,O
described,O
satisfaction,O
with,O
care,O
and,O
/,O
or,O
interactions,O
",",O
a,O
“,O
positive,O
”,O
interaction,O
was,O
inferred,O
.,O
Data,O
Display,O
",",O
Abridged,O
Conceptual,O
frame,O
Code,O
Positive,O
interpretation,O
Negative,O
interpretation,O
Provider,O
behavior,O
Competency,O
Participants,O
who,O
reported,O
positive,O
experiences,O
with,O
provider,O
competency,O
noted,O
TGGNC,O
-,O
related,O
training,O
of,O
staff,O
.,O
“,O
I,O
have,O
had,O
positive,O
experiences,O
(,O
in,O
terms,O
of,O
my,O
trans,O
status,O
),O
in,O
the,O
ER,O
",",O
probably,O
because,O
it,O
is,O
[,O
name,O
of,O
hospital,O
],O
and,O
they,O
are,O
educated,O
for,O
the,O
most,O
part,O
about,O
trans,O
issues,O
.”,O
R134,O
Participants,O
stated,O
that,O
their,O
providers,O
did,O
not,O
know,O
how,O
TGGNC,O
life,O
experience,O
is,O
relevant,O
to,O
a,O
chief,O
complaint,O
or,O
how,O
hormone,O
use,O
affects,O
health,O
.“,O
Treated,O
by,O
a,O
resident,O
",",O
who,O
told,O
me,O
‘,O
I,O
don,O
',O
t,O
understand,O
your,O
body,O
.,O
I,O
will,O
just,O
consider,O
you,O
female,O
",",O
but,O
who,O
knows,O
what,O
those,O
hormones,O
you,O
are,O
taking,O
could,O
be,O
doing,O
to,O
you,O
’.”,O
R155,O
Patient,O
–,O
provider,O
encounter,O
Gendered,O
Some,O
described,O
being,O
properly,O
pronouned,O
or,O
named,O
and,O
feeling,O
respected,O
because,O
of,O
this,O
.“,O
I,O
was,O
actually,O
treated,O
really,O
nicely,O
by,O
the,O
doctors,O
and,O
hospital,O
staff,O
…,O
they,O
treated,O
me,O
like,O
the,O
woman,B-OG
that,O
I,O
am,O
and,O
I,O
would,O
recommend,O
that,O
hospital,O
to,O
anyone,O
who,O
asked,O
.”,O
R86,O
Participants,O
who,O
described,O
being,O
misgendered,O
mostly,O
noted,O
that,O
even,O
after,O
their,O
gender,O
identity,O
or,O
experience,O
was,O
disclosed,O
they,O
were,O
mispronouned,O
.“,O
It,O
was,O
humiliating,O
because,O
I,O
was,O
repeatedly,O
referred,O
to,O
by,O
my,O
birth,O
sex,O
after,O
repeatedly,O
asking,O
them,O
to,O
call,O
me,O
by,O
male,O
pronouns,O
.”,O
R59,O
Patient,O
–,O
provider,O
encounter,O
Inappropriate,O
This,O
code,O
captured,O
participant,O
descriptions,O
of,O
provider,O
gawking,O
",",O
persistent,O
staff,O
focus,O
on,O
genital,O
examinations,O
",",O
unnecessary,O
history,O
taking,O
about,O
gender,O
-,O
related,O
surgeries,O
",",O
sexual,O
history,O
",",O
assumption,O
of,O
sexually,B-DS
transmitted,I-DS
infections,I-DS
",",O
drug,O
use,O
",",O
psychological,B-DS
disorder,I-DS
",",O
and,O
use,O
of,O
patient,O
for,O
“,O
teaching,O
”,O
that,O
was,O
interpreted,O
as,O
being,O
put,O
on,O
display,O
.“,O
I,O
was,O
…,O
repeatedly,O
asked,O
if,O
I,O
was,O
drunk,O
or,O
on,O
drugs,O
.,O
I,O
was,O
neither,O
.,O
Injury,O
to,O
leg,O
required,O
stitches,O
.”,O
R170,O
Self,O
efficacy,O
Self,O
efficacy,O
Those,O
who,O
had,O
others,O
advocate,O
on,O
their,O
behalf,O
reported,O
experiencing,O
respect,O
and,O
proper,O
pronouning,O
.,O
“,O
Emergency,O
appendectomy,O
needed,O
….,O
both,O
my,O
primary,O
physician,O
and,O
spouse,O
took,O
very,O
good,O
care,O
to,O
ensure,O
I,O
was,O
treated,O
respectfully,O
.”,O
R129,O
Those,O
who,O
reported,O
being,O
able,O
to,O
advocate,O
for,O
themselves,O
usually,O
did,O
not,O
have,O
a,O
positive,O
experience,O
;,O
others,O
found,O
themselves,O
unable,O
to,O
advocate,O
for,O
themselves,O
at,O
all,O
.“,O
I,O
had,O
a,O
baby,O
and,O
probably,O
could,O
have,O
used,O
some,O
gender,O
related,O
support,O
from,O
a,O
licensed,O
professional,O
during,O
the,O
delivery,O
",",O
but,O
was,O
too,O
frightened,O
to,O
ask,O
for,O
it,O
.”,O
R18,O
A,O
summary,O
of,O
the,O
context,O
in,O
which,O
each,O
code,O
was,O
found,O
was,O
grouped,O
into,O
the,O
“,O
positive,O
”,O
and,O
/,O
or,O
“,O
negative,O
”,O
column,O
of,O
the,O
data,O
display,O
with,O
illustrative,O
participant,O
quotes,O
.,O
Some,O
codes,O
were,O
only,O
negative,O
",",O
so,O
no,O
positive,O
data,O
were,O
found,O
there,O
.,O
TGGNC,O
",",O
transgender,O
or,O
gender,O
nonconforming,O
.,O
As,O
a,O
team,O
of,O
six,O
investigators,O
with,O
diverse,O
qualities,O
",",O
it,O
was,O
important,O
to,O
recognize,O
how,O
the,O
investigators,O
',O
identities,O
and,O
experiences,O
might,O
shape,O
the,O
analysis,O
and,O
bias,O
findings,O
.,O
Collectively,O
",",O
the,O
team,O
accounted,O
for,O
these,O
subjectivities,O
by,O
working,O
independently,O
first,O
and,O
then,O
coming,O
together,O
",",O
with,O
the,O
consultants,O
",",O
to,O
review,O
strengths,O
and,O
limitations,O
of,O
the,O
separate,O
efforts,O
.,O
For,O
example,O
",",O
the,O
consultants,O
appreciated,O
that,O
most,O
codes,O
were,O
initially,O
biased,O
toward,O
reflecting,O
negative,O
experiences,O
.,O
Hence,O
",",O
many,O
such,O
codes,O
were,O
changed,O
",",O
before,O
being,O
applied,O
to,O
the,O
data,O
",",O
to,O
be,O
neutral,O
",",O
such,O
that,O
positive,O
experiences,O
could,O
be,O
recognized,O
.,O
“,O
Member,O
checking,O
”,O
22,O
was,O
performed,O
",",O
to,O
determine,O
whether,O
the,O
investigators,O
',O
interpretations,O
of,O
these,O
data,O
reflected,O
the,O
experiences,O
of,O
TGGNC,O
-,O
historied,O
persons,O
receiving,O
emergency,O
care,O
in,O
the,O
United,O
States,O
.,O
Advertised,O
for,O
6,O
months,O
on,O
Facebook,O
",",O
this,O
anonymous,O
validation,O
survey,O
was,O
completed,O
by,O
five,O
English,O
-,O
literate,O
",",O
self,O
-,O
identified,O
TGGNC,O
-,O
experienced,O
individuals,O
",",O
some,O
of,O
whom,O
may,O
have,O
participated,O
in,O
the,O
original,O
survey,O
.,O
These,O
persons,O
were,O
given,O
a,O
brief,O
summary,O
of,O
the,O
findings,O
and,O
asked,O
to,O
anonymously,O
report,O
",",O
via,O
SurveyMonkey,O
",",O
whether,O
they,O
considered,O
the,O
results,O
accurate,O
.,O
Results,O
Two,O
hundred,O
forty,O
participants,O
completed,O
the,O
main,O
survey,O
;,O
Table,O
2,O
describes,O
the,O
demographics,O
and,O
medical,O
characteristics,O
of,O
the,O
sample,O
.,O
Table,O
3,O
describes,O
reasons,O
respondents,O
reported,O
for,O
not,O
using,O
EDs,O
;,O
the,O
most,O
common,O
explanations,O
were,O
previous,O
negative,O
experiences,O
or,O
fear,O
of,O
experiencing,O
discrimination,O
.,O
Participant,O
Characteristics,O
%,O
n,O
=,O
240,O
Age,O
(,O
in,O
years,O
),O
18,O
–,O
24,O
17,O
.,O
5,O
42,O
25,O
–,O
35,O
50,O
.,O
4,O
121,O
36,O
–,O
45,O
16,O
.,O
7,O
40,O
46,O
–,O
55,O
9,O
.,O
2,O
22,O
56,O
–,O
64,O
3,O
.,O
8,O
9,O
≥,O
65,O
0,O
.,O
8,O
2,O
Annual,O
income,O
(,O
in,O
USD,O
),O
<,O
11,O
",",O
000,O
16,O
.,O
3,O
39,O
11,O
",",O
001,O
–,O
22,O
",",O
000,O
15,O
.,O
4,O
37,O
22,O
",",O
001,O
–,O
35,O
",",O
000,O
15,O
.,O
4,O
37,O
35,O
",",O
001,O
–,O
45,O
",",O
000,O
10,O
.,O
8,O
26,O
45,O
",",O
001,O
–,O
55,O
",",O
000,O
7,O
.,O
9,O
19,O
55,O
",",O
001,O
–,O
70,O
",",O
000,O
12,O
.,O
1,O
29,O
70,O
",",O
001,O
–,O
90,O
",",O
000,O
6,O
.,O
7,O
16,O
90,O
",",O
001,O
–,O
100,O
",",O
000,O
4,O
.,O
2,O
10,O
>,O
100,O
",",O
000,O
9,O
.,O
2,O
22,O
Highest,O
level,O
of,O
education,O
completed,O
Junior,O
high,O
/,O
middle,O
school,O
1,O
.,O
3,O
3,O
High,O
school,O
6,O
.,O
3,O
15,O
Some,O
college,O
/,O
university,O
22,O
.,O
1,O
53,O
College,O
/,O
university,O
35,O
.,O
4,O
85,O
Certificate,O
program,O
2,O
.,O
1,O
5,O
Graduate,O
/,O
professional,O
school,O
31,O
.,O
3,O
75,O
Race,O
and,O
/,O
or,O
ethnicitya,O
Asian,O
/,O
Asian,O
American,O
4,O
.,O
2,O
10,O
African,O
American,O
/,O
black,O
3,O
.,O
8,O
9,O
Latino,O
/,O
Hispanic,O
10,O
.,O
4,O
25,O
Native,O
American,O
/,O
Amerindian,O
/,O
Alaskan,O
Native,O
/,O
Pacific,O
Islander,O
2,O
.,O
1,O
5,O
White,O
82,O
.,O
5,O
198,O
Other,O
2,O
.,O
5,O
6,O
Sex,O
assigned,O
at,O
birth,O
Female,O
60,O
.,O
4,O
145,O
Male,O
21,O
.,O
7,O
52,O
Other,O
0,O
.,O
8,O
2,O
Ever,O
-,O
used,O
gender,O
-,O
affirming,O
hormones,O
No,O
22,O
.,O
1,O
53,O
Yes,O
65,O
.,O
4,O
157,O
Not,O
applicableb,O
2,O
.,O
1,O
5,O
Prescribed,O
by,O
a,O
licensed,O
provider,O
(,O
n,O
=,O
157,O
),O
No,O
3,O
.,O
8,O
6,O
Yes,O
95,O
.,O
5,O
150,O
At,O
least,O
one,O
gender,O
-,O
affirming,O
surgery,O
No,O
38,O
.,O
3,O
92,O
Yes,O
51,O
.,O
7,O
124,O
Have,O
a,O
primary,O
care,O
provider,O
No,O
17,O
.,O
1,O
41,O
Yes,O
72,O
.,O
5,O
174,O
Ever,O
wanted,O
/,O
needed,O
to,O
use,O
ED,O
No,O
13,O
.,O
3,O
32,O
Yes,O
75,O
180,O
Went,O
to,O
ED,O
(,O
n,O
=,O
180,O
),O
No,O
8,O
.,O
3,O
15,O
Yes,O
90,O
.,O
6,O
163,O
Respondents,O
were,O
able,O
to,O
choose,O
more,O
than,O
one,O
category,O
.,O
Respondents,O
with,O
a,O
gender,O
nonconforming,O
experience,O
may,O
not,O
desire,O
hormone,O
use,O
.,O
ED,O
",",O
emergency,O
department,O
.,O
Reasons,O
for,O
Transgender,O
or,O
Gender,O
Nonconforming,O
Nonuse,O
of,O
U,O
.,O
S,O
.,O
Emergency,O
Departments,O
Conceptual,O
frame,O
Reason,O
Frequency,O
(,O
n,O
=,O
35,O
"),",O
a,O
%,O
(,O
n,O
),O
Personal,O
Lack,O
of,O
medical,O
insurance,O
31,O
.,O
4,O
(,O
11,O
),O
Fear,O
of,O
being,O
outed,O
",",O
misgendered,O
",",O
or,O
experiencing,O
discrimination,O
60,O
(,O
21,O
),O
Provider,O
behavior,O
Past,O
witnessing,O
of,O
medical,O
personnel,O
gossiping,O
",",O
mocking,O
",",O
or,O
telling,O
jokes,O
about,O
the,O
TGGNC,O
patients,O
45,O
.,O
7,O
(,O
16,O
),O
Patient,O
–,O
provider,O
encounter,O
Past,O
experience,O
of,O
being,O
purposely,O
outed,O
by,O
healthcare,O
professional,O
8,O
.,O
6,O
(,O
3,O
),O
Past,O
experience,O
with,O
visibly,O
uncomfortable,O
providers,O
and,O
/,O
or,O
being,O
asked,O
inappropriate,O
questions,O
34,O
.,O
3,O
(,O
12,O
),O
Past,O
experience,O
of,O
staff,O
refusal,O
to,O
use,O
preferred,O
pronouns,O
62,O
.,O
9,O
(,O
22,O
),O
Past,O
experience,O
of,O
transphobia,O
as,O
a,O
patient,O
37,O
.,O
1,O
(,O
13,O
),O
Systems,O
issues,O
Medical,O
facilities,O
are,O
unable,O
to,O
provide,O
accommodations,O
for,O
TGGNC,O
patients,O
42,O
.,O
9,O
(,O
15,O
),O
Providers,O
are,O
poorly,O
educated,O
in,O
TGGNC,O
health,O
-,O
related,O
issues,O
40,O
(,O
14,O
),O
Participants,O
who,O
answered,O
this,O
question,O
could,O
offer,O
multiple,O
reasons,O
.,O
Recommendations,O
were,O
included,O
here,O
if,O
they,O
resonated,O
with,O
responses,O
to,O
other,O
questions,O
",",O
not,O
based,O
on,O
frequency,O
to,O
one,O
question,O
.,O
Two,O
overarching,O
themes,O
emerged,O
from,O
the,O
codes,O
related,O
to,O
experiences,O
of,O
emergency,O
care,O
(,O
Fig,O
.,O
2,O
).,O
The,O
conceptual,O
frame,O
of,O
“,O
Self,O
-,O
Efficacy,O
”,O
allowed,O
the,O
larger,O
theme,O
of,O
Self,O
-,O
Efficacy,O
to,O
materialize,O
;,O
and,O
the,O
conceptual,O
frames,O
“,O
Provider,O
Behavior,O
",”",O
“,O
Patient,O
–,O
Provider,O
Encounter,O
",”",O
and,O
“,O
Systems,O
Issues,O
”,O
were,O
encompassed,O
by,O
the,O
stigma,O
theory,O
-,O
influenced,O
theme,O
of,O
Power,O
Inequity,O
.,O
These,O
two,O
themes,O
guided,O
the,O
analysis,O
toward,O
an,O
appreciation,O
of,O
the,O
altered,O
power,O
dynamic,O
between,O
providers,O
and,O
patients,O
that,O
results,O
from,O
TGGNC,O
-,O
historied,O
patients,O
presenting,O
to,O
EDs,O
.,O
All,O
validation,O
surveys,O
confirmed,O
the,O
interpretation,O
that,O
regardless,O
of,O
intent,O
",",O
the,O
providers,O
',O
efforts,O
to,O
compensate,O
for,O
inexperience,O
with,O
TGGNC,O
-,O
related,O
health,O
issues,O
and,O
to,O
assert,O
themselves,O
as,O
knowledgeable,O
authorities,O
led,O
to,O
negative,O
experiences,O
for,O
many,O
study,O
participants,O
.,O
Thematic,O
analysis,O
.,O
Self,O
-,O
efficacy,O
The,O
code,O
“,O
disclosure,O
”,O
centered,O
on,O
participants,O
',O
discussions,O
about,O
considerations,O
of,O
divulging,O
their,O
TGGNC,O
experience,O
to,O
ED,O
staff,O
.,O
Whether,O
forced,O
or,O
elective,O
",",O
“,O
disclosure,O
”,O
was,O
generally,O
linked,O
to,O
a,O
perception,O
of,O
poor,O
medical,O
care,O
.,O
One,O
respondent,O
recounted,O
",",O
…,O
I,O
revealed,O
my,O
status,O
",",O
which,O
no,O
one,O
knows,O
usually,O
until,O
I,O
tell,O
them,O
.,O
And,O
then,O
things,O
got,O
weird,O
.,O
The,O
doctors,O
were,O
very,O
rude,O
",",O
barely,O
treated,O
me,O
",",O
and,O
tried,O
to,O
get,O
rid,O
of,O
me,O
as,O
quickly,O
as,O
possible,O
.,O
And,O
worst,O
of,O
all,O
",",O
when,O
I,O
tried,O
to,O
use,O
the,O
woman,B-OG
',O
s,O
restroom,O
before,O
I,O
left,O
",",O
they,O
threatened,O
to,O
call,O
security,O
on,O
me,O
.,O
It,O
was,O
humiliating,O
.,O
I,O
would,O
die,O
before,O
I,O
went,O
back,O
there,O
again,O
(,O
R21,O
).,O
Some,O
participants,O
disclosed,O
their,O
TGGNC,O
history,O
and,O
reported,O
being,O
treated,O
with,O
respect,O
",",O
which,O
most,O
attributed,O
to,O
the,O
staff,O
being,O
well,O
trained,O
:,O
“,O
I,O
have,O
had,O
positive,O
experiences,O
(,O
in,O
terms,O
of,O
my,O
trans,O
status,O
),O
in,O
the,O
ER,O
probably,O
because,O
…,O
they,O
are,O
educated,O
for,O
the,O
most,O
part,O
about,O
trans,O
issues,O
”,O
(,O
R133,O
).,O
Another,O
participant,O
',O
s,O
positive,O
experience,O
was,O
attributed,O
to,O
having,O
a,O
support,O
network,O
advocating,O
for,O
quality,O
care,O
:,O
“…,O
both,O
[,O
my,O
],O
primary,O
physician,O
and,O
spouse,O
took,O
very,O
good,O
care,O
to,O
ensure,O
I,O
was,O
treated,O
respectfully,O
”,O
(,O
R127,O
).,O
Some,O
reported,O
not,O
disclosing,O
and,O
feeling,O
respected,O
because,O
they,O
could,O
pass,O
within,O
the,O
gender,O
binary,O
or,O
they,O
were,O
unsure,O
if,O
their,O
clinician,O
(,O
s,O
),O
were,O
aware,O
of,O
their,O
TGGNC,O
history,O
.,O
The,O
“,O
self,O
-,O
efficacy,O
”,O
code,O
was,O
used,O
when,O
participants,O
spoke,O
up,O
for,O
themselves,O
",",O
with,O
resultant,O
positive,O
or,O
negative,O
experiences,O
",",O
and,O
also,O
when,O
participants,O
purposefully,O
had,O
someone,O
else,O
advocate,O
on,O
their,O
behalf,O
.,O
Some,O
found,O
that,O
the,O
traditional,O
provider,O
–,O
patient,O
hierarchy,O
barred,O
their,O
self,O
-,O
efficacy,O
.,O
About,O
a,O
portion,O
of,O
the,O
physical,O
examination,O
that,O
may,O
have,O
been,O
unnecessary,O
",",O
one,O
participant,O
said,O
",",O
“,O
I,O
didn,O
',O
t,O
ask,O
at,O
the,O
time,O
because,O
…,O
I,O
have,O
been,O
taught,O
that,O
doctors,O
know,O
better,O
than,O
I,O
do,O
”,O
(,O
R118,O
).,O
However,O
",",O
even,O
those,O
who,O
reported,O
being,O
able,O
to,O
advocate,O
for,O
themselves,O
often,O
did,O
not,O
have,O
a,O
positive,O
experience,O
:,O
I,O
always,O
remind,O
them,O
when,O
I,O
check,O
in,O
that,O
I,O
am,O
trans,O
(,O
FTM,O
§).,O
I,O
would,O
rather,O
providers,O
feel,O
uncomfortable,O
before,O
they,O
see,O
me,O
and,O
then,O
get,O
their,O
s,O
—-,O
together,O
by,O
the,O
time,O
they,O
come,O
in,O
.,O
Even,O
though,O
I,O
do,O
that,O
",",O
the,O
providers,O
always,O
ask,O
me,O
questions,O
about,O
my,O
penis,O
and,O
fail,O
to,O
ask,O
important,O
questions,O
pertinent,O
to,O
people,O
with,O
female,O
anatomy,O
until,O
I,O
prompt,O
them,O
to,O
.…,O
(,O
R123,O
),O
Those,O
who,O
had,O
others,O
advocate,O
on,O
their,O
behalf,O
experienced,O
respect,O
and,O
proper,O
pronouning,O
.,O
“,O
My,O
experience,O
was,O
generally,O
positive,O
",",O
but,O
I,O
made,O
sure,O
to,O
have,O
a,O
friend,O
come,O
with,O
me,O
.,O
The,O
doctors,O
referred,O
to,O
me,O
by,O
[,O
desired,O
],O
female,O
pronouns,O
…”,O
(,O
R148,O
).,O
Power,O
inequity,O
Many,O
of,O
the,O
negative,O
experiences,O
described,O
by,O
participants,O
included,O
difficulties,O
with,O
practitioner,O
knowledge,O
in,O
treating,O
TGGNC,O
-,O
experienced,O
patients,O
.,O
Generally,O
",",O
providers,O
did,O
not,O
seem,O
to,O
know,O
when,O
and,O
how,O
TGGNC,O
-,O
related,O
medical,O
history,O
was,O
relevant,O
to,O
a,O
chief,O
complaint,O
:,O
“,O
Doctor,O
unable,O
to,O
consider,O
that,O
my,O
female,O
history,O
and,O
male,O
hormones,O
could,O
impact,O
my,O
health,O
in,O
the,O
situation,O
presented,O
”,O
(,O
R132,O
).,O
Participants,O
conveyed,O
expecting,O
providers,O
to,O
be,O
unaware,O
and,O
reported,O
having,O
to,O
explain,O
the,O
medical,O
relevance,O
of,O
TGGNC,O
medical,O
histories,O
.,O
When,O
positive,O
experiences,O
were,O
noted,O
",",O
they,O
were,O
attributed,O
to,O
purposeful,O
training,O
:,O
“,O
Once,O
I,O
spoke,O
with,O
the,O
Dr,O
.,O
the,O
whole,O
team,O
was,O
great,O
.,O
I,O
later,O
learned,O
my,O
primary,O
care,O
Dr,O
.,O
had,O
worked,O
at,O
that,O
hosp,O
.,O
prior,O
",",O
and,O
had,O
explained,O
gender,O
issues,O
with,O
much,O
of,O
the,O
senior,O
staff,O
”,O
(,O
R25,O
).,O
Respondents,O
noticed,O
that,O
in,O
situations,O
in,O
which,O
their,O
clinicians,O
admitted,O
they,O
were,O
not,O
knowledgeable,O
about,O
TGGNC,O
-,O
related,O
health,O
issues,O
",",O
these,O
providers,O
were,O
rude,O
and,O
unprofessional,O
.,O
One,O
participant,O
reported,O
that,O
the,O
nurses,O
“…[,O
said,O
],O
things,O
like,O
how,O
it,O
was,O
against,O
God,O
and,O
just,O
wasn,O
',O
t,O
right,O
”,O
(,O
R82,O
).,O
Providers,O
who,O
demonstrated,O
discomfort,O
with,O
this,O
patient,O
population,O
commonly,O
misgendered,O
patients,O
:,O
“,O
Referred,O
to,O
as,O
a,O
woman,B-OG
even,O
after,O
I,O
explained,O
to,O
the,O
doctor,O
that,O
I,O
was,O
a,O
transmale,O
",",O
they,O
ignored,O
my,O
statement,O
and,O
proceeded,O
to,O
call,O
me,O
she,O
”,O
(,O
R210,O
).,O
In,O
addition,O
to,O
misgendering,O
patients,O
",",O
having,O
insufficient,O
medical,O
knowledge,O
",",O
and,O
visibly,O
expressing,O
discomfort,O
",",O
clinicians,O
were,O
often,O
perceived,O
to,O
perform,O
unnecessary,O
histories,O
and,O
physical,O
examinations,O
.,O
One,O
participant,O
reported,O
being,O
“,O
questioned,O
a,O
lot,O
about,O
my,O
sex,O
life,O
when,O
I,O
went,O
for,O
pneumonia,B-DS
”,O
(,O
R62,O
).,O
Participants,O
described,O
experiencing,O
open,O
gawking,O
",",O
superfluous,O
history,O
taking,O
about,O
gender,O
-,O
related,O
surgeries,O
",",O
assumption,O
of,O
sexually,B-DS
transmitted,I-DS
infections,I-DS
",",O
drug,O
use,O
",",O
and,O
psychiatric,B-DS
disease,I-DS
",",O
and,O
being,O
put,O
on,O
display,O
.,O
One,O
participant,O
shared,O
",",O
“,O
I,O
have,O
also,O
had,O
doctors,O
/,O
nurses,O
call,O
over,O
other,O
people,O
on,O
duty,O
to,O
come,O
look,O
at,O
me,O
for,O
no,O
reason,O
.,O
It,O
made,O
me,O
feel,O
like,O
an,O
animal,O
in,O
a,O
zoo,O
”,O
(,O
R208,O
).,O
Participants,O
also,O
reported,O
having,O
their,O
gender,O
“,O
variance,O
”,O
verbally,O
or,O
physically,O
exposed,O
in,O
the,O
waiting,O
area,O
in,O
front,O
of,O
other,O
patients,O
:,O
“,O
One,O
visit,O
required,O
an,O
ekg,O
",",O
and,O
after,O
telling,O
the,O
staff,O
I,O
was,O
trans,O
",",O
they,O
continued,O
to,O
open,O
my,O
shirt,O
with,O
the,O
doors,O
and,O
curtains,O
open,O
to,O
the,O
ER,O
waiting,O
room,O
”,O
(,O
R10,O
).,O
Moreover,O
",",O
failure,O
of,O
practitioners,O
to,O
communicate,O
led,O
participants,O
to,O
assume,O
they,O
had,O
received,O
an,O
inappropriate,O
examination,O
.,O
For,O
example,O
",",O
one,O
participant,O
survived,O
a,O
motor,O
vehicle,O
collision,O
and,O
experienced,O
head,O
and,O
neck,O
trauma,O
.,O
The,O
participant,O
reported,O
the,O
provider,O
…[,O
felt,O
],O
parts,O
of,O
my,O
lower,O
body,O
(,O
through,O
my,O
clothes,O
),O
that,O
seemed,O
to,O
have,O
nothing,O
to,O
do,O
with,O
my,O
head,O
/,O
neck,O
/,O
spine,O
.,O
He,O
specifically,O
felt,O
where,O
my,O
hips,O
were,O
",",O
using,O
both,O
hands,O
to,O
register,O
where,O
they,O
were,O
.,O
To,O
this,O
day,O
I,O
don,O
',O
t,O
know,O
if,O
this,O
was,O
medically,O
necessary,O
or,O
if,O
he,O
was,O
medically,O
curious,O
about,O
my,O
transsexuality,O
.,O
(,O
R118,O
).,O
Most,O
likely,O
",",O
this,O
participant,O
is,O
describing,O
the,O
basics,O
of,O
a,O
secondary,O
survey,O
",",O
in,O
which,O
the,O
clinician,O
assesses,O
pelvis,O
stability,O
",",O
but,O
in,O
the,O
absence,O
of,O
communication,O
",",O
the,O
patient,O
inferred,O
the,O
worst,O
.,O
To,O
improve,O
ED,O
care,O
",",O
participants,O
recommended,O
that,O
hospitals,O
develop,O
TGGNC,O
-,O
sensitive,O
protocols,O
and,O
practitioner,O
trainings,O
to,O
ensure,O
privacy,O
",",O
respect,O
",",O
and,O
appropriate,O
treatment,O
for,O
patients,O
(,O
Table,O
4,O
).,O
They,O
recommended,O
focusing,O
on,O
the,O
application,O
of,O
gendered,O
language,O
and,O
improving,O
both,O
intake,O
procedures,O
and,O
modes,O
of,O
communication,O
that,O
currently,O
risk,O
unnecessarily,O
exposing,O
a,O
patient,O
',O
s,O
TGGNC,O
experience,O
.,O
Participant,O
Recommendations,O
to,O
Improve,O
the,O
Emergency,O
Department,O
Care,O
of,O
Persons,O
with,O
a,O
Transgender,O
or,O
Gender,O
Nonconforming,O
Experience,O
Conceptual,O
frame,O
Recommendation,O
Frequency,O
(,O
123,O
"),",O
a,O
%,O
(,O
n,O
),O
Provider,O
behavior,O
Do,O
not,O
discuss,O
gender,O
identity,O
or,O
TGGNC,O
experience,O
(,O
e,O
.,O
g,O
".,",O
gender,O
-,O
affirming,O
surgeries,O
),O
with,O
others,O
",",O
including,O
healthcare,O
providers,O
",",O
unless,O
it,O
is,O
relevant,O
to,O
provision,O
of,O
care,O
.,O
22,O
.,O
8,O
(,O
28,O
),O
Ask,O
sensitive,O
questions,O
in,O
private,O
spaces,O
only,O
.,O
5,O
.,O
7,O
(,O
7,O
),O
Call,O
out,O
last,O
names,O
only,O
(,O
no,O
prefixes,O
),O
in,O
group,O
areas,O
",",O
such,O
as,O
waiting,O
rooms,O
.,O
2,O
.,O
4,O
(,O
3,O
),O
Patient,O
–,O
provider,O
encounter,O
Standard,O
practice,O
of,O
providers,O
should,O
be,O
to,O
ask,O
patients,O
',O
preferred,O
pronoun,O
and,O
name,O
and,O
use,O
these,O
throughout,O
care,O
.,O
44,O
.,O
7,O
(,O
55,O
),O
Do,O
not,O
ask,O
about,O
gender,O
and,O
/,O
or,O
TGGNC,O
experience,O
if,O
it,O
is,O
not,O
relevant,O
to,O
ED,O
care,O
.,O
35,O
.,O
8,O
(,O
44,O
),O
Avoid,O
gender,O
-,O
specific,O
terms,O
",",O
including,O
social,O
titles,O
(,O
eg,O
:,O
Ms,O
".,",O
Mr,O
.).,O
1,O
.,O
6,O
(,O
2,O
),O
Systems,O
issues,O
Systematic,O
",",O
required,O
training,O
of,O
ED,O
providers,O
on,O
TGGNC,O
medical,O
issues,O
",",O
including,O
gender,O
-,O
affirming,O
surgeries,O
",",O
potential,O
postoperative,O
complications,O
",",O
common,O
hormone,O
therapies,O
",",O
and,O
related,O
side,O
effects,O
.,O
Providers,O
should,O
also,O
be,O
trained,O
on,O
the,O
social,O
stigma,O
and,O
marginalization,O
this,O
population,O
experiences,O
generally,O
and,O
in,O
healthcare,O
settings,O
.,O
13,O
.,O
8,O
(,O
17,O
),O
Incorporate,O
pronoun,O
and,O
name,O
preference,O
in,O
registration,O
forms,O
.,O
b,O
9,O
.,O
8,O
(,O
12,O
),O
Train,O
clinicians,O
on,O
how,O
to,O
ask,O
",",O
when,O
clinically,O
relevant,O
",",O
about,O
sensitive,O
gender,O
information,O
.,O
4,O
.,O
1,O
(,O
5,O
),O
Offer,O
gender,O
-,O
neutral,O
spaces,O
",",O
including,O
hospital,O
rooms,O
and,O
restrooms,O
.,O
c,O
2,O
.,O
4,O
(,O
3,O
),O
Participants,O
could,O
offer,O
more,O
than,O
one,O
recommendation,O
.,O
Recommendations,O
were,O
included,O
here,O
if,O
they,O
resonated,O
with,O
responses,O
to,O
other,O
questions,O
",",O
not,O
based,O
on,O
frequency,O
to,O
one,O
question,O
.,O
While,O
most,O
who,O
commented,O
on,O
pronoun,O
preference,O
on,O
registration,O
forms,O
were,O
in,O
favor,O
of,O
this,O
addition,O
",",O
some,O
were,O
concerned,O
about,O
the,O
potential,O
ramifications,O
of,O
a,O
TGGNC,O
experience,O
being,O
in,O
their,O
medical,O
record,O
.,O
Applicable,O
to,O
all,O
areas,O
of,O
the,O
hospital,O
",",O
not,O
just,O
emergency,O
departments,O
.,O
Discussion,O
While,O
many,O
factors,O
impact,O
patient,O
satisfaction,O
with,O
ED,O
experiences,O
",",O
clinician,O
knowledge,O
is,O
not,O
usually,O
identified,O
as,O
a,O
key,O
area,O
for,O
improvement,O
.,O
17,O
",",O
23,O
–,O
27,O
However,O
",",O
participants,O
in,O
this,O
study,O
reported,O
having,O
to,O
tell,O
their,O
practitioners,O
if,O
and,O
how,O
their,O
TGGNC,O
medical,O
history,O
was,O
relevant,O
to,O
the,O
presenting,O
complaint,O
.,O
This,O
lack,O
of,O
practitioner,O
knowledge,O
on,O
the,O
issue,O
was,O
strongly,O
tied,O
to,O
negative,O
experiences,O
for,O
TGGNC,O
-,O
experienced,O
patients,O
.,O
Further,O
research,O
should,O
examine,O
the,O
curricula,O
of,O
professional,O
healthcare,O
schools,O
and,O
EDs,O
that,O
provide,O
TGGNC,O
health,O
training,O
to,O
students,O
and,O
staff,O
and,O
explore,O
efforts,O
to,O
systematize,O
such,O
education,O
.,O
Particularly,O
concerning,O
among,O
the,O
negative,O
experiences,O
",",O
multiple,O
participants,O
reported,O
experiencing,O
unwanted,O
examinations,O
",",O
similar,O
to,O
the,O
qualitative,O
findings,O
from,O
a,O
European,O
study,O
.,O
9,O
Even,O
when,O
a,O
clinician,O
considers,O
an,O
examination,O
necessary,O
",",O
patients,O
with,O
capacity,O
have,O
the,O
right,O
to,O
refuse,O
examinations,O
or,O
treatment,O
plans,O
.,O
28,O
–,O
30,O
Examinations,O
performed,O
out,O
of,O
provider,O
desire,O
to,O
learn,O
more,O
about,O
TGGNC,O
-,O
related,O
medicine,O
are,O
appropriate,O
only,O
with,O
patient,O
permission,O
.,O
When,O
practitioners,O
believe,O
an,O
examination,O
(,O
or,O
history,O
element,O
),O
is,O
relevant,O
",",O
it,O
is,O
particularly,O
important,O
to,O
explain,O
the,O
clinical,O
reasoning,O
to,O
patients,O
of,O
marginalized,O
populations,O
",",O
including,O
TGGNC,O
-,O
experienced,O
patients,O
.,O
Not,O
communicating,O
why,O
an,O
examination,O
(,O
or,O
history,O
element,O
),O
is,O
relevant,O
to,O
care,O
alienates,O
this,O
vulnerable,O
and,O
high,O
-,O
risk,O
group,O
.,O
Similar,O
to,O
TGGNC,O
-,O
historied,O
reports,O
of,O
general,O
healthcare,O
avoidance,O
",",O
2,O
",",O
4,O
",",O
7,O
",",O
9,O
–,O
14,O
many,O
participants,O
in,O
this,O
ED,O
-,O
focused,O
study,O
indicated,O
that,O
they,O
have,O
avoided,O
ED,O
care,O
due,O
to,O
fear,O
of,O
or,O
previous,O
experience,O
of,O
unwanted,O
examinations,O
.,O
The,O
negative,O
experiences,O
reported,O
additionally,O
included,O
inappropriate,O
history,O
taking,O
",",O
illness,O
assumption,O
",",O
and,O
misgendering,O
.,O
TGGNC,O
-,O
historied,O
persons,O
have,O
also,O
described,O
these,O
experiences,O
in,O
general,O
medicine,O
reports,O
in,O
Europe,O
",",O
New,O
Zealand,O
",",O
and,O
in,O
some,O
U,O
.,O
S,O
.,O
states,O
.,O
2,O
",",O
4,O
",",O
7,O
",",O
9,O
–,O
14,O
Such,O
staff,O
actions,O
lead,O
to,O
TGGNC,O
-,O
experienced,O
patients,O
",",O
even,O
those,O
who,O
have,O
not,O
used,O
the,O
ED,O
but,O
have,O
heard,O
of,O
such,O
interactions,O
",",O
avoiding,O
needed,O
medical,O
care,O
(,O
Table,O
3,O
).,O
2,O
",",O
4,O
",",O
7,O
",",O
9,O
–,O
14,O
More,O
research,O
is,O
needed,O
to,O
explore,O
why,O
patients,O
who,O
had,O
a,O
cisgender,O
**,O
advocate,O
had,O
more,O
positive,O
ED,O
experiences,O
than,O
those,O
who,O
advocated,O
for,O
themselves,O
;,O
similarly,O
",",O
more,O
research,O
should,O
examine,O
why,O
TGGNC,O
-,O
historied,O
patients,O
who,O
appeared,O
cisgender,O
had,O
a,O
better,O
ED,O
experience,O
than,O
patients,O
who,O
did,O
not,O
.,O
Limitations,O
As,O
a,O
survey,O
promoted,O
by,O
organizations,O
and,O
clinics,O
that,O
serve,O
LGBT,O
populations,O
",",O
this,O
study,O
has,O
limitations,O
.,O
Respondents,O
had,O
relatively,O
high,O
educational,O
and,O
income,O
levels,O
;,O
they,O
may,O
differ,O
from,O
those,O
without,O
access,O
to,O
primary,O
care,O
or,O
kin,O
advocates,O
.,O
Insurance,O
status,O
was,O
not,O
systematically,O
assessed,O
in,O
this,O
study,O
",",O
although,O
several,O
participants,O
noted,O
that,O
not,O
having,O
insurance,O
or,O
the,O
gender,O
marker,O
with,O
their,O
insurance,O
impacted,O
their,O
decision,O
to,O
seek,O
ED,O
care,O
.,O
Further,O
research,O
should,O
explore,O
whether,O
insurance,O
status,O
and,O
insurance,O
gender,O
markers,O
have,O
any,O
impact,O
on,O
ED,O
care,O
experiences,O
among,O
TGGNC,O
-,O
historied,O
persons,O
.,O
Despite,O
specific,O
attempts,O
to,O
optimize,O
diversity,O
",",O
respondents,O
are,O
largely,O
white,O
and,O
were,O
designated,O
“,O
female,O
”,O
at,O
birth,O
.,O
As,O
with,O
any,O
voluntary,O
survey,O
",",O
persons,O
with,O
negative,O
experiences,O
may,O
be,O
more,O
likely,O
to,O
participate,O
than,O
those,O
with,O
positive,O
experiences,O
",",O
and,O
here,O
they,O
may,O
be,O
more,O
likely,O
to,O
attribute,O
their,O
negative,O
experience,O
to,O
a,O
TGGNC,O
history,O
.,O
Nevertheless,O
",",O
the,O
negative,O
experiences,O
reported,O
are,O
concerning,O
and,O
largely,O
elucidate,O
the,O
findings,O
of,O
previous,O
quantitative,O
studies,O
.,O
4,O
",",O
12,O
The,O
written,O
",",O
anonymous,O
format,O
permitted,O
a,O
large,O
",",O
national,O
sample,O
but,O
barred,O
discussion,O
with,O
participants,O
.,O
Still,O
",",O
this,O
study,O
",",O
the,O
first,O
of,O
its,O
kind,O
in,O
the,O
United,O
States,O
",",O
situates,O
the,O
responses,O
within,O
a,O
framework,O
of,O
social,O
theory,O
and,O
contributes,O
to,O
a,O
richer,O
understanding,O
of,O
what,O
shapes,O
the,O
ED,O
experiences,O
of,O
TGGNC,O
-,O
historied,O
persons,O
.,O
Conclusion,O
As,O
the,O
frontline,O
of,O
protection,O
for,O
the,O
nation,O
',O
s,O
public,O
health,O
",",O
U,O
.,O
S,O
.,O
ED,O
providers,O
must,O
be,O
prepared,O
to,O
serve,O
the,O
most,O
vulnerable,O
and,O
high,O
-,O
risk,O
populations,O
:,O
ED,O
visits,O
can,O
be,O
unique,O
opportunities,O
to,O
link,O
marginalized,O
patients,O
to,O
needed,O
social,O
and,O
medical,O
resources,O
with,O
the,O
purpose,O
of,O
comprehensively,O
improving,O
the,O
health,O
of,O
communities,O
.,O
15,O
This,O
study,O
demonstrates,O
that,O
TGGNC,O
-,O
historied,O
patients,O
in,O
the,O
United,O
States,O
have,O
negative,O
and,O
alienating,O
ED,O
experiences,O
",",O
which,O
they,O
attribute,O
to,O
lack,O
of,O
provider,O
training,O
on,O
care,O
provision,O
for,O
this,O
population,O
.,O
Table,O
5,O
lists,O
resources,O
clinicians,O
may,O
find,O
useful,O
in,O
learning,O
more,O
about,O
TGGNC,O
healthcare,O
.,O
Further,O
research,O
is,O
needed,O
to,O
examine,O
interventions,O
that,O
may,O
strengthen,O
EDs,O
',O
ability,O
to,O
function,O
as,O
the,O
safety,O
net,O
for,O
this,O
socially,O
and,O
economically,O
marginalized,O
group,O
with,O
significant,O
health,O
concerns,O
.,O
Educational,O
Resources,O
“,O
Affirmative,O
Care,O
for,O
Transgender,O
and,O
Gender,O
Non,O
-,O
Conforming,O
People,O
:,O
Best,O
Practices,O
for,O
Front,O
-,O
line,O
Healthcare,O
Staff,O
",”",O
by,O
the,O
National,O
LGBT,O
Health,O
Education,O
Center,O
.,O
Available,O
at,O
:,O
www,O
.,O
lgbthealtheducation,O
.,O
org,O
/,O
wp,O
-,O
content,O
/,O
uploads,O
/,O
13,O
-,O
017_TransBestPracticesforFrontlineStaff_v9_04,O
-,O
30,O
-,O
13,O
.,O
pdf,O
“,O
Understanding,O
Transgender,O
:,O
Frequently,O
Asked,O
Questions,O
about,O
Transgender,O
People,O
",”",O
by,O
the,O
National,O
Center,O
for,O
Transgender,O
Equality,O
.,O
Available,O
at,O
:,O
http,O
://,O
transequality,O
.,O
org,O
/,O
issues,O
/,O
resources,O
/,O
understanding,O
-,O
transgender,O
-,O
people,O
-,O
faq,O
“,O
Standards,O
of,O
Care,O
for,O
the,O
Health,O
of,O
Transsexual,O
",",O
Transgender,O
",",O
and,O
Gender,O
-,O
Nonconforming,O
People,O
.”,O
World,O
Professional,O
Association,O
for,O
Transgender,O
Health,O
",",O
7th,O
Version,O
",",O
2012,O
.,O
Available,O
at,O
:,O
www,O
.,O
wpath,O
.,O
org,O
“,O
Transgender,O
Patients,O
in,O
the,O
ED,O
.”,O
Emergency,O
Physicians,O
Monthly,O
",",O
August,O
19,O
",",O
2015,O
.,O
Available,O
at,O
:,O
http,O
://,O
epmonthly,O
.,O
com,O
/,O
article,O
/,O
transgender,O
-,O
patients,O
-,O
in,O
-,O
the,O
-,O
ed,O
/,O
Transgender,O
“,O
life,O
experience,O
”,O
and,O
“,O
history,O
",”",O
instead,O
of,O
transgender,O
“,O
identity,O
",”",O
is,O
used,O
in,O
this,O
article,O
based,O
upon,O
validation,O
survey,O
feedback,O
from,O
experienced,O
leaders,O
in,O
the,O
TGGNC,O
health,O
field,O
:,O
“,O
Transgender,O
”,O
describes,O
an,O
experience,O
",",O
not,O
necessarily,O
an,O
identity,O
.,O
It,O
was,O
noted,O
that,O
“,O
being,O
transgender,O
”,O
leaves,O
out,O
people,O
who,O
simply,O
identify,O
as,O
one,O
gender,O
",",O
but,O
were,O
formerly,O
recognized,O
as,O
another,O
.,O
For,O
example,O
",",O
one,O
might,O
identify,O
as,O
male,O
",",O
but,O
was,O
once,O
recognized,O
as,O
female,O
;,O
such,O
a,O
man,O
may,O
not,O
identify,O
as,O
“,O
transgender,O
",”",O
only,O
as,O
male,O
.,O
“,O
History,O
”,O
and,O
“,O
life,O
experience,O
”,O
were,O
suggested,O
for,O
use,O
as,O
more,O
encompassing,O
of,O
the,O
ways,O
in,O
which,O
people,O
understand,O
themselves,O
.,O
www,O
.,O
Facebook,O
.,O
com,O
/,O
TGinED,O
NVivo,O
is,O
software,O
designed,O
to,O
help,O
qualitative,O
investigators,O
organize,O
",",O
conceptualize,O
",",O
and,O
understand,O
raw,O
",",O
unstructured,O
data,O
such,O
as,O
participant,O
survey,O
responses,O
.,O
FTM,O
:,O
Female,O
to,O
Male,O
.,O
“,O
Cisgender,O
”,O
describes,O
a,O
person,O
whose,O
performed,O
gender,O
conforms,O
to,O
his,O
or,O
her,O
assigned,O
gender,O
at,O
birth,O
.,O
Circulating,O
tumor,B-DS
DNA,O
detection,O
in,O
head,B-DS
and,I-DS
neck,I-DS
cancer,I-DS
:,O
evaluation,O
of,O
two,O
different,O
detection,O
approaches,O
The,O
use,O
of,O
non,O
-,O
invasive,O
biomarkers,O
such,O
as,O
circulating,O
tumor,B-DS
DNA,O
(,O
ctDNA,O
),O
in,O
head,B-DS
and,I-DS
neck,I-DS
tumors,I-DS
may,O
be,O
of,O
relevance,O
in,O
early,O
diagnosis,O
and,O
eventually,O
improved,O
outcome,O
.,O
We,O
evaluated,O
two,O
different,O
approaches,O
from,O
two,O
case,O
series,O
in,O
Europe,O
and,O
South,O
America,O
including,O
(,O
i,O
),O
targeted,O
screening,O
of,O
ctDNA,O
mutations,O
",",O
and,O
(,O
ii,O
),O
detection,O
of,O
TP53,B-GP
mutations,O
in,O
plasma,O
and,O
oral,O
rinses,O
without,O
previous,O
knowledge,O
of,O
mutational,O
status,O
in,O
tumor,B-DS
samples,O
.,O
Targeted,O
sequencing,O
in,O
5,O
genes,O
identified,O
ctDNA,O
mutations,O
in,O
plasma,O
among,O
42,O
%,O
of,O
HNSCC,B-DS
cases,O
",",O
67,O
%,O
of,O
who,O
were,O
early,O
stage,O
cases,O
.,O
No,O
association,O
was,O
found,O
between,O
ctDNA,O
mutation,O
detection,O
and,O
overall,O
survival,O
.,O
Sequencing,O
of,O
the,O
entire,O
coding,O
region,O
of,O
the,O
TP53,B-GP
gene,O
resulted,O
in,O
identification,O
of,O
TP53,B-GP
mutations,O
in,O
76,O
%,O
of,O
tumor,B-DS
cases,O
.,O
However,O
",",O
concordance,O
of,O
mutation,O
detection,O
was,O
low,O
between,O
tumor,B-DS
",",O
oral,O
rinses,O
(,O
11,O
%),O
and,O
plasma,O
(,O
2,O
",",O
7,O
%),O
samples,O
.,O
Identification,O
of,O
5,O
pathogenic,O
TP53,B-GP
mutations,O
in,O
oral,O
rinses,O
from,O
3,O
non,O
-,O
cancer,B-DS
controls,O
gives,O
additional,O
evidence,O
of,O
mutation,O
occurrence,O
in,O
individuals,O
without,O
a,O
diagnosed,O
cancer,B-DS
and,O
presents,O
an,O
additional,O
challenge,O
for,O
the,O
development,O
of,O
ctDNA,O
diagnostic,O
assays,O
.,O
INTRODUCTION,O
Cell,O
-,O
free,O
DNA,O
(,O
cfDNA,O
),O
are,O
small,O
nucleic,O
acid,O
fragments,O
released,O
in,O
body,O
fluids,O
and,O
their,O
levels,O
are,O
a,O
reflection,O
of,O
the,O
dynamics,O
between,O
cellular,O
mechanisms,O
of,O
DNA,O
release,O
and,O
DNA,O
clearance,O
",",O
apoptosis,O
and,O
necrosis,O
",",O
cfDNA,O
stability,O
",",O
blood,O
nuclease,B-GP
activity,O
and,O
uptake,O
and,O
degradation,O
by,O
phagocytes,O
[,O
1,O
",",O
2,O
].,O
Among,O
individuals,O
with,O
cancer,B-DS
a,O
fraction,O
of,O
cfDNA,O
is,O
potentially,O
of,O
tumor,B-DS
origin,O
",",O
i,O
.,O
e,O
.,O
cfDNA,O
fragments,O
harboring,O
tumor,B-DS
somatic,O
nucleic,O
acid,O
changes,O
that,O
are,O
also,O
called,O
circulating,O
tumor,B-DS
DNA,O
(,O
ctDNA,O
).,O
Some,O
studies,O
have,O
correlated,O
the,O
abundance,O
of,O
ctDNA,O
with,O
tumor,B-DS
size,O
and,O
stage,O
",",O
with,O
as,O
much,O
as,O
40,O
%,O
of,O
ctDNA,O
levels,O
in,O
metastatic,B-DS
cancers,I-DS
but,O
as,O
low,O
as,O
0,O
.,O
1,O
-,O
1,O
%,O
in,O
premalignant,O
or,O
early,O
stage,O
disease,O
[,O
3,O
–,O
8,O
].,O
Clinicopathological,O
characteristics,O
for,O
specific,O
tumor,B-DS
types,O
",",O
such,O
as,O
anatomic,O
location,O
",",O
tumor,B-DS
grade,O
",",O
tumor,B-DS
mucinous,O
features,O
and,O
treatment,O
response,O
[,O
4,O
",",O
9,O
",",O
10,O
],O
might,O
also,O
play,O
an,O
important,O
role,O
in,O
the,O
process,O
of,O
cfDNA,O
release,O
and,O
stability,O
in,O
blood,O
circulation,O
.,O
Head,B-DS
and,I-DS
neck,I-DS
squamous,I-DS
cell,I-DS
carcinomas,I-DS
(,O
HNSCC,B-DS
),O
are,O
the,O
seventh,O
most,O
common,O
cause,O
of,O
death,O
in,O
the,O
world,O
accounting,O
for,O
approximately,O
375,O
",",O
000,O
cancer,B-DS
deaths,O
annually,O
.,O
In,O
2012,O
",",O
almost,O
700,O
",",O
000,O
new,O
head,B-DS
and,I-DS
neck,I-DS
cancer,I-DS
cases,O
were,O
estimated,O
to,O
occur,O
worldwide,O
[,O
11,O
].,O
Despite,O
current,O
therapeutic,O
interventions,O
",",O
the,O
prognosis,O
for,O
HNSCC,B-DS
is,O
relatively,O
poor,O
",",O
with,O
a,O
5,O
-,O
year,O
survival,O
ranging,O
from,O
approximately,O
25,O
%,O
to,O
60,O
"%,",O
according,O
to,O
cancer,B-DS
subsite,O
[,O
12,O
].,O
Diagnostic,O
delay,O
is,O
a,O
recognized,O
challenge,O
for,O
patients,O
with,O
HNSCC,B-DS
",",O
and,O
has,O
also,O
been,O
related,O
to,O
higher,O
risk,O
(,O
30,O
%),O
of,O
advanced,O
stage,O
tumor,B-DS
diagnosis,O
eventually,O
impacting,O
negatively,O
on,O
prognosis,O
and,O
survival,O
[,O
13,O
].,O
These,O
delays,O
could,O
be,O
shortened,O
in,O
many,O
patients,O
through,O
the,O
examination,O
of,O
clinically,O
suspicious,O
lesions,O
using,O
non,O
-,O
invasive,O
biomarkers,O
such,O
as,O
ctDNA,O
.,O
In,O
HNSCC,B-DS
patients,O
",",O
besides,O
circulating,O
DNA,O
fragments,O
carrying,O
tumor,B-DS
alterations,O
in,O
plasma,O
",",O
the,O
saliva,O
contains,O
a,O
high,O
fraction,O
of,O
tumor,B-DS
DNA,O
due,O
to,O
its,O
close,O
contact,O
to,O
oral,O
cavity,O
and,O
pharyngeal,B-DS
tumor,I-DS
sites,O
constituting,O
an,O
additional,O
biological,O
source,O
for,O
ctDNA,O
detection,O
and,O
analysis,O
[,O
14,O
–,O
16,O
].,O
Our,O
primary,O
goals,O
were,O
to,O
provide,O
a,O
comprehensive,O
evaluation,O
of,O
the,O
presence,O
of,O
ctDNA,O
in,O
plasma,O
and,O
oral,O
rinses,O
from,O
a,O
series,O
of,O
HNSCC,B-DS
cases,O
at,O
early,O
and,O
late,O
stages,O
and,O
to,O
determine,O
the,O
best,O
approach,O
to,O
use,O
ctDNA,O
analysis,O
in,O
HNSCC,B-DS
early,O
detection,O
.,O
We,O
evaluated,O
two,O
strategies,O
of,O
ctDNA,O
mutation,O
detection,O
.,O
A,O
targeted,O
approach,O
tested,O
for,O
the,O
presence,O
of,O
mutations,O
in,O
plasma,O
samples,O
",",O
previously,O
detected,O
in,O
tumor,B-DS
samples,O
.,O
The,O
second,O
approach,O
involved,O
ctDNA,O
screening,O
detection,O
in,O
plasma,O
and,O
oral,O
rinses,O
without,O
prior,O
knowledge,O
of,O
mutation,O
status,O
in,O
tumors,B-DS
.,O
RESULTS,O
ctDNA,O
targeted,O
detection,O
in,O
plasma,O
samples,O
from,O
the,O
ARCAGE,O
study,O
36,O
HNSCC,B-DS
cases,O
from,O
the,O
ARCAGE,O
study,O
were,O
selected,O
based,O
on,O
carrying,O
one,O
or,O
several,O
mutations,O
in,O
their,O
tumor,B-DS
samples,O
in,O
the,O
5,O
screened,O
genes,O
(,O
TP53,B-GP
",",O
NOTCH1,B-GP
",",O
CDKN2A,B-GP
",",O
CASP8,B-GP
",",O
PTEN,B-GP
),O
(,O
Figure,O
1,O
).,O
All,O
cases,O
were,O
HPV,B-OG
negative,O
.,O
Forty,O
-,O
two,O
percent,O
of,O
cases,O
(,O
15,O
/,O
36,O
),O
had,O
detectable,O
ctDNA,O
mutations,O
in,O
their,O
plasma,O
samples,O
",",O
sixty,O
seven,O
percent,O
of,O
those,O
were,O
early,O
stage,O
(,O
I,O
",",O
II,O
),O
cases,O
.,O
A,O
total,O
of,O
18,O
mutations,O
",",O
previously,O
detected,O
in,O
the,O
matched,O
tumor,B-DS
samples,O
",",O
were,O
detected,O
in,O
plasma,O
with,O
allelic,O
fractions,O
(,O
AF,O
),O
ranging,O
from,O
0,O
",",O
001,O
-,O
0,O
",",O
12,O
(,O
Figure,O
1,O
).,O
Among,O
those,O
mutations,O
",",O
we,O
were,O
able,O
to,O
detect,O
a,O
TP53,B-GP
16,O
-,O
nucleotide,O
frameshift,O
deletion,O
in,O
a,O
stage,O
II,O
oropharyngeal,O
case,O
(,O
Supplementary,O
Figure,O
1,O
).,O
Cases,O
with,O
identified,O
plasma,O
mutations,O
showed,O
no,O
differences,O
in,O
overall,O
survival,O
compare,O
to,O
those,O
without,O
ctDNA,O
mutations,O
(,O
Log,O
rank,O
p,O
=,O
0,O
",",O
47,O
).,O
Targeted,O
mutation,O
detection,O
in,O
plasma,O
of,O
36,O
HNSCC,B-DS
cases,O
from,O
the,O
ARCAGE,O
study,O
Description,O
of,O
clinical,O
and,O
epidemiological,O
characteristics,O
of,O
cases,O
and,O
ctDNA,O
mutation,O
detection,O
in,O
plasma,O
.,O
Cases,O
are,O
organized,O
by,O
stage,O
.,O
In,O
red,O
",",O
mutations,O
identified,O
in,O
matched,O
tumor,B-DS
and,O
plasma,O
samples,O
.,O
AF,O
:,O
mutation,O
allelic,O
frequency,O
.,O
TP53,B-GP
mutation,O
detection,O
in,O
tumor,B-DS
",",O
plasma,O
and,O
oral,O
rinses,O
of,O
HNSCC,B-DS
cases,O
from,O
the,O
LA,O
study,O
We,O
performed,O
independent,O
TP53,B-GP
mutation,O
detection,O
analyses,O
for,O
the,O
37,O
-,O
late,O
stage,O
HNSCC,B-DS
cases,O
in,O
each,O
sample,O
type,O
:,O
tumor,B-DS
",",O
plasma,O
and,O
oral,O
rinses,O
.,O
A,O
total,O
of,O
36,O
TP53,B-GP
mutations,O
were,O
identified,O
in,O
tumors,B-DS
",",O
3,O
in,O
plasma,O
and,O
26,O
in,O
oral,O
rinses,O
.,O
Seventy,O
-,O
six,O
percent,O
(,O
28,O
/,O
37,O
),O
of,O
cases,O
harbored,O
at,O
least,O
one,O
TP53,B-GP
mutation,O
in,O
the,O
tumor,B-DS
sample,O
.,O
One,O
case,O
(,O
ARG5040,O
),O
had,O
a,O
mutation,O
(,O
TP53,B-GP
p,O
.,O
Arg174Trp,O
),O
found,O
exclusively,O
in,O
plasma,O
(,O
Figure,O
2,O
).,O
We,O
found,O
no,O
association,O
between,O
age,O
",",O
subsite,O
",",O
smoking,O
or,O
alcohol,O
status,O
and,O
the,O
presence,O
of,O
TP53,B-GP
mutations,O
in,O
tumors,B-DS
(,O
Supplementary,O
Table,O
1,O
and,O
Figure,O
3B,O
).,O
The,O
proportion,O
of,O
cases,O
with,O
ctDNA,O
TP53,B-GP
variants,O
in,O
oral,O
rinses,O
was,O
higher,O
in,O
patients,O
with,O
tumors,B-DS
in,O
the,O
oral,O
cavity,O
46,O
",",O
2,O
%,O
(,O
n,O
=,O
6,O
),O
and,O
in,O
the,O
oropharynx,O
60,O
%,O
(,O
n,O
=,O
3,O
),O
than,O
in,O
the,O
Larynx,O
16,O
",",O
7,O
%,O
(,O
n,O
=,O
12,O
),O
(,O
Figure,O
3A,O
).,O
More,O
than,O
80,O
%,O
of,O
overall,O
mutations,O
corresponded,O
to,O
missense,O
variants,O
",",O
all,O
localized,O
in,O
the,O
DNA,O
binding,O
domain,O
(,O
aminoacids,O
102,O
-,O
292,O
),O
and,O
86,O
%,O
were,O
non,O
-,O
functional,O
variants,O
according,O
to,O
the,O
functional,O
classification,O
based,O
on,O
the,O
overall,O
transcription,O
activity,O
[,O
17,O
],O
(,O
Figure,O
3B,O
and,O
Supplementary,O
Table,O
2,O
).,O
The,O
mutational,O
distribution,O
along,O
the,O
coding,O
regions,O
and,O
protein,O
domains,O
was,O
comparable,O
for,O
all,O
three,O
sample,O
types,O
(,O
Figure,O
3A,O
).,O
Four,O
cases,O
showed,O
concordance,O
in,O
mutation,O
detection,O
between,O
tumor,B-DS
and,O
oral,O
rinses,O
and,O
only,O
in,O
one,O
additional,O
case,O
",",O
we,O
identified,O
the,O
same,O
mutation,O
in,O
tumor,B-DS
",",O
plasma,O
and,O
oral,O
rinses,O
(,O
Figure,O
2,O
).,O
Fourteen,O
cases,O
(,O
52,O
%),O
showed,O
detectable,O
TP53,B-GP
mutations,O
in,O
tumor,B-DS
but,O
none,O
in,O
plasma,O
or,O
oral,O
rinses,O
.,O
Description,O
of,O
TP53,B-GP
mutations,O
identified,O
in,O
Tumor,B-DS
",",O
plasma,O
and,O
oral,O
rinses,O
from,O
a,O
series,O
of,O
37,O
cases,O
from,O
the,O
LA,O
study,O
Only,O
cases,O
with,O
TP53,B-GP
mutations,O
are,O
shown,O
.,O
In,O
red,O
",",O
mutations,O
identified,O
in,O
matched,O
tumor,B-DS
and,O
oral,O
rinses,O
or,O
plasma,O
samples,O
.,O
AF,O
:,O
average,O
allelic,O
frequency,O
from,O
both,O
libraries,O
.,O
Comparison,O
of,O
TP53,B-GP
mutations,O
found,O
in,O
tumor,B-DS
",",O
plasma,O
and,O
oral,O
rinses,O
from,O
a,O
series,O
of,O
37,O
cases,O
from,O
the,O
LA,O
study,O
(,O
A,O
),O
Proportion,O
of,O
cases,O
harboring,O
TP53,B-GP
mutations,O
in,O
tumor,B-DS
",",O
plasma,O
and,O
oral,O
rinses,O
by,O
subsite,O
.,O
(,O
B,O
),O
Diagrams,O
of,O
mutation,O
distribution,O
along,O
the,O
TP53,B-GP
coding,O
regions,O
and,O
protein,O
domains,O
.,O
Mutation,O
colors,O
represent,O
:,O
green,O
:,O
Missense,O
Mutations,O
;,O
black,O
:,O
Truncating,O
Mutations,O
(,O
Nonsense,O
",",O
Nonstop,O
",",O
Frameshift,O
deletion,O
",",O
Frameshift,O
insertion,O
",",O
Splice,O
site,O
).,O
TP53,B-GP
mutation,O
detection,O
in,O
non,O
-,O
cancer,B-DS
controls,O
One,O
additional,O
finding,O
was,O
the,O
observation,O
that,O
TP53,B-GP
mutations,O
could,O
be,O
detected,O
in,O
the,O
plasma,O
and,O
oral,O
rinses,O
of,O
a,O
few,O
non,O
-,O
cancer,B-DS
individuals,O
.,O
We,O
identified,O
5,O
TP53,B-GP
mutations,O
in,O
oral,O
rinses,O
from,O
3,O
individuals,O
without,O
cancer,B-DS
diagnosis,O
with,O
AFs,O
ranging,O
from,O
0,O
",",O
001,O
-,O
0,O
",",O
004,O
.,O
All,O
5,O
mutations,O
were,O
classified,O
as,O
pathogenic,O
and,O
located,O
in,O
the,O
DNA,O
binding,O
domain,O
.,O
Two,O
of,O
those,O
individuals,O
were,O
both,O
never,O
smokers,O
and,O
non,O
-,O
drinkers,O
(,O
Table,O
1,O
).,O
Description,O
of,O
TP53,B-GP
mutations,O
found,O
in,O
oral,O
rinses,O
of,O
3,O
Argentinian,O
controls,O
with,O
the,O
mutations,O
’,O
allelic,O
fractions,O
detected,O
in,O
the,O
two,O
libraries,O
Control,O
ID,O
Disease,O
classification,O
(,O
ICD,O
-,O
10,O
-,O
CM,O
),O
Coverage,O
Library,O
1,O
Coverage,O
Library,O
2,O
Allelic,O
Fraction,O
Library,O
1,O
Allelic,O
Fraction,O
Library,O
2,O
Chr,O
Start,O
End,O
Ref,O
Alt,O
Mutation,O
Type,O
Cosmic,O
-,O
76,O
Hgvs,O
DNA,O
Change,O
Hgvs,O
Protein,O
Change,O
Transactivation,O
Class,O
ARG553,O
Hydrocele,O
and,O
spermatocele,B-DS
35483,O
36558,O
0,O
",",O
001,O
0,O
",",O
002,O
17,O
7577530,O
7577530,O
T,O
A,O
Missense,O
Mutation,O
COSM43967,O
c,O
.,O
614A,O
>,O
G,O
p,O
.,O
Ile251Phe,O
non,O
-,O
functional,O
ARG410,O
*,O
unspecified,O
disorders,O
of,O
male,O
genital,O
organs,O
28491,O
38571,O
0,O
",",O
004,O
0,O
",",O
003,O
17,O
7577548,O
7577548,O
C,O
T,O
Missense,O
Mutation,O
COSM1640833,O
c,O
.,O
661G,O
>,O
A,O
p,O
.,O
Gly245Ser,O
supertrans,O
ARG594,O
*,O
Osteoarthritis,O
29062,O
27304,O
0,O
",",O
001,O
0,O
",",O
001,O
17,O
7577609,O
7577609,O
C,O
G,O
Splice,O
Site,O
COSM562645,O
c,O
.,O
673,O
-,O
1G,O
>,O
C,O
,O
,O
37034,O
21337,O
0,O
",",O
002,O
0,O
",",O
002,O
17,O
7578188,O
7578188,O
C,O
T,O
Missense,O
Mutation,O
COSM44853,O
c,O
.,O
733G,O
>,O
A,O
p,O
.,O
Glu221Lys,O
non,O
-,O
functional,O
39098,O
22393,O
0,O
",",O
004,O
0,O
",",O
004,O
17,O
7578235,O
7578235,O
T,O
C,O
Missense,O
Mutation,O
COSM99631,O
c,O
.,O
751A,O
>,O
T,O
p,O
.,O
Tyr205Cys,O
non,O
-,O
functional,O
,O
:,O
Not,O
applicable,O
.,O
Chr,O
:,O
Chromosome,O
.,O
*,O
both,O
non,O
-,O
smokers,O
non,O
-,O
drinkers,O
.,O
As,O
was,O
reported,O
before,O
by,O
us,O
",",O
5,O
TP53,B-GP
mutations,O
were,O
found,O
in,O
the,O
plasma,O
of,O
4,O
of,O
the,O
non,O
-,O
cancer,B-DS
individuals,O
analyzed,O
from,O
Argentina,O
",",O
one,O
being,O
confirmed,O
to,O
be,O
a,O
germline,O
variant,O
[,O
18,O
].,O
DISCUSSION,O
Targeted,O
ctDNA,O
screening,O
is,O
an,O
increasingly,O
used,O
non,O
-,O
invasive,O
method,O
for,O
mutation,O
detection,O
in,O
human,B-OG
cancer,B-DS
",",O
both,O
for,O
diagnosis,O
and,O
disease,O
monitoring,O
.,O
Recently,O
",",O
it,O
has,O
been,O
shown,O
that,O
screening,O
for,O
specific,O
mutations,O
in,O
plasma,O
and,O
saliva,O
of,O
HNSCC,B-DS
patients,O
is,O
a,O
sensitive,O
and,O
specific,O
approach,O
[,O
4,O
",",O
14,O
].,O
In,O
our,O
series,O
of,O
36,O
cases,O
from,O
the,O
ARCAGE,O
study,O
",",O
we,O
detected,O
specific,O
tumor,B-DS
-,O
concordant,O
mutations,O
in,O
5,O
genes,O
in,O
the,O
plasma,O
of,O
42,O
%,O
of,O
cases,O
and,O
the,O
majority,O
of,O
those,O
(,O
67,O
%),O
were,O
early,O
-,O
stage,O
cases,O
.,O
However,O
",",O
our,O
overall,O
mutation,O
detection,O
rate,O
in,O
plasma,O
was,O
low,O
as,O
we,O
were,O
able,O
to,O
detect,O
only,O
28,O
%,O
of,O
the,O
total,O
number,O
of,O
mutations,O
tested,O
.,O
Limitations,O
regarding,O
sample,O
preservation,O
might,O
account,O
in,O
part,O
for,O
the,O
low,O
mutation,O
detection,O
rate,O
in,O
plasma,O
.,O
In,O
particular,O
",",O
cfDNA,O
degradation,O
due,O
to,O
prolonged,O
storage,O
is,O
one,O
of,O
the,O
pre,O
-,O
analytical,O
variables,O
that,O
have,O
an,O
impact,O
on,O
cfDNA,O
recovery,O
and,O
mutation,O
detection,O
",",O
and,O
recent,O
studies,O
recommend,O
the,O
use,O
of,O
plasma,O
samples,O
or,O
cfDNA,O
extracts,O
up,O
to,O
nine,O
months,O
of,O
storage,O
at,O
−,O
20,O
°,O
C,O
or,O
−,O
80,O
°,O
C,O
[,O
19,O
].,O
Additionally,O
",",O
preanalytical,O
recommendations,O
for,O
ctDNA,O
analysis,O
indicate,O
that,O
blood,O
samples,O
can,O
be,O
kept,O
up,O
to,O
4,O
hrs,O
at,O
room,O
temperature,O
(,O
RT,O
),O
before,O
plasma,O
preparation,O
without,O
major,O
impact,O
on,O
cfDNA,O
concentration,O
[,O
19,O
].,O
The,O
protocols,O
for,O
blood,O
recovery,O
and,O
processing,O
followed,O
by,O
both,O
studies,O
(,O
ARCAGE,O
and,O
LA,O
),O
allowed,O
a,O
time,O
window,O
for,O
blood,O
processing,O
up,O
to,O
12,O
hrs,O
at,O
RT,O
",",O
which,O
could,O
have,O
resulted,O
in,O
a,O
reduction,O
of,O
cfDNA,O
concentration,O
before,O
plasma,O
storage,O
.,O
This,O
is,O
the,O
first,O
study,O
evaluating,O
ctDNA,O
using,O
retrospective,O
HNSCC,B-DS
samples,O
from,O
a,O
case,O
series,O
where,O
plasma,O
samples,O
exceeded,O
10,O
years,O
of,O
storage,O
at,O
−,O
80,O
°,O
C,O
.,O
Fifty,O
percent,O
of,O
mutation,O
detection,O
in,O
long,O
stored,O
plasma,O
has,O
been,O
only,O
previously,O
reported,O
for,O
KRAS,B-GP
mutations,O
identified,O
by,O
Sanger,O
sequencing,O
in,O
plasma,O
stored,O
up,O
to,O
6,O
years,O
from,O
metastatic,O
colorectal,O
patients,O
[,O
20,O
].,O
Analysis,O
of,O
ctDNA,O
detection,O
and,O
survival,O
in,O
the,O
ARCAGE,O
cases,O
found,O
no,O
association,O
between,O
ctDNA,O
mutation,O
status,O
and,O
HNSCC,B-DS
survival,O
overall,O
.,O
No,O
additional,O
studies,O
have,O
previously,O
evaluated,O
the,O
impact,O
in,O
survival,O
of,O
ctDNA,O
detection,O
in,O
head,B-DS
and,I-DS
neck,I-DS
cancer,I-DS
cases,O
limiting,O
the,O
comparability,O
of,O
our,O
results,O
.,O
Association,O
between,O
ctDNA,O
detection,O
at,O
diagnosis,O
and,O
survival,O
is,O
consistent,O
across,O
several,O
metastatic,O
and,O
advanced,O
tumor,B-DS
types,O
[,O
5,O
",",O
21,O
–,O
23,O
].,O
However,O
",",O
limited,O
data,O
is,O
available,O
on,O
early,O
stages,O
and,O
while,O
ctDNA,O
detection,O
has,O
been,O
found,O
to,O
be,O
associated,O
with,O
poor,O
overall,O
survival,O
in,O
some,O
early,O
stage,O
pancreatic,O
and,O
colorectal,O
cases,O
[,O
7,O
",",O
24,O
],O
no,O
difference,O
was,O
observed,O
in,O
early,O
breast,B-DS
cancer,I-DS
cases,O
[,O
8,O
].,O
Future,O
prospective,O
studies,O
are,O
then,O
necessary,O
to,O
evaluate,O
the,O
prognostic,O
clinical,O
significance,O
of,O
ctDNA,O
detection,O
in,O
both,O
early,O
and,O
late,O
stage,O
HNSCC,B-DS
cases,O
.,O
While,O
targeted,O
sequencing,O
might,O
be,O
sufficient,O
for,O
post,O
-,O
diagnosis,O
uses,O
of,O
ctDNA,O
",",O
in,O
the,O
case,O
of,O
early,O
detection,O
it,O
might,O
be,O
necessary,O
to,O
interrogate,O
the,O
whole,O
coding,O
region,O
of,O
the,O
most,O
frequently,O
altered,O
genes,O
in,O
HNSCC,B-DS
rather,O
than,O
focusing,O
on,O
selected,O
targets,O
.,O
The,O
mutational,O
profile,O
of,O
HNSCC,B-DS
is,O
characterized,O
by,O
recurrent,O
alterations,O
in,O
tumor,B-GP
suppressor,I-GP
genes,I-GP
(,O
of,O
the,O
15,O
most,O
common,O
HNSCC,B-DS
mutated,O
genes,O
only,O
HRAS,B-GP
and,O
PIK3CA,B-GP
are,O
oncogenes,O
),O
where,O
singular,O
hot,O
spots,O
are,O
infrequent,O
and,O
the,O
mutational,O
spectra,O
covers,O
various,O
exon,O
regions,O
and,O
/,O
or,O
specific,O
functional,O
protein,O
coding,O
domains,O
[,O
25,O
].,O
Consistently,O
with,O
previous,O
reports,O
",",O
76,O
%,O
of,O
the,O
tumor,B-DS
cases,O
from,O
the,O
LA,O
study,O
analyzed,O
harbored,O
a,O
TP53,B-GP
mutation,O
[,O
25,O
",",O
26,O
"],",O
which,O
makes,O
TP53,B-GP
one,O
of,O
the,O
suitable,O
biomarkers,O
for,O
non,O
-,O
invasive,O
early,O
detection,O
of,O
HNSCCs,B-DS
.,O
Yet,O
",",O
the,O
concordance,O
in,O
TP53,B-GP
mutation,O
detection,O
between,O
tumor,B-DS
and,O
oral,O
rinses,O
was,O
11,O
%,O
for,O
tumors,B-DS
located,O
in,O
the,O
oral,O
cavity,O
and,O
overlapping,O
sites,O
.,O
The,O
salivary,O
genome,O
consists,O
of,O
various,O
DNAs,O
representing,O
the,O
genome,O
of,O
an,O
individual,O
",",O
oral,O
microbiota,B-OG
and,O
infecting,O
DNA,B-OG
viruses,I-OG
.,O
Such,O
diversity,O
can,O
undermine,O
tumor,B-DS
DNA,O
detection,O
while,O
increasing,O
the,O
mutational,O
background,O
.,O
However,O
",",O
the,O
quality,O
and,O
yield,O
of,O
DNA,O
that,O
can,O
be,O
obtained,O
from,O
saliva,O
as,O
well,O
as,O
its,O
stability,O
for,O
long,O
-,O
term,O
storage,O
might,O
compensate,O
this,O
limitation,O
and,O
might,O
make,O
it,O
a,O
robust,O
analyte,O
choice,O
for,O
diagnostics,O
[,O
15,O
",",O
27,O
].,O
In,O
this,O
regard,O
",",O
Wang,O
and,O
collaborators,O
identified,O
mutations,O
in,O
6,O
commonly,O
mutated,O
genes,O
for,O
HNSCC,B-DS
in,O
both,O
saliva,O
and,O
plasma,O
of,O
93,O
patients,O
and,O
reported,O
100,O
%,O
sensitivity,O
of,O
ctDNA,O
detection,O
in,O
saliva,O
specimens,O
in,O
tumors,B-DS
of,O
the,O
oral,O
cavity,O
[,O
14,O
].,O
Furthermore,O
",",O
the,O
authors,O
found,O
that,O
both,O
the,O
sensitivity,O
and,O
the,O
fraction,O
of,O
mutant,O
alleles,O
decreased,O
in,O
HNSCCs,B-DS
distal,O
to,O
the,O
oral,O
cavity,O
which,O
agrees,O
with,O
the,O
higher,O
percentage,O
of,O
mutations,O
we,O
have,O
found,O
in,O
both,O
oral,O
cavity,O
and,O
oropharynx,O
compared,O
to,O
laryngeal,O
cases,O
.,O
TP53,B-GP
mutations,O
have,O
been,O
previously,O
identified,O
in,O
23,O
",",O
5,O
%,O
of,O
oral,O
rinses,O
from,O
cases,O
with,O
homogeneous,O
oral,B-DS
leukoplakia,I-DS
(,O
OL,B-DS
),O
and,O
in,O
40,O
%,O
of,O
OL,B-DS
cases,O
with,O
an,O
earlier,O
diagnosis,O
of,O
one,O
or,O
several,O
oral,B-DS
squamous,I-DS
cell,I-DS
carcinomas,I-DS
[,O
28,O
].,O
One,O
additional,O
study,O
",",O
based,O
on,O
microsatellite,O
marker,O
detection,O
in,O
tumor,B-DS
and,O
exfoliated,O
oral,O
mucosal,O
cells,O
",",O
detected,O
tumor,B-DS
DNA,O
in,O
44,O
%,O
of,O
oral,O
rinse,O
samples,O
[,O
16,O
].,O
Variations,O
in,O
tumor,B-DS
DNA,O
detection,O
frequencies,O
between,O
these,O
studies,O
might,O
be,O
due,O
to,O
the,O
use,O
of,O
different,O
mutation,O
detection,O
techniques,O
(,O
massive,O
parallel,O
sequencing,O
or,O
Sanger,O
sequencing,O
).,O
Interestingly,O
",",O
we,O
found,O
22,O
additional,O
mutations,O
in,O
oral,O
rinses,O
from,O
11,O
cases,O
not,O
found,O
in,O
their,O
matched,O
tumor,B-DS
samples,O
but,O
identified,O
in,O
similar,O
coding,O
regions,O
(,O
aminoacids102,O
-,O
292,O
),O
and,O
with,O
the,O
same,O
pattern,O
of,O
mutational,O
distribution,O
along,O
the,O
TP53,B-GP
protein,O
domains,O
as,O
those,O
found,O
in,O
tumor,B-DS
samples,O
.,O
The,O
additional,O
burden,O
of,O
mutation,O
in,O
oral,O
rinses,O
might,O
reflect,O
tumor,B-DS
heterogeneity,O
(,O
especially,O
in,O
the,O
case,O
of,O
advanced,O
tumors,B-DS
),O
where,O
sub,O
clonal,O
populations,O
of,O
cells,O
are,O
not,O
necessarily,O
captured,O
by,O
tumor,B-DS
biopsies,O
and,O
/,O
or,O
could,O
reflect,O
genetic,O
alterations,O
in,O
the,O
squamous,O
epithelial,O
cells,O
lining,O
the,O
oral,O
cavity,O
as,O
a,O
result,O
of,O
field,O
cancerization,O
",",O
mostly,O
associated,O
to,O
smoking,O
and,O
alcohol,O
consumption,O
.,O
Evidence,O
of,O
mutational,O
heterogeneity,O
in,O
the,O
oral,O
epithelium,O
of,O
HNSCC,B-DS
cancer,B-DS
patients,O
has,O
been,O
recently,O
reported,O
.,O
Wood,O
and,O
collaborators,O
showed,O
the,O
presence,O
of,O
discordant,O
TP53,B-GP
mutations,O
in,O
dysplastic,O
tissue,O
and,O
adjacent,O
cancer,B-DS
tissue,O
from,O
the,O
same,O
patient,O
.,O
They,O
also,O
reported,O
the,O
presence,O
of,O
different,O
mutations,O
in,O
other,O
genes,O
at,O
very,O
low,O
allelic,O
frequencies,O
(<,O
0,O
",",O
05,O
-,O
0,O
",",O
2,O
),O
reflecting,O
sub,O
clonal,O
cell,O
populations,O
present,O
in,O
either,O
adjacent,O
or,O
distant,O
dysplastic,O
tissue,O
but,O
absent,O
in,O
the,O
pair,O
tumor,B-DS
tissue,O
[,O
29,O
].,O
Our,O
percentage,O
of,O
mutation,O
detection,O
in,O
plasma,O
in,O
cases,O
from,O
Argentina,O
(,O
LA,O
study,O
),O
was,O
much,O
lower,O
(,O
8,O
",",O
1,O
%),O
compared,O
to,O
oral,O
rinses,O
(,O
40,O
",",O
5,O
"%,",O
all,O
sites,O
),O
and,O
restricted,O
to,O
cases,O
in,O
larynx,O
and,O
overlapping,O
sites,O
.,O
These,O
results,O
indicate,O
that,O
the,O
impact,O
on,O
ctDNA,O
detection,O
after,O
long,O
storage,O
of,O
plasma,O
(,O
discussed,O
above,O
),O
had,O
a,O
higher,O
effect,O
on,O
cases,O
from,O
Argentina,O
(,O
8,O
",",O
1,O
%,O
ctDNA,O
plasma,O
detection,O
),O
since,O
these,O
samples,O
were,O
collected,O
4,O
years,O
before,O
samples,O
from,O
the,O
ARCAGE,O
study,O
(,O
28,O
%,O
ctDNA,O
plasma,O
detection,O
).,O
Finally,O
",",O
identification,O
of,O
TP53,B-GP
mutations,O
of,O
non,O
-,O
cancer,B-DS
individuals,O
introduces,O
new,O
questions,O
regarding,O
the,O
biological,O
role,O
of,O
such,O
pathogenic,O
mutations,O
in,O
healthy,O
individuals,O
and,O
challenges,O
the,O
specificity,O
of,O
ctDNA,O
screening,O
in,O
possible,O
diagnostic,O
scenarios,O
.,O
Although,O
detection,O
of,O
TP53,B-GP
mutations,O
in,O
plasma,O
",",O
human,B-OG
skin,O
and,O
peritoneal,O
fluid,O
of,O
healthy,O
individuals,O
has,O
been,O
reported,O
previously,O
[,O
18,O
",",O
30,O
–,O
32,O
"],",O
we,O
detected,O
for,O
the,O
first,O
time,O
",",O
5,O
pathogenic,O
TP53,B-GP
mutations,O
in,O
oral,O
rinses,O
from,O
3,O
non,O
-,O
cancer,B-DS
individuals,O
.,O
However,O
",",O
one,O
limitation,O
of,O
our,O
results,O
is,O
that,O
non,O
-,O
independent,O
germline,O
sample,O
(,O
buffy,O
coat,O
),O
was,O
not,O
available,O
to,O
confirm,O
the,O
somatic,O
origin,O
of,O
these,O
mutations,O
.,O
In,O
fact,O
",",O
the,O
presence,O
of,O
circulating,O
-,O
mutated,O
fragments,O
resulting,O
from,O
clonal,O
hematopoiesis,O
in,O
healthy,O
individuals,O
has,O
been,O
well,O
documented,O
[,O
33,O
–,O
38,O
].,O
Most,O
recently,O
",",O
in,O
53105,O
individuals,O
without,O
a,O
known,O
cancer,B-DS
diagnosis,O
from,O
the,O
Exome,O
Aggregation,O
Consortium,O
",",O
2,O
",",O
7,O
%,O
germline,O
DNA,O
repair,O
mutations,O
were,O
identified,O
[,O
39,O
].,O
Without,O
discarding,O
the,O
plausibility,O
of,O
these,O
mutations,O
being,O
germline,O
alterations,O
",",O
the,O
low,O
allelic,O
fraction,O
in,O
the,O
mutations,O
detected,O
in,O
oral,O
rinses,O
(,O
0,O
",",O
001,O
-,O
0,O
",",O
004,O
),O
suggests,O
that,O
they,O
may,O
well,O
correspond,O
to,O
somatic,O
changes,O
in,O
the,O
oral,O
mucosa,O
.,O
A,O
recent,O
study,O
has,O
reported,O
a,O
higher,O
somatic,O
mutation,O
burden,O
in,O
9,O
head,O
and,O
neck,O
non,O
-,O
malignant,O
tissues,O
compared,O
to,O
61,O
benign,O
tissues,O
[,O
40,O
].,O
Since,O
we,O
used,O
hospital,O
-,O
based,O
controls,O
as,O
a,O
proxy,O
for,O
healthy,O
individuals,O
",",O
mutations,O
identified,O
might,O
reflect,O
biological,O
processes,O
underlining,O
inflammatory,O
responses,O
(,O
for,O
2,O
never,O
smoker,O
",",O
non,O
-,O
drinker,O
controls,O
),O
and,O
/,O
or,O
the,O
smoking,O
and,O
alcohol,O
accumulated,O
effect,O
in,O
the,O
oral,O
mucosa,O
.,O
Together,O
",",O
our,O
findings,O
confirm,O
the,O
feasibility,O
of,O
ctDNA,O
targeted,O
mutation,O
detection,O
in,O
plasma,O
of,O
HNSCC,B-DS
patients,O
including,O
early,O
stages,O
.,O
Blind,O
detection,O
of,O
TP53,B-GP
mutations,O
in,O
oral,O
rinses,O
or,O
saliva,O
had,O
a,O
low,O
concordance,O
compared,O
to,O
mutations,O
identified,O
in,O
the,O
matched,O
tumors,B-DS
.,O
Identification,O
of,O
5,O
TP53,B-GP
mutations,O
in,O
oral,O
rinses,O
from,O
healthy,O
controls,O
confirms,O
the,O
presence,O
of,O
a,O
small,O
percentage,O
of,O
pathogenic,O
mutations,O
in,O
healthy,O
individuals,O
",",O
a,O
fact,O
that,O
should,O
be,O
taken,O
into,O
consideration,O
when,O
developing,O
diagnostic,O
ctDNA,O
assays,O
for,O
early,O
HNSCC,B-DS
detection,O
.,O
Further,O
prospective,O
studies,O
are,O
necessary,O
in,O
order,O
to,O
define,O
both,O
the,O
diagnostic,O
value,O
and,O
prognostic,O
clinical,O
significance,O
of,O
ctDNA,O
detection,O
in,O
HNSCC,B-DS
.,O
MATERIALS,O
AND,O
METHODS,O
Study,O
population,O
and,O
mutation,O
detection,O
design,O
Cases,O
and,O
controls,O
were,O
selected,O
from,O
two,O
multicentre,O
studies,O
:,O
one,O
conducted,O
in,O
South,O
America,O
(,O
LA,O
study,O
),O
between,O
1998,O
and,O
2002,O
and,O
the,O
second,O
between,O
2002,O
and,O
2005,O
in,O
Europe,O
(,O
ARCAGE,O
study,O
"),",O
from,O
which,O
biological,O
samples,O
were,O
available,O
in,O
the,O
IARC,O
biorepository,O
",",O
along,O
with,O
complete,O
epidemiological,O
data,O
.,O
Extensive,O
details,O
on,O
data,O
and,O
sample,O
collection,O
from,O
these,O
studies,O
are,O
included,O
elsewhere,O
[,O
41,O
–,O
43,O
].,O
Briefly,O
",",O
all,O
subjects,O
underwent,O
personal,O
interviews,O
to,O
collect,O
information,O
on,O
lifestyle,O
exposures,O
and,O
hospital,O
records,O
were,O
reviewed,O
to,O
obtain,O
clinical,O
and,O
pathological,O
information,O
[,O
41,O
",",O
42,O
].,O
Centralized,O
HPV,B-OG
testing,O
was,O
completed,O
for,O
both,O
studies,O
determined,O
on,O
serology,O
testing,O
as,O
described,O
before,O
[,O
44,O
].,O
HPV,B-OG
positivity,O
was,O
defined,O
based,O
on,O
HPV16,B-OG
E6,B-GP
status,O
",",O
which,O
has,O
been,O
shown,O
to,O
be,O
a,O
highly,O
sensitive,O
and,O
specific,O
marker,O
of,O
HPV16,B-OG
-,O
related,O
oropharyngeal,B-DS
tumours,I-DS
[,O
43,O
",",O
45,O
",",O
46,O
].,O
Informed,O
consent,O
was,O
obtained,O
from,O
all,O
participants,O
in,O
the,O
two,O
studies,O
",",O
and,O
the,O
analysis,O
was,O
approved,O
by,O
the,O
Ethical,O
Review,O
Committee,O
of,O
the,O
International,O
Agency,O
for,O
Research,O
on,O
Cancer,B-DS
.,O
In,O
order,O
to,O
test,O
the,O
targeted,O
ctDNA,O
detection,O
approach,O
",",O
we,O
selected,O
36,O
HNSCC,B-DS
fresh,O
tumor,B-DS
samples,O
",",O
including,O
14,O
early,O
(,O
stage,O
I,O
and,O
II,O
),O
cases,O
",",O
from,O
the,O
ARCAGE,O
study,O
with,O
available,O
matched,O
plasma,O
samples,O
.,O
Oral,O
rinses,O
were,O
not,O
collected,O
as,O
part,O
of,O
the,O
ARCAGE,O
study,O
[,O
41,O
].,O
DNA,O
from,O
36,O
HNSCC,B-DS
tumors,B-DS
had,O
been,O
previously,O
sequenced,O
and,O
found,O
to,O
carry,O
65,O
mutations,O
in,O
5,O
genes,O
(,O
TP53,B-GP
",",O
NOTCH1,B-GP
",",O
CDKN2A,B-GP
",",O
CASP8,B-GP
",",O
PTEN,B-GP
),O
from,O
a,O
panel,O
of,O
the,O
14,O
most,O
frequently,O
mutated,O
genes,O
(,O
CASP8,B-GP
",",O
CDKN2A,B-GP
",",O
FAT1,B-GP
",",O
FBXW7,B-GP
",",O
HRAS,B-GP
",",O
IRF6,B-GP
",",O
MLL2,B-GP
",",O
NOTCH1,B-GP
",",O
NSD1,B-GP
",",O
PTEN,B-GP
",",O
PIK3CA,B-GP
",",O
RB1,B-GP
",",O
TP53,B-GP
",",O
TP63,B-GP
),O
(,O
unpublished,O
results,O
).,O
Gene,O
selection,O
was,O
based,O
on,O
an,O
independent,O
analysis,O
of,O
TCGA,O
data,O
on,O
HNSCC,B-DS
using,O
MutsigCV,O
algorithm,O
complemented,O
with,O
the,O
list,O
of,O
the,O
most,O
frequently,O
mutated,O
genes,O
reported,O
in,O
the,O
literature,O
.,O
To,O
evaluate,O
detection,O
of,O
ctDNA,O
mutations,O
without,O
previous,O
knowledge,O
of,O
tumor,B-DS
mutational,O
status,O
",",O
we,O
decided,O
to,O
sequence,O
the,O
entire,O
coding,O
region,O
of,O
TP53,B-GP
",",O
as,O
it,O
is,O
the,O
most,O
frequently,O
mutated,O
gene,O
in,O
HNSCC,B-DS
[,O
25,O
",",O
26,O
",",O
47,O
].,O
We,O
selected,O
37,O
cases,O
diagnosed,O
as,O
HNSCC,B-DS
from,O
the,O
LA,O
study,O
",",O
all,O
late,O
stage,O
(,O
III,O
and,O
IV,O
"),",O
from,O
which,O
tumor,B-DS
",",O
plasma,O
and,O
oral,O
rinse,O
samples,O
were,O
available,O
.,O
A,O
total,O
of,O
49,O
hospital,O
based,O
controls,O
from,O
the,O
same,O
study,O
with,O
plasma,O
and,O
oral,O
rinses,O
were,O
selected,O
and,O
matched,O
by,O
sex,O
",",O
age,O
",",O
smoking,O
and,O
alcohol,O
status,O
.,O
Clinical,O
and,O
epidemiological,O
characteristics,O
for,O
all,O
Argentinian,O
cases,O
and,O
controls,O
are,O
described,O
in,O
Supplementary,O
Table,O
3,O
.,O
Sample,O
preparation,O
and,O
DNA,O
extraction,O
All,O
cases,O
had,O
biological,O
samples,O
collected,O
at,O
diagnosis,O
and,O
before,O
any,O
treatment,O
[,O
41,O
–,O
43,O
].,O
When,O
feasible,O
",",O
two,O
10,O
-,O
ml,O
samples,O
of,O
blood,O
were,O
collected,O
.,O
A,O
portion,O
of,O
the,O
blood,O
was,O
centrifuged,O
for,O
10,O
min,O
at,O
2000,O
rpm,O
and,O
white,O
blood,O
cells,O
",",O
red,O
blood,O
cells,O
",",O
and,O
plasma,O
were,O
obtained,O
.,O
All,O
samples,O
were,O
stored,O
locally,O
at,O
−,O
80,O
°,O
C,O
(,O
or,O
at,O
least,O
−,O
70,O
°,O
C,O
depending,O
on,O
type,O
of,O
freezer,O
).,O
The,O
amount,O
of,O
time,O
between,O
sample,O
collection,O
and,O
freezing,O
did,O
not,O
exceed,O
12,O
h,O
.,O
Oral,O
rinses,O
were,O
collected,O
by,O
performing,O
gentle,O
strokes,O
in,O
predefined,O
areas,O
including,O
the,O
right,O
and,O
left,O
buccal,O
mucosa,O
",",O
right,O
",",O
left,O
and,O
dorsal,O
side,O
of,O
the,O
tongue,O
",",O
and,O
inside,O
of,O
the,O
upper,O
and,O
lower,O
lip,O
.,O
Cells,O
from,O
brushes,O
were,O
suspended,O
in,O
tubes,O
containing,O
phosphate,O
-,O
buffered,O
saline,O
(,O
PBS,O
).,O
Participants,O
subsequently,O
gargled,O
with,O
saline,O
",",O
and,O
the,O
resulting,O
suspension,O
was,O
added,O
to,O
the,O
same,O
tube,O
.,O
Samples,O
were,O
centrifuged,O
at,O
3000,O
g,O
for,O
10,O
minutes,O
.,O
Supernatant,O
was,O
discarded,O
leaving,O
∼,O
1,O
",",O
0ml,O
to,O
resuspend,O
the,O
pellet,O
in,O
.,O
Samples,O
were,O
frozen,O
at,O
−,O
70,O
°,O
C,O
until,O
shipment,O
to,O
Lyon,O
(,O
France,O
).,O
Biopsy,O
specimens,O
were,O
placed,O
in,O
liquid,O
nitrogen,O
or,O
in,O
freezers,O
at,O
−,O
70,O
°,O
C,O
",",O
always,O
within,O
8,O
hours,O
of,O
collection,O
.,O
Specimens,O
were,O
shipped,O
on,O
dry,O
ice,O
to,O
Lyon,O
",",O
where,O
they,O
were,O
stored,O
at,O
−,O
70,O
°,O
C,O
.,O
Fresh,O
tumor,B-DS
tissue,O
underwent,O
pathological,O
review,O
in,O
order,O
to,O
select,O
samples,O
with,O
a,O
minimum,O
of,O
60,O
%,O
tumor,B-DS
cellularity,O
for,O
DNA,O
extraction,O
.,O
Tumor,B-DS
DNA,O
was,O
extracted,O
using,O
the,O
DNeasy,O
Blood,O
&,O
Tissue,O
Kit,O
(,O
Qiagen,O
).,O
cfDNA,O
was,O
extracted,O
from,O
0,O
",",O
6,O
-,O
2,O
",",O
1,O
mL,O
of,O
plasma,O
and,O
from,O
1,O
",",O
6,O
to,O
2,O
",",O
0,O
mL,O
of,O
oral,O
rinses,O
using,O
the,O
QIAamp,O
DNA,O
Circulating,O
Nucleic,O
Acid,O
kit,O
(,O
Qiagen,O
),O
and,O
following,O
manufacturer,O
',O
s,O
instructions,O
.,O
cfDNA,O
was,O
eluted,O
into,O
100,O
μL,O
of,O
elution,O
buffer,O
and,O
quantified,O
with,O
the,O
Qubit,O
DNA,O
high,O
-,O
sensitivity,O
assay,O
kit,O
(,O
Invitrogen,O
Corporation,O
).,O
Details,O
regarding,O
plasma,O
and,O
oral,O
rinse,O
volume,O
and,O
amount,O
of,O
cfDNA,O
for,O
all,O
cases,O
are,O
included,O
in,O
the,O
Supplementary,O
Table,O
4,O
.,O
Primer,O
design,O
and,O
amplification,O
of,O
targets,O
Twenty,O
-,O
one,O
amplicons,O
of,O
150,O
bp,O
in,O
size,O
were,O
designed,O
(,O
Eurofins,O
Genomics,O
Ebersberg,O
",",O
Germany,O
),O
to,O
cover,O
targeted,O
regions,O
from,O
the,O
5,O
selected,O
genes,O
",",O
where,O
mutations,O
were,O
identified,O
in,O
HNSCC,B-DS
fresh,O
tumor,B-DS
samples,O
.,O
A,O
validated,O
in,O
-,O
house,O
protocol,O
was,O
used,O
to,O
set,O
up,O
PCRs,O
in,O
20μL,O
reaction,O
volume,O
",",O
containing,O
5,O
ng,O
cfDNA,O
",",O
60,O
nM,O
of,O
primer,O
pool,O
and,O
0,O
",",O
73,O
μL,O
of,O
High,O
fidelity,O
HotStarTaq,O
enzyme,O
.,O
Amplification,O
was,O
carried,O
out,O
in,O
DNA,O
engine,O
Tetrad,O
2,O
Peltier,O
Thermal,O
Cycler,O
(,O
BIORAD,O
),O
as,O
follows,O
:,O
15,O
min,O
at,O
95,O
°,O
C,O
and,O
30,O
cycles,O
of,O
15,O
seconds,O
at,O
95,O
°,O
C,O
and,O
2,O
min,O
at,O
specific,O
annealing,O
temperature,O
and,O
10,O
min,O
at,O
72,O
°,O
C,O
.,O
Primer,O
sequences,O
and,O
amplification,O
conditions,O
are,O
described,O
in,O
Supplementary,O
Table,O
5,O
.,O
Primer,O
design,O
and,O
amplification,O
conditions,O
for,O
the,O
TP53,B-GP
mutation,O
discovery,O
assays,O
followed,O
the,O
procedures,O
previously,O
described,O
[,O
18,O
].,O
Library,O
preparation,O
and,O
sequencing,O
in,O
an,O
ion,O
torrentTM,O
proton,O
sequencer,O
Both,O
targeted,O
and,O
discovery,O
ctDNA,O
sequencing,O
assays,O
followed,O
the,O
same,O
library,O
preparation,O
and,O
sequencing,O
protocol,O
previously,O
described,O
[,O
18,O
].,O
The,O
following,O
sequencing,O
quality,O
controls,O
were,O
applied,O
:,O
Reads,O
with,O
a,O
mapping,O
quality,O
below,O
20,O
were,O
excluded,O
from,O
subsequent,O
analysis,O
.,O
An,O
on,O
-,O
target,O
coverage,O
cut,O
off,O
of,O
400X,O
for,O
tumor,B-DS
and,O
3000X,O
for,O
plasma,O
/,O
oral,O
rinses,O
was,O
used,O
to,O
select,O
libraries,O
.,O
Additionally,O
",",O
libraries,O
for,O
which,O
the,O
on,O
-,O
target,O
median,O
coverage,O
was,O
significantly,O
lower,O
in,O
comparison,O
to,O
the,O
other,O
libraries,O
sequenced,O
in,O
the,O
same,O
batch,O
were,O
excluded,O
.,O
On,O
-,O
target,O
median,O
coverage,O
for,O
both,O
libraries,O
is,O
shown,O
in,O
Supplementary,O
Table,O
2,O
.,O
Sequencing,O
data,O
analyses,O
and,O
validation,O
of,O
detected,O
mutations,O
For,O
the,O
calling,O
of,O
variants,O
",",O
we,O
used,O
Needlestack,O
",",O
an,O
ultra,O
-,O
sensitive,O
variant,O
caller,O
",",O
which,O
estimates,O
the,O
distribution,O
of,O
sequencing,O
errors,O
across,O
multiple,O
samples,O
to,O
reliably,O
identify,O
variants,O
present,O
in,O
very,O
low,O
proportion,O
(,O
https,O
://,O
github,O
.,O
com,O
/,O
IARCbioinfo,O
/,O
needlestack,O
).,O
A,O
detail,O
description,O
of,O
the,O
Needlestack,O
variant,O
caller,O
has,O
been,O
previously,O
published,O
[,O
18,O
",",O
48,O
].,O
Variant,O
calls,O
were,O
annotated,O
using,O
ANNOVAR,O
[,O
49,O
],O
and,O
only,O
TP53,B-GP
mutations,O
reported,O
in,O
COSMIC,O
-,O
76,O
that,O
were,O
indels,O
",",O
nonsense,O
",",O
splicing,O
",",O
or,O
missense,O
variants,O
reported,O
as,O
deleterious,O
in,O
SIFT,O
or,O
Polyphen,O
",",O
were,O
kept,O
for,O
subsequent,O
analyses,O
.,O
OncoPrinter,O
and,O
MutationMapper,O
tools,O
were,O
used,O
for,O
visualization,O
of,O
mutational,O
data,O
[,O
50,O
",",O
51,O
].,O
Technical,O
duplication,O
and,O
false,O
positive,O
filtering,O
To,O
account,O
for,O
the,O
sequencing,O
errors,O
and,O
the,O
potential,O
false,O
positive,O
calls,O
in,O
the,O
TP53,B-GP
discovery,O
assay,O
",",O
additional,O
quality,O
control,O
tests,O
were,O
undertaken,O
:,O
The,O
whole,O
process,O
from,O
PCR,O
amplification,O
",",O
library,O
preparation,O
",",O
and,O
sequencing,O
for,O
each,O
sample,O
(,O
tumor,B-DS
",",O
plasma,O
and,O
oral,O
rinses,O
),O
was,O
carried,O
out,O
in,O
duplicate,O
.,O
Each,O
technical,O
duplicate,O
pair,O
was,O
assessed,O
independently,O
on,O
separate,O
plates,O
to,O
avoid,O
sample,O
contamination,O
.,O
When,O
calling,O
TP53,B-GP
mutations,O
in,O
cases,O
and,O
controls,O
",",O
Needlestack,O
models,O
de,O
distribution,O
of,O
recurring,O
sequencing,O
errors,O
.,O
In,O
some,O
cases,O
",",O
some,O
rare,O
",",O
random,O
errors,O
generated,O
by,O
the,O
DNA,B-GP
polymerase,I-GP
during,O
sequencing,O
will,O
be,O
identified,O
as,O
variants,O
(,O
potential,O
false,O
positives,O
).,O
However,O
",",O
such,O
errors,O
will,O
be,O
generally,O
specific,O
to,O
a,O
particular,O
library,O
preparation,O
and,O
/,O
or,O
library,O
sequencing,O
.,O
To,O
filter,O
out,O
these,O
rare,O
errors,O
",",O
only,O
mutations,O
called,O
in,O
the,O
two,O
independent,O
technical,O
duplicates,O
were,O
considered,O
valid,O
and,O
included,O
in,O
subsequent,O
analyses,O
.,O
Additionally,O
",",O
we,O
identified,O
and,O
excluded,O
a,O
few,O
genomic,O
positions,O
having,O
a,O
particularly,O
high,O
proportion,O
(>,O
10,O
%),O
of,O
false,O
positive,O
calls,O
(,O
i,O
.,O
e,O
.,O
‘,O
variants,O
’,O
with,O
allelic,O
fractions,O
higher,O
than,O
the,O
estimated,O
sequencing,O
error,O
rates,O
",",O
but,O
not,O
replicable,O
in,O
two,O
independent,O
libraries,O
).,O
Statistical,O
analyses,O
Survival,O
data,O
was,O
available,O
for,O
all,O
36,O
ARCAGE,O
cases,O
.,O
Overall,O
survival,O
was,O
calculated,O
from,O
cancer,B-DS
diagnosis,O
to,O
death,O
for,O
any,O
cause,O
or,O
end,O
of,O
follow,O
up,O
(,O
last,O
follow,O
up,O
date,O
:,O
30,O
/,O
01,O
/,O
2013,O
).,O
Follow,O
-,O
up,O
was,O
censored,O
at,O
5,O
years,O
",",O
given,O
that,O
most,O
cancer,B-DS
related,O
events,O
occur,O
before,O
that,O
time,O
.,O
The,O
Kaplan,O
-,O
Meier,O
estimator,O
was,O
used,O
to,O
estimate,O
the,O
distribution,O
of,O
the,O
5,O
-,O
year,O
survival,O
.,O
Multivariate,O
Cox,O
proportional,O
hazard,O
models,O
were,O
used,O
to,O
estimate,O
hazard,O
ratios,O
(,O
HRs,O
),O
and,O
their,O
corresponding,O
p,O
values,O
for,O
ctDNA,O
mutation,O
presence,O
using,O
age,O
",",O
subsite,O
",",O
stage,O
",",O
smoking,O
and,O
alcohol,O
status,O
as,O
covariates,O
.,O
Log,O
-,O
rank,O
test,O
was,O
used,O
to,O
compare,O
the,O
different,O
survival,O
distributions,O
.,O
Clinical,O
characteristics,O
were,O
compared,O
between,O
tumor,B-DS
samples,O
with,O
and,O
without,O
detectable,O
TP53,B-GP
mutations,O
with,O
Fisher,O
',O
s,O
exact,O
test,O
.,O
SUPPLEMENTARY,O
FIGURE,O
AND,O
TABLES,O
Author,O
contributions,O
PB,O
and,O
SP,O
conceived,O
and,O
designed,O
the,O
study,O
.,O
DA,O
",",O
MV,O
",",O
IH,O
",",O
JP,O
",",O
LS,O
",",O
CC,O
and,O
PL,O
coordinated,O
the,O
contributing,O
studies,O
",",O
provided,O
samples,O
and,O
associated,O
data,O
.,O
SP,O
",",O
PA,O
",",O
FLCK,O
",",O
PC,O
and,O
JDM,O
developed,O
and,O
undertook,O
the,O
laboratory,O
procedures,O
.,O
SP,O
",",O
PA,O
",",O
and,O
VLF,O
performed,O
the,O
experiments,O
.,O
BAA,O
reviewed,O
pathological,O
specimens,O
.,O
MF,O
and,O
JDM,O
developed,O
Needlestack,O
.,O
SP,O
and,O
MF,O
performed,O
sequencing,O
analyses,O
.,O
SP,O
analysed,O
and,O
interpreted,O
the,O
data,O
.,O
SP,O
and,O
PB,O
wrote,O
the,O
manuscript,O
.,O
All,O
authors,O
reviewed,O
and,O
approved,O
the,O
final,O
version,O
for,O
publication,O
.,O
CONFLICTs,O
OF,O
INTEREST,O
The,O
authors,O
declare,O
no,O
conflicts,O
of,O
interest,O
.,O
Quality,O
assurance,O
of,O
registration,O
of,O
CT,O
and,O
MRI,O
data,O
sets,O
for,O
treatment,O
planning,O
of,O
radiotherapy,O
for,O
head,B-DS
and,I-DS
neck,I-DS
cancers,I-DS
We,O
are,O
implementing,O
the,O
use,O
of,O
magnetic,O
resonance,O
(,O
MR,O
),O
images,O
for,O
head,O
and,O
neck,O
radiotherapy,O
planning,O
",",O
which,O
involves,O
their,O
registration,O
with,O
computed,O
tomography,O
(,O
CT,O
).,O
The,O
quality,O
assurance,O
(,O
QA,O
),O
of,O
the,O
registration,O
process,O
was,O
an,O
initial,O
step,O
of,O
this,O
program,O
.,O
A,O
phantom,O
was,O
built,O
",",O
and,O
appropriate,O
materials,O
were,O
identified,O
to,O
produce,O
clinically,O
relevant,O
MR,O
T1,O
and,O
T2,O
contrast,O
for,O
its,O
constituent,O
“,O
anatomy,O
.”,O
We,O
performed,O
a,O
characterization,O
of,O
the,O
distortion,O
detectable,O
within,O
our,O
phantom,O
.,O
Finally,O
",",O
we,O
assessed,O
the,O
accuracy,O
of,O
image,O
registration,O
by,O
contouring,O
structures,O
in,O
the,O
registered,O
/,O
fused,O
data,O
sets,O
using,O
the,O
treatment,O
planning,O
system,O
.,O
Each,O
structure,O
was,O
contoured,O
using,O
each,O
modality,O
",",O
in,O
turn,O
",",O
blind,O
of,O
the,O
other,O
.,O
The,O
position,O
",",O
area,O
",",O
and,O
perimeter,O
of,O
each,O
structure,O
were,O
assessed,O
as,O
a,O
measure,O
of,O
accuracy,O
of,O
the,O
entire,O
image,O
registration,O
process,O
.,O
Distortion,O
effects,O
in,O
the,O
MR,O
image,O
were,O
shown,O
to,O
be,O
minimized,O
by,O
choosing,O
a,O
suitable,O
(≥±,O
30,O
kHz,O
),O
receiver,O
bandwidth,O
.,O
Remaining,O
distortion,O
was,O
deemed,O
clinically,O
acceptable,O
within,O
±,O
15,O
cm,O
of,O
the,O
magnetic,O
field,O
isocenter,O
.,O
A,O
coefficient,O
of,O
agreement,O
(,O
A,O
),O
analysis,O
gave,O
values,O
to,O
be,O
within,O
9,O
%,O
of,O
unity,O
",",O
where,O
A,O
=,O
RaRp,O
and,O
Ra,O
/,O
p,O
is,O
the,O
ratio,O
of,O
the,O
area,O
/,O
perimeter,O
of,O
a,O
particular,O
structure,O
on,O
CT,O
to,O
that,O
on,O
MR,O
.,O
The,O
center,O
of,O
each,O
structure,O
of,O
interest,O
agreed,O
to,O
within,O
1,O
.,O
8,O
mm,O
.,O
A,O
QA,O
process,O
has,O
been,O
developed,O
to,O
assess,O
the,O
accuracy,O
of,O
using,O
multimodality,O
image,O
registration,O
in,O
the,O
planning,O
of,O
radiotherapy,O
for,O
the,O
head,O
and,O
neck,O
;,O
we,O
believe,O
its,O
introduction,O
is,O
feasible,O
and,O
safe,O
.,O
PACS,O
numbers,O
:,O
87,O
.,O
53,O
.,O
Xd,O
",",O
87,O
.,O
57,O
.,O
Gg,O
",",O
87,O
.,O
59,O
.,O
Fm,O
;,O
87,O
.,O
61,O
.‐,O
c,O
",",O
87,O
.,O
66,O
.,O
Xa,O
I,O
.,O
INTRODUCTION,O
Modern,O
three,O
‐,O
dimensional,O
radiotherapy,O
treatment,O
planning,O
of,O
cancer,B-DS
demands,O
we,O
use,O
volumetric,O
image,O
data,O
sets,O
to,O
design,O
the,O
conformal,O
therapy,O
of,O
tumors,B-DS
",",O
and,O
conformal,O
avoidance,O
of,O
the,O
proximal,O
",",O
dose,O
limiting,O
",",O
organs,O
at,O
risk,O
.,O
(,O
1,O
),O
Most,O
commonly,O
",",O
X,O
ray,O
computed,O
tomography,O
(,O
CT,O
),O
is,O
used,O
to,O
provide,O
this,O
three,O
‐,O
dimensional,O
model,O
of,O
the,O
patient,O
;,O
furthermore,O
",",O
the,O
Hounsfield,O
/,O
CT,O
number,O
information,O
it,O
provides,O
can,O
be,O
calibrated,O
to,O
give,O
an,O
electron,O
density,O
map,O
of,O
the,O
patient,O
",",O
which,O
is,O
used,O
to,O
make,O
corrections,O
in,O
dose,O
calculations,O
.,O
In,O
order,O
to,O
improve,O
the,O
accuracy,O
of,O
the,O
treatment,O
modeling,O
",",O
there,O
are,O
two,O
aspects,O
of,O
the,O
calculations,O
to,O
consider,O
:,O
One,O
is,O
choosing,O
the,O
correct,O
algorithm,O
for,O
the,O
specific,O
application,O
(,O
2,O
),O
;,O
the,O
other,O
is,O
accurately,O
describing,O
the,O
geometry,O
of,O
the,O
tumor,B-DS
and,O
surrounding,O
tissues,O
.,O
The,O
first,O
point,O
can,O
be,O
addressed,O
by,O
choosing,O
a,O
convolution,O
model,O
calculation,O
.,O
(,O
3,O
),O
Fast,O
Fourier,O
Transform,O
(,O
FFT,O
)‐,O
based,O
algorithms,O
can,O
be,O
used,O
for,O
most,O
anatomical,O
sites,O
(,O
4,O
),O
and,O
“,O
full,O
convolution,O
”,O
superposition,O
(,O
5,O
),O
based,O
algorithms,O
when,O
density,O
corrections,O
play,O
a,O
vital,O
role,O
",",O
for,O
example,O
",",O
in,O
the,O
lung,O
.,O
This,O
point,O
reinforces,O
the,O
need,O
for,O
X,O
ray,O
CT,O
descriptions,O
of,O
the,O
patient,O
",",O
which,O
give,O
electron,O
density,O
information,O
.,O
The,O
second,O
point,O
can,O
be,O
addressed,O
by,O
including,O
imaging,O
data,O
from,O
other,O
modalities,O
",",O
which,O
provide,O
better,O
soft,O
tissue,O
delineation,O
(,O
magnetic,O
resonance,O
imaging,O
",",O
MRI,O
),O
or,O
functional,O
imaging,O
(,O
MR,O
spectroscopy,O
",",O
functional,O
MRI,O
",",O
positron,O
emission,O
tomography,O
).,O
Magnetic,O
resonance,O
imaging,O
is,O
now,O
widely,O
available,O
to,O
oncology,O
departments,O
",",O
and,O
it,O
is,O
beginning,O
to,O
become,O
a,O
popular,O
option,O
for,O
treatment,O
planning,O
of,O
radiotherapy,O
.,O
It,O
has,O
been,O
suggested,O
that,O
MRI,O
is,O
the,O
modality,O
of,O
choice,O
(,O
6,O
),O
for,O
head,O
and,O
neck,O
diagnostic,O
imaging,O
.,O
Prior,O
to,O
the,O
implementation,O
of,O
our,O
current,O
treatment,O
planning,O
system,O
(,O
CMS,O
FOCUS,O
/,O
XiO,O
"),",O
we,O
implemented,O
planning,O
of,O
brain,B-DS
tumors,I-DS
using,O
MRI,O
alone,O
.,O
(,O
7,O
),O
Our,O
current,O
planning,O
system,O
now,O
has,O
the,O
ability,O
to,O
input,O
imaging,O
data,O
from,O
different,O
modalities,O
.,O
These,O
can,O
be,O
registered,O
using,O
the,O
FOCALFusion,O
(,O
CMS,O
),O
software,O
.,O
We,O
are,O
",",O
therefore,O
",",O
implementing,O
multimodality,O
planning,O
for,O
anatomical,O
sites,O
where,O
enhanced,O
tumor,B-DS
/,O
organ,O
delineation,O
and,O
more,O
sophisticated,O
dose,O
calculations,O
will,O
provide,O
benefit,O
.,O
The,O
work,O
in,O
this,O
manuscript,O
relates,O
to,O
the,O
implementation,O
of,O
the,O
inclusion,O
of,O
MRI,O
to,O
our,O
conformal,O
(,O
CT,O
‐,O
based,O
),O
head,O
and,O
neck,O
planning,O
.,O
Computed,O
tomography,O
data,O
is,O
obtained,O
on,O
our,O
dedicated,O
PQ5000,O
CT,O
scanner,O
(,O
Philips,O
),O
and,O
the,O
MRI,O
images,O
from,O
a,O
1,O
.,O
5,O
T,O
Signa,O
EchoSpeed,O
MR,O
scanner,O
(,O
GE,O
),O
in,O
radiology,O
.,O
Once,O
in,O
the,O
planning,O
system,O
",",O
the,O
two,O
image,O
sets,O
are,O
registered,O
using,O
FOCAL,O
Fusion,O
from,O
CMS,O
.,O
Following,O
this,O
",",O
they,O
are,O
used,O
interchangeably,O
to,O
contour,O
structures,O
.,O
It,O
is,O
well,O
known,O
that,O
MR,O
images,O
are,O
prone,O
to,O
distortion,O
",",O
which,O
can,O
introduce,O
uncertainties,O
in,O
their,O
geometrical,O
accuracy,O
.,O
Distortions,O
arise,O
from,O
both,O
system,O
‐,O
and,O
patient,O
‐,O
induced,O
effects,O
;,O
the,O
former,O
are,O
due,O
to,O
inhomogeneities,O
in,O
both,O
the,O
main,O
magnetic,O
field,O
and,O
linear,O
imaging,O
gradients,O
",",O
while,O
the,O
latter,O
is,O
due,O
to,O
changes,O
in,O
magnetic,O
susceptibility,O
and,O
chemical,O
shift,O
effects,O
.,O
It,O
has,O
been,O
shown,O
that,O
distortion,O
is,O
inversely,O
proportional,O
to,O
gradient,O
strength,O
.,O
(,O
7,O
),O
",",O
(,O
8,O
),O
Furthermore,O
",",O
system,O
‐,O
induced,O
distortions,O
are,O
enhanced,O
at,O
the,O
periphery,O
of,O
the,O
field,O
and,O
are,O
expected,O
to,O
be,O
minimized,O
over,O
a,O
certain,O
imaging,O
volume,O
centered,O
on,O
the,O
isocenter,O
of,O
the,O
magnet,O
.,O
(,O
9,O
),O
Depending,O
on,O
the,O
magnitude,O
and,O
extent,O
of,O
these,O
distortions,O
",",O
image,O
correction,O
may,O
or,O
may,O
not,O
be,O
considered,O
necessary,O
.,O
Whereas,O
the,O
current,O
literature,O
contains,O
material,O
on,O
correction,O
of,O
gradient,O
‐,O
induced,O
distortions,O
and,O
other,O
image,O
artifacts,O
",",O
we,O
feel,O
that,O
the,O
particular,O
aspects,O
of,O
the,O
use,O
of,O
MRI,O
in,O
radiotherapy,O
planning,O
have,O
not,O
been,O
addressed,O
.,O
In,O
particular,O
",",O
we,O
wished,O
to,O
demonstrate,O
a,O
systematic,O
analysis,O
that,O
provides,O
quantitative,O
information,O
on,O
the,O
accuracy,O
of,O
the,O
registration,O
process,O
.,O
To,O
do,O
this,O
",",O
we,O
utilized,O
a,O
phantom,O
that,O
is,O
considered,O
clinically,O
relevant,O
",",O
in,O
that,O
its,O
design,O
should,O
reflect,O
the,O
anatomy,O
under,O
study,O
.,O
Therefore,O
",",O
a,O
relevant,O
question,O
to,O
be,O
considered,O
is,O
the,O
following,O
:,O
How,O
accurate,O
and,O
reliable,O
is,O
the,O
tumor,B-DS
volume,O
depicted,O
in,O
the,O
secondary,O
(,O
in,O
this,O
case,O
MRI,O
),O
data,O
set,O
?,O
A,O
second,O
question,O
to,O
answer,O
is,O
:,O
how,O
well,O
do,O
automatic,O
registration,O
processes,O
perform,O
",",O
such,O
as,O
the,O
Mutual,O
Information,O
algorithm,O
(,O
10,O
),O
",",O
(,O
11,O
),O
implemented,O
in,O
our,O
planning,O
system,O
?,O
In,O
order,O
to,O
investigate,O
these,O
issues,O
",",O
we,O
designed,O
and,O
performed,O
a,O
series,O
of,O
experiments,O
that,O
are,O
presented,O
in,O
this,O
paper,O
.,O
II,O
.,O
METHODS,O
AND,O
MATERIALS,O
A,O
head,O
and,O
neck,O
phantom,O
(,O
Fig,O
.,O
1,O
),O
was,O
built,O
using,O
a,O
design,O
similar,O
to,O
that,O
reported,O
by,O
Meyer,O
et,O
al,O
.,O
(,O
12,O
),O
We,O
investigated,O
the,O
most,O
appropriate,O
materials,O
to,O
fill,O
the,O
phantom,O
for,O
the,O
types,O
of,O
imaging,O
sequences,O
that,O
would,O
be,O
used,O
.,O
Two,O
views,O
of,O
the,O
phantom,O
constructed,O
and,O
used,O
in,O
this,O
work,O
.,O
Note,O
the,O
access,O
ports,O
that,O
enable,O
the,O
various,O
features,O
of,O
the,O
phantom,O
to,O
be,O
filled,O
/,O
emptied,O
with,O
fluids,O
appropriate,O
to,O
the,O
scanning,O
modality,O
and,O
sequence,O
used,O
in,O
each,O
instance,O
.,O
At,O
our,O
radiotherapy,O
center,O
",",O
a,O
“,O
head,O
jig,O
”,O
immobilization,O
technique,O
is,O
used,O
",",O
which,O
negates,O
the,O
possibility,O
of,O
using,O
the,O
radiofrequency,O
(,O
RF,O
),O
head,O
coil,O
",",O
which,O
",",O
under,O
normal,O
radiology,O
conditions,O
produces,O
optimal,O
head,O
and,O
neck,O
images,O
.,O
Although,O
our,O
standard,O
head,O
and,O
body,O
coils,O
are,O
of,O
the,O
optimized,O
“,O
birdcage,O
”,O
design,O
",",O
(,O
13,O
),O
the,O
increased,O
size,O
of,O
the,O
body,O
coil,O
indicates,O
the,O
signal,O
‐,O
to,O
‐,O
noise,O
ratio,O
(,O
SNR,O
),O
and,O
image,O
homogeneity,O
are,O
both,O
worse,O
with,O
this,O
coil,O
.,O
As,O
in,O
our,O
previous,O
work,O
",",O
(,O
7,O
),O
we,O
propose,O
using,O
the,O
body,O
coil,O
to,O
obtain,O
head,O
and,O
neck,O
radiotherapy,O
planning,O
scans,O
.,O
Images,O
of,O
the,O
phantom,O
were,O
obtained,O
in,O
the,O
two,O
coils,O
to,O
provide,O
some,O
quantitative,O
analysis,O
of,O
using,O
the,O
seemingly,O
less,O
optimal,O
configuration,O
.,O
Given,O
this,O
choice,O
of,O
using,O
the,O
body,O
coil,O
",",O
a,O
scanning,O
protocol,O
that,O
was,O
expected,O
to,O
be,O
useful,O
was,O
selected,O
.,O
We,O
felt,O
it,O
prudent,O
",",O
therefore,O
",",O
to,O
assess,O
the,O
magnetic,O
field,O
distortion,O
and,O
chemical,O
shift,O
effects,O
.,O
Finally,O
",",O
we,O
address,O
the,O
question,O
central,O
to,O
this,O
work,O
:,O
assessment,O
of,O
the,O
validity,O
and,O
accuracy,O
of,O
the,O
registration,O
process,O
and,O
its,O
reliability,O
for,O
radiotherapy,O
planning,O
for,O
head,O
and,O
neck,O
cases,O
.,O
A,O
.,O
Head,O
and,O
Neck,O
Phantom,O
Design,O
and,O
Filling,O
Materials,O
The,O
phantom,O
was,O
constructed,O
from,O
MR,O
‐,O
compatible,O
materials,O
(,O
Perspex,O
).,O
Essentially,O
",",O
the,O
phantom,O
had,O
to,O
be,O
constructed,O
from,O
materials,O
that,O
do,O
not,O
have,O
undesirable,O
properties,O
",",O
such,O
as,O
RF,O
absorption,O
",",O
and,O
greatly,O
differing,O
susceptibilities,O
between,O
different,O
parts,O
of,O
the,O
phantom,O
.,O
The,O
susceptibility,O
difference,O
between,O
water,O
and,O
Perspex,O
is,O
only,O
0,O
.,O
004,O
ppm,O
",",O
which,O
will,O
produce,O
very,O
little,O
distortion,O
.,O
Perspex,O
is,O
also,O
nonconductive,O
and,O
has,O
an,O
RF,O
absorption,O
similar,O
to,O
that,O
of,O
soft,O
tissue,O
.,O
The,O
dimensions,O
and,O
filling,O
liquids,O
of,O
the,O
phantom,O
were,O
chosen,O
to,O
reflect,O
in,O
vivo,O
characteristics,O
.,O
The,O
phantom,O
consisted,O
of,O
four,O
compartments,O
",",O
which,O
included,O
a,O
trachea,O
and,O
mouth,O
(,O
open,O
to,O
atmosphere,O
"),",O
a,O
spinal,O
cord,O
to,O
simulate,O
cerebrospinal,O
fluid,O
",",O
a,O
homogeneous,O
brain,O
and,O
neck,O
region,O
",",O
and,O
a,O
compartment,O
to,O
mimic,O
subcutaneous,O
fat,O
in,O
the,O
neck,O
.,O
Optimal,O
phantom,O
filling,O
materials,O
were,O
then,O
investigated,O
.,O
The,O
most,O
common,O
materials,O
used,O
in,O
phantom,O
construction,O
to,O
date,O
have,O
included,O
paramagnetic,O
solutions,O
",",O
agar,O
gels,O
",",O
and,O
oils,O
.,O
(,O
14,O
),O
",",O
(,O
15,O
),O
To,O
determine,O
the,O
required,O
MR,O
contrast,O
properties,O
for,O
each,O
compartment,O
of,O
the,O
phantom,O
",",O
three,O
volunteers,O
were,O
imaged,O
.,O
The,O
volunteers,O
were,O
scanned,O
using,O
a,O
clinically,O
relevant,O
T1,O
weighted,O
spin,O
echo,O
sequence,O
[,O
TR,O
/,O
TE,O
=,O
360,O
/,O
20,O
ms,O
",",O
slice,O
thickness,O
/,O
gap,O
=,O
5,O
/,O
205,O
mm,O
",",O
image,O
matrix,O
=,O
256,O
×,O
128,O
",",O
field,O
‐,O
of,O
‐,O
view,O
(,O
FOV,O
)=,O
25,O
×,O
25,O
cm,O
",",O
and,O
2,O
averages,O
(,O
NEX,O
)],O
and,O
a,O
clinically,O
relevant,O
T2,O
weighted,O
spin,O
echo,O
sequence,O
(,O
TR,O
/,O
TE,O
=,O
3000,O
/,O
120,O
",",O
image,O
matrix,O
=,O
256,O
×,O
256,O
",",O
FOV,O
=,O
25,O
×,O
25,O
cm,O
",",O
and,O
2,O
NEX,O
).,O
A,O
reference,O
gel,O
(,O
Diagnostic,O
Sonar,O
Ltd,O
",",O
Livingston,O
),O
contained,O
in,O
a,O
test,O
tube,O
was,O
placed,O
behind,O
the,O
neck,O
and,O
imaged,O
simultaneously,O
.,O
Region,O
‐,O
of,O
‐,O
interest,O
(,O
ROI,O
),O
analysis,O
was,O
then,O
carried,O
out,O
to,O
determine,O
mean,O
signal,O
intensities,O
from,O
fat,O
",",O
brain,O
",",O
CSF,O
",",O
and,O
the,O
reference,O
gel,O
.,O
The,O
ROIs,O
were,O
positioned,O
close,O
to,O
the,O
gel,O
to,O
obtain,O
a,O
similar,O
B1,O
profile,O
of,O
the,O
head,O
coil,O
.,O
Region,O
‐,O
of,O
‐,O
interest,O
sizes,O
were,O
approximately,O
140,O
mm2,O
in,O
the,O
gel,O
and,O
brain,O
but,O
smaller,O
within,O
CSF,O
and,O
fat,O
(,O
80,O
mm2,O
).,O
Ratios,O
of,O
the,O
signal,O
intensity,O
of,O
fat,O
",",O
brain,O
",",O
and,O
CSF,O
to,O
that,O
of,O
the,O
reference,O
gel,O
for,O
both,O
sequences,O
were,O
determined,O
.,O
Various,O
materials,O
were,O
examined,O
for,O
their,O
similarity,O
to,O
MR,O
contrast,O
properties,O
in,O
vivo,O
.,O
A,O
collection,O
of,O
500,O
mL,O
container,O
bottles,O
holding,O
water,O
doped,O
with,O
different,O
concentrations,O
of,O
gadolinium,O
‐,O
diethylene,O
triamine,O
penta,O
‐,O
acetic,O
acid,O
(,O
Gd,O
‐,O
DTPA,O
"),",O
grocery,O
store,O
sunflower,O
oil,O
",",O
and,O
water,O
were,O
imaged,O
together,O
with,O
the,O
reference,O
gel,O
using,O
the,O
same,O
T1,O
and,O
T2,O
weighted,O
scans,O
mentioned,O
previously,O
.,O
B,O
.,O
Comparison,O
of,O
images,O
derived,O
from,O
RF,O
head,O
and,O
body,O
coils,O
The,O
phantom,O
was,O
initially,O
filled,O
with,O
materials,O
commensurate,O
with,O
T2,O
weighted,O
imaging,O
and,O
scanned,O
in,O
a,O
single,O
acquisition,O
using,O
an,O
appropriate,O
T2,O
weighted,O
sequence,O
(,O
fast,O
spin,O
echo,O
",",O
TR,O
/,O
TE,O
=,O
4000,O
/,O
100,O
ms,O
",",O
image,O
matrix,O
=,O
256,O
×,O
256,O
",",O
FOV,O
=,O
24,O
×,O
24,O
cm,O
",",O
BW,O
=,O
62,O
.,O
5,O
kHz,O
",",O
and,O
3,O
NEX,O
).,O
Similarly,O
",",O
the,O
phantom,O
was,O
then,O
imaged,O
with,O
a,O
T1,O
weighted,O
sequence,O
(,O
spin,O
echo,O
",",O
TR,O
/,O
TE,O
=,O
300,O
/,O
20,O
",",O
image,O
matrix,O
=,O
256,O
×,O
256,O
",",O
FOV,O
=,O
24,O
×,O
24,O
cm,O
",",O
BW,O
=,O
16,O
kHZ,O
",",O
and,O
2,O
NEX,O
).,O
Region,O
‐,O
of,O
‐,O
interest,O
analysis,O
was,O
carried,O
out,O
with,O
mean,O
and,O
standard,O
deviation,O
of,O
signal,O
intensity,O
values,O
taken,O
in,O
fat,O
",",O
spine,O
",",O
brain,O
",",O
and,O
background,O
noise,O
for,O
both,O
the,O
T1,O
and,O
T2,O
weighted,O
scans,O
in,O
order,O
to,O
calculate,O
contrast,O
‐,O
to,O
‐,O
noise,O
ratio,O
(,O
CNR,O
),O
and,O
signal,O
‐,O
to,O
‐,O
noise,O
ratio,O
(,O
SNR,O
).,O
Contrast,O
‐,O
to,O
‐,O
noise,O
ratio,O
is,O
given,O
by,O
the,O
following,O
equation,O
:,O
(,O
1,O
),O
CNR,O
=,O
(,O
S1,O
−,O
S2,O
)/(,O
σ12,O
+,O
σ22,O
),O
1,O
/,O
2,O
where,O
S1,O
and,O
S2,O
are,O
signal,O
intensities,O
of,O
two,O
compartments,O
of,O
the,O
phantom,O
",",O
and,O
σ1,O
and,O
σ2,O
are,O
standard,O
deviations,O
of,O
the,O
same,O
two,O
compartments,O
.,O
Signal,O
‐,O
to,O
‐,O
noise,O
ratio,O
is,O
given,O
by,O
(,O
2,O
),O
SNR,O
=,O
S,O
/,O
σ,O
where,O
S,O
is,O
the,O
signal,O
intensity,O
of,O
the,O
ROI,O
",",O
and,O
σ,O
is,O
the,O
standard,O
deviation,O
of,O
the,O
background,O
C,O
.,O
Distortion,O
of,O
images,O
with,O
phantom,O
scanned,O
in,O
body,O
coil,O
C,O
.,O
1,O
Distortion,O
The,O
presence,O
of,O
distortion,O
in,O
images,O
of,O
the,O
phantom,O
",",O
acquired,O
using,O
the,O
RF,O
body,O
coil,O
of,O
the,O
scanner,O
",",O
was,O
investigated,O
.,O
Flexible,O
tubes,O
filled,O
with,O
multimodality,O
visible,O
gel,O
(,O
Aqua,O
Gel,O
"™,",O
Adams,O
Healthcare,O
",",O
Leeds,O
",",O
England,O
),O
were,O
connected,O
to,O
the,O
periphery,O
running,O
parallel,O
along,O
the,O
axis,O
of,O
the,O
phantom,O
in,O
the,O
3,O
",",O
6,O
",",O
9,O
",",O
and,O
12,O
o,O
',O
clock,O
positions,O
to,O
facilitate,O
accurate,O
measurements,O
of,O
distance,O
across,O
the,O
phantom,O
.,O
Magnetic,O
resonance,O
‐,O
compatible,O
spirit,O
levels,O
were,O
attached,O
to,O
the,O
front,O
and,O
end,O
of,O
the,O
phantom,O
in,O
two,O
planes,O
to,O
assist,O
with,O
alignment,O
.,O
A,O
flat,O
board,O
insert,O
was,O
utilized,O
to,O
duplicate,O
the,O
treatment,O
position,O
",",O
and,O
three,O
setup,O
marks,O
on,O
the,O
phantom,O
were,O
aligned,O
with,O
the,O
land,O
marking,O
light,O
on,O
the,O
scanner,O
.,O
The,O
phantom,O
was,O
imaged,O
using,O
a,O
clinically,O
relevant,O
fast,O
spin,O
echo,O
sequence,O
(,O
TR,O
/,O
TE,O
=,O
4000,O
/,O
100,O
ms,O
",",O
image,O
matrix,O
=,O
256,O
×,O
256,O
",",O
FOV,O
=,O
28,O
×,O
28,O
cm,O
",",O
and,O
1,O
NEX,O
).,O
It,O
is,O
known,O
(,O
1,O
),O
",",O
(,O
16,O
),O
that,O
distortion,O
effects,O
are,O
(,O
inversely,O
),O
proportional,O
to,O
receiver,O
bandwidth,O
.,O
Hence,O
",",O
to,O
investigate,O
the,O
degree,O
of,O
distortion,O
under,O
these,O
acquisition,O
conditions,O
",",O
four,O
separate,O
scans,O
were,O
acquired,O
with,O
receiver,O
bandwidths,O
of,O
±,O
62,O
.,O
5,O
",±",O
31,O
.,O
0,O
",±",O
16,O
.,O
0,O
",",O
and,O
±,O
9,O
.,O
0,O
kHz,O
",",O
respectively,O
.,O
The,O
junction,O
at,O
the,O
head,O
and,O
neck,O
of,O
the,O
phantom,O
was,O
placed,O
at,O
the,O
magnet,O
isocenter,O
",",O
and,O
5,O
mm,O
thick,O
slices,O
each,O
separated,O
by,O
5,O
mm,O
were,O
acquired,O
",",O
both,O
inferior,O
and,O
superior,O
to,O
the,O
isocenter,O
",",O
with,O
the,O
most,O
distant,O
slices,O
210,O
mm,O
superior,O
/,O
inferior,O
.,O
The,O
positions,O
of,O
the,O
horizontal,O
and,O
vertical,O
markers,O
were,O
recorded,O
from,O
each,O
axial,O
image,O
.,O
Dimensions,O
and,O
positions,O
were,O
measured,O
on,O
image,O
slices,O
0,O
(,O
isocenter,O
"),",O
10,O
",",O
20,O
",",O
30,O
",",O
"…,",O
and,O
200,O
mm,O
in,O
the,O
superior,O
direction,O
of,O
the,O
phantom,O
.,O
C,O
.,O
2,O
Chemical,O
Shift,O
The,O
influence,O
of,O
chemical,O
shift,O
on,O
the,O
image,O
geometry,O
was,O
examined,O
.,O
Images,O
of,O
the,O
neck,O
compartment,O
of,O
the,O
phantom,O
",",O
which,O
contains,O
subcutaneous,O
fat,O
surrogate,O
material,O
",",O
were,O
examined,O
from,O
the,O
sequence,O
acquired,O
above,O
.,O
D,O
.,O
Quantification,O
of,O
the,O
accuracy,O
of,O
the,O
registration,O
of,O
CT,O
and,O
MR,O
images,O
D,O
.,O
1,O
Acquisition,O
of,O
images,O
For,O
the,O
acquisition,O
of,O
the,O
CT,O
images,O
",",O
the,O
spinal,O
cord,O
of,O
the,O
phantom,O
was,O
filled,O
with,O
water,O
doped,O
with,O
CT,O
contrast,O
(,O
5,O
.,O
5,O
%),O
in,O
order,O
to,O
differentiate,O
it,O
from,O
the,O
bulk,O
head,O
–,O
neck,O
compartment,O
.,O
T2,O
weighted,O
MR,O
images,O
were,O
obtained,O
using,O
a,O
sequence,O
optimized,O
to,O
minimize,O
the,O
distortion,O
and,O
chemical,O
shift,O
effects,O
:,O
spin,O
echo,O
",",O
TE,O
/,O
TR,O
=,O
100,O
ms,O
/,O
4,O
s,O
",",O
256,O
×,O
256,O
matrix,O
",",O
FOV,O
=,O
28,O
×,O
28,O
cm,O
",",O
BW,O
=,O
62,O
.,O
5,O
kHz,O
",",O
and,O
2,O
NEX,O
.,O
It,O
was,O
scanned,O
in,O
two,O
acquisitions,O
to,O
obtain,O
the,O
head,O
section,O
and,O
then,O
the,O
neck,O
section,O
.,O
For,O
each,O
subset,O
",",O
the,O
center,O
of,O
the,O
imaging,O
volume,O
was,O
positioned,O
at,O
the,O
magnet,O
isocenter,O
and,O
scanned,O
10,O
cm,O
either,O
side,O
of,O
this,O
point,O
.,O
Both,O
the,O
CT,O
and,O
MR,O
image,O
sets,O
were,O
obtained,O
as,O
5,O
mm,O
thick,O
contiguous,O
slices,O
.,O
The,O
phantom,O
was,O
aligned,O
in,O
both,O
scanners,O
using,O
patient,O
setup,O
orientation,O
marks,O
and,O
sagittal,O
and,O
lateral,O
side,O
crosses,O
",",O
and,O
was,O
placed,O
on,O
a,O
board,O
to,O
ensure,O
exact,O
positional,O
reproducibility,O
and,O
consistency,O
during,O
an,O
MR,O
or,O
CT,O
image,O
acquisition,O
.,O
Furthermore,O
",",O
MR,O
‐,O
compatible,O
spirit,O
levels,O
attached,O
to,O
the,O
phantom,O
helped,O
ensure,O
it,O
was,O
level,O
at,O
setup,O
.,O
In,O
addition,O
",",O
we,O
acquired,O
MR,O
images,O
with,O
the,O
phantom,O
deliberately,O
misaligned,O
to,O
test,O
the,O
registration,O
software,O
',O
s,O
capability,O
and,O
accuracy,O
.,O
These,O
were,O
as,O
follows,O
:,O
(,O
1,O
),O
with,O
the,O
front,O
of,O
the,O
phantom,O
(,O
base,O
of,O
neck,O
),O
lifted,O
by,O
1,O
cm,O
(,O
2,O
),O
with,O
the,O
right,O
‐,O
hand,O
side,O
of,O
the,O
phantom,O
lifted,O
by,O
1,O
cm,O
(,O
3,O
),O
with,O
the,O
phantom,O
rotated,O
about,O
the,O
front,O
“,O
left,O
”,O
corner,O
",",O
so,O
that,O
the,O
back,O
left,O
corner,O
was,O
translated,O
by,O
1,O
cm,O
D,O
.,O
2,O
Image,O
registration,O
and,O
“,O
organ,O
”,O
delineation,O
The,O
accuracy,O
of,O
the,O
registration,O
process,O
between,O
head,O
and,O
neck,O
CT,O
and,O
MR,O
images,O
was,O
investigated,O
.,O
We,O
are,O
using,O
the,O
FOCALFusion,O
image,O
registration,O
software,O
from,O
CMS,O
with,O
the,O
CT,O
images,O
",",O
the,O
primary,O
data,O
set,O
",",O
to,O
which,O
the,O
MR,O
images,O
",",O
the,O
secondary,O
data,O
set,O
",",O
are,O
registered,O
.,O
During,O
the,O
registration,O
",",O
using,O
the,O
mutual,O
information,O
algorithm,O
",",O
a,O
transformation,O
is,O
found,O
to,O
align,O
the,O
secondary,O
data,O
set,O
to,O
the,O
primary,O
set,O
.,O
This,O
process,O
results,O
in,O
the,O
secondary,O
set,O
being,O
interpolated,O
and,O
reformatted,O
to,O
have,O
the,O
same,O
slice,O
location,O
and,O
resolution,O
as,O
the,O
primary,O
set,O
.,O
Once,O
registered,O
",",O
the,O
two,O
data,O
sets,O
can,O
be,O
used,O
interchangeably,O
.,O
All,O
structures,O
were,O
contoured,O
on,O
CT,O
",",O
blind,O
of,O
the,O
MR,O
images,O
and,O
vice,O
versa,O
.,O
The,O
contours,O
from,O
the,O
two,O
modalities,O
can,O
be,O
qualitatively,O
compared,O
.,O
D,O
.,O
3,O
Quantitative,O
comparison,O
The,O
contour,O
data,O
was,O
extracted,O
from,O
ASCII,O
files,O
using,O
in,O
‐,O
house,O
software,O
.,O
The,O
contours,O
for,O
the,O
trachea,O
",",O
inner,O
neck,O
and,O
fat,O
",",O
and,O
spine,O
and,O
head,O
were,O
recorded,O
at,O
representative,O
axial,O
slice,O
positions,O
throughout,O
the,O
phantom,O
.,O
The,O
“,O
center,O
‐,O
of,O
‐,O
mass,O
”,O
of,O
evenly,O
distributed,O
points,O
placed,O
around,O
the,O
original,O
noncontiguous,O
pixel,O
boundary,O
was,O
also,O
determined,O
using,O
in,O
‐,O
house,O
software,O
.,O
In,O
addition,O
",",O
the,O
area,O
and,O
perimeter,O
were,O
also,O
calculated,O
",",O
and,O
the,O
following,O
coefficient,O
of,O
agreement,O
(,O
A,O
),O
was,O
determined,O
:,O
(,O
3,O
),O
A,O
=,O
RaRp,O
where,O
Ra,O
is,O
the,O
ratio,O
of,O
CT,O
area,O
to,O
MR,O
area,O
",",O
and,O
Rp,O
is,O
the,O
ratio,O
of,O
CT,O
perimeter,O
to,O
MR,O
perimeter,O
for,O
a,O
given,O
contour,O
.,O
To,O
test,O
the,O
sensitivity,O
of,O
this,O
measurement,O
",",O
we,O
compared,O
a,O
square,O
to,O
a,O
circle,O
and,O
a,O
triangle,O
to,O
a,O
circle,O
.,O
Comparison,O
of,O
a,O
square,O
and,O
circle,O
with,O
the,O
same,O
area,O
and,O
center,O
results,O
in,O
A,O
=,O
1,O
.,O
06,O
.,O
Comparison,O
of,O
a,O
triangle,O
and,O
circle,O
",",O
where,O
the,O
vertices,O
of,O
the,O
triangle,O
lie,O
on,O
the,O
circle,O
",",O
results,O
in,O
A,O
=,O
1,O
.,O
71,O
.,O
III,O
.,O
RESULTS,O
A,O
.,O
Head,O
and,O
Neck,O
Phantom,O
Pixel,O
intensity,O
values,O
varied,O
least,O
in,O
the,O
gel,O
",",O
with,O
the,O
SD,O
approximately,O
6,O
%,O
of,O
the,O
mean,O
value,O
.,O
There,O
was,O
more,O
variability,O
in,O
the,O
volunteer,O
ROIs,O
",",O
giving,O
a,O
SD,O
of,O
26,O
%,O
and,O
14,O
%,O
for,O
the,O
T1,O
and,O
T2,O
weighted,O
scans,O
",",O
respectively,O
.,O
Mean,O
±,O
SD,O
values,O
for,O
the,O
T1,O
ratios,O
were,O
1,O
.,O
37,O
±,O
0,O
.,O
16,O
",",O
0,O
.,O
54,O
±,O
0,O
.,O
02,O
",",O
and,O
0,O
.,O
19,O
±,O
0,O
.,O
01,O
for,O
fat,O
",",O
brain,O
",",O
and,O
CSF,O
",",O
respectively,O
",",O
and,O
corresponding,O
values,O
for,O
T2,O
ratios,O
were,O
0,O
.,O
82,O
±,O
0,O
.,O
04,O
",",O
0,O
.,O
53,O
±,O
0,O
.,O
05,O
",",O
and,O
1,O
.,O
19,O
±,O
0,O
.,O
08,O
.,O
The,O
results,O
in,O
the,O
various,O
materials,O
were,O
as,O
follows,O
.,O
The,O
T1,O
ratio,O
for,O
undoped,O
water,O
was,O
0,O
.,O
30,O
.,O
Sunflower,O
oil,O
produced,O
ratios,O
of,O
1,O
.,O
43,O
and,O
0,O
.,O
73,O
for,O
T1,O
and,O
T2,O
sequences,O
",",O
respectively,O
.,O
From,O
a,O
plot,O
of,O
T1,O
and,O
T2,O
ratios,O
against,O
gadolinium,O
concentration,O
",",O
the,O
appropriate,O
brain,O
and,O
CSF,O
compartments,O
of,O
the,O
phantom,O
were,O
chosen,O
.,O
The,O
T1,O
phantom,O
",",O
therefore,O
",",O
consisted,O
of,O
water,O
with,O
0,O
.,O
1,O
mL,O
/,O
L,O
Gd,O
‐,O
DTPA,O
concentration,O
for,O
brain,O
/,O
background,O
contrast,O
",",O
undoped,O
water,O
for,O
spinal,O
cord,O
contrast,O
",",O
and,O
sunflower,O
oil,O
for,O
subcutaneous,O
fat,O
contrast,O
.,O
The,O
T2,O
phantom,O
consisted,O
of,O
water,O
plus,O
3,O
.,O
5,O
mL,O
/,O
L,O
GD,O
‐,O
DTPA,O
for,O
brain,O
/,O
background,O
contrast,O
",",O
water,O
plus,O
2,O
.,O
0,O
mL,O
/,O
L,O
GD,O
‐,O
DTPA,O
for,O
spinal,O
cord,O
contrast,O
",",O
and,O
sunflower,O
oil,O
for,O
subcutaneous,O
fat,O
contrast,O
.,O
In,O
each,O
case,O
",",O
sunflower,O
oil,O
was,O
chosen,O
rather,O
than,O
suitably,O
doped,O
water,O
both,O
to,O
mimic,O
signal,O
intensity,O
and,O
to,O
provide,O
an,O
appropriate,O
chemical,O
composition,O
.,O
B,O
.,O
Comparison,O
of,O
head,O
and,O
body,O
coil,O
Values,O
for,O
SNR,O
and,O
CNR,O
obtained,O
with,O
each,O
coil,O
and,O
for,O
both,O
the,O
T1,O
and,O
T2,O
weighted,O
scans,O
are,O
shown,O
in,O
Tables,O
I,O
(,O
a,O
),O
and,O
I,O
(,O
b,O
).,O
Head,O
and,O
body,O
coil,O
comparison,O
results,O
for,O
T1,O
weighted,O
sequence,O
Phantom,O
compartment,O
Body,O
coil,O
CNR,O
Head,O
coil,O
CNR,O
Body,O
coil,O
SNR,O
Head,O
coil,O
SNR,O
spine,O
9,O
.,O
0,O
15,O
.,O
5,O
19,O
.,O
9,O
53,O
.,O
4,O
fat,O
9,O
.,O
7,O
10,O
.,O
9,O
37,O
.,O
7,O
188,O
.,O
8,O
head,O
10,O
.,O
2,O
15,O
.,O
7,O
13,O
.,O
7,O
66,O
.,O
5,O
Head,O
and,O
body,O
coil,O
comparison,O
results,O
for,O
T2,O
weighted,O
sequence,O
Phantom,O
compartment,O
Body,O
coil,O
CNR,O
Head,O
coil,O
CNR,O
Body,O
coil,O
SNR,O
Head,O
coil,O
SNR,O
spine,O
13,O
.,O
3,O
14,O
.,O
4,O
40,O
.,O
9,O
157,O
.,O
9,O
fat,O
7,O
.,O
2,O
10,O
.,O
3,O
22,O
.,O
0,O
92,O
.,O
0,O
head,O
13,O
.,O
1,O
14,O
.,O
2,O
30,O
.,O
8,O
119,O
.,O
7,O
SNR,O
obtained,O
with,O
the,O
head,O
coil,O
is,O
much,O
greater,O
than,O
with,O
the,O
body,O
coil,O
",",O
with,O
a,O
mean,O
ratio,O
(,O
head,O
SNR,O
/,O
body,O
SNR,O
),O
of,O
4,O
.,O
1,O
for,O
T1,O
sequences,O
and,O
3,O
.,O
9,O
for,O
T2,O
sequences,O
.,O
However,O
",",O
the,O
CNR,O
values,O
are,O
similar,O
",",O
with,O
a,O
mean,O
ratio,O
(,O
head,O
CNR,O
/,O
body,O
CNR,O
),O
of,O
1,O
.,O
4,O
for,O
T1,O
sequences,O
and,O
1,O
.,O
2,O
for,O
T2,O
sequences,O
.,O
C,O
.,O
Distortion,O
and,O
Chemical,O
Shift,O
C,O
.,O
1,O
Distortion,O
Figs,O
.,O
2,O
(,O
a,O
),O
and,O
(,O
b,O
),O
show,O
an,O
axial,O
T2,O
weighted,O
image,O
acquired,O
at,O
a,O
distance,O
of,O
200,O
mm,O
from,O
the,O
magnet,O
isocenter,O
",",O
together,O
with,O
an,O
image,O
acquired,O
at,O
the,O
isocenter,O
superimposed,O
(,O
darker,O
image,O
).,O
Fig,O
.,O
2,O
(,O
a,O
),O
displays,O
a,O
slight,O
shift,O
in,O
image,O
position,O
of,O
the,O
200,O
mm,O
image,O
compared,O
with,O
the,O
corresponding,O
image,O
at,O
the,O
isocenter,O
using,O
a,O
62,O
.,O
5,O
kHz,O
bandwidth,O
.,O
The,O
same,O
image,O
comparison,O
at,O
9,O
kHz,O
(,O
Fig,O
.,O
2,O
(,O
b,O
),O
displays,O
a,O
much,O
greater,O
disparity,O
and,O
implies,O
that,O
image,O
distortion,O
is,O
responsible,O
.,O
In,O
both,O
cases,O
",",O
images,O
at,O
each,O
slice,O
position,O
were,O
viewed,O
in,O
a,O
cine,O
format,O
",",O
and,O
the,O
shift,O
was,O
observed,O
to,O
be,O
minimal,O
up,O
to,O
100,O
mm,O
from,O
the,O
isocenter,O
and,O
then,O
deviated,O
noticeably,O
with,O
the,O
maximum,O
effect,O
at,O
200,O
mm,O
distance,O
.,O
Therefore,O
",",O
these,O
shifts,O
could,O
not,O
be,O
simply,O
a,O
misalignment,O
of,O
the,O
phantom,O
itself,O
.,O
This,O
two,O
axial,O
images,O
obtained,O
using,O
a,O
T2,O
weighted,O
sequence,O
.,O
The,O
image,O
acquired,O
at,O
the,O
isocenter,O
of,O
the,O
magnet,O
is,O
the,O
darker,O
or,O
less,O
transparent,O
of,O
the,O
two,O
images,O
;,O
overlaid,O
on,O
it,O
is,O
that,O
obtained,O
at,O
200,O
mm,O
superiorly,O
from,O
the,O
isocenter,O
.,O
was,O
obtained,O
using,O
a,O
bandwidth,O
of,O
62,O
.,O
5,O
kHz,O
",",O
while,O
a,O
value,O
of,O
9,O
kHz,O
was,O
used,O
for,O
The,O
small,O
bandwidth,O
image,O
clearly,O
demonstrates,O
the,O
greatest,O
distortion,O
.,O
The,O
results,O
of,O
horizontal,O
dimension,O
measurements,O
and,O
image,O
shift,O
relative,O
to,O
the,O
image,O
at,O
the,O
isocenter,O
(,O
S0,O
),O
for,O
bandwidth,O
62,O
.,O
5,O
kHz,O
(,O
taken,O
as,O
gold,O
standard,O
image,O
),O
are,O
shown,O
in,O
Figs,O
.,O
3,O
(,O
a,O
),O
to,O
(,O
d,O
).,O
Plots,O
showing,O
(,O
a,O
),O
horizontal,O
image,O
dimensions,O
",",O
(,O
b,O
),O
position,O
of,O
anterior,O
marker,O
",",O
(,O
c,O
),O
position,O
of,O
right,O
marker,O
",",O
and,O
(,O
d,O
),O
position,O
of,O
left,O
marker,O
relative,O
to,O
the,O
gold,O
standard,O
image,O
(,O
described,O
in,O
text,O
).,O
It,O
should,O
be,O
noted,O
that,O
all,O
shifts,O
seen,O
in,O
(,O
b,O
),O
to,O
–(,O
d,O
),O
are,O
to,O
the,O
right,O
(,O
taken,O
as,O
positive,O
in,O
our,O
convention,O
).,O
Some,O
data,O
points,O
are,O
missing,O
[,O
e,O
.,O
g,O
".,",O
10,O
–,O
50,O
mm,O
in,O
(,O
b,O
)],O
because,O
the,O
marker,O
tubes,O
were,O
not,O
uniformly,O
filled,O
with,O
gel,O
.,O
The,O
precision,O
with,O
which,O
the,O
marker,O
tubes,O
were,O
attached,O
to,O
the,O
phantom,O
together,O
with,O
the,O
nonuniformity,O
of,O
the,O
filling,O
may,O
be,O
responsible,O
for,O
the,O
apparent,O
noise,O
in,O
the,O
plots,O
.,O
Fig,O
.,O
3,O
(,O
a,O
),O
indicates,O
that,O
as,O
the,O
phantom,O
is,O
scanned,O
farther,O
away,O
from,O
the,O
isocenter,O
",",O
the,O
horizontal,O
dimension,O
begins,O
to,O
shrink,O
",",O
with,O
smaller,O
bandwidths,O
exhibiting,O
the,O
largest,O
change,O
.,O
This,O
finding,O
is,O
consistent,O
with,O
the,O
image,O
in,O
Fig,O
.,O
2,O
(,O
b,O
).,O
However,O
",",O
this,O
shrinking,O
effect,O
only,O
seems,O
prominent,O
beyond,O
150,O
mm,O
from,O
the,O
isocenter,O
.,O
Bandwidths,O
62,O
.,O
5,O
",",O
31,O
.,O
0,O
",",O
16,O
.,O
0,O
",",O
and,O
9,O
.,O
0,O
kHz,O
yielded,O
shrinkages,O
(,O
isocenter,O
image,O
compared,O
to,O
200,O
mm,O
superior,O
),O
of,O
2,O
.,O
1,O
",",O
2,O
.,O
2,O
",",O
2,O
.,O
7,O
",",O
and,O
2,O
.,O
7,O
mm,O
",",O
respectively,O
.,O
Figs,O
.,O
3,O
(,O
a,O
),O
to,O
(,O
d,O
),O
illustrate,O
a,O
shift,O
of,O
the,O
phantom,O
images,O
(,O
when,O
normalized,O
to,O
the,O
gold,O
standard,O
image,O
),O
to,O
the,O
right,O
",",O
which,O
is,O
again,O
consistent,O
with,O
the,O
image,O
in,O
Fig,O
.,O
2,O
(,O
b,O
).,O
These,O
shifts,O
are,O
more,O
prominent,O
at,O
a,O
distance,O
greater,O
than,O
150,O
mm,O
from,O
the,O
isocenter,O
",",O
with,O
smaller,O
bandwidths,O
demonstrating,O
greater,O
deviations,O
.,O
C,O
.,O
2,O
Chemical,O
Shift,O
Fig,O
.,O
4,O
(,O
b,O
),O
shows,O
an,O
artifactual,O
shift,O
in,O
the,O
outer,O
“,O
fat,O
”,O
layer,O
in,O
the,O
direction,O
of,O
the,O
frequency,O
encoding,O
gradient,O
(,O
left,O
‐,O
right,O
).,O
This,O
image,O
was,O
acquired,O
with,O
a,O
9,O
kHz,O
receiver,O
bandwidth,O
",",O
whereas,O
this,O
effect,O
is,O
not,O
seen,O
in,O
Fig,O
.,O
4,O
(,O
a,O
),O
(,O
acquired,O
with,O
a,O
bandwidth,O
of,O
62,O
.,O
5,O
kHz,O
).,O
This,O
result,O
was,O
found,O
to,O
be,O
independent,O
of,O
distance,O
from,O
the,O
isocenter,O
and,O
is,O
due,O
to,O
the,O
chemical,O
shift,O
difference,O
of,O
the,O
proton,O
resonance,O
in,O
fat,O
and,O
water,O
.,O
Image,O
of,O
neck,O
compartment,O
of,O
phantom,O
",",O
the,O
bulk,O
of,O
the,O
filling,O
of,O
which,O
is,O
(,O
doped,O
),O
water,O
whereas,O
the,O
outer,O
rim,O
contains,O
a,O
fat,O
surrogate,O
.,O
Two,O
receiver,O
bandwidths,O
were,O
used,O
:,O
(,O
a,O
),O
62,O
.,O
5,O
kHz,O
and,O
(,O
b,O
),O
9,O
kHz,O
.,O
The,O
latter,O
clearly,O
shows,O
a,O
distortion,O
due,O
to,O
the,O
chemical,O
shift,O
effect,O
.,O
Using,O
knowledge,O
of,O
the,O
image,O
matrix,O
size,O
and,O
receiver,O
bandwidth,O
",",O
a,O
theoretical,O
calculation,O
of,O
the,O
magnitude,O
of,O
this,O
effect,O
can,O
be,O
determined,O
.,O
The,O
chemical,O
shift,O
of,O
fat,O
and,O
water,O
at,O
1,O
.,O
5,O
T,O
is,O
approximately,O
225,O
Hz,O
.,O
This,O
is,O
divided,O
by,O
the,O
finite,O
frequency,O
range,O
",",O
which,O
represents,O
each,O
pixel,O
(,O
given,O
by,O
bandwidth,O
/,O
matrix,O
in,O
hertz,O
/,O
pixel,O
).,O
Using,O
a,O
bandwidth,O
of,O
62,O
.,O
5,O
kHz,O
yields,O
a,O
shift,O
of,O
0,O
.,O
46,O
pixels,O
",",O
and,O
a,O
bandwidth,O
of,O
9,O
.,O
0,O
kHz,O
corresponds,O
to,O
a,O
shift,O
of,O
3,O
.,O
2,O
pixels,O
.,O
At,O
the,O
nominal,O
scan,O
resolution,O
",",O
the,O
latter,O
figure,O
equates,O
to,O
a,O
3,O
mm,O
separation,O
.,O
This,O
is,O
consistent,O
with,O
observations,O
;,O
the,O
fat,O
appears,O
to,O
almost,O
“,O
bridge,O
”,O
the,O
Perspex,O
gap,O
in,O
the,O
neck,O
compartment,O
.,O
D,O
.,O
Image,O
registration,O
D,O
.,O
1,O
Analysis,O
of,O
registration,O
between,O
“,O
aligned,O
image,O
sets,O
”,O
In,O
the,O
case,O
where,O
the,O
phantom,O
was,O
aligned,O
perfectly,O
in,O
the,O
MR,O
scan,O
acquisition,O
",",O
the,O
maximum,O
difference,O
between,O
the,O
x,O
center,O
of,O
shape,O
coordinates,O
was,O
",",O
Δx,O
(,O
max,O
)=,O
1,O
.,O
30,O
mm,O
and,O
(,O
the,O
mean,O
±,O
SD,O
),O
Δx,O
(,O
mean,O
)=,O
0,O
.,O
43,O
±,O
0,O
.,O
14,O
mm,O
.,O
The,O
maximum,O
difference,O
between,O
the,O
y,O
center,O
of,O
shape,O
coordinates,O
was,O
Δy,O
(,O
mean,O
)=,O
1,O
.,O
00,O
mm,O
and,O
Δy,O
(,O
mean,O
)=,O
0,O
.,O
37,O
±,O
0,O
.,O
07,O
mm,O
.,O
The,O
coefficients,O
of,O
agreements,O
on,O
each,O
image,O
slice,O
were,O
close,O
to,O
unity,O
",",O
with,O
the,O
maximum,O
value,O
Amax,O
of,O
1,O
.,O
027,O
and,O
the,O
mean,O
value,O
Amean,O
of,O
1,O
.,O
004,O
.,O
This,O
indicates,O
good,O
agreement,O
between,O
CT,O
and,O
MR,O
area,O
values,O
and,O
between,O
CT,O
and,O
MR,O
perimeter,O
values,O
.,O
D,O
.,O
2,O
Analysis,O
of,O
registration,O
with,O
front,O
of,O
phantom,O
(,O
base,O
of,O
neck,O
),O
lifted,O
by,O
1,O
cm,O
during,O
the,O
MR,O
scan,O
The,O
values,O
obtained,O
from,O
this,O
scan,O
were,O
the,O
following,O
:,O
Δx,O
(,O
max,O
)=,O
1,O
.,O
40,O
mm,O
",",O
Δx,O
(,O
mean,O
)=,O
0,O
.,O
59,O
±,O
0,O
.,O
28,O
mm,O
",",O
Δy,O
(,O
max,O
)=−,O
1,O
.,O
40,O
mm,O
",",O
Δy,O
(,O
mean,O
)=,O
0,O
.,O
39,O
±,O
0,O
.,O
26,O
mm,O
",",O
Amax,O
=,O
1,O
.,O
093,O
",",O
and,O
Amean,O
=,O
1,O
.,O
014,O
.,O
D,O
.,O
3,O
Analysis,O
of,O
registration,O
with,O
the,O
right,O
‐,O
hand,O
side,O
of,O
the,O
phantom,O
lifted,O
by,O
1,O
cm,O
during,O
the,O
MR,O
scan,O
Corresponding,O
values,O
are,O
the,O
following,O
:,O
Δx,O
(,O
max,O
)=,O
0,O
.,O
60,O
mm,O
",",O
Δx,O
(,O
mean,O
)=,O
0,O
.,O
29,O
±,O
0,O
.,O
07,O
mm,O
",",O
Δy,O
(,O
max,O
)=,O
1,O
.,O
80,O
mm,O
",",O
Δy,O
(,O
mean,O
)=,O
0,O
.,O
58,O
±,O
0,O
.,O
52,O
mm,O
",",O
Amax,O
=,O
1,O
.,O
025,O
",",O
and,O
Amean,O
=,O
0,O
.,O
998,O
.,O
D,O
.,O
4,O
Analysis,O
of,O
registration,O
with,O
the,O
phantom,O
rotated,O
/,O
pivoted,O
about,O
the,O
front,O
left,O
corner,O
of,O
the,O
phantom,O
",",O
so,O
that,O
the,O
back,O
left,O
corner,O
was,O
translated,O
by,O
1,O
cm,O
during,O
the,O
MR,O
scan,O
Similarly,O
",",O
values,O
were,O
as,O
follows,O
:,O
Δx,O
(,O
max,O
)=−,O
160,O
mm,O
",",O
Δx,O
(,O
mean,O
)=,O
0,O
.,O
45,O
±,O
0,O
.,O
18,O
mm,O
",",O
Δy,O
(,O
max,O
)=,O
0,O
.,O
90,O
mm,O
",",O
Δy,O
(,O
mean,O
)=,O
0,O
.,O
29,O
±,O
0,O
.,O
05,O
mm,O
",",O
Amax,O
=,O
1,O
.,O
055,O
",",O
and,O
Amean,O
=,O
1,O
.,O
010,O
.,O
IV,O
.,O
DISCUSSION,O
Using,O
the,O
materials,O
described,O
in,O
this,O
paper,O
we,O
have,O
constructed,O
a,O
quality,O
assurance,O
phantom,O
to,O
evaluate,O
MR,O
distortions,O
and,O
registration,O
accuracy,O
.,O
In,O
addition,O
",",O
the,O
phantom,O
may,O
be,O
used,O
to,O
investigate,O
various,O
imaging,O
sequences,O
and,O
RF,O
coils,O
.,O
Signal,O
‐,O
to,O
‐,O
noise,O
is,O
on,O
average,O
four,O
times,O
greater,O
for,O
images,O
acquired,O
in,O
the,O
head,O
coil,O
relative,O
to,O
the,O
body,O
coil,O
.,O
However,O
",",O
contrast,O
‐,O
to,O
‐,O
noise,O
is,O
approximately,O
of,O
the,O
same,O
magnitude,O
between,O
head,O
and,O
body,O
coils,O
for,O
both,O
T1,O
and,O
T2,O
weighted,O
scan,O
sequences,O
",",O
which,O
suggests,O
that,O
head,O
and,O
neck,O
patients,O
can,O
be,O
imaged,O
in,O
the,O
body,O
coil,O
without,O
compromising,O
the,O
differentiation,O
of,O
anatomical,O
features,O
.,O
In,O
MRI,O
",",O
linear,O
changes,O
in,O
magnetic,O
field,O
are,O
used,O
to,O
spatially,O
encode,O
the,O
final,O
image,O
.,O
Any,O
perturbations,O
to,O
this,O
linearity,O
will,O
produce,O
image,O
distortions,O
.,O
Inhomogeneities,O
in,O
the,O
main,O
magnetic,O
field,O
or,O
gradients,O
will,O
therefore,O
have,O
a,O
detrimental,O
effect,O
on,O
the,O
final,O
image,O
.,O
While,O
the,O
inhomogeneity,O
of,O
the,O
main,O
field,O
is,O
kept,O
to,O
a,O
minimum,O
under,O
stringent,O
manufacturer,O
specifications,O
",",O
previous,O
studies,O
have,O
demonstrated,O
distortions,O
of,O
several,O
millimeters,O
",",O
(,O
16,O
),O
with,O
the,O
greatest,O
effect,O
observed,O
at,O
the,O
periphery,O
.,O
For,O
open,O
magnets,O
the,O
problem,O
is,O
considerably,O
worse,O
",",O
and,O
15,O
mm,O
deviations,O
have,O
been,O
recorded,O
.,O
(,O
17,O
),O
Our,O
results,O
",",O
using,O
a,O
1,O
.,O
5,O
T,O
system,O
",",O
have,O
shown,O
that,O
while,O
distortion,O
effects,O
are,O
present,O
",",O
they,O
can,O
be,O
minimized,O
by,O
an,O
appreciation,O
of,O
the,O
receiver,O
bandwidth,O
(,O
gradient,O
strength,O
),O
and,O
distance,O
from,O
the,O
isocenter,O
(,O
B0,O
homogeneity,O
).,O
In,O
consideration,O
of,O
both,O
chemical,O
shift,O
and,O
distortion,O
",",O
images,O
should,O
be,O
acquired,O
with,O
high,O
receiver,O
bandwidths,O
",",O
preferably,O
≥,O
30,O
kHz,O
",",O
and,O
should,O
not,O
extend,O
beyond,O
15,O
cm,O
from,O
the,O
isocenter,O
.,O
There,O
is,O
very,O
good,O
agreement,O
between,O
CT,O
and,O
MR,O
area,O
values,O
and,O
between,O
CT,O
and,O
MR,O
perimeter,O
values,O
.,O
Our,O
analysis,O
showed,O
that,O
a,O
maximum,O
coefficient,O
of,O
agreement,O
is,O
only,O
9,O
%,O
greater,O
than,O
unity,O
and,O
the,O
maximum,O
mean,O
value,O
only,O
2,O
.,O
7,O
%,O
above,O
unity,O
.,O
In,O
section,O
II,O
D,O
.,O
3,O
we,O
showed,O
that,O
comparison,O
of,O
contours,O
that,O
were,O
very,O
similar,O
(,O
circle,O
and,O
square,O
of,O
equal,O
area,O
and,O
center,O
),O
scored,O
a,O
coefficient,O
of,O
6,O
%,O
greater,O
than,O
unity,O
.,O
There,O
was,O
no,O
significant,O
deviation,O
from,O
these,O
results,O
for,O
the,O
misaligned,O
scans,O
",",O
suggesting,O
that,O
the,O
mutual,O
information,O
registration,O
algorithm,O
used,O
in,O
the,O
FOCALFusion,O
software,O
can,O
manage,O
with,O
offsets,O
up,O
to,O
1,O
cm,O
.,O
The,O
mean,O
value,O
for,O
the,O
measured,O
coefficients,O
of,O
agreement,O
was,O
equal,O
to,O
1,O
.,O
028,O
",",O
which,O
suggests,O
a,O
small,O
but,O
systematic,O
overestimate,O
of,O
contour,O
shapes,O
/,O
sizes,O
drawn,O
on,O
the,O
CT,O
images,O
.,O
The,O
largest,O
difference,O
in,O
any,O
center,O
of,O
shape,O
coordinate,O
measurement,O
was,O
1,O
.,O
8,O
mm,O
.,O
When,O
mean,O
values,O
of,O
this,O
parameter,O
for,O
each,O
region,O
were,O
examined,O
",",O
the,O
largest,O
value,O
was,O
0,O
.,O
45,O
mm,O
.,O
Corresponding,O
values,O
from,O
the,O
misaligned,O
scans,O
were,O
0,O
.,O
43,O
",",O
0,O
.,O
59,O
",",O
and,O
0,O
.,O
58,O
mm,O
.,O
These,O
values,O
are,O
easily,O
within,O
the,O
tolerances,O
for,O
alignment,O
and,O
contouring,O
.,O
We,O
have,O
shown,O
how,O
a,O
simple,O
phantom,O
can,O
be,O
used,O
to,O
characterize,O
the,O
registration,O
process,O
when,O
utilizing,O
two,O
different,O
imaging,O
modalities,O
.,O
It,O
should,O
be,O
understood,O
",",O
however,O
",",O
that,O
there,O
are,O
three,O
main,O
contributors,O
in,O
such,O
a,O
process,O
",",O
the,O
third,O
being,O
the,O
software,O
used,O
for,O
registration,O
.,O
It,O
is,O
important,O
that,O
the,O
final,O
fused,O
image,O
data,O
sets,O
are,O
compared,O
and,O
analyzed,O
when,O
performing,O
quality,O
assurance,O
on,O
the,O
use,O
of,O
multimodality,O
fusion,O
for,O
treatment,O
planning,O
of,O
radiotherapy,O
.,O
Furthermore,O
",",O
we,O
have,O
shown,O
that,O
some,O
image,O
distortion,O
is,O
seen,O
in,O
axial,O
images,O
",",O
even,O
when,O
using,O
acquisition,O
sequences,O
designed,O
to,O
minimize,O
it,O
.,O
Having,O
understood,O
the,O
practical,O
limitations,O
",",O
scanning,O
protocols,O
can,O
be,O
formulated,O
that,O
really,O
negate,O
the,O
impact,O
of,O
any,O
such,O
(,O
small,O
),O
effects,O
when,O
using,O
MR,O
imaging,O
to,O
delineate,O
the,O
tumor,B-DS
and,O
proximal,O
tissues,O
.,O
However,O
",",O
it,O
is,O
important,O
to,O
recognize,O
that,O
each,O
MR,O
scanner,O
will,O
perform,O
differently,O
",",O
and,O
systematic,O
analysis,O
of,O
these,O
factors,O
should,O
be,O
performed,O
as,O
part,O
of,O
quality,O
assurance,O
to,O
ensure,O
the,O
accuracy,O
of,O
the,O
planning,O
procedure,O
.,O
Finally,O
",",O
we,O
believe,O
that,O
our,O
work,O
shows,O
that,O
MR,O
imaging,O
can,O
be,O
safely,O
used,O
in,O
treatment,O
planning,O
of,O
radiotherapy,O
for,O
the,O
head,O
and,O
neck,O
;,O
given,O
its,O
enhanced,O
soft,O
tissue,O
delineation,O
",",O
it,O
will,O
provide,O
an,O
excellent,O
tool,O
for,O
more,O
discriminate,O
contouring,O
as,O
we,O
implement,O
novel,O
radiotherapy,O
methods,O
",",O
such,O
as,O
intensity,O
‐,O
modulated,O
radiotherapy,O
.,O
(,O
18,O
),O
The,O
work,O
also,O
shows,O
that,O
“,O
discrepancies,O
”,O
seen,O
in,O
perceived,O
structure,O
or,O
tumor,B-DS
delineation,O
in,O
soft,O
tissues,O
can,O
be,O
assumed,O
to,O
be,O
due,O
to,O
the,O
imaging,O
capabilities,O
of,O
the,O
media,O
in,O
question,O
rather,O
than,O
phantom,O
effects,O
from,O
the,O
registration,O
process,O
itself,O
.,O
We,O
are,O
currently,O
extending,O
this,O
work,O
and,O
are,O
redesigning,O
the,O
phantom,O
",",O
making,O
it,O
possible,O
to,O
internally,O
mount,O
flasks,O
containing,O
a,O
gel,O
dosimeter,O
(,O
9,O
),O
",",O
(,O
19,O
),O
in,O
order,O
to,O
make,O
a,O
universal,O
phantom,O
for,O
head,O
and,O
neck,O
radiotherapy,O
.,O
The,O
addition,O
of,O
this,O
facility,O
will,O
allow,O
us,O
to,O
use,O
the,O
phantom,O
for,O
planning,O
highly,O
conformal,O
treatments,O
and,O
then,O
verify,O
the,O
delivery,O
(,O
using,O
gel,O
dosimetry,O
),O
to,O
validate,O
the,O
entire,O
process,O
.,O
Verbal,O
creativity,O
in,O
autism,B-DS
:,O
comprehension,O
and,O
generation,O
of,O
metaphoric,O
language,O
in,O
high,O
-,O
functioning,O
autism,B-DS
spectrum,I-DS
disorder,I-DS
and,O
typical,O
development,O
Edited,O
by,O
:,O
Zbigniew,O
R,O
.,O
Struzik,O
",",O
The,O
University,O
of,O
Tokyo,O
",",O
Japan,O
Reviewed,O
by,O
:,O
Dahlia,O
Zaidel,O
",",O
University,O
of,O
California,O
",",O
Los,O
Angeles,O
",",O
USA,O
;,O
Michael,O
Francis,O
Fitzgerald,O
",",O
Trinity,O
College,O
Dublin,O
",",O
Ireland,O
This,O
article,O
was,O
submitted,O
to,O
the,O
journal,O
Frontiers,O
in,O
Human,O
Neuroscience,O
.,O
Studies,O
on,O
creativity,O
in,O
participants,O
with,O
autism,B-DS
generally,O
show,O
impoverished,O
performance,O
as,O
well,O
as,O
deficient,O
comprehension,O
of,O
metaphoric,O
language,O
.,O
However,O
",",O
very,O
little,O
is,O
known,O
about,O
the,O
ability,O
to,O
generate,O
metaphors,O
in,O
this,O
population,O
.,O
The,O
present,O
study,O
examines,O
verbal,O
creativity,O
in,O
adults,O
with,O
autism,B-DS
-,I-DS
spectrum,I-DS
disorder,I-DS
(,O
ASD,B-DS
),O
through,O
tasks,O
that,O
rely,O
on,O
novel,O
metaphoric,O
language,O
.,O
Seventeen,O
adults,O
with,O
ASD,B-DS
(,O
mean,O
age,O
=,O
21,O
.,O
06,O
),O
and,O
17,O
typically,O
developing,O
peers,O
(,O
mean,O
age,O
=,O
22,O
.,O
71,O
),O
participated,O
in,O
the,O
study,O
.,O
A,O
multiple,O
-,O
choice,O
questionnaire,O
consisting,O
of,O
conventional,O
and,O
novel,O
metaphors,O
was,O
used,O
to,O
test,O
comprehension,O
",",O
and,O
a,O
sentence,O
completion,O
questionnaire,O
was,O
used,O
to,O
test,O
generation,O
of,O
creative,O
language,O
.,O
Results,O
show,O
similar,O
performance,O
in,O
comprehension,O
of,O
conventional,O
and,O
novel,O
metaphors,O
in,O
both,O
groups,O
",",O
whereas,O
adults,O
with,O
ASD,B-DS
generated,O
more,O
creative,O
metaphors,O
relative,O
to,O
the,O
control,O
group,O
.,O
Scores,O
on,O
tests,O
of,O
vocabulary,O
and,O
naming,O
contributed,O
to,O
the,O
prediction,O
of,O
conventional,O
metaphor,O
comprehension,O
",",O
while,O
scores,O
on,O
tests,O
of,O
mental,O
flexibility,O
contributed,O
to,O
the,O
prediction,O
of,O
novel,O
metaphor,O
comprehension,O
.,O
In,O
addition,O
",",O
scores,O
on,O
a,O
test,O
of,O
non,O
-,O
verbal,O
intelligence,O
contributed,O
to,O
the,O
prediction,O
of,O
metaphor,O
generation,O
.,O
The,O
study,O
points,O
to,O
unique,O
verbal,O
creativity,O
in,O
ASD,B-DS
.,O
INTRODUCTION,O
People,O
with,O
autistic,B-DS
-,I-DS
spectrum,I-DS
disorder,I-DS
(,O
ASD,B-DS
),O
experience,O
difficulties,O
in,O
comprehension,O
of,O
figurative,O
language,O
",",O
and,O
tend,O
to,O
give,O
literal,O
interpretation,O
to,O
ambiguous,O
syntactic,O
expressions,O
",",O
to,O
phrases,O
that,O
convey,O
irony,O
",",O
humor,O
",",O
or,O
sarcasm,O
",",O
to,O
idioms,O
",",O
or,O
to,O
metaphors,O
(,O
Happé,O
",",O
1993,O
",",O
1995,O
;,O
Kerbel,O
and,O
Grunwell,O
",",O
1998,O
;,O
Rapin,O
and,O
Dunn,O
",",O
2003,O
;,O
Adachi,O
et,O
al,O
".,",O
2004,O
;,O
Rundblad,O
and,O
Annaz,O
",",O
2010,O
;,O
Mashal,O
and,O
Kasirer,O
",",O
2011,O
).,O
Despite,O
extensive,O
research,O
on,O
comprehension,O
of,O
metaphoric,O
language,O
in,O
autism,B-DS
",",O
very,O
little,O
is,O
known,O
about,O
how,O
people,O
with,O
ASD,B-DS
generate,O
metaphors,O
.,O
In,O
fact,O
",",O
earlier,O
research,O
on,O
creativity,O
in,O
ASD,B-DS
has,O
focused,O
primarily,O
on,O
non,O
-,O
verbal,O
rather,O
than,O
on,O
verbal,O
abilities,O
.,O
Findings,O
have,O
mostly,O
documented,O
deficient,O
performance,O
in,O
ASD,B-DS
",",O
especially,O
when,O
using,O
tasks,O
that,O
are,O
imagination,O
-,O
oriented,O
(,O
e,O
.,O
g,O
".,",O
Frith,O
",",O
1972,O
;,O
Lewis,O
and,O
Boucher,O
",",O
1991,O
;,O
Craig,O
and,O
Baron,O
-,O
Cohen,O
",",O
1999,O
).,O
The,O
present,O
study,O
investigates,O
comprehension,O
and,O
generation,O
of,O
novel,O
metaphors,O
in,O
ASD,B-DS
.,O
In,O
a,O
recent,O
study,O
we,O
found,O
that,O
children,O
with,O
ASD,B-DS
(,O
aged,O
12,O
–,O
15,O
),O
differ,O
from,O
typically,O
developing,O
(,O
TD,O
),O
children,O
in,O
comprehension,O
of,O
conventional,O
metaphors,O
but,O
not,O
in,O
comprehension,O
of,O
novel,O
metaphors,O
(,O
Mashal,O
and,O
Kasirer,O
",",O
2011,O
).,O
In,O
this,O
study,O
we,O
used,O
a,O
multiple,O
-,O
choice,O
task,O
that,O
included,O
conventional,O
metaphors,O
(,O
e,O
.,O
g,O
".,",O
sharp,O
tongue,O
"),",O
novel,O
metaphors,O
(,O
e,O
.,O
g,O
".,",O
joy,O
bits,O
"),",O
and,O
unrelated,O
word,O
-,O
pairs,O
(,O
e,O
.,O
g,O
".,",O
laundry,O
rabbit,B-OG
).,O
Unlike,O
conventional,O
metaphors,O
",",O
which,O
are,O
coded,O
in,O
the,O
mental,O
lexicon,O
",",O
novel,O
metaphors,O
require,O
the,O
computation,O
of,O
on,O
-,O
line,O
interpretation,O
.,O
It,O
might,O
be,O
the,O
case,O
that,O
the,O
ability,O
to,O
create,O
novel,O
semantic,O
connections,O
between,O
apparently,O
unrelated,O
concepts,O
is,O
not,O
impaired,O
in,O
ASD,B-DS
.,O
Consistent,O
with,O
our,O
results,O
",",O
Hermann,O
et,O
al,O
.,O
(,O
2013,O
),O
found,O
that,O
processing,O
of,O
novel,O
metaphors,O
in,O
20,O
adults,O
with,O
Asperger,B-DS
syndrome,I-DS
(,O
aged,O
22,O
–,O
68,O
),O
was,O
similar,O
to,O
performance,O
of,O
age,O
-,O
matched,O
TD,O
individuals,O
.,O
The,O
experiment,O
included,O
a,O
semantic,O
judgment,O
task,O
",",O
in,O
which,O
participants,O
were,O
asked,O
to,O
make,O
rapid,O
decisions,O
about,O
the,O
literal,O
truth,O
of,O
a,O
given,O
sentence,O
.,O
The,O
task,O
consisted,O
of,O
four,O
types,O
of,O
sentences,O
:,O
literally,O
true,O
high,O
-,O
typical,O
sentences,O
(,O
e,O
.,O
g,O
".,",O
Some,O
lawyers,O
are,O
juvenile,O
magistrates,O
);,O
literally,O
true,O
low,O
-,O
typical,O
sentences,O
(,O
e,O
.,O
g,O
".,",O
Some,O
lawyers,O
are,O
tax,O
advisors,O
);,O
metaphors,O
(,O
e,O
.,O
g,O
".,",O
Some,O
lawyers,O
are,O
scale,O
rulers,O
);,O
and,O
scrambled,O
metaphors,O
(,O
e,O
.,O
g,O
".,",O
Some,O
lawyers,O
are,O
days,O
off,O
spring,O
).,O
Responses,O
to,O
metaphors,O
were,O
significantly,O
slower,O
than,O
were,O
responses,O
to,O
the,O
other,O
types,O
of,O
expressions,O
",",O
but,O
this,O
pattern,O
of,O
results,O
characterized,O
both,O
groups,O
",",O
with,O
no,O
impairment,O
in,O
performance,O
seen,O
in,O
the,O
ASD,B-DS
group,O
.,O
Thus,O
",",O
there,O
is,O
evidence,O
that,O
people,O
with,O
ASD,B-DS
demonstrate,O
no,O
difficulties,O
with,O
figurative,O
language,O
",",O
contrary,O
to,O
previous,O
arguments,O
in,O
the,O
literature,O
.,O
Note,O
that,O
some,O
earlier,O
work,O
has,O
suggested,O
that,O
individuals,O
with,O
ASD,B-DS
do,O
not,O
comprehend,O
figurative,O
language,O
due,O
to,O
difficulties,O
in,O
executive,O
functions,O
(,O
Russell,O
",",O
1997,O
).,O
According,O
to,O
this,O
account,O
",",O
ASD,B-DS
impairs,O
planning,O
",",O
set,O
-,O
shifting,O
(,O
flexibility,O
"),",O
working,O
memory,O
",",O
and,O
inhibition,O
(,O
Ozonoff,O
and,O
Strayer,O
",",O
1997,O
).,O
It,O
has,O
been,O
suggested,O
that,O
executive,B-DS
dysfunction,I-DS
contributes,O
to,O
the,O
typical,O
communication,O
and,O
social,O
impairments,O
in,O
ASD,B-DS
(,O
Landa,O
and,O
Goldberg,O
",",O
2005,O
).,O
However,O
",",O
evidence,O
for,O
executive,B-DS
dysfunction,I-DS
in,O
ASD,B-DS
remains,O
equivocal,O
.,O
For,O
example,O
",",O
Robinson,O
et,O
al,O
.,O
(,O
2009,O
),O
found,O
differences,O
in,O
inhibition,O
",",O
planning,O
",",O
and,O
self,O
-,O
monitoring,O
between,O
individuals,O
with,O
ASD,B-DS
and,O
TD,O
participants,O
",",O
but,O
no,O
group,O
differences,O
in,O
cognitive,O
flexibility,O
and,O
verbal,O
fluency,O
were,O
noted,O
.,O
Other,O
studies,O
have,O
recorded,O
difficulties,O
in,O
linguistic,O
and,O
categorical,O
(,O
semantic,O
),O
fluency,O
in,O
ASD,B-DS
(,O
Rumsey,O
and,O
Hamburger,O
",",O
1988,O
).,O
Executive,B-DS
dysfunction,I-DS
has,O
a,O
considerable,O
adverse,O
impact,O
on,O
the,O
ability,O
to,O
plan,O
well,O
formed,O
novel,O
linguistic,O
constructs,O
",",O
and,O
to,O
shift,O
from,O
one,O
meaning,O
of,O
a,O
word,O
or,O
phrase,O
to,O
another,O
",",O
especially,O
in,O
the,O
case,O
of,O
metaphoric,O
language,O
(,O
Landa,O
and,O
Goldberg,O
",",O
2005,O
).,O
The,O
ability,O
to,O
combine,O
the,O
two,O
words,O
that,O
form,O
a,O
metaphor,O
to,O
a,O
meaningful,O
expression,O
might,O
thus,O
be,O
more,O
affected,O
by,O
deficits,O
in,O
executive,O
functions,O
than,O
the,O
ability,O
to,O
interpret,O
literal,O
expressions,O
(,O
Amanzio,O
et,O
al,O
".,",O
2008,O
).,O
Mashal,O
and,O
Kasirer,O
(),O
have,O
indeed,O
demonstrated,O
that,O
executive,B-DS
dysfunction,I-DS
contributed,O
to,O
comprehension,O
of,O
novel,O
metaphors,O
among,O
children,O
with,O
ASD,B-DS
.,O
Executive,O
functions,O
are,O
important,O
not,O
only,O
for,O
comprehension,O
but,O
also,O
for,O
the,O
generation,O
of,O
metaphors,O
(,O
Dietrich,O
",",O
2004,O
;,O
Chiappe,O
and,O
Chiappe,O
",",O
2007,O
).,O
To,O
generate,O
a,O
metaphor,O
that,O
contains,O
a,O
topic,O
and,O
a,O
vehicle,O
",",O
a,O
speaker,O
must,O
first,O
select,O
the,O
property,O
that,O
will,O
be,O
attributed,O
to,O
the,O
topic,O
",",O
and,O
then,O
scan,O
semantic,O
knowledge,O
for,O
suitable,O
vehicles,O
that,O
exemplify,O
the,O
abstract,O
",",O
higher,O
-,O
order,O
attributive,O
category,O
.,O
This,O
process,O
requires,O
that,O
one,O
maintains,O
access,O
to,O
the,O
category,O
while,O
inhibiting,O
features,O
of,O
both,O
topic,O
and,O
possible,O
vehicles,O
that,O
are,O
irrelevant,O
to,O
the,O
higher,O
-,O
order,O
category,O
.,O
That,O
is,O
",",O
highly,O
accessible,O
but,O
irrelevant,O
semantic,O
knowledge,O
(,O
e,O
.,O
g,O
".,",O
adjectival,O
descriptions,O
of,O
the,O
topic,O
),O
as,O
well,O
as,O
many,O
accessible,O
but,O
trite,O
possibilities,O
",",O
such,O
as,O
idioms,O
",",O
clichés,O
",",O
and,O
conventional,O
metaphors,O
must,O
all,O
be,O
inhibited,O
.,O
Finally,O
",",O
the,O
speaker,O
must,O
evaluate,O
whether,O
the,O
metaphor,O
conveys,O
the,O
desired,O
meaning,O
and,O
emotional,O
tone,O
",",O
and,O
then,O
revise,O
it,O
if,O
necessary,O
(,O
Silvia,O
and,O
Beaty,O
",",O
2012,O
).,O
There,O
is,O
evidence,O
that,O
the,O
generation,O
of,O
conventional,O
and,O
novel,O
metaphors,O
relies,O
on,O
different,O
cognitive,O
abilities,O
(,O
Bowdle,O
and,O
Gentner,O
",",O
2005,O
;,O
Mashal,O
",",O
2013,O
).,O
Silvia,O
and,O
Beaty,O
(,O
2013,O
),O
suggested,O
that,O
generation,O
of,O
conventional,O
metaphors,O
is,O
influenced,O
by,O
general,O
knowledge,O
or,O
vocabulary,O
",",O
whereas,O
generation,O
of,O
novel,O
metaphors,O
is,O
affected,O
by,O
fluid,O
intelligence,O
and,O
executive,O
processes,O
.,O
Silvia,O
and,O
Beaty,O
(,O
2012,O
),O
gave,O
their,O
participants,O
two,O
different,O
prompts,O
and,O
instructed,O
them,O
to,O
describe,O
past,O
emotional,O
experiences,O
through,O
a,O
metaphor,O
.,O
The,O
first,O
prompt,O
asked,O
people,O
to,O
“,O
think,O
of,O
the,O
most,O
boring,O
high,O
-,O
school,O
or,O
college,O
class,O
that,O
you,O
have,O
ever,O
had,O
.,O
What,O
was,O
it,O
like,O
to,O
sit,O
through,O
?”,O
For,O
the,O
next,O
prompt,O
",",O
participants,O
were,O
asked,O
to,O
“,O
think,O
about,O
the,O
most,O
disgusting,O
thing,O
you,O
ever,O
ate,O
or,O
drank,O
.,O
What,O
was,O
it,O
like,O
to,O
eat,O
or,O
drink,O
it,O
?”,O
Six,O
measures,O
of,O
inductive,O
reasoning,O
",",O
primarily,O
non,O
-,O
verbal,O
and,O
visuo,O
-,O
spatial,O
",",O
were,O
used,O
to,O
assess,O
fluid,O
intelligence,O
.,O
Results,O
showed,O
that,O
fluid,O
intelligence,O
predicted,O
the,O
creative,O
quality,O
of,O
novel,O
metaphors,O
.,O
This,O
suggests,O
that,O
people,O
with,O
high,O
non,O
-,O
verbal,O
intelligence,O
can,O
produce,O
more,O
creative,O
metaphors,O
than,O
do,O
people,O
with,O
lower,O
intelligence,O
.,O
Within,O
the,O
ASD,B-DS
literature,O
",",O
creativity,O
has,O
been,O
measured,O
primarily,O
by,O
non,O
-,O
verbal,O
tasks,O
that,O
involved,O
the,O
production,O
of,O
spontaneous,O
sequences,O
of,O
colors,O
",",O
tones,O
",",O
or,O
drawings,O
(,O
Frith,O
",",O
1972,O
;,O
Lewis,O
and,O
Boucher,O
",",O
1991,O
;,O
Liu,O
et,O
al,O
".,",O
2011,O
),O
or,O
by,O
verbal,O
fluency,O
tasks,O
(,O
Boucher,O
",",O
1988,O
).,O
No,O
extensive,O
investigation,O
of,O
generation,O
of,O
novel,O
verbal,O
concepts,O
has,O
been,O
conducted,O
.,O
Craig,O
and,O
Baron,O
-,O
Cohen,O
(,O
1999,O
),O
examined,O
creative,O
thinking,O
in,O
children,O
with,O
ASD,B-DS
by,O
using,O
the,O
Torrance,O
Creativity,O
Test,O
(,O
Torrance,O
",",O
1974,O
).,O
Their,O
participants,O
could,O
generate,O
novel,O
uses,O
to,O
an,O
object,O
(,O
e,O
.,O
g,O
".,",O
“,O
what,O
else,O
can,O
a,O
pencil,O
be,O
"?”),",O
but,O
they,O
generated,O
fewer,O
such,O
novel,O
uses,O
overall,O
compared,O
to,O
TD,O
children,O
.,O
Moreover,O
",",O
their,O
ideas,O
tended,O
to,O
be,O
quite,O
concrete,O
rather,O
than,O
imaginary,O
.,O
Liu,O
et,O
al,O
.,O
(,O
2011,O
),O
emphasize,O
that,O
imagination,O
is,O
not,O
necessarily,O
important,O
for,O
successful,O
performance,O
on,O
tasks,O
that,O
involve,O
creativity,O
and,O
originality,O
.,O
They,O
used,O
an,O
exercise,O
in,O
divergent,O
thinking,O
which,O
included,O
12,O
incomplete,O
figures,O
",",O
and,O
asked,O
their,O
participants,O
to,O
complete,O
the,O
figures,O
in,O
an,O
original,O
way,O
as,O
well,O
as,O
to,O
title,O
them,O
.,O
The,O
completed,O
drawings,O
were,O
assessed,O
on,O
domains,O
of,O
fluency,O
",",O
openness,O
",",O
flexibility,O
",",O
originality,O
",",O
and,O
elaboration,O
.,O
According,O
to,O
Liu,O
et,O
al,O
".,",O
children,O
with,O
Asperger,B-DS
’,I-DS
s,I-DS
syndrome,I-DS
demonstrated,O
better,O
elaboration,O
and,O
originality,O
than,O
did,O
age,O
-,O
matched,O
TD,O
peers,O
.,O
The,O
main,O
goal,O
of,O
the,O
current,O
study,O
is,O
to,O
examine,O
metaphor,O
comprehension,O
and,O
generation,O
in,O
adults,O
with,O
high,O
-,O
functioning,O
ASD,B-DS
.,O
Generation,O
of,O
novel,O
and,O
original,O
metaphors,O
is,O
assumed,O
to,O
measure,O
verbal,O
creativity,O
.,O
In,O
addition,O
",",O
we,O
examine,O
executive,O
functions,O
and,O
analyze,O
the,O
contribution,O
of,O
these,O
functions,O
to,O
performance,O
on,O
the,O
metaphor,O
tasks,O
.,O
We,O
hypothesize,O
that,O
adults,O
with,O
ASD,B-DS
will,O
show,O
difficulty,O
in,O
comprehension,O
of,O
conventional,O
metaphors,O
but,O
not,O
in,O
comprehension,O
of,O
novel,O
metaphors,O
.,O
We,O
further,O
expect,O
participants,O
with,O
ASD,B-DS
to,O
be,O
able,O
to,O
generate,O
novel,O
metaphors,O
but,O
to,O
a,O
lesser,O
extent,O
than,O
TD,O
participants,O
.,O
Finally,O
",",O
we,O
assume,O
that,O
executive,O
functions,O
will,O
contribute,O
to,O
metaphor,O
comprehension,O
and,O
generation,O
in,O
both,O
the,O
ASD,B-DS
and,O
the,O
TD,O
groups,O
.,O
MATERIALS,O
AND,O
METHODS,O
PARTICIPANTS,O
Thirty,O
-,O
four,O
participants,O
took,O
part,O
in,O
the,O
study,O
",",O
17,O
adults,O
with,O
high,O
functioning,O
ASD,B-DS
and,O
17,O
age,O
-,O
matched,O
typically,O
developing,O
adults,O
.,O
The,O
ASD,B-DS
group,O
consisted,O
of,O
14,O
men,B-OG
and,O
3,O
women,B-OG
",",O
ranging,O
in,O
age,O
from,O
18,O
to,O
27,O
(,O
mean,O
age,O
=,O
21,O
.,O
06,O
",",O
SD,O
=,O
3,O
.,O
44,O
"),",O
and,O
the,O
TD,O
group,O
consisted,O
of,O
eight,O
men,B-OG
and,O
nine,O
women,B-OG
",",O
ranging,O
in,O
age,O
from,O
18,O
to,O
25,O
(,O
mean,O
age,O
=,O
22,O
.,O
71,O
",",O
SD,O
=,O
2,O
.,O
02,O
).,O
All,O
participants,O
were,O
native,O
Hebrew,O
speakers,O
who,O
completed,O
at,O
least,O
12,O
years,O
of,O
formal,O
education,O
",",O
without,O
learning,B-DS
disabilities,I-DS
or,O
attention,O
problems,O
.,O
The,O
ASD,B-DS
group,O
was,O
recruited,O
through,O
classes,O
integrated,O
within,O
regular,O
high,O
schools,O
and,O
through,O
community,O
services,O
for,O
persons,O
with,O
ASD,B-DS
.,O
Diagnosis,O
was,O
done,O
by,O
a,O
psychiatrist,O
",",O
in,O
line,O
with,O
the,O
Diagnostic,O
and,O
Statistical,O
Manual,O
of,O
Mental,O
Disorders,O
-,O
IV,O
(,O
American,O
Psychiatric,O
Association,O
",",O
2013,O
).,O
Participants,O
also,O
completed,O
the,O
autism,B-DS
-,O
spectrum,O
quotient,O
(,O
AQ,O
),O
questionnaire,O
(,O
Baron,O
-,O
Cohen,O
et,O
al,O
".,",O
2001,O
"),",O
scoring,O
above,O
26,O
on,O
this,O
measure,O
(,O
M,O
=,O
29,O
.,O
17,O
",",O
SD,O
=,O
2,O
.,O
03,O
"),",O
as,O
clinically,O
accepted,O
in,O
Israel,O
(,O
Golan,O
et,O
al,O
".,",O
2009,O
;,O
Gold,O
et,O
al,O
".,",O
2010,O
).,O
The,O
TD,O
group,O
included,O
17,O
volunteers,O
that,O
were,O
recruited,O
from,O
two,O
different,O
regular,O
high,O
schools,O
and,O
one,O
college,O
from,O
central,O
Israel,O
.,O
To,O
be,O
included,O
in,O
the,O
study,O
all,O
participants,O
had,O
to,O
score,O
within,O
the,O
normal,O
age,O
-,O
appropriate,O
range,O
on,O
the,O
screening,O
tests,O
described,O
below,O
.,O
If,O
a,O
participant,O
scored,O
outside,O
this,O
range,O
he,O
or,O
she,O
did,O
not,O
continue,O
with,O
the,O
experimental,O
tasks,O
.,O
All,O
participants,O
signed,O
an,O
informed,O
consent,O
form,O
prior,O
to,O
the,O
research,O
session,O
.,O
MATERIALS,O
Screening,O
tests,O
All,O
participants,O
underwent,O
screening,O
tests,O
that,O
included,O
the,O
test,O
of,O
non,O
-,O
verbal,O
intelligence,O
(,O
TONI,O
-,O
3,O
;,O
Brown,O
et,O
al,O
".,",O
1997,O
"),",O
a,O
Hebrew,O
naming,O
test,O
(,O
Kavé,O
",",O
2005a,O
"),",O
and,O
the,O
vocabulary,O
sub,O
-,O
test,O
from,O
the,O
Wechsler,O
Adult,O
Intelligence,O
Scale,O
(,O
Wechsler,O
",",O
1997,O
).,O
As,O
can,O
be,O
seen,O
in,O
Table,O
1,O
",",O
the,O
groups,O
did,O
not,O
differ,O
in,O
TONI,O
or,O
naming,O
",",O
but,O
the,O
ASD,B-DS
group,O
performed,O
less,O
well,O
on,O
the,O
vocabulary,O
measure,O
.,O
Mean,O
correct,O
responses,O
(,O
and,O
SD,O
),O
on,O
screening,O
tests,O
",",O
by,O
group,O
.,O
ASD,B-DS
(,O
N,O
=,O
17,O
),O
TD,O
(,O
N,O
=,O
17,O
),O
Mean,O
SD,O
Mean,O
SD,O
t,O
TONI,O
-,O
3,O
38,O
.,O
8,O
4,O
.,O
13,O
40,O
.,O
71,O
1,O
.,O
89,O
1,O
.,O
652,O
Hebrew,O
naming,O
46,O
.,O
47,O
1,O
.,O
73,O
46,O
.,O
71,O
1,O
.,O
82,O
0,O
.,O
385,O
Vocabulary,O
48,O
.,O
18,O
6,O
.,O
46,O
55,O
.,O
82,O
3,O
.,O
34,O
4,O
.,O
334,O
**,O
Note,O
:,O
TONI,O
-,O
3,O
",",O
Brown,O
et,O
al,O
.,O
(,O
1997,O
"),",O
Hebrew,O
naming,O
test,O
",",O
Kavé,O
(,O
2005a,O
"),",O
Vocabulary,O
",",O
Wechsler,O
(,O
1997,O
).,O
Metaphor,O
comprehension,O
We,O
used,O
the,O
questionnaire,O
developed,O
by,O
Mashal,O
and,O
Kasirer,O
(,O
2011,O
),O
to,O
test,O
comprehension,O
of,O
conventional,O
metaphors,O
(,O
e,O
.,O
g,O
".,",O
sharp,O
tongue,O
),O
and,O
novel,O
metaphors,O
(,O
e,O
.,O
g,O
".,",O
pure,O
hand,O
).,O
For,O
each,O
metaphoric,O
expression,O
",",O
four,O
alternative,O
responses,O
were,O
offered,O
:,O
a,O
correct,O
metaphoric,O
interpretation,O
",",O
a,O
literal,O
interpretation,O
",",O
an,O
unrelated,O
interpretation,O
",",O
and,O
a,O
choice,O
saying,O
“,O
this,O
expression,O
is,O
meaningless,O
.”,O
Participants,O
were,O
instructed,O
to,O
choose,O
the,O
one,O
answer,O
they,O
thought,O
was,O
the,O
best,O
of,O
the,O
four,O
alternatives,O
.,O
The,O
questionnaire,O
consisted,O
of,O
20,O
items,O
and,O
scores,O
were,O
the,O
sum,O
of,O
all,O
correct,O
answers,O
.,O
Metaphor,O
generation,O
To,O
examine,O
generation,O
of,O
metaphors,O
we,O
constructed,O
a,O
questionnaire,O
that,O
contained,O
10,O
concepts,O
relating,O
to,O
common,O
emotions,O
(,O
e,O
.,O
g,O
".,",O
feeling,O
sad,O
).,O
Participants,O
were,O
asked,O
to,O
create,O
and,O
write,O
down,O
a,O
new,O
way,O
of,O
expressing,O
the,O
meaning,O
of,O
the,O
concept,O
.,O
Instructions,O
emphasized,O
originality,O
so,O
as,O
to,O
encourage,O
participants,O
to,O
create,O
a,O
new,O
expression,O
rather,O
than,O
simply,O
paraphrase,O
the,O
one,O
presented,O
in,O
the,O
questionnaire,O
.,O
Thus,O
",",O
participants,O
were,O
asked,O
“,O
to,O
create,O
and,O
write,O
down,O
a,O
new,O
expression,O
",",O
which,O
is,O
more,O
comprehensible,O
within,O
your,O
peer,O
group,O
than,O
outside,O
it,O
.”,O
We,O
selected,O
the,O
concepts,O
from,O
the,O
stimuli,O
used,O
by,O
Levorato,O
and,O
Cacciari,O
(,O
2002,O
),O
in,O
their,O
study,O
of,O
linguistic,O
creativity,O
.,O
A,O
preliminary,O
test,O
was,O
conducted,O
with,O
20,O
Hebrew,O
speaking,O
adults,O
(,O
age,O
range,O
18,O
–,O
25,O
),O
who,O
were,O
presented,O
with,O
concepts,O
and,O
asked,O
to,O
generate,O
new,O
expressions,O
.,O
Eight,O
concepts,O
were,O
presented,O
in,O
the,O
form,O
of,O
a,O
metaphor,O
(,O
e,O
.,O
g,O
".,",O
love,O
is____,O
),O
and,O
eight,O
concepts,O
were,O
presented,O
in,O
the,O
form,O
of,O
a,O
simile,O
(,O
e,O
.,O
g,O
".,",O
feeling,O
worthless,O
is,O
like____,O
).,O
The,O
aim,O
of,O
this,O
procedure,O
was,O
to,O
adjust,O
the,O
test,O
to,O
Hebrew,O
.,O
Three,O
metaphors,O
and,O
three,O
similes,O
did,O
not,O
produce,O
metaphoric,O
responses,O
and,O
were,O
thus,O
excluded,O
from,O
the,O
study,O
.,O
The,O
final,O
questionnaire,O
included,O
five,O
metaphors,O
and,O
five,O
similes,O
.,O
Two,O
judges,O
independently,O
coded,O
the,O
obtained,O
responses,O
.,O
They,O
were,O
asked,O
to,O
decide,O
whether,O
each,O
expression,O
was,O
literal,O
or,O
figurative,O
.,O
A,O
novel,O
metaphoric,O
response,O
(,O
e,O
.,O
g,O
".,",O
feeling,O
worthless,O
is,O
like,O
a,O
mirror,O
smashed,O
to,O
pieces,O
),O
received,O
three,O
points,O
",",O
a,O
conventional,O
metaphor,O
or,O
idiom,O
(,O
e,O
.,O
g,O
".,",O
feeling,O
embarrassed,O
is,O
like,O
having,O
a,O
red,O
face,O
),O
received,O
two,O
points,O
",",O
and,O
literal,O
responses,O
or,O
paraphrases,O
(,O
e,O
.,O
g,O
".,",O
feeling,O
successful,O
is,O
like,O
a,O
victory,O
),O
received,O
1,O
point,O
.,O
Unrelated,O
expressions,O
received,O
no,O
points,O
.,O
The,O
maximum,O
score,O
was,O
15,O
for,O
metaphors,O
and,O
15,O
for,O
similes,O
.,O
Scores,O
were,O
converted,O
to,O
percentages,O
.,O
Creativity,O
Creative,O
ability,O
was,O
measured,O
by,O
the,O
percent,O
of,O
responses,O
that,O
received,O
three,O
points,O
on,O
the,O
generation,O
test,O
out,O
of,O
the,O
10,O
items,O
.,O
Executive,O
functions,O
Executive,O
functions,O
were,O
assessed,O
by,O
the,O
Ambiguous,O
Word,O
Meaning,O
Generation,O
Test,O
(,O
Mashal,O
and,O
Kasirer,O
",",O
2011,O
"),",O
verbal,O
fluency,O
tests,O
(,O
Kavé,O
",",O
2005b,O
"),",O
and,O
the,O
Trail,O
Making,O
Test,O
(,O
Reitan,O
and,O
Davison,O
",",O
1974,O
).,O
Ambiguous,O
Word,O
Meaning,O
Generation,O
Test,O
.,O
This,O
test,O
investigates,O
the,O
ability,O
to,O
activate,O
different,O
meanings,O
of,O
ambiguous,O
words,O
and,O
then,O
shift,O
between,O
them,O
(,O
Mashal,O
and,O
Kasirer,O
",",O
2011,O
).,O
Participants,O
were,O
presented,O
with,O
a,O
list,O
of,O
20,O
short,O
unbiased,O
sentences,O
that,O
ended,O
with,O
ambiguous,O
words,O
(,O
e,O
.,O
g,O
".,",O
Look,O
at,O
this,O
bank,O
).,O
They,O
were,O
instructed,O
to,O
say,O
aloud,O
all,O
meanings,O
of,O
the,O
final,O
word,O
.,O
For,O
each,O
participant,O
",",O
we,O
counted,O
the,O
number,O
of,O
correct,O
answers,O
.,O
Phonemic,O
fluency,O
.,O
Following,O
Kavé,O
(,O
2005b,O
"),",O
phonemic,O
fluency,O
was,O
assessed,O
by,O
obtaining,O
the,O
number,O
of,O
words,O
generated,O
in,O
1,O
min,O
for,O
the,O
letters,O
bet,O
(,O
b,O
"),",O
gimel,O
(,O
g,O
"),",O
and,O
shin,O
(,O
sh,O
).,O
We,O
used,O
a,O
sum,O
score,O
of,O
all,O
words,O
produced,O
on,O
the,O
three,O
letters,O
.,O
Semantic,O
fluency,O
.,O
Following,O
Kavé,O
(,O
2005b,O
"),",O
semantic,O
fluency,O
was,O
assessed,O
by,O
obtaining,O
the,O
number,O
of,O
words,O
generated,O
in,O
1,O
min,O
for,O
each,O
of,O
the,O
following,O
three,O
semantic,O
categories,O
:,O
animals,B-OG
",",O
fruits,O
and,O
vegetables,O
",",O
and,O
vehicles,O
.,O
We,O
used,O
a,O
sum,O
score,O
of,O
all,O
words,O
produced,O
on,O
the,O
three,O
categories,O
.,O
The,O
Trail,O
Making,O
test,O
.,O
This,O
test,O
consists,O
of,O
two,O
parts,O
",",O
A,O
and,O
B,O
",",O
requiring,O
participants,O
to,O
connect,O
a,O
series,O
of,O
digits,O
placed,O
in,O
random,O
order,O
on,O
a,O
sheet,O
of,O
paper,O
in,O
ascending,O
order,O
(,O
TMT,O
A,O
"),",O
and,O
to,O
connect,O
a,O
series,O
of,O
numbers,O
and,O
letters,O
in,O
ascending,O
order,O
while,O
alternating,O
between,O
numbers,O
and,O
letters,O
(,O
TMT,O
B,O
),O
(,O
Reitan,O
and,O
Davison,O
",",O
1974,O
).,O
Scores,O
were,O
based,O
on,O
time,O
to,O
complete,O
each,O
task,O
.,O
PROCEDURE,O
Participants,O
were,O
tested,O
individually,O
in,O
schools,O
or,O
in,O
their,O
homes,O
.,O
Screening,O
tests,O
were,O
administered,O
on,O
a,O
separate,O
initial,O
session,O
.,O
On,O
a,O
second,O
session,O
",",O
half,O
of,O
the,O
participants,O
were,O
tested,O
on,O
the,O
executive,O
functioning,O
tasks,O
and,O
then,O
on,O
the,O
metaphor,O
comprehension,O
and,O
generation,O
tasks,O
.,O
The,O
rest,O
of,O
the,O
participants,O
were,O
tested,O
in,O
the,O
reverse,O
order,O
.,O
RESULTS,O
METAPHOR,O
COMPREHENSION,O
To,O
examine,O
performance,O
on,O
the,O
comprehension,O
questionnaire,O
",",O
a,O
2,O
×,O
2,O
repeated,O
measures,O
ANOVA,O
was,O
conducted,O
",",O
with,O
group,O
(,O
ASD,B-DS
",",O
TD,O
),O
as,O
the,O
between,O
-,O
subject,O
variable,O
and,O
type,O
of,O
metaphor,O
expression,O
(,O
conventional,O
",",O
novel,O
),O
as,O
the,O
within,O
-,O
subject,O
variable,O
.,O
No,O
main,O
effect,O
of,O
group,O
was,O
found,O
",",O
F,O
(,O
1,O
",",O
32,O
),O
=,O
0,O
.,O
979,O
",",O
ns,O
",",O
η2,O
=,O
0,O
.,O
030,O
(,O
see,O
Table,O
2,O
).,O
The,O
main,O
effect,O
of,O
metaphor,O
expression,O
was,O
significant,O
",",O
F,O
(,O
1,O
",",O
32,O
),O
=,O
5,O
.,O
725,O
",",O
p,O
<,O
0,O
.,O
05,O
",",O
η2,O
=,O
0,O
.,O
152,O
",",O
with,O
better,O
performance,O
on,O
conventional,O
metaphors,O
(,O
M,O
=,O
93,O
.,O
53,O
"%,",O
SD,O
=,O
11,O
.,O
25,O
),O
relative,O
to,O
novel,O
metaphors,O
(,O
M,O
=,O
84,O
.,O
12,O
"%,",O
SD,O
=,O
20,O
.,O
91,O
).,O
There,O
was,O
no,O
significant,O
interaction,O
between,O
group,O
and,O
type,O
of,O
expression,O
",",O
F,O
(,O
1,O
",",O
32,O
),O
=,O
1,O
.,O
811,O
",",O
ns,O
",",O
η2,O
(,O
see,O
Figure,O
1,O
).,O
Mean,O
correct,O
responses,O
(,O
and,O
SD,O
),O
on,O
the,O
comprehension,O
questionnaire,O
",",O
by,O
type,O
of,O
metaphor,O
expression,O
and,O
group,O
.,O
TD,O
ASD,B-DS
Mean,O
SD,O
Mean,O
SD,O
Conventional,O
88,O
.,O
82,O
%,O
14,O
.,O
09,O
98,O
.,O
24,O
%,O
3,O
.,O
93,O
Novel,O
84,O
.,O
71,O
%,O
18,O
.,O
41,O
83,O
.,O
53,O
%,O
23,O
.,O
70,O
Percent,O
of,O
correct,O
responses,O
on,O
the,O
metaphor,O
comprehension,O
questionnaire,O
",",O
by,O
group,O
.,O
EFFECTS,O
OF,O
VOCABULARY,O
ON,O
COMPREHENSION,O
TEST,O
SCORES,O
Since,O
vocabulary,O
scores,O
were,O
significantly,O
lower,O
in,O
the,O
ASD,B-DS
group,O
than,O
in,O
the,O
TD,O
group,O
",",O
we,O
examined,O
the,O
effects,O
of,O
vocabulary,O
knowledge,O
on,O
performance,O
.,O
Vocabulary,O
scores,O
were,O
significantly,O
and,O
positively,O
correlated,O
with,O
comprehension,O
of,O
conventional,O
metaphors,O
",",O
r,O
(,O
32,O
),O
=,O
0,O
.,O
587,O
",",O
p,O
<,O
0,O
.,O
001,O
.,O
There,O
was,O
no,O
significant,O
correlation,O
between,O
vocabulary,O
scores,O
and,O
comprehension,O
of,O
novel,O
metaphors,O
",",O
or,O
between,O
vocabulary,O
scores,O
and,O
generation,O
of,O
either,O
simile,O
or,O
metaphors,O
.,O
Because,O
vocabulary,O
scores,O
were,O
found,O
to,O
be,O
significantly,O
correlated,O
only,O
with,O
comprehension,O
of,O
conventional,O
metaphors,O
",",O
we,O
used,O
vocabulary,O
as,O
a,O
covariate,O
in,O
a,O
further,O
analysis,O
of,O
group,O
effects,O
on,O
this,O
measure,O
.,O
When,O
vocabulary,O
was,O
held,O
constant,O
",",O
the,O
effect,O
of,O
group,O
remained,O
non,O
-,O
significant,O
",",O
F,O
(,O
1,O
",",O
31,O
),O
=,O
0,O
.,O
35,O
",",O
p,O
=,O
0,O
.,O
56,O
",",O
η2,O
=,O
0,O
.,O
01,O
.,O
METAPHOR,O
GENERATION,O
To,O
examine,O
performance,O
on,O
the,O
generation,O
questionnaire,O
",",O
a,O
2,O
×,O
2,O
repeated,O
measures,O
ANOVA,O
was,O
conducted,O
",",O
with,O
group,O
(,O
ASD,B-DS
",",O
TD,O
),O
as,O
the,O
between,O
-,O
subject,O
factor,O
and,O
linguistic,O
constraint,O
(,O
metaphor,O
",",O
simile,O
),O
as,O
the,O
within,O
-,O
subject,O
variable,O
.,O
No,O
main,O
effect,O
of,O
group,O
was,O
found,O
",",O
F,O
(,O
1,O
",",O
32,O
),O
=,O
3,O
.,O
633,O
",",O
ns,O
",",O
η2,O
=,O
0,O
.,O
102,O
(,O
see,O
Table,O
3,O
).,O
The,O
main,O
effect,O
of,O
linguistic,O
constraint,O
was,O
significant,O
",",O
F,O
(,O
1,O
",",O
32,O
),O
=,O
30,O
.,O
460,O
",",O
p,O
<,O
0,O
.,O
001,O
",",O
η2,O
=,O
0,O
.,O
488,O
",",O
with,O
worse,O
performance,O
on,O
metaphors,O
(,O
M,O
=,O
38,O
.,O
43,O
"%,",O
SD,O
=,O
28,O
.,O
00,O
),O
than,O
on,O
similes,O
(,O
M,O
=,O
61,O
.,O
96,O
"%,",O
SD,O
=,O
25,O
.,O
08,O
).,O
There,O
was,O
also,O
a,O
significant,O
interaction,O
between,O
group,O
and,O
",",O
F,O
(,O
1,O
",",O
32,O
),O
=,O
5,O
.,O
288,O
",",O
p,O
<,O
0,O
.,O
05,O
",",O
η2,O
=,O
0,O
.,O
142,O
.,O
A,O
post,O
hoc,O
analysis,O
revealed,O
that,O
the,O
source,O
of,O
the,O
interaction,O
was,O
in,O
greater,O
metaphor,O
generation,O
in,O
the,O
ASD,B-DS
relative,O
to,O
the,O
TD,O
group,O
(,O
p,O
<,O
0,O
.,O
05,O
).,O
No,O
significant,O
group,O
difference,O
was,O
found,O
for,O
simile,O
generation,O
(,O
p,O
=,O
0,O
.,O
59,O
),O
(,O
see,O
Figure,O
2,O
).,O
Mean,O
correct,O
responses,O
(,O
and,O
SD,O
),O
on,O
the,O
generation,O
questionnaire,O
",",O
by,O
stimuli,O
and,O
group,O
.,O
ASD,B-DS
TD,O
Mean,O
SD,O
Mean,O
SD,O
Metaphor,O
50,O
.,O
59,O
%,O
31,O
.,O
89,O
26,O
.,O
27,O
%,O
16,O
.,O
91,O
Simile,O
64,O
.,O
31,O
%,O
27,O
.,O
58,O
59,O
.,O
61,O
%,O
22,O
.,O
91,O
Percent,O
of,O
correct,O
responses,O
on,O
the,O
generation,O
questionnaire,O
.,O
CREATIVITY,O
A,O
t,O
-,O
test,O
for,O
independent,O
samples,O
revealed,O
a,O
significantly,O
greater,O
percent,O
of,O
original,O
responses,O
(,O
receiving,O
a,O
score,O
of,O
3,O
),O
within,O
the,O
ASD,B-DS
group,O
(,O
M,O
=,O
37,O
.,O
06,O
"%,",O
SD,O
=,O
31,O
.,O
38,O
),O
than,O
within,O
the,O
TD,O
group,O
(,O
M,O
=,O
19,O
.,O
41,O
"%,",O
SD,O
=,O
11,O
.,O
97,O
"),",O
t,O
(,O
32,O
),O
=,O
-,O
2,O
.,O
166,O
",",O
p,O
<,O
0,O
.,O
05,O
(,O
see,O
Figure,O
3,O
).,O
Percent,O
of,O
original,O
responses,O
on,O
the,O
generation,O
questionnaire,O
",",O
by,O
group,O
.,O
Next,O
we,O
compared,O
group,O
performance,O
on,O
the,O
five,O
measures,O
of,O
executive,O
functions,O
with,O
independent,O
-,O
samples,O
t,O
-,O
tests,O
.,O
These,O
analyses,O
revealed,O
significant,O
group,O
differences,O
on,O
all,O
measures,O
",",O
with,O
worse,O
performance,O
in,O
the,O
ASD,B-DS
group,O
(,O
see,O
Table,O
4,O
).,O
Mean,O
correct,O
responses,O
(,O
and,O
SD,O
),O
on,O
measures,O
of,O
executive,O
functions,O
",",O
by,O
group,O
.,O
ASD,B-DS
TD,O
Mean,O
SD,O
Mean,O
SD,O
t,O
AMGT,O
16,O
.,O
88,O
4,O
.,O
04,O
19,O
.,O
47,O
0,O
.,O
80,O
2,O
.,O
588,O
*,O
Phonemic,O
fluency,O
28,O
.,O
47,O
11,O
.,O
11,O
39,O
.,O
47,O
9,O
.,O
07,O
3,O
.,O
162,O
**,O
Semantic,O
fluency,O
44,O
.,O
71,O
12,O
.,O
59,O
57,O
.,O
53,O
8,O
.,O
88,O
3,O
.,O
429,O
**,O
TMT,O
-,O
A,O
43,O
.,O
88,O
18,O
.,O
48,O
30,O
.,O
06,O
9,O
.,O
02,O
-,O
2,O
.,O
771,O
**,O
TMT,O
-,O
B,O
76,O
.,O
94,O
30,O
.,O
96,O
59,O
.,O
00,O
16,O
.,O
01,O
-,O
2,O
.,O
122,O
*,O
Note,O
:,O
AMGT,O
Ambiguous,O
Words,O
Meaning,O
Generation,O
Test,O
;,O
TMT,O
Trail,O
Making,O
.,O
PREDICTION,O
OF,O
METAPHOR,O
SCORES,O
BY,O
BACKGROUND,O
TEST,O
SCORES,O
To,O
examine,O
which,O
test,O
predicts,O
comprehension,O
and,O
generation,O
of,O
metaphors,O
",",O
we,O
used,O
a,O
set,O
of,O
four,O
hierarchical,O
and,O
stepwise,O
regression,O
analyses,O
.,O
Predictors,O
included,O
scores,O
on,O
the,O
screening,O
tests,O
(,O
TONI,O
",",O
naming,O
",",O
and,O
vocabulary,O
),O
as,O
well,O
as,O
scores,O
on,O
the,O
tests,O
of,O
executive,O
functions,O
(,O
AMGT,O
",",O
fluency,O
",",O
and,O
TMT,O
).,O
For,O
the,O
comprehension,O
test,O
",",O
we,O
conducted,O
one,O
analysis,O
with,O
conventional,O
metaphors,O
as,O
the,O
predicted,O
variable,O
and,O
one,O
analysis,O
with,O
novel,O
metaphors,O
as,O
the,O
predicted,O
variable,O
.,O
Similarly,O
",",O
for,O
the,O
generation,O
task,O
we,O
conducted,O
one,O
analysis,O
for,O
metaphors,O
and,O
one,O
analysis,O
for,O
similes,O
.,O
In,O
each,O
regression,O
we,O
first,O
entered,O
the,O
group,O
variable,O
(,O
ASD,B-DS
",",O
TD,O
"),",O
and,O
then,O
we,O
entered,O
scores,O
on,O
the,O
three,O
screening,O
tests,O
and,O
the,O
five,O
measures,O
of,O
executive,O
functioning,O
in,O
a,O
stepwise,O
manner,O
.,O
Results,O
of,O
these,O
regression,O
analyses,O
are,O
presented,O
in,O
Table,O
5,O
.,O
The,O
order,O
of,O
the,O
variables,O
presents,O
the,O
order,O
of,O
significance,O
.,O
As,O
can,O
be,O
seen,O
in,O
the,O
table,O
",",O
performance,O
on,O
both,O
the,O
screening,O
tests,O
and,O
the,O
tests,O
of,O
executive,O
functions,O
explained,O
a,O
significant,O
share,O
of,O
the,O
variance,O
across,O
study,O
groups,O
in,O
all,O
four,O
analyses,O
but,O
each,O
dependent,O
variable,O
was,O
predicted,O
by,O
different,O
scores,O
.,O
Summary,O
of,O
regression,O
analyses,O
predicting,O
comprehension,O
and,O
generation,O
by,O
screening,O
tests,O
and,O
measures,O
of,O
executive,O
functions,O
across,O
groups,O
.,O
Predictor,O
variable,O
B,O
SE,O
B,O
β,O
R2,O
ΔR2,O
t,O
Comprehension,O
Conventional,O
metaphors,O
Group,O
-,O
2,O
.,O
98,O
3,O
.,O
84,O
-,O
0,O
.,O
13,O
0,O
.,O
18,O
*,O
0,O
.,O
18,O
*,O
-,O
0,O
.,O
77,O
Vocabulary,O
0,O
.,O
78,O
0,O
.,O
32,O
0,O
.,O
44,O
0,O
.,O
35,O
***,O
0,O
.,O
17,O
**,O
2,O
.,O
51,O
*,O
Naming,O
1,O
.,O
90,O
0,O
.,O
90,O
0,O
.,O
30,O
0,O
.,O
43,O
***,O
0,O
.,O
08,O
*,O
2,O
.,O
11,O
*,O
Novel,O
metaphors,O
Group,O
8,O
.,O
39,O
6,O
.,O
98,O
0,O
.,O
20,O
0,O
.,O
00,O
0,O
.,O
00,O
1,O
.,O
20,O
TMT,O
-,O
B,O
-,O
0,O
.,O
40,O
0,O
.,O
14,O
-,O
0,O
.,O
50,O
0,O
.,O
22,O
*,O
22,O
.,O
0,O
**,O
-,O
2,O
.,O
94,O
**,O
Generation,O
Metaphor,O
Group,O
30,O
.,O
00,O
8,O
.,O
52,O
0,O
.,O
54,O
0,O
.,O
19,O
**,O
0,O
.,O
19,O
**,O
3,O
.,O
52,O
***,O
TONI,O
-,O
3,O
3,O
.,O
12,O
1,O
.,O
31,O
0,O
.,O
37,O
0,O
.,O
32,O
**,O
0,O
.,O
13,O
*,O
2,O
.,O
38,O
*,O
Simile,O
Group,O
12,O
.,O
41,O
7,O
.,O
77,O
0,O
.,O
25,O
0,O
.,O
01,O
0,O
.,O
01,O
1,O
.,O
60,O
TONI,O
-,O
3,O
4,O
.,O
23,O
1,O
.,O
19,O
0,O
.,O
56,O
0,O
.,O
29,O
**,O
0,O
.,O
28,O
***,O
3,O
.,O
54,O
***,O
Comprehension,O
of,O
conventional,O
metaphors,O
was,O
best,O
predicted,O
by,O
vocabulary,O
and,O
picture,O
naming,O
",",O
F,O
(,O
3,O
",",O
30,O
),O
=,O
7,O
.,O
71,O
",",O
p,O
<,O
0,O
.,O
001,O
",",O
which,O
accounted,O
for,O
43,O
.,O
5,O
%,O
of,O
the,O
variance,O
.,O
Comprehension,O
of,O
novel,O
metaphors,O
was,O
best,O
predicted,O
by,O
TMT,O
-,O
B,O
",",O
F,O
(,O
2,O
",",O
31,O
),O
=,O
4,O
.,O
34,O
",",O
p,O
<,O
0,O
.,O
05,O
",",O
which,O
accounted,O
for,O
21,O
.,O
9,O
%,O
of,O
the,O
variance,O
.,O
Generation,O
of,O
metaphors,O
was,O
best,O
predicted,O
by,O
TONI,O
-,O
3,O
",",O
F,O
(,O
2,O
",",O
31,O
),O
=,O
7,O
.,O
25,O
",",O
p,O
<,O
0,O
.,O
01,O
",",O
which,O
accounted,O
for,O
31,O
.,O
9,O
%,O
of,O
the,O
variance,O
",",O
and,O
so,O
was,O
the,O
generation,O
of,O
simile,O
",",O
F,O
(,O
2,O
",",O
31,O
),O
=,O
6,O
.,O
46,O
",",O
p,O
<,O
0,O
.,O
01,O
",",O
in,O
which,O
the,O
TONI,O
-,O
3,O
score,O
accounted,O
for,O
29,O
.,O
4,O
%,O
of,O
the,O
variance,O
.,O
Group,O
differences,O
predicted,O
metaphor,O
generation,O
with,O
a,O
positive,O
beta,O
coefficient,O
",",O
indicating,O
that,O
participants,O
with,O
ASD,B-DS
had,O
higher,O
scores,O
on,O
this,O
test,O
than,O
did,O
TD,O
participants,O
.,O
DISCUSSION,O
The,O
present,O
study,O
examined,O
metaphor,O
processing,O
in,O
adults,O
with,O
ASD,B-DS
",",O
differentiating,O
between,O
conventional,O
and,O
novel,O
metaphors,O
on,O
tests,O
of,O
comprehension,O
and,O
generation,O
.,O
Our,O
results,O
show,O
that,O
adults,O
with,O
ASD,B-DS
demonstrate,O
no,O
difficulties,O
in,O
comprehension,O
of,O
conventional,O
and,O
novel,O
metaphors,O
.,O
Furthermore,O
",",O
adults,O
with,O
ASD,B-DS
outperformed,O
age,O
-,O
matched,O
TD,O
peers,O
in,O
metaphor,O
generation,O
.,O
An,O
inspection,O
of,O
the,O
type,O
of,O
metaphors,O
generated,O
indicated,O
that,O
the,O
ASD,B-DS
group,O
produced,O
more,O
original,O
and,O
creative,O
metaphors,O
than,O
did,O
the,O
TD,O
group,O
.,O
Whereas,O
previous,O
studies,O
highlighted,O
difficulties,O
with,O
metaphoric,O
language,O
comprehension,O
in,O
ASD,B-DS
(,O
e,O
.,O
g,O
".,",O
Happé,O
",",O
1993,O
",",O
1995,O
;,O
Ozonoff,O
and,O
Miller,O
",",O
1996,O
;,O
Rundblad,O
and,O
Annaz,O
",",O
2010,O
;,O
Kaland,O
et,O
al,O
".,",O
2011,O
;,O
Mashal,O
and,O
Kasirer,O
",",O
2011,O
"),",O
the,O
current,O
research,O
shows,O
similar,O
comprehension,O
of,O
metaphors,O
among,O
ASD,B-DS
and,O
age,O
-,O
matched,O
TD,O
peers,O
.,O
One,O
of,O
the,O
differences,O
between,O
our,O
study,O
and,O
earlier,O
studies,O
might,O
be,O
that,O
we,O
examined,O
adults,O
",",O
unlike,O
previous,O
studies,O
that,O
focused,O
primarily,O
on,O
children,O
and,O
adolescents,O
.,O
It,O
is,O
possible,O
that,O
the,O
accumulated,O
verbal,O
knowledge,O
that,O
comes,O
with,O
age,O
leads,O
to,O
greater,O
familiarity,O
with,O
conventional,O
metaphors,O
within,O
the,O
ASD,B-DS
group,O
.,O
Indeed,O
",",O
previous,O
studies,O
have,O
emphasized,O
the,O
contribution,O
of,O
vocabulary,O
to,O
the,O
comprehension,O
of,O
metaphors,O
(,O
Evans,O
and,O
Gamble,O
",",O
1988,O
;,O
Nippold,O
",",O
1998,O
;,O
Chiappe,O
and,O
Chiappe,O
",",O
2007,O
;,O
Silvia,O
and,O
Beaty,O
",",O
2013,O
).,O
Consistent,O
with,O
this,O
observation,O
",",O
we,O
found,O
that,O
higher,O
vocabulary,O
scores,O
were,O
correlated,O
with,O
better,O
comprehension,O
of,O
conventional,O
metaphors,O
(,O
but,O
not,O
with,O
comprehension,O
of,O
novel,O
metaphors,O
).,O
The,O
fact,O
that,O
we,O
found,O
equivalent,O
comprehension,O
across,O
groups,O
might,O
also,O
be,O
related,O
to,O
the,O
task,O
that,O
we,O
used,O
.,O
It,O
is,O
possible,O
that,O
presenting,O
metaphors,O
in,O
a,O
multiple,O
-,O
choice,O
questionnaire,O
facilitated,O
comprehension,O
and,O
was,O
easier,O
than,O
were,O
previously,O
used,O
tasks,O
",",O
such,O
as,O
asking,O
comprehension,O
questions,O
about,O
metaphoric,O
stories,O
(,O
Rundblad,O
and,O
Annaz,O
",",O
2010,O
"),",O
requiring,O
sentence,O
completion,O
(,O
Norbury,O
",",O
2005,O
"),",O
or,O
having,O
participants,O
perform,O
a,O
semantic,O
judgment,O
task,O
(,O
Hermann,O
et,O
al,O
".,",O
2013,O
).,O
As,O
expected,O
",",O
and,O
in,O
line,O
with,O
previous,O
studies,O
(,O
Mashal,O
and,O
Kasirer,O
",",O
2011,O
;,O
Melogno,O
et,O
al,O
".,",O
2012,O
;,O
Hermann,O
et,O
al,O
".,",O
2013,O
"),",O
no,O
difference,O
was,O
found,O
between,O
participants,O
with,O
ASD,B-DS
and,O
TD,O
age,O
-,O
matched,O
peers,O
in,O
comprehension,O
of,O
novel,O
metaphors,O
.,O
Novel,O
metaphor,O
interpretation,O
is,O
not,O
coded,O
in,O
the,O
mental,O
lexicon,O
and,O
hence,O
is,O
not,O
dependent,O
on,O
previous,O
knowledge,O
.,O
Indeed,O
",",O
unlike,O
the,O
correlation,O
between,O
vocabulary,O
and,O
comprehension,O
of,O
conventional,O
metaphors,O
",",O
no,O
association,O
was,O
found,O
between,O
vocabulary,O
and,O
comprehension,O
of,O
novel,O
metaphors,O
.,O
The,O
ability,O
to,O
understand,O
novel,O
semantic,O
connections,O
between,O
seemingly,O
unrelated,O
concepts,O
appears,O
to,O
be,O
intact,O
in,O
ASD,B-DS
",",O
probably,O
because,O
it,O
does,O
not,O
rely,O
on,O
activation,O
of,O
lexicalized,O
expressions,O
.,O
Consistent,O
with,O
this,O
finding,O
",",O
Melogno,O
et,O
al,O
.,O
(,O
2012,O
),O
emphasized,O
that,O
individuals,O
with,O
ASD,B-DS
can,O
explain,O
novel,O
metaphoric,O
phrases,O
in,O
unique,O
ways,O
that,O
rely,O
on,O
phonological,O
or,O
semantic,O
association,O
.,O
Thus,O
",",O
comprehension,O
of,O
novel,O
metaphor,O
is,O
intact,O
in,O
ASD,B-DS
because,O
it,O
relies,O
on,O
good,O
associative,O
abilities,O
rather,O
than,O
on,O
lexicalized,O
verbal,O
knowledge,O
.,O
Another,O
finding,O
of,O
the,O
current,O
study,O
is,O
that,O
contrary,O
to,O
our,O
hypothesis,O
",",O
participants,O
with,O
ASD,B-DS
generated,O
more,O
metaphors,O
than,O
did,O
age,O
-,O
matched,O
peers,O
.,O
We,O
were,O
specifically,O
interested,O
in,O
testing,O
whether,O
adults,O
with,O
ASD,B-DS
relied,O
on,O
previous,O
knowledge,O
",",O
and,O
were,O
thus,O
using,O
familiar,O
metaphors,O
or,O
idioms,O
",",O
or,O
alternatively,O
",",O
whether,O
they,O
generated,O
their,O
own,O
novel,O
and,O
original,O
metaphors,O
.,O
We,O
found,O
that,O
adults,O
with,O
ASD,B-DS
demonstrated,O
greater,O
verbal,O
creativity,O
than,O
did,O
TD,O
individuals,O
.,O
Examples,O
of,O
creative,O
sentence,O
completions,O
included,O
phrases,O
such,O
as,O
“,O
Feeling,O
successful,O
is,O
like,O
seeing,O
the,O
view,O
from,O
the,O
mountaintop,O
”,O
and,O
“,O
Feeling,O
worthless,O
is,O
like,O
offering,O
a,O
salad,O
to,O
South,O
Americans,O
.”,O
These,O
examples,O
contrasted,O
with,O
more,O
conventional,O
figurative,O
expressions,O
provided,O
by,O
TD,O
adults,O
",",O
such,O
as,O
“,O
Feeling,O
sad,O
is,O
to,O
get,O
the,O
blues,O
.”,O
Our,O
results,O
suggest,O
that,O
adults,O
with,O
ASD,B-DS
can,O
create,O
unique,O
verbal,O
associations,O
that,O
are,O
not,O
restricted,O
to,O
previous,O
knowledge,O
",",O
thus,O
pointing,O
to,O
unique,O
verbal,O
creativity,O
in,O
ASD,B-DS
.,O
It,O
has,O
been,O
reported,O
that,O
one,O
in,O
ten,O
people,O
with,O
autism,B-DS
shows,O
some,O
savant,O
skills,O
in,O
such,O
categories,O
as,O
music,O
",",O
art,O
",",O
calendar,O
calculations,O
",",O
or,O
mathematics,O
(,O
Treffert,O
",",O
2009,O
).,O
Yet,O
",",O
most,O
studies,O
have,O
indicated,O
impoverished,O
creativity,O
in,O
autism,B-DS
.,O
For,O
example,O
",",O
in,O
standardized,O
tests,O
such,O
as,O
the,O
Torrance,O
Creativity,O
Test,O
(,O
Torrance,O
",",O
1974,O
"),",O
people,O
with,O
ASD,B-DS
demonstrate,O
difficulties,O
in,O
cognitive,O
flexibility,O
and,O
imaginative,O
fluency,O
",",O
as,O
well,O
as,O
lack,O
of,O
imagination,O
and,O
originality,O
compared,O
to,O
TD,O
participants,O
(,O
Craig,O
and,O
Baron,O
-,O
Cohen,O
",",O
1999,O
).,O
Why,O
",",O
then,O
",",O
do,O
adults,O
with,O
ASD,B-DS
demonstrate,O
greater,O
creativity,O
in,O
metaphor,O
generation,O
when,O
previous,O
studies,O
found,O
that,O
they,O
were,O
lacking,O
in,O
imagination,O
?,O
Baron,O
-,O
Cohen,O
et,O
al,O
.,O
(,O
2009,O
),O
suggest,O
that,O
the,O
hypersensitivity,O
that,O
characterizes,O
autism,B-DS
gives,O
rise,O
to,O
excellent,O
attention,O
to,O
details,O
.,O
With,O
respect,O
to,O
verbal,O
creativity,O
",",O
this,O
attention,O
to,O
details,O
is,O
associated,O
with,O
weak,O
central,O
coherence,O
",",O
leading,O
to,O
greater,O
appreciation,O
of,O
local,O
features,O
over,O
global,O
ones,O
.,O
Lyons,O
and,O
Fitzgerald,O
(,O
2005,O
),O
emphasized,O
that,O
in,O
contrast,O
to,O
their,O
social,O
impairments,O
individuals,O
with,O
Asperger,B-DS
syndrome,I-DS
are,O
gifted,O
with,O
creativity,O
and,O
originality,O
",",O
excellent,O
memory,O
",",O
strong,O
focus,O
of,O
attention,O
and,O
specific,O
cognitive,O
styles,O
.,O
The,O
unique,O
verbal,O
associations,O
generated,O
by,O
the,O
ASD,B-DS
group,O
in,O
the,O
current,O
study,O
could,O
thus,O
reflect,O
memory,O
for,O
details,O
and,O
weak,O
central,O
coherence,O
.,O
Another,O
reason,O
why,O
adults,O
with,O
ASD,B-DS
generated,O
more,O
original,O
metaphors,O
might,O
relate,O
to,O
difficulty,O
in,O
theory,O
of,O
mind,O
.,O
Mind,O
-,O
blindness,O
makes,O
one,O
focus,O
on,O
one,O
’,O
s,O
own,O
thoughts,O
",",O
ignoring,O
the,O
addressee,O
(,O
Happé,O
and,O
Vital,O
",",O
2009,O
"),",O
possibly,O
leading,O
to,O
production,O
of,O
expressions,O
that,O
are,O
less,O
conventional,O
(,O
Liu,O
et,O
al,O
".,",O
2011,O
).,O
Kanner,O
(,O
1946,O
),O
was,O
the,O
first,O
to,O
note,O
that,O
the,O
unique,O
phrases,O
produced,O
by,O
the,O
children,O
he,O
studied,O
could,O
be,O
interpreted,O
as,O
metaphoric,O
language,O
.,O
Asperger,O
(,O
1941,O
),O
also,O
identified,O
certain,O
expressions,O
in,O
the,O
speech,O
of,O
his,O
patients,O
that,O
resembled,O
the,O
novel,O
linguistic,O
forms,O
produced,O
by,O
young,O
TD,O
children,O
.,O
Asperger,O
proposed,O
that,O
characteristics,O
such,O
as,O
concrete,O
intelligence,O
and,O
disregard,O
of,O
social,O
conventions,O
might,O
be,O
prerequisites,O
for,O
certain,O
forms,O
of,O
new,O
thinking,O
and,O
creativity,O
(,O
Gillberg,O
",",O
2002,O
).,O
Fitzgerald,O
(,O
2004,O
),O
also,O
noted,O
that,O
individuals,O
with,O
Asperger,B-DS
syndrome,I-DS
have,O
remarkable,O
capacities,O
for,O
persistence,O
and,O
observation,O
",",O
high,O
levels,O
of,O
energy,O
and,O
motivation,O
",",O
and,O
abilities,O
to,O
focus,O
intensely,O
on,O
a,O
single,O
topic,O
.,O
It,O
appears,O
that,O
some,O
individuals,O
with,O
autism,B-DS
and,O
Asperger,B-DS
syndrome,I-DS
are,O
highly,O
creative,O
",",O
imaginative,O
and,O
original,O
and,O
even,O
their,O
humor,O
can,O
range,O
from,O
word,O
-,O
play,O
and,O
sound,O
associations,O
to,O
precisely,O
formulated,O
",",O
truly,O
witty,O
comments,O
.,O
According,O
to,O
Lyons,O
and,O
Fitzgerald,O
(,O
2004,O
),O
some,O
individuals,O
with,O
autism,B-DS
and,O
Asperger,B-DS
syndrome,I-DS
also,O
seem,O
to,O
master,O
the,O
cognitive,O
processing,O
of,O
humor,O
",",O
i,O
.,O
e,O
".,",O
incongruity,O
and,O
its,O
resolution,O
and,O
switching,O
of,O
meanings,O
as,O
portrayed,O
by,O
the,O
production,O
of,O
relatively,O
sophisticated,O
puns,O
and,O
word,O
games,O
.,O
In,O
our,O
final,O
analysis,O
we,O
sought,O
to,O
identify,O
the,O
extent,O
to,O
which,O
executive,O
functions,O
as,O
well,O
as,O
verbal,O
and,O
non,O
-,O
verbal,O
skills,O
contribute,O
to,O
the,O
prediction,O
of,O
metaphor,O
comprehension,O
and,O
generation,O
.,O
We,O
found,O
that,O
while,O
verbal,O
abilities,O
",",O
i,O
.,O
e,O
".,",O
vocabulary,O
and,O
picture,O
naming,O
",",O
contribute,O
to,O
the,O
comprehension,O
of,O
conventional,O
metaphors,O
",",O
this,O
is,O
not,O
the,O
case,O
with,O
regard,O
to,O
novel,O
metaphors,O
",",O
in,O
line,O
with,O
previous,O
studies,O
(,O
e,O
.,O
g,O
".,",O
Nippold,O
",",O
1998,O
;,O
Chiappe,O
and,O
Chiappe,O
",",O
2007,O
;,O
Silvia,O
and,O
Beaty,O
",",O
2013,O
).,O
Furthermore,O
",",O
executive,O
functions,O
were,O
shown,O
to,O
predict,O
novel,O
metaphor,O
comprehension,O
",",O
as,O
has,O
been,O
previously,O
reported,O
(,O
Pennington,O
and,O
Ozonoff,O
",",O
1996,O
;,O
Amanzio,O
et,O
al,O
".,",O
2008,O
;,O
Mashal,O
and,O
Kasirer,O
",",O
2011,O
;,O
Mashal,O
",",O
2013,O
).,O
More,O
specifically,O
",",O
the,O
TMT,O
-,O
B,O
",",O
which,O
demands,O
mental,O
flexibility,O
",",O
contributed,O
to,O
the,O
prediction,O
of,O
novel,O
metaphor,O
comprehension,O
.,O
We,O
believe,O
that,O
comprehension,O
of,O
novel,O
metaphors,O
relies,O
on,O
flexibility,O
because,O
it,O
is,O
based,O
on,O
a,O
shift,O
between,O
the,O
literal,O
and,O
the,O
metaphoric,O
meanings,O
of,O
the,O
words,O
that,O
appear,O
in,O
the,O
new,O
expression,O
.,O
Champagne,O
-,O
Lavau,O
and,O
Stip,O
(,O
2010,O
),O
also,O
found,O
this,O
correlation,O
between,O
the,O
TMT,O
-,O
B,O
and,O
metaphor,O
comprehension,O
in,O
schizophrenic,O
and,O
TD,O
adults,O
.,O
Finally,O
",",O
metaphor,O
generation,O
was,O
predicted,O
by,O
non,O
-,O
verbal,O
cognitive,O
ability,O
.,O
Indeed,O
",",O
Silvia,O
and,O
Beaty,O
(,O
2012,O
),O
have,O
also,O
emphasized,O
the,O
contribution,O
of,O
fluid,O
intelligence,O
to,O
the,O
generation,O
of,O
creative,O
metaphors,O
.,O
It,O
is,O
possible,O
that,O
generation,O
of,O
metaphors,O
",",O
specifically,O
novel,O
ones,O
",",O
relies,O
on,O
the,O
ability,O
to,O
come,O
up,O
with,O
new,O
solutions,O
",",O
assessed,O
by,O
tests,O
of,O
fluid,O
intelligence,O
.,O
We,O
note,O
that,O
a,O
similar,O
connection,O
was,O
documented,O
in,O
our,O
study,O
between,O
non,O
-,O
verbal,O
intelligence,O
and,O
simile,O
generation,O
",",O
although,O
no,O
group,O
differences,O
in,O
simile,O
generation,O
were,O
found,O
.,O
Some,O
limitations,O
of,O
the,O
study,O
should,O
be,O
taken,O
into,O
account,O
.,O
Our,O
measures,O
of,O
executive,O
functions,O
were,O
rather,O
limited,O
and,O
may,O
need,O
to,O
be,O
expanded,O
to,O
include,O
the,O
assessment,O
of,O
working,O
memory,O
and,O
inhibition,O
.,O
Studies,O
have,O
shown,O
that,O
people,O
with,O
ASD,B-DS
may,O
present,O
difficulties,O
in,O
tasks,O
that,O
require,O
response,O
inhibition,O
(,O
e,O
.,O
g,O
".,",O
Hughes,O
and,O
Russell,O
",",O
1993,O
;,O
Hughes,O
",",O
1996,O
;,O
Russell,O
",",O
1997,O
;,O
Minshew,O
et,O
al,O
".,",O
1999,O
;,O
Hill,O
",",O
2004,O
;,O
Robinson,O
et,O
al,O
".,",O
2009,O
),O
or,O
when,O
they,O
are,O
required,O
to,O
shift,O
from,O
one,O
response,O
set,O
to,O
another,O
(,O
Ozonoff,O
and,O
Strayer,O
",",O
1997,O
;,O
Ozonoff,O
et,O
al,O
".,",O
1998,O
).,O
It,O
is,O
possible,O
that,O
low,O
response,O
inhibition,O
led,O
to,O
generation,O
of,O
unique,O
verbal,O
expressions,O
by,O
our,O
ASD,B-DS
participants,O
.,O
Future,O
studies,O
will,O
have,O
to,O
examine,O
whether,O
inhibition,O
is,O
associated,O
with,O
metaphor,O
generation,O
in,O
ASD,B-DS
.,O
In,O
sum,O
",",O
our,O
findings,O
indicate,O
that,O
adults,O
with,O
ASD,B-DS
are,O
not,O
impaired,O
on,O
comprehension,O
of,O
conventional,O
and,O
novel,O
metaphors,O
.,O
We,O
also,O
found,O
that,O
adults,O
with,O
ASD,B-DS
generate,O
more,O
original,O
metaphors,O
relative,O
to,O
age,O
-,O
matched,O
peers,O
and,O
that,O
non,O
-,O
verbal,O
skills,O
contribute,O
to,O
this,O
ability,O
.,O
The,O
study,O
points,O
to,O
unique,O
verbal,O
creativity,O
in,O
ASD,B-DS
which,O
has,O
not,O
been,O
studied,O
in,O
this,O
way,O
before,O
.,O
Conflict,O
of,O
Interest,O
Statement,O
The,O
authors,O
declare,O
that,O
the,O
research,O
was,O
conducted,O
in,O
the,O
absence,O
of,O
any,O
commercial,O
or,O
financial,O
relationships,O
that,O
could,O
be,O
construed,O
as,O
a,O
potential,O
conflict,O
of,O
interest,O
.,O
Persistent,O
use,O
of,O
psychotropic,O
drugs,O
in,O
nursing,O
home,O
residents,O
in,O
Norway,O
Background,O
The,O
prevalence,O
of,O
psychotropic,O
drug,O
(,O
PTD,O
),O
use,O
in,O
NH,O
residents,O
is,O
high,O
",",O
but,O
few,O
have,O
explored,O
prevalence,O
and,O
persistency,O
in,O
PTD,O
in,O
NH,O
residents,O
and,O
factors,O
associated,O
with,O
persistency,O
.,O
This,O
at,O
the,O
same,O
time,O
as,O
we,O
know,O
that,O
risk,O
of,O
side,O
events,O
may,O
be,O
higher,O
with,O
long,O
-,O
term,O
use,O
in,O
older,O
adults,O
.,O
Thus,O
",",O
the,O
aim,O
of,O
this,O
study,O
was,O
to,O
describe,O
the,O
prevalence,O
and,O
persistence,O
in,O
use,O
of,O
PTD,O
and,O
to,O
explore,O
factors,O
associated,O
with,O
persistence,O
in,O
use,O
of,O
PTD,O
at,O
two,O
consecutive,O
time,O
points,O
in,O
nursing,O
home,O
(,O
NH,O
),O
residents,O
.,O
Methods,O
We,O
included,O
1163,O
NH,O
residents,O
in,O
a,O
72,O
-,O
month,O
longitudinal,O
study,O
with,O
five,O
assessments,O
.,O
Use,O
of,O
PTD,O
",",O
neuropsychiatric,O
symptoms,O
(,O
NPS,O
"),",O
severity,O
of,O
dementia,B-DS
and,O
physical,O
health,O
were,O
assessed,O
each,O
time,O
.,O
Results,O
The,O
prevalence,O
over,O
time,O
and,O
persistent,O
use,O
of,O
antipsychotic,O
drugs,O
",",O
antidepressants,O
",",O
anxiolytics,O
and,O
sedatives,O
at,O
two,O
consecutive,O
time,O
points,O
were,O
high,O
in,O
residents,O
with,O
and,O
without,O
dementia,B-DS
.,O
There,O
was,O
an,O
association,O
between,O
greater,O
NPS,O
at,O
the,O
first,O
time,O
point,O
",",O
and,O
persistent,O
use,O
of,O
these,O
drugs,O
",",O
but,O
changes,O
in,O
NPS,O
between,O
time,O
points,O
",",O
did,O
not,O
explain,O
such,O
use,O
.,O
A,O
longer,O
NH,O
stay,O
increased,O
the,O
odds,O
for,O
persistent,O
use,O
of,O
antipsychotics,O
.,O
Conclusion,O
Psychotropic,O
drugs,O
are,O
frequently,O
used,O
as,O
a,O
long,O
-,O
term,O
treatment,O
among,O
NH,O
residents,O
and,O
are,O
associated,O
with,O
severity,O
of,O
neuropsychiatric,O
symptoms,O
",",O
but,O
not,O
with,O
severity,O
of,O
dementia,B-DS
.,O
Closer,O
attention,O
should,O
be,O
paid,O
to,O
follow,O
-,O
up,O
of,O
psychotropic,O
drug,O
treatment,O
",",O
and,O
especially,O
for,O
long,O
–,O
term,O
use,O
of,O
antipsychotics,O
",",O
since,O
the,O
duration,O
of,O
such,O
treatment,O
should,O
be,O
as,O
short,O
as,O
possible,O
.,O
Background,O
The,O
use,O
of,O
psychotropic,O
drugs,O
in,O
European,O
nursing,O
homes,O
(,O
NH,O
),O
is,O
reported,O
to,O
be,O
quite,O
common,O
.,O
The,O
prevalence,O
of,O
use,O
of,O
any,O
psychotropic,O
drug,O
(,O
PTD,O
),O
varied,O
between,O
42,O
and,O
80,O
%,O
in,O
studies,O
published,O
from,O
2005,O
to,O
2013,O
[,O
1,O
–,O
6,O
],O
and,O
varied,O
between,O
countries,O
[,O
7,O
",",O
8,O
].,O
Among,O
NH,O
residents,O
with,O
dementia,B-DS
or,O
cognitive,B-DS
impairment,I-DS
",",O
the,O
prevalence,O
of,O
any,O
PTD,O
use,O
is,O
similar,O
or,O
even,O
higher,O
than,O
among,O
those,O
with,O
normal,O
cognition,O
(,O
48,O
–,O
90,O
%),O
[,O
9,O
–,O
14,O
],O
and,O
also,O
higher,O
than,O
in,O
community,O
living,O
older,O
adults,O
with,O
dementia,B-DS
[,O
14,O
].,O
In,O
NHs,O
in,O
Scandinavia,O
",",O
the,O
use,O
of,O
any,O
PTD,O
is,O
also,O
high,O
(,O
57,O
–,O
80,O
%),O
[,O
15,O
–,O
19,O
"],",O
especially,O
in,O
studies,O
that,O
only,O
include,O
residents,O
with,O
dementia,B-DS
(,O
68,O
–,O
85,O
%),O
[,O
12,O
",",O
15,O
",",O
17,O
",",O
20,O
",",O
21,O
].,O
Over,O
the,O
years,O
there,O
has,O
been,O
an,O
increase,O
in,O
use,O
of,O
PTD,O
in,O
NH,O
[,O
12,O
",",O
18,O
",",O
22,O
–,O
28,O
],O
except,O
for,O
antipsychotic,O
drugs,O
",",O
where,O
a,O
decrease,O
has,O
been,O
observed,O
in,O
recent,O
years,O
[,O
18,O
",",O
27,O
",",O
29,O
",",O
30,O
].,O
Thus,O
",",O
the,O
prevalence,O
of,O
antipsychotic,O
drug,O
use,O
in,O
Scandinavian,O
NH,O
residents,O
with,O
dementia,B-DS
is,O
among,O
the,O
lowest,O
in,O
Europe,O
(,O
pooled,O
estimates,O
24,O
%),O
[,O
31,O
].,O
Antidepressants,O
are,O
the,O
most,O
commonly,O
used,O
PTD,O
in,O
Norwegian,O
NH,O
residents,O
[,O
16,O
",",O
18,O
",",O
22,O
].,O
Antipsychotic,O
drugs,O
are,O
often,O
used,O
to,O
treat,O
neuropsychiatric,O
symptoms,O
",",O
such,O
as,O
aggression,O
",",O
agitation,O
or,O
psychotic,O
symptoms,O
in,O
NH,O
residents,O
with,O
dementia,B-DS
",",O
although,O
non,O
-,O
pharmacological,O
interventions,O
should,O
be,O
the,O
first,O
choice,O
of,O
treatment,O
for,O
these,O
symptoms,O
[,O
32,O
",",O
33,O
].,O
However,O
",",O
in,O
demanding,O
clinical,O
situations,O
",",O
antipsychotic,O
drugs,O
may,O
be,O
unavoidable,O
",",O
but,O
there,O
is,O
no,O
evidence,O
that,O
long,O
-,O
term,O
use,O
of,O
antipsychotic,O
drugs,O
in,O
the,O
management,O
of,O
neuropsychiatric,O
symptoms,O
is,O
effective,O
[,O
33,O
].,O
Older,O
NH,O
residents,O
with,O
dementia,B-DS
can,O
be,O
withdrawn,O
from,O
long,O
-,O
term,O
antipsychotics,O
without,O
detrimental,O
effects,O
on,O
their,O
behavior,O
",",O
but,O
caution,O
is,O
required,O
in,O
residents,O
with,O
severe,O
neuropsychiatric,O
symptoms,O
[,O
34,O
].,O
Furthermore,O
",",O
the,O
duration,O
of,O
antipsychotic,O
drug,O
treatment,O
should,O
be,O
as,O
short,O
as,O
possible,O
",",O
because,O
of,O
the,O
high,O
risk,O
of,O
side,O
effects,O
[,O
32,O
"],",O
such,O
as,O
more,O
rapid,O
progression,O
of,O
dementia,B-DS
[,O
9,O
],O
or,O
cognitive,B-DS
decline,I-DS
[,O
35,O
"],",O
higher,O
risk,O
of,O
cerebrovascular,O
events,O
[,O
36,O
],O
and,O
increased,O
risk,O
of,O
falling,O
[,O
37,O
].,O
Use,O
of,O
antipsychotic,O
drugs,O
is,O
also,O
associated,O
with,O
increased,O
mortality,O
risk,O
[,O
38,O
].,O
While,O
the,O
side,O
effects,O
of,O
antipsychotics,O
have,O
received,O
the,O
most,O
attention,O
",",O
studies,O
show,O
that,O
there,O
are,O
serious,O
short,O
-,O
and,O
long,O
-,O
term,O
side,O
effects,O
such,O
as,O
falls,O
and,O
fall,O
-,O
related,O
fractures,O
associated,O
with,O
use,O
of,O
antidepressants,O
and,O
with,O
use,O
of,O
benzodiazepines,O
[,O
37,O
].,O
The,O
efficacy,O
of,O
antidepressants,O
on,O
depression,B-DS
in,O
persons,O
with,O
dementia,B-DS
was,O
not,O
confirmed,O
in,O
a,O
meta,O
-,O
analysis,O
summarizing,O
many,O
randomized,O
control,O
trials,O
[,O
39,O
].,O
A,O
recent,O
study,O
of,O
discontinuation,O
of,O
antidepressants,O
in,O
NH,O
residents,O
with,O
dementia,B-DS
and,O
neuropsychiatric,O
symptoms,O
in,O
Norway,O
found,O
that,O
most,O
residents,O
(,O
85,O
%),O
tolerated,O
discontinuation,O
[,O
40,O
].,O
However,O
",",O
when,O
antidepressants,O
are,O
discontinued,O
in,O
residents,O
with,O
dementia,B-DS
they,O
should,O
be,O
monitored,O
carefully,O
to,O
identify,O
those,O
with,O
worsening,O
depressive,O
symptoms,O
[,O
40,O
].,O
Authors,O
who,O
studied,O
retrospectively,O
discontinuation,O
of,O
long,O
-,O
term,O
use,O
of,O
benzodiazepines,O
in,O
older,O
adults,O
with,O
and,O
without,O
dementia,B-DS
in,O
care,O
institutions,O
found,O
limited,O
evidence,O
of,O
adverse,O
outcomes,O
due,O
to,O
discontinuation,O
of,O
benzodiazepines,O
",",O
but,O
close,O
attention,O
should,O
be,O
paid,O
to,O
the,O
possibility,O
of,O
emergent,O
agitation,O
and,O
in,O
patients,O
with,O
anxiety,B-DS
caution,O
should,O
be,O
practiced,O
[,O
41,O
].,O
Discontinuation,O
of,O
long,O
-,O
term,O
use,O
of,O
Benzodiazepines,O
in,O
older,O
adults,O
without,O
dementia,B-DS
has,O
been,O
found,O
to,O
increase,O
handgrip,O
strength,O
",",O
balance,O
and,O
cognitive,O
function,O
[,O
42,O
–,O
44,O
].,O
Of,O
the,O
approximately,O
75,O
studies,O
on,O
PTD,O
in,O
NH,O
facilities,O
published,O
after,O
2004,O
",",O
only,O
a,O
small,O
fraction,O
have,O
examined,O
use,O
of,O
PTD,O
in,O
a,O
longitudinal,O
design,O
[,O
21,O
",",O
45,O
–,O
54,O
].,O
About,O
half,O
of,O
the,O
longitudinal,O
studies,O
have,O
studied,O
the,O
prevalence,O
of,O
different,O
types,O
of,O
PTD,O
over,O
time,O
or,O
persistent,O
use,O
at,O
two,O
time,O
points,O
[,O
21,O
",",O
45,O
–,O
48,O
",",O
50,O
",",O
52,O
"],",O
but,O
very,O
few,O
have,O
studied,O
factors,O
associated,O
with,O
the,O
persistent,O
use,O
of,O
PTD,O
",",O
such,O
as,O
antipsychotic,O
drugs,O
[,O
46,O
",",O
52,O
"],",O
antidepressants,O
",",O
anxiolytics,O
or,O
sedatives,O
.,O
However,O
",",O
as,O
the,O
risk,O
of,O
side,O
events,O
may,O
be,O
higher,O
with,O
long,O
-,O
term,O
use,O
[,O
32,O
",",O
33,O
],O
and,O
is,O
decreased,O
after,O
discontinuation,O
of,O
PTD,O
in,O
older,O
adults,O
[,O
34,O
",",O
55,O
],O
it,O
is,O
of,O
vital,O
importance,O
to,O
study,O
the,O
persistent,O
use,O
of,O
PTD,O
and,O
its,O
associated,O
factors,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
describe,O
the,O
prevalence,O
and,O
persistence,O
of,O
PTD,O
use,O
and,O
to,O
explore,O
factors,O
associated,O
with,O
the,O
persistence,O
in,O
use,O
of,O
PTD,O
at,O
two,O
consecutive,O
time,O
points,O
in,O
a,O
Norwegian,O
sample,O
of,O
NH,O
residents,O
.,O
Method,O
Design,O
This,O
was,O
a,O
72,O
-,O
month,O
longitudinal,O
study,O
with,O
five,O
assessments,O
.,O
Baseline,O
assessment,O
(,O
A1,O
),O
took,O
place,O
between,O
November,O
2004,O
and,O
January,O
2005,O
[,O
56,O
].,O
The,O
follow,O
-,O
up,O
assessments,O
took,O
place,O
after,O
12,O
",",O
31,O
and,O
52,O
and,O
72,O
months,O
(,O
A2,O
–,O
A5,O
).,O
Setting,O
and,O
participants,O
In,O
total,O
",",O
Norway,O
has,O
40,O
",",O
000,O
NH,O
places,O
(,O
beds,O
),O
[,O
57,O
],O
for,O
a,O
population,O
of,O
about,O
five,O
million,O
",",O
with,O
about,O
14,O
%,O
(,O
700,O
",",O
000,O
),O
of,O
those,O
aged,O
65,O
years,O
or,O
older,O
[,O
58,O
].,O
The,O
jurisdiction,O
for,O
public,O
health,O
care,O
services,O
lies,O
with,O
local,O
municipalities,O
",",O
and,O
local,O
authorities,O
offer,O
social,O
services,O
(,O
such,O
as,O
housing,O
and,O
home,O
services,O
"),",O
in,O
-,O
home,O
nursing,O
and,O
institutional,O
care,O
(,O
mainly,O
in,O
NHs,O
"),",O
and,O
provide,O
both,O
long,O
-,O
and,O
short,O
-,O
term,O
care,O
and,O
rehabilitation,O
.,O
This,O
study,O
recruited,O
participants,O
from,O
26,O
NHs,O
in,O
18,O
municipalities,O
.,O
The,O
selection,O
of,O
small,O
",",O
medium,O
",",O
and,O
large,O
municipalities,O
was,O
made,O
to,O
obtain,O
a,O
wide,O
variety,O
of,O
NH,O
-,O
settings,O
in,O
the,O
sample,O
.,O
NH,O
residents,O
with,O
a,O
stay,O
of,O
at,O
least,O
14,O
days,O
were,O
eligible,O
for,O
inclusion,O
",",O
no,O
other,O
inclusion,O
or,O
exclusion,O
criteria,O
were,O
used,O
[,O
56,O
].,O
In,O
all,O
",",O
1165,O
residents,O
were,O
eligible,O
for,O
inclusion,O
and,O
only,O
two,O
declined,O
to,O
participate,O
.,O
Measures,O
Psychotropic,O
drugs,O
were,O
grouped,O
according,O
to,O
the,O
Anatomical,O
Therapeutic,O
Chemical,O
(,O
ATC,O
),O
Classification,O
System,O
into,O
the,O
following,O
groups,O
:,O
antipsychotics,O
(,O
N05A,O
except,O
lithium,O
"),",O
antidepressants,O
(,O
N06A,O
"),",O
anxiolytics,O
(,O
N05B,O
"),",O
hypnotics,O
/,O
sedatives,O
(,O
N05C,O
"),",O
and,O
anti,O
-,O
dementia,B-DS
medication,O
(,O
N06D,O
),O
(,O
yes,O
versus,O
no,O
),O
[,O
59,O
].,O
Combination,O
drugs,O
outside,O
ATC,O
NO5B,O
and,O
NO5Cwere,O
not,O
included,O
.,O
The,O
information,O
was,O
collected,O
from,O
the,O
medical,O
record,O
of,O
each,O
resident,O
[,O
56,O
].,O
Dementia,B-DS
and,O
severity,O
of,O
dementia,B-DS
was,O
assessed,O
using,O
the,O
Clinical,O
Dementia,B-DS
Rating,O
(,O
CDR,O
),O
scale,O
",",O
covering,O
six,O
domains,O
(,O
memory,O
;,O
orientation,O
;,O
judgment,O
and,O
problem,O
solving,O
;,O
community,O
affairs,O
;,O
home,O
and,O
hobbies,O
;,O
and,O
personal,O
care,O
),O
with,O
five,O
response,O
categories,O
(,O
0,O
",",O
0,O
.,O
5,O
",",O
1,O
",",O
2,O
",",O
3,O
),O
[,O
60,O
",",O
61,O
].,O
The,O
total,O
score,O
was,O
calculated,O
using,O
an,O
algorithm,O
that,O
gives,O
priority,O
to,O
memory,O
[,O
60,O
].,O
Residents,O
with,O
a,O
total,O
score,O
of,O
one,O
or,O
higher,O
were,O
regarded,O
as,O
having,O
dementia,B-DS
.,O
The,O
cut,O
-,O
off,O
CDR,O
≥,O
1,O
in,O
defining,O
dementia,B-DS
has,O
been,O
found,O
adequate,O
in,O
previous,O
Norwegian,O
and,O
international,O
studies,O
[,O
62,O
–,O
64,O
].,O
The,O
categorical,O
scores,O
indicate,O
the,O
severity,O
of,O
dementia,B-DS
:,O
a,O
CDR,O
score,O
of,O
1,O
represents,O
mild,B-DS
dementia,I-DS
",",O
a,O
CDR,O
score,O
of,O
2,O
represents,O
moderate,B-DS
dementia,I-DS
",",O
and,O
a,O
CDR,O
score,O
of,O
3,O
represents,O
severe,B-DS
dementia,I-DS
.,O
The,O
sum,O
-,O
score,O
of,O
the,O
six,O
domains,O
(,O
sum,O
of,O
boxes,O
"),",O
ranging,O
from,O
zero,O
to,O
18,O
",",O
can,O
also,O
be,O
used,O
to,O
measure,O
the,O
severity,O
of,O
dementia,B-DS
",",O
as,O
the,O
categorical,O
and,O
continuous,O
scores,O
correlate,O
highly,O
≥,O
0,O
.,O
9,O
[,O
65,O
",",O
66,O
].,O
The,O
Spearman,O
correlation,O
between,O
the,O
categorical,O
CDR,O
score,O
and,O
the,O
CDR,O
sum,O
of,O
boxes,O
score,O
in,O
the,O
present,O
study,O
was,O
0,O
.,O
93,O
.,O
Due,O
to,O
a,O
wider,O
range,O
of,O
values,O
",",O
the,O
CDR,O
sum,O
of,O
boxes,O
offers,O
important,O
advantages,O
when,O
analyzing,O
the,O
data,O
[,O
66,O
].,O
We,O
used,O
the,O
CDR,O
score,O
(,O
CDR,O
≥,O
1,O
),O
as,O
an,O
indication,O
of,O
dementia,B-DS
",",O
as,O
it,O
was,O
not,O
possible,O
to,O
perform,O
a,O
standardized,O
dementia,B-DS
work,O
-,O
up,O
for,O
all,O
residents,O
because,O
many,O
were,O
too,O
frail,O
or,O
mentally,O
impaired,O
to,O
take,O
part,O
in,O
examinations,O
such,O
as,O
CT,O
or,O
MRI,O
.,O
A,O
large,O
number,O
of,O
residents,O
with,O
a,O
CDR,O
score,O
of,O
3,O
could,O
not,O
be,O
tested,O
with,O
any,O
dementia,B-DS
tests,O
such,O
as,O
the,O
Mini,O
Mental,O
Status,O
Examination,O
[,O
67,O
],O
or,O
the,O
Clock,O
Drawing,O
Test,O
[,O
68,O
].,O
Physical,O
health,O
was,O
assessed,O
using,O
the,O
General,O
Medical,O
Health,O
Rating,O
(,O
GMHR,O
),O
scale,O
[,O
69,O
].,O
This,O
is,O
a,O
one,O
-,O
item,O
global,O
rating,O
scale,O
with,O
four,O
categories,O
:,O
good,O
",",O
fairly,O
good,O
",",O
poor,O
",",O
and,O
very,O
poor,O
.,O
The,O
rating,O
was,O
based,O
on,O
all,O
available,O
information,O
on,O
physical,O
health,O
and,O
use,O
of,O
drugs,O
.,O
The,O
scale,O
has,O
been,O
used,O
in,O
large,O
studies,O
including,O
older,O
people,O
with,O
and,O
without,O
dementia,B-DS
[,O
70,O
],O
and,O
has,O
been,O
translated,O
and,O
used,O
in,O
several,O
studies,O
[,O
71,O
",",O
72,O
].,O
The,O
Personal,O
Activities,O
of,O
Daily,O
Living,O
(,O
P,O
-,O
ADL,O
),O
score,O
was,O
assessed,O
with,O
the,O
Physical,O
Self,O
-,O
Maintenance,O
Scale,O
(,O
PSMS,O
"),",O
including,O
six,O
items,O
",",O
with,O
a,O
total,O
score,O
ranging,O
from,O
6,O
to,O
30,O
[,O
73,O
].,O
High,O
scores,O
indicate,O
a,O
lower,O
level,O
of,O
functioning,O
.,O
Neuropsychiatric,O
symptoms,O
(,O
NPS,O
),O
were,O
assessed,O
using,O
the,O
Neuropsychiatric,O
Inventory,O
Nursing,O
Home,O
version,O
(,O
NPI,O
-,O
NH,O
),O
[,O
74,O
",",O
75,O
].,O
The,O
10,O
-,O
item,O
inventory,O
covers,O
the,O
following,O
symptoms,O
:,O
delusion,B-DS
",",O
hallucination,B-DS
",",O
euphoria,O
",",O
agitation,O
/,O
aggression,O
",",O
disinhibition,O
",",O
irritability,O
/,O
lability,O
",",O
depression,B-DS
/,O
dysphoria,B-DS
",",O
anxiety,B-DS
",",O
apathy,O
/,O
indifference,O
",",O
and,O
aberrant,O
motor,O
behavior,O
(,O
no,O
/,O
yes,O
).,O
For,O
each,O
symptom,O
",",O
severity,O
(,O
score,O
1,O
–,O
3,O
),O
multiplied,O
by,O
frequency,O
(,O
score,O
1,O
–,O
4,O
),O
provides,O
a,O
score,O
from,O
zero,O
to,O
12,O
.,O
Based,O
on,O
a,O
previous,O
principal,O
component,O
analysis,O
",",O
psychosis,B-DS
(,O
delusions,B-DS
",",O
hallucination,B-DS
"),",O
agitation,O
(,O
agitation,O
/,O
aggression,O
",",O
disinhibition,O
",",O
irritability,O
"),",O
and,O
affective,O
(,O
depression,B-DS
",",O
anxiety,B-DS
),O
sub,O
-,O
syndrome,O
scores,O
were,O
formed,O
by,O
summing,O
the,O
score,O
of,O
the,O
included,O
items,O
[,O
76,O
–,O
79,O
].,O
The,O
apathy,O
/,O
indifference,O
was,O
analyzed,O
as,O
a,O
single,O
symptom,O
.,O
Demographic,O
information,O
such,O
as,O
age,O
",",O
gender,O
",",O
marital,O
status,O
",",O
and,O
length,O
of,O
stay,O
in,O
the,O
NH,O
at,O
the,O
time,O
of,O
inclusion,O
was,O
collected,O
from,O
medical,O
records,O
.,O
The,O
type,O
of,O
unit,O
was,O
also,O
recorded,O
from,O
among,O
the,O
following,O
options,O
:,O
regular,O
units,O
(,O
RU,O
"),",O
special,O
care,O
unit,O
for,O
people,O
with,O
dementia,B-DS
(,O
SCU,O
"),",O
rehabilitation,O
unit,O
(,O
REU,O
"),",O
and,O
other,O
units,O
(,O
OU,O
"),",O
mainly,O
psychogeriatric,O
wards,O
.,O
The,O
length,O
of,O
stay,O
in,O
a,O
NH,O
before,O
study,O
inclusion,O
was,O
measured,O
in,O
days,O
.,O
Procedure,O
Nurses,O
with,O
extensive,O
clinical,O
experience,O
collected,O
the,O
data,O
.,O
Prior,O
to,O
data,O
collection,O
",",O
all,O
assessors,O
participated,O
in,O
a,O
2,O
-,O
day,O
course,O
on,O
how,O
to,O
apply,O
the,O
standardized,O
questionnaires,O
.,O
A,O
1,O
-,O
day,O
training,O
program,O
was,O
carried,O
out,O
prior,O
to,O
each,O
follow,O
-,O
up,O
assessment,O
.,O
The,O
project,O
leader,O
(,O
GS,O
),O
was,O
available,O
for,O
consultation,O
throughout,O
the,O
data,O
collection,O
period,O
.,O
The,O
nurses,O
collected,O
data,O
from,O
medical,O
records,O
and,O
via,O
a,O
standardized,O
interview,O
with,O
the,O
residents,O
’,O
primary,O
caregivers,O
",",O
all,O
of,O
whom,O
were,O
registered,O
nurses,O
.,O
All,O
assessment,O
scales,O
used,O
were,O
standard,O
translated,O
Norwegian,O
versions,O
.,O
A,O
pilot,O
study,O
including,O
41,O
NH,O
residents,O
was,O
carried,O
out,O
to,O
test,O
inter,O
-,O
rater,O
reliability,O
of,O
CDR,O
prior,O
to,O
the,O
first,O
data,O
collection,O
and,O
the,O
inter,O
-,O
rater,O
reliability,O
was,O
very,O
good,O
.,O
The,O
kappa,O
statistics,O
for,O
the,O
global,O
CDR,O
score,O
were,O
1,O
(,O
between,O
geriatric,O
psychiatrist,O
and,O
registered,O
nurse,O
specialized,O
in,O
psychiatry,O
),O
and,O
0,O
.,O
86,O
(,O
between,O
geriatric,O
psychiatrist,O
and,O
registered,O
nurse,O
).,O
More,O
detailed,O
information,O
of,O
the,O
inter,O
-,O
rating,O
reliability,O
test,O
has,O
been,O
published,O
elsewhere,O
[,O
56,O
].,O
Study,O
information,O
was,O
given,O
to,O
the,O
residents,O
and,O
their,O
family,O
members,O
.,O
The,O
residents,O
and,O
their,O
next,O
of,O
kin,O
were,O
informed,O
that,O
they,O
could,O
refuse,O
to,O
participate,O
at,O
any,O
stage,O
of,O
the,O
study,O
.,O
This,O
procedure,O
was,O
recommended,O
and,O
approved,O
by,O
the,O
Regional,O
Ethics,O
Committee,O
in,O
the,O
south,O
east,O
of,O
Norway,O
",",O
the,O
Data,O
Inspectorate,O
and,O
the,O
Directorate,O
for,O
Health,O
and,O
Social,O
Affairs,O
in,O
2004,O
before,O
data,O
collection,O
.,O
Data,O
analysis,O
Sample,O
characteristics,O
at,O
baseline,O
were,O
described,O
as,O
means,O
and,O
standard,O
deviations,O
(,O
SD,O
),O
or,O
frequencies,O
and,O
percentages,O
.,O
Residents,O
with,O
CDR,O
≥,O
1,O
and,O
CDR,O
<,O
1,O
were,O
compared,O
by,O
Independent,O
samples,O
t,O
-,O
test,O
for,O
continuous,O
and,O
χ2,O
-,O
test,O
for,O
categorical,O
variables,O
.,O
Prevalence,O
and,O
persistence,O
of,O
PTD,O
use,O
among,O
those,O
with,O
and,O
without,O
dementia,B-DS
were,O
compared,O
by,O
Z,O
-,O
test,O
for,O
proportions,O
.,O
The,O
persistence,O
in,O
outcomes,O
",",O
use,O
of,O
antipsychotics,O
",",O
antidepressants,O
",",O
anxiolytics,O
and,O
sedatives,O
were,O
assessed,O
with,O
a,O
logistic,O
regression,O
model,O
for,O
hierarchical,O
data,O
(,O
SAS,O
GLIMMIX,O
procedure,O
).,O
Random,O
effects,O
for,O
type,O
of,O
unit,O
nested,O
in,O
a,O
NH,O
were,O
included,O
into,O
the,O
model,O
.,O
The,O
dependent,O
variable,O
was,O
current,O
use,O
of,O
a,O
specific,O
type,O
of,O
PTD,O
drug,O
",",O
while,O
the,O
independent,O
variable,O
was,O
either,O
use,O
of,O
the,O
same,O
drug,O
at,O
the,O
previous,O
time,O
point,O
(,O
lag,O
1,O
"),",O
two,O
time,O
points,O
previously,O
(,O
lag,O
2,O
),O
or,O
three,O
time,O
points,O
previously,O
(,O
lag,O
3,O
).,O
All,O
models,O
were,O
adjusted,O
for,O
a,O
number,O
of,O
relevant,O
covariates,O
measured,O
at,O
the,O
same,O
time,O
point,O
as,O
the,O
independent,O
variable,O
.,O
A,O
similar,O
model,O
was,O
estimated,O
to,O
assess,O
variables,O
associated,O
to,O
persistent,O
use,O
of,O
drugs,O
",",O
where,O
the,O
outcome,O
was,O
defined,O
as,O
1,O
in,O
the,O
case,O
of,O
use,O
of,O
drugs,O
at,O
two,O
adjacent,O
time,O
points,O
and,O
0,O
otherwise,O
.,O
In,O
addition,O
",",O
exploratory,O
analyses,O
assessing,O
association,O
between,O
change,O
in,O
NPI,O
sub,O
-,O
syndromes,O
and,O
persistent,O
use,O
of,O
drugs,O
were,O
performed,O
.,O
All,O
multivariate,O
models,O
were,O
reduced,O
using,O
Akaike,O
’,O
s,O
Information,O
Criteria,O
",",O
where,O
a,O
lower,O
value,O
means,O
a,O
better,O
model,O
.,O
The,O
results,O
were,O
tabulated,O
as,O
odds,O
ratios,O
(,O
ORs,O
),O
with,O
corresponding,O
95,O
%,O
confidence,O
intervals,O
(,O
CI,O
),O
and,O
presented,O
graphically,O
.,O
All,O
analyses,O
were,O
performed,O
in,O
SPSS,O
version,O
22,O
and,O
SAS,O
v9,O
.,O
3,O
.,O
P,O
-,O
values,O
below,O
0,O
.,O
05,O
were,O
considered,O
statically,O
significant,O
.,O
All,O
tests,O
were,O
two,O
-,O
sided,O
.,O
Results,O
Sample,O
characteristics,O
At,O
baseline,O
",",O
the,O
mean,O
(,O
SD,O
),O
age,O
of,O
the,O
residents,O
was,O
84,O
.,O
4,O
(,O
7,O
.,O
8,O
),O
years,O
and,O
846,O
(,O
72,O
.,O
7,O
%),O
of,O
them,O
were,O
women,B-OG
(,O
Table,O
1,O
).,O
The,O
mean,O
(,O
SD,O
),O
baseline,O
CDR,O
sum,O
of,O
boxes,O
was,O
11,O
.,O
2,O
(,O
5,O
.,O
3,O
),O
and,O
932,O
(,O
80,O
.,O
1,O
%),O
residents,O
had,O
CDR,O
≥,O
1,O
indicating,O
dementia,B-DS
.,O
The,O
mean,O
length,O
of,O
stay,O
at,O
baseline,O
was,O
938,O
.,O
3,O
(,O
1013,O
.,O
1,O
),O
days,O
and,O
the,O
mean,O
(,O
SD,O
),O
number,O
of,O
prescribed,O
drugs,O
taken,O
regularly,O
was,O
6,O
.,O
0,O
(,O
3,O
.,O
1,O
).,O
Of,O
the,O
1163,O
residents,O
at,O
baseline,O
",",O
98,O
(,O
8,O
.,O
4,O
%),O
were,O
still,O
alive,O
and,O
available,O
at,O
the,O
fifth,O
follow,O
-,O
up,O
(,O
see,O
Fig,O
.,O
1,O
).,O
Mean,O
(,O
SD,O
),O
time,O
of,O
follow,O
-,O
up,O
was,O
829,O
.,O
5,O
(,O
690,O
.,O
0,O
),O
days,O
.,O
Table,O
1Sample,O
characteristics,O
at,O
baselineA1CDR,O
≥,O
1CDR,O
<,O
1,O
P,O
-,O
valuesa,O
1163932Socio,O
-,O
demographics,O
AgeMean,O
(,O
SD,O
),O
84,O
.,O
4,O
(,O
7,O
.,O
8,O
),O
84,O
.,O
5,O
(,O
7,O
.,O
5,O
),O
83,O
.,O
8,O
(,O
9,O
.,O
0,O
),O
0,O
.,O
223,O
FemalesN,O
(%),O
846,O
(,O
72,O
.,O
7,O
),O
686,O
(,O
73,O
.,O
6,O
),O
156,O
(,O
68,O
.,O
7,O
),O
0,O
.,O
139,O
Education,O
<,O
10,O
yearsN,O
(%),O
847,O
(,O
74,O
.,O
8,O
),O
673,O
(,O
74,O
.,O
1,O
),O
170,O
(,O
76,O
.,O
9,O
),O
0,O
.,O
390,O
MarriedN,O
(%),O
221,O
(,O
19,O
.,O
0,O
),O
185,O
(,O
19,O
.,O
8,O
),O
36,O
(,O
15,O
.,O
9,O
),O
0,O
.,O
178Health,O
condition,O
GMHR,O
Good,O
Fairly,O
good,O
Poor,O
Very,O
PoorN,O
(%),O
N,O
(%),O
N,O
(%),O
N,O
(%),O
194,O
(,O
17,O
.,O
2,O
),O
386,O
(,O
34,O
.,O
1,O
),O
378,O
(,O
33,O
.,O
4,O
),O
173,O
(,O
15,O
.,O
3,O
),O
142,O
(,O
15,O
.,O
7,O
),O
291,O
(,O
32,O
.,O
2,O
),O
322,O
(,O
35,O
.,O
6,O
),O
150,O
(,O
16,O
.,O
6,O
),O
52,O
(,O
23,O
.,O
4,O
),O
94,O
(,O
42,O
.,O
3,O
),O
53,O
(,O
23,O
.,O
9,O
),O
23,O
(,O
10,O
.,O
4,O
)<,O
0,O
.,O
001,O
PSMS,O
scoreMean,O
(,O
SD,O
),O
18,O
.,O
1,O
(,O
5,O
.,O
4,O
),O
18,O
.,O
8,O
(,O
5,O
.,O
3,O
),O
15,O
.,O
4,O
(,O
4,O
.,O
8,O
)<,O
0,O
.,O
001,O
NPI,O
Agitation,O
sub,O
-,O
syndromeMean,O
(,O
SD,O
),O
5,O
.,O
8,O
(,O
8,O
.,O
0,O
),O
6,O
.,O
5,O
(,O
8,O
.,O
2,O
),O
2,O
.,O
9,O
(,O
6,O
.,O
1,O
)<,O
0,O
.,O
001,O
NPI,O
Psychosis,B-DS
sub,O
-,O
syndromeMean,O
(,O
SD,O
),O
2,O
.,O
8,O
(,O
5,O
.,O
1,O
),O
3,O
.,O
2,O
(,O
5,O
.,O
3,O
),O
1,O
.,O
3,O
(,O
3,O
.,O
8,O
)<,O
0,O
.,O
001,O
NPI,O
Affective,O
sub,O
-,O
syndromeMean,O
(,O
SD,O
),O
3,O
.,O
5,O
(,O
5,O
.,O
3,O
),O
3,O
.,O
7,O
(,O
5,O
.,O
4,O
),O
2,O
.,O
9,O
(,O
4,O
.,O
9,O
),O
0,O
.,O
041,O
NPI,O
ApathyMean,O
(,O
SD,O
),O
2,O
.,O
2,O
(,O
3,O
.,O
7,O
),O
2,O
.,O
4,O
(,O
3,O
.,O
8,O
),O
1,O
.,O
1,O
(,O
2,O
.,O
9,O
)<,O
0,O
.,O
001,O
No,O
of,O
drugsMean,O
(,O
SD,O
),O
6,O
.,O
0,O
(,O
3,O
.,O
1,O
),O
5,O
.,O
8,O
(,O
3,O
.,O
0,O
),O
6,O
.,O
9,O
(,O
3,O
.,O
3,O
)<,O
0,O
.,O
001,O
Days,O
in,O
NHMean,O
(,O
SD,O
),O
938,O
.,O
3,O
(,O
1013,O
.,O
0,O
),O
928,O
.,O
9,O
(,O
910,O
.,O
1,O
),O
975,O
.,O
5,O
(,O
1359,O
.,O
3,O
),O
0,O
.,O
534,O
CDR,O
Clinical,O
Dementia,B-DS
Rating,O
scale,O
GMHR,O
General,O
Medical,O
Health,O
rating,O
PSMS,O
Physical,O
Self,O
-,O
Maintenance,O
Scale,O
NPI,O
Neuropsychiatric,O
Inventory,O
NH,O
Nursing,O
home,O
aCalculated,O
by,O
using,O
t,O
-,O
test,O
for,O
Independent,O
samples,O
for,O
continuous,O
or,O
χ2,O
-,O
test,O
for,O
categorical,O
variables,O
Fig,O
.,O
1Flow,O
chart,O
.,O
Mean,O
(,O
SD,O
),O
time,O
between,O
accessions,O
were,O
11,O
.,O
1,O
(,O
0,O
.,O
5,O
),O
months,O
for,O
A1,O
–,O
A2,O
",",O
18,O
.,O
6,O
(,O
1,O
.,O
3,O
),O
months,O
for,O
A2,O
–,O
A3,O
",",O
20,O
.,O
5,O
(,O
1,O
.,O
7,O
),O
months,O
for,O
A3,O
–,O
A4,O
and,O
20,O
.,O
8,O
(,O
2,O
.,O
8,O
),O
months,O
for,O
A4,O
–,O
A5,O
Prevalence,O
of,O
psychotropic,O
drugs,O
over,O
time,O
The,O
prevalence,O
of,O
PTD,O
use,O
at,O
baseline,O
and,O
each,O
of,O
the,O
follow,O
-,O
up,O
time,O
points,O
are,O
presented,O
in,O
Table,O
2,O
.,O
Antidepressants,O
were,O
most,O
frequently,O
used,O
(,O
38,O
.,O
3,O
%,O
at,O
baseline,O
",",O
32,O
.,O
7,O
%,O
at,O
last,O
follow,O
-,O
up,O
);,O
while,O
anti,O
-,O
dementia,B-DS
drugs,O
were,O
least,O
frequently,O
used,O
(,O
11,O
.,O
3,O
%,O
at,O
baseline,O
",",O
0,O
%,O
at,O
last,O
follow,O
-,O
up,O
).,O
The,O
prevalence,O
of,O
use,O
of,O
any,O
PTD,O
was,O
high,O
throughout,O
the,O
period,O
;,O
at,O
baseline,O
the,O
prevalence,O
was,O
72,O
.,O
9,O
"%,",O
but,O
had,O
fallen,O
to,O
63,O
.,O
3,O
%,O
at,O
the,O
last,O
follow,O
-,O
up,O
.,O
Table,O
2Prevalence,O
and,O
persistence,O
of,O
PTD,O
use,O
according,O
to,O
the,O
presence,O
of,O
dementia,B-DS
at,O
each,O
assessment,O
(%),O
Prevalence,O
in,O
percentagesA1,O
A2,O
A3,O
A4,O
A5,O
All,O
(,O
n,O
=,O
1163,O
),O
D,O
/,O
nD,O
(,O
n,O
=,O
932,O
/,O
227,O
),O
All,O
(,O
n,O
=,O
789,O
),O
D,O
/,O
nD,O
(,O
n,O
=,O
628,O
/,O
159,O
),O
All,O
(,O
n,O
=,O
395,O
),O
D,O
/,O
nD,O
(,O
n,O
=,O
300,O
/,O
94,O
),O
All,O
(,O
n,O
=,O
209,O
),O
D,O
/,O
nD,O
(,O
n,O
=,O
160,O
/,O
48,O
),O
All,O
(,O
n,O
=,O
98,O
),O
D,O
/,O
nD,O
(,O
n,O
=,O
75,O
/,O
22,O
),O
Antipsychotics,O
(,O
AP,O
),O
24,O
.,O
126,O
.,O
0,O
/,O
15,O
.,O
9,O
***,O
25,O
.,O
226,O
.,O
4,O
/,O
20,O
.,O
820,O
.,O
522,O
.,O
0,O
/,O
16,O
.,O
020,O
.,O
622,O
.,O
5,O
/,O
14,O
.,O
620,O
.,O
420,O
.,O
0,O
/,O
22,O
.,O
7,O
Trad,O
.,O
AP11,O
.,O
311,O
.,O
5,O
/,O
11,O
.,O
012,O
.,O
211,O
.,O
6,O
/,O
14,O
.,O
59,O
.,O
49,O
.,O
0,O
/,O
10,O
.,O
68,O
.,O
69,O
.,O
4,O
/,O
6,O
.,O
312,O
.,O
212,O
.,O
0,O
/,O
13,O
.,O
6,O
Atypical,O
AP13,O
.,O
214,O
.,O
9,O
/,O
5,O
.,O
7,O
***,O
13,O
.,O
815,O
.,O
6,O
/,O
6,O
.,O
9,O
***,O
11,O
.,O
913,O
.,O
7,O
/,O
6,O
.,O
4,O
**,O
12,O
.,O
613,O
.,O
1,O
/,O
8,O
.,O
38,O
.,O
28,O
.,O
0,O
/,O
9,O
.,O
1Antidepressants38,O
.,O
339,O
.,O
1,O
/,O
34,O
.,O
837,O
.,O
337,O
.,O
9,O
/,O
34,O
.,O
036,O
.,O
735,O
.,O
3,O
/,O
40,O
.,O
435,O
.,O
433,O
.,O
1,O
/,O
41,O
.,O
732,O
.,O
729,O
.,O
3,O
/,O
40,O
.,O
9Anxiolytics24,O
.,O
223,O
.,O
8,O
/,O
26,O
.,O
424,O
.,O
222,O
.,O
9,O
/,O
29,O
.,O
6,O
*,O
25,O
.,O
121,O
.,O
3,O
/,O
37,O
.,O
2,O
***,O
28,O
.,O
726,O
.,O
9,O
/,O
35,O
.,O
422,O
.,O
421,O
.,O
3,O
/,O
27,O
.,O
3Sedatives29,O
.,O
026,O
.,O
4,O
/,O
39,O
.,O
6,O
***,O
26,O
.,O
623,O
.,O
4,O
/,O
38,O
.,O
4,O
***,O
24,O
.,O
121,O
.,O
0,O
/,O
33,O
.,O
0,O
*,O
23,O
.,O
919,O
.,O
4,O
/,O
37,O
.,O
5,O
**,O
23,O
.,O
520,O
.,O
0,O
/,O
31,O
.,O
8Antidementia,O
drug11,O
.,O
313,O
.,O
5,O
/,O
2,O
.,O
2,O
***,O
9,O
.,O
811,O
.,O
8,O
/,O
1,O
.,O
9,O
***,O
5,O
.,O
36,O
.,O
3,O
/,O
2,O
.,O
1,O
*,O
2,O
.,O
93,O
.,O
1,O
/,O
2,O
.,O
100,O
/,O
0Any,O
PTD72,O
.,O
974,O
.,O
5,O
/,O
66,O
.,O
5,O
*,O
71,O
.,O
471,O
.,O
5,O
/,O
70,O
.,O
470,O
.,O
467,O
.,O
7,O
/,O
78,O
.,O
7,O
*,O
69,O
.,O
466,O
.,O
9,O
/,O
77,O
.,O
163,O
.,O
357,O
.,O
3,O
/,O
81,O
.,O
8,O
**,O
Persistence,O
at,O
two,O
consecutive,O
time,O
points,O
in,O
percentagesA1,O
–,O
A2,O
A2,O
–,O
A3,O
A3,O
–,O
A4,O
A4,O
–,O
A5,O
AllD,O
/,O
nDAllD,O
/,O
nDAllD,O
/,O
nDAllD,O
/,O
nDAntipsychotics,O
(,O
AP,O
),O
76,O
.,O
775,O
.,O
2,O
/,O
88,O
.,O
9,O
*,O
64,O
.,O
967,O
.,O
6,O
/,O
55,O
.,O
069,O
.,O
667,O
.,O
5,O
/,O
83,O
.,O
370,O
.,O
068,O
.,O
8,O
/,O
75,O
.,O
0,O
Trad,O
.,O
AP73,O
.,O
670,O
.,O
8,O
/,O
84,O
.,O
261,O
.,O
463,O
.,O
3,O
/,O
57,O
.,O
173,O
.,O
773,O
.,O
3,O
/,O
75,O
.,O
080,O
.,O
075,O
.,O
0,O
/,O
100,O
Atypical,O
AP74,O
.,O
574,O
.,O
7,O
/,O
80,O
.,O
061,O
.,O
563,O
.,O
0,O
/,O
50,O
.,O
062,O
.,O
159,O
.,O
3,O
/,O
100,O
***,O
60,O
.,O
062,O
.,O
5,O
/,O
50,O
.,O
0Antidepressants80,O
.,O
479,O
.,O
8,O
/,O
82,O
.,O
876,O
.,O
573,O
.,O
1,O
/,O
87,O
.,O
9,O
*,O
72,O
.,O
266,O
.,O
1,O
/,O
89,O
.,O
5,O
**,O
75,O
.,O
776,O
.,O
9,O
/,O
70,O
.,O
0Anxiolytics76,O
.,O
973,O
.,O
6,O
/,O
89,O
.,O
5,O
**,O
69,O
.,O
262,O
.,O
7,O
/,O
84,O
.,O
4,O
**,O
86,O
.,O
882,O
.,O
1,O
/,O
100,O
**,O
66,O
.,O
766,O
.,O
7,O
/,O
66,O
.,O
7Sedatives70,O
.,O
965,O
.,O
8,O
/,O
82,O
.,O
8,O
**,O
64,O
.,O
869,O
.,O
1,O
/,O
55,O
.,O
669,O
.,O
664,O
.,O
9,O
/,O
77,O
.,O
868,O
.,O
058,O
.,O
8,O
/,O
85,O
.,O
7Antidementia,O
drug66,O
.,O
065,O
.,O
3,O
/,O
100,O
***,O
38,O
.,O
136,O
.,O
6,O
/,O
100,O
***,O
27,O
.,O
327,O
.,O
3,O
/,O
000,O
/,O
0Any,O
PTD89,O
.,O
888,O
.,O
7,O
/,O
94,O
.,O
3,O
*,O
85,O
.,O
382,O
.,O
4,O
/,O
94,O
.,O
2,O
**,O
89,O
.,O
386,O
.,O
6,O
/,O
97,O
.,O
3,O
**,O
78,O
.,O
475,O
.,O
5,O
/,O
85,O
.,O
0A1,O
–,O
A5,O
:,O
Assessment,O
1,O
–,O
5,O
D,O
Dementia,B-DS
CDR,O
≥,O
1,O
;,O
nD,O
No,O
dementia,B-DS
CDR,O
<,O
1CDR,O
ratings,O
were,O
missing,O
for,O
4,O
people,O
at,O
A1,O
",",O
2,O
people,O
at,O
A2,O
and,O
2,O
people,O
at,O
A3,O
CDR,O
Clinical,O
Dementia,B-DS
Rating,O
scale,O
Trad,O
Conventional,O
PTD,O
Psychotropic,O
drugs,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
≤,O
0,O
.,O
01,O
;,O
***,O
p,O
≤,O
0,O
.,O
001,O
(,O
Z,O
-,O
test,O
for,O
proportions,O
used,O
),O
At,O
baseline,O
",",O
the,O
use,O
of,O
any,O
PTD,O
occurred,O
more,O
frequently,O
in,O
residents,O
with,O
dementia,B-DS
",",O
while,O
at,O
the,O
last,O
follow,O
-,O
up,O
any,O
PTD,O
was,O
more,O
often,O
used,O
in,O
residents,O
without,O
dementia,B-DS
.,O
Atypical,O
antipsychotics,O
were,O
used,O
more,O
frequently,O
in,O
residents,O
with,O
dementia,B-DS
at,O
A1,O
–,O
A3,O
",",O
whereas,O
residents,O
without,O
dementia,B-DS
used,O
anxiolytics,O
more,O
frequently,O
at,O
A2,O
and,O
A3,O
and,O
sedatives,O
more,O
frequently,O
at,O
A1,O
–,O
A4,O
",",O
respectively,O
.,O
Persistent,O
use,O
of,O
psychotropic,O
drugs,O
The,O
proportion,O
of,O
PTD,O
use,O
at,O
two,O
consecutive,O
time,O
points,O
was,O
high,O
(>,O
50,O
%),O
throughout,O
the,O
period,O
for,O
all,O
types,O
of,O
PTD,O
",",O
except,O
for,O
use,O
of,O
anti,O
-,O
dementia,B-DS
drugs,O
(,O
Table,O
2,O
).,O
Persistent,O
use,O
of,O
anxiolytics,O
at,O
two,O
consecutive,O
time,O
points,O
was,O
higher,O
for,O
residents,O
without,O
dementia,B-DS
than,O
those,O
with,O
dementia,B-DS
.,O
Among,O
those,O
who,O
completed,O
all,O
assessments,O
(,O
n,O
=,O
98,O
"),",O
10,O
.,O
4,O
%,O
used,O
antipsychotic,O
drugs,O
",",O
19,O
.,O
8,O
%,O
used,O
antidepressants,O
",",O
11,O
.,O
5,O
%,O
used,O
anxiolytics,O
and,O
9,O
.,O
4,O
%,O
used,O
sedatives,O
at,O
all,O
assessments,O
.,O
Unadjusted,O
and,O
adjusted,O
odds,O
for,O
use,O
of,O
PTD,O
at,O
one,O
time,O
point,O
",",O
given,O
use,O
of,O
the,O
same,O
type,O
of,O
PTD,O
at,O
an,O
earlier,O
time,O
point,O
was,O
estimated,O
for,O
all,O
types,O
of,O
PTD,O
except,O
for,O
anti,O
-,O
dementia,B-DS
drug,O
use,O
(,O
Table,O
3,O
and,O
Fig,O
.,O
2,O
).,O
Both,O
in,O
unadjusted,O
and,O
adjusted,O
analyses,O
",",O
the,O
odds,O
for,O
persistent,O
use,O
of,O
antipsychotics,O
",",O
antidepressants,O
",",O
anxiolytics,O
and,O
sedative,O
were,O
high,O
.,O
The,O
odds,O
for,O
persistent,O
use,O
of,O
these,O
PTD,O
were,O
highest,O
when,O
compared,O
with,O
use,O
at,O
the,O
closest,O
earlier,O
assessment,O
time,O
point,O
(,O
Lag,O
1,O
),O
and,O
fell,O
successively,O
when,O
the,O
distance,O
between,O
the,O
assessment,O
time,O
points,O
increased,O
(,O
Lags,O
2,O
and,O
3,O
"),",O
with,O
one,O
exception,O
for,O
antipsychotics,O
where,O
the,O
odds,O
slightly,O
increased,O
when,O
there,O
were,O
three,O
time,O
points,O
between,O
assessments,O
(,O
Lag,O
3,O
),O
compared,O
to,O
two,O
time,O
points,O
(,O
Lag,O
2,O
).,O
All,O
results,O
were,O
highly,O
significant,O
(,O
p,O
<,O
0,O
.,O
001,O
).,O
Table,O
3Odds,O
ratios,O
for,O
use,O
of,O
each,O
category,O
of,O
psychotropic,O
drugs,O
at,O
one,O
time,O
point,O
given,O
use,O
of,O
the,O
same,O
category,O
of,O
the,O
psychotropic,O
drug,O
at,O
an,O
earlier,O
time,O
point,O
(,O
the,O
distance,O
between,O
time,O
points,O
is,O
called,O
lag,O
"),",O
unadjusted,O
and,O
adjusted,O
analyses,O
where,O
relevant,O
covariates,O
adjusted,O
for,O
were,O
measured,O
at,O
the,O
same,O
earlier,O
timeVariablesUnadjustedAdjustedOR,O
(,O
95,O
%,O
CI,O
),O
P,O
-,O
valueOR,O
(,O
95,O
%,O
CI,O
),O
P,O
-,O
valueLag,O
1,O
",",O
N,O
=,O
1406,O
observations,O
Antipsychoticsa,O
30,O
.,O
7,O
(,O
21,O
.,O
8,O
;,O
43,O
.,O
1,O
)<,O
0,O
.,O
00128,O
.,O
8,O
(,O
20,O
.,O
31,O
;,O
40,O
.,O
8,O
)<,O
0,O
.,O
001,O
Antidepressantsb,O
32,O
.,O
6,O
(,O
23,O
.,O
8,O
;,O
44,O
.,O
8,O
)<,O
0,O
.,O
00134,O
.,O
1,O
(,O
24,O
.,O
6,O
;,O
47,O
.,O
4,O
)<,O
0,O
.,O
001,O
Anxiolyticsc,O
33,O
.,O
1,O
(,O
23,O
.,O
7,O
;,O
46,O
.,O
2,O
)<,O
0,O
.,O
00132,O
.,O
2,O
(,O
23,O
.,O
1,O
;,O
45,O
.,O
0,O
)<,O
0,O
.,O
001,O
Sedativesd,O
22,O
.,O
6,O
(,O
15,O
.,O
6,O
;,O
30,O
.,O
8,O
)<,O
0,O
.,O
00123,O
.,O
1,O
(,O
16,O
.,O
8,O
;,O
31,O
.,O
7,O
)<,O
0,O
.,O
001Lag,O
2,O
",",O
N,O
=,O
654,O
observations,O
Antipsychoticse,O
13,O
.,O
3,O
(,O
8,O
.,O
3,O
;,O
21,O
.,O
4,O
)<,O
0,O
.,O
00113,O
.,O
5,O
(,O
8,O
.,O
1,O
;,O
22,O
.,O
3,O
)<,O
0,O
.,O
001,O
Antidepressantsf,O
15,O
.,O
5,O
(,O
9,O
.,O
9,O
;,O
24,O
.,O
2,O
)<,O
0,O
.,O
00116,O
.,O
0,O
(,O
10,O
.,O
2,O
;,O
25,O
.,O
3,O
)<,O
0,O
.,O
001,O
Anxiolyticsg,O
21,O
.,O
4,O
(,O
12,O
.,O
8,O
;,O
35,O
.,O
7,O
)<,O
0,O
.,O
00123,O
.,O
4,O
(,O
13,O
.,O
9,O
;,O
39,O
.,O
6,O
)<,O
0,O
.,O
001,O
Sedativesh,O
9,O
.,O
3,O
(,O
5,O
.,O
9,O
;,O
14,O
.,O
4,O
)<,O
0,O
.,O
0019,O
.,O
4,O
(,O
5,O
.,O
9,O
;,O
14,O
.,O
8,O
)<,O
0,O
.,O
001Lag,O
3,O
",",O
N,O
=,O
288,O
observations,O
Antipsychoticsi,O
16,O
.,O
5,O
(,O
7,O
.,O
5,O
;,O
36,O
.,O
3,O
)<,O
0,O
.,O
00117,O
.,O
9,O
(,O
7,O
.,O
5,O
;,O
42,O
.,O
4,O
)<,O
0,O
.,O
001,O
Antidepressantsj,O
10,O
.,O
0,O
(,O
4,O
.,O
9,O
;,O
20,O
.,O
4,O
)<,O
0,O
.,O
00112,O
.,O
6,O
(,O
5,O
.,O
8,O
;,O
27,O
.,O
2,O
)<,O
0,O
.,O
001,O
Anxiolyticsk,O
14,O
.,O
4,O
(,O
6,O
.,O
5,O
;,O
32,O
.,O
1,O
)<,O
0,O
.,O
00114,O
.,O
3,O
(,O
7,O
.,O
0,O
;,O
29,O
.,O
2,O
)<,O
0,O
.,O
001,O
Sedativesl,O
7,O
.,O
0,O
(,O
3,O
.,O
6,O
;,O
13,O
.,O
9,O
)<,O
0,O
.,O
0016,O
.,O
4,O
(,O
3,O
.,O
2,O
;,O
12,O
.,O
6,O
)<,O
0,O
.,O
001Lag,O
1,O
:,O
two,O
consecutive,O
assessment,O
time,O
pointsLag,O
2,O
:,O
one,O
time,O
point,O
between,O
selected,O
time,O
pointsLag,O
3,O
:,O
two,O
time,O
points,O
between,O
selected,O
time,O
points,O
aAdjusted,O
for,O
:,O
PSMS,O
score,O
",",O
NPI,O
Agitation,O
sub,O
-,O
syndrome,O
",",O
NPI,O
Psychosis,B-DS
sub,O
-,O
syndrome,O
",",O
NPI,O
Affective,O
sub,O
-,O
syndrome,O
",",O
NH,O
size,O
age,O
and,O
duration,O
in,O
NH,O
bAdjusted,O
for,O
:,O
PSMS,O
score,O
",",O
NPI,O
-,O
Affective,O
sub,O
-,O
syndrome,O
",",O
NPI,O
Apathy,O
and,O
duration,O
in,O
NH,O
cAdjusted,O
for,O
CDR,O
sum,O
of,O
boxes,O
",",O
NPI,O
-,O
Affective,O
sub,O
-,O
syndrome,O
and,O
level,O
of,O
education,O
dAdjusted,O
for,O
PSMS,O
score,O
",",O
NPI,O
Apathy,O
and,O
duration,O
in,O
NH,O
eAdjusted,O
for,O
PSMS,O
score,O
",",O
NPI,O
Psychosis,B-DS
sub,O
-,O
syndrome,O
",",O
NPI,O
Apathy,O
",",O
Type,O
of,O
nursing,O
home,O
and,O
age,O
fAdjusted,O
for,O
:,O
CDR,O
sum,O
of,O
boxes,O
",",O
PSMS,O
score,O
and,O
NPI,O
-,O
Affective,O
sub,O
-,O
syndrome,O
gAdjusted,O
for,O
CDR,O
sum,O
of,O
boxes,O
",",O
PSMS,O
score,O
and,O
level,O
of,O
education,O
hAdjusted,O
for,O
CDR,O
sum,O
of,O
boxes,O
",",O
PSMS,O
and,O
age,O
iAdjusted,O
for,O
PSMS,O
score,O
and,O
age,O
jAdjusted,O
for,O
:,O
CDR,O
sum,O
of,O
boxes,O
",",O
NPI,O
-,O
Affective,O
sub,O
-,O
syndrome,O
and,O
NPI,O
Apathy,O
kAdjusted,O
for,O
NPI,O
Agitation,O
sub,O
-,O
syndrome,O
",",O
NPI,O
Psychosis,B-DS
sub,O
-,O
syndrome,O
",",O
NPI,O
Affective,O
sub,O
-,O
syndrome,O
",",O
NPI,O
Apathy,O
",",O
level,O
of,O
education,O
and,O
Type,O
of,O
nursing,O
home,O
unit,O
lAdjusted,O
for,O
CDR,O
sum,O
of,O
boxes,O
",",O
NPI,O
Psychosis,B-DS
sub,O
-,O
syndrome,O
and,O
Nursing,O
home,O
size,O
Fig,O
.,O
2Illustration,O
of,O
OR,O
for,O
use,O
of,O
each,O
category,O
of,O
psychotropic,O
drugs,O
at,O
one,O
time,O
point,O
given,O
use,O
of,O
the,O
same,O
category,O
of,O
psychotropic,O
drug,O
at,O
an,O
earlier,O
time,O
point,O
by,O
distance,O
(,O
Lag,O
),O
between,O
the,O
time,O
points,O
",",O
unadjusted,O
and,O
adjusted,O
.,O
a,O
Antipsychotics,O
;,O
b,O
Antidepressants,O
;,O
c,O
Anxiolytics,O
;,O
and,O
d,O
Sedatives,O
Factors,O
associated,O
with,O
use,O
of,O
psychotropic,O
drugs,O
at,O
two,O
consecutive,O
time,O
points,O
The,O
adjusted,O
risk,O
for,O
persistent,O
use,O
of,O
antipsychotics,O
at,O
two,O
consecutive,O
time,O
points,O
was,O
elevated,O
when,O
residents,O
had,O
higher,O
psychosis,B-DS
sub,O
-,O
syndrome,O
score,O
or,O
were,O
younger,O
",",O
were,O
male,O
or,O
had,O
a,O
longer,O
NH,O
stay,O
at,O
baseline,O
(,O
Table,O
4,O
).,O
The,O
adjusted,O
risk,O
for,O
persistent,O
use,O
of,O
antidepressants,O
was,O
elevated,O
when,O
residents,O
had,O
higher,O
P,O
-,O
ADL,O
functioning,O
(,O
lower,O
PSMS,O
score,O
),O
or,O
higher,O
affective,O
sub,O
-,O
syndrome,O
score,O
.,O
The,O
adjusted,O
risk,O
for,O
persistent,O
use,O
of,O
anxiolytics,O
was,O
elevated,O
when,O
residents,O
had,O
higher,O
P,O
-,O
ADL,O
functioning,O
(,O
lower,O
PSMS,O
score,O
),O
or,O
higher,O
affective,O
sub,O
-,O
syndrome,O
score,O
or,O
stayed,O
in,O
a,O
larger,O
NH,O
(,O
Table,O
5,O
).,O
The,O
adjusted,O
risk,O
for,O
persistent,O
use,O
of,O
sedatives,O
was,O
elevated,O
when,O
residents,O
had,O
better,O
cognitive,O
functioning,O
(,O
lower,O
CDR,O
sum,O
of,O
boxes,O
),O
or,O
higher,O
affective,O
sub,O
-,O
syndrome,O
score,O
or,O
lower,O
apathy,O
symptom,O
score,O
.,O
Table,O
4Odds,O
of,O
use,O
of,O
Antipsychotics,O
or,O
Antidepressants,O
at,O
one,O
time,O
point,O
given,O
use,O
of,O
Antipsychotics,O
or,O
Antidepressants,O
at,O
the,O
previous,O
time,O
point,O
",",O
covariates,O
measured,O
at,O
the,O
“,O
previous,O
”,O
time,O
point,O
",",O
N,O
=,O
1406,O
observationsVariablesAntipsychoticsAntidepressantsUnadjustedAdjustedUnadjustedAdjustedOR,O
(,O
95,O
%,O
CI,O
),O
P,O
-,O
valueOR,O
(,O
95,O
%,O
CI,O
),O
P,O
-,O
valueOR,O
(,O
95,O
%,O
CI,O
),O
P,O
-,O
valueOR,O
(,O
95,O
%,O
CI,O
),O
P,O
-,O
valueAssessed,O
at,O
previous,O
time,O
point,O
CDR,O
sum,O
of,O
boxes1,O
.,O
04,O
(,O
1,O
.,O
002,O
;,O
1,O
.,O
07,O
),O
0,O
.,O
0360,O
.,O
97,O
(,O
0,O
.,O
95,O
;,O
0,O
.,O
995,O
),O
0,O
.,O
020,O
GMHR,O
Good1,O
.,O
25,O
(,O
0,O
.,O
66,O
;,O
2,O
.,O
37,O
),O
0,O
.,O
4980,O
.,O
98,O
(,O
0,O
.,O
59,O
;,O
1,O
.,O
63,O
),O
0,O
.,O
9340,O
.,O
63,O
(,O
0,O
.,O
35,O
;,O
1,O
.,O
12,O
),O
3,O
0,O
.,O
111,O
Fairly,O
good1,O
.,O
11,O
(,O
0,O
.,O
63,O
;,O
1,O
.,O
98,O
),O
0,O
.,O
7151,O
.,O
29,O
(,O
0,O
.,O
82,O
;,O
2,O
.,O
02,O
),O
0,O
.,O
2730,O
.,O
92,O
(,O
0,O
.,O
56,O
;,O
1,O
.,O
51,O
),O
8,O
0,O
.,O
745,O
Poor1,O
.,O
53,O
(,O
0,O
.,O
86,O
;,O
2,O
.,O
72,O
),O
0,O
.,O
1511,O
.,O
62,O
(,O
1,O
.,O
03,O
;,O
2,O
.,O
56,O
),O
0,O
.,O
0381,O
.,O
34,O
(,O
0,O
.,O
83,O
;,O
2,O
.,O
16,O
),O
5,O
0,O
.,O
229,O
Very,O
Poor1,O
-,O
1,O
-,O
1,O
-,O
PSMS,O
score1,O
.,O
03,O
(,O
0,O
.,O
997,O
;,O
1,O
.,O
06,O
),O
0,O
.,O
0730,O
.,O
96,O
(,O
0,O
.,O
94,O
;,O
0,O
.,O
98,O
),O
0,O
.,O
0010,O
.,O
94,O
(,O
0,O
.,O
91,O
;,O
0,O
.,O
97,O
),O
2,O
<,O
0,O
.,O
001,O
NPI,O
Agitation,O
sub,O
-,O
syndrome1,O
.,O
05,O
(,O
1,O
.,O
03,O
;,O
1,O
.,O
07,O
)<,O
0,O
.,O
0011,O
.,O
02,O
(,O
0,O
.,O
997,O
;,O
1,O
.,O
04,O
),O
6,O
0,O
.,O
0930,O
.,O
997,O
(,O
0,O
.,O
98,O
;,O
1,O
.,O
01,O
),O
0,O
.,O
714,O
NPI,O
Psychosis,B-DS
sub,O
-,O
syndrome1,O
.,O
09,O
(,O
1,O
.,O
06,O
;,O
1,O
.,O
12,O
)<,O
0,O
.,O
0011,O
.,O
06,O
(,O
1,O
.,O
03,O
;,O
1,O
.,O
10,O
),O
2,O
0,O
.,O
0011,O
.,O
00,O
(,O
0,O
.,O
98,O
;,O
1,O
.,O
03,O
),O
0,O
.,O
9150,O
.,O
97,O
(,O
0,O
.,O
95,O
;,O
1,O
.,O
00,O
),O
4,O
0,O
.,O
060,O
NPI,O
Affective,O
sub,O
-,O
syndrome1,O
.,O
06,O
(,O
1,O
.,O
03,O
;,O
1,O
.,O
09,O
)<,O
0,O
.,O
0011,O
.,O
03,O
(,O
0,O
.,O
999,O
;,O
1,O
.,O
07,O
),O
5,O
0,O
.,O
0601,O
.,O
08,O
(,O
1,O
.,O
05,O
;,O
1,O
.,O
10,O
)<,O
0,O
.,O
0011,O
.,O
08,O
(,O
1,O
.,O
05,O
;,O
1,O
.,O
11,O
),O
1,O
<,O
0,O
.,O
001,O
NPI,O
Apathy1,O
.,O
07,O
(,O
1,O
.,O
03,O
;,O
1,O
.,O
12,O
)<,O
0,O
.,O
0010,O
.,O
99,O
(,O
0,O
.,O
96,O
;,O
1,O
.,O
03,O
),O
0,O
.,O
732Assessed,O
at,O
baseline,O
Age0,O
.,O
95,O
(,O
0,O
.,O
93,O
;,O
0,O
.,O
97,O
)<,O
0,O
.,O
0010,O
.,O
95,O
(,O
0,O
.,O
93,O
;,O
0,O
.,O
97,O
),O
1,O
<,O
0,O
.,O
0010,O
.,O
99,O
(,O
0,O
.,O
98,O
;,O
1,O
.,O
01,O
),O
0,O
.,O
3170,O
.,O
98,O
(,O
0,O
.,O
97,O
;,O
1,O
.,O
00,O
),O
6,O
0,O
.,O
056,O
Females0,O
.,O
56,O
(,O
0,O
.,O
40,O
;,O
0,O
.,O
80,O
),O
0,O
.,O
0010,O
.,O
64,O
(,O
0,O
.,O
44,O
;,O
0,O
.,O
93,O
),O
4,O
0,O
.,O
0191,O
.,O
38,O
(,O
1,O
.,O
02,O
;,O
1,O
.,O
87,O
),O
0,O
.,O
0351,O
.,O
33,O
(,O
0,O
.,O
97,O
;,O
1,O
.,O
82,O
),O
7,O
0,O
.,O
078,O
Education,O
(<=,O
10,O
years,O
),O
0,O
.,O
97,O
(,O
0,O
.,O
68,O
;,O
1,O
.,O
39,O
),O
0,O
.,O
8650,O
.,O
88,O
(,O
0,O
.,O
66,O
;,O
1,O
.,O
17,O
),O
0,O
.,O
385,O
Duration,O
in,O
NH,O
(,O
LN,O
),O
1,O
.,O
21,O
(,O
1,O
.,O
06,O
;,O
1,O
.,O
40,O
),O
0,O
.,O
0071,O
.,O
21,O
(,O
1,O
.,O
05,O
;,O
1,O
.,O
40,O
),O
3,O
0,O
.,O
0110,O
.,O
98,O
(,O
0,O
.,O
88,O
;,O
1,O
.,O
09,O
),O
0,O
.,O
654,O
Nursing,O
home,O
size0,O
.,O
998,O
(,O
0,O
.,O
993,O
;,O
1,O
.,O
003,O
),O
0,O
.,O
3821,O
.,O
00,O
(,O
0,O
.,O
998,O
;,O
1,O
.,O
01,O
),O
0,O
.,O
347,O
Type,O
of,O
nursing,O
home,O
unit,O
RU1,O
-,O
1,O
-,O
REU0,O
.,O
57,O
(,O
0,O
.,O
10,O
;,O
3,O
.,O
41,O
),O
0,O
.,O
5391,O
.,O
03,O
(,O
0,O
.,O
30,O
;,O
3,O
.,O
51,O
),O
0,O
.,O
959,O
SCU1,O
.,O
24,O
(,O
0,O
.,O
78,O
;,O
1,O
.,O
97,O
),O
0,O
.,O
3670,O
.,O
80,O
(,O
0,O
.,O
55,O
;,O
1,O
.,O
17,O
),O
0,O
.,O
248,O
OU3,O
.,O
25,O
(,O
0,O
.,O
63,O
;,O
16,O
.,O
81,O
),O
0,O
.,O
1601,O
.,O
13,O
(,O
0,O
.,O
28,O
;,O
4,O
.,O
61,O
),O
10,O
.,O
865,O
RU,O
Regular,O
units,O
REU,O
rehabilitation,O
unit,O
SCU,O
special,O
care,O
unit,O
for,O
people,O
with,O
dementia,B-DS
OU,O
other,O
unitsThe,O
relative,O
importance,O
of,O
each,O
covariate,O
in,O
the,O
adjusted,O
models,O
is,O
included,O
with,O
a,O
number,O
after,O
the,O
95,O
%,O
CI,O
;,O
lowest,O
number,O
has,O
highest,O
importance,O
Table,O
5Odds,O
of,O
use,O
of,O
Anxiolytics,O
or,O
Sedatives,O
or,O
at,O
one,O
time,O
point,O
given,O
use,O
of,O
Anxiolytics,O
or,O
Sedatives,O
at,O
a,O
previous,O
time,O
point,O
",",O
covariates,O
measured,O
at,O
the,O
“,O
previous,O
”,O
time,O
point,O
",",O
N,O
=,O
1406,O
observationsVariablesAnxiolyticsSedativesUnadjustedAdjustedUnadjustedAdjustedOR,O
(,O
95,O
%,O
CI,O
),O
P,O
-,O
valueOR,O
(,O
95,O
%,O
CI,O
),O
P,O
-,O
valueOR,O
(,O
95,O
%,O
CI,O
),O
P,O
-,O
valueOR,O
(,O
95,O
%,O
CI,O
),O
P,O
-,O
valueAssessed,O
at,O
previous,O
time,O
point,O
CDR,O
sum,O
of,O
boxes0,O
.,O
96,O
(,O
0,O
.,O
94,O
;,O
0,O
.,O
99,O
),O
0,O
.,O
0150,O
.,O
97,O
(,O
0,O
.,O
94,O
;,O
1,O
.,O
01,O
),O
4,O
0,O
.,O
1250,O
.,O
94,O
(,O
0,O
.,O
91,O
;,O
0,O
.,O
97,O
)<,O
0,O
.,O
0010,O
.,O
94,O
(,O
0,O
.,O
91,O
;,O
0,O
.,O
97,O
),O
1,O
<,O
0,O
.,O
001,O
GMHR,O
Good1,O
.,O
31,O
(,O
0,O
.,O
68,O
;,O
2,O
.,O
54,O
),O
0,O
.,O
4211,O
.,O
20,O
(,O
0,O
.,O
65,O
;,O
2,O
.,O
23,O
),O
Fairly,O
good1,O
.,O
56,O
(,O
0,O
.,O
87,O
;,O
2,O
.,O
81,O
),O
0,O
.,O
1381,O
.,O
42,O
(,O
0,O
.,O
82,O
;,O
2,O
.,O
47,O
),O
0,O
.,O
560,O
Poor1,O
.,O
83,O
(,O
1,O
.,O
01,O
;,O
3,O
.,O
30,O
),O
0,O
.,O
0461,O
.,O
43,O
(,O
0,O
.,O
82,O
;,O
2,O
.,O
49,O
),O
0,O
.,O
209,O
Very,O
Poor1,O
-,O
10,O
.,O
212,O
PSMS,O
score0,O
.,O
96,O
(,O
0,O
.,O
93,O
;,O
0,O
.,O
98,O
),O
0,O
.,O
0020,O
.,O
96,O
(,O
0,O
.,O
93,O
;,O
0,O
.,O
99,O
),O
3,O
0,O
.,O
0160,O
.,O
95,O
(,O
0,O
.,O
93,O
;,O
0,O
.,O
98,O
)-,O
NPI,O
Agitation,O
sub,O
-,O
syndrome1,O
.,O
00,O
(,O
0,O
.,O
98,O
;,O
1,O
.,O
02,O
),O
0,O
.,O
9640,O
.,O
99,O
(,O
0,O
.,O
97,O
;,O
1,O
.,O
01,O
),O
0,O
.,O
001,O
NPI,O
Psychosis,B-DS
sub,O
-,O
syndrome1,O
.,O
01,O
(,O
0,O
.,O
98,O
;,O
1,O
.,O
04,O
),O
0,O
.,O
4511,O
.,O
00,O
(,O
0,O
.,O
97,O
;,O
1,O
.,O
04,O
),O
0,O
.,O
358,O
NPI,O
Affective,O
sub,O
-,O
syndrome1,O
.,O
08,O
(,O
1,O
.,O
05,O
;,O
1,O
.,O
11,O
)<,O
0,O
.,O
0011,O
.,O
09,O
(,O
1,O
.,O
06,O
;,O
1,O
.,O
12,O
),O
1,O
<,O
0,O
.,O
0011,O
.,O
04,O
(,O
1,O
.,O
01,O
;,O
1,O
.,O
07,O
),O
0,O
.,O
8780,O
.,O
0051,O
.,O
06,O
(,O
1,O
.,O
03,O
;,O
1,O
.,O
09,O
),O
2,O
<,O
0,O
.,O
001,O
NPI,O
Apathy1,O
.,O
01,O
(,O
0,O
.,O
97,O
;,O
1,O
.,O
05,O
),O
0,O
.,O
6620,O
.,O
94,O
(,O
0,O
.,O
90,O
;,O
0,O
.,O
99,O
),O
0,O
.,O
0120,O
.,O
95,O
(,O
0,O
.,O
90,O
;,O
0,O
.,O
996,O
),O
4,O
0,O
.,O
034Assessed,O
at,O
baseline,O
Age0,O
.,O
997,O
(,O
0,O
.,O
98,O
;,O
1,O
.,O
02,O
),O
0,O
.,O
7751,O
.,O
002,O
(,O
0,O
.,O
98,O
;,O
1,O
.,O
02,O
),O
0,O
.,O
812,O
Females1,O
.,O
01,O
(,O
0,O
.,O
71,O
;,O
1,O
.,O
44,O
),O
0,O
.,O
9671,O
.,O
28,O
(,O
0,O
.,O
89,O
;,O
1,O
.,O
83,O
),O
0,O
.,O
182,O
Education,O
(<=,O
10,O
years,O
),O
1,O
.,O
16,O
(,O
0,O
.,O
81,O
;,O
1,O
.,O
66,O
),O
0,O
.,O
4160,O
.,O
82,O
(,O
0,O
.,O
59,O
;,O
1,O
.,O
15,O
),O
0,O
.,O
2530,O
.,O
77,O
(,O
0,O
.,O
54,O
;,O
1,O
.,O
08,O
),O
5,O
0,O
.,O
125,O
Duration,O
in,O
NH,O
(,O
LN,O
),O
1,O
.,O
07,O
(,O
0,O
.,O
94,O
;,O
1,O
.,O
22,O
),O
0,O
.,O
2921,O
.,O
12,O
(,O
0,O
.,O
98,O
;,O
1,O
.,O
28,O
),O
5,O
0,O
.,O
1010,O
.,O
91,O
(,O
0,O
.,O
81,O
;,O
1,O
.,O
04,O
),O
0,O
.,O
164,O
Nursing,O
home,O
size1,O
.,O
01,O
(,O
1,O
.,O
002,O
;,O
1,O
.,O
01,O
),O
0,O
.,O
0041,O
.,O
007,O
(,O
1,O
.,O
002,O
;,O
1,O
.,O
011,O
),O
2,O
0,O
.,O
0021,O
.,O
00,O
(,O
0,O
.,O
999,O
;,O
1,O
.,O
01,O
),O
0,O
.,O
1091,O
.,O
004,O
(,O
1,O
.,O
00,O
;,O
1,O
.,O
008,O
),O
3,O
0,O
.,O
072,O
Type,O
of,O
nursing,O
home,O
unit,O
RU1,O
-,O
1,O
-,O
REU0,O
.,O
18,O
(,O
0,O
.,O
02,O
;,O
1,O
.,O
83,O
),O
0,O
.,O
1462,O
.,O
35,O
(,O
0,O
.,O
63,O
;,O
8,O
.,O
79,O
),O
0,O
.,O
2060,O
.,O
7540,O
.,O
62,O
(,O
0,O
.,O
39,O
;,O
0,O
.,O
98,O
),O
0,O
.,O
041,O
SCU0,O
.,O
93,O
(,O
0,O
.,O
58,O
;,O
1,O
.,O
49,O
),O
OU2,O
.,O
96,O
(,O
0,O
.,O
54,O
;,O
16,O
.,O
13,O
),O
0,O
.,O
2091,O
.,O
67,O
(,O
0,O
.,O
34,O
;,O
8,O
.,O
19,O
),O
0,O
.,O
526,O
RU,O
Regular,O
units,O
REU,O
rehabilitation,O
unit,O
SCU,O
special,O
care,O
unit,O
for,O
people,O
with,O
dementia,B-DS
OU,O
other,O
unitsThe,O
relative,O
importance,O
of,O
each,O
covariate,O
in,O
the,O
adjusted,O
models,O
is,O
included,O
with,O
a,O
number,O
after,O
the,O
95,O
%,O
CI,O
;,O
lowest,O
number,O
has,O
highest,O
importance,O
In,O
a,O
subsequent,O
analysis,O
where,O
sub,O
-,O
syndrome,O
scores,O
of,O
NPS,O
at,O
the,O
first,O
time,O
point,O
were,O
replaced,O
by,O
change,O
in,O
sub,O
-,O
syndrome,O
score,O
between,O
the,O
two,O
assessments,O
",",O
we,O
found,O
no,O
association,O
between,O
change,O
in,O
the,O
sub,O
-,O
syndrome,O
scores,O
of,O
NPS,O
and,O
persistent,O
use,O
of,O
antipsychotic,O
drugs,O
",",O
antidepressants,O
",",O
anxiolytics,O
or,O
sedatives,O
.,O
Discussion,O
In,O
this,O
Norwegian,O
NH,O
study,O
",",O
the,O
prevalence,O
and,O
persistent,O
use,O
of,O
PTD,O
at,O
two,O
consecutive,O
time,O
points,O
was,O
high,O
",",O
both,O
for,O
residents,O
with,O
and,O
without,O
dementia,B-DS
",",O
except,O
for,O
use,O
of,O
an,O
anti,O
-,O
dementia,B-DS
drug,O
.,O
Close,O
to,O
three,O
-,O
quarters,O
of,O
the,O
dementia,B-DS
and,O
two,O
-,O
thirds,O
of,O
non,O
-,O
dementia,B-DS
residents,O
used,O
PTD,O
at,O
baseline,O
of,O
the,O
data,O
collection,O
.,O
Persistent,O
use,O
of,O
anxiolytics,O
was,O
more,O
common,O
in,O
residents,O
without,O
dementia,B-DS
.,O
The,O
persistent,O
use,O
decreased,O
gradually,O
when,O
the,O
distance,O
between,O
the,O
assessment,O
time,O
points,O
increased,O
(,O
Lags,O
2,O
and,O
3,O
"),",O
with,O
the,O
exception,O
of,O
the,O
use,O
of,O
antipsychotics,O
drugs,O
.,O
More,O
severe,O
NPS,O
were,O
associated,O
with,O
persistent,O
use,O
of,O
antipsychotics,O
drugs,O
",",O
antidepressants,O
",",O
anxiolytics,O
and,O
sedatives,O
at,O
the,O
next,O
time,O
point,O
",",O
but,O
change,O
in,O
NPS,O
between,O
the,O
time,O
points,O
was,O
not,O
associated,O
with,O
persistent,O
use,O
of,O
PTD,O
.,O
Better,O
P,O
-,O
ADL,O
functioning,O
(,O
lower,O
PSMS,O
score,O
),O
was,O
associated,O
with,O
persistent,O
use,O
of,O
antidepressants,O
and,O
anxiolytics,O
.,O
Furthermore,O
",",O
less,O
severe,B-DS
dementia,I-DS
was,O
associated,O
with,O
persistent,O
use,O
of,O
sedatives,O
.,O
Of,O
the,O
organizational,O
variables,O
included,O
in,O
the,O
analysis,O
",",O
we,O
found,O
that,O
a,O
longer,O
stay,O
in,O
NH,O
increased,O
the,O
odds,O
for,O
persistent,O
use,O
of,O
antipsychotics,O
at,O
two,O
consecutive,O
time,O
points,O
and,O
staying,O
in,O
a,O
larger,O
-,O
sized,O
NH,O
increased,O
the,O
odds,O
for,O
persistent,O
use,O
of,O
anxiolytics,O
.,O
Use,O
of,O
antipsychotics,O
The,O
study,O
found,O
that,O
the,O
prevalence,O
of,O
atypical,O
antipsychotics,O
was,O
higher,O
in,O
residents,O
with,O
dementia,B-DS
than,O
in,O
residents,O
without,O
",",O
but,O
only,O
for,O
the,O
first,O
three,O
time,O
points,O
.,O
Use,O
of,O
conventional,O
antipsychotics,O
did,O
not,O
differ,O
between,O
residents,O
with,O
or,O
without,O
dementia,B-DS
at,O
any,O
time,O
point,O
.,O
The,O
persistence,O
in,O
use,O
of,O
both,O
atypical,O
and,O
conventional,O
antipsychotics,O
at,O
two,O
consecutive,O
time,O
points,O
was,O
high,O
(>,O
50,O
%),O
during,O
the,O
entire,O
follow,O
-,O
up,O
period,O
of,O
72,O
months,O
for,O
both,O
groups,O
of,O
residents,O
.,O
A,O
small,O
6,O
-,O
month,O
follow,O
-,O
up,O
study,O
of,O
newly,O
arrived,O
NH,O
residents,O
in,O
Australia,O
has,O
previously,O
reported,O
the,O
persistence,O
of,O
antipsychotics,O
to,O
be,O
equally,O
high,O
[,O
49,O
].,O
Given,O
the,O
strong,O
evidence,O
on,O
the,O
increased,O
mortality,O
risk,O
associated,O
with,O
use,O
of,O
conventional,O
antipsychotics,O
in,O
people,O
with,O
dementia,B-DS
it,O
is,O
rather,O
surprising,O
to,O
see,O
that,O
they,O
are,O
still,O
used,O
to,O
that,O
extent,O
.,O
These,O
findings,O
are,O
alarming,O
",",O
since,O
the,O
duration,O
of,O
such,O
treatment,O
should,O
be,O
as,O
short,O
as,O
possible,O
[,O
32,O
].,O
In,O
the,O
present,O
adjusted,O
logistic,O
regression,O
analysis,O
for,O
persistent,O
use,O
of,O
antipsychotic,O
drugs,O
at,O
two,O
consecutive,O
time,O
points,O
",",O
higher,O
severity,O
of,O
psychosis,B-DS
increased,O
the,O
risk,O
for,O
persistent,O
use,O
of,O
antipsychotics,O
.,O
However,O
",",O
it,O
is,O
surprising,O
that,O
in,O
the,O
exploratory,O
analysis,O
",",O
a,O
change,O
in,O
NPS,O
was,O
not,O
associated,O
with,O
persistent,O
use,O
of,O
antipsychotics,O
.,O
Clinical,O
recommendations,O
have,O
highlighted,O
the,O
need,O
for,O
clinicians,O
to,O
monitor,O
NPS,O
closely,O
and,O
consider,O
discontinuing,O
treatment,O
with,O
antipsychotics,O
when,O
an,O
obvious,O
treatment,O
effect,O
does,O
not,O
occur,O
or,O
the,O
residents,O
have,O
side,O
effects,O
due,O
to,O
the,O
treatment,O
[,O
32,O
].,O
It,O
could,O
be,O
that,O
people,O
receiving,O
PTD,O
had,O
more,O
severe,O
symptoms,O
prior,O
to,O
drug,O
initiation,O
.,O
Also,O
",",O
it,O
could,O
be,O
that,O
antipsychotics,O
were,O
described,O
as,O
unspecific,O
sedatives,O
.,O
Very,O
few,O
studies,O
have,O
examined,O
variables,O
associated,O
with,O
persistent,O
use,O
of,O
antipsychotics,O
in,O
NH,O
residents,O
[,O
46,O
",",O
52,O
"],",O
but,O
none,O
of,O
these,O
studies,O
have,O
explicitly,O
explored,O
the,O
importance,O
of,O
NPS,O
in,O
the,O
persistent,O
use,O
of,O
antipsychotic,O
drugs,O
.,O
However,O
",",O
cross,O
-,O
sectional,O
studies,O
have,O
explored,O
the,O
association,O
between,O
NPS,O
and,O
use,O
of,O
antipsychotic,O
drugs,O
and,O
found,O
that,O
higher,O
total,O
symptom,O
load,O
[,O
80,O
],O
and,O
more,O
severe,O
psychosis,B-DS
sub,O
-,O
syndromes,O
symptoms,O
were,O
associated,O
with,O
use,O
of,O
antipsychotics,O
[,O
11,O
",",O
14,O
",",O
81,O
",",O
82,O
].,O
In,O
the,O
adjusted,O
logistic,O
regression,O
analysis,O
of,O
use,O
of,O
antipsychotics,O
",",O
younger,O
age,O
and,O
male,O
gender,O
increased,O
the,O
risk,O
for,O
persistent,O
use,O
of,O
antipsychotics,O
.,O
In,O
contrast,O
",",O
a,O
small,O
Swedish,O
6,O
-,O
month,O
follow,O
-,O
up,O
study,O
in,O
NH,O
residents,O
with,O
dementia,B-DS
did,O
not,O
find,O
age,O
",",O
gender,O
or,O
other,O
personal,O
characteristics,O
of,O
the,O
residents,O
such,O
as,O
P,O
-,O
ADL,O
or,O
cognitive,O
functioning,O
important,O
for,O
persistent,O
use,O
of,O
antipsychotics,O
[,O
52,O
].,O
Our,O
finding,O
may,O
partly,O
be,O
explained,O
by,O
age,O
and,O
gender,O
-,O
based,O
expressions,O
of,O
behavioral,O
symptoms,O
[,O
80,O
],O
not,O
captured,O
by,O
the,O
NPS,O
.,O
Male,O
and,O
younger,O
residents,O
may,O
be,O
experienced,O
as,O
more,O
threatening,O
in,O
their,O
verbal,O
or,O
physical,O
expressions,O
and,O
are,O
physically,O
stronger,O
compared,O
to,O
women,B-OG
and,O
older,O
residents,O
",",O
and,O
for,O
this,O
reason,O
may,O
be,O
put,O
on,O
antipsychotic,O
drugs,O
.,O
In,O
line,O
with,O
our,O
results,O
",",O
cross,O
-,O
sectional,O
studies,O
of,O
use,O
of,O
antipsychotics,O
in,O
NH,O
residents,O
have,O
found,O
that,O
younger,O
residents,O
[,O
4,O
",",O
8,O
",",O
15,O
",",O
22,O
",",O
80,O
",",O
82,O
",",O
83,O
],O
and,O
male,O
residents,O
[,O
5,O
",",O
80,O
",",O
84,O
],O
are,O
more,O
likely,O
to,O
receive,O
antipsychotics,O
.,O
Persistent,O
use,O
of,O
antipsychotics,O
has,O
been,O
reported,O
to,O
be,O
more,O
frequent,O
in,O
regular,O
care,O
units,O
than,O
in,O
SCU,O
[,O
46,O
].,O
In,O
the,O
present,O
study,O
we,O
did,O
not,O
find,O
an,O
association,O
between,O
the,O
type,O
of,O
care,O
unit,O
and,O
persistent,O
use,O
of,O
antipsychotics,O
.,O
In,O
Norway,O
",",O
SCUs,O
have,O
residents,O
with,O
more,O
severe,O
NPS,O
than,O
other,O
units,O
",",O
which,O
could,O
explain,O
our,O
result,O
[,O
30,O
].,O
However,O
",",O
we,O
found,O
that,O
residents,O
with,O
a,O
longer,O
stay,O
in,O
NH,O
at,O
baseline,O
had,O
an,O
increased,O
likelihood,O
of,O
being,O
persistent,O
users,O
of,O
antipsychotics,O
.,O
We,O
do,O
not,O
have,O
a,O
firm,O
explanation,O
for,O
this,O
",",O
but,O
it,O
may,O
be,O
that,O
newly,O
arrived,O
NH,O
residents,O
receive,O
more,O
attention,O
from,O
the,O
staff,O
or,O
respond,O
better,O
to,O
care,O
that,O
is,O
intended,O
to,O
reduce,O
stress,O
",",O
strain,O
and,O
symptoms,O
related,O
to,O
dementia,B-DS
.,O
Use,O
of,O
antidepressants,O
We,O
found,O
",",O
in,O
line,O
with,O
other,O
studies,O
",",O
that,O
antidepressants,O
were,O
the,O
most,O
frequently,O
used,O
PTD,O
in,O
NH,O
residents,O
[,O
48,O
",",O
49,O
],O
and,O
that,O
the,O
frequency,O
did,O
not,O
differ,O
between,O
residents,O
with,O
or,O
without,O
dementia,B-DS
[,O
85,O
].,O
The,O
persistence,O
of,O
use,O
of,O
antidepressants,O
was,O
also,O
high,O
[,O
49,O
].,O
As,O
we,O
could,O
expect,O
",",O
those,O
with,O
more,O
severe,O
affective,O
symptoms,O
had,O
higher,O
odds,O
for,O
persistent,O
use,O
of,O
antidepressants,O
.,O
This,O
result,O
is,O
in,O
line,O
with,O
cross,O
-,O
sectional,O
studies,O
of,O
associations,O
for,O
use,O
of,O
antidepressants,O
[,O
11,O
",",O
15,O
",",O
81,O
].,O
Even,O
so,O
",",O
the,O
efficacy,O
of,O
antidepressants,O
in,O
treating,O
depression,B-DS
in,O
persons,O
with,O
dementia,B-DS
is,O
uncertain,O
.,O
The,O
high,O
prevalence,O
and,O
persistence,O
of,O
antidepressants,O
use,O
may,O
indicate,O
that,O
these,O
drugs,O
also,O
are,O
used,O
for,O
the,O
treatment,O
of,O
agitation,O
.,O
Better,O
performance,O
in,O
P,O
-,O
ADL,O
was,O
more,O
likely,O
to,O
be,O
associated,O
with,O
persistent,O
antidepressant,O
users,O
.,O
We,O
do,O
not,O
have,O
a,O
firm,O
explanation,O
for,O
this,O
",",O
but,O
it,O
may,O
be,O
that,O
those,O
with,O
better,O
P,O
-,O
ADL,O
also,O
have,O
a,O
better,O
ability,O
to,O
express,O
their,O
emotional,O
state,O
.,O
Use,O
of,O
anxiolytics,O
",",O
sedatives,O
and,O
anti,O
-,O
dementia,B-DS
drugs,O
The,O
prevalence,O
of,O
anxiolytics,O
in,O
the,O
NH,O
residents,O
varied,O
between,O
20,O
and,O
40,O
"%,",O
and,O
was,O
significantly,O
higher,O
in,O
residents,O
without,O
dementia,B-DS
",",O
while,O
the,O
persistent,O
use,O
of,O
anxiolytics,O
in,O
adjusted,O
analysis,O
was,O
not,O
explained,O
by,O
the,O
severity,O
of,O
dementia,B-DS
.,O
As,O
for,O
antidepressants,O
",",O
persistent,O
use,O
of,O
anxiolytics,O
was,O
explained,O
by,O
more,O
severe,O
affective,O
symptoms,O
and,O
better,O
P,O
-,O
ADL,O
functioning,O
",",O
but,O
not,O
by,O
change,O
in,O
affective,O
sub,O
-,O
syndrome,O
symptoms,O
between,O
time,O
points,O
.,O
The,O
size,O
of,O
the,O
NH,O
was,O
associated,O
with,O
persistent,O
use,O
of,O
anxiolytics,O
.,O
We,O
speculate,O
that,O
staff,O
distress,O
[,O
81,O
"],",O
registered,O
nursing,O
hours,O
per,O
resident,O
[,O
86,O
],O
and,O
other,O
organizational,O
factors,O
[,O
5,O
],O
that,O
we,O
have,O
not,O
measured,O
may,O
be,O
related,O
to,O
NH,O
size,O
",",O
quality,O
of,O
care,O
and,O
use,O
or,O
persistent,O
use,O
of,O
anxiolytics,O
.,O
Use,O
of,O
sedatives,O
was,O
higher,O
among,O
residents,O
without,O
dementia,B-DS
than,O
residents,O
with,O
dementia,B-DS
and,O
varied,O
between,O
19,O
and,O
26,O
%,O
in,O
residents,O
with,O
dementia,B-DS
and,O
between,O
32,O
and,O
40,O
%,O
in,O
residents,O
without,O
dementia,B-DS
.,O
A,O
possible,O
explanation,O
may,O
be,O
that,O
residents,O
without,O
dementia,B-DS
are,O
more,O
vulnerable,O
to,O
disturbances,O
in,O
the,O
NH,O
environment,O
and,O
at,O
the,O
same,O
time,O
may,O
be,O
more,O
able,O
to,O
ask,O
for,O
sedatives,O
than,O
residents,O
with,O
dementia,B-DS
.,O
The,O
prevalence,O
of,O
anti,O
-,O
dementia,B-DS
drugs,O
use,O
was,O
at,O
baseline,O
11,O
.,O
3,O
%,O
for,O
all,O
residents,O
and,O
as,O
expected,O
the,O
prevalence,O
of,O
such,O
use,O
declined,O
at,O
each,O
of,O
the,O
follow,O
-,O
ups,O
and,O
at,O
the,O
fifth,O
assessment,O
no,O
one,O
used,O
anti,O
-,O
dementia,B-DS
drugs,O
.,O
At,O
the,O
four,O
first,O
assessment,O
time,O
points,O
between,O
1,O
.,O
9,O
to,O
2,O
.,O
2,O
%,O
of,O
residents,O
with,O
CDR,O
less,O
than,O
1,O
were,O
prescribed,O
anti,O
-,O
dementia,B-DS
drugs,O
.,O
This,O
may,O
indicate,O
that,O
the,O
NH,O
physicians,O
have,O
prescribed,O
the,O
anti,O
-,O
dementia,B-DS
drugs,O
without,O
having,O
a,O
dementia,B-DS
diagnosis,O
(,O
P70,O
"),",O
but,O
the,O
physicians,O
may,O
have,O
used,O
the,O
diagnosis,O
cognitive,O
problems,O
(,O
P20,O
),O
as,O
an,O
indication,O
for,O
prescribing,O
the,O
drug,O
.,O
This,O
is,O
quite,O
common,O
in,O
Norway,O
.,O
However,O
",",O
in,O
a,O
recent,O
Norwegian,O
study,O
it,O
was,O
found,O
that,O
a,O
substantial,O
number,O
of,O
persons,O
who,O
purchased,O
anti,O
-,O
dementia,B-DS
drugs,O
had,O
no,O
diagnosis,O
of,O
dementia,B-DS
or,O
cognitive,O
problems,O
registered,O
in,O
the,O
primary,O
health,O
care,O
service,O
system,O
[,O
87,O
].,O
Strength,O
and,O
limitations,O
The,O
study,O
has,O
significant,O
strengths,O
.,O
Firstly,O
",",O
all,O
nurses,O
participating,O
in,O
the,O
data,O
collection,O
participated,O
in,O
a,O
2,O
-,O
day,O
educational,O
course,O
to,O
ensure,O
that,O
they,O
had,O
adequate,O
knowledge,O
prior,O
to,O
collecting,O
data,O
for,O
this,O
study,O
and,O
participated,O
in,O
a,O
1,O
-,O
day,O
educational,O
course,O
before,O
the,O
follow,O
-,O
up,O
data,O
collections,O
.,O
This,O
ensured,O
high,O
data,O
quality,O
.,O
Secondly,O
",",O
a,O
large,O
sample,O
size,O
allowed,O
us,O
to,O
adjust,O
for,O
many,O
potentially,O
important,O
variables,O
",",O
such,O
as,O
health,O
and,O
demographic,O
factors,O
.,O
Furthermore,O
",",O
this,O
study,O
benefits,O
from,O
the,O
inclusion,O
of,O
NHs,O
located,O
in,O
a,O
large,O
part,O
of,O
the,O
country,O
.,O
However,O
",",O
we,O
cannot,O
guarantee,O
that,O
the,O
sample,O
is,O
representative,O
for,O
Norwegian,O
NH,O
residents,O
since,O
inclusion,O
was,O
not,O
based,O
on,O
random,O
selection,O
from,O
all,O
NHs,O
in,O
Norway,O
.,O
The,O
study,O
has,O
some,O
limitations,O
.,O
Firstly,O
",",O
the,O
data,O
from,O
the,O
present,O
study,O
is,O
quite,O
old,O
since,O
data,O
collection,O
started,O
in,O
2004,O
",",O
and,O
thus,O
",",O
may,O
not,O
represent,O
medication,O
use,O
patterns,O
in,O
Norwegian,O
NHs,O
of,O
today,O
.,O
Secondly,O
",",O
a,O
high,O
drop,O
-,O
out,O
rate,O
mainly,O
due,O
to,O
death,O
might,O
have,O
introduced,O
some,O
bias,O
into,O
the,O
results,O
.,O
However,O
",",O
this,O
methodological,O
problem,O
is,O
inherent,O
to,O
most,O
longitudinal,O
NH,O
studies,O
.,O
Also,O
",",O
we,O
used,O
linear,O
mixed,O
models,O
that,O
include,O
all,O
available,O
data,O
(,O
data,O
from,O
drop,O
-,O
outs,O
as,O
well,O
),O
in,O
the,O
analysis,O
.,O
Due,O
to,O
the,O
low,O
number,O
of,O
participants,O
at,O
the,O
end,O
of,O
the,O
follow,O
-,O
up,O
period,O
",",O
the,O
analysis,O
of,O
persistence,O
was,O
limited,O
to,O
three,O
lags,O
only,O
.,O
Thirdly,O
",",O
the,O
time,O
intervals,O
between,O
the,O
assessments,O
varied,O
somewhat,O
among,O
participants,O
.,O
However,O
",",O
this,O
affects,O
the,O
results,O
only,O
minimally,O
",",O
since,O
the,O
time,O
intervals,O
between,O
assessments,O
were,O
quite,O
long,O
and,O
not,O
used,O
in,O
the,O
models,O
explicitly,O
",",O
only,O
as,O
lags,O
.,O
In,O
the,O
present,O
study,O
the,O
time,O
intervals,O
between,O
the,O
assessments,O
were,O
1,O
year,O
or,O
more,O
and,O
due,O
to,O
the,O
study,O
design,O
",",O
we,O
do,O
not,O
know,O
whether,O
there,O
were,O
changes,O
in,O
PTD,O
use,O
between,O
assessments,O
.,O
Fourthly,O
",",O
there,O
is,O
a,O
limitation,O
on,O
the,O
accuracy,O
of,O
dementia,B-DS
diagnoses,O
",",O
since,O
dementia,B-DS
and,O
degree,O
of,O
dementia,B-DS
are,O
based,O
on,O
the,O
CDR,O
rating,O
of,O
several,O
assessors,O
and,O
the,O
fact,O
that,O
a,O
CDR,O
assessment,O
was,O
used,O
",",O
and,O
not,O
a,O
standardized,O
dementia,B-DS
diagnosis,O
",",O
including,O
neuropsychological,O
tests,O
.,O
A,O
large,O
number,O
of,O
residents,O
with,O
a,O
CDR,O
score,O
of,O
3,O
could,O
not,O
be,O
tested,O
with,O
any,O
dementia,B-DS
tests,O
such,O
as,O
the,O
Mini,O
Mental,O
Status,O
Examination,O
or,O
the,O
Clock,O
Drawing,O
Test,O
.,O
However,O
",",O
CDR,O
is,O
an,O
accepted,O
assessment,O
tool,O
and,O
is,O
commonly,O
used,O
in,O
epidemiological,O
NH,O
studies,O
to,O
identify,O
dementia,B-DS
and,O
measure,O
the,O
severity,O
of,O
dementia,B-DS
[,O
65,O
",",O
88,O
"],",O
and,O
the,O
agreement,O
between,O
CDR,O
and,O
a,O
diagnostic,O
assessment,O
according,O
to,O
the,O
ICD,O
-,O
10,O
is,O
high,O
[,O
62,O
].,O
Conclusion,O
Psychotropic,O
drugs,O
were,O
frequently,O
used,O
as,O
a,O
long,O
-,O
term,O
treatment,O
among,O
NH,O
residents,O
and,O
were,O
associated,O
with,O
severity,O
of,O
neuropsychiatric,O
symptoms,O
",",O
but,O
not,O
with,O
severity,O
of,O
dementia,B-DS
.,O
The,O
high,O
prevalence,O
and,O
persistence,O
of,O
psychotropic,O
drug,O
use,O
may,O
indicate,O
that,O
the,O
treatment,O
is,O
not,O
in,O
line,O
with,O
current,O
treatment,O
recommendation,O
.,O
It,O
is,O
important,O
that,O
clinicians,O
monitor,O
effects,O
and,O
side,O
effects,O
of,O
PTD,O
treatment,O
closely,O
and,O
stop,O
treatment,O
when,O
the,O
risk,O
is,O
not,O
balanced,O
by,O
considerable,O
benefits,O
to,O
the,O
NH,O
resident,O
.,O
Pain,O
relief,O
that,O
matters,O
to,O
patients,O
:,O
systematic,O
review,O
of,O
empirical,O
studies,O
assessing,O
the,O
minimum,O
clinically,O
important,O
difference,O
in,O
acute,O
pain,O
Background,O
The,O
minimum,O
clinically,O
important,O
difference,O
(,O
MCID,O
),O
is,O
used,O
to,O
interpret,O
the,O
clinical,O
relevance,O
of,O
results,O
reported,O
by,O
trials,O
and,O
meta,O
-,O
analyses,O
as,O
well,O
as,O
to,O
plan,O
sample,O
sizes,O
in,O
new,O
studies,O
.,O
However,O
",",O
there,O
is,O
a,O
lack,O
of,O
consensus,O
about,O
the,O
size,O
of,O
MCID,O
in,O
acute,O
pain,O
",",O
which,O
is,O
a,O
core,O
symptom,O
affecting,O
patients,O
across,O
many,O
clinical,O
conditions,O
.,O
Methods,O
We,O
identified,O
and,O
systematically,O
reviewed,O
empirical,O
studies,O
of,O
MCID,O
in,O
acute,O
pain,O
.,O
We,O
searched,O
PubMed,O
",",O
EMBASE,O
and,O
Cochrane,O
Library,O
",",O
and,O
included,O
prospective,O
studies,O
determining,O
MCID,O
using,O
a,O
patient,O
-,O
reported,O
anchor,O
and,O
a,O
one,O
-,O
dimensional,O
pain,O
scale,O
(,O
e,O
.,O
g,O
.,O
100,O
mm,O
visual,O
analogue,O
scale,O
).,O
We,O
summarised,O
results,O
and,O
explored,O
reasons,O
for,O
heterogeneity,O
applying,O
meta,O
-,O
regression,O
",",O
subgroup,O
analyses,O
and,O
individual,O
patient,O
data,O
meta,O
-,O
analyses,O
.,O
Results,O
We,O
included,O
37,O
studies,O
(,O
8479,O
patients,O
).,O
Thirty,O
-,O
five,O
studies,O
used,O
a,O
mean,O
change,O
approach,O
",",O
i,O
.,O
e,O
.,O
MCID,O
was,O
assessed,O
as,O
the,O
mean,O
difference,O
in,O
pain,O
score,O
among,O
patients,O
who,O
reported,O
a,O
minimum,O
degree,O
of,O
improvement,O
",",O
while,O
seven,O
studies,O
used,O
a,O
threshold,O
approach,O
",",O
i,O
.,O
e,O
.,O
MCID,O
was,O
assessed,O
as,O
the,O
threshold,O
in,O
pain,O
reduction,O
associated,O
with,O
the,O
best,O
accuracy,O
(,O
sensitivity,O
and,O
specificity,O
),O
for,O
identifying,O
improved,O
patients,O
.,O
Meta,O
-,O
analyses,O
found,O
considerable,O
heterogeneity,O
between,O
studies,O
(,O
absolute,O
MCID,O
:,O
I2,O
=,O
93,O
"%,",O
relative,O
MCID,O
:,O
I2,O
=,O
75,O
%),O
and,O
results,O
were,O
therefore,O
presented,O
qualitatively,O
",",O
while,O
analyses,O
focused,O
on,O
exploring,O
reasons,O
for,O
heterogeneity,O
.,O
The,O
reported,O
absolute,O
MCID,O
values,O
ranged,O
widely,O
from,O
8,O
to,O
40,O
mm,O
(,O
standardised,O
to,O
a,O
100,O
mm,O
scale,O
),O
and,O
the,O
relative,O
MCID,O
values,O
from,O
13,O
%,O
to,O
85,O
%.,O
From,O
analyses,O
of,O
individual,O
patient,O
data,O
(,O
seven,O
studies,O
",",O
918,O
patients,O
"),",O
we,O
found,O
baseline,O
pain,O
strongly,O
associated,O
with,O
absolute,O
",",O
but,O
not,O
relative,O
",",O
MCID,O
as,O
patients,O
with,O
higher,O
baseline,O
pain,O
needed,O
larger,O
pain,O
reduction,O
to,O
perceive,O
relief,O
.,O
Subgroup,O
analyses,O
showed,O
that,O
the,O
definition,O
of,O
improved,O
patients,O
(,O
one,O
or,O
several,O
categories,O
improvement,O
or,O
meaningful,O
change,O
),O
and,O
the,O
design,O
of,O
studies,O
(,O
single,O
or,O
multiple,O
measurements,O
),O
also,O
influenced,O
MCID,O
values,O
.,O
Conclusions,O
The,O
MCID,O
in,O
acute,O
pain,O
varied,O
greatly,O
between,O
studies,O
and,O
was,O
influenced,O
by,O
baseline,O
pain,O
",",O
definitions,O
of,O
improved,O
patients,O
and,O
study,O
design,O
.,O
MCID,O
is,O
context,O
-,O
specific,O
and,O
potentially,O
misguiding,O
if,O
determined,O
",",O
applied,O
or,O
interpreted,O
inappropriately,O
.,O
Explicit,O
and,O
conscientious,O
reflections,O
on,O
the,O
choice,O
of,O
a,O
reference,O
value,O
are,O
required,O
when,O
using,O
MCID,O
to,O
classify,O
research,O
results,O
as,O
clinically,O
important,O
or,O
trivial,O
.,O
Background,O
It,O
can,O
be,O
challenging,O
to,O
decide,O
whether,O
a,O
modest,O
effect,O
in,O
a,O
randomised,O
clinical,O
trial,O
",",O
or,O
a,O
meta,O
-,O
analysis,O
of,O
several,O
such,O
trials,O
",",O
is,O
clinically,O
relevant,O
.,O
Statistical,O
tests,O
inform,O
on,O
the,O
probability,O
of,O
a,O
result,O
being,O
a,O
chance,O
finding,O
;,O
however,O
",",O
they,O
convey,O
no,O
information,O
on,O
whether,O
a,O
given,O
effect,O
will,O
be,O
experienced,O
as,O
important,O
by,O
patients,O
.,O
The,O
degree,O
of,O
pain,O
reduction,O
that,O
is,O
considered,O
clinically,O
relevant,O
has,O
an,O
impact,O
on,O
which,O
analgesic,O
interventions,O
are,O
regarded,O
clinically,O
useful,O
.,O
This,O
interpretation,O
problem,O
for,O
clinical,O
relevance,O
has,O
been,O
at,O
the,O
core,O
of,O
debates,O
of,O
the,O
importance,O
of,O
several,O
types,O
of,O
interventions,O
intended,O
for,O
reducing,O
acute,O
pain,O
",",O
for,O
example,O
",",O
paracetamol,O
[,O
1,O
–,O
3,O
"],",O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drugs,O
[,O
4,O
",",O
5,O
"],",O
morphine,O
or,O
synthetic,O
opiates,O
[,O
6,O
"],",O
corticosteroids,O
[,O
7,O
"],",O
muscle,O
relaxants,O
[,O
4,O
"],",O
laser,O
therapy,O
[,O
8,O
"],",O
transcranial,O
direct,O
current,O
stimulation,O
[,O
9,O
"],",O
EMLA,O
cream,O
[,O
10,O
"],",O
and,O
acupuncture,O
[,O
11,O
].,O
A,O
related,O
challenge,O
involves,O
the,O
calculation,O
of,O
sample,O
sizes,O
for,O
clinical,O
trials,O
",",O
where,O
researchers,O
need,O
to,O
know,O
the,O
smallest,O
clinically,O
important,O
effect,O
that,O
the,O
trial,O
should,O
not,O
miss,O
to,O
be,O
able,O
to,O
determine,O
an,O
adequate,O
sample,O
size,O
.,O
Jaeschke,O
et,O
al,O
.,O
[,O
12,O
],O
characterised,O
the,O
concept,O
of,O
minimum,O
clinically,O
relevant,O
difference,O
in,O
1989,O
as,O
“,O
the,O
smallest,O
difference,O
in,O
score,O
in,O
the,O
domain,O
of,O
interest,O
which,O
participants,O
perceive,O
as,O
beneficial,O
and,O
which,O
would,O
mandate,O
",",O
in,O
the,O
absence,O
of,O
troublesome,O
side,O
effects,O
and,O
costs,O
",",O
a,O
change,O
in,O
the,O
patient,O
’,O
s,O
management,O
”.,O
The,O
strength,O
of,O
the,O
concept,O
is,O
that,O
it,O
defines,O
a,O
relevant,O
effect,O
size,O
based,O
on,O
clinical,O
considerations,O
and,O
not,O
only,O
statistical,O
significance,O
[,O
13,O
",",O
14,O
].,O
It,O
has,O
subsequently,O
been,O
supplemented,O
by,O
a,O
related,O
concept,O
–,O
the,O
substantial,O
(,O
and,O
not,O
only,O
minimum,O
),O
clinically,O
relevant,O
difference,O
[,O
15,O
].,O
The,O
minimum,O
clinically,O
important,O
difference,O
(,O
MCID,O
),O
is,O
sometimes,O
chosen,O
on,O
the,O
basis,O
of,O
expert,O
consensus,O
judgement,O
[,O
16,O
"],",O
statistical,O
models,O
[,O
17,O
],O
or,O
objective,O
criteria,O
[,O
18,O
].,O
However,O
",",O
in,O
acute,O
pain,O
",",O
it,O
seems,O
reasonable,O
to,O
anchor,O
clinical,O
relevance,O
to,O
the,O
patients,O
’,O
experience,O
.,O
This,O
approach,O
is,O
in,O
accordance,O
with,O
the,O
increasing,O
awareness,O
of,O
the,O
relevance,O
of,O
patient,O
-,O
reported,O
outcomes,O
in,O
clinical,O
research,O
[,O
19,O
].,O
Several,O
such,O
empirical,O
studies,O
have,O
been,O
conducted,O
to,O
determine,O
the,O
MCID,O
in,O
acute,O
pain,O
",",O
but,O
they,O
differ,O
with,O
regard,O
to,O
methodology,O
",",O
clinical,O
condition,O
and,O
findings,O
",",O
and,O
have,O
not,O
yet,O
been,O
systematically,O
reviewed,O
.,O
Since,O
acute,O
pain,O
is,O
a,O
core,O
symptom,O
in,O
healthcare,O
",",O
an,O
assessment,O
of,O
the,O
MCID,O
and,O
a,O
clarification,O
of,O
the,O
causes,O
for,O
its,O
variation,O
will,O
have,O
broad,O
interest,O
.,O
It,O
has,O
been,O
suggested,O
that,O
baseline,O
pain,O
influences,O
absolute,O
values,O
of,O
MCID,O
",",O
but,O
study,O
reports,O
have,O
been,O
conflicting,O
[,O
20,O
",",O
21,O
"],",O
and,O
it,O
remains,O
unclear,O
which,O
other,O
clinical,O
or,O
methodological,O
factors,O
are,O
of,O
importance,O
.,O
We,O
therefore,O
decided,O
to,O
systematically,O
review,O
empirical,O
studies,O
of,O
the,O
MCID,O
in,O
acute,O
pain,O
relief,O
and,O
to,O
examine,O
possible,O
causes,O
for,O
variation,O
between,O
study,O
results,O
",",O
especially,O
their,O
likely,O
dependency,O
on,O
baseline,O
pain,O
levels,O
.,O
We,O
also,O
reviewed,O
studies,O
of,O
the,O
substantial,O
clinically,O
important,O
difference,O
in,O
acute,O
pain,O
relief,O
as,O
well,O
as,O
clinically,O
important,O
differences,O
for,O
worsening,O
of,O
pain,O
.,O
Methods,O
Eligibility,O
criteria,O
We,O
included,O
prospective,O
studies,O
of,O
patients,O
with,O
acute,O
pain,O
",",O
regardless,O
of,O
age,O
",",O
clinical,O
condition,O
",",O
and,O
intervention,O
",",O
in,O
which,O
pain,O
intensity,O
was,O
assessed,O
on,O
a,O
one,O
-,O
dimensional,O
scale,O
",",O
e,O
.,O
g,O
.,O
a,O
100,O
mm,O
visual,O
analogue,O
scale,O
(,O
VAS,O
),O
or,O
a,O
0,O
–,O
10,O
point,O
numerical,O
rating,O
scale,O
(,O
NRS,O
"),",O
and,O
in,O
which,O
the,O
MCID,O
was,O
determined,O
using,O
an,O
anchor,O
-,O
based,O
method,O
using,O
patients,O
’,O
perception,O
of,O
change,O
to,O
determine,O
clinical,O
importance,O
.,O
Pain,O
was,O
considered,O
acute,O
when,O
its,O
duration,O
was,O
less,O
than,O
1,O
month,O
or,O
",",O
if,O
duration,O
was,O
not,O
indicated,O
",",O
when,O
it,O
was,O
described,O
as,O
such,O
in,O
a,O
study,O
report,O
.,O
Studies,O
were,O
excluded,O
if,O
they,O
were,O
not,O
clinical,O
(,O
i,O
.,O
e,O
.,O
used,O
healthy,O
volunteers,O
),O
or,O
determined,O
the,O
MCID,O
from,O
objective,O
criteria,O
(,O
e,O
.,O
g,O
.,O
return,O
to,O
work,O
"),",O
the,O
distribution,O
of,O
data,O
(,O
e,O
.,O
g,O
.,O
the,O
minimum,O
detectable,O
difference,O
),O
or,O
expert,O
consensus,O
.,O
A,O
typical,O
eligible,O
study,O
would,O
ask,O
patients,O
to,O
score,O
their,O
pain,O
intensity,O
",",O
e,O
.,O
g,O
.,O
using,O
a,O
VAS,O
",",O
at,O
baseline,O
and,O
follow,O
-,O
up,O
.,O
At,O
follow,O
-,O
up,O
",",O
patients,O
were,O
also,O
asked,O
to,O
categorise,O
their,O
change,O
in,O
pain,O
intensity,O
using,O
response,O
options,O
such,O
as,O
‘,O
no,O
change,O
"’,",O
‘,O
a,O
little,O
better,O
’/‘,O
somewhat,O
better,O
"’,",O
and,O
‘,O
a,O
lot,O
better,O
’/‘,O
much,O
better,O
’.,O
The,O
MCID,O
was,O
then,O
determined,O
from,O
the,O
change,O
in,O
scores,O
on,O
the,O
pain,O
scale,O
among,O
patients,O
having,O
categorised,O
their,O
change,O
as,O
‘,O
a,O
little,O
better,O
’,O
(,O
or,O
a,O
similar,O
expression,O
indicating,O
a,O
minimum,O
clinically,O
important,O
improvement,O
).,O
We,O
included,O
studies,O
with,O
two,O
types,O
of,O
analytical,O
approaches,O
(,O
1,O
),O
the,O
‘,O
mean,O
change,O
approach,O
"’,",O
i,O
.,O
e,O
.,O
the,O
mean,O
difference,O
in,O
pain,O
scores,O
among,O
patients,O
who,O
reported,O
a,O
minimum,O
degree,O
of,O
pain,O
relief,O
[,O
22,O
];,O
or,O
(,O
2,O
),O
the,O
‘,O
threshold,O
approach,O
"’,",O
i,O
.,O
e,O
.,O
the,O
threshold,O
value,O
for,O
pain,O
score,O
change,O
which,O
most,O
accurately,O
(,O
yield,O
﻿,O
i,O
﻿,O
ng,O
best,O
sensitivity,O
and,O
specificity,O
),O
identified,O
patients,O
experiencing,O
relevant,O
pain,O
relief,O
in,O
analogy,O
with,O
a,O
diagnostic,O
test,O
where,O
the,O
gold,O
standard,O
is,O
patients,O
’,O
perception,O
of,O
change,O
[,O
23,O
].,O
Search,O
strategy,O
We,O
searched,O
PubMed,O
",",O
EMBASE,O
and,O
Cochrane,O
Library,O
until,O
August,O
2016,O
with,O
no,O
language,O
restrictions,O
.,O
The,O
core,O
search,O
string,O
was,O
:,O
(,O
minimal,O
OR,O
minimally,O
OR,O
minimum,O
OR,O
‘,O
clinically,O
significant,O
’,O
OR,O
‘,O
clinically,O
important,O
’,O
OR,O
‘,O
clinically,O
meaningful,O
’,O
OR,O
‘,O
clinically,O
relevant,O
’),O
AND,O
(,O
difference,O
OR,O
change,O
OR,O
relief,O
OR,O
reduction,O
),O
AND,O
(‘,O
pain,O
measurement,O
*’,O
OR,O
‘,O
visual,O
analog,O
scale,O
’,O
OR,O
‘,O
numeric,O
rating,O
scale,O
’),O
AND,O
(,O
pain,O
),O
with,O
variations,O
according,O
to,O
the,O
specific,O
database,O
(,O
Appendix,O
1,O
).,O
The,O
reference,O
lists,O
of,O
all,O
included,O
studies,O
and,O
relevant,O
review,O
papers,O
were,O
read,O
systematically,O
to,O
identify,O
further,O
studies,O
.,O
Screening,O
of,O
titles,O
and,O
abstracts,O
to,O
determine,O
the,O
eligibility,O
of,O
studies,O
was,O
done,O
by,O
the,O
primary,O
author,O
(,O
MFO,O
"),",O
while,O
the,O
selected,O
full,O
-,O
text,O
records,O
were,O
examined,O
by,O
two,O
researchers,O
independently,O
(,O
MFO,O
and,O
either,O
EB,O
",",O
NEL,O
",",O
BT,O
",",O
or,O
MDH,O
).,O
Any,O
disagreement,O
was,O
solved,O
by,O
discussion,O
.,O
Data,O
extraction,O
and,O
retrieval,O
Data,O
extraction,O
was,O
conducted,O
by,O
two,O
researchers,O
independently,O
(,O
MFO,O
and,O
EB,O
",",O
BT,O
",",O
or,O
NEL,O
),O
using,O
pretested,O
data,O
extraction,O
forms,O
generated,O
in,O
EpiData,O
(,O
EpiData,O
Association,O
",",O
Odense,O
",",O
Denmark,O
).,O
Any,O
disagreements,O
were,O
solved,O
by,O
discussion,O
.,O
For,O
each,O
study,O
",",O
we,O
extracted,O
descriptive,O
data,O
including,O
publication,O
year,O
",",O
study,O
design,O
",",O
setting,O
",",O
clinical,O
condition,O
",",O
type,O
of,O
intervention,O
",",O
sampling,O
method,O
",",O
sample,O
size,O
",",O
and,O
definition,O
of,O
patients,O
with,O
relevant,O
change,O
(,O
see,O
Appendix,O
2,O
for,O
complete,O
list,O
).,O
For,O
studies,O
using,O
a,O
mean,O
change,O
approach,O
",",O
we,O
extracted,O
the,O
following,O
outcome,O
data,O
:,O
the,O
MCID,O
for,O
pain,O
relief,O
(,O
absolute,O
values,O
in,O
mm,O
or,O
points,O
and,O
relative,O
value,O
in,O
percent,O
change,O
from,O
baseline,O
),O
and,O
for,O
pain,O
worsening,O
(,O
absolute,O
and,O
relative,O
values,O
"),",O
as,O
well,O
as,O
the,O
substantial,O
clinically,O
important,O
difference,O
for,O
relief,O
and,O
worsening,O
of,O
pain,O
(,O
absolute,O
and,O
relative,O
values,O
).,O
We,O
extracted,O
MCIDs,O
as,O
the,O
mean,O
change,O
in,O
pain,O
score,O
among,O
patients,O
who,O
indicated,O
a,O
one,O
-,O
category,O
improvement,O
(,O
e,O
.,O
g,O
.,O
‘,O
a,O
little,O
better,O
’).,O
If,O
unavailable,O
",",O
we,O
extracted,O
the,O
mean,O
change,O
among,O
patients,O
who,O
were,O
minimally,O
improved,O
by,O
authors,O
’,O
definition,O
(,O
e,O
.,O
g,O
.,O
some,O
authors,O
defined,O
minimum,O
important,O
change,O
as,O
the,O
mean,O
change,O
in,O
pain,O
score,O
among,O
patients,O
with,O
either,O
a,O
one,O
-,O
or,O
two,O
-,O
category,O
improvement,O
).,O
Similarly,O
",",O
we,O
extracted,O
the,O
substantial,O
clinically,O
important,O
differences,O
as,O
the,O
mean,O
change,O
among,O
patients,O
with,O
a,O
two,O
-,O
category,O
improvement,O
or,O
used,O
the,O
authors,O
’,O
definition,O
.,O
We,O
extracted,O
the,O
point,O
estimate,O
of,O
outcomes,O
with,O
their,O
corresponding,O
standard,O
error,O
or,O
",",O
if,O
unavailable,O
",",O
other,O
measures,O
of,O
variation,O
such,O
as,O
standard,O
deviation,O
or,O
95,O
%,O
confidence,O
interval,O
.,O
For,O
studies,O
using,O
a,O
threshold,O
approach,O
",",O
we,O
extracted,O
information,O
about,O
definition,O
of,O
responders,O
(,O
i,O
.,O
e,O
.,O
patients,O
with,O
relevant,O
change,O
),O
and,O
non,O
-,O
responders,O
and,O
the,O
cut,O
-,O
off,O
point,O
with,O
its,O
corresponding,O
sensitivity,O
(,O
i,O
.,O
e,O
.,O
percentage,O
of,O
responders,O
correctly,O
classified,O
as,O
such,O
),O
and,O
specificity,O
(,O
i,O
.,O
e,O
.,O
percentage,O
of,O
non,O
-,O
responders,O
correctly,O
classified,O
as,O
such,O
).,O
If,O
studies,O
reported,O
pain,O
scores,O
from,O
several,O
concurrent,O
pain,O
assessments,O
(,O
e,O
.,O
g,O
.,O
back,O
pain,O
and,O
leg,O
pain,O
"),",O
we,O
extracted,O
the,O
assessment,O
where,O
more,O
data,O
were,O
available,O
or,O
",",O
if,O
no,O
difference,O
found,O
",",O
we,O
randomly,O
selected,O
which,O
to,O
extract,O
.,O
All,O
scales,O
were,O
standardised,O
to,O
a,O
0,O
–,O
100,O
mm,O
scale,O
.,O
When,O
studies,O
reported,O
pain,O
assessments,O
based,O
on,O
both,O
VAS,O
and,O
NRS,O
",",O
we,O
used,O
the,O
assessment,O
based,O
on,O
VAS,O
.,O
If,O
the,O
primary,O
outcome,O
or,O
other,O
key,O
variables,O
were,O
unclear,O
or,O
incompletely,O
reported,O
from,O
a,O
study,O
",",O
we,O
contacted,O
the,O
corresponding,O
author,O
.,O
In,O
cases,O
where,O
authors,O
provided,O
individual,O
patient,O
data,O
",",O
we,O
first,O
checked,O
whether,O
we,O
could,O
replicate,O
a,O
main,O
result,O
of,O
the,O
published,O
paper,O
.,O
We,O
then,O
calculated,O
estimates,O
of,O
absolute,O
and,O
relative,O
MCIDs,O
and,O
their,O
corresponding,O
standard,O
error,O
.,O
For,O
each,O
study,O
",",O
we,O
assessed,O
risk,O
of,O
attrition,O
bias,O
(,O
studies,O
were,O
considered,O
low,O
risk,O
when,O
attrition,O
<,O
10,O
%),O
and,O
risk,O
of,O
non,O
-,O
representative,O
study,O
sample,O
(,O
studies,O
were,O
considered,O
low,O
risk,O
if,O
using,O
consecutive,O
or,O
random,O
sampling,O
).,O
Data,O
synthesis,O
and,O
analysis,O
For,O
each,O
study,O
",",O
we,O
extracted,O
or,O
calculated,O
the,O
MCID,O
for,O
pain,O
relief,O
(,O
absolute,O
and,O
relative,O
change,O
"),",O
and,O
noted,O
results,O
of,O
any,O
study,O
-,O
based,O
exploration,O
of,O
causes,O
for,O
variation,O
",",O
e,O
.,O
g,O
.,O
baseline,O
pain,O
.,O
We,O
then,O
summarised,O
results,O
qualitatively,O
as,O
there,O
was,O
considerable,O
clinical,O
and,O
methodological,O
variation,O
between,O
studies,O
and,O
heterogeneity,O
in,O
their,O
results,O
.,O
To,O
provide,O
an,O
overview,O
",",O
we,O
first,O
reported,O
the,O
range,O
of,O
results,O
for,O
all,O
studies,O
and,O
then,O
the,O
range,O
and,O
median,O
results,O
with,O
inter,O
-,O
quartile,O
ranges,O
(,O
IQR,O
),O
of,O
studies,O
according,O
to,O
analytical,O
strategy,O
(,O
mean,O
change,O
or,O
threshold,O
approach,O
).,O
To,O
facilitate,O
exploration,O
of,O
reasons,O
for,O
heterogeneity,O
",",O
we,O
then,O
pooled,O
results,O
of,O
studies,O
using,O
mean,O
change,O
approach,O
with,O
inverse,O
-,O
variance,O
meta,O
-,O
analysis,O
using,O
random,O
effects,O
models,O
.,O
We,O
studied,O
the,O
association,O
with,O
baseline,O
pain,O
scores,O
in,O
three,O
different,O
analyses,O
.,O
First,O
",",O
we,O
explored,O
the,O
impact,O
of,O
the,O
average,O
population,O
baseline,O
pain,O
in,O
a,O
mixed,O
-,O
effects,O
meta,O
-,O
regression,O
(,O
acknowledging,O
the,O
limitations,O
of,O
aggregated,O
data,O
-,O
level,O
analysis,O
[,O
24,O
]).,O
Second,O
",",O
we,O
pooled,O
individual,O
patient,O
data,O
to,O
estimate,O
the,O
MCID,O
(,O
absolute,O
and,O
relative,O
changes,O
),O
using,O
a,O
two,O
-,O
stage,O
individual,O
participant,O
data,O
meta,O
-,O
analysis,O
.,O
In,O
these,O
models,O
",",O
MCIDs,O
were,O
first,O
estimated,O
in,O
each,O
individual,O
study,O
using,O
a,O
mixed,O
model,O
based,O
on,O
all,O
repeated,O
measurements,O
and,O
participant,O
specific,O
random,O
effects,O
to,O
capture,O
the,O
serial,O
correlation,O
within,O
each,O
participant,O
.,O
Results,O
were,O
then,O
pooled,O
using,O
random,O
-,O
effects,O
inverse,O
-,O
variance,O
meta,O
-,O
analysis,O
.,O
Third,O
",",O
we,O
used,O
the,O
same,O
model,O
to,O
derive,O
outcomes,O
measured,O
at,O
different,O
time,O
points,O
in,O
studies,O
with,O
multiple,O
measurements,O
per,O
patients,O
(,O
i,O
.,O
e,O
.,O
the,O
use,O
of,O
a,O
‘,O
moving,O
baseline,O
’).,O
We,O
furthermore,O
used,O
subgroup,O
analyses,O
to,O
explore,O
whether,O
between,O
-,O
study,O
variation,O
was,O
explained,O
by,O
differences,O
in,O
other,O
clinical,O
and,O
methodological,O
factors,O
including,O
clinical,O
condition,O
",",O
type,O
of,O
pain,O
scale,O
(,O
VAS,O
vs,O
.,O
NRS,O
"),",O
directionality,O
of,O
global,O
transition,O
scale,O
(,O
one,O
-,O
sided,O
vs,O
.,O
two,O
-,O
sided,O
scale,O
"),",O
definition,O
of,O
minimum,O
clinically,O
important,O
change,O
(,O
one,O
category,O
vs,O
.,O
several,O
categories,O
improvement,O
vs,O
.,O
distinction,O
between,O
meaningful,O
and,O
non,O
-,O
meaningful,O
change,O
"),",O
number,O
of,O
pain,O
assessments,O
per,O
patients,O
(,O
single,O
vs,O
.,O
multiple,O
assessments,O
adjusted,O
for,O
correlation,O
vs,O
.,O
multiple,O
unadjusted,O
assessments,O
"),",O
risk,O
of,O
attrition,O
bias,O
(,O
low,O
vs,O
.,O
high,O
or,O
unclear,O
),O
and,O
risk,O
of,O
non,O
-,O
representative,O
sample,O
(,O
low,O
vs,O
.,O
high,O
or,O
unclear,O
).,O
Finally,O
",",O
we,O
used,O
the,O
same,O
analysis,O
strategy,O
for,O
the,O
substantial,O
clinically,O
important,O
difference,O
for,O
pain,O
relief,O
(,O
absolute,O
and,O
relative,O
change,O
),O
and,O
the,O
minimum,O
and,O
substantial,O
clinically,O
important,O
differences,O
for,O
worsening,O
of,O
pain,O
(,O
absolute,O
and,O
relative,O
change,O
).,O
All,O
data,O
analyses,O
were,O
done,O
using,O
Stata,O
/,O
IC,O
version,O
13,O
.,O
Results,O
Study,O
selection,O
We,O
screened,O
1553,O
database,O
records,O
and,O
read,O
273,O
full,O
-,O
text,O
publications,O
(,O
Fig,O
.,O
1,O
).,O
We,O
excluded,O
237,O
publications,O
",",O
mostly,O
because,O
they,O
included,O
patients,O
with,O
chronic,O
pain,O
(,O
n,O
=,O
63,O
),O
or,O
multi,O
-,O
dimensional,O
pain,O
scales,O
(,O
n,O
=,O
53,O
).,O
Thus,O
",",O
we,O
included,O
36,O
publications,O
[,O
21,O
",",O
25,O
–,O
59,O
],O
reporting,O
37,O
studies,O
(,O
8479,O
patients,O
).,O
Fig,O
.,O
1Flow,O
chart,O
of,O
study,O
identification,O
.,O
MCID,O
=,O
Minimal,O
Clinically,O
Important,O
Difference,O
",",O
aAdditional,O
records,O
identified,O
through,O
“,O
related,O
papers,O
”,O
function,O
in,O
databases,O
and,O
reference,O
lists,O
of,O
screened,O
papers,O
",",O
bTwo,O
records,O
include,O
both,O
acute,O
and,O
chronic,O
pain,O
studies,O
",",O
cIncludes,O
studies,O
in,O
which,O
MCID,O
was,O
not,O
based,O
on,O
subjective,O
patient,O
-,O
reported,O
assessment,O
of,O
pain,O
relief,O
Characteristics,O
of,O
included,O
studies,O
The,O
majority,O
of,O
studies,O
were,O
based,O
in,O
emergency,O
departments,O
and,O
included,O
a,O
mix,O
of,O
patients,O
with,O
acute,O
pain,O
of,O
both,O
traumatic,O
and,O
non,O
-,O
traumatic,O
origin,O
(,O
10,O
studies,O
),O
or,O
unspecified,O
pain,O
(,O
7,O
studies,O
).,O
Additional,O
studies,O
included,O
patients,O
with,O
post,O
-,O
operative,O
pain,O
",",O
cancer,B-DS
-,O
related,O
pain,O
",",O
sickle,B-DS
cell,I-DS
crisis,I-DS
",",O
rheumatic,O
pain,O
",",O
abdominal,O
pain,O
",",O
low,O
back,O
pain,O
",",O
or,O
headache,O
(,O
Tables,O
1,O
and,O
2,O
).,O
All,O
studies,O
were,O
published,O
in,O
English,O
.,O
Table,O
1Studies,O
determining,O
minimal,O
clinically,O
important,O
difference,O
as,O
a,O
mean,O
changea,O
(,O
35,O
studies,O
",",O
7894,O
patients,O
),O
StudynPatient,O
characteristicsMethodological,O
characteristicsMCIDClinical,O
conditionAge,O
",",O
years,O
(,O
range,O
),O
b,O
Male,O
sex,O
",",O
%,O
Baseline,O
pain,O
",",O
mmPain,O
scaleTransition,O
scale,O
(,O
directionality,O
",",O
categories,O
),O
Follow,O
-,O
up,O
(,O
Analysis,O
adjusted,O
),O
c,O
Category,O
defining,O
MCIDAbsoluted,O
mm,O
(,O
95,O
%,O
CI,O
),O
Relativee,O
%,O
(,O
95,O
%,O
CI,O
),O
Aicher,O
[,O
25,O
],O
1743Headache38h,O
(,O
16,O
–,O
72,O
),O
2464VAS1,O
-,O
sided,O
",",O
4,O
catSingleLess,O
good,O
efficacy27,O
(,O
25,O
–,O
29,O
),O
NRBailey,O
[,O
26,O
],O
202Mixedg,O
12,O
(,O
8,O
–,O
17,O
),O
57NRNRS2,O
-,O
sided,O
",",O
5,O
catSingleA,O
little,O
better10,O
(,O
0,O
–,O
20,O
),O
h,O
NRBarton,O
2002,O
(,O
reported,O
in,O
Jensen,O
2002,O
[,O
43,O
]),O
125Post,O
-,O
operation,O
pain,O
(,O
laparotomy,O
),O
410NRVAS1,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
unclear,O
),O
A,O
little,O
relief9,O
(,O
7,O
–,O
12,O
),O
13,O
(,O
8,O
–,O
17,O
),O
Bernstein,O
[,O
27,O
],O
135Unspecified42,O
(,O
21,O
–,O
65,O
),O
45100h,O
NRS1,O
-,O
sided,O
",",O
5,O
catSingleA,O
little,O
relief21,O
(,O
18,O
–,O
24,O
),O
NRBijur,O
[,O
28,O
],O
f,O
108Unspecified44,O
(,O
21,O
–,O
85,O
),O
4073VAS,O
+,O
NRS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
no,O
),O
A,O
little,O
less,O
pain16,O
(,O
11,O
–,O
21,O
),O
22,O
(,O
15,O
–,O
28,O
),O
Bijur,O
[,O
29,O
],O
f,O
195Unspecified742774NRS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
yes,O
),O
A,O
little,O
less,O
pain15,O
(,O
14,O
–,O
17,O
),O
24,O
(,O
21,O
–,O
27,O
),O
Bijur,O
[,O
30,O
],O
f,O
214Unspecified743486NRS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
yes,O
),O
A,O
little,O
less,O
pain14,O
(,O
12,O
–,O
15,O
),O
22,O
(,O
19,O
–,O
25,O
),O
Bird,O
[,O
31,O
],O
77Isolated,O
extremity,O
trauma386252VAS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
no,O
),O
A,O
little,O
less,O
pain20,O
(,O
15,O
–,O
25,O
),O
NRBulloch,O
[,O
32,O
],O
121Mixedg,O
(,O
65,O
%,O
traumatic,O
",",O
35,O
%,O
non,O
-,O
traumatic,O
),O
10,O
(,O
5,O
–,O
16,O
),O
5660h,O
VAS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
no,O
),O
A,O
little,O
less,O
pain17,O
(,O
11,O
–,O
23,O
),O
NRCepeda,O
[,O
33,O
],O
700Post,O
-,O
operation,O
pain,O
(,O
mixed,O
),O
41,O
(,O
16,O
–,O
88,O
),O
3879NRS1,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
yes,O
),O
Minimal,O
improvement17,O
(,O
10,O
–,O
20,O
),O
h,O
20,O
(,O
13,O
–,O
30,O
),O
h,O
Chow,O
[,O
34,O
],O
105Pain,O
flare,O
after,O
radiotherapy70h,O
5650NRS2,O
-,O
sided,O
",",O
3,O
catMultiple,O
(,O
no,O
),O
Better23,O
(,O
20,O
–,O
26,O
),O
NRDegerli,O
[,O
35,O
],O
306Thoraco,O
-,O
abdominal,O
pain,O
(,O
non,O
-,O
traumatic,O
),O
42,O
(,O
17,O
–,O
83,O
),O
4067VAS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
no,O
),O
A,O
little,O
less,O
pain25,O
(,O
23,O
–,O
26,O
),O
NRFarrar,O
[,O
36,O
],O
134Cancer,B-DS
-,O
related,O
breakthrough,O
pain55,O
(,O
21,O
–,O
87,O
),O
53NRNRS1,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
yes,O
),O
Slight,O
relief13,O
–,O
19j,O
16,O
–,O
34j,O
Fosnocht,O
[,O
37,O
],O
1490Mixedg,O
36,O
(,O
18,O
–,O
89,O
),O
4763VAS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
no,O
),O
A,O
little,O
less,O
pain21,O
(,O
19,O
–,O
23,O
),O
NRGallagher,O
[,O
38,O
],O
f,O
96Mixedg,O
37,O
(,O
19,O
–,O
71,O
),O
4564VAS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
yes,O
),O
A,O
little,O
less,O
pain15,O
(,O
11,O
–,O
18,O
),O
17,O
(,O
6,O
–,O
29,O
),O
Gallagher,O
[,O
39,O
],O
f,O
101Abdominal,O
pain40,O
(,O
15,O
–,O
88,O
),O
3965VAS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
yes,O
),O
A,O
little,O
less,O
pain18,O
(,O
14,O
–,O
21,O
),O
23,O
(,O
12,O
–,O
33,O
),O
Grilo,O
[,O
40,O
],O
50Rheumatic,O
conditions49,O
(,O
16,O
–,O
85,O
),O
4478VAS1,O
-,O
sided,O
",",O
5,O
catSingleModerate,O
relief40i,O
NRGrotle,O
[,O
41,O
],O
54Acute,O
low,O
back,O
pain382739VAS,O
+,O
NRS2,O
-,O
sided,O
",",O
6,O
catSingleSlightly,O
improved34,O
(,O
20,O
–,O
48,O
),O
Holdgate,O
[,O
42,O
],O
f,O
79Unspecified53,O
(,O
21,O
–,O
93,O
),O
NR54VAS,O
+,O
NRS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
yes,O
),O
A,O
bit,O
better16,O
(,O
12,O
–,O
20,O
),O
34,O
(,O
27,O
–,O
41,O
),O
Kelly,O
[,O
44,O
],O
Kelly,O
[,O
45,O
",",O
46,O
],O
156Mixedg,O
(,O
43,O
%,O
traumatic,O
",",O
57,O
%,O
non,O
-,O
traumatic,O
),O
44,O
(,O
16,O
–,O
97,O
),O
5651VAS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
unclear,O
),O
A,O
little,O
better8,O
(,O
4,O
–,O
12,O
),O
NRKendrick,O
2005,O
[,O
47,O
],O
356Mixedg,O
(,O
35,O
%,O
traumatic,O
",",O
65,O
%,O
non,O
-,O
traumatic,O
),O
41h,O
4266NRS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
no,O
),O
A,O
little,O
less,O
pain15,O
(,O
13,O
–,O
16,O
),O
NRLopez,O
[,O
21,O
],O
74Sickle,O
cell,O
crisisNRNR79VAS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
no,O
),O
A,O
little,O
better14,O
(,O
11,O
–,O
16,O
),O
h,O
",",O
k,O
NRMark,O
[,O
48,O
],O
186Unspecified49,O
(,O
15,O
–,O
87,O
),O
3865VAS2,O
-,O
sided,O
",",O
5,O
catSingleA,O
little,O
better17,O
(,O
14,O
–,O
20,O
),O
k,O
NRMartin,O
[,O
49,O
],O
95Third,O
molar,O
extraction304033VAS2,O
-,O
sided,O
",",O
7,O
catSingleMuch,O
improved,O
or,O
best,O
ever23i,O
72i,O
Martin,O
[,O
49,O
],O
63Third,O
molar,O
extraction254035DoDoDoDo25i,O
69i,O
Martin,O
[,O
49,O
],O
62Third,O
molar,O
extraction275030DoDoDoDo29i,O
85i,O
McConahay,O
[,O
50,O
],O
126Mixedg,O
(,O
48,O
%,O
traumatic,O
",",O
52,O
%,O
non,O
-,O
traumatic,O
),O
9,O
(,O
5,O
–,O
12,O
),O
5683VAS2,O
-,O
sided,O
",",O
5,O
catSingleA,O
little,O
less,O
pain24,O
(,O
17,O
–,O
31,O
),O
NRMohan,O
[,O
51,O
],O
f,O
125Unspecified35h,O
4446VAS,O
+,O
NRS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
yes,O
),O
A,O
bit,O
better13,O
(,O
9,O
–,O
17,O
),O
18,O
(,O
1,O
–,O
35,O
),O
Myrvik,O
[,O
52,O
],O
28Sickle,O
cell,O
crisis15,O
(,O
8,O
–,O
18,O
),O
5075h,O
VAS,O
+,O
NRS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
unclear,O
),O
A,O
little,O
better10,O
(,O
4,O
–,O
15,O
),O
NRPowell,O
[,O
53,O
],O
73Mixed,O
(,O
63,O
%,O
traumatic,O
",",O
37,O
%,O
non,O
-,O
traumatic,O
),O
12,O
(,O
8,O
–,O
15,O
),O
NR60VAS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
yes,O
),O
A,O
bit,O
better11i,O
NRRasmussen,O
2002,O
(,O
reported,O
in,O
Jensen,O
2002,O
[,O
43,O
]),O
123Post,O
-,O
operation,O
pain,O
(,O
knee,O
surgery,O
),O
6534NRVAS1,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
unclear,O
),O
A,O
little,O
relief13,O
(,O
10,O
–,O
17,O
),O
18,O
(,O
14,O
–,O
22,O
),O
Sloman,O
[,O
54,O
],O
150Post,O
-,O
operation,O
pain,O
(,O
mixed,O
),O
47,O
(,O
14,O
–,O
89,O
),O
5367NRS1,O
-,O
sided,O
",",O
5,O
catSingleMinimal,O
relief18i,O
36,O
(,O
21,O
–,O
51,O
),O
Stahmer,O
[,O
55,O
],O
81Mixedg,O
(,O
31,O
%,O
traumatic,O
",",O
69,O
%,O
non,O
-,O
traumatic,O
),O
38,O
(,O
16,O
–,O
87,O
),O
4468NRS1,O
-,O
sided,O
",",O
5,O
catSingleSome,O
relief,O
or,O
partial,O
reliefNR30,O
(,O
18,O
–,O
42,O
),O
Todd,O
[,O
56,O
],O
48Trauma35h,O
(,O
17,O
–,O
76,O
),O
6956VAS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
no,O
),O
A,O
little,O
less,O
pain16,O
(,O
10,O
–,O
22,O
),O
NRVoepel,O
-,O
Lewis,O
[,O
59,O
],O
113Post,O
-,O
operation,O
pain,O
(,O
e,O
.,O
g,O
.,O
spinal,O
fusion,O
",",O
splenectomy,O
),O
13,O
(,O
7,O
–,O
16,O
),O
43NRNRS2,O
-,O
sided,O
",",O
5,O
catMultiple,O
(,O
yes,O
),O
A,O
little,O
better10,O
(,O
5,O
–,O
15,O
),O
NR,O
aMean,O
change,O
in,O
pain,O
score,O
among,O
patients,O
with,O
minimum,O
improvement,O
of,O
pain,O
bMean,O
(,O
range,O
),O
if,O
not,O
otherwise,O
indicated,O
",",O
cEstimate,O
based,O
on,O
single,O
or,O
multiple,O
follow,O
-,O
up,O
measurements,O
(,O
were,O
standard,O
errors,O
adjusted,O
for,O
dependency,O
between,O
multiple,O
measurements,O
?),O
dAbsolute,O
=,O
mm,O
reduction,O
on,O
a,O
100,O
mm,O
scale,O
eRelative,O
=,O
%,O
reduction,O
from,O
baseline,O
fIndividual,O
patient,O
data,O
provided,O
by,O
authors,O
gMixed,O
patient,O
population,O
recruited,O
at,O
Hospital,O
Emergency,O
Department,O
hData,O
is,O
median,O
(,O
inter,O
-,O
quartile,O
range,O
),O
i95,O
%,O
CI,O
unavailable,O
jEstimates,O
for,O
subgroups,O
with,O
different,O
baseline,O
pain,O
kPatients,O
with,O
minimal,O
improvement,O
and,O
worsening,O
of,O
pain,O
were,O
combined,O
MCID,O
minimum,O
clinically,O
important,O
difference,O
",",O
VAS,O
visual,O
analogue,O
scale,O
",",O
NRS,O
numeric,O
rating,O
scale,O
",",O
CI,O
confidence,O
interval,O
",",O
NR,O
not,O
reported,O
Table,O
2Studies,O
determining,O
minimal,O
clinically,O
important,O
difference,O
as,O
a,O
threshold,O
valuea,O
(,O
7,O
studies,O
",",O
2602,O
patients,O
),O
StudynPatient,O
characteristicsMethodological,O
characteristicsMCIDClinical,O
conditionAge,O
",",O
yearsb,O
Male,O
sex,O
",",O
%,O
Baseline,O
pain,O
",",O
mmPain,O
scaleTransition,O
scale,O
(,O
directionality,O
",",O
categories,O
),O
Anchor,O
questionCategories,O
defining,O
respondersAbsolute,O
",",O
mm,O
(,O
sensitivity,O
",",O
specificity,O
),O
Relative,O
",",O
%,O
(,O
sensitivity,O
",",O
specificity,O
),O
Aicher,O
[,O
25,O
],O
1743Headache38b,O
(,O
16,O
–,O
72,O
),O
2464VAS1,O
-,O
sided,O
",",O
4,O
cat,O
(,O
0,O
to,O
+,O
4,O
points,O
")""",O
How,O
do,O
you,O
assess,O
the,O
efficacy,O
of,O
your,O
tablets,O
"?""",O
Good,O
(+,O
3,O
),O
or,O
very,O
good,O
(+,O
4,O
),O
35,O
(,O
76,O
"%,",O
76,O
%),O
NRGrotle,O
[,O
41,O
],O
54Acute,O
low,O
back,O
pain382739VAS,O
+,O
NRS2,O
-,O
sided,O
",",O
6,O
cat,O
(–,O
1,O
to,O
+,O
4,O
points,O
")""",O
To,O
which,O
extent,O
has,O
your,O
back,O
problem,O
changed,O
"?""",O
Slightly,O
improved,O
(+,O
1,O
"),",O
much,O
better,O
(+,O
2,O
"),",O
very,O
much,O
better,O
(+,O
3,O
"),",O
or,O
completely,O
gone,O
(+,O
4,O
),O
10,O
(,O
87,O
"%,",O
81,O
%),O
NRMartin,O
[,O
49,O
],O
63Post,O
-,O
operation,O
pain,O
(,O
third,O
molar,O
extraction,O
),O
304033VAS2,O
-,O
sided,O
",",O
7,O
cat,O
(–,O
3,O
to,O
+,O
3,O
points,O
),O
Assessment,O
of,O
recovery,O
following,O
treatmentMuch,O
improved,O
(+,O
2,O
),O
or,O
best,O
ever,O
(+,O
3,O
),O
10,O
(,O
70,O
"%,",O
82,O
%),O
50,O
(,O
82,O
"%,",O
82,O
%),O
Martin,O
[,O
49,O
],O
62Post,O
-,O
operation,O
pain,O
(,O
third,O
molar,O
extraction,O
),O
254035DoDoDoDo10,O
(,O
71,O
"%,",O
71,O
%),O
50,O
(,O
83,O
"%,",O
86,O
%),O
Martin,O
[,O
49,O
],O
95Post,O
-,O
operation,O
pain,O
(,O
third,O
molar,O
extraction,O
),O
275030DoDoDoDo10,O
(,O
87,O
"%,",O
69,O
%),O
50,O
(,O
97,O
"%,",O
82,O
%),O
Tsze,O
[,O
57,O
],O
314Mixedd,O
1050NRVAS2,O
-,O
sided,O
",",O
5,O
cat,O
(–,O
2,O
to,O
+,O
2,O
points,O
),O
Assessment,O
of,O
change,O
in,O
pain,O
following,O
treatmentA,O
little,O
better,O
(+,O
1,O
),O
10,O
(,O
76,O
"%,",O
74,O
%),O
15,O
(,O
78,O
"%,",O
79,O
%),O
Tubach,O
[,O
58,O
],O
271Rotator,B-DS
cuff,I-DS
syndrome483868NRS2,I-DS
-,O
sided,O
",",O
15,O
cat,O
(–,O
7,O
to,O
+,O
7,O
points,O
),O
Assessment,O
of,O
response,O
to,O
treatmentA,O
good,O
deal,O
better,O
(+,O
5,O
),O
or,O
a,O
great,O
deal,O
better,O
(+,O
6,O
),O
34,O
–,O
63c,O
(,O
75,O
"%,",O
NR,O
),O
NR,O
MCID,O
minimum,O
clinically,O
important,O
difference,O
(,O
mm,O
change,O
on,O
a,O
100,O
mm,O
scale,O
"),",O
VAS,O
visual,O
analogue,O
scale,O
",",O
NRS,O
numeric,O
rating,O
scale,O
",",O
NR,O
not,O
reported,O
aThreshold,O
in,O
pain,O
reduction,O
associated,O
with,O
the,O
best,O
accuracy,O
(,O
sensitivity,O
and,O
specificity,O
),O
for,O
identifying,O
improved,O
patients,O
bData,O
is,O
median,O
(,O
range,O
),O
cEstimates,O
for,O
subgroups,O
with,O
different,O
baseline,O
pain,O
cMixed,O
patient,O
population,O
recruited,O
at,O
Hospital,O
Emergency,O
Department,O
Twenty,O
studies,O
assessed,O
pain,O
using,O
a,O
100,O
mm,O
VAS,O
(,O
or,O
the,O
similar,O
Color,O
Analog,O
Scale,O
"),",O
and,O
12,O
studies,O
used,O
an,O
11,O
-,O
point,O
NRS,O
(,O
0,O
–,O
10,O
"),",O
while,O
five,O
studies,O
used,O
both,O
scales,O
.,O
In,O
32,O
studies,O
",",O
patients,O
compared,O
their,O
current,O
pain,O
intensity,O
with,O
pain,O
at,O
their,O
previous,O
assessment,O
",",O
while,O
they,O
were,O
asked,O
to,O
assess,O
the,O
effect,O
of,O
their,O
treatment,O
in,O
five,O
studies,O
[,O
25,O
",",O
49,O
",",O
58,O
].,O
Transition,O
scales,O
were,O
either,O
two,O
-,O
sided,O
(,O
29,O
studies,O
),O
with,O
3,O
–,O
15,O
response,O
categories,O
for,O
both,O
improvement,O
and,O
deterioration,O
",",O
or,O
one,O
-,O
sided,O
(,O
8,O
studies,O
),O
with,O
five,O
response,O
categories,O
addressing,O
only,O
improvement,O
.,O
For,O
studies,O
using,O
the,O
mean,O
change,O
approach,O
",",O
the,O
majority,O
defined,O
the,O
minimum,O
clinically,O
important,O
improvement,O
as,O
a,O
one,O
-,O
category,O
improvement,O
on,O
the,O
transition,O
scale,O
(,O
31,O
studies,O
).,O
The,O
response,O
categories,O
were,O
similar,O
with,O
wordings,O
such,O
as,O
‘,O
a,O
little,O
less,O
pain,O
"’,",O
‘,O
a,O
bit,O
better,O
"’,",O
‘,O
slightly,O
improved,O
"’,",O
or,O
‘,O
slight,O
relief,O
’.,O
In,O
four,O
studies,O
",",O
the,O
MCID,O
was,O
defined,O
as,O
the,O
mean,O
change,O
in,O
pain,O
score,O
among,O
patients,O
with,O
a,O
one,O
-,O
or,O
two,O
-,O
category,O
improvement,O
",",O
thereby,O
combing,O
patients,O
answering,O
‘,O
some,O
relief,O
’,O
and,O
‘,O
partial,O
relief,O
’,O
[,O
55,O
"],",O
or,O
‘,O
much,O
improved,O
’,O
and,O
‘,O
best,O
ever,O
’,O
[,O
49,O
–,O
51,O
].,O
Finally,O
",",O
two,O
studies,O
differentiated,O
between,O
non,O
-,O
important,O
and,O
important,O
change,O
",",O
using,O
the,O
categories,O
‘,O
inadequate,O
relief,O
’,O
and,O
‘,O
moderate,O
relief,O
’,O
in,O
one,O
study,O
[,O
40,O
"],",O
and,O
‘,O
poor,O
’,O
and,O
‘,O
less,O
good,O
’,O
efficiency,O
of,O
treatment,O
in,O
another,O
[,O
25,O
],O
(,O
Table,O
1,O
).,O
Studies,O
using,O
the,O
threshold,O
approach,O
had,O
large,O
variation,O
in,O
transition,O
scales,O
and,O
definitions,O
of,O
responders,O
versus,O
non,O
-,O
responders,O
;,O
patients,O
were,O
regarded,O
as,O
importantly,O
improved,O
if,O
they,O
indicated,O
a,O
one,O
-,O
category,O
relief,O
in,O
two,O
studies,O
[,O
41,O
",",O
57,O
"],",O
while,O
they,O
needed,O
a,O
five,O
-,O
category,O
improvement,O
in,O
another,O
[,O
58,O
],O
(,O
Table,O
2,O
).,O
Pain,O
intensity,O
was,O
assessed,O
at,O
baseline,O
and,O
a,O
single,O
follow,O
-,O
up,O
measurement,O
in,O
14,O
studies,O
",",O
while,O
it,O
was,O
assessed,O
at,O
multiple,O
(,O
from,O
2,O
to,O
16,O
),O
follow,O
-,O
ups,O
with,O
intervals,O
between,O
10,O
and,O
45,O
minutes,O
in,O
23,O
studies,O
.,O
The,O
latter,O
group,O
then,O
derived,O
their,O
outcome,O
as,O
the,O
summarised,O
mean,O
difference,O
in,O
pain,O
score,O
from,O
the,O
patients,O
’,O
previous,O
pain,O
assessment,O
when,O
they,O
reported,O
minimum,O
relief,O
(,O
i,O
.,O
e,O
.,O
a,O
series,O
of,O
‘,O
moving,O
baselines,O
’).,O
In,O
eight,O
of,O
these,O
studies,O
",",O
the,O
P,O
values,O
of,O
analyses,O
were,O
adjusted,O
for,O
correlation,O
between,O
estimates,O
",",O
for,O
example,O
",",O
with,O
Generalised,O
Estimation,O
Equation,O
",",O
while,O
the,O
remaining,O
studies,O
either,O
made,O
no,O
adjustment,O
or,O
did,O
not,O
report,O
this,O
.,O
Access,O
to,O
individual,O
patient,O
data,O
increased,O
the,O
number,O
of,O
studies,O
with,O
adjusted,O
estimates,O
to,O
11,O
.,O
In,O
10,O
studies,O
",",O
the,O
MCID,O
was,O
defined,O
as,O
a,O
numeric,O
change,O
for,O
all,O
patients,O
with,O
minimum,O
change,O
",",O
regardless,O
of,O
whether,O
pain,O
had,O
improved,O
or,O
worsened,O
.,O
After,O
contacting,O
authors,O
",",O
separate,O
estimates,O
for,O
pain,O
relief,O
were,O
available,O
from,O
eight,O
of,O
these,O
.,O
MCID,O
regardless,O
of,O
analytical,O
approach,O
Standardised,O
to,O
a,O
100,O
-,O
mm,O
scale,O
",",O
the,O
absolute,O
MCID,O
in,O
30,O
studies,O
ranged,O
from,O
8,O
to,O
40,O
mm,O
",",O
and,O
the,O
relative,O
difference,O
in,O
15,O
studies,O
ranged,O
from,O
13,O
%,O
to,O
85,O
%.,O
MCIDs,O
in,O
studies,O
using,O
the,O
mean,O
change,O
approach,O
The,O
determination,O
of,O
the,O
MCID,O
was,O
based,O
on,O
a,O
mean,O
change,O
approach,O
in,O
35,O
studies,O
",",O
of,O
which,O
30,O
(,O
6598,O
patients,O
),O
were,O
included,O
in,O
our,O
analyses,O
and,O
five,O
were,O
disregarded,O
(,O
see,O
below,O
).,O
Twenty,O
-,O
nine,O
studies,O
(,O
6517,O
patients,O
),O
reported,O
absolute,O
values,O
ranging,O
from,O
8,O
to,O
40,O
mm,O
",",O
with,O
a,O
median,O
of,O
17,O
mm,O
(,O
IQR,O
14,O
–,O
23,O
mm,O
),O
(,O
Fig,O
.,O
2a,O
).,O
Only,O
nine,O
of,O
the,O
30,O
studies,O
reported,O
relative,O
MCIDs,O
",",O
but,O
access,O
to,O
individual,O
patient,O
data,O
made,O
relative,O
values,O
available,O
from,O
14,O
studies,O
(,O
1617,O
patients,O
),O
ranging,O
from,O
13,O
%,O
to,O
85,O
"%,",O
with,O
a,O
median,O
of,O
23,O
%,O
(,O
IQR,O
18,O
–,O
36,O
%),O
(,O
Fig,O
.,O
2b,O
).,O
Fig,O
.,O
2,O
a,O
Range,O
of,O
absolute,O
minimal,O
clinically,O
important,O
differences,O
in,O
acute,O
pain,O
assessed,O
by,O
the,O
mean,O
change,O
approach,O
*,O
(,O
29,O
studies,O
",",O
6517,O
patients,O
).,O
*,O
MCID,O
assessed,O
as,O
the,O
mean,O
change,O
in,O
pain,O
score,O
among,O
patients,O
with,O
minimal,O
improvement,O
of,O
pain,O
",",O
MCID,O
=,O
Minimal,O
Clinically,O
Important,O
Difference,O
(,O
mm,O
reduction,O
on,O
a,O
100,O
mm,O
scale,O
"),",O
Studies,O
where,O
standard,O
error,O
(,O
or,O
data,O
for,O
obtaining,O
this,O
),O
was,O
unavailable,O
are,O
presented,O
as,O
point,O
estimates,O
without,O
95,O
%,O
CI,O
(,O
,O
=,O
not,O
applicable,O
).,O
b,O
Range,O
of,O
relative,O
minimal,O
clinically,O
important,O
differences,O
in,O
acute,O
pain,O
assessed,O
by,O
the,O
mean,O
change,O
approach,O
*,O
(,O
14,O
studies,O
",",O
1617,O
patients,O
).,O
*,O
MCID,O
assessed,O
as,O
the,O
mean,O
change,O
in,O
pain,O
score,O
among,O
patients,O
with,O
minimal,O
improvement,O
of,O
pain,O
",",O
MCID,O
=,O
Minimal,O
Clinically,O
Important,O
Difference,O
(%,O
reduction,O
from,O
baseline,O
"),",O
Studies,O
where,O
standard,O
error,O
(,O
or,O
data,O
for,O
obtaining,O
this,O
),O
was,O
unavailable,O
are,O
presented,O
as,O
point,O
estimates,O
without,O
95,O
%,O
CI,O
(,O
,O
=,O
not,O
applicable,O
),O
For,O
data,O
syntheses,O
",",O
we,O
did,O
not,O
include,O
results,O
from,O
five,O
of,O
the,O
35,O
studies,O
(,O
1567,O
patients,O
),O
as,O
they,O
did,O
not,O
differentiate,O
between,O
pain,O
relief,O
and,O
pain,O
worsening,O
[,O
21,O
",",O
48,O
"],",O
because,O
median,O
(,O
and,O
not,O
mean,O
),O
differences,O
in,O
pain,O
were,O
reported,O
[,O
26,O
",",O
33,O
"],",O
or,O
because,O
outcomes,O
were,O
reported,O
for,O
subgroups,O
and,O
no,O
overall,O
estimate,O
could,O
be,O
derived,O
[,O
36,O
].,O
The,O
range,O
of,O
MCID,O
in,O
these,O
studies,O
was,O
comparable,O
to,O
the,O
included,O
studies,O
:,O
10,O
–,O
19,O
mm,O
.,O
An,O
additional,O
six,O
studies,O
(,O
493,O
patients,O
),O
were,O
not,O
included,O
in,O
meta,O
-,O
analysis,O
since,O
information,O
about,O
standard,O
error,O
of,O
estimates,O
was,O
unavailable,O
[,O
40,O
",",O
49,O
",",O
53,O
",",O
54,O
].,O
The,O
results,O
from,O
these,O
studies,O
ranged,O
from,O
11,O
to,O
40,O
mm,O
.,O
We,O
had,O
data,O
usable,O
for,O
meta,O
-,O
analyses,O
from,O
23,O
studies,O
(,O
6024,O
patients,O
),O
reporting,O
absolute,O
values,O
and,O
11,O
studies,O
(,O
1397,O
patients,O
),O
reporting,O
relative,O
values,O
.,O
Meta,O
-,O
analyses,O
of,O
both,O
the,O
absolute,O
and,O
relative,O
values,O
showed,O
considerable,O
heterogeneity,O
:,O
I2,O
=,O
93,O
"%,",O
P,O
<,O
0,O
.,O
001,O
and,O
I2,O
=,O
75,O
"%,",O
P,O
<,O
0,O
.,O
001,O
(,O
Table,O
3,O
).,O
We,O
present,O
the,O
meta,O
-,O
analyses,O
for,O
completeness,O
and,O
as,O
a,O
basis,O
for,O
exploring,O
reasons,O
for,O
the,O
heterogeneity,O
",",O
but,O
stress,O
that,O
medians,O
and,O
interquartile,O
ranges,O
are,O
more,O
appropriate,O
descriptors,O
of,O
the,O
results,O
.,O
Table,O
3Clinically,O
important,O
differences,O
in,O
acute,O
painAnalysis,O
of,O
mediansa,O
Analysis,O
of,O
pooled,O
averageClinically,O
important,O
differenceRangeNumber,O
of,O
studies,O
(,O
patientsb,O
),O
MCID,O
median,O
(,O
IQR,O
),O
Number,O
of,O
studies,O
(,O
patientsb,O
),O
MCID,O
pooled,O
average,O
(,O
95,O
%,O
CI,O
"),",O
I2,O
c,O
Minimum,O
clinically,O
important,O
difference,O
for,O
pain,O
relief,O
Absolute,O
change,O
",",O
mm,O
Mean,O
change,O
approach8,O
to,O
4029,O
(,O
6517,O
),O
17,O
(,O
14,O
to,O
23,O
),O
23,O
(,O
6024,O
),O
17,O
(,O
15,O
to,O
19,O
"),",O
93,O
%,O
Threshold,O
approach10,O
to,O
356,O
(,O
2331,O
),O
10,O
(,O
10,O
to,O
10,O
),O
NANA,O
Relative,O
change,O
",",O
%,O
Mean,O
change,O
approach13,O
to,O
8514,O
(,O
1617,O
),O
23,O
(,O
18,O
to,O
36,O
),O
11,O
(,O
1397,O
),O
22,O
(,O
19,O
to,O
26,O
"),",O
75,O
%,O
Threshold,O
approach15,O
to,O
504,O
(,O
534,O
),O
50,O
(,O
33,O
to,O
50,O
),O
NANASubstantial,O
clinically,O
important,O
difference,O
for,O
pain,O
relief,O
Absolute,O
change,O
",",O
mm,O
Mean,O
change,O
approach18,O
to,O
5423,O
(,O
6114,O
),O
32,O
(,O
24,O
to,O
38,O
),O
21,O
(,O
5891,O
),O
32,O
(,O
27,O
to,O
38,O
"),",O
97,O
%,O
Relative,O
change,O
",",O
%,O
Mean,O
change,O
approach36,O
to,O
7811,O
(,O
1397,O
),O
57,O
(,O
45,O
to,O
65,O
),O
11,O
(,O
1397,O
),O
57,O
(,O
47,O
to,O
67,O
"),",O
94,O
%,O
Minimum,O
clinically,O
important,O
difference,O
for,O
pain,O
worsening,O
Absolute,O
change,O
",",O
mm,O
Mean,O
change,O
approach,O
−,O
21,O
to,O
–,O
818,O
(,O
3822,O
)−,O
11,O
(–,O
13,O
to,O
–,O
10,O
),O
16,O
(,O
3644,O
)−,O
12,O
(–,O
14,O
to,O
–,O
11,O
"),",O
62,O
%,O
Relative,O
change,O
",",O
%,O
Mean,O
change,O
approach,O
−,O
89,O
to,O
–,O
177,O
(,O
918,O
)−,O
44,O
(–,O
90,O
to,O
–,O
16,O
),O
7,O
(,O
918,O
)−,O
35,O
(–,O
47,O
to,O
–,O
23,O
"),",O
67,O
%,O
Substantial,O
clinically,O
important,O
difference,O
for,O
pain,O
worsening,O
Absolute,O
change,O
",",O
mm,O
Mean,O
change,O
approach,O
−,O
66,O
to,O
016,O
(,O
3663,O
)−,O
21,O
(–,O
28,O
to,O
–,O
16,O
),O
14,O
(,O
3464,O
)−,O
24,O
(–,O
29,O
to,O
–,O
18,O
"),",O
71,O
%,O
Relative,O
change,O
",",O
%,O
Mean,O
change,O
approach,O
−,O
292,O
to,O
–,O
187,O
(,O
918,O
)−,O
83,O
(–,O
292,O
to,O
–,O
18,O
),O
7,O
(,O
918,O
)−,O
34,O
(–,O
49,O
to,O
–,O
19,O
"),",O
20,O
%,O
MCID,O
minimum,O
clinically,O
important,O
difference,O
(,O
mm,O
or,O
%,O
reduction,O
on,O
a,O
100,O
mm,O
scale,O
"),",O
SCID,O
substantial,O
clinically,O
important,O
difference,O
(,O
mm,O
or,O
%,O
reduction,O
on,O
a,O
100,O
mm,O
scale,O
"),",O
IQR,O
inter,O
-,O
quartile,O
range,O
",",O
,O
not,O
applicable,O
aThe,O
median,O
is,O
based,O
on,O
studies,O
included,O
in,O
the,O
pooled,O
average,O
as,O
well,O
as,O
studies,O
with,O
unavailable,O
standard,O
errors,O
bTotal,O
number,O
of,O
patients,O
in,O
the,O
included,O
studies,O
cI2,O
is,O
the,O
percentage,O
of,O
the,O
variability,O
in,O
results,O
that,O
is,O
due,O
to,O
heterogeneity,O
rather,O
than,O
sampling,O
error,O
(,O
chance,O
);,O
I2,O
of,O
0,O
%,O
to,O
40,O
%,O
might,O
not,O
be,O
important,O
",",O
30,O
%,O
to,O
60,O
%,O
may,O
represent,O
moderate,O
heterogeneity,O
",",O
50,O
%,O
to,O
90,O
%,O
may,O
represent,O
substantial,O
heterogeneity,O
",",O
and,O
75,O
%,O
to,O
100,O
%,O
represents,O
considerable,O
heterogeneity,O
MCID,O
in,O
studies,O
using,O
the,O
threshold,O
approach,O
Seven,O
of,O
the,O
37,O
included,O
studies,O
(,O
2602,O
patients,O
),O
determined,O
clinically,O
important,O
differences,O
as,O
a,O
threshold,O
to,O
differentiate,O
between,O
patients,O
with,O
or,O
without,O
relevant,O
pain,O
relief,O
.,O
Absolute,O
thresholds,O
ranged,O
from,O
10,O
to,O
35,O
mm,O
in,O
six,O
studies,O
(,O
2331,O
patients,O
),O
with,O
a,O
median,O
of,O
10,O
mm,O
",",O
and,O
the,O
relative,O
threshold,O
ranged,O
from,O
15,O
%,O
to,O
50,O
%,O
in,O
four,O
studies,O
(,O
534,O
patients,O
),O
(,O
Table,O
3,O
).,O
In,O
one,O
additional,O
study,O
[,O
58,O
"],",O
patients,O
were,O
defined,O
as,O
responders,O
if,O
they,O
indicated,O
at,O
least,O
a,O
five,O
-,O
category,O
improvement,O
.,O
The,O
corresponding,O
clinically,O
important,O
differences,O
were,O
thus,O
higher,O
(,O
34,O
to,O
63,O
mm,O
depending,O
on,O
baseline,O
pain,O
),O
than,O
in,O
studies,O
where,O
patients,O
only,O
needed,O
a,O
one,O
-,O
[,O
41,O
",",O
57,O
"],",O
two,O
-,O
[,O
49,O
"],",O
or,O
three,O
-,O
category,O
improvement,O
[,O
25,O
"],",O
respectively,O
",",O
to,O
be,O
defined,O
as,O
responders,O
(,O
Table,O
2,O
).,O
Impact,O
of,O
baseline,O
pain,O
scores,O
on,O
the,O
MCID,O
Eleven,O
studies,O
had,O
assessed,O
the,O
possible,O
influence,O
of,O
baseline,O
pain,O
on,O
minimum,O
clinically,O
improvement,O
(,O
Appendix,O
3,O
).,O
Of,O
nine,O
studies,O
assessing,O
absolute,O
change,O
",",O
seven,O
reported,O
an,O
association,O
[,O
31,O
",",O
33,O
",",O
36,O
",",O
43,O
",",O
58,O
",",O
59,O
].,O
The,O
two,O
remaining,O
studies,O
found,O
no,O
association,O
",",O
but,O
these,O
were,O
disregarded,O
since,O
they,O
determined,O
the,O
MCID,O
without,O
differentiating,O
between,O
pain,O
relief,O
and,O
pain,O
worsening,O
[,O
21,O
",",O
45,O
].,O
Six,O
studies,O
assessed,O
the,O
association,O
between,O
baseline,O
pain,O
and,O
relative,O
change,O
and,O
either,O
found,O
the,O
association,O
to,O
be,O
non,O
-,O
significant,O
or,O
found,O
it,O
to,O
be,O
weaker,O
than,O
for,O
absolute,O
change,O
.,O
Based,O
on,O
meta,O
-,O
regression,O
",",O
we,O
found,O
no,O
association,O
between,O
baseline,O
pain,O
and,O
either,O
absolute,O
(,O
20,O
studies,O
",",O
P,O
=,O
0,O
.,O
70,O
),O
nor,O
relative,O
(,O
9,O
studies,O
",",O
P,O
=,O
0,O
.,O
83,O
),O
estimates,O
of,O
MCIDs,O
.,O
However,O
",",O
based,O
on,O
individual,O
patient,O
data,O
meta,O
-,O
analysis,O
from,O
seven,O
studies,O
(,O
918,O
patients,O
"),",O
we,O
found,O
a,O
strong,O
association,O
between,O
baseline,O
pain,O
and,O
absolute,O
MCID,O
",",O
showing,O
that,O
patients,O
with,O
higher,O
baseline,O
pain,O
need,O
larger,O
pain,O
reduction,O
to,O
reach,O
a,O
minimum,O
clinically,O
relevant,O
difference,O
compared,O
to,O
patients,O
with,O
lower,O
baseline,O
pain,O
.,O
For,O
each,O
10,O
mm,O
increase,O
in,O
baseline,O
pain,O
",",O
MCID,O
increased,O
by,O
3,O
.,O
1,O
mm,O
(,O
95,O
%,O
confidence,O
interval,O
",",O
2,O
.,O
8,O
–,O
3,O
.,O
5,O
mm,O
",",O
P,O
<,O
0,O
.,O
001,O
",",O
I2,O
=,O
0,O
%).,O
Thus,O
",",O
for,O
patients,O
with,O
initial,O
pain,O
levels,O
<,O
40,O
",",O
40,O
–,O
70,O
",",O
and,O
>,O
70,O
mm,O
",",O
the,O
MCIDs,O
were,O
6,O
(,O
4,O
–,O
8,O
),O
mm,O
",",O
13,O
(,O
11,O
–,O
14,O
),O
mm,O
",",O
and,O
21,O
(,O
20,O
–,O
23,O
),O
mm,O
",",O
respectively,O
(,O
Fig,O
.,O
3,O
).,O
The,O
corresponding,O
relative,O
estimates,O
of,O
MCIDs,O
did,O
not,O
differ,O
significantly,O
:,O
17,O
(,O
4,O
–,O
30,O
),O
"%,",O
23,O
(,O
20,O
–,O
25,O
),O
"%,",O
and,O
24,O
(,O
22,O
–,O
26,O
),O
"%,",O
respectively,O
.,O
In,O
contrast,O
",",O
we,O
found,O
that,O
patients,O
with,O
more,O
severe,O
pain,O
perceived,O
worsening,O
of,O
their,O
status,O
with,O
smaller,O
increases,O
of,O
pain,O
intensity,O
:,O
the,O
absolute,O
MCID,O
was,O
2,O
.,O
3,O
mm,O
less,O
for,O
each,O
10,O
mm,O
increase,O
in,O
baseline,O
pain,O
(,O
1,O
.,O
4,O
–,O
3,O
.,O
0,O
",",O
P,O
<,O
0,O
.,O
001,O
",",O
I2,O
=,O
67,O
%).,O
Fig,O
.,O
3Minimum,O
clinically,O
important,O
difference,O
by,O
baseline,O
pain,O
(,O
individual,O
patient,O
data,O
from,O
7,O
studies,O
",",O
918,O
patients,O
).,O
MCID,O
assessed,O
as,O
the,O
mean,O
change,O
in,O
pain,O
score,O
among,O
patients,O
with,O
minimal,O
improvement,O
of,O
pain,O
",",O
MCID,O
=,O
Minimal,O
Clinically,O
Important,O
Difference,O
(,O
mm,O
reduction,O
on,O
a,O
100,O
mm,O
scale,O
).,O
Forest,O
plot,O
of,O
mean,O
pain,O
difference,O
in,O
723,O
episodes,O
where,O
patients,O
reported,O
pain,O
to,O
be,O
“,O
a,O
little,O
better,O
”,O
in,O
7,O
studies,O
including,O
a,O
total,O
of,O
918,O
patients,O
From,O
individual,O
patient,O
data,O
",",O
we,O
also,O
found,O
that,O
the,O
MCID,O
decreased,O
with,O
increasing,O
time,O
from,O
baseline,O
",",O
from,O
17,O
(,O
12,O
to,O
21,O
),O
mm,O
at,O
30,O
minutes,O
to,O
11,O
(,O
8,O
to,O
14,O
),O
mm,O
at,O
120,O
minutes,O
.,O
However,O
",",O
patients,O
’,O
pain,O
level,O
declined,O
accordingly,O
during,O
the,O
multiple,O
follow,O
-,O
ups,O
and,O
estimates,O
expressed,O
as,O
a,O
relative,O
change,O
from,O
the,O
previous,O
assessment,O
therefore,O
did,O
not,O
decline,O
.,O
Impact,O
of,O
other,O
clinical,O
and,O
methodological,O
factors,O
Other,O
causes,O
for,O
variation,O
in,O
the,O
MCID,O
were,O
addressed,O
in,O
10,O
studies,O
.,O
These,O
included,O
sex,O
[,O
33,O
",",O
35,O
",",O
36,O
",",O
44,O
–,O
48,O
",",O
51,O
",",O
54,O
",",O
57,O
",",O
59,O
"],",O
age,O
[,O
33,O
",",O
35,O
",",O
36,O
",",O
44,O
–,O
46,O
",",O
48,O
",",O
51,O
",",O
54,O
",",O
57,O
",",O
59,O
"],",O
education,O
level,O
[,O
35,O
",",O
48,O
",",O
51,O
",",O
54,O
"],",O
ethnicity,O
[,O
54,O
",",O
57,O
"],",O
primary,O
language,O
(,O
English,O
or,O
Spanish,O
),O
[,O
57,O
"],",O
and,O
religion,O
[,O
54,O
"],",O
as,O
well,O
as,O
cause,O
(,O
traumatic,O
or,O
non,O
-,O
traumatic,O
),O
[,O
44,O
–,O
48,O
",",O
57,O
"],",O
duration,O
[,O
35,O
],O
and,O
location,O
[,O
35,O
],O
of,O
pain,O
.,O
,O
of,O
the,O
studies,O
found,O
associations,O
except,O
for,O
one,O
[,O
48,O
"],",O
which,O
reported,O
higher,O
MCIDs,O
for,O
men,B-OG
compared,O
to,O
women,B-OG
and,O
for,O
non,O
-,O
traumatic,O
pain,O
compared,O
to,O
traumatic,O
pain,O
.,O
However,O
",",O
these,O
analyses,O
were,O
not,O
adjusted,O
for,O
differences,O
in,O
baseline,O
pain,O
.,O
The,O
MCIDs,O
of,O
subgroups,O
are,O
presented,O
as,O
medians,O
and,O
pooled,O
averages,O
",",O
respectively,O
(,O
Table,O
4,O
).,O
For,O
most,O
clinical,O
and,O
methodological,O
factors,O
",",O
the,O
number,O
of,O
studies,O
in,O
each,O
subgroup,O
was,O
too,O
small,O
to,O
ensure,O
detection,O
of,O
relevant,O
differences,O
between,O
them,O
.,O
Nevertheless,O
",",O
although,O
only,O
few,O
studies,O
defined,O
the,O
MCID,O
as,O
the,O
mean,O
pain,O
reduction,O
among,O
patients,O
with,O
several,O
categories,O
of,O
improvement,O
",",O
or,O
patients,O
with,O
‘,O
meaningful,O
’,O
(,O
and,O
not,O
just,O
‘,O
minimum,O
’),O
change,O
",",O
it,O
was,O
clear,O
that,O
these,O
studies,O
found,O
higher,O
MCIDs,O
(,O
medians,O
25,O
(,O
IQR,O
23,O
–,O
29,O
),O
and,O
34,O
(,O
IQR,O
27,O
–,O
40,O
"),",O
respectively,O
),O
than,O
studies,O
where,O
it,O
was,O
defined,O
as,O
the,O
mean,O
pain,O
reduction,O
among,O
patients,O
with,O
a,O
one,O
-,O
category,O
improvement,O
(,O
median,O
16,O
(,O
IQR,O
13,O
–,O
21,O
)).,O
It,O
was,O
also,O
clear,O
that,O
the,O
MCID,O
was,O
higher,O
when,O
based,O
on,O
a,O
single,O
assessment,O
involving,O
one,O
fixed,O
baseline,O
value,O
(,O
median,O
25,O
(,O
IQR,O
23,O
–,O
29,O
")),",O
than,O
when,O
summarised,O
from,O
multiple,O
assessments,O
with,O
the,O
previous,O
assessment,O
applied,O
as,O
a,O
‘,O
moving,O
baseline,O
’,O
(,O
medians,O
15,O
(,O
IQR,O
13,O
–,O
16,O
),O
and,O
16,O
(,O
IQR,O
10,O
–,O
21,O
"),",O
respectively,O
).,O
Subgroups,O
of,O
studies,O
among,O
patients,O
with,O
various,O
clinical,O
conditions,O
were,O
underpowered,O
to,O
detect,O
relevant,O
differences,O
.,O
The,O
comparison,O
of,O
one,O
-,O
and,O
two,O
-,O
sided,O
transition,O
scales,O
was,O
also,O
underpowered,O
",",O
but,O
the,O
difference,O
in,O
scales,O
did,O
not,O
seem,O
to,O
affect,O
study,O
results,O
",",O
while,O
the,O
comparison,O
of,O
VAS,O
and,O
NRS,O
included,O
enough,O
studies,O
to,O
conclude,O
that,O
type,O
of,O
pain,O
scale,O
did,O
not,O
influence,O
the,O
MCID,O
.,O
Finally,O
",",O
we,O
did,O
not,O
find,O
differences,O
in,O
outcomes,O
relating,O
to,O
the,O
risk,O
of,O
attrition,O
bias,O
or,O
risk,O
of,O
non,O
-,O
representative,O
samples,O
.,O
Table,O
4Subgroup,O
analyses,O
of,O
absolute,O
minimum,O
clinically,O
important,O
differences,O
(,O
MCIDs,O
),O
for,O
pain,O
reliefSubgroupAnalysis,O
of,O
mediansAnalysis,O
of,O
pooled,O
averageRange,O
",",O
mmNumber,O
of,O
studiesa,O
(,O
patientsb,O
),O
MCID,O
Median,O
",",O
mm,O
(,O
IQR,O
),O
Number,O
of,O
studies,O
(,O
patientsb,O
),O
MCID,O
pooled,O
average,O
",",O
mm,O
(,O
95,O
%,O
CI,O
"),",O
I2,O
c,O
All,O
studies8,O
–,O
4029,O
(,O
6517,O
),O
17,O
(,O
14,O
–,O
23,O
),O
23,O
(,O
6024,O
),O
17,O
(,O
15,O
–,O
19,O
"),",O
93,O
%,O
Clinical,O
conditions,O
Post,O
-,O
operation,O
paind,O
9,O
–,O
297,O
(,O
731,O
),O
18,O
(,O
10,O
–,O
25,O
),O
3,O
(,O
361,O
),O
11,O
(,O
8,O
–,O
14,O
"),",O
42,O
%,O
Trauma16,O
–,O
202,O
(,O
125,O
),O
18,O
(,O
16,O
–,O
20,O
),O
2,O
(,O
125,O
),O
18,O
(,O
15,O
–,O
22,O
"),",O
11,O
%,O
Abdominal,O
pain18,O
–,O
252,O
(,O
407,O
),O
21,O
(,O
18,O
–,O
25,O
),O
2,O
(,O
407,O
),O
21,O
(,O
15,O
–,O
28,O
"),",O
91,O
%,O
Mixed,O
patients,O
at,O
ED8,O
–,O
247,O
(,O
2418,O
),O
15,O
(,O
11,O
–,O
21,O
),O
6,O
(,O
2345,O
),O
16,O
(,O
12,O
–,O
20,O
"),",O
90,O
%,O
Othere,O
10,O
–,O
405,O
(,O
1980,O
),O
27,O
(,O
23,O
–,O
34,O
),O
4,O
(,O
1930,O
),O
22,O
(,O
15,O
–,O
29,O
"),",O
92,O
%,O
Unspecified13,O
–,O
216,O
(,O
856,O
),O
16,O
(,O
14,O
–,O
16,O
),O
6,O
(,O
856,O
),O
16,O
(,O
14,O
–,O
18,O
"),",O
72,O
%,O
Definition,O
of,O
MCID,O
One,O
category,O
improvement8,O
–,O
3424,O
(,O
4504,O
),O
16,O
(,O
13,O
–,O
21,O
),O
22,O
(,O
4281,O
),O
16,O
(,O
14,O
–,O
18,O
"),",O
91,O
%,O
Several,O
categories,O
improvement23,O
–,O
293,O
(,O
220,O
),O
25,O
(,O
23,O
–,O
29,O
),O
NANA,O
Meaningful,O
change27,O
–,O
402,O
(,O
1793,O
),O
34,O
(,O
27,O
–,O
40,O
),O
1,O
(,O
1743,O
),O
27,O
(,O
25,O
–,O
29,O
"),",O
NADirectionality,O
of,O
transition,O
scale,O
One,O
-,O
sided9,O
–,O
405,O
(,O
538,O
),O
18,O
(,O
13,O
–,O
21,O
),O
3,O
(,O
383,O
),O
15,O
(,O
8,O
–,O
21,O
"),",O
93,O
%,O
Two,O
-,O
sided8,O
–,O
2519,O
(,O
3962,O
),O
16,O
(,O
13,O
–,O
20,O
),O
18,O
(,O
3844,O
),O
16,O
(,O
14,O
–,O
19,O
"),",O
91,O
%,O
Pain,O
scale,O
Visual,O
Analogue,O
Scale8,O
–,O
4017,O
(,O
3232,O
),O
17,O
(,O
13,O
–,O
25,O
),O
15,O
(,O
3109,O
),O
16,O
(,O
13,O
–,O
19,O
"),",O
91,O
%,O
Numeric,O
Rating,O
Scale10,O
–,O
237,O
(,O
1268,O
),O
15,O
(,O
14,O
–,O
21,O
),O
6,O
(,O
1118,O
),O
16,O
(,O
14,O
–,O
19,O
"),",O
91,O
%,O
Measurements,O
per,O
patient,O
Single18,O
–,O
404,O
(,O
461,O
),O
25,O
(,O
23,O
–,O
29,O
),O
4,O
(,O
2058,O
),O
22,O
(,O
19,O
–,O
25,O
"),",O
0,O
%,O
Multiple,O
With,O
adjustment10,O
–,O
189,O
(,O
1104,O
),O
15,O
(,O
13,O
–,O
16,O
),O
8,O
(,O
1031,O
),O
15,O
(,O
13,O
–,O
16,O
"),",O
34,O
%,O
Without,O
Adjustment,O
/,O
unclear8,O
–,O
2511,O
(,O
2935,O
),O
16,O
(,O
10,O
–,O
21,O
),O
11,O
(,O
2935,O
),O
16,O
(,O
13,O
–,O
20,O
"),",O
95,O
%,O
Risk,O
of,O
attrition,O
bias,O
Low8,O
–,O
408,O
(,O
1249,O
),O
19,O
(,O
15,O
–,O
25,O
),O
8,O
(,O
1249,O
),O
16,O
(,O
14,O
–,O
18,O
"),",O
81,O
%,O
High,O
or,O
unclear9,O
–,O
2516,O
(,O
3251,O
),O
16,O
(,O
12,O
–,O
19,O
),O
13,O
(,O
2978,O
),O
16,O
(,O
13,O
–,O
19,O
"),",O
93,O
%,O
Risk,O
of,O
non,O
-,O
representative,O
sampling,O
Low8,O
–,O
256,O
(,O
1187,O
),O
16,O
(,O
10,O
–,O
21,O
),O
6,O
(,O
1187,O
),O
16,O
(,O
11,O
–,O
21,O
"),",O
96,O
%,O
High,O
or,O
unclear9,O
–,O
4018,O
(,O
3313,O
),O
18,O
(,O
14,O
–,O
24,O
),O
15,O
(,O
3040,O
),O
16,O
(,O
14,O
–,O
18,O
"),",O
87,O
%,O
IQR,O
inter,O
-,O
quartile,O
range,O
",",O
ED,O
Emergency,O
department,O
",",O
,O
not,O
applicable,O
aThe,O
median,O
is,O
based,O
on,O
studies,O
included,O
in,O
the,O
pooled,O
average,O
as,O
well,O
as,O
studies,O
with,O
unavailable,O
standard,O
errors,O
bTotal,O
number,O
of,O
patients,O
in,O
studies,O
cI2,O
is,O
the,O
percentage,O
of,O
the,O
variability,O
in,O
results,O
that,O
is,O
due,O
to,O
heterogeneity,O
rather,O
than,O
sampling,O
error,O
(,O
chance,O
);,O
I2,O
of,O
0,O
%,O
to,O
40,O
%,O
might,O
not,O
be,O
important,O
",",O
30,O
%,O
to,O
60,O
%,O
may,O
represent,O
moderate,O
heterogeneity,O
",",O
50,O
%,O
to,O
90,O
%,O
may,O
represent,O
substantial,O
heterogeneity,O
",",O
and,O
75,O
%,O
to,O
100,O
%,O
represents,O
considerable,O
heterogeneity,O
dIncludes,O
knee,O
surgery,O
",",O
laparotomy,O
",",O
third,O
molar,O
extraction,O
and,O
mixed,O
surgery,O
(,O
e,O
.,O
g,O
.,O
spinal,O
fusion,O
and,O
splenectomy,O
),O
eIncludes,O
headache,O
",",O
low,O
back,O
pain,O
",",O
sickle,B-DS
cell,I-DS
crisis,I-DS
",",O
rheumatic,O
condition,O
",",O
and,O
pain,O
flare,O
after,O
external,O
beam,O
radiotherapy,O
for,O
bone,B-DS
metastases,I-DS
Supplementary,O
outcomes,O
The,O
supplementary,O
outcomes,O
for,O
pain,O
relief,O
and,O
worsening,O
were,O
only,O
reported,O
from,O
studies,O
using,O
the,O
mean,O
change,O
approach,O
(,O
Table,O
3,O
).,O
The,O
results,O
showed,O
similarly,O
high,O
heterogeneity,O
.,O
The,O
substantial,O
clinically,O
important,O
difference,O
for,O
pain,O
relief,O
ranged,O
from,O
18,O
to,O
54,O
mm,O
(,O
23,O
studies,O
"),",O
while,O
minimum,O
and,O
substantial,O
clinically,O
important,O
differences,O
for,O
worsening,O
of,O
pain,O
ranged,O
from,O
8,O
to,O
21,O
mm,O
increase,O
(,O
18,O
studies,O
),O
and,O
from,O
0,O
to,O
66,O
mm,O
increase,O
(,O
16,O
studies,O
"),",O
respectively,O
.,O
Discussion,O
We,O
included,O
37,O
studies,O
(,O
8479,O
patients,O
),O
assessing,O
the,O
MCID,O
in,O
acute,O
pain,O
",",O
of,O
which,O
35,O
used,O
the,O
mean,O
change,O
approach,O
and,O
seven,O
used,O
the,O
threshold,O
approach,O
.,O
Meta,O
-,O
analyses,O
found,O
considerable,O
heterogeneity,O
between,O
studies,O
and,O
",",O
consequently,O
",",O
no,O
single,O
value,O
of,O
minimum,O
clinical,O
important,O
difference,O
could,O
be,O
meaningfully,O
determined,O
.,O
Study,O
results,O
ranged,O
widely,O
both,O
when,O
they,O
were,O
reported,O
as,O
absolute,O
change,O
(,O
from,O
8,O
to,O
40,O
mm,O
),O
and,O
as,O
relative,O
change,O
from,O
baseline,O
(,O
from,O
13,O
to,O
85,O
%).,O
The,O
median,O
of,O
study,O
results,O
based,O
on,O
the,O
mean,O
change,O
approach,O
was,O
17,O
(,O
IQR,O
14,O
to,O
23,O
),O
mm,O
and,O
23,O
(,O
IQR,O
18,O
to,O
36,O
),O
%,O
for,O
absolute,O
and,O
relative,O
values,O
",",O
respectively,O
.,O
Reasons,O
for,O
heterogeneity,O
were,O
explored,O
and,O
baseline,O
pain,O
was,O
identified,O
as,O
a,O
cause,O
of,O
variation,O
in,O
absolute,O
",",O
but,O
not,O
relative,O
",",O
outcomes,O
.,O
In,O
addition,O
",",O
the,O
definition,O
of,O
minimum,O
clinically,O
important,O
change,O
and,O
the,O
use,O
of,O
multiple,O
assessments,O
per,O
patient,O
influenced,O
study,O
results,O
.,O
High,O
heterogeneity,O
was,O
also,O
found,O
for,O
assessments,O
of,O
substantial,O
clinically,O
important,O
difference,O
as,O
well,O
as,O
for,O
worsening,O
of,O
pain,O
.,O
Strengths,O
and,O
limitations,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
systematic,O
review,O
of,O
MCIDs,O
in,O
acute,O
pain,O
.,O
We,O
identified,O
37,O
studies,O
involving,O
over,O
8000,O
patients,O
and,O
a,O
broad,O
range,O
of,O
clinical,O
conditions,O
",",O
study,O
approaches,O
and,O
pain,O
scales,O
.,O
We,O
gained,O
access,O
to,O
unpublished,O
data,O
from,O
10,O
studies,O
",",O
including,O
individual,O
patient,O
data,O
from,O
seven,O
studies,O
(,O
918,O
patients,O
).,O
This,O
ensured,O
high,O
data,O
quality,O
and,O
uniform,O
analysis,O
",",O
and,O
enabled,O
an,O
adequate,O
assessment,O
of,O
the,O
association,O
with,O
baseline,O
pain,O
avoiding,O
the,O
risk,O
of,O
ecological,O
fallacy,O
[,O
24,O
],O
inherent,O
to,O
aggregated,O
study,O
-,O
level,O
data,O
.,O
The,O
median,O
results,O
of,O
studies,O
providing,O
individual,O
patient,O
data,O
was,O
comparable,O
with,O
the,O
remaining,O
studies,O
and,O
we,O
have,O
no,O
reason,O
to,O
believe,O
these,O
studies,O
were,O
not,O
representative,O
.,O
Association,O
with,O
baseline,O
pain,O
has,O
been,O
reported,O
from,O
individual,O
studies,O
[,O
31,O
",",O
33,O
",",O
36,O
",",O
43,O
",",O
57,O
–,O
59,O
"],",O
but,O
the,O
present,O
review,O
is,O
the,O
first,O
comprehensive,O
assessment,O
of,O
the,O
impact,O
of,O
baseline,O
pain,O
across,O
studies,O
.,O
In,O
addition,O
",",O
we,O
identified,O
variation,O
in,O
study,O
designs,O
(,O
single,O
or,O
multiple,O
assessments,O
),O
and,O
definitions,O
of,O
patients,O
with,O
minimum,O
relief,O
as,O
factors,O
influencing,O
the,O
MCID,O
.,O
However,O
",",O
we,O
were,O
not,O
able,O
to,O
fully,O
explain,O
the,O
large,O
heterogeneity,O
among,O
studies,O
.,O
We,O
found,O
no,O
effects,O
of,O
pain,O
scale,O
",",O
but,O
for,O
the,O
comparison,O
of,O
clinical,O
conditions,O
and,O
directionality,O
of,O
transition,O
scale,O
",",O
subgroups,O
involved,O
too,O
few,O
studies,O
to,O
ensure,O
detection,O
of,O
all,O
relevant,O
associations,O
.,O
In,O
addition,O
",",O
our,O
ability,O
to,O
assess,O
clinical,O
condition,O
was,O
limited,O
by,O
the,O
fact,O
that,O
many,O
studies,O
included,O
a,O
mixed,O
patient,O
group,O
and,O
we,O
did,O
not,O
have,O
access,O
to,O
individual,O
patient,O
diagnoses,O
.,O
Similarly,O
",",O
the,O
studies,O
included,O
a,O
variety,O
of,O
analgesia,O
and,O
other,O
treatments,O
which,O
did,O
not,O
allow,O
an,O
assessment,O
of,O
potential,O
impact,O
of,O
interventions,O
.,O
Regarding,O
the,O
risk,O
of,O
attrition,O
bias,O
and,O
non,O
-,O
representative,O
sampling,O
",",O
the,O
majority,O
of,O
studies,O
were,O
categorised,O
as,O
unclear,O
and,O
potential,O
impact,O
could,O
therefore,O
not,O
be,O
assessed,O
.,O
Most,O
importantly,O
",",O
acknowledging,O
the,O
association,O
with,O
baseline,O
pain,O
",",O
it,O
would,O
have,O
been,O
more,O
accurate,O
to,O
base,O
subgroup,O
analyses,O
on,O
relative,O
outcomes,O
",",O
but,O
the,O
data,O
available,O
only,O
allowed,O
comparison,O
of,O
absolute,O
outcomes,O
.,O
We,O
could,O
not,O
assess,O
impact,O
of,O
various,O
description,O
of,O
pain,O
(,O
e,O
.,O
g,O
.,O
“,O
intensity,O
”),O
or,O
the,O
follow,O
-,O
up,O
time,O
between,O
measurements,O
since,O
there,O
was,O
not,O
enough,O
variation,O
between,O
studies,O
.,O
Furthermore,O
",",O
the,O
available,O
data,O
did,O
not,O
allow,O
an,O
assessment,O
of,O
the,O
potential,O
influence,O
of,O
pre,O
-,O
existing,O
pain,O
level,O
(,O
e,O
.,O
g,O
.,O
if,O
patients,O
are,O
affected,O
by,O
chronic,O
pain,O
in,O
addition,O
to,O
their,O
current,O
episode,O
of,O
acute,O
pain,O
"),",O
pre,O
-,O
existing,O
use,O
of,O
pain,O
relief,O
or,O
the,O
psychological,O
state,O
of,O
patients,O
",",O
since,O
this,O
was,O
not,O
reported,O
by,O
any,O
of,O
the,O
studies,O
.,O
Finally,O
",",O
we,O
cannot,O
dismiss,O
the,O
risk,O
of,O
recall,O
bias,O
in,O
studies,O
where,O
patients,O
simultaneously,O
assess,O
their,O
pain,O
status,O
and,O
perceived,O
change,O
[,O
60,O
].,O
Differences,O
in,O
baseline,O
pain,O
or,O
other,O
methodological,O
or,O
clinical,O
factors,O
may,O
influence,O
subgroup,O
analyses,O
of,O
study,O
-,O
level,O
data,O
.,O
Thus,O
",",O
better,O
access,O
to,O
individual,O
patient,O
data,O
would,O
greatly,O
improve,O
the,O
chances,O
of,O
identifying,O
causes,O
of,O
heterogeneity,O
.,O
Other,O
studies,O
Only,O
few,O
systematic,O
reviews,O
of,O
the,O
minimum,O
clinically,O
relevant,O
change,O
have,O
been,O
published,O
despite,O
a,O
vast,O
number,O
of,O
primary,O
studies,O
.,O
Stauffer,O
[,O
20,O
],O
and,O
Erdogan,O
[,O
61,O
],O
reviewed,O
studies,O
of,O
minimum,O
clinically,O
relevant,O
change,O
in,O
pain,O
scales,O
used,O
for,O
chronic,O
rheumatologic,O
conditions,O
",",O
but,O
we,O
have,O
not,O
identified,O
any,O
systematic,O
reviews,O
focusing,O
on,O
acute,O
pain,O
.,O
The,O
problem,O
of,O
variability,O
in,O
results,O
of,O
studies,O
of,O
minimum,O
clinically,O
relevant,O
change,O
has,O
previously,O
been,O
addressed,O
primarily,O
when,O
attempting,O
to,O
reconcile,O
dissimilar,O
results,O
from,O
different,O
approaches,O
",",O
e,O
.,O
g,O
.,O
anchor,O
-,O
based,O
and,O
distribution,O
-,O
based,O
studies,O
[,O
62,O
].,O
Our,O
study,O
demonstrates,O
considerable,O
unexplained,O
variation,O
also,O
within,O
anchor,O
-,O
based,O
approaches,O
.,O
In,O
line,O
with,O
our,O
findings,O
",",O
Terwee,O
[,O
63,O
],O
found,O
variability,O
between,O
results,O
of,O
five,O
studies,O
of,O
minimum,O
clinically,O
important,O
change,O
on,O
the,O
Western,O
Ontario,O
and,O
McMaster,O
University,O
pain,O
subscale,O
for,O
osteoarthritis,B-DS
.,O
In,O
a,O
systematic,O
review,O
of,O
the,O
minimum,O
clinical,O
important,O
difference,O
in,O
chronic,O
pain,O
",",O
we,O
have,O
found,O
similar,O
issues,O
of,O
high,O
study,O
variability,O
(,O
manuscript,O
in,O
preparation,O
).,O
Mechanisms,O
and,O
perspectives,O
We,O
included,O
studies,O
with,O
a,O
patient,O
-,O
reported,O
anchor,O
.,O
While,O
some,O
find,O
that,O
using,O
a,O
patient,O
-,O
reported,O
criterion,O
as,O
an,O
anchor,O
for,O
a,O
patient,O
-,O
reported,O
score,O
is,O
circular,O
and,O
basically,O
flawed,O
[,O
64,O
"],",O
we,O
would,O
argue,O
that,O
pain,O
intensity,O
is,O
essentially,O
a,O
subjective,O
experience,O
best,O
expressed,O
by,O
and,O
anchored,O
to,O
those,O
experiencing,O
it,O
.,O
Other,O
observer,O
-,O
based,O
anchors,O
may,O
be,O
used,O
when,O
the,O
outcome,O
of,O
interest,O
is,O
return,O
to,O
work,O
or,O
daily,O
level,O
of,O
activity,O
[,O
65,O
].,O
The,O
varying,O
content,O
of,O
the,O
patient,O
-,O
reported,O
anchors,O
is,O
",",O
however,O
",",O
problematic,O
.,O
The,O
applied,O
transition,O
scales,O
were,O
either,O
one,O
-,O
or,O
two,O
-,O
sided,O
",",O
allowing,O
patients,O
to,O
report,O
their,O
degree,O
of,O
change,O
(,O
or,O
only,O
relief,O
),O
by,O
choosing,O
between,O
anywhere,O
from,O
three,O
to,O
15,O
response,O
categories,O
.,O
The,O
majority,O
of,O
studies,O
then,O
determined,O
the,O
MCID,O
as,O
a,O
mean,O
change,O
in,O
pain,O
score,O
among,O
everyone,O
reporting,O
a,O
one,O
-,O
category,O
pain,O
relief,O
.,O
However,O
",",O
this,O
value,O
does,O
not,O
apply,O
to,O
all,O
individuals,O
in,O
the,O
group,O
",",O
since,O
their,O
differences,O
in,O
pain,O
are,O
distributed,O
around,O
the,O
mean,O
[,O
14,O
].,O
In,O
contrast,O
",",O
MCIDs,O
expressed,O
as,O
threshold,O
values,O
are,O
derived,O
with,O
the,O
intention,O
of,O
obtaining,O
the,O
best,O
possible,O
discrimination,O
between,O
patients,O
with,O
and,O
without,O
relevant,O
relief,O
.,O
The,O
frequency,O
of,O
false,O
-,O
positive,O
and,O
false,O
-,O
negative,O
results,O
may,O
be,O
reduced,O
but,O
is,O
not,O
eliminated,O
by,O
this,O
approach,O
.,O
Therefore,O
",",O
caution,O
is,O
always,O
merited,O
when,O
bringing,O
an,O
overall,O
estimate,O
of,O
important,O
change,O
to,O
the,O
level,O
of,O
interpretation,O
for,O
an,O
individual,O
patient,O
[,O
66,O
",",O
67,O
].,O
The,O
studies,O
we,O
included,O
varied,O
considerably,O
both,O
in,O
methods,O
and,O
analytical,O
approaches,O
.,O
As,O
would,O
be,O
expected,O
",",O
differences,O
in,O
the,O
definition,O
of,O
patients,O
with,O
minimum,O
important,O
change,O
impacted,O
study,O
results,O
.,O
We,O
also,O
found,O
that,O
the,O
use,O
of,O
multiple,O
measurements,O
per,O
patient,O
resulted,O
in,O
lower,O
outcomes,O
.,O
This,O
corresponded,O
with,O
the,O
finding,O
that,O
outcomes,O
decreased,O
during,O
several,O
follow,O
-,O
ups,O
as,O
patients,O
’,O
pain,O
declined,O
over,O
time,O
.,O
Furthermore,O
",",O
one,O
in,O
four,O
of,O
the,O
reviewed,O
studies,O
did,O
not,O
differentiate,O
between,O
minimum,O
relief,O
and,O
minimum,O
worsening,O
of,O
pain,O
in,O
their,O
original,O
study,O
reports,O
.,O
The,O
practice,O
of,O
combining,O
groups,O
with,O
minimum,O
change,O
",",O
regardless,O
of,O
its,O
direction,O
",",O
is,O
sometimes,O
based,O
on,O
a,O
seemingly,O
similar,O
distribution,O
of,O
data,O
in,O
the,O
two,O
groups,O
[,O
44,O
].,O
However,O
",",O
although,O
they,O
may,O
be,O
similar,O
at,O
one,O
point,O
",",O
the,O
MCID,O
for,O
pain,O
relief,O
and,O
worsening,O
will,O
change,O
in,O
opposite,O
directions,O
with,O
variations,O
of,O
baseline,O
pain,O
(,O
since,O
patients,O
with,O
higher,O
baseline,O
pain,O
require,O
larger,O
pain,O
reduction,O
to,O
perceive,O
relief,O
",",O
but,O
smaller,O
increase,O
to,O
perceive,O
worsening,O
of,O
their,O
condition,O
).,O
The,O
association,O
between,O
MCID,O
and,O
baseline,O
pain,O
may,O
to,O
some,O
extent,O
be,O
explained,O
by,O
‘,O
regression,O
towards,O
the,O
mean,O
’,O
as,O
patients,O
are,O
likely,O
to,O
score,O
closer,O
to,O
the,O
mean,O
if,O
their,O
initial,O
scores,O
were,O
more,O
extreme,O
because,O
of,O
chance,O
[,O
68,O
].,O
However,O
",",O
it,O
is,O
also,O
very,O
plausible,O
that,O
patients,O
with,O
higher,O
pain,O
require,O
greater,O
decrease,O
to,O
perceive,O
relief,O
.,O
Relative,O
changes,O
are,O
therefore,O
more,O
stable,O
indicators,O
of,O
clinically,O
important,O
differences,O
",",O
although,O
they,O
lack,O
interval,O
scale,O
properties,O
at,O
the,O
scale,O
extremes,O
",",O
e,O
.,O
g,O
.,O
when,O
baseline,O
values,O
are,O
close,O
to,O
zero,O
and,O
small,O
degrees,O
of,O
pain,O
change,O
result,O
in,O
very,O
large,O
relative,O
changes,O
[,O
69,O
].,O
From,O
this,O
review,O
",",O
however,O
",",O
it,O
is,O
clear,O
that,O
the,O
advantage,O
of,O
relative,O
values,O
is,O
largely,O
overlooked,O
",",O
since,O
only,O
10,O
of,O
37,O
studies,O
(,O
27,O
%),O
reported,O
relative,O
change,O
.,O
This,O
review,O
included,O
studies,O
that,O
determined,O
MCID,O
from,O
an,O
anchor,O
-,O
based,O
method,O
using,O
patients,O
’,O
perception,O
of,O
change,O
to,O
determine,O
clinical,O
importance,O
.,O
Although,O
this,O
is,O
the,O
most,O
common,O
approach,O
",",O
it,O
is,O
just,O
one,O
among,O
a,O
wide,O
range,O
of,O
alternative,O
methods,O
.,O
Revicki,O
noted,O
that,O
retrospective,O
self,O
-,O
reports,O
of,O
pain,O
relief,O
tend,O
to,O
correlate,O
more,O
strongly,O
with,O
the,O
end,O
-,O
level,O
of,O
pain,O
than,O
the,O
start,O
level,O
",",O
implying,O
that,O
the,O
current,O
status,O
matters,O
to,O
patients,O
more,O
than,O
the,O
degree,O
of,O
improvement,O
[,O
70,O
].,O
This,O
has,O
led,O
to,O
the,O
development,O
of,O
the,O
concept,O
of,O
‘,O
patient,O
acceptable,O
symptom,O
state,O
"’,",O
defined,O
as,O
the,O
level,O
of,O
symptoms,O
which,O
patients,O
feel,O
is,O
acceptable,O
[,O
71,O
",",O
72,O
].,O
Patient,O
acceptable,O
symptom,O
state,O
corresponds,O
with,O
the,O
dominant,O
aim,O
of,O
clinical,O
patient,O
care,O
to,O
reduce,O
pain,O
to,O
an,O
acceptable,O
level,O
[,O
73,O
],O
and,O
could,O
be,O
a,O
strong,O
candidate,O
for,O
an,O
alternative,O
to,O
MCID,O
.,O
Other,O
promising,O
approaches,O
have,O
integrated,O
intervention,O
costs,O
and,O
side,O
effects,O
[,O
74,O
–,O
77,O
].,O
It,O
is,O
likely,O
that,O
the,O
challenges,O
of,O
MCID,O
",",O
apparent,O
for,O
acute,O
pain,O
",",O
may,O
not,O
be,O
isolated,O
to,O
that,O
specific,O
research,O
area,O
.,O
Acute,O
pain,O
stands,O
out,O
because,O
of,O
the,O
many,O
studies,O
that,O
have,O
been,O
conducted,O
",",O
reflecting,O
the,O
status,O
of,O
acute,O
pain,O
as,O
a,O
core,O
symptom,O
in,O
clinical,O
practice,O
.,O
Our,O
study,O
can,O
thus,O
be,O
seen,O
as,O
a,O
model,O
for,O
a,O
more,O
general,O
challenge,O
with,O
empirical,O
assessments,O
of,O
the,O
MCID,O
.,O
The,O
methodological,O
challenges,O
embedded,O
in,O
the,O
empirical,O
assessment,O
of,O
MCID,O
are,O
of,O
such,O
an,O
extent,O
that,O
merits,O
caution,O
for,O
its,O
use,O
and,O
interpretation,O
.,O
It,O
is,O
clearly,O
inappropriate,O
to,O
use,O
and,O
interpret,O
MCID,O
as,O
a,O
kind,O
of,O
clinical,O
scale,O
constant,O
–,O
a,O
characteristic,O
which,O
",",O
once,O
empirically,O
determined,O
",",O
is,O
universally,O
valid,O
.,O
This,O
is,O
",",O
however,O
",",O
often,O
the,O
practice,O
seen,O
[,O
78,O
].,O
Nevertheless,O
",",O
there,O
is,O
a,O
strong,O
and,O
reasonable,O
demand,O
for,O
a,O
structured,O
approach,O
for,O
evaluating,O
whether,O
effects,O
of,O
interventions,O
are,O
clinically,O
meaningful,O
to,O
patients,O
.,O
Implications,O
The,O
choice,O
of,O
a,O
reference,O
value,O
has,O
large,O
consequences,O
for,O
the,O
number,O
of,O
patients,O
needed,O
in,O
a,O
trial,O
",",O
e,O
.,O
g,O
.,O
four,O
times,O
as,O
many,O
patients,O
will,O
be,O
included,O
",",O
if,O
researchers,O
accept,O
a,O
MCID,O
value,O
of,O
12,O
mm,O
as,O
compared,O
to,O
24,O
mm,O
.,O
Further,O
",",O
the,O
conclusion,O
about,O
the,O
clinical,O
relevance,O
of,O
a,O
trial,O
result,O
is,O
often,O
based,O
on,O
whether,O
a,O
mean,O
difference,O
exceeds,O
a,O
chosen,O
reference,O
value,O
",",O
but,O
with,O
the,O
large,O
span,O
of,O
MCIDs,O
available,O
in,O
the,O
literature,O
",",O
it,O
is,O
highly,O
problematic,O
to,O
randomly,O
pick,O
one,O
or,O
a,O
few,O
single,O
assessments,O
for,O
guidance,O
.,O
The,O
considerable,O
variation,O
means,O
that,O
it,O
is,O
necessary,O
to,O
conscientiously,O
and,O
explicitly,O
reflect,O
on,O
the,O
span,O
of,O
results,O
in,O
relation,O
to,O
context,O
-,O
specific,O
clinical,O
and,O
methodological,O
factors,O
",",O
as,O
presented,O
in,O
this,O
review,O
",",O
with,O
a,O
particular,O
focus,O
of,O
the,O
baseline,O
pain,O
of,O
patients,O
",",O
whether,O
repeated,O
measurements,O
were,O
used,O
",",O
and,O
how,O
minimum,O
relief,O
was,O
defined,O
.,O
A,O
starting,O
point,O
for,O
such,O
an,O
exercise,O
by,O
individual,O
clinicians,O
or,O
researchers,O
",",O
or,O
by,O
consensus,O
building,O
committees,O
",",O
could,O
very,O
well,O
be,O
our,O
overview,O
of,O
studies,O
and,O
their,O
results,O
.,O
In,O
future,O
studies,O
there,O
is,O
a,O
clear,O
need,O
for,O
uniform,O
guidelines,O
for,O
standardised,O
conduct,O
",",O
analyses,O
and,O
reporting,O
of,O
the,O
MCID,O
",",O
especially,O
for,O
how,O
transition,O
scales,O
and,O
questions,O
are,O
structured,O
and,O
how,O
data,O
are,O
analysed,O
.,O
We,O
strongly,O
encourage,O
using,O
values,O
relative,O
to,O
baseline,O
pain,O
–,O
also,O
for,O
multiple,O
measurements,O
where,O
the,O
patient,O
’,O
s,O
last,O
assessment,O
should,O
be,O
applied,O
as,O
a,O
‘,O
moving,O
baseline,O
"’,",O
standardising,O
the,O
definition,O
of,O
relevant,O
pain,O
relief,O
",",O
and,O
distinguishing,O
clearly,O
between,O
improvement,O
and,O
worsening,O
of,O
pain,O
.,O
In,O
addition,O
",",O
since,O
the,O
influence,O
of,O
clinical,O
and,O
methodological,O
factors,O
is,O
difficult,O
to,O
identify,O
from,O
aggregated,O
data,O
",",O
we,O
encourage,O
improved,O
access,O
to,O
individual,O
patient,O
data,O
to,O
enable,O
further,O
exploration,O
of,O
the,O
causes,O
of,O
heterogeneity,O
.,O
Conclusion,O
The,O
MCID,O
in,O
acute,O
pain,O
varied,O
greatly,O
between,O
studies,O
.,O
Absolute,O
MCID,O
ranged,O
from,O
8,O
to,O
40,O
mm,O
in,O
29,O
studies,O
",",O
and,O
relative,O
values,O
ranged,O
from,O
13,O
%,O
to,O
85,O
%,O
in,O
14,O
studies,O
.,O
Baseline,O
pain,O
was,O
strongly,O
associated,O
with,O
absolute,O
",",O
but,O
not,O
relative,O
",",O
values,O
and,O
variation,O
in,O
definitions,O
of,O
minimum,O
relief,O
and,O
study,O
designs,O
influenced,O
study,O
results,O
.,O
Due,O
to,O
the,O
heterogeneity,O
between,O
study,O
results,O
",",O
no,O
meaningful,O
overall,O
value,O
of,O
minimum,O
clinically,O
important,O
change,O
can,O
be,O
concluded,O
.,O
Instead,O
",",O
we,O
recommend,O
that,O
MCIDs,O
are,O
considered,O
context,O
-,O
specific,O
and,O
take,O
account,O
of,O
baseline,O
pain,O
.,O
The,O
MCID,O
in,O
acute,O
pain,O
is,O
central,O
for,O
the,O
interpretation,O
of,O
results,O
of,O
randomised,O
trials,O
and,O
meta,O
-,O
analyses,O
and,O
for,O
determining,O
appropriate,O
sample,O
sizes,O
for,O
new,O
trials,O
",",O
but,O
it,O
is,O
potentially,O
misguiding,O
if,O
determined,O
",",O
applied,O
or,O
interpreted,O
inappropriately,O
.,O
Explicit,O
and,O
conscientious,O
reflections,O
on,O
the,O
choice,O
of,O
a,O
MCID,O
value,O
are,O
required,O
",",O
when,O
using,O
it,O
to,O
classify,O
research,O
results,O
as,O
clinically,O
important,O
or,O
trivial,O
.,O
Relationship,O
between,O
baseline,O
pain,O
and,O
the,O
minimum,O
clinically,O
important,O
differencea,O
Study,O
Subgroups,O
by,O
baseline,O
pain,O
",",O
mm,O
Absolute,O
MCID,O
mm,O
(,O
95,O
%,O
CI,O
),O
Relative,O
MCID,O
%,O
(,O
95,O
%,O
CI,O
),O
Studies,O
assessing,O
MCID,O
stratified,O
by,O
baseline,O
pain,O
Stahmer,O
[,O
55,O
],O
≤,O
50,O
>,O
50,O
NRNR,O
25,O
(,O
SE,O
:,O
10,O
),O
b,O
35,O
(,O
SE,O
:,O
6,O
),O
b,O
Voepel,O
-,O
Lewis,O
[,O
59,O
],O
<,O
50,O
≥,O
50,O
0,O
(−,O
30,O
to,O
20,O
),O
20,O
(,O
13,O
to,O
25,O
),O
NRNR,O
Bird,O
[,O
31,O
],O
<,O
3434,O
–,O
66,O
>,O
66,O
11,O
(,O
7,O
to,O
15,O
),O
17,O
(,O
13,O
to,O
21,O
),O
30,O
(,O
17,O
to,O
43,O
),O
NRNRNR,O
Cepeda,O
[,O
33,O
],O
Moderate,O
(,O
median,O
:,O
60,O
),O
Severe,O
(,O
median,O
:,O
80,O
),O
13,O
(,O
12,O
to,O
14,O
),O
18,O
(,O
17,O
to,O
19,O
),O
20,O
(,O
18,O
to,O
22,O
),O
20,O
(,O
19,O
to,O
22,O
),O
Tsze,O
[,O
57,O
],O
<,O
4040,O
–,O
69,O
≥,O
70,O
NRNRNR,O
13,O
(,O
0,O
to,O
29,O
),O
16,O
(,O
10,O
to,O
23,O
),O
18,O
(,O
11,O
to,O
29,O
),O
Tubach,O
[,O
58,O
],O
Low,O
(,O
mean,O
:,O
55,O
),O
Intermediate,O
(,O
mean,O
:,O
70,O
),O
High,O
(,O
mean,O
:,O
85,O
),O
34,O
(,O
29,O
to,O
38,O
),O
c,O
45c,O
63,O
(,O
54,O
to,O
68,O
),O
c,O
NRNRNR,O
Studies,O
assessing,O
correlation,O
between,O
MCID,O
and,O
baseline,O
pain,O
Barton,O
2002,O
(,O
reported,O
in,O
Jensen,O
2002,O
[,O
43,O
]),O
Correlation,O
with,O
baseline,O
pain,O
0,O
.,O
48,O
(,O
P,O
<,O
0,O
.,O
001,O
),O
0,O
.,O
35,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
Rasmussen,O
2002,O
(,O
reported,O
in,O
Jensen,O
2002,O
[,O
43,O
]),O
Correlation,O
with,O
baseline,O
pain,O
0,O
.,O
52,O
(,O
P,O
<,O
0,O
.,O
001,O
),O
0,O
.,O
34,O
(,O
P,O
<,O
0,O
.,O
01,O
),O
Farrar,O
[,O
36,O
],O
Correlation,O
with,O
baseline,O
pain,O
Patients,O
with,O
higher,O
baseline,O
pain,O
reported,O
greater,O
relief,O
(,O
e,O
.,O
g,O
.,O
90,O
vs,O
.,O
40,O
mm,O
",",O
P,O
=,O
0,O
.,O
048,O
),O
No,O
significant,O
differences,O
in,O
degree,O
of,O
pain,O
relief,O
Lead,O
Exposure,O
Induces,O
Weight,O
Gain,O
in,O
Adult,O
Rats,B-OG
",",O
Accompanied,O
by,O
DNA,O
Hypermethylation,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Conceptualization,O
:,O
YL,O
LY,O
HS,O
NW,O
.,O
Data,O
curation,O
:,O
HS,O
.,O
Formal,O
analysis,O
:,O
HS,O
NW,O
.,O
Funding,O
acquisition,O
:,O
YL,O
HZ,O
NW,O
.,O
Investigation,O
:,O
HS,O
NW,O
XN,O
CC,O
.,O
Methodology,O
:,O
HS,O
NW,O
XN,O
.,O
Project,O
administration,O
:,O
HS,O
NW,O
XN,O
LZ,O
ZC,O
ML,O
.,O
Resources,O
:,O
HS,O
NW,O
QL,O
ZC,O
.,O
Software,O
:,O
NW,O
.,O
Supervision,O
:,O
YL,O
LY,O
.,O
Validation,O
:,O
YL,O
JC,O
HZ,O
FX,O
.,O
Visualization,O
:,O
HS,O
.,O
Writing,O
–,O
original,O
draft,O
:,O
HS,O
NW,O
.,O
Writing,O
–,O
review,O
&,O
editing,O
:,O
FX,O
YL,O
JC,O
.,O
Objective,O
Previous,O
studies,O
have,O
revealed,O
the,O
association,O
of,O
lead,O
(,O
Pb,O
),O
exposure,O
with,O
obesity,B-DS
.,O
DNA,O
methylation,O
alteration,O
has,O
been,O
suggested,O
to,O
be,O
one,O
of,O
the,O
regulatory,O
mechanisms,O
of,O
obesity,B-DS
.,O
We,O
aimed,O
to,O
explore,O
whether,O
Pb,O
exposure,O
is,O
related,O
with,O
weight,O
gain,O
and,O
DNA,O
methylation,O
alteration,O
.,O
Methods,O
Male,O
adult,O
8,O
week,O
Wistar,B-OG
rats,I-OG
were,O
divided,O
into,O
5,O
groups,O
:,O
the,O
normal,O
chow,O
diet,O
(,O
NCD,O
);,O
the,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
;,O
the,O
NCD,O
+,O
0,O
.,O
15,O
%,O
Pb,O
;,O
the,O
NCD,O
+,O
0,O
.,O
45,O
%,O
Pb,O
and,O
the,O
high,O
fat,O
diet,O
.,O
Rats,B-OG
were,O
exposed,O
to,O
different,O
dosages,O
of,O
Pb,O
through,O
drinking,O
water,O
for,O
21,O
weeks,O
.,O
Body,O
weight,O
",",O
fasted,O
blood,O
glucose,O
level,O
",",O
fasted,O
insulin,B-GP
level,O
",",O
homeostasis,O
assessment,O
of,O
insulin,B-DS
resistance,I-DS
(,O
HOMA,O
-,O
IR,B-DS
),O
index,O
and,O
lipid,O
profile,O
were,O
detected,O
.,O
Intra,O
-,O
peritoneal,O
glucose,O
tolerance,O
test,O
(,O
IPGTT,O
),O
was,O
constructed,O
to,O
evaluate,O
the,O
glucose,O
tolerance,O
.,O
Lipid,O
accumulation,O
of,O
liver,O
was,O
detected,O
and,O
liver,O
DNA,O
underwent,O
whole,O
genome,O
bisulfite,O
sequencing,O
.,O
Results,O
The,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
had,O
significantly,O
greater,O
weight,O
",",O
HOMA,O
-,O
IR,B-DS
and,O
triglycerides,O
",",O
and,O
lower,O
glucose,B-DS
intolerance,I-DS
than,O
the,O
NCD,O
group,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
This,O
group,O
also,O
showed,O
hepatic,O
lipid,O
accumulation,O
.,O
These,O
metabolic,O
changes,O
were,O
not,O
observed,O
in,O
the,O
other,O
two,O
Pb,O
dosage,O
groups,O
.,O
Furthermore,O
",",O
DNA,O
hypermethylation,O
extended,O
along,O
pathways,O
related,O
to,O
glucose,O
and,O
lipid,O
metabolism,O
in,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
.,O
Conclusion,O
Pb,O
exposure,O
resulted,O
in,O
dose,O
-,O
specific,O
weight,O
gain,O
in,O
adult,O
Wistar,B-OG
rats,I-OG
",",O
accompanied,O
by,O
alteration,O
of,O
DNA,O
methylation,O
.,O
Introduction,O
The,O
prevalence,O
of,O
overweight,O
and,O
obesity,B-DS
has,O
drawn,O
worldwide,O
attention,O
in,O
all,O
geographic,O
areas,O
during,O
last,O
two,O
decades,O
.,O
In,O
USA,O
",",O
the,O
combined,O
prevalence,O
of,O
overweight,O
and,O
obesity,B-DS
had,O
risen,O
from,O
14,O
.,O
5,O
%,O
to,O
35,O
.,O
1,O
%,O
in,O
adults,O
[,O
1,O
"],",O
which,O
is,O
similar,O
to,O
growth,O
seen,O
in,O
China,O
from,O
14,O
.,O
6,O
%,O
to,O
32,O
.,O
3,O
"%,",O
due,O
to,O
economic,O
boom,O
and,O
lifestyle,O
changes,O
[,O
2,O
].,O
However,O
",",O
environmental,O
factors,O
are,O
attributed,O
to,O
the,O
rising,O
prevalence,O
of,O
obesity,B-DS
",",O
too,O
.,O
Endocrine,O
disrupting,O
chemicals,O
",",O
such,O
as,O
heavy,O
metals,O
",",O
have,O
been,O
confirmed,O
to,O
be,O
associated,O
with,O
obesity,B-DS
[,O
3,O
].,O
Lead,O
(,O
Pb,O
),O
is,O
a,O
kind,O
of,O
heavy,O
metal,O
widely,O
used,O
in,O
gasoline,O
and,O
lead,O
-,O
acid,O
battery,O
industries,O
[,O
2,O
].,O
Pb,O
pollutants,O
may,O
be,O
released,O
as,O
air,O
pollution,O
or,O
waste,O
mixtures,O
into,O
soil,O
and,O
waterways,O
in,O
the,O
process,O
of,O
manufacturing,O
",",O
which,O
were,O
then,O
up,O
-,O
taken,O
through,O
food,O
",",O
water,O
and,O
air,O
[,O
4,O
].,O
Lead,B-DS
poisoning,I-DS
mainly,O
caused,O
brain,B-DS
and,I-DS
neurology,I-DS
defects,I-DS
",",O
namely,O
cognitive,B-DS
disorder,I-DS
",",O
movement,B-DS
and,I-DS
coordination,I-DS
impairment,I-DS
",",O
hearing,O
and,O
visual,B-DS
disturbance,I-DS
[,O
5,O
].,O
Recent,O
studies,O
have,O
suggested,O
Pb,O
as,O
an,O
endocrine,O
disrupting,O
chemical,O
.,O
Pb,O
is,O
not,O
only,O
associated,O
with,O
late,O
-,O
onset,O
puberty,O
[,O
6,O
",",O
7,O
],O
but,O
also,O
acts,O
on,O
hypothalamic,O
-,O
pituitary,O
-,O
adrenal,O
(,O
HPA,O
),O
axis,O
",",O
thus,O
causing,O
high,O
stress,O
-,O
related,O
cortisol,O
levels,O
[,O
8,O
–,O
10,O
].,O
In,O
addition,O
",",O
high,O
bone,O
turnover,O
is,O
related,O
with,O
Pb,O
exposure,O
[,O
11,O
].,O
Furthermore,O
",",O
a,O
lot,O
of,O
studies,O
have,O
investigated,O
the,O
relationship,O
between,O
early,O
Pb,O
exposure,O
with,O
BMI,O
and,O
obesity,B-DS
",",O
and,O
the,O
results,O
were,O
inconclusive,O
.,O
Some,O
epidemiology,O
as,O
well,O
as,O
animal,B-OG
studies,O
revealed,O
that,O
maternal,O
or,O
adolescent,O
lead,O
exposure,O
caused,O
prolonged,O
obesity,B-DS
that,O
persisted,O
into,O
adults,O
[,O
4,O
",",O
5,O
",",O
12,O
",",O
13,O
"],",O
whereas,O
others,O
indicated,O
mother,O
lead,O
level,O
was,O
associated,O
with,O
low,O
birth,O
weight,O
[,O
14,O
",",O
15,O
].,O
However,O
",",O
little,O
has,O
concentrated,O
on,O
the,O
effects,O
of,O
adult,O
Pb,O
exposure,O
on,O
obesity,B-DS
.,O
Our,O
previous,O
investigation,O
from,O
the,O
cross,O
-,O
sectional,O
study,O
revealed,O
positive,O
relationship,O
between,O
blood,O
lead,O
level,O
(,O
BLL,O
),O
and,O
obesity,B-DS
in,O
adults,O
[,O
2,O
].,O
Thus,O
",",O
it,O
is,O
essential,O
to,O
establish,O
an,O
animal,B-OG
model,O
to,O
explore,O
the,O
underlying,O
mechanisms,O
.,O
There,O
is,O
a,O
growing,O
recognition,O
of,O
the,O
impact,O
of,O
environmental,O
factors,O
such,O
as,O
heavy,O
metals,O
",",O
diet,O
and,O
stress,O
on,O
the,O
epigenetic,O
regulation,O
of,O
gene,O
expression,O
",",O
especially,O
in,O
early,O
life,O
or,O
at,O
maternal,O
stage,O
[,O
16,O
].,O
DNA,O
Methylation,O
is,O
one,O
of,O
the,O
most,O
common,O
epigenetic,O
events,O
.,O
Some,O
research,O
has,O
confirmed,O
that,O
both,O
obesity,B-DS
and,O
type,B-DS
2,I-DS
diabetes,I-DS
were,O
accompanied,O
by,O
DNA,O
methylation,O
changes,O
of,O
some,O
metabolic,O
-,O
related,O
genes,O
[,O
17,O
–,O
19,O
].,O
In,O
one,O
study,O
",",O
various,O
levels,O
of,O
maternal,O
lead,O
exposure,O
resulted,O
in,O
the,O
fur,O
color,O
changes,O
of,O
offspring,O
as,O
well,O
as,O
methylation,O
level,O
changes,O
of,O
some,O
gene,O
locus,O
and,O
imprinted,O
genes,O
that,O
determined,O
fur,O
color,O
[,O
4,O
].,O
In,O
our,O
study,O
",",O
we,O
constructed,O
different,O
levels,O
of,O
leaded,O
water,O
on,O
adult,O
rats,B-OG
",",O
to,O
observe,O
the,O
association,O
of,O
Pb,O
and,O
weight,O
gain,O
and,O
other,O
metabolic,O
parameters,O
.,O
Furthermore,O
",",O
using,O
liver,O
samples,O
",",O
we,O
performed,O
a,O
genome,O
-,O
wide,O
methylome,O
analysis,O
to,O
observe,O
DNA,O
methylation,O
signatures,O
.,O
Materials,O
and,O
Methods,O
Animal,B-OG
experiments,O
Twenty,O
-,O
five,O
male,O
8,O
-,O
week,O
-,O
old,O
Wistar,B-OG
rats,I-OG
were,O
purchased,O
from,O
SLAC,O
Laboratories,O
",",O
SIBS,O
",",O
Shanghai,O
",",O
China,O
.,O
Animals,B-OG
were,O
housed,O
at,O
an,O
ambient,O
temperature,O
of,O
22,O
±,O
2,O
°,O
C,O
and,O
maintained,O
under,O
a,O
normal,O
12,O
hours,O
light,O
/,O
dark,O
cycle,O
and,O
allowed,O
access,O
to,O
food,O
and,O
water,O
ad,O
libitum,O
.,O
After,O
one,O
week,O
of,O
acclimatization,O
",",O
rats,B-OG
were,O
randomly,O
assigned,O
to,O
two,O
groups,O
with,O
one,O
(,O
N,O
=,O
20,O
),O
conventionally,O
fed,O
with,O
normal,O
chow,O
diets,O
(,O
NCD,O
;,O
containing,O
10,O
%,O
fat,O
),O
and,O
the,O
other,O
(,O
N,O
=,O
5,O
),O
with,O
high,O
fat,O
diets,O
(,O
HFD,O
;,O
containing,O
40,O
%,O
fat,O
"),",O
the,O
former,O
group,O
was,O
then,O
divided,O
into,O
4,O
sub,O
-,O
groups,O
:,O
NCD,O
(,O
N,O
=,O
5,O
);,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
(,O
N,O
=,O
5,O
);,O
NCD,O
+,O
0,O
.,O
15,O
%,O
Pb,O
(,O
N,O
=,O
5,O
);,O
NCD,O
+,O
0,O
.,O
45,O
%,O
Pb,O
(,O
N,O
=,O
5,O
).,O
Leaded,O
water,O
was,O
made,O
by,O
dissolving,O
Lead,O
(,O
Ⅱ,O
),O
acetate,O
trihydrate,O
((,O
CH3COO,O
),O
2Pb,O
.,O
3H20,O
),O
(,O
Sangon,O
biotech,O
",",O
shanghai,O
),O
in,O
distilled,O
water,O
.,O
Animal,B-OG
treatment,O
lasted,O
for,O
21,O
weeks,O
.,O
Body,O
weight,O
and,O
FBG,O
were,O
measured,O
every,O
two,O
weeks,O
at,O
the,O
overnight,O
fasting,O
condition,O
.,O
For,O
the,O
IPGTT,O
",",O
the,O
animals,B-OG
were,O
intra,O
-,O
peritoneally,O
injected,O
with,O
glucose,O
of,O
2g,O
/,O
kg,O
body,O
weight,O
(,O
Sigma,O
),O
after,O
12,O
h,O
of,O
fasting,O
",",O
and,O
blood,O
glucose,O
levels,O
were,O
measured,O
at,O
baseline,O
and,O
at,O
time,O
points,O
of,O
15min,O
",",O
30min,O
",",O
60min,O
",",O
90min,O
",",O
120min,O
after,O
glucose,O
injection,O
by,O
an,O
electronic,O
glucometer,O
(,O
Terumo,O
",",O
Tokyo,O
",",O
Japan,O
).,O
Animals,B-OG
were,O
sacrificed,O
by,O
anesthesia,O
",",O
bones,O
were,O
obtained,O
immediately,O
and,O
bone,O
lead,O
concentration,O
was,O
detected,O
with,O
inductively,O
coupled,O
plasma,O
atomic,O
emission,O
spectroscopy,O
.,O
All,O
the,O
animal,B-OG
experiments,O
were,O
carried,O
out,O
in,O
accordance,O
with,O
the,O
Guidelines,O
for,O
Care,O
and,O
Use,O
of,O
Laboratory,O
Animals,B-OG
of,O
Shanghai,O
Laboratory,O
Animal,B-OG
Center,O
(,O
SLAC,O
"),",O
Chinese,O
Academy,O
of,O
Sciences,O
",",O
Shanghai,O
",",O
China,O
.,O
All,O
the,O
protocols,O
were,O
approved,O
by,O
the,O
Institutional,O
Animal,B-OG
Care,O
and,O
Use,O
Committee,O
of,O
SLAC,O
(,O
No,O
.,O
2011,O
–,O
007,O
).,O
We,O
have,O
made,O
all,O
efforts,O
to,O
minimize,O
animal,B-OG
suffering,O
.,O
Measurement,O
of,O
insulin,B-GP
and,O
biochemical,O
indexes,O
Tail,O
blood,O
was,O
separately,O
collected,O
from,O
the,O
caudal,O
vein,O
following,O
overnight,O
fasting,O
at,O
the,O
end,O
of,O
the,O
experiment,O
for,O
detection,O
of,O
insulin,B-GP
and,O
biochemical,O
profiles,O
.,O
Alanine,B-GP
aminotransferase,I-GP
(,O
ALT,B-GP
"),",O
aspartate,B-GP
transaminase,I-GP
(,O
AST,B-GP
"),",O
triglycerides,O
(,O
TG,O
"),",O
total,O
cholesterol,O
(,O
TC,O
"),",O
free,O
fatty,O
acid,O
(,O
FFA,O
),O
and,O
low,O
-,O
density,O
lipoprotein,O
cholesterol,O
(,O
LDL,O
-,O
C,O
),O
levels,O
were,O
detected,O
with,O
Siemens,O
Dimension,O
MAX,O
(,O
Siemens,O
Healthcare,O
Diagnostics,O
Inc,O
);,O
FSI,O
was,O
assessed,O
with,O
ELISA,O
kits,O
(,O
Shibayaji,O
",",O
Japan,O
);,O
HOMA,O
-,O
IR,B-DS
index,O
was,O
calculated,O
according,O
to,O
the,O
formula,O
:,O
FBG,O
*,O
FINS,O
/,O
22,O
.,O
5,O
.,O
Oil,O
red,O
staining,O
of,O
liver,O
After,O
the,O
rats,B-OG
were,O
sacrificed,O
",",O
the,O
right,O
lateral,O
lobule,O
of,O
the,O
livers,O
was,O
removed,O
and,O
subsequently,O
fixed,O
in,O
phosphate,O
-,O
buffered,O
10,O
%,O
formalin,O
.,O
The,O
fixed,O
liver,O
was,O
embedded,O
in,O
paraffin,O
blocks,O
and,O
were,O
sliced,O
and,O
stained,O
with,O
oil,O
red,O
to,O
evaluate,O
lipid,O
droplets,O
.,O
Genomic,O
DNA,O
isolation,O
and,O
WGBS,O
library,O
construction,O
Two,O
samples,O
were,O
randomly,O
selected,O
from,O
control,O
group,O
as,O
well,O
as,O
0,O
.,O
05,O
%,O
Pb,O
group,O
",",O
separately,O
.,O
Genomic,O
DNA,O
was,O
isolated,O
and,O
purified,O
from,O
25,O
mg,O
of,O
frozen,O
liver,O
tissue,O
with,O
the,O
DNeasy,O
Tissue,O
Kit,O
(,O
Qiagen,O
",",O
Germany,O
",",O
cat,O
.,O
no,O
.,O
51306,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
protocol,O
.,O
DNA,O
concentration,O
was,O
assessed,O
using,O
a,O
ND1000,O
spectrophotometer,O
(,O
NanoDrop,O
Technology,O
"),",O
and,O
DNA,O
quality,O
was,O
assessed,O
by,O
electrophoresis,O
using,O
a,O
1,O
%,O
agarose,O
gel,O
.,O
3ug,O
of,O
genomic,O
DNA,O
were,O
broken,O
into,O
fragments,O
by,O
Covaris,O
S2,O
system,O
(,O
Covaris,O
",",O
MA,O
),O
for,O
52,O
seconds,O
with,O
20,O
%,O
duty,O
cycle,O
",",O
level,O
5,O
intensity,O
and,O
200,O
cycles,O
per,O
burst,O
.,O
Fragmented,O
DNA,O
were,O
purified,O
by,O
Ampure,O
XP,O
Beads,O
(,O
Beckman,O
Coulter,O
",",O
CA,O
),O
and,O
the,O
fragments,O
were,O
end,O
-,O
repaired,O
",",O
and,O
a,O
single,O
A,O
nucleotide,O
was,O
added,O
to,O
the,O
3,O
',O
ends,O
of,O
the,O
fragments,O
in,O
preparation,O
for,O
ligation,O
to,O
a,O
methylated,O
adapter,O
(,O
Illumina,O
",",O
CA,O
),O
with,O
a,O
single,O
-,O
base,O
T,O
overhang,O
.,O
The,O
ligation,O
products,O
were,O
purified,O
and,O
size,O
-,O
selected,O
(,O
300,O
-,O
400bp,O
),O
using,O
agarose,O
gel,O
electrophoresis,O
(,O
Qiagen,O
Minelute,O
Gel,O
Extraction,O
Kit,O
).,O
DNA,O
was,O
modified,O
with,O
sodium,O
bisulfite,O
to,O
convert,O
unmethylated,O
cytosine,O
to,O
uracil,O
using,O
the,O
Zymo,O
Gold,O
methylation,O
kit,O
(,O
Zymo,O
Research,O
",",O
CA,O
),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
protocol,O
and,O
then,O
purified,O
.,O
The,O
purified,O
converted,O
DNA,O
was,O
amplified,O
with,O
PfuTurbo,O
Cx,O
Hotstart,O
DNA,B-GP
Polymerase,I-GP
(,O
Agilent,O
Technologies,O
",",O
CA,O
),O
and,O
was,O
purified,O
again,O
using,O
AMPure,O
XP,O
beads,O
.,O
Library,O
quality,O
was,O
monitored,O
using,O
the,O
Agilent,O
2100,O
Bio,O
-,O
Analyzer,O
(,O
Agilent,O
),O
and,O
KAPA,O
Library,O
Quantification,O
Kit,O
(,O
Kapa,O
Biosystem,O
).,O
Paired,O
-,O
end,O
sequencing,O
(,O
2,O
×,O
100,O
bp,O
),O
was,O
then,O
carried,O
out,O
using,O
the,O
Illumina,O
Hi,O
-,O
Seq,O
2000,O
.,O
Whole,O
-,O
genome,O
methylation,O
analysis,O
Identification,O
of,O
methylated,O
cytosines,O
After,O
sequencing,O
",",O
raw,O
data,O
were,O
filtered,O
into,O
clean,O
data,O
by,O
removing,O
pollution,O
reads,O
",",O
low,O
quality,O
reads,O
and,O
Adapters,O
.,O
FASTqc,O
software,O
was,O
used,O
to,O
assess,O
sequencing,O
accuracy,O
of,O
the,O
clean,O
data,O
.,O
The,O
sequencing,O
error,O
rates,O
were,O
controlled,O
lower,O
than,O
5,O
%.,O
Clean,O
data,O
were,O
mapped,O
to,O
the,O
reference,O
genome,O
of,O
rats,B-OG
using,O
in,O
silico,O
bisulfite,O
conversion,O
algorithm,O
with,O
Bismark,O
software,O
.,O
Reads,O
with,O
methylated,O
position,O
were,O
reported,O
when,O
sequencing,O
depth,O
was,O
≥,O
1,O
.,O
We,O
used,O
the,O
bulk,O
fractional,O
methylation,O
of,O
mitochondria,O
DNA,O
to,O
measure,O
the,O
rate,O
of,O
false,O
positives,O
.,O
The,O
methylation,O
level,O
of,O
an,O
individual,O
cytosine,O
was,O
calculated,O
from,O
the,O
number,O
of,O
sequenced,O
cytosines,O
divided,O
by,O
the,O
total,O
read,O
depth,O
",",O
i,O
.,O
e,O
.,O
(,O
mC,O
)/(,O
mC,O
+,O
non,O
-,O
mC,O
).,O
The,O
methylation,O
level,O
of,O
a,O
region,O
",",O
named,O
“,O
bulk,O
methylation,O
level,O
"”,",O
which,O
was,O
calculated,O
from,O
(,O
mC,O
)/(,O
mC,O
+,O
non,O
-,O
mC,O
).,O
mC,O
and,O
non,O
-,O
mC,O
referred,O
to,O
the,O
number,O
of,O
methylated,O
and,O
unmethylated,O
cytosines,O
",",O
respectively,O
",",O
in,O
this,O
region,O
.,O
The,O
cytosine,O
methylation,O
level,O
covered,O
by,O
more,O
than,O
5,O
reads,O
were,O
used,O
to,O
calculate,O
DNA,O
methylation,O
levels,O
of,O
whole,O
genome,O
and,O
specific,O
genetic,O
elements,O
such,O
as,O
TTS,O
",",O
TSS,O
",",O
CDS,O
",",O
transposon,O
element,O
etc,O
.,O
TSS,O
was,O
defined,O
as,O
2000bp,O
of,O
upstream,O
and,O
downstream,O
region,O
of,O
gene,O
start,O
sites,O
.,O
TTS,O
was,O
defined,O
as,O
2000bp,O
of,O
upstream,O
and,O
downstream,O
region,O
of,O
gene,O
termination,O
site,O
.,O
Methylation,O
signal,O
intensity,O
values,O
of,O
whole,O
genome,O
were,O
drawn,O
in,O
a,O
circular,O
view,O
using,O
CIRCOS,O
visualization,O
software,O
.,O
Identification,O
and,O
enrichment,O
of,O
differentially,O
methylated,O
regions,O
(,O
DMRs,O
),O
of,O
genes,O
To,O
identify,O
genes,O
with,O
significant,O
differences,O
in,O
DNA,O
methylation,O
between,O
two,O
groups,O
",",O
we,O
locked,O
in,O
TSS,O
regions,O
of,O
genes,O
.,O
Biological,O
replicates,O
of,O
each,O
group,O
were,O
merged,O
",",O
and,O
afterwards,O
genomic,O
sites,O
with,O
methylation,O
cytosine,O
covered,O
by,O
more,O
than,O
2,O
reads,O
were,O
analyzed,O
with,O
DMR,O
caller,O
package,O
of,O
R,O
software,O
.,O
P,O
values,O
were,O
calculated,O
by,O
Fisher,O
’,O
s,O
exact,O
test,O
",",O
and,O
then,O
FDR,O
correction,O
was,O
performed,O
.,O
Cytosines,O
with,O
FDR,O
(<,O
0,O
.,O
05,O
),O
and,O
methylation,O
differences,O
of,O
at,O
least,O
0,O
.,O
05,O
for,O
CG,O
contexts,O
were,O
identified,O
as,O
differentially,O
methylated,O
regions,O
.,O
Single,O
reads,O
of,O
potential,O
DMRs,O
were,O
analyzed,O
using,O
the,O
Integrative,O
Genomic,O
Viewer,O
(,O
IGV,O
),O
Browser,O
.,O
We,O
processed,O
KEGG,O
pathway,O
enrichment,O
of,O
different,O
methylated,O
genes,O
and,O
calculated,O
the,O
significance,O
of,O
every,O
KEGG,O
pathway,O
with,O
hypergeometric,O
distribution,O
testing,O
method,O
.,O
A,O
small,O
P,O
value,O
indicated,O
differential,O
gene,O
enrichment,O
in,O
specific,O
KEGG,O
pathway,O
.,O
Statistics,O
analysis,O
Data,O
were,O
presented,O
as,O
mean,O
±,O
SEM,O
.,O
The,O
overall,O
differences,O
between,O
treatment,O
groups,O
were,O
compared,O
using,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
"),",O
followed,O
by,O
Tukey,O
’,O
s,O
multiple,O
comparison,O
test,O
",",O
and,O
LSD,O
",",O
with,O
or,O
without,O
repeated,O
measures,O
.,O
P,O
<,O
0,O
.,O
05,O
was,O
considered,O
to,O
be,O
statistically,O
significant,O
.,O
GraphPad,O
Prism,O
",",O
Version,O
5,O
(,O
GraphPad,O
Software,O
),O
was,O
used,O
for,O
all,O
statistical,O
analyses,O
.,O
Results,O
Pb,O
was,O
deposited,O
in,O
femur,O
of,O
rats,B-OG
drinking,O
leaded,O
water,O
for,O
21,O
weeks,O
Table,O
1,O
reveals,O
the,O
cumulative,O
bone,O
Pb,O
deposition,O
in,O
each,O
group,O
.,O
Pb,O
was,O
scarcely,O
detectable,O
in,O
femur,O
of,O
both,O
NCD,O
and,O
HFD,O
group,O
.,O
However,O
",",O
significant,O
Pb,O
accumulations,O
were,O
observed,O
in,O
Pb,O
exposure,O
groups,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
The,O
mean,O
Pb,O
content,O
was,O
56,O
.,O
25,O
±,O
7,O
.,O
47,O
ng,O
/,O
mg,O
in,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
",",O
which,O
was,O
tripled,O
in,O
0,O
.,O
15,O
%,O
Pb,O
(,O
160,O
.,O
50,O
±,O
14,O
.,O
15,O
ng,O
/,O
mg,O
),O
exposure,O
group,O
.,O
Interestingly,O
",",O
Pb,O
content,O
in,O
NCD,O
+,O
0,O
.,O
45,O
%,O
Pb,O
group,O
(,O
189,O
.,O
30,O
±,O
18,O
.,O
22,O
ng,O
/,O
mg,O
),O
did,O
not,O
exhibit,O
the,O
same,O
increasing,O
pattern,O
.,O
Bone,O
Pb,O
levels,O
in,O
rats,B-OG
(,O
ng,O
Pb,O
/,O
mg,O
dry,O
wt,O
of,O
femur,O
),O
at,O
21,O
weeks,O
.,O
NCD,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
NCD,O
+,O
0,O
.,O
15,O
%,O
Pb,O
NCD,O
+,O
0,O
.,O
45,O
%,O
Pb,O
HFD,O
Bone,O
lead,O
",",O
ng,O
/,O
mg,O
≤,O
1,O
56,O
.,O
25,O
±,O
7,O
.,O
47a,O
160,O
.,O
50,O
±,O
14,O
.,O
15a,O
189,O
.,O
30,O
±,O
18,O
.,O
22a,O
≤,O
1,O
Data,O
are,O
expressed,O
as,O
mean,O
±,O
SEM,O
.,O
Pb,O
was,O
determined,O
in,O
thigh,O
bone,O
by,O
inductively,O
coupled,O
plasma,O
atomic,O
emission,O
spectroscopy,O
.,O
a,O
P,O
<,O
0,O
.,O
05,O
vs,O
.,O
NCD,O
by,O
one,O
-,O
way,O
ANOVA,O
.,O
0,O
.,O
05,O
%,O
Pb,O
resulted,O
in,O
weight,O
gain,O
Weight,O
gains,O
(,O
Fig,O
1A,O
),O
were,O
observed,O
in,O
all,O
groups,O
.,O
Rats,B-OG
of,O
HFD,O
accumulated,O
significantly,O
more,O
weight,O
than,O
that,O
of,O
NCD,O
at,O
the,O
end,O
of,O
21,O
weeks,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
Both,O
the,O
NCD,O
+,O
0,O
.,O
15,O
%,O
Pb,O
and,O
NCD,O
+,O
0,O
.,O
45,O
%,O
Pb,O
groups,O
exhibited,O
less,O
weight,O
gain,O
in,O
comparison,O
with,O
NCD,O
group,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
Notably,O
",",O
only,O
exposure,O
to,O
0,O
.,O
05,O
%,O
Pb,O
contributed,O
to,O
increased,O
weight,O
compared,O
with,O
the,O
NCD,O
control,O
group,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
Body,O
Weight,O
and,O
Fasted,O
glucose,O
levels,O
of,O
rats,B-OG
after,O
Pb,O
exposure,O
.,O
(,O
a,O
),O
Body,O
weight,O
.,O
(,O
b,O
),O
Fasted,O
glucose,O
level,O
.,O
Data,O
are,O
expressed,O
as,O
mean,O
±,O
SEM,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
vs,O
.,O
NCD,O
by,O
one,O
-,O
way,O
ANOVA,O
.,O
0,O
.,O
05,O
%,O
Pb,O
resulted,O
in,O
glucose,B-DS
intolerance,I-DS
and,O
insulin,B-DS
resistance,I-DS
of,O
rats,B-OG
Though,O
no,O
significant,O
difference,O
in,O
fasted,O
blood,O
glucose,O
level,O
(,O
Fig,O
1B,O
),O
was,O
observed,O
across,O
different,O
groups,O
",",O
in,O
order,O
to,O
evaluate,O
glucose,O
homeostasis,O
",",O
we,O
further,O
conducted,O
IPGTT,O
at,O
the,O
20th,O
week,O
of,O
the,O
study,O
.,O
The,O
curves,O
of,O
HFD,O
group,O
remained,O
at,O
the,O
top,O
during,O
the,O
120,O
minutes,O
(,O
Fig,O
2A,O
).,O
Meanwhile,O
in,O
the,O
NCD,O
groups,O
",",O
0,O
.,O
05,O
%,O
Pb,O
resulted,O
in,O
higher,O
peaking,O
glucose,O
level,O
at,O
the,O
15,O
min,O
time,O
point,O
compared,O
to,O
controls,O
.,O
To,O
quantify,O
glucose,O
tolerance,O
",",O
we,O
calculated,O
the,O
area,O
under,O
curve,O
(,O
AUC,O
),O
for,O
all,O
treatment,O
groups,O
.,O
Exposure,O
to,O
Pb,O
increased,O
the,O
average,O
AUC,O
in,O
NCD,O
groups,O
(,O
Fig,O
2B,O
).,O
Among,O
the,O
NCD,O
groups,O
",",O
the,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
showed,O
a,O
significant,O
higher,O
AUC,O
than,O
NCD,O
control,O
(,O
P,O
<,O
0,O
.,O
05,O
"),",O
which,O
was,O
similar,O
to,O
the,O
AUC,O
of,O
HFD,O
.,O
The,O
AUCs,O
of,O
the,O
other,O
two,O
Pb,O
dosages,O
(,O
0,O
.,O
15,O
%,O
and,O
0,O
.,O
45,O
%),O
were,O
not,O
significantly,O
larger,O
than,O
that,O
of,O
the,O
NCD,O
control,O
group,O
.,O
Glucose,B-DS
intolerance,I-DS
and,O
insulin,B-DS
resistance,I-DS
were,O
observed,O
after,O
Pb,O
exposure,O
.,O
(,O
a,O
),O
IPGTT,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
HFD,O
vs,O
.,O
NCD,O
;,O
#,O
P,O
<,O
0,O
.,O
05,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
vs,O
.,O
NCD,O
by,O
repeated,O
measures,O
data,O
ANOVA,O
.,O
(,O
b,O
),O
AUC,O
of,O
IPGTT,O
.,O
(,O
c,O
),O
Fasted,O
serum,O
insulin,B-GP
levels,O
.,O
(,O
d,O
),O
HOMA,O
-,O
IR,B-DS
indexes,O
.,O
Data,O
are,O
expressed,O
as,O
mean,O
±,O
SEM,O
.,O
(,O
b,O
"),",O
(,O
c,O
"),",O
(,O
d,O
)*,O
P,O
<,O
0,O
.,O
05,O
vs,O
.,O
NCD,O
by,O
one,O
-,O
way,O
ANOVA,O
.,O
Moreover,O
",",O
a,O
significantly,O
elevated,O
fasted,O
insulin,B-GP
level,O
(,O
FSI,O
),O
was,O
observed,O
in,O
the,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
(,O
Fig,O
2C,O
),O
(,O
P,O
<,O
0,O
.,O
05,O
"),",O
which,O
was,O
even,O
higher,O
than,O
in,O
the,O
HFD,O
group,O
(,O
P,O
<,O
0,O
.,O
05,O
).,O
The,O
HOMA,O
-,O
IR,B-DS
index,O
exhibited,O
the,O
same,O
patterns,O
(,O
Fig,O
2D,O
).,O
0,O
.,O
05,O
%,O
Pb,O
led,O
to,O
biochemical,O
changes,O
Alanine,B-GP
aminotransferase,I-GP
(,O
ALT,B-GP
),O
and,O
aspartate,B-GP
aminotransferase,I-GP
(,O
AST,B-GP
),O
were,O
detected,O
to,O
evaluate,O
liver,O
function,O
.,O
The,O
NCD,O
+,O
0,O
.,O
45,O
%,O
Pb,O
group,O
showed,O
slightly,O
higher,O
ALT,B-GP
and,O
AST,B-GP
level,O
than,O
others,O
",",O
indicating,O
high,O
Pb,O
dosage,O
exposure,O
might,O
result,O
in,O
liver,B-DS
damage,I-DS
(,O
Fig,O
3A,O
and,O
3B,O
"),",O
though,O
the,O
differences,O
did,O
not,O
reach,O
significance,O
.,O
The,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
exhibited,O
significantly,O
higher,O
TG,O
level,O
(,O
Fig,O
3C,O
),O
(,O
P,O
<,O
0,O
.,O
05,O
),O
compared,O
to,O
other,O
NCD,O
groups,O
.,O
This,O
group,O
also,O
had,O
higher,O
low,O
-,O
density,O
lipoprotein,O
cholesterol,O
(,O
LDL,O
-,O
C,O
),O
than,O
NCD,O
control,O
group,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
(,O
Fig,O
3E,O
).,O
Differences,O
were,O
not,O
observed,O
in,O
serum,O
total,O
cholesterol,O
(,O
TC,O
),O
and,O
free,O
fatty,O
acid,O
(,O
FFA,O
),O
levels,O
(,O
Fig,O
3D,O
and,O
3F,O
).,O
Biochemical,O
changes,O
after,O
Pb,O
exposure,O
.,O
(,O
a,O
),O
Serum,O
ALT,B-GP
levels,O
;,O
(,O
b,O
),O
Serum,O
AST,B-GP
levels,O
;,O
(,O
c,O
),O
Serum,O
TG,O
levels,O
;,O
(,O
d,O
),O
Serum,O
TC,O
levels,O
;,O
(,O
e,O
),O
Serum,O
LDL,O
-,O
C,O
levels,O
;,O
(,O
f,O
),O
Serum,O
FFA,O
levels,O
.,O
*,O
P,O
<,O
0,O
.,O
05,O
by,O
one,O
-,O
way,O
ANOVA,O
.,O
0,O
.,O
05,O
%,O
Pb,O
led,O
to,O
lipid,O
accumulation,O
of,O
liver,O
Oil,O
red,O
staining,O
showed,O
excessive,O
lipid,O
droplets,O
in,O
the,O
hepatocytes,O
of,O
rats,B-OG
fed,O
with,O
high,O
-,O
fat,O
diet,O
(,O
Fig,O
4,O
).,O
Meanwhile,O
",",O
increased,O
hepatic,O
triglyceride,O
contents,O
were,O
observed,O
in,O
0,O
.,O
05,O
%,O
Pb,O
treated,O
rats,B-OG
compared,O
to,O
the,O
NCD,O
control,O
rats,B-OG
.,O
Oil,O
red,O
staining,O
of,O
liver,O
.,O
Lipid,O
accumulation,O
was,O
observed,O
in,O
rats,B-OG
of,O
HFD,O
group,O
as,O
well,O
as,O
exposed,O
to,O
0,O
.,O
05,O
%,O
Pb,O
.,O
The,O
magnification,O
is,O
400,O
×.,O
Whole,O
genome,O
DNA,O
methylation,O
alteration,O
was,O
observed,O
in,O
0,O
.,O
05,O
%,O
Pb,O
exposed,O
rats,B-OG
The,O
WGBS,O
data,O
has,O
been,O
uploaded,O
to,O
GEO,O
(,O
Series,O
record,O
:,O
GSE89919,O
).,O
Significant,O
metabolic,O
changes,O
were,O
observed,O
in,O
the,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
",",O
thus,O
we,O
conducted,O
the,O
whole,O
genome,O
bisulfite,O
sequencing,O
of,O
liver,O
samples,O
in,O
both,O
the,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
and,O
the,O
NCD,O
control,O
group,O
.,O
As,O
was,O
observed,O
in,O
the,O
CIRCOS,O
map,O
(,O
Fig,O
5A,O
"),",O
the,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
had,O
hypermethylation,O
at,O
the,O
whole,O
genome,O
level,O
",",O
compared,O
to,O
NCD,O
.,O
The,O
density,O
distribution,O
curves,O
revealed,O
that,O
unmethylated,O
CG,O
sites,O
were,O
reduced,O
and,O
100,O
%,O
mCG,O
sites,O
were,O
increased,O
after,O
0,O
.,O
05,O
%,O
Pb,O
treatment,O
(,O
S1,O
Fig,O
).,O
Furthermore,O
",",O
average,O
DNA,O
methylation,O
levels,O
were,O
all,O
elevated,O
in,O
specific,O
genetic,O
functional,O
elements,O
such,O
as,O
gene,O
",",O
intergenic,O
",",O
intron,O
",",O
extron,O
",",O
CpG,O
Island,O
as,O
well,O
as,O
repeated,O
elements,O
(,O
S2,O
Fig,O
).,O
The,O
profiling,O
analysis,O
revealed,O
the,O
overall,O
trend,O
of,O
DNA,O
methylation,O
in,O
different,O
regions,O
of,O
gene,O
",",O
transcription,O
start,O
site,O
(,O
TSS,O
),O
and,O
transcription,O
terminal,O
site,O
(,O
TTS,O
),O
sections,O
(,O
Fig,O
5B,O
–,O
5D,O
).,O
All,O
the,O
three,O
sections,O
showed,O
increased,O
methylation,O
levels,O
at,O
overall,O
length,O
",",O
although,O
there,O
were,O
small,O
differences,O
between,O
two,O
samples,O
of,O
the,O
same,O
group,O
.,O
DNA,O
methylation,O
files,O
of,O
liver,O
genome,O
for,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
compared,O
to,O
NCD,O
group,O
.,O
(,O
a,O
),O
The,O
circus,O
map,O
;,O
(,O
b,O
),O
The,O
profiling,O
of,O
TSS,O
region,O
;,O
(,O
c,O
),O
The,O
profiling,O
of,O
gene,O
body,O
region,O
;,O
(,O
d,O
),O
The,O
profiling,O
of,O
TTS,O
region,O
.,O
Differentially,O
methylated,O
genes,O
associated,O
with,O
glucose,O
and,O
lipid,O
metabolism,O
in,O
0,O
.,O
05,O
%,O
Pb,O
exposed,O
rats,B-OG
KEGG,O
pathway,O
enrichment,O
analysis,O
was,O
employed,O
to,O
identify,O
important,O
pathways,O
that,O
were,O
altered,O
in,O
Pb,O
exposure,O
group,O
compared,O
to,O
control,O
group,O
(,O
Fig,O
6A,O
).,O
Among,O
the,O
top,O
20,O
pathways,O
with,O
altered,O
DNA,O
methylation,O
were,O
metabolic,O
pathways,O
",",O
fatty,O
acid,O
elongation,O
pathway,O
as,O
well,O
as,O
TCA,O
cycle,O
pathway,O
.,O
DNA,O
methylation,O
enrichment,O
and,O
specific,O
genes,O
with,O
altered,O
DNA,O
methylation,O
for,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
compared,O
to,O
NCD,O
group,O
.,O
(,O
a,O
),O
The,O
top,O
10,O
KEGG,O
pathways,O
changed,O
in,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
compared,O
to,O
NCD,O
group,O
.,O
P,O
values,O
were,O
derived,O
from,O
Fisher,O
’,O
s,O
Exact,O
Test,O
.,O
(,O
b,O
),O
The,O
heat,O
map,O
of,O
specific,O
genes,O
related,O
with,O
glucose,O
and,O
lipid,O
metabolism,O
(,O
FDR,O
<,O
0,O
.,O
25,O
).,O
Difference,O
analysis,O
in,O
gene,O
methylation,O
aimed,O
at,O
TSS,O
region,O
indicated,O
that,O
a,O
total,O
of,O
2733,O
genes,O
experienced,O
DNA,O
methylation,O
changes,O
",",O
with,O
2320,O
hypermethylated,O
genes,O
and,O
413,O
hypomethylated,O
genes,O
(,O
S1,O
Table,O
).,O
A,O
heatmap,O
of,O
different,O
methylated,O
genes,O
related,O
to,O
lipid,O
and,O
glucose,O
metabolism,O
were,O
employed,O
(,O
Fig,O
6B,O
).,O
DNA,O
hypermethylation,O
was,O
observed,O
in,O
genes,O
related,O
to,O
fatty,O
acid,O
transport,O
and,O
synthesis,O
(,O
LDLR,B-GP
",",O
FATP,B-GP
",",O
Glyctk,B-GP
",",O
DGAT1,B-GP
and,O
DGAT2,B-GP
),O
and,O
fatty,O
acid,O
oxidation,O
(,O
CPT,B-GP
-,I-GP
2,I-GP
",",O
MCAD,B-GP
",",O
CYP4A,B-GP
",",O
ACO,B-GP
).,O
In,O
addition,O
",",O
genes,O
related,O
to,O
VLDL,O
-,O
TG,O
assembling,O
(,O
MTTP,B-GP
and,O
APO,B-GP
-,I-GP
CⅢ,I-GP
",",O
APO,B-GP
"-,",O
APO,B-GP
-,I-GP
Ⅳ,I-GP
),O
and,O
the,O
transcription,O
factor,O
such,O
as,O
LXR,B-GP
and,O
SREBP,B-GP
-,I-GP
1c,I-GP
were,O
hypermethylated,O
.,O
Some,O
glucose,O
metabolism,O
related,O
genes,O
such,O
as,O
PKA,B-GP
and,O
AKT,B-GP
were,O
hypermethylated,O
.,O
PEPCK,B-GP
(,O
1,O
.,O
45,O
multiple,O
),O
and,O
G6pase,B-GP
(,O
1,O
.,O
18,O
multiple,O
),O
related,O
with,O
gluconeogenesis,O
were,O
also,O
hypermethylated,O
",",O
as,O
well,O
as,O
cholesterol,O
metabolism,O
genes,O
such,O
as,O
CYP51,B-GP
and,O
ACAT,B-GP
.,O
Discussion,O
In,O
our,O
research,O
",",O
we,O
found,O
that,O
0,O
.,O
05,O
%,O
Pb,O
water,O
exposure,O
brought,O
about,O
weight,O
gain,O
and,O
insulin,B-DS
resistance,I-DS
as,O
well,O
as,O
glucose,B-DS
intolerance,I-DS
in,O
the,O
NCD,O
rats,B-OG
",",O
accompanied,O
by,O
elevated,O
serum,O
TG,O
as,O
well,O
as,O
hepatic,O
lipid,O
accumulation,O
",",O
which,O
were,O
not,O
seen,O
in,O
the,O
other,O
two,O
dosages,O
(,O
0,O
.,O
15,O
%,O
and,O
0,O
.,O
45,O
%),O
of,O
NCD,O
groups,O
.,O
Furthermore,O
",",O
compared,O
to,O
the,O
NCD,O
control,O
group,O
",",O
we,O
found,O
the,O
DNA,O
hypermethylation,O
extended,O
along,O
pathways,O
related,O
to,O
glucose,O
and,O
lipid,O
metabolism,O
in,O
the,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
.,O
These,O
results,O
indicated,O
that,O
0,O
.,O
05,O
%,O
Pb,O
may,O
induce,O
abnormal,O
metabolic,O
status,O
through,O
DNA,O
methylation,O
that,O
regulated,O
important,O
genes,O
involved,O
in,O
lipid,O
and,O
glucose,O
metabolism,O
.,O
As,O
a,O
kind,O
of,O
environmental,O
endocrine,O
disruptor,O
",",O
Pb,O
mimics,O
or,O
disrupts,O
hormone,O
function,O
at,O
low,O
doses,O
in,O
ways,O
not,O
predicted,O
by,O
high,O
-,O
dose,O
studies,O
[,O
20,O
].,O
Previous,O
animal,B-OG
studies,O
had,O
found,O
that,O
Pb,O
exposure,O
played,O
both,O
dose,O
-,O
specific,O
and,O
sex,O
-,O
specific,O
roles,O
in,O
body,O
weight,O
and,O
glucose,O
dys,O
-,O
metabolism,O
",",O
however,O
",",O
most,O
of,O
their,O
studies,O
focused,O
on,O
prenatal,O
Pb,O
exposure,O
",",O
and,O
the,O
effective,O
dose,O
and,O
conclusions,O
were,O
discrepant,O
.,O
In,O
one,O
study,O
",",O
prenatal,O
exposure,O
to,O
16ppm,O
and,O
32ppm,O
lead,O
water,O
caused,O
weight,O
gain,O
in,O
male,O
offspring,O
of,O
mice,B-OG
;,O
moreover,O
",",O
body,O
fat,O
and,O
FSI,O
level,O
as,O
well,O
as,O
HOMA,O
-,O
IR,B-DS
level,O
of,O
16ppm,O
male,O
offspring,O
were,O
significantly,O
increased,O
.,O
In,O
contrast,O
",",O
weight,O
gain,O
and,O
body,O
composition,O
changes,O
as,O
well,O
as,O
glucose,B-DS
intolerance,I-DS
were,O
not,O
seen,O
in,O
female,O
offspring,O
[,O
12,O
].,O
In,O
addition,O
",",O
a,O
linear,O
increase,O
in,O
mean,O
weight,O
with,O
increasing,O
pre,O
-,O
weaning,O
lead,O
exposure,O
in,O
male,O
offspring,O
was,O
observed,O
in,O
a,O
study,O
constructed,O
by,O
Faulk,O
et,O
al,O
.,O
[,O
4,O
].,O
The,O
effects,O
of,O
postnatal,O
Pb,O
exposure,O
on,O
metabolism,O
changes,O
were,O
inconclusive,O
.,O
Our,O
previous,O
epidemiology,O
study,O
revealed,O
a,O
positive,O
relationship,O
between,O
BLL,O
and,O
BMI,O
in,O
China,O
[,O
2,O
].,O
In,O
another,O
longitudinal,O
study,O
in,O
Boston,O
",",O
the,O
chronic,O
lead,O
exposure,O
in,O
childhood,O
may,O
result,O
in,O
obesity,B-DS
that,O
persists,O
into,O
adulthood,O
[,O
13,O
].,O
Whereas,O
Both,O
Miguel,O
A,O
.,O
Padilla,O
et,O
al,O
.,O
and,O
Franco,O
Scinicariello,O
et,O
al,O
.,O
reported,O
that,O
BLL,O
associated,O
with,O
lower,O
body,O
weight,O
in,O
adults,O
based,O
on,O
data,O
from,O
NHANES,O
[,O
1,O
",",O
21,O
].,O
In,O
another,O
study,O
",",O
no,O
association,O
was,O
found,O
between,O
BLL,O
and,O
BMI,O
in,O
adults,O
[,O
22,O
].,O
The,O
conflicting,O
results,O
may,O
be,O
due,O
to,O
ethnic,O
variations,O
as,O
well,O
as,O
different,O
BLL,O
of,O
the,O
study,O
population,O
.,O
In,O
one,O
animal,B-OG
study,O
",",O
gestational,O
exposure,O
from,O
27,O
to,O
109ppm,O
of,O
leaded,O
water,O
resulted,O
in,O
late,O
-,O
onset,O
obesity,B-DS
of,O
offspring,O
",",O
which,O
was,O
not,O
observed,O
in,O
the,O
same,O
-,O
dosage,O
treated,O
postnatal,O
groups,O
[,O
5,O
].,O
In,O
another,O
animal,B-OG
study,O
constructed,O
by,O
Eric,O
Beier,O
et,O
al,O
.,O
[,O
11,O
"],",O
postnatal,O
50ppm,O
leaded,O
water,O
ingestion,O
had,O
no,O
effect,O
in,O
either,O
body,O
weight,O
or,O
fat,O
composition,O
of,O
mice,B-OG
",",O
whereas,O
it,O
caused,O
higher,O
fasted,O
glucose,O
level,O
and,O
elevated,O
leptin,B-GP
levels,O
.,O
Gestational,O
exposure,O
has,O
more,O
detrimental,O
effects,O
on,O
offspring,O
",",O
probably,O
due,O
to,O
high,O
efficiency,O
of,O
placenta,O
absorption,O
;,O
thus,O
postnatal,O
Pb,O
exposure,O
in,O
rats,B-OG
may,O
achieve,O
equivalent,O
effect,O
as,O
in,O
prenatal,O
ones,O
only,O
when,O
increasing,O
the,O
exposure,O
dosage,O
.,O
Therefore,O
",",O
higher,O
concentration,O
basis,O
and,O
gradients,O
were,O
set,O
in,O
our,O
experiment,O
compared,O
to,O
previous,O
studies,O
[,O
5,O
",",O
11,O
].,O
In,O
our,O
experiment,O
",",O
weight,O
gain,O
was,O
observed,O
in,O
the,O
NCD,O
rats,B-OG
received,O
0,O
.,O
05,O
%,O
lead,O
acetate,O
",",O
which,O
was,O
partly,O
in,O
accordance,O
with,O
our,O
previous,O
epidemiology,O
study,O
[,O
2,O
],O
Glucose,O
tolerance,O
was,O
also,O
impaired,O
when,O
exposed,O
to,O
Pb,O
",",O
which,O
can,O
be,O
resulted,O
from,O
defects,O
in,O
insulin,B-GP
secretion,O
and,O
/,O
or,O
insulin,B-DS
sensitivity,I-DS
.,O
Both,O
fasting,O
insulin,B-GP
and,O
glucose,O
levels,O
were,O
elevated,O
in,O
the,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
group,O
",",O
indicating,O
excessive,O
hepatic,O
output,O
of,O
glucose,O
and,O
/,O
or,O
insensitivity,O
of,O
peripheral,O
tissues,O
especially,O
liver,O
",",O
which,O
could,O
also,O
be,O
verified,O
by,O
HOMA,O
-,O
IR,B-DS
index,O
.,O
Therefore,O
",",O
it,O
can,O
be,O
speculated,O
that,O
lead,O
may,O
disrupt,O
glucose,O
homeostasis,O
",",O
somewhat,O
",",O
through,O
induction,O
of,O
insulin,B-DS
resistance,I-DS
.,O
Mostafalou,O
et,O
al,O
.,O
[,O
23,O
],O
also,O
found,O
that,O
0,O
.,O
05,O
%,O
Pb,O
level,O
of,O
drinking,O
water,O
could,O
lead,O
to,O
glucose,B-DS
intolerance,I-DS
and,O
insulin,B-DS
resistance,I-DS
in,O
rats,B-OG
.,O
Whereas,O
",",O
overweight,O
itself,O
was,O
a,O
contributing,O
factor,O
to,O
hepatic,O
lipid,O
content,O
and,O
insulin,B-DS
resistance,I-DS
as,O
well,O
as,O
glucose,B-DS
intolerance,I-DS
",",O
all,O
of,O
which,O
could,O
be,O
observed,O
in,O
0,O
.,O
05,O
%,O
Pb,O
received,O
groups,O
",",O
thus,O
it,O
was,O
hard,O
to,O
illustrate,O
whether,O
lead,O
acted,O
mainly,O
as,O
an,O
“,O
obesogen,O
”,O
or,O
directly,O
devoted,O
to,O
insulin,B-DS
resistance,I-DS
.,O
DNA,O
methylation,O
is,O
an,O
important,O
style,O
of,O
epigenetic,O
regulation,O
[,O
24,O
].,O
Previous,O
studies,O
have,O
concentrated,O
on,O
the,O
relationship,O
between,O
Pb,O
exposure,O
and,O
the,O
methylation,O
changes,O
of,O
brain,O
.,O
Developmental,O
Pb,O
exposure,O
not,O
only,O
altered,O
DNA,O
methylation,O
in,O
both,O
specific,O
gene,O
level,O
and,O
global,O
genome,O
level,O
in,O
brain,O
of,O
Alzheimer,B-DS
’,I-DS
s,I-DS
disease,I-DS
model,O
[,O
25,O
–,O
28,O
"],",O
but,O
also,O
could,O
affect,O
the,O
expression,O
of,O
DNA,B-GP
methyltransferase,I-GP
1,I-GP
(,O
DNMT1,B-GP
),O
and,O
DNA,B-GP
methyltransferase,I-GP
3a,I-GP
(,O
DNMT3a,B-GP
),O
in,O
hippocampus,O
[,O
29,O
].,O
In,O
addition,O
",",O
Pb,O
exposure,O
could,O
enhance,O
the,O
mean,O
DNA,O
methylation,O
level,O
and,O
epigenetic,O
drift,O
of,O
several,O
imprinted,O
genes,O
like,O
IGF,B-GP
-,I-GP
2,I-GP
",",O
Igf2r,B-GP
",",O
H19,B-GP
in,O
both,O
cell,O
model,O
and,O
animal,B-OG
tissues,O
[,O
30,O
",",O
31,O
"],",O
although,O
others,O
revealed,O
that,O
increased,O
blood,O
or,O
patella,O
lead,O
levels,O
were,O
associated,O
with,O
hypomethylation,O
of,O
LINE,B-GP
-,I-GP
1,I-GP
in,O
both,O
cell,O
model,O
and,O
population,O
study,O
[,O
32,O
",",O
33,O
].,O
Furthermore,O
",",O
Arko,O
et,O
al,O
.,O
found,O
that,O
Pb,O
exposure,O
during,O
pregnancy,O
affects,O
the,O
DNA,O
methylation,O
status,O
of,O
the,O
fetal,O
germ,O
cells,O
",",O
which,O
led,O
to,O
altered,O
DNA,O
methylation,O
in,O
grandchildren,O
’,O
s,O
neonatal,O
dried,O
blood,O
spots,O
[,O
34,O
].,O
The,O
liver,O
is,O
a,O
critical,O
organ,O
for,O
the,O
regulation,O
of,O
whole,O
body,O
energy,O
homeostasis,O
due,O
to,O
its,O
central,O
role,O
in,O
lipid,O
and,O
glucose,O
metabolism,O
",",O
as,O
well,O
as,O
its,O
close,O
connection,O
via,O
the,O
portal,O
vein,O
to,O
nutrient,O
uptake,O
in,O
the,O
intestine,O
[,O
17,O
].,O
Epigenetic,O
mechanisms,O
may,O
partly,O
explain,O
the,O
pathogenesis,O
and,O
development,O
of,O
metabolic,B-DS
diseases,I-DS
",",O
as,O
previous,O
studies,O
has,O
found,O
altered,O
DNA,O
methylation,O
accompanied,O
by,O
altered,O
transcriptional,O
levels,O
of,O
liver,O
in,O
obesity,B-DS
and,O
type,B-DS
2,I-DS
diabetes,I-DS
.,O
Therefore,O
",",O
we,O
performed,O
a,O
global,O
wide,O
analysis,O
of,O
DNA,O
methylation,O
in,O
liver,O
to,O
explain,O
the,O
mechanism,O
of,O
metabolic,O
changes,O
resulting,O
from,O
adult,O
Pb,O
exposure,O
for,O
the,O
first,O
time,O
.,O
The,O
bisulfite,O
sequencing,O
results,O
revealed,O
a,O
hepatic,O
hypermethylation,O
of,O
whole,O
genome,O
of,O
0,O
.,O
05,O
%,O
Pb,O
exposed,O
rats,B-OG
compared,O
to,O
unexposed,O
ones,O
",",O
which,O
may,O
be,O
explained,O
by,O
changed,O
expression,O
or,O
activity,O
of,O
proteins,O
controlling,O
DNA,O
methylation,O
[,O
18,O
].,O
In,O
addition,O
",",O
a,O
lot,O
of,O
genes,O
involved,O
with,O
glucose,O
and,O
lipid,O
metabolism,O
were,O
observed,O
with,O
apparent,O
DNA,O
methylation,O
alterations,O
at,O
the,O
TSS,O
regions,O
[,O
35,O
].,O
PKB,B-GP
/,O
AKT,B-GP
pathway,O
was,O
essential,O
in,O
regulating,O
lipid,O
and,O
glucose,O
metabolism,O
in,O
liver,O
.,O
Hypermethylation,O
of,O
AKT,B-GP
may,O
result,O
in,O
gene,O
repression,O
and,O
thus,O
inhibiting,O
this,O
pathway,O
",",O
which,O
could,O
lead,O
to,O
reduced,O
glucose,O
uptake,O
and,O
glycogen,O
synthesis,O
but,O
increased,O
gluconeogenesis,O
",",O
thus,O
promoting,O
insulin,B-DS
resistance,I-DS
of,O
liver,O
[,O
17,O
].,O
The,O
hypermethylation,O
of,O
genes,O
involved,O
in,O
fatty,O
acid,O
oxidation,O
such,O
as,O
CPT,B-GP
-,I-GP
2,I-GP
",",O
MCAD,B-GP
",",O
and,O
ACO,B-GP
could,O
result,O
in,O
reduced,O
fatty,O
acid,O
oxidation,O
rate,O
and,O
in,O
turn,O
elevated,O
lipid,O
synthesis,O
in,O
liver,O
.,O
MTTP,B-GP
and,O
lipoprotein,O
like,O
APO,B-GP
-,I-GP
CⅢ,I-GP
",",O
APO,B-GP
-,I-GP
Ⅴ,I-GP
",",O
and,O
APO,B-GP
-,I-GP
Ⅳ,I-GP
were,O
important,O
in,O
VLDL,O
-,O
assembling,O
and,O
TG,O
transportation,O
.,O
Hypermethylation,O
of,O
these,O
proteins,O
may,O
give,O
rise,O
to,O
reduced,O
TG,O
output,O
and,O
a,O
further,O
accumulating,O
of,O
TG,O
in,O
liver,O
[,O
36,O
].,O
Bone,O
lead,O
level,O
is,O
a,O
more,O
reliable,O
biomarker,O
of,O
long,O
-,O
term,O
Pb,O
exposure,O
",",O
while,O
blood,O
lead,O
level,O
reveals,O
recent,O
exposure,O
[,O
15,O
].,O
Thus,O
",",O
we,O
evaluated,O
Pb,O
accumulation,O
by,O
detecting,O
bone,O
lead,O
level,O
instead,O
of,O
blood,O
lead,O
level,O
",",O
which,O
was,O
differed,O
from,O
most,O
previous,O
studies,O
[,O
12,O
",",O
21,O
].,O
Whereas,O
",",O
it,O
would,O
be,O
more,O
rigorous,O
to,O
detect,O
both,O
BLL,O
and,O
bone,O
lead,O
level,O
.,O
Furthermore,O
",",O
the,O
lead,O
level,O
of,O
NCD,O
+,O
0,O
.,O
45,O
%,O
group,O
did,O
not,O
cause,O
corresponding,O
increase,O
in,O
bone,O
lead,O
levels,O
",",O
which,O
may,O
due,O
to,O
the,O
precipitation,O
of,O
the,O
highest,O
concentration,O
of,O
lead,O
in,O
the,O
water,O
.,O
Our,O
study,O
has,O
some,O
merits,O
.,O
Firstly,O
",",O
for,O
the,O
first,O
time,O
",",O
we,O
performed,O
whole,O
genome,O
DNA,O
methylation,O
analysis,O
of,O
liver,O
in,O
both,O
Pb,O
exposure,O
rats,B-OG
and,O
control,O
rats,B-OG
",",O
in,O
order,O
to,O
explore,O
the,O
potential,O
mechanism,O
of,O
metabolic,O
changes,O
after,O
exposure,O
to,O
lead,O
.,O
Secondly,O
",",O
our,O
study,O
concentrated,O
on,O
adult,O
stage,O
but,O
not,O
prenatal,O
or,O
developmental,O
stage,O
.,O
This,O
made,O
good,O
sense,O
in,O
our,O
daily,O
life,O
",",O
because,O
the,O
metabolic,B-DS
disorder,I-DS
and,O
altered,O
DNA,O
methylation,O
of,O
adults,O
may,O
have,O
adverse,O
effects,O
on,O
the,O
next,O
generation,O
.,O
In,O
conclusion,O
",",O
we,O
found,O
that,O
chronic,O
0,O
.,O
05,O
%,O
Pb,O
exposure,O
results,O
in,O
dose,O
-,O
specific,O
insulin,B-DS
resistance,I-DS
and,O
weight,O
gain,O
.,O
These,O
metabolic,B-DS
disorders,I-DS
may,O
be,O
induced,O
through,O
altered,O
methylation,O
of,O
genes,O
related,O
with,O
metabolism,O
.,O
Further,O
studies,O
are,O
warranted,O
to,O
explore,O
the,O
alteration,O
of,O
specific,O
gene,O
expression,O
and,O
its,O
association,O
with,O
DNA,O
methylation,O
in,O
both,O
animal,B-OG
and,O
cellular,O
levels,O
.,O
Supporting,O
Information,O
The,O
density,O
distribution,O
curves,O
of,O
methylated,O
CG,O
sites,O
.,O
(,O
a,O
)(,O
b,O
),O
NCD,O
+,O
0,O
.,O
05,O
%;,O
(,O
c,O
)(,O
d,O
),O
NCD,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Average,O
DNA,O
methylation,O
levels,O
in,O
specific,O
Genetic,O
functional,O
elements,O
.,O
(,O
a,O
)(,O
b,O
),O
NCD,O
+,O
0,O
.,O
05,O
%;,O
(,O
c,O
)(,O
d,O
),O
NCD,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Differential,O
methylated,O
genes,O
.,O
proportion1,O
:,O
NCD,O
;,O
proportion2,O
:,O
NCD,O
+,O
0,O
.,O
05,O
%,O
Pb,O
.,O
(,O
XLS,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Civil,O
society,O
advocacy,O
in,O
Nigeria,O
:,O
promoting,O
democratic,O
norms,O
or,O
donor,O
demands,O
?,O
Background,O
Civil,O
society,O
organizations,O
(,O
CSOs,O
),O
are,O
often,O
assumed,O
to,O
be,O
institutions,O
that,O
facilitate,O
communication,O
between,O
citizens,O
and,O
policymakers,O
.,O
However,O
",",O
CSO,O
advocacy,O
is,O
only,O
as,O
effective,O
as,O
the,O
space,O
allowed,O
by,O
government,O
",",O
the,O
resources,O
available,O
from,O
funders,O
",",O
and,O
their,O
own,O
internal,O
capacity,O
.,O
This,O
article,O
presents,O
findings,O
from,O
a,O
study,O
in,O
Nigeria,O
that,O
explores,O
the,O
advocacy,O
and,O
service,O
delivery,O
roles,O
of,O
CSOs,O
working,O
in,O
Human,B-OG
Immunodeficiency,I-OG
Virus,I-OG
(,O
HIV,B-OG
),O
prevention,O
and,O
mitigation,O
.,O
We,O
will,O
argue,O
that,O
donor,O
and,O
government,O
treatment,O
of,O
civil,O
society,O
as,O
service,O
delivery,O
organizations,O
",",O
rather,O
than,O
as,O
organizations,O
that,O
participate,O
in,O
democratic,O
norms,O
",",O
have,O
shaped,O
how,O
civil,O
society,O
organizations,O
work,O
to,O
mitigate,O
and,O
prevent,O
HIV,B-OG
.,O
Methods,O
From,O
February,O
to,O
April,O
2012,O
",",O
a,O
team,O
of,O
Health,O
Systems,O
20,O
/,O
20,O
staff,O
and,O
one,O
consultant,O
conducted,O
48,O
in,O
-,O
depth,O
interviews,O
with,O
civil,O
society,O
organizations,O
",",O
State,O
AIDS,B-DS
Control,O
Agencies,O
(,O
SACAs,O
"),",O
donors,O
",",O
international,O
organizations,O
",",O
and,O
networks,O
of,O
people,O
living,O
with,O
HIV,B-OG
to,O
examine,O
a,O
wide,O
range,O
of,O
advocacy,O
efforts,O
by,O
CSOs,O
.,O
For,O
quantitative,O
data,O
collection,O
",",O
sampling,O
frames,O
were,O
assembled,O
from,O
lists,O
of,O
HIV,B-OG
-,O
oriented,O
or,O
involved,O
CSOs,O
.,O
This,O
sampling,O
frame,O
consisted,O
of,O
2548,O
CSOs,O
from,O
all,O
36,O
states,O
and,O
the,O
Federal,O
Capital,O
Territory,O
.,O
A,O
random,O
sample,O
was,O
then,O
taken,O
from,O
the,O
sampling,O
frame,O
",",O
and,O
we,O
contacted,O
665,O
CSOs,O
to,O
arrange,O
interviews,O
.,O
With,O
a,O
response,O
rate,O
of,O
80,O
.,O
2,O
"%,",O
the,O
project,O
conducted,O
533,O
surveys,O
in,O
February,O
2012,O
.,O
Results,O
These,O
surveys,O
showed,O
that,O
CSOs,O
advocacy,O
efforts,O
focused,O
on,O
community,O
mobilization,O
related,O
to,O
behavior,O
change,O
",",O
such,O
as,O
peer,O
education,O
(,O
54,O
.,O
9,O
%,O
of,O
CSOs,O
),O
and,O
rallies,O
(,O
58,O
.,O
2,O
%,O
of,O
CSOs,O
"),",O
and,O
not,O
on,O
changing,O
government,O
policies,O
.,O
In,O
-,O
depth,O
interviews,O
highlighted,O
the,O
role,O
of,O
donors,O
and,O
government,O
in,O
shaping,O
a,O
purely,O
apolitical,O
role,O
for,O
most,O
CSOs,O
through,O
funding,O
constraints,O
",",O
regulations,O
",",O
and,O
capacity,O
development,O
choices,O
.,O
Conclusions,O
In,O
light,O
of,O
these,O
findings,O
",",O
we,O
present,O
key,O
points,O
for,O
considering,O
the,O
influence,O
of,O
donors,O
and,O
government,O
on,O
civil,O
society,O
advocacy,O
for,O
HIV,B-OG
services,O
and,O
rights,O
.,O
We,O
present,O
evidence,O
that,O
donors,O
",",O
and,O
international,O
organizations,O
",",O
conceive,O
of,O
civil,O
society,O
as,O
apolitical,O
",",O
and,O
not,O
as,O
independent,O
actors,O
that,O
compete,O
for,O
political,O
space,O
.,O
More,O
democratic,O
and,O
rights,O
-,O
based,O
views,O
of,O
civil,O
society,O
’,O
s,O
role,O
",",O
such,O
as,O
holding,O
government,O
accountable,O
for,O
providing,O
services,O
or,O
promoting,O
policy,O
change,O
",",O
are,O
not,O
emphasized,O
.,O
Background,O
Concepts,O
of,O
civil,O
society,O
can,O
be,O
quite,O
varied,O
",",O
but,O
modern,O
interpretations,O
of,O
the,O
term,O
focus,O
on,O
“,O
political,O
space,O
where,O
voluntary,O
associations,O
explicitly,O
seeking,O
to,O
shape,O
the,O
rules,O
that,O
govern,O
…,O
social,O
life,O
”,O
[,O
1,O
].,O
According,O
to,O
Scholte,O
",",O
these,O
associations,O
can,O
include,O
“,O
academic,O
institutions,O
",",O
business,O
forums,O
",",O
clan,O
and,O
kinship,O
circles,O
",",O
consumer,O
advocates,O
",",O
development,O
cooperation,O
initiatives,O
",",O
environmental,O
movements,O
",",O
ethnic,O
lobbies,O
",",O
foundations,O
",",O
human,B-OG
rights,O
promoters,O
",",O
labour,O
unions,O
",",O
local,O
community,O
groups,O
",",O
relief,O
organisations,O
",",O
peace,O
movements,O
",",O
professional,O
bodies,O
",",O
religious,O
institutions,O
",",O
think,O
tanks,O
",",O
women,B-OG
’,O
s,O
networks,O
",",O
youth,O
associations,O
and,O
more,O
”,O
[,O
1,O
].,O
Conversely,O
",",O
Gramsci,O
views,O
civil,O
society,O
as,O
part,O
of,O
an,O
“,O
extended,O
state,O
"”,",O
by,O
which,O
the,O
ruling,O
class,O
(,O
or,O
the,O
state,O
),O
is,O
able,O
to,O
maintain,O
hegemony,O
over,O
its,O
citizens,O
[,O
2,O
].,O
Gaventa,O
synthesizes,O
these,O
two,O
competing,O
ideas,O
–,O
noting,O
that,O
civil,O
society,O
organizations,O
(,O
CSOs,O
),O
provide,O
a,O
voice,O
for,O
citizens,O
to,O
communicate,O
with,O
government,O
",",O
extend,O
the,O
reach,O
of,O
government,O
by,O
deliver,O
services,O
to,O
citizens,O
",",O
and,O
hold,O
government,O
officials,O
accountable,O
through,O
watchdog,O
efforts,O
[,O
3,O
].,O
With,O
the,O
Third,O
International,O
Conference,O
on,O
Financing,O
for,O
Development,O
highlighting,O
the,O
role,O
of,O
civil,O
society,O
in,O
“,O
strengthening,O
the,O
mobilization,O
and,O
effective,O
use,O
of,O
domestic,O
resources,O
”,O
for,O
development,O
",",O
CSOs,O
must,O
hold,O
governments,O
accountable,O
for,O
funding,O
and,O
service,O
commitments,O
[,O
4,O
].,O
When,O
interacting,O
with,O
government,O
",",O
civil,O
society,O
is,O
often,O
dependent,O
on,O
the,O
space,O
allowed,O
by,O
government,O
for,O
civic,O
action,O
.,O
Coston,O
has,O
pointed,O
out,O
that,O
this,O
space,O
falls,O
on,O
a,O
continuum,O
",",O
from,O
collaboration,O
between,O
government,O
and,O
civil,O
society,O
to,O
government,O
repression,O
[,O
5,O
].,O
Despite,O
the,O
increase,O
in,O
international,O
funding,O
for,O
CSOs,O
to,O
provide,O
HIV,B-OG
services,O
",",O
little,O
research,O
has,O
been,O
done,O
on,O
how,O
donors,O
and,O
governments,O
are,O
influencing,O
CSO,O
advocacy,O
efforts,O
and,O
how,O
CSO,O
advocacy,O
is,O
influenced,O
by,O
donor,O
and,O
government,O
influence,O
.,O
Thus,O
",",O
this,O
article,O
presents,O
the,O
findings,O
from,O
a,O
study,O
in,O
Nigeria,O
that,O
explores,O
the,O
advocacy,O
and,O
service,O
delivery,O
roles,O
of,O
CSOs,O
working,O
in,O
Human,B-OG
Immunodeficiency,I-OG
Virus,I-OG
(,O
HIV,B-OG
),O
prevention,O
and,O
mitigation,O
.,O
We,O
will,O
argue,O
that,O
donors,O
and,O
governments,O
treat,O
civil,O
society,O
as,O
service,O
delivery,O
organizations,O
",",O
rather,O
than,O
as,O
organizations,O
that,O
participate,O
in,O
democratic,O
norms,O
",",O
shaping,O
civil,O
society,O
responses,O
to,O
HIV,B-OG
in,O
ways,O
that,O
address,O
donor,O
and,O
government,O
",",O
rather,O
that,O
citizen,O
",",O
needs,O
.,O
Examining,O
this,O
argument,O
now,O
is,O
critical,O
.,O
The,O
scale,O
up,O
of,O
PEPFAR,O
and,O
the,O
Global,O
Fund,O
in,O
the,O
mid,O
-,O
2000s,O
provided,O
CSOs,O
with,O
significant,O
funding,O
to,O
deliver,O
HIV,B-OG
services,O
.,O
As,O
these,O
sources,O
of,O
funding,O
have,O
stabilized,O
over,O
the,O
last,O
5,O
years,O
",",O
donors,O
increasingly,O
expect,O
governments,O
to,O
fund,O
a,O
larger,O
percentage,O
of,O
the,O
HIV,B-OG
response,O
.,O
Increased,O
domestic,O
resources,O
for,O
HIV,B-OG
will,O
not,O
be,O
generated,O
",",O
however,O
",",O
without,O
strong,O
civil,O
society,O
advocacy,O
to,O
support,O
appropriate,O
policies,O
and,O
increased,O
funding,O
.,O
Donor,O
and,O
government,O
influence,O
on,O
CSO,O
HIV,B-OG
advocacy,O
",",O
however,O
",",O
is,O
an,O
understudied,O
area,O
of,O
research,O
.,O
The,O
nature,O
of,O
this,O
argument,O
does,O
restrict,O
our,O
analysis,O
to,O
organizations,O
that,O
work,O
on,O
HIV,B-OG
-,O
mitigation,O
and,O
prevention,O
.,O
We,O
cannot,O
generalize,O
our,O
findings,O
to,O
CSOs,O
that,O
do,O
other,O
types,O
of,O
work,O
.,O
We,O
examine,O
the,O
argument,O
in,O
a,O
number,O
of,O
ways,O
.,O
First,O
",",O
we,O
review,O
the,O
literature,O
on,O
advocacy,O
and,O
state,O
-,O
society,O
relations,O
to,O
develop,O
a,O
theoretical,O
basis,O
for,O
civil,O
society,O
-,O
government,O
engagement,O
and,O
how,O
international,O
donors,O
affect,O
these,O
relationships,O
.,O
Second,O
",",O
we,O
present,O
the,O
findings,O
of,O
mixed,O
methods,O
research,O
on,O
CSO,O
advocacy,O
in,O
Nigeria,O
.,O
A,O
cross,O
-,O
sectional,O
survey,O
highlights,O
the,O
scope,O
and,O
targets,O
of,O
civil,O
society,O
advocacy,O
and,O
civil,O
society,O
’,O
s,O
relationships,O
with,O
government,O
.,O
In,O
-,O
depth,O
interviews,O
are,O
used,O
to,O
understand,O
the,O
role,O
of,O
networks,O
",",O
organizations,O
with,O
a,O
specific,O
advocacy,O
focus,O
",",O
and,O
donor,O
and,O
government,O
influence,O
on,O
the,O
civil,O
society,O
response,O
to,O
HIV,B-OG
in,O
Nigeria,O
.,O
Our,O
article,O
concludes,O
with,O
an,O
analysis,O
of,O
key,O
points,O
for,O
considering,O
the,O
influence,O
of,O
donors,O
and,O
government,O
on,O
civil,O
society,O
advocacy,O
.,O
State,O
-,O
society,O
relations,O
and,O
the,O
impact,O
of,O
international,O
donors,O
According,O
to,O
the,O
Policy,O
Project,O
",",O
advocacy,O
is,O
a,O
set,O
of,O
targeted,O
actions,O
directed,O
at,O
decision,O
makers,O
in,O
support,O
of,O
a,O
specific,O
policy,O
[,O
6,O
].,O
Advocacy,O
can,O
impact,O
polices,O
at,O
any,O
stage,O
of,O
the,O
policy,O
cycle,O
from,O
agenda,O
setting,O
",",O
formulation,O
",",O
and,O
adoption,O
to,O
implementation,O
and,O
evaluation,O
[,O
7,O
].,O
Building,O
on,O
this,O
definition,O
",",O
Ezell,O
identifies,O
that,O
a,O
client,O
/,O
agent,O
relationship,O
is,O
necessary,O
;,O
advocacy,O
is,O
conducted,O
by,O
",",O
or,O
on,O
behalf,O
of,O
",",O
a,O
specific,O
group,O
toward,O
decision,O
makers,O
[,O
8,O
].,O
Edgett,O
contributes,O
a,O
focus,O
on,O
persuasion,O
;,O
noting,O
that,O
advocates,O
attempt,O
to,O
persuade,O
targeted,O
audiences,O
to,O
accept,O
the,O
point,O
of,O
view,O
of,O
the,O
advocate,O
[,O
9,O
].,O
We,O
can,O
",",O
therefore,O
",",O
think,O
of,O
advocacy,O
as,O
the,O
process,O
of,O
persuading,O
targeted,O
audiences,O
to,O
take,O
a,O
specific,O
policy,O
action,O
",",O
especially,O
government,O
officials,O
.,O
This,O
definition,O
clarifies,O
that,O
the,O
desired,O
outcome,O
should,O
be,O
related,O
to,O
policy,O
change,O
.,O
The,O
extent,O
to,O
which,O
government,O
defines,O
the,O
purpose,O
and,O
limits,O
of,O
civil,O
society,O
engagement,O
has,O
implications,O
for,O
advocacy,O
.,O
Where,O
civil,O
society,O
is,O
not,O
repressed,O
",",O
state,O
posture,O
can,O
vary,O
from,O
passive,O
support,O
",",O
wherein,O
the,O
state,O
neither,O
supports,O
nor,O
opposes,O
civil,O
society,O
engagement,O
",",O
to,O
active,O
encouragement,O
indicating,O
that,O
the,O
state,O
takes,O
action,O
to,O
engage,O
with,O
civil,O
society,O
[,O
5,O
",",O
10,O
].,O
On,O
the,O
passive,O
side,O
",",O
governments,O
do,O
not,O
encourage,O
civil,O
society,O
engagement,O
and,O
citizens,O
must,O
place,O
demands,O
on,O
government,O
without,O
the,O
benefit,O
of,O
state,O
sponsored,O
structures,O
.,O
At,O
the,O
active,O
end,O
of,O
the,O
spectrum,O
",",O
governments,O
conscientiously,O
seek,O
out,O
civil,O
society,O
engagement,O
",",O
and,O
create,O
or,O
promote,O
institutions,O
that,O
require,O
citizen,O
participation,O
[,O
10,O
].,O
In,O
addition,O
to,O
Blair,O
’,O
s,O
model,O
of,O
state,O
response,O
",",O
Brinkerhoff,O
adds,O
clarity,O
by,O
analyzing,O
the,O
dichotomy,O
between,O
service,O
delivery,O
and,O
advocacy,O
roles,O
of,O
civil,O
society,O
[,O
11,O
].,O
Government,O
-,O
sanctioned,O
approaches,O
to,O
citizen,O
-,O
state,O
engagement,O
occur,O
when,O
governments,O
actively,O
support,O
civil,O
society,O
engagement,O
",",O
and,O
tend,O
to,O
have,O
a,O
strong,O
focus,O
on,O
CSO,O
service,O
delivery,O
potential,O
[,O
11,O
].,O
Examples,O
from,O
central,O
Asia,O
and,O
Africa,O
have,O
shown,O
that,O
when,O
governments,O
pre,O
-,O
defined,O
the,O
roles,O
of,O
civil,O
society,O
or,O
business,O
partners,O
",",O
they,O
focus,O
on,O
the,O
potential,O
health,O
service,O
delivery,O
and,O
business,O
investment,O
skills,O
offered,O
by,O
these,O
groups,O
",",O
rather,O
than,O
the,O
potential,O
role,O
of,O
citizen,O
voice,O
[,O
12,O
",",O
13,O
].,O
These,O
groups,O
often,O
require,O
strong,O
incentives,O
",",O
monetary,O
or,O
otherwise,O
",",O
to,O
continue,O
their,O
engagement,O
with,O
government,O
[,O
14,O
].,O
These,O
relationships,O
can,O
be,O
closer,O
to,O
contracting,O
arrangements,O
",",O
as,O
the,O
government,O
decides,O
specific,O
engagement,O
methods,O
and,O
deliverables,O
[,O
14,O
].,O
Government,O
co,O
-,O
option,O
is,O
a,O
significant,O
concern,O
for,O
CSOs,O
under,O
these,O
arrangements,O
.,O
Brinkerhoff,O
notes,O
that,O
",",O
“,O
As,O
nonprofits,O
have,O
entered,O
into,O
cooperative,O
relations,O
with,O
government,O
",",O
sometimes,O
as,O
contracted,O
service,O
deliverers,O
",",O
they,O
have,O
faced,O
the,O
challenge,O
of,O
balancing,O
the,O
associated,O
benefits,O
with,O
remaining,O
accountable,O
to,O
their,O
primary,O
constituents,O
(,O
i,O
.,O
e,O
".,",O
beneficiaries,O
and,O
members,O
)”,O
[,O
11,O
].,O
Citizen,O
-,O
initiated,O
approaches,O
involve,O
active,O
citizen,O
efforts,O
to,O
reach,O
and,O
influence,O
government,O
",",O
and,O
are,O
critical,O
mechanisms,O
to,O
improve,O
state,O
-,O
society,O
relations,O
",",O
especially,O
within,O
states,O
with,O
passive,O
support,O
for,O
civil,O
society,O
.,O
Coalition,O
-,O
building,O
",",O
citizen,O
scorecards,O
",",O
or,O
media,O
watchdog,O
efforts,O
exemplify,O
demand,O
-,O
side,O
approaches,O
.,O
Civil,O
society,O
initiated,O
engagement,O
with,O
the,O
state,O
tends,O
to,O
have,O
a,O
greater,O
advocacy,O
component,O
under,O
passive,O
regimes,O
",",O
as,O
advocates,O
demand,O
changes,O
to,O
existing,O
state,O
services,O
or,O
the,O
introduction,O
of,O
new,O
programs,O
.,O
Qualitative,O
evidence,O
has,O
shown,O
that,O
active,O
state,O
support,O
for,O
citizen,O
engagement,O
may,O
narrow,O
prescribed,O
avenues,O
",",O
while,O
passive,O
state,O
support,O
allows,O
more,O
options,O
for,O
citizen,O
advocacy,O
[,O
15,O
].,O
International,O
donors,O
can,O
significantly,O
alter,O
these,O
dynamics,O
by,O
funding,O
programs,O
that,O
prioritize,O
specific,O
roles,O
.,O
For,O
example,O
",",O
a,O
survey,O
in,O
Southern,O
Africa,O
found,O
that,O
75,O
%,O
of,O
all,O
funding,O
received,O
by,O
CSOs,O
in,O
2005,O
was,O
allocated,O
to,O
program,O
implementation,O
or,O
service,O
delivery,O
",",O
while,O
only,O
1,O
%,O
was,O
allocated,O
for,O
advocacy,O
[,O
16,O
].,O
Seckinelgin,O
found,O
that,O
donors,O
often,O
emphasize,O
quantifiable,O
services,O
",",O
such,O
as,O
condom,O
distribution,O
",",O
HIV,B-OG
counseling,O
and,O
testing,O
",",O
and,O
communication,O
campaigns,O
[,O
17,O
].,O
As,O
civil,O
society,O
groups,O
respond,O
to,O
available,O
funding,O
for,O
HIV,B-OG
-,O
related,O
services,O
",",O
they,O
shift,O
away,O
from,O
advocacy,O
roles,O
[,O
18,O
].,O
This,O
dynamic,O
moves,O
CSOs,O
away,O
from,O
being,O
local,O
-,O
level,O
innovators,O
",",O
as,O
donors,O
ask,O
them,O
to,O
implement,O
large,O
-,O
scale,O
service,O
delivery,O
activities,O
with,O
little,O
influence,O
on,O
policy,O
[,O
16,O
].,O
International,O
donors,O
",",O
through,O
multilateral,O
institutions,O
such,O
as,O
the,O
Global,O
Fund,O
",",O
explicitly,O
attempt,O
to,O
take,O
politics,O
out,O
of,O
health,O
resource,O
allocation,O
decisions,O
[,O
19,O
].,O
These,O
attempts,O
take,O
a,O
technocratic,O
approach,O
by,O
allocating,O
resources,O
solely,O
through,O
neutral,O
cost,O
-,O
benefit,O
analyses,O
",",O
or,O
what,O
Schedler,O
calls,O
‘,O
instrumental,O
anti,O
-,O
politics,O
’,O
[,O
20,O
].,O
Escobar,O
and,O
Ferguson,O
agree,O
",",O
noting,O
that,O
donors,O
“,O
de,O
-,O
politicize,O
”,O
social,O
problems,O
by,O
providing,O
technical,O
",",O
rather,O
than,O
political,O
",",O
solutions,O
[,O
21,O
",",O
22,O
].,O
Within,O
this,O
framing,O
of,O
health,O
as,O
apolitical,O
",",O
there,O
is,O
little,O
room,O
for,O
organizations,O
to,O
tackle,O
challenges,O
from,O
a,O
policy,O
change,O
angle,O
.,O
As,O
a,O
result,O
",",O
donor,O
funding,O
can,O
exclude,O
CSOs,O
from,O
the,O
policy,O
development,O
process,O
",",O
and,O
relegate,O
them,O
to,O
provided,O
apolitical,O
services,O
",",O
pre,O
-,O
determined,O
by,O
international,O
donors,O
and,O
governments,O
[,O
23,O
].,O
There,O
is,O
considerable,O
disagreement,O
about,O
how,O
CSOs,O
can,O
conduct,O
both,O
advocacy,O
and,O
service,O
delivery,O
roles,O
effectively,O
",",O
or,O
if,O
they,O
need,O
to,O
specialize,O
.,O
Dual,O
roles,O
can,O
exacerbate,O
competing,O
interests,O
;,O
CSOs,O
often,O
receive,O
grants,O
from,O
governments,O
for,O
delivering,O
services,O
",",O
while,O
simultaneously,O
attempting,O
to,O
advocate,O
on,O
behalf,O
of,O
citizens,O
receiving,O
those,O
same,O
services,O
[,O
24,O
].,O
Brinkerhoff,O
notes,O
that,O
while,O
particular,O
CSOs,O
often,O
do,O
choose,O
either,O
an,O
advocacy,O
or,O
service,O
delivery,O
role,O
",",O
specialization,O
does,O
not,O
preclude,O
the,O
organization,O
from,O
fulfilling,O
multiple,O
roles,O
[,O
14,O
].,O
Regardless,O
of,O
whether,O
civil,O
society,O
can,O
actually,O
perform,O
dual,O
roles,O
effectively,O
",",O
Jenkins,O
argues,O
that,O
donor,O
emphasis,O
on,O
service,O
delivery,O
excludes,O
organizations,O
that,O
fight,O
for,O
political,O
power,O
",",O
including,O
influencing,O
HIV,B-OG
-,O
related,O
policy,O
frameworks,O
",",O
from,O
receiving,O
funding,O
[,O
23,O
].,O
Recognizing,O
the,O
challenges,O
inherent,O
to,O
playing,O
both,O
service,O
delivery,O
and,O
advocacy,O
roles,O
",",O
CSOs,O
and,O
people,O
living,O
with,O
HIV,B-OG
can,O
form,O
networks,O
to,O
promote,O
their,O
interests,O
.,O
In,O
theory,O
",",O
these,O
networks,O
focus,O
on,O
advocating,O
for,O
the,O
needs,O
of,O
their,O
members,O
",",O
while,O
leaving,O
service,O
delivery,O
to,O
their,O
members,O
[,O
25,O
].,O
These,O
networks,O
can,O
be,O
successful,O
;,O
UNAIDS,O
notes,O
that,O
as,O
a,O
result,O
of,O
these,O
networks,O
",",O
the,O
“,O
meaningful,O
involvement,O
of,O
civil,O
society,O
",",O
and,O
particularly,O
of,O
people,O
living,O
with,O
HIV,B-OG
",",O
is,O
now,O
being,O
written,O
into,O
the,O
policies,O
and,O
strategies,O
of,O
many,O
organizations,O
",",O
institutions,O
and,O
AIDS,B-DS
programmes,O
”,O
[,O
26,O
].,O
Often,O
",",O
however,O
",",O
these,O
networks,O
receive,O
the,O
majority,O
of,O
their,O
funding,O
from,O
international,O
donors,O
and,O
not,O
from,O
membership,O
dues,O
",",O
leading,O
to,O
organizational,O
identity,O
challenges,O
[,O
27,O
].,O
International,O
donors,O
ask,O
networks,O
to,O
focus,O
on,O
donor,O
priorities,O
",",O
such,O
as,O
coordinating,O
member,O
activities,O
",",O
reporting,O
activities,O
to,O
national,O
AIDS,B-DS
councils,O
",",O
and,O
directing,O
services,O
and,O
training,O
",",O
and,O
not,O
on,O
membership,O
identified,O
actions,O
[,O
28,O
",",O
29,O
].,O
As,O
a,O
result,O
",",O
networks,O
are,O
subject,O
to,O
the,O
same,O
de,O
-,O
politicization,O
and,O
co,O
-,O
option,O
pressures,O
that,O
face,O
other,O
CSOs,O
.,O
Current,O
policy,O
landscape,O
in,O
Nigeria,O
In,O
Nigeria,O
",",O
a,O
number,O
of,O
laws,O
",",O
policies,O
",",O
and,O
funding,O
decisions,O
affect,O
PLHIV,O
and,O
HIV,B-OG
programming,O
.,O
For,O
example,O
",",O
the,O
Nigerian,O
government,O
has,O
recently,O
passed,O
a,O
“,O
same,O
-,O
sex,O
”,O
marriage,O
bill,O
",",O
which,O
outlaws,O
Lesbian,O
",",O
Gay,O
",",O
Bisexual,O
or,O
Transgender,O
(,O
LGBT,O
),O
organizations,O
",",O
harshly,O
penalizes,O
anyone,O
who,O
“,O
performs,O
",",O
witnesses,O
",",O
aids,O
",",O
or,O
abets,O
”,O
a,O
same,O
-,O
sex,O
marriage,O
ceremony,O
",",O
and,O
outlaws,O
any,O
display,O
of,O
a,O
“,O
same,O
-,O
sex,O
amorous,O
relationship,O
”,O
[,O
30,O
].,O
Additionally,O
",",O
an,O
anti,O
-,O
discrimination,O
and,O
stigma,O
bill,O
was,O
signed,O
in,O
2012,O
",",O
this,O
law,O
will,O
require,O
monitoring,O
by,O
CSOs,O
to,O
ensure,O
that,O
it,O
is,O
implemented,O
by,O
government,O
actors,O
[,O
31,O
].,O
In,O
addition,O
to,O
legislation,O
",",O
HIV,B-OG
policies,O
",",O
at,O
the,O
federal,O
",",O
state,O
",",O
and,O
facilities,O
level,O
impact,O
the,O
HIV,B-OG
response,O
.,O
The,O
Nigerian,O
government,O
updates,O
the,O
HIV,B-OG
Policy,O
and,O
National,O
Strategic,O
Plan,O
(,O
NSP,O
),O
every,O
5,O
years,O
;,O
the,O
most,O
recent,O
one,O
ended,O
in,O
2015,O
[,O
32,O
].,O
These,O
documents,O
are,O
opportunities,O
for,O
CSOs,O
to,O
shift,O
the,O
response,O
to,O
the,O
epidemic,O
toward,O
their,O
membership,O
’,O
s,O
needs,O
",",O
including,O
addressing,O
user,O
fees,O
and,O
treatment,O
access,O
.,O
CSO,O
monitoring,O
of,O
the,O
President,O
’,O
s,O
Comprehensive,O
Response,O
Plan,O
for,O
HIV,B-OG
/,O
AIDS,B-DS
is,O
also,O
a,O
critical,O
requirement,O
for,O
ensuring,O
that,O
the,O
NSP,O
is,O
implemented,O
[,O
32,O
].,O
Funding,O
for,O
HIV,B-OG
is,O
another,O
area,O
of,O
need,O
for,O
advocacy,O
.,O
In,O
2012,O
",",O
the,O
most,O
recent,O
National,O
AIDS,B-DS
Spending,O
Assessment,O
available,O
",",O
78,O
%,O
of,O
HIV,B-OG
funding,O
came,O
from,O
international,O
sources,O
",",O
though,O
this,O
number,O
had,O
fallen,O
from,O
85,O
%,O
in,O
2007,O
[,O
33,O
].,O
Increased,O
spending,O
from,O
the,O
Nigerian,O
government,O
",",O
at,O
all,O
levels,O
is,O
necessary,O
to,O
meet,O
financing,O
goals,O
set,O
at,O
the,O
Third,O
International,O
Conference,O
on,O
Financing,O
for,O
Development,O
and,O
improve,O
the,O
sustainability,O
and,O
responsiveness,O
of,O
HIV,B-OG
services,O
.,O
Methods,O
and,O
analytical,O
framework,O
Analytic,O
objectives,O
We,O
first,O
examined,O
how,O
frequently,O
Nigerian,O
CSOs,O
",",O
as,O
represented,O
by,O
our,O
survey,O
sample,O
",",O
reported,O
engaging,O
in,O
advocacy,O
work,O
",",O
then,O
examined,O
the,O
advocacy,O
activities,O
CSOs,O
actually,O
carried,O
out,O
.,O
Following,O
this,O
",",O
we,O
sought,O
to,O
identify,O
the,O
characteristics,O
of,O
those,O
CSOs,O
that,O
reported,O
involvement,O
in,O
advocacy,O
work,O
",",O
as,O
compared,O
to,O
those,O
that,O
did,O
not,O
",",O
as,O
well,O
as,O
the,O
characteristics,O
of,O
CSOs,O
involved,O
in,O
self,O
-,O
defined,O
advocacy,O
activities,O
.,O
We,O
also,O
sought,O
information,O
on,O
the,O
landscape,O
and,O
policy,O
environment,O
for,O
CSOs,O
in,O
Nigeria,O
.,O
Data,O
collection,O
From,O
February,O
to,O
April,O
2012,O
",",O
a,O
team,O
of,O
Health,O
Systems,O
20,O
/,O
20,O
staff,O
and,O
one,O
consultant,O
conducted,O
48,O
qualitative,O
in,O
-,O
depth,O
interviews,O
with,O
civil,O
society,O
representatives,O
",",O
State,O
AIDS,B-DS
Control,O
Agencies,O
(,O
SACAs,O
"),",O
donors,O
",",O
international,O
organizations,O
",",O
and,O
networks,O
of,O
people,O
living,O
with,O
HIV,B-OG
to,O
examine,O
a,O
wide,O
range,O
of,O
advocacy,O
efforts,O
by,O
CSOs,O
.,O
Interviewees,O
were,O
selected,O
through,O
discussions,O
with,O
the,O
National,O
AIDS,B-DS
Control,O
Agency,O
(,O
NACA,O
),O
and,O
discussions,O
with,O
NACA,O
-,O
led,O
technical,O
working,O
groups,O
.,O
Data,O
collectors,O
had,O
a,O
set,O
list,O
of,O
questions,O
",",O
but,O
were,O
asked,O
to,O
use,O
their,O
judgment,O
to,O
explore,O
other,O
potential,O
areas,O
of,O
interest,O
.,O
Interview,O
questions,O
focused,O
on,O
CSO,O
service,O
provision,O
",",O
coordination,O
",",O
and,O
HIV,B-OG
-,O
related,O
advocacy,O
",",O
and,O
included,O
perception,O
and,O
process,O
questions,O
.,O
Interviewers,O
took,O
extensive,O
structured,O
notes,O
and,O
used,O
them,O
to,O
develop,O
reports,O
for,O
each,O
interview,O
.,O
Interview,O
notes,O
were,O
taken,O
using,O
pencil,O
and,O
paper,O
and,O
transferred,O
to,O
Word,O
documents,O
.,O
Interviewees,O
were,O
not,O
anonymous,O
in,O
order,O
to,O
identify,O
the,O
perspectives,O
presented,O
in,O
the,O
in,O
-,O
depth,O
interviews,O
.,O
For,O
quantitative,O
data,O
collection,O
",",O
a,O
sampling,O
frame,O
was,O
assembled,O
from,O
lists,O
of,O
HIV,B-OG
-,O
oriented,O
or,O
involved,O
CSOs,O
that,O
were,O
members,O
of,O
Nigerian,O
HIV,B-OG
civil,O
society,O
networks,O
.,O
Membership,O
in,O
these,O
networks,O
was,O
the,O
sole,O
inclusion,O
criteria,O
for,O
the,O
sampling,O
frame,O
.,O
There,O
were,O
no,O
exclusion,O
criteria,O
.,O
This,O
sampling,O
frame,O
consisted,O
of,O
2548,O
CSOs,O
from,O
all,O
36,O
states,O
and,O
the,O
Federal,O
Capital,O
Territory,O
.,O
A,O
random,O
sample,O
was,O
then,O
taken,O
from,O
the,O
sampling,O
frame,O
",",O
and,O
665,O
CSOs,O
were,O
selected,O
and,O
contacted,O
to,O
arrange,O
interviews,O
.,O
With,O
a,O
response,O
rate,O
of,O
80,O
.,O
2,O
"%,",O
the,O
project,O
conducted,O
533,O
surveys,O
.,O
The,O
survey,O
requested,O
detailed,O
information,O
on,O
CSO,O
financial,O
",",O
human,B-OG
and,O
infrastructure,O
resources,O
",",O
as,O
well,O
as,O
projects,O
and,O
advocacy,O
activities,O
.,O
In,O
order,O
to,O
understand,O
the,O
scope,O
of,O
an,O
organization,O
’,O
s,O
activities,O
",",O
respondents,O
were,O
asked,O
to,O
report,O
both,O
the,O
total,O
budget,O
for,O
their,O
organization,O
’,O
s,O
HIV,B-OG
activities,O
",",O
as,O
well,O
as,O
budgets,O
for,O
each,O
individual,O
HIV,B-OG
-,O
related,O
project,O
they,O
were,O
currently,O
implementing,O
.,O
On,O
each,O
question,O
about,O
advocacy,O
",",O
interviewers,O
asked,O
the,O
respondents,O
to,O
list,O
their,O
activities,O
",",O
targets,O
",",O
and,O
monitoring,O
mechanisms,O
;,O
those,O
responses,O
were,O
then,O
grouped,O
together,O
under,O
pre,O
-,O
selected,O
categories,O
by,O
the,O
research,O
team,O
.,O
Data,O
analysis,O
All,O
data,O
was,O
entered,O
into,O
Census,O
and,O
Survey,O
Processing,O
System,O
(,O
CSPro,O
"),",O
and,O
analysis,O
was,O
carried,O
out,O
using,O
Statistical,O
Package,O
for,O
Social,O
Sciences,O
(,O
SPSS,O
),O
Version,O
19,O
.,O
Depending,O
on,O
normality,O
and,O
equality,O
of,O
variances,O
",",O
means,O
testing,O
to,O
identify,O
differences,O
between,O
groups,O
was,O
carried,O
using,O
either,O
Student,O
’,O
s,O
or,O
Welch,O
’,O
s,O
t,O
-,O
tests,O
or,O
Mann,O
–,O
Whitney,O
-,O
Wilcoxon,O
Ranked,O
Sum,O
tests,O
.,O
The,O
authors,O
used,O
Principal,O
Components,O
Analysis,O
(,O
PCA,O
),O
to,O
create,O
three,O
index,O
variables,O
based,O
on,O
the,O
relationship,O
between,O
six,O
variables,O
(,O
the,O
number,O
of,O
full,O
-,O
time,O
employees,O
",",O
total,O
number,O
of,O
offices,O
",",O
total,O
reported,O
budget,O
",",O
total,O
HIV,B-OG
-,O
related,O
activity,O
budget,O
",",O
total,O
number,O
of,O
part,O
time,O
employees,O
",",O
and,O
total,O
number,O
of,O
volunteers,O
"),",O
all,O
related,O
to,O
organizational,O
funding,O
and,O
scale,O
.,O
The,O
three,O
indices,O
captured,O
organization,O
size,O
",",O
organization,O
budget,O
",",O
and,O
organizational,O
access,O
to,O
human,B-OG
resources,O
.,O
The,O
“,O
Size,O
Index,O
”,O
was,O
based,O
on,O
the,O
number,O
of,O
full,O
-,O
time,O
employees,O
",",O
the,O
total,O
number,O
of,O
offices,O
",",O
the,O
total,O
reported,O
budget,O
",",O
and,O
the,O
total,O
HIV,B-OG
-,O
related,O
activity,O
budget,O
and,O
was,O
used,O
in,O
the,O
subsequent,O
analyses,O
.,O
Limitations,O
There,O
are,O
some,O
methodological,O
limitations,O
to,O
our,O
approach,O
.,O
First,O
",",O
because,O
of,O
the,O
relatively,O
small,O
number,O
of,O
organizations,O
in,O
our,O
sampling,O
frame,O
",",O
the,O
results,O
are,O
only,O
valid,O
at,O
the,O
geopolitical,O
zone,O
",",O
not,O
at,O
the,O
state,O
level,O
.,O
Second,O
",",O
we,O
used,O
purposeful,O
sampling,O
to,O
identify,O
key,O
informants,O
",",O
limiting,O
the,O
generalizability,O
of,O
their,O
responses,O
.,O
Finally,O
",",O
we,O
structured,O
the,O
survey,O
to,O
understand,O
the,O
frequency,O
",",O
type,O
",",O
targets,O
",",O
and,O
nature,O
of,O
HIV,B-OG
-,O
focused,O
advocacy,O
.,O
We,O
did,O
not,O
ask,O
questions,O
on,O
specific,O
advocacy,O
“,O
asks,O
”.,O
As,O
a,O
result,O
",",O
specific,O
advocacy,O
issues,O
come,O
from,O
the,O
key,O
informant,O
interviews,O
and,O
mostly,O
reflect,O
national,O
",",O
rather,O
than,O
state,O
or,O
local,O
",",O
issues,O
.,O
Results,O
Scope,O
of,O
civil,O
society,O
advocacy,O
We,O
find,O
that,O
30,O
%,O
of,O
CSOs,O
include,O
advocacy,O
in,O
their,O
mission,O
statements,O
.,O
CSOs,O
that,O
included,O
advocacy,O
in,O
their,O
mission,O
statements,O
had,O
more,O
staff,O
and,O
funding,O
than,O
those,O
that,O
did,O
not,O
",",O
as,O
indicated,O
by,O
statistically,O
significantly,O
higher,O
scores,O
on,O
the,O
mean,O
Size,O
Index,O
[,O
t,O
(,O
221,O
.,O
5,O
),O
=,O
−,O
2,O
.,O
781,O
",",O
p,O
=,O
0,O
.,O
006,O
].,O
Larger,O
organizations,O
are,O
also,O
more,O
likely,O
to,O
have,O
wider,O
ranging,O
mandates,O
and,O
capacities,O
and,O
are,O
more,O
likely,O
to,O
be,O
based,O
in,O
Abuja,O
",",O
the,O
Federal,O
Capital,O
Territory,O
.,O
As,O
Fig,O
.,O
1,O
shows,O
",",O
the,O
vast,O
majority,O
of,O
organizations,O
describe,O
themselves,O
as,O
conducting,O
advocacy,O
.,O
When,O
asked,O
to,O
identify,O
their,O
advocacy,O
activities,O
(,O
Table,O
1,O
"),",O
most,O
respondents,O
described,O
activities,O
clearly,O
oriented,O
towards,O
communication,O
",",O
such,O
as,O
peer,O
education,O
(,O
54,O
.,O
9,O
%),O
or,O
public,O
rallies,O
(,O
58,O
.,O
2,O
%).,O
In,O
-,O
depth,O
interviews,O
revealed,O
that,O
most,O
of,O
these,O
activities,O
were,O
focused,O
on,O
community,O
engagement,O
rather,O
than,O
policy,O
change,O
.,O
For,O
example,O
",",O
one,O
network,O
of,O
HIV,B-OG
organizations,O
noted,O
that,O
their,O
members,O
",",O
“,O
advocate,O
to,O
religious,O
leaders,O
and,O
community,O
leaders,O
to,O
reduce,O
stigma,O
and,O
discrimination,O
",",O
create,O
awareness,O
about,O
HIV,B-OG
",",O
mobilize,O
resources,O
for,O
HIV,B-OG
prevention,O
",",O
and,O
provide,O
care,O
and,O
support,O
to,O
PLWHA,O
.”,O
Table,O
1,O
does,O
show,O
that,O
nearly,O
33,O
%,O
of,O
CSOs,O
reported,O
discussions,O
with,O
elected,O
officials,O
for,O
advocacy,O
purposes,O
.,O
Fig,O
.,O
1Perceived,O
frequency,O
of,O
participation,O
in,O
advocacy,O
on,O
HIV,B-OG
issues,O
Advocacy,O
",",O
with,O
a,O
goal,O
of,O
affecting,O
policy,O
change,O
",",O
was,O
rarely,O
cited,O
as,O
a,O
stand,O
-,O
alone,O
activity,O
with,O
a,O
dedicated,O
funding,O
source,O
.,O
Only,O
14,O
of,O
the,O
533,O
CSOs,O
reported,O
advocacy,O
as,O
a,O
component,O
of,O
an,O
ongoing,O
",",O
funded,O
project,O
.,O
In,O
nine,O
of,O
those,O
14,O
CSOs,O
",",O
advocacy,O
was,O
one,O
objective,O
out,O
of,O
several,O
.,O
Table,O
1Advocacy,O
activities,O
reported,O
by,O
CSOsNumberPercentPeer,O
education28654,O
.,O
9,O
%,O
Rallies30958,O
.,O
2,O
%,O
Discussions,O
w,O
/,O
elected,O
officials17332,O
.,O
6,O
%,O
Mass,O
media,O
campaigns15529,O
.,O
2,O
%,O
Discussions,O
w,O
/,O
regulators9818,O
.,O
5,O
%,O
Policy,O
briefs5810,O
.,O
9,O
%,O
Press,O
releases5310,O
.,O
0,O
%,O
Press,O
conferences427,O
.,O
9,O
%,O
Petitions234,O
.,O
3,O
%,O
Civil,O
society,O
targeting,O
of,O
advocacy,O
activities,O
Table,O
2,O
identifies,O
advocacy,O
targets,O
for,O
CSOs,O
.,O
This,O
table,O
confirms,O
their,O
focus,O
on,O
behavior,O
change,O
rather,O
than,O
influencing,O
government,O
;,O
the,O
most,O
commonly,O
reported,O
targets,O
of,O
advocacy,O
were,O
village,O
leaders,O
and,O
citizens,O
.,O
While,O
it,O
is,O
conceivable,O
that,O
both,O
village,O
leaders,O
and,O
citizens,O
could,O
be,O
targets,O
for,O
mass,O
action,O
to,O
effect,O
policy,O
change,O
",",O
discussions,O
with,O
in,O
-,O
depth,O
interviewees,O
again,O
showed,O
that,O
the,O
CSOs,O
’,O
actual,O
activities,O
focused,O
on,O
HIV,B-OG
prevention,O
",",O
rather,O
than,O
policy,O
change,O
.,O
Respondents,O
also,O
cited,O
Information,O
",",O
Education,O
",",O
and,O
Communication,O
campaigns,O
",",O
which,O
target,O
village,O
leaders,O
and,O
citizens,O
",",O
as,O
the,O
most,O
common,O
HIV,B-OG
prevention,O
activity,O
.,O
In,O
-,O
depth,O
interviewees,O
rounded,O
out,O
this,O
picture,O
;,O
noting,O
that,O
few,O
CSOs,O
have,O
a,O
scope,O
beyond,O
their,O
local,O
village,O
or,O
community,O
and,O
that,O
they,O
are,O
often,O
disconnected,O
from,O
government,O
",",O
at,O
any,O
level,O
.,O
They,O
noted,O
that,O
the,O
highest,O
scale,O
of,O
operation,O
for,O
most,O
CSOs,O
is,O
a,O
single,O
Nigerian,O
state,O
or,O
city,O
",",O
and,O
that,O
links,O
to,O
networks,O
were,O
weak,O
or,O
non,O
-,O
existent,O
.,O
Table,O
2Advocacy,O
targetsNumberPercentVillage,O
leaders39674,O
.,O
6,O
%,O
Citizens24946,O
.,O
9,O
%,O
Elected,O
officials23044,O
.,O
1,O
%,O
Donors14226,O
.,O
7,O
%,O
Civil,O
servants11722,O
.,O
0,O
%,O
Religious,O
leaders7313,O
.,O
7,O
%,O
Youth,O
&,O
students285,O
.,O
3,O
%,O
Women183,O
.,O
4,O
%,O
While,O
citizens,O
and,O
village,O
leaders,O
were,O
the,O
most,O
commonly,O
reported,O
targets,O
of,O
advocacy,O
",",O
CSOs,O
also,O
reported,O
directing,O
advocacy,O
efforts,O
towards,O
elected,O
officials,O
(,O
44,O
.,O
1,O
%).,O
Organizations,O
in,O
our,O
sample,O
reported,O
conducting,O
a,O
median,O
of,O
two,O
such,O
meetings,O
in,O
all,O
of,O
2011,O
(,O
Table,O
3,O
).,O
Only,O
seven,O
percent,O
of,O
CSOs,O
reported,O
meeting,O
with,O
government,O
officials,O
more,O
than,O
once,O
a,O
month,O
(,O
Table,O
3,O
).,O
In,O
in,O
-,O
depth,O
interviews,O
",",O
civil,O
society,O
respondents,O
noted,O
a,O
lack,O
of,O
contact,O
and,O
coordination,O
with,O
government,O
at,O
all,O
levels,O
.,O
Compared,O
to,O
organizations,O
that,O
did,O
not,O
report,O
targeting,O
government,O
officials,O
",",O
organizations,O
that,O
focused,O
their,O
efforts,O
on,O
elected,O
officials,O
and,O
civil,O
servants,O
were,O
significantly,O
larger,O
",",O
as,O
measured,O
by,O
the,O
Size,O
Index,O
[,O
t,O
(,O
304,O
.,O
2,O
),O
=,O
−,O
2,O
.,O
203,O
",",O
p,O
=,O
0,O
.,O
028,O
;,O
and,O
t,O
(,O
294,O
.,O
7,O
),O
=,O
−,O
2,O
.,O
233,O
",",O
p,O
=,O
0,O
.,O
026,O
",",O
respectively,O
].,O
Five,O
organizations,O
reported,O
meeting,O
with,O
government,O
officials,O
at,O
least,O
once,O
a,O
week,O
;,O
these,O
organizations,O
also,O
reported,O
policy,O
change,O
as,O
a,O
goal,O
of,O
their,O
advocacy,O
work,O
",",O
as,O
reflected,O
in,O
their,O
mission,O
statements,O
.,O
Table,O
3Number,O
of,O
one,O
-,O
on,O
-,O
one,O
meetings,O
with,O
governments,O
officials,O
in,O
2011Number,O
of,O
meetingsNumberPercent011622,O
.,O
3,O
%,O
15510,O
.,O
6,O
%,O
2,O
to,O
315930,O
.,O
5,O
%,O
4,O
to,O
69418,O
.,O
0,O
%,O
7,O
to,O
125410,O
.,O
4,O
%,O
13,O
to,O
20203,O
.,O
8,O
%,O
21,O
to,O
30111,O
.,O
3,O
%,O
31,O
to,O
5071,O
.,O
0,O
%,O
51,O
+,O
51,O
.,O
0,O
%,O
Out,O
of,O
521,O
total,O
CSO,O
respondents,O
In,O
in,O
-,O
depth,O
interviews,O
",",O
few,O
CSOs,O
spontaneously,O
named,O
advocacy,O
towards,O
policymakers,O
as,O
a,O
goal,O
.,O
Nonetheless,O
",",O
when,O
asked,O
directly,O
",",O
the,O
majority,O
of,O
CSOs,O
indicated,O
that,O
they,O
would,O
like,O
to,O
influence,O
government,O
policy,O
and,O
decision,O
makers,O
.,O
CSOs,O
",",O
however,O
",",O
rarely,O
devoted,O
financial,O
resources,O
to,O
this,O
goal,O
;,O
advocacy,O
was,O
often,O
pursued,O
in,O
concert,O
with,O
other,O
types,O
of,O
communication,O
strategies,O
.,O
On,O
the,O
other,O
hand,O
",",O
CSOs,O
are,O
generally,O
positive,O
about,O
interacting,O
with,O
government,O
.,O
When,O
asked,O
about,O
challenges,O
to,O
their,O
activities,O
",",O
43,O
.,O
4,O
%,O
of,O
CSOs,O
reported,O
that,O
a,O
lack,O
of,O
political,O
support,O
“,O
never,O
”,O
or,O
“,O
rarely,O
”,O
impeded,O
their,O
work,O
.,O
Only,O
26,O
.,O
5,O
%,O
reported,O
that,O
they,O
“,O
often,O
”,O
or,O
“,O
always,O
”,O
faced,O
political,O
challenges,O
.,O
CSOs,O
",",O
overall,O
",",O
reported,O
having,O
access,O
to,O
government,O
officials,O
.,O
Who,O
are,O
advocacy,O
organizations,O
?,O
In,O
-,O
depth,O
interviews,O
",",O
conducted,O
with,O
representatives,O
of,O
CSOs,O
that,O
explicitly,O
reported,O
advocacy,O
as,O
a,O
core,O
mission,O
",",O
showed,O
that,O
very,O
few,O
CSOs,O
actively,O
advocate,O
for,O
policy,O
change,O
.,O
These,O
organizations,O
fell,O
into,O
one,O
of,O
two,O
broad,O
categories,O
:,O
organizations,O
with,O
explicit,O
advocacy,O
agendas,O
(,O
often,O
supported,O
by,O
foundations,O
",",O
or,O
spun,O
off,O
from,O
international,O
organizations,O
),O
and,O
networks,O
of,O
CSOs,O
.,O
Organizations,O
with,O
explicit,O
advocacy,O
agendas,O
included,O
the,O
Planned,O
Parenthood,O
Federation,O
of,O
Nigeria,O
(,O
PPFN,O
"),",O
The,O
Initiative,O
for,O
Equal,O
Rights,O
",",O
Journalists,O
against,O
AIDS,B-DS
",",O
and,O
the,O
Health,O
Reform,O
Foundation,O
of,O
Nigeria,O
(,O
HERFON,O
).,O
These,O
organizations,O
often,O
mix,O
advocacy,O
activities,O
with,O
service,O
delivery,O
",",O
depending,O
on,O
available,O
grant,O
funding,O
mostly,O
from,O
private,O
foundations,O
and,O
the,O
Department,O
for,O
International,O
Development,O
(,O
DFID,O
).,O
They,O
also,O
conduct,O
research,O
and,O
analysis,O
to,O
inform,O
specific,O
policy,O
requests,O
.,O
For,O
example,O
",",O
PPFN,O
manages,O
a,O
network,O
of,O
68,O
independent,O
clinics,O
",",O
which,O
distribute,O
family,O
planning,O
commodities,O
and,O
information,O
.,O
At,O
the,O
same,O
time,O
",",O
they,O
have,O
directly,O
advocated,O
for,O
changes,O
in,O
Nigeria,O
’,O
s,O
health,O
policy,O
framework,O
",",O
successfully,O
advocating,O
for,O
free,O
antenatal,O
care,O
in,O
four,O
states,O
.,O
According,O
to,O
key,O
informants,O
",",O
networks,O
",",O
such,O
as,O
the,O
Civil,O
Society,O
HIV,B-OG
/,O
AIDS,B-DS
Network,O
",",O
the,O
Network,O
of,O
People,O
Living,O
with,O
HIV,B-OG
/,O
AIDS,B-DS
in,O
Nigeria,O
",",O
and,O
the,O
Youth,O
Network,O
on,O
HIV,B-OG
/,O
AIDS,B-DS
in,O
Nigeria,O
",",O
are,O
caught,O
between,O
two,O
sets,O
of,O
interests,O
:,O
1,O
),O
representing,O
their,O
members,O
and,O
2,O
),O
disseminating,O
government,O
funding,O
and,O
policy,O
priorities,O
to,O
their,O
members,O
.,O
Although,O
networks,O
are,O
supposed,O
to,O
give,O
small,O
",",O
local,O
organizations,O
a,O
voice,O
at,O
the,O
federal,O
level,O
",",O
interviewees,O
claimed,O
that,O
these,O
networks,O
are,O
largely,O
co,O
-,O
opted,O
by,O
the,O
international,O
donors,O
and,O
government,O
agencies,O
that,O
fund,O
them,O
.,O
Though,O
some,O
networks,O
do,O
require,O
membership,O
dues,O
",",O
the,O
amounts,O
are,O
nominal,O
.,O
The,O
vast,O
majority,O
of,O
funding,O
for,O
these,O
networks,O
originates,O
with,O
international,O
sources,O
",",O
such,O
as,O
the,O
Global,O
Fund,O
and,O
the,O
World,O
Bank,O
",",O
but,O
is,O
typically,O
managed,O
",",O
either,O
directly,O
or,O
indirectly,O
by,O
NACA,O
[,O
25,O
].,O
Network,O
interviewees,O
noted,O
that,O
the,O
vast,O
majority,O
of,O
their,O
funding,O
was,O
tied,O
to,O
member,O
coordination,O
and,O
policy,O
dissemination,O
efforts,O
;,O
staff,O
are,O
rarely,O
able,O
to,O
dedicate,O
time,O
to,O
policy,O
analysis,O
and,O
advocacy,O
.,O
Both,O
advocates,O
and,O
networks,O
have,O
attempted,O
to,O
change,O
some,O
Nigerian,O
federal,O
laws,O
",",O
with,O
the,O
support,O
of,O
NACA,O
.,O
As,O
mentioned,O
in,O
the,O
Introduction,O
",",O
advocates,O
focused,O
on,O
two,O
critical,O
bills,O
the,O
“,O
Same,O
Sex,O
Marriage,O
(,O
Prohibition,O
),O
Act,O
",",O
2013,O
”,O
and,O
the,O
“,O
HIV,B-OG
/,O
AIDS,B-DS
Anti,O
-,O
Discrimination,O
Act,O
",",O
2014,O
”.,O
Interviewees,O
fought,O
to,O
prevent,O
the,O
Same,O
Sex,O
Marriage,O
(,O
Prohibition,O
),O
Act,O
from,O
passage,O
",",O
while,O
advocating,O
for,O
some,O
changes,O
to,O
and,O
eventual,O
passage,O
of,O
the,O
HIV,B-OG
/,O
AIDS,B-DS
Anti,O
-,O
Discrimination,O
Act,O
.,O
In,O
January,O
2014,O
",",O
despite,O
advocacy,O
efforts,O
",",O
the,O
same,O
-,O
sex,O
marriage,O
bill,O
was,O
signed,O
into,O
law,O
by,O
President,O
Goodluck,O
Jonathan,O
[,O
30,O
].,O
Advocates,O
did,O
have,O
some,O
success,O
with,O
the,O
latter,O
bill,O
",",O
as,O
HIV,B-OG
criminalization,O
was,O
removed,O
from,O
the,O
anti,O
-,O
discrimination,O
and,O
stigma,O
bill,O
",",O
and,O
it,O
was,O
signed,O
into,O
law,O
in,O
February,O
2015,O
[,O
31,O
].,O
Government,O
viewpoints,O
on,O
advocacy,O
Federal,O
government,O
actors,O
reported,O
holding,O
meetings,O
with,O
civil,O
society,O
to,O
coordinate,O
specific,O
activities,O
or,O
to,O
validate,O
or,O
disseminate,O
specific,O
policies,O
.,O
For,O
example,O
",",O
NACA,O
meets,O
with,O
the,O
networks,O
every,O
2,O
months,O
to,O
get,O
feedback,O
on,O
activities,O
funded,O
through,O
Global,O
Fund,O
or,O
World,O
Bank,O
funding,O
that,O
NACA,O
manages,O
.,O
At,O
the,O
end,O
of,O
the,O
fiscal,O
year,O
",",O
they,O
hold,O
work,O
planning,O
sessions,O
to,O
develop,O
networks,O
’,O
operational,O
plans,O
.,O
NACA,O
does,O
not,O
hold,O
regular,O
meetings,O
to,O
solicit,O
civil,O
society,O
opinions,O
about,O
policy,O
or,O
legislation,O
",",O
though,O
they,O
do,O
hold,O
meetings,O
to,O
disseminate,O
policies,O
on,O
an,O
ad,O
hoc,O
basis,O
.,O
The,O
Federal,O
Ministry,O
of,O
Health,O
reported,O
their,O
main,O
focus,O
is,O
on,O
developing,O
technical,O
guidance,O
and,O
training,O
for,O
service,O
providers,O
",",O
including,O
CSOs,O
.,O
They,O
develop,O
these,O
guidance,O
documents,O
in,O
collaboration,O
with,O
CSOs,O
.,O
At,O
the,O
state,O
level,O
",",O
SACAs,O
are,O
supposed,O
to,O
coordinate,O
the,O
HIV,B-OG
response,O
through,O
policy,O
development,O
and,O
coordination,O
.,O
In,O
interviews,O
",",O
however,O
",",O
SACA,O
staff,O
expressed,O
frustration,O
at,O
having,O
little,O
to,O
no,O
defined,O
role,O
in,O
monitoring,O
",",O
overseeing,O
",",O
or,O
determining,O
which,O
services,O
civil,O
society,O
provides,O
.,O
In,O
contrast,O
to,O
NACA,O
",",O
which,O
sets,O
policy,O
and,O
controls,O
World,O
Bank,O
and,O
Global,O
Fund,O
money,O
",",O
SACAs,O
have,O
little,O
dedicated,O
funding,O
and,O
their,O
policies,O
and,O
strategic,O
plans,O
are,O
often,O
ignored,O
by,O
CSOs,O
and,O
donors,O
who,O
do,O
not,O
align,O
activities,O
with,O
their,O
priorities,O
.,O
As,O
the,O
President,O
’,O
s,O
Emergency,O
Plan,O
for,O
AIDS,B-DS
Relief,O
(,O
PEPFAR,O
),O
and,O
Global,O
Fund,O
financing,O
flows,O
entirely,O
outside,O
of,O
SACA,O
structures,O
",",O
CSOs,O
have,O
sources,O
of,O
financing,O
independent,O
from,O
SACAs,O
.,O
Some,O
SACAs,O
have,O
explored,O
providing,O
small,O
grants,O
to,O
CSOs,O
for,O
discrete,O
services,O
",",O
but,O
few,O
do,O
so,O
because,O
they,O
feel,O
the,O
request,O
process,O
is,O
highly,O
bureaucratic,O
and,O
political,O
.,O
According,O
to,O
interviewees,O
",",O
this,O
coordination,O
gap,O
at,O
the,O
state,O
level,O
impacts,O
policy,O
implementation,O
and,O
monitoring,O
.,O
For,O
example,O
",",O
in,O
one,O
state,O
",",O
CSOs,O
have,O
never,O
provided,O
feedback,O
on,O
HIV,B-OG
policies,O
",",O
nor,O
has,O
the,O
SACA,O
asked,O
for,O
their,O
input,O
.,O
Even,O
in,O
states,O
where,O
CSOs,O
and,O
SACAs,O
do,O
coordinate,O
",",O
CSOs,O
often,O
use,O
reporting,O
tools,O
from,O
their,O
donors,O
which,O
are,O
not,O
aligned,O
to,O
either,O
federal,O
or,O
state,O
guidelines,O
.,O
SACAs,O
do,O
not,O
feel,O
that,O
they,O
are,O
in,O
a,O
position,O
to,O
force,O
compliance,O
",",O
because,O
they,O
cannot,O
provide,O
the,O
community,O
-,O
based,O
services,O
that,O
CSOs,O
can,O
.,O
Some,O
SACA,O
interviewees,O
thought,O
that,O
the,O
federal,O
government,O
preferred,O
that,O
CSOs,O
deliver,O
HIV,B-OG
services,O
instead,O
of,O
state,O
governments,O
",",O
as,O
the,O
federal,O
government,O
retains,O
greater,O
power,O
and,O
influence,O
with,O
weakened,O
states,O
.,O
Some,O
SACA,O
interviewees,O
also,O
thought,O
that,O
CSOs,O
avoid,O
reporting,O
activities,O
in,O
order,O
to,O
hide,O
activities,O
.,O
According,O
to,O
these,O
interviewees,O
",",O
CSOs,O
do,O
not,O
want,O
to,O
be,O
seen,O
as,O
“,O
fully,O
funded,O
"”,",O
in,O
case,O
SACAs,O
receive,O
money,O
for,O
CSO,O
grants,O
.,O
We,O
were,O
unable,O
to,O
verify,O
this,O
perception,O
independently,O
.,O
Even,O
though,O
CSOs,O
conduct,O
a,O
great,O
deal,O
of,O
HIV,B-OG
prevention,O
and,O
mitigation,O
work,O
at,O
the,O
state,O
level,O
",",O
SACAs,O
do,O
not,O
think,O
highly,O
of,O
CSOs,O
",",O
claiming,O
that,O
they,O
exist,O
solely,O
because,O
of,O
“,O
the,O
belief,O
that,O
there,O
is,O
a,O
lot,O
of,O
funding,O
available,O
for,O
HIV,B-OG
-,O
related,O
activities,O
”.,O
Donor,O
and,O
international,O
organization,O
influence,O
on,O
civil,O
society,O
In,O
addition,O
to,O
probing,O
civil,O
society,O
and,O
government,O
viewpoints,O
",",O
we,O
also,O
interviewed,O
representatives,O
of,O
organizations,O
that,O
provide,O
most,O
of,O
the,O
funding,O
for,O
civil,O
society,O
’,O
s,O
response,O
to,O
HIV,B-OG
in,O
Nigeria,O
:,O
international,O
organizations,O
and,O
donors,O
.,O
In,O
in,O
-,O
depth,O
interviews,O
",",O
donors,O
emphasized,O
the,O
role,O
of,O
CSOs,O
in,O
extending,O
the,O
reach,O
of,O
HIV,B-OG
-,O
related,O
services,O
",",O
including,O
prevention,O
",",O
testing,O
",",O
care,O
",",O
and,O
treatment,O
",",O
but,O
none,O
mentioned,O
empowering,O
civil,O
society,O
to,O
advocate,O
for,O
the,O
needs,O
of,O
their,O
membership,O
.,O
With,O
the,O
exception,O
of,O
DFID,O
’,O
s,O
support,O
to,O
HERFON,O
",",O
donor,O
support,O
focused,O
on,O
palliative,O
care,O
",",O
orphans,O
and,O
vulnerable,O
children,O
",",O
and,O
HIV,B-OG
prevention,O
reach,O
communities,O
.,O
One,O
interviewee,O
noted,O
that,O
“,O
CSOs,O
have,O
an,O
important,O
role,O
to,O
play,O
because,O
they,O
are,O
able,O
to,O
provide,O
access,O
to,O
‘,O
hard,O
to,O
reach,O
’,O
and,O
underserved,O
communities,O
”.,O
International,O
organizations,O
recognized,O
the,O
ability,O
of,O
CSOs,O
to,O
reach,O
areas,O
where,O
the,O
Nigerian,O
state,O
cannot,O
reach,O
",",O
but,O
most,O
thought,O
that,O
Nigerian,O
CSOs,O
did,O
not,O
have,O
strong,O
advocacy,O
skills,O
",",O
as,O
a,O
result,O
of,O
poor,O
coordination,O
with,O
other,O
CSOs,O
.,O
Interviewees,O
from,O
international,O
organizations,O
noted,O
that,O
while,O
the,O
technical,O
abilities,O
of,O
civil,O
society,O
were,O
quite,O
good,O
",",O
CSOs,O
often,O
had,O
weak,O
organizational,O
and,O
planning,O
capabilities,O
",",O
did,O
not,O
report,O
activities,O
accurately,O
",",O
and,O
did,O
not,O
fully,O
comply,O
with,O
procedures,O
and,O
timelines,O
.,O
Interviewees,O
from,O
donors,O
and,O
international,O
organizations,O
use,O
solutions,O
that,O
homogenize,O
CSO,O
operations,O
",",O
and,O
included,O
mandating,O
minimum,O
service,O
packages,O
",",O
implementing,O
standard,O
financial,O
systems,O
",",O
and,O
specifying,O
program,O
monitoring,O
mechanisms,O
for,O
every,O
CSO,O
that,O
they,O
fund,O
.,O
One,O
interviewee,O
noted,O
that,O
their,O
technical,O
assistance,O
",",O
site,O
visits,O
and,O
budget,O
reviews,O
often,O
ensure,O
that,O
CSOs,O
are,O
“,O
aligned,O
with,O
the,O
donor,O
’,O
s,O
priorities,O
”.,O
Some,O
interviewees,O
suggested,O
that,O
donors,O
",",O
international,O
organizations,O
",",O
and,O
government,O
needed,O
to,O
play,O
a,O
more,O
activist,O
role,O
in,O
“,O
fixing,O
”,O
the,O
civil,O
society,O
response,O
.,O
They,O
suggested,O
further,O
mandates,O
",",O
such,O
as,O
board,O
governance,O
rules,O
",",O
discouraging,O
CSOs,O
from,O
concentrating,O
in,O
major,O
cities,O
",",O
enforcing,O
efficiency,O
standards,O
",",O
and,O
regulating,O
which,O
communities,O
CSOs,O
serve,O
.,O
No,O
international,O
organizations,O
or,O
donors,O
mentioned,O
strengthening,O
the,O
relational,O
or,O
advocacy,O
capacity,O
of,O
CSOs,O
as,O
part,O
of,O
their,O
capacity,O
development,O
efforts,O
.,O
To,O
promote,O
sustainability,O
",",O
international,O
organizations,O
and,O
donors,O
do,O
try,O
to,O
help,O
CSOs,O
generate,O
internal,O
revenue,O
or,O
appeal,O
to,O
nontraditional,O
funders,O
.,O
They,O
also,O
thought,O
",",O
however,O
",",O
that,O
this,O
work,O
had,O
been,O
unsuccessful,O
",",O
and,O
CSOs,O
would,O
be,O
dependent,O
on,O
international,O
funding,O
to,O
conduct,O
HIV,B-OG
mitigation,O
and,O
prevention,O
activities,O
for,O
the,O
foreseeable,O
future,O
.,O
One,O
interviewee,O
said,O
that,O
“,O
The,O
problem,O
with,O
CSOs,O
is,O
ensuring,O
sustainability,O
because,O
once,O
grants,O
are,O
over,O
",",O
they,O
no,O
longer,O
function,O
.”,O
In,O
addition,O
to,O
being,O
grant,O
dependent,O
",",O
these,O
interviewees,O
thought,O
that,O
CSOs,O
are,O
also,O
grant,O
-,O
responsive,O
.,O
Interviewees,O
from,O
international,O
organizations,O
thought,O
that,O
CSOs,O
are,O
unable,O
to,O
identify,O
organizational,O
priorities,O
",",O
including,O
advocacy,O
.,O
One,O
interviewee,O
noted,O
that,O
",",O
“[,O
CSOs,O
],O
do,O
not,O
have,O
clearly,O
defined,O
mission,O
",",O
vision,O
or,O
mandate,O
.,O
They,O
compete,O
for,O
anything,O
that,O
is,O
tied,O
to,O
a,O
grant,O
.”,O
This,O
same,O
interviewee,O
thought,O
that,O
many,O
CSOs,O
were,O
simply,O
mechanisms,O
for,O
seeking,O
grants,O
",",O
calling,O
them,O
“,O
Non,O
-,O
Governmental,O
Individuals,O
”.,O
Discussion,O
The,O
priorities,O
and,O
activities,O
of,O
civil,O
society,O
in,O
Nigeria,O
did,O
not,O
develop,O
in,O
a,O
vacuum,O
.,O
They,O
are,O
a,O
response,O
to,O
incentives,O
provided,O
by,O
their,O
membership,O
",",O
government,O
policy,O
",",O
and,O
donors,O
.,O
As,O
is,O
apparent,O
from,O
our,O
in,O
-,O
depth,O
interviews,O
",",O
membership,O
plays,O
a,O
limited,O
role,O
in,O
influencing,O
civil,O
society,O
actions,O
in,O
Nigeria,O
.,O
Federal,O
policy,O
clearly,O
influences,O
CSO,O
priorities,O
",",O
but,O
state,O
directives,O
are,O
often,O
ignored,O
.,O
Most,O
importantly,O
",",O
donors,O
and,O
international,O
organizations,O
",",O
through,O
funding,O
choices,O
and,O
capacity,O
development,O
efforts,O
",",O
also,O
shape,O
civil,O
society,O
advocacy,O
.,O
In,O
this,O
section,O
",",O
we,O
will,O
turn,O
toward,O
analyzing,O
the,O
influences,O
on,O
the,O
civil,O
society,O
response,O
to,O
HIV,B-OG
in,O
Nigeria,O
",",O
identifying,O
areas,O
of,O
potential,O
conflict,O
and,O
co,O
-,O
option,O
.,O
Throughout,O
this,O
article,O
",",O
we,O
have,O
found,O
evidence,O
that,O
agreed,O
with,O
Rao,O
and,O
Jenkins,O
[,O
18,O
",",O
23,O
].,O
Donors,O
",",O
and,O
international,O
organizations,O
",",O
tend,O
to,O
conceive,O
of,O
civil,O
society,O
as,O
apolitical,O
",",O
and,O
not,O
as,O
independent,O
actors,O
that,O
compete,O
for,O
political,O
space,O
.,O
More,O
democratic,O
and,O
rights,O
-,O
based,O
views,O
of,O
civil,O
society,O
’,O
s,O
role,O
",",O
such,O
as,O
holding,O
government,O
accountable,O
for,O
providing,O
services,O
or,O
promoting,O
policy,O
change,O
",",O
are,O
not,O
emphasized,O
.,O
In,O
-,O
depth,O
interviews,O
of,O
donors,O
",",O
as,O
well,O
as,O
current,O
project,O
portfolios,O
",",O
confirmed,O
this,O
characterization,O
.,O
Building,O
on,O
the,O
findings,O
from,O
our,O
cross,O
-,O
sectional,O
survey,O
and,O
in,O
-,O
depth,O
interviews,O
",",O
we,O
propose,O
some,O
key,O
analytical,O
points,O
for,O
understanding,O
the,O
influence,O
of,O
donors,O
and,O
government,O
on,O
HIV,B-OG
-,O
related,O
advocacy,O
.,O
International,O
donor,O
actions,O
reduce,O
civil,O
society,O
advocacy,O
potential,O
As,O
noted,O
by,O
Jenkins,O
",",O
donors,O
often,O
seek,O
out,O
CSOs,O
for,O
purely,O
service,O
delivery,O
roles,O
",",O
shutting,O
off,O
advocacy,O
organizations,O
from,O
funding,O
[,O
23,O
].,O
They,O
focus,O
on,O
these,O
roles,O
to,O
meet,O
service,O
delivery,O
mandates,O
from,O
their,O
governments,O
",",O
such,O
as,O
the,O
number,O
of,O
people,O
tested,O
for,O
HIV,B-OG
or,O
reached,O
with,O
prevention,O
messages,O
.,O
Nigeria,O
is,O
no,O
different,O
-,O
the,O
vast,O
majority,O
of,O
international,O
funding,O
for,O
HIV,B-OG
toward,O
project,O
implementation,O
and,O
coordination,O
",",O
rather,O
than,O
policy,O
analysis,O
and,O
advocacy,O
[,O
34,O
].,O
Williamson,O
also,O
estimated,O
that,O
85,O
to,O
90,O
%,O
of,O
HIV,B-OG
-,O
related,O
funding,O
for,O
CSOs,O
originates,O
from,O
these,O
international,O
donors,O
",",O
providing,O
an,O
incentive,O
for,O
civil,O
society,O
to,O
reorient,O
their,O
work,O
toward,O
their,O
preferences,O
[,O
34,O
].,O
Internationally,O
funded,O
HIV,B-OG
projects,O
from,O
2006,O
to,O
2012,O
in,O
Nigeria,O
reflect,O
this,O
service,O
delivery,O
and,O
apolitical,O
framing,O
:,O
the,O
World,O
Bank,O
’,O
s,O
HIV,B-OG
/,O
AIDS,B-DS
Fund,O
(,O
HAF,O
"),",O
the,O
Global,O
Fund,O
’,O
s,O
support,O
to,O
CSOs,O
",",O
and,O
various,O
United,O
States,O
Agency,O
for,O
International,O
Development,O
(,O
USAID,O
),O
and,O
DFID,O
projects,O
primarily,O
focused,O
on,O
service,O
delivery,O
outcomes,O
.,O
Only,O
DFID,O
’,O
s,O
funding,O
of,O
the,O
HERFON,O
stood,O
out,O
as,O
explicitly,O
trying,O
to,O
change,O
federal,O
government,O
policy,O
and,O
legislation,O
.,O
These,O
funding,O
streams,O
focus,O
the,O
attention,O
of,O
civil,O
society,O
.,O
As,O
CSOs,O
respond,O
to,O
these,O
service,O
delivery,O
grants,O
",",O
they,O
have,O
little,O
incentive,O
to,O
promote,O
the,O
demands,O
of,O
their,O
membership,O
",",O
and,O
their,O
survival,O
becomes,O
aligned,O
with,O
the,O
preferences,O
of,O
donors,O
.,O
A,O
World,O
Bank,O
HAF,O
evaluation,O
found,O
a,O
correlation,O
between,O
CSOs,O
that,O
received,O
grants,O
from,O
HAF,O
and,O
reduced,O
advocacy,O
.,O
For,O
CSOs,O
that,O
did,O
not,O
receive,O
HAF,O
grants,O
",",O
36,O
%,O
engaged,O
in,O
advocacy,O
and,O
16,O
%,O
held,O
advocacy,O
meetings,O
[,O
35,O
].,O
At,O
the,O
same,O
time,O
",",O
of,O
those,O
receiving,O
HAF,O
grants,O
",",O
only,O
9,O
%,O
engaged,O
in,O
advocacy,O
and,O
7,O
%,O
held,O
advocacy,O
meetings,O
[,O
35,O
].,O
Through,O
the,O
in,O
-,O
depth,O
interviews,O
",",O
we,O
found,O
donor,O
and,O
international,O
NGO,O
perceive,O
that,O
CSO,O
advocacy,O
",",O
financial,O
",",O
and,O
program,O
management,O
skills,O
are,O
fundamentally,O
very,O
weak,O
",",O
even,O
if,O
these,O
organizations,O
do,O
have,O
strong,O
community,O
reach,O
.,O
The,O
2008,O
Health,O
Systems,O
Assessment,O
agrees,O
with,O
this,O
evaluation,O
",",O
noting,O
that,O
",",O
“,O
Nigerian,O
CSOs,O
…,O
while,O
vibrant,O
and,O
essentially,O
free,O
to,O
work,O
without,O
constraints,O
",",O
lack,O
the,O
technical,O
grasp,O
",",O
advocacy,O
skills,O
",",O
and,O
networking,O
resources,O
necessary,O
for,O
successful,O
health,O
reform,O
advocacy,O
”,O
[,O
36,O
].,O
Donor,O
demands,O
for,O
improved,O
service,O
and,O
financial,O
standards,O
",",O
however,O
admirable,O
",",O
have,O
the,O
real,O
effect,O
of,O
homogenizing,O
civil,O
society,O
actions,O
",",O
reducing,O
the,O
space,O
for,O
innovation,O
.,O
While,O
ensuring,O
that,O
CSOs,O
have,O
the,O
capacity,O
to,O
comply,O
with,O
donor,O
regulations,O
",",O
international,O
organizations,O
often,O
require,O
CSOs,O
to,O
use,O
standard,O
technical,O
approaches,O
",",O
financial,O
systems,O
",",O
and,O
monitoring,O
mechanisms,O
.,O
These,O
requirements,O
have,O
the,O
effect,O
of,O
reducing,O
organizational,O
identity,O
and,O
treating,O
CSOs,O
less,O
as,O
independent,O
organizations,O
",",O
and,O
more,O
as,O
service,O
delivery,O
agents,O
of,O
international,O
donors,O
.,O
Even,O
more,O
perniciously,O
",",O
donors,O
and,O
international,O
organizations,O
expressed,O
a,O
desire,O
to,O
more,O
tightly,O
control,O
and,O
regulate,O
civil,O
society,O
actions,O
.,O
These,O
reforms,O
",",O
while,O
unlikely,O
to,O
take,O
place,O
",",O
would,O
further,O
standardize,O
civil,O
society,O
approaches,O
and,O
de,O
-,O
politicize,O
their,O
actions,O
.,O
The,O
federal,O
government,O
is,O
complicit,O
in,O
promoting,O
an,O
apolitical,O
view,O
of,O
civil,O
society,O
In,O
Nigeria,O
",",O
the,O
federal,O
government,O
is,O
an,O
intermediary,O
between,O
donors,O
and,O
CSO,O
-,O
implemented,O
HIV,B-OG
programs,O
",",O
and,O
donors,O
can,O
influence,O
the,O
federal,O
government,O
’,O
s,O
actions,O
toward,O
CSOs,O
.,O
Grants,O
funded,O
by,O
donors,O
",",O
and,O
managed,O
by,O
the,O
federal,O
government,O
",",O
come,O
with,O
clear,O
disbursement,O
requirements,O
",",O
regulations,O
",",O
and,O
compliance,O
mechanisms,O
.,O
By,O
agreeing,O
to,O
these,O
requirements,O
",",O
the,O
Nigerian,O
government,O
implicitly,O
agrees,O
that,O
CSOs,O
working,O
to,O
mitigate,O
HIV,B-OG
are,O
apolitical,O
actors,O
.,O
The,O
federal,O
government,O
",",O
of,O
course,O
",",O
has,O
every,O
reason,O
to,O
accept,O
this,O
framing,O
.,O
Instead,O
of,O
empowering,O
CSOs,O
to,O
advocate,O
for,O
increased,O
state,O
responses,O
to,O
the,O
HIV,B-OG
epidemic,O
",",O
they,O
can,O
co,O
-,O
opt,O
CSOs,O
into,O
service,O
delivery,O
roles,O
that,O
extend,O
the,O
reach,O
of,O
government,O
to,O
communities,O
without,O
services,O
.,O
This,O
intermediary,O
role,O
also,O
allows,O
the,O
federal,O
government,O
to,O
retain,O
control,O
over,O
funding,O
",",O
further,O
strengthening,O
the,O
power,O
of,O
the,O
state,O
vis,O
-,O
à,O
-,O
vis,O
civil,O
society,O
.,O
As,O
a,O
result,O
",",O
the,O
incentives,O
of,O
the,O
federal,O
government,O
and,O
donors,O
are,O
often,O
aligned,O
.,O
The,O
federal,O
government,O
is,O
acting,O
in,O
support,O
of,O
international,O
donor,O
goals,O
:,O
disbursing,O
service,O
delivery,O
grants,O
and,O
monitoring,O
CSO,O
progress,O
.,O
When,O
CSOs,O
do,O
get,O
involved,O
in,O
policy,O
",",O
they,O
participate,O
in,O
government,O
-,O
directed,O
",",O
and,O
donor,O
-,O
demanded,O
processes,O
",",O
such,O
as,O
HIV,B-OG
strategy,O
or,O
policy,O
development,O
.,O
Civil,O
society,O
service,O
delivery,O
weakens,O
state,O
governments,O
Unlike,O
the,O
federal,O
government,O
",",O
state,O
governments,O
have,O
little,O
to,O
no,O
defined,O
role,O
in,O
monitoring,O
",",O
overseeing,O
",",O
or,O
determining,O
which,O
services,O
civil,O
society,O
provides,O
.,O
SACAs,O
have,O
little,O
to,O
no,O
role,O
in,O
the,O
grant,O
disbursement,O
process,O
or,O
independent,O
funding,O
",",O
and,O
CSOs,O
see,O
little,O
need,O
to,O
report,O
to,O
",",O
or,O
coordinate,O
activities,O
with,O
",",O
them,O
.,O
State,O
governments,O
are,O
often,O
bypassed,O
by,O
the,O
federal,O
government,O
",",O
who,O
coordinates,O
directly,O
with,O
CSOs,O
.,O
As,O
a,O
result,O
",",O
even,O
when,O
states,O
have,O
specific,O
HIV,B-OG
strategies,O
or,O
policies,O
",",O
state,O
officials,O
have,O
little,O
influence,O
on,O
HIV,B-OG
prevention,O
and,O
mitigation,O
activities,O
.,O
Larger,O
CSOs,O
were,O
more,O
likely,O
to,O
have,O
better,O
developed,O
advocacy,O
mechanisms,O
Though,O
our,O
study,O
did,O
not,O
look,O
directly,O
at,O
unrestricted,O
funding,O
",",O
larger,O
organizations,O
do,O
have,O
a,O
wider,O
variety,O
of,O
funding,O
sources,O
",",O
greater,O
potential,O
for,O
generating,O
overhead,O
",",O
and,O
",",O
therefore,O
",",O
more,O
resources,O
to,O
conduct,O
advocacy,O
.,O
Of,O
course,O
",",O
resources,O
are,O
not,O
the,O
only,O
metric,O
to,O
consider,O
.,O
At,O
its,O
core,O
",",O
technical,O
capacity,O
to,O
analyze,O
policy,O
or,O
engage,O
with,O
the,O
government,O
",",O
is,O
a,O
product,O
of,O
institutional,O
decisions,O
about,O
how,O
to,O
allocate,O
resources,O
.,O
CSOs,O
must,O
also,O
see,O
institutional,O
value,O
in,O
allocating,O
scarce,O
resources,O
to,O
advocacy,O
efforts,O
.,O
A,O
few,O
do,O
see,O
this,O
value,O
at,O
the,O
federal,O
level,O
",",O
where,O
a,O
number,O
of,O
advocacy,O
organizations,O
are,O
focused,O
",",O
but,O
they,O
also,O
bypass,O
state,O
governments,O
as,O
irrelevant,O
to,O
their,O
work,O
.,O
CSOs,O
respond,O
to,O
donor,O
and,O
government,O
influence,O
by,O
focusing,O
efforts,O
at,O
the,O
local,O
level,O
Consistent,O
with,O
the,O
donor,O
emphasis,O
on,O
service,O
delivery,O
",",O
CSOs,O
reported,O
focusing,O
their,O
advocacy,O
efforts,O
on,O
village,O
leaders,O
and,O
the,O
community,O
to,O
influence,O
behavior,O
change,O
.,O
This,O
focus,O
on,O
influencing,O
village,O
leaders,O
is,O
a,O
rational,O
response,O
to,O
both,O
donor,O
preferences,O
and,O
the,O
limited,O
community,O
-,O
level,O
reach,O
of,O
the,O
Nigerian,O
government,O
.,O
As,O
a,O
result,O
",",O
most,O
CSOs,O
have,O
little,O
contact,O
with,O
government,O
at,O
any,O
level,O
.,O
While,O
they,O
are,O
often,O
members,O
of,O
networks,O
that,O
ostensibly,O
advocate,O
for,O
their,O
interests,O
at,O
the,O
federal,O
level,O
",",O
these,O
networks,O
",",O
as,O
has,O
been,O
shown,O
earlier,O
",",O
actually,O
take,O
direction,O
from,O
the,O
federal,O
government,O
.,O
Conclusions,O
Over,O
the,O
last,O
decade,O
",",O
billions,O
of,O
dollars,O
have,O
flowed,O
through,O
civil,O
society,O
to,O
prevent,O
and,O
mitigate,O
the,O
effects,O
of,O
HIV,B-OG
.,O
Comparatively,O
little,O
funding,O
has,O
been,O
available,O
to,O
support,O
civil,O
society,O
to,O
challenge,O
repressive,O
policies,O
",",O
advocate,O
for,O
better,O
government,O
services,O
",",O
or,O
hold,O
government,O
accountable,O
for,O
upholding,O
their,O
obligations,O
in,O
the,O
response,O
to,O
HIV,B-OG
.,O
With,O
new,O
emphasis,O
on,O
raising,O
domestic,O
resources,O
to,O
prevent,O
and,O
mitigate,O
HIV,B-OG
",",O
the,O
era,O
of,O
abundant,O
international,O
funding,O
is,O
over,O
.,O
CSOs,O
will,O
have,O
to,O
learn,O
how,O
to,O
hold,O
governments,O
accountable,O
for,O
meeting,O
the,O
commitments,O
to,O
which,O
they,O
have,O
agreed,O
",",O
in,O
order,O
to,O
maintain,O
the,O
momentum,O
that,O
has,O
been,O
built,O
over,O
the,O
last,O
decade,O
.,O
Donor,O
and,O
government,O
actions,O
toward,O
CSOs,O
",",O
which,O
have,O
mostly,O
accommodated,O
an,O
apolitical,O
and,O
service,O
delivery,O
focus,O
",",O
will,O
also,O
have,O
to,O
change,O
to,O
ensure,O
that,O
governments,O
lead,O
HIV,B-OG
mitigation,O
and,O
prevention,O
efforts,O
.,O
Abbreviations,O
AIDS,B-DS
",",O
Acquired,B-DS
Immunodeficiency,I-DS
Syndrome,I-DS
;,O
CSO,O
",",O
Civil,O
Society,O
Organization,O
;,O
CSPro,O
",",O
Census,O
and,O
Survey,O
Processing,O
System,O
;,O
DFID,O
",",O
Department,O
for,O
International,O
Development,O
;,O
HAF,O
",",O
HIV,B-OG
/,O
AIDS,B-DS
Fund,O
;,O
HERFON,O
",",O
Health,O
Reform,O
Foundation,O
of,O
Nigeria,O
;,O
HIV,B-OG
",",O
Human,B-OG
Immunodeficiency,I-OG
Virus,I-OG
;,O
NACA,O
",",O
National,O
Agency,O
for,O
the,O
Control,O
of,O
AIDS,B-DS
;,O
PCA,O
",",O
Principal,O
Components,O
Analysis,O
;,O
PEPFAR,O
",",O
Presidents,O
Emergency,O
Plan,O
for,O
AIDS,B-DS
Relief,O
;,O
PPFN,O
",",O
Planned,O
Parenthood,O
Foundation,O
of,O
Nigeria,O
;,O
SACA,O
",",O
State,O
AIDS,B-DS
Control,O
Agency,O
;,O
SPSS,O
",",O
Statistical,O
Package,O
for,O
the,O
Social,O
Sciences,O
;,O
UNAIDS,O
",",O
Joint,O
United,O
Nations,O
Programme,O
on,O
HIV,B-OG
/,O
AIDS,B-DS
;,O
USAID,O
",",O
United,O
States,O
Agency,O
for,O
International,O
Development,O
Diversity,O
of,O
Plasmodium,B-OG
falciparum,I-OG
Chloroquine,B-GP
Resistance,I-GP
Transporter,I-GP
(,O
pfcrt,B-GP
),O
Exon,O
2,O
Haplotypes,O
in,O
the,O
Pacific,O
from,O
1959,O
to,O
1979,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
RMG,O
JKL,O
.,O
Performed,O
the,O
experiments,O
:,O
CWC,O
RS,O
DMR,O
SEM,O
.,O
Analyzed,O
the,O
data,O
:,O
CWC,O
JKL,O
.,O
Contributed,O
reagents,O
/,O
materials,O
/,O
analysis,O
tools,O
:,O
RMG,O
JKL,O
.,O
Wrote,O
the,O
paper,O
:,O
CWC,O
RMG,O
JKL,O
.,O
Nearly,O
one,O
million,O
deaths,O
are,O
attributed,O
to,O
malaria,B-DS
every,O
year,O
.,O
Recent,O
reports,O
of,O
multi,O
-,O
drug,O
treatment,O
failure,O
of,O
falciparum,B-OG
malaria,B-DS
underscore,O
the,O
need,O
to,O
understand,O
the,O
molecular,O
basis,O
of,O
drug,O
resistance,O
.,O
Multiple,O
mutations,O
in,O
the,O
Plasmodium,B-OG
falciparum,I-OG
chloroquine,B-GP
resistance,I-GP
transporter,I-GP
(,O
pfcrt,B-GP
),O
are,O
involved,O
in,O
chloroquine,O
resistance,O
",",O
but,O
the,O
evolution,O
of,O
complex,O
haplotypes,O
is,O
not,O
yet,O
well,O
understood,O
.,O
Using,O
over,O
4,O
",",O
500,O
archival,O
human,B-OG
serum,O
specimens,O
collected,O
from,O
19,O
Pacific,O
populations,O
between,O
1959,O
and,O
1979,O
",",O
the,O
period,O
including,O
and,O
just,O
prior,O
to,O
the,O
appearance,O
of,O
chloroquine,O
treatment,O
failure,O
in,O
the,O
Pacific,O
",",O
we,O
PCR,O
-,O
amplified,O
and,O
sequenced,O
a,O
portion,O
of,O
the,O
pfcrt,B-GP
exon,O
2,O
from,O
771,O
P,B-OG
.,I-OG
falciparum,I-OG
-,O
infected,O
individuals,O
to,O
explore,O
the,O
spatial,O
and,O
temporal,O
variation,O
in,O
falciparum,B-OG
malaria,B-DS
prevalence,O
and,O
the,O
evolution,O
of,O
chloroquine,O
resistance,O
.,O
In,O
the,O
Pacific,O
",",O
the,O
prevalence,O
of,O
P,B-OG
.,I-OG
falciparum,I-OG
varied,O
considerably,O
across,O
ecological,O
zones,O
.,O
On,O
the,O
island,O
of,O
New,O
Guinea,O
",",O
the,O
decreases,O
in,O
prevalence,O
of,O
P,B-OG
.,I-OG
falciparum,I-OG
in,O
coastal,O
",",O
high,O
-,O
transmission,O
areas,O
over,O
time,O
were,O
contrasted,O
by,O
the,O
increase,O
in,O
prevalence,O
during,O
the,O
same,O
period,O
in,O
the,O
highlands,O
",",O
where,O
transmission,O
was,O
intermittent,O
.,O
We,O
found,O
78,O
unique,O
pfcrt,B-GP
haplotypes,O
consisting,O
of,O
34,O
amino,O
acid,O
substitutions,O
and,O
28,O
synonymous,O
mutations,O
.,O
More,O
importantly,O
",",O
two,O
pfcrt,B-GP
mutations,O
(,O
N75D,O
and,O
K76T,O
),O
implicated,O
in,O
chloroquine,O
resistance,O
were,O
present,O
in,O
parasites,O
from,O
New,O
Hebrides,O
(,O
now,O
Vanuatu,O
),O
eight,O
years,O
before,O
the,O
first,O
report,O
of,O
treatment,O
failure,O
.,O
Our,O
results,O
also,O
revealed,O
unexpectedly,O
high,O
levels,O
of,O
genetic,O
diversity,O
in,O
pfcrt,B-GP
exon,O
2,O
prior,O
to,O
the,O
historical,O
chloroquine,O
resistance,O
selective,O
sweep,O
",",O
particularly,O
in,O
areas,O
where,O
disease,O
burden,O
was,O
relatively,O
low,O
.,O
In,O
the,O
Pacific,O
",",O
parasite,O
genetic,O
isolation,O
",",O
as,O
well,O
as,O
host,O
acquired,O
immune,O
status,O
and,O
genetic,O
resistance,O
to,O
malaria,B-DS
",",O
were,O
important,O
contributors,O
to,O
the,O
evolution,O
of,O
chloroquine,O
resistance,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
.,O
Introduction,O
Malaria,B-DS
caused,O
approximately,O
243,O
million,O
clinical,O
cases,O
and,O
863,O
",",O
000,O
deaths,O
in,O
2008,O
[,O
1,O
].,O
The,O
development,O
of,O
resistance,O
to,O
chloroquine,O
(,O
CQ,O
"),",O
once,O
the,O
mainstay,O
of,O
malaria,B-DS
treatment,O
worldwide,O
",",O
has,O
exacerbated,O
malaria,B-DS
morbidity,O
and,O
mortality,O
over,O
the,O
last,O
few,O
decades,O
",",O
especially,O
in,O
sub,O
-,O
Saharan,O
Africa,O
[,O
2,O
"],",O
[,O
3,O
].,O
An,O
understanding,O
of,O
the,O
evolution,O
of,O
CQ,O
resistance,O
in,O
the,O
malaria,B-DS
parasite,O
Plasmodium,B-OG
falciparum,I-OG
is,O
crucial,O
to,O
providing,O
important,O
insights,O
into,O
the,O
mechanisms,O
by,O
which,O
parasites,O
respond,O
to,O
other,O
aminoquinolines,O
such,O
as,O
amodiaquine,O
",",O
which,O
are,O
currently,O
used,O
as,O
partner,O
drugs,O
with,O
artesunate,O
in,O
artemisinin,O
-,O
based,O
combination,O
therapies,O
(,O
ACTs,O
).,O
Such,O
insights,O
are,O
urgently,O
needed,O
",",O
given,O
recent,O
evidence,O
of,O
diminished,O
efficacies,O
of,O
ACTs,O
in,O
Southeast,O
Asia,O
[,O
4,O
].,O
CQ,O
resistant,O
(,O
CQR,O
),O
P,B-OG
.,I-OG
falciparum,I-OG
show,O
diminished,O
accumulation,O
of,O
CQ,O
in,O
the,O
digestive,O
vacuole,O
(,O
DV,O
"),",O
and,O
this,O
phenotype,O
is,O
correlated,O
with,O
amino,O
acid,O
substitutions,O
in,O
the,O
DV,O
membrane,B-GP
transporter,I-GP
",",O
P,B-OG
.,I-OG
falciparum,I-OG
chloroquine,B-GP
resistance,I-GP
transporter,I-GP
(,O
pfCRT,B-GP
),O
[,O
5,O
].,O
In,O
pfCRT,B-GP
",",O
the,O
lysine,O
to,O
threonine,O
substitution,O
at,O
codon,O
position,O
76,O
(,O
K76T,O
),O
shows,O
the,O
most,O
consistent,O
correlation,O
with,O
CQ,O
resistance,O
",",O
but,O
as,O
many,O
as,O
eight,O
other,O
amino,O
acid,O
substitutions,O
are,O
also,O
involved,O
in,O
distinguishing,O
CQR,O
from,O
CQ,O
sensitive,O
(,O
CQS,O
),O
parasites,O
[,O
5,O
"],",O
[,O
6,O
].,O
Together,O
with,O
K76T,O
",",O
substitutions,O
at,O
positions,O
72,O
",",O
74,O
",",O
and,O
75,O
form,O
complex,O
CQR,O
pfcrt,B-GP
exon,O
2,O
haplotypes,O
that,O
correspond,O
to,O
the,O
geographical,O
origins,O
of,O
CQ,O
resistance,O
[,O
6,O
].,O
However,O
",",O
it,O
is,O
unclear,O
how,O
these,O
CQR,O
pfcrt,B-GP
haplotypes,O
arose,O
due,O
to,O
the,O
lack,O
of,O
previous,O
genetic,O
characterization,O
of,O
parasites,O
during,O
the,O
periods,O
of,O
CQ,O
resistance,O
emergence,O
.,O
Multiple,O
origins,O
of,O
CQ,O
resistance,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
have,O
been,O
suggested,O
based,O
on,O
epidemiological,O
data,O
[,O
7,O
],O
and,O
genetic,O
analyses,O
[,O
5,O
"],",O
[,O
6,O
].,O
CQ,O
treatment,O
failures,O
first,O
appeared,O
simultaneously,O
near,O
the,O
Thai,O
-,O
Cambodian,O
border,O
and,O
in,O
Colombia,O
in,O
the,O
late,O
1950s,O
",",O
and,O
CQR,O
parasites,O
spread,O
from,O
these,O
original,O
foci,O
to,O
neighboring,O
areas,O
[,O
7,O
].,O
Characterization,O
of,O
pfcrt,B-GP
haplotypes,O
from,O
laboratory,O
-,O
adapted,O
P,B-OG
.,I-OG
falciparum,I-OG
clones,O
provided,O
strong,O
support,O
for,O
these,O
two,O
independent,O
origins,O
of,O
CQ,O
resistance,O
",",O
and,O
the,O
invasion,O
of,O
CQR,O
parasites,O
from,O
Southeast,O
Asia,O
to,O
Africa,O
[,O
5,O
"],",O
[,O
6,O
].,O
In,O
Papua,O
New,O
Guinea,O
(,O
PNG,O
"),",O
CQ,O
treatment,O
failure,O
was,O
first,O
reported,O
in,O
1976,O
",",O
and,O
was,O
initially,O
assumed,O
to,O
indicate,O
the,O
expansion,O
of,O
CQR,O
P,B-OG
.,I-OG
falciparum,I-OG
from,O
Southeast,O
Asia,O
into,O
the,O
Pacific,O
[,O
7,O
"],",O
[,O
8,O
].,O
Examination,O
of,O
pfcrt,B-GP
polymorphisms,O
showed,O
that,O
despite,O
the,O
geographic,O
proximity,O
to,O
the,O
Southeast,O
Asian,O
focus,O
of,O
resistance,O
",",O
CQR,O
parasites,O
from,O
PNG,O
harbored,O
a,O
pfcrt,B-GP
exon,O
2,O
haplotype,O
similar,O
to,O
one,O
from,O
South,O
America,O
[,O
9,O
].,O
Since,O
these,O
pfcrt,B-GP
substitutions,O
were,O
associated,O
with,O
a,O
different,O
genetic,O
background,O
[,O
6,O
"],",O
[,O
10,O
"],",O
it,O
was,O
argued,O
that,O
PNG,O
represented,O
another,O
independent,O
focus,O
of,O
CQ,O
resistance,O
[,O
9,O
].,O
In,O
other,O
malarious,O
regions,O
of,O
the,O
Pacific,O
",",O
the,O
evolution,O
of,O
CQ,O
resistance,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
might,O
have,O
been,O
more,O
complex,O
.,O
Nagesha,O
et,O
al,O
.,O
[,O
11,O
],O
identified,O
four,O
pfcrt,B-GP
haplotypes,O
associated,O
with,O
CQ,O
resistance,O
in,O
field,O
isolates,O
from,O
Indonesian,O
Papua,O
(,O
West,O
New,O
Guinea,O
or,O
WNG,O
).,O
These,O
haplotypes,O
were,O
representative,O
of,O
both,O
the,O
Southeast,O
Asian,O
/,O
African,O
(,O
codon,O
72,O
–,O
76,O
:,O
CVIET,O
),O
and,O
the,O
PNG,O
/,O
South,O
American,O
(,O
codon,O
72,O
–,O
76,O
:,O
SVMNT,O
),O
CQR,O
haplotypes,O
",",O
and,O
a,O
third,O
composite,O
(,O
codon,O
72,O
–,O
76,O
:,O
SVIET,O
),O
haplotype,O
.,O
This,O
region,O
of,O
the,O
Pacific,O
is,O
also,O
characterized,O
by,O
very,O
diverse,O
ecologies,O
which,O
affect,O
parasite,O
population,O
dynamics,O
that,O
in,O
turn,O
play,O
a,O
crucial,O
role,O
in,O
the,O
evolution,O
of,O
CQR,O
parasites,O
and,O
their,O
dispersals,O
[,O
12,O
].,O
In,O
this,O
regard,O
",",O
it,O
is,O
important,O
to,O
include,O
parasites,O
from,O
multiple,O
locales,O
and,O
examine,O
their,O
interactions,O
at,O
a,O
population,O
level,O
over,O
time,O
.,O
Archival,O
biological,O
specimens,O
have,O
been,O
shown,O
to,O
be,O
useful,O
in,O
studying,O
past,O
evolutionary,O
events,O
such,O
as,O
CQ,O
resistance,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
[,O
13,O
"],",O
[,O
14,O
].,O
We,O
reasoned,O
that,O
blood,O
samples,O
collected,O
prior,O
to,O
(,O
and,O
slightly,O
after,O
),O
the,O
mid,O
-,O
1970s,O
from,O
populations,O
residing,O
in,O
the,O
malarious,O
Pacific,O
might,O
contain,O
DNA,O
from,O
P,B-OG
.,I-OG
falciparum,I-OG
that,O
was,O
under,O
increasing,O
CQ,O
selection,O
.,O
Genotyping,O
of,O
pfcrt,B-GP
might,O
therefore,O
provide,O
important,O
insights,O
into,O
the,O
evolution,O
of,O
the,O
complex,O
CQR,O
haplotypes,O
.,O
Additionally,O
",",O
by,O
including,O
samples,O
from,O
multiple,O
locations,O
collected,O
at,O
various,O
time,O
periods,O
",",O
we,O
sought,O
to,O
examine,O
the,O
spatial,O
and,O
temporal,O
dynamics,O
of,O
the,O
evolution,O
and,O
spread,O
of,O
CQR,O
P,B-OG
.,I-OG
falciparum,I-OG
across,O
the,O
diverse,O
environments,O
in,O
the,O
Pacific,O
[,O
12,O
].,O
Results,O
from,O
our,O
study,O
indicated,O
that,O
pfcrt,B-GP
exon,O
2,O
was,O
highly,O
diverse,O
prior,O
to,O
the,O
CQ,O
selective,O
sweep,O
",",O
and,O
suggested,O
that,O
CQ,O
resistance,O
in,O
the,O
Pacific,O
evolved,O
in,O
situ,O
and,O
arose,O
first,O
in,O
low,O
transmission,O
areas,O
",",O
where,O
host,O
populations,O
had,O
minimal,O
genetic,O
resistance,O
and,O
acquired,O
immunity,O
against,O
malaria,B-DS
infections,B-DS
.,O
Results,O
Overall,O
",",O
771,O
of,O
4598,O
(,O
16,O
.,O
8,O
%),O
specimens,O
from,O
19,O
populations,O
were,O
positive,O
for,O
P,B-OG
.,I-OG
falciparum,I-OG
(,O
Figure,O
1,O
",",O
Table,O
S1,O
"),",O
as,O
determined,O
by,O
successful,O
PCR,O
amplification,O
and,O
DNA,O
sequencing,O
of,O
a,O
195,O
-,O
bp,O
segment,O
of,O
pfcrt,B-GP
exon,O
2,O
corresponding,O
to,O
codon,O
positions,O
36,O
to,O
99,O
.,O
Rates,O
of,O
P,B-DS
.,I-DS
falciparum,I-DS
infection,I-DS
ranged,O
from,O
0,O
%,O
in,O
the,O
Papua,O
New,O
Guinea,O
(,O
PNG,O
),O
eastern,O
highlands,O
sample,O
of,O
BAR62,O
and,O
the,O
West,O
New,O
Guinea,O
(,O
WNG,O
),O
coastal,O
sample,O
of,O
MRK61,O
to,O
55,O
.,O
4,O
%,O
in,O
the,O
WNG,O
coastal,O
sample,O
of,O
SWC60,O
(,O
Figure,O
1,O
",",O
Table,O
S1,O
).,O
When,O
analyzed,O
by,O
ecological,O
zones,O
",",O
coastal,O
populations,O
from,O
both,O
WNG,O
and,O
PNG,O
showed,O
the,O
highest,O
average,O
rates,O
of,O
P,B-DS
.,I-DS
falciparum,I-DS
infection,I-DS
at,O
26,O
.,O
9,O
%,O
and,O
20,O
.,O
3,O
"%,",O
respectively,O
",",O
followed,O
by,O
those,O
from,O
Island,O
Melanesia,O
at,O
17,O
.,O
4,O
%,O
and,O
PNG,O
Papuan,O
Plateau,O
at,O
13,O
.,O
6,O
"%,",O
with,O
those,O
from,O
the,O
PNG,O
eastern,O
highlands,O
showing,O
the,O
lowest,O
rate,O
at,O
3,O
.,O
14,O
%,O
(,O
Table,O
S1,O
).,O
Our,O
results,O
from,O
PNG,O
were,O
consistent,O
with,O
the,O
observation,O
that,O
malaria,B-DS
prevalence,O
decreases,O
with,O
increasing,O
altitude,O
[,O
15,O
].,O
Approximate,O
locations,O
of,O
populations,O
.,O
Populations,O
are,O
denoted,O
by,O
their,O
sample,O
codes,O
(,O
Table,O
S1,O
),O
and,O
assigned,O
to,O
one,O
of,O
five,O
ecological,O
zones,O
as,O
indicated,O
by,O
colors,O
as,O
followed,O
:,O
WNG,O
coast,O
(,O
purple,O
"),",O
PNG,O
coasts,O
(,O
green,O
"),",O
PNG,O
Papuan,O
Plateau,O
(,O
blue,O
"),",O
PNG,O
eastern,O
highlands,O
(,O
red,O
"),",O
and,O
Island,O
Melanesia,O
(,O
orange,O
).,O
Samples,O
collected,O
from,O
the,O
same,O
locations,O
in,O
different,O
years,O
(,O
e,O
.,O
g,O
.,O
SWC60,O
",",O
SWC62,O
",",O
and,O
SWC69,O
),O
did,O
not,O
represent,O
repeated,O
samplings,O
from,O
the,O
same,O
populations,O
.,O
For,O
three,O
of,O
the,O
five,O
ecological,O
zones,O
",",O
longitudinal,O
samples,O
allowed,O
for,O
crude,O
estimates,O
of,O
temporal,O
variation,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
prevalences,O
.,O
On,O
the,O
WNG,O
coast,O
",",O
the,O
infection,B-DS
rates,O
remained,O
high,O
from,O
1960,O
to,O
1969,O
",",O
while,O
on,O
the,O
PNG,O
coasts,O
",",O
there,O
was,O
a,O
steady,O
decrease,O
in,O
prevalence,O
from,O
1960,O
to,O
1979,O
.,O
In,O
contrast,O
",",O
P,B-OG
.,I-OG
falciparum,I-OG
prevalence,O
increased,O
slightly,O
over,O
the,O
same,O
period,O
in,O
the,O
PNG,O
eastern,O
highlands,O
(,O
Figure,O
2,O
).,O
Temporal,O
variation,O
in,O
P,B-DS
.,I-DS
falciparum,I-DS
infection,I-DS
rates,O
(,O
bar,O
),O
and,O
pfcrt,B-GP
haplotype,O
diversities,O
(,O
line,O
).,O
Ecological,O
zones,O
are,O
indicated,O
by,O
colors,O
as,O
followed,O
:,O
PNG,O
eastern,O
highlands,O
(,O
red,O
"),",O
WNG,O
coast,O
(,O
purple,O
"),",O
and,O
PNG,O
coasts,O
(,O
green,O
).,O
Approximately,O
8,O
.,O
95,O
%,O
(,O
69,O
/,O
771,O
),O
of,O
P,B-OG
.,I-OG
falciparum,I-OG
-,O
positive,O
specimens,O
showed,O
two,O
distinct,O
pfcrt,B-GP
exon,O
2,O
genotypes,O
",",O
yielding,O
a,O
total,O
of,O
840,O
sequences,O
(,O
GenBank,O
accession,O
numbers,O
HM019533,O
–,O
HM020128,O
",",O
HM020130,O
–,O
HM020332,O
",",O
and,O
HM202334,O
–,O
HM020374,O
).,O
Samples,O
from,O
the,O
PNG,O
eastern,O
highlands,O
and,O
Island,O
Melanesia,O
showed,O
the,O
highest,O
frequencies,O
of,O
individuals,O
with,O
multiple,O
infections,B-DS
(,O
Table,O
S1,O
).,O
Seventy,O
eight,O
unique,O
pfcrt,B-GP
haplotypes,O
were,O
identified,O
",",O
of,O
which,O
the,O
wildtype,O
pfcrt,B-GP
sequence,O
accounted,O
for,O
83,O
.,O
8,O
%,O
(,O
704,O
/,O
840,O
),O
of,O
sequences,O
.,O
We,O
calculated,O
pfcrt,B-GP
haplotye,O
diversities,O
to,O
compare,O
the,O
amounts,O
of,O
genetic,O
variation,O
among,O
populations,O
and,O
ecological,O
zones,O
.,O
Haplotype,O
diversity,O
indices,O
range,O
between,O
0,O
and,O
1,O
.,O
A,O
measure,O
of,O
0,O
indicates,O
that,O
all,O
haplotypes,O
within,O
a,O
population,O
or,O
ecological,O
zone,O
are,O
identical,O
to,O
one,O
another,O
",",O
whereas,O
a,O
measure,O
of,O
1,O
indicates,O
that,O
all,O
haplotypes,O
within,O
a,O
population,O
or,O
ecological,O
zone,O
are,O
unique,O
.,O
When,O
analyzed,O
by,O
individual,O
populations,O
",",O
pfcrt,B-GP
haplotype,O
diversity,O
ranged,O
from,O
0,O
in,O
EHP60,O
",",O
WSP65,O
",",O
and,O
ONB69,O
",",O
to,O
0,O
.,O
722,O
in,O
EHP79,O
(,O
Table,O
S1,O
).,O
When,O
grouped,O
into,O
ecological,O
zones,O
",",O
populations,O
from,O
the,O
PNG,O
eastern,O
highlands,O
and,O
Island,O
Melanesia,O
had,O
higher,O
haplotype,O
diversities,O
than,O
those,O
from,O
the,O
other,O
ecological,O
zones,O
",",O
although,O
the,O
difference,O
was,O
not,O
statistically,O
significant,O
(,O
ANOVA,O
;,O
p,O
=,O
0,O
.,O
106,O
),O
(,O
Table,O
S1,O
).,O
Pfcrt,B-GP
haplotype,O
diversities,O
did,O
not,O
vary,O
substantially,O
over,O
time,O
along,O
the,O
WNG,O
coast,O
",",O
but,O
in,O
both,O
PNG,O
coasts,O
and,O
eastern,O
highlands,O
the,O
levels,O
of,O
diversity,O
showed,O
substantial,O
fluctuations,O
",",O
with,O
an,O
appreciable,O
increase,O
over,O
time,O
in,O
the,O
PNG,O
eastern,O
highlands,O
(,O
Figure,O
2,O
).,O
Among,O
the,O
77,O
mutant,O
pfcrt,B-GP
haplotypes,O
",",O
non,O
-,O
synonymous,O
substitutions,O
were,O
more,O
abundant,O
(,O
34,O
vs,O
.,O
28,O
),O
and,O
occurred,O
more,O
frequently,O
(,O
94,O
vs,O
.,O
75,O
),O
than,O
synonymous,O
substitutions,O
.,O
During,O
the,O
two,O
early,O
periods,O
(,O
1959,O
–,O
61,O
and,O
1962,O
–,O
65,O
"),",O
no,O
differences,O
were,O
found,O
in,O
the,O
distribution,O
of,O
mutant,O
pfcrt,B-GP
haplotypes,O
among,O
populations,O
(,O
Figures,O
3,O
",",O
4,O
).,O
Between,O
1969,O
and,O
1972,O
",",O
significantly,O
more,O
(,O
p,O
<,O
0,O
.,O
001,O
),O
mutant,O
pfcrt,B-GP
haplotypes,O
were,O
found,O
in,O
populations,O
from,O
Island,O
Melanesia,O
than,O
those,O
from,O
the,O
PNG,O
Papuan,O
Plateau,O
and,O
the,O
WNG,O
coast,O
(,O
Figure,O
5,O
).,O
In,O
1979,O
",",O
the,O
PNG,O
eastern,O
highlands,O
have,O
significantly,O
more,O
(,O
p,O
=,O
0,O
.,O
018,O
),O
mutant,O
pfcrt,B-GP
haplotypes,O
than,O
the,O
PNG,O
coast,O
(,O
Figure,O
6,O
).,O
Fifty,O
two,O
(,O
67,O
.,O
5,O
%),O
mutant,O
pfcrt,B-GP
haplotypes,O
contained,O
at,O
least,O
one,O
non,O
-,O
synonymous,O
substitution,O
.,O
Most,O
mutations,O
observed,O
were,O
either,O
private,O
or,O
present,O
at,O
very,O
low,O
frequencies,O
.,O
Only,O
five,O
mutant,O
haplotypes,O
(,O
6,O
",",O
14,O
",",O
24,O
",",O
26,O
",",O
and,O
39,O
),O
were,O
found,O
in,O
five,O
or,O
more,O
individuals,O
(,O
Figures,O
3,O
–,O
6,O
).,O
Three,O
amino,O
acid,O
substitutions,O
previously,O
implicated,O
in,O
CQ,O
resistance,O
were,O
detected,O
in,O
our,O
samples,O
.,O
In,O
NNH72,O
",",O
the,O
N75D,O
(,O
codon,O
72,O
–,O
76,O
:,O
CVMDK,O
),O
and,O
the,O
K76T,O
(,O
codon,O
72,O
–,O
76,O
:,O
CVMNT,O
),O
substitutions,O
were,O
found,O
individually,O
in,O
two,O
specimens,O
(,O
Figure,O
5,O
"),",O
while,O
the,O
K76N,O
(,O
codon,O
72,O
–,O
76,O
:,O
CVMNN,O
),O
substitution,O
was,O
found,O
in,O
one,O
specimen,O
from,O
EHP79,O
(,O
Figure,O
6,O
).,O
Median,O
-,O
joining,O
network,O
of,O
pfcrt,B-GP
haplotypes,O
(,O
A,O
),O
and,O
alignment,O
of,O
translated,O
sequences,O
(,O
B,O
),O
from,O
1959,O
–,O
61,O
.,O
In,O
the,O
network,O
diagram,O
",",O
each,O
unique,O
pfcrt,B-GP
haplotype,O
is,O
represented,O
by,O
a,O
node,O
",",O
and,O
the,O
size,O
of,O
each,O
node,O
is,O
proportional,O
to,O
the,O
frequency,O
of,O
the,O
haplotype,O
.,O
Substitutions,O
are,O
represented,O
by,O
branches,O
",",O
with,O
the,O
branch,O
length,O
proportional,O
to,O
the,O
number,O
of,O
substitutions,O
.,O
Non,O
-,O
synonymous,O
substitutions,O
are,O
represented,O
by,O
branches,O
in,O
bold,O
.,O
Pfcrt,B-GP
haplotypes,O
that,O
appeared,O
in,O
more,O
than,O
one,O
time,O
period,O
are,O
noted,O
by,O
their,O
haplotype,O
numbers,O
.,O
In,O
the,O
amino,O
acid,O
sequence,O
alignment,O
",",O
the,O
shaded,O
region,O
represents,O
transmembrane,O
domain,O
1,O
.,O
Synonymous,O
substitutions,O
are,O
represented,O
by,O
dashes,O
(-),O
and,O
synonymous,O
substitutions,O
by,O
asterisks,O
(*).,O
Populations,O
are,O
denoted,O
by,O
their,O
sample,O
codes,O
(,O
Table,O
S1,O
).,O
Median,O
-,O
joining,O
network,O
of,O
pfcrt,B-GP
haplotypes,O
(,O
A,O
),O
and,O
alignment,O
of,O
translated,O
sequences,O
(,O
B,O
),O
from,O
1962,O
–,O
5,O
.,O
Median,O
-,O
joining,O
network,O
of,O
pfcrt,B-GP
haplotypes,O
(,O
A,O
),O
and,O
alignment,O
of,O
translated,O
sequences,O
(,O
B,O
),O
from,O
1969,O
–,O
72,O
.,O
Hypothetical,O
nodes,O
are,O
indicated,O
by,O
arrows,O
.,O
Median,O
-,O
joining,O
network,O
of,O
pfcrt,B-GP
haplotypes,O
(,O
A,O
),O
and,O
alignment,O
of,O
translated,O
sequences,O
(,O
B,O
),O
from,O
1979,O
.,O
The,O
relationship,O
among,O
pfcrt,B-GP
exon,O
2,O
haplotypes,O
from,O
each,O
time,O
period,O
is,O
shown,O
by,O
a,O
median,O
-,O
joining,O
network,O
diagram,O
(,O
Figures,O
3,O
–,O
6,O
).,O
The,O
wildtype,O
pfcrt,B-GP
haplotype,O
was,O
shared,O
by,O
all,O
populations,O
.,O
Nine,O
mutant,O
pfcrt,B-GP
haplotypes,O
(,O
3,O
",",O
6,O
",",O
10,O
",",O
11,O
",",O
12,O
",",O
14,O
",",O
24,O
",",O
25,O
",",O
and,O
26,O
),O
were,O
found,O
in,O
samples,O
from,O
at,O
least,O
two,O
time,O
periods,O
(,O
Figures,O
3,O
–,O
6,O
).,O
Four,O
of,O
these,O
haplotypes,O
(,O
6,O
",",O
11,O
",",O
24,O
",",O
and,O
26,O
),O
harbored,O
non,O
-,O
synonymous,O
substitutions,O
while,O
the,O
remaining,O
five,O
had,O
only,O
synonymous,O
mutations,O
(,O
Figures,O
3,O
–,O
6,O
).,O
Overall,O
",",O
83,O
.,O
3,O
%,O
(,O
65,O
/,O
78,O
),O
of,O
haplotypes,O
were,O
population,O
specific,O
.,O
Of,O
the,O
12,O
mutant,O
pfcrt,B-GP
haplotypes,O
shared,O
between,O
two,O
or,O
more,O
populations,O
",",O
10,O
were,O
shared,O
between,O
populations,O
from,O
different,O
ecological,O
zones,O
.,O
We,O
also,O
calculated,O
pairwise,O
FST,O
genetic,O
distances,O
to,O
infer,O
gene,O
flow,O
among,O
parasite,O
populations,O
across,O
ecological,O
zones,O
and,O
persistence,O
of,O
parasite,O
populations,O
within,O
ecological,O
zones,O
over,O
time,O
.,O
Gene,O
flow,O
among,O
populations,O
from,O
the,O
same,O
time,O
period,O
",",O
as,O
defined,O
by,O
non,O
-,O
statistically,O
significant,O
(,O
p,O
>,O
0,O
.,O
05,O
),O
pairwise,O
FST,O
values,O
",",O
is,O
illustrated,O
in,O
Figure,O
7,O
.,O
During,O
the,O
two,O
early,O
periods,O
(,O
1959,O
–,O
61,O
and,O
1962,O
–,O
65,O
"),",O
parasite,O
populations,O
from,O
different,O
ecological,O
zones,O
were,O
not,O
significantly,O
differentiated,O
from,O
one,O
another,O
(,O
Figures,O
7A,O
and,O
7B,O
).,O
Between,O
1969,O
and,O
1972,O
",",O
parasite,O
populations,O
in,O
Island,O
Melanesia,O
were,O
significantly,O
differentiated,O
from,O
those,O
in,O
the,O
PNG,O
Papuan,O
Plateau,O
and,O
the,O
WNG,O
coast,O
(,O
Figure,O
7C,O
).,O
In,O
1979,O
",",O
parasites,O
in,O
the,O
PNG,O
eastern,O
highlands,O
were,O
significantly,O
differentiated,O
from,O
those,O
in,O
the,O
PNG,O
coast,O
(,O
Figure,O
7D,O
).,O
No,O
statistically,O
significant,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
FST,O
values,O
were,O
found,O
among,O
temporally,O
distinct,O
samples,O
within,O
the,O
same,O
ecological,O
region,O
",",O
suggesting,O
that,O
parasite,O
populations,O
within,O
a,O
particular,O
region,O
generally,O
persisted,O
through,O
time,O
.,O
The,O
spatial,O
and,O
temporal,O
patterns,O
of,O
gene,O
flow,O
as,O
inferred,O
from,O
pairwise,O
FST,O
distances,O
suggested,O
that,O
P,B-OG
.,I-OG
falciparum,I-OG
CQ,O
resistance,O
in,O
the,O
Pacific,O
likely,O
arose,O
locally,O
and,O
evolved,O
in,O
situ,O
.,O
Gene,O
flow,O
among,O
P,B-OG
.,I-OG
falciparum,I-OG
populations,O
from,O
different,O
ecological,O
zones,O
.,O
Gene,O
flow,O
among,O
parasite,O
populations,O
from,O
(,O
A,O
),O
1959,O
–,O
61,O
",",O
(,O
B,O
),O
1962,O
–,O
5,O
",",O
(,O
C,O
),O
1969,O
–,O
72,O
",",O
and,O
(,O
D,O
),O
1979,O
",",O
is,O
represented,O
by,O
solid,O
lines,O
.,O
Gene,O
flow,O
is,O
inferred,O
from,O
pairwise,O
FST,O
distances,O
determined,O
to,O
be,O
non,O
-,O
statistically,O
significant,O
(,O
p,O
>,O
0,O
.,O
05,O
).,O
Discussion,O
Malaria,B-DS
endemicity,O
in,O
the,O
Pacific,O
is,O
inversely,O
correlated,O
with,O
latitude,O
and,O
altitude,O
[,O
15,O
"],",O
[,O
16,O
].,O
In,O
PNG,O
",",O
malaria,B-DS
transmission,O
is,O
most,O
intense,O
in,O
coastal,O
lowlands,O
where,O
both,O
temperature,O
and,O
rainfall,O
remain,O
high,O
throughout,O
the,O
year,O
",",O
whereas,O
in,O
the,O
highlands,O
",",O
transmission,O
is,O
epidemic,O
and,O
coincides,O
with,O
the,O
conclusion,O
of,O
the,O
rainy,O
season,O
[,O
15,O
].,O
In,O
Vanuatu,O
",",O
a,O
Y,O
-,O
shaped,O
archipelago,O
that,O
extends,O
along,O
the,O
north,O
-,O
south,O
axis,O
in,O
the,O
southern,O
hemisphere,O
",",O
malaria,B-DS
transmission,O
in,O
the,O
northern,O
islands,O
is,O
in,O
general,O
more,O
intense,O
than,O
in,O
the,O
southern,O
islands,O
",",O
with,O
the,O
southernmost,O
island,O
of,O
Aneityum,O
being,O
free,O
of,O
malaria,B-DS
since,O
1991,O
[,O
16,O
"],",O
[,O
17,O
].,O
In,O
our,O
archival,O
samples,O
",",O
the,O
pattern,O
of,O
P,B-OG
.,I-OG
falciparum,I-OG
prevalences,O
as,O
determined,O
by,O
our,O
PCR,O
and,O
sequencing,O
assays,O
was,O
consistent,O
with,O
that,O
obtained,O
by,O
current,O
malariometric,O
surveys,O
.,O
Since,O
all,O
four,O
commonly,O
recognized,O
human,B-OG
malaria,B-DS
species,O
are,O
present,O
in,O
the,O
southwest,O
Pacific,O
[,O
15,O
"],",O
and,O
our,O
molecular,O
techniques,O
specifically,O
targeted,O
template,O
DNA,O
from,O
P,B-OG
.,I-OG
falciparum,I-OG
",",O
it,O
is,O
likely,O
that,O
the,O
rates,O
of,O
malaria,B-DS
infections,B-DS
in,O
these,O
archival,O
samples,O
were,O
higher,O
than,O
reported,O
here,O
",",O
especially,O
in,O
the,O
PNG,O
highlands,O
",",O
where,O
unstable,O
malaria,B-DS
transmission,O
has,O
historically,O
favored,O
the,O
predominance,O
of,O
P,B-OG
.,I-OG
vivax,I-OG
[,O
18,O
"],",O
[,O
19,O
].,O
The,O
prevalence,O
of,O
P,B-DS
.,I-DS
falciparum,I-DS
infections,I-DS
in,O
coastal,O
and,O
highland,O
samples,O
of,O
New,O
Guinea,O
showed,O
opposite,O
longitudinal,O
trends,O
",",O
which,O
are,O
consistent,O
with,O
changing,O
social,O
factors,O
of,O
the,O
times,O
.,O
In,O
the,O
coastal,O
lowlands,O
of,O
both,O
PNG,O
and,O
WNG,O
",",O
the,O
decreasing,O
prevalence,O
over,O
time,O
coincided,O
with,O
the,O
initiation,O
of,O
malaria,B-DS
eradication,O
programs,O
.,O
Malaria,B-DS
control,O
measures,O
began,O
in,O
both,O
PNG,O
and,O
WNG,O
in,O
1952,O
",",O
consisting,O
of,O
residual,O
insecticide,O
spraying,O
",",O
introduction,O
of,O
Gambusia,B-OG
spp,I-OG
.,I-OG
to,O
swampy,O
areas,O
",",O
and,O
in,O
some,O
places,O
mass,O
drug,O
administration,O
of,O
CQ,O
and,O
/,O
or,O
pyrimethamine,O
[,O
20,O
].,O
Although,O
complete,O
eradication,O
proved,O
elusive,O
",",O
notable,O
reduction,O
in,O
malaria,B-DS
prevalence,O
was,O
accomplished,O
in,O
many,O
lowland,O
areas,O
despite,O
technical,O
and,O
logistical,O
difficulties,O
[,O
20,O
]–[,O
23,O
].,O
In,O
contrast,O
to,O
the,O
overall,O
decrease,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
prevalence,O
in,O
the,O
lowlands,O
",",O
we,O
observed,O
a,O
slight,O
increase,O
in,O
infection,B-DS
rate,O
in,O
the,O
PNG,O
eastern,O
highlands,O
over,O
time,O
.,O
Radford,O
et,O
al,O
.,O
[,O
24,O
],O
argued,O
that,O
social,O
factors,O
were,O
important,O
in,O
changing,O
malaria,B-DS
epidemiology,O
in,O
the,O
highlands,O
.,O
Increased,O
contact,O
and,O
the,O
opening,O
of,O
the,O
Highland,O
Highways,O
facilitated,O
the,O
movement,O
of,O
people,O
and,O
malaria,B-DS
parasites,O
from,O
the,O
highly,O
malarious,O
coastal,O
areas,O
to,O
the,O
highlands,O
",",O
while,O
many,O
highlanders,O
recruited,O
as,O
wage,O
laborers,O
in,O
lowland,O
plantations,O
served,O
as,O
parasite,O
reservoirs,O
when,O
they,O
returned,O
to,O
the,O
highlands,O
.,O
Establishment,O
of,O
plantations,O
and,O
adoption,O
of,O
western,O
-,O
style,O
housing,O
in,O
the,O
highlands,O
also,O
created,O
additional,O
mosquito,O
breeding,O
sites,O
that,O
led,O
to,O
increased,O
malaria,B-DS
transmission,O
[,O
19,O
"],",O
[,O
24,O
].,O
The,O
increase,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
prevalence,O
in,O
our,O
PNG,O
eastern,O
highland,O
samples,O
might,O
also,O
represent,O
a,O
gradual,O
shift,O
in,O
species,O
predominance,O
from,O
P,B-OG
.,I-OG
vivax,I-OG
to,O
P,B-OG
.,I-OG
falciparum,I-OG
",",O
as,O
recently,O
noted,O
by,O
Mueller,O
et,O
al,O
.,O
[,O
19,O
"],",O
although,O
this,O
will,O
require,O
molecular,O
surveys,O
of,O
P,B-OG
.,I-OG
vivax,I-OG
to,O
confirm,O
.,O
In,O
the,O
Pacific,O
",",O
CQ,O
treatment,O
failure,O
was,O
first,O
reported,O
in,O
WNG,O
(,O
Irian,O
Jaya,O
),O
in,O
1974,O
[,O
25,O
],O
and,O
by,O
1980,O
resistance,O
had,O
been,O
confirmed,O
in,O
all,O
malaria,B-DS
endemic,O
countries,O
in,O
the,O
region,O
[,O
7,O
].,O
Two,O
CQ,O
resistance,O
-,O
implicated,O
amino,O
acid,O
substitutions,O
",",O
N75D,O
and,O
K76T,O
were,O
observed,O
individually,O
in,O
two,O
specimens,O
from,O
NNH72,O
",",O
resulting,O
in,O
the,O
haplotypes,O
CVMDK,O
and,O
CVMNT,O
",",O
respectively,O
.,O
The,O
pfcrt,B-GP
K76T,O
substitution,O
has,O
consistently,O
been,O
shown,O
to,O
correlate,O
with,O
CQ,O
resistance,O
[,O
5,O
"],",O
[,O
16,O
"],",O
[,O
26,O
"],",O
and,O
the,O
CVMNT,O
haplotype,O
has,O
previously,O
been,O
described,O
in,O
CQR,O
parasites,O
from,O
South,O
America,O
[,O
5,O
],O
and,O
Papua,O
[,O
11,O
].,O
The,O
N75D,O
substitution,O
was,O
associated,O
with,O
the,O
K76T,O
substitution,O
in,O
parasites,O
from,O
Cambodia,O
[,O
27,O
"],",O
Thailand,O
and,O
Laos,O
[,O
28,O
"],",O
although,O
in,O
the,O
absence,O
of,O
the,O
diagnostic,O
K76T,O
substitution,O
",",O
it,O
is,O
unclear,O
if,O
this,O
CVMDK,O
-,O
bearing,O
parasite,O
had,O
an,O
altered,O
response,O
to,O
CQ,O
.,O
The,O
presence,O
of,O
these,O
substitutions,O
in,O
parasites,O
from,O
northern,O
New,O
Hebrides,O
in,O
1972,O
agrees,O
with,O
the,O
long,O
held,O
suspicion,O
that,O
CQ,O
resistance,O
had,O
been,O
present,O
in,O
New,O
Hebrides,O
many,O
years,O
before,O
it,O
was,O
clinically,O
and,O
experimentally,O
confirmed,O
in,O
1980,O
[,O
29,O
"],",O
[,O
30,O
].,O
We,O
also,O
detected,O
the,O
replacement,O
of,O
lysine,O
by,O
asparagine,O
at,O
pfcrt,B-GP
codon,O
76,O
in,O
EHP79,O
.,O
This,O
K76N,O
substitution,O
was,O
previously,O
experimentally,O
induced,O
when,O
the,O
CQS,O
laboratory,O
clone,O
106,O
/,O
1,O
",",O
which,O
already,O
had,O
six,O
of,O
the,O
seven,O
pfcrt,B-GP
mutations,O
found,O
in,O
CQR,O
parasites,O
from,O
Asia,O
and,O
Africa,O
",",O
was,O
exposed,O
to,O
high,O
levels,O
of,O
CQ,O
[,O
31,O
].,O
However,O
",",O
it,O
is,O
unclear,O
whether,O
the,O
76N,O
bearing,O
parasite,O
we,O
identified,O
in,O
this,O
study,O
was,O
CQR,O
",",O
since,O
it,O
was,O
associated,O
with,O
a,O
different,O
pfcrt,B-GP
genetic,O
background,O
.,O
Whereas,O
the,O
mutant,O
106,O
/,O
1,O
parasite,O
carried,O
the,O
CVIEN,O
haplotype,O
[,O
31,O
"],",O
our,O
parasite,O
carried,O
the,O
CVMNN,O
haplotype,O
.,O
This,O
rare,O
haplotype,O
has,O
been,O
reported,O
twice,O
in,O
parasite,O
isolates,O
from,O
Indonesia,O
",",O
although,O
in,O
both,O
studies,O
the,O
in,O
vitro,O
response,O
to,O
CQ,O
was,O
not,O
evaluated,O
[,O
28,O
"],",O
[,O
32,O
].,O
Archival,O
biological,O
samples,O
from,O
PNG,O
provide,O
crucial,O
insights,O
into,O
the,O
evolution,O
and,O
spread,O
of,O
CQR,O
parasites,O
[,O
13,O
"],",O
[,O
14,O
"],",O
[,O
28,O
].,O
Using,O
samples,O
collected,O
from,O
12,O
locations,O
in,O
PNG,O
during,O
the,O
early,O
1980s,O
",",O
Mehlotra,O
et,O
al,O
.,O
[,O
13,O
],O
found,O
a,O
high,O
frequency,O
(,O
97,O
%;,O
33,O
/,O
34,O
),O
of,O
the,O
CQR,O
SVMNT,O
pfcrt,B-GP
haplotype,O
",",O
which,O
was,O
consistent,O
with,O
a,O
nation,O
-,O
wide,O
epidemiological,O
survey,O
reporting,O
widespread,O
CQ,O
resistance,O
conducted,O
during,O
that,O
period,O
[,O
33,O
].,O
In,O
contrast,O
",",O
the,O
CQS,O
CVMNK,O
haplotype,O
predominated,O
(,O
97,O
%;,O
34,O
/,O
35,O
),O
in,O
our,O
PNG,O
samples,O
collected,O
in,O
1979,O
(,O
EHP79,O
and,O
WSP79,O
"),",O
indicating,O
that,O
strong,O
CQ,O
selection,O
resulted,O
in,O
the,O
nearly,O
complete,O
replacement,O
of,O
CQS,O
parasites,O
by,O
their,O
resistant,O
counterparts,O
in,O
as,O
few,O
as,O
three,O
years,O
",",O
and,O
the,O
latter,O
',O
s,O
persistence,O
to,O
the,O
present,O
[,O
9,O
"],",O
[,O
34,O
].,O
It,O
is,O
unclear,O
whether,O
the,O
CVMNN,O
haplotype,O
observed,O
in,O
our,O
sample,O
represented,O
a,O
transitional,O
strain,O
that,O
ultimately,O
gave,O
rise,O
to,O
parasites,O
carrying,O
the,O
more,O
ubiquitous,O
SVMNT,O
haplotype,O
seen,O
today,O
",",O
or,O
was,O
replaced,O
by,O
invading,O
parasites,O
carrying,O
the,O
latter,O
haplotype,O
",",O
nonetheless,O
our,O
data,O
are,O
consistent,O
with,O
previous,O
interpretation,O
that,O
CQ,O
resistance,O
in,O
the,O
Pacific,O
evolved,O
in,O
situ,O
[,O
9,O
].,O
Analyses,O
of,O
additional,O
samples,O
from,O
this,O
critical,O
period,O
are,O
currently,O
underway,O
and,O
will,O
hopefully,O
shed,O
light,O
on,O
the,O
relationships,O
among,O
these,O
haplotypes,O
.,O
Of,O
the,O
34,O
amino,O
acid,O
substitutions,O
observed,O
in,O
our,O
samples,O
",",O
20,O
are,O
considered,O
to,O
be,O
non,O
-,O
conservative,O
",",O
involving,O
a,O
side,O
-,O
chain,O
property,O
change,O
in,O
either,O
polarity,O
and,O
/,O
or,O
charge,O
that,O
might,O
affect,O
the,O
function,O
of,O
the,O
protein,O
.,O
Two,O
such,O
substitutions,O
",",O
I59T,O
and,O
I63T,O
were,O
observed,O
in,O
14,O
and,O
19,O
samples,O
respectively,O
.,O
In,O
particular,O
",",O
mutant,O
pfcrt,B-GP
haplotypes,O
harboring,O
the,O
I63T,O
substitution,O
persisted,O
through,O
time,O
and,O
later,O
dispersed,O
into,O
multiple,O
regions,O
",",O
suggesting,O
that,O
these,O
haplotypes,O
may,O
reflect,O
a,O
drug,O
tolerant,O
if,O
not,O
resistant,O
phenotype,O
(,O
Figures,O
3,O
–,O
6,O
).,O
Transfections,O
of,O
CQS,O
P,B-OG
.,I-OG
falciparum,I-OG
clones,O
with,O
I63T,O
and,O
other,O
novel,O
substitutions,O
identified,O
in,O
this,O
study,O
are,O
currently,O
underway,O
to,O
evaluate,O
their,O
effects,O
on,O
CQ,O
response,O
.,O
It,O
remains,O
unclear,O
how,O
the,O
historical,O
use,O
of,O
other,O
antimalarials,O
prior,O
to,O
our,O
earliest,O
samples,O
(,O
1959,O
),O
might,O
have,O
contributed,O
to,O
the,O
selection,O
of,O
pfcrt,B-GP
alleles,O
observed,O
in,O
this,O
study,O
.,O
During,O
WWII,O
",",O
malaria,B-DS
was,O
a,O
major,O
cause,O
of,O
casualties,O
for,O
both,O
the,O
Japanese,O
and,O
the,O
Allied,O
troops,O
stationed,O
in,O
the,O
Southwest,O
Pacific,O
[,O
35,O
"],",O
[,O
36,O
].,O
Quinine,O
and,O
quinacrine,O
",",O
also,O
known,O
as,O
mepacrine,O
or,O
Atabrine,O
",",O
were,O
used,O
extensively,O
to,O
prevent,O
and,O
treat,O
malaria,B-DS
infections,B-DS
",",O
especially,O
among,O
Allied,O
soldiers,O
[,O
37,O
].,O
The,O
mode,O
of,O
action,O
for,O
quinine,O
is,O
thought,O
to,O
be,O
similar,O
to,O
that,O
of,O
CQ,O
[,O
38,O
"],",O
and,O
cross,O
resistance,O
with,O
CQ,O
has,O
been,O
suggested,O
[,O
39,O
"],",O
[,O
40,O
"],",O
although,O
the,O
association,O
between,O
quinine,O
resistance,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
and,O
specific,O
substitutions,O
in,O
pfcrt,B-GP
has,O
been,O
inconclusive,O
[,O
41,O
].,O
Quinacrine,O
resistance,O
was,O
first,O
noted,O
in,O
P,B-OG
.,I-OG
falciparum,I-OG
from,O
the,O
Wewak,O
-,O
Aitape,O
region,O
along,O
the,O
north,O
coast,O
of,O
New,O
Guinea,O
in,O
1944,O
[,O
37,O
].,O
We,O
did,O
observe,O
in,O
our,O
earliest,O
sample,O
from,O
the,O
same,O
region,O
(,O
ESP61,O
),O
a,O
non,O
-,O
synonymous,O
substitution,O
(,O
F48L,O
),O
at,O
relatively,O
high,O
frequency,O
(,O
6,O
.,O
1,O
%;,O
3,O
/,O
49,O
),O
(,O
Figure,O
3,O
"),",O
which,O
might,O
reflect,O
previous,O
selection,O
by,O
quinacrine,O
and,O
warrants,O
further,O
studies,O
.,O
However,O
",",O
it,O
should,O
be,O
noted,O
that,O
the,O
genetic,O
basis,O
for,O
quinacrine,O
resistance,O
is,O
unknown,O
",",O
and,O
the,O
use,O
of,O
quinacrine,O
was,O
largely,O
abandoned,O
after,O
WWII,O
in,O
favor,O
of,O
CQ,O
[,O
42,O
"],",O
such,O
that,O
little,O
selective,O
pressure,O
was,O
maintained,O
during,O
the,O
intervening,O
years,O
between,O
the,O
end,O
of,O
the,O
war,O
and,O
the,O
collection,O
of,O
our,O
samples,O
.,O
Four,O
factors,O
may,O
have,O
contributed,O
to,O
the,O
unexpectedly,O
higher,O
levels,O
of,O
pfcrt,B-GP
exon,O
2,O
genetic,O
diversity,O
in,O
parasites,O
from,O
the,O
PNG,O
eastern,O
highlands,O
and,O
Island,O
Melanesia,O
.,O
First,O
",",O
in,O
Island,O
Melanesia,O
the,O
high,O
level,O
of,O
parasite,O
genetic,O
diversity,O
might,O
have,O
resulted,O
from,O
population,O
structure,O
.,O
Samples,O
from,O
NNH72,O
and,O
SSI72,O
were,O
collected,O
from,O
populations,O
on,O
13,O
and,O
three,O
different,O
islands,O
",",O
respectively,O
.,O
While,O
variable,O
levels,O
of,O
travel,O
among,O
islands,O
within,O
each,O
archipelago,O
were,O
noted,O
[,O
43,O
"],",O
more,O
recently,O
extensive,O
human,B-OG
contact,O
has,O
been,O
essential,O
for,O
gene,O
flow,O
between,O
parasites,O
on,O
different,O
islands,O
[,O
44,O
"],",O
[,O
45,O
].,O
When,O
subdivided,O
into,O
individual,O
islands,O
",",O
parasites,O
on,O
some,O
islands,O
were,O
found,O
to,O
be,O
genetically,O
distinct,O
from,O
those,O
on,O
neighboring,O
islands,O
.,O
For,O
example,O
",",O
parasites,O
from,O
Gaua,O
in,O
northern,O
New,O
Hebrides,O
were,O
significantly,O
distinct,O
from,O
those,O
on,O
nearby,O
Mota,O
Lava,O
(,O
FST,O
=,O
0,O
.,O
04155,O
;,O
p,O
=,O
0,O
.,O
03604,O
),O
and,O
Vanua,O
Lava,O
(,O
FST,O
=,O
0,O
.,O
01819,O
;,O
p,O
=,O
0,O
.,O
03604,O
).,O
This,O
implies,O
that,O
isolation,O
and,O
genetic,O
drift,O
on,O
individual,O
islands,O
",",O
although,O
reducing,O
diversity,O
locally,O
",",O
have,O
increased,O
the,O
genetic,O
diversity,O
of,O
the,O
archipelago,O
as,O
a,O
whole,O
.,O
Second,O
",",O
in,O
these,O
areas,O
of,O
relatively,O
low,O
transmission,O
",",O
the,O
use,O
of,O
antimalarials,O
was,O
often,O
reserved,O
for,O
treatments,O
only,O
[,O
43,O
"],",O
such,O
that,O
intermittent,O
CQ,O
pressure,O
might,O
have,O
selected,O
for,O
a,O
suite,O
of,O
different,O
non,O
-,O
synonymous,O
substitutions,O
that,O
only,O
slightly,O
altered,O
the,O
parasites,O
',O
response,O
to,O
CQ,O
.,O
In,O
contrast,O
to,O
high,O
transmission,O
areas,O
where,O
competition,O
among,O
different,O
genetic,O
strains,O
is,O
intense,O
[,O
46,O
"],",O
even,O
in,O
the,O
absence,O
of,O
continuous,O
CQ,O
selection,O
",",O
genetic,O
drift,O
may,O
have,O
maintained,O
these,O
non,O
-,O
synonymous,O
substitutions,O
in,O
small,O
parasite,O
populations,O
as,O
suggested,O
by,O
low,O
rates,O
of,O
infection,B-DS
in,O
these,O
low,O
transmission,O
areas,O
.,O
Third,O
",",O
host,O
immune,O
status,O
played,O
an,O
important,O
role,O
in,O
the,O
occurrence,O
of,O
multiple,O
infections,B-DS
.,O
In,O
high,O
transmission,O
areas,O
the,O
host,O
acquired,O
immunity,O
to,O
malaria,B-DS
is,O
constantly,O
maintained,O
by,O
recurrent,O
infections,B-DS
",",O
whereas,O
in,O
low,O
transmission,O
areas,O
malaria,B-DS
infections,B-DS
by,O
multiple,O
genetic,O
strains,O
might,O
be,O
more,O
common,O
since,O
parasite,O
clearance,O
in,O
semi,O
-,O
immune,O
individuals,O
is,O
less,O
effective,O
[,O
47,O
].,O
In,O
this,O
study,O
",",O
the,O
frequencies,O
of,O
multiple,O
infections,B-DS
were,O
significantly,O
correlated,O
with,O
pfcrt,B-GP
haplotype,O
diversities,O
(,O
R2,O
=,O
0,O
.,O
9361,O
",",O
p,O
=,O
0,O
.,O
007,O
"),",O
suggesting,O
that,O
lowered,O
host,O
acquired,O
immunity,O
in,O
the,O
PNG,O
Eastern,O
Highlands,O
and,O
Island,O
Melanesia,O
might,O
have,O
contributed,O
to,O
the,O
high,O
level,O
of,O
parasite,O
genetic,O
diversities,O
in,O
these,O
low,O
transmission,O
areas,O
.,O
Lastly,O
",",O
differences,O
in,O
host,O
genetics,O
may,O
have,O
affected,O
the,O
degree,O
to,O
which,O
populations,O
living,O
in,O
different,O
ecological,O
regions,O
were,O
susceptible,O
to,O
infection,B-DS
by,O
multiple,O
genetic,O
strains,O
of,O
P,B-OG
.,I-OG
falciparum,I-OG
.,O
Strong,O
selection,O
in,O
the,O
coastal,O
lowland,O
populations,O
of,O
PNG,O
results,O
in,O
the,O
maintenance,O
of,O
a,O
number,O
of,O
red,O
cell,O
polymorphisms,O
conferring,O
resistance,O
to,O
malaria,B-DS
",",O
including,O
Southeast,O
Asian,O
ovalocytosis,B-DS
[,O
48,O
]–[,O
50,O
"],",O
alpha,B-DS
-,I-DS
thalassemia,I-DS
[,O
51,O
"],",O
beta,B-DS
-,I-DS
thalassemia,I-DS
[,O
52,O
"],",O
and,O
Gerbich,O
negativity,O
[,O
53,O
].,O
It,O
is,O
possible,O
that,O
in,O
high,O
transmission,O
areas,O
",",O
individuals,O
with,O
one,O
or,O
more,O
of,O
these,O
malaria,B-DS
resistant,O
alleles,O
present,O
a,O
less,O
hospitable,O
environment,O
to,O
parasites,O
",",O
such,O
that,O
only,O
those,O
that,O
are,O
most,O
adapted,O
",",O
i,O
.,O
e,O
.,O
either,O
wildtype,O
(,O
with,O
no,O
pfcrt,B-GP
mutations,O
),O
or,O
fully,O
CQR,O
(,O
with,O
a,O
complete,O
suite,O
of,O
CQR,O
pfcrt,B-GP
mutations,O
"),",O
can,O
survive,O
.,O
Conversely,O
in,O
low,O
transmission,O
areas,O
",",O
host,O
selection,O
against,O
parasites,O
might,O
be,O
less,O
severe,O
",",O
thus,O
allowing,O
slightly,O
less,O
fit,O
parasite,O
strains,O
",",O
i,O
.,O
e,O
.,O
those,O
with,O
only,O
one,O
or,O
two,O
pfcrt,B-GP
mutations,O
",",O
to,O
evolve,O
and,O
persist,O
.,O
Genetic,O
characterization,O
of,O
P,B-OG
.,I-OG
falciparum,I-OG
in,O
the,O
Pacific,O
from,O
the,O
period,O
of,O
CQ,O
resistance,O
emergence,O
revealed,O
that,O
prior,O
to,O
complete,O
CQ,O
selective,O
sweep,O
",",O
pfcrt,B-GP
exon,O
2,O
was,O
highly,O
diverse,O
",",O
highlighted,O
by,O
a,O
number,O
of,O
previously,O
undescribed,O
substitutions,O
including,O
several,O
implicated,O
in,O
CQ,O
resistance,O
",",O
consistent,O
with,O
in,O
situ,O
evolution,O
of,O
resistance,O
within,O
the,O
Pacific,O
.,O
In,O
addition,O
to,O
CQ,O
selection,O
",",O
isolation,O
among,O
parasite,O
populations,O
and,O
reduced,O
strain,O
competition,O
in,O
small,O
parasite,O
populations,O
",",O
combined,O
with,O
lowered,O
acquired,O
immunity,O
and,O
genetic,O
resistance,O
to,O
malaria,B-DS
among,O
hosts,O
in,O
low,O
transmission,O
areas,O
",",O
might,O
have,O
been,O
crucial,O
to,O
the,O
evolution,O
and,O
initial,O
establishment,O
of,O
CQR,O
P,B-OG
.,I-OG
falciparum,I-OG
in,O
the,O
Pacific,O
.,O
These,O
data,O
suggest,O
that,O
populations,O
at,O
the,O
peripheries,O
of,O
malaria,B-DS
endemic,O
areas,O
may,O
be,O
the,O
most,O
crucial,O
to,O
monitor,O
for,O
parasites,O
evolving,O
tolerance,O
and,O
resistance,O
to,O
currently,O
used,O
antimalarials,O
.,O
Materials,O
and,O
Methods,O
Ethics,O
Statement,O
This,O
study,O
was,O
submitted,O
to,O
the,O
Human,B-OG
Subjects,O
Research,O
Review,O
Committee,O
of,O
Binghamton,O
University,O
",",O
where,O
it,O
was,O
reviewed,O
and,O
determined,O
exempt,O
because,O
no,O
human,B-OG
DNA,O
was,O
examined,O
(,O
Protocol,O
#,O
787,O
-,O
08,O
).,O
Archival,O
Human,B-OG
Serum,O
Collections,O
Samples,O
used,O
in,O
this,O
study,O
were,O
provided,O
by,O
the,O
Binghamton,O
University,O
Serum,O
Archive,O
Facility,O
at,O
Binghamton,O
",",O
NY,O
",",O
USA,O
",",O
and,O
their,O
use,O
in,O
this,O
study,O
was,O
approved,O
by,O
the,O
institutional,O
review,O
board,O
of,O
Binghamton,O
University,O
.,O
Samples,O
were,O
collected,O
under,O
the,O
ethical,O
and,O
legal,O
guidelines,O
of,O
the,O
United,O
States,O
National,O
Institutes,O
of,O
Health,O
and,O
all,O
existing,O
international,O
standards,O
of,O
the,O
time,O
",",O
and,O
their,O
continued,O
use,O
for,O
biomedical,O
research,O
has,O
recently,O
been,O
reaffirmed,O
by,O
the,O
Papua,O
New,O
Guinea,O
Medical,O
Research,O
Advisory,O
Committee,O
(,O
documentation,O
available,O
upon,O
request,O
).,O
A,O
total,O
of,O
4598,O
specimens,O
from,O
19,O
Pacific,O
populations,O
sampled,O
between,O
1959,O
and,O
1979,O
was,O
included,O
in,O
this,O
study,O
.,O
The,O
locations,O
of,O
sample,O
collections,O
and,O
brief,O
descriptions,O
are,O
given,O
in,O
figure,O
1,O
and,O
table,O
S1,O
",",O
respectively,O
.,O
Samples,O
collected,O
from,O
the,O
same,O
locations,O
in,O
different,O
years,O
did,O
not,O
represent,O
repeated,O
samplings,O
of,O
the,O
same,O
populations,O
.,O
Nucleic,O
Acid,O
Extraction,O
DNA,O
was,O
extracted,O
from,O
200,O
µl,O
of,O
human,B-OG
serum,O
using,O
either,O
the,O
QIAamp,O
Blood,O
Mini,O
Kit,O
(,O
QIAgen,O
Biosciences,O
",",O
Germantown,O
",",O
MD,O
),O
or,O
the,O
automated,O
Maxwell,O
-,O
16,O
system,O
(,O
Promega,O
",",O
Madison,O
",",O
WI,O
),O
according,O
to,O
the,O
respective,O
manufacturers,O
',O
instructions,O
.,O
Eluted,O
DNA,O
was,O
frozen,O
at,O
−,O
20,O
°,O
C,O
until,O
use,O
.,O
Molecular,O
Analysis,O
A,O
segment,O
of,O
the,O
pfcrt,B-GP
exon,O
2,O
was,O
PCR,O
-,O
amplified,O
in,O
a,O
12,O
.,O
5,O
µl,O
reaction,O
containing,O
4,O
µl,O
of,O
DNA,O
",",O
0,O
.,O
2,O
mM,O
of,O
dNTP,O
",",O
2,O
mM,O
of,O
MgCl2,O
",",O
0,O
.,O
5,O
µM,O
of,O
each,O
primer,O
(,O
CRT76,O
-,O
sense,O
5,O
′-,O
GGTGGAGGTTCTTGTCTTGG,O
-,O
3,O
′,O
and,O
CRT76,O
-,O
antisense,O
5,O
′-,O
ATAAAGTTGTGAGTTTCGGATG,O
-,O
3,O
′),O
[,O
54,O
"],",O
and,O
0,O
.,O
25,O
unit,O
of,O
HotStar,O
Taq,B-OG
DNA,B-GP
polymerase,I-GP
(,O
QIAgen,O
Biosciences,O
",",O
Germantown,O
",",O
MD,O
).,O
The,O
cycling,O
conditions,O
consisted,O
of,O
15,O
minutes,O
at,O
95,O
°,O
C,O
",",O
90,O
seconds,O
at,O
61,O
°,O
C,O
",",O
60,O
seconds,O
at,O
72,O
°,O
C,O
for,O
1,O
cycle,O
;,O
10,O
seconds,O
at,O
95,O
°,O
C,O
",",O
90,O
seconds,O
at,O
61,O
°,O
C,O
",",O
and,O
2,O
minutes,O
at,O
72,O
°,O
C,O
for,O
50,O
cycles,O
",",O
and,O
a,O
final,O
extension,O
for,O
10,O
minutes,O
at,O
72,O
°,O
C,O
.,O
PCR,O
amplicons,O
were,O
purified,O
using,O
the,O
Millipore,O
Manu03050,O
Filter,O
Plate,O
(,O
Millipore,O
",",O
Billerica,O
",",O
MA,O
"),",O
and,O
were,O
sequenced,O
in,O
both,O
directions,O
using,O
internal,O
primers,O
",",O
CRTD1,O
5,O
′-,O
TGTGCTCATGTGTTTAAACTT,O
-,O
3,O
′,O
and,O
CRTD2,O
5,O
′-,O
CAAAACTATAGTTACCAATTTTG,O
-,O
3,O
′,O
[,O
55,O
"],",O
with,O
the,O
BigDye,O
Terminator,O
Kit,O
v,O
.,O
3,O
.,O
1,O
on,O
an,O
ABI,O
3730xl,O
DNA,O
Analyzer,O
(,O
Applied,O
Biosystems,O
",",O
Foster,O
City,O
",",O
CA,O
).,O
Electropherograms,O
were,O
visually,O
checked,O
using,O
Sequencing,O
Analysis,O
2,O
.,O
1,O
(,O
Applied,O
Biosystems,O
",",O
Foster,O
City,O
",",O
CA,O
).,O
Infection,B-DS
by,O
genetically,O
distinct,O
P,B-OG
.,I-OG
falciparum,I-OG
strains,O
was,O
inferred,O
when,O
heterologous,O
peaks,O
were,O
present,O
in,O
a,O
single,O
specimen,O
.,O
In,O
cases,O
where,O
heterologous,O
peaks,O
were,O
observed,O
at,O
more,O
than,O
one,O
nucleotide,O
position,O
in,O
a,O
single,O
specimen,O
",",O
pfcrt,B-GP
haplotypes,O
were,O
constructed,O
based,O
on,O
the,O
relative,O
peak,O
heights,O
at,O
each,O
nucleotide,O
position,O
in,O
question,O
.,O
Assuming,O
that,O
multiple,O
substitutions,O
in,O
a,O
lineage,O
arose,O
in,O
a,O
stepwise,O
manner,O
",",O
we,O
examined,O
the,O
position,O
of,O
the,O
constructed,O
halpotypes,O
in,O
the,O
network,O
diagrams,O
(,O
Figures,O
3,O
–,O
6,O
),O
[,O
56,O
].,O
Only,O
two,O
branches,O
directly,O
stemming,O
from,O
the,O
wildtype,O
pfcrt,B-GP
haplotype,O
contained,O
hypothetical,O
internal,O
nodes,O
(,O
Figure,O
5,O
"),",O
indicating,O
that,O
most,O
of,O
these,O
constructed,O
haplotypes,O
were,O
derived,O
from,O
simpler,O
haplotypes,O
that,O
were,O
also,O
present,O
in,O
our,O
data,O
set,O
.,O
Statistical,O
Analyses,O
Prevalence,O
of,O
P,B-DS
.,I-DS
falciparum,I-DS
infection,I-DS
was,O
determined,O
at,O
two,O
hierarchical,O
levels,O
.,O
Since,O
malaria,B-DS
endemicity,O
in,O
the,O
Pacific,O
varies,O
by,O
altitude,O
and,O
latitude,O
[,O
15,O
"],",O
[,O
16,O
"],",O
in,O
addition,O
to,O
comparisons,O
among,O
all,O
samples,O
",",O
individual,O
samples,O
were,O
assigned,O
to,O
one,O
of,O
five,O
ecological,O
zones,O
:,O
(,O
1,O
),O
PNG,O
eastern,O
highlands,O
",",O
(,O
2,O
),O
WNG,O
coast,O
",",O
(,O
3,O
),O
PNG,O
coasts,O
",",O
(,O
4,O
),O
PNG,O
Papuan,O
Plateau,O
",",O
and,O
(,O
5,O
),O
Island,O
Melanesia,O
",",O
consisting,O
of,O
New,O
Hebrides,O
(,O
now,O
Vanuatu,O
),O
and,O
Solomon,O
Islands,O
(,O
Figure,O
1,O
).,O
Samples,O
used,O
in,O
this,O
study,O
were,O
collected,O
over,O
a,O
span,O
of,O
20,O
years,O
(,O
1959,O
–,O
79,O
"),",O
and,O
were,O
therefore,O
divided,O
into,O
the,O
following,O
periods,O
",",O
(,O
A,O
),O
1959,O
–,O
61,O
",",O
(,O
B,O
),O
1962,O
–,O
5,O
",",O
(,O
C,O
),O
1969,O
–,O
72,O
",",O
and,O
(,O
D,O
),O
1979,O
",",O
to,O
account,O
for,O
temporal,O
variation,O
and,O
assess,O
the,O
persistence,O
of,O
genotypes,O
over,O
time,O
.,O
Pfcrt,B-GP
haplotype,O
diversity,O
was,O
calculated,O
for,O
each,O
population,O
and,O
each,O
ecological,O
zone,O
using,O
the,O
equation,O
:,O
H,O
=,O
n,O
(,O
1,O
−∑,O
Xi,O
2,O
)/(,O
n,O
−,O
1,O
"),",O
where,O
n,O
is,O
the,O
number,O
of,O
pfcrt,B-GP
sequences,O
",",O
and,O
Xi,O
is,O
the,O
frequency,O
of,O
the,O
i,O
-,O
th,O
haplotype,O
[,O
57,O
].,O
Mean,O
pfcrt,B-GP
haplotype,O
diversities,O
among,O
ecological,O
zones,O
were,O
compared,O
using,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
).,O
For,O
each,O
time,O
period,O
",",O
G,O
-,O
test,O
for,O
homogeneity,O
was,O
used,O
to,O
compare,O
the,O
distribution,O
of,O
mutant,O
pfcrt,B-GP
haplotypes,O
among,O
populations,O
.,O
Median,O
-,O
joining,O
network,O
diagrams,O
were,O
constructed,O
using,O
the,O
software,O
Network,O
4,O
.,O
600,O
to,O
illustrate,O
the,O
phylogenetic,O
relationships,O
among,O
all,O
pfcrt,B-GP
sequences,O
for,O
each,O
period,O
[,O
56,O
"],",O
[,O
58,O
].,O
To,O
infer,O
gene,O
flow,O
among,O
populations,O
",",O
two,O
sets,O
of,O
pairwise,O
FST,O
genetic,O
distances,O
were,O
calculated,O
using,O
Arlequin,O
3,O
.,O
1,O
[,O
59,O
].,O
The,O
first,O
set,O
consisted,O
of,O
comparisons,O
of,O
samples,O
from,O
the,O
same,O
time,O
period,O
to,O
examine,O
gene,O
flow,O
across,O
ecological,O
zones,O
",",O
while,O
the,O
second,O
consisted,O
of,O
samples,O
from,O
the,O
same,O
ecological,O
zone,O
but,O
were,O
collected,O
in,O
different,O
periods,O
to,O
infer,O
replacement,O
(,O
or,O
persistence,O
),O
over,O
time,O
.,O
The,O
statistical,O
significance,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
of,O
the,O
observed,O
values,O
was,O
evaluated,O
by,O
randomly,O
permuting,O
sequences,O
among,O
populations,O
approximately,O
10,O
",",O
000,O
times,O
to,O
generate,O
a,O
,O
distribution,O
against,O
which,O
the,O
observed,O
values,O
were,O
compared,O
.,O
Supporting,O
Information,O
The,O
approximate,O
geographic,O
locations,O
of,O
these,O
samples,O
are,O
shown,O
in,O
Figure,O
1,O
.,O
Samples,O
collected,O
from,O
the,O
same,O
locations,O
in,O
different,O
years,O
did,O
not,O
represent,O
repeated,O
samplings,O
of,O
the,O
same,O
population,O
.,O
Ages,O
of,O
donors,O
for,O
the,O
sample,O
EHP79,O
were,O
not,O
available,O
.,O
(,O
DOC,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Nitrogen,O
-,O
induced,O
metabolic,O
changes,O
and,O
molecular,O
determinants,O
of,O
carbon,O
allocation,O
in,O
Dunaliella,B-OG
tertiolecta,I-OG
Certain,O
species,O
of,O
microalgae,B-OG
are,O
natural,O
accumulators,O
of,O
lipids,O
",",O
while,O
others,O
are,O
more,O
inclined,O
to,O
store,O
starch,O
.,O
However,O
",",O
what,O
governs,O
the,O
preference,O
to,O
store,O
lipids,O
or,O
starch,O
is,O
not,O
well,O
understood,O
.,O
In,O
this,O
study,O
",",O
the,O
microalga,B-OG
Dunaliella,B-OG
tertiolecta,I-OG
was,O
used,O
as,O
a,O
model,O
to,O
study,O
the,O
global,O
gene,O
expression,O
profile,O
regulating,O
starch,O
accumulation,O
in,O
microalgae,B-OG
.,O
D,B-OG
.,I-OG
tertiolecta,I-OG
",",O
when,O
depleted,O
of,O
nitrogen,O
",",O
produced,O
only,O
1,O
%,O
of,O
dry,O
cell,O
weight,O
(,O
DCW,O
),O
in,O
neutral,O
lipids,O
",",O
while,O
starch,O
was,O
rapidly,O
accumulated,O
up,O
to,O
46,O
%,O
DCW,O
.,O
The,O
increased,O
in,O
starch,O
content,O
was,O
accompanied,O
by,O
a,O
coordinated,O
overexpression,O
of,O
genes,O
shunting,O
carbon,O
towards,O
starch,O
synthesis,O
",",O
a,O
response,O
not,O
seen,O
in,O
the,O
oleaginous,O
microalgae,B-OG
Nannochloropsis,B-OG
oceanica,I-OG
",",O
Chlamydomonas,B-OG
reinhardtii,I-OG
or,O
Chlorella,B-OG
vulgaris,I-OG
.,O
Genes,O
in,O
the,O
central,O
carbon,O
metabolism,O
pathways,O
",",O
particularly,O
those,O
of,O
the,O
tricarboxylic,O
acid,O
cycle,O
",",O
were,O
also,O
simultaneously,O
upregulated,O
",",O
indicating,O
a,O
robust,O
interchange,O
of,O
carbon,O
skeletons,O
for,O
anabolic,O
and,O
catabolic,O
processes,O
.,O
In,O
contrast,O
",",O
fatty,O
acid,O
and,O
triacylglycerol,O
synthesis,O
genes,O
were,O
downregulated,O
or,O
unchanged,O
",",O
suggesting,O
that,O
lipids,O
are,O
not,O
a,O
preferred,O
form,O
of,O
storage,O
in,O
these,O
cells,O
.,O
This,O
study,O
reveals,O
the,O
transcriptomic,O
influence,O
behind,O
storage,O
reserve,O
allocation,O
in,O
D,B-OG
.,I-OG
tertiolecta,I-OG
and,O
provides,O
valuable,O
insights,O
into,O
the,O
possible,O
manipulation,O
of,O
genes,O
for,O
engineering,O
microorganisms,B-OG
to,O
synthesize,O
products,O
of,O
interest,O
.,O
In,O
recent,O
years,O
",",O
microalgae,B-OG
have,O
emerged,O
as,O
a,O
promising,O
source,O
for,O
the,O
production,O
of,O
renewable,O
biofuels,O
",",O
as,O
well,O
as,O
additional,O
feedstock,O
for,O
food,O
",",O
feed,O
",",O
and,O
chemicals123,O
.,O
Compared,O
to,O
terrestrial,O
plants,B-OG
",",O
microalgae,B-OG
boast,O
higher,O
photosynthetic,O
efficiency,O
and,O
are,O
able,O
to,O
channel,O
most,O
of,O
their,O
energy,O
into,O
cell,O
division,O
",",O
allowing,O
for,O
rapid,O
biomass,O
production,O
rates234,O
.,O
In,O
addition,O
",",O
they,O
can,O
be,O
cultivated,O
in,O
wastewater,O
and,O
saltwater,O
systems,O
which,O
will,O
not,O
directly,O
compete,O
with,O
resources,O
necessary,O
for,O
agricultural,O
food,O
production56,O
.,O
When,O
cultivated,O
under,O
stressful,O
conditions,O
such,O
as,O
nitrogen,O
depletion,O
(,O
N,O
-,O
depletion,O
"),",O
photosynthetic,O
microalgae,B-OG
alter,O
their,O
metabolism,O
to,O
redirect,O
energy,O
towards,O
the,O
production,O
and,O
accumulation,O
of,O
energy,O
-,O
rich,O
storage,O
compounds,O
such,O
as,O
starch,O
and,O
lipids789,O
",",O
but,O
at,O
the,O
cost,O
of,O
diminished,O
growth,O
.,O
This,O
ability,O
enables,O
the,O
microalgae,B-OG
to,O
survive,O
adverse,O
environmental,O
changes,O
as,O
the,O
energy,O
deposits,O
can,O
be,O
easily,O
mobilized,O
when,O
growth,O
conditions,O
are,O
restored10,O
.,O
Some,O
microalgae,B-OG
species,O
are,O
oleaginous,O
and,O
are,O
capable,O
of,O
producing,O
up,O
to,O
60,O
%,O
of,O
neutral,O
lipids,O
(,O
i,O
.,O
e,O
.,O
triacylglyerols,O
;,O
TAGs,O
),O
per,O
gram,O
of,O
dry,O
weight11,O
",",O
while,O
non,O
-,O
oleaginous,O
microalgae,B-OG
specialize,O
in,O
accumulating,O
carbohydrates12,O
.,O
What,O
influences,O
one,O
microalgae,B-OG
to,O
store,O
lipids,O
and,O
another,O
to,O
preferentially,O
store,O
starch,O
is,O
poorly,O
understood,O
.,O
Traditionally,O
",",O
Nannochloropsis,B-OG
oceanica,I-OG
strains,O
are,O
favored,O
for,O
studying,O
lipid,O
accumulation131415,O
",",O
and,O
the,O
freshwater,O
microalgal,O
species,O
Chlamydomonas,O
reinhardtii1617,O
and,O
Chlorella,B-OG
vulgaris81819,O
are,O
most,O
commonly,O
studied,O
for,O
starch,O
accumulation,O
.,O
The,O
latter,O
two,O
species,O
have,O
thus,O
far,O
been,O
cultivated,O
mixotrophically,O
or,O
heterotrophically,O
with,O
the,O
addition,O
of,O
organic,O
carbon,O
such,O
as,O
acetate,O
and,O
glucose20,O
.,O
However,O
",",O
there,O
are,O
significant,O
drawbacks,O
in,O
this,O
strategy,O
as,O
it,O
would,O
expose,O
the,O
culture,O
to,O
higher,O
risks,O
of,O
contamination,O
and,O
is,O
not,O
ideal,O
for,O
microalgal,O
CO2,O
fixation21,O
.,O
Dunaliella,B-OG
tertiolecta,I-OG
–,O
a,O
non,O
-,O
model,O
flagellate,O
microalga,B-OG
belonging,O
to,O
the,O
phylum,O
Chlorophyta,B-OG
–,O
is,O
one,O
of,O
the,O
most,O
promising,O
candidates,O
for,O
industrial,O
use,O
as,O
it,O
is,O
among,O
the,O
top,O
microalgal,O
biomass,O
-,O
producers1222,O
",",O
is,O
halotolerant,O
and,O
can,O
be,O
grown,O
in,O
high,O
salinity,O
environments,O
(,O
up,O
to,O
4,O
M,O
NaCl,O
),O
such,O
as,O
saltwater,O
",",O
wastewater,O
or,O
brackish,O
water23,O
",",O
which,O
could,O
exclude,O
contaminating,O
species,O
and,O
would,O
not,O
compete,O
with,O
freshwater,O
sources,O
.,O
Importantly,O
",",O
it,O
is,O
a,O
robust,O
species,O
that,O
is,O
able,O
to,O
maintain,O
high,O
growth,O
rates,O
in,O
a,O
wide,O
range,O
of,O
pH,O
",",O
temperature,O
and,O
light,O
",",O
and,O
contain,O
relatively,O
high,O
lipid,O
content22425,O
.,O
Unlike,O
most,O
microalgae,B-OG
D,B-OG
.,I-OG
tertiolecta,I-OG
do,O
not,O
have,O
a,O
cell,O
wall,O
",",O
making,O
cell,O
lysis,O
much,O
less,O
energy,O
intensive,O
while,O
auto,O
-,O
flocculation,O
drastically,O
reduces,O
energy,O
required,O
for,O
harvesting26,O
.,O
A,O
shortcoming,O
is,O
that,O
its,O
genome,O
is,O
unsequenced,O
",",O
which,O
largely,O
limits,O
our,O
understanding,O
of,O
its,O
behavior,O
at,O
the,O
molecular,O
level,O
.,O
In,O
2011,O
",",O
Rismani,O
-,O
Yazdi,O
et,O
al,O
.,O
provided,O
a,O
preliminary,O
annotation,O
of,O
available,O
genes,O
and,O
putative,O
pathways,O
in,O
D,B-OG
.,I-OG
tertiolecta,I-OG
based,O
on,O
sequence,O
similarity,O
between,O
Chlamydomonas,B-OG
reinhardtii,I-OG
and,O
Volvox,B-OG
carteri27,I-OG
",",O
but,O
did,O
not,O
compare,O
the,O
transcriptomic,O
response,O
between,O
physiological,O
states,O
.,O
Recently,O
",",O
several,O
new,O
transcriptomic,O
studies,O
of,O
Dunaliella,B-OG
species,O
have,O
been,O
conducted282930,O
.,O
Yao,O
et,O
al,O
.,O
created,O
a,O
draft,O
database,O
for,O
annotation,O
of,O
RNA,O
-,O
seq,O
data,O
from,O
D,B-OG
.,I-OG
tertiolecta,I-OG
and,O
described,O
pathway,O
analyses,O
of,O
a,O
random,O
mutant,O
with,O
enhanced,O
lipid,O
production28,O
.,O
Similarly,O
",",O
Shin,O
et,O
al,O
.,O
independently,O
annotated,O
the,O
transcriptome,O
of,O
D,B-OG
.,I-OG
tertiolecta,I-OG
and,O
studied,O
possible,O
genes,O
related,O
to,O
growth,O
limitation,O
during,O
N,O
-,O
depletion29,O
.,O
In,O
this,O
study,O
",",O
we,O
aim,O
to,O
determine,O
the,O
underlying,O
changes,O
in,O
gene,O
expression,O
which,O
may,O
influence,O
storage,O
product,O
accumulation,O
in,O
D,B-OG
.,I-OG
tertiolecta,I-OG
",",O
and,O
thus,O
establish,O
a,O
transcriptomic,O
basis,O
for,O
the,O
preference,O
of,O
D,B-OG
.,I-OG
tertiolecta,I-OG
to,O
store,O
one,O
product,O
over,O
another,O
.,O
We,O
tracked,O
for,O
dynamic,O
changes,O
of,O
storage,O
components,O
including,O
starch,O
",",O
glycerol,O
",",O
neutral,O
lipids,O
and,O
total,O
fatty,O
acids,O
",",O
and,O
compared,O
the,O
transcriptome,O
profile,O
of,O
the,O
cell,O
in,O
the,O
exponential,O
and,O
stationary,O
phases,O
after,O
nitrogen,O
has,O
been,O
depleted,O
in,O
the,O
media,O
.,O
Our,O
investigations,O
into,O
the,O
transcriptome,O
profile,O
via,O
RNA,O
-,O
seq,O
uncovered,O
key,O
characteristics,O
linked,O
to,O
increased,O
activity,O
in,O
the,O
central,O
carbon,O
metabolism,O
(,O
CCM,O
),O
pathways,O
such,O
as,O
the,O
tricarboxylic,O
acid,O
(,O
TCA,O
),O
cycle,O
",",O
glycolysis,O
and,O
the,O
oxidative,O
pentose,O
phosphate,O
pathway,O
(,O
OPPP,O
),O
that,O
may,O
contribute,O
to,O
carbon,O
flux,O
and,O
starch,O
synthesis,O
.,O
Finally,O
",",O
we,O
compared,O
our,O
findings,O
with,O
microalgae,B-OG
species,O
of,O
varying,O
oleaginicity,O
to,O
better,O
understand,O
the,O
underlying,O
differences,O
that,O
determine,O
the,O
preferred,O
production,O
of,O
starch,O
and,O
/,O
or,O
lipids,O
.,O
Results,O
Physiological,O
response,O
of,O
D,B-OG
.,I-OG
tertiolecta,I-OG
under,O
Nitrogen,O
depletion,O
In,O
the,O
Dunaliella,B-OG
genus,O
which,O
dominates,O
list,O
of,O
top,O
strains,O
for,O
carbohydrate,O
production,O
",",O
D,B-OG
.,I-OG
tertiolecta,I-OG
is,O
one,O
of,O
the,O
most,O
researched,O
species,O
due,O
to,O
its,O
ease,O
of,O
culture,O
",",O
tolerance,O
to,O
varied,O
environmental,O
conditions,O
",",O
fast,O
growth,O
rate,O
",",O
high,O
accumulation,O
of,O
storage,O
compounds,O
per,O
dry,O
weight,O
(,O
protein,O
",",O
starch,O
",",O
lipids,O
"),",O
and,O
overall,O
biomass,O
productivity1231,O
",",O
making,O
it,O
an,O
attractive,O
microalgal,O
feedstock,O
for,O
commercial,O
mass,O
cultivation32,O
.,O
D,B-OG
.,I-OG
tertiolecta,I-OG
strain,I-OG
UTEX,I-OG
LB,I-OG
999,I-OG
was,O
grown,O
in,O
ATCC,O
-,O
1174,O
DA,O
medium,O
with,O
an,O
initial,O
nitrate,O
concentration,O
of,O
5,O
mM,O
and,O
0,O
.,O
5,O
mM,O
for,O
N,O
-,O
replete,O
and,O
N,O
-,O
deplete,O
cultures,O
respectively,O
.,O
From,O
day,O
1,O
to,O
15,O
",",O
cell,O
density,O
for,O
N,O
-,O
replete,O
cultures,O
increased,O
from,O
0,O
.,O
75,O
×,O
106,O
to,O
14,O
.,O
4,O
×,O
106,O
cells,O
/,O
mL,O
",",O
before,O
dropping,O
to,O
13,O
.,O
88,O
×,O
106,O
cells,O
/,O
mL,O
(,O
Fig,O
.,O
1a,O
"),",O
suggesting,O
that,O
cell,O
division,O
had,O
ceased,O
.,O
On,O
the,O
other,O
hand,O
",",O
N,O
-,O
deplete,O
cultures,O
could,O
only,O
reach,O
a,O
maximum,O
cell,O
density,O
of,O
4,O
.,O
28,O
×,O
106,O
cells,O
/,O
mL,O
",",O
on,O
day,O
8,O
.,O
The,O
nitrate,O
concentrations,O
in,O
the,O
culture,O
medium,O
was,O
depleted,O
after,O
3,O
days,O
for,O
N,O
-,O
deplete,O
cells,O
",",O
and,O
9,O
days,O
for,O
N,O
-,O
replete,O
cells,O
(,O
Fig,O
.,O
1a,O
"),",O
but,O
cell,O
growth,O
continued,O
for,O
N,O
-,O
replete,O
cells,O
",",O
likely,O
driven,O
by,O
intracellular,O
nitrogen,O
stores,O
.,O
For,O
the,O
purpose,O
of,O
this,O
study,O
",",O
cells,O
were,O
harvested,O
for,O
metabolite,O
analyses,O
at,O
days,O
3,O
",",O
5,O
",",O
8,O
",",O
12,O
",",O
and,O
17,O
to,O
capture,O
the,O
passage,O
through,O
exponential,O
and,O
stationary,O
growth,O
phases,O
.,O
Although,O
cell,O
division,O
has,O
slowed,O
for,O
N,O
-,O
deplete,O
cells,O
from,O
the,O
fourth,O
day,O
onwards,O
",",O
the,O
increase,O
in,O
dry,O
weight,O
(,O
Fig,O
.,O
1d,O
),O
was,O
largely,O
due,O
to,O
the,O
accumulation,O
of,O
storage,O
compounds,O
such,O
as,O
starch,O
and,O
glycerol,O
",",O
as,O
the,O
cells,O
continue,O
to,O
accumulate,O
organic,O
carbon,O
(,O
Fig,O
.,O
1b,O
",",O
c,O
).,O
Over,O
the,O
course,O
of,O
the,O
experiment,O
",",O
N,O
-,O
depletion,O
also,O
led,O
to,O
reduced,O
total,O
chlorophyll,O
content,O
(,O
Fig,O
.,O
1e,O
),O
and,O
photosynthetic,O
yield,O
(,O
Fv,O
/,O
Fm,O
),O
(,O
Fig,O
.,O
1f,O
).,O
Although,O
there,O
was,O
a,O
decrease,O
in,O
chlorophyll,O
content,O
for,O
both,O
N,O
-,O
replete,O
and,O
N,O
-,O
deplete,O
cultures,O
on,O
day,O
3,O
",",O
N,O
-,O
replete,O
cultures,O
subsequently,O
recovered,O
chlorophyll,O
levels,O
to,O
the,O
original,O
state,O
(,O
i,O
.,O
e,O
.,O
Day,O
0,O
),O
during,O
the,O
exponential,O
growth,O
phase,O
",",O
while,O
those,O
of,O
N,O
-,O
deplete,O
cultures,O
continue,O
to,O
fall,O
(,O
Fig,O
.,O
1e,O
).,O
The,O
health,O
of,O
photosystem,O
II,O
as,O
determined,O
by,O
Fv,O
/,O
Fm,O
",",O
held,O
steady,O
at,O
around,O
0,O
.,O
68,O
–,O
0,O
.,O
74,O
for,O
N,O
-,O
replete,O
cultures,O
.,O
On,O
the,O
other,O
hand,O
",",O
N,O
-,O
deplete,O
cultures,O
experience,O
a,O
drop,O
in,O
photosynthetic,O
yield,O
from,O
0,O
.,O
59,O
to,O
0,O
.,O
41,O
",",O
indicative,O
of,O
cell,O
stress,O
and,O
possible,O
damage,O
to,O
photosystem,O
II,O
(,O
Fig,O
.,O
1f,O
).,O
Accumulation,O
pattern,O
of,O
storage,O
compounds,O
upon,O
N,O
-,O
depletion,O
Lipid,O
",",O
starch,O
and,O
glycerol,O
synthesis,O
pathways,O
share,O
common,O
carbon,O
precursors,O
fed,O
from,O
the,O
glycolytic,O
pathway,O
",",O
but,O
the,O
regulation,O
of,O
carbon,O
allocation,O
into,O
these,O
routes,O
is,O
not,O
well,O
understood3334,O
.,O
Under,O
the,O
favorable,O
condition,O
where,O
nitrogen,O
is,O
available,O
",",O
N,O
-,O
replete,O
D,B-OG
.,I-OG
tertiolecta,I-OG
maintained,O
basal,O
levels,O
of,O
starch,O
(,O
7,O
–,O
8,O
pg,O
/,O
cell,O
),O
during,O
the,O
first,O
5,O
days,O
of,O
cultivation,O
;,O
consequently,O
",",O
when,O
nitrogen,O
is,O
depleted,O
",",O
it,O
increasing,O
to,O
19,O
pg,O
/,O
cell,O
on,O
day,O
8,O
(,O
Fig,O
.,O
2a,O
).,O
In,O
contrast,O
",",O
N,O
-,O
deplete,O
cultures,O
had,O
starch,O
rapidly,O
accumulated,O
on,O
the,O
third,O
day,O
(,O
27,O
pg,O
/,O
cell,O
"),",O
and,O
the,O
starch,O
content,O
of,O
the,O
latter,O
remained,O
higher,O
during,O
the,O
entire,O
process,O
.,O
Interestingly,O
",",O
starch,O
was,O
accumulated,O
much,O
earlier,O
and,O
in,O
greater,O
absolute,O
amounts,O
compared,O
to,O
lipids,O
(,O
neutral,O
lipids,O
and,O
total,O
lipids,O
),O
(,O
Fig,O
.,O
2b,O
",",O
c,O
).,O
Notably,O
",",O
despite,O
a,O
large,O
increase,O
in,O
neutral,O
lipids,O
(,O
Figs,O
2b,O
and,O
3c,O
"),",O
N,O
-,O
depletion,O
did,O
not,O
result,O
in,O
a,O
corresponding,O
increase,O
in,O
total,O
lipids,O
(,O
Fig,O
.,O
2c,O
).,O
On,O
the,O
contrary,O
",",O
it,O
led,O
to,O
a,O
cessation,O
in,O
its,O
production,O
(,O
5,O
.,O
8,O
%,O
in,O
N,O
-,O
deplete,O
vs,O
.,O
9,O
.,O
5,O
%,O
in,O
N,O
-,O
replete,O
on,O
Day,O
17,O
).,O
Intracellular,O
glycerol,O
was,O
relatively,O
constant,O
for,O
both,O
cultures,O
throughout,O
the,O
experiment,O
(,O
Fig,O
.,O
2d,O
"),",O
with,O
only,O
extracellular,O
glycerol,O
showing,O
marked,O
increase,O
",",O
especially,O
by,O
N,O
-,O
deplete,O
cells,O
(,O
Fig,O
.,O
2e,O
).,O
This,O
is,O
consistent,O
with,O
findings,O
in,O
current,O
literature,O
implicating,O
the,O
continued,O
release,O
of,O
glycerol,O
by,O
D,B-OG
.,I-OG
tertiolecta,I-OG
into,O
the,O
culture,O
medium3536,O
.,O
The,O
amount,O
of,O
extracellular,O
glycerol,O
produced,O
was,O
able,O
to,O
reach,O
higher,O
quantities,O
as,O
it,O
is,O
not,O
restricted,O
by,O
cell,O
volume,O
",",O
enabling,O
it,O
to,O
deliver,O
microgram,O
levels,O
per,O
cell,O
not,O
achievable,O
with,O
intracellular,O
glycerol,O
",",O
starch,O
or,O
lipids,O
.,O
When,O
presented,O
on,O
a,O
percentage,O
dry,O
cell,O
weight,O
(,O
DCW,O
),O
basis,O
",",O
similar,O
trends,O
were,O
observed,O
with,O
subtle,O
differences,O
.,O
Starch,O
content,O
of,O
N,O
-,O
deplete,O
cells,O
peaked,O
sharply,O
on,O
day,O
3,O
(,O
28,O
%,O
DCW,O
),O
compared,O
to,O
N,O
-,O
replete,O
cells,O
where,O
it,O
moderately,O
increased,O
until,O
the,O
media,O
is,O
deprived,O
of,O
nitrogen,O
on,O
day,O
8,O
(,O
25,O
%,O
DCW,O
),O
(,O
Fig,O
.,O
2f,O
).,O
Intracellular,O
glycerol,O
accounted,O
for,O
9,O
–,O
14,O
%,O
of,O
DCW,O
in,O
N,O
-,O
replete,O
cells,O
and,O
N,O
-,O
deplete,O
cells,O
.,O
However,O
",",O
in,O
the,O
latter,O
stages,O
(,O
Day,O
8,O
–,O
17,O
"),",O
intracellular,O
glycerol,O
representation,O
in,O
N,O
-,O
deplete,O
cells,O
dropped,O
to,O
2,O
–,O
3,O
%,O
DCW,O
as,O
the,O
DCW,O
increased,O
while,O
intracellular,O
glycerol,O
content,O
remained,O
the,O
same,O
.,O
Total,O
lipid,O
production,O
was,O
greatly,O
attenuated,O
in,O
N,O
-,O
deplete,O
cultures,O
",",O
accounting,O
for,O
5,O
.,O
8,O
%,O
DCW,O
on,O
day,O
17,O
",",O
which,O
is,O
39,O
%,O
less,O
than,O
the,O
N,O
-,O
replete,O
culture,O
(,O
Fig,O
.,O
2f,O
).,O
There,O
were,O
minimal,O
changes,O
to,O
the,O
fatty,O
acid,O
(,O
FA,O
),O
composition,O
between,O
either,O
cultures,O
;,O
C18,O
:,O
3,O
is,O
the,O
most,O
abundant,O
FA,O
in,O
D,B-OG
.,I-OG
tertiolecta,I-OG
",",O
making,O
up,O
to,O
66,O
%,O
of,O
its,O
profile,O
(,O
Fig,O
.,O
3a,O
",",O
b,O
).,O
The,O
proportion,O
of,O
C16,O
:,O
0,O
",",O
however,O
",",O
appears,O
to,O
increase,O
over,O
time,O
particularly,O
for,O
cells,O
experiencing,O
N,O
-,O
depletion,O
",",O
while,O
those,O
of,O
C18,O
:,O
2,O
and,O
C18,O
:,O
3,O
levels,O
declined,O
.,O
Analysis,O
of,O
gene,O
expression,O
by,O
transcriptomics,O
The,O
growth,O
of,O
D,B-OG
.,I-OG
tertiolecta,I-OG
in,O
either,O
cultures,O
presented,O
two,O
distinctive,O
phases,O
:,O
Exponential,O
and,O
Stationary,O
(,O
Fig,O
.,O
1a,O
).,O
To,O
assess,O
the,O
transcriptional,O
regulation,O
of,O
selective,O
carbon,O
partitioning,O
",",O
we,O
carried,O
out,O
transcriptome,O
analyses,O
at,O
2,O
times,O
points,O
representing,O
N,O
-,O
deplete,O
exponential,O
phase,O
(,O
N,O
-,O
replete,O
vs,O
.,O
N,O
-,O
deplete,O
;,O
both,O
in,O
Day,O
3,O
exponential,O
phase,O
),O
and,O
stationary,O
phase,O
(,O
N,O
-,O
replete,O
exponential,O
vs,O
.,O
N,O
-,O
deplete,O
Day,O
5,O
stationary,O
phase,O
).,O
Gene,O
expression,O
was,O
expressed,O
as,O
fold,O
change,O
relative,O
to,O
N,O
-,O
replete,O
samples,O
.,O
Out,O
of,O
all,O
the,O
annotated,O
genes,O
for,O
Day,O
3,O
(,O
D3,O
),O
and,O
Day,O
5,O
(,O
D5,O
),O
samples,O
",",O
we,O
filtered,O
for,O
significantly,O
expressed,O
genes,O
using,O
a,O
False,O
discovery,O
rate,O
(,O
FDR,O
)-,O
corrected,O
p,O
-,O
value,O
≤,O
0,O
.,O
05,O
.,O
This,O
translated,O
to,O
3,O
",",O
962,O
and,O
1,O
",",O
234,O
significantly,O
expressed,O
genes,O
for,O
D3,O
and,O
D5,O
",",O
accounting,O
respectively,O
for,O
~,O
17,O
and,O
6,O
%,O
of,O
all,O
genes,O
annotated,O
(,O
Table,O
S2,O
).,O
Among,O
this,O
filtered,O
set,O
of,O
genes,O
",",O
96,O
%,O
(,O
D3,O
),O
and,O
89,O
%,O
(,O
D5,O
),O
of,O
genes,O
were,O
over,O
/,O
under,O
-,O
expressed,O
(≤−,O
2x,O
or,O
≥,O
2x,O
fold,O
-,O
change,O
),O
in,O
N,O
-,O
deplete,O
samples,O
relative,O
to,O
N,O
-,O
replete,O
samples,O
.,O
Functional,O
annotation,O
and,O
enrichment,O
of,O
differentially,O
expressed,O
genes,O
Gene,O
Ontology,O
(,O
GO,O
),O
enrichment,O
of,O
the,O
differentially,O
expressed,O
genes,O
showed,O
that,O
in,O
D3,O
",",O
upregulated,O
genes,O
form,O
the,O
majority,O
of,O
categories,O
while,O
in,O
D5,O
most,O
genes,O
were,O
downregulated,O
(,O
Figs,O
S2,O
",",O
S3,O
).,O
Nitrogen,O
compound,O
metabolic,O
process,O
was,O
upregulated,O
in,O
both,O
D3,O
and,O
D5,O
",",O
an,O
indication,O
that,O
the,O
cells,O
were,O
increasing,O
capacity,O
for,O
utilizing,O
nitrogen,O
in,O
response,O
to,O
the,O
nutrient,O
’,O
s,O
depletion,O
.,O
The,O
top,O
10,O
most,O
highly,O
expressed,O
or,O
repressed,O
genes,O
were,O
related,O
to,O
nitrogen,O
-,O
scavenging,O
or,O
photosynthesis,O
(,O
Table,O
S3,O
).,O
For,O
instance,O
",",O
THB1,B-GP
",",O
a,O
truncated,B-GP
hemoglobin,I-GP
highly,O
expressed,O
in,O
the,O
presence,O
of,O
nitric,O
oxide37,O
",",O
was,O
repressed,O
by,O
almost,O
300,O
-,O
fold,O
.,O
Likewise,O
",",O
three,O
subunits,O
of,O
the,O
urea,B-GP
active,I-GP
transporter,I-GP
were,O
upregulated,O
between,O
52,O
-,O
and,O
72,O
-,O
fold,O
",",O
representing,O
one,O
of,O
the,O
many,O
enzymes,O
whose,O
expression,O
are,O
known,O
to,O
increase,O
to,O
harvest,O
nitrogen,O
from,O
nitrogen,O
-,O
containing,O
compounds,O
such,O
as,O
ammonium,O
",",O
nitrate,O
",",O
nitrite,O
",",O
urea,O
",",O
purines,O
",",O
pyrimidines,O
and,O
amino,O
acids38,O
.,O
In,O
D3,O
",",O
the,O
upregulated,O
genes,O
frequently,O
represented,O
those,O
involved,O
in,O
central,O
carbon,O
metabolism,O
(,O
CCM,O
),O
39,O
",",O
which,O
includes,O
the,O
pathways,O
of,O
TCA,O
cycle,O
(,O
75,O
%,O
enriched,O
"),",O
glycolysis,O
(,O
28,O
.,O
6,O
%,O
enriched,O
"),",O
and,O
the,O
oxidative,O
pentose,O
phosphate,O
pathway,O
(,O
OPPP,O
),O
(,O
enrichment,O
of,O
glucose,B-GP
-,I-GP
6,I-GP
-,I-GP
phosphate,I-GP
dehydrogenase,I-GP
activity,O
),O
(,O
Fig,O
.,O
S2,O
).,O
Moreover,O
",",O
mitochondrial,O
electron,O
transport,O
and,O
enzymatic,O
activity,O
on,O
NADH,O
or,O
NADPH,O
(,O
85,O
–,O
88,O
%),O
were,O
significantly,O
upregulated,O
",",O
as,O
well,O
as,O
pyruvate,B-GP
kinase,I-GP
activity,O
(,O
62,O
.,O
5,O
%),O
and,O
malate,B-GP
dehydrogenase,I-GP
activity,O
(,O
75,O
"%),",O
while,O
those,O
of,O
photosynthesis,O
(,O
17,O
%),O
were,O
slightly,O
downregulated,O
(,O
Fig,O
.,O
S2,O
).,O
As,O
the,O
cells,O
progress,O
to,O
stationary,O
phase,O
on,O
D5,O
",",O
the,O
most,O
obvious,O
difference,O
was,O
the,O
enrichment,O
for,O
multiple,O
downregulated,O
categories,O
in,O
photosynthesis,O
:,O
Chlorophyll,O
biosynthetic,O
process,O
(,O
75,O
"%),",O
photosynthesis,O
(,O
56,O
.,O
5,O
"%),",O
photosystem,O
I,O
(,O
50,O
"%),",O
photosynthesis,O
",",O
light,O
harvesting,O
(,O
41,O
.,O
7,O
%),O
(,O
Fig,O
.,O
S3,O
).,O
Nevertheless,O
",",O
TCA,O
cycle,O
(,O
37,O
.,O
5,O
%),O
and,O
glycolysis,O
(,O
14,O
.,O
3,O
%),O
continue,O
to,O
be,O
upregulated,O
",",O
albeit,O
to,O
a,O
lesser,O
degree,O
.,O
Surprisingly,O
",",O
FA,O
biosynthesis,O
(,O
46,O
.,O
1,O
%),O
and,O
acetyl,B-GP
-,I-GP
CoA,I-GP
carboxylase,I-GP
activity,O
(,O
66,O
.,O
7,O
%),O
were,O
downregulated,O
in,O
N,O
-,O
replete,O
samples,O
",",O
suggesting,O
a,O
repression,O
of,O
de,O
novo,O
FA,O
synthesis,O
.,O
Likewise,O
",",O
KEGG,O
pathway,O
analysis,O
reflect,O
enrichments,O
in,O
carbon,O
metabolism,O
",",O
TCA,O
cycle,O
",",O
and,O
pyruvate,O
metabolism,O
for,O
both,O
D3,O
and,O
D5,O
",",O
while,O
only,O
D5,O
had,O
significant,O
enrichments,O
in,O
glycolysis,O
and,O
photosynthesis,O
(,O
Fig,O
.,O
S4,O
).,O
Coordinated,O
expression,O
of,O
central,O
carbon,O
metabolism,O
genes,O
for,O
storage,O
compound,O
synthesis,O
Photosynthetic,O
components,O
and,O
antenna,B-GP
proteins,I-GP
were,O
severely,O
affected,O
in,O
N,O
-,O
deplete,O
cells,O
",",O
as,O
evidenced,O
by,O
the,O
global,O
downregulation,O
of,O
genes,O
encoding,O
for,O
light,O
-,O
harvesting,O
complexes,O
",",O
photosystem,O
",",O
and,O
RuBisCO,B-GP
activase,I-GP
",",O
an,O
enzyme,O
catalyzing,O
the,O
activation,O
of,O
RuBisCO,B-GP
(,O
Figs,O
4,O
",",O
S8,O
",",O
S9,O
).,O
Nonetheless,O
",",O
carbon,O
continued,O
to,O
be,O
assimilated,O
as,O
seen,O
from,O
the,O
upregulation,O
of,O
three,O
isoforms,O
of,O
gamma,B-GP
carbonic,I-GP
anhydrase,I-GP
(,O
CAG1,B-GP
",",O
CAG2,B-GP
",",O
CAG3,B-GP
),O
in,O
D3,O
(,O
Supplementary,O
dataset,O
"),",O
which,O
would,O
provide,O
a,O
source,O
of,O
bicarbonate,O
from,O
CO2,O
assimilation,O
.,O
Pyruvate,B-GP
phosphate,I-GP
dikinase,I-GP
(,O
PPD2,B-GP
),O
was,O
upregulated,O
by,O
23,O
-,O
fold,O
on,O
D3,O
and,O
4,O
-,O
fold,O
on,O
D5,O
.,O
PPD2,B-GP
is,O
used,O
in,O
the,O
C4,O
carbon,O
-,O
concentrating,O
mechanism,O
pathway,O
",",O
where,O
it,O
converts,O
pyruvate,O
to,O
PEP,O
",",O
which,O
then,O
reacts,O
with,O
bicarbonate,O
to,O
produce,O
oxaloacetate,O
(,O
Fig,O
.,O
4,O
).,O
The,O
CCM,O
pathways,O
were,O
notably,O
active,O
during,O
N,O
-,O
depletion,O
.,O
Glycolysis,O
breaks,O
down,O
glucose,O
to,O
form,O
pyruvate,O
and,O
acetyl,O
-,O
CoA,O
.,O
Phosphofructokinase,B-GP
(,O
PFK2,B-GP
"),",O
pyruvate,B-GP
kinase,I-GP
(,O
PYK1,B-GP
",",O
2,O
),O
and,O
the,O
E2,O
subunit,O
of,O
pyruvate,B-GP
dehydrogenase,I-GP
complex,I-GP
(,O
DLA1,B-GP
;,O
dihydrolipoamide,B-GP
acetyltransferase,I-GP
),O
were,O
upregulated,O
",",O
forming,O
pyruvate,O
and,O
acetyl,O
-,O
CoA,O
which,O
feeds,O
into,O
the,O
TCA,O
cycle,O
.,O
Similarly,O
",",O
genes,O
in,O
the,O
TCA,O
cycle,O
were,O
simultaneously,O
upregulated,O
;,O
transcripts,O
of,O
citrate,B-GP
synthase,I-GP
(,O
CIS1,B-GP
"),",O
aconitase,B-GP
(,O
ACH1,B-GP
"),",O
isocitrate,B-GP
dehydrogenase,I-GP
(,O
IDH2,B-GP
"),",O
oxoglutarate,B-GP
dehydrogenase,I-GP
(,O
OGD1,B-GP
"),",O
succinate,B-GP
dehydrogenase,I-GP
(,O
SDH2,B-GP
"),",O
fumarate,B-GP
hydratase,I-GP
(,O
FUM1,B-GP
),O
and,O
malate,B-GP
dehydrogenase,I-GP
(,O
MDH3,B-GP
),O
were,O
greatly,O
enhanced,O
on,O
both,O
D3,O
and,O
D5,O
N,O
-,O
deplete,O
samples,O
(,O
Figs,O
4,O
",",O
S5,O
",",O
S6,O
).,O
Interestingly,O
",",O
a,O
triose,B-GP
phosphate,I-GP
/,I-GP
phosphoenolpyruvate,I-GP
translocator,I-GP
(,O
TPT1,B-GP
),O
was,O
dramatically,O
upregulated,O
29,O
-,O
and,O
24,O
-,O
fold,O
on,O
D3,O
and,O
D5,O
.,O
TPT1,B-GP
could,O
export,O
dihydroxyacetone,O
phosphate,O
(,O
DHAP,O
),O
out,O
of,O
the,O
chloroplast,O
for,O
use,O
in,O
glycerol,O
synthesis,O
as,O
the,O
expression,O
of,O
glycerol,B-GP
-,I-GP
3,I-GP
-,I-GP
phosphate,I-GP
dehydrogenase,I-GP
(,O
GPDH,B-GP
),O
was,O
also,O
increased,O
.,O
Particularly,O
",",O
genes,O
participating,O
in,O
starch,O
metabolism,O
were,O
upregulated,O
",",O
including,O
ADP,B-GP
-,I-GP
glucose,I-GP
pyrophosphorylase,I-GP
(,O
STA1,B-GP
"),",O
starch,B-GP
synthase,I-GP
(,O
SSS1,B-GP
),O
and,O
UDP,B-GP
-,I-GP
glucose,I-GP
pyrophosphorylase,I-GP
(,O
UGP1,B-GP
),O
and,O
starch,B-GP
branching,I-GP
enzyme,I-GP
(,O
SBE2,B-GP
"),",O
which,O
together,O
coordinate,O
the,O
synthesis,O
of,O
starch,O
from,O
glucose,O
-,O
1,O
-,O
phosphate,O
(,O
Figs,O
4,O
",",O
S7,O
).,O
ATP,B-GP
:,I-GP
citrate,I-GP
lyase,I-GP
(,O
ACLB1,B-GP
),O
and,O
NADP,B-GP
-,I-GP
malic,I-GP
enzyme,I-GP
(,O
MME2,B-GP
),O
were,O
overexpressed,O
",",O
which,O
would,O
supply,O
the,O
cell,O
with,O
acetyl,O
-,O
CoA,O
and,O
NADPH,O
respectively,O
.,O
In,O
addition,O
",",O
glucose,B-GP
-,I-GP
6,I-GP
-,I-GP
phosphate,I-GP
dehydrogenase,I-GP
(,O
G6PDH,B-GP
"),",O
a,O
provider,O
of,O
reducing,O
power,O
from,O
the,O
OPPP,O
",",O
was,O
also,O
upregulated,O
.,O
Surprisingly,O
",",O
genes,O
involved,O
in,O
the,O
FA,O
synthesis,O
pathway,O
were,O
largely,O
unchanged,O
except,O
for,O
some,O
downregulation,O
;,O
expression,O
levels,O
of,O
malonyl,B-GP
-,I-GP
CoA,I-GP
-,I-GP
acyl,I-GP
carrier,I-GP
protein,I-GP
transacylase,I-GP
(,O
MCAT,B-GP
),O
and,O
acetyl,B-GP
-,I-GP
CoA,I-GP
carboxylase,I-GP
(,O
ACCase,B-GP
),O
subunits,O
were,O
depressed,O
.,O
Comparing,O
the,O
N,O
-,O
depletion,O
response,O
in,O
D,B-OG
.,I-OG
tertiolecta,I-OG
and,O
other,O
oleaginous,O
and,O
non,O
-,O
oleaginous,O
microorganisms,B-OG
To,O
evaluate,O
the,O
differences,O
in,O
storage,O
product,O
accumulation,O
between,O
oleaginous,O
and,O
non,O
-,O
oleaginous,O
microalgae,B-OG
during,O
N,O
-,O
depletion,O
",",O
we,O
compared,O
the,O
published,O
physiological,O
and,O
transcriptomic,O
data,O
of,O
three,O
widely,O
studied,O
oleaginous,O
species,O
:,O
Nannochloropsis,B-OG
oceanica740,I-OG
",",O
Chlamydomonas,O
reinhardtii174142,O
",",O
and,O
Chlorella,B-OG
vulgaris43,O
(,O
Figs,O
5,O
and,O
6,O
).,O
D,B-OG
.,I-OG
tertiolecta,I-OG
accumulates,O
very,O
low,O
amounts,O
of,O
TAGs,O
in,O
N,O
-,O
replete,O
and,O
N,O
-,O
deplete,O
conditions,O
(,O
0,O
.,O
2,O
and,O
1,O
%,O
DCW,O
respectively,O
"),",O
but,O
stores,O
a,O
large,O
amount,O
of,O
starch,O
",",O
thus,O
making,O
it,O
a,O
high,O
starch,O
and,O
low,O
TAG,O
accumulator,O
(,O
Fig,O
.,O
6,O
",",O
Table,O
S4,O
).,O
Interestingly,O
",",O
although,O
N,B-OG
.,I-OG
oceanica,I-OG
–,O
a,O
marine,O
microalga,B-OG
alike,O
D,B-OG
.,I-OG
tertiolecta,I-OG
–,O
stores,O
the,O
same,O
amount,O
of,O
TAGs,O
under,O
N,O
-,O
replete,O
conditions,O
",",O
it,O
rapidly,O
accumulates,O
TAGs,O
under,O
N,O
-,O
deplete,O
conditions,O
(,O
up,O
to,O
40,O
%,O
DCW,O
);,O
it,O
however,O
lacks,O
starch,O
as,O
a,O
storage,O
compound1344,O
.,O
C,B-OG
.,I-OG
reinhardtii,I-OG
and,O
C,B-OG
.,I-OG
vulgaris,I-OG
",",O
both,O
heterotrophically,O
grown,O
microalgae,B-OG
",",O
accumulates,O
high,O
amounts,O
of,O
starch,O
and,O
TAGs,O
during,O
N,O
-,O
depletion,O
.,O
Analysis,O
of,O
the,O
expression,O
of,O
key,O
genes,O
in,O
the,O
FA,O
",",O
TAG,O
and,O
starch,O
synthesis,O
pathways,O
showed,O
that,O
upon,O
N,O
-,O
depletion,O
",",O
the,O
oleaginous,O
microalga,B-OG
N,B-OG
.,I-OG
oceanica,I-OG
and,O
moderate,O
TAG,O
accumulator,O
C,B-OG
.,I-OG
vulgaris,I-OG
experienced,O
downregulation,O
in,O
the,O
FA,O
synthesis,O
pathway,O
",",O
a,O
pattern,O
similar,O
to,O
that,O
in,O
the,O
low,O
TAG,O
-,O
accumulating,O
D,B-OG
.,I-OG
tertiolecta,I-OG
from,O
this,O
study,O
(,O
Fig,O
.,O
5,O
",",O
Table,O
S5,O
).,O
In,O
contrast,O
",",O
C,B-OG
.,I-OG
reinhardtii,I-OG
had,O
moderate,O
overexpression,O
of,O
its,O
FA,O
synthesis,O
genes,O
.,O
TAG,O
synthesis,O
genes,O
had,O
variable,O
changes,O
in,O
each,O
microalga,B-OG
:,O
In,O
D,B-OG
.,I-OG
tertiolecta,I-OG
GPAT,B-GP
was,O
downregulated,O
while,O
LPAAT,B-GP
was,O
upregulated,O
",",O
N,B-OG
.,I-OG
oceanica,I-OG
and,O
C,B-OG
.,I-OG
reinhardtii,I-OG
genes,O
were,O
mostly,O
unchanged,O
",",O
while,O
C,B-OG
.,I-OG
vulgaris,I-OG
genes,O
were,O
upregulated,O
.,O
Noticeably,O
",",O
D,B-OG
.,I-OG
tertiolecta,I-OG
has,O
most,O
of,O
its,O
starch,O
synthesis,O
genes,O
upregulated,O
",",O
suggesting,O
a,O
coordinated,O
push,O
towards,O
starch,O
accumulation,O
during,O
N,O
-,O
depletion,O
.,O
Discussion,O
In,O
microalgae,B-OG
",",O
TAGs,O
and,O
starch,O
are,O
the,O
two,O
primary,O
energy,O
storage,O
products,O
and,O
both,O
synthesis,O
pathways,O
share,O
common,O
carbon,O
precursors,O
.,O
It,O
has,O
been,O
reported,O
that,O
oleaginous,O
microalgae,B-OG
are,O
able,O
to,O
accumulate,O
large,O
amounts,O
of,O
TAGs,O
(,O
up,O
to,O
60,O
%,O
of,O
dry,O
weight,O
),O
under,O
N,O
-,O
depletions414243444546,O
.,O
Although,O
these,O
studies,O
show,O
that,O
N,O
-,O
depletion,O
enabled,O
oleaginous,O
cells,O
to,O
channel,O
carbon,O
to,O
TAGs,O
",",O
little,O
attention,O
has,O
been,O
paid,O
to,O
non,O
-,O
oleaginous,O
species,O
which,O
prefer,O
alternative,O
carbon,O
stores,O
such,O
as,O
starch,O
and,O
glycerol,O
",",O
and,O
the,O
transcriptomic,O
basis,O
governing,O
these,O
carbon,O
fluxes,O
.,O
In,O
this,O
study,O
",",O
we,O
tracked,O
the,O
storage,O
product,O
accumulation,O
and,O
global,O
gene,O
expression,O
profile,O
of,O
the,O
halophilic,O
",",O
high,O
-,O
starch,O
accumulating,O
microalga,B-OG
D,B-OG
.,I-OG
tertiolecta,I-OG
upon,O
N,O
-,O
depletion,O
",",O
and,O
compared,O
its,O
preference,O
of,O
storage,O
products,O
with,O
other,O
oleaginous,O
microalgae,B-OG
.,O
A,O
coordinated,O
upregulation,O
of,O
genes,O
involved,O
in,O
central,O
carbon,O
metabolism,O
was,O
identified,O
in,O
exponentially,O
growing,O
cells,O
",",O
suggesting,O
that,O
the,O
genetic,O
response,O
to,O
N,O
-,O
depletion,O
occurs,O
prior,O
to,O
the,O
cessation,O
of,O
cell,O
growth,O
(,O
i,O
.,O
e,O
.,O
stationary,O
phase,O
).,O
Surprisingly,O
",",O
the,O
transcriptome,O
profile,O
of,O
D,B-OG
.,I-OG
tertiolecta,I-OG
–,O
specifically,O
the,O
upregulation,O
of,O
CCM,O
genes,O
contributing,O
to,O
the,O
supply,O
of,O
acetyl,O
-,O
CoA,O
and,O
NADPH,O
–,O
were,O
vastly,O
similar,O
to,O
oleaginous,O
microalgae,B-OG
including,O
N,B-OG
.,I-OG
oceanica7,I-OG
and,O
C,O
.,O
reinhardtii47,O
.,O
The,O
increased,O
transcript,O
levels,O
of,O
TCA,O
cycle,O
genes,O
and,O
genes,O
contributing,O
to,O
reducing,O
power,O
such,O
as,O
G6PDH,B-GP
and,O
ME,B-GP
were,O
correspondingly,O
observed,O
in,O
heterotrophic,O
fungi,B-OG
such,O
as,O
Mortierella,B-OG
alpina48,I-OG
and,O
Mucor,B-OG
circinelloides4950,I-OG
to,O
be,O
critical,O
determinants,O
of,O
lipid,O
synthesis,O
.,O
Nitrogen,O
is,O
a,O
key,O
component,O
for,O
the,O
synthesis,O
of,O
chlorophyll,O
and,O
essential,O
proteins,O
of,O
the,O
photosystem,O
(,O
e,O
.,O
g,O
.,O
LHCII,B-GP
apoprotein,I-GP
"),",O
thus,O
the,O
restriction,O
of,O
nitrogen,O
supply,O
could,O
hinder,O
both,O
structural,O
and,O
physiological,O
components,O
of,O
photosynthesis51,O
.,O
The,O
observed,O
drop,O
in,O
chlorophyll,O
content,O
and,O
decreased,O
PSII,O
quantum,O
yield,O
(,O
Fig,O
.,O
1e,O
",",O
f,O
),O
coincides,O
with,O
previous,O
reports,O
that,O
demonstrated,O
the,O
degradation,O
of,O
chlorophyll,O
and,O
carotenoids,O
in,O
D,B-OG
.,I-OG
tertiolecta,I-OG
upon,O
nitrogen,O
starvation515253,O
.,O
Corresponding,O
downregulation,O
of,O
most,O
light,O
harvesting,O
complex,O
genes,O
(,O
Figs,O
S8,O
",",O
S9,O
),O
suggest,O
that,O
N,O
-,O
depletion,O
triggered,O
a,O
response,O
of,O
the,O
cell,O
to,O
reorganize,O
its,O
photosynthetic,O
apparatus,O
.,O
Multiple,O
studies,O
of,O
nutrient,O
limitation,O
in,O
microalgae,B-OG
point,O
to,O
the,O
degradation,O
of,O
thylakoid,O
membranes,O
in,O
favour,O
of,O
the,O
de,O
novo,O
synthesis,O
of,O
TAGs,O
where,O
intracellular,O
membrane,O
remodeling,O
substantially,O
contribute,O
to,O
neutral,O
lipid,O
accumulation54555657,O
.,O
Our,O
present,O
study,O
shows,O
that,O
D,B-OG
.,I-OG
tertiolecta,I-OG
is,O
able,O
to,O
accumulate,O
up,O
to,O
six,O
times,O
more,O
neutral,O
lipids,O
under,O
N,O
-,O
deplete,O
conditions,O
(,O
Fig,O
.,O
2b,O
"),",O
but,O
concurrently,O
experienced,O
a,O
substantial,O
decrease,O
in,O
total,O
lipid,O
content,O
relative,O
to,O
N,O
-,O
replete,O
samples,O
(,O
9,O
.,O
5,O
%,O
of,O
DCW,O
in,O
N,O
-,O
replete,O
vs,O
.,O
5,O
.,O
8,O
%,O
of,O
DCW,O
in,O
N,O
-,O
deplete,O
),O
(,O
Fig,O
.,O
2c,O
).,O
This,O
is,O
similar,O
to,O
other,O
researchers,O
who,O
observe,O
similar,O
declines,O
in,O
total,O
fatty,O
acid,O
content,O
in,O
D,B-OG
.,I-OG
tertiolecta,I-OG
under,O
N,O
-,O
depletion,O
(,O
7,O
.,O
5,O
%,O
of,O
DCW,O
in,O
N,O
-,O
sufficient,O
vs,O
5,O
.,O
9,O
%,O
of,O
DCW,O
in,O
N,O
-,O
deficient,O
),O
29,O
.,O
The,O
parallel,O
increase,O
in,O
neutral,O
lipids,O
could,O
be,O
explained,O
by,O
a,O
dramatic,O
shift,O
in,O
intracellular,O
processes,O
",",O
from,O
the,O
catabolic,O
degradation,O
of,O
thylakoid,O
membranes,O
(,O
which,O
contribute,O
to,O
total,O
lipids,O
),O
to,O
the,O
anabolic,O
reactions,O
of,O
storage,O
compound,O
accumulation,O
(,O
neutral,O
lipids,O
and,O
starch,O
content,O
).,O
This,O
notion,O
is,O
supported,O
by,O
a,O
recent,O
report,O
which,O
showed,O
that,O
when,O
cultured,O
under,O
N,O
-,O
depleted,O
conditions,O
",",O
D,B-OG
.,I-OG
tertiolecta,I-OG
had,O
significant,O
decreases,O
in,O
the,O
lipid,O
classes,O
of,O
diacylglyceryltrimethylhomoserine,O
(,O
DGTS,O
),O
and,O
digalactosyldiacylglycerol,O
(,O
DGDG,O
"),",O
a,O
main,O
component,O
of,O
chloroplast,O
membranes52,O
.,O
This,O
suggests,O
the,O
occurrence,O
of,O
a,O
major,O
remodeling,O
of,O
lipid,O
membranes,O
during,O
nitrogen,O
starvation,O
in,O
D,B-OG
.,I-OG
tertiolecta,I-OG
",",O
a,O
response,O
akin,O
to,O
other,O
microalgae54555657,O
.,O
Glycolytic,O
genes,O
that,O
shunt,O
carbon,O
precursors,O
to,O
de,O
novo,O
FA,O
synthesis,O
",",O
including,O
phosphofructokinase,B-GP
",",O
pyruvate,B-GP
kinase,I-GP
and,O
pyruvate,B-GP
dehydrogenase,I-GP
complex,I-GP
(,O
PDC,B-GP
"),",O
are,O
upregulated,O
in,O
N,B-OG
.,I-OG
oceanica,I-OG
and,O
C,B-OG
.,I-OG
reinhardtii,I-OG
under,O
N,O
-,O
depleted,O
conditions,O
correlating,O
with,O
TAG,O
accumulation,O
up,O
to,O
40,O
%,O
DCW,O
",",O
despite,O
a,O
downregulation,O
of,O
the,O
genes,O
directly,O
involved,O
in,O
TAG,O
and,O
FA,O
synthesis758,O
.,O
This,O
transcriptome,O
response,O
is,O
unexpectedly,O
similar,O
to,O
D,B-OG
.,I-OG
tertiolecta,I-OG
in,O
this,O
study,O
(,O
Fig,O
.,O
4,O
"),",O
which,O
accumulates,O
more,O
starch,O
(,O
46,O
%,O
DCW,O
),O
than,O
lipids,O
(,O
Figs,O
2f,O
and,O
5,O
).,O
Even,O
more,O
striking,O
is,O
the,O
similarity,O
in,O
the,O
overexpression,O
of,O
genes,O
involved,O
in,O
the,O
TCA,O
cycle,O
in,O
the,O
mitochondria,O
(,O
Fig,O
.,O
4,O
"),",O
which,O
is,O
also,O
greatly,O
enhanced,O
in,O
N,B-OG
.,I-OG
oceanica,I-OG
and,O
was,O
attributed,O
to,O
the,O
utilization,O
of,O
carbon,O
skeletons,O
derived,O
from,O
membrane,O
lipids,O
to,O
produce,O
energy,O
for,O
TAG,O
or,O
its,O
precursors7,O
.,O
As,O
Nannochloropsis,B-OG
cells,O
lack,O
starch,O
synthesis,O
genes,O
consistent,O
with,O
the,O
absence,O
of,O
pyrenoid,O
starch135960,O
",",O
it,O
may,O
be,O
logical,O
the,O
excess,O
carbon,O
and,O
energy,O
derived,O
from,O
the,O
breakdown,O
of,O
membrane,O
lipids,O
are,O
channeled,O
to,O
TAGs,O
.,O
However,O
",",O
in,O
D,B-OG
.,I-OG
tertiolecta,I-OG
the,O
response,O
was,O
to,O
channel,O
more,O
carbon,O
to,O
starch,O
instead,O
of,O
TAGs,O
",",O
as,O
can,O
be,O
seen,O
from,O
the,O
synchronized,O
upregulation,O
of,O
genes,O
in,O
gluconeogenesis,O
and,O
starch,O
synthesis,O
genes,O
(,O
Table,O
S5,O
).,O
Thus,O
",",O
the,O
increased,O
activity,O
of,O
CCM,O
pathways,O
and,O
genes,O
contributing,O
to,O
the,O
generation,O
of,O
acetyl,O
-,O
CoA,O
and,O
NADPH,O
may,O
merely,O
be,O
a,O
general,O
response,O
of,O
microalgae,B-OG
cells,O
to,O
N,O
-,O
depletion,O
rather,O
than,O
a,O
determinant,O
of,O
oleaginicity,O
.,O
Indeed,O
",",O
it,O
has,O
been,O
previously,O
proposed,O
that,O
the,O
CCM,O
could,O
play,O
varied,O
roles,O
upon,O
N,O
-,O
depletion,O
;,O
the,O
pathways,O
could,O
be,O
involved,O
in,O
providing,O
carbon,O
skeletons,O
",",O
for,O
nitrogen,O
reassimilation,O
",",O
or,O
for,O
channeling,O
excess,O
carbon,O
into,O
FA,O
synthesis61,O
.,O
Noting,O
that,O
most,O
TCA,O
cycle,O
enzymes,O
are,O
bidirectional,O
",",O
Sweetlove,O
et,O
al,O
.,O
62,O
proposed,O
that,O
the,O
TCA,O
cycle,O
could,O
catalyze,O
reverse,O
reactions,O
and,O
be,O
highly,O
adaptable,O
to,O
changing,O
conditions,O
of,O
the,O
cell,O
.,O
Hence,O
",",O
the,O
TCA,O
cycle,O
may,O
act,O
as,O
a,O
central,O
hub,O
",",O
balancing,O
between,O
demands,O
for,O
specific,O
carbon,O
skeletons,O
for,O
anabolic,O
processes,O
",",O
and,O
the,O
energetic,O
needs,O
of,O
the,O
cell,O
in,O
absence,O
of,O
photosynthetic,O
activity,O
as,O
they,O
produce,O
reducing,O
equivalents,O
for,O
ATP,O
synthesis,O
.,O
The,O
preference,O
to,O
store,O
carbon,O
as,O
starch,O
may,O
stem,O
from,O
the,O
fact,O
that,O
it,O
is,O
energetically,O
more,O
favourable,O
to,O
make,O
than,O
TAGs,O
",",O
and,O
is,O
the,O
preferential,O
reserve,O
which,O
is,O
rapidly,O
mobilized,O
during,O
switch,O
from,O
N,O
-,O
deplete,O
to,O
N,O
-,O
replete,O
conditions17,O
.,O
On,O
a,O
per,O
carbon,O
basis,O
",",O
a,O
55,O
-,O
carbon,O
TAG,O
molecule,O
requires,O
6,O
.,O
25,O
ATP,O
and,O
2,O
.,O
93,O
NADPH,O
",",O
while,O
55,O
carbon,O
units,O
of,O
starch,O
requires,O
4,O
.,O
16,O
ATP,O
and,O
2,O
NADPH33,O
;,O
TAG,O
synthesis,O
require,O
50,O
%,O
more,O
ATP,O
and,O
45,O
%,O
more,O
NADPH,O
per,O
carbon,O
to,O
make,O
.,O
While,O
TAGs,O
return,O
more,O
ATP,O
than,O
sugars,O
during,O
metabolism,O
",",O
the,O
energy,O
recovered,O
is,O
less,O
than,O
the,O
energy,O
invested,O
in,O
its,O
synthesis3334,O
",",O
chiefly,O
due,O
to,O
the,O
carbon,O
lost,O
during,O
the,O
conversion,O
of,O
pyruvate,O
to,O
acetyl,O
-,O
CoA,O
by,O
PDC,B-GP
.,O
Much,O
of,O
this,O
begs,O
the,O
question,O
:,O
Why,O
do,O
some,O
microalgae,B-OG
prefer,O
to,O
store,O
more,O
TAGs,O
and,O
others,O
prefer,O
to,O
store,O
predominantly,O
starch,O
",",O
while,O
some,O
are,O
able,O
to,O
store,O
moderately,O
equal,O
amounts,O
of,O
both,O
?,O
One,O
possible,O
explanation,O
is,O
that,O
as,O
lipids,O
require,O
more,O
ATP,O
and,O
reducing,O
power,O
than,O
starch,O
for,O
production,O
",",O
photoheterotrophically,O
grown,O
cells,O
such,O
as,O
C,B-OG
.,I-OG
reinhardtii,I-OG
and,O
C,B-OG
.,I-OG
vulgaris,I-OG
(,O
Table,O
S4,O
),O
can,O
generate,O
more,O
substrates,O
needed,O
for,O
FA,O
synthesis,O
due,O
to,O
their,O
ability,O
to,O
assimilate,O
organic,O
carbon,O
sources,O
on,O
top,O
of,O
inorganic,O
carbon,O
fixation,O
from,O
photosynthesis,O
.,O
For,O
instance,O
",",O
acetate,O
can,O
be,O
directly,O
converted,O
into,O
acetyl,O
-,O
CoA,O
from,O
acetyl,B-GP
-,I-GP
CoA,I-GP
synthetase,I-GP
(,O
ACS,B-GP
"),",O
and,O
incorporate,O
immediately,O
into,O
the,O
TCA,O
cycle,O
or,O
used,O
in,O
FA,O
synthesis,O
by,O
C,O
.,O
reinhardtii34,O
.,O
Likewise,O
",",O
Chlorella,B-OG
grown,O
in,O
acetate,O
medium,O
use,O
ACS,B-GP
to,O
directly,O
incorporate,O
acetate,O
into,O
acetyl,O
-,O
CoA,O
",",O
by,O
-,O
passing,O
the,O
PDC,B-GP
route,O
for,O
acetyl,O
-,O
CoA,O
production,O
and,O
enabling,O
a,O
high,O
rate,O
of,O
lipid,O
synthesis,O
under,O
N,O
-,O
depletion63,O
.,O
Furthermore,O
",",O
glucose,O
-,O
fed,O
Chlorella,B-OG
cultures,O
generate,O
more,O
reducing,O
power,O
in,O
the,O
dark,O
than,O
photoautotrophically,O
cultured,O
Chlorella,B-OG
in,O
the,O
light,O
",",O
thus,O
the,O
former,O
accumulates,O
more,O
lipids,O
and,O
less,O
starch64,O
.,O
This,O
explanation,O
does,O
not,O
extend,O
to,O
Nannochloropsis,B-OG
however,O
",",O
due,O
to,O
its,O
inability,O
to,O
synthesize,O
starch135960,O
.,O
Rather,O
",",O
it,O
stores,O
small,O
amounts,O
of,O
carbohydrates,O
(,O
5,O
–,O
17,O
%),O
while,O
channeling,O
majority,O
of,O
carbon,O
to,O
TAGs,O
during,O
N,O
-,O
depletion,O
.,O
Microalgae,B-OG
of,O
the,O
genus,O
Dunaliella,B-OG
dominate,O
the,O
ranks,O
of,O
top,O
carbohydrate,O
producers,O
",",O
and,O
D,B-OG
.,I-OG
tertiolecta,I-OG
–,O
with,O
the,O
ability,O
to,O
accumulate,O
up,O
to,O
63,O
%,O
DCW,O
in,O
carbohydrates,O
–,O
leads,O
the,O
list12,O
.,O
In,O
this,O
study,O
",",O
we,O
show,O
that,O
D,B-OG
.,I-OG
tertiolecta,I-OG
rapidly,O
accumulates,O
starch,O
in,O
response,O
to,O
N,O
-,O
depletion,O
",",O
suggesting,O
that,O
D,B-OG
.,I-OG
tertiolecta,I-OG
cells,O
tend,O
to,O
favor,O
starch,O
over,O
TAGs,O
as,O
an,O
efficient,O
strategy,O
for,O
chemical,O
energy,O
accumulation,O
(,O
Fig,O
.,O
2a,O
",",O
f,O
).,O
As,O
an,O
obligate,O
photoautotroph,O
that,O
cannot,O
use,O
dissolved,O
organic,O
compounds3265,O
",",O
efficient,O
energy,O
storage,O
and,O
utilization,O
is,O
of,O
paramount,O
importance,O
",",O
especially,O
since,O
photosynthesis,O
is,O
inefficient,O
with,O
less,O
than,O
8,O
%,O
conversion,O
of,O
solar,O
energy,O
chemical,O
energy33,O
.,O
Notably,O
",",O
starch,O
reserves,O
provide,O
the,O
energy,O
required,O
in,O
the,O
dark,O
for,O
DNA,O
replication,O
and,O
general,O
cell,O
metabolism66,O
.,O
This,O
is,O
in,O
line,O
with,O
the,O
increase,O
in,O
gene,O
expression,O
of,O
starch,O
-,O
degrading,O
enzymes,O
in,O
D,B-OG
.,I-OG
tertiolecta,I-OG
during,O
N,O
-,O
depletion,O
(,O
Fig,O
.,O
4,O
",",O
Fig,O
.,O
S7,O
"),",O
when,O
photosynthesis,O
is,O
compromised,O
.,O
D,B-OG
.,I-OG
tertiolecta,I-OG
also,O
specifically,O
degrade,O
starch,O
in,O
high,O
salinity,O
stress,O
conditions,O
to,O
yield,O
DHAP,O
which,O
can,O
be,O
used,O
to,O
produce,O
glycerol67,O
",",O
making,O
starch,O
a,O
more,O
suitable,O
storage,O
compound,O
as,O
the,O
cells,O
can,O
respond,O
to,O
both,O
nutrient,O
deficiency,O
and,O
salinity,O
stress,O
",",O
conditions,O
which,O
could,O
fluctuate,O
greatly,O
in,O
their,O
natural,O
environments68,O
.,O
In,O
light,O
of,O
these,O
observations,O
",",O
it,O
is,O
reasonable,O
to,O
assume,O
that,O
carbon,O
would,O
be,O
channeled,O
to,O
TAG,O
production,O
once,O
starch,O
synthesis,O
is,O
blocked,O
.,O
However,O
",",O
this,O
notion,O
was,O
refuted,O
as,O
there,O
was,O
no,O
increase,O
in,O
oil,O
among,O
three,O
starchless,O
C,B-OG
.,I-OG
reinhardtii,I-OG
mutants,O
examined17,O
",",O
suggesting,O
that,O
blocking,O
starch,O
synthesis,O
does,O
not,O
result,O
in,O
oil,O
accumulation,O
.,O
Preference,O
of,O
starch,O
and,O
TAG,O
accumulation,O
in,O
microalgae,B-OG
may,O
instead,O
stem,O
from,O
natural,O
evolutionary,O
patterns,O
and,O
exposure,O
to,O
different,O
carbon,O
sources,O
.,O
D,B-OG
.,I-OG
tertiolecta,I-OG
was,O
previously,O
reported,O
to,O
accumulate,O
and,O
release,O
glycerol,O
into,O
the,O
external,O
medium,O
",",O
and,O
that,O
the,O
process,O
was,O
not,O
affected,O
by,O
nutrient,O
starvation,O
or,O
cell,O
death36,O
.,O
In,O
this,O
study,O
",",O
we,O
show,O
that,O
under,O
N,O
-,O
depletion,O
increased,O
amounts,O
of,O
glycerol,O
were,O
present,O
in,O
the,O
extracellular,O
medium,O
(,O
Fig,O
.,O
2e,O
"),",O
indicating,O
that,O
glycerol,O
synthesis,O
and,O
export,O
is,O
a,O
response,O
to,O
nutrient,O
stress,O
.,O
This,O
is,O
supported,O
by,O
the,O
marked,O
upregulation,O
of,O
a,O
triose,B-GP
phosphate,I-GP
translocator,I-GP
",",O
which,O
exports,O
photosynthetically,O
fixed,O
carbon,O
or,O
carbon,O
derived,O
from,O
starch,O
breakdown,O
from,O
the,O
chloroplast,O
to,O
the,O
cytosol,O
",",O
where,O
the,O
enzyme,O
GPDH,B-GP
converts,O
into,O
glycerol,O
(,O
Fig,O
.,O
4,O
).,O
D,B-OG
.,I-OG
tertiolecta,I-OG
is,O
known,O
to,O
uptake,O
exogenous,O
glycerol,O
in,O
response,O
to,O
stress69,O
",",O
and,O
as,O
releasing,O
glycerol,O
to,O
the,O
external,O
medium,O
provides,O
the,O
cells,O
with,O
an,O
expansive,O
carbon,O
sink,O
not,O
restricted,O
by,O
cell,O
size,O
",",O
the,O
extracellular,O
glycerol,O
may,O
serve,O
as,O
a,O
readily,O
utilizable,O
carbon,O
source,O
for,O
the,O
cells,O
in,O
anticipation,O
of,O
improving,O
nutrient,O
environments36,O
.,O
The,O
present,O
study,O
identifies,O
the,O
unique,O
transcriptome,O
signatures,O
of,O
D,B-OG
.,I-OG
tertiolecta,I-OG
",",O
a,O
high,O
starch,O
-,O
accumulating,O
microalga,B-OG
in,O
response,O
to,O
N,O
-,O
depletion,O
.,O
In,O
particular,O
",",O
its,O
coordinated,O
upregulation,O
of,O
genes,O
involved,O
in,O
starch,O
synthesis,O
could,O
be,O
attributed,O
to,O
its,O
preference,O
to,O
store,O
starch,O
over,O
TAGs,O
.,O
However,O
",",O
D,B-OG
.,I-OG
tertiolecta,I-OG
also,O
shares,O
similar,O
upregulation,O
of,O
CCM,O
genes,O
as,O
the,O
oleaginous,O
microalga,B-OG
N,B-OG
.,I-OG
oceanica,I-OG
",",O
where,O
CCM,O
pathways,O
were,O
suggested,O
to,O
provide,O
substrates,O
for,O
FA,O
and,O
TAG,O
synthesis,O
during,O
N,O
-,O
depletion,O
.,O
The,O
perplexing,O
similarities,O
and,O
differences,O
in,O
transcriptomic,O
and,O
metabolic,O
responses,O
of,O
oleaginous,O
and,O
non,O
-,O
oleaginous,O
microalgae,B-OG
thus,O
demands,O
a,O
relook,O
into,O
the,O
role,O
of,O
biochemical,O
pathways,O
governing,O
the,O
allocation,O
of,O
carbon,O
and,O
energy,O
in,O
the,O
cell,O
.,O
Addressing,O
these,O
issues,O
would,O
advance,O
our,O
understanding,O
of,O
starch,O
and,O
lipid,O
synthesis,O
in,O
microalgae,B-OG
as,O
well,O
as,O
facilitate,O
the,O
genetic,O
engineering,O
of,O
microorganisms,B-OG
designed,O
to,O
accumulate,O
either,O
storage,O
product,O
of,O
interest,O
.,O
Methods,O
Microalgae,B-OG
Strain,O
and,O
Culture,O
Conditions,O
The,O
Dunaliella,B-OG
tertiolecta,I-OG
strain,I-OG
(,I-OG
UTEX,I-OG
LB,I-OG
999,I-OG
),I-OG
was,O
obtained,O
from,O
the,O
University,O
of,O
Texas,O
at,O
Austin,O
(,O
UTEX,O
),O
and,O
maintained,O
in,O
sterile,O
ATCC,O
-,O
1174,O
DA,O
medium,O
under,O
nitrogen,O
-,O
replete,O
condition,O
of,O
5,O
mM,O
KNO3,O
(,O
American,O
Type,O
Culture,O
Collection,O
at,O
Manassas,O
",",O
Virginia,O
),O
containing,O
0,O
.,O
5,O
M,O
NaCl,O
(,O
Table,O
S1,O
).,O
The,O
cells,O
were,O
grown,O
in,O
50,O
-,O
mL,O
batch,O
cultures,O
on,O
a,O
rotary,O
shaker,O
at,O
25,O
°,O
C,O
and,O
illuminated,O
with,O
30,O
μmol,O
photons,O
m2,O
/,O
s,O
under,O
a,O
photoperiod,O
of,O
14,O
h,O
Light,O
/,O
10,O
h,O
Dark,O
",",O
with,O
or,O
without,O
5,O
%,O
CO2,O
aeration,O
.,O
Cell,O
densities,O
were,O
determined,O
using,O
an,O
automated,O
cell,O
counter,O
(,O
TC20TM,O
automated,O
cell,O
counter,O
",",O
Biorad,O
Laboratories,O
).,O
Prior,O
to,O
counting,O
",",O
D,B-OG
.,I-OG
tertiolecta,I-OG
cells,O
were,O
fixed,O
with,O
2,O
%,O
paraformaldehyde,O
.,O
Optical,O
density,O
measurements,O
(,O
OD680,O
),O
were,O
conducted,O
with,O
an,O
UV,O
spectrophotometer,O
(,O
Genesys,O
10,O
S,O
UV,O
-,O
VIS,O
",",O
ThermoFisher,O
Scientific,O
).,O
Biomass,O
was,O
determined,O
by,O
dry,O
cell,O
weight,O
(,O
DCW,O
),O
(,O
g,O
/,O
mL,O
),O
measurement,O
and,O
combined,O
with,O
cell,O
density,O
(,O
cells,O
/,O
mL,O
),O
to,O
get,O
dcw,O
per,O
cell,O
(,O
g,O
/,O
cell,O
).,O
Ten,O
-,O
milliliter,O
(,O
10,O
mL,O
),O
of,O
cells,O
were,O
collected,O
by,O
filtration,O
on,O
pre,O
-,O
weighed,O
Advantec,O
GB,O
-,O
140,O
filter,O
paper,O
(,O
0,O
.,O
4,O
μm,O
pore,O
size,O
;,O
diameter,O
47,O
mm,O
"),",O
and,O
washed,O
with,O
isotonic,O
0,O
.,O
5,O
M,O
ammonium,O
formate,O
(,O
40,O
mL,O
),O
to,O
remove,O
salts,O
without,O
causing,O
the,O
cells,O
to,O
burst,O
.,O
Cells,O
captured,O
on,O
filter,O
paper,O
discs,O
were,O
dried,O
in,O
oven,O
at,O
95,O
°,O
C,O
until,O
the,O
weight,O
was,O
constant,O
.,O
Work,O
conducted,O
throughout,O
the,O
paper,O
is,O
based,O
on,O
biological,O
triplicates,O
unless,O
otherwise,O
stated,O
.,O
Nitrogen,O
Depletion,O
and,O
Cultivation,O
D,B-OG
.,I-OG
tertiolecta,I-OG
subjected,O
to,O
nitrogen,O
depletion,O
(,O
N,O
-,O
depletion,O
),O
were,O
grown,O
in,O
nitrogen,O
-,O
limited,O
media,O
(,O
ATCC,O
-,O
1174,O
DA,O
medium,O
containing,O
0,O
.,O
5,O
mM,O
KNO3,O
",",O
equivalent,O
to,O
10,O
%,O
of,O
original,O
KNO3,O
concentration,O
;,O
K,O
substituted,O
with,O
KCl,O
),O
(,O
Table,O
S1,O
).,O
N,O
-,O
depletion,O
was,O
achieved,O
by,O
harvesting,O
exponentially,O
growing,O
cells,O
(,O
cell,O
density,O
approximately,O
3,O
×,O
106,O
cells,O
/,O
mL,O
),O
and,O
twice,O
washing,O
them,O
with,O
fresh,O
ATCC,O
medium,O
containing,O
10,O
%,O
KNO3,O
.,O
All,O
experimental,O
cultures,O
began,O
at,O
an,O
OD680,O
of,O
0,O
.,O
1,O
for,O
standardization,O
.,O
Nitrate,O
concentration,O
was,O
determined,O
using,O
a,O
UV,O
spectrophotometric,O
method,O
measuring,O
the,O
difference,O
between,O
OD220,O
and,O
OD275,O
",",O
and,O
converted,O
with,O
a,O
standard,O
curve,O
(,O
Fig,O
.,O
S1,O
).,O
Cells,O
were,O
harvested,O
at,O
regular,O
time,O
intervals,O
corresponding,O
to,O
exponential,O
",",O
late,O
-,O
exponential,O
and,O
stationary,O
phases,O
for,O
RNA,O
extraction,O
",",O
neutral,O
lipid,O
analysis,O
",",O
fluorescence,O
microscopy,O
",",O
and,O
biomass,O
measurements,O
.,O
Experiments,O
were,O
conducted,O
as,O
independent,O
biological,O
triplicates,O
.,O
Total,O
Organic,O
Carbon,O
",",O
chlorophyll,O
",",O
photosynthetic,O
yield,O
",",O
starch,O
and,O
glycerol,O
measurements,O
Intracellular,O
total,O
organic,O
carbon,O
(,O
TOC,O
),O
content,O
was,O
measured,O
using,O
an,O
automated,O
High,O
Temperature,O
Combustion,O
TOC,O
Analyzer,O
(,O
LOTIX,O
;,O
Teledyne,O
Tekmar,O
"),",O
installed,O
with,O
a,O
Non,O
-,O
Dispersive,O
Infrared,O
Detector,O
.,O
Cell,O
densities,O
of,O
3,O
×,O
107,O
cells,O
were,O
harvested,O
",",O
spun,O
down,O
and,O
washed,O
with,O
1,O
mL,O
of,O
0,O
.,O
08,O
M,O
NaCl,O
",",O
reconstituted,O
in,O
ultrapure,O
water,O
to,O
a,O
final,O
volume,O
of,O
20,O
mL,O
",",O
and,O
transferred,O
to,O
the,O
TOC,O
analyzer,O
for,O
analysis,O
.,O
Starch,O
content,O
was,O
measured,O
using,O
the,O
Starch,O
Assay,O
Kit,O
(,O
STA20,O
;,O
Sigma,O
-,O
Aldrich,O
"),",O
performed,O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
instructions,O
.,O
Glycerol,O
content,O
was,O
measured,O
using,O
the,O
Free,O
Glycerol,O
Determination,O
Kit,O
(,O
FG0100,O
;,O
Sigma,O
-,O
Aldrich,O
),O
as,O
previously,O
reported,O
by,O
Chow,O
et,O
al,O
.,O
35,O
.,O
Harvested,O
cells,O
were,O
centrifuged,O
(,O
10,O
",",O
000,O
g,O
for,O
10,O
mins,O
",",O
4,O
°,O
C,O
),O
and,O
the,O
cell,O
pellet,O
and,O
supernatant,O
were,O
separated,O
for,O
measurement,O
of,O
intracellular,O
and,O
extracellular,O
glycerol,O
respectively,O
.,O
For,O
intracellular,O
glycerol,O
",",O
the,O
cell,O
pellet,O
was,O
washed,O
with,O
equivalent,O
volume,O
of,O
0,O
.,O
5,O
M,O
NaCl,O
and,O
centrifuged,O
again,O
to,O
remove,O
remaining,O
extracellular,O
glycerol,O
.,O
The,O
cell,O
pellet,O
was,O
then,O
resuspended,O
in,O
200,O
μL,O
of,O
ultrapure,O
water,O
",",O
vortexed,O
and,O
boiled,O
for,O
15,O
mins,O
.,O
Subsequently,O
",",O
the,O
samples,O
were,O
centrifuged,O
to,O
remove,O
cell,O
debris,O
",",O
and,O
the,O
supernatant,O
collected,O
for,O
intracellular,O
glycerol,O
analysis,O
.,O
Photosynthetic,O
yields,O
(,O
maximum,O
efficiency,O
of,O
photosystem,O
II,O
;,O
Fv,O
/,O
Fm,O
),O
were,O
evaluated,O
using,O
chlorophyll,O
fluorescence,O
measured,O
with,O
AquaPen,O
-,O
C,O
fluorometer,O
(,O
AP,O
-,O
C,O
100,O
/,O
USB,O
;,O
Photon,O
Systems,O
Instruments,O
).,O
Cells,O
were,O
dark,O
-,O
adapted,O
for,O
5,O
mins,O
before,O
using,O
the,O
fluorometer,O
to,O
measure,O
Fv,O
/,O
Fm,O
values,O
according,O
to,O
the,O
user,O
’,O
s,O
manual,O
.,O
For,O
chlorophyll,O
measurements,O
",",O
cells,O
were,O
centrifuged,O
(,O
10,O
",",O
000,O
g,O
for,O
10,O
mins,O
",",O
4,O
°,O
C,O
"),",O
supernatant,O
were,O
removed,O
",",O
and,O
the,O
cell,O
pellet,O
resuspended,O
in,O
0,O
.,O
5,O
mL,O
DMSO,O
and,O
vortexed,O
for,O
1,O
min,O
until,O
the,O
pellet,O
disintegrated,O
.,O
An,O
equivalent,O
volume,O
of,O
90,O
%,O
acetone,O
was,O
added,O
and,O
mixed,O
well,O
",",O
followed,O
by,O
centrifugation,O
to,O
remove,O
cell,O
debris,O
.,O
The,O
supernatant,O
(,O
extraction,O
volume,O
of,O
800,O
μL,O
),O
was,O
used,O
for,O
measuring,O
absorbances,O
at,O
630,O
nm,O
",",O
647,O
nm,O
",",O
664,O
nm,O
",",O
665,O
nm,O
",",O
and,O
750,O
nm,O
using,O
a,O
UV,O
spectrophotometer,O
.,O
Correction,O
of,O
pheopigments,O
was,O
done,O
by,O
adding,O
40,O
μL,O
of,O
1,O
M,O
HCl,O
to,O
To,O
the,O
mixture,O
and,O
incubating,O
at,O
room,O
temperature,O
for,O
90,O
secs,O
.,O
Absorbances,O
were,O
measured,O
again,O
at,O
665,O
nm,O
and,O
750,O
nm,O
.,O
Chlorophyll,O
amounts,O
were,O
calculated,O
according,O
to,O
trichromatic,O
equations70,O
and,O
the,O
monochromatic,O
equation,O
for,O
pheopigment,O
correction71,O
.,O
1,O
.,O
Trichromatic,O
equations,O
:,O
2,O
.,O
Monochromatic,O
equation,O
for,O
pheopigment,O
correction,O
:,O
where,O
L,O
=,O
Light,O
path,O
of,O
the,O
cuvette,O
(,O
cm,O
),O
Ve,O
=,O
Extraction,O
volume,O
(,O
mL,O
),O
Vs,O
=,O
Sample,O
volume,O
which,O
was,O
harvested,O
(,O
mL,O
),O
R,O
=,O
maximum,O
absorbance,O
ratio,O
of,O
OD665o,O
/,O
OD665a,O
in,O
the,O
absence,O
of,O
pheopigments,O
=,O
1,O
.,O
7,O
K,O
=,O
R,O
/(,O
R,O
−,O
1,O
),O
=,O
2,O
.,O
43,O
Total,O
chlorophyll,O
(,O
μg,O
/,O
mL,O
),O
=,O
Chlorophyll,O
b,O
(,O
μg,O
/,O
mL,O
),O
+,O
Corrected,O
chlorophyll,O
a,O
(,O
μg,O
/,O
mL,O
),O
Neutral,O
Lipid,O
Quantification,O
A,O
modified,O
Nile,O
Red,O
staining,O
method28,O
was,O
used,O
to,O
quantify,O
intracellular,O
TAGs,O
.,O
Briefly,O
",",O
cells,O
were,O
harvested,O
by,O
centrifugation,O
(,O
3000,O
g,O
for,O
10,O
min,O
at,O
4,O
°,O
C,O
"),",O
supernatant,O
was,O
removed,O
and,O
the,O
pellet,O
resuspended,O
in,O
fresh,O
0,O
.,O
5,O
M,O
ATCC,O
-,O
1174,O
DA,O
media,O
to,O
an,O
OD680,O
of,O
0,O
.,O
3,O
.,O
Triolein,O
was,O
used,O
as,O
a,O
standard,O
for,O
determining,O
neutral,O
lipid,O
concentrations,O
by,O
Nile,O
Red,O
(,O
Fig,O
.,O
S10,O
).,O
Two,O
hundred,O
microliters,O
of,O
triolein,O
standards,O
(,O
40,O
",",O
20,O
",",O
10,O
",",O
5,O
",",O
2,O
.,O
5,O
",",O
0,O
μg,O
/,O
mL,O
),O
and,O
cell,O
suspensions,O
were,O
loaded,O
as,O
technical,O
triplicates,O
onto,O
a,O
96,O
-,O
well,O
black,O
",",O
clear,O
bottom,O
plate,O
(,O
CLS3603,O
;,O
Sigma,O
-,O
Aldrich,O
).,O
Prior,O
to,O
staining,O
",",O
Nile,O
red,O
stock,O
is,O
diluted,O
in,O
acetone,O
to,O
obtain,O
a,O
working,O
solution,O
(,O
25,O
μg,O
/,O
mL,O
"),",O
and,O
2,O
μL,O
of,O
the,O
Nile,O
red,O
working,O
solution,O
is,O
added,O
to,O
each,O
well,O
of,O
sample,O
and,O
standard,O
",",O
followed,O
by,O
a,O
5,O
min,O
incubation,O
in,O
the,O
dark,O
.,O
Fluorescence,O
of,O
each,O
sample,O
was,O
detected,O
using,O
a,O
microplate,O
reader,O
(,O
Infinite,O
M200,O
PRO,O
",",O
Tecan,O
),O
at,O
excitation,O
and,O
emission,O
wavelengths,O
of,O
524,O
nm,O
and,O
586,O
nm,O
.,O
Fluorescence,O
imaging,O
of,O
Nile,O
Red,O
-,O
stained,O
cells,O
was,O
performed,O
with,O
an,O
automated,O
fluorescence,O
microscope,O
(,O
Olympus,O
BX63,O
).,O
Acquisition,O
and,O
processing,O
of,O
data,O
was,O
done,O
using,O
the,O
cellSens,O
software,O
.,O
Total,O
Lipid,O
Analysis,O
by,O
Gas,O
Chromatography,O
-,O
Mass,O
Spectrometry,O
To,O
analyze,O
the,O
accumulation,O
of,O
total,O
lipids,O
",",O
cells,O
were,O
harvested,O
",",O
snap,O
-,O
frozen,O
in,O
liquid,O
nitrogen,O
and,O
stored,O
at,O
−,O
80,O
°,O
C,O
until,O
analysis,O
.,O
Frozen,O
culture,O
samples,O
were,O
lyophilized,O
by,O
freeze,O
-,O
drying,O
and,O
lipids,O
were,O
extracted,O
by,O
hexane,O
using,O
direct,O
transesterification72,O
as,O
it,O
was,O
reported,O
to,O
be,O
a,O
convenient,O
and,O
accurate,O
method,O
for,O
analyzing,O
total,O
fatty,O
acids73,O
.,O
Biomass,O
quantities,O
of,O
between,O
5,O
and,O
10,O
mg,O
of,O
biomass,O
were,O
weighed,O
into,O
glass,O
55,O
-,O
mL,O
PYREX,O
culture,O
tubes,O
with,O
polytetrafluoroethylene,O
(,O
PTFE,O
)-,O
lined,O
phenolic,O
caps,O
(,O
25,O
mm,O
diameter,O
×,O
150,O
mm,O
height,O
",",O
PYREX,O
#,O
9826,O
–,O
25,O
",",O
Corning,O
).,O
To,O
each,O
sample,O
",",O
0,O
.,O
2,O
mL,O
of,O
chloroform,O
-,O
methanol,O
(,O
2,O
:,O
1,O
",",O
v,O
/,O
v,O
),O
was,O
added,O
and,O
mixed,O
by,O
vortexing,O
",",O
followed,O
by,O
simultaneous,O
transesterification,O
of,O
lipids,O
with,O
0,O
.,O
3,O
mL,O
of,O
1,O
.,O
25,O
M,O
methanolic,O
HCl,O
and,O
vortexed,O
to,O
mix,O
.,O
An,O
internal,O
standard,O
(,O
100,O
μg,O
Methyl,O
tridecanoate,O
",",O
C13,O
-,O
Fatty,O
Acid,O
Methyl,O
Ester,O
",",O
C13,O
-,O
FAME,O
;,O
Cat,O
.,O
no,O
.,O
91558,O
",",O
Sigma,O
-,O
Aldrich,O
),O
was,O
included,O
to,O
correct,O
for,O
the,O
loss,O
of,O
FAME,O
during,O
the,O
reaction,O
",",O
and,O
to,O
correct,O
for,O
subsequent,O
incomplete,O
extraction,O
of,O
hexane74,O
.,O
The,O
culture,O
tube,O
was,O
then,O
incubated,O
in,O
a,O
50,O
°,O
C,O
waterbath,O
overnight,O
.,O
After,O
24,O
hours,O
",",O
1,O
mL,O
of,O
hexane,O
was,O
added,O
and,O
mixed,O
by,O
vortex,O
",",O
and,O
incubated,O
at,O
room,O
temperature,O
for,O
1,O
hour,O
.,O
The,O
upper,O
organic,O
phase,O
containing,O
FAMEs,O
was,O
removed,O
using,O
a,O
glass,O
pipette,O
",",O
filtered,O
through,O
a,O
0,O
.,O
22,O
-,O
μm,O
PTFE,O
syringe,O
filter,O
(,O
Agilent,O
Technologies,O
"),",O
and,O
collected,O
in,O
a,O
250,O
-,O
μL,O
glass,O
vial,O
insert,O
(,O
Part,O
no,O
.,O
5181,O
–,O
1270,O
",",O
Agilent,O
Technologies,O
).,O
FAME,O
extracts,O
were,O
injected,O
into,O
a,O
GC,O
system,O
(,O
Model,O
7890B,O
",",O
Agilent,O
Technologies,O
),O
equipped,O
with,O
an,O
Agilent,O
19091S,O
-,O
433UI,O
column,O
(,O
30,O
m,O
×,O
250,O
μm,O
×,O
0,O
.,O
25,O
μm,O
),O
interfaced,O
with,O
a,O
mass,O
spectrometric,O
detector,O
(,O
Model,O
5977,O
A,O
",",O
Agilent,O
Technologies,O
).,O
Injection,O
volume,O
was,O
set,O
at,O
1,O
μL,O
with,O
a,O
5,O
:,O
1,O
split,O
ratio,O
at,O
a,O
GC,O
inlet,O
temperature,O
of,O
250,O
°,O
C,O
.,O
Helium,O
was,O
used,O
as,O
the,O
carrier,O
gas,O
in,O
a,O
fixed,O
flow,O
of,O
1,O
mL,O
/,O
min,O
throughout,O
.,O
Temperature,O
program,O
is,O
as,O
follows,O
:,O
initial,O
oven,O
temperature,O
of,O
70,O
°,O
C,O
held,O
for,O
3,O
mins,O
",",O
ramp,O
to,O
130,O
°,O
C,O
at,O
20,O
°,O
C,O
/,O
min,O
",",O
178,O
°,O
C,O
at,O
4,O
°,O
C,O
/,O
min,O
",",O
190,O
°,O
C,O
at,O
1,O
°,O
C,O
/,O
min,O
",",O
and,O
290,O
°,O
C,O
at,O
10,O
°,O
C,O
/,O
min,O
.,O
The,O
total,O
run,O
time,O
was,O
40,O
minutes,O
.,O
Shifting,O
of,O
retention,O
times,O
(,O
RTs,O
),O
were,O
eliminated,O
by,O
comparing,O
the,O
RTs,O
of,O
each,O
FA,O
compound,O
to,O
the,O
C13,O
-,O
FAME,O
internal,O
standard,O
.,O
Analysis,O
was,O
performed,O
using,O
the,O
MassHunter,O
WorkStation,O
Qualitative,O
Analysis,O
B,O
.,O
07,O
.,O
00,O
software,O
(,O
Agilent,O
Technologies,O
),O
and,O
compounds,O
were,O
identified,O
with,O
the,O
NIST,O
mass,O
spectral,O
library,O
(,O
National,O
Institute,O
of,O
Standards,O
and,O
Technology,O
",",O
Data,O
Version,O
:,O
NIST,O
14,O
).,O
Preparation,O
of,O
cDNA,O
Libraries,O
for,O
Transcriptome,O
-,O
sequencing,O
Total,O
RNA,O
of,O
N,O
-,O
replete,O
and,O
N,O
-,O
deplete,O
cells,O
on,O
day,O
3,O
and,O
day,O
5,O
were,O
used,O
for,O
RNA,O
-,O
seq,O
as,O
they,O
correspond,O
to,O
late,O
-,O
exponential,O
and,O
stationary,O
phases,O
of,O
cells,O
grown,O
under,O
N,O
-,O
deplete,O
conditions,O
",",O
compared,O
to,O
N,O
-,O
replete,O
cells,O
which,O
are,O
in,O
exponential,O
phase,O
.,O
RNA,O
integrity,O
was,O
assessed,O
on,O
an,O
Agilent,O
2100,O
Bioanalyzer,O
(,O
Agilent,O
Technologies,O
),O
using,O
the,O
RNA,O
6000,O
Nano,O
Kit,O
(,O
Cat,O
.,O
no,O
.,O
5067,O
–,O
1511,O
;,O
Agilent,O
Technologies,O
).,O
Construction,O
of,O
cDNA,O
was,O
performed,O
with,O
approximately,O
2,O
μg,O
of,O
RNA,O
using,O
a,O
TruSeq,O
Stranded,O
Total,O
RNA,O
LT,O
Sample,O
Prep,O
Kit,O
(,O
Illumina,O
),O
following,O
the,O
manufacturer,O
’,O
s,O
procedures,O
(,O
first,O
and,O
second,O
strand,O
cDNA,O
synthesis,O
",",O
3,O
′,O
end,O
adenylation,O
",",O
adapter,O
ligation,O
",",O
DNA,O
fragment,O
enrichment,O
of,O
~,O
300,O
bp,O
in,O
length,O
).,O
Ribo,O
-,O
Zero,O
rRNA,O
Removal,O
Kit,O
for,O
Plant,O
(,O
Illumina,O
),O
was,O
used,O
to,O
reduce,O
ribosomal,O
RNA,O
amount,O
in,O
each,O
sample,O
.,O
The,O
quality,O
of,O
constructed,O
cDNA,O
libraries,O
and,O
size,O
of,O
DNA,O
fragments,O
were,O
validated,O
on,O
the,O
Bioanalyzer,O
with,O
Agilent,O
DNA,O
1000,O
kit,O
(,O
Cat,O
.,O
no,O
.,O
5067,O
–,O
1505,O
;,O
Agilent,O
Technologies,O
"),",O
before,O
being,O
quantified,O
by,O
qPCR,O
with,O
the,O
KAPA,O
Library,O
Quantification,O
Kit,O
for,O
Illumina,O
platforms,O
(,O
Cat,O
.,O
no,O
.,O
KK4824,O
;,O
Kapa,O
Biosystems,O
).,O
RNA,O
-,O
Seq,O
and,O
Differential,O
Gene,O
Expression,O
Analysis,O
The,O
cDNA,O
libraries,O
were,O
normalized,O
to,O
10,O
nM,O
",",O
pooled,O
in,O
equal,O
volumes,O
",",O
and,O
sequenced,O
for,O
2,O
×,O
300,O
-,O
bp,O
runs,O
(,O
paired,O
-,O
end,O
),O
using,O
Illumina,O
MiSeq,O
Sequencer,O
(,O
Illumina,O
).,O
A,O
set,O
of,O
four,O
cDNA,O
libraries,O
were,O
sequenced,O
per,O
run,O
in,O
order,O
to,O
generate,O
sufficient,O
reads,O
for,O
each,O
sample,O
.,O
FASTQ,O
datasets,O
generated,O
from,O
Illumina,O
Miseq,O
were,O
uploaded,O
into,O
a,O
Partek,O
®,O
Flow,O
®,O
web,O
server,O
(,O
version,O
4,O
.,O
0,O
",",O
Partek,O
Inc,O
.).,O
To,O
ensure,O
quality,O
",",O
the,O
raw,O
data,O
were,O
trimmed,O
from,O
both,O
ends,O
with,O
the,O
following,O
criteria,O
:,O
Phred,O
-,O
equivalent,O
quality,O
score,O
of,O
more,O
than,O
20,O
",",O
minimum,O
read,O
length,O
of,O
25,O
",",O
quality,O
encoding,O
=,O
autodetect,O
.,O
The,O
filtered,O
reads,O
were,O
aligned,O
with,O
STAR,O
aligner,O
(,O
version,O
2,O
.,O
3,O
.,O
1j,O
;,O
default,O
parameters,O
),O
75,O
to,O
an,O
assembled,O
D,B-OG
.,I-OG
tertiolecta,I-OG
transcriptome,O
database,O
previously,O
created,O
by,O
our,O
colleagues28,O
.,O
Data,O
aligned,O
to,O
the,O
transcriptome,O
from,O
STAR,O
were,O
used,O
to,O
test,O
for,O
differential,O
expression,O
of,O
genes,O
between,O
N,O
-,O
replete,O
and,O
N,O
-,O
deplete,O
samples,O
.,O
This,O
was,O
performed,O
at,O
transcript,O
level,O
with,O
the,O
Gene,O
-,O
specific,O
analysis,O
(,O
GSA,O
),O
approach,O
from,O
Partek,O
®,O
Flow,O
®,O
(,O
Poisson,O
model,O
was,O
selected,O
),O
and,O
normalized,O
to,O
RPKM,O
(,O
Reads,O
Per,O
Kilobase,O
per,O
Million,O
mapped,O
reads,O
),O
values,O
.,O
Genes,O
were,O
considered,O
to,O
be,O
significantly,O
differentially,O
expressed,O
if,O
their,O
expression,O
values,O
had,O
at,O
least,O
a,O
fold,O
change,O
greater,O
than,O
±,O
2,O
",",O
a,O
false,O
discovery,O
rate,O
(,O
FDR,O
)-,O
corrected,O
p,O
value,O
of,O
≤,O
0,O
.,O
05,O
(,O
Benjamini,O
-,O
Hochberg,O
step,O
-,O
up,O
correction,O
"),",O
and,O
the,O
read,O
coverage,O
at,O
either,O
of,O
the,O
culture,O
conditions,O
were,O
≥,O
10,O
.,O
The,O
RNA,O
-,O
seq,O
raw,O
data,O
were,O
deposited,O
in,O
the,O
Sequence,O
Read,O
Archive,O
database,O
(,O
http,O
://,O
www,O
.,O
ncbi,O
.,O
nlm,O
.,O
nih,O
.,O
gov,O
/,O
Traces,O
/,O
sra,O
/),O
under,O
the,O
accession,O
numbers,O
SRR4011621,O
",",O
SRR4011622,O
",",O
SRR4011623,O
",",O
SRR4011624,O
",",O
SRR4011625,O
",",O
SRR4011626,O
",",O
SRR4011627,O
",",O
and,O
SRR4011628,O
.,O
Functional,O
Annotation,O
and,O
Biological,O
Interpretation,O
of,O
RNA,O
-,O
seq,O
data,O
Functional,O
annotation,O
of,O
cDNA,O
reads,O
was,O
performed,O
with,O
the,O
Partek,O
®,O
Genomics,O
Suite,O
®,O
(,O
PGS,O
),O
software,O
(,O
version,O
6,O
.,O
6,O
",",O
Partek,O
Inc,O
.).,O
The,O
GSA,O
file,O
containing,O
filtered,O
genes,O
and,O
their,O
associated,O
information,O
was,O
imported,O
into,O
PGS,O
and,O
merged,O
with,O
the,O
assembled,O
D,B-OG
.,I-OG
tertiolecta,I-OG
transcriptome,O
annotation,O
file,O
according,O
to,O
the,O
name,O
of,O
D,B-OG
.,I-OG
tertiolecta,I-OG
contigs,O
.,O
The,O
annotated,O
data,O
was,O
subsequently,O
used,O
to,O
perform,O
Gene,O
Ontology,O
(,O
GO,O
),O
enrichment,O
with,O
a,O
modified,O
C,B-OG
.,I-OG
reinhardtii,I-OG
GO,O
annotation,O
file28,O
downloaded,O
from,O
JGI,O
website,O
(,O
http,O
://,O
jgi,O
.,O
doe,O
.,O
gov,O
/).,O
Representative,O
pathways,O
were,O
discovered,O
by,O
mapping,O
the,O
gene,O
names,O
to,O
the,O
C,B-OG
.,I-OG
reinhardtii,I-OG
Kyoto,O
Encyclopedia,O
of,O
Genes,O
and,O
Genomes,O
(,O
KEGG,O
),O
database,O
(,O
http,O
://,O
www,O
.,O
genome,O
.,O
jp,O
/),O
using,O
the,O
pathway,O
analysis,O
tool7677,O
.,O
Both,O
GO,O
enrichment,O
and,O
KEGG,O
pathway,O
analyses,O
were,O
conducted,O
using,O
the,O
Fisher,O
’,O
s,O
Exact,O
test,O
;,O
the,O
analysis,O
was,O
restricted,O
to,O
pathways,O
with,O
more,O
than,O
2,O
genes,O
",",O
and,O
results,O
were,O
filtered,O
by,O
enrichment,O
p,O
-,O
value,O
of,O
less,O
than,O
0,O
.,O
05,O
.,O
Additional,O
Information,O
How,O
to,O
cite,O
this,O
article,O
:,O
Tan,O
",",O
K,O
.,O
W,O
.,O
M,O
.,O
et,O
al,O
.,O
Nitrogen,O
-,O
induced,O
metabolic,O
changes,O
and,O
molecular,O
determinants,O
of,O
carbon,O
allocation,O
in,O
Dunaliella,B-OG
tertiolecta,I-OG
.,O
Sci,O
.,O
Rep,O
.,O
6,O
",",O
37235,O
;,O
doi,O
:,O
10,O
.,O
1038,O
/,O
srep37235,O
(,O
2016,O
).,O
Publisher,O
’,O
s,O
note,O
:,O
Springer,O
Nature,O
remains,O
neutral,O
with,O
regard,O
to,O
jurisdictional,O
claims,O
in,O
published,O
maps,O
and,O
institutional,O
affiliations,O
.,O
Supplementary,O
Material,O
Supplementary,O
Information,O
Author,O
Contributions,O
K,O
.,O
W,O
.,O
M,O
.,O
T,O
.,O
and,O
Y,O
.,O
K,O
.,O
L,O
.,O
conceived,O
and,O
designed,O
the,O
experiments,O
",",O
K,O
.,O
W,O
.,O
M,O
.,O
T,O
.,O
and,O
H,O
.,O
X,O
.,O
L,O
.,O
performed,O
the,O
experiments,O
.,O
H,O
.,O
S,O
.,O
participated,O
in,O
experiment,O
coordination,O
and,O
design,O
",",O
and,O
in,O
revising,O
the,O
manuscript,O
.,O
K,O
.,O
W,O
.,O
M,O
.,O
T,O
.,O
and,O
Y,O
.,O
K,O
.,O
L,O
.,O
analyzed,O
the,O
data,O
and,O
drafted,O
the,O
paper,O
.,O
All,O
authors,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
D,O
.,O
tertiolecta,O
was,O
cultured,O
in,O
50,O
-,O
mL,O
batch,O
cultures,O
supplemented,O
with,O
5,O
%,O
CO2,O
.,O
Cell,O
growth,O
and,O
media,O
nitrogen,O
concentration,O
(,O
a,O
),O
was,O
measured,O
every,O
day,O
.,O
Total,O
organic,O
carbon,O
(,O
b,O
",",O
c,O
),O
and,O
dry,O
cell,O
weight,O
(,O
d,O
"),",O
chlorophyll,O
(,O
e,O
),O
and,O
photosynthetic,O
yield,O
(,O
f,O
),O
were,O
measured,O
at,O
different,O
time,O
points,O
(,O
Day,O
0,O
",",O
3,O
",",O
5,O
",",O
8,O
",",O
12,O
",",O
17,O
),O
to,O
illustrate,O
the,O
different,O
phases,O
of,O
growth,O
.,O
Error,O
bars,O
represent,O
standard,O
deviations,O
from,O
three,O
independent,O
biological,O
replicates,O
.,O
Asterisks,O
indicate,O
statistically,O
significant,O
differences,O
between,O
N,O
-,O
replete,O
and,O
N,O
-,O
deplete,O
samples,O
after,O
two,O
-,O
tailed,O
t,O
-,O
tests,O
(*,O
p,O
value,O
≤,O
0,O
.,O
05,O
;,O
**,O
p,O
value,O
≤,O
0,O
.,O
01,O
).,O
The,O
starch,O
(,O
a,O
"),",O
neutral,O
lipids,O
(,O
b,O
"),",O
total,O
lipids,O
(,O
c,O
"),",O
intracellular,O
glycerol,O
(,O
d,O
),O
and,O
extracellular,O
glycerol,O
(,O
e,O
),O
content,O
in,O
D,O
.,O
tertiolecta,O
cells,O
under,O
nitrogen,O
-,O
replete,O
and,O
nitrogen,O
-,O
deplete,O
conditions,O
in,O
different,O
phases,O
of,O
cell,O
growth,O
.,O
Proportion,O
of,O
starch,O
",",O
total,O
lipids,O
and,O
intracellular,O
glycerol,O
are,O
presented,O
as,O
a,O
percentage,O
of,O
dry,O
cell,O
weight,O
(,O
f,O
).,O
Error,O
bars,O
represent,O
standard,O
deviations,O
from,O
three,O
independent,O
biological,O
replicates,O
.,O
Asterisks,O
indicate,O
statistically,O
significant,O
differences,O
between,O
N,O
-,O
replete,O
and,O
N,O
-,O
deplete,O
samples,O
after,O
two,O
-,O
tailed,O
t,O
-,O
tests,O
(*,O
p,O
value,O
≤,O
0,O
.,O
05,O
;,O
**,O
p,O
value,O
≤,O
0,O
.,O
01,O
).,O
Proportion,O
of,O
the,O
major,O
types,O
of,O
fatty,O
acids,O
(,O
a,O
",",O
b,O
),O
are,O
expressed,O
as,O
percentages,O
of,O
total,O
lipids,O
.,O
After,O
staining,O
with,O
the,O
nonpolar,O
lipid,O
fluorophore,O
Nile,O
red,O
",",O
cells,O
were,O
examined,O
by,O
fluorescence,O
microscopy,O
which,O
showed,O
the,O
formation,O
of,O
lipid,O
droplets,O
corresponding,O
with,O
the,O
state,O
of,O
nitrogen,O
depletion,O
(,O
c,O
).,O
Yellow,O
fluorescence,O
reflects,O
the,O
staining,O
of,O
neutral,O
lipids,O
",",O
which,O
form,O
lipid,O
droplets,O
.,O
Red,O
fluorescence,O
corresponds,O
to,O
background,O
chlorophyll,O
auto,O
-,O
fluorescence,O
.,O
Arrows,O
represent,O
potential,O
carbon,O
fluxes,O
.,O
Enzymes,O
are,O
in,O
bold,O
italics,O
.,O
Blue,O
arrows,O
represent,O
reducing,O
power,O
(,O
NADPH,O
),O
and,O
red,O
arrows,O
represent,O
acetyl,O
-,O
CoA,O
.,O
Black,O
boxes,O
denote,O
pathway,O
names,O
.,O
A,O
recently,O
proposed,O
C4,O
-,O
like,O
carbon,O
-,O
concentrating,O
mechanism,O
(,O
CCM,O
),O
in,O
microalgae78798081,O
is,O
shown,O
to,O
depict,O
an,O
alternative,O
route,O
for,O
carbon,O
assimilation,O
.,O
Neutral,O
lipid,O
droplets,O
found,O
in,O
microalgae,O
consist,O
mostly,O
of,O
triacylglycerols,O
(,O
TAGs,O
"),",O
formed,O
by,O
combining,O
FAs,O
and,O
glycerol,O
.,O
Legend,O
:,O
ACCase,O
",",O
acetyl,O
-,O
CoA,O
carboxylase,O
;,O
ACD,O
",",O
acyl,O
-,O
CoA,O
dehydrogenase,O
;,O
ACL,O
",",O
ATP,O
-,O
citrate,O
lyase,O
;,O
ACS,O
",",O
acyl,O
-,O
CoA,O
synthetase,O
;,O
AGPP,O
",",O
ADP,O
-,O
glucose,O
pyrophosphorylase,O
;,O
AMY,O
",",O
amylase,O
;,O
CA,O
",",O
carbonic,O
anhydrase,O
;,O
DGAT,O
",",O
diacylglycerol,O
acyltransferase,O
;,O
DHAP,O
",",O
dihydroxyacetone,O
phosphate,O
;,O
F1,O
",",O
6,O
P,O
",",O
fructose,O
1,O
",",O
6,O
-,O
bisphosphate,O
;,O
F6P,O
",",O
fructose,O
6,O
-,O
phosphate,O
;,O
FAT,O
",",O
fatty,O
acyl,O
-,O
acyl,O
carrier,O
protein,O
(,O
ACP,O
),O
thioesterase,O
;,O
G1P,O
",",O
glucose,O
1,O
-,O
phosphate,O
;,O
G6P,O
",",O
glucose,O
6,O
-,O
phosphate,O
;,O
G6PDH,O
:,O
G6P,O
dehydrogenase,O
",",O
GAP,O
",",O
glyceraldehyde,O
3,O
-,O
phosphate,O
;,O
GPAT,O
",",O
glycerol,O
-,O
3,O
-,O
phosphate,O
acyltransferase,O
;,O
GPDH,O
",",O
glycerol,O
-,O
3,O
-,O
phosphate,O
dehydrogenase,O
;,O
MAL,O
",",O
malate,O
;,O
MDH,O
",",O
malate,O
dehydrogenase,O
;,O
MME,O
:,O
NADP,O
-,O
malic,O
enzyme,O
;,O
OAA,O
",",O
oxaloacetate,O
;,O
PDC,O
",",O
pyruvate,O
dehydrogenase,O
complex,O
;,O
PEP,O
",",O
phosphoenolpyruvate,O
;,O
PEPC,O
",",O
PEP,O
carboxylase,O
;,O
PK,O
",",O
pyruvate,O
kinase,O
;,O
Ru5P,O
",",O
ribulose,O
5,O
-,O
phosphate,O
;,O
Ru1,O
",",O
5BP,O
",",O
ribulose,O
1,O
",",O
5,O
-,O
bisphosphate,O
;,O
RuBisCO,O
",",O
Ru1,O
",",O
5BP,O
carboxylase,O
/,O
oxygenase,O
;,O
TPT,O
",",O
triose,O
phosphate,O
translocator,O
;,O
3,O
-,O
PGA,O
",",O
3,O
-,O
phosphoglycerate,O
;,O
6PGDH,O
",",O
6,O
-,O
phosphogluconate,O
dehydrogenase,O
.,O
Please,O
refer,O
to,O
Supplementary,O
Information,O
for,O
abbreviations,O
of,O
genes,O
involved,O
in,O
starch,O
synthesis,O
and,O
photosynthesis,O
and,O
antenna,O
proteins,O
.,O
Red,O
bars,O
:,O
Gene,O
expression,O
up,O
-,O
regulated,O
",",O
Green,O
bars,O
:,O
Gene,O
expression,O
down,O
-,O
regulated,O
",",O
Grey,O
bars,O
:,O
Gene,O
expression,O
unchanged,O
",",O
Yellow,O
bars,O
:,O
Gene,O
not,O
identified,O
in,O
transcriptome,O
analysis,O
.,O
For,O
more,O
information,O
regarding,O
fold,O
change,O
",",O
please,O
refer,O
to,O
Supplementary,O
Information,O
Table,O
S5,O
.,O
*,O
ACCase,O
denotes,O
the,O
Acetyl,O
-,O
CoA,O
biotin,O
carboxyl,O
carrier,O
subunit,O
as,O
it,O
was,O
the,O
most,O
reported,O
gene,O
among,O
the,O
literature,O
.,O
Refer,O
to,O
Supplementary,O
Information,O
Table,O
S4,O
and,O
S5,O
for,O
more,O
information,O
on,O
the,O
composition,O
of,O
storage,O
compounds,O
and,O
gene,O
expression,O
in,O
N,O
-,O
replete,O
and,O
N,O
-,O
deplete,O
conditions,O
.,O
Time,O
of,O
Administration,O
of,O
Acute,O
or,O
Chronic,O
Doses,O
of,O
Imipramine,O
Affects,O
its,O
Antidepressant,O
Action,O
in,O
Rats,B-OG
The,O
pathogenesis,O
and,O
therapeutics,O
of,O
depression,B-DS
are,O
linked,O
to,O
the,O
operation,O
of,O
the,O
circadian,O
system,O
.,O
Here,O
",",O
we,O
studied,O
the,O
chronopharmacological,O
action,O
of,O
a,O
tricyclic,O
antidepressant,O
",",O
imipramine,O
.,O
Male,O
adult,O
Wistar,B-OG
–,I-OG
Hannover,I-OG
rats,I-OG
were,O
administered,O
imipramine,O
acutely,O
or,O
chronically,O
in,O
the,O
morning,O
or,O
in,O
the,O
evening,O
.,O
The,O
antidepressant,O
action,O
of,O
imipramine,O
was,O
analyzed,O
using,O
the,O
forced,O
swim,O
test,O
(,O
FST,O
).,O
A,O
single,O
dose,O
of,O
imipramine,O
(,O
30,O
mg,O
/,O
kg,O
),O
in,O
the,O
morning,O
",",O
but,O
not,O
in,O
the,O
evening,O
",",O
reduced,O
immobility,O
and,O
increased,O
climbing,O
in,O
the,O
FST,O
.,O
The,O
plasma,O
concentrations,O
of,O
imipramine,O
and,O
its,O
metabolite,O
",",O
desipramine,O
",",O
were,O
slightly,O
higher,O
in,O
the,O
morning,O
than,O
in,O
the,O
evening,O
",",O
which,O
might,O
explain,O
the,O
dosing,O
time,O
-,O
dependent,O
action,O
of,O
imipramine,O
.,O
Next,O
",",O
we,O
analyzed,O
the,O
effect,O
of,O
chronic,O
imipramine,O
treatment,O
.,O
Rats,B-OG
received,O
imipramine,O
in,O
the,O
morning,O
or,O
in,O
the,O
evening,O
for,O
2,O
weeks,O
.,O
The,O
morning,O
treatment,O
resulted,O
in,O
larger,O
effects,O
in,O
the,O
FST,O
than,O
the,O
evening,O
treatment,O
",",O
and,O
was,O
effective,O
at,O
a,O
dose,O
that,O
was,O
ineffective,O
when,O
administered,O
acutely,O
.,O
The,O
levels,O
of,O
brain,O
α,B-GP
-,I-GP
adrenergic,I-GP
receptors,I-GP
tended,O
to,O
decrease,O
after,O
chronic,O
imipramine,O
treatment,O
.,O
Imipramine,O
might,O
interact,O
with,O
noradrenergic,O
neurons,O
",",O
and,O
this,O
interaction,O
might,O
chronically,O
alter,O
receptor,O
expression,O
.,O
This,O
alteration,O
seemed,O
greater,O
in,O
the,O
morning,O
than,O
in,O
the,O
evening,O
",",O
which,O
might,O
explain,O
the,O
dosing,O
time,O
-,O
dependent,O
action,O
of,O
imipramine,O
.,O
Introduction,O
The,O
pharmacological,O
action,O
of,O
many,O
substances,O
is,O
dependent,O
on,O
the,O
circadian,O
system,O
",",O
and,O
a,O
drug,O
’,O
s,O
dosing,O
time,O
can,O
affect,O
both,O
its,O
therapeutic,O
and,O
toxic,O
effects,O
[,O
12345,O
].,O
Some,O
drugs,O
work,O
better,O
in,O
the,O
daytime,O
",",O
while,O
other,O
drugs,O
work,O
better,O
at,O
night,O
.,O
The,O
best,O
timing,O
for,O
a,O
treatment,O
depends,O
on,O
the,O
chronopharmacological,O
profile,O
of,O
the,O
drug,O
.,O
Therefore,O
",",O
precise,O
knowledge,O
of,O
the,O
chronopharmacological,O
profile,O
of,O
a,O
drug,O
is,O
essential,O
to,O
provide,O
effective,O
medication,O
.,O
Depression,B-DS
is,O
strongly,O
associated,O
with,O
the,O
circadian,O
system,O
.,O
Patients,O
with,O
depression,B-DS
often,O
show,O
a,O
disturbance,O
of,O
the,O
circadian,O
rhythm,O
of,O
various,O
physiological,O
functions,O
(,O
e,O
.,O
g,O
".,",O
a,O
sleep,O
disturbance,O
).,O
Depression,B-DS
and,O
circadian,O
disturbance,O
may,O
be,O
physiologically,O
linked,O
and,O
deteriorate,O
synergistically,O
[,O
678,O
].,O
However,O
",",O
the,O
circadian,O
system,O
has,O
been,O
linked,O
not,O
only,O
to,O
the,O
pathogenesis,O
of,O
depression,B-DS
but,O
also,O
to,O
its,O
therapeutics,O
[,O
910111213,O
].,O
Wehr,O
et,O
al,O
.,O
reported,O
that,O
the,O
circadian,O
phase,O
was,O
advanced,O
and,O
desynchronized,O
with,O
the,O
sleep,O
-,O
wake,O
cycle,O
in,O
patients,O
with,O
depression,B-DS
",",O
and,O
that,O
phase,O
advance,O
of,O
the,O
sleep,O
-,O
wake,O
cycle,O
exerted,O
an,O
antidepressant,O
effect,O
[,O
10,O
].,O
Phase,O
entrainment,O
by,O
bright,O
light,O
in,O
the,O
morning,O
is,O
also,O
effective,O
to,O
improve,O
depressive,O
symptoms,O
[,O
1112,O
].,O
Chronotherapy,O
of,O
depression,B-DS
by,O
the,O
combination,O
of,O
sleep,O
deprivation,O
",",O
sleep,O
phase,O
advance,O
",",O
and,O
bright,O
light,O
treatment,O
induces,O
rapid,O
amelioration,O
in,O
patients,O
with,O
depression,B-DS
[,O
13,O
].,O
Some,O
antidepressants,O
can,O
interact,O
with,O
and,O
modify,O
the,O
biological,O
clock,O
[,O
141516171819,O
].,O
In,O
addition,O
",",O
some,O
antidepressants,O
show,O
dosing,O
time,O
-,O
dependent,O
action,O
in,O
animal,B-OG
models,O
[,O
2021,O
],O
and,O
in,O
clinical,O
settings,O
[,O
2223,O
].,O
However,O
",",O
the,O
therapeutic,O
significance,O
of,O
these,O
actions,O
remains,O
to,O
be,O
clarified,O
.,O
Further,O
research,O
on,O
the,O
relationship,O
between,O
the,O
circadian,O
system,O
and,O
depression,B-DS
could,O
lead,O
to,O
the,O
development,O
of,O
an,O
effective,O
therapy,O
for,O
depression,B-DS
.,O
The,O
forced,O
swim,O
test,O
(,O
FST,O
),O
is,O
one,O
of,O
the,O
most,O
common,O
behavioral,O
tests,O
in,O
rodents,B-OG
.,O
Since,O
the,O
FST,O
has,O
high,O
predictive,O
validity,O
",",O
reliability,O
",",O
and,O
robustness,O
",",O
it,O
is,O
useful,O
for,O
screening,O
and,O
analysis,O
of,O
antidepressant,O
activity,O
[,O
24,O
].,O
However,O
",",O
there,O
is,O
an,O
inconsistency,O
between,O
the,O
effects,O
of,O
antidepressants,O
in,O
the,O
FST,O
and,O
those,O
in,O
clinical,O
settings,O
.,O
A,O
single,O
dose,O
or,O
2,O
–,O
3,O
injections,O
of,O
the,O
antidepressant,O
within,O
24,O
hours,O
induce,O
reduction,O
of,O
immobility,O
indicative,O
of,O
antidepressant,O
activity,O
in,O
the,O
FST,O
[,O
252627,O
"],",O
whereas,O
most,O
antidepressants,O
are,O
ineffective,O
when,O
administered,O
acutely,O
or,O
subacutely,O
in,O
clinical,O
settings,O
",",O
usually,O
taking,O
several,O
weeks,O
to,O
show,O
therapeutic,O
effects,O
in,O
patients,O
[,O
24,O
].,O
Chronic,O
antidepressant,O
treatment,O
alters,O
brain,O
function,O
by,O
regulating,O
receptor,O
expression,O
levels,O
",",O
which,O
might,O
contribute,O
to,O
alleviating,O
the,O
depressive,O
symptoms,O
[,O
282930,O
].,O
Those,O
changes,O
are,O
not,O
detectable,O
in,O
acute,O
treatment,O
.,O
In,O
order,O
to,O
analyze,O
the,O
biochemical,O
alterations,O
related,O
to,O
antidepressant,O
activity,O
",",O
an,O
animal,B-OG
model,O
of,O
chronic,O
treatment,O
would,O
be,O
necessary,O
.,O
Several,O
animal,B-OG
and,O
clinical,O
studies,O
have,O
reported,O
the,O
chronopharmacological,O
action,O
of,O
antidepressants,O
.,O
Amitriptyline,O
",",O
fluvoxamine,O
",",O
and,O
milnacipran,O
show,O
dosing,O
time,O
-,O
dependent,O
antidepressant,O
activity,O
in,O
rodents,B-OG
[,O
2021,O
].,O
However,O
",",O
these,O
studies,O
have,O
used,O
an,O
acute,O
treatment,O
model,O
with,O
the,O
FST,O
.,O
Several,O
clinical,O
studies,O
analyzed,O
the,O
chronopharmacology,O
of,O
chronic,O
antidepressant,O
treatment,O
[,O
223132,O
].,O
However,O
",",O
no,O
such,O
analysis,O
has,O
been,O
performed,O
in,O
animal,B-OG
models,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
aimed,O
to,O
develop,O
a,O
chronic,O
animal,B-OG
model,O
to,O
analyze,O
the,O
chronopharmacological,O
action,O
of,O
the,O
antidepressant,O
imipramine,O
and,O
to,O
reveal,O
the,O
biochemical,O
alterations,O
that,O
contribute,O
to,O
the,O
chronopharmacological,O
action,O
of,O
this,O
antidepressant,O
in,O
this,O
model,O
.,O
The,O
present,O
study,O
analyzed,O
the,O
dosing,O
time,O
-,O
dependent,O
action,O
of,O
imipramine,O
in,O
an,O
acute,O
and,O
chronic,O
treatment,O
model,O
using,O
the,O
FST,O
.,O
We,O
also,O
analyzed,O
the,O
dosing,O
time,O
-,O
dependent,O
imipramine,O
metabolism,O
in,O
the,O
acute,O
model,O
and,O
the,O
dosing,O
time,O
-,O
dependent,O
effects,O
of,O
the,O
chronic,O
imipramine,O
treatment,O
on,O
the,O
brain,O
levels,O
of,O
the,O
α1,B-GP
adrenergic,I-GP
receptor,I-GP
(,O
α1AR,B-GP
),O
and,O
α2,B-GP
adrenergic,I-GP
receptor,I-GP
(,O
α2AR,B-GP
).,O
We,O
hypothesized,O
that,O
the,O
circadian,O
fluctuation,O
of,O
imipramine,O
metabolism,O
may,O
induce,O
dosing,O
time,O
-,O
dependent,O
changes,O
in,O
the,O
efficiency,O
of,O
the,O
interaction,O
between,O
imipramine,O
and,O
the,O
adrenergic,O
system,O
",",O
a,O
target,O
system,O
of,O
imipramine,O
.,O
Repeated,O
interaction,O
caused,O
by,O
chronic,O
imipramine,O
treatment,O
may,O
induce,O
a,O
dosing,O
time,O
-,O
dependent,O
alteration,O
of,O
adrenergic,B-GP
receptors,I-GP
protein,O
expression,O
",",O
which,O
might,O
contribute,O
to,O
the,O
chronopharmacological,O
antidepressant,O
action,O
of,O
imipramine,O
.,O
Methods,O
Chemicals,O
Imipramine,O
and,O
other,O
chemicals,O
were,O
obtained,O
from,O
Wako,O
Pure,O
Chemical,O
Industries,O
(,O
Osaka,O
",",O
Japan,O
"),",O
unless,O
otherwise,O
described,O
.,O
Pentobarbital,O
was,O
obtained,O
from,O
Kyoritsu,O
Seiyaku,O
(,O
Tokyo,O
",",O
Japan,O
).,O
Protease,B-GP
inhibitor,O
cocktail,O
and,O
anti,O
-,O
β,B-GP
-,I-GP
actin,I-GP
antibody,B-GP
(,O
A5441,O
),O
were,O
obtained,O
from,O
Sigma,O
-,O
Aldrich,O
(,O
St,O
.,O
Louis,O
",",O
MO,O
",",O
USA,O
).,O
Anti,O
-,O
α2,B-GP
-,I-GP
adrenergic,I-GP
receptor,I-GP
antibody,B-GP
(,O
sc,O
-,O
28983,O
),O
was,O
obtained,O
from,O
Santa,O
Cruz,O
Biotechnology,O
(,O
Dallas,O
",",O
TX,O
",",O
USA,O
).,O
Anti,O
-,O
α1,B-GP
-,I-GP
adrenergic,I-GP
receptor,I-GP
antibody,B-GP
(,O
ab137123,O
"),",O
anti,O
-,O
rabbit,B-OG
immunoglobulin,B-GP
G,I-GP
(,O
IgG,B-GP
),O
horseradish,B-OG
peroxidase,B-GP
-,O
conjugated,O
secondary,O
antibody,B-GP
(,O
ab97051,O
"),",O
and,O
anti,O
-,O
mouse,B-OG
IgG,B-GP
horseradish,B-OG
peroxidase,B-GP
-,O
conjugated,O
secondary,O
antibody,B-GP
(,O
ab79023,O
),O
were,O
obtained,O
from,O
Abcam,O
(,O
Cambridge,O
",",O
MA,O
",",O
USA,O
).,O
Animals,B-OG
Male,O
adult,O
Wistar,B-OG
–,I-OG
Hannover,I-OG
rats,I-OG
(,O
weighing,O
200,O
–,O
250,O
g,O
),O
were,O
obtained,O
from,O
CLEA,O
Japan,O
(,O
Tokyo,O
"),",O
and,O
were,O
maintained,O
in,O
an,O
air,O
-,O
conditioned,O
room,O
at,O
24,O
±,O
2,O
°,O
C,O
with,O
a,O
12,O
/,O
12,O
-,O
hour,O
light,O
/,O
dark,O
cycle,O
(,O
lights,O
on,O
at,O
7,O
:,O
00,O
a,O
.,O
m,O
.).,O
The,O
rats,B-OG
had,O
free,O
access,O
to,O
food,O
and,O
water,O
.,O
The,O
time,O
of,O
the,O
day,O
is,O
expressed,O
as,O
the,O
zeitgeber,O
time,O
(,O
ZT,O
"),",O
defined,O
as,O
follows,O
:,O
the,O
light,O
onset,O
time,O
(,O
7,O
:,O
00,O
a,O
.,O
m,O
.,O
clock,O
time,O
),O
is,O
ZT0,O
;,O
the,O
dark,O
onset,O
time,O
(,O
7,O
:,O
00,O
p,O
.,O
m,O
.,O
clock,O
time,O
),O
is,O
ZT12,O
;,O
and,O
ZT24,O
is,O
the,O
ZT0,O
of,O
the,O
next,O
day,O
.,O
Animal,B-OG
maintenance,O
and,O
treatments,O
were,O
in,O
accordance,O
with,O
the,O
general,O
recommendations,O
of,O
animal,B-OG
protection,O
legislation,O
in,O
Japan,O
.,O
All,O
procedures,O
were,O
approved,O
by,O
the,O
Institutional,O
Animal,B-OG
Care,O
and,O
Use,O
Committee,O
of,O
Josai,O
International,O
University,O
(,O
approval,O
numbers,O
:,O
32,O
and,O
57,O
).,O
Schedule,O
for,O
the,O
analysis,O
of,O
the,O
effects,O
of,O
acute,O
imipramine,O
treatment,O
One,O
day,O
before,O
measurement,O
",",O
rats,B-OG
were,O
exposed,O
to,O
the,O
FST,O
apparatus,O
as,O
described,O
below,O
.,O
Twenty,O
-,O
three,O
hours,O
after,O
the,O
first,O
exposure,O
",",O
rats,B-OG
were,O
intraperitoneally,O
administered,O
10,O
",",O
20,O
",",O
30,O
",",O
or,O
50,O
mg,O
/,O
kg,O
of,O
imipramine,O
(,O
as,O
a,O
hydrochloride,O
salt,O
),O
at,O
8,O
:,O
00,O
a,O
.,O
m,O
.,O
(,O
ZT1,O
),O
or,O
8,O
:,O
00,O
p,O
.,O
m,O
.,O
(,O
ZT13,O
).,O
Control,O
rats,B-OG
were,O
administered,O
saline,O
.,O
One,O
hour,O
after,O
administration,O
",",O
the,O
FST,O
was,O
carried,O
out,O
.,O
Schedule,O
for,O
the,O
analysis,O
of,O
the,O
effects,O
of,O
chronic,O
imipramine,O
treatment,O
Rats,B-OG
were,O
exposed,O
to,O
the,O
FST,O
apparatus,O
as,O
described,O
below,O
",",O
and,O
the,O
drug,O
treatment,O
was,O
started,O
the,O
next,O
day,O
.,O
The,O
rats,B-OG
were,O
intraperitoneally,O
administered,O
saline,O
or,O
imipramine,O
for,O
2,O
weeks,O
.,O
To,O
equalize,O
the,O
number,O
and,O
the,O
timing,O
of,O
the,O
intraperitoneal,O
injections,O
among,O
the,O
groups,O
",",O
all,O
rats,B-OG
were,O
injected,O
twice,O
a,O
day,O
as,O
shown,O
in,O
Table,O
1,O
.,O
Control,O
rats,B-OG
were,O
administered,O
saline,O
at,O
ZT1,O
and,O
ZT13,O
;,O
the,O
morning,O
group,O
was,O
administered,O
imipramine,O
at,O
ZT1,O
and,O
saline,O
at,O
ZT13,O
;,O
and,O
the,O
evening,O
group,O
was,O
administered,O
saline,O
at,O
ZT1,O
and,O
imipramine,O
at,O
ZT13,O
.,O
Two,O
days,O
after,O
the,O
last,O
administration,O
",",O
the,O
rats,B-OG
were,O
administered,O
imipramine,O
at,O
a,O
low,O
dose,O
(,O
10,O
mg,O
/,O
kg,O
),O
during,O
the,O
early,O
light,O
period,O
(,O
ZT1,O
–,O
3,O
"),",O
and,O
1,O
hour,O
after,O
the,O
administration,O
",",O
the,O
FST,O
was,O
carried,O
out,O
.,O
The,O
rats,B-OG
were,O
returned,O
to,O
their,O
home,O
cage,O
after,O
the,O
FST,O
",",O
and,O
they,O
were,O
sacrificed,O
for,O
biochemical,O
analysis,O
on,O
the,O
next,O
day,O
.,O
Daily,O
administration,O
schedule,O
for,O
the,O
analysis,O
of,O
chronic,O
imipramine,O
treatment,O
.,O
Group,O
Administration,O
time,O
ZT1,O
ZT13,O
Control,O
Saline,O
Saline,O
Morning,O
(,O
imipramine,O
at,O
ZT1,O
),O
Imipramine,O
Saline,O
Evening,O
(,O
imipramine,O
at,O
ZT13,O
),O
Saline,O
Imipramine,O
Forced,O
swim,O
test,O
(,O
FST,O
),O
We,O
used,O
a,O
modified,O
FST,O
according,O
to,O
the,O
method,O
of,O
Detke,O
et,O
al,O
.,O
[,O
26,O
].,O
On,O
the,O
day,O
before,O
the,O
first,O
treatment,O
of,O
imipramine,O
or,O
saline,O
",",O
each,O
rat,B-OG
was,O
individually,O
placed,O
in,O
a,O
tank,O
made,O
of,O
an,O
opaque,O
plastic,O
cylinder,O
(,O
24,O
cm,O
in,O
diameter,O
",",O
50,O
cm,O
in,O
height,O
),O
filled,O
with,O
room,O
-,O
temperature,O
water,O
(,O
24,O
±,O
2,O
°,O
C,O
),O
to,O
a,O
depth,O
of,O
30,O
cm,O
.,O
The,O
rat,B-OG
was,O
left,O
in,O
the,O
tank,O
for,O
10,O
minutes,O
",",O
then,O
removed,O
from,O
the,O
cylinder,O
",",O
allowed,O
to,O
dry,O
in,O
a,O
clean,O
cage,O
",",O
and,O
returned,O
to,O
its,O
home,O
cage,O
.,O
On,O
the,O
day,O
of,O
measurement,O
",",O
the,O
rat,B-OG
was,O
again,O
placed,O
in,O
the,O
tank,O
of,O
room,O
-,O
temperature,O
water,O
",",O
and,O
its,O
behaviors,O
were,O
analyzed,O
for,O
5,O
minutes,O
:,O
at,O
regular,O
5,O
-,O
second,O
intervals,O
",",O
trained,O
observers,O
recorded,O
which,O
of,O
the,O
following,O
three,O
behaviors,O
was,O
predominant,O
:,O
immobility,O
",",O
swimming,O
",",O
or,O
climbing,O
.,O
The,O
total,O
counts,O
for,O
each,O
behavior,O
over,O
the,O
5,O
-,O
minute,O
test,O
session,O
were,O
analyzed,O
as,O
the,O
FST,O
score,O
.,O
All,O
tests,O
were,O
observed,O
and,O
scored,O
by,O
two,O
or,O
more,O
trained,O
observers,O
to,O
prevent,O
scoring,O
errors,O
.,O
Analysis,O
of,O
plasma,O
imipramine,O
concentration,O
Rats,B-OG
were,O
administered,O
intraperitoneally,O
with,O
30,O
mg,O
/,O
kg,O
of,O
imipramine,O
at,O
ZT1,O
or,O
ZT13,O
.,O
One,O
hour,O
after,O
administration,O
",",O
the,O
rats,B-OG
were,O
anesthetized,O
with,O
pentobarbital,O
",",O
and,O
blood,O
samples,O
were,O
removed,O
from,O
the,O
postcaval,O
vein,O
with,O
a,O
heparinized,O
needle,O
attached,O
to,O
a,O
heparinized,O
syringe,O
.,O
The,O
blood,O
samples,O
were,O
centrifuged,O
at,O
1,O
",",O
200,O
×,O
g,O
for,O
10,O
minutes,O
to,O
obtain,O
plasma,O
",",O
which,O
were,O
immediately,O
frozen,O
in,O
liquid,O
nitrogen,O
and,O
kept,O
at,O
–,O
80,O
°,O
C,O
until,O
use,O
.,O
Diazepam,O
at,O
10,O
nmol,O
was,O
added,O
to,O
1,O
mL,O
of,O
plasma,O
as,O
an,O
internal,O
standard,O
.,O
The,O
sample,O
was,O
alkalinized,O
with,O
0,O
.,O
1,O
mL,O
of,O
5,O
M,O
NaOH,O
and,O
extracted,O
twice,O
with,O
1,O
mL,O
of,O
n,O
-,O
hexane,O
/,O
methanol,O
(,O
4,O
/,O
1,O
).,O
The,O
organic,O
layer,O
was,O
extracted,O
twice,O
with,O
0,O
.,O
1,O
mL,O
of,O
0,O
.,O
05,O
%,O
phosphoric,O
acid,O
.,O
The,O
extract,O
was,O
filtered,O
through,O
a,O
0,O
.,O
45,O
-,O
μm,O
filter,O
.,O
A,O
portion,O
of,O
the,O
filtrate,O
was,O
subjected,O
to,O
high,O
-,O
performance,O
liquid,O
chromatography,O
(,O
HPLC,O
),O
analysis,O
.,O
Imipramine,O
and,O
desipramine,O
were,O
analyzed,O
with,O
HPLC,O
-,O
UV,O
.,O
An,O
LC,O
-,O
10AD,O
/,O
SPD,O
-,O
10A,O
system,O
(,O
Shimadzu,O
",",O
Kyoto,O
",",O
Japan,O
),O
was,O
used,O
.,O
Separation,O
was,O
performed,O
on,O
Gemini,O
ODS,O
(,O
2,O
.,O
1,O
mm,O
in,O
inner,O
diameter,O
×,O
150,O
mm,O
",",O
Phenomenex,O
",",O
Torrance,O
",",O
CA,O
",",O
USA,O
),O
with,O
a,O
precolumn,O
(,O
SecurityGuard,O
",",O
Phenomenex,O
),O
at,O
40,O
°,O
C,O
.,O
The,O
eluents,O
were,O
80,O
%,O
50,O
mM,O
sodium,O
phosphate,O
buffer,O
(,O
pH,O
3,O
.,O
8,O
"),",O
20,O
%,O
acetonitrile,O
.,O
The,O
flow,O
rate,O
was,O
maintained,O
at,O
0,O
.,O
2,O
mL,O
/,O
minute,O
.,O
Compounds,O
were,O
detected,O
at,O
254,O
nm,O
.,O
Analysis,O
of,O
protein,O
in,O
the,O
brain,O
by,O
western,O
blotting,O
Rats,B-OG
were,O
anesthetized,O
with,O
pentobarbital,O
and,O
sacrificed,O
by,O
decapitation,O
.,O
The,O
brain,O
was,O
rapidly,O
dissected,O
out,O
and,O
divided,O
into,O
sections,O
.,O
The,O
prefrontal,O
cortex,O
(,O
PFC,O
),O
and,O
hippocampus,O
were,O
immediately,O
frozen,O
in,O
liquid,O
nitrogen,O
and,O
kept,O
at,O
–,O
80,O
°,O
C,O
until,O
use,O
.,O
The,O
brain,O
tissues,O
were,O
homogenized,O
in,O
5,O
volumes,O
of,O
lysis,O
buffer,O
(,O
50,O
mM,O
Tris,O
HCl,O
buffer,O
[,O
pH,O
7,O
.,O
4,O
"],",O
150,O
mM,O
NaCl,O
",",O
1,O
%,O
Triton,O
X,O
-,O
100,O
",",O
0,O
.,O
5,O
%,O
sodium,O
deoxycholate,O
",",O
1,O
%,O
sodium,O
dodecyl,O
sulfate,O
[,O
SDS,O
"],",O
1,O
mM,O
sodium,O
orthovanadate,O
",",O
1,O
mM,O
NaF,O
",",O
1,O
mM,O
phenylmethylsulfonyl,O
fluoride,O
[,O
PMSF,O
"],",O
2,O
μL,O
/,O
mL,O
of,O
protease,B-GP
inhibitor,O
cocktail,O
"),",O
and,O
centrifuged,O
at,O
20,O
",",O
000,O
×,O
g,O
for,O
20,O
minutes,O
at,O
4,O
°,O
C,O
.,O
The,O
protein,O
contents,O
of,O
the,O
supernatant,O
were,O
determined,O
using,O
the,O
bicinchoninic,O
acid,O
(,O
BCA,O
),O
assay,O
kit,O
(,O
Thermo,O
Fisher,O
Scientific,O
",",O
Waltham,O
",",O
MA,O
",",O
USA,O
).,O
An,O
aliquot,O
of,O
the,O
supernatant,O
was,O
used,O
to,O
prepare,O
the,O
SDS,O
sample,O
(,O
1,O
μg,O
protein,O
/,O
μL,O
in,O
SDS,O
loading,O
buffer,O
).,O
The,O
SDS,O
samples,O
were,O
incubated,O
at,O
95,O
°,O
C,O
for,O
2,O
minutes,O
",",O
and,O
loaded,O
at,O
10,O
μg,O
protein,O
onto,O
10,O
%,O
SDS,O
-,O
polyacrylamide,O
gels,O
.,O
Proteins,O
were,O
separated,O
at,O
60,O
V,O
and,O
then,O
blotted,O
to,O
PVDF,O
membranes,O
in,O
Tris,O
-,O
glycine,O
transfer,O
buffer,O
at,O
100,O
V,O
for,O
2,O
hours,O
.,O
The,O
membrane,O
was,O
incubated,O
with,O
5,O
%,O
skim,O
milk,O
in,O
phosphate,O
-,O
buffered,O
saline,O
containing,O
0,O
.,O
1,O
%,O
Tween,O
-,O
20,O
(,O
PBS,O
-,O
T,O
),O
for,O
1,O
hour,O
at,O
room,O
temperature,O
",",O
primary,O
antibody,B-GP
overnight,O
at,O
4,O
°,O
C,O
",",O
and,O
horseradish,B-OG
peroxidase,B-GP
-,O
conjugated,O
secondary,O
antibody,B-GP
for,O
1,O
hour,O
at,O
room,O
temperature,O
.,O
The,O
membrane,O
was,O
washed,O
with,O
PBS,O
-,O
T,O
3,O
times,O
for,O
5,O
minutes,O
after,O
the,O
incubation,O
with,O
the,O
primary,O
and,O
secondary,O
antibody,B-GP
.,O
The,O
membrane,O
was,O
developed,O
with,O
the,O
ECL,O
prime,O
western,O
blotting,O
detection,O
reagent,O
(,O
Amersham,O
",",O
Piscataway,O
",",O
NJ,O
",",O
USA,O
"),",O
and,O
analyzed,O
using,O
an,O
imaging,O
analyzer,O
LAS,O
-,O
3000,O
(,O
Fujifilm,O
",",O
Tokyo,O
",",O
Japan,O
).,O
Blots,O
with,O
anti,O
-,O
β,B-GP
-,I-GP
actin,I-GP
antibody,B-GP
were,O
used,O
as,O
loading,O
control,O
.,O
Statistical,O
analysis,O
Data,O
are,O
expressed,O
as,O
the,O
means,O
±,O
standard,O
error,O
of,O
the,O
mean,O
(,O
SEM,O
).,O
Dose,O
-,O
dependent,O
changes,O
against,O
the,O
control,O
group,O
were,O
analyzed,O
using,O
the,O
Williams,O
test,O
(,O
Figure,O
1,O
).,O
Differences,O
between,O
two,O
groups,O
were,O
analyzed,O
with,O
Student,O
’,O
s,O
t,O
-,O
test,O
(,O
Figure,O
2,O
).,O
Effects,O
of,O
two,O
factors,O
were,O
analyzed,O
using,O
2,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
),O
(,O
Figure,O
3,O
).,O
Multiple,O
pairwise,O
comparisons,O
among,O
three,O
or,O
more,O
groups,O
were,O
analyzed,O
with,O
Tukey,O
’,O
s,O
test,O
(,O
Figures,O
4,O
and,O
5,O
).,O
The,O
significance,O
level,O
was,O
set,O
at,O
p,O
<,O
0,O
.,O
05,O
.,O
The,O
JMP,O
procedure,O
(,O
SAS,O
Institute,O
",",O
Cary,O
",",O
NC,O
",",O
USA,O
),O
was,O
applied,O
for,O
statistical,O
analysis,O
.,O
Imipramine,O
exerts,O
dose,O
-,O
dependent,O
antidepressant,O
actions,O
in,O
rats,B-OG
.,O
The,O
rats,B-OG
received,O
imipramine,O
intraperitoneally,O
",",O
after,O
which,O
they,O
were,O
subjected,O
to,O
the,O
forced,O
swim,O
test,O
.,O
Each,O
column,O
represents,O
the,O
mean,O
±,O
standard,O
error,O
of,O
the,O
mean,O
(,O
SEM,O
),O
(,O
n,O
=,O
6,O
–,O
8,O
).,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
vs,O
.,O
control,O
by,O
Williams,O
test,O
.,O
Acute,O
imipramine,O
treatment,O
produces,O
dosing,O
time,O
-,O
dependent,O
effects,O
in,O
the,O
forced,O
swim,O
test,O
(,O
FST,O
).,O
The,O
rats,B-OG
were,O
administered,O
imipramine,O
at,O
ZT1,O
(,O
A,O
),O
or,O
ZT13,O
(,O
B,O
).,O
One,O
hour,O
after,O
imipramine,O
administration,O
",",O
the,O
rats,B-OG
were,O
subjected,O
to,O
the,O
FST,O
.,O
Each,O
column,O
represents,O
the,O
mean,O
±,O
standard,O
error,O
of,O
the,O
mean,O
(,O
SEM,O
),O
(,O
n,O
=,O
10,O
–,O
13,O
).,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
by,O
Student,O
’,O
s,O
t,O
-,O
test,O
.,O
Dosing,O
time,O
affects,O
the,O
plasma,O
levels,O
of,O
imipramine,O
and,O
desipramine,O
following,O
acute,O
imipramine,O
treatment,O
.,O
Imipramine,O
(,O
30,O
mg,O
/,O
kg,O
),O
was,O
administered,O
at,O
ZT1,O
or,O
ZT13,O
",",O
and,O
the,O
plasma,O
concentrations,O
of,O
imipramine,O
and,O
desipramine,O
were,O
measured,O
1,O
hour,O
later,O
.,O
Each,O
column,O
represents,O
the,O
mean,O
±,O
standard,O
error,O
of,O
the,O
mean,O
(,O
SEM,O
),O
(,O
n,O
=,O
3,O
).,O
*,O
p,O
<,O
0,O
.,O
05,O
by,O
2,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
).,O
Chronic,O
imipramine,O
treatment,O
produces,O
dosing,O
time,O
-,O
dependent,O
effects,O
in,O
the,O
forced,O
swim,O
test,O
(,O
FST,O
).,O
The,O
rats,B-OG
were,O
administered,O
imipramine,O
at,O
ZT1,O
or,O
ZT13,O
for,O
2,O
weeks,O
",",O
and,O
then,O
subjected,O
to,O
the,O
FST,O
.,O
The,O
effects,O
of,O
chronic,O
imipramine,O
treatment,O
at,O
10,O
mg,O
/,O
kg,O
(,O
A,O
),O
and,O
30,O
mg,O
/,O
kg,O
(,O
B,O
),O
are,O
shown,O
.,O
Each,O
column,O
represents,O
the,O
mean,O
±,O
standard,O
error,O
of,O
the,O
mean,O
(,O
SEM,O
),O
(,O
n,O
=,O
8,O
–,O
18,O
).,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
by,O
Tukey,O
’,O
s,O
test,O
.,O
Chronic,O
imipramine,O
treatment,O
alters,O
the,O
protein,O
level,O
of,O
adrenergic,B-GP
receptors,I-GP
.,O
Imipramine,O
(,O
30,O
mg,O
/,O
kg,O
),O
was,O
chronically,O
administered,O
at,O
ZT1,O
or,O
ZT13,O
",",O
and,O
the,O
protein,O
levels,O
of,O
α1AR,B-GP
and,O
α2AR,B-GP
were,O
analyzed,O
with,O
western,O
blotting,O
.,O
The,O
levels,O
of,O
α1AR,B-GP
(,O
A,O
",",O
B,O
),O
and,O
α2AR,B-GP
(,O
C,O
",",O
D,O
),O
in,O
the,O
prefrontal,O
cortex,O
(,O
PFC,O
),O
(,O
A,O
",",O
C,O
),O
and,O
hippocampus,O
(,O
B,O
",",O
D,O
),O
are,O
shown,O
.,O
Each,O
column,O
shows,O
the,O
mean,O
±,O
standard,O
error,O
of,O
the,O
mean,O
(,O
SEM,O
),O
(,O
n,O
=,O
4,O
).,O
No,O
statistically,O
significant,O
difference,O
was,O
detected,O
between,O
groups,O
by,O
Tukey,O
’,O
s,O
test,O
.,O
Results,O
Effects,O
of,O
acute,O
imipramine,O
treatment,O
on,O
the,O
FST,O
The,O
effects,O
of,O
acute,O
imipramine,O
treatment,O
at,O
various,O
doses,O
on,O
the,O
FST,O
are,O
shown,O
in,O
Figure,O
1,O
.,O
In,O
this,O
experiment,O
",",O
imipramine,O
was,O
administered,O
at,O
ZT1,O
.,O
Williams,O
test,O
detected,O
a,O
significant,O
reduction,O
of,O
immobility,O
and,O
a,O
significant,O
increase,O
of,O
climbing,O
at,O
doses,O
equal,O
to,O
or,O
higher,O
than,O
20,O
mg,O
/,O
kg,O
of,O
imipramine,O
(,O
immobility,O
:,O
p,O
=,O
0,O
.,O
0210,O
",",O
0,O
.,O
0197,O
",",O
and,O
0,O
.,O
0275,O
for,O
20,O
",",O
30,O
",",O
and,O
50,O
mg,O
/,O
kg,O
",",O
respectively,O
;,O
climbing,O
:,O
p,O
=,O
0,O
.,O
0245,O
",",O
0,O
.,O
0068,O
",",O
and,O
0,O
.,O
0078,O
for,O
20,O
",",O
30,O
",",O
and,O
50,O
mg,O
/,O
kg,O
",",O
respectively,O
).,O
Since,O
the,O
effect,O
at,O
30,O
mg,O
/,O
kg,O
was,O
larger,O
than,O
the,O
effect,O
at,O
other,O
doses,O
",",O
we,O
used,O
imipramine,O
at,O
30,O
mg,O
/,O
kg,O
in,O
the,O
following,O
analysis,O
.,O
The,O
rats,B-OG
treated,O
with,O
imipramine,O
at,O
ZT1,O
or,O
ZT13,O
were,O
subjected,O
to,O
the,O
FST,O
in,O
order,O
to,O
analyze,O
the,O
effect,O
of,O
dosing,O
time,O
on,O
antidepressant,O
activity,O
.,O
The,O
results,O
are,O
shown,O
in,O
Figure,O
2,O
.,O
Imipramine,O
significantly,O
reduced,O
immobility,O
and,O
increased,O
climbing,O
when,O
administered,O
at,O
ZT1,O
(,O
p,O
=,O
0,O
.,O
0009,O
and,O
p,O
=,O
0,O
.,O
0126,O
",",O
respectively,O
),O
(,O
Figure,O
2A,O
"),",O
but,O
not,O
at,O
ZT13,O
(,O
Figure,O
2B,O
).,O
Plasma,O
concentration,O
of,O
imipramine,O
The,O
plasma,O
concentrations,O
of,O
imipramine,O
and,O
its,O
metabolite,O
",",O
desipramine,O
",",O
following,O
imipramine,O
treatment,O
are,O
shown,O
in,O
Figure,O
3,O
.,O
Two,O
-,O
way,O
ANOVA,O
detected,O
no,O
interaction,O
(,O
F1,O
",",O
8,O
=,O
0,O
.,O
0013,O
",",O
p,O
=,O
0,O
.,O
9719,O
).,O
The,O
main,O
effect,O
in,O
compound,O
",",O
imipramine,O
and,O
desipramine,O
",",O
was,O
significant,O
(,O
F1,O
",",O
8,O
=,O
34,O
.,O
0154,O
",",O
p,O
=,O
0,O
.,O
0004,O
).,O
Although,O
the,O
main,O
effect,O
in,O
dosing,O
time,O
was,O
not,O
significant,O
(,O
F1,O
",",O
8,O
=,O
3,O
.,O
8042,O
",",O
p,O
=,O
0,O
.,O
0869,O
"),",O
both,O
imipramine,O
and,O
desipramine,O
were,O
slightly,O
increased,O
at,O
ZT1,O
compared,O
to,O
ZT13,O
.,O
Effects,O
of,O
chronic,O
imipramine,O
treatment,O
on,O
the,O
FST,O
The,O
effects,O
of,O
chronic,O
imipramine,O
treatment,O
on,O
the,O
FST,O
are,O
shown,O
in,O
Figure,O
4,O
.,O
In,O
this,O
experiment,O
",",O
imipramine,O
was,O
administered,O
at,O
ZT1,O
or,O
ZT13,O
for,O
2,O
weeks,O
.,O
We,O
used,O
two,O
doses,O
:,O
the,O
same,O
dose,O
as,O
in,O
the,O
acute,O
treatment,O
(,O
30,O
mg,O
/,O
kg,O
"),",O
and,O
the,O
dose,O
that,O
was,O
not,O
effective,O
in,O
the,O
acute,O
treatment,O
(,O
10,O
mg,O
/,O
kg,O
).,O
At,O
low,O
dose,O
",",O
the,O
ZT1,O
group,O
showed,O
24,O
%,O
reduction,O
in,O
immobility,O
and,O
116,O
%,O
increase,O
in,O
climbing,O
against,O
the,O
control,O
(,O
p,O
=,O
0,O
.,O
0126,O
and,O
p,O
=,O
0,O
.,O
0144,O
",",O
respectively,O
),O
(,O
Figure,O
4A,O
).,O
The,O
differences,O
between,O
ZT1,O
and,O
ZT13,O
were,O
not,O
significant,O
(,O
p,O
=,O
0,O
.,O
1359,O
for,O
immobility,O
",",O
p,O
=,O
0,O
.,O
1778,O
for,O
climbing,O
).,O
At,O
high,O
dose,O
",",O
significant,O
differences,O
in,O
immobility,O
and,O
climbing,O
were,O
detected,O
in,O
the,O
ZT1,O
and,O
ZT13,O
groups,O
against,O
the,O
control,O
(,O
p,O
=,O
0,O
.,O
0001,O
and,O
p,O
=,O
0,O
.,O
0030,O
for,O
immobility,O
",",O
p,O
<,O
0,O
.,O
0001,O
and,O
p,O
=,O
0,O
.,O
0006,O
for,O
climbing,O
",",O
respectively,O
),O
(,O
Figure,O
4B,O
).,O
The,O
differences,O
between,O
ZT1,O
and,O
ZT13,O
were,O
not,O
significant,O
(,O
p,O
=,O
0,O
.,O
4310,O
for,O
immobility,O
",",O
p,O
=,O
0,O
.,O
0883,O
for,O
climbing,O
).,O
Effects,O
of,O
chronic,O
imipramine,O
administration,O
on,O
adrenergic,B-GP
receptors,I-GP
In,O
order,O
to,O
investigate,O
the,O
alterations,O
of,O
the,O
noradrenergic,O
system,O
induced,O
by,O
chronic,O
treatment,O
of,O
imipramine,O
",",O
the,O
protein,O
levels,O
of,O
α1AR,B-GP
and,O
α2AR,B-GP
were,O
analyzed,O
with,O
western,O
blotting,O
(,O
Figure,O
5,O
).,O
No,O
significant,O
differences,O
were,O
detected,O
in,O
the,O
levels,O
of,O
α1AR,B-GP
and,O
α2AR,B-GP
.,O
However,O
",",O
the,O
mean,O
values,O
of,O
imipramine,O
-,O
treated,O
groups,O
were,O
lower,O
than,O
those,O
of,O
the,O
control,O
.,O
In,O
particular,O
",",O
imipramine,O
at,O
ZT1,O
resulted,O
in,O
37,O
%,O
reduction,O
of,O
α2AR,B-GP
in,O
the,O
hippocampus,O
against,O
the,O
control,O
",",O
although,O
the,O
difference,O
was,O
not,O
significant,O
(,O
p,O
=,O
0,O
.,O
1018,O
vs,O
.,O
control,O
",",O
p,O
=,O
0,O
.,O
6794,O
vs,O
.,O
ZT13,O
).,O
Discussion,O
The,O
present,O
study,O
examined,O
the,O
chronopharmacological,O
effects,O
of,O
acute,O
and,O
chronic,O
imipramine,O
treatment,O
.,O
We,O
showed,O
that,O
imipramine,O
works,O
more,O
efficiently,O
in,O
the,O
morning,O
than,O
in,O
the,O
evening,O
in,O
rats,B-OG
.,O
The,O
antidepressant,O
effect,O
was,O
observed,O
in,O
the,O
morning,O
(,O
ZT1,O
"),",O
but,O
not,O
in,O
the,O
evening,O
(,O
ZT13,O
),O
with,O
a,O
single,O
dose,O
of,O
30,O
mg,O
/,O
kg,O
of,O
imipramine,O
.,O
The,O
same,O
trend,O
was,O
observed,O
in,O
the,O
chronic,O
treatment,O
model,O
.,O
Chronic,O
imipramine,O
in,O
the,O
morning,O
induced,O
antidepressant,O
effects,O
in,O
the,O
FST,O
even,O
when,O
the,O
dose,O
was,O
lower,O
than,O
the,O
effective,O
dose,O
in,O
the,O
acute,O
treatment,O
model,O
.,O
Chronic,O
imipramine,O
might,O
increase,O
the,O
drug,O
susceptibility,O
of,O
the,O
rat,B-OG
brain,O
most,O
efficiently,O
in,O
the,O
morning,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
report,O
that,O
shows,O
the,O
chronopharmacological,O
effects,O
of,O
an,O
antidepressant,O
in,O
a,O
chronic,O
treatment,O
model,O
.,O
Since,O
antidepressants,O
are,O
usually,O
used,O
chronically,O
in,O
clinical,O
settings,O
",",O
this,O
model,O
could,O
be,O
a,O
useful,O
model,O
to,O
analyze,O
the,O
chronopharmacological,O
profile,O
of,O
antidepressants,O
and,O
the,O
underlying,O
mechanism,O
of,O
their,O
chronopharmacological,O
activity,O
.,O
In,O
the,O
chronic,O
treatment,O
model,O
",",O
the,O
rats,B-OG
were,O
administered,O
a,O
low,O
dose,O
(,O
10,O
mg,O
/,O
kg,O
),O
of,O
imipramine,O
one,O
hour,O
before,O
the,O
FST,O
as,O
described,O
in,O
the,O
Methods,O
.,O
Since,O
imipramine,O
was,O
ineffective,O
at,O
this,O
dose,O
when,O
administered,O
acutely,O
(,O
Figure,O
1,O
"),",O
the,O
reduction,O
of,O
immobility,O
and,O
the,O
increase,O
of,O
climbing,O
observed,O
in,O
Figure,O
4,O
could,O
not,O
be,O
because,O
of,O
the,O
acute,O
effect,O
of,O
the,O
last,O
low,O
dose,O
administration,O
.,O
This,O
suggests,O
that,O
the,O
chronic,O
imipramine,O
treatment,O
caused,O
these,O
antidepressant,O
effects,O
.,O
Chronic,O
imipramine,O
treatment,O
might,O
induce,O
alterations,O
of,O
the,O
adrenergic,O
system,O
(,O
target,O
system,O
of,O
imipramine,O
),O
such,O
as,O
an,O
enhancement,O
of,O
noradrenergic,O
neurons,O
’,O
susceptibility,O
to,O
imipramine,O
",",O
which,O
would,O
induce,O
the,O
antidepressant,O
effects,O
seen,O
after,O
the,O
administration,O
of,O
a,O
low,O
dose,O
of,O
imipramine,O
.,O
Chronopharmacological,O
effects,O
can,O
be,O
induced,O
by,O
the,O
circadian,O
fluctuation,O
of,O
the,O
pharmacokinetics,O
or,O
pharmacodynamics,O
of,O
a,O
drug,O
[,O
2,O
].,O
Various,O
drugs,O
show,O
dosing,O
time,O
-,O
dependent,O
pharmacokinetics,O
[,O
23333435,O
].,O
Imipramine,O
is,O
metabolized,O
to,O
desipramine,O
by,O
CYP1A2,B-GP
",",O
3A4,O
",",O
and,O
2C19,O
",",O
and,O
imipramine,O
and,O
desipramine,O
are,O
hydroxylated,O
to,O
the,O
2,O
-,O
OH,O
form,O
by,O
CYP2D6,B-GP
[,O
3637,O
].,O
Both,O
imipramine,O
and,O
desipramine,O
have,O
antidepressant,O
activity,O
",",O
while,O
the,O
2,O
-,O
OH,O
form,O
of,O
both,O
compounds,O
does,O
not,O
have,O
antidepressant,O
activity,O
.,O
Therefore,O
",",O
intra,O
-,O
day,O
fluctuation,O
of,O
the,O
activity,O
of,O
CYP2D6,B-GP
could,O
explain,O
the,O
chronopharmacological,O
action,O
of,O
imipramine,O
.,O
The,O
expression,O
of,O
CYPs,B-GP
is,O
controlled,O
by,O
biological,O
clocks,O
",",O
and,O
their,O
expression,O
and,O
activity,O
show,O
a,O
circadian,O
rhythm,O
[,O
383940414243,O
].,O
The,O
expression,O
of,O
CYP2D9,B-GP
",",O
the,O
murine,O
homolog,O
of,O
human,B-OG
CYP2D6,B-GP
",",O
shows,O
a,O
circadian,O
rhythm,O
with,O
a,O
peak,O
at,O
night,O
in,O
the,O
mouse,B-OG
liver,O
[,O
43,O
].,O
Figure,O
3,O
shows,O
that,O
the,O
plasma,O
concentrations,O
of,O
imipramine,O
and,O
desipramine,O
were,O
17,O
–,O
37,O
%,O
higher,O
at,O
ZT1,O
than,O
at,O
ZT13,O
.,O
Although,O
the,O
difference,O
(,O
p,O
=,O
0,O
.,O
0869,O
),O
did,O
not,O
meet,O
the,O
criteria,O
of,O
statistical,O
significance,O
",",O
we,O
suspect,O
that,O
the,O
circadian,O
fluctuation,O
of,O
CYP2D9,B-GP
might,O
have,O
caused,O
the,O
difference,O
in,O
imipramine,O
concentrations,O
between,O
ZT1,O
and,O
ZT13,O
",",O
which,O
might,O
contribute,O
to,O
the,O
chronopharmacological,O
action,O
of,O
imipramine,O
to,O
some,O
extent,O
.,O
Pharmacodynamics,O
should,O
also,O
be,O
considered,O
.,O
In,O
brain,O
monoaminergic,O
systems,O
",",O
the,O
contents,O
of,O
neurotransmitters,O
and,O
the,O
expression,O
of,O
receptors,O
and,O
transporters,B-GP
show,O
circadian,O
rhythm,O
[,O
202144,O
].,O
Since,O
imipramine,O
exerts,O
antidepressant,O
activity,O
by,O
its,O
interaction,O
with,O
the,O
serotonergic,O
and,O
noradrenergic,O
systems,O
",",O
the,O
circadian,O
rhythm,O
of,O
these,O
neuronal,O
systems,O
could,O
cause,O
the,O
chronopharmacological,O
action,O
of,O
imipramine,O
.,O
In,O
the,O
modified,O
FST,O
",",O
the,O
increase,O
of,O
swimming,O
and,O
climbing,O
is,O
related,O
to,O
the,O
activation,O
of,O
serotonergic,O
and,O
noradrenergic,O
activity,O
in,O
the,O
brain,O
",",O
respectively,O
[,O
26,O
].,O
Imipramine,O
increased,O
climbing,O
in,O
the,O
present,O
study,O
",",O
suggesting,O
that,O
the,O
noradrenergic,O
system,O
should,O
dominantly,O
contribute,O
to,O
the,O
antidepressant,O
activity,O
of,O
imipramine,O
in,O
rats,B-OG
.,O
We,O
suspected,O
that,O
desipramine,O
played,O
a,O
major,O
role,O
in,O
this,O
noradrenergic,O
effect,O
.,O
Imipramine,O
and,O
desipramine,O
inhibit,O
both,O
the,O
serotonin,B-GP
transporter,I-GP
(,O
SERT,B-GP
),O
and,O
the,O
noradrenaline,B-GP
transporter,I-GP
(,O
NAT,B-GP
).,O
However,O
",",O
the,O
selectivity,O
was,O
different,O
between,O
imipramine,O
and,O
desipramine,O
.,O
The,O
inhibitory,O
action,O
of,O
imipramine,O
is,O
27,O
times,O
more,O
potent,O
on,O
SERT,B-GP
than,O
on,O
NAT,B-GP
",",O
whereas,O
that,O
of,O
desipramine,O
is,O
21,O
times,O
more,O
potent,O
on,O
NAT,B-GP
than,O
on,O
SERT,B-GP
[,O
45,O
].,O
Since,O
the,O
plasma,O
concentration,O
of,O
desipramine,O
was,O
higher,O
than,O
that,O
of,O
imipramine,O
(,O
Figure,O
3,O
"),",O
the,O
effects,O
of,O
desipramine,O
might,O
appear,O
dominantly,O
in,O
the,O
FST,O
.,O
Most,O
antidepressants,O
are,O
effective,O
only,O
after,O
chronic,O
treatment,O
in,O
clinical,O
settings,O
.,O
Chronic,O
treatment,O
with,O
antidepressants,O
induces,O
alterations,O
in,O
the,O
brain,O
function,O
",",O
which,O
may,O
lead,O
to,O
the,O
alleviation,O
of,O
depressive,O
symptoms,O
.,O
The,O
involvement,O
of,O
α2AR,B-GP
has,O
been,O
reported,O
both,O
in,O
animal,B-OG
and,O
clinical,O
studies,O
.,O
Brain,O
α2AR,B-GP
density,O
is,O
upregulated,O
in,O
patients,O
with,O
depression,B-DS
[,O
3046,O
].,O
Chronic,O
treatment,O
with,O
a,O
tricyclic,O
antidepressant,O
induces,O
the,O
downregulation,O
of,O
α2AR,B-GP
in,O
various,O
brain,O
regions,O
of,O
model,O
animals,B-OG
[,O
3047,O
].,O
The,O
present,O
results,O
are,O
consistent,O
with,O
those,O
of,O
previous,O
studies,O
.,O
Although,O
we,O
could,O
not,O
detect,O
significant,O
differences,O
",",O
the,O
protein,O
levels,O
of,O
α1AR,B-GP
and,O
α2AR,B-GP
tended,O
to,O
be,O
reduced,O
following,O
chronic,O
imipramine,O
treatment,O
(,O
Figure,O
5,O
).,O
Comparing,O
ZT1,O
and,O
ZT3,O
groups,O
",",O
the,O
reduction,O
seemed,O
larger,O
in,O
the,O
ZT1,O
group,O
",",O
especially,O
for,O
α2AR,B-GP
in,O
the,O
hippocampus,O
.,O
Since,O
α2AR,B-GP
exists,O
in,O
the,O
presynaptic,O
neurons,O
and,O
negatively,O
modulates,O
noradrenaline,O
release,O
[,O
30,O
"],",O
the,O
downregulation,O
of,O
the,O
α2AR,B-GP
might,O
lead,O
to,O
increased,O
noradrenergic,O
neural,O
transmission,O
",",O
which,O
might,O
induce,O
antidepressant,O
effects,O
.,O
There,O
are,O
some,O
concerns,O
about,O
the,O
validity,O
of,O
the,O
FST,O
.,O
In,O
this,O
study,O
",",O
a,O
low,O
dose,O
(,O
10,O
mg,O
/,O
kg,O
),O
of,O
imipramine,O
was,O
sufficient,O
for,O
an,O
antidepressant,O
effect,O
in,O
the,O
chronic,O
model,O
;,O
however,O
",",O
a,O
higher,O
dose,O
was,O
necessary,O
to,O
have,O
an,O
antidepressant,O
effect,O
in,O
the,O
acute,O
model,O
.,O
These,O
results,O
are,O
consistent,O
with,O
previous,O
studies,O
looking,O
at,O
other,O
drugs,O
.,O
Amitriptyline,O
",",O
mianserin,O
",",O
desipramine,O
",",O
and,O
fluoxetine,O
have,O
an,O
antidepressant,O
effect,O
in,O
the,O
FST,O
when,O
chronically,O
administered,O
at,O
a,O
particular,O
dose,O
",",O
but,O
this,O
same,O
dose,O
does,O
not,O
have,O
an,O
antidepressant,O
effect,O
when,O
administered,O
acutely,O
[,O
4849,O
].,O
Another,O
study,O
indicated,O
that,O
some,O
drugs,O
",",O
such,O
as,O
mepyramine,O
and,O
promethazine,O
",",O
are,O
effective,O
with,O
acute,O
treatment,O
but,O
not,O
with,O
chronic,O
treatment,O
[,O
50,O
].,O
These,O
findings,O
suggest,O
that,O
the,O
mechanism,O
involved,O
in,O
the,O
imipramine,O
-,O
induced,O
anti,O
-,O
immobility,O
effect,O
in,O
the,O
FST,O
is,O
different,O
in,O
the,O
chronic,O
and,O
acute,O
models,O
.,O
Since,O
chronic,O
treatment,O
is,O
usually,O
necessary,O
for,O
effective,O
antidepressant,O
therapy,O
in,O
clinical,O
settings,O
[,O
24,O
"],",O
the,O
physiological,O
changes,O
observed,O
in,O
the,O
acute,O
model,O
may,O
be,O
different,O
from,O
the,O
changes,O
seen,O
in,O
human,B-OG
depression,B-DS
.,O
The,O
FST,O
used,O
in,O
the,O
acute,O
model,O
may,O
not,O
be,O
a,O
good,O
model,O
for,O
the,O
analysis,O
of,O
the,O
mechanisms,O
involved,O
in,O
human,B-OG
depression,B-DS
.,O
However,O
",",O
the,O
acute,O
FST,O
is,O
a,O
useful,O
tool,O
for,O
high,O
throughput,O
screening,O
and,O
analysis,O
of,O
antidepressant,O
activity,O
.,O
There,O
are,O
some,O
inconsistencies,O
about,O
the,O
chronopharmacological,O
profile,O
of,O
antidepressant,O
between,O
the,O
present,O
results,O
and,O
those,O
of,O
previous,O
studies,O
.,O
A,O
tricyclic,O
antidepressant,O
",",O
amitriptyline,O
",",O
shows,O
circadian,O
activity,O
rhythm,O
with,O
a,O
peak,O
at,O
early,O
night,O
in,O
an,O
acute,O
mouse,B-OG
model,O
[,O
20,O
].,O
A,O
serotonin,O
noradrenaline,O
reuptake,O
inhibitor,O
(,O
SNRI,O
"),",O
milnacipran,O
",",O
induces,O
a,O
large,O
increase,O
in,O
climbing,O
at,O
ZT13,O
rather,O
than,O
at,O
ZT1,O
in,O
an,O
acute,O
rat,B-OG
model,O
[,O
21,O
].,O
In,O
the,O
present,O
study,O
",",O
imipramine,O
induced,O
a,O
large,O
reduction,O
in,O
immobility,O
and,O
an,O
increase,O
in,O
climbing,O
in,O
the,O
morning,O
(,O
ZT1,O
),O
in,O
an,O
acute,O
rat,B-OG
model,O
(,O
Figure,O
2,O
).,O
We,O
are,O
unable,O
to,O
explain,O
these,O
inconsistencies,O
based,O
on,O
the,O
available,O
data,O
.,O
However,O
",",O
we,O
suspect,O
that,O
differences,O
in,O
the,O
mechanism,O
of,O
action,O
might,O
contribute,O
to,O
the,O
different,O
chronopharmacological,O
profiles,O
.,O
Although,O
amitriptyline,O
",",O
milnacipran,O
",",O
and,O
imipramine,O
inhibit,O
both,O
SERT,B-GP
and,O
NAT,B-GP
",",O
the,O
relative,O
activity,O
to,O
SERT,B-GP
and,O
NAT,B-GP
is,O
different,O
among,O
these,O
compounds,O
[,O
45,O
].,O
Since,O
serotonergic,O
and,O
noradrenergic,O
systems,O
show,O
circadian,O
activity,O
rhythms,O
with,O
different,O
peak,O
times,O
[,O
2144,O
"],",O
the,O
relative,O
activity,O
of,O
different,O
antidepressants,O
on,O
these,O
neurons,O
may,O
be,O
an,O
important,O
factor,O
that,O
determines,O
their,O
chronopharmacological,O
profiles,O
.,O
There,O
are,O
limitations,O
to,O
the,O
present,O
study,O
.,O
(,O
1,O
),O
The,O
chronopharmacological,O
effect,O
was,O
analyzed,O
with,O
only,O
two,O
time,O
points,O
.,O
(,O
2,O
),O
The,O
contributions,O
of,O
neuronal,O
systems,O
other,O
than,O
the,O
noradrenergic,O
system,O
were,O
not,O
addressed,O
.,O
(,O
3,O
),O
Antidepressant,O
activity,O
was,O
evaluated,O
only,O
with,O
the,O
FST,O
and,O
by,O
using,O
normal,O
naïve,O
rats,B-OG
.,O
Firstly,O
",",O
it,O
is,O
impossible,O
to,O
determine,O
the,O
exact,O
time,O
point,O
at,O
which,O
imipramine,O
shows,O
maximal,O
antidepressant,O
activity,O
during,O
the,O
day,O
.,O
Although,O
we,O
observed,O
higher,O
antidepressant,O
activity,O
in,O
the,O
morning,O
than,O
in,O
the,O
evening,O
",",O
the,O
data,O
could,O
not,O
exclude,O
the,O
possibility,O
that,O
imipramine,O
shows,O
maximal,O
antidepressant,O
activity,O
during,O
the,O
afternoon,O
or,O
at,O
midnight,O
.,O
Chronopharmacological,O
analysis,O
with,O
three,O
or,O
more,O
time,O
points,O
should,O
be,O
important,O
to,O
discuss,O
the,O
precise,O
chronopharmacological,O
profiles,O
of,O
imipramine,O
and,O
other,O
antidepressants,O
",",O
as,O
well,O
as,O
to,O
clarify,O
the,O
relationships,O
between,O
the,O
chronopharmacological,O
profile,O
and,O
the,O
mechanism,O
of,O
action,O
of,O
antidepressants,O
.,O
Secondly,O
",",O
the,O
present,O
study,O
analyzed,O
the,O
effect,O
of,O
chronic,O
imipramine,O
administration,O
only,O
on,O
the,O
adrenergic,B-GP
receptors,I-GP
.,O
However,O
",",O
other,O
neuronal,O
systems,O
such,O
as,O
the,O
serotonergic,O
",",O
dopaminergic,O
",",O
and,O
glutamatergic,O
systems,O
may,O
also,O
play,O
an,O
important,O
role,O
in,O
the,O
action,O
of,O
antidepressants,O
[,O
51,O
].,O
We,O
could,O
not,O
exclude,O
the,O
possibility,O
that,O
these,O
systems,O
show,O
larger,O
circadian,O
fluctuations,O
of,O
the,O
activity,O
compared,O
to,O
the,O
adrenergic,O
system,O
",",O
and,O
that,O
these,O
fluctuations,O
are,O
crucial,O
in,O
the,O
chronopharmacological,O
action,O
of,O
imipramine,O
.,O
The,O
effects,O
of,O
antidepressants,O
on,O
these,O
systems,O
and,O
their,O
circadian,O
system,O
functionality,O
should,O
be,O
considered,O
.,O
Thirdly,O
",",O
the,O
chronopharmacological,O
effects,O
of,O
antidepressants,O
in,O
depression,B-DS
patients,O
or,O
depressive,O
-,O
like,O
animals,B-OG
are,O
still,O
unknown,O
.,O
Some,O
physiological,O
functions,O
in,O
depressive,O
-,O
like,O
animals,B-OG
may,O
be,O
impaired,O
and,O
different,O
from,O
those,O
in,O
normal,O
animals,B-OG
",",O
which,O
may,O
alter,O
the,O
chronopharmacological,O
effects,O
of,O
the,O
antidepressants,O
.,O
Some,O
drugs,O
cannot,O
induce,O
antidepressant,O
effects,O
in,O
animal,B-OG
models,O
of,O
depression,B-DS
even,O
though,O
they,O
have,O
antidepressant,O
effects,O
in,O
normal,O
animals,B-OG
[,O
5253,O
].,O
Patients,O
with,O
depression,B-DS
and,O
animal,B-OG
models,O
of,O
depression,B-DS
sometimes,O
show,O
disturbances,O
in,O
circadian,O
system,O
functionality,O
[,O
678545556,O
].,O
Chronopharmacological,O
profiles,O
of,O
antidepressant,O
activity,O
in,O
depressive,O
-,O
like,O
animals,B-OG
could,O
be,O
different,O
from,O
those,O
in,O
normal,O
animals,B-OG
.,O
Analyses,O
using,O
animal,B-OG
models,O
of,O
depression,B-DS
may,O
clarify,O
the,O
chronopharmacological,O
effects,O
of,O
antidepressants,O
on,O
behavior,O
and,O
brain,O
monoaminergic,O
systems,O
in,O
the,O
depression,B-DS
.,O
Conclusion,O
In,O
this,O
study,O
",",O
we,O
revealed,O
the,O
chronopharmacological,O
activity,O
of,O
imipramine,O
in,O
rats,B-OG
.,O
In,O
particular,O
",",O
we,O
found,O
that,O
chronic,O
imipramine,O
treatment,O
produced,O
dosing,O
time,O
-,O
dependent,O
antidepressant,O
effects,O
at,O
a,O
dose,O
that,O
was,O
ineffective,O
when,O
given,O
acutely,O
.,O
In,O
the,O
FST,O
",",O
imipramine,O
showed,O
greater,O
antidepressant,O
effects,O
in,O
the,O
morning,O
than,O
in,O
the,O
evening,O
.,O
Imipramine,O
could,O
interact,O
with,O
noradrenergic,O
neurons,O
more,O
effectively,O
in,O
the,O
morning,O
than,O
in,O
the,O
evening,O
",",O
and,O
the,O
chronic,O
interaction,O
with,O
the,O
neurons,O
might,O
induce,O
the,O
alterations,O
of,O
the,O
receptor,O
expression,O
",",O
which,O
might,O
explain,O
the,O
dosing,O
time,O
-,O
dependent,O
antidepressant,O
effects,O
of,O
imipramine,O
.,O
This,O
low,O
-,O
dose,O
chronic,O
model,O
using,O
the,O
FST,O
might,O
be,O
a,O
useful,O
model,O
for,O
the,O
chronopharmacological,O
analysis,O
of,O
antidepressants,O
.,O
MiR,O
-,O
338,O
-,O
3p,O
regulates,O
neuronal,O
maturation,O
and,O
suppresses,O
glioblastoma,B-DS
proliferation,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Conceptualization,O
:,O
BWL,O
.,O
Data,O
curation,O
:,O
JRH,O
GJR,O
.,O
Formal,O
analysis,O
:,O
JRH,O
ESL,O
SES,O
EC,O
GBR,O
JFL,O
GJR,O
LBH,O
BWL,O
.,O
Funding,O
acquisition,O
:,O
BWL,O
.,O
Investigation,O
:,O
JRH,O
ESL,O
SES,O
EC,O
GBR,O
JFL,O
LBH,O
KRR,O
PDS,O
.,O
Methodology,O
:,O
GJR,O
BWL,O
.,O
Project,O
administration,O
:,O
BWL,O
.,O
Resources,O
:,O
BWL,O
.,O
Software,O
:,O
GJR,O
.,O
Supervision,O
:,O
BWL,O
.,O
Visualization,O
:,O
JRH,O
ESL,O
SES,O
GJR,O
JFL,O
LBH,O
BWL,O
.,O
Writing,O
–,O
original,O
draft,O
:,O
JRH,O
.,O
Writing,O
–,O
review,O
&,O
editing,O
:,O
JRH,O
SES,O
GJR,O
JFL,O
LBH,O
KRR,O
PDS,O
BWL,O
.,O
Neurogenesis,O
is,O
a,O
highly,O
-,O
regulated,O
process,O
occurring,O
in,O
the,O
dentate,O
gyrus,O
that,O
has,O
been,O
linked,O
to,O
learning,O
",",O
memory,O
",",O
and,O
antidepressant,O
efficacy,O
.,O
MicroRNAs,O
(,O
miRNAs,O
),O
have,O
been,O
previously,O
shown,O
to,O
play,O
an,O
important,O
role,O
in,O
the,O
regulation,O
of,O
neuronal,O
development,O
and,O
neurogenesis,O
in,O
the,O
dentate,O
gyrus,O
via,O
modulation,O
of,O
gene,O
expression,O
.,O
However,O
",",O
this,O
mode,O
of,O
regulation,O
is,O
both,O
incompletely,O
described,O
in,O
the,O
literature,O
thus,O
far,O
and,O
highly,O
multifactorial,O
.,O
In,O
this,O
study,O
",",O
we,O
designed,O
sensors,O
and,O
detected,O
relative,O
levels,O
of,O
expression,O
of,O
10,O
different,O
miRNAs,O
and,O
found,O
miR,O
-,O
338,O
-,O
3p,O
was,O
most,O
highly,O
expressed,O
in,O
the,O
dentate,O
gyrus,O
.,O
Comparison,O
of,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
with,O
neuronal,O
markers,O
of,O
maturity,O
indicates,O
miR,O
-,O
338,O
-,O
3p,O
is,O
expressed,O
most,O
highly,O
in,O
the,O
mature,O
neuron,O
.,O
We,O
also,O
designed,O
a,O
viral,O
“,O
sponge,O
”,O
to,O
knock,O
down,O
in,O
vivo,O
expression,O
of,O
miR,O
-,O
338,O
-,O
3p,O
.,O
When,O
miR,O
-,O
338,O
-,O
3p,O
is,O
knocked,O
down,O
",",O
neurons,O
sprout,O
multiple,O
primary,O
dendrites,O
that,O
branch,O
off,O
of,O
the,O
soma,O
in,O
a,O
disorganized,O
manner,O
",",O
cellular,O
proliferation,O
is,O
upregulated,O
",",O
and,O
neoplasms,B-DS
form,O
spontaneously,O
in,O
vivo,O
.,O
Additionally,O
",",O
miR,O
-,O
338,O
-,O
3p,O
overexpression,O
in,O
glioblastoma,B-DS
cell,O
lines,O
slows,O
their,O
proliferation,O
in,O
vitro,O
.,O
Further,O
",",O
low,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
is,O
associated,O
with,O
increased,O
mortality,O
and,O
disease,O
progression,O
in,O
patients,O
with,O
glioblastoma,B-DS
.,O
These,O
data,O
identify,O
miR,O
-,O
338,O
-,O
3p,O
as,O
a,O
clinically,O
relevant,O
tumor,B-DS
suppressor,O
in,O
glioblastoma,B-DS
.,O
Introduction,O
In,O
humans,B-OG
",",O
neurogenesis,O
has,O
been,O
observed,O
in,O
two,O
regions,O
of,O
the,O
adult,O
brain,O
:,O
the,O
subventricular,O
zone,O
of,O
the,O
lateral,O
ventricles,O
and,O
the,O
subgranular,O
zone,O
of,O
the,O
dentate,O
gyrus,O
in,O
the,O
hippocampus,O
[,O
1,O
",",O
2,O
].,O
Neurogenesis,O
in,O
the,O
dentate,O
gyrus,O
has,O
been,O
linked,O
to,O
numerous,O
phenomena,O
",",O
including,O
but,O
not,O
limited,O
to,O
learning,O
",",O
memory,O
",",O
conditioning,O
",",O
and,O
pattern,O
separation,O
[,O
3,O
].,O
Some,O
animal,B-OG
models,O
of,O
depression,B-DS
demonstrate,O
reduced,O
dentate,O
gyrus,O
neurogenesis,O
;,O
neurogenesis,O
is,O
necessary,O
for,O
certain,O
antidepressants,O
to,O
be,O
effective,O
[,O
4,O
",",O
5,O
].,O
Developing,O
a,O
better,O
understanding,O
of,O
the,O
mechanisms,O
underlying,O
dentate,O
gyrus,O
neurogenesis,O
could,O
provide,O
strategies,O
to,O
manipulate,O
these,O
neural,O
processes,O
for,O
therapeutic,O
gain,O
.,O
Over,O
the,O
course,O
of,O
adult,O
neurogenesis,O
in,O
the,O
dentate,O
gyrus,O
",",O
continuously,O
dividing,O
neuronal,O
progenitor,O
cells,O
residing,O
in,O
the,O
subgranular,O
zone,O
migrate,O
as,O
immature,O
neurons,O
to,O
the,O
granule,O
cell,O
layer,O
of,O
the,O
dentate,O
gyrus,O
",",O
where,O
they,O
differentiate,O
into,O
granule,O
cells,O
[,O
6,O
].,O
These,O
neurons,O
also,O
functionally,O
integrate,O
into,O
hippocampal,O
circuitry,O
by,O
extending,O
both,O
axons,O
and,O
dendrites,O
",",O
subsequently,O
forming,O
synapses,O
with,O
mature,O
neurons,O
[,O
7,O
].,O
The,O
transition,O
of,O
neurons,O
from,O
an,O
immature,O
to,O
a,O
mature,O
state,O
involves,O
many,O
changes,O
to,O
diverse,O
cellular,O
functions,O
",",O
one,O
being,O
cell,O
cycle,O
arrest,O
.,O
Long,O
-,O
term,O
cell,O
cycle,O
arrest,O
",",O
the,O
G0,O
or,O
quiescent,O
phase,O
",",O
is,O
crucial,O
for,O
maintenance,O
of,O
the,O
highly,O
specialized,O
mature,O
neuronal,O
phenotype,O
.,O
Failure,O
of,O
neurons,O
to,O
maintain,O
the,O
G0,O
phase,O
is,O
associated,O
with,O
numerous,O
neurodegenerative,B-DS
diseases,I-DS
",",O
such,O
as,O
Alzheimer,B-DS
’,I-DS
s,I-DS
and,O
Parkinson,B-DS
’,I-DS
s,I-DS
disease,I-DS
[,O
8,O
–,O
10,O
].,O
Recent,O
studies,O
show,O
microRNAs,O
(,O
miRNAs,O
),O
play,O
a,O
key,O
role,O
in,O
regulating,O
neuronal,O
gene,O
expression,O
",",O
which,O
can,O
impact,O
neurogenesis,O
in,O
the,O
dentate,O
gyrus,O
[,O
11,O
].,O
These,O
miRNAs,O
include,O
miR,O
-,O
132,O
",",O
which,O
is,O
most,O
highly,O
expressed,O
in,O
mature,O
neurons,O
",",O
and,O
miR,O
-,O
137,O
",",O
which,O
inhibits,O
synaptic,O
integration,O
and,O
dendritic,O
spine,O
growth,O
when,O
knocked,O
down,O
[,O
12,O
",",O
13,O
].,O
Neurogenesis,O
is,O
a,O
highly,O
activity,O
-,O
dependent,O
phenomenon,O
.,O
Proliferation,O
of,O
newborn,O
neurons,O
in,O
the,O
dentate,O
gyrus,O
increases,O
in,O
response,O
to,O
direct,O
hippocampal,O
stimulation,O
as,O
well,O
as,O
processes,O
stimulating,O
the,O
hippocampus,O
",",O
such,O
as,O
exercise,O
",",O
spatial,O
learning,O
",",O
and,O
an,O
enriched,O
environment,O
[,O
14,O
–,O
16,O
].,O
If,O
these,O
newborn,O
neurons,O
do,O
not,O
receive,O
sufficient,O
stimulation,O
",",O
they,O
become,O
much,O
less,O
likely,O
to,O
survive,O
to,O
maturity,O
[,O
17,O
].,O
Once,O
these,O
neurons,O
begin,O
forming,O
synapses,O
",",O
successful,O
integration,O
into,O
existing,O
neurocircuits,O
also,O
depends,O
on,O
the,O
level,O
of,O
stimulation,O
they,O
receive,O
[,O
18,O
",",O
19,O
].,O
Earlier,O
studies,O
identified,O
10,O
activity,O
-,O
dependent,O
miRNAs,O
significantly,O
upregulated,O
following,O
pilocarpine,O
-,O
induced,O
seizures,O
[,O
20,O
].,O
To,O
determine,O
which,O
of,O
these,O
miRNAs,O
plays,O
a,O
role,O
in,O
neurogenesis,O
",",O
we,O
developed,O
a,O
lentiviral,O
sensor,O
to,O
detect,O
miRNAs,O
in,O
vivo,O
",",O
and,O
found,O
significant,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
in,O
the,O
dentate,O
gyrus,O
of,O
adult,O
mice,B-OG
.,O
Using,O
immunohistochemistry,O
",",O
we,O
determined,O
miR,O
-,O
338,O
-,O
3p,O
to,O
be,O
most,O
highly,O
expressed,O
in,O
mature,O
neurons,O
.,O
In,O
vivo,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
revealed,O
that,O
granule,O
cells,O
deficient,O
in,O
miR,O
-,O
338,O
-,O
3p,O
sprout,O
multiple,O
primary,O
dendrites,O
and,O
change,O
their,O
overall,O
organization,O
",",O
increasing,O
their,O
number,O
of,O
dendrites,O
and,O
altering,O
branching,O
angles,O
.,O
We,O
observed,O
in,O
vivo,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
created,O
regions,O
of,O
cellular,O
neoplasia,B-DS
resembling,O
glioblastoma,B-DS
(,O
GBM,B-DS
),O
in,O
the,O
dentate,O
gyrus,O
.,O
Overexpressing,O
miR,O
-,O
338,O
-,O
3p,O
in,O
vitro,O
confirmed,O
our,O
findings,O
with,O
regards,O
to,O
neoplasia,B-DS
",",O
significantly,O
decreasing,O
the,O
proliferation,O
rate,O
of,O
miR,O
-,O
338,O
-,O
3p,O
-,O
deficient,O
GBM,B-DS
cell,O
lines,O
.,O
Thus,O
",",O
we,O
conclude,O
miR,O
-,O
338,O
-,O
3p,O
endogenously,O
regulates,O
maturation,O
of,O
neurons,O
",",O
and,O
miR,O
-,O
338,O
-,O
3p,O
loss,O
-,O
of,O
-,O
function,O
could,O
contribute,O
to,O
tumorigenesis,O
.,O
Results,O
MiR,O
-,O
338,O
-,O
3p,O
is,O
expressed,O
at,O
high,O
levels,O
in,O
the,O
dentate,O
gyrus,O
We,O
previously,O
determined,O
which,O
miRNAs,O
were,O
most,O
likely,O
to,O
affect,O
neurogenesis,O
by,O
identifying,O
miRNAs,O
whose,O
expression,O
is,O
induced,O
by,O
neuronal,O
activity,O
in,O
a,O
pilocarpine,O
seizure,B-DS
model,O
[,O
20,O
].,O
We,O
selected,O
the,O
-,O
3p,O
and,O
-,O
5p,O
species,O
of,O
the,O
five,O
most,O
upregulated,O
miRNAs,O
for,O
the,O
current,O
study,O
.,O
We,O
designed,O
a,O
lentiviral,O
sensor,O
system,O
to,O
detect,O
the,O
miRNAs,O
of,O
interest,O
via,O
their,O
binding,O
to,O
complementary,O
mRNA,O
sequences,O
",",O
which,O
blocks,O
translation,O
.,O
We,O
achieved,O
this,O
by,O
cloning,O
two,O
miRNA,O
-,O
complementary,O
target,O
sequences,O
into,O
the,O
3,O
’,O
UTR,O
of,O
mCherry,B-GP
in,O
a,O
lentiviral,O
vector,O
(,O
Fig,O
1A,O
).,O
Thus,O
",",O
endogenous,O
miRNAs,O
will,O
bind,O
the,O
mCherry,B-GP
transcript,O
’,O
s,O
target,O
sequences,O
",",O
blocking,O
its,O
translation,O
and,O
reducing,O
the,O
level,O
of,O
mCherry,B-GP
fluorescence,O
in,O
cells,O
expressing,O
the,O
miRNA,O
of,O
interest,O
.,O
Thus,O
",",O
if,O
the,O
cell,O
expresses,O
the,O
miRNA,O
of,O
interest,O
",",O
mCherry,B-GP
fluorescence,O
will,O
be,O
inhibited,O
.,O
In,O
vivo,O
detection,O
of,O
selected,O
miRNAs,O
using,O
an,O
mCherry,B-GP
sensor,O
.,O
(,O
A,O
),O
Construction,O
of,O
the,O
lentiviral,O
vector,O
",",O
using,O
an,O
FUCW,O
backbone,O
and,O
two,O
target,O
-,O
complementary,O
sequences,O
immediately,O
downstream,O
of,O
mCherry,B-GP
.,O
(,O
B,O
),O
Co,O
-,O
injection,O
of,O
control,O
GFP,B-GP
-,O
expressing,O
and,O
mCherry,B-GP
-,O
expressing,O
viruses,B-OG
(,O
equal,O
titer,O
),O
into,O
the,O
dentate,O
gyrus,O
of,O
adult,O
mice,B-OG
results,O
in,O
roughly,O
equal,O
infection,B-DS
rates,O
;,O
sections,O
counter,O
-,O
stained,O
with,O
DAPI,O
.,O
(,O
C,O
),O
Co,O
-,O
injection,O
of,O
miR137,O
-,O
3p,O
sensor,O
(,O
red,O
),O
and,O
control,O
GFP,B-GP
-,O
expressing,O
virus,B-OG
.,O
(,O
D,O
),O
Co,O
-,O
injection,O
of,O
miR338,O
-,O
3p,O
sensor,O
(,O
red,O
),O
and,O
control,O
GFP,B-GP
-,O
expressing,O
virus,B-OG
.,O
(,O
E,O
),O
Expression,O
levels,O
of,O
10,O
different,O
miRNAs,O
in,O
the,O
dentate,O
gyrus,O
relative,O
to,O
control,O
mCherry,B-GP
-,O
expressing,O
vector,O
.,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
",",O
***,O
p,O
<,O
0,O
.,O
001,O
;,O
one,O
-,O
way,O
ANOVA,O
",",O
analyzed,O
post,O
-,O
hoc,O
using,O
Tukey,O
’,O
s,O
range,O
test,O
.,O
Results,O
show,O
mean,O
±,O
SEM,O
.,O
We,O
co,O
-,O
injected,O
equal,O
titers,O
of,O
lentiviral,O
controls,O
containing,O
green,B-GP
fluorescent,I-GP
protein,I-GP
(,O
GFP,B-GP
),O
or,O
mCherry,B-GP
without,O
sensor,O
into,O
the,O
dentate,O
gyrus,O
of,O
adult,O
mice,B-OG
(,O
7,O
–,O
8,O
weeks,O
).,O
We,O
use,O
the,O
GFP,B-GP
-,O
expressing,O
lentivirus,B-OG
to,O
provide,O
a,O
baseline,O
number,O
of,O
infected,O
cells,O
for,O
comparison,O
(,O
Fig,O
1B,O
).,O
Next,O
",",O
we,O
co,O
-,O
injected,O
each,O
of,O
the,O
10,O
miRNA,O
sensors,O
and,O
GFP,B-GP
control,O
into,O
the,O
dentate,O
gyri,O
of,O
adult,O
mice,B-OG
(,O
7,O
–,O
8,O
weeks,O
).,O
Qualitatively,O
",",O
we,O
found,O
that,O
the,O
miR,O
-,O
137,O
-,O
3p,O
and,O
miR,O
-,O
338,O
-,O
3p,O
were,O
the,O
most,O
strongly,O
detected,O
in,O
vivo,O
(,O
Fig,O
1C,O
and,O
1D,O
).,O
We,O
subsequently,O
quantified,O
the,O
expression,O
level,O
of,O
each,O
miRNA,O
of,O
interest,O
by,O
comparing,O
the,O
number,O
of,O
cells,O
expressing,O
the,O
mCherry,B-GP
microRNA,O
sensor,O
to,O
the,O
number,O
of,O
cells,O
expressing,O
the,O
GFP,B-GP
control,O
(,O
Fig,O
1E,O
).,O
We,O
determined,O
miR,O
-,O
137,O
-,O
3p,O
and,O
mir,O
-,O
338,O
-,O
3p,O
were,O
the,O
most,O
highly,O
-,O
expressed,O
assayed,O
miRNAs,O
in,O
the,O
dentate,O
gyrus,O
",",O
based,O
on,O
mean,O
mCherry,B-GP
expression,O
levels,O
of,O
3,O
.,O
11,O
±,O
0,O
.,O
53,O
%,O
(,O
n,O
=,O
3,O
),O
and,O
3,O
.,O
68,O
±,O
1,O
.,O
04,O
%,O
(,O
n,O
=,O
4,O
),O
of,O
cells,O
",",O
respectively,O
",",O
compared,O
to,O
GFP,B-GP
(,O
Fig,O
1E,O
",",O
S1,O
Table,O
).,O
Based,O
on,O
these,O
results,O
",",O
we,O
decided,O
to,O
focus,O
on,O
miR,O
-,O
338,O
-,O
3p,O
in,O
subsequent,O
experiments,O
.,O
MiR,O
-,O
338,O
-,O
3p,O
is,O
most,O
highly,O
expressed,O
in,O
mature,O
neurons,O
To,O
further,O
characterize,O
the,O
temporal,O
expression,O
pattern,O
of,O
endogenous,O
miRNAs,O
in,O
developing,O
neurons,O
",",O
we,O
immunostained,O
murine,O
dentate,O
gyrus,O
sections,O
with,O
neuronal,O
maturation,O
markers,O
.,O
We,O
used,O
Nestin,B-GP
",",O
an,O
intermediate,O
filament,B-GP
protein,I-GP
",",O
as,O
a,O
neural,O
progenitor,O
cell,O
marker,O
.,O
We,O
used,O
doublecortin,B-GP
(,O
DCX,B-GP
"),",O
a,O
microtubule,B-GP
-,I-GP
associated,I-GP
protein,I-GP
expressed,O
during,O
neuronal,O
migration,O
",",O
to,O
mark,O
neuronal,O
precursor,O
cells,O
and,O
newly,O
differentiated,O
neurons,O
.,O
Finally,O
",",O
we,O
used,O
Neuronal,B-GP
Nuclei,I-GP
Antigen,O
(,O
NeuN,B-GP
"),",O
a,O
neuron,O
-,O
specific,O
antigen,O
localizing,O
to,O
the,O
cell,O
nucleus,O
",",O
to,O
mark,O
mature,O
neurons,O
.,O
We,O
compared,O
the,O
co,O
-,O
staining,O
for,O
these,O
markers,O
with,O
a,O
control,O
virus,B-OG
constitutively,O
expressing,O
mCherry,B-GP
",",O
the,O
sensor,O
for,O
both,O
the,O
-,O
3p,O
and,O
-,O
5p,O
transcripts,O
of,O
miR,O
-,O
338,O
or,O
the,O
sensor,O
for,O
the,O
-,O
3p,O
and,O
-,O
5p,O
transcripts,O
of,O
the,O
previously,O
characterized,O
miR,O
-,O
132,O
[,O
13,O
].,O
In,O
tissue,O
injected,O
with,O
the,O
mCherry,B-GP
control,O
virus,B-OG
",",O
14,O
.,O
05,O
±,O
1,O
.,O
19,O
%,O
(,O
n,O
=,O
4,O
),O
of,O
all,O
mCherry,B-GP
-,O
positive,O
cells,O
were,O
nestin,B-GP
-,O
positive,O
",",O
14,O
.,O
60,O
±,O
2,O
.,O
26,O
%,O
(,O
n,O
=,O
4,O
),O
were,O
DCX,B-GP
-,O
positive,O
",",O
and,O
90,O
.,O
23,O
±,O
3,O
.,O
37,O
%,O
(,O
n,O
=,O
4,O
),O
were,O
NeuN,B-GP
-,O
positive,O
(,O
Fig,O
2E,O
–,O
2G,O
",",O
S2,O
Table,O
).,O
Some,O
cells,O
co,O
-,O
expressed,O
DCX,B-GP
with,O
nestin,B-GP
or,O
NeuN,B-GP
",",O
so,O
the,O
total,O
proportions,O
summed,O
to,O
greater,O
than,O
100,O
%.,O
These,O
results,O
indicate,O
the,O
dentate,O
gyrus,O
is,O
mostly,O
comprised,O
of,O
mature,O
neurons,O
(,O
NeuN,B-GP
"),",O
along,O
with,O
a,O
smaller,O
population,O
of,O
precursor,O
cells,O
(,O
nestin,B-GP
),O
and,O
newly,O
differentiated,O
neurons,O
(,O
DCX,B-GP
"),",O
which,O
corresponds,O
to,O
prior,O
findings,O
examining,O
the,O
relative,O
number,O
of,O
each,O
cell,O
population,O
in,O
the,O
dentate,O
gyrus,O
",",O
indicating,O
the,O
proportion,O
of,O
cells,O
labeled,O
by,O
the,O
sensor,O
approximately,O
reflects,O
physiological,O
proportions,O
[,O
21,O
",",O
22,O
].,O
MiR,O
-,O
338,O
-,O
3p,O
expression,O
increases,O
with,O
maturity,O
in,O
dentate,O
gyrus,O
granule,O
neurons,O
.,O
(,O
A,O
),O
Co,O
-,O
localization,O
of,O
nestin,B-GP
(,O
arrowheads,O
),O
with,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
.,O
(,O
B,O
),O
Co,O
-,O
localization,O
of,O
nestin,B-GP
(,O
arrowheads,O
),O
with,O
miR,O
-,O
132,O
-,O
3p,O
sensor,O
.,O
(,O
C,O
),O
Co,O
-,O
localization,O
of,O
NeuN,B-GP
(,O
arrowheads,O
),O
and,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
.,O
(,O
D,O
),O
Co,O
-,O
localization,O
of,O
NeuN,B-GP
(,O
arrowheads,O
),O
and,O
miR,O
-,O
132,O
-,O
3p,O
sensor,O
.,O
(,O
E,O
),O
Percentage,O
of,O
cells,O
co,O
-,O
labeled,O
with,O
one,O
of,O
the,O
sensors,O
and,O
nestin,B-GP
as,O
compared,O
to,O
control,O
mCherry,B-GP
virus,B-OG
.,O
(,O
F,O
),O
Percentage,O
of,O
cells,O
co,O
-,O
labeled,O
with,O
one,O
of,O
the,O
sensors,O
and,O
doublecortin,B-GP
as,O
compared,O
to,O
control,O
mCherry,B-GP
virus,B-OG
.,O
(,O
G,O
),O
Percentage,O
of,O
cells,O
co,O
-,O
labeled,O
with,O
one,O
of,O
the,O
sensors,O
and,O
NeuN,B-GP
as,O
compared,O
to,O
control,O
mCherry,B-GP
virus,B-OG
.,O
(,O
H,O
),O
Ratio,O
of,O
cells,O
co,O
-,O
labeled,O
with,O
either,O
the,O
miR,O
-,O
338,O
-,O
3p,O
or,O
miR,O
-,O
132,O
-,O
3p,O
sensor,O
and,O
nestin,B-GP
as,O
compared,O
to,O
control,O
mCherry,B-GP
virus,B-OG
.,O
(,O
I,O
),O
Ratio,O
of,O
cells,O
co,O
-,O
labeled,O
with,O
either,O
the,O
miR,O
-,O
338,O
-,O
3p,O
or,O
miR,O
-,O
132,O
-,O
3p,O
sensor,O
and,O
doublecortin,B-GP
as,O
compared,O
to,O
control,O
mCherry,B-GP
virus,B-OG
.,O
(,O
J,O
),O
Ratio,O
of,O
cells,O
co,O
-,O
labeled,O
with,O
either,O
the,O
miR,O
-,O
338,O
-,O
3p,O
or,O
miR,O
-,O
132,O
-,O
3p,O
sensor,O
and,O
NeuN,B-GP
as,O
compared,O
to,O
control,O
mCherry,B-GP
virus,B-OG
.,O
ns,O
p,O
>,O
0,O
.,O
05,O
",",O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
**,O
p,O
<,O
0,O
.,O
01,O
",",O
***,O
p,O
<,O
0,O
.,O
001,O
",",O
****,O
p,O
<,O
0,O
.,O
0001,O
;,O
one,O
-,O
way,O
ANOVA,O
",",O
analyzed,O
post,O
-,O
hoc,O
using,O
Tukey,O
’,O
s,O
range,O
test,O
.,O
Results,O
show,O
mean,O
±,O
SEM,O
.,O
We,O
next,O
quantified,O
the,O
percentage,O
of,O
nestin,B-GP
"-,",O
DCX,B-GP
"-,",O
and,O
NeuN,B-GP
-,O
positive,O
cells,O
labeled,O
by,O
the,O
sensor,O
in,O
the,O
dentate,O
gyri,O
of,O
adult,O
mice,B-OG
injected,O
with,O
either,O
the,O
miR,O
-,O
338,O
-,O
3p,O
(,O
Fig,O
2A,O
and,O
2C,O
),O
or,O
the,O
miR,O
-,O
132,O
-,O
3p,O
sensor,O
(,O
Fig,O
2B,O
and,O
2D,O
).,O
Of,O
cells,O
labeled,O
by,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
",",O
67,O
.,O
50,O
±,O
2,O
.,O
70,O
%,O
(,O
n,O
=,O
4,O
),O
were,O
nestin,B-GP
-,O
positive,O
",",O
43,O
.,O
97,O
±,O
6,O
.,O
79,O
%,O
(,O
n,O
=,O
4,O
),O
were,O
DCX,B-GP
-,O
positive,O
",",O
and,O
44,O
.,O
87,O
±,O
5,O
.,O
87,O
%,O
(,O
n,O
=,O
4,O
),O
were,O
NeuN,B-GP
-,O
positive,O
(,O
Fig,O
2E,O
–,O
2G,O
).,O
Of,O
the,O
miR,O
-,O
132,O
-,O
3p,O
sensor,O
-,O
expressing,O
cells,O
",",O
77,O
.,O
84,O
±,O
4,O
.,O
24,O
%,O
(,O
n,O
=,O
6,O
),O
were,O
nestin,B-GP
positive,O
",",O
33,O
.,O
56,O
±,O
5,O
.,O
22,O
%,O
(,O
n,O
=,O
6,O
),O
were,O
DCX,B-GP
-,O
positive,O
and,O
36,O
.,O
38,O
±,O
8,O
.,O
33,O
%,O
(,O
n,O
=,O
6,O
),O
were,O
NeuN,B-GP
-,O
positive,O
(,O
Fig,O
2E,O
–,O
2G,O
).,O
To,O
illustrate,O
the,O
changes,O
in,O
expression,O
for,O
miR,O
-,O
338,O
-,O
3p,O
and,O
miR,O
-,O
132,O
-,O
3p,O
specific,O
to,O
different,O
points,O
in,O
neuronal,O
maturity,O
while,O
compensating,O
for,O
any,O
possible,O
unforeseen,O
biases,O
toward,O
specific,O
cell,O
types,O
potentially,O
induced,O
by,O
differential,O
tropism,O
",",O
we,O
described,O
these,O
percentages,O
normalized,O
to,O
an,O
mCherry,B-GP
control,O
utilizing,O
the,O
same,O
backbone,O
(,O
Fig,O
2H,O
–,O
2J,O
).,O
Compared,O
to,O
control,O
",",O
there,O
was,O
a,O
5,O
.,O
54,O
±,O
1,O
.,O
29,O
-,O
fold,O
(,O
p,O
<,O
0,O
.,O
0001,O
),O
and,O
4,O
.,O
80,O
±,O
1,O
.,O
10,O
-,O
fold,O
(,O
p,O
<,O
0,O
.,O
0001,O
),O
fold,O
increase,O
in,O
the,O
miR,O
-,O
132,O
-,O
3p,O
and,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
expression,O
in,O
nestin,B-GP
-,O
positive,O
cells,O
(,O
Fig,O
2H,O
).,O
Of,O
all,O
cells,O
expressing,O
the,O
miR,O
-,O
132,O
-,O
3p,O
sensor,O
",",O
there,O
was,O
a,O
2,O
.,O
30,O
±,O
1,O
.,O
16,O
-,O
fold,O
decrease,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
in,O
co,O
-,O
labeling,O
of,O
DCX,B-GP
and,O
the,O
sensor,O
compared,O
to,O
the,O
control,O
",",O
and,O
a,O
3,O
.,O
01,O
±,O
1,O
.,O
61,O
-,O
fold,O
decrease,O
(,O
p,O
<,O
0,O
.,O
01,O
),O
in,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
-,O
expressing,O
neurons,O
(,O
Fig,O
2I,O
).,O
We,O
found,O
a,O
2,O
.,O
48,O
±,O
.,O
22,O
(,O
p,O
<,O
0,O
.,O
001,O
),O
and,O
1,O
.,O
69,O
±,O
.,O
27,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
fold,O
decrease,O
in,O
co,O
-,O
labeling,O
of,O
NeuN,B-GP
with,O
miR,O
-,O
132,O
-,O
3p,O
and,O
miR,O
-,O
338,O
-,O
3p,O
sensors,O
",",O
respectively,O
(,O
Fig,O
2J,O
).,O
These,O
data,O
indicate,O
an,O
increase,O
in,O
relative,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
with,O
advancing,O
neuronal,O
maturity,O
.,O
Given,O
the,O
expression,O
profile,O
of,O
miR,O
-,O
338,O
-,O
3p,O
",",O
we,O
posit,O
that,O
it,O
may,O
have,O
a,O
role,O
regulating,O
the,O
maturation,O
of,O
a,O
proliferating,O
neural,O
precursor,O
cell,O
into,O
a,O
mature,O
neuron,O
.,O
Granule,O
cell,O
morphology,O
is,O
altered,O
by,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
To,O
evaluate,O
the,O
function,O
of,O
miR,O
-,O
338,O
-,O
3p,O
in,O
vivo,O
",",O
we,O
generated,O
a,O
miR,O
-,O
338,O
-,O
3p,O
lentiviral,O
and,O
retroviral,O
‘,O
sponge,O
’,O
to,O
reduce,O
activity,O
of,O
miR,O
-,O
338,O
-,O
3p,O
by,O
binding,O
it,O
and,O
preventing,O
the,O
miRNA,O
from,O
interacting,O
with,O
its,O
endogenous,O
targets,O
.,O
The,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
contains,O
6,O
targets,O
downstream,O
from,O
both,O
the,O
U6,O
and,O
H1,O
promoters,O
",",O
for,O
a,O
total,O
of,O
12,O
sponge,O
targets,O
.,O
We,O
generated,O
the,O
sponge,O
using,O
the,O
previously,O
described,O
sensor,O
cassette,O
that,O
has,O
2,O
miR,O
-,O
338,O
-,O
3p,O
targets,O
downstream,O
from,O
GFP,B-GP
driven,O
by,O
a,O
ubiquitin,B-GP
promoter,O
",",O
allowing,O
simultaneous,O
knockdown,O
and,O
detection,O
of,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
in,O
vivo,O
(,O
Fig,O
3A,O
).,O
In,O
vivo,O
verification,O
of,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
efficacy,O
.,O
(,O
A,O
),O
Design,O
of,O
lentiviral,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
with,O
a,O
sensor,O
cassette,O
.,O
The,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
cassette,O
contains,O
2,O
perfectly,O
complementary,O
miR,O
-,O
338,O
-,O
3p,O
target,O
sequences,O
downstream,O
of,O
GFP,B-GP
driven,O
by,O
the,O
pUbiquitin,B-GP
promoter,O
and,O
the,O
sponge,O
cassette,O
consists,O
of,O
6,O
targets,O
downstream,O
of,O
both,O
the,O
H1,O
and,O
U6,O
promoters,O
for,O
a,O
total,O
of,O
2,O
sensor,O
targets,O
to,O
sense,O
miR,O
-,O
338,O
-,O
3p,O
activity,O
and,O
12,O
sponge,O
targets,O
to,O
sequester,O
endogenous,O
miR,O
-,O
338,O
-,O
3p,O
.,O
(,O
B,O
),O
Low,O
magnification,O
images,O
of,O
dentate,O
gyrus,O
show,O
the,O
mCherry,B-GP
control,O
and,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
exhibit,O
similarly,O
high,O
levels,O
of,O
expression,O
.,O
(,O
C,O
),O
Images,O
from,O
(,O
B,O
"),",O
but,O
under,O
high,O
magnification,O
.,O
This,O
demonstrates,O
the,O
ability,O
of,O
the,O
sponge,O
cassette,O
to,O
sequester,O
ligand,O
away,O
from,O
the,O
miR,O
-,O
338,O
-,O
3p,O
targets,O
expressed,O
in,O
the,O
sensor,O
cassette,O
.,O
We,O
determined,O
effectiveness,O
of,O
the,O
sponge,O
in,O
vivo,O
by,O
injecting,O
a,O
virus,B-OG
that,O
expresses,O
both,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
and,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
cassettes,O
.,O
When,O
infected,O
with,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
",",O
the,O
average,O
number,O
of,O
cells,O
labeled,O
per,O
tissue,O
section,O
is,O
3,O
.,O
0,O
±,O
2,O
.,O
19,O
cells,O
/,O
section,O
(,O
n,O
=,O
6,O
"),",O
while,O
an,O
equal,O
titer,O
of,O
a,O
control,O
virus,B-OG
expressing,O
only,O
mCherry,B-GP
labeled,O
182,O
.,O
1,O
±,O
12,O
.,O
81,O
cells,O
/,O
section,O
",",O
(,O
n,O
=,O
8,O
),O
indicating,O
strong,O
regulation,O
of,O
the,O
sensor,O
by,O
endogenous,O
miR,O
-,O
338,O
-,O
3p,O
(,O
S3,O
Table,O
).,O
In,O
contrast,O
",",O
when,O
mice,B-OG
are,O
injected,O
with,O
a,O
virus,B-OG
expressing,O
both,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
and,O
the,O
sponge,O
",",O
101,O
.,O
5,O
±,O
6,O
.,O
57,O
cells,O
/,O
section,O
(,O
n,O
=,O
8,O
),O
were,O
labeled,O
(,O
S3,O
Table,O
).,O
This,O
increase,O
in,O
the,O
number,O
of,O
labeled,O
cells,O
infected,O
with,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
shows,O
the,O
sponge,O
effectively,O
knocks,O
down,O
endogenous,O
miR,O
-,O
338,O
-,O
3p,O
.,O
The,O
efficacy,O
of,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
was,O
also,O
demonstrated,O
by,O
co,O
-,O
injection,O
with,O
an,O
equal,O
titer,O
of,O
a,O
control,O
virus,B-OG
expressing,O
mCherry,B-GP
alone,O
(,O
Fig,O
3B,O
and,O
3C,O
).,O
We,O
found,O
that,O
most,O
cells,O
labeled,O
by,O
the,O
mCherry,B-GP
control,O
were,O
also,O
labeled,O
with,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
virus,B-OG
",",O
but,O
the,O
control,O
virus,B-OG
labeled,O
a,O
higher,O
proportion,O
of,O
mature,O
-,O
appearing,O
granule,O
neurons,O
compared,O
to,O
the,O
sponge,O
(,O
Fig,O
3C,O
).,O
However,O
",",O
an,O
analysis,O
of,O
the,O
proportion,O
of,O
sponge,O
-,O
infected,O
cells,O
expressing,O
nestin,B-GP
versus,O
NeuN,B-GP
showed,O
no,O
significant,O
changes,O
to,O
the,O
overall,O
relative,O
maturity,O
of,O
sponge,O
-,O
infected,O
cells,O
(,O
S1,O
Fig,O
",",O
S4,O
Table,O
).,O
These,O
results,O
indicate,O
that,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
effectively,O
knocked,O
down,O
miR,O
-,O
338,O
-,O
3p,O
but,O
does,O
not,O
alter,O
the,O
proportion,O
that,O
are,O
nestin,B-GP
or,O
NeuN,B-GP
positive,O
.,O
To,O
determine,O
the,O
function,O
of,O
miR,O
-,O
338,O
-,O
3p,O
in,O
the,O
development,O
of,O
dentate,O
gyrus,O
granule,O
neurons,O
",",O
we,O
cloned,O
a,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
cassette,O
into,O
the,O
pRubi,O
retroviral,O
backbone,O
.,O
Injection,O
of,O
this,O
retrovirus,B-OG
results,O
in,O
specific,O
infection,B-DS
of,O
actively,O
proliferating,O
cells,O
",",O
allowing,O
us,O
to,O
examine,O
the,O
development,O
of,O
newborn,O
granule,O
neurons,O
in,O
vivo,O
.,O
Two,O
retroviruses,B-OG
",",O
one,O
expressing,O
the,O
sponge,O
construct,O
with,O
mCherry,B-GP
and,O
one,O
expressing,O
GFP,B-GP
only,O
",",O
were,O
co,O
-,O
injected,O
into,O
the,O
neonatal,O
dentate,O
gyrus,O
.,O
21,O
days,O
after,O
injection,O
",",O
the,O
granule,O
layer,O
was,O
highly,O
infected,O
.,O
The,O
majority,O
of,O
labeled,O
cells,O
were,O
either,O
infected,O
by,O
the,O
sponge,O
or,O
co,O
-,O
infected,O
with,O
both,O
the,O
sponge,O
and,O
the,O
GFP,B-GP
control,O
",",O
and,O
only,O
a,O
small,O
minority,O
was,O
infected,O
solely,O
with,O
the,O
GFP,B-GP
control,O
(,O
Fig,O
4A,O
).,O
We,O
limited,O
our,O
morphological,O
analysis,O
solely,O
to,O
granule,O
neurons,O
.,O
MiR,O
-,O
338,O
-,O
3p,O
knockdown,O
results,O
in,O
abnormal,O
granule,O
cell,O
morphology,O
in,O
neonatal,O
dentate,O
gyrus,O
.,O
(,O
A,O
),O
Representative,O
images,O
of,O
granule,O
cells,O
infected,O
with,O
the,O
retroviral,O
GFP,B-GP
control,O
or,O
the,O
mCherry,B-GP
miR,O
-,O
338,O
-,O
3p,O
sponge,O
(,O
red,O
).,O
(,O
B,O
),O
Granule,O
neurons,O
expressing,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
(,O
red,O
),O
displaying,O
primary,O
dendrites,O
projecting,O
at,O
divergent,O
angles,O
from,O
the,O
soma,O
compared,O
to,O
control,O
neurons,O
.,O
(,O
C,O
),O
Granule,O
cells,O
infected,O
with,O
the,O
control,O
virus,B-OG
showing,O
bipolar,O
organization,O
",",O
while,O
the,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
neurons,O
(,O
red,O
),O
show,O
multiple,O
primary,O
dendrites,O
.,O
(,O
D,O
),O
Branching,O
angles,O
of,O
primary,O
dendrites,O
infected,O
with,O
the,O
control,O
vector,O
or,O
infected,O
with,O
the,O
sponge,O
.,O
(,O
E,O
),O
Proportion,O
of,O
granule,O
cells,O
with,O
multiple,O
primary,O
dendrites,O
relative,O
to,O
all,O
granule,O
cells,O
in,O
both,O
control,O
and,O
knockdown,O
conditions,O
.,O
Each,O
separate,O
image,O
was,O
treated,O
as,O
an,O
independent,O
sample,O
within,O
the,O
mouse,B-OG
of,O
both,O
the,O
control,O
and,O
knockdown,O
populations,O
.,O
*,O
p,O
<,O
0,O
.,O
05,O
",",O
****,O
p,O
<,O
0,O
.,O
0001,O
;,O
t,O
-,O
test,O
.,O
Results,O
show,O
mean,O
±,O
SEM,O
.,O
The,O
granule,O
neurons,O
expressing,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
often,O
displayed,O
abnormal,O
dendritic,O
architecture,O
with,O
dendrites,O
protruding,O
from,O
the,O
soma,O
at,O
abnormal,O
angles,O
(,O
Fig,O
4B,O
).,O
The,O
granule,O
cell,O
is,O
a,O
bipolar,O
neuron,O
",",O
projecting,O
a,O
single,O
dendrite,O
into,O
the,O
molecular,O
layer,O
oriented,O
at,O
a,O
right,O
angle,O
to,O
the,O
hilus,O
/,O
granule,O
cell,O
border,O
.,O
To,O
quantify,O
the,O
change,O
in,O
this,O
angle,O
caused,O
by,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
",",O
we,O
created,O
a,O
line,O
90,O
°,O
from,O
the,O
granule,O
layer,O
/,O
hilus,O
border,O
to,O
the,O
center,O
of,O
the,O
soma,O
and,O
a,O
second,O
line,O
along,O
the,O
axis,O
of,O
the,O
dendrite,O
",",O
then,O
measured,O
the,O
angle,O
between,O
the,O
cell,O
body,O
and,O
dendrite,O
(,O
Fig,O
4B,O
).,O
The,O
granule,O
cells,O
expressing,O
only,O
the,O
control,O
vector,O
had,O
a,O
mean,O
branching,O
angle,O
of,O
163,O
.,O
9,O
±,O
2,O
.,O
2,O
°,O
(,O
n,O
=,O
5,O
"),",O
while,O
the,O
granule,O
cells,O
expressing,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
had,O
a,O
mean,O
branching,O
angle,O
155,O
.,O
8,O
±,O
1,O
.,O
7,O
°,O
(,O
n,O
=,O
5,O
"),",O
with,O
a,O
mean,O
difference,O
in,O
branching,O
angle,O
of,O
8,O
.,O
0,O
±,O
2,O
.,O
8,O
"°,",O
indicating,O
a,O
significant,O
deviation,O
from,O
the,O
mean,O
branching,O
angle,O
in,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
neurons,O
(,O
Fig,O
4D,O
",",O
S5,O
Table,O
;,O
p,O
<,O
0,O
.,O
01,O
).,O
Some,O
of,O
the,O
observed,O
granule,O
cells,O
also,O
appear,O
to,O
sprout,O
multiple,O
primary,O
dendrites,O
(,O
Fig,O
4C,O
).,O
In,O
neurons,O
expressing,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
",",O
there,O
were,O
1,O
.,O
28,O
±,O
0,O
.,O
04,O
(,O
n,O
=,O
5,O
),O
primary,O
dendrites,O
/,O
neuron,O
on,O
average,O
",",O
while,O
control,O
neurons,O
averaged,O
1,O
.,O
07,O
±,O
.,O
04,O
(,O
n,O
=,O
5,O
),O
primary,O
dendrites,O
/,O
neuron,O
",",O
showing,O
a,O
significant,O
increase,O
in,O
the,O
number,O
of,O
primary,O
dendrites,O
/,O
neuron,O
in,O
miR,O
-,O
338,O
-,O
3p,O
-,O
deficient,O
cells,O
(,O
Fig,O
4E,O
",",O
S6,O
Table,O
;,O
p,O
<,O
0,O
.,O
001,O
).,O
The,O
majority,O
of,O
neurons,O
with,O
multiple,O
primary,O
dendrites,O
had,O
two,O
",",O
a,O
minority,O
had,O
three,O
",",O
but,O
none,O
had,O
four,O
or,O
greater,O
.,O
When,O
neurons,O
expressed,O
the,O
aberrant,O
phenotype,O
",",O
the,O
primary,O
dendrites,O
organized,O
in,O
one,O
of,O
two,O
arrangements,O
:,O
one,O
primary,O
dendrite,O
in,O
the,O
correct,O
orientation,O
and,O
the,O
other,O
branching,O
off,O
at,O
an,O
angle,O
approximately,O
perpendicular,O
to,O
the,O
other,O
(,O
Fig,O
4C,O
",",O
second,O
image,O
"),",O
or,O
both,O
branching,O
out,O
at,O
angles,O
close,O
to,O
the,O
wild,O
-,O
type,O
orientation,O
",",O
diverging,O
away,O
from,O
the,O
soma,O
in,O
opposite,O
directions,O
(,O
Fig,O
4C,O
",",O
third,O
and,O
fourth,O
image,O
).,O
Taken,O
together,O
",",O
these,O
morphological,O
changes,O
are,O
indicative,O
of,O
aberrant,O
granule,O
neuron,O
development,O
when,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
is,O
knocked,O
down,O
.,O
We,O
did,O
not,O
observe,O
any,O
statistically,O
significant,O
changes,O
in,O
dendritic,O
spine,O
density,O
",",O
length,O
",",O
or,O
head,O
area,O
(,O
p,O
>,O
0,O
.,O
05,O
",",O
S7,O
Table,O
).,O
Analyses,O
of,O
soma,O
size,O
and,O
length,O
",",O
number,O
of,O
dendritic,O
nodes,O
",",O
number,O
of,O
dendritic,O
termini,O
",",O
total,O
dendrite,O
length,O
",",O
and,O
mean,O
dendrite,O
length,O
all,O
returned,O
non,O
-,O
significant,O
results,O
(,O
p,O
>,O
0,O
.,O
05,O
",",O
S8,O
Table,O
).,O
Sholl,O
analyses,O
of,O
dendrite,O
intersections,O
and,O
dendrite,O
length,O
yielded,O
similarly,O
non,O
-,O
significant,O
results,O
as,O
well,O
(,O
p,O
>,O
0,O
.,O
05,O
",",O
S8,O
Table,O
).,O
Thus,O
",",O
we,O
can,O
infer,O
that,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
only,O
induces,O
significant,O
changes,O
in,O
the,O
number,O
of,O
dendrites,O
and,O
their,O
orientation,O
",",O
but,O
not,O
to,O
the,O
soma,O
itself,O
or,O
to,O
dendritic,O
arborization,O
and,O
spine,O
density,O
.,O
MiR,O
-,O
338,O
-,O
3p,O
knockdown,O
in,O
vivo,O
results,O
in,O
neoplasia,B-DS
We,O
noticed,O
regions,O
of,O
cellular,O
neoplasia,B-DS
after,O
injection,O
of,O
either,O
the,O
retroviral,O
or,O
lentiviral,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
.,O
Co,O
-,O
injection,O
of,O
the,O
lentiviral,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
with,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
(,O
n,O
=,O
6,O
),O
resulted,O
in,O
cellular,O
neoplasia,B-DS
without,O
exception,O
at,O
7,O
days,O
post,O
-,O
infection,B-DS
(,O
DPI,O
),O
in,O
regions,O
of,O
high,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
expression,O
local,O
to,O
the,O
injection,O
region,O
(,O
Fig,O
5,O
).,O
When,O
a,O
lentiviral,O
sponge,O
construct,O
for,O
miR,O
-,O
132,O
-,O
3p,O
with,O
a,O
similar,O
overall,O
design,O
was,O
injected,O
instead,O
(,O
n,O
=,O
4,O
"),",O
no,O
such,O
regions,O
of,O
cellular,O
neoplasia,B-DS
were,O
observed,O
at,O
7,O
DPI,O
(,O
S2,O
Fig,O
).,O
MiR,O
-,O
338,O
-,O
3p,O
knockdown,O
results,O
in,O
cellular,O
neoplasia,B-DS
in,O
vivo,O
.,O
Neoplasm,B-DS
infected,O
with,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
(,O
red,O
),O
and,O
sponge,O
(,O
green,O
),O
and,O
stained,O
for,O
(,O
A,O
),O
nestin,B-GP
(,O
blue,O
),O
as,O
a,O
marker,O
for,O
immature,O
neurons,O
",",O
(,O
B,O
),O
GFAP,B-GP
(,O
blue,O
),O
as,O
a,O
marker,O
for,O
astrocytes,O
",",O
and,O
(,O
C,O
),O
NeuN,B-GP
(,O
blue,O
),O
as,O
a,O
marker,O
for,O
mature,O
neurons,O
.,O
To,O
determine,O
the,O
composition,O
of,O
these,O
abnormal,O
cell,O
clusters,O
",",O
we,O
stained,O
for,O
nestin,B-GP
",",O
glial,B-GP
fibrillary,I-GP
acidic,I-GP
protein,I-GP
(,O
GFAP,B-GP
"),",O
and,O
NeuN,B-GP
.,O
Qualitatively,O
",",O
Nestin,B-GP
expression,O
seemed,O
to,O
be,O
almost,O
entirely,O
localized,O
to,O
the,O
neoplasm,B-DS
’,O
s,O
margins,O
",",O
while,O
mostly,O
absent,O
from,O
the,O
neoplasm,B-DS
’,O
s,O
center,O
(,O
Fig,O
5A,O
).,O
GFAP,B-GP
also,O
appeared,O
to,O
be,O
highly,O
expressed,O
at,O
the,O
margins,O
of,O
the,O
neoplastic,O
growths,O
(,O
Fig,O
5B,O
).,O
NeuN,B-GP
was,O
observed,O
at,O
a,O
much,O
lower,O
level,O
than,O
in,O
the,O
uninfected,O
neurons,O
surrounding,O
the,O
neoplasm,B-DS
.,O
However,O
",",O
we,O
did,O
sporadically,O
observe,O
some,O
NeuN,B-GP
-,O
positive,O
cells,O
within,O
regions,O
of,O
neoplasia,B-DS
(,O
Fig,O
5C,O
).,O
Overall,O
",",O
these,O
neoplasms,B-DS
appear,O
to,O
be,O
generally,O
composed,O
of,O
a,O
‘,O
core,O
’,O
expressing,O
few,O
biomarkers,O
surrounded,O
by,O
a,O
region,O
of,O
nestin,B-GP
-,O
and,O
GFAP,B-GP
-,O
positive,O
cells,O
with,O
small,O
numbers,O
of,O
neurons,O
interspersed,O
throughout,O
the,O
two,O
.,O
This,O
histological,O
organization,O
is,O
reminiscent,O
of,O
GBM,B-DS
[,O
23,O
].,O
To,O
determine,O
how,O
these,O
neoplasms,B-DS
proliferated,O
",",O
we,O
injected,O
5,O
-,O
bromo,O
-,O
2,O
’-,O
deoxyuridine,O
(,O
BrdU,O
),O
twice,O
at,O
5,O
and,O
6,O
days,O
after,O
injection,O
(,O
n,O
=,O
3,O
),O
of,O
the,O
lentiviral,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
and,O
perfused,O
the,O
animals,B-OG
at,O
7,O
DPI,O
(,O
Fig,O
6,O
).,O
All,O
mice,B-OG
injected,O
displayed,O
neoplasia,B-DS
local,O
to,O
the,O
injection,O
region,O
.,O
In,O
observed,O
neoplasms,B-DS
",",O
few,O
cells,O
expressing,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
were,O
BrdU,O
-,O
positive,O
.,O
We,O
found,O
most,O
BrdU,O
-,O
positive,O
cells,O
on,O
the,O
edge,O
of,O
the,O
neoplasm,B-DS
",",O
with,O
few,O
in,O
histologically,O
normal,O
regions,O
",",O
suggesting,O
the,O
cells,O
on,O
the,O
margins,O
of,O
the,O
neoplasm,B-DS
",",O
adjacent,O
to,O
the,O
sponge,O
-,O
infected,O
cells,O
on,O
the,O
margin,O
",",O
proliferate,O
at,O
an,O
abnormally,O
high,O
rate,O
(,O
Fig,O
6A,O
).,O
These,O
BrdU,O
-,O
positive,O
cells,O
tended,O
to,O
co,O
-,O
express,O
GFAP,B-GP
as,O
well,O
",",O
but,O
not,O
all,O
BrdU,O
-,O
positive,O
cells,O
were,O
also,O
GFAP,B-GP
-,O
positive,O
",",O
and,O
these,O
BrdU,O
-,O
expressing,O
cells,O
were,O
a,O
minority,O
of,O
GFAP,B-GP
-,O
positive,O
cells,O
overall,O
(,O
Fig,O
6B,O
).,O
These,O
data,O
support,O
the,O
interpretation,O
that,O
there,O
is,O
a,O
cell,O
non,O
-,O
autonomous,O
contribution,O
of,O
the,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
to,O
cellular,O
proliferation,O
.,O
MiR,O
-,O
338,O
-,O
3p,O
knockdown,O
results,O
in,O
proliferation,O
of,O
GFAP,B-GP
-,O
positive,O
cells,O
.,O
(,O
A,O
),O
Expression,O
pattern,O
of,O
of,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
(,O
green,O
),O
and,O
BrdU,O
(,O
blue,O
"),",O
a,O
marker,O
of,O
cellular,O
proliferation,O
",",O
in,O
a,O
dentate,O
gyrus,O
neoplasm,B-DS
following,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
.,O
(,O
B,O
),O
Co,O
-,O
localization,O
of,O
GFAP,B-GP
(,O
red,O
),O
and,O
BrdU,O
(,O
blue,O
),O
in,O
dentate,O
gyrus,O
neoplasm,B-DS
following,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
.,O
MiR,O
-,O
338,O
-,O
3p,O
overexpression,O
inhibits,O
proliferation,O
in,O
GBM,B-DS
cell,O
lines,O
To,O
examine,O
miR,O
-,O
338,O
-,O
3p,O
function,O
in,O
GBM,B-DS
",",O
we,O
used,O
an,O
in,O
vitro,O
model,O
of,O
miR,O
-,O
338,O
-,O
3p,O
activity,O
.,O
The,O
U251,O
and,O
SF295,O
GBM,B-DS
cell,O
lines,O
have,O
previously,O
been,O
shown,O
to,O
be,O
miR,O
-,O
338,O
-,O
3p,O
deficient,O
[,O
24,O
].,O
To,O
determine,O
whether,O
miR,O
-,O
338,O
-,O
3p,O
can,O
directly,O
impact,O
cell,O
division,O
",",O
we,O
designed,O
a,O
lentiviral,O
vector,O
to,O
overexpress,O
miR,O
-,O
338,O
-,O
3p,O
",",O
expressing,O
GFP,B-GP
under,O
control,O
of,O
the,O
ubiquitin,B-GP
promoter,O
and,O
two,O
miR,O
-,O
338,O
-,O
3p,O
sequences,O
under,O
control,O
of,O
the,O
U6,O
promoter,O
(,O
Fig,O
7A,O
).,O
We,O
verified,O
both,O
U251,O
and,O
SF295,O
cells,O
lack,O
miR,O
-,O
338,O
-,O
3p,O
by,O
co,O
-,O
infecting,O
them,O
with,O
miRNA,O
-,O
338,O
-,O
3p,O
sensor,O
virus,B-OG
and,O
a,O
control,O
virus,B-OG
expressing,O
GFP,B-GP
alone,O
.,O
The,O
cells,O
highly,O
expressed,O
mCherry,B-GP
compared,O
to,O
GFP,B-GP
",",O
indicating,O
low,O
endogenous,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
(,O
Fig,O
7B,O
and,O
7D,O
).,O
Overexpression,O
of,O
miR,O
-,O
338,O
-,O
3p,O
decreases,O
in,O
vitro,O
proliferation,O
of,O
GBM,B-DS
cells,O
.,O
(,O
A,O
),O
Construction,O
of,O
miR,O
-,O
338,O
-,O
3p,O
overexpressor,O
lentivirus,B-OG
containing,O
a,O
GFP,B-GP
-,O
coding,O
region,O
to,O
indicate,O
expression,O
along,O
with,O
two,O
miR,O
-,O
338,O
-,O
3p,O
transcripts,O
downstream,O
of,O
the,O
U6,O
promoter,O
.,O
(,O
B,O
),O
Endogenous,O
expression,O
of,O
miR,O
-,O
338,O
-,O
3p,O
in,O
U251,O
GBM,B-DS
cells,O
",",O
as,O
indicated,O
by,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
lentivirus,B-OG
(,O
red,O
),O
expression,O
compared,O
to,O
control,O
lentivirus,B-OG
expressing,O
GFP,B-GP
-,O
only,O
.,O
(,O
C,O
),O
Expression,O
of,O
miR,O
-,O
338,O
-,O
3p,O
following,O
infection,B-DS
with,O
overexpressor,O
virus,B-OG
in,O
U251,O
GBM,B-DS
cells,O
as,O
indicated,O
by,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
(,O
red,O
).,O
(,O
D,O
),O
Endogenous,O
expression,O
of,O
miR,O
-,O
338,O
-,O
3p,O
in,O
SF295,O
GBM,B-DS
cells,O
",",O
as,O
indicated,O
by,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
lentivirus,B-OG
(,O
red,O
),O
expression,O
compared,O
to,O
control,O
lentivirus,B-OG
expressing,O
GFP,B-GP
-,O
only,O
.,O
(,O
E,O
),O
Expression,O
of,O
miR,O
-,O
338,O
-,O
3p,O
following,O
infection,B-DS
with,O
overexpressor,O
virus,B-OG
in,O
and,O
SF295,O
GBM,B-DS
cells,O
as,O
indicated,O
by,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
(,O
red,O
).,O
(,O
F,O
),O
Population,O
growth,O
kinetics,O
of,O
U251,O
GBM,B-DS
cells,O
infected,O
with,O
an,O
empty,O
vector,O
or,O
miR,O
-,O
338,O
-,O
3p,O
overexpressor,O
(,O
7,O
–,O
12,O
DPI,O
).,O
(,O
G,O
),O
Population,O
growth,O
kinetics,O
of,O
SF295,O
GBM,B-DS
cells,O
infected,O
with,O
an,O
empty,O
vector,O
or,O
miR,O
-,O
338,O
-,O
3p,O
overexpressor,O
(,O
7,O
–,O
10,O
DPI,O
).,O
Dotted,O
lines,O
in,O
(,O
F,O
),O
and,O
(,O
G,O
),O
fit,O
theoretical,O
population,O
growth,O
curves,O
to,O
the,O
observed,O
data,O
",",O
using,O
the,O
equation,O
:,O
Y,O
=,O
25,O
×,O
2t,O
/,O
DT,O
",",O
where,O
Y,O
is,O
the,O
number,O
of,O
cells,O
at,O
time,O
t,O
",",O
and,O
DT,O
is,O
the,O
doubling,O
time,O
.,O
****,O
p,O
<,O
0,O
.,O
001,O
;,O
Pearson,O
’,O
s,O
chi,O
-,O
squared,O
test,O
.,O
Results,O
show,O
mean,O
±,O
SEM,O
.,O
We,O
ensured,O
the,O
overexpressor,O
functioned,O
as,O
intended,O
by,O
co,O
-,O
infecting,O
the,O
two,O
cell,O
lines,O
with,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
and,O
either,O
the,O
miR,O
-,O
338,O
-,O
3p,O
overexpressor,O
or,O
a,O
control,O
virus,B-OG
expressing,O
only,O
GFP,B-GP
(,O
Fig,O
7B,O
–,O
7E,O
).,O
We,O
noted,O
a,O
dramatic,O
decrease,O
in,O
mCherry,B-GP
expression,O
",",O
indicating,O
an,O
increase,O
in,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
in,O
infected,O
cells,O
.,O
From,O
this,O
",",O
we,O
concluded,O
our,O
overexpressor,O
was,O
an,O
effective,O
inducer,O
of,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
in,O
both,O
cell,O
lines,O
.,O
To,O
investigate,O
the,O
impact,O
of,O
miR,O
-,O
338,O
-,O
3p,O
on,O
cellular,O
proliferation,O
",",O
we,O
examined,O
population,O
growth,O
kinetics,O
for,O
the,O
U251,O
and,O
SF295,O
cell,O
lines,O
infected,O
with,O
the,O
miR,O
-,O
338,O
-,O
3p,O
overexpressor,O
.,O
In,O
both,O
cell,O
lines,O
",",O
miR,O
-,O
338,O
-,O
3p,O
overexpression,O
decreased,O
the,O
proliferation,O
rate,O
compared,O
to,O
control,O
(,O
Fig,O
7F,O
and,O
7G,O
",",O
S9,O
Table,O
).,O
The,O
control,O
population,O
was,O
approximately,O
double,O
that,O
of,O
the,O
miR,O
-,O
338,O
-,O
3p,O
overexpressing,O
population,O
at,O
the,O
final,O
time,O
point,O
in,O
both,O
cell,O
lines,O
.,O
In,O
U251,O
",",O
there,O
were,O
34,O
.,O
1,O
±,O
4,O
.,O
95,O
×,O
105,O
cells,O
in,O
the,O
control,O
population,O
and,O
18,O
.,O
7,O
±,O
1,O
.,O
55,O
×,O
105,O
cells,O
in,O
the,O
miR,O
-,O
338,O
-,O
3p,O
-,O
overexpressing,O
population,O
at,O
12,O
DPI,O
",",O
with,O
corresponding,O
doubling,O
times,O
of,O
16,O
.,O
9,O
and,O
19,O
.,O
3,O
hours,O
respectively,O
",",O
indicating,O
an,O
overall,O
reduction,O
in,O
proliferation,O
rate,O
(,O
Fig,O
7F,O
;,O
p,O
<,O
0,O
.,O
0001,O
).,O
In,O
SF295,O
",",O
13,O
.,O
05,O
±,O
1,O
.,O
38,O
×,O
105,O
control,O
cells,O
and,O
7,O
.,O
525,O
±,O
0,O
.,O
275,O
×,O
105,O
miR,O
-,O
338,O
-,O
3p,O
overexpressing,O
cells,O
were,O
present,O
at,O
10,O
DPI,O
",",O
with,O
respective,O
doubling,O
times,O
of,O
12,O
.,O
6,O
and,O
14,O
.,O
7,O
hours,O
(,O
Fig,O
7G,O
;,O
p,O
<,O
0,O
.,O
0001,O
).,O
These,O
results,O
indicate,O
miR,O
-,O
338,O
-,O
3p,O
inhibits,O
GBM,B-DS
proliferation,O
in,O
vitro,O
.,O
MiR,O
-,O
338,O
-,O
3p,O
expression,O
is,O
associated,O
with,O
overall,O
and,O
disease,O
-,O
free,O
survival,O
in,O
GBM,B-DS
patients,O
We,O
next,O
determined,O
whether,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
could,O
be,O
clinically,O
significant,O
.,O
To,O
do,O
this,O
",",O
we,O
examined,O
data,O
from,O
The,O
Cancer,O
Genome,O
Atlas,O
(,O
TGCA,O
).,O
Using,O
data,O
from,O
157,O
GBM,B-DS
patients,O
with,O
miRNA,O
expression,O
profiling,O
of,O
their,O
tumors,B-DS
",",O
we,O
show,O
that,O
low,O
expression,O
of,O
miR,O
-,O
338,O
-,O
3p,O
corresponded,O
to,O
a,O
decrease,O
in,O
overall,O
and,O
disease,O
-,O
free,O
survival,O
(,O
Fig,O
8,O
).,O
These,O
data,O
suggest,O
miR,O
-,O
338,O
-,O
3p,O
is,O
a,O
clinically,O
relevant,O
miRNA,O
with,O
tumor,B-DS
suppressor,O
properties,O
.,O
Outcomes,O
in,O
GBM,B-DS
patients,O
based,O
on,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
level,O
.,O
GBM,B-DS
patients,O
with,O
low,O
mir,O
-,O
338,O
-,O
3p,O
expression,O
exhibit,O
decreased,O
overall,O
and,O
disease,O
-,O
free,O
survival,O
.,O
Kaplan,O
-,O
Meier,O
(,O
A,O
),O
survival,O
and,O
(,O
B,O
),O
disease,O
-,O
free,O
survival,O
curves,O
of,O
GBM,B-DS
patients,O
grouped,O
by,O
mir,O
-,O
338,O
-,O
3p,O
expression,O
level,O
.,O
P,O
-,O
values,O
determined,O
by,O
the,O
log,O
-,O
rank,O
test,O
are,O
indicated,O
in,O
the,O
graphs,O
.,O
Discussion,O
These,O
findings,O
demonstrate,O
a,O
clear,O
regulatory,O
role,O
for,O
miR,O
-,O
338,O
-,O
3p,O
in,O
the,O
development,O
and,O
proliferation,O
of,O
neurons,O
in,O
the,O
dentate,O
gyrus,O
.,O
Expression,O
of,O
miR,O
-,O
338,O
-,O
3p,O
increases,O
as,O
a,O
cell,O
in,O
the,O
dentate,O
gyrus,O
matures,O
",",O
peaking,O
in,O
NeuN,B-GP
-,O
positive,O
mature,O
neurons,O
.,O
This,O
pattern,O
of,O
expression,O
suggests,O
a,O
potential,O
regulatory,O
role,O
in,O
the,O
development,O
of,O
a,O
dividing,O
neural,O
precursor,O
cell,O
into,O
a,O
mature,O
",",O
terminally,O
differentiated,O
neuron,O
.,O
This,O
potential,O
activity,O
of,O
miR,O
-,O
338,O
-,O
3p,O
is,O
supported,O
by,O
its,O
pattern,O
of,O
co,O
-,O
expression,O
during,O
maturation,O
with,O
miR,O
-,O
132,O
",",O
itself,O
an,O
inhibitory,O
regulator,O
of,O
quiescence,O
in,O
other,O
cell,O
types,O
[,O
25,O
].,O
The,O
role,O
of,O
miR,O
-,O
338,O
-,O
3p,O
in,O
neuronal,O
development,O
is,O
also,O
apparent,O
from,O
our,O
observations,O
of,O
aberrant,O
morphology,O
in,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
neurons,O
.,O
The,O
two,O
most,O
obvious,O
differences,O
between,O
wild,O
type,O
and,O
miR,O
-,O
338,O
-,O
3p,O
-,O
deficient,O
neurons,O
are,O
their,O
increased,O
likelihood,O
to,O
sprout,O
multiple,O
primary,O
dendrites,O
and,O
subsequently,O
branch,O
off,O
at,O
deviant,O
angles,O
with,O
respect,O
to,O
the,O
soma,O
.,O
These,O
changes,O
indicate,O
that,O
miR,O
-,O
338,O
-,O
3p,O
regulates,O
proteins,O
involved,O
in,O
neuronal,O
polarization,O
and,O
neurite,O
formation,O
.,O
Others,O
have,O
shown,O
miR,O
-,O
338,O
-,O
3p,O
regulates,O
morphological,O
polarity,O
in,O
other,O
cell,O
types,O
by,O
facilitating,O
the,O
activity,O
of,O
β,B-GP
-,I-GP
integrin,I-GP
[,O
26,O
].,O
It,O
is,O
possible,O
that,O
a,O
similar,O
mechanism,O
could,O
be,O
responsible,O
for,O
aberrant,O
dendrite,O
placement,O
on,O
the,O
soma,O
.,O
The,O
process,O
of,O
neuronal,O
polarization,O
begins,O
very,O
early,O
in,O
the,O
maturing,O
neuron,O
’,O
s,O
life,O
",",O
which,O
is,O
when,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
is,O
increasing,O
[,O
27,O
].,O
The,O
mechanisms,O
underlying,O
initiation,O
and,O
termination,O
of,O
both,O
neurite,O
formation,O
and,O
neuronal,O
polarization,O
are,O
not,O
particularly,O
well,O
characterized,O
",",O
and,O
verification,O
of,O
these,O
hypotheses,O
will,O
require,O
further,O
study,O
[,O
28,O
].,O
This,O
study,O
is,O
the,O
first,O
to,O
examine,O
the,O
effects,O
of,O
miR,O
-,O
338,O
-,O
3p,O
on,O
the,O
morphology,O
of,O
dentate,O
gyrus,O
granule,O
neurons,O
",",O
but,O
other,O
studies,O
have,O
described,O
other,O
changes,O
to,O
neural,O
morphology,O
induced,O
by,O
miR,O
-,O
338,O
-,O
3p,O
",",O
by,O
a,O
variety,O
of,O
molecular,O
targets,O
.,O
MiR,O
-,O
338,O
-,O
3p,O
regulates,O
axonal,O
outgrowth,O
in,O
cortical,O
neurons,O
through,O
regulation,O
of,O
Robo2,B-GP
",",O
an,O
axonal,O
guidance,O
protein,O
[,O
29,O
].,O
It,O
also,O
regulates,O
axonal,O
outgrowth,O
in,O
superior,O
cervical,O
ganglion,O
neurons,O
through,O
COXIV,B-GP
and,O
ATP5G1,B-GP
",",O
two,O
mitochondrial,O
mRNAs,O
active,O
in,O
oxidative,O
phosphorylation,O
[,O
30,O
].,O
MiR,O
-,O
338,O
-,O
3p,O
is,O
also,O
expressed,O
in,O
spinal,O
cord,O
oligodendrocytes,O
",",O
where,O
it,O
exerts,O
a,O
related,O
effect,O
",",O
inducing,O
maturation,O
and,O
differentiation,O
of,O
precursors,O
into,O
mature,O
oligodendrocytes,O
by,O
repressing,O
Sox5,B-GP
and,O
Hes6,B-GP
",",O
two,O
maturation,O
-,O
inhibiting,O
transcription,B-GP
factors,I-GP
[,O
31,O
",",O
32,O
].,O
Studying,O
the,O
effect,O
of,O
miR,O
-,O
338,O
-,O
3p,O
on,O
the,O
expression,O
of,O
any,O
of,O
these,O
genes,O
or,O
any,O
in,O
the,O
same,O
pathway,O
could,O
possibly,O
provide,O
a,O
mechanistic,O
understanding,O
for,O
how,O
these,O
primary,O
dendrite,O
changes,O
are,O
induced,O
.,O
Surprisingly,O
",",O
both,O
aberrant,O
dendrite,O
orientation,O
and,O
the,O
presence,O
of,O
multiple,O
primary,O
dendrites,O
have,O
been,O
previously,O
described,O
in,O
studies,O
of,O
hippocampal,O
neuron,O
phenotypes,O
in,O
schizophrenia,B-DS
[,O
33,O
–,O
36,O
].,O
Additionally,O
",",O
miR,O
-,O
338,O
is,O
downregulated,O
in,O
the,O
brains,O
of,O
individuals,O
suffering,O
from,O
schizophrenia,B-DS
[,O
37,O
].,O
Investigation,O
of,O
a,O
potential,O
causal,O
link,O
between,O
miR,O
-,O
338,O
-,O
3p,O
and,O
schizophrenia,B-DS
could,O
be,O
promising,O
.,O
Our,O
morphological,O
data,O
from,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
indicate,O
a,O
relatively,O
specialized,O
role,O
in,O
regulating,O
hippocampal,O
neuron,O
morphology,O
.,O
General,O
loss,O
of,O
miRNA,O
function,O
through,O
Dicer1,B-GP
ablation,O
produces,O
a,O
wide,O
range,O
of,O
changes,O
in,O
hippocampal,O
dendrites,O
",",O
including,O
but,O
not,O
limited,O
to,O
increased,O
dendritic,O
spine,O
length,O
",",O
reduced,O
dendritic,O
arborization,O
",",O
and,O
a,O
bias,O
toward,O
arborization,O
more,O
distal,O
to,O
the,O
soma,O
[,O
38,O
",",O
39,O
].,O
However,O
",",O
we,O
did,O
not,O
observe,O
any,O
of,O
these,O
morphological,O
changes,O
in,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
neurons,O
",",O
indicating,O
miR,O
-,O
338,O
-,O
3p,O
is,O
unlikely,O
to,O
contribute,O
to,O
miRNA,O
regulation,O
of,O
these,O
facets,O
of,O
hippocampal,O
neuron,O
morphology,O
.,O
The,O
suite,O
of,O
changes,O
we,O
did,O
observe,O
were,O
not,O
studied,O
in,O
Dicer1,B-GP
-,O
inactivated,O
neurons,O
",",O
and,O
examination,O
of,O
such,O
changes,O
in,O
loss,O
of,O
general,O
miRNA,O
function,O
could,O
prove,O
interesting,O
as,O
well,O
.,O
In,O
addition,O
to,O
changing,O
the,O
morphology,O
of,O
dentate,O
granule,O
neurons,O
",",O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
results,O
in,O
cellular,O
neoplasia,B-DS
characterized,O
by,O
abnormal,O
cellular,O
proliferation,O
.,O
MiR,O
-,O
338,O
-,O
3p,O
has,O
previously,O
been,O
implicated,O
in,O
tumor,B-DS
suppression,O
in,O
hepatocarcinoma,B-DS
",",O
gastric,B-DS
cancer,I-DS
",",O
and,O
brain,B-DS
cancer,I-DS
[,O
40,O
–,O
44,O
].,O
In,O
this,O
study,O
",",O
we,O
found,O
miR,O
-,O
338,O
-,O
3p,O
knockdown,O
leads,O
to,O
the,O
formation,O
of,O
multiple,O
neoplastic,O
growths,O
resembling,O
GBM,B-DS
",",O
showing,O
a,O
direct,O
causal,O
link,O
between,O
loss,O
of,O
miR,O
-,O
338,O
-,O
3p,O
function,O
and,O
hippocampal,O
tumorigenesis,O
.,O
Further,O
",",O
we,O
find,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
in,O
GBM,B-DS
cell,O
lines,O
decreases,O
their,O
proliferation,O
in,O
vitro,O
.,O
Another,O
study,O
shows,O
reduced,O
cell,O
viability,O
and,O
increased,O
apoptosis,O
in,O
certain,O
glioma,B-DS
cell,O
lines,O
following,O
overexpression,O
of,O
miR,O
-,O
338,O
-,O
3p,O
",",O
which,O
may,O
at,O
least,O
partially,O
explain,O
the,O
change,O
in,O
proliferation,O
we,O
observe,O
[,O
40,O
].,O
However,O
",",O
a,O
recent,O
study,O
expressing,O
miR,O
-,O
338,O
-,O
3p,O
in,O
U251,O
cells,O
describes,O
a,O
different,O
phenomenon,O
",",O
where,O
induction,O
of,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
has,O
no,O
effect,O
on,O
U251,O
proliferation,O
[,O
45,O
].,O
These,O
differences,O
could,O
be,O
explained,O
by,O
divergent,O
methodologies,O
.,O
Wang,O
et,O
al,O
.,O
examined,O
changes,O
during,O
the,O
first,O
96,O
hours,O
of,O
infection,B-DS
",",O
while,O
this,O
study,O
begins,O
analysis,O
7,O
days,O
after,O
infection,B-DS
;,O
differences,O
in,O
the,O
time,O
course,O
of,O
regulated,O
genes,O
’,O
activity,O
could,O
underlie,O
differences,O
observed,O
between,O
the,O
two,O
studies,O
.,O
Differences,O
could,O
also,O
be,O
explained,O
by,O
the,O
manner,O
of,O
infection,B-DS
:,O
while,O
our,O
vector,O
contained,O
only,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sequence,O
",",O
Wang,O
et,O
al,O
.,O
uses,O
a,O
longer,O
sequence,O
surrounding,O
miR,O
-,O
338,O
-,O
3p,O
.,O
Regulatory,O
elements,O
within,O
the,O
sequence,O
or,O
miRNA,O
processing,O
differences,O
could,O
also,O
contribute,O
to,O
the,O
difference,O
in,O
effects,O
observed,O
.,O
We,O
also,O
determined,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
does,O
have,O
an,O
impact,O
on,O
GBM,B-DS
severity,O
in,O
patients,O
.,O
Our,O
analysis,O
of,O
the,O
TCGA,O
database,O
indicates,O
that,O
when,O
GBM,B-DS
lack,O
miR,O
-,O
338,O
-,O
3p,O
",",O
they,O
become,O
more,O
aggressive,O
and,O
more,O
lethal,O
.,O
While,O
miR,O
-,O
338,O
-,O
3p,O
is,O
instrumental,O
to,O
tumor,B-DS
suppression,O
",",O
we,O
do,O
not,O
know,O
its,O
exact,O
mechanism,O
.,O
In,O
this,O
study,O
",",O
we,O
have,O
determined,O
that,O
miR,O
-,O
338,O
-,O
3p,O
inhibits,O
cellular,O
proliferation,O
in,O
GBM,B-DS
cell,O
lines,O
",",O
mirroring,O
the,O
results,O
of,O
a,O
similar,O
analysis,O
done,O
on,O
the,O
role,O
of,O
miR,O
-,O
338,O
-,O
3p,O
in,O
colorectal,B-DS
carcinoma,I-DS
implicating,O
loss,O
of,O
SMO,B-GP
inhibition,O
[,O
44,O
].,O
It,O
is,O
possible,O
these,O
two,O
tumor,B-DS
types,O
could,O
be,O
suppressed,O
via,O
the,O
same,O
method,O
of,O
regulation,O
.,O
Future,O
studies,O
are,O
required,O
to,O
understand,O
whether,O
miR,O
-,O
338,O
-,O
3p,O
operates,O
through,O
a,O
similar,O
mechanism,O
in,O
GBM,B-DS
.,O
Upon,O
histological,O
examination,O
of,O
the,O
tumor,B-DS
",",O
it,O
is,O
clear,O
that,O
not,O
every,O
neoplastic,O
cell,O
is,O
miR,O
-,O
338,O
-,O
3p,O
deficient,O
",",O
but,O
rather,O
the,O
core,O
lacks,O
miR,O
-,O
338,O
-,O
3p,O
while,O
cells,O
at,O
the,O
periphery,O
of,O
the,O
neoplasm,B-DS
maintain,O
relatively,O
normal,O
levels,O
of,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
.,O
Interestingly,O
",",O
a,O
similar,O
pattern,O
of,O
miR,O
-,O
338,O
-,O
3p,O
expression,O
was,O
found,O
in,O
the,O
tumors,B-DS
of,O
15,O
GBM,B-DS
patients,O
[,O
46,O
].,O
Further,O
",",O
the,O
proliferating,O
BrdU,O
-,O
positive,O
cells,O
in,O
the,O
neoplasms,B-DS
we,O
describe,O
appear,O
to,O
be,O
those,O
peripheral,O
cells,O
not,O
expressing,O
low,O
levels,O
of,O
miR,O
-,O
338,O
-,O
3p,O
.,O
Such,O
a,O
pattern,O
of,O
proliferation,O
suggests,O
a,O
potential,O
cell,O
-,O
nonautonomous,O
regulatory,O
mechanism,O
",",O
which,O
has,O
not,O
described,O
previously,O
.,O
This,O
result,O
is,O
unexpected,O
",",O
based,O
on,O
our,O
other,O
data,O
",",O
and,O
warrants,O
further,O
study,O
.,O
One,O
prior,O
study,O
in,O
pituitary,B-DS
adenoma,I-DS
describes,O
a,O
mechanism,O
of,O
tumor,B-DS
suppression,O
via,O
regulation,O
of,O
Pttg,B-GP
",",O
a,O
paracrine,O
growth,O
factor,O
",",O
in,O
pituitary,B-DS
adenoma,I-DS
.,O
However,O
",",O
this,O
study,O
did,O
not,O
examine,O
in,O
vivo,O
proliferation,O
",",O
and,O
the,O
gene,O
’,O
s,O
expression,O
has,O
not,O
been,O
described,O
in,O
the,O
hippocampus,O
thus,O
far,O
[,O
47,O
].,O
Regulation,O
of,O
CyclinD1,B-GP
expression,O
has,O
been,O
similarly,O
implicated,O
as,O
a,O
potential,O
mechanism,O
by,O
which,O
miR,O
-,O
338,O
-,O
3p,O
affects,O
cell,O
proliferation,O
[,O
48,O
].,O
CyclinD1,B-GP
and,O
associated,O
CDKs,B-GP
may,O
act,O
as,O
a,O
“,O
switch,O
”,O
in,O
the,O
cell,O
cycle,O
",",O
and,O
their,O
activity,O
is,O
inhibited,O
in,O
terminally,O
differentiated,O
neurons,O
but,O
high,O
in,O
the,O
embryonic,O
nervous,O
system,O
[,O
48,O
–,O
51,O
].,O
Furthermore,O
",",O
CyclinD1,B-GP
and,O
these,O
CDKs,B-GP
may,O
control,O
angles,O
of,O
neurite,O
formation,O
in,O
hippocampal,O
granule,O
cells,O
[,O
51,O
].,O
Thus,O
",",O
the,O
phenotypes,O
observed,O
in,O
this,O
study,O
are,O
consistent,O
with,O
the,O
finding,O
that,O
miR,O
-,O
338,O
-,O
3p,O
regulates,O
CyclinD1,B-GP
.,O
Another,O
possibility,O
is,O
that,O
these,O
changes,O
are,O
induced,O
by,O
loss,O
of,O
inhibition,O
of,O
PREX2a,B-GP
",",O
another,O
target,O
of,O
miR,O
-,O
338,O
-,O
3p,O
[,O
43,O
].,O
A,O
phenotype,O
with,O
multiple,O
primary,O
dendrites,O
is,O
associated,O
with,O
loss,O
of,O
Pten,B-GP
",",O
which,O
inhibits,O
the,O
PI3K,B-GP
/,O
AKT,B-GP
pathway,O
[,O
52,O
].,O
PREX2a,B-GP
inhibits,O
Pten,B-GP
activity,O
itself,O
",",O
and,O
the,O
phenotype,O
resulting,O
from,O
loss,O
of,O
PREX2a,B-GP
regulation,O
by,O
miR,O
-,O
338,O
-,O
3p,O
should,O
resemble,O
the,O
one,O
resulting,O
from,O
loss,O
of,O
Pten,B-GP
.,O
Prior,O
studies,O
have,O
already,O
shown,O
miR,O
-,O
338,O
-,O
3p,O
’,O
s,O
inhibition,O
of,O
PREX2a,B-GP
is,O
crucial,O
in,O
suppression,O
of,O
neuroblastoma,B-DS
proliferation,O
[,O
43,O
].,O
In,O
this,O
study,O
",",O
we,O
identified,O
a,O
regulatory,O
role,O
for,O
miR,O
-,O
338,O
-,O
3p,O
in,O
neuronal,O
proliferation,O
",",O
maturation,O
",",O
and,O
neurite,O
outgrowth,O
and,O
organization,O
in,O
the,O
dentate,O
gyrus,O
",",O
while,O
also,O
acting,O
as,O
a,O
tumor,B-DS
suppressor,O
in,O
vivo,O
.,O
While,O
we,O
did,O
observe,O
physiological,O
changes,O
in,O
the,O
neuron,O
",",O
the,O
mechanisms,O
by,O
which,O
miR,O
-,O
338,O
-,O
3p,O
activity,O
regulates,O
these,O
processes,O
in,O
the,O
dentate,O
gyrus,O
are,O
not,O
yet,O
fully,O
characterized,O
.,O
An,O
important,O
topic,O
for,O
further,O
research,O
will,O
be,O
the,O
determination,O
of,O
which,O
pathways,O
are,O
responsible,O
for,O
the,O
myriad,O
changes,O
observed,O
in,O
the,O
miR,O
-,O
338,O
-,O
3p,O
-,O
deficient,O
hippocampal,O
neuron,O
.,O
However,O
",",O
our,O
results,O
in,O
GBM,B-DS
are,O
encouraging,O
",",O
and,O
could,O
indicate,O
GBM,B-DS
therapeutics,O
targeting,O
miR,O
-,O
338,O
-,O
3p,O
could,O
be,O
a,O
promising,O
line,O
of,O
inquiry,O
.,O
Materials,O
and,O
methods,O
Subjects,O
All,O
procedures,O
were,O
approved,O
by,O
the,O
Institutional,O
Animal,O
Care,O
and,O
Use,O
Committee,O
at,O
the,O
Geisel,O
School,O
of,O
Medicine,O
at,O
Dartmouth,O
College,O
and,O
conformed,O
to,O
federal,O
",",O
state,O
",",O
local,O
",",O
and,O
Association,O
for,O
Assessment,O
and,O
Accreditation,O
of,O
Laboratory,O
Animal,O
Care,O
standards,O
",",O
under,O
Protocol,O
Numbers,O
11,O
-,O
01,O
-,O
01,O
and,O
00002030,O
(,O
a,O
).,O
All,O
mice,B-OG
used,O
were,O
of,O
the,O
C57BL,O
/,O
6J,O
genetic,O
background,O
",",O
obtained,O
from,O
The,O
Jackson,O
Laboratory,O
.,O
Morphology,O
experiments,O
used,O
neonates,O
(,O
postnatal,O
day,O
7,O
),O
and,O
all,O
others,O
used,O
adults,O
(,O
7,O
–,O
8,O
weeks,O
of,O
age,O
).,O
Experiments,O
used,O
mixed,O
-,O
sex,O
groups,O
of,O
mice,B-OG
with,O
equivalent,O
numbers,O
of,O
each,O
sex,O
.,O
Animals,B-OG
were,O
housed,O
in,O
a,O
vivarium,O
on,O
a,O
12,O
hour,O
light,O
/,O
dark,O
cycle,O
with,O
food,O
and,O
water,O
provided,O
ad,O
libitum,O
.,O
Reporter,O
and,O
overexpressor,O
virus,B-OG
design,O
and,O
creation,O
To,O
generate,O
the,O
miRNA,O
reporter,O
viruses,B-OG
",",O
two,O
perfect,O
miRNA,O
targets,O
were,O
cloned,O
into,O
the,O
EcoR1,B-GP
site,O
in,O
the,O
3,O
’,O
UTR,O
of,O
mCherry,B-GP
in,O
the,O
FUCW,O
viral,O
vector,O
[,O
13,O
].,O
Complementary,O
oligonucleotides,O
containing,O
two,O
perfect,O
target,O
sequences,O
for,O
that,O
miRNA,O
flanked,O
by,O
overhangs,O
for,O
EcoR1,B-GP
cloning,O
sites,O
",",O
were,O
designed,O
and,O
ordered,O
from,O
Integrated,O
DNA,O
Technologies,O
.,O
Target,O
sequences,O
were,O
100,O
%,O
homologous,O
to,O
the,O
reverse,O
complement,O
of,O
the,O
mature,O
miR,O
sequence,O
as,O
listed,O
on,O
miRBase,O
(,O
www,O
.,O
mirbase,O
.,O
org,O
).,O
Each,O
pair,O
of,O
complimentary,O
oligonucleotides,O
were,O
annealed,O
and,O
ligated,O
into,O
the,O
digested,O
FUCW,O
",",O
using,O
NEB,O
Quick,O
Ligase,B-GP
.,O
To,O
generate,O
the,O
miR,O
-,O
338,O
-,O
3p,O
overexpressor,O
virus,B-OG
",",O
the,O
mature,O
miR,O
-,O
338,O
-,O
3p,O
sequence,O
with,O
a,O
canonical,O
stem,O
loop,O
(,O
5,O
’-,O
TTCAAGAGA,O
-,O
3,O
’),O
was,O
cloned,O
into,O
the,O
BbsI,B-GP
/,O
BglII,B-GP
site,O
of,O
pCMVU6,O
",",O
and,O
the,O
U6,O
promoter,O
and,O
miR338,O
-,O
3p,O
sequence,O
was,O
excised,O
and,O
placed,O
into,O
the,O
PacI,B-GP
/,O
BstB1,B-GP
site,O
of,O
the,O
lentiviral,O
FUGW,O
vector,O
.,O
Colonies,O
were,O
sequenced,O
to,O
verify,O
that,O
the,O
insert,O
containing,O
target,O
sequences,O
was,O
successfully,O
ligated,O
into,O
FUCW,O
in,O
the,O
desired,O
direction,O
.,O
The,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
was,O
constructed,O
by,O
inserting,O
6,O
perfect,O
miR,O
-,O
338,O
-,O
3p,O
target,O
sequences,O
downstream,O
of,O
the,O
U6,O
promotor,O
and,O
6,O
perfect,O
miR,O
-,O
338,O
-,O
3p,O
target,O
sequences,O
downstream,O
of,O
the,O
H1,O
promotor,O
via,O
complimentary,O
overhangs,O
to,O
Bbs1,B-GP
/,O
BglII,B-GP
.,O
This,O
U6,O
cassette,O
was,O
placed,O
into,O
the,O
FUGW,O
lentiviral,O
vector,O
via,O
PacI,B-GP
/,O
BstBI,B-GP
and,O
the,O
H1,O
cassette,O
was,O
placed,O
into,O
the,O
PacI,B-GP
site,O
.,O
The,O
sponge,O
cassette,O
was,O
transferred,O
into,O
the,O
retroviral,O
pRubi,O
backbone,O
via,O
ligation,O
into,O
the,O
BstBI,B-GP
and,O
BamHI,B-GP
sites,O
of,O
redRubi,O
.,O
All,O
DNA,O
was,O
collected,O
using,O
the,O
NucleoBond,O
Xtra,O
Maxi,O
protocol,O
(,O
Macherey,O
-,O
Negel,O
).,O
Viral,O
packaging,O
FUCW,O
-,O
miR,O
vectors,O
",",O
along,O
with,O
pCMVΔ8,O
.,O
9,O
and,O
pVSV,O
-,O
g,O
",",O
were,O
transfected,O
into,O
HEK,O
293,O
-,O
FT,O
cells,O
.,O
HEK,O
293,O
-,O
FT,O
cells,O
were,O
sustained,O
with,O
media,O
composed,O
of,O
Iscove,O
’,O
s,O
modified,O
Dulbecco,O
’,O
s,O
medium,O
(,O
IMDM,O
),O
(,O
high,O
glucose,O
),O
(,O
Gibco,O
12440,O
–,O
053,O
"),",O
10,O
%,O
fetal,O
bovine,O
serum,O
(,O
FBS,O
"),",O
0,O
.,O
1,O
mM,O
MEM,O
Non,O
-,O
Essential,O
Amino,O
Acids,O
",",O
2mM,O
L,O
-,O
glutamine,O
",",O
1,O
%,O
Pen,O
-,O
Strep,O
and,O
500,O
μg,O
/,O
ml,O
Geneticin,O
®,O
(,O
only,O
used,O
during,O
growth,O
).,O
One,O
day,O
prior,O
to,O
transfection,O
",",O
293,O
-,O
FT,O
cells,O
were,O
split,O
to,O
a,O
concentration,O
of,O
2,O
.,O
5,O
–,O
3,O
.,O
0,O
x,O
106,O
cells,O
/,O
10,O
centimeter,O
plate,O
.,O
To,O
one,O
polystyrene,O
tube,O
",",O
40,O
μl,O
transfer,O
vector,O
",",O
26,O
μl,O
pCMVΔ8,O
.,O
9,O
",",O
18,O
μl,O
pVSV,O
-,O
g,O
",",O
1720,O
μl,O
H2O,O
and,O
200,O
μl,O
2,O
.,O
5M,O
CaCl2,O
were,O
added,O
and,O
gently,O
mixed,O
.,O
The,O
contents,O
of,O
this,O
tube,O
were,O
slowly,O
added,O
to,O
a,O
second,O
polystyrene,O
tube,O
containing,O
2000,O
μl,O
2xHBS,O
(,O
281,O
mM,O
NaCl,O
",",O
50,O
mM,O
HEPES,O
",",O
1,O
.,O
5,O
mM,O
Na2HPO4,O
heptahydrate,O
monobasic,O
",",O
pH,O
to,O
exactly,O
7,O
.,O
0,O
).,O
After,O
leaving,O
this,O
tube,O
in,O
the,O
dark,O
for,O
30,O
minutes,O
",",O
1,O
mL,O
of,O
the,O
mixture,O
was,O
added,O
to,O
each,O
of,O
four,O
separate,O
plates,O
of,O
HEK,O
293,O
-,O
FT,O
cells,O
.,O
After,O
24,O
hours,O
",",O
the,O
plates,O
were,O
refreshed,O
with,O
new,O
media,O
",",O
containing,O
2,O
%,O
FBS,O
.,O
At,O
48,O
and,O
72,O
hours,O
after,O
transfection,O
",",O
viral,O
particles,O
were,O
collected,O
",",O
spun,O
at,O
2000g,O
for,O
10,O
minutes,O
",",O
and,O
then,O
filtered,O
through,O
a,O
0,O
.,O
45,O
μm,O
PES,O
low,O
protein,O
binding,O
syringe,O
filter,O
.,O
To,O
concentrate,O
the,O
viral,O
particles,O
",",O
a,O
5x,O
PEG6000,O
(,O
8,O
%,O
PEG6000,O
",",O
0,O
.,O
3M,O
NaCl,O
),O
solution,O
was,O
added,O
to,O
the,O
filtrate,O
",",O
and,O
the,O
solution,O
was,O
incubated,O
at,O
4,O
°,O
C,O
for,O
12,O
hours,O
before,O
being,O
spun,O
at,O
2500g,O
for,O
45,O
minutes,O
.,O
The,O
pellet,O
was,O
then,O
resuspended,O
in,O
PBS,O
and,O
the,O
virus,B-OG
stored,O
at,O
-,O
80,O
°,O
C,O
until,O
injection,O
.,O
Stereotactic,O
injections,O
Mice,B-OG
were,O
anesthetized,O
using,O
an,O
isoflurane,O
gas,O
system,O
(,O
Veterinary,O
Anesthesia,O
Systems,O
Co,O
.),O
with,O
4,O
%,O
isofluorane,O
.,O
The,O
mice,B-OG
were,O
secured,O
in,O
a,O
Stoelting,O
lab,O
stereotaxic,O
frame,O
and,O
continued,O
to,O
receive,O
2,O
%,O
isoflurane,O
through,O
a,O
gas,O
nose,O
cone,O
.,O
In,O
order,O
to,O
deliver,O
the,O
virus,B-OG
into,O
the,O
dentate,O
gyrus,O
of,O
adults,O
",",O
a,O
one,O
-,O
inch,O
incision,O
was,O
made,O
in,O
the,O
scalp,O
",",O
and,O
holes,O
were,O
drilled,O
through,O
the,O
skull,O
(±,O
1,O
.,O
1,O
mm,O
lateral,O
",",O
-,O
1,O
.,O
9,O
mm,O
anteroposterior,O
",",O
-,O
2,O
.,O
5,O
–,O
2,O
.,O
3,O
mm,O
ventral,O
from,O
bregma,O
).,O
In,O
neonates,O
",",O
incisions,O
were,O
made,O
directly,O
into,O
the,O
skull,O
(±,O
1,O
.,O
3,O
mm,O
lateral,O
",",O
+,O
1,O
.,O
55,O
horizontal,O
",",O
-,O
2,O
.,O
3,O
–,O
2,O
.,O
0,O
mm,O
ventral,O
from,O
lambda,O
),O
Using,O
a,O
Stoelting,O
Quintessential,O
Sterotaxic,O
Injector,O
and,O
a,O
10μl,O
Hamilton,O
syringe,O
",",O
up,O
to,O
2,O
μl,O
of,O
lentivirus,B-OG
was,O
injected,O
into,O
each,O
hemisphere,O
.,O
The,O
syringe,O
was,O
left,O
in,O
place,O
for,O
2,O
minutes,O
after,O
injection,O
before,O
being,O
slowly,O
withdrawn,O
.,O
The,O
scalp,O
incision,O
above,O
the,O
injection,O
site,O
was,O
sutured,O
;,O
mice,B-OG
received,O
post,O
-,O
operative,O
topical,O
lidocaine,O
",",O
betadine,O
",",O
and,O
antibiotic,O
ointment,O
at,O
the,O
incision,O
site,O
as,O
well,O
as,O
a,O
peritoneal,O
injection,O
of,O
ketaprofen,O
in,O
saline,O
",",O
and,O
then,O
were,O
placed,O
in,O
a,O
recovery,O
chamber,O
until,O
they,O
regained,O
consciousness,O
.,O
Mice,B-OG
were,O
examined,O
and,O
weighed,O
each,O
day,O
up,O
to,O
a,O
week,O
post,O
-,O
operation,O
",",O
and,O
care,O
(,O
including,O
but,O
not,O
limited,O
to,O
re,O
-,O
suturing,O
",",O
topical,O
anesthetic,O
",",O
and,O
antibiotics,O
),O
was,O
provided,O
pro,O
re,O
nata,O
.,O
Histology,O
and,O
BrdU,O
labeling,O
To,O
determine,O
the,O
effect,O
of,O
miR,O
-,O
338,O
-,O
3p,O
on,O
cellular,O
proliferation,O
",",O
some,O
mice,B-OG
were,O
given,O
an,O
intraperitoneal,O
injection,O
of,O
BrdU,O
(,O
150mg,O
/,O
kg,O
),O
in,O
0,O
.,O
9,O
%,O
sterile,O
saline,O
solution,O
5,O
and,O
6,O
days,O
post,O
-,O
viral,O
injection,O
(,O
DPI,O
).,O
Mice,B-OG
were,O
then,O
perfused,O
7,O
DPI,O
",",O
24,O
hours,O
after,O
the,O
second,O
BrdU,O
injection,O
.,O
Mice,B-OG
used,O
for,O
morphological,O
analysis,O
were,O
perfused,O
21,O
DPI,O
.,O
Mice,B-OG
were,O
deeply,O
anesthetized,O
with,O
2,O
%,O
avertin,O
",",O
and,O
were,O
intracardially,O
perfused,O
with,O
cold,O
PBS,O
+,O
4,O
%,O
sucrose,O
for,O
approximately,O
5,O
minutes,O
",",O
followed,O
by,O
a,O
solution,O
of,O
4,O
%,O
PFA,O
(,O
paraformaldehyde,O
),O
in,O
PBS,O
+,O
4,O
%,O
sucrose,O
for,O
approximately,O
15,O
minutes,O
.,O
Each,O
brain,O
was,O
post,O
-,O
fixed,O
in,O
4,O
%,O
PFA,O
in,O
PBS,O
+,O
4,O
%,O
sucrose,O
solution,O
overnight,O
.,O
For,O
all,O
procedures,O
with,O
the,O
exception,O
of,O
morphological,O
analysis,O
",",O
50,O
μm,O
thick,O
coronal,O
sections,O
were,O
cut,O
using,O
a,O
Leica,O
1200S,O
vibratome,O
.,O
Free,O
-,O
floating,O
sections,O
were,O
permeabilized,O
for,O
30,O
minutes,O
with,O
PBS,O
-,O
T,O
",",O
followed,O
by,O
2,O
quick,O
rinses,O
with,O
PBS,O
-,O
T,O
.,O
For,O
BrdU,O
staining,O
",",O
sections,O
were,O
treated,O
with,O
1,O
.,O
5M,O
HCl,O
in,O
PBS,O
for,O
30,O
minutes,O
",",O
then,O
heat,O
treated,O
with,O
sodium,O
citrate,O
for,O
30,O
minutes,O
",",O
cooled,O
at,O
room,O
temperature,O
for,O
20,O
minutes,O
",",O
followed,O
by,O
1,O
hour,O
of,O
blocking,O
with,O
10,O
%,O
DHS,O
/,O
PBS,O
-,O
T,O
.,O
Sections,O
were,O
treated,O
with,O
primary,O
antibodies,O
in,O
PBS,O
with,O
2,O
%,O
donkey,B-OG
serum,O
and,O
0,O
.,O
3,O
%,O
Triton,O
X,O
-,O
100,O
overnight,O
at,O
4,O
degrees,O
with,O
a,O
combination,O
of,O
no,O
more,O
than,O
three,O
of,O
the,O
following,O
primary,O
antibodies,O
overnight,O
:,O
rat,B-OG
anti,O
-,O
BrdU,O
(,O
1,O
:,O
200,O
Serotec,O
/,O
Bio,O
-,O
Rad,O
"),",O
Chicken,B-OG
anti,O
-,O
GFP,B-GP
(,O
1,O
:,O
2000,O
Abcam,O
"),",O
mouse,B-OG
anti,O
-,O
Nestin,B-GP
(,O
1,O
:,O
100,O
Chemicon,O
MAB353,O
"),",O
rabbit,B-OG
anti,O
-,O
GFAP,B-GP
(,O
1,O
:,O
5000,O
Advanced,O
Immunochemicals,O
"),",O
mouse,B-OG
anti,O
-,O
NeuN,B-GP
(,O
1,O
:,O
500,O
Abcam,O
"),",O
and,O
rabbit,B-OG
anti,O
-,O
mCherry,B-GP
(,O
1,O
:,O
2000,O
",",O
Abcam,O
).,O
The,O
following,O
day,O
",",O
sections,O
were,O
washed,O
3,O
times,O
every,O
15,O
minutes,O
",",O
followed,O
by,O
2,O
quick,O
rinses,O
with,O
PBS,O
-,O
T,O
.,O
Primary,O
antibodies,O
were,O
detected,O
using,O
the,O
following,O
secondary,O
antibodies,O
in,O
a,O
1,O
:,O
200,O
dilution,O
:,O
Dylight,O
647,O
anti,O
-,O
rat,B-OG
",",O
Alexa488,O
anti,O
-,O
chicken,B-OG
",",O
Cy3,O
anti,O
-,O
mouse,B-OG
",",O
and,O
Cy3,O
anti,O
-,O
rabbit,B-OG
(,O
all,O
Jackson,O
Immunoresearch,O
).,O
Sections,O
were,O
incubated,O
overnight,O
before,O
mounting,O
.,O
Measurement,O
of,O
granule,O
cell,O
morphology,O
All,O
neurons,O
were,O
measured,O
using,O
ImageJ,O
.,O
To,O
determine,O
the,O
angle,O
of,O
the,O
neurons,O
’,O
primary,O
dendrites,O
",",O
the,O
border,O
between,O
the,O
granule,O
layer,O
and,O
the,O
molecular,O
layer,O
was,O
traced,O
.,O
All,O
granule,O
cells,O
with,O
clearly,O
defined,O
somas,O
and,O
primary,O
dendrite,O
branch,O
points,O
were,O
analyzed,O
.,O
The,O
centers,O
of,O
all,O
analyzed,O
neurons,O
’,O
somas,O
were,O
determined,O
and,O
marked,O
with,O
a,O
black,O
point,O
",",O
and,O
a,O
line,O
orthogonal,O
to,O
the,O
border,O
between,O
the,O
two,O
layers,O
was,O
made,O
from,O
the,O
border,O
to,O
the,O
center,O
of,O
the,O
soma,O
.,O
A,O
line,O
was,O
then,O
made,O
from,O
the,O
center,O
of,O
the,O
soma,O
to,O
the,O
point,O
where,O
the,O
primary,O
dendrite,O
branched,O
off,O
of,O
the,O
soma,O
.,O
The,O
angle,O
created,O
by,O
the,O
two,O
lines,O
",",O
with,O
the,O
soma,O
’,O
s,O
center,O
as,O
the,O
vertex,O
",",O
was,O
then,O
measured,O
.,O
To,O
determine,O
the,O
proportion,O
of,O
neurons,O
with,O
multiple,O
primary,O
dendrites,O
",",O
multiple,O
images,O
were,O
captured,O
from,O
sections,O
of,O
each,O
dendrite,O
",",O
and,O
the,O
number,O
of,O
neurons,O
with,O
multiple,O
primary,O
dendrites,O
was,O
divided,O
by,O
the,O
total,O
number,O
of,O
neurons,O
in,O
the,O
image,O
for,O
each,O
condition,O
.,O
Total,O
dendritic,O
arborization,O
and,O
soma,O
size,O
were,O
also,O
analyzed,O
using,O
NeuroLucida,O
(,O
MBF,O
Bioscience,O
).,O
Preparation,O
of,O
in,O
vitro,O
samples,O
and,O
analysis,O
of,O
cellular,O
proliferation,O
The,O
U251,O
and,O
SF295,O
cell,O
lines,O
were,O
generously,O
donated,O
by,O
the,O
Israel,O
laboratory,O
at,O
the,O
Geisel,O
School,O
of,O
Medicine,O
at,O
Dartmouth,O
.,O
Cells,O
were,O
grown,O
in,O
triplicate,O
in,O
10,O
cm,O
plates,O
(,O
Corning,O
Incorporated,O
),O
in,O
Dulbecco,O
’,O
s,O
Modified,O
Eagle,O
Medium,O
(,O
Life,O
Technologies,O
),O
containing,O
10,O
%,O
fetal,O
bovine,O
serum,O
and,O
1,O
%,O
penicillin,O
/,O
streptomycin,O
.,O
Cells,O
were,O
counted,O
using,O
a,O
hemocytometer,O
",",O
and,O
once,O
each,O
plate,O
reached,O
200,O
",",O
000,O
cells,O
",",O
the,O
cells,O
were,O
infected,O
with,O
either,O
the,O
miR,O
-,O
338,O
-,O
3p,O
overexpressor,O
virus,B-OG
or,O
a,O
control,O
virus,B-OG
expressing,O
only,O
the,O
fluorophore,O
at,O
a,O
multiplicity,O
of,O
infection,B-DS
of,O
20,O
.,O
The,O
cells,O
were,O
then,O
left,O
to,O
grow,O
for,O
7,O
days,O
to,O
fully,O
express,O
the,O
viral,O
product,O
.,O
At,O
7,O
days,O
post,O
-,O
infection,B-DS
",",O
the,O
cells,O
were,O
re,O
-,O
plated,O
at,O
25,O
",",O
000,O
/,O
plate,O
and,O
counted,O
every,O
24,O
hours,O
for,O
the,O
next,O
5,O
days,O
",",O
and,O
visualized,O
using,O
an,O
Olympus,O
IX,O
-,O
73,O
fluorescence,O
microscope,O
with,O
a,O
10x,O
objective,O
lens,O
.,O
We,O
were,O
able,O
to,O
perform,O
a,O
cell,O
count,O
for,O
the,O
U251,O
line,O
at,O
all,O
time,O
points,O
",",O
but,O
SF295,O
cells,O
became,O
overconfluent,O
at,O
96,O
hours,O
.,O
Despite,O
this,O
",",O
growth,O
curves,O
and,O
proliferation,O
rates,O
could,O
be,O
calculated,O
from,O
the,O
data,O
at,O
significance,O
for,O
both,O
cell,O
lines,O
.,O
Imaging,O
and,O
image,O
analysis,O
Histological,O
sections,O
stained,O
with,O
antibodies,O
for,O
NeuN,B-GP
",",O
Nestin,B-GP
",",O
doublecortin,B-GP
",",O
or,O
BrdU,O
were,O
imaged,O
using,O
a,O
Zeiss,O
LSM,O
510,O
confocal,O
microscope,O
(,O
40X,O
oil,O
lens,O
),O
and,O
quantified,O
over,O
the,O
maximum,O
possible,O
analyzable,O
depth,O
.,O
All,O
other,O
sections,O
were,O
imaged,O
with,O
the,O
20X,O
lens,O
and,O
analyzed,O
over,O
a,O
depth,O
of,O
5,O
–,O
16μm,O
and,O
an,O
area,O
of,O
650,O
.,O
5,O
μm,O
by,O
650,O
.,O
5,O
μm,O
.,O
A,O
63x,O
oil,O
lens,O
with,O
3x,O
digital,O
zoom,O
was,O
used,O
to,O
take,O
images,O
of,O
dendrite,O
segments,O
of,O
neurons,O
immunostained,O
with,O
Alexa488,O
.,O
Point,O
-,O
spread,O
functions,O
(,O
PSFs,O
),O
were,O
generated,O
for,O
the,O
image,O
using,O
the,O
PSF,O
Generator,O
plugin,O
for,O
ImageJ,O
",",O
and,O
then,O
images,O
were,O
deconvolved,O
using,O
a,O
Richardson,O
-,O
Lucy,O
function,O
based,O
in,O
the,O
DeconvolutionLab,O
plugin,O
for,O
ImageJ,O
.,O
The,O
NeuronStudio,O
program,O
was,O
then,O
used,O
to,O
automatically,O
quantify,O
deconvolved,O
segments,O
of,O
dendrites,O
for,O
spine,O
density,O
",",O
spine,O
length,O
",",O
and,O
spine,O
head,O
diameter,O
.,O
Between,O
one,O
to,O
three,O
images,O
were,O
quantified,O
per,O
injected,O
mouse,B-OG
.,O
To,O
correct,O
for,O
variability,O
in,O
overall,O
staining,O
intensity,O
",",O
the,O
background,O
fluorescence,O
intensity,O
of,O
the,O
entire,O
image,O
was,O
subtracted,O
from,O
the,O
intensity,O
of,O
the,O
individual,O
cell,O
of,O
interest,O
.,O
Using,O
ImageJ,O
",",O
all,O
cells,O
labeled,O
with,O
FUCW,O
or,O
both,O
FUCW,O
and,O
antibody,O
were,O
counted,O
.,O
Between,O
one,O
to,O
three,O
images,O
were,O
quantified,O
per,O
injected,O
mouse,B-OG
.,O
TGCA,O
data,O
TCGA,O
data,O
was,O
mined,O
as,O
previously,O
described,O
using,O
Level,O
3,O
data,O
from,O
Chin,O
L,O
",",O
et,O
al,O
.,O
[,O
53,O
",",O
54,O
].,O
A,O
Z,O
-,O
value,O
of,O
-,O
0,O
.,O
4,O
or,O
less,O
defined,O
the,O
mir,O
-,O
338,O
-,O
3p,O
low,O
subgroup,O
.,O
The,O
remaining,O
patients,O
constituted,O
the,O
mir,O
-,O
338,O
-,O
3p,O
high,O
subgroup,O
.,O
Statistical,O
analysis,O
For,O
the,O
in,O
vitro,O
proliferation,O
assays,O
",",O
we,O
performed,O
Poisson,O
regression,O
in,O
Stata,O
.,O
Significance,O
was,O
determined,O
using,O
Pearson,O
’,O
s,O
chi,O
-,O
squared,O
test,O
",",O
where,O
α,O
=,O
0,O
.,O
05,O
.,O
Figures,O
were,O
created,O
using,O
GraphPad,O
Prism,O
.,O
For,O
histological,O
analysis,O
",",O
t,O
-,O
tests,O
or,O
one,O
-,O
way,O
ANOVA,O
analyzed,O
post,O
-,O
hoc,O
via,O
Tukey,O
’,O
s,O
range,O
test,O
were,O
used,O
unless,O
otherwise,O
indicated,O
.,O
We,O
accounted,O
for,O
individual,O
differences,O
in,O
counts,O
and,O
measurements,O
of,O
neurons,O
between,O
mice,B-OG
using,O
previously,O
described,O
models,O
[,O
41,O
].,O
Significance,O
was,O
set,O
at,O
p,O
<,O
0,O
.,O
05,O
for,O
all,O
analyses,O
.,O
For,O
TGCA,O
data,O
analysis,O
",",O
GraphPad,O
Prism,O
6,O
was,O
used,O
for,O
statistical,O
analysis,O
.,O
Log,O
-,O
rank,O
(,O
Mantel,O
-,O
Cox,O
),O
was,O
used,O
to,O
perform,O
significance,O
analysis,O
on,O
survival,O
curves,O
with,O
2,O
groups,O
.,O
Supporting,O
information,O
MiR,O
-,O
338,O
-,O
3p,O
knockdown,O
does,O
not,O
alter,O
relative,O
maturity,O
of,O
affected,O
cells,O
.,O
A,O
.,O
Representative,O
images,O
displaying,O
co,O
-,O
localization,O
of,O
nestin,B-GP
(,O
blue,O
),O
with,O
an,O
mCherry,B-GP
control,O
virus,B-OG
(,O
red,O
),O
and,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
virus,B-OG
(,O
green,O
).,O
B,O
.,O
Representative,O
images,O
displaying,O
co,O
-,O
localization,O
of,O
nestin,B-GP
(,O
blue,O
),O
with,O
an,O
mCherry,B-GP
control,O
virus,B-OG
(,O
red,O
),O
and,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
virus,B-OG
(,O
green,O
).,O
C,O
.,O
Ratio,O
of,O
co,O
-,O
labeling,O
of,O
cells,O
by,O
nestin,B-GP
and,O
either,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
(,O
n,O
=,O
4,O
),O
or,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
(,O
n,O
=,O
4,O
),O
normalized,O
to,O
respective,O
co,O
-,O
expressed,O
mCherry,B-GP
and,O
nestin,B-GP
co,O
-,O
labeling,O
.,O
D,O
.,O
Ratio,O
of,O
co,O
-,O
labeling,O
of,O
cells,O
by,O
NeuN,B-GP
and,O
either,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sensor,O
(,O
n,O
=,O
4,O
),O
or,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
(,O
n,O
=,O
5,O
),O
normalized,O
to,O
respective,O
co,O
-,O
expressed,O
mCherry,B-GP
and,O
NeuN,B-GP
co,O
-,O
labeling,O
.,O
ns,O
p,O
>,O
0,O
.,O
05,O
",",O
one,O
way,O
ANOVA,O
.,O
Results,O
show,O
mean,O
±,O
SEM,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
MiR,O
-,O
132,O
-,O
3p,O
knockdown,O
does,O
not,O
result,O
in,O
glioblastoma,B-DS
.,O
A,O
.,O
Design,O
of,O
lentiviral,O
miR,O
-,O
132,O
-,O
3p,O
sponge,O
with,O
a,O
sensor,O
cassette,O
",",O
using,O
the,O
same,O
vector,O
backbone,O
as,O
the,O
miR,O
-,O
338,O
-,O
3p,O
sponge,O
.,O
The,O
miR,O
-,O
132,O
-,O
3p,O
sensor,O
cassette,O
contains,O
2,O
perfectly,O
complementary,O
miR,O
-,O
132,O
-,O
3p,O
target,O
sequences,O
downstream,O
of,O
GFP,B-GP
driven,O
by,O
the,O
pUbiquitin,B-GP
promoter,O
and,O
the,O
sponge,O
cassette,O
consists,O
of,O
6,O
targets,O
downstream,O
of,O
both,O
the,O
H1,O
and,O
U6,O
promoters,O
for,O
a,O
total,O
of,O
2,O
sensor,O
targets,O
to,O
sense,O
miR,O
-,O
132,O
-,O
3p,O
activity,O
and,O
12,O
sponge,O
targets,O
to,O
sequester,O
endogenous,O
miR,O
-,O
132,O
-,O
3p,O
.,O
B,O
.,O
Dentate,O
gyrus,O
histology,O
at,O
7,O
DPI,O
after,O
miR,O
-,O
132,O
-,O
3p,O
sponge,O
injection,O
.,O
The,O
miR,O
-,O
132,O
-,O
3p,O
sponge,O
knocks,O
down,O
miR,O
-,O
132,O
-,O
3p,O
expression,O
in,O
a,O
subset,O
of,O
dentate,O
gyrus,O
neurons,O
",",O
allowing,O
expression,O
of,O
the,O
GFP,B-GP
sensor,O
construct,O
(,O
green,O
).,O
No,O
neoplastic,O
glioblastoma,B-DS
-,O
like,O
histology,O
was,O
observed,O
.,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Baseline,O
sensor,O
expression,O
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Sensor,O
co,O
-,O
expression,O
with,O
maturity,O
biomarkers,O
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
MiR,O
-,O
338,O
-,O
3p,O
sponge,O
validation,O
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Sponge,O
co,O
-,O
expression,O
with,O
maturity,O
biomarkers,O
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Dendritic,O
branch,O
angles,O
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Primary,O
dendrite,O
quantities,O
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Dendritic,O
spine,O
properties,O
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Dendritic,O
arborization,O
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
GBM,B-DS
proliferation,O
.,O
(,O
CSV,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
MeCP2,B-GP
-,O
Related,O
Diseases,O
and,O
Animal,B-OG
Models,O
The,O
role,O
of,O
epigenetics,O
in,O
human,B-OG
disease,O
has,O
become,O
an,O
area,O
of,O
increased,O
research,O
interest,O
.,O
Collaborative,O
efforts,O
from,O
scientists,O
and,O
clinicians,O
have,O
led,O
to,O
a,O
better,O
understanding,O
of,O
the,O
molecular,O
mechanisms,O
by,O
which,O
epigenetic,O
regulation,O
is,O
involved,O
in,O
the,O
pathogenesis,O
of,O
many,O
human,B-OG
diseases,O
.,O
Several,O
neurological,O
and,O
non,O
-,O
neurological,B-DS
disorders,I-DS
are,O
associated,O
with,O
mutations,O
in,O
genes,O
that,O
encode,O
for,O
epigenetic,O
factors,O
.,O
One,O
of,O
the,O
most,O
studied,O
proteins,O
that,O
impacts,O
human,B-OG
disease,O
and,O
is,O
associated,O
with,O
deregulation,O
of,O
epigenetic,O
processes,O
is,O
Methyl,B-GP
CpG,I-GP
binding,I-GP
protein,I-GP
2,I-GP
(,O
MeCP2,B-GP
).,O
MeCP2,B-GP
is,O
an,O
epigenetic,O
regulator,O
that,O
modulates,O
gene,O
expression,O
by,O
translating,O
epigenetic,O
DNA,O
methylation,O
marks,O
into,O
appropriate,O
cellular,O
responses,O
.,O
In,O
order,O
to,O
highlight,O
the,O
importance,O
of,O
epigenetics,O
to,O
development,O
and,O
disease,O
",",O
we,O
will,O
discuss,O
how,O
MeCP2,B-GP
emerges,O
as,O
a,O
key,O
epigenetic,O
player,O
in,O
human,B-OG
neurodevelopmental,O
",",O
neurological,O
",",O
and,O
non,O
-,O
neurological,B-DS
disorders,I-DS
.,O
We,O
will,O
review,O
our,O
current,O
knowledge,O
on,O
MeCP2,B-GP
-,O
related,O
diseases,O
",",O
including,O
Rett,B-DS
Syndrome,I-DS
",",O
Angelman,B-DS
Syndrome,I-DS
",",O
Fetal,B-DS
Alcohol,I-DS
Spectrum,I-DS
Disorder,I-DS
",",O
Hirschsprung,B-DS
disease,I-DS
",",O
and,O
Cancer,B-DS
.,O
Additionally,O
",",O
we,O
will,O
briefly,O
discuss,O
about,O
the,O
existing,O
MeCP2,B-GP
animal,B-OG
models,O
that,O
have,O
been,O
generated,O
for,O
a,O
better,O
understanding,O
of,O
how,O
MeCP2,B-GP
impacts,O
certain,O
human,B-OG
diseases,O
.,O
1,O
.,O
Introduction,O
Methyl,B-GP
CpG,I-GP
binding,I-GP
protein,I-GP
2,I-GP
(,O
MeCP2,B-GP
),O
was,O
first,O
identified,O
and,O
characterized,O
as,O
a,O
DNA,B-GP
binding,I-GP
protein,I-GP
that,O
specifically,O
binds,O
to,O
methyl,O
-,O
CpG,O
dinucleotides,O
[,O
1,O
].,O
The,O
MECP2,B-GP
gene,O
is,O
localized,O
on,O
the,O
X,O
-,O
chromosome,O
and,O
contains,O
complex,O
regulatory,O
elements,O
that,O
control,O
its,O
precise,O
expression,O
levels,O
[,O
2,O
–,O
5,O
].,O
In,O
both,O
human,B-OG
and,O
mouse,B-OG
",",O
the,O
MECP2,B-GP
/,O
Mecp2,B-GP
gene,O
consists,O
of,O
four,O
exons,O
encoding,O
for,O
two,O
different,O
protein,O
isoforms,O
",",O
MeCP2E1,O
and,O
MeCP2E2,O
[,O
6,O
",",O
7,O
].,O
The,O
two,O
Mecp2,B-GP
/,O
MeCP2,B-GP
isoforms,O
show,O
differential,O
temporal,O
and,O
brain,O
region,O
-,O
specific,O
differences,O
in,O
their,O
distribution,O
[,O
7,O
"],",O
and,O
we,O
previously,O
showed,O
that,O
MeCP2E1,O
isoform,O
is,O
similarly,O
distributed,O
compared,O
to,O
total,O
MeCP2,B-GP
in,O
murine,O
brain,O
cells,O
[,O
8,O
].,O
The,O
main,O
functional,O
protein,O
domains,O
of,O
MeCP2,B-GP
include,O
the,O
methyl,O
binding,O
domain,O
(,O
MBD,O
"),",O
the,O
transcriptional,O
repression,O
domain,O
(,O
TRD,O
"),",O
the,O
C,O
-,O
terminal,O
domain,O
(,O
CTD,O
"),",O
and,O
the,O
inter,O
domain,O
(,O
ID,O
),O
[,O
9,O
",",O
10,O
].,O
The,O
MBD,O
facilitates,O
binding,O
to,O
methylated,O
CpG,O
dinucleotides,O
and,O
the,O
preference,O
for,O
adjacent,O
A,O
/,O
T,O
-,O
rich,O
motifs,O
[,O
9,O
",",O
11,O
].,O
It,O
is,O
also,O
capable,O
of,O
binding,O
to,O
non,O
-,O
methylated,O
DNA,O
sequences,O
such,O
as,O
the,O
four,O
-,O
way,O
DNA,O
junctions,O
[,O
12,O
",",O
13,O
].,O
The,O
TRD,O
domain,O
mediates,O
the,O
transcriptional,O
repressor,O
role,O
of,O
MeCP2,B-GP
",",O
and,O
interacts,O
with,O
co,O
-,O
repressor,O
complexes,O
",",O
such,O
as,O
c,B-GP
-,I-GP
Ski,I-GP
",",O
mSin3A,B-GP
",",O
HDAC1,B-GP
",",O
and,O
HDAC2,B-GP
[,O
5,O
",",O
9,O
",",O
14,O
",",O
15,O
].,O
The,O
CTD,O
is,O
suggested,O
to,O
be,O
important,O
for,O
MeCP2,B-GP
function,O
and,O
its,O
chromatin,O
binding,O
activities,O
[,O
12,O
].,O
Inter,O
domain,O
interactions,O
significantly,O
impacts,O
MeCP2,B-GP
structure,O
and,O
increases,O
the,O
stability,O
of,O
the,O
protein,O
[,O
16,O
",",O
17,O
].,O
MeCP2,B-GP
is,O
a,O
nuclear,O
protein,O
that,O
is,O
mainly,O
localized,O
to,O
methylated,O
pericentromeric,O
heterochromatin,O
",",O
referred,O
to,O
as,O
chromocenters,O
[,O
18,O
].,O
MeCP2,B-GP
is,O
widely,O
expressed,O
in,O
several,O
tissues,O
",",O
and,O
is,O
suggested,O
to,O
mediate,O
transcriptional,O
regulation,O
through,O
association,O
with,O
5,O
-,O
methyl,O
cytosine,O
(,O
5mC,O
),O
and,O
5,O
-,O
hydroxymethlcytosine,O
(,O
5hmC,O
"),",O
the,O
two,O
major,O
types,O
of,O
DNA,O
modifications,O
[,O
19,O
–,O
21,O
].,O
MeCP2,B-GP
binding,O
to,O
5mC,O
is,O
associated,O
with,O
repressive,O
functions,O
through,O
its,O
interaction,O
with,O
co,O
-,O
repressor,O
complexes,O
",",O
while,O
binding,O
to,O
5hmC,O
is,O
suggested,O
to,O
facilitate,O
gene,O
expression,O
through,O
the,O
organization,O
of,O
dynamic,O
chromatin,O
[,O
15,O
",",O
22,O
–,O
24,O
].,O
Research,O
studies,O
on,O
MeCP2,B-GP
have,O
shown,O
diverse,O
functions,O
of,O
this,O
protein,O
including,O
transcriptional,O
repression,O
",",O
transcriptional,O
activation,O
[,O
25,O
–,O
27,O
"],",O
RNA,O
splicing,O
[,O
28,O
",",O
29,O
"],",O
long,O
range,O
chromatin,O
remodeling,O
[,O
30,O
",",O
31,O
"],",O
modulation,O
of,O
chromatin,O
architecture,O
",",O
and,O
maintenance,O
of,O
DNA,O
methylation,O
[,O
32,O
].,O
This,O
diversity,O
in,O
the,O
function,O
of,O
MeCP2,B-GP
underscores,O
its,O
role,O
in,O
many,O
disorders,O
.,O
MeCP2,B-GP
is,O
a,O
multifunctional,O
epigenetic,O
regulator,O
that,O
is,O
involved,O
in,O
transcriptional,O
regulation,O
as,O
well,O
as,O
modulating,O
chromatin,O
structure,O
[,O
17,O
",",O
33,O
].,O
Epigenetics,O
control,O
gene,O
expression,O
without,O
altering,O
the,O
corresponding,O
DNA,O
sequences,O
and,O
impact,O
development,O
and,O
disease,O
[,O
21,O
",",O
34,O
–,O
36,O
].,O
Epigenetic,O
mechanisms,O
control,O
the,O
expression,O
of,O
many,O
neurodevelopmentally,O
important,O
genes,O
through,O
chromatin,O
remodeling,O
",",O
histone,O
modifications,O
and,O
DNA,O
methylation,O
[,O
37,O
–,O
41,O
].,O
The,O
prevailing,O
view,O
of,O
MeCP2,B-GP
as,O
an,O
epigenetic,O
modulator,O
is,O
related,O
to,O
its,O
ability,O
to,O
associate,O
with,O
different,O
epigenetic,O
marks,O
(,O
either,O
through,O
direct,O
DNA,O
binding,O
or,O
recruiting,O
other,O
transcription,B-GP
factors,I-GP
).,O
Thus,O
",",O
MeCP2,B-GP
acts,O
as,O
an,O
‘,O
epigenetic,O
reader,O
’,O
that,O
contributes,O
in,O
the,O
establishment,O
of,O
functional,O
states,O
of,O
chromatin,O
structure,O
",",O
a,O
process,O
that,O
is,O
fundamental,O
for,O
normal,O
cellular,O
function,O
.,O
However,O
",",O
it,O
is,O
still,O
not,O
fully,O
understood,O
whether,O
MeCP2,B-GP
acts,O
as,O
a,O
genome,O
-,O
wide,O
epigenetic,O
regulator,O
or,O
as,O
a,O
gene,O
-,O
specific,O
transcriptional,O
modulator,O
",",O
and,O
evidence,O
exists,O
in,O
favor,O
of,O
both,O
mechanisms,O
[,O
15,O
",",O
42,O
].,O
MeCP2,B-GP
protein,O
is,O
highly,O
expressed,O
in,O
the,O
brain,O
compared,O
to,O
other,O
tissues,O
[,O
18,O
",",O
43,O
",",O
44,O
].,O
The,O
protein,O
expression,O
pattern,O
within,O
the,O
brain,O
follows,O
a,O
defined,O
pattern,O
",",O
with,O
early,O
appearing,O
structures,O
",",O
such,O
as,O
brainstem,O
and,O
thalamus,O
",",O
expressing,O
the,O
protein,O
before,O
more,O
rostral,O
structures,O
",",O
such,O
as,O
the,O
cortex,O
[,O
18,O
",",O
43,O
].,O
Temporally,O
",",O
MeCP2,B-GP
protein,O
expression,O
profile,O
is,O
low,O
at,O
birth,O
",",O
and,O
increases,O
dramatically,O
at,O
specific,O
time,O
periods,O
coinciding,O
with,O
the,O
process,O
of,O
neuronal,O
maturation,O
and,O
synaptogenesis,O
in,O
different,O
parts,O
of,O
the,O
brain,O
[,O
43,O
",",O
45,O
].,O
Cell,O
type,O
-,O
specific,O
studies,O
have,O
revealed,O
that,O
MeCP2,B-GP
levels,O
are,O
highest,O
in,O
mature,O
neurons,O
",",O
while,O
astrocytes,O
and,O
immature,O
neurons,O
express,O
lower,O
levels,O
of,O
MeCP2,B-GP
[,O
8,O
",",O
46,O
",",O
47,O
].,O
The,O
increased,O
levels,O
of,O
MeCP2,B-GP
expression,O
in,O
mature,O
neurons,O
are,O
maintained,O
throughout,O
adulthood,O
",",O
implying,O
a,O
requirement,O
for,O
postmitotic,O
neuronal,O
function,O
[,O
47,O
–,O
49,O
].,O
In,O
neurons,O
",",O
MeCP2,B-GP
is,O
involved,O
in,O
neuronal,O
maturation,O
",",O
dendrite,O
formation,O
",",O
and,O
synaptic,O
functions,O
[,O
15,O
",",O
49,O
",",O
50,O
].,O
Studies,O
of,O
mouse,B-OG
models,O
lacking,O
Mecp2,B-GP
expression,O
in,O
neurons,O
further,O
demonstrate,O
the,O
critical,O
role,O
of,O
MeCP2,B-GP
for,O
normal,O
brain,O
function,O
",",O
especially,O
with,O
regard,O
to,O
synaptic,O
modulation,O
and,O
maintenance,O
[,O
18,O
",",O
51,O
].,O
Most,O
MeCP2,B-GP
mutations,O
are,O
de,O
novo,O
and,O
can,O
be,O
grouped,O
into,O
three,O
general,O
categories,O
;,O
severe,O
loss,O
-,O
of,O
-,O
function,O
mutations,O
",",O
mild,O
loss,O
-,O
of,O
-,O
function,O
mutations,O
and,O
a,O
broad,O
group,O
of,O
duplications,O
and,O
other,O
non,O
-,O
coding,O
mutations,O
[,O
52,O
",",O
53,O
].,O
Each,O
category,O
of,O
mutation,O
is,O
associated,O
with,O
(,O
a,O
),O
subset,O
(,O
s,O
),O
of,O
neurological,O
symptoms,O
.,O
Genotype,O
-,O
phenotype,O
analyses,O
have,O
shown,O
that,O
there,O
is,O
no,O
direct,O
and,O
simple,O
correlation,O
with,O
the,O
type,O
of,O
observed,O
mutations,O
and,O
the,O
resulting,O
disease,O
phenotypes,O
.,O
The,O
difficulty,O
in,O
attributing,O
a,O
particular,O
type,O
of,O
mutation,O
to,O
a,O
specific,O
phenotype,O
might,O
be,O
in,O
part,O
due,O
to,O
the,O
pattern,O
of,O
X,O
-,O
chromosome,O
inactivation,O
(,O
XCI,O
),O
[,O
54,O
",",O
55,O
].,O
Overall,O
",",O
MeCP2,B-GP
-,O
related,O
diseases,O
that,O
are,O
associated,O
with,O
protein,O
dysfunction,O
are,O
mainly,O
characterized,O
by,O
cognitive,B-DS
impairment,I-DS
and,O
intellectual,B-DS
disabilities,I-DS
[,O
33,O
].,O
However,O
",",O
dysregulation,O
of,O
the,O
protein,O
are,O
also,O
frequently,O
observed,O
in,O
cases,O
of,O
inherited,O
disorders,O
and,O
autoimmune,B-DS
diseases,I-DS
such,O
as,O
systemic,B-DS
lupus,I-DS
erythematosus,I-DS
(,O
SLE,B-DS
),O
[,O
56,O
].,O
In,O
this,O
review,O
",",O
we,O
will,O
primarily,O
focus,O
on,O
human,B-OG
diseases,O
that,O
are,O
associated,O
with,O
MeCP2,B-GP
dysfunction,O
",",O
and,O
will,O
aim,O
to,O
highlight,O
the,O
role,O
of,O
MeCP2,B-GP
in,O
neurological,O
/,O
neuropsychiatric,O
and,O
non,O
-,O
neurological,B-DS
disorders,I-DS
.,O
In,O
addition,O
",",O
animal,B-OG
models,O
that,O
have,O
enabled,O
a,O
better,O
understanding,O
of,O
the,O
mechanism,O
of,O
MeCP2,B-GP
action,O
will,O
be,O
discussed,O
.,O
2,O
.,O
The,O
Role,O
of,O
MeCP2,B-GP
in,O
Neurological,B-DS
Disorders,I-DS
2,O
.,O
1,O
.,O
Rett,B-DS
Syndrome,I-DS
Rett,B-DS
Syndrome,I-DS
(,O
RTT,B-DS
),O
is,O
a,O
progressive,O
X,O
-,O
linked,O
neurological,B-DS
disorder,I-DS
that,O
mainly,O
affects,O
young,O
girls,O
with,O
an,O
incidence,O
rate,O
of,O
1,O
:,O
10,O
",",O
000,O
–,O
1,O
:,O
15,O
",",O
000,O
[,O
15,O
",",O
57,O
].,O
RTT,B-DS
is,O
",",O
perhaps,O
",",O
the,O
most,O
common,O
cause,O
of,O
mental,B-DS
retardation,I-DS
in,O
females,O
[,O
58,O
",",O
59,O
].,O
Although,O
it,O
was,O
initially,O
thought,O
to,O
occur,O
exclusively,O
in,O
females,O
",",O
males,O
have,O
also,O
been,O
identified,O
with,O
classic,O
RTT,B-DS
[,O
60,O
].,O
In,O
approximately,O
90,O
%,O
of,O
RTT,B-DS
cases,O
",",O
the,O
disease,O
is,O
due,O
to,O
MECP2,B-GP
gene,O
mutations,O
[,O
61,O
].,O
MECP2,B-GP
mutations,O
that,O
cause,O
classical,O
RTT,B-DS
in,O
females,O
typically,O
result,O
in,O
neonatal,B-DS
encephalopathy,I-DS
and,O
death,O
in,O
the,O
first,O
year,O
of,O
life,O
in,O
males,O
.,O
However,O
",",O
similar,O
MECP2,B-GP
mutations,O
may,O
result,O
in,O
RTT,B-DS
phenotypes,O
in,O
males,O
with,O
Kleinfelter,B-DS
syndrome,I-DS
(,O
47,O
",",O
XXY,O
"),",O
or,O
somatic,O
mosaicism,O
[,O
62,O
",",O
63,O
].,O
There,O
is,O
the,O
classic,O
RTT,B-DS
as,O
well,O
as,O
atypical,O
forms,O
of,O
RTT,B-DS
that,O
deviate,O
from,O
the,O
classical,O
clinical,O
presentation,O
.,O
Classic,O
RTT,B-DS
is,O
noticed,O
primarily,O
during,O
infancy,O
and,O
can,O
be,O
divided,O
into,O
four,O
stages,O
that,O
reflect,O
the,O
characteristic,O
abnormalities,O
displayed,O
in,O
RTT,B-DS
patients,O
[,O
64,O
].,O
The,O
first,O
stage,O
takes,O
place,O
after,O
a,O
period,O
of,O
normal,O
development,O
",",O
during,O
the,O
first,O
6,O
–,O
18,O
months,O
after,O
birth,O
",",O
when,O
developmental,O
progression,O
ceases,O
and,O
acquisition,O
of,O
new,O
skills,O
is,O
delayed,O
.,O
General,O
motor,O
performance,O
such,O
as,O
crawling,O
",",O
sitting,O
",",O
and,O
walking,O
are,O
also,O
severely,O
impaired,O
at,O
this,O
stage,O
[,O
58,O
",",O
65,O
",",O
66,O
].,O
The,O
second,O
stage,O
of,O
RTT,B-DS
starts,O
at,O
approximately,O
one,O
to,O
four,O
years,O
",",O
with,O
developmental,O
stagnation,O
accompanied,O
by,O
general,O
growth,B-DS
retardation,I-DS
",",O
loss,O
of,O
purposeful,O
hand,O
movements,O
and,O
speech,O
",",O
tongue,O
protrusion,O
",",O
abnormal,O
facial,O
expression,O
",",O
weight,O
loss,O
",",O
and,O
gait,O
ataxia,B-DS
/,O
apraxia,B-DS
[,O
58,O
",",O
64,O
",",O
67,O
].,O
Autonomic,B-DS
dysfunction,I-DS
such,O
as,O
irregular,O
breathing,O
patterns,O
",",O
forced,O
expulsion,O
of,O
air,O
and,O
saliva,O
",",O
and,O
apnea,B-DS
can,O
also,O
be,O
observed,O
at,O
this,O
stage,O
[,O
68,O
].,O
The,O
duration,O
of,O
this,O
stage,O
is,O
from,O
weeks,O
to,O
approximately,O
a,O
year,O
.,O
The,O
third,O
RTT,B-DS
stage,O
is,O
regarded,O
as,O
a,O
relatively,O
‘,O
quiet,O
’,O
period,O
as,O
stabilization,O
of,O
some,O
of,O
the,O
symptoms,O
occurs,O
.,O
However,O
",",O
neuromotor,O
regression,O
and,O
stereotypic,O
hand,O
movements,O
still,O
persists,O
[,O
58,O
",",O
64,O
",",O
67,O
].,O
A,O
defining,O
feature,O
at,O
this,O
stage,O
is,O
the,O
occurrence,O
of,O
seizures,O
",",O
which,O
ranges,O
from,O
easily,O
controlled,O
to,O
intractable,B-DS
epilepsy,I-DS
[,O
69,O
].,O
The,O
duration,O
of,O
this,O
stage,O
is,O
usually,O
from,O
years,O
to,O
decades,O
[,O
67,O
].,O
The,O
last,O
RTT,B-DS
stage,O
takes,O
place,O
from,O
ages,O
5,O
–,O
15,O
years,O
and,O
beyond,O
.,O
Motor,O
deterioration,O
continues,O
and,O
results,O
in,O
loss,O
of,O
mobility,O
and,O
dependence,O
on,O
wheel,O
chair,O
.,O
Additional,O
abnormalities,O
include,O
dystonia,B-DS
",",O
severe,O
constipation,O
",",O
oropharyngeal,O
dysfunction,O
",",O
and,O
cardiac,O
abnormalities,O
[,O
68,O
].,O
As,O
patients,O
become,O
older,O
they,O
often,O
develop,O
Parkinson,O
’,O
s,O
-,O
like,O
features,O
[,O
64,O
",",O
68,O
].,O
The,O
duration,O
of,O
this,O
stage,O
varies,O
with,O
individuals,O
",",O
and,O
usually,O
lasts,O
for,O
decades,O
.,O
Atypical,O
forms,O
of,O
RTT,B-DS
deviate,O
from,O
classic,O
RTT,B-DS
with,O
respect,O
to,O
age,O
of,O
disease,O
onset,O
",",O
clinical,O
profile,O
and,O
severity,O
of,O
symptoms,O
.,O
These,O
forms,O
of,O
RTT,B-DS
occur,O
due,O
to,O
skewing,O
of,O
XCI,O
",",O
and,O
may,O
range,O
from,O
milder,O
forms,O
to,O
more,O
severe,O
manifestations,O
than,O
classic,O
RTT,B-DS
[,O
70,O
",",O
71,O
].,O
Mild,O
variants,O
of,O
RTT,B-DS
are,O
characterized,O
by,O
a,O
later,O
age,O
of,O
onset,O
",",O
typically,O
occurring,O
between,O
one,O
to,O
three,O
years,O
of,O
age,O
and,O
display,O
mild,O
stereotypic,O
movements,O
and,O
neurologic,O
symptoms,O
.,O
The,O
preserved,O
speech,O
or,O
the,O
Zappella,O
variant,O
is,O
a,O
mild,O
variant,O
of,O
RTT,B-DS
characterized,O
by,O
the,O
ability,O
of,O
patients,O
to,O
speak,O
a,O
few,O
words,O
.,O
Patients,O
with,O
this,O
variant,O
have,O
a,O
normal,O
head,O
size,O
and,O
are,O
usually,O
overweight,O
[,O
72,O
].,O
The,O
more,O
severe,O
variants,O
include,O
the,O
congenital,O
form,O
(,O
also,O
known,O
as,O
the,O
Rolando,O
variant,O
),O
that,O
lack,O
the,O
early,O
period,O
of,O
normal,O
development,O
",",O
and,O
a,O
form,O
of,O
classical,O
RTT,B-DS
with,O
early,O
onset,O
seizures,O
before,O
the,O
age,O
of,O
six,O
months,O
(,O
also,O
known,O
as,O
the,O
Hanefeld,O
variant,O
),O
[,O
73,O
",",O
74,O
].,O
Mutations,O
in,O
cyclin,B-GP
-,I-GP
dependent,I-GP
kinase,I-GP
-,I-GP
like,I-GP
5,I-GP
(,O
CDKL5,B-GP
),O
are,O
associated,O
with,O
the,O
early,O
-,O
onset,O
seizure,O
variant,O
form,O
of,O
RTT,B-DS
",",O
while,O
mutations,O
in,O
forkhead,B-GP
box,I-GP
protein,I-GP
G1,I-GP
(,O
FOXG1,B-GP
),O
are,O
associated,O
with,O
congenital,B-DS
RTT,I-DS
Syndrome,I-DS
variant,O
[,O
75,O
",",O
76,O
].,O
Magnetic,O
resonance,O
imaging,O
(,O
MRI,O
),O
and,O
autopsy,O
examination,O
have,O
shown,O
that,O
major,O
morphological,O
abnormalities,O
detected,O
in,O
the,O
central,O
nervous,O
system,O
of,O
RTT,B-DS
patients,O
include,O
an,O
overall,O
decrease,O
in,O
the,O
size,O
of,O
the,O
brain,O
and,O
of,O
individual,O
neurons,O
[,O
77,O
].,O
The,O
reduction,O
in,O
brain,O
size,O
is,O
distributed,O
throughout,O
the,O
brain,O
and,O
affects,O
both,O
white,O
",",O
and,O
to,O
a,O
greater,O
extent,O
the,O
grey,O
matter,O
in,O
different,O
brain,O
regions,O
[,O
78,O
",",O
79,O
].,O
Cortical,O
and,O
cerebellar,O
degeneration,O
have,O
also,O
been,O
demonstrated,O
to,O
progressively,O
occur,O
with,O
increasing,O
age,O
in,O
RTT,B-DS
patients,O
[,O
80,O
].,O
2,O
.,O
2,O
.,O
MECP2,B-GP
Duplication,O
Disorder,O
MECP2,B-GP
duplication,O
syndrome,O
was,O
predicted,O
by,O
the,O
observation,O
that,O
mice,B-OG
engineered,O
to,O
overexpress,O
MECP2,B-GP
develop,O
a,O
progressive,O
neurological,B-DS
disorder,I-DS
including,O
stereotyped,O
and,O
repetitive,O
movements,O
",",O
epilepsy,B-DS
",",O
spasticity,O
",",O
hypoactivity,O
",",O
and,O
early,O
death,O
[,O
81,O
",",O
82,O
].,O
This,O
gain,O
of,O
function,O
mutation,O
occurs,O
mostly,O
in,O
males,O
[,O
83,O
].,O
Males,O
with,O
this,O
disorder,O
present,O
clinical,O
features,O
",",O
such,O
as,O
infantile,O
hypotonia,O
",",O
severe,O
to,O
profound,O
mental,B-DS
retardation,I-DS
",",O
poor,O
speech,O
development,O
",",O
recurrent,O
infections,B-DS
",",O
epilepsy,B-DS
",",O
and,O
progressive,O
spasticity,O
[,O
84,O
",",O
85,O
].,O
The,O
incidence,O
rate,O
of,O
MECP2,B-GP
duplication,O
disorder,O
is,O
estimated,O
to,O
be,O
1,O
%,O
of,O
unexplained,O
X,O
-,O
linked,O
diseases,O
and,O
most,O
of,O
the,O
reported,O
cases,O
are,O
inherited,O
[,O
86,O
].,O
However,O
",",O
de,O
novo,O
cases,O
have,O
also,O
been,O
documented,O
[,O
87,O
].,O
There,O
is,O
considerable,O
clinical,O
overlap,O
in,O
patients,O
with,O
classic,O
RTT,B-DS
and,O
MECP2,B-GP
duplication,O
disorder,O
specifically,O
in,O
behavioral,O
phenotypes,O
",",O
such,O
as,O
stereotypic,O
hand,O
/,O
body,O
movements,O
",",O
anxiety,O
",",O
and,O
social,O
avoidance,O
[,O
88,O
].,O
However,O
",",O
in,O
contrast,O
to,O
RTT,B-DS
",",O
immunodeficiency,O
is,O
observed,O
in,O
patients,O
with,O
MECP2,B-GP
duplication,O
disorder,O
.,O
It,O
remains,O
unclear,O
if,O
this,O
phenotype,O
occurs,O
due,O
to,O
secondary,O
effects,O
from,O
increased,O
dosage,O
of,O
MeCP2,B-GP
protein,O
[,O
89,O
].,O
Approximately,O
40,O
%,O
of,O
males,O
with,O
MECP2,B-GP
duplication,O
reported,O
so,O
far,O
have,O
died,O
before,O
their,O
25th,O
birthday,O
",",O
usually,O
from,O
respiratory,B-DS
infections,I-DS
[,O
90,O
].,O
2,O
.,O
3,O
.,O
Angelman,B-DS
Syndrome,I-DS
MECP2,B-GP
mutations,O
that,O
cause,O
RTT,B-DS
have,O
also,O
been,O
reported,O
in,O
cases,O
of,O
Angelman,B-DS
Syndrome,I-DS
(,O
AS,B-DS
),O
[,O
91,O
–,O
93,O
].,O
Angelman,B-DS
Syndrome,I-DS
is,O
primarily,O
caused,O
by,O
mutations,O
or,O
imprinting,O
errors,O
of,O
the,O
UBE3A,B-GP
gene,O
located,O
on,O
chromosome,O
15,O
",",O
and,O
is,O
characterized,O
by,O
intellectual,B-DS
disability,I-DS
;,O
severe,O
speech,O
impairment,O
and,O
gait,O
ataxia,B-DS
.,O
Considerable,O
phenotypic,O
overlap,O
exists,O
between,O
AS,B-DS
and,O
RTT,B-DS
;,O
however,O
they,O
differ,O
with,O
respect,O
to,O
timing,O
of,O
symptom,O
onset,O
.,O
Angelman,B-DS
Syndrome,I-DS
has,O
an,O
earlier,O
onset,O
and,O
patients,O
are,O
characterized,O
with,O
low,O
hypotonicity,O
at,O
birth,O
[,O
91,O
].,O
2,O
.,O
4,O
.,O
X,O
-,O
linked,O
Mental,B-DS
Retardation,I-DS
X,O
-,O
linked,O
mental,B-DS
retardation,I-DS
(,O
XLMR,O
),O
is,O
a,O
genetic,B-DS
disorder,I-DS
arising,O
from,O
mutations,O
or,O
duplication,O
of,O
genes,O
across,O
the,O
X,O
chromosome,O
",",O
including,O
the,O
MECP2,B-GP
gene,O
.,O
MECP2,B-GP
point,O
mutations,O
have,O
been,O
identified,O
in,O
up,O
to,O
2,O
%,O
of,O
individuals,O
with,O
XLMR,O
and,O
duplications,O
of,O
the,O
gene,O
are,O
also,O
implicated,O
in,O
approximately,O
1,O
%,O
to,O
2,O
%,O
of,O
XLMR,O
cases,O
[,O
86,O
",",O
94,O
].,O
MECP2,B-GP
mutations,O
that,O
cause,O
RTT,B-DS
or,O
severe,O
neonatal,B-DS
encephalopathy,I-DS
are,O
not,O
identified,O
in,O
XLMR,O
patients,O
and,O
vice,O
versa,O
[,O
86,O
",",O
95,O
].,O
In,O
addition,O
",",O
the,O
molecular,O
lesions,O
underlying,O
MECP2,B-GP
duplications,O
that,O
result,O
in,O
XLMR,O
are,O
different,O
from,O
those,O
observed,O
in,O
MECP2,B-GP
duplication,O
syndrome,O
[,O
96,O
].,O
Males,O
with,O
XLMR,O
show,O
phenotypes,O
",",O
such,O
as,O
severe,O
intellectual,B-DS
disability,I-DS
",",O
speech,O
impairment,O
",",O
and,O
motor,O
abnormalities,O
",",O
whereas,O
females,O
display,O
mild,O
intellectual,B-DS
disability,I-DS
or,O
are,O
unaffected,O
[,O
86,O
].,O
2,O
.,O
5,O
.,O
Severe,O
Neonatal,B-DS
Encephalopathy,I-DS
Males,O
with,O
a,O
normal,O
karyotype,O
and,O
a,O
mutation,O
in,O
the,O
MECP2,B-GP
gene,O
present,O
with,O
a,O
distinct,O
clinical,O
condition,O
",",O
and,O
severe,O
neonatal,B-DS
encephalopathy,I-DS
(,O
SNE,O
),O
[,O
97,O
].,O
Severe,O
neonatal,B-DS
encephalopathy,I-DS
is,O
a,O
disorder,O
characterized,O
by,O
a,O
static,B-DS
encephalopathy,I-DS
",",O
severe,O
developmental,O
delays,O
and,O
respiratory,O
abnormalities,O
.,O
The,O
mutations,O
are,O
usually,O
inherited,O
from,O
mothers,O
with,O
favorable,O
XCI,O
skewing,O
that,O
display,O
mild,O
/,O
no,O
RTT,B-DS
symptoms,O
.,O
Males,O
with,O
SNE,O
often,O
die,O
within,O
the,O
first,O
years,O
of,O
their,O
life,O
due,O
to,O
autonomic,B-DS
dysfunction,I-DS
[,O
95,O
",",O
98,O
].,O
Some,O
MECP2,B-GP
mutations,O
that,O
do,O
not,O
cause,O
RTT,B-DS
in,O
females,O
have,O
also,O
been,O
implicated,O
in,O
moderate,O
to,O
profound,O
mental,B-DS
retardation,I-DS
",",O
deficits,O
in,O
language,O
and,O
motor,O
skills,O
",",O
obesity,B-DS
",",O
autistic,O
features,O
",",O
and,O
psychiatric,B-DS
disorders,I-DS
in,O
males,O
[,O
54,O
].,O
2,O
.,O
6,O
.,O
Autism,B-DS
Autism,B-DS
and,O
RTT,B-DS
are,O
similar,O
developmental,B-DS
disorders,I-DS
that,O
belong,O
to,O
the,O
spectrum,O
of,O
autism,B-DS
disorders,I-DS
classified,O
as,O
pervasive,B-DS
developmental,I-DS
disorders,I-DS
",",O
or,O
Autism,B-DS
Spectrum,I-DS
Disorders,I-DS
(,O
ASD,B-DS
),O
[,O
99,O
].,O
Although,O
they,O
are,O
similar,O
developmental,B-DS
disorders,I-DS
",",O
autism,B-DS
differs,O
from,O
RTT,B-DS
with,O
respect,O
to,O
its,O
genetic,O
basis,O
.,O
While,O
RTT,B-DS
is,O
caused,O
by,O
MECP2,B-GP
mutations,O
",",O
the,O
genetic,O
basis,O
of,O
autism,B-DS
is,O
not,O
fully,O
clear,O
and,O
is,O
proposed,O
to,O
involve,O
multiple,O
genes,O
[,O
100,O
].,O
Mutations,O
in,O
the,O
MECP2,B-GP
regulatory,O
elements,O
(,O
resulting,O
in,O
decreased,O
expression,O
of,O
the,O
protein,O
),O
are,O
commonly,O
associated,O
with,O
autism,B-DS
[,O
101,O
].,O
Reduced,O
expression,O
of,O
MeCP2,B-GP
protein,O
has,O
been,O
shown,O
to,O
occur,O
frequently,O
in,O
the,O
frontal,O
cortex,O
of,O
autistic,O
patients,O
and,O
is,O
correlated,O
with,O
increased,O
MECP2,B-GP
promoter,O
DNA,O
methylation,O
[,O
102,O
].,O
The,O
silencing,O
of,O
autism,B-DS
-,O
related,O
genes,O
through,O
promoter,O
DNA,O
hypermethylation,O
is,O
commonly,O
associated,O
with,O
autism,B-DS
",",O
and,O
drugs,O
that,O
can,O
demethylate,O
promoters,O
might,O
be,O
useful,O
in,O
activating,O
these,O
genes,O
[,O
103,O
",",O
104,O
].,O
In,O
a,O
recent,O
study,O
",",O
we,O
show,O
that,O
reduced,O
DNA,O
demethylation,O
at,O
the,O
Mecp2,B-GP
promoter,O
and,O
intron,O
1,O
regulatory,O
elements,O
treated,O
with,O
Decitabine,O
is,O
associated,O
with,O
increased,O
Mecp2,B-GP
expression,O
.,O
Our,O
results,O
provide,O
insight,O
on,O
use,O
of,O
such,O
drugs,O
for,O
future,O
therapeutic,O
interventions,O
of,O
autism,B-DS
[,O
105,O
].,O
Moreover,O
",",O
MECP2,B-GP
mutations,O
that,O
are,O
associated,O
with,O
classic,O
RTT,B-DS
have,O
been,O
identified,O
in,O
a,O
number,O
of,O
autistic,O
females,O
who,O
do,O
not,O
meet,O
the,O
diagnostic,O
criteria,O
for,O
RTT,B-DS
[,O
100,O
].,O
This,O
makes,O
it,O
difficult,O
to,O
determine,O
if,O
a,O
MECP2,B-GP
mutation,O
that,O
is,O
associated,O
with,O
autism,B-DS
diagnosis,O
is,O
a,O
different,O
disorder,O
from,O
RTT,B-DS
",",O
or,O
if,O
both,O
disorders,O
are,O
simply,O
different,O
representations,O
on,O
a,O
spectrum,O
associated,O
with,O
MECP2,B-GP
mutations,O
.,O
MECP2,B-GP
mutations,O
have,O
also,O
been,O
reported,O
in,O
patients,O
with,O
mild,O
cognitive,O
and,O
motor,O
difficulties,O
and,O
early,B-DS
-,I-DS
onset,I-DS
schizophrenia,I-DS
[,O
106,O
].,O
2,O
.,O
7,O
.,O
Fetal,B-DS
Alcohol,I-DS
Spectrum,I-DS
Disorders,I-DS
Prenatal,O
exposure,O
to,O
alcohol,O
is,O
associated,O
with,O
adverse,O
effects,O
on,O
neurodevelopment,O
",",O
and,O
results,O
in,O
a,O
set,O
of,O
severe,O
neurodevelopmental,B-DS
disorders,I-DS
known,O
as,O
fetal,B-DS
alcohol,I-DS
spectrum,I-DS
disorders,I-DS
(,O
FASD,B-DS
),O
[,O
107,O
",",O
108,O
].,O
The,O
incidence,O
of,O
FASD,B-DS
is,O
estimated,O
to,O
be,O
as,O
high,O
as,O
1,O
in,O
100,O
births,O
and,O
this,O
disorder,O
commonly,O
manifests,O
as,O
cognitive,O
and,O
intellectual,B-DS
disabilities,I-DS
[,O
108,O
].,O
Accumulating,O
evidence,O
-,O
implicating,O
MeCP2,B-GP
in,O
FASD,B-DS
pathogenesis,O
further,O
reinforces,O
the,O
critical,O
role,O
of,O
MeCP2,B-GP
for,O
central,O
nervous,O
system,O
function,O
.,O
Several,O
studies,O
have,O
demonstrated,O
aberrant,O
expression,O
levels,O
of,O
MeCP2,B-GP
in,O
rodent,O
FASD,B-DS
models,O
",",O
and,O
this,O
is,O
suggested,O
to,O
be,O
an,O
important,O
epigenetic,O
determinant,O
in,O
FASD,B-DS
[,O
109,O
",",O
110,O
].,O
For,O
example,O
",",O
prenatal,O
exposure,O
to,O
ethanol,O
has,O
been,O
demonstrated,O
to,O
significantly,O
decrease,O
MeCP2,B-GP
expression,O
in,O
both,O
prefrontal,O
cortex,O
and,O
striatum,O
of,O
rodent,O
offspring,O
[,O
109,O
].,O
Research,O
in,O
animal,B-OG
models,O
suggests,O
that,O
the,O
global,O
epigenetic,O
changes,O
due,O
to,O
ethanol,O
are,O
related,O
to,O
variations,O
in,O
the,O
levels,O
",",O
duration,O
as,O
well,O
as,O
time,O
of,O
exposure,O
[,O
108,O
",",O
111,O
].,O
Further,O
supporting,O
the,O
potential,O
role,O
of,O
MeCP2,B-GP
in,O
FASD,B-DS
",",O
RTT,B-DS
-,O
causing,O
mutations,O
have,O
been,O
reported,O
in,O
a,O
FASD,B-DS
patient,O
[,O
112,O
].,O
MeCP2,B-GP
has,O
been,O
also,O
shown,O
to,O
modulate,O
the,O
alcohol,O
intake,O
and,O
sensitivity,O
to,O
alcohol,O
",",O
demonstrating,O
the,O
role,O
of,O
MeCP2,B-GP
in,O
alcoholism,B-DS
[,O
113,O
].,O
2,O
.,O
8,O
.,O
Huntington,B-DS
’,I-DS
s,I-DS
Disease,I-DS
Huntington,B-DS
’,I-DS
s,I-DS
disease,I-DS
(,O
HD,B-DS
),O
is,O
a,O
progressive,O
neurodegenerative,B-DS
disorder,I-DS
that,O
affects,O
muscle,O
coordination,O
and,O
results,O
in,O
cognitive,B-DS
decline,I-DS
and,O
psychiatric,B-DS
disorders,I-DS
[,O
114,O
",",O
115,O
].,O
It,O
is,O
one,O
of,O
several,O
tri,O
-,O
nucleotide,O
repeat,O
disorders,O
caused,O
by,O
the,O
length,O
of,O
a,O
repeated,O
section,O
of,O
a,O
gene,O
exceeding,O
a,O
normal,O
range,O
.,O
Expansion,O
of,O
a,O
CAG,O
triplet,O
repeat,O
stretch,O
within,O
the,O
Huntingtin,B-GP
gene,O
(,O
HTT,B-GP
),O
results,O
in,O
a,O
mutant,O
form,O
of,O
the,O
protein,O
",",O
which,O
gradually,O
damages,O
brain,O
cells,O
[,O
114,O
",",O
116,O
].,O
Transcriptional,O
dysregulation,O
has,O
been,O
suggested,O
to,O
play,O
major,O
roles,O
in,O
HD,B-DS
pathology,O
",",O
and,O
it,O
was,O
recently,O
demonstrated,O
that,O
the,O
huntingtin,B-GP
protein,O
(,O
Htt,B-GP
),O
directly,O
interacts,O
with,O
MeCP2,B-GP
in,O
mouse,B-OG
and,O
cellular,O
models,O
of,O
HD,B-DS
.,O
Aberrant,O
interactions,O
between,O
Htt,B-GP
and,O
MeCP2,B-GP
is,O
suggested,O
to,O
contribute,O
to,O
aberrant,O
transcription,O
in,O
Huntington,B-DS
’,I-DS
s,I-DS
disease,I-DS
by,O
regulating,O
brain,B-GP
-,I-GP
derived,I-GP
neurotrophic,I-GP
factor,I-GP
(,O
BDNF,B-GP
),O
levels,O
[,O
117,O
].,O
The,O
implication,O
of,O
MeCP2,B-GP
in,O
such,O
diverse,O
range,O
of,O
neurological,B-DS
disorders,I-DS
necessitates,O
a,O
complete,O
understanding,O
of,O
its,O
relationship,O
to,O
brain,O
development,O
and,O
function,O
",",O
as,O
well,O
as,O
its,O
interaction,O
with,O
other,O
epigenetic,O
factors,O
that,O
mediate,O
dysregulation,O
of,O
normal,O
epigenetic,O
program,O
of,O
the,O
brain,O
.,O
3,O
.,O
Non,O
-,O
Neurological,B-DS
Disorders,I-DS
Associated,O
with,O
MeCP2,B-GP
3,O
.,O
1,O
.,O
Cancer,B-DS
Apart,O
from,O
to,O
its,O
role,O
in,O
neurological,B-DS
disorders,I-DS
",",O
MeCP2,B-GP
has,O
also,O
been,O
shown,O
to,O
play,O
a,O
role,O
in,O
many,O
cancers,B-DS
such,O
as,O
breast,O
",",O
colorectal,O
",",O
lung,O
",",O
liver,O
",",O
and,O
prostate,B-DS
cancer,I-DS
[,O
118,O
–,O
123,O
].,O
MeCP2,B-GP
role,O
in,O
cancer,B-DS
is,O
related,O
to,O
the,O
epigenetic,O
regulation,O
of,O
cancer,B-DS
-,O
related,O
genes,O
",",O
particularly,O
mechanisms,O
that,O
involve,O
hypermethylation,O
of,O
gene,O
promoters,O
[,O
118,O
].,O
The,O
growth,O
-,O
promoting,O
role,O
of,O
MeCP2,B-GP
in,O
prostate,B-DS
cancer,I-DS
cells,O
has,O
been,O
demonstrated,O
previously,O
",",O
where,O
it,O
was,O
shown,O
to,O
control,O
mechanisms,O
",",O
such,O
as,O
cell,O
proliferation,O
and,O
apoptosis,O
[,O
119,O
].,O
In,O
gastric,B-DS
cancer,I-DS
",",O
the,O
depth,O
of,O
invasion,O
has,O
been,O
shown,O
to,O
be,O
associated,O
with,O
MeCP2,B-GP
protein,O
levels,O
.,O
In,O
gastric,B-DS
carcinoma,I-DS
cells,O
",",O
microRNA,O
miR,O
-,O
212,O
was,O
shown,O
to,O
suppress,O
translation,O
of,O
MECP2,B-GP
transcripts,O
",",O
which,O
in,O
turn,O
resulted,O
in,O
reduced,O
depth,O
of,O
cellular,O
invasion,O
[,O
124,O
].,O
In,O
addition,O
",",O
MeCP2,B-GP
has,O
been,O
linked,O
to,O
other,O
cancers,B-DS
",",O
such,O
as,O
myeloma,B-DS
[,O
125,O
"],",O
hematological,B-DS
malignancies,I-DS
[,O
126,O
"],",O
ductal,B-DS
carcinomas,I-DS
[,O
127,O
"],",O
and,O
cervical,B-DS
cancers,I-DS
[,O
128,O
].,O
3,O
.,O
2,O
.,O
Systemic,B-DS
Lupus,I-DS
Erythematosus,I-DS
Systemic,B-DS
lupus,I-DS
erythematosus,I-DS
(,O
SLE,B-DS
),O
is,O
a,O
systemic,B-DS
autoimmune,I-DS
disease,I-DS
that,O
affects,O
multiple,O
organs,O
.,O
The,O
disease,O
predominantly,O
affects,O
females,O
",",O
with,O
a,O
female,O
to,O
male,O
ratio,O
that,O
ranges,O
from,O
4,O
.,O
3,O
–,O
13,O
.,O
6,O
to,O
1,O
[,O
56,O
",",O
129,O
].,O
Although,O
the,O
cause,O
of,O
SLE,B-DS
is,O
still,O
not,O
clear,O
",",O
evidence,O
supports,O
an,O
important,O
role,O
for,O
abnormal,O
T,O
cell,O
DNA,O
methylation,O
in,O
the,O
pathogenesis,O
of,O
SLE,B-DS
",",O
as,O
methylation,O
sensitive,O
genes,O
show,O
increased,O
expression,O
in,O
T,O
cells,O
of,O
SLE,B-DS
patients,O
[,O
130,O
].,O
In,O
active,O
SLE,B-DS
T,O
-,O
cells,O
",",O
the,O
expression,O
of,O
DNA,B-GP
methyltransferase,I-GP
1,I-GP
(,O
DNMT1,B-GP
"),",O
the,O
main,O
enzyme,O
that,O
maintains,O
DNA,O
methylation,O
during,O
cell,O
division,O
",",O
is,O
reduced,O
",",O
resulting,O
in,O
promoter,O
hypomethylation,O
of,O
these,O
methylation,O
-,O
sensitive,O
genes,O
[,O
56,O
",",O
131,O
",",O
132,O
].,O
MeCP2,B-GP
is,O
suggested,O
to,O
play,O
an,O
important,O
role,O
in,O
this,O
process,O
as,O
it,O
is,O
critical,O
for,O
the,O
epigenetic,O
regulation,O
of,O
methylation,O
-,O
sensitive,O
genes,O
",",O
and,O
genetic,O
polymorphisms,O
in,O
MECP2,B-GP
have,O
also,O
been,O
identified,O
in,O
patients,O
with,O
SLE,B-DS
[,O
56,O
",",O
133,O
",",O
134,O
].,O
Moreover,O
",",O
MeCP2,B-GP
associates,O
with,O
DNMT1,B-GP
",",O
the,O
association,O
of,O
which,O
is,O
required,O
to,O
maintain,O
DNA,O
methylation,O
[,O
32,O
].,O
The,O
association,O
between,O
MeCP2,B-GP
",",O
DNMT,B-GP
",",O
and,O
methylation,O
-,O
sensitive,O
genes,O
suggests,O
an,O
important,O
role,O
for,O
epigenetic,O
regulation,O
in,O
the,O
pathogenesis,O
of,O
SLE,B-DS
and,O
other,O
autoimmune,B-DS
diseases,I-DS
.,O
3,O
.,O
3,O
.,O
Rheumatoid,B-DS
Arthritis,I-DS
Rheumatoid,B-DS
arthritis,I-DS
(,O
RA,B-DS
),O
is,O
a,O
systemic,B-DS
autoimmune,I-DS
disease,I-DS
that,O
results,O
in,O
chronic,O
inflammation,O
and,O
destruction,O
of,O
many,O
tissues,O
and,O
organs,O
",",O
primarily,O
flexible,O
synovial,O
joints,O
[,O
135,O
–,O
137,O
].,O
It,O
is,O
characterized,O
by,O
the,O
presence,O
of,O
auto,O
antibodies,O
",",O
which,O
may,O
be,O
detected,O
in,O
the,O
blood,O
long,O
before,O
the,O
onset,O
of,O
disease,O
[,O
138,O
",",O
139,O
].,O
Increasing,O
evidence,O
suggests,O
that,O
DNA,O
methylation,O
and,O
histone,O
modifications,O
regulate,O
the,O
progression,O
of,O
Rheumatoid,B-DS
arthritis,I-DS
.,O
Interestingly,O
",",O
it,O
has,O
been,O
shown,O
that,O
MeCP2,B-GP
expression,O
levels,O
were,O
up,O
-,O
regulated,O
in,O
rodent,O
models,O
of,O
RA,B-DS
",",O
and,O
it,O
is,O
hypothesized,O
that,O
the,O
increased,O
MeCP2,B-GP
protein,O
levels,O
play,O
a,O
role,O
in,O
the,O
pathogenesis,O
of,O
RA,B-DS
through,O
the,O
canonical,O
Wnt,O
pathway,O
[,O
140,O
",",O
141,O
].,O
3,O
.,O
4,O
.,O
Hirschsprung,B-DS
’,I-DS
s,I-DS
Disease,I-DS
Hirschsprung,B-DS
’,I-DS
s,I-DS
disease,I-DS
(,O
HSCR,B-DS
),O
is,O
a,O
congenital,B-DS
disorder,I-DS
of,O
the,O
colon,O
characterized,O
by,O
the,O
absence,O
of,O
certain,O
nerve,O
cells,O
known,O
as,O
ganglion,O
cells,O
[,O
142,O
",",O
143,O
].,O
The,O
incidence,O
of,O
HSCR,B-DS
is,O
about,O
1,O
:,O
2000,O
–,O
5000,O
",",O
with,O
males,O
being,O
affected,O
4,O
times,O
more,O
frequently,O
than,O
females,O
[,O
144,O
].,O
The,O
lack,O
of,O
ganglion,O
cells,O
is,O
associated,O
with,O
impaired,O
craniocaudal,O
migration,O
of,O
neural,O
crest,O
cells,O
",",O
and,O
results,O
in,O
severe,O
constipation,O
or,O
intestinal,B-DS
obstruction,I-DS
[,O
145,O
",",O
146,O
].,O
Defects,O
in,O
the,O
differentiation,O
of,O
neuroblasts,O
into,O
ganglion,O
cells,O
may,O
also,O
contribute,O
to,O
the,O
disorder,O
[,O
142,O
].,O
A,O
recent,O
study,O
implicating,O
MeCP2,B-GP
in,O
the,O
pathogenesis,O
of,O
HSCR,B-DS
suggests,O
that,O
aberrant,O
reduced,O
levels,O
of,O
MeCP2,B-GP
may,O
play,O
an,O
important,O
role,O
in,O
suppressing,O
the,O
proliferative,O
ability,O
of,O
cells,O
in,O
patients,O
with,O
Hirschsprung,B-DS
’,I-DS
s,I-DS
disease,I-DS
[,O
147,O
].,O
Table,O
1,O
represents,O
a,O
list,O
of,O
MeCP2,B-GP
-,O
associated,O
diseases,O
and,O
the,O
genders,O
that,O
are,O
mostly,O
affected,O
.,O
4,O
.,O
Animal,B-OG
Models,O
of,O
MeCP2,B-GP
Dysfunction,O
Several,O
animal,B-OG
models,O
have,O
been,O
generated,O
in,O
order,O
to,O
better,O
understand,O
the,O
molecular,O
mechanisms,O
",",O
progression,O
and,O
pathology,O
of,O
disorders,O
that,O
are,O
associated,O
with,O
MeCP2,B-GP
dysfunction,O
.,O
These,O
include,O
mostly,O
rodent,O
models,O
(,O
particularly,O
mouse,B-OG
models,O
),O
as,O
well,O
as,O
zebrafish,B-OG
and,O
Drosophila,B-OG
models,O
.,O
Different,O
strategies,O
are,O
often,O
employed,O
to,O
alter,O
the,O
expression,O
and,O
function,O
of,O
MeCP2,B-GP
in,O
these,O
animal,B-OG
models,O
.,O
4,O
.,O
1,O
.,O
Mecp2,B-GP
Null,O
Mouse,B-OG
Models,O
Mecp2,B-GP
knockout,O
mice,B-OG
have,O
been,O
generated,O
using,O
the,O
Cre,B-GP
recombinase,I-GP
-,O
loxP,O
system,O
.,O
These,O
mice,B-OG
appear,O
normal,O
until,O
approximately,O
three,O
to,O
four,O
weeks,O
of,O
age,O
",",O
when,O
they,O
begin,O
to,O
exhibit,O
behavioral,O
phenotypes,O
such,O
as,O
unusual,O
gait,O
",",O
hindlimb,O
clasping,O
",",O
seizures,O
",",O
tremors,O
",",O
anxiety,O
",",O
learning,O
and,O
memory,O
deficits,O
",",O
and,O
irregular,O
breathing,O
.,O
Brain,O
neuropathology,O
observed,O
in,O
Mecp2,B-GP
knockout,O
mice,B-OG
is,O
similar,O
to,O
that,O
observed,O
in,O
RTT,B-DS
individuals,O
.,O
Mecp2,B-GP
knockout,O
mice,B-OG
have,O
smaller,O
densely,O
packed,O
neurons,O
",",O
reduced,O
dendritic,O
spine,O
density,O
",",O
deficits,O
in,O
axonal,O
fasciculation,O
and,O
reduced,O
number,O
of,O
mature,O
synapses,O
.,O
Mecp2,B-GP
knockout,O
mice,B-OG
die,O
at,O
approximately,O
10,O
weeks,O
of,O
life,O
[,O
150,O
–,O
152,O
].,O
The,O
reactivation,O
of,O
Mecp2,B-GP
in,O
the,O
brains,O
of,O
Mecp2,B-GP
,O
mice,B-OG
rescued,O
many,O
RTT,B-DS
-,O
phenotypes,O
seen,O
in,O
the,O
,O
mice,B-OG
",",O
including,O
delayed,O
disease,O
progression,O
",",O
increased,O
life,O
span,O
",",O
deceased,O
mortality,O
",",O
and,O
restored,O
neurological,O
functions,O
[,O
153,O
",",O
154,O
].,O
4,O
.,O
2,O
.,O
Mecp2,B-GP
Mutant,O
Mice,B-OG
Mecp2,B-GP
mutant,O
mice,B-OG
differ,O
from,O
the,O
above,O
-,O
mentioned,O
knockout,O
mice,B-OG
as,O
they,O
express,O
a,O
truncated,O
/,O
mutant,O
MeCP2,B-GP
protein,O
.,O
One,O
of,O
such,O
mutant,O
mice,B-OG
is,O
the,O
Jaenisch,O
strain,O
(,O
Mecp2tm1,O
.,O
1jae,O
"),",O
generated,O
by,O
deletion,O
of,O
exon,O
3,O
of,O
the,O
Mecp2,B-GP
gene,O
.,O
Jaenisch,O
mice,B-OG
display,O
behavioral,O
phenotypes,O
similar,O
to,O
the,O
Mecp2,B-GP
knockout,O
mice,B-OG
",",O
although,O
the,O
phenotype,O
is,O
slightly,O
milder,O
and,O
the,O
lifespan,O
is,O
longer,O
(,O
12,O
weeks,O
),O
[,O
82,O
",",O
155,O
].,O
Another,O
Mecp2,B-GP
mutant,O
mouse,B-OG
model,O
has,O
been,O
generated,O
that,O
expresses,O
a,O
protein,O
truncated,O
at,O
amino,O
acid,O
308,O
(,O
Mecp2308,O
).,O
It,O
is,O
assumed,O
that,O
the,O
truncated,O
MeCP2,B-GP
protein,O
produced,O
in,O
these,O
mice,B-OG
has,O
residual,O
unknown,O
functions,O
.,O
Mecp2308,O
mice,B-OG
appear,O
normal,O
until,O
approximately,O
six,O
weeks,O
of,O
age,O
when,O
they,O
develop,O
similar,O
but,O
milder,O
neurological,O
phenotype,O
as,O
Mecp2,B-GP
knockout,O
mice,B-OG
[,O
156,O
].,O
4,O
.,O
3,O
.,O
Mecp2,B-GP
Conditional,O
-,O
Mutant,O
Mice,B-OG
Brain,O
-,O
specific,O
deletion,O
of,O
Mecp2,B-GP
in,O
neural,O
precursor,O
cells,O
",",O
beginning,O
at,O
embryonic,O
day,O
12,O
(,O
Nestin,B-GP
-,O
cre,B-GP
line,O
"),",O
results,O
in,O
mice,B-OG
that,O
display,O
phenotypes,O
similar,O
to,O
Mecp2,B-GP
knockout,O
mice,B-OG
[,O
150,O
",",O
155,O
].,O
This,O
suggests,O
that,O
MeCP2,B-GP
dysfunction,O
in,O
the,O
CNS,O
is,O
sufficient,O
to,O
cause,O
phenotypes,O
observed,O
in,O
RTT,B-DS
.,O
Selective,O
loss,O
of,O
Mecp2,B-GP
in,O
hypothalamic,O
and,O
amygdala,O
neurons,O
(,O
Sim1,B-GP
-,O
cre,B-GP
line,O
),O
results,O
in,O
mice,B-OG
that,O
display,O
similar,O
abnormal,O
physiological,O
stress,O
response,O
as,O
that,O
observed,O
in,O
brain,O
-,O
specific,O
conditional,O
mice,B-OG
.,O
These,O
mice,B-OG
were,O
also,O
obese,O
and,O
aggressive,O
",",O
suggesting,O
a,O
role,O
for,O
MeCP2,B-GP
in,O
regulating,O
social,O
and,O
feeding,O
behaviors,O
[,O
157,O
].,O
Deletion,O
of,O
Mecp2,B-GP
in,O
other,O
parts,O
of,O
the,O
brain,O
such,O
as,O
in,O
brainstem,O
neurons,O
(,O
TH,B-GP
-,O
cre,B-GP
line,O
),O
significantly,O
affects,O
locomotor,O
activity,O
",",O
with,O
no,O
effect,O
on,O
social,O
interaction,O
",",O
breathing,O
patterns,O
",",O
learning,O
and,O
memory,O
[,O
158,O
",",O
159,O
].,O
4,O
.,O
4,O
.,O
Mice,B-OG
Overexpressing,O
MECP2,B-GP
Mice,B-OG
overexpressing,O
human,B-OG
MECP2,B-GP
at,O
approximately,O
twice,O
the,O
endogenous,O
levels,O
exhibit,O
delayed,O
neurological,O
symptoms,O
at,O
approximately,O
10,O
weeks,O
.,O
These,O
symptoms,O
include,O
enhanced,O
motor,O
learning,O
and,O
synaptic,O
plasticity,O
in,O
the,O
hippocampus,O
.,O
However,O
at,O
20,O
weeks,O
",",O
these,O
mice,B-OG
develop,O
seizures,O
and,O
become,O
hypoactive,O
and,O
the,O
majority,O
of,O
them,O
die,O
by,O
approximately,O
one,O
year,O
of,O
age,O
[,O
81,O
].,O
Increased,O
MeCP2,B-GP
expression,O
in,O
other,O
transgenic,O
lines,O
also,O
results,O
in,O
motor,O
abnormalities,O
and,O
neurological,O
symptoms,O
[,O
160,O
].,O
These,O
transgenic,O
mice,B-OG
mimic,O
MECP2,B-GP
duplication,O
syndrome,O
that,O
is,O
observed,O
in,O
humans,B-OG
",",O
and,O
reinforces,O
the,O
notion,O
of,O
a,O
critical,O
requirement,O
for,O
precise,O
dosage,O
of,O
MeCP2,B-GP
protein,O
.,O
4,O
.,O
5,O
.,O
Mouse,B-OG
Models,O
Carrying,O
Rett,B-DS
Syndrome,I-DS
-,O
Associated,O
Mutations,O
A,O
mouse,B-OG
model,O
of,O
Rett,B-DS
syndrome,I-DS
was,O
generated,O
by,O
introducing,O
a,O
premature,O
STOP,O
codon,O
at,O
the,O
amino,O
acid,O
position,O
168,O
",",O
and,O
resulted,O
in,O
a,O
truncated,O
MeCP2,B-GP
protein,O
(,O
Mecp2R168X,O
).,O
These,O
mice,B-OG
display,O
neurological,O
phenotypes,O
such,O
as,O
hind,O
limb,O
clasping,O
and,O
breathing,O
irregularities,O
similar,O
to,O
other,O
mouse,B-OG
models,O
[,O
161,O
].,O
Another,O
RTT,B-DS
mouse,B-OG
model,O
is,O
the,O
A140V,O
Mecp2,B-GP
mutant,O
mice,B-OG
(,O
Mecp2A140V,O
).,O
This,O
MeCP2,B-GP
mutation,O
has,O
also,O
been,O
described,O
in,O
cases,O
of,O
X,O
-,O
linked,O
mental,B-DS
retardation,I-DS
and,O
manic,B-DS
-,I-DS
depressive,I-DS
behaviors,O
.,O
A140V,O
mutant,O
mice,B-OG
produce,O
a,O
mutant,O
MeCP2,B-GP
protein,O
that,O
lacks,O
the,O
ability,O
to,O
bind,O
to,O
Alpha,B-GP
thalassemia,I-GP
/,I-GP
mental,I-GP
retardation,I-GP
syndrome,I-GP
X,I-GP
-,I-GP
linked,I-GP
(,O
ATRX,B-GP
),O
protein,O
.,O
These,O
mice,B-OG
have,O
an,O
apparently,O
normal,O
life,O
span,O
",",O
and,O
lack,O
specific,O
phenotypes,O
that,O
are,O
displayed,O
in,O
other,O
mouse,B-OG
models,O
including,O
seizures,O
",",O
tremors,O
",",O
and,O
breathing,O
irregularities,O
.,O
However,O
they,O
show,O
increased,O
cellular,O
packing,O
and,O
reduced,O
dendrite,O
branching,O
similar,O
to,O
what,O
is,O
observed,O
in,O
autopsy,O
brains,O
from,O
RTT,B-DS
individuals,O
[,O
162,O
].,O
MeCP2,B-GP
partners,O
with,O
ATRX,B-GP
and,O
is,O
involved,O
in,O
the,O
silencing,O
of,O
imprinted,O
genes,O
in,O
brain,O
[,O
163,O
].,O
Recently,O
",",O
a,O
Mecp2e1,O
-,O
deficient,O
mouse,B-OG
model,O
was,O
developed,O
with,O
a,O
point,O
mutation,O
in,O
exon,O
1,O
changing,O
translational,O
start,O
site,O
of,O
the,O
first,O
exon,O
from,O
“,O
ATG,O
”,O
into,O
“,O
TTG,O
”.,O
These,O
mice,B-OG
show,O
many,O
phenotypes,O
observed,O
in,O
Mecp2,B-GP
,O
mice,B-OG
including,O
hindlimb,O
clasping,O
",",O
forelimb,O
stereotypy,O
",",O
and,O
excessive,O
grooming,O
followed,O
by,O
death,O
within,O
7,O
to,O
31,O
weeks,O
[,O
164,O
].,O
In,O
order,O
to,O
demonstrate,O
the,O
functions,O
of,O
neuronal,O
activity,O
-,O
dependent,O
phosphorylation,O
at,O
S80,O
",",O
S421,O
and,O
S424,O
",",O
two,O
knock,O
-,O
in,O
mice,B-OG
models,O
were,O
generated,O
;,O
Mecp2S80A,O
and,O
Mecp2S421A,O
;,O
S424A,O
abolishing,O
the,O
phosphorylation,O
at,O
S80,O
and,O
S421,O
sites,O
.,O
The,O
Mecp2S80A,O
mice,B-OG
showed,O
reduced,O
locomotion,O
while,O
opposite,O
locomotors,O
behaviors,O
were,O
seen,O
in,O
Mecp2S421A,O
;,O
S424A,O
",",O
providing,O
insights,O
on,O
the,O
functions,O
of,O
S80,O
phosphorylation,O
in,O
resting,O
neurons,O
and,O
S421,O
in,O
active,O
neurons,O
[,O
165,O
].,O
A,O
rat,B-OG
model,O
of,O
Rett,B-DS
Syndrome,I-DS
was,O
also,O
generated,O
with,O
reduced,O
Mecp2,B-GP
expression,O
in,O
the,O
brain,O
.,O
This,O
RTT,B-DS
rodent,O
model,O
revealed,O
reduced,O
expression,O
of,O
Bdnf,B-GP
",",O
with,O
no,O
significant,O
phenotypes,O
that,O
mimic,O
RTT,B-DS
[,O
166,O
].,O
Other,O
RTT,B-DS
animal,B-OG
models,O
include,O
the,O
Drosophila,B-OG
and,O
zebrafish,B-OG
models,O
.,O
The,O
Drosophila,B-OG
RTT,B-DS
model,O
was,O
generated,O
by,O
overexpressing,O
known,O
RTT,B-DS
mutations,O
such,O
as,O
R294X,O
and,O
R106W,O
",",O
which,O
resulted,O
in,O
locomotary,O
dysfunction,O
[,O
167,O
].,O
The,O
recently,O
reported,O
zebrafish,B-OG
model,O
of,O
RTT,B-DS
was,O
generated,O
by,O
introducing,O
a,O
C,O
to,O
T,O
transition,O
-,O
mutation,O
at,O
position,O
187,O
of,O
the,O
Mecp2,B-GP
coding,O
sequence,O
.,O
This,O
resulted,O
in,O
a,O
nonsense,O
mutation,O
and,O
a,O
truncation,O
of,O
the,O
MeCP2,B-GP
protein,O
at,O
the,O
position,O
63,O
(,O
Mecp2Q63,O
*).,O
RTT,B-DS
zebrafish,B-OG
model,O
display,O
altered,O
motor,O
behaviors,O
",",O
although,O
the,O
phenotype,O
is,O
weaker,O
in,O
comparison,O
to,O
other,O
Mecp2,B-GP
-,O
deficient,O
animal,B-OG
models,O
.,O
In,O
contrast,O
to,O
MeCP2,B-GP
-,O
,O
mouse,B-OG
models,O
",",O
Mecp2,B-GP
-,O
,O
zebrafish,B-OG
are,O
viable,O
and,O
fertile,O
[,O
168,O
].,O
Other,O
than,O
animal,B-OG
models,O
",",O
in,O
vitro,O
cellular,O
models,O
of,O
Mecp2,B-GP
dysfunction,O
have,O
also,O
been,O
established,O
in,O
order,O
to,O
better,O
understand,O
the,O
how,O
the,O
effects,O
of,O
MeCP2,B-GP
deficiency,O
impairs,O
normal,O
brain,O
function,O
.,O
Loss,O
of,O
Mecp2,B-GP
from,O
cultured,O
neuronal,O
cell,O
populations,O
obtained,O
from,O
embryonic,O
or,O
postnatal,O
Mecp2,B-GP
-,O
deficient,O
mice,B-OG
indicate,O
biochemical,O
and,O
morphological,O
abnormalities,O
similar,O
to,O
Mecp2,B-GP
,O
animals,B-OG
[,O
49,O
",",O
159,O
",",O
169,O
].,O
Moreover,O
",",O
other,O
studies,O
have,O
revealed,O
putative,O
roles,O
of,O
MeCP2,B-GP
in,O
astrocytes,O
and,O
microglia,O
despite,O
the,O
low,O
levels,O
of,O
MeCP2,B-GP
in,O
these,O
cell,O
types,O
.,O
Mecp2,B-GP
-,O
deficient,O
astrocytes,O
and,O
microglia,O
have,O
been,O
demonstrated,O
to,O
produce,O
aberrant,O
levels,O
of,O
soluble,O
factors,O
",",O
such,O
as,O
glutamate,O
",",O
which,O
inhibit,O
dendrite,O
branching,O
from,O
co,O
-,O
cultured,O
neurons,O
in,O
vitro,O
[,O
47,O
",",O
48,O
",",O
170,O
].,O
In,O
addition,O
",",O
loss,O
of,O
Mecp2,B-GP
from,O
astrocytes,O
has,O
been,O
demonstrated,O
to,O
affect,O
astrocytic,O
gap,O
junction,O
function,O
",",O
thereby,O
resulting,O
in,O
their,O
failure,O
to,O
adequately,O
support,O
dendritic,O
development,O
[,O
48,O
].,O
Table,O
2,O
presents,O
an,O
overview,O
of,O
animal,B-OG
models,O
that,O
are,O
developed,O
to,O
study,O
the,O
molecular,O
function,O
of,O
MeCP2,B-GP
.,O
5,O
.,O
Closing,O
Remarks,O
Epigenetic,O
regulation,O
of,O
gene,O
expression,O
is,O
fundamental,O
for,O
proper,O
organism,O
development,O
and,O
function,O
.,O
MeCP2,B-GP
is,O
a,O
multifunctional,O
epigenetic,O
regulator,O
and,O
the,O
malleability,O
in,O
its,O
function,O
underscores,O
its,O
role,O
in,O
many,O
human,B-OG
diseases,O
.,O
Since,O
its,O
discovery,O
",",O
significant,O
progress,O
has,O
been,O
made,O
to,O
understand,O
its,O
dynamic,O
molecular,O
properties,O
",",O
and,O
increasing,O
evidence,O
reveals,O
its,O
central,O
position,O
in,O
many,O
neurological,O
",",O
neurodevelopmental,O
",",O
neuropsychiatric,O
and,O
non,O
-,O
neurological,B-DS
disorders,I-DS
.,O
Despite,O
tremendous,O
progress,O
in,O
understanding,O
the,O
molecular,O
mechanisms,O
by,O
which,O
dysregulation,O
of,O
MeCP2,B-GP
expression,O
and,O
function,O
results,O
in,O
these,O
disorders,O
",",O
we,O
are,O
still,O
far,O
from,O
translating,O
this,O
knowledge,O
towards,O
effective,O
therapeutic,O
approaches,O
.,O
The,O
availability,O
of,O
excellent,O
animal,B-OG
models,O
promises,O
",",O
not,O
only,O
hope,O
",",O
but,O
also,O
a,O
better,O
strategy,O
to,O
overcome,O
the,O
challenge,O
of,O
translational,O
research,O
.,O
It,O
is,O
very,O
likely,O
that,O
the,O
number,O
of,O
diseases,O
associated,O
with,O
MeCP2,B-GP
dysfunction,O
will,O
grow,O
rapidly,O
in,O
near,O
future,O
",",O
thus,O
",",O
a,O
better,O
understanding,O
of,O
how,O
MeCP2,B-GP
functions,O
in,O
complex,O
regulatory,O
networks,O
will,O
pave,O
the,O
way,O
for,O
the,O
discovery,O
of,O
better,O
disease,O
biomarkers,O
as,O
well,O
as,O
novel,O
targets,O
for,O
treatments,O
.,O
Conflicts,O
of,O
Interest,O
The,O
authors,O
declare,O
no,O
conflict,O
of,O
interest,O
.,O
Human,O
diseases,O
associated,O
with,O
Methyl,O
CpG,O
binding,O
protein,O
2,O
(,O
MeCP2,O
),O
and,O
gender,O
mostly,O
affected,O
.,O
Disease,O
Gender,O
mostly,O
affected,O
References,O
Rett,O
Syndrome,O
Females,O
(,O
also,O
males,O
with,O
kleinfelter,O
syndrome,O
47,O
XXY,O
",",O
or,O
somatic,O
mosaicism,O
),O
[,O
15,O
",",O
62,O
",",O
63,O
",",O
148,O
],O
MECP2,O
duplication,O
disorder,O
Males,O
[,O
81,O
–,O
83,O
],O
Angelman,O
Syndrome,O
Females,O
[,O
91,O
",",O
93,O
],O
X,O
-,O
linked,O
mental,O
retardation,O
Males,O
[,O
86,O
",",O
94,O
",",O
95,O
],O
Severe,O
neonatal,O
encephalopathy,O
Males,O
[,O
95,O
",",O
97,O
",",O
98,O
],O
Autism,O
Both,O
[,O
100,O
–,O
102,O
],O
Fetal,O
alcohol,O
spectrum,O
disorders,O
Both,O
(,O
Studies,O
from,O
animal,O
models,O
only,O
),O
[,O
109,O
",",O
110,O
",",O
113,O
],O
Huntington,O
’,O
s,O
disease,O
Both,O
[,O
117,O
],O
Early,O
-,O
onset,O
schizophrenia,O
Both,O
[,O
106,O
],O
Cancers,O
Both,O
[,O
119,O
–,O
128,O
",",O
149,O
],O
Systemic,O
lupus,O
erythematosus,O
Females,O
[,O
56,O
",",O
133,O
",",O
134,O
],O
Rheumatoid,O
arthritis,O
Females,O
[,O
140,O
",",O
141,O
],O
Hirschsprung,O
’,O
s,O
disease,O
Males,O
[,O
147,O
],O
Animal,O
models,O
of,O
MeCP2,O
dysfunction,O
.,O
Animal,O
models,O
Description,O
Phenotype,O
References,O
Mouse,O
Mecp2,O
,O
mouse,O
models,O
:,O
Exon,O
3,O
and,O
4,O
deletion,O
.,O
MeCP2,O
expression,O
and,O
function,O
are,O
abolished,O
Unusual,O
gait,O
",",O
hindlimb,O
clasping,O
",",O
seizures,O
",",O
irregular,O
breathing,O
[,O
150,O
",",O
151,O
],O
Mecp2tm1,O
.,O
1bird,O
Mecp2tm1,O
.,O
Tam,O
Mecp2lox,O
Stop,O
/,O
y,O
or,O
Mecp2tm2,O
.,O
bird,O
Gene,O
silencing,O
by,O
Cre,O
recombinase,O
insertion,O
into,O
intron,O
2,O
.,O
No,O
protein,O
is,O
detected,O
(,O
behaves,O
as,O
a,O
,O
allele,O
),O
Phenotypes,O
similar,O
to,O
the,O
,O
mice,O
with,O
abnormal,O
behavior,O
",",O
RTT,O
-,O
like,O
phenotypes,O
and,O
breathing,O
irregularities,O
.,O
[,O
153,O
],O
Mecp2,O
mutant,O
mice,O
:,O
Mecp2tm1,O
.,O
1jae,O
Exon,O
3,O
deletion,O
.,O
MeCP2,O
expression,O
and,O
function,O
are,O
abolished,O
.,O
Neurological,O
phenotype,O
similar,O
to,O
Mecp2,O
,O
mice,O
",",O
however,O
lifespan,O
is,O
longer,O
.,O
[,O
155,O
],O
Mecp2308,O
Introduction,O
of,O
a,O
premature,O
STOP,O
codon,O
in,O
exon,O
4,O
.,O
Truncated,O
MeCP2,O
protein,O
with,O
residual,O
unknown,O
function,O
Milder,O
neurological,O
phenotype,O
compared,O
to,O
Mecp2,O
,O
mice,O
[,O
156,O
],O
Mecp2,O
conditional,O
-,O
mutant,O
mice,O
:,O
Nestin,O
-,O
cre,O
knockout,O
Brain,O
-,O
specific,O
deletion,O
Similar,O
to,O
Mecp2,O
,O
mice,O
except,O
for,O
breathing,O
phenotype,O
[,O
150,O
",",O
155,O
],O
Sim,O
1,O
-,O
cre,O
knockout,O
Selective,O
deletion,O
in,O
neurons,O
of,O
hypothalamus,O
and,O
amygdala,O
Abnormal,O
stress,O
response,O
",",O
stranger,O
aggression,O
[,O
157,O
],O
TH,O
-,O
cre,O
knockout,O
Selective,O
deletion,O
in,O
dopaminergic,O
and,O
noradrenergic,O
neurons,O
.,O
Hypoactivity,O
",",O
reduced,O
expression,O
of,O
tyrosine,O
hydroxylase,O
[,O
158,O
",",O
159,O
],O
CamKII,O
-,O
cre,O
knockout,O
Forebrain,O
-,O
specific,O
deletion,O
Impaired,O
motor,O
co,O
-,O
ordination,O
",",O
anxiety,O
[,O
171,O
],O
Pet1,O
-,O
cre,O
knockout,O
Selective,O
deletion,O
in,O
serotonergic,O
neurons,O
Increased,O
aggression,O
",",O
hyperactivity,O
[,O
159,O
],O
Viaat,O
-,O
cre,O
knockout,O
Selective,O
deletion,O
in,O
GABAergic,O
neurons,O
Reduced,O
lifespan,O
",",O
self,O
-,O
mutilation,O
[,O
169,O
],O
Mice,O
overexpressing,O
MECP2,O
MeCP2Tg1,O
MECP2,O
overexpression,O
in,O
all,O
cells,O
Seizures,O
",",O
premature,O
death,O
",",O
abnormal,O
social,O
behaviors,O
",",O
hypoactivity,O
[,O
160,O
],O
Tau,O
-,O
MECP2,O
-,O
rescue,O
MECP2,O
overexpression,O
in,O
neurons,O
Hypoactivity,O
",",O
impaired,O
cognition,O
[,O
81,O
],O
Rett,O
Syndrome,O
mouse,O
models,O
:,O
Mecp2R168X,O
Premature,O
STOP,O
codon,O
at,O
amino,O
acid,O
168,O
Hindlimb,O
clasping,O
",",O
breathing,O
irregularities,O
[,O
161,O
],O
Mecp2A140V,O
Missense,O
mutation,O
that,O
produces,O
mutant,O
MeCP2,O
protein,O
Normal,O
life,O
span,O
",",O
reduced,O
dendrite,O
branching,O
[,O
162,O
],O
Mecp2T308A,O
Knock,O
-,O
in,O
mutation,O
that,O
causes,O
loss,O
of,O
interaction,O
with,O
NCoR,O
complex,O
Motor,O
abnormalities,O
",",O
hindlimb,O
clasping,O
[,O
172,O
],O
Mecp2R306C,O
Knock,O
-,O
in,O
mutation,O
that,O
causes,O
loss,O
of,O
interaction,O
with,O
NCoR,O
/,O
SMRT,O
Impaired,O
motor,O
function,O
",",O
hindlimb,O
clasping,O
[,O
173,O
],O
Mecp2T158A,O
Knock,O
-,O
in,O
mutation,O
that,O
disrupts,O
protein,O
stability,O
Developmental,O
regression,O
",",O
hypoactivity,O
[,O
174,O
],O
Mecp2,O
-,O
e1,O
Point,O
mutation,O
of,O
ATG,O
in,O
exon,O
1,O
to,O
TTG,O
Forelimb,O
stereotypy,O
",",O
hindlimb,O
clasping,O
",",O
excessive,O
grooming,O
",",O
and,O
hypoactivity,O
[,O
164,O
],O
Mecp2S80A,O
Knock,O
-,O
in,O
mouse,O
model,O
with,O
abolished,O
phosphorylation,O
at,O
S80,O
.,O
Reduced,O
locomotion,O
similar,O
to,O
that,O
of,O
Mecp2,O
,O
mice,O
and,O
RTT,O
patients,O
[,O
165,O
],O
Mecp2S421A,O
;,O
S424A,O
Double,O
mutant,O
mouse,O
model,O
which,O
lacks,O
phosphorylation,O
at,O
both,O
S421A,O
and,O
S424A,O
Phenotypes,O
opposite,O
to,O
Mecp2S80A,O
mice,O
(,O
increased,O
locomotion,O
),O
[,O
165,O
],O
Mecp2,O
Mouse,O
models,O
of,O
phenotypic,O
rescue,O
Mecp2lox,O
Stop,O
/,O
y,O
;,O
cre,O
ER,O
Activation,O
of,O
Mecp2,O
gene,O
in,O
Mecp2l,O
°,O
x,O
St,O
°,O
p,O
/,O
y,O
mouse,O
model,O
by,O
cre,O
-,O
ER,O
and,O
Tamoxifen,O
injections,O
.,O
Rescued,O
majority,O
of,O
RTT,O
phenotypes,O
including,O
increased,O
lifespan,O
",",O
delayed,O
disease,O
progression,O
[,O
153,O
],O
Mecp2,O
+/,O
;,O
CAGGS,O
LSL,O
Mecp2,O
Conditional,O
activation,O
(,O
rescue,O
),O
of,O
Mecp2,O
gene,O
in,O
brain,O
using,O
synthetic,O
CAGGS,O
promoter,O
Partial,O
rescue,O
of,O
RTT,O
phenotypes,O
",",O
including,O
delayed,O
disease,O
progression,O
",",O
reduced,O
lethality,O
and,O
improved,O
behaviors,O
[,O
154,O
],O
Rat,O
Mecp2,O
-,O
sh,O
-,O
1,O
Viral,O
mediated,O
RNAi,O
-,O
induced,O
downregulation,O
of,O
Mecp2,O
Transient,O
neurobehavioral,O
abnormalities,O
",",O
reduced,O
Bdnf,O
expression,O
in,O
hippocampus,O
[,O
166,O
],O
Zebrafish,O
Mecp2Q63,O
*.,O
Nonsense,O
mutation,O
and,O
a,O
truncation,O
of,O
MeCP2,O
at,O
position,O
63,O
Altered,O
motor,O
behaviors,O
",",O
however,O
viable,O
and,O
fertile,O
[,O
168,O
],O
Drosophila,O
GMR,O
-,O
Gal4,O
:,O
UAS,O
-,O
MeCP2,O
R106W,O
/+.,O
GMR,O
-,O
Gal4,O
:,O
UAS,O
-,O
MeCP2,O
R294X,O
/+.,O
Overexpression,O
of,O
mutant,O
MeCP2,O
protein,O
Locomotar,O
dysfunction,O
",",O
external,O
eye,O
disruption,O
[,O
167,O
],O
Differential,O
morphology,O
and,O
transcriptome,O
profile,O
between,O
the,O
incompletely,O
fused,O
carpels,O
ovary,O
and,O
its,O
wild,O
-,O
type,O
in,O
maize,B-OG
These,O
authors,O
contributed,O
equally,O
to,O
this,O
work,O
.,O
We,O
have,O
isolated,O
a,O
new,O
mutation,O
in,O
maize,B-OG
",",O
incompletely,O
fused,O
carpels,O
(,O
ifc,O
"),",O
which,O
results,O
in,O
an,O
open,O
stylar,O
canal,O
on,O
the,O
ovary,O
and,O
an,O
incomplete,O
pericarp,O
at,O
the,O
top,O
of,O
the,O
kernel,O
.,O
The,O
maize,B-OG
ovary,O
derives,O
from,O
the,O
fusion,O
of,O
three,O
carpels,O
;,O
however,O
",",O
the,O
molecular,O
networks,O
regulating,O
maize,B-OG
carpel,O
fusion,O
remain,O
largely,O
unclear,O
.,O
In,O
this,O
study,O
",",O
RNA,O
sequencing,O
(,O
RNA,O
-,O
seq,O
),O
was,O
performed,O
on,O
wild,O
-,O
type,O
(,O
WT,O
),O
and,O
ifc,O
ovaries,O
that,O
were,O
collected,O
after,O
carpel,O
fusion,O
defects,O
could,O
be,O
morphologically,O
distinguished,O
.,O
In,O
total,O
",",O
877,O
differentially,O
expressed,O
genes,O
were,O
identified,O
.,O
Functional,O
analysis,O
revealed,O
overexpression,O
of,O
genes,O
related,O
to,O
“,O
DNA,O
binding,O
"”,",O
“,O
transcription,O
regulation,O
"”,",O
“,O
hormones,O
"”,",O
and,O
“,O
stress,O
responses,O
”.,O
Among,O
the,O
88,O
differentially,O
expressed,O
transcription,B-GP
factor,I-GP
(,O
TF,B-GP
),O
genes,O
",",O
five,O
showed,O
a,O
high,O
degree,O
of,O
conservation,O
(,O
77,O
.,O
7,O
–,O
88,O
.,O
0,O
%,O
amino,O
acid,O
identity,O
),O
of,O
their,O
conserved,O
domains,O
with,O
genes,O
associated,O
with,O
carpel,O
fusion,O
deficiency,O
in,O
Arabidopsis,B-OG
thaliana,I-OG
",",O
suggesting,O
that,O
these,O
five,O
genes,O
might,O
control,O
carpel,O
fusion,O
in,O
maize,B-OG
.,O
In,O
addition,O
",",O
30,O
genes,O
encoding,O
components,O
of,O
hormone,O
synthesis,O
and,O
signaling,O
pathways,O
were,O
differentially,O
expressed,O
between,O
ifc,O
and,O
WT,O
ovaries,O
",",O
indicating,O
complex,O
hormonal,O
regulation,O
during,O
carpel,O
fusion,O
.,O
These,O
results,O
help,O
elucidate,O
the,O
underlying,O
mechanisms,O
that,O
regulate,O
carpel,O
fusion,O
",",O
supporting,O
the,O
functional,O
analysis,O
of,O
genes,O
involved,O
in,O
producing,O
this,O
phenotype,O
.,O
The,O
plant,B-OG
ovary,O
is,O
derived,O
from,O
carpels,O
",",O
and,O
its,O
formation,O
requires,O
the,O
coordinated,O
growth,O
and,O
development,O
of,O
carpel,O
marginal,O
tissue,O
",",O
which,O
is,O
of,O
critical,O
importance,O
for,O
fruit,O
shape,O
",",O
seed,O
dispersal,O
",",O
and,O
grain,O
yield,O
.,O
The,O
molecular,O
regulation,O
of,O
carpel,O
development,O
relies,O
on,O
a,O
complex,O
regulatory,O
pathway,O
involving,O
microRNA,O
genes,O
",",O
transcription,B-GP
factors,I-GP
(,O
TFs,B-GP
"),",O
and,O
hormonal,O
components1,O
.,O
The,O
carpel,O
",",O
which,O
harbors,O
and,O
promotes,O
the,O
fertilization,O
of,O
ovules,O
",",O
is,O
a,O
unit,O
structure,O
of,O
the,O
gynoecium,O
.,O
The,O
gynoecium,O
is,O
a,O
structure,O
formed,O
from,O
the,O
fusion,O
of,O
one,O
or,O
more,O
carpels,O
that,O
constitutes,O
the,O
inner,O
whorl,O
of,O
the,O
floral,O
organ,O
.,O
In,O
cereals,O
",",O
the,O
gynoecium,O
",",O
which,O
is,O
composed,O
of,O
the,O
ovule,O
and,O
ovary,O
wall,O
",",O
develops,O
into,O
the,O
kernel,O
.,O
In,O
maize,B-OG
",",O
the,O
female,O
inflorescence,O
or,O
the,O
ear,O
initiates,O
florets,O
composed,O
of,O
four,O
types,O
of,O
floral,O
organs,O
:,O
the,O
palea,O
",",O
lodicule,O
",",O
stamen,O
",",O
and,O
pistil,O
.,O
Each,O
pistil,O
develops,O
into,O
a,O
single,O
fruit,O
",",O
the,O
kernel,O
.,O
At,O
maturity,O
",",O
the,O
maize,B-OG
ear,O
is,O
an,O
aggregation,O
of,O
fruits,O
",",O
and,O
each,O
of,O
the,O
fruits,O
is,O
a,O
child,O
or,O
a,O
seed,O
.,O
The,O
maternally,O
derived,O
ovary,O
wall,O
of,O
the,O
kernel,O
undergoes,O
morphological,O
changes,O
and,O
develops,O
into,O
a,O
mature,O
pericarp,O
",",O
which,O
completely,O
encloses,O
the,O
seed2,O
.,O
In,O
maize,B-OG
",",O
the,O
gynoecium,O
is,O
formed,O
from,O
three,O
carpels,O
by,O
congenitally,O
fusing,O
their,O
edges,O
",",O
with,O
two,O
indeterminate,O
abaxial,O
carpels,O
fusing,O
to,O
form,O
the,O
silk,O
",",O
and,O
the,O
third,O
elongating,O
only,O
enough,O
to,O
cover,O
the,O
ovule23,O
.,O
The,O
stylar,O
canal,O
is,O
formed,O
at,O
the,O
point,O
where,O
the,O
adaxial,O
carpel,O
and,O
the,O
two,O
abaxial,O
carpels,O
meet4,O
.,O
The,O
stylar,O
canal,O
represents,O
the,O
only,O
route,O
from,O
outside,O
of,O
the,O
ovary,O
to,O
the,O
ovary,O
cell,O
walls5,O
.,O
Defects,O
in,O
the,O
stylar,O
canal,O
result,O
in,O
aberrant,O
ovary,O
development,O
and,O
susceptibility,O
of,O
the,O
kernel,O
to,O
pathogenic,O
infections,B-DS
",",O
which,O
have,O
serious,O
consequences,O
for,O
seed,O
vigor,O
and,O
grain,O
yield6,O
.,O
Kernels,O
with,O
a,O
closed,O
stylar,O
canal,O
are,O
used,O
for,O
selecting,O
maize,B-OG
lines,O
that,O
exhibit,O
increased,O
resistance,O
to,O
diseases5,O
.,O
Previous,O
studies,O
have,O
revealed,O
a,O
complex,O
functional,O
hierarchy,O
of,O
genes,O
involved,O
in,O
carpel,O
development,O
in,O
the,O
model,O
plant,B-OG
Arabidopsis,B-OG
(,O
Arabidopsis,B-OG
thaliana,I-OG
),O
7,O
.,O
Carpel,O
identity,O
is,O
specified,O
by,O
at,O
least,O
two,O
separate,O
pathways,O
:,O
one,O
is,O
mediated,O
by,O
the,O
class,O
C,O
gene,O
AGAMOUS,B-GP
(,O
AG,B-GP
),O
8,O
",",O
and,O
class,O
E,O
or,O
SEPALLATA,B-GP
genes,O
",",O
as,O
described,O
in,O
the,O
expanded,O
ABC,O
model9,O
;,O
the,O
second,O
is,O
an,O
AG,B-GP
-,O
independent,O
pathway,O
involving,O
SPT,B-GP
and,O
CRC,B-GP
genes10,O
",",O
both,O
of,O
which,O
are,O
negatively,O
regulated,O
by,O
class,O
A,O
genes11,O
",",O
such,O
as,O
APETALA2,B-GP
(,O
AP2,B-GP
),O
and,O
LEUNIG,B-GP
(,O
LUG,B-GP
),O
121314,O
.,O
In,O
addition,O
",",O
the,O
Arabidopsis,B-OG
thaliana,I-OG
CUP,B-GP
-,I-GP
SHAPED,I-GP
COTYLEDON,I-GP
(,O
AtCUC2,B-GP
),O
gene,O
",",O
together,O
with,O
AtCUC1,B-GP
",",O
is,O
required,O
for,O
the,O
specification,O
of,O
the,O
carpel,O
boundary,O
primordium15,O
.,O
Overexpression,O
of,O
AtCUC2,B-GP
can,O
prevent,O
congenital,O
carpel,O
fusion16,O
.,O
Furthermore,O
",",O
microRNA164,O
",",O
which,O
mediates,O
the,O
repression,O
of,O
AtCUC1,B-GP
and,O
AtCUC2,B-GP
",",O
is,O
necessary,O
for,O
organ,O
boundary,O
formation17,O
.,O
The,O
development,O
of,O
the,O
valve,O
or,O
carpel,O
margin,O
lays,O
the,O
very,O
early,O
foundation,O
for,O
gynoecium,O
development1,O
.,O
Previous,O
studies,O
focused,O
on,O
the,O
determination,O
of,O
carpel,O
organ,O
identity,O
and,O
carpel,O
margin,O
differentiation,O
",",O
but,O
the,O
development,O
and,O
regulation,O
of,O
carpel,O
fusion,O
remains,O
less,O
clear,O
.,O
In,O
maize,B-OG
(,O
Zea,B-OG
mays,I-OG
L,I-OG
".),",O
much,O
less,O
is,O
known,O
than,O
in,O
Arabidopsis,B-OG
about,O
the,O
gene,O
regulatory,O
networks,O
that,O
regulate,O
the,O
differentiation,O
and,O
determine,O
the,O
congenital,O
fusion,O
of,O
the,O
carpels,O
.,O
This,O
is,O
because,O
there,O
are,O
very,O
few,O
known,O
mutations,O
with,O
a,O
phenotype,O
restricted,O
to,O
the,O
carpel,O
",",O
although,O
some,O
aspects,O
of,O
carpel,O
tissue,O
development,O
are,O
conserved,O
in,O
Arabidopsis,B-OG
.,O
For,O
example,O
",",O
mutations,O
in,O
maize,B-OG
homologs,O
of,O
the,O
Arabidopsis,B-OG
class,O
C,O
gene,O
AG,B-GP
result,O
in,O
extra,O
carpels,O
that,O
fail,O
to,O
fuse,O
into,O
functional,O
silk,O
in,O
the,O
zag1,B-GP
mutant,O
",",O
suggesting,O
that,O
at,O
least,O
some,O
class,O
C,O
genes,O
that,O
function,O
in,O
carpel,O
identity,O
are,O
conserved1819,O
.,O
In,O
maize,B-OG
",",O
the,O
homeobox,B-GP
gene,I-GP
knotted1,B-GP
(,O
kn1,B-GP
),O
is,O
also,O
required,O
for,O
female,O
floret,O
development,O
.,O
Mutations,O
in,O
kn1,B-GP
result,O
in,O
extra,O
carpels,O
with,O
proliferating,O
ovule,O
tissue4,O
.,O
These,O
genes,O
provide,O
a,O
framework,O
for,O
the,O
molecular,O
regulation,O
of,O
pistil,O
development,O
in,O
maize,B-OG
and,O
indicate,O
the,O
existence,O
of,O
distinct,O
genes,O
and,O
regulatory,O
programs,O
restricted,O
to,O
carpel,O
development,O
.,O
Thus,O
",",O
genes,O
need,O
to,O
be,O
identified,O
and,O
characterized,O
more,O
precisely,O
to,O
understand,O
exactly,O
how,O
carpel,O
tissue,O
morphologies,O
are,O
specified,O
in,O
maize,B-OG
.,O
The,O
concerted,O
action,O
of,O
multiple,O
hormones,O
is,O
required,O
for,O
the,O
control,O
of,O
carpel,O
development,O
.,O
In,O
particular,O
",",O
genes,O
involved,O
in,O
the,O
auxin,O
pathway,O
play,O
a,O
key,O
role,O
in,O
the,O
regulation,O
of,O
carpel,O
development,O
and,O
gynoecium,O
patterning2021,O
",",O
and,O
there,O
is,O
increasing,O
evidence,O
of,O
involvement,O
of,O
auxin,O
biosynthesis,O
and,O
signaling,O
in,O
floral,O
tissue,O
development,O
in,O
Arabidopsis22,O
.,O
However,O
",",O
a,O
specific,O
description,O
of,O
auxin,O
-,O
related,O
gene,O
expression,O
associated,O
with,O
carpel,O
fusion,O
is,O
currently,O
lacking,O
.,O
Moreover,O
",",O
other,O
hormones,O
",",O
including,O
gibberellin,O
(,O
GA,O
),O
23,O
",",O
cytokinin,O
(,O
CK,O
),O
24,O
",",O
and,O
brassinosteroids,O
(,O
BRs,O
),O
25,O
",",O
have,O
been,O
implicated,O
in,O
Arabidopsis,B-OG
carpel,O
development,O
",",O
but,O
detailed,O
knowledge,O
of,O
their,O
activity,O
and,O
related,O
patterns,O
of,O
gene,O
expression,O
associated,O
with,O
maize,B-OG
carpel,O
fusion,O
are,O
limited,O
.,O
Despite,O
recent,O
advances,O
in,O
the,O
regulation,O
of,O
flower,O
development,O
and,O
ovary,O
formation1,O
",",O
the,O
mechanisms,O
by,O
which,O
transcriptional,B-GP
regulators,I-GP
and,O
hormonal,O
activity,O
interact,O
to,O
coordinate,O
the,O
growth,O
and,O
differentiation,O
of,O
carpel,O
fusion,O
remain,O
poorly,O
understood,O
.,O
Although,O
previous,O
studies,O
analyzing,O
carpel,O
mutations,O
have,O
used,O
forward,O
genetic,O
methods,O
to,O
screen,O
genes,O
",",O
they,O
have,O
typically,O
lacked,O
mapping,O
and,O
quantification,O
of,O
the,O
overall,O
transcriptome,O
to,O
uncover,O
biological,O
pathways,O
and,O
regulatory,O
networks262728,O
.,O
In,O
this,O
study,O
",",O
we,O
conducted,O
morphological,O
and,O
histological,O
surveys,O
to,O
capture,O
the,O
progressive,O
stages,O
of,O
carpel,O
development,O
.,O
Moreover,O
",",O
we,O
performed,O
RNA,O
-,O
seq,O
analysis,O
to,O
investigate,O
transcriptional,O
networks,O
that,O
are,O
likely,O
to,O
regulate,O
ifc,O
ovary,O
formation,O
.,O
The,O
aims,O
of,O
this,O
study,O
were,O
to,O
understand,O
carpel,O
fusion,O
in,O
the,O
maize,B-OG
ovary,O
and,O
to,O
identify,O
significant,O
differences,O
in,O
the,O
transcriptome,O
between,O
the,O
ifc,O
ovary,O
and,O
its,O
wild,O
-,O
type,O
(,O
WT,O
).,O
Maize,B-OG
exhibits,O
a,O
similar,O
floret,O
morphology,O
to,O
a,O
typical,O
dicot,O
flower,O
",",O
along,O
with,O
the,O
conserved,O
genetic,O
mechanism,O
underlying,O
flower,O
development,O
",",O
and,O
is,O
therefore,O
suitable,O
for,O
use,O
in,O
studies,O
investigating,O
reproductive,O
organ,O
developmental2,O
.,O
Here,O
",",O
we,O
report,O
a,O
preliminary,O
atlas,O
of,O
the,O
transcriptome,O
characteristics,O
of,O
ifc,O
and,O
wild,O
-,O
type,O
ovaries,O
to,O
begin,O
to,O
decipher,O
carpel,O
development,O
and,O
",",O
ultimately,O
",",O
to,O
provide,O
fundamental,O
insight,O
into,O
the,O
underlying,O
mechanisms,O
that,O
determine,O
ovary,O
formation,O
",",O
grain,O
yield,O
",",O
and,O
seed,O
quality,O
.,O
Results,O
Morphological,O
and,O
Histological,O
Analysis,O
of,O
ifc,O
Ovary,O
Development,O
To,O
understand,O
the,O
molecular,O
regulation,O
of,O
carpel,O
fusion,O
during,O
maize,B-OG
ovary,O
development,O
",",O
we,O
characterized,O
the,O
ifc,O
phenotype,O
of,O
YU,O
-,O
A474,O
(,O
an,O
inbred,O
line,O
),O
in,O
detail,O
.,O
This,O
phenotype,O
was,O
discovered,O
based,O
on,O
a,O
mature,O
kernel,O
(,O
Fig,O
.,O
1A,O
",",O
D,O
–,O
F,O
),O
with,O
a,O
gap,O
on,O
the,O
top,O
",",O
which,O
was,O
close,O
to,O
the,O
silk,O
and,O
back,O
to,O
the,O
embryo,O
(,O
Fig,O
.,O
1F,O
).,O
Careful,O
examination,O
of,O
many,O
ears,O
showed,O
that,O
the,O
ifc,O
phenotype,O
of,O
the,O
pistil,O
arose,O
before,O
pollination,O
(,O
Fig,O
.,O
1B,O
",",O
C,O
",",O
G,O
–,O
J,O
"),",O
and,O
the,O
gap,O
at,O
the,O
top,O
of,O
the,O
ifc,O
ovary,O
was,O
observed,O
ahead,O
of,O
the,O
extruding,O
nucellus,O
(,O
Fig,O
.,O
1H,O
",",O
J,O
).,O
It,O
was,O
also,O
found,O
that,O
there,O
was,O
no,O
significant,O
difference,O
in,O
silk,O
length,O
between,O
the,O
ifc,O
ovaries,O
and,O
their,O
wild,O
-,O
type,O
(,O
Table,O
S1,O
).,O
The,O
ovaries,O
of,O
ifc,O
pistils,O
were,O
normally,O
enough,O
to,O
satisfy,O
pollination,O
and,O
fertilization,O
(,O
Fig,O
.,O
1F,O
;,O
Figure,O
S1,O
).,O
There,O
were,O
no,O
detectable,O
abnormalities,O
in,O
other,O
organs,O
.,O
The,O
pistil,O
",",O
which,O
is,O
the,O
inner,O
whorl,O
of,O
the,O
floret,O
",",O
begins,O
as,O
a,O
ridge,O
on,O
the,O
abaxial,O
surface,O
of,O
the,O
apical,O
meristem,O
.,O
Continued,O
overgrowth,O
of,O
ridge,O
tissue,O
initiates,O
silk,O
development,O
and,O
leads,O
to,O
the,O
formation,O
of,O
the,O
stylar,O
canal,O
(,O
Fig,O
.,O
2A,O
).,O
Initially,O
",",O
some,O
ears,O
exhibited,O
a,O
few,O
kernels,O
with,O
a,O
gap,O
at,O
the,O
top,O
at,O
maturity,O
",",O
and,O
the,O
phenotype,O
was,O
very,O
weak,O
.,O
After,O
additional,O
generations,O
of,O
self,O
-,O
pollination,O
",",O
a,O
strong,O
phenotype,O
was,O
observed,O
.,O
However,O
",",O
a,O
maximum,O
of,O
80,O
%,O
of,O
the,O
kernels,O
from,O
the,O
self,O
-,O
crossed,O
ifc,O
progenies,O
displayed,O
an,O
incomplete,O
pericarp,O
",",O
and,O
the,O
remaining,O
kernels,O
showed,O
an,O
intact,O
pericarp,O
",",O
indicating,O
partial,O
penetrance,O
of,O
the,O
ifc,O
phenotype,O
.,O
To,O
determine,O
whether,O
ifc,O
is,O
a,O
dominant,O
or,O
recessive,O
mutation,O
",",O
F1,O
ears,O
from,O
two,O
reciprocal,O
crosses,O
of,O
plants,B-OG
were,O
investigated,O
.,O
We,O
did,O
not,O
observe,O
any,O
F1,O
ears,O
with,O
the,O
ifc,O
phenotype,O
(,O
Table,O
S2,O
).,O
In,O
addition,O
",",O
831,O
ears,O
of,O
BC1,O
plants,B-OG
and,O
790,O
ears,O
of,O
F2,O
plants,B-OG
showed,O
1,O
.,O
10,O
:,O
1,O
(,O
χ2,O
=,O
2,O
.,O
02,O
;,O
χ20,O
.,O
05,O
",",O
1,O
=,O
3,O
.,O
84,O
;,O
χ2,O
<,O
χ20,O
.,O
05,O
",",O
1,O
),O
and,O
2,O
.,O
67,O
:,O
1,O
(,O
χ2,O
=,O
2,O
.,O
07,O
;,O
χ20,O
.,O
05,O
",",O
1,O
=,O
3,O
.,O
84,O
;,O
χ2,O
<,O
χ20,O
.,O
05,O
",",O
1,O
),O
segregation,O
",",O
respectively,O
(,O
Table,O
S2,O
).,O
This,O
genetic,O
analysis,O
suggested,O
that,O
ifc,O
is,O
a,O
recessive,O
allele,O
.,O
We,O
examined,O
the,O
ears,O
",",O
which,O
represent,O
a,O
range,O
of,O
developmental,O
stages,O
from,O
5,O
to,O
70,O
mm,O
in,O
length,O
",",O
via,O
SEM,O
.,O
Early,O
ear,O
development,O
preceded,O
normally,O
(,O
Fig,O
.,O
2B,O
"),",O
and,O
no,O
defects,O
were,O
observed,O
in,O
the,O
branch,O
meristem,O
",",O
spikelet,O
pair,O
meristem,O
",",O
or,O
spikelet,O
meristem,O
(,O
data,O
not,O
shown,O
).,O
An,O
aberrant,O
phenotype,O
first,O
became,O
apparent,O
in,O
the,O
ears,O
when,O
they,O
were,O
approximately,O
60,O
mm,O
long,O
(,O
Fig,O
.,O
2C,O
",",O
D,O
),O
at,O
which,O
time,O
they,O
were,O
sufficiently,O
well,O
developed,O
to,O
exhibit,O
some,O
florets,O
with,O
incompletely,O
fused,O
carpels,O
",",O
distinguished,O
by,O
an,O
open,O
stylar,O
canal,O
",",O
rather,O
than,O
the,O
completely,O
fused,O
carpels,O
observed,O
in,O
the,O
WT,O
(,O
Fig,O
.,O
2D,O
",",O
E,O
).,O
This,O
phenotype,O
was,O
particularly,O
prominent,O
in,O
the,O
more,O
advanced,O
ears,O
(>,O
60,O
mm,O
),O
(,O
Fig,O
.,O
2E,O
–,O
G,O
"),",O
especially,O
after,O
pollination,O
.,O
The,O
ifc,O
ovary,O
exhibited,O
an,O
incomplete,O
kernel,O
surface,O
with,O
a,O
distinct,O
transition,O
from,O
the,O
pericarp,O
to,O
the,O
seed,O
coat,O
(,O
Fig,O
.,O
2H,O
"),",O
which,O
was,O
completely,O
wrapped,O
inside,O
in,O
the,O
WT,O
kernel,O
(,O
Fig,O
.,O
2I,O
).,O
In,O
the,O
ifc,O
maize,B-OG
kernel,O
",",O
the,O
seed,O
coat,O
was,O
exposed,O
on,O
the,O
outside,O
(,O
Fig,O
.,O
2J,O
"),",O
without,O
a,O
covering,O
.,O
Additionally,O
",",O
the,O
aleurone,O
was,O
neatly,O
arranged,O
in,O
a,O
one,O
-,O
celled,O
layer,O
in,O
the,O
ifc,O
kernel,O
(,O
Fig,O
.,O
2K,O
).,O
Then,O
",",O
we,O
performed,O
histological,O
examination,O
of,O
the,O
kernels,O
after,O
pollination,O
to,O
examine,O
the,O
changes,O
in,O
the,O
kernel,O
surface,O
structure,O
.,O
It,O
was,O
found,O
that,O
the,O
seed,O
coat,O
gradually,O
became,O
a,O
thin,O
membrane,O
between,O
the,O
aleurone,O
and,O
the,O
pericarp,O
and,O
was,O
reduced,O
to,O
a,O
thin,O
remnant,O
in,O
both,O
the,O
WT,O
and,O
ifc,O
kernels,O
(,O
Fig,O
.,O
2L,O
–,O
O,O
).,O
While,O
the,O
arrangement,O
of,O
the,O
aleurone,O
layer,O
was,O
not,O
so,O
neat,O
in,O
the,O
ifc,O
kernels,O
as,O
in,O
the,O
WT,O
kernels,O
",",O
it,O
was,O
constrained,O
only,O
by,O
the,O
seed,O
coat,O
(,O
Fig,O
.,O
2N,O
",",O
O,O
).,O
Serial,O
observations,O
from,O
pistil,O
formation,O
to,O
the,O
mature,O
kernel,O
further,O
confirmed,O
that,O
there,O
was,O
no,O
ovary,O
wall,O
/,O
pericarp,O
on,O
the,O
surface,O
of,O
the,O
gap,O
.,O
Mapping,O
and,O
Analysis,O
of,O
Transcriptome,O
Sequence,O
Data,O
To,O
compare,O
the,O
transcriptomes,O
of,O
ifc,O
ovaries,O
and,O
WT,O
ovaries,O
",",O
we,O
conducted,O
high,O
-,O
throughput,O
RNA,O
-,O
seq,O
using,O
the,O
Illumina,O
HiSeq,O
-,O
2500,O
platform,O
.,O
Ovaries,O
were,O
collected,O
when,O
the,O
ifc,O
phenotype,O
first,O
became,O
apparent,O
(,O
Fig,O
.,O
1H,O
).,O
We,O
selected,O
this,O
stage,O
because,O
early,O
floral,O
organogenesis,O
could,O
not,O
be,O
identified,O
to,O
deviate,O
from,O
normal,O
development,O
",",O
and,O
at,O
later,O
stages,O
",",O
the,O
aberrant,O
phenotype,O
became,O
particularly,O
prominent,O
and,O
was,O
farther,O
away,O
from,O
the,O
point,O
of,O
complete,O
carpel,O
fusion,O
in,O
the,O
WT,O
ovary,O
(,O
Figure,O
S1,O
).,O
Three,O
biological,O
replicates,O
for,O
both,O
phenotypes,O
were,O
collected,O
for,O
the,O
production,O
of,O
RNA,O
-,O
seq,O
libraries,O
.,O
Sequencing,O
resulted,O
in,O
an,O
average,O
of,O
52,O
million,O
paired,O
-,O
end,O
reads,O
(,O
125,O
-,O
bp,O
read,O
length,O
),O
for,O
each,O
sample,O
(,O
Figure,O
S2A,O
;,O
Table,O
S3,O
).,O
We,O
checked,O
the,O
quality,O
of,O
the,O
generated,O
reads,O
and,O
mapped,O
them,O
to,O
the,O
maize,B-OG
reference,O
genome,O
(,O
ZmB73_RefGen_v3,O
),O
29,O
(,O
Table,O
S3,O
).,O
Among,O
the,O
resulting,O
mapped,O
reads,O
",",O
an,O
average,O
of,O
81,O
.,O
4,O
%,O
of,O
the,O
reads,O
mapped,O
to,O
a,O
unique,O
position,O
in,O
the,O
genome,O
(,O
Fig,O
.,O
3A,O
"),",O
and,O
89,O
.,O
7,O
%,O
of,O
the,O
reads,O
mapped,O
to,O
exonic,O
sequences,O
(,O
Fig,O
.,O
3B,O
).,O
Moreover,O
",",O
among,O
the,O
reads,O
that,O
mapped,O
to,O
splice,O
events,O
and,O
splice,O
junctions,O
",",O
94,O
.,O
8,O
%,O
and,O
76,O
.,O
3,O
"%,",O
respectively,O
",",O
were,O
annotated,O
(,O
Figure,O
S2B,O
",",O
C,O
).,O
The,O
genomic,O
distribution,O
of,O
the,O
RNA,O
-,O
seq,O
reads,O
demonstrated,O
that,O
the,O
majority,O
of,O
the,O
detected,O
genes,O
were,O
predicted,O
in,O
the,O
maize,B-OG
annotation,O
.,O
The,O
exonic,O
reads,O
were,O
then,O
subjected,O
to,O
Cufflinks,O
assembly30,O
and,O
reported,O
as,O
fragments,O
per,O
kilobase,O
of,O
transcript,O
per,O
million,O
mapped,O
reads,O
(,O
FPKM,O
),O
31,O
.,O
A,O
gene,O
was,O
considered,O
to,O
be,O
expressed,O
in,O
a,O
given,O
sample,O
if,O
the,O
lower,O
boundary,O
of,O
its,O
FPKM,O
95,O
%,O
confidence,O
interval,O
(,O
FPKM_conf_lo,O
),O
was,O
greater,O
than,O
zero32,O
.,O
Based,O
on,O
this,O
criterion,O
",",O
we,O
identified,O
a,O
total,O
of,O
35,O
",",O
905,O
(,O
90,O
.,O
6,O
%,O
of,O
total,O
),O
genes,O
that,O
were,O
expressed,O
in,O
at,O
least,O
one,O
of,O
the,O
six,O
samples,O
(,O
Table,O
S4,O
).,O
Pairwise,O
Spearman,O
correlation,O
coefficient,O
(,O
SCC,O
),O
analysis,O
showed,O
that,O
the,O
triplicate,O
FPKM,O
values,O
from,O
both,O
the,O
WT,O
and,O
ifc,O
ovaries,O
were,O
highly,O
correlated,O
(,O
r,O
=,O
0,O
.,O
96,O
to,O
0,O
.,O
98,O
;,O
Figure,O
S3,O
"),",O
indicating,O
high,O
reproducibility,O
of,O
the,O
RNA,O
-,O
seq,O
experiments,O
.,O
The,O
proportions,O
of,O
genes,O
exhibiting,O
high,O
expression,O
(,O
FPKM,O
≥,O
10,O
"),",O
intermediate,O
expression,O
(,O
2,O
≤,O
FPKM,O
<,O
10,O
"),",O
and,O
low,O
expression,O
(,O
FPKM,O
<,O
2,O
),O
were,O
relatively,O
similar,O
in,O
the,O
two,O
phenotypes,O
(,O
Fig,O
.,O
3C,O
;,O
Table,O
S5,O
).,O
There,O
was,O
little,O
variation,O
in,O
the,O
total,O
number,O
and,O
distribution,O
of,O
the,O
abundance,O
of,O
genes,O
represented,O
in,O
the,O
two,O
phenotypes,O
",",O
similar,O
to,O
other,O
transcriptomic,O
studies,O
on,O
ear,O
development,O
mutant33,O
.,O
Taken,O
together,O
",",O
our,O
analysis,O
of,O
transcriptome,O
sequence,O
data,O
indicates,O
that,O
we,O
obtained,O
sufficient,O
coverage,O
of,O
the,O
mRNA,O
population,O
to,O
distinguish,O
the,O
functional,O
complexity,O
of,O
gene,O
networks,O
associated,O
with,O
carpel,O
fusion,O
.,O
The,O
ifc,O
and,O
WT,O
Ovaries,O
Exhibit,O
Distinct,O
mRNA,O
Populations,O
We,O
employed,O
Cuffdiff30,O
to,O
identify,O
differentially,O
expressed,O
genes,O
",",O
using,O
the,O
following,O
criteria,O
:,O
fold,O
change,O
>,O
1,O
.,O
5,O
between,O
WT,O
and,O
ifc,O
",",O
p,O
value,O
<,O
0,O
.,O
05,O
",",O
and,O
FPKM,O
value,O
>,O
2,O
in,O
at,O
least,O
one,O
of,O
the,O
samples,O
(,O
Table,O
S6,O
).,O
This,O
analysis,O
identified,O
a,O
total,O
of,O
877,O
differentially,O
expressed,O
genes,O
between,O
the,O
two,O
phenotypes,O
(,O
Table,O
S7,O
"),",O
representing,O
3,O
.,O
5,O
%,O
of,O
the,O
ovary,O
expressed,O
genes,O
(,O
25,O
",",O
369,O
),O
identified,O
in,O
the,O
two,O
phenotypes,O
.,O
Because,O
the,O
WT,O
and,O
ifc,O
mutant,O
ovaries,O
came,O
from,O
the,O
same,O
ear,O
",",O
this,O
indicated,O
that,O
most,O
of,O
the,O
detected,O
genes,O
displayed,O
similar,O
expression,O
levels,O
between,O
WT,O
and,O
ifc,O
.,O
Compared,O
with,O
WT,O
",",O
592,O
genes,O
were,O
up,O
-,O
regulated,O
in,O
ifc,O
mutant,O
ovaries,O
",",O
and,O
285,O
genes,O
were,O
down,O
-,O
regulated,O
(,O
Table,O
S7,O
).,O
We,O
detected,O
a,O
small,O
fraction,O
of,O
transcripts,O
derived,O
from,O
transposable,O
elements,O
(,O
TEs,O
),O
annotated,O
in,O
release,O
5b,O
.,O
60,O
",",O
with,O
an,O
average,O
of,O
2,O
",",O
996,O
expressed,O
TEs,O
in,O
both,O
phenotypes,O
(,O
Table,O
S8,O
).,O
To,O
confirm,O
the,O
differential,O
expression,O
identified,O
by,O
RNA,O
-,O
seq,O
analysis,O
",",O
we,O
used,O
qRT,O
-,O
PCR,O
to,O
validate,O
the,O
expression,O
levels,O
of,O
39,O
transcripts,O
and,O
of,O
which,O
37,O
(,O
94,O
.,O
9,O
%),O
showed,O
expression,O
level,O
differences,O
consistent,O
with,O
the,O
transcriptomic,O
data,O
(,O
Figs,O
4,O
and,O
5,O
).,O
Additionally,O
",",O
24,O
genes,O
with,O
differential,O
expression,O
at,O
a,O
fold,O
change,O
of,O
2,O
or,O
bigger,O
than,O
1,O
.,O
5,O
were,O
also,O
confirmed,O
by,O
qRT,O
-,O
PCR,O
among,O
all,O
the,O
39,O
selected,O
genes,O
(,O
Fig,O
.,O
5,O
).,O
The,O
results,O
showed,O
that,O
22,O
genes,O
had,O
a,O
significant,O
difference,O
based,O
on,O
one,O
-,O
tailed,O
t,O
-,O
test,O
analysis,O
",",O
which,O
indicated,O
that,O
the,O
differences,O
in,O
gene,O
expression,O
were,O
well,O
confirmed,O
by,O
qRT,O
-,O
PCR,O
",",O
as,O
shown,O
in,O
Figs,O
4,O
and,O
5,O
.,O
Functions,O
of,O
Differentially,O
Expressed,O
Genes,O
Between,O
Wild,O
-,O
type,O
and,O
Carpel,O
Fusion,O
Deficient,O
Ovaries,O
A,O
Gene,O
Ontology,O
(,O
GO,O
),O
term,O
enrichment,O
analysis,O
of,O
the,O
differentially,O
expressed,O
genes,O
between,O
WT,O
and,O
ifc,O
mutant,O
ovaries,O
was,O
performed,O
.,O
The,O
represented,O
biological,O
processes,O
corresponded,O
to,O
the,O
regulation,O
of,O
transcription,O
",",O
transport,O
",",O
and,O
metabolic,O
processes,O
(,O
Fig,O
.,O
6A,O
;,O
Figure,O
S4,O
;,O
Table,O
S9,O
).,O
Among,O
the,O
genes,O
that,O
were,O
up,O
-,O
regulated,O
in,O
the,O
ifc,O
mutant,O
ovary,O
",",O
the,O
categories,O
of,O
DNA,O
replication,O
",",O
nucleus,O
",",O
cell,O
wall,O
",",O
and,O
DNA,O
binding,O
were,O
overrepresented,O
",",O
suggesting,O
that,O
cell,O
division,O
",",O
elongation,O
",",O
and,O
expansion,O
were,O
active,O
in,O
ifc,O
ovaries,O
(,O
Fig,O
.,O
6A,O
;,O
Figures,O
S5,O
and,O
6,O
;,O
Table,O
S9,O
).,O
Genes,O
associated,O
with,O
the,O
stress,O
response,O
and,O
water,O
deprivation,O
were,O
also,O
up,O
-,O
regulated,O
in,O
ifc,O
mutant,O
ovaries,O
.,O
Genes,O
that,O
were,O
down,O
-,O
regulated,O
in,O
ifc,O
mutant,O
ovaries,O
showed,O
enrichment,O
in,O
the,O
functions,O
of,O
DNA,O
biological,O
processes,O
that,O
are,O
primarily,O
involved,O
in,O
DNA,O
binding,O
",",O
regulation,O
of,O
transcription,O
",",O
and,O
metal,O
ion,O
transport,O
(,O
Figure,O
S4,O
;,O
Table,O
S9,O
).,O
One,O
down,O
-,O
regulated,O
gene,O
",",O
GRMZM2G160730,B-GP
",",O
which,O
encodes,O
a,O
protein,O
related,O
to,O
the,O
specification,O
of,O
organ,O
identity,O
",",O
was,O
also,O
included,O
.,O
The,O
protein,O
has,O
two,O
predicted,O
AP2,B-GP
domains,O
",",O
and,O
it,O
has,O
been,O
reported,O
that,O
genes,O
within,O
this,O
character,O
in,O
AP2,B-GP
family,O
are,O
involved,O
in,O
gynoecium,O
development2634,O
.,O
We,O
used,O
MapMan35,O
to,O
explore,O
the,O
differential,O
biological,O
pathways,O
between,O
the,O
WT,O
and,O
ifc,O
ovaries,O
.,O
Twenty,O
-,O
four,O
biological,O
pathways,O
were,O
partitioned,O
between,O
WT,O
and,O
ifc,O
mutant,O
ovaries,O
(,O
Fig,O
.,O
6B,O
).,O
Interestingly,O
",",O
genes,O
involved,O
in,O
the,O
hormone,O
metabolism,O
of,O
ethylene,O
",",O
auxin,O
",",O
and,O
jasmonate,O
were,O
overrepresented,O
in,O
ifc,O
ovaries,O
",",O
whereas,O
genes,O
related,O
to,O
auxin,O
signaling,O
were,O
overrepresented,O
in,O
WT,O
ovaries,O
(,O
Fig,O
.,O
6B,O
",",O
C,O
;,O
Table,O
S10,O
"),",O
which,O
indicates,O
that,O
the,O
complex,O
hormone,O
regulation,O
network,O
is,O
altered,O
between,O
WT,O
and,O
ifc,O
ovaries,O
.,O
Together,O
",",O
these,O
data,O
demonstrate,O
that,O
the,O
major,O
differences,O
in,O
the,O
ifc,O
mutant,O
ovary,O
are,O
reflected,O
in,O
part,O
by,O
transcription,O
regulation,O
and,O
hormone,O
signaling,O
networks,O
.,O
Differential,O
Expression,O
of,O
TFs,B-GP
between,O
the,O
WT,O
and,O
ifc,O
Ovary,O
To,O
investigate,O
potential,O
regulators,O
involved,O
in,O
ovary,O
wall,O
formation,O
",",O
we,O
focused,O
our,O
analysis,O
on,O
TF,B-GP
genes,O
exhibiting,O
differential,O
expression,O
between,O
WT,O
and,O
ifc,O
ovaries,O
.,O
Collectively,O
",",O
among,O
the,O
1,O
",",O
341,O
expressed,O
TFs,B-GP
detected,O
in,O
association,O
with,O
the,O
two,O
phenotypes,O
",",O
88,O
were,O
differentially,O
expressed,O
(,O
with,O
FPKM,O
>,O
2,O
in,O
at,O
least,O
one,O
of,O
the,O
samples,O
"),",O
which,O
were,O
classified,O
into,O
27,O
TF,B-GP
families,O
(,O
Fig,O
.,O
7A,O
",",O
B,O
;,O
Table,O
S11,O
),O
according,O
to,O
the,O
Plant,B-OG
Transcription,B-GP
Factor,I-GP
database,O
v3,O
.,O
036,O
.,O
Overall,O
",",O
two,O
-,O
thirds,O
of,O
the,O
TFs,B-GP
were,O
up,O
-,O
regulated,O
in,O
the,O
ifc,O
mutant,O
ovary,O
(,O
Fig,O
.,O
7A,O
;,O
Table,O
S11,O
).,O
Statistical,O
analysis,O
according,O
to,O
the,O
hypergeometric,O
distribution,O
showed,O
that,O
10,O
TF,B-GP
families,O
were,O
significantly,O
differentially,O
expressed,O
",",O
among,O
which,O
the,O
WRKY,B-GP
",",O
HD,O
-,O
ZIP,O
",",O
bHLH,B-GP
",",O
ERF,B-GP
",",O
RAV,B-GP
",",O
and,O
NAC,B-GP
families,O
were,O
significantly,O
up,O
-,O
regulated,O
in,O
the,O
ifc,O
ovary,O
",",O
while,O
the,O
G2,B-GP
-,I-GP
like,I-GP
family,I-GP
was,O
significantly,O
down,O
-,O
regulated,O
(,O
p,O
<,O
0,O
.,O
05,O
",",O
hypergeometric,O
test,O
).,O
While,O
the,O
C2H2,B-GP
",",O
AP2,B-GP
",",O
and,O
MYB,B-GP
TF,B-GP
families,O
were,O
also,O
significantly,O
differentially,O
expressed,O
(,O
p,O
<,O
0,O
.,O
05,O
",",O
hypergeometric,O
test,O
),O
(,O
Table,O
S12,O
).,O
Two,O
members,O
of,O
the,O
differentially,O
expressed,O
NAC,B-GP
family,O
",",O
GRMZM5G898290,B-GP
and,O
GRMZM2G009892,B-GP
",",O
shared,O
81,O
.,O
75,O
%,O
and,O
80,O
.,O
16,O
%,O
identity,O
",",O
respectively,O
",",O
with,O
the,O
AtCUC2,B-GP
protein,O
of,O
Arabidopsis,B-OG
in,O
the,O
conserved,O
NAM,O
domain,O
at,O
the,O
amino,O
acid,O
sequence,O
level,O
.,O
These,O
results,O
suggest,O
putative,O
functions,O
of,O
the,O
two,O
NAC,B-GP
genes,O
in,O
carpel,O
development,O
given,O
that,O
overexpression,O
of,O
AtCUC2,B-GP
prevents,O
congenital,O
carpel,O
fusion,O
in,O
Arabidopsis15,O
.,O
Basic,B-GP
helix,I-GP
-,I-GP
loop,I-GP
-,I-GP
helix,I-GP
(,I-GP
bHLH,I-GP
),I-GP
TFs,I-GP
have,O
been,O
associated,O
with,O
the,O
regulation,O
of,O
diverse,O
processes,O
",",O
including,O
organ,O
morphogenesis,O
",",O
anthocyanin,O
production,O
",",O
trichome,O
development,O
",",O
and,O
light,O
signaling,O
through,O
phytochromes10,O
.,O
In,O
this,O
study,O
",",O
eight,O
members,O
of,O
the,O
bHLH,B-GP
family,O
of,O
TFs,B-GP
were,O
found,O
to,O
present,O
differential,O
expression,O
",",O
and,O
seven,O
members,O
were,O
up,O
regulated,O
in,O
the,O
ifc,O
mutant,O
ovary,O
.,O
One,O
of,O
these,O
TFs,B-GP
",",O
GRMZM2G094892,B-GP
",",O
showed,O
a,O
predicted,O
amino,O
acid,O
sequence,O
similarity,O
of,O
78,O
.,O
12,O
%,O
in,O
the,O
HLH,B-GP
superfamily,O
DNA,O
binding,O
domain,O
with,O
the,O
HECATE1,B-GP
protein,O
",",O
a,O
known,O
regulator,O
of,O
carpel,O
development,O
in,O
Arabidopsis37,O
.,O
The,O
up,O
-,O
regulation,O
of,O
bHLH,B-GP
TFs,B-GP
in,O
the,O
ifc,O
mutant,O
ovary,O
is,O
consistent,O
with,O
their,O
reported,O
role,O
in,O
initiating,O
gynoecium,O
development,O
in,O
Arabidopsis37,O
.,O
The,O
TFs,B-GP
C2H2,B-GP
and,O
MYB,B-GP
were,O
also,O
differentially,O
expressed,O
between,O
ifc,O
mutant,O
ovaries,O
and,O
WT,O
ovaries,O
",",O
most,O
of,O
which,O
are,O
associated,O
with,O
floral,O
organ,O
-,O
specific,O
transcriptional,O
regulation3839,O
.,O
In,O
this,O
study,O
",",O
we,O
identified,O
GRMZM2G160840,B-GP
as,O
showing,O
77,O
.,O
66,O
%,O
amino,O
acid,O
sequence,O
identity,O
to,O
the,O
AtMYB21,B-GP
protein,O
in,O
the,O
conserved,O
DNA,O
binding,O
domain,O
",",O
whose,O
ectopic,O
expression,O
causes,O
malformation,O
of,O
various,O
flower,O
tissues,O
",",O
including,O
hooked,O
and,O
twisted,O
carpels38,O
.,O
One,O
C2H2,B-GP
family,O
member,O
",",O
GRMZM2G058868,B-GP
",",O
a,O
homolog,O
of,O
Arabidopsis,B-OG
ZFP10,B-GP
",",O
showed,O
88,O
%,O
similarity,O
to,O
the,O
SUPERMAN,B-GP
protein,O
in,O
the,O
single,O
zinc,O
finger,O
domain,O
.,O
These,O
results,O
suggest,O
the,O
transcriptional,O
regulation,O
of,O
gene,O
expression,O
underlying,O
the,O
carpel,O
wall,O
fusion,O
event,O
.,O
However,O
",",O
we,O
note,O
that,O
these,O
predicted,O
TFs,B-GP
require,O
further,O
experimental,O
validation,O
",",O
such,O
as,O
genetic,O
regulation,O
network,O
analysis,O
and,O
more,O
precise,O
mapping,O
and,O
functional,O
studies,O
.,O
Differentially,O
Expressed,O
Genes,O
Participate,O
in,O
Hormone,O
Responses,O
and,O
Biosynthesis,O
Our,O
transcriptome,O
analysis,O
revealed,O
several,O
genes,O
that,O
participate,O
in,O
biosynthesis,O
",",O
signaling,O
",",O
and,O
the,O
response,O
components,O
of,O
hormonal,O
pathways,O
.,O
Auxin,O
is,O
a,O
major,O
controlling,O
signal,O
that,O
synchronizes,O
flower,O
development,O
and,O
controls,O
carpel,O
marginal,O
tissue,O
formation,O
during,O
gynoecium,O
morphogenesis20,O
in,O
Arabidopsis,B-OG
.,O
Genes,O
involved,O
in,O
auxin,O
biosynthesis,O
and,O
responses,O
were,O
represented,O
in,O
the,O
list,O
of,O
differentially,O
expressed,O
genes,O
.,O
Two,O
members,O
of,O
the,O
SAUR,B-GP
-,I-GP
auxin,I-GP
-,I-GP
responsive,I-GP
(,I-GP
SAUR,I-GP
),I-GP
families,I-GP
were,O
down,O
-,O
regulated,O
",",O
and,O
one,O
was,O
up,O
-,O
regulated,O
in,O
the,O
ifc,O
mutant,O
ovary,O
(,O
Fig,O
.,O
8,O
).,O
One,O
Auxin,O
(,O
Aux,O
)/,O
Indole,O
-,O
3,O
-,O
Acetic,O
Acid,O
(,O
IAA,O
),O
family,O
member,O
",",O
IAA8,B-GP
",",O
whose,O
homolog,O
is,O
involved,O
in,O
hormonal,O
signaling,O
pathways,O
in,O
Arabidopsis21,O
",",O
was,O
also,O
down,O
-,O
regulated,O
.,O
In,O
contrast,O
",",O
four,O
key,O
genes,O
involved,O
in,O
auxin,O
biosynthesis,O
were,O
up,O
-,O
regulated,O
.,O
The,O
expression,O
levels,O
of,O
indole,B-GP
-,I-GP
3,I-GP
-,I-GP
glycerol,I-GP
phosphate,I-GP
lyase,I-GP
and,O
indole,B-GP
-,I-GP
3,I-GP
-,I-GP
acetate,I-GP
beta,I-GP
-,I-GP
glucosyl,I-GP
transferase,I-GP
",",O
which,O
have,O
been,O
described,O
in,O
auxin,O
conjugation40,O
",",O
were,O
up,O
-,O
regulated,O
(,O
Fig,O
.,O
8,O
).,O
Additionally,O
",",O
Cytokinin,B-GP
-,I-GP
O,I-GP
-,I-GP
glucosyltransferase,I-GP
",",O
an,O
enzyme,O
that,O
catalyzes,O
the,O
formation,O
of,O
glucosides,O
from,O
CK,O
",",O
was,O
down,O
-,O
regulated,O
in,O
the,O
ifc,O
mutant,O
ovary,O
.,O
Another,O
differentially,O
expressed,O
gene,O
homolog,O
to,O
Arabidopsis,B-OG
response,B-GP
regulator,I-GP
9,I-GP
(,O
ARR9,B-GP
"),",O
a,O
member,O
of,O
the,O
type,B-GP
-,I-GP
A,I-GP
ARR,I-GP
proteins,O
",",O
was,O
down,O
-,O
regulated,O
in,O
the,O
ifc,O
mutant,O
ovary,O
(,O
Fig,O
.,O
8,O
).,O
Type,B-GP
-,I-GP
A,I-GP
ARRs,I-GP
exhibit,O
short,O
C,O
-,O
terminal,O
domains,O
and,O
are,O
rapidly,O
transcriptionally,O
up,O
-,O
regulated,O
by,O
CK,O
treatment41,O
.,O
Genes,O
involved,O
in,O
gibberellin,O
biosynthesis,O
and,O
responses,O
and,O
genes,O
encoding,O
JASMONATE,O
Zim,O
-,O
domain,O
(,O
JAZ,B-GP
)/,O
TIFY,B-GP
proteins,O
were,O
also,O
present,O
in,O
the,O
list,O
of,O
differentially,O
expressed,O
genes,O
.,O
JAZ,B-GP
proteins,O
belong,O
to,O
the,O
larger,O
family,O
of,O
TIFY,B-GP
proteins42,O
.,O
Recently,O
",",O
JASMONATE,B-GP
ZIM,I-GP
-,I-GP
domain,I-GP
(,I-GP
JAZ,I-GP
),I-GP
proteins,I-GP
have,O
been,O
identified,O
as,O
repressors,O
of,O
Jasmonic,O
Acid,O
(,O
JA,O
),O
signaling43,O
.,O
Expression,O
of,O
JAZ1,B-GP
/,O
TIFY10A,B-GP
can,O
be,O
induced,O
by,O
JA,O
",",O
which,O
is,O
also,O
an,O
early,O
auxin,O
-,O
responsive,O
gene44,O
.,O
In,O
this,O
study,O
",",O
nine,O
differentially,O
expressed,O
homologs,O
of,O
Arabidopsis,B-OG
JAZ,B-GP
/,O
TIFY,B-GP
were,O
found,O
to,O
be,O
up,O
-,O
regulated,O
.,O
Additionally,O
",",O
two,O
GID1L2,B-GP
gibberellin,B-GP
receptor,I-GP
genes,O
were,O
up,O
-,O
regulated,O
in,O
the,O
ifc,O
mutant,O
ovary,O
",",O
while,O
one,O
was,O
down,O
-,O
regulated,O
.,O
Gibberellin,B-GP
20,I-GP
-,I-GP
oxidase,I-GP
and,O
gibberellin,B-GP
2,I-GP
-,I-GP
beta,I-GP
-,I-GP
dioxygenase,I-GP
",",O
which,O
are,O
enzymes,O
involved,O
in,O
the,O
biosynthetic,O
pathway,O
for,O
gibberellin,O
",",O
were,O
also,O
up,O
-,O
regulated,O
(,O
Fig,O
.,O
8,O
).,O
Together,O
",",O
these,O
results,O
indicated,O
the,O
complicated,O
roles,O
played,O
by,O
hormones,O
in,O
the,O
ifc,O
mutant,O
ovary,O
",",O
especially,O
in,O
the,O
case,O
of,O
auxin,O
and,O
CK,O
hormones,O
",",O
which,O
may,O
play,O
an,O
important,O
role,O
in,O
aberrant,O
carpel,O
fusion,O
in,O
ifc,O
ovaries,O
.,O
Discussion,O
Incompletely,O
Fused,O
Carpels,O
Affect,O
the,O
Integrity,O
of,O
the,O
Maize,B-OG
Kernel,O
Pericarp,O
",",O
Resulting,O
in,O
a,O
Gap,O
on,O
the,O
Top,O
According,O
to,O
botanical,O
definition,O
",",O
the,O
maize,B-OG
kernel,O
is,O
classified,O
as,O
a,O
caryopsis,O
",",O
a,O
complex,O
tissue,O
in,O
which,O
maternal,O
and,O
filial,O
tissues,O
follow,O
distinct,O
",",O
but,O
coordinated,O
developmental,O
programs,O
.,O
The,O
pericarp,O
consists,O
of,O
the,O
transformed,O
ovary,O
wall,O
covering,O
the,O
seed,O
.,O
Interestingly,O
",",O
the,O
ifc,O
mutant,O
exhibited,O
an,O
incomplete,O
kernel,O
surface,O
structure,O
.,O
Initially,O
",",O
we,O
suggested,O
either,O
an,O
incomplete,O
ovary,O
wall,O
or,O
overgrowth,O
of,O
nucellus,O
tissue,O
that,O
outgrows,O
the,O
ovary,O
wall,O
as,O
possible,O
explanations,O
for,O
the,O
ifc,O
phenotype,O
.,O
To,O
confirm,O
which,O
of,O
these,O
possible,O
developmental,O
changes,O
gave,O
rise,O
to,O
this,O
mutant,O
and,O
to,O
determine,O
the,O
emergence,O
of,O
the,O
phenotype,O
",",O
we,O
examined,O
the,O
development,O
of,O
the,O
florets,O
",",O
pistils,O
",",O
and,O
kernels,O
through,O
scanning,O
electron,O
microscopy,O
(,O
SEM,O
),O
(,O
Fig,O
.,O
2B,O
–,O
K,O
),O
and,O
based,O
on,O
histology,O
(,O
Fig,O
.,O
2L,O
–,O
O,O
).,O
The,O
ifc,O
kernel,O
had,O
a,O
gap,O
on,O
the,O
surface,O
with,O
a,O
distinct,O
structure,O
transition,O
.,O
The,O
gap,O
on,O
the,O
top,O
of,O
the,O
mature,O
kernel,O
was,O
located,O
at,O
the,O
same,O
position,O
as,O
the,O
stylar,O
canal,O
",",O
which,O
is,O
close,O
to,O
the,O
silk,O
and,O
back,O
to,O
the,O
embryo,O
(,O
Figs,O
1G,O
",",O
I,O
and,O
2A,O
).,O
Through,O
serial,O
observations,O
",",O
we,O
found,O
that,O
the,O
gap,O
on,O
the,O
top,O
of,O
the,O
ovary,O
was,O
first,O
observable,O
before,O
the,O
extruding,O
nucellus,O
(,O
Fig,O
.,O
1H,O
"),",O
and,O
the,O
protruding,O
nucellus,O
tissue,O
in,O
the,O
ifc,O
mutant,O
ovaries,O
may,O
therefore,O
not,O
be,O
due,O
to,O
overgrowth,O
of,O
the,O
tissue,O
",",O
but,O
rather,O
",",O
to,O
being,O
free,O
from,O
carpel,O
wall,O
constraints,O
.,O
These,O
findings,O
were,O
consistent,O
with,O
the,O
hypothesis,O
that,O
the,O
formation,O
of,O
the,O
gap,O
in,O
the,O
ifc,O
ovary,O
wall,O
is,O
derived,O
from,O
the,O
open,O
stylar,O
canal,O
due,O
to,O
its,O
incompletely,O
fused,O
carpels,O
.,O
Histological,O
examination,O
(,O
Fig,O
.,O
2L,O
–,O
O,O
),O
via,O
vertical,O
sectioning,O
of,O
the,O
ovaries,O
and,O
kernels,O
revealed,O
that,O
the,O
exposed,O
seed,O
coat,O
(,O
Fig,O
.,O
2M,O
–,O
O,O
),O
in,O
the,O
ifc,O
ovaries,O
lacked,O
pericarp,O
wrapping,O
.,O
However,O
",",O
the,O
structure,O
of,O
aleurone,O
layer,O
",",O
a,O
part,O
of,O
the,O
endosperm,O
",",O
was,O
not,O
affected,O
",",O
and,O
this,O
one,O
-,O
celled,O
layer,O
could,O
be,O
clearly,O
observed,O
under,O
the,O
thin,O
",",O
suberized,O
seed,O
coat,O
(,O
Fig,O
.,O
2O,O
).,O
The,O
pericarp,O
is,O
derived,O
from,O
the,O
carpel,O
wall,O
/,O
ovary,O
wall,O
",",O
and,O
along,O
with,O
defects,O
in,O
growth,O
and,O
development,O
",",O
the,O
ifc,O
kernels,O
lacked,O
pericarp,O
wrapping,O
on,O
the,O
gap,O
surface,O
.,O
Additionally,O
",",O
the,O
position,O
of,O
the,O
defect,O
fit,O
well,O
within,O
the,O
stylar,O
canal,O
(,O
Fig,O
.,O
1A,O
",",O
D,O
",",O
F,O
;,O
Fig,O
.,O
S1,O
).,O
Therefore,O
",",O
these,O
results,O
were,O
consistent,O
with,O
the,O
observations,O
from,O
SEM,O
analysis,O
",",O
indicating,O
that,O
the,O
gap,O
on,O
the,O
top,O
of,O
the,O
ifc,O
kernel,O
may,O
be,O
an,O
open,O
stylar,O
canal,O
resulting,O
from,O
incompletely,O
fused,O
carpels,O
.,O
The,O
stylar,O
canal,O
is,O
an,O
opening,O
through,O
the,O
ovary,O
wall,O
(,O
pericarp,O
),O
and,O
has,O
been,O
reported,O
as,O
location,O
of,O
infections,B-DS
because,O
it,O
allows,O
fungal,O
pathogens,O
to,O
enter,O
unwounded,O
kernels,O
",",O
with,O
the,O
severity,O
of,O
infection,B-DS
depending,O
on,O
the,O
degree,O
of,O
opening,O
of,O
the,O
canal5,O
.,O
In,O
the,O
ifc,O
ovary,O
",",O
the,O
length,O
of,O
the,O
silk,O
derived,O
from,O
the,O
two,O
abaxial,O
carpels,O
(,O
Table,O
S1,O
),O
displayed,O
no,O
difference,O
from,O
the,O
length,O
of,O
silk,O
in,O
the,O
wild,O
-,O
type,O
ovary,O
.,O
Both,O
the,O
length,O
of,O
the,O
silk,O
in,O
the,O
ifc,O
ovary,O
and,O
the,O
ability,O
to,O
undergo,O
fertilization,O
(,O
assessed,O
based,O
on,O
the,O
development,O
of,O
ifc,O
kernels,O
on,O
different,O
days,O
after,O
pollination,O
),O
were,O
normal,O
(,O
Fig,O
.,O
S1,O
).,O
Nevertheless,O
",",O
the,O
stylar,O
canal,O
was,O
open,O
in,O
the,O
ifc,O
ovary,O
",",O
as,O
shown,O
in,O
Fig,O
.,O
2C,O
",",O
which,O
showed,O
the,O
ifc,O
ovary,O
and,O
its,O
wild,O
type,O
on,O
the,O
same,O
position,O
in,O
the,O
same,O
ear,O
when,O
carpel,O
fusion,O
defects,O
could,O
be,O
morphologically,O
distinguished,O
.,O
Compared,O
with,O
the,O
normal,O
ovary,O
",",O
the,O
ifc,O
ovary,O
exhibited,O
normal,O
length,O
of,O
the,O
silk,O
derived,O
from,O
the,O
fusion,O
of,O
abaxial,O
carpels,O
but,O
presented,O
an,O
open,O
stylar,O
canal,O
resulting,O
from,O
the,O
fusion,O
of,O
the,O
third,O
carpel,O
with,O
the,O
abaxial,O
carpels,O
.,O
In,O
contrast,O
to,O
the,O
closed,O
stylar,O
canal,O
of,O
the,O
wild,O
-,O
type,O
ovary,O
",",O
it,O
is,O
clear,O
that,O
the,O
open,O
stylar,O
canal,O
of,O
the,O
ifc,O
ovary,O
is,O
due,O
to,O
insufficient,O
growth,O
of,O
the,O
third,O
carpel,O
.,O
This,O
conclusion,O
is,O
consistent,O
with,O
previous,O
findings,O
that,O
the,O
aberrant,O
development,O
of,O
the,O
third,O
carpel,O
has,O
no,O
effect,O
on,O
the,O
other,O
two,O
carpels3,O
.,O
For,O
example,O
",",O
the,O
third,O
carpel,O
gives,O
rise,O
to,O
two,O
ovules,O
",",O
but,O
the,O
other,O
two,O
carpels,O
can,O
normally,O
develop,O
into,O
silk,O
",",O
which,O
grows,O
indeterminately,O
to,O
form,O
the,O
longest,O
stigma,O
of,O
any,O
species3,O
.,O
Maize,B-OG
WT,O
and,O
ifc,O
ovaries,O
can,O
be,O
distinguished,O
by,O
their,O
capacity,O
to,O
produce,O
completely,O
fused,O
carpels4,O
.,O
Interestingly,O
",",O
kernels,O
on,O
the,O
same,O
ear,O
displayed,O
different,O
pericarp,O
integrities,O
.,O
In,O
the,O
WT,O
kernel,O
",",O
the,O
pericarp,O
was,O
intact,O
with,O
a,O
closed,O
stylar,O
canal,O
",",O
while,O
in,O
the,O
ifc,O
ovary,O
",",O
there,O
was,O
a,O
gap,O
at,O
the,O
top,O
of,O
the,O
kernel,O
",",O
resulting,O
from,O
incompletely,O
fused,O
carpels,O
.,O
One,O
explanation,O
for,O
the,O
difference,O
between,O
the,O
WT,O
and,O
ifc,O
mutant,O
ovaries,O
is,O
differential,O
gene,O
expression,O
.,O
To,O
better,O
understand,O
the,O
molecular,O
basis,O
of,O
this,O
variation,O
",",O
we,O
performed,O
transcriptome,O
analysis,O
at,O
a,O
stage,O
when,O
the,O
incompletely,O
fused,O
carpels,O
were,O
just,O
beginning,O
to,O
be,O
distinguishable,O
.,O
Analysis,O
of,O
Transcriptional,O
Changes,O
Outlining,O
the,O
Main,O
Molecular,O
Processes,O
in,O
the,O
ifc,O
Ovary,O
We,O
performed,O
deep,O
transcriptomic,O
surveys,O
of,O
the,O
WT,O
and,O
ifc,O
ovaries,O
in,O
maize,B-OG
using,O
RNA,O
-,O
seq,O
technology,O
.,O
The,O
total,O
number,O
of,O
expressed,O
mRNAs,O
was,O
approximately,O
35,O
",",O
000,O
",",O
which,O
is,O
equivalent,O
to,O
the,O
number,O
of,O
identified,O
in,O
a,O
recent,O
profiling,O
analysis,O
of,O
maize,B-OG
kernel,O
samples,O
from,O
8,O
–,O
12,O
DAP45,O
.,O
These,O
similar,O
numbers,O
suggest,O
that,O
our,O
sequencing,O
procedure,O
was,O
sufficient,O
to,O
thoroughly,O
capture,O
nearly,O
all,O
genes,O
expressed,O
in,O
maize,B-OG
kernels,O
.,O
A,O
total,O
of,O
877,O
differentially,O
expressed,O
genes,O
were,O
detected,O
in,O
the,O
present,O
study,O
(,O
Fig,O
.,O
3C,O
;,O
Table,O
S7,O
"),",O
some,O
of,O
which,O
might,O
form,O
a,O
complex,O
transcriptional,O
regulatory,O
network,O
that,O
plays,O
an,O
important,O
part,O
in,O
the,O
development,O
of,O
carpels,O
",",O
as,O
suggested,O
previously,O
for,O
Arabidopsis1546,O
.,O
In,O
the,O
ifc,O
mutant,O
ovary,O
",",O
the,O
exposed,O
nucellus,O
produced,O
from,O
the,O
ovule,O
primordium,O
without,O
constraint,O
by,O
the,O
carpels,O
has,O
the,O
potential,O
to,O
become,O
a,O
large,O
mass,O
of,O
tissue,O
and,O
be,O
extruded,O
from,O
the,O
surrounding,O
carpel,O
wall,O
(,O
Fig,O
.,O
1H,O
",",O
J,O
).,O
In,O
the,O
ifc,O
ovary,O
",",O
a,O
number,O
of,O
differentially,O
expressed,O
genes,O
associated,O
with,O
cell,O
wall,O
biosynthesis,O
were,O
overrepresented,O
.,O
Cell,O
divisions,O
leading,O
to,O
nucellus,O
meristems,O
might,O
provide,O
a,O
large,O
number,O
of,O
new,O
meristematic,O
cells,O
",",O
which,O
is,O
a,O
process,O
that,O
requires,O
enhanced,O
cell,O
wall,O
biosynthesis,O
.,O
Stress,O
-,O
related,O
genes,O
were,O
also,O
overrepresented,O
among,O
the,O
differentially,O
expressed,O
genes,O
.,O
The,O
major,O
function,O
of,O
the,O
endocarp,O
",",O
the,O
innermost,O
layer,O
of,O
the,O
pericarp,O
",",O
is,O
water,O
transport47,O
.,O
The,O
incompletely,O
fused,O
carpelsincompletely,O
fused,O
carpels,O
created,O
a,O
defective,O
ovary,O
wall,O
",",O
suggesting,O
that,O
the,O
normal,O
circulation,O
and,O
supply,O
of,O
water,O
via,O
the,O
ovary,O
wall,O
might,O
be,O
insufficient,O
.,O
This,O
could,O
lead,O
to,O
induction,O
of,O
stress,O
-,O
related,O
genes,O
in,O
the,O
ifc,O
mutant,O
ovary,O
.,O
Moreover,O
",",O
the,O
functional,O
category,O
of,O
transport,O
was,O
overrepresented,O
among,O
the,O
differentially,O
expressed,O
genes,O
.,O
It,O
is,O
not,O
surprising,O
given,O
that,O
the,O
pericarp,O
of,O
the,O
ifc,O
ovary,O
is,O
incomplete,O
",",O
and,O
there,O
is,O
a,O
gap,O
at,O
the,O
top,O
of,O
the,O
kernel,O
.,O
One,O
of,O
the,O
functions,O
of,O
the,O
pericarp,O
is,O
transportation,O
of,O
mineral,O
nutrients,O
and,O
small,O
molecules47,O
",",O
and,O
an,O
incomplete,O
ovary,O
wall,O
might,O
therefore,O
affect,O
the,O
normal,O
transport,O
of,O
mineral,O
nutrients,O
and,O
small,O
molecules,O
in,O
the,O
ifc,O
ovary,O
.,O
This,O
suggests,O
that,O
the,O
differentially,O
expressed,O
genes,O
in,O
this,O
category,O
are,O
a,O
result,O
of,O
changes,O
in,O
upstream,O
gene,O
expression,O
",",O
giving,O
rise,O
to,O
the,O
observed,O
phenotypic,O
variation,O
.,O
Transcription,B-GP
Factor,I-GP
Expression,O
Analysis,O
Indicates,O
Potential,O
Gene,O
Regulation,O
in,O
the,O
Carpel,O
Fusion,O
-,O
Deficient,O
Ovary,O
In,O
Arabidopsis,B-OG
",",O
at,O
least,O
86,O
genes,O
are,O
involved,O
in,O
the,O
processes,O
of,O
carpel,O
margin,O
meristem,O
and,O
carpel,O
marginal,O
tissue,O
development,O
",",O
and,O
at,O
least,O
57,O
(,O
65,O
%),O
of,O
these,O
genes,O
with,O
corresponding,O
mutant,O
phenotypes,O
in,O
the,O
gynoecium,O
are,O
TFs1,O
.,O
In,O
maize,B-OG
",",O
however,O
",",O
the,O
functions,O
of,O
TF,B-GP
genes,O
in,O
controlling,O
carpel,O
marginal,O
tissue,O
development,O
and,O
carpel,O
fusion,O
remain,O
largely,O
elusive,O
.,O
Hence,O
",",O
our,O
RNA,O
-,O
seq,O
dataset,O
might,O
serve,O
as,O
a,O
resource,O
for,O
developing,O
and,O
testing,O
hypotheses,O
regarding,O
the,O
regulatory,O
networks,O
that,O
govern,O
carpel,O
fusion,O
",",O
for,O
example,O
",",O
through,O
the,O
analysis,O
of,O
TFs,B-GP
with,O
differential,O
expression,O
levels,O
.,O
The,O
differential,O
expression,O
of,O
TF,B-GP
genes,O
suggests,O
a,O
role,O
of,O
some,O
of,O
these,O
genes,O
in,O
specifying,O
carpel,O
margin,O
fusion,O
development,O
.,O
For,O
instance,O
",",O
five,O
members,O
of,O
the,O
NAC,B-GP
",",O
bHLH,B-GP
",",O
C2H2,B-GP
",",O
and,O
MYB,B-GP
TF,B-GP
families,O
were,O
found,O
to,O
accumulate,O
preferentially,O
in,O
the,O
ifc,O
ovary,O
.,O
Mutation,O
of,O
these,O
TFs,B-GP
homologs,O
in,O
Arabidopsis,B-OG
resulted,O
in,O
carpel,O
fusion,O
defects15373839,O
",",O
implying,O
that,O
these,O
five,O
genes,O
show,O
a,O
high,O
probability,O
of,O
regulation,O
associated,O
with,O
carpel,O
fusion,O
in,O
maize,B-OG
.,O
The,O
genes,O
encoding,O
these,O
TFs,B-GP
are,O
excellent,O
candidates,O
for,O
future,O
functional,O
genomics,O
studies,O
to,O
dissect,O
carpel,O
fusion,O
development,O
in,O
maize,B-OG
.,O
It,O
is,O
noteworthy,O
that,O
a,O
maize,B-OG
homolog,O
of,O
AP2,B-GP
was,O
found,O
to,O
be,O
down,O
-,O
regulated,O
in,O
the,O
ifc,O
ovary,O
.,O
AP2,B-GP
",",O
a,O
class,O
A,O
gene,O
",",O
plays,O
a,O
central,O
role,O
in,O
establishing,O
the,O
floral,O
meristem,O
",",O
specifying,O
floral,O
organ,O
identity,O
",",O
and,O
regulating,O
floral,O
homeotic,O
gene,O
expression,O
in,O
Arabidopsis26,O
.,O
In,O
addition,O
",",O
in,O
strong,O
ap2,B-GP
mutants,O
",",O
carpel,O
fusion,O
is,O
often,O
defective48,O
.,O
In,O
Arabidopsis,B-OG
",",O
the,O
specification,O
of,O
carpel,O
identity,O
is,O
achieved,O
through,O
at,O
least,O
two,O
separate,O
pathways,O
.,O
Both,O
pathways,O
are,O
negatively,O
regulated,O
by,O
class,O
A,O
genes49,O
.,O
The,O
SPT,B-GP
gene,O
",",O
a,O
component,O
of,O
the,O
AG,B-GP
-,O
independent,O
pathway49,O
",",O
has,O
been,O
shown,O
to,O
interact,O
with,O
three,O
HECATE1,B-GP
proteins,O
in,O
yeast,B-OG
two,O
-,O
hybrid,O
experiments37,O
.,O
The,O
transcription,B-GP
factor,I-GP
GRMZM2G094892,B-GP
",",O
which,O
is,O
78,O
.,O
12,O
%,O
identical,O
with,O
HECATE1,B-GP
in,O
the,O
amino,O
acid,O
sequence,O
of,O
conserved,O
domains,O
",",O
was,O
up,O
-,O
regulated,O
in,O
the,O
ifc,O
ovary,O
.,O
Therefore,O
",",O
we,O
propose,O
that,O
GRMZM2G094892,B-GP
is,O
one,O
component,O
of,O
the,O
AG,B-GP
-,O
independent,O
pathway,O
and,O
is,O
negatively,O
regulated,O
by,O
AP2,B-GP
in,O
maize,B-OG
.,O
Expression,O
of,O
Hormone,O
-,O
Related,O
Genes,O
in,O
the,O
Carpel,O
Fusion,O
-,O
Deficient,O
Ovary,O
Analysis,O
of,O
the,O
expression,O
of,O
genes,O
involved,O
in,O
the,O
biosynthesis,O
and,O
signaling,O
of,O
different,O
plant,B-OG
hormones,O
provided,O
evidence,O
that,O
these,O
genes,O
also,O
play,O
an,O
important,O
role,O
in,O
normal,O
carpel,O
marginal,O
tissue,O
development,O
.,O
Two,O
auxin,O
-,O
responsive,O
genes,O
were,O
differentially,O
expressed,O
(,O
Fig,O
.,O
7B,O
).,O
Mutations,O
in,O
genes,O
involved,O
in,O
ARF,B-GP
TFs,B-GP
have,O
been,O
shown,O
to,O
lead,O
to,O
alterations,O
in,O
gynoecium,O
development,O
and,O
patterning,O
",",O
including,O
clear,O
defects,O
in,O
marginal,O
tissue2050,O
.,O
All,O
JAZ,B-GP
/,O
TIFY,B-GP
genes,O
",",O
including,O
six,O
JAZ1,B-GP
/,O
TIFY10A,B-GP
genes,O
",",O
were,O
preferentially,O
enriched,O
in,O
the,O
ifc,O
mutant,O
ovary,O
.,O
The,O
expression,O
of,O
JAZ1,B-GP
/,O
TIFY10A,B-GP
is,O
auxin,O
-,O
inducible,O
and,O
independent,O
of,O
the,O
JA,O
signaling,O
pathway,O
but,O
is,O
controlled,O
by,O
the,O
ARF,B-GP
signaling,O
pathway44,O
.,O
However,O
",",O
genes,O
related,O
to,O
auxin,O
biosynthesis,O
were,O
also,O
up,O
-,O
regulated,O
in,O
the,O
ifc,O
mutant,O
ovary,O
",",O
implying,O
complex,O
interactions,O
between,O
these,O
genes,O
during,O
carpel,O
fusion,O
-,O
deficient,O
ovary,O
development,O
.,O
We,O
also,O
found,O
evidence,O
of,O
the,O
involvement,O
of,O
a,O
different,O
gene,O
family,O
associated,O
with,O
GA,O
biosynthesis,O
and,O
signaling,O
.,O
Transcriptional,B-GP
repressors,I-GP
of,O
GA,O
signaling,O
result,O
in,O
a,O
moderate,O
increase,O
in,O
style,O
length,O
and,O
stigma,O
width,O
",",O
which,O
is,O
related,O
to,O
cell,O
elongation,O
",",O
but,O
not,O
to,O
carpel,O
marginal,O
tissue,O
development23,O
.,O
Our,O
data,O
regarding,O
GA,O
metabolism,O
are,O
consistent,O
with,O
previous,O
reports,O
showing,O
induction,O
of,O
GA,O
biosynthesis,O
through,O
increasing,O
GA20ox,B-GP
transcription51,O
.,O
GA,O
and,O
auxin,O
signaling,O
are,O
known,O
to,O
interact,O
during,O
fruit,O
set,O
and,O
development,O
",",O
as,O
observed,O
in,O
this,O
study,O
from,O
the,O
up,O
-,O
regulation,O
of,O
GA,O
biosynthesis,O
corresponding,O
to,O
auxin,O
",",O
and,O
it,O
is,O
thought,O
that,O
auxin,O
activity,O
induces,O
GA,O
biosynthesis,O
by,O
increasing,O
GA20ox,B-GP
transcription51,O
.,O
We,O
suggest,O
high,O
possibility,O
of,O
relevance,O
between,O
up,O
-,O
regulation,O
of,O
GA20ox,B-GP
transcription,O
and,O
gene,O
encoding,O
auxin,O
biosynthesis,O
in,O
the,O
ifc,O
ovary,O
.,O
Finally,O
",",O
the,O
gene,O
encoding,O
CK,B-GP
O,I-GP
-,I-GP
glucosyl,I-GP
transferase,I-GP
(,O
the,O
enzyme,O
that,O
inactivates,O
CK,O
),O
was,O
up,O
-,O
regulated,O
in,O
the,O
ifc,O
mutant,O
ovary,O
.,O
Experimental,O
evidence,O
indicates,O
that,O
the,O
CK,O
pathway,O
is,O
regulated,O
by,O
the,O
TF,B-GP
SHOOT,B-GP
MERISTEMLESS52,I-GP
",",O
and,O
mutations,O
of,O
this,O
TF,B-GP
lead,O
to,O
conspicuous,O
defects,O
in,O
gynoecium,O
morphology,O
in,O
Arabidopsis53,O
.,O
It,O
has,O
been,O
demonstrated,O
that,O
a,O
differentiated,O
state,O
requires,O
high,O
levels,O
of,O
GA,O
and,O
low,O
levels,O
of,O
CK,O
",",O
and,O
the,O
hormonal,O
balance,O
appears,O
to,O
be,O
controlled,O
by,O
the,O
KNOX,B-GP
proteins52,O
.,O
The,O
diverse,O
expression,O
profiles,O
of,O
genes,O
related,O
to,O
the,O
hormone,O
response,O
and,O
biosynthesis,O
identified,O
in,O
this,O
study,O
might,O
constitute,O
the,O
basis,O
for,O
the,O
diversification,O
of,O
hormone,O
signaling,O
pathways,O
in,O
carpel,O
fusion,O
development,O
.,O
In,O
summary,O
",",O
our,O
analysis,O
of,O
RNA,O
-,O
seq,O
data,O
and,O
morphological,O
",",O
and,O
histological,O
analyses,O
offer,O
a,O
valuable,O
resource,O
for,O
identifying,O
candidate,O
genes,O
involved,O
in,O
carpel,O
fusion,O
.,O
We,O
found,O
that,O
the,O
deficiency,O
on,O
the,O
top,O
of,O
the,O
kernel,O
is,O
caused,O
by,O
incomplete,O
fusion,O
of,O
the,O
carpels,O
.,O
We,O
illustrated,O
the,O
key,O
transcription,B-GP
regulators,I-GP
and,O
hormonal,O
interactions,O
underpinning,O
this,O
development,O
",",O
adding,O
insights,O
into,O
the,O
biological,O
and,O
cellular,O
processes,O
.,O
However,O
",",O
the,O
nature,O
of,O
the,O
key,O
regulatory,O
factors,O
remains,O
to,O
be,O
explored,O
.,O
In,O
particular,O
",",O
future,O
studies,O
should,O
aim,O
to,O
characterize,O
TFs,B-GP
and,O
hormonal,O
regulation,O
functionally,O
for,O
a,O
deeper,O
understanding,O
of,O
carpel,O
fusion,O
in,O
maize,B-OG
by,O
integrating,O
genetic,O
",",O
biochemical,O
",",O
and,O
cytological,O
approaches,O
.,O
Materials,O
and,O
Methods,O
Plant,B-OG
Materials,O
and,O
Growth,O
Zea,B-OG
mays,I-OG
L,I-OG
.,O
(,O
maize,B-OG
),O
inbred,O
Yu,O
-,O
A474,O
plants,B-OG
were,O
grown,O
at,O
a,O
research,O
farm,O
at,O
Henan,O
Agricultural,O
University,O
",",O
Henan,O
Province,O
",",O
China,O
(,O
34,O
°,O
53,O
′,O
N,O
",",O
113,O
°,O
35,O
′,O
E,O
",",O
94,O
m,O
altitude,O
),O
under,O
non,O
-,O
stressed,O
conditions,O
between,O
June,O
and,O
October,O
2014,O
.,O
Yu,O
-,O
A474,O
",",O
an,O
inbred,O
line,O
belonging,O
to,O
the,O
Reid,O
germplasm,O
",",O
is,O
the,O
female,O
parent,O
of,O
the,O
commercial,O
hybrid,O
YD603,O
.,O
It,O
shares,O
close,O
relatives,O
with,O
zheng58,O
",",O
the,O
female,O
parent,O
of,O
another,O
hybrid,O
(,O
ZD958,O
),O
that,O
is,O
widely,O
grown,O
in,O
China,O
.,O
Yu,O
-,O
A474,O
exhibits,O
strong,O
heterosis,O
with,O
Yu,O
-,O
B469,O
",",O
which,O
is,O
a,O
descendants,O
of,O
Huangzaosi,O
and,O
has,O
a,O
normal,O
kernel,O
pericarp,O
.,O
The,O
meteorological,O
conditions,O
in,O
Henan,O
province,O
",",O
including,O
the,O
average,O
temperature,O
and,O
length,O
of,O
the,O
light,O
",",O
are,O
shown,O
in,O
Table,O
S13,O
.,O
Before,O
pollination,O
",",O
the,O
ear,O
shoots,O
of,O
Yu,O
-,O
A474,O
were,O
covered,O
before,O
silking,O
to,O
prevent,O
fertilization,O
.,O
The,O
ovaries,O
were,O
collected,O
when,O
the,O
carpel,O
wall,O
was,O
first,O
observed,O
to,O
deviate,O
from,O
normal,O
development,O
.,O
Biological,O
replicates,O
were,O
obtained,O
from,O
three,O
different,O
ear,O
rows,O
",",O
and,O
each,O
set,O
of,O
ovaries,O
was,O
generated,O
on,O
the,O
same,O
ear,O
and,O
during,O
the,O
same,O
time,O
of,O
the,O
day,O
.,O
In,O
all,O
cases,O
",",O
the,O
ovaries,O
were,O
selected,O
on,O
the,O
middle,O
of,O
the,O
ear,O
where,O
a,O
normal,O
ovary,O
was,O
adjacent,O
to,O
a,O
captured,O
ifc,O
mutant,O
ovary,O
.,O
The,O
ovaries,O
were,O
isolated,O
by,O
removing,O
the,O
glumes,O
",",O
lemma,O
",",O
and,O
palea,O
and,O
then,O
pinching,O
off,O
the,O
ovary,O
at,O
the,O
base,O
using,O
a,O
pair,O
of,O
forceps,O
.,O
The,O
ovaries,O
were,O
then,O
immediately,O
frozen,O
in,O
liquid,O
nitrogen,O
and,O
stored,O
at,O
−,O
80,O
°,O
C,O
until,O
RNA,O
extraction,O
.,O
Three,O
biological,O
replicates,O
of,O
both,O
phenotypes,O
were,O
used,O
for,O
RNA,O
-,O
seq,O
.,O
The,O
triplicate,O
samples,O
were,O
subsequently,O
used,O
for,O
quantitative,O
RT,O
-,O
PCR,O
(,O
qRT,O
-,O
PCR,O
),O
analyses,O
",",O
with,O
each,O
assay,O
containing,O
three,O
technical,O
replicates,O
.,O
Measurement,O
of,O
Silk,O
Length,O
A,O
total,O
of,O
30,O
selected,O
ears,O
",",O
whose,O
ear,O
shoots,O
were,O
covered,O
before,O
silking,O
to,O
prevent,O
fertilization,O
",",O
were,O
harvested,O
at,O
silking,O
from,O
plants,B-OG
showing,O
consistent,O
growth,O
.,O
Each,O
ear,O
was,O
divided,O
into,O
3,O
parts,O
:,O
basal,O
(,O
the,O
bottommost,O
3,O
–,O
10,O
circles,O
of,O
ovaries,O
"),",O
middle,O
(,O
between,O
the,O
basal,O
and,O
apical,O
parts,O
"),",O
and,O
apical,O
(,O
the,O
topmost,O
3,O
–,O
10,O
circles,O
of,O
ovaries,O
).,O
Altogether,O
",",O
10,O
–,O
15,O
silks,O
from,O
four,O
sides,O
in,O
each,O
part,O
of,O
the,O
ear,O
were,O
measured,O
.,O
The,O
one,O
-,O
tailed,O
t,O
-,O
test,O
was,O
used,O
to,O
detect,O
significant,O
differences,O
.,O
Microscope,O
Sections,O
For,O
histological,O
analysis,O
",",O
maize,B-OG
ovaries,O
were,O
collected,O
at,O
silking,O
",",O
when,O
it,O
was,O
possible,O
to,O
observe,O
the,O
carpel,O
wall,O
deviating,O
from,O
normal,O
development,O
",",O
after,O
repeated,O
observation,O
and,O
discrimination,O
.,O
Maize,B-OG
kernels,O
were,O
harvested,O
after,O
2,O
",",O
3,O
",",O
4,O
",",O
6,O
",",O
8,O
",",O
10,O
",",O
12,O
",",O
15,O
",",O
18,O
",",O
21,O
",",O
24,O
",",O
27,O
",",O
30,O
",",O
and,O
35,O
days,O
of,O
pollination,O
",",O
representing,O
a,O
wide,O
range,O
of,O
pericarp,O
changes,O
noted,O
during,O
visual,O
observations,O
.,O
Briefly,O
",",O
after,O
fixation,O
in,O
5,O
mL,O
of,O
formaldehyde,O
",",O
5,O
mL,O
of,O
acetic,O
acid,O
",",O
and,O
90,O
mL,O
of,O
50,O
%,O
ethanol,O
(,O
FAA,O
),O
at,O
4,O
°,O
C,O
for,O
24,O
h,O
",",O
the,O
samples,O
were,O
dehydrated,O
through,O
an,O
increasing,O
ethanol,O
series,O
(,O
10,O
–,O
100,O
"%),",O
infiltrated,O
and,O
embedded,O
in,O
paraffin,O
(,O
Sigma,O
"),",O
then,O
sliced,O
into,O
8,O
-,O
μm,O
-,O
thick,O
sections,O
using,O
a,O
rotary,O
microtome,O
(,O
Leica,O
).,O
The,O
sections,O
were,O
subsequently,O
stained,O
with,O
Safranin,O
-,O
Fast,O
Green,O
(,O
Safranin,O
O,O
",",O
Sigma,O
).,O
After,O
staining,O
",",O
the,O
sections,O
were,O
dehydrated,O
through,O
a,O
reverse,O
water,O
/,O
ethanol,O
/,O
xylene,O
series,O
.,O
Permanent,O
slides,O
were,O
mounted,O
with,O
synthetic,O
resin,O
(,O
Entellan,O
).,O
Observations,O
were,O
carried,O
out,O
with,O
a,O
Nikon,O
80I,O
optical,O
microscope,O
(,O
Tokyo,O
",",O
Japan,O
"),",O
and,O
images,O
of,O
the,O
maize,B-OG
ovaries,O
and,O
kernels,O
were,O
collected,O
using,O
a,O
Nikon,O
SSZ1500,O
dissecting,O
microscope,O
(,O
Tokyo,O
",",O
Japan,O
).,O
Scanning,O
Electron,O
Microscopy,O
Young,O
",",O
primary,O
ears,O
and,O
florets,O
were,O
dissected,O
under,O
a,O
stereomicroscope,O
.,O
The,O
organs,O
in,O
the,O
outer,O
whorls,O
",",O
including,O
the,O
lemma,O
",",O
palea,O
",",O
and,O
lodicule,O
",",O
were,O
removed,O
by,O
“,O
cutting,O
”,O
them,O
with,O
forceps,O
to,O
view,O
the,O
innermost,O
pistil,O
.,O
For,O
observation,O
of,O
the,O
aleurone,O
layer,O
in,O
WT,O
ovaries,O
",",O
the,O
pericarp,O
tissues,O
were,O
micro,O
-,O
dissected,O
using,O
a,O
sharp,O
blade,O
and,O
anatomical,O
tweezers,O
.,O
The,O
samples,O
were,O
fixed,O
in,O
2,O
%,O
glutaraldehyde,O
in,O
0,O
.,O
2,O
M,O
sodium,O
phosphate,O
buffer,O
(,O
pH,O
7,O
.,O
2,O
),O
at,O
4,O
°,O
C,O
for,O
at,O
least,O
24,O
h,O
.,O
The,O
slides,O
were,O
then,O
rinsed,O
in,O
0,O
.,O
2,O
M,O
sodium,O
phosphate,O
(,O
pH,O
7,O
.,O
2,O
),O
and,O
dehydrated,O
in,O
a,O
graded,O
ethanol,O
series,O
at,O
4,O
°,O
C,O
.,O
Finally,O
",",O
the,O
slides,O
were,O
immersed,O
in,O
tertiary,O
butyl,O
alcohol,O
and,O
stored,O
in,O
a,O
refrigerator,O
at,O
4,O
°,O
C,O
.,O
Thereafter,O
",",O
the,O
samples,O
were,O
placed,O
in,O
the,O
bell,O
jar,O
of,O
a,O
vacuum,O
evaporator,O
overnight,O
and,O
evacuated,O
with,O
a,O
rotary,O
pump,O
at,O
4,O
°,O
C,O
.,O
After,O
sublimation,O
of,O
the,O
frozen,O
tertiary,O
butyl,O
alcohol,O
in,O
the,O
vacuum,O
",",O
the,O
samples,O
were,O
completely,O
dried,O
.,O
Finally,O
",",O
the,O
samples,O
were,O
mounted,O
on,O
SEM,O
stubs,O
with,O
double,O
-,O
sided,O
tape,O
",",O
sputter,O
-,O
coated,O
with,O
gold,O
",",O
and,O
viewed,O
in,O
a,O
Hitachi,O
S,O
-,O
3400NIISEM,O
using,O
accelerating,O
voltages,O
of,O
5,O
–,O
10,O
kV,O
.,O
RNA,O
extraction,O
",",O
cDNA,O
Synthesis,O
",",O
and,O
Amplification,O
Total,O
RNA,O
for,O
RNA,O
-,O
seq,O
and,O
qRT,O
-,O
PCR,O
analyses,O
was,O
extracted,O
from,O
maize,B-OG
ovaries,O
using,O
TRIzol,O
reagent,O
(,O
Invitrogen,O
"),",O
following,O
the,O
manufacturer,O
’,O
s,O
instructions,O
.,O
Residual,O
genomic,O
DNA,O
was,O
removed,O
by,O
on,O
-,O
column,O
DNase,B-GP
I,I-GP
treatment,O
(,O
Qiagen,O
"),",O
and,O
RNA,O
was,O
further,O
purified,O
by,O
passaging,O
through,O
RNAeasy,O
columns,O
(,O
Qiagen,O
).,O
For,O
each,O
of,O
the,O
six,O
samples,O
",",O
ribosomal,O
RNA,O
(,O
rRNA,O
),O
was,O
removed,O
from,O
the,O
total,O
RNA,O
samples,O
using,O
Ribo,O
-,O
Zero,O
™,O
Magnetic,O
(,O
Epicentre,O
).,O
cDNA,O
synthesis,O
and,O
amplification,O
of,O
each,O
replicate,O
were,O
performed,O
according,O
the,O
manufacturer,O
’,O
s,O
protocols,O
(,O
Illumina,O
),O
with,O
minor,O
modifications,O
.,O
The,O
integrity,O
and,O
quality,O
of,O
the,O
RNA,O
and,O
amplified,O
cDNA,O
were,O
checked,O
using,O
a,O
Bioanalyzer,O
2100,O
(,O
Agilent,O
).,O
Library,O
Construction,O
and,O
Sequencing,O
For,O
the,O
construction,O
and,O
sequencing,O
of,O
RNA,O
-,O
seq,O
libraries,O
",",O
approximately,O
10,O
μg,O
of,O
rRNA,O
-,O
depleted,O
RNA,O
was,O
used,O
to,O
construct,O
strand,O
-,O
specific,O
cDNA,O
libraries,O
with,O
a,O
mean,O
size,O
400,O
±,O
50,O
bp,O
",",O
following,O
a,O
previously,O
described,O
procedure54,O
for,O
deep,O
sequencing,O
according,O
to,O
the,O
standard,O
Illumina,O
protocol,O
.,O
Paired,O
-,O
end,O
sequencing,O
(,O
2,O
×,O
125,O
bp,O
),O
was,O
performed,O
on,O
the,O
Illumina,O
HiSeq,O
-,O
2500,O
platform,O
.,O
After,O
the,O
raw,O
reads,O
were,O
generated,O
",",O
low,O
-,O
quality,O
reads,O
(,O
reads,O
containing,O
sequencing,O
adaptors,O
;,O
reads,O
containing,O
sequencing,O
primers,O
;,O
nucleotides,O
with,O
a,O
Q,O
quality,O
score,O
lower,O
than,O
20,O
),O
were,O
trimmed,O
using,O
the,O
Trimmomatic,O
program55,O
.,O
The,O
quality,O
of,O
the,O
raw,O
reads,O
was,O
checked,O
using,O
the,O
FastQC,O
(,O
http,O
://,O
www,O
.,O
bioinformatics,O
.,O
babraham,O
.,O
ac,O
.,O
uk,O
/,O
projects,O
/,O
fastqc,O
/).,O
Data,O
Mapping,O
and,O
Analysis,O
RNA,O
-,O
seq,O
reads,O
were,O
mapped,O
against,O
the,O
maize,B-OG
reference,O
genome,O
version,O
3,O
(,O
B73,O
RefGen_v3,O
),O
29,O
using,O
TopHat256,O
.,O
Intron,O
length,O
was,O
set,O
to,O
45,O
–,O
40,O
",",O
000,O
nucleotides,O
",",O
while,O
the,O
maximum,O
number,O
of,O
mismatches,O
per,O
read,O
was,O
set,O
to,O
3,O
.,O
To,O
eliminate,O
the,O
effect,O
of,O
read,O
mapping,O
in,O
intergenic,O
and,O
/,O
or,O
repeated,O
genomic,O
regions,O
",",O
the,O
reads,O
that,O
were,O
mapped,O
to,O
exonic,O
regions,O
were,O
extracted,O
using,O
the,O
intersect,O
function,O
of,O
BEDTools,O
v2,O
.,O
17,O
.,O
057,O
and,O
were,O
provided,O
as,O
input,O
to,O
Cufflinks,O
v2,O
.,O
1,O
.,O
131,O
for,O
normalization,O
and,O
estimation,O
of,O
gene,O
expression,O
levels,O
.,O
Transcript,O
assembly,O
was,O
performed,O
using,O
Cufflinks,O
",",O
and,O
differentially,O
expressed,O
genes,O
were,O
identified,O
with,O
Cuffdiff,O
using,O
the,O
multi,O
-,O
mapped,O
read,O
correction,O
",",O
fragment,O
bias,O
correction,O
",",O
and,O
quartile,O
normalization,O
options3031,O
.,O
To,O
quantify,O
the,O
expression,O
of,O
genes,O
and,O
transcripts,O
",",O
gene,O
expression,O
levels,O
were,O
reported,O
as,O
FPKM,O
values,O
.,O
The,O
upper,O
and,O
lower,O
boundary,O
FPKM,O
values,O
(,O
FPKM_conf_hi,O
and,O
FPKM_conf_lo,O
",",O
respectively,O
),O
from,O
Cufflinks,O
for,O
the,O
95,O
%,O
confidence,O
interval,O
of,O
each,O
gene,O
were,O
used,O
.,O
When,O
the,O
FPKM_conf_lo,O
was,O
greater,O
than,O
zero,O
",",O
a,O
gene,O
was,O
defined,O
as,O
being,O
expressed,O
in,O
a,O
sample,O
.,O
The,O
information,O
related,O
to,O
maize,B-OG
genome,O
annotation,O
used,O
in,O
this,O
study,O
was,O
obtained,O
from,O
Ensembl,O
Plants,B-OG
(,O
plants,B-OG
.,O
ensembl,O
.,O
org,O
",",O
release,O
28,O
).,O
The,O
reproducibility,O
of,O
the,O
data,O
between,O
the,O
triplicate,O
samples,O
from,O
WT,O
and,O
ifc,O
ovaries,O
was,O
quantified,O
through,O
SCC,O
analysis32,O
.,O
Log2,O
-,O
transformed,O
FPKM,O
values,O
[,O
log2,O
(,O
FPKM,O
+,O
1,O
)],O
of,O
the,O
expressed,O
genes,O
were,O
used,O
as,O
the,O
input,O
for,O
the,O
SCC,O
analysis,O
.,O
According,O
to,O
the,O
high,O
correlation,O
of,O
gene,O
expression,O
profiles,O
among,O
the,O
biological,O
replicates,O
",",O
exonic,O
reads,O
were,O
pooled,O
to,O
create,O
a,O
union,O
for,O
both,O
sets,O
of,O
triplicates,O
",",O
and,O
FPKMs,O
were,O
recalculated,O
for,O
the,O
two,O
pooled,O
samples,O
.,O
The,O
cutoff,O
for,O
differential,O
gene,O
expression,O
was,O
set,O
at,O
a,O
fold,O
change,O
greater,O
than,O
1,O
.,O
5,O
and,O
a,O
P,O
-,O
value,O
<,O
0,O
.,O
05,O
.,O
Gene,O
Annotation,O
and,O
Functional,O
Enrichment,O
Analysis,O
The,O
locus,O
information,O
and,O
functional,O
annotations,O
for,O
maize,B-OG
genes,O
were,O
based,O
on,O
information,O
from,O
Ensemble,O
Plants,B-OG
.,O
TF,B-GP
family,O
members,O
were,O
classified,O
according,O
to,O
the,O
Plant,B-OG
Transcription,B-GP
Factor,I-GP
Database,O
v3,O
.,O
036,O
.,O
The,O
putative,O
functions,O
of,O
the,O
genes,O
of,O
interest,O
were,O
redefined,O
and,O
inspected,O
manually,O
using,O
BLAST,O
searches,O
and,O
database,O
annotations,O
.,O
Gene,O
Ontology,O
(,O
GO,O
),O
annotations,O
and,O
enrichment,O
analyses,O
of,O
the,O
genes,O
were,O
performed,O
using,O
Blast2GO,O
(,O
Fisher,O
’,O
s,O
exact,O
test,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
software,O
(,O
http,O
://,O
www,O
.,O
blast2go,O
.,O
com,O
/).,O
GO,O
annotations,O
for,O
maize,B-OG
genes,O
were,O
obtained,O
from,O
Gramene,O
(,O
gramene,O
.,O
org,O
",",O
release,O
40,O
).,O
MapMan,O
annotation,O
was,O
performed,O
according,O
to,O
Thimm35,O
.,O
For,O
each,O
functional,O
enrichment,O
",",O
only,O
the,O
protein,O
-,O
coding,O
genes,O
(,O
i,O
.,O
e,O
".,",O
transposable,O
elements,O
",",O
microRNA,O
genes,O
",",O
and,O
pseudogenes,O
were,O
excluded,O
),O
were,O
subject,O
to,O
analysis,O
",",O
with,O
modified,O
MapMan,O
bins,O
as,O
the,O
functional,O
categories,O
.,O
Fisher,O
’,O
s,O
exact,O
test,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
was,O
used,O
to,O
investigate,O
the,O
significance,O
level,O
of,O
each,O
category,O
.,O
Real,O
-,O
Time,O
RT,O
-,O
PCR,O
Analysis,O
To,O
validate,O
the,O
RNA,O
-,O
seq,O
results,O
",",O
real,O
-,O
time,O
PCR,O
was,O
performed,O
using,O
SYBR,O
Green,O
(,O
Applied,O
Biosystems,O
),O
and,O
the,O
7900,O
HT,O
Sequence,O
Detection,O
System,O
(,O
Applied,O
Biosystems,O
"),",O
followed,O
by,O
real,O
-,O
time,O
PCR,O
analysis,O
.,O
The,O
absence,O
of,O
contaminant,O
genomic,O
DNA,O
was,O
confirmed,O
in,O
the,O
reactions,O
using,O
RNase,B-GP
-,O
free,O
",",O
DNase,B-GP
-,O
treated,O
RNA,O
samples,O
as,O
a,O
template,O
.,O
Reverse,O
transcription,O
and,O
qRT,O
-,O
PCR,O
were,O
performed,O
as,O
previously,O
described58,O
.,O
EF1a,B-GP
(,O
gene,O
ID,O
:,O
GRMZM2G153541,B-GP
),O
was,O
found,O
to,O
show,O
the,O
lowest,O
level,O
of,O
variation,O
and,O
was,O
therefore,O
used,O
as,O
an,O
internal,O
reference,O
gene,O
to,O
normalize,O
the,O
amount,O
of,O
template,O
cDNA,O
.,O
These,O
values,O
were,O
then,O
compared,O
with,O
FPKM,O
estimates,O
to,O
determine,O
whether,O
our,O
original,O
samples,O
for,O
RNA,O
-,O
seq,O
were,O
reliable,O
.,O
Three,O
biological,O
replicates,O
were,O
conducted,O
via,O
quantitative,O
RT,O
-,O
PCR,O
.,O
The,O
primers,O
used,O
in,O
these,O
experiments,O
are,O
listed,O
in,O
Table,O
S14,O
.,O
The,O
one,O
-,O
tailed,O
t,O
-,O
test,O
was,O
employed,O
to,O
compare,O
the,O
significance,O
of,O
the,O
differences,O
in,O
the,O
gene,O
expression,O
data,O
obtained,O
through,O
RT,O
-,O
PCR,O
.,O
Additional,O
Information,O
Accession,O
codes,O
:,O
The,O
raw,O
data,O
have,O
been,O
deposited,O
at,O
the,O
National,O
Center,O
for,O
Biotechnology,O
Information,O
Gene,O
Expression,O
Omnibus,O
.,O
The,O
following,O
link,O
has,O
been,O
created,O
to,O
allow,O
the,O
review,O
of,O
record,O
GSE76800,O
while,O
its,O
status,O
is,O
private,O
:,O
(,O
http,O
://,O
www,O
.,O
ncbi,O
.,O
nlm,O
.,O
nih,O
.,O
gov,O
/,O
geo,O
/,O
query,O
/,O
acc,O
.,O
cgi,O
?,O
token,O
=,O
gbufooyabjgbxex,O
&,O
acc,O
=,O
GSE76800,O
).,O
How,O
to,O
cite,O
this,O
article,O
:,O
Li,O
",",O
H,O
.,O
et,O
al,O
.,O
Differential,O
morphology,O
and,O
transcriptome,O
profile,O
between,O
the,O
incompletely,O
fused,O
carpels,O
ovary,O
and,O
its,O
wild,O
-,O
type,O
in,O
maize,B-OG
.,O
Sci,O
.,O
Rep,O
.,O
6,O
",",O
32652,O
;,O
doi,O
:,O
10,O
.,O
1038,O
/,O
srep32652,O
(,O
2016,O
).,O
Supplementary,O
Material,O
Supplementary,O
Information,O
Supplementary,O
Table,O
S4,O
Supplementary,O
Table,O
S6,O
Supplementary,O
Table,O
S7,O
Supplementary,O
Table,O
S9,O
Supplementary,O
Table,O
S10,O
Supplementary,O
Table,O
S11,O
Supplementary,O
Table,O
S14,O
Author,O
Contributions,O
L,O
.,O
C,O
.,O
H,O
.,O
participated,O
in,O
the,O
design,O
of,O
the,O
study,O
and,O
drafting,O
of,O
the,O
manuscript,O
.,O
L,O
.,O
H,O
.,O
P,O
.,O
performed,O
the,O
experiments,O
and,O
the,O
data,O
analysis,O
and,O
wrote,O
a,O
draft,O
of,O
the,O
manuscript,O
.,O
W,O
.,O
Y,O
.,O
F,O
.,O
helped,O
analyze,O
the,O
data,O
and,O
revised,O
the,O
manuscript,O
.,O
Z,O
.,O
Y,O
.,O
L,O
.,O
participated,O
in,O
the,O
data,O
analysis,O
.,O
H,O
.,O
X,O
.,O
L,O
.,O
participated,O
in,O
the,O
data,O
and,O
histological,O
analyses,O
.,O
W,O
.,O
Q,O
.,O
participated,O
in,O
the,O
data,O
analysis,O
.,O
C,O
.,O
J,O
.,O
F,O
.,O
participated,O
in,O
the,O
data,O
analysis,O
and,O
field,O
management,O
.,O
D,O
.,O
P,O
.,O
F,O
.,O
participated,O
in,O
analyzing,O
the,O
data,O
and,O
sampling,O
.,O
Z,O
.,O
M,O
.,O
B,O
.,O
participated,O
in,O
sampling,O
.,O
All,O
authors,O
reviewed,O
the,O
manuscript,O
.,O
(,O
A,O
",",O
D,O
),O
Mature,O
ear,O
with,O
WT,O
and,O
ifc,O
kernels,O
.,O
(,O
B,O
",",O
C,O
),O
Ear,O
at,O
2,O
days,O
after,O
silking,O
;,O
ifc,O
ovaries,O
were,O
interspersed,O
among,O
WT,O
ovaries,O
",",O
and,O
are,O
indicated,O
by,O
arrows,O
in,O
(,O
C,O
",",O
D,O
).,O
(,O
E,O
),O
Mature,O
WT,O
kernels,O
with,O
an,O
intact,O
pericarp,O
.,O
(,O
F,O
),O
Mature,O
ifc,O
kernels,O
without,O
a,O
pericarp,O
wrapping,O
at,O
the,O
top,O
.,O
(,O
G,O
to,O
J,O
),O
Structure,O
of,O
the,O
WT,O
and,O
ifc,O
pistils,O
.,O
(,O
H,O
),O
A,O
ifc,O
pistil,O
with,O
a,O
small,O
carpel,O
rupture,O
(,O
indicated,O
with,O
an,O
arrow,O
),O
that,O
is,O
just,O
becoming,O
observable,O
.,O
(,O
J,O
),O
A,O
ifc,O
pistil,O
at,O
silking,O
with,O
a,O
protruding,O
nucellus,O
(,O
indicated,O
by,O
the,O
arrow,O
).,O
(,O
G,O
",",O
I,O
),O
WT,O
pistils,O
in,O
the,O
same,O
period,O
as,O
those,O
in,O
H,O
and,O
J,O
",",O
respectively,O
.,O
Bars,O
=,O
1,O
cm,O
(,O
A,O
to,O
D,O
),O
and,O
1,O
mm,O
(,O
E,O
to,O
J,O
).,O
WT,O
",",O
wild,O
-,O
type,O
;,O
ifc,O
",",O
incompletely,O
fused,O
carpels,O
.,O
(,O
A,O
),O
Diagram,O
of,O
a,O
cross,O
-,O
section,O
through,O
a,O
developing,O
maize,O
ovary,O
.,O
(,O
B,O
",",O
C,O
),O
Two,O
stages,O
of,O
ear,O
development,O
.,O
(,O
B,O
"),",O
A,O
1,O
cm,O
-,O
long,O
portion,O
of,O
an,O
ear,O
.,O
(,O
C,O
),O
A,O
4,O
cm,O
-,O
long,O
portion,O
of,O
an,O
ear,O
.,O
(,O
D,O
",",O
E,O
),O
Anatomical,O
structure,O
of,O
the,O
pistils,O
with,O
the,O
glumes,O
removed,O
in,O
4,O
cm,O
-,O
and,O
6,O
cm,O
-,O
long,O
ears,O
",",O
respectively,O
.,O
(,O
F,O
",",O
G,O
),O
Close,O
-,O
up,O
views,O
of,O
WT,O
and,O
ifc,O
ovaries,O
in,O
8,O
cm,O
-,O
long,O
ears,O
",",O
respectively,O
.,O
(,O
H,O
to,O
K,O
"),",O
Histological,O
features,O
of,O
the,O
maize,O
kernel,O
surface,O
in,O
WT,O
(,O
I,O
",",O
K,O
),O
and,O
ifc,O
(,O
H,O
",",O
J,O
).,O
(,O
H,O
),O
Surface,O
of,O
an,O
ifc,O
kernel,O
showing,O
the,O
transition,O
from,O
the,O
pericarp,O
to,O
the,O
seed,O
coat,O
.,O
(,O
I,O
),O
Surface,O
of,O
a,O
WT,O
kernel,O
.,O
(,O
J,O
),O
Close,O
-,O
up,O
view,O
of,O
the,O
seed,O
coat,O
in,O
(,O
H,O
),O
without,O
pericarp,O
packaging,O
.,O
(,O
K,O
),O
The,O
surface,O
of,O
the,O
aleurone,O
layer,O
with,O
the,O
cells,O
arranged,O
neatly,O
in,O
the,O
WT,O
kernel,O
in,O
DAP,O
15,O
.,O
The,O
outer,O
pericarp,O
was,O
removed,O
.,O
(,O
L,O
to,O
O,O
),O
Longitudinal,O
section,O
through,O
WT,O
(,O
L,O
",",O
N,O
),O
and,O
ifc,O
(,O
M,O
",",O
O,O
),O
ovaries,O
at,O
DAP,O
3,O
(,O
L,O
",",O
M,O
),O
and,O
DAP,O
30,O
(,O
N,O
",",O
O,O
"),",O
showing,O
an,O
incomplete,O
pericarp,O
(,O
P,O
),O
and,O
an,O
exposed,O
seed,O
coat,O
outside,O
the,O
aleurone,O
layer,O
(,O
A,O
),O
in,O
ifc,O
mutants,O
",",O
versus,O
an,O
intact,O
pericarp,O
and,O
seed,O
coat,O
wrapping,O
in,O
WT,O
.,O
The,O
normal,O
stylar,O
canal,O
is,O
indicated,O
by,O
white,O
arrows,O
in,O
(,O
D,O
–,O
F,O
),O
and,O
the,O
unfused,O
stylar,O
canal,O
is,O
indicated,O
by,O
red,O
arrows,O
in,O
(,O
D,O
",",O
E,O
",",O
G,O
).,O
DAP,O
",",O
days,O
after,O
pollination,O
;,O
WT,O
",",O
wild,O
-,O
type,O
;,O
ifc,O
",",O
incompletely,O
fused,O
carpels,O
;,O
OW,O
",",O
ovary,O
wall,O
;,O
EN,O
",",O
endosperm,O
;,O
P,O
",",O
pericarp,O
;,O
A,O
",",O
aleurone,O
layer,O
;,O
Si,O
",",O
silk,O
.,O
Bars,O
=,O
1,O
mm,O
(,O
B,O
to,O
G,O
",",O
H,O
",",O
L,O
",",O
M,O
),O
and,O
100,O
μm,O
(,O
I,O
to,O
K,O
",",O
N,O
",",O
O,O
).,O
(,O
A,O
),O
Statistics,O
for,O
the,O
raw,O
reads,O
after,O
being,O
filtered,O
and,O
aligned,O
to,O
the,O
B73,O
v3,O
reference,O
genome,O
.,O
(,O
B,O
),O
Distribution,O
of,O
the,O
reads,O
among,O
maize,O
reference,O
genomic,O
features,O
.,O
(,O
C,O
),O
Number,O
of,O
genes,O
showing,O
different,O
expression,O
levels,O
(,O
based,O
on,O
FPKM,O
),O
in,O
each,O
sample,O
.,O
WT,O
",",O
wild,O
-,O
type,O
;,O
ifc,O
",",O
incompletely,O
fused,O
carpels,O
.,O
Biological,O
replicates,O
are,O
indicated,O
as,O
−,O
1,O
",",O
−,O
2,O
",",O
and,O
−,O
3,O
.,O
For,O
information,O
on,O
the,O
primers,O
used,O
to,O
evaluate,O
these,O
genes,O
through,O
qRT,O
-,O
PCR,O
",",O
see,O
Figure,O
S12,O
.,O
“//”,O
indicates,O
3,O
–,O
3,O
.,O
1,O
.,O
Error,O
bars,O
represent,O
the,O
standard,O
error,O
(,O
SD,O
).,O
Values,O
are,O
means,O
±,O
SD,O
.,O
WT,O
",",O
wild,O
-,O
type,O
;,O
ifc,O
",",O
incompletely,O
fused,O
carpels,O
.,O
*,O
P,O
value,O
<,O
0,O
.,O
05,O
;,O
**,O
P,O
value,O
<,O
0,O
.,O
01,O
.,O
“//”,O
represents,O
32,O
–,O
33,O
.,O
WT,O
",",O
wild,O
-,O
type,O
;,O
ifc,O
",",O
incompletely,O
fused,O
carpels,O
.,O
(,O
A,O
),O
The,O
enriched,O
GO,O
“,O
biological,O
processes,O
”,O
among,O
the,O
up,O
-,O
regulated,O
genes,O
in,O
ifc,O
ovaries,O
.,O
Rich,O
factor,O
represents,O
the,O
ratio,O
of,O
the,O
number,O
of,O
differentially,O
expressed,O
genes,O
over,O
the,O
total,O
number,O
of,O
genes,O
in,O
the,O
GO,O
item,O
.,O
For,O
the,O
details,O
of,O
the,O
GO,O
enrichment,O
analysis,O
",",O
see,O
Table,O
S9,O
.,O
(,O
B,O
),O
MapMan,O
enrichment,O
analysis,O
of,O
the,O
up,O
-,O
regulated,O
genes,O
in,O
ifc,O
and,O
WT,O
ovaries,O
.,O
(,O
C,O
),O
Summary,O
of,O
the,O
nine,O
primary,O
functional,O
categories,O
obtained,O
after,O
MapMan,O
enrichment,O
of,O
all,O
differentially,O
expressed,O
genes,O
identified,O
between,O
WT,O
and,O
ifc,O
ovaries,O
.,O
The,O
percentage,O
represents,O
the,O
ratio,O
of,O
the,O
number,O
of,O
differentially,O
expressed,O
genes,O
in,O
each,O
category,O
over,O
the,O
total,O
number,O
of,O
all,O
enriched,O
differentially,O
expressed,O
genes,O
in,O
the,O
MapMan,O
analysis,O
.,O
For,O
complete,O
information,O
about,O
the,O
MapMan,O
enrichment,O
analysis,O
",",O
see,O
Table,O
S10,O
.,O
WT,O
",",O
wild,O
-,O
type,O
;,O
ifc,O
",",O
incompletely,O
fused,O
carpels,O
;,O
CHO,O
",",O
Carbohydrate,O
.,O
(,O
A,O
),O
Up,O
-,O
regulated,O
TF,O
genes,O
in,O
WT,O
(,O
red,O
),O
and,O
ifc,O
(,O
blue,O
),O
ovaries,O
.,O
(,O
B,O
),O
The,O
exact,O
number,O
of,O
up,O
-,O
regulated,O
genes,O
in,O
each,O
family,O
identified,O
in,O
WT,O
(,O
red,O
),O
and,O
ifc,O
(,O
blue,O
),O
ovaries,O
is,O
shown,O
.,O
For,O
detailed,O
TF,O
-,O
related,O
gene,O
information,O
",",O
see,O
Table,O
S11,O
.,O
WT,O
",",O
wild,O
-,O
type,O
;,O
ifc,O
",",O
incompletely,O
fused,O
carpels,O
.,O
“//”,O
indicates,O
FPKM,O
values,O
from,O
12,O
.,O
8,O
to,O
13,O
.,O
WT,O
",",O
wild,O
-,O
type,O
;,O
ifc,O
",",O
incompletely,O
fused,O
carpels,O
.,O
miR,O
-,O
148,O
Regulates,O
Mitf,B-GP
in,O
Melanoma,B-DS
Cells,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
BSH,O
ES,O
.,O
Performed,O
the,O
experiments,O
:,O
BSH,O
KB,O
CP,O
.,O
Analyzed,O
the,O
data,O
:,O
BSH,O
.,O
Wrote,O
the,O
paper,O
:,O
BSH,O
ES,O
.,O
The,O
Microphthalmia,B-GP
associated,I-GP
transcription,I-GP
factor,I-GP
(,O
Mitf,B-GP
),O
is,O
an,O
important,O
regulator,O
in,O
melanocyte,O
development,O
and,O
has,O
been,O
shown,O
to,O
be,O
involved,O
in,O
melanoma,B-DS
progression,O
.,O
The,O
current,O
model,O
for,O
the,O
role,O
of,O
Mitf,B-GP
in,O
melanoma,B-DS
assumes,O
that,O
the,O
total,O
activity,O
of,O
the,O
protein,O
is,O
tightly,O
regulated,O
in,O
order,O
to,O
secure,O
cell,O
proliferation,O
.,O
Previous,O
research,O
has,O
shown,O
that,O
regulation,O
of,O
Mitf,B-GP
is,O
complex,O
and,O
involves,O
regulation,O
of,O
expression,O
",",O
splicing,O
",",O
protein,O
stability,O
and,O
post,O
-,O
translational,O
modifications,O
.,O
Here,O
we,O
show,O
that,O
microRNAs,O
(,O
miRNAs,O
),O
are,O
also,O
involved,O
in,O
regulating,O
Mitf,B-GP
in,O
melanoma,B-DS
cells,O
.,O
Sequence,O
analysis,O
revealed,O
conserved,O
binding,O
sites,O
for,O
several,O
miRNAs,O
in,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
.,O
Furthermore,O
",",O
miR,O
-,O
148,O
was,O
shown,O
to,O
affect,O
Mitf,B-GP
mRNA,O
expression,O
in,O
melanoma,B-DS
cells,O
through,O
a,O
conserved,O
binding,O
site,O
in,O
the,O
3,O
′,O
UTR,O
sequence,O
of,O
mouse,B-OG
and,O
human,B-OG
Mitf,B-GP
.,O
In,O
addition,O
we,O
confirm,O
the,O
previously,O
reported,O
effects,O
of,O
miR,O
-,O
137,O
on,O
Mitf,B-GP
.,O
Other,O
miRNAs,O
",",O
miR,O
-,O
27a,O
",",O
miR,O
-,O
32,O
and,O
miR,O
-,O
124,O
which,O
all,O
have,O
conserved,O
binding,O
sites,O
in,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
did,O
not,O
have,O
effects,O
on,O
Mitf,B-GP
.,O
Our,O
data,O
show,O
that,O
miR,O
-,O
148,O
and,O
miR,O
-,O
137,O
present,O
an,O
additional,O
level,O
of,O
regulating,O
Mitf,B-GP
expression,O
in,O
melanocytes,O
and,O
melanoma,B-DS
cells,O
.,O
Loss,O
of,O
this,O
regulation,O
",",O
either,O
by,O
mutations,O
or,O
by,O
shortening,O
of,O
the,O
3,O
′,O
UTR,O
sequence,O
",",O
is,O
therefore,O
a,O
likely,O
factor,O
in,O
melanoma,B-DS
formation,O
and,O
/,O
or,O
progression,O
.,O
Introduction,O
The,O
MITF,B-GP
(,O
Microphthalmia,B-GP
associated,I-GP
transcription,I-GP
factor,I-GP
),O
protein,O
is,O
a,O
master,O
regulator,O
of,O
melanocyte,O
development,O
and,O
is,O
important,O
in,O
several,O
other,O
cell,O
types,O
including,O
the,O
retinal,O
pigment,O
epithelium,O
(,O
RPE,O
),O
of,O
the,O
eye,O
",",O
osteoclasts,O
and,O
mast,O
cells,O
[,O
1,O
].,O
More,O
recently,O
",",O
MITF,B-GP
was,O
shown,O
to,O
play,O
a,O
role,O
in,O
melanocyte,O
stem,O
cells,O
in,O
the,O
hair,O
follicle,O
[,O
2,O
].,O
The,O
Mitf,B-GP
gene,O
encodes,O
a,O
bHLH,B-GP
-,I-GP
Zip,I-GP
transcription,I-GP
factor,I-GP
of,O
the,O
Myc,B-GP
family,O
[,O
3,O
"],",O
[,O
4,O
],O
which,O
regulates,O
melanocyte,O
differentiation,O
by,O
activating,O
other,O
known,O
melanocyte,O
determinants,O
",",O
including,O
Tyrosinase,B-GP
(,O
Tyr,B-GP
"),",O
Tyrosinase,B-GP
-,I-GP
related,I-GP
protein,I-GP
-,I-GP
1,I-GP
(,O
Tyrp,B-GP
-,I-GP
1,I-GP
),O
and,O
DCT,B-GP
/,O
Tyrp,B-GP
-,I-GP
2,I-GP
[,O
5,O
"],",O
[,O
6,O
].,O
In,O
addition,O
to,O
regulating,O
differentiation,O
",",O
MITF,B-GP
is,O
required,O
for,O
melanocyte,O
cell,O
survival,O
[,O
7,O
"],",O
[,O
8,O
"],",O
proliferation,O
and,O
cell,O
cycle,O
progression,O
[,O
9,O
"],",O
[,O
10,O
"],",O
[,O
11,O
"],",O
[,O
12,O
"],",O
[,O
13,O
].,O
The,O
diverse,O
roles,O
that,O
MITF,B-GP
plays,O
in,O
the,O
development,O
of,O
different,O
cell,O
types,O
suggests,O
that,O
the,O
expression,O
and,O
function,O
of,O
Mitf,B-GP
must,O
be,O
highly,O
regulated,O
.,O
In,O
fact,O
",",O
Mitf,B-GP
is,O
regulated,O
at,O
multiple,O
levels,O
",",O
including,O
transcription,O
",",O
alternative,O
splicing,O
",",O
post,O
-,O
translational,O
modifications,O
and,O
protein,O
stability,O
.,O
The,O
Mitf,B-GP
gene,O
has,O
at,O
least,O
nine,O
different,O
promoters,O
",",O
each,O
with,O
a,O
unique,O
5,O
′,O
exon,O
which,O
is,O
alternatively,O
spliced,O
to,O
the,O
remaining,O
exons,O
2,O
through,O
9,O
resulting,O
in,O
several,O
different,O
Mitf,B-GP
isoforms,O
[,O
reviewed,O
in,O
1,O
].,O
At,O
the,O
protein,O
level,O
",",O
MITF,B-GP
is,O
modified,O
post,O
-,O
transcriptionally,O
and,O
has,O
been,O
shown,O
to,O
be,O
phosphorylated,O
at,O
multiple,O
sites,O
leading,O
to,O
either,O
increase,O
in,O
transcriptional,O
activation,O
or,O
decrease,O
in,O
protein,O
stability,O
[,O
14,O
"],",O
[,O
15,O
"],",O
[,O
16,O
"],",O
[,O
17,O
].,O
In,O
addition,O
",",O
ubiquitination,O
marks,O
MITF,B-GP
for,O
degradaton,O
[,O
18,O
],O
and,O
sumoylation,O
has,O
been,O
shown,O
to,O
affect,O
DNA,O
binding,O
specificity,O
[,O
19,O
"],",O
[,O
20,O
].,O
In,O
addition,O
to,O
its,O
essential,O
role,O
in,O
melanocyte,O
development,O
",",O
expression,O
of,O
Mitf,B-GP
and,O
its,O
target,O
genes,O
is,O
seen,O
in,O
many,O
melanoma,B-DS
cells,O
[,O
21,O
"],",O
[,O
22,O
].,O
Continued,O
expression,O
of,O
MITF,B-GP
has,O
been,O
shown,O
to,O
be,O
essential,O
for,O
melanoma,B-DS
cell,O
proliferation,O
and,O
survival,O
and,O
",",O
in,O
fact,O
",",O
MITF,B-GP
has,O
been,O
proposed,O
to,O
act,O
as,O
a,O
lineage,O
survival,O
oncogene,B-GP
in,O
melanoma,B-DS
[,O
23,O
].,O
Significantly,O
increased,O
levels,O
of,O
MITF,B-GP
",",O
however,O
",",O
reduce,O
melanoma,B-DS
cell,O
proliferation,O
and,O
tumorigenicity,O
[,O
24,O
"],",O
[,O
25,O
].,O
Consistent,O
with,O
this,O
",",O
there,O
is,O
less,O
MITF,B-GP
expressed,O
in,O
melanoma,B-DS
cells,O
than,O
in,O
normal,O
melanocytes,O
[,O
25,O
].,O
Therefore,O
",",O
it,O
has,O
been,O
proposed,O
that,O
MITF,B-GP
levels,O
dictate,O
functional,O
outcome,O
such,O
that,O
high,O
levels,O
result,O
in,O
cell,O
cycle,O
arrest,O
and,O
differentiation,O
",",O
intermediate,O
levels,O
promote,O
proliferation,O
and,O
tumorigenesis,O
whereas,O
low,O
levels,O
lead,O
to,O
cell,O
cycle,O
arrest,O
and,O
apoptosis,O
.,O
According,O
to,O
this,O
model,O
",",O
it,O
is,O
extremely,O
important,O
to,O
regulate,O
MITF,B-GP
expression,O
in,O
melanoma,B-DS
cells,O
.,O
miRNAs,O
have,O
been,O
proven,O
to,O
be,O
involved,O
in,O
many,O
different,O
cell,O
processes,O
including,O
cell,O
-,O
cycle,O
regulation,O
",",O
differentiation,O
",",O
proliferation,O
and,O
apoptosis,O
[,O
reviewed,O
in,O
26,O
].,O
miRNAs,O
are,O
thought,O
to,O
regulate,O
about,O
30,O
%,O
of,O
coding,O
genes,O
in,O
the,O
human,B-OG
genome,O
and,O
to,O
date,O
677,O
miRNA,O
genes,O
have,O
been,O
discovered,O
in,O
the,O
human,B-OG
genome,O
and,O
491,O
in,O
the,O
mouse,B-OG
(,O
www,O
.,O
microRNA,O
.,O
org,O
),O
[,O
27,O
].,O
Misexpression,O
of,O
miRNA,O
genes,O
has,O
been,O
seen,O
in,O
both,O
benign,O
and,O
malignant,B-DS
cancer,I-DS
and,O
miRNA,O
genes,O
can,O
act,O
as,O
either,O
tumor,B-DS
suppressors,O
or,O
oncogenes,B-GP
as,O
is,O
seen,O
for,O
the,O
role,O
of,O
coding,O
genes,O
in,O
cancer,B-DS
progression,O
.,O
Studies,O
have,O
shown,O
that,O
miRNA,O
expression,O
differs,O
between,O
melanoma,B-DS
cell,O
lines,O
[,O
28,O
],O
and,O
that,O
miRNA,O
expression,O
profiles,O
can,O
be,O
used,O
to,O
classify,O
solid,B-DS
tumors,I-DS
in,O
terms,O
of,O
their,O
differentiation,O
stage,O
and,O
developmental,O
lineage,O
[,O
29,O
].,O
In,O
an,O
extensive,O
comparative,O
study,O
on,O
miRNA,O
expression,O
in,O
normal,O
melanocyte,O
and,O
melanoma,B-DS
cell,O
lines,O
derived,O
from,O
solid,B-DS
tumors,I-DS
and,O
melanoma,B-DS
metastases,O
",",O
various,O
miRNAs,O
were,O
found,O
to,O
be,O
differentially,O
regulated,O
in,O
melanoma,B-DS
cells,O
compared,O
to,O
normal,O
melanocytes,O
[,O
30,O
].,O
Many,O
had,O
not,O
been,O
linked,O
to,O
cancer,B-DS
formation,O
before,O
.,O
Other,O
miRNAs,O
had,O
been,O
shown,O
to,O
be,O
oncogenic,O
or,O
to,O
contain,O
tumor,B-DS
suppressive,O
potential,O
in,O
other,O
types,O
of,O
cancer,B-DS
[,O
30,O
].,O
A,O
few,O
miRNAs,O
have,O
already,O
been,O
linked,O
to,O
Mitf,B-GP
expression,O
.,O
Bemis,O
et,O
al,O
.,O
(,O
2008,O
),O
showed,O
that,O
miR,O
-,O
137,O
downregulates,O
MITF,B-GP
in,O
melanoma,B-DS
cells,O
[,O
31,O
].,O
In,O
addition,O
",",O
it,O
has,O
been,O
shown,O
that,O
miR,O
-,O
182,O
targets,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
in,O
the,O
retina,O
[,O
32,O
"],",O
and,O
recently,O
Segura,O
et,O
al,O
.,O
(,O
2009,O
),O
showed,O
that,O
miR,O
-,O
182,O
promotes,O
migration,O
and,O
survival,O
of,O
melanoma,B-DS
cells,O
by,O
downregulating,O
Mitf,B-GP
expression,O
[,O
33,O
].,O
Here,O
we,O
study,O
miRNAs,O
with,O
conserved,O
binding,O
sites,O
in,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
and,O
characterize,O
their,O
effects,O
on,O
Mitf,B-GP
using,O
a,O
reporter,O
construct,O
.,O
Effects,O
on,O
the,O
endogenous,O
human,B-OG
MITF,B-GP
gene,O
were,O
also,O
determined,O
in,O
melanoma,B-DS
cells,O
.,O
Our,O
results,O
show,O
that,O
miRNAs,O
play,O
an,O
important,O
role,O
in,O
regulating,O
MITF,B-GP
mRNA,O
in,O
melanoma,B-DS
through,O
conserved,O
sites,O
in,O
the,O
3,O
′,O
UTR,O
.,O
Materials,O
and,O
Methods,O
PCR,O
amplification,O
of,O
the,O
3,O
′,O
UTR,O
sequence,O
of,O
Mitf,B-GP
A,O
reporter,O
gene,O
construct,O
was,O
generated,O
which,O
contains,O
the,O
mouse,B-OG
Mitf,B-GP
-,O
3,O
′,O
UTR,O
sequence,O
downstream,O
of,O
the,O
luciferase,B-GP
reporter,O
gene,O
.,O
The,O
construct,O
was,O
termed,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
.,O
To,O
do,O
this,O
",",O
the,O
3,O
′,O
UTR,O
sequence,O
of,O
the,O
mouse,B-OG
Mitf,B-GP
gene,O
(,O
which,O
is,O
contained,O
in,O
a,O
single,O
exon,O
),O
was,O
amplified,O
from,O
BAC,O
clone,O
rpci,O
-,O
23,O
-,O
9a13t7,O
using,O
Pfu,B-GP
polymerase,I-GP
and,O
the,O
primers,O
3UTRSacI,O
-,O
Forw,O
:,O
5,O
′-,O
gag,O
ctc,O
cga,O
gcc,O
tgc,O
ctt,O
gct,O
ctg,O
-,O
3,O
′,O
and,O
3UTRNheI,O
-,O
Rev,O
:,O
5,O
′-,O
gct,O
agc,O
atg,O
tga,O
aaa,O
acc,O
aaa,O
tgc,O
ttt,O
aat,O
ga,O
-,O
3,O
′.,O
The,O
primers,O
included,O
new,O
restriction,O
sites,O
",",O
SacI,B-GP
at,O
the,O
5,O
′,O
end,O
and,O
NheI,B-GP
at,O
the,O
3,O
′,O
end,O
(,O
underlined,O
bases,O
).,O
The,O
restriction,O
sites,O
were,O
used,O
for,O
cloning,O
into,O
the,O
Pis0,O
vector,O
",",O
a,O
Firefly,B-OG
luciferase,B-GP
vector,O
",",O
modified,O
from,O
the,O
PGL3,O
Control,O
Vector,O
from,O
Promega,O
by,O
adding,O
restriction,O
sites,O
to,O
the,O
3,O
′,O
end,O
.,O
The,O
Pis0,O
vector,O
was,O
purchased,O
from,O
Addgene,O
Inc,O
.,O
Cambridge,O
",",O
MA,O
",",O
USA,O
(,O
Addgene,O
plasmid,O
12178,O
),O
[,O
34,O
].,O
Site,O
directed,O
mutagenesis,O
was,O
used,O
to,O
alter,O
the,O
miRNA,O
target,O
sites,O
using,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
clone,O
as,O
a,O
template,O
.,O
MicroRNA,O
molecules,O
MicroRNAs,O
used,O
in,O
this,O
study,O
were,O
purchased,O
from,O
Ambion,O
",",O
Inc,O
.,O
and,O
are,O
the,O
following,O
:,O
hsa,O
-,O
miR,O
-,O
27a,O
(,O
Product,O
ID,O
:,O
PM10939,O
"),",O
hsa,O
-,O
miR,O
-,O
32,O
(,O
Product,O
ID,O
:,O
PM10124,O
"),",O
hsa,O
-,O
miR,O
-,O
101,O
(,O
Product,O
ID,O
:,O
PM10537,O
"),",O
mmu,O
-,O
miR,O
-,O
124a,O
(,O
Product,O
ID,O
:,O
PM10691,O
"),",O
mmu,O
-,O
miR,O
-,O
137,O
(,O
Product,O
ID,O
:,O
PM10513,O
"),",O
hsa,O
-,O
miR,O
-,O
148a,O
(,O
Product,O
ID,O
:,O
PM10263,O
"),",O
hsa,O
-,O
miR,O
-,O
182,O
.,O
(,O
Product,O
ID,O
:,O
PM11090,O
"),",O
Pre,O
-,O
miR,O
-,O
neg,O
#,O
2,O
(,O
Cat,O
.,O
no,O
.,O
AM17111,O
"),",O
Cy3,O
-,O
labeled,O
Pre,O
-,O
miR,O
Negative,O
Control,O
#,O
1,O
(,O
Cat,O
.,O
no,O
.,O
AM17120,O
).,O
MicroRNA,O
inhibitors,O
anti,O
-,O
microRNA,O
where,O
purchased,O
from,O
Ambion,O
and,O
are,O
the,O
following,O
:,O
anti,O
-,O
miR,O
-,O
137,O
(,O
Product,O
ID,O
:,O
AM10513,O
),O
and,O
anti,O
-,O
miR,O
-,O
148,O
(,O
Product,O
ID,O
:,O
AM10263,O
).,O
Cell,O
culture,O
conditions,O
Human,B-OG
embryonic,O
kidney,O
cells,O
(,O
HEK293,O
),O
were,O
cultured,O
in,O
DMEM,O
medium,O
with,O
10,O
%,O
FBS,O
",",O
penicillin,O
-,O
streptomycin,O
(,O
50,O
U,O
/,O
ml,O
),O
and,O
2,O
mM,O
glutamine,O
.,O
501mel,O
melanoma,B-DS
cells,O
were,O
cultured,O
in,O
RPMI,O
medium,O
with,O
10,O
%,O
FBS,O
and,O
penicillin,O
-,O
streptomycin,O
(,O
50,O
U,O
/,O
ml,O
).,O
MeWo,O
melanoma,B-DS
cells,O
were,O
cultured,O
in,O
DMEM,O
medium,O
with,O
7,O
%,O
FBS,O
",",O
penicillin,O
-,O
streptomycin,O
(,O
50,O
U,O
/,O
ml,O
),O
and,O
2,O
mM,O
glutamine,O
.,O
Cells,O
were,O
grown,O
at,O
37,O
°,O
C,O
with,O
5,O
%,O
CO2,O
.,O
Co,O
-,O
transfection,O
DNA,O
and,O
miRNAs,O
were,O
co,O
-,O
transfected,O
into,O
HEK293,O
and,O
501mel,O
cells,O
with,O
Lipofectamine,O
2000,O
from,O
Invitrogen,O
(,O
Cat,O
no,O
.,O
11668,O
-,O
019,O
),O
in,O
Optimem,O
I,O
+,O
Glutamax,O
-,O
I,O
Reduced,O
Serum,O
Medium,O
from,O
Invitrogen,O
(,O
Cat,O
.,O
no,O
.,O
51985,O
"),",O
according,O
to,O
the,O
manufacturers,O
protocol,O
.,O
Cells,O
were,O
grown,O
in,O
96,O
well,O
plates,O
.,O
In,O
each,O
well,O
10,O
ng,O
vector,O
DNA,O
",",O
0,O
.,O
2,O
ng,O
of,O
Renilla,B-OG
luciferase,B-GP
DNA,O
and,O
an,O
miRNA,O
at,O
either,O
0,O
.,O
1,O
pmol,O
",",O
0,O
.,O
5,O
pmol,O
or,O
1,O
pmol,O
concentration,O
were,O
co,O
-,O
transfected,O
.,O
A,O
negative,O
control,O
was,O
included,O
in,O
all,O
co,O
-,O
transfections,O
.,O
For,O
co,O
-,O
tranfection,O
with,O
the,O
mutated,O
3,O
′,O
UTR,O
clones,O
we,O
analysed,O
the,O
highest,O
concentration,O
in,O
each,O
case,O
",",O
or,O
1,O
pmol,O
miRNA,O
.,O
miRNA,O
inhibitors,O
were,O
transfected,O
at,O
concentration,O
of,O
1,O
pmol,O
miRNA,O
.,O
Transfected,O
cells,O
were,O
incubated,O
for,O
48,O
hrs,O
.,O
at,O
37,O
°,O
C,O
with,O
5,O
%,O
CO2,O
before,O
luciferase,B-GP
expression,O
was,O
measured,O
.,O
Experiments,O
were,O
repeated,O
three,O
times,O
in,O
6,O
replicates,O
",",O
except,O
experiments,O
when,O
two,O
different,O
miRNAs,O
were,O
co,O
-,O
transfected,O
simultaneously,O
which,O
was,O
done,O
only,O
once,O
in,O
six,O
replicates,O
.,O
Luciferase,B-GP
measurements,O
The,O
Dual,O
Luciferase,B-GP
Reporter,O
Assay,O
System,O
from,O
Promega,O
was,O
used,O
to,O
measure,O
luciferase,B-GP
expression,O
on,O
a,O
Wallac,O
Victor,O
2,O
1420,O
Multilabel,O
counter,O
.,O
Mutagenesis,O
Locations,O
of,O
miRNA,O
binding,O
sites,O
were,O
determined,O
using,O
the,O
mRNA,O
sequence,O
of,O
mouse,B-OG
Mitf,B-GP
3,O
′,O
UTR,O
and,O
are,O
numbered,O
starting,O
at,O
the,O
first,O
nucleotide,O
after,O
the,O
stop,O
codon,O
.,O
Quikchange,O
Lightning,O
Site,O
-,O
directed,O
Mutagenesis,O
Kit,O
from,O
Stratagene,O
(,O
Cat,O
.,O
no,O
.#,O
10518,O
),O
was,O
used,O
to,O
mutate,O
the,O
miRNA,O
binding,O
sites,O
in,O
the,O
mouse,B-OG
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
.,O
Primers,O
were,O
designed,O
using,O
the,O
Primerdesign,O
program,O
from,O
Promega,O
(,O
Table,O
1,O
).,O
In,O
order,O
to,O
avoid,O
the,O
possibility,O
that,O
the,O
mutated,O
sequence,O
itself,O
forms,O
a,O
microRNA,O
target,O
",",O
the,O
corresponding,O
“,O
new,O
”,O
seed,O
region,O
was,O
used,O
to,O
search,O
for,O
predicted,O
targets,O
of,O
novel,O
small,O
RNAs,O
in,O
TargetscanCustom,O
4,O
.,O
2,O
.,O
(,O
http,O
://,O
www,O
.,O
targetscan,O
.,O
org,O
/,O
vert_42,O
/,O
seedmatch,O
.,O
html,O
).,O
Primers,O
used,O
for,O
mutagenesis,O
.,O
Primer,O
name,O
Sequence,O
miR,O
-,O
124,O
(,O
548,O
-,O
554,O
),O
F,O
5,O
′-,O
ggcaatttcctggtactcgggcccagacacagtgccc,O
-,O
3,O
′,O
miR,O
-,O
124,O
(,O
548,O
-,O
554,O
),O
R,O
5,O
′-,O
gggcactgtgtctgggcccgagtaccaggaaattgcc,O
-,O
3,O
′,O
miR,O
-,O
124,O
(,O
1639,O
-,O
1646,O
),O
F,O
5,O
′-,O
gcataccctttcagaatgaagccgggccaaaatctcagcagtctc,O
-,O
3,O
′,O
miR,O
-,O
124,O
(,O
1639,O
-,O
1646,O
),O
R,O
5,O
′-,O
gagactgctgagattttggcccgg,O
cttcattctgaaagggtatgc,O
-,O
3,O
′,O
miR,O
-,O
137,O
(,O
2495,O
-,O
2501,O
),O
F,O
5,O
′-,O
gctgggagaggcaggccccgggcttagaggtgacaacataggg,O
-,O
3,O
′,O
miR,O
-,O
137,O
(,O
2495,O
-,O
2501,O
),O
R,O
5,O
′-,O
ccctatgttgtcacctctaagcccggggcctgcctctcccagc,O
-,O
3,O
′,O
miR,O
-,O
137,O
(,O
2782,O
-,O
2788,O
),O
F,O
5,O
′-,O
gccaaaaactgtgccccgggcctggtcatacccagagcatgatgcag,O
-,O
3,O
′,O
miR,O
-,O
137,O
(,O
2782,O
-,O
2788,O
),O
R,O
5,O
′-,O
ctgcatcatgctctgggtatgaccaggcccggggcacagtttttggc,O
-,O
3,O
′,O
miR,O
-,O
137,O
(,O
2842,O
-,O
2848,O
),O
F,O
5,O
′-,O
ggttgtttgtaaacaataaccgggccagaataaacaaaatgcacagg,O
-,O
3,O
′,O
miR,O
-,O
137,O
(,O
2842,O
-,O
2848,O
),O
R,O
5,O
′-,O
cctgtgcattttgtttattctggcccggttattgtttacaaacaacc,O
-,O
3,O
′,O
miR,O
-,O
137,O
(,O
3061,O
-,O
3067,O
),O
F,O
5,O
′-,O
gccccccgctgttgggtacccgggccctttctgtatggtccgc,O
-,O
3,O
′,O
miR,O
-,O
137,O
(,O
3061,O
-,O
3067,O
),O
R,O
5,O
′-,O
gcggaccatacagaaagggcccgggtacccaacagcggggggc,O
-,O
3,O
′,O
miR,O
-,O
148,O
/,O
152,O
(,O
1674,O
-,O
1680,O
),O
F,O
5,O
′-,O
cagcagtctcttttggaccagcagcccctgaactgtaactaggag,O
-,O
3,O
′,O
miR,O
-,O
148,O
/,O
152,O
(,O
1674,O
-,O
1680,O
),O
R,O
5,O
′-,O
ctcctagttacagttcaggggctgctggtccaaaagagactgctg,O
-,O
3,O
′,O
miR,O
-,O
148,O
/,O
152,O
(,O
2931,O
-,O
2937,O
),O
F,O
5,O
′-,O
gttaatatttctgaaaaaaaaccgggccgggagaagttgatgttg,O
-,O
3,O
′,O
miR,O
-,O
148,O
/,O
152,O
(,O
2931,O
-,O
2937,O
),O
R,O
5,O
′-,O
caacatcaacttctcccggcccggttttttttcagaaatattaac,O
-,O
3,O
′,O
Mutated,O
bases,O
are,O
bold,O
and,O
underlined,O
.,O
Transfection,O
of,O
miRNAs,O
into,O
MeWo,O
cells,O
Cells,O
were,O
plated,O
at,O
1,O
.,O
4,O
−,O
2,O
×,O
105,O
density,O
on,O
6,O
well,O
plates,O
.,O
The,O
following,O
day,O
",",O
20,O
pmol,O
miRNA,O
or,O
20,O
pmol,O
miRNA,O
together,O
with,O
20,O
pmol,O
of,O
the,O
anti,O
-,O
miRNA,O
were,O
transfected,O
in,O
triplicate,O
with,O
Lipofectamin,O
2000,O
and,O
total,O
RNA,O
isolated,O
for,O
qRT,O
-,O
PCR,O
analysis,O
48,O
hrs,O
.,O
post,O
transfection,O
.,O
Subsequently,O
",",O
proteins,O
were,O
extracted,O
and,O
analyzed,O
.,O
RNA,O
extraction,O
and,O
cDNA,O
synthesis,O
Total,O
RNA,O
was,O
extracted,O
from,O
MeWo,O
cells,O
using,O
TRIzol,O
Reagent,O
(,O
Invitrogen,O
"),",O
according,O
to,O
the,O
manufacturers,O
protocol,O
[,O
35,O
].,O
RNA,O
quantity,O
was,O
measured,O
using,O
Nanodrop,O
Spectrophotometer,O
ND,O
-,O
1000,O
and,O
RNA,O
integrity,O
was,O
determined,O
using,O
Agilent,O
2100,O
Bioanalyzer,O
.,O
RNA,O
Integrity,O
number,O
was,O
above,O
7,O
.,O
6,O
in,O
all,O
cases,O
.,O
RNA,O
was,O
treated,O
with,O
DNAseI,B-GP
and,O
purified,O
with,O
the,O
RNEasy,O
Minelute,O
kit,O
from,O
Qiagen,O
.,O
Purified,O
RNA,O
(,O
1,O
µg,O
in,O
10,O
µl,O
reaction,O
),O
was,O
used,O
for,O
cDNA,O
synthesis,O
with,O
Superscript,O
III,O
RT,O
(,O
200,O
U,O
/,O
µl,O
"),",O
and,O
anchored,O
Oligo,O
(,O
dT,O
),O
20,O
primer,O
according,O
to,O
the,O
manufacturers,O
protocol,O
.,O
The,O
RNA,O
samples,O
were,O
tested,O
for,O
absence,O
of,O
inhibitors,O
using,O
the,O
SPUD,O
assay,O
-,O
no,O
inhibitors,O
were,O
detected,O
[,O
36,O
].,O
Quantitative,O
reverse,O
transcription,O
PCR,O
Human,B-OG
MITF,B-GP
mRNA,O
was,O
measured,O
in,O
total,O
RNA,O
samples,O
extracted,O
from,O
MeWo,O
cells,O
",",O
using,O
the,O
human,B-OG
MITF,B-GP
FAM,O
-,O
labelled,O
TaqMan,O
Gene,O
Expression,O
Assay,O
(,O
hs01115560,O
),O
(,O
Applied,O
Biosystems,O
).,O
Samples,O
were,O
measured,O
in,O
triplicate,O
.,O
Two,O
controls,O
were,O
included,O
",",O
one,O
without,O
RT,O
and,O
the,O
other,O
without,O
template,O
.,O
Standard,O
conditions,O
for,O
TaqMan,O
reagents,O
were,O
used,O
.,O
The,O
results,O
were,O
normalized,O
to,O
total,O
RNA,O
(,O
Log250,O
).,O
β,B-GP
-,I-GP
actin,I-GP
was,O
used,O
as,O
a,O
control,O
for,O
the,O
miRNA,O
inhibitor,O
experiment,O
.,O
qRT,O
-,O
PCR,O
results,O
were,O
analysed,O
using,O
the,O
GenEx,O
Std,O
.,O
4,O
.,O
4,O
.,O
2,O
.,O
software,O
from,O
MultiD,O
analyses,O
AB,O
(,O
Sweden,O
).,O
Western,O
blot,O
Proteins,O
were,O
isolated,O
from,O
the,O
phenol,O
-,O
ethanol,O
supernatant,O
after,O
RNA,O
and,O
DNA,O
had,O
been,O
isolated,O
using,O
the,O
Trizol,O
reagent,O
(,O
Invitrogen,O
"),",O
according,O
to,O
the,O
manufacturers,O
protocol,O
[,O
35,O
].,O
The,O
proteins,O
were,O
separated,O
on,O
a,O
10,O
%,O
SDS,O
-,O
PAGE,O
polyacrylamide,O
gel,O
.,O
The,O
proteins,O
were,O
electroblotted,O
onto,O
a,O
PVDF,O
transfer,O
membrane,O
(,O
Thermo,O
Scientific,O
).,O
The,O
membrane,O
was,O
immunoblotted,O
overnight,O
at,O
4,O
°,O
C,O
with,O
primary,O
antibody,O
",",O
(,O
C5,O
mouse,B-OG
-,O
anti,O
-,O
Mitf,B-GP
monoclonal,O
antibody,O
"),",O
in,O
Tris,O
-,O
buffered,O
saline,O
with,O
5,O
%,O
milk,O
.,O
The,O
C5,O
mouse,B-OG
-,O
anti,O
-,O
Mitf,B-GP
monoclonal,O
antibody,O
is,O
raised,O
against,O
the,O
N,O
-,O
terminus,O
of,O
MITF,B-GP
.,O
This,O
antibody,O
detects,O
all,O
isoforms,O
of,O
MITF,B-GP
and,O
does,O
not,O
differentiate,O
between,O
them,O
.,O
A,O
horse,B-OG
-,I-OG
radish,I-OG
peroxidase,B-GP
labelled,O
anti,O
-,O
mouse,B-OG
secondary,O
antibody,O
(,O
Jackson,O
),O
was,O
incubated,O
with,O
the,O
membrane,O
for,O
1,O
hr,O
.,O
after,O
washing,O
with,O
TBST,O
.,O
Signals,O
were,O
detected,O
with,O
ECL,O
reagent,O
from,O
Thermo,O
Scientific,O
.,O
Endogenous,O
miRNA,O
expression,O
Total,O
RNA,O
was,O
isolated,O
from,O
MeWo,O
",",O
501mel,O
and,O
HEK293,O
cells,O
as,O
before,O
and,O
samples,O
in,O
triplicate,O
were,O
sent,O
to,O
Exiqon,O
for,O
analysis,O
using,O
the,O
miRCURY,O
LNA,O
microRNA,O
PCR,O
system,O
.,O
PCR,O
assays,O
for,O
hsa,O
-,O
miR,O
-,O
137,O
(,O
MIMAT0000429,O
"),",O
hsa,O
-,O
miR,O
-,O
124,O
(,O
MIMAT0000422,O
"),",O
hsa,O
-,O
miR,O
-,O
506,O
(,O
MIMAT0002878,O
"),",O
hsa,O
-,O
miR,O
-,O
148a,O
(,O
MIMAT0000243,O
"),",O
hsa,O
-,O
miR,O
-,O
148b,O
(,O
MIMAT0000759,O
),O
and,O
hsa,O
-,O
miR,O
-,O
152,O
(,O
MIMAT0000438,O
),O
were,O
used,O
to,O
measure,O
endogenous,O
miRNA,O
expression,O
.,O
Statistical,O
analysis,O
T,O
-,O
test,O
analysis,O
(,O
for,O
independent,O
groups,O
),O
was,O
performed,O
on,O
results,O
from,O
the,O
luciferase,B-GP
assays,O
",",O
qRT,O
-,O
PCR,O
results,O
from,O
transfection,O
in,O
MeWo,O
cells,O
and,O
endogenous,O
miRNA,O
expression,O
analysis,O
.,O
Results,O
The,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
and,O
potential,O
microRNA,O
binding,O
sites,O
The,O
mouse,B-OG
and,O
human,B-OG
Mitf,B-GP
3,O
′,O
UTR,O
sequences,O
are,O
unusually,O
long,O
or,O
over,O
3,O
kb,O
in,O
length,O
.,O
This,O
is,O
considerably,O
larger,O
than,O
the,O
average,O
mouse,B-OG
and,O
human,B-OG
3,O
′,O
UTR,O
sequences,O
which,O
are,O
559,O
and,O
826,O
nucleotides,O
",",O
respectively,O
[,O
37,O
].,O
The,O
overall,O
conservation,O
of,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
in,O
11,O
vertebrate,O
species,O
is,O
36,O
%,O
[,O
38,O
],O
which,O
is,O
very,O
high,O
for,O
a,O
non,O
-,O
coding,O
region,O
.,O
This,O
suggests,O
a,O
functional,O
relevance,O
of,O
the,O
3,O
′,O
UTR,O
sequence,O
of,O
Mitf,B-GP
.,O
Using,O
the,O
TargetScan,O
program,O
(,O
www,O
.,O
targetscan,O
.,O
org,O
"),",O
we,O
identified,O
several,O
miRNA,O
binding,O
sites,O
located,O
in,O
the,O
most,O
conserved,O
areas,O
of,O
the,O
3,O
′,O
UTR,O
region,O
.,O
We,O
tested,O
the,O
effects,O
of,O
microRNAs,O
which,O
have,O
conserved,O
binding,O
sites,O
in,O
the,O
3,O
′,O
UTR,O
region,O
of,O
Mitf,B-GP
",",O
including,O
miR,O
-,O
27a,O
(,O
located,O
at,O
229,O
–,O
235,O
in,O
the,O
mouse,B-OG
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
"),",O
miR,O
-,O
25,O
/,O
32,O
/,O
92,O
/,O
363,O
/,O
367,O
(,O
1491,O
–,O
1497,O
"),",O
miR,O
-,O
101,O
/,O
144,O
(,O
3023,O
–,O
3029,O
"),",O
miR,O
-,O
124,O
/,O
506,O
(,O
1639,O
–,O
1646,O
),O
and,O
miR,O
-,O
148,O
/,O
152,O
(,O
1674,O
–,O
1680,O
and,O
2931,O
–,O
2937,O
),O
(,O
Fig,O
.,O
1A,O
and,O
1B,O
).,O
miR,O
-,O
124,O
/,O
506,O
also,O
has,O
a,O
less,O
conserved,O
binding,O
site,O
at,O
548,O
–,O
554,O
",",O
and,O
was,O
therefore,O
also,O
tested,O
in,O
our,O
study,O
.,O
In,O
addition,O
",",O
the,O
potential,O
binding,O
sites,O
for,O
miR,O
-,O
137,O
were,O
tested,O
as,O
the,O
mouse,B-OG
and,O
human,B-OG
Mitf,B-GP
3,O
′,O
UTR,O
sequences,O
both,O
contain,O
two,O
well,O
conserved,O
miR,O
-,O
137,O
binding,O
sites,O
located,O
in,O
close,O
proximity,O
to,O
each,O
other,O
",",O
137C,O
(,O
2842,O
–,O
2848,O
),O
and,O
137D,O
(,O
3061,O
–,O
3067,O
).,O
Two,O
additional,O
less,O
conserved,O
miR,O
-,O
137,O
binding,O
sites,O
were,O
found,O
",",O
one,O
only,O
in,O
the,O
mouse,B-OG
3,O
′,O
UTR,O
",",O
namely,O
137A,O
(,O
2495,O
–,O
2501,O
),O
and,O
one,O
conserved,O
in,O
the,O
mouse,B-OG
and,O
rat,B-OG
3,O
′,O
UTR,O
sequences,O
",",O
137B,O
(,O
2782,O
–,O
2788,O
).,O
It,O
has,O
been,O
shown,O
that,O
single,O
miRNAs,O
with,O
multiple,O
binding,O
sites,O
in,O
a,O
3,O
′,O
UTR,O
sequence,O
have,O
increased,O
effects,O
as,O
compared,O
to,O
miRNAs,O
with,O
only,O
a,O
single,O
binding,O
site,O
[,O
39,O
"],",O
[,O
40,O
].,O
This,O
is,O
also,O
true,O
when,O
the,O
binding,O
sites,O
are,O
located,O
in,O
close,O
proximity,O
to,O
each,O
other,O
[,O
41,O
].,O
In,O
some,O
cases,O
",",O
several,O
different,O
miRNA,O
molecules,O
can,O
potentially,O
bind,O
to,O
the,O
same,O
binding,O
site,O
.,O
In,O
these,O
cases,O
only,O
one,O
representative,O
miRNA,O
molecule,O
was,O
chosen,O
to,O
test,O
the,O
functionality,O
of,O
that,O
specific,O
binding,O
site,O
.,O
If,O
the,O
representative,O
miRNA,O
was,O
able,O
to,O
downregulate,O
via,O
the,O
binding,O
site,O
",",O
it,O
indicates,O
that,O
the,O
other,O
potential,O
miRNAs,O
may,O
also,O
be,O
able,O
to,O
regulate,O
Mitf,B-GP
expression,O
.,O
miR,O
-,O
182,O
has,O
been,O
shown,O
previously,O
to,O
target,O
the,O
3,O
′,O
UTR,O
of,O
Mitf,B-GP
and,O
was,O
used,O
as,O
a,O
positive,O
control,O
[,O
32,O
].,O
Schematic,O
presentation,O
of,O
the,O
mouse,B-OG
Mitf,B-GP
-,O
3,O
′,O
UTR,O
sequence,O
.,O
A,O
.,O
The,O
line,O
indicates,O
the,O
3,O
′,O
UTR,O
region,O
of,O
the,O
mouse,B-OG
Mitf,B-GP
gene,O
",",O
including,O
the,O
coding,O
region,O
of,O
exon,O
9,O
.,O
Potential,O
binding,O
sites,O
for,O
miR,O
-,O
27,O
",",O
miR,O
-,O
124,O
/,O
506,O
",",O
miR,O
-,O
25,O
/,O
32,O
/,O
92,O
/,O
363,O
/,O
367,O
",",O
miR,O
-,O
148,O
/,O
152,O
",",O
miR,O
-,O
137,O
and,O
miR,O
-,O
101,O
/,O
144,O
in,O
the,O
mMitf,B-GP
3,O
′,O
UTR,O
sequence,O
are,O
indicated,O
below,O
the,O
line,O
and,O
potential,O
PAS,O
sites,O
above,O
.,O
Positions,O
are,O
based,O
on,O
the,O
mouse,B-OG
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
and,O
are,O
numbered,O
starting,O
at,O
the,O
first,O
nucleotide,O
after,O
the,O
stop,O
codon,O
.,O
Black,O
bars,O
:,O
miR,O
-,O
124,O
/,O
506,O
binding,O
sites,O
",",O
dark,O
grey,O
bars,O
:,O
miR,O
-,O
137,O
binding,O
sites,O
",",O
light,O
grey,O
bars,O
:,O
miR,O
-,O
148,O
/,O
152,O
binding,O
sites,O
",",O
white,O
bars,O
:,O
miR,O
-,O
27,O
",",O
miR,O
-,O
25,O
/,O
32,O
/,O
92,O
/,O
363,O
/,O
367,O
and,O
miR,O
-,O
101,O
/,O
144,O
.,O
B,O
.,O
The,O
conservation,O
of,O
potential,O
miRNA,O
binding,O
sites,O
in,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
.,O
Dots,O
represent,O
a,O
conserved,O
base,O
",",O
short,O
lines,O
represent,O
absence,O
of,O
a,O
sequence,O
at,O
this,O
location,O
.,O
C,O
.,O
Mutations,O
made,O
in,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
.,O
The,O
wild,O
type,O
mouse,B-OG
Mitf,B-GP
mRNA,O
sequence,O
is,O
shown,O
with,O
potential,O
binding,O
sites,O
indicated,O
in,O
red,O
.,O
The,O
mature,O
miRNA,O
sequence,O
and,O
potential,O
binding,O
between,O
the,O
miRNA,O
seed,O
region,O
to,O
the,O
3,O
′,O
UTR,O
sequence,O
are,O
shown,O
and,O
mutated,O
bases,O
are,O
indicated,O
above,O
the,O
mRNA,O
sequence,O
.,O
miR,O
-,O
148,O
/,O
152,O
affects,O
mMitf,B-GP
RNA,O
in,O
melanoma,B-DS
cells,O
To,O
test,O
the,O
functionality,O
of,O
the,O
miRNA,O
binding,O
sites,O
",",O
the,O
mouse,B-OG
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
was,O
cloned,O
downstream,O
of,O
a,O
luciferase,B-GP
reporter,O
gene,O
.,O
This,O
vector,O
was,O
then,O
co,O
-,O
transfected,O
into,O
cells,O
together,O
with,O
single,O
miRNA,O
molecules,O
and,O
effects,O
of,O
the,O
specific,O
miRNAs,O
on,O
expression,O
determined,O
by,O
measuring,O
luciferase,B-GP
activity,O
.,O
In,O
501mel,O
cells,O
",",O
miR,O
-,O
148,O
had,O
significant,O
effects,O
on,O
expression,O
of,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
(,O
Fig,O
.,O
2A,O
).,O
Co,O
-,O
transfection,O
with,O
miR,O
-,O
101,O
resulted,O
in,O
some,O
downregulation,O
of,O
the,O
reporter,O
whereas,O
other,O
miRNAs,O
tested,O
did,O
not,O
show,O
statistically,O
significant,O
effects,O
compared,O
to,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
vector,O
alone,O
.,O
When,O
determining,O
how,O
effective,O
each,O
miRNA,O
was,O
in,O
our,O
assay,O
",",O
the,O
expression,O
from,O
the,O
vector,O
when,O
co,O
-,O
transfected,O
with,O
the,O
miRNA,O
was,O
compared,O
to,O
the,O
expression,O
from,O
the,O
vector,O
alone,O
.,O
Effects,O
of,O
microRNAs,O
on,O
the,O
Mitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
.,O
A,O
.,O
Effects,O
of,O
miRNAs,O
on,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
in,O
501melanoma,O
cells,O
.,O
Three,O
concentrations,O
of,O
miRNAs,O
were,O
tested,O
:,O
0,O
.,O
1,O
pmol,O
",",O
0,O
.,O
5,O
pmol,O
and,O
1,O
pmol,O
.,O
Results,O
in,O
all,O
panels,O
are,O
presented,O
as,O
mean,O
values,O
±,O
SD,O
.,O
Difference,O
between,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
vector,O
with,O
and,O
without,O
co,O
-,O
transfected,O
miRNA,O
was,O
considered,O
statistically,O
significant,O
when,O
p,O
<,O
0,O
.,O
05,O
",",O
shown,O
with,O
an,O
asterisk,O
(,O
T,O
-,O
test,O
",",O
95,O
%,O
confidence,O
level,O
).,O
P,O
-,O
values,O
are,O
presented,O
in,O
Table,O
S1,O
.,O
B,O
.,O
Effects,O
of,O
miRNAs,O
on,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
vector,O
in,O
HEK293,O
cells,O
.,O
Three,O
concentrations,O
of,O
miRNAs,O
were,O
tested,O
:,O
0,O
.,O
1,O
pmol,O
",",O
0,O
.,O
5,O
pmol,O
and,O
1,O
pmol,O
.,O
C,O
.,O
Effects,O
of,O
miRNAs,O
when,O
transfected,O
in,O
combination,O
with,O
another,O
miRNA,O
on,O
the,O
reporter,O
.,O
Concentration,O
of,O
each,O
miRNA,O
is,O
0,O
.,O
5,O
pmol,O
.,O
miR,O
-,O
137,O
and,O
miR,O
-,O
124,O
/,O
506,O
affect,O
mMitf,B-GP
RNA,O
in,O
HEK293,O
cells,O
The,O
luciferase,B-GP
assay,O
experiments,O
were,O
also,O
performed,O
in,O
human,B-OG
embryonic,O
kidney,O
cells,O
(,O
HEK293,O
"),",O
which,O
do,O
not,O
express,O
Mitf,B-GP
at,O
significant,O
levels,O
.,O
The,O
effects,O
of,O
the,O
miRNAs,O
in,O
HEK293,O
cells,O
are,O
different,O
from,O
the,O
effects,O
seen,O
in,O
501mel,O
melanoma,B-DS
cells,O
.,O
In,O
HEK293,O
cells,O
the,O
microRNA,O
miR,O
-,O
137,O
negatively,O
affected,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
construct,O
",",O
compared,O
to,O
the,O
reporter,O
construct,O
alone,O
(,O
Fig,O
.,O
2B,O
).,O
miR,O
-,O
148,O
affected,O
the,O
reporter,O
only,O
when,O
transfected,O
at,O
the,O
highest,O
concentration,O
(,O
1pmol,O
),O
(,O
Fig,O
.,O
2B,O
).,O
miR,O
-,O
124,O
",",O
however,O
resulted,O
in,O
significant,O
increase,O
in,O
reporter,O
gene,O
expression,O
.,O
The,O
other,O
miRNAs,O
tested,O
",",O
miR,O
-,O
27,O
",",O
miR,O
-,O
32,O
and,O
miR,O
-,O
101,O
did,O
not,O
show,O
significant,O
effects,O
on,O
luciferase,B-GP
expression,O
in,O
this,O
assay,O
(,O
Fig,O
.,O
2B,O
).,O
This,O
is,O
surprising,O
as,O
the,O
binding,O
sites,O
for,O
these,O
three,O
miRNAs,O
are,O
very,O
well,O
conserved,O
.,O
All,O
Mitf,B-GP
3,O
′,O
UTR,O
sequences,O
in,O
11,O
vertebrate,O
species,O
analysed,O
contain,O
the,O
miR,O
-,O
27,O
",",O
miR,O
-,O
25,O
/,O
32,O
/,O
92,O
/,O
363,O
/,O
367,O
and,O
the,O
miR,O
-,O
101,O
/,O
144,O
binding,O
sites,O
(,O
Fig,O
.,O
1B,O
).,O
In,O
addition,O
",",O
seven,O
species,O
contain,O
a,O
conserved,O
second,O
miR,O
-,O
101,O
/,O
144,O
binding,O
site,O
.,O
Despite,O
this,O
conservation,O
",",O
these,O
sites,O
do,O
not,O
seem,O
to,O
be,O
regulated,O
by,O
miRNAs,O
in,O
our,O
assays,O
.,O
The,O
different,O
results,O
in,O
melanoma,B-DS
cells,O
as,O
compared,O
to,O
HEK293,O
cells,O
might,O
be,O
explained,O
by,O
different,O
levels,O
of,O
endogenous,O
miRNA,O
expression,O
in,O
these,O
cell,O
types,O
.,O
If,O
one,O
of,O
the,O
miRNAs,O
tested,O
has,O
high,O
endogenous,O
expression,O
in,O
one,O
of,O
the,O
cell,O
types,O
it,O
would,O
affect,O
the,O
expression,O
of,O
the,O
reporter,O
alone,O
.,O
Adding,O
more,O
of,O
the,O
miRNA,O
would,O
presumably,O
not,O
make,O
a,O
major,O
difference,O
.,O
Thus,O
",",O
the,O
effects,O
of,O
the,O
transfected,O
miRNA,O
would,O
be,O
masked,O
by,O
the,O
endogenous,O
expression,O
of,O
the,O
miRNA,O
.,O
Many,O
different,O
miRNAs,O
can,O
bind,O
simultaneously,O
to,O
a,O
specific,O
3,O
′,O
UTR,O
sequence,O
and,O
affect,O
expression,O
.,O
Thus,O
",",O
we,O
tested,O
if,O
transfecting,O
two,O
different,O
miRNAs,O
simultaneously,O
would,O
reveal,O
additive,O
effects,O
.,O
The,O
results,O
are,O
compared,O
to,O
expression,O
by,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
alone,O
.,O
When,O
miR,O
-,O
137,O
was,O
combined,O
with,O
other,O
miRNAs,O
",",O
the,O
effects,O
were,O
always,O
equal,O
to,O
the,O
effects,O
observed,O
with,O
miR,O
-,O
137,O
alone,O
.,O
Also,O
",",O
when,O
miR,O
-,O
124,O
was,O
combined,O
with,O
other,O
miRNAs,O
",",O
the,O
effects,O
were,O
always,O
equal,O
to,O
the,O
effects,O
observed,O
with,O
miR,O
-,O
124,O
alone,O
.,O
When,O
miR,O
-,O
124,O
and,O
miR,O
-,O
137,O
were,O
combined,O
",",O
the,O
same,O
effect,O
was,O
observed,O
as,O
when,O
miR,O
-,O
137,O
was,O
transfected,O
alone,O
(,O
Fig,O
.,O
2C,O
).,O
Other,O
combinations,O
of,O
two,O
miRNAs,O
did,O
not,O
show,O
increased,O
effects,O
.,O
Thus,O
",",O
we,O
detect,O
no,O
cooperation,O
among,O
the,O
miRNA,O
molecules,O
with,O
respect,O
to,O
effects,O
on,O
Mitf,B-GP
.,O
Roles,O
of,O
individual,O
miRNA,O
target,O
sites,O
revealed,O
through,O
mutagenesis,O
To,O
confirm,O
that,O
the,O
miRNAs,O
which,O
show,O
effects,O
on,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
are,O
in,O
fact,O
operating,O
through,O
the,O
predicted,O
potential,O
binding,O
sites,O
",",O
the,O
miRNA,O
binding,O
sites,O
were,O
mutated,O
in,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
vector,O
and,O
the,O
vector,O
then,O
co,O
-,O
transfected,O
into,O
cells,O
together,O
with,O
the,O
specific,O
miRNAs,O
",",O
as,O
before,O
.,O
miRNAs,O
bind,O
to,O
their,O
3,O
′,O
UTR,O
binding,O
site,O
through,O
a,O
seed,O
region,O
located,O
at,O
position,O
2,O
–,O
7,O
or,O
2,O
–,O
8,O
in,O
the,O
mature,O
miRNA,O
sequence,O
[,O
27,O
"],",O
[,O
42,O
].,O
We,O
mutated,O
all,O
7,O
bases,O
in,O
the,O
3,O
′,O
UTR,O
binding,O
site,O
matching,O
the,O
seed,O
region,O
of,O
the,O
mature,O
miRNAs,O
in,O
order,O
to,O
abolish,O
completely,O
the,O
binding,O
of,O
the,O
miRNA,O
.,O
In,O
the,O
case,O
of,O
one,O
of,O
the,O
miR,O
-,O
148,O
binding,O
site,O
",",O
148,O
/,O
152A,O
",",O
only,O
4,O
bases,O
were,O
mutated,O
as,O
a,O
clone,O
with,O
the,O
fully,O
mutated,O
binding,O
site,O
was,O
not,O
generated,O
successfully,O
.,O
The,O
mutations,O
are,O
shown,O
in,O
Fig,O
.,O
1C,O
and,O
the,O
primers,O
used,O
for,O
mutagenesis,O
in,O
Table,O
1,O
.,O
Role,O
of,O
the,O
miR,O
-,O
148,O
/,O
152,O
target,O
sites,O
There,O
are,O
two,O
target,O
sites,O
for,O
miR,O
-,O
148,O
/,O
152,O
in,O
the,O
mouse,B-OG
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
.,O
Each,O
of,O
the,O
two,O
sites,O
were,O
mutated,O
",",O
148,O
/,O
152A,O
located,O
at,O
1674,O
–,O
1680,O
",",O
and,O
148,O
/,O
152B,O
located,O
at,O
2931,O
–,O
2937,O
(,O
Fig,O
1A,O
).,O
In,O
these,O
experiments,O
",",O
we,O
define,O
the,O
expression,O
level,O
of,O
the,O
vector,O
alone,O
as,O
100,O
%.,O
When,O
determining,O
how,O
effective,O
each,O
mutation,O
was,O
in,O
our,O
assays,O
",",O
expression,O
of,O
luciferase,B-GP
from,O
the,O
mutated,O
vector,O
alone,O
was,O
compared,O
to,O
expression,O
from,O
the,O
mutated,O
vector,O
when,O
co,O
-,O
transfected,O
with,O
the,O
appropriate,O
miRNA,O
.,O
When,O
both,O
binding,O
sites,O
were,O
functional,O
miR,O
-,O
148,O
downregulated,O
reporter,O
gene,O
expression,O
to,O
50,O
–,O
60,O
%,O
compared,O
to,O
expression,O
from,O
the,O
vector,O
alone,O
in,O
501mel,O
cells,O
(,O
p,O
=,O
0,O
.,O
0140,O
),O
(,O
Fig,O
.,O
3A,O
).,O
When,O
the,O
148,O
/,O
152A,O
binding,O
site,O
was,O
mutated,O
",",O
miR,O
-,O
148,O
downregulated,O
reporter,O
gene,O
expression,O
to,O
47,O
%,O
(,O
p,O
=,O
0,O
.,O
0049,O
).,O
However,O
",",O
when,O
the,O
148,O
/,O
152B,O
binding,O
site,O
was,O
mutated,O
",",O
miR,O
-,O
148,O
was,O
no,O
longer,O
able,O
to,O
downregulate,O
reporter,O
gene,O
expression,O
(,O
p,O
=,O
0,O
.,O
3929,O
).,O
When,O
both,O
binding,O
sites,O
were,O
mutated,O
",",O
reporter,O
gene,O
expression,O
was,O
the,O
same,O
as,O
when,O
148,O
/,O
152B,O
was,O
mutated,O
(,O
118,O
"%,",O
p,O
=,O
0,O
.,O
4918,O
).,O
These,O
results,O
indicate,O
that,O
miR,O
-,O
148,O
is,O
able,O
to,O
downregulate,O
Mitf,B-GP
expression,O
by,O
binding,O
to,O
the,O
148,O
/,O
152B,O
binding,O
site,O
.,O
Mutating,O
miRNA,O
binding,O
sites,O
affects,O
the,O
Mitf,B-GP
mRNA,O
.,O
A,O
.,O
Effects,O
of,O
miR,O
-,O
148,O
on,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
when,O
the,O
potential,O
binding,O
sites,O
are,O
mutated,O
.,O
Results,O
in,O
all,O
panels,O
are,O
presented,O
as,O
mean,O
values,O
±,O
SD,O
.,O
Difference,O
between,O
the,O
appropriate,O
vector,O
(,O
labeled,O
on,O
the,O
X,O
-,O
axis,O
),O
with,O
and,O
without,O
co,O
-,O
transfected,O
miRNA,O
was,O
considered,O
statistically,O
significant,O
when,O
p,O
<,O
0,O
.,O
05,O
",",O
shown,O
with,O
an,O
asterisk,O
(,O
T,O
-,O
test,O
",",O
95,O
%,O
confidence,O
level,O
).,O
P,O
-,O
values,O
are,O
presented,O
in,O
Table,O
S1,O
.,O
B,O
.,O
Effects,O
of,O
miR,O
-,O
137,O
on,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
when,O
the,O
potential,O
binding,O
sites,O
are,O
mutated,O
.,O
C,O
.,O
Effects,O
of,O
miR,O
-,O
124,O
on,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
when,O
the,O
potential,O
binding,O
sites,O
are,O
mutated,O
.,O
Role,O
of,O
the,O
miR,O
-,O
137,O
target,O
sites,O
The,O
four,O
target,O
sites,O
for,O
miR,O
-,O
137,O
in,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
",",O
137A,O
(,O
2495,O
–,O
2501,O
"),",O
137B,O
(,O
2782,O
–,O
2788,O
"),",O
137C,O
(,O
2842,O
–,O
2848,O
),O
and,O
137D,O
(,O
3061,O
–,O
3067,O
),O
were,O
mutated,O
seperatly,O
.,O
In,O
addition,O
",",O
a,O
double,O
mutant,O
was,O
created,O
where,O
the,O
most,O
conserved,O
sites,O
137C,O
and,O
137D,O
were,O
changed,O
simultaneously,O
",",O
a,O
triple,O
mutant,O
with,O
137B,O
",",O
137C,O
and,O
137D,O
mutated,O
and,O
a,O
mutant,O
where,O
all,O
four,O
potential,O
binding,O
sites,O
were,O
changed,O
(,O
Fig,O
.,O
1C,O
).,O
The,O
mutated,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
constructs,O
were,O
co,O
-,O
transfected,O
together,O
with,O
the,O
miRNAs,O
in,O
HEK293,O
cells,O
.,O
When,O
all,O
the,O
miR,O
-,O
137,O
binding,O
sites,O
are,O
functional,O
",",O
miR,O
-,O
137,O
reduced,O
expression,O
from,O
the,O
luciferase,B-GP
reporter,O
to,O
only,O
10,O
%,O
(,O
p,O
=,O
0,O
.,O
0015,O
),O
compared,O
to,O
the,O
vector,O
alone,O
(,O
Fig,O
.,O
3B,O
).,O
When,O
miR,O
-,O
137,O
was,O
co,O
-,O
transfected,O
with,O
a,O
reporter,O
construct,O
containing,O
the,O
mutant,O
site,O
137A,O
",",O
expression,O
from,O
the,O
luciferase,B-GP
reporter,O
was,O
7,O
%,O
compared,O
to,O
the,O
vector,O
alone,O
(,O
p,O
<,O
0,O
.,O
0001,O
).,O
This,O
is,O
similar,O
reduction,O
as,O
was,O
seen,O
with,O
the,O
wild,O
type,O
construct,O
",",O
suggesting,O
that,O
this,O
site,O
has,O
no,O
role,O
in,O
the,O
response,O
to,O
miR,O
-,O
137,O
(,O
Fig,O
.,O
3B,O
).,O
Mutating,O
the,O
137B,O
site,O
resulted,O
in,O
16,O
%,O
expression,O
(,O
p,O
<,O
0,O
.,O
0001,O
),O
which,O
is,O
a,O
little,O
less,O
reduction,O
than,O
was,O
seen,O
when,O
all,O
the,O
potential,O
binding,O
sites,O
were,O
functional,O
.,O
When,O
the,O
more,O
conserved,O
site,O
137C,O
was,O
mutated,O
",",O
expression,O
from,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
was,O
reduced,O
to,O
19,O
%,O
(,O
p,O
=,O
0,O
.,O
0001,O
),O
(,O
Fig,O
.,O
3B,O
"),",O
indicating,O
a,O
functional,O
role,O
of,O
miR,O
-,O
137C,O
.,O
Mutating,O
the,O
other,O
well,O
conserved,O
binding,O
site,O
137D,O
resulted,O
in,O
reduction,O
to,O
23,O
%,O
expression,O
(,O
p,O
=,O
0,O
.,O
0001,O
),O
of,O
the,O
mutated,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
(,O
Fig,O
.,O
3B,O
"),",O
again,O
indicating,O
a,O
functional,O
target,O
site,O
.,O
When,O
the,O
two,O
best,O
conserved,O
binding,O
sites,O
(,O
137C,O
and,O
137D,O
),O
were,O
simultaneously,O
mutated,O
",",O
reporter,O
expression,O
was,O
32,O
%,O
(,O
p,O
=,O
0,O
.,O
0001,O
),O
compared,O
to,O
expression,O
from,O
the,O
mutated,O
vector,O
alone,O
",",O
suggesting,O
that,O
sites,O
C,O
and,O
D,O
play,O
a,O
major,O
role,O
in,O
the,O
response,O
to,O
miR,O
-,O
137,O
.,O
Surprisingly,O
",",O
when,O
miR,O
-,O
137,O
was,O
co,O
-,O
transfected,O
with,O
a,O
reporter,O
construct,O
lacking,O
the,O
3,O
′,O
UTR,O
sequence,O
of,O
Mitf,B-GP
",",O
miR,O
-,O
137,O
downregulated,O
luciferase,B-GP
expression,O
to,O
27,O
%,O
(,O
Fig,O
.,O
3B,O
).,O
This,O
suggests,O
that,O
the,O
luciferase,B-GP
vector,O
has,O
binding,O
sites,O
for,O
miR,O
-,O
137,O
.,O
Indeed,O
",",O
our,O
search,O
for,O
miR,O
-,O
137,O
binding,O
sites,O
in,O
the,O
luciferase,B-GP
gene,O
itself,O
resulted,O
in,O
3,O
matching,O
sequences,O
.,O
There,O
are,O
reports,O
showing,O
that,O
binding,O
sites,O
within,O
the,O
coding,O
regions,O
of,O
genes,O
can,O
result,O
in,O
effects,O
on,O
gene,O
expression,O
[,O
43,O
].,O
It,O
is,O
also,O
possible,O
that,O
the,O
miR,O
-,O
137,O
is,O
affecting,O
other,O
components,O
(,O
genes,O
/,O
transcripts,O
),O
that,O
are,O
involved,O
in,O
the,O
transcription,O
of,O
the,O
luciferase,B-GP
gene,O
.,O
Thus,O
",",O
when,O
sites,O
137C,O
and,O
137D,O
were,O
mutated,O
simultaneously,O
",",O
the,O
expression,O
of,O
the,O
reporter,O
was,O
reduced,O
to,O
32,O
%,O
which,O
is,O
very,O
similar,O
to,O
the,O
level,O
of,O
expression,O
when,O
all,O
miR,O
-,O
137,O
binding,O
sites,O
are,O
funcional,O
(,O
27,O
"%),",O
suggesting,O
that,O
all,O
the,O
effects,O
of,O
miR,O
-,O
137,O
on,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
are,O
mediated,O
through,O
these,O
two,O
sites,O
.,O
When,O
three,O
or,O
all,O
four,O
miR,O
-,O
137,O
binding,O
sites,O
were,O
mutated,O
simultaneously,O
",",O
the,O
mutated,O
vector,O
alone,O
was,O
unable,O
to,O
express,O
the,O
luciferase,B-GP
gene,O
(,O
data,O
not,O
shown,O
).,O
One,O
possible,O
explanation,O
for,O
this,O
might,O
be,O
that,O
the,O
structure,O
of,O
the,O
3,O
′,O
UTR,O
is,O
altered,O
when,O
21,O
or,O
28,O
conserved,O
bases,O
are,O
mutated,O
",",O
leading,O
to,O
reduced,O
stability,O
or,O
effects,O
on,O
translation,O
of,O
the,O
message,O
.,O
miR,O
-,O
137,O
has,O
previously,O
been,O
shown,O
to,O
target,O
Mitf,B-GP
by,O
acting,O
through,O
the,O
best,O
conserved,O
miR,O
-,O
137,O
target,O
sites,O
[,O
31,O
].,O
However,O
",",O
in,O
that,O
study,O
",",O
only,O
a,O
portion,O
of,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
was,O
used,O
in,O
the,O
analysis,O
[,O
31,O
].,O
In,O
our,O
analysis,O
",",O
however,O
",",O
the,O
entire,O
3,O
′,O
UTR,O
sequence,O
from,O
mouse,B-OG
Mitf,B-GP
(,O
over,O
3,O
kb,O
),O
was,O
used,O
to,O
analyse,O
the,O
role,O
of,O
the,O
binding,O
sites,O
.,O
This,O
more,O
closely,O
resembles,O
the,O
endogenous,O
situation,O
.,O
Our,O
results,O
therefore,O
confirm,O
the,O
role,O
of,O
miR,O
-,O
137,O
in,O
regulating,O
Mitf,B-GP
expression,O
.,O
Role,O
of,O
the,O
miR,O
-,O
124,O
/,O
506,O
target,O
sites,O
There,O
are,O
two,O
binding,O
sites,O
for,O
miR,O
-,O
124,O
/,O
506,O
in,O
the,O
mouse,B-OG
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
.,O
Site,O
124,O
/,O
506A,O
is,O
located,O
at,O
548,O
-,O
554,O
and,O
site,O
124,O
/,O
506B,O
at,O
1639,O
-,O
1646,O
in,O
the,O
mMitf,B-GP
3,O
′,O
UTR,O
sequence,O
.,O
When,O
both,O
binding,O
sites,O
are,O
functional,O
",",O
miR,O
-,O
124,O
positively,O
affects,O
luciferase,B-GP
expression,O
up,O
to,O
3,O
fold,O
compared,O
to,O
expression,O
from,O
the,O
vector,O
alone,O
in,O
HEK293,O
cells,O
(,O
p,O
=,O
0,O
.,O
0086,O
),O
(,O
Fig,O
.,O
3C,O
).,O
We,O
mutated,O
each,O
target,O
site,O
alone,O
and,O
also,O
made,O
a,O
double,O
mutation,O
changing,O
both,O
sites,O
.,O
When,O
the,O
124,O
/,O
506A,O
binding,O
site,O
was,O
mutated,O
",",O
miR,O
-,O
124,O
no,O
longer,O
affected,O
expression,O
of,O
the,O
reporter,O
gene,O
.,O
The,O
expression,O
was,O
only,O
81,O
%,O
compared,O
to,O
315,O
%,O
in,O
the,O
vector,O
alone,O
(,O
P,O
=,O
0,O
.,O
1376,O
).,O
When,O
the,O
124,O
/,O
506B,O
binding,O
site,O
was,O
mutated,O
",",O
miR,O
-,O
124,O
still,O
upregulated,O
lucifease,O
expression,O
to,O
240,O
%,O
(,O
p,O
=,O
0,O
.,O
0030,O
).,O
When,O
both,O
binding,O
sites,O
were,O
mutated,O
",",O
miR,O
-,O
124,O
did,O
not,O
result,O
in,O
increased,O
expression,O
of,O
the,O
luciferase,B-GP
reporter,O
",",O
at,O
least,O
not,O
as,O
effectively,O
as,O
when,O
both,O
potential,O
binding,O
sites,O
were,O
functional,O
(,O
146,O
%,O
expression,O
",",O
p,O
=,O
0,O
.,O
1864,O
).,O
These,O
results,O
suggest,O
that,O
miR,O
-,O
124,O
leads,O
to,O
positive,O
effects,O
on,O
the,O
Mitf,B-GP
mRNA,O
by,O
binding,O
to,O
the,O
124,O
/,O
506A,O
binding,O
site,O
.,O
At,O
present,O
",",O
it,O
is,O
not,O
clear,O
how,O
miR,O
-,O
124,O
mediates,O
this,O
upregulation,O
.,O
The,O
effects,O
of,O
miR,O
-,O
506,O
",",O
that,O
binds,O
to,O
the,O
same,O
target,O
site,O
",",O
were,O
not,O
tested,O
.,O
miR,O
-,O
148,O
and,O
miR,O
-,O
137,O
affect,O
expression,O
of,O
the,O
endogenous,O
MITF,B-GP
In,O
order,O
to,O
test,O
if,O
these,O
miRNAs,O
affect,O
the,O
level,O
of,O
endogenous,O
MITF,B-GP
mRNA,O
in,O
melanoma,B-DS
cells,O
",",O
we,O
used,O
qRT,O
-,O
PCR,O
to,O
determine,O
MITF,B-GP
mRNA,O
expression,O
after,O
transfecting,O
MeWo,O
melanoma,B-DS
cells,O
with,O
the,O
miRNAs,O
miR,O
-,O
124,O
",",O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
.,O
MeWo,O
cells,O
express,O
less,O
MITF,B-GP
than,O
the,O
501mel,O
cells,O
used,O
previously,O
.,O
Therefore,O
",",O
the,O
difference,O
in,O
expression,O
upon,O
treatment,O
was,O
more,O
easily,O
detected,O
with,O
the,O
amount,O
of,O
miRNA,O
used,O
.,O
The,O
results,O
",",O
normalized,O
to,O
total,O
RNA,O
",",O
are,O
shown,O
in,O
Fig,O
.,O
4A,O
and,O
confirm,O
our,O
previous,O
findings,O
.,O
When,O
miR,O
-,O
137,O
was,O
transfected,O
into,O
MeWo,O
cells,O
",",O
the,O
level,O
of,O
MITF,B-GP
mRNA,O
was,O
reduced,O
to,O
68,O
%,O
(,O
Cp,O
value,O
22,O
.,O
3,O
",",O
p,O
=,O
0,O
.,O
0069,O
),O
compared,O
to,O
100,O
%,O
in,O
untreated,O
cells,O
(,O
No,O
-,O
miR,O
",",O
Cp,O
value,O
21,O
.,O
7,O
).,O
Similarily,O
",",O
when,O
miR,O
-,O
148,O
was,O
transfected,O
into,O
these,O
cells,O
",",O
MITF,B-GP
mRNA,O
level,O
was,O
reduced,O
to,O
48,O
%,O
(,O
Cp,O
value,O
22,O
.,O
8,O
",",O
p,O
=,O
0,O
.,O
0051,O
),O
compared,O
to,O
untreated,O
cells,O
.,O
Simultaneous,O
transfection,O
with,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
did,O
not,O
result,O
in,O
further,O
effects,O
on,O
MITF,B-GP
expression,O
as,O
it,O
reduced,O
expression,O
to,O
67,O
%,O
(,O
Cp,O
value,O
22,O
.,O
3,O
",",O
p,O
=,O
0,O
.,O
0051,O
"),",O
which,O
is,O
similar,O
to,O
the,O
reduction,O
seen,O
with,O
miR,O
-,O
137,O
alone,O
(,O
Fig,O
.,O
4A,O
).,O
Thus,O
",",O
these,O
miRNAs,O
do,O
not,O
seem,O
to,O
work,O
synergistically,O
in,O
downregulating,O
MITF,B-GP
.,O
Effects,O
of,O
miRNAs,O
on,O
endogenous,O
MITF,B-GP
.,O
A,O
.,O
Expression,O
of,O
human,B-OG
MITF,B-GP
mRNA,O
in,O
MeWo,O
cells,O
transfected,O
with,O
miR,O
-,O
124,O
",",O
miR,O
-,O
137,O
",",O
miR,O
-,O
148,O
or,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
combined,O
.,O
The,O
figure,O
shows,O
average,O
expression,O
levels,O
of,O
three,O
replicates,O
for,O
each,O
sample,O
relative,O
to,O
untreated,O
cells,O
(,O
No,O
-,O
miR,O
).,O
Negative,O
control,O
is,O
a,O
scramble,O
miRNA,O
sequence,O
(,O
scramble,O
).,O
Statistically,O
significant,O
difference,O
between,O
untreated,O
cells,O
and,O
treated,O
cells,O
are,O
shown,O
with,O
an,O
asterisk,O
(,O
T,O
-,O
test,O
",",O
95,O
%,O
confidence,O
level,O
).,O
P,O
-,O
values,O
are,O
:,O
Scramble,O
=,O
0,O
.,O
0396,O
;,O
miR,O
-,O
124,O
=,O
0,O
.,O
2228,O
;,O
miR,O
-,O
137,O
=,O
0,O
.,O
0069,O
;,O
miR,O
-,O
148,O
=,O
0,O
.,O
0051,O
;,O
miR,O
-,O
137,O
+,O
148,O
=,O
0,O
.,O
0051,O
.,O
B,O
.,O
Western,O
blot,O
analysis,O
on,O
MITF,B-GP
protein,O
levels,O
in,O
MeWo,O
cells,O
",",O
when,O
transfected,O
with,O
miR,O
-,O
124,O
",",O
miR,O
-,O
137,O
",",O
miR,O
-,O
148,O
or,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
combined,O
.,O
Similar,O
to,O
what,O
we,O
observed,O
using,O
the,O
luciferase,B-GP
-,O
reporter,O
assay,O
",",O
miR,O
-,O
124,O
was,O
able,O
to,O
upregulate,O
MITF,B-GP
expression,O
in,O
the,O
MeWo,O
cells,O
.,O
The,O
expression,O
was,O
increased,O
to,O
122,O
%,O
(,O
Cp,O
value,O
21,O
.,O
5,O
),O
compared,O
to,O
untreated,O
cells,O
;,O
however,O
",",O
this,O
difference,O
is,O
not,O
statistically,O
significant,O
(,O
p,O
=,O
0,O
.,O
2228,O
).,O
The,O
same,O
experiment,O
was,O
performed,O
once,O
in,O
501mel,O
cells,O
",",O
the,O
only,O
signifant,O
downregulation,O
was,O
by,O
miR,O
-,O
137,O
when,O
compared,O
to,O
transfection,O
with,O
a,O
scramble,O
miRNA,O
(,O
data,O
not,O
shown,O
).,O
These,O
results,O
show,O
that,O
the,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
have,O
the,O
same,O
effects,O
on,O
expression,O
of,O
the,O
endogenous,O
MITF,B-GP
gene,O
as,O
seen,O
using,O
the,O
luciferase,B-GP
reporter,O
assay,O
.,O
The,O
effects,O
of,O
miRNAs,O
on,O
MITF,B-GP
protein,O
level,O
were,O
also,O
tested,O
in,O
MeWo,O
cells,O
and,O
confirmed,O
our,O
previous,O
findings,O
(,O
Fig,O
.,O
4B,O
).,O
When,O
the,O
cells,O
were,O
transfected,O
with,O
either,O
miR,O
-,O
137,O
",",O
miR,O
-,O
148,O
or,O
simultaneously,O
with,O
both,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
",",O
MITF,B-GP
protein,O
levels,O
were,O
reduced,O
.,O
Also,O
",",O
when,O
miR,O
-,O
124,O
was,O
transfected,O
",",O
higher,O
MITF,B-GP
protein,O
levels,O
were,O
observed,O
(,O
Fig,O
.,O
4B,O
).,O
In,O
order,O
to,O
test,O
the,O
specificity,O
of,O
the,O
miRNAs,O
",",O
we,O
used,O
specific,O
anti,O
-,O
miRNAs,O
to,O
inhibit,O
the,O
effects,O
of,O
the,O
miRNAs,O
used,O
in,O
our,O
experiments,O
.,O
Consistent,O
with,O
previous,O
results,O
",",O
cells,O
simultaneously,O
transfected,O
with,O
the,O
luciferase,B-GP
vector,O
construct,O
",",O
the,O
miR,O
-,O
148,O
and,O
the,O
anti,O
-,O
miR,O
-,O
148,O
showed,O
that,O
the,O
anti,O
-,O
miR148,O
molecule,O
effectively,O
inhibited,O
the,O
effects,O
of,O
miR,O
-,O
148,O
(,O
Fig,O
.,O
5A,O
).,O
Similarly,O
",",O
the,O
effects,O
of,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
on,O
endogenous,O
MITF,B-GP
mRNAs,O
are,O
inhibited,O
when,O
MeWo,O
cells,O
were,O
co,O
-,O
transfected,O
with,O
anti,O
-,O
miRNAs,O
(,O
Fig,O
.,O
5B,O
).,O
These,O
results,O
further,O
verifies,O
that,O
the,O
effects,O
on,O
Mitf,B-GP
mRNA,O
are,O
specific,O
to,O
these,O
microRNAs,O
.,O
Inhibiting,O
the,O
miRNAs,O
blocks,O
their,O
effect,O
.,O
A,O
.,O
Co,O
-,O
transfection,O
of,O
anti,O
-,O
miR,O
-,O
148,O
and,O
miR,O
-,O
148,O
simultaneously,O
with,O
the,O
Mitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
vector,O
inhibits,O
the,O
effect,O
of,O
miR,O
-,O
148,O
.,O
Results,O
are,O
presented,O
as,O
mean,O
values,O
±,O
SD,O
.,O
Expression,O
levels,O
were,O
compared,O
to,O
a,O
sample,O
where,O
no,O
microRNAs,O
were,O
added,O
(,O
No,O
-,O
miR,O
),O
and,O
were,O
considered,O
statistically,O
significant,O
when,O
p,O
<,O
0,O
.,O
05,O
",",O
shown,O
with,O
an,O
asterisk,O
(,O
T,O
-,O
test,O
",",O
95,O
%,O
confidence,O
level,O
).,O
The,O
p,O
-,O
values,O
are,O
;,O
miR,O
-,O
neg,O
=,O
0,O
.,O
14,O
miR,O
-,O
148,O
=,O
0,O
.,O
007,O
",",O
miR,O
-,O
148,O
+,O
anti,O
-,O
miR,O
-,O
148,O
=,O
0,O
.,O
119,O
.,O
B,O
.,O
Transfecting,O
miRNAs,O
and,O
anti,O
-,O
miRNAs,O
blocked,O
the,O
effect,O
of,O
the,O
miRNAs,O
on,O
endogenous,O
human,B-OG
MITF,B-GP
mRNA,O
levels,O
in,O
MeWo,O
cells,O
.,O
P,O
-,O
values,O
when,O
compared,O
to,O
the,O
no,O
-,O
miR,O
sample,O
are,O
:,O
Neg,O
control,O
=,O
0,O
.,O
064,O
",",O
miR,O
-,O
137,O
=,O
0,O
.,O
006,O
",",O
miR,O
-,O
137,O
+,O
anti,O
-,O
miR,O
-,O
137,O
=,O
0,O
.,O
854,O
",",O
miR,O
-,O
148,O
=,O
0,O
.,O
004,O
",",O
miR,O
-,O
148,O
+,O
anti,O
-,O
miR,O
-,O
148,O
=,O
0,O
.,O
632,O
.,O
Endogenous,O
miRNA,O
expression,O
The,O
expression,O
of,O
miRNAs,O
137,O
",",O
124,O
",",O
506,O
",",O
148a,O
",",O
148b,O
and,O
152,O
was,O
determined,O
in,O
the,O
HEK293,O
",",O
501mel,O
and,O
MeWo,O
cell,O
lines,O
.,O
The,O
expression,O
of,O
the,O
miRNAs,O
was,O
measured,O
using,O
the,O
MiRcury,O
LNA,O
Universal,O
RT,O
microRNA,O
PCR,O
method,O
.,O
An,O
RNA,O
pool,O
from,O
20,O
different,O
tissues,O
was,O
used,O
as,O
a,O
positive,O
control,O
and,O
the,O
results,O
were,O
normalized,O
to,O
the,O
expression,O
of,O
miR,O
-,O
16,O
and,O
miR,O
-,O
103,O
.,O
Cp,O
values,O
(,O
crossing,O
point,O
),O
are,O
shown,O
in,O
Table,O
2,O
.,O
Cp,O
values,O
for,O
determining,O
endogenous,O
miRNA,O
expression,O
.,O
miRNA,O
HEK293,O
501mel,O
MeWo,O
Positive,O
contr,O
.,O
miR,O
-,O
137,O
ND,O
(,O
1,O
/,O
9,O
),O
ND,O
(,O
0,O
/,O
9,O
),O
34,O
.,O
69,O
(,O
7,O
/,O
9,O
),O
37,O
.,O
39,O
(,O
1,O
/,O
3,O
),O
miR,O
-,O
124,O
34,O
.,O
37,O
(,O
9,O
/,O
9,O
),O
34,O
.,O
73,O
(,O
5,O
/,O
9,O
),O
35,O
.,O
09,O
(,O
2,O
/,O
9,O
),O
32,O
.,O
68,O
(,O
3,O
/,O
3,O
),O
miR,O
-,O
506,O
35,O
.,O
19,O
(,O
2,O
/,O
9,O
),O
34,O
.,O
73,O
(,O
3,O
/,O
9,O
),O
32,O
.,O
87,O
(,O
9,O
/,O
9,O
),O
ND,O
(,O
0,O
/,O
9,O
),O
miR,O
-,O
148a,O
27,O
.,O
90,O
(,O
9,O
/,O
9,O
),O
28,O
.,O
29,O
(,O
9,O
/,O
9,O
),O
28,O
.,O
82,O
(,O
9,O
/,O
9,O
),O
33,O
.,O
12,O
(,O
3,O
/,O
3,O
),O
miR,O
-,O
148b,O
28,O
.,O
37,O
(,O
9,O
/,O
9,O
),O
28,O
.,O
65,O
(,O
9,O
/,O
9,O
),O
29,O
.,O
37,O
(,O
9,O
/,O
9,O
),O
35,O
.,O
19,O
(,O
1,O
/,O
3,O
),O
miR,O
-,O
152,O
34,O
.,O
08,O
(,O
9,O
/,O
9,O
),O
35,O
.,O
12,O
(,O
9,O
/,O
9,O
),O
34,O
.,O
26,O
(,O
9,O
/,O
9,O
),O
35,O
.,O
05,O
(,O
2,O
/,O
3,O
),O
miR,O
-,O
16,O
contr,O
.,O
26,O
.,O
19,O
(,O
9,O
/,O
9,O
),O
25,O
.,O
72,O
(,O
9,O
/,O
9,O
),O
25,O
.,O
92,O
(,O
9,O
/,O
9,O
),O
31,O
.,O
83,O
(,O
3,O
/,O
3,O
),O
miR,O
-,O
103,O
contr,O
.,O
27,O
.,O
07,O
(,O
9,O
/,O
9,O
),O
26,O
.,O
76,O
(,O
9,O
/,O
9,O
),O
27,O
.,O
81,O
(,O
9,O
/,O
9,O
),O
33,O
.,O
09,O
(,O
3,O
/,O
3,O
),O
Cp,O
values,O
for,O
average,O
normalised,O
values,O
are,O
shown,O
for,O
each,O
miRNA,O
tested,O
in,O
HEK293,O
",",O
501mel,O
and,O
MeWo,O
cells,O
as,O
well,O
as,O
the,O
positive,O
control,O
.,O
Each,O
assay,O
was,O
preformed,O
in,O
triplicate,O
for,O
three,O
RNA,O
samples,O
from,O
each,O
cell,O
type,O
.,O
The,O
number,O
of,O
samples,O
that,O
each,O
miRNA,O
was,O
detected,O
in,O
",",O
is,O
shown,O
in,O
parenthesis,O
.,O
ND,O
=,O
not,O
detected,O
.,O
miR,O
-,O
148,O
and,O
miR,O
-,O
152,O
The,O
microRNAs,O
miR,O
-,O
148a,O
and,O
miR,O
-,O
148b,O
have,O
similar,O
expression,O
levels,O
in,O
all,O
the,O
cell,O
types,O
tested,O
.,O
Expression,O
in,O
the,O
melanoma,B-DS
cell,O
lines,O
501mel,O
and,O
MeWo,O
was,O
around,O
1,O
.,O
5,O
fold,O
less,O
than,O
expression,O
in,O
HEK293,O
cells,O
(,O
Fig,O
.,O
6,O
).,O
Higher,O
endogenous,O
expression,O
in,O
HEK293,O
cells,O
might,O
explain,O
why,O
transfected,O
miR,O
-,O
148,O
had,O
no,O
effect,O
on,O
reporter,O
gene,O
expression,O
in,O
HEK293,O
cells,O
",",O
except,O
at,O
the,O
highest,O
concentration,O
.,O
miR,O
-,O
148,O
affected,O
reporter,O
gene,O
expression,O
more,O
significantly,O
in,O
501mel,O
cells,O
.,O
Expression,O
of,O
miR,O
-,O
152,O
in,O
501mel,O
was,O
2,O
.,O
7,O
fold,O
lower,O
than,O
in,O
HEK293,O
cells,O
and,O
was,O
much,O
lower,O
then,O
the,O
expression,O
of,O
miR,O
-,O
148a,O
and,O
miR,O
-,O
148b,O
in,O
all,O
cell,O
types,O
(,O
see,O
Table,O
2,O
).,O
Low,O
expression,O
of,O
miR,O
-,O
148a,O
",",O
148b,O
and,O
152,O
in,O
the,O
melanoma,B-DS
cell,O
lines,O
is,O
therefore,O
consistent,O
with,O
the,O
relatively,O
high,O
level,O
of,O
MITF,B-GP
expression,O
in,O
these,O
cells,O
.,O
Endogenous,O
miRNA,O
expression,O
.,O
Expression,O
of,O
endogenous,O
miRNAs,O
miR,O
-,O
148a,O
",",O
miR,O
-,O
148b,O
and,O
miR,O
-,O
152,O
in,O
HEK293,O
",",O
501mel,O
and,O
MeWo,O
cells,O
.,O
The,O
figure,O
shows,O
average,O
expression,O
levels,O
of,O
three,O
replicates,O
for,O
each,O
sample,O
relative,O
to,O
HEK293,O
cells,O
.,O
Expression,O
was,O
normalized,O
to,O
miR,O
-,O
16,O
and,O
miR,O
-,O
103,O
.,O
Statistically,O
significant,O
levels,O
of,O
expression,O
in,O
MeWo,O
and,O
501mel,O
compared,O
to,O
HEK293,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
are,O
shown,O
with,O
an,O
asterisk,O
.,O
P,O
-,O
values,O
are,O
:,O
miR,O
-,O
148a,O
expression,O
in,O
501mel,O
=,O
0,O
.,O
0940,O
and,O
in,O
MeWo,O
=,O
0,O
.,O
0148,O
.,O
miR,O
-,O
148b,O
expression,O
in,O
501mel,O
=,O
0,O
.,O
0023,O
and,O
in,O
MeWo,O
=,O
0,O
.,O
0065,O
.,O
miR,O
-,O
152,O
expression,O
in,O
501mel,O
=,O
0,O
.,O
0054,O
and,O
in,O
MeWo,O
=,O
0,O
.,O
9316,O
.,O
miR,O
-,O
137,O
Endogenous,O
miR,O
-,O
137,O
was,O
only,O
detected,O
in,O
MeWo,O
cells,O
",",O
not,O
in,O
HEK293,O
",",O
501mel,O
or,O
the,O
positive,O
control,O
.,O
Expression,O
in,O
the,O
MeWo,O
cells,O
",",O
although,O
at,O
rather,O
low,O
levels,O
(,O
average,O
Cp,O
value,O
34,O
.,O
7,O
compared,O
to,O
the,O
controls,O
(,O
miR,O
-,O
16,O
and,O
103,O
),O
at,O
25,O
.,O
9,O
and,O
27,O
.,O
8,O
respectively,O
"),",O
indicates,O
possible,O
involvement,O
in,O
regulating,O
the,O
endogenous,O
levels,O
of,O
MITF,B-GP
in,O
this,O
cell,O
type,O
.,O
MITF,B-GP
is,O
expressed,O
in,O
MeWo,O
cells,O
but,O
at,O
a,O
lower,O
level,O
than,O
in,O
501mel,O
cells,O
which,O
is,O
consistent,O
with,O
the,O
expression,O
of,O
miR,O
-,O
137,O
in,O
MeWo,O
cells,O
and,O
its,O
absence,O
in,O
501mel,O
cells,O
.,O
miR,O
-,O
137,O
affected,O
reporter,O
gene,O
expression,O
in,O
HEK293,O
cells,O
",",O
which,O
is,O
in,O
line,O
with,O
the,O
absence,O
of,O
endogenous,O
miR,O
-,O
137,O
in,O
this,O
cell,O
type,O
.,O
It,O
is,O
unclear,O
why,O
transfected,O
miR,O
-,O
137,O
did,O
not,O
affect,O
reporter,O
gene,O
expression,O
in,O
501mel,O
cells,O
where,O
endogenous,O
miR,O
-,O
137,O
was,O
not,O
detected,O
.,O
The,O
absence,O
of,O
miR,O
-,O
137,O
in,O
501mel,O
cells,O
might,O
be,O
explained,O
by,O
mutations,O
in,O
the,O
miR,O
-,O
137,O
gene,O
itself,O
as,O
has,O
been,O
shown,O
to,O
be,O
the,O
case,O
in,O
other,O
melanoma,B-DS
cells,O
[,O
31,O
"],",O
thus,O
allowing,O
high,O
levels,O
of,O
MITF,B-GP
expression,O
.,O
miR,O
-,O
124,O
and,O
miR,O
-,O
506,O
The,O
level,O
of,O
miR,O
-,O
124,O
expression,O
was,O
considered,O
to,O
be,O
too,O
low,O
to,O
be,O
detected,O
in,O
all,O
cell,O
types,O
.,O
We,O
therefore,O
can,O
not,O
definitely,O
conclude,O
anything,O
about,O
the,O
expression,O
of,O
miR,O
-,O
124,O
in,O
our,O
samples,O
.,O
miR,O
-,O
506,O
was,O
detected,O
in,O
501mel,O
and,O
MeWo,O
cells,O
.,O
The,O
expression,O
level,O
was,O
higher,O
in,O
MeWo,O
cells,O
(,O
Cp,O
value,O
32,O
.,O
9,O
),O
compared,O
to,O
501mel,O
cells,O
(,O
Cp,O
value,O
34,O
.,O
7,O
).,O
Lower,O
expression,O
in,O
501mel,O
might,O
be,O
a,O
factor,O
allowing,O
a,O
high,O
level,O
of,O
MITF,B-GP
expression,O
in,O
this,O
melanoma,B-DS
cell,O
type,O
.,O
Discussion,O
We,O
have,O
tested,O
the,O
role,O
of,O
six,O
different,O
miRNAs,O
with,O
conserved,O
potential,O
binding,O
sites,O
in,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
for,O
their,O
ability,O
to,O
affect,O
Mitf,B-GP
mRNA,O
expression,O
.,O
We,O
show,O
that,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
negatively,O
affect,O
Mitf,B-GP
mRNA,O
in,O
melanoma,B-DS
cells,O
through,O
conserved,O
binding,O
sites,O
in,O
the,O
3,O
′,O
UTR,O
sequence,O
.,O
Other,O
miRNAs,O
tested,O
",",O
miR,O
-,O
27,O
and,O
miR,O
-,O
25,O
/,O
32,O
/,O
92,O
/,O
363,O
/,O
367,O
have,O
highly,O
conserved,O
binding,O
sites,O
but,O
did,O
not,O
have,O
an,O
effect,O
on,O
reporter,O
gene,O
expression,O
in,O
HEK293,O
or,O
501mel,O
cells,O
.,O
The,O
microRNA,O
miR,O
-,O
101,O
has,O
a,O
highly,O
conserved,O
binding,O
site,O
but,O
did,O
not,O
affect,O
reporter,O
gene,O
expression,O
in,O
HEK293,O
cells,O
.,O
However,O
in,O
501mel,O
cells,O
",",O
miR,O
-,O
101,O
downregulated,O
reporter,O
gene,O
expression,O
at,O
the,O
two,O
highest,O
concentrations,O
used,O
suggesting,O
that,O
it,O
may,O
play,O
a,O
role,O
in,O
melanocytes,O
or,O
melanoma,B-DS
cells,O
.,O
The,O
roles,O
of,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
were,O
analysed,O
further,O
by,O
mutating,O
the,O
binding,O
sites,O
in,O
the,O
mouseMitf,B-GP
-,O
3,O
′,O
UTR,O
-,O
luciferase,B-GP
reporter,O
construct,O
.,O
The,O
results,O
of,O
this,O
analysis,O
suggest,O
direct,O
effects,O
on,O
the,O
Mitf,B-GP
mRNA,O
.,O
When,O
the,O
148,O
/,O
152B,O
binding,O
sites,O
were,O
mutated,O
",",O
the,O
effects,O
of,O
miR,O
-,O
148,O
were,O
eliminated,O
.,O
When,O
the,O
most,O
conserved,O
binding,O
sites,O
for,O
miR,O
-,O
137,O
(,O
137C,O
and,O
D,O
),O
were,O
mutated,O
",",O
the,O
effects,O
of,O
miR,O
-,O
137,O
were,O
eliminated,O
.,O
,O
of,O
the,O
miR,O
-,O
137,O
-,O
mutations,O
restore,O
luciferase,B-GP
expression,O
to,O
the,O
level,O
observed,O
with,O
the,O
negative,O
control,O
.,O
This,O
might,O
indicate,O
that,O
all,O
the,O
miR,O
-,O
137,O
binding,O
sites,O
contribute,O
to,O
the,O
regulation,O
of,O
Mitf,B-GP
.,O
However,O
",",O
it,O
should,O
be,O
noted,O
that,O
miR,O
-,O
137,O
can,O
target,O
the,O
luciferase,B-GP
construct,O
lacking,O
the,O
3,O
′,O
UTR,O
sequence,O
such,O
that,O
in,O
the,O
presence,O
of,O
miR,O
-,O
137,O
",",O
luciferase,B-GP
expression,O
cannot,O
reach,O
the,O
same,O
level,O
of,O
expression,O
as,O
is,O
seen,O
with,O
the,O
negative,O
control,O
(,O
miR,O
-,O
neg,O
#,O
2,O
).,O
The,O
effects,O
of,O
the,O
miRNAs,O
were,O
further,O
confirmed,O
by,O
transfecting,O
the,O
microRNAs,O
into,O
MeWo,O
melanoma,B-DS
cells,O
and,O
then,O
measuring,O
the,O
endogenous,O
MITF,B-GP
mRNA,O
and,O
protein,O
levels,O
.,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
both,O
led,O
to,O
reduced,O
levels,O
of,O
MITF,B-GP
mRNA,O
and,O
protein,O
.,O
Simultaneous,O
transfection,O
with,O
anti,O
-,O
miR,O
-,O
148,O
blocked,O
the,O
effect,O
of,O
miR,O
-,O
148,O
in,O
both,O
the,O
luciferase,B-GP
reporter,O
assays,O
and,O
on,O
the,O
endogenous,O
MITF,B-GP
mRNA,O
.,O
Transfection,O
with,O
anti,O
-,O
miR,O
-,O
137,O
similarly,O
blocked,O
the,O
effects,O
of,O
miR,O
-,O
137,O
on,O
the,O
endogenous,O
MITF,B-GP
mRNA,O
(,O
Fig,O
.,O
5B,O
).,O
miR,O
-,O
137,O
did,O
not,O
significantly,O
affect,O
the,O
luciferase,B-GP
reporter,O
in,O
melanoma,B-DS
cells,O
.,O
However,O
",",O
simultaneous,O
transfection,O
of,O
anti,O
-,O
miR,O
-,O
137,O
and,O
miR,O
-,O
137,O
with,O
the,O
Mitf,B-GP
-,O
3,O
′,O
UTR,O
luciferase,B-GP
in,O
MeWo,O
cells,O
blocked,O
the,O
effect,O
of,O
miR,O
-,O
137,O
(,O
data,O
not,O
shown,O
).,O
Combining,O
both,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
did,O
not,O
result,O
in,O
added,O
effects,O
on,O
endogenous,O
MITF,B-GP
mRNA,O
levels,O
.,O
Possible,O
explanations,O
for,O
this,O
might,O
be,O
that,O
the,O
maximum,O
effects,O
are,O
reached,O
with,O
one,O
of,O
the,O
miRNAs,O
and,O
adding,O
another,O
does,O
not,O
increase,O
the,O
effects,O
.,O
Another,O
explanation,O
for,O
the,O
lack,O
of,O
additive,O
effects,O
is,O
that,O
the,O
miRNAs,O
might,O
not,O
be,O
able,O
to,O
bind,O
simultaneously,O
to,O
the,O
3,O
′,O
UTR,O
sequences,O
.,O
The,O
137C,O
",",O
137D,O
and,O
148,O
/,O
152B,O
binding,O
sites,O
are,O
all,O
located,O
in,O
close,O
proximity,O
to,O
each,O
other,O
in,O
the,O
Mitf,B-GP
-,O
3,O
′,O
UTR,O
sequence,O
(,O
Fig,O
.,O
1A,O
).,O
Accessibility,O
might,O
be,O
limited,O
by,O
one,O
of,O
the,O
miRNAs,O
.,O
A,O
third,O
possibility,O
is,O
that,O
specific,O
binding,O
proteins,O
block,O
the,O
other,O
sites,O
when,O
one,O
is,O
occupied,O
.,O
Specific,O
RNA,B-GP
binding,I-GP
proteins,I-GP
have,O
been,O
show,O
to,O
block,O
the,O
binding,O
of,O
miRNAs,O
to,O
the,O
MITF,B-GP
mRNA,O
[,O
44,O
].,O
The,O
fact,O
that,O
miR,O
-,O
137,O
has,O
an,O
effect,O
in,O
MeWo,O
cells,O
(,O
q,O
-,O
RT,O
-,O
PCR,O
),O
and,O
not,O
in,O
501mel,O
cells,O
might,O
be,O
due,O
to,O
the,O
fact,O
that,O
MITF,B-GP
mRNA,O
levels,O
are,O
higher,O
in,O
501mel,O
cells,O
than,O
in,O
MeWo,O
cells,O
.,O
Thus,O
",",O
more,O
miR,O
-,O
137,O
might,O
be,O
needed,O
in,O
501mel,O
cells,O
then,O
in,O
MeWo,O
cells,O
.,O
The,O
effects,O
of,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
when,O
transfected,O
seperatly,O
",",O
are,O
blocked,O
when,O
the,O
cells,O
are,O
transfected,O
with,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
inhibitors,O
.,O
miR,O
-,O
124,O
resulted,O
in,O
increased,O
luciferase,B-GP
expression,O
as,O
seen,O
using,O
the,O
reporter,O
gene,O
construct,O
in,O
HEK293,O
cells,O
.,O
Furthermore,O
",",O
we,O
observed,O
upregulation,O
of,O
the,O
endogenous,O
MITF,B-GP
in,O
MeWo,O
cells,O
at,O
both,O
mRNA,O
and,O
protein,O
levels,O
;,O
the,O
upregulation,O
of,O
MITF,B-GP
mRNA,O
was,O
not,O
statistically,O
significant,O
.,O
The,O
effects,O
of,O
miR,O
-,O
124,O
might,O
be,O
an,O
artifact,O
of,O
the,O
reporter,O
system,O
.,O
The,O
effects,O
on,O
endogenous,O
MITF,B-GP
could,O
not,O
be,O
measured,O
in,O
HEK293,O
cells,O
as,O
there,O
is,O
no,O
endogenous,O
MITF,B-GP
expression,O
in,O
those,O
cells,O
.,O
As,O
mentioned,O
earlier,O
",",O
miR,O
-,O
137,O
has,O
previously,O
been,O
shown,O
to,O
target,O
MITF,B-GP
in,O
melanoma,B-DS
cells,O
[,O
31,O
].,O
Interestingly,O
",",O
searching,O
for,O
miR,O
-,O
137,O
binding,O
sites,O
within,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
of,O
11,O
vertebrate,O
species,O
revealed,O
that,O
all,O
species,O
have,O
at,O
least,O
two,O
miR,O
-,O
137,O
binding,O
sites,O
and,O
some,O
species,O
have,O
three,O
or,O
four,O
binding,O
sites,O
.,O
All,O
species,O
contain,O
either,O
137C,O
or,O
137D,O
and,O
nine,O
contain,O
them,O
both,O
(,O
data,O
not,O
shown,O
).,O
miR,O
-,O
137,O
expression,O
has,O
been,O
shown,O
to,O
be,O
affected,O
in,O
cancer,B-DS
.,O
It,O
is,O
silenced,O
by,O
DNA,O
methylation,O
in,O
colorectal,B-DS
cancer,I-DS
[,O
45,O
],O
and,O
oral,O
carcinogenesis,O
[,O
46,O
"],",O
suggesting,O
tumor,B-DS
suppressor,O
abilities,O
.,O
In,O
addition,O
",",O
both,O
miR,O
-,O
137,O
and,O
miR,O
-,O
124,O
induced,O
differentiation,O
of,O
adult,O
mouse,B-OG
neural,O
stem,O
cells,O
and,O
were,O
able,O
to,O
induce,O
cell,O
cycle,O
arrest,O
of,O
glioblastoma,B-DS
multiforme,I-DS
cells,O
[,O
47,O
].,O
Upregulation,O
of,O
miR,O
-,O
137,O
in,O
lymph,O
node,O
metastasis,O
in,O
colon,B-DS
cancer,I-DS
has,O
also,O
been,O
observed,O
[,O
48,O
].,O
The,O
3,O
′,O
UTR,O
sequences,O
of,O
Mitf,B-GP
in,O
11,O
vertebrate,O
species,O
all,O
contain,O
the,O
two,O
conserved,O
miR,O
-,O
148,O
/,O
152,O
binding,O
sites,O
.,O
In,O
six,O
vertebrate,O
species,O
there,O
is,O
an,O
additional,O
conserved,O
binding,O
site,O
(,O
data,O
not,O
shown,O
).,O
It,O
has,O
not,O
been,O
shown,O
previously,O
that,O
miR,O
-,O
148,O
and,O
/,O
or,O
miR,O
-,O
152,O
can,O
target,O
Mitf,B-GP
.,O
However,O
",",O
both,O
miRNAs,O
have,O
been,O
shown,O
to,O
be,O
downregulated,O
in,O
melanoma,B-DS
cells,O
[,O
30,O
].,O
Microarray,O
analysis,O
revealed,O
that,O
miR,O
-,O
148b,O
is,O
downregulated,O
in,O
early,O
melanoma,B-DS
progression,O
",",O
although,O
it,O
was,O
not,O
confirmed,O
using,O
qRT,O
-,O
PCR,O
[,O
30,O
].,O
Similarly,O
",",O
miR,O
-,O
152,O
was,O
shown,O
to,O
be,O
downregulated,O
in,O
a,O
highly,O
invasive,B-DS
melanoma,I-DS
cell,O
line,O
(,O
Mel,O
Im,O
),O
[,O
30,O
].,O
Other,O
studies,O
have,O
suggested,O
that,O
miR,O
-,O
148,O
and,O
miR,O
-,O
152,O
can,O
play,O
a,O
role,O
as,O
tumor,B-DS
suppressors,O
.,O
miR,O
-,O
148,O
expression,O
has,O
been,O
shown,O
to,O
be,O
downregulated,O
in,O
tissue,O
samples,O
from,O
undifferentiated,O
gastric,B-DS
cancer,I-DS
compared,O
to,O
normal,O
tissue,O
[,O
49,O
].,O
Similarly,O
",",O
hypermethylation,O
of,O
the,O
miR,O
-,O
148,O
",",O
124a3,O
and,O
miR,O
-,O
152,O
genes,O
was,O
found,O
in,O
34,O
-,O
86,O
%,O
of,O
primary,O
human,B-OG
breast,B-DS
cancer,I-DS
specimens,O
[,O
50,O
].,O
The,O
binding,O
sites,O
for,O
microRNAs,O
miR,O
-,O
124,O
/,O
506,O
are,O
very,O
well,O
conserved,O
in,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
.,O
Ten,O
vertebrate,O
species,O
contain,O
both,O
miR,O
-,O
124,O
/,O
506,O
binding,O
site,O
;,O
the,O
Loxodonta,B-OG
africana,I-OG
sequence,O
only,O
contains,O
124,O
/,O
506B,O
.,O
It,O
has,O
not,O
been,O
shown,O
previously,O
that,O
miR,O
-,O
124,O
and,O
/,O
or,O
miR,O
-,O
506,O
can,O
affect,O
Mitf,B-GP
mRNA,O
.,O
However,O
",",O
miR,O
-,O
506,O
was,O
shown,O
to,O
be,O
upregulated,O
in,O
early,O
melanoma,B-DS
progression,O
and,O
downregulated,O
later,O
in,O
metastatic,B-DS
melanoma,I-DS
[,O
30,O
],O
and,O
may,O
therefore,O
play,O
an,O
important,O
role,O
in,O
this,O
cell,O
type,O
.,O
miR,O
-,O
124,O
is,O
predominantly,O
expressed,O
in,O
the,O
brain,O
",",O
specifically,O
in,O
differentiating,O
and,O
mature,O
neurons,O
[,O
51,O
"],",O
[,O
52,O
"],",O
[,O
53,O
].,O
miR,O
-,O
124,O
is,O
interesting,O
considering,O
its,O
expression,O
in,O
the,O
retina,O
[,O
54,O
"],",O
as,O
Mitf,B-GP
plays,O
an,O
important,O
role,O
in,O
eye,O
development,O
.,O
Mitf,B-GP
is,O
expressed,O
in,O
the,O
retina,O
early,O
in,O
development,O
and,O
is,O
later,O
downregulated,O
in,O
this,O
tissue,O
[,O
55,O
"],",O
[,O
56,O
"],",O
[,O
57,O
].,O
The,O
mechanisms,O
that,O
mediate,O
this,O
downregulation,O
have,O
not,O
been,O
described,O
and,O
may,O
involve,O
miR,O
-,O
124,O
.,O
However,O
",",O
our,O
results,O
show,O
upregulation,O
by,O
miR,O
-,O
124,O
in,O
melanoma,B-DS
cells,O
",",O
rather,O
than,O
downregulation,O
.,O
The,O
possible,O
role,O
of,O
miR,O
-,O
124,O
in,O
regulating,O
the,O
expression,O
of,O
Mitf,B-GP
during,O
eye,O
development,O
needs,O
to,O
be,O
tested,O
further,O
.,O
Although,O
miRNAs,O
are,O
better,O
known,O
for,O
downregulating,O
target,O
genes,O
",",O
there,O
have,O
been,O
reports,O
on,O
effects,O
through,O
upregulation,O
by,O
miRNAs,O
by,O
binding,O
to,O
their,O
promoter,O
region,O
[,O
58,O
"],",O
[,O
59,O
].,O
However,O
",",O
this,O
is,O
unlikely,O
to,O
play,O
a,O
role,O
in,O
regulating,O
Mitf,B-GP
mRNA,O
through,O
effects,O
on,O
the,O
3,O
′,O
UTR,O
since,O
our,O
reporter,O
construct,O
only,O
contained,O
3,O
′,O
UTR,O
sequences,O
.,O
It,O
has,O
been,O
shown,O
that,O
two,O
thirds,O
of,O
genes,O
targeted,O
by,O
miRNA,O
have,O
alternative,O
3,O
′,O
UTRs,O
.,O
The,O
microRNAs,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
have,O
many,O
other,O
potential,O
target,O
genes,O
according,O
to,O
online,O
prediction,O
programs,O
(,O
Targetscan,O
).,O
In,O
humans,B-OG
",",O
miR,O
-,O
137,O
has,O
857,O
conserved,O
targets,O
",",O
with,O
a,O
total,O
of,O
949,O
conserved,O
sites,O
and,O
120,O
poorly,O
conserved,O
sites,O
.,O
miR,O
-,O
148,O
has,O
536,O
conserved,O
targets,O
",",O
with,O
a,O
total,O
of,O
581,O
conserved,O
sites,O
and,O
134,O
poorly,O
conserved,O
sites,O
.,O
Of,O
these,O
potential,O
target,O
genes,O
",",O
66,O
are,O
common,O
targets,O
of,O
both,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
.,O
It,O
is,O
therefore,O
unlikely,O
that,O
these,O
miRNAs,O
exclusively,O
affect,O
Mitf,B-GP
expression,O
.,O
As,O
miRNA,O
binding,O
sites,O
are,O
often,O
located,O
close,O
to,O
polyadenylation,O
signals,O
(,O
PAS,O
),O
[,O
60,O
"],",O
shortening,O
of,O
the,O
3,O
′,O
UTRs,O
may,O
lead,O
to,O
loss,O
of,O
miRNA,O
binding,O
sequences,O
and,O
thus,O
loss,O
of,O
microRNA,O
-,O
mediated,O
regulation,O
.,O
The,O
mouse,B-OG
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
contains,O
twelve,O
potential,O
PAS,O
sequences,O
(,O
two,O
are,O
AAUAAA,O
",",O
four,O
AUUAAA,O
",",O
four,O
AAGAAA,O
and,O
two,O
UAUAAA,O
",",O
there,O
is,O
no,O
AGUAAA,O
sequence,O
).,O
Comparing,O
these,O
potential,O
PAS,O
sites,O
in,O
the,O
3,O
′,O
UTR,O
sequences,O
of,O
Mitf,B-GP
from,O
11,O
vertebrate,O
species,O
revealed,O
a,O
well,O
conserved,O
PAS,O
located,O
at,O
2837,O
-,O
2842,O
",",O
adjacent,O
to,O
the,O
miR,O
-,O
137,O
C,O
binding,O
site,O
(,O
Fig,O
.,O
1A,O
).,O
Ten,O
species,O
contain,O
a,O
PAS,O
at,O
this,O
location,O
.,O
The,O
PAS,O
located,O
closest,O
to,O
the,O
3,O
′,O
end,O
is,O
conserved,O
in,O
all,O
species,O
and,O
represents,O
the,O
signal,O
for,O
the,O
longest,O
mRNA,O
version,O
.,O
Several,O
other,O
PAS,O
',O
s,O
are,O
well,O
conserved,O
whereas,O
others,O
are,O
less,O
conserved,O
.,O
miRNAs,O
can,O
have,O
an,O
impact,O
on,O
cancer,B-DS
progression,O
in,O
several,O
ways,O
",",O
including,O
loss,O
of,O
expression,O
of,O
a,O
tumor,B-DS
-,O
suppressor,O
miRNA,O
gene,O
and,O
over,O
-,O
activation,O
of,O
an,O
oncogenic,O
miRNA,O
.,O
Loss,O
of,O
miRNA,O
binding,O
sites,O
in,O
3,O
′,O
UTR,O
sequences,O
of,O
the,O
target,O
genes,O
caused,O
by,O
mutations,O
or,O
translocations,O
are,O
also,O
possible,O
.,O
Shortening,O
of,O
the,O
3,O
′,O
UTR,O
sequence,O
",",O
and,O
therefore,O
loss,O
of,O
miRNA,O
binding,O
sites,O
",",O
can,O
lead,O
to,O
oncogenic,O
activation,O
[,O
61,O
].,O
The,O
conservation,O
of,O
several,O
of,O
the,O
alternative,O
polyadenylation,O
signals,O
found,O
in,O
the,O
3,O
′,O
UTR,O
sequences,O
of,O
Mitf,B-GP
suggests,O
their,O
significance,O
.,O
Thus,O
",",O
Mitf,B-GP
might,O
be,O
able,O
to,O
evade,O
miRNA,O
-,O
mediated,O
regulation,O
using,O
the,O
alternative,O
polyadenylation,O
sites,O
",",O
thus,O
leading,O
to,O
a,O
shorter,O
transcript,O
lacking,O
the,O
miRNA,O
binding,O
sequences,O
.,O
It,O
was,O
recently,O
shown,O
that,O
MITF,B-GP
mRNAs,O
with,O
shorter,O
3,O
′,O
UTR,O
sequences,O
are,O
more,O
abundant,O
in,O
melanoma,B-DS
cell,O
lines,O
than,O
transcripts,O
with,O
full,O
-,O
length,O
3,O
′,O
UTR,O
sequences,O
[,O
44,O
].,O
In,O
this,O
case,O
the,O
miR,O
-,O
340,O
is,O
involved,O
in,O
regulating,O
the,O
shorter,O
transcript,O
and,O
",",O
interestingly,O
",",O
the,O
RNA,B-GP
binding,I-GP
protein,I-GP
CRD,B-GP
-,I-GP
BP,I-GP
prevents,O
binding,O
of,O
the,O
miRNA,O
.,O
Thus,O
",",O
in,O
the,O
case,O
of,O
MITF,B-GP
",",O
microRNAs,O
do,O
not,O
act,O
alone,O
in,O
mediating,O
regulation,O
through,O
the,O
3,O
′,O
UTR,O
sequences,O
.,O
Interestingly,O
",",O
the,O
MITF,B-GP
protein,O
has,O
been,O
shown,O
to,O
bind,O
to,O
the,O
promoter,O
of,O
miR,O
-,O
148b,O
that,O
is,O
shown,O
there,O
to,O
have,O
functional,O
target,O
site,O
within,O
the,O
Mitf,B-GP
3,O
′,O
UTR,O
sequence,O
[,O
62,O
].,O
This,O
indicates,O
a,O
possible,O
negative,O
feedback,O
loop,O
where,O
higher,O
amounts,O
of,O
MITF,B-GP
would,O
lead,O
to,O
more,O
miR,O
-,O
148,O
expression,O
which,O
in,O
turn,O
adjusts,O
MITF,B-GP
protein,O
at,O
desirable,O
levels,O
.,O
It,O
is,O
clear,O
that,O
miRNA,O
function,O
is,O
diverse,O
and,O
its,O
role,O
in,O
cancer,B-DS
and,O
other,O
disease,O
is,O
complex,O
.,O
Some,O
miRNAs,O
seem,O
to,O
have,O
a,O
tissue,O
-,O
specific,O
function,O
like,O
miR,O
-,O
124,O
in,O
neurons,O
wheras,O
other,O
miRNAs,O
are,O
found,O
more,O
universally,O
.,O
Mitf,B-GP
functions,O
in,O
diverse,O
cell,O
types,O
and,O
may,O
therefore,O
be,O
regulated,O
by,O
different,O
miRNAs,O
in,O
the,O
different,O
tissues,O
.,O
In,O
melanoma,B-DS
cells,O
",",O
Mitf,B-GP
is,O
regulated,O
by,O
miR,O
-,O
137,O
and,O
miR,O
-,O
148,O
/,O
152,O
.,O
As,O
MITF,B-GP
is,O
a,O
lineage,O
survival,O
oncogene,B-GP
in,O
melanoma,B-DS
[,O
23,O
],O
whose,O
expression,O
needs,O
to,O
be,O
maintained,O
at,O
a,O
certain,O
level,O
",",O
it,O
is,O
likely,O
that,O
these,O
miRNAs,O
play,O
an,O
important,O
role,O
in,O
regulating,O
MITF,B-GP
mRNA,O
levels,O
in,O
this,O
cell,O
type,O
.,O
Dysregulation,O
of,O
these,O
microRNAs,O
",",O
or,O
loss,O
of,O
the,O
binding,O
sites,O
in,O
the,O
3,O
′,O
UTR,O
",",O
might,O
lead,O
to,O
increased,O
expression,O
of,O
Mitf,B-GP
",",O
thus,O
leading,O
to,O
differentiation,O
and,O
cell,O
-,O
cycle,O
arrest,O
.,O
As,O
the,O
miRNAs,O
involved,O
may,O
have,O
significant,O
therapeutic,O
potential,O
",",O
it,O
will,O
be,O
important,O
to,O
characterize,O
this,O
regulation,O
in,O
more,O
detail,O
in,O
further,O
studies,O
.,O
Supporting,O
Information,O
P,O
-,O
values,O
for,O
data,O
presented,O
in,O
Figures,O
2,O
and,O
3,O
.,O
(,O
0,O
.,O
02,O
MB,O
PDF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Mesenchymal,O
stem,O
cell,O
therapy,O
for,O
acute,B-DS
radiation,I-DS
syndrome,I-DS
:,O
innovative,O
medical,O
approaches,O
in,O
military,O
medicine,O
After,O
a,O
radiological,O
or,O
nuclear,O
event,O
",",O
acute,B-DS
radiation,I-DS
syndrome,I-DS
(,O
ARS,B-DS
),O
will,O
present,O
complex,O
medical,O
challenges,O
that,O
could,O
involve,O
the,O
treatment,O
of,O
hundreds,O
to,O
thousands,O
of,O
patients,O
.,O
Current,O
medical,O
doctrine,O
is,O
based,O
on,O
limited,O
clinical,O
data,O
and,O
remains,O
inadequate,O
.,O
Efforts,O
to,O
develop,O
medical,O
innovations,O
that,O
address,O
ARS,B-DS
complications,O
are,O
unlikely,O
to,O
be,O
generated,O
by,O
industry,O
because,O
of,O
market,O
uncertainties,O
specific,O
to,O
this,O
type,O
of,O
injury,O
.,O
A,O
prospective,O
strategy,O
could,O
be,O
the,O
integration,O
of,O
cellular,O
therapy,O
to,O
meet,O
the,O
medical,O
demands,O
of,O
ARS,B-DS
.,O
The,O
most,O
clinically,O
advanced,O
cellular,O
therapy,O
to,O
date,O
is,O
the,O
administration,O
of,O
mesenchymal,O
stem,O
cells,O
(,O
MSCs,O
).,O
Results,O
of,O
currently,O
published,O
investigations,O
describing,O
MSC,O
safety,O
and,O
efficacy,O
in,O
a,O
variety,O
of,O
injury,O
and,O
disease,O
models,O
demonstrate,O
the,O
unique,O
qualities,O
of,O
this,O
reparative,O
cell,O
population,O
in,O
adapting,O
to,O
the,O
specific,O
requirements,O
of,O
the,O
damaged,O
tissue,O
in,O
which,O
the,O
cells,O
integrate,O
.,O
This,O
report,O
puts,O
forward,O
a,O
rationale,O
for,O
the,O
further,O
evaluation,O
of,O
MSC,O
therapy,O
to,O
address,O
the,O
current,O
unmet,O
medical,O
needs,O
of,O
ARS,B-DS
.,O
We,O
propose,O
that,O
the,O
exploration,O
of,O
this,O
novel,O
therapy,O
for,O
the,O
treatment,O
of,O
the,O
multivariate,O
complications,O
of,O
ARS,B-DS
could,O
be,O
of,O
invaluable,O
benefit,O
to,O
military,O
medicine,O
.,O
Introduction,O
The,O
inclusion,O
of,O
cellular,O
therapies,O
in,O
the,O
treatment,O
of,O
battlefield,O
injuries,O
provides,O
a,O
novel,O
and,O
promising,O
approach,O
for,O
addressing,O
long,O
-,O
standing,O
challenges,O
in,O
tissue,O
repair,O
with,O
regard,O
to,O
both,O
structural,O
and,O
functional,O
improvements,O
.,O
The,O
results,O
of,O
currently,O
published,O
investigations,O
describing,O
adult,O
stem,O
cell,O
efficacy,O
in,O
a,O
variety,O
of,O
injury,O
and,O
disease,O
models,O
demonstrate,O
the,O
unique,O
qualities,O
of,O
reparative,O
cell,O
populations,O
present,O
in,O
adult,O
tissues,O
.,O
Bone,O
marrow,O
-,O
derived,O
mesenchymal,O
stem,O
cells,O
(,O
MSCs,O
"),",O
adipose,O
derived,O
stem,O
cells,O
",",O
and,O
endothelial,O
progenitor,O
cells,O
",",O
for,O
example,O
",",O
exhibit,O
a,O
remarkable,O
capacity,O
to,O
adapt,O
to,O
the,O
requirements,O
of,O
the,O
damaged,O
tissue,O
in,O
which,O
the,O
cells,O
integrate,O
.,O
In,O
this,O
study,O
",",O
we,O
focus,O
on,O
the,O
potential,O
use,O
of,O
MSC,O
therapy,O
as,O
a,O
medical,O
countermeasure,O
for,O
the,O
treatment,O
of,O
acute,B-DS
radiation,I-DS
syndrome,I-DS
(,O
ARS,B-DS
).,O
MSC,O
therapy,O
represents,O
a,O
single,O
medical,O
intervention,O
that,O
can,O
simultaneously,O
provide,O
a,O
broad,O
range,O
of,O
therapeutic,O
efficacy,O
",",O
with,O
local,O
activity,O
",",O
at,O
multiple,O
tissue,O
and,O
organ,O
sites,O
.,O
Although,O
ARS,B-DS
is,O
rare,O
",",O
it,O
is,O
a,O
complex,O
and,O
medically,O
challenging,O
disorder,O
that,O
has,O
the,O
potential,O
for,O
large,O
-,O
scale,O
incidence,O
on,O
the,O
battlefield,O
or,O
in,O
conjunction,O
with,O
a,O
domestic,O
terrorist,O
attack,O
.,O
Currently,O
",",O
medical,O
intervention,O
for,O
numerous,O
aspects,O
of,O
ARS,B-DS
is,O
limited,O
to,O
supportive,O
care,O
.,O
Since,O
the,O
end,O
of,O
the,O
Second,O
World,O
War,O
",",O
nearly,O
all,O
radiation,O
injuries,O
have,O
been,O
caused,O
by,O
accidents,O
in,O
the,O
medical,O
and,O
nuclear,O
power,O
industries,O
.,O
However,O
",",O
the,O
rise,O
in,O
global,O
terrorism,O
",",O
the,O
proliferation,O
of,O
nuclear,O
technology,O
",",O
and,O
the,O
undocumented,O
dispersal,O
of,O
enriched,O
uranium,O
",",O
plutonium,O
",",O
and,O
other,O
radioactive,O
compounds,O
have,O
intensified,O
concerns,O
regarding,O
the,O
use,O
of,O
a,O
radiological,O
or,O
nuclear,O
weapon,O
to,O
inflict,O
extensive,O
military,O
casualties,O
",",O
civilian,O
casualties,O
",",O
or,O
both,O
.,O
Detonating,O
an,O
improvised,O
radiological,O
device,O
or,O
nuclear,O
warhead,O
could,O
necessitate,O
the,O
medical,O
management,O
of,O
hundreds,O
to,O
thousands,O
of,O
patients,O
with,O
ARS,B-DS
",",O
which,O
typically,O
occurs,O
to,O
some,O
degree,O
following,O
a,O
whole,O
body,O
dose,O
of,O
1,O
Gray,O
(,O
Gy,O
),O
or,O
more,O
[,O
1,O
",",O
2,O
].,O
The,O
underlying,O
pathology,O
of,O
ARS,B-DS
involves,O
physical,O
and,O
chemical,O
damage,O
to,O
DNA,O
",",O
which,O
affects,O
the,O
rapidly,O
dividing,O
cells,O
of,O
the,O
hematopoietic,O
system,O
and,O
the,O
gastrointestinal,O
(,O
GI,O
),O
tract,O
.,O
As,O
a,O
result,O
",",O
ARS,B-DS
symptoms,O
are,O
often,O
subclassified,O
into,O
the,O
hematopoietic,O
and,O
GI,B-DS
syndromes,I-DS
",",O
which,O
occur,O
simultaneously,O
at,O
higher,O
exposure,O
levels,O
.,O
As,O
discussed,O
below,O
",",O
the,O
therapeutic,O
benefit,O
of,O
MSC,O
therapy,O
for,O
these,O
individuals,O
could,O
include,O
the,O
facilitation,O
of,O
hematopoietic,O
recovery,O
",",O
enhancement,O
of,O
healing,O
of,O
the,O
GI,O
tract,O
and,O
the,O
skin,O
",",O
and,O
the,O
possible,O
mitigation,O
or,O
treatment,O
of,O
a,O
variety,O
of,O
additional,O
ARS,B-DS
complications,O
.,O
MSC,O
biology,O
and,O
clinical,O
use,O
MSC,O
-,O
based,O
therapeutics,O
have,O
emerged,O
as,O
the,O
most,O
clinically,O
advanced,O
multipotent,O
stem,O
cell,O
therapy,O
to,O
date,O
.,O
At,O
least,O
178,O
Phase,O
II,O
or,O
Phase,O
III,O
trials,O
have,O
been,O
completed,O
or,O
are,O
currently,O
recruiting,O
patients,O
to,O
evaluate,O
MSC,O
therapy,O
for,O
the,O
treatment,O
of,O
a,O
diverse,O
array,O
of,O
indications,O
(,O
www,O
.,O
clinicaltrials,O
.,O
gov,O
",",O
September,O
2014,O
[,O
3,O
]).,O
A,O
commercial,O
product,O
consisting,O
of,O
purified,O
MSCs,O
has,O
received,O
regulatory,O
approval,O
in,O
both,O
Canada,O
and,O
New,O
Zealand,O
for,O
the,O
treatment,O
of,O
graft,B-DS
vs,I-DS
.,I-DS
host,I-DS
disease,I-DS
(,O
GvHD,B-DS
"),",O
a,O
potentially,O
lethal,O
complication,O
of,O
allogeneic,O
bone,O
marrow,O
transplant,O
arising,O
from,O
the,O
severe,O
immune,O
reaction,O
of,O
the,O
donated,O
immune,O
cells,O
against,O
the,O
host,O
tissues,O
(,O
Osiris,O
Therapeutics,O
",",O
Inc,O
".,",O
Columbia,O
",",O
MD,O
).,O
The,O
currently,O
marketed,O
cell,O
-,O
based,O
treatment,O
regimen,O
does,O
not,O
contain,O
embryonic,O
cells,O
or,O
any,O
constituent,O
derived,O
from,O
fetal,O
sources,O
.,O
Although,O
other,O
forms,O
of,O
stem,O
cell,O
therapies,O
based,O
on,O
induced,O
pluripotent,O
stem,O
cells,O
",",O
embryonic,O
stem,O
cells,O
",",O
or,O
umbilical,O
cord,O
blood,O
continue,O
to,O
show,O
promise,O
in,O
pre,O
-,O
clinical,O
studies,O
",",O
MSC,O
therapy,O
represents,O
an,O
approach,O
that,O
is,O
rapidly,O
gaining,O
acceptance,O
in,O
clinical,O
practice,O
.,O
No,O
other,O
multipotent,O
stem,O
cell,O
therapy,O
has,O
established,O
an,O
extensive,O
safety,O
profile,O
in,O
the,O
clinical,O
setting,O
.,O
Intravenously,O
(,O
IV,O
),O
infused,O
MSCs,O
have,O
been,O
shown,O
to,O
specifically,O
migrate,O
to,O
sites,O
of,O
tissue,O
damage,O
in,O
multiple,O
preclinical,O
injury,O
models,O
[,O
4,O
",",O
5,O
].,O
MSC,O
infusion,O
mimics,O
a,O
naturally,O
occurring,O
process,O
in,O
which,O
endogenous,O
MSCs,O
leave,O
the,O
bone,O
marrow,O
compartment,O
in,O
response,O
to,O
injury,O
",",O
enter,O
the,O
circulation,O
",",O
and,O
travel,O
to,O
sites,O
of,O
tissue,O
damage,O
",",O
guided,O
by,O
chemotactic,O
homing,O
signals,O
released,O
at,O
each,O
compromised,O
site,O
.,O
The,O
clinical,O
development,O
of,O
MSC,O
formulations,O
for,O
therapeutic,O
use,O
has,O
involved,O
the,O
isolation,O
of,O
MSCs,O
from,O
bone,O
marrow,O
and,O
expansion,O
in,O
culture,O
[,O
6,O
].,O
Numerous,O
studies,O
have,O
indicated,O
that,O
donor,O
-,O
derived,O
",",O
IV,O
-,O
administered,O
MSCs,O
retain,O
the,O
ability,O
to,O
localize,O
to,O
damaged,O
tissue,O
and,O
facilitate,O
repair,O
in,O
a,O
variety,O
of,O
injury,O
and,O
disease,O
settings,O
.,O
Cell,O
culture,O
-,O
expanded,O
MSCs,O
demonstrate,O
the,O
potential,O
to,O
form,O
several,O
specialized,O
cell,O
types,O
",",O
including,O
neurons,O
",",O
skin,O
",",O
bone,O
",",O
fat,O
",",O
cartilage,O
",",O
tendon,O
",",O
muscle,O
(,O
cardiac,O
and,O
skeletal,O
"),",O
epithelium,O
(,O
lung,O
",",O
gut,O
",",O
and,O
kidney,O
"),",O
and,O
many,O
others,O
.,O
Once,O
engrafted,O
within,O
damaged,O
tissues,O
",",O
MSCs,O
participate,O
in,O
the,O
healing,O
process,O
both,O
directly,O
",",O
through,O
differentiation,O
to,O
replace,O
lost,O
cell,O
types,O
",",O
and,O
indirectly,O
",",O
through,O
the,O
local,O
secretion,O
of,O
cytokines,B-GP
and,O
other,O
bioactive,O
molecules,O
that,O
facilitate,O
a,O
reduction,O
in,O
inflammation,O
",",O
the,O
inhibition,O
of,O
scar,O
formation,O
",",O
and,O
the,O
enhancement,O
of,O
endogenous,O
mechanisms,O
of,O
tissue,O
reconstruction,O
[,O
7,O
].,O
The,O
molecular,O
basis,O
for,O
MSC,O
homing,O
to,O
injury,O
sites,O
has,O
been,O
evaluated,O
by,O
several,O
independent,O
laboratories,O
using,O
both,O
in,O
vitro,O
and,O
in,O
vivo,O
approaches,O
.,O
The,O
data,O
describe,O
MSC,O
chemotaxis,O
toward,O
a,O
variety,O
of,O
chemokines,B-GP
",",O
including,O
monocyte,B-GP
chemoattractant,I-GP
protein,I-GP
-,I-GP
1,I-GP
(,O
MCP,B-GP
-,I-GP
1,I-GP
"),",O
macrophage,B-GP
inflammatory,I-GP
protein,I-GP
-,I-GP
1α,I-GP
(,O
MIP,B-GP
-,I-GP
1α,I-GP
"),",O
interleukin,B-GP
-,I-GP
8,I-GP
(,O
IL,B-GP
-,I-GP
8,I-GP
"),",O
and,O
stromal,B-GP
derived,I-GP
factor,I-GP
-,I-GP
1,I-GP
(,O
SDF,B-GP
-,I-GP
1,I-GP
),O
[,O
8,O
",",O
9,O
].,O
For,O
example,O
",",O
Wang,O
et,O
al,O
.,O
[,O
8,O
],O
observed,O
in,O
vitro,O
MSC,O
migration,O
toward,O
purified,O
MCP,B-GP
-,I-GP
1,I-GP
",",O
MIP,B-GP
-,I-GP
1α,I-GP
",",O
and,O
IL,B-GP
-,I-GP
8,I-GP
",",O
as,O
well,O
as,O
toward,O
extracts,O
prepared,O
from,O
brain,O
tissue,O
injured,O
by,O
oxygen,O
deprivation,O
(,O
ischemic,O
injury,O
).,O
The,O
involvement,O
of,O
the,O
specific,O
chemokine,B-GP
in,O
question,O
was,O
verified,O
by,O
the,O
inhibition,O
of,O
directional,O
migration,O
in,O
the,O
presence,O
of,O
a,O
blocking,O
antibody,B-GP
to,O
each,O
cytokine,B-GP
.,O
Once,O
engrafted,O
to,O
damaged,O
tissues,O
",",O
MSCs,O
elicit,O
a,O
broad,O
range,O
of,O
effects,O
with,O
regard,O
to,O
modulation,O
of,O
the,O
inflammatory,O
response,O
to,O
injury,O
.,O
MSCs,O
express,O
a,O
low,O
level,O
of,O
major,B-GP
histocompatibility,I-GP
(,I-GP
MHC,I-GP
),I-GP
class,I-GP
I,I-GP
molecules,O
",",O
but,O
they,O
lack,O
expression,O
of,O
MHC,B-GP
class,I-GP
II,I-GP
and,O
the,O
B7,B-GP
co,O
-,O
stimulatory,O
molecule,O
.,O
These,O
molecules,O
are,O
involved,O
in,O
antigen,O
presentation,O
at,O
the,O
cell,O
surface,O
.,O
MSCs,O
are,O
therefore,O
rendered,O
“,O
immune,O
privileged,O
”,O
by,O
the,O
capacity,O
to,O
evade,O
recognition,O
by,O
both,O
CD4,B-GP
+,O
T,O
helper,O
and,O
CD8,B-GP
+,O
cytotoxic,O
T,O
cells,O
.,O
In,O
addition,O
to,O
being,O
immune,O
privileged,O
MSCs,O
also,O
actively,O
attenuate,O
immune,O
activity,O
.,O
Cell,O
surface,O
markers,O
of,O
lymphocyte,O
activation,O
",",O
including,O
CD25,B-GP
",",O
CD38,B-GP
",",O
and,O
CD69,B-GP
",",O
have,O
been,O
shown,O
to,O
decrease,O
in,O
the,O
presence,O
of,O
MSCs,O
.,O
T,O
cell,O
proliferation,O
is,O
inhibited,O
by,O
MSCs,O
through,O
a,O
block,O
in,O
cyclin,B-GP
D2,I-GP
expression,O
",",O
resulting,O
in,O
cell,O
cycle,O
arrest,O
.,O
Finally,O
",",O
MSCs,O
have,O
also,O
been,O
shown,O
to,O
inhibit,O
the,O
innate,O
immune,O
response,O
by,O
blocking,O
the,O
IL,B-GP
-,I-GP
2,I-GP
-,O
mediated,O
activation,O
of,O
natural,O
killer,O
cells,O
[,O
10,O
].,O
In,O
addition,O
to,O
the,O
initial,O
anti,O
-,O
inflammatory,O
properties,O
of,O
MSCs,O
",",O
engraftment,O
induces,O
the,O
local,O
secretion,O
of,O
multiple,O
paracrine,O
factors,O
that,O
facilitate,O
wound,O
healing,O
.,O
These,O
factors,O
include,O
angiogenic,O
",",O
anti,O
-,O
apoptotic,O
",",O
mitogenic,O
",",O
and,O
homing,O
signals,O
",",O
such,O
as,O
vascular,B-GP
endothelial,I-GP
growth,I-GP
factor,I-GP
(,O
VEGF,B-GP
"),",O
hepatocyte,B-GP
growth,I-GP
factor,I-GP
(,O
HGF,B-GP
"),",O
insulin,B-GP
-,I-GP
like,I-GP
growth,I-GP
factor,I-GP
-,I-GP
1,I-GP
(,O
IGF,B-GP
-,I-GP
1,I-GP
"),",O
basic,B-GP
fibroblast,I-GP
growth,I-GP
factor,I-GP
(,O
bFGF,B-GP
"),",O
and,O
SDF,B-GP
-,I-GP
1,I-GP
",",O
resulting,O
in,O
the,O
accumulation,O
of,O
several,O
distinct,O
populations,O
of,O
blood,O
vessel,O
precursor,O
cells,O
and,O
other,O
tissue,O
-,O
specific,O
progenitor,O
cells,O
[,O
7,O
",",O
9,O
",",O
11,O
",",O
12,O
].,O
Both,O
preclinical,O
and,O
clinical,O
studies,O
have,O
demonstrated,O
the,O
safety,O
and,O
efficacy,O
of,O
allogeneic,O
(,O
non,O
-,O
immunologically,O
matched,O
),O
MSC,O
delivery,O
(,O
see,O
recent,O
reviews,O
by,O
Inamdar,O
et,O
al,O
.,O
[,O
13,O
];,O
Sheng,O
et,O
al,O
.,O
[,O
14,O
];,O
and,O
Honmou,O
et,O
al,O
.,O
[,O
15,O
]).,O
The,O
general,O
consensus,O
for,O
efficacy,O
with,O
the,O
use,O
of,O
allogeneically,O
derived,O
MSCs,O
is,O
increasingly,O
ascribed,O
to,O
anti,O
-,O
inflammatory,O
and,O
paracrine,O
activity,O
[,O
16,O
].,O
However,O
",",O
significant,O
interest,O
still,O
remains,O
in,O
evaluating,O
the,O
role,O
of,O
MSCs,O
",",O
as,O
a,O
stem,O
cell,O
population,O
",",O
in,O
promoting,O
wound,O
repair,O
by,O
direct,O
differentiation,O
to,O
replace,O
cells,O
lost,O
to,O
injury,O
.,O
In,O
the,O
context,O
of,O
addressing,O
the,O
consequences,O
of,O
battlefield,O
injury,O
",",O
we,O
see,O
a,O
distinct,O
and,O
specific,O
value,O
for,O
the,O
use,O
of,O
either,O
allogeneic,O
or,O
autologous,O
(,O
patient,O
-,O
derived,O
),O
MSC,O
therapy,O
.,O
The,O
rationale,O
for,O
determining,O
the,O
MSC,O
source,O
will,O
be,O
dependent,O
on,O
the,O
treatment,O
goals,O
for,O
each,O
indication,O
.,O
For,O
example,O
",",O
early,O
treatment,O
for,O
a,O
blast,O
injury,O
may,O
be,O
focused,O
on,O
the,O
anti,O
-,O
inflammatory,O
and,O
paracrine,O
properties,O
of,O
MSCs,O
.,O
Stockpiled,O
",",O
“,O
off,O
-,O
the,O
-,O
shelf,O
”,O
allogeneic,O
MSCs,O
would,O
be,O
appropriate,O
for,O
use,O
in,O
this,O
case,O
and,O
could,O
be,O
administered,O
in,O
a,O
Combat,O
Support,O
Hospital,O
.,O
The,O
use,O
of,O
MSCs,O
for,O
reconstructive,O
procedures,O
to,O
replace,O
significant,O
tissue,O
loss,O
",",O
however,O
",",O
would,O
likely,O
require,O
autologously,O
derived,O
cells,O
that,O
would,O
not,O
be,O
cleared,O
by,O
the,O
immune,O
system,O
after,O
the,O
cells,O
mature,O
and,O
begin,O
to,O
express,O
donor,O
-,O
specific,O
proteins,O
.,O
The,O
characteristic,O
anti,O
-,O
inflammatory,O
",",O
tissue,O
repair,O
",",O
and,O
hematopoietic,O
support,O
capabilities,O
of,O
this,O
particular,O
stem,O
cell,O
population,O
suggest,O
that,O
MSC,O
therapy,O
may,O
be,O
ideal,O
for,O
inclusion,O
in,O
medical,O
preparedness,O
planning,O
for,O
a,O
radiological,O
or,O
nuclear,O
event,O
.,O
Given,O
the,O
broad,O
applicability,O
of,O
MSC,O
treatments,O
to,O
numerous,O
diverse,O
injuries,O
and,O
diseases,O
",",O
the,O
development,O
of,O
MSC,O
treatment,O
for,O
ARS,B-DS
is,O
also,O
likely,O
to,O
benefit,O
treatment,O
strategies,O
for,O
a,O
wide,O
array,O
of,O
additional,O
conditions,O
.,O
Therapeutic,O
potential,O
of,O
MSC,O
treatment,O
of,O
hematopoietic,B-DS
syndrome,I-DS
The,O
hematopoietic,B-DS
syndrome,I-DS
is,O
the,O
principal,O
cause,O
of,O
mortality,O
in,O
radiation,O
exposure,O
doses,O
from,O
1,O
to,O
10,O
Gy,O
[,O
1,O
].,O
The,O
manifest,O
illness,O
is,O
typically,O
characterized,O
by,O
intense,O
immunosuppression,B-DS
",",O
anemia,B-DS
",",O
and,O
thrombocytopenia,B-DS
resulting,O
from,O
the,O
death,O
and,O
/,O
or,O
reduced,O
replication,O
of,O
hematopoietic,O
progenitor,O
cells,O
following,O
irradiation,O
.,O
Current,O
data,O
from,O
studies,O
on,O
animals,B-OG
and,O
humans,B-OG
suggest,O
that,O
the,O
mean,O
lethal,O
dose,O
of,O
whole,O
body,O
radiation,O
required,O
to,O
kill,O
50,O
%,O
of,O
patients,O
in,O
60,O
days,O
is,O
between,O
3,O
and,O
4,O
Gy,O
.,O
When,O
patients,O
are,O
given,O
appropriate,O
medical,O
management,O
with,O
intravenous,O
hydration,O
",",O
antiemetics,O
",",O
analgesics,O
",",O
antibiotics,O
",",O
and,O
blood,O
transfusions,O
",",O
the,O
LD50,O
is,O
estimated,O
to,O
lie,O
between,O
approximately,O
6,O
and,O
7,O
Gy,O
[,O
1,O
].,O
Current,O
guidelines,O
recommend,O
short,O
-,O
term,O
cytokine,B-GP
therapy,O
with,O
granulocyte,B-GP
colony,I-GP
-,I-GP
stimulating,I-GP
factor,I-GP
(,O
Neupogen,O
®,O
[,O
Filgrastim,O
",",O
Amgen,O
",",O
Inc,O
".]),",O
granulocyte,B-GP
-,I-GP
macrophage,I-GP
colony,I-GP
-,I-GP
stimulating,I-GP
factor,I-GP
(,O
GM,B-GP
-,I-GP
CSF,I-GP
"),",O
and,O
pegylated,O
G,B-GP
-,I-GP
CSF,I-GP
to,O
facilitate,O
hematopoietic,O
recovery,O
[,O
17,O
].,O
Both,O
in,O
vitro,O
and,O
in,O
vivo,O
(,O
including,O
clinical,O
),O
data,O
indicate,O
that,O
the,O
addition,O
of,O
MSC,O
therapy,O
to,O
standard,O
care,O
can,O
promote,O
more,O
rapid,O
recovery,O
of,O
the,O
hematopoietic,O
system,O
.,O
MSCs,O
constitutively,O
secrete,O
a,O
broad,O
range,O
of,O
hematopoietic,B-GP
cytokines,I-GP
",",O
such,O
as,O
IL,B-GP
-,I-GP
6,I-GP
",",O
IL,B-GP
-,I-GP
7,I-GP
",",O
IL,B-GP
-,I-GP
8,I-GP
",",O
IL,B-GP
-,I-GP
11,I-GP
",",O
IL,B-GP
-,I-GP
14,I-GP
",",O
IL,B-GP
-,I-GP
15,I-GP
",",O
macrophage,B-GP
colony,I-GP
-,I-GP
stimulating,I-GP
factor,I-GP
",",O
Flt,B-GP
-,I-GP
3,I-GP
ligand,I-GP
",",O
and,O
stem,B-GP
-,I-GP
cell,I-GP
factor,I-GP
(,O
SFC,B-GP
).,O
IL,B-GP
-,I-GP
1a,I-GP
induces,O
MSC,O
production,O
of,O
IL,B-GP
-,I-GP
1a,I-GP
",",O
leukemia,B-GP
-,I-GP
inhibiting,I-GP
factor,I-GP
",",O
G,B-GP
-,I-GP
CSF,I-GP
",",O
and,O
GM,B-GP
-,I-GP
CSF,I-GP
[,O
18,O
].,O
In,O
vitro,O
evaluations,O
have,O
provided,O
detailed,O
evidence,O
that,O
these,O
factors,O
",",O
as,O
well,O
as,O
other,O
members,O
of,O
the,O
MSC,O
secretome,O
(,O
the,O
array,O
of,O
proteins,O
produced,O
and,O
secreted,O
by,O
MSCs,O
"),",O
support,O
the,O
growth,O
of,O
hematopoietic,O
stem,O
cells,O
(,O
HSCs,O
),O
and,O
their,O
progeny,O
in,O
an,O
ex,O
vivo,O
environment,O
.,O
MSC,O
deposition,O
of,O
extracellular,O
matrix,O
constituents,O
that,O
are,O
native,O
to,O
the,O
bone,O
marrow,O
compartment,O
is,O
likely,O
to,O
significantly,O
contribute,O
to,O
this,O
phenomenon,O
.,O
Relevant,O
to,O
hematopoietic,O
recovery,O
after,O
radiation,O
exposure,O
",",O
in,O
vitro,O
studies,O
have,O
also,O
shown,O
a,O
positive,O
influence,O
of,O
the,O
presence,O
of,O
MSCs,O
on,O
the,O
expansion,O
of,O
irradiated,O
blood,O
cell,O
precursors,O
:,O
irradiated,O
CD34,B-GP
+,O
cells,O
demonstrate,O
a,O
several,O
-,O
fold,O
growth,O
increase,O
when,O
cultured,O
in,O
the,O
presence,O
vs,O
.,O
the,O
absence,O
of,O
MSCs,O
[,O
19,O
].,O
At,O
higher,O
radiation,O
exposure,O
levels,O
",",O
patients,O
will,O
require,O
an,O
HSC,O
transplant,O
.,O
In,O
a,O
mass,O
casualty,O
scenario,O
",",O
the,O
timely,O
treatment,O
of,O
large,O
numbers,O
of,O
patients,O
will,O
be,O
challenging,O
and,O
will,O
require,O
innovative,O
medical,O
intervention,O
.,O
Preclinical,O
work,O
in,O
animal,B-OG
models,O
has,O
evaluated,O
the,O
influence,O
of,O
HSC,O
–,O
MSC,O
co,O
-,O
transplant,O
on,O
hematopoietic,O
recovery,O
.,O
The,O
results,O
of,O
these,O
analyses,O
suggest,O
that,O
HSC,O
–,O
MSC,O
coinfusion,O
facilitates,O
HSC,O
engraftment,O
and,O
hematopoietic,O
recovery,O
[,O
20,O
",",O
21,O
].,O
Furthermore,O
",",O
MSC,O
coinfusion,O
increases,O
the,O
success,O
rates,O
of,O
HSC,O
transplants,O
",",O
even,O
under,O
sub,O
-,O
optimal,O
transplant,O
conditions,O
.,O
These,O
scenarios,O
include,O
the,O
transplantation,O
of,O
a,O
limited,O
number,O
of,O
HSCs,O
[,O
21,O
",",O
22,O
],O
or,O
situations,O
in,O
which,O
transplanted,O
HSCs,O
have,O
been,O
obtained,O
from,O
two,O
immunologically,O
disparate,O
donors,O
[,O
23,O
].,O
Fortunately,O
",",O
the,O
promising,O
results,O
obtained,O
in,O
preclinical,O
studies,O
are,O
being,O
realized,O
in,O
the,O
clinical,O
setting,O
as,O
well,O
.,O
A,O
successful,O
clinical,O
use,O
has,O
been,O
the,O
coinfusion,O
of,O
HSC,O
–,O
MSC,O
following,O
ablative,O
radiation,O
or,O
chemotherapy,O
for,O
the,O
treatment,O
of,O
both,O
malignant,O
and,O
non,O
-,O
malignant,O
disorders,O
.,O
A,O
large,O
body,O
of,O
data,O
supports,O
the,O
concept,O
that,O
MSC,O
therapy,O
provides,O
a,O
safe,O
and,O
effective,O
treatment,O
modality,O
to,O
facilitate,O
hematopoietic,O
recovery,O
and,O
overall,O
survival,O
following,O
medical,O
intervention,O
that,O
involves,O
an,O
HSC,O
transplant,O
(,O
reviewed,O
in,O
Tolar,O
[,O
24,O
]).,O
The,O
majority,O
of,O
published,O
reports,O
discuss,O
clinical,O
outcomes,O
from,O
small,O
or,O
single,O
-,O
patient,O
case,O
studies,O
.,O
Despite,O
differences,O
in,O
the,O
particular,O
medical,O
disorder,O
",",O
patient,O
demographics,O
",",O
and,O
treatment,O
regimen,O
",",O
the,O
collective,O
results,O
suggest,O
an,O
increase,O
in,O
both,O
HSC,O
graft,O
stability,O
and,O
overall,O
patient,O
survival,O
.,O
Importantly,O
",",O
larger,O
clinical,O
trials,O
have,O
evaluated,O
results,O
from,O
a,O
treated,O
subject,O
pool,O
against,O
relevant,O
historical,O
control,O
patients,O
.,O
These,O
studies,O
have,O
demonstrated,O
significant,O
efficacy,O
with,O
the,O
use,O
of,O
HSC,O
–,O
MSC,O
coinfusion,O
to,O
promote,O
the,O
rapid,O
recovery,O
of,O
cellular,O
blood,O
constituents,O
.,O
For,O
example,O
",",O
a,O
Phase,O
I,O
/,O
II,O
clinical,O
study,O
by,O
Ball,O
et,O
al,O
.,O
([,O
25,O
]),O
followed,O
14,O
patients,O
who,O
were,O
co,O
-,O
transplanted,O
with,O
donor,O
MSCs,O
and,O
human,B-GP
leukocyte,I-GP
antigen,I-GP
(,O
HLA,B-GP
)-,O
disparate,O
peripheral,O
blood,O
HSCs,O
.,O
The,O
results,O
were,O
compared,O
to,O
47,O
historic,O
control,O
subjects,O
.,O
Study,O
subjects,O
were,O
treated,O
at,O
the,O
same,O
two,O
medical,O
facilities,O
as,O
control,O
patients,O
.,O
The,O
infusion,O
dose,O
ranged,O
from,O
1,O
to,O
5,O
million,O
MSCs,O
/,O
kg,O
body,O
weight,O
.,O
MSC,O
-,O
treated,O
subjects,O
experienced,O
faster,O
recovery,O
in,O
total,O
leukocyte,O
count,O
(,O
above,O
1,O
.,O
0,O
×,O
109,O
/,O
L,O
),O
in,O
comparison,O
to,O
historic,O
controls,O
",",O
with,O
patients,O
in,O
this,O
study,O
having,O
a,O
mean,O
time,O
to,O
recovery,O
of,O
11,O
.,O
5,O
days,O
and,O
the,O
control,O
group,O
recovering,O
in,O
14,O
.,O
9,O
days,O
(,O
P,O
=,O
0,O
.,O
009,O
).,O
Although,O
control,O
subjects,O
experienced,O
a,O
graft,O
failure,O
rate,O
of,O
15,O
"%,",O
all,O
patients,O
who,O
were,O
given,O
MSCs,O
in,O
this,O
study,O
showed,O
sustained,O
hematopoietic,O
engraftment,O
without,O
adverse,O
reactions,O
.,O
Rapid,O
hematopoietic,O
reconstitution,O
was,O
also,O
reported,O
for,O
28,O
subjects,O
enrolled,O
in,O
a,O
breast,B-DS
cancer,I-DS
study,O
that,O
had,O
received,O
high,O
-,O
dose,O
chemotherapy,O
followed,O
by,O
the,O
coinfusion,O
of,O
peripheral,O
blood,O
stem,O
cells,O
and,O
MSCs,O
.,O
In,O
this,O
investigation,O
",",O
all,O
patients,O
received,O
1,O
to,O
2,O
.,O
2,O
million,O
autologous,O
MSCs,O
/,O
kg,O
body,O
mass,O
in,O
conjunction,O
with,O
G,B-GP
-,I-GP
CSF,I-GP
therapy,O
.,O
Neutrophil,O
recovery,O
(,O
judged,O
as,O
greater,O
than,O
500,O
/,O
μl,O
),O
ranged,O
from,O
6,O
to,O
11,O
days,O
",",O
with,O
an,O
average,O
of,O
8,O
days,O
.,O
Platelet,O
engraftment,O
(,O
judged,O
as,O
greater,O
than,O
20,O
",",O
000,O
/,O
μl,O
),O
ranged,O
from,O
4,O
to,O
19,O
days,O
",",O
with,O
an,O
average,O
of,O
8,O
.,O
5,O
days,O
[,O
26,O
].,O
Historical,O
control,O
data,O
specifically,O
relevant,O
to,O
this,O
institute,O
or,O
by,O
these,O
researchers,O
are,O
not,O
reported,O
.,O
However,O
",",O
these,O
values,O
for,O
neutrophil,O
and,O
platelet,O
recovery,O
are,O
more,O
favorable,O
compared,O
with,O
the,O
results,O
of,O
large,O
clinical,O
trials,O
published,O
elsewhere,O
in,O
which,O
patients,O
received,O
G,B-GP
-,I-GP
CSF,I-GP
treatment,O
(,O
e,O
.,O
g,O
".,",O
Amadori,O
[,O
27,O
"],",O
Usuki,O
[,O
28,O
"],",O
Nivison,O
-,O
Smith,O
[,O
29,O
"],",O
Godwin,O
[,O
30,O
"],",O
Lowenberg,O
[,O
31,O
"],",O
Hassan,O
[,O
32,O
"],",O
Rowe,O
[,O
33,O
"],",O
Stone,O
[,O
34,O
"],",O
Ottmann,O
[,O
35,O
]).,O
Depending,O
on,O
the,O
scale,O
of,O
a,O
radiological,O
or,O
nuclear,O
incident,O
",",O
medical,O
response,O
logistics,O
",",O
and,O
the,O
availability,O
of,O
suitable,O
donors,O
",",O
the,O
number,O
of,O
ARS,B-DS
victims,O
that,O
can,O
be,O
given,O
an,O
HSC,O
transplant,O
may,O
be,O
highly,O
limited,O
.,O
Studies,O
in,O
animal,B-OG
models,O
and,O
clinical,O
investigations,O
suggest,O
that,O
the,O
infusion,O
of,O
allogeneic,O
MSCs,O
alone,O
may,O
be,O
an,O
achievable,O
and,O
efficacious,O
alternative,O
strategy,O
for,O
stimulating,O
hematopoietic,O
recovery,O
in,O
patients,O
[,O
36,O
",",O
37,O
].,O
A,O
clinical,O
approach,O
that,O
closely,O
mimics,O
this,O
scenario,O
is,O
allogeneic,O
MSC,O
infusion,O
to,O
treat,O
patients,O
in,O
which,O
HSC,O
engraftment,O
has,O
failed,O
.,O
In,O
both,O
cases,O
",",O
MSCs,O
are,O
administered,O
without,O
HSC,O
coinfusion,O
.,O
MSC,O
engraftment,O
to,O
the,O
bone,O
marrow,O
enhances,O
the,O
HSC,O
niche,O
to,O
a,O
level,O
that,O
promotes,O
the,O
growth,O
and,O
maturation,O
of,O
residual,O
HSCs,O
.,O
Although,O
the,O
currently,O
available,O
data,O
are,O
limited,O
",",O
MSC,O
infusion,O
as,O
a,O
rescue,O
therapy,O
for,O
HSC,O
graft,O
failure,O
has,O
shown,O
generally,O
positive,O
outcomes,O
.,O
Significant,O
improvement,O
in,O
the,O
bone,O
marrow,O
microenvironment,O
and,O
",",O
in,O
some,O
cases,O
",",O
rapid,O
and,O
sustained,O
hematopoietic,O
recovery,O
",",O
have,O
been,O
observed,O
in,O
subjects,O
who,O
had,O
failed,O
to,O
respond,O
to,O
conventional,O
treatment,O
[,O
38,O
-,O
40,O
].,O
To,O
provide,O
timely,O
administration,O
under,O
this,O
scenario,O
",",O
an,O
option,O
would,O
be,O
to,O
stockpile,O
allogeneic,O
MSCs,O
that,O
would,O
be,O
readily,O
available,O
in,O
the,O
event,O
of,O
a,O
radiological,O
or,O
nuclear,O
emergency,O
.,O
This,O
option,O
is,O
an,O
attainable,O
goal,O
because,O
relatively,O
few,O
donors,O
would,O
be,O
required,O
to,O
generate,O
a,O
sufficient,O
number,O
of,O
doses,O
to,O
treat,O
hundreds,O
to,O
thousands,O
of,O
patients,O
.,O
Efficacy,O
potential,O
of,O
MSC,O
therapy,O
for,O
GI,B-DS
syndrome,I-DS
In,O
addition,O
to,O
hematological,O
crisis,O
",",O
victims,O
exposed,O
to,O
radiation,O
levels,O
exceeding,O
7,O
Gy,O
will,O
develop,O
complications,O
that,O
are,O
characteristic,O
of,O
radiation,O
-,O
induced,O
GI,B-DS
syndrome,I-DS
.,O
These,O
symptoms,O
include,O
dehydration,B-DS
",",O
electrolyte,O
imbalance,O
",",O
malaise,O
",",O
anorexia,B-DS
",",O
severe,O
diarrhea,O
",",O
and,O
fever,O
.,O
The,O
basis,O
of,O
the,O
injury,O
to,O
the,O
GI,O
tract,O
is,O
associated,O
with,O
the,O
loss,O
of,O
rapidly,O
dividing,O
stem,O
cells,O
of,O
the,O
intestinal,O
crypts,O
",",O
which,O
replenish,O
the,O
epithelial,O
layer,O
of,O
the,O
gut,O
during,O
normal,O
tissue,O
turnover,O
.,O
The,O
resulting,O
breach,O
in,O
the,O
GI,O
barrier,O
",",O
in,O
combination,O
with,O
immune,B-DS
suppression,I-DS
",",O
presents,O
a,O
high,O
risk,O
of,O
life,O
-,O
threatening,O
infection,B-DS
.,O
Patients,O
diagnosed,O
with,O
GI,B-DS
syndrome,I-DS
have,O
an,O
extremely,O
low,O
survival,O
rate,O
",",O
and,O
no,O
currently,O
approved,O
medical,O
countermeasure,O
specifically,O
addresses,O
this,O
component,O
of,O
ARS,B-DS
.,O
Similar,O
to,O
the,O
influence,O
of,O
MSCs,O
on,O
HSCs,O
within,O
the,O
bone,O
marrow,O
compartment,O
",",O
both,O
in,O
vitro,O
and,O
in,O
vivo,O
data,O
support,O
the,O
role,O
of,O
MSC,O
therapy,O
in,O
promoting,O
the,O
restoration,O
of,O
intestinal,O
epithelium,O
by,O
nurturing,O
the,O
growth,O
of,O
the,O
residual,O
surviving,O
crypt,O
stem,O
cells,O
.,O
A,O
mechanism,O
through,O
which,O
this,O
support,O
occurs,O
is,O
the,O
local,O
secretion,O
of,O
growth,O
factors,O
and,O
chemotactic,O
signals,O
that,O
draw,O
in,O
epithelial,O
progenitors,O
to,O
the,O
sites,O
of,O
tissue,O
damage,O
.,O
Preclinical,O
models,O
of,O
abdominal,O
and,O
total,O
body,O
irradiation,O
have,O
demonstrated,O
increased,O
survival,O
with,O
MSC,O
infusion,O
accompanied,O
by,O
intestinal,O
crypt,O
cell,O
regeneration,O
",",O
restitution,O
of,O
the,O
stem,O
cell,O
niche,O
",",O
and,O
increased,O
xylose,O
absorption,O
.,O
Serum,O
levels,O
of,O
intestinal,O
radioprotective,O
factors,O
(,O
including,O
R,B-GP
-,I-GP
Spondin1,I-GP
",",O
KGF,B-GP
",",O
PDGF,B-GP
and,O
FGF2,B-GP
),O
and,O
anti,B-GP
-,I-GP
inflammatory,I-GP
cytokines,I-GP
were,O
increased,O
",",O
whereas,O
inflammatory,B-GP
cytokines,I-GP
were,O
down,O
-,O
regulated,O
[,O
41,O
-,O
43,O
].,O
Clinical,O
data,O
specifically,O
related,O
to,O
irradiation,O
injury,O
of,O
the,O
gut,O
are,O
extremely,O
limited,O
.,O
However,O
",",O
systemic,O
allogeneic,O
MSC,O
infusion,O
to,O
accidentally,O
over,O
-,O
irradiated,O
prostate,B-DS
cancer,I-DS
patients,O
with,O
radiation,O
-,O
induced,O
colitis,B-DS
has,O
been,O
reported,O
.,O
These,O
patients,O
experienced,O
a,O
reduction,O
in,O
pain,O
",",O
diarrhea,O
",",O
hemorrhage,O
",",O
inflammation,O
",",O
and,O
fistulization,O
[,O
44,O
].,O
Additionally,O
",",O
successful,O
clinical,O
use,O
of,O
MSC,O
therapy,O
has,O
been,O
reported,O
in,O
treating,O
certain,O
inflammatory,B-DS
bowel,I-DS
diseases,I-DS
that,O
involve,O
the,O
significant,O
loss,O
of,O
intestinal,O
epithelium,O
",",O
such,O
as,O
GvHD,B-DS
[,O
45,O
],O
and,O
Crohn,B-DS
’,I-DS
s,I-DS
disease,I-DS
[,O
46,O
].,O
Considering,O
the,O
highly,O
similar,O
pathophysiology,O
of,O
these,O
conditions,O
",",O
the,O
same,O
mechanisms,O
that,O
are,O
active,O
in,O
the,O
treatment,O
of,O
GvHD,B-DS
and,O
Crohn,B-DS
’,I-DS
s,I-DS
disease,I-DS
may,O
also,O
be,O
effective,O
against,O
the,O
GI,O
symptoms,O
of,O
ARS,B-DS
.,O
A,O
well,O
-,O
characterized,O
model,O
of,O
GI,B-DS
syndrome,I-DS
in,O
non,O
-,O
human,B-OG
primates,B-OG
recently,O
developed,O
by,O
MacVittie,O
et,O
al,O
.,O
[,O
47,O
],O
may,O
prove,O
to,O
be,O
an,O
invaluable,O
tool,O
for,O
developing,O
countermeasures,O
for,O
GI,B-DS
syndrome,I-DS
.,O
Therapeutic,O
rationale,O
for,O
MSC,O
treatment,O
of,O
cutaneous,O
and,O
combined,O
injury,O
Battlefield,O
injuries,O
commonly,O
involve,O
severe,O
and,O
extensive,O
cutaneous,O
tissue,O
damage,O
.,O
The,O
efficacy,O
of,O
MSC,O
treatment,O
in,O
promoting,O
skin,O
regeneration,O
has,O
been,O
shown,O
in,O
multiple,O
preclinical,O
injury,O
models,O
",",O
including,O
laceration,O
[,O
48,O
"],",O
thermal,O
burn,O
[,O
49,O
"],",O
and,O
radiation,O
exposure,O
[,O
50,O
-,O
52,O
].,O
The,O
results,O
of,O
these,O
studies,O
demonstrate,O
more,O
expedient,O
wound,O
closure,O
",",O
decreased,O
incidence,O
of,O
infection,B-DS
",",O
increased,O
vasculogenesis,O
and,O
elasticity,O
",",O
and,O
reduced,O
scar,O
formation,O
.,O
Lacerative,O
injury,O
concurrent,O
with,O
irradiation,O
presents,O
a,O
daunting,O
treatment,O
challenge,O
.,O
This,O
scenario,O
has,O
been,O
specifically,O
evaluated,O
by,O
Hao,O
et,O
al,O
.,O
([,O
53,O
]).,O
A,O
combined,O
radiation,O
–,O
wound,O
injury,O
was,O
generated,O
in,O
rats,B-OG
by,O
producing,O
an,O
excisional,O
wound,O
equal,O
to,O
2,O
%,O
body,O
surface,O
in,O
subjects,O
that,O
had,O
received,O
6,O
Gy,O
total,O
body,O
irradiation,O
.,O
MSCs,O
were,O
then,O
directly,O
injected,O
into,O
the,O
wound,O
bed,O
and,O
margins,O
.,O
At,O
14,O
days,O
post,O
-,O
injury,O
",",O
the,O
wound,O
area,O
was,O
approximately,O
half,O
the,O
size,O
in,O
MSC,O
-,O
treated,O
animals,B-OG
vs,O
.,O
control,O
subjects,O
.,O
Evidence,O
that,O
MSCs,O
play,O
a,O
natural,O
role,O
in,O
the,O
process,O
of,O
skin,O
regeneration,O
in,O
humans,B-OG
has,O
been,O
collected,O
in,O
a,O
clinical,O
study,O
",",O
in,O
which,O
the,O
number,O
of,O
MSCs,O
circulating,O
in,O
the,O
peripheral,O
blood,O
of,O
thermal,O
-,O
burn,O
patients,O
was,O
quantified,O
and,O
compared,O
to,O
the,O
number,O
of,O
circulating,O
MSCs,O
in,O
the,O
blood,O
of,O
healthy,O
volunteers,O
[,O
54,O
].,O
MSC,O
phenotype,O
was,O
determined,O
by,O
the,O
positive,O
expression,O
of,O
five,O
specific,O
cell,O
surface,O
markers,O
and,O
the,O
negative,O
expression,O
of,O
eight,O
other,O
markers,O
.,O
The,O
percentage,O
of,O
MSCs,O
in,O
circulating,O
blood,O
was,O
more,O
than,O
20,O
-,O
fold,O
greater,O
in,O
burn,O
patients,O
compared,O
to,O
that,O
in,O
healthy,O
individuals,O
",",O
and,O
the,O
degree,O
of,O
increase,O
was,O
correlated,O
with,O
the,O
size,O
and,O
severity,O
of,O
the,O
burn,O
.,O
These,O
results,O
offer,O
data,O
from,O
human,B-OG
subjects,O
that,O
suggest,O
MSCs,O
play,O
an,O
important,O
role,O
in,O
skin,O
regenerative,O
processes,O
because,O
the,O
cells,O
appear,O
to,O
be,O
mobilized,O
from,O
the,O
bone,O
marrow,O
in,O
response,O
to,O
injury,O
.,O
In,O
addition,O
to,O
MSC,O
efficacy,O
in,O
facilitating,O
hematopoietic,O
recovery,O
and,O
in,O
promoting,O
gut,O
and,O
skin,O
repair,O
",",O
both,O
structural,O
and,O
functional,O
improvements,O
for,O
a,O
variety,O
of,O
other,O
injury,O
types,O
have,O
been,O
described,O
.,O
For,O
example,O
",",O
the,O
results,O
of,O
preclinical,O
injury,O
studies,O
suggest,O
effective,O
MSC,O
-,O
based,O
treatment,O
of,O
skeletal,O
muscle,O
[,O
55,O
"],",O
bone,O
[,O
56,O
"],",O
tendon,O
[,O
57,O
"],",O
lung,O
[,O
58,O
"],",O
brain,O
[,O
59,O
"],",O
heart,O
[,O
60,O
"],",O
cornea,O
[,O
61,O
",",O
62,O
"],",O
liver,O
[,O
63,O
"],",O
and,O
kidney,O
[,O
64,O
].,O
The,O
homing,O
ability,O
and,O
adaptability,O
of,O
cellular,O
therapy,O
to,O
conditions,O
that,O
are,O
local,O
to,O
the,O
injury,O
site,O
make,O
this,O
approach,O
ideal,O
for,O
medical,O
defense,O
",",O
particularly,O
in,O
cases,O
involving,O
more,O
than,O
one,O
injury,O
site,O
or,O
injury,O
type,O
.,O
MSC,O
production,O
methodology,O
at,O
United,O
States,O
Army,O
medical,O
research,O
institute,O
of,O
chemical,O
defense,O
A,O
logical,O
next,O
step,O
in,O
expanding,O
the,O
clinical,O
use,O
of,O
MSC,O
therapy,O
is,O
to,O
develop,O
efficient,O
and,O
consistently,O
reliable,O
methods,O
for,O
the,O
production,O
of,O
pharmaceutical,O
quantities,O
of,O
MSC,O
product,O
.,O
The,O
United,O
States,O
Army,O
Medical,O
Research,O
Institute,O
of,O
Chemical,O
Defense,O
(,O
USAMRICD,O
),O
has,O
developed,O
production,O
methods,O
designed,O
to,O
facilitate,O
the,O
clinical,O
transition,O
of,O
an,O
MSC,O
-,O
based,O
countermeasure,O
",",O
with,O
the,O
intention,O
of,O
actualizing,O
the,O
availability,O
of,O
this,O
promising,O
cellular,O
therapeutic,O
to,O
health,O
care,O
providers,O
responsible,O
for,O
treating,O
warfighters,O
[,O
65,O
].,O
The,O
establishment,O
of,O
a,O
defined,O
MSC,O
manufacturing,O
paradigm,O
will,O
be,O
critical,O
for,O
the,O
progression,O
of,O
the,O
technology,O
to,O
the,O
Army,O
’,O
s,O
advanced,O
development,O
group,O
(,O
United,O
States,O
Army,O
Medical,O
Materiel,O
Development,O
Activity,O
",",O
USAMMDA,O
"),",O
for,O
work,O
leading,O
to,O
potential,O
FDA,O
approval,O
.,O
Although,O
this,O
report,O
has,O
focused,O
on,O
the,O
development,O
of,O
MSC,O
technology,O
to,O
produce,O
a,O
medical,O
countermeasure,O
to,O
ARS,B-DS
",",O
such,O
a,O
product,O
may,O
be,O
significant,O
in,O
the,O
treatment,O
of,O
additional,O
battlefield,O
indications,O
(,O
such,O
as,O
trauma,O
",",O
chemical,O
exposure,O
",",O
and,O
blast,O
injury,O
).,O
One,O
improvement,O
in,O
MSC,O
production,O
methodology,O
has,O
proven,O
to,O
be,O
the,O
inclusion,O
of,O
fibronectin,B-GP
(,O
Fn,B-GP
),O
as,O
a,O
surface,O
coating,O
for,O
culture,O
vessels,O
.,O
Fn,B-GP
is,O
one,O
of,O
the,O
most,O
abundant,O
extracellular,B-GP
matrix,I-GP
proteins,I-GP
in,O
the,O
bone,O
marrow,O
.,O
The,O
presence,O
of,O
Fn,B-GP
in,O
MSC,O
culture,O
provides,O
an,O
environment,O
that,O
more,O
closely,O
mimics,O
the,O
endogenous,O
MSC,O
niche,O
and,O
promotes,O
overall,O
cell,O
health,O
and,O
retention,O
of,O
stem,O
cell,O
differentiation,O
potential,O
.,O
A,O
second,O
modification,O
of,O
standard,O
practice,O
that,O
we,O
have,O
put,O
in,O
place,O
is,O
to,O
actively,O
prevent,O
high,O
cell,O
density,O
",",O
including,O
the,O
initial,O
(,O
passage,O
0,O
),O
MSC,O
culture,O
.,O
Although,O
the,O
maintenance,O
of,O
lower,O
cell,O
density,O
is,O
fairly,O
easy,O
to,O
achieve,O
during,O
later,O
cell,O
passages,O
",",O
no,O
report,O
has,O
suggested,O
the,O
dispersion,O
of,O
cells,O
from,O
original,O
colonies,O
formed,O
by,O
the,O
initial,O
plated,O
bone,O
marrow,O
as,O
a,O
significant,O
consideration,O
in,O
MSC,O
production,O
strategy,O
.,O
This,O
approach,O
ensures,O
that,O
cells,O
do,O
not,O
experience,O
high,O
density,O
confluency,O
for,O
significant,O
periods,O
at,O
any,O
stage,O
of,O
the,O
production,O
process,O
.,O
The,O
methods,O
we,O
have,O
established,O
for,O
MSC,O
culture,O
expansion,O
have,O
induced,O
consistently,O
high,O
yields,O
in,O
production,O
lots,O
derived,O
from,O
human,B-OG
and,O
animal,B-OG
bone,O
marrow,O
.,O
Freshly,O
plated,O
bone,O
marrow,O
forms,O
small,O
MSC,O
colonies,O
that,O
are,O
seen,O
to,O
generate,O
an,O
environment,O
that,O
supports,O
the,O
survival,O
and,O
growth,O
of,O
HSCs,O
(,O
Figure,O
1A,O
).,O
Cultures,O
left,O
to,O
grow,O
to,O
form,O
a,O
complete,O
monolayer,O
show,O
the,O
common,O
swirled,O
pattern,O
that,O
is,O
typical,O
of,O
100,O
%,O
confluent,O
MSC,O
cultures,O
(,O
B,O
).,O
Under,O
appropriate,O
conditions,O
",",O
MSCs,O
can,O
be,O
induced,O
to,O
mature,O
along,O
the,O
osteogenic,O
(,O
C,O
-,O
D,O
),O
and,O
adipogenic,O
(,O
E,O
-,O
F,O
),O
pathways,O
.,O
Our,O
methods,O
allow,O
for,O
the,O
generation,O
of,O
one,O
production,O
lot,O
of,O
high,O
-,O
quality,O
",",O
differentiation,O
-,O
capable,O
MSCs,O
that,O
reach,O
passage,O
3,O
in,O
16,O
days,O
or,O
less,O
.,O
“,O
Passage,O
3,O
”,O
cells,O
have,O
completed,O
an,O
initial,O
5,O
-,O
to,O
7,O
-,O
day,O
period,O
of,O
outgrowth,O
from,O
a,O
plated,O
bone,O
marrow,O
sample,O
",",O
followed,O
by,O
3,O
rounds,O
of,O
expansion,O
in,O
cell,O
culture,O
that,O
typically,O
requires,O
2,O
to,O
3,O
days,O
of,O
growth,O
each,O
.,O
In,O
the,O
absence,O
of,O
early,O
passage,O
0,O
colony,O
dispersal,O
and,O
an,O
Fn,B-GP
-,O
coated,O
growth,O
surface,O
",",O
MSC,O
cultures,O
require,O
approximately,O
twice,O
the,O
cultivation,O
time,O
to,O
reach,O
passage,O
3,O
[,O
6,O
",",O
66,O
",",O
67,O
].,O
A,O
rapid,O
MSC,O
production,O
methodology,O
will,O
be,O
critical,O
for,O
applications,O
that,O
may,O
require,O
autologous,O
MSC,O
delivery,O
",",O
such,O
as,O
tissue,O
engineering,O
and,O
reconstruction,O
.,O
Finally,O
",",O
the,O
manufacturing,O
process,O
for,O
MSC,O
production,O
has,O
been,O
designed,O
to,O
be,O
completely,O
scalable,O
using,O
commercially,O
available,O
“,O
multi,O
-,O
stack,O
”,O
cultivation,O
vessels,O
",",O
with,O
final,O
cell,O
yields,O
that,O
solely,O
depend,O
on,O
the,O
volume,O
of,O
bone,O
marrow,O
input,O
at,O
culture,O
initiation,O
.,O
Figure,O
1Growth,O
and,O
differentiation,O
of,O
MSCs,O
.,O
Freshly,O
plated,O
bone,O
marrow,O
contains,O
mature,O
blood,O
cells,O
",",O
HSCs,O
",",O
and,O
MSCs,O
.,O
Media,O
changes,O
result,O
in,O
the,O
formation,O
of,O
small,O
MSC,O
colonies,O
because,O
of,O
the,O
differential,O
adhesion,O
properties,O
of,O
MSCs,O
.,O
These,O
small,O
groups,O
of,O
adherent,O
cells,O
generate,O
an,O
environment,O
that,O
supports,O
the,O
survival,O
and,O
growth,O
of,O
HSCs,O
and,O
(,O
Panel,O
A,O
).,O
Long,O
-,O
term,O
confluent,O
MSC,O
cultures,O
form,O
the,O
typical,O
swirled,O
pattern,O
characteristic,O
of,O
this,O
cell,O
type,O
(,O
Panel,O
B,O
).,O
MSCs,O
can,O
be,O
induced,O
to,O
mature,O
along,O
the,O
osteogenic,O
differentiation,O
pathway,O
",",O
as,O
shown,O
by,O
calcium,O
deposition,O
staining,O
(,O
Panel,O
C,O
),O
and,O
alkaline,B-GP
phosphatase,I-GP
activity,O
staining,O
(,O
Panel,O
D,O
).,O
Adipogenic,O
maturation,O
is,O
signified,O
by,O
Oil,O
Red,O
O,O
staining,O
(,O
Panel,O
E,O
),O
and,O
LipidTox,O
Red,O
uptake,O
(,O
Panel,O
F,O
).,O
Conclusion,O
The,O
dynamic,O
nature,O
of,O
medical,O
threats,O
that,O
are,O
faced,O
by,O
warfighters,O
calls,O
for,O
the,O
development,O
of,O
countermeasures,O
that,O
address,O
a,O
broad,O
range,O
of,O
tissue,O
pathologies,O
.,O
The,O
adaptability,O
of,O
the,O
cellular,O
therapy,O
approach,O
discussed,O
in,O
this,O
report,O
provides,O
a,O
promising,O
option,O
to,O
address,O
the,O
unmet,O
needs,O
that,O
are,O
critically,O
important,O
in,O
medical,O
defense,O
.,O
Current,O
preclinical,O
and,O
clinical,O
results,O
of,O
MSC,O
efficacy,O
investigations,O
have,O
demonstrated,O
success,O
in,O
a,O
variety,O
of,O
injury,O
and,O
disease,O
settings,O
that,O
share,O
a,O
similar,O
pathophysiology,O
to,O
the,O
indications,O
of,O
interest,O
.,O
The,O
administration,O
of,O
MSCs,O
by,O
IV,O
infusion,O
has,O
shown,O
clinical,O
benefit,O
on,O
surface,O
wounds,O
and,O
can,O
also,O
reach,O
tissue,O
damage,O
located,O
deeper,O
within,O
the,O
body,O
.,O
This,O
capability,O
is,O
derived,O
from,O
the,O
remarkable,O
and,O
well,O
-,O
demonstrated,O
behavior,O
of,O
systemically,O
delivered,O
MSCs,O
to,O
distribute,O
to,O
sites,O
of,O
compromised,O
tissue,O
under,O
the,O
influence,O
of,O
chemokine,B-GP
homing,O
signals,O
produced,O
at,O
one,O
or,O
more,O
injury,O
sites,O
.,O
The,O
injury,O
-,O
specific,O
distribution,O
of,O
MSCs,O
following,O
infusion,O
provides,O
a,O
particular,O
advantage,O
in,O
the,O
treatment,O
of,O
combined,O
injury,O
(,O
e,O
.,O
g,O
".,",O
laceration,O
in,O
combination,O
with,O
exposure,O
to,O
chemically,O
or,O
radiologically,O
induced,O
tissue,O
damage,O
).,O
IV,O
MSC,O
delivery,O
represents,O
an,O
approach,O
in,O
which,O
the,O
administration,O
of,O
a,O
single,O
therapeutic,O
can,O
facilitate,O
tissue,O
repair,O
at,O
multiple,O
injury,O
sites,O
and,O
for,O
various,O
injury,O
types,O
",",O
in,O
accordance,O
with,O
the,O
specific,O
requirements,O
for,O
the,O
repair,O
of,O
each,O
compromised,O
site,O
during,O
the,O
healing,O
process,O
.,O
Significantly,O
",",O
the,O
outstanding,O
safety,O
profile,O
of,O
this,O
cellular,O
therapeutic,O
has,O
been,O
extensively,O
demonstrated,O
in,O
the,O
clinic,O
.,O
To,O
date,O
",",O
more,O
than,O
1,O
",",O
400,O
patients,O
enrolled,O
in,O
clinical,O
trials,O
have,O
received,O
the,O
first,O
marketed,O
MSC,O
therapeutic,O
",",O
Prochymal,O
®,O
(,O
Osiris,O
Therapeutics,O
",",O
Inc,O
".),",O
with,O
no,O
reports,O
of,O
serious,O
adverse,O
events,O
linked,O
to,O
treatment,O
(,O
ClinicalTrials,O
.,O
gov,O
",",O
September,O
2014,O
[,O
3,O
]).,O
The,O
advancement,O
of,O
MSC,O
therapeutics,O
to,O
address,O
the,O
broad,O
array,O
of,O
rare,O
but,O
treatment,O
-,O
challenging,O
injuries,O
faced,O
by,O
warfighters,O
will,O
require,O
the,O
development,O
of,O
appropriate,O
injury,O
-,O
specific,O
preclinical,O
models,O
.,O
Investigations,O
designed,O
to,O
statistically,O
evaluate,O
MSC,O
efficacy,O
for,O
the,O
treatment,O
of,O
injuries,O
induced,O
by,O
radiation,O
",",O
chemical,O
",",O
or,O
blast,O
exposure,O
are,O
critical,O
for,O
regulatory,O
approval,O
.,O
The,O
advancement,O
of,O
translational,O
research,O
directed,O
toward,O
treating,O
battlefield,O
injury,O
will,O
have,O
multiple,O
cross,O
-,O
over,O
opportunities,O
for,O
dual,O
-,O
use,O
applications,O
within,O
the,O
general,O
population,O
.,O
The,O
challenging,O
nature,O
of,O
modern,O
warfare,O
injuries,O
requires,O
that,O
military,O
medicine,O
remain,O
at,O
the,O
forefront,O
of,O
innovative,O
medical,O
approaches,O
.,O
Competing,O
interests,O
The,O
authors,O
declare,O
that,O
they,O
have,O
no,O
competing,O
interests,O
.,O
Authors,O
’,O
contributions,O
EE,O
:,O
EE,O
made,O
substantial,O
contributions,O
to,O
the,O
analysis,O
and,O
interpretation,O
of,O
the,O
published,O
data,O
and,O
was,O
substantially,O
involved,O
in,O
writing,O
the,O
manuscript,O
and,O
revising,O
it,O
critically,O
for,O
important,O
intellectual,O
content,O
.,O
In,O
addition,O
",",O
EE,O
carried,O
out,O
the,O
work,O
and,O
generated,O
the,O
graphics,O
for,O
Figure,O
1,O
.,O
TV,O
:,O
TV,O
is,O
the,O
Laboratory,O
Principal,O
Investigator,O
",",O
who,O
made,O
substantial,O
contributions,O
to,O
the,O
analysis,O
and,O
interpretation,O
of,O
the,O
published,O
data,O
and,O
was,O
substantially,O
involved,O
in,O
writing,O
the,O
manuscript,O
and,O
revising,O
it,O
critically,O
for,O
important,O
intellectual,O
content,O
.,O
Both,O
authors,O
have,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
In,O
addition,O
",",O
both,O
authors,O
agree,O
to,O
be,O
accountable,O
for,O
all,O
aspects,O
of,O
the,O
work,O
and,O
to,O
ensure,O
that,O
questions,O
related,O
to,O
the,O
accuracy,O
or,O
integrity,O
of,O
any,O
part,O
of,O
the,O
work,O
are,O
appropriately,O
investigated,O
and,O
resolved,O
.,O
Authors,O
’,O
information,O
Dr,O
.,O
Timothy,O
R,O
.,O
Varney,O
",",O
Principal,O
Investigator,O
",",O
Research,O
Interests,O
:,O
cellular,O
therapy,O
",",O
chemical,O
and,O
radiological,O
injury,O
;,O
SGT,O
Erik,O
B,O
.,O
Eaton,O
",",O
Medical,O
Laboratory,O
Technician,O
.,O
Research,O
Interests,O
:,O
combat,O
casualty,O
care,O
",",O
MSC,O
biology,O
.,O
Neo,O
-,O
sex,O
chromosomes,O
in,O
the,O
black,B-OG
muntjac,I-OG
recapitulate,O
incipient,O
evolution,O
of,O
mammalian,O
sex,O
chromosomes,O
The,O
nascent,O
neo,O
-,O
sex,O
chromosomes,O
of,O
black,B-OG
muntjacs,I-OG
show,O
that,O
regulatory,O
mutations,O
could,O
accelerate,O
the,O
degeneration,O
of,O
the,O
Y,O
chromosome,O
and,O
contribute,O
to,O
the,O
further,O
evolution,O
of,O
dosage,O
compensation,O
.,O
Background,O
The,O
regular,O
mammalian,O
X,O
and,O
Y,O
chromosomes,O
diverged,O
from,O
each,O
other,O
at,O
least,O
166,O
to,O
148,O
million,O
years,O
ago,O
",",O
leaving,O
few,O
traces,O
of,O
their,O
early,O
evolution,O
",",O
including,O
degeneration,O
of,O
the,O
Y,O
chromosome,O
and,O
evolution,O
of,O
dosage,O
compensation,O
.,O
Results,O
We,O
studied,O
the,O
intriguing,O
case,O
of,O
black,B-OG
muntjac,I-OG
",",O
in,O
which,O
a,O
recent,O
X,O
-,O
autosome,O
fusion,O
and,O
a,O
subsequent,O
large,O
autosomal,O
inversion,O
within,O
just,O
the,O
past,O
0,O
.,O
5,O
million,O
years,O
have,O
led,O
to,O
inheritance,O
patterns,O
identical,O
to,O
the,O
traditional,O
X,O
-,O
Y,O
(,O
neo,O
-,O
sex,O
chromosomes,O
).,O
We,O
compared,O
patterns,O
of,O
genome,O
evolution,O
in,O
35,O
-,O
kilobase,O
noncoding,O
regions,O
and,O
23,O
gene,O
pairs,O
on,O
the,O
homologous,O
neo,O
-,O
sex,O
chromosomes,O
.,O
We,O
found,O
that,O
neo,O
-,O
Y,O
alleles,O
have,O
accumulated,O
more,O
mutations,O
",",O
comprising,O
a,O
wide,O
variety,O
of,O
mutation,O
types,O
",",O
which,O
indicates,O
cessation,O
of,O
recombination,O
and,O
is,O
consistent,O
with,O
an,O
ongoing,O
neo,O
-,O
Y,O
degeneration,O
process,O
.,O
Putative,O
deleterious,O
mutations,O
were,O
observed,O
in,O
coding,O
regions,O
of,O
eight,O
investigated,O
genes,O
as,O
well,O
as,O
cis,O
-,O
regulatory,O
regions,O
of,O
two,O
housekeeping,O
genes,O
.,O
In,O
vivo,O
assays,O
characterized,O
a,O
neo,O
-,O
Y,O
insertion,O
in,O
the,O
promoter,O
of,O
the,O
CLTC,B-GP
gene,O
that,O
causes,O
a,O
significant,O
reduction,O
in,O
allelic,O
expression,O
.,O
A,O
neo,O
-,O
Y,O
-,O
linked,O
deletion,O
in,O
the,O
3,O
'-,O
untranslated,O
region,O
of,O
gene,O
SNX22,B-GP
abolished,O
a,O
microRNA,O
target,O
site,O
.,O
Finally,O
",",O
expression,O
analyses,O
revealed,O
complex,O
patterns,O
of,O
expression,O
divergence,O
between,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
alleles,O
.,O
Conclusion,O
The,O
nascent,O
neo,O
-,O
sex,O
chromosome,O
system,O
of,O
black,B-OG
muntjacs,I-OG
is,O
a,O
valuable,O
model,O
in,O
which,O
to,O
study,O
the,O
evolution,O
of,O
sex,O
chromosomes,O
in,O
mammals,B-OG
.,O
Our,O
results,O
illustrate,O
the,O
degeneration,O
scenarios,O
in,O
various,O
genomic,O
regions,O
.,O
Of,O
particular,O
importance,O
",",O
we,O
report,O
-,O
for,O
the,O
first,O
time,O
-,O
that,O
regulatory,O
mutations,O
were,O
probably,O
able,O
to,O
accelerate,O
the,O
degeneration,O
process,O
of,O
Y,O
and,O
contribute,O
to,O
further,O
evolution,O
of,O
dosage,O
compensation,O
.,O
Background,O
It,O
is,O
believed,O
that,O
in,O
human,B-OG
and,O
other,O
eutherian,B-OG
mammals,I-OG
",",O
the,O
heteromorphic,O
sex,O
chromosomes,O
evolved,O
from,O
a,O
pair,O
of,O
ordinary,O
autosomes,O
between,O
166,O
and,O
148,O
million,O
years,O
ago,O
[,O
1,O
-,O
4,O
].,O
After,O
the,O
birth,O
of,O
the,O
sex,O
-,O
determining,O
gene,O
",",O
extensive,O
recombination,O
suppression,O
evolved,O
between,O
proto,O
-,O
X,O
and,O
proto,O
-,O
Y,O
to,O
prevent,O
the,O
sexual,O
reversal,O
along,O
the,O
entirety,O
of,O
the,O
chromosome,O
pair,O
",",O
with,O
the,O
exception,O
of,O
a,O
short,O
',O
pseudoautosomal,O
region,O
',O
(,O
PAR,O
),O
[,O
5,O
].,O
Theoretical,O
models,O
predict,O
that,O
proto,O
-,O
Y,O
chromosomes,O
would,O
further,O
suffer,O
a,O
rapid,O
accumulation,O
of,O
deleterious,O
mutations,O
and,O
be,O
subjected,O
to,O
drastic,O
gene,O
loss,O
[,O
6,O
"],",O
consistent,O
with,O
only,O
45,O
genes,O
surviving,O
on,O
the,O
human,B-OG
Y,O
chromosome,O
as,O
compared,O
with,O
1,O
",",O
000,O
functional,O
genes,O
on,O
the,O
X,O
[,O
1,O
",",O
3,O
",",O
7,O
].,O
Y,O
degeneration,O
is,O
expected,O
to,O
be,O
driven,O
by,O
multiple,O
forces,O
",",O
including,O
Muller,O
',O
s,O
ratchet,O
",",O
background,O
selection,O
",",O
the,O
Hill,O
-,O
Robertson,O
effect,O
with,O
weak,O
selection,O
",",O
and,O
the,O
',O
hitchhiking,O
',O
of,O
deleterious,O
alleles,O
by,O
favorable,O
mutations,O
[,O
5,O
].,O
These,O
factors,O
can,O
work,O
on,O
both,O
ancient,O
Y,O
and,O
heterosynaptic,O
autosomes,O
with,O
suppressed,O
recombination,O
because,O
of,O
the,O
diminished,O
efficiency,O
of,O
natural,O
selection,O
along,O
them,O
.,O
Newly,O
evolved,O
sex,O
chromosome,O
systems,O
are,O
required,O
to,O
test,O
hypotheses,O
about,O
Y,O
degeneration,O
because,O
ancient,O
Y,O
chromosomes,O
bear,O
few,O
remaining,O
traceable,O
ancestral,O
sequences,O
.,O
Such,O
cases,O
include,O
the,O
recently,O
originated,O
sex,O
determination,O
system,O
",",O
like,O
that,O
of,O
Silene,B-OG
[,O
8,O
"],",O
or,O
',O
neo,O
-,O
sex,O
chromosomes,O
"',",O
formed,O
through,O
a,O
recent,O
fusion,O
or,O
translocation,O
between,O
an,O
autosome,O
and,O
a,O
sex,O
chromosome,O
followed,O
by,O
extensive,O
recombination,O
suppression,O
",",O
and,O
thus,O
showing,O
inheritance,O
patterns,O
like,O
that,O
of,O
the,O
better,O
known,O
ancient,O
sex,O
chromosomes,O
[,O
9,O
",",O
10,O
].,O
Our,O
current,O
knowledge,O
of,O
neo,O
-,O
sex,O
chromosome,O
evolution,O
is,O
primarily,O
due,O
to,O
extensive,O
work,O
in,O
Drosophila,B-OG
and,O
plants,B-OG
[,O
8,O
",",O
10,O
-,O
12,O
].,O
Most,O
of,O
them,O
focused,O
on,O
degeneration,O
patterns,O
in,O
protein,O
-,O
coding,O
regions,O
of,O
neo,O
-,O
Y,O
alleles,O
.,O
However,O
",",O
given,O
the,O
elaborate,O
regulation,O
of,O
gene,O
expression,O
[,O
13,O
",",O
14,O
"],",O
the,O
scenarios,O
of,O
Y,O
degeneration,O
involving,O
both,O
gradual,O
loss,O
of,O
functions,O
of,O
protein,O
products,O
as,O
well,O
as,O
regulatory,O
disorders,O
remain,O
to,O
be,O
elucidated,O
.,O
Furthermore,O
",",O
sex,O
chromosome,O
systems,O
have,O
evolved,O
independently,O
in,O
different,O
phyla,O
many,O
times,O
",",O
creating,O
a,O
need,O
to,O
examine,O
their,O
evolution,O
in,O
different,O
taxa,O
[,O
15,O
].,O
Sex,O
chromosomes,O
in,O
mammals,B-OG
",",O
including,O
our,O
own,O
",",O
have,O
different,O
autosomal,O
origins,O
from,O
those,O
of,O
other,O
organisms,O
",",O
involving,O
entirely,O
distinct,O
gene,O
sets,O
in,O
the,O
process,O
of,O
sex,O
determination,O
and,O
dosage,O
compensation,O
[,O
15,O
",",O
16,O
].,O
The,O
inhibition,O
of,O
recombination,O
between,O
the,O
mammalian,O
proto,O
-,O
X,O
and,O
proto,O
-,O
Y,O
was,O
achieved,O
through,O
chromosomal,O
inversions,O
on,O
the,O
Y,O
chromosome,O
",",O
whereas,O
it,O
was,O
achieved,O
through,O
zero,O
crossover,O
in,O
male,O
germline,O
cells,O
in,O
Drosophila,B-OG
[,O
5,O
",",O
17,O
].,O
Finally,O
",",O
different,O
generation,O
time,O
and,O
population,O
size,O
between,O
mammals,B-OG
and,O
other,O
species,O
would,O
have,O
great,O
impact,O
on,O
the,O
rate,O
and,O
patterns,O
of,O
mammalian,O
Y,O
-,O
chromosome,O
degeneration,O
[,O
18,O
].,O
Thus,O
",",O
direct,O
investigation,O
of,O
a,O
neo,O
-,O
sex,O
chromosome,O
system,O
in,O
a,O
mammal,B-OG
promises,O
new,O
insights,O
into,O
several,O
fundamental,O
issues,O
",",O
including,O
both,O
mode,O
and,O
tempo,O
of,O
mammalian,O
Y,O
degeneration,O
",",O
and,O
how,O
mammals,B-OG
cope,O
with,O
degenerated,O
Y,O
alleles,O
before,O
the,O
creation,O
of,O
Xist,O
-,O
dependent,O
dosage,O
compensation,O
[,O
19,O
].,O
In,O
this,O
study,O
we,O
sought,O
to,O
address,O
these,O
questions,O
using,O
the,O
black,B-OG
muntjac,I-OG
(,O
Muntiacus,B-OG
crinifrons,I-OG
"),",O
an,O
Asian,B-OG
barking,I-OG
deer,I-OG
",",O
as,O
the,O
model,O
[,O
20,O
].,O
In,O
this,O
species,O
",",O
a,O
male,O
-,O
specific,O
extensive,O
chromosome,O
inversion,O
on,O
autosome,O
4,O
and,O
fusion,O
of,O
its,O
homolog,O
to,O
the,O
ancient,O
X,O
[,O
21,O
",",O
22,O
],O
has,O
led,O
to,O
the,O
very,O
recent,O
creation,O
(,O
within,O
the,O
past,O
approximately,O
0,O
.,O
5,O
million,O
years,O
),O
[,O
23,O
],O
of,O
a,O
neo,O
-,O
sex,O
chromosome,O
system,O
",",O
similar,O
to,O
the,O
inferred,O
creation,O
of,O
the,O
ancient,O
mammalian,O
X,O
-,O
Y,O
system,O
.,O
Such,O
a,O
rare,O
nascent,O
mammalian,O
neo,O
-,O
sex,O
chromosome,O
system,O
provides,O
an,O
unprecedented,O
opportunity,O
to,O
study,O
sex,O
chromosome,O
evolution,O
in,O
mammals,B-OG
.,O
Results,O
and,O
discussion,O
Neo,O
-,O
sex,O
chromosomes,O
in,O
the,O
black,B-OG
muntjac,I-OG
The,O
black,B-OG
muntjac,I-OG
is,O
endemic,O
to,O
a,O
narrow,O
region,O
of,O
southeastern,O
China,O
[,O
20,O
].,O
Habitat,O
disruption,O
in,O
recent,O
decades,O
has,O
rendered,O
the,O
species,O
one,O
of,O
the,O
most,O
endangered,O
mammals,B-OG
in,O
the,O
world,O
.,O
Cytogenetic,O
analysis,O
revealed,O
a,O
compact,O
karyotype,O
",",O
with,O
2n,O
=,O
8,O
♀/,O
9,O
"♂,",O
and,O
half,O
of,O
the,O
genome,O
forms,O
a,O
pentavalent,O
(,O
Figure,O
1a,O
),O
during,O
male,O
meiosis,O
[,O
24,O
].,O
The,O
chromosome,O
4,O
pair,O
has,O
been,O
shaped,O
by,O
several,O
large,O
chromosomal,O
events,O
.,O
First,O
",",O
one,O
copy,O
experienced,O
a,O
centric,O
fusion,O
to,O
the,O
regular,O
X,O
chromosome,O
",",O
forming,O
a,O
new,O
',O
X,O
+,O
4,O
',O
(,O
see,O
Additional,O
data,O
file,O
1,O
).,O
In,O
addition,O
",",O
the,O
short,O
arm,O
of,O
chromosome,O
1,O
has,O
undergone,O
a,O
male,O
-,O
specific,O
translocation,O
to,O
the,O
homologous,O
chromosome,O
4,O
",",O
creating,O
a,O
primitive,O
',O
1p,O
+,O
4,O
',O
chromosome,O
[,O
21,O
",",O
22,O
].,O
Surprisingly,O
",",O
subsequent,O
inversions,O
involving,O
large,O
part,O
of,O
the,O
primitive,O
1p,O
+,O
4,O
were,O
proposed,O
to,O
take,O
place,O
in,O
male,O
black,B-OG
muntjacs,I-OG
(,O
regions,O
from,O
',O
22a,O
',O
to,O
',O
17a,O
';,O
Additional,O
data,O
file,O
1,O
),O
[,O
21,O
",",O
22,O
].,O
We,O
further,O
confirmed,O
this,O
chromosomal,O
rearrangement,O
using,O
dual,O
-,O
color,O
fluorescence,O
in,O
situ,O
hybridization,O
(,O
FISH,O
),O
with,O
two,O
bacterial,O
artificial,O
chromosome,O
(,O
BAC,O
),O
clones,O
of,O
the,O
Indian,B-OG
muntjac,I-OG
(,O
Muntiacus,B-OG
muntjac,I-OG
vaginalis,I-OG
),O
as,O
probes,O
(,O
Figure,O
1b,O
).,O
The,O
green,O
signal,O
in,O
the,O
middle,O
of,O
X,O
+,O
4,O
has,O
switched,O
its,O
location,O
to,O
the,O
distal,O
end,O
of,O
1p,O
+,O
4,O
as,O
a,O
result,O
of,O
the,O
inversion,O
(,O
Figure,O
1b,O
).,O
Because,O
no,O
inversion,O
loop,O
has,O
been,O
detected,O
during,O
meiosis,O
of,O
male,O
black,B-OG
muntjacs,I-OG
[,O
24,O
"],",O
the,O
whole,O
1p,O
+,O
4,O
should,O
remain,O
heterosynaptic,O
except,O
for,O
the,O
two,O
distal,O
ends,O
",",O
which,O
are,O
not,O
involved,O
in,O
the,O
inversion,O
.,O
These,O
two,O
ends,O
are,O
analogous,O
to,O
those,O
of,O
ancient,O
human,B-OG
Y,O
chromosome,O
",",O
which,O
can,O
still,O
synapse,O
with,O
each,O
other,O
and,O
can,O
thus,O
be,O
regarded,O
new,O
',O
PAR,O
',O
s,O
.,O
The,O
X,O
+,O
4,O
chromosome,O
can,O
thus,O
be,O
regarded,O
as,O
a,O
',O
neo,O
-,O
X,O
"',",O
and,O
the,O
1p,O
+,O
4,O
as,O
a,O
',O
neo,O
-,O
Y,O
',O
chromosome,O
",",O
because,O
of,O
probable,O
lack,O
of,O
recombination,O
in,O
the,O
inverted,O
region,O
.,O
Neo,O
-,O
sex,O
chromosomes,O
of,O
Muntiacus,B-OG
crinifrons,I-OG
.,O
(,O
a,O
),O
Paring,O
patterns,O
in,O
male,O
and,O
female,O
black,B-OG
muntjacs,I-OG
during,O
meiosis,O
.,O
The,O
black,O
areas,O
on,O
chromosomes,O
represent,O
homosynapsis,O
regions,O
",",O
whereas,O
gray,O
areas,O
represent,O
heterosynapsis,O
regions,O
.,O
Cross,O
lines,O
between,O
chromosomes,O
represent,O
homologous,O
recombination,O
.,O
A,O
pentavalent,O
involving,O
five,O
chromosomes,O
will,O
form,O
during,O
meiosis,O
of,O
male,O
black,B-OG
muntjacs,I-OG
",",O
whereas,O
such,O
structures,O
are,O
absent,O
in,O
female,O
black,B-OG
muntjac,I-OG
.,O
(,O
b,O
),O
Inversion,O
on,O
the,O
neo,O
-,O
Y,O
chromosome,O
revealed,O
by,O
fluorescence,O
in,O
situ,O
hybridization,O
using,O
two,O
Indian,B-OG
muntjac,I-OG
bacterial,O
artificial,O
chromosome,O
(,O
BAC,O
),O
clones,O
",",O
06G7,O
(,O
green,O
),O
and,O
07B3,O
(,O
red,O
"),",O
as,O
probes,O
.,O
The,O
black,B-OG
muntjac,I-OG
X,O
+,O
4,O
:,O
1p,O
+,O
4,O
neo,O
-,O
sex,O
chromosome,O
pair,O
comprises,O
approximately,O
one,O
-,O
fifth,O
of,O
the,O
entire,O
genome,O
and,O
thus,O
bears,O
thousands,O
of,O
neo,O
-,O
sex,O
gene,O
pairs,O
[,O
21,O
",",O
24,O
].,O
Although,O
X,O
-,O
autosome,O
fusions,O
were,O
also,O
detected,O
in,O
other,O
muntjac,B-OG
species,O
",",O
such,O
1p,O
+,O
4,O
inversion,O
is,O
found,O
exclusively,O
in,O
male,O
black,B-OG
muntjacs,I-OG
[,O
25,O
].,O
The,O
absence,O
of,O
such,O
a,O
system,O
within,O
Muntiacus,B-OG
genus,O
",",O
from,O
which,O
black,B-OG
muntjac,I-OG
is,O
estimated,O
to,O
have,O
diverged,O
within,O
the,O
past,O
0,O
.,O
5,O
million,O
years,O
[,O
23,O
"],",O
indicates,O
a,O
very,O
recent,O
origin,O
",",O
and,O
makes,O
this,O
system,O
the,O
youngest,O
known,O
mammalian,O
neo,O
-,O
sex,O
systems,O
.,O
Variation,O
pattern,O
in,O
neo,O
-,O
Y,O
noncoding,O
regions,O
To,O
seek,O
molecular,O
evidence,O
for,O
inhibition,O
of,O
recombination,O
and,O
to,O
compare,O
the,O
evolutionary,O
patterns,O
of,O
neo,O
-,O
X,O
and,O
neo,O
-,O
Y,O
chromosomes,O
",",O
we,O
sequenced,O
the,O
intergenic,O
and,O
intronic,O
fragments,O
from,O
the,O
inverted,O
region,O
composing,O
a,O
total,O
of,O
35,O
.,O
1,O
kilobases,O
(,O
kb,O
"),",O
as,O
well,O
as,O
12,O
.,O
6,O
kb,O
from,O
the,O
new,O
',O
PAR,O
',O
s,O
and,O
autosomal,O
regions,O
for,O
two,O
male,O
and,O
one,O
female,O
black,B-OG
muntjacs,I-OG
",",O
as,O
well,O
as,O
the,O
orthologous,O
segments,O
from,O
one,O
male,O
Indian,B-OG
muntjac,I-OG
",",O
which,O
is,O
taken,O
as,O
the,O
outgroup,O
.,O
Under,O
neutrality,O
",",O
intraspecific,O
genetic,O
diversity,O
(,O
θ,O
),O
is,O
expected,O
to,O
be,O
proportional,O
to,O
the,O
effective,O
population,O
size,O
(,O
Ne,O
),O
times,O
the,O
mutation,O
rate,O
(,O
μ,O
;,O
specifically,O
",",O
θ,O
=,O
4Neμ,O
),O
[,O
26,O
].,O
Therefore,O
",",O
if,O
recombination,O
has,O
authentically,O
ceased,O
between,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
",",O
then,O
we,O
would,O
expect,O
a,O
reduced,O
DNA,O
polymorphism,O
caused,O
by,O
reduced,O
Ne,O
for,O
the,O
neo,O
-,O
Y,O
regions,O
[,O
6,O
",",O
27,O
].,O
Otherwise,O
",",O
the,O
polymorphism,O
level,O
of,O
neo,O
-,O
Y,O
should,O
be,O
similar,O
to,O
that,O
of,O
',O
PAR,O
',O
regions,O
or,O
autosomes,O
.,O
Consistent,O
with,O
the,O
former,O
expectation,O
",",O
we,O
found,O
a,O
significantly,O
lower,O
number,O
of,O
segregating,O
sites,O
(,O
χ2,O
test,O
",",O
P,O
<,O
0,O
.,O
01,O
;,O
see,O
Materials,O
and,O
methods,O
[,O
below,O
]),O
and,O
a,O
lower,O
polymorphism,O
level,O
of,O
neo,O
-,O
Y,O
regions,O
(,O
0,O
.,O
00168,O
±,O
0,O
.,O
00120,O
versus,O
0,O
.,O
00190,O
±,O
0,O
.,O
00029,O
),O
compared,O
with,O
regions,O
that,O
undergo,O
homologous,O
meiotic,O
pairing,O
(,O
Table,O
1,O
"),",O
indicating,O
suppression,O
of,O
recombination,O
between,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
.,O
Of,O
course,O
",",O
other,O
factors,O
including,O
the,O
Hill,O
-,O
Robertson,O
effect,O
",",O
background,O
selection,O
",",O
hitchhiking,O
effect,O
",",O
or,O
Muller,O
',O
s,O
ratchet,O
could,O
have,O
all,O
reduced,O
the,O
polymorphism,O
level,O
within,O
the,O
investigated,O
noncoding,O
regions,O
[,O
6,O
].,O
In,O
contrast,O
",",O
the,O
',O
male,O
-,O
driven,O
evolution,O
',O
effect,O
",",O
which,O
proposes,O
that,O
the,O
neo,O
-,O
Y,O
would,O
undergo,O
more,O
rounds,O
of,O
cell,O
division,O
per,O
generation,O
in,O
male,O
than,O
in,O
female,O
germlines,O
",",O
would,O
increase,O
the,O
mutation,O
rate,O
and,O
polymorphism,O
level,O
of,O
neo,O
-,O
Y,O
alleles,O
compared,O
with,O
those,O
of,O
neo,O
-,O
X,O
and,O
autosomes,O
[,O
28,O
].,O
Our,O
phylogenetic,O
analysis,O
of,O
neo,O
-,O
X,O
and,O
neo,O
-,O
Y,O
sequences,O
in,O
the,O
male,O
black,B-OG
muntjac,I-OG
confirms,O
that,O
the,O
neo,O
-,O
Y,O
alleles,O
have,O
accumulated,O
far,O
more,O
mutations,O
than,O
neo,O
-,O
X,O
(,O
Figure,O
2,O
;,O
statistically,O
significant,O
",",O
by,O
Tajima,O
',O
s,O
relative,O
rate,O
tests,O
",",O
P,O
<,O
0,O
.,O
001,O
).,O
Dendrogram,O
constructed,O
using,O
noncoding,O
sequences,O
of,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
fragments,O
.,O
A,O
total,O
of,O
35,O
.,O
1,O
-,O
kilobase,O
noncoding,O
sequences,O
of,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
alleles,O
in,O
the,O
black,B-OG
muntjac,I-OG
and,O
the,O
orthologous,O
sequences,O
in,O
the,O
Indian,B-OG
muntjac,I-OG
as,O
the,O
outgroup,O
were,O
used,O
to,O
construct,O
the,O
dentrogram,O
.,O
',O
BM,O
',O
stands,O
for,O
',O
male,O
black,B-OG
muntjac,I-OG
';,O
',O
IM,O
',O
stands,O
for,O
',O
Indian,B-OG
muntjac,I-OG
';,O
',O
1,O
',O
and,O
',O
2,O
',O
represent,O
the,O
two,O
male,O
black,B-OG
muntjac,I-OG
individuals,O
separately,O
.,O
(,O
a,O
),O
Tree,O
constructed,O
by,O
neighbor,O
-,O
joining,O
method,O
.,O
Branch,O
lengths,O
calculated,O
using,O
Kimura,O
',O
s,O
two,O
-,O
parameter,O
method,O
are,O
shown,O
above,O
the,O
corresponding,O
branches,O
.,O
(,O
b,O
),O
Tree,O
constructed,O
by,O
maximum,O
likelihood,O
method,O
.,O
Branch,O
lengths,O
calculated,O
by,O
baseml,O
in,O
PAML,O
package,O
using,O
',O
HKY85,O
',O
method,O
were,O
shown,O
above,O
the,O
corresponding,O
branches,O
.,O
Segregating,O
sites,O
and,O
polymorphism,O
in,O
noncoding,O
sequences,O
of,O
different,O
genomic,O
regions,O
in,O
two,O
male,O
black,B-OG
muntjacs,I-OG
neo,O
-,O
Y,O
regions,O
PAR,O
/,O
autosomal,O
regions,O
Sequenced,O
length,O
(,O
bp,O
),O
35,O
",",O
156,O
12,O
",",O
653,O
Segregating,O
sitesa,O
59,O
44,O
Segregating,O
sites,O
/,O
kb,O
1,O
.,O
68,O
3,O
.,O
48,O
Polymorphism,O
(,O
θw,O
),O
0,O
.,O
00168,O
±,O
0,O
.,O
00120,O
0,O
.,O
00190,O
±,O
0,O
.,O
00029,O
aSegregating,O
sites,O
means,O
total,O
sites,O
with,O
substitutions,O
in,O
the,O
investigated,O
alleles,O
.,O
Standard,O
deviations,O
calculated,O
based,O
on,O
variance,O
(,O
see,O
Materials,O
and,O
methods,O
),O
were,O
shown,O
for,O
polymorphism,O
data,O
.,O
bp,O
",",O
base,O
pairs,O
;,O
kb,O
",",O
kilobases,O
;,O
PAR,O
",",O
pseudoautosomal,O
region,O
.,O
A,O
direct,O
estimate,O
of,O
the,O
degree,O
of,O
male,O
-,O
driven,O
evolution,O
effect,O
(,O
α,O
),O
on,O
neo,O
-,O
Y,O
can,O
be,O
derived,O
from,O
the,O
comparison,O
of,O
branch,O
lengths,O
of,O
homologous,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
.,O
We,O
calculated,O
the,O
ratios,O
of,O
neo,O
-,O
Y,O
to,O
neo,O
-,O
X,O
mutations,O
separately,O
from,O
internal,O
",",O
external,O
",",O
and,O
summed,O
branch,O
lengths,O
of,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
",",O
and,O
we,O
further,O
estimated,O
the,O
α,O
values,O
based,O
on,O
the,O
method,O
proposed,O
by,O
Miyata,O
and,O
coworkers,O
[,O
29,O
],O
(,O
Table,O
2,O
;,O
see,O
Materials,O
and,O
methods,O
[,O
below,O
]).,O
Because,O
all,O
of,O
the,O
ratios,O
are,O
higher,O
than,O
3,O
",",O
the,O
α,O
values,O
estimated,O
from,O
different,O
branches,O
all,O
approach,O
to,O
infinity,O
[,O
29,O
].,O
This,O
indicates,O
a,O
strong,O
male,O
-,O
driven,O
effect,O
on,O
the,O
neo,O
-,O
Y,O
chromosome,O
in,O
the,O
male,O
black,B-OG
muntjac,I-OG
",",O
and,O
a,O
small,O
effect,O
of,O
ancestral,O
polymorphism,O
on,O
the,O
estimate,O
[,O
29,O
-,O
31,O
].,O
It,O
has,O
been,O
reported,O
that,O
great,O
variation,O
in,O
mutation,O
rates,O
in,O
different,O
genomic,O
regions,O
greatly,O
affect,O
the,O
estimation,O
of,O
α,O
value,O
[,O
32,O
].,O
However,O
",",O
such,O
effects,O
may,O
be,O
limited,O
in,O
our,O
case,O
because,O
the,O
investigated,O
regions,O
are,O
randomly,O
sampled,O
along,O
the,O
neo,O
-,O
Y,O
chromosome,O
and,O
then,O
concatenated,O
together,O
to,O
represent,O
a,O
chromosome,O
-,O
wide,O
estimate,O
(,O
see,O
Materials,O
and,O
methods,O
[,O
below,O
]).,O
Male,O
-,O
specific,O
methylation,O
effects,O
in,O
the,O
germline,O
may,O
also,O
make,O
little,O
contribution,O
to,O
such,O
differences,O
in,O
mutation,O
rate,O
between,O
neo,O
-,O
X,O
and,O
neo,O
-,O
Y,O
alleles,O
.,O
It,O
predicts,O
a,O
greater,O
GC,O
content,O
on,O
neo,O
-,O
X,O
alleles,O
and,O
an,O
elevated,O
rate,O
of,O
C,O
→,O
T,O
transitions,O
on,O
neo,O
-,O
Y,O
alleles,O
[,O
33,O
].,O
However,O
",",O
we,O
detected,O
a,O
similar,O
GC,O
content,O
and,O
an,O
almost,O
identical,O
ratio,O
of,O
GC,O
→,O
AT,O
versus,O
AT,O
→,O
GC,O
substitutions,O
between,O
the,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
alleles,O
(,O
Additional,O
data,O
file,O
2,O
).,O
Estimation,O
of,O
α,O
(,O
male,O
:,O
female,O
ratio,O
of,O
mutation,O
rate,O
),O
from,O
different,O
branch,O
lengths,O
in,O
the,O
neo,O
-,O
sex,O
system,O
of,O
black,B-OG
muntjac,I-OG
neo,O
-,O
Y,O
/,O
neo,O
-,O
X,O
α,O
95,O
%,O
CI,O
of,O
α,O
Internal,O
branches,O
4,O
.,O
0442,O
±,O
1,O
.,O
2633,O
∞,O
25,O
.,O
3848,O
to,O
∞,O
External,O
branches,O
3,O
.,O
2768,O
±,O
1,O
.,O
2356,O
∞,O
4,O
.,O
2578,O
to,O
∞,O
Summed,O
branches,O
3,O
.,O
6857,O
±,O
0,O
.,O
8867,O
∞,O
27,O
.,O
8507,O
to,O
∞,O
Note,O
that,O
we,O
calculated,O
neo,O
-,O
Y,O
:,O
neo,O
-,O
X,O
ratios,O
of,O
mutation,O
rate,O
from,O
branch,O
lengths,O
designated,O
in,O
Figure,O
2a,O
.,O
We,O
further,O
calculated,O
their,O
confidence,O
intervals,O
(,O
CIs,O
),O
and,O
estimated,O
α,O
values,O
following,O
[,O
30,O
",",O
31,O
].,O
The,O
net,O
effect,O
of,O
all,O
of,O
these,O
factors,O
explains,O
why,O
the,O
polymorphism,O
of,O
neo,O
-,O
Y,O
region,O
(,O
0,O
.,O
00168,O
),O
is,O
one,O
-,O
quarter,O
higher,O
than,O
that,O
of,O
recombining,O
regions,O
(,O
0,O
.,O
00190,O
/,O
4,O
;,O
Table,O
1,O
).,O
Finally,O
",",O
other,O
factors,O
",",O
including,O
sexual,O
selection,O
and,O
population,O
subdivisions,O
",",O
could,O
have,O
effects,O
on,O
the,O
polymorphism,O
pattern,O
[,O
34,O
].,O
These,O
findings,O
indicate,O
that,O
it,O
is,O
highly,O
likely,O
that,O
recombination,O
has,O
ceased,O
between,O
the,O
inverted,O
neo,O
-,O
Y,O
region,O
and,O
its,O
homolog,O
.,O
Degeneration,O
in,O
coding,O
regions,O
of,O
neo,O
-,O
Y,O
-,O
linked,O
genes,O
Because,O
of,O
the,O
limited,O
sample,O
size,O
of,O
neo,O
-,O
Y,O
alleles,O
",",O
the,O
polymorphism,O
data,O
exhibit,O
a,O
high,O
degree,O
of,O
variance,O
",",O
and,O
differences,O
between,O
recombining,O
and,O
nonrecombining,O
noncoding,O
regions,O
may,O
only,O
be,O
indicative,O
rather,O
than,O
statistically,O
significant,O
(,O
Table,O
1,O
).,O
That,O
stated,O
",",O
we,O
continued,O
to,O
seek,O
for,O
other,O
typical,O
evidence,O
of,O
recombination,O
inhibition,O
(,O
accumulation,O
of,O
deleterious,O
mutations,O
due,O
to,O
reduced,O
efficiency,O
of,O
natural,O
selection,O
),O
[,O
6,O
].,O
To,O
evaluate,O
the,O
degeneration,O
effects,O
of,O
such,O
mutations,O
on,O
neo,O
-,O
Y,O
-,O
linked,O
genes,O
",",O
we,O
characterized,O
23,O
gene,O
pairs,O
that,O
are,O
located,O
in,O
the,O
inverted,O
region,O
on,O
the,O
neo,O
-,O
Y,O
chromosome,O
(,O
Additional,O
data,O
file,O
1,O
"),",O
one,O
pair,O
in,O
the,O
neo,O
-,O
Y,O
',O
PAR,O
',O
region,O
",",O
and,O
six,O
pairs,O
on,O
autosomes,O
.,O
These,O
genes,O
were,O
selected,O
based,O
on,O
the,O
annotations,O
of,O
BAC,O
sequences,O
of,O
the,O
Indian,B-OG
muntjac,I-OG
and,O
cow,B-OG
genomic,O
information,O
in,O
order,O
to,O
represent,O
a,O
diversity,O
of,O
regions,O
across,O
the,O
neo,O
-,O
sex,O
chromosomes,O
[,O
35,O
].,O
In,O
total,O
",",O
we,O
obtained,O
about,O
25,O
kb,O
cDNA,O
sequences,O
in,O
the,O
inverted,O
region,O
and,O
6,O
.,O
3,O
kb,O
in,O
noninverted,O
regions,O
from,O
two,O
male,O
black,B-OG
muntjacs,I-OG
",",O
one,O
female,O
black,B-OG
muntjac,I-OG
",",O
and,O
one,O
male,O
Indian,B-OG
muntjac,I-OG
.,O
Among,O
the,O
23,O
gene,O
pairs,O
located,O
in,O
the,O
inverted,O
region,O
",",O
we,O
observed,O
14,O
mutations,O
in,O
eight,O
genes,O
shared,O
by,O
the,O
two,O
males,O
in,O
the,O
protein,O
-,O
coding,O
or,O
untranslated,O
regions,O
(,O
UTRs,O
),O
of,O
the,O
neo,O
-,O
Y,O
alleles,O
(,O
Table,O
3,O
).,O
In,O
contrast,O
",",O
we,O
detected,O
no,O
variation,O
in,O
genes,O
located,O
in,O
the,O
neo,O
-,O
Y,O
',O
PAR,O
',O
region,O
.,O
For,O
the,O
autosomal,O
region,O
",",O
only,O
one,O
out,O
of,O
six,O
genes,O
is,O
heterozygous,O
at,O
one,O
site,O
in,O
both,O
the,O
two,O
male,O
black,B-OG
muntjacs,I-OG
.,O
Such,O
an,O
elevated,O
rate,O
of,O
gene,O
evolution,O
exhibited,O
by,O
neo,O
-,O
Y,O
alleles,O
relative,O
to,O
their,O
neo,O
-,O
X,O
homologs,O
and,O
other,O
autosomal,O
genes,O
is,O
consistent,O
with,O
reduced,O
efficiency,O
of,O
natural,O
selection,O
against,O
deleterious,O
mutations,O
in,O
the,O
neo,O
-,O
Y,O
.,O
Combined,O
with,O
the,O
variation,O
patterns,O
in,O
intronic,O
and,O
intergenic,O
regions,O
(,O
see,O
the,O
section,O
above,O
"),",O
these,O
findings,O
confirmed,O
the,O
recombination,O
inhibition,O
on,O
the,O
neo,O
-,O
Y,O
chromosome,O
.,O
Summary,O
of,O
neo,O
-,O
Y,O
specific,O
mutations,O
occurred,O
in,O
the,O
cDNA,O
of,O
investigated,O
genes,O
Gene,O
symbol,O
Positions,O
on,O
neo,O
-,O
Ya,O
Shared,O
mutation,O
Polymorphic,O
mutation,O
MYO1D,B-GP
17a,O
One,O
synonymous,O
substitution,O
RPL19,B-GP
17a,O
One,O
synonymous,O
substitution,O
One,O
synonymous,O
substitution,O
CACNB1,B-GP
17a,O
A,O
to,O
Sb,O
CLTC,B-GP
17a,O
Two,O
synonymous,O
substitutions,O
ZNF24,B-GP
17a,O
One,O
synonymous,O
substitution,O
AKAP7,B-GP
3b,O
Three,O
synonymous,O
substitutions,O
;,O
V,O
to,O
M,O
SYNE1,B-GP
3b,O
One,O
synonymous,O
substitution,O
;,O
I,O
to,O
V,O
;,O
V,O
to,O
Eb,O
Two,O
synonymous,O
substitutions,O
SNX22,B-GP
8,O
46,O
bp,O
deletion,O
in,O
3,O
'-,O
UTR,O
RIC8B,B-GP
1a,O
S,O
to,O
Pb,O
SCN1A,B-GP
3a,O
D,O
to,O
Gb,O
MPPE1,O
4a,O
One,O
synonymous,O
substitution,O
aPositions,O
correspond,O
to,O
chromosomal,O
regions,O
depicted,O
in,O
Figure,O
1a,O
.,O
bMissense,O
mutations,O
with,O
drastic,O
change,O
of,O
biochemical,O
property,O
of,O
amino,O
acid,O
(,O
polarity,O
or,O
charge,O
"),",O
and,O
those,O
in,O
bold,O
represent,O
sites,O
that,O
are,O
highly,O
conserved,O
in,O
other,O
eutherian,B-OG
mammals,I-OG
with,O
published,O
sequences,O
.,O
We,O
defined,O
',O
shared,O
mutations,O
',O
as,O
those,O
mutations,O
detected,O
in,O
neo,O
-,O
Y,O
alleles,O
in,O
both,O
male,O
black,B-OG
muntjacs,I-OG
",",O
whereas,O
',O
polymorphic,O
mutation,O
',O
are,O
those,O
detected,O
in,O
only,O
one,O
male,O
black,B-OG
muntjac,I-OG
.,O
Specifically,O
",",O
four,O
nonsynonymous,O
substitutions,O
shared,O
by,O
the,O
two,O
male,O
black,B-OG
muntjacs,I-OG
and,O
two,O
polymorphic,O
nonsynonymous,O
substitutions,O
in,O
one,O
of,O
the,O
males,O
were,O
observed,O
(,O
Table,O
3,O
).,O
Of,O
these,O
six,O
changes,O
",",O
four,O
are,O
highly,O
conserved,O
in,O
amino,O
acids,O
across,O
six,O
other,O
eutherian,B-OG
mammals,I-OG
(,O
human,B-OG
",",O
chimpanzee,B-OG
",",O
dog,B-OG
",",O
mouse,B-OG
",",O
rat,B-OG
",",O
and,O
cow,B-OG
;,O
Table,O
3,O
).,O
These,O
four,O
mutations,O
change,O
the,O
polarity,O
or,O
charge,O
of,O
the,O
amino,O
acid,O
",",O
which,O
might,O
severely,O
affect,O
the,O
protein,O
function,O
of,O
the,O
neo,O
-,O
Y,O
copies,O
.,O
We,O
also,O
detected,O
a,O
neo,O
-,O
Y,O
-,O
linked,O
deletion,O
in,O
3,O
'-,O
UTR,O
of,O
the,O
gene,O
SNX22,B-GP
in,O
both,O
males,O
investigated,O
.,O
This,O
deletion,O
abolishes,O
a,O
microRNA,O
target,O
site,O
(,O
see,O
below,O
),O
and,O
thus,O
may,O
affect,O
stability,O
of,O
the,O
neo,O
-,O
Y,O
allele,O
',O
s,O
mRNA,O
[,O
36,O
",",O
37,O
].,O
By,O
taking,O
into,O
account,O
the,O
above,O
-,O
described,O
four,O
possible,O
deleterious,O
nonsynonymous,O
mutations,O
and,O
the,O
deletion,O
in,O
the,O
3,O
'-,O
UTR,O
of,O
SNX22,B-GP
",",O
we,O
conservatively,O
estimate,O
the,O
rate,O
of,O
accumulation,O
of,O
deleterious,O
mutations,O
in,O
exon,O
regions,O
of,O
neo,O
-,O
Y,O
genes,O
to,O
be,O
approximately,O
0,O
.,O
4,O
mutations,O
/,O
kb,O
per,O
million,O
years,O
(,O
5,O
mutations,O
/,O
25,O
kb,O
per,O
0,O
.,O
5,O
million,O
years,O
).,O
We,O
also,O
estimated,O
that,O
only,O
about,O
1,O
.,O
3,O
nonsense,O
mutations,O
would,O
be,O
expected,O
within,O
25,O
kb,O
of,O
investigated,O
cDNA,O
sequences,O
",",O
assuming,O
equal,O
chance,O
of,O
mutation,O
at,O
each,O
site,O
(,O
see,O
Materials,O
and,O
methods,O
[,O
below,O
]).,O
Such,O
a,O
low,O
probability,O
of,O
nonsense,O
mutation,O
plus,O
the,O
effect,O
of,O
possible,O
purifying,O
selection,O
give,O
credence,O
to,O
our,O
observation,O
that,O
there,O
were,O
no,O
coding,O
frame,O
-,O
disrupting,O
mutations,O
among,O
the,O
investigated,O
muntjac,B-OG
neo,O
-,O
Y,O
alleles,O
.,O
This,O
finding,O
differs,O
from,O
that,O
of,O
a,O
recent,O
investigation,O
conducted,O
in,O
the,O
neo,O
-,O
sex,O
system,O
of,O
Drosophila,B-OG
miranda,I-OG
[,O
38,O
"],",O
which,O
found,O
that,O
the,O
neo,O
-,O
Y,O
alleles,O
of,O
24,O
out,O
of,O
64,O
genes,O
contain,O
premature,O
stop,O
codons,O
and,O
/,O
or,O
frameshift,O
mutations,O
",",O
suggesting,O
an,O
average,O
loss,O
rate,O
of,O
20,O
genes,O
per,O
million,O
years,O
in,O
the,O
proto,O
-,O
Y,O
of,O
Drosophila,B-OG
.,O
Such,O
a,O
drastic,O
difference,O
in,O
the,O
degeneration,O
rate,O
between,O
neo,O
-,O
Y,O
chromosomes,O
of,O
mammals,B-OG
and,O
Drosophila,B-OG
could,O
be,O
attributable,O
to,O
the,O
great,O
differences,O
in,O
their,O
mutation,O
rates,O
(,O
2,O
.,O
2,O
×,O
10,O
-,O
9,O
versus,O
3,O
.,O
1,O
×,O
10,O
-,O
7,O
per,O
base,O
per,O
year,O
for,O
mammal,B-OG
and,O
Drosophila,B-OG
",",O
respectively,O
),O
[,O
39,O
",",O
40,O
"],",O
generation,O
time,O
",",O
DNA,O
repair,O
efficiencies,O
[,O
41,O
"],",O
and,O
effective,O
population,O
size,O
[,O
18,O
].,O
It,O
also,O
suggests,O
that,O
",",O
during,O
the,O
nonlinear,O
process,O
of,O
mammalian,O
Y,O
degeneration,O
[,O
3,O
"],",O
the,O
rate,O
of,O
gene,O
loss,O
might,O
be,O
very,O
slow,O
in,O
the,O
early,O
stage,O
of,O
mammalian,O
Y,O
chromosome,O
evolution,O
.,O
Multiple,O
factors,O
can,O
fix,O
the,O
above,O
neo,O
-,O
Y,O
specific,O
mutations,O
in,O
populations,O
in,O
both,O
coding,O
and,O
noncoding,O
regions,O
",",O
such,O
as,O
Muller,O
',O
s,O
ratchet,O
",",O
background,O
selection,O
",",O
hitchhiking,O
effects,O
on,O
linked,O
deleterious,O
mutations,O
",",O
and,O
faster,O
mutation,O
rate,O
in,O
males,O
[,O
6,O
",",O
28,O
",",O
42,O
",",O
43,O
].,O
Muller,O
',O
s,O
ratchet,O
must,O
have,O
had,O
strong,O
effect,O
on,O
accumulation,O
of,O
these,O
mutations,O
",",O
given,O
that,O
the,O
number,O
of,O
mutant,O
-,O
free,O
chromosomes,O
in,O
a,O
population,O
is,O
positively,O
correlated,O
with,O
the,O
effective,O
population,O
size,O
(,O
Ne,O
),O
[,O
6,O
",",O
18,O
].,O
Because,O
of,O
the,O
usual,O
small,O
Ne,O
values,O
of,O
mammals,B-OG
",",O
mutant,O
-,O
free,O
neo,O
-,O
Y,O
alleles,O
should,O
be,O
vulnerable,O
to,O
an,O
irreversible,O
loss,O
by,O
random,O
drift,O
by,O
the,O
',O
ratchet,O
',O
process,O
",",O
which,O
further,O
leads,O
to,O
accumulation,O
of,O
deleterious,O
mutations,O
.,O
It,O
is,O
less,O
likely,O
that,O
the,O
observed,O
neo,O
-,O
Y,O
variations,O
were,O
from,O
either,O
ancestral,O
polymorphism,O
or,O
gene,O
conversion,O
between,O
neo,O
-,O
X,O
and,O
neo,O
-,O
Y,O
",",O
because,O
we,O
used,O
both,O
female,O
black,B-OG
muntjac,I-OG
and,O
Indian,B-OG
muntjac,I-OG
genes,O
as,O
the,O
references,O
to,O
define,O
neo,O
-,O
Y,O
mutations,O
[,O
42,O
].,O
It,O
is,O
also,O
less,O
likely,O
that,O
there,O
were,O
recent,O
selective,O
sweeps,O
on,O
the,O
neo,O
-,O
Y,O
of,O
the,O
black,B-OG
muntjac,I-OG
",",O
based,O
on,O
the,O
DNA,O
polymorphism,O
data,O
.,O
Recent,O
strong,O
positive,O
selection,O
would,O
homogenize,O
the,O
neo,O
-,O
Y,O
chromosomes,O
among,O
individuals,O
[,O
6,O
"],",O
but,O
we,O
observed,O
many,O
polymorphic,O
sites,O
existing,O
in,O
both,O
noncoding,O
and,O
coding,O
regions,O
of,O
the,O
muntjac,B-OG
neo,O
-,O
Y,O
chromosome,O
(,O
Tables,O
1,O
and,O
3,O
).,O
Regarding,O
other,O
processes,O
",",O
because,O
of,O
the,O
difficulty,O
associated,O
with,O
collecting,O
population,O
data,O
for,O
such,O
a,O
rare,O
species,O
",",O
we,O
cannot,O
currently,O
test,O
the,O
existence,O
of,O
either,O
a,O
slower,O
rate,O
of,O
adaptive,O
evolution,O
[,O
44,O
],O
or,O
background,O
selection,O
[,O
6,O
"],",O
as,O
previously,O
proposed,O
for,O
D,B-OG
.,I-OG
miranda,I-OG
[,O
10,O
].,O
Degeneration,O
in,O
cis,O
-,O
regulatory,O
regions,O
of,O
neo,O
-,O
Y,O
-,O
linked,O
genes,O
Recent,O
studies,O
have,O
revealed,O
that,O
cis,O
-,O
regulatory,O
regions,O
more,O
often,O
underlie,O
the,O
expression,O
divergence,O
between,O
species,O
and,O
evolution,O
of,O
morphologic,O
diversity,O
[,O
14,O
",",O
45,O
",",O
46,O
].,O
Apart,O
from,O
the,O
direct,O
evidence,O
of,O
degeneration,O
in,O
coding,O
regions,O
presented,O
above,O
",",O
we,O
sought,O
to,O
survey,O
degeneration,O
in,O
regulatory,O
regions,O
on,O
the,O
neo,O
-,O
Y,O
chromosome,O
.,O
We,O
analyzed,O
putative,O
promoters,O
expanding,O
1,O
.,O
5,O
kb,O
around,O
transcriptional,O
start,O
sites,O
(,O
TSSs,O
),O
of,O
eight,O
neo,O
-,O
Y,O
genes,O
",",O
which,O
have,O
mutations,O
shared,O
by,O
the,O
two,O
male,O
black,B-OG
muntjacs,I-OG
in,O
their,O
protein,O
-,O
coding,O
/,O
UTR,O
regions,O
(,O
Table,O
3,O
).,O
We,O
detected,O
neo,O
-,O
Y,O
specific,O
mutations,O
shared,O
by,O
both,O
males,O
present,O
in,O
the,O
investigated,O
regions,O
in,O
three,O
out,O
of,O
eight,O
genes,O
(,O
see,O
Additional,O
Data,O
File,O
3,O
).,O
In,O
order,O
to,O
assess,O
the,O
effect,O
of,O
these,O
mutations,O
on,O
gene,O
expression,O
",",O
allelic,O
promoters,O
were,O
subsequently,O
cloned,O
into,O
pGL3,O
-,O
Basic,O
plasmid,O
in,O
front,O
of,O
a,O
firefly,B-OG
luciferase,B-GP
reporter,O
gene,O
.,O
Each,O
plasmid,O
was,O
mixed,O
with,O
a,O
plasmid,O
(,O
pRLs,O
-,O
TK,O
),O
containing,O
a,O
constitutive,O
promoter,O
driving,O
sea,B-OG
-,I-OG
pansy,I-OG
luciferase,B-GP
reporter,O
gene,O
and,O
co,O
-,O
transfected,O
into,O
Hela,O
cells,O
and,O
male,O
black,B-OG
muntjac,I-OG
fibroblast,O
cells,O
.,O
The,O
ratios,O
of,O
firefly,B-OG
luciferase,B-GP
to,O
sea,B-OG
-,I-OG
pansy,I-OG
luciferase,B-GP
",",O
representing,O
normalized,O
promoter,O
activity,O
",",O
were,O
compared,O
between,O
neo,O
-,O
Y,O
-,O
linked,O
promoters,O
and,O
neo,O
-,O
X,O
-,O
linked,O
promoters,O
.,O
We,O
found,O
a,O
significant,O
decrease,O
in,O
neo,O
-,O
Y,O
promoter,O
activity,O
in,O
both,O
Hela,O
and,O
black,B-OG
muntjac,I-OG
cell,O
lines,O
for,O
the,O
CLTC,B-GP
gene,O
(,O
Figure,O
3,O
).,O
We,O
did,O
not,O
detect,O
promoter,O
activities,O
for,O
the,O
cloned,O
fragments,O
of,O
other,O
two,O
genes,O
;,O
specifically,O
",",O
there,O
is,O
no,O
detectable,O
expression,O
of,O
the,O
reporter,O
genes,O
using,O
the,O
cloned,O
fragments,O
as,O
the,O
promoters,O
.,O
The,O
only,O
detected,O
neo,O
-,O
Y,O
specific,O
mutation,O
is,O
a,O
1,O
base,O
pair,O
(,O
bp,O
),O
insertion,O
55,O
base,O
pairs,O
upstream,O
of,O
the,O
putative,O
TSS,O
of,O
the,O
CLTC,B-GP
gene,O
shared,O
by,O
both,O
males,O
(,O
Additional,O
data,O
file,O
3,O
).,O
It,O
is,O
probably,O
the,O
mutation,O
responsible,O
for,O
reducing,O
the,O
transcription,O
level,O
of,O
neo,O
-,O
Y,O
",",O
given,O
that,O
this,O
region,O
was,O
proposed,O
to,O
contribute,O
positively,O
to,O
the,O
core,O
promoter,O
activity,O
by,O
a,O
recent,O
comprehensive,O
analysis,O
of,O
387,O
promoter,O
structures,O
in,O
humans,B-OG
[,O
47,O
].,O
Mutation,O
in,O
the,O
promoter,O
of,O
CLTC,B-GP
gene,O
severely,O
causes,O
downregulation,O
of,O
the,O
neo,O
-,O
Y,O
copy,O
.,O
Dual,O
-,O
reporter,O
assay,O
of,O
promoter,O
activities,O
of,O
CLTC,B-GP
.,O
Standard,O
error,O
among,O
triplicates,O
was,O
shown,O
on,O
the,O
bar,O
.,O
In,O
addition,O
to,O
mutations,O
in,O
promoter,O
regions,O
",",O
we,O
also,O
detected,O
a,O
neo,O
-,O
Y,O
specific,O
deletion,O
shared,O
by,O
both,O
male,O
black,B-OG
muntjacs,I-OG
in,O
the,O
3,O
'-,O
UTR,O
of,O
the,O
gene,O
SNX22,B-GP
as,O
mentioned,O
above,O
(,O
Table,O
3,O
).,O
The,O
abundance,O
of,O
microRNA,O
targeted,O
sequences,O
in,O
this,O
region,O
drove,O
us,O
to,O
investigate,O
whether,O
this,O
deletion,O
would,O
affect,O
such,O
motifs,O
[,O
36,O
",",O
37,O
].,O
Using,O
human,B-OG
microRNA,O
database,O
as,O
a,O
reference,O
",",O
we,O
found,O
that,O
the,O
deleted,O
region,O
on,O
the,O
neo,O
-,O
Y,O
is,O
in,O
fact,O
predicted,O
to,O
be,O
a,O
binding,O
motif,O
targeted,O
by,O
the,O
microRNA,O
hsa,O
-,O
mir,O
-,O
210,O
[,O
48,O
"],",O
which,O
also,O
has,O
orthologs,O
in,O
cow,B-OG
and,O
mouse,B-OG
with,O
validated,O
expression,O
.,O
Intriguingly,O
",",O
we,O
found,O
evidence,O
that,O
this,O
same,O
microRNA,O
targeted,O
motif,O
is,O
also,O
deleted,O
because,O
of,O
male,O
-,O
specific,O
RNA,O
editing,O
in,O
intact,O
neo,O
-,O
X,O
alleles,O
(,O
see,O
Additional,O
data,O
file,O
4,O
);,O
23,O
bp,O
overlapping,O
the,O
target,O
sequence,O
are,O
absent,O
from,O
transcripts,O
in,O
males,O
(,O
the,O
edited,O
form,O
is,O
much,O
less,O
frequent,O
in,O
females,O
;,O
see,O
Additional,O
data,O
file,O
5,O
).,O
The,O
diminutive,O
size,O
of,O
the,O
involved,O
sequence,O
and,O
lack,O
of,O
splicing,O
boundaries,O
suggest,O
that,O
it,O
is,O
a,O
true,O
RNA,O
editing,O
event,O
rather,O
than,O
a,O
splicing,O
event,O
.,O
It,O
could,O
be,O
a,O
result,O
of,O
selection,O
against,O
allelic,O
expression,O
imbalance,O
between,O
neo,O
-,O
X,O
and,O
neo,O
-,O
Y,O
or,O
a,O
sign,O
of,O
degeneration,O
of,O
trans,O
factors,O
on,O
neo,O
-,O
Y,O
in,O
males,O
",",O
which,O
control,O
the,O
RNA,O
-,O
editing,O
degree,O
in,O
the,O
3,O
'-,O
UTR,O
of,O
SNX22,B-GP
.,O
One,O
of,O
the,O
fundamental,O
issues,O
in,O
the,O
process,O
of,O
Y,O
-,O
chromosome,O
degeneration,O
is,O
whether,O
it,O
is,O
mainly,O
driven,O
by,O
direct,O
degradation,O
of,O
the,O
protein,O
products,O
(,O
for,O
example,O
",",O
in,O
D,B-OG
.,I-OG
miranda,I-OG
),O
or,O
reducing,O
gene,O
expression,O
levels,O
on,O
an,O
evolving,O
Y,O
[,O
6,O
].,O
Our,O
results,O
suggest,O
that,O
these,O
two,O
processes,O
may,O
work,O
in,O
concert,O
after,O
the,O
immediate,O
recombination,O
suppression,O
on,O
the,O
neo,O
-,O
Y,O
chromosome,O
.,O
It,O
is,O
proposed,O
that,O
deleterious,O
mutations,O
with,O
mild,O
fitness,O
effects,O
have,O
a,O
higher,O
rate,O
of,O
fixation,O
on,O
a,O
degenerating,O
Y,O
[,O
6,O
"],",O
as,O
illustrated,O
in,O
Table,O
3,O
.,O
After,O
accumulation,O
of,O
such,O
mutations,O
in,O
the,O
protein,O
coding,O
regions,O
",",O
a,O
subsequent,O
reduced,O
expression,O
of,O
Y,O
would,O
be,O
favored,O
by,O
natural,O
selection,O
to,O
prevent,O
the,O
production,O
of,O
defective,O
Y,O
-,O
linked,O
products,O
[,O
6,O
",",O
18,O
].,O
Alternatively,O
",",O
reduced,O
expression,O
of,O
Y,O
may,O
take,O
place,O
before,O
the,O
accumulation,O
of,O
deleterious,O
mutations,O
in,O
protein,O
products,O
.,O
In,O
the,O
case,O
of,O
CLTC,B-GP
and,O
SNX22,B-GP
",",O
both,O
are,O
broadly,O
expressed,O
genes,O
in,O
most,O
of,O
the,O
human,B-OG
tissues,O
",",O
with,O
orthologs,O
present,O
in,O
all,O
vertebrates,B-OG
whose,O
genomes,O
have,O
been,O
sequenced,O
.,O
CLTC,B-GP
plays,O
an,O
critical,O
role,O
through,O
coating,O
membrane,O
vesicles,O
during,O
endocytosis,O
[,O
49,O
],O
and,O
SNX22,B-GP
is,O
a,O
member,O
of,O
the,O
protein,O
family,O
responsible,O
for,O
protein,O
trafficking,O
[,O
50,O
].,O
The,O
protein,O
coding,O
regions,O
of,O
these,O
housekeeping,O
genes,O
must,O
be,O
under,O
strong,O
selective,O
constraints,O
",",O
in,O
which,O
no,O
amino,O
acid,O
replacement,O
substitution,O
was,O
detected,O
(,O
Table,O
3,O
).,O
On,O
the,O
other,O
hand,O
",",O
recent,O
studies,O
showed,O
that,O
cis,O
-,O
regulatory,O
regions,O
-,O
especially,O
microRNA,O
and,O
transcription,O
factor,O
binding,O
sites,O
-,O
usually,O
have,O
lower,O
interspecies,O
sequence,O
conservation,O
compared,O
with,O
protein,O
coding,O
regions,O
",",O
suggesting,O
that,O
regulatory,O
mutations,O
can,O
be,O
more,O
easily,O
fixed,O
[,O
46,O
",",O
51,O
].,O
This,O
suggests,O
a,O
scenario,O
involving,O
two,O
independent,O
steps,O
of,O
degeneration,O
.,O
First,O
",",O
mutations,O
in,O
regulatory,O
regions,O
(,O
for,O
example,O
",",O
the,O
promoter,O
of,O
CLTC,B-GP
),O
would,O
decrease,O
or,O
even,O
turn,O
off,O
the,O
gene,O
expression,O
of,O
the,O
Y,O
alleles,O
.,O
Second,O
",",O
decreased,O
expression,O
could,O
reduce,O
selective,O
constraints,O
acting,O
on,O
the,O
protein,O
products,O
of,O
proto,O
/,O
neo,O
-,O
Y,O
-,O
linked,O
genes,O
[,O
52,O
].,O
We,O
note,O
that,O
both,O
these,O
processes,O
could,O
in,O
fact,O
be,O
favored,O
to,O
maintain,O
the,O
optimal,O
gene,O
dose,O
between,O
males,O
and,O
females,O
after,O
the,O
establishment,O
of,O
dosage,O
compensation,O
in,O
X,O
[,O
53,O
].,O
Also,O
",",O
both,O
processes,O
would,O
further,O
accelerate,O
the,O
degeneration,O
process,O
in,O
the,O
Y,O
-,O
linked,O
coding,O
regions,O
",",O
which,O
is,O
supported,O
by,O
the,O
recent,O
finding,O
that,O
lower,O
expressed,O
neo,O
-,O
Y,O
genes,O
appear,O
to,O
have,O
a,O
faster,O
accumulation,O
rate,O
of,O
deleterious,O
mutations,O
in,O
D,B-OG
.,I-OG
miranda,I-OG
[,O
54,O
].,O
Transcription,O
divergence,O
between,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
alleles,O
We,O
semi,O
-,O
quantified,O
and,O
compared,O
the,O
mRNA,O
abundance,O
of,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
alleles,O
in,O
11,O
genes,O
with,O
mutations,O
listed,O
in,O
Table,O
3,O
.,O
Consistent,O
with,O
our,O
promoter,O
assay,O
",",O
CLTC,B-GP
exhibits,O
a,O
lower,O
expression,O
level,O
on,O
neo,O
-,O
Y,O
.,O
We,O
found,O
significant,O
expression,O
difference,O
between,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
allele,O
only,O
in,O
the,O
gene,O
SNX22,B-GP
(,O
Fisher,O
',O
s,O
exact,O
test,O
",",O
P,O
<,O
0,O
.,O
01,O
).,O
However,O
",",O
this,O
gene,O
was,O
further,O
excluded,O
from,O
the,O
result,O
",",O
together,O
with,O
SCN1A,B-GP
",",O
because,O
of,O
their,O
effects,O
of,O
allelic,O
-,O
biased,O
amplification,O
(,O
see,O
Materials,O
and,O
methods,O
[,O
below,O
]).,O
Eight,O
of,O
the,O
remaining,O
nine,O
genes,O
exhibited,O
differential,O
expression,O
;,O
interestingly,O
",",O
as,O
many,O
showed,O
higher,O
expression,O
on,O
neo,O
-,O
Y,O
as,O
on,O
neo,O
-,O
X,O
(,O
4,O
versus,O
4,O
;,O
Figure,O
4,O
).,O
This,O
finding,O
suggests,O
that,O
neo,O
-,O
Y,O
alleles,O
can,O
be,O
distorted,O
from,O
normal,O
expression,O
level,O
",",O
either,O
downregulated,O
or,O
upregulated,O
",",O
as,O
a,O
result,O
of,O
degenerating,O
control,O
of,O
gene,O
expression,O
.,O
Together,O
with,O
the,O
mutation,O
analysis,O
results,O
presented,O
above,O
",",O
the,O
expression,O
patterns,O
of,O
the,O
nine,O
investigated,O
genes,O
exhibit,O
a,O
similar,O
random,O
inactivation,O
mode,O
of,O
gene,O
evolution,O
on,O
a,O
degenerating,O
Y,O
chromosome,O
proposed,O
for,O
D,B-OG
.,I-OG
miranda,I-OG
[,O
12,O
].,O
This,O
model,O
predicts,O
that,O
neo,O
-,O
Y,O
genes,O
are,O
randomly,O
inactivated,O
",",O
regardless,O
of,O
their,O
level,O
of,O
adaptation,O
.,O
As,O
shown,O
in,O
Figure,O
4,O
",",O
the,O
regulation,O
direction,O
of,O
neo,O
-,O
Y,O
genes,O
fluctuates,O
along,O
the,O
neo,O
-,O
Y,O
chromosome,O
",",O
and,O
between,O
some,O
adjacent,O
genes,O
it,O
is,O
even,O
opposite,O
",",O
suggesting,O
that,O
there,O
is,O
no,O
large,O
segment,O
inactivation,O
in,O
the,O
black,B-OG
muntjac,I-OG
',O
s,O
neo,O
-,O
Y,O
chromosome,O
.,O
Two,O
genes,O
(,O
CLTC,B-GP
and,O
ZNF24,B-GP
),O
with,O
only,O
synonymous,O
neo,O
-,O
Y,O
mutations,O
exhibited,O
lower,O
expression,O
level,O
",",O
whereas,O
two,O
genes,O
(,O
SYNE1,B-GP
and,O
AKAP7,B-GP
),O
with,O
nonsynonymous,O
neo,O
-,O
Y,O
mutations,O
exhibited,O
higher,O
expression,O
level,O
.,O
In,O
addition,O
",",O
the,O
human,B-OG
orthologs,O
of,O
all,O
nine,O
investigated,O
genes,O
are,O
widely,O
expressed,O
housekeeping,O
genes,O
.,O
Therefore,O
",",O
whether,O
a,O
neo,O
-,O
Y,O
allele,O
is,O
subjected,O
to,O
expression,O
alteration,O
or,O
the,O
direction,O
of,O
alteration,O
may,O
be,O
not,O
strongly,O
correlated,O
with,O
the,O
characteristics,O
of,O
the,O
gene,O
.,O
Expression,O
divergences,O
between,O
nine,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
gene,O
pairs,O
.,O
All,O
expression,O
assays,O
were,O
done,O
in,O
duplicate,O
and,O
double,O
checked,O
in,O
both,O
male,O
individuals,O
.,O
Mean,O
expression,O
ratios,O
of,O
neo,O
-,O
Y,O
to,O
neo,O
-,O
X,O
are,O
shown,O
.,O
The,O
genes,O
are,O
arranged,O
following,O
the,O
order,O
from,O
the,O
centromere,O
to,O
the,O
distal,O
region,O
of,O
the,O
1p,O
+,O
4,O
chromosome,O
.,O
This,O
random,O
inactivation,O
pattern,O
indicates,O
that,O
the,O
Xist,O
-,O
dependent,O
dosage,O
compensation,O
[,O
19,O
],O
has,O
not,O
spread,O
across,O
the,O
whole,O
neo,O
-,O
X,O
chromosome,O
in,O
females,O
within,O
the,O
past,O
0,O
.,O
5,O
million,O
years,O
.,O
This,O
could,O
be,O
attributed,O
to,O
a,O
lack,O
of,O
sufficient,O
time,O
for,O
the,O
establishment,O
of,O
action,O
of,O
Xist,O
on,O
neo,O
-,O
X,O
regions,O
.,O
Concordantly,O
",",O
there,O
is,O
also,O
clear,O
molecular,O
evidence,O
that,O
neo,O
-,O
X,O
chromosome,O
in,O
male,O
D,B-OG
.,I-OG
miranda,I-OG
is,O
only,O
partially,O
dosage,O
compensated,O
[,O
55,O
].,O
A,O
recent,O
study,O
[,O
56,O
],O
showed,O
that,O
even,O
in,O
the,O
',O
ancient,O
',O
sex,O
determination,O
system,O
",",O
such,O
as,O
that,O
of,O
human,B-OG
",",O
15,O
%,O
of,O
X,O
-,O
linked,O
genes,O
would,O
escape,O
the,O
X,O
inactivation,O
",",O
suggesting,O
that,O
the,O
mammalian,O
dosage,O
compensation,O
mechanism,O
is,O
leaky,O
and,O
its,O
evolution,O
process,O
might,O
be,O
slow,O
.,O
As,O
suggested,O
by,O
our,O
results,O
in,O
male,O
black,B-OG
muntjacs,I-OG
described,O
above,O
",",O
not,O
all,O
the,O
neo,O
-,O
Y,O
alleles,O
have,O
been,O
subjected,O
to,O
the,O
reduction,O
of,O
gene,O
expression,O
.,O
A,O
nonspecific,O
whole,O
-,O
set,O
dosage,O
compensation,O
mechanism,O
is,O
likely,O
to,O
be,O
seriously,O
deleterious,O
for,O
genes,O
that,O
are,O
transcriptionally,O
active,O
or,O
are,O
undergoing,O
degeneration,O
.,O
It,O
is,O
also,O
possible,O
that,O
a,O
major,O
regulator,O
of,O
dosage,O
compensation,O
",",O
such,O
as,O
Tsix,O
gene,O
",",O
counteracted,O
Xist,O
RNA,O
on,O
neo,O
-,O
X,O
regions,O
to,O
prevent,O
such,O
deleterious,O
effects,O
[,O
57,O
",",O
58,O
].,O
However,O
",",O
such,O
delicate,O
regulation,O
is,O
less,O
likely,O
to,O
have,O
been,O
established,O
within,O
such,O
a,O
short,O
evolutionary,O
time,O
.,O
Overall,O
",",O
we,O
propose,O
here,O
that,O
in,O
the,O
early,O
stages,O
",",O
dosage,O
compensation,O
in,O
males,O
might,O
have,O
evolved,O
gradually,O
in,O
a,O
gene,O
-,O
by,O
-,O
gene,O
fashion,O
.,O
This,O
model,O
is,O
also,O
consistent,O
with,O
the,O
conjecture,O
that,O
evolution,O
is,O
accomplished,O
more,O
through,O
small,O
steps,O
than,O
large,O
changes,O
[,O
59,O
].,O
Charlesworth,O
[,O
18,O
],O
has,O
proposed,O
two,O
models,O
to,O
describe,O
evolution,O
of,O
dosage,O
compensation,O
in,O
manners,O
similar,O
to,O
the,O
two,O
paths,O
of,O
Y,O
-,O
chromosome,O
degeneration,O
mentioned,O
above,O
.,O
The,O
common,O
features,O
of,O
both,O
models,O
involve,O
the,O
upregulation,O
of,O
gene,O
expression,O
from,O
the,O
proto,O
-,O
X,O
chromosome,O
at,O
the,O
initial,O
stage,O
of,O
Y,O
degeneration,O
[,O
18,O
"],",O
which,O
has,O
been,O
suggested,O
by,O
recent,O
global,O
expression,O
analyses,O
conducted,O
in,O
Drosophila,B-OG
",",O
worm,B-OG
",",O
and,O
mammals,B-OG
[,O
60,O
",",O
61,O
].,O
One,O
model,O
proposed,O
by,O
Charlesworth,O
suggests,O
that,O
there,O
would,O
be,O
selection,O
promoting,O
upregulation,O
of,O
the,O
transcription,O
of,O
X,O
alleles,O
to,O
compensate,O
for,O
defective,O
products,O
",",O
with,O
mutations,O
accumulated,O
in,O
the,O
coding,O
regions,O
of,O
Y,O
alleles,O
.,O
Alternatively,O
",",O
mutations,O
could,O
arise,O
to,O
make,O
the,O
Y,O
alleles,O
less,O
responsive,O
to,O
the,O
regulatory,O
molecules,O
",",O
as,O
exemplified,O
by,O
the,O
case,O
of,O
CLTC,B-GP
in,O
this,O
study,O
.,O
It,O
would,O
consequently,O
be,O
a,O
passive,O
process,O
",",O
upregulating,O
the,O
X,O
alleles,O
',O
expression,O
as,O
a,O
result,O
of,O
the,O
excess,O
of,O
regulatory,O
molecules,O
from,O
the,O
Y,O
alleles,O
[,O
18,O
].,O
Further,O
study,O
into,O
the,O
paths,O
of,O
Y,O
chromosome,O
degeneration,O
and,O
comparison,O
of,O
neo,O
-,O
X,O
expression,O
between,O
males,O
and,O
females,O
using,O
more,O
gene,O
pairs,O
would,O
be,O
able,O
to,O
uncover,O
which,O
model,O
mainly,O
contributes,O
to,O
the,O
Y,O
degeneration,O
and,O
evolution,O
of,O
dosage,O
compensation,O
.,O
Conclusion,O
Here,O
we,O
characterize,O
the,O
recently,O
formed,O
neo,O
-,O
sex,O
system,O
of,O
the,O
black,B-OG
muntjac,I-OG
.,O
This,O
unprecedented,O
system,O
is,O
valuable,O
for,O
studying,O
mammalian,O
Y,O
-,O
chromosome,O
degeneration,O
and,O
evolution,O
of,O
dosage,O
compensation,O
.,O
Our,O
results,O
provided,O
molecular,O
evidence,O
for,O
recombination,O
suppression,O
in,O
the,O
neo,O
-,O
Y,O
chromosome,O
.,O
As,O
a,O
result,O
",",O
excess,O
of,O
putatively,O
deleterious,O
mutations,O
were,O
observed,O
in,O
the,O
coding,O
regions,O
of,O
the,O
investigated,O
genes,O
",",O
probably,O
because,O
of,O
the,O
Muller,O
',O
s,O
ratchet,O
effect,O
or,O
background,O
selection,O
.,O
Most,O
importantly,O
",",O
we,O
report,O
here,O
the,O
first,O
study,O
of,O
the,O
role,O
of,O
regulatory,O
mutations,O
during,O
the,O
degeneration,O
process,O
of,O
mammalian,O
Y,O
",",O
and,O
we,O
provide,O
empirical,O
data,O
showing,O
their,O
degenerative,O
effect,O
on,O
gene,O
expression,O
.,O
Such,O
mutations,O
might,O
further,O
accelerate,O
the,O
degeneration,O
and,O
give,O
rise,O
to,O
the,O
evolution,O
of,O
dosage,O
compensation,O
in,O
a,O
gene,O
-,O
by,O
-,O
gene,O
manner,O
.,O
These,O
results,O
demonstrate,O
that,O
mammalian,O
Y,O
degeneration,O
is,O
a,O
complex,O
gradual,O
process,O
spanning,O
diverse,O
genomic,O
structures,O
.,O
Materials,O
and,O
methods,O
FISH,O
",",O
separation,O
of,O
1p,O
+,O
4,O
by,O
cell,O
Sorter,O
",",O
PCR,O
",",O
and,O
sequence,O
analysis,O
Frozen,O
kidney,O
from,O
a,O
male,O
black,B-OG
muntjac,I-OG
",",O
and,O
fibroblast,O
cell,O
lines,O
of,O
another,O
male,O
(,O
KCB82001,O
),O
and,O
a,O
female,O
black,B-OG
muntjac,I-OG
(,O
KCB81002E,O
),O
were,O
provided,O
by,O
Kunming,O
Cell,O
Bank,O
of,O
the,O
Chinese,O
Academy,O
of,O
Sciences,O
.,O
Total,O
genomic,O
DNA,O
was,O
extracted,O
using,O
the,O
PURRGENE,O
®,O
DNA,O
Isolation,O
Kit,O
(,O
Gentra,O
Systems,O
Inc,O
".,",O
Minneapolis,O
",",O
MN,O
USA,O
"),",O
and,O
total,O
RNA,O
was,O
extracted,O
using,O
RNeasy,O
®,O
Mini,O
Kit,O
(,O
Qiagen,O
",",O
Valencia,O
",",O
CA,O
USA,O
).,O
Based,O
on,O
the,O
syntenic,O
relationship,O
among,O
black,B-OG
muntjac,I-OG
",",O
Indian,B-OG
muntjac,I-OG
",",O
and,O
cow,B-OG
and,O
annotation,O
results,O
of,O
Indian,B-OG
muntjac,I-OG
[,O
35,O
"],",O
we,O
selected,O
genes,O
randomly,O
distributed,O
along,O
the,O
neo,O
-,O
Y,O
chromosome,O
",",O
PAR,O
region,O
",",O
and,O
autosomal,O
regions,O
for,O
primer,O
designs,O
(,O
Table,O
3,O
).,O
The,O
investigated,O
noncoding,O
regions,O
are,O
introns,O
or,O
flanking,O
intergenic,O
regions,O
of,O
these,O
selected,O
genes,O
.,O
We,O
prepared,O
cell,O
suspensions,O
of,O
the,O
male,O
black,B-OG
muntjac,I-OG
for,O
further,O
FISH,O
and,O
flow,O
sorting,O
of,O
1p,O
+,O
4,O
chromosomes,O
.,O
The,O
sorting,O
procedure,O
using,O
a,O
FACStar,O
Plus,O
flow,O
sorter,O
(,O
Becton,O
Dickinson,O
",",O
Franklin,O
Lakes,O
",",O
NJ,O
USA,O
),O
and,O
FISH,O
analysis,O
using,O
Indian,B-OG
muntjac,I-OG
BAC,O
clones,O
(,O
06G7,O
and,O
07B3,O
),O
as,O
probes,O
were,O
performed,O
as,O
previously,O
described,O
[,O
21,O
].,O
We,O
used,O
two,O
strategies,O
to,O
discriminate,O
neo,O
-,O
X,O
and,O
neo,O
-,O
Y,O
alleles,O
.,O
First,O
",",O
we,O
compared,O
genomic,O
DNA,O
PCR,O
products,O
of,O
Indian,B-OG
muntjac,I-OG
",",O
and,O
female,O
and,O
male,O
black,B-OG
muntjacs,I-OG
",",O
and,O
we,O
inferred,O
neo,O
-,O
Y,O
-,O
specific,O
alleles,O
.,O
We,O
also,O
used,O
flow,O
-,O
sorted,O
1p,O
+,O
4,O
chromosomes,O
as,O
PCR,O
templates,O
to,O
confirm,O
the,O
neo,O
-,O
Y,O
-,O
specific,O
mutations,O
.,O
The,O
products,O
were,O
subject,O
to,O
sequencing,O
with,O
BigDye,O
Terminators,O
v3,O
.,O
0,O
(,O
Applied,O
Biosystems,O
),O
after,O
purification,O
(,O
QIAquick,O
®,O
PCR,O
Purification,O
Kit,O
;,O
Qiagen,O
",",O
Valencia,O
",",O
CA,O
USA,O
).,O
Trace,O
data,O
were,O
manually,O
trimmed,O
and,O
aligned,O
from,O
both,O
directions,O
using,O
Lasergene,O
suite,O
(,O
DNASTAR,O
Inc,O
".,",O
Madison,O
",",O
WI,O
USA,O
).,O
We,O
concatenated,O
sequences,O
of,O
noncoding,O
regions,O
together,O
for,O
further,O
analysis,O
.,O
Segregating,O
sites,O
in,O
these,O
regions,O
were,O
counted,O
and,O
polymorphism,O
data,O
were,O
analyzed,O
using,O
DnaSP,O
4,O
.,O
0,O
[,O
62,O
].,O
Confidence,O
intervals,O
for,O
polymorphisms,O
were,O
calculated,O
by,O
variance,O
[,O
63,O
].,O
If,O
we,O
assume,O
the,O
1p,O
+,O
4,O
chromosome,O
can,O
recombine,O
with,O
its,O
homologous,O
chromosome,O
",",O
then,O
its,O
polymorphism,O
level,O
is,O
expected,O
to,O
be,O
similar,O
to,O
that,O
of,O
other,O
autosomes,O
or,O
',O
PAR,O
',O
regions,O
.,O
Under,O
such,O
a,O
,O
hypothesis,O
",",O
we,O
test,O
the,O
significance,O
of,O
difference,O
for,O
polymorphism,O
between,O
1p,O
+,O
4,O
and,O
other,O
chromosome,O
regions,O
with,O
χ2,O
test,O
.,O
Sequences,O
of,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
alleles,O
were,O
subjected,O
to,O
construction,O
of,O
phylogenetic,O
trees,O
and,O
distance,O
calculation,O
with,O
MEGA,O
3,O
.,O
1,O
[,O
64,O
].,O
After,O
removing,O
regions,O
with,O
indels,O
",",O
gene,O
tree,O
was,O
constructed,O
using,O
the,O
neighbour,O
joining,O
and,O
maximum,O
likelihood,O
method,O
",",O
and,O
distances,O
were,O
calculated,O
with,O
Kimura,O
',O
s,O
two,O
-,O
parameter,O
and,O
HKY85,O
model,O
",",O
respectively,O
[,O
65,O
].,O
We,O
used,O
internal,O
",",O
external,O
",",O
and,O
summed,O
branch,O
lengths,O
in,O
Figure,O
2a,O
to,O
estimate,O
α,O
.,O
Comparison,O
of,O
α,O
estimates,O
from,O
different,O
branch,O
lengths,O
can,O
be,O
used,O
to,O
test,O
whether,O
the,O
ancestral,O
polymorphism,O
have,O
affected,O
the,O
calculation,O
[,O
31,O
].,O
According,O
to,O
the,O
method,O
proposed,O
by,O
Miyata,O
and,O
coworkers,O
[,O
29,O
"],",O
Y,O
/,O
X,O
=,O
3α,O
/(,O
2,O
+,O
α,O
"),",O
where,O
Y,O
and,O
X,O
stand,O
for,O
mutation,O
rate,O
for,O
Y,O
-,O
linked,O
and,O
X,O
-,O
linked,O
sequences,O
",",O
respectively,O
.,O
The,O
variance,O
of,O
Y,O
is,O
V,O
(,O
Y,O
),O
=,O
Y,O
(,O
1,O
-,O
Y,O
)/(,O
L,O
[,O
1,O
-,O
4Y,O
/,O
3,O
],O
2,O
),O
and,O
the,O
variance,O
of,O
X,O
is,O
V,O
(,O
X,O
),O
=,O
Y,O
(,O
1,O
-,O
X,O
)/(,O
L,O
[,O
1,O
-,O
4X,O
/,O
3,O
],O
2,O
"),",O
where,O
L,O
is,O
the,O
length,O
of,O
the,O
sequence,O
[,O
31,O
].,O
The,O
variance,O
of,O
Y,O
/,O
X,O
is,O
V,O
(,O
Y,O
/,O
X,O
),O
=,O
V,O
(,O
Y,O
)/,O
E,O
(,O
X,O
),O
2,O
+,O
E,O
(,O
Y,O
),O
2V,O
(,O
X,O
)/,O
E,O
(,O
X,O
),O
4,O
.,O
The,O
95,O
%,O
confidence,O
interval,O
of,O
α,O
was,O
estimated,O
",",O
following,O
the,O
method,O
proposed,O
by,O
Huang,O
and,O
coworkers,O
[,O
30,O
].,O
Because,O
Y,O
/,O
X,O
(,O
0,O
.,O
001189,O
/,O
0,O
.,O
000294,O
",",O
internal,O
branches,O
),O
is,O
greater,O
than,O
3,O
based,O
on,O
branch,O
lengths,O
of,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
in,O
this,O
study,O
",",O
the,O
α,O
value,O
approaches,O
infinity,O
.,O
To,O
estimate,O
expected,O
stop,O
condon,O
number,O
E,O
(,O
S,O
),O
in,O
the,O
investigated,O
coding,O
regions,O
",",O
we,O
assume,O
that,O
only,O
one,O
substitution,O
would,O
arise,O
per,O
codon,O
",",O
given,O
the,O
extremely,O
young,O
age,O
of,O
this,O
neo,O
-,O
sex,O
system,O
.,O
Assuming,O
the,O
chances,O
of,O
mutation,O
are,O
equal,O
across,O
the,O
sequences,O
",",O
E,O
(,O
S,O
),O
would,O
be,O
given,O
by,O
the,O
following,O
:,O
E,O
(,O
S,O
)=,O
3μt,O
∑,O
i,O
=,O
1npi,O
",",O
where,O
μ,O
is,O
the,O
estimated,O
mammalian,O
mutation,O
rate,O
measured,O
per,O
base,O
[,O
39,O
"],",O
t,O
is,O
the,O
age,O
of,O
the,O
neo,O
-,O
sex,O
system,O
",",O
n,O
is,O
the,O
number,O
of,O
the,O
codon,O
in,O
the,O
investigated,O
region,O
and,O
pi,O
is,O
the,O
probability,O
of,O
a,O
certain,O
codon,O
becoming,O
a,O
stop,O
codon,O
.,O
Promoter,O
assay,O
We,O
predicted,O
the,O
TSS,O
information,O
for,O
black,B-OG
muntjac,I-OG
genes,O
with,O
ClustalW,O
[,O
66,O
"],",O
using,O
orthologous,O
human,B-OG
",",O
mouse,B-OG
",",O
and,O
cow,B-OG
sequence,O
as,O
reference,O
.,O
Regions,O
expanding,O
1,O
kb,O
upstream,O
and,O
500,O
bp,O
downstream,O
of,O
the,O
predicted,O
TSS,O
were,O
amplified,O
as,O
putative,O
promoter,O
regions,O
in,O
black,B-OG
muntjacs,I-OG
.,O
The,O
PCR,O
products,O
were,O
subject,O
to,O
TA,O
cloning,O
using,O
pMD19,O
-,O
T,O
vector,O
(,O
TaKaRa,O
",",O
Dalian,O
",",O
Shangdong,O
China,O
),O
for,O
screening,O
products,O
without,O
PCR,O
artifacts,O
and,O
further,O
enzyme,O
digestion,O
.,O
The,O
digested,O
PCR,O
product,O
was,O
cloned,O
into,O
pGL3,O
-,O
Basic,O
firefly,B-OG
luciferase,B-GP
vector,O
(,O
Promega,O
",",O
Madison,O
",",O
WI,O
USA,O
),O
using,O
T4,B-OG
ligase,B-GP
(,O
Invitrogen,O
",",O
Carlsbad,O
",",O
CA,O
USA,O
).,O
Then,O
the,O
vector,O
was,O
transformed,O
into,O
competent,O
cell,O
(,O
TOP10,O
;,O
Invitrogen,O
",",O
Carlsbad,O
",",O
CA,O
USA,O
),O
and,O
purified,O
by,O
QIAprep,O
®,O
Spin,O
Miniprep,O
Kit,O
(,O
Qiagen,O
",",O
Valencia,O
",",O
CA,O
USA,O
).,O
Hela,O
and,O
male,O
black,B-OG
muntjac,I-OG
fibroblast,O
cell,O
lines,O
were,O
respectively,O
seeded,O
into,O
24,O
-,O
well,O
plates,O
to,O
reach,O
densities,O
of,O
104,O
to,O
105,O
cells,O
per,O
well,O
24,O
hours,O
before,O
transfection,O
.,O
Generally,O
",",O
0,O
.,O
2,O
μg,O
pGL3,O
-,O
Basic,O
vector,O
with,O
cloned,O
promoter,O
and,O
0,O
.,O
04,O
μg,O
Renilla,B-OG
(,O
sea,B-OG
-,I-OG
pansy,I-OG
),O
luciferase,B-GP
vector,O
(,O
pRL,O
-,O
TK,O
;,O
Promega,O
",",O
Madison,O
",",O
WI,O
USA,O
),O
were,O
mixed,O
in,O
Opti,O
-,O
MEM,O
®,O
I,O
Reduced,O
Serum,O
Medium,O
(,O
Invitrogen,O
",",O
Carlsbad,O
",",O
CA,O
USA,O
),O
and,O
co,O
-,O
transfected,O
into,O
cells,O
with,O
Lipofectamine,O
™,O
2000,O
(,O
Invitrogen,O
",",O
Carlsbad,O
",",O
CA,O
USA,O
).,O
We,O
used,O
pGL,O
-,O
Basic,O
vector,O
as,O
negative,O
control,O
and,O
assayed,O
the,O
luciferase,B-GP
signal,O
with,O
the,O
Dual,O
-,O
Luciferase,B-GP
®,O
Reporter,O
1000,O
Assay,O
System,O
(,O
Promega,O
",",O
Madison,O
",",O
WI,O
USA,O
).,O
The,O
ratios,O
of,O
firefly,B-OG
luciferase,B-GP
to,O
sea,B-OG
pansy,I-OG
luciferase,B-GP
were,O
compared,O
between,O
neo,O
-,O
Y,O
-,O
linked,O
promoters,O
and,O
neo,O
-,O
X,O
-,O
linked,O
promoters,O
.,O
All,O
of,O
the,O
assays,O
for,O
each,O
promoter,O
were,O
done,O
in,O
triplicate,O
.,O
Expression,O
abundance,O
analysis,O
We,O
amplified,O
coding,O
regions,O
containing,O
neo,O
-,O
Y,O
-,O
linked,O
mutations,O
from,O
genomic,O
DNA,O
and,O
total,O
RNA,O
(,O
One,O
Step,O
RNA,O
PCR,O
Kit,O
",",O
TaKaRa,O
",",O
Dalian,O
",",O
Shangdong,O
China,O
"),",O
respectively,O
.,O
The,O
genomic,O
PCR,O
was,O
used,O
as,O
a,O
control,O
to,O
exclude,O
PCR,O
biases,O
caused,O
by,O
allelic,O
preferential,O
amplification,O
.,O
Out,O
of,O
11,O
genes,O
",",O
we,O
observed,O
biased,O
amplification,O
for,O
only,O
two,O
genes,O
",",O
namely,O
SCN1A,B-GP
and,O
SNX22,B-GP
;,O
the,O
extent,O
of,O
the,O
amplification,O
bias,O
is,O
similar,O
to,O
the,O
copy,O
abundance,O
difference,O
observed,O
in,O
the,O
mRNA,O
assay,O
.,O
The,O
reaction,O
was,O
done,O
for,O
25,O
to,O
30,O
cycles,O
",",O
and,O
the,O
PCR,O
products,O
were,O
cloned,O
into,O
pMD19,O
-,O
T,O
vector,O
(,O
TaKaRa,O
",",O
Dalian,O
",",O
Shangdong,O
China,O
).,O
Twenty,O
to,O
30,O
white,O
clones,O
were,O
randomly,O
picked,O
and,O
were,O
subject,O
to,O
further,O
sequencing,O
.,O
The,O
expression,O
ratio,O
of,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
alleles,O
was,O
determined,O
by,O
counting,O
the,O
number,O
of,O
separate,O
alleles,O
.,O
All,O
assays,O
were,O
conducted,O
in,O
duplicate,O
and,O
double,O
checked,O
in,O
both,O
male,O
individuals,O
.,O
We,O
further,O
compared,O
the,O
mean,O
expression,O
ratio,O
of,O
duplicates,O
for,O
different,O
genes,O
.,O
Abbreviations,O
BAC,O
",",O
bacterial,O
artificial,O
chromosome,O
;,O
bp,O
",",O
base,O
pair,O
;,O
FISH,O
",",O
fluorescence,O
in,O
situ,O
hybridization,O
;,O
kb,O
",",O
kilobases,O
;,O
Ne,O
",",O
effective,O
population,O
size,O
;,O
PAR,O
",",O
pseudoautosomal,O
region,O
;,O
PCR,O
",",O
polymerase,O
chain,O
reaction,O
;,O
TSS,O
",",O
transcriptional,O
start,O
site,O
;,O
UTR,O
",",O
untranslated,O
region,O
.,O
Competing,O
interests,O
The,O
authors,O
declare,O
that,O
they,O
have,O
no,O
competing,O
interests,O
.,O
Authors,O
',O
contributions,O
WW,O
and,O
FY,O
designed,O
the,O
project,O
",",O
analyzed,O
the,O
data,O
",",O
and,O
wrote,O
the,O
paper,O
.,O
QZ,O
",",O
JW,O
",",O
and,O
LH,O
performed,O
the,O
PCR,O
experiments,O
",",O
and,O
expression,O
and,O
promoter,O
assays,O
.,O
WN,O
",",O
JW,O
",",O
YL,O
",",O
and,O
XZ,O
cultivated,O
the,O
fibroblast,O
cells,O
and,O
performed,O
the,O
FISH,O
experiments,O
.,O
QZ,O
and,O
JW,O
analyzed,O
the,O
data,O
and,O
wrote,O
the,O
paper,O
.,O
All,O
authors,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
Additional,O
data,O
files,O
The,O
following,O
additional,O
data,O
are,O
available,O
with,O
this,O
paper,O
.,O
Additional,O
data,O
file,O
1,O
is,O
a,O
schematic,O
ideogram,O
showing,O
the,O
neo,O
-,O
sex,O
system,O
of,O
Muntiacus,B-OG
crinifrons,I-OG
.,O
Additional,O
data,O
file,O
2,O
is,O
a,O
description,O
with,O
a,O
table,O
showing,O
substitution,O
patterns,O
on,O
noncoding,O
sequences,O
of,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
.,O
Additional,O
data,O
file,O
3,O
is,O
a,O
table,O
showing,O
neo,O
-,O
Y,O
linked,O
mutations,O
in,O
promoter,O
regions,O
and,O
their,O
effects,O
on,O
allelic,O
expression,O
.,O
Additional,O
data,O
file,O
4,O
is,O
a,O
figure,O
showing,O
the,O
RNA,O
editing,O
process,O
of,O
neo,O
-,O
X,O
allele,O
in,O
3,O
'-,O
UTR,O
of,O
SNX22,B-GP
.,O
Additional,O
data,O
file,O
5,O
is,O
a,O
table,O
showing,O
the,O
RNA,O
editing,O
degree,O
of,O
SNX22,B-GP
neo,O
-,O
X,O
allele,O
in,O
male,O
black,B-OG
muntjacs,I-OG
is,O
higher,O
than,O
that,O
in,O
female,O
.,O
Supplementary,O
Material,O
Additional,O
data,O
file,O
1,O
Numbers,O
beside,O
the,O
chromosomes,O
represent,O
homologous,O
chromosomes,O
of,O
Muntiacus,B-OG
reevesi,I-OG
defined,O
by,O
comparative,O
chromosomal,O
painting,O
[,O
21,O
].,O
Only,O
the,O
proximal,O
region,O
17b,O
and,O
the,O
distal,O
region,O
below,O
17a,O
can,O
form,O
homologous,O
pairing,O
and,O
thus,O
recombine,O
with,O
their,O
homologs,O
.,O
Regions,O
spanning,O
from,O
',O
22a,O
',O
to,O
',O
17a,O
',O
cannot,O
recombine,O
because,O
of,O
a,O
large,O
intrachromosomal,O
inversion,O
.,O
Regions,O
',O
8,O
"',",O
',O
17a,O
"',",O
and,O
',O
17b,O
',O
were,O
derived,O
from,O
short,O
arm,O
of,O
autosome,O
1,O
(,O
1p,O
),O
and,O
further,O
experienced,O
rearrangements,O
",",O
forming,O
the,O
current,O
order,O
along,O
1p,O
+,O
4,O
.,O
We,O
also,O
showed,O
location,O
information,O
for,O
the,O
investigated,O
23,O
genes,O
[,O
22,O
",",O
35,O
].,O
Click,O
here,O
for,O
file,O
Additional,O
data,O
file,O
2,O
Presented,O
is,O
a,O
description,O
with,O
a,O
table,O
showing,O
substitution,O
patterns,O
on,O
noncoding,O
sequences,O
of,O
neo,O
-,O
Y,O
and,O
neo,O
-,O
X,O
.,O
Click,O
here,O
for,O
file,O
Additional,O
data,O
file,O
3,O
Presented,O
is,O
a,O
table,O
showing,O
neo,O
-,O
Y,O
linked,O
mutations,O
in,O
promoter,O
regions,O
and,O
their,O
effects,O
on,O
allelic,O
expression,O
.,O
Click,O
here,O
for,O
file,O
Additional,O
data,O
file,O
4,O
The,O
UTR,O
region,O
is,O
designated,O
in,O
lower,O
case,O
",",O
whereas,O
the,O
protein,O
-,O
coding,O
region,O
is,O
presented,O
in,O
uppercase,O
.,O
Splicing,O
is,O
unlikely,O
because,O
there,O
is,O
no,O
splicing,O
signal,O
at,O
the,O
boundaries,O
of,O
deleted,O
region,O
and,O
an,O
intron,O
shorter,O
than,O
30,O
bp,O
is,O
scarce,O
in,O
mammals,B-OG
.,O
Click,O
here,O
for,O
file,O
Additional,O
data,O
file,O
5,O
Presented,O
is,O
a,O
table,O
showing,O
the,O
RNA,O
editing,O
degree,O
of,O
SNX22,B-GP
neo,O
-,O
X,O
allele,O
in,O
male,O
black,B-OG
muntjacs,I-OG
is,O
higher,O
than,O
that,O
in,O
female,O
.,O
Click,O
here,O
for,O
file,O
Preliminary,O
Findings,O
Show,O
Maternal,B-DS
Hypothyroidism,I-DS
May,O
Contribute,O
to,O
Abnormal,O
Cortical,O
Morphology,O
in,O
Offspring,O
Edited,O
by,O
:,O
Alfonso,O
Carreon,O
-,O
Rodriguez,O
",",O
Instituto,O
Nacional,O
de,O
Salud,O
Pública,O
",",O
Mexico,O
Reviewed,O
by,O
:,O
Luis,O
Concha,O
",",O
Universidad,O
Nacional,O
Autónoma,O
de,O
México,O
",",O
Mexico,O
;,O
Gonzalo,O
Aranda,O
",",O
Centro,O
de,O
Investigaciones,O
Cerebrales,O
",",O
Mexico,O
;,O
Akhgar,O
Ghassabian,O
",",O
National,O
Institute,O
of,O
Child,O
Health,O
and,O
Human,B-OG
Development,O
",",O
USA,O
;,O
John,O
Lazarus,O
",",O
formerly,O
affiliated,O
with,O
Cardiff,O
University,O
School,O
of,O
Medicine,O
",",O
UK,O
(,O
Retired,O
),O
Specialty,O
section,O
:,O
This,O
article,O
was,O
submitted,O
to,O
Neuroendocrine,O
Science,O
",",O
a,O
section,O
of,O
the,O
journal,O
Frontiers,O
in,O
Endocrinology,O
In,O
rodents,B-OG
",",O
insufficient,O
thyroid,O
hormone,O
(,O
TH,O
),O
gestationally,O
has,O
adverse,O
effects,O
on,O
cerebral,O
cortex,O
development,O
.,O
Comparable,O
studies,O
of,O
humans,B-OG
examining,O
how,O
TH,B-DS
insufficiency,I-DS
affects,O
cortical,O
morphology,O
are,O
limited,O
to,O
children,O
with,O
congenital,B-DS
hypothyroidism,I-DS
or,O
offspring,O
of,O
hypothyroxinemic,O
women,B-OG
;,O
effects,O
on,O
cortex,O
of,O
children,O
born,O
to,O
women,B-OG
with,O
clinically,O
diagnosed,O
hypothyroidism,B-DS
are,O
not,O
known,O
.,O
We,O
studied,O
archived,O
MRI,O
scans,O
from,O
22,O
children,O
aged,O
10,O
–,O
12,O
years,O
born,O
to,O
women,B-OG
treated,O
for,O
preexisting,O
or,O
de,O
novo,O
hypothyroidism,B-DS
in,I-DS
pregnancy,I-DS
(,O
HYPO,B-DS
),O
and,O
24,O
similar,O
age,O
and,O
sex,O
controls,O
from,O
euthyroid,O
women,B-OG
.,O
FreeSurfer,O
Image,O
Analysis,O
Suite,O
software,O
was,O
used,O
to,O
measure,O
cortical,O
thickness,O
(,O
CT,O
),O
and,O
a,O
vertex,O
-,O
based,O
approach,O
served,O
to,O
compare,O
HYPO,B-DS
versus,O
control,O
groups,O
and,O
Severe,O
versus,O
Mild,O
HYPO,B-DS
subgroups,O
as,O
well,O
as,O
to,O
perform,O
regression,O
analyses,O
examining,O
effects,O
of,O
trimester,O
-,O
specific,O
maternal,O
TSH,B-GP
on,O
CT,O
.,O
Results,O
showed,O
that,O
relative,O
to,O
controls,O
",",O
HYPO,B-DS
had,O
multiple,O
regions,O
of,O
both,O
cortical,O
thinning,O
and,O
thickening,O
",",O
which,O
differed,O
for,O
left,O
and,O
right,O
hemispheres,O
.,O
In,O
HYPO,B-DS
",",O
thinning,O
was,O
confined,O
to,O
medial,O
and,O
mid,O
-,O
lateral,O
regions,O
of,O
each,O
hemisphere,O
and,O
thickening,O
to,O
superior,O
regions,O
(,O
primarily,O
frontal,O
),O
of,O
the,O
left,O
hemisphere,O
and,O
inferior,O
regions,O
(,O
particularly,O
occipital,O
and,O
temporal,O
),O
of,O
the,O
right,O
.,O
The,O
Severe,O
HYPO,B-DS
subgroup,O
showed,O
more,O
thinning,O
than,O
Mild,O
in,O
frontal,O
and,O
temporal,O
regions,O
and,O
more,O
thickening,O
in,O
bilateral,O
posterior,O
and,O
frontal,O
regions,O
.,O
Maternal,O
TSH,B-GP
values,O
predicted,O
degree,O
of,O
thinning,O
and,O
thickening,O
within,O
multiple,O
brain,O
regions,O
",",O
with,O
the,O
pattern,O
and,O
direction,O
of,O
correlations,O
differing,O
by,O
trimester,O
.,O
Notably,O
",",O
some,O
correlations,O
remained,O
when,O
cases,O
born,O
to,O
women,B-OG
with,O
severe,B-DS
hypothyroidism,I-DS
were,O
removed,O
from,O
the,O
analyses,O
",",O
suggesting,O
that,O
mild,O
variations,O
of,O
maternal,O
TH,O
may,O
permanently,O
affect,O
offspring,O
cortex,O
.,O
We,O
conclude,O
that,O
maternal,B-DS
hypothyroidism,I-DS
during,O
pregnancy,O
has,O
long,O
-,O
lasting,O
manifestations,O
on,O
the,O
cortical,O
morphology,O
of,O
their,O
offspring,O
with,O
specific,O
effects,O
reflecting,O
both,O
severity,O
and,O
timing,O
of,O
maternal,O
TH,B-DS
insufficiency,I-DS
.,O
Introduction,O
Thyroid,O
hormone,O
(,O
TH,O
),O
is,O
essential,O
for,O
normal,O
brain,O
development,O
from,O
the,O
start,O
of,O
pregnancy,O
until,O
the,O
first,O
few,O
years,O
of,O
life,O
(,O
1,O
",",O
2,O
).,O
Because,O
the,O
fetal,O
thyroid,O
system,O
matures,O
late,O
in,O
gestation,O
",",O
maternal,O
TH,O
is,O
needed,O
at,O
the,O
beginning,O
of,O
pregnancy,O
for,O
normal,O
fetal,O
brain,O
development,O
and,O
serves,O
as,O
a,O
supplementary,O
",",O
albeit,O
essential,O
",",O
source,O
later,O
(,O
3,O
).,O
However,O
",",O
if,O
the,O
mother,O
’,O
s,O
TH,O
supply,O
is,O
inadequate,O
due,O
to,O
clinical,O
or,O
subclinical,B-DS
hypothyroidism,I-DS
",",O
offspring,O
neurodevelopment,O
will,O
be,O
compromised,O
leading,O
to,O
a,O
reduced,O
IQ,O
",",O
cognitive,O
and,O
learning,O
deficits,O
",",O
and,O
behavior,O
problems,O
(,O
4,O
–,O
10,O
).,O
Although,O
these,O
consequences,O
are,O
mostly,O
associated,O
with,O
early,O
gestational,O
TH,B-DS
deficiencies,I-DS
(,O
11,O
"),",O
adverse,O
effects,O
of,O
later,O
TH,B-DS
insufficiency,I-DS
are,O
also,O
known,O
(,O
12,O
).,O
To,O
date,O
",",O
most,O
of,O
the,O
research,O
has,O
been,O
based,O
on,O
global,O
endpoints,O
(,O
e,O
.,O
g,O
".,",O
IQ,O
"),",O
which,O
may,O
be,O
insensitive,O
to,O
subtle,O
manifestations,O
or,O
localized,O
brain,O
changes,O
(,O
3,O
",",O
13,O
"),",O
while,O
little,O
direct,O
evidence,O
exists,O
on,O
offspring,O
brain,O
development,O
(,O
14,O
",",O
15,O
).,O
In,O
rodents,B-OG
",",O
abundant,O
research,O
shows,O
a,O
wide,O
range,O
of,O
brain,O
abnormalities,O
in,O
the,O
progeny,O
when,O
pregnant,O
dams,O
are,O
rendered,O
TH,O
-,O
insufficient,O
at,O
different,O
stages,O
of,O
pregnancy,O
(,O
11,O
",",O
16,O
",",O
17,O
).,O
Diverse,O
cortical,O
abnormalities,O
(,O
18,O
",",O
19,O
),O
reflecting,O
both,O
severity,O
and,O
timing,O
of,O
maternal,O
TH,B-DS
deficiency,I-DS
(,O
20,O
),O
include,O
neuronal,O
migration,O
defects,O
",",O
atypical,O
layering,O
(,O
21,O
",",O
22,O
"),",O
reduced,O
growth,O
of,O
axons,O
and,O
dendrites,O
(,O
23,O
",",O
24,O
"),",O
and,O
increased,O
apoptosis,O
(,O
25,O
).,O
These,O
effects,O
are,O
generally,O
localized,O
to,O
middle,O
and,O
posterior,O
brain,O
regions,O
",",O
especially,O
parietal,O
and,O
occipital,O
cortices,O
(,O
26,O
–,O
29,O
"),",O
which,O
underlie,O
sensorimotor,O
",",O
visual,O
",",O
and,O
auditory,O
functions,O
(,O
2,O
",",O
30,O
).,O
By,O
contrast,O
",",O
the,O
frontal,O
lobes,O
",",O
which,O
are,O
important,O
for,O
executive,O
processing,O
and,O
attention,O
require,O
TH,O
in,O
the,O
postnatal,O
period,O
(,O
31,O
"),",O
signifying,O
a,O
posterior,O
-,O
to,O
-,O
anterior,O
progression,O
of,O
TH,O
need,O
within,O
the,O
cortex,O
.,O
Recent,O
advances,O
in,O
the,O
analysis,O
of,O
MRI,O
scans,O
to,O
evaluate,O
cortical,O
morphology,O
now,O
make,O
it,O
possible,O
to,O
directly,O
study,O
the,O
human,B-OG
cortex,O
.,O
The,O
available,O
automated,O
programs,O
serve,O
to,O
recreate,O
and,O
measure,O
surface,O
features,O
of,O
the,O
cortex,O
",",O
such,O
as,O
cortical,O
thickness,O
(,O
CT,O
),O
and,O
surface,O
area,O
(,O
SA,O
),O
(,O
32,O
"),",O
which,O
differ,O
as,O
to,O
underlying,O
genetic,O
determinants,O
",",O
cellular,O
processes,O
",",O
and,O
timing,O
effects,O
(,O
33,O
).,O
CT,O
",",O
the,O
most,O
commonly,O
studied,O
parameter,O
",",O
refers,O
to,O
the,O
distance,O
between,O
the,O
brain,O
’,O
s,O
inner,O
white,O
-,O
matter,O
(,O
WM,O
),O
and,O
outer,O
gray,O
-,O
matter,O
(,O
GM,O
),O
(,O
i,O
.,O
e,O
".,",O
pial,O
),O
surfaces,O
measured,O
across,O
the,O
entire,O
cortex,O
(,O
34,O
).,O
A,O
number,O
of,O
neurodevelopmental,O
conditions,O
",",O
such,O
as,O
autism,B-DS
spectrum,I-DS
disorder,I-DS
",",O
attention,B-DS
-,I-DS
deficit,I-DS
hyperactive,I-DS
disorder,I-DS
",",O
human,B-OG
X,O
monosomy,O
",",O
fetal,B-DS
alcohol,I-DS
spectrum,I-DS
disorder,I-DS
",",O
and,O
William,B-DS
’,I-DS
s,I-DS
syndrome,I-DS
show,O
a,O
wide,O
variety,O
of,O
CT,O
abnormalities,O
(,O
35,O
–,O
42,O
"),",O
which,O
are,O
typically,O
attributed,O
to,O
defects,O
in,O
neuronal,O
migration,O
or,O
cortical,O
layering,O
(,O
43,O
",",O
44,O
).,O
Recently,O
",",O
we,O
reported,O
that,O
children,O
with,O
congenital,B-DS
hypothyroidism,I-DS
(,O
CH,B-DS
"),",O
who,O
are,O
TH,O
-,O
deficient,O
in,O
the,O
period,O
from,O
late,O
gestation,O
until,O
the,O
first,O
month,O
or,O
two,O
of,O
life,O
",",O
show,O
cortical,O
thinning,O
and,O
thickening,O
in,O
diverse,O
regions,O
with,O
specific,O
effects,O
reflecting,O
initial,O
disease,O
severity,O
and,O
predicting,O
current,O
neuropsychological,O
functioning,O
(,O
45,O
).,O
By,O
contrast,O
",",O
studies,O
from,O
the,O
Netherlands,O
examining,O
children,O
’,O
s,O
cortical,O
morphology,O
report,O
normal,O
CT,O
and,O
SA,O
measurements,O
if,O
mothers,O
had,O
hypothyroxinemia,O
in,O
early,O
pregnancy,O
(,O
i,O
.,O
e,O
".,",O
low,O
thyroxine,O
or,O
T4,O
but,O
normal,O
thyroid,B-GP
-,I-GP
stimulating,I-GP
hormone,I-GP
or,O
TSH,B-GP
),O
(,O
46,O
),O
but,O
cortical,O
volumes,O
were,O
reduced,O
if,O
mothers,O
’,O
free,O
T4,O
levels,O
were,O
at,O
the,O
low,O
or,O
high,O
extremes,O
of,O
the,O
normal,O
range,O
(,O
47,O
).,O
Not,O
known,O
",",O
however,O
",",O
is,O
whether,O
children,O
exposed,O
to,O
insufficient,O
TH,O
during,O
gestation,O
due,O
to,O
inadequately,O
treated,O
clinical,O
hypothyroidism,B-DS
in,O
the,O
mother,O
show,O
abnormal,O
cortical,O
development,O
.,O
The,O
current,O
study,O
examined,O
CT,O
in,O
young,O
adolescents,O
from,O
a,O
cohort,O
born,O
between,O
1996,O
and,O
2001,O
and,O
regularly,O
followed,O
since,O
infancy,O
.,O
Included,O
were,O
offspring,O
of,O
women,B-OG
treated,O
for,O
clinical,O
hypothyroidism,B-DS
in,I-DS
pregnancy,I-DS
(,O
HYPO,B-DS
),O
and,O
of,O
euthyroid,O
women,B-OG
(,O
controls,O
).,O
At,O
time,O
of,O
entry,O
into,O
our,O
project,O
",",O
public,O
knowledge,O
that,O
HYPO,B-DS
required,O
a,O
substantial,O
increase,O
in,O
dosage,O
of,O
TH,O
was,O
not,O
available,O
(,O
48,O
),O
nor,O
were,O
guidelines,O
for,O
managing,O
maternal,O
HYPO,B-DS
(,O
49,O
",",O
50,O
).,O
Consequently,O
",",O
most,O
mothers,O
were,O
undertreated,O
while,O
their,O
children,O
were,O
exposed,O
to,O
some,O
gestational,O
TH,B-DS
insufficiency,I-DS
.,O
We,O
presently,O
performed,O
CT,O
studies,O
on,O
archived,O
structural,O
scans,O
in,O
order,O
(,O
i,O
),O
to,O
determine,O
if,O
HYPO,B-DS
and,O
controls,O
differ,O
and,O
identify,O
where,O
differences,O
reside,O
and,O
(,O
ii,O
),O
to,O
examine,O
if,O
CT,O
and,O
maternal,B-DS
hypothyroidism,I-DS
severity,O
are,O
related,O
.,O
We,O
hypothesized,O
that,O
relative,O
to,O
controls,O
",",O
HYPO,B-DS
would,O
show,O
atypical,O
cortical,O
morphology,O
that,O
would,O
reflect,O
severity,O
and,O
timing,O
of,O
maternal,B-DS
hypothyroidism,I-DS
.,O
We,O
did,O
not,O
have,O
specific,O
predictions,O
as,O
to,O
where,O
regionally,O
or,O
in,O
what,O
hemisphere,O
differences,O
would,O
occur,O
and,O
their,O
extent,O
;,O
however,O
",",O
we,O
expected,O
effects,O
to,O
be,O
relatively,O
posterior,O
given,O
rodent,B-OG
findings,O
showing,O
a,O
posterior,O
-,O
to,O
-,O
anterior,O
progression,O
of,O
TH,O
need,O
in,O
the,O
brain,O
.,O
Materials,O
and,O
Methods,O
Participants,O
The,O
current,O
sample,O
consisted,O
of,O
48,O
healthy,O
children,O
(,O
30,O
males,O
",",O
18,O
females,O
),O
whose,O
mothers,O
were,O
recruited,O
between,O
1996,O
and,O
2001,O
during,O
pregnancy,O
or,O
shortly,O
after,O
delivery,O
.,O
Children,O
were,O
previously,O
studied,O
at,O
6,O
",",O
12,O
",",O
and,O
18,O
months,O
and,O
5,O
years,O
of,O
age,O
.,O
Recently,O
at,O
10,O
–,O
12,O
years,O
",",O
they,O
participated,O
in,O
a,O
large,O
-,O
scale,O
study,O
investigating,O
their,O
neuropsychological,O
characteristics,O
(,O
particularly,O
memory,O
),O
and,O
brain,O
anatomy,O
based,O
on,O
structural,O
and,O
functional,O
MRI,O
scans,O
(,O
14,O
",",O
15,O
).,O
The,O
HYPO,B-DS
group,O
included,O
24,O
from,O
a,O
birth,O
cohort,O
consisting,O
of,O
66,O
children,O
whose,O
mothers,O
were,O
originally,O
recruited,O
during,O
pregnancy,O
via,O
posters,O
placed,O
in,O
local,O
endocrinologists,O
and,O
obstetricians,O
’,O
offices,O
",",O
while,O
a,O
small,O
subset,O
was,O
also,O
directly,O
recruited,O
from,O
the,O
records,O
of,O
an,O
antenatal,O
counseling,O
service,O
at,O
The,O
Hospital,O
for,O
Sick,O
Children,O
(,O
SickKids,O
),O
for,O
teratogen,O
and,O
medication,O
exposure,O
.,O
Most,O
non,O
-,O
participants,O
were,O
lost,O
to,O
follow,O
-,O
up,O
or,O
not,O
able,O
to,O
participate,O
due,O
to,O
time,O
constraints,O
.,O
Mothers,O
of,O
current,O
and,O
non,O
-,O
participants,O
did,O
not,O
differ,O
in,O
TH,O
levels,O
or,O
socioeconomic,O
status,O
(,O
SES,O
).,O
Their,O
children,O
did,O
not,O
differ,O
in,O
gestational,O
age,O
or,O
birth,O
weight,O
.,O
The,O
24,O
HYPO,B-DS
cases,O
were,O
born,O
to,O
23,O
women,B-OG
;,O
one,O
mother,O
",",O
who,O
was,O
diagnosed,O
in,O
the,O
first,O
pregnancy,O
",",O
contributed,O
two,O
children,O
.,O
Most,O
women,B-OG
(,O
83,O
%),O
were,O
treated,O
with,O
thyroxine,O
prior,O
to,O
pregnancy,O
",",O
while,O
17,O
%,O
began,O
it,O
during,O
pregnancy,O
.,O
The,O
majority,O
was,O
diagnosed,O
with,O
Hashimotos,B-DS
thyroiditis,I-DS
",",O
while,O
two,O
women,B-OG
had,O
thyroid,O
ablation,O
",",O
one,O
for,O
hyperthyroidism,B-DS
and,O
one,O
for,O
thyroid,B-DS
cancer,I-DS
.,O
Thyroid,O
function,O
test,O
results,O
(,O
primarily,O
TSH,B-GP
),O
were,O
available,O
from,O
the,O
pregnancy,O
records,O
of,O
all,O
but,O
one,O
woman,O
",",O
who,O
however,O
was,O
told,O
by,O
her,O
physician,O
that,O
her,O
TSH,B-GP
levels,O
were,O
extremely,O
elevated,O
.,O
As,O
some,O
women,B-OG
only,O
began,O
treatment,O
during,O
the,O
second,O
trimester,O
",",O
their,O
second,O
-,O
trimester,O
values,O
were,O
carried,O
back,O
to,O
replace,O
their,O
missing,O
data,O
.,O
Based,O
on,O
current,O
trimester,O
-,O
specific,O
ranges,O
for,O
TSH,B-GP
(,O
51,O
"),",O
two,O
women,B-OG
had,O
normal,O
TSH,B-GP
levels,O
during,O
each,O
trimester,O
",",O
whereas,O
the,O
remainder,O
had,O
an,O
elevated,O
value,O
in,O
one,O
or,O
more,O
trimesters,O
.,O
The,O
HYPO,B-DS
group,O
was,O
also,O
stratified,O
into,O
Mild,O
and,O
Severe,O
subgroups,O
based,O
on,O
a,O
median,O
split,O
of,O
mothers,O
’,O
TSH,B-GP
levels,O
from,O
the,O
first,O
and,O
/,O
or,O
second,O
trimesters,O
(,O
TSH,B-GP
+,O
8,O
.,O
8,O
levels,O
).,O
For,O
15,O
children,O
",",O
newborn,O
TSH,B-GP
values,O
obtained,O
from,O
provincial,O
screening,O
-,O
lab,O
records,O
were,O
all,O
in,O
the,O
normal,O
range,O
(,O
mean,O
=,O
4,O
.,O
11,O
mU,O
/,O
l,O
",",O
range,O
=,O
1,O
.,O
5,O
–,O
12,O
.,O
6,O
mU,O
/,O
l,O
).,O
Controls,O
were,O
24,O
typically,O
developing,O
youth,O
(,O
15,O
males,O
",",O
9,O
females,O
),O
from,O
the,O
same,O
memory,O
study,O
and,O
individually,O
matched,O
with,O
HYPO,B-DS
for,O
sex,O
",",O
age,O
(+,O
6,O
months,O
"),",O
and,O
SES,O
(,O
same,O
class,O
value,O
except,O
for,O
one,O
pair,O
differing,O
by,O
one,O
class,O
level,O
).,O
Twenty,O
-,O
one,O
were,O
from,O
the,O
original,O
birth,O
cohort,O
",",O
one,O
was,O
a,O
participant,O
in,O
a,O
previous,O
study,O
in,O
the,O
lab,O
",",O
and,O
two,O
were,O
newly,O
recruited,O
for,O
the,O
memory,O
study,O
.,O
All,O
mothers,O
reported,O
not,O
being,O
hypothyroid,O
in,O
pregnancy,O
or,O
since,O
delivery,O
.,O
At,O
the,O
time,O
when,O
the,O
birth,O
cohort,O
was,O
originally,O
recruited,O
",",O
thyroid,O
function,O
testing,O
was,O
not,O
routinely,O
performed,O
in,O
pregnancy,O
in,O
our,O
province,O
;,O
however,O
",",O
a,O
small,O
subset,O
was,O
tested,O
by,O
one,O
of,O
the,O
participating,O
obstetricians,O
and,O
all,O
had,O
normal,O
-,O
range,O
TH,O
results,O
.,O
Newborn,O
TSH,B-GP
values,O
available,O
on,O
13,O
control,O
children,O
were,O
all,O
in,O
the,O
normal,O
range,O
(,O
mean,O
=,O
3,O
.,O
68,O
mU,O
/,O
l,O
",",O
range,O
=,O
1,O
.,O
2,O
–,O
11,O
.,O
0,O
mU,O
/,O
l,O
).,O
Procedures,O
As,O
part,O
of,O
the,O
larger,O
study,O
",",O
all,O
children,O
received,O
over,O
the,O
course,O
of,O
2,O
days,O
",",O
an,O
extensive,O
battery,O
of,O
neuropsychological,O
tests,O
and,O
questionnaires,O
and,O
structural,O
and,O
functional,O
MRI,O
scans,O
",",O
approximately,O
2,O
weeks,O
apart,O
(,O
14,O
).,O
Tests,O
included,O
the,O
two,O
-,O
subtest,O
version,O
of,O
the,O
Wechsler,O
Abbreviated,O
Scale,O
of,O
Intelligence,O
(,O
WASI,O
),O
(,O
52,O
"),",O
which,O
yielded,O
a,O
Full,O
Scale,O
IQ,O
(,O
FSIQ,O
),O
score,O
from,O
these,O
two,O
subtests,O
",",O
Vocabulary,O
and,O
Matrix,O
Reasoning,O
subtests,O
",",O
that,O
were,O
given,O
.,O
Results,O
from,O
remaining,O
tests,O
are,O
reported,O
elsewhere,O
(,O
14,O
",",O
15,O
).,O
Parents,O
provided,O
informed,O
consent,O
while,O
children,O
gave,O
assent,O
.,O
All,O
procedures,O
were,O
approved,O
by,O
the,O
Research,O
Ethics,O
Board,O
at,O
SickKids,O
.,O
Imaging,O
Acquisition,O
and,O
Processing,O
Whole,O
-,O
brain,O
T1,O
images,O
were,O
acquired,O
in,O
a,O
1,O
.,O
5,O
-,O
T,O
GE,O
Signa,O
Excite,O
research,O
scanner,O
with,O
an,O
anatomical,O
Inversion,O
Recovery,O
Prepared,O
T1,O
-,O
weighted,O
fast,O
spoiled,O
gradient,O
echo,O
sequence,O
.,O
The,O
following,O
acquisition,O
parameters,O
were,O
used,O
:,O
repetition,O
time,O
=,O
10,O
.,O
09,O
ms,O
",",O
echo,O
time,O
=,O
4,O
.,O
2,O
ms,O
",",O
inversion,O
time,O
=,O
400,O
ms,O
",",O
flip,O
angle,O
=,O
20,O
"°,",O
acquisition,O
matrix,O
=,O
256,O
mm,O
×,O
192,O
mm,O
",",O
voxel,O
size,O
=,O
0,O
.,O
9375,O
mm,O
×,O
0,O
.,O
9375,O
mm,O
",",O
and,O
slice,O
thickness,O
=,O
1,O
.,O
5,O
mm,O
.,O
Acquisition,O
time,O
was,O
7,O
min,O
.,O
All,O
scans,O
were,O
examined,O
by,O
a,O
staff,O
neuroradiologist,O
who,O
reported,O
on,O
incidental,O
brain,O
abnormalities,O
.,O
Any,O
child,O
with,O
a,O
scan,O
indicating,O
a,O
significant,O
neuroradiological,O
abnormality,O
that,O
would,O
affect,O
cortical,O
measurements,O
was,O
excluded,O
.,O
As,O
one,O
child,O
with,O
a,O
large,O
right,O
frontal,O
dysembryoplastic,B-DS
neuroepithelial,I-DS
tumor,I-DS
was,O
removed,O
",",O
23,O
HYPO,B-DS
and,O
24,O
control,O
scans,O
were,O
available,O
for,O
cortical,O
morphology,O
analysis,O
.,O
Image,O
analysis,O
was,O
performed,O
on,O
a,O
Linux,O
Fedora,O
operating,O
system,O
using,O
FreeSurfer,O
Image,O
Analysis,O
Suite,O
version,O
4,O
.,O
4,O
(,O
53,O
).,O
When,O
this,O
study,O
originally,O
began,O
",",O
this,O
version,O
was,O
the,O
most,O
current,O
and,O
used,O
in,O
other,O
research,O
in,O
our,O
lab,O
(,O
45,O
).,O
FreeSurfer,O
consists,O
of,O
a,O
series,O
of,O
automated,O
algorithms,O
that,O
reproduce,O
the,O
brain,O
’,O
s,O
inner,O
and,O
outer,O
surfaces,O
and,O
measure,O
distances,O
between,O
these,O
surfaces,O
on,O
a,O
point,O
-,O
to,O
-,O
point,O
basis,O
for,O
the,O
entire,O
cortical,O
mantle,O
.,O
Processing,O
steps,O
included,O
the,O
following,O
:,O
transforming,O
each,O
subject,O
’,O
s,O
native,O
brain,O
into,O
Talairach,O
space,O
",",O
intensity,O
normalization,O
",",O
removal,O
of,O
non,O
-,O
brain,O
tissue,O
",",O
and,O
segmentation,O
of,O
GM,O
/,O
WM,O
tissue,O
(,O
54,O
"),",O
and,O
smoothing,O
using,O
a,O
Gaussian,O
kernel,O
with,O
a,O
full,O
width,O
half,O
maximum,O
of,O
10,O
mm,O
.,O
Total,O
processing,O
time,O
per,O
subject,O
was,O
24,O
h,O
.,O
Initially,O
",",O
each,O
cortex,O
was,O
manually,O
inspected,O
for,O
quality,O
control,O
and,O
motion,O
by,O
Jovanka,O
Skocic,O
",",O
who,O
was,O
blinded,O
to,O
participant,O
group,O
status,O
.,O
Any,O
scan,O
showing,O
extensive,O
motion,O
was,O
eliminated,O
from,O
the,O
analysis,O
.,O
We,O
also,O
checked,O
surface,O
extraction,O
for,O
systematic,O
errors,O
.,O
In,O
the,O
HYPO,B-DS
group,O
",",O
one,O
scan,O
was,O
removed,O
for,O
excessive,O
motion,O
yielding,O
a,O
final,O
sample,O
size,O
of,O
22,O
HYPO,B-DS
and,O
24,O
controls,O
.,O
Whole,O
-,O
brain,O
vertex,O
-,O
based,O
CT,O
statistical,O
analyses,O
were,O
performed,O
using,O
FreeSurfer,O
’,O
s,O
Qdec,O
program,O
.,O
These,O
were,O
conducted,O
separately,O
by,O
hemisphere,O
.,O
Also,O
provided,O
by,O
FreeSurfer,O
were,O
measures,O
of,O
surface,O
area,O
and,O
gyrification,O
and,O
intracranial,O
",",O
GM,O
",",O
WM,O
",",O
and,O
cerebrospinal,O
fluid,O
volumes,O
.,O
For,O
current,O
purposes,O
",",O
only,O
CT,O
and,O
total,O
intracranial,O
volume,O
data,O
were,O
used,O
.,O
For,O
all,O
analyses,O
",",O
the,O
Destrieux,O
Atlas,O
identified,O
locations,O
of,O
significant,O
clusters,O
.,O
Data,O
Analyses,O
Demographic,O
and,O
volumetric,O
data,O
were,O
originally,O
analyzed,O
in,O
SPSSv21,O
using,O
t,O
-,O
and,O
chi,O
-,O
square,O
tests,O
.,O
Within,O
FreeSurfer,O
",",O
two,O
sets,O
of,O
between,O
-,O
group,O
comparisons,O
were,O
performed,O
using,O
the,O
General,O
Linear,O
Model,O
analysis,O
program,O
",",O
one,O
contrasting,O
HYPO,B-DS
and,O
control,O
groups,O
and,O
the,O
other,O
",",O
Mild,O
and,O
Severe,O
HYPO,B-DS
subgroups,O
.,O
To,O
examine,O
relations,O
between,O
trimester,O
-,O
specific,O
maternal,O
TSH,B-GP
levels,O
and,O
CT,O
",",O
regression,O
analyses,O
were,O
performed,O
on,O
the,O
scans,O
of,O
children,O
whose,O
mothers,O
had,O
TH,O
data,O
.,O
All,O
analyses,O
were,O
conducted,O
across,O
the,O
entire,O
cortical,O
surface,O
of,O
~,O
80,O
",",O
000,O
vertices,O
per,O
hemisphere,O
.,O
Since,O
we,O
had,O
no,O
prior,O
hypotheses,O
on,O
specificity,O
",",O
we,O
did,O
not,O
examine,O
within,O
specific,O
regions,O
or,O
lobes,O
.,O
The,O
threshold,O
for,O
group,O
comparisons,O
was,O
set,O
at,O
p,O
<,O
0,O
.,O
05,O
and,O
for,O
regressions,O
",",O
at,O
p,O
<,O
0,O
.,O
01,O
.,O
To,O
correct,O
for,O
multiple,O
comparisons,O
",",O
we,O
used,O
a,O
cluster,O
-,O
wise,O
procedure,O
involving,O
the,O
Monte,O
Carlo,O
,O
-,O
z,O
simulation,O
with,O
5000,O
permutations,O
.,O
However,O
",",O
we,O
only,O
report,O
group,O
-,O
comparison,O
results,O
at,O
p,O
<,O
0,O
.,O
001,O
to,O
further,O
reduce,O
the,O
possibility,O
of,O
Type,O
1,O
errors,O
.,O
For,O
all,O
regions,O
showing,O
regression,O
effects,O
",",O
we,O
also,O
extracted,O
individual,O
CT,O
values,O
at,O
the,O
peak,O
vertex,O
of,O
each,O
significant,O
cluster,O
and,O
in,O
SPSSv23,O
",",O
correlated,O
the,O
derived,O
CT,O
values,O
with,O
trimester,O
-,O
specific,O
maternal,O
TSH,B-GP
levels,O
.,O
Results,O
Demographic,O
and,O
Total,O
Brain,O
Volume,O
Data,O
Table,O
1,O
providing,O
the,O
mean,O
demographic,O
data,O
for,O
HYPO,B-DS
(,O
n,O
=,O
22,O
),O
and,O
control,O
(,O
n,O
=,O
24,O
),O
groups,O
shows,O
that,O
they,O
did,O
not,O
differ,O
in,O
age,O
",",O
sex,O
",",O
SES,O
",",O
or,O
handedness,O
.,O
All,O
participants,O
scored,O
above,O
80,O
in,O
IQ,O
",",O
although,O
HYPO,B-DS
’,O
s,O
scores,O
were,O
on,O
average,O
3,O
.,O
7,O
points,O
below,O
control,O
values,O
",",O
but,O
the,O
difference,O
was,O
not,O
significant,O
.,O
For,O
the,O
entire,O
sample,O
",",O
total,O
intracranial,O
volumes,O
ranged,O
from,O
1351,O
.,O
1,O
to,O
2085,O
.,O
5,O
cm3,O
and,O
did,O
not,O
differ,O
between,O
groups,O
.,O
Because,O
groups,O
did,O
not,O
differ,O
on,O
any,O
of,O
the,O
above,O
indices,O
",",O
we,O
did,O
not,O
include,O
any,O
covariates,O
in,O
the,O
subsequent,O
analyses,O
.,O
Demographic,O
data,O
for,O
HYPO,B-DS
and,O
control,O
groups,O
.,O
HYPOa,O
(,O
n,O
=,O
22,O
),O
Control,O
(,O
n,O
=,O
24,O
),O
p,O
-,O
value,O
Age,O
(,O
years,O
),O
10,O
.,O
3,O
(,O
0,O
.,O
6,O
),O
10,O
.,O
5,O
(,O
0,O
.,O
71,O
),O
0,O
.,O
28,O
Sex,O
(,O
male,O
/,O
female,O
),O
14,O
/,O
8,O
15,O
/,O
9,O
Socioeconomic,O
statusb,O
1,O
.,O
86,O
(,O
0,O
.,O
77,O
),O
1,O
.,O
83,O
(,O
0,O
.,O
86,O
),O
0,O
.,O
9,O
Handedness,O
(,O
right,O
/,O
left,O
),O
c,O
21,O
/,O
1,O
23,O
/,O
1,O
Full,O
Scale,O
IQ,O
113,O
.,O
1,O
(,O
12,O
.,O
6,O
),O
116,O
.,O
8,O
(,O
10,O
.,O
2,O
),O
0,O
.,O
27,O
Intracranial,O
volume,O
1774,O
.,O
5,O
(,O
180,O
.,O
5,O
),O
1750,O
.,O
0,O
(,O
152,O
.,O
5,O
),O
0,O
.,O
4,O
TSH,B-GP
(,O
mU,O
/,O
l,O
),O
d,O
Trimester,O
1,O
8,O
.,O
70,O
(,O
6,O
.,O
71,O
),O
Trimester,O
2,O
6,O
.,O
30,O
(,O
8,O
.,O
50,O
),O
Trimester,O
3,O
3,O
.,O
24,O
(,O
4,O
.,O
17,O
),O
Free,O
T4,O
(,O
nmol,O
/,O
L,O
),O
e,O
Trimester,O
1,O
11,O
.,O
05,O
(,O
2,O
.,O
65,O
),O
Trimester,O
2,O
13,O
.,O
02,O
(,O
2,O
.,O
17,O
),O
Trimester,O
3,O
12,O
.,O
54,O
(,O
2,O
.,O
15,O
),O
Thyroxine,O
dosage,O
(,O
μg,O
/,O
day,O
),O
103,O
.,O
5,O
(,O
41,O
.,O
8,O
),O
Range,O
50,O
–,O
200,O
aThis,O
number,O
represents,O
the,O
remaining,O
sample,O
after,O
the,O
two,O
cases,O
with,O
unacceptable,O
scans,O
were,O
eliminated,O
.,O
bBased,O
on,O
Hollingshead,O
and,O
Redlich,O
’,O
s,O
(,O
1975,O
),O
5,O
-,O
point,O
rating,O
scale,O
for,O
socioeconomic,O
status,O
(,O
SES,O
),O
derived,O
from,O
occupations,O
and,O
educational,O
levels,O
of,O
both,O
parents,O
;,O
this,O
information,O
was,O
ascertained,O
from,O
a,O
case,O
-,O
history,O
questionnaire,O
given,O
to,O
parents,O
.,O
A,O
rating,O
value,O
of,O
1,O
signifies,O
the,O
highest,O
SES,O
level,O
and,O
of,O
5,O
",",O
the,O
lowest,O
.,O
cBased,O
on,O
a,O
10,O
-,O
item,O
questionnaire,O
completed,O
during,O
by,O
children,O
during,O
the,O
neuropsychological,O
assessment,O
.,O
dBased,O
on,O
21,O
women,B-OG
for,O
trimester,O
1,O
",",O
19,O
for,O
trimester,O
2,O
",",O
and,O
16,O
for,O
trimester,O
3,O
;,O
values,O
elevated,O
in,O
all,O
trimesters,O
.,O
eBased,O
on,O
14,O
women,B-OG
for,O
trimester,O
1,O
",",O
12,O
for,O
trimester,O
2,O
",",O
and,O
10,O
for,O
trimester,O
3,O
;,O
values,O
low,O
but,O
not,O
significantly,O
so,O
for,O
each,O
trimester,O
.,O
Table,O
1,O
also,O
provides,O
for,O
the,O
HYPO,B-DS
group,O
",",O
mean,O
TSH,B-GP
and,O
T4,O
level,O
values,O
from,O
each,O
trimester,O
as,O
well,O
as,O
the,O
initial,O
dose,O
level,O
of,O
thyroxine,O
in,O
pregnancy,O
.,O
TSH,B-GP
values,O
were,O
consistently,O
elevated,O
",",O
whereas,O
free,O
T4,O
levels,O
were,O
normal,O
or,O
below,O
but,O
not,O
significantly,O
low,O
.,O
Even,O
though,O
dose,O
levels,O
varied,O
among,O
the,O
women,B-OG
",",O
their,O
dosages,O
did,O
not,O
directly,O
reflect,O
TSH,B-GP
values,O
.,O
For,O
example,O
",",O
the,O
woman,O
with,O
the,O
most,O
aberrant,O
TSH,B-GP
values,O
was,O
receiving,O
125,O
μg,O
/,O
day,O
l,O
-,O
thyroxine,O
",",O
which,O
was,O
relatively,O
high,O
.,O
Between,O
-,O
Group,O
Comparisons,O
of,O
Cortical,O
Thickness,O
The,O
HYPO,B-DS
group,O
included,O
only,O
children,O
born,O
to,O
women,B-OG
with,O
elevated,O
TSH,B-GP
levels,O
in,O
pregnancy,O
since,O
the,O
two,O
women,B-OG
with,O
normal,O
TSH,B-GP
levels,O
in,O
pregnancy,O
were,O
technically,O
not,O
gestationally,O
hypothyroid,O
(,O
likely,O
because,O
their,O
treatment,O
was,O
sufficient,O
to,O
maintain,O
their,O
TSH,B-GP
levels,O
in,O
the,O
normal,O
range,O
).,O
The,O
child,O
whose,O
mother,O
was,O
told,O
by,O
her,O
physician,O
that,O
her,O
levels,O
were,O
extremely,O
elevated,O
was,O
included,O
.,O
The,O
final,O
sample,O
size,O
for,O
these,O
analyses,O
was,O
20,O
HYPO,B-DS
and,O
24,O
controls,O
.,O
It,O
should,O
be,O
noted,O
that,O
as,O
none,O
of,O
the,O
analyses,O
survived,O
with,O
smoothed,O
data,O
",",O
results,O
shown,O
presently,O
are,O
based,O
on,O
unsmoothed,O
findings,O
.,O
Table,O
2,O
provides,O
results,O
from,O
the,O
between,O
-,O
group,O
comparisons,O
",",O
while,O
Figure,O
1,O
shows,O
spatial,O
maps,O
of,O
the,O
regions,O
differentiating,O
groups,O
.,O
Because,O
HYPO,B-DS
was,O
compared,O
against,O
controls,O
(,O
i,O
.,O
e,O
".,",O
Control,O
minus,O
HYPO,B-DS
"),",O
red,O
clusters,O
signify,O
regions,O
of,O
significant,O
thinning,O
in,O
HYPO,B-DS
(,O
Controls,O
>,O
HYPO,B-DS
as,O
per,O
heat,O
bars,O
),O
while,O
blue,O
clusters,O
signify,O
regions,O
of,O
significant,O
thickening,O
(,O
Controls,O
<,O
HYPO,B-DS
).,O
HYPO,B-DS
demonstrated,O
five,O
regions,O
that,O
were,O
significantly,O
thinner,O
than,O
in,O
controls,O
",",O
two,O
in,O
the,O
left,O
hemisphere,O
(,O
viz,O
".,",O
insula,O
and,O
fusiform,O
gyrus,O
),O
and,O
three,O
in,O
the,O
right,O
(,O
viz,O
".,",O
frontomarginal,O
sulcus,O
",",O
inferior,O
parietal,O
gyrus,O
",",O
and,O
precuneus,O
).,O
By,O
contrast,O
",",O
HYPO,B-DS
demonstrated,O
eight,O
regions,O
(,O
five,O
left,O
",",O
three,O
right,O
),O
of,O
significant,O
thickening,O
compared,O
with,O
controls,O
(,O
Figure,O
1,O
",",O
blue,O
clusters,O
).,O
In,O
the,O
left,O
hemisphere,O
",",O
thickening,O
was,O
primarily,O
frontal,O
(,O
positive,O
y,O
-,O
value,O
in,O
coordinates,O
in,O
Table,O
2,O
),O
and,O
/,O
or,O
superior,O
(,O
high,O
positive,O
z,O
-,O
value,O
"),",O
whereas,O
in,O
the,O
right,O
",",O
it,O
was,O
posterior,O
(,O
negative,O
y,O
-,O
value,O
),O
or,O
inferior,O
(,O
negative,O
z,O
-,O
value,O
).,O
As,O
Table,O
2,O
indicates,O
",",O
right,O
-,O
hemisphere,O
thickening,O
was,O
confined,O
to,O
temporal,O
and,O
occipital,O
regions,O
",",O
namely,O
the,O
temporal,O
pole,O
",",O
inferior,O
temporal,O
gyrus,O
",",O
and,O
pericalcarine,O
sulcus,O
(,O
i,O
.,O
e,O
".,",O
occipital,O
pole,O
).,O
Cortical,O
regions,O
showing,O
differences,O
between,O
HYPO,B-DS
(,O
n,O
=,O
20,O
),O
and,O
control,O
(,O
n,O
=,O
24,O
),O
groupsa,O
.,O
Hemisphere,O
Region,O
Lobe,O
Brodmann,O
area,O
Coordinatesb,O
Size,O
(,O
mm3,O
),O
Number,O
of,O
vertices,O
p,O
-,O
value,O
Thinning,O
(,O
HYPO,B-DS
<,O
Control,O
),O
c,O
Left,O
Insula,O
Frontal,O
13,O
−,O
37,O
",",O
−,O
15,O
",",O
8,O
108,O
.,O
4,O
220,O
0,O
.,O
008,O
Fusiform,O
gyrus,O
Temporal,O
37,O
−,O
32,O
",",O
−,O
57,O
",",O
−,O
11,O
93,O
.,O
8,O
146,O
0,O
.,O
026,O
Right,O
Frontomarginal,O
sulcus,O
Frontal,O
10,O
25,O
",",O
48,O
",",O
−,O
4,O
90,O
.,O
8,O
137,O
0,O
.,O
029,O
Inferior,O
parietal,O
gyrus,O
Parietal,O
39,O
53,O
",",O
−,O
48,O
",",O
28,O
97,O
.,O
6,O
210,O
0,O
.,O
015,O
Precuneus,O
gyrus,O
Parietal,O
31,O
15,O
",",O
−,O
48,O
",",O
35,O
86,O
.,O
8,O
265,O
0,O
.,O
04,O
Thickening,O
(,O
HYPO,B-DS
>,O
Control,O
),O
d,O
Left,O
Rostral,O
middle,O
frontal,O
gyrus,O
Frontal,O
10,O
−,O
32,O
",",O
46,O
",",O
13,O
105,O
.,O
6,O
155,O
0,O
.,O
007,O
Superior,O
frontal,O
gyrus,O
Frontal,O
6,O
−,O
19,O
",",O
−,O
4,O
",",O
58,O
160,O
.,O
0,O
315,O
0,O
.,O
0002,O
Superior,O
frontal,O
gyrus,O
Frontal,O
6,O
−,O
10,O
",",O
−,O
7,O
",",O
56,O
109,O
.,O
8,O
244,O
0,O
.,O
005,O
Superior,O
parietal,O
gyrus,O
Parietal,O
7,O
−,O
11,O
",",O
−,O
64,O
",",O
53,O
88,O
.,O
9,O
178,O
0,O
.,O
028,O
Postcentral,O
sulcus,O
Parietal,O
2,O
−,O
54,O
",",O
−,O
18,O
",",O
31,O
90,O
.,O
2,O
187,O
0,O
.,O
025,O
Right,O
Temporal,O
pole,O
Temporal,O
38,O
41,O
",",O
11,O
",",O
−,O
32,O
138,O
.,O
9,O
203,O
0,O
.,O
0008,O
Inferior,O
temporal,O
gyrus,O
Temporal,O
37,O
48,O
",",O
−,O
36,O
",",O
−,O
17,O
115,O
.,O
7,O
232,O
0,O
.,O
003,O
Pericalcarine,O
sulcus,O
Occipital,O
17,O
19,O
",",O
−,O
69,O
",",O
13,O
91,O
.,O
6,O
162,O
0,O
.,O
03,O
aExcluded,O
from,O
the,O
original,O
HYPO,B-DS
group,O
were,O
two,O
children,O
with,O
unacceptable,O
scans,O
and,O
two,O
whose,O
mothers,O
’,O
TSH,B-GP
values,O
were,O
in,O
the,O
normal,O
range,O
throughout,O
pregnancy,O
.,O
bTalairach,O
coordinates,O
(,O
x,O
",",O
y,O
",",O
z,O
),O
provide,O
a,O
three,O
-,O
dimensional,O
atlas,O
system,O
that,O
serves,O
to,O
map,O
locations,O
of,O
specific,O
brain,O
structures,O
;,O
the,O
x,O
-,O
coordinate,O
indicates,O
location,O
in,O
the,O
right,O
(,O
positive,O
)/,O
left,O
(,O
negative,O
),O
direction,O
",",O
y,O
indicates,O
anterior,O
(,O
positive,O
)/,O
posterior,O
(,O
negative,O
),O
direction,O
",",O
and,O
z,O
signifies,O
superior,O
(,O
positive,O
)/,O
interior,O
(,O
negative,O
),O
direction,O
.,O
cShown,O
as,O
red,O
tones,O
in,O
Figure,O
1,O
to,O
denote,O
Control,O
>,O
HYPO,B-DS
",",O
as,O
per,O
heat,O
bars,O
.,O
dShown,O
as,O
blue,O
tones,O
in,O
Figure,O
1,O
to,O
denote,O
Control,O
<,O
HYPO,B-DS
.,O
Regions,O
showing,O
significant,O
cortical,O
thickness,O
differences,O
between,O
groups,O
.,O
(,O
A,O
),O
Left,O
lateral,O
-,O
view,O
spatial,O
map,O
showing,O
regions,O
of,O
significant,O
thinning,O
(,O
red,O
),O
and,O
thickening,O
(,O
blue,O
),O
in,O
HYPO,B-DS
.,O
(,O
B,O
),O
Right,O
lateral,O
-,O
view,O
spatial,O
map,O
showing,O
regions,O
of,O
significant,O
thinning,O
(,O
red,O
),O
and,O
thickening,O
(,O
blue,O
),O
in,O
HYPO,B-DS
.,O
(,O
C,O
),O
Left,O
inferior,O
-,O
view,O
spatial,O
map,O
showing,O
regions,O
of,O
significant,O
thinning,O
(,O
red,O
),O
in,O
HYPO,B-DS
.,O
(,O
D,O
),O
Right,O
inferior,O
-,O
view,O
spatial,O
map,O
showing,O
regions,O
of,O
significant,O
thickening,O
(,O
blue,O
),O
in,O
HYPO,B-DS
.,O
As,O
per,O
heat,O
bars,O
",",O
regions,O
depicted,O
in,O
red,O
signify,O
thinning,O
in,O
HYPO,B-DS
(,O
Control,O
>,O
HYPO,B-DS
),O
and,O
regions,O
shown,O
in,O
blue,O
signify,O
thickening,O
in,O
HYPO,B-DS
(,O
Control,O
<,O
HYPO,B-DS
).,O
Within,O
-,O
Group,O
Analyses,O
by,O
Severity,O
of,O
Maternal,B-DS
Hypothyroidism,I-DS
Two,O
series,O
of,O
analyses,O
were,O
conducted,O
",",O
one,O
examining,O
differences,O
between,O
Mild,O
and,O
Severe,O
subgroups,O
and,O
the,O
other,O
correlating,O
trimester,O
-,O
specific,O
maternal,O
TSH,B-GP
levels,O
with,O
CT,O
.,O
In,O
order,O
to,O
capture,O
a,O
broad,O
range,O
of,O
TSH,B-GP
values,O
and,O
increase,O
sample,O
size,O
",",O
we,O
included,O
all,O
HYPO,B-DS
cases,O
but,O
excluded,O
the,O
child,O
whose,O
mother,O
lacked,O
actual,O
TSH,B-GP
data,O
and,O
only,O
reported,O
having,O
been,O
severely,O
hypothyroid,O
for,O
a,O
final,O
sample,O
size,O
of,O
21,O
(,O
10,O
Mild,O
and,O
11,O
Severe,O
).,O
Table,O
3,O
and,O
Figure,O
2,O
provide,O
the,O
subgroup,O
-,O
comparison,O
results,O
.,O
The,O
Severe,O
subgroup,O
showed,O
thinning,O
in,O
two,O
left,O
-,O
and,O
one,O
right,O
-,O
hemisphere,O
regions,O
relative,O
to,O
Mild,O
(,O
Figure,O
2,O
red,O
clusters,O
as,O
per,O
heat,O
bar,O
),O
and,O
thickening,O
in,O
three,O
left,O
-,O
and,O
two,O
right,O
-,O
hemisphere,O
regions,O
(,O
Figure,O
2,O
blue,O
clusters,O
).,O
Thinning,O
in,O
the,O
Severe,O
subgroup,O
was,O
largely,O
frontal,O
or,O
inferior,O
(,O
e,O
.,O
g,O
".,",O
right,O
orbital,O
gyrus,O
",",O
left,O
fusiform,O
gyrus,O
"),",O
whereas,O
their,O
thickening,O
differed,O
by,O
hemisphere,O
.,O
Specifically,O
",",O
the,O
Severe,O
subgroup,O
showed,O
more,O
extensive,O
thickening,O
than,O
Mild,O
in,O
the,O
left,O
hemisphere,O
spanning,O
from,O
frontal,O
to,O
occipital,O
lobes,O
.,O
Right,O
-,O
hemisphere,O
thickening,O
was,O
confined,O
to,O
frontal,O
regions,O
.,O
Regions,O
showing,O
cortical,O
thickness,O
differences,O
between,O
Severe,O
(,O
n,O
=,O
11,O
),O
and,O
Mild,O
(,O
n,O
=,O
10,O
),O
a,O
HYPO,B-DS
subgroupsb,O
.,O
Hemisphere,O
Region,O
Lobe,O
Coordinatesc,O
Size,O
(,O
mm2,O
),O
Number,O
of,O
vertices,O
p,O
-,O
value,O
Thinning,O
(,O
Severe,O
<,O
Mild,O
),O
d,O
Left,O
Medial,O
orbitofrontal,O
sulcus,O
Frontal,O
−,O
7,O
",",O
25,O
",",O
−,O
11,O
108,O
.,O
88,O
223,O
0,O
.,O
0002,O
Fusiform,O
gyrus,O
Temporal,O
−,O
40,O
",",O
−,O
70,O
",",O
−,O
11,O
53,O
.,O
80,O
80,O
0,O
.,O
03,O
Right,O
Orbital,O
gyrus,O
Frontal,O
24,O
",",O
10,O
",",O
−,O
15,O
54,O
.,O
22,O
145,O
0,O
.,O
03,O
Thickening,O
(,O
Severe,O
>,O
Mild,O
),O
e,O
Left,O
Precentral,O
gyrus,O
Frontal,O
−,O
21,O
",",O
−,O
15,O
",",O
65,O
56,O
.,O
06,O
150,O
0,O
.,O
025,O
Precuneus,O
gyrus,O
Parietal,O
−,O
8,O
",",O
−,O
54,O
",",O
38,O
118,O
.,O
68,O
213,O
0,O
.,O
0002,O
Superior,O
occipital,O
sulcus,O
Occipital,O
−,O
22,O
",",O
−,O
74,O
",",O
34,O
74,O
.,O
79,O
110,O
0,O
.,O
002,O
Right,O
Precentral,O
gyrus,O
Frontal,O
44,O
",",O
2,O
",",O
37,O
51,O
.,O
08,O
81,O
0,O
.,O
05,O
Lateral,O
orbital,O
sulcus,O
Frontal,O
19,O
",",O
22,O
",",O
−,O
17,O
54,O
.,O
47,O
100,O
0,O
.,O
03,O
aSample,O
size,O
includes,O
the,O
two,O
children,O
whose,O
mothers,O
had,O
normal,O
-,O
range,O
TSH,B-GP
values,O
throughout,O
pregnancy,O
but,O
excludes,O
the,O
one,O
child,O
whose,O
mothers,O
’,O
specific,O
TH,O
value,O
information,O
was,O
missing,O
.,O
bDefined,O
as,O
TSH,B-GP
above,O
or,O
below,O
8,O
.,O
8,O
mU,O
/,O
l,O
in,O
first,O
or,O
second,O
trimesters,O
.,O
Ranges,O
:,O
Mild,O
=,O
0,O
.,O
1,O
–,O
8,O
.,O
4,O
;,O
Severe,O
=,O
8,O
.,O
8,O
–,O
38,O
.,O
5,O
mU,O
/,O
l,O
.,O
cSee,O
description,O
of,O
Talairach,O
coordinates,O
in,O
Table,O
2,O
.,O
dShown,O
as,O
red,O
tones,O
in,O
Figure,O
2,O
to,O
denote,O
Mild,O
>,O
Severe,O
.,O
eShown,O
as,O
blue,O
tones,O
in,O
Figure,O
2,O
to,O
denote,O
Mild,O
<,O
Severe,O
.,O
Regions,O
showing,O
significant,O
cortical,O
thickness,O
differences,O
between,O
Severe,O
and,O
Mild,O
HYPO,B-DS
subgroups,O
.,O
(,O
A,O
),O
Left,O
lateral,O
-,O
view,O
spatial,O
map,O
showing,O
two,O
regions,O
(,O
blue,O
arrows,O
),O
of,O
significant,O
thickening,O
(,O
blue,O
),O
in,O
Severe,O
subgroup,O
.,O
(,O
B,O
),O
Left,O
medial,O
-,O
view,O
spatial,O
map,O
showing,O
regions,O
of,O
significant,O
thickening,O
(,O
blue,O
),O
and,O
thinning,O
(,O
orange,O
/,O
red,O
),O
in,O
Severe,O
subgroup,O
;,O
(,O
C,O
),O
Right,O
lateral,O
-,O
view,O
spatial,O
map,O
showing,O
a,O
region,O
of,O
significant,O
thickening,O
(,O
blue,O
),O
in,O
Severe,O
subgroup,O
.,O
As,O
per,O
heat,O
bars,O
",",O
regions,O
depicted,O
in,O
red,O
signify,O
thinning,O
in,O
the,O
Severe,O
subgroup,O
(,O
i,O
.,O
e,O
".,",O
Mild,O
>,O
Severe,O
),O
and,O
regions,O
shown,O
in,O
blue,O
signify,O
thickening,O
(,O
i,O
.,O
e,O
".,",O
Mild,O
<,O
Severe,O
).,O
Note,O
:,O
significant,O
subgroup,O
differences,O
in,O
left,O
fusiform,O
gyrus,O
",",O
right,O
orbital,O
gyrus,O
",",O
and,O
right,O
lateral,O
orbital,O
sulcus,O
were,O
not,O
evident,O
in,O
current,O
views,O
.,O
To,O
assess,O
the,O
impact,O
of,O
degree,O
of,O
maternal,B-DS
hypothyroidism,I-DS
severity,O
on,O
cortical,O
morphology,O
",",O
we,O
conducted,O
regression,O
analyses,O
in,O
FreeSurfer,O
between,O
maternal,O
TSH,B-GP
levels,O
and,O
CT,O
.,O
Regressions,O
were,O
performed,O
on,O
the,O
23,O
HYPO,B-DS
with,O
TSH,B-GP
data,O
.,O
In,O
addition,O
",",O
to,O
check,O
if,O
the,O
child,O
whose,O
mother,O
consistently,O
had,O
very,O
elevated,O
TSH,B-GP
levels,O
was,O
driving,O
any,O
of,O
the,O
regression,O
effects,O
",",O
we,O
repeated,O
these,O
analyses,O
excluding,O
M12,O
.,O
Table,O
4,O
presents,O
the,O
regression,O
results,O
for,O
the,O
full,O
HYPO,B-DS
group,O
",",O
while,O
Table,O
5,O
contains,O
the,O
results,O
without,O
M12,O
.,O
In,O
Figure,O
3,O
are,O
shown,O
sample,O
findings,O
of,O
instances,O
of,O
thickening,O
(,O
positive,O
correlations,O
represented,O
as,O
red,O
clusters,O
in,O
spatial,O
maps,O
),O
and,O
thinning,O
(,O
negative,O
correlations,O
represented,O
as,O
blue,O
clusters,O
).,O
Regions,O
showing,O
significant,O
correlations,O
(,O
p,O
<,O
0,O
.,O
01,O
),O
between,O
maternal,O
TSH,B-GP
values,O
by,O
trimester,O
and,O
vertex,O
-,O
based,O
cortical,O
thickness,O
results,O
for,O
entire,O
HYPO,B-DS
group,O
.,O
Region,O
Lobe,O
Effect,O
Coordinates,O
Number,O
of,O
vertices,O
Cluster,O
-,O
wise,O
p,O
-,O
value,O
Trimester,O
1,O
L,O
Precentral,O
sulcus,O
Frontal,O
Thickening,O
−,O
15,O
",",O
−,O
13,O
",",O
60,O
91,O
0,O
.,O
004,O
R,O
Supramarginal,O
gyrus,O
Parietal,O
Thickening,O
46,O
",",O
−,O
26,O
",",O
24,O
93,O
0,O
.,O
005,O
R,O
Supramarginal,O
gyrus,O
Parietal,O
Thickening,O
53,O
",",O
−,O
39,O
",",O
35,O
68,O
0,O
.,O
006,O
R,O
Cuneus,O
Occipital,O
Thickening,O
7,O
",",O
−,O
84,O
",",O
20,O
43,O
0,O
.,O
005,O
Trimester,O
2,O
L,O
Precentral,O
gyrus,O
Frontal,O
Thickening,O
−,O
33,O
",",O
−,O
16,O
",",O
62,O
111,O
0,O
.,O
0002,O
R,O
Postcentral,O
sulcus,O
Parietal,O
Thickening,O
28,O
",",O
−,O
39,O
",",O
51,O
131,O
0,O
.,O
0002,O
R,O
Cuneus,O
Occipital,O
Thickening,O
8,O
.,O
5,O
",",O
−,O
84,O
",",O
19,O
64,O
0,O
.,O
0002,O
Trimester,O
3,O
L,O
Pericallosal,O
sulcus,O
Temporal,O
Thinning,O
−,O
6,O
",",O
11,O
",",O
24,O
99,O
0,O
.,O
008,O
R,O
Inferior,O
angular,O
gyrus,O
Parietal,O
Thinning,O
44,O
",",O
−,O
65,O
",",O
30,O
58,O
0,O
.,O
007,O
L,O
Precentral,O
sulcus,O
Frontal,O
Thickening,O
−,O
15,O
",",O
12,O
",",O
59,O
91,O
0,O
.,O
003,O
R,O
Postcentral,O
sulcus,O
Parietal,O
Thickening,O
28,O
",",O
−,O
39,O
",",O
51,O
.,O
5,O
135,O
0,O
.,O
002,O
L,O
Inferior,O
occipital,O
gyrus,O
/,O
sulcus,O
Occipital,O
Thickening,O
−,O
31,O
",",O
−,O
86,O
",",O
−,O
1,O
42,O
0,O
.,O
008,O
R,O
Cuneus,O
Occipital,O
Thickening,O
12,O
",",O
−,O
86,O
",",O
18,O
53,O
0,O
.,O
008,O
Values,O
in,O
bold,O
italics,O
indicate,O
relationship,O
maintained,O
through,O
three,O
trimesters,O
and,O
in,O
italics,O
only,O
",",O
relationship,O
maintained,O
in,O
two,O
consecutive,O
trimesters,O
.,O
Regions,O
showing,O
significant,O
correlations,O
(,O
p,O
<,O
0,O
.,O
01,O
),O
between,O
maternal,O
TSH,B-GP
values,O
and,O
vertex,O
-,O
based,O
cortical,O
thickness,O
results,O
with,O
primary,O
outlier,O
removed,O
.,O
Region,O
Lobe,O
Effect,O
Coordinates,O
Number,O
of,O
vertices,O
Cluster,O
-,O
wise,O
p,O
-,O
value,O
Trimester,O
1,O
R,O
Inferior,O
supramarginal,O
gyrus,O
Parietal,O
Thickening,O
53,O
",",O
−,O
40,O
",",O
35,O
76,O
0,O
.,O
0018,O
Trimester,O
2,O
R,O
Middle,O
temporal,O
gyrus,O
Temporal,O
Thinning,O
60,O
",",O
−,O
49,O
",",O
1,O
90,O
0,O
.,O
0002,O
L,O
Inferior,O
angular,O
gyrus,O
Parietal,O
Thinning,O
−,O
45,O
",",O
−,O
68,O
",",O
27,O
58,O
0,O
.,O
004,O
L,O
Precuneus,O
gyrus,O
Parietal,O
Thinning,O
−,O
8,O
",",O
−,O
69,O
",",O
43,O
67,O
0,O
.,O
007,O
L,O
Inferior,O
frontal,O
gyrus,O
Frontal,O
Thickening,O
−,O
54,O
",",O
20,O
",",O
14,O
63,O
0,O
.,O
009,O
L,O
Pericallosal,O
sulcus,O
Temporal,O
Thickening,O
−,O
36,O
",",O
−,O
27,O
",",O
9,O
92,O
0,O
.,O
006,O
L,O
Postcentral,O
sulcus,O
Parietal,O
Thickening,O
−,O
33,O
",",O
−,O
33,O
",",O
52,O
78,O
0,O
.,O
003,O
Trimester,O
3,O
L,O
Insula,O
circular,O
sulcus,O
Frontal,O
Thickening,O
−,O
27,O
",",O
18,O
",",O
−,O
16,O
731,O
0,O
.,O
008,O
Values,O
shown,O
in,O
italics,O
are,O
also,O
seen,O
in,O
Table,O
4,O
",",O
signifying,O
effect,O
remains,O
with,O
outlier,O
removed,O
.,O
Sample,O
regions,O
showing,O
significant,O
correlations,O
between,O
CT,O
and,O
second,O
-,O
and,O
third,O
-,O
trimester,O
maternal,O
TSH,B-GP
.,O
(,O
A,O
),O
Right,O
medial,O
-,O
view,O
spatial,O
map,O
showing,O
increased,O
thickening,O
(,O
red,O
),O
in,O
right,O
cuneus,O
as,O
maternal,O
second,O
-,O
trimester,O
TSH,B-GP
increased,O
.,O
(,O
B,O
),O
Correlation,O
plot,O
between,O
individual,O
CT,O
values,O
and,O
second,O
-,O
trimester,O
maternal,O
TSH,B-GP
levels,O
in,O
right,O
cuneus,O
.,O
(,O
C,O
),O
Right,O
lateral,O
-,O
view,O
spatial,O
map,O
showing,O
increased,O
thinning,O
(,O
blue,O
),O
in,O
right,O
inferior,O
parietal,O
angular,O
gyrus,O
(,O
circled,O
),O
as,O
third,O
-,O
trimester,O
maternal,O
TSH,B-GP
increased,O
.,O
(,O
D,O
),O
Correlation,O
plot,O
between,O
individual,O
CT,O
values,O
and,O
third,O
-,O
trimester,O
maternal,O
TSH,B-GP
levels,O
in,O
right,O
inferior,O
parietal,O
angular,O
gyrus,O
.,O
Note,O
",",O
these,O
analyses,O
included,O
M12,O
outlier,O
;,O
however,O
",",O
when,O
M12,O
was,O
not,O
included,O
in,O
FreeSurfer,O
analyses,O
",",O
thinning,O
in,O
right,O
inferior,O
parietal,O
angular,O
gyrus,O
still,O
remained,O
(,O
p,O
=,O
0,O
.,O
01,O
).,O
For,O
the,O
first,O
set,O
of,O
regressions,O
with,O
M12,O
included,O
",",O
Table,O
4,O
indicates,O
mainly,O
positive,O
relationships,O
signifying,O
more,O
thickening,O
than,O
thinning,O
as,O
maternal,O
TSH,B-GP
levels,O
increased,O
.,O
First,O
-,O
and,O
second,O
-,O
trimester,O
TSH,B-GP
levels,O
were,O
only,O
associated,O
with,O
thickening,O
",",O
whereas,O
third,O
-,O
trimester,O
maternal,O
TSH,B-GP
levels,O
were,O
associated,O
with,O
both,O
thinning,O
and,O
thickening,O
.,O
The,O
thinning,O
associated,O
with,O
third,O
-,O
trimester,O
TSH,B-GP
was,O
seen,O
in,O
the,O
",",O
left,O
pericallosal,O
sulcus,O
and,O
right,O
inferior,O
angular,O
gyrus,O
.,O
Most,O
regions,O
that,O
became,O
thicker,O
as,O
maternal,O
TSH,B-GP
levels,O
increased,O
were,O
located,O
frontally,O
in,O
the,O
left,O
hemisphere,O
and,O
more,O
posteriorly,O
in,O
the,O
right,O
.,O
Two,O
of,O
the,O
regions,O
showing,O
thickening,O
",",O
namely,O
left,O
precentral,O
sulcus,O
/,O
gyrus,O
and,O
right,O
cuneus,O
",",O
showed,O
significant,O
correlations,O
with,O
TSH,B-GP
levels,O
from,O
all,O
three,O
trimesters,O
while,O
one,O
region,O
",",O
right,O
postcentral,O
sulcus,O
",",O
showed,O
positive,O
correlations,O
with,O
second,O
-,O
and,O
third,O
-,O
trimester,O
TSH,B-GP
levels,O
.,O
Figure,O
3,O
provides,O
sample,O
findings,O
for,O
both,O
effects,O
.,O
The,O
upper,O
panel,O
shows,O
thickening,O
in,O
the,O
right,O
cuneus,O
as,O
maternal,O
second,O
-,O
trimester,O
TSH,B-GP
levels,O
increased,O
while,O
the,O
lower,O
panel,O
shows,O
thinning,O
of,O
the,O
right,O
inferior,O
parietal,O
angular,O
gyrus,O
as,O
maternal,O
third,O
-,O
trimester,O
TSH,B-GP
levels,O
increased,O
.,O
When,O
M12,O
’,O
s,O
data,O
were,O
removed,O
from,O
the,O
regression,O
analysis,O
",",O
only,O
two,O
of,O
the,O
regions,O
remained,O
",",O
namely,O
right,O
inferior,O
supramarginal,O
gyrus,O
with,O
first,O
-,O
trimester,O
TSH,B-GP
levels,O
and,O
left,O
pericallosal,O
sulcus,O
with,O
second,O
-,O
trimester,O
(,O
see,O
Table,O
5,O
).,O
Figure,O
4,O
depicts,O
the,O
findings,O
between,O
first,O
-,O
trimester,O
maternal,O
TSH,B-GP
and,O
right,O
supramarginal,O
gyrus,O
CT,O
including,O
(,O
upper,O
panel,O
),O
and,O
excluding,O
(,O
lower,O
panel,O
),O
the,O
data,O
from,O
M12,O
.,O
The,O
similar,O
patterns,O
across,O
both,O
sets,O
of,O
figures,O
indicate,O
the,O
effect,O
was,O
not,O
driven,O
by,O
this,O
outlier,O
",",O
signifying,O
that,O
even,O
mildly,O
elevated,O
maternal,O
TSH,B-GP
can,O
disrupt,O
cortical,O
development,O
in,O
this,O
region,O
.,O
Sample,O
regions,O
showing,O
significant,O
correlations,O
between,O
CT,O
and,O
first,O
-,O
trimester,O
maternal,O
TSH,B-GP
.,O
(,O
A,O
),O
Right,O
lateral,O
-,O
view,O
spatial,O
map,O
showing,O
two,O
nearby,O
regions,O
",",O
indicating,O
significant,O
(,O
p,O
<,O
0,O
.,O
001,O
),O
thickening,O
(,O
red,O
),O
as,O
first,O
-,O
trimester,O
maternal,O
TSH,B-GP
levels,O
increased,O
.,O
(,O
B,O
),O
Correlation,O
plots,O
between,O
individual,O
CT,O
values,O
and,O
first,O
-,O
trimester,O
maternal,O
TSH,B-GP
levels,O
in,O
two,O
regions,O
of,O
right,O
supramarginal,O
gyrus,O
.,O
(,O
C,O
),O
Right,O
lateral,O
-,O
view,O
spatial,O
map,O
showing,O
significant,O
thickening,O
(,O
red,O
),O
as,O
first,O
-,O
trimester,O
maternal,O
TSH,B-GP
levels,O
increased,O
with,O
M12,O
removed,O
from,O
FreeSurfer,O
analysis,O
.,O
(,O
D,O
),O
Correlation,O
plot,O
between,O
individual,O
CT,O
values,O
and,O
first,O
-,O
trimester,O
maternal,O
TSH,B-GP
levels,O
in,O
right,O
supramarginal,O
gyrus,O
with,O
M12,O
removed,O
from,O
FreeSurfer,O
analysis,O
.,O
Note,O
:,O
correlations,O
were,O
retained,O
when,O
both,O
outlying,O
cases,O
(,O
M12,O
and,O
M41,O
),O
were,O
removed,O
from,O
SPSS,O
analyses,O
shown,O
in,O
B,O
(,O
p,O
=,O
0,O
.,O
006,O
and,O
p,O
=,O
0,O
.,O
01,O
),O
and,O
when,O
M41,O
was,O
removed,O
from,O
analysis,O
shown,O
in,O
D,O
(,O
p,O
=,O
0,O
.,O
002,O
).,O
A,O
supplementary,O
series,O
of,O
simple,O
correlations,O
was,O
conducted,O
between,O
trimester,O
-,O
specific,O
maternal,O
TSH,B-GP
values,O
and,O
individually,O
extracted,O
CT,O
values,O
at,O
the,O
peak,O
vertex,O
for,O
each,O
of,O
the,O
significant,O
clusters,O
listed,O
in,O
Table,O
4,O
;,O
values,O
were,O
derived,O
from,O
the,O
FreeSurfer,O
analysis,O
conducted,O
with,O
all,O
HYPO,B-DS
participants,O
included,O
.,O
Table,O
6,O
shows,O
results,O
for,O
three,O
series,O
of,O
correlations,O
performed,O
in,O
SPSS,O
(,O
version,O
23,O
"),",O
one,O
using,O
the,O
entire,O
HYPO,B-DS
group,O
",",O
one,O
eliminating,O
M12,O
from,O
the,O
analyses,O
",",O
and,O
a,O
third,O
eliminating,O
both,O
M12,O
and,O
another,O
less,O
severe,O
outlier,O
(,O
M41,O
).,O
Notably,O
",",O
many,O
but,O
not,O
all,O
correlations,O
remained,O
when,O
the,O
outliers,O
were,O
removed,O
",",O
particularly,O
those,O
involving,O
analyses,O
with,O
first,O
-,O
and,O
second,O
-,O
trimester,O
TSH,B-GP
levels,O
.,O
Coefficients,O
for,O
correlation,O
analyses,O
between,O
maternal,O
TSH,B-GP
and,O
individually,O
extracted,O
CT,O
values,O
performed,O
with,O
and,O
without,O
outliers,O
.,O
Region,O
Lobe,O
Coordinates,O
Total,O
Sample,O
Without,O
M12,O
Without,O
M12,O
and,O
M41,O
First,O
-,O
trimester,O
tsh,B-GP
Thickening,O
L,O
Precentral,O
sulcus,O
Frontal,O
−,O
15,O
",",O
−,O
13,O
",",O
60,O
0,O
.,O
725,O
***,O
0,O
.,O
468,O
*,O
0,O
.,O
255,O
R,O
Supramarginal,O
gyrus,O
Parietal,O
45,O
",",O
−,O
26,O
",",O
24,O
0,O
.,O
679,O
***,O
0,O
.,O
699,O
***,O
0,O
.,O
553,O
**,O
R,O
Supramarginal,O
gyrus,O
Parietal,O
53,O
",",O
−,O
39,O
",",O
35,O
0,O
.,O
732,O
***,O
0,O
.,O
687,O
***,O
0,O
.,O
595,O
**,O
R,O
Cuneus,O
Occipital,O
7,O
",",O
−,O
84,O
",",O
20,O
0,O
.,O
708,O
**,O
0,O
.,O
737,O
**,O
0,O
.,O
561,O
*,O
Second,O
-,O
trimester,O
tsh,B-GP
Thickening,O
L,O
Precentral,O
gyrus,O
Frontal,O
−,O
33,O
",",O
−,O
16,O
",",O
62,O
0,O
.,O
764,O
***,O
0,O
.,O
453,O
*,O
0,O
.,O
462,O
*,O
R,O
Postcentral,O
sulcus,O
Parietal,O
28,O
",",O
−,O
39,O
",",O
57,O
0,O
.,O
972,O
***,O
0,O
.,O
403,O
0,O
.,O
406,O
R,O
Cuneus,O
Occipital,O
8,O
.,O
5,O
",",O
−,O
84,O
",",O
19,O
0,O
.,O
793,O
***,O
0,O
.,O
611,O
**,O
0,O
.,O
614,O
**,O
Third,O
-,O
trimester,O
tsh,B-GP
Thinning,O
L,O
Pericallosal,O
sulcus,O
Temporal,O
−,O
6,O
",",O
11,O
",",O
24,O
−,O
0,O
.,O
700,O
***,O
−,O
0,O
.,O
366,O
−,O
0,O
.,O
395,O
R,O
Inferior,O
angular,O
gyrus,O
Parietal,O
44,O
",",O
−,O
65,O
",",O
30,O
−,O
0,O
.,O
704,O
***,O
−,O
0,O
.,O
548,O
**,O
−,O
0,O
.,O
496,O
*,O
Thickening,O
L,O
Precentral,O
sulcus,O
Frontal,O
−,O
15,O
",",O
12,O
",",O
59,O
0,O
.,O
738,O
***,O
0,O
.,O
405,O
0,O
.,O
469,O
*,O
R,O
Postcentral,O
sulcus,O
Parietal,O
28,O
",",O
−,O
39,O
",",O
52,O
0,O
.,O
815,O
***,O
0,O
.,O
074,O
0,O
.,O
045,O
L,O
Inferior,O
occipital,O
gyrus,O
/,O
sulcus,O
Occipital,O
−,O
31,O
",",O
−,O
86,O
",",O
−,O
1,O
0,O
.,O
557,O
**,O
0,O
.,O
175,O
0,O
.,O
119,O
R,O
Cuneus,O
Occipital,O
12,O
",",O
−,O
86,O
",",O
18,O
0,O
.,O
745,O
***,O
0,O
.,O
273,O
0,O
.,O
253,O
All,O
results,O
obtained,O
from,O
FreeSurfer,O
analyses,O
performed,O
on,O
entire,O
sample,O
",",O
as,O
shown,O
in,O
Table,O
4,O
;,O
***,O
p,O
<,O
0,O
.,O
001,O
;,O
**,O
p,O
<,O
0,O
.,O
01,O
;,O
*,O
p,O
<,O
0,O
.,O
05,O
.,O
Discussion,O
Current,O
findings,O
provide,O
preliminary,O
support,O
for,O
our,O
hypothesis,O
that,O
children,O
exposed,O
gestationally,O
to,O
insufficient,O
TH,O
due,O
to,O
mother,O
’,O
s,O
hypothyroidism,B-DS
will,O
show,O
atypical,O
cortical,O
development,O
reflecting,O
the,O
severity,O
and,O
timing,O
of,O
her,O
condition,O
.,O
We,O
found,O
that,O
when,O
they,O
were,O
compared,O
with,O
children,O
born,O
to,O
normothyroid,O
women,B-OG
",",O
the,O
offspring,O
of,O
women,B-OG
with,O
HYPO,B-DS
showed,O
a,O
number,O
of,O
cortical,O
regions,O
that,O
were,O
thinner,O
or,O
thicker,O
than,O
in,O
controls,O
.,O
Thinning,O
was,O
bilateral,O
and,O
in,O
frontal,O
",",O
parietal,O
",",O
and,O
temporal,O
regions,O
",",O
whereas,O
thickening,O
differed,O
by,O
hemisphere,O
and,O
tended,O
to,O
be,O
superior,O
in,O
the,O
left,O
hemisphere,O
and,O
inferior,O
or,O
posterior,O
(,O
e,O
.,O
g,O
".,",O
temporal,O
and,O
occipital,O
poles,O
),O
in,O
the,O
right,O
.,O
However,O
",",O
only,O
one,O
of,O
the,O
regions,O
differentiating,O
groups,O
was,O
associated,O
with,O
severity,O
of,O
hypothyroidism,B-DS
in,O
the,O
mother,O
(,O
based,O
on,O
subgroup,O
analysis,O
"),",O
namely,O
left,O
fusiform,O
gyrus,O
.,O
Correlations,O
between,O
mothers,O
’,O
trimester,O
-,O
specific,O
TSH,B-GP
levels,O
and,O
CT,O
values,O
revealed,O
a,O
greater,O
number,O
of,O
positive,O
than,O
negative,O
effects,O
",",O
signifying,O
greater,O
thickening,O
from,O
more,O
severe,O
maternal,B-DS
hypothyroidism,I-DS
.,O
While,O
some,O
effects,O
were,O
driven,O
by,O
one,O
or,O
two,O
outliers,O
born,O
to,O
women,B-OG
with,O
the,O
most,O
extreme,O
HYPO,B-DS
",",O
a,O
number,O
of,O
other,O
effects,O
remained,O
when,O
these,O
children,O
were,O
removed,O
from,O
the,O
analyses,O
",",O
suggesting,O
that,O
even,O
a,O
mild,O
degree,O
of,O
maternal,B-DS
hypothyroidism,I-DS
can,O
disturb,O
offspring,O
cortical,O
development,O
.,O
Cortical,O
thinning,O
in,O
HYPO,B-DS
was,O
observed,O
in,O
left,O
fusiform,O
gyrus,O
and,O
insula,O
and,O
in,O
right,O
frontomarginal,O
sulcus,O
",",O
inferior,O
parietal,O
gyrus,O
",",O
and,O
precuneus,O
.,O
Stratification,O
by,O
severity,O
of,O
maternal,B-DS
hypothyroidism,I-DS
(,O
in,O
first,O
half,O
of,O
pregnancy,O
),O
revealed,O
that,O
",",O
relative,O
to,O
the,O
Mild,O
subgroup,O
",",O
the,O
Severe,O
subgroup,O
manifested,O
thinning,O
in,O
left,O
fusiform,O
gyrus,O
and,O
also,O
left,O
orbitofrontal,O
sulcus,O
and,O
right,O
orbital,O
gyrus,O
.,O
Consistent,O
findings,O
from,O
between,O
-,O
and,O
within,O
-,O
group,O
analyses,O
in,O
the,O
left,O
fusiform,O
gyrus,O
suggest,O
that,O
this,O
region,O
is,O
quite,O
sensitive,O
to,O
severe,O
maternal,B-DS
hypothyroidism,I-DS
",",O
as,O
the,O
Severe,O
subgroup,O
was,O
likely,O
driving,O
the,O
difference,O
with,O
controls,O
.,O
However,O
",",O
the,O
other,O
regions,O
differentiating,O
HYPO,B-DS
and,O
control,O
groups,O
(,O
e,O
.,O
g,O
".,",O
left,O
insula,O
),O
not,O
seen,O
in,O
subgroup,O
comparisons,O
may,O
mean,O
either,O
no,O
effect,O
of,O
hypothyroidism,B-DS
severity,O
(,O
based,O
on,O
early,O
-,O
pregnancy,O
maternal,O
TSH,B-GP
levels,O
),O
or,O
our,O
sample,O
size,O
was,O
too,O
small,O
for,O
the,O
subgroup,O
analysis,O
to,O
show,O
significant,O
differences,O
.,O
By,O
contrast,O
",",O
the,O
Severe,O
subgroup,O
showed,O
thinning,O
relative,O
to,O
Mild,O
in,O
inferior,O
frontal,O
areas,O
(,O
viz,O
".,",O
left,O
medial,O
orbitofrontal,O
sulcus,O
and,O
right,O
orbital,O
gyrus,O
"),",O
signifying,O
that,O
since,O
stratification,O
was,O
based,O
on,O
mothers,O
’,O
TSH,B-GP
levels,O
from,O
the,O
first,O
half,O
of,O
pregnancy,O
",",O
some,O
anterior,O
parts,O
of,O
the,O
cortex,O
had,O
a,O
very,O
early,O
need,O
for,O
TH,O
.,O
The,O
thinning,O
observed,O
across,O
analyses,O
suggests,O
that,O
both,O
early,O
and,O
later,O
aspects,O
of,O
corticogenesis,O
may,O
be,O
disrupted,O
by,O
maternal,B-DS
hypothyroidism,I-DS
(,O
32,O
).,O
Explanations,O
for,O
thinning,O
based,O
on,O
rodent,B-OG
evidence,O
suggest,O
that,O
several,O
key,O
developmental,O
processes,O
may,O
be,O
disturbed,O
by,O
TH,B-DS
insufficiency,I-DS
from,O
hypothyroidism,B-DS
early,O
in,O
gestation,O
.,O
For,O
example,O
",",O
symmetric,O
division,O
may,O
have,O
failed,O
to,O
stop,O
leading,O
to,O
an,O
accumulation,O
of,O
neurons,O
in,O
the,O
ventricular,O
zone,O
with,O
fewer,O
ultimately,O
reaching,O
the,O
cortical,O
mantle,O
(,O
25,O
).,O
Alternatively,O
",",O
some,O
early,O
effects,O
may,O
reflect,O
neuronal,O
migration,O
abnormalities,O
due,O
to,O
increased,O
tangential,O
and,O
less,O
radial,O
migration,O
(,O
21,O
",",O
22,O
),O
with,O
the,O
result,O
that,O
fewer,O
neurons,O
ultimately,O
reach,O
certain,O
cortical,O
regions,O
and,O
others,O
have,O
more,O
neurons,O
(,O
see,O
below,O
).,O
Also,O
",",O
disturbances,O
in,O
the,O
antioxidant,O
defense,O
system,O
can,O
lead,O
to,O
reduced,O
survival,O
of,O
proliferating,O
neurons,O
during,O
early,O
gestation,O
",",O
as,O
also,O
seen,O
in,O
a,O
murine,O
model,O
of,O
maternal,B-DS
hypothyroidism,I-DS
(,O
55,O
).,O
In,O
rodents,B-OG
",",O
maternal,O
TH,B-DS
insufficiency,I-DS
later,O
in,O
gestation,O
also,O
affects,O
more,O
advanced,O
cortical,O
processes,O
",",O
such,O
as,O
dendritic,O
arborization,O
",",O
which,O
is,O
reduced,O
(,O
21,O
"),",O
and,O
apoptosis,O
",",O
which,O
is,O
increased,O
(,O
25,O
).,O
Overall,O
",",O
these,O
findings,O
suggest,O
that,O
",",O
in,O
humans,B-OG
",",O
multiple,O
developmental,O
processes,O
are,O
likely,O
perturbed,O
by,O
maternal,B-DS
hypothyroidism,I-DS
",",O
while,O
specific,O
effects,O
reflect,O
the,O
exact,O
timing,O
of,O
mother,O
’,O
s,O
TH,B-DS
deficiency,I-DS
in,O
relation,O
to,O
ongoing,O
non,O
-,O
uniform,O
brain,O
development,O
.,O
Accordingly,O
",",O
all,O
of,O
these,O
effects,O
can,O
give,O
the,O
appearance,O
in,O
FreeSurfer,O
of,O
a,O
thinner,O
cortex,O
in,O
specific,O
regions,O
.,O
Children,O
born,O
to,O
hypothyroid,O
mothers,O
also,O
showed,O
extensive,O
thickening,O
across,O
the,O
entire,O
cortical,O
mantle,O
;,O
thickening,O
was,O
more,O
prevalent,O
than,O
thinning,O
.,O
Within,O
the,O
left,O
hemisphere,O
",",O
effects,O
were,O
predominantly,O
in,O
superior,O
and,O
anterior,O
regions,O
and,O
in,O
the,O
right,O
hemisphere,O
",",O
within,O
inferior,O
and,O
posterior,O
regions,O
(,O
Table,O
2,O
).,O
Within,O
-,O
group,O
analyses,O
revealed,O
that,O
the,O
Severe,O
subgroup,O
had,O
thickening,O
across,O
the,O
left,O
cortex,O
relative,O
to,O
Mild,O
but,O
this,O
occurred,O
only,O
frontally,O
in,O
the,O
right,O
hemisphere,O
(,O
Table,O
3,O
).,O
By,O
contrast,O
",",O
regression,O
results,O
showed,O
that,O
maternal,O
TSH,B-GP
levels,O
were,O
primarily,O
correlated,O
with,O
CT,O
in,O
left,O
frontal,O
regions,O
",",O
whereas,O
effects,O
were,O
more,O
widespread,O
in,O
the,O
right,O
hemisphere,O
.,O
Although,O
there,O
is,O
no,O
ready,O
explanation,O
for,O
these,O
contradictory,O
findings,O
between,O
the,O
two,O
sets,O
of,O
analyses,O
",",O
these,O
findings,O
may,O
suggest,O
inter,O
-,O
hemispheric,O
differences,O
in,O
timing,O
of,O
need,O
for,O
TH,O
.,O
Since,O
effects,O
were,O
primarily,O
posterior,O
in,O
the,O
right,O
hemisphere,O
and,O
since,O
developmental,O
progression,O
seems,O
to,O
be,O
in,O
a,O
posterior,O
-,O
to,O
-,O
anterior,O
direction,O
",",O
this,O
suggests,O
the,O
right,O
hemisphere,O
may,O
lag,O
behind,O
the,O
left,O
both,O
developmentally,O
and,O
in,O
vulnerability,O
to,O
hypothyroidism,B-DS
.,O
Separate,O
regressions,O
with,O
and,O
without,O
outliers,O
also,O
suggest,O
different,O
specific,O
effects,O
depending,O
on,O
whether,O
hypothyroidism,B-DS
is,O
severe,O
or,O
not,O
.,O
With,O
outliers,O
removed,O
",",O
the,O
observed,O
thickening,O
in,O
regions,O
such,O
as,O
the,O
right,O
supramarginal,O
gyrus,O
and,O
precentral,O
gyrus,O
suggests,O
that,O
mild,O
elevations,O
in,O
TSH,B-GP
among,O
treated,O
hypothyroid,O
women,B-OG
can,O
have,O
a,O
significant,O
and,O
sustained,O
impact,O
on,O
the,O
developing,O
fetal,O
brain,O
.,O
Explanations,O
for,O
cortical,O
thickening,O
based,O
on,O
rodent,B-OG
evidence,O
may,O
also,O
reflect,O
different,O
aspects,O
of,O
cortical,O
migration,O
.,O
First,O
",",O
due,O
to,O
diminishment,O
of,O
the,O
glial,O
scaffold,O
needed,O
for,O
radial,O
migration,O
toward,O
the,O
cortical,O
plate,O
(,O
22,O
"),",O
some,O
neurons,O
may,O
have,O
remained,O
in,O
lower,O
layers,O
or,O
even,O
WM,O
",",O
thus,O
giving,O
the,O
appearance,O
of,O
a,O
longer,O
–,O
and,O
hence,O
thicker,O
–,O
human,B-OG
cortex,O
.,O
Alternatively,O
",",O
the,O
increased,O
tangential,O
and,O
decreased,O
radial,O
migration,O
associated,O
with,O
TH,B-DS
insufficiency,I-DS
may,O
mean,O
that,O
some,O
regions,O
had,O
augmented,O
number,O
of,O
neurons,O
as,O
opposed,O
to,O
others,O
that,O
had,O
fewer,O
neurons,O
(,O
see,O
above,O
discussion,O
on,O
thinning,O
and,O
migration,O
).,O
Second,O
",",O
it,O
is,O
also,O
possible,O
that,O
the,O
observed,O
cortical,O
thickening,O
reflected,O
alterations,O
in,O
the,O
boundaries,O
between,O
GM,O
and,O
WM,O
",",O
given,O
that,O
unmyelinated,O
peripheral,O
axonal,O
fibers,O
look,O
similar,O
to,O
GM,O
(,O
56,O
).,O
Finally,O
",",O
since,O
maternal,B-DS
hypothyroidism,I-DS
is,O
known,O
to,O
disrupt,O
the,O
balance,O
between,O
astrocytes,O
and,O
oligodendrocytes,O
(,O
i,O
.,O
e,O
".,",O
fewer,O
oligodendrocytes,O
",",O
more,O
astrocytes,O
),O
(,O
57,O
"),",O
this,O
may,O
mean,O
that,O
the,O
number,O
of,O
exposed,O
unmyelinated,O
axons,O
is,O
increased,O
leading,O
to,O
more,O
GM,O
than,O
WM,O
",",O
which,O
in,O
FreeSurfer,O
can,O
also,O
appear,O
as,O
increased,O
thickening,O
of,O
the,O
cortex,O
.,O
Lateralized,O
differences,O
in,O
thinning,O
and,O
thickening,O
may,O
reflect,O
timing,O
of,O
need,O
for,O
TH,O
given,O
the,O
unique,O
cell,O
compositions,O
and,O
different,O
rates,O
of,O
development,O
of,O
the,O
right,O
and,O
left,O
hemispheres,O
(,O
58,O
",",O
59,O
).,O
These,O
laterality,O
effects,O
are,O
to,O
our,O
knowledge,O
unique,O
and,O
not,O
similarly,O
reported,O
in,O
the,O
rodent,B-OG
literature,O
.,O
Additionally,O
",",O
since,O
different,O
cortical,O
regions,O
vary,O
as,O
to,O
phases,O
of,O
cell,O
development,O
and,O
positioning,O
when,O
cell,O
cycle,O
is,O
completed,O
and,O
apoptosis,O
occurs,O
(,O
25,O
"),",O
this,O
may,O
explain,O
our,O
unexpected,O
findings,O
also,O
of,O
both,O
thinning,O
and,O
thickening,O
in,O
nearby,O
regions,O
(,O
e,O
.,O
g,O
".,",O
right,O
orbital,O
gyrus,O
and,O
right,O
lateral,O
orbital,O
gyrus,O
",",O
see,O
Table,O
3,O
).,O
It,O
is,O
relevant,O
to,O
note,O
we,O
recently,O
reported,O
that,O
children,O
with,O
CH,B-DS
",",O
who,O
underwent,O
a,O
brief,O
circumscribed,O
period,O
of,O
TH,B-DS
insufficiency,I-DS
that,O
occurred,O
somewhat,O
later,O
and,O
extended,O
longer,O
than,O
in,O
HYPO,B-DS
",",O
also,O
showed,O
that,O
cortical,O
thinning,O
and,O
thickening,O
relative,O
to,O
controls,O
and,O
effects,O
reflected,O
the,O
severity,O
of,O
their,O
hypothyroidism,B-DS
(,O
45,O
).,O
Both,O
CH,B-DS
and,O
HYPO,B-DS
conditions,O
showed,O
thinning,O
of,O
the,O
right,O
precuneus,O
and,O
thickening,O
in,O
right,O
occipital,O
regions,O
",",O
while,O
left,O
precentral,O
gyrus,O
and,O
right,O
cuneus,O
and,O
postcentral,O
gyrus,O
thickening,O
were,O
correlated,O
with,O
late,O
gestational,O
or,O
perinatal,O
TH,O
elevations,O
in,O
both,O
populations,O
.,O
However,O
",",O
CH,B-DS
showed,O
more,O
instances,O
of,O
thinning,O
than,O
thickening,O
compared,O
with,O
HYPO,B-DS
",",O
particularly,O
in,O
the,O
frontal,O
lobes,O
(,O
as,O
well,O
as,O
temporal,O
pole,O
and,O
inferior,O
temporal,O
gyrus,O
),O
and,O
on,O
regression,O
analyses,O
showed,O
more,O
negative,O
correlations,O
with,O
TSH,B-GP
levels,O
.,O
Differences,O
between,O
CH,B-DS
and,O
HYPO,B-DS
studies,O
may,O
reflect,O
their,O
different,O
timing,O
of,O
TH,B-DS
insufficiency,I-DS
",",O
which,O
was,O
later,O
in,O
CH,B-DS
.,O
Thus,O
",",O
the,O
increased,O
thinning,O
in,O
CH,B-DS
versus,O
HYPO,B-DS
may,O
reflect,O
the,O
impact,O
of,O
their,O
later,O
TH,O
loss,O
on,O
more,O
protracted,O
aspects,O
of,O
cortical,O
formation,O
",",O
such,O
as,O
process,O
growth,O
and,O
apoptosis,O
.,O
On,O
the,O
other,O
hand,O
",",O
differences,O
between,O
studies,O
may,O
reflect,O
the,O
slightly,O
older,O
ages,O
of,O
the,O
CH,B-DS
group,O
and,O
their,O
matched,O
controls,O
than,O
the,O
HYPO,B-DS
group,O
and,O
their,O
controls,O
",",O
especially,O
given,O
longitudinal,O
evidence,O
that,O
thickening,O
normally,O
occurs,O
up,O
to,O
a,O
specific,O
age,O
in,O
puberty,O
followed,O
by,O
thinning,O
(,O
60,O
).,O
Our,O
observations,O
of,O
a,O
broad,O
range,O
of,O
cortical,O
regions,O
with,O
atypical,O
morphology,O
in,O
the,O
offspring,O
of,O
hypothyroid,O
women,B-OG
have,O
important,O
implications,O
for,O
the,O
daily,O
functioning,O
of,O
their,O
children,O
.,O
For,O
example,O
",",O
their,O
thinning,O
in,O
the,O
right,O
fusiform,O
gyrus,O
may,O
contribute,O
to,O
face,O
-,O
and,O
object,O
-,O
processing,O
difficulties,O
",",O
while,O
effects,O
in,O
the,O
right,O
precuneus,O
may,O
be,O
associated,O
with,O
weak,O
spatial,O
and,O
math,O
skills,O
(,O
4,O
",",O
47,O
",",O
61,O
).,O
Also,O
",",O
their,O
cortical,O
thinning,O
in,O
right,O
precuneus,O
and,O
frontomarginal,O
sulcus,O
can,O
contribute,O
to,O
the,O
autobiographical,O
memory,O
weaknesses,O
we,O
previously,O
noted,O
in,O
this,O
population,O
(,O
62,O
",",O
63,O
).,O
On,O
the,O
other,O
hand,O
",",O
increased,O
thickening,O
in,O
posterior,O
structures,O
may,O
correspond,O
to,O
our,O
previous,O
findings,O
that,O
these,O
children,O
had,O
visual,O
processing,O
difficulties,O
",",O
including,O
poor,O
contrast,O
sensitivity,O
",",O
when,O
mothers,O
were,O
severely,O
hypothyroid,O
(,O
64,O
);,O
this,O
may,O
also,O
lead,O
to,O
the,O
observed,O
non,O
-,O
verbal,O
difficulties,O
following,O
maternal,O
hypothyroxinemia,O
(,O
46,O
).,O
Observed,O
thickening,O
in,O
frontal,O
regions,O
may,O
contribute,O
to,O
problems,O
in,O
executive,O
functioning,O
",",O
including,O
difficulties,O
in,O
sustaining,O
and,O
maintaining,O
attention,O
(,O
4,O
",",O
8,O
",",O
65,O
),O
and,O
increased,O
risk,O
of,O
attention,B-DS
-,I-DS
deficit,I-DS
disorder,I-DS
and,O
autism,B-DS
(,O
10,O
",",O
65,O
).,O
Finally,O
",",O
our,O
finding,O
of,O
thickening,O
within,O
the,O
right,O
supramarginal,O
gyrus,O
of,O
the,O
parietal,O
lobe,O
has,O
important,O
implications,O
for,O
social,O
functioning,O
",",O
given,O
this,O
region,O
is,O
critical,O
for,O
empathy,O
and,O
emotion,O
processing,O
(,O
66,O
).,O
Furthermore,O
",",O
this,O
finding,O
may,O
be,O
a,O
prelude,O
to,O
recent,O
reports,O
of,O
increased,O
emotional,B-DS
problems,I-DS
they,O
exhibit,O
as,O
adults,O
(,O
67,O
",",O
68,O
).,O
Interestingly,O
in,O
a,O
preliminary,O
analysis,O
",",O
we,O
recently,O
observed,O
a,O
positive,O
correlation,O
between,O
degree,O
of,O
thickening,O
and,O
their,O
emotion,O
regulation,O
in,O
our,O
adolescent,O
sample,O
.,O
Our,O
findings,O
also,O
revealed,O
that,O
thickening,O
effects,O
in,O
some,O
regions,O
",",O
such,O
as,O
the,O
postcentral,O
gyrus,O
and,O
sulcus,O
and,O
pericallosal,O
sulcus,O
",",O
which,O
are,O
important,O
for,O
sensory,O
processing,O
",",O
but,O
these,O
disappeared,O
once,O
outliers,O
were,O
removed,O
",",O
suggesting,O
that,O
central,O
regions,O
may,O
be,O
especially,O
vulnerable,O
to,O
severe,O
TH,B-DS
deficiency,I-DS
in,O
pregnancy,O
.,O
Present,O
results,O
also,O
have,O
important,O
clinical,O
significance,O
for,O
pregnant,O
women,B-OG
whose,O
offspring,O
may,O
be,O
affected,O
by,O
mild,O
elevations,O
in,O
maternal,O
TSH,B-GP
depending,O
on,O
trimester,O
of,O
TH,B-DS
deficiency,I-DS
.,O
Consequently,O
",",O
it,O
is,O
important,O
to,O
closely,O
and,O
frequently,O
monitor,O
women,B-OG
with,O
hypothyroidism,B-DS
in,O
order,O
to,O
ensure,O
their,O
dosages,O
are,O
sufficient,O
to,O
maintain,O
their,O
TH,O
levels,O
within,O
the,O
normal,O
range,O
throughout,O
pregnancy,O
.,O
It,O
is,O
important,O
to,O
note,O
that,O
Korevaar,O
and,O
colleagues,O
recently,O
showed,O
that,O
for,O
normothyroid,O
women,B-OG
",",O
those,O
with,O
early,O
-,O
to,O
-,O
mid,O
pregnancy,O
levels,O
at,O
the,O
extremities,O
of,O
the,O
normal,O
range,O
had,O
children,O
with,O
lower,O
IQs,O
and,O
smaller,O
cortical,O
volumes,O
(,O
47,O
).,O
Although,O
this,O
study,O
is,O
unique,O
because,O
it,O
includes,O
offspring,O
of,O
hypothyroid,O
women,B-OG
followed,O
for,O
a,O
minimum,O
of,O
10,O
–,O
12,O
years,O
from,O
or,O
shortly,O
after,O
pregnancy,O
and,O
detailed,O
assessments,O
(,O
described,O
elsewhere,O
),O
and,O
structural,O
(,O
14,O
",",O
15,O
),O
and,O
functional,O
(,O
in,O
progress,O
),O
MRI,O
scans,O
",",O
our,O
study,O
is,O
also,O
subject,O
to,O
a,O
number,O
of,O
limitations,O
.,O
Our,O
small,O
sample,O
size,O
represents,O
an,O
approximately,O
two,O
-,O
thirds,O
loss,O
from,O
the,O
original,O
group,O
;,O
however,O
",",O
no,O
bias,O
was,O
observed,O
in,O
those,O
who,O
dropped,O
out,O
versus,O
those,O
who,O
participated,O
currently,O
.,O
Nevertheless,O
",",O
this,O
has,O
meant,O
we,O
could,O
not,O
analyze,O
for,O
other,O
factors,O
",",O
such,O
as,O
sex,O
or,O
age,O
",",O
which,O
can,O
influence,O
CT,O
(,O
69,O
",",O
70,O
).,O
Also,O
",",O
the,O
age,O
range,O
of,O
our,O
sample,O
spans,O
when,O
the,O
normal,O
age,O
-,O
trajectory,O
for,O
cortical,O
thickening,O
reaches,O
its,O
peak,O
and,O
then,O
starts,O
to,O
thin,O
(,O
60,O
",",O
71,O
);,O
consequently,O
",",O
HYPO,B-DS
’,O
s,O
observed,O
thickening,O
can,O
reflect,O
either,O
a,O
permanent,O
defect,O
or,O
a,O
delay,O
in,O
development,O
relative,O
to,O
controls,O
.,O
Likewise,O
",",O
we,O
did,O
not,O
assess,O
for,O
pubertal,O
maturity,O
",",O
which,O
additionally,O
affects,O
CT,O
(,O
69,O
).,O
Furthermore,O
",",O
although,O
we,O
had,O
thyroid,O
information,O
on,O
most,O
mothers,O
",",O
many,O
had,O
only,O
TSH,B-GP
data,O
and,O
in,O
most,O
cases,O
",",O
only,O
a,O
single,O
measurement,O
per,O
trimester,O
.,O
Consequently,O
",",O
we,O
could,O
not,O
examine,O
for,O
degree,O
of,O
variability,O
within,O
a,O
trimester,O
and,O
as,O
we,O
used,O
averaged,O
values,O
within,O
each,O
trimester,O
(,O
when,O
a,O
mother,O
provided,O
more,O
than,O
one,O
measurement,O
per,O
trimester,O
"),",O
we,O
could,O
not,O
examine,O
for,O
the,O
impact,O
of,O
very,O
low,O
or,O
very,O
high,O
TH,O
levels,O
.,O
We,O
also,O
could,O
not,O
examine,O
for,O
effects,O
of,O
hypothyroxinemia,O
.,O
While,O
our,O
control,O
group,O
came,O
from,O
ostensibly,O
normothyroid,O
women,B-OG
who,O
were,O
ascertained,O
similarly,O
to,O
the,O
HYPO,B-DS
group,O
",",O
we,O
lacked,O
direct,O
evidence,O
they,O
were,O
in,O
fact,O
euthyroid,O
",",O
except,O
for,O
a,O
small,O
group,O
of,O
normothyroid,O
women,B-OG
who,O
were,O
assessed,O
and,O
showed,O
normal,O
levels,O
.,O
Finally,O
",",O
as,O
this,O
study,O
was,O
preliminary,O
",",O
results,O
were,O
not,O
correlated,O
with,O
indices,O
of,O
neuropsychological,O
functioning,O
and,O
this,O
needs,O
to,O
be,O
done,O
in,O
future,O
research,O
on,O
this,O
population,O
.,O
Several,O
methodological,O
issues,O
may,O
also,O
influence,O
our,O
findings,O
.,O
Scans,O
were,O
obtained,O
on,O
a,O
1,O
.,O
5,O
-,O
T,O
scanner,O
",",O
for,O
which,O
resolution,O
between,O
cortical,O
layers,O
may,O
be,O
less,O
clear,O
than,O
with,O
higher,O
Tesla,O
scanners,O
",",O
while,O
analyses,O
were,O
performed,O
using,O
an,O
early,O
version,O
of,O
FreeSurfer,O
",",O
which,O
may,O
yield,O
CT,O
differences,O
from,O
later,O
versions,O
.,O
Also,O
",",O
FreeSurfer,O
(,O
34,O
),O
uses,O
an,O
adult,O
template,O
to,O
label,O
gyri,O
and,O
sulci,O
and,O
as,O
our,O
participants,O
were,O
pre,O
-,O
adolescents,O
",",O
some,O
regional,O
differences,O
may,O
not,O
accurately,O
reflect,O
those,O
designated,O
by,O
the,O
coordinates,O
in,O
the,O
output,O
.,O
In,O
addition,O
",",O
as,O
our,O
results,O
are,O
based,O
on,O
unsmoothed,O
and,O
hence,O
noisy,O
data,O
",",O
some,O
results,O
may,O
be,O
false,O
positives,O
.,O
Furthermore,O
",",O
we,O
performed,O
correlations,O
between,O
maternal,O
TSH,B-GP
and,O
CT,O
measurements,O
derived,O
from,O
the,O
peak,O
vertex,O
only,O
",",O
not,O
CT,O
averaged,O
across,O
the,O
identified,O
cluster,O
",",O
and,O
this,O
may,O
give,O
an,O
incomplete,O
picture,O
of,O
the,O
full,O
impact,O
of,O
maternal,B-DS
hypothyroidism,I-DS
on,O
offspring,O
cortical,O
development,O
.,O
Conclusion,O
Young,O
adolescents,O
exposed,O
to,O
insufficient,O
maternal,O
TH,O
in,O
utero,O
show,O
abnormal,O
cortical,O
development,O
reflecting,O
both,O
thinning,O
and,O
thickening,O
in,O
different,O
regions,O
.,O
Thickening,O
was,O
more,O
common,O
and,O
extensive,O
than,O
thinning,O
and,O
appeared,O
to,O
reflect,O
early,O
TH,B-DS
insufficiency,I-DS
.,O
Since,O
specific,O
regional,O
and,O
hemispheric,O
differences,O
depended,O
on,O
the,O
trimester,O
of,O
TH,B-DS
insufficiency,I-DS
",",O
this,O
may,O
reflect,O
the,O
spatiotemporal,O
dynamics,O
of,O
the,O
developing,O
human,B-OG
brain,O
in,O
its,O
need,O
for,O
TH,O
during,O
gestation,O
.,O
However,O
",",O
given,O
the,O
limitations,O
and,O
our,O
preliminary,O
approach,O
",",O
further,O
research,O
using,O
larger,O
samples,O
and,O
in,O
relation,O
to,O
other,O
gestational,O
TH,B-DS
deficiencies,I-DS
(,O
e,O
.,O
g,O
".,",O
resistance,O
to,O
TH,O
",",O
hypothyroxinemia,O
of,O
prematurity,O
),O
or,O
forms,O
of,O
maternal,O
TH,B-DS
insufficiency,I-DS
(,O
e,O
.,O
g,O
".,",O
subclinical,B-DS
hypothyroidism,I-DS
",",O
hypothyroxinemia,O
",",O
iodine,B-DS
deficiency,I-DS
),O
is,O
warranted,O
.,O
Future,O
studies,O
also,O
need,O
to,O
examine,O
the,O
relations,O
between,O
aspects,O
of,O
cortical,O
development,O
and,O
higher,O
-,O
order,O
cognitive,O
and,O
sociobehavioral,O
functions,O
in,O
order,O
to,O
better,O
characterize,O
the,O
full,O
impact,O
of,O
maternal,B-DS
hypothyroidism,I-DS
on,O
the,O
progeny,O
.,O
Nevertheless,O
",",O
our,O
findings,O
do,O
signify,O
that,O
TH,O
plays,O
a,O
central,O
in,O
human,B-OG
corticogenesis,O
.,O
Author,O
Contributions,O
JR,O
conceptualized,O
",",O
obtained,O
funding,O
",",O
and,O
managed,O
the,O
original,O
study,O
from,O
which,O
scans,O
were,O
derived,O
.,O
JEL,O
",",O
HC,O
",",O
and,O
JR,O
conceived,O
the,O
current,O
study,O
.,O
JS,O
conducted,O
the,O
FreeSurfer,O
analyses,O
.,O
JEL,O
",",O
JS,O
",",O
and,O
interpreted,O
the,O
data,O
.,O
JEL,O
under,O
the,O
supervision,O
of,O
JR,O
drafted,O
the,O
first,O
manuscript,O
version,O
",",O
while,O
JS,O
and,O
HC,O
conducted,O
revisions,O
to,O
this,O
draft,O
.,O
JR,O
wrote,O
the,O
final,O
manuscript,O
version,O
",",O
while,O
JEL,O
",",O
JS,O
",",O
and,O
HC,O
revised,O
and,O
approved,O
this,O
for,O
submission,O
for,O
publication,O
.,O
Conflict,O
of,O
Interest,O
Statement,O
The,O
authors,O
declare,O
that,O
the,O
research,O
was,O
conducted,O
in,O
the,O
absence,O
of,O
any,O
commercial,O
or,O
financial,O
relationships,O
that,O
could,O
be,O
construed,O
as,O
a,O
potential,O
conflict,O
of,O
interest,O
.,O
Minimum,O
requirements,O
for,O
ookinete,O
to,O
oocyst,O
transformation,O
in,O
Plasmodium,B-OG
Present,O
address,O
:,O
Department,O
of,O
Infectious,O
&,O
Tropical,O
Diseases,O
",",O
Pathology,O
Molecular,O
Biology,O
Unit,O
",",O
London,O
School,O
of,O
Hygiene,O
&,O
Tropical,O
Medicine,O
",",O
Keppel,O
Street,O
",",O
London,O
WC1E,O
7HT,O
",",O
UK,O
.,O
During,O
their,O
passage,O
through,O
a,O
mosquito,B-OG
vector,O
",",O
malaria,B-DS
parasites,O
undergo,O
several,O
developmental,O
transformations,O
including,O
that,O
from,O
a,O
motile,O
zygote,O
",",O
the,O
ookinete,O
",",O
to,O
a,O
sessile,O
oocyst,O
that,O
develops,O
beneath,O
the,O
basal,O
lamina,O
of,O
the,O
midgut,O
epithelium,O
.,O
This,O
transformation,O
process,O
is,O
poorly,O
understood,O
and,O
the,O
oocyst,O
is,O
the,O
least,O
studied,O
of,O
all,O
the,O
stages,O
in,O
the,O
malaria,B-DS
life,O
cycle,O
.,O
We,O
have,O
used,O
an,O
in,O
vitro,O
culture,O
system,O
to,O
monitor,O
morphological,O
features,O
associated,O
with,O
transformation,O
of,O
Plasmodium,B-OG
berghei,I-OG
ookinetes,O
and,O
the,O
role,O
of,O
basal,O
lamina,O
components,O
in,O
this,O
process,O
.,O
We,O
also,O
describe,O
the,O
minimal,O
requirements,O
for,O
transformation,O
and,O
early,O
oocyst,O
development,O
.,O
A,O
defined,O
sequence,O
of,O
events,O
begins,O
with,O
the,O
break,O
-,O
up,O
of,O
the,O
inner,O
surface,O
membrane,O
",",O
specifically,O
along,O
the,O
convex,O
side,O
of,O
the,O
ookinete,O
",",O
where,O
a,O
protrusion,O
occurs,O
.,O
A,O
distinct,O
form,O
",",O
the,O
transforming,O
ookinete,O
or,O
took,O
",",O
has,O
been,O
identified,O
in,O
vitro,O
and,O
also,O
observed,O
in,O
vivo,O
.,O
Contrary,O
to,O
previous,O
suggestions,O
",",O
we,O
have,O
shown,O
that,O
no,O
basal,O
lamina,O
components,O
are,O
required,O
to,O
trigger,O
ookinete,O
to,O
oocyst,O
transformation,O
in,O
vitro,O
.,O
We,O
have,O
demonstrated,O
that,O
transformation,O
does,O
not,O
occur,O
spontaneously,O
;,O
it,O
is,O
initiated,O
in,O
the,O
presence,O
of,O
bicarbonate,O
added,O
to,O
PBS,O
",",O
but,O
it,O
is,O
not,O
mediated,O
by,O
changes,O
in,O
pH,O
alone,O
.,O
Transformation,O
is,O
a,O
two,O
-,O
step,O
process,O
that,O
is,O
not,O
completed,O
unless,O
a,O
range,O
of,O
nutrients,O
are,O
also,O
present,O
.,O
A,O
minimal,O
medium,O
is,O
defined,O
which,O
supports,O
transformation,O
and,O
oocyst,O
growth,O
from,O
7,O
.,O
8,O
to,O
11,O
.,O
4,O
μm,O
by,O
day,O
5,O
with,O
84,O
%,O
viability,O
.,O
We,O
conclude,O
that,O
ookinete,O
transformation,O
is,O
mediated,O
by,O
bicarbonate,O
and,O
occurs,O
in,O
a,O
similar,O
manner,O
to,O
the,O
differentiation,O
of,O
sporozoite,O
to,O
the,O
hepatic,O
stage,O
.,O
Introduction,O
Malaria,B-DS
remains,O
a,O
major,O
life,O
-,O
threatening,O
disease,O
in,O
tropical,O
and,O
sub,O
-,O
tropical,O
parts,O
of,O
the,O
world,O
",",O
causing,O
300,O
–,O
500,O
million,O
clinical,O
cases,O
",",O
over,O
one,O
million,O
deaths,O
and,O
severe,O
economic,O
and,O
social,O
losses,O
(,O
Sachs,O
and,O
Malaney,O
",",O
2002,O
).,O
The,O
causative,O
agents,O
of,O
the,O
disease,O
",",O
apicomplexans,B-OG
of,O
the,O
genus,O
Plasmodium,B-OG
",",O
are,O
amongst,O
the,O
most,O
studied,O
parasites,O
because,O
of,O
their,O
devastating,O
impact,O
on,O
human,B-OG
health,O
and,O
welfare,O
.,O
Plasmodium,B-OG
parasites,O
cycle,O
between,O
a,O
vertebrate,B-OG
host,O
and,O
mosquito,B-OG
vector,O
",",O
experiencing,O
changing,O
environmental,O
conditions,O
as,O
they,O
develop,O
from,O
invasive,O
to,O
intracellular,O
forms,O
in,O
the,O
vertebrate,B-OG
",",O
and,O
invasive,O
",",O
intracellular,O
and,O
extracellular,O
forms,O
in,O
the,O
mosquito,B-OG
.,O
Despite,O
the,O
importance,O
of,O
mosquito,B-OG
stages,O
for,O
malaria,B-DS
transmission,O
",",O
the,O
majority,O
of,O
research,O
on,O
Plasmodium,B-OG
is,O
focused,O
upon,O
the,O
asexual,O
stages,O
that,O
invade,O
vertebrate,B-OG
erythrocytes,O
;,O
studies,O
facilitated,O
by,O
the,O
development,O
",",O
in,O
1976,O
(,O
Trager,O
and,O
Jensen,O
",",O
1976,O
"),",O
of,O
an,O
in,O
vitro,O
culture,O
technique,O
that,O
has,O
rendered,O
these,O
stages,O
more,O
accessible,O
to,O
experimentation,O
(,O
Hurd,O
et,O
al,O
".,",O
2003,O
).,O
In,O
the,O
mosquito,B-OG
",",O
gametocytes,O
complete,O
their,O
differentiation,O
",",O
fertilisation,O
occurs,O
and,O
the,O
zygote,O
transforms,O
into,O
a,O
motile,O
ookinete,O
within,O
24,O
h,O
of,O
having,O
imbibed,O
a,O
blood,O
meal,O
.,O
This,O
extracellular,O
ookinete,O
migrates,O
out,O
of,O
the,O
blood,O
bolus,O
",",O
traverses,O
the,O
midgut,O
epithelium,O
and,O
transforms,O
into,O
a,O
vegetative,O
oocyst,O
in,O
the,O
basal,O
subepithelial,O
space,O
between,O
the,O
midgut,O
epithelium,O
and,O
the,O
basal,O
lamina,O
(,O
BL,O
).,O
The,O
young,O
oocyst,O
grows,O
and,O
undergoes,O
sporogony,O
",",O
producing,O
sporozoites,O
that,O
migrate,O
to,O
the,O
salivary,O
glands,O
.,O
Experimentation,O
with,O
systems,O
that,O
substitute,O
for,O
conditions,O
in,O
the,O
vector,O
for,O
a,O
period,O
of,O
some,O
50,O
years,O
finally,O
led,O
to,O
the,O
development,O
of,O
methods,O
to,O
culture,O
all,O
the,O
mosquito,B-OG
stages,O
of,O
several,O
malaria,B-DS
species,O
.,O
Species,O
that,O
have,O
been,O
successfully,O
cultured,O
from,O
gametocyte,O
to,O
sporozoite,O
include,O
Plasmodium,B-OG
falciparum,I-OG
(,O
Warburg,O
and,O
Schneider,O
",",O
1993,O
"),",O
Plasmodium,B-OG
gallinaceum,I-OG
(,O
Warburg,O
and,O
Miller,O
",",O
1992,O
"),",O
Plasmodium,B-OG
berghei,I-OG
(,O
Al,O
-,O
Olayan,O
et,O
al,O
".,",O
2002a,O
),O
and,O
Plasmodium,B-OG
yoelii,I-OG
(,O
Porter,O
-,O
Kelley,O
et,O
al,O
".,",O
2006,O
).,O
For,O
one,O
of,O
these,O
species,O
",",O
P,B-OG
.,I-OG
berghei,I-OG
",",O
a,O
method,O
for,O
the,O
efficient,O
production,O
of,O
ookinetes,O
in,O
vitro,O
has,O
been,O
developed,O
(,O
Rosales,O
-,O
Ronquillo,O
and,O
Silverman,O
",",O
1974,O
;,O
Weiss,O
and,O
Vanderberg,O
",",O
1977,O
),O
and,O
this,O
has,O
provided,O
material,O
for,O
detailed,O
studies,O
of,O
gametogenesis,O
",",O
fertilisation,O
and,O
zygote,O
development,O
.,O
Several,O
studies,O
have,O
demonstrated,O
that,O
initiation,O
of,O
Plasmodium,B-OG
gametogenesis,O
requires,O
specific,O
triggers,O
.,O
The,O
change,O
in,O
environment,O
from,O
a,O
mammalian,O
to,O
insect,B-OG
host,O
provides,O
cues,O
such,O
as,O
a,O
drop,O
in,O
temperature,O
",",O
and,O
a,O
mosquito,B-OG
factor,O
identified,O
as,O
xanthurenic,O
acid,O
(,O
Nijhout,O
and,O
Carter,O
",",O
1978,O
;,O
Arai,O
et,O
al,O
".,",O
2001,O
),O
which,O
can,O
regulate,O
gametogenesis,O
.,O
These,O
triggers,O
",",O
or,O
substitutes,O
for,O
them,O
",",O
are,O
present,O
in,O
the,O
in,O
vitro,O
systems,O
used,O
to,O
produce,O
ookinetes,O
(,O
Weiss,O
and,O
Vanderberg,O
",",O
1977,O
;,O
Carter,O
et,O
al,O
".,",O
2003,O
).,O
The,O
next,O
critical,O
event,O
in,O
the,O
development,O
of,O
the,O
sporogonic,O
stages,O
of,O
Plasmodium,B-OG
is,O
that,O
of,O
the,O
transformation,O
of,O
ookinete,O
to,O
oocyst,O
.,O
Our,O
knowledge,O
of,O
this,O
phase,O
of,O
development,O
is,O
minimal,O
and,O
the,O
process,O
of,O
rounding,O
up,O
of,O
the,O
ookinete,O
to,O
form,O
an,O
oocyst,O
had,O
not,O
been,O
studied,O
in,O
vitro,O
previous,O
to,O
this,O
work,O
.,O
We,O
have,O
identified,O
components,O
of,O
the,O
culture,O
system,O
that,O
are,O
essential,O
requirements,O
to,O
initiate,O
and,O
sustain,O
the,O
formation,O
of,O
young,O
oocysts,O
from,O
ookinetes,O
.,O
It,O
had,O
been,O
proposed,O
that,O
contact,O
with,O
components,O
of,O
the,O
BL,O
may,O
act,O
as,O
a,O
trigger,O
for,O
ookinete,O
transformation,O
in,O
vivo,O
(,O
Weathersby,O
",",O
1952,O
;,O
Meis,O
and,O
Ponnudurai,O
",",O
1987,O
;,O
Ramasamy,O
et,O
al,O
".,",O
1997,O
;,O
Adini,O
and,O
Warburg,O
",",O
1999,O
;,O
Schneider,O
and,O
Shahabuddin,O
",",O
2000,O
;,O
Dessens,O
et,O
al,O
".,",O
2003,O
;,O
Arrighi,O
et,O
al,O
".,",O
2005,O
;,O
Vlachou,O
et,O
al,O
".,",O
2006,O
),O
and,O
culture,O
systems,O
that,O
allow,O
the,O
transformation,O
of,O
ookinetes,O
to,O
oocysts,O
",",O
oocyst,O
growth,O
and,O
sporozoite,O
production,O
have,O
included,O
a,O
BL,O
substitute,O
",",O
Matrigel,O
and,O
a,O
co,O
-,O
cultured,O
cell,O
line,O
such,O
as,O
Drosophila,B-OG
melanogaster,I-OG
S2,O
",",O
that,O
may,O
also,O
contribute,O
molecules,O
present,O
in,O
the,O
mosquito,B-OG
BL,O
(,O
Warburg,O
and,O
Miller,O
",",O
1992,O
;,O
Warburg,O
and,O
Schneider,O
",",O
1993,O
;,O
Al,O
-,O
Olayan,O
et,O
al,O
".,",O
2002a,O
).,O
Matrigel,O
",",O
an,O
extracellular,O
matrix,O
derived,O
from,O
Engelbreth,B-DS
–,I-DS
Holm,I-DS
–,I-DS
Swarm,I-DS
mouse,I-DS
sarcoma,I-DS
",",O
is,O
comprised,O
of,O
laminin,B-GP
(,O
56,O
"%),",O
collagen,B-GP
IV,I-GP
(,O
31,O
"%),",O
enactin,B-GP
(,O
8,O
"%),",O
heparan,B-GP
sulfate,I-GP
proteoglycans,I-GP
and,O
growth,O
factors,O
(,O
BD,O
Biosciences,O
).,O
Several,O
ookinete,O
proteins,O
",",O
such,O
as,O
the,O
surface,B-GP
proteins,I-GP
P25,I-GP
/,O
P28,B-GP
(,O
Siden,O
-,O
Kiamos,O
et,O
al,O
".,",O
2000,O
"),",O
secreted,B-GP
ookinete,I-GP
adhesive,I-GP
protein,I-GP
(,O
SOAP,B-GP
),O
(,O
Dessens,O
et,O
al,O
".,",O
2003,O
"),",O
circumsporozoite,B-GP
-,I-GP
and,I-GP
TRAP,I-GP
-,I-GP
related,I-GP
protein,I-GP
(,O
CTRP,B-GP
),O
(,O
Dessens,O
et,O
al,O
".,",O
1999,O
),O
and,O
von,B-GP
Willebrand,I-GP
factor,I-GP
A,I-GP
domain,I-GP
-,I-GP
related,I-GP
-,I-GP
protein,I-GP
(,O
WARP,B-GP
),O
(,O
Yuda,O
et,O
al,O
".,",O
2001,O
"),",O
that,O
are,O
reportedly,O
essential,O
for,O
ookinete,O
and,O
oocyst,O
development,O
in,O
vivo,O
",",O
have,O
been,O
shown,O
to,O
bind,O
to,O
BL,O
components,O
such,O
as,O
laminin,B-GP
and,O
collagen,B-GP
(,O
Adini,O
and,O
Warburg,O
",",O
1999,O
;,O
Arrighi,O
et,O
al,O
".,",O
2005,O
).,O
This,O
binding,O
could,O
provide,O
a,O
signal,O
that,O
induces,O
transformation,O
",",O
thus,O
adding,O
weight,O
to,O
the,O
hypothesis,O
that,O
contact,O
with,O
the,O
BL,O
may,O
be,O
essential,O
for,O
parasite,O
development,O
(,O
Dessens,O
et,O
al,O
".,",O
2003,O
).,O
Alternatively,O
",",O
other,O
components,O
of,O
the,O
culture,O
system,O
such,O
as,O
those,O
present,O
in,O
the,O
insect,B-OG
cell,O
medium,O
used,O
as,O
a,O
substitute,O
for,O
haemolymph,O
",",O
may,O
be,O
essential,O
requirements,O
for,O
ookinete,O
transformation,O
.,O
In,O
vivo,O
",",O
ookinete,O
transformation,O
is,O
a,O
transient,O
and,O
unsynchronised,O
event,O
but,O
in,O
vitro,O
we,O
can,O
observe,O
the,O
process,O
occurring,O
in,O
thousands,O
of,O
ookinetes,O
at,O
any,O
one,O
time,O
.,O
Additionally,O
",",O
controlled,O
interventions,O
that,O
enable,O
careful,O
dissection,O
of,O
putative,O
transformation,O
signals,O
can,O
be,O
made,O
and,O
the,O
minimal,O
nutritional,O
/,O
environmental,O
requirements,O
for,O
sporogonic,O
development,O
can,O
be,O
assessed,O
.,O
Using,O
ookinetes,O
that,O
had,O
been,O
obtained,O
in,O
vitro,O
(,O
Carter,O
et,O
al,O
".,",O
2003,O
),O
as,O
a,O
starting,O
point,O
",",O
we,O
have,O
been,O
able,O
to,O
describe,O
the,O
process,O
of,O
transformation,O
and,O
to,O
identify,O
a,O
novel,O
transient,O
stage,O
that,O
we,O
have,O
called,O
a,O
transforming,O
ookinete,O
or,O
took,O
.,O
We,O
have,O
demonstrated,O
that,O
",",O
contrary,O
to,O
previous,O
suggestions,O
",",O
BL,O
components,O
",",O
and,O
in,O
particular,O
laminin,B-GP
",",O
are,O
not,O
required,O
for,O
transformation,O
and,O
early,O
oocyst,O
growth,O
and,O
that,O
transformation,O
appears,O
to,O
be,O
a,O
two,O
-,O
step,O
process,O
in,O
which,O
initiation,O
is,O
bicarbonate,O
-,O
dependent,O
and,O
complete,O
transformation,O
requires,O
a,O
range,O
of,O
nutrients,O
.,O
Materials,O
and,O
methods,O
All,O
reagents,O
were,O
purchased,O
from,O
Sigma,O
unless,O
otherwise,O
specified,O
.,O
Parasites,O
and,O
ookinete,O
harvesting,O
Experiments,O
were,O
carried,O
out,O
in,O
accordance,O
with,O
the,O
UK,O
Animals,O
(,O
Scientific,O
Procedures,O
),O
Act,O
1986,O
using,O
approved,O
protocols,O
.,O
CD,O
mice,B-OG
were,O
treated,O
with,O
phenylhydrazine,O
2,O
days,O
prior,O
to,O
infection,B-DS
by,O
i,O
.,O
p,O
.,O
inoculation,O
with,O
P,B-OG
.,I-OG
berghei,I-OG
(,O
clone,O
259cl2,O
expressing,O
green,B-GP
fluorescent,I-GP
protein,I-GP
(,O
Franke,O
-,O
Fayard,O
et,O
al,O
".,",O
2004,O
)),O
obtained,O
from,O
a,O
donor,O
mouse,B-OG
between,O
the,O
second,O
and,O
sixth,O
passage,O
from,O
cryopreserved,O
stock,O
.,O
Infected,O
blood,O
was,O
collected,O
from,O
mice,B-OG
with,O
a,O
parasitaemia,O
of,O
10,O
–,O
20,O
%,O
via,O
cardiac,O
puncture,O
into,O
a,O
heparinised,O
syringe,O
.,O
Gametocytaemic,O
blood,O
was,O
passed,O
through,O
a,O
pre,O
-,O
equilibrated,O
",",O
5,O
ml,O
sterile,O
column,O
containing,O
1,O
ml,O
glass,O
wool,O
and,O
3,O
ml,O
of,O
Whatman,O
CF11,O
cellulose,O
powder,O
(,O
Beckton,O
&,O
Dickenson,O
),O
to,O
remove,O
white,O
blood,O
cells,O
.,O
The,O
blood,O
was,O
collected,O
into,O
T25,O
culture,O
flasks,O
with,O
RPMI,O
1640,O
medium,O
supplemented,O
with,O
24,O
mM,O
sodium,O
bicarbonate,O
",",O
0,O
.,O
4,O
mM,O
hypoxanthine,O
",",O
10,O
",",O
000,O
U,O
penicillin,O
/,O
10,O
mg,O
streptomycin,O
and,O
20,O
%,O
FBS,O
in,O
a,O
1,O
:,O
10,O
ratio,O
(,O
blood,O
:,O
media,O
).,O
Gametocytes,O
developed,O
into,O
ookinetes,O
after,O
18,O
h,O
of,O
culture,O
at,O
19,O
°,O
C,O
.,O
Ookinetes,O
were,O
separated,O
on,O
a,O
MidiMacs,O
(,O
Miltenyi,O
Biotec,O
",",O
Germany,O
),O
separation,O
system,O
as,O
previously,O
described,O
(,O
Carter,O
et,O
al,O
".,",O
2003,O
).,O
Briefly,O
this,O
involved,O
passing,O
the,O
blood,O
and,O
supplemented,O
RPMI,O
mixture,O
through,O
a,O
pre,O
-,O
separation,O
filter,O
(,O
to,O
remove,O
cellular,O
debris,O
and,O
coagulated,O
blood,O
),O
and,O
a,O
MidiMac,O
LS,O
column,O
mounted,O
on,O
a,O
magnet,O
.,O
Ookinetes,O
adhere,O
to,O
magnetised,O
beads,O
packed,O
within,O
the,O
column,O
and,O
can,O
be,O
eluted,O
by,O
removing,O
the,O
column,O
from,O
the,O
magnet,O
.,O
The,O
rate,O
of,O
blood,O
flow,O
was,O
reduced,O
by,O
adding,O
a,O
23G,O
needle,O
to,O
the,O
base,O
of,O
the,O
LS,O
column,O
to,O
increase,O
parasite,O
contact,O
time,O
with,O
the,O
column,O
.,O
Culture,O
conditions,O
Culture,O
conditions,O
were,O
as,O
previously,O
described,O
(,O
Al,O
-,O
Olayan,O
et,O
al,O
".,",O
2002a,O
).,O
Ookinetes,O
were,O
seeded,O
at,O
a,O
density,O
of,O
1,O
×,O
104,O
per,O
well,O
into,O
8,O
-,O
well,O
LabTek,O
chamber,O
slides,O
or,O
into,O
48,O
-,O
well,O
plates,O
(,O
IWAKI,O
),O
and,O
cultured,O
in,O
oocyst,O
culture,O
medium,O
(,O
OCM,O
:,O
see,O
Table,O
1,O
),O
unless,O
otherwise,O
stated,O
.,O
Wells,O
were,O
either,O
pre,O
-,O
coated,O
with,O
Matrigel,O
diluted,O
1,O
:,O
1,O
with,O
Schneider,O
’,O
s,O
Drosophila,B-OG
insect,B-OG
medium,O
or,O
incubation,O
took,O
place,O
in,O
non,O
-,O
coated,O
chamber,O
slides,O
.,O
Parasites,O
were,O
either,O
co,O
-,O
cultured,O
in,O
a,O
10,O
:,O
1,O
ratio,O
with,O
D,B-OG
.,I-OG
melanogaster,I-OG
S2,O
cells,O
(,O
Matrigel,O
+,O
S2,O
"),",O
cultured,O
in,O
non,O
-,O
coated,O
chamber,O
slides,O
with,O
S2,O
cells,O
(,O
no,O
-,O
coating,O
+,O
S2,O
"),",O
or,O
in,O
non,O
-,O
coated,O
slides,O
without,O
co,O
-,O
cultured,O
cells,O
(,O
no,O
-,O
coating,O
−,O
S2,O
).,O
Parasites,O
were,O
maintained,O
at,O
19,O
°,O
C,O
for,O
5,O
days,O
",",O
unless,O
otherwise,O
stated,O
.,O
Media,O
was,O
replenished,O
on,O
day,O
3,O
(,O
100,O
μl,O
removed,O
and,O
replaced,O
).,O
All,O
experiments,O
were,O
performed,O
with,O
six,O
replicate,O
wells,O
on,O
two,O
or,O
three,O
separate,O
occasions,O
.,O
Drosophila,B-OG
melanogaster,I-OG
S2,O
cells,O
were,O
maintained,O
in,O
T25,O
culture,O
flasks,O
(,O
Griener,O
Bio,O
-,O
One,O
),O
at,O
27,O
°,O
C,O
in,O
supplemented,O
Schneider,O
’,O
s,O
insect,B-OG
cell,O
culture,O
medium,O
(,O
ICM,O
),O
with,O
10,O
%,O
heat,O
-,O
inactivated,O
insect,B-OG
cell,O
culture,O
tested,O
FBS,O
",",O
penicillin,O
(,O
50,O
U,O
/,O
ml,O
),O
and,O
streptomycin,O
(,O
50,O
μg,O
/,O
ml,O
).,O
Assessment,O
of,O
viability,O
and,O
transformation,O
Initially,O
",",O
a,O
comparison,O
was,O
made,O
between,O
a,O
Live,O
/,O
Dead,O
viability,O
/,O
cytotoxicity,O
kit,O
(,O
Molecular,O
Probes,O
),O
used,O
according,O
to,O
the,O
manufacturers,O
’,O
instructions,O
",",O
and,O
Erythrosin,O
B,O
(,O
0,O
.,O
1,O
%,O
in,O
PBS,O
diluted,O
1,O
:,O
1,O
with,O
the,O
parasite,O
culture,O
medium,O
),O
exclusion,O
(,O
Krause,O
et,O
al,O
".,",O
1984,O
).,O
No,O
difference,O
was,O
detected,O
between,O
the,O
results,O
for,O
cell,O
viability,O
between,O
these,O
tests,O
(,O
data,O
not,O
shown,O
),O
and,O
the,O
latter,O
test,O
was,O
used,O
routinely,O
in,O
this,O
study,O
.,O
Material,O
was,O
removed,O
from,O
culture,O
wells,O
and,O
centrifuged,O
at,O
2000g,O
for,O
1,O
min,O
to,O
pellet,O
parasites,O
or,O
insect,B-OG
cells,O
.,O
For,O
parasite,O
transformation,O
rates,O
",",O
sample,O
pellets,O
were,O
resuspended,O
in,O
5,O
μl,O
of,O
PBS,O
and,O
5,O
μl,O
of,O
Erythrosin,O
B,O
and,O
mounted,O
onto,O
a,O
glass,O
slide,O
for,O
quantification,O
.,O
One,O
-,O
hundred,O
live,O
parasites,O
were,O
counted,O
for,O
each,O
condition,O
under,O
oil,O
immersion,O
",",O
and,O
classified,O
according,O
to,O
their,O
morphological,O
appearance,O
of,O
ookinete,O
(,O
banana,O
"),",O
transforming,O
ookinete,O
(,O
snail,O
-,O
like,O
),O
or,O
oocyst,O
(,O
sphere,O
with,O
a,O
minimum,O
diameter,O
of,O
7,O
μm,O
and,O
highly,O
motile,O
internal,O
contents,O
).,O
Counts,O
were,O
performed,O
on,O
triplicate,O
samples,O
.,O
Transformation,O
rates,O
were,O
determined,O
by,O
counting,O
the,O
number,O
of,O
live,O
(,O
Erythrosin,O
B,O
-,O
excluding,O
),O
ookinetes,O
present,O
on,O
the,O
initial,O
day,O
of,O
culture,O
",",O
compared,O
with,O
the,O
number,O
after,O
transformation,O
(,O
disappearance,O
of,O
ookinetes,O
with,O
concomitant,O
increase,O
in,O
young,O
oocysts,O
denotes,O
transformation,O
as,O
non,O
-,O
transforming,O
ookinetes,O
remain,O
intact,O
for,O
several,O
days,O
).,O
For,O
visualisation,O
of,O
nuclear,O
material,O
",",O
ookinetes,O
were,O
fixed,O
for,O
10,O
min,O
in,O
1,O
:,O
1,O
ice,O
cold,O
acetone,O
:,O
methanol,O
",",O
washed,O
and,O
then,O
incubated,O
with,O
anti,O
-,O
P28,B-GP
monoclonal,O
antibody,B-GP
for,O
1,O
h,O
at,O
room,O
temperature,O
before,O
further,O
washing,O
and,O
incubation,O
with,O
an,O
anti,O
-,O
mouse,B-OG
IgG,B-GP
antibody,B-GP
diluted,O
1,O
:,O
200,O
for,O
1,O
h,O
.,O
Samples,O
were,O
washed,O
again,O
then,O
mounted,O
in,O
Vectashield,O
containing,O
DAPI,O
(,O
Vector,O
Laboratories,O
),O
and,O
visualised,O
on,O
an,O
inverted,O
Lieca,O
DM,O
IRB,O
fluorescence,O
microscope,O
(,O
Lieca,O
Microsystems,O
",",O
Germany,O
).,O
Electron,O
microscopy,O
Plasmodium,B-OG
berghei,I-OG
samples,O
were,O
pelleted,O
at,O
500g,O
for,O
4,O
min,O
2,O
days,O
post,O
-,O
culture,O
and,O
fixed,O
in,O
2,O
.,O
5,O
%,O
glutaraldehyde,O
in,O
sodium,O
cacodylate,O
buffer,O
(,O
0,O
.,O
1,O
M,O
",",O
pH,O
7,O
.,O
4,O
).,O
Samples,O
were,O
post,O
-,O
fixed,O
in,O
1,O
%,O
osmium,O
tetroxide,O
dispersed,O
in,O
3,O
%,O
agar,O
",",O
dehydrated,O
in,O
graded,O
ethyl,O
alcohols,O
and,O
embedded,O
in,O
Spurr,O
’,O
s,O
resin,O
following,O
standard,O
protocols,O
.,O
Ultrathin,O
sections,O
",",O
cut,O
with,O
a,O
diamond,O
knife,O
on,O
a,O
Reichart,O
“,O
Ultracut,O
E,O
"”,",O
were,O
mounted,O
on,O
grids,O
and,O
stained,O
with,O
uranyl,O
acetate,O
.,O
Grids,O
were,O
examined,O
with,O
a,O
JOEL,O
1230,O
TEM,O
and,O
images,O
recorded,O
using,O
“,O
analySIS,O
”,O
software,O
.,O
Ookinete,O
rescue,O
Ookinetes,O
were,O
observed,O
to,O
remain,O
viable,O
when,O
cultured,O
in,O
PBS,O
alone,O
for,O
up,O
to,O
7,O
days,O
",",O
as,O
determined,O
by,O
Erythrosin,O
B,O
exclusion,O
",",O
but,O
did,O
not,O
transform,O
.,O
To,O
initiate,O
transformation,O
",",O
PBS,O
(,O
100,O
",",O
200,O
or,O
300,O
μl,O
),O
was,O
removed,O
from,O
the,O
culture,O
well,O
and,O
replaced,O
with,O
100,O
",",O
200,O
or,O
300,O
μl,O
of,O
full,O
-,O
oocyst,O
medium,O
on,O
day,O
1,O
",",O
2,O
or,O
3,O
of,O
culture,O
.,O
Samples,O
were,O
centrifuged,O
at,O
2000g,O
for,O
1,O
min,O
and,O
parasite,O
viability,O
was,O
assessed,O
as,O
above,O
.,O
Mosquito,B-OG
infections,B-DS
Anopheles,B-OG
stephensi,I-OG
were,O
starved,O
for,O
24,O
h,O
prior,O
to,O
bloodfeeding,O
for,O
20,O
min,O
on,O
gametocytaemic,O
CD,O
mice,B-OG
infected,O
with,O
P,B-OG
.,I-OG
berghei,I-OG
(,O
PbGFPCON,O
clone,O
259cl2,O
).,O
The,O
mosquitoes,B-OG
were,O
thereafter,O
maintained,O
on,O
a,O
4,O
%,O
glucose,O
solution,O
and,O
dissected,O
in,O
PBS,O
26,O
–,O
27,O
h,O
p,O
.,O
i,O
.,O
Midguts,O
from,O
infected,O
mosquitoes,B-OG
were,O
cut,O
open,O
and,O
the,O
blood,O
meal,O
vigorously,O
washed,O
out,O
with,O
PBS,O
before,O
examination,O
under,O
oil,O
emersion,O
on,O
the,O
inverted,O
fluorescence,O
microscope,O
for,O
the,O
presence,O
of,O
tooks,O
on,O
the,O
BL,O
side,O
of,O
the,O
gut,O
.,O
ELISA,O
Drosophila,B-OG
S2,O
cells,O
have,O
been,O
reported,O
to,O
secrete,O
laminin,B-GP
(,O
Fessler,O
et,O
al,O
".,",O
1987,O
).,O
To,O
confirm,O
secretion,O
of,O
laminin,B-GP
by,O
our,O
cell,O
line,O
",",O
Drosophila,B-OG
S2,O
cells,O
from,O
a,O
confluent,O
flask,O
were,O
counted,O
on,O
a,O
haemocytometer,O
and,O
the,O
total,O
volume,O
of,O
supernatant,O
from,O
the,O
culture,O
was,O
measured,O
to,O
calculate,O
the,O
number,O
of,O
cell,O
equivalents,O
per,O
100,O
μl,O
of,O
medium,O
.,O
Additionally,O
",",O
conditioned,O
medium,O
was,O
collected,O
from,O
wells,O
in,O
which,O
1,O
×,O
105,O
cells,O
were,O
incubated,O
for,O
1,O
",",O
3,O
",",O
5,O
",",O
7,O
or,O
9,O
days,O
at,O
19,O
°,O
C,O
in,O
400,O
μl,O
of,O
OCM,O
(,O
2,O
.,O
5,O
×,O
104,O
cells,O
per,O
100,O
μl,O
),O
to,O
determine,O
if,O
laminin,B-GP
secretion,O
could,O
be,O
detected,O
in,O
parasite,O
culture,O
conditions,O
.,O
ELISA,O
plates,O
were,O
coated,O
with,O
100,O
μl,O
of,O
conditioned,O
medium,O
",",O
diluted,O
1,O
:,O
50,O
in,O
coating,O
buffer,O
(,O
15,O
mM,O
Na2CO3,O
",",O
35,O
mM,O
NaHCO3,O
",",O
pH,O
9,O
.,O
6,O
),O
and,O
serial,O
dilutions,O
made,O
thereafter,O
to,O
1,O
:,O
2000,O
and,O
allowed,O
to,O
bind,O
overnight,O
at,O
4,O
°,O
C,O
.,O
Plates,O
were,O
washed,O
",",O
blocked,O
and,O
incubated,O
with,O
antibodies,B-GP
raised,O
against,O
the,O
β,O
-,O
and,O
γ,O
-,O
chains,O
of,O
Drosophila,B-OG
laminin,B-GP
(,O
Kumagai,O
et,O
al,O
".,",O
1997,O
),O
diluted,O
at,O
1,O
:,O
1000,O
in,O
milk,O
/,O
PBS,O
/,O
Tween,O
.,O
Plates,O
were,O
then,O
washed,O
",",O
incubated,O
with,O
an,O
alkaline,B-GP
phosphatase,I-GP
(,O
AP,B-GP
)-,O
conjugated,O
secondary,O
antibody,B-GP
(,O
Sigma,O
),O
diluted,O
1,O
:,O
1000,O
in,O
milk,O
/,O
PBS,O
/,O
Tween,O
",",O
and,O
washed,O
again,O
.,O
The,O
substrate,O
",",O
p,O
-,O
nitrophenylphosphate,O
",",O
was,O
used,O
for,O
visualisation,O
.,O
Control,O
wells,O
had,O
primary,O
antibody,B-GP
omitted,O
.,O
In,O
addition,O
",",O
Schneider,O
’,O
s,O
medium,O
and,O
FBS,O
were,O
tested,O
for,O
laminin,B-GP
and,O
its,O
absence,O
confirmed,O
.,O
Detection,O
of,O
laminin,B-GP
bound,O
to,O
culture,O
plates,O
To,O
establish,O
whether,O
laminin,B-GP
could,O
bind,O
to,O
culture,O
plates,O
",",O
making,O
it,O
unavailable,O
in,O
solution,O
to,O
developing,O
parasites,O
",",O
culture,O
plates,O
were,O
incubated,O
for,O
24,O
h,O
at,O
19,O
°,O
C,O
with,O
100,O
μg,O
of,O
mouse,B-OG
laminin,B-GP
in,O
PBS,O
.,O
The,O
plates,O
were,O
washed,O
with,O
PBS,O
and,O
assayed,O
for,O
laminin,B-GP
by,O
immunofluorescence,O
using,O
a,O
polyclonal,O
anti,O
-,O
laminin,B-GP
antibody,B-GP
directed,O
against,O
all,O
three,O
chains,O
.,O
Similarly,O
",",O
Drosophila,B-OG
S2,O
cells,O
were,O
cultured,O
in,O
OCM,O
for,O
24,O
h,O
",",O
the,O
cells,O
were,O
then,O
removed,O
",",O
and,O
the,O
culture,O
plates,O
assayed,O
to,O
determine,O
whether,O
laminin,B-GP
secreted,O
by,O
the,O
cells,O
was,O
bound,O
to,O
the,O
plate,O
.,O
Minimal,O
media,O
Using,O
sterile,O
PBS,O
as,O
a,O
base,O
",",O
components,O
of,O
OCM,O
(,O
Schneider,O
’,O
s,O
medium,O
",",O
heat,O
-,O
inactivated,O
FBS,O
",",O
lipoprotein,O
and,O
cholesterol,O
",",O
NaHCO3,O
and,O
hypoxanthine,O
),O
were,O
added,O
singularly,O
or,O
in,O
combination,O
at,O
appropriate,O
concentrations,O
.,O
During,O
further,O
medium,O
minimisation,O
",",O
Albumax,O
II,O
(,O
Invitrogen,O
),O
was,O
used,O
as,O
a,O
replacement,O
for,O
FBS,O
and,O
Schneider,O
’,O
s,O
medium,O
was,O
replaced,O
by,O
individual,O
components,O
in,O
groups,O
of,O
(,O
i,O
),O
amino,O
acids,O
",",O
(,O
ii,O
),O
inorganic,O
salts,O
and,O
(,O
iii,O
),O
other,O
components,O
",",O
as,O
listed,O
by,O
the,O
manufacturer,O
.,O
Media,O
pH,O
Full,O
-,O
media,O
were,O
used,O
for,O
studies,O
on,O
the,O
effects,O
of,O
the,O
media,O
pH,O
.,O
Media,O
were,O
adjusted,O
by,O
adding,O
5,O
M,O
NaOH,O
at,O
room,O
temperature,O
before,O
filtration,O
(,O
0,O
.,O
22,O
μm,O
).,O
However,O
",",O
as,O
pH,O
was,O
found,O
to,O
steadily,O
rise,O
during,O
the,O
culture,O
period,O
",",O
25,O
mM,O
N,O
-,O
2,O
-,O
hydroxyethylpiperazine,O
-,O
N,O
′-,O
2,O
-,O
ethanesulfonic,O
acid,O
(,O
Hepes,O
),O
was,O
also,O
used,O
as,O
a,O
buffer,O
to,O
maintain,O
initial,O
pH,O
values,O
of,O
6,O
",",O
7,O
",",O
8,O
and,O
9,O
.,O
PBS,O
adjusted,O
to,O
pH,O
6,O
",",O
7,O
",",O
8,O
or,O
9,O
was,O
used,O
for,O
comparison,O
.,O
Culture,O
vessels,O
In,O
the,O
absence,O
of,O
either,O
Matrigel,O
or,O
co,O
-,O
cultured,O
cells,O
",",O
ookinetes,O
were,O
observed,O
to,O
adhere,O
to,O
the,O
surface,O
(,O
IWAKI,O
Cat,O
.,O
No,O
.,O
3830,O
-,O
048,O
);,O
as,O
determined,O
by,O
no,O
movement,O
upon,O
gentle,O
agitation,O
.,O
To,O
eliminate,O
possible,O
cues,O
received,O
from,O
adhesion,O
",",O
ookinetes,O
were,O
seeded,O
into,O
non,O
-,O
treated,O
IWAKI,O
multiwell,O
plates,O
(,O
Cat,O
.,O
No,O
.,O
1830,O
-,O
048,O
),O
at,O
the,O
same,O
density,O
.,O
To,O
remove,O
potential,O
transformation,O
cues,O
received,O
from,O
mutual,O
adhesion,O
",",O
ookinetes,O
were,O
placed,O
one,O
per,O
well,O
in,O
treated,O
and,O
non,O
-,O
treated,O
plates,O
.,O
Statistical,O
analyses,O
Data,O
were,O
analysed,O
using,O
Minitab,O
version,O
14,O
.,O
The,O
Anderson,O
-,O
Darling,O
and,O
Bartlett,O
’,O
s,O
test,O
were,O
used,O
to,O
test,O
for,O
normal,O
distribution,O
and,O
equality,O
of,O
variance,O
",",O
respectively,O
.,O
Data,O
from,O
repeat,O
experiments,O
were,O
compared,O
using,O
a,O
General,O
Linear,O
Model,O
and,O
",",O
if,O
not,O
significantly,O
different,O
",",O
pooled,O
",",O
tested,O
for,O
normality,O
and,O
equality,O
of,O
variance,O
and,O
analysed,O
using,O
the,O
General,O
Linear,O
Model,O
to,O
compare,O
transformation,O
rates,O
",",O
growth,O
and,O
viability,O
across,O
conditions,O
and,O
across,O
time,O
.,O
Results,O
Markers,O
for,O
viability,O
A,O
major,O
constraint,O
in,O
characterising,O
the,O
process,O
of,O
transformation,O
has,O
been,O
to,O
demonstrate,O
conclusively,O
that,O
an,O
ookinete,O
has,O
undergone,O
differentiation,O
to,O
become,O
an,O
oocyst,O
.,O
Using,O
P,B-OG
.,I-OG
berghei,I-OG
(,O
PbGFPCON,O
clone,O
259cl2,O
),O
that,O
constitutively,O
expresses,O
green,B-GP
fluorescent,I-GP
protein,I-GP
(,O
GFP,B-GP
"),",O
we,O
have,O
observed,O
that,O
GFP,B-GP
expression,O
",",O
although,O
becoming,O
faint,O
",",O
often,O
persists,O
in,O
parasites,O
permeable,O
to,O
Erythrosin,O
B,O
.,O
GFP,B-GP
expression,O
was,O
therefore,O
deemed,O
a,O
less,O
reliable,O
viability,O
indicator,O
in,O
our,O
culture,O
system,O
.,O
Viability,O
of,O
ookinetes,O
at,O
the,O
outset,O
typically,O
ranged,O
from,O
80,O
%,O
to,O
90,O
%.,O
Parasites,O
continued,O
to,O
exclude,O
the,O
vital,O
dye,O
Erythrosin,O
B,O
after,O
rounding,O
up,O
to,O
form,O
oocysts,O
",",O
thus,O
supporting,O
the,O
view,O
that,O
the,O
changing,O
morphology,O
that,O
we,O
observe,O
during,O
transformation,O
is,O
not,O
associated,O
with,O
dying,O
ookinetes,O
.,O
Markers,O
for,O
transformation,O
A,O
P,B-OG
.,I-OG
berghei,I-OG
ookinete,O
transforms,O
from,O
a,O
banana,O
-,O
like,O
shape,O
",",O
approximately,O
10,O
μm,O
in,O
length,O
",",O
to,O
become,O
a,O
spherical,O
young,O
oocyst,O
with,O
a,O
diameter,O
of,O
7,O
–,O
8,O
μm,O
.,O
In,O
an,O
attempt,O
to,O
find,O
mRNA,O
markers,O
that,O
would,O
help,O
to,O
identify,O
a,O
newly,O
transformed,O
oocyst,O
and,O
distinguish,O
it,O
from,O
other,O
parasite,O
stages,O
that,O
may,O
be,O
present,O
in,O
the,O
culture,O
",",O
we,O
looked,O
at,O
the,O
following,O
well,O
-,O
characterised,O
housekeeping,O
or,O
putative,O
ookinete,O
/,O
early,O
oocyst,O
-,O
specific,O
molecules,O
for,O
signs,O
of,O
changes,O
in,O
transcription,O
:,O
CTRP,B-GP
",",O
WARP,B-GP
",",O
sporozoite,B-GP
microneme,I-GP
protein,I-GP
essential,I-GP
for,I-GP
cell,I-GP
traversal,I-GP
(,O
SPECT,B-GP
"),",O
Myosin,B-GP
A,I-GP
",",O
hypoxanthine,B-GP
–,I-GP
guanine,I-GP
phosphorybosyltransferase,I-GP
(,O
HGPRT,B-GP
"),",O
scavenger,B-GP
receptor,I-GP
",",O
P28,B-GP
",",O
RNA,O
S,O
and,O
circumsporozoite,B-GP
protein,I-GP
(,O
CSP,B-GP
).,O
However,O
",",O
none,O
of,O
these,O
were,O
suitable,O
as,O
no,O
change,O
in,O
transcript,O
abundance,O
occurred,O
during,O
the,O
transformation,O
process,O
or,O
in,O
the,O
early,O
oocyst,O
(,O
data,O
not,O
shown,O
).,O
We,O
were,O
therefore,O
unable,O
to,O
positively,O
identify,O
the,O
presence,O
of,O
early,O
oocyst,O
-,O
specific,O
features,O
by,O
PCR,O
analysis,O
and,O
assessment,O
has,O
relied,O
on,O
morphological,O
observations,O
and,O
the,O
demonstration,O
of,O
growth,O
.,O
Morphological,O
and,O
ultra,O
-,O
structural,O
description,O
of,O
transformation,O
The,O
in,O
vitro,O
transformation,O
of,O
P,B-OG
.,I-OG
berghei,I-OG
ookinetes,O
to,O
young,O
oocysts,O
follows,O
a,O
precise,O
morphological,O
pattern,O
",",O
distinct,O
from,O
that,O
of,O
zygote,O
through,O
retort,O
to,O
ookinete,O
.,O
Whereas,O
immature,O
ookinetes,O
form,O
via,O
an,O
extension,O
from,O
a,O
spherical,O
zygote,O
",",O
projecting,O
from,O
just,O
one,O
region,O
(,O
Sinden,O
et,O
al,O
".,",O
1985,O
",",O
1987,O
"),",O
fully,O
mature,O
",",O
banana,O
-,O
shaped,O
ookinetes,O
progress,O
to,O
oocysts,O
by,O
rounding,O
up,O
via,O
the,O
formation,O
of,O
a,O
protrusion,O
in,O
the,O
middle,O
of,O
the,O
ookinete,O
that,O
always,O
originates,O
on,O
the,O
outer,O
convex,O
edge,O
.,O
We,O
have,O
identified,O
this,O
phase,O
as,O
a,O
transforming,O
ookinete,O
(,O
took,O
),O
(,O
see,O
Fig,O
.,O
1A,O
–,O
C,O
and,O
F,O
).,O
The,O
nucleus,O
is,O
in,O
the,O
hump,O
",",O
the,O
two,O
-,O
tail,O
ends,O
of,O
the,O
ookinete,O
are,O
still,O
visible,O
in,O
late,O
tooks,O
(,O
Fig,O
.,O
1B,O
and,O
D,O
),O
and,O
DAPI,O
-,O
positive,O
material,O
appears,O
to,O
increase,O
in,O
size,O
when,O
in,O
the,O
newly,O
forming,O
oocyst,O
(,O
Fig,O
.,O
1C,O
).,O
We,O
regarded,O
fully,O
rounded,O
tooks,O
as,O
having,O
completed,O
transformation,O
to,O
an,O
early,O
oocyst,O
.,O
Within,O
each,O
culture,O
",",O
the,O
process,O
of,O
transformation,O
of,O
mature,O
ookinetes,O
to,O
oocysts,O
is,O
asynchronous,O
but,O
all,O
viable,O
ookinetes,O
have,O
become,O
oocysts,O
in,O
24,O
–,O
48,O
h,O
.,O
Ookinetes,O
that,O
have,O
permeable,O
membranes,O
do,O
not,O
complete,O
transformation,O
.,O
Plasmodium,B-OG
berghei,I-OG
(,O
PbGFPCON,O
),O
tooks,O
have,O
also,O
been,O
observed,O
in,O
vivo,O
on,O
mosquito,B-OG
midguts,O
28,O
h,O
post,O
-,O
feeding,O
on,O
gametocytaemic,O
blood,O
(,O
Fig,O
.,O
1E,O
).,O
At,O
the,O
ultra,O
-,O
structural,O
level,O
",",O
in,O
vitro,O
",",O
the,O
single,O
plasmalemma,O
of,O
the,O
newly,O
forming,O
oocyst,O
can,O
be,O
distinguished,O
from,O
the,O
triple,O
membrane,O
of,O
the,O
ookinete,O
pellicle,O
and,O
microtubules,O
are,O
no,O
longer,O
visible,O
in,O
this,O
area,O
(,O
Fig,O
.,O
2B,O
–,O
F,O
).,O
A,O
distinct,O
junction,O
between,O
the,O
ookinete,O
pellicle,O
and,O
the,O
single,O
plasmalemma,O
can,O
be,O
seen,O
(,O
Fig,O
.,O
2D,O
and,O
E,O
),O
and,O
the,O
nucleus,O
can,O
be,O
observed,O
in,O
the,O
hump,O
of,O
the,O
took,O
(,O
Fig,O
.,O
2C,O
).,O
The,O
role,O
of,O
basal,O
lamina,O
components,O
and,O
co,O
-,O
cultured,O
cells,O
in,O
ookinete,O
to,O
oocyst,O
transformation,O
Following,O
incubation,O
of,O
gametocytaemic,O
blood,O
for,O
18,O
h,O
",",O
cultures,O
were,O
enriched,O
for,O
ookinetes,O
;,O
however,O
",",O
they,O
still,O
contained,O
asexual,O
stage,O
parasites,O
",",O
gametocytes,O
and,O
zygotes,O
in,O
the,O
process,O
of,O
transforming,O
into,O
ookinetes,O
.,O
The,O
proportion,O
of,O
ookinetes,O
in,O
the,O
total,O
parasite,O
population,O
decreased,O
from,O
∼,O
25,O
%,O
on,O
day,O
0,O
to,O
∼,O
3,O
%,O
on,O
day,O
1,O
and,O
less,O
than,O
1,O
%,O
on,O
day,O
2,O
post,O
-,O
culture,O
.,O
No,O
tooks,O
were,O
present,O
on,O
day,O
0,O
but,O
they,O
represented,O
approximately,O
10,O
%,O
of,O
the,O
total,O
fluorescing,O
parasites,O
when,O
viewed,O
on,O
days,O
1,O
and,O
2,O
",",O
and,O
a,O
concomitant,O
increase,O
in,O
diameter,O
of,O
spherical,O
parasites,O
from,O
approximately,O
7,O
to,O
8,O
μm,O
occurred,O
from,O
day,O
1,O
to,O
day,O
2,O
.,O
As,O
development,O
can,O
only,O
proceed,O
in,O
one,O
direction,O
",",O
these,O
spheres,O
were,O
regarded,O
as,O
newly,O
transformed,O
oocysts,O
.,O
Over,O
90,O
%,O
of,O
the,O
ookinetes,O
cultured,O
with,O
Drosophila,B-OG
S2,O
cells,O
in,O
the,O
presence,O
of,O
the,O
basal,O
lamina,O
substitute,O
",",O
Matrigel,O
",",O
transformed,O
into,O
young,O
oocysts,O
(,O
termed,O
maximal,O
transformation,O
rate,O
),O
over,O
a,O
1,O
to,O
2,O
day,O
period,O
and,O
underwent,O
some,O
growth,O
in,O
diameter,O
by,O
day,O
3,O
.,O
Two,O
potential,O
sources,O
of,O
BL,O
components,O
had,O
been,O
identified,O
;,O
namely,O
Matrigel,O
and,O
the,O
Drosophila,B-OG
S2,O
cells,O
",",O
which,O
have,O
been,O
reported,O
to,O
produce,O
basal,O
lamina,O
components,O
such,O
as,O
laminin,B-GP
(,O
Fessler,O
et,O
al,O
".,",O
1987,O
).,O
In,O
our,O
hands,O
",",O
S2,O
cells,O
secreted,O
the,O
β,O
-,O
and,O
γ,O
-,O
chains,O
of,O
laminin,B-GP
into,O
supplemented,O
Schneider,O
’,O
s,O
medium,O
(,O
Fig,O
.,O
3A,O
),O
and,O
laminin,B-GP
was,O
detected,O
at,O
levels,O
more,O
than,O
twofold,O
above,O
background,O
from,O
200,O
cell,O
equivalents,O
from,O
a,O
confluent,O
flask,O
of,O
Drosophila,B-OG
S2,O
cells,O
(,O
Fig,O
.,O
3B,O
"),",O
thus,O
confirming,O
that,O
the,O
cell,O
line,O
used,O
can,O
secrete,O
laminin,B-GP
.,O
However,O
",",O
when,O
cells,O
were,O
cultured,O
with,O
OCM,O
no,O
laminin,B-GP
was,O
detectable,O
in,O
the,O
medium,O
or,O
bound,O
to,O
the,O
culture,O
plate,O
(,O
IFAT,O
),O
on,O
days,O
1,O
–,O
9,O
post,O
-,O
culture,O
.,O
Taken,O
together,O
these,O
results,O
suggest,O
that,O
laminin,B-GP
is,O
not,O
secreted,O
in,O
detectable,O
amounts,O
by,O
the,O
Drosophila,B-OG
S2,O
cells,O
in,O
our,O
in,O
vitro,O
culture,O
conditions,O
.,O
Upon,O
removal,O
of,O
Matrigel,O
or,O
Matrigel,O
and,O
Drosophila,B-OG
S2,O
cells,O
from,O
the,O
cultures,O
",",O
no,O
significant,O
difference,O
was,O
detected,O
in,O
the,O
percentage,O
of,O
transformed,O
parasites,O
between,O
culture,O
conditions,O
(,O
with,O
and,O
without,O
cells,O
or,O
Matrigel,O
),O
(,O
ANOVA,O
",",O
F,O
(,O
2,O
",",O
2,O
),O
=,O
0,O
.,O
90,O
",",O
P,O
=,O
0,O
.,O
422,O
),O
(,O
Fig,O
.,O
4,O
).,O
This,O
suggests,O
that,O
transformation,O
cues,O
/,O
triggers,O
",",O
if,O
required,O
",",O
are,O
not,O
provided,O
by,O
the,O
BL,O
-,O
like,O
substitute,O
Matrigel,O
or,O
the,O
co,O
-,O
cultured,O
cells,O
.,O
Thus,O
",",O
BL,O
components,O
such,O
as,O
laminin,B-GP
do,O
not,O
initiate,O
transformation,O
.,O
Transforming,O
ookinetes,O
often,O
clump,O
together,O
and,O
sink,O
to,O
the,O
bottom,O
of,O
the,O
culture,O
wells,O
",",O
thus,O
physical,O
contact,O
with,O
other,O
parasites,O
or,O
a,O
solid,O
surface,O
may,O
be,O
required,O
for,O
transformation,O
.,O
This,O
hypothesis,O
was,O
not,O
upheld,O
as,O
parasites,O
cultured,O
in,O
culture,O
plates,O
treated,O
to,O
become,O
hydrophilic,O
or,O
non,O
-,O
treated,O
plates,O
and,O
parasites,O
maintained,O
singly,O
or,O
at,O
various,O
densities,O
still,O
transformed,O
into,O
oocysts,O
by,O
day,O
2,O
of,O
culture,O
.,O
Is,O
an,O
extrinsic,O
trigger,O
required,O
for,O
transformation,O
?,O
Following,O
removal,O
of,O
both,O
BL,O
and,O
co,O
-,O
cultured,O
cells,O
",",O
we,O
sought,O
to,O
determine,O
whether,O
ookinetes,O
would,O
transform,O
into,O
oocysts,O
spontaneously,O
",",O
without,O
any,O
added,O
trigger,O
.,O
PBS,O
alone,O
did,O
not,O
support,O
transformation,O
",",O
therefore,O
precluding,O
time,O
-,O
dependent,O
transformation,O
in,O
these,O
minimal,O
conditions,O
.,O
Viable,O
ookinetes,O
could,O
be,O
maintained,O
in,O
PBS,O
for,O
up,O
to,O
7,O
days,O
(,O
e,O
.,O
g,O
.,O
viability,O
on,O
day,O
1,O
",",O
84,O
%;,O
day,O
3,O
",",O
65,O
%,O
and,O
day,O
6,O
",",O
5,O
%).,O
Removal,O
of,O
100,O
",",O
200,O
or,O
300,O
μl,O
of,O
the,O
PBS,O
and,O
replacement,O
with,O
the,O
same,O
quantity,O
of,O
OCM,O
stimulated,O
transformation,O
in,O
a,O
time,O
and,O
volume,O
dependent,O
manner,O
(,O
see,O
Table,O
2,O
).,O
If,O
still,O
viable,O
",",O
ookinetes,O
could,O
be,O
induced,O
to,O
transform,O
up,O
to,O
3,O
days,O
post,O
-,O
PBS,O
culture,O
",",O
thus,O
suggesting,O
that,O
the,O
transformation,O
process,O
will,O
not,O
be,O
supported,O
unless,O
appropriate,O
cues,O
are,O
received,O
by,O
the,O
parasite,O
",",O
and,O
that,O
these,O
cues,O
are,O
present,O
in,O
OCM,O
in,O
limiting,O
amounts,O
.,O
Minimal,O
requirements,O
for,O
ookinete,O
to,O
oocyst,O
transformation,O
The,O
addition,O
of,O
single,O
OCM,O
components,O
to,O
PBS,O
had,O
varying,O
effects,O
on,O
parasite,O
development,O
(,O
Table,O
3,O
).,O
Notably,O
",",O
sodium,O
bicarbonate,O
(,O
23,O
.,O
8,O
mM,O
),O
alone,O
supported,O
transformation,O
of,O
ookinetes,O
to,O
live,O
tooks,O
",",O
but,O
parasites,O
failed,O
to,O
complete,O
the,O
entire,O
rounding,O
-,O
up,O
process,O
to,O
form,O
young,O
oocysts,O
.,O
In,O
contrast,O
",",O
a,O
0,O
.,O
2,O
%,O
lipid,O
/,O
cholesterol,O
component,O
was,O
toxic,O
to,O
ookinetes,O
",",O
killing,O
approximately,O
25,O
%,O
within,O
4,O
h,O
of,O
culture,O
and,O
all,O
ookinetes,O
within,O
24,O
h,O
",",O
and,O
although,O
a,O
tenth,O
of,O
the,O
concentration,O
was,O
not,O
toxic,O
",",O
it,O
did,O
not,O
stimulate,O
transformation,O
.,O
The,O
addition,O
of,O
combinations,O
of,O
heat,O
-,O
inactivated,O
FBS,O
(,O
HI,O
FBS,O
),O
and,O
sodium,O
bicarbonate,O
or,O
Schneider,O
’,O
s,O
medium,O
and,O
sodium,O
bicarbonate,O
to,O
PBS,O
permitted,O
complete,O
transformation,O
at,O
maximal,O
rates,O
.,O
However,O
",",O
the,O
latter,O
combination,O
resulted,O
in,O
the,O
appearance,O
of,O
a,O
white,O
precipitate,O
",",O
obscuring,O
views,O
of,O
ookinetes,O
and,O
leading,O
to,O
the,O
death,O
of,O
parasites,O
within,O
2,O
–,O
3,O
days,O
.,O
Transformation,O
also,O
occurred,O
when,O
sodium,O
bicarbonate,O
was,O
replaced,O
with,O
sodium,O
carbonate,O
",",O
although,O
a,O
precipitate,O
was,O
again,O
formed,O
.,O
Growth,O
of,O
viable,O
oocysts,O
proceeded,O
for,O
5,O
days,O
in,O
PBS,O
containing,O
15,O
%,O
HI,O
FBS,O
and,O
23,O
.,O
8,O
mM,O
sodium,O
bicarbonate,O
(,O
minimal,O
media,O
),O
The,O
mean,O
diameter,O
of,O
young,O
oocysts,O
increased,O
from,O
7,O
to,O
8,O
μm,O
on,O
day,O
1,O
post,O
-,O
culture,O
to,O
11,O
–,O
12,O
μm,O
on,O
day,O
5,O
(,O
Table,O
4,O
).,O
However,O
",",O
maintaining,O
the,O
parasites,O
in,O
minimal,O
media,O
did,O
not,O
permit,O
complete,O
sporogonic,O
development,O
and,O
oocysts,O
were,O
no,O
longer,O
viable,O
after,O
7,O
days,O
.,O
As,O
serum,O
is,O
notoriously,O
difficult,O
to,O
define,O
",",O
we,O
substituted,O
15,O
%,O
FBS,O
in,O
PBS,O
with,O
15,O
%,O
Albumax,O
",",O
but,O
this,O
failed,O
to,O
support,O
transformation,O
.,O
We,O
therefore,O
tried,O
to,O
identify,O
groups,O
of,O
components,O
of,O
Schneider,O
’,O
s,O
medium,O
(,O
e,O
.,O
g,O
.,O
amino,O
acids,O
",",O
salts,O
",",O
sugars,O
or,O
yeast,B-OG
),O
that,O
alone,O
might,O
sustain,O
development,O
.,O
,O
of,O
these,O
groups,O
permitted,O
oocyst,O
development,O
",",O
however,O
partial,O
transformation,O
did,O
occur,O
in,O
the,O
inorganic,O
salts,O
group,O
(,O
data,O
not,O
shown,O
).,O
These,O
results,O
indicate,O
that,O
",",O
whilst,O
bicarbonate,O
alone,O
may,O
initiate,O
transformation,O
",",O
complete,O
transformation,O
requires,O
a,O
combination,O
of,O
essential,O
nutrients,O
and,O
thus,O
transformation,O
may,O
be,O
a,O
two,O
-,O
stage,O
process,O
.,O
Media,O
pH,O
and,O
transformation,O
As,O
the,O
pH,O
of,O
bicarbonate,O
buffers,O
is,O
strongly,O
influenced,O
by,O
pCO2,O
and,O
hence,O
sodium,O
bicarbonate,O
concentration,O
",",O
we,O
adjusted,O
the,O
pH,O
of,O
OCM,O
to,O
establish,O
if,O
this,O
alone,O
was,O
critical,O
for,O
transformation,O
(,O
Table,O
5,O
).,O
A,O
high,O
pH,O
(,O
9,O
.,O
0,O
),O
greatly,O
accelerated,O
the,O
rate,O
of,O
transformation,O
;,O
which,O
began,O
within,O
4,O
h,O
of,O
culture,O
.,O
However,O
",",O
at,O
pH,O
9,O
.,O
0,O
",",O
GFP,B-GP
fluorescence,O
was,O
less,O
intense,O
and,O
oocyst,O
plasma,O
membrane,O
breakdown,O
occurred,O
from,O
day,O
2,O
post,O
-,O
culture,O
",",O
after,O
oocysts,O
had,O
attained,O
diameters,O
of,O
10,O
–,O
15,O
μm,O
.,O
Low,O
pH,O
(,O
6,O
.,O
0,O
),O
severely,O
impaired,O
oocyst,O
growth,O
.,O
Transformation,O
was,O
maximal,O
at,O
pH,O
7,O
and,O
8,O
.,O
Discussion,O
Using,O
our,O
in,O
vitro,O
system,O
",",O
we,O
have,O
been,O
able,O
to,O
observe,O
many,O
thousands,O
of,O
ookinetes,O
undergo,O
transformation,O
to,O
young,O
oocysts,O
.,O
Our,O
observations,O
of,O
tooks,O
in,O
vivo,O
have,O
been,O
far,O
less,O
frequent,O
",",O
as,O
only,O
a,O
few,O
of,O
an,O
invading,O
population,O
will,O
be,O
transforming,O
at,O
any,O
one,O
time,O
.,O
However,O
",",O
it,O
is,O
clear,O
that,O
this,O
method,O
of,O
transformation,O
certainly,O
occurs,O
in,O
vivo,O
.,O
It,O
would,O
appear,O
that,O
the,O
break,O
-,O
up,O
of,O
the,O
inner,O
surface,O
membrane,O
of,O
the,O
ookinete,O
begins,O
specifically,O
along,O
the,O
convex,O
side,O
of,O
the,O
ookinete,O
and,O
spreads,O
from,O
this,O
point,O
",",O
and,O
there,O
is,O
likely,O
to,O
be,O
an,O
increase,O
in,O
the,O
surface,O
area,O
of,O
the,O
single,O
plasmalemma,O
during,O
this,O
process,O
.,O
We,O
were,O
unable,O
to,O
detect,O
remnants,O
of,O
the,O
inner,O
surface,O
membrane,O
in,O
areas,O
where,O
a,O
single,O
plasmalemma,O
was,O
visible,O
and,O
the,O
apical,O
complex,O
did,O
not,O
appear,O
to,O
undergo,O
immediate,O
de,O
-,O
differentiation,O
(,O
Canning,O
and,O
Sinden,O
",",O
1973,O
),O
but,O
persisted,O
until,O
late,O
into,O
the,O
took,O
phase,O
.,O
The,O
process,O
of,O
transformation,O
thus,O
appears,O
to,O
be,O
similar,O
to,O
that,O
of,O
the,O
sporozoite,O
to,O
the,O
exoerythrocytic,O
stage,O
in,O
the,O
hepatocyte,O
(,O
Meis,O
et,O
al,O
".,",O
1983,O
).,O
Ookinete,O
to,O
oocyst,O
transformation,O
represents,O
one,O
of,O
the,O
most,O
severe,O
bottlenecks,O
for,O
the,O
malaria,B-DS
parasite,O
",",O
often,O
reducing,O
ookinete,O
numbers,O
to,O
single,O
digits,O
(,O
Dimopoulos,O
et,O
al,O
".,",O
2002,O
).,O
Culturing,O
the,O
mosquito,B-OG
stages,O
of,O
the,O
rodent,B-OG
malaria,B-DS
parasite,O
in,O
vitro,O
",",O
in,O
the,O
absence,O
of,O
the,O
unfavorable,O
conditions,O
generated,O
in,O
the,O
blood,O
meal,O
bolus,O
and,O
by,O
the,O
insects,B-OG
’,O
innate,O
defence,O
system,O
",",O
permits,O
transformation,O
of,O
the,O
majority,O
of,O
live,O
ookinetes,O
to,O
the,O
oocyst,O
stage,O
and,O
thereby,O
suggests,O
that,O
most,O
parasites,O
have,O
the,O
potential,O
to,O
develop,O
rather,O
than,O
undergoing,O
apoptosis,O
as,O
they,O
do,O
in,O
the,O
midgut,O
lumen,O
(,O
Al,O
-,O
Olayan,O
et,O
al,O
".,",O
2002b,O
).,O
The,O
investigations,O
reported,O
here,O
suggest,O
that,O
this,O
transformation,O
is,O
not,O
internally,O
controlled,O
but,O
that,O
specific,O
external,O
compounds,O
are,O
required,O
to,O
stimulate,O
this,O
process,O
.,O
Some,O
authors,O
have,O
made,O
observations,O
that,O
suggest,O
that,O
the,O
BL,O
provides,O
the,O
necessary,O
cues,O
for,O
oocyst,O
transformation,O
(,O
Adini,O
and,O
Warburg,O
",",O
1999,O
;,O
Arrighi,O
et,O
al,O
".,",O
2005,O
).,O
For,O
example,O
",",O
when,O
gametocytes,O
are,O
injected,O
directly,O
into,O
the,O
haemocoel,O
",",O
ectopic,O
oocysts,O
develop,O
attached,O
to,O
the,O
BL,O
surrounding,O
tissues,O
such,O
as,O
the,O
fat,O
body,O
and,O
Malpighian,O
tubules,O
(,O
Weathersby,O
",",O
1954,O
;,O
Beaudoin,O
et,O
al,O
".,",O
1974,O
).,O
For,O
these,O
reasons,O
",",O
many,O
culture,O
protocols,O
have,O
employed,O
a,O
BL,O
substitute,O
(,O
Matrigel,O
),O
and,O
it,O
has,O
been,O
proposed,O
that,O
interactions,O
between,O
ookinete,O
surface,O
or,O
microneme,O
proteins,O
and,O
the,O
mosquito,B-OG
BL,O
play,O
some,O
role,O
in,O
oocyst,O
development,O
(,O
for,O
review,O
see,O
Siden,O
-,O
Kiamos,O
and,O
Louis,O
",",O
2004,O
).,O
Here,O
",",O
we,O
demonstrate,O
conclusively,O
that,O
ookinetes,O
will,O
transform,O
in,O
the,O
absence,O
of,O
any,O
source,O
of,O
BL,O
components,O
such,O
as,O
laminin,B-GP
or,O
collagen,B-GP
.,O
Additionally,O
",",O
adhesion,O
to,O
a,O
solid,O
substrate,O
or,O
other,O
cells,O
is,O
not,O
required,O
to,O
trigger,O
transformation,O
.,O
This,O
may,O
indicate,O
that,O
ookinete,O
transformation,O
is,O
driven,O
by,O
soluble,O
factors,O
derived,O
from,O
the,O
haemolymph,O
.,O
Developing,O
below,O
the,O
BL,O
",",O
in,O
the,O
subepithelial,O
space,O
",",O
ookinetes,O
and,O
oocysts,O
are,O
bathed,O
in,O
haemolymph,O
components,O
",",O
although,O
direct,O
contact,O
with,O
haemocytes,O
is,O
unlikely,O
.,O
Haemolymph,O
from,O
infected,O
or,O
non,O
-,O
infected,O
A,B-OG
.,I-OG
stephensi,I-OG
mosquitoes,B-OG
has,O
been,O
recorded,O
to,O
have,O
a,O
pH,O
ranging,O
from,O
6,O
.,O
5,O
to,O
6,O
.,O
8,O
(,O
Mack,O
and,O
Vanderberg,O
",",O
1978,O
).,O
Whilst,O
our,O
in,O
vitro,O
investigation,O
indicates,O
that,O
maximal,O
initiation,O
of,O
ookinete,O
to,O
oocyst,O
transformation,O
and,O
subsequent,O
growth,O
occurs,O
within,O
a,O
pH,O
range,O
of,O
7,O
–,O
8,O
we,O
did,O
not,O
examine,O
events,O
at,O
pHs,O
between,O
6,O
and,O
7,O
",",O
leaving,O
the,O
possibility,O
that,O
a,O
pH,O
in,O
this,O
range,O
may,O
be,O
more,O
favourable,O
.,O
With,O
the,O
addition,O
of,O
sodium,O
bicarbonate,O
alone,O
",",O
ookinetes,O
proceed,O
to,O
early,O
stages,O
of,O
transformation,O
as,O
indicated,O
by,O
a,O
change,O
in,O
shape,O
",",O
but,O
do,O
not,O
complete,O
development,O
to,O
young,O
oocysts,O
.,O
It,O
would,O
appear,O
that,O
sodium,O
bicarbonate,O
is,O
important,O
for,O
transformation,O
and,O
we,O
suggest,O
it,O
may,O
be,O
a,O
requirement,O
for,O
the,O
first,O
part,O
of,O
a,O
two,O
-,O
step,O
process,O
.,O
Following,O
took,O
formation,O
",",O
nutrients,O
such,O
as,O
amino,O
acids,O
and,O
sugars,O
are,O
needed,O
for,O
transformation,O
to,O
be,O
completed,O
and,O
some,O
growth,O
to,O
occur,O
.,O
These,O
findings,O
appear,O
to,O
reflect,O
those,O
reported,O
in,O
an,O
investigation,O
of,O
triggers,O
for,O
in,O
vitro,O
exflagellation,O
in,O
P,B-OG
.,I-OG
berghei,I-OG
.,O
Exflagellation,O
could,O
be,O
stimulated,O
in,O
an,O
extracellular,O
bicarbonate,O
concentration,O
of,O
28,O
mM,O
",",O
whereas,O
variation,O
of,O
the,O
pH,O
from,O
7,O
.,O
2,O
to,O
8,O
.,O
6,O
in,O
a,O
solution,O
depleted,O
of,O
bicarbonate,O
did,O
not,O
",",O
alone,O
",",O
provide,O
the,O
stimulus,O
(,O
Claudianos,O
et,O
al,O
".,",O
2002,O
).,O
The,O
requirement,O
for,O
a,O
range,O
of,O
nutrients,O
for,O
the,O
second,O
step,O
of,O
transformation,O
suggests,O
metabolite,O
stores,O
are,O
severely,O
limited,O
in,O
the,O
ookinete,O
and,O
insufficient,O
to,O
sustain,O
the,O
immediate,O
morphological,O
changes,O
that,O
occur,O
during,O
complete,O
transformation,O
.,O
In,O
contrast,O
to,O
the,O
majority,O
of,O
parasites,O
that,O
infect,O
mosquitoes,B-OG
",",O
both,O
Hepatozoon,B-OG
caiman,I-OG
(,O
Lainson,O
et,O
al,O
".,",O
2003,O
),O
and,O
Plasmodium,B-OG
spp,I-OG
.,O
develop,O
underneath,O
the,O
BL,O
on,O
the,O
midgut,O
of,O
their,O
respective,O
vectors,O
",",O
namely,O
Culex,B-OG
fatigans,I-OG
and,O
Anopheles,B-OG
spp,I-OG
".,",O
and,O
do,O
not,O
enter,O
the,O
haemocoel,O
immediately,O
after,O
exiting,O
the,O
gut,O
lumen,O
.,O
This,O
suggests,O
that,O
there,O
may,O
be,O
an,O
advantage,O
to,O
be,O
gained,O
by,O
developing,O
in,O
this,O
site,O
.,O
Recently,O
",",O
using,O
double,O
-,O
stranded,O
RNA,O
(,O
dsRNA,O
),O
gene,O
silencing,O
technology,O
",",O
Arrighi,O
et,O
al,O
.,O
(,O
2005,O
),O
demonstrated,O
that,O
depletion,O
of,O
mosquito,B-OG
laminin,B-GP
led,O
to,O
a,O
substantial,O
decrease,O
in,O
oocyst,O
numbers,O
and,O
suggested,O
that,O
the,O
presence,O
and,O
integrity,O
of,O
the,O
BL,O
is,O
vital,O
for,O
parasite,O
development,O
.,O
So,O
far,O
",",O
its,O
role,O
has,O
not,O
been,O
elucidated,O
but,O
it,O
may,O
be,O
of,O
importance,O
in,O
vivo,O
but,O
not,O
in,O
vitro,O
.,O
The,O
proposal,O
that,O
interactions,O
between,O
mosquito,B-OG
laminin,B-GP
and,O
molecules,O
in,O
the,O
oocyst,O
capsule,O
may,O
result,O
in,O
the,O
masking,O
of,O
the,O
oocyst,O
from,O
the,O
mosquito,B-OG
’,O
s,O
immune,O
system,O
",",O
thereby,O
protecting,O
the,O
developing,O
oocyst,O
from,O
being,O
melanised,O
",",O
has,O
been,O
recently,O
supported,O
by,O
findings,O
of,O
Warburg,O
et,O
al,O
.,O
(,O
2007,O
).,O
They,O
demonstrated,O
that,O
beads,O
coated,O
in,O
laminin,B-GP
or,O
the,O
ookinete,B-GP
surface,I-GP
protein,I-GP
P28,I-GP
are,O
protected,O
from,O
melanisation,O
when,O
injected,O
into,O
the,O
mosquito,B-OG
haemocoel,O
.,O
It,O
would,O
be,O
useful,O
investigate,O
this,O
hypothesis,O
further,O
using,O
a,O
refractory,O
",",O
melanizing,O
",",O
strain,O
of,O
mosquito,B-OG
.,O
In,O
conclusion,O
",",O
we,O
believe,O
we,O
present,O
the,O
first,O
description,O
of,O
an,O
intermediary,O
form,O
between,O
ookinete,O
and,O
oocyst,O
",",O
namely,O
the,O
took,O
.,O
Transformation,O
of,O
P,B-OG
.,I-OG
berghei,I-OG
ookinetes,O
to,O
young,O
oocysts,O
in,O
vitro,O
is,O
not,O
a,O
simple,O
time,O
-,O
dependent,O
phenomenon,O
;,O
it,O
requires,O
a,O
precise,O
environmental,O
stimulus,O
",",O
but,O
not,O
one,O
provided,O
by,O
basal,O
lamina,O
components,O
.,O
The,O
first,O
stage,O
of,O
transformation,O
is,O
bicarbonate,O
dependent,O
",",O
yet,O
full,O
transformation,O
also,O
requires,O
nutrients,O
and,O
a,O
suitable,O
pH,O
.,O
Minimal,O
requirements,O
for,O
transformation,O
have,O
been,O
reduced,O
in,O
this,O
culture,O
system,O
to,O
15,O
%,O
HI,O
FBS,O
and,O
23,O
.,O
8,O
mM,O
sodium,O
bicarbonate,O
adjusted,O
to,O
pH,O
7,O
.,O
0,O
.,O
These,O
findings,O
advance,O
our,O
understanding,O
of,O
the,O
least,O
studied,O
phase,O
of,O
malaria,B-DS
parasites,O
",",O
that,O
of,O
the,O
oocyst,O
.,O
They,O
demonstrate,O
the,O
benefit,O
that,O
an,O
in,O
vitro,O
system,O
can,O
bring,O
to,O
investigations,O
of,O
the,O
biology,O
of,O
the,O
mosquito,B-OG
stages,O
of,O
the,O
parasite,O
.,O
In,O
addition,O
",",O
re,O
-,O
evaluation,O
of,O
the,O
potential,O
for,O
attenuated,O
sporozoite,O
-,O
based,O
malaria,B-DS
vaccines,O
(,O
Good,O
",",O
2005,O
;,O
Waters,O
et,O
al,O
".,",O
2005,O
),O
has,O
brought,O
to,O
the,O
forefront,O
the,O
need,O
for,O
competent,O
systems,O
to,O
culture,O
sporogonic,O
stages,O
of,O
the,O
life,O
cycle,O
.,O
Formation,O
of,O
young,O
Plasmodium,B-OG
berghei,I-OG
oocysts,O
in,O
vitro,O
.,O
(,O
A,O
–,O
C,O
),O
P28,B-GP
(,O
surface,O
),O
and,O
DAPI,O
(,O
nuclear,O
),O
staining,O
of,O
ookinetes,O
(,O
A,O
"),",O
tooks,O
(,O
B,O
),O
and,O
young,O
oocysts,O
(,O
C,O
).,O
(,O
D,O
),O
PbGFPCON,O
tooks,O
during,O
late,O
transformation,O
in,O
culture,O
.,O
(,O
E,O
),O
PbGFPCON,O
early,O
transforming,O
ookinetes,O
in,O
Anopheles,B-OG
stephensi,I-OG
midguts,O
27,O
h,O
post,O
-,O
blood,O
feeding,O
(,O
composite,O
of,O
three,O
images,O
).,O
(,O
F,O
),O
Image,O
adapted,O
from,O
Sinden,O
et,O
al,O
.,O
(,O
1987,O
),O
(,O
i,O
–,O
iv,O
),O
to,O
incorporate,O
ookinete,O
to,O
oocyst,O
transformation,O
(,O
v,O
–,O
vii,O
).,O
Transformation,O
begins,O
with,O
a,O
small,O
hump,O
forming,O
on,O
the,O
outer,O
",",O
convex,O
",",O
edge,O
of,O
the,O
ookinete,O
",",O
often,O
towards,O
the,O
apical,O
end,O
.,O
Transforming,O
ookinetes,O
(,O
tooks,O
),O
then,O
take,O
on,O
a,O
snail,O
-,O
like,O
appearance,O
(,O
v,O
),O
and,O
the,O
nucleus,O
is,O
observed,O
to,O
move,O
into,O
the,O
developing,O
oocyst,O
.,O
Remnants,O
of,O
the,O
ookinete,O
tips,O
are,O
clearly,O
visible,O
(,O
distinguishing,O
these,O
forms,O
from,O
zygotes,O
;,O
(,O
vi,O
),O
just,O
prior,O
to,O
the,O
formation,O
of,O
spherical,O
young,O
oocysts,O
.,O
The,O
entire,O
population,O
of,O
ookinetes,O
transform,O
in,O
12,O
–,O
36,O
h,O
",",O
depending,O
on,O
nutrient,O
availability,O
.,O
TEM,O
images,O
of,O
an,O
ookinete,O
(,O
A,O
"),",O
and,O
tooks,O
(,O
B,O
–,O
F,O
),O
in,O
vitro,O
.,O
(,O
A,O
),O
Ookinete,O
",",O
with,O
nucleus,O
(,O
N,O
"),",O
pellicle,O
(,O
P,O
),O
and,O
apical,O
complex,O
(,O
AC,O
),O
visible,O
.,O
(,O
B,O
),O
Early,O
took,O
:,O
the,O
AC,O
is,O
still,O
clearly,O
visible,O
as,O
are,O
the,O
microtubules,O
(,O
MT,O
),O
and,O
the,O
beginning,O
of,O
the,O
early,O
oocyst,O
wall,O
",",O
forming,O
a,O
hump,O
on,O
the,O
outer,O
ookinete,O
edge,O
.,O
Membrane,O
generated,O
during,O
this,O
process,O
differs,O
from,O
the,O
ookinete,O
pellicle,O
(,O
single,O
arrow,O
"),",O
and,O
forms,O
the,O
basis,O
of,O
the,O
oocyst,O
wall,O
(,O
OW,O
).,O
(,O
C,O
),O
Early,O
took,O
:,O
nuclear,O
material,O
can,O
be,O
seen,O
to,O
have,O
moved,O
into,O
the,O
newly,O
formed,O
area,O
.,O
Double,O
and,O
single,O
membranes,O
define,O
the,O
new,O
OW,O
and,O
ookinete,O
pellicle,O
.,O
Broken,O
arrows,O
indicate,O
the,O
transition,O
areas,O
from,O
double,O
to,O
newly,O
formed,O
single,O
membranes,O
.,O
(,O
D,O
and,O
E,O
),O
Mid,O
-,O
stage,O
tooks,O
showing,O
microtubules,O
below,O
the,O
remaining,O
pellicle,O
.,O
(,O
F,O
),O
Late,O
took,O
:,O
remnants,O
of,O
the,O
ookinete,O
tips,O
with,O
double,O
membranes,O
can,O
be,O
seen,O
at,O
either,O
end,O
of,O
the,O
forming,O
oocyst,O
:,O
scale,O
bar,O
:,O
A,O
–,O
C,O
",",O
2,O
μm,O
;,O
D,O
–,O
F,O
",",O
1,O
μm,O
.,O
Production,O
of,O
laminin,B-GP
by,O
Drosophila,B-OG
melanogaster,I-OG
S2,O
cells,O
.,O
Cells,O
were,O
cultured,O
at,O
27,O
°,O
C,O
in,O
Schneider,O
’,O
s,O
Insect,B-OG
Cell,O
Medium,O
supplemented,O
with,O
FBS,O
and,O
Pen,O
/,O
Strep,O
.,O
(,O
A,O
),O
Western,O
blot,O
to,O
visualise,O
laminin,B-GP
secreted,O
into,O
the,O
medium,O
.,O
The,O
supernatant,O
from,O
a,O
confluent,O
flask,O
was,O
subjected,O
to,O
SDS,O
–,O
PAGE,O
and,O
transferred,O
to,O
a,O
nitrocellulose,O
membrane,O
.,O
The,O
blots,O
were,O
probed,O
with,O
anti,O
-,O
D,B-OG
.,I-OG
melanogaster,I-OG
laminin,B-GP
-,I-GP
1,I-GP
(,O
β,O
-,O
and,O
γ,O
-,O
chains,O
),O
polyclonal,O
antibodies,B-GP
(,O
lane,O
1,O
).,O
Molecular,O
markers,O
are,O
shown,O
on,O
the,O
right,O
(,O
lane,O
2,O
),O
and,O
the,O
corresponding,O
molecular,O
weight,O
labelled,O
.,O
(,O
B,O
),O
Laminin,B-GP
secretion,O
by,O
S2,O
cells,O
was,O
determined,O
by,O
ELISA,O
and,O
readings,O
are,O
expressed,O
as,O
cell,O
equivalents,O
per,O
100,O
μl,O
of,O
medium,O
.,O
Error,O
bars,O
=,O
SEM,O
and,O
n,O
=,O
3,O
wells,O
.,O
Maximal,O
ookinete,O
to,O
oocyst,O
transformation,O
rates,O
24,O
-,O
h,O
post,O
-,O
culture,O
.,O
Transformation,O
rates,O
were,O
assessed,O
by,O
counting,O
the,O
number,O
of,O
parasites,O
out,O
of,O
100,O
that,O
had,O
changed,O
from,O
ookinete,O
shape,O
to,O
young,O
oocysts,O
.,O
No,O
significant,O
difference,O
(,O
ANOVA,O
",",O
F,O
(,O
2,O
",",O
2,O
),O
=,O
0,O
.,O
90,O
",",O
P,O
=,O
0,O
.,O
422,O
),O
was,O
observed,O
between,O
full,O
-,O
culture,O
conditions,O
",",O
culture,O
without,O
Matrigel,O
and,O
culture,O
without,O
Matrigel,O
and,O
Drosophila,B-OG
S2,O
cells,O
.,O
Bars,O
represent,O
SEM,O
.,O
The,O
experiment,O
was,O
repeated,O
three,O
times,O
and,O
parasites,O
counted,O
in,O
three,O
separate,O
wells,O
for,O
each,O
condition,O
.,O
Components,O
of,O
full,O
-,O
oocyst,O
medium,O
(,O
OCM,O
),O
per,O
100,O
ml,O
Oocyst,O
medium,O
component,O
Final,O
concentration,O
/,O
100,O
ml,O
Sodium,O
bicarbonate,O
(,O
mM,O
),O
23,O
.,O
8,O
Hypoxanthine,O
(,O
mM,O
),O
3,O
.,O
68,O
Penicillin,O
(,O
U,O
)/,O
streptomycin,O
(,O
mg,O
),O
10,O
",",O
000,O
;,O
10,O
Gentamicin,O
(,O
mg,O
),O
20,O
Para,O
-,O
aminobenzoic,O
acid,O
(,O
μM,O
),O
44,O
Foetal,O
bovine,O
serum,O
(%),O
15,O
Lipid,O
/,O
cholesterol,O
(%),O
0,O
.,O
2,O
Schneider,O
’,O
s,O
medium,O
(%),O
85,O
Transformation,O
of,O
ookinetes,O
to,O
oocysts,O
maintained,O
in,O
PBS,O
Oocyst,O
medium,O
added,O
Day,O
0,O
Day,O
1,O
Day,O
2,O
Day,O
3,O
Day,O
4,O
Day,O
5,O
400,O
μl,O
added,O
day,O
0,O
–,O
✓,O
✓✓,O
✓✓,O
✓✓,O
✓✓,O
100,O
μl,O
added,O
day,O
0,O
–,O
–,O
✓,O
✓✓,O
✓✓,O
✓✓,O
100,O
μl,O
added,O
day,O
1,O
–,O
–,O
–,O
✓,O
✓✓,O
✓✓,O
100,O
μl,O
added,O
day,O
2,O
–,O
–,O
–,O
–,O
✓,O
✓✓,O
200,O
μl,O
added,O
day,O
0,O
–,O
✓,O
✓✓,O
✓✓,O
✓✓,O
✓✓,O
200,O
μl,O
added,O
day,O
1,O
–,O
–,O
✓,O
✓✓,O
✓✓,O
✓✓,O
200,O
μl,O
added,O
day,O
2,O
–,O
–,O
–,O
✓,O
✓✓,O
✓✓,O
300,O
μl,O
added,O
day,O
0,O
–,O
✓,O
✓✓,O
✓✓,O
✓✓,O
✓✓,O
300,O
μl,O
added,O
day,O
1,O
–,O
–,O
✓,O
✓✓,O
✓✓,O
✓✓,O
300,O
μl,O
added,O
day,O
2,O
–,O
–,O
–,O
✓,O
✓✓,O
✓✓,O
Minimal,O
requirements,O
for,O
triggering,O
ookinete,O
to,O
oocyst,O
transformation,O
in,O
PBS,O
Oocyst,O
medium,O
component,O
Day,O
0,O
Day,O
1,O
Day,O
2,O
Day,O
3,O
Full,O
-,O
media,O
–,O
✓,O
✓✓,O
✓✓,O
PBS,O
alone,O
–,O
–,O
–,O
–,O
PBS,O
+,O
hypoxanthine,O
–,O
–,O
–,O
–,O
PBS,O
+,O
PABA,O
–,O
–,O
–,O
–,O
PBS,O
+,O
lipids,O
–,O
×,O
×,O
×,O
PBS,O
+,O
sodium,O
bicarbonate,O
–,O
✓,O
✓,O
✓,O
PBS,O
+,O
Schneider,O
’,O
s,O
medium,O
–,O
✓,O
✓,O
✓✓,O
PBS,O
+,O
HI,O
FBS,O
–,O
✓,O
✓,O
✓✓,O
PBS,O
+,O
Schneider,O
’,O
s,O
+,O
sodium,O
bicarbonate,O
–,O
✓,O
✓✓,O
✓✓,O
PBS,O
+,O
HI,O
FBS,O
+,O
sodium,O
bicarbonate,O
–,O
✓,O
✓✓,O
✓✓,O
Growth,O
and,O
viability,O
of,O
Plasmodium,O
berghei,O
oocysts,O
over,O
a,O
5,O
day,O
period,O
of,O
culture,O
in,O
minimal,O
media,O
Time,O
post,O
-,O
culture,O
Day,O
1,O
Day,O
3,O
Day,O
5,O
Viability,O
(,O
n,O
=,O
100,O
),O
(%),O
92,O
89,O
84,O
Mean,O
oocyst,O
size,O
(,O
n,O
=,O
100,O
),O
(,O
μm,O
),O
7,O
.,O
80,O
±,O
0,O
.,O
1,O
9,O
.,O
51,O
±,O
0,O
.,O
17,O
11,O
.,O
36,O
±,O
0,O
.,O
15,O
Example,O
of,O
oocyst,O
Effects,O
of,O
pH,O
on,O
transformation,O
rates,O
pH,O
Day,O
1,O
Day,O
2,O
Day,O
3,O
Day,O
4,O
Day,O
5,O
Full,O
-,O
media,O
6,O
–,O
–,O
✓,O
✓,O
✓✓,O
7,O
✓,O
✓✓,O
✓✓,O
✓✓,O
✓✓,O
8,O
✓,O
✓✓,O
✓✓,O
✓✓,O
✓✓,O
9,O
✓✓,O
✓✓,O
✓✓,O
×,O
×,O
PBS,O
6,O
–,O
–,O
–,O
–,O
–,O
7,O
–,O
–,O
–,O
–,O
–,O
8,O
–,O
–,O
–,O
–,O
–,O
9,O
–,O
–,O
–,O
–,O
–,O
Cell,O
death,O
in,O
amastigote,O
forms,O
of,O
Leishmania,B-OG
amazonensis,I-OG
induced,O
by,O
parthenolide,O
Background,O
Leishmania,B-DS
amazonensis,I-DS
infection,I-DS
results,O
in,O
diverse,O
clinical,O
manifestations,O
:,O
cutaneous,O
",",O
mucocutaneous,O
or,O
visceral,B-DS
leishmaniasis,I-DS
.,O
The,O
arsenal,O
of,O
drugs,O
available,O
for,O
treating,O
Leishmania,B-DS
infections,I-DS
is,O
limited,O
.,O
Therefore,O
",",O
new,O
",",O
effective,O
",",O
and,O
less,O
toxic,O
leishmaniasis,B-DS
treatments,O
are,O
still,O
needed,O
.,O
We,O
verified,O
cell,O
death,O
in,O
amastigote,O
forms,O
of,O
Leishmania,B-OG
amazonensis,I-OG
induced,O
by,O
the,O
sesquiterpene,O
lactone,O
parthenolide,O
.,O
Results,O
The,O
tested,O
compound,O
was,O
able,O
to,O
concentration,O
-,O
dependently,O
affect,O
axenic,O
and,O
intracellular,O
amastigotes,O
",",O
with,O
IC50,O
values,O
of,O
1,O
.,O
3,O
μM,O
and,O
2,O
.,O
9,O
μM,O
",",O
respectively,O
after,O
72,O
h,O
incubation,O
.,O
No,O
genotoxic,O
effects,O
were,O
observed,O
in,O
a,O
micronucleus,O
test,O
in,O
mice,B-OG
.,O
Parthenolide,O
induced,O
morphological,O
and,O
ultrastructural,O
changes,O
in,O
axenic,O
amastigotes,O
",",O
including,O
a,O
loss,O
of,O
membrane,O
integrity,O
",",O
swelling,O
of,O
the,O
mitochondrion,O
",",O
cytoplasmic,O
vacuoles,O
",",O
and,O
intense,O
exocytic,O
activity,O
in,O
the,O
region,O
of,O
the,O
flagellar,O
pocket,O
.,O
These,O
results,O
led,O
us,O
to,O
investigate,O
the,O
occurrence,O
of,O
autophagic,O
vacuoles,O
with,O
monodansylcadaverine,O
and,O
the,O
integrity,O
of,O
the,O
plasma,O
membrane,O
and,O
mitochondrial,O
membrane,O
potential,O
using,O
flow,O
cytometry,O
.,O
In,O
all,O
of,O
the,O
tests,O
",",O
parthenolide,O
had,O
positive,O
results,O
.,O
Conclusions,O
Our,O
results,O
indicate,O
that,O
the,O
antileishmanial,O
action,O
of,O
parthenolide,O
is,O
associated,O
with,O
autophagic,O
vacuole,O
appearance,O
",",O
a,O
reduction,O
of,O
fluidity,O
",",O
a,O
loss,O
of,O
membrane,O
integrity,O
",",O
and,O
mitochondrial,O
dysfunction,O
.,O
Considering,O
the,O
limited,O
repertoire,O
of,O
existing,O
antileishmanial,O
compounds,O
",",O
the,O
products,O
derived,O
from,O
medicinal,O
plants,B-OG
has,O
been,O
one,O
the,O
greatest,O
advances,O
to,O
help,O
develop,O
new,O
chemotherapeutic,O
approaches,O
.,O
Background,O
Leishmaniasis,B-DS
is,O
associated,O
with,O
high,O
morbidity,O
but,O
low,O
mortality,O
.,O
It,O
is,O
a,O
poverty,O
-,O
related,O
disease,O
and,O
has,O
become,O
a,O
serious,O
impediment,O
to,O
socioeconomic,O
development,O
.,O
The,O
true,O
burden,O
of,O
this,O
illness,O
remains,O
unclear,O
because,O
the,O
notification,O
of,O
the,O
disease,O
is,O
compulsory,O
in,O
only,O
32,O
of,O
the,O
88,O
affected,O
countries,O
",",O
and,O
most,O
of,O
the,O
affected,O
people,O
live,O
in,O
remote,O
areas,O
.,O
Additionally,O
",",O
the,O
disfiguring,O
scars,O
caused,O
by,O
Leishmania,B-OG
keep,O
patients,O
hidden,O
.,O
An,O
estimated,O
1,O
.,O
5,O
million,O
new,O
cases,O
of,O
cutaneous,B-DS
leishmaniasis,I-DS
and,O
500,O
",",O
000,O
cases,O
of,O
visceral,B-DS
leishmaniasis,I-DS
occur,O
annually,O
",",O
with,O
approximately,O
12,O
million,O
people,O
currently,O
infected,O
[,O
1,O
].,O
Moreover,O
",",O
cases,O
of,O
Leishmania,B-OG
and,O
human,B-DS
immunodeficiency,I-DS
virus,I-DS
co,I-DS
-,I-DS
infection,I-DS
are,O
becoming,O
more,O
frequent,O
[,O
2,O
",",O
3,O
].,O
Leishmania,B-DS
(,I-DS
Leishmania,I-DS
),I-DS
amazonensis,I-DS
infection,I-DS
results,O
in,O
diverse,O
clinical,O
manifestations,O
",",O
ranging,O
from,O
cutaneous,O
to,O
mucocutaneous,O
or,O
visceral,O
involvement,O
[,O
4,O
].,O
This,O
is,O
attributable,O
to,O
the,O
genetic,O
diversity,O
of,O
L,B-OG
.,I-OG
amazonensis,I-OG
strains,O
",",O
and,O
this,O
divergence,O
extends,O
to,O
variations,O
of,O
chromosome,O
size,O
[,O
5,O
].,O
The,O
arsenal,O
of,O
drugs,O
available,O
for,O
treating,O
Leishmania,B-DS
infections,I-DS
is,O
limited,O
.,O
The,O
basic,O
treatment,O
consists,O
of,O
administering,O
pentavalent,O
antimonial,O
compounds,O
[,O
6,O
].,O
However,O
",",O
the,O
choice,O
of,O
medication,O
depends,O
on,O
the,O
species,O
involved,O
and,O
type,O
of,O
clinical,O
manifestation,O
[,O
7,O
].,O
The,O
usefulness,O
of,O
antileishmanial,O
drugs,O
has,O
been,O
limited,O
by,O
their,O
toxicity,O
",",O
and,O
treatment,O
failure,O
is,O
often,O
attributable,O
to,O
drug,O
resistance,O
[,O
8,O
].,O
To,O
solve,O
this,O
problem,O
",",O
developing,O
less,O
toxic,O
drugs,O
and,O
discovering,O
cellular,O
and,O
molecular,O
markers,O
in,O
parasites,O
to,O
identify,O
the,O
phenotype,O
of,O
chemoresistance,O
against,O
leishmanicidal,O
drugs,O
are,O
necessary,O
[,O
8,O
",",O
9,O
].,O
These,O
problems,O
led,O
to,O
the,O
development,O
of,O
additional,O
antileishmanial,O
drugs,O
.,O
Some,O
drug,O
-,O
delivery,O
systems,O
",",O
plants,B-OG
",",O
and,O
synthetic,O
compounds,O
are,O
being,O
developed,O
as,O
effective,O
treatments,O
for,O
the,O
disease,O
[,O
7,O
].,O
Previous,O
studies,O
demonstrated,O
the,O
in,O
vitro,O
activity,O
of,O
parthenolide,O
",",O
a,O
sesquiterpene,O
lactone,O
purified,O
from,O
Tanacetum,B-OG
parthenium,I-OG
",",O
against,O
promastigotes,O
and,O
intracellular,O
amastigotes,O
(,O
inside,O
J774G8,O
macrophages,O
),O
of,O
L,B-OG
.,I-OG
amazonensis,I-OG
[,O
10,O
].,O
Moreover,O
",",O
significant,O
alterations,O
in,O
promastigote,O
forms,O
were,O
demonstrated,O
by,O
light,O
microscopy,O
and,O
scanning,O
and,O
transmission,O
electron,O
microscopy,O
[,O
11,O
].,O
We,O
evaluated,O
the,O
activity,O
of,O
parthenolide,O
against,O
L,B-OG
.,I-OG
amazonensis,I-OG
axenic,O
amastigotes,O
and,O
demonstrated,O
a,O
possible,O
mechanism,O
of,O
action,O
of,O
this,O
compound,O
in,O
this,O
life,O
stage,O
of,O
the,O
parasite,O
.,O
Results,O
Antileishmanial,O
assays,O
The,O
addition,O
of,O
4,O
.,O
0,O
μM,O
parthenolide,O
to,O
the,O
culture,O
of,O
axenic,O
amastigotes,O
induced,O
growth,O
arrest,O
and,O
partial,O
cell,O
lysis,O
after,O
48,O
h,O
(,O
i,O
.,O
e,O
".,",O
growth,O
inhibition,O
up,O
to,O
90,O
%).,O
When,O
the,O
cells,O
were,O
treated,O
with,O
2,O
.,O
0,O
μM,O
parthenolide,O
",",O
the,O
percentage,O
of,O
growth,O
inhibition,O
was,O
approximately,O
70,O
%.,O
Parthenolide,O
had,O
an,O
IC50,O
of,O
1,O
.,O
3,O
μM,O
and,O
IC90,O
of,O
3,O
.,O
3,O
μM,O
after,O
72,O
h,O
incubation,O
(,O
Figure,O
1A,O
).,O
Effects,O
of,O
parthenolide,O
(,O
A,O
),O
and,O
amphotericin,O
B,O
(,O
B,O
),O
on,O
the,O
growth,O
of,O
L,B-OG
.,I-OG
amazonensis,I-OG
axenic,O
amastigotes,O
.,O
After,O
treatment,O
with,O
different,O
concentrations,O
of,O
the,O
drugs,O
",",O
parasites,O
were,O
counted,O
",",O
and,O
the,O
percentage,O
of,O
parasite,O
growth,O
inhibition,O
was,O
determined,O
daily,O
for,O
120,O
h,O
.,O
The,O
data,O
indicate,O
the,O
average,O
of,O
the,O
two,O
independent,O
experiments,O
performed,O
twice,O
.,O
Statistical,O
analysis,O
:,O
the,O
data,O
of,O
each,O
incubation,O
period,O
were,O
compared,O
statistically,O
at,O
p,O
<,O
0,O
.,O
05,O
.,O
Bars,O
that,O
are,O
not,O
indicated,O
with,O
letters,O
in,O
common,O
are,O
statistically,O
different,O
.,O
A,O
concentration,O
of,O
1,O
.,O
0,O
or,O
0,O
.,O
5,O
μM,O
of,O
the,O
reference,O
drug,O
amphotericin,O
B,O
inhibited,O
more,O
than,O
93,O
%,O
of,O
L,B-OG
.,I-OG
amazonensis,I-OG
amastigote,O
cell,O
growth,O
.,O
This,O
drug,O
had,O
an,O
IC50,O
and,O
IC90,O
of,O
0,O
.,O
22,O
μM,O
and,O
0,O
.,O
45,O
μM,O
",",O
respectively,O
",",O
after,O
culturing,O
for,O
72,O
h,O
(,O
Figure,O
1B,O
).,O
Parthenolide,O
also,O
inhibited,O
the,O
growth,O
of,O
intracellular,O
amastigotes,O
in,O
mouse,B-OG
resident,O
peritoneal,O
macrophages,O
after,O
24,O
h,O
incubation,O
.,O
Treatment,O
with,O
4,O
.,O
0,O
",",O
3,O
.,O
2,O
",",O
2,O
.,O
4,O
",",O
and,O
1,O
.,O
6,O
μM,O
parthenolide,O
reduced,O
the,O
proliferation,O
of,O
parasites,O
into,O
macrophages,O
(,O
survival,O
index,O
),O
by,O
82,O
.,O
5,O
",",O
59,O
.,O
4,O
",",O
37,O
.,O
3,O
",",O
and,O
6,O
.,O
1,O
"%,",O
respectively,O
",",O
compared,O
with,O
the,O
control,O
.,O
The,O
survival,O
index,O
indicated,O
that,O
parthenolide,O
inhibited,O
the,O
intracellular,O
viability,O
and,O
multiplication,O
of,O
Leishmania,B-OG
in,O
infected,O
murine,O
macrophages,O
and,O
showed,O
50,O
%,O
inhibition,O
of,O
cell,O
survival,O
at,O
a,O
concentration,O
of,O
2,O
.,O
9,O
μM,O
(,O
Figure,O
2,O
).,O
Effect,O
of,O
parthenolide,O
on,O
amastigotes,O
of,O
L,B-OG
.,I-OG
amazonensis,I-OG
in,O
mouse,B-OG
resident,O
peritoneal,O
macrophages,O
.,O
Peritoneal,O
macrophage,O
cells,O
were,O
infected,O
with,O
promastigote,O
forms,O
",",O
and,O
then,O
intracellular,O
amastigotes,O
were,O
treated,O
with,O
different,O
concentrations,O
of,O
parthenolide,O
.,O
After,O
24,O
h,O
treatment,O
",",O
the,O
survival,O
index,O
was,O
calculated,O
by,O
multiplying,O
the,O
percentage,O
of,O
macrophages,O
with,O
internalized,O
parasites,O
and,O
mean,O
number,O
of,O
internalized,O
parasites,O
per,O
macrophage,O
.,O
The,O
results,O
shown,O
are,O
from,O
one,O
representative,O
experiment,O
of,O
two,O
independent,O
experiments,O
performed,O
in,O
duplicate,O
.,O
The,O
data,O
were,O
compared,O
statistically,O
at,O
p,O
<,O
0,O
.,O
05,O
.,O
Bars,O
that,O
are,O
not,O
indicated,O
with,O
letters,O
in,O
common,O
are,O
statistically,O
different,O
.,O
Previous,O
studies,O
showed,O
that,O
when,O
J774G8,O
murine,O
macrophages,O
were,O
treated,O
with,O
parthenolide,O
",",O
the,O
50,O
%,O
cytotoxic,O
concentration,O
(,O
CC50,O
),O
was,O
56,O
.,O
4,O
μM,O
[,O
10,O
].,O
By,O
comparing,O
the,O
toxicity,O
for,O
J774G8,O
macrophages,O
and,O
activity,O
against,O
intracellular,O
amastigotes,O
",",O
obtaining,O
the,O
selectivity,O
index,O
ratio,O
is,O
possible,O
(,O
CC50,O
for,O
J774G8,O
cells,O
/,O
IC50,O
for,O
protozoa,B-OG
).,O
In,O
the,O
present,O
study,O
",",O
parthenolide,O
had,O
an,O
IC50,O
of,O
2,O
.,O
9,O
μM,O
",",O
presenting,O
a,O
selectivity,O
index,O
ratio,O
of,O
19,O
.,O
4,O
(,O
i,O
.,O
e,O
".,",O
the,O
compound,O
is,O
19,O
.,O
4,O
-,O
times,O
more,O
selective,O
against,O
parasites,O
than,O
host,O
cells,O
).,O
Mutagenicity,O
evaluation,O
The,O
results,O
of,O
the,O
in,O
vivo,O
bone,O
marrow,O
micronucleus,O
test,O
in,O
rats,B-OG
are,O
shown,O
in,O
Table,O
1,O
.,O
Parthenolide,O
did,O
not,O
induce,O
genotoxic,O
effects,O
at,O
a,O
concentration,O
of,O
3,O
.,O
75,O
mg,O
/,O
kg,O
body,O
weight,O
",",O
with,O
no,O
significant,O
increase,O
in,O
the,O
frequency,O
of,O
MNPCE,O
(,O
10,O
.,O
0,O
±,O
1,O
.,O
6,O
),O
compared,O
with,O
the,O
vehicle,O
control,O
group,O
(,O
7,O
.,O
0,O
±,O
1,O
.,O
8,O
).,O
In,O
contrast,O
",",O
a,O
significant,O
increase,O
in,O
the,O
frequency,O
of,O
MNPCE,O
was,O
observed,O
in,O
the,O
positive,O
control,O
group,O
(,O
cyclophosphamide,O
;,O
27,O
.,O
0,O
±,O
4,O
.,O
0,O
).,O
In,O
the,O
present,O
study,O
",",O
no,O
clinical,O
signs,O
of,O
toxicity,O
were,O
observed,O
in,O
treated,O
animals,B-OG
.,O
However,O
",",O
further,O
studies,O
should,O
be,O
performed,O
with,O
higher,O
concentrations,O
of,O
parthenolide,O
to,O
exclude,O
the,O
possibility,O
of,O
genotoxicity,O
.,O
Micronucleated,O
polychromatic,O
erythrocyte,O
(,O
MNPCE,O
),O
score,O
in,O
2,O
",",O
000,O
reticulocytes,O
from,O
bone,O
marrow,O
of,O
mice,B-OG
Treatment,O
MNPCE,O
(,O
mean,O
±,O
SD,O
),O
Vehicle,O
7,O
.,O
0,O
±,O
1,O
.,O
8,O
Cyclophosphamide,O
27,O
.,O
0,O
±,O
4,O
.,O
0b,O
Parthenolide,O
10,O
.,O
0,O
±,O
1,O
.,O
6a,O
Findings,O
after,O
24,O
h,O
oral,O
treatment,O
with,O
vehicle,O
(,O
negative,O
control,O
"),",O
cyclophosphamide,O
(,O
positive,O
control,O
"),",O
and,O
parthenolide,O
.,O
aNo,O
significant,O
difference,O
compared,O
with,O
negative,O
control,O
and,O
significant,O
difference,O
compared,O
with,O
positive,O
control,O
(,O
p,O
<,O
0,O
.,O
05,O
).,O
bSignificant,O
difference,O
compared,O
with,O
negative,O
control,O
(,O
p,O
<,O
0,O
.,O
05,O
).,O
Scanning,O
and,O
transmission,O
electron,O
microscopy,O
To,O
determine,O
the,O
morphological,O
and,O
ultrastructural,O
changes,O
in,O
L,B-OG
.,I-OG
amazonensis,I-OG
axenic,O
amastigotes,O
induced,O
by,O
parthenolide,O
",",O
the,O
cells,O
were,O
treated,O
with,O
the,O
IC50,O
(,O
1,O
.,O
3,O
μM,O
),O
of,O
the,O
compound,O
.,O
Untreated,O
controls,O
showed,O
no,O
morphological,O
(,O
Figure,O
3A,O
),O
or,O
ultrastructural,O
(,O
Figure,O
3D,O
),O
differences,O
.,O
Similarly,O
",",O
cells,O
incubated,O
with,O
0,O
.,O
05,O
%,O
DMSO,O
(,O
i,O
.,O
e,O
".,",O
the,O
same,O
concentration,O
used,O
in,O
the,O
final,O
solutions,O
of,O
parthenolide,O
),O
remained,O
unaltered,O
(,O
data,O
not,O
shown,O
).,O
When,O
treated,O
with,O
parthenolide,O
",",O
changes,O
in,O
form,O
were,O
visualized,O
by,O
scanning,O
electron,O
microscopy,O
(,O
Figure,O
3B,O
and,O
C,O
).,O
Transmission,O
electron,O
microscopy,O
showed,O
a,O
loss,O
of,O
membrane,O
integrity,O
associated,O
with,O
amphotericin,O
B,O
exposure,O
at,O
the,O
IC50,O
concentration,O
(,O
Figure,O
3E,O
).,O
Parthenolide,O
caused,O
intense,O
swelling,O
of,O
the,O
mitochondrion,O
(,O
Figure,O
3F,O
),O
and,O
cytoplasmic,O
blebbing,O
(,O
Figure,O
3G,O
).,O
Finally,O
",",O
the,O
ultrastructural,O
analysis,O
showed,O
that,O
amastigotes,O
treated,O
with,O
parthenolide,O
formed,O
multiple,O
cytoplasmic,O
vacuoles,O
(,O
Figure,O
3H,O
"),",O
and,O
intense,O
exocytic,O
activity,O
was,O
observed,O
in,O
the,O
region,O
of,O
the,O
flagellar,O
pocket,O
",",O
appearing,O
as,O
concentric,O
membranes,O
within,O
the,O
pocket,O
(,O
Figure,O
3I,O
).,O
Scanning,O
(,O
A,O
-,O
C,O
),O
and,O
transmission,O
(,O
D,O
-,O
I,O
),O
electron,O
microscopy,O
of,O
axenic,O
amastigotes,O
of,O
L,B-OG
.,I-OG
amazonensis,I-OG
treated,O
with,O
parthenolide,O
.,O
Amastigotes,O
were,O
incubated,O
for,O
72,O
h,O
in,O
the,O
absence,O
(,O
A,O
and,O
D,O
),O
or,O
presence,O
(,O
B,O
",",O
C,O
",",O
F,O
-,O
I,O
),O
of,O
the,O
IC50,O
(,O
1,O
.,O
3,O
μM,O
),O
of,O
parthenolide,O
.,O
For,O
transmission,O
electron,O
microscopy,O
",",O
the,O
treatment,O
of,O
amastigotes,O
was,O
also,O
accomplished,O
using,O
the,O
IC50,O
of,O
amphotericin,O
B,O
as,O
a,O
reference,O
drug,O
that,O
acts,O
on,O
the,O
cytoplasmic,O
membrane,O
(,O
E,O
).,O
The,O
arrows,O
indicate,O
plasma,O
membrane,O
blebs,O
or,O
loss,O
of,O
membrane,O
integrity,O
",",O
and,O
the,O
asterisks,O
indicate,O
vesicles,O
located,O
in,O
the,O
cytoplasm,O
or,O
flagellar,O
pocket,O
.,O
n,O
",",O
nucleus,O
;,O
f,O
",",O
flagellum,O
;,O
fp,O
",",O
flagellar,O
pocket,O
;,O
m,O
",",O
mitochondrion,O
;,O
k,O
",",O
kinetoplast,O
.,O
Scale,O
bars,O
=,O
1,O
μm,O
.,O
Labeling,O
of,O
autophagic,O
vacuoles,O
with,O
monodansylcadaverine,O
We,O
studied,O
the,O
incorporation,O
of,O
monodancylcadaverine,O
(,O
MDC,O
),O
in,O
cells,O
in,O
which,O
autophagy,O
was,O
stimulated,O
by,O
parthenolide,O
.,O
Axenic,O
amastigotes,O
treated,O
with,O
the,O
IC50,O
(,O
Figure,O
4B,O
),O
or,O
IC90,O
(,O
Figure,O
4C,O
),O
of,O
parthenolide,O
showed,O
an,O
increase,O
in,O
the,O
number,O
of,O
vesicles,O
",",O
indicating,O
that,O
the,O
compound,O
induced,O
the,O
formation,O
of,O
MDC,O
-,O
labeled,O
vacuoles,O
in,O
the,O
cytoplasm,O
.,O
MDC,O
-,O
positive,O
cells,O
were,O
visualized,O
in,O
treated,O
cells,O
but,O
not,O
in,O
control,O
cells,O
(,O
Figure,O
4A,O
),O
or,O
amphotericin,O
-,O
treated,O
cells,O
(,O
data,O
not,O
shown,O
).,O
These,O
results,O
show,O
that,O
parthenolide,O
treatment,O
",",O
unlike,O
amphotericin,O
B,O
",",O
led,O
to,O
the,O
formation,O
of,O
autophagic,O
vacuoles,O
in,O
L,B-OG
.,I-OG
amazonensis,I-OG
amastigotes,O
.,O
Monodansylcadaverine,O
(,O
MDC,O
)-,O
labeled,O
vesicles,O
in,O
axenic,O
amastigotes,O
of,O
L,B-OG
.,I-OG
amazonensis,I-OG
induced,O
by,O
parthenolide,O
treatment,O
.,O
Amastigotes,O
were,O
incubated,O
for,O
72,O
h,O
in,O
Schneider,O
medium,O
(,O
control,O
cells,O
),O
(,O
A,O
),O
or,O
in,O
the,O
presence,O
of,O
the,O
IC50,O
(,O
B,O
),O
or,O
IC90,O
(,O
C,O
),O
of,O
parthenolide,O
.,O
The,O
data,O
are,O
representative,O
of,O
at,O
least,O
three,O
independent,O
experiments,O
.,O
Scale,O
bars,O
=,O
5,O
μm,O
.,O
Flow,O
cytometric,O
measurement,O
of,O
amastigote,O
culture,O
Live,O
L,B-OG
.,I-OG
amazonensis,I-OG
cells,O
were,O
incubated,O
with,O
propidium,O
iodide,O
and,O
rhodamine,O
123,O
",",O
and,O
fluorescence,O
was,O
measured,O
by,O
flow,O
cytometry,O
.,O
The,O
gated,O
percentage,O
of,O
propidium,O
iodide,O
-,O
stained,O
amastigotes,O
after,O
treatment,O
with,O
amphotericin,O
B,O
(,O
positive,O
control,O
),O
was,O
71,O
.,O
4,O
"%,",O
much,O
higher,O
than,O
untreated,O
parasites,O
(,O
negative,O
control,O
),O
that,O
presented,O
6,O
.,O
0,O
%,O
(,O
Figure,O
5A,O
).,O
When,O
the,O
cells,O
were,O
treated,O
with,O
20,O
and,O
40,O
μM,O
parthenolide,O
",",O
the,O
percentages,O
of,O
labeled,O
amastigotes,O
were,O
34,O
.,O
2,O
%,O
and,O
56,O
.,O
2,O
"%,",O
respectively,O
(,O
Figure,O
5B,O
"),",O
possibly,O
indicating,O
a,O
considerable,O
increase,O
in,O
plasma,O
membrane,O
permeability,O
.,O
To,O
prove,O
that,O
Leishmania,B-OG
cells,O
functionally,O
respond,O
to,O
the,O
pharmacological,O
alteration,O
of,O
ΔΨm,O
",",O
amastigotes,O
were,O
treated,O
with,O
the,O
protonophore,O
carbonyl,O
cyanide,O
m,O
-,O
chlorophenylhydrazone,O
(,O
CCCP,O
"),",O
which,O
has,O
been,O
shown,O
to,O
interfere,O
with,O
mitochondrial,O
membrane,O
potential,O
in,O
various,O
cell,O
types,O
[,O
12,O
].,O
The,O
results,O
showed,O
that,O
82,O
.,O
5,O
%,O
of,O
the,O
amastigotes,O
without,O
treatment,O
(,O
negative,O
control,O
),O
presented,O
a,O
maximal,O
increase,O
in,O
fluorescence,O
",",O
and,O
with,O
200,O
μM,O
CCCP,O
",",O
46,O
.,O
7,O
%,O
showed,O
fluorescence,O
",",O
indicating,O
a,O
loss,O
of,O
ΔΨm,O
(,O
Figure,O
5C,O
).,O
We,O
next,O
observed,O
ΔΨm,O
reductions,O
of,O
68,O
.,O
4,O
%,O
and,O
56,O
.,O
1,O
%,O
when,O
the,O
amastigotes,O
were,O
treated,O
with,O
20,O
and,O
40,O
μM,O
parthenolide,O
",",O
respectively,O
",",O
suggesting,O
that,O
this,O
compound,O
interferes,O
with,O
the,O
mitochondrial,O
membrane,O
potential,O
leading,O
to,O
alteration,O
of,O
ATP,O
generation,O
and,O
in,O
consequence,O
cell,O
damage,O
takes,O
place,O
.,O
Flow,O
cytometry,O
analysis,O
of,O
propidium,O
iodide,O
-,O
(,O
A,O
",",O
B,O
),O
and,O
rhodamine,O
123,O
-,O
(,O
C,O
",",O
D,O
),O
labeled,O
axenic,O
amastigotes,O
of,O
L,B-OG
.,I-OG
amazonensis,I-OG
.,O
(,O
A,O
),O
Untreated,O
cells,O
:,O
negative,O
control,O
(,O
C,O
-),O
and,O
amphotericin,O
B,O
as,O
positive,O
control,O
(,O
C,O
+).,O
(,O
B,O
),O
Amastigotes,O
treated,O
with,O
20,O
or,O
40,O
μM,O
parthenolide,O
(,O
Pt,O
20,O
or,O
Pt,O
40,O
).,O
(,O
C,O
),O
Untreated,O
cells,O
:,O
negative,O
control,O
and,O
carbonyl,O
cyanide,O
m,O
-,O
chlorophenylhydrazone,O
as,O
a,O
positive,O
control,O
.,O
(,O
D,O
),O
Amastigotes,O
treated,O
with,O
20,O
or,O
40,O
μM,O
parthenolide,O
(,O
Pt,O
20,O
or,O
Pt,O
40,O
).,O
The,O
data,O
are,O
representative,O
of,O
at,O
least,O
two,O
independent,O
experiments,O
.,O
EPR,O
spectra,O
of,O
spin,O
-,O
labeled,O
Leishmania,B-OG
The,O
experimental,O
and,O
best,O
-,O
fit,O
EPR,O
spectra,O
of,O
spin,O
-,O
label,O
5,O
-,O
DSA,O
structured,O
in,O
the,O
plasma,O
membrane,O
of,O
Leishmania,B-OG
are,O
shown,O
in,O
Figure,O
6,O
.,O
These,O
EPR,O
spectra,O
are,O
typical,O
for,O
cellular,O
membranes,O
that,O
contain,O
an,O
appreciable,O
amount,O
of,O
integral,O
proteins,O
.,O
Treatment,O
with,O
parthenolide,O
increased,O
two,O
EPR,O
parameters,O
",",O
the,O
outer,O
hyperfine,O
splitting,O
",",O
2A,O
"//,",O
and,O
rotational,O
correlation,O
time,O
",",O
τC,O
",",O
indicating,O
a,O
significant,O
reduction,O
of,O
membrane,O
lipid,O
dynamics,O
.,O
2A,O
//,O
is,O
a,O
practice,O
parameter,O
measured,O
directly,O
in,O
EPR,O
spectra,O
that,O
has,O
been,O
widely,O
used,O
to,O
monitor,O
membrane,O
fluidity,O
",",O
although,O
in,O
principle,O
it,O
is,O
a,O
static,O
parameter,O
associated,O
with,O
the,O
orientation,O
distribution,O
of,O
the,O
spin,O
labels,O
in,O
the,O
membrane,O
.,O
The,O
theoretical,O
EPR,O
spectrum,O
of,O
spin,O
-,O
label,O
5,O
-,O
DSA,O
in,O
the,O
plasma,O
membrane,O
of,O
Leishmania,B-OG
was,O
best,O
fitted,O
using,O
a,O
model,O
of,O
two,O
spectral,O
components,O
.,O
This,O
indicates,O
that,O
the,O
membrane,O
has,O
two,O
populations,O
of,O
spin,O
labels,O
of,O
distinct,O
mobility,O
.,O
The,O
EPR,O
spectra,O
of,O
spin,O
labels,O
in,O
lipid,O
bilayers,O
are,O
well,O
known,O
to,O
contain,O
proteins,O
sometimes,O
composed,O
of,O
two,O
spectral,O
components,O
.,O
The,O
more,O
restricted,O
component,O
is,O
associated,O
with,O
boundary,O
lipids,O
where,O
the,O
spin,O
labels,O
surround,O
the,O
hydrophobic,O
regions,O
of,O
proteins,O
",",O
whereas,O
the,O
more,O
mobile,O
component,O
arises,O
from,O
the,O
spin,O
labels,O
located,O
in,O
the,O
bulk,O
bilayer,O
phase,O
",",O
away,O
from,O
the,O
protein,O
[,O
13,O
].,O
The,O
fitting,O
program,O
provides,O
the,O
τ,O
c,O
and,O
population,O
of,O
each,O
component,O
.,O
Thus,O
",",O
the,O
mean,O
of,O
the,O
rotational,O
correlation,O
time,O
was,O
calculated,O
as,O
τ,O
c,O
=,O
N,O
1,O
*,O
τ,O
c1,O
+,O
N,O
2,O
*,O
τ,O
c2,O
",",O
in,O
which,O
N,O
1,O
and,O
N,O
2,O
are,O
the,O
fractions,O
of,O
the,O
population,O
in,O
components,O
1,O
and,O
2,O
",",O
respectively,O
",",O
and,O
τ,O
c1,O
and,O
τ,O
c2,O
are,O
the,O
corresponding,O
rotational,O
time,O
correlations,O
.,O
Experimental,O
EPR,O
spectra,O
(,O
black,O
line,O
),O
and,O
theoretical,O
fits,O
(,O
red,O
line,O
),O
of,O
spin,O
-,O
label,O
5,O
-,O
DSA,O
in,O
Leishmania,B-OG
membrane,O
.,O
The,O
experiment,O
was,O
conducted,O
at,O
26,O
°,O
C,O
for,O
samples,O
untreated,O
and,O
treated,O
with,O
parthenolide,O
at,O
the,O
indicated,O
concentrations,O
.,O
EPR,O
spectra,O
were,O
simulated,O
with,O
the,O
NLLS,O
fitting,O
program,O
",",O
and,O
the,O
values,O
of,O
the,O
parameter,O
rotational,O
correlation,O
time,O
",",O
τC,O
",",O
obtained,O
from,O
the,O
fit,O
for,O
each,O
spectrum,O
are,O
indicated,O
on,O
a,O
nanosecond,O
scale,O
.,O
The,O
EPR,O
parameter,O
2A,O
//,O
is,O
the,O
separation,O
in,O
magnetic,O
-,O
field,O
units,O
between,O
the,O
first,O
and,O
last,O
resonance,O
lines,O
of,O
the,O
spectrum,O
.,O
The,O
vertical,O
lines,O
indicate,O
the,O
2A,O
//,O
for,O
the,O
control,O
samples,O
",",O
and,O
the,O
smaller,O
vertical,O
lines,O
illustrate,O
the,O
increase,O
in,O
2A,O
//,O
for,O
the,O
sample,O
treated,O
with,O
9,O
×,O
109,O
molecules,O
/,O
cell,O
.,O
The,O
measured,O
2A,O
//,O
values,O
and,O
τC,O
values,O
indicate,O
that,O
the,O
presence,O
of,O
parthenolide,O
significantly,O
reduced,O
lipid,O
fluidity,O
.,O
The,O
estimated,O
experimental,O
errors,O
for,O
the,O
2A,O
//,O
and,O
τC,O
parameters,O
are,O
0,O
.,O
5,O
G,O
and,O
1,O
.,O
0,O
ns,O
",",O
respectively,O
.,O
Discussion,O
For,O
many,O
years,O
",",O
parasites,O
of,O
the,O
genus,O
Leishmania,B-OG
have,O
displayed,O
extraordinary,O
plasticity,O
to,O
face,O
modifications,O
in,O
their,O
environment,O
[,O
14,O
].,O
The,O
expansion,O
of,O
risk,O
factors,O
related,O
to,O
environmental,O
changes,O
and,O
man,B-OG
-,O
made,O
transformations,O
are,O
making,O
leishmaniasis,B-DS
a,O
growing,O
public,O
health,O
concern,O
in,O
many,O
countries,O
worldwide,O
[,O
15,O
].,O
Leishmaniasis,B-DS
urgently,O
needs,O
novel,O
drugs,O
with,O
improved,O
features,O
",",O
and,O
many,O
compounds,O
primarily,O
derived,O
from,O
plants,B-OG
are,O
promising,O
leads,O
for,O
the,O
development,O
of,O
novel,O
chemotherapeutics,O
[,O
16,O
].,O
The,O
development,O
of,O
axenic,O
cultures,O
of,O
amastigotes,O
of,O
Leishmania,B-OG
species,O
yielded,O
new,O
opportunities,O
to,O
investigate,O
the,O
antileishmanial,O
activities,O
of,O
new,O
compounds,O
directly,O
at,O
the,O
mammalian,O
stage,O
of,O
the,O
parasite,O
[,O
17,O
].,O
Assays,O
that,O
use,O
intracellular,O
amastigote,O
cell,O
cultures,O
are,O
relevant,O
because,O
this,O
life,O
cycle,O
stage,O
of,O
the,O
parasite,O
is,O
important,O
to,O
its,O
pathogenicity,O
",",O
and,O
data,O
obtained,O
exclusively,O
from,O
promastigote,O
cell,O
lines,O
are,O
insufficient,O
[,O
16,O
].,O
Therefore,O
",",O
in,O
the,O
present,O
study,O
",",O
we,O
determined,O
the,O
leishmanicidal,O
activity,O
of,O
parthenolide,O
",",O
which,O
is,O
naturally,O
occurring,O
",",O
in,O
both,O
axenic,O
and,O
intracellular,O
amastigotes,O
.,O
To,O
discover,O
better,O
leishmanicidal,O
compounds,O
",",O
the,O
isolation,O
and,O
purification,O
of,O
the,O
active,O
ingredients,O
of,O
medicinal,O
plants,B-OG
are,O
gaining,O
attention,O
[,O
18,O
].,O
Many,O
new,O
natural,O
product,O
groups,O
",",O
such,O
as,O
terpenes,O
",",O
have,O
exhibited,O
antiprotozoal,O
potential,O
and,O
attracted,O
renewed,O
interest,O
with,O
surprising,O
efficacy,O
and,O
selectivity,O
[,O
19,O
].,O
Parthenolide,O
is,O
a,O
lipophilic,O
hydrocarbon,O
compound,O
formed,O
by,O
units,O
of,O
isoprene,O
.,O
The,O
accumulation,O
of,O
lipophilic,O
compounds,O
in,O
the,O
cytoplasmic,O
membrane,O
and,O
membrane,O
constituents,O
of,O
microorganisms,O
has,O
considerable,O
effects,O
on,O
the,O
loss,O
of,O
cellular,O
integrity,O
and,O
inhibition,O
of,O
respiratory,O
cellular,O
activity,O
in,O
mitochondria,O
[,O
20,O
].,O
This,O
interaction,O
with,O
cell,O
membranes,O
eventually,O
leads,O
to,O
cell,O
death,O
.,O
In,O
our,O
research,O
",",O
parthenolide,O
had,O
antileishmanial,O
effects,O
against,O
axenic,O
and,O
intracellular,O
amastigotes,O
of,O
L,B-OG
.,I-OG
amazonensis,I-OG
presenting,O
IC50,O
of,O
1,O
.,O
3,O
after,O
72,O
h,O
growth,O
and,O
2,O
.,O
9,O
μM,O
after,O
24,O
h,O
growth,O
",",O
respectively,O
.,O
The,O
differences,O
in,O
IC50,O
values,O
can,O
be,O
explained,O
because,O
the,O
experiments,O
with,O
axenic,O
amastigotes,O
are,O
directed,O
against,O
the,O
relevant,O
stage,O
of,O
the,O
parasite,O
whereas,O
the,O
use,O
of,O
intracellular,O
amastigotes,O
will,O
give,O
essential,O
information,O
on,O
the,O
capacity,O
of,O
the,O
drugs,O
to,O
target,O
intracellular,O
organisms,O
.,O
The,O
role,O
played,O
by,O
the,O
macrophages,O
on,O
drug,O
-,O
mediated,O
toxicity,O
may,O
be,O
important,O
.,O
Their,O
presence,O
may,O
limit,O
the,O
availability,O
of,O
the,O
compounds,O
under,O
evaluation,O
[,O
21,O
",",O
22,O
].,O
The,O
toxicity,O
for,O
J774G8,O
macrophages,O
and,O
the,O
activity,O
against,O
intracellular,O
amastigotes,O
were,O
compared,O
by,O
using,O
the,O
selectivity,O
index,O
ratio,O
(,O
CC50,O
for,O
J774G8,O
cells,O
/,O
IC50,O
for,O
protozoa,B-OG
),O
[,O
10,O
].,O
The,O
parthenolide,O
was,O
more,O
selective,O
against,O
the,O
intracellular,O
amastigotes,O
than,O
the,O
mammalian,O
cells,O
",",O
with,O
a,O
selectivity,O
index,O
ratio,O
of,O
19,O
.,O
4,O
.,O
It,O
is,O
generally,O
considered,O
that,O
biological,O
efficacy,O
is,O
not,O
due,O
to,O
in,O
vitro,O
cytotoxicity,O
when,O
this,O
index,O
is,O
≥,O
10,O
[,O
23,O
",",O
24,O
].,O
The,O
low,O
toxicity,O
against,O
mammalian,O
cells,O
is,O
an,O
important,O
criterion,O
in,O
the,O
search,O
for,O
active,O
compounds,O
with,O
antiprotozoal,O
activity,O
.,O
For,O
this,O
purpose,O
",",O
the,O
genotoxicity,O
of,O
parthenolide,O
in,O
a,O
mouse,B-OG
model,O
was,O
determined,O
using,O
a,O
micronucleus,O
test,O
and,O
cyclophosphamide,O
as,O
the,O
positive,O
control,O
because,O
it,O
is,O
a,O
known,O
genotoxin,O
[,O
25,O
].,O
Micronuclei,O
are,O
masses,O
of,O
cytoplasmic,O
chromatin,O
that,O
appear,O
outside,O
the,O
main,O
nucleus,O
as,O
a,O
result,O
of,O
chromosomal,O
damage,O
or,O
damage,O
to,O
the,O
mitotic,O
apparatus,O
in,O
the,O
erythroblasts,O
of,O
the,O
test,O
species,O
",",O
and,O
they,O
can,O
be,O
used,O
as,O
an,O
indicator,O
of,O
the,O
effects,O
of,O
agents,O
that,O
cause,O
DNA,O
damage,O
[,O
26,O
].,O
In,O
mice,B-OG
",",O
micronuclei,O
in,O
mature,O
erythrocytes,O
in,O
peripheral,O
blood,O
live,O
approximately,O
1,O
month,O
",",O
providing,O
a,O
measure,O
of,O
average,O
chromosomal,O
damage,O
[,O
27,O
].,O
Our,O
results,O
showed,O
no,O
differences,O
in,O
the,O
frequency,O
of,O
MNPCE,O
compared,O
with,O
the,O
negative,O
control,O
",",O
demonstrating,O
no,O
toxic,O
effects,O
on,O
bone,O
marrow,O
at,O
the,O
dose,O
tested,O
(,O
3,O
.,O
75,O
mg,O
/,O
kg,O
body,O
weight,O
).,O
Electron,O
microscopic,O
studies,O
revealed,O
extensive,O
cytoplasmic,O
vacuolization,O
",",O
leading,O
to,O
the,O
examination,O
of,O
the,O
possibility,O
that,O
parthenolide,O
induces,O
autophagic,O
cell,O
death,O
.,O
Autophagy,O
cell,O
death,O
is,O
a,O
process,O
that,O
is,O
thought,O
to,O
occur,O
in,O
all,O
eukaryotes,B-OG
and,O
is,O
characterized,O
by,O
an,O
accumulation,O
of,O
autophagic,O
vacuoles,O
.,O
This,O
mechanism,O
occurs,O
for,O
energy,O
production,O
for,O
survival,O
when,O
cells,O
recycle,O
their,O
cytoplasmic,O
contents,O
during,O
periods,O
of,O
environmental,O
stress,O
or,O
certain,O
stages,O
of,O
development,O
.,O
A,O
double,O
-,O
membrane,O
vesicle,O
called,O
the,O
autophagosome,O
forms,O
in,O
the,O
cytosol,O
",",O
engulfing,O
organelles,O
and,O
bulk,O
cytoplasm,O
.,O
Subsequently,O
",",O
these,O
vesicles,O
fuse,O
with,O
lysosomes,O
",",O
where,O
their,O
contents,O
are,O
degraded,O
and,O
recycled,O
[,O
28,O
].,O
One,O
of,O
the,O
most,O
frequently,O
used,O
methods,O
to,O
examine,O
autophagy,O
is,O
staining,O
with,O
acidotropic,O
dyes,O
[,O
29,O
"],",O
and,O
MDC,O
is,O
considered,O
an,O
autofluorescent,O
compound,O
and,O
specific,O
marker,O
for,O
autophagic,O
vacuoles,O
[,O
30,O
].,O
MDC,O
staining,O
is,O
only,O
obtained,O
when,O
the,O
compartments,O
into,O
which,O
it,O
loads,O
are,O
acidic,O
.,O
Neutralization,O
of,O
these,O
compartments,O
leads,O
to,O
a,O
swift,O
loss,O
of,O
MDC,O
staining,O
or,O
lack,O
of,O
MDC,O
uptake,O
[,O
31,O
].,O
Therefore,O
",",O
we,O
suggest,O
that,O
the,O
vacuoles,O
that,O
were,O
observed,O
under,O
a,O
transmission,O
electron,O
microscope,O
are,O
autophagosomes,O
.,O
Another,O
study,O
used,O
MDC,O
as,O
a,O
marker,O
to,O
analyze,O
the,O
molecular,O
level,O
of,O
the,O
machinery,O
involved,O
in,O
the,O
autophagic,O
process,O
[,O
32,O
],O
and,O
was,O
also,O
used,O
to,O
demonstrate,O
that,O
antimicrobial,B-GP
peptides,I-GP
induce,O
autophagic,O
cell,O
death,O
in,O
L,B-OG
.,I-OG
donovani,I-OG
[,O
33,O
].,O
Amphotericin,O
B,O
was,O
used,O
as,O
a,O
positive,O
control,O
in,O
some,O
of,O
our,O
experiments,O
because,O
this,O
polyene,O
antibiotic,O
forms,O
aqueous,O
and,O
nonaqueous,O
pores,O
in,O
membranes,O
",",O
which,O
is,O
the,O
basis,O
of,O
leishmanicidal,O
action,O
[,O
34,O
].,O
Using,O
transmission,O
electron,O
microscopy,O
",",O
we,O
could,O
see,O
the,O
loss,O
of,O
membrane,O
integrity,O
induced,O
by,O
this,O
antimicrobial,O
agent,O
.,O
Similarly,O
",",O
alterations,O
in,O
the,O
cytoplasmic,O
membrane,O
",",O
including,O
membrane,O
blebbing,O
and,O
disruption,O
",",O
could,O
be,O
visualized,O
in,O
axenic,O
amastigotes,O
treated,O
with,O
parthenolide,O
.,O
Studies,O
have,O
shown,O
that,O
a,O
flow,O
cytometric,O
membrane,O
potential,O
assay,O
can,O
be,O
used,O
as,O
a,O
reliable,O
tool,O
for,O
studying,O
the,O
interactions,O
between,O
amphotericin,O
B,O
and,O
the,O
Leishmania,B-OG
membrane,O
[,O
35,O
].,O
Alterations,O
in,O
membrane,O
permeability,O
are,O
detected,O
by,O
propidium,O
iodide,O
nucleic,O
acid,O
stain,O
that,O
selectively,O
passes,O
through,O
plasma,O
membranes,O
and,O
bind,O
to,O
DNA,O
",",O
emitting,O
high,O
fluorescence,O
when,O
excited,O
by,O
an,O
argon,O
ion,O
laser,O
[,O
36,O
].,O
Since,O
its,O
introduction,O
",",O
the,O
propidium,O
iodide,O
flow,O
cytometric,O
assay,O
has,O
also,O
been,O
widely,O
used,O
as,O
a,O
quantitative,O
measure,O
of,O
cell,O
apoptosis,O
.,O
During,O
apoptosis,O
",",O
DNA,O
fragmentation,O
occurs,O
",",O
with,O
a,O
subsequent,O
loss,O
of,O
cellular,O
DNA,O
content,O
[,O
37,O
].,O
Terpenoic,O
compounds,O
can,O
produce,O
major,O
changes,O
in,O
the,O
cellular,O
and,O
mitochondrial,O
membrane,O
structures,O
of,O
different,O
pathogenic,O
agents,O
",",O
modifying,O
their,O
permeability,O
and,O
integrity,O
[,O
20,O
].,O
Ultrastructural,O
findings,O
also,O
revealed,O
mitochondrial,O
damage,O
induced,O
by,O
parthenolide,O
.,O
We,O
used,O
flow,O
cytometry,O
analysis,O
to,O
determine,O
whether,O
the,O
compound,O
interferes,O
with,O
the,O
mitochondrial,O
membrane,O
potential,O
of,O
the,O
amastigotes,O
.,O
The,O
flow,O
cytometry,O
results,O
showed,O
that,O
transmembrane,O
potential,O
decreased,O
",",O
reflected,O
by,O
a,O
reduction,O
of,O
rhodamine,O
123,O
fluorescence,O
.,O
Rhodamine,O
123,O
is,O
a,O
fluorescent,O
cationic,O
stain,O
for,O
mitochondria,O
in,O
living,O
cells,O
and,O
is,O
subsequently,O
washed,O
out,O
of,O
the,O
cells,O
once,O
the,O
mitochondrion,O
’,O
s,O
membrane,O
potential,O
is,O
lost,O
[,O
38,O
].,O
The,O
present,O
results,O
indicated,O
an,O
increase,O
in,O
proton,O
permeability,O
through,O
the,O
internal,O
mitochondrial,O
membrane,O
",",O
inhibition,O
of,O
electron,O
transport,O
",",O
or,O
decrease,O
in,O
mitochondrial,O
substrate,O
transport,O
/,O
oxidation,O
",",O
which,O
would,O
impair,O
proton,O
pumping,O
by,O
mitochondrial,O
complexes,O
and,O
reduce,O
adenosine,O
triphosphate,O
synthesis,O
",",O
resulting,O
in,O
parasite,O
cell,O
death,O
[,O
39,O
].,O
CCCP,O
was,O
used,O
as,O
positive,O
control,O
because,O
it,O
is,O
an,O
uncoupler,O
of,O
oxidative,O
phosphorylation,O
and,O
reduces,O
mitochondrial,O
membrane,O
potential,O
by,O
directly,O
attacking,O
the,O
proton,O
gradient,O
across,O
the,O
inner,O
mitochondrial,O
membrane,O
[,O
12,O
",",O
40,O
].,O
Amastigotes,O
treated,O
with,O
parthenolide,O
presented,O
severe,O
plasma,O
membrane,O
and,O
mitochondrial,O
damage,O
",",O
suggesting,O
an,O
autophagic,O
process,O
[,O
39,O
].,O
Treatment,O
with,O
parthenolide,O
induced,O
shedding,O
of,O
the,O
membranes,O
into,O
the,O
flagellar,O
pocket,O
",",O
appearing,O
as,O
concentric,O
membranes,O
and,O
suggesting,O
intense,O
exocytic,O
activity,O
because,O
this,O
site,O
is,O
where,O
endocytosis,O
and,O
exocytosis,O
occur,O
in,O
trypanosomatids,O
.,O
Treatment,O
of,O
promastigote,O
forms,O
of,O
L,B-OG
.,I-OG
amazonensis,I-OG
with,O
edelfosine,O
for,O
1,O
day,O
[,O
41,O
],O
and,O
parthenolide,O
for,O
3,O
days,O
[,O
10,O
],O
also,O
led,O
to,O
the,O
appearance,O
of,O
a,O
large,O
number,O
of,O
vesicles,O
inside,O
the,O
flagellar,O
pocket,O
",",O
suggesting,O
a,O
process,O
of,O
exacerbated,O
protein,O
production,O
by,O
cells,O
as,O
they,O
attempt,O
to,O
survive,O
.,O
Other,O
studies,O
indicated,O
that,O
the,O
plasma,O
membrane,O
of,O
human,B-OG
promyelocytic,O
leukemic,O
HL,O
-,O
60,O
cells,O
appears,O
to,O
be,O
one,O
of,O
the,O
targets,O
of,O
parthenolide,O
because,O
its,O
integrity,O
is,O
lost,O
very,O
early,O
during,O
cell,O
death,O
",",O
reflected,O
by,O
atypical,O
apoptosis,O
and,O
primary,O
necrosis,O
(,O
i,O
.,O
e,O
".,",O
lysis,O
of,O
the,O
membrane,O
),O
[,O
42,O
].,O
The,O
lipid,O
spin,O
probe,O
5,O
-,O
DSA,O
was,O
incorporated,O
into,O
the,O
plasmatic,O
membrane,O
of,O
Leishmania,B-OG
in,O
the,O
usual,O
way,O
",",O
and,O
the,O
EPR,O
spectra,O
obtained,O
were,O
typical,O
for,O
cell,O
membranes,O
.,O
Interestingly,O
",",O
the,O
spectra,O
of,O
the,O
Leishmania,B-OG
membrane,O
were,O
very,O
similar,O
to,O
those,O
for,O
the,O
same,O
spin,O
label,O
in,O
erythrocyte,O
membranes,O
[,O
43,O
].,O
The,O
erythrocyte,O
membrane,O
of,O
spin,O
-,O
labeled,O
lipids,O
has,O
been,O
well,O
characterized,O
by,O
EPR,O
spectroscopy,O
and,O
is,O
considered,O
to,O
have,O
certain,O
rigidity,O
",",O
particularly,O
because,O
of,O
its,O
high,O
content,O
of,O
protein,O
and,O
cholesterol,O
.,O
The,O
presence,O
of,O
sesquiterpene,O
parthenolide,O
significantly,O
increased,O
the,O
rigidity,O
of,O
the,O
membrane,O
of,O
Leishmania,B-OG
when,O
applied,O
to,O
the,O
cell,O
suspension,O
at,O
a,O
ratio,O
of,O
3,O
×,O
109,O
parthenolide,O
molecules,O
/,O
cell,O
.,O
Parthenolide,O
also,O
showed,O
dose,O
-,O
dependent,O
anti,O
-,O
Leishmania,B-OG
activity,O
against,O
the,O
amastigote,O
form,O
.,O
The,O
IC50,O
was,O
1,O
.,O
3,O
μM,O
parthenolide,O
/,O
ml,O
for,O
a,O
cell,O
concentration,O
of,O
1,O
×,O
106,O
cell,O
/,O
ml,O
.,O
Therefore,O
",",O
the,O
effect,O
of,O
parthenolide,O
against,O
the,O
amastigote,O
forms,O
of,O
Leishmania,B-OG
was,O
observed,O
at,O
a,O
ratio,O
of,O
7,O
.,O
8,O
×,O
108,O
parthenolide,O
molecules,O
/,O
cell,O
.,O
The,O
greatest,O
change,O
in,O
membrane,O
fluidity,O
was,O
observed,O
at,O
a,O
concentration,O
3,O
.,O
8,O
-,O
fold,O
higher,O
than,O
for,O
growth,O
inhibition,O
.,O
Membrane,O
stiffness,O
",",O
assessed,O
by,O
EPR,O
spectroscopy,O
of,O
the,O
spin,O
label,O
",",O
has,O
been,O
associated,O
with,O
lipid,O
peroxidation,O
[,O
44,O
",",O
45,O
].,O
A,O
detailed,O
study,O
of,O
the,O
interaction,O
between,O
parthenolide,O
and,O
membranes,O
and,O
their,O
role,O
as,O
a,O
pro,O
-,O
oxidant,O
in,O
simpler,O
systems,O
is,O
necessary,O
to,O
determine,O
whether,O
the,O
membrane,O
rigidity,O
observed,O
here,O
was,O
attributable,O
to,O
lipid,O
peroxidation,O
.,O
Conclusions,O
Our,O
results,O
indicated,O
that,O
the,O
antileishmanial,O
action,O
of,O
parthenolide,O
is,O
associated,O
with,O
autophagic,O
vacuole,O
appearance,O
",",O
membrane,O
stiffness,O
",",O
the,O
loss,O
of,O
membrane,O
integrity,O
",",O
and,O
mitochondrial,O
dysfunction,O
.,O
These,O
results,O
indicate,O
that,O
parthenolide,O
induced,O
amastigote,O
cell,O
death,O
by,O
autophagy,O
",",O
but,O
other,O
mechanisms,O
of,O
cell,O
death,O
cannot,O
be,O
dismissed,O
",",O
such,O
as,O
apoptosis,O
and,O
necrosis,O
.,O
Considering,O
the,O
limited,O
repertoire,O
of,O
existing,O
antileishmanial,O
compounds,O
",",O
continuously,O
developing,O
new,O
leishmanicidal,O
compounds,O
is,O
essential,O
.,O
In,O
the,O
ongoing,O
search,O
for,O
the,O
best,O
antileishmanial,O
compounds,O
",",O
products,O
derived,O
from,O
plants,B-OG
are,O
gaining,O
ground,O
.,O
The,O
isolation,O
and,O
purification,O
of,O
the,O
active,O
components,O
of,O
medicinal,O
plants,B-OG
has,O
been,O
one,O
the,O
greatest,O
advances,O
.,O
Additionally,O
",",O
delineation,O
of,O
the,O
biochemical,O
mechanisms,O
involved,O
in,O
mediating,O
effect,O
of,O
these,O
compounds,O
would,O
help,O
develop,O
new,O
chemotherapeutic,O
approaches,O
.,O
Methods,O
Drugs,O
Parthenolide,O
(,O
minimum,O
90,O
%),O
was,O
purchased,O
from,O
Sigma,O
-,O
Aldrich,O
(,O
Steinheim,O
",",O
Germany,O
).,O
Amphotericin,O
B,O
(,O
Cristália,O
",",O
Produtos,O
Químicos,O
Farmacêuticos,O
Ltda,O
",",O
Itapira,O
",",O
SP,O
",",O
Brazil,O
),O
was,O
used,O
as,O
a,O
positive,O
control,O
.,O
In,O
all,O
of,O
the,O
tests,O
",",O
0,O
.,O
05,O
%,O
dimethyl,O
sulfoxide,O
(,O
DMSO,O
;,O
Sigma,O
",",O
St,O
.,O
Louis,O
",",O
MO,O
",",O
USA,O
),O
was,O
used,O
to,O
dissolve,O
the,O
highest,O
dose,O
of,O
the,O
compounds,O
and,O
had,O
no,O
effect,O
on,O
the,O
parasites,O
’,O
proliferation,O
or,O
morphology,O
.,O
Axenic,O
amastigotes,O
Promastigotes,O
of,O
the,O
Leishmania,B-OG
species,O
differentiate,O
to,O
amastigotes,O
with,O
the,O
combination,O
of,O
low,O
pH,O
and,O
high,O
temperature,O
[,O
46,O
].,O
The,O
WHOM,O
/,O
BR,O
/,O
75,O
/,O
Josefa,O
strain,O
of,O
Leishmania,B-OG
amazonensis,I-OG
",",O
isolated,O
by,O
C,O
.,O
A,O
.,O
Cuba,O
-,O
Cuba,O
(,O
University,O
of,O
Brasília,O
",",O
Brasília,O
",",O
Distrito,O
Federal,O
",",O
Brazil,O
),O
from,O
a,O
human,B-OG
case,O
of,O
diffuse,B-DS
cutaneous,I-DS
leishmaniasis,I-DS
",",O
was,O
used,O
in,O
the,O
present,O
study,O
.,O
Axenic,O
amastigote,O
cultures,O
were,O
obtained,O
by,O
the,O
in,O
vitro,O
differentiation,O
of,O
promastigotes,O
from,O
the,O
stationary,O
phase,O
in,O
25,O
cm2,O
tissue,O
culture,O
flasks,O
by,O
progressive,O
temperature,O
increase,O
and,O
pH,O
decrease,O
[,O
47,O
].,O
The,O
cultures,O
were,O
maintained,O
at,O
32,O
°,O
C,O
in,O
Schneider,O
’,O
s,O
insect,O
medium,O
(,O
Sigma,O
",",O
St,O
.,O
Louis,O
",",O
MO,O
",",O
USA,O
"),",O
pH,O
4,O
.,O
6,O
",",O
with,O
20,O
%,O
fetal,O
bovine,O
serum,O
through,O
weekly,O
serial,O
sub,O
-,O
culturing,O
for,O
further,O
studies,O
.,O
Antiproliferative,O
effect,O
For,O
the,O
parasite,O
growth,O
inhibition,O
assays,O
",",O
L,B-OG
.,I-OG
amazonensis,I-OG
axenic,O
amastigotes,O
were,O
harvested,O
during,O
the,O
exponential,O
phase,O
of,O
growth,O
",",O
and,O
106,O
cells,O
were,O
added,O
to,O
each,O
well,O
of,O
a,O
24,O
-,O
well,O
plate,O
and,O
treated,O
with,O
different,O
concentrations,O
of,O
parthenolide,O
and,O
amphotericin,O
B,O
.,O
Medium,O
alone,O
and,O
0,O
.,O
05,O
%,O
DMSO,O
were,O
used,O
as,O
negative,O
controls,O
.,O
For,O
each,O
treatment,O
",",O
the,O
parasites,O
were,O
observed,O
and,O
counted,O
daily,O
using,O
a,O
Neubauer,O
chamber,O
with,O
an,O
optical,O
microscope,O
.,O
Each,O
experiment,O
was,O
performed,O
in,O
duplicate,O
and,O
twice,O
on,O
different,O
occasions,O
.,O
The,O
antiproliferative,O
effect,O
(,O
percentage,O
of,O
growth,O
inhibition,O
),O
was,O
evaluated,O
with,O
5,O
day,O
treatment,O
",",O
and,O
the,O
data,O
are,O
expressed,O
as,O
the,O
mean,O
±,O
standard,O
error,O
of,O
the,O
mean,O
(,O
Microsoft,O
Excel,O
).,O
The,O
corresponding,O
50,O
%,O
and,O
90,O
%,O
inhibitory,O
concentrations,O
(,O
IC50,O
and,O
IC90,O
),O
were,O
determined,O
from,O
the,O
concentration,O
-,O
response,O
curves,O
(,O
Excel,O
software,O
).,O
Data,O
were,O
compared,O
via,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
),O
followed,O
by,O
Tukey,O
’,O
s,O
multiple,O
range,O
test,O
for,O
statistically,O
significant,O
differences,O
at,O
p,O
<,O
0,O
.,O
05,O
.,O
Activity,O
of,O
parthenolide,O
in,O
infection,B-DS
of,O
murine,O
macrophages,O
The,O
effect,O
of,O
parthenolide,O
on,O
L,B-OG
.,I-OG
amazonensis,I-OG
-,O
infected,O
mouse,B-OG
peritoneal,O
macrophages,O
was,O
evaluated,O
.,O
The,O
experimental,O
protocol,O
was,O
approved,O
by,O
the,O
Animal,O
Ethics,O
Committee,O
of,O
the,O
Universidade,O
Estadual,O
de,O
Maringá,O
(,O
no,O
.,O
013,O
/,O
2010,O
).,O
BALB,B-OG
/,I-OG
c,I-OG
mice,I-OG
resident,O
peritoneal,O
cells,O
were,O
harvested,O
in,O
phosphate,O
-,O
buffered,O
saline,O
(,O
PBS,O
;,O
0,O
.,O
01,O
M,O
",",O
pH,O
7,O
.,O
2,O
),O
and,O
centrifuged,O
",",O
and,O
the,O
sediment,O
was,O
resuspended,O
in,O
RPMI,O
1640,O
medium,O
supplemented,O
with,O
10,O
%,O
fetal,O
bovine,O
serum,O
.,O
Cells,O
(,O
1,O
×,O
105,O
),O
were,O
seeded,O
on,O
13,O
-,O
mm,O
coverslips,O
in,O
24,O
-,O
well,O
plates,O
and,O
incubated,O
at,O
37,O
°,O
C,O
in,O
a,O
5,O
%,O
CO2,O
atmosphere,O
.,O
After,O
15,O
h,O
",",O
macrophages,O
were,O
infected,O
with,O
promastigotes,O
at,O
a,O
10,O
:,O
1,O
parasite,O
:,O
cell,O
ratio,O
and,O
incubated,O
again,O
for,O
6,O
h,O
.,O
The,O
remaining,O
noninternalized,O
parasites,O
were,O
removed,O
.,O
The,O
infected,O
host,O
cells,O
were,O
treated,O
with,O
parthenolide,O
at,O
concentrations,O
of,O
4,O
.,O
0,O
",",O
3,O
.,O
2,O
",",O
2,O
.,O
4,O
",",O
and,O
1,O
.,O
6,O
μM,O
.,O
After,O
24,O
h,O
",",O
the,O
coverslips,O
were,O
washed,O
with,O
PBS,O
",",O
fixed,O
in,O
methanol,O
",",O
stained,O
with,O
Giemsa,O
",",O
mounted,O
in,O
Entellan,O
(,O
Merck,O
"),",O
and,O
examined,O
under,O
an,O
optical,O
microscope,O
.,O
The,O
rate,O
of,O
cell,O
infection,B-DS
and,O
number,O
of,O
amastigotes,O
per,O
cell,O
were,O
evaluated,O
by,O
counting,O
200,O
random,O
cells,O
in,O
duplicate,O
cultures,O
in,O
at,O
least,O
two,O
independent,O
experiments,O
.,O
The,O
survival,O
index,O
was,O
calculated,O
by,O
multiplying,O
the,O
percentage,O
of,O
infected,O
macrophages,O
and,O
mean,O
number,O
of,O
internalized,O
parasites,O
per,O
macrophage,O
.,O
Data,O
were,O
compared,O
via,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
),O
followed,O
by,O
Tukey,O
’,O
s,O
multiple,O
range,O
test,O
for,O
statistically,O
significant,O
differences,O
at,O
p,O
<,O
0,O
.,O
05,O
.,O
Genotoxicity,O
study,O
To,O
assess,O
the,O
toxicity,O
of,O
parthenolide,O
in,O
mice,B-OG
",",O
a,O
micronucleus,O
test,O
was,O
conducted,O
in,O
groups,O
of,O
five,O
male,O
and,O
five,O
female,O
Swiss,B-OG
albino,I-OG
mice,I-OG
(,O
Mus,B-OG
musculus,I-OG
),O
that,O
weighed,O
approximately,O
42,O
g,O
.,O
The,O
animals,B-OG
were,O
obtained,O
from,O
the,O
Central,O
Animal,O
House,O
of,O
the,O
Universidade,O
Estadual,O
de,O
Maringá,O
",",O
Paraná,O
",",O
Brazil,O
.,O
They,O
were,O
housed,O
in,O
plastic,O
cages,O
at,O
22,O
±,O
1,O
°,O
C,O
and,O
55,O
±,O
10,O
%,O
humidity,O
",",O
with,O
a,O
12,O
h,O
/,O
12,O
h,O
light,O
/,O
dark,O
cycle,O
and,O
free,O
access,O
to,O
water,O
and,O
food,O
(,O
Nuvilab,O
Cr1,O
).,O
The,O
study,O
was,O
conducted,O
according,O
to,O
experimental,O
standards,O
approved,O
by,O
the,O
Animal,O
Ethics,O
Committee,O
of,O
the,O
Universidade,O
Estadual,O
de,O
Maringá,O
(,O
protocol,O
no,O
.,O
013,O
/,O
2010,O
).,O
The,O
animals,B-OG
received,O
3,O
.,O
75,O
mg,O
parthenolide,O
/,O
kg,O
body,O
weight,O
suspended,O
in,O
10,O
%,O
DMSO,O
by,O
oral,O
gavage,O
.,O
The,O
negative,O
control,O
was,O
a,O
vehicle,O
group,O
",",O
and,O
the,O
positive,O
control,O
was,O
a,O
group,O
that,O
received,O
40,O
mg,O
cyclophosphamide,O
/,O
kg,O
body,O
weight,O
.,O
The,O
mice,B-OG
were,O
examined,O
regularly,O
for,O
mortality,O
and,O
clinical,O
signs,O
of,O
toxicity,O
until,O
sacrifice,O
by,O
carbon,O
dioxide,O
asphyxiation,O
",",O
which,O
occurred,O
24,O
h,O
after,O
treatment,O
.,O
Both,O
femurs,O
were,O
dissected,O
",",O
and,O
bone,O
marrow,O
was,O
flushed,O
with,O
fetal,O
calf,O
serum,O
.,O
After,O
centrifugation,O
for,O
5,O
min,O
at,O
2,O
",",O
000,O
×,O
g,O
",",O
10,O
μl,O
of,O
the,O
sediment,O
was,O
smeared,O
on,O
glass,O
slides,O
and,O
air,O
-,O
dried,O
.,O
The,O
smears,O
were,O
fixed,O
with,O
absolute,O
methanol,O
for,O
5,O
min,O
and,O
stained,O
with,O
May,O
-,O
Grunwald,O
-,O
Giemsa,O
to,O
detect,O
micronucleated,O
polychromatic,O
erythrocytes,O
(,O
MNPCE,O
).,O
The,O
number,O
of,O
micronucleated,O
cells,O
was,O
counted,O
in,O
2,O
",",O
000,O
reticulocytes,O
per,O
animal,B-OG
using,O
an,O
Olympus,O
BH,O
-,O
2,O
microscope,O
at,O
1,O
",",O
000,O
×,O
magnification,O
[,O
26,O
].,O
The,O
statistical,O
analyses,O
were,O
made,O
with,O
a,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
),O
followed,O
by,O
Dunnet,O
test,O
.,O
Differences,O
were,O
considered,O
significant,O
at,O
p,O
value,O
of,O
less,O
than,O
0,O
.,O
05,O
.,O
Scanning,O
and,O
transmission,O
electron,O
microscopy,O
After,O
treatment,O
with,O
the,O
IC50,O
(,O
72,O
h,O
),O
of,O
parthenolide,O
",",O
axenic,O
amastigotes,O
were,O
washed,O
in,O
PBS,O
and,O
fixed,O
in,O
2,O
.,O
5,O
%,O
glutaraldehyde,O
in,O
0,O
.,O
1,O
M,O
sodium,O
cacodylate,O
buffer,O
at,O
4ºC,O
.,O
For,O
scanning,O
electron,O
microscopy,O
",",O
amastigotes,O
were,O
placed,O
on,O
a,O
specimen,O
support,O
with,O
a,O
poly,O
-,O
L,O
-,O
lysine,O
-,O
coated,O
coverslip,O
and,O
washed,O
in,O
cacodylate,O
buffer,O
.,O
The,O
cells,O
were,O
dehydrated,O
in,O
an,O
increasing,O
ethanol,O
gradient,O
",",O
critical,O
-,O
point,O
-,O
dried,O
in,O
CO2,O
",",O
sputter,O
-,O
coated,O
with,O
gold,O
",",O
and,O
observed,O
in,O
a,O
Shimadzu,O
SS,O
-,O
550,O
SEM,O
scanning,O
electron,O
microscope,O
.,O
For,O
transmission,O
electron,O
microscopy,O
",",O
amastigote,O
forms,O
were,O
treated,O
with,O
the,O
IC50,O
of,O
parthenolide,O
and,O
the,O
IC50,O
of,O
amphotericin,O
B,O
and,O
fixed,O
as,O
described,O
above,O
.,O
The,O
cells,O
were,O
postfixed,O
in,O
a,O
solution,O
that,O
contained,O
1,O
%,O
osmium,O
tetroxide,O
",",O
0,O
.,O
8,O
%,O
potassium,O
ferrocyanide,O
",",O
and,O
10,O
mM,O
calcium,O
chloride,O
in,O
0,O
.,O
1,O
M,O
cacodylate,O
buffer,O
",",O
dehydrated,O
in,O
an,O
increasing,O
acetone,O
gradient,O
",",O
and,O
embedded,O
in,O
Epon,O
resin,O
.,O
Ultrathin,O
sections,O
were,O
stained,O
with,O
uranyl,O
acetate,O
and,O
lead,O
citrate,O
",",O
and,O
the,O
images,O
were,O
examined,O
in,O
a,O
Zeiss,O
900,O
transmission,O
electron,O
microscope,O
.,O
Fluorescence,O
of,O
monodansylcadaverine,O
during,O
cell,O
death,O
Axenic,O
amastigotes,O
were,O
treated,O
with,O
IC50,O
and,O
IC90,O
equivalents,O
of,O
parthenolide,O
.,O
After,O
72,O
h,O
",",O
the,O
cells,O
were,O
washed,O
and,O
resuspended,O
in,O
PBS,O
.,O
To,O
verify,O
the,O
induction,O
of,O
autophagy,O
by,O
parthenolide,O
",",O
the,O
cells,O
were,O
incubated,O
with,O
0,O
.,O
05,O
mM,O
monodansylcadaverine,O
(,O
MDC,O
),O
at,O
37,O
°,O
C,O
for,O
10,O
min,O
.,O
After,O
incubation,O
",",O
the,O
cells,O
were,O
washed,O
three,O
times,O
with,O
PBS,O
to,O
remove,O
excess,O
MDC,O
",",O
immediately,O
analyzed,O
by,O
fluorescence,O
microscopy,O
at,O
an,O
excitation,O
wavelength,O
of,O
360,O
–,O
380,O
nm,O
and,O
emission,O
wavelength,O
of,O
525,O
nm,O
",",O
and,O
photographed,O
using,O
a,O
charge,O
-,O
coupled,O
-,O
device,O
camera,O
.,O
This,O
study,O
was,O
qualitative,O
.,O
Flow,O
cytometry,O
The,O
antileishmanial,O
activity,O
of,O
parthenolide,O
(,O
20,O
and,O
40,O
μM,O
),O
on,O
the,O
integrity,O
of,O
the,O
plasma,O
membrane,O
and,O
mitochondrial,O
membrane,O
potential,O
of,O
axenic,O
amastigotes,O
(,O
5,O
×,O
106,O
cells,O
/,O
ml,O
),O
was,O
determined,O
after,O
3,O
h,O
treatment,O
.,O
Amphotericin,O
B,O
(,O
5,O
.,O
0,O
μM,O
),O
and,O
carbonyl,O
cyanide,O
m,O
-,O
chlorophenylhydrazone,O
(,O
200,O
μM,O
),O
were,O
used,O
as,O
positive,O
controls,O
.,O
Untreated,O
amastigotes,O
were,O
used,O
as,O
a,O
negative,O
control,O
.,O
Each,O
flow,O
-,O
cytometric,O
technique,O
was,O
evaluated,O
by,O
repeating,O
each,O
experiment,O
three,O
times,O
to,O
verify,O
reproducibility,O
.,O
The,O
integrity,O
of,O
the,O
plasma,O
membrane,O
was,O
assessed,O
using,O
L,B-OG
.,I-OG
amazonensis,I-OG
amastigotes,O
at,O
an,O
average,O
density,O
of,O
5,O
×,O
106,O
cells,O
suspended,O
in,O
500,O
μl,O
PBS,O
and,O
stained,O
with,O
50,O
μl,O
propidium,O
iodide,O
(,O
2,O
μg,O
/,O
ml,O
),O
for,O
5,O
min,O
at,O
room,O
temperature,O
.,O
To,O
measure,O
mitochondrial,O
membrane,O
potential,O
(,O
ΔΨm,O
"),",O
1,O
ml,O
of,O
saline,O
that,O
contained,O
1,O
×,O
106,O
of,O
treated,O
amastigotes,O
was,O
mixed,O
with,O
1,O
μl,O
rhodamine,O
123,O
(,O
5,O
mg,O
/,O
mL,O
),O
for,O
15,O
min,O
at,O
37,O
°,O
C,O
.,O
The,O
cells,O
were,O
washed,O
",",O
resuspended,O
in,O
PBS,O
",",O
and,O
incubated,O
at,O
the,O
same,O
temperature,O
for,O
30,O
min,O
.,O
A,O
total,O
of,O
10,O
",",O
000,O
events,O
were,O
analyzed,O
per,O
sample,O
using,O
a,O
FACSCalibur,O
cytometer,O
",",O
and,O
numeric,O
data,O
were,O
processed,O
with,O
Cellquest,O
software,O
(,O
both,O
from,O
Becton,O
Dickinson,O
).,O
Propidium,O
iodide,O
and,O
rhodamine,O
123,O
are,O
excited,O
with,O
a,O
480,O
nm,O
argon,O
ion,O
laser,O
",",O
and,O
fluorescence,O
emission,O
occurs,O
at,O
560,O
–,O
580,O
nm,O
and,O
515,O
–,O
530,O
nm,O
",",O
respectively,O
.,O
Electron,O
paramagnetic,O
resonance,O
spectroscopy,O
Spin,O
-,O
label,O
5,O
-,O
doxyl,O
stearic,O
acid,O
(,O
5,O
-,O
DSA,O
"),",O
with,O
a,O
nitroxide,O
radical,O
moiety,O
(,O
doxyl,O
),O
in,O
the,O
fifth,O
carbon,O
atom,O
of,O
the,O
acyl,O
chain,O
",",O
was,O
purchased,O
from,O
Sigma,O
(,O
St,O
.,O
Louis,O
",",O
MO,O
",",O
USA,O
).,O
A,O
small,O
aliquot,O
(,O
3,O
μl,O
),O
of,O
stock,O
solution,O
of,O
the,O
spin,O
label,O
in,O
ethanol,O
(,O
2,O
mg,O
/,O
ml,O
),O
was,O
transferred,O
to,O
a,O
glass,O
tube,O
.,O
After,O
the,O
solvent,O
evaporated,O
",",O
approximately,O
2,O
.,O
4,O
×,O
108,O
cells,O
of,O
Leishmania,B-OG
suspended,O
in,O
40,O
μl,O
PBS,O
was,O
added,O
to,O
the,O
film,O
of,O
the,O
spin,O
label,O
with,O
gentle,O
agitation,O
.,O
In,O
a,O
second,O
tube,O
",",O
6,O
μl,O
of,O
a,O
stock,O
solution,O
of,O
parthenolide,O
in,O
chloroform,O
(,O
201,O
mM,O
),O
was,O
added,O
.,O
After,O
evaporation,O
of,O
the,O
solvent,O
",",O
the,O
first,O
spin,O
-,O
labeled,O
cell,O
suspension,O
was,O
placed,O
on,O
the,O
parthenolide,O
film,O
and,O
gently,O
agitated,O
.,O
The,O
cells,O
were,O
then,O
introduced,O
into,O
a,O
1,O
mm,O
inner,O
diameter,O
capillary,O
column,O
for,O
electron,O
paramagnetic,O
resonance,O
(,O
EPR,O
),O
measurements,O
",",O
which,O
was,O
sealed,O
by,O
flame,O
.,O
Samples,O
were,O
also,O
prepared,O
that,O
contained,O
double,O
and,O
triple,O
the,O
concentrations,O
of,O
parthenolide,O
used,O
in,O
the,O
first,O
sample,O
(,O
using,O
12,O
and,O
18,O
μl,O
of,O
the,O
solution,O
of,O
parthenolide,O
in,O
chloroform,O
",",O
respectively,O
).,O
Electron,O
paramagnetic,O
resonance,O
spectroscopy,O
was,O
performed,O
with,O
a,O
Bruker,O
ESP,O
300,O
spectrometer,O
(,O
Rheinstetten,O
",",O
Germany,O
),O
equipped,O
with,O
an,O
ER,O
4102,O
ST,O
resonator,O
.,O
The,O
instrument,O
settings,O
were,O
the,O
following,O
:,O
microwave,O
power,O
",",O
10,O
mW,O
;,O
modulation,O
frequency,O
",",O
100,O
KHz,O
;,O
modulation,O
amplitude,O
",",O
1,O
.,O
0,O
G,O
.,O
Electron,O
paramagnetic,O
resonance,O
spectra,O
simulations,O
were,O
performed,O
using,O
the,O
NLLS,O
program,O
developed,O
by,O
Budil,O
and,O
coworkers,O
[,O
48,O
].,O
In,O
the,O
spectral,O
calculations,O
",",O
the,O
NLLS,O
program,O
includes,O
the,O
magnetic,O
g,O
-,O
and,O
A,O
-,O
tensors,O
and,O
rotational,O
diffusion,O
tensor,O
",",O
R,O
",",O
which,O
are,O
expressed,O
in,O
a,O
system,O
of,O
Cartesian,O
axes,O
fixed,O
in,O
the,O
spin,O
-,O
labeled,O
molecule,O
.,O
To,O
reduce,O
the,O
number,O
of,O
parameters,O
in,O
the,O
fittings,O
and,O
simplify,O
the,O
simulation,O
",",O
the,O
average,O
rotational,O
diffusion,O
rate,O
",",O
R,O
bar,O
",",O
was,O
calculated,O
by,O
the,O
fitting,O
program,O
using,O
the,O
relationship,O
R,O
bar,O
=,O
(,O
R,O
per,O
2,O
•,O
R,O
par,O
),O
1,O
/,O
3,O
",",O
in,O
which,O
R,O
per,O
is,O
the,O
perpendicular,O
component,O
of,O
the,O
rotational,O
diffusion,O
",",O
and,O
R,O
par,O
is,O
the,O
parallel,O
component,O
of,O
the,O
rotational,O
diffusion,O
.,O
R,O
bar,O
was,O
converted,O
to,O
the,O
parameter,O
rotational,O
correlation,O
time,O
",",O
τ,O
c,O
",",O
following,O
the,O
relationship,O
τ,O
c,O
=,O
1,O
/,O
6,O
R,O
bar,O
.,O
Similar,O
to,O
previous,O
studies,O
[,O
49,O
",",O
50,O
"],",O
the,O
magnetic,O
parameters,O
were,O
determined,O
based,O
on,O
a,O
global,O
analysis,O
of,O
the,O
overall,O
spectra,O
obtained,O
in,O
this,O
work,O
",",O
and,O
all,O
of,O
the,O
EPR,O
spectra,O
were,O
simulated,O
using,O
the,O
same,O
predetermined,O
parameters,O
.,O
In,O
this,O
work,O
",",O
the,O
spectra,O
were,O
simulated,O
with,O
a,O
model,O
of,O
two,O
spectral,O
components,O
.,O
Competing,O
interests,O
The,O
authors,O
declare,O
that,O
they,O
have,O
no,O
competing,O
interests,O
.,O
Authors,O
’,O
contributions,O
TST,O
conceived,O
and,O
designed,O
the,O
study,O
",",O
carried,O
out,O
all,O
the,O
experimental,O
studies,O
and,O
drafted,O
the,O
manuscript,O
.,O
TUN,O
participated,O
in,O
the,O
design,O
of,O
the,O
study,O
.,O
AA,O
assisted,O
with,O
EPR,O
spectra,O
and,O
helped,O
to,O
draft,O
the,O
manuscript,O
.,O
CVN,O
conceived,O
of,O
the,O
study,O
",",O
and,O
participated,O
in,O
its,O
design,O
and,O
coordination,O
and,O
helped,O
to,O
draft,O
the,O
manuscript,O
.,O
All,O
authors,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
Comparison,O
of,O
the,O
Ex,O
Vivo,O
Expansion,O
of,O
UCB,O
-,O
Derived,O
CD34,B-GP
+,O
in,O
3D,O
DBM,O
/,O
MBA,O
Scaffolds,O
with,O
USSC,O
as,O
a,O
Feeder,O
Layer,O
Objective,O
(,O
s,O
):,O
Ex,O
vivo,O
expansion,O
of,O
hematopoitic,O
stem,O
cells,O
is,O
an,O
alternative,O
way,O
to,O
increase,O
umbilical,O
cord,O
blood,O
(,O
UCB,O
)-,O
CD34,B-GP
+,O
cells,O
for,O
bone,O
marrow,O
transplantation,O
.,O
For,O
this,O
purpose,O
demineralized,O
bone,O
matrix,O
(,O
DBM,O
),O
and,O
mineralized,O
bone,O
allograft,O
(,O
MBA,O
),O
as,O
two,O
scaffolds,O
based,O
on,O
bone,O
matrix,O
and,O
stem,O
cell,O
niche,O
",",O
were,O
simultaneously,O
used,O
to,O
enhance,O
the,O
effect,O
of,O
human,B-OG
mesenchymal,O
progenitor,O
cells,O
(,O
MPCs,O
),O
-,O
unrestricted,O
somatic,O
stem,O
cells,O
(,O
USSCs,O
),O
-,O
as,O
a,O
feeder,O
layer,O
.,O
Materials,O
and,O
Methods,O
:,O
USSCs,O
were,O
isolated,O
and,O
characterized,O
by,O
morphological,O
and,O
immunological,O
analysis,O
then,O
seeded,O
on,O
both,O
scaffolds,O
as,O
a,O
feeder,O
layer,O
.,O
UCB,O
-,O
CD34,B-GP
+,O
were,O
isolated,O
by,O
MACS,O
method,O
and,O
were,O
co,O
-,O
culture,O
expanded,O
by,O
USSC,O
in,O
3D,O
and,O
2D,O
environments,O
.,O
After,O
3,O
weeks,O
expansion,O
",",O
cells,O
were,O
counted,O
and,O
were,O
assessed,O
by,O
karyotype,O
",",O
flow,O
cytometry,O
",",O
clonogenic,O
activity,O
",",O
and,O
long,O
-,O
term,O
culture,O
-,O
initiating,O
cells,O
(,O
LTC,O
-,O
IC,O
).,O
Results,O
:,O
Co,O
-,O
culture,O
expansion,O
in,O
DBM,O
and,O
MBA,O
was,O
29,O
.,O
22,O
-,O
fold,O
and,O
27,O
.,O
77,O
-,O
fold,O
",",O
no,O
significant,O
differences,O
in,O
colony,O
and,O
LTC,O
-,O
IC,O
were,O
obtained,O
.,O
Maximum,O
number,O
of,O
colonies,O
belonged,O
to,O
the,O
day,O
14,O
with,O
the,O
73,O
%,O
CFU,O
-,O
GM,O
(,O
Colony,O
Forming,O
Unit,O
-,O
Granulocyte,O
/,O
Macrophage,O
),O
in,O
contrast,O
to,O
the,O
day,O
0,O
which,O
was,O
BFU,O
-,O
E,O
/,O
CFU,O
-,O
E,O
(,O
Burst,O
/,O
Colony,O
Forming,O
Unit,O
-,O
Erythroid,O
).,O
Flow,O
cytometry,O
indicated,O
that,O
the,O
percentage,O
of,O
CD34,B-GP
+,O
marker,O
was,O
decreased,O
in,O
USSC,O
co,O
-,O
culture,O
and,O
the,O
highest,O
percentage,O
was,O
observed,O
in,O
simple,O
2D,O
culture,O
.,O
Conclusion,O
:,O
Because,O
of,O
acid,O
extraction,O
in,O
the,O
DBM,O
production,O
process,O
",",O
mineral,O
materials,O
were,O
removed,O
and,O
the,O
protein,O
background,O
that,O
was,O
more,O
flexible,O
was,O
presented,O
.,O
Therefore,O
these,O
results,O
suggest,O
that,O
USSC,O
-,O
DBM,O
can,O
be,O
a,O
suitable,O
ex,O
vivo,O
mimicry,O
niche,O
by,O
intensifying,O
of,O
surface,O
/,O
volume,O
ratio,O
and,O
supporting,O
the,O
stem,O
cell,O
differentiation,O
and,O
expansion,O
.,O
Introduction,O
Currently,O
bone,O
marrow,O
transplantation,O
(,O
BMT,O
),O
is,O
considered,O
a,O
clinical,O
treatment,O
for,O
many,O
congenital,O
and,O
acquired,O
blood,B-DS
diseases,I-DS
(,O
1,O
).,O
For,O
this,O
treatment,O
hematopoietic,O
progenitor,O
cells,O
(,O
HPCs,O
),O
are,O
used,O
(,O
2,O
-,O
3,O
).,O
BMT,O
is,O
performed,O
either,O
as,O
an,O
autologous,O
or,O
an,O
allogeneic,O
transplantation,O
.,O
The,O
requirement,O
for,O
hematopoietic,O
stem,O
cells,O
(,O
HSCs,O
),O
in,O
an,O
allogeneic,O
transplantation,O
is,O
100,O
",",O
000,O
times,O
greater,O
than,O
for,O
an,O
autologous,O
transplantation,O
(,O
4,O
).,O
There,O
are,O
three,O
sources,O
for,O
prior,O
HSCs,O
:,O
bone,O
marrow,O
",",O
peripheral,O
blood,O
and,O
cord,O
blood,O
.,O
Between,O
these,O
3,O
sources,O
",",O
cord,O
blood,O
sample,O
is,O
the,O
healthy,O
and,O
safe,O
source,O
of,O
HPC,O
cells,O
for,O
the,O
recipient,O
(,O
5,O
",",O
6,O
).,O
But,O
on,O
the,O
other,O
hand,O
the,O
total,O
number,O
of,O
cells,O
derived,O
from,O
umbilical,O
cord,O
blood,O
(,O
UCB,O
),O
was,O
low,O
and,O
this,O
is,O
an,O
important,O
barrier,O
.,O
In,O
adult,O
recipients,O
",",O
BMT,O
is,O
limited,O
mainly,O
by,O
a,O
low,O
CD34,B-GP
+,O
cell,O
dose,O
(,O
7,O
).,O
To,O
overcome,O
this,O
problem,O
",",O
CD34,B-GP
+,O
expansion,O
is,O
recommended,O
(,O
8,O
).,O
Therefore,O
UCB,O
CD34,B-GP
+,O
cells,O
were,O
ex,O
vivo,O
expanded,O
and,O
then,O
injected,O
into,O
the,O
patient,O
to,O
replicate,O
(,O
9,O
).,O
In,O
nature,O
",",O
HSCs,O
are,O
in,O
the,O
microenvironment,O
",",O
or,O
niche,O
",",O
such,O
that,O
they,O
are,O
surrounded,O
by,O
stromal,O
and,O
mesenchymal,O
cells,O
.,O
The,O
niche,O
can,O
control,O
the,O
number,O
of,O
stem,O
cells,O
in,O
the,O
body,O
and,O
prevent,O
them,O
from,O
multiplying,O
too,O
.,O
Interaction,O
between,O
the,O
stem,O
cell,O
and,O
spatial,O
position,O
in,O
the,O
niche,O
establish,O
its,O
equilibrium,O
to,O
proliferation,O
or,O
differentiation,O
(,O
10,O
",",O
11,O
).,O
Stem,O
cells,O
(,O
SCs,O
),O
cannot,O
survive,O
for,O
long,O
outside,O
the,O
niche,O
(,O
12,O
).,O
Ex,O
vivo,O
-,O
like,O
conditions,O
are,O
composed,O
of,O
a,O
three,O
-,O
dimensional,O
(,O
3D,O
),O
structure,O
(,O
scaffold,O
),O
and,O
a,O
feeder,O
layer,O
.,O
Scaffolding,O
features,O
are,O
similar,O
to,O
the,O
extracellular,O
matrix,O
(,O
ECM,O
).,O
ECM,O
has,O
an,O
important,O
role,O
in,O
physical,O
and,O
chemical,O
signals,O
that,O
are,O
amplified,O
.,O
The,O
3D,O
environment,O
for,O
HSC,O
niche,O
with,O
helper,O
cells,O
is,O
associated,O
with,O
the,O
basal,O
material,O
.,O
In,O
3D,O
cultures,O
",",O
cells,O
are,O
grown,O
in,O
a,O
type,O
of,O
in,O
vivo,O
-,O
like,O
morphology,O
and,O
the,O
interaction,O
between,O
them,O
can,O
be,O
done,O
better,O
.,O
Three,O
dimensional,O
cultures,O
in,O
tissue,O
engineering,O
research,O
by,O
using,O
biochemical,O
materials,O
as,O
the,O
scaffold,O
is,O
rapidly,O
growing,O
.,O
3D,O
structures,O
in,O
tissue,O
engineering,O
is,O
a,O
multidisciplinary,O
field,O
and,O
is,O
a,O
new,O
and,O
exciting,O
technique,O
.,O
It,O
has,O
the,O
potential,O
to,O
create,O
organs,O
and,O
tissues,O
de,O
novo,O
(,O
13,O
).,O
It,O
involves,O
the,O
in,O
vitro,O
seeding,O
and,O
attachment,O
of,O
human,B-OG
cells,O
onto,O
the,O
scaffold,O
.,O
These,O
cells,O
then,O
proliferate,O
",",O
migrate,O
and,O
differentiate,O
into,O
the,O
specific,O
tissue,O
while,O
secreting,O
the,O
extracellular,O
matrix,O
components,O
required,O
for,O
creating,O
the,O
tissue,O
.,O
These,O
scaffolds,O
have,O
some,O
major,O
properties,O
:,O
They,O
are,O
biocompatible,O
",",O
injectable,O
and,O
biodegradable,O
(,O
14,O
).,O
The,O
3D,O
structure,O
is,O
used,O
for,O
providing,O
increased,O
surface,O
/,O
volume,O
ratio,O
of,O
culture,O
.,O
These,O
factors,O
let,O
the,O
scaffold,O
improve,O
the,O
efficiency,O
of,O
the,O
culture,O
.,O
Scaffolds,O
are,O
critical,O
",",O
both,O
ex,O
vivo,O
as,O
well,O
as,O
in,O
vivo,O
",",O
to,O
mimic,O
the,O
in,O
vivo,O
milieu,O
and,O
allow,O
cells,O
to,O
influence,O
their,O
own,O
microenvironments,O
.,O
Here,O
",",O
we,O
try,O
to,O
imitate,O
HSC,O
microenvironment,O
or,O
niche,O
in,O
3D,O
culture,O
.,O
For,O
bone,O
marrow,O
and,O
cartilage,O
",",O
the,O
most,O
commonly,O
used,O
scaffolds,O
are,O
MBA,O
(,O
mineralized,O
bone,O
allograft,O
),O
and,O
DBM,O
(,O
de,O
-,O
mineralized,O
bone,O
matrix,O
),O
(,O
15,O
).,O
Basically,O
",",O
they,O
are,O
used,O
for,O
repair,O
",",O
clinical,O
surgery,O
",",O
bone,O
allograft,O
and,O
transplantation,O
(,O
16,O
).,O
These,O
are,O
based,O
on,O
the,O
bone,O
matrix,O
but,O
the,O
only,O
difference,O
between,O
them,O
is,O
the,O
lack,O
of,O
mineralized,O
materials,O
in,O
DBM,O
by,O
the,O
acid,O
extraction,O
method,O
(,O
17,O
).,O
As,O
described,O
above,O
",",O
to,O
provide,O
a,O
similar,O
environment,O
in,O
vitro,O
",",O
human,B-OG
cord,O
blood,O
as,O
a,O
novel,O
source,O
of,O
human,B-OG
mesenchymal,O
progenitor,O
cell,O
(,O
MPC,O
),O
(,O
18,O
),O
-,O
unrestricted,O
somatic,O
stem,O
cells,O
(,O
USSCs,O
),O
-,O
was,O
integrated,O
in,O
an,O
attempt,O
to,O
use,O
as,O
a,O
feeder,O
layer,O
(,O
19,O
-,O
21,O
).,O
USSC,O
cells,O
on,O
the,O
MBA,O
and,O
DBM,O
scaffolds,O
are,O
same,O
as,O
the,O
matrix,O
for,O
UCB,O
-,O
CD34,B-GP
+,O
cell,O
growth,O
support,O
.,O
The,O
culture,O
system,O
appeared,O
to,O
provide,O
a,O
different,O
microenvironment,O
from,O
the,O
2D,O
flask,O
culture,O
and,O
might,O
be,O
used,O
as,O
an,O
alternative,O
model,O
for,O
hematopoiesis,O
.,O
Our,O
goal,O
then,O
",",O
understands,O
the,O
importance,O
of,O
the,O
presence,O
of,O
the,O
mineral,O
materials,O
for,O
the,O
expansion,O
of,O
HSCs,O
and,O
the,O
extent,O
of,O
the,O
influence,O
of,O
the,O
self,O
-,O
renewal,O
of,O
stem,O
cells,O
in,O
the,O
3D,O
culture,O
by,O
USSC,O
feeder,O
in,O
contrast,O
to,O
the,O
2D,O
culture,O
.,O
This,O
research,O
aims,O
to,O
increase,O
the,O
number,O
of,O
hematopoietic,O
stem,O
cells,O
with,O
minimal,O
genetic,O
manipulation,O
in,O
three,O
-,O
dimensional,O
culture,O
.,O
However,O
",",O
to,O
reduce,O
the,O
risk,O
of,O
rejection,O
minimal,O
genetic,O
manipulation,O
and,O
techniques,O
should,O
be,O
involved,O
.,O
Materials,O
and,O
Methods,O
Generation,O
and,O
expansion,O
of,O
USSCs,O
from,O
fresh,O
UCB,O
UCB,O
samples,O
were,O
collected,O
from,O
full,O
term,O
",",O
normal,O
deliveries,O
according,O
to,O
the,O
approved,O
ethical,O
procedures,O
at,O
Tarbiat,O
Modares,O
University,O
(,O
Iran,O
",",O
Tehran,O
",",O
Shariati,O
Hospital,O
).,O
From,O
each,O
donor,O
",",O
informed,O
consent,O
was,O
acquired,O
according,O
to,O
patient,O
sample,O
collection,O
for,O
research,O
studies,O
protocol,O
approved,O
by,O
the,O
ethics,O
committee,O
.,O
After,O
that,O
USSCs,O
were,O
isolated,O
according,O
to,O
a,O
protocol,O
by,O
Kogler,O
et,O
al,O
.,O
To,O
isolate,O
the,O
mononuclear,O
cells,O
(,O
MNCs,O
),O
and,O
reduce,O
RBC,O
contamination,O
of,O
the,O
upper,O
phase,O
to,O
the,O
minimum,O
level,O
",",O
low,O
-,O
density,O
(,O
less,O
than,O
1,O
.,O
077,O
g,O
/,O
ml,O
),O
cell,O
isolation,O
was,O
performed,O
by,O
Ficoll,O
-,O
Hypaque,O
gradient,O
centrifugation,O
(,O
Pharmacia,O
",",O
Uppsala,O
",",O
Sweden,O
).,O
After,O
2,O
washes,O
by,O
phosphate,O
buffered,O
saline,O
(,O
PBS,O
"),",O
cells,O
were,O
cultured,O
in,O
T25,O
flasks,O
and,O
specific,O
media,O
:,O
low,O
-,O
glucose,O
DMEM,O
supplemented,O
with,O
10,O
-,O
7,O
M,O
Dexamethasone,O
",",O
30,O
%,O
FCS,O
",",O
2,O
mM,O
ultraglutamine,O
",",O
100U,O
/,O
ml,O
penicillin,O
G,O
",",O
100,O
µg,O
/,O
ml,O
streptomycin,O
",",O
it,O
will,O
be,O
better,O
by,O
used,O
of,O
Myelocult,O
medium,O
containing,O
12,O
.,O
5,O
%,O
FCS,O
and,O
12,O
.,O
5,O
%,O
horse,B-OG
serum,O
.,O
Cells,O
were,O
incubated,O
at,O
37,O
°,O
C,O
in,O
5,O
%,O
CO2,O
in,O
a,O
fully,O
humidified,O
.,O
After,O
two,O
weeks,O
the,O
adherent,O
USSC,O
colonies,O
were,O
observed,O
.,O
Monoclonal,O
antibodies,B-GP
for,O
immunophenotyping,O
of,O
USSCs,O
Fluorescein,O
isothiocyanate,O
-,O
conjugated,O
antibodies,B-GP
(,O
Abs,B-GP
),O
were,O
obtained,O
as,O
follows,O
:,O
USSC,O
cells,O
were,O
analyzed,O
by,O
flow,O
cytometry,O
assay,O
to,O
detect,O
their,O
markers,O
.,O
These,O
cells,O
were,O
positive,O
for,O
CD166,B-GP
",",O
CD73,B-GP
",",O
CD105,B-GP
",",O
CD90,B-GP
",",O
CD44,B-GP
",",O
weak,O
positive,O
expression,O
for,O
KDR,B-GP
",",O
and,O
negative,O
for,O
CD117,B-GP
",",O
CD34,B-GP
",",O
CD45,B-GP
and,O
Cadherin,B-GP
V,I-GP
.,O
Transdifferentiation,O
of,O
USSCs,O
into,O
adipocytes,O
and,O
osteoblasts,O
In,O
order,O
to,O
confirm,O
the,O
source,O
USSCs,O
as,O
the,O
human,B-OG
mesenchymal,O
progenitor,O
cells,O
",",O
and,O
the,O
process,O
of,O
differentiation,O
",",O
we,O
check,O
differentiation,O
potential,O
of,O
USSC,O
cells,O
.,O
For,O
osteogenic,O
differentiation,O
",",O
the,O
cultured,O
cells,O
were,O
incubated,O
in,O
osteogenic,O
medium,O
containing,O
DMEM,O
supplemented,O
with,O
10,O
%,O
FBS,O
",",O
β,O
-,O
glycerol,O
phosphate,O
10,O
mM,O
",",O
dexamethasone,O
10,O
-,O
7M,O
",",O
and,O
ascorbic,O
acid,O
bi,O
-,O
phosphate,O
50,O
µg,O
/,O
ml,O
(,O
Sigma,O
).,O
The,O
culture,O
media,O
were,O
changed,O
twice,O
a,O
week,O
for,O
3,O
weeks,O
.,O
Afterwards,O
",",O
cells,O
were,O
fixed,O
in,O
4,O
%,O
paraformaldehyde,O
for,O
20,O
min,O
",",O
washed,O
with,O
PBS,O
and,O
stained,O
with,O
Alizarin,O
-,O
Red,O
solution,O
(,O
in,O
60,O
%,O
isopropanol,O
),O
for,O
10,O
min,O
",",O
followed,O
by,O
repeated,O
washings,O
.,O
To,O
induce,O
adipocyte,O
differentiation,O
",",O
USSCs,O
were,O
cultured,O
in,O
DMEM,O
supplemented,O
with,O
10,O
%,O
FBS,O
",",O
dexamethasone,O
250,O
nM,O
",",O
insulin,O
66nM,O
",",O
isobutyl,O
-,O
methylxanthine,O
0,O
.,O
5,O
mM,O
",",O
and,O
indomethacine,O
0,O
.,O
2mM,O
for,O
3,O
weeks,O
and,O
also,O
for,O
specific,O
staining,O
",",O
cells,O
were,O
fixed,O
and,O
incubated,O
with,O
Oil,O
-,O
Red,O
.,O
USSCs,O
were,O
cultured,O
as,O
a,O
feeder,O
layer,O
These,O
isolated,O
cells,O
were,O
cultured,O
on,O
a,O
48,O
-,O
well,O
plate,O
.,O
When,O
the,O
cells,O
reached,O
80,O
%,O
confluence,O
",",O
their,O
mitotic,O
activity,O
was,O
disabled,O
by,O
Mitomycin,O
-,O
C,O
10,O
µg,O
/,O
ml,O
(,O
Sigma,O
),O
according,O
to,O
its,O
protocol,O
:,O
culture,O
media,O
was,O
removed,O
and,O
cells,O
were,O
incubated,O
by,O
mitomycin,O
-,O
C,O
for,O
2,O
hours,O
.,O
After,O
incubation,O
time,O
it,O
was,O
washed,O
2,O
times,O
by,O
PBS,O
and,O
fresh,O
media,O
was,O
added,O
.,O
For,O
3D,O
culture,O
",",O
these,O
cells,O
should,O
seed,O
on,O
the,O
scaffolds,O
.,O
First,O
MBA,O
and,O
DBM,O
slices,O
were,O
cut,O
to,O
the,O
desired,O
size,O
(,O
6,O
to,O
8,O
mm,O
sided,O
cubic,O
pieces,O
),O
by,O
the,O
sterile,O
scalpel,O
.,O
Then,O
the,O
surfaces,O
of,O
the,O
scaffolds,O
were,O
prepared,O
.,O
To,O
prepare,O
and,O
dispose,O
",",O
they,O
were,O
immersed,O
overnight,O
in,O
the,O
PBS,O
with,O
gelatin,O
0,O
.,O
1,O
%,O
which,O
opens,O
the,O
pores,O
like,O
a,O
spongy,O
tissue,O
",",O
ready,O
to,O
work,O
.,O
Afterwards,O
",",O
nearly,O
3,O
×,O
106,O
USSC,O
cells,O
from,O
three,O
T75,O
culture,O
flasks,O
were,O
removed,O
by,O
the,O
trypsin,B-GP
0,O
.,O
25,O
%,O
(,O
GIBCO,O
).,O
This,O
number,O
of,O
cells,O
in,O
the,O
DMEM,O
media,O
supplemented,O
by,O
30,O
%,O
FBS,O
were,O
added,O
to,O
MBA,O
and,O
DBM,O
scaffolds,O
(,O
9,O
pieces,O
each,O
).,O
This,O
concentrated,O
cell,O
suspension,O
was,O
rotating,O
for,O
8,O
hours,O
during,O
the,O
incubation,O
.,O
After,O
this,O
time,O
the,O
media,O
was,O
replaced,O
by,O
fresh,O
DMEM,O
.,O
This,O
rotation,O
is,O
needed,O
to,O
push,O
the,O
cells,O
into,O
the,O
pores,O
of,O
the,O
scaffolds,O
.,O
After,O
3,O
days,O
",",O
this,O
feeder,O
layer,O
can,O
be,O
disabled,O
by,O
Mitomycin,O
-,O
C,O
too,O
.,O
These,O
scaffolds,O
were,O
placed,O
in,O
18,O
wells,O
of,O
a,O
48,O
well,O
plate,O
that,O
were,O
previously,O
coated,O
with,O
a,O
USSC,O
feeder,O
layer,O
(,O
9,O
wells,O
for,O
DBM,O
and,O
9,O
wells,O
for,O
MBA,O
).,O
Scanning,O
e,O
lectron,O
m,O
icroscope,O
(,O
SEM,O
),O
For,O
SEM,O
imaging,O
",",O
we,O
should,O
choose,O
a,O
process,O
that,O
preserves,O
the,O
structure,O
of,O
freshly,O
killed,O
material,O
in,O
a,O
state,O
that,O
most,O
closely,O
resembles,O
the,O
structure,O
and,O
/,O
or,O
composition,O
of,O
the,O
original,O
living,O
state,O
.,O
For,O
chemical,O
fixation,O
as,O
the,O
non,O
-,O
coagulative,O
process,O
",",O
we,O
need,O
paraformaldehyde,O
4,O
%.,O
In,O
this,O
process,O
",",O
first,O
the,O
culture,O
media,O
was,O
removed,O
",",O
and,O
fixed,O
in,O
paraformaldehyde,O
(,O
pH,O
7,O
),O
at,O
4oC,O
for,O
20,O
min,O
.,O
the,O
scaffold,O
samples,O
were,O
then,O
dehydrated,O
through,O
a,O
graded,O
ethanol,O
series,O
and,O
ultra,O
-,O
structurally,O
scoped,O
using,O
an,O
electron,O
microscope,O
(,O
Philips,O
).,O
HSC,O
isolation,O
by,O
MACS,O
(,O
m,O
agnetic,O
a,O
ctivated,O
c,O
ell,O
s,O
orting,O
),O
method,O
MNCs,O
were,O
isolated,O
as,O
described,O
above,O
",",O
and,O
then,O
the,O
CD34,B-GP
+,O
cells,O
were,O
isolated,O
from,O
this,O
MNC,O
population,O
",",O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
instructions,O
for,O
the,O
CD34,B-GP
cell,O
isolation,O
kit,O
(,O
Miltenyi,O
Biotech,O
",",O
BergischGladbach,O
",",O
Germany,O
).,O
The,O
cell,O
suspension,O
was,O
adjacent,O
by,O
blocking,O
agent,O
and,O
an,O
antibody,B-GP
labeled,O
with,O
a,O
magnet,O
to,O
one,O
hr,O
at,O
4,O
°,O
C,O
and,O
dark,O
place,O
.,O
This,O
antibody,B-GP
was,O
against,O
CD34,B-GP
marker,O
.,O
After,O
this,O
period,O
",",O
samples,O
were,O
washed,O
with,O
EDTA,O
-,O
PBS,O
buffer,O
.,O
Afterwards,O
",",O
the,O
suspension,O
was,O
passed,O
through,O
the,O
LS,O
separation,O
columns,O
(,O
Miltenyi,O
Biotech,O
",",O
BergischGladbach,O
",",O
Germany,O
),O
and,O
eventually,O
with,O
the,O
help,O
of,O
the,O
piston,O
and,O
pressure,O
cells,O
",",O
CD34,B-GP
+,O
from,O
other,O
cord,O
blood,O
mononuclear,O
cells,O
were,O
separated,O
.,O
As,O
a,O
result,O
the,O
purity,O
of,O
CD34,B-GP
+,O
cells,O
ranged,O
from,O
85,O
to,O
95,O
%.,O
Ex,O
vivo,O
expansion,O
of,O
cord,O
blood,O
hematopoietic,O
cells,O
Isolated,O
hematopoietic,O
cells,O
were,O
then,O
cultured,O
in,O
StemSpan,O
(,O
Stemcell,O
Technologies,O
#,O
09600,O
),O
containing,O
stem,B-GP
cell,I-GP
factor,I-GP
(,O
SCF,B-GP
),O
100,O
ng,O
/,O
mL,O
and,O
FMS,B-GP
-,I-GP
like,I-GP
tyrosine,I-GP
kinase,I-GP
-,I-GP
3,I-GP
100,O
ng,O
/,O
ml,O
",",O
and,O
100,O
ng,O
/,O
mL,O
thrombopoietin,B-GP
.,O
They,O
were,O
separated,O
and,O
cultured,O
in,O
48,O
well,O
plates,O
in,O
four,O
culture,O
conditions,O
:,O
first,O
in,O
2D,O
culture,O
(,O
without,O
feeder,O
layer,O
and,O
scaffolds,O
),O
that,O
is,O
simple,O
2D,O
culture,O
(,O
S2D,O
"),",O
second,O
in,O
2D,O
culture,O
with,O
the,O
USSCs,O
as,O
a,O
feeder,O
layer,O
(,O
F2D,O
"),",O
third,O
in,O
3D,O
culture,O
(,O
DBM,O
scaffold,O
accompanied,O
by,O
USSC,O
feeder,O
layer,O
),O
and,O
fourth,O
in,O
3D,O
culture,O
again,O
(,O
MBA,O
scaffold,O
accompanied,O
by,O
USSC,O
feeder,O
layer,O
).,O
In,O
every,O
condition,O
they,O
were,O
cultured,O
in,O
9,O
wells,O
of,O
48,O
-,O
well,O
plates,O
.,O
These,O
9,O
wells,O
were,O
counted,O
within,O
3,O
weeks,O
expansion,O
and,O
were,O
done,O
triplicate,O
per,O
week,O
.,O
Flow,O
cytometry,O
Hematopoietic,O
cells,O
were,O
analyzed,O
before,O
and,O
after,O
3,O
weeks,O
ex,O
vivo,O
expansion,O
by,O
two,O
-,O
color,O
ﬂow,O
cytometry,O
(,O
PARTEC,O
",",O
Germany,O
).,O
Nearly,O
105,O
cells,O
were,O
re,O
-,O
suspended,O
in,O
PBS,O
-,O
5,O
%,O
FBS,O
and,O
were,O
stained,O
with,O
ﬂuorescein,O
isothiocyanate,O
(,O
FITC,O
)-,O
conjugated,O
anti,O
-,O
human,B-OG
CD34,B-GP
.,O
These,O
cells,O
were,O
gated,O
with,O
low,O
side,O
scatter,O
.,O
In,O
order,O
to,O
confirm,O
the,O
speciﬁcity,O
of,O
staining,O
",",O
we,O
stained,O
hematopoietic,O
cells,O
by,O
an,O
isotype,O
control,O
with,O
FITC,O
-,O
mouse,B-OG
IgG1,B-GP
in,O
a,O
replicate,O
manner,O
to,O
ensure,O
the,O
speciﬁcity,O
of,O
staining,O
.,O
Acquired,O
data,O
using,O
PARTEC,O
ﬂow,O
cytometer,O
were,O
then,O
analyzed,O
by,O
FloMax,O
software,O
.,O
Clonogenic,O
assay,O
In,O
the,O
isolation,O
day,O
and,O
at,O
the,O
end,O
of,O
1st,O
",",O
2nd,O
and,O
3rd,O
weeks,O
for,O
all,O
3,O
groups,O
",",O
we,O
prepared,O
three,O
dilutions,O
of,O
expanded,O
cells,O
500,O
",",O
1000,O
",",O
1500,O
per,O
each,O
culture,O
condition,O
.,O
Every,O
cell,O
dilution,O
was,O
mixed,O
with,O
1,O
ml,O
of,O
Methocult,O
™,O
GF,O
+,O
H4435,O
methylcellulose,O
medium,O
(,O
Stemcell,O
Technologies,O
#,O
04435,O
),O
in,O
separate,O
tubes,O
",",O
according,O
to,O
the,O
manufacturer,O
’,O
s,O
instructions,O
",",O
the,O
contents,O
of,O
each,O
tube,O
were,O
plated,O
within,O
separate,O
wells,O
of,O
6,O
-,O
well,O
plates,O
.,O
Plates,O
were,O
incubated,O
at,O
37,O
°,O
C,O
with,O
more,O
than,O
95,O
%,O
humidity,O
and,O
5,O
%,O
CO2,O
for,O
2,O
weeks,O
.,O
To,O
maintain,O
culture,O
humidity,O
",",O
one,O
well,O
was,O
filled,O
with,O
sterile,O
water,O
.,O
USSC,O
cells,O
in,O
the,O
specific,O
media,O
.,O
A,O
),O
USSC,O
colonies,O
after,O
2,O
weeks,O
.,O
B,O
),O
USSC,O
cells,O
by,O
80,O
%,O
confluency,O
Long,O
-,O
term,O
culture,O
-,O
initiating,O
cells,O
(,O
LTC,O
-,O
IC,O
),O
LTC,O
-,O
IC,O
assay,O
was,O
performed,O
according,O
to,O
the,O
technique,O
described,O
below,O
.,O
Bone,O
marrow,O
cells,O
were,O
cultivated,O
as,O
feeder,O
-,O
layer,O
cells,O
in,O
96,O
-,O
well,O
plate,O
format,O
.,O
These,O
cells,O
were,O
harvested,O
and,O
incubated,O
with,O
mitomycin,O
-,O
C,O
.,O
A,O
day,O
later,O
",",O
the,O
stromal,O
layers,O
were,O
charged,O
with,O
CD34,B-GP
+,O
cells,O
in,O
the,O
specific,O
Myelocult,O
medium,O
(,O
Stemcell,O
Technologies,O
#,O
05100,O
),O
containing,O
10,O
−,O
6M,O
hydrocortisone,O
(,O
Stem,O
Cell,O
Technologies,O
#,O
07904,O
).,O
A,O
minimum,O
of,O
1,O
l03,O
up,O
to,O
a,O
maximum,O
of,O
4,O
×,O
l03,O
expanded,O
hematopoietic,O
cells,O
per,O
well,O
were,O
plated,O
.,O
After,O
5,O
weeks,O
of,O
incubation,O
",",O
cells,O
were,O
removed,O
and,O
assay,O
in,O
the,O
CFC,O
assay,O
as,O
described,O
above,O
.,O
A,O
well,O
is,O
scored,O
as,O
positive,O
if,O
one,O
or,O
more,O
BFU,O
-,O
E,O
",",O
CFU,O
-,O
GM,O
or,O
CFU,O
-,O
GEMM,O
is,O
detected,O
or,O
as,O
negative,O
if,O
no,O
colonies,O
are,O
present,O
.,O
The,O
LTC,O
-,O
IC,O
frequency,O
in,O
the,O
test,O
cell,O
population,O
is,O
calculated,O
from,O
the,O
proportion,O
of,O
negative,O
wells,O
(,O
no,O
CFC,O
present,O
),O
and,O
the,O
method,O
of,O
maximum,O
likelihood,O
then,O
statistical,O
analysis,O
can,O
be,O
performed,O
.,O
Mitotic,O
chromosome,O
preparations,O
for,O
karyotyping,O
After,O
high,O
expansion,O
in,O
cell,O
count,O
",",O
the,O
cells,O
should,O
be,O
checked,O
for,O
chromosome,O
number,O
and,O
banding,O
pattern,O
to,O
determine,O
if,O
they,O
were,O
altered,O
from,O
the,O
normal,O
(,O
expected,O
),O
pattern,O
.,O
For,O
harvesting,O
cells,O
",",O
at,O
first,O
0,O
.,O
15,O
ml,O
of,O
50,O
µg,O
/,O
ml,O
Colchicine,O
solution,O
was,O
added,O
to,O
each,O
culture,O
tube,O
containing,O
expanded,O
CD34,B-GP
+,O
cells,O
and,O
followed,O
by,O
incubation,O
at,O
37,O
°,O
C,O
and,O
centrifuge,O
.,O
Then,O
2,O
-,O
3,O
ml,O
of,O
prewarmed,O
0,O
.,O
075,O
M,O
KCl,O
solution,O
was,O
added,O
to,O
the,O
cell,O
pellet,O
which,O
after,O
10,O
min,O
centrifugation,O
at,O
500,O
×,O
g,O
",",O
were,O
gently,O
pipeted,O
by,O
fixative,O
solution,O
(,O
3,O
:,O
1,O
(,O
v,O
/,O
v,O
),O
methanol,O
/,O
glacial,O
acetic,O
acid,O
),O
followed,O
by,O
incubation,O
at,O
room,O
temperature,O
and,O
centrifuge,O
.,O
This,O
step,O
was,O
repeated,O
twice,O
more,O
by,O
applying,O
a,O
small,O
drop,O
of,O
cell,O
suspension,O
onto,O
the,O
surface,O
of,O
a,O
slide,O
and,O
allowing,O
it,O
to,O
spread,O
.,O
Slide,O
was,O
stained,O
by,O
Giemsa,O
solution,O
.,O
Statistical,O
analysis,O
Results,O
were,O
expressed,O
as,O
mean,O
±,O
SD,O
and,O
analyzed,O
by,O
the,O
T,O
test,O
.,O
Differences,O
were,O
considered,O
to,O
be,O
significant,O
at,O
P,O
<,O
0,O
.,O
05,O
.,O
Population,O
doubling,O
time,O
of,O
USSCs,O
cells,O
in,O
primary,O
culture,O
up,O
to,O
the,O
30,O
passages,O
.,O
Average,O
of,O
PDT,O
was,O
49,O
.,O
48,O
±,O
0,O
.,O
3,O
hr,O
Results,O
Cell,O
culture,O
USSC,O
colonies,O
were,O
observed,O
after,O
2,O
weeks,O
of,O
USSC,O
cell,O
culture,O
(,O
Figure,O
1A,O
).,O
After,O
each,O
passage,O
these,O
spindle,O
-,O
shaped,O
cells,O
reached,O
complete,O
confluency,O
(,O
Figure,O
1B,O
).,O
It,O
didn,O
’,O
t,O
take,O
longer,O
to,O
reach,O
confluency,O
and,O
their,O
morphology,O
didn,O
’,O
t,O
change,O
with,O
each,O
passage,O
.,O
The,O
results,O
related,O
to,O
the,O
PDT,O
(,O
population,O
doubling,O
time,O
),O
in,O
different,O
passages,O
of,O
the,O
USSCs,O
are,O
shown,O
in,O
Figure,O
2,O
.,O
PDT,O
didn,O
’,O
t,O
change,O
during,O
the,O
experiment,O
periods,O
from,O
primary,O
culture,O
to,O
passage,O
30,O
.,O
Characterization,O
of,O
USSCs,O
by,O
flow,O
cytometry,O
USSCs,O
in,O
4th,O
passage,O
were,O
subjected,O
to,O
flow,O
cytometry,O
for,O
the,O
presence,O
or,O
absence,O
of,O
hematopoietic,O
and,O
endothelial,O
markers,O
.,O
USSCs,O
typically,O
expressed,O
the,O
surface,O
antigens,O
CD105,B-GP
",",O
CD44,B-GP
and,O
CD73,B-GP
(,O
Figure,O
3,O
"),",O
and,O
showed,O
low,O
level,O
of,O
KDR,B-GP
but,O
were,O
negative,O
for,O
CD34,B-GP
and,O
CD45,B-GP
",",O
which,O
are,O
the,O
early,O
hematopoietic,O
markers,O
.,O
Analysis,O
of,O
cell,O
surface,O
markers,O
by,O
FACS,O
analysis,O
were,O
confirmed,O
these,O
isolated,O
cells,O
.,O
Differentiation,O
of,O
USSCs,O
to,O
osteogenic,O
and,O
adipogenic,O
USSC,O
cultures,O
in,O
adipogenic,O
differentiation,O
medium,O
after,O
2,O
weeks,O
",",O
presenting,O
fat,O
vacuoles,O
in,O
the,O
cytoplasm,O
can,O
be,O
appeared,O
by,O
oil,O
red,O
staining,O
(,O
Figure,O
4A,O
).,O
For,O
osteogenic,O
inductive,O
medium,O
",",O
appearance,O
of,O
refringent,O
crystals,O
were,O
be,O
observed,O
by,O
Alizarin,O
Red,O
staining,O
(,O
Figure,O
4B,O
).,O
Scanning,O
electron,O
microscope,O
views,O
About,O
40,O
%,O
of,O
scaffold,O
surface,O
pictures,O
showed,O
porosity,O
.,O
Figure,O
5,O
shows,O
the,O
surface,O
of,O
scaffolds,O
without,O
cells,O
as,O
the,O
control,O
",",O
so,O
that,O
very,O
small,O
pores,O
in,O
the,O
scaffold,O
can,O
be,O
seen,O
under,O
a,O
microscope,O
in,O
which,O
these,O
pores,O
are,O
so,O
deeply,O
dark,O
.,O
When,O
the,O
scaffolds,O
were,O
seeded,O
by,O
USSCs,O
as,O
the,O
feeder,O
layer,O
",",O
the,O
empty,O
scaffold,O
is,O
less,O
clear,O
.,O
Elongated,O
and,O
spindle,O
-,O
shaped,O
cells,O
covered,O
the,O
surface,O
but,O
few,O
of,O
these,O
surrounded,O
cells,O
entered,O
into,O
the,O
cavities,O
and,O
pores,O
.,O
Cells,O
were,O
more,O
coated,O
on,O
the,O
outer,O
face,O
.,O
Cell,O
size,O
was,O
about,O
100,O
µm,O
and,O
with,O
more,O
magnification,O
each,O
cell,O
could,O
be,O
observed,O
separately,O
as,O
a,O
light,O
band,O
.,O
However,O
",",O
with,O
the,O
same,O
zoom,O
level,O
on,O
the,O
control,O
scaffold,O
",",O
only,O
the,O
dark,O
face,O
without,O
the,O
light,O
bands,O
were,O
visible,O
(,O
Figure,O
5B,O
",",O
E,O
).,O
The,O
effect,O
of,O
USSC,O
and,O
scaffold,O
combination,O
on,O
the,O
expansion,O
of,O
UCB,O
-,O
CD34,B-GP
+,O
over,O
3,O
weeks,O
.,O
Values,O
are,O
expressed,O
as,O
mean,O
±,O
SD,O
for,O
3,O
numbers,O
of,O
experiments,O
.,O
Fold,O
expansion,O
was,O
calculated,O
based,O
on,O
the,O
cell,O
counts,O
(,O
1000,O
),O
on,O
day,O
0,O
Total,O
Cells,O
(,O
fold,O
exp,O
.),O
Groups,O
1st,O
wk,O
2nd,O
wk,O
3rd,O
wk,O
S2D,O
(,O
n,O
=,O
3,O
),O
13800,O
±,O
1600,O
(,O
13,O
.,O
8,O
±,O
1,O
.,O
6,O
),O
53400,O
±,O
3200,O
(,O
53,O
.,O
4,O
±,O
3,O
.,O
2,O
),O
101900,O
±,O
8000,O
(,O
101,O
.,O
9,O
±,O
8,O
),O
F2D,O
(,O
n,O
=,O
3,O
),O
28700,O
±,O
3400,O
(,O
28,O
.,O
7,O
±,O
3,O
.,O
4,O
),O
104300,O
±,O
11000,O
(,O
104,O
.,O
3,O
±,O
11,O
),O
194200,O
±,O
4600,O
(,O
194,O
.,O
2,O
±,O
4,O
.,O
6,O
),O
MBA,O
(,O
n,O
=,O
3,O
),O
40800,O
±,O
4100,O
(,O
40,O
.,O
8,O
±,O
4,O
.,O
1,O
),O
145500,O
±,O
5800,O
(,O
145,O
.,O
5,O
±,O
5,O
.,O
8,O
),O
271700,O
±,O
13000,O
(,O
271,O
.,O
7,O
±,O
13,O
.,O
2,O
),O
DBM,O
(,O
n,O
=,O
3,O
),O
44200,O
±,O
1600,O
(,O
44,O
.,O
2,O
±,O
1,O
.,O
6,O
),O
176700,O
±,O
6400,O
(,O
176,O
.,O
7,O
±,O
6,O
.,O
4,O
),O
305800,O
±,O
12700,O
(,O
305,O
.,O
8,O
±,O
12,O
.,O
7,O
),O
Abbreviation,O
:,O
simple,O
2D,O
culture,O
(,O
S2D,O
"),",O
simple,O
2D,O
culture,O
with,O
feeder,O
(,O
F2D,O
"),",O
mineralized,O
bone,O
allograft,O
(,O
MBA,O
"),",O
de,O
-,O
mineralized,O
bone,O
matrix,O
(,O
DBM,O
),O
Immunophenotypes,O
of,O
USSCs,O
.,O
USSC,O
preparations,O
were,O
labeled,O
with,O
the,O
monoclonal,O
Abs,B-GP
specific,O
for,O
the,O
molecule,O
indicated,O
(,O
filled,O
histograms,O
),O
or,O
isotype,O
controls,O
(,O
open,O
histograms,O
).,O
USSC,O
are,O
positive,O
for,O
CD73,B-GP
",",O
CD44,B-GP
and,O
CD105,B-GP
but,O
have,O
weak,O
positive,O
expression,O
for,O
KDR,B-GP
Isolation,O
and,O
differentiation,O
characteristics,O
of,O
human,B-OG
UCB,O
-,O
derived,O
USSCs,O
.,O
A,O
),O
The,O
results,O
of,O
Oil,O
Red,O
-,O
O,O
-,O
staining,O
in,O
differentiated,O
adipogenic,O
cells,O
.,O
B,O
),O
Results,O
of,O
osteogenic,O
differentiation,O
by,O
Alizarin,O
Red,O
-,O
staining,O
.,O
Ex,O
vivo,O
expansion,O
of,O
cord,O
blood,O
hematopoietic,O
cells,O
UCB,O
CD34,B-GP
+,O
cells,O
were,O
seeded,O
at,O
a,O
concentration,O
of,O
1,O
×,O
103,O
cells,O
per,O
each,O
well,O
in,O
the,O
48,O
-,O
well,O
plate,O
in,O
the,O
hematopoietic,O
stem,O
cell,O
expansion,O
medium,O
(,O
StemSpan,O
supplemented,O
by,O
3,O
cocktail,O
cytokines,B-GP
:,O
Flt3,B-GP
-,I-GP
L,I-GP
",",O
SCF,B-GP
",",O
TPO,B-GP
).,O
CD34,B-GP
+,O
cells,O
in,O
4,O
groups,O
were,O
expanded,O
:,O
S2D,O
",",O
F2D,O
",",O
DBM,O
and,O
MBA,O
.,O
These,O
4,O
groups,O
were,O
counted,O
after,O
each,O
week,O
during,O
3,O
weeks,O
by,O
triplicate,O
for,O
each,O
group,O
.,O
The,O
result,O
is,O
shown,O
in,O
Table,O
1,O
.,O
In,O
F2D,O
culture,O
",",O
the,O
CD34,B-GP
+,O
cells,O
were,O
co,O
-,O
cultivated,O
on,O
the,O
USSC,O
-,O
feeder,O
layer,O
.,O
USSCs,O
showed,O
their,O
ability,O
to,O
support,O
the,O
expansion,O
of,O
CD34,B-GP
+,O
cells,O
over,O
three,O
weeks,O
(,O
Figure,O
6,O
).,O
The,O
highest,O
cell,O
count,O
was,O
in,O
3D,O
culture,O
but,O
DBM,O
was,O
a,O
little,O
more,O
than,O
MBA,O
.,O
The,O
total,O
cell,O
count,O
on,O
the,O
USSC,O
layer,O
in,O
DBM,O
culture,O
increased,O
within,O
the,O
21,O
-,O
day,O
period,O
",",O
it,O
was,O
44,O
.,O
2,O
-,O
fold,O
±,O
1,O
.,O
6,O
-,O
fold,O
after,O
7,O
days,O
",",O
176,O
.,O
7,O
-,O
fold,O
±,O
6,O
.,O
4,O
-,O
fold,O
after,O
14,O
days,O
",",O
and,O
305,O
.,O
8,O
-,O
fold,O
±,O
12,O
.,O
7,O
-,O
fold,O
after,O
21,O
days,O
.,O
SEM,O
views,O
of,O
scaffold,O
surface,O
in,O
black,O
and,O
white,O
version,O
.,O
A,O
-,O
B,O
),O
empty,O
MBA,O
without,O
USSC,O
cells,O
.,O
C,O
),O
MBA,O
with,O
seeded,O
USSC,O
.,O
D,O
-,O
E,O
),O
empty,O
DBM,O
without,O
USSC,O
cells,O
.,O
F,O
),O
DBM,O
with,O
seeded,O
USSC,O
The,O
effect,O
of,O
USSC,O
presence,O
as,O
the,O
feeder,O
layer,O
on,O
the,O
colony,O
formation,O
of,O
UCB,O
-,O
CD34,B-GP
+,O
over,O
3,O
weeks,O
.,O
CFC,O
counts,O
were,O
performed,O
from,O
the,O
expanding,O
cultures,O
at,O
days,O
0,O
",",O
7,O
",",O
14,O
",",O
and,O
21,O
.,O
The,O
results,O
are,O
expressed,O
as,O
mean,O
±,O
SD,O
for,O
total,O
cells,O
",",O
CFC,O
",",O
BFU,O
-,O
E,O
/,O
CFU,O
-,O
E,O
",",O
CFU,O
-,O
GM,O
",",O
and,O
CFU,O
-,O
mix,O
Total,O
cells,O
CFC,O
/,O
103,O
cells,O
BFU,O
/,O
CFU,O
-,O
E,O
/,O
103,O
cells,O
CFU,O
-,O
GM,O
/,O
103,O
cells,O
CFU,O
-,O
mix,O
/,O
103,O
cells,O
Day,O
0,O
1000,O
30,O
.,O
9,O
±,O
2,O
.,O
1,O
22,O
.,O
6,O
±,O
0,O
.,O
7,O
9,O
.,O
5,O
±,O
1,O
.,O
1,O
2,O
.,O
8,O
±,O
0,O
.,O
3,O
1st,O
week,O
F2D,O
28700,O
23,O
.,O
2,O
±,O
1,O
.,O
5,O
9,O
.,O
4,O
±,O
0,O
.,O
5,O
12,O
.,O
2,O
±,O
0,O
.,O
7,O
1,O
.,O
6,O
±,O
0,O
.,O
3,O
MBA,O
40800,O
16,O
.,O
0,O
±,O
1,O
.,O
8,O
6,O
.,O
1,O
±,O
0,O
.,O
3,O
7,O
.,O
3,O
±,O
1,O
.,O
1,O
1,O
.,O
0,O
±,O
0,O
.,O
4,O
DBM,O
44200,O
16,O
.,O
3,O
±,O
2,O
.,O
7,O
7,O
.,O
3,O
±,O
0,O
.,O
9,O
7,O
.,O
9,O
±,O
1,O
.,O
7,O
1,O
.,O
1,O
±,O
0,O
.,O
1,O
2nd,O
week,O
F2D,O
104300,O
35,O
.,O
6,O
±,O
1,O
.,O
8,O
8,O
.,O
8,O
±,O
1,O
.,O
2,O
26,O
.,O
2,O
±,O
0,O
.,O
6,O
0,O
.,O
6,O
±,O
0,O
.,O
0,O
MBA,O
145500,O
28,O
.,O
6,O
±,O
2,O
.,O
0,O
7,O
.,O
1,O
±,O
0,O
.,O
7,O
20,O
.,O
7,O
±,O
1,O
.,O
3,O
0,O
.,O
8,O
±,O
0,O
.,O
0,O
DBM,O
176700,O
30,O
.,O
1,O
±,O
3,O
.,O
3,O
7,O
.,O
9,O
±,O
2,O
.,O
1,O
21,O
.,O
9,O
±,O
0,O
.,O
8,O
1,O
.,O
9,O
±,O
0,O
.,O
4,O
3rd,O
week,O
F2D,O
194200,O
24,O
.,O
4,O
±,O
1,O
.,O
8,O
6,O
.,O
2,O
±,O
0,O
.,O
9,O
17,O
.,O
1,O
±,O
0,O
.,O
7,O
1,O
.,O
1,O
±,O
0,O
.,O
2,O
MBA,O
271700,O
22,O
.,O
5,O
±,O
1,O
.,O
4,O
3,O
.,O
1,O
±,O
0,O
.,O
6,O
17,O
.,O
9,O
±,O
0,O
.,O
5,O
1,O
.,O
5,O
±,O
0,O
.,O
3,O
DBM,O
305800,O
23,O
.,O
9,O
±,O
1,O
.,O
7,O
4,O
.,O
7,O
±,O
0,O
.,O
3,O
18,O
.,O
4,O
±,O
1,O
.,O
0,O
1,O
.,O
0,O
±,O
0,O
.,O
4,O
Abbreviation,O
:,O
simple,O
2D,O
culture,O
with,O
feeder,O
(,O
F2D,O
"),",O
mineralized,O
bone,O
allograft,O
(,O
MBA,O
"),",O
de,O
-,O
mineralized,O
bone,O
matrix,O
(,O
DBM,O
"),",O
Colony,O
Forming,O
Count,O
(,O
CFC,O
"),",O
Burst,O
Forming,O
Unit,O
/,O
Colony,O
Forming,O
Unit,O
-,O
Erythroid,O
(,O
BFU,O
/,O
CFU,O
-,O
E,O
"),",O
Colony,O
Forming,O
Unit,O
-,O
Granulocyte,O
/,O
Macrophage,O
(,O
CFU,O
-,O
GM,O
"),",O
Colony,O
Forming,O
Unit,O
-,O
mix,O
(,O
CFU,O
-,O
mix,O
),O
Flow,O
cytometry,O
CD34,B-GP
+,O
cells,O
were,O
enriched,O
by,O
nearly,O
90,O
percent,O
(,O
Figure,O
7,O
),O
and,O
subsequently,O
after,O
3,O
weeks,O
expansion,O
",",O
CD34,B-GP
+,O
cells,O
were,O
analyzed,O
by,O
FACS,O
method,O
to,O
observe,O
their,O
CD34,B-GP
marker,O
ratio,O
(,O
Figure,O
8,O
).,O
The,O
global,O
competition,O
indicated,O
that,O
the,O
lowest,O
CD34,B-GP
marker,O
belonged,O
to,O
the,O
3D,O
culture,O
(,O
8,O
.,O
6,O
%,O
and,O
9,O
.,O
2,O
%,O
respectively,O
for,O
DBM,O
and,O
MBA,O
).,O
But,O
no,O
significant,O
difference,O
was,O
observed,O
between,O
MBA,O
and,O
DBM,O
in,O
the,O
kind,O
of,O
3D,O
condition,O
.,O
The,O
highest,O
CD34,B-GP
marker,O
was,O
observed,O
in,O
S2D,O
culture,O
(,O
17,O
.,O
3,O
%),O
and,O
finally,O
for,O
the,O
F2D,O
group,O
it,O
was,O
10,O
.,O
5,O
%.,O
Percent,O
drop,O
in,O
CD34,B-GP
+,O
cells,O
was,O
greater,O
in,O
the,O
three,O
-,O
dimensional,O
culture,O
.,O
This,O
problem,O
can,O
partly,O
explain,O
the,O
high,O
levels,O
of,O
secreted,O
factors,O
attributed,O
myeloid,O
line,O
distinction,O
",",O
such,O
as,O
GM,B-GP
-,I-GP
CSF,I-GP
",",O
M,B-GP
-,I-GP
CSF,I-GP
",",O
IL,B-GP
-,I-GP
6,I-GP
",",O
IL,B-GP
-,I-GP
11,I-GP
and,O
SCF,B-GP
.,O
Also,O
the,O
IL,B-GP
-,I-GP
1B,I-GP
factor,O
secretion,O
by,O
both,O
USSC,O
and,O
CD34,B-GP
+,O
cells,O
strongly,O
enhanced,O
the,O
G,B-GP
-,I-GP
CSF,I-GP
production,O
by,O
USSC,O
cells,O
leading,O
to,O
the,O
differentiation,O
of,O
CD34,B-GP
+,O
cells,O
into,O
a,O
specific,O
cell,O
line,O
.,O
This,O
low,O
percentage,O
in,O
contrast,O
to,O
the,O
highest,O
expansion,O
and,O
CD34,B-GP
+,O
count,O
in,O
3D,O
condition,O
can,O
be,O
ignored,O
.,O
On,O
the,O
first,O
day,O
we,O
charged,O
each,O
group,O
by,O
1000,O
cells,O
with,O
89,O
.,O
57,O
%,O
CD34,B-GP
+,O
cells,O
or,O
nearly,O
900,O
CD34,B-GP
+,O
cells,O
.,O
For,O
S2D,O
",",O
we,O
counted,O
101900,O
cells,O
by,O
17,O
.,O
3,O
%,O
or,O
about,O
17600,O
CD34,B-GP
+,O
cells,O
.,O
Therefore,O
fold,O
expansion,O
by,O
flow,O
cytometry,O
was,O
19,O
.,O
55,O
-,O
fold,O
±,O
1,O
.,O
5,O
-,O
fold,O
.,O
Other,O
HSCs,O
expansion,O
evaluation,O
by,O
flow,O
cytometry,O
is,O
shown,O
in,O
Figure,O
9,O
.,O
The,O
most,O
expansion,O
belonged,O
to,O
the,O
DBM,O
group,O
.,O
Colony,O
assay,O
Each,O
week,O
",",O
nonadherent,O
hematopoietic,O
cells,O
(,O
CD34,B-GP
+,O
cells,O
),O
from,O
the,O
adherent,O
feeder,O
cells,O
were,O
separated,O
and,O
analyzed,O
by,O
CFC,O
to,O
evaluate,O
the,O
progenitor,O
content,O
and,O
CD34,B-GP
+,O
cells,O
.,O
As,O
summarized,O
in,O
Table,O
2,O
and,O
Figure,O
10,O
.,O
For,O
total,O
CFC,O
",",O
the,O
highest,O
CFC,O
expansion,O
was,O
observed,O
at,O
day,O
14,O
:,O
35,O
.,O
6,O
-,O
fold,O
±,O
1,O
.,O
8,O
-,O
fold,O
",",O
28,O
.,O
6,O
-,O
fold,O
±,O
2,O
.,O
0,O
-,O
fold,O
and,O
30,O
.,O
1,O
-,O
fold,O
±,O
3,O
.,O
3,O
-,O
fold,O
for,O
F2D,O
",",O
MBA,O
and,O
DBM,O
",",O
respectively,O
.,O
Similarly,O
",",O
amplification,O
of,O
CFU,O
-,O
GM,O
and,O
BFU,O
-,O
E,O
/,O
CFU,O
-,O
E,O
was,O
highest,O
",",O
whereas,O
CFC,O
was,O
reduced,O
after,O
2,O
weeks,O
.,O
The,O
composition,O
of,O
CFC,O
clearly,O
showed,O
that,O
after,O
2,O
weeks,O
about,O
73,O
%,O
of,O
colonies,O
obtained,O
were,O
CFU,O
-,O
GM,O
.,O
But,O
on,O
day,O
0,O
nearly,O
73,O
%,O
of,O
colonies,O
were,O
BFU,O
-,O
E,O
/,O
CFU,O
-,O
E,O
.,O
When,O
total,O
number,O
of,O
cells,O
generated,O
in,O
3D,O
culture,O
was,O
compared,O
to,O
2D,O
culture,O
",",O
significantly,O
higher,O
colony,O
counts,O
for,O
3D,O
were,O
determined,O
at,O
each,O
time,O
point,O
.,O
Because,O
these,O
colony,O
counts,O
were,O
in,O
1000,O
cells,O
",",O
so,O
that,O
in,O
comparison,O
with,O
total,O
cells,O
in,O
F2D,O
",",O
MBA,O
and,O
DBM,O
the,O
CFC,O
counts,O
were,O
3713,O
±,O
188,O
",",O
4161,O
±,O
291,O
and,O
5318,O
±,O
583,O
.,O
USSCs,O
co,O
-,O
cultivate,O
with,O
UCB,O
-,O
CD34,B-GP
+,O
over,O
1,O
A,O
"),",O
2,O
B,O
"),",O
and,O
3,O
C,O
),O
weeks,O
expansion,O
The,O
frequency,O
of,O
long,O
-,O
term,O
culture,O
-,O
initiating,O
cells,O
in,O
different,O
condition,O
during,O
3,O
weeks,O
expansion,O
Frequency,O
of,O
LTC,O
-,O
IC,O
cells,O
Day,O
0,O
1,O
in,O
8372,O
1st,O
wk,O
2nd,O
wk,O
3rd,O
wk,O
S2D,O
1,O
in,O
11634,O
S2D,O
1,O
in,O
14840,O
S2D,O
1,O
in,O
22478,O
F2D,O
1,O
in,O
7389,O
F2D,O
1,O
in,O
5125,O
F2D,O
1,O
in,O
11650,O
MBA,O
1,O
in,O
7760,O
MBA,O
1,O
in,O
6192,O
MBA,O
1,O
in,O
13289,O
DBM,O
1,O
in,O
7554,O
DBM,O
1,O
in,O
5992,O
DBM,O
1,O
in,O
12673,O
Abbreviation,O
:,O
simple,O
2D,O
culture,O
(,O
S2D,O
"),",O
simple,O
2D,O
culture,O
with,O
feeder,O
(,O
F2D,O
"),",O
mineralized,O
bone,O
allograft,O
(,O
MBA,O
"),",O
de,O
-,O
mineralized,O
bone,O
matrix,O
(,O
DBM,O
),O
A,O
),O
enumeration,O
of,O
CD34,B-GP
+,O
at,O
isolation,O
day,O
was,O
89,O
.,O
57,O
percentage,O
.,O
B,O
),O
CD34,B-GP
+,O
cells,O
were,O
labeled,O
with,O
FITC,O
-,O
conjugated,O
antibody,B-GP
and,O
B,O
),O
with,O
IgG1,B-GP
as,O
the,O
control,O
antibody,B-GP
LTC,O
-,O
IC,O
After,O
3,O
weeks,O
co,O
-,O
cultivation,O
of,O
CD34,B-GP
+,O
cells,O
on,O
the,O
USSC,O
layer,O
(,O
2D,O
and,O
3D,O
conditions,O
),O
no,O
significant,O
differentiation,O
between,O
them,O
was,O
observed,O
in,O
contrast,O
to,O
the,O
simple,O
2D,O
culture,O
where,O
the,O
total,O
number,O
of,O
long,O
-,O
term,O
culture,O
-,O
initiating,O
cells,O
dropped,O
after,O
each,O
week,O
(,O
Table,O
3,O
).,O
The,O
culture,O
by,O
feeder,O
(,O
F2D,O
",",O
MBA,O
and,O
DBM,O
),O
could,O
make,O
an,O
expansion,O
in,O
1,O
.,O
13,O
-,O
fold,O
",",O
1,O
.,O
07,O
-,O
fold,O
and,O
1,O
.,O
10,O
-,O
fold,O
in,O
the,O
first,O
week,O
and,O
also,O
in,O
1,O
.,O
63,O
-,O
fold,O
",",O
1,O
.,O
35,O
-,O
fold,O
and,O
1,O
.,O
39,O
-,O
fold,O
in,O
the,O
second,O
week,O
in,O
contrast,O
to,O
the,O
day,O
0,O
.,O
But,O
in,O
the,O
3rd,O
week,O
this,O
expansion,O
dropped,O
and,O
maintaining,O
of,O
LTC,O
-,O
IC,O
cells,O
reached,O
nearly,O
0,O
.,O
6,O
-,O
fold,O
.,O
Therefore,O
USSC,O
cells,O
could,O
only,O
preserve,O
the,O
hematopoietic,O
initiating,O
cells,O
just,O
for,O
2,O
weeks,O
in,O
the,O
ex,O
vivo,O
condition,O
and,O
make,O
long,O
term,O
hematopoesis,O
.,O
Karyotyping,O
For,O
research,O
in,O
genetics,O
and,O
cytogenetics,O
",",O
Karyotyping,O
was,O
developed,O
.,O
The,O
G,O
-,O
banded,O
karyotype,O
is,O
useful,O
in,O
the,O
identification,O
of,O
aberrant,O
chromosomes,O
and,O
absent,O
",",O
additional,O
",",O
or,O
aberrant,O
chromosomes,O
",",O
which,O
can,O
include,O
deletions,O
",",O
inversions,O
",",O
reciprocal,O
translocations,O
",",O
duplications,O
",",O
insertions,O
",",O
and,O
Robertsonian,O
chromosomes,O
.,O
Figure,O
11,O
shows,O
the,O
G,O
banding,O
pattern,O
in,O
normal,O
chromosomes,O
.,O
No,O
aberrations,O
were,O
obtained,O
and,O
did,O
not,O
alter,O
the,O
normal,O
banding,O
pattern,O
.,O
The,O
human,B-OG
karyotype,O
contains,O
22,O
autosomal,O
pairs,O
and,O
two,O
sex,O
chromosomes,O
.,O
The,O
female,O
karyotypes,O
contain,O
two,O
large,O
X,O
chromosomes,O
(,O
the,O
inactive,O
X,O
may,O
be,O
very,O
darkly,O
stained,O
"),",O
whereas,O
the,O
male,O
karyotypes,O
contain,O
one,O
large,O
X,O
chromosome,O
and,O
a,O
small,O
one,O
.,O
Normal,O
karyotype,O
of,O
the,O
expanded,O
CD34,B-GP
+,O
cells,O
after,O
21,O
days,O
in,O
3D,O
DBM,O
condition,O
by,O
305,O
.,O
8,O
-,O
fold,O
expansion,O
was,O
obtained,O
.,O
Chromosome,O
count,O
was,O
46,O
as,O
in,O
normal,O
cells,O
and,O
no,O
abnormalities,O
in,O
quantity,O
(,O
aneuploidy,O
),O
or,O
quality,O
were,O
observed,O
and,O
no,O
fusion,O
between,O
stromal,O
and,O
HSCs,O
occurred,O
.,O
The,O
CD34,B-GP
+,O
stem,O
cell,O
populations,O
after,O
3,O
weeks,O
ex,O
vivo,O
expansion,O
were,O
evaluated,O
by,O
means,O
of,O
flow,O
cytometry,O
.,O
Flow,O
cytometry,O
assay,O
showed,O
that,O
18,O
.,O
3,O
%,O
for,O
S2D,O
A,O
"),",O
11,O
.,O
5,O
%,O
for,O
F2D,O
B,O
"),",O
8,O
.,O
2,O
%,O
for,O
MBA,O
C,O
),O
and,O
7,O
.,O
6,O
%,O
for,O
DBM,O
D,O
),O
Discussion,O
In,O
previous,O
studies,O
",",O
at,O
first,O
",",O
nutritious,O
feeder,O
layer,O
(,O
mesenchymal,O
stem,O
cells,O
),O
was,O
used,O
for,O
cell,O
proliferation,O
as,O
the,O
Dexter,O
culture,O
(,O
1977,O
).,O
But,O
Miller,O
showed,O
that,O
growth,O
factors,O
can,O
also,O
create,O
a,O
similar,O
environment,O
for,O
expansion,O
(,O
22,O
).,O
The,O
nutrients,O
and,O
growth,O
factors,O
layer,O
",",O
for,O
cell,O
proliferation,O
of,O
SCID,O
/,O
NOD,O
were,O
used,O
simultaneously,O
(,O
23,O
).,O
But,O
they,O
also,O
understood,O
that,O
over,O
a,O
long,O
period,O
of,O
time,O
",",O
this,O
environment,O
cannot,O
provide,O
reliable,O
cell,O
(,O
24,O
),O
and,O
showed,O
that,O
stem,O
cells,O
are,O
sensitive,O
to,O
their,O
microenvironment,O
.,O
Here,O
the,O
porous,O
tantalum,O
scaffold,O
(,O
tantalum,O
-,O
coated,O
porous,O
biomaterial,O
(,O
TCPB,O
")),",O
only,O
after,O
a,O
week,O
",",O
showed,O
1,O
.,O
5,O
increasing,O
fold,O
compared,O
with,O
the,O
two,O
-,O
dimensional,O
culture,O
(,O
25,O
).,O
In,O
this,O
regard,O
",",O
the,O
engineering,O
matrices,O
and,O
other,O
polymer,O
or,O
nanomer,O
materials,O
were,O
used,O
(,O
26,O
-,O
31,O
).,O
The,O
result,O
of,O
these,O
experiments,O
for,O
replication,O
(,O
32,O
-,O
34,O
),O
or,O
differentiation,O
(,O
35,O
),O
of,O
stem,O
cells,O
was,O
performed,O
.,O
Finally,O
it,O
caused,O
better,O
BMT,O
and,O
other,O
hematic,O
transplantations,O
(,O
36,O
-,O
38,O
),O
or,O
even,O
without,O
entering,O
the,O
clinical,O
stage,O
",",O
biological,O
or,O
synthetic,O
structures,O
were,O
used,O
for,O
stem,O
cell,O
proliferation,O
(,O
39,O
-,O
42,O
).,O
In,O
Tan,O
and,O
colleagues,O
research,O
-,O
2011,O
(,O
43,O
"),",O
three,O
-,O
dimensional,O
structure,O
was,O
derived,O
from,O
the,O
bone,O
tissue,O
for,O
stem,O
cell,O
proliferation,O
to,O
achieve,O
7,O
.,O
5,O
-,O
fold,O
expansion,O
.,O
In,O
this,O
structure,O
a,O
feeder,O
layer,O
of,O
mesenchymal,O
stem,O
cells,O
was,O
used,O
but,O
scaffolding,O
explanation,O
was,O
not,O
provided,O
so,O
the,O
real,O
significance,O
of,O
this,O
scaffold,O
is,O
the,O
substances,O
that,O
are,O
present,O
.,O
In,O
other,O
studies,O
",",O
non,O
-,O
mineralized,O
bone,O
matrix,O
was,O
used,O
as,O
scaffold,O
.,O
With,O
general,O
comparison,O
of,O
previous,O
research,O
",",O
we,O
want,O
to,O
investigate,O
the,O
applicability,O
and,O
effectiveness,O
of,O
simultaneously,O
using,O
the,O
mineralized,O
scaffold,O
with,O
USSCs,O
feeder,O
layer,O
for,O
proliferation,O
of,O
hematopoietic,O
stem,O
cells,O
(,O
15,O
",",O
17,O
",",O
44,O
-,O
47,O
).,O
The,O
results,O
of,O
our,O
research,O
are,O
also,O
in,O
line,O
with,O
previous,O
studies,O
and,O
showed,O
that,O
proliferation,O
in,O
three,O
-,O
dimensional,O
conditions,O
is,O
better,O
.,O
Kinetics,O
of,O
ex,O
vivo,O
expansion,O
of,O
CD34,B-GP
+,O
cells,O
by,O
flow,O
cytometry,O
in,O
different,O
culture,O
conditions,O
after,O
21,O
days,O
.,O
The,O
results,O
are,O
expressed,O
as,O
mean,O
fold,O
±,O
SD,O
for,O
S2D,O
",",O
F2D,O
",",O
MBA,O
and,O
DBM,O
.,O
P,O
-,O
value,O
compare,O
to,O
the,O
S2D,O
for,O
each,O
condition,O
was,O
significant,O
Kinetics,O
of,O
colony,O
formation,O
of,O
CB,O
-,O
CD34,B-GP
+,O
cells,O
expanded,O
on,O
USSC,O
.,O
CFC,O
counts,O
were,O
performed,O
from,O
the,O
expanding,O
cultures,O
at,O
days,O
0,O
A,O
),O
and,O
14,O
B,O
),O
Karyotype,O
of,O
the,O
expanded,O
CD34,B-GP
+,O
cells,O
after,O
21,O
days,O
in,O
3D,O
condition,O
.,O
Chromosome,O
number,O
is,O
46,O
like,O
a,O
normal,O
cell,O
and,O
no,O
fusion,O
between,O
stromal,O
and,O
HSCs,O
in,O
cytogenetic,O
term,O
were,O
obtained,O
b,O
In,O
order,O
to,O
improve,O
efficiency,O
of,O
the,O
tissue,O
and,O
cell,O
culture,O
in,O
tissue,O
engineering,O
",",O
we,O
need,O
to,O
create,O
three,O
-,O
dimensional,O
ex,O
vivo,O
conditions,O
that,O
mimic,O
inside,O
of,O
body,O
(,O
in,O
vivo,O
).,O
For,O
this,O
purpose,O
",",O
the,O
cells,O
are,O
cultured,O
on,O
the,O
suitable,O
scaffolds,O
.,O
To,O
achieve,O
this,O
goal,O
",",O
we,O
need,O
to,O
mimic,O
the,O
inside,O
of,O
body,O
which,O
contains,O
co,O
-,O
culture,O
of,O
purpose,O
cells,O
with,O
the,O
stromal,O
cells,O
simultaneously,O
(,O
51,O
",",O
52,O
).,O
MNCs,O
cannot,O
form,O
colonies,O
in,O
the,O
culture,O
without,O
supportive,O
environment,O
(,O
53,O
).,O
As,O
described,O
above,O
the,O
only,O
difference,O
between,O
DBM,O
and,O
MBA,O
is,O
the,O
lack,O
of,O
mineral,O
in,O
DBM,O
.,O
We,O
know,O
that,O
bone,O
marrow,O
is,O
composed,O
of,O
a,O
protein,O
matrix,O
and,O
a,O
mineral,O
section,O
necessary,O
for,O
hardness,O
",",O
rigidity,O
and,O
stability,O
that,O
enables,O
the,O
skeleton,O
to,O
resist,O
gravitational,O
and,O
mechanical,O
loading,O
",",O
also,O
has,O
the,O
ability,O
to,O
transfer,O
specific,O
signals,O
to,O
stimulate,O
cell,O
division,O
of,O
stem,O
cells,O
.,O
Features,O
of,O
these,O
two,O
scaffolds,O
are,O
similar,O
to,O
bone,O
tissue,O
and,O
were,O
used,O
for,O
bone,O
tissue,O
engineering,O
(,O
54,O
).,O
Three,O
-,O
dimensional,O
geometry,O
and,O
topography,O
of,O
these,O
porous,O
scaffolds,O
with,O
the,O
adherent,O
stromal,O
cells,O
(,O
USSCs,O
),O
could,O
emulate,O
the,O
bone,O
marrow,O
microenvironment,O
and,O
hematopoesis,O
(,O
55,O
",",O
56,O
).,O
For,O
HSCs,O
",",O
sticky,O
stromal,O
cells,O
are,O
considered,O
as,O
the,O
co,O
-,O
culture,O
to,O
increase,O
the,O
density,O
of,O
blood,O
cells,O
(,O
57,O
",",O
58,O
).,O
Production,O
of,O
extracellular,O
matrix,O
",",O
hematopoietic,B-GP
cytokine,I-GP
",",O
connection,O
and,O
interaction,O
between,O
molecules,O
could,O
be,O
increased,O
in,O
the,O
small,O
cell,O
area,O
.,O
Therefore,O
DBM,O
and,O
MBA,O
by,O
USSC,O
can,O
be,O
a,O
suitable,O
ex,O
vivo,O
mimicry,O
niche,O
by,O
intensifying,O
surface,O
/,O
volume,O
ratio,O
(,O
59,O
),O
and,O
supporting,O
the,O
stem,O
cell,O
differentiation,O
and,O
expansion,O
.,O
Finally,O
",",O
the,O
production,O
of,O
nutrient,O
materials,O
",",O
growth,O
factors,O
",",O
hormones,O
",",O
autocrine,O
",",O
paracrine,O
",",O
and,O
exocrine,O
(,O
60,O
),O
factors,O
will,O
be,O
maximum,O
just,O
in,O
the,O
small,O
location,O
called,O
local,O
concentrations,O
of,O
factors,O
(,O
61,O
).,O
Stromal,O
cells,O
are,O
a,O
source,O
of,O
adhesion,B-GP
molecules,I-GP
and,O
growth,O
factors,O
for,O
supporting,O
stem,O
cell,O
expansion,O
(,O
62,O
).,O
USSCs,O
in,O
contrast,O
to,O
the,O
mesenchymal,O
stem,O
cells,O
have,O
the,O
longer,O
telomerase,O
that,O
cause,O
more,O
expansion,O
capacity,O
and,O
self,O
-,O
renewal,O
in,O
these,O
cells,O
.,O
USSC,O
can,O
produce,O
a,O
lot,O
of,O
cytokines,B-GP
such,O
as,O
CSF,B-GP
",",O
LIF,B-GP
(,O
Leukemia,B-GP
Inhibitory,I-GP
Factor,I-GP
"),",O
TGF,B-GP
-,I-GP
1β,I-GP
(,O
Transforming,B-GP
Growth,I-GP
Factor,I-GP
-,I-GP
1,I-GP
beta,I-GP
"),",O
VEGF,B-GP
(,O
Vascular,B-GP
Endothelial,I-GP
Growth,I-GP
Factor,I-GP
"),",O
GM,B-GP
-,I-GP
CSF,I-GP
",",O
M,B-GP
-,I-GP
CSF,I-GP
",",O
IL,B-GP
-,I-GP
1β,I-GP
",",O
IL,B-GP
-,I-GP
6,I-GP
",",O
IL,B-GP
-,I-GP
8,I-GP
",",O
IL,B-GP
-,I-GP
11,I-GP
",",O
IL,B-GP
-,I-GP
12,I-GP
",",O
IL,B-GP
-,I-GP
15,I-GP
",",O
SDF,B-GP
-,I-GP
1α,I-GP
(,O
Stromal,B-GP
Derived,I-GP
Factor,I-GP
-,I-GP
1,I-GP
alpha,I-GP
),O
(,O
56,O
).,O
When,O
feeder,O
cells,O
are,O
in,O
contact,O
with,O
the,O
environment,O
in,O
three,O
dimensions,O
",",O
the,O
result,O
is,O
increased,O
secretion,O
of,O
factors,O
that,O
can,O
improve,O
the,O
efficiency,O
of,O
the,O
feeder,O
.,O
Therefore,O
focus,O
on,O
three,O
factors,O
increased,O
secretion,O
and,O
this,O
effect,O
is,O
direct,O
contact,O
of,O
the,O
humeral,O
(,O
61,O
).,O
The,O
scaffold,O
was,O
a,O
6,O
-,O
8mm,O
sided,O
cube,O
and,O
porosity,O
was,O
40,O
%,O
so,O
every,O
aspect,O
of,O
the,O
six,O
-,O
way,O
area,O
scaffold,O
was,O
68,O
.,O
6mm2,O
{(,O
7,O
×,O
7,O
)+,O
0,O
.,O
4,O
×(,O
7,O
×,O
7,O
)}.,O
With,O
regard,O
to,O
the,O
sixth,O
aspect,O
",",O
the,O
general,O
area,O
of,O
​​,O
the,O
scaffold,O
was,O
411,O
.,O
6mm2,O
.,O
The,O
well,O
’,O
s,O
diagonal,O
of,O
each,O
48,O
-,O
well,O
plate,O
was,O
12mm,O
therefore,O
well,O
area,O
was,O
113,O
.,O
04,O
mm2,O
.,O
Finally,O
for,O
MBA,O
and,O
DBM,O
the,O
general,O
surface,O
was,O
524,O
.,O
64mm2,O
that,O
was,O
4,O
.,O
64,O
-,O
fold,O
of,O
S2D,O
.,O
Conclusion,O
Stem,O
cells,O
in,O
the,O
body,O
depends,O
on,O
the,O
three,O
-,O
dimensional,O
mode,O
will,O
be,O
simulate,O
to,O
differentiate,O
or,O
prolife,O
state,O
.,O
Their,O
power,O
of,O
proliferation,O
cannot,O
survive,O
for,O
long,O
outside,O
of,O
niche,O
(,O
63,O
).,O
Niche,O
could,O
control,O
the,O
number,O
of,O
stem,O
cells,O
in,O
the,O
body,O
and,O
prevent,O
them,O
from,O
multiplying,O
too,O
(,O
12,O
).,O
Stem,O
cell,O
expansion,O
out,O
of,O
the,O
niche,O
such,O
as,O
in,O
2D,O
culture,O
or,O
even,O
in,O
the,O
erythropoesis,O
Dexter,O
culture,O
with,O
abnormal,O
face,O
",",O
or,O
uncontrolled,O
proliferation,O
can,O
lead,O
to,O
aneuploidy,O
and,O
cancer,B-DS
.,O
HSCs,O
niche,O
has,O
helper,O
cells,O
with,O
basic,O
materials,O
.,O
This,O
background,O
material,O
or,O
extracellular,O
matrix,O
has,O
a,O
lot,O
of,O
proteins,O
such,O
as,O
fibronectin,B-GP
(,O
64,O
"),",O
collagen,B-GP
(,O
65,O
-,O
66,O
),O
and,O
gelatin,O
(,O
67,O
),O
that,O
were,O
synthesized,O
for,O
a,O
lot,O
of,O
scaffolds,O
based,O
on,O
them,O
(,O
68,O
).,O
Acid,O
extraction,O
removes,O
the,O
minerals,O
thus,O
the,O
protein,O
surface,O
of,O
the,O
scaffold,O
(,O
flexible,O
microenvironment,O
),O
is,O
presented,O
which,O
is,O
familiar,O
for,O
the,O
cells,O
.,O
Therefore,O
DBM,O
will,O
be,O
so,O
soft,O
",",O
porous,O
and,O
spongy,O
(,O
45,O
),O
and,O
the,O
rate,O
of,O
cytokine,B-GP
production,O
and,O
ex,O
vivo,O
hematopoiesis,O
-,O
supporting,O
activity,O
of,O
UCB,O
-,O
derived,O
USSC,O
in,O
3D,O
culture,O
is,O
improved,O
.,O
This,O
is,O
therefore,O
suggested,O
for,O
better,O
3D,O
culture,O
results,O
in,O
tissue,O
engineering,O
.,O
This,O
result,O
shows,O
that,O
multiline,O
age,O
expansion,O
of,O
CD34,B-GP
derived,O
UCB,O
is,O
feasible,O
in,O
the,O
feeder,O
contact,O
cultures,O
without,O
further,O
addition,O
of,O
cytokines,B-GP
.,O
Intraluminal,O
Administration,O
of,O
Poly,O
I,O
:,O
C,O
Causes,O
an,O
Enteropathy,B-DS
That,O
Is,O
Exacerbated,O
by,O
Administration,O
of,O
Oral,O
Dietary,O
Antigen,O
Competing,O
Interests,O
:,O
E,O
.,O
F,O
.,O
V,O
.,O
receives,O
grant,O
support,O
from,O
Nestle,O
Research,O
Center,O
",",O
Switzerland,O
",",O
unrelated,O
to,O
this,O
study,O
.,O
The,O
remaining,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interest,O
exist,O
.,O
This,O
does,O
not,O
alter,O
the,O
authors,O
',O
adherence,O
to,O
PLOS,O
ONE,O
policies,O
on,O
sharing,O
data,O
and,O
materials,O
.,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
RA,O
EV,O
FGC,O
.,O
Performed,O
the,O
experiments,O
:,O
RA,O
JJ,O
.,O
Analyzed,O
the,O
data,O
:,O
RA,O
EV,O
FGC,O
.,O
Contributed,O
reagents,O
/,O
materials,O
/,O
analysis,O
tools,O
:,O
CB,O
.,O
Wrote,O
the,O
paper,O
:,O
RA,O
EV,O
FGC,O
.,O
Systemic,O
administration,O
of,O
polyinosinic,O
:,O
polycytidylic,O
acid,O
(,O
poly,O
I,O
:,O
C,O
"),",O
mimics,O
virally,O
-,O
induced,O
activation,O
of,O
TLR3,B-GP
signalling,O
causing,O
acute,O
small,O
intestine,O
damage,O
",",O
but,O
whether,O
and,O
how,O
mucosal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
causes,O
enteropathy,B-DS
is,O
less,O
clear,O
.,O
Our,O
aim,O
was,O
to,O
investigate,O
the,O
inflammatory,O
pathways,O
elicited,O
after,O
intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
and,O
determine,O
acute,O
and,O
delayed,O
consequences,O
of,O
this,O
locally,O
induced,O
immune,O
activation,O
.,O
Intraluminal,O
poly,O
I,O
:,O
C,O
induced,O
rapid,O
mucosal,O
immune,O
activation,O
in,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
involving,O
IFNβ,B-GP
and,O
the,O
CXCL10,B-GP
/,O
CXCR3,B-GP
axis,O
",",O
that,O
may,O
drive,O
inflammation,O
towards,O
a,O
Th1,O
profile,O
.,O
Intraluminal,O
poly,O
I,O
:,O
C,O
also,O
caused,O
enteropathy,B-DS
and,O
gut,O
dysfunction,O
in,O
gliadin,B-GP
-,O
sensitive,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
",",O
and,O
this,O
was,O
prolonged,O
by,O
concomitant,O
oral,O
administration,O
of,O
gliadin,B-GP
.,O
Our,O
results,O
indicate,O
that,O
small,O
intestine,O
pathology,O
can,O
be,O
induced,O
in,O
mice,B-OG
by,O
intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
and,O
that,O
this,O
is,O
exacerbated,O
by,O
subsequent,O
oral,O
delivery,O
of,O
a,O
relevant,O
dietary,O
antigen,O
.,O
Introduction,O
Detection,O
of,O
components,O
of,O
microorganisms,O
by,O
a,O
complex,O
system,O
of,O
pattern,O
recognition,O
receptors,O
leads,O
to,O
immune,O
host,O
defense,O
.,O
In,O
the,O
gut,O
",",O
home,O
to,O
1013,O
–,O
1014,O
resident,O
bacteria,B-OG
",",O
but,O
also,O
fungi,B-OG
and,O
viruses,B-OG
",",O
the,O
immune,O
mechanisms,O
elicited,O
have,O
a,O
critical,O
role,O
in,O
tissue,O
homeostasis,O
[,O
1,O
].,O
However,O
",",O
uncontrolled,O
activation,O
of,O
these,O
pathways,O
may,O
lead,O
to,O
pathology,O
",",O
as,O
demonstrated,O
in,O
studies,O
using,O
intraperitoneal,O
(,O
ip,O
),O
administration,O
of,O
double,O
stranded,O
RNA,O
(,O
dsRNA,O
),O
that,O
induces,O
overactivation,O
of,O
TLR3,B-GP
signalling,O
[,O
2,O
"],",O
[,O
3,O
"],",O
[,O
4,O
"],",O
[,O
5,O
].,O
Polyinosinic,O
:,O
polycytidylic,O
acid,O
(,O
poly,O
I,O
:,O
C,O
),O
is,O
a,O
synthetic,O
analogue,O
of,O
dsRNA,O
used,O
to,O
mimic,O
the,O
intermediates,O
of,O
replication,O
present,O
in,O
cells,O
infected,O
with,O
RNA,O
viruses,B-OG
and,O
some,O
DNA,O
viruses,B-OG
[,O
6,O
].,O
In,O
addition,O
to,O
TLR3,B-GP
",",O
dsRNA,O
sensors,O
include,O
two,O
cytoplasmic,O
receptors,O
",",O
retinoic,B-GP
acid,I-GP
-,I-GP
inducible,I-GP
gene,I-GP
I,I-GP
(,O
RIG,B-GP
-,I-GP
I,I-GP
),O
and,O
melanoma,B-GP
differentiation,I-GP
-,I-GP
associated,I-GP
gene,I-GP
5,I-GP
(,O
MDA5,B-GP
),O
[,O
7,O
].,O
NFκB,B-GP
and,O
IRF3,B-GP
/,O
7,O
are,O
the,O
dominant,O
nuclear,O
factors,O
involved,O
in,O
the,O
control,O
of,O
the,O
expression,O
of,O
inflammatory,O
cytokines,B-GP
and,O
chemokines,B-GP
and,O
Type,B-GP
I,I-GP
IFN,I-GP
",",O
respectively,O
",",O
upon,O
activation,O
by,O
dsRNA,O
[,O
8,O
].,O
McAllister,O
C,O
.,O
et,O
al,O
.,O
5,O
showed,O
that,O
signaling,O
pathways,O
activated,O
through,O
dsRNA,O
sensors,O
and,O
particularly,O
",",O
TLR3,B-GP
/,O
TRIF,B-GP
/,O
caspase,B-GP
8,I-GP
",",O
drive,O
intestinal,O
pathology,O
but,O
also,O
host,O
protection,O
during,O
viral,B-DS
infection,I-DS
.,O
However,O
",",O
the,O
role,O
of,O
locally,O
induced,O
",",O
rather,O
than,O
systemic,O
pathways,O
in,O
these,O
models,O
",",O
remain,O
unclear,O
.,O
More,O
importantly,O
there,O
is,O
a,O
scarcity,O
of,O
models,O
directly,O
relevant,O
to,O
small,O
intestinal,O
induction,O
of,O
pathology,O
and,O
gut,O
dysfunction,O
.,O
Epidemiological,O
studies,O
support,O
the,O
association,O
of,O
enteric,O
infections,B-DS
with,O
the,O
subsequent,O
development,O
of,O
inflammatory,O
or,O
functional,O
gastrointestinal,B-DS
disease,I-DS
[,O
9,O
"],",O
[,O
10,O
].,O
Viral,B-DS
infections,I-DS
",",O
in,O
particular,O
enterovirus,B-OG
such,O
as,O
rotavirus,B-OG
",",O
have,O
been,O
suggested,O
to,O
increase,O
the,O
incidence,O
of,O
celiac,B-DS
disease,I-DS
(,O
CD,B-DS
"),",O
a,O
permanent,O
intolerance,O
to,O
gluten,B-GP
that,O
occurs,O
in,O
genetically,O
susceptible,O
people,O
[,O
11,O
"],",O
[,O
12,O
].,O
Case,O
reports,O
have,O
also,O
suggested,O
the,O
association,O
of,O
enteric,O
infections,B-DS
with,O
CD,B-DS
onset,O
[,O
13,O
].,O
Currently,O
",",O
the,O
underlying,O
mechanisms,O
that,O
support,O
this,O
association,O
are,O
poorly,O
understood,O
.,O
However,O
",",O
it,O
is,O
well,O
known,O
that,O
innate,O
immune,O
activation,O
generates,O
a,O
rapid,O
and,O
strong,O
anti,O
-,O
viral,O
response,O
",",O
which,O
essentially,O
involves,O
the,O
production,O
of,O
Type,B-GP
I,I-GP
IFNs,I-GP
and,O
other,O
components,O
of,O
the,O
inflammatory,O
response,O
.,O
The,O
link,O
among,O
enterovirus,B-DS
infection,I-DS
and,O
CD,B-DS
raises,O
the,O
hypothesis,O
that,O
Type,B-GP
I,I-GP
IFNs,I-GP
may,O
be,O
involved,O
in,O
loss,O
of,O
tolerance,O
to,O
gluten,B-GP
through,O
the,O
ability,O
to,O
promote,O
inflammation,O
and,O
an,O
strong,O
Th1,O
response,O
[,O
14,O
].,O
In,O
this,O
work,O
",",O
we,O
aimed,O
to,O
mimic,O
the,O
local,O
intestinal,O
immune,O
response,O
as,O
triggered,O
by,O
enteric,O
viral,B-DS
infection,I-DS
.,O
We,O
used,O
intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
to,O
wild,O
type,O
mice,B-OG
and,O
evaluated,O
the,O
immediate,O
in,O
vivo,O
immune,O
and,O
pathological,O
mechanisms,O
triggered,O
at,O
the,O
small,O
intestinal,O
mucosa,O
.,O
We,O
also,O
investigated,O
the,O
potential,O
influence,O
of,O
this,O
initial,O
immune,O
activation,O
on,O
long,O
lasting,O
gut,O
functional,O
responses,O
to,O
administration,O
of,O
a,O
relevant,O
dietary,O
antigen,O
.,O
For,O
this,O
",",O
we,O
used,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
",",O
a,O
model,O
that,O
allows,O
in,O
vivo,O
evaluation,O
of,O
functional,O
and,O
immune,O
responses,O
to,O
gliadin,B-GP
",",O
the,O
storage,O
protein,O
in,O
cereals,O
[,O
15,O
].,O
Animal,B-OG
models,O
rarely,O
recapitulate,O
the,O
full,O
spectrum,O
of,O
human,B-OG
complex,O
diseases,O
.,O
Moreover,O
",",O
human,B-OG
diseases,O
often,O
express,O
different,O
clinical,O
phenotypes,O
.,O
Thus,O
the,O
usefulness,O
of,O
animal,B-OG
models,O
resides,O
in,O
mimicking,O
certain,O
aspects,O
of,O
disease,O
pathogenesis,O
in,O
order,O
to,O
generate,O
hypotheses,O
to,O
be,O
tested,O
in,O
clinical,O
trials,O
.,O
In,O
this,O
work,O
",",O
we,O
used,O
two,O
animal,B-OG
models,O
to,O
investigate,O
two,O
different,O
questions,O
.,O
First,O
",",O
the,O
effect,O
of,O
oral,O
poly,O
I,O
:,O
C,O
in,O
the,O
early,O
stages,O
of,O
the,O
mucosal,O
innate,O
immune,O
response,O
",",O
and,O
second,O
the,O
influence,O
of,O
the,O
administration,O
of,O
a,O
specific,O
dietary,O
antigen,O
in,O
preconditioned,O
mice,B-OG
.,O
We,O
observed,O
that,O
luminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
activated,O
the,O
innate,O
immune,O
response,O
and,O
caused,O
acute,O
enteropathy,B-DS
.,O
Administration,O
of,O
gliadin,B-GP
to,O
gliadin,B-GP
-,O
sensitive,O
mice,B-OG
previously,O
treated,O
with,O
poly,O
I,O
:,O
C,O
",",O
prolonged,O
gliadin,B-GP
-,O
induced,O
gut,O
dysfunction,O
.,O
We,O
propose,O
a,O
mucosally,O
-,O
driven,O
model,O
of,O
enteropathy,B-DS
by,O
poly,O
I,O
:,O
C,O
in,O
which,O
post,O
inflammatory,O
mechanisms,O
of,O
gastrointestinal,B-DS
disease,I-DS
can,O
be,O
investigated,O
.,O
Materials,O
and,O
Methods,O
Mice,B-OG
Eight,O
-,O
week,O
female,O
C57BL,B-OG
/,I-OG
6J,I-OG
mice,I-OG
were,O
purchased,O
to,O
the,O
Animal,B-OG
Care,O
Facility,O
of,O
the,O
Faculty,O
of,O
Exact,O
and,O
Natural,O
Sciences,O
of,O
the,O
University,O
of,O
Buenos,O
Aires,O
.,O
Mice,B-OG
were,O
housed,O
in,O
plastic,O
cages,O
and,O
fed,O
ad,O
libitum,O
with,O
balanced,O
food,O
and,O
water,O
.,O
They,O
were,O
maintained,O
on,O
a,O
12h,O
light,O
/,O
darkness,O
cycle,O
and,O
acclimatized,O
to,O
the,O
surrounding,O
conditions,O
for,O
1,O
week,O
before,O
the,O
experimental,O
procedure,O
.,O
Transgenic,O
mice,B-OG
that,O
express,O
HLA,B-GP
-,O
DQ8,O
in,O
an,O
endogenous,O
MHC,B-GP
class,I-GP
II,I-GP
-,O
deficient,O
background,O
were,O
backcrossed,O
to,O
NOD,B-OG
mice,I-OG
for,O
10,O
generations,O
and,O
intercrossed,O
to,O
produce,O
congenic,O
NOD,B-OG
AB,I-OG
°,I-OG
DQ8,I-OG
mice,I-OG
[,O
16,O
].,O
Eight,O
-,O
to,O
10,O
-,O
wk,O
-,O
old,O
male,O
mice,B-OG
were,O
used,O
for,O
experiments,O
.,O
Mice,B-OG
were,O
weaned,O
and,O
maintained,O
on,O
a,O
low,O
-,O
fat,O
(,O
4,O
.,O
4,O
"%),",O
gluten,B-GP
-,O
free,O
diet,O
.,O
The,O
original,O
breeding,O
pairs,O
of,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
were,O
kindly,O
provided,O
by,O
Dr,O
.,O
Chella,O
David,O
and,O
Dr,O
.,O
Joseph,O
Murray,O
from,O
Mayo,O
Clinic,O
",",O
Rochester,O
",",O
USA,O
",",O
and,O
subsequently,O
bred,O
in,O
specific,O
pathogen,O
-,O
free,O
conditions,O
at,O
McMaster,O
University,O
.,O
All,O
the,O
studies,O
were,O
performed,O
in,O
accordance,O
with,O
international,O
protocols,O
for,O
laboratory,O
animal,B-OG
care,O
(,O
Canadian,O
Council,O
on,O
Animal,B-OG
Care,O
).,O
Experiments,O
were,O
conducted,O
with,O
approval,O
from,O
the,O
McMaster,O
University,O
Animal,B-OG
Care,O
Committee,O
and,O
the,O
National,O
University,O
of,O
La,O
Plata,O
Ethic,O
Committee,O
.,O
Poly,O
I,O
:,O
C,O
treatment,O
and,O
oral,O
gavage,O
Mice,B-OG
were,O
kept,O
on,O
the,O
gluten,B-GP
free,O
diet,O
at,O
the,O
time,O
of,O
the,O
surgery,O
.,O
Poly,O
I,O
:,O
C,O
(,O
Sigma,O
-,O
Aldrich,O
),O
or,O
PBS,O
was,O
intraluminally,O
administrated,O
throughout,O
an,O
intestinal,O
microsurgery,O
that,O
allows,O
inject,O
the,O
stimuli,O
directly,O
in,O
the,O
lumen,O
of,O
small,O
intestine,O
.,O
Mice,B-OG
were,O
anaesthetized,O
with,O
Ketamine,O
80,O
mg,O
/,O
kg,O
of,O
weight,O
and,O
Xilacine,O
10,O
mg,O
/,O
kg,O
of,O
weight,O
.,O
Once,O
mice,B-OG
were,O
asleep,O
",",O
30μg,O
/,O
g,O
of,O
weight,O
of,O
poly,O
I,O
:,O
C,O
solution,O
in,O
PBS,O
were,O
injected,O
in,O
the,O
lumen,O
of,O
small,O
intestine,O
",",O
2,O
cm,O
after,O
the,O
stomach,O
",",O
to,O
avoid,O
the,O
enzymatic,O
degradation,O
of,O
the,O
poly,O
I,O
:,O
C,O
(,O
mainly,O
because,O
of,O
nuclease,B-GP
activity,O
from,O
pancreatic,O
enzymes,O
).,O
Control,O
mice,B-OG
receipted,O
only,O
PBS,O
in,O
the,O
lumen,O
.,O
After,O
the,O
surgery,O
",",O
a,O
fluid,O
replacement,O
was,O
done,O
and,O
mice,B-OG
were,O
strictly,O
monitored,O
until,O
they,O
were,O
able,O
to,O
walk,O
around,O
the,O
cage,O
.,O
A,O
group,O
of,O
mice,B-OG
was,O
sacrificed,O
after,O
3h,O
or,O
12h,O
post,O
-,O
treatment,O
with,O
poly,O
I,O
:,O
C,O
or,O
PBS,O
",",O
and,O
samples,O
of,O
blood,O
and,O
small,O
intestine,O
were,O
collected,O
for,O
further,O
analysis,O
.,O
Other,O
group,O
of,O
mice,B-OG
was,O
orally,O
gavaged,O
with,O
5,O
mg,O
of,O
α,B-GP
-,I-GP
gliadin,I-GP
/,O
time,O
",",O
three,O
times,O
a,O
week,O
during,O
2,O
weeks,O
",",O
starting,O
at,O
24h,O
post,O
-,O
surgery,O
.,O
α,B-GP
-,I-GP
Gliadin,I-GP
(,O
by,O
Sigma,O
-,O
Aldrich,O
),O
was,O
dissolved,O
in,O
endotoxin,O
-,O
free,O
acetic,O
acid,O
0,O
.,O
02,O
M,O
.,O
Control,O
mice,B-OG
were,O
gavaged,O
with,O
the,O
acetic,O
acid,O
solution,O
only,O
(,O
Gluten,B-GP
-,O
free,O
diet,O
mice,B-OG
).,O
All,O
solutions,O
were,O
controlled,O
and,O
endotoxin,O
free,O
preparations,O
were,O
determined,O
using,O
E,O
-,O
TOXATE,O
endotoxin,O
kit,O
(,O
Sigma,O
).,O
Mice,B-OG
were,O
weighed,O
three,O
times,O
a,O
week,O
during,O
the,O
2,O
weeks,O
",",O
after,O
the,O
oral,O
gavage,O
.,O
Histologic,O
evaluation,O
Cross,O
-,O
sections,O
of,O
the,O
proximal,O
small,O
intestine,O
were,O
fixed,O
in,O
10,O
%,O
formalin,O
",",O
embedded,O
in,O
paraffin,O
",",O
and,O
stained,O
with,O
H,O
&,O
E,O
staining,O
for,O
histological,O
evaluation,O
by,O
using,O
a,O
Nikon,O
Eclipse,O
Ti,O
fluorescence,O
microscope,O
with,O
X,O
-,O
Cites,O
Series,O
120,O
Q,O
light,O
source,O
.,O
Images,O
were,O
taken,O
with,O
Nikon,O
Digital,O
Sight,O
DS,O
Ri1,O
camera,O
using,O
Nis,O
-,O
Elements,O
software,O
and,O
measurements,O
were,O
performed,O
using,O
Image,O
J,O
software,O
properly,O
calibrated,O
.,O
Two,O
sections,O
of,O
the,O
proximal,O
small,O
intestine,O
were,O
evaluated,O
for,O
evidence,O
of,O
inflammation,O
.,O
At,O
least,O
thirty,O
villus,O
-,O
to,O
-,O
crypt,O
ratios,O
were,O
measured,O
for,O
each,O
mouse,B-OG
in,O
a,O
blinded,O
fashion,O
.,O
Intraepithelial,O
lymphocytes,O
(,O
IELs,O
),O
per,O
30,O
enterocytes,O
in,O
ten,O
randomly,O
chosen,O
villus,O
tips,O
were,O
counted,O
according,O
to,O
the,O
previously,O
described,O
methods,O
and,O
expressed,O
as,O
IEL,O
/,O
100,O
enterocytes,O
[,O
17,O
].,O
Histological,O
scores,O
were,O
obtained,O
from,O
the,O
small,O
intestinal,O
sections,O
stained,O
with,O
H,O
&,O
E,O
",",O
following,O
the,O
Park,O
-,O
Chiu,O
criteria,O
[,O
18,O
]:,O
0,O
",",O
normal,O
mucosa,O
;,O
1,O
",",O
subepithelial,O
space,O
at,O
villus,O
tips,O
;,O
2,O
",",O
extension,O
of,O
subepithelial,O
space,O
with,O
moderate,O
lifting,O
;,O
3,O
",",O
massive,O
lifting,O
down,O
sides,O
of,O
villi,O
",",O
some,O
denuded,O
tips,O
;,O
4,O
",",O
denuded,O
villi,O
",",O
dilated,O
capillaries,O
;,O
5,O
",",O
disintegration,O
of,O
lamina,O
propria,O
;,O
6,O
",",O
Crypt,O
layer,O
injury,O
;,O
7,O
",",O
transmucosal,O
infarction,O
;,O
8,O
",",O
transmural,O
infarction,O
.,O
Ussing,O
chambers,O
Two,O
sections,O
of,O
proximal,O
small,O
intestine,O
from,O
each,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mouse,I-OG
were,O
used,O
for,O
Ussing,O
chamber,O
experiments,O
as,O
described,O
previously,O
[,O
15,O
"],",O
[,O
19,O
"],",O
[,O
20,O
].,O
A,O
3,O
–,O
4,O
-,O
cm,O
piece,O
of,O
small,O
intestine,O
was,O
collected,O
(,O
3,O
cm,O
from,O
the,O
stomach,O
"),",O
cut,O
into,O
two,O
sections,O
",",O
and,O
placed,O
in,O
Krebs,O
buffer,O
aerated,O
with,O
95,O
%,O
O2,O
and,O
5,O
%,O
CO2,O
(,O
pH,O
7,O
.,O
3,O
–,O
7,O
.,O
4,O
).,O
Each,O
segment,O
of,O
intestine,O
was,O
cut,O
open,O
along,O
the,O
mesenteric,O
border,O
to,O
form,O
a,O
flat,O
sheet,O
and,O
mounted,O
into,O
an,O
Ussing,O
chamber,O
.,O
The,O
chamber,O
exposed,O
0,O
.,O
7,O
cm2,O
of,O
tissue,O
surface,O
area,O
to,O
8,O
ml,O
of,O
circulating,O
oxygenated,O
Krebs,O
buffer,O
containing,O
10,O
mM,O
glucose,O
(,O
serosal,O
side,O
),O
and,O
10,O
mM,O
mannitol,O
(,O
mucosal,O
side,O
),O
maintained,O
at,O
37,O
°,O
C,O
.,O
Net,O
active,O
ion,O
transport,O
across,O
the,O
epithelium,O
was,O
measured,O
via,O
a,O
short,O
circuit,O
current,O
(,O
Isc,O
",",O
mA,O
),O
injected,O
across,O
the,O
tissue,O
under,O
voltage,O
-,O
clamp,O
conditions,O
.,O
Tissue,O
conductance,O
(,O
the,O
passive,O
permeability,O
to,O
ions,O
),O
was,O
calculated,O
using,O
Ohm,O
',O
s,O
law,O
.,O
Baseline,O
Isc,O
(,O
mA,O
/,O
cm2,O
),O
and,O
conductance,O
(,O
mS,O
/,O
cm2,O
),O
were,O
recorded,O
at,O
equilibrium,O
",",O
20,O
min,O
after,O
mounting,O
small,O
intestine,O
sections,O
.,O
Cytokine,B-GP
analysis,O
The,O
presence,O
of,O
proinflammatory,O
cytokines,B-GP
in,O
serum,O
from,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
was,O
determined,O
using,O
a,O
Cytometric,O
Bead,O
Array,O
Inflammation,O
kit,O
(,O
BD,O
Biosciences,O
),O
and,O
analyzed,O
using,O
BD,O
FACSarray,O
Bioanalyzer,O
System,O
(,O
BD,O
Biosciences,O
).,O
Real,O
Time,O
PCR,O
Small,O
Intestinal,O
samples,O
from,O
C57BL,O
/,O
6,O
and,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
were,O
stored,O
in,O
RNA,O
later,O
in,O
-,O
80,O
°,O
C,O
freezer,O
until,O
be,O
used,O
.,O
Tissues,O
were,O
disrupted,O
and,O
RNA,O
extraction,O
was,O
performed,O
using,O
RNeasy,O
Mini,O
Kit,O
(,O
Qiagen,O
).,O
cDNA,O
synthesis,O
was,O
performed,O
from,O
isolated,O
RNA,O
samples,O
(,O
2,O
-,O
5µg,O
"),",O
using,O
iScript,O
Reverse,O
Transcription,O
Supermix,O
(,O
Bio,O
-,O
Rad,O
).,O
Real,O
Time,O
PCR,O
reaction,O
was,O
performed,O
with,O
SsoFast,O
EvaGreen,O
Supermix,O
(,O
Bio,O
-,O
Rad,O
),O
using,O
the,O
adequate,O
forward,O
and,O
reverse,O
primers,O
and,O
the,O
iQ5,O
thermocycler,O
with,O
fluorescence,O
detection,O
(,O
Bio,O
-,O
Rad,O
).,O
Reactions,O
were,O
run,O
in,O
triplicate,O
.,O
The,O
Real,O
Time,O
PCR,O
protocol,O
was,O
:,O
Cycle,O
1,O
(,O
1X,O
),O
95,O
°,O
C,O
for,O
10min,O
;,O
Cycle2,O
(,O
40X,O
),O
60,O
°,O
C,O
for,O
1min,O
and,O
95,O
°,O
for,O
15sec,O
.,O
Primers,O
were,O
synthesized,O
as,O
it,O
was,O
previously,O
described,O
[,O
21,O
].,O
The,O
primer,O
sequences,O
are,O
provided,O
in,O
Table,O
1,O
.,O
The,O
geometric,O
mean,O
of,O
housekeeping,O
gene,O
HPRT,B-GP
was,O
used,O
as,O
an,O
internal,O
control,O
to,O
normalize,O
the,O
variability,O
in,O
expression,O
levels,O
.,O
All,O
results,O
were,O
expressed,O
as,O
a,O
fold,O
increase,O
of,O
PBS,O
and,O
PIC,O
treatment,O
versus,O
the,O
mean,O
of,O
PBS,O
treatment,O
in,O
every,O
time,O
point,O
(,O
2,O
−,O
ΔΔCt,O
method,O
).,O
Primers,O
used,O
for,O
quantitative,O
PCR,O
.,O
Gene,O
Forward,O
Reverse,O
HPRT,B-GP
CAATGCAAACTTTGCTTTCC,O
CAAATCCAACAAAGTCTGGC,O
MDA5,B-GP
CGATCCGAATGATTGATGCA,O
AGTTGGTCATTGCAACTGCT,O
RIG,B-GP
-,I-GP
I,I-GP
CAGACAGATCCGAGACACTA,O
TGCAAGACCTTTGGCCAGTT,O
TLR3,B-GP
GAAGATGATGCAGTCTTTCCA,O
CCTGTATCATATTCTACTCCTTGC,O
IFNβ,B-GP
AATGGAAAGATCAACCTCAC,O
AAGGCAGTGTAACTCTTCTG,O
CXCL10,B-GP
ATAGGGAAGCTTGAAATCATCC,O
TTCATCGTGGCAATGATCTC,O
CXCR3,B-GP
TGTAGTTGGGCTAGCTCGAACTT,O
ACCTGGATATATGCTGAGCTGTCA,O
TNFα,B-GP
CTCCCTCTCATCAGTTCTATGG,O
TTGAGAAGATGATCTGAGTGTG,O
IL,B-GP
-,I-GP
15,I-GP
CATCCATCTCGTGCTACTTGTGTT,O
CATCTATCCAGTTGGCCTCTGTTT,O
MCP1,B-GP
CTACAAGAGGATCACCAGCAG,O
TTCTGATCTCATTTGGTTCCG,O
CXCL2,B-GP
AAGATACTGAACAAAGGCAAGG,O
TTCTTTCTCTTTGGTTCTTCCG,O
IL,B-GP
-,I-GP
1β,I-GP
CGTTCCCATTAGACAACTGC,O
CTCATGGAGAATATCACTTGTTGG,O
IL,B-GP
-,I-GP
18,I-GP
GATCAAAGTGCCAGTGAACC,O
GATCTTGTTCTTACAGGAGAGG,O
IL,B-GP
-,I-GP
6,I-GP
CATGTTCTCTGGGAAATCGT,O
TATATCCAGTTTGGTAGCATCC,O
IFNγ,B-GP
CTGAGACAATGAACGCTACAC,O
TTTCTTCCACATCTATGCCAC,O
Bax,B-GP
TGCTACAGGGTTTCATCCAG,O
ATTGCTGTCCAGTTCATCTC,O
Bcl2,B-GP
GATCTCTGGTTGGGATTCCT,O
ACAACTTGCAATGAATCGGG,O
Fluorescence,O
microscopy,O
Small,O
intestinal,O
sections,O
from,O
PBS,O
-,O
and,O
PIC,O
-,O
treated,O
mice,B-OG
were,O
deparaffinized,O
and,O
an,O
immunofluorescence,O
protocol,O
was,O
performed,O
.,O
Antigenicity,O
recovery,O
was,O
performed,O
using,O
Antigen,O
Retrieval,O
AR,O
-,O
10,O
Solution,O
(,O
BioGenex,O
).,O
After,O
blocking,O
with,O
2,O
%,O
goat,B-OG
serum,O
",",O
goat,B-OG
anti,O
-,O
IL,B-GP
-,I-GP
15,I-GP
IgG,B-GP
antibody,O
(,O
R,O
&,O
D,O
),O
was,O
added,O
in,O
a,O
concentration,O
of,O
2,O
µg,O
/,O
ml,O
for,O
1h,O
.,O
Alexa488,O
donkey,B-OG
anti,O
-,O
goat,B-OG
antibody,O
(,O
Molecular,O
Probes,O
),O
in,O
a,O
concentration,O
of,O
10,O
µg,O
/,O
ml,O
was,O
added,O
for,O
1h,O
.,O
Nuclei,O
were,O
stained,O
with,O
propidium,O
iodide,O
at,O
1,O
µg,O
/,O
ml,O
for,O
15,O
minutes,O
.,O
Images,O
were,O
obtained,O
and,O
analyzed,O
in,O
a,O
TCS,O
SP5,O
Confocal,O
Microscope,O
combined,O
with,O
Leica,O
LAS,O
AF,O
software,O
.,O
Statistical,O
analysis,O
Statistical,O
analysis,O
was,O
performed,O
with,O
GraphPad,O
Prism,O
software,O
.,O
For,O
more,O
than,O
two,O
treatment,O
groups,O
",",O
an,O
ANOVA,O
with,O
a,O
Bonferroni,O
post,O
hoc,O
test,O
for,O
multiple,O
comparisons,O
was,O
used,O
.,O
When,O
two,O
groups,O
were,O
compared,O
",",O
an,O
unpaired,O
t,O
test,O
was,O
used,O
;,O
p,O
<,O
0,O
.,O
05,O
was,O
considered,O
significant,O
.,O
Data,O
are,O
displayed,O
as,O
mean,O
±,O
SEM,O
.,O
Results,O
Intraluminal,O
poly,O
I,O
:,O
C,O
induces,O
histological,O
changes,O
in,O
the,O
small,O
intestinal,O
mucosa,O
We,O
first,O
evaluated,O
the,O
capacity,O
of,O
poly,O
I,O
:,O
C,O
delivered,O
at,O
the,O
mucosal,O
site,O
to,O
induce,O
enteropathy,B-DS
in,O
wild,O
type,O
mice,B-OG
.,O
Intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
to,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
produced,O
severe,O
enteropathy,B-DS
.,O
At,O
12h,O
post,O
poly,O
I,O
:,O
C,O
",",O
we,O
observed,O
shortening,O
and,O
widening,O
of,O
villi,O
",",O
edema,O
",",O
and,O
increased,O
cell,O
infiltration,O
in,O
the,O
lamina,O
propria,O
(,O
LP,O
).,O
Using,O
H,O
&,O
E,O
staining,O
edema,O
",",O
dilated,O
capillaries,O
and,O
interstitial,O
spaces,O
were,O
observed,O
in,O
intestinal,O
villi,O
(,O
Figure,O
1A,O
).,O
Furthermore,O
",",O
V,O
/,O
C,O
ratios,O
were,O
decreased,O
",",O
while,O
the,O
number,O
of,O
IELs,O
and,O
global,O
histological,O
score,O
increased,O
compared,O
to,O
PBS,O
-,O
treated,O
mice,B-OG
(,O
Figure,O
1B,O
).,O
At,O
72h,O
post,O
poly,O
I,O
:,O
C,O
",",O
there,O
was,O
partial,O
recovery,O
of,O
villus,O
-,O
to,O
-,O
crypt,O
(,O
V,O
/,O
C,O
),O
ratios,O
.,O
In,O
contrast,O
to,O
control,O
mice,B-OG
",",O
morphometric,O
parameters,O
remained,O
altered,O
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
mice,B-OG
(,O
Figure,O
1C,O
).,O
As,O
expected,O
",",O
the,O
surgical,O
procedure,O
altered,O
intestinal,O
histology,O
.,O
However,O
",",O
this,O
change,O
was,O
transient,O
",",O
and,O
control,O
mice,B-OG
exhibited,O
a,O
faster,O
recovery,O
after,O
treatment,O
.,O
We,O
also,O
tested,O
whether,O
molecular,O
weight,O
of,O
poly,O
I,O
:,O
Cs,O
influenced,O
inflammation,O
and,O
mucosal,O
damage,O
.,O
We,O
did,O
not,O
detect,O
significant,O
differences,O
among,O
the,O
tested,O
poly,O
I,O
:,O
Cs,O
(,O
Figure,O
S1,O
"),",O
and,O
therefore,O
the,O
remaining,O
experiments,O
were,O
carried,O
out,O
using,O
the,O
commonly,O
used,O
commercial,O
poly,O
I,O
:,O
C,O
.,O
Intraluminal,O
poly,O
I,O
:,O
C,O
induces,O
enteropathy,B-DS
.,O
Representative,O
H,O
&,O
E,O
stained,O
sections,O
of,O
proximal,O
small,O
intestine,O
of,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
after,O
12hs,O
and,O
72hs,O
of,O
intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
or,O
PBS,O
(,O
A,O
).,O
Morphological,O
analysis,O
of,O
small,O
intestine,O
from,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
:,O
villus,O
-,O
to,O
-,O
crypt,O
(,O
V,O
/,O
C,O
),O
ratio,O
",",O
number,O
of,O
IELs,O
and,O
histological,O
score,O
after,O
12h,O
(,O
B,O
),O
and,O
72h,O
(,O
C,O
),O
(,O
Stats,O
:,O
N,O
=,O
4,O
mice,B-OG
per,O
group,O
",",O
Unpaired,O
t,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
",",O
**,O
P,O
<,O
0,O
.,O
01,O
",",O
***,O
P,O
<,O
0,O
.,O
001,O
).,O
Inflammatory,O
mediators,O
and,O
receptors,O
MDA5,B-GP
",",O
RIGI,B-GP
and,O
TLR3,B-GP
are,O
induced,O
by,O
intraluminal,O
poly,O
I,O
:,O
C,O
in,O
small,O
intestine,O
We,O
next,O
explored,O
the,O
signaling,O
pathways,O
induced,O
by,O
intraluminal,O
poly,O
I,O
:,O
C,O
.,O
For,O
this,O
we,O
analyzed,O
the,O
kinetics,O
of,O
expression,O
of,O
inflammatory,O
mediators,O
and,O
three,O
receptors,O
for,O
poly,O
I,O
:,O
C,O
in,O
a,O
time,O
-,O
course,O
experiment,O
using,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
.,O
In,O
the,O
small,O
intestine,O
",",O
there,O
was,O
a,O
rapid,O
and,O
strong,O
increment,O
of,O
IFNβ,B-GP
2h,O
after,O
treatment,O
",",O
while,O
CXCL10,B-GP
and,O
TNFα,B-GP
peaked,O
4h,O
after,O
intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
(,O
Figure,O
2A,O
).,O
Analysis,O
of,O
expression,O
of,O
proinflammatory,O
cytokines,B-GP
such,O
as,O
IL,B-GP
-,I-GP
18,I-GP
",",O
IL,B-GP
-,I-GP
1β,I-GP
",",O
IL,B-GP
-,I-GP
15,I-GP
and,O
IFNγ,B-GP
",",O
chemokines,B-GP
such,O
as,O
MCP1,B-GP
and,O
CXCL2,B-GP
",",O
and,O
anti,O
-,O
and,O
pro,O
-,O
apoptotic,O
molecules,O
Bcl,B-GP
-,I-GP
2,I-GP
and,O
Bax,B-GP
",",O
respectively,O
",",O
did,O
not,O
show,O
any,O
differences,O
between,O
groups,O
(,O
data,O
not,O
shown,O
).,O
Since,O
recognition,O
of,O
poly,O
I,O
:,O
C,O
is,O
mediated,O
by,O
TLR3,B-GP
",",O
MDA5,B-GP
and,O
RIGI,B-GP
and,O
their,O
expressions,O
are,O
modulated,O
by,O
poly,O
I,O
:,O
C,O
",",O
we,O
evaluated,O
whether,O
the,O
expression,O
of,O
these,O
receptors,O
were,O
induced,O
in,O
the,O
small,O
intestine,O
of,O
treated,O
mice,B-OG
.,O
The,O
time,O
course,O
experiment,O
showed,O
that,O
MDA5,B-GP
",",O
RIGI,B-GP
and,O
TLR3,B-GP
mRNA,O
were,O
similarly,O
upregulated,O
in,O
small,O
intestine,O
by,O
intraluminal,O
injection,O
of,O
poly,O
I,O
:,O
C,O
.,O
Expression,O
of,O
the,O
three,O
receptors,O
peaked,O
6h,O
post,O
-,O
treatment,O
(,O
Figure,O
2B,O
).,O
Furthermore,O
",",O
we,O
analyzed,O
the,O
protein,O
expression,O
of,O
IL,B-GP
-,I-GP
15,I-GP
",",O
obtaining,O
no,O
relevant,O
differences,O
among,O
poly,O
I,O
:,O
C,O
and,O
PBS,O
treatments,O
after,O
12h,O
(,O
data,O
not,O
shown,O
).,O
Intraluminal,O
poly,O
I,O
:,O
C,O
generates,O
a,O
proinflammatory,O
response,O
and,O
the,O
induction,O
of,O
MDA5,B-GP
",",O
RIG,B-GP
-,I-GP
I,I-GP
and,O
TLR3,B-GP
mRNA,O
expression,O
in,O
small,O
intestine,O
.,O
Real,O
Time,O
-,O
PCR,O
analysis,O
of,O
small,O
intestinal,O
samples,O
from,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
after,O
intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
or,O
PBS,O
was,O
performed,O
.,O
Plots,O
shows,O
mRNA,O
expression,O
after,O
2,O
to,O
12h,O
of,O
poly,O
I,O
:,O
C,O
(,O
black,O
dots,O
),O
or,O
PBS,O
(,O
empty,O
dots,O
),O
treatment,O
.,O
IFNβ,B-GP
",",O
CXCL10,B-GP
",",O
and,O
TNFα,B-GP
mRNA,O
expression,O
(,O
A,O
).,O
MDA5,B-GP
",",O
RIG,B-GP
-,I-GP
I,I-GP
",",O
and,O
TLR3,B-GP
mRNA,O
expression,O
(,O
B,O
).,O
All,O
values,O
were,O
normalized,O
with,O
the,O
housekeeping,O
mRNA,O
expression,O
(,O
HPRT,B-GP
).,O
Results,O
were,O
expressed,O
as,O
fold,O
increase,O
of,O
PBS,O
and,O
poly,O
I,O
:,O
C,O
treatment,O
versus,O
the,O
mean,O
of,O
PBS,O
treatment,O
in,O
every,O
time,O
point,O
(,O
2,O
-,O
ΔΔCt,O
method,O
).,O
Stats,O
:,O
N,O
=,O
4,O
mice,B-OG
per,O
group,O
",",O
Unpaired,O
t,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
",",O
**,O
P,O
<,O
0,O
.,O
01,O
",",O
***,O
P,O
<,O
0,O
.,O
001,O
",",O
poly,O
I,O
:,O
C,O
treated,O
mice,B-OG
versus,O
PBS,O
control,O
in,O
the,O
same,O
time,O
point,O
.,O
Inflammatory,O
response,O
induced,O
by,O
intraluminal,O
poly,O
I,O
:,O
C,O
in,O
the,O
small,O
intestine,O
of,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
The,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mouse,I-OG
represents,O
one,O
useful,O
model,O
of,O
gluten,B-GP
sensitivity,O
[,O
15,O
].,O
Nevertheless,O
",",O
the,O
model,O
has,O
particular,O
phenotypes,O
given,O
by,O
the,O
DQ8,O
restriction,O
and,O
the,O
NOD,O
background,O
[,O
22,O
].,O
Thus,O
",",O
prior,O
to,O
gliadin,B-GP
antigen,O
administration,O
",",O
we,O
first,O
examined,O
in,O
detail,O
the,O
immune,O
responses,O
to,O
poly,O
I,O
:,O
C,O
in,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
Indeed,O
",",O
poly,O
I,O
:,O
C,O
caused,O
severe,O
mucosal,O
damage,O
in,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
characterized,O
by,O
cell,O
infiltration,O
of,O
the,O
LP,O
",",O
edema,O
and,O
shortening,O
of,O
villi,O
at,O
12h,O
post,O
-,O
treatment,O
(,O
Figure,O
3A,O
).,O
Morphometric,O
parameters,O
revealed,O
marked,O
reduction,O
in,O
the,O
V,O
/,O
C,O
ratio,O
in,O
poly,O
I,O
:,O
C,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
Also,O
",",O
IELs,O
numbers,O
and,O
histological,O
scores,O
were,O
higher,O
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
mice,B-OG
than,O
in,O
control,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
(,O
Figure,O
3B,O
).,O
Intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
induces,O
enteropathy,B-DS
in,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
Representative,O
H,O
&,O
E,O
-,O
stained,O
sections,O
of,O
the,O
proximal,O
small,O
intestine,O
in,O
PBS,O
and,O
poly,O
I,O
:,O
C,O
-,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
at,O
12h,O
post,O
-,O
treatment,O
(,O
A,O
).,O
Morphological,O
analysis,O
of,O
small,O
intestine,O
from,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
:,O
villus,O
-,O
to,O
-,O
crypt,O
(,O
V,O
/,O
C,O
),O
ratio,O
",",O
number,O
of,O
IELs,O
and,O
histological,O
score,O
after,O
12h,O
.,O
Stats,O
:,O
N,O
=,O
4,O
mice,B-OG
per,O
group,O
",",O
Unpaired,O
t,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
",",O
**,O
P,O
<,O
0,O
.,O
01,O
(,O
B,O
).,O
We,O
found,O
that,O
IFNβ,B-GP
mRNA,O
expression,O
was,O
increased,O
in,O
the,O
small,O
intestinal,O
mucosa,O
of,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
at,O
3h,O
post,O
-,O
poly,O
I,O
:,O
C,O
compared,O
to,O
controls,O
(,O
Figure,O
4,O
).,O
A,O
40,O
-,O
fold,O
increment,O
in,O
CXCL10,B-GP
mRNA,O
was,O
observed,O
at,O
3,O
h,O
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
mice,B-OG
.,O
At,O
12,O
hours,O
",",O
CXCL10,B-GP
levels,O
remained,O
higher,O
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
mice,B-OG
than,O
in,O
controls,O
.,O
The,O
cytoplasmic,O
pattern,O
recognition,O
receptors,O
for,O
poly,O
I,O
:,O
C,O
",",O
MDA5,B-GP
and,O
RIG,B-GP
-,I-GP
I,I-GP
",",O
were,O
also,O
induced,O
in,O
the,O
small,O
mucosa,O
of,O
poly,O
I,O
:,O
C,O
-,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
Expression,O
of,O
both,O
receptors,O
was,O
increased,O
at,O
3h,O
",",O
but,O
was,O
higher,O
at,O
12,O
h,O
after,O
treatment,O
.,O
The,O
upregulation,O
of,O
these,O
receptors,O
was,O
observed,O
later,O
than,O
in,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
.,O
At,O
3h,O
and,O
12h,O
post,O
-,O
Poly,O
I,O
:,O
C,O
injection,O
we,O
did,O
not,O
observe,O
differences,O
in,O
TLR3,B-GP
expression,O
when,O
compared,O
to,O
PBS,O
controls,O
.,O
Inflammatory,O
mediators,O
elicited,O
by,O
intraluminal,O
poly,O
I,O
:,O
C,O
were,O
also,O
evaluated,O
in,O
peripheral,O
blood,O
.,O
Concentration,O
of,O
TNFα,B-GP
",",O
IL,B-GP
-,I-GP
6,I-GP
and,O
MCP1,B-GP
was,O
significantly,O
higher,O
3h,O
after,O
intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
than,O
in,O
controls,O
(,O
Figure,O
5,O
"),",O
while,O
IL,B-GP
-,I-GP
10,I-GP
",",O
IL,B-GP
-,I-GP
12p70,I-GP
and,O
IFNγ,B-GP
did,O
not,O
show,O
changes,O
in,O
poly,O
I,O
:,O
C,O
-,O
stimulated,O
mice,B-OG
versus,O
PBS,O
controls,O
(,O
data,O
not,O
shown,O
).,O
Altogether,O
these,O
results,O
suggest,O
a,O
systemic,O
pro,O
-,O
inflammatory,O
state,O
.,O
Poly,O
I,O
:,O
C,O
generates,O
a,O
proinflammatory,O
response,O
and,O
induces,O
RIG,B-GP
-,I-GP
I,I-GP
and,O
MDA5,B-GP
mRNA,O
expression,O
in,O
the,O
small,O
intestine,O
from,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
Real,O
Time,O
-,O
PCR,O
analysis,O
of,O
the,O
IFNβ,B-GP
",",O
CXCL10,B-GP
",",O
TLR3,B-GP
",",O
MDA5,B-GP
",",O
and,O
RIG,B-GP
-,I-GP
I,I-GP
mRNA,O
expression,O
at,O
3,O
and,O
12,O
h,O
post,O
-,O
treatment,O
with,O
poly,O
I,O
:,O
C,O
(,O
black,O
bar,O
),O
or,O
PBS,O
(,O
white,O
bar,O
).,O
All,O
values,O
were,O
normalized,O
to,O
the,O
housekeeping,O
mRNA,O
expression,O
(,O
HPRT,B-GP
).,O
All,O
results,O
were,O
expressed,O
as,O
a,O
fold,O
increase,O
of,O
PBS,O
and,O
poly,O
I,O
:,O
C,O
treatment,O
versus,O
the,O
mean,O
of,O
PBS,O
treatment,O
in,O
every,O
time,O
point,O
(,O
2,O
−,O
ΔΔCt,O
).,O
Stats,O
:,O
N,O
=,O
4,O
mice,B-OG
per,O
group,O
",",O
Unpaired,O
t,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
",",O
**,O
P,O
<,O
0,O
.,O
01,O
",",O
poly,O
I,O
:,O
C,O
-,O
treated,O
mice,B-OG
versus,O
PBS,O
control,O
in,O
the,O
same,O
time,O
point,O
.,O
Increased,O
serum,O
levels,O
of,O
TNFα,B-GP
",",O
MCP,B-GP
-,I-GP
1,I-GP
",",O
and,O
IL,B-GP
-,I-GP
6,I-GP
after,O
intraluminal,O
poly,O
I,O
:,O
C,O
administration,O
.,O
TNFα,B-GP
",",O
MCP,B-GP
-,I-GP
1,I-GP
",",O
and,O
IL,B-GP
-,I-GP
6,I-GP
concentration,O
was,O
assessed,O
in,O
serum,O
after,O
3h,O
of,O
poly,O
I,O
:,O
C,O
or,O
PBS,O
treatment,O
",",O
using,O
a,O
cytometric,O
bead,O
array,O
inflammation,O
kit,O
.,O
The,O
dotted,O
line,O
represents,O
the,O
limit,O
of,O
detection,O
.,O
Stats,O
:,O
N,O
=,O
4,O
mice,B-OG
per,O
group,O
",",O
Unpaired,O
t,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
",",O
**,O
P,O
<,O
0,O
.,O
01,O
.,O
Intraluminal,O
poly,O
I,O
:,O
C,O
and,O
oral,O
dietary,O
antigen,O
induce,O
prolonged,O
enteropathy,B-DS
in,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
Once,O
we,O
had,O
determined,O
the,O
local,O
and,O
systemic,O
immune,O
responses,O
of,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
to,O
mucosally,O
-,O
administered,O
poly,O
I,O
:,O
C,O
",",O
we,O
evaluated,O
whether,O
this,O
was,O
potentiated,O
or,O
prolonged,O
by,O
oral,O
administration,O
of,O
relevant,O
dietary,O
antigen,O
.,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
were,O
treated,O
with,O
poly,O
I,O
:,O
C,O
and,O
fed,O
gliadin,B-GP
or,O
a,O
gluten,B-GP
-,O
free,O
chow,O
",",O
starting,O
24h,O
later,O
",",O
three,O
times,O
a,O
week,O
during,O
two,O
weeks,O
.,O
Small,O
intestinal,O
sections,O
and,O
blood,O
samples,O
were,O
collected,O
after,O
two,O
weeks,O
.,O
A,O
gluten,B-GP
-,O
free,O
chow,O
did,O
not,O
affect,O
the,O
level,O
of,O
enteropathy,B-DS
in,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
induced,O
by,O
intraluminal,O
poly,O
I,O
:,O
C,O
.,O
H,O
&,O
E,O
staining,O
showed,O
subepithelial,O
edema,O
and,O
moderate,O
lifting,O
of,O
villi,O
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
mice,B-OG
with,O
or,O
without,O
gliadin,B-GP
(,O
Figure,O
6A,O
).,O
Histological,O
parameters,O
revealed,O
that,O
both,O
groups,O
had,O
an,O
altered,O
V,O
/,O
C,O
ratio,O
",",O
but,O
similar,O
IELs,O
counts,O
",",O
2,O
weeks,O
after,O
poly,O
I,O
:,O
C,O
administration,O
(,O
Figure,O
6B,O
).,O
However,O
",",O
persistent,O
morphological,O
changes,O
in,O
the,O
small,O
intestinal,O
mucosa,O
were,O
only,O
observed,O
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
that,O
were,O
subsequently,O
challenged,O
with,O
gliadin,B-GP
",",O
indicating,O
maintenance,O
of,O
intestinal,O
damage,O
by,O
oral,O
antigen,O
administration,O
.,O
Gliadin,B-GP
induces,O
histological,O
damage,O
in,O
intraluminal,O
poly,O
I,O
:,O
C,O
-,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
Representative,O
H,O
&,O
E,O
-,O
stained,O
sections,O
of,O
the,O
proximal,O
small,O
intestine,O
from,O
PBS,O
and,O
poly,O
I,O
:,O
C,O
-,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
on,O
a,O
gluten,B-GP
free,O
diet,O
(,O
GFD,O
),O
or,O
orally,O
gavaged,O
with,O
gliadin,B-GP
during,O
2,O
weeks,O
(,O
A,O
).,O
Morphological,O
analysis,O
of,O
small,O
intestine,O
from,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
treated,O
with,O
poly,O
I,O
:,O
C,O
or,O
PBS,O
under,O
a,O
gluten,B-GP
free,O
diet,O
(,O
GFD,O
),O
or,O
gavaged,O
with,O
gliadin,B-GP
during,O
2,O
weeks,O
:,O
V,O
/,O
C,O
ratio,O
",",O
number,O
of,O
IELs,O
and,O
histological,O
score,O
.,O
Stats,O
:,O
N,O
=,O
4,O
-,O
5,O
mice,B-OG
per,O
group,O
",",O
Unpaired,O
t,O
test,O
",",O
**,O
P,O
<,O
0,O
.,O
01,O
",",O
***,O
P,O
<,O
0,O
.,O
001,O
(,O
B,O
).,O
We,O
also,O
evaluated,O
intestinal,O
barrier,O
function,O
by,O
Ussing,O
chamber,O
technique,O
.,O
Oral,O
gavage,O
of,O
gliadin,B-GP
for,O
two,O
weeks,O
was,O
associated,O
with,O
increased,O
transepithelial,O
conductance,O
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
This,O
change,O
was,O
not,O
observed,O
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
mice,B-OG
fed,O
a,O
gluten,B-GP
free,O
chow,O
or,O
in,O
control,O
mice,B-OG
(,O
Figure,O
7A,O
).,O
The,O
evaluation,O
of,O
isotopic,O
flux,O
of,O
51Cr,O
-,O
EDTA,O
showed,O
increased,O
paracellular,O
permeability,O
two,O
weeks,O
after,O
poly,O
I,O
:,O
C,O
treatment,O
regardless,O
of,O
the,O
diet,O
.,O
However,O
the,O
percentage,O
increase,O
was,O
higher,O
in,O
mice,B-OG
receiving,O
gliadin,B-GP
gavages,O
than,O
in,O
those,O
on,O
gluten,B-GP
-,O
free,O
chow,O
(,O
mean,O
value,O
for,O
each,O
treatment,O
:,O
PBS,O
-,O
GFD,O
:,O
0,O
.,O
095,O
"%,",O
poly,O
I,O
:,O
C,O
-,O
GFD,O
:,O
0,O
.,O
22,O
"%,",O
PBS,O
-,O
gliadin,B-GP
:,O
0,O
",",O
17,O
"%,",O
poly,O
I,O
:,O
C,O
-,O
Gliadin,B-GP
:,O
0,O
",",O
56,O
%,O
Hot,O
/,O
h,O
/,O
cm2,O
).,O
The,O
levels,O
of,O
the,O
proinflammatory,O
cytokines,B-GP
IL,B-GP
-,I-GP
12p70,I-GP
and,O
TNFα,B-GP
were,O
increased,O
in,O
peripheral,O
blood,O
of,O
mice,B-OG
gavaged,O
with,O
gliadin,B-GP
after,O
2,O
weeks,O
compared,O
with,O
those,O
on,O
gluten,B-GP
free,O
chow,O
",",O
even,O
in,O
the,O
absence,O
of,O
poly,O
I,O
:,O
C,O
treatment,O
(,O
Figure,O
7B,O
).,O
However,O
no,O
differences,O
were,O
observed,O
in,O
MCP,B-GP
-,I-GP
1,I-GP
",",O
IL,B-GP
-,I-GP
6,I-GP
and,O
IFNγ,B-GP
cytokine,B-GP
production,O
in,O
any,O
of,O
groups,O
(,O
data,O
not,O
shown,O
).,O
Gliadin,B-GP
gavages,O
also,O
induced,O
an,O
increment,O
in,O
the,O
anti,O
-,O
inflammatory,O
cytokine,B-GP
IL,B-GP
-,I-GP
10,I-GP
in,O
serum,O
.,O
Remarkably,O
",",O
poly,O
I,O
:,O
C,O
treatment,O
abolished,O
the,O
production,O
of,O
IL,B-GP
-,I-GP
10,I-GP
induced,O
by,O
gliadin,B-GP
.,O
Therefore,O
",",O
orally,O
delivered,O
gliadin,B-GP
in,O
poly,O
I,O
:,O
C,O
treated,O
mice,B-OG
produced,O
a,O
substantial,O
imbalance,O
in,O
the,O
IL,B-GP
-,I-GP
12p70,I-GP
/,O
IL,B-GP
-,I-GP
10,I-GP
ratio,O
",",O
suggesting,O
a,O
long,O
lasting,O
proinflammatory,O
milieu,O
.,O
Serum,O
levels,O
of,O
IL,B-GP
-,I-GP
12p70,I-GP
and,O
IL,B-GP
-,I-GP
10,I-GP
were,O
below,O
the,O
limit,O
of,O
detection,O
in,O
mice,B-OG
on,O
gluten,B-GP
-,O
free,O
chow,O
.,O
These,O
results,O
suggest,O
that,O
local,O
inflammatory,O
and,O
functional,O
processes,O
in,O
the,O
small,O
intestine,O
induced,O
by,O
intraluminal,O
poly,O
I,O
:,O
C,O
predispose,O
to,O
stronger,O
functional,O
impairment,O
and,O
inflammatory,O
response,O
to,O
a,O
relevant,O
orally,O
-,O
administered,O
dietary,O
antigen,O
.,O
Gliadin,B-GP
induces,O
barrier,O
dysfunction,O
and,O
proinflammatory,O
cytokines,B-GP
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
After,O
24h,O
of,O
the,O
final,O
gavage,O
",",O
sections,O
of,O
small,O
intestine,O
were,O
mounted,O
in,O
Ussing,O
chambers,O
and,O
tissue,O
conductance,O
(,O
mS,O
/,O
cm2,O
),O
and,O
isotopic,O
flux,O
(%,O
Hot,O
/,O
h,O
/,O
cm2,O
),O
were,O
measured,O
.,O
Each,O
dot,O
represents,O
an,O
individual,O
mouse,B-OG
and,O
is,O
a,O
mean,O
of,O
2,O
independent,O
tissues,O
.,O
Stats,O
:,O
N,O
=,O
3,O
-,O
4,O
mice,B-OG
per,O
group,O
",",O
Two,O
way,O
ANOVA,O
and,O
Bonferroni,O
post,O
-,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
(,O
A,O
).,O
Analysis,O
of,O
IL,B-GP
-,I-GP
12p70,I-GP
",",O
TNFα,B-GP
and,O
IL,B-GP
-,I-GP
10,I-GP
in,O
serum,O
samples,O
from,O
poly,O
I,O
:,O
C,O
or,O
PBS,O
-,O
treated,O
mice,B-OG
on,O
a,O
gluten,B-GP
-,O
free,O
diet,O
(,O
GFD,O
),O
or,O
gavaged,O
with,O
gliadin,B-GP
for,O
2,O
weeks,O
.,O
IL,B-GP
-,I-GP
12p70,I-GP
/,O
IL,B-GP
-,I-GP
10,I-GP
ratio,O
was,O
determined,O
.,O
Serum,O
concentration,O
of,O
cytokines,B-GP
was,O
determined,O
by,O
a,O
cytometric,O
bead,O
array,O
inflammation,O
kit,O
.,O
The,O
dotted,O
line,O
represents,O
the,O
limit,O
of,O
detection,O
.,O
Stats,O
:,O
N,O
=,O
4,O
-,O
5,O
mice,B-OG
per,O
group,O
",",O
Two,O
way,O
ANOVA,O
and,O
Bonferroni,O
post,O
-,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
",",O
**,O
P,O
<,O
0,O
.,O
01,O
gliadin,B-GP
versus,O
GFD,O
mice,B-OG
;,O
#,O
P,O
<,O
0,O
.,O
05,O
poly,O
I,O
:,O
C,O
versus,O
PBS,O
in,O
Gliadin,B-GP
-,O
gavaged,O
mice,B-OG
(,O
B,O
).,O
Discussion,O
We,O
showed,O
that,O
induction,O
of,O
local,O
small,O
intestinal,O
inflammation,O
can,O
be,O
elicited,O
by,O
intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
to,O
both,O
wild,O
type,O
and,O
gliadin,B-GP
-,O
sensitive,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
We,O
determined,O
that,O
the,O
severe,O
enteropathy,B-DS
induced,O
by,O
intraluminal,O
poly,O
I,O
:,O
C,O
",",O
predisposed,O
to,O
functional,O
impairment,O
of,O
small,O
intestine,O
in,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
receiving,O
the,O
dietary,O
antigen,O
",",O
gliadin,B-GP
.,O
During,O
viral,O
enteric,O
infections,B-DS
",",O
intermediates,O
of,O
replication,O
",",O
such,O
as,O
dsRNA,O
",",O
are,O
produced,O
in,O
infected,O
cells,O
[,O
6,O
],O
and,O
trigger,O
a,O
rapid,O
inflammatory,O
cascade,O
",",O
which,O
involves,O
the,O
activation,O
of,O
TLR3,B-GP
and,O
RNA,B-GP
helicases,I-GP
such,O
as,O
RIG,B-GP
-,I-GP
I,I-GP
and,O
MDA5,B-GP
[,O
7,O
].,O
Poly,O
I,O
:,O
C,O
is,O
a,O
synthetic,O
analogue,O
commonly,O
used,O
to,O
mimic,O
the,O
effects,O
of,O
dsRNA,O
which,O
causes,O
intestinal,O
pathology,O
when,O
injected,O
parentally,O
[,O
2,O
"],",O
[,O
3,O
"],",O
[,O
4,O
].,O
The,O
marked,O
villus,O
shortening,O
and,O
increased,O
enterocyte,O
apoptosis,O
observed,O
after,O
parenteral,O
poly,O
I,O
:,O
C,O
has,O
been,O
suggested,O
to,O
be,O
caused,O
by,O
TLR3,B-GP
/,O
TRIF,B-GP
/,O
Caspase,B-GP
8,I-GP
activation,O
[,O
5,O
].,O
We,O
used,O
instead,O
intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
and,O
demonstrated,O
it,O
produced,O
severe,O
intestinal,O
pathology,O
",",O
as,O
assessed,O
by,O
reduced,O
V,O
/,O
C,O
ratio,O
",",O
increased,O
IELs,O
counts,O
and,O
increased,O
global,O
histological,O
scores,O
.,O
Induction,O
of,O
dsRNA,O
sensors,O
TLR3,B-GP
",",O
MDA5,B-GP
and,O
RIG,B-GP
-,I-GP
I,I-GP
was,O
transient,O
",",O
peaked,O
at,O
6h,O
and,O
returned,O
to,O
basal,O
levels,O
at,O
12h,O
.,O
In,O
previous,O
models,O
using,O
parenteral,O
poly,O
I,O
:,O
C,O
administration,O
",",O
mucosal,O
damage,O
seemed,O
to,O
be,O
specific,O
for,O
TLR3,B-GP
activation,O
[,O
3,O
"],",O
[,O
4,O
"],",O
[,O
5,O
].,O
The,O
underlying,O
mechanisms,O
proposed,O
for,O
intestinal,O
damage,O
include,O
NK,O
cells,O
[,O
2,O
],O
and,O
CD8αα,B-GP
+,O
IELs,O
with,O
critical,O
participation,O
of,O
IL,B-GP
-,I-GP
15,I-GP
[,O
3,O
"],",O
[,O
4,O
].,O
A,O
recent,O
study,O
however,O
has,O
proposed,O
that,O
",",O
neither,O
NK,O
cells,O
",",O
IELs,O
or,O
IL,B-GP
-,I-GP
15,I-GP
are,O
involved,O
in,O
the,O
induction,O
of,O
intestinal,O
pathology,O
[,O
5,O
].,O
Using,O
intraluminal,O
poly,O
I,O
:,O
C,O
",",O
we,O
found,O
a,O
strong,O
and,O
early,O
increase,O
of,O
IFNβ,B-GP
mRNA,O
levels,O
in,O
the,O
small,O
intestine,O
of,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
2h,O
post,O
-,O
treatment,O
",",O
indicating,O
a,O
mucosal,O
specific,O
poly,O
I,O
:,O
C,O
-,O
signaling,O
activation,O
.,O
TNFα,B-GP
",",O
a,O
cytokine,B-GP
commonly,O
involved,O
in,O
the,O
early,O
inflammatory,O
response,O
",",O
was,O
also,O
transiently,O
upregulated,O
.,O
Remarkably,O
",",O
a,O
60,O
-,O
fold,O
increase,O
in,O
CXCL10,B-GP
expression,O
was,O
observed,O
4h,O
after,O
intraluminal,O
poly,O
I,O
:,O
C,O
.,O
CXCL10,B-GP
has,O
previously,O
been,O
shown,O
to,O
be,O
upregulated,O
by,O
poly,O
I,O
:,O
C,O
in,O
different,O
experimental,O
strategies,O
[,O
23,O
"],",O
and,O
it,O
may,O
play,O
a,O
crucial,O
role,O
in,O
the,O
development,O
of,O
small,O
intestine,O
pathology,O
since,O
it,O
is,O
a,O
major,O
chemo,O
-,O
attractant,O
for,O
Th1,O
CXCR3,B-GP
+,O
cells,O
into,O
inflamed,O
tissues,O
[,O
24,O
"],",O
[,O
25,O
].,O
The,O
mRNA,O
expression,O
of,O
proinflammatory,O
cytokines,B-GP
such,O
as,O
IL,B-GP
-,I-GP
15,I-GP
",",O
IL,B-GP
-,I-GP
18,I-GP
",",O
IL,B-GP
-,I-GP
1β,I-GP
and,O
IFNγ,B-GP
",",O
chemokines,B-GP
such,O
as,O
MCP1,B-GP
and,O
CXCL2,B-GP
and,O
anti,O
-,O
and,O
pro,O
-,O
apoptotic,O
molecules,O
as,O
Bcl,B-GP
-,I-GP
2,I-GP
and,O
Bax,B-GP
respectively,O
",",O
were,O
analyzed,O
",",O
but,O
no,O
changes,O
were,O
observed,O
(,O
data,O
not,O
shown,O
).,O
This,O
is,O
consistent,O
with,O
the,O
report,O
by,O
McAllister,O
C,O
.,O
et,O
al,O
.,O
[,O
5,O
],O
using,O
a,O
parenteral,O
poly,O
I,O
:,O
C,O
model,O
.,O
Since,O
poly,O
I,O
:,O
C,O
triggers,O
a,O
cascade,O
of,O
inflammatory,O
reactions,O
involving,O
different,O
signaling,O
pathways,O
some,O
of,O
the,O
effects,O
after,O
poly,O
I,O
:,O
C,O
administration,O
may,O
also,O
have,O
diverse,O
origins,O
.,O
The,O
observation,O
that,O
transglutaminase,B-GP
2,I-GP
(,O
TG2,B-GP
),O
is,O
activated,O
in,O
small,O
intestine,O
by,O
intraperitoneal,O
poly,O
I,O
:,O
C,O
administration,O
highlights,O
that,O
different,O
players,O
may,O
contribute,O
to,O
additional,O
dysregulation,O
of,O
gut,O
homeostasis,O
[,O
26,O
].,O
Upregulation,O
of,O
TG2,B-GP
has,O
also,O
been,O
related,O
to,O
NFkB,B-GP
pathway,O
",",O
driving,O
an,O
amplification,O
loop,O
of,O
inflammation,O
and,O
damage,O
at,O
the,O
small,O
intestinal,O
mucosa,O
[,O
27,O
].,O
Overall,O
our,O
results,O
suggest,O
that,O
intraluminal,O
poly,O
I,O
:,O
C,O
induces,O
rapid,O
mucosal,O
immune,O
activation,O
involving,O
IFNβ,B-GP
",",O
and,O
the,O
CXCL10,B-GP
/,O
CXCR3,B-GP
axis,O
that,O
may,O
drive,O
inflammation,O
towards,O
a,O
Th1,O
profile,O
.,O
Understanding,O
the,O
early,O
and,O
delayed,O
consequences,O
of,O
immune,O
activation,O
by,O
enteric,O
viral,B-DS
infections,I-DS
",",O
or,O
dsRNA,O
",",O
has,O
important,O
implications,O
for,O
post,O
-,O
infectious,O
inflammatory,O
and,O
functional,O
consequences,O
[,O
10,O
].,O
Thus,O
our,O
second,O
aim,O
was,O
to,O
determine,O
whether,O
a,O
single,O
intraluminal,O
administration,O
of,O
poly,O
I,O
:,O
C,O
influenced,O
subsequent,O
responses,O
to,O
gliadin,B-GP
",",O
a,O
dietary,O
antigen,O
that,O
causes,O
CD,B-DS
in,O
genetically,O
susceptible,O
people,O
",",O
but,O
which,O
may,O
be,O
involved,O
in,O
gut,O
functional,O
abnormalities,O
in,O
a,O
subgroup,O
of,O
patients,O
with,O
irritable,B-DS
bowel,I-DS
syndrome,I-DS
(,O
non,B-DS
celiac,I-DS
gluten,I-DS
sensitivity,I-DS
),O
[,O
28,O
].,O
For,O
this,O
we,O
used,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
",",O
which,O
lack,O
all,O
endogenous,O
class,O
II,O
molecules,O
and,O
express,O
the,O
human,B-OG
HLA,B-GP
-,O
DQ8,O
gene,O
involved,O
in,O
CD,B-DS
[,O
16,O
"],",O
[,O
29,O
].,O
Previous,O
studies,O
using,O
this,O
model,O
have,O
shown,O
that,O
gliadin,B-GP
sensitization,O
results,O
in,O
barrier,O
dysfunction,O
and,O
moderate,O
enteropathy,B-DS
[,O
15,O
].,O
Poly,O
I,O
:,O
C,O
-,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
developed,O
mucosal,O
damage,O
characterized,O
by,O
higher,O
histological,O
score,O
than,O
in,O
control,O
mice,B-OG
",",O
cell,O
infiltration,O
in,O
LP,O
",",O
reduction,O
of,O
V,O
/,O
C,O
ratio,O
",",O
increased,O
IEL,O
counts,O
",",O
and,O
upregulation,O
of,O
IFNβ,B-GP
and,O
CXCL10,B-GP
mRNA,O
in,O
intestinal,O
mucosa,O
.,O
This,O
was,O
also,O
accompanied,O
by,O
higher,O
levels,O
of,O
TNFα,B-GP
",",O
IL,B-GP
-,I-GP
6,I-GP
and,O
MCP1,B-GP
in,O
peripheral,O
blood,O
.,O
After,O
poly,O
I,O
:,O
C,O
administration,O
",",O
one,O
group,O
of,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
was,O
subjected,O
to,O
oral,O
gliadin,B-GP
challenges,O
while,O
another,O
was,O
fed,O
a,O
gluten,B-GP
free,O
chow,O
.,O
51Cr,O
-,O
EDTA,O
flux,O
studies,O
indicated,O
increased,O
paracellular,O
permeability,O
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
mice,B-OG
after,O
two,O
weeks,O
regardless,O
of,O
the,O
dietary,O
treatments,O
.,O
Poly,O
I,O
:,O
C,O
also,O
induced,O
alterations,O
in,O
V,O
/,O
C,O
ratio,O
compared,O
to,O
control,O
mice,B-OG
in,O
both,O
gliadin,B-GP
challenged,O
and,O
gluten,B-GP
free,O
mice,B-OG
.,O
However,O
",",O
only,O
poly,O
I,O
:,O
C,O
-,O
treated,O
mice,B-OG
receiving,O
gliadin,B-GP
presented,O
higher,O
global,O
histological,O
scores,O
",",O
demonstrating,O
severe,O
changes,O
in,O
the,O
mucosa,O
.,O
More,O
importantly,O
",",O
increased,O
transepithelial,O
conductance,O
was,O
only,O
observed,O
in,O
poly,O
I,O
:,O
C,O
-,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
that,O
were,O
subsequently,O
challenged,O
with,O
gliadin,B-GP
.,O
Remarkably,O
",",O
after,O
two,O
weeks,O
of,O
gliadin,B-GP
ingestion,O
",",O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
showed,O
increased,O
levels,O
of,O
the,O
proinflammatory,O
cytokines,B-GP
IL,B-GP
-,I-GP
12p70,I-GP
and,O
TNFα,B-GP
in,O
peripheral,O
blood,O
",",O
compared,O
with,O
those,O
on,O
gluten,B-GP
-,O
free,O
chow,O
",",O
indicating,O
a,O
causal,O
link,O
to,O
gliadin,B-GP
challenges,O
and,O
not,O
to,O
poly,O
I,O
:,O
C,O
treatment,O
.,O
Moreover,O
",",O
IL,B-GP
-,I-GP
10,I-GP
induction,O
by,O
gliadin,B-GP
",",O
a,O
feature,O
observed,O
in,O
-,O
DQ8,O
mouse,B-OG
models,O
of,O
gluten,B-GP
sensitivity,O
before,O
[,O
15,O
"],",O
[,O
30,O
"],",O
[,O
31,O
"],",O
was,O
inhibited,O
in,O
previously,O
poly,O
I,O
:,O
C,O
-,O
treated,O
mice,B-OG
.,O
An,O
imbalance,O
in,O
the,O
IL,B-GP
-,I-GP
12p70,I-GP
/,O
IL,B-GP
-,I-GP
10,I-GP
ratio,O
was,O
observed,O
in,O
gliadin,B-GP
challenged,O
and,O
poly,O
I,O
:,O
C,O
-,O
treated,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
The,O
inflammatory,O
effects,O
elicited,O
by,O
IL,B-GP
-,I-GP
12p70,I-GP
and,O
TNFα,B-GP
have,O
been,O
shown,O
to,O
have,O
direct,O
effects,O
on,O
barrier,O
function,O
and,O
intestinal,O
damage,O
.,O
The,O
correct,O
assembly,O
of,O
tight,O
junction,O
components,O
is,O
critical,O
to,O
preserve,O
barrier,O
integrity,O
and,O
TNFα,B-GP
is,O
recognised,O
as,O
one,O
of,O
the,O
main,O
mediators,O
associated,O
with,O
inflammation,O
in,O
Crohn,B-DS
',I-DS
s,I-DS
disease,I-DS
and,O
CD,B-DS
.,O
TNFα,B-GP
signalling,O
activates,O
myosin,B-GP
light,I-GP
chain,I-GP
kinase,I-GP
(,O
MLCK,B-GP
),O
and,O
tight,O
junction,O
remodelling,O
leading,O
to,O
loss,O
of,O
barrier,O
function,O
[,O
32,O
"],",O
[,O
33,O
].,O
It,O
is,O
noteworthy,O
that,O
gliadin,B-GP
peptides,O
can,O
also,O
increase,O
permeability,O
by,O
innate,O
mechanisms,O
amplifying,O
the,O
circuit,O
of,O
mucosal,O
damage,O
[,O
34,O
"],",O
[,O
35,O
"],",O
[,O
36,O
"],",O
[,O
37,O
].,O
We,O
did,O
not,O
observe,O
changes,O
in,O
IL,B-GP
-,I-GP
15,I-GP
expression,O
associated,O
with,O
this,O
model,O
.,O
IL,B-GP
-,I-GP
15,I-GP
expression,O
has,O
a,O
complex,O
post,O
-,O
transcriptional,O
control,O
which,O
is,O
particularly,O
important,O
to,O
maintain,O
an,O
adequate,O
balance,O
of,O
the,O
immune,O
response,O
in,O
gut,O
.,O
Remarkably,O
",",O
IL,B-GP
-,I-GP
15,I-GP
expression,O
has,O
been,O
shown,O
to,O
be,O
modulated,O
by,O
p31,O
-,O
43,O
gliadin,B-GP
peptide,O
",",O
which,O
triggers,O
different,O
innate,O
responses,O
in,O
Caco,O
-,O
2,O
cells,O
as,O
well,O
as,O
in,O
human,B-OG
duodenum,O
[,O
38,O
].,O
Though,O
we,O
did,O
not,O
specifically,O
work,O
with,O
p31,O
-,O
43,O
",",O
we,O
have,O
performed,O
significant,O
characterization,O
of,O
the,O
NOD,O
-,O
DQ8,O
model,O
[,O
15,O
].,O
Given,O
the,O
NOD,O
background,O
of,O
mice,B-OG
this,O
model,O
is,O
not,O
specifically,O
IL,B-GP
-,I-GP
15,I-GP
driven,O
.,O
Thus,O
",",O
neither,O
mRNA,O
nor,O
protein,O
IL,B-GP
-,I-GP
15,I-GP
determinations,O
in,O
this,O
particular,O
model,O
are,O
useful,O
markers,O
.,O
In,O
conclusion,O
",",O
intraluminal,O
poly,O
I,O
:,O
C,O
induced,O
a,O
severe,O
but,O
transitory,O
damage,O
in,O
the,O
small,O
intestinal,O
mucosa,O
in,O
both,O
wild,O
-,O
type,O
and,O
NOD,B-OG
-,I-OG
DQ8,I-OG
mice,I-OG
.,O
The,O
combination,O
of,O
poly,O
I,O
:,O
C,O
and,O
subsequent,O
gliadin,B-GP
feeding,O
in,O
the,O
genetically,O
susceptible,O
mouse,B-OG
strain,O
NOD,O
-,O
DQ8,O
",",O
led,O
to,O
a,O
proinflammatory,O
synergistic,O
effect,O
and,O
impairment,O
of,O
gut,O
barrier,O
function,O
.,O
Our,O
results,O
raise,O
the,O
intriguing,O
hypothesis,O
thattype,O
I,O
IFNs,O
constitute,O
an,O
important,O
contributor,O
to,O
the,O
loss,O
of,O
tolerance,O
to,O
dietary,O
antigens,O
such,O
as,O
gluten,B-GP
",",O
after,O
a,O
viral,B-DS
infection,I-DS
.,O
This,O
may,O
be,O
particularly,O
important,O
in,O
genetically,O
susceptible,O
hosts,O
",",O
by,O
promoting,O
inflammation,O
as,O
well,O
as,O
a,O
biased,O
Th1,O
response,O
.,O
We,O
hypothesize,O
that,O
this,O
may,O
provide,O
a,O
mechanistic,O
explanation,O
for,O
the,O
clinical,O
link,O
between,O
enteric,O
infections,B-DS
and,O
post,O
-,O
inflammatory,O
and,O
functional,O
disorders,O
[,O
11,O
"],",O
[,O
12,O
"],",O
[,O
39,O
"],",O
[,O
40,O
"],",O
[,O
41,O
].,O
Supporting,O
Information,O
Different,O
molecular,O
weight,O
poly,O
I,O
:,O
Cs,O
cause,O
enteropathy,B-DS
.,O
Analysis,O
of,O
different,O
molecular,O
weight,O
poly,O
I,O
:,O
Cs,O
by,O
ethidium,O
bromide,O
-,O
stained,O
agarose,O
gel,O
electrophoresis,O
",",O
commercial,O
poly,O
I,O
:,O
C,O
(,O
PICs,O
),O
(,O
Sigma,O
-,O
Aldrich,O
"),",O
PICL,O
(,O
LMW,O
-,O
PIC,O
),O
and,O
PICH,O
(,O
HMW,O
-,O
PIC,O
),O
(,O
Invivogen,O
),O
(,O
A,O
).,O
Morphological,O
analysis,O
performed,O
in,O
C57BL,B-OG
/,I-OG
6,I-OG
mice,I-OG
intraluminally,O
treated,O
with,O
PICs,O
",",O
PICL,O
or,O
PICH,O
in,O
a,O
time,O
-,O
course,O
experiment,O
(,O
from,O
12,O
up,O
to,O
72hs,O
),O
(,O
B,O
):,O
V,O
/,O
C,O
ratio,O
vs,O
.,O
time,O
(,O
i,O
);,O
V,O
/,O
C,O
ratio,O
at,O
72h,O
post,O
-,O
treatment,O
with,O
different,O
poly,O
I,O
:,O
Cs,O
or,O
PBS,O
(,O
ii,O
);,O
Histological,O
score,O
at,O
12h,O
and,O
72h,O
after,O
different,O
poly,O
I,O
:,O
Cs,O
treatments,O
(,O
iii,O
).,O
(,O
Stats,O
:,O
N,O
=,O
4,O
mice,B-OG
per,O
group,O
",",O
Unpaired,O
t,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
",",O
**,O
P,O
<,O
0,O
.,O
01,O
",",O
***,O
P,O
<,O
0,O
.,O
001,O
).,O
(,O
TIF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
A,O
New,O
and,O
Inexpensive,O
Pyranometer,O
for,O
the,O
Visible,O
Spectral,O
Range,O
This,O
paper,O
presents,O
the,O
design,O
",",O
construction,O
and,O
testing,O
of,O
a,O
new,O
photodiode,O
-,O
based,O
pyranometer,O
for,O
the,O
visible,O
spectral,O
range,O
(,O
approx,O
.,O
400,O
to,O
750,O
nm,O
"),",O
whose,O
principal,O
characteristics,O
are,O
:,O
accuracy,O
",",O
ease,O
of,O
connection,O
",",O
immunity,O
to,O
noise,O
",",O
remote,O
programming,O
and,O
operation,O
",",O
interior,O
temperature,O
regulation,O
",",O
cosine,O
error,O
minimisation,O
and,O
all,O
this,O
at,O
a,O
very,O
low,O
cost,O
",",O
tens,O
of,O
times,O
lower,O
than,O
that,O
of,O
commercial,O
thermopile,O
-,O
based,O
devices,O
.,O
This,O
new,O
photodiode,O
-,O
based,O
pyranometer,O
overcomes,O
traditional,O
problems,O
in,O
this,O
type,O
of,O
device,O
and,O
offers,O
similar,O
characteristics,O
to,O
those,O
of,O
thermopile,O
-,O
based,O
pyranometers,O
and,O
",",O
therefore,O
",",O
can,O
be,O
used,O
in,O
any,O
installation,O
where,O
reliable,O
measurement,O
of,O
solar,O
irradiance,O
is,O
necessary,O
",",O
especially,O
in,O
those,O
where,O
cost,O
is,O
a,O
deciding,O
factor,O
in,O
the,O
choice,O
of,O
a,O
meter,O
.,O
This,O
new,O
pyranometer,O
has,O
been,O
registered,O
in,O
the,O
Spanish,O
Patent,O
and,O
Trademark,O
Office,O
under,O
the,O
number,O
P200703162,O
.,O
Introduction,O
This,O
paper,O
presents,O
the,O
design,O
",",O
construction,O
and,O
testing,O
of,O
a,O
new,O
pyranometer,O
for,O
measuring,O
global,O
solar,O
irradiance,O
(,O
W,O
/,O
m2,O
),O
or,O
global,O
solar,O
radiation,O
flux,O
density,O
within,O
the,O
visible,O
spectral,O
range,O
(,O
approx,O
.,O
400,O
to,O
750,O
nm,O
).,O
Although,O
the,O
sensing,O
element,O
is,O
a,O
silicon,O
photodiode,O
",",O
the,O
developed,O
pyranometer,O
presents,O
some,O
characteristics,O
and,O
features,O
similar,O
to,O
those,O
of,O
pyranometers,O
based,O
on,O
thermopiles,O
[,O
1,O
],O
at,O
a,O
price,O
which,O
is,O
tens,O
of,O
times,O
lower,O
.,O
This,O
new,O
pyranometer,O
also,O
incorporates,O
significant,O
additional,O
features,O
in,O
terms,O
of,O
connectivity,O
",",O
measuring,O
and,O
remote,O
programming,O
and,O
operation,O
.,O
The,O
presented,O
pyranometer,O
can,O
be,O
used,O
in,O
any,O
installation,O
where,O
reliable,O
measurement,O
of,O
solar,O
irradiance,O
is,O
necessary,O
",",O
especially,O
in,O
those,O
where,O
cost,O
may,O
be,O
a,O
deciding,O
factor,O
in,O
the,O
choice,O
of,O
a,O
meter,O
.,O
Generically,O
",",O
a,O
pyranometer,O
is,O
a,O
device,O
for,O
measuring,O
solar,O
radiation,O
on,O
a,O
normally,O
flat,O
surface,O
",",O
in,O
a,O
field,O
of,O
180,O
degrees,O
.,O
Measurement,O
of,O
solar,O
radiation,O
per,O
unit,O
of,O
surface,O
(,O
W,O
/,O
m2,O
),O
is,O
termed,O
irradiance,O
.,O
Irradiance,O
measurement,O
requires,O
",",O
by,O
definition,O
",",O
that,O
the,O
pyranometer,O
',O
s,O
sensor,O
',O
s,O
response,O
to,O
radiation,O
varies,O
with,O
the,O
cosine,O
of,O
the,O
angle,O
of,O
incidence,O
from,O
a,O
line,O
vertical,O
to,O
the,O
surface,O
of,O
the,O
sensor,O
.,O
That,O
is,O
",",O
the,O
maximum,O
response,O
is,O
obtained,O
when,O
the,O
radiation,O
reaches,O
the,O
sensor,O
perpendicularly,O
(,O
the,O
sun,O
at,O
its,O
zenith,O
"),",O
while,O
no,O
response,O
is,O
obtained,O
when,O
the,O
sun,O
is,O
on,O
the,O
horizon,O
(,O
an,O
angle,O
of,O
incidence,O
of,O
90,O
°),O
and,O
the,O
response,O
is,O
half,O
of,O
the,O
maximum,O
when,O
the,O
incident,O
radiation,O
is,O
at,O
60,O
°.,O
Therefore,O
",",O
it,O
can,O
be,O
deduced,O
from,O
the,O
definition,O
that,O
a,O
pyranometer,O
must,O
have,O
a,O
“,O
directional,O
”,O
response,O
or,O
",",O
as,O
it,O
is,O
usually,O
termed,O
",",O
a,O
cosine,O
response,O
to,O
emphasise,O
the,O
fact,O
that,O
its,O
response,O
must,O
ideally,O
be,O
analogous,O
to,O
the,O
cosine,O
function,O
.,O
The,O
difference,O
between,O
the,O
pyranometer,O
',O
s,O
real,O
response,O
and,O
the,O
ideal,O
cosine,O
response,O
is,O
termed,O
cosine,O
error,O
[,O
2,O
",",O
3,O
].,O
Pyranometers,O
are,O
widely,O
used,O
in,O
meteorology,O
",",O
climatology,O
",",O
agriculture,O
[,O
4,O
"],",O
solar,O
energy,O
studies,O
[,O
5,O
],O
and,O
building,O
physics,O
.,O
In,O
photovoltaic,O
solar,O
installations,O
they,O
are,O
normally,O
mounted,O
with,O
the,O
sensor,O
surface,O
in,O
the,O
plane,O
of,O
the,O
panel,O
.,O
In,O
spite,O
of,O
the,O
interest,O
in,O
measuring,O
solar,O
radiation,O
",",O
the,O
use,O
of,O
pyranometers,O
is,O
still,O
not,O
very,O
widespread,O
outside,O
the,O
field,O
of,O
research,O
",",O
probably,O
due,O
to,O
their,O
high,O
cost,O
.,O
The,O
element,O
that,O
characterises,O
a,O
pyranometer,O
is,O
the,O
sensor,O
it,O
uses,O
",",O
which,O
may,O
be,O
thermal,O
(,O
thermopile,O
),O
or,O
photovoltaic,O
.,O
Photovoltaic,O
sensors,O
are,O
a,O
cheap,O
alternative,O
",",O
whose,O
only,O
advantage,O
in,O
principle,O
over,O
thermopiles,O
in,O
measuring,O
radiation,O
",",O
aside,O
from,O
their,O
price,O
",",O
is,O
their,O
response,O
speed,O
.,O
Thus,O
",",O
while,O
photodiode,O
-,O
based,O
pyranometers,O
have,O
a,O
response,O
time,O
of,O
around,O
10,O
μs,O
[,O
6,O
"],",O
in,O
those,O
based,O
on,O
thermopiles,O
",",O
response,O
time,O
ranges,O
between,O
1,O
and,O
10,O
s,O
",",O
thus,O
making,O
them,O
less,O
suitable,O
for,O
measuring,O
very,O
rapid,O
changes,O
in,O
radiation,O
.,O
The,O
influence,O
of,O
temperature,O
on,O
pyranometer,O
',O
s,O
measurement,O
is,O
also,O
well,O
known,O
.,O
Although,O
this,O
influence,O
exists,O
",",O
it,O
is,O
lower,O
in,O
thermopile,O
pyranometers,O
[,O
1,O
",",O
7,O
-,O
10,O
],O
than,O
in,O
photodiode,O
devices,O
[,O
11,O
-,O
14,O
].,O
With,O
regard,O
to,O
integrating,O
a,O
pyranometer,O
into,O
an,O
instrumentation,O
system,O
(,O
generally,O
into,O
any,O
measuring,O
device,O
"),",O
there,O
is,O
a,O
series,O
of,O
very,O
important,O
factors,O
to,O
take,O
into,O
consideration,O
",",O
namely,O
:,O
ease,O
of,O
connection,O
",",O
signal,O
degradation,O
due,O
to,O
the,O
transmission,O
process,O
[,O
15,O
].,O
In,O
order,O
to,O
achieve,O
the,O
objective,O
proposed,O
in,O
this,O
work,O
",",O
designing,O
and,O
building,O
a,O
photodiode,O
-,O
based,O
pyranometer,O
[,O
16,O
],O
with,O
similar,O
characteristics,O
to,O
those,O
of,O
a,O
thermopile,O
-,O
based,O
device,O
",",O
also,O
incorporating,O
significant,O
connection,O
",",O
measuring,O
and,O
programming,O
utilities,O
[,O
17,O
"],",O
the,O
authors,O
have,O
analysed,O
and,O
corrected,O
both,O
the,O
defects,O
mentioned,O
in,O
literature,O
and,O
those,O
observed,O
during,O
the,O
testing,O
of,O
various,O
commercial,O
units,O
.,O
That,O
is,O
",",O
the,O
pyranometer,O
developed,O
has,O
the,O
following,O
original,O
features,O
:,O
Excellent,O
cosine,O
response,O
guaranteed,O
by,O
both,O
the,O
level,O
gauge,O
(,O
to,O
guarantee,O
horizontality,O
"),",O
which,O
is,O
incorporated,O
",",O
and,O
by,O
the,O
specifically,O
designed,O
solar,O
radiation,O
diffuser,O
.,O
Insensitivity,O
in,O
measuring,O
variations,O
in,O
ambient,O
temperature,O
:,O
A,O
control,O
circuit,O
keeps,O
temperature,O
constant,O
in,O
the,O
interior,O
of,O
the,O
device,O
.,O
Its,O
interior,O
incorporates,O
all,O
necessary,O
electronics,O
for,O
both,O
conditioning,O
",",O
and,O
controlling,O
and,O
communications,O
",",O
which,O
minimises,O
noise,O
and,O
the,O
need,O
for,O
auxiliary,O
electronics,O
.,O
It,O
can,O
be,O
connected,O
directly,O
to,O
a,O
standard,O
instrumentation,O
system,O
(,O
PC,O
",",O
weather,O
station,O
",",O
etc,O
.):,O
For,O
this,O
",",O
the,O
developed,O
pyranometer,O
has,O
an,O
RS,O
485,O
full,O
-,O
duplex,O
serial,O
digital,O
port,O
incorporated,O
(,O
i,O
.,O
e,O
".,",O
directly,O
-,O
transmitted,O
and,O
received,O
signals,O
are,O
digital,O
).,O
It,O
is,O
equipped,O
with,O
a,O
specifically,O
designed,O
virtual,O
instrument,O
(,O
VI,O
),O
which,O
allows,O
acquiring,O
and,O
storing,O
measurements,O
in,O
different,O
formats,O
",",O
configuring,O
the,O
parameters,O
of,O
the,O
pyranometer,O
(,O
internal,O
temperature,O
",",O
communications,O
",",O
etc,O
".),",O
reprogramming,O
",",O
controlling,O
the,O
pyranometer,O
via,O
the,O
INTERNET,O
",",O
etc,O
.,O
from,O
a,O
PC,O
.,O
Connection,O
features,O
in,O
the,O
developed,O
pyranometer,O
are,O
significant,O
",",O
both,O
in,O
terms,O
of,O
their,O
quality,O
(,O
ease,O
",",O
robustness,O
",",O
immunity,O
to,O
noise,O
",",O
etc,O
.),O
and,O
the,O
cost,O
-,O
saving,O
involved,O
in,O
not,O
having,O
to,O
transmit,O
and,O
condition,O
analogue,O
signals,O
outside,O
the,O
device,O
.,O
In,O
order,O
to,O
avoid,O
internal,O
condensation,O
due,O
to,O
the,O
temperature,O
and,O
air,O
-,O
tightness,O
of,O
the,O
device,O
—,O
which,O
may,O
degrade,O
its,O
electronic,O
circuitry,O
and,O
steam,O
up,O
the,O
lens,O
of,O
the,O
photodiode,O
sensor,O
—,O
the,O
developed,O
pyranometer,O
is,O
equipped,O
with,O
a,O
hygroscopic,O
-,O
salts,O
container,O
.,O
The,O
cost,O
is,O
tens,O
of,O
times,O
cheaper,O
than,O
that,O
of,O
a,O
thermopile,O
-,O
based,O
pyranometer,O
of,O
similar,O
quality,O
(,O
including,O
all,O
signal,O
conditioning,O
and,O
transmission,O
circuitry,O
).,O
The,O
present,O
paper,O
is,O
laid,O
out,O
as,O
follows,O
:,O
Section,O
2,O
shall,O
detail,O
all,O
the,O
elements,O
and,O
systems,O
constituting,O
the,O
pyranometer,O
;,O
Section,O
3,O
is,O
devoted,O
to,O
experimental,O
calibration,O
procedures,O
",",O
measurement,O
of,O
relative,O
spectral,O
response,O
and,O
calculation,O
of,O
cosine,O
error,O
;,O
and,O
",",O
finally,O
",",O
Section,O
4,O
presents,O
the,O
conclusions,O
drawn,O
.,O
System,O
description,O
The,O
developed,O
pyranometer,O
is,O
shown,O
outlined,O
in,O
its,O
housing,O
in,O
Figure,O
1,O
.,O
The,O
sensor,O
element,O
is,O
a,O
silicon,O
diode,O
",",O
mounted,O
on,O
a,O
plastic,O
base,O
",",O
covered,O
with,O
a,O
Teflon,O
™,O
diffuser,O
.,O
The,O
whole,O
unit,O
is,O
placed,O
on,O
a,O
base,O
with,O
a,O
level,O
control,O
to,O
ensure,O
horizontality,O
.,O
In,O
order,O
to,O
reduce,O
undesirable,O
effects,O
of,O
ambient,O
temperature,O
on,O
measurement,O
",",O
the,O
device,O
is,O
equipped,O
with,O
a,O
temperature,O
control,O
system,O
",",O
so,O
interior,O
temperature,O
remains,O
constant,O
while,O
working,O
",",O
with,O
an,O
instruction,O
issued,O
by,O
the,O
control,O
software,O
and,O
set,O
by,O
default,O
at,O
40,O
°,O
C,O
(,O
obviously,O
this,O
temperature,O
may,O
depend,O
on,O
the,O
geographical,O
area,O
where,O
the,O
pyranometer,O
is,O
installed,O
",",O
therefore,O
being,O
adjustable,O
by,O
using,O
software,O
via,O
the,O
VI,O
).,O
As,O
it,O
is,O
well,O
known,O
[,O
18,O
"],",O
all,O
the,O
characteristics,O
of,O
photodiodes,O
—,O
parallel,O
resistance,O
",",O
dark,O
current,O
",",O
breakdown,O
voltage,O
",",O
responsivity,O
[,O
19,O
],O
and,O
",",O
to,O
a,O
lesser,O
extent,O
",",O
transition,O
capacitance,O
—,O
are,O
affected,O
by,O
temperature,O
changes,O
.,O
The,O
developed,O
pyranometer,O
generates,O
an,O
electrical,O
signal,O
proportional,O
to,O
the,O
irradiance,O
received,O
in,O
W,O
/,O
m2,O
",",O
which,O
is,O
subsequently,O
converted,O
inside,O
the,O
same,O
device,O
into,O
digital,O
format,O
.,O
Each,O
of,O
the,O
systems,O
and,O
elements,O
with,O
which,O
the,O
pyranometer,O
is,O
equipped,O
will,O
be,O
described,O
below,O
.,O
They,O
are,O
shown,O
as,O
a,O
block,O
diagram,O
in,O
Figure,O
1,O
and,O
as,O
a,O
circuit,O
diagram,O
in,O
Figure,O
2,O
.,O
Radiation,O
diffuser,O
and,O
pyranometer,O
housing,O
As,O
a,O
protective,O
element,O
for,O
the,O
sensor,O
and,O
at,O
the,O
same,O
time,O
a,O
solar,O
radiation,O
diffuser,O
(,O
see,O
Figure,O
1,O
"),",O
a,O
5,O
mm,O
thick,O
Teflon,O
™,O
cover,O
has,O
been,O
designed,O
and,O
manufactured,O
.,O
Several,O
thicknesses,O
were,O
tested,O
for,O
this,O
piece,O
(,O
namely,O
",",O
2,O
",",O
3,O
",",O
4,O
and,O
5,O
mm,O
"),",O
although,O
the,O
one,O
providing,O
the,O
best,O
cosine,O
response,O
",",O
with,O
no,O
loss,O
incident,O
radiation,O
",",O
was,O
the,O
5,O
-,O
mm,O
one,O
.,O
This,O
piece,O
is,O
located,O
just,O
above,O
the,O
photodiode,O
(,O
see,O
Figure,O
4,O
.,O
a,O
).,O
To,O
a,O
large,O
extent,O
this,O
diffuser,O
allows,O
elimination,O
of,O
the,O
cosine,O
error,O
[,O
2,O
",",O
20,O
",",O
21,O
].,O
Teflon,O
has,O
been,O
used,O
because,O
it,O
is,O
a,O
good,O
diffuser,O
and,O
is,O
also,O
resistant,O
to,O
the,O
elements,O
and,O
ultra,O
-,O
violet,O
(,O
UV,O
),O
radiation,O
[,O
22,O
",",O
23,O
"],",O
given,O
its,O
capability,O
to,O
diffuse,O
transmitting,O
lights,O
nearly,O
perfectly,O
.,O
Moreover,O
",",O
the,O
optical,O
properties,O
of,O
PTFE,O
(,O
Teflon,O
™),O
remain,O
constant,O
over,O
a,O
wide,O
range,O
of,O
wavelengths,O
",",O
from,O
UV,O
up,O
to,O
near,O
infrared,O
.,O
Within,O
this,O
region,O
",",O
the,O
relation,O
of,O
its,O
regular,O
transmittance,O
to,O
diffuse,O
transmittance,O
is,O
negligibly,O
small,O
",",O
so,O
light,O
transmitted,O
through,O
a,O
diffuser,O
radiates,O
like,O
Lambert,O
',O
s,O
cosine,O
law,O
.,O
Initially,O
",",O
a,O
completely,O
flat,O
diffuser,O
was,O
designed,O
and,O
manufactured,O
.,O
However,O
",",O
after,O
calibrating,O
the,O
pyranometer,O
for,O
the,O
first,O
time,O
at,O
the,O
internationally,O
homologated,O
INTA,O
(,O
Spanish,O
National,O
Institute,O
for,O
Aerospace,O
Technology,O
),O
laboratory,O
",",O
it,O
was,O
changed,O
for,O
other,O
machined,O
ones,O
at,O
different,O
angles,O
.,O
After,O
a,O
certain,O
number,O
of,O
tests,O
",",O
it,O
was,O
decided,O
that,O
the,O
best,O
option,O
was,O
the,O
one,O
machined,O
at,O
45,O
"°,",O
since,O
—,O
as,O
shown,O
in,O
Figure,O
3,O
—,O
the,O
lowest,O
cosine,O
error,O
was,O
obtained,O
at,O
this,O
angle,O
.,O
Most,O
commercial,O
pyranometers,O
use,O
a,O
glass,O
dome,O
which,O
",",O
apart,O
from,O
being,O
more,O
expensive,O
than,O
the,O
Teflon,O
™,O
diffuser,O
used,O
in,O
this,O
pyranometer,O
",",O
becomes,O
affected,O
by,O
continuous,O
solar,O
radiation,O
and,O
traps,O
higher,O
amounts,O
of,O
dirt,O
[,O
24,O
].,O
As,O
a,O
result,O
",",O
it,O
must,O
be,O
replaced,O
frequently,O
to,O
ensure,O
device,O
precision,O
.,O
The,O
Teflon,O
diffuser,O
is,O
housed,O
together,O
with,O
the,O
photodiode,O
in,O
the,O
top,O
of,O
the,O
pyranometer,O
and,O
is,O
joined,O
onto,O
the,O
rest,O
of,O
the,O
body,O
via,O
six,O
screws,O
and,O
a,O
50,O
mm,O
O,O
-,O
ring,O
",",O
which,O
allows,O
complete,O
air,O
-,O
tightness,O
in,O
the,O
unit,O
(,O
see,O
Figure,O
4a,O
).,O
The,O
pyranometer,O
housing,O
contains,O
the,O
photodiode,O
and,O
all,O
the,O
signal,O
conditioning,O
and,O
distribution,O
electronics,O
.,O
It,O
is,O
manufactured,O
from,O
a,O
single,O
piece,O
of,O
10,O
mm,O
thick,O
black,O
polyethylene,O
",",O
since,O
polyethylene,O
is,O
a,O
material,O
which,O
resists,O
the,O
elements,O
very,O
well,O
and,O
also,O
shows,O
excellent,O
characteristics,O
as,O
a,O
thermal,O
insulator,O
.,O
Figure,O
4b,O
shows,O
the,O
body,O
of,O
the,O
developed,O
pyranometer,O
.,O
It,O
highlights,O
the,O
location,O
of,O
the,O
watertight,O
connection,O
for,O
data,O
input,O
/,O
output,O
",",O
the,O
level,O
gauge,O
(,O
to,O
achieve,O
complete,O
horizontality,O
of,O
the,O
device,O
),O
and,O
the,O
hygroscopic,O
-,O
salts,O
container,O
(,O
to,O
avoid,O
condensation,O
inside,O
the,O
pyranometer,O
"),",O
which,O
is,O
accessible,O
from,O
the,O
outside,O
.,O
Sensor,O
The,O
choice,O
of,O
pyranometer,O
sensor,O
element,O
(,O
photodiode,O
),O
has,O
required,O
an,O
exhaustive,O
study,O
of,O
the,O
commercial,O
devices,O
available,O
",",O
since,O
it,O
constitutes,O
one,O
of,O
the,O
key,O
elements,O
to,O
being,O
able,O
to,O
obtain,O
better,O
performance,O
from,O
the,O
developed,O
pyranometer,O
.,O
A,O
photodiode,O
was,O
required,O
with,O
a,O
response,O
within,O
the,O
visible,O
spectrum,O
[,O
25,O
"],",O
a,O
high,O
value,O
and,O
as,O
linear,O
as,O
possible,O
.,O
In,O
the,O
search,O
for,O
the,O
best,O
sensor,O
we,O
worked,O
in,O
two,O
different,O
ways,O
",",O
on,O
the,O
one,O
hand,O
using,O
the,O
characteristics,O
in,O
the,O
datasheets,O
supplied,O
by,O
the,O
manufacturers,O
",",O
and,O
on,O
the,O
other,O
carrying,O
out,O
real,O
tests,O
in,O
our,O
laboratories,O
with,O
the,O
photodiodes,O
selected,O
.,O
The,O
great,O
variety,O
of,O
photodiodes,O
analysed,O
were,O
classified,O
into,O
two,O
types,O
",",O
namely,O
",",O
those,O
which,O
incorporate,O
the,O
conditioning,O
circuit,O
and,O
those,O
which,O
do,O
not,O
.,O
The,O
former,O
were,O
rejected,O
immediately,O
",",O
as,O
they,O
exhibited,O
problems,O
of,O
saturation,O
at,O
high,O
luminosity,O
.,O
As,O
for,O
the,O
latter,O
",",O
the,O
following,O
were,O
analysed,O
:,O
BPW21,O
",",O
OSD5,O
-,O
5T,O
",",O
OSD15,O
-,O
5T,O
and,O
S9219,O
-,O
01,O
.,O
In,O
the,O
datasheets,O
for,O
each,O
photodiode,O
the,O
following,O
characteristics,O
were,O
studied,O
:,O
Radiant,O
sensitive,O
area,O
(,O
mm2,O
),O
and,O
spectral,O
sensitivity,O
(,O
A,O
/,O
W,O
).,O
For,O
a,O
given,O
irradiance,O
(,O
W,O
/,O
m2,O
"),",O
these,O
two,O
characteristics,O
allow,O
the,O
level,O
of,O
the,O
signal,O
provided,O
by,O
the,O
photodiode,O
to,O
be,O
known,O
.,O
Noise,O
equivalent,O
Power,O
(,O
W,O
/,O
Hz1,O
/,O
2,O
).,O
Based,O
on,O
spectral,O
sensitivity,O
",",O
this,O
characteristic,O
allows,O
the,O
noise,O
-,O
signal,O
to,O
be,O
calculated,O
.,O
The,O
signal,O
produced,O
by,O
the,O
photodiode,O
divided,O
by,O
the,O
noise,O
-,O
signal,O
is,O
its,O
signal,O
-,O
to,O
-,O
noise,O
ratio,O
(,O
SNR,O
).,O
Price,O
.,O
The,O
prices,O
of,O
the,O
aforementioned,O
photodiodes,O
range,O
from,O
7,O
to,O
20,O
Euros,O
",",O
with,O
the,O
cheapest,O
being,O
the,O
BPW21,O
.,O
After,O
the,O
previous,O
analysis,O
",",O
a,O
practical,O
test,O
on,O
the,O
four,O
photodiodes,O
mentioned,O
was,O
carried,O
out,O
in,O
the,O
laboratory,O
.,O
For,O
this,O
",",O
the,O
following,O
experiment,O
was,O
prepared,O
to,O
measure,O
the,O
voltage,O
of,O
each,O
photodiode,O
in,O
short,O
-,O
circuit,O
at,O
different,O
levels,O
of,O
irradiance,O
.,O
The,O
lamp,O
used,O
in,O
the,O
calibration,O
laboratory,O
is,O
a,O
quartz,O
tungsten,O
1,O
",",O
000,O
W,O
standard,O
spectrum,O
irradiance,O
lamp,O
(,O
200A,O
-,O
H,O
),O
with,O
horizontal,O
spiral,O
filament,O
",",O
designated,O
as,O
S,O
-,O
1066,O
",",O
certified,O
by,O
NIST,O
",",O
and,O
provided,O
by,O
Optronic,O
Laboratories,O
.,O
Since,O
instruments,O
must,O
be,O
calibrated,O
at,O
the,O
position,O
in,O
which,O
they,O
normally,O
operate,O
",",O
using,O
a,O
lamp,O
with,O
horizontal,O
filament,O
becomes,O
necessary,O
[,O
26,O
].,O
This,O
lamp,O
",",O
which,O
was,O
placed,O
50,O
cm,O
from,O
the,O
photodiode,O
",",O
was,O
used,O
to,O
emit,O
the,O
illuminance,O
to,O
be,O
measured,O
.,O
Figure,O
5,O
shows,O
the,O
response,O
of,O
photodiodes,O
(,O
connected,O
to,O
a,O
0,O
.,O
1,O
Ω,O
shunt,O
element,O
to,O
carry,O
out,O
measurements,O
in,O
short,O
-,O
circuit,O
),O
to,O
different,O
illuminances,O
.,O
The,O
response,O
curves,O
are,O
certainly,O
quite,O
similar,O
and,O
the,O
one,O
showing,O
the,O
lowest,O
response,O
was,O
that,O
of,O
OSD5,O
-,O
5T,O
.,O
VTB,O
101,O
was,O
discarded,O
because,O
at,O
low,O
illuminance,O
showed,O
a,O
strange,O
behaviour,O
",",O
while,O
it,O
was,O
also,O
observed,O
that,O
its,O
output,O
was,O
strongly,O
dependant,O
on,O
temperature,O
",",O
since,O
—,O
insofar,O
as,O
lightness,O
and,O
",",O
therefore,O
",",O
photodiode,O
temperature,O
increased,O
—,O
it,O
showed,O
irregular,O
behaviour,O
.,O
Subsequently,O
",",O
we,O
proceeded,O
to,O
complete,O
a,O
more,O
detailed,O
analysis,O
on,O
the,O
selected,O
photodiodes,O
(,O
namely,O
",",O
BPW21,O
",",O
OSD,O
5,O
",",O
OSD,O
15,O
and,O
S9219,O
-,O
01,O
).,O
Table,O
1,O
was,O
completed,O
with,O
the,O
features,O
provided,O
by,O
manufacturers,O
.,O
The,O
signal,O
provided,O
by,O
each,O
photodiode,O
is,O
the,O
product,O
of,O
irradiance,O
by,O
active,O
surface,O
and,O
by,O
spectrum,O
responsivity,O
;,O
therefore,O
",",O
from,O
1,O
",",O
000,O
W,O
/,O
m2,O
of,O
irradiance,O
onwards,O
",",O
the,O
following,O
is,O
obtained,O
for,O
each,O
photodiode,O
(,O
in,O
the,O
same,O
order,O
as,O
that,O
shown,O
in,O
Table,O
1,O
):,O
(,O
1,O
),O
Ip1,O
=,O
1000Wm27,O
.,O
34,O
×,O
10,O
−,O
6m20,O
.,O
34AW,O
=,O
2,O
.,O
49,O
×,O
10,O
−,O
3,O
(,O
2,O
),O
Ip2,O
=,O
1000Wm25,O
×,O
10,O
−,O
6m20,O
.,O
15AW,O
=,O
7,O
.,O
5,O
×,O
10,O
−,O
3,O
(,O
3,O
),O
Ip3,O
=,O
1000Wm215,O
×,O
10,O
−,O
6m20,O
.,O
21AW,O
=,O
3,O
.,O
15,O
×,O
10,O
−,O
3,O
(,O
4,O
),O
Ip4,O
=,O
1000Wm212,O
.,O
96,O
×,O
10,O
−,O
6m20,O
.,O
22AW,O
=,O
2,O
.,O
85,O
×,O
10,O
−,O
3,O
As,O
it,O
might,O
be,O
expected,O
",",O
the,O
greater,O
the,O
active,O
surface,O
is,O
",",O
the,O
greater,O
the,O
generated,O
signal,O
is,O
;,O
however,O
",",O
noise,O
also,O
increases,O
with,O
surface,O
.,O
Therefore,O
",",O
signal,O
-,O
to,O
-,O
noise,O
ratio,O
(,O
SNR,O
),O
is,O
a,O
relative,O
criterion,O
which,O
allows,O
comparing,O
them,O
to,O
select,O
the,O
most,O
suitable,O
.,O
Assuming,O
that,O
measure,O
circuits,O
for,O
each,O
photodiode,O
have,O
the,O
same,O
bandwidth,O
",",O
noise,O
for,O
each,O
photodiode,O
is,O
:,O
(,O
5,O
),O
In1,O
=,O
0,O
.,O
34AW7,O
.,O
2,O
×,O
10,O
−,O
14WHz1,O
/,O
2,O
=,O
2,O
.,O
44,O
×,O
10,O
−,O
14AHz1,O
/,O
2,O
(,O
6,O
),O
In2,O
=,O
0,O
.,O
15AW2,O
.,O
4,O
×,O
10,O
−,O
13WHz1,O
/,O
2,O
=,O
3,O
.,O
6,O
×,O
10,O
−,O
14AHz1,O
/,O
2,O
(,O
7,O
),O
In3,O
=,O
0,O
.,O
21AW3,O
×,O
10,O
−,O
13WHz1,O
/,O
2,O
=,O
6,O
.,O
3,O
×,O
10,O
−,O
14AHz1,O
/,O
2,O
Note,O
that,O
noise,O
produced,O
by,O
photodiode,O
S,O
-,O
9219,O
-,O
01,O
is,O
not,O
shown,O
",",O
since,O
the,O
manufacturer,O
provides,O
no,O
NEP,O
(,O
noise,O
-,O
equivalent,O
power,O
).,O
Therefore,O
",",O
the,O
SNR,O
for,O
each,O
photodiode,O
is,O
:,O
(,O
8,O
),O
SNR,O
(,O
ph1,O
)=,O
Ip1In1,O
=,O
2,O
.,O
49,O
×,O
10,O
−,O
3A2,O
.,O
44,O
×,O
10,O
−,O
14A,O
/,O
Hz,O
=,O
1,O
.,O
02,O
×,O
1011,O
(,O
9,O
),O
SNR,O
(,O
ph2,O
)=,O
Ip2In2,O
=,O
7,O
.,O
5,O
×,O
10,O
−,O
4A3,O
.,O
6,O
×,O
10,O
−,O
14A,O
/,O
Hz,O
=,O
2,O
.,O
08,O
×,O
1010,O
(,O
10,O
),O
SNR,O
(,O
ph3,O
)=,O
Ip3In3,O
=,O
3,O
.,O
15,O
×,O
10,O
−,O
3A6,O
.,O
3,O
×,O
10,O
−,O
14A,O
/,O
Hz,O
=,O
5,O
×,O
1010,O
Note,O
that,O
BPW21,O
shows,O
the,O
best,O
SNR,O
.,O
Consequently,O
",",O
bearing,O
linearity,O
",",O
cost,O
",",O
photodiode,O
active,O
-,O
surface,O
and,O
signal,O
-,O
to,O
-,O
noise,O
ratio,O
in,O
mind,O
",",O
we,O
decided,O
that,O
the,O
most,O
suitable,O
photodiode,O
for,O
this,O
application,O
was,O
BPW21,O
.,O
Conditioning,O
system,O
The,O
transimpedance,O
amplifier,O
[,O
27,O
],O
shown,O
in,O
Figure,O
6,O
",",O
configured,O
around,O
the,O
LM308N,O
operational,O
amplifier,O
(,O
OPAM,O
"),",O
was,O
used,O
for,O
signal,O
conditioning,O
from,O
the,O
photodiode,O
(,O
see,O
Figure,O
2,O
).,O
In,O
this,O
circuit,O
Ip,O
is,O
the,O
photocurrent,O
from,O
the,O
diode,O
and,O
C,O
its,O
parasitic,O
capacitor,O
.,O
Cc,O
",",O
Rc,O
and,O
Cr,O
are,O
compensation,O
",",O
correction,O
and,O
stabilisation,O
elements,O
respectively,O
.,O
Their,O
value,O
and,O
function,O
shall,O
be,O
seen,O
later,O
.,O
Finally,O
",",O
Rf,O
is,O
the,O
feedback,O
resistor,O
which,O
fixes,O
the,O
DC,O
gain,O
in,O
the,O
circuit,O
",",O
so,O
the,O
output,O
from,O
this,O
is,O
V0,O
=,O
IpRf,O
.,O
Note,O
that,O
the,O
noise,O
current,O
in,O
the,O
photodiode,O
has,O
not,O
been,O
taken,O
into,O
consideration,O
",",O
since,O
the,O
BPW21,O
has,O
an,O
excellent,O
SNR,O
.,O
To,O
calculate,O
the,O
value,O
of,O
Rf,O
a,O
nominal,O
irradiance,O
of,O
1,O
",",O
000,O
W,O
/,O
m2,O
is,O
used,O
.,O
For,O
this,O
",",O
the,O
BPW21,O
photodiode,O
produces,O
the,O
photocurrent,O
Ip,O
=,O
2,O
.,O
49,O
×,O
10,O
-,O
3,O
A,O
.,O
Therefore,O
",",O
as,O
the,O
maximum,O
analogue,O
input,O
value,O
accepted,O
by,O
the,O
Analogue,O
-,O
to,O
-,O
Digital,O
Converter,O
(,O
ADC,O
),O
is,O
2,O
.,O
5,O
V,O
",",O
the,O
value,O
of,O
Rf,O
is,O
1KΩ,O
",",O
which,O
is,O
implemented,O
using,O
a,O
2,O
KΩ,O
multi,O
-,O
turn,O
potentiometer,O
to,O
carry,O
out,O
precise,O
adjustment,O
.,O
In,O
order,O
to,O
correct,O
the,O
DC,O
error,O
due,O
to,O
polarisation,O
currents,O
",",O
a,O
resistor,O
(,O
Rc,O
),O
is,O
connected,O
to,O
the,O
non,O
-,O
inverting,O
input,O
of,O
the,O
OPAM,O
.,O
This,O
resistor,O
has,O
a,O
detrimental,O
effect,O
in,O
terms,O
of,O
noise,O
[,O
28,O
"],",O
which,O
is,O
amplified,O
;,O
this,O
is,O
why,O
a,O
100,O
pF,O
compensation,O
capacitor,O
Cc,O
is,O
connected,O
in,O
parallel,O
with,O
it,O
.,O
The,O
parasitic,O
capacitor,O
on,O
the,O
photodiode,O
BPW21,O
",",O
C,O
",",O
is,O
580,O
pF,O
.,O
This,O
capacitor,O
has,O
to,O
be,O
taken,O
into,O
consideration,O
",",O
as,O
it,O
can,O
influence,O
the,O
stability,O
of,O
the,O
assembly,O
(,O
reducing,O
its,O
phase,O
margin,O
",",O
and,O
therefore,O
",",O
its,O
relative,O
stability,O
).,O
To,O
improve,O
the,O
stability,O
of,O
the,O
amplifier,O
a,O
capacitor,O
Cr,O
is,O
connected,O
in,O
parallel,O
with,O
the,O
feedback,O
resistor,O
Rf,O
.,O
Following,O
the,O
procedure,O
laid,O
down,O
in,O
the,O
bibliography,O
[,O
27,O
",",O
28,O
],O
it,O
is,O
calculated,O
that,O
an,O
appropriate,O
value,O
for,O
the,O
capacitor,O
is,O
100,O
pF,O
.,O
Finally,O
",",O
a,O
low,O
-,O
pass,O
filter,O
is,O
connected,O
to,O
the,O
amplifier,O
output,O
(,O
see,O
Figure,O
2,O
),O
set,O
at,O
the,O
frequency,O
of,O
10,O
Hz,O
(,O
R,O
=,O
6K8,O
Ω,O
and,O
C,O
=,O
2,O
.,O
2,O
μF,O
).,O
In,O
this,O
way,O
the,O
possible,O
interference,O
that,O
could,O
affect,O
the,O
ADC,O
input,O
is,O
minimised,O
.,O
Control,O
system,O
A,O
PIC,O
-,O
type,O
micro,O
-,O
controller,O
(,O
μc,O
;,O
manufactured,O
by,O
Microchip,O
Technology,O
Inc,O
".,",O
see,O
Figure,O
2,O
),O
is,O
used,O
to,O
control,O
the,O
entire,O
pyranometer,O
.,O
The,O
integrated,O
circuit,O
(,O
IC,O
),O
selected,O
is,O
16F88,O
",",O
which,O
incorporates,O
an,O
ADC,O
.,O
The,O
ADC,O
in,O
the,O
PIC,O
acquires,O
the,O
conditioned,O
analogue,O
signal,O
from,O
the,O
photodiode,O
and,O
converts,O
it,O
into,O
digital,O
format,O
.,O
Then,O
",",O
the,O
digital,O
signal,O
generated,O
is,O
sent,O
to,O
the,O
transmission,O
system,O
",",O
made,O
up,O
of,O
an,O
RS,O
485,O
full,O
-,O
duplex,O
serial,O
bus,O
converter,O
:,O
MAX3080,O
.,O
The,O
PIC,O
also,O
maintains,O
the,O
inside,O
of,O
the,O
pyranometer,O
at,O
a,O
constant,O
temperature,O
.,O
For,O
this,O
reason,O
",",O
it,O
receives,O
the,O
signal,O
from,O
an,O
analogue,O
temperature,O
sensor,O
:,O
LM35,O
(,O
chosen,O
for,O
its,O
stability,O
and,O
precision,O
"),",O
fitted,O
in,O
the,O
interior,O
of,O
the,O
pyranometer,O
housing,O
.,O
Based,O
on,O
measured,O
temperature,O
",",O
the,O
PIC,O
executes,O
the,O
command,O
to,O
activate,O
the,O
heaters,O
or,O
not,O
.,O
This,O
temperature,O
can,O
be,O
adjusted,O
by,O
the,O
user,O
from,O
a,O
PC,O
by,O
using,O
the,O
VI,O
(,O
see,O
Figure,O
7,O
),O
for,O
monitoring,O
and,O
controlling,O
the,O
pyranometer,O
.,O
Interior,O
temperature,O
is,O
to,O
be,O
adjusted,O
according,O
to,O
the,O
climatic,O
conditions,O
in,O
the,O
area,O
where,O
the,O
pyranometer,O
is,O
to,O
be,O
used,O
.,O
Specifically,O
",",O
in,O
the,O
area,O
where,O
tests,O
were,O
carried,O
out,O
(,O
37,O
°,O
12,O
′,O
02,O
.,O
70,O
″,O
N,O
",",O
6,O
°,O
55,O
′,O
10,O
.,O
19,O
″,O
W,O
",",O
elev,O
.,O
19,O
m,O
"),",O
temperature,O
was,O
adjusted,O
to,O
40,O
°,O
C,O
.,O
Finally,O
",",O
the,O
PIC,O
also,O
controls,O
disconnection,O
of,O
heaters,O
automatically,O
during,O
the,O
night,O
with,O
the,O
aim,O
of,O
avoiding,O
unnecessary,O
energy,O
consumption,O
when,O
the,O
pyranometer,O
is,O
out,O
of,O
use,O
.,O
Transmission,O
/,O
reception,O
system,O
The,O
transmission,O
of,O
bidirectional,O
information,O
between,O
the,O
pyranometer,O
and,O
the,O
instrumentation,O
system,O
used,O
(,O
generally,O
a,O
PC,O
",",O
weather,O
station,O
or,O
similar,O
"),",O
is,O
carried,O
out,O
in,O
RS,O
485,O
full,O
-,O
duplex,O
standard,O
serial,O
digital,O
format,O
[,O
29,O
].,O
This,O
format,O
is,O
used,O
over,O
others,O
because,O
it,O
allows,O
connections,O
between,O
devices,O
over,O
a,O
large,O
distance,O
(,O
up,O
to,O
1,O
Km,O
without,O
the,O
use,O
of,O
signal,O
repeaters,O
"),",O
it,O
is,O
robust,O
and,O
very,O
immune,O
to,O
noise,O
.,O
Control,O
of,O
communications,O
is,O
carried,O
out,O
by,O
means,O
of,O
the,O
IC,O
MAX3080,O
.,O
This,O
IC,O
was,O
chosen,O
because,O
it,O
is,O
completely,O
programmable,O
and,O
allows,O
all,O
the,O
communication,O
parameters,O
to,O
be,O
configured,O
via,O
software,O
:,O
transmission,O
speed,O
",",O
parity,O
",",O
number,O
of,O
bits,O
",",O
full,O
or,O
half,O
duplex,O
",",O
etc,O
.,O
TSB89,O
specifications,O
were,O
followed,O
for,O
the,O
actual,O
work,O
of,O
cabling,O
[,O
30,O
].,O
The,O
total,O
number,O
of,O
wires,O
to,O
connect,O
the,O
developed,O
pyranometer,O
is,O
eight,O
[,O
31,O
].,O
That,O
is,O
",",O
four,O
for,O
transmission,O
of,O
data,O
and,O
control,O
-,O
signals,O
",",O
three,O
for,O
power,O
supply,O
and,O
one,O
for,O
the,O
earth,O
.,O
Heating,O
system,O
Its,O
job,O
is,O
to,O
keep,O
the,O
temperature,O
in,O
the,O
interior,O
of,O
the,O
pyranometer,O
constant,O
at,O
all,O
times,O
.,O
Based,O
on,O
the,O
operating,O
temperature,O
set,O
by,O
the,O
user,O
",",O
the,O
control,O
system,O
sends,O
a,O
signal,O
to,O
the,O
thermostatisation,O
system,O
to,O
activate,O
the,O
heaters,O
until,O
this,O
temperature,O
is,O
reached,O
.,O
The,O
heaters,O
are,O
heating,O
meshes,O
(,O
circular,O
elements,O
),O
which,O
run,O
on,O
12,O
V,O
with,O
an,O
approximate,O
current,O
consumption,O
of,O
400,O
mA,O
.,O
Logically,O
",",O
the,O
control,O
signal,O
from,O
the,O
PIC,O
is,O
not,O
applied,O
directly,O
to,O
the,O
heaters,O
",",O
but,O
to,O
an,O
electronic,O
power,O
stage,O
",",O
made,O
up,O
of,O
BD137,O
and,O
TIP,O
111,O
transistors,O
(,O
see,O
Figure,O
2,O
).,O
The,O
total,O
power,O
consumption,O
of,O
the,O
device,O
depends,O
on,O
the,O
exterior,O
temperature,O
.,O
However,O
",",O
the,O
system,O
is,O
highly,O
optimised,O
",",O
since,O
the,O
body,O
of,O
the,O
pyranometer,O
",",O
made,O
from,O
10,O
mm,O
thick,O
polyethylene,O
",",O
acts,O
as,O
an,O
excellent,O
thermal,O
insulator,O
.,O
From,O
the,O
pyranometer,O
control,O
software,O
",",O
the,O
user,O
can,O
select,O
the,O
minimum,O
level,O
of,O
irradiance,O
for,O
the,O
heating,O
system,O
to,O
operate,O
.,O
This,O
allows,O
",",O
for,O
example,O
",",O
the,O
pyranometer,O
to,O
stop,O
working,O
automatically,O
at,O
night,O
and,O
to,O
start,O
working,O
",",O
also,O
automatically,O
",",O
by,O
day,O
.,O
This,O
utility,O
allows,O
optimisation,O
of,O
energy,O
costs,O
.,O
Results,O
and,O
Discussion,O
Calibration,O
Following,O
construction,O
of,O
the,O
pyranometer,O
according,O
to,O
the,O
specifications,O
and,O
methodology,O
described,O
",",O
the,O
next,O
step,O
was,O
calibration,O
of,O
it,O
[,O
11,O
",",O
21,O
",",O
32,O
-,O
34,O
].,O
With,O
the,O
aim,O
of,O
carrying,O
out,O
real,O
comparisons,O
of,O
the,O
effect,O
the,O
changes,O
in,O
ambient,O
temperature,O
produced,O
in,O
the,O
response,O
from,O
the,O
pyranometer,O
",",O
two,O
identical,O
pyranometers,O
were,O
constructed,O
(,O
the,O
same,O
geometry,O
",",O
sensor,O
",",O
diffuser,O
and,O
electronics,O
),O
with,O
a,O
single,O
difference,O
:,O
one,O
had,O
its,O
interior,O
temperature,O
regulated,O
and,O
the,O
other,O
did,O
not,O
.,O
The,O
process,O
of,O
calibrating,O
the,O
two,O
pyranometers,O
constructed,O
to,O
the,O
elements,O
was,O
carried,O
out,O
following,O
the,O
ISO,O
9847,O
standard,O
[,O
35,O
"],",O
by,O
comparison,O
with,O
a,O
standard,O
pyranometer,O
(,O
SP,O
"),",O
specifically,O
the,O
Kipp,O
&,O
Zonen,O
CM21,O
which,O
belongs,O
to,O
the,O
secondary,O
standard,O
class,O
",",O
or,O
the,O
best,O
.,O
Pyranometers,O
are,O
standardised,O
according,O
to,O
the,O
ISO,O
9060,O
standard,O
[,O
36,O
"],",O
which,O
is,O
also,O
adopted,O
by,O
the,O
World,O
Meteorological,O
Organisation,O
(,O
WMO,O
).,O
This,O
standard,O
discriminates,O
three,O
classes,O
.,O
The,O
best,O
is,O
(,O
confusingly,O
),O
called,O
secondary,O
standard,O
",",O
the,O
second,O
best,O
first,O
class,O
and,O
the,O
last,O
one,O
second,O
class,O
.,O
Figure,O
8,O
shows,O
the,O
two,O
pyranometers,O
constructed,O
together,O
with,O
the,O
SP,O
during,O
the,O
calibration,O
process,O
outside,O
our,O
laboratories,O
(,O
37,O
°,O
12,O
′,O
02,O
.,O
70,O
″,O
N,O
",",O
6,O
°,O
55,O
′,O
10,O
.,O
19,O
″,O
W,O
",",O
elev,O
.,O
19,O
m,O
).,O
The,O
three,O
pyranometers,O
took,O
irradiance,O
measurements,O
during,O
2008,O
",",O
with,O
the,O
aim,O
of,O
testing,O
all,O
the,O
angles,O
and,O
intensity,O
of,O
solar,O
radiation,O
.,O
The,O
measurements,O
were,O
carried,O
out,O
every,O
10,O
s,O
and,O
were,O
averaged,O
every,O
minute,O
.,O
Below,O
are,O
shown,O
",",O
by,O
way,O
of,O
an,O
example,O
(,O
see,O
Figures,O
9a,O
-,O
d,O
"),",O
the,O
measurements,O
obtained,O
on,O
four,O
days,O
spread,O
throughout,O
2008,O
.,O
SP,O
is,O
the,O
standard,O
pyranometer,O
;,O
UTP,O
is,O
the,O
unregulated,O
temperature,O
pyranometer,O
and,O
RTP,O
the,O
regulated,O
temperature,O
pyranometer,O
.,O
Looking,O
at,O
Figures,O
9a,O
-,O
d,O
",",O
it,O
can,O
be,O
observed,O
that,O
the,O
RTP,O
faithfully,O
follows,O
the,O
SP,O
curve,O
at,O
every,O
time,O
of,O
day,O
.,O
Note,O
how,O
at,O
times,O
in,O
the,O
middle,O
of,O
the,O
day,O
when,O
the,O
ambient,O
temperature,O
is,O
appreciably,O
constant,O
",",O
the,O
RTP,O
and,O
UTP,O
reveal,O
quite,O
similar,O
behaviour,O
",",O
however,O
",",O
early,O
and,O
late,O
in,O
the,O
day,O
",",O
the,O
UTP,O
is,O
much,O
more,O
sensitive,O
to,O
changes,O
in,O
ambient,O
temperature,O
.,O
This,O
can,O
be,O
observed,O
in,O
more,O
detail,O
in,O
Figures,O
10a,O
",",O
b,O
",",O
where,O
the,O
early,O
and,O
late,O
times,O
of,O
day,O
respectively,O
have,O
been,O
amplified,O
from,O
Figure,O
9a,O
",",O
corresponding,O
to,O
the,O
curve,O
for,O
3rd,O
May,O
2008,O
.,O
Note,O
in,O
the,O
Figure,O
how,O
early,O
in,O
the,O
day,O
the,O
UTP,O
cannot,O
follow,O
the,O
SP,O
curve,O
.,O
Although,O
its,O
behaviour,O
is,O
worse,O
than,O
the,O
RTP,O
",",O
in,O
the,O
last,O
hours,O
of,O
the,O
day,O
(,O
Figure10b,O
"),",O
the,O
UTP,O
',O
s,O
deviation,O
is,O
not,O
as,O
pronounced,O
as,O
early,O
in,O
the,O
day,O
.,O
This,O
is,O
due,O
to,O
the,O
fact,O
that,O
the,O
pyranometer,O
housing,O
accumulates,O
the,O
heat,O
of,O
the,O
whole,O
day,O
and,O
",",O
therefore,O
",",O
its,O
sensitivity,O
to,O
changes,O
in,O
ambient,O
temperature,O
",",O
diminish,O
when,O
the,O
sun,O
sets,O
.,O
Averaged,O
throughout,O
the,O
year,O
",",O
the,O
absolute,O
error,O
in,O
relation,O
to,O
the,O
standard,O
pyranometer,O
",",O
is,O
2,O
.,O
31,O
%,O
for,O
the,O
UTP,O
and,O
1,O
.,O
54,O
%,O
for,O
the,O
RTP,O
.,O
However,O
",",O
the,O
UTP,O
has,O
very,O
good,O
response,O
",",O
and,O
at,O
least,O
in,O
geographical,O
locations,O
similar,O
to,O
those,O
in,O
this,O
work,O
",",O
it,O
is,O
a,O
serious,O
option,O
for,O
applications,O
which,O
are,O
not,O
excessively,O
demanding,O
.,O
Relative,O
Spectral,O
Response,O
(,O
RSR,O
),O
In,O
order,O
to,O
measure,O
the,O
pyranometer,O
',O
s,O
spectral,O
response,O
(,O
see,O
Figure,O
11,O
"),",O
the,O
device,O
underwent,O
testing,O
at,O
the,O
INTA,O
calibration,O
laboratory,O
.,O
The,O
calibration,O
equipment,O
consists,O
of,O
a,O
Jobin,O
Yvon,O
Gemini,O
180,O
double,O
monochromator,O
",",O
which,O
has,O
a,O
450,O
W,O
xenon,O
light,O
source,O
connected,O
to,O
it,O
.,O
This,O
device,O
has,O
three,O
slits,O
whose,O
apertures,O
are,O
located,O
so,O
that,O
there,O
is,O
2,O
nm,O
Fwhm,O
(,O
Full,O
width,O
at,O
half,O
maximum,O
),O
monochromatic,O
light,O
at,O
the,O
exit,O
.,O
An,O
integrating,O
sphere,O
with,O
two,O
exits,O
is,O
placed,O
at,O
the,O
double,O
monochromator,O
exit,O
.,O
A,O
photodiode,O
calibrated,O
by,O
the,O
WRC,O
(,O
World,O
Radiation,O
Center,O
),O
is,O
placed,O
at,O
one,O
of,O
the,O
sphere,O
',O
s,O
exits,O
and,O
the,O
pyranometer,O
to,O
be,O
characterised,O
is,O
placed,O
at,O
the,O
other,O
.,O
A,O
scan,O
is,O
performed,O
within,O
the,O
range,O
300,O
to,O
750,O
nm,O
in,O
2,O
nm,O
steps,O
.,O
In,O
this,O
way,O
the,O
RSR,O
is,O
determined,O
for,O
the,O
developed,O
pyranometer,O
",",O
using,O
the,O
photodiode,O
calibrated,O
by,O
the,O
WRC,O
as,O
a,O
norm,O
(,O
see,O
Figure,O
11,O
).,O
The,O
results,O
obtained,O
are,O
shown,O
in,O
Figure,O
12,O
.,O
Note,O
that,O
the,O
pyranometer,O
',O
s,O
spectral,O
response,O
is,O
approximately,O
between,O
300,O
and,O
750,O
nm,O
.,O
Although,O
the,O
maximum,O
response,O
is,O
obtained,O
around,O
500,O
nm,O
",",O
the,O
pyranometer,O
response,O
curve,O
is,O
reasonably,O
flat,O
(±,O
0,O
.,O
15,O
mV,O
over,O
0,O
.,O
01105,O
V,O
",",O
i,O
.,O
e,O
".,",O
±,O
1,O
.,O
36,O
%),O
throughout,O
the,O
visible,O
light,O
range,O
(,O
approx,O
.,O
400,O
to,O
750,O
nm,O
).,O
Calculation,O
of,O
the,O
cosine,O
error,O
In,O
order,O
to,O
calculate,O
the,O
cosine,O
error,O
for,O
the,O
pyranometer,O
",",O
the,O
device,O
underwent,O
testing,O
at,O
the,O
INTA,O
calibration,O
laboratory,O
.,O
The,O
measuring,O
procedure,O
in,O
the,O
laboratory,O
consists,O
of,O
rotating,O
the,O
pyranometer,O
at,O
a,O
constant,O
distance,O
from,O
a,O
calibrated,O
lamp,O
",",O
in,O
such,O
a,O
way,O
that,O
the,O
distance,O
between,O
the,O
lamp,O
and,O
the,O
photodiode,O
is,O
such,O
that,O
the,O
filament,O
can,O
be,O
considered,O
a,O
point,O
source,O
",",O
so,O
that,O
there,O
is,O
no,O
error,O
introduced,O
into,O
the,O
calibration,O
.,O
The,O
equipment,O
used,O
is,O
that,O
photographed,O
in,O
Figure,O
13,O
.,O
In,O
it,O
can,O
be,O
seen,O
the,O
lamp,O
at,O
the,O
top,O
and,O
the,O
pyranometer,O
undergoing,O
calibration,O
",",O
mounted,O
on,O
a,O
articulated,O
robotic,O
arm,O
",",O
which,O
allows,O
it,O
to,O
be,O
turned,O
between,O
±,O
90,O
°,O
with,O
a,O
high,O
degree,O
of,O
precision,O
.,O
It,O
is,O
important,O
to,O
ensure,O
that,O
the,O
lamp,O
is,O
perpendicular,O
to,O
the,O
pyranometer,O
sensor,O
when,O
the,O
angle,O
of,O
incidence,O
is,O
zero,O
above,O
the,O
rotating,O
system,O
",",O
since,O
",",O
if,O
this,O
were,O
not,O
the,O
case,O
",",O
false,O
results,O
might,O
be,O
produced,O
at,O
higher,O
angles,O
.,O
A,O
laser,O
is,O
used,O
to,O
perform,O
this,O
alignment,O
.,O
The,O
automated,O
system,O
carries,O
out,O
an,O
initial,O
measurement,O
at,O
0,O
°,O
and,O
starts,O
to,O
turn,O
one,O
degree,O
at,O
a,O
time,O
taking,O
measurements,O
from,O
-,O
90,O
°,O
to,O
+,O
90,O
.,O
The,O
results,O
of,O
the,O
measured,O
cosine,O
response,O
are,O
shown,O
in,O
Figure,O
14,O
.,O
The,O
Figure,O
shows,O
the,O
measured,O
cosine,O
response,O
for,O
the,O
RTP,O
.,O
That,O
obtained,O
for,O
the,O
UTP,O
is,O
analogous,O
if,O
the,O
effect,O
of,O
temperature,O
variation,O
is,O
isolated,O
",",O
i,O
.,O
e,O
.,O
if,O
the,O
temperature,O
of,O
the,O
UTP,O
is,O
kept,O
constant,O
during,O
the,O
experiment,O
.,O
The,O
curve,O
in,O
Figure,O
14,O
represents,O
the,O
pyranometer,O
',O
s,O
percentage,O
response,O
based,O
on,O
the,O
radiation,O
',O
s,O
angle,O
of,O
incidence,O
from,O
vertical,O
.,O
Since,O
the,O
pyranometer,O
',O
s,O
ideal,O
response,O
must,O
be,O
analogous,O
to,O
the,O
cosine,O
of,O
the,O
radiation,O
',O
s,O
angle,O
of,O
incidence,O
",",O
when,O
this,O
is,O
perpendicular,O
to,O
the,O
surface,O
of,O
the,O
sensor,O
(,O
the,O
sun,O
at,O
its,O
zenith,O
"),",O
the,O
response,O
must,O
be,O
maximum,O
(,O
100,O
%).,O
The,O
response,O
must,O
be,O
50,O
%,O
when,O
the,O
angle,O
of,O
incidence,O
is,O
60,O
°,O
and,O
nil,O
when,O
the,O
sun,O
is,O
on,O
the,O
horizon,O
(,O
angle,O
of,O
incidence,O
of,O
90,O
°).,O
Based,O
on,O
the,O
data,O
obtained,O
from,O
the,O
calibration,O
test,O
",",O
the,O
cosine,O
error,O
[,O
1,O
"],",O
δcos,O
",",O
is,O
calculated,O
by,O
means,O
of,O
Equation,O
(,O
11,O
):,O
(,O
11,O
),O
δcos,O
=(,O
U,O
(,O
z,O
)+,O
U,O
(−,O
z,O
)),O
2,O
−,O
zero,O
(,O
z,O
)[,O
U,O
(,O
0o,O
)+,O
U,O
(,O
0o,O
),O
2,O
−,O
zero,O
(,O
z,O
)],O
cos,O
(,O
z,O
),O
100,O
%,O
Where,O
U,O
(,O
0,O
°),O
is,O
the,O
pyranometer,O
output,O
voltage,O
for,O
normal,O
incidence,O
",",O
U,O
(,O
z,O
"),",O
the,O
pyranometer,O
output,O
voltage,O
for,O
angles,O
(,O
z,O
"),",O
and,O
zero,O
(,O
z,O
),O
the,O
dark,O
signal,O
for,O
angles,O
(,O
z,O
).,O
The,O
data,O
obtained,O
show,O
that,O
deviation,O
from,O
ideal,O
response,O
is,O
less,O
than,O
2,O
%,O
from,O
0,O
to,O
±,O
75,O
degrees,O
and,O
less,O
than,O
3,O
%,O
from,O
±,O
75,O
to,O
±,O
85,O
degrees,O
.,O
If,O
we,O
take,O
into,O
consideration,O
that,O
the,O
manufacturer,O
[,O
1,O
],O
provides,O
a,O
deviation,O
from,O
ideal,O
response,O
of,O
+/-,O
2,O
%,O
at,O
60,O
°,O
and,O
+/-,O
6,O
%,O
at,O
80,O
°,O
for,O
the,O
SP,O
(,O
CM21,O
),O
we,O
can,O
qualify,O
the,O
cosine,O
response,O
from,O
the,O
developed,O
pyranometer,O
as,O
excellent,O
.,O
Conclusions,O
This,O
paper,O
presents,O
the,O
design,O
",",O
construction,O
and,O
testing,O
of,O
a,O
photodiode,O
-,O
based,O
pyranometer,O
for,O
the,O
visible,O
spectrum,O
.,O
Tests,O
carried,O
out,O
on,O
the,O
developed,O
device,O
show,O
it,O
can,O
compete,O
successfully,O
with,O
high,O
-,O
end,O
commercially,O
available,O
pyranometers,O
at,O
a,O
much,O
lower,O
price,O
and,O
with,O
additional,O
features,O
in,O
terms,O
of,O
connectivity,O
",",O
measurement,O
and,O
remote,O
programming,O
and,O
operation,O
.,O
The,O
newly,O
developed,O
pyranometer,O
can,O
be,O
used,O
in,O
any,O
installation,O
where,O
reliable,O
measurement,O
of,O
solar,O
irradiance,O
is,O
necessary,O
",",O
especially,O
if,O
cost,O
becomes,O
a,O
deciding,O
factor,O
when,O
choosing,O
a,O
pyranometer,O
.,O
This,O
new,O
pyranometer,O
presented,O
in,O
this,O
work,O
brings,O
together,O
features,O
which,O
make,O
it,O
a,O
very,O
competitive,O
alternative,O
to,O
what,O
the,O
market,O
offers,O
at,O
present,O
time,O
.,O
These,O
features,O
are,O
:,O
(,O
1,O
),O
Excellent,O
cosine,O
response,O
.,O
(,O
2,O
),O
Measurement,O
insensitivity,O
to,O
variations,O
in,O
ambient,O
temperature,O
.,O
(,O
3,O
),O
Incorporation,O
of,O
all,O
necessary,O
electronics,O
in,O
the,O
device,O
itself,O
",",O
both,O
for,O
conditioning,O
and,O
control,O
and,O
communications,O
",",O
which,O
minimises,O
noise,O
and,O
the,O
need,O
for,O
auxiliary,O
electronics,O
.,O
(,O
4,O
),O
It,O
allows,O
direct,O
connection,O
to,O
a,O
standard,O
instrumentation,O
system,O
.,O
(,O
5,O
),O
It,O
is,O
equipped,O
with,O
a,O
specifically,O
designed,O
virtual,O
instrument,O
(,O
VI,O
),O
which,O
allows,O
acquiring,O
and,O
storing,O
measurements,O
in,O
different,O
formats,O
",",O
configuring,O
the,O
pyranometer,O
',O
s,O
parameters,O
(,O
interior,O
temperature,O
",",O
communications,O
",",O
etc,O
".),",O
reprogramming,O
",",O
control,O
via,O
Internet,O
",",O
etc,O
.,O
All,O
the,O
previous,O
can,O
be,O
carried,O
out,O
from,O
a,O
PC,O
.,O
(,O
6,O
),O
The,O
connection,O
features,O
included,O
by,O
the,O
developed,O
pyranometer,O
are,O
significant,O
",",O
both,O
in,O
terms,O
of,O
their,O
quality,O
(,O
ease,O
",",O
robustness,O
",",O
immunity,O
to,O
noise,O
",",O
etc,O
.),O
and,O
cost,O
-,O
saving,O
",",O
since,O
no,O
signals,O
must,O
be,O
transmitted,O
and,O
conditioned,O
outside,O
the,O
device,O
.,O
(,O
7,O
),O
It,O
incorporates,O
a,O
hygroscopic,O
-,O
salts,O
container,O
which,O
prevents,O
internal,O
condensation,O
due,O
to,O
the,O
temperature,O
and,O
air,O
-,O
tightness,O
of,O
the,O
device,O
",",O
which,O
may,O
degrade,O
its,O
electronic,O
circuitry,O
and,O
steam,O
up,O
the,O
lens,O
of,O
the,O
photodiode,O
sensor,O
.,O
(,O
8,O
),O
Its,O
cost,O
is,O
several,O
tens,O
of,O
times,O
cheaper,O
than,O
a,O
thermopile,O
-,O
based,O
pyranometer,O
of,O
similar,O
quality,O
(,O
including,O
all,O
signal,O
conditioning,O
and,O
transmission,O
circuitry,O
).,O
As,O
shown,O
in,O
the,O
present,O
paper,O
",",O
an,O
unregulated,O
temperature,O
version,O
has,O
been,O
developed,O
",",O
manufactured,O
and,O
tested,O
",",O
which,O
is,O
even,O
cheaper,O
and,O
perfectly,O
suitable,O
for,O
not,O
excessively,O
demanding,O
applications,O
at,O
a,O
very,O
low,O
cost,O
.,O
The,O
cost,O
of,O
the,O
RTP,O
—,O
taking,O
into,O
account,O
materials,O
",",O
labour,O
and,O
industrial,O
profit,O
—,O
is,O
around,O
70,O
Euros,O
",",O
that,O
of,O
the,O
UTP,O
being,O
55,O
Euros,O
.,O
This,O
new,O
pyranometer,O
has,O
been,O
registered,O
in,O
the,O
Spanish,O
Patent,O
and,O
Trademark,O
Office,O
under,O
the,O
number,O
P200703162,O
.,O
Pyranometer,O
block,O
diagram,O
.,O
Pyranometer,O
circuit,O
diagram,O
.,O
Deviation,O
from,O
ideal,O
cosine,O
response,O
for,O
different,O
angles,O
in,O
the,O
machined,O
in,O
the,O
Teflon,O
™,O
diffuser,O
.,O
Developed,O
pyranometer,O
:,O
(,O
a,O
),O
Detail,O
of,O
the,O
diffuser,O
in,O
the,O
pyranometer,O
top,O
.,O
(,O
b,O
),O
Body,O
of,O
the,O
pyranometer,O
showing,O
the,O
container,O
of,O
hygroscopic,O
salts,O
and,O
gauge,O
level,O
.,O
Curves,O
of,O
response,O
of,O
the,O
different,O
photodiodes,O
analyzed,O
",",O
showing,O
the,O
voltage,O
measured,O
in,O
the,O
0,O
.,O
1,O
Ω,O
shunt,O
depending,O
on,O
different,O
illuminance,O
levels,O
.,O
Transimpedance,O
amplifier,O
to,O
condition,O
the,O
Ip,O
signal,O
provided,O
by,O
the,O
photodiode,O
.,O
Virtual,O
Instrument,O
(,O
VI,O
),O
produced,O
to,O
control,O
the,O
pyranometer,O
.,O
Location,O
for,O
calibrating,O
the,O
two,O
pyranometers,O
constructed,O
",",O
in,O
relation,O
to,O
the,O
standard,O
pyranometer,O
.,O
(,O
a,O
)-(,O
d,O
),O
Irradiance,O
measurements,O
from,O
the,O
three,O
pyranometers,O
(,O
SP,O
is,O
the,O
standard,O
pyranometer,O
",",O
UTP,O
is,O
the,O
unregulated,O
temperature,O
pyranometer,O
and,O
RTP,O
the,O
regulated,O
temperature,O
pyranometer,O
),O
on,O
four,O
days,O
spread,O
throughout,O
2008,O
.,O
(,O
a,O
)-(,O
b,O
).,O
Detail,O
of,O
the,O
irradiance,O
measurements,O
from,O
the,O
3rd,O
May,O
2008,O
.,O
In,O
it,O
the,O
inferior,O
performance,O
of,O
the,O
UTP,O
against,O
the,O
RTP,O
can,O
be,O
observed,O
.,O
Photograph,O
of,O
the,O
test,O
carried,O
out,O
to,O
determine,O
the,O
RSR,O
(,O
Relative,O
Spectral,O
Response,O
),O
in,O
the,O
INTA,O
(,O
the,O
Spanish,O
Institute,O
of,O
Aerospace,O
Technology,O
),O
calibration,O
laboratory,O
in,O
Huelva,O
(,O
Spain,O
).,O
Spectral,O
response,O
curve,O
obtained,O
for,O
the,O
RTP,O
pyranometer,O
in,O
the,O
INTA,O
calibration,O
laboratory,O
.,O
Photograph,O
of,O
the,O
test,O
carried,O
out,O
in,O
the,O
INTA,O
calibration,O
laboratory,O
to,O
calculate,O
the,O
cosine,O
error,O
of,O
the,O
pyranometer,O
.,O
Ideal,O
response,O
and,O
real,O
measured,O
response,O
curves,O
",",O
both,O
according,O
to,O
the,O
angle,O
of,O
incidence,O
Features,O
of,O
selected,O
photodiodes,O
.,O
Photodiode,O
Sensitive,O
area,O
(,O
mm2,O
),O
Responsivity,O
(,O
Rλ,O
),O
(,O
A,O
/,O
W,O
),O
NEP,O
(,O
W,O
/,O
Hz1,O
/,O
2,O
),O
Price,O
(,O
Euros,O
),O
BPW21,O
(,O
ph1,O
),O
7,O
.,O
34,O
0,O
.,O
34,O
7,O
.,O
2,O
×,O
10,O
-,O
14,O
7,O
.,O
30,O
OSD,O
5,O
-,O
5T,O
(,O
ph2,O
),O
5,O
0,O
.,O
15,O
2,O
.,O
4,O
×,O
10,O
-,O
13,O
16,O
.,O
50,O
OSD,O
15,O
-,O
5T,O
(,O
ph3,O
),O
15,O
0,O
.,O
21,O
3,O
×,O
10,O
-,O
13,O
17,O
.,O
53,O
S9219,O
-,O
01,O
(,O
ph4,O
),O
12,O
.,O
96,O
0,O
.,O
22,O
————,O
————,O
Techniques,O
for,O
transferring,O
host,O
-,O
pathogen,O
protein,O
interactions,O
knowledge,O
to,O
new,O
tasks,O
Edited,O
by,O
:,O
Nicola,O
Holden,O
",",O
The,O
James,O
Hutton,O
Institute,O
",",O
UK,O
Reviewed,O
by,O
:,O
Leighton,O
Pritchard,O
",",O
James,O
Hutton,O
Institute,O
",",O
UK,O
;,O
Eric,O
Kemen,O
",",O
Max,O
Planck,O
Institute,O
for,O
Plant,B-OG
Breeding,O
Research,O
",",O
Germany,O
This,O
article,O
was,O
submitted,O
to,O
Plant,B-OG
-,O
Microbe,O
Interaction,O
",",O
a,O
specialty,O
of,O
Frontiers,O
in,O
Microbiology,O
.,O
We,O
consider,O
the,O
problem,O
of,O
building,O
a,O
model,O
to,O
predict,O
protein,O
-,O
protein,O
interactions,O
(,O
PPIs,O
),O
between,O
the,O
bacterial,O
species,O
Salmonella,B-OG
Typhimurium,I-OG
and,O
the,O
plant,B-OG
host,O
Arabidopsis,B-OG
thaliana,I-OG
which,O
is,O
a,O
host,O
-,O
pathogen,O
pair,O
for,O
which,O
no,O
known,O
PPIs,O
are,O
available,O
.,O
To,O
achieve,O
this,O
",",O
we,O
present,O
approaches,O
",",O
which,O
use,O
homology,O
and,O
statistical,O
learning,O
methods,O
called,O
“,O
transfer,O
learning,O
.”,O
In,O
the,O
transfer,O
learning,O
setting,O
",",O
the,O
task,O
of,O
predicting,O
PPIs,O
between,O
Arabidopsis,B-OG
and,O
its,O
pathogen,O
S,O
.,O
Typhimurium,O
is,O
called,O
the,O
“,O
target,O
task,O
.”,O
The,O
presented,O
approaches,O
utilize,O
labeled,O
data,O
i,O
.,O
e,O
".,",O
known,O
PPIs,O
of,O
other,O
host,O
-,O
pathogen,O
pairs,O
(,O
we,O
call,O
these,O
PPIs,O
the,O
“,O
source,O
tasks,O
”).,O
The,O
homology,O
based,O
approaches,O
use,O
heuristics,O
based,O
on,O
biological,O
intuition,O
to,O
predict,O
PPIs,O
.,O
The,O
transfer,O
learning,O
methods,O
use,O
the,O
similarity,O
of,O
the,O
PPIs,O
from,O
the,O
source,O
tasks,O
to,O
the,O
target,O
task,O
to,O
build,O
a,O
model,O
.,O
For,O
a,O
quantitative,O
evaluation,O
we,O
consider,O
Salmonella,B-OG
-,O
mouse,B-OG
PPI,O
prediction,O
and,O
some,O
other,O
host,O
-,O
pathogen,O
tasks,O
where,O
known,O
PPIs,O
exist,O
.,O
We,O
use,O
metrics,O
such,O
as,O
precision,O
and,O
recall,O
and,O
our,O
results,O
show,O
that,O
our,O
methods,O
perform,O
well,O
on,O
the,O
target,O
task,O
in,O
various,O
transfer,O
settings,O
.,O
We,O
present,O
a,O
brief,O
qualitative,O
analysis,O
of,O
the,O
Arabidopsis,B-OG
-,O
Salmonella,B-OG
predicted,O
interactions,O
.,O
We,O
filter,O
the,O
predictions,O
from,O
all,O
approaches,O
using,O
Gene,O
Ontology,O
term,O
enrichment,O
and,O
only,O
those,O
interactions,O
involving,O
Salmonella,B-OG
effectors,O
.,O
Thereby,O
we,O
observe,O
that,O
Arabidopsis,B-OG
proteins,O
involved,O
e,O
.,O
g,O
".,",O
in,O
transcriptional,O
regulation,O
",",O
hormone,O
mediated,O
signaling,O
and,O
defense,O
response,O
may,O
be,O
affected,O
by,O
Salmonella,B-OG
.,O
1,O
.,O
Introduction,O
Understanding,O
the,O
workings,O
of,O
plant,B-OG
responses,O
to,O
pathogens,O
is,O
an,O
important,O
fundamental,O
questions,O
that,O
also,O
has,O
enormous,O
economic,O
importance,O
due,O
to,O
the,O
role,O
of,O
pathogens,O
in,O
food,O
production,O
and,O
processing,O
.,O
While,O
“,O
classical,O
”,O
plant,B-OG
pathogens,O
cause,O
crop,O
losses,O
during,O
production,O
by,O
impacting,O
on,O
plant,B-OG
health,O
",",O
processing,O
of,O
plant,B-OG
-,O
based,O
food,O
can,O
lead,O
to,O
contamination,O
by,O
opportunistic,O
pathogens,O
.,O
It,O
is,O
becoming,O
increasingly,O
supported,O
by,O
experimental,O
evidence,O
that,O
some,O
human,B-OG
bacterial,O
pathogens,O
can,O
colonize,O
plants,B-OG
and,O
cause,O
disease,O
(,O
Kirzinger,O
et,O
al,O
".,",O
2011,O
).,O
Salmonella,B-OG
is,O
one,O
of,O
these,O
bacterial,O
species,O
with,O
extremely,O
broad,O
host,O
range,O
that,O
infects,O
not,O
only,O
animals,B-OG
",",O
but,O
also,O
plants,B-OG
(,O
Hernandez,O
-,O
Reyes,O
and,O
Schikora,O
",",O
2013,O
).,O
Evidence,O
increases,O
that,O
Salmonella,B-OG
can,O
utilize,O
plants,B-OG
as,O
alternative,O
host,O
and,O
can,O
be,O
considered,O
as,O
a,O
bona,O
fide,O
plant,B-OG
pathogen,O
.,O
In,O
this,O
respect,O
it,O
has,O
been,O
reported,O
that,O
(,O
a,O
),O
Salmonella,B-OG
actively,O
invades,O
plant,B-OG
cells,O
",",O
proliferates,O
there,O
and,O
can,O
cause,O
disease,O
symptoms,O
(,O
Schikora,O
et,O
al,O
".,",O
2008,O
;,O
Berger,O
et,O
al,O
".,",O
2011,O
),O
(,O
b,O
),O
the,O
plant,B-OG
recognizes,O
Salmonella,B-OG
and,O
plant,B-OG
defense,O
responses,O
are,O
activated,O
(,O
Iniguez,O
et,O
al,O
".,",O
2005,O
;,O
Schikora,O
et,O
al,O
".,",O
2008,O
),O
and,O
(,O
c,O
),O
that,O
functional,O
Type,B-GP
Three,I-GP
Secretion,I-GP
Systems,I-GP
(,B-GP
TTSS,I-GP
),I-GP
1,I-GP
and,O
2,O
are,O
important,O
for,O
Salmonella,B-OG
pathogenicity,O
in,O
plants,B-OG
with,O
respect,O
to,O
bacterial,O
proliferation,O
and,O
suppression,O
of,O
plant,B-OG
defense,O
responses,O
(,O
Iniguez,O
et,O
al,O
".,",O
2005,O
;,O
Schikora,O
et,O
al,O
".,",O
2011,O
;,O
Shirron,O
and,O
Yaron,O
",",O
2011,O
).,O
Salmonella,B-OG
TTSS,B-GP
-,I-GP
1,I-GP
and,O
2,O
encode,O
proteins,O
",",O
so,O
called,O
effectors,O
",",O
which,O
are,O
known,O
to,O
be,O
translocated,O
into,O
the,O
animal,O
host,O
cell,O
in,O
order,O
to,O
manipulate,O
host,O
cell,O
mechanisms,O
mainly,O
via,O
PPIs,O
(,O
Schleker,O
et,O
al,O
".,",O
2012,O
).,O
Hence,O
",",O
it,O
may,O
be,O
assumed,O
that,O
Salmonella,B-OG
utilizes,O
the,O
same,O
proteins,O
during,O
its,O
communication,O
with,O
animals,B-OG
and,O
plant,B-OG
.,O
However,O
",",O
the,O
details,O
of,O
this,O
communication,O
are,O
not,O
known,O
.,O
A,O
critical,O
component,O
of,O
the,O
communication,O
between,O
any,O
host,O
and,O
its,O
pathogen,O
are,O
PPIs,O
.,O
However,O
",",O
the,O
infection,B-DS
of,O
plants,B-OG
by,O
Salmonella,B-OG
is,O
only,O
a,O
nascent,O
field,O
",",O
so,O
there,O
are,O
no,O
known,O
PPIs,O
for,O
Salmonella,B-OG
with,O
any,O
plant,B-OG
reported,O
yet,O
.,O
Even,O
for,O
the,O
well,O
established,O
pathogen,O
-,O
host,O
pair,O
",",O
Salmonella,B-OG
-,O
human,B-OG
",",O
relatively,O
few,O
interactions,O
are,O
known,O
(,O
Schleker,O
et,O
al,O
".,",O
2012,O
).,O
Only,O
62,O
interactions,O
between,O
Salmonella,B-OG
and,O
mostly,O
human,B-OG
proteins,O
(,O
some,O
Salmonella,B-OG
interactions,O
involve,O
other,O
mammalian,O
species,O
",",O
such,O
as,O
mouse,B-OG
and,O
rat,B-OG
),O
are,O
known,O
to,O
date,O
.,O
Because,O
there,O
exists,O
no,O
plant,B-OG
-,O
Salmonella,B-OG
interactions,O
data,O
",",O
we,O
need,O
to,O
rely,O
on,O
computational,O
methods,O
to,O
predict,O
them,O
[,O
reviewed,O
in,O
the,O
accompanying,O
paper,O
(,O
Schleker,O
et,O
al,O
".,",O
2015,O
)].,O
In,O
this,O
paper,O
",",O
we,O
describe,O
techniques,O
to,O
build,O
computational,O
models,O
to,O
predict,O
interactions,O
between,O
the,O
model,O
plant,B-OG
",",O
A,B-OG
.,I-OG
thaliana,I-OG
",",O
and,O
S,B-OG
.,I-OG
Typhimurium,I-OG
.,O
Typhimurium,O
.,O
Since,O
there,O
is,O
no,O
labeled,O
data,O
of,O
this,O
host,O
-,O
pathogen,O
pair,O
available,O
",",O
we,O
aim,O
to,O
transfer,O
knowledge,O
from,O
known,O
host,O
-,O
pathogen,O
PPI,O
data,O
of,O
other,O
organisms,O
.,O
We,O
use,O
various,O
statistical,O
methods,O
to,O
build,O
models,O
for,O
predicting,O
host,O
-,O
pathogen,O
PPIs,O
.,O
In,O
each,O
case,O
",",O
we,O
cast,O
the,O
PPI,O
prediction,O
problem,O
as,O
a,O
binary,O
classification,O
task,O
",",O
where,O
given,O
two,O
proteins,O
the,O
goal,O
is,O
to,O
learn,O
a,O
function,O
that,O
predicts,O
whether,O
the,O
pair,O
would,O
interact,O
or,O
not,O
.,O
We,O
derive,O
features,O
on,O
every,O
protein,O
pair,O
using,O
protein,O
sequence,O
data,O
.,O
Each,O
host,O
-,O
pathogen,O
PPI,O
prediction,O
problem,O
is,O
considered,O
as,O
one,O
task,O
.,O
Figure,O
1,O
shows,O
our,O
problem,O
setting,O
.,O
The,O
upper,O
host,O
-,O
pathogen,O
task,O
with,O
Salmonella,B-OG
as,O
pathogen,O
and,O
human,B-OG
as,O
the,O
host,O
is,O
the,O
source,O
task,O
.,O
The,O
lower,O
task,O
is,O
the,O
target,O
task,O
.,O
The,O
arrow,O
shows,O
the,O
direction,O
of,O
knowledge,O
transfer,O
.,O
Transfer,O
of,O
PPIs,O
from,O
the,O
source,O
host,O
(,O
for,O
ex,O
:,O
human,B-OG
),O
to,O
another,O
host,O
",",O
the,O
target,O
host,O
(,O
for,O
example,O
Arabidopsis,B-OG
"),",O
for,O
the,O
common,O
pathogen,O
",",O
Salmonella,B-OG
.,O
In,O
order,O
to,O
transfer,O
knowledge,O
from,O
one,O
organism,O
to,O
another,O
",",O
we,O
need,O
to,O
utilize,O
some,O
measure,O
of,O
similarity,O
between,O
them,O
.,O
This,O
similarity,O
can,O
be,O
defined,O
between,O
smaller,O
units,O
such,O
as,O
individual,O
proteins,O
or,O
genes,O
from,O
the,O
organisms,O
or,O
higher,O
level,O
units,O
.,O
The,O
higher,O
the,O
similarity,O
",",O
the,O
greater,O
the,O
information,O
transfer,O
between,O
them,O
.,O
Hence,O
the,O
notion,O
of,O
similarity,O
is,O
very,O
critical,O
to,O
the,O
results,O
we,O
obtain,O
from,O
such,O
a,O
transfer,O
based,O
method,O
and,O
should,O
be,O
biologically,O
motivated,O
.,O
Our,O
methods,O
enable,O
the,O
transfer,O
of,O
knowledge,O
using,O
the,O
following,O
mechanisms,O
:,O
We,O
use,O
the,O
structural,O
similarity,O
between,O
the,O
individual,O
proteins,O
of,O
the,O
two,O
hosts,O
measured,O
using,O
protein,O
sequence,O
alignment,O
.,O
This,O
follows,O
from,O
the,O
biological,O
intuition,O
that,O
structurally,O
similar,O
proteins,O
in,O
two,O
different,O
organisms,O
are,O
very,O
likely,O
to,O
have,O
similar,O
functions,O
.,O
Hence,O
a,O
pathogen,O
that,O
wants,O
to,O
disrupt,O
a,O
specific,O
function,O
will,O
target,O
structurally,O
similar,O
proteins,O
in,O
different,O
hosts,O
.,O
Interactome,O
-,O
level,O
similarity,O
",",O
comparing,O
the,O
human,B-OG
PPI,O
graph,O
with,O
the,O
plant,B-OG
PPI,O
graph,O
.,O
Any,O
biological,O
process,O
in,O
an,O
organism,O
involves,O
the,O
participation,O
of,O
several,O
proteins,O
and,O
more,O
importantly,O
the,O
interactions,O
between,O
these,O
.,O
By,O
comparing,O
the,O
interactomes,O
of,O
different,O
hosts,O
",",O
we,O
are,O
comparing,O
them,O
at,O
the,O
biological,O
process,O
-,O
level,O
.,O
The,O
components,O
of,O
the,O
two,O
graphs,O
that,O
are,O
highly,O
similar,O
will,O
most,O
likely,O
correspond,O
to,O
similar,O
processes,O
in,O
the,O
two,O
organisms,O
.,O
Distributional,O
similarity,O
between,O
the,O
protein,O
pairs,O
:,O
here,O
",",O
we,O
identify,O
which,O
of,O
the,O
human,B-OG
-,O
Salmonella,B-OG
protein,O
pairs,O
are,O
the,O
most,O
similar,O
(,O
hence,O
most,O
relevant,O
),O
to,O
the,O
plant,B-OG
-,O
Salmonella,B-OG
protein,O
pairs,O
.,O
This,O
similarity,O
is,O
computed,O
using,O
the,O
features,O
of,O
the,O
protein,O
-,O
pairs,O
.,O
Since,O
it,O
is,O
distributional,O
similarity,O
",",O
it,O
involves,O
a,O
comparison,O
over,O
all,O
protein,O
pairs,O
from,O
both,O
organisms,O
.,O
Only,O
the,O
most,O
relevant,O
human,B-OG
-,O
Salmonella,B-OG
protein,O
pairs,O
are,O
used,O
to,O
build,O
a,O
model,O
.,O
The,O
main,O
contributions,O
of,O
this,O
paper,O
are,O
:,O
We,O
present,O
methods,O
that,O
combine,O
known,O
PPIs,O
from,O
various,O
sources,O
to,O
build,O
a,O
model,O
for,O
a,O
new,O
task,O
We,O
evaluate,O
our,O
methods,O
quantitatively,O
and,O
our,O
results,O
show,O
the,O
benefits,O
in,O
performance,O
that,O
are,O
possible,O
if,O
we,O
incorporate,O
the,O
similarity,O
information,O
discussed,O
in,O
the,O
previous,O
paragraphs,O
We,O
present,O
the,O
first,O
machine,O
learning,O
based,O
predictions,O
for,O
plant,B-OG
-,O
Salmonella,B-OG
PPIs,O
.,O
In,O
the,O
rest,O
of,O
the,O
paper,O
",",O
we,O
start,O
by,O
describing,O
the,O
host,O
-,O
pathogen,O
PPI,O
datasets,O
we,O
use,O
in,O
Section,O
2,O
",",O
followed,O
by,O
a,O
detailed,O
description,O
of,O
our,O
methods,O
in,O
Section,O
3,O
and,O
a,O
quantitative,O
and,O
qualitative,O
analysis,O
of,O
the,O
results,O
in,O
Section,O
5,O
.,O
2,O
.,O
Source,O
tasks,O
As,O
source,O
tasks,O
we,O
used,O
the,O
known,O
PPIs,O
between,O
various,O
other,O
hosts,O
and,O
pathogens,O
.,O
Many,O
of,O
these,O
interactions,O
were,O
obtained,O
from,O
the,O
PHISTO,O
(,O
Tekir,O
et,O
al,O
".,",O
2012,O
),O
database,O
which,O
reports,O
literature,O
-,O
curated,O
known,O
interactions,O
.,O
For,O
PPIs,O
between,O
human,B-OG
and,O
Salmonella,B-OG
we,O
use,O
the,O
manually,O
literature,O
-,O
curated,O
interactions,O
reported,O
in,O
Schleker,O
et,O
al,O
.,O
(,O
2012,O
).,O
Please,O
note,O
that,O
all,O
of,O
these,O
interactions,O
come,O
from,O
biochemical,O
and,O
biophysical,O
experiments,O
.,O
The,O
details,O
of,O
the,O
dataset,O
used,O
in,O
each,O
approach,O
are,O
shown,O
in,O
Table,O
1,O
and,O
they,O
are,O
available,O
for,O
download,O
from,O
http,O
://,O
www,O
.,O
cs,O
.,O
cmu,O
.,O
edu,O
/~,O
mkshirsa,O
/,O
data,O
/,O
frontiers2014,O
/,O
data,O
.,O
zip,O
.,O
Our,O
first,O
approach,O
is,O
a,O
rule,O
-,O
based,O
approach,O
and,O
it,O
uses,O
human,B-OG
-,O
Salmonella,B-OG
PPIs,O
from,O
two,O
sources,O
:,O
the,O
62,O
experimentally,O
generated,O
PPIs,O
reported,O
in,O
Schleker,O
et,O
al,O
.,O
(,O
2012,O
),O
and,O
the,O
predicted,O
PPIs,O
from,O
Kshirsagar,O
et,O
al,O
.,O
(,O
2012,O
).,O
Please,O
note,O
that,O
this,O
is,O
the,O
only,O
method,O
that,O
uses,O
any,O
predicted,O
PPIs,O
as,O
“,O
ground,O
truth,O
.”,O
All,O
other,O
methods,O
discussed,O
in,O
subsequent,O
sections,O
of,O
this,O
paper,O
do,O
not,O
use,O
any,O
predicted,O
PPIs,O
as,O
source,O
.,O
They,O
use,O
only,O
PPIs,O
validated,O
experimentally,O
by,O
biochemical,O
and,O
biophysical,O
methods,O
.,O
Datasets,O
used,O
in,O
the,O
various,O
approaches,O
",",O
their,O
sizes,O
and,O
the,O
appropriate,O
citations,O
.,O
Approach,O
(,O
es,O
),O
Source,O
task,O
(,O
s,O
),O
Number,O
of,O
interactions,O
Citation,O
for,O
interactions,O
data,O
Feature,O
set,O
1,O
.,O
Homology,O
based,O
Human,B-OG
-,O
Salmonella,B-OG
known,O
PPI,O
Human,B-OG
-,O
Salmonella,B-OG
predictions,O
62,O
190,O
",",O
868,O
Schleker,O
et,O
al,O
".,",O
2012,O
*,O
Kshirsagar,O
et,O
al,O
".,",O
2012,O
No,O
feature,O
set,O
.,O
Heuristics,O
are,O
used,O
to,O
infer,O
interactions,O
2,O
.,O
T,O
-,O
SVM,O
#,O
Human,B-OG
-,O
Salmonella,B-OG
known,O
PPI,O
62,O
Schleker,O
et,O
al,O
".,",O
2012,O
*,O
(,O
a,O
),O
Protein,O
sequence,O
k,O
-,O
mers,O
(,O
b,O
),O
Gene,O
expression,O
(,O
from,O
GEO,O
),O
(,O
c,O
),O
GO,O
term,O
similarity,O
3,O
.,O
KMM,O
†-,O
SVM,O
Human,B-OG
-,O
Salmonella,B-OG
known,O
PPI,O
62,O
Schleker,O
et,O
al,O
".,",O
2012,O
*,O
Human,B-OG
-,O
Francisella,B-OG
tularensis,I-OG
1380,O
Human,B-OG
-,O
E,B-OG
.,I-OG
coli,I-OG
32,O
A,B-OG
.,I-OG
thaliana,I-OG
-,O
Agrobact,O
.,O
tumefaciens,O
22,O
PHISTO,O
*,O
Protein,O
sequence,O
k,O
-,O
mers,O
A,B-OG
.,I-OG
thaliana,I-OG
-,O
E,B-OG
.,I-OG
coli,I-OG
15,O
(,O
Tekir,O
et,O
al,O
".,",O
2012,O
),O
A,B-OG
.,I-OG
thaliana,I-OG
-,O
Pseudomonas,B-OG
syringae,I-OG
13,O
A,B-OG
.,I-OG
thaliana,I-OG
-,O
Synechocyctis,O
23,O
KMM,O
",",O
Kernel,O
Mean,O
Matching,O
;,O
SVM,O
",",O
Support,O
Vector,O
Machine,O
;,O
GO,O
",",O
Gene,O
Ontology,O
.,O
This,O
source,O
reports,O
PPIs,O
validated,O
experimentally,O
by,O
biochemical,O
and,O
biophysical,O
methods,O
.,O
2,O
.,O
1,O
.,O
Salmonella,B-OG
species,O
/,O
strains,O
considered,O
The,O
source,O
data,O
that,O
we,O
use,O
for,O
human,B-OG
-,O
Salmonella,B-OG
from,O
Schleker,O
et,O
al,O
.,O
(,O
2012,O
),O
comes,O
from,O
two,O
different,O
strains,O
:,O
Salmonella,B-OG
Typhimurium,I-OG
strain,I-OG
LT2,I-OG
and,O
Salmonella,B-OG
Typhimurium,I-OG
strain,I-OG
SL,I-OG
1344,I-OG
.,O
One,O
of,O
our,O
three,O
approaches,O
(,O
row,O
-,O
1,O
of,O
Table,O
1,O
),O
uses,O
human,B-OG
-,O
Salmonella,B-OG
predicted,O
PPIs,O
.,O
These,O
predicted,O
PPIs,O
from,O
Kshirsagar,O
et,O
al,O
.,O
(,O
2012,O
),O
contain,O
Salmonella,B-OG
proteins,O
from,O
two,O
additional,O
strains,O
:,O
Salmonella,B-OG
enteritidis,I-OG
PT4,I-OG
and,O
Salmonella,B-OG
Typhi,I-OG
.,O
From,O
henceforth,O
",",O
for,O
the,O
sake,O
of,O
brevity,O
",",O
we,O
will,O
refer,O
to,O
proteins,O
from,O
all,O
strains,O
as,O
Salmonella,B-OG
proteins,O
.,O
For,O
Salmonella,B-OG
proteins,O
",",O
we,O
used,O
the,O
UniprotKB,O
database,O
(,O
The,O
UniProt,O
Consortium,O
",",O
2014,O
),O
to,O
obtain,O
all,O
proteins,O
from,O
the,O
various,O
strains,O
.,O
For,O
Arabidopsis,B-OG
thaliana,I-OG
proteins,O
",",O
we,O
used,O
the,O
TAIR,O
database,O
(,O
Lamesch,O
et,O
al,O
".,",O
2012,O
).,O
3,O
.,O
Methods,O
In,O
the,O
previous,O
section,O
",",O
we,O
described,O
the,O
dataset,O
used,O
in,O
our,O
various,O
approaches,O
.,O
We,O
now,O
describe,O
the,O
details,O
of,O
the,O
methods,O
we,O
use,O
.,O
3,O
.,O
1,O
.,O
Approach,O
-,O
1,O
:,O
homology,O
based,O
transfer,O
In,O
this,O
approach,O
",",O
we,O
use,O
the,O
sequence,O
similarity,O
between,O
the,O
plant,B-OG
and,O
human,B-OG
protein,O
sequences,O
to,O
infer,O
new,O
interactions,O
.,O
We,O
use,O
two,O
techniques,O
to,O
predict,O
interactions,O
between,O
plant,B-OG
and,O
Salmonella,B-OG
proteins,O
.,O
The,O
first,O
technique,O
uses,O
plant,B-OG
-,O
human,B-OG
orthologs,O
and,O
the,O
second,O
is,O
based,O
on,O
plant,B-OG
-,O
human,B-OG
homology,O
(,O
sequence,O
alignment,O
scores,O
).,O
Both,O
techniques,O
use,O
two,O
sources,O
of,O
interactions,O
:,O
true,O
PPIs,O
from,O
Schleker,O
et,O
al,O
.,O
(,O
2012,O
),O
and,O
predicted,O
PPIs,O
from,O
Kshirsagar,O
et,O
al,O
.,O
(,O
2012,O
).,O
Please,O
note,O
that,O
this,O
is,O
the,O
only,O
method,O
that,O
uses,O
any,O
predicted,O
PPIs,O
as,O
“,O
ground,O
truth,O
.”,O
All,O
other,O
methods,O
discussed,O
in,O
subsequent,O
sections,O
of,O
this,O
paper,O
do,O
not,O
use,O
any,O
predicted,O
PPIs,O
as,O
source,O
.,O
Homologs,O
and,O
Orthologs,O
:,O
Homologous,O
pairs,O
of,O
genes,O
are,O
related,O
by,O
descent,O
from,O
a,O
common,O
ancestral,O
DNA,O
sequence,O
.,O
These,O
can,O
be,O
either,O
orthologs,O
:,O
genes,O
that,O
evolved,O
from,O
a,O
common,O
ancestral,O
gene,O
by,O
speciation,O
or,O
paralogs,O
:,O
genes,O
separated,O
by,O
the,O
event,O
of,O
genetic,O
duplication,O
.,O
We,O
obtained,O
orthologs,O
from,O
the,O
InParanoid,O
database,O
(,O
Ostlund,O
et,O
al,O
".,",O
2010,O
).,O
To,O
find,O
homologous,O
pairs,O
of,O
proteins,O
",",O
we,O
used,O
BLAST,O
sequence,O
alignment,O
with,O
an,O
e,O
-,O
value,O
threshold,O
of,O
0,O
.,O
01,O
.,O
Host,O
ortholog,O
based,O
predictions,O
:,O
We,O
start,O
with,O
the,O
known,O
human,B-OG
-,O
Salmonella,B-OG
PPIs,O
.,O
For,O
each,O
interaction,O
",",O
we,O
search,O
for,O
an,O
ortholog,O
of,O
the,O
human,B-OG
protein,O
in,O
Arabidopsis,B-OG
.,O
If,O
one,O
exists,O
",",O
we,O
infer,O
an,O
interaction,O
between,O
the,O
Salmonella,B-OG
and,O
the,O
Arabidopsis,B-OG
protein,O
.,O
This,O
is,O
similar,O
to,O
finding,O
interologs,O
",",O
with,O
the,O
exception,O
that,O
we,O
restrict,O
ourselves,O
to,O
orthologs,O
of,O
the,O
host,O
protein,O
rather,O
than,O
considering,O
all,O
possible,O
homologs,O
of,O
both,O
the,O
host,O
and,O
pathogen,O
proteins,O
.,O
Figure,O
2,O
illustrates,O
this,O
simple,O
heuristic,O
.,O
There,O
are,O
62,O
human,B-OG
-,O
Salmonella,B-OG
PPIs,O
in,O
our,O
dataset,O
.,O
Using,O
this,O
ortholog,O
based,O
inference,O
for,O
the,O
host,O
proteins,O
",",O
we,O
obtained,O
a,O
total,O
of,O
25,O
plant,B-OG
-,O
Salmonella,B-OG
PPIs,O
as,O
some,O
of,O
the,O
human,B-OG
proteins,O
did,O
not,O
have,O
any,O
plant,B-OG
orthologs,O
.,O
The,O
orthologous,O
Arabidopsis,B-OG
proteins,O
for,O
the,O
human,B-OG
proteins,O
were,O
obtained,O
from,O
the,O
InParanoid,O
database,O
(,O
Ostlund,O
et,O
al,O
".,",O
2010,O
).,O
Host,O
graph,O
alignment,O
based,O
predictions,O
:,O
This,O
method,O
uses,O
homologs,O
between,O
the,O
human,B-OG
and,O
plant,B-OG
proteins,O
.,O
Since,O
the,O
set,O
of,O
known,O
PPIs,O
is,O
very,O
small,O
(,O
62,O
interactions,O
"),",O
here,O
we,O
use,O
them,O
to,O
generate,O
“,O
bootstrap,O
”,O
interactions,O
.,O
The,O
known,O
62,O
PPIs,O
are,O
used,O
to,O
build,O
a,O
classifier,O
using,O
the,O
method,O
published,O
in,O
Kshirsagar,O
et,O
al,O
.,O
(,O
2012,O
),O
to,O
generate,O
a,O
total,O
of,O
190,O
",",O
868,O
human,B-OG
-,O
Salmonella,B-OG
PPI,O
predictions,O
.,O
These,O
predicted,O
PPIs,O
form,O
the,O
“,O
bootstrap,O
”,O
PPIs,O
and,O
will,O
be,O
used,O
in,O
a,O
graph,O
-,O
based,O
transfer,O
approach,O
.,O
In,O
this,O
graph,O
-,O
based,O
transfer,O
method,O
",",O
we,O
first,O
align,O
the,O
PPI,O
graphs,O
of,O
the,O
two,O
host,O
organisms,O
using,O
NetworkBlast,O
(,O
Sharan,O
et,O
al,O
".,",O
2005,O
).,O
The,O
human,B-OG
PPI,O
network,O
was,O
obtained,O
from,O
the,O
HPRD,O
database,O
(,O
Prasad,O
et,O
al,O
".,",O
2009,O
),O
and,O
the,O
plant,B-OG
-,O
plant,B-OG
PPIs,O
from,O
TAIR,O
database,O
(,O
Lamesch,O
et,O
al,O
".,",O
2012,O
).,O
The,O
algorithm,O
aligns,O
the,O
human,B-OG
PPI,O
graph,O
with,O
the,O
plant,B-OG
PPI,O
graph,O
using,O
the,O
pairs,O
of,O
homologous,O
proteins,O
between,O
the,O
two,O
organisms,O
.,O
To,O
find,O
the,O
homologous,O
proteins,O
",",O
we,O
used,O
BLAST,O
sequence,O
alignment,O
with,O
an,O
e,O
-,O
value,O
threshold,O
of,O
0,O
.,O
01,O
.,O
Next,O
",",O
we,O
use,O
NetworkBlast,O
to,O
find,O
the,O
graph,O
components,O
that,O
are,O
the,O
most,O
similar,O
across,O
the,O
two,O
graphs,O
.,O
We,O
call,O
them,O
the,O
“,O
enriched,O
components,O
.”,O
By,O
comparing,O
the,O
interactomes,O
of,O
the,O
two,O
hosts,O
",",O
we,O
are,O
comparing,O
them,O
at,O
the,O
biological,O
process,O
-,O
level,O
.,O
The,O
components,O
of,O
the,O
two,O
graphs,O
that,O
are,O
highly,O
similar,O
will,O
most,O
likely,O
correspond,O
to,O
similar,O
processes,O
in,O
the,O
two,O
organisms,O
.,O
NetworkBlast,O
finds,O
a,O
total,O
of,O
2329,O
enriched,O
protein,O
complex,O
pairs,O
between,O
the,O
two,O
host,O
organisms,O
.,O
Figure,O
3,O
shows,O
one,O
such,O
enriched,O
protein,O
complex,O
pair,O
:,O
the,O
complex,O
on,O
the,O
left,O
is,O
from,O
Arabidopsis,B-OG
and,O
the,O
one,O
on,O
the,O
right,O
is,O
from,O
human,B-OG
.,O
Using,O
these,O
we,O
determine,O
the,O
plant,B-OG
proteins,O
that,O
are,O
the,O
most,O
likely,O
targets,O
for,O
the,O
different,O
Salmonella,B-OG
proteins,O
as,O
shown,O
in,O
the,O
Figure,O
3,O
.,O
For,O
each,O
PPI,O
between,O
a,O
human,B-OG
protein,O
from,O
an,O
enriched,O
protein,O
complex,O
",",O
we,O
infer,O
an,O
equivalent,O
PPI,O
between,O
the,O
corresponding,O
plant,B-OG
protein,O
and,O
the,O
Salmonella,B-OG
protein,O
(,O
example,O
",",O
sipA,B-GP
in,O
the,O
Figure,O
3,O
).,O
This,O
filtering,O
procedure,O
gives,O
us,O
a,O
final,O
of,O
23,O
",",O
664,O
plant,B-OG
-,O
Salmonella,B-OG
PPIs,O
.,O
The,O
biological,O
relevance,O
for,O
using,O
the,O
enriched,O
graph,O
components,O
lies,O
in,O
the,O
premise,O
that,O
clusters,O
of,O
similarly,O
interacting,O
proteins,O
across,O
the,O
two,O
organisms,O
will,O
represent,O
biological,O
processes,O
that,O
have,O
been,O
conserved,O
in,O
the,O
two,O
organisms,O
.,O
Hence,O
",",O
the,O
proteins,O
in,O
these,O
components,O
are,O
also,O
likely,O
to,O
be,O
conserved,O
as,O
pathogen,O
targets,O
.,O
Approach,O
-,O
1,O
(,O
a,O
),O
Ortholog,O
based,O
protein,O
interaction,O
inference,O
.,O
“,O
S1,O
”,O
represents,O
a,O
Salmonella,B-OG
protein,O
and,O
S2,O
is,O
the,O
homolog,O
of,O
S1,O
or,O
S1,O
itself,O
.,O
H,O
represents,O
a,O
human,B-OG
protein,O
and,O
A,O
represents,O
an,O
Arabidopsis,B-OG
protein,O
that,O
is,O
an,O
ortholog,O
of,O
the,O
human,B-OG
protein,O
.,O
Approach,O
-,O
1,O
(,O
b,O
),O
Graph,O
based,O
interaction,O
transfer,O
.,O
The,O
big,O
circles,O
show,O
the,O
two,O
protein,O
complexes,O
found,O
to,O
be,O
enriched,O
by,O
Network,O
Blast,O
:,O
the,O
Arabidopsis,B-OG
protein,O
complex,O
on,O
the,O
left,O
",",O
and,O
the,O
human,B-OG
protein,O
complex,O
on,O
the,O
right,O
.,O
The,O
edges,O
within,O
a,O
protein,O
complex,O
are,O
the,O
PPIs,O
within,O
the,O
host,O
organism,O
.,O
The,O
edges,O
connecting,O
the,O
two,O
protein,O
complexes,O
(,O
i,O
.,O
e,O
".,",O
the,O
two,O
circles,O
),O
are,O
the,O
homology,O
edges,O
.,O
The,O
solid,O
line,O
connecting,O
sipA,B-GP
with,O
a,O
human,B-OG
protein,O
node,O
is,O
a,O
bootstrap,O
interaction,O
.,O
We,O
use,O
this,O
to,O
infer,O
the,O
new,O
plant,B-OG
-,O
Salmonella,B-OG
interaction,O
indicated,O
by,O
the,O
dotted,O
line,O
.,O
3,O
.,O
2,O
.,O
Approach,O
-,O
2,O
:,O
transductive,O
learning,O
This,O
method,O
considers,O
the,O
target,O
task,O
i,O
.,O
e,O
".,",O
plant,B-OG
proteins,O
while,O
building,O
a,O
model,O
.,O
It,O
provides,O
a,O
way,O
of,O
incorporating,O
the,O
target,O
task,O
information,O
during,O
model,O
construction,O
.,O
Conventional,O
inductive,O
learning,O
approaches,O
such,O
as,O
the,O
Support,O
Vector,O
Machine,O
classifier,O
use,O
only,O
the,O
training,O
examples,O
to,O
build,O
a,O
model,O
.,O
Transductive,O
learning,O
approaches,O
also,O
use,O
the,O
distribution,O
of,O
the,O
unlabeled,O
test,O
examples,O
.,O
They,O
jointly,O
learn,O
the,O
labels,O
on,O
the,O
test,O
examples,O
while,O
minimizing,O
the,O
error,O
on,O
the,O
labeled,O
training,O
examples,O
.,O
This,O
often,O
results,O
in,O
a,O
good,O
performance,O
",",O
as,O
the,O
classifier,O
has,O
additional,O
information,O
about,O
the,O
unseen,O
test,O
data,O
.,O
In,O
our,O
work,O
here,O
",",O
we,O
use,O
transductive,O
learning,O
for,O
transfer,O
learning,O
in,O
particular,O
the,O
Transductive,O
Support,O
Vector,O
Machine,O
algorithm,O
(,O
T,O
-,O
SVM,O
),O
(,O
Joachims,O
",",O
1999,O
).,O
The,O
training,O
examples,O
are,O
the,O
source,O
task,O
examples,O
",",O
i,O
.,O
e,O
".,",O
human,B-OG
-,O
Salmonella,B-OG
protein,O
interactions,O
.,O
We,O
use,O
the,O
target,O
task,O
examples,O
as,O
the,O
test,O
data,O
.,O
Training,O
negatives,O
:,O
Since,O
there,O
are,O
62,O
known,O
PPIs,O
in,O
the,O
source,O
task,O
",",O
we,O
sample,O
a,O
set,O
of,O
random,O
6200,O
human,B-OG
-,O
Salmonella,B-OG
protein,O
pairs,O
to,O
maintain,O
the,O
positive,O
:,O
negative,O
class,O
ratio,O
at,O
1,O
:,O
100,O
.,O
Figure,O
4,O
depicts,O
this,O
setting,O
.,O
This,O
method,O
thus,O
builds,O
a,O
model,O
by,O
using,O
data,O
from,O
both,O
hosts,O
.,O
The,O
optimization,O
function,O
of,O
T,O
-,O
SVM,O
jointly,O
minimizes,O
the,O
training,O
error,O
on,O
the,O
known,O
human,B-OG
-,O
pathogen,O
interactions,O
and,O
the,O
label,O
assignments,O
on,O
the,O
unknown,O
plant,B-OG
-,O
pathogen,O
interactions,O
.,O
The,O
set,O
of,O
target,O
examples,O
can,O
not,O
be,O
used,O
entirely,O
as,O
it,O
is,O
very,O
large,O
and,O
makes,O
the,O
T,O
-,O
SVM,O
algorithm,O
very,O
computationally,O
expensive,O
.,O
Hence,O
we,O
randomly,O
sample,O
1,O
percent,O
of,O
the,O
target,O
dataset,O
.,O
For,O
the,O
T,O
-,O
SVM,O
based,O
algorithm,O
to,O
be,O
effective,O
",",O
the,O
kernel,O
function,O
that,O
is,O
used,O
to,O
compute,O
the,O
similarity,O
between,O
examples,O
matters,O
a,O
lot,O
.,O
We,O
use,O
a,O
homology,O
-,O
based,O
kernel,O
function,O
that,O
incorporates,O
the,O
BLAST,O
similarity,O
score,O
between,O
the,O
proteins,O
.,O
Let,O
xis,O
be,O
the,O
feature,O
-,O
vector,O
representing,O
a,O
source,O
task,O
example,O
:,O
the,O
protein,O
pair,O
<,O
ss,O
",",O
hs,O
>,O
where,O
ss,O
is,O
the,O
Salmonella,B-OG
protein,O
(,O
i,O
.,O
e,O
".,",O
the,O
pathogen,O
protein,O
),O
and,O
hs,O
is,O
the,O
host,O
protein,O
.,O
Let,O
the,O
target,O
task,O
example,O
be,O
the,O
protein,O
pair,O
<,O
st,O
",",O
at,O
>,O
where,O
at,O
is,O
the,O
Arabidopsis,B-OG
protein,O
;,O
and,O
the,O
corresponding,O
feature,O
vector,O
be,O
xkt,O
.,O
The,O
kernel,O
function,O
that,O
computes,O
the,O
similarity,O
between,O
the,O
given,O
two,O
pairs,O
of,O
proteins,O
(,O
i,O
.,O
e,O
".,",O
their,O
feature,O
vectors,O
),O
is,O
defined,O
as,O
shown,O
below,O
.,O
Transductive,O
Support,O
Vector,O
Machine,O
(,O
SVM,O
),O
for,O
transfer,O
learning,O
.,O
The,O
first,O
panel,O
shows,O
the,O
conventional,O
SVM,O
classifier,O
.,O
The,O
second,O
panel,O
shows,O
T,O
-,O
SVM,O
with,O
circles,O
representing,O
unlabeled,O
examples,O
.,O
We,O
use,O
examples,O
from,O
the,O
target,O
task,O
i,O
.,O
e,O
".,",O
Arabidopsis,B-OG
-,O
Salmonella,B-OG
protein,O
pairs,O
as,O
the,O
unlabeled,O
examples,O
to,O
influence,O
the,O
classifier,O
boundary,O
.,O
The,O
first,O
equation,O
is,O
used,O
in,O
the,O
case,O
where,O
the,O
two,O
protein,O
pairs,O
come,O
from,O
different,O
tasks,O
.,O
We,O
use,O
homology,O
-,O
distance,O
between,O
the,O
pathogen,O
proteins,O
and,O
the,O
host,O
proteins,O
to,O
compute,O
the,O
kernel,O
.,O
The,O
homology,O
distance,O
itself,O
is,O
simply,O
the,O
BLAST,O
protein,O
sequence,O
alignment,O
score,O
.,O
The,O
next,O
two,O
equations,O
show,O
the,O
computation,O
when,O
the,O
examples,O
both,O
come,O
from,O
the,O
same,O
task,O
.,O
Here,O
we,O
simply,O
take,O
the,O
dot,O
product,O
of,O
the,O
two,O
feature,O
vectors,O
.,O
This,O
kernel,O
is,O
symmetric,O
.,O
The,O
similarity,O
between,O
two,O
sequences,O
sim,O
(,O
m,O
",",O
n,O
),O
is,O
computed,O
using,O
the,O
bit,O
-,O
score,O
from,O
BLAST,O
sequence,O
alignment,O
",",O
normalized,O
using,O
the,O
sequence,O
length,O
of,O
the,O
larger,O
protein,O
.,O
We,O
used,O
the,O
SVMlight,O
package,O
(,O
Joachims,O
",",O
2008,O
),O
and,O
incorporated,O
our,O
kernel,O
function,O
into,O
it,O
.,O
The,O
parameter,O
tuning,O
for,O
T,O
-,O
SVM,O
(,O
the,O
regularization,O
parameter,O
C,O
),O
was,O
done,O
using,O
cross,O
validation,O
on,O
the,O
PPIs,O
where,O
we,O
have,O
the,O
true,O
labels,O
.,O
We,O
found,O
C,O
=,O
0,O
.,O
1,O
was,O
the,O
best,O
setting,O
.,O
This,O
best,O
model,O
is,O
subsequently,O
used,O
to,O
generate,O
predictions,O
on,O
all,O
Arabidopsis,B-OG
-,O
Salmonella,B-OG
protein,O
-,O
pairs,O
.,O
The,O
model,O
outputs,O
a,O
score,O
indicating,O
the,O
distance,O
from,O
the,O
classifier,O
hyperplane,O
.,O
A,O
positive,O
score,O
indicates,O
that,O
the,O
protein,O
-,O
pair,O
is,O
on,O
the,O
positive,O
side,O
of,O
the,O
hyperplane,O
and,O
hence,O
closer,O
to,O
the,O
known,O
interacting,O
protein,O
-,O
pairs,O
.,O
All,O
such,O
protein,O
-,O
pairs,O
will,O
be,O
considered,O
as,O
potential,O
interactions,O
predicted,O
by,O
this,O
model,O
.,O
3,O
.,O
3,O
.,O
Approach,O
-,O
3,O
:,O
kernel,O
mean,O
matching,O
Our,O
transfer,O
learning,O
scenario,O
here,O
consist,O
of,O
the,O
following,O
setting,O
:,O
multiple,O
“,O
source,O
”,O
tasks,O
with,O
small,O
amounts,O
of,O
labeled,O
data,O
",",O
a,O
single,O
“,O
target,O
”,O
task,O
with,O
no,O
labeled,O
data,O
.,O
The,O
first,O
challenge,O
is,O
to,O
pick,O
the,O
best,O
instances,O
from,O
the,O
source,O
tasks,O
",",O
such,O
that,O
the,O
resultant,O
model,O
when,O
applied,O
on,O
the,O
target,O
task,O
generates,O
high,O
confidence,O
predictions,O
.,O
Toward,O
this,O
",",O
we,O
use,O
the,O
instance,O
reweighting,O
technique,O
Kernel,O
Mean,O
Matching,O
(,O
KMM,O
).,O
The,O
reweighted,O
source,O
task,O
instances,O
are,O
used,O
to,O
build,O
a,O
kernelized,O
support,O
vector,O
machine,O
(,O
SVM,O
),O
model,O
",",O
which,O
is,O
applied,O
on,O
the,O
target,O
task,O
data,O
to,O
get,O
the,O
predicted,O
PPIs,O
.,O
This,O
brings,O
forth,O
the,O
second,O
challenge,O
—,O
selecting,O
appropriate,O
hyperparameters,O
while,O
building,O
a,O
model,O
for,O
a,O
task,O
with,O
no,O
labeled,O
data,O
.,O
For,O
simplicity,O
we,O
also,O
use,O
the,O
same,O
set,O
of,O
features,O
across,O
all,O
tasks,O
(,O
protein,O
sequence,O
features,O
).,O
However,O
the,O
data,O
distribution,O
will,O
be,O
different,O
across,O
tasks,O
due,O
to,O
the,O
different,O
organisms,O
involved,O
.,O
This,O
approach,O
is,O
based,O
on,O
instance,O
-,O
transfer,O
where,O
the,O
goal,O
is,O
to,O
pick,O
from,O
each,O
of,O
the,O
source,O
tasks,O
",",O
the,O
most,O
relevant,O
instances,O
w,O
.,O
r,O
.,O
t,O
the,O
target,O
task,O
.,O
We,O
use,O
a,O
two,O
-,O
step,O
process,O
:,O
(,O
1,O
),O
the,O
first,O
step,O
does,O
the,O
instance,O
weighting,O
on,O
the,O
source,O
tasks,O
.,O
(,O
2,O
),O
the,O
second,O
step,O
uses,O
the,O
reweighted,O
instance,O
to,O
build,O
several,O
SVM,O
classifier,O
models,O
—,O
one,O
model,O
for,O
each,O
hyper,O
-,O
parameter,O
setting,O
.,O
To,O
deal,O
with,O
the,O
second,O
challenge,O
",",O
we,O
present,O
two,O
heuristic,O
methods,O
to,O
select,O
the,O
best,O
set,O
of,O
hyperparameters,O
.,O
3,O
.,O
3,O
.,O
1,O
.,O
Step,O
-,O
1,O
:,O
instance,O
reweighting,O
The,O
similarity,O
between,O
the,O
source,O
and,O
target,O
data,O
can,O
be,O
expressed,O
using,O
the,O
similarity,O
in,O
their,O
distributions,O
PS,O
(,O
x,O
",",O
y,O
),O
and,O
Pt,O
(,O
x,O
",",O
y,O
).,O
Here,O
PS,O
represents,O
the,O
joint,O
distribution,O
of,O
all,O
source,O
tasks,O
.,O
Since,O
we,O
do,O
not,O
have,O
access,O
to,O
the,O
labels,O
y,O
on,O
the,O
target,O
",",O
we,O
make,O
a,O
simplifying,O
assumption,O
that,O
there,O
is,O
only,O
a,O
covariate,O
shift,O
between,O
the,O
source,O
and,O
target,O
tasks,O
—,O
i,O
.,O
e,O
".,",O
the,O
conditional,O
distribution,O
P,O
(,O
y,O
|,O
x,O
),O
is,O
the,O
same,O
for,O
both,O
tasks,O
.,O
Mathematically,O
",",O
PS,O
(,O
x,O
",",O
y,O
),O
Pt,O
(,O
x,O
",",O
y,O
)=,O
PS,O
(,O
x,O
),O
Pt,O
(,O
x,O
)=,O
r,O
(,O
x,O
).,O
Many,O
methods,O
have,O
been,O
proposed,O
for,O
estimating,O
the,O
ratio,O
r,O
.,O
Sugiyama,O
et,O
al,O
.,O
(,O
2008,O
),O
proposed,O
an,O
algorithm,O
Kullback,O
-,O
Leibler,O
Importance,O
Estimation,O
Procedure,O
(,O
KLIEP,O
),O
to,O
estimate,O
r,O
directly,O
without,O
estimating,O
the,O
densities,O
of,O
the,O
two,O
distributions,O
.,O
We,O
use,O
the,O
nonparametric,O
Kernel,O
Mean,O
Matching,O
(,O
KMM,O
),O
(,O
Huang,O
et,O
al,O
".,",O
2007,O
"),",O
which,O
was,O
originally,O
developed,O
to,O
handle,O
the,O
problem,O
of,O
covariate,O
shift,O
between,O
the,O
training,O
and,O
test,O
data,O
distributions,O
.,O
KMM,O
reweighs,O
the,O
training,O
data,O
instances,O
such,O
that,O
the,O
means,O
of,O
the,O
training,O
and,O
test,O
data,O
distributions,O
are,O
close,O
in,O
a,O
reproducing,O
kernel,O
Hilbert,O
space,O
(,O
RKHS,O
).,O
This,O
approach,O
does,O
not,O
require,O
distribution,O
estimation,O
.,O
Let,O
xSi,O
~,O
PS,O
and,O
nS,O
be,O
the,O
number,O
of,O
source,O
instances,O
from,O
all,O
source,O
tasks,O
.,O
Let,O
xti,O
~,O
Pt,O
and,O
nt,O
be,O
the,O
number,O
of,O
target,O
instances,O
.,O
Let,O
βi,O
represent,O
the,O
“,O
importance,O
”,O
of,O
the,O
source,O
instances,O
.,O
KMM,O
uses,O
a,O
function,O
based,O
on,O
the,O
maximum,O
mean,O
discrepancy,O
statistic,O
(,O
MMD,O
).,O
In,O
the,O
form,O
written,O
below,O
",",O
it,O
minimizes,O
the,O
difference,O
between,O
the,O
empirical,O
means,O
of,O
the,O
joint,O
source,O
and,O
target,O
distributions,O
.,O
K,O
is,O
the,O
kernel,O
matrix,O
over,O
all,O
the,O
source,O
examples,O
.,O
The,O
function,O
(,O
1,O
),O
is,O
a,O
quadratic,O
program,O
and,O
can,O
be,O
efficiently,O
solved,O
using,O
sequential,O
minimal,O
optimization,O
(,O
SMO,O
"),",O
projected,O
gradient,O
based,O
methods,O
.,O
We,O
use,O
the,O
KMM,O
implementation,O
from,O
the,O
Shogun,O
(,O
Sonnenburg,O
et,O
al,O
".,",O
2010,O
),O
package,O
.,O
3,O
.,O
3,O
.,O
1,O
.,O
1,O
.,O
Selecting,O
an,O
appropriate,O
set,O
of,O
source,O
and,O
target,O
instances,O
.,O
Using,O
all,O
instances,O
in,O
the,O
optimization,O
problem,O
in,O
equation,O
(,O
1,O
),O
is,O
infeasible,O
for,O
two,O
reasons,O
.,O
The,O
optimization,O
involves,O
the,O
computation,O
of,O
the,O
gram,O
matrix,O
K,O
of,O
O,O
(,O
n2,O
),O
where,O
n,O
is,O
the,O
number,O
of,O
instances,O
.,O
Typically,O
the,O
total,O
number,O
of,O
protein,O
-,O
protein,O
pairs,O
between,O
a,O
host,O
-,O
pathogen,O
are,O
of,O
the,O
order,O
of,O
100,O
million,O
.,O
Secondly,O
",",O
the,O
total,O
number,O
of,O
labeled,O
source,O
instances,O
is,O
quite,O
small,O
(≈,O
1500,O
).,O
This,O
set,O
is,O
likely,O
to,O
get,O
underweighted,O
(,O
i,O
.,O
e,O
".,",O
βi,O
≈,O
0,O
),O
if,O
there,O
are,O
too,O
many,O
unlabeled,O
source,O
instances,O
.,O
To,O
represent,O
the,O
source,O
',O
s,O
empirical,O
mean,O
",",O
in,O
addition,O
to,O
the,O
labeled,O
instances,O
we,O
randomly,O
sample,O
four,O
times,O
as,O
many,O
unlabeled,O
instances,O
.,O
For,O
the,O
target,O
",",O
we,O
randomly,O
sampled,O
nS,O
instances,O
.,O
3,O
.,O
3,O
.,O
2,O
.,O
Step,O
-,O
2,O
:,O
model,O
learning,O
Once,O
we,O
have,O
the,O
optimal,O
set,O
of,O
source,O
instances,O
",",O
we,O
can,O
train,O
a,O
Kernel,O
-,O
SVM,O
model,O
using,O
these,O
.,O
Along,O
with,O
the,O
first,O
step,O
",",O
we,O
thus,O
call,O
this,O
two,O
step,O
process,O
KMM,O
-,O
SVM,O
.,O
We,O
pick,O
a,O
kernel,O
-,O
based,O
learning,O
algorithm,O
since,O
we,O
plan,O
to,O
extend,O
our,O
work,O
to,O
deal,O
with,O
different,O
feature,O
spaces,O
across,O
the,O
tasks,O
.,O
In,O
such,O
a,O
scenario,O
",",O
the,O
only,O
mechanism,O
to,O
operate,O
on,O
the,O
target,O
data,O
is,O
via,O
similarities,O
",",O
i,O
.,O
e,O
".,",O
the,O
kernel,O
.,O
The,O
dual,O
formulation,O
for,O
the,O
weighted,O
version,O
of,O
SVM,O
solves,O
the,O
following,O
problem,O
",",O
where,O
the,O
weights,O
βi,O
were,O
obtained,O
in,O
Step,O
-,O
1,O
.,O
3,O
.,O
3,O
.,O
3,O
.,O
Model,O
selection,O
Parameter,O
tuning,O
and,O
selecting,O
the,O
best,O
model,O
in,O
the,O
absence,O
of,O
labeled,O
data,O
is,O
a,O
very,O
hard,O
problem,O
.,O
The,O
model,O
built,O
on,O
the,O
source,O
data,O
cannot,O
be,O
tuned,O
using,O
cross,O
validation,O
on,O
the,O
source,O
data,O
because,O
doing,O
so,O
will,O
optimize,O
it,O
for,O
the,O
source,O
distribution,O
.,O
Hence,O
we,O
developed,O
two,O
heuristic,O
approaches,O
to,O
select,O
the,O
best,O
hyperparameters,O
.,O
The,O
first,O
one,O
uses,O
the,O
expected,O
class,O
-,O
skew,O
on,O
the,O
target,O
task,O
while,O
the,O
second,O
uses,O
reweighted,O
cross,O
-,O
validation,O
.,O
Class,O
-,O
skew,O
based,O
parameter,O
selection,O
:,O
We,O
first,O
built,O
several,O
models,O
by,O
doing,O
a,O
grid,O
-,O
search,O
on,O
the,O
classifier,O
hyper,O
-,O
parameters,O
.,O
There,O
are,O
3,O
parameters,O
to,O
tune,O
for,O
the,O
Kernel,O
-,O
SVM,O
:,O
the,O
kernel,O
width,O
γ,O
",",O
the,O
cost,O
parameter,O
C,O
",",O
the,O
weight,O
parameter,O
for,O
the,O
positive,O
class,O
w,O
+.,O
The,O
total,O
number,O
of,O
parameter,O
combinations,O
in,O
our,O
grid,O
-,O
search,O
were,O
50,O
.,O
We,O
thus,O
had,O
50,O
models,O
trained,O
on,O
the,O
reweighted,O
source,O
data,O
obtained,O
after,O
KMM,O
in,O
Step,O
-,O
1,O
(,O
Section,O
3,O
.,O
3,O
.,O
1,O
).,O
We,O
applied,O
each,O
model,O
on,O
the,O
target,O
data,O
and,O
computed,O
the,O
predicted,O
class,O
-,O
skew,O
rpred,O
using,O
the,O
predicted,O
class,O
labels,O
.,O
The,O
expected,O
class,O
skew,O
based,O
on,O
our,O
understanding,O
of,O
the,O
PPI,O
experimental,O
literature,O
is,O
roughly,O
1,O
:,O
100,O
(=,O
rtrue,O
).,O
We,O
ranked,O
all,O
50,O
models,O
on,O
the,O
statistic,O
|,O
rpred,O
−,O
rtrue,O
|.,O
The,O
top,O
k,O
models,O
were,O
selected,O
based,O
on,O
this,O
criteria,O
and,O
a,O
weighted,O
voting,O
ensemble,O
was,O
built,O
using,O
them,O
.,O
This,O
ensemble,O
was,O
used,O
to,O
get,O
the,O
final,O
class,O
label,O
on,O
the,O
target,O
data,O
.,O
We,O
used,O
k,O
=,O
5,O
.,O
Aggregating,O
the,O
models,O
and,O
assigning,O
interaction,O
scores,O
:,O
In,O
our,O
experiments,O
",",O
we,O
used,O
k,O
=,O
5,O
to,O
pick,O
the,O
best,O
models,O
w,O
.,O
r,O
.,O
t,O
the,O
ranking,O
statistic,O
described,O
above,O
.,O
Note,O
that,O
each,O
model,O
gives,O
us,O
a,O
classifier,O
score,O
for,O
every,O
protein,O
-,O
pair,O
in,O
the,O
test,O
data,O
",",O
which,O
can,O
be,O
considered,O
to,O
be,O
the,O
probability,O
of,O
interaction,O
.,O
For,O
k,O
=,O
5,O
",",O
we,O
have,O
five,O
scores,O
for,O
each,O
test,O
protein,O
-,O
pair,O
.,O
These,O
scores,O
were,O
aggregated,O
using,O
two,O
criteria,O
:,O
The,O
majority,O
vote,O
over,O
the,O
five,O
models,O
where,O
each,O
model,O
votes,O
“,O
yes,O
”,O
if,O
the,O
output,O
probability,O
score,O
is,O
greater,O
than,O
or,O
equal,O
to,O
0,O
.,O
5,O
.,O
The,O
averaged,O
of,O
all,O
five,O
probability,O
scores,O
.,O
3,O
.,O
3,O
.,O
4,O
.,O
Spectrum,O
RBF,O
kernel,O
We,O
used,O
a,O
variant,O
of,O
the,O
spectrum,O
kernel,O
",",O
based,O
on,O
the,O
features,O
used,O
by,O
Dyer,O
et,O
al,O
.,O
(,O
2007,O
),O
for,O
HIV,B-OG
-,O
human,B-OG
PPI,O
prediction,O
.,O
The,O
kernel,O
uses,O
the,O
n,O
-,O
mers,O
of,O
a,O
given,O
input,O
sequence,O
and,O
is,O
defined,O
as,O
:,O
kspn,O
(,O
x,O
",",O
x,O
′)=,O
exp,O
{−‖,O
ϕspn,O
(,O
x,O
)−,O
ϕspn,O
(,O
x,O
′)‖,O
2σ2,O
"},",O
where,O
x,O
",",O
x,O
′,O
are,O
two,O
sequences,O
over,O
an,O
alphabet,O
Σ,O
.,O
Instead,O
of,O
using,O
the,O
20,O
amino,O
acids,O
as,O
the,O
alphabet,O
Σ,O
",",O
we,O
used,O
a,O
classification,O
of,O
the,O
amino,O
-,O
acids,O
.,O
There,O
are,O
seven,O
classes,O
based,O
on,O
the,O
electrostatic,O
and,O
hydrophobic,O
properties,O
of,O
proteins,O
",",O
i,O
.,O
e,O
".,",O
|,O
Σ,O
|,O
=,O
7,O
.,O
Here,O
ϕnsp,O
transforms,O
a,O
sequence,O
s,O
into,O
a,O
|,O
Σ,O
|,O
n,O
-,O
dimensional,O
feature,O
-,O
space,O
.,O
One,O
dimension,O
of,O
ϕnsp,O
corresponds,O
to,O
the,O
normalized,O
frequency,O
of,O
one,O
of,O
the,O
7n,O
possible,O
strings,O
in,O
s,O
.,O
We,O
use,O
n,O
=,O
2,O
",",O
3,O
",",O
4,O
",",O
5,O
.,O
4,O
.,O
Negative,O
examples,O
and,O
feature,O
-,O
set,O
Classification,O
techniques,O
need,O
a,O
negative,O
class,O
(,O
set,O
of,O
non,O
-,O
interactions,O
),O
in,O
order,O
to,O
identify,O
the,O
special,O
characteristics,O
of,O
the,O
positives,O
(,O
i,O
.,O
e,O
".,",O
interactions,O
).,O
Since,O
there,O
is,O
no,O
published,O
experimental,O
evidence,O
about,O
“,O
non,O
-,O
interacting,O
”,O
host,O
-,O
pathogen,O
proteins,O
for,O
any,O
plant,B-OG
with,O
Salmonella,B-OG
",",O
we,O
construct,O
the,O
negative,O
class,O
using,O
random,O
pairs,O
of,O
proteins,O
sampled,O
from,O
the,O
set,O
of,O
all,O
possible,O
host,O
-,O
pathogen,O
protein,O
pairs,O
.,O
The,O
number,O
of,O
random,O
pairs,O
chosen,O
as,O
the,O
negative,O
class,O
is,O
decided,O
by,O
what,O
we,O
expect,O
the,O
interaction,O
ratio,O
to,O
be,O
.,O
It,O
is,O
a,O
parameter,O
that,O
can,O
be,O
changed,O
as,O
our,O
knowledge,O
of,O
the,O
size,O
and,O
nature,O
of,O
the,O
host,O
-,O
pathogen,O
interactome,O
improves,O
.,O
The,O
interaction,O
ratio,O
/,O
negative,O
examples,O
are,O
used,O
in,O
different,O
ways,O
as,O
described,O
below,O
.,O
The,O
homology,O
-,O
based,O
transfer,O
method,O
does,O
not,O
directly,O
use,O
any,O
negative,O
examples,O
/,O
interaction,O
ratios,O
.,O
In,O
the,O
case,O
of,O
T,O
-,O
SVM,O
",",O
while,O
training,O
the,O
transductive,O
model,O
",",O
we,O
use,O
negative,O
examples,O
from,O
the,O
source,O
task,O
.,O
In,O
the,O
case,O
of,O
KMM,O
-,O
SVM,O
",",O
the,O
data,O
used,O
to,O
build,O
the,O
model,O
comes,O
from,O
the,O
source,O
tasks,O
",",O
where,O
negative,O
examples,O
from,O
each,O
source,O
task,O
are,O
used,O
.,O
Next,O
",",O
during,O
the,O
model,O
selection,O
phase,O
we,O
pick,O
the,O
best,O
models,O
based,O
on,O
the,O
interaction,O
ratio,O
of,O
the,O
model,O
over,O
the,O
predictions,O
on,O
the,O
target,O
task,O
(,O
See,O
Section,O
3,O
.,O
3,O
.,O
3,O
for,O
details,O
).,O
No,O
explicit,O
negative,O
examples,O
are,O
used,O
in,O
this,O
part,O
;,O
the,O
interaction,O
ratio,O
is,O
simply,O
used,O
to,O
pick,O
the,O
best,O
model,O
.,O
We,O
initially,O
chose,O
a,O
positive,O
:,O
negative,O
class,O
ratio,O
of,O
1,O
:,O
100,O
meaning,O
that,O
we,O
expect,O
1,O
in,O
every,O
100,O
random,O
bacteria,B-OG
-,O
human,B-OG
protein,O
pairs,O
to,O
interact,O
with,O
each,O
other,O
.,O
This,O
has,O
been,O
a,O
common,O
practice,O
in,O
host,O
-,O
pathogen,O
PPI,O
prediction,O
in,O
the,O
past,O
(,O
Dyer,O
et,O
al,O
".,",O
2007,O
;,O
Tastan,O
et,O
al,O
".,",O
2009,O
).,O
Recently,O
published,O
work,O
(,O
Mukhtar,O
et,O
al,O
".,",O
2011,O
),O
involving,O
a,O
yeast,B-OG
-,O
2,O
-,O
hybrid,O
study,O
on,O
plant,B-OG
-,O
bacterial,O
PPIs,O
suggests,O
a,O
higher,O
interaction,O
ratio,O
of,O
around,O
1,O
:,O
1000,O
.,O
Our,O
choice,O
of,O
1,O
:,O
100,O
as,O
the,O
class,O
-,O
skew,O
is,O
an,O
overestimate,O
when,O
considering,O
interactions,O
with,O
all,O
Salmonella,B-OG
genes,O
",",O
but,O
if,O
we,O
restrict,O
the,O
binding,O
partners,O
to,O
only,O
the,O
so,O
-,O
called,O
Salmonella,B-OG
effector,O
proteins,O
",",O
the,O
ratio,O
we,O
use,O
is,O
reasonable,O
.,O
(,O
There,O
are,O
≈,O
85,O
known,O
Salmonella,B-OG
effector,O
genes,O
).,O
Also,O
note,O
that,O
",",O
while,O
the,O
exact,O
examples,O
that,O
we,O
choose,O
as,O
negative,O
data,O
may,O
not,O
be,O
true,O
negatives,O
",",O
we,O
expect,O
the,O
false,O
negative,O
rate,O
to,O
be,O
low,O
enough,O
(≈,O
1,O
%),O
to,O
justify,O
our,O
choice,O
of,O
this,O
heuristic,O
.,O
The,O
class,O
skew,O
is,O
an,O
important,O
parameter,O
in,O
any,O
machine,O
learning,O
method,O
.,O
The,O
choice,O
of,O
this,O
parameter,O
determines,O
the,O
properties,O
of,O
the,O
resultant,O
model,O
.,O
A,O
very,O
balanced,O
class,O
skew,O
of,O
1,O
:,O
1,O
will,O
result,O
in,O
a,O
model,O
that,O
is,O
over,O
-,O
predictive,O
i,O
.,O
e,O
".,",O
has,O
a,O
very,O
high,O
false,O
positive,O
rate,O
when,O
applied,O
on,O
the,O
target,O
task,O
.,O
On,O
the,O
other,O
hand,O
",",O
a,O
very,O
skewed,O
setting,O
of,O
1,O
:,O
1000,O
could,O
give,O
a,O
lower,O
false,O
positive,O
rate,O
but,O
is,O
likely,O
to,O
have,O
a,O
poor,O
recall,O
as,O
compared,O
to,O
models,O
with,O
lower,O
class,O
skews,O
.,O
This,O
parameter,O
thus,O
offers,O
a,O
trade,O
-,O
off,O
between,O
the,O
precision,O
and,O
recall,O
of,O
the,O
resultant,O
model,O
.,O
Our,O
choice,O
of,O
a,O
class,O
ratio,O
of,O
1,O
:,O
100,O
will,O
result,O
in,O
a,O
higher,O
recall,O
as,O
compared,O
to,O
models,O
trained,O
on,O
higher,O
class,O
skews,O
.,O
It,O
will,O
however,O
",",O
have,O
some,O
false,O
positives,O
.,O
From,O
a,O
statistical,O
perspective,O
",",O
a,O
model,O
trained,O
with,O
a,O
high,O
class,O
skew,O
such,O
as,O
1,O
:,O
1000,O
will,O
capture,O
the,O
distribution,O
of,O
the,O
negatives,O
since,O
they,O
hugely,O
outnumber,O
the,O
positives,O
.,O
Since,O
the,O
negative,O
class,O
examples,O
are,O
not,O
true,O
negatives,O
",",O
the,O
goodness,O
of,O
a,O
model,O
which,O
depends,O
mostly,O
on,O
noisy,O
negatives,O
is,O
debatable,O
.,O
Computationally,O
",",O
the,O
time,O
required,O
for,O
training,O
a,O
model,O
increases,O
as,O
we,O
increase,O
the,O
number,O
of,O
examples,O
.,O
In,O
the,O
case,O
of,O
a,O
high,O
class,O
skew,O
such,O
as,O
1,O
:,O
1000,O
",",O
there,O
will,O
be,O
thousand,O
times,O
as,O
many,O
examples,O
as,O
the,O
number,O
of,O
positives,O
.,O
This,O
makes,O
training,O
a,O
model,O
very,O
slow,O
",",O
especially,O
for,O
the,O
Kernel,O
-,O
SVM,O
algorithm,O
and,O
Transductive,O
SVM,O
models,O
that,O
are,O
used,O
by,O
our,O
methods,O
.,O
Nonetheless,O
",",O
we,O
also,O
calculated,O
the,O
predictions,O
for,O
a,O
higher,O
skew,O
of,O
1,O
:,O
500,O
.,O
The,O
results,O
are,O
described,O
in,O
Section,O
5,O
.,O
The,O
features,O
used,O
in,O
each,O
approach,O
are,O
shown,O
in,O
Table,O
1,O
.,O
A,O
detailed,O
description,O
of,O
each,O
feature,O
and,O
the,O
biological,O
significance,O
of,O
it,O
follows,O
.,O
We,O
derive,O
protein,O
sequence,O
based,O
features,O
similar,O
to,O
the,O
ones,O
derived,O
by,O
Dyer,O
et,O
al,O
.,O
(,O
2011,O
),O
for,O
HIV,B-OG
-,O
human,B-OG
PPI,O
prediction,O
.,O
Protein,O
sequence,O
n,O
-,O
mer,O
or,O
n,O
-,O
gram,O
features,O
:,O
Since,O
the,O
sequence,O
of,O
a,O
protein,O
determines,O
its,O
function,O
to,O
a,O
great,O
extent,O
",",O
it,O
may,O
be,O
possible,O
to,O
predict,O
PPIs,O
using,O
the,O
amino,O
acid,O
sequence,O
of,O
a,O
protein,O
pair,O
.,O
Shen,O
et,O
al,O
.,O
(,O
2007,O
),O
introduced,O
the,O
“,O
conjoint,O
triad,O
model,O
”,O
for,O
predicting,O
PPIs,O
using,O
only,O
amino,O
acid,O
sequences,O
.,O
Shen,O
et,O
al,O
.,O
(,O
2007,O
),O
partitioned,O
the,O
twenty,O
amino,O
acids,O
into,O
seven,O
classes,O
based,O
on,O
their,O
electrostatic,O
and,O
hydrophobic,O
properties,O
.,O
For,O
each,O
protein,O
",",O
they,O
counted,O
the,O
number,O
of,O
times,O
each,O
distinct,O
three,O
-,O
mer,O
(,O
set,O
of,O
three,O
consecutive,O
amino,O
acids,O
),O
occurred,O
in,O
the,O
sequence,O
.,O
To,O
account,O
for,O
protein,O
size,O
",",O
they,O
normalized,O
these,O
counts,O
by,O
linearly,O
transforming,O
them,O
to,O
lie,O
between,O
0,O
and,O
1,O
(,O
see,O
Shen,O
et,O
al,O
.,O
(,O
2007,O
),O
for,O
details,O
).,O
They,O
represented,O
the,O
protein,O
with,O
a,O
343,O
-,O
element,O
feature,O
vector,O
",",O
where,O
the,O
value,O
of,O
each,O
feature,O
is,O
the,O
normalized,O
count,O
for,O
each,O
of,O
the,O
343,O
(,O
73,O
),O
possible,O
amino,O
acid,O
three,O
-,O
mers,O
.,O
We,O
use,O
two,O
"-,",O
three,O
"-,",O
four,O
"-,",O
and,O
five,O
-,O
mers,O
.,O
For,O
each,O
host,O
-,O
pathogen,O
protein,O
pair,O
",",O
we,O
concatenated,O
the,O
feature,O
vectors,O
of,O
the,O
individual,O
proteins,O
.,O
Therefore,O
",",O
each,O
host,O
-,O
pathogen,O
protein,O
pair,O
had,O
a,O
feature,O
vector,O
of,O
length,O
at,O
most,O
98,O
",",O
646,O
",",O
4802,O
",",O
and,O
33614,O
",",O
in,O
the,O
cases,O
of,O
two,O
"-,",O
three,O
"-,",O
four,O
"-,",O
and,O
five,O
-,O
mers,O
",",O
respectively,O
.,O
Gene,O
expression,O
features,O
:,O
These,O
features,O
depend,O
only,O
on,O
the,O
human,B-OG
protein,O
(,O
gene,O
),O
involved,O
in,O
a,O
human,B-OG
-,O
Salmonella,B-OG
protein,O
pair,O
.,O
We,O
selected,O
3,O
transcriptomic,O
datasets,O
from,O
GEO,O
(,O
Barrett,O
et,O
al,O
".,",O
2011,O
"),",O
which,O
give,O
the,O
differential,O
gene,O
expression,O
of,O
human,B-OG
genes,O
infected,O
by,O
Salmonella,B-OG
.,O
The,O
3,O
datasets,O
(,O
GDS77,O
",",O
GDS78,O
",",O
GDS80,O
),O
give,O
us,O
a,O
total,O
of,O
7,O
features,O
representing,O
differential,O
gene,O
expression,O
of,O
human,B-OG
genes,O
in,O
7,O
different,O
control,O
conditions,O
.,O
The,O
intuition,O
behind,O
this,O
feature,O
is,O
that,O
genes,O
that,O
are,O
significantly,O
differentially,O
regulated,O
are,O
more,O
likely,O
to,O
be,O
involved,O
in,O
the,O
infection,B-DS
process,O
",",O
and,O
thereby,O
in,O
interactions,O
with,O
bacterial,O
proteins,O
.,O
Note,O
:,O
these,O
were,O
used,O
in,O
only,O
the,O
human,B-OG
-,O
Salmonella,B-OG
task,O
.,O
GO,O
similarity,O
features,O
:,O
These,O
features,O
model,O
the,O
similarity,O
between,O
the,O
functional,O
properties,O
of,O
two,O
proteins,O
.,O
These,O
were,O
used,O
in,O
only,O
the,O
human,B-OG
-,O
Salmonella,B-OG
task,O
.,O
Gene,O
Ontology,O
(,O
Ashburner,O
et,O
al,O
".,",O
2000,O
),O
provides,O
GO,O
-,O
term,O
annotations,O
for,O
three,O
important,O
protein,O
properties,O
:,O
molecular,O
function,O
(,O
F,O
"),",O
cellular,O
component,O
(,O
C,O
),O
and,O
biological,O
process,O
(,O
P,O
).,O
We,O
derive,O
6,O
types,O
of,O
features,O
using,O
these,O
properties,O
.,O
For,O
each,O
of,O
“,O
F,O
",”",O
“,O
C,O
",”",O
and,O
“,O
P,O
",”",O
two,O
types,O
of,O
GO,O
similarity,O
features,O
were,O
defined,O
:,O
(,O
a,O
),O
pair,O
-,O
level,O
similarity,O
and,O
(,O
b,O
),O
similarity,O
with,O
human,B-OG
protein,O
',O
s,O
binding,O
partners,O
.,O
The,O
similarity,O
between,O
two,O
individual,O
GO,O
terms,O
was,O
computed,O
using,O
the,O
G,O
-,O
Sesame,O
algorithm,O
(,O
Du,O
et,O
al,O
".,",O
2009,O
).,O
This,O
feature,O
is,O
a,O
matrix,O
of,O
all,O
the,O
GO,O
term,O
combinations,O
found,O
in,O
a,O
given,O
protein,O
pair,O
:,O
<,O
ps,O
",",O
ph,O
">,",O
the,O
rows,O
of,O
the,O
matrix,O
represent,O
GO,O
terms,O
from,O
protein,O
ps,O
and,O
the,O
columns,O
represent,O
GO,O
terms,O
from,O
ph,O
.,O
Analogously,O
",",O
the,O
second,O
feature,O
type,O
-(,O
b,O
),O
computes,O
the,O
similarity,O
between,O
the,O
GO,O
term,O
sets,O
of,O
the,O
Salmonella,B-OG
protein,O
and,O
the,O
human,B-OG
protein,O
',O
s,O
binding,O
partners,O
in,O
the,O
human,B-OG
interactome,O
.,O
We,O
used,O
HPRD,O
to,O
get,O
the,O
human,B-OG
interactome,O
.,O
Code,O
:,O
The,O
executable,O
files,O
from,O
the,O
packages,O
used,O
to,O
build,O
our,O
methods,O
",",O
and,O
the,O
scripts,O
that,O
we,O
used,O
to,O
run,O
these,O
can,O
be,O
downloaded,O
here,O
:,O
http,O
://,O
www,O
.,O
cs,O
.,O
cmu,O
.,O
edu,O
/~,O
mkshirsa,O
/,O
data,O
/,O
frontiers2014,O
/,O
code,O
.,O
zip,O
.,O
5,O
.,O
Results,O
and,O
discussion,O
A,O
quantitative,O
evaluation,O
on,O
the,O
target,O
task,O
i,O
.,O
e,O
".,",O
plant,B-OG
-,O
Salmonella,B-OG
is,O
currently,O
not,O
feasible,O
as,O
there,O
is,O
no,O
known,O
PPI,O
data,O
.,O
Hence,O
for,O
the,O
purpose,O
of,O
evaluation,O
",",O
we,O
used,O
some,O
of,O
the,O
PPI,O
datasets,O
as,O
“,O
sources,O
”,O
for,O
building,O
a,O
model,O
and,O
one,O
as,O
the,O
“,O
target,O
.”,O
We,O
evaluate,O
the,O
machine,O
-,O
learning,O
based,O
methods,O
in,O
two,O
settings,O
of,O
transfer,O
:,O
pathogen,O
-,O
level,O
transfer,O
",",O
where,O
the,O
host,O
is,O
fixed,O
to,O
be,O
human,B-OG
and,O
the,O
pathogen,O
is,O
one,O
of,O
various,O
bacterial,O
species,O
.,O
The,O
second,O
setting,O
host,O
-,O
level,O
transfer,O
",",O
is,O
more,O
relevant,O
and,O
refers,O
to,O
the,O
case,O
where,O
the,O
pathogen,O
is,O
fixed,O
to,O
be,O
Salmonella,B-OG
and,O
we,O
modify,O
the,O
host,O
species,O
.,O
Since,O
there,O
are,O
few,O
known,O
PPIs,O
involving,O
Salmonella,B-OG
",",O
we,O
are,O
only,O
able,O
to,O
experiment,O
with,O
mouse,B-OG
as,O
an,O
alternate,O
host,O
.,O
There,O
are,O
14,O
known,O
mouse,B-OG
-,O
Salmonella,B-OG
PPIs,O
.,O
Interestingly,O
they,O
involve,O
mouse,B-OG
proteins,O
whose,O
human,B-OG
homologs,O
also,O
interact,O
with,O
the,O
same,O
Salmonella,B-OG
proteins,O
—,O
i,O
.,O
e,O
".,",O
these,O
14,O
PPIs,O
have,O
interologs,O
in,O
the,O
human,B-OG
-,O
Salmonella,B-OG
dataset,O
.,O
Our,O
evaluation,O
criteria,O
does,O
not,O
use,O
accuracy,O
(,O
which,O
measures,O
performance,O
on,O
both,O
the,O
positives,O
and,O
negatives,O
).,O
Our,O
PPI,O
datasets,O
are,O
highly,O
imbalanced,O
with,O
a,O
large,O
number,O
of,O
negative,O
samples,O
",",O
and,O
a,O
trivial,O
classifier,O
that,O
calls,O
all,O
protein,O
pairs,O
as,O
“,O
negative,O
”,O
will,O
achieve,O
a,O
very,O
good,O
performance,O
.,O
So,O
we,O
instead,O
use,O
precision,O
(,O
P,O
"),",O
recall,O
(,O
R,O
),O
and,O
F,O
-,O
score,O
(,O
F1,O
),O
computed,O
on,O
the,O
interacting,O
pairs,O
(,O
positive,O
class,O
).,O
The,O
source,O
tasks,O
(,O
i,O
.,O
e,O
".,",O
training,O
data,O
),O
and,O
target,O
task,O
(,O
i,O
.,O
e,O
".,",O
test,O
datasets,O
),O
are,O
shown,O
in,O
the,O
Table,O
2,O
.,O
Parameters,O
for,O
all,O
methods,O
are,O
tuned,O
using,O
a,O
class,O
-,O
skew,O
based,O
model,O
selection,O
similar,O
to,O
the,O
one,O
described,O
in,O
Section,O
3,O
.,O
3,O
.,O
3,O
for,O
the,O
KMM,O
-,O
SVM,O
method,O
.,O
We,O
compare,O
the,O
following,O
machine,O
-,O
learning,O
based,O
methods,O
:,O
Inductive,O
Kernel,O
-,O
SVM,O
(,O
Baseline,O
):,O
This,O
model,O
assumes,O
that,O
the,O
source,O
and,O
target,O
distributions,O
are,O
identical,O
.,O
All,O
source,O
data,O
is,O
pooled,O
together,O
and,O
used,O
to,O
build,O
a,O
single,O
model,O
.,O
For,O
the,O
kernel,O
we,O
used,O
the,O
RBF,O
-,O
spectrum,O
kernel,O
.,O
Transductive,O
SVM,O
(,O
T,O
-,O
SVM,O
):,O
This,O
is,O
the,O
method,O
described,O
in,O
Section,O
3,O
.,O
2,O
.,O
KMM,O
-,O
SVM,O
:,O
This,O
method,O
is,O
discussed,O
in,O
Section,O
3,O
.,O
3,O
.,O
Performance,O
of,O
the,O
machine,O
learning,O
based,O
methods,O
on,O
various,O
transfer,O
settings,O
.,O
Source,O
task,O
(,O
s,O
),O
(,O
training,O
data,O
),O
Target,O
task,O
(,O
test,O
data,O
),O
Method,O
P,O
†,O
R,O
†,O
F1,O
†,O
HOST,O
-,O
LEVEL,O
TRANSFER,O
Salmonella,B-OG
-,O
human,B-OG
Salmonella,B-OG
-,O
mouse,B-OG
Baseline,O
42,O
.,O
8,O
93,O
.,O
7,O
58,O
.,O
8,O
T,O
-,O
SVM,O
45,O
.,O
4,O
93,O
.,O
7,O
61,O
.,O
2,O
KMM,O
-,O
SVM,O
51,O
.,O
7,O
93,O
.,O
7,O
66,O
.,O
7,O
Salmonella,B-OG
-,O
mouse,B-OG
Salmonella,B-OG
-,O
human,B-OG
Baseline,O
95,O
.,O
4,O
33,O
.,O
8,O
50,O
T,O
-,O
SVM,O
67,O
.,O
5,O
43,O
.,O
5,O
52,O
.,O
9,O
KMM,O
-,O
SVM,O
100,O
35,O
.,O
5,O
52,O
PATHOGEN,O
-,O
LEVEL,O
TRANSFER,O
Francisella,B-OG
-,O
human,B-OG
",",O
E,B-OG
.,I-OG
coli,I-OG
-,O
human,B-OG
Salmonella,B-OG
-,O
human,B-OG
Baseline,O
17,O
.,O
8,O
12,O
.,O
9,O
14,O
.,O
9,O
T,O
-,O
SVM,O
15,O
14,O
.,O
5,O
14,O
.,O
7,O
KMM,O
-,O
SVM,O
25,O
.,O
7,O
16,O
.,O
1,O
19,O
.,O
9,O
Francisella,B-OG
-,O
human,B-OG
",",O
Salmonella,B-OG
-,O
human,B-OG
E,B-OG
.,I-OG
coli,I-OG
-,O
human,B-OG
Baseline,O
12,O
.,O
9,O
12,O
.,O
5,O
12,O
.,O
7,O
T,O
-,O
SVM,O
10,O
.,O
4,O
15,O
.,O
6,O
12,O
.,O
5,O
KMM,O
-,O
SVM,O
15,O
.,O
9,O
21,O
.,O
9,O
18,O
.,O
4,O
We,O
compare,O
them,O
with,O
a,O
simple,O
baseline,O
:,O
inductive,O
kernel,O
-,O
SVM,O
.,O
We,O
report,O
precision,O
(,O
P,O
"),",O
recall,O
(,O
R,O
),O
and,O
f,O
-,O
score,O
(,O
F1,O
).,O
The,O
data,O
that,O
was,O
used,O
to,O
build,O
each,O
of,O
the,O
models,O
is,O
shown,O
in,O
the,O
first,O
column,O
.,O
The,O
second,O
column,O
shows,O
the,O
target,O
task,O
—,O
the,O
data,O
on,O
which,O
we,O
evaluate,O
the,O
model,O
.,O
The,O
numbers,O
in,O
bold,O
font,O
indicate,O
the,O
highest,O
performance,O
in,O
that,O
column,O
(,O
i,O
.,O
e,O
".,",O
for,O
that,O
metric,O
).,O
Computed,O
using,O
the,O
default,O
classifier,O
threshold,O
:,O
0,O
.,O
5,O
.,O
The,O
positive,O
:,O
negative,O
class,O
ratio,O
in,O
all,O
datasets,O
was,O
1,O
:,O
100,O
.,O
The,O
performance,O
of,O
a,O
random,O
classifier,O
would,O
be,O
F,O
-,O
score,O
=,O
1,O
.,O
The,O
host,O
-,O
level,O
transfer,O
performance,O
is,O
shown,O
in,O
the,O
first,O
two,O
rows,O
of,O
Table,O
2,O
.,O
The,O
KMM,O
-,O
SVM,O
based,O
method,O
performs,O
much,O
better,O
while,O
transferring,O
from,O
Salmonella,B-OG
-,O
human,B-OG
to,O
Salmonella,B-OG
-,O
mouse,B-OG
.,O
The,O
recall,O
is,O
very,O
high,O
at,O
93,O
.,O
7,O
since,O
the,O
mouse,B-OG
-,O
pathogen,O
PPIs,O
are,O
interologs,O
of,O
the,O
human,B-OG
-,O
pathogen,O
PPIs,O
.,O
The,O
precision,O
is,O
not,O
as,O
high,O
as,O
some,O
additional,O
positives,O
are,O
predicted,O
and,O
we,O
found,O
that,O
they,O
had,O
a,O
high,O
classifier,O
score,O
.,O
These,O
“,O
false,O
positives,O
”,O
are,O
likely,O
to,O
be,O
true,O
interactions,O
.,O
For,O
the,O
reverse,O
setting,O
",",O
T,O
-,O
SVM,O
does,O
slightly,O
better,O
than,O
the,O
KMM,O
-,O
SVM,O
and,O
2,O
points,O
higher,O
than,O
the,O
baseline,O
.,O
Note,O
that,O
here,O
",",O
the,O
source,O
data,O
is,O
very,O
small,O
in,O
size,O
with,O
only,O
14,O
PPIs,O
.,O
In,O
the,O
pathogen,O
-,O
level,O
transfer,O
",",O
on,O
the,O
Salmonella,B-OG
-,O
human,B-OG
target,O
task,O
",",O
the,O
F1,O
of,O
the,O
KMM,O
-,O
SVM,O
method,O
is,O
the,O
highest,O
at,O
19,O
.,O
9,O
and,O
is,O
5,O
points,O
better,O
than,O
the,O
other,O
two,O
methods,O
.,O
On,O
the,O
E,B-OG
.,I-OG
coli,I-OG
-,O
human,B-OG
task,O
",",O
the,O
performance,O
is,O
18,O
.,O
4,O
which,O
is,O
5,O
.,O
7,O
points,O
better,O
than,O
the,O
other,O
methods,O
.,O
A,O
very,O
interesting,O
observation,O
to,O
make,O
from,O
the,O
table,O
is,O
",",O
the,O
performance,O
on,O
the,O
target,O
task,O
:,O
Salmonella,B-OG
-,O
human,B-OG
in,O
the,O
two,O
settings,O
.,O
In,O
the,O
host,O
-,O
level,O
transfer,O
",",O
the,O
F1,O
is,O
52,O
whereas,O
in,O
the,O
pathogen,O
-,O
level,O
transfer,O
it,O
is,O
much,O
lower,O
at,O
19,O
.,O
9,O
.,O
The,O
hosts,O
human,B-OG
and,O
mouse,B-OG
are,O
much,O
more,O
similar,O
than,O
the,O
group,O
of,O
bacterial,O
species,O
namely,O
:,O
Salmonella,B-OG
",",O
E,B-OG
.,I-OG
coli,I-OG
and,O
F,B-OG
.,I-OG
tularensis,I-OG
.,O
The,O
source,O
tasks,O
are,O
indeed,O
very,O
critical,O
in,O
determining,O
the,O
performance,O
on,O
the,O
target,O
.,O
5,O
.,O
1,O
.,O
Analysis,O
We,O
apply,O
the,O
models,O
trained,O
using,O
the,O
procedures,O
from,O
previous,O
sections,O
on,O
Arabidopsis,B-OG
-,O
Salmonella,B-OG
protein,O
-,O
pairs,O
to,O
get,O
predictions,O
for,O
potential,O
interactions,O
.,O
The,O
homology,O
based,O
approach,O
does,O
not,O
assign,O
any,O
confidence,O
scores,O
to,O
the,O
predictions,O
while,O
both,O
T,O
-,O
SVM,O
and,O
KMM,O
-,O
SVM,O
allow,O
us,O
to,O
obtain,O
a,O
score,O
for,O
every,O
predicted,O
interaction,O
.,O
All,O
predictions,O
from,O
T,O
-,O
SVM,O
with,O
a,O
positive,O
score,O
(>,O
0,O
),O
are,O
considered,O
to,O
be,O
interacting,O
.,O
For,O
the,O
KMM,O
-,O
SVM,O
method,O
",",O
we,O
filter,O
the,O
predictions,O
using,O
a,O
threshold,O
of,O
0,O
.,O
7,O
on,O
the,O
averaged,O
probability,O
-,O
score,O
.,O
(,O
See,O
Section,O
3,O
.,O
3,O
.,O
3,O
for,O
details,O
on,O
the,O
probability,O
score,O
computation,O
for,O
the,O
KMM,O
-,O
SVM,O
method,O
).,O
We,O
chose,O
this,O
threshold,O
of,O
0,O
.,O
7,O
since,O
all,O
positives,O
in,O
our,O
training,O
data,O
are,O
assigned,O
a,O
score,O
≥,O
0,O
.,O
7,O
by,O
the,O
classifier,O
model,O
.,O
The,O
full,O
lists,O
of,O
predicted,O
interactions,O
from,O
all,O
three,O
approaches,O
are,O
available,O
at,O
the,O
following,O
link,O
:,O
http,O
://,O
www,O
.,O
cs,O
.,O
cmu,O
.,O
edu,O
/~,O
mkshirsa,O
/,O
data,O
/,O
frontiers2014,O
/,O
predictions,O
.,O
zip,O
.,O
The,O
total,O
number,O
of,O
PPI,O
predictions,O
based,O
on,O
the,O
score,O
thresholds,O
described,O
above,O
are,O
:,O
106,O
",",O
807,O
for,O
homology,O
-,O
based,O
",",O
1088,O
for,O
T,O
-,O
SVM,O
and,O
163,O
",",O
644,O
from,O
KMM,O
-,O
SVM,O
.,O
Hundreds,O
of,O
thousands,O
of,O
interacting,O
pairs,O
may,O
not,O
be,O
likely,O
and,O
we,O
therefore,O
expect,O
that,O
many,O
of,O
the,O
predictions,O
are,O
likely,O
to,O
be,O
false,O
positives,O
(,O
FPs,O
).,O
We,O
would,O
like,O
to,O
emphasize,O
that,O
",",O
by,O
ranking,O
the,O
predictions,O
on,O
the,O
classifier,O
scores,O
and,O
picking,O
only,O
the,O
top,O
few,O
we,O
are,O
likely,O
to,O
filter,O
out,O
most,O
of,O
the,O
false,O
positives,O
",",O
since,O
the,O
machine,O
learning,O
models,O
are,O
expected,O
to,O
score,O
FPs,O
lower,O
than,O
the,O
true,O
positives,O
.,O
The,O
threshold,O
of,O
0,O
.,O
7,O
for,O
KMM,O
-,O
SVM,O
was,O
chosen,O
just,O
to,O
ensure,O
consistency,O
with,O
the,O
threshold,O
that,O
we,O
observed,O
in,O
the,O
training,O
data,O
(,O
i,O
.,O
e,O
".,",O
in,O
the,O
known,O
interactions,O
).,O
If,O
one,O
considers,O
say,O
the,O
top,O
10,O
%,O
of,O
the,O
predictions,O
from,O
the,O
KMM,O
-,O
SVM,O
method,O
",",O
we,O
have,O
1636,O
PPIs,O
over,O
≈,O
1300,O
unique,O
Arabidopsis,B-OG
proteins,O
and,O
5,O
Salmonella,B-OG
proteins,O
.,O
Choosing,O
by,O
thresholding,O
the,O
prediction,O
score,O
is,O
one,O
way,O
to,O
select,O
potential,O
interactions,O
for,O
further,O
scrutiny,O
.,O
Another,O
approach,O
is,O
to,O
analyze,O
the,O
predictions,O
based,O
on,O
the,O
biological,O
functions,O
one,O
is,O
interested,O
in,O
.,O
To,O
demonstrate,O
the,O
type,O
of,O
biological,O
functions,O
that,O
are,O
represented,O
in,O
the,O
predictions,O
",",O
we,O
performed,O
GO,O
term,O
enrichment,O
analysis,O
of,O
the,O
Arabidopsis,B-OG
proteins,O
involved,O
in,O
the,O
predictions,O
.,O
We,O
can,O
then,O
look,O
at,O
Arabidopsis,B-OG
genes,O
with,O
the,O
most,O
enriched,O
GO,O
terms,O
and,O
what,O
their,O
predicted,O
Salmonella,B-OG
partners,O
are,O
.,O
A,O
Venn,O
diagram,O
depicting,O
the,O
overlap,O
between,O
the,O
predicted,O
pairs,O
of,O
proteins,O
interacting,O
according,O
to,O
the,O
three,O
approaches,O
is,O
shown,O
in,O
Figure,O
5,O
.,O
The,O
PPIs,O
reported,O
by,O
each,O
approach,O
are,O
quite,O
different,O
from,O
the,O
others,O
.,O
Only,O
189,O
are,O
shared,O
between,O
T,O
-,O
SVM,O
and,O
KMM,O
-,O
SVM,O
and,O
4305,O
between,O
the,O
homology,O
approach,O
and,O
KMM,O
-,O
SVM,O
.,O
No,O
overlap,O
was,O
found,O
between,O
the,O
homology,O
approach,O
and,O
the,O
T,O
-,O
SVM,O
approaches,O
.,O
These,O
relatively,O
small,O
overlaps,O
are,O
due,O
to,O
the,O
different,O
input,O
sources,O
(,O
tasks,O
),O
used,O
by,O
each,O
approach,O
.,O
Further,O
",",O
the,O
machine,O
-,O
learning,O
based,O
approaches,O
KMM,O
-,O
SVM,O
and,O
T,O
-,O
SVM,O
use,O
a,O
discriminative,O
model,O
which,O
employs,O
negative,O
examples,O
whereas,O
the,O
heuristics,O
based,O
approach,O
does,O
not,O
use,O
any,O
such,O
negative,O
data,O
and,O
hence,O
has,O
a,O
small,O
overlap,O
with,O
the,O
other,O
two,O
.,O
The,O
two,O
machine,O
-,O
learning,O
based,O
approaches,O
differ,O
due,O
to,O
the,O
use,O
of,O
different,O
kernels,O
.,O
The,O
KMM,O
-,O
SVM,O
approach,O
is,O
the,O
only,O
approach,O
that,O
shows,O
overlap,O
in,O
predictions,O
to,O
both,O
",",O
the,O
heuristics,O
and,O
the,O
T,O
-,O
SVM,O
approaches,O
",",O
and,O
the,O
results,O
are,O
therefore,O
discussed,O
in,O
detail,O
in,O
the,O
accompanying,O
paper,O
(,O
Schleker,O
et,O
al,O
".,",O
2015,O
).,O
Overlap,O
amongst,O
the,O
novel,O
PPI,O
predictions,O
from,O
each,O
approach,O
.,O
All,O
predictions,O
from,O
the,O
homology,O
based,O
approach,O
and,O
the,O
T,O
-,O
SVM,O
are,O
shown,O
.,O
For,O
the,O
KMM,O
-,O
SVM,O
method,O
",",O
we,O
filter,O
the,O
predictions,O
using,O
a,O
threshold,O
of,O
0,O
.,O
7,O
on,O
the,O
interaction,O
probability,O
reported,O
by,O
the,O
classifier,O
.,O
We,O
picked,O
this,O
threshold,O
based,O
on,O
the,O
interaction,O
probabilities,O
reported,O
on,O
the,O
known,O
interactions,O
.,O
Because,O
the,O
ratio,O
of,O
1,O
positive,O
to,O
100,O
negative,O
pairs,O
likely,O
overestimates,O
the,O
number,O
of,O
interactions,O
",",O
we,O
next,O
changed,O
this,O
ratio,O
to,O
1,O
:,O
500,O
and,O
generated,O
a,O
new,O
model,O
.,O
As,O
expected,O
",",O
a,O
much,O
smaller,O
number,O
of,O
pairs,O
are,O
predicted,O
namely,O
",",O
6035,O
.,O
This,O
is,O
a,O
more,O
manageable,O
list,O
and,O
the,O
predictions,O
of,O
the,O
new,O
model,O
are,O
provided,O
at,O
http,O
://,O
www,O
.,O
cs,O
.,O
cmu,O
.,O
edu,O
/~,O
mkshirsa,O
/,O
data,O
/,O
frontiers2014,O
/,O
predictions_class_skew_500,O
.,O
txt,O
.,O
5,O
.,O
2,O
.,O
Qualitative,O
analysis,O
of,O
predicted,O
interactions,O
As,O
with,O
any,O
predictions,O
",",O
experimental,O
validation,O
is,O
ultimately,O
needed,O
to,O
verify,O
them,O
.,O
The,O
choice,O
depends,O
on,O
the,O
interest,O
of,O
the,O
experimentalist,O
.,O
Here,O
we,O
have,O
chosen,O
for,O
discussion,O
a,O
few,O
predictions,O
that,O
are,O
interesting,O
to,O
us,O
",",O
but,O
we,O
encourage,O
the,O
reader,O
to,O
look,O
at,O
the,O
list,O
of,O
predictions,O
for,O
others,O
of,O
potential,O
biological,O
interest,O
.,O
We,O
calculated,O
Gene,O
Ontology,O
(,O
GO,O
),O
enrichment,O
in,O
the,O
Arabidopsis,B-OG
proteins,O
predicted,O
to,O
be,O
targeted,O
by,O
the,O
Salmonella,B-OG
proteins,O
.,O
We,O
are,O
interested,O
in,O
analyzing,O
the,O
characteristics,O
of,O
the,O
plant,B-OG
proteins,O
predicted,O
to,O
be,O
the,O
most,O
popular,O
targets,O
for,O
pathogenesis,O
.,O
We,O
defined,O
the,O
“,O
popular,O
targets,O
”,O
using,O
the,O
following,O
criteria,O
:,O
(,O
a,O
),O
the,O
Arabidopsis,B-OG
protein,O
is,O
predicted,O
to,O
be,O
targeted,O
by,O
at,O
least,O
3,O
Salmonella,B-OG
effectors,O
with,O
a,O
probability,O
greater,O
than,O
0,O
.,O
9,O
and,O
(,O
b,O
),O
the,O
GO,O
term,O
annotations,O
of,O
the,O
Arabidopsis,B-OG
protein,O
are,O
significantly,O
enriched,O
[,O
with,O
a,O
p,O
-,O
value,O
of,O
<,O
0,O
.,O
001,O
as,O
obtained,O
by,O
GO,O
enrichment,O
analysis,O
using,O
FuncAssociate,O
(,O
Berriz,O
et,O
al,O
".,",O
2003,O
)].,O
There,O
are,O
a,O
total,O
of,O
5247,O
Arabidopsis,B-OG
proteins,O
satisfying,O
these,O
criteria,O
.,O
In,O
Table,O
3,O
",",O
we,O
show,O
20,O
Arabidopsis,B-OG
genes,O
selected,O
randomly,O
from,O
this,O
set,O
of,O
highly,O
targeted,O
Arabidopsis,B-OG
proteins,O
.,O
In,O
Table,O
4,O
",",O
we,O
show,O
the,O
list,O
of,O
all,O
enriched,O
GO,O
terms,O
.,O
GO,O
terms,O
that,O
were,O
enriched,O
in,O
the,O
most,O
targetted,O
Arabidopsis,B-OG
proteins,O
in,O
our,O
predictions,O
.,O
Arabidopsis,B-OG
(,O
TAIR,O
id,O
),O
Protein,O
name,O
/,O
gene,O
Enriched,O
Gene,O
Ontology,O
annotations,O
Enriched,O
GO,O
terms,O
(,O
corresp,O
.,O
to,O
column,O
3,O
),O
AT1G01030,O
B3,B-GP
domain,I-GP
containing,I-GP
transcription,I-GP
factor,I-GP
Sequence,O
-,O
specific,O
DNA,O
binding,O
transcription,O
factor,O
activity,O
;,O
regulation,O
of,O
transcription,O
",",O
DNA,O
-,O
templated,O
GO,O
:,O
0003700,O
GO,O
:,O
0006355,O
AT1G06160,O
Ethylene,B-GP
-,I-GP
responsive,I-GP
transcription,I-GP
factor,I-GP
ERF094,I-GP
DNA,O
binding,O
;,O
sequence,O
-,O
specific,O
DNA,O
binding,O
transcription,O
factor,O
activity,O
;,O
regulation,O
of,O
transcription,O
from,O
RNA,B-GP
-,I-GP
polymerase,I-GP
II,I-GP
promoter,O
;,O
response,O
to,O
jasmonic,O
acid,O
stimulus,O
GO,O
:,O
0003677,O
GO,O
:,O
0003700,O
GO,O
:,O
0006355,O
GO,O
:,O
0009753,O
AT1G01060,O
Myb,B-GP
-,I-GP
related,I-GP
putative,I-GP
transcription,I-GP
factor,I-GP
Response,O
to,O
cadmium,O
ion,O
;,O
response,O
to,O
salt,O
stress,O
;,O
response,O
to,O
auxin,O
stimulus,O
;,O
response,O
to,O
cold,O
GO,O
:,O
0046686,O
GO,O
:,O
0009651,O
GO,O
:,O
0009733,O
GO,O
:,O
0009409,O
AT1G13180,O
Actin,B-GP
-,O
related,O
protein,O
3,O
Actin,B-GP
binding,O
GO,O
:,O
0003779,O
AT2G40220,O
Ethylene,B-GP
-,I-GP
responsive,I-GP
transcription,I-GP
factor,I-GP
ABI4,I-GP
.,O
Protein,O
glucose,O
insensitive,O
6,O
DNA,O
binding,O
;,O
response,O
to,O
water,O
deprivation,O
;,O
positive,O
regulation,O
of,O
transcription,O
",",O
DNA,O
-,O
dependent,O
;,O
sequence,O
-,O
specific,O
DNA,O
binding,O
GO,O
:,O
0003677,O
GO,O
:,O
0009414,O
GO,O
:,O
0045893,O
GO,O
:,O
0043565,O
AT2G46400,O
Putative,O
WRKY,O
transcription,O
factor,O
46,O
Response,O
to,O
chitin,O
GO,O
:,O
0010200,O
AT1G01080,O
Ribonucleoprotein,B-GP
",",O
putative,O
nucleic,O
acid,O
binding,O
;,O
RNA,O
binding,O
GO,O
:,O
0003676,O
GO,O
:,O
0003723,O
AT3G12110,O
Actin,B-GP
-,I-GP
11,I-GP
Chloroplast,O
stroma,O
GO,O
:,O
0009570,O
AT3G56400,O
Probable,B-GP
WRKY,I-GP
transcription,I-GP
factor,I-GP
70,I-GP
Response,O
to,O
salicylic,O
acid,O
stimulus,O
;,O
sequence,O
-,O
specific,O
DNA,O
binding,O
transcription,O
factor,O
activity,O
;,O
protein,O
amino,O
acid,O
binding,O
GO,O
:,O
0009751,O
GO,O
:,O
0003700,O
GO,O
:,O
0005515,O
AT1G01090,O
Pyruvate,O
dehydrogenase,O
E1,O
component,O
subunit,O
alpha,O
-,O
3,O
",",O
chloroplastic,O
Chloroplast,O
stroma,O
GO,O
:,O
0009570,O
AT4G09570,O
Ca,B-GP
-,I-GP
dependent,I-GP
protein,I-GP
kinase,I-GP
4,I-GP
protein,O
amino,O
acid,O
binding,O
GO,O
:,O
0005515,O
AT1G01150,O
Homeodomain,B-GP
-,I-GP
like,I-GP
protein,I-GP
with,I-GP
RING,I-GP
-,I-GP
type,I-GP
zinc,I-GP
finger,I-GP
domain,I-GP
Zinc,O
ion,O
binding,O
;,O
regulation,O
of,O
transcription,O
",",O
DNA,O
-,O
templated,O
GO,O
:,O
0008270,O
GO,O
:,O
0006355,O
AT4G18170,O
Probable,B-GP
WRKY,I-GP
transcription,I-GP
factor,I-GP
28,I-GP
Regulation,O
of,O
transcription,O
",",O
DNA,O
-,O
templated,O
;,O
sequence,O
-,O
specific,O
DNA,O
binding,O
transcription,O
factor,O
activity,O
GO,O
:,O
0006355,O
GO,O
:,O
0003700,O
AT1G01160,O
GRF1,B-GP
-,I-GP
interacting,I-GP
factor,I-GP
2,I-GP
Protein,O
amino,O
acid,O
binding,O
GO,O
:,O
0005515,O
AT1G01200,O
Ras,B-GP
-,I-GP
related,I-GP
protein,I-GP
RABA3,I-GP
GTP,O
binding,O
;,O
small,O
GTPase,B-GP
mediated,O
signal,O
transduction,O
;,O
protein,O
transport,O
GO,O
:,O
0005525,O
GO,O
:,O
0007264,O
GO,O
:,O
0015031,O
AT5G47220,O
Ethylene,B-GP
-,I-GP
responsive,I-GP
transcription,I-GP
factor,I-GP
2,I-GP
Positive,O
regulation,O
of,O
transcription,O
",",O
DNA,O
-,O
dependent,O
;,O
ethylene,O
mediated,O
signaling,O
pathway,O
GO,O
:,O
0045893,O
GO,O
:,O
0009873,O
AT1G01250,O
Ethylene,B-GP
-,I-GP
responsive,I-GP
TF,I-GP
ERF023,I-GP
Sequence,O
-,O
specific,O
DNA,O
binding,O
transcription,O
factor,O
activity,O
;,O
nuclear,O
envelope,O
GO,O
:,O
0003700,O
GO,O
:,O
0005634,O
AT1G01350,O
Zinc,B-GP
finger,I-GP
CCCH,I-GP
domain,I-GP
-,I-GP
containing,I-GP
protein,I-GP
1,I-GP
Nucleic,O
acid,O
binding,O
;,O
zinc,O
ion,O
binding,O
GO,O
:,O
0003676,O
GO,O
:,O
0008270,O
AT1G01370,O
Histone,B-GP
H3,I-GP
-,I-GP
like,I-GP
centromeric,I-GP
protein,I-GP
HTR12,I-GP
DNA,O
binding,O
;,O
protein,O
amino,O
acid,O
binding,O
GO,O
:,O
0003677,O
GO,O
:,O
0005515,O
To,O
get,O
this,O
list,O
",",O
we,O
performed,O
a,O
GO,O
term,O
enrichment,O
analysis,O
using,O
the,O
FuncAssociate,O
tool,O
(,O
Berriz,O
et,O
al,O
".,",O
2003,O
).,O
We,O
then,O
procure,O
the,O
set,O
of,O
Arabidopsis,B-OG
genes,O
which,O
correspond,O
to,O
the,O
enriched,O
GO,O
terms,O
;,O
i,O
.,O
e,O
".,",O
GO,O
terms,O
with,O
a,O
p,O
-,O
value,O
of,O
<,O
0,O
.,O
001,O
.,O
We,O
further,O
filter,O
this,O
set,O
to,O
include,O
only,O
those,O
Arabidopsis,B-OG
genes,O
predicted,O
to,O
interact,O
with,O
at,O
least,O
3,O
Salmonella,B-OG
effector,O
proteins,O
.,O
In,O
this,O
table,O
",",O
we,O
show,O
around,O
20,O
such,O
Arabidopsis,B-OG
genes,O
for,O
the,O
lack,O
of,O
space,O
.,O
The,O
remaining,O
are,O
available,O
via,O
the,O
download,O
link,O
.,O
List,O
of,O
all,O
enriched,O
GO,O
terms,O
obtained,O
by,O
applying,O
enrichment,O
analysis,O
tool,O
FuncAssociate,O
(,O
Berriz,O
et,O
al,O
".,",O
2003,O
),O
on,O
the,O
set,O
of,O
highly,O
targeted,O
Arabidopsis,B-OG
proteins,O
(,O
i,O
.,O
e,O
".,",O
Arabidopsis,B-OG
proteins,O
predicted,O
to,O
interact,O
with,O
at,O
least,O
3,O
Salmonella,B-OG
effectors,O
).,O
GO,O
term,O
Description,O
GO,O
:,O
0003676,O
Nucleic,O
acid,O
binding,O
GO,O
:,O
0003677,O
DNA,O
binding,O
GO,O
:,O
0003700,O
Sequence,O
-,O
specific,O
DNA,O
binding,O
TF,O
activity,O
GO,O
:,O
0003723,O
RNA,O
binding,O
GO,O
:,O
0003735,O
Structural,O
constituent,O
of,O
ribosome,O
GO,O
:,O
0003755,O
peptidyl,O
-,O
prolyl,O
cis,O
-,O
trans,O
isomerase,O
activity,O
GO,O
:,O
0003779,O
Actin,B-GP
binding,O
GO,O
:,O
0003899,O
DNA,O
-,O
directed,O
RNA,O
polymerase,O
activity,O
GO,O
:,O
0004298,O
Threonine,O
-,O
type,O
endopeptidase,O
activity,O
GO,O
:,O
0004693,O
Cyclin,O
-,O
dependent,O
protein,O
serine,O
/,O
threonine,O
kinase,O
activity,O
GO,O
:,O
0004842,O
Ubiquitin,O
-,O
protein,O
transferase,O
activity,O
GO,O
:,O
0004871,O
Signal,O
transducer,O
activity,O
GO,O
:,O
0005484,O
SNAP,O
receptor,O
activity,O
GO,O
:,O
0005507,O
Copper,O
ion,O
binding,O
GO,O
:,O
0005509,O
Calcium,O
ion,O
binding,O
GO,O
:,O
0005515,O
Protein,O
binding,O
GO,O
:,O
0005525,O
GTP,O
binding,O
GO,O
:,O
0005576,O
Extracellular,O
region,O
GO,O
:,O
0005622,O
Intracellular,O
region,O
GO,O
:,O
0005634,O
Nuclear,O
envelope,O
GO,O
:,O
0005839,O
Proteasome,B-GP
core,O
complex,O
GO,O
:,O
0005840,O
Ribosome,O
GO,O
:,O
0006351,O
Transcription,O
",",O
DNA,O
-,O
templated,O
GO,O
:,O
0006355,O
Regulation,O
of,O
transcription,O
",",O
DNA,O
-,O
templated,O
GO,O
:,O
0006412,O
Translation,O
GO,O
:,O
0006413,O
Translational,O
initiation,O
GO,O
:,O
0006457,O
Protein,O
folding,O
GO,O
:,O
0006511,O
Ubiquitin,B-GP
-,O
dependent,O
protein,O
catabolic,O
process,O
GO,O
:,O
0007264,O
Small,O
GTPase,B-GP
mediated,O
signal,O
transduction,O
GO,O
:,O
0007267,O
Cell,O
-,O
cell,O
signaling,O
GO,O
:,O
0008233,O
Peptidase,O
activity,O
GO,O
:,O
0008270,O
Zinc,O
ion,O
binding,O
GO,O
:,O
0008794,O
Arsenate,B-GP
reductase,I-GP
(,O
glutaredoxin,B-GP
),O
activity,O
GO,O
:,O
0009408,O
Response,O
to,O
heat,O
GO,O
:,O
0009409,O
Response,O
to,O
cold,O
GO,O
:,O
0009414,O
Response,O
to,O
water,O
deprivation,O
GO,O
:,O
0009570,O
Chloroplast,O
stroma,O
GO,O
:,O
0009579,O
Thylakoid,O
GO,O
:,O
0009651,O
Response,O
to,O
salt,O
stress,O
GO,O
:,O
0009733,O
Response,O
to,O
auxin,O
GO,O
:,O
0009737,O
Response,O
to,O
abscisic,O
acid,O
GO,O
:,O
0009739,O
Response,O
to,O
gibberellin,O
GO,O
:,O
0009751,O
Response,O
to,O
salicylic,O
acid,O
GO,O
:,O
0009753,O
Response,O
to,O
jasmonic,O
acid,O
GO,O
:,O
0009828,O
Plant,B-OG
-,O
type,O
cell,O
wall,O
loosening,O
GO,O
:,O
0009873,O
Ethylene,O
mediated,O
signaling,O
pathway,O
GO,O
:,O
0010200,O
Response,O
to,O
chitin,O
GO,O
:,O
0015031,O
Protein,O
transport,O
GO,O
:,O
0015035,O
Protein,O
disulfide,O
oxidoreductase,O
activity,O
GO,O
:,O
0016491,O
Oxidoreductase,O
activity,O
GO,O
:,O
0016607,O
Nuclear,O
speck,O
GO,O
:,O
0016762,O
Xyloglucan,O
:,O
xyloglucosyl,O
transferase,O
activity,O
GO,O
:,O
0022626,O
Cytosolic,O
ribosome,O
GO,O
:,O
0022627,O
Cytosolic,O
small,O
ribosomal,O
subunit,O
GO,O
:,O
0042254,O
Ribosome,O
biogenesis,O
GO,O
:,O
0042742,O
Defense,O
response,O
to,O
bacterium,B-OG
GO,O
:,O
0043565,O
Sequence,O
-,O
specific,O
DNA,O
binding,O
GO,O
:,O
0045454,O
Cell,O
redox,O
homeostasis,O
GO,O
:,O
0045892,O
Negative,O
regulation,O
of,O
transcription,O
",",O
DNA,O
-,O
templated,O
GO,O
:,O
0045893,O
Positive,O
regulation,O
of,O
transcription,O
",",O
DNA,O
-,O
templated,O
GO,O
:,O
0046686,O
Response,O
to,O
cadmium,O
ion,O
GO,O
:,O
0046872,O
Metal,O
ion,O
binding,O
GO,O
:,O
0051726,O
Regulation,O
of,O
cell,O
cycle,O
The,O
shown,O
terms,O
had,O
a,O
p,O
-,O
value,O
less,O
than,O
0,O
.,O
001,O
.,O
For,O
each,O
gene,O
we,O
show,O
the,O
description,O
and,O
the,O
enriched,O
GO,O
annotations,O
.,O
Among,O
the,O
presented,O
Arabidopsis,B-OG
proteins,O
",",O
nearly,O
one,O
third,O
are,O
transcription,O
factors,O
.,O
These,O
function,O
e,O
.,O
g,O
".,",O
in,O
hormone,O
-,O
mediated,O
signaling,O
pathways,O
.,O
It,O
has,O
been,O
reported,O
that,O
jasmonic,O
acid,O
and,O
ethylene,O
signaling,O
pathways,O
are,O
involved,O
in,O
plant,B-OG
defense,O
response,O
against,O
Salmonella,B-OG
(,O
Schikora,O
et,O
al,O
".,",O
2008,O
).,O
Other,O
examples,O
that,O
highlight,O
the,O
role,O
of,O
transcription,O
factors,O
in,O
plant,B-OG
-,O
pathogen,O
interaction,O
are,O
e,O
.,O
g,O
".,",O
that,O
a,O
Xanthomonas,B-OG
effector,O
protein,O
targets,O
an,O
ethylene,B-GP
responsive,I-GP
transcription,I-GP
factor,I-GP
(,O
ERF,B-GP
),O
in,O
tomato,B-OG
to,O
inhibit,O
ethylene,O
induced,O
transcription,O
(,O
Kim,O
et,O
al,O
".,",O
2013,O
),O
and,O
systemic,O
immunity,O
in,O
barley,B-OG
induced,O
by,O
Xanthomonas,B-OG
and,O
Pseudomonas,B-OG
bacteria,B-OG
may,O
involve,O
WRKY,B-GP
and,O
ERF,B-GP
-,O
like,O
transcription,O
factors,O
(,O
Dey,O
et,O
al,O
".,",O
2014,O
).,O
Further,O
",",O
actin,B-GP
-,I-GP
11,I-GP
and,O
actin,B-GP
-,O
related,O
proteins,O
involved,O
in,O
actin,B-GP
polymerization,O
and,O
depolymerization,O
are,O
obtained,O
.,O
It,O
is,O
well,O
known,O
that,O
Salmonella,B-OG
translocates,O
effectors,O
into,O
the,O
mammalian,O
host,O
cell,O
in,O
order,O
to,O
interact,O
with,O
actin,B-GP
and,O
e,O
.,O
g,O
".,",O
modify,O
the,O
cell,O
cytoskeleton,O
to,O
allow,O
bacterial,O
entry,O
(,O
for,O
review,O
see,O
Schleker,O
et,O
al,O
".,",O
2012,O
).,O
Our,O
analysis,O
revealed,O
growth,B-GP
regulating,I-GP
factor,I-GP
1,I-GP
(,O
GRF1,B-GP
)-,O
interacting,O
factor,O
2,O
",",O
a,O
transcriptional,O
co,O
-,O
activator,O
which,O
is,O
part,O
of,O
a,O
regulatory,O
complex,O
with,O
GRF1,B-GP
and,O
microRNA,O
(,O
miRNA,O
),O
396,O
.,O
MiRNAs,O
are,O
involved,O
in,O
plant,B-OG
disease,O
resistance,O
to,O
bacteria,B-OG
and,O
miRNA396,O
has,O
been,O
shown,O
to,O
be,O
upregulated,O
in,O
plants,B-OG
upon,O
flg22,O
treatment,O
(,O
Li,O
et,O
al,O
".,",O
2010,O
).,O
Liu,O
et,O
al,O
.,O
(,O
2014,O
),O
reported,O
that,O
putative,O
GRF1,B-GP
targets,O
in,O
Arabidopsis,B-OG
are,O
heavily,O
involved,O
in,O
biosynthetic,O
and,O
metabolic,O
pathways,O
",",O
e,O
.,O
g,O
".,",O
phenylpropanoid,O
",",O
amino,O
acids,O
and,O
lignin,O
biosynthesis,O
as,O
well,O
as,O
plant,B-OG
hormone,O
signal,O
transduction,O
indicating,O
the,O
role,O
of,O
GRF1,B-GP
in,O
plant,B-OG
defense,O
mechanisms,O
.,O
Other,O
examples,O
of,O
predicted,O
interactions,O
and,O
more,O
details,O
of,O
their,O
possible,O
relevance,O
in,O
Salmonella,B-OG
-,O
plant,B-OG
interplay,O
are,O
discussed,O
in,O
the,O
accompanying,O
paper,O
(,O
Schleker,O
et,O
al,O
".,",O
2015,O
).,O
5,O
.,O
3,O
.,O
Limitations,O
and,O
future,O
work,O
In,O
this,O
paper,O
",",O
we,O
addressed,O
the,O
challenge,O
of,O
predicting,O
the,O
Salmonella,B-OG
-,O
Arabidopsis,B-OG
interactome,O
in,O
the,O
absence,O
of,O
any,O
experimentally,O
known,O
interactions,O
.,O
Previous,O
work,O
in,O
this,O
area,O
was,O
based,O
purely,O
on,O
homology,O
between,O
human,B-OG
and,O
Arabidopsis,B-OG
proteins,O
and,O
was,O
therefore,O
limited,O
to,O
proteins,O
that,O
do,O
display,O
sequence,O
similarity,O
.,O
Due,O
to,O
the,O
large,O
divergence,O
between,O
the,O
two,O
organisms,O
",",O
this,O
approach,O
neglects,O
a,O
large,O
fraction,O
of,O
potential,O
Arabidopsis,B-OG
targets,O
.,O
We,O
therefore,O
presented,O
here,O
three,O
different,O
sophisticated,O
computational,O
and,O
machine,O
learning,O
methods,O
to,O
predict,O
hereto,O
unknown,O
Salmonella,B-OG
-,O
plant,B-OG
interactions,O
from,O
a,O
relatively,O
small,O
list,O
of,O
known,O
Salmonella,B-OG
-,O
human,B-OG
interactions,O
.,O
This,O
is,O
a,O
very,O
challenging,O
task,O
because,O
it,O
is,O
not,O
possible,O
to,O
quantitatively,O
validate,O
the,O
predictions,O
.,O
Nonetheless,O
",",O
the,O
predictions,O
provide,O
a,O
gold,O
-,O
mine,O
for,O
discovery,O
because,O
they,O
provide,O
experimentally,O
testable,O
hypotheses,O
on,O
the,O
communication,O
mechanisms,O
between,O
plant,B-OG
and,O
Salmonella,B-OG
without,O
restriction,O
to,O
known,O
effectors,O
in,O
the,O
pathogen,O
or,O
sequences,O
of,O
similarity,O
to,O
those,O
observed,O
in,O
better,O
studied,O
eukaryotic,O
organisms,O
.,O
With,O
these,O
advantages,O
comes,O
a,O
set,O
of,O
limitations,O
to,O
be,O
aware,O
of,O
.,O
Since,O
machine,O
learning,O
methods,O
need,O
some,O
known,O
interactions,O
to,O
evaluate,O
the,O
models,O
on,O
",",O
and,O
to,O
pick,O
the,O
best,O
set,O
of,O
predictions,O
",",O
their,O
application,O
in,O
the,O
current,O
paper,O
has,O
limitations,O
.,O
For,O
example,O
",",O
we,O
can,O
obtain,O
different,O
predictions,O
from,O
our,O
methods,O
by,O
varying,O
the,O
parameters,O
",",O
especially,O
the,O
class,O
skew,O
(,O
we,O
studied,O
the,O
ratios,O
1,O
:,O
100,O
and,O
1,O
:,O
500,O
in,O
this,O
paper,O
).,O
Because,O
there,O
are,O
currently,O
no,O
known,O
Salmonella,B-OG
-,O
plant,B-OG
interactions,O
",",O
we,O
are,O
not,O
able,O
to,O
quantify,O
which,O
of,O
these,O
sets,O
of,O
predictions,O
is,O
more,O
reliable,O
.,O
Augmenting,O
the,O
predictions,O
with,O
some,O
other,O
biological,O
information,O
from,O
the,O
target,O
task,O
can,O
help,O
in,O
picking,O
the,O
most,O
plausible,O
PPIs,O
.,O
This,O
is,O
a,O
direction,O
for,O
future,O
research,O
.,O
Further,O
",",O
The,O
interactome,O
predicted,O
by,O
each,O
method,O
is,O
not,O
the,O
true,O
interactome,O
",",O
but,O
is,O
a,O
set,O
of,O
predictions,O
.,O
There,O
will,O
be,O
false,O
positive,O
and,O
false,O
negative,O
interactions,O
.,O
Thus,O
",",O
each,O
individual,O
prediction,O
has,O
to,O
be,O
considered,O
a,O
hypothesis,O
not,O
a,O
fact,O
.,O
In,O
line,O
with,O
point,O
1,O
above,O
",",O
the,O
size,O
of,O
the,O
predicted,O
interactomes,O
does,O
not,O
necessarily,O
relate,O
to,O
the,O
true,O
interactome,O
.,O
We,O
dont,O
know,O
how,O
many,O
interactions,O
to,O
expect,O
.,O
Our,O
different,O
predictions,O
vary,O
greatly,O
in,O
size,O
",",O
with,O
one,O
method,O
predicting,O
only,O
one,O
thousand,O
interactions,O
",",O
while,O
others,O
predict,O
more,O
than,O
100,O
",",O
000,O
interactions,O
.,O
While,O
it,O
is,O
more,O
likely,O
that,O
smaller,O
numbers,O
of,O
interactions,O
are,O
more,O
likely,O
",",O
it,O
does,O
not,O
mean,O
that,O
this,O
method,O
is,O
inherently,O
better,O
than,O
the,O
other,O
methods,O
.,O
The,O
size,O
of,O
the,O
predicted,O
interactions,O
list,O
also,O
depends,O
on,O
a,O
critical,O
parameter,O
",",O
the,O
positive,O
to,O
negative,O
class,O
ratio,O
.,O
This,O
parameter,O
is,O
important,O
but,O
it,O
is,O
tuneable,O
",",O
so,O
the,O
methods,O
validity,O
is,O
not,O
dependent,O
on,O
its,O
choice,O
.,O
However,O
",",O
it,O
is,O
important,O
to,O
appreciate,O
that,O
the,O
predictions,O
will,O
differ,O
greatly,O
when,O
this,O
parameter,O
is,O
changed,O
.,O
Thus,O
",",O
biological,O
insight,O
in,O
choosing,O
predictions,O
to,O
validate,O
still,O
needs,O
to,O
be,O
applied,O
",",O
regardless,O
of,O
the,O
prior,O
choice,O
of,O
ratio,O
in,O
generating,O
the,O
model,O
.,O
These,O
general,O
limitations,O
in,O
the,O
context,O
of,O
the,O
specific,O
results,O
of,O
the,O
models,O
presented,O
here,O
translate,O
to,O
the,O
following,O
issues,O
",",O
pointed,O
out,O
by,O
a,O
reviewer,O
of,O
this,O
paper,O
:,O
The,O
data,O
presented,O
for,O
the,O
KMM,O
-,O
SVM,O
model,O
indicate,O
that,O
163,O
",",O
644,O
PPIs,O
are,O
predicted,O
(,O
Figure,O
5,O
).,O
This,O
is,O
of,O
the,O
same,O
order,O
of,O
magnitude,O
as,O
the,O
number,O
of,O
false,O
positives,O
that,O
would,O
be,O
predicted,O
",",O
given,O
the,O
reported,O
false,O
positive,O
rate,O
of,O
the,O
method,O
that,O
indicate,O
≈,O
180,O
",",O
000,O
false,O
positive,O
PPIs,O
would,O
be,O
expected,O
.,O
This,O
raises,O
the,O
possibility,O
that,O
the,O
bulk,O
of,O
the,O
predictions,O
may,O
be,O
false,O
positives,O
.,O
The,O
data,O
presented,O
for,O
the,O
KMM,O
-,O
SVM,O
model,O
also,O
indicates,O
that,O
25,O
",",O
124,O
distinct,O
Arabidopsis,B-OG
genes,O
participate,O
in,O
PPIs,O
with,O
31,O
distinct,O
Salmonella,B-OG
genes,O
(,O
Figure,O
5,O
).,O
This,O
implies,O
that,O
91,O
%,O
of,O
the,O
Arabidopsis,B-OG
protein,O
-,O
coding,O
gene,O
complement,O
(,O
TAIR10,O
:,O
27,O
",",O
416,O
genes,O
—,O
http,O
://,O
www,O
.,O
arabidopsis,B-OG
.,O
org,O
/,O
portals,O
/,O
genAnnotation,O
/,O
gene_structural_annotation,O
/,O
annotation_data,O
.,O
jsp,O
),O
enters,O
into,O
productive,O
interaction,O
with,O
only,O
31,O
Salmonella,B-OG
proteins,O
.,O
It,O
also,O
implies,O
that,O
",",O
on,O
average,O
",",O
each,O
interacting,O
Salmonella,B-OG
protein,O
is,O
capable,O
of,O
productive,O
interaction,O
with,O
over,O
5000,O
Arabidopsis,B-OG
proteins,O
.,O
It,O
is,O
unlikely,O
that,O
this,O
is,O
the,O
case,O
",",O
again,O
suggesting,O
that,O
a,O
large,O
number,O
of,O
false,O
positives,O
have,O
to,O
be,O
expected,O
.,O
Conflict,O
of,O
interest,O
statement,O
The,O
authors,O
declare,O
that,O
the,O
research,O
was,O
conducted,O
in,O
the,O
absence,O
of,O
any,O
commercial,O
or,O
financial,O
relationships,O
that,O
could,O
be,O
construed,O
as,O
a,O
potential,O
conflict,O
of,O
interest,O
.,O
An,O
algorithm,O
to,O
enumerate,O
all,O
possible,O
protein,O
conformations,O
verifying,O
a,O
set,O
of,O
distance,O
constraints,O
Background,O
The,O
determination,O
of,O
protein,O
structures,O
satisfying,O
distance,O
constraints,O
is,O
an,O
important,O
problem,O
in,O
structural,O
biology,O
.,O
Whereas,O
the,O
most,O
common,O
method,O
currently,O
employed,O
is,O
simulated,O
annealing,O
",",O
there,O
have,O
been,O
other,O
methods,O
previously,O
proposed,O
in,O
the,O
literature,O
.,O
Most,O
of,O
them,O
",",O
however,O
",",O
are,O
designed,O
to,O
find,O
one,O
solution,O
only,O
.,O
Results,O
In,O
order,O
to,O
explore,O
exhaustively,O
the,O
feasible,O
conformational,O
space,O
",",O
we,O
propose,O
here,O
an,O
interval,O
Branch,O
-,O
and,O
-,O
Prune,O
algorithm,O
(,O
iBP,O
),O
to,O
solve,O
the,O
Distance,O
Geometry,O
Problem,O
(,O
DGP,O
),O
associated,O
to,O
protein,O
structure,O
determination,O
.,O
This,O
algorithm,O
is,O
based,O
on,O
a,O
discretization,O
of,O
the,O
problem,O
obtained,O
by,O
recursively,O
constructing,O
a,O
search,O
space,O
having,O
the,O
structure,O
of,O
a,O
tree,O
",",O
and,O
by,O
verifying,O
whether,O
the,O
generated,O
atomic,O
positions,O
are,O
feasible,O
or,O
not,O
by,O
making,O
use,O
of,O
pruning,O
devices,O
.,O
The,O
pruning,O
devices,O
used,O
here,O
are,O
directly,O
related,O
to,O
features,O
of,O
protein,O
conformations,O
.,O
Conclusions,O
We,O
described,O
the,O
new,O
algorithm,O
iBP,O
to,O
generate,O
protein,O
conformations,O
satisfying,O
distance,O
constraints,O
",",O
that,O
would,O
potentially,O
allows,O
a,O
systematic,O
exploration,O
of,O
the,O
conformational,O
space,O
.,O
The,O
algorithm,O
iBP,O
has,O
been,O
applied,O
on,O
three,O
α,O
-,O
helical,O
peptides,O
.,O
Background,O
Protein,O
structure,O
determination,O
is,O
crucial,O
for,O
understanding,O
protein,O
function,O
",",O
as,O
it,O
paves,O
the,O
way,O
to,O
the,O
discovery,O
of,O
new,O
chemical,O
compounds,O
and,O
of,O
new,O
approaches,O
to,O
control,O
the,O
biological,O
processes,O
.,O
The,O
problem,O
of,O
protein,O
structure,O
determination,O
is,O
certainly,O
a,O
problem,O
with,O
multiple,O
solutions,O
",",O
as,O
proteins,O
are,O
flexible,O
polymers,O
.,O
As,O
most,O
of,O
the,O
experimental,O
techniques,O
of,O
the,O
structural,O
biology,O
obtain,O
measurements,O
averaged,O
on,O
an,O
ensemble,O
of,O
protein,O
conformations,O
",",O
the,O
usual,O
approaches,O
for,O
structure,O
determination,O
intend,O
to,O
find,O
an,O
average,O
structure,O
or,O
a,O
set,O
of,O
conformations,O
describing,O
fluctuations,O
around,O
an,O
average,O
structure,O
.,O
A,O
path,O
intending,O
to,O
get,O
a,O
complete,O
coverage,O
of,O
the,O
conformational,O
space,O
",",O
given,O
a,O
series,O
of,O
constraints,O
",",O
is,O
usually,O
not,O
taken,O
",",O
although,O
such,O
an,O
approach,O
could,O
provide,O
precious,O
information,O
about,O
the,O
conformational,O
equilibrium,O
",",O
which,O
is,O
essential,O
in,O
the,O
function,O
of,O
many,O
proteins,O
",",O
as,O
the,O
HIV,B-OG
protease,B-GP
[,O
1,O
].,O
An,O
important,O
class,O
of,O
experimental,O
methods,O
for,O
protein,O
structure,O
determination,O
is,O
based,O
on,O
the,O
measurement,O
of,O
inter,O
-,O
atomic,O
distances,O
and,O
angles,O
",",O
such,O
as,O
Nuclear,O
Magnetic,O
Resonance,O
(,O
NMR,O
),O
spectroscopy,O
[,O
2,O
],O
and,O
cross,O
-,O
linking,O
coupled,O
to,O
mass,O
spectrometry,O
[,O
3,O
].,O
In,O
NMR,O
",",O
distance,O
intervals,O
between,O
hydrogens,O
are,O
determined,O
from,O
the,O
measurement,O
of,O
nuclear,O
Overhauser,O
effects,O
(,O
NOE,O
).,O
The,O
experimentally,O
measured,O
distances,O
are,O
then,O
used,O
as,O
constraints,O
for,O
protein,O
structure,O
calculations,O
.,O
Pure,O
in,O
silico,O
approaches,O
have,O
been,O
also,O
developed,O
based,O
on,O
the,O
use,O
of,O
inter,O
-,O
atomic,O
distance,O
constraints,O
",",O
such,O
as,O
homology,O
modeling,O
[,O
4,O
],O
or,O
prediction,O
of,O
protein,O
-,O
protein,O
complexes,O
[,O
5,O
],O
and,O
ligand,O
poses,O
[,O
6,O
].,O
The,O
Distance,O
Geometry,O
Problem,O
(,O
DGP,O
),O
[,O
7,O
",",O
8,O
],O
consists,O
in,O
identifying,O
the,O
sets,O
of,O
points,O
which,O
satisfy,O
a,O
set,O
of,O
constraints,O
based,O
on,O
relative,O
distances,O
between,O
some,O
pairs,O
of,O
such,O
points,O
.,O
The,O
present,O
work,O
describes,O
an,O
algorithm,O
developed,O
to,O
solve,O
DGP,O
in,O
the,O
context,O
of,O
protein,O
structure,O
determination,O
:,O
the,O
points,O
represent,O
the,O
protein,O
atoms,O
.,O
The,O
DGP,O
is,O
a,O
constraint,O
satisfaction,O
problem,O
.,O
Several,O
approaches,O
solve,O
this,O
problem,O
by,O
reformulating,O
it,O
[,O
8,O
],O
as,O
a,O
global,O
optimization,O
problem,O
having,O
a,O
continuous,O
search,O
domain,O
",",O
and,O
whose,O
objective,O
function,O
is,O
generally,O
a,O
penalty,O
function,O
designed,O
to,O
measure,O
the,O
violation,O
of,O
the,O
distance,O
constraints,O
.,O
Over,O
the,O
years,O
",",O
the,O
solution,O
of,O
DGPs,O
arising,O
in,O
structural,O
biology,O
have,O
been,O
typically,O
attempted,O
by,O
Simulated,O
Annealing,O
(,O
SA,O
),O
approaches,O
based,O
on,O
molecular,O
dynamics,O
[,O
9,O
].,O
Other,O
proposed,O
approaches,O
are,O
based,O
on,O
various,O
optimization,O
methods,O
as,O
in,O
[,O
10,O
].,O
As,O
all,O
meta,O
-,O
heuristic,O
approaches,O
",",O
SA,O
may,O
provide,O
approximate,O
solutions,O
but,O
does,O
not,O
deliver,O
optimality,O
certificates,O
.,O
In,O
the,O
case,O
of,O
protein,O
structure,O
determination,O
",",O
since,O
the,O
optimization,O
problem,O
is,O
a,O
reformulation,O
of,O
a,O
constraint,O
satisfaction,O
problem,O
",",O
solutions,O
given,O
by,O
SA,O
can,O
be,O
successively,O
verified,O
by,O
checking,O
the,O
violations,O
of,O
the,O
distance,O
constraints,O
.,O
However,O
",",O
additional,O
solutions,O
may,O
exist,O
but,O
go,O
undetected,O
by,O
SA,O
.,O
Thus,O
",",O
an,O
algorithm,O
for,O
the,O
systematic,O
enumeration,O
of,O
the,O
possible,O
conformations,O
of,O
a,O
given,O
protein,O
could,O
find,O
a,O
widespread,O
field,O
of,O
application,O
.,O
Branch,O
-,O
and,O
-,O
prune,O
algorithms,O
and,O
similar,O
were,O
proposed,O
in,O
the,O
general,O
context,O
of,O
protein,O
structure,O
determination,O
[,O
11,O
-,O
16,O
"],",O
(,O
see,O
also,O
[,O
8,O
],O
and,O
references,O
therein,O
).,O
However,O
",",O
these,O
studies,O
primarily,O
addressed,O
the,O
question,O
of,O
defining,O
relative,O
orientations,O
of,O
protein,O
monomers,O
in,O
symmetric,O
oligomers,O
",",O
not,O
the,O
determination,O
of,O
all,O
possible,O
conformation,O
of,O
a,O
polypeptide,O
chain,O
with,O
a,O
very,O
large,O
number,O
of,O
degrees,O
of,O
freedom,O
from,O
distance,O
constraints,O
.,O
Systematic,O
exploration,O
was,O
proved,O
to,O
be,O
useful,O
in,O
the,O
case,O
of,O
residual,O
dipolar,O
couplings,O
(,O
RDC,O
),O
constraints,O
[,O
17,O
"],",O
for,O
exploring,O
the,O
sidechains,O
conformations,O
[,O
18,O
",",O
19,O
],O
and,O
for,O
assignment,O
of,O
NOEs,O
",",O
provided,O
that,O
the,O
structure,O
is,O
known,O
[,O
20,O
].,O
For,O
the,O
structure,O
determination,O
from,O
RDCs,O
",",O
it,O
has,O
been,O
shown,O
[,O
21,O
],O
that,O
when,O
using,O
RDCs,O
but,O
only,O
sparse,O
NOEs,O
the,O
problem,O
can,O
be,O
solved,O
in,O
polynomial,O
time,O
.,O
Such,O
approaches,O
have,O
also,O
been,O
used,O
for,O
structure,O
determination,O
in,O
X,O
-,O
ray,O
crystallography,O
for,O
non,O
-,O
crystallographic,O
symmetry,O
by,O
orienting,O
and,O
translating,O
symmetric,O
protein,O
subunits,O
[,O
22,O
].,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
in,O
this,O
paper,O
we,O
present,O
the,O
first,O
application,O
of,O
a,O
Branch,O
-,O
and,O
-,O
Prune,O
algorithm,O
to,O
the,O
problem,O
of,O
full,O
protein,O
structure,O
determination,O
based,O
on,O
unambiguous,O
distance,O
information,O
.,O
Under,O
certain,O
conditions,O
",",O
DGPs,O
can,O
be,O
discretized,O
[,O
23,O
],O
(,O
see,O
below,O
"),",O
which,O
means,O
that,O
the,O
search,O
domain,O
for,O
the,O
corresponding,O
optimization,O
problem,O
can,O
be,O
reduced,O
to,O
a,O
discrete,O
set,O
",",O
which,O
has,O
the,O
structure,O
of,O
a,O
tree,O
.,O
The,O
discretization,O
makes,O
the,O
enumeration,O
of,O
the,O
entire,O
solution,O
set,O
of,O
DGP,O
instances,O
possible,O
.,O
This,O
is,O
important,O
when,O
the,O
experimental,O
constraints,O
do,O
not,O
specify,O
the,O
protein,O
conformation,O
uniquely,O
",",O
i,O
.,O
e,O
".,",O
more,O
than,O
one,O
conformation,O
satisfies,O
all,O
constraints,O
.,O
For,O
solving,O
discretized,O
DGP,O
",",O
we,O
employ,O
an,O
interval,O
branch,O
-,O
and,O
-,O
prune,O
(,O
iBP,O
),O
algorithm,O
[,O
24,O
"],",O
which,O
is,O
based,O
on,O
the,O
idea,O
of,O
recursively,O
exploring,O
the,O
tree,O
while,O
generating,O
new,O
candidate,O
atomic,O
positions,O
(,O
branching,O
phase,O
),O
and,O
to,O
verify,O
the,O
feasibility,O
of,O
such,O
positions,O
(,O
pruning,O
phase,O
),O
(,O
Figure,O
1,O
).,O
By,O
making,O
use,O
of,O
pruning,O
devices,O
",",O
branches,O
rooted,O
at,O
infeasible,O
positions,O
can,O
be,O
discarded,O
from,O
the,O
tree,O
",",O
so,O
that,O
the,O
search,O
can,O
be,O
reduced,O
to,O
the,O
feasible,O
parts,O
of,O
the,O
tree,O
(,O
Figure,O
2,O
).,O
Pruning,O
devices,O
can,O
be,O
conceived,O
and,O
integrated,O
in,O
iBP,O
to,O
improve,O
the,O
performances,O
of,O
the,O
pruning,O
phase,O
and,O
thus,O
of,O
the,O
algorithm,O
.,O
Figure,O
1,O
The,O
i,O
BP,O
recursive,O
algorithm,O
.,O
Description,O
of,O
the,O
iBP,O
algorithm,O
.,O
Figure,O
2,O
The,O
branch,O
-,O
and,O
-,O
prune,O
search,O
tree,O
.,O
Example,O
of,O
branch,O
-,O
and,O
-,O
prune,O
search,O
tree,O
exploration,O
.,O
With,O
solid,O
line,O
",",O
we,O
depict,O
the,O
path,O
currently,O
in,O
use,O
",",O
with,O
dotted,O
arcs,O
pruned,O
paths,O
",",O
and,O
with,O
dashed,O
arcs,O
paths,O
not,O
yet,O
explored,O
.,O
The,O
squared,O
node,O
corresponds,O
to,O
a,O
feasible,O
solution,O
.,O
In,O
the,O
present,O
work,O
",",O
we,O
first,O
describe,O
the,O
branching,O
phase,O
and,O
the,O
pruning,O
devices,O
used,O
to,O
determine,O
the,O
solutions,O
to,O
the,O
Distance,O
Geometry,O
problem,O
.,O
Then,O
",",O
an,O
overall,O
view,O
of,O
the,O
method,O
is,O
given,O
along,O
with,O
the,O
use,O
of,O
the,O
branching,O
and,O
pruning,O
devices,O
at,O
different,O
steps,O
and,O
the,O
complexity,O
of,O
the,O
algorithm,O
is,O
analyzed,O
.,O
We,O
finally,O
illustrate,O
the,O
algorithm,O
application,O
with,O
three,O
proteins,O
for,O
which,O
α,O
-,O
helical,O
regions,O
are,O
known,O
along,O
with,O
few,O
long,O
-,O
range,O
NMR,O
constraints,O
(,O
ie,O
.,O
constraints,O
measured,O
between,O
residues,O
i,O
and,O
j,O
such,O
that,O
|,O
i,O
−,O
j,O
|>,O
3,O
in,O
the,O
protein,O
sequence,O
).,O
The,O
obtained,O
conformations,O
display,O
good,O
stereochemical,O
quality,O
parameters,O
",",O
and,O
the,O
conformational,O
space,O
explored,O
is,O
larger,O
than,O
the,O
one,O
sampled,O
with,O
traditional,O
optimization,O
methods,O
such,O
as,O
simulated,O
annealing,O
.,O
Methods,O
In,O
order,O
to,O
sample,O
the,O
conformational,O
space,O
of,O
a,O
protein,O
",",O
we,O
use,O
a,O
Branch,O
-,O
and,O
-,O
Prune,O
algorithm,O
to,O
build,O
a,O
tree,O
in,O
which,O
each,O
node,O
represents,O
a,O
solution,O
for,O
one,O
atomic,O
position,O
.,O
We,O
limit,O
ourselves,O
in,O
the,O
present,O
work,O
to,O
the,O
calculation,O
of,O
the,O
backbone,O
and,O
C,O
β,O
atomic,O
coordinates,O
.,O
The,O
constraints,O
used,O
to,O
generate,O
atomic,O
coordinates,O
along,O
the,O
Branch,O
-,O
and,O
-,O
Prune,O
algorithm,O
are,O
the,O
following,O
:,O
covalent,O
distance,O
constraints,O
corresponding,O
to,O
bond,O
lengths,O
and,O
bond,O
angles,O
",",O
whose,O
values,O
are,O
derived,O
from,O
high,O
-,O
resolution,O
small,O
molecule,O
X,O
-,O
ray,O
crystal,O
structures,O
[,O
25,O
];,O
NMR,O
distance,O
constraints,O
;,O
van,O
der,O
Waals,O
radii,O
of,O
atoms,O
between,O
non,O
-,O
bonded,O
atom,O
pairs,O
(,O
i,O
",",O
j,O
):,O
a,O
fraction,O
of,O
the,O
sum,O
of,O
the,O
van,O
der,O
Waals,O
radii,O
of,O
each,O
atom,O
provides,O
a,O
lower,O
bound,O
to,O
the,O
corresponding,O
inter,O
-,O
atomic,O
distances,O
:,O
(,O
1,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
d_,O
{,O
ij,O
}\,O
geq,O
\,O
sigma,O
(,O
r,O
^{,O
vdw,O
},O
_,O
{,O
i,O
},O
+,O
r,O
^{,O
vdw,O
},O
_,O
{,O
j,O
"}),",O
$$,O
\,O
end,O
{,O
document,O
},O
dij,O
≥,O
σ,O
(,O
rivdw,O
+,O
rjvdw,O
"),",O
where,O
σ,O
∈,O
[,O
0,O
",",O
1,O
"],",O
and,O
is,O
typically,O
around,O
0,O
.,O
85,O
.,O
The,O
values,O
for,O
the,O
radii,O
are,O
given,O
in,O
Table,O
1,O
[,O
26,O
",",O
27,O
].,O
These,O
lower,O
bounds,O
apply,O
only,O
in,O
the,O
cases,O
where,O
no,O
larger,O
lower,O
bound,O
has,O
been,O
determined,O
from,O
NMR,O
distance,O
constraints,O
;,O
Table,O
1,O
Van,O
der,O
Waals,O
radii,O
(,O
see,O
[,O
26,O
],O
and,O
[,O
27,O
]),O
atom,O
O,O
H,O
C,O
N,O
r,O
vdw,O
(,O
Å,O
),O
1,O
.,O
41,O
.,O
01,O
.,O
71,O
.,O
5,O
distances,O
derived,O
from,O
the,O
backbone,O
torsion,O
angles,O
ϕ,O
and,O
ψ,O
;,O
hydrogen,O
bonds,O
in,O
α,O
-,O
helix,O
;,O
amino,O
-,O
acid,O
chirality,O
;,O
α,O
-,O
helix,O
geometry,O
.,O
The,O
atom,O
coordinates,O
are,O
calculated,O
",",O
one,O
by,O
one,O
",",O
following,O
the,O
atom,O
order,O
P,O
ato,O
described,O
in,O
Figure,O
3,O
and,O
previously,O
proposed,O
in,O
[,O
24,O
].,O
In,O
this,O
order,O
",",O
some,O
atoms,O
are,O
repeated,O
to,O
insure,O
that,O
any,O
entered,O
atom,O
is,O
defined,O
by,O
distance,O
constraints,O
with,O
respect,O
to,O
three,O
preceding,O
atoms,O
in,O
P,O
ato,O
[,O
24,O
].,O
The,O
carbonyl,O
oxygens,O
and,O
the,O
atoms,O
C,O
β,O
",",O
which,O
were,O
not,O
present,O
in,O
the,O
order,O
P,O
ato,O
",",O
are,O
calculated,O
separately,O
.,O
Figure,O
3,O
Order,O
P,O
ato,O
of,O
the,O
atoms,O
parsed,O
during,O
the,O
branch,O
-,O
and,O
-,O
prune,O
algorithm,O
.,O
Then,O
",",O
the,O
tree,O
is,O
built,O
using,O
a,O
recursive,O
procedure,O
to,O
create,O
each,O
node,O
of,O
the,O
tree,O
.,O
This,O
procedure,O
is,O
called,O
branching,O
phase,O
.,O
The,O
created,O
nodes,O
are,O
then,O
submitted,O
to,O
the,O
pruning,O
devices,O
in,O
order,O
to,O
decide,O
whether,O
the,O
node,O
should,O
be,O
kept,O
or,O
removed,O
.,O
If,O
the,O
node,O
is,O
removed,O
",",O
the,O
possible,O
branches,O
starting,O
from,O
this,O
node,O
are,O
also,O
pruned,O
.,O
A,O
pruning,O
device,O
is,O
responsible,O
for,O
checking,O
whether,O
a,O
partial,O
solution,O
is,O
feasible,O
",",O
i,O
.,O
e,O
.,O
to,O
check,O
whether,O
a,O
set,O
of,O
embedded,O
atoms,O
fulfill,O
the,O
constraints,O
(,O
1,O
)-(,O
7,O
),O
described,O
above,O
.,O
In,O
the,O
following,O
",",O
we,O
describe,O
the,O
branching,O
phase,O
and,O
the,O
pruning,O
devices,O
.,O
Then,O
",",O
the,O
complexity,O
of,O
the,O
algorithm,O
is,O
described,O
from,O
a,O
theoretical,O
point,O
of,O
view,O
",",O
before,O
presenting,O
some,O
application,O
cases,O
.,O
Branching,O
devices,O
The,O
tree,O
parsed,O
during,O
iBP,O
is,O
formed,O
by,O
nodes,O
",",O
each,O
corresponding,O
to,O
one,O
set,O
of,O
atomic,O
coordinates,O
from,O
the,O
order,O
P,O
ato,O
(,O
Figure,O
3,O
),O
[,O
24,O
].,O
At,O
each,O
level,O
of,O
the,O
tree,O
",",O
the,O
atomic,O
coordinates,O
of,O
the,O
corresponding,O
atom,O
are,O
calculated,O
by,O
making,O
use,O
of,O
a,O
recursive,O
procedure,O
",",O
called,O
branching,O
phase,O
.,O
The,O
current,O
atom,O
position,O
is,O
defined,O
by,O
distance,O
constraints,O
to,O
three,O
other,O
atoms,O
.,O
These,O
distances,O
are,O
obtained,O
from,O
the,O
constraints,O
(,O
1,O
-,O
3,O
),O
described,O
above,O
:,O
(,O
1,O
),O
the,O
covalent,O
constraints,O
",",O
(,O
2,O
),O
the,O
NMR,O
distance,O
constraints,O
",",O
(,O
3,O
),O
the,O
van,O
der,O
Waals,O
radii,O
.,O
If,O
the,O
distance,O
constraints,O
specify,O
a,O
unique,O
value,O
rather,O
than,O
an,O
interval,O
",",O
this,O
signifies,O
that,O
the,O
distances,O
to,O
three,O
immediate,O
predecessors,O
from,O
the,O
current,O
vertex,O
are,O
known,O
:,O
these,O
are,O
the,O
centers,O
of,O
the,O
three,O
spheres,O
",",O
and,O
the,O
distances,O
are,O
the,O
radii,O
of,O
these,O
spheres,O
.,O
The,O
position,O
of,O
the,O
current,O
vertex,O
/,O
atom,O
is,O
thus,O
defined,O
by,O
the,O
intersection,O
of,O
three,O
spheres,O
",",O
so,O
there,O
are,O
at,O
most,O
two,O
solutions,O
for,O
the,O
current,O
atom,O
position,O
:,O
this,O
is,O
called,O
a,O
2,O
-,O
branching,O
situation,O
(,O
Figure,O
4,O
).,O
Figure,O
4,O
Intersection,O
of,O
three,O
spheres,O
.,O
Intersection,O
of,O
three,O
spheres,O
",",O
colored,O
in,O
yellow,O
",",O
green,O
and,O
cyan,O
.,O
The,O
two,O
points,O
produced,O
by,O
the,O
intersection,O
are,O
indicated,O
with,O
red,O
spots,O
.,O
When,O
a,O
distance,O
is,O
not,O
uniquely,O
defined,O
",",O
but,O
rather,O
defined,O
by,O
lower,O
and,O
upper,O
bounds,O
",",O
i,O
.,O
e,O
.,O
d,O
i,O
",",O
j,O
∈[,O
l,O
i,O
",",O
j,O
",",O
u,O
i,O
",",O
j,O
"],",O
this,O
distance,O
is,O
uniformly,O
discretized,O
by,O
sampling,O
b,O
≥,O
1,O
values,O
in,O
[,O
l,O
i,O
",",O
j,O
",",O
u,O
i,O
",",O
j,O
"],",O
as,O
depicted,O
in,O
Figure,O
5,O
.,O
(,O
2,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
\,O
tilde,O
d_,O
{,O
i,O
}=\,O
left,O
\{,O
l_,O
{,O
i,O
",",O
i,O
-,O
3,O
},O
+,O
(,O
t,O
-,O
1,O
)\,O
frac,O
{(,O
u_,O
{,O
i,O
",",O
i,O
-,O
3,O
}-,O
l_,O
{,O
i,O
",",O
i,O
-,O
3,O
})}{,O
b,O
},O
:,O
t,O
=,O
1,O
",\",O
ldots,O
",",O
b,O
\,O
right,O
\}.,O
$$,O
\,O
end,O
{,O
document,O
},O
d,O
~,O
i,O
=,O
li,O
",",O
i,O
−,O
3,O
+(,O
t,O
−,O
1,O
)(,O
ui,O
",",O
i,O
−,O
3,O
−,O
li,O
",",O
i,O
−,O
3,O
),O
b,O
:,O
t,O
=,O
1,O
",…,",O
b,O
.,O
Figure,O
5,O
Discretization,O
of,O
the,O
distance,O
constraints,O
.,O
An,O
example,O
of,O
discretization,O
of,O
the,O
distance,O
d,O
i,O
",",O
i,O
−,O
3,O
.,O
The,O
solid,O
circle,O
represents,O
the,O
result,O
of,O
the,O
intersection,O
of,O
the,O
spheres,O
centered,O
in,O
i,O
−,O
1,O
",",O
i,O
−,O
2,O
with,O
radii,O
d,O
i,O
",",O
i,O
−,O
1,O
",",O
d,O
i,O
",",O
i,O
−,O
2,O
",",O
respectively,O
.,O
The,O
distance,O
d,O
i,O
",",O
i,O
−,O
3,O
is,O
discretized,O
accordingly,O
to,O
Equation,O
2,O
with,O
b,O
=,O
5,O
:,O
dotted,O
circles,O
represent,O
the,O
intersections,O
of,O
spheres,O
centered,O
in,O
i,O
−,O
3,O
with,O
radii,O
in,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$\,O
tilde,O
d_,O
{,O
i,O
}$,O
\,O
end,O
{,O
document,O
},O
d,O
~,O
i,O
with,O
the,O
plane,O
containing,O
the,O
i,O
−,O
3,O
",",O
i,O
−,O
2,O
and,O
i,O
−,O
1,O
.,O
Thick,O
gray,O
arcs,O
represent,O
the,O
feasible,O
regions,O
for,O
the,O
atom,O
i,O
.,O
In,O
this,O
case,O
",",O
we,O
have,O
a,O
b,O
-,O
branching,O
situation,O
.,O
The,O
algorithm,O
used,O
for,O
calculating,O
the,O
atom,O
coordinates,O
is,O
then,O
applied,O
to,O
each,O
set,O
of,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$\,O
tilde,O
{,O
d,O
},O
_,O
{,O
i,O
}$,O
\,O
end,O
{,O
document,O
},O
d,O
~,O
i,O
values,O
sampled,O
for,O
the,O
distance,O
constraints,O
.,O
The,O
choice,O
of,O
the,O
discretization,O
factor,O
b,O
is,O
a,O
crucial,O
point,O
:,O
a,O
small,O
value,O
might,O
lead,O
to,O
an,O
infeasible,O
problem,O
because,O
we,O
may,O
not,O
select,O
any,O
feasible,O
distance,O
;,O
a,O
larger,O
value,O
increases,O
the,O
computational,O
burden,O
.,O
In,O
general,O
",",O
the,O
finer,O
the,O
discretization,O
",",O
the,O
more,O
accurate,O
the,O
computation,O
is,O
",",O
but,O
it,O
is,O
not,O
trivial,O
to,O
figure,O
out,O
the,O
optimal,O
value,O
for,O
b,O
.,O
One,O
way,O
to,O
choose,O
b,O
is,O
to,O
consider,O
that,O
the,O
number,O
of,O
nodes,O
in,O
the,O
search,O
tree,O
is,O
bounded,O
by,O
3,O
+(,O
2l,O
b,O
k,O
"),",O
where,O
l,O
is,O
the,O
number,O
of,O
tree,O
levels,O
where,O
we,O
have,O
a,O
2,O
-,O
branching,O
situation,O
",",O
and,O
k,O
is,O
the,O
number,O
of,O
tree,O
levels,O
where,O
we,O
have,O
a,O
b,O
-,O
branching,O
situation,O
[,O
28,O
].,O
Appropriate,O
values,O
of,O
b,O
should,O
result,O
in,O
a,O
manageable,O
number,O
of,O
nodes,O
.,O
Given,O
the,O
position,O
of,O
the,O
three,O
previous,O
atoms,O
k,O
−,O
3,O
",",O
k,O
−,O
2,O
",",O
k,O
−,O
1,O
in,O
the,O
order,O
P,O
ato,O
and,O
given,O
the,O
constraints,O
to,O
these,O
atoms,O
of,O
the,O
atom,O
k,O
to,O
be,O
embedded,O
",",O
the,O
position,O
of,O
k,O
is,O
calculated,O
by,O
a,O
recursive,O
matrix,O
multiplication,O
by,O
making,O
use,O
of,O
the,O
set,O
of,O
distances,O
d,O
={,O
d,O
k,O
",",O
k,O
−,O
1,O
",",O
d,O
k,O
",",O
k,O
−,O
2,O
",",O
d,O
k,O
",",O
k,O
−,O
3,O
},O
between,O
the,O
previous,O
atoms,O
and,O
k,O
.,O
Although,O
there,O
are,O
several,O
methods,O
to,O
compute,O
sphere,O
intersections,O
[,O
29,O
"],",O
in,O
our,O
experience,O
",",O
the,O
best,O
trade,O
-,O
off,O
between,O
efficiency,O
and,O
numerical,O
stability,O
is,O
given,O
by,O
the,O
use,O
of,O
recursion,O
matrices,O
[,O
23,O
"],",O
and,O
of,O
the,O
two,O
following,O
angles,O
:,O
(,O
i,O
),O
the,O
torsion,O
angle,O
ω,O
3,O
formed,O
by,O
atoms,O
{,O
k,O
",",O
k,O
−,O
1,O
",",O
k,O
−,O
2,O
",",O
k,O
−,O
3,O
},O
which,O
depends,O
on,O
the,O
distance,O
between,O
k,O
and,O
k,O
−,O
3,O
",",O
(,O
ii,O
),O
the,O
angle,O
θ,O
2,O
formed,O
by,O
atoms,O
{,O
k,O
",",O
k,O
−,O
1,O
",",O
k,O
−,O
2,O
}.,O
The,O
recursion,O
is,O
applied,O
through,O
the,O
equation,O
:,O
(,O
3,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
\,O
begin,O
{,O
aligned,O
},O
\,O
left,O
[\,O
begin,O
{,O
array,O
}{,O
c,O
},O
x_,O
{,O
k,O
},O
\\,O
y_,O
{,O
k,O
},O
\\,O
z_,O
{,O
k,O
},O
\\,O
1,O
\,O
end,O
{,O
array,O
},O
\,O
right,O
],O
&=,O
B_,O
{,O
1,O
},O
B_,O
{,O
2,O
},O
B_,O
{,O
3,O
},O
\,O
ldots,O
B_,O
{,O
k,O
}(,O
d,O
",\",O
sigma,O
),O
\,O
left,O
[\,O
begin,O
{,O
array,O
}{,O
c,O
},O
0,O
\\,O
0,O
\\,O
0,O
\\,O
1,O
\,O
end,O
{,O
array,O
}\,O
right,O
]\\,O
&=,O
Q_,O
{,O
k,O
-,O
1,O
},O
B_,O
{,O
k,O
}(,O
d,O
",\",O
sigma,O
),O
\,O
left,O
[\,O
begin,O
{,O
array,O
}{,O
c,O
},O
0,O
\\,O
0,O
\\,O
0,O
\\,O
1,O
\,O
end,O
{,O
array,O
}\,O
right,O
],O
=,O
Q_,O
{,O
k,O
},O
\,O
left,O
[\,O
begin,O
{,O
array,O
}{,O
c,O
},O
0,O
\\,O
0,O
\\,O
0,O
\\,O
1,O
\,O
end,O
{,O
array,O
}\,O
right,O
"],",O
\,O
end,O
{,O
aligned,O
},O
$$,O
\,O
end,O
{,O
document,O
},O
xkykzk1,O
=,O
B1B2B3,O
…,O
Bk,O
(,O
d,O
",",O
σ,O
),O
0001,O
=,O
Qk,O
−,O
1Bk,O
(,O
d,O
",",O
σ,O
),O
0001,O
=,O
Qk0001,O
",",O
where,O
:,O
(,O
4,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
{\,O
fontsize,O
{,O
7,O
}{,O
6,O
}\,O
begin,O
{,O
aligned,O
},O
B_,O
{,O
k,O
},O
(,O
d,O
",\",O
sigma,O
),O
=,O
\,O
left,O
[\,O
begin,O
{,O
array,O
}{,O
cccc,O
},O
-\,O
cos,O
\,O
theta_,O
{,O
2,O
},O
&,O
-\,O
sigma,O
\,O
sin,O
\,O
theta_,O
{,O
2,O
},O
&,O
0,O
&,O
-,O
d_,O
{,O
k,O
",",O
k,O
-,O
1,O
}\,O
cos,O
\,O
theta_,O
{,O
2,O
}\\,O
\,O
sigma,O
\,O
sin,O
\,O
theta_,O
{,O
2,O
}\,O
cos,O
\,O
omega_,O
{,O
3,O
},O
&,O
-\,O
cos,O
\,O
theta_,O
{,O
2,O
}\,O
cos,O
\,O
omega_,O
{,O
3,O
},O
&,O
-\,O
sin,O
\,O
omega_,O
{,O
3,O
}&,O
\,O
sigma,O
d_,O
{,O
k,O
",",O
k,O
-,O
1,O
},O
\,O
sin,O
\,O
theta_,O
{,O
2,O
}\,O
cos,O
\,O
omega_,O
{,O
3,O
}\\,O
\,O
sigma,O
\,O
sin,O
\,O
theta_,O
{,O
2,O
}\,O
sin,O
\,O
omega_,O
{,O
3,O
},O
&,O
-\,O
cos,O
\,O
theta_,O
{,O
2,O
},O
\,O
sin,O
\,O
omega_,O
{,O
3,O
}&\,O
cos,O
\,O
omega_,O
{,O
3,O
},O
&\,O
sigma,O
d_,O
{,O
k,O
",",O
k,O
-,O
1,O
},O
\,O
sin,O
\,O
theta_,O
{,O
2,O
}\,O
sin,O
\,O
omega_,O
{,O
3,O
}\\,O
0,O
&,O
0,O
&,O
0,O
&,O
1,O
\,O
end,O
{,O
array,O
}\,O
right,O
"],",O
\,O
end,O
{,O
aligned,O
}},O
$$,O
\,O
end,O
{,O
document,O
},O
Bk,O
(,O
d,O
",",O
σ,O
)=−,O
cosθ2,O
−,O
σsinθ20,O
−,O
dk,O
",",O
k,O
−,O
1cosθ2σsinθ2cosω3,O
−,O
cosθ2cosω3,O
−,O
sinω3σdk,O
",",O
k,O
−,O
1sinθ2cosω3σsinθ2sinω3,O
−,O
cosθ2sinω3cosω3σdk,O
",",O
k,O
−,O
1sinθ2sinω30001,O
",",O
and,O
σ,O
∈{+,O
1,O
",−",O
1,O
}.,O
The,O
series,O
of,O
recursion,O
matrices,O
is,O
initialized,O
as,O
:,O
(,O
5,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
\,O
begin,O
{,O
aligned,O
},O
B_,O
{,O
1,O
}=,O
\,O
left,O
[\,O
begin,O
{,O
array,O
}{,O
cccc,O
},O
1,O
&,O
0,O
&,O
0,O
&,O
0,O
\\,O
0,O
&,O
1,O
&,O
0,O
&,O
0,O
\\,O
0,O
&,O
0,O
&,O
1,O
&,O
0,O
\\,O
0,O
&,O
0,O
&,O
0,O
&,O
1,O
\,O
end,O
{,O
array,O
}\,O
right,O
"],",O
B_,O
{,O
2,O
}=,O
\,O
left,O
[\,O
begin,O
{,O
array,O
}{,O
cccc,O
},O
-,O
1,O
&,O
0,O
&,O
0,O
&,O
-,O
d_,O
{,O
2,O
",",O
1,O
}\\,O
0,O
&,O
1,O
&,O
0,O
&,O
0,O
\\,O
0,O
&,O
0,O
&,O
-,O
1,O
&,O
0,O
\\,O
0,O
&,O
0,O
&,O
0,O
&,O
1,O
\,O
end,O
{,O
array,O
}\,O
right,O
"],\\",O
B_,O
{,O
3,O
}=,O
\,O
left,O
[\,O
begin,O
{,O
array,O
}{,O
cccc,O
},O
-\,O
cos,O
\,O
theta_,O
{,O
3,O
},O
&,O
-\,O
sin,O
\,O
theta_,O
{,O
3,O
},O
&,O
0,O
&,O
-,O
d_,O
{,O
3,O
",",O
2,O
}\,O
cos,O
\,O
theta_,O
{,O
3,O
}\\,O
\,O
sin,O
\,O
theta_,O
{,O
3,O
}&,O
-\,O
cos,O
\,O
theta_,O
{,O
3,O
},O
&,O
0,O
&,O
d_,O
{,O
3,O
",",O
2,O
},O
\,O
cos,O
\,O
theta_,O
{,O
3,O
}\\,O
0,O
&,O
0,O
&,O
1,O
&,O
0,O
\\,O
0,O
&,O
0,O
&,O
0,O
&,O
1,O
\,O
end,O
{,O
array,O
}\,O
right,O
].,O
\,O
end,O
{,O
aligned,O
},O
$$,O
\,O
end,O
{,O
document,O
},O
B1,O
=,O
1000010000100001,O
",",O
B2,O
=−,O
100,O
−,O
d2,O
",",O
1010000,O
−,O
100001,O
",",O
B3,O
=−,O
cosθ3,O
−,O
sinθ30,O
−,O
d3,O
",",O
2cosθ3sinθ3,O
−,O
cosθ30d3,O
",",O
2cosθ300100001,O
.,O
d,O
2,O
",",O
1,O
being,O
the,O
distance,O
between,O
the,O
first,O
and,O
the,O
second,O
atom,O
",",O
and,O
d,O
3,O
",",O
2,O
the,O
distance,O
between,O
the,O
third,O
and,O
the,O
second,O
atom,O
in,O
the,O
order,O
P,O
ato,O
.,O
The,O
total,O
number,O
of,O
B,O
k,O
matrices,O
to,O
be,O
calculated,O
along,O
the,O
parsing,O
of,O
the,O
tree,O
is,O
bounded,O
by,O
2,O
∣,O
P,O
ato,O
∣,O
b,O
",",O
where,O
∣,O
P,O
ato,O
∣,O
is,O
the,O
size,O
of,O
the,O
ordered,O
atom,O
list,O
P,O
ato,O
.,O
The,O
product,O
Q,O
k,O
−,O
1,O
B,O
k,O
is,O
calculated,O
in,O
two,O
steps,O
:,O
(,O
1,O
),O
the,O
fourth,O
column,O
of,O
Q,O
k,O
",",O
which,O
gives,O
us,O
the,O
coordinates,O
of,O
k,O
",",O
is,O
computed,O
;,O
(,O
2,O
),O
only,O
if,O
k,O
is,O
not,O
pruned,O
",",O
the,O
three,O
remaining,O
columns,O
are,O
computed,O
.,O
We,O
must,O
distinguish,O
two,O
cases,O
when,O
embedding,O
an,O
atom,O
k,O
.,O
If,O
it,O
is,O
the,O
first,O
appearance,O
of,O
k,O
in,O
P,O
ato,O
",",O
we,O
use,O
equation,O
3,O
to,O
compute,O
all,O
possible,O
embeddings,O
of,O
k,O
for,O
σ,O
∈{+,O
1,O
",−",O
1,O
},O
and,O
the,O
set,O
of,O
distances,O
d,O
.,O
If,O
it,O
is,O
not,O
the,O
first,O
appearance,O
of,O
k,O
in,O
P,O
ato,O
",",O
we,O
need,O
to,O
take,O
into,O
account,O
the,O
fact,O
that,O
numerical,O
instabilities,O
generate,O
matrices,O
which,O
will,O
lead,O
to,O
slightly,O
different,O
coordinates,O
for,O
k,O
than,O
those,O
computed,O
the,O
first,O
time,O
.,O
In,O
order,O
to,O
decrease,O
the,O
impact,O
of,O
these,O
numerical,O
errors,O
",",O
we,O
compute,O
the,O
set,O
of,O
distances,O
d,O
",",O
the,O
angles,O
θ,O
2,O
",",O
ω,O
3,O
and,O
for,O
σ,O
∈{+,O
1,O
",−",O
1,O
},O
the,O
corresponding,O
matrices,O
B,O
k,O
(,O
d,O
",+",O
1,O
"),",O
B,O
k,O
(,O
d,O
",−",O
1,O
"),",O
which,O
lead,O
to,O
two,O
possible,O
embeddings,O
of,O
k,O
(,O
Equation,O
3,O
"),",O
as,O
k,O
+=,O
Q,O
k,O
−,O
1,O
B,O
k,O
(,O
d,O
",+",O
1,O
),O
and,O
k,O
−=,O
Q,O
k,O
−,O
1,O
B,O
k,O
(,O
d,O
",−",O
1,O
).,O
We,O
choose,O
the,O
value,O
of,O
k,O
that,O
yields,O
the,O
updated,O
coordinates,O
of,O
k,O
being,O
the,O
closest,O
to,O
the,O
previous,O
coordinates,O
of,O
this,O
atom,O
.,O
Each,O
carbonyl,O
oxygen,O
O,O
i,O
−,O
1,O
is,O
uniquely,O
determined,O
for,O
residue,O
i,O
",",O
once,O
C,O
i,O
−,O
1,O
",",O
N,O
i,O
and,O
H,O
i,O
have,O
been,O
embedded,O
",",O
since,O
these,O
atoms,O
are,O
all,O
part,O
of,O
the,O
peptide,O
plane,O
[,O
30,O
].,O
As,O
is,O
common,O
practice,O
(,O
see,O
",",O
e,O
.,O
g,O
".,",O
[,O
31,O
-,O
33,O
"]),",O
we,O
fix,O
here,O
the,O
torsion,O
angle,O
ω,O
of,O
the,O
peptide,O
plane,O
to,O
-,O
180,O
°,O
or,O
0,O
°.,O
In,O
a,O
previous,O
implementation,O
[,O
34,O
"],",O
the,O
positions,O
of,O
the,O
carboxylic,O
oxygens,O
were,O
not,O
stored,O
.,O
Although,O
this,O
approach,O
leads,O
to,O
memory,O
savings,O
",",O
the,O
availability,O
of,O
carboxylic,O
oxygen,O
positions,O
can,O
improve,O
the,O
definition,O
of,O
the,O
α,O
-,O
helix,O
secondary,O
structure,O
.,O
The,O
positions,O
of,O
the,O
carbonyl,O
oxygens,O
are,O
thus,O
now,O
calculated,O
in,O
the,O
following,O
way,O
.,O
If,O
k,O
=,O
O,O
i,O
−,O
1,O
is,O
the,O
carboxylic,O
oxygen,O
atom,O
located,O
at,O
the,O
vertex,O
k,O
",",O
and,O
{,O
v,O
1,O
",",O
v,O
2,O
",",O
v,O
3,O
},O
are,O
the,O
vertices,O
corresponding,O
to,O
atoms,O
{,O
C,O
i,O
−,O
1,O
",",O
N,O
i,O
",",O
H,O
i,O
"},",O
belonging,O
on,O
the,O
same,O
peptide,O
plane,O
π,O
",",O
we,O
denote,O
n,O
π,O
the,O
normal,O
vector,O
to,O
π,O
.,O
The,O
coordinates,O
of,O
k,O
can,O
then,O
be,O
computed,O
by,O
solving,O
the,O
following,O
non,O
-,O
linear,O
system,O
:,O
(,O
6,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
\,O
left,O
\{,O
\,O
begin,O
{,O
array,O
}{,O
ll,O
},O
\|,O
k,O
-,O
v_,O
{,O
i,O
},O
\|^{,O
2,O
},O
=,O
d_,O
{,O
ki,O
}^{,O
2,O
"},",O
&,O
i,O
=,O
1,O
",",O
2,O
",",O
3,O
\\,O
n_,O
{\,O
pi,O
}^{,O
T,O
},O
(,O
v_,O
{,O
1,O
},O
-,O
k,O
),O
=,O
0,O
&,O
\,O
end,O
{,O
array,O
},O
\,O
right,O
..,O
$$,O
\,O
end,O
{,O
document,O
}∥,O
k,O
−,O
vi,O
∥,O
2,O
=,O
dki2,O
",",O
i,O
=,O
1,O
",",O
2,O
",",O
3nπT,O
(,O
v1,O
−,O
k,O
)=,O
0,O
.,O
where,O
d,O
ki,O
are,O
the,O
distances,O
between,O
atoms,O
k,O
and,O
i,O
.,O
Using,O
an,O
approach,O
similar,O
to,O
those,O
employed,O
in,O
[,O
35,O
"],",O
we,O
obtain,O
the,O
equivalent,O
linear,O
system,O
:,O
(,O
7,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
\,O
left,O
\{,O
\,O
begin,O
{,O
array,O
}{,O
l,O
},O
2,O
(,O
v_,O
{,O
2,O
},O
-,O
v_,O
{,O
1,O
})^{,O
T,O
},O
k,O
=,O
d_,O
{,O
k1,O
}^{,O
2,O
},O
-,O
d_,O
{,O
k2,O
}^{,O
2,O
},O
-\|,O
v_,O
{,O
1,O
}\|^{,O
2,O
},O
+\|,O
v_,O
{,O
2,O
}\|^{,O
2,O
}\\,O
2,O
(,O
v_,O
{,O
3,O
},O
-,O
v_,O
{,O
1,O
})^{,O
T,O
},O
k,O
=,O
d_,O
{,O
k1,O
}^{,O
2,O
},O
-,O
d_,O
{,O
k3,O
}^{,O
2,O
},O
-\|,O
v_,O
{,O
1,O
}\|^{,O
2,O
},O
+\|,O
v_,O
{,O
3,O
}\|^{,O
2,O
}\\,O
n_,O
{\,O
pi,O
}^{,O
T,O
},O
(,O
v_,O
{,O
1,O
},O
-,O
k,O
),O
=,O
0,O
\,O
end,O
{,O
array,O
},O
\,O
right,O
.,O
$$,O
\,O
end,O
{,O
document,O
},O
2,O
(,O
v2,O
−,O
v1,O
),O
Tk,O
=,O
dk12,O
−,O
dk22,O
−∥,O
v1,O
∥,O
2,O
+∥,O
v2,O
∥,O
22,O
(,O
v3,O
−,O
v1,O
),O
Tk,O
=,O
dk12,O
−,O
dk32,O
−∥,O
v1,O
∥,O
2,O
+∥,O
v3,O
∥,O
2nπT,O
(,O
v1,O
−,O
k,O
)=,O
0,O
The,O
parameter,O
d,O
k1,O
is,O
the,O
length,O
of,O
the,O
bond,O
connecting,O
O,O
i,O
−,O
1,O
and,O
C,O
i,O
−,O
1,O
",",O
the,O
parameters,O
d,O
k2,O
and,O
d,O
k3,O
are,O
the,O
distances,O
between,O
k,O
=,O
O,O
i,O
−,O
1,O
and,O
N,O
i,O
",",O
H,O
i,O
",",O
calculated,O
from,O
bond,O
angles,O
and,O
bond,O
lengths,O
between,O
atoms,O
of,O
the,O
peptide,O
plane,O
",",O
and,O
the,O
angle,O
ω,O
of,O
180,O
°,O
in,O
a,O
trans,O
peptide,O
plane,O
.,O
The,O
case,O
of,O
the,O
cis,O
peptide,O
plane,O
can,O
be,O
treated,O
in,O
the,O
same,O
way,O
",",O
modifying,O
the,O
value,O
of,O
ω,O
to,O
be,O
0,O
°.,O
Following,O
the,O
idea,O
proposed,O
for,O
carbonyl,O
oxygens,O
",",O
the,O
coordinates,O
k,O
of,O
a,O
C,O
β,O
atom,O
can,O
be,O
computed,O
from,O
previously,O
calculated,O
atoms,O
",",O
because,O
the,O
four,O
distances,O
of,O
k,O
to,O
atoms,O
{,O
v,O
1,O
=,O
C,O
α,O
",",O
v,O
2,O
=,O
H,O
α,O
",",O
v,O
3,O
=,O
N,O
",",O
v,O
4,O
=,O
C,O
},O
are,O
exactly,O
known,O
",",O
and,O
because,O
these,O
five,O
atoms,O
are,O
not,O
coplanar,O
.,O
The,O
coordinates,O
k,O
are,O
calculated,O
by,O
solving,O
the,O
linear,O
system,O
:,O
(,O
8,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
\,O
left,O
\{,O
\,O
begin,O
{,O
aligned,O
},O
2,O
(,O
v_,O
{,O
2,O
},O
-,O
v_,O
{,O
1,O
})^{,O
T,O
},O
k,O
=,O
d_,O
{,O
k1,O
}^{,O
2,O
},O
-,O
d_,O
{,O
k2,O
}^{,O
2,O
},O
-\|,O
v_,O
{,O
1,O
}\|^{,O
2,O
},O
+\|,O
v_,O
{,O
2,O
}\|^{,O
2,O
}\\,O
2,O
(,O
v_,O
{,O
3,O
},O
-,O
v_,O
{,O
1,O
})^{,O
T,O
},O
k,O
=,O
d_,O
{,O
k1,O
}^{,O
2,O
},O
-,O
d_,O
{,O
k3,O
}^{,O
2,O
},O
-\|,O
v_,O
{,O
1,O
}\|^{,O
2,O
},O
+\|,O
v_,O
{,O
3,O
}\|^{,O
2,O
}\\,O
2,O
(,O
v_,O
{,O
4,O
},O
-,O
v_,O
{,O
1,O
})^{,O
T,O
},O
k,O
=,O
d_,O
{,O
k1,O
}^{,O
2,O
},O
-,O
d_,O
{,O
k4,O
}^{,O
2,O
},O
-\|,O
v_,O
{,O
1,O
}\|^{,O
2,O
},O
+\|,O
v_,O
{,O
4,O
}\|^{,O
2,O
},O
\,O
end,O
{,O
aligned,O
},O
\,O
right,O
.,O
$$,O
\,O
end,O
{,O
document,O
},O
2,O
(,O
v2,O
−,O
v1,O
),O
Tk,O
=,O
dk12,O
−,O
dk22,O
−∥,O
v1,O
∥,O
2,O
+∥,O
v2,O
∥,O
22,O
(,O
v3,O
−,O
v1,O
),O
Tk,O
=,O
dk12,O
−,O
dk32,O
−∥,O
v1,O
∥,O
2,O
+∥,O
v3,O
∥,O
22,O
(,O
v4,O
−,O
v1,O
),O
Tk,O
=,O
dk12,O
−,O
dk42,O
−∥,O
v1,O
∥,O
2,O
+∥,O
v4,O
∥,O
2,O
The,O
parameter,O
d,O
k1,O
is,O
the,O
length,O
of,O
the,O
bond,O
connecting,O
k,O
=,O
C,O
β,O
and,O
C,O
α,O
",",O
the,O
parameters,O
d,O
k2,O
",",O
d,O
k3,O
and,O
d,O
k4,O
are,O
the,O
distances,O
between,O
k,O
=,O
C,O
β,O
and,O
H,O
α,O
",",O
N,O
",",O
C,O
",",O
calculated,O
from,O
bond,O
angles,O
and,O
bond,O
lengths,O
between,O
these,O
atoms,O
.,O
Pruning,O
devices,O
Once,O
the,O
set,O
of,O
possible,O
coordinates,O
of,O
the,O
atom,O
k,O
has,O
been,O
determined,O
in,O
the,O
branching,O
phase,O
described,O
above,O
",",O
pruning,O
devices,O
are,O
used,O
to,O
check,O
whether,O
the,O
coordinates,O
of,O
k,O
are,O
feasible,O
.,O
In,O
some,O
cases,O
described,O
below,O
",",O
the,O
coordinates,O
of,O
k,O
along,O
with,O
the,O
coordinates,O
of,O
previously,O
embedded,O
atoms,O
are,O
checked,O
together,O
.,O
If,O
the,O
check,O
is,O
negative,O
",",O
the,O
solution,O
obtained,O
for,O
k,O
is,O
discarded,O
",",O
which,O
prunes,O
all,O
tree,O
branches,O
originating,O
from,O
the,O
node,O
k,O
.,O
In,O
this,O
section,O
",",O
we,O
present,O
the,O
pruning,O
devices,O
used,O
to,O
accept,O
or,O
discard,O
the,O
coordinates,O
of,O
the,O
atom,O
k,O
generated,O
by,O
the,O
branching,O
devices,O
.,O
The,O
pruning,O
device,O
applies,O
all,O
these,O
tests,O
as,O
soon,O
as,O
the,O
involved,O
atoms,O
have,O
been,O
embedded,O
.,O
Direct,O
distance,O
feasibility,O
(,O
DDF,O
),O
As,O
the,O
coordinates,O
for,O
an,O
atom,O
k,O
are,O
determined,O
",",O
we,O
first,O
check,O
that,O
all,O
distances,O
between,O
k,O
and,O
the,O
other,O
embedded,O
atoms,O
respect,O
the,O
given,O
lower,O
and,O
upper,O
bounds,O
arising,O
from,O
the,O
constraints,O
(,O
1,O
-,O
3,O
),O
listed,O
in,O
section,O
“,O
Solving,O
the,O
DGP,O
with,O
iBP,O
”.,O
Torsion,O
angle,O
feasibility,O
(,O
TAF,O
),O
The,O
values,O
of,O
the,O
backbone,O
torsion,O
angles,O
ϕ,O
",",O
ψ,O
",",O
are,O
used,O
as,O
a,O
pruning,O
device,O
",",O
checking,O
whether,O
they,O
are,O
located,O
in,O
the,O
permitted,O
regions,O
of,O
the,O
Ramachandran,O
plot,O
.,O
The,O
pruning,O
device,O
",",O
first,O
introduced,O
in,O
[,O
34,O
"],",O
is,O
implemented,O
in,O
the,O
following,O
way,O
.,O
The,O
torsion,O
angle,O
ξ,O
ijkl,O
defined,O
by,O
a,O
quadruple,O
of,O
atoms,O
{,O
i,O
",",O
j,O
",",O
k,O
",",O
l,O
},O
falls,O
into,O
a,O
domain,O
Ξ,O
ijkl,O
",",O
up,O
to,O
a,O
certain,O
tolerance,O
ε,O
t,O
>,O
0,O
.,O
In,O
general,O
",",O
Ξ,O
ijkl,O
is,O
the,O
union,O
of,O
κ,O
dis,O
-,O
joined,O
intervals,O
",",O
i,O
.,O
e,O
.,O
(,O
9,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
\,O
Xi_,O
{,O
ijkl,O
},O
=,O
\,O
bigcup,O
\,O
limits_,O
{,O
c,O
=,O
1,O
}^{\,O
kappa,O
},O
\,O
Xi_,O
{,O
ijkl,O
}^{,O
c,O
},O
$$,O
\,O
end,O
{,O
document,O
},O
Ξijkl,O
=⋃,O
c,O
=,O
1κΞijklc,O
From,O
the,O
bounds,O
on,O
a,O
torsion,O
angle,O
ξ,O
ijkl,O
it,O
is,O
possible,O
to,O
derive,O
bounds,O
on,O
the,O
distance,O
d,O
il,O
",",O
noticing,O
that,O
(,O
10,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
d_,O
{,O
il,O
}(\,O
xi_,O
{,O
ijkl,O
}),O
=,O
\,O
sqrt,O
{,O
d_,O
{,O
ij,O
}^{,O
2,O
},O
+,O
d_,O
{,O
lj,O
}^{,O
2,O
},O
-,O
2,O
(\,O
cos,O
(\,O
xi_,O
{,O
ijkl,O
})\,O
sqrt,O
{,O
ef,O
},O
+,O
bc,O
),O
d_,O
{,O
ij,O
},O
d_,O
{,O
lj,O
},O
"},",O
$$,O
\,O
end,O
{,O
document,O
},O
dil,O
(,O
ξijkl,O
)=,O
dij2,O
+,O
dlj2,O
−,O
2,O
(,O
cos,O
(,O
ξijkl,O
),O
ef,O
+,O
bc,O
),O
dijdlj,O
",",O
where,O
:,O
(,O
11,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
\,O
begin,O
{,O
aligned,O
},O
b,O
&=,O
\,O
frac,O
{,O
1,O
}{,O
2,O
}\,O
frac,O
{,O
d_,O
{,O
lj,O
}^{,O
2,O
},O
+,O
d_,O
{,O
jk,O
}^{,O
2,O
},O
-,O
d_,O
{,O
lk,O
}^{,O
2,O
}}{,O
d_,O
{,O
lj,O
},O
d_,O
{,O
kj,O
}},O
\\,O
c,O
&=,O
\,O
frac,O
{,O
1,O
}{,O
2,O
}\,O
frac,O
{,O
d_,O
{,O
ij,O
}^{,O
2,O
},O
+,O
d_,O
{,O
jk,O
}^{,O
2,O
},O
-,O
d_,O
{,O
ik,O
}^{,O
2,O
}}{,O
d_,O
{,O
ij,O
},O
d_,O
{,O
jk,O
}}\\,O
e,O
&=,O
1,O
-,O
b,O
^{,O
2,O
"},",O
f,O
=,O
1,O
-,O
c,O
^{,O
2,O
}.\\,O
\,O
end,O
{,O
aligned,O
},O
$$,O
\,O
end,O
{,O
document,O
},O
b,O
=,O
12dlj2,O
+,O
djk2,O
−,O
dlk2dljdkjc,O
=,O
12dij2,O
+,O
djk2,O
−,O
dik2dijdjke,O
=,O
1,O
−,O
b2,O
",",O
f,O
=,O
1,O
−,O
c2,O
.,O
Taking,O
the,O
maximum,O
and,O
minimum,O
values,O
of,O
d,O
(,O
ξ,O
ijkl,O
),O
for,O
ξ,O
ijkl,O
∈,O
Ξ,O
ijkl,O
",",O
we,O
obtain,O
an,O
interval,O
[,O
l,O
il,O
",",O
u,O
il,O
],O
for,O
the,O
distance,O
d,O
il,O
.,O
The,O
sign,O
of,O
the,O
angle,O
ξ,O
ijkl,O
is,O
used,O
as,O
an,O
additional,O
pruning,O
criterion,O
along,O
with,O
the,O
d,O
il,O
interval,O
.,O
Dijkstra,O
shortest,O
-,O
path,O
(,O
DSP,O
),O
As,O
introduced,O
in,O
[,O
23,O
"],",O
we,O
can,O
exploit,O
the,O
fact,O
that,O
the,O
distances,O
are,O
Euclidean,O
to,O
improve,O
the,O
iBP,O
pruning,O
capabilities,O
.,O
We,O
extend,O
and,O
generalize,O
the,O
procedure,O
presented,O
in,O
[,O
36,O
],O
in,O
the,O
following,O
way,O
.,O
We,O
introduce,O
an,O
auxiliary,O
graph,O
G,O
+,O
with,O
the,O
same,O
topology,O
as,O
the,O
graph,O
connecting,O
the,O
atoms,O
in,O
the,O
protein,O
",",O
but,O
such,O
that,O
the,O
weight,O
of,O
each,O
edge,O
(,O
i,O
",",O
j,O
),O
is,O
the,O
upper,O
bound,O
of,O
the,O
distance,O
d,O
ij,O
.,O
For,O
every,O
pair,O
of,O
atoms,O
i,O
",",O
j,O
",",O
the,O
shortest,O
-,O
path,O
between,O
i,O
",",O
j,O
in,O
G,O
+,O
is,O
a,O
valid,O
over,O
-,O
estimate,O
of,O
d,O
ij,O
.,O
Thus,O
we,O
used,O
an,O
all,O
-,O
to,O
-,O
all,O
shortest,O
-,O
path,O
algorithm,O
",",O
the,O
Floyd,O
-,O
Warshall,O
algorithm,O
[,O
37,O
"],",O
to,O
refine,O
the,O
upper,O
bound,O
for,O
each,O
pair,O
of,O
atoms,O
.,O
The,O
Dijkstra,O
Shortest,O
-,O
Path,O
pruning,O
device,O
uses,O
the,O
refined,O
upper,O
bounds,O
of,O
inter,O
-,O
atomic,O
distances,O
in,O
the,O
following,O
way,O
.,O
According,O
to,O
Lemma,O
4,O
in,O
[,O
23,O
"],",O
for,O
an,O
atom,O
k,O
and,O
for,O
each,O
atom,O
pair,O
i,O
",",O
j,O
such,O
that,O
i,O
<,O
j,O
<,O
k,O
in,O
the,O
order,O
P,O
ato,O
and,O
for,O
which,O
d,O
ik,O
is,O
known,O
",",O
the,O
embedding,O
of,O
k,O
can,O
be,O
pruned,O
if,O
:,O
(,O
12,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
\|,O
i,O
-,O
j,O
\|,O
-,O
d_,O
{,O
ik,O
}>,O
u_,O
{,O
jk,O
},O
$$,O
\,O
end,O
{,O
document,O
}∥,O
i,O
−,O
j,O
∥−,O
dik,O
>,O
ujk,O
where,O
u,O
jk,O
is,O
the,O
upper,O
bound,O
of,O
the,O
atom,O
pair,O
(,O
j,O
",",O
k,O
),O
obtained,O
using,O
the,O
Floyd,O
-,O
Warshall,O
algorithm,O
[,O
37,O
].,O
Chirality,O
(,O
CHI,O
),O
The,O
pruning,O
of,O
atom,O
coordinates,O
through,O
the,O
amino,O
-,O
acid,O
chirality,O
is,O
implemented,O
through,O
the,O
so,O
-,O
called,O
CORN,O
rule,O
of,O
thumb,O
:,O
in,O
amino,O
acids,O
",",O
the,O
groups,O
COOH,O
",",O
R,O
(,O
sidechain,O
"),",O
NH2,O
and,O
H,O
are,O
bonded,O
to,O
the,O
chiral,O
center,O
C,O
α,O
carbon,O
.,O
Starting,O
with,O
the,O
hydrogen,O
atom,O
away,O
from,O
the,O
viewer,O
",",O
if,O
these,O
groups,O
are,O
arranged,O
clockwise,O
around,O
the,O
C,O
α,O
carbon,O
",",O
then,O
the,O
amino,O
-,O
acid,O
is,O
in,O
the,O
D,O
-,O
form,O
.,O
If,O
these,O
groups,O
are,O
arranged,O
counter,O
-,O
clockwise,O
",",O
the,O
amino,O
-,O
acid,O
is,O
in,O
the,O
L,O
-,O
form,O
.,O
The,O
CORN,O
rule,O
was,O
restated,O
by,O
imposing,O
that,O
the,O
torsion,O
angle,O
defined,O
by,O
the,O
atoms,O
C,O
",",O
C,O
β,O
",",O
N,O
",",O
H,O
α,O
of,O
residue,O
i,O
for,O
the,O
D,O
-,O
form,O
or,O
C,O
",",O
N,O
",",O
C,O
β,O
",",O
H,O
α,O
of,O
residue,O
i,O
for,O
the,O
L,O
-,O
form,O
",",O
is,O
positive,O
.,O
α,O
-,O
helix,O
secondary,O
structure,O
We,O
proposed,O
the,O
use,O
of,O
α,O
helix,O
information,O
as,O
a,O
pruning,O
device,O
in,O
the,O
context,O
of,O
the,O
iBP,O
algorithm,O
first,O
in,O
[,O
34,O
].,O
The,O
α,O
helix,O
location,O
can,O
be,O
determined,O
from,O
an,O
analysis,O
of,O
the,O
NMR,O
chemical,O
shifts,O
by,O
TALOS,O
[,O
38,O
].,O
Four,O
criteria,O
are,O
used,O
to,O
enforce,O
the,O
formation,O
of,O
an,O
α,O
helix,O
:,O
(,O
i,O
),O
the,O
formation,O
of,O
backbone,O
hydrogen,O
bonds,O
between,O
amide,O
hydrogens,O
and,O
carbonyl,O
oxygens,O
",",O
(,O
ii,O
),O
the,O
alignment,O
of,O
the,O
amide,O
and,O
carbonyl,O
functions,O
checked,O
by,O
a,O
qualitative,O
condition,O
on,O
the,O
energy,O
of,O
the,O
hydrogen,O
bond,O
",",O
(,O
iii,O
),O
the,O
definition,O
of,O
backbone,O
ϕ,O
and,O
ψ,O
torsion,O
angles,O
already,O
described,O
in,O
the,O
Torsion,O
Angle,O
Feasibility,O
",",O
(,O
iv,O
),O
the,O
definition,O
of,O
three,O
additional,O
angles,O
θ,O
",",O
θ,O
’,O
and,O
θ,O
”,O
similar,O
to,O
the,O
ones,O
introduced,O
by,O
Grishaev,O
et,O
al,O
.,O
[,O
39,O
].,O
On,O
a,O
sequence,O
of,O
m,O
+,O
1,O
contiguous,O
residues,O
I,O
α,O
={,O
i,O
",",O
i,O
+,O
1,O
",…,",O
i,O
+,O
m,O
},O
forming,O
an,O
α,O
helix,O
",",O
for,O
any,O
pair,O
of,O
residues,O
(,O
i,O
−,O
4,O
",",O
i,O
),O
belonging,O
to,O
I,O
α,O
",",O
the,O
lower,O
and,O
upper,O
bounds,O
on,O
the,O
distance,O
between,O
the,O
carboxylic,O
oxygen,O
O,O
i,O
−,O
4,O
and,O
the,O
amide,O
hydrogen,O
H,O
i,O
should,O
be,O
compatible,O
with,O
the,O
formation,O
of,O
an,O
hydrogen,O
bond,O
.,O
The,O
upper,O
and,O
lower,O
bounds,O
are,O
defined,O
in,O
an,O
input,O
parameter,O
file,O
of,O
iBP,O
",",O
and,O
were,O
set,O
to,O
1,O
.,O
9,O
and,O
3,O
.,O
0,O
Å,O
in,O
the,O
present,O
work,O
.,O
The,O
condition,O
checking,O
the,O
alignment,O
of,O
atoms,O
involved,O
in,O
the,O
hydrogen,O
bond,O
is,O
implemented,O
by,O
calculating,O
a,O
local,O
energy,O
information,O
defined,O
in,O
the,O
DSSP,O
package,O
[,O
40,O
]:,O
(,O
13,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
q_,O
{,O
1,O
},O
q_,O
{,O
2,O
}\!\,O
left,O
[,O
\,O
frac,O
{,O
1,O
}{,O
d_,O
{,O
O_,O
{,O
i,O
-,O
4,O
},O
N_,O
{,O
i,O
}}}\!,O
+\!,O
\,O
frac,O
{,O
1,O
}{,O
d_,O
{,O
C_,O
{,O
i,O
-,O
4,O
},O
H_,O
{,O
i,O
}}}-,O
\,O
frac,O
{,O
1,O
}{,O
d_,O
{,O
O_,O
{,O
i,O
-,O
4,O
},O
H_,O
{,O
i,O
}}}\!,O
-,O
\!\,O
frac,O
{,O
1,O
}{,O
d_,O
{,O
C_,O
{,O
i,O
-,O
4,O
},O
N_,O
{,O
i,O
}}},O
\,O
right,O
]\,O
cdot,O
f,O
<,O
-,O
0,O
.,O
5,O
",",O
$$,O
\,O
end,O
{,O
document,O
},O
q1q21dOi,O
−,O
4Ni,O
+,O
1dCi,O
−,O
4Hi,O
−,O
1dOi,O
−,O
4Hi,O
−,O
1dCi,O
−,O
4Ni,O
·,O
f,O
<−,O
0,O
.,O
5,O
",",O
with,O
q,O
1,O
=,O
0,O
.,O
42,O
",",O
q,O
2,O
=,O
0,O
.,O
2,O
and,O
f,O
=,O
332,O
",",O
and,O
d,O
AB,O
correspond,O
to,O
the,O
distance,O
between,O
atoms,O
A,O
and,O
B,O
.,O
The,O
last,O
criterion,O
enforces,O
the,O
angles,O
θ,O
",",O
θ,O
"’,",O
θ,O
”,O
to,O
be,O
respectively,O
into,O
the,O
interval,O
values,O
0,O
/,O
70,O
"°,",O
0,O
/,O
90,O
°,O
and,O
110,O
/,O
180,O
°.,O
Implementation,O
details,O
In,O
this,O
section,O
we,O
provide,O
an,O
overview,O
of,O
the,O
main,O
implementation,O
features,O
.,O
The,O
iBP,O
algorithm,O
has,O
been,O
coded,O
in,O
C,O
++,O
with,O
extensive,O
use,O
of,O
template,O
meta,O
-,O
programming,O
[,O
41,O
"],",O
STL,O
[,O
42,O
",",O
43,O
"],",O
and,O
BOOST,O
(,O
www,O
.,O
boost,O
.,O
org,O
).,O
Linear,O
systems,O
",",O
as,O
for,O
instance,O
(,O
7,O
"),",O
are,O
solved,O
using,O
the,O
LAPACK,O
library,O
[,O
44,O
].,O
Discretizable,O
DGP,O
instances,O
were,O
represented,O
by,O
simple,O
weighted,O
undirected,O
graphs,O
G,O
=(,O
V,O
",",O
E,O
",",O
d,O
"),",O
which,O
were,O
handled,O
by,O
the,O
Boost,O
Graph,O
Library,O
(,O
BGL,O
),O
[,O
45,O
].,O
The,O
points,O
in,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$\,O
mathbb,O
{,O
R,O
}^{,O
3,O
}$,O
\,O
end,O
{,O
document,O
},O
ℝ3,O
were,O
represented,O
using,O
the,O
Boost,O
Geometry,O
Library,O
(,O
also,O
known,O
as,O
Generic,O
Geometry,O
Library,O
",",O
GGL,O
:,O
www,O
.,O
boost,O
.,O
org,O
).,O
Constraints,O
on,O
distances,O
",",O
angles,O
or,O
energy,O
are,O
typically,O
expressed,O
by,O
enforcing,O
a,O
variable,O
x,O
to,O
take,O
values,O
in,O
a,O
domain,O
",",O
which,O
is,O
generally,O
the,O
union,O
of,O
intervals,O
and,O
singletons,O
:,O
(,O
14,O
)\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$$,O
\,O
mathcal,O
{,O
D,O
},O
=\,O
left,O
\{,O
\,O
bigcup_,O
{,O
j,O
=,O
1,O
}^{,O
m,O
},O
\,O
bar,O
x_,O
{,O
j,O
},O
\,O
right,O
\}\,O
cup,O
\,O
left,O
\{,O
\,O
bigcup_,O
{,O
i,O
=,O
1,O
}^{,O
k,O
},O
\,O
left,O
[{,O
x_,O
{,O
i,O
}^{,O
l,O
"}},{",O
x_,O
{,O
i,O
}^{,O
u,O
}}\,O
right,O
]\,O
right,O
\}.,O
$$,O
\,O
end,O
{,O
document,O
},O
D,O
=⋃,O
j,O
=,O
1mx,O
¯,O
j,O
∪⋃,O
i,O
=,O
1kxil,O
",",O
xiu,O
.,O
The,O
Boost,O
Interval,O
Library,O
(,O
BIL,O
–,O
see,O
[,O
46,O
",",O
47,O
]),O
was,O
used,O
to,O
store,O
such,O
representation,O
",",O
and,O
to,O
perform,O
basic,O
operations,O
for,O
intervals,O
and,O
singletons,O
.,O
On,O
top,O
of,O
the,O
BIL,O
",",O
we,O
define,O
the,O
type,O
domain,O
which,O
contains,O
a,O
set,O
of,O
intervals,O
and,O
operations,O
as,O
intersection,O
",",O
scaling,O
",",O
etc,O
.,O
The,O
BIL,O
allows,O
also,O
to,O
select,O
the,O
underlining,O
data,O
format,O
for,O
the,O
interval,O
(,O
single,O
/,O
double,O
precision,O
real,O
",",O
integer,O
).,O
Theory,O
In,O
this,O
section,O
we,O
give,O
some,O
details,O
about,O
the,O
worst,O
-,O
case,O
asymptotic,O
complexity,O
behavior,O
of,O
the,O
iBP,O
algorithm,O
.,O
The,O
description,O
given,O
above,O
includes,O
many,O
details,O
which,O
are,O
useful,O
for,O
finding,O
the,O
structure,O
of,O
proteins,O
but,O
which,O
somewhat,O
complicate,O
the,O
precise,O
mathematical,O
treatment,O
.,O
We,O
first,O
give,O
a,O
very,O
brief,O
abstract,O
description,O
of,O
the,O
iBP,O
and,O
of,O
the,O
formal,O
problem,O
it,O
solves,O
",",O
and,O
then,O
proceed,O
to,O
discuss,O
its,O
complexity,O
.,O
Formally,O
speaking,O
",",O
the,O
DGP,O
is,O
the,O
following,O
decision,O
problem,O
:,O
given,O
an,O
integer,O
K,O
>,O
0,O
",",O
a,O
simple,O
undirected,O
graph,O
G,O
=(,O
V,O
",",O
E,O
),O
and,O
an,O
edge,O
weight,O
function,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
d,O
:,O
E,O
\,O
to,O
\,O
mathbb,O
{,O
R,O
},O
_,O
{+}$,O
\,O
end,O
{,O
document,O
},O
d,O
:,O
E,O
→,O
ℝ,O
"+,",O
is,O
there,O
a,O
realization,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
x,O
:,O
V,O
\,O
to,O
\,O
mathbb,O
{,O
R,O
}^{,O
K,O
}$,O
\,O
end,O
{,O
document,O
},O
x,O
:,O
V,O
→,O
ℝK,O
such,O
that,O
for,O
each,O
{,O
u,O
",",O
v,O
}∈,O
E,O
we,O
have,O
∥,O
x,O
u,O
−,O
x,O
v,O
∥,O
2,O
=,O
d,O
uv,O
?,O
Note,O
that,O
we,O
are,O
writing,O
x,O
u,O
for,O
x,O
(,O
u,O
),O
and,O
d,O
uv,O
for,O
d,O
(,O
u,O
",",O
v,O
).,O
We,O
also,O
remark,O
that,O
in,O
the,O
more,O
“,O
applied,O
”,O
interpretation,O
given,O
in,O
the,O
preceding,O
section,O
",",O
the,O
range,O
of,O
the,O
edge,O
function,O
d,O
is,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$\,O
mathbb,O
{,O
IR,O
},O
_,O
{+}$,O
\,O
end,O
{,O
document,O
},O
𝕀ℝ,O
"+,",O
i,O
.,O
e,O
.,O
the,O
set,O
of,O
all,O
non,O
-,O
negative,O
closed,O
real,O
intervals,O
",",O
and,O
K,O
=,O
3,O
.,O
The,O
DGP,O
is,O
NP,O
-,O
hard,O
for,O
any,O
K,O
>,O
1,O
and,O
NP,O
-,O
complete,O
for,O
K,O
=,O
1,O
[,O
48,O
].,O
Since,O
we,O
are,O
interested,O
in,O
finding,O
all,O
solutions,O
of,O
the,O
DGP,O
rather,O
than,O
just,O
one,O
",",O
we,O
denote,O
by,O
X,O
the,O
set,O
of,O
all,O
realizations,O
of,O
G,O
.,O
Assumptions,O
on,O
the,O
DGP,O
input,O
data,O
In,O
fact,O
",",O
due,O
to,O
the,O
fact,O
that,O
our,O
data,O
come,O
from,O
a,O
protein,O
structure,O
setting,O
",",O
we,O
can,O
also,O
make,O
the,O
following,O
assumptions,O
about,O
G,O
and,O
d,O
:,O
there,O
is,O
an,O
order,O
1,O
",",O
2,O
",…,",O
n,O
on,O
the,O
vertices,O
such,O
that,O
1,O
",",O
2,O
",",O
3,O
is,O
a,O
triangle,O
in,O
the,O
graph,O
G,O
and,O
",",O
for,O
each,O
vertex,O
v,O
>,O
3,O
",",O
v,O
is,O
adjacent,O
to,O
v,O
−,O
1,O
",",O
v,O
−,O
2,O
",",O
v,O
−,O
3,O
;,O
the,O
set,O
of,O
edges,O
E,O
can,O
be,O
partitioned,O
in,O
two,O
subsets,O
E,O
D,O
and,O
E,O
P,O
",",O
such,O
that,O
E,O
P,O
consists,O
of,O
all,O
edges,O
{,O
u,O
",",O
v,O
},O
with,O
v,O
>,O
4,O
and,O
|,O
v,O
−,O
u,O
|>,O
3,O
",",O
and,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
E_,O
{,O
D,O
}=,O
E,O
\,O
smallsetminus,O
E_,O
{,O
P,O
}$,O
\,O
end,O
{,O
document,O
},O
ED,O
=,O
E,O
\,O
EP,O
;,O
E,O
D,O
can,O
be,O
further,O
subdivided,O
in,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
E_,O
{,O
D,O
}^{\,O
prime,O
}$,O
\,O
end,O
{,O
document,O
},O
ED,O
′,O
and,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
E_,O
{,O
D,O
}^{\,O
prime,O
\,O
prime,O
}$,O
\,O
end,O
{,O
document,O
},O
ED,O
"′′,",O
so,O
that,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
E_,O
{,O
D,O
}^{\,O
prime,O
\,O
prime,O
}$,O
\,O
end,O
{,O
document,O
},O
ED,O
′′,O
consists,O
of,O
all,O
edges,O
{,O
u,O
",",O
v,O
},O
with,O
|,O
v,O
−,O
u,O
|=,O
3,O
",",O
and,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
E_,O
{,O
D,O
}^{\,O
prime,O
}=,O
E_,O
{,O
D,O
}\,O
smallsetminus,O
E_,O
{,O
D,O
}^{\,O
prime,O
\,O
prime,O
}$,O
\,O
end,O
{,O
document,O
},O
ED,O
′=,O
ED,O
\,O
ED,O
′′;,O
the,O
distance,O
function,O
d,O
is,O
such,O
that,O
:,O
(,O
a,O
),O
d,O
uv,O
is,O
a,O
scalar,O
for,O
each,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$\{,O
u,O
",",O
v,O
\}\,O
in,O
E,O
^{\,O
prime,O
},O
_,O
{,O
D,O
}$,O
\,O
end,O
{,O
document,O
}{,O
u,O
",",O
v,O
}∈,O
ED,O
′;,O
(,O
b,O
),O
d,O
uv,O
consists,O
of,O
a,O
discrete,O
set,O
of,O
b,O
scalars,O
for,O
each,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$\{,O
u,O
",",O
v,O
\}\,O
in,O
E,O
^{\,O
prime,O
\,O
prime,O
},O
_,O
{,O
D,O
}$,O
\,O
end,O
{,O
document,O
}{,O
u,O
",",O
v,O
}∈,O
ED,O
′′;,O
(,O
c,O
),O
d,O
uv,O
is,O
a,O
general,O
interval,O
for,O
all,O
{,O
u,O
",",O
v,O
}∈,O
E,O
P,O
.,O
We,O
remark,O
that,O
the,O
above,O
definitions,O
can,O
be,O
appropriately,O
extended,O
to,O
Euclidean,O
spaces,O
of,O
any,O
dimension,O
K,O
>,O
0,O
",",O
not,O
just,O
K,O
=,O
3,O
.,O
We,O
call,O
E,O
D,O
the,O
discretization,O
edges,O
and,O
E,O
P,O
the,O
pruning,O
edges,O
.,O
Discretization,O
edges,O
ensure,O
that,O
the,O
graph,O
G,O
is,O
rigid,O
",",O
which,O
implies,O
that,O
there,O
are,O
finitely,O
many,O
realizations,O
of,O
G,O
in,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$\,O
mathbb,O
{,O
R,O
}^{,O
K,O
}$,O
\,O
end,O
{,O
document,O
},O
ℝK,O
.,O
Pruning,O
edges,O
make,O
some,O
of,O
those,O
realizations,O
infeasible,O
",",O
and,O
thereby,O
make,O
the,O
solution,O
set,O
X,O
smaller,O
.,O
A,O
few,O
remarks,O
are,O
in,O
order,O
:,O
we,O
consider,O
that,O
distances,O
which,O
are,O
known,O
because,O
of,O
covalent,O
bond,O
relations,O
are,O
sufficiently,O
precise,O
to,O
be,O
represented,O
by,O
a,O
scalar,O
;,O
we,O
consider,O
that,O
distances,O
which,O
are,O
known,O
from,O
NOESY,O
(,O
or,O
other,O
),O
experiments,O
can,O
be,O
represented,O
by,O
intervals,O
;,O
we,O
assume,O
that,O
a,O
limited,O
number,O
of,O
the,O
intervals,O
can,O
be,O
discretized,O
into,O
sets,O
containing,O
a,O
finite,O
number,O
b,O
of,O
values,O
within,O
the,O
intervals,O
;,O
the,O
edges,O
in,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
E_,O
{,O
D,O
}^{\,O
prime,O
}$,O
\,O
end,O
{,O
document,O
},O
ED,O
′,O
represent,O
atom,O
pairs,O
of,O
the,O
form,O
{,O
v,O
",",O
v,O
−,O
1,O
},O
or,O
{,O
v,O
",",O
v,O
−,O
2,O
},O
for,O
any,O
v,O
>,O
2,O
:,O
these,O
are,O
involved,O
in,O
covalent,O
bonds,O
;,O
the,O
edges,O
in,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
E_,O
{,O
D,O
}^{\,O
prime,O
\,O
prime,O
}$,O
\,O
end,O
{,O
document,O
},O
ED,O
′′,O
represent,O
atom,O
pairs,O
which,O
are,O
assigned,O
a,O
certain,O
number,O
b,O
of,O
possible,O
values,O
(,O
optionally,O
b,O
=,O
1,O
for,O
certain,O
pairs,O
);,O
the,O
edges,O
in,O
E,O
P,O
represent,O
atom,O
pairs,O
for,O
which,O
the,O
distance,O
might,O
be,O
a,O
general,O
interval,O
.,O
We,O
remark,O
that,O
the,O
order,O
on,O
V,O
was,O
initially,O
intended,O
to,O
follow,O
the,O
protein,O
backbone,O
[,O
49,O
"],",O
but,O
new,O
orders,O
which,O
better,O
exploit,O
the,O
hydrogen,O
atoms,O
in,O
or,O
close,O
to,O
the,O
backbone,O
have,O
been,O
defined,O
in,O
[,O
50,O
",",O
51,O
]:,O
these,O
are,O
the,O
orders,O
on,O
which,O
the,O
above,O
assumptions,O
are,O
based,O
.,O
The,O
DGP,O
with,O
the,O
restrictions,O
above,O
",",O
but,O
where,O
all,O
intervals,O
are,O
replaced,O
by,O
scalars,O
",",O
is,O
called,O
DISCRETIZABLE,O
MOLECULAR,O
DGP,O
(,O
DMDGP,O
).,O
Both,O
the,O
DMDGP,O
and,O
its,O
generalization,O
to,O
any,O
K,O
(,O
denoted,O
by,O
KDMDGP,O
),O
are,O
NP,O
-,O
hard,O
[,O
52,O
",",O
53,O
].,O
The,O
problem,O
defined,O
above,O
",",O
involving,O
intervals,O
",",O
obviously,O
contains,O
the,O
DMDGP,O
as,O
a,O
sub,O
-,O
case,O
and,O
is,O
hence,O
also,O
NP,O
-,O
hard,O
by,O
inclusion,O
.,O
When,O
all,O
distances,O
are,O
precise,O
We,O
first,O
focus,O
on,O
the,O
simplest,O
case,O
",",O
where,O
all,O
intervals,O
are,O
replaced,O
by,O
scalar,O
values,O
.,O
Then,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
d,O
:,O
E,O
\,O
to,O
\,O
mathbb,O
{,O
R,O
},O
_,O
{+}$,O
\,O
end,O
{,O
document,O
},O
d,O
:,O
E,O
→,O
ℝ,O
"+,",O
and,O
b,O
=,O
1,O
.,O
In,O
this,O
simplified,O
setting,O
",",O
the,O
iBP,O
is,O
simply,O
called,O
BP,O
[,O
52,O
"],",O
and,O
the,O
order,O
on,O
V,O
is,O
called,O
a,O
contiguous,O
trilateration,O
order,O
[,O
54,O
],O
or,O
a,O
DMDGP,O
order,O
[,O
55,O
].,O
The,O
BP,O
can,O
be,O
defined,O
as,O
a,O
recursive,O
procedure,O
:,O
assuming,O
we,O
already,O
found,O
a,O
realization,O
x,O
1,O
",…,",O
x,O
v,O
−,O
1,O
for,O
the,O
vertices,O
1,O
",…,",O
v,O
−,O
1,O
",",O
and,O
that,O
we,O
mean,O
to,O
find,O
a,O
consistent,O
realization,O
x,O
v,O
for,O
v,O
",",O
the,O
discretization,O
edges,O
E,O
D,O
guarantee,O
that,O
there,O
will,O
be,O
at,O
most,O
two,O
positions,O
for,O
x,O
v,O
compatible,O
with,O
the,O
distances,O
restricted,O
to,O
E,O
D,O
[,O
49,O
].,O
This,O
can,O
be,O
intuitively,O
understood,O
in,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$\,O
mathbb,O
{,O
R,O
}^{,O
3,O
}$,O
\,O
end,O
{,O
document,O
},O
ℝ3,O
by,O
considering,O
the,O
intersection,O
of,O
three,O
spheres,O
centered,O
at,O
x,O
v,O
−,O
1,O
",",O
x,O
v,O
−,O
2,O
",",O
x,O
v,O
−,O
3,O
with,O
radii,O
d,O
v,O
",",O
v,O
−,O
1,O
",",O
d,O
v,O
",",O
v,O
−,O
2,O
",",O
d,O
v,O
",",O
v,O
−,O
3,O
:,O
the,O
first,O
two,O
spheres,O
either,O
do,O
not,O
meet,O
or,O
their,O
intersection,O
is,O
in,O
general,O
a,O
circle,O
",",O
and,O
the,O
intersection,O
of,O
the,O
third,O
sphere,O
with,O
this,O
circle,O
is,O
either,O
empty,O
or,O
consists,O
in,O
general,O
of,O
two,O
points,O
[,O
56,O
].,O
We,O
can,O
now,O
consider,O
the,O
distances,O
defined,O
on,O
pruning,O
edges,O
in,O
E,O
P,O
",",O
linking,O
v,O
to,O
its,O
preceding,O
vertices,O
in,O
order,O
to,O
accept,O
or,O
reject,O
these,O
two,O
points,O
.,O
For,O
each,O
accepted,O
point,O
we,O
recursively,O
call,O
BP,O
with,O
v,O
replaced,O
by,O
v,O
+,O
1,O
",",O
for,O
all,O
v,O
<,O
n,O
.,O
When,O
v,O
=,O
n,O
we,O
have,O
a,O
valid,O
realization,O
of,O
the,O
graph,O
:,O
we,O
save,O
it,O
in,O
X,O
",",O
and,O
proceed,O
to,O
complete,O
the,O
recursive,O
search,O
.,O
This,O
yields,O
a,O
search,O
tree,O
which,O
is,O
explored,O
depth,O
-,O
first,O
.,O
The,O
recursion,O
starts,O
after,O
placing,O
the,O
initial,O
triangle,O
1,O
",",O
2,O
",",O
3,O
(,O
either,O
arbitrarily,O
or,O
by,O
using,O
BP,O
restricted,O
to,O
subspaces,O
"),",O
so,O
this,O
tree,O
starts,O
branching,O
at,O
level,O
4,O
.,O
It,O
can,O
be,O
proved,O
that,O
",",O
at,O
completion,O
",",O
X,O
contains,O
all,O
incongruent,O
(,O
modulo,O
translations,O
and,O
rotations,O
),O
realizations,O
of,O
G,O
.,O
In,O
the,O
case,O
where,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
E_,O
{,O
P,O
}=\,O
varnothing,O
$,O
\,O
end,O
{,O
document,O
},O
EP,O
"=∅,",O
the,O
search,O
tree,O
is,O
a,O
complete,O
binary,O
tree,O
with,O
2n,O
−,O
3,O
nodes,O
at,O
the,O
n,O
-,O
th,O
(,O
and,O
last,O
),O
level,O
:,O
in,O
other,O
words,O
",",O
its,O
depth,O
is,O
n,O
and,O
its,O
width,O
is,O
2n,O
−,O
3,O
.,O
This,O
is,O
the,O
worst,O
case,O
",",O
since,O
the,O
BP,O
must,O
explore,O
all,O
of,O
the,O
nodes,O
in,O
the,O
tree,O
",",O
and,O
proves,O
that,O
the,O
BP,O
(,O
and,O
hence,O
the,O
iBP,O
",",O
since,O
it,O
generalizes,O
the,O
BP,O
),O
is,O
an,O
exponential,O
-,O
time,O
algorithm,O
in,O
n,O
.,O
When,O
\,O
documentclass,O
[,O
12pt,O
]{,O
minimal,O
},O
\,O
usepackage,O
{,O
amsmath,O
},O
\,O
usepackage,O
{,O
wasysym,O
},O
\,O
usepackage,O
{,O
amsfonts,O
},O
\,O
usepackage,O
{,O
amssymb,O
},O
\,O
usepackage,O
{,O
amsbsy,O
},O
\,O
usepackage,O
{,O
mathrsfs,O
},O
\,O
usepackage,O
{,O
upgreek,O
},O
\,O
setlength,O
{\,O
oddsidemargin,O
}{-,O
69pt,O
},O
\,O
begin,O
{,O
document,O
},O
$,O
E_,O
{,O
P,O
}\,O
not,O
=\,O
varnothing,O
$,O
\,O
end,O
{,O
document,O
},O
EP,O
"≠∅,",O
it,O
was,O
shown,O
that,O
X,O
almost,O
always,O
contains,O
a,O
number,O
of,O
solutions,O
which,O
is,O
either,O
zero,O
or,O
a,O
power,O
of,O
two,O
[,O
55,O
];,O
this,O
discovery,O
led,O
to,O
a,O
set,O
of,O
results,O
where,O
the,O
BP,O
search,O
tree,O
width,O
can,O
be,O
kept,O
polynomial,O
in,O
n,O
during,O
the,O
search,O
[,O
53,O
].,O
Since,O
the,O
exponential,O
behavior,O
is,O
only,O
due,O
to,O
the,O
tree,O
width,O
",",O
this,O
yields,O
a,O
set,O
of,O
cases,O
where,O
the,O
BP,O
is,O
actually,O
fixed,O
-,O
parameter,O
tractable,O
(,O
FPT,O
).,O
Throughout,O
all,O
our,O
experiments,O
with,O
protein,O
data,O
we,O
were,O
always,O
able,O
to,O
fix,O
the,O
parameter,O
controlling,O
the,O
exponential,O
growth,O
of,O
the,O
tree,O
width,O
to,O
a,O
universal,O
constant,O
",",O
which,O
makes,O
BP,O
“,O
polynomial,O
on,O
proteins,O
”,O
(,O
this,O
is,O
an,O
informal,O
statement,O
—,O
the,O
precise,O
statement,O
is,O
given,O
in,O
[,O
53,O
]).,O
Intervals,O
and,O
discrete,O
distance,O
sets,O
The,O
theory,O
supporting,O
the,O
case,O
where,O
d,O
might,O
map,O
edges,O
to,O
discrete,O
sets,O
of,O
distance,O
values,O
or,O
intervals,O
",",O
which,O
is,O
the,O
case,O
treated,O
in,O
this,O
paper,O
",",O
is,O
not,O
so,O
clearly,O
understood,O
yet,O
.,O
As,O
it,O
generalizes,O
the,O
simpler,O
case,O
sketched,O
above,O
",",O
in,O
a,O
certain,O
sense,O
it,O
inherits,O
its,O
properties,O
",",O
but,O
this,O
is,O
an,O
oversimplification,O
:,O
for,O
instance,O
",",O
if,O
all,O
intervals,O
are,O
[,O
0,O
",∞],",O
it,O
is,O
obvious,O
that,O
the,O
problem,O
is,O
easy,O
independently,O
of,O
the,O
graph,O
topology,O
",",O
since,O
every,O
realization,O
is,O
valid,O
.,O
Some,O
bounds,O
on,O
the,O
cardinality,O
of,O
X,O
in,O
the,O
presence,O
of,O
discrete,O
sets,O
and,O
intervals,O
are,O
given,O
in,O
[,O
55,O
].,O
Our,O
understanding,O
is,O
that,O
if,O
the,O
intervals,O
are,O
small,O
enough,O
",",O
the,O
theory,O
which,O
led,O
to,O
fixed,O
-,O
parameter,O
tractability,O
goes,O
through,O
with,O
few,O
changes,O
",",O
but,O
we,O
have,O
no,O
way,O
so,O
far,O
of,O
establishing,O
an,O
aprioristic,O
maximum,O
width,O
for,O
the,O
intervals,O
.,O
If,O
the,O
intervals,O
are,O
very,O
large,O
the,O
problem,O
might,O
become,O
tractable,O
",",O
as,O
mentioned,O
above,O
",",O
for,O
the,O
purposes,O
of,O
finding,O
at,O
least,O
one,O
solution,O
.,O
The,O
iBP,O
would,O
still,O
behave,O
exponentially,O
",",O
however,O
.,O
Results,O
and,O
discussion,O
We,O
applied,O
the,O
presented,O
algorithm,O
to,O
three,O
examples,O
of,O
proteins,O
displaying,O
α,O
helical,O
secondary,O
structures,O
.,O
Before,O
presenting,O
the,O
obtained,O
results,O
",",O
we,O
emphasize,O
that,O
the,O
method,O
proposed,O
here,O
has,O
a,O
completely,O
different,O
philosophy,O
than,O
classical,O
optimization,O
approaches,O
commonly,O
used,O
in,O
the,O
field,O
of,O
NMR,O
structure,O
determination,O
.,O
In,O
the,O
present,O
approach,O
",",O
each,O
constraint,O
is,O
treated,O
in,O
the,O
strict,O
sense,O
",",O
that,O
is,O
",",O
no,O
violation,O
",",O
however,O
small,O
",",O
is,O
tolerated,O
.,O
This,O
is,O
why,O
we,O
consistently,O
use,O
the,O
word,O
constraint,O
in,O
the,O
paper,O
.,O
This,O
is,O
what,O
potentially,O
allows,O
us,O
to,O
systematically,O
explore,O
the,O
entire,O
search,O
space,O
.,O
However,O
",",O
the,O
use,O
of,O
the,O
procedure,O
demands,O
that,O
the,O
data,O
have,O
been,O
pre,O
-,O
processed,O
accordingly,O
",",O
and,O
all,O
geometric,O
inconsistencies,O
that,O
exist,O
in,O
three,O
–,O
dimensional,O
space,O
have,O
been,O
removed,O
.,O
For,O
the,O
proteins,O
studied,O
here,O
",",O
if,O
one,O
includes,O
the,O
ensemble,O
of,O
NMR,O
interval,O
distance,O
constraints,O
stored,O
in,O
the,O
.,O
mr,O
file,O
at,O
the,O
Protein,O
Data,O
Bank,O
(,O
PDB,O
),O
[,O
57,O
],O
as,O
well,O
as,O
all,O
pruning,O
devices,O
described,O
above,O
",",O
all,O
solutions,O
are,O
pruned,O
out,O
",",O
indicating,O
that,O
no,O
solution,O
to,O
the,O
distance,O
geometry,O
problem,O
exists,O
with,O
the,O
deposited,O
data,O
.,O
This,O
is,O
not,O
really,O
surprising,O
",",O
since,O
the,O
optimization,O
algorithms,O
generally,O
used,O
in,O
NMR,O
structure,O
determination,O
are,O
based,O
on,O
optimization,O
of,O
a,O
target,O
function,O
or,O
hybrid,O
energy,O
rather,O
than,O
on,O
strict,O
constraint,O
satisfaction,O
.,O
That,O
is,O
",",O
there,O
is,O
always,O
a,O
phase,O
where,O
the,O
algorithm,O
tries,O
to,O
find,O
a,O
trade,O
-,O
off,O
when,O
inconsistencies,O
exist,O
between,O
constraints,O
.,O
The,O
optimization,O
thus,O
produces,O
solutions,O
in,O
which,O
chemical,O
and,O
NMR,O
constraints,O
are,O
optimized,O
",",O
but,O
in,O
which,O
small,O
violations,O
are,O
always,O
present,O
.,O
These,O
inconsistencies,O
are,O
present,O
in,O
any,O
structure,O
determination,O
",",O
in,O
particular,O
because,O
distance,O
constraints,O
are,O
imprecise,O
",",O
due,O
to,O
experimental,O
limitations,O
.,O
Since,O
the,O
data,O
in,O
the,O
PDB,O
for,O
the,O
examples,O
presented,O
here,O
were,O
not,O
pre,O
-,O
processed,O
the,O
way,O
our,O
algorithm,O
requires,O
",",O
we,O
decided,O
to,O
use,O
a,O
subset,O
of,O
the,O
stored,O
data,O
sets,O
:,O
the,O
definition,O
of,O
α,O
-,O
helix,O
regions,O
and,O
a,O
few,O
long,O
-,O
range,O
distance,O
constraints,O
arbitrary,O
selected,O
from,O
the,O
set,O
of,O
NMR,O
constraints,O
for,O
structures,O
with,O
more,O
than,O
one,O
α,O
-,O
helix,O
.,O
In,O
order,O
to,O
further,O
reduce,O
the,O
risk,O
of,O
all,O
solutions,O
being,O
pruned,O
",",O
we,O
used,O
tolerance,O
values,O
for,O
atomic,O
positions,O
and,O
angles,O
between,O
atoms,O
(,O
Table,O
2,O
).,O
Table,O
2,O
Analysis,O
of,O
conformations,O
obtained,O
by,O
the,O
branch,O
-,O
and,O
-,O
pruning,O
algorithm,O
on,O
the,O
three,O
proteins,O
targets,O
:,O
2JMY,O
",",O
2KXA,O
and,O
2KSL,O
Proteins,O
2JMY,O
2JMY_1,O
2JMY_2,O
2KXA,O
2KSL,O
Number,O
ofresidues1515152451Number,O
ofvertices107107107170359Definitionof,O
α,O
helices1,O
-,O
153,O
-,O
135,O
-,O
111,O
-,O
11,O
",",O
13,O
-,O
234,O
-,O
11,O
",",O
13,O
-,O
27,O
",",O
29,O
-,O
36,O
",",O
41,O
-,O
50Positiontolerance,O
(,O
Å,O
),O
0,O
.,O
20,O
.,O
20,O
.,O
20,O
.,O
20,O
.,O
2Angletolerance,O
(°),O
22244,O
b,O
value44484Number,O
oflong,O
-,O
rangeconstraints00013Number,O
of,O
savedconformations110000100001000010000Number,O
of,O
generatedconformations1633,O
",",O
937928,O
",",O
3993,O
",",O
380,O
",",O
964491,O
",",O
498CPU,O
time,O
-,O
1,O
min1,O
min25,O
min31,O
minNumber,O
of,O
violatedconstraints,O
(>,O
1Å,O
),O
04,O
.,O
0,O
±,O
2,O
.,O
111,O
.,O
6,O
±,O
3,O
.,O
69,O
.,O
6,O
±,O
2,O
.,O
912,O
.,O
8,O
±,O
1,O
.,O
1Maximumviolation,O
(,O
Å,O
),O
03,O
.,O
3,O
±,O
1,O
.,O
44,O
.,O
8,O
±,O
0,O
.,O
73,O
.,O
7,O
±,O
1,O
.,O
08,O
.,O
1,O
±,O
0,O
.,O
6Mininum,O
RMSDfrom,O
PDB,O
structure,O
(,O
Å,O
),O
1,O
.,O
41,O
.,O
32,O
.,O
11,O
.,O
13,O
.,O
0RMSD,O
from,O
PDB,O
structurefor,O
minimum,O
violatedconformations,O
(,O
Å,O
),O
1,O
.,O
42,O
.,O
92,O
.,O
81,O
.,O
33,O
.,O
5PROCHECKcore,O
residues,O
(%),O
10065,O
.,O
7,O
±,O
25,O
.,O
949,O
.,O
2,O
±,O
7,O
.,O
660,O
.,O
4,O
±,O
8,O
.,O
176,O
.,O
9,O
±,O
2,O
.,O
4allowed,O
residues,O
(%),O
017,O
.,O
9,O
±,O
9,O
.,O
740,O
.,O
9,O
±,O
8,O
.,O
339,O
.,O
6,O
±,O
8,O
.,O
021,O
.,O
3,O
±,O
2,O
.,O
8gen,O
.,O
allow,O
.,O
residues,O
(%),O
03,O
.,O
6,O
±,O
4,O
.,O
89,O
.,O
9,O
±,O
7,O
.,O
20,O
.,O
0,O
±,O
0,O
.,O
01,O
.,O
9,O
±,O
1,O
.,O
7disall,O
.,O
residues,O
(%),O
00,O
.,O
0,O
±,O
0,O
.,O
00,O
.,O
0,O
±,O
0,O
.,O
00,O
.,O
0,O
±,O
0,O
.,O
00,O
.,O
0,O
±,O
0,O
.,O
02JMY_1,O
and,O
2JMY_2,O
correspond,O
to,O
the,O
target,O
2JMY,O
with,O
shorter,O
definitions,O
of,O
α,O
helices,O
.,O
The,O
total,O
number,O
of,O
generated,O
conformations,O
is,O
given,O
",",O
along,O
with,O
the,O
number,O
conformations,O
filtered,O
according,O
to,O
RMSD,O
values,O
.,O
The,O
three,O
examples,O
we,O
chose,O
to,O
illustrate,O
the,O
algorithm,O
display,O
an,O
increasing,O
structural,O
complexity,O
:,O
(,O
i,O
),O
a,O
single,O
α,O
helix,O
",",O
corresponding,O
to,O
the,O
structure,O
of,O
peptide,O
CM15,O
determined,O
in,O
micelles,O
(,O
PDB,O
id,O
:,O
2JMY,O
[,O
58,O
"]),",O
(,O
ii,O
),O
an,O
α,O
helical,O
hairpin,O
(,O
PDB,O
id,O
:,O
2KXA,O
[,O
59,O
"]),",O
(,O
iii,O
),O
the,O
insecticidial,O
toxin,O
TAITX,O
-,O
1a,O
",",O
formed,O
as,O
a,O
bundle,O
of,O
four,O
α,O
helices,O
",",O
restrained,O
by,O
three,O
disulphide,O
bridges,O
(,O
PDB,O
id,O
:,O
2KSL,O
).,O
The,O
main,O
characteristics,O
of,O
the,O
studied,O
proteins,O
are,O
given,O
in,O
Table,O
2,O
.,O
All,O
three,O
examples,O
were,O
originally,O
determined,O
by,O
NMR,O
spectroscopy,O
",",O
and,O
the,O
corresponding,O
constraint,O
lists,O
are,O
available,O
from,O
the,O
PDB,O
.,O
The,O
analysis,O
by,O
PROCHECK,O
[,O
60,O
],O
of,O
the,O
Ramachandran,O
diagram,O
of,O
these,O
three,O
PDB,O
structures,O
shows,O
that,O
more,O
than,O
85,O
%,O
of,O
the,O
residues,O
are,O
located,O
in,O
the,O
core,O
region,O
.,O
For,O
2KXA,O
and,O
2KSL,O
",",O
more,O
than,O
95,O
%,O
of,O
the,O
residues,O
are,O
located,O
in,O
the,O
core,O
and,O
allowed,O
region,O
",",O
whereas,O
in,O
2JMY,O
",",O
7,O
%,O
of,O
the,O
residues,O
are,O
located,O
in,O
the,O
generously,O
allowed,O
region,O
.,O
For,O
2KXA,O
",",O
one,O
PRO,O
residue,O
was,O
replaced,O
by,O
an,O
ALA,O
",",O
as,O
the,O
PRO,O
cycle,O
has,O
not,O
yet,O
been,O
included,O
in,O
the,O
current,O
version,O
of,O
the,O
iBP,O
algorithm,O
.,O
We,O
generated,O
conformations,O
using,O
the,O
branching,O
phase,O
and,O
the,O
pruning,O
devices,O
described,O
above,O
.,O
The,O
long,O
-,O
range,O
constraints,O
added,O
for,O
the,O
calculations,O
of,O
2KXA,O
and,O
2KSL,O
",",O
are,O
:,O
for,O
2KXA,O
",",O
one,O
constraint,O
between,O
H,O
α,O
hydrogen,O
and,O
carbonyl,O
oxygen,O
of,O
Ala,O
-,O
5,O
and,O
Met,O
-,O
17,O
",",O
enforcing,O
the,O
pairing,O
of,O
the,O
two,O
α,O
-,O
helices,O
",",O
for,O
2KSL,O
",",O
three,O
constraints,O
between,O
Carbons,O
β,O
of,O
Cys,O
-,O
7,O
and,O
Cys,O
-,O
37,O
",",O
of,O
Cys,O
-,O
23,O
and,O
Cys,O
-,O
33,O
and,O
of,O
Cys,O
-,O
26,O
and,O
Cys,O
-,O
46,O
",",O
corresponding,O
to,O
the,O
formation,O
of,O
the,O
three,O
disulphide,O
bridges,O
.,O
For,O
all,O
calculations,O
",",O
except,O
the,O
one,O
of,O
2JMY,O
with,O
the,O
α,O
helix,O
defined,O
along,O
the,O
whole,O
sequence,O
",",O
the,O
obtained,O
conformations,O
were,O
filtered,O
according,O
to,O
the,O
coordinate,O
root,O
mean,O
-,O
squared,O
deviation,O
(,O
RMSD,O
:,O
1,O
.,O
5,O
Å,O
),O
with,O
respect,O
to,O
the,O
previously,O
obtained,O
conformation,O
in,O
the,O
iBP,O
procedure,O
.,O
Enforcing,O
an,O
RMSD,O
value,O
larger,O
than,O
1,O
.,O
5,O
Å,O
between,O
two,O
successively,O
stored,O
conformations,O
",",O
avoids,O
an,O
oversampling,O
of,O
the,O
conformational,O
space,O
.,O
Each,O
calculation,O
was,O
stopped,O
after,O
storing,O
10000,O
filtered,O
conformations,O
.,O
For,O
our,O
three,O
examples,O
",",O
five,O
calculations,O
were,O
performed,O
in,O
total,O
:,O
three,O
on,O
2JMY,O
with,O
different,O
definitions,O
of,O
the,O
α,O
helix,O
(,O
residues,O
1,O
-,O
15,O
",",O
3,O
-,O
13,O
and,O
5,O
-,O
11,O
"),",O
and,O
one,O
each,O
for,O
2KXA,O
and,O
2KSL,O
.,O
For,O
the,O
first,O
calculation,O
on,O
2JMY,O
",",O
one,O
conformation,O
was,O
obtained,O
and,O
saved,O
.,O
The,O
second,O
and,O
third,O
calculations,O
on,O
2JMY,O
were,O
quite,O
short,O
",",O
of,O
the,O
order,O
of,O
minutes,O
(,O
Table,O
2,O
"),",O
which,O
is,O
due,O
to,O
the,O
small,O
size,O
of,O
the,O
corresponding,O
tree,O
.,O
For,O
the,O
2KXA,O
and,O
2KSL,O
calculations,O
",",O
10000,O
conformations,O
were,O
obtained,O
in,O
about,O
30,O
mins,O
of,O
calculation,O
.,O
Large,O
total,O
numbers,O
of,O
conformations,O
were,O
generated,O
:,O
this,O
number,O
increases,O
from,O
∼,O
634,O
",",O
000,O
(,O
2JMY_1,O
),O
up,O
to,O
∼,O
3,O
",",O
400,O
",",O
000,O
(,O
2KXA,O
),O
with,O
the,O
size,O
of,O
the,O
considered,O
problem,O
",",O
depending,O
on,O
the,O
number,O
of,O
residues,O
and,O
on,O
the,O
number,O
of,O
constraints,O
.,O
Despite,O
2KSL,O
being,O
the,O
largest,O
example,O
",",O
the,O
second,O
smallest,O
number,O
of,O
conformations,O
was,O
generated,O
",",O
which,O
is,O
the,O
sign,O
of,O
a,O
severe,O
pruning,O
arising,O
from,O
a,O
rather,O
restricted,O
conformational,O
space,O
.,O
The,O
reliability,O
of,O
the,O
obtained,O
conformations,O
was,O
checked,O
in,O
three,O
ways,O
.,O
First,O
",",O
the,O
whole,O
set,O
of,O
NMR,O
constraints,O
deposited,O
along,O
with,O
the,O
PDB,O
entries,O
and,O
involving,O
backbone,O
hydrogens,O
",",O
were,O
probed,O
on,O
the,O
conformations,O
.,O
Second,O
",",O
the,O
quality,O
of,O
the,O
obtained,O
conformations,O
was,O
checked,O
using,O
PROCHECK,O
[,O
60,O
],O
analysis,O
of,O
the,O
Ramachandran,O
plot,O
.,O
Third,O
",",O
the,O
obtained,O
conformations,O
were,O
clustered,O
with,O
an,O
unsupervised,O
clustering,O
method,O
",",O
namely,O
the,O
self,O
-,O
organizing,O
map,O
or,O
SOM,O
[,O
61,O
-,O
64,O
"],",O
in,O
order,O
to,O
investigate,O
the,O
properties,O
of,O
sampled,O
conformations,O
.,O
The,O
agreement,O
of,O
the,O
obtained,O
conformations,O
with,O
the,O
backbone,O
NMR,O
constraints,O
deposited,O
with,O
the,O
PDB,O
structures,O
was,O
checked,O
by,O
calculating,O
the,O
distances,O
between,O
the,O
backbone,O
hydrogens,O
in,O
each,O
obtained,O
conformation,O
.,O
The,O
distances,O
larger,O
than,O
the,O
upper,O
bound,O
of,O
the,O
constraint,O
correspond,O
to,O
violations,O
of,O
this,O
constraint,O
.,O
The,O
mean,O
number,O
of,O
violated,O
constraints,O
along,O
with,O
the,O
mean,O
value,O
of,O
the,O
difference,O
to,O
the,O
upper,O
bound,O
for,O
these,O
constraints,O
were,O
calculated,O
on,O
all,O
conformations,O
(,O
Table,O
2,O
).,O
For,O
the,O
2JMY,O
calculation,O
with,O
the,O
1,O
-,O
15,O
α,O
helix,O
definition,O
",",O
no,O
violation,O
of,O
the,O
NMR,O
constraints,O
could,O
be,O
observed,O
.,O
As,O
expected,O
",",O
when,O
the,O
α,O
helix,O
definition,O
is,O
reduced,O
(,O
2JMY_1,O
and,O
2JMY_2,O
"),",O
the,O
average,O
number,O
of,O
violations,O
increases,O
as,O
well,O
as,O
the,O
average,O
maximum,O
violation,O
.,O
Not,O
surprisingly,O
",",O
the,O
most,O
violated,O
constraints,O
involve,O
residues,O
located,O
at,O
the,O
N,O
and,O
C,O
terminal,O
parts,O
of,O
the,O
α,O
-,O
helix,O
",",O
TRP,O
-,O
2,O
",",O
PHE,O
-,O
5,O
",",O
LYS,O
-,O
3,O
",",O
LYS,O
-,O
6,O
and,O
VAL,O
-,O
11,O
",",O
VAL,O
-,O
14,O
",",O
LEU,O
-,O
15,O
for,O
2JMY_1,O
and,O
2JMY_2,O
.,O
The,O
largest,O
violations,O
and,O
number,O
of,O
violations,O
are,O
of,O
the,O
same,O
order,O
or,O
value,O
for,O
2KXA,O
than,O
for,O
2JMY_1,O
and,O
2JMY_2,O
.,O
In,O
contrast,O
",",O
the,O
largest,O
violations,O
and,O
number,O
of,O
violations,O
are,O
observed,O
for,O
2KSL,O
and,O
involve,O
residues,O
CYS,O
-,O
33,O
",",O
GLU,O
-,O
34,O
",",O
PHE,O
-,O
38,O
",",O
TYR,O
-,O
43,O
.,O
Such,O
over,O
-,O
restraining,O
of,O
NMR,O
structures,O
have,O
been,O
put,O
in,O
evidence,O
in,O
the,O
past,O
",",O
through,O
molecular,O
dynamics,O
simulations,O
[,O
65,O
],O
and,O
analysis,O
of,O
the,O
structure,O
quality,O
[,O
66,O
].,O
The,O
average,O
number,O
of,O
violations,O
is,O
similar,O
for,O
2JMY_2,O
",",O
2KXA,O
and,O
2KSL,O
",",O
but,O
the,O
average,O
maximum,O
violation,O
for,O
2KSL,O
is,O
twice,O
as,O
large,O
as,O
that,O
for,O
2JMY_2,O
and,O
2KXA,O
.,O
This,O
might,O
be,O
due,O
to,O
the,O
very,O
restrained,O
conformations,O
of,O
2KSL,O
",",O
which,O
contain,O
three,O
disulphide,O
bridges,O
.,O
Due,O
to,O
this,O
restrained,O
conformation,O
",",O
the,O
NMR,O
constraint,O
list,O
is,O
probably,O
more,O
prone,O
to,O
contain,O
inconsistencies,O
",",O
and,O
large,O
mechanical,O
strain,O
can,O
be,O
stored,O
in,O
the,O
structure,O
if,O
one,O
uses,O
an,O
optimization,O
procedure,O
such,O
as,O
simulated,O
annealing,O
.,O
In,O
contrast,O
",",O
no,O
mechanical,O
strain,O
whatsoever,O
is,O
generated,O
by,O
the,O
iBP,O
algorithm,O
",",O
and,O
the,O
obtained,O
conformations,O
might,O
have,O
a,O
stronger,O
tendency,O
to,O
deviate,O
from,O
the,O
PDB,O
conformations,O
.,O
For,O
each,O
example,O
",",O
the,O
obtained,O
conformations,O
were,O
compared,O
to,O
the,O
first,O
conformation,O
deposited,O
in,O
the,O
PDB,O
.,O
Minimum,O
RMSD,O
values,O
in,O
the,O
range,O
1,O
.,O
1,O
-,O
2,O
.,O
1,O
Å,O
were,O
obtained,O
for,O
all,O
targets,O
",",O
except,O
2KSL,O
for,O
which,O
the,O
minimum,O
RMSD,O
value,O
was,O
3,O
.,O
0,O
Å,O
.,O
Thus,O
the,O
Branch,O
-,O
and,O
-,O
Prune,O
algorithm,O
was,O
able,O
to,O
capture,O
conformations,O
close,O
to,O
the,O
PDB,O
conformations,O
",",O
the,O
larger,O
value,O
obtained,O
for,O
2KSL,O
arising,O
from,O
the,O
larger,O
mechanical,O
strain,O
quoted,O
above,O
.,O
For,O
each,O
calculation,O
",",O
the,O
conformation,O
displaying,O
the,O
smallest,O
number,O
of,O
NMR,O
constraint,O
violations,O
was,O
compared,O
to,O
the,O
first,O
conformation,O
deposited,O
in,O
the,O
PDB,O
.,O
The,O
RMSD,O
values,O
are,O
smaller,O
than,O
1,O
.,O
5,O
Å,O
for,O
2JMY,O
and,O
2KXA,O
.,O
This,O
shows,O
that,O
",",O
in,O
the,O
context,O
of,O
the,O
iBP,O
algorithm,O
",",O
the,O
measured,O
NMR,O
constraints,O
also,O
push,O
the,O
structure,O
toward,O
the,O
PDB,O
structure,O
.,O
For,O
2JMY_1,O
and,O
2JMY_2,O
",",O
the,O
RMSD,O
value,O
increases,O
since,O
the,O
definition,O
of,O
the,O
α,O
helical,O
region,O
is,O
shorter,O
.,O
For,O
2KSL,O
",",O
the,O
conformation,O
displaying,O
the,O
smallest,O
number,O
of,O
constraint,O
violations,O
",",O
displays,O
an,O
RMSD,O
of,O
3,O
.,O
5Å,O
with,O
the,O
PDB,O
first,O
conformation,O
",",O
which,O
agrees,O
with,O
the,O
maximum,O
number,O
of,O
violations,O
observed,O
for,O
this,O
protein,O
and,O
with,O
the,O
minimum,O
RMSD,O
with,O
the,O
PDB,O
structure,O
analyzed,O
above,O
.,O
From,O
the,O
PROCHECK,O
[,O
60,O
],O
analysis,O
",",O
the,O
percentage,O
of,O
residues,O
located,O
in,O
core,O
and,O
allowed,O
Ramachandran,O
regions,O
",",O
is,O
larger,O
than,O
95,O
%,O
for,O
all,O
targets,O
except,O
2JMY_1,O
",",O
2JMY_2,O
",",O
for,O
which,O
the,O
percentages,O
are,O
about,O
80,O
%,O
due,O
to,O
the,O
reduced,O
definition,O
of,O
the,O
α,O
helix,O
.,O
For,O
all,O
targets,O
",",O
the,O
percentage,O
of,O
residues,O
in,O
disallowed,O
regions,O
is,O
equal,O
to,O
zero,O
.,O
The,O
relatively,O
important,O
percentage,O
of,O
residues,O
located,O
in,O
the,O
allowed,O
region,O
may,O
arise,O
from,O
the,O
systematic,O
exploration,O
performed,O
by,O
the,O
Branch,O
-,O
and,O
-,O
Prune,O
algorithm,O
",",O
the,O
strict,O
nature,O
of,O
the,O
constraints,O
",",O
and,O
the,O
nature,O
of,O
the,O
pruning,O
devices,O
.,O
In,O
order,O
to,O
further,O
probe,O
the,O
robustness,O
of,O
the,O
proposed,O
algorithm,O
",",O
iBP,O
calculations,O
on,O
2KXA,O
and,O
2KSL,O
have,O
been,O
performed,O
",",O
using,O
input,O
data,O
degraded,O
in,O
the,O
following,O
way,O
:,O
(,O
i,O
),O
the,O
length,O
of,O
each,O
α,O
helix,O
has,O
been,O
reduced,O
by,O
1,O
residues,O
at,O
each,O
extremity,O
",",O
(,O
ii,O
),O
the,O
lower,O
and,O
upper,O
bounds,O
of,O
the,O
long,O
-,O
range,O
distance,O
constraints,O
have,O
been,O
increased,O
by,O
0,O
.,O
5,O
Å,O
.,O
The,O
introduction,O
of,O
this,O
noise,O
into,O
the,O
α,O
helical,O
and,O
long,O
-,O
range,O
constraints,O
makes,O
the,O
iBP,O
solution,O
moving,O
apart,O
from,O
the,O
PDB,O
structure,O
",",O
as,O
the,O
minimum,O
RMSD,O
to,O
PDB,O
structure,O
changes,O
from,O
1,O
.,O
1,O
to,O
2,O
Å,O
for,O
2KXA,O
",",O
and,O
from,O
3,O
.,O
0,O
to,O
4,O
.,O
3,O
Å,O
for,O
2KSL,O
.,O
Nevertheless,O
",",O
the,O
quality,O
of,O
the,O
Ramachandran,O
diagram,O
remains,O
satisfying,O
",",O
with,O
93,O
.,O
3,O
%,O
and,O
95,O
.,O
4,O
%,O
of,O
the,O
residues,O
located,O
in,O
the,O
core,O
and,O
allowed,O
regions,O
of,O
the,O
Ramachandran,O
plot,O
for,O
2KXA,O
and,O
2KSL,O
.,O
The,O
conformations,O
were,O
clustered,O
using,O
a,O
self,O
-,O
organizing,O
map,O
(,O
SOM,O
),O
approach,O
[,O
62,O
",",O
63,O
"],",O
on,O
which,O
the,O
coordinate,O
RMSD,O
values,O
between,O
the,O
conformers,O
obtained,O
by,O
Branch,O
-,O
and,O
-,O
Prune,O
and,O
the,O
corresponding,O
PDB,O
structure,O
",",O
were,O
projected,O
on,O
the,O
SOMs,O
(,O
Figure,O
6,O
).,O
These,O
RMSD,O
values,O
lay,O
in,O
the,O
1,O
.,O
3,O
-,O
3,O
.,O
2,O
Å,O
range,O
for,O
2JMY_1,O
",",O
in,O
the,O
2,O
.,O
4,O
-,O
4,O
.,O
9,O
Å,O
range,O
for,O
2JMY_2,O
",",O
in,O
the,O
1,O
.,O
5,O
-,O
4,O
.,O
0,O
Å,O
range,O
for,O
2KXA,O
",",O
and,O
in,O
the,O
3,O
.,O
2,O
-,O
6,O
.,O
0,O
Å,O
for,O
2KSL,O
.,O
Figure,O
6,O
Clustering,O
of,O
the,O
conformations,O
obtained,O
by,O
the,O
i,O
BP,O
algorithm,O
.,O
Self,O
-,O
organizing,O
maps,O
describing,O
the,O
clustering,O
of,O
the,O
conformations,O
obtained,O
by,O
the,O
iBP,O
algorithm,O
on,O
2JMY,O
",",O
2KXA,O
and,O
2KSL,O
.,O
The,O
contour,O
plots,O
(,O
lines,O
),O
represent,O
the,O
local,O
similarity,O
between,O
the,O
clustered,O
conformations,O
.,O
The,O
color,O
scales,O
(,O
on,O
plot,O
left,O
),O
extend,O
from,O
blue,O
to,O
red,O
(,O
from,O
very,O
similar,O
to,O
very,O
dissimilar,O
conformations,O
).,O
The,O
small,O
red,O
points,O
are,O
drawn,O
on,O
the,O
SOM,O
neuron,O
for,O
which,O
the,O
largest,O
local,O
similarity,O
is,O
observed,O
between,O
conformations,O
.,O
Each,O
SOM,O
neuron,O
is,O
colored,O
according,O
to,O
the,O
average,O
value,O
of,O
the,O
coordinates,O
RMSD,O
of,O
the,O
neuron,O
conformations,O
with,O
respect,O
to,O
the,O
PDB,O
structure,O
.,O
The,O
color,O
scales,O
extend,O
(,O
on,O
plot,O
right,O
),O
from,O
purple,O
to,O
green,O
(,O
from,O
very,O
similar,O
to,O
very,O
dissimilar,O
to,O
the,O
PDB,O
structure,O
).,O
The,O
similarity,O
between,O
SOM,O
neurons,O
as,O
well,O
as,O
the,O
RMSD,O
to,O
the,O
PDB,O
structure,O
are,O
expressed,O
in,O
Å,O
for,O
comparison,O
purposes,O
.,O
In,O
the,O
SOMs,O
for,O
the,O
four,O
calculations,O
(,O
Figure,O
6,O
"),",O
the,O
RMSD,O
values,O
are,O
colored,O
according,O
to,O
their,O
RMSD,O
from,O
the,O
PDB,O
entry,O
",",O
violet,O
color,O
indicating,O
values,O
smaller,O
than,O
the,O
median,O
value,O
of,O
the,O
sampled,O
RMSD,O
value,O
",",O
green,O
color,O
indicating,O
RMSD,O
values,O
larger,O
than,O
this,O
median,O
value,O
.,O
For,O
2JMY_1,O
",",O
2KXA,O
and,O
2KSL,O
",",O
a,O
larger,O
number,O
of,O
neurons,O
of,O
the,O
SOMs,O
belongs,O
to,O
the,O
second,O
group,O
",",O
which,O
is,O
the,O
sign,O
of,O
an,O
enhanced,O
sampling,O
of,O
the,O
conformational,O
space,O
with,O
respect,O
to,O
the,O
region,O
sampled,O
by,O
simulated,O
annealing,O
.,O
For,O
2JMY_2,O
",",O
the,O
inverse,O
picture,O
is,O
observed,O
",",O
which,O
may,O
arise,O
from,O
the,O
more,O
limited,O
conformational,O
space,O
available,O
to,O
be,O
sampled,O
for,O
a,O
unique,O
α,O
-,O
helix,O
.,O
In,O
2KSL,O
and,O
2KXA,O
SOMs,O
",",O
the,O
protein,O
conformations,O
corresponding,O
to,O
the,O
region,O
displaying,O
the,O
smallest,O
coordinate,O
RMSD,O
values,O
with,O
respect,O
to,O
the,O
PDB,O
structure,O
",",O
were,O
extracted,O
(,O
Figure,O
7,O
).,O
These,O
sets,O
of,O
conformers,O
are,O
similar,O
to,O
the,O
superimposed,O
conformations,O
obtained,O
in,O
a,O
usual,O
NMR,O
calculation,O
.,O
Figure,O
7,O
Superimposed,O
2KXA,O
and,O
2KSL,O
conformations,O
.,O
Superimposition,O
of,O
2KXA,O
and,O
2KSL,O
conformations,O
extracted,O
from,O
the,O
SOM,O
",",O
as,O
the,O
ones,O
displaying,O
the,O
minimum,O
coordinates,O
RMSD,O
with,O
respect,O
to,O
the,O
first,O
conformer,O
of,O
the,O
corresponding,O
PDB,O
structures,O
.,O
The,O
N,O
and,O
C,O
terminal,O
extremities,O
are,O
labeled,O
",",O
and,O
the,O
conformations,O
",",O
drawn,O
in,O
cartoon,O
",",O
are,O
colored,O
from,O
blue,O
to,O
red,O
",",O
according,O
to,O
the,O
conformational,O
index,O
.,O
Conclusions,O
We,O
proposed,O
here,O
a,O
Branch,O
-,O
and,O
-,O
Prune,O
algorithm,O
(,O
iBP,O
),O
to,O
solve,O
the,O
Distance,O
Geometry,O
Problem,O
",",O
in,O
order,O
to,O
sample,O
exhaustively,O
the,O
conformational,O
space,O
of,O
the,O
backbone,O
of,O
α,O
-,O
helical,O
proteins,O
.,O
The,O
iBP,O
algorithm,O
bears,O
a,O
very,O
slight,O
reminiscence,O
to,O
variable,O
target,O
function,O
approaches,O
for,O
example,O
implemented,O
in,O
DISMAN,O
[,O
67,O
"],",O
due,O
to,O
the,O
sequential,O
nature,O
of,O
introducing,O
constraints,O
and,O
non,O
-,O
bonded,O
interactions,O
.,O
However,O
",",O
the,O
precise,O
way,O
of,O
introducing,O
the,O
constraints,O
and,O
non,O
-,O
bonded,O
interactions,O
differs,O
significantly,O
",",O
and,O
DISMAN,O
does,O
not,O
systematically,O
search,O
space,O
but,O
is,O
an,O
optimization,O
approach,O
.,O
We,O
introduced,O
new,O
pruning,O
devices,O
integrated,O
in,O
the,O
iBP,O
algorithm,O
for,O
DGP,O
with,O
intervals,O
and,O
we,O
tested,O
our,O
iBP,O
implementation,O
on,O
the,O
backbones,O
of,O
α,O
-,O
helical,O
proteins,O
.,O
Several,O
pruning,O
devices,O
have,O
been,O
designed,O
to,O
enforce,O
amino,O
-,O
acid,O
chirality,O
",",O
α,O
-,O
helix,O
geometry,O
and,O
van,O
der,O
Waals,O
steric,O
hindrance,O
.,O
The,O
algorithm,O
allowed,O
to,O
efficiently,O
reconstruct,O
backbone,O
conformations,O
of,O
three,O
α,O
-,O
helical,O
peptides,O
",",O
of,O
various,O
sizes,O
",",O
and,O
for,O
which,O
the,O
structure,O
were,O
previously,O
solved,O
by,O
NMR,O
.,O
The,O
obtained,O
solutions,O
satisfy,O
most,O
of,O
the,O
NMR,O
constraints,O
involving,O
backbone,O
hydrogen,O
bonds,O
",",O
and,O
display,O
very,O
acceptable,O
Ramachandran,O
statistics,O
.,O
The,O
present,O
work,O
represents,O
a,O
first,O
successful,O
step,O
on,O
the,O
way,O
to,O
reconstruct,O
protein,O
structures,O
using,O
a,O
branch,O
-,O
and,O
-,O
prune,O
algorithm,O
applied,O
to,O
the,O
Distance,O
Geometry,O
problem,O
.,O
Applications,O
where,O
this,O
approach,O
could,O
have,O
significant,O
advantages,O
are,O
cases,O
where,O
there,O
are,O
few,O
distances,O
defining,O
the,O
tertiary,O
structure,O
of,O
a,O
protein,O
",",O
where,O
it,O
is,O
important,O
to,O
characterize,O
the,O
space,O
of,O
all,O
solutions,O
.,O
It,O
might,O
also,O
be,O
useful,O
as,O
part,O
iterative,O
automated,O
assignment,O
algorithms,O
such,O
as,O
ARIA,O
[,O
68,O
"],",O
CYANA,O
[,O
69,O
],O
or,O
UNIO,O
[,O
70,O
"],",O
where,O
in,O
a,O
first,O
iteration,O
all,O
solutions,O
compatible,O
with,O
a,O
few,O
unambiguous,O
long,O
-,O
range,O
constraints,O
could,O
be,O
generated,O
to,O
reduce,O
the,O
ambiguity,O
of,O
the,O
remaining,O
constraints,O
.,O
Another,O
application,O
of,O
the,O
approach,O
proposed,O
here,O
would,O
be,O
to,O
provide,O
input,O
molecular,O
conformations,O
to,O
model,O
the,O
structure,O
of,O
multi,O
-,O
subunit,O
complexes,O
into,O
an,O
electron,O
microscopy,O
density,O
map,O
[,O
71,O
].,O
Some,O
limitations,O
of,O
the,O
current,O
version,O
of,O
iBP,O
prevent,O
for,O
the,O
moment,O
its,O
use,O
with,O
real,O
nuclear,O
Overhauser,O
effect,O
(,O
NOE,O
),O
data,O
.,O
These,O
limitations,O
are,O
the,O
use,O
of,O
unambiguous,O
distance,O
constraints,O
",",O
the,O
non,O
-,O
inclusion,O
of,O
protein,O
side,O
-,O
chains,O
",",O
the,O
loss,O
of,O
information,O
intervals,O
and,O
the,O
appropriate,O
weighting,O
of,O
the,O
various,O
constraints,O
in,O
order,O
to,O
overcome,O
the,O
inconsistencies,O
contained,O
among,O
the,O
whole,O
constraint,O
set,O
.,O
Protein,O
side,O
-,O
chains,O
can,O
be,O
added,O
to,O
the,O
protein,O
backbone,O
afterward,O
.,O
The,O
discretization,O
of,O
circle,O
arcs,O
could,O
be,O
tackled,O
using,O
algebraic,O
geometry,O
and,O
geometric,O
algebra,O
approaches,O
[,O
72,O
].,O
The,O
Bayesian,O
approach,O
[,O
73,O
],O
developed,O
for,O
the,O
objective,O
weighting,O
of,O
various,O
NMR,O
contraints,O
according,O
to,O
the,O
data,O
quality,O
could,O
be,O
used,O
to,O
alleviate,O
the,O
inconsistency,O
problems,O
.,O
The,O
use,O
of,O
unambiguous,O
distance,O
constraints,O
is,O
probably,O
the,O
most,O
unavoidable,O
aspect,O
of,O
the,O
current,O
set,O
-,O
up,O
of,O
the,O
algorithm,O
.,O
Competing,O
interests,O
The,O
authors,O
declare,O
that,O
they,O
have,O
no,O
competing,O
interests,O
.,O
Authors,O
’,O
contributions,O
AC,O
",",O
TM,O
",",O
MN,O
",",O
LL,O
and,O
AM,O
designed,O
the,O
work,O
.,O
AC,O
implemented,O
the,O
algorithm,O
.,O
TM,O
",",O
GB,O
and,O
BB,O
performed,O
and,O
analyzed,O
the,O
application,O
cases,O
.,O
AC,O
",",O
BB,O
",",O
AM,O
",",O
LL,O
",",O
CL,O
",",O
RA,O
",",O
MN,O
and,O
TM,O
wrote,O
the,O
manuscript,O
.,O
All,O
authors,O
read,O
and,O
approved,O
the,O
final,O
manuscript,O
.,O
Females,O
Choose,O
Mates,O
Based,O
on,O
Genetic,O
Relatedness,O
in,O
a,O
Small,O
Dasyurid,B-OG
Marsupial,B-OG
",",O
the,O
Agile,B-OG
Antechinus,I-OG
(,O
Antechinus,B-OG
agilis,I-OG
),O
Competing,O
Interests,O
:,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
MLP,O
SJW,O
PDT,O
-,O
S,O
.,O
Performed,O
the,O
experiments,O
:,O
MLP,O
.,O
Analyzed,O
the,O
data,O
:,O
MLP,O
SJW,O
PDT,O
-,O
S,O
LS,O
.,O
Contributed,O
reagents,O
/,O
materials,O
/,O
analysis,O
tools,O
:,O
MLP,O
.,O
Wrote,O
the,O
paper,O
:,O
MLP,O
.,O
Supervised,O
MLP,O
',O
s,O
PhD,O
research,O
:,O
SJW,O
PDT,O
-,O
S,O
LS,O
.,O
Edited,O
the,O
manuscript,O
:,O
SJW,O
PDT,O
-,O
S,O
LS,O
Females,O
in,O
a,O
variety,O
of,O
taxa,O
mate,O
with,O
more,O
than,O
one,O
male,O
during,O
a,O
single,O
oestrus,O
and,O
exhibit,O
mate,O
preferences,O
for,O
genetically,O
compatible,O
males,O
",",O
but,O
the,O
influence,O
of,O
female,O
mate,O
choice,O
on,O
siring,O
success,O
is,O
not,O
clearly,O
understood,O
.,O
Whether,O
females,O
choose,O
to,O
mate,O
with,O
more,O
than,O
one,O
male,O
or,O
endure,O
forced,O
copulations,O
is,O
also,O
often,O
unknown,O
.,O
Here,O
",",O
we,O
examined,O
the,O
effects,O
of,O
genetic,O
relatedness,O
on,O
female,O
mate,O
choice,O
and,O
siring,O
success,O
in,O
a,O
small,O
semelparous,O
carnivorous,O
marsupial,B-OG
",",O
the,O
agile,B-OG
antechinus,I-OG
(,O
Antechinus,B-OG
agilis,I-OG
"),",O
during,O
two,O
consecutive,O
breeding,O
seasons,O
.,O
Experimental,O
trials,O
were,O
conducted,O
in,O
captivity,O
over,O
periods,O
of,O
72,O
hours,O
using,O
interconnected,O
enclosures,O
in,O
which,O
female,O
antechinus,B-OG
could,O
choose,O
to,O
access,O
any,O
of,O
four,O
separated,O
males,O
",",O
but,O
males,O
were,O
only,O
able,O
to,O
access,O
females,O
that,O
entered,O
their,O
quarters,O
.,O
Females,O
had,O
access,O
to,O
two,O
genetically,O
similar,O
and,O
two,O
genetically,O
dissimilar,O
males,O
simultaneously,O
and,O
all,O
behavioural,O
interactions,O
were,O
observed,O
and,O
scored,O
from,O
continuous,O
video,O
recordings,O
.,O
Genetic,O
similarity,O
between,O
mates,O
and,O
paternity,O
of,O
young,O
was,O
determined,O
by,O
microsatellite,O
analyses,O
.,O
Some,O
females,O
chose,O
to,O
enter,O
and,O
mate,O
with,O
more,O
than,O
one,O
male,O
during,O
a,O
single,O
oestrus,O
period,O
.,O
Although,O
females,O
investigated,O
all,O
males,O
",",O
they,O
spent,O
significantly,O
more,O
time,O
visiting,O
",",O
and,O
mated,O
more,O
times,O
with,O
",",O
genetically,O
dissimilar,O
males,O
.,O
Males,O
that,O
were,O
genetically,O
dissimilar,O
to,O
the,O
female,O
sired,O
88,O
%,O
of,O
subsequent,O
offspring,O
.,O
Whilst,O
males,O
mated,O
readily,O
with,O
most,O
females,O
",",O
they,O
rejected,O
the,O
advances,O
of,O
some,O
receptive,O
females,O
",",O
indicating,O
a,O
previously,O
unexpected,O
level,O
of,O
male,O
mate,O
choice,O
.,O
The,O
results,O
show,O
that,O
genetic,O
relatedness,O
between,O
mates,O
has,O
a,O
significant,O
influence,O
on,O
mate,O
choice,O
",",O
breeding,O
and,O
siring,O
success,O
in,O
the,O
agile,B-OG
antechinus,I-OG
.,O
Introduction,O
A,O
female,O
’,O
s,O
choice,O
of,O
mate,O
can,O
significantly,O
affect,O
her,O
reproductive,O
success,O
[,O
1,O
].,O
In,O
social,O
systems,O
that,O
involve,O
no,O
paternal,O
investment,O
other,O
than,O
spermatozoa,O
",",O
females,O
are,O
expected,O
to,O
choose,O
males,O
that,O
confer,O
greater,O
survival,O
and,O
future,O
reproductive,O
success,O
to,O
their,O
offspring,O
(,O
reviewed,O
in,O
[,O
1,O
",",O
2,O
]).,O
Females,O
that,O
are,O
permitted,O
to,O
choose,O
mates,O
in,O
captivity,O
may,O
produce,O
greater,O
quality,O
offspring,O
with,O
improved,O
survival,O
",",O
social,O
dominance,O
",",O
larger,O
home,O
ranges,O
",",O
better,O
nest,O
sites,O
and,O
nests,O
[,O
3,O
],O
and,O
increased,O
attractiveness,O
as,O
mates,O
[,O
4,O
].,O
Similarly,O
",",O
in,O
the,O
wild,O
",",O
a,O
female,O
’,O
s,O
choice,O
of,O
mate,O
can,O
lead,O
to,O
increased,O
fitness,O
and,O
parasite,O
resistance,O
in,O
offspring,O
[,O
5,O
].,O
Females,O
in,O
a,O
variety,O
of,O
taxa,O
may,O
choose,O
males,O
based,O
on,O
a,O
number,O
of,O
criteria,O
",",O
including,O
‘,O
good,O
’,O
or,O
compatible,O
genes,O
with,O
a,O
females,O
own,O
genotype,O
",",O
genes,O
of,O
the,O
major,B-GP
histocompatibility,I-GP
complex,I-GP
(,O
MHC,B-GP
),O
that,O
can,O
offer,O
a,O
reliable,O
olfactory,O
indicator,O
of,O
male,O
health,O
",",O
genetic,O
diversity,O
and,O
quality,O
([,O
2,O
"]),",O
viability,O
genes,O
or,O
genetic,O
relatedness,O
[,O
6,O
",",O
7,O
",",O
8,O
].,O
While,O
viability,O
genes,O
are,O
often,O
expressed,O
through,O
secondary,O
sexual,O
characteristics,O
",",O
it,O
is,O
less,O
clear,O
how,O
females,O
assess,O
the,O
genetic,O
relatedness,O
or,O
incompatibility,O
of,O
potential,O
mates,O
and,O
how,O
this,O
affects,O
the,O
siring,O
success,O
of,O
individual,O
males,O
[,O
6,O
",",O
1,O
",",O
9,O
",",O
10,O
].,O
Such,O
information,O
is,O
lacking,O
for,O
numerous,O
species,O
and,O
the,O
mechanisms,O
for,O
multiple,O
mate,O
selection,O
and,O
the,O
effects,O
of,O
female,O
mate,O
preferences,O
on,O
siring,O
success,O
are,O
still,O
poorly,O
understood,O
.,O
Females,O
mate,O
with,O
more,O
than,O
one,O
male,O
during,O
a,O
single,O
oestrus,O
in,O
a,O
range,O
of,O
species,O
(,O
e,O
.,O
g,O
.,O
common,B-OG
shrews,I-OG
",",O
Sorex,B-OG
araneus,I-OG
[,O
11,O
];,O
Gunnison,B-OG
’,I-OG
s,I-OG
prairie,I-OG
dogs,I-OG
",",O
Cynomys,B-OG
gunnisoni,I-OG
",",O
[,O
12,O
];,O
agile,B-OG
antechinus,I-OG
",",O
Antechinus,B-OG
agilis,I-OG
",",O
[,O
13,O
",",O
14,O
];,O
feathertail,B-OG
gliders,I-OG
",",O
Acrobates,B-OG
pygmaeus,I-OG
",",O
[,O
15,O
"],",O
saltmarsh,B-OG
sparrows,I-OG
(,O
Ammodramus,B-OG
caudacutus,I-OG
;,O
[,O
16,O
"]),",O
grass,B-OG
snakes,I-OG
(,O
Natrix,B-OG
natrix,I-OG
",",O
[,O
17,O
"]),",O
eastern,B-OG
water,I-OG
skinks,I-OG
(,O
Eulamprus,B-OG
quoyii,I-OG
;,O
[,O
18,O
"]),",O
but,O
it,O
is,O
often,O
difficult,O
to,O
determine,O
whether,O
females,O
choose,O
to,O
mate,O
with,O
more,O
than,O
one,O
male,O
or,O
endure,O
forced,O
copulations,O
.,O
Females,O
that,O
mate,O
with,O
a,O
number,O
of,O
different,O
males,O
potentially,O
face,O
greater,O
risk,O
of,O
injury,O
or,O
disease,O
[,O
19,O
",",O
20,O
"],",O
but,O
may,O
benefit,O
through,O
increased,O
reproductive,O
output,O
by,O
ensuring,O
adequate,O
levels,O
of,O
sperm,O
for,O
fertilisation,O
[,O
21,O
",",O
22,O
",",O
18,O
],O
and,O
/,O
or,O
safeguarding,O
against,O
the,O
possible,O
incompatibility,O
or,O
sterility,O
of,O
some,O
males,O
[,O
2,O
",",O
23,O
].,O
Females,O
may,O
also,O
rely,O
on,O
competition,O
between,O
spermatozoa,O
from,O
two,O
or,O
more,O
males,O
to,O
fertilise,O
ova,O
and,O
produce,O
the,O
highest,O
quality,O
young,O
[,O
24,O
",",O
25,O
].,O
Species,O
with,O
multiple,O
mating,O
strategies,O
often,O
produce,O
litters,O
that,O
are,O
sired,O
by,O
more,O
than,O
one,O
male,O
which,O
may,O
increase,O
the,O
success,O
and,O
survival,O
of,O
litters,O
by,O
increasing,O
genetic,O
variability,O
[,O
26,O
],O
and,O
heterozygosity,O
[,O
6,O
",",O
21,O
].,O
This,O
research,O
investigated,O
the,O
effects,O
of,O
genetic,O
relatedness,O
between,O
mates,O
on,O
female,O
choice,O
and,O
the,O
outcomes,O
of,O
multiple,O
mating,O
in,O
the,O
agile,B-OG
antechinus,I-OG
.,O
This,O
species,O
is,O
promiscuous,O
[,O
11,O
",",O
27,O
",",O
28,O
],O
with,O
multiple,O
paternity,O
occurring,O
in,O
96,O
%–,O
98,O
%,O
of,O
litters,O
and,O
an,O
average,O
of,O
three,O
to,O
four,O
sires,O
per,O
litter,O
([,O
14,O
"],",O
MLP,O
unpub,O
.,O
data,O
).,O
Most,O
males,O
sire,O
young,O
in,O
wild,O
populations,O
with,O
81,O
%,O
siring,O
offspring,O
in,O
a,O
year,O
where,O
the,O
population,O
was,O
at,O
parity,O
and,O
100,O
%,O
siring,O
offspring,O
when,O
the,O
population,O
was,O
female,O
biased,O
(,O
MLP,O
unpub,O
.,O
data,O
).,O
Little,O
is,O
known,O
about,O
mate,O
selection,O
in,O
antechinus,B-OG
",",O
but,O
the,O
level,O
of,O
information,O
available,O
on,O
other,O
aspects,O
of,O
their,O
reproduction,O
makes,O
them,O
an,O
ideal,O
model,O
species,O
in,O
which,O
to,O
examine,O
the,O
effects,O
of,O
female,O
preference,O
on,O
multiple,O
matings,O
and,O
siring,O
success,O
.,O
Larger,O
males,O
sire,O
a,O
higher,O
proportion,O
of,O
young,O
in,O
wild,O
populations,O
([,O
29,O
"],",O
MLP,O
unpub,O
.,O
data,O
"),",O
but,O
captive,O
studies,O
have,O
shown,O
that,O
females,O
choose,O
mates,O
on,O
other,O
criteria,O
",",O
including,O
scent,O
and,O
genetic,O
relatedness,O
",",O
rather,O
than,O
on,O
male,O
size,O
[,O
30,O
",",O
31,O
].,O
In,O
wild,O
situations,O
",",O
larger,O
males,O
may,O
secure,O
forced,O
copulations,O
",",O
have,O
increased,O
stamina,O
or,O
travel,O
greater,O
distances,O
to,O
pursue,O
females,O
",",O
or,O
exclude,O
smaller,O
males,O
from,O
mating,O
",",O
and,O
override,O
any,O
opportunity,O
for,O
female,O
mate,O
choice,O
[,O
30,O
].,O
Sperm,O
precedence,O
",",O
where,O
the,O
male,O
that,O
mates,O
closest,O
to,O
ovulation,O
during,O
oestrous,O
receptivity,O
in,O
females,O
sires,O
the,O
highest,O
proportion,O
of,O
young,O
",",O
also,O
significantly,O
influences,O
paternity,O
success,O
[,O
26,O
",",O
32,O
].,O
In,O
this,O
study,O
",",O
a,O
series,O
of,O
captive,O
mating,O
trials,O
was,O
conducted,O
in,O
which,O
receptive,O
females,O
were,O
provided,O
with,O
a,O
simultaneous,O
choice,O
of,O
four,O
males,O
",",O
but,O
these,O
males,O
could,O
not,O
follow,O
a,O
female,O
out,O
of,O
his,O
enclosure,O
and,O
could,O
not,O
interact,O
directly,O
with,O
other,O
males,O
.,O
The,O
combination,O
of,O
males,O
within,O
each,O
trial,O
was,O
selected,O
to,O
provide,O
each,O
female,O
with,O
a,O
range,O
of,O
potential,O
mates,O
that,O
were,O
of,O
similar,O
size,O
",",O
but,O
varied,O
in,O
their,O
degree,O
of,O
relatedness,O
to,O
her,O
.,O
This,O
allowed,O
us,O
to,O
analyse,O
female,O
and,O
male,O
mate,O
choice,O
behaviours,O
and,O
interactions,O
",",O
and,O
test,O
the,O
following,O
hypotheses,O
:,O
1,O
),O
that,O
females,O
prefer,O
males,O
that,O
are,O
genetically,O
dissimilar,O
to,O
themselves,O
;,O
2,O
),O
that,O
female,O
agile,B-OG
antechinus,I-OG
choose,O
to,O
mate,O
with,O
more,O
than,O
one,O
male,O
;,O
and,O
3,O
),O
that,O
genetically,O
dissimilar,O
males,O
have,O
a,O
greater,O
siring,O
success,O
than,O
males,O
that,O
are,O
more,O
genetically,O
similar,O
to,O
the,O
female,O
.,O
Materials,O
and,O
Methods,O
Ethics,O
Statement,O
This,O
research,O
adhered,O
to,O
Animal,B-OG
Behaviour,O
Society,O
Guidelines,O
for,O
the,O
use,O
of,O
animals,B-OG
and,O
was,O
carried,O
out,O
with,O
ethics,O
approval,O
from,O
the,O
Animal,B-OG
Ethics,O
Sub,O
-,O
Committee,O
at,O
the,O
University,O
of,O
Melbourne,O
(,O
AEC,O
02181,O
),O
and,O
under,O
Department,O
of,O
Sustainability,O
and,O
Environment,O
Wildlife,O
permits,O
(,O
10002396,O
and,O
10002889,O
).,O
Animal,B-OG
maintenance,O
Agile,B-OG
antechinus,I-OG
were,O
trapped,O
in,O
the,O
Mt,O
Disappointment,O
State,O
Forest,O
",",O
Victoria,O
",",O
in,O
July,O
2003,O
(,O
n,O
=,O
28,O
",",O
12,O
males,O
and,O
16,O
females,O
),O
and,O
2004,O
(,O
n,O
=,O
24,O
",",O
12,O
males,O
and,O
12,O
females,O
),O
and,O
maintained,O
in,O
captivity,O
as,O
described,O
in,O
Parrott,O
et,O
al,O
.,O
[,O
30,O
",",O
31,O
].,O
Due,O
to,O
extreme,O
drought,O
conditions,O
during,O
the,O
study,O
",",O
animals,B-OG
were,O
in,O
poor,O
condition,O
(,O
based,O
on,O
comparisons,O
of,O
weight,O
with,O
non,O
-,O
drought,O
years,O
",",O
emaciated,O
appearance,O
and,O
dull,O
",",O
rough,O
fur,O
),O
when,O
collected,O
[,O
33,O
"],",O
but,O
all,O
females,O
used,O
in,O
this,O
study,O
survived,O
and,O
were,O
successfully,O
maintained,O
in,O
captivity,O
.,O
On,O
completion,O
of,O
the,O
mate,O
selection,O
experiments,O
",",O
males,O
were,O
released,O
to,O
their,O
original,O
points,O
of,O
capture,O
",",O
except,O
for,O
any,O
that,O
had,O
reached,O
their,O
natural,O
die,O
-,O
off,O
period,O
.,O
Females,O
remained,O
in,O
captivity,O
until,O
young,O
were,O
born,O
and,O
all,O
were,O
then,O
released,O
in,O
their,O
natal,O
nest,O
-,O
boxes,O
back,O
to,O
the,O
wild,O
at,O
their,O
original,O
points,O
of,O
capture,O
.,O
Female,O
choice,O
equipment,O
Experimental,O
enclosures,O
constructed,O
from,O
16,O
mm,O
thick,O
white,O
melamine,O
coated,O
particle,O
board,O
(,O
whiteboard,O
panels,O
",",O
Laminex,O
Industries,O
",",O
Tullamarine,O
",",O
Victoria,O
",",O
Australia,O
;,O
n,O
=,O
3,O
;,O
Fig,O
1A,O
),O
were,O
designed,O
with,O
five,O
compartments,O
",",O
one,O
inner,O
containing,O
2,O
females,O
and,O
4,O
outer,O
each,O
housing,O
a,O
male,O
",",O
which,O
were,O
covered,O
by,O
clear,O
perspex,O
sheets,O
to,O
facilitate,O
observation,O
and,O
video,O
recording,O
.,O
Pairs,O
of,O
females,O
were,O
used,O
as,O
females,O
better,O
adjust,O
to,O
captivity,O
when,O
housed,O
socially,O
(,O
F,O
Kraaijeveld,O
-,O
Smit,O
pers,O
comm,O
).,O
Food,O
was,O
provided,O
in,O
each,O
compartment,O
daily,O
and,O
water,O
(,O
supplemented,O
with,O
Pentavite,O
),O
was,O
available,O
ad,O
libitum,O
[,O
30,O
",",O
31,O
].,O
All,O
compartments,O
were,O
lined,O
with,O
white,O
paper,O
.,O
Enclosures,O
for,O
female,O
choice,O
experiments,O
.,O
(,O
a,O
),O
Enclosure,O
seen,O
from,O
above,O
",",O
showing,O
the,O
four,O
male,O
and,O
one,O
female,O
compartments,O
and,O
furnishings,O
.,O
Four,O
outer,O
compartments,O
",",O
with,O
external,O
measurements,O
400,O
mm,O
×,O
300,O
mm,O
×,O
300,O
mm,O
high,O
",",O
each,O
housed,O
a,O
single,O
male,O
and,O
the,O
middle,O
compartment,O
",",O
measuring,O
800,O
mm,O
×,O
200,O
mm,O
×,O
300,O
mm,O
",",O
housed,O
two,O
females,O
.,O
Each,O
male,O
compartment,O
contained,O
a,O
stainless,O
steel,O
nest,O
-,O
box,O
(,O
130,O
mm,O
×,O
130,O
mm,O
×,O
130,O
mm,O
),O
filled,O
with,O
cotton,O
bedding,O
",",O
a,O
cardboard,O
tube,O
",",O
water,O
bowl,O
",",O
feed,O
tray,O
and,O
plastic,O
climbing,O
lattice,O
on,O
one,O
wall,O
.,O
The,O
female,O
compartment,O
contained,O
a,O
nest,O
-,O
tube,O
with,O
cotton,O
bedding,O
(,O
200,O
mm,O
long,O
×,O
100,O
mm,O
diameter,O
),O
which,O
had,O
entrance,O
/,O
exit,O
holes,O
at,O
each,O
end,O
",",O
plus,O
a,O
water,O
bowl,O
",",O
feed,O
tray,O
and,O
lattice,O
placed,O
at,O
each,O
end,O
.,O
Holes,O
(,O
3,O
mm,O
diameter,O
),O
were,O
drilled,O
every,O
30,O
mm,O
around,O
the,O
base,O
and,O
top,O
of,O
the,O
four,O
outer,O
walls,O
of,O
the,O
enclosures,O
to,O
allow,O
air,O
flow,O
and,O
in,O
two,O
lines,O
near,O
the,O
base,O
of,O
the,O
walls,O
between,O
the,O
male,O
and,O
female,O
compartments,O
to,O
facilitate,O
movement,O
of,O
animal,B-OG
scents,O
.,O
In,O
the,O
centre,O
of,O
the,O
wall,O
separating,O
each,O
male,O
compartment,O
from,O
the,O
female,O
compartment,O
",",O
a,O
70,O
mm,O
×,O
70,O
mm,O
gap,O
was,O
covered,O
by,O
a,O
removable,O
clear,O
perspex,O
‘,O
door,O
’,O
which,O
contained,O
a,O
15,O
mm,O
diameter,O
hole,O
.,O
The,O
size,O
of,O
the,O
hole,O
allowed,O
the,O
exclusion,O
of,O
the,O
larger,O
males,O
which,O
were,O
unable,O
to,O
leave,O
their,O
own,O
compartment,O
in,O
this,O
sexually,O
dimorphic,O
species,O
and,O
allowed,O
almost,O
all,O
females,O
to,O
move,O
in,O
and,O
out,O
of,O
the,O
male,O
and,O
female,O
compartments,O
uninhibited,O
.,O
Females,O
were,O
able,O
to,O
see,O
and,O
interact,O
with,O
males,O
through,O
the,O
perspex,O
and,O
hole,O
.,O
Doors,O
were,O
recessed,O
into,O
a,O
groove,O
across,O
the,O
centre,O
of,O
a,O
wooden,O
‘,O
door,O
step,O
’,O
(,O
60,O
mm,O
×,O
70,O
mm,O
×,O
20,O
mm,O
high,O
),O
with,O
grooves,O
on,O
either,O
side,O
of,O
the,O
door,O
to,O
provide,O
grip,O
.,O
(,O
b,O
),O
Video,O
surveillance,O
set,O
-,O
up,O
showing,O
the,O
enclosure,O
",",O
video,O
camera,O
and,O
video,O
recorder,O
.,O
A,O
small,O
black,O
and,O
white,O
closed,O
-,O
circuit,O
digital,O
camera,O
(,O
1,O
/,O
4,O
B,O
/,O
W,O
G,O
type,O
security,O
surveillance,O
camera,O
",",O
Jaycar,O
",",O
Silverwater,O
",",O
NSW,O
",",O
Australia,O
),O
suspended,O
above,O
the,O
centre,O
of,O
each,O
enclosure,O
was,O
connected,O
to,O
a,O
video,O
recorder,O
(,O
V,O
-,O
W58H,O
6,O
head,O
HiFi,O
VCR,O
",",O
Toshiba,O
",",O
Mt,O
.,O
Waverley,O
",",O
Victoria,O
",",O
Australia,O
;,O
Fig,O
1B,O
).,O
Light,O
cycles,O
mimicked,O
natural,O
conditions,O
with,O
a,O
dim,O
red,O
light,O
(,O
12,O
W,O
dark,O
room,O
infrared,O
globe,O
",",O
Philips,O
",",O
North,O
Ryde,O
",",O
NSW,O
",",O
Australia,O
),O
on,O
during,O
night,O
hours,O
to,O
allow,O
video,O
recording,O
and,O
direct,O
observation,O
.,O
An,O
observer,O
(,O
MLP,O
),O
was,O
present,O
in,O
the,O
room,O
during,O
all,O
night,O
hours,O
",",O
and,O
most,O
hours,O
during,O
the,O
day,O
",",O
to,O
record,O
direct,O
observations,O
and,O
ensure,O
no,O
animals,B-OG
became,O
trapped,O
or,O
injured,O
.,O
Behaviours,O
were,O
observed,O
via,O
video,O
output,O
on,O
a,O
TV,O
screen,O
or,O
from,O
a,O
distance,O
to,O
minimise,O
disturbance,O
to,O
the,O
animals,B-OG
and,O
ensure,O
animal,B-OG
movements,O
were,O
not,O
influenced,O
.,O
Any,O
females,O
that,O
were,O
seized,O
and,O
held,O
through,O
doors,O
by,O
males,O
and,O
appeared,O
unable,O
to,O
free,O
themselves,O
after,O
~,O
2,O
minutes,O
were,O
freed,O
by,O
the,O
observer,O
by,O
gently,O
prodding,O
the,O
male,O
with,O
a,O
light,O
",",O
blunt,O
instrument,O
.,O
This,O
occurred,O
only,O
once,O
when,O
an,O
observer,O
was,O
not,O
present,O
and,O
the,O
female,O
freed,O
herself,O
after,O
~,O
8,O
minutes,O
.,O
No,O
females,O
were,O
injured,O
or,O
lost,O
fur,O
when,O
seized,O
.,O
Ambient,O
temperature,O
was,O
maintained,O
at,O
21,O
±,O
1,O
°,O
C,O
",",O
but,O
temperature,O
was,O
approximately,O
2,O
°,O
C,O
higher,O
inside,O
the,O
enclosures,O
.,O
Between,O
trials,O
",",O
enclosures,O
were,O
cleaned,O
with,O
detergent,O
",",O
water,O
and,O
70,O
%,O
ethanol,O
and,O
allowed,O
to,O
air,O
-,O
dry,O
to,O
remove,O
scents,O
and,O
other,O
contaminating,O
material,O
that,O
may,O
have,O
influenced,O
behavioural,O
interactions,O
in,O
the,O
next,O
trial,O
.,O
Female,O
choice,O
experiment,O
In,O
2003,O
",",O
eight,O
trials,O
using,O
a,O
total,O
of,O
12,O
males,O
and,O
16,O
females,O
were,O
performed,O
",",O
while,O
in,O
2004,O
",",O
this,O
was,O
reduced,O
to,O
six,O
trials,O
using,O
12,O
males,O
and,O
12,O
females,O
.,O
To,O
determine,O
the,O
onset,O
of,O
mating,O
receptivity,O
and,O
ovulation,O
",",O
urine,O
from,O
each,O
female,O
was,O
examined,O
daily,O
to,O
monitor,O
numbers,O
of,O
cornified,O
epithelial,O
cells,O
with,O
‘,O
Day,O
0,O
’,O
of,O
the,O
receptive,O
period,O
corresponding,O
to,O
the,O
time,O
of,O
detection,O
of,O
the,O
first,O
high,O
levels,O
of,O
cornified,O
epithelial,O
cells,O
[,O
34,O
].,O
Females,O
have,O
a,O
receptive,O
period,O
during,O
which,O
they,O
mate,O
",",O
when,O
numbers,O
of,O
cornified,O
epithelial,O
cell,O
in,O
their,O
urine,O
are,O
high,O
for,O
up,O
to,O
20,O
days,O
before,O
ovulation,O
",",O
and,O
continuing,O
after,O
ovulation,O
when,O
such,O
cell,O
numbers,O
start,O
to,O
decline,O
[,O
35,O
].,O
However,O
",",O
the,O
most,O
fertile,O
receptive,O
period,O
when,O
the,O
percentage,O
of,O
normal,O
embryos,O
is,O
high,O
(,O
60,O
–,O
100,O
%),O
occurs,O
5,O
–,O
13,O
days,O
before,O
ovulation,O
[,O
13,O
],O
due,O
to,O
declining,O
fertilizing,O
capacity,O
of,O
stored,O
sperm,O
outside,O
that,O
period,O
.,O
All,O
trials,O
were,O
conducted,O
after,O
day,O
3,O
of,O
the,O
receptive,O
period,O
and,O
during,O
the,O
most,O
fertile,O
portion,O
of,O
the,O
receptive,O
period,O
wherever,O
possible,O
(,O
22,O
/,O
28,O
females,O
;,O
with,O
3,O
females,O
paired,O
on,O
days,O
4,O
–,O
6,O
and,O
3,O
females,O
paired,O
after,O
day,O
14,O
due,O
to,O
time,O
constraints,O
"),",O
and,O
all,O
were,O
completed,O
prior,O
to,O
ovulation,O
.,O
Male,O
urine,O
was,O
analysed,O
prior,O
to,O
experiments,O
to,O
ensure,O
all,O
males,O
were,O
producing,O
sperm,O
.,O
Females,O
were,O
provided,O
with,O
two,O
males,O
that,O
were,O
more,O
genetically,O
similar,O
and,O
two,O
less,O
genetically,O
similar,O
(,O
dissimilar,O
),O
to,O
themselves,O
(,O
see,O
below,O
).,O
Females,O
in,O
each,O
pair,O
were,O
identified,O
by,O
black,O
permanent,O
marker,O
on,O
their,O
tails,O
with,O
two,O
thin,O
stripes,O
given,O
to,O
one,O
female,O
and,O
two,O
thick,O
bands,O
given,O
to,O
the,O
other,O
.,O
To,O
remove,O
any,O
influence,O
of,O
male,O
size,O
on,O
mate,O
selection,O
or,O
male,O
success,O
and,O
enable,O
a,O
more,O
controlled,O
examination,O
of,O
female,O
preference,O
for,O
genetic,O
relatedness,O
",",O
males,O
in,O
each,O
trial,O
were,O
selected,O
to,O
be,O
roughly,O
of,O
equal,O
weight,O
",",O
with,O
less,O
than,O
3,O
g,O
difference,O
between,O
them,O
(,O
mean,O
±,O
SE,O
",",O
2003,O
:,O
31,O
.,O
8,O
±,O
0,O
.,O
3,O
g,O
;,O
2004,O
:,O
37,O
.,O
7,O
±,O
0,O
.,O
8,O
g,O
).,O
No,O
males,O
were,O
able,O
to,O
leave,O
their,O
compartments,O
through,O
size,O
exclusion,O
doors,O
.,O
Females,O
chosen,O
for,O
this,O
experiment,O
were,O
in,O
their,O
first,O
breeding,O
season,O
and,O
had,O
not,O
previously,O
mated,O
(,O
mean,O
weight,O
±,O
SE,O
",",O
2003,O
:,O
20,O
.,O
1,O
±,O
0,O
.,O
4,O
g,O
;,O
2004,O
:,O
18,O
.,O
9,O
±,O
0,O
.,O
6,O
g,O
).,O
Females,O
that,O
attempted,O
to,O
enter,O
areas,O
and,O
were,O
observed,O
to,O
insert,O
a,O
head,O
and,O
torso,O
",",O
but,O
could,O
not,O
enter,O
due,O
to,O
the,O
width,O
of,O
their,O
pelvis,O
(,O
n,O
=,O
3,O
"),",O
were,O
placed,O
with,O
males,O
and,O
observed,O
at,O
all,O
times,O
.,O
This,O
occurred,O
only,O
once,O
while,O
an,O
observer,O
was,O
not,O
present,O
one,O
afternoon,O
",",O
but,O
the,O
female,O
was,O
introduced,O
to,O
the,O
male,O
compartment,O
when,O
she,O
tried,O
to,O
enter,O
again,O
that,O
night,O
.,O
When,O
females,O
attempted,O
to,O
leave,O
",",O
they,O
were,O
removed,O
from,O
the,O
male,O
compartment,O
by,O
the,O
experimenter,O
(,O
MLP,O
"),",O
who,O
was,O
present,O
at,O
all,O
times,O
the,O
female,O
was,O
in,O
the,O
compartment,O
.,O
There,O
was,O
no,O
difference,O
in,O
the,O
mating,O
behaviour,O
or,O
breeding,O
success,O
rates,O
of,O
these,O
females,O
compared,O
with,O
females,O
that,O
could,O
enter,O
and,O
leave,O
of,O
their,O
own,O
accord,O
(,O
n,O
=,O
25,O
).,O
Primiparous,O
females,O
were,O
chosen,O
for,O
this,O
experiment,O
as,O
few,O
females,O
survive,O
to,O
produce,O
a,O
litter,O
in,O
a,O
second,O
year,O
",",O
with,O
no,O
second,O
-,O
year,O
females,O
producing,O
a,O
litter,O
during,O
drought,O
[,O
33,O
].,O
Each,O
trial,O
was,O
conducted,O
over,O
72,O
hours,O
(,O
three,O
days,O
),O
with,O
constant,O
video,O
recording,O
",",O
providing,O
around,O
1008,O
hours,O
of,O
video,O
for,O
analysis,O
.,O
Males,O
were,O
allowed,O
one,O
day,O
rest,O
between,O
trials,O
.,O
Videos,O
were,O
analysed,O
to,O
determine,O
for,O
each,O
female,O
1,O
),O
the,O
number,O
of,O
visits,O
to,O
each,O
male,O
door,O
;,O
2,O
),O
the,O
time,O
spent,O
investigating,O
each,O
male,O
;,O
3,O
),O
which,O
male,O
compartments,O
she,O
entered,O
;,O
4,O
),O
the,O
time,O
spent,O
in,O
each,O
male,O
compartment,O
;,O
and,O
5,O
),O
which,O
males,O
she,O
mated,O
with,O
during,O
the,O
trial,O
.,O
Timing,O
of,O
copulation,O
and,O
intromission,O
were,O
not,O
analysed,O
as,O
mating,O
pairs,O
often,O
moved,O
in,O
and,O
out,O
of,O
nest,O
boxes,O
during,O
copulation,O
.,O
A,O
visit,O
involved,O
the,O
female,O
stopping,O
to,O
look,O
",",O
sniff,O
",",O
chew,O
or,O
climb,O
on,O
male,O
doors,O
and,O
doorsteps,O
and,O
did,O
not,O
include,O
the,O
female,O
walking,O
past,O
doors,O
without,O
stopping,O
.,O
Female,O
visits,O
that,O
lasted,O
five,O
seconds,O
or,O
longer,O
were,O
timed,O
.,O
Behaviours,O
that,O
included,O
male,O
/,O
female,O
and,O
female,O
/,O
female,O
agonistic,O
encounters,O
",",O
scent,O
marking,O
",",O
chasing,O
and,O
sexual,O
positions,O
[,O
36,O
",",O
37,O
],O
were,O
counted,O
as,O
distinct,O
bouts,O
.,O
Genetic,O
analyses,O
Prior,O
to,O
each,O
experiment,O
",",O
animals,B-OG
were,O
genotyped,O
using,O
seven,O
microsatellite,O
markers,O
as,O
described,O
in,O
Parrott,O
et,O
al,O
.,O
[,O
30,O
",",O
31,O
].,O
Relatedness,O
between,O
all,O
members,O
of,O
the,O
captive,O
colony,O
was,O
determined,O
using,O
the,O
GENEPOP,O
3,O
.,O
4,O
program,O
to,O
analyse,O
allele,O
frequencies,O
and,O
Kinship,O
1,O
.,O
3,O
.,O
1,O
to,O
give,O
a,O
numerical,O
score,O
.,O
Kinship,O
values,O
in,O
relation,O
to,O
each,O
female,O
were,O
used,O
when,O
choosing,O
females,O
and,O
their,O
four,O
potential,O
mates,O
in,O
this,O
experiment,O
.,O
Mean,O
(±,O
SE,O
),O
Kinship,O
values,O
were,O
0,O
.,O
14,O
±,O
0,O
.,O
02,O
(,O
median,O
0,O
.,O
12,O
",",O
range,O
-,O
0,O
.,O
07,O
–,O
0,O
.,O
38,O
),O
for,O
the,O
two,O
more,O
genetically,O
similar,O
and,O
-,O
0,O
.,O
10,O
±,O
0,O
.,O
01,O
(,O
median,O
-,O
0,O
.,O
10,O
",",O
-,O
0,O
.,O
31,O
–,O
0,O
.,O
09,O
.),O
for,O
the,O
two,O
more,O
genetically,O
dissimilar,O
males,O
compared,O
to,O
each,O
female,O
over,O
both,O
years,O
and,O
this,O
difference,O
was,O
significant,O
for,O
each,O
female,O
(,O
paired,O
t,O
-,O
test,O
t,O
=,O
-,O
16,O
.,O
87,O
",",O
p,O
<,O
0,O
.,O
001,O
).,O
Female,O
pairs,O
in,O
each,O
experiment,O
differed,O
in,O
genetic,O
relatedness,O
to,O
each,O
other,O
and,O
males,O
differed,O
in,O
relatedness,O
to,O
each,O
of,O
the,O
females,O
.,O
This,O
allowed,O
each,O
female,O
different,O
choices,O
of,O
mates,O
that,O
were,O
genetically,O
dissimilar,O
or,O
similar,O
to,O
themselves,O
.,O
Pouch,O
young,O
born,O
from,O
matings,O
during,O
these,O
experiments,O
were,O
genotyped,O
at,O
five,O
microsatellite,O
loci,O
using,O
DNA,O
extracted,O
from,O
tail,O
tip,O
samples,O
(<,O
1,O
mm,O
of,O
skin,O
),O
taken,O
at,O
four,O
weeks,O
of,O
age,O
[,O
30,O
",",O
31,O
].,O
The,O
paternity,O
of,O
each,O
pouch,O
young,O
was,O
allocated,O
using,O
the,O
CERVUS,O
2,O
.,O
0,O
program,O
with,O
100,O
%,O
confidence,O
.,O
Analysis,O
of,O
results,O
Males,O
were,O
divided,O
into,O
either,O
the,O
genetically,O
similar,O
(,O
2,O
males,O
/,O
female,O
),O
or,O
genetically,O
dissimilar,O
(,O
2,O
males,O
/,O
female,O
),O
categories,O
based,O
on,O
Kinship,O
values,O
described,O
above,O
for,O
analyses,O
of,O
female,O
choice,O
and,O
paternity,O
.,O
Efforts,O
were,O
made,O
to,O
reduce,O
pseudoreplication,O
in,O
the,O
dataset,O
",",O
though,O
this,O
was,O
not,O
always,O
possible,O
.,O
Comparisons,O
between,O
the,O
measures,O
of,O
female,O
behaviour,O
directed,O
toward,O
similar,O
verses,O
dissimilar,O
males,O
and,O
the,O
reproductive,O
outcomes,O
were,O
performed,O
using,O
either,O
repeated,O
measures,O
ANOVA,O
to,O
correct,O
for,O
between,O
-,O
individual,O
differences,O
or,O
chi,O
-,O
square,O
tests,O
(,O
when,O
the,O
dependent,O
variable,O
was,O
binary,O
),O
using,O
the,O
statistical,O
program,O
SYSTAT,O
[,O
38,O
].,O
Weights,O
of,O
individuals,O
that,O
produced,O
offspring,O
and,O
those,O
that,O
did,O
not,O
were,O
compared,O
using,O
t,O
-,O
tests,O
.,O
Results,O
Mate,O
choice,O
Investigation,O
by,O
females,O
All,O
but,O
one,O
female,O
(,O
27,O
/,O
28,O
),O
visited,O
the,O
four,O
male,O
doors,O
prior,O
to,O
focussing,O
on,O
a,O
preferred,O
male,O
(,O
s,O
).,O
There,O
was,O
no,O
significant,O
difference,O
in,O
the,O
number,O
of,O
times,O
a,O
female,O
visited,O
the,O
door,O
of,O
the,O
males,O
that,O
were,O
more,O
genetically,O
similar,O
or,O
dissimilar,O
to,O
herself,O
(,O
F1,O
",",O
26,O
=,O
2,O
.,O
46,O
",",O
p,O
=,O
0,O
.,O
13,O
;,O
Fig,O
2,O
).,O
However,O
",",O
females,O
spent,O
significantly,O
more,O
time,O
investigating,O
the,O
doors,O
of,O
males,O
that,O
were,O
genetically,O
dissimilar,O
to,O
themselves,O
(,O
F1,O
",",O
26,O
=,O
11,O
.,O
05,O
",",O
p,O
=,O
0,O
.,O
003,O
;,O
Fig,O
2,O
).,O
Once,O
interested,O
in,O
a,O
particular,O
male,O
(,O
s,O
"),",O
females,O
would,O
chew,O
",",O
push,O
and,O
climb,O
on,O
doors,O
of,O
these,O
males,O
prior,O
to,O
gaining,O
access,O
.,O
Genetically,O
dissimilar,O
males,O
attracted,O
significantly,O
more,O
bouts,O
of,O
chewing,O
",",O
pushing,O
and,O
climbing,O
behaviours,O
than,O
similar,O
males,O
(,O
mean,O
±,O
SE,O
per,O
female,O
",",O
Similar,O
:,O
9,O
.,O
1,O
±,O
1,O
.,O
7,O
times,O
;,O
Dissimilar,O
:,O
16,O
.,O
2,O
±,O
3,O
.,O
4,O
times,O
;,O
F1,O
",",O
26,O
=,O
6,O
.,O
50,O
",",O
p,O
=,O
0,O
.,O
017,O
).,O
The,O
number,O
of,O
visits,O
and,O
time,O
spent,O
at,O
male,O
doors,O
.,O
The,O
mean,O
(±,O
SE,O
),O
number,O
of,O
times,O
female,O
agile,B-OG
antechinus,I-OG
(,O
n,O
=,O
28,O
),O
visited,O
the,O
doors,O
of,O
males,O
that,O
were,O
more,O
genetically,O
similar,O
and,O
more,O
dissimilar,O
to,O
themselves,O
(,O
left,O
),O
and,O
the,O
mean,O
(±,O
SE,O
),O
time,O
(,O
seconds,O
),O
female,O
agile,B-OG
antechinus,I-OG
(,O
n,O
=,O
28,O
),O
spent,O
visiting,O
the,O
doors,O
of,O
males,O
that,O
were,O
more,O
genetically,O
similar,O
and,O
more,O
dissimilar,O
to,O
themselves,O
(,O
right,O
).,O
An,O
asterisk,O
(*),O
indicates,O
a,O
significant,O
difference,O
from,O
the,O
other,O
value,O
(,O
p,O
=,O
0,O
.,O
003,O
).,O
Females,O
investigated,O
males,O
that,O
were,O
acting,O
in,O
an,O
aggressive,O
or,O
vocal,O
manner,O
from,O
a,O
distance,O
",",O
returning,O
to,O
examine,O
them,O
after,O
being,O
chased,O
from,O
and,O
/,O
or,O
grabbed,O
through,O
doors,O
.,O
There,O
was,O
no,O
difference,O
in,O
the,O
number,O
of,O
chases,O
/,O
attacks,O
from,O
genetically,O
similar,O
or,O
dissimilar,O
males,O
(,O
mean,O
±,O
SE,O
per,O
female,O
",",O
Similar,O
:,O
9,O
.,O
8,O
±,O
1,O
.,O
4,O
;,O
Dissimilar,O
:,O
11,O
.,O
8,O
±,O
2,O
.,O
0,O
;,O
F1,O
",",O
26,O
=,O
0,O
.,O
75,O
",",O
p,O
=,O
0,O
.,O
39,O
).,O
Most,O
females,O
that,O
were,O
seized,O
by,O
males,O
through,O
doors,O
were,O
able,O
to,O
quickly,O
free,O
themselves,O
(,O
67,O
"%,",O
n,O
=,O
30,O
times,O
"),",O
while,O
others,O
were,O
released,O
after,O
observer,O
intervention,O
(,O
33,O
"%,",O
n,O
=,O
15,O
times,O
).,O
No,O
females,O
attempted,O
to,O
enter,O
compartments,O
with,O
males,O
vocalising,O
or,O
acting,O
in,O
an,O
aggressive,O
manner,O
(,O
n,O
=,O
0,O
/,O
28,O
females,O
).,O
Entries,O
to,O
male,O
compartments,O
Females,O
entered,O
into,O
the,O
compartments,O
of,O
both,O
genetically,O
similar,O
and,O
dissimilar,O
males,O
and,O
there,O
was,O
no,O
difference,O
in,O
the,O
number,O
of,O
times,O
they,O
did,O
so,O
(,O
Repeated,O
measures,O
ANOVA,O
;,O
F1,O
",",O
26,O
=,O
0,O
.,O
29,O
",",O
p,O
=,O
0,O
.,O
60,O
;,O
Fig,O
3,O
).,O
However,O
",",O
females,O
typically,O
spent,O
more,O
than,O
double,O
the,O
time,O
in,O
the,O
enclosures,O
of,O
genetically,O
dissimilar,O
males,O
(,O
F1,O
",",O
26,O
=,O
4,O
.,O
38,O
",",O
p,O
=,O
0,O
.,O
046,O
;,O
Fig,O
3,O
).,O
Half,O
the,O
females,O
(,O
14,O
/,O
28,O
),O
entered,O
male,O
compartments,O
more,O
than,O
once,O
with,O
two,O
females,O
entering,O
different,O
male,O
compartments,O
a,O
combined,O
total,O
of,O
41,O
and,O
32,O
times,O
respectively,O
(,O
mean,O
±,O
SD,O
=,O
4,O
.,O
64,O
±,O
9,O
.,O
45,O
;,O
Table,O
1,O
).,O
The,O
number,O
of,O
entries,O
and,O
time,O
spent,O
in,O
male,O
enclosures,O
.,O
The,O
mean,O
(±,O
SE,O
),O
number,O
of,O
times,O
female,O
agile,B-OG
antechinus,I-OG
(,O
n,O
=,O
28,O
),O
entered,O
into,O
the,O
compartments,O
of,O
males,O
that,O
were,O
more,O
genetically,O
similar,O
and,O
more,O
dissimilar,O
to,O
themselves,O
(,O
left,O
),O
and,O
the,O
mean,O
(±,O
SE,O
),O
time,O
(,O
hours,O
),O
female,O
agile,B-OG
antechinus,I-OG
(,O
n,O
=,O
21,O
),O
spent,O
in,O
the,O
compartments,O
of,O
males,O
that,O
were,O
more,O
genetically,O
similar,O
and,O
more,O
dissimilar,O
to,O
themselves,O
(,O
right,O
).,O
An,O
asterisk,O
(*),O
indicates,O
a,O
significant,O
difference,O
from,O
the,O
other,O
value,O
(,O
p,O
=,O
0,O
.,O
046,O
).,O
Overview,O
of,O
female,O
visits,O
",",O
entries,O
",",O
matings,O
and,O
pouch,O
young,O
produced,O
.,O
Number,O
of,O
females,O
Additional,O
data,O
Entry,O
into,O
1,O
male,O
compartment,O
14,O
/,O
28,O
Entry,O
into,O
>,O
1,O
male,O
compartment,O
14,O
/,O
28,O
Actively,O
seeking,O
mate,O
and,O
entered,O
male,O
nest,O
box,O
21,O
/,O
28,O
7,O
females,O
entered,O
the,O
male,O
area,O
",",O
but,O
fled,O
from,O
the,O
male,O
when,O
approached,O
.,O
2,O
females,O
were,O
rejected,O
by,O
males,O
despite,O
attempts,O
to,O
gain,O
male,O
attention,O
.,O
Mated,O
with,O
1,O
male,O
13,O
/,O
28,O
6,O
/,O
13,O
females,O
produced,O
young,O
Mated,O
with,O
>,O
1,O
male,O
6,O
/,O
28,O
5,O
/,O
6,O
females,O
produced,O
young,O
Failed,O
to,O
mate,O
9,O
/,O
28,O
Produced,O
pouch,O
young,O
11,O
/,O
28,O
Total,O
of,O
47,O
young,O
produced,O
(,O
range,O
1,O
–,O
9,O
PY,O
/,O
litter,O
;,O
mean,O
±,O
SE,O
litter,O
size,O
4,O
.,O
27,O
±,O
0,O
.,O
79,O
),O
The,O
number,O
of,O
females,O
that,O
entered,O
into,O
one,O
",",O
or,O
more,O
than,O
one,O
",",O
male,O
compartment,O
",",O
sought,O
to,O
mate,O
with,O
males,O
",",O
mated,O
with,O
single,O
or,O
multiple,O
males,O
and,O
produced,O
pouch,O
young,O
",",O
including,O
additional,O
data,O
on,O
female,O
behaviour,O
and,O
the,O
number,O
of,O
young,O
produced,O
.,O
Genetic,O
relatedness,O
and,O
mating,O
behaviour,O
Females,O
actively,O
sought,O
males,O
and,O
entered,O
into,O
nest,O
-,O
boxes,O
with,O
males,O
of,O
their,O
own,O
accord,O
(,O
n,O
=,O
21,O
).,O
Females,O
often,O
mated,O
with,O
a,O
male,O
multiple,O
times,O
before,O
leaving,O
his,O
compartment,O
(,O
n,O
=,O
11,O
females,O
"),",O
but,O
it,O
was,O
not,O
possible,O
to,O
score,O
the,O
exact,O
number,O
of,O
matings,O
during,O
each,O
visit,O
.,O
Some,O
females,O
(,O
n,O
=,O
6,O
),O
chose,O
to,O
enter,O
and,O
mate,O
with,O
more,O
than,O
one,O
male,O
",",O
but,O
most,O
females,O
mated,O
with,O
only,O
one,O
male,O
(,O
n,O
=,O
13,O
),O
and,O
9,O
females,O
failed,O
to,O
mate,O
(,O
Table,O
1,O
).,O
Four,O
females,O
re,O
-,O
entered,O
male,O
compartments,O
and,O
mated,O
with,O
the,O
same,O
male,O
up,O
to,O
5,O
times,O
.,O
Some,O
of,O
these,O
re,O
-,O
entries,O
(,O
n,O
=,O
3,O
females,O
),O
were,O
sequential,O
",",O
while,O
one,O
was,O
after,O
mating,O
with,O
different,O
males,O
.,O
Females,O
were,O
more,O
likely,O
to,O
mate,O
with,O
one,O
or,O
both,O
of,O
the,O
more,O
genetically,O
dissimilar,O
males,O
(,O
17,O
/,O
28,O
),O
than,O
with,O
one,O
or,O
both,O
of,O
the,O
more,O
genetically,O
similar,O
males,O
(,O
7,O
/,O
28,O
;,O
X2,O
=,O
7,O
.,O
29,O
",",O
df,O
=,O
1,O
",",O
p,O
=,O
0,O
.,O
007,O
;,O
Fig,O
4,O
).,O
Females,O
that,O
mated,O
with,O
more,O
than,O
one,O
male,O
did,O
not,O
appear,O
to,O
trade,O
up,O
to,O
more,O
genetically,O
dissimilar,O
males,O
with,O
four,O
females,O
mating,O
with,O
the,O
more,O
genetically,O
dissimilar,O
male,O
first,O
",",O
one,O
mating,O
with,O
the,O
more,O
similar,O
of,O
their,O
two,O
males,O
first,O
",",O
and,O
one,O
female,O
mating,O
with,O
a,O
similar,O
male,O
in,O
between,O
two,O
more,O
genetically,O
dissimilar,O
males,O
.,O
Some,O
males,O
in,O
each,O
year,O
(,O
2003,O
:,O
n,O
=,O
2,O
/,O
12,O
;,O
2004,O
:,O
n,O
=,O
2,O
/,O
12,O
),O
were,O
disproportionately,O
popular,O
",",O
regardless,O
of,O
genetic,O
relatedness,O
and,O
were,O
chosen,O
by,O
all,O
females,O
they,O
encountered,O
.,O
The,O
number,O
females,O
that,O
mated,O
with,O
genetically,O
similar,O
and,O
dissimilar,O
males,O
and,O
paternity,O
of,O
young,O
produced,O
.,O
The,O
mean,O
(±,O
SE,O
),O
number,O
of,O
females,O
that,O
mated,O
with,O
the,O
more,O
genetically,O
similar,O
and,O
more,O
dissimilar,O
males,O
(,O
left,O
"),",O
and,O
the,O
number,O
of,O
agile,B-OG
antechinus,I-OG
young,O
sired,O
by,O
the,O
more,O
genetically,O
similar,O
and,O
more,O
dissimilar,O
males,O
.,O
Asterisks,O
(*),O
indicate,O
significant,O
differences,O
in,O
pairs,O
of,O
values,O
(,O
number,O
of,O
matings,O
",",O
p,O
<,O
0,O
.,O
001,O
;,O
number,O
of,O
young,O
",",O
p,O
<,O
0,O
.,O
016,O
).,O
Females,O
did,O
not,O
appear,O
to,O
follow,O
each,O
other,O
and,O
entered,O
into,O
the,O
same,O
male,O
compartment,O
simultaneously,O
in,O
only,O
three,O
trials,O
.,O
In,O
two,O
of,O
those,O
trials,O
females,O
pushed,O
",",O
chased,O
and,O
bit,O
each,O
other,O
until,O
one,O
left,O
from,O
the,O
males,O
’,O
nest,O
-,O
boxes,O
and,O
compartments,O
.,O
Both,O
females,O
that,O
were,O
chased,O
from,O
a,O
male,O
compartment,O
later,O
re,O
-,O
entered,O
the,O
compartment,O
and,O
one,O
stayed,O
to,O
mate,O
with,O
the,O
male,O
.,O
Female,O
agonistic,O
behaviour,O
was,O
observed,O
only,O
near,O
males,O
with,O
low,O
levels,O
occurring,O
during,O
or,O
following,O
mating,O
events,O
",",O
except,O
in,O
one,O
instance,O
where,O
it,O
also,O
occurred,O
near,O
the,O
female,O
nest,O
-,O
tube,O
and,O
food,O
trays,O
.,O
Females,O
chose,O
to,O
mate,O
with,O
the,O
same,O
male,O
in,O
one,O
trial,O
only,O
",",O
with,O
one,O
of,O
the,O
females,O
in,O
that,O
trial,O
mating,O
with,O
3,O
of,O
the,O
four,O
males,O
available,O
.,O
Male,O
behavior,O
All,O
males,O
(,O
n,O
=,O
24,O
),O
scent,O
marked,O
their,O
compartments,O
using,O
urine,O
and,O
paracloacal,O
and,O
cutaneous,O
sternal,O
glands,O
.,O
Scent,O
marking,O
behaviour,O
and,O
wet,O
scent,O
-,O
marked,O
areas,O
were,O
most,O
often,O
apparent,O
near,O
the,O
door,O
areas,O
where,O
females,O
had,O
scent,O
-,O
marked,O
and,O
on,O
the,O
upright,O
climbing,O
lattices,O
.,O
Males,O
appeared,O
to,O
show,O
interest,O
in,O
and,O
accept,O
most,O
females,O
regardless,O
of,O
whether,O
the,O
female,O
showed,O
passive,O
or,O
agonistic,O
(,O
hissing,O
and,O
biting,O
),O
behaviours,O
",",O
but,O
ignored,O
the,O
advances,O
of,O
others,O
.,O
Females,O
were,O
able,O
to,O
enter,O
the,O
compartments,O
and,O
nest,O
-,O
boxes,O
of,O
these,O
males,O
while,O
the,O
male,O
was,O
awake,O
without,O
any,O
male,O
reaction,O
(,O
n,O
=,O
6,O
females,O
).,O
Three,O
of,O
these,O
females,O
pushed,O
and,O
climbed,O
over,O
males,O
and,O
assumed,O
mating,O
positions,O
",",O
but,O
did,O
not,O
elicit,O
a,O
response,O
and,O
left,O
soon,O
after,O
.,O
Four,O
females,O
that,O
were,O
rejected,O
by,O
some,O
males,O
were,O
accepted,O
by,O
others,O
.,O
Two,O
females,O
were,O
rejected,O
by,O
all,O
males,O
",",O
but,O
the,O
males,O
in,O
these,O
trials,O
mated,O
with,O
the,O
other,O
female,O
present,O
",",O
showing,O
that,O
these,O
males,O
were,O
interested,O
in,O
females,O
and,O
capable,O
of,O
mating,O
.,O
The,O
two,O
females,O
ignored,O
by,O
all,O
males,O
were,O
within,O
their,O
most,O
fertile,O
receptive,O
period,O
and,O
were,O
within,O
the,O
weight,O
range,O
of,O
females,O
mated,O
by,O
males,O
",",O
though,O
were,O
two,O
of,O
the,O
lighter,O
females,O
that,O
year,O
(,O
rejected,O
females,O
:,O
14,O
.,O
4,O
and,O
14,O
.,O
8,O
g,O
;,O
mean,O
of,O
all,O
females,O
in,O
2003,O
=,O
15,O
.,O
1,O
±,O
0,O
.,O
22,O
",",O
range,O
=,O
14,O
–,O
17,O
g,O
).,O
Offspring,O
production,O
and,O
genetic,O
relatedness,O
In,O
2003,O
",",O
6,O
females,O
gave,O
birth,O
to,O
28,O
young,O
following,O
this,O
experiment,O
.,O
Samples,O
were,O
taken,O
from,O
23,O
pouch,O
young,O
(,O
5,O
young,O
were,O
lost,O
before,O
they,O
were,O
large,O
enough,O
to,O
sample,O
).,O
In,O
2004,O
",",O
5,O
females,O
gave,O
birth,O
to,O
19,O
young,O
following,O
these,O
experiments,O
",",O
all,O
of,O
which,O
were,O
sampled,O
(,O
Table,O
1,O
).,O
Females,O
that,O
produced,O
litters,O
were,O
mated,O
in,O
their,O
most,O
fertile,O
period,O
(,O
n,O
=,O
8,O
),O
or,O
towards,O
the,O
end,O
their,O
receptive,O
period,O
(,O
n,O
=,O
3,O
).,O
Females,O
that,O
did,O
not,O
give,O
birth,O
were,O
either,O
in,O
(,O
n,O
=,O
14,O
"),",O
or,O
at,O
the,O
beginning,O
of,O
their,O
most,O
fertile,O
period,O
(,O
days,O
4,O
–,O
6,O
;,O
n,O
=,O
3,O
"),",O
and,O
nine,O
of,O
those,O
females,O
failed,O
to,O
mate,O
.,O
There,O
was,O
no,O
difference,O
in,O
weight,O
between,O
females,O
that,O
produced,O
young,O
(,O
16,O
.,O
4,O
±,O
0,O
.,O
5,O
g,O
),O
and,O
did,O
not,O
produce,O
young,O
(,O
15,O
.,O
6,O
±,O
0,O
.,O
4,O
g,O
;,O
t,O
=,O
1,O
.,O
30,O
",",O
p,O
=,O
0,O
.,O
21,O
"),",O
or,O
in,O
males,O
that,O
sired,O
(,O
26,O
.,O
2,O
±,O
0,O
.,O
6,O
g,O
),O
or,O
did,O
not,O
sire,O
young,O
(,O
27,O
.,O
4,O
±,O
0,O
.,O
8,O
g,O
;,O
t,O
=,O
-,O
1,O
.,O
19,O
",",O
p,O
=,O
0,O
.,O
25,O
).,O
Of,O
the,O
19,O
females,O
that,O
were,O
observed,O
to,O
have,O
mated,O
",",O
offspring,O
were,O
produced,O
by,O
5,O
of,O
the,O
6,O
that,O
had,O
mated,O
with,O
more,O
than,O
one,O
male,O
and,O
6,O
of,O
the,O
13,O
that,O
had,O
mated,O
with,O
only,O
one,O
male,O
(,O
X2,O
=,O
2,O
.,O
33,O
",",O
df,O
=,O
1,O
",",O
p,O
=,O
0,O
.,O
13,O
).,O
Of,O
the,O
11,O
females,O
that,O
produced,O
young,O
",",O
mean,O
litter,O
size,O
was,O
4,O
.,O
66,O
±,O
1,O
.,O
05,O
among,O
females,O
that,O
mated,O
to,O
one,O
male,O
and,O
2,O
.,O
80,O
±,O
0,O
.,O
73,O
among,O
females,O
that,O
mated,O
to,O
more,O
than,O
one,O
male,O
(,O
ANOVA,O
;,O
F1,O
",",O
9,O
=,O
1,O
.,O
94,O
",",O
p,O
=,O
0,O
.,O
20,O
).,O
Of,O
the,O
13,O
females,O
that,O
mated,O
with,O
only,O
one,O
male,O
",",O
offspring,O
were,O
produced,O
by,O
6,O
/,O
11,O
that,O
mated,O
with,O
a,O
more,O
dissimilar,O
male,O
and,O
0,O
/,O
2,O
that,O
mated,O
with,O
a,O
more,O
similar,O
male,O
(,O
X2,O
=,O
2,O
.,O
03,O
",",O
df,O
=,O
1,O
",",O
p,O
=,O
0,O
.,O
16,O
).,O
Multiple,O
paternity,O
was,O
observed,O
in,O
2,O
/,O
11,O
litters,O
with,O
two,O
fathers,O
in,O
each,O
.,O
Of,O
the,O
four,O
females,O
that,O
mated,O
with,O
both,O
dissimilar,O
and,O
similar,O
males,O
and,O
produced,O
offspring,O
",",O
the,O
dissimilar,O
mates,O
sired,O
more,O
young,O
on,O
average,O
in,O
two,O
cases,O
and,O
the,O
similar,O
mate,O
more,O
young,O
in,O
the,O
other,O
two,O
cases,O
.,O
Overall,O
",",O
females,O
were,O
more,O
likely,O
to,O
produce,O
offspring,O
with,O
genetically,O
dissimilar,O
males,O
(,O
10,O
/,O
28,O
),O
than,O
similar,O
males,O
(,O
2,O
/,O
28,O
;,O
X2,O
=,O
6,O
.,O
79,O
",",O
df,O
=,O
1,O
",",O
p,O
=,O
0,O
.,O
01,O
),O
and,O
produced,O
",",O
on,O
average,O
",",O
more,O
young,O
with,O
their,O
pair,O
of,O
dissimilar,O
males,O
(,O
1,O
.,O
32,O
±,O
0,O
.,O
44,O
),O
than,O
similar,O
males,O
(,O
0,O
.,O
19,O
±,O
0,O
.,O
13,O
;,O
F1,O
",",O
54,O
=,O
6,O
.,O
24,O
",",O
p,O
=,O
0,O
.,O
016,O
).,O
In,O
total,O
",",O
88,O
%,O
of,O
young,O
produced,O
were,O
sired,O
by,O
the,O
genetically,O
dissimilar,O
males,O
.,O
Two,O
males,O
sired,O
young,O
in,O
two,O
litters,O
",",O
while,O
nine,O
males,O
sired,O
a,O
litter,O
with,O
one,O
female,O
.,O
Discussion,O
This,O
study,O
has,O
shown,O
for,O
the,O
first,O
time,O
that,O
female,O
agile,B-OG
antechinus,I-OG
actively,O
seek,O
",",O
and,O
are,O
receptive,O
to,O
",",O
matings,O
with,O
more,O
than,O
one,O
male,O
and,O
that,O
mate,O
choice,O
is,O
an,O
important,O
strategy,O
in,O
the,O
antechinus,B-OG
breeding,O
system,O
.,O
Although,O
females,O
watched,O
and,O
interacted,O
with,O
all,O
the,O
males,O
",",O
they,O
spent,O
significantly,O
more,O
time,O
investigating,O
males,O
that,O
were,O
genetically,O
dissimilar,O
to,O
themselves,O
.,O
Females,O
also,O
mated,O
and,O
produced,O
young,O
with,O
genetically,O
dissimilar,O
males,O
significantly,O
more,O
times,O
than,O
with,O
the,O
genetically,O
similar,O
males,O
.,O
Female,O
agile,B-OG
antechinus,I-OG
in,O
wild,O
populations,O
almost,O
always,O
produce,O
litters,O
that,O
are,O
sired,O
by,O
more,O
than,O
one,O
male,O
([,O
14,O
"],",O
MLP,O
unpub,O
.,O
data,O
).,O
Here,O
",",O
despite,O
the,O
availability,O
of,O
four,O
males,O
",",O
the,O
majority,O
of,O
females,O
chose,O
to,O
be,O
monandrous,O
",",O
often,O
returning,O
to,O
mate,O
with,O
a,O
single,O
male,O
multiple,O
times,O
.,O
This,O
differs,O
to,O
the,O
field,O
data,O
and,O
may,O
suggest,O
that,O
when,O
constraints,O
exerted,O
by,O
males,O
are,O
relieved,O
",",O
females,O
avoid,O
multiple,O
matings,O
.,O
Females,O
that,O
mate,O
with,O
more,O
than,O
one,O
male,O
may,O
hedge,O
their,O
bets,O
against,O
the,O
possibility,O
of,O
a,O
mate,O
being,O
sterile,O
or,O
incompatible,O
[,O
2,O
",",O
39,O
"],",O
but,O
females,O
in,O
this,O
study,O
chose,O
males,O
that,O
were,O
more,O
genetically,O
dissimilar,O
to,O
themselves,O
and,O
so,O
avoided,O
mating,O
with,O
males,O
more,O
likely,O
to,O
be,O
genetically,O
incompatible,O
.,O
In,O
this,O
study,O
",",O
genetic,O
relatedness,O
was,O
determined,O
using,O
seven,O
microsatellite,O
markers,O
",",O
thus,O
questions,O
remain,O
regarding,O
the,O
levels,O
of,O
relatedness,O
between,O
potential,O
mates,O
.,O
Further,O
research,O
with,O
additional,O
markers,O
and,O
research,O
into,O
genes,O
of,O
the,O
Major,B-GP
Histocompatibility,I-GP
Complex,I-GP
could,O
be,O
used,O
to,O
further,O
clarify,O
relationships,O
in,O
the,O
future,O
.,O
Females,O
may,O
also,O
mate,O
with,O
an,O
available,O
male,O
and,O
then,O
‘,O
trade,O
up,O
’,O
by,O
mating,O
with,O
a,O
higher,O
quality,O
male,O
if,O
encountered,O
[,O
40,O
",",O
41,O
].,O
Each,O
trial,O
in,O
this,O
experiment,O
was,O
run,O
for,O
72,O
hours,O
",",O
so,O
offered,O
the,O
opportunity,O
for,O
females,O
to,O
trade,O
up,O
to,O
higher,O
quality,O
available,O
males,O
.,O
However,O
",",O
the,O
majority,O
of,O
females,O
in,O
this,O
experiment,O
that,O
mated,O
with,O
more,O
than,O
one,O
male,O
did,O
so,O
with,O
a,O
more,O
dissimilar,O
male,O
first,O
and,O
showed,O
the,O
highest,O
level,O
of,O
interest,O
in,O
their,O
first,O
mate,O
.,O
As,O
all,O
males,O
were,O
simultaneously,O
available,O
",",O
this,O
may,O
not,O
be,O
indicative,O
of,O
a,O
wild,O
situation,O
where,O
females,O
may,O
be,O
expected,O
to,O
encounter,O
new,O
males,O
at,O
different,O
times,O
during,O
their,O
long,O
receptive,O
period,O
.,O
Last,O
male,O
sperm,O
precedence,O
operates,O
in,O
the,O
agile,B-OG
antechinus,I-OG
[,O
26,O
",",O
32,O
"],",O
so,O
females,O
may,O
be,O
able,O
to,O
influence,O
the,O
paternity,O
of,O
their,O
young,O
by,O
trading,O
up,O
to,O
genetically,O
superior,O
males,O
during,O
their,O
most,O
fertile,O
periods,O
[,O
42,O
].,O
The,O
small,O
litter,O
sizes,O
produced,O
in,O
this,O
study,O
may,O
have,O
resulted,O
in,O
the,O
decreased,O
incidence,O
of,O
mixed,O
paternity,O
when,O
compared,O
with,O
wild,O
data,O
.,O
However,O
",",O
all,O
but,O
one,O
female,O
that,O
mated,O
with,O
more,O
than,O
one,O
male,O
produced,O
young,O
",",O
while,O
less,O
than,O
half,O
the,O
females,O
that,O
mated,O
with,O
one,O
male,O
produced,O
a,O
litter,O
",",O
suggesting,O
that,O
females,O
that,O
mate,O
with,O
multiple,O
partners,O
increase,O
their,O
reproductive,O
success,O
.,O
Research,O
has,O
shown,O
that,O
female,O
brown,B-OG
antechinus,I-OG
(,O
Antechinus,B-OG
stuartii,I-OG
),O
that,O
mate,O
with,O
multiple,O
males,O
during,O
a,O
single,O
receptive,O
period,O
produce,O
significantly,O
more,O
young,O
than,O
females,O
allowed,O
to,O
mate,O
with,O
only,O
one,O
male,O
[,O
43,O
].,O
A,O
similar,O
effect,O
has,O
been,O
observed,O
in,O
European,B-OG
adders,I-OG
(,O
Vipera,B-OG
berus,I-OG
"),",O
where,O
females,O
that,O
mated,O
with,O
more,O
than,O
one,O
male,O
had,O
fewer,O
stillborn,O
young,O
[,O
44,O
].,O
In,O
sand,B-OG
lizards,I-OG
",",O
increased,O
number,O
of,O
mates,O
correlated,O
with,O
increased,O
egg,O
-,O
hatching,O
success,O
and,O
survival,O
of,O
young,O
[,O
45,O
"],",O
while,O
",",O
female,O
blue,B-OG
tits,I-OG
(,O
Parus,B-OG
caeruleus,I-OG
),O
and,O
tree,B-OG
swallows,I-OG
(,O
Tachycineta,B-OG
bicolor,I-OG
),O
increase,O
the,O
heterozygosity,O
and,O
thus,O
the,O
potential,O
fitness,O
and,O
reproductive,O
success,O
of,O
their,O
offspring,O
through,O
additional,O
extra,O
-,O
pair,O
matings,O
[,O
46,O
",",O
47,O
].,O
Conversely,O
",",O
females,O
may,O
avoid,O
mating,O
with,O
multiple,O
males,O
to,O
reduce,O
the,O
risk,O
of,O
parasite,O
transmission,O
",",O
illness,O
or,O
injury,O
sustained,O
during,O
mating,O
[,O
20,O
].,O
Here,O
",",O
females,O
avoided,O
males,O
that,O
were,O
particularly,O
vocal,O
or,O
aggressive,O
at,O
their,O
doors,O
",",O
regardless,O
of,O
the,O
level,O
of,O
genetic,O
dissimilarity,O
between,O
the,O
pair,O
.,O
The,O
relationships,O
between,O
female,O
mate,O
choice,O
",",O
male,O
coercion,O
and,O
reproductive,O
success,O
are,O
complex,O
and,O
warrant,O
further,O
investigation,O
.,O
Males,O
that,O
were,O
genetically,O
dissimilar,O
to,O
females,O
obtained,O
more,O
matings,O
than,O
genetically,O
similar,O
males,O
and,O
sired,O
more,O
young,O
",",O
as,O
has,O
been,O
observed,O
in,O
a,O
variety,O
of,O
taxa,O
[,O
6,O
",",O
1,O
",",O
10,O
].,O
However,O
",",O
compared,O
with,O
the,O
number,O
of,O
matings,O
obtained,O
by,O
males,O
in,O
each,O
category,O
",",O
genetically,O
dissimilar,O
males,O
sired,O
a,O
disproportionately,O
higher,O
number,O
of,O
young,O
than,O
genetically,O
similar,O
males,O
per,O
mating,O
event,O
.,O
Previous,O
research,O
by,O
Kraaijeveld,O
-,O
Smit,O
et,O
al,O
.,O
[,O
32,O
],O
suggested,O
that,O
spermatozoa,O
from,O
genetically,O
dissimilar,O
males,O
may,O
be,O
more,O
successful,O
due,O
to,O
sperm,O
competition,O
[,O
40,O
].,O
Female,O
agile,B-OG
antechinus,I-OG
store,O
sperm,O
in,O
specialised,O
isthmic,O
crypts,O
in,O
their,O
oviducts,O
for,O
up,O
to,O
15,O
days,O
[,O
13,O
",",O
34,O
",",O
48,O
],O
providing,O
time,O
and,O
a,O
suitable,O
environment,O
for,O
sperm,O
competition,O
.,O
Potentially,O
",",O
males,O
that,O
are,O
genetically,O
dissimilar,O
to,O
females,O
are,O
not,O
only,O
chosen,O
pre,O
-,O
copulation,O
",",O
but,O
their,O
spermatozoa,O
also,O
compete,O
more,O
successfully,O
post,O
-,O
copulation,O
by,O
cryptic,O
female,O
selection,O
of,O
sperm,O
within,O
the,O
reproductive,O
tract,O
[,O
40,O
",",O
49,O
",",O
50,O
",",O
51,O
].,O
It,O
is,O
possible,O
that,O
part,O
of,O
the,O
uterine,O
mortality,O
encountered,O
in,O
this,O
species,O
which,O
progressively,O
reduces,O
viable,O
embryos,O
to,O
60,O
%,O
by,O
the,O
neurula,O
stage,O
[,O
34,O
],O
is,O
due,O
to,O
matings,O
between,O
genetically,O
similar,O
individuals,O
.,O
In,O
natural,O
populations,O
",",O
larger,O
males,O
may,O
also,O
secure,O
more,O
matings,O
and,O
sire,O
more,O
young,O
([,O
14,O
"],",O
MLP,O
unpub,O
data,O
"),",O
but,O
ex,O
situ,O
research,O
into,O
female,O
mate,O
choice,O
shows,O
that,O
female,O
agile,B-OG
antechinus,I-OG
do,O
not,O
choose,O
males,O
based,O
on,O
size,O
[,O
30,O
].,O
Regardless,O
",",O
the,O
effect,O
of,O
male,O
size,O
on,O
mate,O
selection,O
in,O
this,O
experiment,O
was,O
excluded,O
as,O
a,O
confounding,O
factor,O
by,O
selection,O
of,O
males,O
of,O
similar,O
sizes,O
.,O
There,O
was,O
no,O
evidence,O
of,O
mate,O
copying,O
",",O
as,O
occurs,O
in,O
species,O
including,O
the,O
guppy,B-OG
[,O
52,O
],O
and,O
sage,B-OG
grouse,I-OG
(,O
Centrocercus,B-OG
urophasianus,I-OG
;,O
[,O
53,O
]),O
where,O
females,O
copy,O
the,O
preferences,O
of,O
other,O
females,O
",",O
even,O
changing,O
from,O
their,O
original,O
choice,O
[,O
52,O
].,O
Although,O
female,O
antechinus,B-OG
entered,O
the,O
enclosures,O
of,O
the,O
same,O
males,O
",",O
two,O
females,O
chose,O
to,O
mate,O
with,O
the,O
same,O
male,O
in,O
only,O
one,O
of,O
14,O
trials,O
.,O
One,O
male,O
sired,O
young,O
in,O
two,O
litters,O
",",O
but,O
all,O
other,O
sires,O
produced,O
one,O
litter,O
each,O
.,O
Due,O
to,O
the,O
72,O
hour,O
time,O
period,O
of,O
the,O
trials,O
",",O
females,O
had,O
time,O
to,O
access,O
all,O
males,O
",",O
regardless,O
of,O
whether,O
another,O
female,O
had,O
chosen,O
the,O
male,O
.,O
Female,O
antechinus,B-OG
can,O
determine,O
the,O
difference,O
between,O
scents,O
from,O
more,O
and,O
less,O
genetically,O
similar,O
males,O
and,O
prefer,O
chemosensory,O
cues,O
from,O
genetically,O
dissimilar,O
males,O
[,O
31,O
"],",O
suggesting,O
that,O
the,O
process,O
of,O
mate,O
choice,O
in,O
this,O
experiment,O
was,O
influenced,O
by,O
these,O
cues,O
(,O
see,O
review,O
in,O
[,O
54,O
]).,O
Although,O
important,O
",",O
genetic,O
relatedness,O
between,O
mates,O
may,O
be,O
only,O
one,O
aspect,O
of,O
a,O
set,O
of,O
mate,O
preference,O
criteria,O
used,O
by,O
females,O
",",O
particularly,O
in,O
the,O
wild,O
.,O
Some,O
males,O
in,O
this,O
experiment,O
were,O
preferred,O
by,O
all,O
females,O
they,O
encountered,O
",",O
regardless,O
of,O
the,O
level,O
of,O
genetic,O
relatedness,O
.,O
This,O
occurred,O
in,O
both,O
years,O
",",O
suggesting,O
that,O
it,O
was,O
not,O
an,O
anomaly,O
and,O
that,O
certain,O
traits,O
possessed,O
by,O
some,O
males,O
that,O
we,O
were,O
not,O
able,O
to,O
identify,O
in,O
this,O
study,O
may,O
override,O
the,O
importance,O
of,O
genetic,O
relatedness,O
.,O
Following,O
this,O
experiment,O
",",O
47,O
young,O
were,O
born,O
to,O
11,O
mothers,O
.,O
This,O
was,O
fewer,O
than,O
expected,O
and,O
differs,O
from,O
wild,O
populations,O
in,O
which,O
all,O
teats,O
are,O
generally,O
occupied,O
[,O
55,O
",",O
56,O
].,O
There,O
are,O
two,O
likely,O
reasons,O
for,O
this,O
outcome,O
.,O
Firstly,O
",",O
animals,B-OG
used,O
in,O
this,O
experiment,O
were,O
collected,O
during,O
severe,O
drought,O
conditions,O
which,O
significantly,O
decreased,O
weight,O
",",O
survival,O
and,O
litter,O
sizes,O
in,O
the,O
wild,O
[,O
33,O
].,O
This,O
probably,O
also,O
influenced,O
fertility,O
in,O
the,O
captive,O
population,O
used,O
in,O
this,O
study,O
",",O
despite,O
the,O
availability,O
of,O
increased,O
nutrition,O
",",O
because,O
animals,B-OG
were,O
collected,O
less,O
than,O
one,O
month,O
prior,O
to,O
the,O
breeding,O
season,O
and,O
were,O
in,O
poor,O
condition,O
[,O
33,O
].,O
Secondly,O
",",O
most,O
litters,O
(,O
8,O
),O
were,O
produced,O
from,O
matings,O
in,O
the,O
most,O
fertile,O
period,O
of,O
receptivity,O
",",O
with,O
the,O
remaining,O
three,O
produced,O
from,O
matings,O
late,O
in,O
the,O
receptive,O
period,O
.,O
No,O
young,O
were,O
produced,O
from,O
females,O
paired,O
on,O
days,O
4,O
–,O
6,O
of,O
their,O
receptive,O
period,O
.,O
This,O
concurs,O
with,O
the,O
findings,O
of,O
Selwood,O
and,O
McCallum,O
[,O
13,O
],O
who,O
showed,O
that,O
matings,O
that,O
occurred,O
more,O
than,O
14,O
days,O
",",O
or,O
less,O
than,O
5,O
days,O
",",O
from,O
the,O
spontaneous,O
ovulation,O
resulted,O
in,O
low,O
numbers,O
of,O
normal,O
fertile,O
embryos,O
and,O
few,O
young,O
.,O
In,O
antechinus,B-OG
and,O
some,O
other,O
dasyurid,B-OG
marsupials,B-OG
oestrus,O
is,O
difficult,O
to,O
define,O
[,O
35,O
].,O
Females,O
may,O
be,O
receptive,O
to,O
mating,O
at,O
times,O
when,O
conception,O
is,O
unlikely,O
(,O
eg,O
too,O
early,O
or,O
late,O
in,O
respect,O
to,O
ovulation,O
",",O
or,O
even,O
during,O
gestation,O
),O
and,O
the,O
female,O
may,O
not,O
be,O
fertile,O
[,O
35,O
].,O
Selwood,O
and,O
McCallum,O
[,O
13,O
],O
demonstrated,O
that,O
for,O
single,O
inseminations,O
",",O
sperm,O
survival,O
time,O
is,O
finite,O
.,O
For,O
single,O
inseminations,O
outside,O
that,O
period,O
ie,O
0,O
to,O
4,O
days,O
before,O
ovulation,O
and,O
14,O
–,O
20,O
days,O
before,O
ovulation,O
",",O
the,O
percentage,O
of,O
normal,O
embryos,O
is,O
0,O
to,O
58,O
%,O
and,O
the,O
averages,O
for,O
these,O
periods,O
are,O
44,O
.,O
5,O
and,O
27,O
%,O
respectively,O
[,O
13,O
].,O
Thus,O
",",O
some,O
females,O
in,O
this,O
study,O
mated,O
outside,O
their,O
period,O
of,O
optimum,O
fertility,O
which,O
is,O
likely,O
to,O
have,O
influenced,O
their,O
reproductive,O
successs,O
.,O
Additionally,O
",",O
previous,O
studies,O
have,O
shown,O
that,O
antechinus,B-OG
can,O
have,O
a,O
lower,O
breeding,O
success,O
in,O
captivity,O
than,O
in,O
the,O
wild,O
(,O
e,O
.,O
g,O
.,O
[,O
57,O
]).,O
Male,O
mate,O
choice,O
has,O
received,O
less,O
attention,O
than,O
mate,O
choice,O
by,O
females,O
",",O
but,O
may,O
also,O
be,O
important,O
[,O
58,O
].,O
Mate,O
choice,O
by,O
males,O
may,O
occur,O
when,O
there,O
is,O
a,O
female,O
-,O
bias,O
in,O
the,O
operational,O
sex,O
ratio,O
[,O
59,O
"],",O
when,O
females,O
show,O
secondary,O
sexual,O
characteristics,O
such,O
as,O
colour,O
or,O
ornamentation,O
as,O
seen,O
in,O
a,O
variety,O
of,O
birds,B-OG
and,O
fish,B-OG
[,O
60,O
",",O
61,O
",",O
62,O
"],",O
when,O
there,O
is,O
a,O
preference,O
for,O
novel,O
over,O
resident,O
females,O
[,O
63,O
"],",O
when,O
female,O
fertility,O
is,O
correlated,O
with,O
her,O
body,O
size,O
[,O
64,O
],O
and,O
/,O
or,O
choice,O
may,O
be,O
based,O
on,O
genetic,O
relatedness,O
[,O
65,O
].,O
Here,O
",",O
we,O
describe,O
the,O
first,O
case,O
of,O
male,O
mate,O
choice,O
in,O
a,O
marsupial,B-OG
to,O
our,O
knowledge,O
",",O
with,O
male,O
antechinus,B-OG
appearing,O
disinterested,O
in,O
some,O
females,O
and,O
ignoring,O
their,O
efforts,O
to,O
gain,O
attention,O
.,O
Males,O
prefer,O
novel,O
females,O
rather,O
than,O
familiar,O
previously,O
-,O
mated,O
females,O
in,O
green,B-OG
anole,I-OG
lizards,I-OG
(,O
Anolis,B-OG
carolinensis,I-OG
;,O
[,O
64,O
"]),",O
but,O
familiarity,O
with,O
the,O
female,O
did,O
not,O
appear,O
to,O
influence,O
male,O
mate,O
choice,O
in,O
the,O
agile,B-OG
antechinus,I-OG
.,O
Males,O
re,O
-,O
mated,O
with,O
the,O
same,O
females,O
if,O
they,O
stayed,O
with,O
them,O
or,O
re,O
-,O
entered,O
the,O
compartment,O
.,O
This,O
was,O
unexpected,O
as,O
males,O
have,O
a,O
relatively,O
small,O
and,O
finite,O
number,O
of,O
spermatozoa,O
available,O
for,O
insemination,O
[,O
66,O
],O
and,O
may,O
be,O
expected,O
to,O
maximise,O
the,O
number,O
of,O
females,O
inseminated,O
to,O
increase,O
their,O
siring,O
success,O
.,O
Male,O
mate,O
choice,O
also,O
did,O
not,O
appear,O
to,O
be,O
affected,O
by,O
his,O
level,O
of,O
genetic,O
relatedness,O
to,O
the,O
female,O
nor,O
by,O
her,O
fertility,O
status,O
which,O
can,O
be,O
an,O
influence,O
in,O
some,O
species,O
[,O
67,O
].,O
In,O
oldfield,B-OG
mice,I-OG
(,O
Peromyscus,B-OG
polionotus,I-OG
rhoads,O
"),",O
males,O
paired,O
with,O
preferred,O
females,O
had,O
a,O
greater,O
siring,O
success,O
than,O
those,O
paired,O
with,O
non,O
-,O
preferred,O
females,O
based,O
on,O
compatibility,O
of,O
mates,O
[,O
68,O
].,O
Here,O
",",O
females,O
that,O
were,O
rejected,O
by,O
some,O
males,O
were,O
accepted,O
by,O
others,O
and,O
successfully,O
produced,O
young,O
",",O
suggesting,O
compatibility,O
",",O
rather,O
than,O
the,O
fertility,O
or,O
attractiveness,O
of,O
the,O
female,O
",",O
affected,O
male,O
choice,O
.,O
Female,O
agonistic,O
behaviour,O
did,O
not,O
appear,O
to,O
deter,O
males,O
",",O
a,O
similar,O
observation,O
to,O
that,O
made,O
by,O
Shimmin,O
et,O
al,O
.,O
[,O
37,O
"],",O
and,O
female,O
body,O
mass,O
also,O
did,O
not,O
appear,O
to,O
influence,O
male,O
choice,O
or,O
female,O
reproductive,O
success,O
in,O
this,O
experiment,O
with,O
the,O
lightest,O
and,O
heaviest,O
females,O
mating,O
and,O
no,O
differences,O
in,O
weight,O
between,O
females,O
that,O
did,O
and,O
did,O
not,O
produce,O
young,O
.,O
The,O
reason,O
(,O
s,O
),O
for,O
the,O
preference,O
by,O
male,O
agile,B-OG
antechinus,I-OG
of,O
certain,O
females,O
over,O
others,O
is,O
not,O
clear,O
.,O
The,O
role,O
of,O
male,O
mate,O
choice,O
and,O
its,O
effects,O
on,O
breeding,O
success,O
in,O
the,O
agile,B-OG
antechinus,I-OG
and,O
other,O
species,O
warrants,O
further,O
examination,O
.,O
This,O
research,O
has,O
provided,O
new,O
and,O
important,O
insights,O
into,O
the,O
effects,O
of,O
genetic,O
relatedness,O
and,O
female,O
mate,O
choice,O
on,O
siring,O
success,O
.,O
It,O
also,O
provides,O
new,O
knowledge,O
about,O
the,O
unusual,O
mating,O
system,O
of,O
the,O
agile,B-OG
antechinus,I-OG
.,O
Future,O
studies,O
of,O
mate,O
choice,O
and,O
its,O
effects,O
on,O
reproductive,O
success,O
will,O
shed,O
light,O
on,O
the,O
evolution,O
of,O
the,O
mating,O
system,O
of,O
the,O
agile,B-OG
antechinus,I-OG
",",O
which,O
provides,O
an,O
interesting,O
and,O
useful,O
paradigm,O
for,O
studies,O
in,O
other,O
related,O
species,O
.,O
Progressive,O
Muscle,O
Cell,O
Delivery,O
as,O
a,O
Solution,O
for,O
Volumetric,O
Muscle,O
Defect,O
Repair,O
These,O
authors,O
contributed,O
equally,O
to,O
this,O
work,O
.,O
Reconstructing,O
functional,O
volumetric,O
tissue,O
in,O
vivo,O
following,O
implantation,O
remains,O
a,O
critical,O
challenge,O
facing,O
cell,O
-,O
based,O
approaches,O
.,O
Several,O
pre,O
-,O
vascularization,O
approaches,O
have,O
been,O
developed,O
to,O
increase,O
cell,O
viability,O
following,O
implantation,O
.,O
Structural,O
and,O
functional,O
restoration,O
was,O
achieved,O
in,O
a,O
preclinical,O
rodent,O
tissue,O
defect,O
;,O
however,O
",",O
the,O
approach,O
used,O
in,O
this,O
model,O
fails,O
to,O
repair,O
larger,O
(>,O
mm,O
),O
defects,O
as,O
observed,O
in,O
a,O
clinical,O
setting,O
.,O
We,O
propose,O
an,O
effective,O
cell,O
delivery,O
system,O
utilizing,O
appropriate,O
vascularization,O
at,O
the,O
site,O
of,O
cell,O
implantation,O
that,O
results,O
in,O
volumetric,O
and,O
functional,O
tissue,O
reconstruction,O
.,O
Our,O
method,O
of,O
multiple,O
cell,O
injections,O
in,O
a,O
progressive,O
manner,O
yielded,O
improved,O
cell,O
survival,O
and,O
formed,O
volumetric,O
muscle,O
tissues,O
in,O
an,O
ectopic,O
muscle,O
site,O
.,O
In,O
addition,O
",",O
this,O
strategy,O
supported,O
the,O
reconstruction,O
of,O
functional,O
skeletal,O
muscle,O
tissue,O
in,O
a,O
rodent,O
volumetric,O
muscle,O
loss,O
injury,B-DS
model,O
.,O
Results,O
from,O
our,O
study,O
suggest,O
that,O
our,O
method,O
may,O
be,O
used,O
to,O
repair,O
volumetric,O
tissue,O
defects,O
by,O
overcoming,O
diffusion,O
limitations,O
and,O
facilitating,O
adequate,O
vascularization,O
.,O
Cell,O
-,O
based,O
therapies,O
in,O
tissue,O
engineering,O
(,O
TE,O
),O
and,O
regenerative,O
medicine,O
(,O
RM,O
),O
provide,O
promise,O
to,O
restore,O
normal,O
functions,O
of,O
damaged,O
and,O
injured,O
tissues,O
and,O
organs1,O
.,O
Such,O
strategies,O
include,O
cell,O
transplantation,O
and,O
implantation,O
of,O
engineered,O
tissue,O
constructs,O
",",O
where,O
efficient,O
cell,O
survival,O
following,O
implantation,O
is,O
a,O
critical,O
factor,O
to,O
the,O
success,O
.,O
Cell,O
-,O
based,O
strategies,O
have,O
been,O
used,O
successfully,O
in,O
preclinical,O
and,O
clinical,O
trials,O
to,O
treat,O
defects,O
in,O
avascular,O
tissues,O
",",O
such,O
as,O
cartilage,O
and,O
cornea,O
",",O
which,O
do,O
not,O
necessitate,O
blood,O
supply,O
to,O
maintain,O
cellular,O
viability,O
and,O
function,O
under,O
hypoxic,O
conditions234,O
.,O
Small,O
injuries,O
in,O
the,O
vascularized,O
tissues,O
that,O
correspond,O
to,O
a,O
few,O
microns,O
can,O
be,O
repaired,O
using,O
cell,O
-,O
based,O
approaches,O
because,O
the,O
implanted,O
cells,O
will,O
remain,O
viable,O
due,O
to,O
direct,O
transport,O
of,O
oxygen,O
and,O
nutrients,O
within,O
200,O
μm56789,O
from,O
host,O
vasculatures,O
as,O
well,O
as,O
diffusion,O
from,O
adjacent,O
host,O
blood,O
vessels,O
.,O
Skin,O
regeneration,O
has,O
been,O
achieved,O
using,O
cell,O
-,O
based,O
therapy,O
;,O
1011,O
however,O
",",O
efficient,O
treatment,O
of,O
defects,O
larger,O
than,O
millimeter,O
or,O
centimeter,O
scale,O
in,O
vascularized,O
tissues,O
and,O
organs,O
such,O
as,O
heart,O
",",O
liver,O
",",O
and,O
skeletal,O
muscle,O
remains,O
challenging,O
.,O
In,O
most,O
cases,O
",",O
repair,O
of,O
larger,O
tissue,O
defects,O
requires,O
implantation,O
of,O
large,O
",",O
volumetric,O
engineered,O
tissue,O
constructs,O
or,O
implantation,O
of,O
high,O
-,O
dose,O
cells121314,O
to,O
restore,O
normal,O
functions,O
.,O
Under,O
such,O
conditions,O
",",O
oxygen,O
transport,O
to,O
all,O
of,O
the,O
implanted,O
cells,O
is,O
difficult,O
.,O
In,O
particular,O
",",O
cells,O
located,O
in,O
the,O
center,O
of,O
thick,O
tissues,O
(,O
a,O
few,O
millimeter,O
scales,O
),O
with,O
low,O
oxygen,O
concentration,O
will,O
become,O
necrotic,O
leading,O
to,O
failure,O
of,O
tissue,O
grafts,O
.,O
To,O
improve,O
the,O
cellular,O
viability,O
within,O
large,O
-,O
sized,O
defects,O
",",O
efficient,O
nutrient,O
and,O
oxygen,O
supply,O
are,O
necessary,O
;,O
11516,O
therefore,O
",",O
strategies,O
need,O
to,O
be,O
developed,O
for,O
volumetric,O
tissue,O
repair,O
to,O
improve,O
vascularization,O
",",O
which,O
will,O
have,O
a,O
positive,O
impact,O
on,O
cell,O
survival,O
.,O
To,O
date,O
",",O
several,O
strategies,O
have,O
been,O
developed,O
to,O
accelerate,O
vascularization,O
of,O
engineered,O
tissues,O
.,O
The,O
conventional,O
method,O
used,O
in,O
early,O
studies,O
promoted,O
vascularization,O
for,O
survival,O
of,O
the,O
implanted,O
cells,O
through,O
stimulation,O
of,O
in,O
vivo,O
microenvironments,O
at,O
the,O
time,O
of,O
implantation,O
.,O
To,O
stimulate,O
vascular,O
environments,O
",",O
pro,B-GP
-,I-GP
angiogenic,I-GP
factors,I-GP
such,O
as,O
vascular,B-GP
endothelial,I-GP
growth,I-GP
factors,I-GP
and,O
fibroblast,B-GP
growth,I-GP
factors,I-GP
were,O
incorporated,O
with,O
engineered,O
tissue,O
constructs,O
",",O
followed,O
by,O
the,O
implantation17,O
.,O
In,O
other,O
cases,O
",",O
exogenous,O
endothelial,O
stem,O
or,O
progenitor,O
cells,O
were,O
co,O
-,O
seeded,O
with,O
tissue,O
-,O
specific,O
cells,O
before,O
implantation1819,O
.,O
Although,O
incorporation,O
of,O
such,O
vascularization,O
cues,O
resulted,O
in,O
improved,O
vascularization,O
in,O
vivo,O
",",O
formation,O
of,O
new,O
blood,O
vessels,O
within,O
the,O
implant,O
site,O
was,O
too,O
slow,O
to,O
support,O
the,O
majority,O
of,O
implanted,O
cells7161920,O
.,O
Pre,O
-,O
fabrication,O
of,O
vascular,O
networks,O
within,O
engineered,O
tissue,O
constructs,O
during,O
in,O
vitro,O
cell,O
culture,O
of,O
the,O
seeded,O
scaffolds,O
provides,O
an,O
alternative,O
strategy,O
for,O
the,O
repair,O
of,O
a,O
volumetric,O
muscle,O
defect,O
.,O
Morphological,O
characterization,O
has,O
revealed,O
that,O
in,O
vitro,O
pre,O
-,O
vascularized,O
tissues,O
contained,O
well,O
-,O
organized,O
vascular,O
structures,O
and,O
could,O
accelerate,O
vascularization,O
time,O
by,O
providing,O
adequate,O
blood,O
supply,O
to,O
the,O
seeded,O
cells,O
.,O
Unfortunately,O
",",O
host,O
-,O
implant,O
anastomosis,O
of,O
in,O
vitro,O
pre,O
-,O
vascularized,O
tissues,O
usually,O
occurs,O
within,O
several,O
days,O
after,O
implantation,O
;,O
212223,O
thus,O
",",O
integration,O
of,O
reconstructed,O
tissue,O
with,O
the,O
host,O
was,O
inefficient,O
.,O
An,O
in,O
vivo,O
pre,O
-,O
vascularization,O
strategy,O
has,O
been,O
developed,O
to,O
fabricate,O
large,O
-,O
sized,O
",",O
vascularized,O
implantable,O
constructs,O
.,O
By,O
implanting,O
the,O
cell,O
-,O
seeded,O
scaffold,O
into,O
the,O
highly,O
vascularized,O
site,O
",",O
vascular,O
tissues,O
could,O
be,O
obtained,O
in,O
vivo,O
and,O
transferred,O
to,O
the,O
target,O
site24252627,O
.,O
In,O
another,O
study,O
",",O
the,O
polysurgery,O
approach,O
was,O
proposed,O
to,O
produce,O
thick,O
",",O
viable,O
myocardial,O
tissues,O
at,O
an,O
ectopic,O
site28,O
.,O
This,O
work,O
shows,O
that,O
repeated,O
cell,O
-,O
sheet,O
transplantation,O
at,O
time,O
intervals,O
of,O
1,O
–,O
2,O
days,O
can,O
generate,O
vascularized,O
cardiomyocyte,O
sheets,O
in,O
vivo,O
.,O
While,O
those,O
strategies,O
is,O
a,O
promising,O
approach,O
in,O
terms,O
of,O
addressing,O
volumetric,O
tissue,O
defects,O
",",O
several,O
issues,O
such,O
as,O
delayed,O
perfusion,O
",",O
numerous,O
surgical,O
interventions,O
",",O
and,O
inefficient,O
cell,O
grafting,O
within,O
the,O
vascularized,O
explanted,O
tissue,O
must,O
be,O
addressed,O
before,O
clinical,O
use15,O
.,O
Therefore,O
",",O
none,O
of,O
the,O
conventional,O
vascularization,O
strategies,O
is,O
appropriate,O
for,O
volumetric,O
tissue,O
repair,O
.,O
Towards,O
this,O
end,O
",",O
we,O
proposed,O
a,O
novel,O
and,O
simple,O
cell,O
delivery,O
method,O
that,O
enables,O
reconstruction,O
of,O
viable,O
",",O
large,O
tissues,O
in,O
vivo,O
for,O
restoration,O
of,O
volumetric,O
tissue,B-DS
injury,I-DS
through,O
an,O
efficient,O
vascularization,O
strategy,O
.,O
As,O
described,O
above,O
",",O
conventional,O
cell,O
-,O
based,O
approaches,O
for,O
volumetric,O
tissue,O
repair,O
are,O
limited,O
due,O
to,O
inefficient,O
blood,O
supply,O
for,O
implanted,O
cells,O
.,O
Therefore,O
",",O
we,O
hypothesized,O
that,O
multiple,O
injections,O
of,O
a,O
high,O
dose,O
of,O
cells,O
in,O
a,O
progressive,O
manner,O
would,O
maintain,O
cellular,O
viability,O
through,O
the,O
vascularization,O
process,O
when,O
compared,O
to,O
single,O
injection,O
of,O
the,O
same,O
number,O
of,O
cells,O
for,O
implantation,O
.,O
We,O
utilized,O
the,O
normal,O
vascularization,O
process,O
that,O
occurs,O
during,O
the,O
natural,O
regeneration,O
process,O
(,O
Fig,O
.,O
1,O
).,O
To,O
show,O
the,O
feasibility,O
of,O
restoring,O
functional,O
volumetric,O
tissues,O
in,O
the,O
defect,O
site,O
",",O
multiple,O
",",O
progressive,O
delivery,O
of,O
cells,O
was,O
performed,O
using,O
ectopic,O
cell,O
transplantation,O
in,O
a,O
subcutaneous,O
site,O
.,O
Appropriate,O
cell,O
delivery,O
parameters,O
such,O
as,O
cell,O
density,O
",",O
cell,O
injection,O
volume,O
",",O
and,O
time,O
interval,O
between,O
injections,O
were,O
tested,O
.,O
The,O
efficiency,O
of,O
volumetric,O
tissue,O
formation,O
was,O
compared,O
with,O
single,O
injection,O
of,O
the,O
same,O
number,O
of,O
cells,O
that,O
were,O
used,O
for,O
multiple,O
injections,O
.,O
Furthermore,O
",",O
this,O
cell,O
delivery,O
technique,O
using,O
C2C12,O
cells,O
and,O
human,B-OG
muscle,O
progenitor,O
cells,O
(,O
hMPCs,O
),O
was,O
applied,O
to,O
a,O
rodent,O
volumetric,O
muscle,O
loss,O
(,O
VML,O
),O
model,O
;,O
moreover,O
",",O
histological,O
and,O
functional,O
recovery,O
was,O
evaluated,O
to,O
determine,O
the,O
possibility,O
for,O
applications,O
to,O
treat,O
critical,O
-,O
size,O
muscle,O
defects,O
.,O
Results,O
Ectopic,O
muscle,O
construction,O
by,O
multiple,O
and,O
progressive,O
cell,O
injection,O
To,O
investigate,O
the,O
feasibility,O
of,O
restoring,O
volumetric,O
muscle,O
tissues,O
by,O
multiple,O
cell,O
injections,O
in,O
a,O
progressive,O
manner,O
",",O
C2C12,O
cells,O
were,O
subcutaneously,O
injected,O
in,O
athymic,O
mice,B-OG
",",O
and,O
the,O
volume,O
of,O
the,O
newly,O
formed,O
tissues,O
was,O
measured,O
at,O
pre,O
-,O
determined,O
injection,O
points,O
for,O
comparison,O
.,O
Multiple,O
-,O
cell,O
injections,O
with,O
one,O
week,O
interval,O
between,O
each,O
injection,O
resulted,O
in,O
an,O
increased,O
volume,O
of,O
the,O
implants,O
(,O
see,O
Supplementary,O
Fig,O
.,O
S2a,O
).,O
Quantitatively,O
",",O
increased,O
number,O
of,O
cell,O
injections,O
(,O
up,O
to,O
8,O
injections,O
),O
correlated,O
with,O
an,O
increased,O
implant,O
volume,O
(,O
Fig,O
.,O
2a,O
).,O
Particularly,O
",",O
6,O
–,O
8,O
cell,O
injections,O
demonstrated,O
a,O
statically,O
significant,O
difference,O
(,O
ANOVA,O
and,O
post,O
hoc,O
Tukey,O
Test,O
),O
when,O
compared,O
with,O
2,O
–,O
4,O
cell,O
injections,O
(*,O
P,O
<,O
0,O
.,O
0001,O
and,O
†,O
P,O
<,O
0,O
.,O
005,O
",",O
respectively,O
).,O
The,O
volumes,O
of,O
implants,O
in,O
all,O
multiple,O
",",O
progressive,O
cell,O
injected,O
groups,O
showed,O
a,O
significant,O
increase,O
compared,O
to,O
the,O
progressive,O
gel,O
only,O
-,O
injected,O
groups,O
(,O
ANOVA,O
",",O
‡,O
P,O
<,O
0,O
.,O
001,O
).,O
In,O
hematoxylin,O
and,O
eosin,O
(,O
H,O
&,O
E,O
),O
and,O
masson,O
’,O
s,O
trichrome,O
(,O
MT,O
),O
staining,O
images,O
(,O
see,O
Supplementary,O
Fig,O
.,O
S2b,O
"),",O
increase,O
in,O
the,O
volume,O
of,O
reconstructed,O
tissue,O
formation,O
was,O
notable,O
between,O
2,O
and,O
4,O
cell,O
injections,O
",",O
but,O
no,O
significant,O
size,O
difference,O
was,O
observed,O
beyond,O
4,O
cell,O
injections,O
.,O
In,O
each,O
group,O
",",O
the,O
MT,O
images,O
demonstrated,O
that,O
the,O
newly,O
formed,O
tissue,O
structures,O
were,O
skeletal,O
muscle,O
fibers,O
as,O
confirmed,O
by,O
red,O
staining,O
within,O
the,O
implant,O
.,O
The,O
efficiency,O
of,O
progressive,O
cell,O
delivery,O
in,O
the,O
reconstruction,O
of,O
volumetric,O
tissue,O
was,O
determined,O
by,O
comparing,O
to,O
the,O
single,O
injection,O
of,O
cells,O
.,O
In,O
this,O
comparison,O
",",O
total,O
volume,O
(,O
1,O
.,O
2,O
ml,O
),O
and,O
cell,O
number,O
was,O
set,O
to,O
be,O
equal,O
between,O
multiple,O
(,O
4,O
×,O
0,O
.,O
3,O
ml,O
per,O
injection,O
),O
and,O
single,O
injection,O
(,O
1,O
.,O
2,O
ml,O
for,O
one,O
injection,O
);,O
furthermore,O
",",O
4,O
progressive,O
cell,O
injections,O
were,O
selected,O
as,O
more,O
than,O
4,O
injections,O
would,O
yield,O
an,O
unimplantable,O
volume,O
for,O
single,O
injection,O
to,O
the,O
animal,B-OG
.,O
The,O
volume,O
of,O
the,O
reconstructed,O
tissue,O
of,O
the,O
progressive,O
cell,O
injection,O
group,O
showed,O
approximately,O
4,O
-,O
fold,O
increase,O
as,O
compared,O
to,O
that,O
of,O
the,O
single,O
injection,O
of,O
cells,O
with,O
a,O
statistical,O
difference,O
(,O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
n,O
=,O
4,O
",",O
*,O
P,O
<,O
0,O
.,O
0001,O
),O
(,O
Fig,O
.,O
2b,O
).,O
Interestingly,O
",",O
the,O
results,O
of,O
green,B-GP
fluorescent,I-GP
protein,I-GP
(,O
GFP,B-GP
),O
immunostaining,O
revealed,O
that,O
the,O
progressively,O
-,O
injected,O
C2C12,O
cells,O
contributed,O
to,O
the,O
formation,O
of,O
muscle,O
fibers,O
in,O
vivo,O
as,O
confirmed,O
by,O
GFP,B-GP
+,O
muscle,O
fiber,O
-,O
like,O
structures,O
within,O
the,O
reconstructed,O
tissue,O
(,O
Fig,O
.,O
2c,O
"),",O
while,O
a,O
few,O
GFP,B-GP
+,O
C2C12,O
cells,O
scattered,O
in,O
the,O
implant,O
were,O
found,O
in,O
the,O
single,O
injection,O
.,O
This,O
result,O
demonstrates,O
that,O
multiple,O
",",O
progressive,O
cell,O
injections,O
are,O
more,O
effective,O
than,O
single,O
injection,O
for,O
the,O
formation,O
of,O
a,O
volumetric,O
muscle,O
-,O
like,O
structure,O
at,O
a,O
muscle,O
ectopic,O
site,O
.,O
Efficient,O
muscle,O
cell,O
survival,O
",",O
muscle,O
tissue,O
formation,O
",",O
and,O
vascularization,O
by,O
progressively,O
injected,O
cells,O
To,O
examine,O
the,O
muscle,O
tissue,O
formation,O
and,O
maturation,O
of,O
progressively,O
injected,O
C2C12,O
cells,O
",",O
myosin,B-GP
heavy,I-GP
chain,I-GP
(,O
MHC,B-GP
),O
immunostaining,O
was,O
performed,O
on,O
the,O
reconstructed,O
tissue,O
.,O
Throughout,O
the,O
reconstructed,O
tissue,O
",",O
viable,O
MHC,B-GP
+,O
muscle,O
fiber,O
-,O
like,O
structures,O
and,O
cells,O
were,O
clearly,O
visualized,O
as,O
indicated,O
by,O
the,O
dotted,O
lines,O
(,O
Fig,O
.,O
3b,O
",",O
first,O
row,O
).,O
In,O
the,O
area,O
of,O
the,O
early,O
1st,O
injection,O
(,O
inner,O
site,O
of,O
the,O
implant,O
"),",O
a,O
number,O
of,O
MHC,B-GP
+,O
multi,O
-,O
nucleated,O
muscle,O
fibers,O
were,O
observed,O
",",O
while,O
a,O
few,O
MHC,B-GP
+,O
cells,O
with,O
pre,O
-,O
matured,O
structures,O
were,O
found,O
in,O
the,O
area,O
of,O
the,O
last,O
4th,O
injection,O
(,O
outer,O
site,O
).,O
The,O
observable,O
difference,O
in,O
muscle,O
maturation,O
demonstrates,O
that,O
multiple,O
cell,O
injections,O
performed,O
in,O
a,O
progressive,O
manner,O
allows,O
muscle,O
cell,O
survival,O
",",O
muscle,O
formation,O
",",O
and,O
maturation,O
of,O
the,O
injected,O
cells,O
in,O
an,O
ectopic,O
site,O
.,O
Vascularization,O
of,O
the,O
injected,O
C2C12,O
cells,O
in,O
a,O
timely,O
manner,O
is,O
a,O
critical,O
factor,O
to,O
re,O
-,O
create,O
volumetric,O
muscle,O
tissue,O
by,O
providing,O
an,O
adequate,O
blood,O
supply,O
to,O
the,O
grafted,O
cells,O
.,O
We,O
hypothesized,O
that,O
each,O
injection,O
of,O
cells,O
in,O
a,O
progressive,O
manner,O
would,O
promote,O
efficient,O
vascularization,O
with,O
the,O
host,O
.,O
To,O
test,O
the,O
hypothesis,O
",",O
double,O
staining,O
of,O
GFP,B-GP
and,O
von,B-GP
Willebrand,I-GP
factor,I-GP
(,O
vWF,B-GP
),O
was,O
performed,O
to,O
determine,O
whether,O
the,O
injected,O
GFP,B-GP
+,O
C2C12,O
cells,O
are,O
localized,O
with,O
vWF,B-GP
+,O
blood,O
vessels,O
for,O
improved,O
cell,O
survival,O
.,O
The,O
double,O
fluorescent,O
imaging,O
showed,O
that,O
GFP,B-GP
+,O
C2C12,O
cells,O
are,O
present,O
throughout,O
the,O
injected,O
area,O
and,O
are,O
localized,O
within,O
100,O
–,O
200,O
μm,O
of,O
vWF,B-GP
+,O
blood,O
vessels,O
(,O
Fig,O
.,O
3b,O
",",O
second,O
row,O
).,O
This,O
finding,O
suggests,O
that,O
progressively,O
injected,O
cells,O
remained,O
viable,O
along,O
with,O
newly,O
-,O
formed,O
vasculatures,O
in,O
the,O
injected,O
area,O
up,O
to,O
4,O
weeks,O
after,O
injection,O
.,O
Vascularization,O
and,O
neuronal,O
ingrowth,O
by,O
progressive,O
cell,O
injections,O
To,O
compare,O
vascularization,O
outcomes,O
between,O
the,O
progressive,O
and,O
single,O
cell,O
injections,O
",",O
vWF,B-GP
/,O
α,B-GP
-,I-GP
smooth,I-GP
muscle,I-GP
actin,I-GP
(,O
α,B-GP
-,I-GP
SMA,I-GP
),O
immunostaining,O
was,O
performed,O
in,O
each,O
group,O
(,O
Fig,O
.,O
3a,O
",",O
b,O
).,O
Quantitatively,O
",",O
new,O
blood,O
vessel,O
formation,O
and,O
vascular,O
maturation,O
were,O
assessed,O
by,O
counting,O
the,O
number,O
of,O
vWF,B-GP
+,O
vessels,O
(,O
per,O
field,O
"),",O
and,O
calculating,O
the,O
area,O
of,O
vWF,B-GP
+,O
vessels,O
(,O
μm2,O
per,O
field,O
"),",O
maturation,O
index,O
(%),O
and,O
percentage,O
of,O
different,O
vessel,O
sizes,O
(,O
Fig,O
.,O
3c,O
",",O
n,O
=,O
4,O
",",O
9,O
–,O
12,O
fields,O
per,O
each,O
sample,O
).,O
The,O
number,O
and,O
area,O
of,O
vWF,B-GP
+,O
vessels,O
(/,O
field,O
),O
in,O
the,O
progressive,O
injection,O
samples,O
significantly,O
increased,O
",",O
as,O
compared,O
to,O
that,O
of,O
the,O
single,O
cell,O
injection,O
group,O
(,O
Fig,O
.,O
3c,O
-,O
i,O
",",O
c,O
-,O
ii,O
",",O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
).,O
However,O
",",O
the,O
level,O
of,O
vascular,O
maturation,O
showed,O
no,O
significant,O
difference,O
between,O
the,O
two,O
groups,O
(,O
Fig,O
.,O
3c,O
-,O
iii,O
",",O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
P,O
>,O
0,O
.,O
05,O
).,O
The,O
majority,O
of,O
blood,O
vessels,O
observed,O
in,O
the,O
single,O
cell,O
injection,O
group,O
was,O
less,O
than,O
200,O
μm,O
in,O
diameter,O
",",O
whereas,O
a,O
higher,O
percentage,O
of,O
larger,O
blood,O
vessels,O
greater,O
than,O
500,O
μm,O
in,O
diameter,O
was,O
present,O
in,O
the,O
progressive,O
cell,O
injection,O
group,O
(,O
Fig,O
.,O
3c,O
-,O
iv,O
",",O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
).,O
These,O
results,O
indicate,O
that,O
multiple,O
",",O
progressive,O
cell,O
injection,O
is,O
an,O
effective,O
cell,O
delivery,O
method,O
to,O
achieve,O
vascularized,O
volumetric,O
muscle,O
structure,O
.,O
To,O
examine,O
whether,O
vascularization,O
and,O
maturation,O
during,O
progressive,O
cell,O
injections,O
occur,O
in,O
a,O
normal,O
and,O
physiological,O
manner,O
",",O
blood,O
vessels,O
formation,O
of,O
progressively,O
injected,O
areas,O
(,O
the,O
1st,O
",",O
2nd,O
–,O
3rd,O
",",O
and,O
4th,O
injected,O
areas,O
),O
was,O
quantified,O
by,O
using,O
vWF,B-GP
/,O
α,B-GP
-,I-GP
SMA,I-GP
immunostaining,O
images,O
(,O
Fig,O
.,O
3d,O
",",O
n,O
=,O
4,O
",",O
3,O
–,O
5,O
fields,O
per,O
each,O
area,O
in,O
each,O
sample,O
).,O
Large,O
and,O
matured,O
vessels,O
(,O
vWF,B-GP
+,O
α,B-GP
-,I-GP
SMA,I-GP
+),O
were,O
observed,O
in,O
both,O
areas,O
surrounding,O
the,O
1st,O
injection,O
site,O
and,O
the,O
2nd,O
–,O
3rd,O
injection,O
(,O
Fig,O
.,O
3b,O
",",O
third,O
row,O
).,O
More,O
immature,O
vessels,O
(,O
vWF,B-GP
+,O
α,B-GP
-,I-GP
SMA,I-GP
−),O
are,O
visualized,O
in,O
the,O
area,O
of,O
the,O
4th,O
injection,O
(,O
last,O
injection,O
),O
than,O
any,O
of,O
the,O
other,O
sites,O
.,O
The,O
site,O
of,O
the,O
4th,O
injection,O
showed,O
the,O
highest,O
number,O
of,O
vWF,B-GP
+,O
blood,O
vessels,O
and,O
the,O
lowest,O
area,O
of,O
vWF,B-GP
+,O
vessels,O
with,O
a,O
significant,O
difference,O
(,O
Fig,O
.,O
3d,O
-,O
I,O
",",O
d,O
-,O
ii,O
",",O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
with,O
the,O
1st,O
injection,O
",",O
†,O
P,O
<,O
0,O
.,O
05,O
with,O
the,O
2nd,O
injection,O
",",O
Tukey,O
test,O
"),",O
which,O
demonstrated,O
more,O
newly,O
formed,O
small,O
-,O
sized,O
capillaries,O
at,O
the,O
injection,O
site,O
when,O
compared,O
to,O
that,O
of,O
the,O
earlier,O
injected,O
sites,O
.,O
In,O
terms,O
of,O
the,O
degree,O
of,O
blood,O
vessel,O
maturation,O
",",O
the,O
1st,O
injection,O
site,O
(,O
inner,O
site,O
),O
showed,O
highest,O
maturation,O
index,O
compared,O
with,O
the,O
other,O
three,O
sites,O
(,O
Fig,O
.,O
3d,O
-,O
iii,O
",",O
ANOVA,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
with,O
the,O
1st,O
injection,O
",",O
†,O
P,O
<,O
0,O
.,O
05,O
with,O
the,O
2nd,O
injection,O
",",O
Tukey,O
test,O
).,O
These,O
quantitative,O
results,O
correlate,O
with,O
the,O
percentage,O
of,O
blood,O
vessels,O
as,O
a,O
function,O
of,O
blood,O
vessels,O
size,O
(,O
Fig,O
.,O
3d,O
-,O
iv,O
).,O
This,O
finding,O
is,O
consistent,O
with,O
normal,O
angiogenesis,O
that,O
can,O
be,O
found,O
in,O
another,O
study29,O
.,O
In,O
contrast,O
",",O
inner,O
area,O
of,O
implants,O
constructed,O
by,O
single,O
cell,O
injection,O
showed,O
the,O
lowest,O
area,O
of,O
vWF,B-GP
+,O
vessels,O
",",O
and,O
there,O
were,O
no,O
significant,O
differences,O
in,O
number,O
",",O
maturation,O
and,O
percentage,O
of,O
blood,O
vessels,O
among,O
inner,O
",",O
middle,O
",",O
outer,O
areas,O
(,O
see,O
Supplementary,O
Fig,O
.,O
S3,O
).,O
In,O
addition,O
",",O
neuronal,O
ingrowth,O
",",O
which,O
is,O
a,O
critical,O
cellular,O
event,O
in,O
functional,O
muscle,O
regeneration,O
",",O
appeared,O
to,O
occur,O
in,O
a,O
normal,O
condition,O
.,O
The,O
progressive,O
cell,O
injection,O
facilitated,O
recruitment,O
of,O
Neurofilament,B-GP
(,O
NF,B-GP
)+,O
peripheral,O
nerves,O
at,O
each,O
injection,O
site,O
(,O
Fig,O
.,O
3b,O
",",O
lowest,O
row,O
).,O
These,O
results,O
showed,O
that,O
multiple,O
cell,O
injections,O
in,O
a,O
progressive,O
manner,O
maintained,O
viability,O
of,O
the,O
delivered,O
cells,O
within,O
the,O
muscle,O
ectopic,O
site,O
while,O
single,O
injection,O
did,O
not,O
;,O
furthermore,O
",",O
the,O
vascularization,O
and,O
neuronal,O
ingrowth,O
were,O
observed,O
that,O
facilitated,O
the,O
volumetric,O
skeletal,O
muscle,O
construct,O
in,O
vivo,O
.,O
Improved,O
structural,O
and,O
functional,O
recovery,O
of,O
critical,O
defect,O
in,O
TA,O
muscle,O
by,O
progressive,O
cell,O
injection,O
Encouraged,O
by,O
promising,O
outcomes,O
in,O
the,O
ectopic,O
implantation,O
study,O
",",O
we,O
applied,O
the,O
progressive,O
cell,O
delivery,O
method,O
to,O
restore,O
muscle,O
function,O
of,O
the,O
injured,O
skeletal,O
muscle,O
.,O
To,O
test,O
the,O
possibility,O
",",O
a,O
volumetric,O
muscle,O
defect,O
in,O
a,O
critical,O
-,O
size,O
was,O
utilized,O
to,O
test,O
the,O
efficiency,O
of,O
the,O
progressive,O
cell,O
delivery,O
method,O
.,O
As,O
a,O
volumetric,O
muscle,O
defect,O
model,O
",",O
30,O
%,O
of,O
original,O
tibialis,O
anterior,O
(,O
TA,O
),O
muscle,O
mass,O
was,O
excised,O
and,O
this,O
level,O
of,O
muscle,O
loss,O
is,O
incapable,O
of,O
fully,O
restoring,O
the,O
TA,O
muscle,O
for,O
several,O
months,O
without,O
any,O
treatment,O
.,O
Therapeutic,O
efficacy,O
of,O
progressive,O
cell,O
injections,O
was,O
evaluated,O
by,O
anatomical,O
and,O
functional,O
analysis,O
(,O
n,O
=,O
4,O
per,O
each,O
group,O
).,O
Grossly,O
",",O
the,O
TA,O
muscle,O
of,O
progressive,O
injections,O
was,O
harvested,O
at,O
4,O
weeks,O
after,O
first,O
injection,O
and,O
showed,O
better,O
TA,O
anatomy,O
than,O
no,O
treatment,O
(,O
defect,O
only,O
"),",O
gel,O
only,O
",",O
or,O
single,O
injection,O
group,O
(,O
see,O
Supplementary,O
Fig,O
.,O
S4,O
).,O
As,O
observed,O
in,O
the,O
gross,O
images,O
",",O
single,O
injection,O
of,O
C2C12,O
recovered,O
the,O
defected,O
TA,O
muscle,O
by,O
a,O
1,O
.,O
3,O
-,O
fold,O
increase,O
in,O
TA,O
muscle,O
mass,O
compared,O
with,O
no,O
treatment,O
and,O
gel,O
only,O
injection,O
group,O
(,O
Fig,O
.,O
4a,O
).,O
The,O
ratio,O
of,O
the,O
treated,O
-,O
to,O
contralateral,O
TA,O
muscle,O
mass,O
of,O
the,O
progressive,O
C2C12,O
injection,O
group,O
showed,O
a,O
1,O
.,O
3,O
-,O
fold,O
increase,O
compared,O
to,O
that,O
of,O
the,O
single,O
C2C12,O
injection,O
group,O
with,O
a,O
significant,O
difference,O
(,O
ANOVA,O
and,O
Tukey,O
test,O
",",O
§,O
P,O
<,O
0,O
.,O
017,O
),O
(,O
Fig,O
.,O
4a,O
).,O
Interestingly,O
",",O
the,O
increased,O
muscle,O
mass,O
correlates,O
with,O
improved,O
muscle,O
function,O
.,O
Tetanic,O
muscle,O
force,O
of,O
the,O
progressive,O
C2C12,O
muscle,O
injection,O
group,O
showed,O
a,O
2,O
-,O
fold,O
increase,O
",",O
as,O
compared,O
to,O
that,O
of,O
the,O
single,O
C2C12,O
injection,O
group,O
(,O
ANOVA,O
and,O
Tukey,O
test,O
",",O
§,O
P,O
<,O
0,O
.,O
016,O
).,O
Muscle,O
function,O
improvement,O
demonstrated,O
by,O
the,O
progressive,O
C2C12,O
injections,O
was,O
approximately,O
42,O
%,O
of,O
normal,O
TA,O
muscle,O
.,O
The,O
multiple,O
progressive,O
injections,O
of,O
hMPCs,O
also,O
showed,O
a,O
similar,O
pattern,O
",",O
in,O
terms,O
of,O
muscle,O
function,O
improvement,O
.,O
When,O
compared,O
with,O
the,O
single,O
hMPC,O
injection,O
",",O
the,O
progressive,O
hMPC,O
injections,O
facilitated,O
a,O
1,O
.,O
5,O
-,O
and,O
2,O
.,O
6,O
-,O
fold,O
increase,O
in,O
muscle,O
mass,O
and,O
function,O
",",O
respectively,O
(,O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
),O
(,O
Fig,O
.,O
4c,O
).,O
Progressively,O
injected,O
hMPCs,O
in,O
the,O
TA,O
muscle,O
showed,O
39,O
%,O
restoration,O
of,O
the,O
muscle,O
function,O
",",O
as,O
compared,O
with,O
normal,O
TA,O
muscle,O
.,O
Improved,O
functional,O
outcome,O
by,O
both,O
cell,O
types,O
was,O
evidenced,O
by,O
histological,O
analysis,O
.,O
Based,O
on,O
the,O
H,O
&,O
E,O
images,O
",",O
TA,O
muscle,O
thicknesses,O
of,O
progressive,O
C2C12,O
and,O
hMPC,O
injection,O
groups,O
were,O
1,O
.,O
6,O
-,O
and,O
1,O
.,O
2,O
-,O
fold,O
higher,O
than,O
that,O
of,O
single,O
injections,O
with,O
a,O
statistical,O
difference,O
(,O
ANOVA,O
and,O
Tukey,O
test,O
",",O
§,O
P,O
<,O
0,O
.,O
001,O
and,O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
*,O
P,O
<,O
0,O
.,O
003,O
),O
(,O
Fig,O
.,O
4b,O
",",O
d,O
"),",O
respectively,O
.,O
To,O
evaluate,O
the,O
level,O
of,O
fibrosis,O
in,O
muscle,O
tissue,O
",",O
collagen,B-GP
I,I-GP
/,O
MHC,B-GP
immunostaining,O
was,O
performed,O
.,O
The,O
percentage,O
of,O
collagen,B-GP
I,I-GP
+,O
area,O
of,O
inner,O
TA,O
and,O
outer,O
TA,O
was,O
quantified,O
(,O
n,O
=,O
4,O
",",O
3,O
random,O
fields,O
per,O
each,O
area,O
in,O
each,O
sample,O
),O
(,O
see,O
Supplementary,O
Fig,O
.,O
S5,O
).,O
In,O
all,O
groups,O
",",O
severe,O
fibrosis,O
was,O
observed,O
in,O
the,O
outer,O
area,O
of,O
injection,O
sites,O
",",O
when,O
compared,O
with,O
the,O
inner,O
TA,O
.,O
However,O
",",O
the,O
progressive,O
injection,O
group,O
",",O
regardless,O
of,O
the,O
cell,O
types,O
",",O
resulted,O
in,O
reduced,O
levels,O
of,O
fibrosis,O
",",O
as,O
compared,O
with,O
the,O
single,O
cell,O
injection,O
group,O
in,O
both,O
the,O
inner,O
TA,O
and,O
outer,O
TA,O
(,O
ANOVA,O
and,O
Tukey,O
test,O
",",O
P,O
<,O
0,O
.,O
05,O
).,O
Particularly,O
",",O
the,O
degree,O
of,O
fibrosis,O
of,O
the,O
inner,O
area,O
in,O
the,O
progressive,O
C2C12,O
injection,O
group,O
was,O
comparable,O
to,O
normal,O
TA,O
muscle,O
with,O
no,O
statistical,O
difference,O
(,O
ANOVA,O
and,O
Tukey,O
test,O
",",O
*,O
P,O
>,O
0,O
.,O
997,O
).,O
Overall,O
",",O
multiple,O
cell,O
injections,O
in,O
a,O
progressive,O
manner,O
is,O
an,O
effective,O
cell,O
delivery,O
method,O
in,O
term,O
of,O
anatomical,O
and,O
functional,O
improvement,O
of,O
volumetric,O
muscle,O
defect,O
",",O
when,O
compared,O
with,O
no,O
treatment,O
",",O
cell,O
delivery,O
vehicle,O
only,O
and,O
single,O
delivery,O
of,O
same,O
cell,O
number,O
.,O
Muscle,O
fiber,O
formation,O
of,O
progressively,O
injected,O
cells,O
and,O
vascularization,O
and,O
neuronal,O
ingrowth,O
To,O
examine,O
whether,O
each,O
progressive,O
cell,O
injection,O
can,O
efficiently,O
deliver,O
the,O
infused,O
cells,O
to,O
occupy,O
the,O
defect,O
space,O
within,O
the,O
TA,O
muscle,O
defect,O
site,O
",",O
the,O
GFP,B-GP
+,O
C2C12,O
cells,O
were,O
fluorescently,O
labeled,O
before,O
implantation,O
",",O
and,O
the,O
localized,O
cells,O
were,O
tracked,O
by,O
a,O
double,O
fluorescent,O
imaging,O
based,O
on,O
GFP,B-GP
expression,O
and,O
fluorescent,O
labeling,O
.,O
Progressively,O
-,O
injected,O
C2C12,O
cells,O
showed,O
distinguishable,O
localization,O
within,O
the,O
TA,O
defect,O
site,O
(,O
Fig,O
.,O
5a,O
),O
where,O
the,O
cells,O
were,O
fluorescently,O
labeled,O
only,O
for,O
1st,O
and,O
4th,O
injection,O
.,O
In,O
the,O
double,O
GFP,B-GP
+,O
fluorescent,O
labeling,O
imaging,O
",",O
fluorescently,O
labeled,O
C2C12,O
cells,O
at,O
1st,O
and,O
4th,O
injection,O
site,O
were,O
clearly,O
visualized,O
as,O
red,O
fluorescence,O
(,O
yellow,O
arrows,O
along,O
with,O
dotted,O
lines,O
in,O
whole,O
TA,O
),O
while,O
cells,O
injected,O
during,O
the,O
2,O
–,O
3rd,O
injection,O
were,O
stained,O
with,O
GFP,B-GP
without,O
red,O
fluorescent,O
labeling,O
.,O
Single,O
injection,O
of,O
C2C12,O
cells,O
",",O
which,O
represents,O
the,O
same,O
cell,O
number,O
as,O
the,O
total,O
cell,O
number,O
delivered,O
by,O
progressive,O
injections,O
",",O
also,O
showed,O
a,O
few,O
fluorescent,O
signals,O
in,O
the,O
outer,O
part,O
of,O
the,O
TA,O
muscle,O
.,O
In,O
magnified,O
images,O
",",O
the,O
number,O
of,O
injected,O
cells,O
with,O
fluorescently,O
labeled,O
GFP,B-GP
+,O
MHC,B-GP
+,O
C2C12,O
cells,O
(,O
white,O
arrows,O
),O
is,O
higher,O
with,O
progressive,O
injections,O
than,O
that,O
by,O
single,O
injection,O
(,O
Inner,O
TA,O
).,O
In,O
the,O
inner,O
part,O
of,O
the,O
TA,O
muscle,O
(,O
Fig,O
.,O
5a,O
"),",O
the,O
majority,O
of,O
infused,O
C2C12,O
cells,O
by,O
progressive,O
injection,O
formed,O
muscle,O
fibers,O
(,O
MHC,B-GP
+,O
staining,O
),O
and,O
newly,O
formed,O
muscle,O
fibers,O
(,O
chimeric,O
),O
(,O
MHC,B-GP
+,O
GFP,B-GP
+,O
labeling,O
",",O
as,O
indicated,O
by,O
white,O
arrows,O
),O
organized,O
with,O
the,O
host,O
muscle,O
tissue,O
.,O
The,O
outer,O
site,O
of,O
the,O
TA,O
muscle,O
showed,O
different,O
cell,O
localization,O
compared,O
with,O
the,O
inner,O
site,O
.,O
In,O
the,O
progressive,O
group,O
",",O
a,O
number,O
of,O
injected,O
C2C12,O
cells,O
with,O
fluorescent,O
labeling,O
are,O
found,O
to,O
contribute,O
to,O
the,O
muscle,O
formation,O
with,O
host,O
muscle,O
tissues,O
(,O
white,O
arrows,O
).,O
More,O
interestingly,O
",",O
the,O
number,O
of,O
GFP,B-GP
+,O
MHC,B-GP
+,O
fluorescent,O
-,O
labeling,O
positive,O
cells,O
is,O
higher,O
in,O
the,O
progressive,O
injection,O
group,O
than,O
in,O
the,O
single,O
injection,O
group,O
.,O
In,O
addition,O
",",O
a,O
few,O
fluorescently,O
labeled,O
-,O
GFP,B-GP
+,O
C2C12,O
cells,O
at,O
the,O
surface,O
site,O
of,O
the,O
TA,O
muscle,O
are,O
not,O
involved,O
in,O
the,O
muscle,O
formation,O
as,O
indicated,O
by,O
white,O
arrowheads,O
.,O
hMPC,O
injection,O
also,O
showed,O
a,O
similar,O
pattern,O
of,O
cell,O
distribution,O
with,O
C2C12,O
cells,O
(,O
Fig,O
.,O
5b,O
).,O
Progressive,O
injection,O
of,O
hMPCs,O
resulted,O
in,O
efficient,O
distribution,O
at,O
the,O
entire,O
site,O
of,O
the,O
TA,O
muscle,O
",",O
as,O
confirmed,O
by,O
double,O
staining,O
of,O
MHC,B-GP
and,O
human,B-GP
leukocyte,I-GP
antigen,I-GP
(,O
HLA,B-GP
),O
staining,O
(,O
Fig,O
.,O
5b,O
",",O
lower,O
row,O
).,O
More,O
HLA,B-GP
+,O
MHC,B-GP
+,O
chimeric,O
muscle,O
fibers,O
are,O
clearly,O
found,O
in,O
both,O
inner,O
and,O
outer,O
TA,O
site,O
(,O
white,O
arrows,O
),O
by,O
progressive,O
injection,O
but,O
not,O
with,O
single,O
injection,O
.,O
Interestingly,O
",",O
some,O
of,O
chimeric,O
muscle,O
fibers,O
(,O
white,O
arrows,O
),O
in,O
the,O
progressive,O
group,O
in,O
the,O
outer,O
area,O
of,O
the,O
TA,O
muscle,O
tissue,O
are,O
notable,O
in,O
terms,O
of,O
clear,O
involvement,O
of,O
the,O
injected,O
hMPCs,O
(,O
white,O
arrows,O
in,O
outer,O
TA,O
).,O
Differentiation,O
of,O
injected,O
C2C12,O
cells,O
and,O
hMPCs,O
into,O
myofibers,O
or,O
myotubes,O
was,O
quantified,O
by,O
calculating,O
the,O
percentage,O
of,O
fluorescent,O
-,O
labeled,O
-,O
Myogenin,B-GP
+,O
C2C12,O
cells,O
and,O
Myogenin,B-GP
+,O
human,B-GP
nuclear,I-GP
antigen,I-GP
(,O
HNA,B-GP
)+,O
cells,O
in,O
the,O
C2C12,O
-,O
injected,O
group,O
and,O
hMPCs,O
-,O
injected,O
TA,O
muscles,O
",",O
respectively,O
(,O
n,O
=,O
3,O
–,O
4,O
",",O
3,O
–,O
5,O
fields,O
per,O
sample,O
).,O
In,O
both,O
C2C12,O
-,O
injected,O
group,O
and,O
hMPCs,O
-,O
injected,O
TA,O
muscle,O
",",O
the,O
percentage,O
of,O
fluorescently,O
labeled,O
Myogenin,B-GP
+,O
cells,O
and,O
Myogenin,B-GP
+,O
HNA,B-GP
+,O
cells,O
was,O
higher,O
with,O
progressive,O
injections,O
than,O
that,O
by,O
single,O
injection,O
with,O
a,O
statistical,O
difference,O
(,O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
(,O
42,O
.,O
74,O
%,O
±,O
10,O
.,O
63,O
%,O
and,O
19,O
.,O
18,O
%,O
±,O
6,O
.,O
04,O
%,O
in,O
progressive,O
C2C12,O
and,O
hMPCs,O
injection,O
",",O
respectively,O
),O
(,O
see,O
Supplementary,O
Figs,O
S6,O
and,O
S7,O
).,O
Notably,O
",",O
it,O
was,O
clearly,O
seen,O
that,O
fluorescently,O
labeled,O
C2C12,O
cells,O
were,O
fused,O
to,O
form,O
muscle,O
fibers,O
with,O
host,O
muscle,O
tissues,O
",",O
some,O
of,O
which,O
was,O
Myogenin,B-GP
+,O
cells,O
.,O
Proliferation,O
of,O
injected,O
cells,O
in,O
the,O
TA,O
muscles,O
was,O
evaluated,O
by,O
fluorescent,O
staining,O
images,O
of,O
proliferating,B-GP
cell,I-GP
nuclear,I-GP
antigen,I-GP
(,O
PCNA,B-GP
).,O
The,O
percentage,O
of,O
proliferating,O
C2C12,O
cells,O
(,O
fluorescent,O
labeled,O
PCNA,B-GP
+),O
and,O
hMPCs,O
(,O
PCNA,B-GP
+,O
HNA,B-GP
+,O
cells,O
),O
in,O
the,O
progressive,O
injection,O
group,O
was,O
33,O
.,O
31,O
%,O
±,O
15,O
.,O
56,O
%,O
and,O
31,O
.,O
99,O
%,O
±,O
15,O
.,O
84,O
"%,",O
respectively,O
",",O
which,O
is,O
higher,O
than,O
in,O
the,O
single,O
injection,O
group,O
(,O
n,O
=,O
3,O
–,O
4,O
",",O
3,O
–,O
5,O
fields,O
per,O
each,O
sample,O
",",O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
(,O
see,O
Supplementary,O
Figs,O
S6,O
and,O
S7,O
).,O
To,O
examine,O
the,O
vascularization,O
and,O
neuronal,O
ingrowth,O
by,O
the,O
injected,O
hMPCs,O
",",O
vWF,B-GP
/,O
α,B-GP
-,I-GP
SMA,I-GP
and,O
NF,B-GP
/,O
AChR,B-GP
/,O
MHC,B-GP
immunostaining,O
were,O
performed,O
",",O
and,O
double,O
-,O
and,O
triple,O
-,O
positive,O
staining,O
was,O
visualized,O
",",O
respectively,O
.,O
Quantitative,O
results,O
of,O
vascularization,O
indicated,O
that,O
only,O
progressive,O
hMPCs,O
injections,O
showed,O
increased,O
vascularization,O
",",O
in,O
terms,O
of,O
number,O
and,O
area,O
of,O
vWF,B-GP
+,O
vessels,O
(/,O
field,O
),O
(,O
n,O
=,O
3,O
–,O
4,O
",",O
6,O
–,O
10,O
fields,O
per,O
sample,O
",",O
ANOVA,O
and,O
Tukey,O
test,O
",",O
P,O
<,O
0,O
.,O
05,O
),O
(,O
Fig,O
.,O
6b,O
",",O
c,O
"),",O
while,O
the,O
degree,O
of,O
vascularization,O
was,O
not,O
statistically,O
different,O
among,O
the,O
no,O
treatment,O
",",O
gel,O
only,O
and,O
single,O
hMPCs,O
injection,O
groups,O
(,O
ANOVA,O
and,O
Tukey,O
test,O
",",O
P,O
>,O
0,O
.,O
05,O
).,O
Meanwhile,O
",",O
the,O
degree,O
of,O
vascularization,O
between,O
inner,O
region,O
and,O
outer,O
region,O
in,O
each,O
group,O
was,O
not,O
statistically,O
different,O
in,O
terms,O
of,O
the,O
number,O
and,O
area,O
of,O
vWF,B-GP
+,O
vessels,O
(/,O
field,O
"),",O
maturation,O
index,O
(%),O
and,O
percentage,O
of,O
different,O
vessel,O
sizes,O
(,O
data,O
not,O
shown,O
",",O
Student,O
’,O
s,O
t,O
-,O
test,O
",",O
P,O
>,O
0,O
.,O
05,O
).,O
Neuronal,O
ingrowth,O
of,O
the,O
TA,O
muscle,O
was,O
confirmed,O
as,O
NF,B-GP
+/,O
AChR,B-GP
+/,O
MHC,B-GP
+,O
staining,O
in,O
both,O
progressive,O
and,O
single,O
injection,O
",",O
and,O
the,O
level,O
of,O
neuronal,O
ingrowth,O
was,O
not,O
significantly,O
different,O
between,O
the,O
injection,O
methods,O
(,O
see,O
Supplementary,O
Fig,O
.,O
S8,O
).,O
Discussion,O
With,O
increasing,O
interests,O
in,O
translation,O
of,O
cell,O
-,O
based,O
therapies,O
from,O
pre,O
-,O
clinical,O
to,O
clinical,O
applications,O
",",O
appropriate,O
treatment,O
of,O
large,O
volumetric,O
tissue,O
defects,O
relies,O
on,O
efficient,O
cell,O
survival,O
following,O
implantation1530,O
.,O
While,O
several,O
cell,O
-,O
based,O
approaches,O
using,O
TE,O
and,O
RM,O
techniques,O
have,O
facilitated,O
successful,O
outcomes,O
in,O
terms,O
of,O
recovery,O
of,O
avascular,O
tissue,O
function,O
through,O
an,O
effective,O
tissue,O
regeneration,O
conditions234,O
",",O
reconstruction,O
of,O
volumetric,O
and,O
highly,O
-,O
vascularized,O
tissues,O
or,O
organs,O
on,O
a,O
large,O
scale,O
(>,O
mm,O
to,O
cm,O
),O
in,O
vivo,O
remains,O
challenging,O
.,O
Decreased,O
cell,O
survival,O
of,O
the,O
implanted,O
cells,O
due,O
to,O
an,O
insufficient,O
blood,O
supply,O
to,O
the,O
implanted,O
cells,O
has,O
limited,O
the,O
efficient,O
integration,O
of,O
such,O
large,O
constructs,O
with,O
the,O
host,O
vascularization11516,O
.,O
To,O
address,O
this,O
issue,O
",",O
several,O
pre,O
-,O
vascularization,O
approaches,O
have,O
been,O
developed,O
and,O
many,O
have,O
demonstrated,O
successful,O
reconstruction,O
of,O
vascularized,O
tissues,O
in,O
in,O
vitro,O
and,O
in,O
vivo1531,O
.,O
The,O
time,O
-,O
consuming,O
vascularization,O
process,O
",",O
however,O
",",O
must,O
be,O
overcome,O
to,O
allow,O
for,O
the,O
volumetric,O
repair1530,O
.,O
Currently,O
",",O
efficient,O
method,O
is,O
available,O
to,O
treat,O
the,O
volumetric,O
tissue,O
defect,O
;,O
therefore,O
",",O
we,O
developed,O
an,O
effective,O
cell,O
delivery,O
method,O
to,O
construct,O
a,O
large,O
size,O
muscle,O
tissue,O
through,O
an,O
efficient,O
vascularization,O
process,O
in,O
vivo,O
.,O
Our,O
results,O
from,O
histological,O
and,O
immunohistochemical,O
analysis,O
demonstrate,O
that,O
muscle,O
cell,O
delivery,O
by,O
multiple,O
cell,O
injection,O
in,O
a,O
progressive,O
manner,O
facilitated,O
large,O
scale,O
muscle,O
(>,O
mm,O
),O
tissue,O
formation,O
in,O
an,O
ectopic,O
mouse,B-OG
model,O
",",O
and,O
the,O
reconstructed,O
tissue,O
is,O
well,O
-,O
integrated,O
with,O
the,O
host,O
vascular,O
system,O
and,O
neuronal,O
ingrowth,O
.,O
When,O
this,O
technique,O
was,O
applied,O
to,O
a,O
skeletal,B-DS
muscle,I-DS
injury,I-DS
model,O
with,O
a,O
critical,O
volumetric,O
defect,O
",",O
the,O
progressive,O
cell,O
injection,O
demonstrated,O
enhanced,O
muscle,O
tissue,O
reconstruction,O
and,O
improved,O
functional,O
recovery,O
when,O
compared,O
with,O
single,O
injection,O
.,O
From,O
these,O
results,O
",",O
we,O
suggest,O
that,O
our,O
cell,O
delivery,O
system,O
in,O
a,O
multiple,O
progressive,O
manner,O
is,O
a,O
promising,O
and,O
effective,O
method,O
to,O
reconstruct,O
volumetric,O
muscle,O
and,O
thereby,O
improve,O
muscle,O
function,O
in,O
vivo,O
.,O
The,O
idea,O
of,O
‘,O
multiple,O
and,O
progressive,O
cell,O
delivery,O
’,O
for,O
volumetric,O
tissue,O
reconstruction,O
arose,O
from,O
the,O
phenomena,O
frequently,O
observed,O
in,O
cell,O
-,O
based,O
approaches,O
;,O
32,O
which,O
includes,O
decreased,O
cell,O
survival,O
of,O
transplanted,O
cells,O
or,O
implantation,O
of,O
engineered,O
tissue,O
construct,O
due,O
to,O
the,O
insufficient,O
delivery,O
of,O
oxygen,O
and,O
nutrients,O
as,O
a,O
result,O
of,O
the,O
time,O
-,O
consuming,O
process,O
of,O
vascularization,O
.,O
Large,O
defect,O
sizes,O
(,O
e,O
.,O
g,O
.,O
mm,O
-,O
cm,O
in,O
size,O
),O
are,O
particularly,O
affected,O
by,O
decreased,O
cell,O
viability,O
when,O
in,O
the,O
vascularized,O
tissues,O
needs,O
to,O
be,O
repaired,O
.,O
In,O
this,O
case,O
",",O
a,O
high,O
number,O
of,O
cells,O
are,O
usually,O
required,O
for,O
treatment,O
",",O
and,O
the,O
requirement,O
for,O
oxygen,O
and,O
nutrients,O
increases,O
with,O
the,O
increased,O
cell,O
number1,O
.,O
To,O
address,O
this,O
critical,O
issue,O
",",O
we,O
hypothesized,O
that,O
a,O
multiple,O
number,O
of,O
cell,O
injections,O
performed,O
in,O
a,O
progressive,O
manner,O
would,O
effectively,O
enhance,O
volumetric,O
tissue,O
in,O
vivo,O
(,O
Fig,O
.,O
1,O
).,O
This,O
delivery,O
method,O
is,O
primarily,O
designed,O
to,O
improve,O
the,O
viability,O
of,O
the,O
delivered,O
cells,O
at,O
each,O
injection,O
to,O
allow,O
for,O
efficient,O
vascularization,O
surrounding,O
the,O
cells,O
at,O
the,O
delivery,O
site,O
.,O
The,O
first,O
injection,O
of,O
cells,O
at,O
an,O
appropriate,O
cell,O
number,O
and,O
injection,O
volume,O
will,O
obtain,O
sufficient,O
oxygen,O
from,O
the,O
host,O
vessels,O
at,O
the,O
injection,O
site,O
.,O
Following,O
the,O
first,O
injection,O
",",O
the,O
host,O
vasculature,O
will,O
surround,O
the,O
site,O
of,O
the,O
injection,O
within,O
a,O
few,O
days,O
and,O
provide,O
vascular,O
beds,O
for,O
subsequent,O
cell,O
injections,O
.,O
The,O
period,O
of,O
vascularization,O
following,O
each,O
subsequent,O
injection,O
results,O
in,O
the,O
formation,O
of,O
a,O
suitable,O
angiogenic,O
environment,O
for,O
the,O
injected,O
cells,O
.,O
Repeating,O
the,O
cell,O
injection,O
process,O
allows,O
a,O
larger,O
and,O
thicker,O
tissue,O
with,O
structural,O
and,O
functional,O
properties,O
to,O
be,O
reconstructed,O
in,O
vivo,O
(,O
Fig,O
.,O
1,O
).,O
To,O
test,O
the,O
hypothesis,O
",",O
we,O
utilized,O
an,O
ectopic,O
implantation,O
model,O
through,O
subcutaneous,O
injection,O
in,O
athymic,O
mice,B-OG
.,O
The,O
subcutaneous,O
injection,O
model,O
was,O
chosen,O
for,O
several,O
reasons,O
including,O
a,O
highly,O
vascularized,O
",",O
non,O
-,O
myogenic,O
tissue,O
that,O
was,O
easily,O
accessible,O
for,O
cell,O
injection,O
.,O
It,O
was,O
particularly,O
important,O
to,O
evaluate,O
muscle,O
regeneration,O
within,O
a,O
non,O
-,O
myogenic,O
environment,O
to,O
evaluate,O
whether,O
the,O
volumetric,O
muscle,O
formation,O
in,O
vivo,O
occurred,O
as,O
a,O
result,O
of,O
the,O
injected,O
muscle,O
cells,O
following,O
the,O
progressive,O
cell,O
injection,O
strategy,O
and,O
without,O
any,O
contribution,O
of,O
host,O
muscle,O
tissue,O
.,O
Using,O
this,O
model,O
",",O
we,O
first,O
attempted,O
to,O
optimize,O
cell,O
density,O
for,O
injection,O
.,O
Subcutaneous,O
injection,O
of,O
three,O
different,O
cell,O
concentrations,O
showed,O
dramatically,O
different,O
results,O
in,O
terms,O
of,O
cell,O
survival,O
",",O
where,O
highest,O
cell,O
density,O
(,O
30,O
×,O
106,O
cells,O
per,O
ml,O
),O
indicated,O
higher,O
necrosis,O
with,O
an,O
exponential,O
increase,O
(,O
see,O
Supplementary,O
Fig,O
.,O
S1,O
"),",O
thus,O
",",O
indicating,O
that,O
a,O
higher,O
cell,O
density,O
within,O
the,O
implanted,O
area,O
exceeded,O
the,O
amount,O
of,O
oxygen,O
and,O
nutrients,O
that,O
could,O
be,O
supplied,O
by,O
the,O
host,O
.,O
It,O
is,O
plausible,O
that,O
high,O
cell,O
concentration,O
increased,O
oxygen,O
consumption,O
by,O
cells,O
",",O
while,O
diffusion,O
of,O
oxygen,O
decreased,O
in,O
denser,O
tissues,O
.,O
Therefore,O
",",O
cell,O
concentration,O
of,O
10,O
×,O
106,O
cells,O
per,O
ml,O
was,O
selected,O
for,O
this,O
study,O
to,O
prevent,O
necrosis,O
and,O
improve,O
tissue,O
formation,O
.,O
In,O
addition,O
to,O
the,O
selection,O
of,O
an,O
appropriate,O
cell,O
density,O
for,O
the,O
cell,O
injection,O
",",O
the,O
time,O
interval,O
between,O
each,O
cell,O
injection,O
was,O
an,O
important,O
parameter,O
to,O
be,O
considered,O
.,O
As,O
a,O
proof,O
-,O
of,O
-,O
concept,O
study,O
",",O
we,O
chose,O
an,O
interval,O
of,O
one,O
week,O
between,O
each,O
of,O
the,O
multiple,O
cell,O
injections,O
based,O
on,O
the,O
time,O
for,O
normal,O
vascularization,O
to,O
occur,O
in,O
the,O
body29,O
.,O
Generally,O
",",O
the,O
new,O
vascularization,O
surrounding,O
the,O
cell,O
injection,O
site,O
will,O
occur,O
within,O
one,O
week,O
and,O
new,O
blood,O
vessel,O
formation,O
under,O
maturation,O
will,O
occur,O
at,O
2,O
–,O
3,O
weeks,O
.,O
We,O
attempted,O
to,O
perform,O
four,O
series,O
of,O
cell,O
injections,O
in,O
a,O
progressive,O
manner,O
in,O
the,O
ectopic,O
implantation,O
study,O
(,O
Fig,O
.,O
3,O
);,O
therefore,O
",",O
we,O
expected,O
that,O
the,O
1st,O
–,O
3rd,O
injection,O
",",O
which,O
occurred,O
at,O
least,O
two,O
weeks,O
before,O
harvesting,O
the,O
reconstruct,O
tissue,O
formation,O
",",O
would,O
form,O
the,O
appropriate,O
vascular,O
maturation,O
while,O
the,O
4th,O
(,O
final,O
),O
injection,O
site,O
would,O
show,O
newly,O
formed,O
capillaries,O
.,O
The,O
results,O
of,O
immunostaining,O
and,O
quantification,O
analysis,O
confirm,O
that,O
one,O
week,O
between,O
each,O
injection,O
established,O
an,O
appropriate,O
time,O
interval,O
to,O
produce,O
efficient,O
vascularization,O
along,O
each,O
cell,O
injection,O
(,O
Fig,O
.,O
3b,O
",",O
d,O
).,O
Our,O
results,O
are,O
consistent,O
with,O
the,O
outcomes,O
from,O
another,O
study,O
that,O
established,O
a,O
vascular,O
chamber,O
in,O
vivo,O
using,O
an,O
arterio,O
-,O
venous,O
loop,O
(,O
AV,O
loop,O
),O
and,O
optimized,O
the,O
timing,O
of,O
cell,O
implantation,O
to,O
determine,O
efficient,O
cell,O
survival33,O
.,O
Their,O
results,O
showed,O
that,O
angiogenic,O
activity,O
peaked,O
between,O
7,O
–,O
10,O
days,O
after,O
insertion,O
of,O
the,O
AV,O
loop,O
and,O
suggested,O
that,O
as,O
further,O
vascularization,O
led,O
to,O
an,O
increased,O
survival,O
among,O
the,O
implanted,O
cells,O
.,O
This,O
study,O
revealed,O
that,O
delayed,O
cell,O
implantation,O
(,O
at,O
day,O
7,O
),O
into,O
a,O
site,O
with,O
well,O
-,O
established,O
vessels,O
could,O
improve,O
cell,O
survival33,O
.,O
Another,O
parameter,O
for,O
successful,O
cell,O
injection,O
strategy,O
involves,O
an,O
accurately,O
controlled,O
injection,O
volume,O
to,O
reduce,O
cell,O
necrosis,O
after,O
cell,O
transplantation,O
.,O
Generally,O
",",O
the,O
implanted,O
cells,O
can,O
obtain,O
an,O
adequate,O
oxygen,O
and,O
nutrient,O
supply,O
within,O
200,O
μm,O
from,O
adjacent,O
vasculatures,O
as,O
well,O
as,O
through,O
diffusion,O
at,O
a,O
distance,O
of,O
0,O
.,O
2,O
–,O
0,O
.,O
3,O
cm134,O
.,O
While,O
cell,O
density,O
was,O
optimized,O
at,O
10,O
×,O
106,O
cells,O
per,O
ml,O
for,O
injection,O
(,O
see,O
Supplementary,O
Fig,O
.,O
S1,O
"),",O
the,O
higher,O
cell,O
injection,O
volume,O
in,O
the,O
single,O
injection,O
resulted,O
in,O
significantly,O
lower,O
cell,O
survival,O
compared,O
to,O
progressive,O
injection,O
(,O
Fig,O
.,O
2c,O
).,O
Thus,O
",",O
injection,O
volume,O
can,O
affect,O
cell,O
survival,O
.,O
Since,O
the,O
volume,O
of,O
1,O
.,O
2,O
ml,O
for,O
the,O
single,O
injection,O
can,O
prepare,O
1,O
.,O
2,O
cm3,O
in,O
dimension,O
(>,O
1,O
×,O
1,O
×,O
1,O
cm,O
"),",O
the,O
cells,O
localized,O
to,O
the,O
center,O
of,O
the,O
fibrin,B-GP
gel,O
will,O
encounter,O
a,O
hypoxic,O
condition,O
with,O
limited,O
oxygen,O
diffusion,O
from,O
the,O
host,O
vessels1151620,O
",",O
and,O
the,O
result,O
will,O
be,O
increased,O
cell,O
necrosis,O
.,O
Eventually,O
",",O
the,O
increased,O
cell,O
death,O
will,O
lead,O
to,O
the,O
failure,O
of,O
the,O
volumetric,O
tissue,O
construction,O
(,O
Fig,O
.,O
2c,O
",",O
single,O
injection,O
).,O
Meanwhile,O
",",O
the,O
volume,O
of,O
each,O
injection,O
in,O
the,O
progressive,O
injection,O
model,O
was,O
0,O
.,O
3,O
ml,O
and,O
is,O
equivalent,O
to,O
0,O
.,O
3,O
cm3,O
",",O
which,O
can,O
reconstruct,O
an,O
implant,O
of,O
approximately,O
300,O
mm3,O
in,O
volume,O
due,O
to,O
the,O
diffusion,O
of,O
oxygen,O
from,O
the,O
surrounding,O
blood,O
vessels,O
.,O
The,O
injected,O
cells,O
obtain,O
an,O
adequate,O
blood,O
supply,O
through,O
diffusion,O
and,O
have,O
greater,O
survival,O
.,O
Therefore,O
",",O
the,O
volume,O
for,O
injection,O
should,O
be,O
controlled,O
to,O
ensure,O
cell,O
survival,O
and,O
subsequent,O
formation,O
of,O
tissue,O
reconstruction,O
within,O
the,O
implant,O
site,O
(,O
Fig,O
.,O
3,O
).,O
Optimization,O
of,O
several,O
parameters,O
such,O
as,O
cell,O
density,O
",",O
time,O
interval,O
between,O
cell,O
injections,O
",",O
and,O
volume,O
for,O
cell,O
injections,O
allowed,O
us,O
to,O
demonstrate,O
the,O
possibility,O
to,O
use,O
a,O
progressive,O
cell,O
injection,O
model,O
to,O
facilitate,O
volumetric,O
muscle,O
tissue,O
construction,O
through,O
efficient,O
vascularization,O
events,O
in,O
an,O
ectopic,O
site,O
(,O
Fig,O
.,O
3,O
).,O
We,O
show,O
that,O
the,O
levels,O
of,O
vascularization,O
in,O
the,O
progressive,O
cell,O
injection,O
group,O
were,O
significantly,O
higher,O
than,O
that,O
of,O
the,O
single,O
injection,O
group,O
in,O
the,O
ectopic,O
implantation,O
study,O
.,O
Notably,O
",",O
the,O
vascular,O
formation,O
pattern,O
in,O
the,O
core,O
region,O
was,O
significantly,O
different,O
.,O
While,O
the,O
progressive,O
cell,O
injections,O
resulted,O
in,O
the,O
formation,O
of,O
larger,O
(>,O
500,O
μm,O
),O
and,O
mature,O
blood,O
vessels,O
in,O
the,O
core,O
region,O
",",O
the,O
area,O
of,O
blood,O
vessels,O
present,O
in,O
the,O
single,O
injection,O
group,O
was,O
significantly,O
lower,O
by,O
a,O
300,O
-,O
fold,O
difference,O
.,O
Interestingly,O
",",O
the,O
majority,O
of,O
the,O
blood,O
vessels,O
(,O
90,O
%),O
found,O
in,O
the,O
single,O
cell,O
injection,O
group,O
consisted,O
of,O
small,O
size,O
capillaries,O
(<,O
200,O
μm,O
),O
(,O
Fig,O
.,O
3,O
and,O
Supplementary,O
Fig,O
.,O
S3,O
).,O
As,O
such,O
",",O
it,O
is,O
speculated,O
that,O
the,O
progressive,O
cell,O
injection,O
strategy,O
facilitates,O
the,O
formation,O
of,O
volumetric,O
viable,O
tissue,O
by,O
establishing,O
vascular,O
networks,O
throughout,O
the,O
tissue,O
construct,O
",",O
even,O
in,O
the,O
core,O
region,O
",",O
thus,O
overcoming,O
the,O
problems,O
resulting,O
from,O
the,O
conventional,O
single,O
cell,O
injection,O
method,O
",",O
such,O
as,O
necrotic,O
tissue,O
core,O
due,O
to,O
diffusion,O
limitation,O
.,O
Encouraged,O
by,O
the,O
promising,O
outcomes,O
",",O
this,O
novel,O
cell,O
delivery,O
system,O
was,O
applied,O
to,O
treat,O
a,O
critical,O
-,O
sized,O
muscle,O
tissue,O
defect,O
.,O
As,O
the,O
first,O
target,O
for,O
reconstruction,O
of,O
damaged,O
tissues,O
or,O
organs,O
",",O
the,O
strategy,O
of,O
progressive,O
cell,O
injections,O
was,O
applied,O
to,O
skeletal,B-DS
muscle,I-DS
tissue,I-DS
injuries,I-DS
",",O
particularly,O
VML,O
",",O
which,O
is,O
caused,O
by,O
traumatic,O
or,O
surgical,O
loss,O
.,O
VML,O
is,O
a,O
challenging,O
clinical,O
problem,O
for,O
military,O
",",O
civilian,O
",",O
and,O
sports,O
medicine,O
since,O
skeletal,O
muscle,O
is,O
a,O
relatively,O
large,O
",",O
thick,O
tissue,O
that,O
often,O
involves,O
other,O
tissue,O
or,O
organ,O
damage,O
such,O
as,O
skin,O
",",O
bone,O
",",O
and,O
internal,O
organs35,O
.,O
As,O
an,O
animal,B-OG
model,O
for,O
VML,O
",",O
we,O
utilized,O
a,O
rat,B-OG
TA,O
muscle,O
defect,O
model,O
that,O
was,O
developed,O
by,O
Wu,O
",",O
X,O
.,O
et,O
al36,O
.,O
after,O
modification,O
.,O
This,O
is,O
a,O
standardized,O
rodent,O
model,O
of,O
VML,O
injury,B-DS
generated,O
by,O
excising,O
~,O
20,O
%,O
of,O
the,O
middle,O
of,O
the,O
TA,O
muscle,O
",",O
and,O
muscle,O
weight,O
and,O
tetanic,O
muscle,O
force,O
are,O
not,O
recovered,O
until,O
6,O
months3637,O
.,O
In,O
this,O
study,O
",",O
we,O
introduced,O
a,O
larger,O
defect,O
size,O
(~,O
30,O
%,O
excision,O
of,O
TA,O
muscles,O
),O
to,O
produce,O
a,O
critical,O
sized,O
muscle,O
defect,O
animal,B-OG
model,O
.,O
The,O
anatomical,O
and,O
functional,O
analysis,O
demonstrated,O
that,O
our,O
progressive,O
cell,O
injection,O
model,O
could,O
significantly,O
increase,O
muscle,O
mass,O
and,O
thickness,O
",",O
reduce,O
fibrosis,O
and,O
partial,O
restoration,O
of,O
muscle,O
function,O
in,O
the,O
TA,O
defect,O
when,O
compared,O
to,O
that,O
of,O
a,O
single,O
injection,O
(,O
Fig,O
.,O
4,O
);,O
moreover,O
",",O
recovery,O
was,O
confirmed,O
by,O
myotubes,O
or,O
myofibers,O
formation,O
by,O
progressively,O
injected,O
cells,O
(,O
Fig,O
.,O
5,O
and,O
Supplementary,O
Figs,O
S6,O
and,O
S7,O
),O
as,O
well,O
as,O
vascularization,O
(,O
Fig,O
.,O
6,O
),O
and,O
neuronal,O
ingrowth,O
(,O
see,O
Supplementary,O
Fig,O
.,O
S8,O
).,O
Multiple,O
cell,O
injections,O
in,O
a,O
progressive,O
manner,O
showed,O
better,O
cell,O
engraftment,O
over,O
the,O
single,O
injection,O
method,O
",",O
as,O
evidenced,O
by,O
the,O
presence,O
of,O
numerous,O
GFP,B-GP
+,O
or,O
DiI,O
+,O
cells,O
and,O
HLA,B-GP
+,O
or,O
HNA,B-GP
+,O
cells,O
in,O
the,O
progressive,O
cell,O
injection,O
group,O
",",O
as,O
compared,O
with,O
those,O
in,O
the,O
single,O
cell,O
injection,O
group,O
.,O
In,O
addition,O
",",O
higher,O
proliferation,O
of,O
the,O
engrafted,O
cells,O
(,O
30,O
%,O
of,O
engrafted,O
hMPCs,O
),O
was,O
observed,O
in,O
the,O
progressive,O
injection,O
group,O
than,O
in,O
the,O
single,O
cell,O
injection,O
group,O
.,O
Based,O
on,O
these,O
observations,O
",",O
it,O
is,O
speculated,O
that,O
if,O
the,O
same,O
number,O
of,O
cells,O
are,O
injected,O
",",O
the,O
strategy,O
of,O
progressive,O
cell,O
injections,O
would,O
increase,O
cell,O
engraftment,O
and,O
proliferation,O
",",O
as,O
compared,O
to,O
the,O
single,O
injection,O
method,O
.,O
Moreover,O
",",O
the,O
myogenic,O
capacity,O
of,O
engrafted,O
cells,O
would,O
be,O
increased,O
by,O
the,O
progressive,O
injection,O
strategy,O
.,O
The,O
percentage,O
of,O
differentiating,O
cells,O
in,O
the,O
progressive,O
-,O
C2C12,O
and,O
hMPCs,O
injection,O
was,O
43,O
.,O
74,O
%,O
and,O
19,O
.,O
18,O
"%,",O
respectively,O
",",O
at,O
1,O
week,O
after,O
the,O
final,O
injection,O
.,O
While,O
the,O
current,O
study,O
showed,O
the,O
significant,O
potential,O
of,O
the,O
progressive,O
cell,O
injection,O
strategy,O
",",O
several,O
limitations,O
remain,O
to,O
be,O
solved,O
before,O
the,O
application,O
could,O
be,O
translated,O
.,O
Since,O
volumetric,O
tissue,O
repair,O
and,O
functional,O
recovery,O
was,O
evaluated,O
only,O
up,O
to,O
4,O
weeks,O
in,O
a,O
VML,O
injury,B-DS
model,O
",",O
reliability,O
of,O
the,O
therapeutic,O
effects,O
need,O
to,O
be,O
demonstrated,O
over,O
a,O
long,O
-,O
term,O
.,O
In,O
terms,O
of,O
defect,O
size,O
",",O
in,O
this,O
study,O
",",O
we,O
used,O
a,O
TA,O
injury,B-DS
model,O
of,O
approximately,O
30,O
%,O
muscle,O
mass,O
defect,O
.,O
Although,O
the,O
extent,O
of,O
defect,O
is,O
significant,O
in,O
a,O
rodent,O
model,O
",",O
it,O
is,O
unclear,O
whether,O
this,O
defect,O
size,O
reflects,O
the,O
clinical,O
conditions,O
presented,O
in,O
humans,B-OG
.,O
Further,O
investigations,O
using,O
a,O
larger,O
animal,B-OG
model,O
with,O
critical,O
defect,O
size,O
and,O
mass38,O
should,O
be,O
performed,O
to,O
determine,O
the,O
effectiveness,O
of,O
the,O
progressive,O
cell,O
injections,O
strategy,O
.,O
Muscle,O
function,O
is,O
closely,O
related,O
to,O
innervation,O
and,O
anti,O
-,O
fibrosis,O
;,O
therefore,O
",",O
specific,O
factors,O
that,O
facilitate,O
efficient,O
innervation,O
and,O
reduction,O
in,O
fibrosis,O
should,O
be,O
considered,O
to,O
improve,O
muscle,O
function,O
.,O
Such,O
factors,O
include,O
agrin39,B-GP
or,O
suramin40,O
to,O
accelerate,O
innervation,O
or,O
reduce,O
fibrosis,O
",",O
respectively,O
.,O
This,O
manuscript,O
describes,O
a,O
proof,O
-,O
of,O
-,O
concept,O
study,O
showing,O
that,O
multiple,O
cell,O
injections,O
result,O
in,O
enhanced,O
cell,O
survival,O
than,O
single,O
injection,O
",",O
which,O
contributes,O
to,O
improved,O
muscle,O
function,O
structurally,O
and,O
physically,O
.,O
To,O
prove,O
the,O
hypothesis,O
",",O
we,O
developed,O
a,O
multiple,O
injection,O
protocol,O
that,O
is,O
performed,O
in,O
a,O
progressive,O
manner,O
with,O
several,O
cell,O
injection,O
parameters,O
.,O
Although,O
we,O
have,O
obtained,O
positive,O
outcomes,O
",",O
in,O
terms,O
of,O
muscle,O
recovery,O
using,O
a,O
pre,O
-,O
clinical,O
animal,B-OG
model,O
",",O
translation,O
of,O
this,O
technology,O
into,O
the,O
clinical,O
settings,O
requires,O
further,O
optimization,O
and,O
refinement,O
",",O
as,O
well,O
as,O
validation,O
in,O
a,O
clinically,O
relevant,O
animal,B-OG
model,O
.,O
For,O
example,O
",",O
translation,O
of,O
this,O
technique,O
to,O
clinical,O
applications,O
needs,O
modification,O
of,O
the,O
cell,O
injection,O
parameters,O
",",O
depending,O
on,O
the,O
target,O
tissue,O
and,O
defect,O
size,O
including,O
injection,O
volume,O
",",O
injection,O
time,O
interval,O
and,O
cell,O
concentration,O
.,O
Selection,O
of,O
a,O
cell,O
delivery,O
vehicle,O
should,O
also,O
be,O
considered,O
for,O
clinical,O
translation,O
.,O
In,O
this,O
study,O
",",O
fibrin,B-GP
gel,O
was,O
used,O
as,O
a,O
cell,O
delivery,O
vehicle,O
since,O
it,O
has,O
been,O
widely,O
used,O
in,O
various,O
clinical,O
applications,O
.,O
Since,O
a,O
hydrogel,O
system,O
such,O
as,O
fibrin,B-GP
gel,O
usually,O
displays,O
weakness,O
in,O
mechanical,O
property,O
",",O
other,O
biocompatible,O
materials,O
with,O
enhanced,O
mechanical,O
strength,O
should,O
be,O
identified,O
in,O
order,O
to,O
maintain,O
the,O
implant,O
volume,O
for,O
a,O
longer,O
period,O
of,O
time,O
.,O
In,O
conclusion,O
",",O
our,O
study,O
provides,O
a,O
novel,O
cell,O
delivery,O
strategy,O
utilizing,O
an,O
appropriate,O
and,O
efficient,O
in,O
vivo,O
vascularization,O
process,O
to,O
overcome,O
the,O
reduced,O
cell,O
survival,O
limitation,O
of,O
current,O
cell,O
-,O
based,O
therapies,O
.,O
The,O
concept,O
of,O
“,O
multiple,O
and,O
progressive,O
cell,O
injections,O
”,O
was,O
supported,O
by,O
demonstrating,O
that,O
the,O
progressive,O
cell,O
injections,O
resulted,O
in,O
an,O
improved,O
cell,O
survival,O
through,O
normal,O
and,O
efficient,O
angiogeneic,O
events,O
surrounding,O
the,O
implant,O
and,O
led,O
to,O
reconstruction,O
of,O
volumetric,O
muscle,O
tissues,O
in,O
vivo,O
.,O
In,O
addition,O
",",O
this,O
novel,O
strategy,O
was,O
applied,O
to,O
a,O
critical,O
-,O
size,O
muscle,O
defect,O
to,O
show,O
restoration,O
of,O
muscle,O
mass,O
and,O
function,O
in,O
a,O
VML,O
animal,B-OG
model,O
.,O
Therefore,O
",",O
multiple,O
cell,O
injections,O
in,O
a,O
progress,O
manner,O
present,O
a,O
promising,O
strategy,O
for,O
volumetric,O
tissue,O
repair,O
in,O
TE,O
and,O
RM,O
.,O
Methods,O
Cell,O
culture,O
and,O
materials,O
preparation,O
C2C12,O
mouse,B-OG
myoblasts,O
(,O
ATCC,O
",",O
Manassas,O
",",O
VA,O
),O
were,O
transduced,O
with,O
GFP,B-GP
to,O
prepare,O
GFP,B-GP
+,O
-,O
C2C12,O
with,O
a,O
method,O
developed,O
previously41,O
.,O
GFP,B-GP
+,O
-,O
C2C12,O
cells,O
were,O
cultured,O
in,O
DMEM,O
/,O
high,O
glucose,O
(,O
Thermo,O
Scientific,O
Inc,O
".,",O
Waltham,O
",",O
MA,O
),O
supplemented,O
with,O
10,O
%,O
fetal,O
bovine,O
serum,O
(,O
FBS,O
",",O
Gibco,O
",",O
Carlsbad,O
",",O
CA,O
),O
and,O
1,O
%,O
penicillin,O
/,O
streptomycin,O
(,O
PS,O
",",O
Thermo,O
Scientific,O
),O
at,O
37,O
°,O
C,O
with,O
5,O
%,O
CO2,O
.,O
During,O
the,O
cell,O
culture,O
",",O
the,O
GFP,B-GP
expression,O
of,O
C2C12,O
cells,O
was,O
confirmed,O
by,O
a,O
fluorescent,O
imaging,O
.,O
As,O
another,O
cell,O
source,O
for,O
this,O
study,O
",",O
hMPCs,O
were,O
used,O
after,O
isolation,O
and,O
expansion,O
.,O
hMPC,O
were,O
isolated,O
from,O
human,B-OG
muscle,O
biopsies,O
as,O
previously,O
described42,O
and,O
expanded,O
in,O
a,O
growth,O
medium,O
composed,O
of,O
DMEM,O
/,O
high,O
glucose,O
",",O
20,O
%,O
FBS,O
",",O
2,O
%,O
chicken,B-OG
embryo,O
extract,O
(,O
Gemini,O
Bio,O
-,O
Products,O
",",O
West,O
Sacramento,O
",",O
CA,O
),O
and,O
1,O
%,O
PS,O
.,O
Cells,O
were,O
expanded,O
up,O
to,O
passage,O
4,O
for,O
cell,O
injection,O
study,O
.,O
As,O
a,O
vehicle,O
for,O
the,O
cell,O
injection,O
",",O
a,O
fibrin,B-GP
gel,O
system,O
was,O
used,O
.,O
To,O
form,O
the,O
fibrin,B-GP
gel,O
",",O
40,O
mg,O
ml,O
−,O
1,O
of,O
fibrinogen,B-GP
solution,O
and,O
40,O
U,O
ml,O
−,O
1,O
of,O
thrombin,B-GP
solution,O
(,O
Sigma,O
",",O
St,O
.,O
Louis,O
",",O
MO,O
),O
were,O
prepared,O
by,O
dissolving,O
fibrinogen,B-GP
from,O
bovine,O
plasma,O
(,O
Sigma,O
),O
in,O
0,O
.,O
9,O
%,O
sodium,O
chloride,O
saline,O
solution,O
",",O
and,O
bovine,O
thrombin,B-GP
(,O
Sigma,O
),O
in,O
25,O
mM,O
CaCl2,O
in,O
saline,O
solution,O
",",O
respectively,O
.,O
For,O
cell,O
injection,O
",",O
the,O
muscle,O
cells,O
were,O
suspended,O
with,O
fibrinogen,B-GP
solution,O
and,O
adjusted,O
to,O
a,O
cell,O
concentration,O
of,O
20,O
×,O
106,O
cells,O
per,O
ml,O
to,O
yield,O
a,O
final,O
cell,O
concentration,O
of,O
10,O
×,O
106,O
cells,O
per,O
ml,O
in,O
the,O
fibrin,B-GP
gel,O
after,O
mixing,O
with,O
thrombin,B-GP
solution,O
at,O
a,O
1,O
:,O
1,O
ratio,O
.,O
Ectopic,O
cell,O
injection,O
All,O
animal,B-OG
procedures,O
were,O
performed,O
in,O
accordance,O
with,O
a,O
protocol,O
approved,O
by,O
the,O
Institutional,O
Animal,B-OG
Care,O
and,O
Use,O
Committee,O
at,O
Wake,O
Forest,O
University,O
School,O
of,O
Medicine,O
.,O
Male,O
athymic,O
mice,B-OG
(,O
6,O
–,O
8,O
weeks,O
old,O
",",O
total,O
24,O
mice,B-OG
),O
were,O
obtained,O
from,O
Charles,O
River,O
Laboratory,O
(,O
Wilmington,O
",",O
MA,O
).,O
Anesthesia,O
was,O
induced,O
by,O
using,O
3,O
%,O
isoflurane,O
before,O
surgical,O
procedures,O
.,O
Under,O
aseptic,O
conditions,O
",",O
subcutaneous,O
injections,O
into,O
the,O
dorsal,O
to,O
dorso,O
-,O
lateral,O
region,O
were,O
performed,O
.,O
For,O
progressive,O
cell,O
injections,O
",",O
C2C12,O
cells,O
in,O
a,O
fibrin,B-GP
gel,O
were,O
delivered,O
into,O
the,O
left,O
dorsal,O
regions,O
of,O
mice,B-OG
;,O
2,O
",",O
4,O
",",O
6,O
",",O
and,O
8,O
injections,O
(,O
n,O
=,O
3,O
–,O
4,O
).,O
Injections,O
were,O
performed,O
every,O
7,O
days,O
at,O
the,O
same,O
site,O
where,O
the,O
former,O
injection,O
was,O
done,O
.,O
As,O
control,O
",",O
the,O
same,O
volume,O
of,O
gel,O
without,O
cells,O
was,O
injected,O
into,O
the,O
contralateral,O
region,O
of,O
each,O
animal,B-OG
in,O
the,O
same,O
manner,O
.,O
For,O
each,O
injection,O
",",O
150,O
μl,O
volume,O
of,O
fibrinogen,B-GP
solution,O
with,O
or,O
without,O
cells,O
was,O
injected,O
using,O
a,O
26,O
-,O
gauge,O
needle,O
.,O
An,O
equal,O
volume,O
of,O
thrombin,B-GP
solution,O
was,O
immediately,O
injected,O
at,O
the,O
same,O
site,O
",",O
where,O
the,O
injected,O
cells,O
will,O
be,O
placed,O
within,O
the,O
fibrin,B-GP
gel,O
.,O
Animals,B-OG
were,O
euthanized,O
1,O
week,O
after,O
the,O
final,O
injection,O
.,O
To,O
determine,O
efficiency,O
of,O
progressive,O
cell,O
injection,O
",",O
the,O
volume,O
of,O
implant,O
after,O
4,O
injections,O
was,O
evaluated,O
and,O
the,O
measured,O
volume,O
was,O
compared,O
with,O
that,O
by,O
single,O
injection,O
of,O
cells,O
.,O
For,O
the,O
single,O
injection,O
",",O
600,O
μl,O
of,O
fibrinogen,B-GP
solution,O
with,O
cells,O
and,O
600,O
μl,O
of,O
thrombin,B-GP
solution,O
were,O
injected,O
",",O
of,O
which,O
number,O
of,O
cells,O
is,O
equal,O
to,O
the,O
total,O
number,O
of,O
4,O
injections,O
.,O
The,O
single,O
or,O
progressive,O
injection,O
group,O
was,O
euthanized,O
4,O
weeks,O
after,O
injection,O
or,O
1,O
week,O
after,O
the,O
4th,O
injection,O
",",O
respectively,O
.,O
Implant,O
volume,O
was,O
measured,O
by,O
water,O
displacement,O
method,O
",",O
then,O
implant,O
was,O
evaluated,O
by,O
histological,O
and,O
immunohistological,O
analysis43,O
.,O
VML,O
injury,B-DS
model,O
and,O
cells,O
injection,O
The,O
VML,O
injury,B-DS
model,O
was,O
created,O
in,O
nude,B-OG
rats,I-OG
(,O
male,O
",",O
12,O
–,O
14,O
weeks,O
old,O
",",O
Charles,O
River,O
Laboratory,O
),O
36,O
.,O
Under,O
anesthesia,O
",",O
the,O
fascia,O
was,O
separated,O
from,O
the,O
TA,O
muscle,O
",",O
and,O
then,O
approximately,O
30,O
%,O
of,O
middle,O
third,O
TA,O
muscle,O
was,O
excised,O
.,O
The,O
excised,O
TA,O
muscle,O
weight,O
was,O
estimated,O
by,O
following,O
using,O
the,O
equation,O
:,O
y,O
(,O
g,O
),O
=,O
0,O
.,O
0017,O
×,O
body,O
weight,O
(,O
g,O
),O
–,O
0,O
.,O
0716,O
.,O
In,O
addition,O
to,O
the,O
TA,O
muscle,O
excision,O
",",O
extensor,O
digitorum,O
longus,O
(,O
EDL,O
),O
and,O
extensor,O
hallucis,O
longus,O
(,O
EHL,O
),O
muscles,O
were,O
removed,O
to,O
exclude,O
compensatory,O
hypertrophy,O
during,O
muscle,O
regeneration,O
following,O
TA,O
excision,O
.,O
The,O
remaining,O
TA,O
muscle,O
was,O
covered,O
with,O
fascia,O
and,O
skin,O
was,O
closed,O
using,O
sutures,O
and,O
surgical,O
glue,O
.,O
Fibrin,B-GP
gels,O
with,O
or,O
without,O
cells,O
were,O
injected,O
into,O
the,O
defect,O
sites,O
.,O
In,O
this,O
study,O
",",O
7,O
groups,O
were,O
investigated,O
(,O
n,O
=,O
4,O
per,O
group,O
",",O
total,O
28,O
rats,B-OG
);,O
(,O
1,O
),O
normal,O
(,O
age,O
-,O
matched,O
control,O
"),",O
(,O
2,O
),O
no,O
treatment,O
(,O
defect,O
only,O
"),",O
(,O
3,O
),O
multiple,O
injection,O
-,O
gel,O
only,O
",",O
(,O
4,O
),O
single,O
injection,O
-,O
C2C12,O
",",O
(,O
5,O
"),",O
progressive,O
injection,O
-,O
C2C12,O
",",O
(,O
6,O
),O
single,O
injection,O
-,O
hMPC,O
",",O
(,O
7,O
),O
progressive,O
injection,O
-,O
hMPC,O
.,O
For,O
a,O
single,O
injection,O
",",O
300,O
μl,O
of,O
fibrinogen,B-GP
solution,O
with,O
cells,O
was,O
delivered,O
into,O
the,O
defect,O
sites,O
with,O
a,O
26,O
-,O
gauge,O
needle,O
followed,O
immediately,O
by,O
an,O
additional,O
injection,O
of,O
300,O
μl,O
of,O
thrombin,B-GP
solution,O
at,O
the,O
same,O
injection,O
site,O
to,O
form,O
fibrin,B-GP
gel,O
(,O
total,O
injection,O
volume,O
=,O
600,O
μl,O
).,O
The,O
volume,O
of,O
600,O
μl,O
filled,O
the,O
defect,O
in,O
the,O
TA,O
muscle,O
.,O
For,O
multiple,O
and,O
progressive,O
injections,O
",",O
4,O
cell,O
injections,O
were,O
performed,O
every,O
week,O
.,O
The,O
first,O
injection,O
was,O
performed,O
with,O
a,O
total,O
volume,O
of,O
300,O
μl,O
and,O
subsequent,O
three,O
injections,O
were,O
done,O
with,O
a,O
volume,O
of,O
100,O
μl,O
per,O
injection,O
.,O
To,O
track,O
the,O
injected,O
cells,O
within,O
the,O
TA,O
muscle,O
",",O
C2C12,O
cells,O
were,O
labeled,O
with,O
DiI,O
(,O
Vybrant,O
®,O
Multicolor,O
Cell,O
-,O
Labeling,O
Kit,O
",",O
Thermo,O
Scientific,O
",",O
Inc,O
.),O
for,O
the,O
1st,O
and,O
4th,O
injections,O
and,O
co,O
-,O
labeling,O
of,O
DiI,O
and,O
GFP,B-GP
was,O
used,O
to,O
identify,O
the,O
injected,O
C2C12,O
cells,O
within,O
the,O
TA,O
defect,O
.,O
In,O
vivo,O
functional,O
analysis,O
of,O
TA,O
muscle,O
To,O
examine,O
restoration,O
of,O
muscle,O
function,O
",",O
tetanic,O
force,O
of,O
TA,O
muscle,O
was,O
measured,O
at,O
4,O
weeks,O
after,O
surgery,O
(,O
1,O
week,O
after,O
4th,O
injection,O
in,O
the,O
multiple,O
and,O
progressive,O
injection,O
).,O
Anterior,O
crural,O
muscle,O
in,O
vivo,O
mechanical,O
properties,O
were,O
analyzed,O
with,O
the,O
dual,O
-,O
mode,O
muscle,O
lever,O
system,O
(,O
Aurora,O
Scientific,O
",",O
Inc,O
".,",O
Mod,O
",",O
305b,O
",",O
Aurora,O
",",O
Canada,O
),O
36,O
.,O
The,O
foot,O
to,O
be,O
measured,O
was,O
attached,O
to,O
a,O
foot,O
plate,O
and,O
knee,O
and,O
ankle,O
were,O
positioned,O
at,O
90,O
-,O
degree,O
angle,O
.,O
Tetanic,O
analysis,O
was,O
performed,O
by,O
stimulating,O
the,O
peroneal,O
nerve,O
using,O
a,O
Grass,O
stimulator,O
(,O
S88,O
),O
at,O
100,O
Hz,O
with,O
a,O
pulse,O
-,O
width,O
of,O
0,O
.,O
1,O
msec,O
and,O
10,O
V,O
.,O
Muscle,O
force,O
(,O
N,O
Kg,O
−,O
1,O
),O
was,O
calculated,O
by,O
peak,O
isometric,O
torque,O
per,O
body,O
weight,O
(,O
n,O
=,O
4,O
per,O
group,O
).,O
After,O
the,O
functional,O
assessment,O
and,O
harvesting,O
of,O
TA,O
muscle,O
",",O
the,O
retrieved,O
TA,O
muscle,O
tissue,O
was,O
weighed,O
and,O
processed,O
for,O
histological,O
analysis,O
.,O
The,O
percentage,O
of,O
muscle,O
mass,O
was,O
calculated,O
by,O
the,O
ratio,O
of,O
the,O
weight,O
of,O
injured,O
TA,O
muscle,O
to,O
that,O
of,O
contralateral,O
TA,O
muscle,O
(,O
n,O
=,O
4,O
per,O
group,O
).,O
Histological,O
and,O
immunofluorescent,O
analysis,O
The,O
harvested,O
TA,O
muscles,O
were,O
freshly,O
frozen,O
in,O
liquid,O
nitrogen,O
immediately,O
for,O
cryo,O
-,O
embedding,O
or,O
fixed,O
with,O
4,O
%,O
paraformaldehyde,O
for,O
paraffin,O
embedding,O
.,O
For,O
histological,O
evaluations,O
",",O
H,O
&,O
E,O
staining,O
and,O
MT,O
staining,O
were,O
performed,O
on,O
the,O
tissue,O
sections,O
.,O
To,O
evaluate,O
TA,O
muscle,O
thickness,O
of,O
each,O
group,O
",",O
three,O
different,O
regions,O
in,O
the,O
middle,O
of,O
the,O
TA,O
muscles,O
in,O
the,O
H,O
&,O
E,O
images,O
were,O
chosen,O
and,O
the,O
thickness,O
was,O
measured,O
(,O
n,O
=,O
4,O
of,O
each,O
per,O
group,O
),O
in,O
blinded,O
fashion,O
.,O
For,O
immunostaining,O
",",O
the,O
cryosections,O
(,O
7,O
μm,O
),O
were,O
fixed,O
with,O
4,O
%,O
paraformaldehyde,O
.,O
Paraffin,O
sections,O
(,O
5,O
μm,O
),O
were,O
deparaffinized,O
and,O
processed,O
for,O
antigen,O
retrieval,O
with,O
the,O
heat,O
-,O
induced,O
process,O
using,O
sodium,O
citrate,O
buffer,O
.,O
Tissue,O
sections,O
were,O
incubated,O
with,O
methanol,O
at,O
−,O
20,O
°,O
C,O
for,O
10,O
minutes,O
",",O
acetone,O
at,O
room,O
temperature,O
for,O
7,O
minutes,O
or,O
0,O
.,O
2,O
%,O
Triton,O
X,O
-,O
100,O
for,O
30,O
minutes,O
at,O
room,O
temperature,O
for,O
permeabilization,O
",",O
and,O
then,O
blocked,O
using,O
a,O
serum,O
-,O
free,O
blocking,O
agent,O
(,O
X090930,O
-,O
1,O
;,O
Dako,O
",",O
Carpentaria,O
",",O
CA,O
),O
for,O
1,O
h,O
at,O
room,O
temperature,O
.,O
All,O
antibodies,O
were,O
diluted,O
with,O
antibody,O
diluent,O
(,O
S302283,O
-,O
1,O
;,O
Dako,O
"),",O
and,O
the,O
blocked,O
sections,O
were,O
incubated,O
with,O
primary,O
antibodies,O
at,O
room,O
temperature,O
for,O
1,O
h,O
or,O
incubated,O
at,O
4,O
°,O
C,O
for,O
overnight,O
.,O
Secondary,O
antibodies,O
such,O
as,O
Alexa,O
488,O
-,O
conjugated,O
anti,O
-,O
mouse,B-OG
or,O
anti,O
-,O
rabbit,B-OG
antibody,O
(,O
A11017,O
;,O
A11070,O
;,O
1,O
:,O
200,O
dilution,O
;,O
Invitrogen,O
",",O
Eugene,O
",",O
OR,O
"),",O
Texas,O
Red,O
-,O
conjugated,O
anti,O
-,O
mouse,B-OG
",",O
anti,O
-,O
rabbit,B-OG
",",O
or,O
anti,O
-,O
rat,B-OG
antibody,O
(,O
TI,O
-,O
2000,O
;,O
TI,O
-,O
1000,O
;,O
TI,O
-,O
9400,O
;,O
1,O
:,O
200,O
dilution,O
;,O
Vector,O
Labs,O
",",O
Burlingame,O
",",O
CA,O
"),",O
or,O
Cy5,O
-,O
conjugated,O
anti,O
-,O
mouse,B-OG
or,O
anti,O
-,O
rabbit,B-OG
antibody,O
(,O
A10524,O
;,O
A10523,O
;,O
1,O
:,O
200,O
dilution,O
;,O
Invitrogen,O
),O
were,O
treated,O
at,O
room,O
temperature,O
for,O
40,O
min,O
.,O
Tissue,O
sections,O
were,O
then,O
mounted,O
with,O
VECTASHIELD,O
Mounting,O
Media,O
with,O
DAPI,O
(,O
H,O
-,O
1200,O
;,O
Vector,O
Labs,O
),O
and,O
analyzed,O
by,O
fluorescent,O
imaging,O
using,O
an,O
upright,O
(,O
LEICA,O
),O
and,O
confocal,O
microscope,O
(,O
Olympus,O
).,O
To,O
identify,O
the,O
injected,O
GFP,B-GP
+,O
-,O
C2C12,O
cells,O
",",O
the,O
sections,O
were,O
incubated,O
with,O
mouse,B-OG
anti,O
-,O
GFP,B-GP
antibody,O
(,O
sc,O
-,O
9996,O
;,O
1,O
:,O
100,O
dilution,O
;,O
Santa,O
Cruz,O
Biotechnology,O
",",O
Santa,O
Cruz,O
",",O
CA,O
),O
or,O
rabbit,B-OG
anti,O
-,O
GFP,B-GP
antibody,O
(,O
ab290,O
;,O
1,O
:,O
500,O
dilution,O
;,O
Abcam,O
",",O
Cambridge,O
",",O
MA,O
).,O
For,O
hMPC,O
tracking,O
",",O
tissues,O
were,O
stained,O
with,O
rabbit,B-OG
anti,O
-,O
HLA,B-GP
A,I-GP
(,O
ab52922,O
;,O
1,O
:,O
100,O
dilution,O
;,O
Abcam,O
),O
or,O
mouse,B-OG
anti,O
-,O
HNA,B-GP
(,O
MAB1281,O
;,O
1,O
:,O
100,O
dilution,O
;,O
EMD,O
Millipore,O
",",O
Darmstadt,O
",",O
Germany,O
).,O
Muscle,O
differentiation,O
was,O
examined,O
by,O
immunostaining,O
for,O
mouse,B-OG
anti,O
-,O
MHC,B-GP
(,O
MF20,O
;,O
1,O
:,O
30,O
dilution,O
;,O
Developmental,O
Studies,O
Hybridoma,O
Bank,O
",",O
Iowa,O
City,O
",",O
IA,O
),O
or,O
mouse,B-OG
or,O
rabbit,B-OG
anti,O
-,O
Myogenin,B-GP
(,O
ab1835,O
;,O
1,O
:,O
100,O
dilution,O
",",O
ab124800,O
;,O
1,O
:,O
200,O
Abcam,O
).,O
Cells,O
proliferation,O
was,O
estimated,O
by,O
immunostaining,O
for,O
mouse,B-OG
or,O
rabbit,B-OG
anti,O
-,O
PCNA,B-GP
(,O
ab29,O
;,O
1,O
:,O
500,O
dilution,O
",",O
ab18197,O
;,O
1,O
:,O
1000,O
dilution,O
",",O
Abcam,O
).,O
To,O
evaluate,O
muscle,O
fibrosis,O
",",O
tissue,O
sections,O
were,O
stained,O
with,O
rabbit,B-OG
anti,O
-,O
collagen,B-GP
I,I-GP
(,O
ab34710,O
;,O
1,O
:,O
200,O
dilution,O
;,O
Abcam,O
).,O
For,O
vascular,O
integration,O
",",O
the,O
tissue,O
sections,O
were,O
stained,O
with,O
rabbit,B-OG
anti,O
-,O
vWF,B-GP
(,O
A0082,O
;,O
1,O
:,O
400,O
dilution,O
;,O
DAKO,O
),O
and,O
mouse,B-OG
anti,O
-,O
α,B-GP
-,I-GP
SMA,I-GP
(,O
sc,O
-,O
32251,O
;,O
1,O
:,O
50,O
dilution,O
;,O
Santa,O
Cruz,O
).,O
Neuronal,O
ingrowth,O
was,O
visualized,O
by,O
immunostaining,O
with,O
rabbit,B-OG
anti,O
-,O
NF,B-GP
(,O
N4142,O
;,O
NF200,O
",",O
1,O
:,O
80,O
dilution,O
;,O
Sigma,O
),O
and,O
rat,B-OG
anti,O
-,O
AChR,B-GP
(,O
ab24719,O
;,O
1,O
:,O
100,O
dilution,O
;,O
Abcam,O
).,O
To,O
evaluate,O
vascularization,O
and,O
the,O
vascular,O
maturation,O
",",O
vWF,B-GP
/,O
α,B-GP
-,I-GP
SMA,I-GP
double,O
immunostaining,O
was,O
performed,O
and,O
using,O
3,O
to,O
5,O
randomly,O
selected,O
images,O
from,O
each,O
injected,O
regions,O
of,O
the,O
retrieved,O
tissues,O
(,O
x400,O
magnification,O
",",O
n,O
=,O
4,O
per,O
group,O
),O
44,O
.,O
The,O
number,O
of,O
vWF,B-GP
+,O
vessels,O
(,O
per,O
field,O
of,O
400x,O
magnified,O
image,O
"),",O
area,O
of,O
vWF,B-GP
+,O
vessels,O
(,O
μm2,O
per,O
field,O
of,O
400x,O
magnified,O
image,O
"),",O
and,O
percentage,O
of,O
each,O
size,O
of,O
vessels,O
were,O
quantified,O
and,O
the,O
maturation,O
index,O
(%),O
was,O
determined,O
as,O
the,O
ratio,O
of,O
α,B-GP
-,I-GP
SMA,I-GP
+,O
vessels,O
to,O
the,O
total,O
number,O
of,O
vessels4546,O
.,O
Blood,O
vessels,O
were,O
quantitatively,O
analyzed,O
with,O
image,O
analysis,O
software,O
(,O
Image,O
J,O
),O
in,O
blinded,O
fashion,O
.,O
To,O
identify,O
whether,O
the,O
infused,O
cells,O
contributed,O
to,O
formation,O
of,O
muscle,O
fibers,O
in,O
vivo,O
",",O
GFP,B-GP
/,O
MHC,B-GP
and,O
HLA,B-GP
/,O
MHC,B-GP
staining,O
was,O
performed,O
on,O
the,O
GFP,B-GP
+,O
-,O
C2C12,O
-,O
and,O
hMPC,O
-,O
injected,O
TA,O
muscles,O
",",O
respectively,O
.,O
Double,O
positive,O
staining,O
in,O
the,O
fluorescent,O
images,O
was,O
considered,O
to,O
be,O
a,O
contribution,O
of,O
the,O
injected,O
cells,O
in,O
the,O
muscle,O
fiber,O
formation,O
.,O
Myogenesis,O
of,O
injected,O
cells,O
were,O
also,O
identified,O
by,O
Myogenin,B-GP
+/,O
DiI,O
-,O
labeled,O
cells,O
in,O
C2C12,O
-,O
injected,O
TA,O
muscles,O
and,O
Myogenin,B-GP
+/,O
HNA,B-GP
+,O
cells,O
in,O
hMPC,O
-,O
injected,O
TA,O
muscles,O
(,O
x400,O
magnification,O
",",O
n,O
=,O
3,O
–,O
4,O
per,O
group,O
",",O
3,O
–,O
5,O
fields,O
per,O
each,O
sample,O
).,O
Proliferation,O
of,O
injected,O
C2C12,O
and,O
hMPCs,O
were,O
evaluated,O
by,O
double,O
positive,O
of,O
PCNA,B-GP
/,O
DiI,O
-,O
labeled,O
cells,O
in,O
C2C12,O
-,O
injected,O
TA,O
muscles,O
and,O
PCNA,B-GP
/,O
HNA,B-GP
cells,O
in,O
hMPC,O
-,O
injected,O
TA,O
muscles,O
(,O
x400,O
magnification,O
",",O
n,O
=,O
3,O
–,O
4,O
per,O
group,O
",",O
3,O
–,O
5,O
fields,O
per,O
each,O
sample,O
).,O
TA,O
muscle,O
fibrosis,O
of,O
inner,O
and,O
outer,O
area,O
was,O
quantified,O
by,O
percentage,O
of,O
collagen,B-GP
I,I-GP
positive,O
area,O
in,O
the,O
fluorescent,O
images,O
of,O
collagen,B-GP
I,I-GP
/,O
MHC,B-GP
staining,O
(,O
x200,O
magnification,O
",",O
n,O
=,O
4,O
per,O
group,O
",",O
3,O
fields,O
of,O
each,O
area,O
per,O
each,O
sample,O
).,O
Statistical,O
analysis,O
Results,O
were,O
analyzed,O
with,O
Origin,O
Pro,O
8,O
.,O
5,O
(,O
OriginLab,O
Co,O
",",O
Northampton,O
",",O
MA,O
",",O
USA,O
),O
and,O
SPSS,O
software,O
(,O
SPSS,O
",",O
version,O
19,O
;,O
IBM,O
",",O
Armonk,O
",",O
NY,O
).,O
One,O
-,O
way,O
analysis,O
of,O
variance,O
(,O
ANOVA,O
"),",O
Tukey,O
post,O
hoc,O
testing,O
and,O
Student,O
’,O
s,O
t,O
-,O
test,O
were,O
applied,O
to,O
mean,O
comparisons,O
.,O
Variables,O
are,O
expressed,O
as,O
mean,O
±,O
standard,O
deviation,O
",",O
and,O
differences,O
were,O
considered,O
significant,O
at,O
P,O
<,O
0,O
.,O
05,O
.,O
Additional,O
Information,O
How,O
to,O
cite,O
this,O
article,O
:,O
Kim,O
",",O
J,O
.,O
H,O
.,O
et,O
al,O
.,O
Progressive,O
Muscle,O
Cell,O
Delivery,O
as,O
a,O
Solution,O
for,O
Volumetric,O
Muscle,O
Defect,O
Repair,O
.,O
Sci,O
.,O
Rep,O
.,O
6,O
",",O
38754,O
;,O
doi,O
:,O
10,O
.,O
1038,O
/,O
srep38754,O
(,O
2016,O
).,O
Publisher,O
',O
s,O
note,O
:,O
Springer,O
Nature,O
remains,O
neutral,O
with,O
regard,O
to,O
jurisdictional,O
claims,O
in,O
published,O
maps,O
and,O
institutional,O
affiliations,O
.,O
Supplementary,O
Material,O
Supplementary,O
Information,O
Author,O
Contributions,O
J,O
.,O
H,O
.,O
K,O
".,",O
I,O
.,O
K,O
.,O
K,O
".,",O
J,O
.,O
J,O
.,O
Y,O
.,O
and,O
A,O
.,O
A,O
.,O
designed,O
experiments,O
.,O
J,O
.,O
H,O
.,O
K,O
.,O
and,O
I,O
.,O
K,O
.,O
K,O
.,O
performed,O
data,O
acquisition,O
",",O
analysis,O
and,O
interpretation,O
and,O
wrote,O
the,O
manuscript,O
.,O
All,O
authors,O
discussed,O
the,O
results,O
and,O
reviewed,O
the,O
manuscript,O
.,O
(,O
a,O
),O
Multiple,O
cells,O
in,O
gel,O
or,O
gel,O
only,O
injections,O
in,O
a,O
progressive,O
manner,O
were,O
performed,O
with,O
athymic,O
mice,O
and,O
the,O
volume,O
of,O
implant,O
was,O
measured,O
by,O
injection,O
time,O
(,O
2,O
",",O
4,O
",",O
6,O
",",O
and,O
8,O
injections,O
).,O
Each,O
injection,O
of,O
GFP,O
+,O
-,O
C2C12,O
was,O
performed,O
once,O
in,O
a,O
week,O
with,O
the,O
equal,O
volume,O
of,O
cells,O
in,O
gel,O
or,O
gel,O
only,O
.,O
ANOVA,O
",",O
Tukey,O
test,O
(,O
n,O
=,O
3,O
–,O
4,O
).,O
*,O
P,O
<,O
0,O
.,O
0001,O
with,O
2,O
times,O
of,O
progressive,O
cell,O
injection,O
",",O
†,O
P,O
<,O
0,O
.,O
003,O
with,O
4,O
times,O
of,O
progressive,O
cell,O
injection,O
",",O
‡,O
P,O
<,O
0,O
.,O
001,O
with,O
2,O
times,O
of,O
gel,O
only,O
injection,O
.,O
(,O
b,O
",",O
c,O
),O
The,O
efficacy,O
of,O
progressive,O
cell,O
delivery,O
was,O
compared,O
with,O
single,O
cell,O
delivery,O
for,O
implanted,O
cells,O
survival,O
and,O
volumetric,O
tissue,O
construction,O
.,O
Total,O
injected,O
volume,O
of,O
4,O
-,O
progressive,O
cells,O
in,O
gel,O
injection,O
was,O
same,O
as,O
that,O
of,O
single,O
injection,O
.,O
Volume,O
of,O
implant,O
(,O
mm2,O
),O
of,O
single,O
and,O
4,O
-,O
progressive,O
injection,O
was,O
compared,O
in,O
(,O
b,O
).,O
Student,O
’,O
s,O
t,O
-,O
test,O
(,O
n,O
=,O
4,O
).,O
*,O
P,O
<,O
0,O
.,O
0001,O
with,O
single,O
cells,O
in,O
gel,O
injection,O
.,O
Representative,O
H,O
&,O
E,O
images,O
of,O
single,O
and,O
progressive,O
cells,O
in,O
gel,O
injections,O
were,O
shown,O
in,O
upper,O
row,O
of,O
(,O
c,O
).,O
Scale,O
bars,O
",",O
1,O
mm,O
.,O
Implants,O
were,O
stained,O
for,O
GFP,O
(,O
green,O
),O
to,O
identify,O
injected,O
cells,O
and,O
their,O
representative,O
images,O
were,O
shown,O
in,O
lower,O
row,O
of,O
(,O
c,O
).,O
Implanted,O
site,O
of,O
single,O
cells,O
in,O
gel,O
were,O
distinguished,O
by,O
white,O
dash,O
line,O
.,O
Scale,O
bars,O
",",O
200,O
μm,O
.,O
(,O
a,O
),O
Representative,O
vWF,O
(,O
green,O
)/,O
α,O
-,O
SMA,O
(,O
red,O
),O
staining,O
images,O
of,O
implants,O
constructed,O
by,O
single,O
injection,O
.,O
(,O
b,O
),O
Representative,O
staining,O
images,O
of,O
implants,O
constructed,O
by,O
4,O
-,O
progressive,O
injection,O
.,O
MHC,O
(,O
red,O
),O
in,O
the,O
first,O
row,O
",",O
GFP,O
(,O
green,O
)/,O
vWF,O
(,O
red,O
),O
in,O
the,O
second,O
row,O
",",O
vWF,O
(,O
green,O
)/,O
α,O
-,O
SMA,O
(,O
red,O
),O
in,O
the,O
third,O
row,O
",",O
NF,O
(,O
green,O
)/,O
AChR,O
(,O
red,O
),O
in,O
the,O
fourth,O
row,O
.,O
Low,O
magnification,O
images,O
of,O
implants,O
were,O
shown,O
in,O
left,O
column,O
.,O
Scale,O
bars,O
",",O
200,O
μm,O
.,O
High,O
magnification,O
images,O
of,O
the,O
firstly,O
",",O
secondary,O
and,O
thirdly,O
",",O
and,O
fourthly,O
injected,O
areas,O
were,O
shown,O
in,O
second,O
",",O
third,O
and,O
fourth,O
columns,O
",",O
respectively,O
.,O
Scale,O
bars,O
",",O
50,O
μm,O
(,O
x400,O
magnification,O
).,O
(,O
c,O
",",O
d,O
),O
In,O
-,O
vivo,O
vascularization,O
of,O
single,O
injection,O
vs,O
progressive,O
injection,O
(,O
c,O
),O
and,O
each,O
injected,O
area,O
in,O
progressive,O
injection,O
(,O
d,O
),O
was,O
evaluated,O
with,O
staining,O
images,O
for,O
vWF,O
/,O
α,O
-,O
SMA,O
(,O
x400,O
magnification,O
),O
in,O
aspects,O
of,O
number,O
of,O
vWF,O
+,O
vessels,O
(,O
per,O
field,O
",",O
i,O
"),",O
area,O
of,O
vWF,O
+,O
vessels,O
(,O
μm2,O
per,O
field,O
",",O
ii,O
"),",O
maturation,O
index,O
"(%,",O
iii,O
),O
and,O
percentage,O
of,O
each,O
size,O
of,O
vessels,O
(,O
iv,O
).,O
Maturation,O
index,O
(%),O
=,O
α,O
-,O
SMA,O
+,O
vessels,O
/,O
total,O
vessels,O
×,O
100,O
.,O
(,O
c,O
),O
Student,O
’,O
s,O
t,O
-,O
test,O
(,O
n,O
=,O
4,O
",",O
3,O
–,O
4,O
fields,O
of,O
each,O
sample,O
"),",O
*,O
P,O
<,O
0,O
.,O
05,O
with,O
single,O
injection,O
.,O
(,O
d,O
),O
ANOVA,O
",",O
Tukey,O
test,O
(,O
n,O
=,O
4,O
",",O
3,O
–,O
5,O
fields,O
per,O
each,O
area,O
in,O
each,O
sample,O
).,O
*,O
P,O
<,O
0,O
.,O
05,O
with,O
the,O
1st,O
injection,O
",",O
†,O
P,O
<,O
0,O
.,O
05,O
with,O
the,O
2nd,O
–,O
3rd,O
injection,O
.,O
Tibialis,O
anterior,O
(,O
TA,O
),O
muscle,O
injury,O
was,O
created,O
in,O
nude,O
rats,O
and,O
4,O
-,O
progressive,O
injection,O
of,O
C2C12,O
(,O
a,O
",",O
b,O
),O
and,O
hMPCs,O
(,O
c,O
",",O
d,O
),O
were,O
performed,O
.,O
The,O
TA,O
muscles,O
were,O
harvested,O
at,O
1,O
week,O
after,O
the,O
fourth,O
injection,O
.,O
(,O
a,O
",",O
c,O
),O
TA,O
muscle,O
mass,O
(,O
defected,O
TA,O
per,O
Contralateral,O
TA,O
),O
and,O
muscle,O
force,O
(,O
N,O
Kg,O
−,O
1,O
),O
of,O
C2C12,O
injection,O
in,O
(,O
a,O
),O
and,O
hMPC,O
injection,O
in,O
(,O
c,O
).,O
(,O
b,O
",",O
d,O
),O
Representative,O
H,O
&,O
E,O
and,O
masson,O
’,O
s,O
trichrome,O
staining,O
images,O
and,O
TA,O
muscle,O
thickness,O
(,O
mm,O
),O
of,O
C2C12,O
injection,O
in,O
(,O
b,O
),O
and,O
hMPC,O
injection,O
in,O
(,O
d,O
).,O
The,O
TA,O
muscle,O
thickness,O
(,O
mm,O
),O
was,O
measured,O
by,O
using,O
H,O
&,O
E,O
staining,O
images,O
.,O
Three,O
different,O
injected,O
areas,O
of,O
the,O
TA,O
per,O
sample,O
were,O
chosen,O
to,O
measure,O
the,O
TA,O
muscle,O
thickness,O
.,O
H,O
&,O
E,O
staining,O
images,O
in,O
upper,O
row,O
.,O
Masson,O
’,O
s,O
trichrome,O
staining,O
images,O
in,O
lower,O
row,O
.,O
Scale,O
bars,O
",",O
500,O
μm,O
.,O
(,O
a,O
),O
ANOVA,O
",",O
Tukey,O
test,O
(,O
n,O
=,O
4,O
).,O
In,O
TA,O
muscle,O
mass,O
",",O
*,O
P,O
<,O
0,O
.,O
05,O
with,O
Normal,O
",",O
†,O
P,O
<,O
0,O
.,O
001,O
with,O
No,O
treatment,O
",",O
‡,O
P,O
<,O
0,O
.,O
001,O
with,O
Gel,O
only,O
",",O
§,O
P,O
<,O
0,O
.,O
017,O
with,O
Single,O
C2C12,O
.,O
In,O
muscle,O
function,O
",",O
*,O
P,O
<,O
0,O
.,O
001,O
with,O
Normal,O
",",O
†,O
P,O
<,O
0,O
.,O
015,O
with,O
No,O
treatment,O
",",O
‡,O
P,O
<,O
0,O
.,O
045,O
with,O
Gel,O
only,O
",",O
§,O
P,O
<,O
0,O
.,O
016,O
with,O
Single,O
C2C12,O
.,O
(,O
b,O
),O
ANOVA,O
",",O
Tukey,O
test,O
(,O
n,O
=,O
4,O
).,O
*,O
P,O
<,O
0,O
.,O
001,O
with,O
Normal,O
",",O
†,O
P,O
<,O
0,O
.,O
001,O
with,O
No,O
treatment,O
",",O
‡,O
P,O
<,O
0,O
.,O
003,O
with,O
Gel,O
only,O
",",O
§,O
P,O
<,O
0,O
.,O
001,O
with,O
Single,O
C2C12,O
.,O
(,O
c,O
),O
Student,O
’,O
s,O
t,O
-,O
test,O
(,O
n,O
=,O
4,O
).,O
*,O
P,O
<,O
0,O
.,O
045,O
with,O
Single,O
hMPC,O
in,O
TA,O
muscle,O
mass,O
",",O
*,O
P,O
<,O
0,O
.,O
038,O
with,O
Single,O
hMPC,O
in,O
muscle,O
function,O
.,O
(,O
d,O
),O
Student,O
’,O
s,O
t,O
-,O
test,O
(,O
n,O
=,O
4,O
).,O
*,O
P,O
<,O
0,O
.,O
003,O
with,O
Single,O
hMPC,O
.,O
(,O
a,O
),O
Representative,O
staining,O
images,O
of,O
single,O
-,O
C2C12,O
and,O
progressive,O
-,O
C2C12,O
injected,O
TA,O
muscles,O
.,O
For,O
both,O
single,O
and,O
progressive,O
injection,O
",",O
GFP,O
+,O
-,O
C2C12,O
was,O
injected,O
and,O
identified,O
by,O
staining,O
for,O
GFP,O
(,O
green,O
).,O
Myotubes,O
or,O
myofibers,O
were,O
stained,O
for,O
MHC,O
(,O
grey,O
).,O
GFP,O
+,O
-,O
C2C12,O
was,O
labeled,O
with,O
DiI,O
(,O
red,O
),O
in,O
single,O
-,O
C2C12,O
injection,O
.,O
In,O
progressive,O
-,O
C2C12,O
injection,O
",",O
the,O
firstly,O
and,O
fourthly,O
injected,O
GFP,O
+,O
-,O
C2C12,O
were,O
labeled,O
with,O
DiI,O
(,O
red,O
).,O
Yellow,O
arrows,O
",",O
GFP,O
+/,O
DiI,O
+,O
cells,O
.,O
White,O
arrows,O
",",O
MHC,O
+/,O
GFP,O
+/,O
DiI,O
+,O
cells,O
.,O
White,O
arrowheads,O
",",O
MHC,O
-/,O
GFP,O
+/,O
DiI,O
+,O
cells,O
.,O
(,O
b,O
),O
Representative,O
staining,O
images,O
of,O
single,O
-,O
hMPC,O
and,O
progressive,O
-,O
hMPC,O
injected,O
TA,O
muscles,O
.,O
Injected,O
hMPC,O
were,O
identified,O
by,O
HLA,O
staining,O
(,O
red,O
),O
and,O
myotubes,O
or,O
myofibers,O
were,O
stained,O
for,O
MHC,O
(,O
green,O
).,O
White,O
arrows,O
",",O
MHC,O
+/,O
HLA,O
+,O
cells,O
.,O
(,O
a,O
",",O
b,O
),O
Scale,O
bars,O
",",O
500,O
μm,O
in,O
left,O
column,O
and,O
50,O
μm,O
in,O
middle,O
and,O
right,O
columns,O
.,O
(,O
a,O
),O
Representative,O
vWF,O
(,O
green,O
)/,O
α,O
-,O
SMA,O
(,O
red,O
),O
staining,O
images,O
of,O
hMPCs,O
-,O
injected,O
TA,O
muscles,O
.,O
Low,O
magnification,O
images,O
of,O
implants,O
were,O
shown,O
in,O
upper,O
row,O
.,O
Scale,O
bars,O
",",O
200,O
μm,O
.,O
High,O
magnification,O
images,O
of,O
inner,O
and,O
outer,O
TA,O
muscles,O
were,O
shown,O
in,O
middle,O
and,O
lower,O
rows,O
",",O
respectively,O
.,O
Scale,O
bars,O
",",O
50,O
μm,O
(,O
x400,O
magnification,O
).,O
(,O
b,O
–,O
e,O
),O
Vascularization,O
of,O
each,O
group,O
was,O
quantified,O
with,O
staining,O
images,O
for,O
vWF,O
/,O
α,O
-,O
SMA,O
(,O
x400,O
magnification,O
),O
in,O
terms,O
of,O
number,O
of,O
vWF,O
+,O
vessels,O
(,O
per,O
field,O
",",O
b,O
"),",O
area,O
of,O
vWF,O
+,O
vessels,O
(,O
μm2,O
per,O
field,O
",",O
c,O
"),",O
maturation,O
index,O
"(%,",O
d,O
),O
and,O
percentage,O
of,O
each,O
size,O
of,O
vessels,O
(,O
e,O
).,O
Maturation,O
index,O
(%),O
=,O
α,O
-,O
SMA,O
+,O
vessels,O
/,O
total,O
vessels,O
×,O
100,O
.,O
ANOVA,O
",",O
Tukey,O
test,O
(,O
n,O
=,O
4,O
",",O
6,O
–,O
10,O
fields,O
of,O
each,O
sample,O
).,O
*,O
P,O
<,O
0,O
.,O
018,O
with,O
Normal,O
",",O
†,O
P,O
<,O
0,O
.,O
001,O
with,O
No,O
treatment,O
",",O
‡,O
P,O
<,O
0,O
.,O
001,O
with,O
Gel,O
only,O
",",O
§,O
P,O
<,O
0,O
.,O
001,O
with,O
Single,O
hMPCs,O
.,O
Role,O
of,O
the,O
Lipoperoxidation,O
Product,O
4,O
-,O
Hydroxynonenal,O
in,O
the,O
Pathogenesis,O
of,O
Severe,O
Malaria,B-DS
Anemia,I-DS
and,O
Malaria,B-DS
Immunodepression,O
Academic,O
Editor,O
:,O
Thomas,O
Kietzmann,O
Oxidative,O
stress,O
plays,O
an,O
important,O
role,O
in,O
the,O
pathogenesis,O
of,O
falciparum,B-DS
malaria,I-DS
",",O
a,O
disease,O
still,O
claiming,O
close,O
to,O
1,O
million,O
deaths,O
and,O
200,O
million,O
new,O
cases,O
per,O
year,O
.,O
Most,O
frequent,O
complications,O
are,O
severe,O
anemia,B-DS
",",O
cerebral,B-DS
malaria,I-DS
",",O
and,O
immunodepression,O
",",O
the,O
latter,O
being,O
constantly,O
present,O
in,O
all,O
forms,O
of,O
malaria,B-DS
.,O
Complications,O
are,O
associated,O
with,O
oxidative,O
stress,O
and,O
lipoperoxidation,O
.,O
Its,O
final,O
product,O
4,O
-,O
hydroxynonenal,O
(,O
4,O
-,O
HNE,O
"),",O
a,O
stable,O
yet,O
very,O
reactive,O
and,O
diffusible,O
molecule,O
",",O
forms,O
covalent,O
conjugates,O
with,O
proteins,O
",",O
DNA,O
",",O
and,O
phospholipids,O
and,O
modulates,O
important,O
cell,O
functions,O
at,O
very,O
low,O
concentrations,O
.,O
Since,O
oxidative,O
stress,O
plays,O
important,O
roles,O
in,O
the,O
pathogenesis,O
of,O
severe,O
malaria,B-DS
",",O
it,O
appears,O
important,O
to,O
explore,O
the,O
role,O
of,O
4,O
-,O
HNE,O
in,O
two,O
important,O
malaria,B-DS
complications,O
such,O
as,O
malaria,B-DS
anemia,I-DS
and,O
malaria,B-DS
immunodepression,O
where,O
oxidative,O
stress,O
is,O
considered,O
to,O
be,O
involved,O
.,O
In,O
this,O
review,O
we,O
will,O
summarize,O
data,O
about,O
4,O
-,O
HNE,O
chemistry,O
",",O
its,O
biologically,O
relevant,O
chemical,O
properties,O
",",O
and,O
its,O
role,O
as,O
regulator,O
of,O
physiologic,O
processes,O
and,O
as,O
pathogenic,O
factor,O
.,O
We,O
will,O
review,O
studies,O
documenting,O
the,O
role,O
of,O
4,O
-,O
HNE,O
in,O
severe,O
malaria,B-DS
with,O
emphasis,O
on,O
malaria,B-DS
anemia,I-DS
and,O
immunodepression,O
.,O
Data,O
from,O
other,O
diseases,O
qualify,O
4,O
-,O
HNE,O
both,O
as,O
oxidative,O
stress,O
marker,O
and,O
as,O
pathomechanistically,O
important,O
molecule,O
.,O
Further,O
studies,O
are,O
needed,O
to,O
establish,O
4,O
-,O
HNE,O
as,O
accepted,O
pathogenic,O
factor,O
in,O
severe,O
malaria,B-DS
.,O
1,O
.,O
Introduction,O
In,O
malaria,B-DS
pathophysiology,O
",",O
oxidative,O
stress,O
plays,O
an,O
important,O
role,O
in,O
many,O
fatal,O
endpoints,O
of,O
the,O
disease,O
[,O
1,O
",",O
2,O
].,O
Imbalance,O
in,O
redox,O
metabolism,O
may,O
be,O
important,O
under,O
two,O
aspects,O
.,O
On,O
the,O
one,O
hand,O
",",O
prooxidative,O
reactions,O
are,O
important,O
in,O
the,O
host,O
response,O
to,O
combat,O
malaria,B-DS
infection,B-DS
in,O
a,O
controlled,O
manner,O
.,O
Some,O
protective,O
mechanisms,O
against,O
malaria,B-DS
",",O
such,O
as,O
glucose,B-DS
-,I-DS
6,I-DS
-,I-DS
phosphate,I-DS
dehydrogenase,I-DS
-,I-DS
(,I-DS
G6PD,I-DS
-),I-DS
deficiency,I-DS
[,O
3,O
",",O
4,O
],O
and,O
hemoglobinopathies,B-DS
",",O
were,O
proposed,O
to,O
be,O
connected,O
with,O
oxidative,O
stress,O
(,O
reviewed,O
in,O
[,O
1,O
",",O
2,O
]).,O
Reactive,O
nitrogen,O
species,O
were,O
claimed,O
to,O
have,O
a,O
protective,O
role,O
against,O
blood,O
-,O
stage,O
malaria,B-DS
[,O
5,O
].,O
However,O
",",O
such,O
protective,O
role,O
has,O
been,O
denied,O
in,O
other,O
studies,O
[,O
6,O
].,O
On,O
the,O
other,O
hand,O
",",O
excess,O
oxidative,O
stress,O
is,O
harmful,O
for,O
the,O
host,O
and,O
may,O
contribute,O
to,O
malaria,B-DS
complications,O
with,O
potentially,O
fatal,O
outcome,O
",",O
such,O
as,O
severe,O
malaria,B-DS
anemia,I-DS
and,O
immunodepression,O
.,O
Indications,O
for,O
excess,O
lipoperoxidation,O
have,O
been,O
shown,O
in,O
malaria,B-DS
",",O
where,O
plasma,O
lipid,O
peroxides,O
are,O
increased,O
[,O
7,O
],O
and,O
red,O
blood,O
cells,O
(,O
RBCs,O
),O
displayed,O
increased,O
lipid,O
peroxidation,O
and,O
decreased,O
antioxidative,O
defense,O
[,O
8,O
",",O
9,O
],O
in,O
clinical,B-DS
malaria,I-DS
.,O
Cellular,O
dysfunctions,O
following,O
excess,O
oxidative,O
stress,O
are,O
frequently,O
mediated,O
by,O
lipoperoxidation,O
products,O
of,O
nonenzymatic,O
degradation,O
of,O
polyunsaturated,O
fatty,O
acids,O
(,O
PUFAs,O
).,O
Lipid,O
peroxidation,O
progresses,O
by,O
free,O
radical,O
chain,O
reactions,O
with,O
lipid,O
hydroperoxides,O
as,O
immediate,O
unstable,O
products,O
that,O
decompose,O
to,O
a,O
series,O
of,O
very,O
reactive,O
products,O
.,O
Among,O
these,O
products,O
",",O
hydroxyaldehydes,O
like,O
4,O
-,O
hydroxynonenal,O
(,O
4,O
-,O
HNE,O
),O
are,O
particularly,O
important,O
because,O
they,O
reach,O
relatively,O
high,O
concentrations,O
",",O
are,O
more,O
stable,O
as,O
radicals,O
",",O
and,O
are,O
able,O
to,O
diffuse,O
inside,O
or,O
even,O
outside,O
the,O
cell,O
to,O
reach,O
distant,O
targets,O
.,O
Target,O
molecules,O
",",O
with,O
which,O
4,O
-,O
HNE,O
forms,O
covalent,O
conjugates,O
",",O
are,O
proteins,O
",",O
DNA,O
",",O
and,O
phospholipids,O
[,O
10,O
",",O
11,O
].,O
Thus,O
",",O
4,O
-,O
HNE,O
can,O
be,O
considered,O
the,O
final,O
mediator,O
and,O
marker,O
of,O
oxidative,O
stress,O
in,O
cells,O
and,O
whole,O
organisms,O
.,O
The,O
role,O
of,O
4,O
-,O
HNE,O
in,O
malaria,B-DS
pathogenesis,O
was,O
recently,O
considered,O
",",O
and,O
the,O
malaria,B-DS
anemia,I-DS
is,O
under,O
special,O
focus,O
",",O
since,O
4,O
-,O
HNE,O
was,O
shown,O
to,O
play,O
a,O
pathomechanistic,O
role,O
in,O
this,O
potentially,O
deadly,O
complication,O
.,O
2,O
.,O
4,O
-,O
HNE,O
Chemistry,O
(,O
Generation,O
",",O
Biologically,O
Relevant,O
Properties,O
",",O
and,O
Metabolism,O
),O
4,O
-,O
HNE,O
is,O
the,O
final,O
product,O
of,O
two,O
sequential,O
processes,O
:,O
first,O
the,O
generation,O
of,O
the,O
hydroperoxide,O
omega,O
-,O
6,O
polyunsaturated,O
fatty,O
acid,O
(,O
PUFA,O
),O
during,O
lipid,O
peroxidation,O
and,O
second,O
the,O
carbon,O
-,O
chain,O
break,O
of,O
the,O
peroxidized,O
PUFA,O
together,O
with,O
the,O
introduction,O
of,O
a,O
hydroxyl,O
group,O
.,O
Only,O
omega,O
-,O
6,O
PUFAs,O
",",O
such,O
as,O
the,O
essential,O
fatty,O
acids,O
linoleic,O
acid,O
and,O
arachidonic,O
acid,O
",",O
play,O
a,O
role,O
in,O
4,O
-,O
HNE,O
generation,O
(,O
Figure,O
1,O
).,O
Lipid,O
peroxidation,O
is,O
a,O
powerful,O
nonenzymatic,O
chain,O
reaction,O
that,O
continuously,O
provides,O
free,O
lipid,O
radicals,O
for,O
further,O
peroxidation,O
.,O
PUFAs,O
are,O
attacked,O
by,O
free,O
radicals,O
regardless,O
of,O
whether,O
the,O
fatty,O
acid,O
is,O
in,O
free,O
form,O
(,O
e,O
.,O
g,O
".,",O
in,O
the,O
circulation,O
",",O
noncovalently,O
bound,O
to,O
albumin,B-GP
),O
or,O
esterified,O
in,O
phospholipids,O
in,O
the,O
cellular,O
membranes,O
[,O
12,O
].,O
Thanks,O
to,O
their,O
unpaired,O
electron,O
",",O
free,O
radicals,O
are,O
highly,O
reactive,O
compounds,O
.,O
One,O
of,O
the,O
most,O
reactive,O
representatives,O
of,O
oxygen,O
radicals,O
is,O
the,O
hydroxyl,O
radical,O
(•,O
OH,O
),O
that,O
is,O
able,O
to,O
initiate,O
the,O
peroxidation,O
process,O
by,O
hydrogen,O
abstraction,O
from,O
a,O
C,O
-,O
atom,O
positioned,O
between,O
two,O
conjugated,O
double,O
bonds,O
in,O
PUFAs,O
(,O
Figure,O
2,O
).,O
Similarly,O
",",O
iron,O
(,O
Fe2,O
+/,O
Fe3,O
+),O
can,O
act,O
as,O
a,O
catalyst,O
for,O
this,O
step,O
and,O
produce,O
additional,O
hydroxyl,O
radicals,O
.,O
The,O
result,O
of,O
hydrogen,O
abstraction,O
is,O
a,O
PUFA,O
radical,O
which,O
binds,O
molecular,O
oxygen,O
",",O
becoming,O
highly,O
reactive,O
peroxide,O
that,O
propagates,O
the,O
peroxidation,O
chain,O
reaction,O
by,O
“,O
stealing,O
”,O
hydrogen,O
from,O
a,O
further,O
PUFA,O
to,O
become,O
a,O
PUFA,O
hydroperoxide,O
(,O
PUFA,O
-,O
OOH,O
).,O
The,O
newly,O
formed,O
PUFA,O
radical,O
may,O
continue,O
the,O
peroxidation,O
chain,O
reaction,O
.,O
Similar,O
to,O
free,O
iron,O
",",O
iron,O
-,O
containing,O
heme,O
is,O
a,O
highly,O
efficient,O
catalyst,O
and,O
accelerates,O
substantially,O
the,O
lipoperoxidation,O
process,O
.,O
The,O
peroxidized,O
PUFA,O
rearranges,O
the,O
hydroperoxy,O
group,O
within,O
the,O
molecule,O
(,O
Hock,O
rearrangement,O
[,O
13,O
"]),",O
and,O
the,O
bond,O
between,O
carbons,O
9,O
and,O
10,O
of,O
the,O
fatty,O
acid,O
chain,O
is,O
destabilized,O
and,O
breaks,O
up,O
.,O
The,O
so,O
-,O
called,O
Hock,O
cleavage,O
splits,O
the,O
peroxidized,O
PUFA,O
molecule,O
between,O
the,O
C11,O
and,O
C12,O
carbon,O
atoms,O
(,O
in,O
case,O
of,O
arachidonic,O
acid,O
),O
and,O
the,O
rearranged,O
peroxy,O
-,O
group,O
and,O
releases,O
the,O
aldehyde,O
nonenal,O
and,O
the,O
oxidized,O
residual,O
11,O
-,O
C,O
fatty,O
acid,O
.,O
Nonenal,O
consists,O
of,O
the,O
last,O
9,O
carbons,O
of,O
the,O
omega,O
-,O
6,O
fatty,O
acid,O
.,O
A,O
further,O
peroxidation,O
with,O
hydrogen,O
abstraction,O
and,O
oxygen,O
binding,O
occurs,O
at,O
position,O
4,O
and,O
the,O
resulting,O
4,O
-,O
hydroperoxynonenal,O
is,O
finally,O
reduced,O
to,O
4,O
-,O
HNE,O
.,O
All,O
reactions,O
may,O
run,O
efficiently,O
without,O
enzyme,O
catalysis,O
and,O
are,O
enhanced,O
by,O
heme,O
.,O
4,O
-,O
HNE,O
is,O
a,O
9,O
C,O
-,O
atom,O
long,O
aldehyde,O
with,O
a,O
double,O
bond,O
between,O
the,O
carbon,O
atoms,O
C2,O
and,O
C3,O
conjugated,O
to,O
the,O
head,O
aldehyde,O
group,O
(,O
C1,O
),O
and,O
a,O
hydroxyl,O
group,O
at,O
the,O
C4,O
position,O
(,O
Figure,O
2,O
).,O
While,O
the,O
aldehyde,O
group,O
is,O
hydrophilic,O
",",O
the,O
nonpolar,O
carbon,O
chain,O
from,O
C5,O
to,O
C9,O
is,O
hydrophobic,O
.,O
This,O
explains,O
the,O
preferential,O
enrichment,O
of,O
the,O
molecule,O
in,O
lipid,O
-,O
rich,O
structures,O
like,O
membranes,O
as,O
well,O
as,O
the,O
capacity,O
to,O
cross,O
the,O
cell,O
membrane,O
.,O
Thus,O
",",O
4,O
-,O
HNE,O
produced,O
in,O
a,O
cell,O
is,O
enriched,O
intracellularly,O
but,O
is,O
not,O
confined,O
to,O
the,O
cell,O
of,O
origin,O
but,O
is,O
found,O
also,O
extracellularly,O
.,O
4,O
-,O
HNE,O
was,O
described,O
to,O
interfere,O
with,O
membrane,O
fluidity,O
and,O
phospholipid,O
asymmetry,O
[,O
14,O
",",O
15,O
].,O
The,O
molecule,O
is,O
highly,O
reactive,O
due,O
to,O
two,O
reactive,O
sites,O
",",O
the,O
C3,O
carbon,O
atom,O
and,O
the,O
aldehyde,O
group,O
.,O
First,O
",",O
the,O
conjugated,O
system,O
of,O
C,O
=,O
C,O
double,O
bond,O
and,O
C,O
=,O
O,O
carbonyl,O
group,O
plus,O
the,O
hydroxyl,O
group,O
makes,O
the,O
C3,O
atom,O
more,O
electropositive,O
and,O
thus,O
susceptible,O
to,O
nucleophilic,O
attacks,O
",",O
which,O
allow,O
the,O
formation,O
of,O
Michael,O
adducts,O
with,O
cysteine,O
",",O
histidine,O
",",O
and,O
lysine,O
residues,O
",",O
and,O
less,O
frequently,O
with,O
arginine,O
residues,O
of,O
polypeptide,O
chains,O
.,O
Second,O
",",O
the,O
aldehyde,O
group,O
may,O
react,O
with,O
free,O
amino,O
group,O
of,O
lysine,O
residues,O
forming,O
so,O
-,O
called,O
Schiff,O
bases,O
frequently,O
seen,O
in,O
lipoproteins,O
.,O
Due,O
to,O
the,O
presence,O
of,O
the,O
two,O
reactive,O
sites,O
in,O
4,O
-,O
HNE,O
mentioned,O
before,O
",",O
high,O
concentrations,O
of,O
4,O
-,O
HNE,O
can,O
also,O
cross,O
-,O
link,O
two,O
peptide,O
chains,O
(,O
reviewed,O
in,O
[,O
16,O
]).,O
Further,O
",",O
4,O
-,O
HNE,O
was,O
described,O
to,O
form,O
adducts,O
with,O
purine,O
bases,O
in,O
DNA,O
(,O
4,O
-,O
HNE,O
-,O
deoxyguanosine,O
).,O
This,O
modification,O
may,O
play,O
a,O
role,O
in,O
tumor,B-DS
pathogenesis,O
[,O
17,O
",",O
18,O
].,O
The,O
second,O
nonprotein,O
targets,O
of,O
4,O
-,O
HNE,O
-,O
conjugation,O
are,O
phosphatidylethanolamine,O
and,O
phosphatidylserine,O
that,O
react,O
with,O
their,O
free,O
amino,O
groups,O
forming,O
Michael,O
adducts,O
and,O
Schiff,O
bases,O
[,O
19,O
–,O
21,O
].,O
Also,O
vitamin,O
C,O
(,O
ascorbic,O
acid,O
),O
and,O
pyridoxamine,O
",",O
the,O
precursor,O
of,O
vitamin,O
B6,O
",",O
are,O
targets,O
for,O
4,O
-,O
HNE,O
-,O
conjugation,O
.,O
Ascorbylation,O
is,O
assumed,O
to,O
play,O
a,O
role,O
in,O
the,O
elimination,O
of,O
4,O
-,O
HNE,O
from,O
the,O
body,O
[,O
22,O
",",O
23,O
].,O
In,O
parallel,O
",",O
unconjugated,O
4,O
-,O
HNE,O
is,O
metabolized,O
for,O
detoxification,O
and,O
better,O
excretion,O
.,O
The,O
main,O
enzymes,O
involved,O
in,O
4,O
-,O
HNE,O
metabolism,O
are,O
glutathione,B-GP
-,I-GP
S,I-GP
-,I-GP
transferase,I-GP
(,O
GSTA4,B-GP
-,I-GP
4,I-GP
",",O
EC,O
2,O
.,O
5,O
.,O
1,O
.,O
18,O
),O
that,O
catalyzes,O
the,O
synthesis,O
of,O
the,O
4,O
-,O
HNE,O
-,O
GSH,O
adducts,O
",",O
aldehyde,B-GP
reductase,I-GP
(,O
EC,O
1,O
.,O
1,O
.,O
1,O
.,O
21,O
),O
that,O
oxidizes,O
4,O
-,O
HNE,O
to,O
hydroxynonenoic,O
acid,O
(,O
HNA,O
"),",O
and,O
alcohol,B-GP
dehydrogenase,I-GP
(,O
EC,O
1,O
.,O
1,O
.,O
1,O
.,O
1,O
),O
that,O
reduces,O
4,O
-,O
HNE,O
to,O
1,O
",",O
4,O
-,O
dihydroxynonene,O
(,O
DHN,O
),O
[,O
24,O
",",O
25,O
].,O
Proteins,O
modified,O
by,O
4,O
-,O
HNE,O
are,O
degraded,O
by,O
the,O
proteasome,O
in,O
the,O
cell,O
cytosol,O
but,O
accumulate,O
in,O
case,O
of,O
high,O
oxidative,O
stress,O
and,O
may,O
contribute,O
to,O
functional,O
losses,O
[,O
26,O
].,O
3,O
.,O
4,O
-,O
HNE,O
Role,O
in,O
Health,O
and,O
Disease,O
3,O
.,O
1,O
.,O
Cellular,O
Targets,O
of,O
4,O
-,O
HNE,O
and,O
Its,O
Potential,O
Functional,O
Importance,O
The,O
concentrations,O
of,O
4,O
-,O
HNE,O
detectable,O
in,O
human,B-OG
serum,O
under,O
nonpathological,O
conditions,O
are,O
0,O
.,O
05,O
–,O
0,O
.,O
15,O
micromoles,O
per,O
liter,O
",",O
increasing,O
with,O
age,O
.,O
Kidney,O
tubular,O
cells,O
",",O
hepatocytes,O
",",O
and,O
monocytes,O
revealed,O
higher,O
tissue,O
concentrations,O
(,O
between,O
1,O
and,O
100,O
micromoles,O
per,O
liter,O
),O
varying,O
by,O
tissue,O
type,O
and,O
organism,O
condition,O
(,O
for,O
review,O
see,O
[,O
10,O
",",O
27,O
]).,O
Although,O
it,O
seems,O
unlikely,O
that,O
overall,O
concentration,O
may,O
reach,O
100,O
micromoles,O
per,O
liter,O
in,O
organs,O
",",O
it,O
is,O
plausible,O
that,O
such,O
levels,O
may,O
build,O
up,O
locally,O
near,O
peroxidized,O
membranes,O
.,O
4,O
-,O
HNE,O
was,O
calculated,O
to,O
reach,O
4,O
millimoles,O
per,O
liter,O
in,O
microsomes,O
.,O
Due,O
to,O
cumulative,O
effect,O
in,O
the,O
membrane,O
",",O
4,O
-,O
HNE,O
may,O
attack,O
critical,O
target,O
proteins,O
in,O
or,O
near,O
the,O
lipid,O
bilayer,O
.,O
Accordingly,O
",",O
monocytes,O
where,O
the,O
enzyme,O
NADPH,B-GP
-,I-GP
oxidase,I-GP
produces,O
oxygen,O
radicals,O
directed,O
against,O
extracellular,O
and,O
intracellular,O
microbes,B-OG
during,O
the,O
oxidative,O
burst,O
reaction,O
may,O
contain,O
40,O
micromoles,O
per,O
liter,O
or,O
higher,O
4,O
-,O
HNE,O
concentrations,O
[,O
28,O
",",O
29,O
].,O
At,O
low,O
concentration,O
",",O
4,O
-,O
HNE,O
is,O
considered,O
an,O
efficient,O
signaling,O
molecule,O
",",O
whilst,O
under,O
oxidative,O
stress,O
the,O
metabolism,O
of,O
4,O
-,O
HNE,O
may,O
be,O
saturated,O
and,O
modifications,O
of,O
biomolecules,O
may,O
elicit,O
pathological,O
effects,O
.,O
Protein,O
modifications,O
represent,O
the,O
main,O
known,O
mechanism,O
by,O
which,O
4,O
-,O
HNE,O
influences,O
physiological,O
and,O
pathological,O
processes,O
.,O
A,O
high,O
and,O
increasing,O
number,O
of,O
4,O
-,O
HNE,O
target,O
proteins,O
have,O
been,O
identified,O
.,O
The,O
binding,O
sites,O
of,O
4,O
-,O
HNE,O
to,O
the,O
protein,O
chain,O
were,O
determined,O
by,O
mass,O
spectrometry,O
for,O
about,O
half,O
of,O
the,O
proteins,O
functionally,O
modified,O
by,O
4,O
-,O
HNE,O
.,O
The,O
functional,O
annotation,O
of,O
the,O
structurally,O
and,O
/,O
or,O
functionally,O
modified,O
proteins,O
covers,O
a,O
wide,O
spectrum,O
including,O
enzymes,O
in,O
energy,O
metabolism,O
",",O
protein,B-GP
kinases,I-GP
and,O
phospholipases,B-GP
involved,O
in,O
cellular,O
signaling,O
",",O
enzymes,O
involved,O
in,O
intracellular,O
proteolysis,O
by,O
the,O
proteasome,O
",",O
extracellular,B-GP
matrix,I-GP
metalloproteinases,I-GP
",",O
membrane,B-GP
receptors,I-GP
for,O
neurotransmitter,O
and,O
growth,O
factors,O
",",O
membrane,B-GP
ion,I-GP
transporter,I-GP
and,O
carriers,O
in,O
the,O
plasma,O
membrane,O
",",O
some,O
plasma,O
proteins,O
",",O
cytoskeletal,B-GP
proteins,I-GP
",",O
heat,B-GP
-,I-GP
shock,I-GP
proteins,I-GP
",",O
and,O
proteins,O
involved,O
in,O
translation,O
[,O
10,O
",",O
27,O
",",O
30,O
–,O
35,O
].,O
3,O
.,O
2,O
.,O
Regulation,O
of,O
Physiological,O
Processes,O
The,O
cellular,O
increase,O
of,O
4,O
-,O
HNE,O
in,O
response,O
to,O
oxidative,O
stress,O
can,O
potently,O
activate,O
stress,O
response,O
mechanisms,O
.,O
Nontoxic,O
levels,O
of,O
4,O
-,O
HNE,O
have,O
been,O
described,O
to,O
modify,O
(,O
i,O
),O
signal,O
transduction,O
regulating,O
the,O
de,O
novo,O
synthesis,O
of,O
detoxifying,O
enzymes,O
(,O
e,O
.,O
g,O
".,",O
via,O
transcription,B-GP
factor,I-GP
Nrf2,B-GP
and,O
the,O
transcription,O
-,O
enhancer,O
antioxidant,O
response,O
element,O
ARE,O
);,O
(,O
ii,O
),O
cell,O
proliferation,O
(,O
e,O
.,O
g,O
".,",O
via,O
c,B-GP
-,I-GP
Jun,I-GP
N,I-GP
-,I-GP
terminal,I-GP
kinase,I-GP
JNK,B-GP
);,O
(,O
iii,O
),O
apoptosis,O
and,O
cell,O
cycle,O
regulation,O
(,O
e,O
.,O
g,O
".,",O
via,O
p53,B-GP
);,O
(,O
iv,O
),O
differentiation,O
(,O
e,O
.,O
g,O
".,",O
via,O
mitogen,B-GP
-,I-GP
activated,I-GP
protein,I-GP
kinase,I-GP
MAPK,B-GP
and,O
growth,B-GP
factor,I-GP
receptors,I-GP
);,O
(,O
v,O
),O
inflammatory,O
response,O
;,O
(,O
vi,O
),O
expression,O
of,O
the,O
cellular,B-GP
adhesion,I-GP
molecules,I-GP
ICAM,B-GP
-,I-GP
1,I-GP
",",O
VCAM,B-GP
-,I-GP
1,I-GP
",",O
and,O
E,B-GP
-,I-GP
selectin,I-GP
(,O
e,O
.,O
g,O
".,",O
via,O
transcription,B-GP
factors,I-GP
p38,B-GP
and,O
NF,B-GP
-,I-GP
kappaB,I-GP
);,O
and,O
(,O
vii,O
),O
protein,O
turnover,O
(,O
via,O
proteasome,O
activity,O
),O
[,O
10,O
",",O
11,O
",",O
36,O
–,O
38,O
].,O
Modification,O
of,O
these,O
pathways,O
may,O
be,O
associated,O
with,O
survival,O
mechanisms,O
of,O
cells,O
or,O
tissues,O
under,O
stress,O
condition,O
.,O
3,O
.,O
3,O
.,O
Association,O
of,O
4,O
-,O
HNE,O
with,O
Pathologies,O
Uncontrolled,O
or,O
excessive,O
production,O
of,O
4,O
-,O
HNE,O
could,O
interfere,O
with,O
basal,O
cellular,O
signaling,O
and,O
play,O
a,O
role,O
in,O
the,O
pathogenesis,O
of,O
several,O
diseases,O
accompanied,O
by,O
oxidative,O
stress,O
.,O
In,O
39,O
different,O
human,B-OG
diseases,O
increased,O
steady,O
-,O
state,O
levels,O
of,O
4,O
-,O
HNE,O
have,O
been,O
either,O
reported,O
in,O
the,O
affected,O
organ,O
or,O
generalized,O
in,O
the,O
blood,O
plasma,O
or,O
both,O
[,O
10,O
",",O
39,O
],O
which,O
suggests,O
a,O
pathogenic,O
role,O
of,O
the,O
aldehyde,O
in,O
the,O
disease,O
pattern,O
and,O
progression,O
.,O
It,O
is,O
now,O
accepted,O
that,O
4,O
-,O
HNE,O
plays,O
a,O
role,O
in,O
inflammation,O
-,O
related,O
cell,O
signaling,O
.,O
Importantly,O
",",O
inflammation,O
represents,O
the,O
main,O
driving,O
force,O
in,O
progression,O
of,O
most,O
chronic,B-DS
diseases,I-DS
",",O
in,O
acute,B-DS
inflammatory,I-DS
diseases,I-DS
and,O
in,O
some,O
anemias,B-DS
",",O
as,O
renal,B-DS
anemia,I-DS
[,O
40,O
].,O
4,O
.,O
4,O
-,O
HNE,O
Production,O
in,O
Malaria,B-DS
4,O
-,O
HNE,O
has,O
received,O
little,O
attention,O
by,O
malariologists,O
as,O
yet,O
",",O
although,O
elevated,O
levels,O
of,O
free,O
",",O
unconjugated,O
4,O
-,O
HNE,O
had,O
been,O
described,O
in,O
RBCs,O
of,O
P,B-OG
.,I-OG
vinckei,I-OG
-,O
infected,O
mice,B-OG
as,O
early,O
as,O
1988,O
[,O
41,O
];,O
one,O
study,O
reported,O
the,O
growth,O
inhibition,O
of,O
in,O
vitro,O
cultured,O
parasites,O
by,O
4,O
-,O
HNE,O
[,O
42,O
"],",O
and,O
the,O
general,O
presence,O
of,O
oxidative,O
stress,O
in,O
malaria,B-DS
was,O
detected,O
long,O
ago,O
[,O
43,O
–,O
46,O
].,O
4,O
.,O
1,O
.,O
4,O
-,O
HNE,O
from,O
the,O
Parasite,O
During,O
its,O
development,O
the,O
malaria,B-DS
parasite,O
digests,O
the,O
major,O
part,O
of,O
host,O
RBC,O
hemoglobin,B-GP
and,O
polymerizes,O
the,O
undigested,O
and,O
prooxidant,O
heme,O
to,O
HZ,O
(,O
hemozoin,O
",",O
malaria,B-DS
pigment,O
),O
in,O
close,O
contact,O
with,O
the,O
membrane,O
of,O
the,O
digestive,O
vacuole,O
of,O
the,O
parasite,O
[,O
47,O
].,O
Similar,O
to,O
free,O
heme,O
",",O
isolated,O
HZ,O
catalyzes,O
in,O
vitro,O
the,O
peroxidation,O
of,O
PUFAs,O
with,O
subsequent,O
degradation,O
to,O
4,O
-,O
HNE,O
and,O
other,O
products,O
(,O
Figures,O
1,O
and,O
2,O
and,O
[,O
48,O
]).,O
The,O
onset,O
of,O
hemoglobin,B-GP
degradation,O
and,O
HZ,O
formation,O
at,O
young,O
trophozoite,O
stage,O
coincided,O
with,O
a,O
significantly,O
enhanced,O
formation,O
of,O
4,O
-,O
HNE,O
and,O
4,O
-,O
HNE,O
-,O
membrane,B-GP
protein,I-GP
conjugates,O
in,O
parasitized,O
RBCs,O
",",O
compared,O
to,O
nonparasitized,O
control,O
RBCs,O
.,O
The,O
progressive,O
HZ,O
generation,O
during,O
parasite,O
growth,O
was,O
accompanied,O
by,O
the,O
increase,O
of,O
4,O
-,O
HNE,O
conjugates,O
up,O
to,O
15,O
-,O
fold,O
higher,O
levels,O
in,O
HZ,O
-,O
rich,O
schizonts,O
compared,O
to,O
young,O
HZ,O
-,O
free,O
ring,O
-,O
forms,O
(,O
Figure,O
3,O
).,O
The,O
conjugates,O
can,O
be,O
detected,O
and,O
quantified,O
by,O
flow,O
cytometry,O
or,O
fluorescence,O
microscopy,O
after,O
recognition,O
by,O
specific,O
antibodies,B-GP
[,O
11,O
",",O
49,O
",",O
50,O
].,O
4,O
-,O
HNE,O
conjugates,O
are,O
not,O
confined,O
to,O
4,O
-,O
HNE,O
-,O
producing,O
cells,O
but,O
were,O
also,O
found,O
in,O
nonparasitized,O
RBCs,O
(,O
npRBCs,O
),O
cytoadherent,O
to,O
trophozoites,O
(,O
see,O
Figure,O
4,O
),O
[,O
51,O
].,O
4,O
.,O
2,O
.,O
4,O
-,O
HNE,O
from,O
the,O
Residual,O
Body,O
The,O
synthetic,O
beta,O
-,O
hematin,O
core,O
of,O
natural,O
HZ,O
(,O
nHZ,O
),O
is,O
able,O
to,O
catalyze,O
in,O
vitro,O
the,O
PUFA,O
peroxidation,O
with,O
formation,O
of,O
4,O
-,O
HNE,O
and,O
hydroxy,O
-,O
fatty,O
acids,O
such,O
as,O
hydroxylated,O
arachidonic,O
acid,O
(,O
hydroxyeicosatetraenoic,O
acid,O
",",O
HETE,O
),O
or,O
hydroxylated,O
linoleic,O
acid,O
(,O
hydroxyoctadecadienoic,O
acid,O
",",O
HODE,O
),O
(,O
Figure,O
2,O
",",O
[,O
48,O
]).,O
At,O
the,O
end,O
of,O
the,O
48,O
h,O
parasite,O
growth,O
cycle,O
in,O
the,O
RBC,O
",",O
the,O
daughter,O
parasites,O
leave,O
the,O
RBC,O
to,O
infect,O
fresh,O
RBCs,O
(,O
schizogony,O
).,O
In,O
parallel,O
the,O
residual,O
body,O
(,O
RB,O
),O
or,O
nHZ,O
",",O
that,O
is,O
",",O
the,O
membrane,O
-,O
enveloped,O
",",O
HZ,O
-,O
containing,O
digestive,O
vacuole,O
",",O
is,O
expelled,O
into,O
the,O
bloodstream,O
.,O
The,O
RBs,O
collected,O
from,O
culture,O
supernatant,O
contained,O
50,O
micromoles,O
per,O
liter,O
of,O
free,O
4,O
-,O
HNE,O
(,O
Figure,O
3,O
",",O
[,O
52,O
"]),",O
which,O
was,O
released,O
and,O
transferred,O
to,O
adjacent,O
cells,O
in,O
an,O
in,O
vitro,O
erythropoiesis,O
model,O
(,O
Figure,O
5,O
).,O
Hence,O
",",O
RBs,O
represent,O
an,O
additional,O
source,O
of,O
4,O
-,O
HNE,O
in,O
pathology,O
[,O
52,O
].,O
4,O
.,O
3,O
.,O
4,O
-,O
HNE,O
from,O
Human,B-OG
Phagocytes,O
RBs,O
released,O
into,O
plasma,O
bind,O
preferentially,O
host,O
fibrinogen,B-GP
and,O
to,O
a,O
lesser,O
extent,O
immunoglobulins,B-GP
(,O
IgGs,B-GP
),O
and,O
complement,B-GP
factors,I-GP
.,O
Fibrinogen,B-GP
was,O
constantly,O
present,O
at,O
10,O
–,O
100,O
",",O
000,O
fibrinogen,B-GP
molecules,O
per,O
residual,O
body,O
and,O
was,O
stably,O
bound,O
to,O
nHZ,O
collected,O
from,O
plasma,O
-,O
cultured,O
parasites,O
[,O
53,O
].,O
Surface,O
-,O
binding,O
changes,O
the,O
conformation,O
of,O
fibrinogen,B-GP
and,O
makes,O
it,O
recognizable,O
by,O
Toll,B-GP
-,I-GP
like,I-GP
receptor,I-GP
4,I-GP
(,O
TLR4,B-GP
),O
on,O
monocytes,O
.,O
RBs,O
coated,O
with,O
fibrinogen,B-GP
become,O
excellent,O
ligands,O
for,O
TLR4,B-GP
and,O
were,O
responsible,O
for,O
the,O
rapid,O
100,O
-,O
fold,O
stronger,O
production,O
of,O
reactive,O
oxygen,O
species,O
by,O
human,B-OG
monocytes,O
[,O
53,O
].,O
Close,O
contact,O
of,O
HZ,O
with,O
the,O
cell,O
membrane,O
",",O
together,O
with,O
extensive,O
oxidative,O
burst,O
during,O
HZ,O
phagocytosis,O
",",O
resulted,O
in,O
fast,O
and,O
persistent,O
6,O
-,O
fold,O
increase,O
of,O
lipid,O
peroxides,O
in,O
RB,O
-,O
fed,O
monocytes,O
compared,O
to,O
the,O
transient,O
2,O
-,O
fold,O
increase,O
after,O
RBC,O
phagocytosis,O
[,O
54,O
].,O
4,O
-,O
HNE,O
was,O
significantly,O
increased,O
at,O
2,O
h,O
after,O
feeding,O
monocytes,O
with,O
HZ,O
and,O
peaked,O
at,O
5,O
h,O
attaining,O
50,O
-,O
fold,O
levels,O
compared,O
to,O
unfed,O
controls,O
and,O
was,O
still,O
almost,O
15,O
-,O
fold,O
the,O
control,O
levels,O
after,O
12,O
h,O
[,O
28,O
].,O
The,O
long,O
-,O
lasting,O
generation,O
of,O
4,O
-,O
HNE,O
(,O
Figure,O
3,O
),O
is,O
caused,O
by,O
a,O
persisting,O
lipoperoxidation,O
catalyzed,O
by,O
HZ,O
after,O
its,O
uptake,O
into,O
the,O
lysosome,O
of,O
the,O
monocytes,O
.,O
The,O
generation,O
of,O
4,O
-,O
HNE,O
in,O
HZ,O
-,O
fed,O
monocytes,O
is,O
followed,O
by,O
a,O
significant,O
increase,O
of,O
4,O
-,O
HNE,O
conjugate,O
formation,O
with,O
membrane,B-GP
proteins,I-GP
[,O
52,O
].,O
In,O
summary,O
",",O
HZ,O
can,O
be,O
considered,O
to,O
be,O
source,O
and,O
shuttle,O
for,O
4,O
-,O
HNE,O
in,O
malaria,B-DS
and,O
4,O
-,O
HNE,O
is,O
likely,O
one,O
molecular,O
mediator,O
of,O
the,O
HZ,O
effects,O
(,O
reviewed,O
in,O
[,O
55,O
",",O
56,O
]).,O
5,O
.,O
4,O
-,O
HNE,O
Effect,O
on,O
Immune,O
Response,O
and,O
Malaria,B-DS
Anemia,I-DS
HZ,O
or,O
RB,O
has,O
been,O
described,O
to,O
interfere,O
with,O
several,O
immune,O
processes,O
that,O
might,O
play,O
a,O
role,O
in,O
malaria,B-DS
and,O
contribute,O
to,O
the,O
lack,O
of,O
sterile,O
immunity,O
as,O
well,O
as,O
in,O
complicated,O
forms,O
of,O
malaria,B-DS
[,O
56,O
].,O
As,O
described,O
above,O
",",O
HZ,O
acts,O
as,O
catalyst,O
and,O
shuttle,O
for,O
4,O
-,O
HNE,O
in,O
malaria,B-DS
.,O
Thus,O
",",O
a,O
series,O
of,O
HZ,O
effects,O
were,O
recapitulated,O
by,O
exogenously,O
added,O
4,O
-,O
HNE,O
",",O
and,O
molecular,O
targets,O
for,O
4,O
-,O
HNE,O
listed,O
above,O
were,O
modified,O
by,O
4,O
-,O
HNE,O
in,O
HZ,O
-,O
fed,O
cells,O
.,O
The,O
roles,O
of,O
4,O
-,O
HNE,O
on,O
the,O
pathophysiologically,O
relevant,O
processes,O
are,O
listed,O
below,O
.,O
5,O
.,O
1,O
.,O
Phagocytosis,O
",",O
Oxidative,O
Burst,O
",",O
and,O
MHC,B-GP
Class,I-GP
II,I-GP
Expression,O
:,O
Protein,B-GP
Kinase,I-GP
C,I-GP
(,O
PKC,B-GP
),O
Involvement,O
Phagocytosis,O
and,O
oxidative,O
burst,O
are,O
first,O
-,O
line,O
defense,O
mechanisms,O
against,O
the,O
blood,O
-,O
stage,O
malaria,B-DS
parasite,O
.,O
After,O
avid,O
phagocytosis,O
of,O
HZ,O
and,O
a,O
violent,O
oxidative,O
burst,O
elicited,O
by,O
mature,O
parasites,O
and,O
released,O
RB,O
",",O
both,O
phagocytosis,O
and,O
burst,O
are,O
switched,O
off,O
after,O
approximately,O
6,O
–,O
12,O
h,O
from,O
initial,O
phagocytosis,O
and,O
remain,O
inactive,O
during,O
the,O
observation,O
period,O
of,O
3,O
days,O
[,O
54,O
].,O
Phagocytes,O
do,O
not,O
die,O
and,O
do,O
not,O
show,O
signs,O
of,O
apoptosis,O
[,O
54,O
",",O
57,O
],O
that,O
could,O
explain,O
the,O
inactivation,O
.,O
In,O
malaria,B-DS
disease,O
large,O
proportions,O
of,O
resident,O
macrophages,O
and,O
circulating,O
monocytes,O
and,O
neutrophils,O
contain,O
massive,O
amounts,O
of,O
HZ,O
.,O
When,O
fed,O
with,O
HZ,O
in,O
vitro,O
",",O
the,O
precursors,O
of,O
macrophages,O
",",O
the,O
monocytes,O
",",O
lose,O
their,O
capacity,O
to,O
upregulate,O
the,O
antigen,O
presenting,O
MHC,B-GP
class,I-GP
II,I-GP
in,O
response,O
to,O
interferon,B-GP
-,I-GP
gamma,I-GP
suggesting,O
that,O
HZ,O
loading,O
may,O
contribute,O
to,O
the,O
impairment,O
of,O
the,O
immune,O
response,O
and,O
derangement,O
of,O
antigen,O
presentation,O
previously,O
reported,O
in,O
falciparum,B-DS
malaria,I-DS
[,O
56,O
",",O
58,O
].,O
Protein,B-GP
kinase,I-GP
C,I-GP
(,O
PKC,B-GP
"),",O
the,O
common,O
regulator,O
protein,O
that,O
coordinates,O
phagocytosis,O
",",O
burst,O
",",O
and,O
antigen,O
presentation,O
",",O
was,O
shown,O
to,O
be,O
inactivated,O
by,O
4,O
-,O
HNE,O
-,O
conjugation,O
in,O
vitro,O
",",O
and,O
HZ,O
-,O
fed,O
monocytes,O
exhibited,O
a,O
high,O
level,O
of,O
4,O
-,O
HNE,O
-,O
conjugated,O
PKC,B-GP
[,O
28,O
].,O
The,O
kinetics,O
of,O
4,O
-,O
HNE,O
production,O
and,O
conjugate,O
formation,O
after,O
HZ,O
phagocytosis,O
fit,O
with,O
the,O
quick,O
loss,O
of,O
active,O
membrane,O
-,O
associated,O
PKC,B-GP
and,O
the,O
subsequent,O
disappearing,O
responsiveness,O
of,O
cytosolic,O
PKC,B-GP
to,O
activators,O
in,O
HZ,O
-,O
fed,O
monocytes,O
[,O
59,O
].,O
Thus,O
",",O
we,O
consider,O
4,O
-,O
HNE,O
to,O
be,O
a,O
molecular,O
mediator,O
in,O
the,O
HZ,O
-,O
provoked,O
modulation,O
of,O
immune,O
responses,O
such,O
as,O
inhibition,O
of,O
oxidative,O
burst,O
",",O
phagocytosis,O
",",O
and,O
antigen,O
presentation,O
by,O
MHC,B-GP
class,I-GP
II,I-GP
.,O
Comparison,O
of,O
transcriptional,O
changes,O
elicited,O
by,O
synthetic,O
HZ,O
and,O
4,O
-,O
HNE,O
in,O
murine,O
macrophages,O
suggests,O
that,O
both,O
are,O
involved,O
in,O
the,O
modulation,O
of,O
inflammatory,O
responses,O
",",O
transcription,B-GP
factor,I-GP
NF,B-GP
-,I-GP
kappaB,I-GP
-,O
dependent,O
signal,O
transduction,O
",",O
and,O
extracellular,O
matrix,O
degradation,O
[,O
60,O
],O
further,O
confirming,O
4,O
-,O
HNE,O
as,O
an,O
immune,O
-,O
modulating,O
factor,O
of,O
interest,O
in,O
malaria,B-DS
.,O
5,O
.,O
2,O
.,O
Dendritic,O
Cell,O
Differentiation,O
and,O
Maturation,O
Enhanced,O
4,O
-,O
HNE,O
production,O
and,O
formation,O
of,O
membrane,B-GP
protein,I-GP
-,O
4,O
-,O
HNE,O
conjugates,O
were,O
observed,O
in,O
HZ,O
-,O
fed,O
monocytes,O
in,O
their,O
differentiation,O
towards,O
DC,O
[,O
52,O
].,O
Functionally,O
",",O
phagocytosis,O
of,O
HZ,O
-,O
containing,O
parasites,O
or,O
HZ,O
by,O
itself,O
(,O
HZ,O
is,O
here,O
synonymous,O
with,O
RBs,O
"),",O
as,O
well,O
as,O
4,O
-,O
HNE,O
and,O
/,O
or,O
HETE,O
generated,O
and,O
carried,O
by,O
HZ,O
",",O
inhibited,O
the,O
differentiation,O
and,O
maturation,O
of,O
DC,O
[,O
57,O
].,O
In,O
particular,O
",",O
4,O
-,O
HNE,O
significantly,O
inhibited,O
the,O
expression,O
of,O
CD83,B-GP
",",O
the,O
functionally,O
important,O
marker,O
for,O
mature,O
DCs,O
",",O
mimicking,O
the,O
effect,O
of,O
HZ,O
or,O
HETE,O
[,O
56,O
",",O
57,O
].,O
Moreover,O
",",O
4,O
-,O
HNE,O
dose,O
dependently,O
inhibited,O
the,O
expression,O
of,O
CD83,B-GP
in,O
differentiating,O
DCs,O
[,O
52,O
],O
and,O
4,O
-,O
HNE,O
added,O
at,O
reasonably,O
low,O
doses,O
significantly,O
inhibited,O
the,O
protein,O
expression,O
of,O
MHC,B-GP
classes,I-GP
I,I-GP
and,O
II,O
",",O
CD1a,B-GP
",",O
and,O
accessory,O
molecules,O
",",O
which,O
can,O
modulate,O
the,O
ability,O
of,O
immune,O
cells,O
to,O
develop,O
or,O
perform,O
their,O
functions,O
[,O
61,O
"],",O
such,O
as,O
CD40,B-GP
",",O
CD54,B-GP
",",O
and,O
CD83,B-GP
[,O
57,O
].,O
Additionally,O
",",O
4,O
-,O
HNE,O
modified,O
the,O
responsiveness,O
of,O
GM,B-GP
-,I-GP
CSF,I-GP
receptor,I-GP
",",O
the,O
crucial,O
growth,O
factor,O
for,O
dendritic,O
cell,O
differentiation,O
in,O
vitro,O
[,O
52,O
].,O
Similar,O
to,O
phagocytosis,O
of,O
HZ,O
",",O
the,O
addition,O
of,O
4,O
-,O
HNE,O
resulted,O
in,O
increased,O
expression,O
of,O
the,O
nuclear,B-GP
receptor,I-GP
PPAR,B-GP
-,I-GP
gamma,I-GP
(,O
peroxisome,B-GP
proliferator,I-GP
-,I-GP
activated,I-GP
receptor,I-GP
gamma,I-GP
),O
in,O
the,O
immune,O
cells,O
[,O
36,O
",",O
57,O
].,O
After,O
activation,O
(,O
e,O
.,O
g,O
".,",O
by,O
HETE,O
),O
PPAR,B-GP
-,I-GP
gamma,I-GP
moves,O
into,O
the,O
nucleus,O
where,O
it,O
regulates,O
immune,O
cell,O
functions,O
[,O
62,O
],O
and,O
functionally,O
suppresses,O
the,O
transcription,B-GP
factor,I-GP
NF,B-GP
-,I-GP
kappaB,I-GP
[,O
63,O
].,O
NF,B-GP
-,I-GP
kappaB,I-GP
controls,O
proinflammatory,O
immune,O
responses,O
[,O
64,O
"],",O
DC,O
differentiation,O
",",O
DC,O
maturation,O
",",O
and,O
CD83,B-GP
expression,O
related,O
to,O
the,O
latter,O
process,O
.,O
5,O
.,O
3,O
.,O
Cell,O
Cycle,O
Control,O
and,O
Membrane,B-GP
Receptor,I-GP
Expression,O
in,O
Erythropoiesis,O
Dyserythropoiesis,O
(,O
defective,O
production,O
of,O
RBC,O
),O
is,O
an,O
important,O
determinant,O
of,O
severe,O
malaria,B-DS
anemia,I-DS
.,O
Erythropoiesis,O
prominently,O
occurs,O
in,O
the,O
bone,O
marrow,O
erythroblastic,O
islands,O
",",O
microenvironmental,O
niches,O
in,O
which,O
erythroid,O
progenitors,O
proliferate,O
",",O
differentiate,O
",",O
and,O
finally,O
expel,O
their,O
nucleus,O
at,O
the,O
end,O
of,O
the,O
maturation,O
process,O
.,O
An,O
island,O
is,O
formed,O
by,O
a,O
central,O
macrophage,O
surrounded,O
by,O
developing,O
and,O
differentiating,O
erythroid,O
cells,O
from,O
early,O
stages,O
through,O
reticulocytes,O
[,O
65,O
].,O
Marrow,O
macrophages,O
and,O
erythroid,O
precursors,O
have,O
been,O
shown,O
to,O
contain,O
HZ,O
in,O
malaria,B-DS
patients,O
[,O
66,O
",",O
67,O
].,O
4,O
-,O
HNE,O
",",O
the,O
production,O
of,O
which,O
is,O
enhanced,O
by,O
HZ,O
",",O
was,O
first,O
shown,O
to,O
interfere,O
with,O
erythropoiesis,O
in,O
an,O
in,O
vitro,O
model,O
of,O
the,O
initial,O
stages,O
of,O
erythroid,O
development,O
in,O
the,O
bone,O
marrow,O
[,O
68,O
].,O
Both,O
supplemented,O
free,O
4,O
-,O
HNE,O
and,O
4,O
-,O
HNE,O
contained,O
in,O
HZ,O
supernatants,O
inhibited,O
erythroid,O
cell,O
colony,O
growth,O
.,O
Application,O
of,O
advanced,O
cell,O
culture,O
protocols,O
allows,O
the,O
complete,O
differentiation,O
of,O
umbilical,O
cord,O
blood,O
-,O
derived,O
erythroid,O
stem,O
cells,O
to,O
fully,O
mature,O
enucleated,O
RBCs,O
and,O
to,O
analyze,O
biochemical,O
parameters,O
crucial,O
for,O
this,O
proliferation,O
-,O
dependent,O
differentiation,O
program,O
.,O
Erythroid,O
stem,O
cells,O
incubated,O
with,O
4,O
-,O
HNE,O
displayed,O
sustained,O
high,O
levels,O
of,O
4,O
-,O
HNE,O
-,O
protein,O
conjugate,O
on,O
their,O
surface,O
[,O
69,O
].,O
Human,B-OG
phagocytes,O
either,O
HZ,O
-,O
laden,O
or,O
cocultured,O
with,O
HZ,O
were,O
able,O
to,O
shed,O
4,O
-,O
HNE,O
that,O
diffused,O
to,O
the,O
surrounding,O
erythroid,O
cells,O
and,O
was,O
detected,O
on,O
the,O
surface,O
of,O
those,O
cells,O
as,O
4,O
-,O
HNE,O
-,O
protein,O
conjugate,O
(,O
Figure,O
5,O
).,O
4,O
-,O
HNE,O
inhibits,O
the,O
erythroid,O
cell,O
proliferation,O
during,O
the,O
whole,O
period,O
of,O
erythropoiesis,O
",",O
involving,O
the,O
molecular,O
regulators,O
of,O
the,O
cell,O
cycle,O
",",O
a,O
series,O
of,O
controlled,O
events,O
that,O
take,O
place,O
in,O
a,O
cell,O
leading,O
to,O
its,O
division,O
[,O
69,O
].,O
Both,O
natural,O
HZ,O
and,O
4,O
-,O
HNE,O
treatment,O
of,O
erythroid,O
cells,O
results,O
in,O
(,O
i,O
),O
increased,O
regulatory,B-GP
proteins,I-GP
:,O
p53,B-GP
(,O
tumor,B-GP
suppressor,I-GP
protein,I-GP
53,I-GP
),O
and,O
p21,B-GP
(,O
cyclin,B-GP
-,I-GP
dependent,I-GP
kinase,I-GP
inhibitor,I-GP
1,I-GP
);,O
(,O
ii,O
),O
unbalanced,O
phosphorylation,O
of,O
the,O
retinoblastoma,B-GP
protein,I-GP
Rb,I-GP
;,O
(,O
iii,O
),O
decreased,O
levels,O
of,O
cyclins,B-GP
A,I-GP
and,O
D,O
.,O
Importantly,O
",",O
neither,O
HZ,O
nor,O
4,O
-,O
HNE,O
added,O
at,O
reasonable,O
concentrations,O
induced,O
programmed,O
cell,O
death,O
(,O
apoptosis,O
).,O
Further,O
",",O
low,O
micromolar,O
4,O
-,O
HNE,O
delays,O
the,O
differentiation,O
marker,O
expression,O
:,O
the,O
functionally,O
important,O
membrane,B-GP
receptors,I-GP
for,O
transferrin,B-GP
(,O
TfR1,B-GP
",",O
CD71,B-GP
"),",O
stem,B-GP
cell,I-GP
factor,I-GP
c,I-GP
-,I-GP
kit,I-GP
(,O
CD117,B-GP
"),",O
interleukin,B-GP
-,I-GP
3,I-GP
(,O
CD123,B-GP
"),",O
and,O
erythropoietin,B-GP
(,O
EpoR,B-GP
),O
as,O
well,O
as,O
the,O
stem,O
cell,O
marker,O
CD34,B-GP
",",O
and,O
the,O
RBC,O
markers,O
glycophorin,B-GP
A,I-GP
and,O
hemoglobin,B-GP
.,O
GATA,B-GP
-,I-GP
1,I-GP
",",O
the,O
master,O
transcription,B-GP
factor,I-GP
that,O
controls,O
the,O
differentiation,O
processes,O
in,O
erythropoiesis,O
",",O
was,O
less,O
expressed,O
in,O
HZ,O
-,O
and,O
4,O
-,O
HNE,O
-,O
treated,O
cells,O
.,O
The,O
impaired,O
cell,O
cycle,O
and,O
reduced,O
receptor,O
expression,O
decreased,O
the,O
total,O
cell,O
yield,O
and,O
specifically,O
the,O
yield,O
of,O
differentiated,O
erythroid,O
cells,O
[,O
69,O
].,O
These,O
results,O
reconfirm,O
the,O
inhibitory,O
role,O
of,O
HZ,O
",",O
identify,O
4,O
-,O
HNE,O
as,O
HZ,O
-,O
generated,O
inhibitory,O
molecule,O
for,O
proliferation,O
and,O
differentiation,O
",",O
and,O
describe,O
molecular,O
targets,O
of,O
4,O
-,O
HNE,O
in,O
erythroid,O
progenitors,O
possibly,O
involved,O
in,O
the,O
inhibition,O
of,O
erythropoiesis,O
in,O
malaria,B-DS
anemia,I-DS
.,O
5,O
.,O
4,O
.,O
RBC,O
Membrane,B-GP
Proteins,I-GP
and,O
Phagocytosis,O
Excessive,O
loss,O
of,O
npRBC,O
",",O
in,O
addition,O
to,O
impaired,O
erythropoiesis,O
",",O
is,O
considered,O
to,O
be,O
cause,O
for,O
malaria,B-DS
anemia,I-DS
.,O
Parasitized,O
RBCs,O
generate,O
4,O
-,O
HNE,O
that,O
conjugates,O
with,O
membrane,B-GP
skeleton,I-GP
proteins,I-GP
such,O
as,O
spectrin,B-GP
and,O
actin,B-GP
and,O
the,O
integral,B-GP
membrane,I-GP
protein,I-GP
band,B-GP
3,I-GP
[,O
51,O
",",O
70,O
],O
that,O
contributes,O
to,O
anchoring,O
the,O
cytoskeleton,O
to,O
the,O
membrane,O
.,O
4,O
-,O
HNE,O
-,O
conjugation,O
is,O
not,O
confined,O
to,O
the,O
parasitized,O
RBCs,O
but,O
4,O
-,O
HNE,O
is,O
transferred,O
and,O
binds,O
to,O
adjacent,O
npRBCs,O
as,O
shown,O
in,O
Figure,O
4,O
where,O
the,O
central,O
trophozoite,O
-,O
infected,O
RBC,O
is,O
surrounded,O
by,O
npRBCs,O
[,O
51,O
].,O
The,O
differential,O
labeling,O
of,O
pRBCs,O
and,O
npRBCs,O
with,O
a,O
nuclear,O
fluorescent,O
probe,O
(,O
e,O
.,O
g,O
".,",O
ethidium,O
bromide,O
),O
allows,O
the,O
separate,O
analysis,O
by,O
flow,O
cytometry,O
of,O
membrane,B-GP
protein,I-GP
-,O
4,O
-,O
HNE,O
conjugates,O
in,O
both,O
cell,O
cohorts,O
[,O
51,O
].,O
Similar,O
to,O
npRBCs,O
",",O
protein,O
-,O
4,O
-,O
HNE,O
conjugates,O
are,O
detectable,O
in,O
4,O
-,O
HNE,O
-,O
treated,O
RBCs,O
causing,O
loss,O
in,O
deformability,O
and,O
increased,O
phagocytosis,O
[,O
51,O
].,O
As,O
decreased,O
deformability,O
and,O
increased,O
phagocytosis,O
add,O
to,O
RBC,O
elimination,O
in,O
the,O
spleen,O
",",O
4,O
-,O
HNE,O
is,O
suggested,O
to,O
be,O
instrumental,O
for,O
the,O
removal,O
of,O
large,O
numbers,O
of,O
npRBCs,O
.,O
5,O
.,O
5,O
.,O
Cytoskeleton,O
Modifications,O
and,O
Impairment,O
of,O
Chemotactic,O
Motility,O
and,O
Transendothelial,O
Migration,O
of,O
Monocytes,O
Immune,O
cell,O
motility,O
is,O
an,O
important,O
physiological,O
process,O
",",O
relatively,O
poorly,O
studied,O
in,O
malaria,B-DS
.,O
Recently,O
it,O
was,O
shown,O
that,O
nHZ,O
phagocytosis,O
by,O
human,B-OG
primary,O
monocytes,O
impaired,O
their,O
chemotactic,O
motility,O
toward,O
MCP,B-GP
-,I-GP
1,I-GP
",",O
TNF,B-GP
",",O
and,O
FMLP,O
and,O
their,O
diapedesis,O
across,O
a,O
confluent,O
endothelial,O
cell,O
layer,O
toward,O
MCP,B-GP
-,I-GP
1,I-GP
[,O
71,O
].,O
No,O
inhibition,O
was,O
detected,O
in,O
control,O
latex,O
-,O
fed,O
or,O
unfed,O
monocytes,O
.,O
Microscopic,O
analysis,O
has,O
shown,O
that,O
the,O
polarization,O
defect,O
in,O
nHZ,O
-,O
fed,O
monocytes,O
was,O
due,O
to,O
irregular,O
actin,B-GP
polymerization,O
.,O
Similar,O
to,O
nHZ,O
phagocytosis,O
",",O
the,O
exposure,O
of,O
monocytes,O
to,O
in,O
vivo,O
-,O
compatible,O
4,O
-,O
HNE,O
concentrations,O
inhibited,O
cell,O
motility,O
in,O
both,O
the,O
presence,O
and,O
the,O
absence,O
of,O
chemotactic,O
stimuli,O
",",O
suggesting,O
the,O
impairment,O
of,O
cytoskeleton,O
dynamics,O
.,O
Consequently,O
",",O
4,O
-,O
HNE,O
conjugates,O
with,O
the,O
cytoskeleton,B-GP
proteins,I-GP
β,B-GP
-,I-GP
actin,I-GP
and,O
coronin,B-GP
-,I-GP
1A,I-GP
were,O
identified,O
in,O
nHZ,O
-,O
fed,O
monocytes,O
and,O
localized,O
in,O
domains,O
of,O
protein,O
-,O
protein,O
interactions,O
involved,O
in,O
cytoskeleton,O
reorganization,O
and,O
cell,O
motility,O
.,O
The,O
molecular,O
and,O
functional,O
modifications,O
of,O
actin,B-GP
and,O
coronin,B-GP
by,O
nHZ,O
/,O
4,O
-,O
HNE,O
may,O
also,O
explain,O
impaired,O
phagocytosis,O
",",O
another,O
motility,O
-,O
dependent,O
process,O
previously,O
described,O
in,O
nHZ,O
-,O
fed,O
monocytes,O
[,O
54,O
].,O
This,O
study,O
indicates,O
that,O
impaired,O
monocyte,O
motility,O
may,O
contribute,O
to,O
the,O
immune,O
depression,O
and,O
the,O
frequent,O
occurrence,O
of,O
secondary,B-DS
infections,I-DS
observed,O
in,O
malaria,B-DS
patients,O
[,O
71,O
].,O
Figure,O
6,O
summarizes,O
molecules,O
and,O
processes,O
of,O
potential,O
relevance,O
for,O
malaria,B-DS
pathology,O
that,O
were,O
structurally,O
or,O
functionally,O
modified,O
by,O
4,O
-,O
HNE,O
.,O
6,O
.,O
4,O
-,O
HNE,O
in,O
Clinical,B-DS
Malaria,I-DS
and,O
in,O
Malaria,B-DS
Anemia,I-DS
In,O
vitro,O
and,O
clinical,O
data,O
strongly,O
indicate,O
that,O
oxidative,O
stress,O
plays,O
important,O
roles,O
in,O
falciparum,B-DS
malaria,I-DS
",",O
notably,O
in,O
the,O
pathogenesis,O
of,O
severe,O
anemia,B-DS
.,O
However,O
",",O
oxidative,O
modifications,O
of,O
the,O
RBC,O
membrane,O
by,O
4,O
-,O
HNE,O
",",O
which,O
may,O
mechanistically,O
clarify,O
the,O
pathogenesis,O
of,O
clinical,B-DS
malaria,I-DS
as,O
described,O
above,O
",",O
have,O
not,O
been,O
tested,O
for,O
their,O
clinical,O
significance,O
until,O
recent,O
times,O
.,O
Two,O
important,O
clinical,O
trials,O
",",O
performed,O
from,O
2005,O
to,O
2011,O
in,O
malaria,B-DS
endemic,O
regions,O
of,O
Mozambique,O
[,O
9,O
],O
and,O
Kenya,O
[,O
51,O
"],",O
have,O
shown,O
that,O
increased,O
4,O
-,O
HNE,O
generation,O
is,O
occurring,O
in,O
clinical,B-DS
malaria,I-DS
.,O
Small,O
cohorts,O
with,O
mild,O
to,O
severe,O
anemia,B-DS
have,O
been,O
studied,O
to,O
see,O
whether,O
a,O
correlation,O
between,O
4,O
-,O
HNE,O
-,O
conjugation,O
and,O
anemia,B-DS
was,O
present,O
.,O
6,O
.,O
1,O
.,O
Elevated,O
4,O
-,O
HNE,O
Conjugates,O
in,O
Clinical,B-DS
Malaria,I-DS
Oxidative,O
stress,O
markers,O
including,O
4,O
-,O
HNE,O
conjugates,O
in,O
RBC,O
membranes,O
and,O
advanced,O
oxidation,O
protein,O
products,O
(,O
AOPP,O
),O
were,O
longitudinally,O
assessed,O
in,O
a,O
large,O
cohort,O
of,O
nonimmune,O
Mozambican,O
newborns,O
.,O
The,O
study,O
was,O
performed,O
in,O
the,O
period,O
from,O
2,O
.,O
5,O
to,O
24,O
months,O
of,O
age,O
",",O
and,O
additionally,O
at,O
the,O
first,O
clinical,B-DS
malaria,I-DS
episode,O
and,O
in,O
convalescence,O
",",O
and,O
included,O
analysis,O
of,O
association,O
with,O
the,O
malaria,B-DS
incidence,O
rate,O
until,O
2,O
years,O
of,O
age,O
[,O
9,O
].,O
A,O
large,O
data,O
base,O
for,O
control,O
values,O
and,O
values,O
in,O
clinical,B-DS
malaria,I-DS
of,O
the,O
same,O
cohort,O
of,O
very,O
young,O
children,O
allows,O
defining,O
the,O
influence,O
of,O
clinical,O
disease,O
on,O
4,O
-,O
HNE,O
generation,O
:,O
(,O
i,O
),O
4,O
-,O
HNE,O
conjugates,O
significantly,O
increased,O
by,O
approximately,O
75,O
%,O
in,O
parasitized,O
and,O
nonparasitized,O
RBCs,O
during,O
clinical,B-DS
malaria,I-DS
;,O
(,O
ii,O
),O
4,O
-,O
HNE,O
conjugates,O
correlated,O
with,O
plasma,O
but,O
not,O
with,O
RBC,O
oxidative,O
stress,O
markers,O
during,O
clinical,B-DS
malaria,I-DS
;,O
(,O
iii,O
),O
in,O
contrast,O
to,O
plasma,O
oxidative,O
stress,O
markers,O
",",O
4,O
-,O
HNE,O
conjugates,O
remained,O
significantly,O
elevated,O
in,O
convalescence,O
after,O
clearing,O
of,O
malaria,B-DS
parasites,O
from,O
peripheral,O
blood,O
in,O
comparison,O
to,O
the,O
healthy,O
state,O
before,O
clinical,B-DS
malaria,I-DS
;,O
and,O
(,O
iv,O
),O
high,O
levels,O
of,O
4,O
-,O
HNE,O
conjugates,O
in,O
individual,O
healthy,O
children,O
were,O
predictive,O
of,O
increased,O
malaria,B-DS
incidence,O
rates,O
until,O
2,O
years,O
of,O
age,O
[,O
9,O
].,O
Above,O
data,O
underscore,O
the,O
clinical,O
significance,O
of,O
4,O
-,O
HNE,O
in,O
malaria,B-DS
immunology,O
and,O
the,O
potential,O
role,O
of,O
4,O
-,O
HNE,O
for,O
impaired,O
immune,O
functions,O
of,O
phagocytes,O
as,O
described,O
in,O
Sections,O
5,O
.,O
1,O
and,O
5,O
.,O
2,O
.,O
6,O
.,O
2,O
.,O
Role,O
of,O
4,O
-,O
HNE,O
in,O
Malaria,B-DS
Anemia,I-DS
As,O
outlined,O
before,O
",",O
4,O
-,O
HNE,O
demonstrated,O
a,O
strong,O
inhibitory,O
effect,O
on,O
ex,O
vivo,O
erythropoiesis,O
of,O
human,B-OG
erythroid,O
stem,O
cells,O
",",O
also,O
contributing,O
to,O
enhanced,O
phagocytosis,O
of,O
RBCs,O
in,O
vitro,O
.,O
Both,O
erythropoiesis,O
inhibition,O
and,O
enhanced,O
phagocytosis,O
of,O
npRBCs,O
were,O
shown,O
to,O
contribute,O
to,O
severe,O
malaria,B-DS
anemia,I-DS
.,O
First,O
indications,O
for,O
the,O
clinical,O
relevance,O
of,O
4,O
-,O
HNE,O
as,O
a,O
molecular,O
pathogenic,O
factor,O
for,O
malaria,B-DS
anemia,I-DS
come,O
from,O
studies,O
in,O
Mozambique,O
and,O
Kenya,O
mentioned,O
before,O
[,O
9,O
",",O
51,O
].,O
Elevated,O
or,O
increasing,O
4,O
-,O
HNE,O
conjugate,O
levels,O
in,O
convalescence,O
were,O
associated,O
with,O
sustained,O
anemia,B-DS
or,O
aggravated,O
anemia,B-DS
during,O
convalescence,O
(,O
Figure,O
7,O
",",O
[,O
5,O
]).,O
Children,O
with,O
severe,O
malaria,B-DS
anemia,I-DS
had,O
significantly,O
higher,O
percentages,O
of,O
4,O
-,O
HNE,O
-,O
conjugate,O
-,O
positive,O
npRBCs,O
compared,O
to,O
children,O
with,O
uncomplicated,O
malaria,B-DS
[,O
51,O
].,O
In,O
conclusion,O
",",O
4,O
-,O
HNE,O
is,O
suggested,O
to,O
play,O
a,O
role,O
in,O
the,O
phagocytic,O
removal,O
of,O
npRBCs,O
",",O
one,O
hallmark,O
of,O
severe,O
malaria,B-DS
anemia,I-DS
.,O
Of,O
note,O
",",O
field,O
studies,O
have,O
shown,O
that,O
another,O
blood,O
oxidative,O
stress,O
marker,O
",",O
the,O
advanced,O
oxidative,O
protein,O
products,O
(,O
AOPP,O
"),",O
has,O
been,O
shown,O
to,O
be,O
predictive,O
of,O
malaria,B-DS
anemia,I-DS
[,O
72,O
].,O
This,O
data,O
",",O
together,O
with,O
the,O
correlation,O
between,O
AOPP,O
and,O
4,O
-,O
HNE,O
conjugates,O
level,O
on,O
RBC,O
established,O
in,O
clinical,B-DS
malaria,I-DS
[,O
9,O
"],",O
will,O
strengthen,O
the,O
role,O
of,O
increased,O
4,O
-,O
HNE,O
levels,O
as,O
part,O
of,O
systemic,O
oxidative,O
stress,O
.,O
7,O
.,O
Conclusions,O
Results,O
of,O
studies,O
summarized,O
in,O
this,O
review,O
indicate,O
that,O
4,O
-,O
HNE,O
is,O
a,O
highly,O
active,O
molecule,O
produced,O
by,O
the,O
malaria,B-DS
parasite,O
and,O
by,O
the,O
host,O
immune,O
system,O
in,O
response,O
to,O
infection,B-DS
.,O
In,O
ex,O
vivo,O
cell,O
cultures,O
4,O
-,O
HNE,O
was,O
found,O
to,O
impair,O
several,O
immune,O
functions,O
of,O
phagocytic,O
cells,O
that,O
certainly,O
contribute,O
to,O
malaria,B-DS
pathology,O
.,O
Similarly,O
",",O
4,O
-,O
HNE,O
was,O
found,O
to,O
impair,O
the,O
development,O
of,O
mature,O
RBCs,O
and,O
to,O
enhance,O
their,O
elimination,O
by,O
the,O
spleen,O
leading,O
to,O
anemia,B-DS
.,O
Clinically,O
",",O
malaria,B-DS
disease,O
is,O
accompanied,O
by,O
elevated,O
4,O
-,O
HNE,O
levels,O
.,O
Clinical,O
studies,O
indicate,O
that,O
4,O
-,O
HNE,O
is,O
involved,O
in,O
the,O
pathogenesis,O
of,O
malaria,B-DS
anemia,I-DS
.,O
However,O
",",O
despite,O
abundant,O
evidence,O
from,O
current,O
research,O
",",O
further,O
clinical,O
studies,O
are,O
necessary,O
to,O
better,O
establish,O
this,O
promising,O
molecule,O
as,O
an,O
accepted,O
pathogenic,O
factor,O
in,O
severe,O
malaria,B-DS
.,O
Omega,O
-,O
6,O
PUFAs,O
are,O
the,O
source,O
of,O
4,O
-,O
hydroxynonenal,O
(,O
4,O
-,O
HNE,O
).,O
The,O
formation,O
of,O
4,O
-,O
HNE,O
from,O
arachidonic,O
acid,O
by,O
lipid,O
peroxidation,O
",",O
chain,O
break,O
",",O
and,O
hydroxylation,O
.,O
In,O
malaria,O
",",O
it,O
was,O
shown,O
that,O
the,O
heme,O
core,O
of,O
hemozoin,O
(,O
HZ,O
",",O
malaria,O
pigment,O
),O
could,O
catalyze,O
the,O
lipoperoxidation,O
of,O
PUFAs,O
.,O
Resulting,O
hydroperoxides,O
are,O
chemically,O
unstable,O
:,O
they,O
(,O
i,O
),O
are,O
reduced,O
to,O
the,O
hydroxy,O
-,O
fatty,O
acid,O
such,O
as,O
hydroxyeicosatetraenoic,O
acid,O
(,O
HETE,O
),O
from,O
arachidonic,O
(,O
note,O
",",O
HETEs,O
are,O
bioactive,O
PPAR,O
-,O
γ,O
(,O
peroxisome,O
proliferator,O
-,O
activated,O
receptor,O
gamma,O
),O
ligands,O
),O
or,O
(,O
ii,O
),O
are,O
decomposed,O
to,O
4,O
-,O
HNE,O
.,O
C1,O
and,O
C3,O
are,O
4,O
-,O
HNE,O
reactive,O
sites,O
.,O
Biologically,O
relevant,O
properties,O
of,O
4,O
-,O
HNE,O
are,O
listed,O
in,O
blue,O
.,O
4,O
-,O
HNE,O
source,O
in,O
malaria,O
.,O
4,O
-,O
HNE,O
transfer,O
from,O
parasitized,O
to,O
nonparasitized,O
RBCs,O
in,O
rosettes,O
in,O
vitro,O
.,O
Micrographs,O
of,O
4,O
-,O
HNE,O
-,O
positive,O
parasitized,O
RBCs,O
and,O
nonparasitized,O
RBCs,O
.,O
This,O
result,O
was,O
originally,O
published,O
in,O
British,O
Journal,O
of,O
Haematology,O
",",O
Blackwell,O
Publishing,O
Ltd,O
.,O
(,O
Uyoga,O
et,O
al,O
.,O
2012,O
",",O
©,O
John,O
Wiley,O
&,O
Sons,O
Ltd,O
.).,O
4,O
-,O
HNE,O
conjugates,O
on,O
the,O
cell,O
surface,O
of,O
erythroid,O
cells,O
cocultivated,O
with,O
residual,O
body,O
(,O
RB,O
or,O
natural,O
HZ,O
),O
visible,O
as,O
green,O
fluorescence,O
.,O
This,O
research,O
was,O
originally,O
published,O
in,O
Blood,O
(,O
Skorokhod,O
et,O
al,O
.,O
2010,O
",",O
supplemental,O
materials,O
©,O
the,O
American,O
Society,O
of,O
Hematology,O
).,O
Proteins,O
and,O
processes,O
of,O
potential,O
relevance,O
for,O
malaria,O
pathology,O
structurally,O
or,O
functionally,O
modified,O
by,O
4,O
-,O
HNE,O
.,O
Association,O
of,O
4,O
-,O
HNE,O
conjugate,O
levels,O
on,O
RBCs,O
with,O
sustained,O
moderate,O
anemia,O
during,O
convalescence,O
.,O
Children,O
presenting,O
with,O
Hb,O
<,O
100,O
g,O
/,O
L,O
at,O
their,O
first,O
acute,O
malaria,O
episode,O
were,O
grouped,O
according,O
to,O
their,O
capacity,O
to,O
recover,O
from,O
anemia,O
by,O
increasing,O
Hb,O
levels,O
during,O
convalescence,O
or,O
to,O
worsen,O
their,O
state,O
by,O
decreasing,O
or,O
sustained,O
low,O
Hb,O
levels,O
during,O
convalescence,O
(,O
1,O
month,O
after,O
acute,O
malaria,O
episode,O
).,O
4,O
-,O
HNE,O
binding,O
to,O
the,O
RBCs,O
of,O
children,O
was,O
assessed,O
as,O
MFI,O
at,O
acute,O
and,O
convalescence,O
states,O
.,O
Mean,O
MFI,O
-,O
values,O
±,O
SE,O
during,O
convalescence,O
are,O
plotted,O
for,O
the,O
groups,O
with,O
increasing,O
Hb,O
(+,O
35,O
",",O
3,O
±,O
6,O
",",O
5,O
%;,O
N,O
=,O
34,O
),O
and,O
decreasing,O
Hb,O
(−,O
15,O
",",O
4,O
±,O
6,O
",",O
0,O
%;,O
N,O
=,O
8,O
),O
(,O
a,O
).,O
The,O
change,O
in,O
4,O
-,O
HNE,O
conjugate,O
levels,O
in,O
the,O
RBC,O
membrane,O
during,O
recovery,O
from,O
malaria,O
disease,O
is,O
shown,O
(,O
b,O
).,O
The,O
mean,O
±,O
SE,O
of,O
the,O
ratio,O
of,O
4,O
-,O
HNE,O
conjugates,O
measured,O
during,O
convalescence,O
and,O
at,O
acute,O
state,O
is,O
plotted,O
for,O
the,O
increasing,O
(+,O
38,O
",",O
5,O
±,O
9,O
",",O
2,O
%;,O
N,O
=,O
22,O
),O
and,O
decreasing,O
(−,O
26,O
",",O
8,O
±,O
6,O
",",O
2,O
%;,O
N,O
=,O
4,O
),O
Hb,O
groups,O
",",O
respectively,O
(,O
b,O
).,O
The,O
significance,O
of,O
differences,O
between,O
groups,O
is,O
indicated,O
by,O
∗,O
when,O
P,O
<,O
0,O
.,O
05,O
.,O
MFI,O
",",O
mean,O
fluorescence,O
intensity,O
;,O
Hb,O
",",O
hemoglobin,O
.,O
This,O
result,O
was,O
originally,O
published,O
in,O
British,O
Journal,O
of,O
Haematology,O
",",O
Blackwell,O
Publishing,O
Ltd,O
.,O
(,O
Aguilar,O
et,O
al,O
.,O
2014,O
",",O
©,O
John,O
Wiley,O
&,O
Sons,O
Ltd,O
.).,O
Range,O
contraction,O
and,O
increasing,O
isolation,O
of,O
a,O
polar,B-OG
bear,I-OG
subpopulation,O
in,O
an,O
era,O
of,O
sea,O
‐,O
ice,O
loss,O
Abstract,O
Climate,O
change,O
is,O
expected,O
to,O
result,O
in,O
range,O
shifts,O
and,O
habitat,O
fragmentation,O
for,O
many,O
species,O
.,O
In,O
the,O
Arctic,O
",",O
loss,O
of,O
sea,O
ice,O
will,O
reduce,O
barriers,O
to,O
dispersal,O
or,O
eliminate,O
movement,O
corridors,O
",",O
resulting,O
in,O
increased,O
connectivity,O
or,O
geographic,O
isolation,O
with,O
sweeping,O
implications,O
for,O
conservation,O
.,O
We,O
used,O
satellite,O
telemetry,O
",",O
data,O
from,O
individually,O
marked,O
animals,B-OG
(,O
research,O
and,O
harvest,O
"),",O
and,O
microsatellite,O
genetic,O
data,O
to,O
examine,O
changes,O
in,O
geographic,O
range,O
",",O
emigration,O
",",O
and,O
interpopulation,O
connectivity,O
of,O
the,O
Baffin,O
Bay,O
(,O
BB,O
),O
polar,B-OG
bear,I-OG
(,O
Ursus,B-OG
maritimus,I-OG
),O
subpopulation,O
over,O
a,O
25,O
‐,O
year,O
period,O
of,O
sea,O
‐,O
ice,O
loss,O
.,O
Satellite,O
telemetry,O
collected,O
from,O
n,O
=,O
43,O
(,O
1991,O
–,O
1995,O
),O
and,O
38,O
(,O
2009,O
–,O
2015,O
),O
adult,O
females,O
revealed,O
a,O
significant,O
contraction,O
in,O
subpopulation,O
range,O
size,O
(,O
95,O
%,O
bivariate,O
normal,O
kernel,O
range,O
),O
in,O
most,O
months,O
and,O
seasons,O
",",O
with,O
the,O
most,O
marked,O
reduction,O
being,O
a,O
70,O
%,O
decline,O
in,O
summer,O
from,O
716,O
",",O
000,O
km2,O
(,O
SE,O
58,O
",",O
000,O
),O
to,O
211,O
",",O
000,O
km2,O
(,O
SE,O
23,O
",",O
000,O
),O
(,O
p,O
<,O
.,O
001,O
).,O
Between,O
the,O
1990s,O
and,O
2000s,O
",",O
there,O
was,O
a,O
significant,O
shift,O
northward,O
during,O
the,O
on,O
‐,O
ice,O
seasons,O
(,O
2,O
.,O
6,O
°,O
shift,O
in,O
winter,O
median,O
latitude,O
",",O
1,O
.,O
1,O
°,O
shift,O
in,O
spring,O
median,O
latitude,O
),O
and,O
a,O
significant,O
range,O
contraction,O
in,O
the,O
ice,O
‐,O
free,O
summers,O
.,O
Bears,B-OG
in,O
the,O
2000s,O
were,O
less,O
likely,O
to,O
leave,O
BB,O
",",O
with,O
significant,O
reductions,O
in,O
the,O
numbers,O
of,O
bears,B-OG
moving,O
into,O
Davis,O
Strait,O
(,O
DS,O
),O
in,O
winter,O
and,O
Lancaster,O
Sound,O
(,O
LS,O
),O
in,O
summer,O
.,O
Harvest,O
recoveries,O
suggested,O
both,O
short,O
and,O
long,O
‐,O
term,O
fidelity,O
to,O
BB,O
remained,O
high,O
over,O
both,O
periods,O
(,O
83,O
–,O
99,O
%,O
of,O
marked,O
bears,B-OG
remained,O
in,O
BB,O
).,O
Genetic,O
analyses,O
using,O
eight,O
polymorphic,O
microsatellites,O
confirmed,O
a,O
previously,O
documented,O
differentiation,O
between,O
BB,O
",",O
DS,O
",",O
and,O
LS,O
;,O
yet,O
weakly,O
differentiated,O
BB,O
from,O
Kane,O
Basin,O
(,O
KB,O
),O
for,O
the,O
first,O
time,O
.,O
Our,O
results,O
provide,O
the,O
first,O
multiple,O
lines,O
of,O
evidence,O
for,O
an,O
increasingly,O
geographically,O
and,O
functionally,O
isolated,O
subpopulation,O
of,O
polar,B-OG
bears,I-OG
in,O
the,O
context,O
of,O
long,O
‐,O
term,O
sea,O
‐,O
ice,O
loss,O
.,O
This,O
may,O
be,O
indicative,O
of,O
future,O
patterns,O
for,O
other,O
polar,B-OG
bear,I-OG
subpopulations,O
under,O
climate,O
change,O
.,O
Range,O
contraction,O
and,O
increasing,O
isolation,O
of,O
a,O
polar,B-OG
bear,I-OG
subpopulation,O
in,O
an,O
era,O
of,O
sea,O
‐,O
ice,O
loss,O
INTRODUCTION,O
Conservation,O
of,O
wildlife,O
populations,O
across,O
dynamic,O
landscapes,O
requires,O
information,O
on,O
population,O
structure,O
and,O
boundaries,O
for,O
establishing,O
a,O
valid,O
ecological,O
and,O
demographic,O
basis,O
for,O
determining,O
population,O
abundance,O
",",O
rates,O
of,O
population,O
change,O
",",O
and,O
the,O
impacts,O
of,O
human,B-OG
activities,O
(,O
Thomas,O
",",O
2010,O
;,O
Weinbaum,O
",",O
Brashares,O
",",O
Golden,O
",",O
&,O
Getz,O
",",O
2013,O
).,O
In,O
an,O
era,O
of,O
climate,O
change,O
",",O
barriers,O
to,O
dispersal,O
are,O
quickly,O
being,O
altered,O
",",O
which,O
can,O
facilitate,O
functional,O
or,O
genetic,O
transfer,O
between,O
animals,B-OG
where,O
it,O
was,O
once,O
absent,O
",",O
or,O
lead,O
to,O
increasing,O
isolation,O
because,O
corridors,O
of,O
exchange,O
are,O
no,O
longer,O
available,O
(,O
Ching,O
Chen,O
",",O
Hill,O
",",O
Ohlemuller,O
",",O
Roy,O
",",O
&,O
Thomas,O
",",O
2011,O
;,O
Rubidge,O
et,O
al,O
".,",O
2012,O
).,O
Concurrently,O
",",O
many,O
species,O
are,O
shifting,O
to,O
higher,O
latitudes,O
and,O
higher,O
elevations,O
in,O
response,O
to,O
a,O
warming,O
earth,O
(,O
Loarie,O
et,O
al,O
".,",O
2009,O
).,O
Shifts,O
or,O
reductions,O
in,O
ranges,O
will,O
likely,O
result,O
in,O
reduced,O
genetic,O
diversity,O
and,O
in,O
extreme,O
cases,O
",",O
genetic,O
impoverishment,O
that,O
may,O
reduce,O
population,O
viability,O
(,O
Yannic,O
et,O
al,O
".,",O
2013,O
).,O
This,O
can,O
have,O
rapid,O
and,O
sweeping,O
impacts,O
on,O
conservation,O
of,O
large,O
mobile,O
species,O
",",O
especially,O
those,O
subject,O
to,O
subsistence,O
harvests,O
(,O
Laidre,O
et,O
al,O
".,",O
2015,O
).,O
The,O
Arctic,O
is,O
losing,O
sea,O
ice,O
at,O
a,O
rapid,O
rate,O
(,O
Overland,O
&,O
Wang,O
",",O
2013,O
).,O
This,O
large,O
‐,O
scale,O
habitat,O
change,O
is,O
predicted,O
to,O
have,O
multiple,O
and,O
significant,O
consequences,O
for,O
ice,O
‐,O
dependent,O
species,O
(,O
Laidre,O
et,O
al,O
".,",O
2015,O
).,O
A,O
key,O
question,O
is,O
whether,O
loss,O
of,O
sea,O
ice,O
will,O
reduce,O
or,O
enhance,O
dispersal,O
",",O
given,O
sea,O
ice,O
serves,O
as,O
both,O
a,O
platform,O
for,O
movement,O
and,O
a,O
physical,O
barrier,O
.,O
In,O
the,O
case,O
of,O
cetaceans,B-OG
",",O
loss,O
of,O
sea,O
ice,O
has,O
opened,O
new,O
habitats,O
and,O
resulted,O
in,O
positive,O
population,O
responses,O
(,O
George,O
",",O
Druckenmiller,O
",",O
Laidre,O
",",O
Suydam,O
",",O
&,O
Person,O
",",O
2015,O
);,O
however,O
",",O
this,O
has,O
generally,O
not,O
been,O
the,O
case,O
for,O
other,O
species,O
that,O
rely,O
on,O
sea,O
ice,O
for,O
key,O
aspects,O
of,O
their,O
life,O
history,O
",",O
such,O
as,O
polar,B-OG
bears,I-OG
(,O
Ursus,B-OG
maritimus,I-OG
;,O
Amstrup,O
&,O
Gardner,O
",",O
1994,O
;,O
PBSG,O
2010,O
;,O
Regehr,O
et,O
al,O
".,",O
2016,O
).,O
Contrasting,O
patterns,O
may,O
emerge,O
depending,O
on,O
a,O
species,O
’,O
dispersal,O
ability,O
and,O
how,O
changes,O
in,O
sea,O
‐,O
ice,O
extent,O
",",O
formation,O
",",O
or,O
break,O
‐,O
up,O
structure,O
habitat,O
(,O
e,O
.,O
g,O
".,",O
Travis,O
et,O
al,O
".,",O
2013,O
).,O
Polar,B-OG
bears,I-OG
are,O
found,O
throughout,O
the,O
circumpolar,O
Arctic,O
in,O
19,O
subpopulations,O
that,O
differ,O
in,O
productivity,O
",",O
size,O
",",O
and,O
degree,O
of,O
connectedness,O
with,O
adjacent,O
subpopulations,O
(,O
PBSG,O
2010,O
).,O
In,O
areas,O
with,O
multiyear,O
sea,O
ice,O
",",O
some,O
polar,B-OG
bears,I-OG
may,O
remain,O
on,O
sea,O
ice,O
year,O
‐,O
round,O
",",O
however,O
",",O
in,O
areas,O
where,O
the,O
annual,O
sea,O
ice,O
melts,O
completely,O
in,O
summer,O
most,O
bears,B-OG
spend,O
up,O
to,O
several,O
months,O
on,O
land,O
",",O
largely,O
fasting,O
until,O
freeze,O
‐,O
up,O
(,O
e,O
.,O
g,O
".,",O
Stirling,O
",",O
Lunn,O
",",O
&,O
Iacozza,O
",",O
1999,O
;,O
Stirling,O
&,O
Parkinson,O
",",O
2006,O
).,O
The,O
Baffin,O
Bay,O
(,O
BB,O
),O
subpopulation,O
of,O
polar,B-OG
bears,I-OG
is,O
located,O
in,O
the,O
seasonal,O
ice,O
ecoregion,O
where,O
sea,O
ice,O
forms,O
and,O
disappears,O
each,O
year,O
(,O
Amstrup,O
",",O
Marcot,O
",",O
&,O
Douglas,O
",",O
2008,O
;,O
Taylor,O
et,O
al,O
".,",O
2001,O
;,O
Figure,O
1,O
).,O
In,O
the,O
1990s,O
",",O
analyses,O
of,O
movements,O
from,O
satellite,O
‐,O
collared,O
bears,B-OG
(,O
Taylor,O
et,O
al,O
".,",O
2001,O
"),",O
genetic,O
analyses,O
(,O
Paetkau,O
et,O
al,O
".,",O
1999,O
"),",O
and,O
recaptures,O
and,O
harvest,O
recoveries,O
of,O
individually,O
marked,O
bears,B-OG
(,O
Taylor,O
&,O
Lee,O
",",O
1995,O
;,O
Taylor,O
et,O
al,O
".,",O
2001,O
),O
indicated,O
limited,O
interchange,O
among,O
BB,O
and,O
adjacent,O
subpopulations,O
including,O
Davis,O
Strait,O
(,O
DS,O
),O
and,O
Lancaster,O
Sound,O
(,O
LS,O
;,O
Taylor,O
et,O
al,O
".,",O
2001,O
).,O
However,O
",",O
BB,O
bears,B-OG
could,O
not,O
be,O
genetically,O
differentiated,O
from,O
the,O
adjacent,O
Kane,O
Basin,O
(,O
KB,O
),O
subpopulation,O
to,O
the,O
north,O
(,O
Paetkau,O
et,O
al,O
".,",O
1999,O
).,O
As,O
those,O
studies,O
",",O
the,O
BB,O
subpopulation,O
has,O
been,O
considered,O
a,O
distinct,O
demographic,O
unit,O
with,O
its,O
dynamics,O
largely,O
driven,O
by,O
intrinsic,O
rates,O
of,O
reproduction,O
and,O
mortality,O
rather,O
than,O
exchange,O
between,O
neighboring,O
subpopulations,O
(,O
SWG,O
2016,O
).,O
The,O
BB,O
subpopulation,O
currently,O
supports,O
a,O
subsistence,O
harvest,O
of,O
approximately,O
134,O
bears,B-OG
per,O
year,O
",",O
which,O
provides,O
a,O
nutritional,O
",",O
cultural,O
",",O
and,O
economic,O
resource,O
to,O
Inuit,O
communities,O
(,O
PBSG,O
2010,O
).,O
Declining,O
sea,O
ice,O
in,O
Baffin,O
Bay,O
has,O
resulted,O
in,O
a,O
lengthening,O
of,O
the,O
ice,O
‐,O
free,O
season,O
by,O
>,O
12,O
days,O
per,O
decade,O
during,O
the,O
period,O
1979,O
–,O
2014,O
(,O
Stern,O
&,O
Laidre,O
",",O
2016,O
).,O
There,O
is,O
evidence,O
for,O
positive,O
correlation,O
between,O
sea,O
‐,O
ice,O
availability,O
and,O
BB,O
subpopulation,O
reproductive,O
rates,O
(,O
SWG,O
",",O
2016,O
).,O
Furthermore,O
",",O
recent,O
studies,O
suggest,O
low,O
apparent,O
survival,O
for,O
male,O
polar,B-OG
bears,I-OG
in,O
BB,O
",",O
which,O
may,O
reflect,O
either,O
increased,O
natural,O
mortality,O
or,O
emigration,O
(,O
SWG,O
",",O
2016,O
).,O
Distribution,O
of,O
capture,O
locations,O
of,O
adult,O
female,O
polar,B-OG
bears,I-OG
fitted,O
with,O
satellite,O
collars,O
in,O
Baffin,O
Bay,O
during,O
the,O
1990s,O
and,O
2000s,O
We,O
conducted,O
an,O
assessment,O
of,O
the,O
extent,O
to,O
which,O
sea,O
ice,O
trends,O
have,O
affected,O
the,O
distribution,O
and,O
boundaries,O
of,O
the,O
BB,O
subpopulation,O
and,O
discuss,O
results,O
in,O
the,O
context,O
of,O
other,O
polar,B-OG
bear,I-OG
subpopulations,O
facing,O
sea,O
‐,O
ice,O
loss,O
",",O
as,O
well,O
as,O
near,O
‐,O
term,O
management,O
and,O
long,O
‐,O
term,O
conservation,O
planning,O
.,O
We,O
used,O
home,O
range,O
estimators,O
from,O
satellite,O
telemetry,O
to,O
delineate,O
subpopulation,O
range,O
boundaries,O
",",O
movement,O
data,O
from,O
collared,O
adult,O
females,O
and,O
from,O
the,O
recapture,O
or,O
harvest,O
of,O
marked,O
individuals,O
to,O
assess,O
latitudinal,O
shifts,O
or,O
changes,O
in,O
immigration,O
/,O
emigration,O
",",O
and,O
genetic,O
analyses,O
to,O
assess,O
relationships,O
between,O
BB,O
and,O
adjacent,O
subpopulations,O
.,O
Our,O
objective,O
was,O
to,O
explore,O
multiple,O
lines,O
of,O
evidence,O
with,O
respect,O
to,O
the,O
delineation,O
of,O
the,O
BB,O
subpopulation,O
in,O
an,O
era,O
of,O
rapid,O
sea,O
‐,O
ice,O
loss,O
.,O
We,O
discuss,O
the,O
implications,O
of,O
the,O
results,O
for,O
effective,O
conservation,O
and,O
management,O
strategies,O
and,O
identify,O
where,O
additional,O
research,O
and,O
monitoring,O
will,O
be,O
needed,O
in,O
the,O
future,O
.,O
MATERIALS,O
AND,O
METHODS,O
Study,O
area,O
The,O
boundaries,O
of,O
the,O
BB,O
subpopulation,O
encompass,O
~,O
1,O
million,O
km2,O
",",O
covering,O
approximately,O
656,O
",",O
000,O
km2,O
of,O
ocean,O
as,O
well,O
as,O
portions,O
of,O
Baffin,O
Island,O
",",O
all,O
of,O
Bylot,O
Island,O
in,O
Nunavut,O
/,O
Canada,O
",",O
and,O
parts,O
of,O
West,O
and,O
Northwest,O
Greenland,O
(,O
66,O
°,O
N,O
to,O
77,O
°,O
N,O
;,O
Taylor,O
et,O
al,O
".,",O
2005,O
),O
(,O
Figure,O
1,O
).,O
During,O
late,O
spring,O
and,O
summer,O
break,O
‐,O
up,O
",",O
sea,O
ice,O
recedes,O
from,O
Greenland,O
westward,O
across,O
Baffin,O
Bay,O
;,O
the,O
last,O
remnants,O
of,O
ice,O
typically,O
occur,O
off,O
the,O
coast,O
of,O
Baffin,O
Island,O
.,O
Most,O
polar,B-OG
bears,I-OG
remain,O
on,O
the,O
sea,O
ice,O
as,O
it,O
recedes,O
and,O
then,O
come,O
ashore,O
to,O
spend,O
the,O
ice,O
‐,O
free,O
period,O
on,O
Baffin,O
and,O
Bylot,O
Islands,O
(,O
Taylor,O
et,O
al,O
".,",O
2005,O
).,O
An,O
unknown,O
but,O
probably,O
small,O
number,O
of,O
bears,B-OG
remain,O
on,O
land,O
in,O
Melville,O
Bay,O
",",O
NW,O
Greenland,O
throughout,O
the,O
ice,O
‐,O
free,O
period,O
(,O
Born,O
",",O
1995,O
;,O
Born,O
",",O
Heilmann,O
",",O
Holm,O
",",O
&,O
Laidre,O
",",O
2011,O
;,O
SWG,O
",",O
2016,O
).,O
Radio,O
telemetry,O
Handling,O
and,O
collaring,O
Adult,O
female,O
polar,B-OG
bears,I-OG
(,O
AF,O
),O
were,O
captured,O
in,O
NW,O
Greenland,O
on,O
the,O
fast,O
and,O
pack,O
ice,O
between,O
mid,O
‐,O
March,O
and,O
mid,O
‐,O
April,O
2009,O
–,O
2013,O
in,O
Baffin,O
Bay,O
.,O
Searches,O
for,O
bears,B-OG
occurred,O
between,O
70,O
°,O
22,O
′,O
N,O
and,O
76,O
°,O
20,O
′,O
N,O
",",O
to,O
a,O
maximum,O
distance,O
of,O
ca,O
.,O
150,O
km,O
from,O
the,O
coast,O
and,O
included,O
areas,O
at,O
glacier,O
fronts,O
.,O
Bears,B-OG
were,O
located,O
and,O
captured,O
from,O
a,O
helicopter,O
using,O
standard,O
chemical,O
immobilization,O
techniques,O
(,O
Stirling,O
",",O
Spencer,O
",",O
&,O
Andriashek,O
",",O
1989,O
).,O
Field,O
estimates,O
of,O
age,O
and,O
reproductive,O
status,O
were,O
recorded,O
",",O
with,O
age,O
later,O
estimated,O
by,O
counting,O
cementum,O
growth,O
layers,O
on,O
a,O
premolar,O
tooth,O
extracted,O
during,O
capture,O
(,O
Calvert,O
&,O
Ramsay,O
",",O
1998,O
).,O
Thirty,O
‐,O
eight,O
AF,O
were,O
fitted,O
with,O
Argos,O
‐,O
linked,O
satellite,O
transmitters,O
(,O
i,O
.,O
e,O
".,",O
Platform,O
Transmitter,O
Terminal,O
",",O
or,O
PTT,O
),O
(,O
Model,O
TAW,O
‐,O
4610H,O
",",O
Telonics,O
",",O
Mesa,O
",",O
Arizona,O
",",O
USA,O
),O
(,O
Table,O
1,O
",",O
Figure,O
1,O
"),",O
which,O
provided,O
information,O
on,O
geographic,O
location,O
",",O
internal,O
transmitter,O
temperature,O
",",O
and,O
activity,O
.,O
These,O
data,O
were,O
combined,O
with,O
a,O
historical,O
data,O
set,O
of,O
43,O
AF,O
that,O
were,O
collared,O
within,O
the,O
BB,O
subpopulation,O
management,O
boundaries,O
(,O
PBSG,O
",",O
2010,O
),O
between,O
1991,O
and,O
1995,O
(,O
Ferguson,O
",",O
Taylor,O
",",O
&,O
Messier,O
",",O
1997,O
;,O
Taylor,O
et,O
al,O
".,",O
2001,O
).,O
The,O
majority,O
of,O
the,O
1990s,O
tags,O
were,O
deployed,O
during,O
the,O
ice,O
‐,O
free,O
season,O
in,O
fall,O
on,O
Baffin,O
Island,O
(,O
with,O
the,O
exception,O
of,O
n,O
=,O
9,O
deployed,O
in,O
spring,O
in,O
NW,O
Greenland,O
).,O
Number,O
of,O
adult,O
female,O
(,O
AF,O
),O
polar,B-OG
bears,I-OG
collared,O
in,O
Baffin,O
Bay,O
in,O
the,O
1990s,O
and,O
2000s,O
in,O
relation,O
to,O
accompanying,O
bears,B-OG
(,O
AM,O
",",O
adult,O
male,O
in,O
breeding,O
pair,O
;,O
COY,O
",",O
dependent,O
cub,O
‐,O
of,O
‐,O
the,O
‐,O
year,O
;,O
YRLG,O
",",O
dependent,O
yearling,O
cub,O
;,O
2YR,O
",",O
dependent,O
2,O
‐,O
year,O
‐,O
old,O
cub,O
),O
AF,O
alone,O
AF,O
+,O
AM,O
AF,O
+,O
COY,O
AF,O
+,O
YRLG,O
AF,O
+,O
2YR,O
Sum,O
1990s,O
9,O
0,O
19,O
13,O
2,O
43,O
2000s,O
10,O
2,O
6,O
12,O
8,O
38,O
Data,O
filtering,O
and,O
sub,O
‐,O
sampling,O
Locations,O
and,O
transmitter,O
status,O
were,O
collected,O
via,O
the,O
Argos,O
Location,O
Service,O
Plus,O
system,O
(,O
Toulouse,O
",",O
France,O
).,O
The,O
quality,O
of,O
each,O
location,O
was,O
assigned,O
by,O
ARGOS,O
with,O
location,O
qualities,O
of,O
0,O
–,O
3,O
estimated,O
to,O
have,O
errors,O
of,O
1,O
.,O
5,O
km,O
or,O
less,O
and,O
those,O
categorized,O
as,O
“,O
A,O
",”",O
“,O
B,O
",”",O
or,O
“,O
Z,O
”,O
had,O
no,O
predicted,O
accuracy,O
.,O
Unrealistic,O
and,O
poor,O
quality,O
locations,O
were,O
removed,O
using,O
a,O
speed,O
and,O
angle,O
filter,O
in,O
R,O
version,O
2,O
.,O
13,O
.,O
2,O
(,O
R,O
Development,O
Core,O
Team,O
2012,O
),O
using,O
the,O
package,O
“,O
argosfilter,O
”,O
(,O
Freitas,O
",",O
Kovacs,O
",",O
Lydersen,O
",",O
&,O
Ims,O
",",O
2008,O
).,O
Positions,O
exceeding,O
a,O
maximum,O
between,O
‐,O
location,O
travel,O
velocity,O
(,O
10,O
km,O
/,O
hr,O
based,O
on,O
previous,O
movement,O
studies,O
of,O
polar,B-OG
bears,I-OG
",",O
Laidre,O
et,O
al,O
".,",O
2013,O
),O
and,O
angle,O
(,O
measured,O
from,O
the,O
track,O
between,O
three,O
successive,O
locations,O
;,O
set,O
to,O
the,O
default,O
),O
were,O
removed,O
by,O
the,O
filtering,O
algorithm,O
.,O
The,O
resulting,O
locations,O
for,O
each,O
bear,B-OG
were,O
reduced,O
to,O
a,O
single,O
position,O
per,O
day,O
to,O
reduce,O
autocorrelation,O
bias,O
",",O
standardize,O
temporal,O
sampling,O
",",O
and,O
address,O
the,O
effects,O
of,O
variable,O
duty,O
cycling,O
among,O
PTTs,O
.,O
The,O
first,O
",",O
best,O
quality,O
location,O
within,O
the,O
period,O
of,O
peak,O
satellite,O
passage,O
was,O
selected,O
to,O
obtain,O
a,O
daily,O
position,O
for,O
each,O
PTT,O
.,O
Daily,O
positions,O
",",O
after,O
filtering,O
and,O
optimal,O
daily,O
position,O
selection,O
",",O
only,O
consisted,O
of,O
ARGOS,O
qualities,O
1,O
–,O
3,O
.,O
Distances,O
between,O
successive,O
daily,O
positions,O
were,O
calculated,O
as,O
the,O
great,O
circle,O
route,O
and,O
used,O
to,O
compute,O
minimum,O
daily,O
displacements,O
.,O
As,O
a,O
result,O
of,O
variable,O
experimental,O
objectives,O
in,O
both,O
decades,O
",",O
different,O
duty,O
cycles,O
were,O
used,O
for,O
tags,O
in,O
an,O
effort,O
to,O
extend,O
battery,O
life,O
or,O
gather,O
information,O
from,O
specific,O
time,O
periods,O
.,O
Collars,O
in,O
the,O
2000s,O
were,O
programmed,O
to,O
transmit,O
during,O
one,O
6,O
‐,O
hr,O
period,O
each,O
day,O
on,O
4,O
‐,O
day,O
intervals,O
.,O
The,O
1990s,O
collars,O
were,O
programmed,O
to,O
transmit,O
on,O
varying,O
and,O
intermittent,O
intervals,O
",",O
ranging,O
from,O
1,O
to,O
6,O
days,O
.,O
We,O
subsampled,O
the,O
1990s,O
data,O
and,O
created,O
a,O
strict,O
4,O
"‐,",O
5,O
"‐,",O
or,O
6,O
‐,O
day,O
interval,O
time,O
series,O
for,O
each,O
individual,O
to,O
best,O
match,O
the,O
2000s,O
data,O
.,O
This,O
ensured,O
that,O
serial,O
autocorrelation,O
was,O
consistent,O
among,O
decades,O
.,O
Telemetry,O
data,O
were,O
divided,O
into,O
seasons,O
:,O
spring,O
(,O
March,O
–,O
July,O
",",O
which,O
included,O
the,O
peak,O
of,O
sea,O
‐,O
ice,O
coverage,O
and,O
initiation,O
of,O
sea,O
‐,O
ice,O
break,O
‐,O
up,O
"),",O
summer,O
(,O
August,O
–,O
October,O
",",O
which,O
included,O
the,O
end,O
of,O
break,O
‐,O
up,O
and,O
the,O
on,O
‐,O
land,O
period,O
"),",O
and,O
winter,O
(,O
November,O
–,O
February,O
",",O
which,O
included,O
the,O
freeze,O
‐,O
up,O
period,O
and,O
time,O
when,O
bears,B-OG
returned,O
to,O
the,O
sea,O
ice,O
).,O
All,O
periods,O
when,O
collared,O
females,O
were,O
denning,O
(,O
use,O
of,O
maternity,O
and,O
shelter,O
dens,O
),O
were,O
identified,O
(,O
Escajeda,O
et,O
al,O
".,",O
2018,O
),O
and,O
removed,O
from,O
analyses,O
.,O
Bears,B-OG
with,O
<,O
3,O
locations,O
were,O
removed,O
from,O
analyses,O
when,O
transmitter,O
failure,O
occurred,O
immediately,O
after,O
deployment,O
.,O
Comparison,O
of,O
1990s,O
and,O
2000s,O
BB,O
satellite,O
telemetry,O
data,O
Polar,B-OG
bears,I-OG
collared,O
in,O
this,O
study,O
ranged,O
over,O
the,O
entire,O
Baffin,O
Bay,O
region,O
(,O
SWG,O
",",O
2016,O
).,O
All,O
captures,O
occurred,O
within,O
the,O
bounds,O
of,O
the,O
BB,O
subpopulation,O
management,O
unit,O
(,O
PBSG,O
",",O
2010,O
),O
and,O
bears,B-OG
moved,O
back,O
and,O
forth,O
freely,O
between,O
Canada,O
and,O
Greenland,O
during,O
both,O
periods,O
(,O
Figure,O
1,O
).,O
However,O
",",O
seasonal,O
and,O
geographic,O
differences,O
in,O
capture,O
locations,O
occurred,O
in,O
our,O
study,O
between,O
the,O
two,O
periods,O
of,O
fieldwork,O
.,O
In,O
the,O
1990s,O
",",O
it,O
was,O
possible,O
to,O
deploy,O
collars,O
on,O
AFs,O
on,O
both,O
the,O
Canadian,O
and,O
Greenlandic,O
sides,O
of,O
Baffin,O
Bay,O
(,O
Figure,O
1,O
).,O
However,O
",",O
in,O
the,O
2000s,O
",",O
it,O
was,O
only,O
possible,O
to,O
deploy,O
collars,O
on,O
the,O
Greenlandic,O
side,O
of,O
Baffin,O
Bay,O
due,O
to,O
community,O
reservations,O
in,O
Nunavut,O
about,O
polar,B-OG
bear,I-OG
immobilization,O
and,O
handling,O
(,O
SWG,O
",",O
2016,O
).,O
This,O
reservation,O
was,O
not,O
shared,O
in,O
Greenland,O
by,O
hunters,O
and,O
management,O
authorities,O
.,O
Prior,O
to,O
conducting,O
interdecadal,O
analyses,O
of,O
polar,B-OG
bear,I-OG
movement,O
data,O
",",O
we,O
evaluated,O
the,O
1990s,O
and,O
2000s,O
data,O
to,O
identify,O
potential,O
effects,O
of,O
differences,O
in,O
collar,O
deployment,O
location,O
.,O
First,O
",",O
we,O
compared,O
the,O
fall,O
telemetry,O
locations,O
of,O
bears,B-OG
collared,O
on,O
the,O
Greenlandic,O
side,O
in,O
spring,O
in,O
the,O
2000s,O
",",O
with,O
the,O
dates,O
of,O
the,O
fall,O
capture,O
locations,O
of,O
bears,B-OG
collared,O
on,O
the,O
Canadian,O
side,O
(,O
on,O
Baffin,O
Island,O
),O
in,O
the,O
1990s,O
.,O
We,O
then,O
quantified,O
what,O
overall,O
range,O
of,O
latitudes,O
on,O
land,O
on,O
Baffin,O
Island,O
was,O
used,O
by,O
polar,B-OG
bears,I-OG
in,O
both,O
decades,O
.,O
Finally,O
",",O
we,O
subset,O
the,O
1990s,O
dataset,O
to,O
conduct,O
interdecadal,O
analyses,O
on,O
range,O
size,O
using,O
a,O
subsample,O
of,O
1990s,O
bears,B-OG
(,O
n,O
=,O
9,O
),O
collared,O
in,O
spring,O
on,O
the,O
sea,O
ice,O
in,O
Greenland,O
compared,O
with,O
range,O
size,O
of,O
bears,B-OG
collared,O
in,O
the,O
same,O
area,O
in,O
the,O
2000s,O
(,O
see,O
Figure,O
1,O
).,O
This,O
essentially,O
replicated,O
some,O
analyses,O
we,O
present,O
in,O
this,O
manuscript,O
(,O
but,O
with,O
a,O
substantially,O
reduced,O
sample,O
size,O
in,O
the,O
1990s,O
).,O
Overall,O
",",O
excluding,O
permanent,O
residents,O
of,O
Melville,O
Bay,O
",",O
92,O
%,O
of,O
the,O
AF,O
bears,B-OG
collared,O
in,O
spring,O
in,O
West,O
Greenland,O
in,O
the,O
2000s,O
moved,O
to,O
Baffin,O
Island,O
by,O
fall,O
and,O
were,O
located,O
inside,O
the,O
same,O
fall,O
collaring,O
area,O
used,O
in,O
the,O
1990s,O
(,O
defined,O
as,O
a,O
polygon,O
around,O
1990s,O
collaring,O
sites,O
).,O
Further,O
",",O
AF,O
bears,B-OG
collared,O
in,O
West,O
Greenland,O
in,O
the,O
2000s,O
were,O
distributed,O
over,O
the,O
same,O
range,O
of,O
on,O
‐,O
land,O
latitudes,O
on,O
Baffin,O
Island,O
in,O
fall,O
as,O
those,O
collared,O
in,O
the,O
1990s,O
(,O
66,O
°,O
30,O
′,O
N,O
to,O
73,O
°,O
50,O
′,O
N,O
"),",O
confirming,O
bears,B-OG
from,O
West,O
Greenland,O
use,O
the,O
same,O
areas,O
as,O
those,O
captured,O
in,O
the,O
1990s,O
.,O
Finally,O
",",O
our,O
analyses,O
using,O
the,O
subset,O
of,O
1990s,O
AF,O
bears,B-OG
collared,O
in,O
spring,O
on,O
the,O
sea,O
ice,O
in,O
West,O
Greenland,O
(,O
n,O
=,O
9,O
),O
compared,O
to,O
the,O
full,O
sample,O
of,O
2000s,O
bears,B-OG
reproduced,O
the,O
same,O
results,O
on,O
summer,O
range,O
size,O
reduction,O
and,O
range,O
shift,O
as,O
the,O
full,O
sample,O
comparison,O
(,O
see,O
Results,O
).,O
These,O
analyses,O
support,O
our,O
comparative,O
work,O
between,O
decades,O
on,O
the,O
subpopulation,O
of,O
polar,B-OG
bears,I-OG
tracked,O
in,O
Baffin,O
Bay,O
.,O
Monthly,O
and,O
seasonal,O
kernel,O
density,O
estimates,O
We,O
estimated,O
the,O
geographic,O
area,O
characterized,O
by,O
a,O
high,O
probability,O
of,O
use,O
by,O
collared,O
AF,O
polar,B-OG
bears,I-OG
in,O
Baffin,O
Bay,O
using,O
a,O
fixed,O
kernel,O
density,O
approach,O
(,O
Worton,O
",",O
1989,O
).,O
Kernel,O
density,O
estimators,O
provide,O
a,O
nonparametric,O
probability,O
of,O
using,O
a,O
given,O
point,O
in,O
space,O
and,O
are,O
reliably,O
used,O
to,O
define,O
the,O
utilization,O
distribution,O
",",O
or,O
home,O
range,O
",",O
for,O
marine,O
and,O
terrestrial,O
wildlife,O
(,O
Kie,O
et,O
al,O
".,",O
2010,O
).,O
We,O
calculated,O
Gaussian,O
bivariate,O
normal,O
kernel,O
density,O
estimates,O
for,O
each,O
decade,O
(,O
n,O
=,O
2,O
"),",O
month,O
(,O
n,O
=,O
12,O
"),",O
and,O
season,O
(,O
n,O
=,O
3,O
),O
for,O
all,O
bears,B-OG
in,O
the,O
sample,O
.,O
Kernel,O
density,O
estimates,O
(,O
KDEs,O
),O
were,O
calculated,O
using,O
the,O
“,O
bkde2D,O
”,O
function,O
in,O
“,O
KernSmooth,O
”,O
R,O
package,O
(,O
Wand,O
",",O
1994,O
;,O
Wand,O
&,O
Jones,O
",",O
1995,O
).,O
As,O
the,O
sample,O
size,O
of,O
collared,O
bears,B-OG
slightly,O
differed,O
between,O
the,O
1990s,O
and,O
2000s,O
(,O
Table,O
1,O
"),",O
we,O
generated,O
random,O
samples,O
of,O
equal,O
size,O
(,O
n,O
=,O
38,O
),O
from,O
the,O
pool,O
of,O
AF,O
bears,B-OG
in,O
each,O
decade,O
.,O
We,O
sampled,O
bears,B-OG
with,O
replacement,O
1,O
",",O
000,O
times,O
for,O
each,O
monthly,O
and,O
seasonal,O
KDE,O
and,O
calculated,O
the,O
area,O
of,O
the,O
95,O
%,O
contour,O
polygon,O
(,O
bounding,O
95,O
%,O
of,O
the,O
KDE,O
surface,O
volume,O
).,O
We,O
produced,O
a,O
mean,O
and,O
bootstrapped,O
standard,O
error,O
(,O
SE,O
),O
for,O
monthly,O
and,O
seasonal,O
home,O
ranges,O
",",O
and,O
used,O
the,O
“,O
intersect,O
”,O
tool,O
in,O
ArcGIS,O
to,O
calculate,O
overlap,O
in,O
home,O
ranges,O
between,O
decades,O
.,O
We,O
also,O
estimated,O
the,O
proportion,O
of,O
home,O
range,O
overlap,O
between,O
the,O
1990s,O
and,O
the,O
2000s,O
(,O
Fieberg,O
&,O
Kochanny,O
",",O
2005,O
),O
based,O
on,O
the,O
bootstrapped,O
mean,O
.,O
We,O
used,O
a,O
cell,O
size,O
of,O
6,O
km,O
and,O
bandwidth,O
of,O
50,O
km,O
(,O
approximately,O
50,O
%,O
of,O
the,O
4,O
‐,O
day,O
movement,O
step,O
of,O
AFs,O
in,O
this,O
study,O
),O
to,O
calculated,O
KDEs,O
.,O
We,O
also,O
examined,O
whether,O
there,O
has,O
been,O
a,O
distributional,O
shift,O
by,O
calculating,O
the,O
median,O
seasonal,O
latitude,O
values,O
for,O
AFs,O
in,O
the,O
1990s,O
and,O
2000s,O
of,O
the,O
KDE,O
and,O
of,O
the,O
pooled,O
location,O
data,O
.,O
We,O
compared,O
changes,O
in,O
median,O
latitude,O
and,O
longitude,O
across,O
decades,O
with,O
t,O
tests,O
at,O
a,O
significance,O
level,O
of,O
α,O
=,O
0,O
.,O
05,O
.,O
Movements,O
across,O
subpopulation,O
boundaries,O
Using,O
each,O
complete,O
individual,O
AF,O
bear,B-OG
trajectory,O
as,O
a,O
single,O
sample,O
",",O
we,O
calculated,O
the,O
number,O
of,O
days,O
each,O
bear,B-OG
spent,O
in,O
BB,O
during,O
the,O
tracking,O
period,O
.,O
We,O
examined,O
the,O
departures,O
from,O
BB,O
using,O
telemetry,O
data,O
by,O
estimating,O
the,O
fraction,O
of,O
bears,B-OG
that,O
crossed,O
BB,O
management,O
boundaries,O
up,O
to,O
300,O
days,O
after,O
capture,O
.,O
Specifically,O
",",O
we,O
calculated,O
the,O
number,O
of,O
days,O
since,O
capture,O
until,O
each,O
polar,B-OG
bear,I-OG
left,O
BB,O
or,O
until,O
the,O
end,O
of,O
their,O
observation,O
period,O
for,O
those,O
that,O
were,O
not,O
observed,O
to,O
leave,O
.,O
For,O
each,O
decade,O
",",O
statistical,O
methods,O
for,O
censored,O
event,O
times,O
were,O
used,O
to,O
construct,O
“,O
survival,O
”,O
curves,O
(,O
Kaplan,O
–,O
Meier,O
),O
to,O
characterize,O
the,O
distribution,O
of,O
first,O
exit,O
times,O
",",O
to,O
estimate,O
departure,O
probabilities,O
from,O
BB,O
",",O
and,O
test,O
for,O
differences,O
among,O
decades,O
(,O
log,O
‐,O
rank,O
test,O
of,O
equality,O
),O
with,O
α,O
=,O
0,O
.,O
05,O
.,O
We,O
considered,O
a,O
departure,O
to,O
be,O
at,O
least,O
30,O
days,O
long,O
",",O
thus,O
bears,B-OG
that,O
departed,O
BB,O
but,O
returned,O
in,O
<,O
30,O
days,O
were,O
not,O
included,O
in,O
the,O
estimates,O
.,O
We,O
summarized,O
which,O
subpopulation,O
bears,B-OG
departed,O
to,O
",",O
the,O
departure,O
month,O
",",O
and,O
compared,O
this,O
across,O
decades,O
.,O
We,O
also,O
tested,O
whether,O
1990s,O
capture,O
season,O
(,O
spring,O
or,O
fall,O
),O
impacted,O
the,O
time,O
until,O
departure,O
from,O
BB,O
by,O
assessing,O
capture,O
season,O
as,O
a,O
factor,O
.,O
Harvest,O
recoveries,O
and,O
recaptures,O
of,O
marked,O
bears,B-OG
We,O
evaluated,O
spatial,O
patterns,O
in,O
live,O
recaptures,O
and,O
dead,O
recoveries,O
of,O
marked,O
bears,B-OG
.,O
We,O
included,O
bears,B-OG
that,O
were,O
marked,O
in,O
spring,O
(,O
April,O
–,O
May,O
),O
or,O
fall,O
(,O
August,O
–,O
October,O
),O
during,O
two,O
periods,O
when,O
BB,O
subpopulation,O
mark,O
–,O
recapture,O
studies,O
were,O
undertaken,O
;,O
1991,O
–,O
1997,O
and,O
2009,O
–,O
2014,O
.,O
From,O
1991,O
to,O
1997,O
",",O
881,O
polar,B-OG
bears,I-OG
were,O
captured,O
",",O
physically,O
marked,O
",",O
and,O
tissue,O
samples,O
were,O
collected,O
(,O
Taylor,O
et,O
al,O
".,",O
2005,O
).,O
Between,O
2011,O
and,O
2013,O
",",O
1,O
",",O
111,O
unique,O
individual,O
bears,B-OG
were,O
remotely,O
biopsied,O
(,O
Pagano,O
",",O
Peacock,O
",",O
&,O
McKinney,O
",",O
2014,O
),O
in,O
western,O
Baffin,O
Bay,O
",",O
and,O
between,O
2009,O
and,O
2013,O
",",O
139,O
bears,B-OG
were,O
physically,O
captured,O
or,O
biopsied,O
in,O
eastern,O
Baffin,O
Bay,O
(,O
SWG,O
",",O
2016,O
;,O
Table,O
2,O
).,O
During,O
this,O
second,O
marking,O
period,O
(,O
2009,O
–,O
2013,O
"),",O
all,O
sampled,O
bears,B-OG
were,O
genotyped,O
to,O
determine,O
sex,O
and,O
individual,O
identification,O
.,O
Since,O
most,O
bears,B-OG
in,O
the,O
2000s,O
were,O
remotely,O
biopsied,O
",",O
we,O
also,O
genotyped,O
635,O
of,O
the,O
881,O
bears,B-OG
physically,O
tagged,O
in,O
the,O
1990s,O
that,O
had,O
neither,O
been,O
reported,O
in,O
the,O
subsistence,O
harvest,O
in,O
Nunavut,O
or,O
Greenland,O
nor,O
were,O
>,O
35,O
years,O
old,O
(,O
maximum,O
expected,O
lifetime,O
for,O
polar,B-OG
bears,I-OG
),O
at,O
the,O
start,O
of,O
the,O
genetic,O
sampling,O
in,O
2011,O
and,O
were,O
thus,O
potentially,O
alive,O
.,O
This,O
allowed,O
us,O
to,O
detect,O
the,O
number,O
of,O
bears,B-OG
sampled,O
in,O
the,O
2000s,O
that,O
had,O
been,O
originally,O
physically,O
marked,O
in,O
the,O
1990s,O
.,O
Number,O
of,O
genetic,O
samples,O
used,O
from,O
polar,B-OG
bears,I-OG
from,O
the,O
Baffin,O
Bay,O
(,O
BB,O
"),",O
Kane,O
Basin,O
(,O
KB,O
"),",O
Lancaster,O
Sound,O
(,O
LS,O
"),",O
and,O
Davis,O
Strait,O
(,O
DS,O
),O
subpopulations,O
for,O
the,O
winter,O
‐,O
spring,O
analyses,O
.,O
For,O
BB,O
",",O
66,O
samples,O
came,O
from,O
the,O
subsistence,O
harvest,O
in,O
the,O
Baffin,O
Island,O
region,O
(,O
2011,O
–,O
2014,O
),O
and,O
74,O
from,O
biopsies,O
taken,O
in,O
West,O
Greenland,O
by,O
scientists,O
during,O
tagging,O
operations,O
(,O
2009,O
–,O
2013,O
),O
BB,O
(,O
2009,O
–,O
2014,O
),O
KB,O
(,O
2012,O
–,O
2014,O
),O
LS,O
(,O
2011,O
–,O
2013,O
),O
DS,O
(,O
2012,O
–,O
2013,O
),O
N,O
Biopsy,O
and,O
Harvest,O
Biopsy,O
Harvest,O
Harvest,O
Total,O
Subadults,O
31,O
21,O
30,O
11,O
93,O
Adult,O
females,O
54,O
54,O
15,O
11,O
134,O
Adult,O
males,O
55,O
24,O
69,O
26,O
174,O
Adults,O
combined,O
109,O
78,O
84,O
38,O
309,O
Total,O
sample,O
140,O
99,O
114,O
49,O
402,O
Recapture,O
or,O
harvest,O
recovery,O
of,O
physically,O
or,O
genetically,O
marked,O
individuals,O
was,O
detected,O
by,O
two,O
means,O
.,O
Prior,O
to,O
2011,O
",",O
when,O
biopsy,O
darting,O
began,O
in,O
BB,O
",",O
marked,O
individuals,O
were,O
identifiable,O
by,O
uniquely,O
numbered,O
ear,O
tags,O
and,O
lip,O
tattoos,O
applied,O
at,O
first,O
capture,O
.,O
Recaptures,O
of,O
these,O
marked,O
individuals,O
were,O
recorded,O
during,O
physical,O
capture,O
sampling,O
in,O
BB,O
and,O
surrounding,O
subpopulations,O
which,O
took,O
place,O
1991,O
–,O
1997,O
(,O
BB,O
",",O
KB,O
",",O
and,O
LS,O
),O
and,O
2005,O
–,O
2007,O
(,O
DS,O
).,O
Baffin,O
Bay,O
and,O
adjacent,O
subpopulations,O
(,O
KB,O
",",O
DS,O
",",O
LS,O
),O
support,O
a,O
subsistence,O
harvest,O
of,O
polar,B-OG
bears,I-OG
",",O
which,O
is,O
characterized,O
by,O
high,O
hunter,O
reporting,O
and,O
management,O
strategies,O
designed,O
to,O
achieve,O
maximum,O
sustainable,O
yield,O
based,O
on,O
demographic,O
data,O
estimated,O
from,O
capture,O
–,O
recapture,O
studies,O
(,O
SWG,O
",",O
2016,O
).,O
Harvest,O
recoveries,O
of,O
marked,O
bears,B-OG
were,O
detected,O
via,O
hunter,O
returns,O
of,O
ear,O
tags,O
and,O
lip,O
tattoos,O
as,O
part,O
of,O
the,O
continuous,O
harvest,O
monitoring,O
program,O
across,O
all,O
subpopulations,O
in,O
Canada,O
and,O
Greenland,O
(,O
Peacock,O
",",O
Laake,O
",",O
Laidre,O
",",O
Born,O
",",O
&,O
Atkinson,O
",",O
2012,O
"),",O
though,O
over,O
time,O
tag,O
loss,O
leads,O
to,O
lower,O
probability,O
of,O
detection,O
of,O
recapture,O
of,O
physically,O
marked,O
individuals,O
.,O
Genetic,O
identifications,O
of,O
individuals,O
were,O
analogous,O
to,O
the,O
physical,O
tags,O
;,O
however,O
",",O
genetic,O
marks,O
do,O
not,O
suffer,O
from,O
tag,O
loss,O
.,O
The,O
recapture,O
or,O
harvest,O
recovery,O
of,O
marked,O
individuals,O
was,O
detected,O
by,O
the,O
presence,O
of,O
physical,O
marks,O
or,O
by,O
matching,O
genetic,O
ids,O
.,O
We,O
summarized,O
the,O
frequencies,O
and,O
proportions,O
of,O
marked,O
bears,B-OG
that,O
were,O
recaptured,O
or,O
recovered,O
inside,O
versus,O
outside,O
BB,O
to,O
provide,O
a,O
crude,O
assessment,O
of,O
the,O
fidelity,O
of,O
marked,O
bears,B-OG
to,O
the,O
BB,O
subpopulation,O
.,O
With,O
respect,O
to,O
short,O
‐,O
term,O
fidelity,O
",",O
the,O
frequencies,O
of,O
harvest,O
recovery,O
of,O
individuals,O
marked,O
between,O
2011,O
and,O
2013,O
were,O
examined,O
to,O
assess,O
whether,O
bears,B-OG
sampled,O
during,O
the,O
recent,O
BB,O
mark,O
–,O
recapture,O
study,O
(,O
SWG,O
",",O
2016,O
),O
remained,O
within,O
the,O
subpopulation,O
during,O
the,O
sampling,O
interval,O
.,O
For,O
this,O
assessment,O
",",O
all,O
recoveries,O
were,O
detected,O
by,O
matching,O
genotypes,O
of,O
harvested,O
bears,B-OG
to,O
genotypes,O
of,O
marked,O
individuals,O
.,O
A,O
few,O
of,O
these,O
individuals,O
were,O
also,O
detected,O
by,O
hunter,O
returns,O
of,O
tags,O
and,O
tattoos,O
.,O
We,O
also,O
updated,O
previously,O
reported,O
information,O
on,O
long,O
‐,O
term,O
fidelity,O
and,O
patterns,O
of,O
harvest,O
recovery,O
in,O
BB,O
(,O
Taylor,O
&,O
Lee,O
",",O
1995,O
;,O
Taylor,O
et,O
al,O
".,",O
2001,O
;,O
Peacock,O
et,O
al,O
".,",O
2012,O
),O
by,O
examining,O
the,O
frequencies,O
of,O
bears,B-OG
originally,O
marked,O
in,O
the,O
1990s,O
that,O
were,O
recovered,O
in,O
the,O
harvest,O
between,O
1991,O
and,O
2014,O
.,O
Recoveries,O
were,O
detected,O
via,O
several,O
means,O
during,O
this,O
14,O
‐,O
year,O
monitoring,O
period,O
.,O
From,O
1991,O
to,O
2010,O
",",O
recoveries,O
were,O
detected,O
solely,O
by,O
hunter,O
returns,O
of,O
tags,O
and,O
lip,O
tattoos,O
from,O
marked,O
bears,B-OG
.,O
From,O
2011,O
to,O
2014,O
",",O
recoveries,O
were,O
detected,O
either,O
by,O
tag,O
and,O
tattoos,O
or,O
by,O
matching,O
the,O
genotype,O
of,O
a,O
harvested,O
bear,B-OG
to,O
the,O
genotype,O
of,O
one,O
of,O
the,O
635,O
marked,O
individuals,O
that,O
could,O
theoretically,O
have,O
been,O
alive,O
in,O
2011,O
.,O
Finally,O
",",O
we,O
used,O
mark,O
–,O
recapture,O
data,O
from,O
1991,O
to,O
1997,O
and,O
2011,O
to,O
2013,O
in,O
BB,O
together,O
with,O
over,O
1,O
",",O
500,O
physical,O
captures,O
of,O
polar,B-OG
bears,I-OG
in,O
the,O
neighboring,O
DS,O
subpopulation,O
between,O
2005,O
and,O
2007,O
(,O
Peacock,O
",",O
Taylor,O
",",O
Laake,O
",",O
&,O
Stirling,O
",",O
2013,O
),O
to,O
summarize,O
recapture,O
frequencies,O
.,O
Given,O
the,O
loss,O
of,O
sea,O
ice,O
that,O
has,O
occurred,O
in,O
both,O
areas,O
(,O
Stern,O
&,O
Laidre,O
",",O
2016,O
),O
and,O
the,O
opportunity,O
presented,O
by,O
having,O
three,O
intensive,O
periods,O
of,O
mark,O
–,O
recapture,O
that,O
were,O
relatively,O
close,O
in,O
time,O
",",O
we,O
used,O
these,O
data,O
to,O
assess,O
movement,O
between,O
these,O
two,O
subpopulations,O
.,O
In,O
particular,O
",",O
we,O
examined,O
whether,O
there,O
was,O
evidence,O
that,O
DS,O
bears,B-OG
had,O
moved,O
northward,O
",",O
in,O
concert,O
with,O
sea,O
‐,O
ice,O
loss,O
",",O
across,O
the,O
BB,O
‐,O
DS,O
subpopulation,O
boundary,O
.,O
For,O
this,O
assessment,O
",",O
recaptures,O
were,O
detected,O
by,O
several,O
means,O
.,O
Recaptures,O
of,O
bears,B-OG
originally,O
marked,O
in,O
BB,O
1991,O
–,O
1997,O
were,O
detected,O
during,O
sampling,O
in,O
DS,O
(,O
2005,O
–,O
2007,O
),O
by,O
observations,O
of,O
tags,O
and,O
lip,O
tattoos,O
.,O
Recaptures,O
of,O
bear,B-OG
marked,O
in,O
DS,O
(,O
2005,O
–,O
2007,O
),O
were,O
detected,O
during,O
sampling,O
in,O
BB,O
(,O
2011,O
–,O
2013,O
),O
by,O
matching,O
genotypes,O
.,O
Genetic,O
methods,O
We,O
used,O
a,O
contemporary,O
subsample,O
of,O
genetic,O
data,O
from,O
402,O
biopsied,O
",",O
physically,O
captured,O
",",O
and,O
harvested,O
polar,B-OG
bears,I-OG
sampled,O
during,O
the,O
winter,O
and,O
spring,O
(,O
November,O
–,O
May,O
2009,O
–,O
2014,O
),O
representing,O
polar,B-OG
bears,I-OG
from,O
four,O
neighboring,O
subpopulations,O
:,O
BB,O
",",O
KB,O
",",O
LS,O
",",O
and,O
DS,O
(,O
Figure,O
1,O
",",O
Table,O
2,O
).,O
We,O
used,O
samples,O
collected,O
only,O
within,O
these,O
two,O
seasons,O
because,O
bears,B-OG
are,O
widely,O
distributed,O
within,O
their,O
purported,O
management,O
boundaries,O
and,O
it,O
excludes,O
displacement,O
of,O
large,O
groups,O
of,O
polar,B-OG
bears,I-OG
during,O
the,O
ice,O
‐,O
free,O
season,O
(,O
see,O
Appendix,O
S1,O
).,O
While,O
these,O
samples,O
were,O
collected,O
and,O
analyzed,O
primarily,O
for,O
a,O
genetic,O
mark,O
–,O
recapture,O
(,O
MR,O
),O
assessment,O
(,O
SWG,O
",",O
2016,O
"),",O
the,O
eight,O
polymorphic,O
microsatellites,O
selected,O
were,O
used,O
in,O
population,O
genetic,O
analyses,O
with,O
the,O
objective,O
of,O
assessing,O
differentiation,O
between,O
BB,O
and,O
neighboring,O
subpopulations,O
.,O
As,O
the,O
samples,O
were,O
recent,O
and,O
temporally,O
congruent,O
",",O
these,O
analyses,O
provided,O
an,O
update,O
to,O
past,O
population,O
genetic,O
studies,O
(,O
Paetkau,O
et,O
al,O
".,",O
1999,O
;,O
Peacock,O
et,O
al,O
".,",O
2015,O
;,O
Malenfant,O
",",O
Davis,O
",",O
Cullingham,O
",",O
&,O
Coltman,O
",",O
2016,O
),O
that,O
used,O
samples,O
from,O
the,O
1990s,O
.,O
We,O
used,O
standardized,O
population,O
genetic,O
analytical,O
tools,O
and,O
methods,O
to,O
investigate,O
genetic,O
connectivity,O
between,O
subpopulations,O
(,O
ADEGENET,O
package,O
",",O
Jombart,O
",",O
2008,O
;,O
ARLEQUIN,O
Version,O
3,O
.,O
5,O
.,O
1,O
",",O
Excoffier,O
&,O
Lischer,O
",",O
2010,O
;,O
BA3,O
‐,O
3,O
.,O
0,O
.,O
3,O
",",O
Wilson,O
&,O
Rannala,O
",",O
2003,O
;,O
DAPC,O
",",O
Jombart,O
",",O
Devillard,O
",",O
&,O
Balloux,O
",",O
2010,O
;,O
FSTAT,O
",",O
Goudet,O
",",O
1995,O
;,O
GENECLASS2,O
",",O
Piry,O
et,O
al,O
".,",O
2004,O
;,O
GENELAND,O
",",O
Guillot,O
",",O
Mortier,O
",",O
&,O
Estoup,O
",",O
2005,O
;,O
Guillot,O
",",O
2008,O
;,O
STRUCTURE,O
",",O
Pritchard,O
",",O
Stephens,O
",",O
&,O
Donnelly,O
",",O
2000,O
).,O
Genetic,O
differentiation,O
between,O
groups,O
was,O
analyzed,O
using,O
unbiased,O
F,O
ST,O
statistics,O
(,O
Weir,O
&,O
Cockerham,O
",",O
1984,O
),O
in,O
ARLEQUIN,O
Version,O
3,O
.,O
5,O
.,O
1,O
(,O
Excoffier,O
&,O
Lischer,O
",",O
2010,O
).,O
The,O
degree,O
of,O
population,O
differentiation,O
was,O
analyzed,O
after,O
10,O
",",O
000,O
permutations,O
to,O
estimate,O
the,O
genetic,O
variability,O
between,O
subpopulations,O
(,O
see,O
Appendix,O
S1,O
).,O
RESULTS,O
Radio,O
telemetry,O
Adult,O
females,O
in,O
all,O
reproductive,O
states,O
were,O
fitted,O
with,O
collars,O
in,O
the,O
1990s,O
(,O
n,O
=,O
43,O
),O
and,O
2000s,O
(,O
n,O
=,O
38,O
),O
(,O
Table,O
1,O
).,O
Collars,O
deployed,O
between,O
1991,O
and,O
1995,O
transmitted,O
for,O
an,O
average,O
of,O
438,O
days,O
(,O
SD,O
98,O
"),",O
through,O
1997,O
.,O
Collars,O
deployed,O
between,O
2009,O
and,O
2013,O
transmitted,O
for,O
an,O
average,O
of,O
662,O
days,O
(,O
SD,O
346,O
"),",O
through,O
April,O
2015,O
(,O
Figure,O
2,O
).,O
In,O
the,O
1990s,O
",",O
31,O
bears,B-OG
(,O
72,O
%,O
of,O
the,O
total,O
sample,O
),O
were,O
collared,O
in,O
fall,O
on,O
land,O
on,O
Baffin,O
Island,O
",",O
6,O
%,O
on,O
the,O
sea,O
ice,O
off,O
the,O
Baffin,O
Island,O
coast,O
",",O
and,O
21,O
%,O
on,O
the,O
sea,O
ice,O
in,O
West,O
Greenland,O
.,O
Due,O
to,O
a,O
shift,O
away,O
from,O
immobilization,O
of,O
wildlife,O
for,O
research,O
studies,O
in,O
Nunavut,O
",",O
Canada,O
after,O
the,O
1990s,O
",",O
all,O
collaring,O
of,O
adult,O
females,O
in,O
the,O
2000s,O
occurred,O
on,O
the,O
spring,O
sea,O
ice,O
in,O
West,O
Greenland,O
.,O
Polar,B-OG
bears,I-OG
in,O
both,O
decades,O
ranged,O
over,O
the,O
entire,O
Baffin,O
Bay,O
during,O
the,O
ice,O
‐,O
covered,O
season,O
",",O
freely,O
moving,O
back,O
and,O
forth,O
between,O
Baffin,O
Island,O
and,O
West,O
Greenland,O
",",O
though,O
the,O
disappearance,O
of,O
the,O
sea,O
‐,O
ice,O
platform,O
in,O
the,O
southern,O
extent,O
of,O
the,O
range,O
prevented,O
long,O
‐,O
distance,O
movements,O
into,O
Davis,O
Strait,O
in,O
the,O
2000s,O
(,O
Figure,O
1,O
).,O
Movements,O
of,O
adult,O
female,O
polar,B-OG
bears,I-OG
collared,O
in,O
Baffin,O
Bay,O
in,O
the,O
1990s,O
(,O
left,O
),O
and,O
2000s,O
(,O
right,O
).,O
Colored,O
symbols,O
show,O
locations,O
where,O
the,O
bears,B-OG
were,O
captured,O
(,O
cf,O
.,O
Figure,O
1,O
),O
Subpopulation,O
ranges,O
In,O
the,O
1990s,O
",",O
monthly,O
95,O
%,O
bivariate,O
kernel,O
range,O
sizes,O
varied,O
between,O
460,O
",",O
000,O
and,O
805,O
",",O
000,O
km2,O
(,O
Figure,O
3,O
),O
Monthly,O
range,O
sizes,O
in,O
the,O
2000s,O
varied,O
between,O
178,O
",",O
000,O
and,O
600,O
",",O
000,O
km2,O
(,O
Figure,O
3,O
),O
and,O
were,O
significantly,O
smaller,O
in,O
all,O
months,O
except,O
January,O
",",O
May,O
",",O
and,O
June,O
.,O
Seasonal,O
range,O
sizes,O
also,O
exhibited,O
significant,O
reductions,O
between,O
the,O
1990s,O
and,O
2000s,O
(,O
Figure,O
4,O
).,O
During,O
the,O
on,O
‐,O
ice,O
seasons,O
",",O
there,O
was,O
a,O
17,O
%,O
range,O
reduction,O
in,O
winter,O
(,O
1990s,O
=,O
906,O
",",O
657,O
km2,O
",",O
2000s,O
=,O
593,O
",",O
077,O
km2,O
",",O
p,O
=,O
.,O
012,O
",",O
Figure,O
4a,O
),O
and,O
a,O
30,O
%,O
range,O
reduction,O
in,O
spring,O
(,O
1990s,O
=,O
837,O
",",O
036,O
km2,O
",",O
2000s,O
=,O
593,O
",",O
077,O
km2,O
",",O
p,O
<,O
.,O
001,O
",",O
Figure,O
4b,O
).,O
During,O
the,O
ice,O
‐,O
free,O
season,O
in,O
summer,O
",",O
we,O
found,O
a,O
70,O
%,O
reduction,O
in,O
range,O
size,O
(,O
1990s,O
=,O
716,O
",",O
767,O
km2,O
",",O
2000s,O
=,O
211,O
",",O
476,O
km2,O
",",O
p,O
<,O
.,O
001,O
",",O
Figure,O
4c,O
).,O
To,O
evaluate,O
whether,O
the,O
substantial,O
summer,O
range,O
reduction,O
was,O
influenced,O
by,O
capture,O
location,O
",",O
we,O
compared,O
range,O
sizes,O
between,O
a,O
subsample,O
of,O
the,O
1990s,O
bears,B-OG
collared,O
in,O
Melville,O
Bay,O
",",O
West,O
Greenland,O
on,O
the,O
spring,O
pack,O
ice,O
(,O
n,O
=,O
9,O
"),",O
and,O
the,O
full,O
sample,O
from,O
the,O
2000s,O
.,O
We,O
found,O
similar,O
patterns,O
;,O
the,O
subsample,O
of,O
bears,B-OG
in,O
the,O
1990s,O
also,O
used,O
significantly,O
larger,O
ranges,O
in,O
summer,O
(,O
i,O
.,O
e,O
".,",O
Figure,O
4c,O
"),",O
and,O
this,O
resulted,O
in,O
a,O
>,O
35,O
%,O
summer,O
range,O
reduction,O
for,O
the,O
2000s,O
(,O
p,O
<,O
.,O
001,O
).,O
95,O
%,O
mean,O
kernel,O
range,O
sizes,O
(,O
km2,O
),O
estimated,O
from,O
a,O
bootstrap,O
method,O
for,O
adult,O
female,O
polar,B-OG
bears,I-OG
in,O
Baffin,O
Bay,O
by,O
decade,O
and,O
month,O
(,O
1990s,O
purple,O
;,O
2000s,O
green,O
).,O
Line,O
represents,O
the,O
mean,O
values,O
and,O
shaded,O
area,O
represents,O
±,O
2,O
SE,O
;,O
thus,O
",",O
lack,O
of,O
overlap,O
between,O
shaded,O
areas,O
indicates,O
statistical,O
significance,O
.,O
Graph,O
excludes,O
year,O
‐,O
round,O
residents,O
in,O
Melville,O
Bay,O
",",O
West,O
Greenland,O
95,O
%,O
bivariate,O
kernel,O
ranges,O
for,O
adult,O
female,O
Baffin,O
Bay,O
polar,B-OG
bears,I-OG
captured,O
in,O
the,O
1990s,O
and,O
2000s,O
by,O
season,O
(,O
a,O
‐,O
winter,O
",",O
b,O
‐,O
spring,O
",",O
c,O
‐,O
summer,O
),O
The,O
reduction,O
in,O
range,O
sizes,O
resulted,O
in,O
a,O
reduced,O
habitat,O
area,O
used,O
by,O
bears,B-OG
in,O
the,O
2000s,O
.,O
There,O
was,O
<,O
50,O
%,O
overlap,O
in,O
ranges,O
for,O
bears,B-OG
in,O
the,O
1990s,O
and,O
2000s,O
in,O
all,O
months,O
and,O
seasons,O
.,O
Range,O
overlap,O
across,O
decades,O
was,O
lowest,O
in,O
September,O
and,O
October,O
(~,O
30,O
%),O
and,O
higher,O
in,O
winter,O
and,O
spring,O
(,O
60,O
–,O
80,O
%).,O
Additionally,O
",",O
there,O
was,O
a,O
significant,O
northward,O
shift,O
in,O
the,O
median,O
subpopulation,O
latitude,O
in,O
both,O
winter,O
(,O
1990s,O
",",O
median,O
69,O
.,O
4,O
°,O
N,O
;,O
2000s,O
",",O
median,O
72,O
.,O
0,O
°,O
N,O
2000s,O
;,O
p,O
<,O
.,O
001,O
),O
and,O
spring,O
(,O
1990s,O
",",O
median,O
71,O
.,O
7,O
°,O
N,O
;,O
2000s,O
",",O
median,O
72,O
.,O
7,O
°,O
N,O
;,O
p,O
<,O
.,O
001,O
).,O
There,O
was,O
no,O
northward,O
shift,O
between,O
decades,O
during,O
summer,O
.,O
However,O
",",O
there,O
was,O
a,O
significant,O
contraction,O
around,O
70,O
.,O
5,O
–,O
71,O
°,O
N,O
between,O
the,O
two,O
decades,O
(,O
Figure,O
5,O
).,O
These,O
same,O
patterns,O
were,O
demonstrated,O
by,O
the,O
analyses,O
of,O
the,O
subsample,O
using,O
n,O
=,O
9,O
bears,B-OG
from,O
the,O
1990s,O
.,O
Box,O
plots,O
and,O
interquartile,O
range,O
(,O
shaded,O
area,O
),O
of,O
median,O
latitude,O
of,O
adult,O
female,O
polar,B-OG
bears,I-OG
in,O
Baffin,O
Bay,O
by,O
season,O
in,O
the,O
1990s,O
and,O
2000s,O
shown,O
for,O
each,O
season,O
.,O
Plots,O
exclude,O
year,O
‐,O
round,O
residents,O
in,O
Melville,O
Bay,O
",",O
West,O
Greenland,O
Movement,O
between,O
subpopulations,O
Overall,O
",",O
a,O
significantly,O
lower,O
fraction,O
of,O
collared,O
polar,B-OG
bears,I-OG
left,O
BB,O
in,O
the,O
2000s,O
than,O
in,O
the,O
1990s,O
(,O
χ2,O
=,O
6,O
.,O
8,O
",",O
df,O
=,O
1,O
",",O
p,O
=,O
.,O
009,O
).,O
The,O
reductions,O
in,O
numbers,O
of,O
bears,B-OG
departing,O
BB,O
across,O
subpopulation,O
boundaries,O
were,O
due,O
to,O
fewer,O
bears,B-OG
moving,O
south,O
into,O
DS,O
and,O
fewer,O
bears,B-OG
moving,O
west,O
into,O
LS,O
.,O
In,O
the,O
1990s,O
",",O
14,O
of,O
43,O
(,O
33,O
%),O
radio,O
‐,O
collared,O
bears,B-OG
moved,O
south,O
into,O
DS,O
",",O
and,O
12,O
of,O
43,O
(,O
28,O
%),O
bears,B-OG
moved,O
west,O
into,O
LS,O
.,O
In,O
the,O
2000s,O
",",O
movements,O
occurred,O
to,O
these,O
areas,O
but,O
at,O
a,O
significantly,O
lower,O
rate,O
;,O
three,O
of,O
38,O
(,O
8,O
%),O
tagged,O
bears,B-OG
moved,O
to,O
DS,O
",",O
and,O
three,O
of,O
38,O
(,O
8,O
%),O
tagged,O
bears,B-OG
moved,O
to,O
LS,O
.,O
In,O
the,O
2000s,O
",",O
five,O
of,O
38,O
(,O
13,O
%),O
bears,B-OG
also,O
moved,O
north,O
directly,O
from,O
BB,O
into,O
KB,O
",",O
and,O
an,O
additional,O
two,O
moved,O
to,O
KB,O
after,O
first,O
moving,O
to,O
LS,O
.,O
In,O
the,O
1990s,O
",",O
n,O
=,O
2,O
of,O
43,O
bears,B-OG
moved,O
to,O
KB,O
and,O
both,O
initially,O
moved,O
into,O
LS,O
.,O
At,O
100,O
days,O
after,O
capture,O
",",O
approximately,O
73,O
%,O
(,O
95,O
%,O
CI,O
:,O
60,O
%–,O
88,O
%),O
of,O
collared,O
bears,B-OG
remained,O
in,O
BB,O
in,O
the,O
1990s,O
",",O
whereas,O
in,O
the,O
2000s,O
91,O
%,O
(,O
95,O
%,O
CI,O
:,O
81,O
%–,O
100,O
%),O
remained,O
(,O
Z,O
=,O
2,O
.,O
041,O
",",O
p,O
=,O
.,O
041,O
),O
(,O
Figure,O
6,O
).,O
At,O
300,O
days,O
after,O
capture,O
",",O
approximately,O
55,O
%,O
(,O
95,O
%,O
CI,O
:,O
43,O
%–,O
74,O
%),O
of,O
collared,O
bears,B-OG
remained,O
in,O
BB,O
in,O
the,O
1990s,O
",",O
whereas,O
in,O
the,O
2000s,O
",",O
84,O
%,O
(,O
95,O
%,O
CI,O
:,O
72,O
%–,O
98,O
%),O
remained,O
(,O
Z,O
=,O
2,O
.,O
732,O
",",O
p,O
=,O
.,O
006,O
;,O
Figure,O
6,O
).,O
Overall,O
",",O
56,O
%,O
of,O
the,O
collared,O
bears,B-OG
never,O
left,O
BB,O
during,O
the,O
1990s,O
tracking,O
period,O
",",O
whereas,O
79,O
%,O
never,O
left,O
in,O
the,O
2000s,O
tracking,O
period,O
(,O
Table,O
3,O
).,O
Individuals,O
departed,O
and,O
returned,O
several,O
times,O
over,O
the,O
course,O
of,O
the,O
tracking,O
period,O
.,O
Formal,O
estimation,O
of,O
rates,O
of,O
return,O
was,O
complicated,O
by,O
highly,O
variable,O
follow,O
‐,O
up,O
times,O
;,O
however,O
",",O
bears,B-OG
generally,O
moved,O
back,O
and,O
forth,O
more,O
frequently,O
between,O
BB,O
and,O
DS,O
in,O
the,O
1990s,O
.,O
Results,O
indicated,O
that,O
capture,O
season,O
in,O
the,O
1990s,O
(,O
spring,O
vs,O
.,O
summer,O
),O
did,O
not,O
influence,O
timing,O
of,O
departure,O
(,O
p,O
=,O
.,O
562,O
).,O
Percent,O
of,O
polar,B-OG
bears,I-OG
remaining,O
in,O
Baffin,O
Bay,O
after,O
capture,O
(,O
1990s,O
and,O
2000s,O
),O
as,O
a,O
function,O
of,O
time,O
.,O
Departures,O
are,O
for,O
areas,O
outside,O
of,O
the,O
BB,O
subpopulation,O
management,O
boundaries,O
.,O
Only,O
departures,O
>,O
30,O
days,O
were,O
considered,O
Number,O
of,O
subpopulation,O
boundary,O
crossings,O
made,O
by,O
individual,O
radio,O
‐,O
collared,O
adult,O
female,O
bears,B-OG
in,O
Baffin,O
Bay,O
in,O
1990s,O
(,O
n,O
=,O
43,O
),O
and,O
the,O
2000s,O
(,O
n,O
=,O
38,O
),O
for,O
departures,O
of,O
>,O
30,O
days,O
.,O
Percentages,O
shown,O
as,O
percent,O
of,O
total,O
collared,O
bears,B-OG
Number,O
of,O
subpopulation,O
boundary,O
crossings,O
0,O
1,O
2,O
3,O
4,O
5,O
6,O
7,O
1990s,O
24,O
(,O
56,O
%),O
8,O
(,O
19,O
%),O
6,O
(,O
14,O
%),O
1,O
(,O
2,O
%),O
1,O
(,O
2,O
%),O
1,O
(,O
2,O
%),O
1,O
(,O
2,O
%),O
1,O
(,O
2,O
%),O
2000s,O
30,O
(,O
79,O
%),O
3,O
(,O
8,O
%),O
2,O
(,O
5,O
%),O
0,O
1,O
(,O
3,O
%),O
1,O
(,O
3,O
%),O
0,O
1,O
(,O
3,O
%),O
The,O
timing,O
of,O
departures,O
over,O
the,O
annual,O
cycle,O
varied,O
with,O
patterns,O
of,O
seasonal,O
ice,O
coverage,O
in,O
BB,O
.,O
Bears,B-OG
were,O
significantly,O
more,O
likely,O
to,O
leave,O
and,O
move,O
south,O
into,O
DS,O
during,O
the,O
winter,O
or,O
early,O
spring,O
(,O
November,O
through,O
April,O
),O
when,O
DS,O
was,O
covered,O
with,O
pack,O
ice,O
(,O
p,O
<,O
.,O
001,O
",",O
Fisher,O
',O
s,O
exact,O
test,O
).,O
During,O
June,O
through,O
September,O
",",O
bears,B-OG
in,O
the,O
1990s,O
were,O
more,O
likely,O
to,O
move,O
into,O
LS,O
where,O
summer,O
remnants,O
of,O
sea,O
ice,O
were,O
available,O
in,O
the,O
archipelago,O
(,O
p,O
=,O
.,O
003,O
",",O
Fisher,O
',O
s,O
exact,O
test,O
).,O
This,O
summer,O
movement,O
pattern,O
was,O
only,O
weakly,O
present,O
in,O
the,O
2000s,O
.,O
Harvest,O
recoveries,O
and,O
recaptures,O
of,O
marked,O
bears,B-OG
Of,O
the,O
1,O
",",O
250,O
bears,B-OG
marked,O
in,O
BB,O
(,O
2011,O
–,O
2013,O
"),",O
85,O
individuals,O
were,O
recovered,O
in,O
the,O
reported,O
subsistence,O
harvest,O
in,O
Nunavut,O
and,O
Greenland,O
or,O
detected,O
through,O
genotyping,O
during,O
2011,O
–,O
2014,O
.,O
Of,O
these,O
individuals,O
",",O
84,O
(,O
99,O
%),O
were,O
recovered,O
in,O
the,O
BB,O
harvest,O
",",O
and,O
one,O
bear,B-OG
was,O
harvested,O
in,O
DS,O
.,O
Also,O
during,O
this,O
period,O
",",O
11,O
bears,B-OG
marked,O
in,O
the,O
1990s,O
in,O
BB,O
were,O
recovered,O
in,O
the,O
harvest,O
(,O
all,O
in,O
BB,O
).,O
Of,O
the,O
881,O
bears,B-OG
marked,O
in,O
BB,O
from,O
1991,O
to,O
1997,O
",",O
181,O
individuals,O
were,O
recovered,O
in,O
the,O
subsistence,O
harvest,O
in,O
Canada,O
and,O
Greenland,O
between,O
1991,O
and,O
2014,O
;,O
83,O
%,O
of,O
these,O
recoveries,O
occurred,O
within,O
BB,O
.,O
Recoveries,O
of,O
marked,O
BB,O
bears,B-OG
outside,O
the,O
bounds,O
of,O
the,O
BB,O
subpopulation,O
tended,O
to,O
be,O
male,O
‐,O
biased,O
(,O
3,O
.,O
29,O
males,O
per,O
female,O
),O
relative,O
to,O
recoveries,O
within,O
BB,O
(,O
1,O
.,O
85,O
males,O
per,O
female,O
"),",O
although,O
this,O
was,O
not,O
statistically,O
significant,O
(,O
p,O
=,O
.,O
483,O
",",O
Fisher,O
',O
s,O
exact,O
test,O
).,O
Of,O
the,O
1,O
",",O
518,O
unique,O
individuals,O
captured,O
in,O
DS,O
in,O
the,O
mid,O
‐,O
2000s,O
(,O
Peacock,O
et,O
al,O
".,",O
2013,O
"),",O
13,O
(,O
0,O
.,O
8,O
%),O
were,O
recaptures,O
from,O
the,O
sample,O
of,O
881,O
bears,B-OG
originally,O
marked,O
in,O
BB,O
between,O
1991,O
and,O
1997,O
.,O
Of,O
the,O
bears,B-OG
sampled,O
in,O
BB,O
from,O
2009,O
to,O
2013,O
(,O
1,O
",",O
250,O
unique,O
individuals,O
",",O
1,O
",",O
623,O
capture,O
events,O
"),",O
16,O
(,O
1,O
%),O
were,O
originally,O
marked,O
in,O
DS,O
between,O
2005,O
and,O
2007,O
.,O
In,O
sum,O
",",O
from,O
a,O
total,O
of,O
2,O
",",O
771,O
bears,B-OG
marked,O
in,O
either,O
BB,O
or,O
DS,O
during,O
2005,O
–,O
2013,O
",",O
29,O
instances,O
were,O
detected,O
where,O
marked,O
bears,B-OG
moved,O
from,O
one,O
subpopulation,O
to,O
the,O
other,O
.,O
Despite,O
extensive,O
marking,O
of,O
bears,B-OG
throughout,O
the,O
range,O
of,O
both,O
subpopulations,O
",",O
the,O
frequency,O
of,O
recorded,O
interpopulation,O
movements,O
was,O
relatively,O
low,O
and,O
mainly,O
clustered,O
near,O
the,O
boundary,O
.,O
Based,O
on,O
straight,O
line,O
distance,O
between,O
capture,O
location,O
and,O
the,O
BB,O
‐,O
DS,O
subpopulation,O
boundary,O
",",O
the,O
29,O
individuals,O
that,O
made,O
interpopulation,O
movements,O
were,O
first,O
captured,O
significantly,O
closer,O
to,O
the,O
boundary,O
than,O
other,O
bears,B-OG
marked,O
in,O
these,O
subpopulations,O
(,O
χ2,O
=,O
169,O
.,O
48,O
",",O
df,O
=,O
11,O
",",O
p,O
<,O
.,O
001,O
).,O
Seventy,O
percent,O
of,O
bears,B-OG
known,O
to,O
have,O
made,O
interpopulation,O
movements,O
were,O
originally,O
captured,O
within,O
100,O
km,O
of,O
the,O
boundary,O
",",O
compared,O
to,O
20,O
%,O
for,O
bears,B-OG
that,O
did,O
not,O
make,O
such,O
movements,O
.,O
Genetic,O
connectivity,O
between,O
Baffin,O
Bay,O
and,O
other,O
subpopulations,O
The,O
average,O
expected,O
heterozygosity,O
",",O
based,O
on,O
eight,O
polymorphic,O
microsatellites,O
",",O
for,O
402,O
polar,B-OG
bears,I-OG
sampled,O
during,O
winter,O
–,O
spring,O
(,O
November,O
–,O
May,O
),O
in,O
2009,O
–,O
2014,O
ranged,O
from,O
0,O
.,O
779,O
±,O
0,O
.,O
018,O
(,O
KB,O
),O
to,O
0,O
.,O
804,O
±,O
0,O
.,O
012,O
(,O
BB,O
and,O
LS,O
).,O
No,O
significant,O
deviation,O
from,O
Hardy,O
–,O
Weinberg,O
Equilibrium,O
was,O
observed,O
in,O
any,O
of,O
the,O
datasets,O
(,O
Table,O
S1,O
),O
nor,O
was,O
a,O
linkage,O
disequilibrium,O
observed,O
between,O
all,O
pairs,O
of,O
loci,O
within,O
the,O
dataset,O
.,O
Population,O
structure,O
estimated,O
using,O
multilocus,O
F,O
ST,O
statistics,O
was,O
generally,O
low,O
",",O
although,O
tests,O
were,O
statistically,O
significant,O
after,O
sequential,O
Bonferroni,O
correction,O
(,O
Rice,O
",",O
1989,O
),O
at,O
α,O
=,O
5,O
%,O
level,O
(,O
Table,O
4,O
).,O
Pairwise,O
F,O
ST,O
values,O
showed,O
low,O
but,O
significant,O
differentiation,O
for,O
BB,O
between,O
KB,O
",",O
DS,O
",",O
and,O
LS,O
when,O
comparing,O
the,O
winter,O
and,O
spring,O
samples,O
for,O
bears,B-OG
of,O
all,O
ages,O
and,O
sexes,O
",",O
adults,O
of,O
both,O
sexes,O
",",O
and,O
adult,O
females,O
(,O
Table,O
4,O
).,O
There,O
were,O
no,O
significant,O
differences,O
for,O
adult,O
males,O
and,O
subadults,O
(,O
both,O
sexes,O
).,O
These,O
results,O
provide,O
the,O
first,O
evidence,O
for,O
a,O
genetic,O
difference,O
between,O
BB,O
and,O
KB,O
",",O
in,O
contrast,O
to,O
previous,O
studies,O
by,O
Paetkau,O
et,O
al,O
.,O
(,O
1999,O
"),",O
Peacock,O
et,O
al,O
.,O
(,O
2015,O
"),",O
and,O
Malenfant,O
et,O
al,O
.,O
(,O
2016,O
).,O
The,O
discriminant,O
analysis,O
of,O
principal,O
components,O
(,O
DAPC,O
",",O
Jombart,O
et,O
al,O
".,",O
2010,O
"),",O
separated,O
BB,O
and,O
KB,O
from,O
LS,O
and,O
DS,O
",",O
supporting,O
the,O
grouping,O
observed,O
using,O
GENELAND,O
(,O
Figures,O
S1,O
–,O
S4,O
",",O
Table,O
2,O
).,O
Of,O
note,O
",",O
Bayesian,O
clustering,O
method,O
in,O
STRUCTURE,O
did,O
not,O
separate,O
BB,O
and,O
KB,O
",",O
possibly,O
due,O
to,O
low,O
FST,O
values,O
(,O
see,O
Appendix,O
S1,O
).,O
Pairwise,O
F,O
ST,O
estimates,O
testing,O
for,O
population,O
structure,O
across,O
Baffin,O
Bay,O
(,O
BB,O
"),",O
Kane,O
Basin,O
(,O
KB,O
"),",O
Lancaster,O
Sound,O
(,O
LS,O
"),",O
and,O
Davis,O
Strait,O
(,O
DS,O
),O
polar,B-OG
bear,I-OG
subpopulations,O
BB,O
LS,O
DS,O
Subadults,O
LS,O
0,O
.,O
003,O
DS,O
0,O
.,O
012,O
0,O
.,O
018,O
KB,O
0,O
.,O
01,O
0,O
.,O
008,O
0,O
.,O
024,O
Adult,O
females,O
LS,O
0,O
.,O
005,O
DS,O
0,O
.,O
007,O
0,O
.,O
012,O
KB,O
0,O
.,O
008,O
0,O
.,O
003,O
0,O
.,O
022,O
Adult,O
males,O
LS,O
0,O
.,O
013,O
DS,O
0,O
.,O
009,O
0,O
.,O
016,O
KB,O
0,O
.,O
003,O
0,O
.,O
010,O
0,O
.,O
013,O
Adults,O
combined,O
LS,O
0,O
.,O
008,O
DS,O
0,O
.,O
01,O
0,O
.,O
015,O
KB,O
0,O
.,O
006,O
0,O
.,O
013,O
0,O
.,O
016,O
All,O
Bears,B-OG
LS,O
0,O
.,O
007,O
DS,O
0,O
.,O
009,O
0,O
.,O
014,O
KB,O
0,O
.,O
005,O
0,O
.,O
012,O
0,O
.,O
015,O
Bold,O
value,O
is,O
significant,O
at,O
p,O
<,O
.,O
05,O
after,O
sequential,O
Bonferroni,O
correction,O
(,O
Rice,O
",",O
1989,O
).,O
DISCUSSION,O
Over,O
the,O
past,O
three,O
decades,O
",",O
there,O
has,O
been,O
a,O
significant,O
decline,O
in,O
sea,O
ice,O
in,O
Baffin,O
Bay,O
and,O
surrounding,O
areas,O
(,O
Stern,O
&,O
Laidre,O
",",O
2016,O
"),",O
which,O
has,O
directly,O
translated,O
to,O
loss,O
of,O
habitat,O
available,O
to,O
the,O
BB,O
polar,B-OG
bear,I-OG
subpopulation,O
.,O
We,O
document,O
that,O
BB,O
subpopulation,O
has,O
become,O
increasingly,O
isolated,O
through,O
contraction,O
of,O
seasonal,O
ranges,O
and,O
reductions,O
in,O
emigration,O
across,O
subpopulation,O
boundaries,O
.,O
We,O
suggest,O
that,O
this,O
is,O
a,O
consequence,O
of,O
ongoing,O
loss,O
of,O
sea,O
ice,O
in,O
Baffin,O
Bay,O
and,O
reflects,O
climate,O
impacts,O
that,O
are,O
likely,O
to,O
occur,O
for,O
other,O
subpopulations,O
in,O
the,O
seasonal,O
sea,O
‐,O
ice,O
ecoregion,O
(,O
Amstrup,O
et,O
al,O
".,",O
2008,O
).,O
Satellite,O
telemetry,O
The,O
reliability,O
of,O
inferences,O
about,O
population,O
structure,O
based,O
on,O
movement,O
data,O
is,O
dependent,O
on,O
the,O
extent,O
to,O
which,O
sampled,O
individuals,O
represent,O
the,O
subpopulation,O
of,O
interest,O
.,O
This,O
is,O
a,O
function,O
of,O
sampling,O
strategy,O
",",O
timing,O
",",O
and,O
sample,O
size,O
.,O
In,O
this,O
study,O
",",O
we,O
investigated,O
the,O
movement,O
of,O
AFs,O
and,O
interpret,O
the,O
data,O
as,O
representative,O
for,O
the,O
subpopulation,O
as,O
a,O
whole,O
.,O
The,O
movements,O
of,O
individual,O
polar,B-OG
bears,I-OG
have,O
been,O
studied,O
using,O
satellite,O
telemetry,O
for,O
decades,O
(,O
e,O
.,O
g,O
".,",O
Amstrup,O
",",O
Durner,O
",",O
Stirling,O
",",O
Lunn,O
",",O
&,O
Messier,O
",",O
2000,O
;,O
Born,O
",",O
Wiig,O
",",O
&,O
Thomassen,O
",",O
1997,O
;,O
Laidre,O
et,O
al,O
".,",O
2013,O
",",O
2015,O
;,O
Wiig,O
",",O
Born,O
",",O
&,O
Pedersen,O
",",O
2003,O
"),",O
and,O
inference,O
has,O
almost,O
exclusively,O
been,O
based,O
on,O
adult,O
females,O
because,O
of,O
the,O
challenges,O
of,O
instrumenting,O
adult,O
males,O
(,O
Wiig,O
et,O
al,O
".,",O
2017,O
).,O
Our,O
analyses,O
",",O
which,O
also,O
included,O
harvest,O
recoveries,O
of,O
both,O
sexes,O
",",O
did,O
not,O
indicate,O
vastly,O
different,O
movement,O
between,O
males,O
and,O
females,O
.,O
Previous,O
studies,O
in,O
BB,O
also,O
indicated,O
that,O
both,O
sexes,O
utilize,O
the,O
same,O
habitats,O
in,O
spring,O
(,O
Laidre,O
et,O
al,O
".,",O
2013,O
).,O
We,O
therefore,O
suggest,O
our,O
satellite,O
telemetry,O
data,O
are,O
a,O
representative,O
index,O
of,O
broad,O
population,O
movement,O
patterns,O
.,O
Our,O
analyses,O
addressed,O
differences,O
in,O
sampling,O
between,O
decades,O
to,O
ensure,O
that,O
the,O
1990s,O
and,O
2000s,O
data,O
",",O
which,O
were,O
collected,O
within,O
the,O
boundaries,O
of,O
BB,O
but,O
different,O
areas,O
and,O
seasons,O
",",O
were,O
comparable,O
.,O
Bears,B-OG
collared,O
in,O
West,O
Greenland,O
in,O
the,O
2000s,O
used,O
nearly,O
the,O
entire,O
Baffin,O
Island,O
coastline,O
in,O
fall,O
and,O
were,O
distributed,O
over,O
the,O
same,O
capture,O
region,O
and,O
same,O
range,O
of,O
latitudes,O
where,O
females,O
in,O
the,O
1990s,O
were,O
collared,O
",",O
with,O
the,O
exception,O
of,O
the,O
southern,O
point,O
around,O
Cape,O
Dyer,O
.,O
Further,O
",",O
subsample,O
analyses,O
of,O
a,O
small,O
number,O
of,O
bears,B-OG
collared,O
in,O
spring,O
in,O
a,O
restricted,O
area,O
of,O
West,O
Greenland,O
in,O
the,O
1990s,O
(,O
n,O
=,O
9,O
),O
provided,O
the,O
same,O
significant,O
results,O
on,O
summer,O
range,O
reduction,O
as,O
the,O
larger,O
dataset,O
.,O
Overall,O
",",O
in,O
our,O
study,O
",",O
sample,O
sizes,O
for,O
each,O
decade,O
were,O
roughly,O
equivalent,O
(,O
1990s,O
",",O
n,O
=,O
43,O
;,O
2000s,O
",",O
n,O
=,O
38,O
"),",O
sampling,O
durations,O
were,O
similar,O
(,O
6,O
‐,O
to,O
7,O
‐,O
year,O
tracking,O
periods,O
in,O
each,O
decade,O
"),",O
and,O
collars,O
in,O
both,O
decades,O
transmitted,O
up,O
to,O
3,O
years,O
.,O
Finally,O
",",O
in,O
both,O
decades,O
",",O
collar,O
deployments,O
were,O
distributed,O
over,O
multiple,O
years,O
and,O
over,O
broad,O
geographic,O
areas,O
within,O
BB,O
management,O
boundaries,O
(,O
Figure,O
1,O
).,O
We,O
found,O
that,O
seasonal,O
ranges,O
of,O
adult,O
females,O
in,O
BB,O
became,O
significantly,O
smaller,O
",",O
by,O
a,O
third,O
to,O
a,O
half,O
",",O
between,O
the,O
1990s,O
and,O
2000s,O
.,O
This,O
range,O
contraction,O
coincided,O
with,O
a,O
northward,O
shift,O
during,O
the,O
on,O
‐,O
ice,O
season,O
.,O
There,O
was,O
no,O
northward,O
shift,O
in,O
summer,O
because,O
bears,B-OG
’,O
ranges,O
contracted,O
on,O
land,O
around,O
similar,O
latitudes,O
as,O
used,O
in,O
the,O
1990s,O
.,O
Further,O
there,O
was,O
<,O
50,O
%,O
overlap,O
in,O
habitats,O
used,O
in,O
the,O
1990s,O
and,O
the,O
2000s,O
.,O
The,O
same,O
patterns,O
and,O
statistical,O
significance,O
were,O
found,O
when,O
a,O
small,O
fraction,O
of,O
Greenland,O
resident,O
bears,B-OG
(,O
AFs,O
that,O
remain,O
year,O
‐,O
round,O
at,O
Melville,O
Bay,O
glacier,O
fronts,O
",",O
SWG,O
",",O
2016,O
),O
were,O
excluded,O
from,O
the,O
analyses,O
.,O
Satellite,O
telemetry,O
also,O
demonstrated,O
significant,O
reduction,O
in,O
emigration,O
from,O
BB,O
since,O
the,O
1990s,O
.,O
Finally,O
",",O
microsatellite,O
analyses,O
for,O
the,O
first,O
time,O
indicated,O
a,O
weak,O
but,O
significant,O
differentiation,O
between,O
adults,O
in,O
BB,O
and,O
KB,O
.,O
Harvest,O
recoveries,O
suggest,O
fidelity,O
to,O
BB,O
has,O
remained,O
high,O
both,O
across,O
and,O
within,O
decades,O
.,O
Our,O
results,O
indicate,O
the,O
BB,O
subpopulation,O
has,O
become,O
more,O
discrete,O
",",O
with,O
less,O
exchange,O
between,O
other,O
neighboring,O
subpopulations,O
.,O
These,O
changes,O
are,O
likely,O
due,O
to,O
reduced,O
sea,O
‐,O
ice,O
extent,O
in,O
winter,O
",",O
early,O
break,O
‐,O
up,O
in,O
spring,O
(,O
Stern,O
&,O
Laidre,O
",",O
2016,O
"),",O
and,O
complete,O
absence,O
of,O
sea,O
ice,O
in,O
summer,O
(,O
SWG,O
2016,O
).,O
Recovery,O
of,O
marks,O
Although,O
the,O
use,O
of,O
tag,O
recoveries,O
is,O
a,O
relatively,O
coarse,O
means,O
of,O
assessing,O
subpopulation,O
closure,O
",",O
it,O
can,O
facilitate,O
the,O
inclusion,O
of,O
data,O
from,O
large,O
numbers,O
of,O
individuals,O
and,O
be,O
complementary,O
to,O
telemetry,O
.,O
The,O
probability,O
of,O
detecting,O
interpopulation,O
movements,O
depends,O
on,O
many,O
factors,O
",",O
including,O
the,O
number,O
of,O
initial,O
marks,O
deployed,O
",",O
the,O
persistence,O
and,O
probability,O
of,O
detecting,O
marks,O
",",O
and,O
the,O
intensity,O
of,O
harvest,O
to,O
recover,O
marks,O
.,O
Additionally,O
",",O
the,O
detection,O
of,O
movement,O
amongst,O
subpopulations,O
does,O
not,O
provide,O
a,O
means,O
of,O
quantifying,O
rates,O
of,O
permanent,O
emigration,O
or,O
immigration,O
.,O
Nevertheless,O
",",O
data,O
on,O
harvest,O
recoveries,O
of,O
marked,O
bears,B-OG
provide,O
a,O
supplemental,O
line,O
of,O
evidence,O
to,O
support,O
subpopulation,O
delineations,O
based,O
on,O
more,O
detailed,O
methods,O
such,O
as,O
cluster,O
analysis,O
of,O
movement,O
data,O
(,O
Taylor,O
et,O
al,O
".,",O
2001,O
).,O
We,O
documented,O
very,O
low,O
levels,O
of,O
harvest,O
recovery,O
of,O
bears,B-OG
outside,O
their,O
subpopulation,O
of,O
origin,O
based,O
on,O
data,O
collected,O
between,O
2011,O
and,O
2014,O
.,O
Bears,B-OG
marked,O
in,O
the,O
final,O
year,O
of,O
study,O
had,O
a,O
near,O
zero,O
probability,O
of,O
recovery,O
because,O
harvest,O
monitoring,O
was,O
not,O
extended,O
far,O
beyond,O
the,O
last,O
year,O
of,O
marking,O
(,O
in,O
2013,O
).,O
However,O
",",O
bears,B-OG
marked,O
in,O
the,O
first,O
2,O
years,O
were,O
available,O
for,O
recovery,O
in,O
the,O
harvest,O
",",O
subject,O
to,O
rates,O
of,O
natural,O
mortality,O
.,O
The,O
total,O
number,O
of,O
bears,B-OG
marked,O
in,O
2011,O
and,O
2012,O
was,O
equivalent,O
to,O
~,O
32,O
%,O
of,O
the,O
point,O
estimate,O
of,O
abundance,O
for,O
the,O
BB,O
subpopulation,O
(,O
SWG,O
",",O
2016,O
).,O
Despite,O
marking,O
a,O
large,O
proportion,O
of,O
the,O
subpopulation,O
and,O
the,O
continuous,O
monitoring,O
of,O
harvest,O
within,O
BB,O
and,O
surrounding,O
subpopulations,O
",",O
instances,O
of,O
emigration,O
were,O
only,O
approximately,O
1,O
%,O
of,O
the,O
recoveries,O
of,O
BB,O
marks,O
.,O
Our,O
findings,O
imply,O
that,O
BB,O
bears,B-OG
exhibit,O
a,O
high,O
degree,O
of,O
short,O
‐,O
term,O
fidelity,O
to,O
this,O
geographically,O
defined,O
unit,O
",",O
which,O
is,O
consistent,O
with,O
estimates,O
of,O
site,O
fidelity,O
derived,O
from,O
mark,O
–,O
recapture,O
analyses,O
(,O
SWG,O
",",O
2016,O
).,O
Examining,O
long,O
‐,O
term,O
harvest,O
recoveries,O
of,O
marked,O
bears,B-OG
over,O
a,O
14,O
‐,O
year,O
period,O
",",O
we,O
found,O
that,O
83,O
%,O
of,O
recovered,O
bears,B-OG
marked,O
in,O
BB,O
in,O
the,O
1990,O
',O
s,O
were,O
recovered,O
within,O
BB,O
.,O
Considering,O
BB,O
and,O
adjacent,O
subpopulations,O
were,O
subject,O
to,O
broadly,O
similar,O
harvest,O
rates,O
and,O
management,O
regimes,O
during,O
this,O
interval,O
",",O
this,O
suggests,O
relatively,O
high,O
long,O
‐,O
term,O
fidelity,O
to,O
BB,O
(,O
PBSG,O
2010,O
).,O
Of,O
note,O
",",O
prior,O
to,O
2006,O
when,O
quotas,O
were,O
introduced,O
in,O
Greenland,O
",",O
there,O
was,O
significant,O
uncertainty,O
in,O
the,O
accuracy,O
of,O
the,O
reported,O
polar,B-OG
bear,I-OG
harvest,O
from,O
BB,O
and,O
KB,O
(,O
SWG,O
",",O
2016,O
).,O
The,O
extent,O
to,O
which,O
marked,O
bears,B-OG
were,O
under,O
or,O
over,O
reported,O
prior,O
to,O
that,O
date,O
is,O
unknown,O
",",O
however,O
",",O
new,O
monitoring,O
and,O
mandatory,O
reporting,O
laws,O
have,O
substantially,O
improved,O
reporting,O
since,O
then,O
.,O
For,O
comparison,O
with,O
our,O
results,O
",",O
recent,O
demographic,O
analyses,O
for,O
BB,O
used,O
live,O
‐,O
recapture,O
–,O
dead,O
‐,O
recovery,O
models,O
to,O
estimate,O
probabilities,O
of,O
natural,O
survival,O
",",O
harvest,O
mortality,O
",",O
and,O
fidelity,O
in,O
a,O
unified,O
modeling,O
framework,O
(,O
SWG,O
",",O
2016,O
"),",O
with,O
estimated,O
time,O
‐,O
constant,O
fidelity,O
rates,O
of,O
0,O
.,O
97,O
for,O
males,O
age,O
≥,O
2,O
years,O
",",O
and,O
0,O
.,O
96,O
for,O
other,O
sex,O
and,O
age,O
classes,O
for,O
the,O
period,O
1993,O
–,O
2013,O
.,O
Although,O
sample,O
sizes,O
were,O
insufficient,O
to,O
investigate,O
complex,O
patterns,O
and,O
“,O
fidelity,O
”,O
was,O
defined,O
relative,O
to,O
the,O
onshore,O
",",O
summer,O
sampling,O
area,O
(,O
as,O
opposed,O
to,O
the,O
BB,O
management,O
unit,O
",",O
in,O
the,O
current,O
analysis,O
),O
results,O
from,O
capture,O
–,O
recapture,O
modeling,O
support,O
our,O
finding,O
of,O
relatively,O
high,O
fidelity,O
of,O
polar,B-OG
bears,I-OG
in,O
BB,O
.,O
Movements,O
between,O
Baffin,O
Bay,O
and,O
Davis,O
Strait,O
The,O
boundary,O
between,O
the,O
BB,O
and,O
DS,O
subpopulations,O
is,O
spanned,O
by,O
pack,O
ice,O
in,O
spring,O
that,O
provides,O
a,O
continuous,O
platform,O
for,O
bears,B-OG
to,O
move,O
between,O
subpopulations,O
(,O
Stern,O
&,O
Laidre,O
",",O
2016,O
).,O
Nevertheless,O
",",O
consistent,O
differences,O
between,O
BB,O
and,O
DS,O
polar,B-OG
bears,I-OG
have,O
been,O
shown,O
through,O
genetics,O
(,O
Paetkau,O
et,O
al,O
".,",O
1999,O
;,O
Peacock,O
et,O
al,O
".,",O
2015,O
;,O
this,O
study,O
"),",O
movements,O
(,O
Taylor,O
et,O
al,O
".,",O
2001,O
"),",O
and,O
diet,O
(,O
Thiemann,O
",",O
Iverson,O
",",O
&,O
Stirling,O
",",O
2008,O
"),",O
suggesting,O
a,O
functional,O
boundary,O
between,O
them,O
.,O
Here,O
",",O
we,O
investigated,O
if,O
there,O
has,O
been,O
an,O
increased,O
exchange,O
of,O
polar,B-OG
bears,I-OG
across,O
this,O
boundary,O
",",O
which,O
could,O
contribute,O
to,O
exchange,O
between,O
subpopulations,O
.,O
Since,O
1990,O
",",O
marking,O
effort,O
(,O
i,O
.,O
e,O
".,",O
number,O
of,O
unique,O
individuals,O
marked,O
),O
in,O
BB,O
and,O
DS,O
was,O
equivalent,O
to,O
41,O
%,O
(,O
BB,O
1991,O
–,O
1997,O
"),",O
70,O
%,O
(,O
DS,O
2005,O
–,O
2007,O
"),",O
and,O
44,O
%,O
(,O
BB,O
2011,O
–,O
2013,O
),O
of,O
estimated,O
abundance,O
at,O
the,O
time,O
of,O
marking,O
(,O
Peacock,O
et,O
al,O
".,",O
2013,O
;,O
SWG,O
",",O
2016,O
).,O
The,O
large,O
number,O
of,O
marks,O
released,O
",",O
combined,O
with,O
few,O
interpopulation,O
recaptures,O
or,O
recoveries,O
between,O
BB,O
and,O
DS,O
(,O
1,O
%,O
in,O
each,O
direction,O
"),",O
suggest,O
that,O
the,O
boundary,O
between,O
these,O
two,O
subpopulations,O
remains,O
relatively,O
strong,O
.,O
Similarly,O
",",O
the,O
telemetry,O
data,O
of,O
collared,O
BB,O
bears,B-OG
demonstrate,O
a,O
reduced,O
frequency,O
of,O
visitation,O
to,O
DS,O
.,O
Bears,B-OG
that,O
moved,O
between,O
BB,O
and,O
DS,O
tended,O
to,O
be,O
initially,O
captured,O
close,O
to,O
the,O
BB,O
‐,O
DS,O
boundary,O
(<,O
100,O
km,O
).,O
This,O
may,O
reflect,O
the,O
high,O
degree,O
of,O
fidelity,O
shown,O
by,O
BB,O
and,O
DS,O
bears,B-OG
to,O
their,O
seasonal,O
onshore,O
range,O
(,O
e,O
.,O
g,O
".,",O
Taylor,O
et,O
al,O
".,",O
2001,O
"),",O
similar,O
for,O
other,O
subpopulations,O
(,O
Wiig,O
",",O
1995,O
;,O
Mauritzen,O
",",O
Derocher,O
",",O
&,O
Wiig,O
",",O
2001,O
;,O
Stirling,O
",",O
Lunn,O
",",O
Iacozza,O
",",O
Elliott,O
",",O
&,O
Obbard,O
",",O
2004,O
;,O
Zeyl,O
",",O
Ehrich,O
",",O
Aars,O
",",O
Bachmann,O
",",O
&,O
Wiig,O
",",O
2010,O
).,O
Genetic,O
connectivity,O
between,O
subpopulations,O
Previous,O
analysis,O
of,O
polar,B-OG
bear,I-OG
population,O
structure,O
using,O
microsatellites,O
showed,O
no,O
significant,O
genetic,O
differences,O
between,O
BB,O
and,O
neighboring,O
KB,O
(,O
Paetkau,O
et,O
al,O
".,",O
1999,O
"),",O
though,O
studies,O
have,O
found,O
that,O
bears,B-OG
from,O
BB,O
‐,O
KB,O
differed,O
genetically,O
from,O
the,O
LS,O
and,O
DS,O
subpopulations,O
(,O
Paetkau,O
et,O
al,O
".,",O
1999,O
;,O
Peacock,O
et,O
al,O
".,",O
2015,O
;,O
Malenfant,O
et,O
al,O
".,",O
2016,O
).,O
In,O
contrast,O
",",O
we,O
found,O
low,O
but,O
significant,O
FST,O
estimates,O
between,O
winter,O
–,O
spring,O
samples,O
from,O
BB,O
and,O
KB,O
.,O
This,O
could,O
be,O
due,O
to,O
groupings,O
of,O
closely,O
related,O
individuals,O
(,O
e,O
.,O
g,O
".,",O
siblings,O
or,O
parent,O
‐,O
offspring,O
in,O
the,O
samples,O
).,O
However,O
",",O
another,O
explanation,O
is,O
that,O
the,O
results,O
may,O
be,O
an,O
early,O
indication,O
of,O
increasing,O
differentiation,O
between,O
the,O
two,O
subpopulations,O
.,O
This,O
pattern,O
was,O
not,O
captured,O
by,O
the,O
Bayesian,O
methods,O
due,O
to,O
the,O
low,O
observed,O
F,O
ST,O
estimates,O
as,O
Bayesian,O
STRUCTURE,O
does,O
not,O
always,O
infer,O
the,O
correct,O
number,O
of,O
clusters,O
when,O
F,O
ST,O
<,O
0,O
.,O
02,O
(,O
Chen,O
",",O
Durand,O
",",O
Forbes,O
",",O
&,O
François,O
",",O
2007,O
;,O
Latch,O
",",O
Dharmarajan,O
",",O
Glaubitz,O
",",O
&,O
Rhodes,O
",",O
2006,O
).,O
Our,O
study,O
provides,O
an,O
updated,O
genetic,O
comparison,O
between,O
BB,O
and,O
KB,O
based,O
on,O
recent,O
data,O
collected,O
after,O
the,O
onset,O
of,O
large,O
‐,O
scale,O
sea,O
‐,O
ice,O
loss,O
in,O
Baffin,O
Bay,O
and,O
Kane,O
Basin,O
.,O
In,O
all,O
prior,O
studies,O
",",O
the,O
KB,O
samples,O
were,O
collected,O
in,O
the,O
early,O
1990s,O
(,O
Paetkau,O
et,O
al,O
".,",O
1999,O
;,O
Peacock,O
et,O
al,O
".,",O
2015,O
;,O
Malenfant,O
et,O
al,O
".,",O
2016,O
).,O
Future,O
sea,O
‐,O
ice,O
loss,O
is,O
expected,O
to,O
fragment,O
polar,B-OG
bear,I-OG
subpopulations,O
",",O
increase,O
isolation,O
",",O
alter,O
gene,O
flow,O
",",O
and,O
disrupt,O
population,O
boundaries,O
(,O
Derocher,O
",",O
Lunn,O
",",O
&,O
Stirling,O
",",O
2004,O
;,O
Kutschera,O
et,O
al,O
".,",O
2016,O
;,O
Sahanatian,O
&,O
Derocher,O
",",O
2012,O
).,O
Genetic,O
variation,O
in,O
polar,B-OG
bears,I-OG
is,O
relatively,O
low,O
",",O
and,O
genetics,O
is,O
a,O
relatively,O
insensitive,O
means,O
of,O
identifying,O
",",O
defining,O
",",O
or,O
detecting,O
change,O
in,O
subpopulation,O
structure,O
",",O
especially,O
when,O
compared,O
to,O
individual,O
‐,O
based,O
telemetry,O
and,O
tag,O
recoveries,O
.,O
Time,O
‐,O
lag,O
effects,O
in,O
genetic,O
composition,O
are,O
influenced,O
by,O
the,O
relatively,O
long,O
generation,O
length,O
for,O
polar,B-OG
bears,I-OG
(~,O
11,O
.,O
5,O
years,O
;,O
Regehr,O
et,O
al,O
".,",O
2016,O
"),",O
and,O
several,O
generations,O
may,O
be,O
needed,O
to,O
demonstrate,O
increased,O
genetic,O
isolation,O
as,O
a,O
consequence,O
of,O
climate,O
‐,O
induced,O
range,O
contraction,O
.,O
Collectively,O
",",O
our,O
findings,O
from,O
multiple,O
lines,O
of,O
evidence,O
suggest,O
that,O
the,O
current,O
BB,O
subpopulation,O
boundaries,O
continue,O
to,O
be,O
relevant,O
for,O
harvest,O
management,O
and,O
subpopulation,O
monitoring,O
.,O
However,O
",",O
an,O
important,O
consideration,O
is,O
that,O
the,O
subpopulation,O
range,O
is,O
contracting,O
and,O
there,O
appears,O
to,O
be,O
reduced,O
connectivity,O
with,O
subpopulations,O
to,O
the,O
west,O
and,O
south,O
.,O
Our,O
results,O
provide,O
evidence,O
that,O
the,O
BB,O
subpopulation,O
is,O
becoming,O
increasing,O
isolated,O
",",O
with,O
reduced,O
range,O
sizes,O
",",O
shifts,O
northward,O
",",O
and,O
reduced,O
emigration,O
across,O
subpopulation,O
boundaries,O
.,O
These,O
changes,O
are,O
almost,O
certainly,O
driven,O
by,O
loss,O
of,O
sea,O
ice,O
(,O
Stern,O
&,O
Laidre,O
",",O
2016,O
).,O
In,O
general,O
",",O
telemetry,O
and,O
genetics,O
share,O
major,O
advantages,O
including,O
standardized,O
objective,O
methodologies,O
for,O
delineating,O
demographic,O
structure,O
allowing,O
for,O
broad,O
inferences,O
on,O
movements,O
and,O
for,O
calculating,O
immigration,O
and,O
emigration,O
rates,O
.,O
In,O
our,O
study,O
",",O
both,O
telemetry,O
and,O
tag,O
recovery,O
data,O
provided,O
early,O
signals,O
of,O
range,O
shifts,O
and,O
changes,O
in,O
individual,O
movements,O
between,O
local,O
populations,O
.,O
Although,O
our,O
genetic,O
analyses,O
had,O
relatively,O
coarse,O
resolution,O
",",O
primarily,O
because,O
the,O
markers,O
used,O
were,O
intended,O
for,O
mark,O
–,O
recapture,O
and,O
not,O
dispersal,O
",",O
the,O
results,O
indicated,O
a,O
differentiation,O
between,O
the,O
BB,O
and,O
KB,O
subpopulations,O
.,O
More,O
detailed,O
genetic,O
analyses,O
would,O
be,O
worthwhile,O
to,O
explore,O
this,O
further,O
.,O
Sea,O
‐,O
ice,O
loss,O
is,O
predicted,O
to,O
continue,O
and,O
information,O
from,O
telemetry,O
and,O
marked,O
or,O
recovered,O
bears,B-OG
through,O
long,O
‐,O
term,O
monitoring,O
programs,O
(,O
i,O
.,O
e,O
".,",O
Laidre,O
et,O
al,O
".,",O
2015,O
),O
will,O
be,O
critical,O
to,O
understanding,O
increased,O
fragmentation,O
among,O
polar,B-OG
bear,I-OG
subpopulations,O
.,O
One,O
key,O
question,O
unanswered,O
is,O
how,O
loss,O
of,O
sea,O
ice,O
will,O
alter,O
dispersal,O
patterns,O
of,O
apex,O
predators,O
",",O
either,O
by,O
increasing,O
genetic,O
exchange,O
as,O
barriers,O
to,O
dispersal,O
are,O
removed,O
or,O
by,O
increasing,O
isolation,O
as,O
platforms,O
for,O
genetic,O
transfer,O
disappear,O
.,O
In,O
some,O
cases,O
",",O
different,O
patterns,O
may,O
emerge,O
within,O
a,O
species,O
",",O
depending,O
on,O
their,O
dispersal,O
ability,O
and,O
how,O
loss,O
of,O
habitat,O
redistributes,O
subpopulations,O
.,O
For,O
example,O
",",O
in,O
areas,O
around,O
the,O
Arctic,O
Basin,O
where,O
sea,O
ice,O
converges,O
or,O
diverges,O
(,O
Amstrup,O
et,O
al,O
".,",O
2008,O
"),",O
polar,B-OG
bears,I-OG
from,O
multiple,O
subpopulations,O
may,O
become,O
aggregated,O
or,O
even,O
mix,O
.,O
However,O
",",O
in,O
the,O
seasonal,O
ice,O
polar,B-OG
bear,I-OG
ecoregion,O
(,O
Amstrup,O
et,O
al,O
".,",O
2008,O
"),",O
where,O
annual,O
sea,O
ice,O
exerts,O
strong,O
control,O
on,O
movements,O
and,O
directly,O
influences,O
the,O
amount,O
of,O
time,O
and,O
area,O
bears,B-OG
have,O
to,O
use,O
and,O
interact,O
",",O
the,O
loss,O
of,O
sea,O
ice,O
is,O
likely,O
to,O
make,O
subpopulations,O
more,O
isolated,O
.,O
These,O
findings,O
and,O
methods,O
may,O
prove,O
useful,O
for,O
reassessing,O
polar,B-OG
bear,I-OG
subpopulation,O
boundaries,O
in,O
a,O
future,O
with,O
reduced,O
sea,O
ice,O
.,O
Changes,O
in,O
exchange,O
between,O
subpopulations,O
are,O
expected,O
with,O
climate,O
change,O
and,O
broadly,O
the,O
concept,O
of,O
boundaries,O
may,O
have,O
to,O
be,O
reassessed,O
.,O
CONFLICT,O
OF,O
INTEREST,O
,O
declared,O
.,O
AUTHORS,O
CONTRIBUTION,O
EWB,O
",",O
KLL,O
",",O
NJL,O
",",O
SNA,O
",",O
and,O
ØW,O
conceived,O
and,O
designed,O
the,O
study,O
and,O
sampling,O
scheme,O
.,O
EWB,O
",",O
MD,O
",",O
and,O
SNA,O
acquired,O
permits,O
.,O
EWB,O
",",O
KLL,O
",",O
MD,O
",",O
SNA,O
",",O
and,O
ØW,O
conducted,O
the,O
fieldwork,O
.,O
KLL,O
",",O
LWA,O
",",O
PH,O
",",O
RMG,O
",",O
and,O
SNA,O
analyzed,O
the,O
data,O
.,O
All,O
authors,O
contributed,O
to,O
writing,O
of,O
the,O
manuscript,O
and,O
approved,O
the,O
final,O
published,O
version,O
.,O
Supporting,O
information,O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Longitudinal,O
Genome,O
-,O
Wide,O
Association,O
of,O
Cardiovascular,B-DS
Disease,I-DS
Risk,O
Factors,O
in,O
the,O
Bogalusa,O
Heart,O
Study,O
Conceived,O
and,O
designed,O
the,O
experiments,O
:,O
ENS,O
MK,O
TL,O
LP,O
OTR,O
RMS,O
NJS,O
EJT,O
GSB,O
SSM,O
.,O
Performed,O
the,O
experiments,O
:,O
ENS,O
MK,O
TL,O
MS,O
SSM,O
.,O
Analyzed,O
the,O
data,O
:,O
ENS,O
JK,O
OTR,O
RMS,O
SSM,O
.,O
Contributed,O
reagents,O
/,O
materials,O
/,O
analysis,O
tools,O
:,O
WC,O
MK,O
JK,O
TL,O
LP,O
OTR,O
SRS,O
JSV,O
GSB,O
.,O
Wrote,O
the,O
paper,O
:,O
ENS,O
TL,O
OTR,O
NJS,O
SSM,O
.,O
Cardiovascular,B-DS
disease,I-DS
(,O
CVD,B-DS
),O
is,O
the,O
leading,O
cause,O
of,O
death,O
worldwide,O
.,O
Recent,O
genome,O
-,O
wide,O
association,O
(,O
GWA,O
),O
studies,O
have,O
pinpointed,O
many,O
loci,O
associated,O
with,O
CVD,B-DS
risk,O
factors,O
in,O
adults,O
.,O
It,O
is,O
unclear,O
",",O
however,O
",",O
if,O
these,O
loci,O
predict,O
trait,O
levels,O
at,O
all,O
ages,O
",",O
if,O
they,O
are,O
associated,O
with,O
how,O
a,O
trait,O
develops,O
over,O
time,O
",",O
or,O
if,O
they,O
could,O
be,O
used,O
to,O
screen,O
individuals,O
who,O
are,O
pre,O
-,O
symptomatic,O
to,O
provide,O
the,O
opportunity,O
for,O
preventive,O
measures,O
before,O
disease,O
onset,O
.,O
We,O
completed,O
a,O
genome,O
-,O
wide,O
association,O
study,O
on,O
participants,O
in,O
the,O
longitudinal,O
Bogalusa,O
Heart,O
Study,O
(,O
BHS,O
),O
and,O
have,O
characterized,O
the,O
association,O
between,O
genetic,O
factors,O
and,O
the,O
development,O
of,O
CVD,B-DS
risk,O
factors,O
from,O
childhood,O
to,O
adulthood,O
.,O
We,O
report,O
7,O
genome,O
-,O
wide,O
significant,O
associations,O
involving,O
CVD,B-DS
risk,O
factors,O
",",O
two,O
of,O
which,O
have,O
been,O
previously,O
reported,O
.,O
Top,O
regions,O
were,O
tested,O
for,O
replication,O
in,O
the,O
Young,O
Finns,O
Study,O
(,O
YF,O
),O
and,O
two,O
associations,O
strongly,O
replicated,O
:,O
rs247616,O
in,O
CETP,B-GP
with,O
HDL,O
levels,O
(,O
combined,O
P,O
=,O
9,O
.,O
7,O
×,O
10,O
−,O
24,O
"),",O
and,O
rs445925,O
at,O
APOE,B-GP
with,O
LDL,O
levels,O
(,O
combined,O
P,O
=,O
8,O
.,O
7,O
×,O
10,O
−,O
19,O
).,O
We,O
show,O
that,O
SNPs,O
previously,O
identified,O
in,O
adult,O
cross,O
-,O
sectional,O
studies,O
tend,O
to,O
show,O
age,O
-,O
independent,O
effects,O
in,O
the,O
BHS,O
with,O
effect,O
sizes,O
consistent,O
with,O
previous,O
reports,O
.,O
Previously,O
identified,O
variants,O
were,O
associated,O
with,O
adult,O
trait,O
levels,O
above,O
and,O
beyond,O
those,O
seen,O
in,O
childhood,O
;,O
however,O
",",O
variants,O
with,O
time,O
-,O
dependent,O
effects,O
were,O
also,O
promising,O
predictors,O
.,O
This,O
is,O
the,O
first,O
GWA,O
study,O
to,O
evaluate,O
the,O
role,O
of,O
common,O
genetic,O
variants,O
in,O
the,O
development,O
of,O
CVD,B-DS
risk,O
factors,O
in,O
children,O
as,O
they,O
advance,O
through,O
adulthood,O
and,O
highlights,O
the,O
utility,O
of,O
using,O
longitudinal,O
studies,O
to,O
identify,O
genetic,O
predictors,O
of,O
adult,O
traits,O
in,O
children,O
.,O
Author,O
Summary,O
We,O
have,O
studied,O
the,O
association,O
between,O
genetic,O
factors,O
on,O
a,O
whole,O
genome,O
level,O
and,O
cardiovascular,B-DS
disease,I-DS
(,O
CVD,B-DS
),O
risk,O
factors,O
in,O
a,O
population,O
of,O
individuals,O
studied,O
from,O
childhood,O
through,O
adulthood,O
.,O
The,O
longitudinal,O
study,O
design,O
has,O
enabled,O
the,O
investigation,O
of,O
genetic,O
variation,O
influencing,O
trait,O
values,O
over,O
time,O
.,O
We,O
have,O
identified,O
DNA,O
variants,O
that,O
are,O
associated,O
with,O
CVD,B-DS
trait,O
values,O
consistently,O
over,O
time,O
",",O
and,O
a,O
second,O
set,O
of,O
variants,O
that,O
are,O
associated,O
with,O
CVD,B-DS
trait,O
values,O
in,O
a,O
time,O
-,O
dependent,O
manner,O
.,O
We,O
also,O
show,O
that,O
variants,O
previously,O
identified,O
in,O
adult,O
populations,O
have,O
consistent,O
effects,O
within,O
our,O
population,O
and,O
that,O
these,O
effects,O
are,O
usually,O
similar,O
across,O
childhood,O
through,O
adulthood,O
.,O
The,O
discovery,O
of,O
time,O
-,O
dependent,O
variants,O
that,O
influence,O
CVD,B-DS
trait,O
values,O
over,O
time,O
can,O
potentially,O
be,O
used,O
to,O
screen,O
young,O
individuals,O
who,O
are,O
pre,O
-,O
symptomatic,O
and,O
provide,O
the,O
opportunity,O
for,O
preventive,O
measures,O
decades,O
before,O
disease,O
onset,O
.,O
Introduction,O
Cardiovascular,B-DS
disease,I-DS
(,O
CVD,B-DS
),O
affects,O
over,O
79,O
million,O
people,O
in,O
the,O
United,O
States,O
[,O
1,O
"],",O
and,O
is,O
the,O
leading,O
cause,O
of,O
death,O
worldwide,O
[,O
2,O
]–[,O
4,O
].,O
Identifying,O
the,O
genetic,O
determinants,O
of,O
CVD,B-DS
can,O
lead,O
to,O
more,O
effective,O
diagnostics,O
",",O
prognostics,O
",",O
therapeutics,O
",",O
and,O
",",O
ultimately,O
",",O
preventive,O
strategies,O
.,O
The,O
best,O
chance,O
for,O
prevention,O
would,O
be,O
to,O
identify,O
risk,O
at,O
the,O
earliest,O
possible,O
age,O
.,O
Genome,O
-,O
wide,O
association,O
(,O
GWA,O
),O
leveraging,O
cross,O
-,O
sectional,O
phenotypic,O
data,O
has,O
been,O
a,O
particularly,O
useful,O
approach,O
to,O
identifying,O
loci,O
that,O
influence,O
many,O
of,O
the,O
quantitative,O
risk,O
factors,O
of,O
CVD,B-DS
[,O
5,O
]–[,O
10,O
"],",O
however,O
the,O
use,O
of,O
cross,O
sectional,O
data,O
does,O
not,O
provide,O
insight,O
into,O
how,O
such,O
risk,O
factors,O
develop,O
over,O
time,O
.,O
Longitudinal,O
studies,O
",",O
particularly,O
those,O
that,O
begin,O
in,O
childhood,O
",",O
allow,O
for,O
the,O
identification,O
of,O
risk,O
profiles,O
of,O
susceptible,O
individuals,O
before,O
disease,O
onset,O
.,O
The,O
Bogalusa,O
Heart,O
Study,O
(,O
BHS,O
),O
is,O
a,O
longitudinal,O
study,O
focused,O
on,O
the,O
early,O
natural,O
history,O
of,O
CVD,B-DS
.,O
The,O
BHS,O
began,O
in,O
1973,O
and,O
includes,O
up,O
to,O
9,O
phenotypic,O
screenings,O
in,O
childhood,O
(,O
4,O
–,O
17,O
years,O
of,O
age,O
),O
and,O
up,O
to,O
10,O
adult,O
(,O
18,O
–,O
48,O
years,O
of,O
age,O
),O
cross,O
-,O
sectional,O
screenings,O
.,O
We,O
have,O
conducted,O
a,O
longitudinal,O
genome,O
-,O
wide,O
association,O
study,O
on,O
a,O
subset,O
of,O
the,O
total,O
sample,O
of,O
unrelated,O
individuals,O
with,O
a,O
large,O
number,O
of,O
measurements,O
(,O
mean,O
number,O
of,O
measurements,O
=,O
8,O
",",O
range,O
=,O
4,O
–,O
13,O
),O
and,O
are,O
of,O
European,O
Ancestry,O
(,O
N,O
=,O
525,O
).,O
Results,O
Longitudinal,O
GWA,O
We,O
conducted,O
a,O
genome,O
-,O
wide,O
association,O
study,O
of,O
longitudinal,O
measures,O
of,O
12,O
traits,O
measured,O
from,O
childhood,O
through,O
adulthood,O
on,O
participants,O
of,O
the,O
BHS,O
of,O
European,O
ancestry,O
:,O
anthropomorphic,O
(,O
height,O
",",O
weight,O
",",O
and,O
waist,O
circumference,O
"),",O
blood,O
pressure,O
(,O
BP,O
),O
(,O
diastolic,O
and,O
systolic,O
BP,O
"),",O
heart,O
rate,O
",",O
blood,O
lipids,O
(,O
low,O
density,O
lipoprotein,O
cholesterol,O
(,O
LDL,O
"),",O
high,O
density,O
lipoprotein,O
cholesterol,O
(,O
HDL,O
"),",O
total,O
cholesterol,O
(,O
TC,O
"),",O
and,O
triglycerides,O
"),",O
and,O
metabolic,O
traits,O
(,O
glucose,O
and,O
insulin,B-GP
).,O
Genotyping,O
was,O
performed,O
on,O
the,O
Illumina,O
Human610,O
and,O
HumanCVD,O
BeadChips,O
[,O
11,O
],O
for,O
a,O
total,O
of,O
545,O
",",O
821,O
SNPs,O
passing,O
QC,O
and,O
allele,O
frequency,O
filters,O
(,O
see,O
Materials,O
and,O
Methods,O
).,O
Imputation,O
was,O
performed,O
using,O
the,O
CEU,O
HapMap,O
2,O
as,O
a,O
reference,O
population,O
with,O
the,O
computer,O
program,O
MACH,O
v,O
.,O
1,O
.,O
0,O
.,O
16,O
(,O
http,O
://,O
www,O
.,O
sph,O
.,O
umich,O
.,O
edu,O
/,O
csg,O
/,O
yli,O
/,O
mach,O
/),O
[,O
12,O
"],",O
providing,O
genotype,O
estimates,O
for,O
an,O
additional,O
1,O
",",O
622,O
",",O
114,O
SNPs,O
.,O
For,O
each,O
SNP,O
",",O
we,O
tested,O
whether,O
it,O
had,O
an,O
average,O
linear,O
effect,O
over,O
time,O
(,O
SNP,O
effect,O
"),",O
and,O
whether,O
it,O
entered,O
into,O
a,O
time,O
-,O
dependent,O
effect,O
(,O
SNPxAGE,O
interaction,O
effect,O
"),",O
such,O
that,O
the,O
genotype,O
is,O
associated,O
with,O
variation,O
in,O
the,O
linear,O
trajectory,O
of,O
the,O
trait,O
from,O
childhood,O
through,O
adulthood,O
.,O
Both,O
SNP,O
and,O
SNPxAGE,O
effects,O
were,O
calculated,O
using,O
linear,O
mixed,O
models,O
as,O
implemented,O
in,O
the,O
R,O
nlme,O
package,O
[,O
13,O
"],",O
adjusting,O
for,O
age,O
and,O
gender,O
.,O
Table,O
1,O
lists,O
all,O
regions,O
showing,O
SNP,O
effect,O
associations,O
(,O
P,O
<,O
10,O
−,O
6,O
),O
and,O
Table,O
2,O
lists,O
all,O
regions,O
showing,O
association,O
(,O
P,O
<,O
10,O
−,O
6,O
),O
with,O
SNPxAGE,O
effects,O
.,O
We,O
analyzed,O
the,O
regions,O
surrounding,O
the,O
top,O
associations,O
for,O
consistency,O
with,O
recombination,O
hotspots,O
and,O
LD,O
relationships,O
(,O
Figure,O
S1,O
),O
and,O
provide,O
Manhattan,O
plots,O
of,O
each,O
trait,O
association,O
(,O
Figure,O
S2,O
).,O
From,O
both,O
sets,O
of,O
analyses,O
",",O
there,O
were,O
5,O
novel,O
associations,O
with,O
a,O
P,O
-,O
value,O
less,O
than,O
5,O
×,O
10,O
−,O
8,O
and,O
6,O
novel,O
regions,O
where,O
there,O
were,O
at,O
least,O
10,O
genotyped,O
or,O
imputed,O
SNPs,O
with,O
P,O
<,O
10,O
−,O
5,O
.,O
The,O
most,O
significant,O
association,O
(,O
rs7890572,O
",",O
P,O
=,O
3,O
.,O
8,O
×,O
10,O
−,O
10,O
),O
was,O
observed,O
with,O
a,O
linear,O
triglyceride,O
trajectory,O
effect,O
(,O
i,O
.,O
e,O
".,",O
SNPxAGE,O
effect,O
),O
on,O
the,O
X,O
chromosome,O
within,O
the,O
IL1RAPL1,B-GP
gene,O
and,O
near,O
the,O
gene,O
encoding,O
glycerol,B-GP
kinase,I-GP
(,O
GK,B-GP
"),",O
in,O
which,O
mutations,O
have,O
been,O
implicated,O
in,O
pseudo,O
-,O
hypertriglyceridemia,B-DS
",",O
caused,O
by,O
high,O
levels,O
of,O
glycerol,O
creating,O
measurement,O
artifacts,O
in,O
the,O
triglyceride,O
assay,O
[,O
14,O
].,O
A,O
novel,O
association,O
of,O
potential,O
biological,O
interest,O
involved,O
a,O
SNP,O
effect,O
on,O
insulin,B-GP
levels,O
with,O
variation,O
in,O
the,O
CHN2,B-GP
locus,O
(,O
rs3793275,O
",",O
P,O
=,O
5,O
.,O
8,O
×,O
10,O
−,O
9,O
"),",O
a,O
beta,B-GP
-,I-GP
chimerin,I-GP
that,O
has,O
recently,O
been,O
described,O
as,O
part,O
of,O
a,O
fusion,O
gene,O
also,O
containing,O
the,O
insulin,B-GP
receptor,I-GP
that,O
was,O
shown,O
to,O
be,O
responsible,O
for,O
severe,O
insulin,B-GP
deficiency,O
[,O
15,O
].,O
This,O
SNP,O
is,O
also,O
associated,O
with,O
glucose,O
trajectories,O
in,O
our,O
dataset,O
(,O
SNPxAGE,O
;,O
P,O
=,O
1,O
.,O
5,O
×,O
10,O
−,O
7,O
).,O
In,O
the,O
7q11,O
region,O
",",O
25,O
SNPs,O
are,O
associated,O
(,O
P,O
<,O
10,O
−,O
5,O
),O
with,O
diastolic,O
BP,O
(,O
SNP,O
effect,O
;,O
peak,O
SNP,O
rs709595,O
",",O
P,O
=,O
7,O
.,O
0,O
×,O
10,O
−,O
7,O
).,O
The,O
calcitonin,B-GP
gene,I-GP
-,I-GP
related,I-GP
peptide,I-GP
receptor,I-GP
(,O
CRCP,B-GP
),O
is,O
approximately,O
200,O
kb,O
from,O
the,O
top,O
SNP,O
",",O
but,O
contains,O
SNPs,O
that,O
are,O
in,O
LD,O
with,O
the,O
top,O
SNP,O
(,O
see,O
Figure,O
S1,O
).,O
The,O
calcitonin,B-GP
gene,I-GP
-,I-GP
related,I-GP
peptide,I-GP
is,O
a,O
vasodilator,O
[,O
16,O
],O
and,O
its,O
receptor,O
CRCP,B-GP
has,O
been,O
previously,O
implicated,O
in,O
hypertension,B-DS
in,O
a,O
small,O
candidate,O
gene,O
association,O
study,O
of,O
hypertension,B-DS
in,O
Japanese,O
individuals,O
[,O
17,O
].,O
Top,O
SNP,O
effect,O
GWA,O
hits,O
for,O
12,O
phenotypes,O
.,O
Trait,O
Cytoband,O
Gene,O
(,O
s,O
),O
Top,O
SNP,O
",",O
Alleles,O
#,O
SNPs,O
@,O
P,O
<,O
10,O
−,O
5,O
Risk,O
AF,O
Beta,O
(,O
SE,O
),O
P,O
diastolic,O
BP,O
5p13,O
.,O
3,O
CDH9,O
/,O
CDH6,O
rs7704530,O
G,O
/,O
A,O
2,O
/,O
3,O
0,O
.,O
26,O
8,O
.,O
44,O
(,O
1,O
.,O
57,O
),O
1,O
.,O
1,O
×,O
10,O
−,O
7,O
diastolic,O
BP,O
7q11,O
.,O
21,O
TPST1,O
rs709595,O
C,O
/,O
G,O
8,O
/,O
17,O
0,O
.,O
39,O
7,O
.,O
18,O
(,O
1,O
.,O
43,O
),O
7,O
.,O
0,O
×,O
10,O
−,O
7,O
glucose,O
2q24,O
.,O
3,O
G6PC2,B-GP
",",O
ABCB11,O
rs853773,O
A,O
/,O
G,O
4,O
/,O
1,O
0,O
.,O
53,O
−,O
8,O
.,O
72,O
(,O
1,O
.,O
73,O
),O
7,O
.,O
0,O
×,O
10,O
−,O
7,O
glucose,O
6q22,O
.,O
31,O
NKAIN2,O
/,O
RNF217,O
rs781718,O
*,O
G,O
/,O
A,O
1,O
/,O
4,O
0,O
.,O
89,O
−,O
3,O
.,O
46,O
(,O
0,O
.,O
69,O
),O
8,O
.,O
4,O
×,O
10,O
−,O
7,O
HDL,O
-,O
cholesterol,O
16q12,O
.,O
2,O
HERPUD1,O
/,O
CETP,B-GP
rs247616,O
*,O
T,O
/,O
C,O
4,O
/,O
2,O
0,O
.,O
33,O
3,O
.,O
77,O
(,O
0,O
.,O
75,O
),O
6,O
.,O
6,O
×,O
10,O
−,O
7,O
insulin,B-GP
7p14,O
.,O
3,O
CHN2,B-GP
rs3793275,O
*,O
A,O
/,O
T,O
1,O
/,O
3,O
0,O
.,O
94,O
−,O
4,O
.,O
63,O
(,O
0,O
.,O
78,O
),O
5,O
.,O
8,O
×,O
10,O
−,O
9,O
insulin,B-GP
20p13,O
RNF24,O
/,O
SMOX,O
rs6052399,O
*,O
T,O
/,O
C,O
0,O
/,O
1,O
0,O
.,O
93,O
−,O
4,O
.,O
55,O
(,O
0,O
.,O
84,O
),O
9,O
.,O
8,O
×,O
10,O
−,O
8,O
insulin,B-GP
6q14,O
.,O
1,O
BCKDHB,O
/,O
FAM46A,O
rs16892328,O
*,O
C,O
/,O
T,O
0,O
/,O
1,O
0,O
.,O
94,O
−,O
4,O
.,O
93,O
(,O
0,O
.,O
92,O
),O
1,O
.,O
3,O
×,O
10,O
−,O
7,O
insulin,B-GP
18p11,O
.,O
31,O
MRLC2,O
/,O
TGIF1,O
rs1613695,O
*,O
G,O
/,O
A,O
0,O
/,O
1,O
0,O
.,O
95,O
−,O
5,O
.,O
68,O
(,O
1,O
.,O
07,O
),O
1,O
.,O
7,O
×,O
10,O
−,O
7,O
insulin,B-GP
14q13,O
.,O
3,O
TTC6,O
/,O
SSTR1,O
rs10498337,O
T,O
/,O
G,O
1,O
/,O
0,O
0,O
.,O
81,O
−,O
9,O
.,O
3,O
(,O
1,O
.,O
87,O
),O
8,O
.,O
9,O
×,O
10,O
−,O
7,O
LDL,O
-,O
cholesterol,O
21q22,O
.,O
11,O
MRPS6,B-GP
/,O
KCNE2,B-GP
rs8131349,O
*,O
A,O
/,O
G,O
0,O
/,O
1,O
0,O
.,O
06,O
17,O
.,O
6,O
(,O
3,O
.,O
05,O
),O
1,O
.,O
4,O
×,O
10,O
−,O
8,O
LDL,O
-,O
cholesterol,O
19q13,O
.,O
33,O
APOE,B-GP
/,O
APOC1,O
rs7412,O
T,O
/,O
C,O
1,O
/,O
1,O
0,O
.,O
07,O
−,O
69,O
.,O
74,O
(,O
12,O
.,O
15,O
),O
1,O
.,O
6,O
×,O
10,O
−,O
8,O
LDL,O
-,O
cholesterol,O
6q22,O
.,O
31,O
C6orf170,B-GP
/,O
GJA1,B-GP
rs7738656,O
G,O
/,O
A,O
1,O
/,O
0,O
0,O
.,O
84,O
−,O
42,O
.,O
39,O
(,O
8,O
.,O
11,O
),O
2,O
.,O
5,O
×,O
10,O
−,O
7,O
LDL,O
-,O
cholesterol,O
5q33,O
.,O
2,O
KIF4B,O
/,O
SGCD,O
rs10044666,O
*,O
G,O
/,O
T,O
1,O
/,O
3,O
0,O
.,O
72,O
−,O
8,O
.,O
57,O
(,O
1,O
.,O
68,O
),O
4,O
.,O
7,O
×,O
10,O
−,O
7,O
systolic,O
BP,O
11q24,O
.,O
1,O
ASAM,O
/,O
GRAMD1B,O
rs11822822,O
G,O
/,O
A,O
2,O
/,O
4,O
0,O
.,O
24,O
10,O
.,O
74,O
(,O
2,O
.,O
12,O
),O
5,O
.,O
6,O
×,O
10,O
−,O
7,O
systolic,O
BP,O
15q22,O
.,O
1,O
RORA,O
/,O
VPS13C,O
rs726914,O
G,O
/,O
A,O
2,O
/,O
0,O
0,O
.,O
62,O
9,O
.,O
21,O
(,O
1,O
.,O
83,O
),O
7,O
.,O
1,O
×,O
10,O
−,O
7,O
total,O
cholesterol,O
21q22,O
.,O
11,O
MRPS6,B-GP
/,O
KCNE2,B-GP
rs8131349,O
*,O
A,O
/,O
G,O
2,O
/,O
2,O
0,O
.,O
06,O
18,O
.,O
4,O
(,O
3,O
.,O
32,O
),O
4,O
.,O
6,O
×,O
10,O
−,O
8,O
total,O
cholesterol,O
4p16,O
.,O
1,O
ABLIM2,O
rs6829649,O
T,O
/,O
G,O
1,O
/,O
2,O
0,O
.,O
87,O
−,O
50,O
.,O
96,O
(,O
9,O
.,O
42,O
),O
9,O
.,O
6,O
×,O
10,O
−,O
8,O
total,O
cholesterol,O
6q22,O
.,O
31,O
C6orf170,B-GP
/,O
GJA1,B-GP
rs7738656,O
G,O
/,O
A,O
1,O
/,O
1,O
0,O
.,O
84,O
−,O
46,O
.,O
21,O
(,O
8,O
.,O
79,O
),O
2,O
.,O
1,O
×,O
10,O
−,O
7,O
total,O
cholesterol,O
8q24,O
.,O
22,O
ST3GAL1,O
/,O
ZFAT,B-GP
rs4897695,O
*,O
C,O
/,O
G,O
1,O
/,O
6,O
0,O
.,O
91,O
13,O
.,O
66,O
(,O
2,O
.,O
62,O
),O
2,O
.,O
7,O
×,O
10,O
−,O
7,O
waist,O
circumference,O
8q24,O
.,O
13,O
MTSS1,O
/,O
ZNF572,O
rs891541,O
*,O
A,O
/,O
G,O
4,O
/,O
7,O
0,O
.,O
29,O
4,O
.,O
55,O
(,O
0,O
.,O
91,O
),O
7,O
.,O
7,O
×,O
10,O
−,O
7,O
A,O
list,O
of,O
all,O
SNP,O
effect,O
P,O
-,O
values,O
less,O
than,O
10,O
−,O
6,O
in,O
the,O
BHS,O
.,O
SNP,O
names,O
marked,O
with,O
an,O
“*”,O
are,O
imputed,O
",",O
while,O
those,O
that,O
are,O
unmarked,O
are,O
directly,O
genotyped,O
.,O
SNP,O
alleles,O
are,O
reported,O
as,O
risk,O
/,O
nonrisk,O
and,O
are,O
in,O
genome,O
forward,O
orientation,O
(,O
build,O
36,O
.,O
3,O
).,O
The,O
number,O
of,O
SNPs,O
@,O
P,O
<,O
10,O
−,O
5,O
corresponds,O
to,O
the,O
number,O
of,O
genotyped,O
/,O
imputed,O
SNPs,O
with,O
P,O
<,O
10,O
−,O
5,O
within,O
200kb,O
up,O
and,O
downstream,O
of,O
the,O
top,O
SNP,O
.,O
Associations,O
at,O
P,O
<,O
5,O
×,O
10,O
−,O
8,O
are,O
indicated,O
in,O
bold,O
.,O
Top,O
SNPxAGE,O
effect,O
GWA,O
hits,O
for,O
12,O
phenotypes,O
.,O
Trait,O
Cytoband,O
Gene,O
(,O
s,O
),O
Top,O
SNP,O
",",O
Alleles,O
#,O
SNPs,O
@,O
P,O
<,O
10,O
−,O
5,O
Risk,O
AF,O
Beta,O
(,O
SE,O
),O
P,O
distolic,O
BP,O
14q24,O
.,O
3,O
ESRRB,B-GP
/,O
VASH1,B-GP
rs17104804,O
G,O
/,O
A,O
1,O
/,O
2,O
0,O
.,O
92,O
−,O
0,O
.,O
76,O
(,O
0,O
.,O
15,O
),O
5,O
.,O
9,O
×,O
10,O
−,O
7,O
glucose,O
16q21,O
CDH5,O
/,O
TK2,O
rs4783595,O
T,O
/,O
C,O
2,O
/,O
1,O
0,O
.,O
87,O
−,O
1,O
.,O
67,O
(,O
0,O
.,O
31,O
),O
9,O
.,O
5,O
×,O
10,O
−,O
8,O
glucose,O
7p14,O
.,O
3,O
CHN2,B-GP
rs3793275,O
*,O
A,O
/,O
T,O
1,O
/,O
3,O
0,O
.,O
94,O
−,O
0,O
.,O
61,O
(,O
0,O
.,O
12,O
),O
1,O
.,O
5,O
×,O
10,O
−,O
7,O
glucose,O
Xp22,O
.,O
2,O
ATXN3L,O
/,O
EGFL6,O
rs5979903,O
T,O
/,O
C,O
1,O
/,O
0,O
0,O
.,O
06,O
1,O
.,O
88,O
(,O
0,O
.,O
36,O
),O
1,O
.,O
9,O
×,O
10,O
−,O
7,O
glucose,O
11q13,O
.,O
5,O
WNT11,O
/,O
PRKRIR,O
rs12807555,O
*,O
G,O
/,O
T,O
0,O
/,O
1,O
0,O
.,O
90,O
−,O
0,O
.,O
47,O
(,O
0,O
.,O
09,O
),O
2,O
.,O
7,O
×,O
10,O
−,O
7,O
glucose,O
17q25,O
.,O
1,O
PRPSAP1,O
/,O
SPHK1,O
rs9909931,O
G,O
/,O
A,O
2,O
/,O
3,O
0,O
.,O
19,O
1,O
.,O
36,O
(,O
0,O
.,O
27,O
),O
4,O
.,O
3,O
×,O
10,O
−,O
7,O
glucose,O
1q32,O
.,O
1,O
PLXNA2,O
/,O
LOC642587,O
rs12069004,O
*,O
C,O
/,O
T,O
0,O
/,O
1,O
0,O
.,O
91,O
−,O
0,O
.,O
54,O
(,O
0,O
.,O
11,O
),O
5,O
.,O
8,O
×,O
10,O
−,O
7,O
glucose,O
8q24,O
.,O
22,O
ZFAT,B-GP
/,O
KHDRBS3,O
rs12548494,O
*,O
C,O
/,O
G,O
0,O
/,O
1,O
0,O
.,O
93,O
−,O
0,O
.,O
6,O
(,O
0,O
.,O
12,O
),O
7,O
.,O
1,O
×,O
10,O
−,O
7,O
glucose,O
7p21,O
.,O
1,O
AHR,O
/,O
SNX13,O
rs10260737,O
G,O
/,O
A,O
2,O
/,O
12,O
0,O
.,O
89,O
−,O
1,O
.,O
77,O
(,O
0,O
.,O
36,O
),O
7,O
.,O
3,O
×,O
10,O
−,O
7,O
glucose,O
8q23,O
.,O
2,O
KCNV1,O
/,O
CSMD3,O
rs3019325,O
*,O
G,O
/,O
C,O
0,O
/,O
6,O
0,O
.,O
70,O
−,O
0,O
.,O
31,O
(,O
0,O
.,O
06,O
),O
7,O
.,O
5,O
×,O
10,O
−,O
7,O
heart,O
rate,O
3q24,O
RASA2,O
/,O
RNF7,O
rs6440031,O
G,O
/,O
A,O
1,O
/,O
0,O
0,O
.,O
90,O
1,O
.,O
33,O
(,O
0,O
.,O
25,O
),O
1,O
.,O
8,O
×,O
10,O
−,O
7,O
heart,O
rate,O
12q21,O
.,O
2,O
NAV3,O
/,O
SYT1,O
rs1449460,O
G,O
/,O
A,O
2,O
/,O
6,O
0,O
.,O
08,O
−,O
1,O
.,O
36,O
(,O
0,O
.,O
27,O
),O
7,O
.,O
4,O
×,O
10,O
−,O
7,O
height,O
11q23,O
.,O
3,O
CADM1,B-GP
/,O
BUD13,B-GP
rs1144036,O
C,O
/,O
T,O
1,O
/,O
0,O
0,O
.,O
16,O
1,O
.,O
17,O
(,O
0,O
.,O
23,O
),O
2,O
.,O
4,O
×,O
10,O
−,O
7,O
height,O
19q13,O
.,O
32,O
PSG3,O
rs8103264,O
*,O
C,O
/,O
G,O
2,O
/,O
10,O
0,O
.,O
93,O
−,O
0,O
.,O
38,O
(,O
0,O
.,O
08,O
),O
5,O
.,O
6,O
×,O
10,O
−,O
7,O
insulin,B-GP
12p11,O
.,O
23,O
TM7SF3,O
rs1552257,O
*,O
C,O
/,O
T,O
4,O
/,O
10,O
0,O
.,O
20,O
0,O
.,O
18,O
(,O
0,O
.,O
04,O
),O
7,O
.,O
5,O
×,O
10,O
−,O
7,O
LDL,O
17q22,O
AKAP1,B-GP
/,O
MSI2,B-GP
rs8073909,O
T,O
/,O
C,O
1,O
/,O
0,O
0,O
.,O
64,O
−,O
1,O
.,O
41,O
(,O
0,O
.,O
27,O
),O
1,O
.,O
4,O
×,O
10,O
−,O
7,O
LDL,O
10p13,O
FRMD4A,O
rs11258628,O
*,O
A,O
/,O
T,O
0,O
/,O
1,O
0,O
.,O
92,O
−,O
0,O
.,O
69,O
(,O
0,O
.,O
14,O
),O
4,O
.,O
1,O
×,O
10,O
−,O
7,O
systolic,O
BP,O
19p13,O
.,O
3,O
RFX2,O
rs1046391,O
*,O
G,O
/,O
T,O
0,O
/,O
1,O
0,O
.,O
86,O
0,O
.,O
21,O
(,O
0,O
.,O
04,O
),O
4,O
.,O
1,O
×,O
10,O
−,O
7,O
systolic,O
BP,O
14q24,O
.,O
3,O
ESRRB,B-GP
/,O
VASH1,B-GP
rs17104804,O
G,O
/,O
A,O
3,O
/,O
5,O
0,O
.,O
92,O
−,O
0,O
.,O
91,O
(,O
0,O
.,O
19,O
),O
9,O
.,O
3,O
×,O
10,O
−,O
7,O
total,O
cholesterol,O
17q22,O
AKAP1,B-GP
/,O
MSI2,B-GP
rs8073909,O
T,O
/,O
C,O
1,O
/,O
4,O
0,O
.,O
64,O
−,O
1,O
.,O
68,O
(,O
0,O
.,O
31,O
),O
6,O
.,O
9,O
×,O
10,O
−,O
8,O
triglycerides,O
Xp21,O
.,O
2,O
IL1RAPL1,B-GP
rs7890572,O
G,O
/,O
A,O
5,O
/,O
0,O
0,O
.,O
07,O
9,O
.,O
75,O
(,O
1,O
.,O
55,O
),O
3,O
.,O
8,O
×,O
10,O
−,O
10,O
triglycerides,O
11q23,O
.,O
3,O
CADM1,B-GP
/,O
BUD13,B-GP
rs12280753,O
*,O
T,O
/,O
C,O
7,O
/,O
11,O
0,O
.,O
07,O
2,O
.,O
64,O
(,O
0,O
.,O
47,O
),O
1,O
.,O
8,O
×,O
10,O
−,O
8,O
triglycerides,O
9q21,O
.,O
2,O
PSAT1,O
/,O
CHCHD9,O
rs13290397,O
*,O
C,O
/,O
G,O
1,O
/,O
3,O
0,O
.,O
89,O
−,O
1,O
.,O
98,O
(,O
0,O
.,O
38,O
),O
2,O
.,O
4,O
×,O
10,O
−,O
7,O
triglycerides,O
2p16,O
.,O
3,O
FSHR,O
/,O
NRXN1,O
rs6726786,O
*,O
G,O
/,O
T,O
1,O
/,O
3,O
0,O
.,O
89,O
−,O
2,O
.,O
09,O
(,O
0,O
.,O
41,O
),O
2,O
.,O
9,O
×,O
10,O
−,O
7,O
triglycerides,O
3q22,O
.,O
3,O
IL20RB,O
/,O
SOX14,O
rs12330441,O
T,O
/,O
G,O
2,O
/,O
4,O
0,O
.,O
93,O
−,O
9,O
.,O
54,O
(,O
1,O
.,O
86,O
),O
3,O
.,O
0,O
×,O
10,O
−,O
7,O
waist,O
circumference,O
20q13,O
.,O
32,O
APCDD1L,O
/,O
STX16,O
rs127430,O
*,O
G,O
/,O
A,O
2,O
/,O
13,O
0,O
.,O
86,O
−,O
0,O
.,O
33,O
(,O
0,O
.,O
06,O
),O
3,O
.,O
3,O
×,O
10,O
−,O
8,O
waist,O
circumference,O
11q24,O
.,O
1,O
SORL1,O
/,O
BLID,O
rs7121446,O
G,O
/,O
A,O
1,O
/,O
7,O
0,O
.,O
78,O
−,O
1,O
.,O
09,O
(,O
0,O
.,O
21,O
),O
3,O
.,O
6,O
×,O
10,O
−,O
7,O
waist,O
circumference,O
17p13,O
.,O
2,O
SHPK,O
rs7210277,O
*,O
C,O
/,O
T,O
0,O
/,O
1,O
0,O
.,O
91,O
−,O
0,O
.,O
39,O
(,O
0,O
.,O
08,O
),O
7,O
.,O
0,O
×,O
10,O
−,O
7,O
waist,O
circumference,O
10q24,O
.,O
2,O
CNNM1,O
rs17568778,O
C,O
/,O
A,O
1,O
/,O
0,O
0,O
.,O
92,O
−,O
1,O
.,O
55,O
(,O
0,O
.,O
31,O
),O
8,O
.,O
2,O
×,O
10,O
−,O
7,O
weight,O
4q35,O
.,O
1,O
ODZ3,O
rs6552560,O
T,O
/,O
C,O
3,O
/,O
7,O
0,O
.,O
23,O
1,O
.,O
35,O
(,O
0,O
.,O
25,O
),O
8,O
.,O
5,O
×,O
10,O
−,O
8,O
A,O
list,O
of,O
all,O
SNPxAGE,O
effect,O
P,O
-,O
values,O
less,O
than,O
10,O
−,O
6,O
in,O
the,O
BHS,O
.,O
Associations,O
at,O
P,O
<,O
5,O
×,O
10,O
−,O
8,O
are,O
indicated,O
in,O
bold,O
.,O
SNP,O
names,O
marked,O
with,O
an,O
“*”,O
are,O
imputed,O
",",O
while,O
those,O
that,O
are,O
unmarked,O
are,O
not,O
.,O
SNP,O
alleles,O
are,O
reported,O
as,O
risk,O
/,O
nonrisk,O
and,O
are,O
in,O
genome,O
forward,O
orientaiton,O
(,O
build,O
36,O
.,O
3,O
).,O
The,O
number,O
of,O
SNPs,O
at,O
P,O
<,O
10,O
−,O
5,O
corresponds,O
to,O
the,O
number,O
of,O
genotyped,O
/,O
imputed,O
SNPs,O
with,O
P,O
<,O
10,O
−,O
5,O
within,O
200kb,O
up,O
and,O
downstream,O
of,O
the,O
top,O
SNP,O
.,O
In,O
addition,O
to,O
novel,O
associations,O
",",O
there,O
were,O
three,O
regions,O
showing,O
SNP,O
associations,O
that,O
have,O
been,O
previously,O
identified,O
in,O
GWA,O
studies,O
:,O
rs853773,O
[,O
18,O
],O
near,O
G6PC2,B-GP
was,O
associated,O
with,O
a,O
glucose,O
SNP,O
effect,O
(,O
P,O
=,O
7,O
.,O
0,O
×,O
10,O
−,O
7,O
"),",O
rs247616,O
[,O
5,O
],O
near,O
CETP,B-GP
was,O
associated,O
with,O
an,O
HDL,O
SNP,O
effect,O
(,O
P,O
=,O
6,O
.,O
6,O
×,O
10,O
−,O
7,O
"),",O
and,O
the,O
APOE,B-GP
e2,O
SNP,O
rs7412,O
[,O
19,O
],O
was,O
associated,O
with,O
a,O
genome,O
-,O
wide,O
significant,O
LDL,O
SNP,O
effect,O
(,O
P,O
=,O
1,O
.,O
6,O
×,O
10,O
−,O
8,O
).,O
A,O
region,O
near,O
APOA5,B-GP
that,O
had,O
been,O
previously,O
implicated,O
in,O
triglyceride,O
levels,O
showed,O
a,O
significant,O
SNPxAGE,O
effect,O
on,O
triglycerides,O
in,O
our,O
study,O
(,O
rs12280753,O
;,O
P,O
=,O
1,O
.,O
8,O
×,O
10,O
−,O
8,O
).,O
Although,O
the,O
nearest,O
gene,O
to,O
rs12280753,O
is,O
not,O
APOA5,B-GP
",",O
this,O
SNP,O
was,O
also,O
the,O
most,O
strongly,O
associated,O
SNP,O
in,O
previous,O
studies,O
of,O
adult,O
triglyceride,O
levels,O
[,O
5,O
"],",O
[,O
10,O
"],",O
[,O
20,O
].,O
Replication,O
in,O
the,O
Young,O
Finns,O
We,O
pursued,O
replication,O
of,O
these,O
findings,O
in,O
genotyped,O
individuals,O
within,O
the,O
Young,O
Finns,O
(,O
YF,O
),O
cohort,O
",",O
consisting,O
of,O
2,O
",",O
442,O
Finnish,O
individuals,O
tracked,O
from,O
childhood,O
through,O
middle,O
adulthood,O
(,O
ages,O
3,O
–,O
45,O
),O
with,O
three,O
measures,O
in,O
young,O
individuals,O
(,O
ages,O
3,O
–,O
24,O
),O
and,O
two,O
measures,O
in,O
older,O
individuals,O
(,O
ages,O
24,O
–,O
45,O
).,O
These,O
individuals,O
have,O
been,O
genotyped,O
on,O
a,O
custom,O
-,O
built,O
Illumina,O
genotyping,O
chip,O
(,O
670K,O
).,O
Using,O
the,O
same,O
analysis,O
methods,O
",",O
we,O
tested,O
whether,O
the,O
top,O
SNP,O
was,O
associated,O
in,O
the,O
YF,O
study,O
(,O
Table,O
3,O
).,O
Imputed,O
genotype,O
dosages,O
were,O
used,O
when,O
direct,O
genotype,O
data,O
was,O
not,O
available,O
.,O
For,O
the,O
APOE,B-GP
-,O
e2,O
SNP,O
rs7412,O
",",O
which,O
is,O
not,O
in,O
HapMap,O
or,O
on,O
the,O
670K,O
chip,O
",",O
we,O
used,O
the,O
SNP,O
with,O
the,O
next,O
strongest,O
association,O
in,O
the,O
BHS,O
(,O
rs445925,O
).,O
There,O
were,O
two,O
SNPs,O
that,O
significantly,O
replicated,O
beyond,O
the,O
multiple,O
testing,O
threshold,O
(,O
P,O
<,O
0,O
.,O
05,O
/,O
51,O
=,O
1,O
×,O
10,O
−,O
3,O
):,O
the,O
rs247616,O
SNP,O
at,O
CETP,B-GP
(,O
P,O
=,O
1,O
.,O
7,O
×,O
10,O
−,O
18,O
"),",O
and,O
rs445925,O
at,O
APOE,B-GP
(,O
P,O
=,O
4,O
.,O
1,O
×,O
10,O
−,O
15,O
).,O
There,O
was,O
no,O
trend,O
to,O
replicate,O
the,O
direction,O
of,O
effect,O
between,O
the,O
studies,O
:,O
within,O
the,O
SNP,O
effects,O
",",O
there,O
were,O
12,O
/,O
21,O
(,O
57,O
"%,",O
chi,O
-,O
square,O
P,O
=,O
0,O
.,O
51,O
),O
markers,O
that,O
showed,O
the,O
same,O
direction,O
of,O
effect,O
",",O
while,O
within,O
SNPxAGE,O
effects,O
",",O
there,O
were,O
14,O
/,O
30,O
(,O
47,O
"%,",O
chi,O
-,O
square,O
P,O
=,O
0,O
.,O
72,O
).,O
The,O
samples,O
were,O
combined,O
and,O
P,O
-,O
values,O
were,O
calculated,O
for,O
the,O
combined,O
BHS,O
and,O
YF,O
data,O
",",O
using,O
study,O
as,O
a,O
covariate,O
(,O
Table,O
3,O
).,O
The,O
associations,O
at,O
rs247616,O
at,O
CETP,B-GP
with,O
HDL,O
-,O
cholesterol,O
(,O
P,O
=,O
9,O
.,O
7,O
×,O
10,O
−,O
24,O
),O
and,O
rs445925,O
at,O
APOE,B-GP
with,O
LDL,O
-,O
cholesterol,O
(,O
P,O
=,O
8,O
.,O
7,O
×,O
10,O
−,O
19,O
),O
were,O
strongly,O
significant,O
",",O
but,O
no,O
other,O
regions,O
in,O
the,O
combined,O
BHS,O
/,O
YF,O
data,O
reached,O
genome,O
-,O
wide,O
significance,O
of,O
P,O
<,O
5,O
×,O
10,O
−,O
8,O
.,O
Replication,O
results,O
in,O
the,O
Young,O
Finns,O
.,O
BHS,O
YF,O
BHS,O
+,O
YF,O
combined,O
Trait,O
Top,O
SNP,O
(,O
Alleles,O
),O
Effect,O
Beta,O
(,O
SE,O
),O
P,O
Beta,O
(,O
SE,O
),O
P,O
Beta,O
(,O
SE,O
),O
P,O
diastolic,O
BP,O
rs7704530,O
G,O
/,O
A,O
SNP,O
8,O
.,O
44,O
(,O
1,O
.,O
57,O
),O
1,O
.,O
1,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
05,O
(,O
0,O
.,O
22,O
),O
0,O
.,O
82,O
0,O
.,O
4,O
(,O
0,O
.,O
2,O
),O
0,O
.,O
04,O
diastolic,O
BP,O
rs709595,O
C,O
/,O
G,O
SNP,O
7,O
.,O
18,O
(,O
1,O
.,O
43,O
),O
7,O
.,O
0,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
03,O
(,O
0,O
.,O
21,O
),O
0,O
.,O
88,O
0,O
.,O
38,O
(,O
0,O
.,O
19,O
),O
0,O
.,O
04,O
glucose,O
rs853773,O
A,O
/,O
G,O
SNP,O
−,O
8,O
.,O
72,O
(,O
1,O
.,O
73,O
),O
7,O
.,O
0,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
33,O
(,O
0,O
.,O
37,O
),O
0,O
.,O
37,O
−,O
0,O
.,O
73,O
(,O
0,O
.,O
32,O
),O
0,O
.,O
02,O
glucose,O
rs781718,O
*,O
G,O
/,O
A,O
SNP,O
−,O
3,O
.,O
46,O
(,O
0,O
.,O
69,O
),O
8,O
.,O
4,O
×,O
10,O
−,O
7,O
0,O
.,O
71,O
(,O
0,O
.,O
7,O
),O
0,O
.,O
31,O
−,O
0,O
.,O
32,O
(,O
0,O
.,O
59,O
),O
0,O
.,O
58,O
HDL,O
-,O
cholesterol,O
rs247616,O
*,O
T,O
/,O
C,O
SNP,O
3,O
.,O
77,O
(,O
0,O
.,O
75,O
),O
6,O
.,O
6,O
×,O
10,O
−,O
7,O
2,O
.,O
8,O
(,O
0,O
.,O
32,O
),O
1,O
.,O
7,O
×,O
10,O
−,O
18,O
2,O
.,O
99,O
(,O
0,O
.,O
29,O
),O
9,O
.,O
7,O
×,O
10,O
−,O
24,O
insulin,B-GP
rs3793275,O
*,O
A,O
/,O
T,O
SNP,O
−,O
4,O
.,O
63,O
(,O
0,O
.,O
78,O
),O
5,O
.,O
8,O
×,O
10,O
−,O
9,O
0,O
.,O
36,O
(,O
0,O
.,O
3,O
),O
0,O
.,O
23,O
−,O
0,O
.,O
13,O
(,O
0,O
.,O
26,O
),O
0,O
.,O
63,O
insulin,B-GP
rs6052399,O
*,O
T,O
/,O
C,O
SNP,O
−,O
4,O
.,O
55,O
(,O
0,O
.,O
84,O
),O
9,O
.,O
8,O
×,O
10,O
−,O
8,O
−,O
0,O
.,O
01,O
(,O
0,O
.,O
44,O
),O
0,O
.,O
99,O
−,O
0,O
.,O
7,O
(,O
0,O
.,O
37,O
),O
0,O
.,O
06,O
insulin,B-GP
rs16892328,O
*,O
C,O
/,O
T,O
SNP,O
−,O
4,O
.,O
93,O
(,O
0,O
.,O
92,O
),O
1,O
.,O
3,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
81,O
(,O
0,O
.,O
54,O
),O
0,O
.,O
14,O
−,O
1,O
.,O
64,O
(,O
0,O
.,O
45,O
),O
0,O
.,O
00027,O
insulin,B-GP
rs1613695,O
*,O
G,O
/,O
A,O
SNP,O
−,O
5,O
.,O
68,O
(,O
1,O
.,O
07,O
),O
1,O
.,O
7,O
×,O
10,O
−,O
7,O
0,O
.,O
35,O
(,O
0,O
.,O
36,O
),O
0,O
.,O
32,O
−,O
0,O
.,O
13,O
(,O
0,O
.,O
31,O
),O
0,O
.,O
68,O
insulin,B-GP
rs10498337,O
T,O
/,O
G,O
SNP,O
−,O
9,O
.,O
3,O
(,O
1,O
.,O
87,O
),O
8,O
.,O
9,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
05,O
(,O
0,O
.,O
22,O
),O
0,O
.,O
81,O
−,O
0,O
.,O
35,O
(,O
0,O
.,O
18,O
),O
0,O
.,O
06,O
LDL,O
-,O
cholesterol,O
rs8131349,O
*,O
A,O
/,O
G,O
SNP,O
17,O
.,O
6,O
(,O
3,O
.,O
05,O
),O
1,O
.,O
4,O
×,O
10,O
−,O
8,O
−,O
1,O
.,O
14,O
(,O
1,O
.,O
29,O
),O
0,O
.,O
38,O
1,O
.,O
46,O
(,O
1,O
.,O
2,O
),O
0,O
.,O
23,O
LDL,O
-,O
cholesterol,O
rs445925,O
*#,O
G,O
/,O
A,O
SNP,O
12,O
.,O
8,O
(,O
2,O
.,O
63,O
),O
1,O
.,O
5,O
×,O
10,O
−,O
6,O
12,O
.,O
16,O
(,O
1,O
.,O
54,O
),O
4,O
.,O
1,O
×,O
10,O
−,O
15,O
11,O
.,O
96,O
(,O
1,O
.,O
34,O
),O
8,O
.,O
7,O
×,O
10,O
−,O
19,O
LDL,O
-,O
cholesterol,O
rs7738656,O
G,O
/,O
A,O
SNP,O
−,O
42,O
.,O
39,O
(,O
8,O
.,O
11,O
),O
2,O
.,O
5,O
×,O
10,O
−,O
7,O
−,O
1,O
.,O
52,O
(,O
0,O
.,O
9,O
),O
0,O
.,O
09,O
−,O
2,O
.,O
91,O
(,O
0,O
.,O
83,O
),O
0,O
.,O
00049,O
LDL,O
-,O
cholesterol,O
rs10044666,O
*,O
G,O
/,O
T,O
SNP,O
−,O
8,O
.,O
57,O
(,O
1,O
.,O
68,O
),O
4,O
.,O
7,O
×,O
10,O
−,O
7,O
−,O
1,O
.,O
25,O
(,O
0,O
.,O
91,O
),O
0,O
.,O
17,O
−,O
2,O
.,O
93,O
(,O
0,O
.,O
81,O
),O
0,O
.,O
00029,O
systolic,O
BP,O
rs11822822,O
G,O
/,O
A,O
SNP,O
10,O
.,O
74,O
(,O
2,O
.,O
12,O
),O
5,O
.,O
6,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
34,O
(,O
0,O
.,O
35,O
),O
0,O
.,O
34,O
0,O
.,O
44,O
(,O
0,O
.,O
3,O
),O
0,O
.,O
14,O
systolic,O
BP,O
rs726914,O
G,O
/,O
A,O
SNP,O
9,O
.,O
21,O
(,O
1,O
.,O
83,O
),O
7,O
.,O
1,O
×,O
10,O
−,O
7,O
0,O
.,O
07,O
(,O
0,O
.,O
27,O
),O
0,O
.,O
81,O
0,O
.,O
55,O
(,O
0,O
.,O
23,O
),O
0,O
.,O
02,O
total,O
cholesterol,O
rs8131349,O
*,O
A,O
/,O
G,O
SNP,O
18,O
.,O
4,O
(,O
3,O
.,O
32,O
),O
4,O
.,O
6,O
×,O
10,O
−,O
8,O
−,O
1,O
.,O
26,O
(,O
1,O
.,O
43,O
),O
0,O
.,O
38,O
1,O
.,O
44,O
(,O
1,O
.,O
32,O
),O
0,O
.,O
28,O
total,O
cholesterol,O
rs6829649,O
T,O
/,O
G,O
SNP,O
−,O
50,O
.,O
96,O
(,O
9,O
.,O
42,O
),O
9,O
.,O
6,O
×,O
10,O
−,O
8,O
0,O
.,O
09,O
(,O
1,O
.,O
23,O
),O
0,O
.,O
94,O
−,O
2,O
.,O
06,O
(,O
1,O
.,O
1,O
),O
0,O
.,O
06,O
total,O
cholesterol,O
rs7738656,O
G,O
/,O
A,O
SNP,O
−,O
46,O
.,O
21,O
(,O
8,O
.,O
79,O
),O
2,O
.,O
1,O
×,O
10,O
−,O
7,O
−,O
1,O
.,O
51,O
(,O
1,O
),O
0,O
.,O
13,O
−,O
3,O
.,O
04,O
(,O
0,O
.,O
92,O
),O
0,O
.,O
00094,O
total,O
cholesterol,O
rs4897695,O
*,O
C,O
/,O
G,O
SNP,O
13,O
.,O
66,O
(,O
2,O
.,O
62,O
),O
2,O
.,O
7,O
×,O
10,O
−,O
7,O
0,O
.,O
51,O
(,O
1,O
.,O
7,O
),O
0,O
.,O
76,O
4,O
.,O
14,O
(,O
1,O
.,O
44,O
),O
0,O
.,O
0041,O
waist,O
circumference,O
rs891541,O
*,O
A,O
/,O
G,O
SNP,O
4,O
.,O
55,O
(,O
0,O
.,O
91,O
),O
7,O
.,O
7,O
×,O
10,O
−,O
7,O
0,O
.,O
28,O
(,O
0,O
.,O
37,O
),O
0,O
.,O
44,O
1,O
.,O
18,O
(,O
0,O
.,O
35,O
),O
0,O
.,O
00076,O
distolic,O
BP,O
rs17104804,O
G,O
/,O
A,O
SNPxAGE,O
−,O
0,O
.,O
76,O
(,O
0,O
.,O
15,O
),O
5,O
.,O
9,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
02,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
63,O
−,O
0,O
.,O
1,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
00047,O
glucose,O
rs4783595,O
T,O
/,O
C,O
SNPxAGE,O
−,O
1,O
.,O
67,O
(,O
0,O
.,O
31,O
),O
9,O
.,O
5,O
×,O
10,O
−,O
8,O
−,O
0,O
.,O
04,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
29,O
−,O
0,O
.,O
12,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
00021,O
glucose,O
rs3793275,O
*,O
A,O
/,O
T,O
SNPxAGE,O
−,O
0,O
.,O
61,O
(,O
0,O
.,O
12,O
),O
1,O
.,O
5,O
×,O
10,O
−,O
7,O
0,O
.,O
04,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
43,O
−,O
0,O
.,O
09,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
05,O
glucose,O
rs5979903,O
T,O
/,O
C,O
SNPxAGE,O
1,O
.,O
88,O
(,O
0,O
.,O
36,O
),O
1,O
.,O
9,O
×,O
10,O
−,O
7,O
0,O
.,O
08,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
07,O
0,O
.,O
16,O
(,O
0,O
.,O
04,O
),O
9,O
.,O
8,O
×,O
10,O
−,O
5,O
glucose,O
rs12807555,O
*,O
G,O
/,O
T,O
SNPxAGE,O
−,O
0,O
.,O
47,O
(,O
0,O
.,O
09,O
),O
2,O
.,O
7,O
×,O
10,O
−,O
7,O
0,O
.,O
01,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
78,O
−,O
0,O
.,O
1,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
02,O
glucose,O
rs9909931,O
G,O
/,O
A,O
SNPxAGE,O
1,O
.,O
36,O
(,O
0,O
.,O
27,O
),O
4,O
.,O
3,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
02,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
56,O
0,O
.,O
06,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
06,O
glucose,O
rs12069004,O
*,O
C,O
/,O
T,O
SNPxAGE,O
−,O
0,O
.,O
54,O
(,O
0,O
.,O
11,O
),O
5,O
.,O
8,O
×,O
10,O
−,O
7,O
0,O
.,O
02,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
7,O
−,O
0,O
.,O
1,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
03,O
glucose,O
rs12548494,O
*,O
C,O
/,O
G,O
SNPxAGE,O
−,O
0,O
.,O
6,O
(,O
0,O
.,O
12,O
),O
7,O
.,O
1,O
×,O
10,O
−,O
7,O
1,O
.,O
4,O
×,O
10,O
−,O
4,O
(,O
0,O
.,O
09,O
),O
1,O
−,O
0,O
.,O
18,O
(,O
0,O
.,O
07,O
),O
0,O
.,O
01,O
glucose,O
rs10260737,O
G,O
/,O
A,O
SNPxAGE,O
−,O
1,O
.,O
77,O
(,O
0,O
.,O
36,O
),O
7,O
.,O
3,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
02,O
(,O
0,O
.,O
06,O
),O
0,O
.,O
8,O
−,O
0,O
.,O
11,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
03,O
glucose,O
rs3019325,O
*,O
G,O
/,O
C,O
SNPxAGE,O
−,O
0,O
.,O
31,O
(,O
0,O
.,O
06,O
),O
7,O
.,O
5,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
02,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
55,O
−,O
0,O
.,O
07,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
0097,O
heart,O
rate,O
rs6440031,O
G,O
/,O
A,O
SNPxAGE,O
1,O
.,O
33,O
(,O
0,O
.,O
25,O
),O
1,O
.,O
8,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
01,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
72,O
0,O
.,O
03,O
(,O
0,O
.,O
02,O
),O
0,O
.,O
16,O
heart,O
rate,O
rs1449460,O
G,O
/,O
A,O
SNPxAGE,O
−,O
1,O
.,O
36,O
(,O
0,O
.,O
27,O
),O
7,O
.,O
4,O
×,O
10,O
−,O
7,O
0,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
93,O
−,O
0,O
.,O
05,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
1,O
height,O
rs1144036,O
C,O
/,O
T,O
SNPxAGE,O
1,O
.,O
17,O
(,O
0,O
.,O
23,O
),O
2,O
.,O
4,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
07,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
09,O
0,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
91,O
height,O
rs8103264,O
*,O
C,O
/,O
G,O
SNPxAGE,O
−,O
0,O
.,O
38,O
(,O
0,O
.,O
08,O
),O
5,O
.,O
6,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
04,O
(,O
0,O
.,O
06,O
),O
0,O
.,O
42,O
−,O
0,O
.,O
11,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
02,O
insulin,B-GP
rs1552257,O
*,O
C,O
/,O
T,O
SNPxAGE,O
0,O
.,O
18,O
(,O
0,O
.,O
04,O
),O
7,O
.,O
5,O
×,O
10,O
−,O
7,O
0,O
(,O
0,O
.,O
02,O
),O
0,O
.,O
79,O
0,O
.,O
02,O
(,O
0,O
.,O
02,O
),O
0,O
.,O
27,O
LDL,O
rs8073909,O
T,O
/,O
C,O
SNPxAGE,O
−,O
1,O
.,O
41,O
(,O
0,O
.,O
27,O
),O
1,O
.,O
4,O
×,O
10,O
−,O
7,O
0,O
.,O
06,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
08,O
0,O
.,O
04,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
32,O
LDL,O
rs11258628,O
*,O
A,O
/,O
T,O
SNPxAGE,O
−,O
0,O
.,O
69,O
(,O
0,O
.,O
14,O
),O
4,O
.,O
1,O
×,O
10,O
−,O
7,O
0,O
.,O
02,O
(,O
0,O
.,O
09,O
),O
0,O
.,O
84,O
−,O
0,O
.,O
38,O
(,O
0,O
.,O
09,O
),O
1,O
.,O
8,O
×,O
10,O
−,O
5,O
systolic,O
BP,O
rs1046391,O
*,O
G,O
/,O
T,O
SNPxAGE,O
0,O
.,O
21,O
(,O
0,O
.,O
04,O
),O
4,O
.,O
1,O
×,O
10,O
−,O
7,O
0,O
.,O
01,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
78,O
0,O
.,O
05,O
(,O
0,O
.,O
02,O
),O
0,O
.,O
03,O
systolic,O
BP,O
rs17104804,O
G,O
/,O
A,O
SNPxAGE,O
−,O
0,O
.,O
91,O
(,O
0,O
.,O
19,O
),O
9,O
.,O
3,O
×,O
10,O
−,O
7,O
0,O
.,O
01,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
63,O
−,O
0,O
.,O
05,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
06,O
total,O
cholesterol,O
rs8073909,O
T,O
/,O
C,O
SNPxAGE,O
−,O
1,O
.,O
68,O
(,O
0,O
.,O
31,O
),O
6,O
.,O
9,O
×,O
10,O
−,O
8,O
0,O
.,O
06,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
13,O
0,O
.,O
03,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
51,O
triglycerides,O
rs7890572,O
G,O
/,O
A,O
SNPxAGE,O
9,O
.,O
75,O
(,O
1,O
.,O
55,O
),O
3,O
.,O
8,O
×,O
10,O
−,O
10,O
0,O
.,O
1,O
(,O
0,O
.,O
22,O
),O
0,O
.,O
66,O
0,O
.,O
97,O
(,O
0,O
.,O
18,O
),O
1,O
.,O
2,O
×,O
10,O
−,O
7,O
triglycerides,O
rs12280753,O
*,O
T,O
/,O
C,O
SNPxAGE,O
2,O
.,O
64,O
(,O
0,O
.,O
47,O
),O
1,O
.,O
8,O
×,O
10,O
−,O
8,O
0,O
.,O
28,O
(,O
0,O
.,O
16,O
),O
0,O
.,O
09,O
0,O
.,O
69,O
(,O
0,O
.,O
15,O
),O
7,O
.,O
8,O
×,O
10,O
−,O
6,O
triglycerides,O
rs13290397,O
*,O
C,O
/,O
G,O
SNPxAGE,O
−,O
1,O
.,O
98,O
(,O
0,O
.,O
38,O
),O
2,O
.,O
4,O
×,O
10,O
−,O
7,O
0,O
.,O
21,O
(,O
0,O
.,O
15,O
),O
0,O
.,O
17,O
−,O
0,O
.,O
25,O
(,O
0,O
.,O
14,O
),O
0,O
.,O
08,O
triglycerides,O
rs6726786,O
*,O
G,O
/,O
T,O
SNPxAGE,O
−,O
2,O
.,O
09,O
(,O
0,O
.,O
41,O
),O
2,O
.,O
9,O
×,O
10,O
−,O
7,O
0,O
.,O
1,O
(,O
0,O
.,O
15,O
),O
0,O
.,O
49,O
−,O
0,O
.,O
32,O
(,O
0,O
.,O
14,O
),O
0,O
.,O
02,O
triglycerides,O
rs12330441,O
T,O
/,O
G,O
SNPxAGE,O
−,O
9,O
.,O
54,O
(,O
1,O
.,O
86,O
),O
3,O
.,O
0,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
05,O
(,O
0,O
.,O
16,O
),O
0,O
.,O
75,O
−,O
0,O
.,O
47,O
(,O
0,O
.,O
16,O
),O
0,O
.,O
0025,O
waist,O
circumference,O
rs127430,O
*,O
G,O
/,O
A,O
SNPxAGE,O
−,O
0,O
.,O
33,O
(,O
0,O
.,O
06,O
),O
3,O
.,O
3,O
×,O
10,O
−,O
8,O
−,O
0,O
.,O
02,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
65,O
−,O
0,O
.,O
19,O
(,O
0,O
.,O
04,O
),O
1,O
.,O
4,O
×,O
10,O
−,O
6,O
waist,O
circumference,O
rs7121446,O
G,O
/,O
A,O
SNPxAGE,O
−,O
1,O
.,O
09,O
(,O
0,O
.,O
21,O
),O
3,O
.,O
6,O
×,O
10,O
−,O
7,O
−,O
0,O
.,O
07,O
(,O
0,O
.,O
04,O
),O
0,O
.,O
11,O
−,O
0,O
.,O
15,O
(,O
0,O
.,O
03,O
),O
2,O
.,O
5,O
×,O
10,O
−,O
6,O
waist,O
circumference,O
rs7210277,O
*,O
C,O
/,O
T,O
SNPxAGE,O
−,O
0,O
.,O
39,O
(,O
0,O
.,O
08,O
),O
7,O
.,O
0,O
×,O
10,O
−,O
7,O
0,O
.,O
04,O
(,O
0,O
.,O
06,O
),O
0,O
.,O
48,O
−,O
0,O
.,O
17,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
00043,O
waist,O
circumference,O
rs17568778,O
C,O
/,O
A,O
SNPxAGE,O
−,O
1,O
.,O
55,O
(,O
0,O
.,O
31,O
),O
8,O
.,O
2,O
×,O
10,O
−,O
7,O
0,O
(,O
0,O
.,O
06,O
),O
0,O
.,O
98,O
−,O
0,O
.,O
17,O
(,O
0,O
.,O
05,O
),O
0,O
.,O
00024,O
weight,O
rs6552560,O
T,O
/,O
C,O
SNPxAGE,O
1,O
.,O
35,O
(,O
0,O
.,O
25,O
),O
8,O
.,O
5,O
×,O
10,O
−,O
8,O
−,O
0,O
.,O
02,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
5,O
0,O
.,O
06,O
(,O
0,O
.,O
03,O
),O
0,O
.,O
03,O
Replication,O
effects,O
and,O
P,O
-,O
values,O
in,O
the,O
Young,O
Finns,O
(,O
YF,O
),O
Study,O
and,O
in,O
combined,O
data,O
",",O
adjusted,O
for,O
study,O
.,O
SNP,O
names,O
marked,O
with,O
an,O
“*”,O
are,O
imputed,O
",",O
while,O
those,O
that,O
are,O
unmarked,O
were,O
directly,O
genotyped,O
.,O
SNP,O
alleles,O
are,O
reported,O
as,O
risk,O
/,O
nonrisk,O
and,O
are,O
in,O
genome,O
forward,O
orientation,O
(,O
build,O
36,O
.,O
3,O
).,O
#,O
rs445925,O
is,O
a,O
proxy,O
for,O
rs7412,O
.,O
Prediction,O
of,O
adult,O
values,O
given,O
childhood,O
values,O
Genetic,O
variants,O
will,O
be,O
most,O
useful,O
for,O
trait,O
prediction,O
when,O
they,O
are,O
associated,O
with,O
a,O
trait,O
above,O
and,O
beyond,O
other,O
known,O
risk,O
factors,O
.,O
In,O
addition,O
",",O
the,O
ability,O
to,O
predict,O
adult,O
trait,O
levels,O
in,O
children,O
",",O
before,O
disease,O
onset,O
",",O
can,O
lead,O
to,O
a,O
disease,O
prevention,O
strategy,O
.,O
In,O
longitudinal,O
studies,O
starting,O
in,O
childhood,O
and,O
going,O
into,O
adulthood,O
",",O
we,O
can,O
ask,O
whether,O
genetic,O
loci,O
are,O
associated,O
with,O
the,O
adult,O
trait,O
level,O
above,O
and,O
beyond,O
the,O
trait,O
level,O
seen,O
in,O
the,O
first,O
measure,O
taken,O
in,O
childhood,O
.,O
To,O
test,O
this,O
hypothesis,O
",",O
we,O
evaluated,O
whether,O
our,O
associated,O
markers,O
were,O
likely,O
to,O
be,O
predictive,O
of,O
adult,O
levels,O
of,O
the,O
traits,O
",",O
after,O
adjustment,O
for,O
trait,O
levels,O
in,O
childhood,O
.,O
To,O
account,O
for,O
variation,O
in,O
data,O
collection,O
",",O
we,O
also,O
included,O
the,O
age,O
at,O
each,O
of,O
these,O
measures,O
as,O
well,O
as,O
gender,O
as,O
covariates,O
in,O
the,O
analysis,O
.,O
Within,O
the,O
BHS,O
",",O
variants,O
that,O
were,O
characterized,O
as,O
SNPxAGE,O
effects,O
were,O
more,O
likely,O
to,O
be,O
predictive,O
of,O
adult,O
values,O
after,O
correcting,O
for,O
childhood,O
values,O
",",O
which,O
is,O
expected,O
since,O
these,O
variants,O
were,O
characterized,O
in,O
BHS,O
initially,O
(,O
Table,O
4,O
).,O
In,O
the,O
YF,O
study,O
",",O
however,O
",",O
we,O
also,O
saw,O
more,O
SNPxAGE,O
variants,O
associated,O
with,O
adult,O
levels,O
given,O
childhood,O
levels,O
(,O
Table,O
4,O
).,O
There,O
were,O
6,O
variants,O
that,O
were,O
associated,O
with,O
adult,O
levels,O
in,O
the,O
YF,O
study,O
at,O
P,O
<,O
0,O
.,O
05,O
",",O
with,O
2,O
corresponding,O
to,O
the,O
genome,O
-,O
wide,O
significant,O
SNP,O
effects,O
and,O
4,O
corresponding,O
to,O
BHS,O
SNPxAGE,O
variants,O
.,O
Only,O
the,O
association,O
of,O
rs445925,O
with,O
LDL,O
-,O
cholesterol,O
was,O
strong,O
enough,O
to,O
withstand,O
multiple,O
corrections,O
.,O
Further,O
analysis,O
of,O
this,O
observation,O
is,O
warranted,O
in,O
a,O
larger,O
cohort,O
.,O
Association,O
of,O
GWAS,O
SNPs,O
with,O
adult,O
trait,O
levels,O
after,O
adjusting,O
for,O
childhood,O
levels,O
.,O
Trait,O
Top,O
SNP,O
(,O
Alleles,O
),O
Effect,O
BHS,O
Adult,O
prediction,O
P,O
YF,O
Adult,O
prediction,O
P,O
diastolic,O
BP,O
rs7704530,O
G,O
/,O
A,O
SNP,O
0,O
.,O
07,O
0,O
.,O
74,O
diastolic,O
BP,O
rs709595,O
C,O
/,O
G,O
SNP,O
0,O
.,O
26,O
0,O
.,O
09,O
glucose,O
rs853773,O
A,O
/,O
G,O
SNP,O
0,O
.,O
003,O
0,O
.,O
24,O
glucose,O
rs781718,O
*,O
G,O
/,O
A,O
SNP,O
0,O
.,O
27,O
0,O
.,O
21,O
HDL,O
-,O
cholesterol,O
rs247616,O
*,O
T,O
/,O
C,O
SNP,O
8,O
.,O
1,O
×,O
10,O
−,O
4,O
0,O
.,O
0067,O
insulin,B-GP
rs3793275,O
*,O
A,O
/,O
T,O
SNP,O
0,O
.,O
89,O
0,O
.,O
36,O
insulin,B-GP
rs6052399,O
*,O
T,O
/,O
C,O
SNP,O
0,O
.,O
014,O
0,O
.,O
89,O
insulin,B-GP
rs16892328,O
*,O
C,O
/,O
T,O
SNP,O
0,O
.,O
22,O
0,O
.,O
14,O
insulin,B-GP
rs1613695,O
*,O
G,O
/,O
A,O
SNP,O
0,O
.,O
16,O
0,O
.,O
67,O
insulin,B-GP
rs10498337,O
T,O
/,O
G,O
SNP,O
0,O
.,O
38,O
0,O
.,O
88,O
LDL,O
-,O
cholesterol,O
rs8131349,O
*,O
A,O
/,O
G,O
SNP,O
0,O
.,O
14,O
0,O
.,O
16,O
LDL,O
-,O
cholesterol,O
rs445925,O
*,O
G,O
/,O
A,O
SNP,O
0,O
.,O
025,O
2,O
.,O
3,O
×,O
10,O
−,O
6,O
LDL,O
-,O
cholesterol,O
rs7738656,O
G,O
/,O
A,O
SNP,O
0,O
.,O
042,O
0,O
.,O
25,O
LDL,O
-,O
cholesterol,O
rs10044666,O
*,O
G,O
/,O
T,O
SNP,O
0,O
.,O
015,O
0,O
.,O
78,O
systolic,O
BP,O
rs11822822,O
G,O
/,O
A,O
SNP,O
0,O
.,O
002,O
0,O
.,O
63,O
systolic,O
BP,O
rs726914,O
G,O
/,O
A,O
SNP,O
0,O
.,O
004,O
0,O
.,O
54,O
total,O
cholesterol,O
rs8131349,O
*,O
A,O
/,O
G,O
SNP,O
0,O
.,O
051,O
0,O
.,O
3,O
total,O
cholesterol,O
rs6829649,O
T,O
/,O
G,O
SNP,O
0,O
.,O
56,O
0,O
.,O
44,O
total,O
cholesterol,O
rs7738656,O
G,O
/,O
A,O
SNP,O
0,O
.,O
028,O
0,O
.,O
08,O
total,O
cholesterol,O
rs4897695,O
*,O
C,O
/,O
G,O
SNP,O
0,O
.,O
24,O
0,O
.,O
91,O
waist,O
circumference,O
rs891541,O
*,O
A,O
/,O
G,O
SNP,O
0,O
.,O
14,O
0,O
.,O
28,O
distolic,O
BP,O
rs17104804,O
G,O
/,O
A,O
SNPxAGE,O
1,O
.,O
5,O
×,O
10,O
−,O
4,O
0,O
.,O
46,O
glucose,O
rs4783595,O
T,O
/,O
C,O
SNPxAGE,O
8,O
.,O
7,O
×,O
10,O
−,O
8,O
0,O
.,O
4,O
glucose,O
rs3793275,O
*,O
A,O
/,O
T,O
SNPxAGE,O
5,O
.,O
7,O
×,O
10,O
−,O
7,O
0,O
.,O
44,O
glucose,O
rs5979903,O
T,O
/,O
C,O
SNPxAGE,O
3,O
.,O
0,O
×,O
10,O
−,O
4,O
0,O
.,O
45,O
glucose,O
rs12807555,O
*,O
G,O
/,O
T,O
SNPxAGE,O
1,O
.,O
2,O
×,O
10,O
−,O
8,O
0,O
.,O
93,O
glucose,O
rs9909931,O
G,O
/,O
A,O
SNPxAGE,O
5,O
.,O
0,O
×,O
10,O
−,O
7,O
0,O
.,O
67,O
glucose,O
rs12069004,O
*,O
C,O
/,O
T,O
SNPxAGE,O
3,O
.,O
2,O
×,O
10,O
−,O
5,O
0,O
.,O
88,O
glucose,O
rs12548494,O
*,O
C,O
/,O
G,O
SNPxAGE,O
2,O
.,O
7,O
×,O
10,O
−,O
6,O
0,O
.,O
45,O
glucose,O
rs10260737,O
G,O
/,O
A,O
SNPxAGE,O
1,O
.,O
2,O
×,O
10,O
−,O
5,O
1,O
glucose,O
rs3019325,O
*,O
G,O
/,O
C,O
SNPxAGE,O
2,O
.,O
2,O
×,O
10,O
−,O
5,O
0,O
.,O
56,O
heart,O
rate,O
rs6440031,O
G,O
/,O
A,O
SNPxAGE,O
1,O
.,O
2,O
×,O
10,O
−,O
3,O
0,O
.,O
77,O
heart,O
rate,O
rs1449460,O
G,O
/,O
A,O
SNPxAGE,O
0,O
.,O
0302,O
0,O
.,O
81,O
height,O
rs1144036,O
C,O
/,O
T,O
SNPxAGE,O
0,O
.,O
2199,O
0,O
.,O
01,O
height,O
rs8103264,O
*,O
C,O
/,O
G,O
SNPxAGE,O
0,O
.,O
0360,O
0,O
.,O
49,O
insulin,B-GP
rs1552257,O
*,O
C,O
/,O
T,O
SNPxAGE,O
3,O
.,O
8,O
×,O
10,O
−,O
5,O
0,O
.,O
61,O
LDL,O
rs8073909,O
T,O
/,O
C,O
SNPxAGE,O
1,O
.,O
2,O
×,O
10,O
−,O
6,O
0,O
.,O
007,O
LDL,O
rs11258628,O
*,O
A,O
/,O
T,O
SNPxAGE,O
7,O
.,O
3,O
×,O
10,O
−,O
6,O
0,O
.,O
88,O
systolic,O
BP,O
rs1046391,O
*,O
G,O
/,O
T,O
SNPxAGE,O
6,O
.,O
2,O
×,O
10,O
−,O
4,O
0,O
.,O
74,O
systolic,O
BP,O
rs17104804,O
G,O
/,O
A,O
SNPxAGE,O
0,O
.,O
0015,O
0,O
.,O
36,O
total,O
cholesterol,O
rs8073909,O
T,O
/,O
C,O
SNPxAGE,O
2,O
.,O
0,O
×,O
10,O
−,O
7,O
0,O
.,O
008,O
triglycerides,O
rs7890572,O
G,O
/,O
A,O
SNPxAGE,O
4,O
.,O
2,O
×,O
10,O
−,O
6,O
0,O
.,O
43,O
triglycerides,O
rs12280753,O
*,O
T,O
/,O
C,O
SNPxAGE,O
9,O
.,O
9,O
×,O
10,O
−,O
9,O
0,O
.,O
24,O
triglycerides,O
rs13290397,O
*,O
C,O
/,O
G,O
SNPxAGE,O
6,O
.,O
8,O
×,O
10,O
−,O
7,O
0,O
.,O
33,O
triglycerides,O
rs6726786,O
*,O
G,O
/,O
T,O
SNPxAGE,O
3,O
.,O
9,O
×,O
10,O
−,O
6,O
0,O
.,O
74,O
triglycerides,O
rs12330441,O
T,O
/,O
G,O
SNPxAGE,O
3,O
.,O
1,O
×,O
10,O
−,O
5,O
0,O
.,O
79,O
waist,O
circumference,O
rs127430,O
*,O
G,O
/,O
A,O
SNPxAGE,O
2,O
.,O
1,O
×,O
10,O
−,O
7,O
0,O
.,O
71,O
waist,O
circumference,O
rs7121446,O
G,O
/,O
A,O
SNPxAGE,O
2,O
.,O
2,O
×,O
10,O
−,O
6,O
0,O
.,O
68,O
waist,O
circumference,O
rs7210277,O
*,O
C,O
/,O
T,O
SNPxAGE,O
1,O
.,O
2,O
×,O
10,O
−,O
6,O
0,O
.,O
9,O
waist,O
circumference,O
rs17568778,O
C,O
/,O
A,O
SNPxAGE,O
9,O
.,O
0,O
×,O
10,O
−,O
7,O
0,O
.,O
99,O
weight,O
rs6552560,O
T,O
/,O
C,O
SNPxAGE,O
1,O
.,O
8,O
×,O
10,O
−,O
5,O
0,O
.,O
04,O
Adult,O
prediction,O
P,O
-,O
values,O
correspond,O
to,O
the,O
association,O
between,O
the,O
SNP,O
and,O
the,O
last,O
adult,O
measurement,O
",",O
after,O
adjusting,O
for,O
the,O
first,O
measure,O
in,O
childhood,O
.,O
Previously,O
identified,O
markers,O
We,O
assessed,O
whether,O
associations,O
that,O
have,O
been,O
described,O
in,O
previous,O
adult,O
cross,O
-,O
sectional,O
GWA,O
studies,O
exhibit,O
consistent,O
effects,O
over,O
time,O
and,O
whether,O
the,O
effect,O
sizes,O
observed,O
in,O
children,O
through,O
middle,O
-,O
aged,O
adults,O
are,O
consistent,O
with,O
those,O
previously,O
described,O
.,O
We,O
identified,O
169,O
SNP,O
-,O
trait,O
associations,O
(,O
see,O
Materials,O
and,O
Methods,O
),O
for,O
which,O
we,O
had,O
directly,O
genotyped,O
or,O
imputed,O
genotype,O
data,O
.,O
We,O
first,O
estimated,O
our,O
power,O
to,O
detect,O
each,O
previous,O
association,O
at,O
alpha,O
=,O
0,O
.,O
05,O
under,O
a,O
more,O
structured,O
",",O
but,O
similar,O
study,O
design,O
(,O
i,O
.,O
e,O
".,",O
8,O
equally,O
spaced,O
measurements,O
"),",O
given,O
the,O
previously,O
reported,O
effect,O
size,O
and,O
allele,O
frequency,O
.,O
Under,O
this,O
model,O
",",O
we,O
would,O
expect,O
to,O
have,O
detected,O
40,O
/,O
169,O
(,O
24,O
%),O
associations,O
at,O
P,O
<,O
0,O
.,O
05,O
",",O
and,O
we,O
observed,O
a,O
similar,O
number,O
of,O
SNP,O
effects,O
in,O
the,O
BHS,O
data,O
(,O
32,O
/,O
169,O
;,O
19,O
%).,O
We,O
evaluated,O
the,O
associations,O
across,O
all,O
traits,O
together,O
by,O
comparing,O
how,O
well,O
the,O
previously,O
reported,O
effect,O
size,O
was,O
recapitulated,O
in,O
the,O
BHS,O
GWA,O
(,O
Figure,O
1A,O
).,O
For,O
consistency,O
across,O
studies,O
and,O
traits,O
",",O
if,O
an,O
effect,O
size,O
was,O
not,O
already,O
expressed,O
in,O
terms,O
of,O
percent,O
standard,O
deviation,O
(%,O
SD,O
"),",O
we,O
converted,O
the,O
previously,O
reported,O
effect,O
size,O
into,O
%,O
SD,O
and,O
compared,O
the,O
previous,O
effect,O
size,O
to,O
the,O
SNP,O
effect,O
.,O
The,O
previously,O
reported,O
effect,O
size,O
was,O
a,O
strong,O
predictor,O
of,O
the,O
SNP,O
effect,O
(,O
slope,O
=,O
0,O
.,O
47,O
",",O
P,O
=,O
1,O
.,O
2,O
×,O
10,O
−,O
21,O
"),",O
suggesting,O
that,O
SNPs,O
that,O
have,O
been,O
previously,O
identified,O
in,O
adult,O
cross,O
-,O
sectional,O
GWA,O
studies,O
are,O
good,O
predictors,O
of,O
time,O
-,O
averaged,O
effects,O
in,O
the,O
BHS,O
sample,O
.,O
Effects,O
of,O
previously,O
identified,O
variants,O
in,O
the,O
BHS,O
.,O
A,O
),O
Effect,O
sizes,O
of,O
previously,O
identified,O
markers,O
are,O
plotted,O
against,O
observed,O
effects,O
in,O
the,O
BHS,O
.,O
SNP,O
-,O
trait,O
associations,O
are,O
plotted,O
by,O
shape,O
and,O
color,O
to,O
indicate,O
trait,O
.,O
The,O
size,O
of,O
the,O
point,O
indicates,O
the,O
power,O
to,O
detect,O
an,O
association,O
of,O
the,O
magnitude,O
previously,O
described,O
",",O
and,O
whether,O
a,O
point,O
is,O
filled,O
in,O
or,O
not,O
indicates,O
whether,O
the,O
association,O
was,O
significant,O
at,O
P,O
<,O
0,O
.,O
05,O
in,O
the,O
BHS,O
.,O
Linear,O
regression,O
lines,O
are,O
shown,O
",",O
with,O
the,O
slope,O
and,O
p,O
-,O
value,O
of,O
the,O
association,O
between,O
previously,O
reported,O
effect,O
sizes,O
and,O
the,O
observed,O
effect,O
sizes,O
.,O
B,O
),O
Individuals,O
were,O
scored,O
based,O
on,O
the,O
effect,O
size,O
of,O
each,O
previously,O
identified,O
marker,O
and,O
are,O
grouped,O
and,O
color,O
-,O
coded,O
based,O
on,O
the,O
decile,O
of,O
their,O
score,O
.,O
Linear,O
lines,O
are,O
linear,O
regression,O
estimates,O
of,O
the,O
average,O
trajectory,O
of,O
each,O
decile,O
group,O
.,O
We,O
also,O
determined,O
whether,O
the,O
same,O
previously,O
identified,O
SNPs,O
were,O
likely,O
to,O
show,O
effects,O
on,O
a,O
trait,O
over,O
time,O
(,O
SNPxAGE,O
effects,O
).,O
Under,O
a,O
simple,O
model,O
that,O
assumed,O
that,O
all,O
of,O
the,O
effect,O
in,O
adults,O
is,O
due,O
to,O
a,O
locus,O
that,O
has,O
no,O
effect,O
in,O
childhood,O
",",O
we,O
estimated,O
power,O
to,O
detect,O
such,O
an,O
interaction,O
effect,O
in,O
a,O
similarly,O
structured,O
study,O
with,O
8,O
repeated,O
measures,O
.,O
Given,O
these,O
assumptions,O
",",O
we,O
would,O
have,O
expected,O
to,O
see,O
24,O
/,O
169,O
(,O
14,O
%),O
SNPxAGE,O
associations,O
.,O
We,O
observed,O
6,O
/,O
169,O
(,O
3,O
.,O
6,O
%),O
SNPs,O
that,O
showed,O
SNPxAGE,O
effects,O
at,O
P,O
<,O
0,O
.,O
05,O
",",O
indicating,O
that,O
effects,O
seen,O
in,O
SNPs,O
described,O
in,O
adult,O
GWA,O
studies,O
are,O
not,O
due,O
primarily,O
to,O
differences,O
in,O
effects,O
over,O
time,O
",",O
although,O
larger,O
studies,O
will,O
be,O
required,O
to,O
definitively,O
characterize,O
this,O
.,O
Composite,O
scoring,O
We,O
considered,O
whether,O
a,O
composite,O
genotype,O
score,O
would,O
better,O
predict,O
overall,O
CVD,B-DS
risk,O
factor,O
trajectories,O
or,O
time,O
-,O
dependent,O
effects,O
than,O
any,O
single,O
locus,O
.,O
For,O
each,O
person,O
and,O
each,O
trait,O
",",O
we,O
created,O
a,O
score,O
by,O
summing,O
the,O
expected,O
effect,O
in,O
percent,O
standard,O
deviation,O
of,O
each,O
allele,O
that,O
the,O
person,O
carried,O
.,O
We,O
then,O
determined,O
whether,O
the,O
score,O
was,O
associated,O
with,O
the,O
trait,O
',O
s,O
average,O
value,O
and,O
trajectory,O
by,O
using,O
this,O
score,O
as,O
a,O
predictor,O
for,O
each,O
trait,O
in,O
a,O
linear,O
mixed,O
model,O
",",O
adjusting,O
for,O
age,O
and,O
gender,O
.,O
We,O
assessed,O
the,O
score,O
',O
s,O
average,O
effect,O
across,O
time,O
(,O
score,O
effect,O
),O
and,O
whether,O
or,O
not,O
there,O
was,O
a,O
time,O
-,O
dependent,O
effect,O
(,O
score,O
*,O
age,O
effect,O
).,O
The,O
traits,O
HDL,O
",",O
LDL,O
",",O
total,O
cholesterol,O
",",O
triglycerides,O
",",O
and,O
height,O
showed,O
strongly,O
significant,O
score,O
effects,O
",",O
while,O
only,O
triglycerides,O
showed,O
a,O
score,O
*,O
age,O
effect,O
(,O
Table,O
5,O
).,O
Longitudinal,O
data,O
was,O
visualized,O
by,O
color,O
-,O
coding,O
the,O
individuals,O
according,O
to,O
the,O
decile,O
of,O
their,O
overall,O
score,O
and,O
the,O
average,O
linear,O
trend,O
of,O
each,O
group,O
was,O
plotted,O
(,O
LDL,O
",",O
Figure,O
1B,O
and,O
others,O
in,O
Figure,O
S3,O
).,O
These,O
results,O
indicate,O
that,O
the,O
cumulative,O
effects,O
of,O
SNPs,O
that,O
are,O
identified,O
in,O
large,O
adult,O
cross,O
-,O
sectional,O
studies,O
are,O
generally,O
age,O
-,O
independent,O
effects,O
",",O
with,O
an,O
exception,O
in,O
triglycerides,O
",",O
which,O
was,O
the,O
only,O
trait,O
to,O
show,O
a,O
significant,O
score,O
*,O
age,O
effect,O
.,O
We,O
additionally,O
tested,O
whether,O
previously,O
identified,O
variants,O
were,O
predictive,O
of,O
adult,O
levels,O
after,O
adjusting,O
for,O
childhood,O
levels,O
(,O
Table,O
6,O
).,O
We,O
saw,O
that,O
25,O
/,O
169,O
(,O
14,O
.,O
8,O
%),O
showed,O
association,O
at,O
P,O
<,O
0,O
.,O
05,O
.,O
These,O
observations,O
in,O
the,O
BHS,O
data,O
suggest,O
that,O
even,O
though,O
results,O
from,O
existing,O
GWA,O
studies,O
demonstrate,O
age,O
-,O
independent,O
effects,O
",",O
they,O
can,O
be,O
predictive,O
of,O
trait,O
values,O
in,O
adults,O
.,O
P,O
-,O
values,O
associated,O
with,O
score,O
and,O
score,O
*,O
age,O
effects,O
(,O
Age,O
and,O
Sex,O
adjusted,O
).,O
Score,O
Score,O
×,O
AGE,O
weight,O
0,O
.,O
03,O
0,O
.,O
11,O
diastolic,O
BP,O
0,O
.,O
62,O
0,O
.,O
92,O
HDL,O
-,O
cholesterol,O
1,O
.,O
9,O
×,O
10,O
−,O
5,O
0,O
.,O
11,O
height,O
8,O
.,O
8,O
×,O
10,O
−,O
12,O
0,O
.,O
86,O
LDL,O
-,O
cholesterol,O
5,O
.,O
7,O
×,O
10,O
−,O
10,O
0,O
.,O
27,O
systolic,O
BP,O
0,O
.,O
11,O
0,O
.,O
21,O
total,O
cholesterol,O
6,O
.,O
6,O
×,O
10,O
−,O
9,O
0,O
.,O
21,O
triglycerides,O
4,O
.,O
1,O
×,O
10,O
−,O
8,O
2,O
.,O
9,O
×,O
10,O
−,O
5,O
Scores,O
based,O
on,O
the,O
genotypes,O
of,O
previously,O
reported,O
SNPs,O
were,O
used,O
to,O
test,O
for,O
association,O
with,O
effects,O
across,O
time,O
(,O
Score,O
),O
or,O
time,O
-,O
dependent,O
effects,O
(,O
Score,O
×,O
Age,O
).,O
P,O
-,O
values,O
for,O
predictive,O
ability,O
of,O
previously,O
identified,O
SNPs,O
",",O
after,O
adjusting,O
for,O
first,O
measure,O
in,O
childhood,O
.,O
Trait,O
SNP,O
Alleles,O
BETA,O
SE,O
P,O
diastolic,O
BP,O
rs653178,O
T,O
/,O
C,O
−,O
1,O
.,O
2,O
0,O
.,O
5,O
0,O
.,O
025,O
glucose,O
rs560887,O
T,O
/,O
C,O
−,O
3,O
.,O
0,O
1,O
.,O
5,O
0,O
.,O
046,O
HDL,O
-,O
cholesterol,O
rs1532624,O
A,O
/,O
C,O
2,O
.,O
1,O
0,O
.,O
7,O
0,O
.,O
005,O
HDL,O
-,O
cholesterol,O
rs964184,O
G,O
/,O
C,O
−,O
2,O
.,O
8,O
1,O
.,O
1,O
0,O
.,O
015,O
HDL,O
-,O
cholesterol,O
rs157580,O
A,O
/,O
G,O
−,O
1,O
.,O
6,O
0,O
.,O
7,O
0,O
.,O
027,O
HDL,O
-,O
cholesterol,O
rs7395662,O
A,O
/,O
G,O
−,O
1,O
.,O
5,O
0,O
.,O
7,O
0,O
.,O
038,O
HDL,O
-,O
cholesterol,O
rs471364,O
T,O
/,O
C,O
2,O
.,O
2,O
1,O
.,O
1,O
0,O
.,O
049,O
height,O
rs185819,O
T,O
/,O
C,O
0,O
.,O
9,O
0,O
.,O
3,O
0,O
.,O
003,O
height,O
rs3748069,O
A,O
/,O
G,O
0,O
.,O
9,O
0,O
.,O
3,O
0,O
.,O
006,O
height,O
rs710841,O
C,O
/,O
T,O
−,O
0,O
.,O
8,O
0,O
.,O
3,O
0,O
.,O
013,O
height,O
rs4896582,O
A,O
/,O
G,O
−,O
0,O
.,O
8,O
0,O
.,O
3,O
0,O
.,O
013,O
height,O
rs967417,O
G,O
/,O
A,O
0,O
.,O
7,O
0,O
.,O
3,O
0,O
.,O
013,O
height,O
rs757608,O
G,O
/,O
A,O
−,O
0,O
.,O
7,O
0,O
.,O
3,O
0,O
.,O
031,O
height,O
rs3760318,O
A,O
/,O
G,O
−,O
0,O
.,O
6,O
0,O
.,O
3,O
0,O
.,O
032,O
height,O
rs16896068,O
A,O
/,O
G,O
−,O
0,O
.,O
8,O
0,O
.,O
4,O
0,O
.,O
037,O
height,O
rs6060373,O
A,O
/,O
G,O
−,O
0,O
.,O
6,O
0,O
.,O
3,O
0,O
.,O
048,O
LDL,O
-,O
cholesterol,O
rs12740374,O
G,O
/,O
T,O
6,O
.,O
3,O
2,O
.,O
4,O
0,O
.,O
009,O
LDL,O
-,O
cholesterol,O
rs12272004,O
A,O
/,O
C,O
−,O
8,O
.,O
7,O
4,O
.,O
1,O
0,O
.,O
034,O
systolic,O
BP,O
rs3184504,O
C,O
/,O
T,O
−,O
1,O
.,O
6,O
0,O
.,O
7,O
0,O
.,O
023,O
total,O
cholesterol,O
rs693,O
G,O
/,O
A,O
−,O
5,O
.,O
7,O
2,O
.,O
3,O
0,O
.,O
013,O
total,O
cholesterol,O
rs2304130,O
A,O
/,O
G,O
8,O
.,O
9,O
4,O
.,O
1,O
0,O
.,O
031,O
triglycerides,O
rs964184,O
G,O
/,O
C,O
51,O
.,O
7,O
10,O
.,O
7,O
1,O
.,O
9,O
×,O
10,O
−,O
6,O
triglycerides,O
rs780094,O
C,O
/,O
T,O
−,O
19,O
.,O
1,O
7,O
.,O
2,O
0,O
.,O
009,O
triglycerides,O
rs7819412,O
A,O
/,O
G,O
13,O
.,O
4,O
6,O
.,O
7,O
0,O
.,O
045,O
weight,O
rs7138803,O
G,O
/,O
A,O
−,O
2,O
.,O
2,O
1,O
.,O
0,O
0,O
.,O
037,O
Previously,O
associated,O
SNPs,O
were,O
tested,O
for,O
whether,O
they,O
were,O
associated,O
with,O
adult,O
level,O
traits,O
after,O
adjusting,O
for,O
the,O
trait,O
level,O
seen,O
in,O
childhood,O
.,O
Only,O
associations,O
at,O
P,O
<,O
0,O
.,O
05,O
are,O
shown,O
.,O
Discussion,O
We,O
identified,O
seven,O
associations,O
at,O
P,O
<,O
5,O
×,O
10,O
−,O
8,O
showing,O
either,O
time,O
-,O
averaged,O
or,O
time,O
-,O
dependent,O
effects,O
on,O
CVD,B-DS
risk,O
factors,O
in,O
the,O
BHS,O
",",O
two,O
of,O
which,O
have,O
been,O
previously,O
characterized,O
.,O
Of,O
all,O
associations,O
with,O
P,O
<,O
10,O
−,O
6,O
",",O
we,O
were,O
able,O
to,O
strongly,O
replicate,O
the,O
association,O
in,O
the,O
YF,O
with,O
HDL,O
-,O
cholesterol,O
at,O
CETP,B-GP
with,O
a,O
combined,O
P,O
=,O
9,O
.,O
7,O
×,O
10,O
−,O
24,O
",",O
and,O
LDL,O
-,O
cholesterol,O
at,O
APOE,B-GP
with,O
a,O
combined,O
P,O
=,O
8,O
.,O
7,O
×,O
10,O
−,O
19,O
.,O
Differences,O
that,O
exist,O
between,O
the,O
cohorts,O
",",O
such,O
as,O
birth,O
year,O
(,O
15,O
year,O
difference,O
"),",O
and,O
environmental,O
differences,O
could,O
have,O
influenced,O
replication,O
of,O
the,O
remaining,O
SNPs,O
.,O
Larger,O
discovery,O
studies,O
will,O
also,O
have,O
better,O
resolution,O
and,O
power,O
to,O
accurately,O
estimate,O
longitudinal,O
effect,O
sizes,O
",",O
likely,O
allowing,O
for,O
more,O
robust,O
replication,O
.,O
We,O
evaluated,O
the,O
longitudinal,O
effects,O
of,O
markers,O
that,O
have,O
been,O
previously,O
identified,O
in,O
adult,O
GWA,O
studies,O
.,O
We,O
found,O
that,O
previously,O
identified,O
markers,O
showed,O
time,O
-,O
averaged,O
effects,O
consistent,O
with,O
their,O
reported,O
effect,O
size,O
.,O
This,O
argues,O
that,O
the,O
linear,O
mixed,O
model,O
is,O
an,O
effective,O
tool,O
for,O
modeling,O
time,O
-,O
averaged,O
effects,O
in,O
a,O
GWA,O
setting,O
and,O
that,O
adult,O
GWA,O
studies,O
may,O
be,O
capturing,O
variation,O
that,O
tends,O
to,O
have,O
consistent,O
effects,O
over,O
time,O
.,O
Using,O
a,O
scoring,O
approach,O
",",O
the,O
overall,O
signal,O
from,O
previously,O
identified,O
markers,O
tended,O
to,O
have,O
strong,O
associations,O
with,O
time,O
-,O
averaged,O
effects,O
",",O
but,O
except,O
in,O
the,O
case,O
of,O
triglycerides,O
",",O
did,O
not,O
show,O
time,O
-,O
dependent,O
effects,O
.,O
Previously,O
identified,O
markers,O
were,O
also,O
likely,O
to,O
be,O
associated,O
with,O
adult,O
trait,O
levels,O
above,O
and,O
beyond,O
childhood,O
levels,O
.,O
Although,O
we,O
primarily,O
describe,O
time,O
-,O
averaged,O
effects,O
for,O
previously,O
identified,O
markers,O
",",O
there,O
may,O
be,O
more,O
subtle,O
time,O
-,O
dependent,O
effects,O
that,O
larger,O
studies,O
will,O
be,O
better,O
able,O
to,O
capture,O
.,O
It,O
is,O
important,O
to,O
note,O
that,O
although,O
we,O
focused,O
on,O
analysis,O
of,O
linear,O
trends,O
over,O
time,O
",",O
a,O
linear,O
model,O
may,O
not,O
best,O
capture,O
these,O
trends,O
.,O
Other,O
approaches,O
could,O
be,O
explored,O
further,O
such,O
as,O
non,O
-,O
linear,O
models,O
when,O
there,O
is,O
an,O
a,O
priori,O
expectation,O
of,O
trait,O
trajectory,O
",",O
or,O
model,O
free,O
approaches,O
.,O
These,O
additional,O
models,O
could,O
lead,O
to,O
additional,O
variations,O
that,O
influence,O
trajectories,O
",",O
or,O
more,O
precise,O
estimations,O
of,O
effect,O
size,O
.,O
Longitudinal,O
studies,O
are,O
particularly,O
suited,O
to,O
capturing,O
effects,O
that,O
vary,O
over,O
time,O
.,O
Genetic,O
variation,O
that,O
shows,O
a,O
time,O
-,O
dependent,O
effect,O
may,O
help,O
predict,O
those,O
that,O
will,O
go,O
onto,O
develop,O
disease,O
before,O
they,O
show,O
symptomatic,O
traits,O
.,O
The,O
discovery,O
of,O
variants,O
associated,O
with,O
SNPxAGE,O
interaction,O
effects,O
could,O
thus,O
be,O
used,O
to,O
screen,O
young,O
individuals,O
who,O
are,O
pre,O
-,O
symptomatic,O
and,O
provide,O
the,O
opportunity,O
for,O
preventive,O
measures,O
decades,O
before,O
disease,O
onset,O
.,O
We,O
explored,O
how,O
well,O
the,O
markers,O
that,O
we,O
identified,O
predicted,O
adult,O
traits,O
after,O
correcting,O
for,O
childhood,O
traits,O
and,O
suggest,O
further,O
study,O
of,O
variants,O
with,O
SNPxAGE,O
effects,O
as,O
possibly,O
better,O
predictors,O
of,O
adult,O
trait,O
levels,O
above,O
and,O
beyond,O
childhood,O
levels,O
.,O
These,O
results,O
are,O
consistent,O
with,O
the,O
idea,O
that,O
longitudinal,O
studies,O
may,O
be,O
a,O
useful,O
tool,O
to,O
better,O
capture,O
time,O
-,O
dependent,O
variation,O
that,O
could,O
ultimately,O
be,O
better,O
predictive,O
of,O
future,O
outcomes,O
.,O
Materials,O
and,O
Methods,O
Ethics,O
statement,O
The,O
study,O
was,O
approved,O
by,O
the,O
institutional,O
review,O
board,O
and,O
the,O
ethics,O
committee,O
of,O
each,O
institution,O
.,O
Written,O
informed,O
consent,O
was,O
obtained,O
from,O
each,O
participant,O
in,O
accordance,O
with,O
institutional,O
requirements,O
and,O
the,O
Declaration,O
of,O
Helsinki,O
Principles,O
.,O
All,O
subjects,O
in,O
the,O
BHS,O
gave,O
informed,O
consent,O
at,O
each,O
examination,O
",",O
and,O
for,O
those,O
under,O
18,O
years,O
of,O
age,O
",",O
consent,O
of,O
a,O
parent,O
/,O
guardian,O
was,O
obtained,O
.,O
Study,O
protocols,O
were,O
approved,O
by,O
the,O
Institutional,O
Review,O
Board,O
of,O
the,O
Tulane,O
University,O
Health,O
Sciences,O
Center,O
.,O
The,O
Bogalusa,O
Heart,O
Study,O
(,O
BHS,O
),O
Between,O
1973,O
and,O
2008,O
",",O
9,O
cross,O
-,O
sectional,O
surveys,O
of,O
children,O
aged,O
4,O
–,O
17,O
years,O
and,O
10,O
cross,O
-,O
sectional,O
surveys,O
of,O
adults,O
aged,O
18,O
–,O
48,O
years,O
(,O
Figure,O
S4,O
"),",O
who,O
had,O
been,O
previously,O
examined,O
as,O
children,O
",",O
were,O
conducted,O
for,O
CVD,B-DS
risk,O
factor,O
examinations,O
in,O
Bogalusa,O
",",O
Louisiana,O
.,O
This,O
panel,O
design,O
of,O
repeated,O
cross,O
-,O
sectional,O
examinations,O
has,O
resulted,O
in,O
serial,O
observations,O
from,O
childhood,O
to,O
adulthood,O
.,O
By,O
linking,O
the,O
19,O
surveys,O
",",O
12,O
",",O
163,O
individuals,O
have,O
been,O
examined,O
",",O
with,O
37,O
",",O
317,O
observations,O
.,O
In,O
the,O
ongoing,O
Longitudinal,O
Aging,O
Study,O
funded,O
by,O
NIH,O
and,O
NIA,O
since,O
2000,O
",",O
there,O
are,O
1,O
",",O
202,O
subjects,O
who,O
have,O
been,O
examined,O
4,O
–,O
14,O
times,O
from,O
childhood,O
to,O
adulthood,O
and,O
have,O
DNA,O
available,O
for,O
GWA,O
genotyping,O
.,O
Based,O
on,O
the,O
analysis,O
of,O
identity,O
-,O
by,O
-,O
state,O
(,O
IBS,O
),O
sharing,O
from,O
whole,O
genome,O
genotyping,O
data,O
",",O
we,O
focus,O
on,O
a,O
subset,O
of,O
525,O
genotyped,O
individuals,O
who,O
are,O
of,O
European,O
ancestry,O
and,O
unrelated,O
(,O
229,O
male,O
",",O
296,O
female,O
).,O
The,O
average,O
number,O
of,O
measurements,O
per,O
individual,O
is,O
8,O
(,O
range,O
4,O
–,O
13,O
).,O
The,O
Cardiovascular,O
Risk,O
in,O
Young,O
Finns,O
Study,O
(,O
YF,O
),O
The,O
YF,O
cohort,O
is,O
a,O
Finnish,O
longitudinal,O
population,O
study,O
sample,O
on,O
the,O
evolution,O
of,O
cardiovascular,O
risk,O
factors,O
from,O
childhood,O
to,O
adulthood,O
[,O
21,O
].,O
The,O
first,O
cross,O
-,O
sectional,O
study,O
was,O
conducted,O
in,O
1980,O
in,O
five,O
centers,O
and,O
included,O
3,O
",",O
596,O
participants,O
in,O
the,O
age,O
groups,O
of,O
3,O
",",O
6,O
",",O
9,O
",",O
12,O
",",O
15,O
",",O
and,O
18,O
",",O
who,O
were,O
randomly,O
chosen,O
from,O
the,O
national,O
population,O
register,O
.,O
After,O
baseline,O
in,O
1980,O
these,O
subjects,O
have,O
been,O
re,O
-,O
examined,O
in,O
1983,O
and,O
1986,O
as,O
young,O
individuals,O
",",O
and,O
in,O
2001,O
and,O
2007,O
as,O
older,O
individuals,O
.,O
Genotype,O
data,O
for,O
the,O
present,O
analysis,O
(,O
DNA,O
collected,O
in,O
1980,O
",",O
2001,O
and,O
2007,O
),O
was,O
available,O
for,O
2,O
",",O
442,O
individuals,O
.,O
In,O
the,O
latest,O
follow,O
-,O
up,O
in,O
2001,O
",",O
a,O
total,O
of,O
2,O
",",O
283,O
participants,O
(,O
of,O
which,O
DNA,O
is,O
available,O
from,O
2,O
",",O
265,O
participants,O
),O
were,O
examined,O
for,O
numerous,O
study,O
variables,O
",",O
including,O
serum,O
lipoproteins,O
",",O
glucose,O
",",O
insulin,B-GP
",",O
obesity,B-DS
indices,O
",",O
blood,O
pressure,O
",",O
life,O
-,O
style,O
factors,O
",",O
smoking,O
status,O
",",O
alcohol,O
use,O
and,O
general,O
health,O
status,O
.,O
Genotyping,O
&,O
QC,O
BHS,O
genotyping,O
We,O
genotyped,O
1,O
",",O
202,O
BHS,O
samples,O
using,O
the,O
Illumina,O
Human610,O
Genotyping,O
BeadChip,O
[,O
22,O
"],",O
and,O
HumanCVD,O
BeadChip,O
[,O
11,O
].,O
Genotypes,O
were,O
called,O
using,O
a,O
clustering,O
algorithm,O
in,O
Illumina,O
',O
s,O
BeadStudio,O
software,O
.,O
Three,O
samples,O
on,O
the,O
Human610,O
BeadChip,O
gave,O
poor,O
results,O
(,O
call,O
rates,O
<,O
99,O
%),O
and,O
were,O
discarded,O
from,O
the,O
study,O
.,O
In,O
addition,O
",",O
3,O
samples,O
had,O
a,O
different,O
estimated,O
gender,O
from,O
genotype,O
data,O
versus,O
gender,O
provided,O
with,O
the,O
phenotype,O
data,O
and,O
were,O
also,O
discarded,O
.,O
SNPs,O
with,O
call,O
rates,O
<,O
90,O
%,O
were,O
discarded,O
",",O
and,O
SNPs,O
with,O
call,O
rates,O
between,O
90,O
–,O
95,O
%,O
or,O
cluster,O
separation,O
score,O
<,O
0,O
.,O
3,O
were,O
manually,O
inspected,O
and,O
cluster,O
positions,O
were,O
edited,O
if,O
needed,O
.,O
We,O
removed,O
approximately,O
30,O
",",O
000,O
SNP,O
loci,O
(,O
4,O
.,O
9,O
%),O
due,O
to,O
poor,O
performance,O
.,O
The,O
final,O
average,O
sample,O
call,O
rate,O
was,O
99,O
.,O
95,O
%,O
for,O
the,O
Human610,O
BeadChip,O
",",O
and,O
99,O
.,O
32,O
%,O
for,O
the,O
CVD,B-DS
BeadChip,O
.,O
We,O
assessed,O
reproducibility,O
by,O
genotyping,O
29,O
samples,O
in,O
duplicate,O
(,O
18,O
known,O
replicates,O
",",O
11,O
blind,O
replicates,O
"),",O
and,O
observed,O
>,O
99,O
.,O
99,O
%,O
identical,O
genotype,O
calls,O
on,O
both,O
BeadChips,O
.,O
Finally,O
we,O
observed,O
99,O
.,O
98,O
%,O
genotype,O
concordance,O
in,O
12,O
",",O
581,O
overlapping,O
SNPs,O
between,O
the,O
610,O
and,O
CVD,B-DS
BeadChips,O
.,O
A,O
final,O
list,O
of,O
545,O
",",O
821,O
unique,O
SNPs,O
passed,O
QC,O
and,O
allele,O
frequency,O
filters,O
.,O
YF,O
study,O
genotyping,O
For,O
replication,O
",",O
we,O
had,O
genome,O
-,O
wide,O
SNP,O
data,O
from,O
a,O
custom,O
Illumina,O
BeadChip,O
containing,O
670,O
",",O
000,O
SNPs,O
and,O
CNV,O
probes,O
from,O
2,O
",",O
442,O
YF,O
participants,O
(,O
1,O
",",O
123,O
males,O
",",O
1,O
",",O
319,O
females,O
).,O
The,O
custom,O
content,O
on,O
the,O
custom,O
670K,O
array,O
replaced,O
some,O
poor,O
performing,O
SNPs,O
on,O
the,O
Human610,O
BeadChip,O
and,O
added,O
more,O
CNV,O
content,O
",",O
and,O
includes,O
546,O
",",O
677,O
SNPs,O
passing,O
QC,O
from,O
594,O
",",O
210,O
SNPs,O
on,O
the,O
chip,O
.,O
The,O
custom,O
670K,O
chip,O
shares,O
562,O
",",O
643,O
SNPs,O
in,O
common,O
with,O
the,O
Illumina,O
Human610,O
BeadChip,O
.,O
Genotypes,O
were,O
called,O
using,O
Illumina,O
',O
s,O
clustering,O
algorithm,O
[,O
23,O
].,O
A,O
total,O
of,O
2,O
",",O
556,O
samples,O
were,O
genotyped,O
.,O
After,O
initial,O
clustering,O
",",O
we,O
removed,O
2,O
subjects,O
for,O
poor,O
call,O
rates,O
(,O
CR,O
<,O
0,O
.,O
90,O
"),",O
and,O
54,O
samples,O
failed,O
subsequent,O
QC,O
(,O
i,O
.,O
e,O
".,",O
duplicated,O
samples,O
",",O
heterozygosity,O
",",O
low,O
call,O
rate,O
",",O
or,O
custom,O
SNP,O
fingerprint,O
genotype,O
discrepancy,O
).,O
The,O
following,O
filters,O
were,O
applied,O
to,O
the,O
remaining,O
data,O
:,O
MAF,O
0,O
.,O
01,O
",",O
GENO,O
0,O
.,O
05,O
",",O
MIND,O
0,O
.,O
05,O
",",O
and,O
HWE,O
1,O
×,O
10,O
−,O
6,O
.,O
Three,O
of,O
2,O
",",O
500,O
individuals,O
were,O
removed,O
for,O
low,O
genotyping,O
(,O
MIND,O
>,O
0,O
.,O
05,O
"),",O
11,O
",",O
766,O
markers,O
were,O
excluded,O
based,O
on,O
HWE,O
test,O
(,O
P,O
≤,O
1,O
×,O
10,O
−,O
6,O
"),",O
7,O
",",O
746,O
SNPs,O
failed,O
missingness,O
test,O
(,O
GENO,O
>,O
0,O
.,O
05,O
"),",O
34,O
",",O
596,O
SNPs,O
failed,O
frequency,O
test,O
(,O
MAF,O
<,O
0,O
.,O
01,O
),O
and,O
one,O
individual,O
failed,O
gender,O
check,O
.,O
A,O
final,O
list,O
of,O
546,O
",",O
677,O
SNPs,O
passed,O
QC,O
and,O
allele,O
frequency,O
filters,O
.,O
Assessing,O
cryptic,O
relatedness,O
Bogalusa,O
participants,O
with,O
genotype,O
data,O
were,O
filtered,O
for,O
relatedness,O
.,O
Whole,O
-,O
genome,O
genotype,O
data,O
was,O
used,O
to,O
calculate,O
identity,O
-,O
by,O
-,O
descent,O
(,O
PI_HAT,O
),O
values,O
in,O
PLINK,O
[,O
24,O
].,O
Individuals,O
were,O
then,O
removed,O
such,O
that,O
no,O
pair,O
of,O
individuals,O
retained,O
a,O
PI_HAT,O
value,O
greater,O
than,O
0,O
.,O
10,O
.,O
PI_HAT,O
values,O
were,O
consistent,O
with,O
known,O
sibling,O
and,O
half,O
-,O
sibling,O
relationships,O
.,O
The,O
final,O
list,O
consisted,O
of,O
525,O
BHS,O
individuals,O
.,O
In,O
the,O
YF,O
data,O
",",O
there,O
were,O
546,O
",",O
770,O
SNPs,O
and,O
2,O
",",O
496,O
individuals,O
which,O
were,O
utilized,O
to,O
generate,O
an,O
identity,O
-,O
by,O
-,O
descent,O
(,O
IBD,O
),O
matrix,O
file,O
in,O
PLINK,O
[,O
24,O
].,O
There,O
were,O
51,O
pairs,O
of,O
individuals,O
with,O
pi,O
-,O
hat,O
greater,O
than,O
0,O
.,O
2,O
thus,O
these,O
individuals,O
removed,O
due,O
to,O
possible,O
relatedness,O
.,O
One,O
of,O
the,O
pair,O
was,O
removed,O
using,O
greater,O
missingness,O
as,O
criteria,O
.,O
The,O
final,O
list,O
consisted,O
of,O
2,O
",",O
442,O
YF,O
subjects,O
.,O
Imputation,O
We,O
imputed,O
genotypes,O
in,O
genotyped,O
BHS,O
individuals,O
for,O
all,O
HapMap,O
(,O
phase,O
II,O
",",O
release,O
22,O
),O
SNPs,O
using,O
the,O
program,O
MACH,O
[,O
12,O
].,O
The,O
best,O
estimate,O
of,O
the,O
quantitative,O
allele,O
dosage,O
was,O
used,O
as,O
the,O
predictor,O
in,O
association,O
tests,O
.,O
The,O
CEU,O
HapMap,O
phased,O
haplotypes,O
were,O
used,O
as,O
a,O
reference,O
(,O
N,O
=,O
60,O
unrelated,O
individuals,O
).,O
This,O
resulted,O
in,O
overall,O
allelic,O
error,O
rates,O
of,O
1,O
.,O
6,O
%.,O
SNPs,O
were,O
filtered,O
for,O
minor,O
allele,O
frequency,O
(<,O
5,O
%),O
and,O
r2,O
with,O
respect,O
to,O
genotyped,O
SNPs,O
(<,O
0,O
.,O
30,O
"),",O
resulting,O
in,O
genotype,O
data,O
in,O
a,O
total,O
of,O
2,O
",",O
173,O
",",O
391,O
SNPs,O
.,O
Imputation,O
was,O
performed,O
in,O
the,O
YF,O
samples,O
using,O
MACH,O
with,O
the,O
HapMap,O
release,O
22,O
CEU,O
haplotypes,O
as,O
reference,O
.,O
Prediction,O
ability,O
Previously,O
identified,O
markers,O
were,O
obtained,O
through,O
the,O
NHGRI,O
database,O
[,O
25,O
],O
(,O
accessed,O
5,O
/,O
20,O
/,O
09,O
).,O
Marker,O
associations,O
",",O
alleles,O
",",O
and,O
allele,O
frequencies,O
were,O
verified,O
with,O
those,O
reported,O
in,O
the,O
original,O
papers,O
and,O
corrected,O
if,O
required,O
.,O
Markers,O
were,O
used,O
if,O
the,O
alleles,O
at,O
the,O
locus,O
provided,O
unambiguous,O
orientation,O
or,O
if,O
the,O
allele,O
frequencies,O
were,O
different,O
enough,O
between,O
A,O
/,O
T,O
and,O
C,O
/,O
G,O
SNPs,O
to,O
distinguish,O
which,O
allele,O
was,O
the,O
associated,O
allele,O
.,O
We,O
thus,O
excluded,O
any,O
A,O
/,O
T,O
or,O
C,O
/,O
G,O
SNPs,O
with,O
a,O
minor,O
allele,O
frequency,O
>,O
0,O
.,O
4,O
and,O
required,O
that,O
the,O
allele,O
frequency,O
in,O
the,O
previously,O
reported,O
study,O
be,O
within,O
10,O
%,O
of,O
the,O
allele,O
frequency,O
in,O
the,O
BHS,O
.,O
We,O
excluded,O
studies,O
of,O
non,O
-,O
European,O
Ancestry,O
origin,O
.,O
One,O
SNP,O
per,O
cytogenic,O
region,O
was,O
used,O
for,O
each,O
phenotype,O
:,O
the,O
SNP,O
with,O
the,O
smallest,O
previously,O
reported,O
p,O
-,O
value,O
was,O
used,O
.,O
Effect,O
size,O
was,O
translated,O
to,O
percent,O
standard,O
deviation,O
.,O
If,O
the,O
effect,O
size,O
was,O
reported,O
in,O
an,O
absolute,O
measure,O
(,O
e,O
.,O
g,O
.,O
cm,O
for,O
height,O
"),",O
then,O
the,O
standard,O
deviation,O
from,O
the,O
BHS,O
study,O
was,O
used,O
.,O
Standard,O
deviation,O
was,O
calculated,O
from,O
the,O
standard,O
error,O
of,O
the,O
SNP,O
association,O
reported,O
in,O
the,O
linear,O
mixed,O
model,O
.,O
For,O
glucose,O
",",O
cholesterol,O
",",O
and,O
triglycerides,O
measures,O
",",O
units,O
were,O
converted,O
to,O
mg,O
/,O
dl,O
before,O
converting,O
to,O
%,O
SD,O
.,O
A,O
risk,O
value,O
was,O
calculated,O
for,O
each,O
individual,O
based,O
on,O
the,O
imputed,O
genotype,O
and,O
previously,O
reported,O
effect,O
size,O
",",O
converted,O
to,O
%,O
SD,O
.,O
The,O
%,O
SD,O
was,O
multiplied,O
by,O
the,O
allelic,O
dosage,O
for,O
each,O
SNP,O
and,O
summed,O
over,O
all,O
the,O
associated,O
SNPs,O
for,O
each,O
phenotype,O
.,O
The,O
resulting,O
risk,O
value,O
was,O
then,O
used,O
as,O
a,O
predictor,O
for,O
the,O
BHS,O
individuals,O
.,O
Genome,O
-,O
wide,O
association,O
GWA,O
was,O
performed,O
using,O
linear,O
mixed,O
model,O
regression,O
with,O
fixed,O
covariates,O
of,O
age,O
and,O
sex,O
",",O
random,O
slope,O
",",O
and,O
random,O
intercept,O
.,O
Genotypes,O
were,O
coded,O
as,O
0,O
",",O
1,O
",",O
or,O
2,O
when,O
the,O
SNP,O
was,O
genotyped,O
and,O
by,O
dosage,O
(,O
scale,O
0,O
–,O
2,O
),O
when,O
imputed,O
.,O
Analysis,O
was,O
performed,O
within,O
the,O
nlme,O
package,O
in,O
R,O
[,O
13,O
].,O
Covariance,O
structures,O
were,O
determined,O
by,O
testing,O
all,O
spatial,O
covariance,O
structures,O
(,O
exponential,O
",",O
Gaussian,O
",",O
linear,O
",",O
rational,O
quadradics,O
",",O
and,O
spherical,O
),O
with,O
covariates,O
and,O
a,O
sample,O
of,O
SNPs,O
",",O
and,O
picking,O
the,O
structure,O
that,O
best,O
fit,O
the,O
data,O
as,O
measured,O
by,O
the,O
lowest,O
AIC,O
(,O
Akaike,O
Information,O
Criteria,O
),O
value,O
.,O
SNP,O
and,O
SNPxAGE,O
interaction,O
effects,O
were,O
estimated,O
separately,O
.,O
Although,O
the,O
default,O
nlme,O
optimizer,O
tended,O
to,O
have,O
difficulty,O
converging,O
",",O
we,O
obtained,O
good,O
results,O
by,O
using,O
the,O
optim,O
optimizer,O
on,O
data,O
where,O
all,O
missing,O
data,O
was,O
removed,O
.,O
The,O
number,O
of,O
SNPs,O
that,O
converged,O
and,O
for,O
which,O
we,O
obtained,O
results,O
is,O
listed,O
in,O
Table,O
S1,O
.,O
Analyses,O
were,O
performed,O
on,O
a,O
compute,O
cluster,O
with,O
600,O
",",O
000,O
tests,O
taking,O
∼,O
3,O
hrs,O
on,O
64,O
processors,O
.,O
Filtering,O
for,O
genomic,O
inflation,O
If,O
genomic,O
inflation,O
factors,O
were,O
inflated,O
or,O
deflated,O
",",O
we,O
reran,O
the,O
GWA,O
using,O
the,O
first,O
four,O
MDS,O
components,O
as,O
covariates,O
.,O
If,O
the,O
inflation,O
factor,O
was,O
still,O
less,O
than,O
0,O
.,O
90,O
or,O
greater,O
than,O
1,O
.,O
05,O
",",O
we,O
removed,O
the,O
analysis,O
.,O
In,O
addition,O
",",O
we,O
filtered,O
body,O
mass,O
index,O
(,O
BMI,O
),O
SNP,O
",",O
BMI,O
SNPxAGE,O
",",O
and,O
weight,O
SNP,O
analyses,O
completely,O
from,O
the,O
analysis,O
due,O
to,O
a,O
combination,O
of,O
consistently,O
inflated,O
or,O
deflated,O
genomic,O
inflation,O
factors,O
or,O
a,O
long,O
list,O
of,O
highly,O
associated,O
SNPs,O
.,O
Power,O
Power,O
was,O
calculated,O
using,O
G,O
*,O
Power,O
3,O
[,O
26,O
].,O
We,O
used,O
the,O
MANOVA,O
repeated,O
measures,O
module,O
with,O
8,O
repeated,O
measures,O
with,O
a,O
correlation,O
of,O
0,O
.,O
5,O
between,O
them,O
",",O
similar,O
to,O
the,O
correlations,O
seen,O
in,O
this,O
study,O
.,O
We,O
estimated,O
power,O
for,O
between,O
-,O
factor,O
and,O
between,O
-,O
within,O
interaction,O
effects,O
.,O
Effect,O
size,O
(,O
f,O
),O
was,O
calculated,O
asand,O
R2,O
was,O
calculated,O
from,O
the,O
allele,O
frequencies,O
as,O
reported,O
in,O
the,O
original,O
associations,O
(,O
p,O
and,O
q,O
),O
and,O
the,O
effect,O
size,O
in,O
terms,O
of,O
%,O
SD,O
[,O
27,O
].,O
Supporting,O
Information,O
Regional,O
plots,O
of,O
top,O
SNP,O
and,O
SNPxAGE,O
associations,O
.,O
Regions,O
are,O
ordered,O
by,O
phenotype,O
and,O
significance,O
as,O
in,O
Table,O
1,O
and,O
2,O
.,O
SNPs,O
are,O
indicated,O
by,O
triangle,O
(,O
directly,O
genotyped,O
),O
or,O
square,O
(,O
imputed,O
"),",O
and,O
colored,O
according,O
to,O
LD,O
(,O
r2,O
),O
with,O
the,O
top,O
SNP,O
with,O
increasing,O
shades,O
of,O
red,O
indicating,O
stronger,O
LD,O
.,O
Blue,O
lines,O
indicate,O
recombination,O
hotspots,O
and,O
refSeq,O
genes,O
are,O
indicated,O
.,O
(,O
8,O
.,O
26,O
MB,O
PDF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Manhattan,O
Plots,O
of,O
GWAS,O
results,O
for,O
each,O
trait,O
.,O
Manhattan,O
plots,O
are,O
shown,O
for,O
each,O
SNP,O
and,O
SNPxAGE,O
GWAS,O
.,O
Each,O
point,O
corresponds,O
to,O
an,O
association,O
with,O
triangles,O
indicating,O
directly,O
genotyped,O
data,O
and,O
circles,O
indicating,O
imputed,O
data,O
.,O
A,O
horizontal,O
line,O
is,O
plotted,O
at,O
P,O
=,O
10,O
−,O
6,O
and,O
SNPs,O
above,O
this,O
point,O
are,O
outlined,O
in,O
pink,O
.,O
These,O
SNPs,O
occur,O
in,O
Tables,O
1,O
",",O
2,O
",",O
and,O
3,O
.,O
Chromosomes,O
are,O
plotted,O
in,O
alternating,O
blue,O
and,O
grey,O
.,O
P,O
-,O
values,O
greater,O
than,O
0,O
.,O
001,O
are,O
not,O
plotted,O
.,O
(,O
8,O
.,O
19,O
MB,O
PDF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Longitudinal,O
profiles,O
of,O
cumulative,O
score,O
from,O
previously,O
identified,O
SNPs,O
.,O
Individuals,O
were,O
scored,O
based,O
on,O
the,O
effect,O
size,O
of,O
each,O
previously,O
identified,O
marker,O
as,O
in,O
Figure,O
1B,O
.,O
Individuals,O
are,O
grouped,O
and,O
color,O
-,O
coded,O
based,O
on,O
the,O
decile,O
of,O
their,O
score,O
.,O
Linear,O
lines,O
were,O
calculated,O
using,O
linear,O
regression,O
with,O
all,O
points,O
from,O
all,O
individuals,O
in,O
a,O
given,O
decile,O
.,O
(,O
1,O
.,O
26,O
MB,O
PDF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Age,O
at,O
measurement,O
in,O
the,O
BHS,O
.,O
All,O
exam,O
dates,O
that,O
were,O
included,O
in,O
the,O
study,O
are,O
plotted,O
as,O
a,O
function,O
of,O
the,O
age,O
of,O
participant,O
at,O
the,O
exam,O
date,O
.,O
Individuals,O
had,O
between,O
4,O
–,O
13,O
measurements,O
.,O
A,O
single,O
individual,O
is,O
highlighted,O
in,O
red,O
.,O
(,O
0,O
.,O
27,O
MB,O
PDF,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
Number,O
of,O
SNPs,O
that,O
successfully,O
converged,O
and,O
produced,O
association,O
statistics,O
.,O
(,O
0,O
.,O
06,O
MB,O
XLSX,O
),O
Click,O
here,O
for,O
additional,O
data,O
file,O
.,O
The,O
authors,O
have,O
declared,O
that,O
no,O
competing,O
interests,O
exist,O
.,O
Intraductal,O
cisplatin,O
treatment,O
in,O
a,O
BRCA,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
mouse,B-OG
model,O
attenuates,O
tumor,B-DS
development,O
but,O
leads,O
to,O
systemic,O
tumors,B-DS
in,O
aged,O
female,O
mice,B-OG
BRCA,B-GP
deficiency,O
predisposes,O
to,O
the,O
development,O
of,O
invasive,B-DS
breast,I-DS
cancer,I-DS
.,O
In,O
BRCA,B-GP
mutation,O
carriers,O
this,O
risk,O
can,O
increase,O
up,O
to,O
80,O
%.,O
Currently,O
",",O
bilateral,O
prophylactic,O
mastectomy,O
and,O
prophylactic,O
bilateral,O
salpingo,O
-,O
oophorectomy,O
are,O
the,O
only,O
preventive,O
",",O
albeit,O
radical,O
invasive,O
strategies,O
to,O
prevent,O
breast,B-DS
cancer,I-DS
in,O
BRCA,B-GP
mutation,O
carriers,O
.,O
An,O
alternative,O
non,O
-,O
invasive,O
way,O
to,O
prevent,O
BRCA1,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
may,O
be,O
local,O
prophylactic,O
treatment,O
via,O
the,O
nipple,O
.,O
Using,O
a,O
non,O
-,O
invasive,O
intraductal,O
(,O
ID,O
),O
preclinical,O
intervention,O
strategy,O
",",O
we,O
explored,O
the,O
use,O
of,O
combined,O
cisplatin,O
and,O
poly,B-GP
(,I-GP
ADP,I-GP
)-,I-GP
ribose,I-GP
polymerase,I-GP
1,I-GP
(,O
PARP1,B-GP
),O
inhibition,O
to,O
prevent,O
the,O
development,O
of,O
hereditary,B-DS
breast,I-DS
cancer,I-DS
.,O
We,O
show,O
that,O
ID,O
cisplatin,O
and,O
PARP,B-GP
-,O
inhibition,O
can,O
successfully,O
ablate,O
mammary,O
epithelial,O
cells,O
",",O
and,O
this,O
approach,O
attenuated,O
tumor,B-DS
onset,O
in,O
a,O
mouse,B-OG
model,O
of,O
Brca1,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
from,O
153,O
to,O
239,O
days,O
.,O
Long,O
-,O
term,O
carcinogenicity,O
studies,O
in,O
150,O
syngeneic,O
wild,O
-,O
type,O
mice,B-OG
demonstrated,O
that,O
tumor,B-DS
incidence,O
was,O
increased,O
in,O
the,O
ID,O
treated,O
mammary,O
glands,O
by,O
6,O
.,O
3,O
%,O
due,O
to,O
systemic,O
exposure,O
to,O
cisplatin,O
.,O
Although,O
this,O
was,O
only,O
evident,O
in,O
aged,O
mice,B-OG
(,O
median,O
age,O
=,O
649,O
days,O
"),",O
we,O
conclude,O
that,O
ID,O
cisplatin,O
treatment,O
only,O
presents,O
a,O
safe,O
and,O
feasible,O
local,O
prevention,O
option,O
if,O
systemic,O
exposure,O
to,O
the,O
chemotherapy,O
used,O
can,O
be,O
avoided,O
.,O
INTRODUCTION,O
Breast,B-DS
cancer,I-DS
risk,O
increases,O
dramatically,O
in,O
women,O
carrying,O
mutations,O
in,O
a,O
breast,B-DS
cancer,I-DS
susceptibility,O
gene,O
",",O
most,O
frequently,O
BRCA1,B-GP
or,O
BRCA2,B-GP
[,O
1,O
].,O
Depending,O
on,O
the,O
type,O
of,O
mutation,O
and,O
the,O
presence,O
of,O
genetic,O
modifiers,O
",",O
this,O
risk,O
can,O
increase,O
to,O
more,O
than,O
80,O
%,O
[,O
2,O
",",O
3,O
].,O
Mammary,O
gland,O
architecture,O
is,O
dynamic,O
and,O
changes,O
during,O
puberty,O
",",O
pregnancy,O
",",O
lactation,O
and,O
involution,O
post,O
partum,O
and,O
post,O
menopause,O
[,O
4,O
",",O
5,O
].,O
At,O
puberty,O
",",O
the,O
mouse,B-OG
mammary,O
ductal,O
system,O
starts,O
growing,O
from,O
the,O
nipple,O
to,O
fill,O
up,O
the,O
mammary,O
fat,O
pad,O
at,O
the,O
age,O
of,O
3,O
-,O
12,O
weeks,O
.,O
The,O
epithelial,O
lining,O
consists,O
of,O
luminal,O
cells,O
that,O
produce,O
milk,O
",",O
and,O
myoepithelial,O
cells,O
that,O
are,O
responsible,O
for,O
contraction,O
during,O
lactation,O
[,O
4,O
].,O
Different,O
theories,O
regarding,O
the,O
mammary,O
stem,O
cell,O
exist,O
.,O
One,O
model,O
proposes,O
the,O
existence,O
of,O
basal,O
stem,O
cells,O
with,O
the,O
property,O
of,O
generating,O
both,O
luminal,O
and,O
basal,O
/,O
myoepithelial,O
lineages,O
[,O
6,O
",",O
7,O
].,O
Another,O
hypothesis,O
is,O
that,O
luminal,O
and,O
basal,O
/,O
myoepithelial,O
are,O
generated,O
by,O
a,O
committed,O
lineage,O
-,O
restricted,O
progenitor,O
cell,O
[,O
8,O
].,O
Although,O
controversy,O
still,O
surrounds,O
the,O
field,O
",",O
current,O
evidence,O
points,O
to,O
a,O
scenario,O
whereby,O
a,O
luminal,O
progenitor,O
may,O
be,O
at,O
the,O
origin,O
of,O
basal,O
-,O
like,O
BRCA,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
[,O
9,O
",",O
10,O
].,O
Standard,O
treatment,O
of,O
BRCA1,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
does,O
not,O
differ,O
from,O
other,O
types,O
of,O
breast,B-DS
cancer,I-DS
",",O
although,O
targeted,O
approaches,O
are,O
emerging,O
.,O
However,O
",",O
because,O
BRCA,B-GP
-,O
deficient,O
cells,O
are,O
unable,O
to,O
correct,O
stalled,O
DNA,O
replication,O
forks,O
via,O
homologous,O
repair,O
",",O
these,O
cells,O
are,O
sensitive,O
to,O
platinum,O
-,O
based,O
chemotherapeutics,O
that,O
arrest,O
replication,O
[,O
11,O
-,O
15,O
].,O
Accordingly,O
",",O
BRCA,B-GP
-,O
deficient,O
cells,O
are,O
more,O
sensitive,O
to,O
poly,B-GP
(,I-GP
ADP,I-GP
)-,I-GP
ribose,I-GP
polymerase,I-GP
1,I-GP
(,O
PARP1,B-GP
),O
inhibition,O
",",O
which,O
is,O
involved,O
in,O
base,O
excision,O
repair,O
[,O
16,O
].,O
Clinical,O
trials,O
have,O
already,O
tested,O
the,O
efficacy,O
of,O
pharmacological,O
inhibition,O
of,O
PARP,B-GP
with,O
overall,O
promising,O
results,O
[,O
17,O
-,O
24,O
].,O
The,O
only,O
effective,O
preventive,O
options,O
for,O
BRCA,B-GP
mutation,O
carriers,O
are,O
currently,O
bilateral,O
prophylactic,O
mastectomy,O
(,O
PM,O
),O
and,O
prophylactic,O
bilateral,O
salpingo,O
-,O
oophorectomy,O
(,O
PBSO,O
).,O
PM,O
yields,O
a,O
risk,O
reducing,O
effect,O
of,O
more,O
than,O
90,O
-,O
100,O
%,O
in,O
healthy,O
BRCA1,B-GP
and,O
BRCA2,B-GP
mutation,O
carriers,O
[,O
25,O
-,O
27,O
],O
and,O
PBSO,O
decreases,O
breast,B-DS
cancer,I-DS
risk,O
in,O
BRCA,B-GP
mutation,O
carriers,O
without,O
prior,O
breast,B-DS
cancer,I-DS
approximately,O
by,O
50,O
%,O
[,O
26,O
",",O
28,O
",",O
29,O
].,O
An,O
alternative,O
and,O
less,O
invasive,O
preventive,O
strategy,O
option,O
is,O
the,O
use,O
of,O
hormonal,O
therapy,O
as,O
chemo,O
prevention,O
.,O
Inhibition,O
of,O
estrogen,B-GP
receptor,I-GP
function,O
decreases,O
breast,B-DS
cancer,I-DS
risk,O
in,O
healthy,O
BRCA2,B-GP
mutation,O
carriers,O
",",O
but,O
not,O
in,O
BRCA1,B-GP
mutation,O
carriers,O
[,O
30,O
].,O
Alternatively,O
",",O
cancer,B-DS
-,O
related,O
mortality,O
in,O
BRCA,B-GP
mutation,O
carriers,O
may,O
be,O
managed,O
through,O
intensive,O
surveillance,O
using,O
mammography,O
and,O
MRI,O
",",O
or,O
biomarkers,O
in,O
nipple,O
fluid,O
like,O
methylation,O
[,O
31,O
].,O
Efficiency,O
of,O
this,O
approach,O
however,O
is,O
limited,O
because,O
of,O
high,O
breast,O
tissue,O
density,O
in,O
young,O
women,O
and,O
the,O
aggressive,O
",",O
fast,O
developing,O
nature,O
of,O
BRCA,B-GP
-,O
associated,O
breast,B-DS
tumors,I-DS
.,O
Annual,O
MRI,O
detects,O
the,O
majority,O
of,O
breast,B-DS
cancers,I-DS
at,O
an,O
early,O
and,O
favorable,O
stage,O
[,O
32,O
",",O
33,O
"],",O
but,O
a,O
drawback,O
of,O
MRI,O
is,O
the,O
higher,O
rate,O
of,O
false,O
-,O
positive,O
results,O
leading,O
to,O
biopsies,O
of,O
non,O
-,O
diseased,O
tissue,O
and,O
distress,O
[,O
34,O
-,O
37,O
].,O
An,O
alternative,O
and,O
attractive,O
way,O
to,O
prevent,O
breast,B-DS
cancer,I-DS
development,O
in,O
BRCA,B-GP
mutation,O
carriers,O
may,O
be,O
the,O
local,O
administration,O
of,O
ablative,O
agents,O
to,O
the,O
mammary,O
ductal,O
system,O
via,O
the,O
nipple,O
.,O
Preclinical,O
studies,O
in,O
which,O
chemotherapeutics,O
were,O
used,O
intraductally,O
(,O
ID,O
"),",O
such,O
as,O
pegylated,O
liposomal,O
doxorubicin,O
(,O
PLD,O
"),",O
5,O
-,O
fluorouracil,O
",",O
carboplatin,O
",",O
methotrexate,O
",",O
and,O
paclitaxel,O
",",O
show,O
promising,O
results,O
[,O
38,O
-,O
40,O
].,O
ID,O
chemotherapy,O
was,O
also,O
explored,O
in,O
phase,O
I,O
trials,O
in,O
women,O
with,O
ductal,B-DS
carcinoma,I-DS
in,I-DS
situ,I-DS
(,O
DCIS,B-DS
),O
and,O
invasive,B-DS
breast,I-DS
cancer,I-DS
prior,O
to,O
mastectomy,O
",",O
where,O
ID,O
administration,O
of,O
PLD,O
and,O
cisplatin,O
was,O
well,O
tolerated,O
with,O
mild,O
adverse,O
events,O
.,O
Moreover,O
",",O
pathological,O
changes,O
could,O
be,O
found,O
in,O
the,O
treated,O
ducts,O
[,O
40,O
-,O
42,O
].,O
Here,O
",",O
we,O
explored,O
the,O
efficacy,O
and,O
safety,O
of,O
ID,O
cisplatin,O
treatment,O
as,O
an,O
alternative,O
prophylactic,O
therapy,O
in,O
the,O
prevention,O
of,O
BRCA1,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
formation,O
",",O
in,O
combination,O
with,O
PARP,B-GP
-,O
inhibition,O
.,O
RESULTS,O
Intraductal,O
cisplatin,O
reduces,O
repopulating,O
capacity,O
of,O
the,O
mammary,O
gland,O
To,O
test,O
the,O
effect,O
of,O
ID,O
administered,O
platinum,O
on,O
ductal,O
outgrowth,O
",",O
we,O
injected,O
post,O
-,O
breeder,O
wild,O
type,O
mice,B-OG
(,O
ranging,O
in,O
age,O
between,O
12,O
-,O
30,O
weeks,O
;,O
primiparous,O
;,O
average,O
litter,O
size,O
of,O
7,O
;,O
mean,O
time,O
post,O
weaning,O
of,O
42,O
days,O
),O
twice,O
with,O
ID,O
cisplatin,O
in,O
gland,O
number,O
3,O
",",O
4,O
",",O
and,O
5,O
on,O
the,O
right,O
side,O
and,O
with,O
control,O
on,O
the,O
left,O
side,O
with,O
a,O
4,O
-,O
week,O
interval,O
(,O
Figure,O
1A,O
).,O
One,O
week,O
after,O
the,O
second,O
treatment,O
",",O
we,O
isolated,O
mouse,B-OG
mammary,O
epithelial,O
cells,O
(,O
MMECs,O
),O
from,O
the,O
3rd,O
and,O
4th,O
mammary,O
glands,O
that,O
were,O
injected,O
into,O
the,O
cleared,O
mammary,O
fat,O
pad,O
of,O
3,O
-,O
week,O
old,O
syngeneic,O
recipient,O
mice,B-OG
.,O
ID,O
cisplatin,O
significantly,O
lowered,O
outgrowth,O
after,O
transplantation,O
compared,O
to,O
control,O
injection,O
(,O
p,O
=,O
0,O
.,O
010,O
;,O
Figure,O
1B,O
;,O
1C,O
).,O
Whole,O
mount,O
analysis,O
showed,O
ductal,O
outgrowth,O
in,O
17,O
of,O
18,O
(,O
94,O
.,O
4,O
%),O
transplantations,O
of,O
the,O
control,O
-,O
treated,O
mammary,O
glands,O
and,O
in,O
11,O
of,O
19,O
transplantations,O
in,O
the,O
cisplatin,O
-,O
treated,O
glands,O
(,O
57,O
.,O
9,O
"%),",O
of,O
which,O
2,O
showed,O
only,O
rudimentary,O
duct,O
formation,O
.,O
ID,O
cisplatin,O
treatment,O
reduces,O
epithelial,O
viability,O
and,O
leads,O
to,O
an,O
inhibition,O
of,O
mammary,O
gland,O
repopulation,O
A,O
.,O
Experimental,O
set,O
-,O
up,O
.,O
Post,O
-,O
breeder,O
mice,B-OG
were,O
subjected,O
to,O
2,O
ID,O
cisplatin,O
treatments,O
with,O
a,O
4,O
-,O
week,O
interval,O
in,O
the,O
right,O
-,O
sided,O
glands,O
number,O
3,O
",",O
4,O
",",O
and,O
5,O
.,O
The,O
contralateral,O
corresponding,O
mammary,O
glands,O
served,O
as,O
control,O
.,O
Next,O
",",O
MMECs,O
were,O
harvested,O
and,O
transplanted,O
into,O
syngeneic,O
mice,B-OG
(,O
upper,O
part,O
),O
or,O
analyzed,O
by,O
FACS,O
(,O
lower,O
part,O
).,O
B,O
.,O
and,O
C,O
.,O
Cisplatin,O
inhibits,O
the,O
mammary,O
repopulating,O
capacity,O
.,O
Depicted,O
are,O
representative,O
samples,O
of,O
whole,O
mount,O
analyses,O
",",O
showing,O
complete,O
outgrowth,O
after,O
control,O
treatment,O
(,O
B,O
;,O
left,O
"),",O
rudimentary,O
outgrowth,O
(,O
B,O
;,O
middle,O
"),",O
or,O
no,O
outgrowth,O
(,O
B,O
;,O
right,O
),O
after,O
ID,O
cisplatin,O
treatment,O
.,O
Quantifications,O
of,O
the,O
control,O
(,O
left,O
pie,O
chart,O
),O
and,O
ID,O
cisplatin,O
treated,O
glands,O
(,O
right,O
pie,O
chart,O
),O
are,O
shown,O
in,O
(,O
C,O
).,O
D,O
.,O
and,O
E,O
.,O
ID,O
cisplatin,O
treatment,O
leads,O
to,O
an,O
overall,O
reduction,O
of,O
MMECs,O
.,O
Representative,O
plots,O
of,O
the,O
basal,O
and,O
luminal,O
cell,O
populations,O
using,O
FACS,O
analysis,O
after,O
control,O
(,O
D,O
;,O
left,O
dot,O
plot,O
"),",O
or,O
ID,O
cisplatin,O
treatment,O
(,O
D,O
;,O
right,O
dot,O
plot,O
).,O
Quantifications,O
of,O
basal,O
and,O
luminal,O
MMECs,O
are,O
shown,O
in,O
(,O
E,O
).,O
Basal,O
MMECs,O
were,O
defined,O
as,O
DAPI,O
-;,O
CD45,B-GP
-;,O
Sca,B-GP
-;,O
CD24,B-GP
+/,O
low,O
and,O
luminal,O
MMECs,O
as,O
DAPI,O
-;,O
CD45,B-GP
-;,O
Sca,B-GP
-,O
or,O
+;,O
CD24,B-GP
+/,O
hi,O
.,O
Shown,O
is,O
an,O
average,O
of,O
9,O
mice,B-OG
per,O
condition,O
.,O
Error,O
bars,O
represent,O
SEM,O
;,O
*,O
=,O
p,O
<,O
0,O
.,O
05,O
.,O
F,O
.,O
Cisplatin,O
-,O
treated,O
glands,O
showed,O
morphological,O
changes,O
matching,O
apoptosis,O
and,O
an,O
induction,O
of,O
cleaved,O
caspase,B-GP
3,I-GP
expression,O
in,O
the,O
epithelial,O
lining,O
of,O
the,O
mammary,O
duct,O
.,O
Representative,O
pictures,O
of,O
H,O
&,O
E,O
and,O
cleaved,O
caspase,B-GP
3,I-GP
stainings,O
of,O
mammary,O
gland,O
tissue,O
slides,O
after,O
ID,O
cisplatin,O
treatment,O
are,O
shown,O
.,O
Scale,O
bar,O
is,O
100,O
μm,O
",",O
upper,O
right,O
pictures,O
are,O
blow,O
-,O
ups,O
of,O
caspase,B-GP
3,I-GP
positive,O
cells,O
.,O
Next,O
",",O
we,O
performed,O
FACS,O
analysis,O
",",O
which,O
indicated,O
that,O
ID,O
administered,O
cisplatin,O
induced,O
a,O
significant,O
and,O
uniform,O
reduction,O
in,O
the,O
basal,O
and,O
luminal,O
populations,O
(,O
p,O
=,O
0,O
.,O
008,O
compared,O
to,O
control,O
for,O
luminal,O
",",O
and,O
p,O
<,O
0,O
.,O
001,O
for,O
basal,O
population,O
in,O
n,O
=,O
9,O
analyzed,O
glands,O
;,O
Figure,O
1D,O
;,O
1E,O
).,O
The,O
effect,O
of,O
cisplatin,O
appeared,O
to,O
specifically,O
reduce,O
the,O
epithelial,O
mammary,O
cells,O
",",O
since,O
the,O
number,O
of,O
non,O
-,O
epithelial,O
cells,O
was,O
not,O
decreased,O
proportionally,O
after,O
ID,O
treatment,O
(,O
Figure,O
1D,O
;,O
upper,O
left,O
quadrant,O
).,O
Further,O
",",O
we,O
observed,O
that,O
cisplatin,O
-,O
treated,O
glands,O
showed,O
an,O
induction,O
of,O
cleaved,O
caspase,B-GP
3,I-GP
expression,O
in,O
the,O
epithelial,O
lining,O
of,O
the,O
mammary,O
duct,O
(,O
Figure,O
1F,O
).,O
We,O
therefore,O
conclude,O
that,O
ID,O
cisplatin,O
treatment,O
reduces,O
the,O
repopulating,O
capacity,O
of,O
the,O
wild,O
type,O
mammary,O
gland,O
.,O
Intraductal,O
cisplatin,O
impairs,O
lobulo,O
-,O
alveolar,O
development,O
To,O
assess,O
the,O
effect,O
of,O
treatment,O
on,O
pregnancy,O
-,O
associated,O
lobulo,O
-,O
alveolar,O
development,O
",",O
we,O
analyzed,O
mammary,O
gland,O
whole,O
mounts,O
after,O
ID,O
treatment,O
of,O
both,O
non,O
-,O
pregnant,O
and,O
pregnant,O
mice,B-OG
(,O
Figure,O
2A,O
).,O
ID,O
cisplatin,O
reduced,O
ductulo,O
-,O
lobular,O
outgrowth,O
in,O
both,O
non,O
-,O
pregnant,O
and,O
pregnant,O
mice,B-OG
.,O
Representative,O
whole,O
mounts,O
and,O
corresponding,O
H,O
&,O
E,O
and,O
β,B-GP
-,I-GP
casein,I-GP
stainings,O
are,O
shown,O
in,O
Figure,O
2B,O
.,O
In,O
all,O
control,O
mammary,O
glands,O
from,O
both,O
non,O
-,O
pregnant,O
and,O
pregnant,O
mice,B-OG
",",O
ductal,O
outgrowth,O
and,O
alveolar,O
differentiation,O
was,O
uniform,O
and,O
complete,O
.,O
ID,O
cisplatin,O
showed,O
no,O
effect,O
in,O
13,O
glands,O
of,O
23,O
non,O
-,O
pregnant,O
mice,B-OG
(,O
56,O
.,O
6,O
"%),",O
partial,O
effect,O
in,O
5,O
(,O
21,O
.,O
7,O
"%),",O
subtotal,O
in,O
4,O
(,O
17,O
.,O
4,O
"%),",O
and,O
total,O
effect,O
in,O
1,O
(,O
4,O
.,O
3,O
%),O
(,O
Figure,O
2C,O
).,O
In,O
pregnant,O
mice,B-OG
ID,O
cisplatin,O
did,O
not,O
lead,O
to,O
an,O
inhibition,O
of,O
alveolar,O
development,O
in,O
12,O
of,O
21,O
mice,B-OG
(,O
57,O
.,O
1,O
"%),",O
while,O
we,O
observed,O
a,O
partial,O
response,O
in,O
2,O
(,O
9,O
.,O
5,O
"%),",O
subtotal,O
in,O
4,O
(,O
19,O
.,O
0,O
"%),",O
and,O
total,O
response,O
in,O
3,O
(,O
14,O
.,O
3,O
%),O
glands,O
(,O
Figure,O
2D,O
).,O
In,O
summary,O
",",O
ID,O
cisplatin,O
administration,O
induced,O
a,O
significant,O
reduction,O
in,O
ductal,O
outgrowth,O
(,O
defined,O
as,O
(,O
sub,O
),O
total,O
effect,O
),O
in,O
both,O
non,O
-,O
pregnant,O
and,O
pregnant,O
mice,B-OG
(,O
p,O
=,O
0,O
.,O
018,O
and,O
0,O
.,O
004,O
",",O
respectively,O
).,O
Functional,O
effect,O
of,O
ID,O
cisplatin,O
on,O
the,O
mammary,O
gland,O
and,O
pregnancy,O
-,O
induced,O
lobulo,O
-,O
alveolar,O
development,O
A,O
.,O
Experimental,O
set,O
-,O
up,O
.,O
Post,O
-,O
breeder,O
mice,B-OG
were,O
subjected,O
to,O
two,O
ID,O
cisplatin,O
treatments,O
with,O
a,O
4,O
-,O
week,O
interval,O
in,O
the,O
right,O
-,O
sided,O
glands,O
number,O
3,O
",",O
4,O
",",O
and,O
5,O
.,O
The,O
contralateral,O
corresponding,O
mammary,O
glands,O
served,O
as,O
control,O
.,O
Next,O
",",O
whole,O
mounts,O
were,O
analyzed,O
at,O
day,O
17,O
.,O
5,O
of,O
pregnancy,O
or,O
at,O
a,O
similar,O
time,O
point,O
in,O
non,O
-,O
pregnant,O
mice,B-OG
.,O
B,O
.,O
Representative,O
pictures,O
showing,O
no,O
effect,O
in,O
control,O
(,O
first,O
column,O
),O
or,O
partial,O
(,O
second,O
column,O
"),",O
subtotal,O
(,O
third,O
column,O
"),",O
or,O
total,O
effect,O
(,O
fourth,O
column,O
),O
after,O
ID,O
cisplatin,O
treatment,O
.,O
The,O
top,O
two,O
rows,O
show,O
whole,O
mount,O
analyses,O
",",O
followed,O
by,O
H,O
&,O
E,O
stainings,O
",",O
and,O
β,B-GP
-,I-GP
casein,I-GP
IHC,O
.,O
Scale,O
bar,O
is,O
100,O
μm,O
in,O
lower,O
magnifications,O
and,O
50,O
μm,O
in,O
higher,O
magnifications,O
.,O
C,O
.,O
ID,O
cisplatin,O
reduces,O
ductal,O
outgrowth,O
in,O
non,O
-,O
pregnant,O
mice,B-OG
(,O
n,O
=,O
23,O
).,O
Quantifications,O
of,O
mammary,O
ductal,O
outgrowth,O
after,O
control,O
(,O
left,O
chart,O
),O
or,O
ID,O
cisplatin,O
treatment,O
(,O
right,O
chart,O
).,O
D,O
.,O
ID,O
cisplatin,O
reduces,O
lobulo,O
-,O
alveolar,O
development,O
in,O
pregnant,O
mice,B-OG
(,O
n,O
=,O
21,O
).,O
Quantifications,O
of,O
mammary,O
ductal,O
outgrowth,O
after,O
control,O
(,O
left,O
chart,O
),O
or,O
ID,O
cisplatin,O
treatment,O
(,O
right,O
chart,O
).,O
Intraductal,O
cisplatin,O
and,O
olaparib,O
increase,O
tumor,B-DS
-,O
free,O
latency,O
in,O
a,O
mouse,B-OG
model,O
of,O
BRCA1,B-GP
-,O
associated,O
human,B-OG
breast,B-DS
cancer,I-DS
We,O
next,O
investigated,O
the,O
preventive,O
effect,O
of,O
ID,O
cisplatin,O
in,O
a,O
mouse,B-OG
model,O
for,O
BRCA1,B-GP
-,O
associated,O
human,B-OG
breast,B-DS
cancer,I-DS
.,O
Since,O
tumors,B-DS
in,O
a,O
K14cre,O
-,O
driven,O
variant,O
of,O
this,O
model,O
were,O
highly,O
sensitive,O
to,O
a,O
combination,O
of,O
cisplatin,O
and,O
the,O
PARP,B-GP
-,O
inhibitor,O
olaparib,O
[,O
14,O
"],",O
we,O
tested,O
both,O
prophylactic,O
monotherapies,O
and,O
the,O
combination,O
of,O
ID,O
cisplatin,O
and,O
olaparib,O
in,O
the,O
whey,B-GP
acidic,I-GP
protein,I-GP
(,O
WAP,B-GP
),O
cre,B-GP
-,O
driven,O
tumor,B-DS
model,O
.,O
We,O
chose,O
the,O
WAPcre,O
model,O
for,O
our,O
studies,O
because,O
the,O
overt,O
induction,O
of,O
skin,B-DS
tumors,I-DS
in,O
the,O
K14cre,O
models,O
interferes,O
with,O
the,O
analysis,O
of,O
mammary,B-DS
tumor,I-DS
formation,O
[,O
43,O
].,O
Tumor,B-DS
latency,O
and,O
incidence,O
in,O
the,O
WAPCre,O
;,O
Brca1F,O
/,O
F,O
;,O
Trp53F,O
/,O
F,O
model,O
are,O
shown,O
in,O
Supplementary,O
Figure,O
S1,O
and,O
PCR,O
results,O
of,O
tumors,B-DS
in,O
Supplemental,O
Figure,O
2,O
.,O
Female,O
virgin,O
WAPcre,O
;,O
Brca1F,O
/,O
F,O
;,O
Trp53F,O
/,O
F,O
mice,B-OG
were,O
injected,O
twice,O
in,O
glands,O
3,O
and,O
4,O
.,O
Either,O
all,O
third,O
and,O
fourth,O
glands,O
were,O
treated,O
with,O
control,O
or,O
all,O
4,O
treated,O
glands,O
were,O
injected,O
with,O
cisplatin,O
at,O
the,O
age,O
of,O
12,O
and,O
16,O
weeks,O
.,O
Prior,O
",",O
during,O
and,O
post,O
ID,O
cisplatin,O
treatment,O
",",O
mice,B-OG
were,O
daily,O
injected,O
intraperitoneally,O
(,O
IP,O
),O
with,O
control,O
or,O
olaparib,O
and,O
followed,O
for,O
tumor,B-DS
formation,O
(,O
Figure,O
3A,O
).,O
ID,O
cisplatin,O
monotherapy,O
significantly,O
increased,O
the,O
median,O
tumor,B-DS
-,O
free,O
latency,O
(,O
T50,O
),O
in,O
ID,O
injected,O
glands,O
from,O
153,O
days,O
in,O
control,O
to,O
210,O
days,O
in,O
cisplatin,O
treated,O
mice,B-OG
(,O
p,O
<,O
0,O
.,O
0001,O
;,O
Figure,O
3B,O
).,O
IP,O
treatment,O
using,O
olaparib,O
monotherapy,O
also,O
led,O
to,O
an,O
increase,O
in,O
tumor,B-DS
-,O
free,O
latency,O
(,O
T50,O
=,O
203,O
versus,O
153,O
days,O
;,O
p,O
<,O
0,O
.,O
001,O
;,O
Figure,O
3B,O
).,O
Moreover,O
",",O
using,O
a,O
combination,O
therapy,O
of,O
ID,O
cisplatin,O
and,O
IP,O
olaparib,O
",",O
we,O
observed,O
an,O
increase,O
in,O
T50,O
from,O
153,O
to,O
239,O
days,O
(,O
p,O
<,O
0,O
.,O
001,O
;,O
Figure,O
3B,O
).,O
Dual,O
therapy,O
using,O
ID,O
cisplatin,O
and,O
olaparib,O
led,O
to,O
a,O
longer,O
tumor,B-DS
-,O
free,O
latency,O
compared,O
to,O
olaparib,O
monotherapy,O
(,O
p,O
=,O
0,O
.,O
004,O
),O
but,O
not,O
compared,O
to,O
cisplatin,O
monotherapy,O
(,O
p,O
=,O
0,O
.,O
506,O
).,O
Combined,O
prophylactic,O
cisplatin,O
and,O
olaparib,O
treatment,O
in,O
a,O
WAPCre,O
;,O
Brca1F,O
/,O
F,O
;,O
Trp53F,O
/,O
F,O
sporadic,O
mouse,B-OG
model,O
leads,O
to,O
a,O
later,O
onset,O
of,O
breast,B-DS
tumor,I-DS
formation,O
A,O
.,O
Experimental,O
set,O
-,O
up,O
.,O
Virgin,O
WAPCre,O
;,O
Brca1F,O
/,O
F,O
;,O
Trp53F,O
/,O
F,O
were,O
treated,O
twice,O
in,O
glands,O
number,O
3,O
and,O
4,O
with,O
either,O
control,O
or,O
cisplatin,O
at,O
the,O
age,O
of,O
12,O
and,O
16,O
weeks,O
.,O
During,O
the,O
ID,O
treatments,O
",",O
mice,B-OG
were,O
IP,O
injected,O
with,O
control,O
or,O
olaparib,O
on,O
a,O
daily,O
basis,O
from,O
the,O
age,O
of,O
10,O
to,O
18,O
weeks,O
.,O
In,O
total,O
4,O
treatment,O
groups,O
were,O
analyzed,O
",",O
i,O
.,O
e,O
.,O
control,O
(,O
n,O
=,O
24,O
"),",O
ID,O
cisplatin,O
monotherapy,O
(,O
n,O
=,O
20,O
"),",O
IP,O
olaparib,O
monotherapy,O
(,O
n,O
=,O
29,O
),O
and,O
ID,O
cisplatin,O
combined,O
with,O
IP,O
olaparib,O
combination,O
therapy,O
(,O
n,O
=,O
27,O
).,O
B,O
.,O
Kaplan,O
-,O
Meier,O
curves,O
showing,O
the,O
tumor,B-DS
-,O
free,O
latency,O
post,O
treatment,O
of,O
mammary,O
glands,O
tumor,B-DS
in,O
the,O
treated,O
(,O
glands,O
number,O
3,O
and,O
4,O
;,O
left,O
graph,O
),O
and,O
untreated,O
mammary,O
glands,O
(,O
glands,O
number,O
1,O
",",O
2,O
",",O
and,O
5,O
;,O
right,O
graph,O
).,O
Strikingly,O
",",O
similar,O
effects,O
were,O
obtained,O
when,O
analyzing,O
untreated,O
mammary,O
glands,O
",",O
i,O
.,O
e,O
.,O
glands,O
number,O
1,O
",",O
2,O
and,O
5,O
.,O
Here,O
",",O
the,O
T50,O
increased,O
significantly,O
from,O
157,O
days,O
in,O
control,O
to,O
225,O
days,O
in,O
cisplatin,O
treated,O
animals,B-OG
(,O
p,O
<,O
0,O
.,O
0001,O
;,O
Figure,O
3B,O
).,O
Olaparib,O
induced,O
an,O
increase,O
in,O
T50,O
to,O
219,O
days,O
(,O
p,O
<,O
0,O
.,O
0001,O
"),",O
and,O
combination,O
treatment,O
led,O
to,O
T50,O
of,O
241,O
days,O
(,O
p,O
<,O
0,O
.,O
0001,O
;,O
Figure,O
3B,O
"),",O
suggesting,O
that,O
local,O
ID,O
treatment,O
results,O
in,O
systemic,O
exposure,O
and,O
subsequent,O
inhibition,O
of,O
tumor,B-DS
development,O
.,O
ID,O
cisplatin,O
reduced,O
tumor,B-DS
incidence,O
in,O
the,O
locally,O
treated,O
gland,O
to,O
85,O
.,O
0,O
%,O
(,O
p,O
=,O
0,O
.,O
086,O
compared,O
to,O
control,O
).,O
For,O
olaparib,O
this,O
was,O
89,O
.,O
7,O
%,O
(,O
p,O
=,O
0,O
.,O
242,O
"),",O
and,O
in,O
the,O
combination,O
group,O
tumor,B-DS
incidence,O
was,O
81,O
.,O
5,O
%,O
(,O
p,O
=,O
0,O
.,O
052,O
).,O
Monotherapy,O
with,O
cisplatin,O
ID,O
did,O
not,O
significantly,O
differ,O
from,O
olaparib,O
monotherapy,O
regarding,O
tumor,B-DS
incidence,O
(,O
p,O
=,O
0,O
.,O
677,O
).,O
Also,O
",",O
a,O
dual,O
ID,O
cisplatin,O
and,O
olaparib,O
treatment,O
was,O
not,O
significantly,O
better,O
than,O
either,O
monotherapies,O
.,O
Tumor,B-DS
incidence,O
of,O
the,O
untreated,O
glands,O
decreased,O
to,O
85,O
.,O
0,O
%,O
in,O
cisplatin,O
(,O
p,O
=,O
0,O
.,O
086,O
"),",O
75,O
.,O
9,O
%,O
in,O
olaparib,O
(,O
p,O
=,O
0,O
.,O
012,O
"),",O
and,O
66,O
.,O
7,O
%,O
in,O
the,O
combination,O
treatment,O
group,O
(,O
p,O
=,O
0,O
.,O
002,O
).,O
Metastases,O
formation,O
did,O
not,O
significantly,O
change,O
between,O
different,O
treatment,O
groups,O
(,O
Supplementary,O
Table,O
S1,O
).,O
In,O
short,O
",",O
a,O
combination,O
of,O
ID,O
cisplatin,O
with,O
systemic,O
olaparib,O
increases,O
tumor,B-DS
-,O
free,O
latency,O
in,O
a,O
mouse,B-OG
model,O
of,O
Brca1,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
.,O
However,O
",",O
ID,O
injection,O
leads,O
to,O
systemic,O
exposure,O
of,O
cisplatin,O
.,O
Pharmacokinetics,O
of,O
intraductal,O
cisplatin,O
To,O
determine,O
the,O
extent,O
of,O
systemic,O
exposure,O
to,O
platinum,O
after,O
ID,O
injection,O
",",O
we,O
harvested,O
plasma,O
samples,O
after,O
ID,O
treatment,O
with,O
cisplatin,O
injection,O
of,O
the,O
3rd,O
and,O
4th,O
mammary,O
glands,O
of,O
12,O
week,O
old,O
wild,O
type,O
mice,B-OG
(,O
Figure,O
4A,O
).,O
Highest,O
plasma,O
concentrations,O
were,O
measured,O
15,O
minutes,O
after,O
treatment,O
with,O
an,O
average,O
of,O
4,O
.,O
6,O
μg,O
/,O
ml,O
(,O
Figure,O
4B,O
).,O
After,O
5,O
minutes,O
",",O
platinum,O
was,O
detected,O
in,O
plasma,O
with,O
a,O
mean,O
concentration,O
of,O
1,O
.,O
0,O
μg,O
/,O
ml,O
when,O
injecting,O
one,O
mammary,O
gland,O
.,O
After,O
96,O
hours,O
the,O
AUC,O
value,O
was,O
45,O
.,O
6,O
μg,O
•,O
ml,O
/,O
h,O
",",O
comparable,O
to,O
a,O
reported,O
AUC,O
of,O
47,O
.,O
9,O
μg,O
•,O
ml,O
/,O
h,O
after,O
intra,O
-,O
tumoral,O
(,O
IT,O
),O
injection,O
of,O
a,O
similar,O
dose,O
of,O
cisplatin,O
[,O
44,O
].,O
Pharmacokinetics,O
of,O
the,O
ID,O
cisplatin,O
treatment,O
A,O
.,O
Experimental,O
set,O
-,O
up,O
.,O
Virgin,O
wild,O
type,O
mice,B-OG
were,O
treated,O
with,O
ID,O
cisplatin,O
in,O
glands,O
number,O
3,O
and,O
4,O
at,O
the,O
age,O
of,O
12,O
weeks,O
.,O
Mice,B-OG
were,O
sacrificed,O
at,O
different,O
time,O
points,O
after,O
ID,O
injections,O
(,O
see,O
text,O
for,O
details,O
",",O
n,O
=,O
3,O
mice,B-OG
per,O
time,O
point,O
),O
and,O
plasma,O
and,O
mammary,O
gland,O
tissue,O
samples,O
were,O
harvested,O
.,O
B,O
.,O
Plasma,O
platinum,O
concentrations,O
after,O
ID,O
treatment,O
.,O
Shown,O
are,O
the,O
average,O
concentrations,O
per,O
time,O
point,O
with,O
SEM,O
.,O
C,O
.,O
Mammary,O
gland,O
platinum,O
concentrations,O
after,O
ID,O
cisplatin,O
treatment,O
.,O
The,O
black,O
line,O
shows,O
the,O
concentrations,O
in,O
untreated,O
glands,O
(,O
gland,O
number,O
2,O
).,O
The,O
pink,O
line,O
depicts,O
the,O
concentrations,O
in,O
the,O
treated,O
mammary,O
glands,O
(,O
gland,O
number,O
4,O
).,O
Shown,O
are,O
the,O
average,O
concentrations,O
per,O
time,O
point,O
with,O
SEM,O
;,O
*,O
=,O
p,O
<,O
0,O
.,O
05,O
.,O
We,O
also,O
determined,O
platinum,O
tissue,O
concentrations,O
in,O
locally,O
treated,O
and,O
distant,O
untreated,O
mammary,O
glands,O
(,O
4th,O
and,O
2nd,O
mammary,O
glands,O
",",O
respectively,O
",",O
see,O
Figure,O
4C,O
).,O
Concentrations,O
peaked,O
at,O
15,O
minutes,O
with,O
a,O
mean,O
platinum,O
concentration,O
of,O
3,O
.,O
32,O
μg,O
/,O
ml,O
in,O
locally,O
treated,O
versus,O
0,O
.,O
99,O
μg,O
/,O
ml,O
in,O
the,O
untreated,O
glands,O
.,O
Platinum,O
concentrations,O
in,O
the,O
untreated,O
glands,O
were,O
significantly,O
lower,O
than,O
in,O
locally,O
treated,O
glands,O
(,O
p,O
=,O
0,O
.,O
015,O
).,O
After,O
96,O
hours,O
the,O
AUC,O
value,O
of,O
locally,O
treated,O
glands,O
was,O
18,O
.,O
75,O
μg,O
•,O
ml,O
/,O
h,O
compared,O
to,O
4,O
.,O
73,O
μg,O
•,O
ml,O
/,O
h,O
in,O
systemically,O
treated,O
glands,O
",",O
which,O
is,O
25,O
.,O
2,O
%,O
of,O
the,O
locally,O
exposed,O
glands,O
.,O
Long,O
-,O
term,O
local,O
and,O
systemic,O
effects,O
of,O
intraductal,O
cisplatin,O
To,O
serve,O
as,O
an,O
alternative,O
prophylaxis,O
in,O
young,O
BRCA,B-GP
-,O
mutation,O
carriers,O
",",O
long,O
-,O
term,O
carcinogenicity,O
of,O
ID,O
cisplatin,O
must,O
be,O
minimal,O
.,O
To,O
test,O
this,O
",",O
we,O
ID,O
injected,O
the,O
3rd,O
and,O
4th,O
mammary,O
glands,O
of,O
post,O
-,O
pubertal,O
wild,O
type,O
mice,B-OG
at,O
the,O
age,O
of,O
12,O
and,O
16,O
weeks,O
with,O
either,O
control,O
(,O
n,O
=,O
67,O
),O
or,O
cisplatin,O
(,O
n,O
=,O
86,O
"),",O
which,O
were,O
followed,O
longitudinally,O
until,O
death,O
or,O
disease,O
(,O
Figure,O
5A,O
).,O
Due,O
to,O
early,O
death,O
caused,O
by,O
mammary,B-DS
tumor,I-DS
formation,O
in,O
the,O
mouse,B-OG
model,O
carrying,O
conditional,O
homozygous,O
Trp53,B-GP
alleles,O
we,O
",",O
used,O
allogeneic,O
wild,O
-,O
type,O
mice,B-OG
for,O
long,O
-,O
term,O
carcinogenicity,O
studies,O
.,O
Although,O
ID,O
treatment,O
of,O
cisplatin,O
induced,O
a,O
shorter,O
tumor,B-DS
-,O
free,O
latency,O
based,O
on,O
histopathology,O
data,O
",",O
the,O
reduction,O
in,O
latency,O
was,O
only,O
observed,O
in,O
aged,O
(>,O
560,O
days,O
),O
mice,B-OG
(,O
Figure,O
5B,O
).,O
Also,O
",",O
we,O
observed,O
an,O
effect,O
on,O
overall,O
survival,O
when,O
comparing,O
treated,O
versus,O
control,O
female,O
mice,B-OG
(,O
p,O
=,O
0,O
.,O
019,O
;,O
Figure,O
5B,O
).,O
Mammary,B-DS
tumors,I-DS
developed,O
more,O
often,O
in,O
the,O
ID,O
cisplatin,O
treated,O
mammary,O
glands,O
(,O
21,O
of,O
336,O
locally,O
treated,O
glands,O
(,O
6,O
.,O
3,O
%)),O
than,O
in,O
control,O
mice,B-OG
(,O
0,O
of,O
252,O
locally,O
treated,O
glands,O
;,O
p,O
<,O
0,O
.,O
001,O
;,O
Figure,O
5C,O
and,O
5D,O
"),",O
albeit,O
in,O
aged,O
female,O
mice,B-OG
(,O
679,O
days,O
after,O
the,O
second,O
ID,O
injection,O
"),",O
which,O
did,O
not,O
lead,O
to,O
an,O
increase,O
metastatic,O
dissemination,O
.,O
Importantly,O
",",O
tumor,B-DS
incidence,O
in,O
distant,O
untreated,O
glands,O
was,O
increased,O
.,O
Cisplatin,O
treated,O
mice,B-OG
developed,O
breast,B-DS
tumors,I-DS
in,O
untreated,O
glands,O
in,O
3,O
.,O
6,O
%,O
(,O
18,O
of,O
504,O
glands,O
),O
compared,O
to,O
0,O
.,O
8,O
%,O
in,O
control,O
mice,B-OG
(,O
3,O
of,O
378,O
glands,O
;,O
p,O
=,O
0,O
.,O
007,O
;,O
Figure,O
5C,O
and,O
5D,O
).,O
Finally,O
",",O
primary,O
adenocarcinomas,B-DS
of,I-DS
the,I-DS
lung,I-DS
were,O
found,O
in,O
48,O
.,O
9,O
%,O
in,O
cisplatin,O
versus,O
29,O
.,O
7,O
%,O
in,O
control,O
treated,O
mice,B-OG
(,O
p,O
=,O
0,O
.,O
019,O
;,O
Figure,O
5C,O
).,O
The,O
incidence,O
of,O
gynecological,O
",",O
lymphoproliferative,O
and,O
other,O
tumors,B-DS
did,O
not,O
significantly,O
differ,O
between,O
both,O
treatment,O
groups,O
(,O
p,O
=,O
0,O
.,O
741,O
",",O
0,O
.,O
493,O
and,O
0,O
.,O
692,O
",",O
respectively,O
;,O
Figure,O
5C,O
).,O
Benign,O
pathology,O
of,O
the,O
aged,O
female,O
mice,B-OG
is,O
shown,O
in,O
Supplementary,O
Table,O
S2,O
.,O
Long,O
-,O
term,O
effects,O
of,O
ID,O
cisplatin,O
treatment,O
A,O
.,O
Experimental,O
-,O
set,O
up,O
.,O
Virgin,O
F1,O
(,O
FVB,O
/,O
N,O
;,O
Ola129Hsd,O
),O
mice,B-OG
were,O
treated,O
twice,O
in,O
glands,O
3,O
and,O
4,O
with,O
either,O
cisplatin,O
or,O
control,O
at,O
the,O
age,O
of,O
12,O
and,O
16,O
weeks,O
.,O
Next,O
",",O
mice,B-OG
were,O
followed,O
in,O
time,O
for,O
tumor,B-DS
development,O
.,O
B,O
.,O
Kaplan,O
-,O
Meier,O
curves,O
showing,O
overall,O
survival,O
of,O
control,O
(,O
black,O
line,O
;,O
n,O
=,O
67,O
),O
or,O
ID,O
cisplatin,O
(,O
pink,O
line,O
;,O
n,O
=,O
86,O
),O
treated,O
mice,B-OG
.,O
C,O
.,O
Table,O
showing,O
the,O
incidence,O
of,O
malignancies,O
in,O
control,O
and,O
ID,O
cisplatin,O
treated,O
mice,B-OG
.,O
The,O
category,O
‘,O
other,O
tumors,B-DS
’,O
consisted,O
of,O
sarcoma,B-DS
of,O
unknown,O
origin,O
",",O
hemangiosarcoma,B-DS
of,I-DS
the,I-DS
spleen,I-DS
",",O
carcinoma,B-DS
of,I-DS
the,I-DS
oral,I-DS
cavity,I-DS
",",O
and,O
squamous,B-DS
carcinoma,I-DS
in,O
the,O
anogenital,O
region,O
in,O
control,O
mice,B-OG
.,O
In,O
ID,O
cisplatin,O
treated,O
mice,B-OG
‘,O
other,O
tumors,B-DS
’,O
comprised,O
hepatocellular,B-DS
carcinoma,I-DS
(,O
n,O
=,O
2,O
"),",O
carcinoma,B-DS
of,I-DS
the,I-DS
salivary,I-DS
gland,I-DS
",",O
and,O
angiosarcoma,B-DS
in,O
the,O
mammary,O
gland,O
.,O
D,O
.,O
Bar,O
graph,O
showing,O
the,O
breast,B-DS
tumor,I-DS
incidence,O
in,O
control,O
and,O
ID,O
cisplatin,O
treated,O
mice,B-OG
per,O
mammary,O
gland,O
.,O
Given,O
the,O
increase,O
in,O
both,O
local,O
and,O
systemic,O
tumor,B-DS
incidence,O
in,O
mice,B-OG
",",O
we,O
conclude,O
that,O
ID,O
administration,O
of,O
cisplatin,O
under,O
these,O
conditions,O
cannot,O
upfront,O
be,O
regarded,O
as,O
a,O
safe,O
alternative,O
prophylactic,O
therapy,O
to,O
prevent,O
BRCA1,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
formation,O
in,O
humans,B-OG
.,O
DISCUSSION,O
ID,O
cisplatin,O
treatment,O
leads,O
to,O
a,O
uniform,O
reduction,O
of,O
the,O
epithelial,O
mammary,O
cells,O
and,O
thereby,O
prolongs,O
breast,B-DS
tumor,I-DS
-,O
free,O
latency,O
in,O
a,O
conditional,O
BRCA1,B-GP
-,O
associated,O
mouse,B-OG
model,O
.,O
However,O
",",O
our,O
results,O
also,O
show,O
that,O
the,O
success,O
rate,O
of,O
ID,O
treatment,O
using,O
cisplatin,O
is,O
variable,O
.,O
Multiple,O
functional,O
assays,O
",",O
including,O
whole,O
mount,O
and,O
transplantation,O
assays,O
",",O
resulted,O
in,O
a,O
successful,O
ablation,O
in,O
approximately,O
half,O
of,O
the,O
recipient,O
mice,B-OG
.,O
This,O
partial,O
effect,O
can,O
be,O
explained,O
by,O
e,O
.,O
g,O
.,O
incomplete,O
injection,O
penetrance,O
",",O
whereby,O
not,O
all,O
ductal,O
branches,O
have,O
been,O
exposed,O
to,O
cisplatin,O
.,O
Moreover,O
",",O
the,O
progenitor,O
cell,O
leading,O
to,O
cancer,B-DS
is,O
presumably,O
a,O
low,O
proliferating,O
cell,O
and,O
as,O
such,O
less,O
susceptible,O
to,O
platinum,O
-,O
based,O
drugs,O
.,O
Another,O
explanation,O
could,O
be,O
the,O
that,O
proliferative,O
differences,O
due,O
to,O
estrus,O
cycling,O
may,O
influence,O
the,O
effectiveness,O
of,O
cisplatin,O
[,O
45,O
",",O
46,O
"],",O
which,O
suggests,O
that,O
ID,O
treatment,O
should,O
be,O
tailored,O
to,O
specific,O
estrus,O
stages,O
for,O
successful,O
cisplatin,O
-,O
based,O
prophylaxis,O
.,O
To,O
our,O
surprise,O
",",O
ID,O
cisplatin,O
prolonged,O
tumor,B-DS
-,O
free,O
latency,O
in,O
untreated,O
mammary,O
glands,O
.,O
Since,O
Brca1,B-GP
inactivation,O
and,O
subsequent,O
tumor,B-DS
formation,O
in,O
the,O
WAPcre,O
-,O
driven,O
model,O
occurs,O
during,O
the,O
first,O
estrus,O
cycle,O
(,O
independent,O
of,O
pregnancy,O
-,O
induced,O
WAP,B-GP
activation,O
),O
[,O
43,O
"],",O
we,O
anticipate,O
that,O
this,O
is,O
probably,O
due,O
to,O
the,O
fact,O
that,O
prior,O
to,O
treatment,O
",",O
WAPcre,O
;,O
Brca1F,O
/,O
F,O
;,O
Trp53F,O
/,O
F,O
female,O
mice,B-OG
contain,O
Brca1,B-GP
-,O
deficient,O
mammary,O
epithelial,O
cells,O
.,O
Also,O
",",O
because,O
Brca,B-GP
-/-,O
mouse,B-OG
embryonic,O
stem,O
cell,O
lines,O
are,O
5,O
-,O
fold,O
more,O
sensitive,O
to,O
cisplatin,O
than,O
Brca,B-GP
+/+,O
wild,O
type,O
cells,O
[,O
11,O
"],",O
it,O
is,O
likely,O
that,O
Brca1,B-GP
loss,O
underpins,O
the,O
observed,O
sensitivity,O
to,O
cisplatin,O
.,O
Although,O
rapid,O
systemic,O
distribution,O
of,O
platinum,O
drugs,O
is,O
evident,O
after,O
ID,O
treatment,O
(,O
our,O
data,O
and,O
[,O
41,O
"]),",O
we,O
also,O
showed,O
that,O
platinum,O
levels,O
in,O
the,O
circulation,O
and,O
untreated,O
glands,O
were,O
lower,O
than,O
can,O
be,O
expected,O
after,O
systemic,O
treatment,O
[,O
44,O
].,O
A,O
study,O
using,O
intra,O
tumor,B-DS
(,O
IT,O
),O
injection,O
of,O
cisplatin,O
and,O
found,O
a,O
comparable,O
AUC,O
to,O
the,O
value,O
we,O
found,O
after,O
ID,O
injection,O
.,O
Compared,O
to,O
IP,O
injection,O
",",O
IT,O
administration,O
led,O
to,O
lower,O
plasma,O
concentrations,O
.,O
Systemic,O
exposure,O
to,O
platinum,O
after,O
IT,O
injection,O
was,O
calculated,O
to,O
be,O
65,O
-,O
75,O
%,O
of,O
the,O
exposure,O
after,O
systemic,O
administration,O
.,O
Since,O
IT,O
and,O
ID,O
cisplatin,O
administration,O
showed,O
a,O
similar,O
pharmacokinetic,O
profile,O
",",O
we,O
expect,O
that,O
also,O
ID,O
cisplatin,O
will,O
lead,O
to,O
lower,O
systemic,O
platinum,O
levels,O
compared,O
to,O
systemic,O
treatment,O
[,O
44,O
].,O
Our,O
findings,O
are,O
in,O
agreement,O
with,O
studies,O
showing,O
that,O
ID,O
treatment,O
with,O
other,O
chemotherapeutics,O
also,O
leads,O
to,O
systemic,O
exposure,O
[,O
39,O
",",O
40,O
].,O
Long,O
-,O
term,O
carcinogenicity,O
is,O
a,O
major,O
point,O
of,O
concern,O
in,O
prophylactic,O
treatments,O
using,O
chemotherapeutics,O
.,O
The,O
same,O
cytotoxic,O
agent,O
can,O
be,O
used,O
to,O
treat,O
cancer,B-DS
",",O
but,O
can,O
also,O
drive,O
carcinogenesis,O
[,O
47,O
].,O
ID,O
PLD,O
is,O
reported,O
to,O
induce,O
malignant,O
mammary,O
gland,O
tumors,B-DS
in,O
wild,O
type,O
mice,B-OG
after,O
a,O
follow,O
-,O
up,O
of,O
42,O
weeks,O
[,O
48,O
].,O
When,O
MMECs,O
were,O
isolated,O
from,O
mice,B-OG
treated,O
with,O
ID,O
PLD,O
",",O
recipients,O
developed,O
tumors,B-DS
[,O
48,O
].,O
Our,O
current,O
study,O
shows,O
that,O
cisplatin,O
leads,O
to,O
tumor,B-DS
formation,O
in,O
6,O
.,O
3,O
%,O
of,O
treated,O
mammary,O
glands,O
more,O
than,O
95,O
weeks,O
post,O
treatment,O
.,O
The,O
induction,O
of,O
late,O
tumors,B-DS
also,O
affected,O
overall,O
survival,O
after,O
cisplatin,O
treatment,O
.,O
The,O
induction,O
of,O
secondary,O
malignancies,O
may,O
be,O
explained,O
by,O
platinum,O
release,O
from,O
regenerating,O
tissue,O
leading,O
to,O
circulating,O
plasma,O
platinum,O
levels,O
up,O
to,O
20,O
years,O
after,O
treatment,O
[,O
49,O
",",O
50,O
].,O
Ovarian,B-DS
cancer,I-DS
survivors,O
show,O
an,O
increased,O
breast,B-DS
cancer,I-DS
risk,O
",",O
however,O
the,O
influence,O
of,O
chemotherapy,O
was,O
either,O
not,O
investigated,O
or,O
not,O
convincingly,O
shown,O
[,O
51,O
",",O
52,O
].,O
Genetic,O
and,O
reproductive,O
factors,O
predisposing,O
to,O
ovarian,B-DS
cancer,I-DS
may,O
also,O
have,O
contributed,O
to,O
breast,B-DS
cancer,I-DS
development,O
[,O
52,O
].,O
In,O
contrast,O
to,O
our,O
findings,O
in,O
mice,B-OG
",",O
it,O
was,O
shown,O
that,O
long,O
-,O
term,O
testicular,O
and,O
ovarian,B-DS
cancer,I-DS
survivors,O
have,O
no,O
increased,O
lung,B-DS
cancer,I-DS
risk,O
[,O
51,O
-,O
53,O
"],",O
and,O
testicular,B-DS
cancer,I-DS
patients,O
treated,O
with,O
chemotherapy,O
only,O
do,O
not,O
develop,O
more,O
lung,B-DS
tumors,I-DS
during,O
follow,O
-,O
up,O
[,O
54,O
].,O
Despite,O
the,O
obvious,O
species,O
differences,O
in,O
rodents,B-OG
and,O
humans,B-OG
that,O
may,O
underlie,O
the,O
long,O
-,O
term,O
tumor,B-DS
formation,O
after,O
intraductal,O
cisplatin,O
in,O
our,O
used,O
preclinical,O
models,O
",",O
we,O
think,O
that,O
ID,O
administration,O
of,O
solvable,O
cisplatin,O
cannot,O
upfront,O
be,O
regarded,O
as,O
a,O
safe,O
alternative,O
to,O
prevent,O
BRCA,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
in,O
genetic,O
carriers,O
.,O
Possible,O
alternative,O
ways,O
of,O
delivering,O
an,O
immobilized,O
yet,O
locally,O
active,O
chemotherapy,O
should,O
be,O
developed,O
to,O
prevent,O
systemic,O
exposure,O
.,O
Since,O
intraductal,O
PLD,O
also,O
induced,O
mammary,B-DS
tumors,I-DS
",",O
we,O
feel,O
that,O
this,O
precludes,O
the,O
use,O
of,O
ID,O
chemotherapy,O
in,O
general,O
for,O
preventive,O
purposes,O
.,O
Using,O
local,O
therapy,O
intraductally,O
however,O
seems,O
to,O
be,O
feasible,O
and,O
effective,O
and,O
could,O
be,O
combined,O
with,O
the,O
use,O
of,O
nanocarriers,O
[,O
55,O
"],",O
liposomes,O
[,O
56,O
"],",O
or,O
antidotes,O
[,O
57,O
].,O
Olaparib,O
was,O
already,O
shown,O
to,O
be,O
effective,O
in,O
breast,B-DS
cancer,I-DS
treatment,O
[,O
17,O
-,O
21,O
",",O
23,O
",",O
24,O
"],",O
but,O
now,O
we,O
also,O
demonstrate,O
the,O
prophylactic,O
effect,O
of,O
systemic,O
PARP,B-GP
-,O
inhibition,O
in,O
Brca1,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
.,O
Combining,O
ID,O
cisplatin,O
and,O
olaparib,O
led,O
to,O
an,O
additional,O
effect,O
in,O
breast,B-DS
tumor,I-DS
incidence,O
compared,O
to,O
both,O
monotherapies,O
without,O
increasing,O
toxicity,O
.,O
Future,O
studies,O
are,O
needed,O
to,O
investigate,O
the,O
optimal,O
dosages,O
of,O
combination,O
treatment,O
and,O
the,O
long,O
-,O
term,O
safety,O
of,O
olaparib,O
treatment,O
.,O
In,O
conclusion,O
",",O
we,O
demonstrate,O
that,O
although,O
ID,O
treatment,O
using,O
cisplatin,O
",",O
especially,O
in,O
combination,O
with,O
PARP,B-GP
-,O
inhibition,O
successfully,O
attenuates,O
tumor,B-DS
formation,O
in,O
a,O
clinically,O
relevant,O
mouse,B-OG
model,O
of,O
BRCA1,B-GP
-,O
associated,O
breast,B-DS
cancer,I-DS
",",O
it,O
leads,O
to,O
long,O
-,O
term,O
local,O
and,O
systemic,O
secondary,O
malignancies,O
in,O
mice,B-OG
and,O
may,O
not,O
be,O
safe,O
in,O
humans,B-OG
.,O
MATERIALS,O
AND,O
METHODS,O
Mice,B-OG
F1,O
Wild,O
type,O
mice,B-OG
were,O
derived,O
from,O
crossings,O
between,O
FVB,O
/,O
NCrl,O
(,O
Charles,O
River,O
),O
and,O
129P2,O
/,O
OlaHsd,O
(,O
Harlan,O
).,O
WAPcre,O
;,O
BrcaF,O
/,O
F,O
;,O
Trp53F,O
/,O
F,O
mice,B-OG
were,O
generated,O
by,O
crossing,O
Brca1F,O
/,O
F,O
conditional,O
female,O
mice,B-OG
[,O
58,O
],O
with,O
male,O
WAPcre,O
;,O
Trp53F,O
/,O
F,O
mice,B-OG
[,O
43,O
].,O
Female,O
mice,B-OG
in,O
a,O
model,O
using,O
WAPCre,O
as,O
a,O
promoter,O
",",O
develop,O
mammary,B-DS
tumors,I-DS
for,O
which,O
the,O
onset,O
",",O
incidence,O
and,O
metastasis,O
are,O
pregnancy,O
and,O
lactation,O
-,O
independent,O
[,O
43,O
].,O
Genotyping,O
and,O
deletion,O
status,O
of,O
the,O
Trp53F,B-GP
",",O
Trp53Δ,O
",",O
Brca1F,B-GP
",",O
Brca1Δ,O
and,O
WAPcre,O
alleles,O
was,O
done,O
as,O
described,O
[,O
43,O
",",O
58,O
].,O
Onset,O
of,O
tumor,B-DS
growth,O
was,O
monitored,O
twice,O
weekly,O
from,O
the,O
age,O
of,O
4,O
months,O
onward,O
.,O
Mammary,B-DS
tumor,I-DS
volume,O
was,O
determined,O
by,O
caliper,O
measurements,O
using,O
the,O
following,O
formula,O
:,O
4,O
/,O
3,O
*((,O
3,O
.,O
14,O
)*((,O
length,O
+,O
width,O
)/,O
4,O
)^,O
3,O
).,O
Animals,B-OG
were,O
euthanized,O
if,O
mammary,B-DS
tumors,I-DS
reached,O
a,O
size,O
of,O
1000,O
mm3,O
or,O
in,O
case,O
of,O
severe,O
discomfort,O
otherwise,O
.,O
Animals,B-OG
were,O
scored,O
as,O
having,O
a,O
tumor,B-DS
when,O
there,O
was,O
a,O
tumor,B-DS
palpable,O
or,O
based,O
on,O
post,O
mortem,O
histological,O
assessment,O
.,O
Tumor,B-DS
-,O
free,O
latency,O
was,O
calculated,O
as,O
the,O
number,O
of,O
days,O
after,O
the,O
second,O
ID,O
injection,O
.,O
All,O
animal,B-OG
experiments,O
were,O
performed,O
according,O
to,O
institutional,O
guidelines,O
and,O
national,O
regulations,O
(,O
DEC2010,O
.,O
III,O
.,O
08,O
.,O
102,O
",",O
2011,O
.,O
III,O
.,O
04,O
.,O
050,O
",",O
2012,O
.,O
III,O
.,O
01,O
.,O
005,O
",",O
2012,O
.,O
III,O
.,O
09,O
.,O
086,O
).,O
Drugs,O
Cisplatin,O
(,O
1,O
mg,O
/,O
mL,O
in,O
saline,O
",",O
Pharmachemie,O
B,O
.,O
V,O
.),O
was,O
administered,O
ID,O
in,O
a,O
total,O
volume,O
of,O
50,O
μl,O
per,O
mammary,O
gland,O
.,O
To,O
visualize,O
extravasation,O
or,O
incorrect,O
injection,O
",",O
cisplatin,O
or,O
control,O
was,O
mixed,O
with,O
0,O
.,O
05,O
%,O
methylene,O
blue,O
.,O
Olaparib,O
was,O
synthesized,O
by,O
Syncom,O
with,O
a,O
purity,O
of,O
more,O
than,O
99,O
%,O
by,O
HPLC,O
.,O
Olaparib,O
was,O
used,O
by,O
diluting,O
50,O
mg,O
/,O
ml,O
stocks,O
in,O
DMSO,O
with,O
10,O
%,O
2,O
-,O
hydroxyl,O
-,O
propyl,O
-,O
β,O
-,O
cyclodextrine,O
/,O
PBS,O
such,O
that,O
the,O
final,O
volume,O
administered,O
intraperitoneally,O
(,O
IP,O
),O
was,O
10,O
μL,O
/,O
g,O
of,O
body,O
weight,O
.,O
Saline,O
0,O
.,O
9,O
%,O
(,O
Fresenius,O
Kabi,O
),O
was,O
used,O
as,O
control,O
.,O
Intraductal,O
injection,O
Mice,B-OG
were,O
anesthetized,O
by,O
isoflurane,O
and,O
100,O
μl,O
(,O
0,O
.,O
03,O
mg,O
/,O
ml,O
),O
Temgesic,O
(,O
buprenorphine,O
),O
was,O
injected,O
subcutaneously,O
(,O
SC,O
),O
as,O
analgesic,O
treatment,O
.,O
Mammary,O
ducts,O
were,O
cannulated,O
using,O
a,O
1,O
.,O
0,O
-,O
cm,O
",",O
33G,O
",",O
blunt,O
-,O
ended,O
needle,O
(,O
Hamilton,O
",",O
66780305,O
),O
attached,O
to,O
a,O
50,O
μl,O
glass,O
syringe,O
(,O
Hamilton,O
66765501,O
).,O
Drugs,O
or,O
control,O
were,O
injected,O
into,O
the,O
mammary,O
gland,O
while,O
visualizing,O
the,O
nipple,O
opening,O
under,O
a,O
dissection,O
microscope,O
[,O
39,O
].,O
Orthotopic,O
transplantation,O
MMECs,O
Primary,O
mouse,B-OG
mammary,O
epithelium,O
cells,O
(,O
MMECs,O
),O
were,O
obtained,O
from,O
mammary,O
glands,O
after,O
removal,O
of,O
the,O
intra,O
-,O
mammary,O
lymph,O
nodes,O
.,O
Tissue,O
was,O
finely,O
chopped,O
three,O
times,O
using,O
a,O
McIlwain,O
tissue,O
chopper,O
(,O
The,O
Mickle,O
Laboratory,O
Engineering,O
Co,O
.),O
and,O
digested,O
for,O
1,O
hr,O
at,O
37,O
°,O
C,O
in,O
serum,O
-,O
free,O
DMEM,O
-,O
F12,O
medium,O
(,O
Invitrogen,O
Life,O
Technologies,O
),O
containing,O
0,O
.,O
1,O
mg,O
/,O
ml,O
porcine,O
pancreatic,O
trypsin,B-GP
(,O
Gibco,O
),O
and,O
0,O
.,O
2,O
mg,O
/,O
ml,O
collagenase,B-GP
A,I-GP
(,O
Roche,O
).,O
Cells,O
were,O
washed,O
and,O
fibroblasts,O
were,O
allowed,O
to,O
adhere,O
for,O
1,O
hr,O
at,O
37,O
°,O
C,O
.,O
Non,O
-,O
adherent,O
epithelial,O
cells,O
were,O
collected,O
",",O
washed,O
",",O
pelleted,O
in,O
40,O
μl,O
serum,O
-,O
free,O
DMEM,O
-,O
F12,O
and,O
kept,O
on,O
ice,O
until,O
transplantation,O
.,O
MMECs,O
were,O
transplanted,O
in,O
3,O
-,O
week,O
-,O
old,O
wild,O
type,O
syngeneic,O
female,O
recipient,O
mice,B-OG
.,O
Recipient,O
mice,B-OG
were,O
anesthetized,O
by,O
isoflurane,O
.,O
Temgesic,O
(,O
buprenorphine,O
;,O
100,O
μl,O
(,O
0,O
.,O
03,O
mg,O
/,O
ml,O
)),O
was,O
injected,O
SC,O
as,O
analgesic,O
treatment,O
.,O
The,O
fourth,O
(,O
inguinal,O
),O
mammary,O
gland,O
was,O
exposed,O
and,O
endogenous,O
mammary,O
epithelial,O
tissue,O
was,O
removed,O
.,O
Next,O
",",O
MMECs,O
were,O
injected,O
in,O
the,O
cleared,O
fat,O
pad,O
using,O
a,O
50,O
μl,O
Hamilton,O
syringe,O
",",O
after,O
which,O
the,O
animals,B-OG
were,O
sutured,O
.,O
Whole,O
mount,O
analysis,O
was,O
performed,O
8,O
weeks,O
after,O
transplantation,O
.,O
FACS,O
analysis,O
After,O
enzymatic,O
digestion,O
of,O
the,O
mammary,O
tissue,O
",",O
cells,O
were,O
incubated,O
with,O
red,O
blood,O
cell,O
lysis,O
buffer,O
(,O
8,O
.,O
26,O
g,O
NH4Cl,O
",",O
1,O
g,O
NaHCO3,O
",",O
0,O
.,O
0378,O
g,O
EDTA,O
in,O
1,O
L,O
dH20,O
),O
to,O
remove,O
erythrocytes,O
(,O
15,O
minutes,O
).,O
Cells,O
were,O
washed,O
and,O
fibroblasts,O
were,O
allowed,O
to,O
adhere,O
for,O
1,O
hr,O
at,O
37,O
°,O
C,O
.,O
Non,O
-,O
adherent,O
epithelial,O
cells,O
were,O
collected,O
",",O
washed,O
in,O
0,O
.,O
02,O
%,O
EDTA,O
-,O
PBS,O
solution,O
",",O
pelleted,O
and,O
resuspended,O
in,O
0,O
.,O
25,O
%,O
w,O
/,O
v,O
trypsin,B-GP
/,O
0,O
.,O
2,O
%,O
w,O
/,O
v,O
EDTA,O
in,O
PBS,O
for,O
incubation,O
at,O
37,O
°,O
C,O
for,O
2,O
minutes,O
.,O
Cells,O
were,O
dissociated,O
through,O
a,O
70,O
μm,O
cell,O
strainer,O
and,O
resuspended,O
in,O
fresh,O
RPMI,O
/,O
10,O
%,O
FCS,O
for,O
quantification,O
.,O
Cells,O
were,O
incubated,O
with,O
primary,O
antibodies,B-GP
for,O
45,O
minutes,O
on,O
ice,O
(,O
FITC,O
-,O
conjugated,O
anti,O
-,O
CD24,B-GP
(,O
clone,O
M1,O
/,O
69,O
",",O
BD,O
Biosciences,O
",",O
0,O
.,O
5,O
μg,O
/,O
ml,O
"),",O
PE,B-GP
-,O
Cy5,O
-,O
conjugated,O
anti,O
-,O
CD45,B-GP
(,O
clone,O
30,O
-,O
F11,O
",",O
BD,O
Biosciences,O
",",O
0,O
.,O
25,O
μg,O
/,O
ml,O
"),",O
and,O
PE,B-GP
-,O
conjugated,O
anti,O
-,O
Sca,B-GP
-,I-GP
1,I-GP
(,O
clone,O
D7,O
",",O
0,O
.,O
5,O
μg,O
/,O
ml,O
;,O
BD,O
Biosciences,O
",",O
0,O
.,O
5,O
μg,O
/,O
ml,O
)).,O
Before,O
FACS,O
analysis,O
",",O
cells,O
were,O
incubated,O
with,O
0,O
.,O
01,O
%,O
4,O
"’,",O
6,O
-,O
diamidino,O
-,O
2,O
-,O
phenylindole,O
dihydrochloride,O
(,O
DAPI,O
),O
for,O
15,O
minutes,O
.,O
Analyses,O
were,O
carried,O
out,O
on,O
a,O
BD,O
FACSVantageSE,O
DiVa,O
(,O
BD,O
Biosciences,O
),O
and,O
gating,O
was,O
performed,O
as,O
described,O
[,O
59,O
].,O
Flow,O
Jo,O
software,O
version,O
10,O
was,O
used,O
for,O
analysis,O
.,O
Whole,O
mount,O
analysis,O
Mammary,O
glands,O
were,O
dissected,O
and,O
stretched,O
on,O
a,O
glass,O
slide,O
.,O
Glands,O
were,O
fixed,O
in,O
a,O
mixture,O
of,O
methanol,O
:,O
1,O
",",O
1,O
",",O
1,O
-,O
trichloroethane,O
:,O
acetic,O
acid,O
(,O
6,O
:,O
3,O
:,O
1,O
),O
for,O
4,O
hours,O
and,O
stained,O
overnight,O
with,O
carmine,O
aluminium,O
staining,O
solution,O
(,O
2,O
g,O
/,O
l,O
carmine,O
",",O
5,O
g,O
/,O
l,O
aluminium,O
potassium,O
sulphate,O
dissolved,O
in,O
water,O
).,O
After,O
stepwise,O
dehydration,O
in,O
70,O
"%,",O
95,O
%,O
and,O
100,O
%,O
ethanol,O
",",O
glands,O
were,O
cleared,O
in,O
xylene,O
for,O
10,O
minutes,O
and,O
photographs,O
were,O
taken,O
with,O
a,O
Zeiss,O
Stemi,O
2000,O
-,O
C,O
stereo,O
microscope,O
.,O
We,O
defined,O
effect,O
size,O
as,O
follows,O
:,O
total,O
effect,O
(,O
0,O
%,O
outgrowth,O
"),",O
subtotal,O
(,O
up,O
to,O
25,O
%,O
outgrowth,O
"),",O
partial,O
(,O
more,O
than,O
25,O
%,O
outgrowth,O
"),",O
and,O
no,O
effect,O
(,O
100,O
%,O
outgrowth,O
).,O
Histological,O
analysis,O
Tissues,O
were,O
isolated,O
and,O
fixed,O
in,O
4,O
%,O
formaldehyde,O
.,O
Tissues,O
were,O
dehydrated,O
",",O
cut,O
into,O
4,O
μm,O
sections,O
",",O
and,O
stained,O
with,O
hematoxylin,O
and,O
eosin,O
.,O
For,O
immunohistochemical,O
stainings,O
",",O
fixed,O
sections,O
were,O
rehydrated,O
and,O
incubated,O
with,O
primary,O
antibodies,B-GP
against,O
β,B-GP
-,I-GP
casein,I-GP
(,O
Santa,O
-,O
Cruz,O
SC,O
-,O
30042,O
",",O
FL,O
-,O
231,O
",",O
rabbit,B-OG
",",O
1,O
:,O
100,O
),O
and,O
cleaved,O
caspase,B-GP
3,I-GP
(,O
Cell,O
Signaling,O
9661,O
",",O
rabbit,B-OG
",",O
1,O
:,O
500,O
).,O
Endogenous,O
peroxidases,B-GP
were,O
blocked,O
with,O
3,O
%,O
H2O2,O
and,O
biotin,O
-,O
conjugated,O
secondary,O
antibodies,B-GP
were,O
used,O
",",O
followed,O
by,O
incubation,O
with,O
HRP,B-GP
-,O
conjugated,O
streptavidin,B-GP
-,O
biotin,O
complex,O
(,O
DAKO,O
).,O
Substrate,O
was,O
developed,O
with,O
DAB,O
(,O
DAKO,O
),O
and,O
pictures,O
were,O
made,O
using,O
a,O
Nikon,O
Eclipse,O
E800,O
with,O
a,O
Nikon,O
digital,O
camera,O
DXM1200,O
.,O
Appropriate,O
positive,O
and,O
negative,O
controls,O
were,O
used,O
throughout,O
.,O
Pharmacokinetic,O
analysis,O
Mice,B-OG
were,O
euthanized,O
at,O
5,O
minutes,O
",",O
15,O
minutes,O
",",O
30,O
minutes,O
",",O
1,O
",",O
2,O
",",O
4,O
",",O
8,O
",",O
24,O
",",O
48,O
",",O
72,O
and,O
96,O
hour,O
intervals,O
after,O
ID,O
injection,O
.,O
Blood,O
was,O
collected,O
via,O
cardiac,O
puncture,O
and,O
tissue,O
was,O
isolated,O
and,O
frozen,O
.,O
Platinum,O
concentrations,O
were,O
measured,O
by,O
a,O
validated,O
Inductively,O
Coupled,O
Plasma,O
Mass,O
Spectrometry,O
(,O
ICPMS,O
),O
method,O
as,O
described,O
by,O
Brouwers,O
et,O
al,O
.,O
[,O
60,O
].,O
Statistical,O
analysis,O
For,O
statistical,O
analyses,O
IBM,O
SPSS,O
Statistics,O
Version,O
20,O
was,O
used,O
.,O
For,O
dichotomous,O
variables,O
Chi,O
square,O
tests,O
were,O
used,O
;,O
for,O
continuous,O
variables,O
t,O
-,O
test,O
(,O
normal,O
distribution,O
"),",O
Mann,O
Whitney,O
test,O
(,O
no,O
normal,O
distribution,O
",",O
no,O
paired,O
data,O
),O
or,O
Wilcoxon,O
signed,O
rank,O
test,O
(,O
no,O
normal,O
distribution,O
",",O
paired,O
data,O
).,O
For,O
survival,O
analysis,O
Kaplan,O
-,O
Meier,O
curves,O
and,O
Log,O
-,O
rank,O
(,O
Mantel,O
-,O
Cox,O
),O
tests,O
were,O
performed,O
.,O
A,O
two,O
-,O
sided,O
p,O
-,O
value,O
<,O
0,O
.,O
05,O
was,O
considered,O
statistically,O
significant,O
.,O
SUPPLEMENTARY,O
MATERIALS,O
FIGURES,O
AND,O
TABLES,O
Author,O
contributions,O
JSG,O
",",O
PJD,O
",",O
JHB,O
",",O
JJ,O
",",O
EW,O
and,O
PWBD,O
conceived,O
study,O
design,O
.,O
JSG,O
",",O
PJD,O
",",O
MA,O
",",O
EJV,O
",",O
XP,O
",",O
NDH,O
",",O
and,O
HR,O
carried,O
out,O
experiments,O
.,O
JSG,O
",",O
PJD,O
",",O
HR,O
",",O
SAY,O
",",O
AB,O
and,O
PWBD,O
analyzed,O
data,O
.,O
All,O
authors,O
were,O
involved,O
in,O
writing,O
the,O
paper,O
and,O
had,O
final,O
approval,O
of,O
the,O
submitted,O
and,O
published,O
versions,O
.,O
CONFLICTS,O
OF,O
INTEREST,O
The,O
author,O
(,O
s,O
),O
declare,O
that,O
they,O
have,O
no,O
competing,O
interests,O
.,O
Effect,O
of,O
Rebound,O
Exercises,O
and,O
Circuit,O
Training,O
on,O
Complications,O
Associated,O
with,O
Type,B-DS
2,I-DS
Diabetes,I-DS
:,O
Protocol,O
for,O
a,O
Randomized,O
Controlled,O
Trial,O
Background,O
The,O
incidence,O
of,O
type,B-DS
2,I-DS
diabetes,I-DS
mellitus,I-DS
",",O
a,O
chronic,O
lifestyle,O
disease,O
",",O
and,O
its,O
complications,O
are,O
on,O
the,O
rise,O
.,O
Exercise,O
has,O
been,O
documented,O
as,O
being,O
effective,O
in,O
the,O
management,O
of,O
musculoskeletal,O
pain,O
",",O
depression,B-DS
",",O
and,O
reduction,O
of,O
hyperglycemia,B-DS
in,O
diabetic,O
patients,O
.,O
However,O
",",O
there,O
is,O
no,O
consensus,O
regarding,O
the,O
types,O
of,O
exercise,O
that,O
reduce,O
musculoskeletal,O
pain,O
and,O
depression,B-DS
and,O
improve,O
quality,O
of,O
life,O
as,O
well,O
as,O
respiratory,O
function,O
among,O
individuals,O
with,O
type,B-DS
2,I-DS
diabetes,I-DS
.,O
Objective,O
The,O
objective,O
of,O
this,O
study,O
is,O
to,O
determine,O
the,O
effects,O
of,O
rebound,O
and,O
circuit,O
training,O
on,O
musculoskeletal,O
pain,O
",",O
blood,O
glucose,O
level,O
",",O
cholesterol,O
level,O
",",O
quality,O
of,O
life,O
",",O
depression,B-DS
",",O
and,O
respiratory,O
parameters,O
in,O
patients,O
with,O
type,B-DS
2,I-DS
diabetes,I-DS
mellitus,I-DS
.,O
Methods,O
A,O
total,O
of,O
70,O
participants,O
are,O
expected,O
to,O
be,O
recruited,O
in,O
this,O
single,O
blind,O
randomized,O
controlled,O
trial,O
.,O
Computer,O
-,O
generated,O
random,O
numbers,O
will,O
be,O
used,O
to,O
randomize,O
the,O
participants,O
into,O
3,O
groups,O
",",O
namely,O
",",O
the,O
rebound,O
exercise,O
group,O
",",O
the,O
circuit,O
exercise,O
group,O
",",O
and,O
the,O
control,O
group,O
.,O
Measurements,O
will,O
be,O
taken,O
at,O
baseline,O
and,O
at,O
the,O
end,O
of,O
the,O
8,O
weeks,O
of,O
the,O
study,O
.,O
Participants,O
’,O
musculoskeletal,O
pain,O
will,O
be,O
assessed,O
using,O
the,O
visual,O
analog,O
scale,O
",",O
quality,O
of,O
life,O
will,O
be,O
assessed,O
using,O
the,O
SF,O
12,O
Health,O
Survey,O
Questionnaire,O
",",O
depression,B-DS
using,O
the,O
Beck,O
Depression,B-DS
Inventory,O
",",O
respiratory,O
parameters,O
using,O
the,O
spirometer,O
",",O
and,O
biochemical,O
parameters,O
such,O
as,O
glucose,O
level,O
and,O
cholesterol,O
level,O
using,O
the,O
glucometer,O
.,O
Data,O
will,O
be,O
analyzed,O
using,O
descriptive,O
statistics,O
and,O
inferential,O
statistics,O
of,O
multivariate,O
analysis,O
of,O
variance,O
between,O
the,O
groups,O
and,O
paired,O
t,O
test,O
within,O
the,O
group,O
.,O
Alpha,O
will,O
be,O
set,O
at,O
.,O
05,O
.,O
Results,O
The,O
results,O
of,O
this,O
study,O
will,O
identify,O
the,O
effectiveness,O
of,O
rebound,O
exercise,O
and,O
circuit,O
training,O
",",O
compared,O
with,O
the,O
control,O
",",O
in,O
the,O
management,O
of,O
type,B-DS
2,I-DS
diabetes,I-DS
mellitus,I-DS
and,O
on,O
quality,O
of,O
life,O
",",O
musculoskeletal,O
pain,O
",",O
depression,B-DS
",",O
glycemic,O
control,O
",",O
cholesterol,O
level,O
",",O
as,O
well,O
as,O
improvement,O
in,O
respiratory,O
function,O
.,O
Conclusions,O
Though,O
different,O
additional,O
strategies,O
such,O
as,O
exercise,O
and,O
dietary,O
and,O
lifestyle,O
modifications,O
exist,O
for,O
the,O
control,O
of,O
type,B-DS
2,I-DS
diabetes,I-DS
",",O
they,O
are,O
mostly,O
applied,O
for,O
the,O
control,O
of,O
glucose,O
level,O
.,O
No,O
strategies,O
have,O
been,O
identified,O
for,O
the,O
control,O
of,O
complications,O
associated,O
with,O
diabetes,B-DS
such,O
as,O
musculoskeletal,O
pain,O
",",O
depression,B-DS
",",O
and,O
reduction,O
in,O
quality,O
of,O
life,O
.,O
Trial,O
Registration,O
Clinicaltrials,O
.,O
gov,O
NCT03200795,O
;,O
https,O
://,O
clinicaltrials,O
.,O
gov,O
/,O
ct2,O
/,O
show,O
/,O
NCT03200795,O
(,O
Archived,O
by,O
WebCite,O
at,O
http,O
://,O
www,O
.,O
webcitation,O
.,O
org,O
/,O
6mBgcj6z7,O
),O
Introduction,O
Overview,O
Diabetes,B-DS
is,O
a,O
global,O
epidemic,B-DS
disease,I-DS
[,O
1,O
].,O
The,O
global,O
prevalence,O
of,O
diabetics,O
is,O
currently,O
estimated,O
to,O
be,O
415,O
million,O
and,O
is,O
projected,O
to,O
rise,O
to,O
over,O
642,O
million,O
by,O
the,O
year,O
2040,O
",",O
with,O
Asians,O
suffering,O
the,O
bulk,O
of,O
the,O
total,O
diabetes,B-DS
epidemic,O
[,O
2,O
].,O
The,O
International,O
Diabetes,B-DS
Federation,O
(,O
IDF,O
),O
estimated,O
that,O
there,O
were,O
14,O
.,O
2,O
million,O
diabetes,B-DS
patients,O
living,O
in,O
Africa,O
in,O
2015,O
",",O
excluding,O
the,O
67,O
%,O
of,O
patients,O
that,O
are,O
undiagnosed,O
",",O
and,O
the,O
projection,O
rate,O
is,O
expected,O
to,O
rise,O
to,O
34,O
.,O
2,O
million,O
by,O
2040,O
[,O
2,O
].,O
South,O
Africa,O
is,O
among,O
the,O
most,O
populous,O
African,O
countries,O
with,O
the,O
highest,O
number,O
of,O
people,O
with,O
diabetes,B-DS
with,O
2,O
.,O
3,O
million,O
people,O
",",O
followed,O
by,O
Democratic,O
Republic,O
of,O
Congo,O
1,O
.,O
8,O
million,O
",",O
Nigeria,O
1,O
.,O
6,O
million,O
",",O
and,O
Ethiopia,O
1,O
.,O
3,O
million,O
.,O
Nearly,O
half,O
of,O
the,O
adults,O
with,O
diabetes,B-DS
live,O
in,O
these,O
countries,O
.,O
In,O
South,O
Africa,O
",",O
the,O
prevalence,O
of,O
diabetes,B-DS
mellitus,I-DS
(,O
DM,B-DS
),O
is,O
estimated,O
to,O
be,O
about,O
6,O
"%,",O
excluding,O
the,O
undiagnosed,O
cases,O
",",O
whereas,O
9,O
%,O
of,O
the,O
population,O
has,O
prediabetes,B-DS
.,O
DM,B-DS
accounts,O
for,O
58,O
deaths,O
daily,O
and,O
is,O
the,O
fifth,O
highest,O
cause,O
of,O
natural,O
deaths,O
[,O
3,O
].,O
The,O
highest,O
prevalence,O
of,O
diabetes,B-DS
is,O
among,O
the,O
Indian,O
population,O
(,O
11,O
%-,O
13,O
"%),",O
as,O
this,O
group,O
has,O
a,O
strong,O
genetic,O
predisposition,O
to,O
diabetes,B-DS
.,O
This,O
is,O
followed,O
by,O
8,O
%,O
to,O
10,O
%,O
in,O
the,O
colored,O
community,O
",",O
5,O
%,O
to,O
8,O
%,O
among,O
blacks,O
",",O
and,O
4,O
%,O
among,O
whites,O
.,O
The,O
prevalence,O
of,O
diabetes,B-DS
in,O
the,O
public,O
health,O
sector,O
of,O
KwaZulu,O
-,O
Natal,O
was,O
found,O
to,O
be,O
14,O
.,O
3,O
%,O
higher,O
than,O
the,O
national,O
prevalence,O
estimates,O
[,O
3,O
].,O
Diabetes,B-DS
is,O
a,O
systemic,B-DS
disease,I-DS
that,O
affects,O
multiple,O
body,O
functions,O
and,O
structure,O
.,O
The,O
typical,O
spectrum,O
of,O
problems,O
of,O
patients,O
with,O
DM,B-DS
can,O
now,O
be,O
defined,O
based,O
on,O
the,O
International,O
Classification,O
of,O
Functioning,O
",",O
Disability,O
and,O
Health,O
(,O
ICF,O
).,O
For,O
practical,O
purposes,O
and,O
in,O
line,O
with,O
the,O
concept,O
of,O
condition,O
-,O
specific,O
health,O
status,O
measures,O
",",O
DM,B-DS
problems,O
can,O
be,O
classified,O
as,O
follows,O
:,O
body,O
function,O
as,O
hematological,O
system,O
function,O
",",O
sensation,O
of,O
pain,O
",",O
musculoskeletal,O
system,O
",",O
and,O
respiratory,O
system,O
.,O
On,O
the,O
basis,O
of,O
activities,O
and,O
participation,O
restriction,O
",",O
DM,B-DS
problems,O
can,O
be,O
classified,O
as,O
quality,O
of,O
life,O
(,O
QoL,O
),O
and,O
psychosocial,O
factors,O
.,O
These,O
will,O
serve,O
as,O
a,O
guide,O
in,O
clinical,O
studies,O
with,O
DM,B-DS
or,O
as,O
a,O
guide,O
to,O
multidisciplinary,O
assessments,O
in,O
patients,O
with,O
DM,B-DS
[,O
4,O
].,O
In,O
2004,O
",",O
the,O
US,O
National,O
Health,O
Interview,O
Survey,O
reported,O
that,O
58,O
%,O
of,O
diabetic,O
patients,O
would,O
have,O
a,O
functional,O
disability,O
[,O
5,O
].,O
The,O
percentage,O
of,O
diabetic,O
patients,O
with,O
a,O
functional,O
disability,O
will,O
increase,O
as,O
the,O
number,O
of,O
diabetic,O
patients,O
increases,O
and,O
will,O
constitute,O
a,O
major,O
public,O
health,O
problem,O
.,O
Recent,O
data,O
show,O
that,O
the,O
prevalence,O
of,O
musculoskeletal,O
pain,O
(,O
MSKP,O
),O
manifestations,O
in,O
the,O
hands,O
and,O
shoulders,O
in,O
patients,O
with,O
type,O
1,O
or,O
type,B-DS
2,I-DS
diabetes,I-DS
is,O
30,O
%.,O
These,O
manifestations,O
are,O
closely,O
linked,O
to,O
age,O
[,O
6,O
],O
and,O
prolonged,O
disease,O
duration,O
[,O
7,O
",",O
8,O
].,O
Musculoskeletal,B-DS
disorders,I-DS
are,O
very,O
common,O
in,O
diabetes,B-DS
and,O
are,O
associated,O
with,O
poor,O
glycemic,O
control,O
and,O
more,O
complications,O
.,O
Assessment,O
of,O
musculoskeletal,B-DS
disorders,I-DS
among,O
diabetics,O
should,O
include,O
an,O
estimate,O
of,O
cholesterol,O
",",O
glycemic,O
control,O
",",O
MSKP,O
",",O
respiratory,O
parameters,O
",",O
and,O
QoL,O
.,O
People,O
with,O
diabetes,B-DS
are,O
at,O
twice,O
as,O
high,O
a,O
risk,O
of,O
suffering,O
from,O
premorbid,O
depression,B-DS
as,O
the,O
general,O
population,O
[,O
5,O
].,O
The,O
coexistence,O
of,O
depression,B-DS
in,O
people,O
with,O
diabetes,B-DS
catalyzes,O
serious,O
disease,O
comorbidities,O
",",O
MSKP,O
",",O
decreased,O
respiratory,O
capacity,O
",",O
poor,O
glycemic,O
control,O
which,O
may,O
lead,O
to,O
hyperlipidemia,B-DS
and,O
poor,O
QoL,O
",",O
and,O
escalated,O
health,O
care,O
expenditures,O
[,O
9,O
].,O
Depressive,O
symptoms,O
are,O
more,O
likely,O
to,O
persist,O
among,O
persons,O
with,O
multiple,O
diabetic,B-DS
-,I-DS
related,I-DS
complications,I-DS
such,O
as,O
musculoskeletal,B-DS
disorders,I-DS
.,O
Increase,O
in,O
pain,O
may,O
lead,O
to,O
increased,O
depression,B-DS
and,O
reduction,O
in,O
respiratory,O
capacity,O
and,O
QoL,O
.,O
Studies,O
have,O
shown,O
that,O
both,O
exercises,O
and,O
pharmacotherapy,O
[,O
10,O
],O
can,O
decrease,O
depression,B-DS
and,O
improve,O
glycemic,O
control,O
and,O
overall,O
QoL,O
in,O
persons,O
with,O
diabetes,B-DS
and,O
thus,O
",",O
in,O
addition,O
",",O
provide,O
substantial,O
financial,O
savings,O
and,O
improved,O
medical,O
care,O
for,O
these,O
individuals,O
.,O
Exercise,O
",",O
in,O
addition,O
to,O
diet,O
modification,O
and,O
medication,O
",",O
has,O
long,O
been,O
recommended,O
as,O
one,O
of,O
the,O
3,O
main,O
components,O
of,O
diabetic,O
therapy,O
[,O
11,O
].,O
The,O
low,O
cost,O
and,O
nonpharmacological,O
nature,O
of,O
exercise,O
enhances,O
its,O
therapeutic,O
appeal,O
among,O
type,O
2,O
diabetic,O
patients,O
.,O
Published,O
exercise,O
intervention,O
trials,O
[,O
12,O
-,O
15,O
"],",O
using,O
different,O
types,O
of,O
intervention,O
",",O
usually,O
have,O
small,O
sample,O
sizes,O
and,O
the,O
findings,O
of,O
their,O
studies,O
have,O
varied,O
.,O
The,O
optimal,O
type,O
",",O
frequency,O
",",O
intensity,O
",",O
and,O
duration,O
of,O
exercise,O
for,O
achieving,O
therapeutic,O
goals,O
in,O
type,B-DS
2,I-DS
diabetes,I-DS
are,O
not,O
known,O
.,O
The,O
psychosocial,O
variables,O
and,O
cardiorespiratory,O
-,O
related,O
health,O
of,O
diabetics,O
appear,O
to,O
be,O
underexplored,O
in,O
exercise,O
-,O
related,O
interventions,O
[,O
11,O
].,O
Moreover,O
",",O
prospective,O
randomized,O
controlled,O
trials,O
(,O
RCTs,O
),O
on,O
the,O
effects,O
of,O
exercise,O
in,O
the,O
prevention,O
or,O
treatment,O
of,O
musculoskeletal,O
complications,O
and,O
disability,O
seen,O
in,O
diabetes,B-DS
patients,O
are,O
needed,O
[,O
16,O
].,O
Exercise,O
has,O
been,O
documented,O
as,O
effective,O
in,O
the,O
management,O
of,O
MSKP,O
;,O
however,O
",",O
there,O
is,O
no,O
consensus,O
regarding,O
the,O
type,O
of,O
exercises,O
that,O
improve,O
MSKP,O
.,O
The,O
effectiveness,O
of,O
exercise,O
in,O
reducing,O
MSKP,O
as,O
well,O
as,O
depression,B-DS
and,O
in,O
improving,O
respiratory,O
function,O
among,O
individuals,O
with,O
type,B-DS
2,I-DS
diabetes,I-DS
has,O
not,O
been,O
documented,O
.,O
Rebound,O
exercise,O
is,O
a,O
type,O
of,O
exercise,O
that,O
can,O
aid,O
the,O
management,O
of,O
type,B-DS
2,I-DS
diabetes,I-DS
[,O
17,O
],O
and,O
is,O
likely,O
to,O
improve,O
MSKP,O
and,O
depression,B-DS
.,O
Circuit,O
resistance,O
training,O
(,O
CRT,O
),O
has,O
recently,O
been,O
documented,O
to,O
be,O
safe,O
in,O
the,O
management,O
of,O
type,B-DS
2,I-DS
diabetes,I-DS
;,O
however,O
",",O
its,O
effects,O
on,O
MSKP,O
and,O
depression,B-DS
have,O
not,O
been,O
assessed,O
[,O
1,O
].,O
Rebound,O
exercise,O
on,O
the,O
mini,O
trampoline,O
moves,O
all,O
parts,O
of,O
the,O
body,O
at,O
once,O
",",O
so,O
it,O
is,O
also,O
called,O
cellular,O
exercise,O
[,O
18,O
].,O
It,O
may,O
be,O
superior,O
to,O
any,O
other,O
type,O
of,O
exercise,O
as,O
it,O
utilizes,O
gravity,O
and,O
forces,O
of,O
acceleration,O
and,O
deceleration,O
so,O
that,O
at,O
the,O
top,O
of,O
the,O
bounce,O
one,O
experiences,O
weightlessness,O
and,O
at,O
the,O
bottom,O
the,O
weight,O
doubles,O
pulling,O
into,O
the,O
center,O
of,O
the,O
rebounder,O
.,O
Rebound,O
exercise,O
is,O
also,O
a,O
form,O
of,O
aerobic,O
exercise,O
that,O
increases,O
oxygen,O
consumption,O
and,O
stimulates,O
immune,O
response,O
.,O
Circuit,O
training,O
is,O
a,O
combination,O
of,O
strength,O
training,O
and,O
aerobic,O
exercises,O
.,O
Strengthening,O
exercise,O
is,O
a,O
resistance,O
exercise,O
that,O
helps,O
to,O
keep,O
the,O
muscles,O
flexible,O
and,O
strong,O
and,O
also,O
strengthens,O
the,O
bones,O
.,O
Aerobic,O
exercise,O
",",O
on,O
the,O
other,O
hand,O
",",O
is,O
a,O
less,O
vigorous,O
exercise,O
that,O
increases,O
oxygen,O
consumption,O
;,O
the,O
increase,O
in,O
oxygen,O
consumption,O
helps,O
to,O
burn,O
more,O
calories,O
and,O
stimulates,O
immune,O
response,O
and,O
cardiovascular,O
health,O
[,O
19,O
].,O
Rehabilitation,O
can,O
assist,O
to,O
retain,O
physical,O
and,O
functional,O
abilities,O
as,O
well,O
as,O
control,O
psychological,O
emotions,O
[,O
20,O
].,O
Therefore,O
",",O
comprehensive,O
rehabilitation,O
to,O
manage,O
diabetes,B-DS
-,I-DS
related,I-DS
complications,I-DS
that,O
encompasses,O
exercises,O
such,O
as,O
rebound,O
and,O
circuit,O
training,O
may,O
improve,O
glycemic,O
control,O
",",O
reduce,O
depression,B-DS
",",O
and,O
improve,O
QoL,O
and,O
musculoskeletal,O
functions,O
.,O
Theoretical,O
Framework,O
Previous,O
studies,O
have,O
assessed,O
the,O
effect,O
of,O
combined,O
resistance,O
and,O
aerobic,O
exercises,O
on,O
type,B-DS
2,I-DS
DM,I-DS
patients,O
and,O
observed,O
significant,O
reductions,O
in,O
HbA1c,O
[,O
21,O
-,O
23,O
].,O
However,O
",",O
Geirsdottir,O
et,O
al,O
[,O
24,O
],O
did,O
not,O
observe,O
any,O
favorable,O
changes,O
in,O
fasting,O
glucose,O
or,O
HbA1c,O
in,O
patients,O
with,O
type,B-DS
2,I-DS
diabetes,I-DS
.,O
Therefore,O
",",O
there,O
is,O
no,O
consensus,O
on,O
the,O
effect,O
of,O
CRT,O
in,O
type,B-DS
2,I-DS
diabetes,I-DS
.,O
Rebound,O
exercise,O
has,O
been,O
documented,O
to,O
be,O
effective,O
in,O
reducing,O
plasma,O
fasting,O
glucose,O
",",O
HbA1c,O
",",O
and,O
body,O
mass,O
index,O
(,O
BMI,O
),O
in,O
type,B-DS
2,I-DS
diabetes,I-DS
.,O
It,O
is,O
also,O
simple,O
",",O
inexpensive,O
and,O
enjoyable,O
[,O
23,O
].,O
Moreover,O
",",O
it,O
has,O
been,O
documented,O
to,O
improve,O
QoL,O
in,O
patients,O
with,O
type,B-DS
2,I-DS
diabetes,I-DS
[,O
17,O
].,O
However,O
",",O
its,O
effect,O
on,O
MSKP,O
",",O
respiratory,O
parameters,O
",",O
and,O
depression,B-DS
has,O
not,O
been,O
documented,O
.,O
Prospective,O
RCTs,O
on,O
the,O
effects,O
of,O
exercise,O
in,O
the,O
prevention,O
or,O
treatment,O
of,O
musculoskeletal,O
complications,O
",",O
cardiorespiratory,O
parameters,O
",",O
and,O
psychosocial,O
variables,O
seen,O
in,O
diabetes,B-DS
patients,O
are,O
needed,O
[,O
16,O
].,O
In,O
African,O
countries,O
",",O
there,O
is,O
a,O
paucity,O
of,O
reports,O
that,O
describe,O
musculoskeletal,B-DS
disorders,I-DS
in,O
diabetic,O
patients,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
no,O
clinical,O
trial,O
has,O
been,O
conducted,O
that,O
compares,O
the,O
effect,O
of,O
rebound,O
exercises,O
and,O
circuit,O
training,O
on,O
MSKP,O
",",O
respiratory,O
parameters,O
",",O
and,O
psychosocial,O
variables,O
among,O
patients,O
with,O
type,B-DS
2,I-DS
diabetes,I-DS
.,O
No,O
previous,O
studies,O
had,O
been,O
conducted,O
to,O
assess,O
the,O
effect,O
of,O
any,O
treatment,O
or,O
prevalence,O
of,O
MSKP,O
manifestations,O
in,O
diabetic,O
patients,O
or,O
to,O
evaluate,O
the,O
predisposing,O
factors,O
.,O
This,O
study,O
is,O
",",O
therefore,O
",",O
proposed,O
to,O
determine,O
the,O
effect,O
of,O
rebound,O
exercises,O
and,O
circuit,O
training,O
on,O
MSKP,O
",",O
as,O
well,O
as,O
selected,O
biochemical,O
and,O
psychosocial,O
factors,O
among,O
individuals,O
with,O
type,B-DS
2,I-DS
diabetes,I-DS
.,O
Objective,O
The,O
objective,O
of,O
this,O
research,O
is,O
to,O
investigate,O
the,O
effect,O
of,O
rebound,O
exercises,O
and,O
circuit,O
training,O
and,O
compare,O
them,O
to,O
the,O
routine,O
care,O
of,O
type,O
2,O
diabetic,O
patients,O
.,O
The,O
objectives,O
of,O
this,O
research,O
are,O
as,O
follows,O
;,O
To,O
investigate,O
the,O
effect,O
of,O
rebound,O
exercises,O
on,O
glycemic,O
control,O
",",O
cholesterol,O
level,O
",",O
respiratory,O
parameters,O
",",O
pain,O
scores,O
",",O
depression,B-DS
",",O
and,O
QoL,O
among,O
type,B-DS
2,I-DS
diabetes,I-DS
patients,O
To,O
investigate,O
the,O
effect,O
of,O
CRT,O
on,O
glycemic,O
control,O
",",O
cholesterol,O
level,O
",",O
respiratory,O
parameters,O
",",O
pain,O
scores,O
",",O
depression,B-DS
",",O
and,O
QoL,O
among,O
type,B-DS
2,I-DS
diabetes,I-DS
patients,O
To,O
investigate,O
the,O
effect,O
of,O
routine,O
care,O
(,O
control,O
group,O
),O
on,O
glycemic,O
control,O
",",O
cholesterol,O
level,O
",",O
respiratory,O
parameters,O
",",O
pain,O
scores,O
",",O
depression,B-DS
",",O
and,O
QoL,O
among,O
type,B-DS
2,I-DS
diabetes,I-DS
patients,O
To,O
compare,O
the,O
effect,O
of,O
circuit,O
training,O
",",O
rebound,O
exercises,O
",",O
and,O
routine,O
care,O
on,O
glycemic,O
control,O
",",O
cholesterol,O
level,O
",",O
respiratory,O
parameters,O
",",O
pain,O
scores,O
",",O
depression,B-DS
",",O
and,O
QoL,O
among,O
type,B-DS
2,I-DS
diabetes,I-DS
patients,O
.,O
Methods,O
Study,O
Design,O
The,O
study,O
is,O
a,O
single,O
-,O
blind,O
",",O
parallel,O
RCT,O
.,O
RCTs,O
are,O
quantitative,O
",",O
comparative,O
",",O
controlled,O
experiments,O
in,O
which,O
investigators,O
study,O
2,O
or,O
more,O
interventions,O
in,O
a,O
series,O
of,O
individuals,O
who,O
receive,O
them,O
in,O
random,O
order,O
.,O
The,O
RCT,O
is,O
one,O
of,O
the,O
simplest,O
and,O
most,O
powerful,O
tools,O
in,O
clinical,O
research,O
.,O
Participants,O
The,O
participants,O
for,O
the,O
study,O
will,O
be,O
patients,O
diagnosed,O
with,O
type,B-DS
2,I-DS
diabetes,I-DS
by,O
the,O
attending,O
physician,O
at,O
King,O
Edward,O
Hospital,O
.,O
Participants,O
will,O
be,O
considered,O
eligible,O
if,O
they,O
have,O
been,O
diagnosed,O
with,O
type,B-DS
2,I-DS
diabetes,I-DS
for,O
at,O
least,O
4,O
years,O
and,O
have,O
been,O
on,O
oral,O
hypoglycemic,O
control,O
.,O
They,O
will,O
be,O
recruited,O
consecutively,O
as,O
they,O
are,O
available,O
through,O
the,O
outpatient,O
endocrinology,O
clinic,O
of,O
the,O
hospital,O
by,O
a,O
member,O
of,O
the,O
research,O
team,O
.,O
Only,O
participants,O
with,O
MSKP,O
and,O
depression,B-DS
will,O
be,O
included,O
in,O
the,O
study,O
.,O
They,O
will,O
be,O
screened,O
for,O
MSKP,O
using,O
the,O
Nordic,O
Musculoskeletal,O
Symptoms,O
Questionnaire,O
and,O
for,O
depression,B-DS
using,O
the,O
Beck,O
Depression,B-DS
Inventory,O
(,O
BDI,O
).,O
The,O
participants,O
must,O
be,O
aged,O
between,O
20,O
and,O
55,O
years,O
.,O
Those,O
within,O
this,O
age,O
limit,O
are,O
considered,O
to,O
be,O
adults,O
with,O
musculoskeletal,O
affectation,O
",",O
as,O
indicated,O
by,O
Nordic,O
Musculoskeletal,O
Symptom,O
Questionnaire,O
",",O
and,O
with,O
at,O
least,O
≥,O
11,O
score,O
on,O
the,O
BDI,O
.,O
Only,O
participants,O
who,O
meet,O
the,O
inclusion,O
criteria,O
will,O
be,O
considered,O
for,O
the,O
randomization,O
into,O
the,O
groups,O
.,O
The,O
consent,O
of,O
the,O
participants,O
will,O
be,O
sought,O
before,O
they,O
participate,O
in,O
the,O
study,O
.,O
Patients,O
will,O
be,O
excluded,O
from,O
the,O
study,O
if,O
they,O
are,O
involved,O
in,O
sporting,O
activities,O
or,O
if,O
their,O
musculoskeletal,O
problems,O
are,O
severe,O
and,O
may,O
prevent,O
them,O
from,O
performing,O
some,O
of,O
the,O
exercises,O
.,O
Moreover,O
",",O
individuals,O
with,O
hypertension,B-DS
",",O
coronary,B-DS
artery,I-DS
disease,I-DS
",",O
or,O
myocardial,B-DS
infarction,I-DS
;,O
or,O
who,O
have,O
had,O
cardiac,O
or,O
abdominal,O
surgery,O
within,O
the,O
previous,O
6,O
months,O
;,O
or,O
who,O
have,O
a,O
history,O
of,O
fractures,O
of,O
the,O
spine,O
",",O
hip,O
",",O
knee,O
",",O
or,O
ankle,O
joints,O
;,O
as,O
well,O
as,O
those,O
with,O
lower,O
limb,O
weakness,O
and,O
deformities,O
with,O
a,O
loss,O
of,O
protective,O
sensation,O
in,O
the,O
feet,O
will,O
be,O
excluded,O
.,O
Similarly,O
",",O
pregnancy,O
or,O
lactation,O
",",O
use,O
of,O
insulin,B-GP
",",O
and,O
the,O
presence,O
of,O
retinopathy,B-DS
or,O
nephropathy,B-DS
will,O
make,O
a,O
patient,O
ineligible,O
.,O
Finally,O
",",O
subjects,O
who,O
do,O
not,O
consent,O
to,O
participate,O
will,O
be,O
excluded,O
from,O
the,O
study,O
.,O
Participants,O
who,O
meet,O
the,O
inclusion,O
criteria,O
will,O
be,O
randomized,O
into,O
1,O
of,O
the,O
3,O
groups,O
of,O
the,O
study,O
.,O
Setting,O
The,O
research,O
will,O
be,O
conducted,O
at,O
the,O
Performance,O
Laboratory,O
of,O
the,O
Department,O
of,O
Physiotherapy,O
",",O
School,O
of,O
Health,O
Sciences,O
",",O
University,O
of,O
KwaZulu,O
-,O
Natal,O
.,O
The,O
participants,O
will,O
be,O
recruited,O
from,O
the,O
King,O
Edward,O
Hospital,O
",",O
Durban,O
.,O
King,O
Edward,O
Hospital,O
is,O
a,O
tertiary,O
hospital,O
that,O
provides,O
specialist,O
services,O
to,O
the,O
people,O
of,O
KwaZulu,O
-,O
Natal,O
.,O
It,O
is,O
located,O
in,O
Durban,O
City,O
",",O
Ethekwini,O
Municipality,O
",",O
KwaZulu,O
-,O
Natal,O
Province,O
",",O
South,O
Africa,O
.,O
Study,O
Team,O
The,O
study,O
team,O
will,O
consist,O
of,O
4,O
physiotherapists,O
",",O
of,O
which,O
2,O
are,O
clinicians,O
and,O
the,O
other,O
2,O
are,O
both,O
clinicians,O
and,O
researchers,O
.,O
The,O
team,O
will,O
also,O
include,O
an,O
endocrinologist,O
who,O
is,O
a,O
physician,O
with,O
10,O
years,O
of,O
research,O
experience,O
.,O
In,O
addition,O
",",O
2,O
among,O
the,O
physiotherapists,O
will,O
be,O
research,O
assistants,O
and,O
they,O
will,O
administer,O
the,O
treatment,O
.,O
The,O
endocrinologist,O
will,O
screen,O
the,O
patients,O
and,O
ensure,O
that,O
they,O
take,O
the,O
same,O
medications,O
and,O
that,O
they,O
are,O
medically,O
fit,O
",",O
whereas,O
the,O
researchers,O
will,O
screen,O
the,O
participants,O
to,O
ensure,O
that,O
they,O
meet,O
the,O
inclusion,O
criteria,O
.,O
Intervention,O
The,O
study,O
will,O
comprise,O
3,O
groups,O
;,O
the,O
rebound,O
exercise,O
group,O
",",O
the,O
circuit,O
resistance,O
exercise,O
training,O
group,O
",",O
and,O
the,O
routine,O
care,O
group,O
(,O
the,O
control,O
).,O
The,O
routine,O
care,O
group,O
will,O
undergo,O
one,O
exercise,O
training,O
after,O
8,O
weeks,O
of,O
enrollment,O
.,O
Participants,O
will,O
be,O
monitored,O
for,O
subjective,O
fatigue,O
",",O
dyspnea,O
",",O
respiratory,O
distress,O
",",O
profuse,O
sweating,O
",",O
or,O
unsteady,O
gait,O
during,O
the,O
exercise,O
activities,O
",",O
as,O
these,O
may,O
be,O
indications,O
that,O
they,O
have,O
reached,O
maximum,O
exertion,O
.,O
Rebound,O
Exercise,O
Group,O
Participants,O
randomized,O
to,O
this,O
group,O
will,O
be,O
instructed,O
on,O
the,O
proper,O
techniques,O
of,O
the,O
desired,O
movements,O
(,O
hopping,O
),O
on,O
the,O
rebounder,O
.,O
All,O
instruction,O
and,O
training,O
will,O
be,O
provided,O
by,O
the,O
research,O
assistants,O
who,O
are,O
physiotherapists,O
practicing,O
in,O
South,O
Africa,O
.,O
They,O
will,O
teach,O
the,O
participants,O
how,O
to,O
rebound,O
during,O
the,O
session,O
.,O
To,O
ensure,O
exercise,O
endurance,O
",",O
patients,O
allocated,O
to,O
this,O
group,O
will,O
complete,O
a,O
6,O
-,O
min,O
walk,O
test,O
(,O
6MWT,O
"),",O
as,O
prescribed,O
by,O
the,O
American,O
Thoracic,O
Society,O
[,O
25,O
"],",O
which,O
will,O
be,O
conducted,O
along,O
a,O
straight,O
40,O
-,O
m,O
Department,O
of,O
Physiotherapy,O
passageway,O
.,O
On,O
successful,O
completion,O
of,O
the,O
6MWT,O
",",O
patients,O
will,O
be,O
given,O
an,O
opportunity,O
to,O
familiarize,O
themselves,O
with,O
the,O
equipment,O
.,O
Each,O
participant,O
will,O
undergo,O
3,O
sessions,O
a,O
week,O
for,O
8,O
weeks,O
",",O
with,O
each,O
session,O
lasting,O
between,O
15,O
and,O
25,O
min,O
.,O
The,O
exercise,O
will,O
involve,O
bouncing,O
on,O
the,O
center,O
portion,O
of,O
a,O
mini,O
trampoline,O
(,O
2013,O
Portable,O
Model,O
Half,O
-,O
Fold,O
Cellerciser,O
),O
with,O
feet,O
slightly,O
apart,O
and,O
knees,O
in,O
full,O
extension,O
.,O
Each,O
foot,O
strike,O
equals,O
one,O
step,O
or,O
bounce,O
with,O
step,O
height,O
.,O
This,O
will,O
be,O
defined,O
as,O
the,O
distance,O
between,O
the,O
foot,O
at,O
a,O
maximum,O
height,O
of,O
the,O
jump,O
and,O
the,O
bed,O
of,O
the,O
center,O
of,O
the,O
trampoline,O
ranging,O
between,O
10,O
and,O
15,O
cm,O
[,O
23,O
].,O
Exercise,O
durations,O
were,O
set,O
at,O
5,O
-,O
min,O
intervals,O
with,O
3,O
-,O
min,O
rest,O
periods,O
.,O
Each,O
exercise,O
program,O
session,O
will,O
last,O
15,O
min,O
with,O
9,O
min,O
of,O
rest,O
for,O
the,O
first,O
4,O
weeks,O
",",O
progressing,O
to,O
25,O
min,O
with,O
15,O
min,O
of,O
rest,O
in,O
the,O
subsequent,O
4,O
weeks,O
",",O
3,O
times,O
per,O
week,O
over,O
8,O
weeks,O
.,O
Bouncing,O
frequency,O
will,O
be,O
determined,O
by,O
signals,O
from,O
a,O
metronome,O
and,O
will,O
be,O
set,O
at,O
between,O
90,O
and,O
120,O
bounces,O
per,O
minute,O
.,O
Heart,O
rate,O
training,O
zone,O
will,O
be,O
maintained,O
during,O
the,O
exercise,O
at,O
a,O
moderate,O
intensity,O
of,O
40,O
%,O
to,O
60,O
%,O
and,O
will,O
be,O
calculated,O
using,O
the,O
Karvonen,O
formula,O
([,O
heart,O
rate,O
reserve,O
×,O
training,O
percentage,O
]+,O
resting,O
heart,O
rate,O
),O
[,O
23,O
].,O
The,O
heart,O
rate,O
will,O
be,O
monitored,O
using,O
the,O
heart,O
rate,O
monitor,O
(,O
Polar,O
Electro,O
Oy,O
),O
that,O
will,O
display,O
the,O
participant,O
’,O
s,O
heart,O
rate,O
and,O
emit,O
a,O
warning,O
signal,O
if,O
the,O
heart,O
rate,O
goes,O
outside,O
the,O
prescribed,O
training,O
zone,O
",",O
thus,O
serving,O
as,O
a,O
guide,O
and,O
indicator,O
for,O
the,O
participant,O
to,O
adjust,O
the,O
steps,O
and,O
bounce,O
while,O
on,O
the,O
trampoline,O
.,O
In,O
addition,O
",",O
the,O
Borg,O
scale,O
will,O
be,O
used,O
to,O
assess,O
the,O
rate,O
of,O
perceived,O
exertion,O
.,O
Circuit,O
Exercise,O
Group,O
The,O
circuit,O
exercise,O
for,O
the,O
participants,O
in,O
this,O
group,O
will,O
be,O
designed,O
for,O
each,O
participant,O
.,O
To,O
ensure,O
exercise,O
endurance,O
",",O
patients,O
allocated,O
to,O
this,O
group,O
will,O
complete,O
a,O
6MWT,O
",",O
as,O
prescribed,O
by,O
the,O
American,O
Thoracic,O
Society,O
[,O
25,O
"],",O
which,O
will,O
be,O
conducted,O
along,O
a,O
straight,O
40,O
-,O
m,O
Department,O
of,O
Physiotherapy,O
passageway,O
.,O
On,O
successful,O
completion,O
of,O
the,O
6MWT,O
",",O
patients,O
will,O
be,O
given,O
an,O
opportunity,O
to,O
familiarize,O
themselves,O
with,O
the,O
circuit,O
exercise,O
equipment,O
.,O
Exercise,O
sessions,O
will,O
take,O
place,O
3,O
times,O
a,O
week,O
for,O
8,O
weeks,O
.,O
The,O
participants,O
will,O
undergo,O
10,O
min,O
of,O
warm,O
up,O
before,O
and,O
10,O
min,O
of,O
cool,O
down,O
after,O
the,O
training,O
.,O
The,O
stations,O
for,O
circuit,O
training,O
include,O
2,O
stations,O
—,O
1,O
and,O
2,O
.,O
Station,O
1,O
is,O
the,O
resistance,O
exercise,O
",",O
whereas,O
station,O
2,O
is,O
the,O
aerobic,O
exercise,O
with,O
the,O
bicycle,O
ergometer,O
.,O
Station,O
1,O
comprises,O
the,O
following,O
6,O
substations,O
:,O
station,O
A,O
—,O
bench,O
press,O
",",O
station,O
B,O
—,O
seated,O
row,O
",",O
station,O
C,O
—,O
lateral,O
pull,O
down,O
",",O
station,O
D,O
—,O
biceps,O
forward,O
",",O
station,O
E,O
—,O
front,O
thigh,O
and,O
back,O
thigh,O
",",O
and,O
station,O
F,O
—,O
leg,O
press,O
.,O
Resistance,O
exercises,O
will,O
be,O
performed,O
on,O
weight,O
machines,O
.,O
Throughout,O
the,O
resistance,O
training,O
program,O
",",O
participants,O
will,O
rotate,O
among,O
the,O
different,O
machines,O
until,O
they,O
have,O
used,O
every,O
one,O
:,O
the,O
bench,O
press,O
",",O
seated,O
row,O
",",O
lateral,O
pull,O
down,O
",",O
biceps,O
forward,O
",",O
front,O
thigh,O
",",O
back,O
thigh,O
",",O
leg,O
press,O
",",O
and,O
rowing,O
.,O
Participants,O
will,O
be,O
instructed,O
to,O
exhale,O
while,O
lifting,O
a,O
weight,O
and,O
inhale,O
while,O
lowering,O
it,O
",",O
to,O
minimize,O
blood,O
pressure,O
excursions,O
",",O
and,O
to,O
rest,O
for,O
2,O
-,O
3,O
min,O
between,O
sets,O
.,O
Participants,O
will,O
perform,O
1,O
set,O
of,O
resistance,O
exercise,O
3,O
times,O
weekly,O
for,O
the,O
first,O
2,O
weeks,O
",",O
4,O
sets,O
of,O
each,O
resistance,O
exercise,O
3,O
times,O
weekly,O
during,O
weeks,O
3,O
and,O
4,O
",",O
and,O
complete,O
set,O
of,O
resistance,O
exercise,O
in,O
the,O
last,O
4,O
weeks,O
.,O
For,O
each,O
station,O
",",O
the,O
participants,O
will,O
spend,O
10,O
min,O
;,O
this,O
includes,O
the,O
substations,O
.,O
Resistance,O
will,O
be,O
increased,O
by,O
5,O
-,O
10,O
kg,O
",",O
once,O
the,O
participant,O
is,O
able,O
to,O
perform,O
more,O
than,O
15,O
repetitions,O
while,O
maintaining,O
proper,O
form,O
.,O
All,O
the,O
aerobic,O
activities,O
of,O
the,O
circuit,O
training,O
will,O
be,O
performed,O
on,O
a,O
cycle,O
ergometer,O
.,O
Participants,O
will,O
be,O
free,O
to,O
vary,O
the,O
machine,O
used,O
from,O
one,O
visit,O
to,O
the,O
next,O
.,O
Exercise,O
intensity,O
will,O
be,O
standardized,O
by,O
using,O
heart,O
rate,O
monitors,O
(,O
Polar,O
Electro,O
Oy,O
),O
that,O
will,O
display,O
the,O
participant,O
’,O
s,O
heart,O
rate,O
and,O
emit,O
a,O
warning,O
signal,O
if,O
the,O
heart,O
rate,O
goes,O
outside,O
the,O
prescribed,O
training,O
zone,O
",",O
thus,O
guiding,O
the,O
participant,O
to,O
adjust,O
the,O
workload,O
up,O
or,O
down,O
to,O
achieve,O
the,O
desired,O
intensity,O
.,O
In,O
addition,O
",",O
the,O
rate,O
of,O
perceived,O
exertion,O
will,O
be,O
measured,O
using,O
the,O
Borg,O
scale,O
.,O
The,O
Routine,O
Care,O
Group,O
(,O
Control,O
Group,O
),O
Participants,O
in,O
the,O
control,O
group,O
will,O
receive,O
routine,O
medication,O
as,O
prescribed,O
by,O
the,O
attending,O
physicians,O
at,O
the,O
diabetes,B-DS
clinic,O
and,O
will,O
be,O
monitored,O
.,O
Their,O
prescriptions,O
will,O
be,O
guided,O
by,O
the,O
IDF,O
guidelines,O
.,O
After,O
8,O
weeks,O
of,O
routine,O
care,O
",",O
the,O
participants,O
will,O
be,O
enrolled,O
into,O
either,O
the,O
rebound,O
exercise,O
or,O
circuit,O
exercise,O
group,O
.,O
The,O
control,O
group,O
will,O
be,O
given,O
health,O
magazines,O
to,O
read,O
",",O
whereas,O
the,O
exercise,O
groups,O
will,O
be,O
engaged,O
in,O
the,O
exercise,O
programs,O
.,O
All,O
the,O
3,O
groups,O
will,O
receive,O
routine,O
medication,O
and,O
counseling,O
regarding,O
diet,O
",",O
weight,O
control,O
",",O
and,O
information,O
to,O
identify,O
",",O
minimize,O
",",O
or,O
avoid,O
complications,O
of,O
diabetes,B-DS
.,O
Measurement,O
The,O
following,O
measurement,O
would,O
be,O
taken,O
during,O
the,O
data,O
collection,O
they,O
are,O
as,O
follows,O
:,O
Sociodemographic,O
variables,O
:,O
The,O
sociodemographic,O
variables,O
of,O
the,O
participants,O
will,O
be,O
recorded,O
before,O
the,O
commencement,O
of,O
the,O
study,O
.,O
These,O
include,O
age,O
",",O
race,O
",",O
gender,O
",",O
height,O
",",O
weight,O
",",O
educational,O
level,O
",",O
duration,O
of,O
diabetes,B-DS
",",O
level,O
of,O
pain,O
",",O
blood,O
pressure,O
",",O
pulse,O
rate,O
",",O
and,O
heart,O
rate,O
.,O
Pain,O
intensity,O
:,O
The,O
alternate,O
visual,O
analog,O
scale,O
will,O
be,O
used,O
to,O
assess,O
the,O
pain,O
level,O
of,O
the,O
participants,O
.,O
The,O
participants,O
will,O
be,O
requested,O
to,O
rate,O
on,O
a,O
0,O
-,O
10,O
scale,O
",",O
the,O
level,O
of,O
pain,O
they,O
felt,O
6,O
weeks,O
before,O
and,O
at,O
present,O
.,O
On,O
the,O
scale,O
",",O
0,O
indicates,O
no,O
pain,O
or,O
no,O
interference,O
",",O
whereas,O
10,O
is,O
pain,O
as,O
bad,O
as,O
it,O
could,O
be,O
/,O
extreme,O
interference,O
[,O
26,O
].,O
The,O
alternate,O
visual,O
analogue,O
scale,O
has,O
been,O
reported,O
to,O
have,O
a,O
high,O
validity,O
",",O
increased,O
patient,O
compliance,O
",",O
greater,O
sensitivity,O
of,O
measurement,O
",",O
and,O
reduced,O
bias,O
[,O
26,O
].,O
BDI,O
:,O
This,O
will,O
be,O
used,O
to,O
assess,O
and,O
screen,O
participants,O
for,O
depression,B-DS
.,O
The,O
BDI,O
is,O
a,O
21,O
-,O
item,O
multiple,O
choice,O
self,O
-,O
reported,O
inventory,O
",",O
widely,O
used,O
to,O
assess,O
the,O
presence,O
and,O
degree,O
of,O
depression,B-DS
in,O
adolescents,O
and,O
adults,O
[,O
27,O
].,O
The,O
BDI,O
is,O
a,O
self,O
-,O
administered,O
questionnaire,O
and,O
it,O
has,O
a,O
high,O
test,O
-,O
retest,O
reliability,O
(,O
Pearson,O
r,O
).,O
QoL,O
:,O
The,O
General,O
Health,O
Survey,O
Short,O
Form,O
(,O
SF,O
-,O
36,O
),O
will,O
be,O
used,O
to,O
measure,O
changes,O
in,O
the,O
participant,O
’,O
s,O
QoL,O
.,O
The,O
instrument,O
has,O
shown,O
good,O
validity,O
and,O
reliability,O
of,O
Cronbach,O
alpha,O
of,O
.,O
85,O
and,O
reliability,O
coefficient,O
of,O
.,O
75,O
for,O
all,O
the,O
domains,O
except,O
social,O
functioning,O
[,O
28,O
].,O
The,O
short,O
form,O
",",O
SF,O
-,O
36,O
",",O
measures,O
perceived,O
health,O
in,O
the,O
areas,O
of,O
physical,O
functioning,O
",",O
role,O
-,O
physical,O
",",O
bodily,O
pain,O
",",O
general,O
health,O
",",O
vitality,O
",",O
social,O
functioning,O
",",O
role,O
-,O
emotional,O
",",O
and,O
mental,O
health,O
",",O
with,O
higher,O
scores,O
(,O
range,O
0,O
-,O
100,O
),O
reflecting,O
better,O
-,O
perceived,O
health,O
.,O
Biochemical,O
parameters,O
:,O
Fasting,O
blood,O
glucose,O
in,O
mmol,O
/,O
L,O
",",O
blood,O
total,O
cholesterol,O
(,O
TC,O
),O
in,O
mmol,O
/,O
L,O
",",O
low,O
-,O
density,O
lipoprotein,O
(,O
LDL,O
),O
mmol,O
/,O
L,O
",",O
very,O
low,O
-,O
density,O
lipoproteins,O
(,O
VLDL,O
),O
mmol,O
/,O
L,O
",",O
and,O
high,O
-,O
density,O
lipoprotein,O
(,O
HDL,O
),O
mmol,O
/,O
L,O
will,O
be,O
determined,O
at,O
baseline,O
and,O
after,O
8,O
weeks,O
of,O
the,O
program,O
.,O
A,O
blood,O
sample,O
will,O
be,O
taken,O
by,O
pinprick,O
using,O
Accu,O
-,O
check,O
Sofclix,O
Pro,O
Roche,O
Diabetes,B-DS
care,O
",",O
South,O
Africa,O
.,O
Then,O
",",O
the,O
following,O
parameters,O
will,O
be,O
evaluated,O
:,O
fasting,O
glucose,O
level,O
using,O
Accutrend,O
(,O
Roche,O
Diagnostics,O
",",O
GmbH,O
Germany,O
);,O
HDL,O
-,O
C,O
using,O
PEG,O
þ,O
cholesterol,B-GP
oxidase,I-GP
(,O
Roche,O
Diagnostics,O
GmbH,O
Germany,O
);,O
triglycerides,O
using,O
glycerol,O
phosphate,O
-,O
PAP,B-GP
(,O
Roche,O
Diagnostics,O
GmbH,O
Germany,O
);,O
and,O
TC,O
using,O
cholesterol,B-GP
oxidase,I-GP
-,O
PAP,B-GP
(,O
Roche,O
Diagnostics,O
GmbH,O
Germany,O
),O
to,O
evaluate,O
TC,O
",",O
LDL,O
",",O
VLDL,O
",",O
and,O
HDL,O
-,O
C,O
.,O
Pulmonary,O
parameters,O
:,O
Pulmonary,O
function,O
parameters,O
will,O
be,O
measured,O
at,O
baseline,O
and,O
after,O
the,O
8,O
weeks,O
of,O
the,O
study,O
using,O
Spiro,O
232,O
(,O
PK,O
Morgan,O
",",O
India,O
).,O
The,O
following,O
parameters,O
will,O
be,O
measured,O
:,O
Forced,O
expiratory,O
volume,O
in,O
first,O
second,O
(,O
FEV1,O
),O
(,O
It,O
"),",O
forced,O
vital,O
capacity,O
(,O
FVC,O
"),",O
FEV1,O
/,O
FVC,O
ratio,O
",",O
peak,O
expiratory,O
flow,O
rate,O
",",O
and,O
maximal,O
voluntary,O
ventilation,O
(,O
It,O
/,O
min,O
).,O
The,O
spirometer,O
will,O
be,O
connected,O
to,O
a,O
computer,O
that,O
will,O
record,O
all,O
the,O
values,O
.,O
Sample,O
Size,O
and,O
Power,O
Calculation,O
The,O
sample,O
size,O
(,O
N,O
),O
will,O
be,O
determined,O
using,O
Cohen,O
table,O
[,O
29,O
],O
at,O
alpha,O
=.,O
05,O
and,O
degree,O
of,O
freedom,O
(,O
µ,O
)=,O
k,O
−,O
1,O
",",O
where,O
k,O
is,O
the,O
number,O
of,O
groups,O
",",O
with,O
effect,O
size,O
f,O
=,O
0,O
.,O
35,O
.,O
From,O
the,O
previous,O
study,O
[,O
17,O
],O
and,O
power,O
(,O
w,O
),O
80,O
"%,",O
sample,O
size,O
n,O
=,O
20,O
.,O
Sample,O
size,O
(,O
N,O
),O
will,O
be,O
60,O
",",O
and,O
12,O
extra,O
participants,O
will,O
be,O
added,O
to,O
make,O
room,O
for,O
attrition,O
.,O
Therefore,O
",",O
the,O
sample,O
size,O
will,O
be,O
72,O
participants,O
",",O
and,O
each,O
group,O
will,O
be,O
24,O
participants,O
.,O
Randomization,O
and,O
Blinding,O
Randomization,O
will,O
be,O
conducted,O
using,O
a,O
computer,O
-,O
generated,O
random,O
allocation,O
sequence,O
schedule,O
conducted,O
by,O
a,O
physiotherapist,O
who,O
is,O
not,O
involved,O
in,O
the,O
research,O
and,O
has,O
experience,O
in,O
research,O
",",O
who,O
will,O
randomly,O
allocate,O
recruited,O
participants,O
into,O
the,O
rebound,O
exercise,O
group,O
",",O
circuit,O
training,O
group,O
",",O
and,O
the,O
control,O
group,O
.,O
To,O
eliminate,O
bias,O
",",O
the,O
assessment,O
of,O
outcome,O
will,O
be,O
performed,O
by,O
experienced,O
assessors,O
who,O
will,O
be,O
blinded,O
to,O
the,O
type,O
of,O
intervention,O
as,O
well,O
as,O
the,O
intervention,O
groups,O
of,O
the,O
participants,O
.,O
Participants,O
will,O
also,O
be,O
instructed,O
not,O
to,O
disclose,O
their,O
individual,O
intervention,O
groups,O
to,O
the,O
assessors,O
.,O
Figure,O
1,O
shows,O
the,O
flow,O
diagram,O
.,O
Procedures,O
Assessment,O
of,O
participants,O
will,O
be,O
conducted,O
at,O
2,O
stages,O
:,O
at,O
baseline,O
and,O
at,O
the,O
end,O
of,O
8,O
weeks,O
of,O
intervention,O
.,O
To,O
ensure,O
a,O
comprehensive,O
assessment,O
",",O
a,O
battery,O
of,O
measures,O
was,O
chosen,O
covering,O
the,O
WHO,O
-,O
ICF,O
model,O
[,O
30,O
].,O
Certain,O
tools,O
were,O
selected,O
to,O
cover,O
the,O
3,O
key,O
domains,O
proposed,O
by,O
the,O
ICF,O
:,O
body,O
structures,O
and,O
function,O
(,O
hematological,O
variables,O
",",O
MSKP,O
",",O
and,O
respiratory,O
parameters,O
"),",O
activity,O
",",O
and,O
participation,O
(,O
QoL,O
and,O
depression,B-DS
).,O
At,O
baseline,O
",",O
participants,O
will,O
be,O
assessed,O
for,O
sociodemographic,O
characteristics,O
",",O
which,O
will,O
include,O
personal,O
demographic,O
information,O
and,O
diabetes,B-DS
-,O
specific,O
information,O
.,O
The,O
personal,O
demographic,O
information,O
will,O
include,O
age,O
",",O
sex,O
",",O
height,O
",",O
weight,O
",",O
marital,O
status,O
",",O
educational,O
qualification,O
",",O
and,O
employment,O
.,O
The,O
diabetes,B-DS
-,O
specific,O
information,O
will,O
include,O
type,O
of,O
diabetes,B-DS
and,O
duration,O
since,O
diagnosis,O
.,O
At,O
the,O
baseline,O
",",O
the,O
outcome,O
measures,O
to,O
be,O
used,O
for,O
these,O
assessments,O
are,O
presented,O
in,O
the,O
measurement,O
section,O
.,O
Table,O
1,O
shows,O
the,O
instruments,O
.,O
Data,O
Management,O
Data,O
from,O
the,O
trial,O
will,O
be,O
monitored,O
by,O
regularly,O
scrutinizing,O
data,O
files,O
for,O
omissions,O
and,O
errors,O
.,O
All,O
manually,O
entered,O
data,O
will,O
be,O
double,O
entered,O
",",O
and,O
the,O
source,O
of,O
any,O
inconsistencies,O
will,O
be,O
explored,O
and,O
resolved,O
.,O
Electronic,O
data,O
will,O
be,O
stored,O
on,O
password,O
-,O
protected,O
servers,O
at,O
the,O
Department,O
of,O
Physiotherapy,O
",",O
School,O
of,O
Health,O
Sciences,O
",",O
University,O
of,O
KwaZulu,O
-,O
Natal,O
",",O
Durban,O
",",O
and,O
written,O
forms,O
and,O
data,O
will,O
be,O
stored,O
in,O
locked,O
filing,O
cabinets,O
at,O
the,O
Department,O
of,O
Physiotherapy,O
",",O
School,O
of,O
Health,O
Sciences,O
",",O
University,O
of,O
KwaZulu,O
-,O
Natal,O
",",O
Durban,O
.,O
Data,O
will,O
only,O
be,O
accessible,O
to,O
the,O
researcher,O
.,O
Each,O
participant,O
in,O
the,O
study,O
will,O
be,O
provided,O
with,O
an,O
identification,O
number,O
.,O
All,O
recorded,O
data,O
will,O
be,O
coded,O
using,O
this,O
number,O
.,O
CONSORT,O
flow,O
chart,O
.,O
Study,O
assessment,O
tools,O
.,O
Scales,O
or,O
tools,O
Function,O
or,O
applications,O
Metronome,O
To,O
provide,O
signals,O
for,O
participants,O
during,O
exercises,O
Mini,O
trampoline,O
For,O
rebound,O
exercise,O
Treadmill,O
For,O
aerobic,O
component,O
of,O
circuit,O
training,O
Biodata,O
form,O
To,O
record,O
the,O
sociodemographic,O
variables,O
of,O
participants,O
Alternate,O
visual,O
analog,O
scale,O
To,O
assess,O
change,O
in,O
pain,O
scores,O
of,O
participants,O
Beck,O
Depression,B-DS
Inventory,O
To,O
assess,O
change,O
in,O
depression,B-DS
of,O
participants,O
General,O
health,O
survey,O
short,O
form,O
(,O
SF,O
-,O
36,O
),O
To,O
assess,O
change,O
in,O
quality,O
of,O
life,O
of,O
participants,O
Accutrend,O
plus,O
To,O
assess,O
the,O
fasting,O
glucose,O
-,O
level,O
change,O
and,O
cholesterol,O
-,O
level,O
change,O
in,O
participants,O
Spiro232,O
The,O
spirometer,O
will,O
be,O
used,O
to,O
measure,O
change,O
in,O
forced,O
expiratory,O
volume,O
",",O
forced,O
vital,O
capacity,O
",",O
peak,O
expiratory,O
flow,O
rate,O
",",O
and,O
maximal,O
voluntary,O
ventilation,O
Data,O
Analysis,O
Preliminary,O
analysis,O
will,O
be,O
performed,O
to,O
test,O
the,O
normality,O
of,O
the,O
data,O
using,O
the,O
Kolmogorov,O
V,O
-,O
Smirnov,O
test,O
before,O
the,O
analysis,O
.,O
Demographic,O
data,O
will,O
be,O
analyzed,O
using,O
descriptive,O
statistics,O
",",O
whereas,O
data,O
on,O
QoL,O
and,O
depression,B-DS
will,O
be,O
analyzed,O
within,O
the,O
group,O
using,O
the,O
Wilcoxon,O
signed,O
rank,O
test,O
and,O
between,O
the,O
groups,O
using,O
the,O
Kruskal,O
-,O
Wallis,O
test,O
.,O
Post,O
hoc,O
test,O
will,O
be,O
used,O
for,O
any,O
significant,O
F,O
values,O
.,O
The,O
paired,O
t,O
test,O
will,O
be,O
used,O
within,O
the,O
group,O
for,O
pain,O
scores,O
",",O
fasting,O
glucose,O
",",O
and,O
cholesterol,O
level,O
of,O
the,O
participants,O
and,O
between,O
groups,O
using,O
1,O
-,O
way,O
multivariate,O
analysis,O
of,O
variance,O
.,O
Post,O
hoc,O
test,O
will,O
be,O
used,O
for,O
any,O
significant,O
F,O
values,O
.,O
The,O
level,O
of,O
significance,O
will,O
be,O
set,O
at,O
.,O
05,O
.,O
The,O
SPSS,O
version,O
23,O
will,O
be,O
used,O
for,O
the,O
analysis,O
.,O
Ethics,O
and,O
Informed,O
Consent,O
Ethical,O
approval,O
was,O
sought,O
and,O
obtained,O
from,O
the,O
University,O
of,O
KwaZulu,O
-,O
Natal,O
Biomedical,O
Research,O
Ethics,O
Committee,O
South,O
Africa,O
(,O
BREC,O
/,O
BF,O
/,O
371,O
/,O
17,O
),O
and,O
registered,O
with,O
Clinicaltrials,O
.,O
gov,O
:,O
NCT03200795,O
.,O
Informed,O
consent,O
will,O
also,O
be,O
obtained,O
from,O
the,O
participants,O
.,O
Results,O
The,O
results,O
of,O
this,O
study,O
are,O
expected,O
to,O
provide,O
additional,O
information,O
on,O
the,O
effect,O
of,O
rebound,O
exercise,O
and,O
circuit,O
training,O
in,O
the,O
management,O
of,O
patients,O
with,O
musculoskeletal,O
complications,O
of,O
diabetes,B-DS
in,O
South,O
Africa,O
.,O
It,O
is,O
hoped,O
that,O
it,O
will,O
lead,O
to,O
improvement,O
in,O
the,O
QoL,O
",",O
reduction,O
in,O
MSKP,O
and,O
depression,B-DS
",",O
improvement,O
in,O
glycemic,O
control,O
",",O
reduction,O
in,O
cholesterol,O
level,O
",",O
as,O
well,O
as,O
improvement,O
in,O
respiratory,O
capacity,O
of,O
type,B-DS
2,I-DS
diabetes,I-DS
patients,O
.,O
It,O
is,O
also,O
expected,O
to,O
give,O
information,O
about,O
which,O
of,O
the,O
exercises,O
is,O
most,O
effective,O
in,O
the,O
management,O
of,O
patients,O
with,O
musculoskeletal,O
diabetes,B-DS
complications,I-DS
in,O
terms,O
of,O
pain,O
relief,O
",",O
glycemic,O
control,O
",",O
cholesterol,O
level,O
",",O
improvement,O
in,O
QoL,O
",",O
level,O
of,O
depression,B-DS
",",O
and,O
respiratory,O
capacity,O
.,O
Discussion,O
Though,O
different,O
additional,O
strategies,O
such,O
as,O
exercise,O
and,O
dietary,O
and,O
lifestyle,O
modifications,O
exist,O
for,O
the,O
control,O
of,O
type,B-DS
2,I-DS
diabetes,I-DS
",",O
they,O
are,O
mostly,O
applied,O
for,O
the,O
control,O
of,O
glucose,O
level,O
.,O
No,O
strategies,O
have,O
been,O
identified,O
for,O
the,O
control,O
of,O
complications,O
associated,O
with,O
diabetes,B-DS
such,O
as,O
MSKP,O
",",O
depression,B-DS
",",O
and,O
reduction,O
in,O
the,O
QoL,O
.,O
To,O
date,O
no,O
additional,O
rehabilitation,O
[,O
31,O
],O
that,O
is,O
aimed,O
at,O
alleviating,O
MSKP,O
associated,O
with,O
diabetes,B-DS
complication,I-DS
.,O
Exercises,O
in,O
the,O
management,O
of,O
type,B-DS
2,I-DS
DM,I-DS
are,O
of,O
different,O
type,O
of,O
different,O
modes,O
and,O
intensity,O
",",O
most,O
of,O
the,O
exercises,O
are,O
aerobic,O
in,O
nature,O
and,O
involves,O
weight,O
bearing,O
",",O
and,O
strength,O
training,O
",",O
mostly,O
targeted,O
for,O
glycemic,O
control,O
",",O
cholesterol,O
",",O
and,O
few,O
in,O
QoL,O
.,O
Exercises,O
that,O
are,O
nonweight,O
bearing,O
",",O
such,O
as,O
rebound,O
exercises,O
",",O
and,O
that,O
require,O
less,O
equipment,O
are,O
used,O
in,O
the,O
management,O
of,O
type,B-DS
2,I-DS
diabetes,I-DS
[,O
23,O
].,O
Studies,O
on,O
rebound,O
exercises,O
mostly,O
focus,O
on,O
the,O
glycemic,O
control,O
and,O
change,O
in,O
cholesterol,O
level,O
.,O
This,O
trial,O
is,O
focused,O
on,O
the,O
effect,O
of,O
exercises,O
such,O
as,O
rebound,O
exercise,O
on,O
respiratory,O
parameters,O
",",O
MSKP,O
",",O
and,O
QoL,O
.,O
The,O
current,O
literature,O
suggests,O
that,O
emphasis,O
in,O
any,O
current,O
trial,O
in,O
the,O
management,O
of,O
type,B-DS
2,I-DS
DM,I-DS
should,O
focus,O
on,O
QoL,O
",",O
respiratory,O
capacity,O
",",O
and,O
psychosocial,O
variables,O
[,O
32,O
-,O
34,O
].,O
Moreover,O
",",O
if,O
studies,O
on,O
exercises,O
among,O
patients,O
with,O
diabetes,B-DS
focus,O
on,O
respiratory,O
and,O
musculoskeletal,O
complications,O
",",O
they,O
are,O
likely,O
to,O
result,O
in,O
improved,O
functions,O
and,O
reduce,O
complications,O
.,O
The,O
possible,O
limitation,O
of,O
this,O
protocol,O
is,O
that,O
it,O
is,O
limited,O
to,O
the,O
short,O
-,O
term,O
effect,O
.,O
It,O
is,O
hoped,O
that,O
subsequent,O
trials,O
will,O
look,O
into,O
the,O
long,O
-,O
term,O
effect,O
of,O
both,O
rebound,O
exercise,O
and,O
circuit,O
training,O
in,O
the,O
management,O
of,O
MSKP,O
associated,O
with,O
diabetes,B-DS
.,O
Conflicts,O
of,O
Interest,O
:,O
,O
declared,O
.,O
Sialylation,O
of,O
the,O
prion,B-GP
protein,O
glycans,O
controls,O
prion,B-GP
replication,O
rate,O
and,O
glycoform,O
ratio,O
Prion,B-GP
or,O
PrPSc,O
is,O
a,O
proteinaceous,O
infectious,O
agent,O
that,O
consists,O
of,O
a,O
misfolded,O
and,O
aggregated,O
form,O
of,O
a,O
sialoglycoprotein,B-GP
called,O
prion,B-GP
protein,O
or,O
PrPC,O
.,O
PrPC,O
has,O
two,O
sialylated,O
N,O
-,O
linked,O
carbohydrates,O
.,O
In,O
PrPSc,O
",",O
the,O
glycans,O
are,O
directed,O
outward,O
",",O
with,O
the,O
terminal,O
sialic,O
acid,O
residues,O
creating,O
a,O
negative,O
charge,O
on,O
the,O
surface,O
of,O
prion,B-GP
particles,O
.,O
The,O
current,O
study,O
proposes,O
a,O
new,O
hypothesis,O
that,O
electrostatic,O
repulsion,O
between,O
sialic,O
residues,O
creates,O
structural,O
constraints,O
that,O
control,O
prion,B-GP
replication,O
and,O
PrPSc,O
glycoform,O
ratio,O
.,O
In,O
support,O
of,O
this,O
hypothesis,O
",",O
here,O
we,O
show,O
that,O
diglycosylated,O
PrPC,O
molecules,O
that,O
have,O
more,O
sialic,O
groups,O
per,O
molecule,O
than,O
monoglycosylated,O
PrPC,O
were,O
preferentially,O
excluded,O
from,O
conversion,O
.,O
However,O
",",O
when,O
partially,O
desialylated,O
PrPC,O
was,O
used,O
as,O
a,O
substrate,O
",",O
recruitment,O
of,O
three,O
glycoforms,O
into,O
PrPSc,O
was,O
found,O
to,O
be,O
proportional,O
to,O
their,O
respective,O
populations,O
in,O
the,O
substrate,O
.,O
In,O
addition,O
",",O
hypersialylated,O
molecules,O
were,O
also,O
excluded,O
from,O
conversion,O
in,O
the,O
strains,O
with,O
the,O
strongest,O
structural,O
constraints,O
",",O
a,O
strategy,O
that,O
helped,O
reduce,O
electrostatic,O
repulsion,O
.,O
Moreover,O
",",O
as,O
predicted,O
by,O
the,O
hypothesis,O
",",O
partial,O
desialylation,O
of,O
PrPC,O
significantly,O
increased,O
the,O
replication,O
rate,O
.,O
This,O
study,O
illustrates,O
that,O
sialylation,O
of,O
N,O
-,O
linked,O
glycans,O
creates,O
a,O
prion,B-GP
replication,O
barrier,O
that,O
controls,O
replication,O
rate,O
and,O
glycoform,O
ratios,O
and,O
has,O
broad,O
implications,O
.,O
Prion,B-DS
diseases,I-DS
are,O
a,O
family,O
of,O
lethal,O
",",O
transmissible,O
",",O
neurodegenerative,B-DS
disorders,I-DS
that,O
can,O
be,O
sporadic,O
",",O
inheritable,O
or,O
transmissible,O
in,O
origin12,O
.,O
A,O
central,O
event,O
underlying,O
the,O
molecular,O
mechanism,O
of,O
prion,B-DS
diseases,I-DS
involves,O
conformational,O
changes,O
of,O
the,O
cellular,O
form,O
of,O
the,O
prion,B-GP
protein,O
(,O
PrPC,O
),O
into,O
the,O
disease,O
-,O
associated,O
transmissible,O
form,O
(,O
PrPSc,O
),O
1,O
.,O
Multiple,O
alternative,O
",",O
conformationally,O
distinct,O
",",O
self,O
-,O
replicating,O
states,O
referred,O
to,O
as,O
prion,B-GP
strains,O
that,O
give,O
rise,O
to,O
different,O
prion,B-DS
disease,I-DS
phenotypes,O
can,O
be,O
produced,O
within,O
the,O
same,O
host,O
or,O
PrPC,O
amino,O
acid,O
sequence3456,O
.,O
Among,O
the,O
parameters,O
identified,O
over,O
the,O
years,O
that,O
control,O
prion,B-GP
transmission,O
and,O
replication,O
are,O
the,O
amino,O
acid,O
sequence,O
of,O
PrPC,O
and,O
strain,O
-,O
specific,O
structure,O
of,O
PrPSc7,O
.,O
PrPC,O
is,O
subject,O
to,O
two,O
types,O
of,O
posttranslational,O
modifications,O
",",O
which,O
include,O
attachment,O
of,O
GPI,O
anchor,O
to,O
the,O
C,O
-,O
terminal,O
residue,O
Ser,O
-,O
231,O
and,O
up,O
to,O
two,O
N,O
-,O
linked,O
carbohydrates,O
to,O
residues,O
Asn,O
-,O
181,O
and,O
Asn,O
-,O
197891011,O
.,O
Roles,O
of,O
N,O
-,O
linked,O
glycans,O
and,O
the,O
GPI,O
-,O
anchor,O
in,O
prion,B-GP
transmission,O
",",O
spread,O
",",O
and,O
pathogenesis,O
have,O
been,O
the,O
subjects,O
of,O
a,O
number,O
of,O
studies,O
in,O
the,O
last,O
decade1213141516,O
.,O
The,O
N,O
-,O
linked,O
glycans,O
are,O
sialylated,O
at,O
the,O
terminal,O
positions,O
",",O
with,O
each,O
glycan,O
being,O
able,O
to,O
carry,O
up,O
to,O
five,O
sialic,O
acid,O
residues17,O
.,O
Despite,O
the,O
discovery,O
of,O
PrP,B-GP
sialylation,O
more,O
than,O
25,O
years,O
ago,O
",",O
the,O
potential,O
role,O
of,O
sialylation,O
in,O
prion,B-GP
replication,O
has,O
not,O
been,O
explored,O
.,O
Terminal,O
sialylation,O
of,O
glycans,O
significantly,O
alters,O
the,O
physical,O
properties,O
of,O
both,O
states,O
",",O
PrPC,O
and,O
PrPSc,O
.,O
In,O
the,O
absence,O
of,O
posttranslational,O
modifications,O
",",O
the,O
theoretical,O
pI,O
of,O
the,O
full,O
-,O
length,O
prion,B-GP
protein,O
is,O
9,O
.,O
6,O
and,O
the,O
estimated,O
charge,O
at,O
pH,O
7,O
.,O
5,O
is,O
+,O
9,O
.,O
518,O
.,O
However,O
",",O
due,O
to,O
glycan,O
sialylation,O
",",O
the,O
actual,O
pI,O
of,O
PrP,B-GP
molecules,O
was,O
found,O
to,O
be,O
highly,O
heterogeneous,O
and,O
spread,O
from,O
pH,O
9,O
.,O
6,O
to,O
acidic,O
pH1819,O
.,O
In,O
intact,O
PrPSc,O
",",O
the,O
glycans,O
are,O
believed,O
to,O
be,O
directed,O
outwards,O
",",O
with,O
the,O
terminal,O
sialic,O
acid,O
residues,O
located,O
at,O
the,O
interface,O
with,O
the,O
extracellular,O
environment,O
or,O
solvent202122,O
.,O
Because,O
sialic,O
acid,O
residues,O
create,O
a,O
dense,O
negative,O
charge,O
on,O
the,O
PrPSc,O
surface,O
",",O
glycan,O
sialylation,O
might,O
play,O
a,O
major,O
role,O
in,O
modulating,O
interactions,O
between,O
PrPSc,O
and,O
PrPC,O
and,O
defining,O
prion,B-GP
replication,O
rate,O
.,O
In,O
previous,O
study,O
",",O
we,O
showed,O
that,O
sialylation,O
level,O
of,O
PrPSc,O
controls,O
prion,B-GP
infectivity18,O
.,O
We,O
also,O
noticed,O
that,O
changes,O
in,O
sialylation,O
levels,O
of,O
PrPC,O
influence,O
PrPSc,O
replication,O
rate,O
and,O
the,O
ratio,O
of,O
three,O
glycoforms,O
within,O
newly,O
formed,O
PrPSc,O
.,O
These,O
findings,O
led,O
to,O
a,O
new,O
hypothesis,O
that,O
electrostatic,O
repulsion,O
between,O
sialic,O
acid,O
residues,O
creates,O
a,O
replication,O
barrier,O
that,O
slows,O
down,O
prion,B-GP
replication,O
.,O
Moreover,O
",",O
as,O
diglycosylated,O
glycoforms,O
have,O
more,O
sialic,O
acid,O
residues,O
per,O
PrP,B-GP
molecule,O
than,O
mono,O
-,O
or,O
unglycosylated,O
glycoforms,O
",",O
this,O
hypothesis,O
also,O
proposes,O
that,O
sialylation,O
controls,O
PrPSc,O
glycoform,O
ratios,O
.,O
In,O
previous,O
studies,O
that,O
examined,O
prions,O
formed,O
in,O
familial,O
and,O
sporadic,O
prion,B-DS
diseases,I-DS
",",O
the,O
three,O
glycoforms,O
were,O
found,O
to,O
be,O
recruited,O
into,O
PrPSc,O
in,O
a,O
selective,O
fashion23,O
.,O
PrPSc,O
glycoform,O
ratios,O
are,O
believed,O
to,O
be,O
an,O
intrinsic,O
characteristic,O
of,O
prion,B-GP
strains,O
or,O
subtypes,O
and,O
",",O
as,O
such,O
",",O
have,O
been,O
used,O
for,O
strain,O
typing2425,O
.,O
However,O
",",O
it,O
still,O
remains,O
puzzling,O
as,O
to,O
why,O
the,O
proportions,O
of,O
three,O
glycoforms,O
vary,O
in,O
a,O
strain,O
-,O
specific,O
manner,O
",",O
even,O
within,O
the,O
same,O
host,O
.,O
Here,O
we,O
propose,O
that,O
diglycosylated,O
glycoforms,O
are,O
selectively,O
excluded,O
to,O
reduce,O
electrostatic,O
repulsion,O
between,O
sialic,O
acid,O
residues,O
within,O
PrPSc,O
.,O
The,O
current,O
study,O
tests,O
the,O
above,O
hypothesis,O
on,O
the,O
role,O
of,O
sialylation,O
in,O
controlling,O
the,O
prion,B-GP
replication,O
barrier,O
and,O
glycoform,O
ratios,O
.,O
Results,O
Sialylation,O
status,O
controls,O
strain,O
-,O
specific,O
glycoform,O
ratio,O
of,O
PrPSc,O
For,O
establishing,O
a,O
relationship,O
between,O
sialylation,O
status,O
and,O
glycoform,O
ratios,O
",",O
a,O
panel,O
of,O
hamster,B-OG
(,O
263K,O
",",O
HY,O
",",O
DY,O
and,O
SSLOW,O
),O
and,O
mouse,B-OG
(,O
ME7,O
",",O
22L,O
and,O
RML,O
),O
strains,O
were,O
employed,O
.,O
To,O
produce,O
PrPSc,O
with,O
reduced,O
sialylation,O
levels,O
",",O
normal,O
brain,O
homogenate,O
(,O
NBH,O
),O
was,O
treated,O
with,O
sialidase,B-GP
from,O
Arthrobacter,B-OG
ureafaciens,I-OG
",",O
which,O
has,O
broad,O
substrate,O
specificity,O
and,O
cleaves,O
α2,O
–,O
3,O
and,O
α2,O
–,O
6,O
linked,O
sialic,O
acid,O
residues,O
on,O
N,O
-,O
linked,O
glycans,O
.,O
Sialidase,B-GP
treated,O
NBH,O
was,O
used,O
as,O
a,O
substrate,O
for,O
PMCAb,O
(,O
a,O
PMCAb,O
format,O
that,O
utilizes,O
desialylated,O
substrate,O
will,O
be,O
referred,O
to,O
as,O
dsPMCAb,O
),O
as,O
previously,O
described18,O
.,O
Western,O
blots,O
were,O
used,O
to,O
compare,O
the,O
glycoform,O
ratios,O
in,O
PrPSc,O
and,O
dsPMCAb,O
products,O
(,O
Fig,O
.,O
1,O
).,O
All,O
mouse,B-OG
and,O
hamster,B-OG
strains,O
tested,O
showed,O
significant,O
increase,O
in,O
diglycosylated,O
glycoforms,O
at,O
the,O
expense,O
of,O
mono,O
-,O
and,O
unglycosylated,O
glycoforms,O
in,O
dsPMCAb,O
products,O
in,O
comparison,O
to,O
corresponding,O
brain,O
-,O
derived,O
materials,O
(,O
Fig,O
.,O
1A,O
",",O
B,O
).,O
All,O
three,O
mouse,B-OG
strains,O
(,O
ME7,O
",",O
22L,O
",",O
RML,O
),O
showed,O
considerable,O
amounts,O
of,O
mono,O
-,O
and,O
unglycosylated,O
glycoforms,O
in,O
dsPMCAb,O
products,O
relative,O
to,O
that,O
of,O
dsPMCAb,O
-,O
derived,O
material,O
of,O
hamster,B-OG
strains,O
(,O
263K,O
",",O
HY,O
",",O
DY,O
",",O
SSLOW,O
).,O
This,O
higher,O
proportion,O
of,O
mono,O
-,O
and,O
non,O
-,O
glycosylated,O
forms,O
is,O
a,O
distinct,O
trait,O
of,O
mouse,B-OG
strains,O
",",O
as,O
all,O
brain,O
-,O
derived,O
mouse,B-OG
materials,O
also,O
showed,O
higher,O
proportions,O
of,O
mono,O
-,O
and,O
unglycosylated,O
forms,O
relative,O
to,O
those,O
of,O
hamster,B-OG
strains26,O
.,O
Nevertheless,O
",",O
a,O
considerable,O
shift,O
in,O
glycoform,O
ratios,O
in,O
favor,O
of,O
diglycosylated,O
forms,O
was,O
observed,O
in,O
all,O
mouse,B-OG
and,O
hamster,B-OG
strains,O
.,O
The,O
differences,O
in,O
sialylation,O
status,O
between,O
brain,O
-,O
and,O
dsPMCAb,O
-,O
derived,O
materials,O
were,O
analyzed,O
using,O
2D,O
gel,O
electrophoresis,O
.,O
The,O
two,O
N,O
-,O
linked,O
glycans,O
can,O
carry,O
up,O
to,O
five,O
terminal,O
sialic,O
acid,O
residues,O
each,O
adding,O
negative,O
charges,O
to,O
individual,O
PrP,B-GP
molecules17,O
.,O
Because,O
the,O
samples,O
were,O
denatured,O
prior,O
to,O
2D,O
gel,O
electrophoresis,O
",",O
the,O
distribution,O
of,O
charge,O
isoforms,O
in,O
the,O
horizontal,O
dimension,O
reflects,O
sialylation,O
status,O
of,O
individual,O
PrP,B-GP
molecules,O
",",O
where,O
hypersialylated,O
molecules,O
run,O
toward,O
acidic,O
pH,O
and,O
hyposialylated,O
toward,O
basic,O
pH18,O
.,O
Consistent,O
with,O
previous,O
studies2728,O
",",O
unglycosylated,O
forms,O
that,O
lack,O
glycans,O
and,O
glycan,O
-,O
linked,O
sialylation,O
typically,O
showed,O
more,O
than,O
one,O
charge,O
isoforms,O
(,O
Fig,O
.,O
2,O
).,O
This,O
charge,O
heterogeneity,O
is,O
attributed,O
to,O
the,O
structural,O
heterogeneity,O
of,O
the,O
GPI,O
anchors,O
",",O
a,O
fraction,O
of,O
which,O
could,O
be,O
also,O
subject,O
to,O
single,O
sialylation8,O
.,O
Unglycosylated,O
forms,O
could,O
serve,O
as,O
a,O
reference,O
for,O
charge,O
heterogeneity,O
resolved,O
by,O
2D,O
not,O
attributable,O
to,O
sialylation,O
of,O
N,O
-,O
linked,O
glycans,O
.,O
For,O
all,O
strains,O
tested,O
",",O
the,O
distribution,O
of,O
dsPMCAb,O
-,O
derived,O
products,O
was,O
shifted,O
towards,O
basic,O
pH,O
relative,O
to,O
that,O
of,O
brain,O
-,O
derived,O
materials,O
as,O
expected,O
(,O
Fig,O
.,O
2,O
).,O
Such,O
shifts,O
document,O
changes,O
in,O
sialylation,O
status,O
of,O
dsPMCAb,O
-,O
derived,O
materials,O
that,O
were,O
produced,O
from,O
a,O
partially,O
desialylated,O
substrate,O
.,O
To,O
analyze,O
individual,O
sialylation,O
profiles,O
",",O
charged,O
isoforms,O
were,O
separated,O
arbitrarily,O
into,O
two,O
categories,O
",",O
as,O
described,O
in,O
Methods,O
.,O
Isoforms,O
located,O
toward,O
acidic,O
pH,O
from,O
pI,O
7,O
.,O
5,O
will,O
be,O
designated,O
as,O
hypersialylated,O
and,O
those,O
toward,O
basic,O
pH,O
will,O
be,O
designated,O
as,O
hyposialylated,O
.,O
The,O
percentage,O
of,O
sum,O
intensities,O
of,O
hypersialylated,O
isoforms,O
relative,O
to,O
the,O
total,O
intensities,O
of,O
all,O
isoforms,O
was,O
used,O
to,O
compare,O
the,O
samples,O
.,O
To,O
establish,O
a,O
correlation,O
between,O
sialylation,O
status,O
and,O
glycoform,O
ratio,O
",",O
the,O
percentage,O
of,O
PrPSc,O
diglycosylated,O
forms,O
was,O
plotted,O
as,O
a,O
function,O
of,O
the,O
percentage,O
of,O
hypersialylated,O
isoforms,O
for,O
brain,O
-,O
and,O
dsPMCAb,O
-,O
derived,O
materials,O
(,O
Fig,O
.,O
3,O
).,O
This,O
plot,O
revealed,O
a,O
relationship,O
between,O
sialylation,O
status,O
and,O
glycoform,O
ratio,O
:,O
a,O
decrease,O
in,O
sialylation,O
levels,O
of,O
dsPMCA,O
-,O
derived,O
products,O
always,O
resulted,O
in,O
considerable,O
increase,O
in,O
recruitment,O
of,O
diglycosylated,O
forms,O
into,O
PrPSc,O
at,O
the,O
expense,O
of,O
mono,O
-,O
and,O
unglycosylated,O
glycoforms,O
.,O
This,O
correlation,O
was,O
observed,O
for,O
all,O
strains,O
tested,O
from,O
two,O
different,O
hosts,O
.,O
In,O
summary,O
",",O
the,O
changes,O
in,O
glycoform,O
ratios,O
in,O
response,O
to,O
changes,O
in,O
sialylation,O
status,O
support,O
the,O
hypothesis,O
that,O
negative,O
charges,O
of,O
sialic,O
acid,O
residues,O
create,O
electrostatic,O
repulsion,O
that,O
limits,O
recruitments,O
of,O
diglycosylated,O
glycoforms,O
.,O
Partial,O
desialylation,O
of,O
PrPC,O
abolishes,O
electrostatic,O
repulsion,O
",",O
and,O
as,O
a,O
result,O
",",O
the,O
proportion,O
of,O
diglycosylated,O
glycoforms,O
rises,O
.,O
The,O
following,O
testable,O
predictions,O
were,O
postulated,O
based,O
on,O
the,O
above,O
hypothesis,O
.,O
First,O
",",O
it,O
is,O
predicted,O
that,O
negative,O
selection,O
of,O
diglycosylated,O
forms,O
upon,O
conversion,O
of,O
PrPC,O
into,O
PrPSc,O
takes,O
place,O
",",O
i,O
.,O
e,O
the,O
proportion,O
of,O
diglycosylated,O
glycoforms,O
in,O
PrPSc,O
should,O
be,O
lower,O
than,O
that,O
in,O
PrPC,O
.,O
The,O
extent,O
of,O
negative,O
selection,O
should,O
depend,O
on,O
a,O
strain,O
-,O
specific,O
structure,O
and,O
degree,O
of,O
electrostatic,O
repulsion,O
.,O
For,O
strain,O
structures,O
with,O
close,O
proximity,O
of,O
glycan,O
moieties,O
",",O
the,O
negative,O
selection,O
should,O
be,O
the,O
strongest,O
.,O
Second,O
",",O
to,O
counteract,O
electrostatic,O
repulsion,O
",",O
it,O
is,O
predicted,O
that,O
negative,O
selection,O
of,O
hypersialylated,O
diglycosylated,O
isoforms,O
takes,O
place,O
in,O
addition,O
to,O
negative,O
selection,O
of,O
diglycosylated,O
forms,O
in,O
general,O
.,O
This,O
negative,O
selection,O
should,O
be,O
the,O
strongest,O
for,O
those,O
strains,O
that,O
show,O
the,O
strongest,O
negative,O
selection,O
of,O
diglycosylated,O
glycoforms,O
",",O
i,O
.,O
e,O
.,O
for,O
strains,O
with,O
the,O
highest,O
proportion,O
of,O
monoglycosylated,O
forms,O
.,O
Third,O
",",O
if,O
glycan,O
sialylation,O
indeed,O
creates,O
a,O
barrier,O
for,O
prion,B-GP
conversion,O
",",O
desialylation,O
of,O
PrPC,O
is,O
predicted,O
to,O
remove,O
this,O
barrier,O
and,O
lead,O
to,O
an,O
increase,O
in,O
prion,B-GP
amplification,O
rates,O
.,O
Negative,O
selection,O
of,O
diglycosylated,O
forms,O
upon,O
conversion,O
of,O
PrPC,O
into,O
PrPSc,O
To,O
test,O
whether,O
diglycosylated,O
forms,O
are,O
underrepresented,O
in,O
PrPSc,O
in,O
comparison,O
to,O
that,O
of,O
PrPC,O
",",O
glycoform,O
profiles,O
of,O
three,O
mouse,B-OG
strains,O
were,O
compared,O
to,O
that,O
of,O
mouse,B-OG
PrPC,O
(,O
Fig,O
.,O
1A,O
",",O
C,O
–,O
E,O
).,O
Consistent,O
with,O
previous,O
studies26,O
",",O
in,O
PrPC,O
the,O
diglycosylated,O
forms,O
were,O
found,O
to,O
be,O
predominant,O
",",O
while,O
unglycosylated,O
were,O
the,O
least,O
represented,O
(,O
Fig,O
.,O
1C,O
).,O
In,O
PrPSc,O
of,O
all,O
three,O
strains,O
",",O
the,O
proportion,O
of,O
di,O
-,O
versus,O
mono,O
-,O
and,O
unglycosylated,O
forms,O
shifted,O
in,O
favor,O
of,O
mono,O
-,O
and,O
unglycosylated,O
glycoforms,O
(,O
Fig,O
.,O
1A,O
",",O
B,O
).,O
This,O
result,O
argues,O
that,O
the,O
diglycosylated,O
form,O
is,O
subject,O
to,O
negative,O
selection,O
upon,O
conversion,O
of,O
PrPC,O
into,O
PrPSc,O
.,O
The,O
shift,O
was,O
most,O
substantial,O
for,O
the,O
RML,O
strain,O
",",O
illustrating,O
that,O
the,O
extent,O
of,O
a,O
negative,O
selection,O
is,O
determined,O
by,O
a,O
strain,O
-,O
specific,O
structure,O
.,O
Remarkably,O
",",O
upon,O
desialylation,O
of,O
the,O
substrate,O
",",O
the,O
dsPMCA,O
-,O
derived,O
products,O
showed,O
a,O
glycoform,O
profile,O
reminiscent,O
of,O
that,O
of,O
normal,O
substrate,O
",",O
where,O
diglycosylated,O
forms,O
were,O
predominant,O
(,O
Fig,O
.,O
1C,O
",",O
E,O
).,O
Moreover,O
",",O
in,O
dsPMCA,O
-,O
derived,O
products,O
all,O
three,O
strains,O
exhibited,O
a,O
very,O
similar,O
glycoform,O
profile,O
(,O
Fig,O
.,O
1E,O
).,O
These,O
results,O
demonstrate,O
that,O
reducing,O
the,O
content,O
of,O
sialic,O
acid,O
residues,O
on,O
PrPC,O
glycans,O
result,O
in,O
recruitment,O
of,O
the,O
three,O
glycoforms,O
into,O
PrPSc,O
proportionally,O
to,O
their,O
relative,O
populations,O
in,O
a,O
substrate,O
.,O
A,O
similar,O
trend,O
was,O
found,O
in,O
hamster,B-OG
strains,O
",",O
although,O
it,O
was,O
less,O
pronounced,O
(,O
Fig,O
.,O
1B,O
"),",O
because,O
diglycosylated,O
forms,O
were,O
predominant,O
in,O
brain,O
-,O
derived,O
PrPSc,O
.,O
Together,O
",",O
these,O
results,O
illustrate,O
that,O
diglycosylated,O
glycoforms,O
are,O
underrepresented,O
in,O
PrPSc,O
",",O
the,O
extent,O
of,O
this,O
effect,O
is,O
strain,O
-,O
and,O
species,O
-,O
specific,O
",",O
and,O
that,O
PrPSc,O
structures,O
of,O
hamster,B-OG
strains,O
accommodate,O
diglycosylated,O
glycoforms,O
better,O
than,O
those,O
of,O
mouse,B-OG
strains,O
.,O
Negative,O
selection,O
of,O
hypersialylated,O
diglycosylated,O
isoforms,O
Among,O
three,O
glycoforms,O
",",O
diglycosylated,O
PrP,B-GP
exhibit,O
the,O
highest,O
charge,O
heterogeneity,O
",",O
as,O
it,O
can,O
accommodate,O
up,O
to,O
ten,O
negatively,O
charged,O
sialic,O
acid,O
residues,O
on,O
two,O
glycans,O
per,O
molecule17,O
.,O
As,O
a,O
result,O
",",O
the,O
charge,O
distribution,O
of,O
diglycosylated,O
isoforms,O
is,O
shifted,O
toward,O
acidic,O
pH,O
and,O
typically,O
extends,O
beyond,O
that,O
of,O
monoglycosylated,O
isoforms,O
",",O
which,O
accommodate,O
only,O
up,O
to,O
five,O
sialic,O
residues,O
per,O
molecule,O
.,O
The,O
extent,O
to,O
which,O
diglycosylated,O
isoforms,O
migrate,O
beyond,O
monoglycosylated,O
isoforms,O
toward,O
acidic,O
pH,O
reports,O
on,O
recruitment,O
of,O
hypersialylated,O
diglycosylated,O
isoforms,O
.,O
Careful,O
analysis,O
of,O
2D,O
results,O
revealed,O
that,O
in,O
brain,O
-,O
derived,O
PrPSc,O
hypersialylated,O
diglycosylated,O
molecules,O
were,O
recruited,O
in,O
a,O
strain,O
-,O
specific,O
manner,O
(,O
Fig,O
.,O
2,O
).,O
Hamster,B-OG
strains,O
showed,O
the,O
most,O
substantial,O
extension,O
of,O
diglycosylated,O
isoforms,O
toward,O
acidic,O
pH,O
relative,O
to,O
the,O
distribution,O
of,O
monoglycosylated,O
isoforms,O
(,O
Figs,O
2B,O
and,O
4,O
).,O
This,O
observation,O
suggests,O
that,O
hypersialylated,O
diglycosylated,O
molecules,O
are,O
well,O
represented,O
in,O
PrPSc,O
.,O
It,O
is,O
also,O
consistent,O
with,O
the,O
previous,O
results,O
showing,O
that,O
structures,O
of,O
hamster,B-OG
strains,O
accommodate,O
diglycosylated,O
PrP,B-GP
relatively,O
well,O
.,O
In,O
contrast,O
to,O
hamster,B-OG
strains,O
",",O
in,O
mouse,B-OG
strain,O
RML,O
the,O
distribution,O
of,O
diglycosylated,O
isoforms,O
does,O
not,O
extend,O
beyond,O
that,O
of,O
monoglycosylated,O
isoforms,O
at,O
acidic,O
pH,O
(,O
Figs,O
2A,O
and,O
4,O
).,O
This,O
indicates,O
that,O
a,O
negative,O
selection,O
of,O
hypersialylated,O
diglycosylated,O
molecules,O
takes,O
place,O
in,O
addition,O
to,O
a,O
general,O
negative,O
selection,O
of,O
diglycosylated,O
glycoforms,O
.,O
For,O
the,O
other,O
two,O
mouse,B-OG
strains,O
22L,O
and,O
ME7,O
",",O
the,O
diglycosylated,O
isoforms,O
extended,O
beyond,O
monoglycosylated,O
isoforms,O
at,O
acidic,O
pH,O
",",O
although,O
not,O
to,O
such,O
a,O
degree,O
as,O
those,O
of,O
hamster,B-OG
strains,O
(,O
Figs,O
2A,O
and,O
4,O
).,O
Overall,O
",",O
the,O
strain,O
-,O
specific,O
structures,O
that,O
tolerate,O
less,O
diglycosylated,O
forms,O
also,O
tend,O
to,O
exclude,O
hypersialylated,O
diglycosylated,O
forms,O
.,O
In,O
fact,O
",",O
plotting,O
strain,O
-,O
specific,O
percentage,O
of,O
diglycosylated,O
isoforms,O
versus,O
percentage,O
of,O
hypersialylated,O
isoforms,O
revealed,O
a,O
correlation,O
between,O
the,O
two,O
parameters,O
that,O
fits,O
well,O
to,O
a,O
linear,O
function,O
with,O
R,O
-,O
squared,O
value,O
of,O
0,O
.,O
89,O
(,O
Fig,O
.,O
3,O
).,O
Sialylation,O
of,O
PrPC,O
glycans,O
controls,O
replication,O
barrier,O
It,O
is,O
predicted,O
that,O
sialylation,O
of,O
PrPC,O
glycans,O
creates,O
a,O
replication,O
barrier,O
.,O
To,O
test,O
this,O
hypothesis,O
",",O
we,O
compared,O
amplification,O
rates,O
of,O
ME7,O
",",O
RML,O
and,O
22L,O
in,O
normal,O
versus,O
desialylated,O
substrates,O
using,O
PMCAb,O
and,O
dsPMCAb,O
",",O
respectively,O
.,O
For,O
comparing,O
amplification,O
rates,O
",",O
sets,O
of,O
serial,O
PMCAb,O
or,O
dsPMCAb,O
reactions,O
were,O
conducted,O
with,O
dilution,O
folds,O
between,O
serial,O
rounds,O
starting,O
from,O
1,O
:,O
3,O
and,O
higher,O
(,O
Fig,O
.,O
5,O
).,O
The,O
amplification,O
rate,O
is,O
defined,O
operationally,O
as,O
the,O
highest,O
dilution,O
between,O
serial,O
rounds,O
at,O
which,O
amplification,O
is,O
still,O
capable,O
of,O
compensating,O
the,O
effect,O
of,O
dilution,O
as,O
described,O
previously2930,O
.,O
In,O
desialylated,O
substrate,O
",",O
the,O
amplification,O
rate,O
increased,O
from,O
5,O
-,O
to,O
100,O
-,O
fold,O
for,O
ME7,O
and,O
from,O
10,O
-,O
to,O
at,O
least,O
500,O
-,O
fold,O
for,O
RML,O
and,O
22,O
L,O
.,O
Notably,O
",",O
consistent,O
with,O
previous,O
results,O
",",O
dsPMCAb,O
-,O
derived,O
products,O
showed,O
a,O
higher,O
proportion,O
of,O
diglycosylated,O
glycoforms,O
relative,O
to,O
PMCAb,O
-,O
derived,O
products,O
in,O
all,O
three,O
strains,O
(,O
Fig,O
.,O
5,O
).,O
Discussion,O
In,O
the,O
absence,O
of,O
posttranslational,O
modifications,O
",",O
prion,B-GP
protein,O
has,O
a,O
strong,O
positive,O
charge,O
at,O
physiological,O
pH,O
with,O
the,O
theoretical,O
pI,O
of,O
9,O
.,O
618,O
.,O
Sialylation,O
of,O
glycans,O
can,O
add,O
up,O
to,O
ten,O
negatively,O
charged,O
residues,O
and,O
shifts,O
the,O
pI,O
toward,O
acidic,O
pH,O
",",O
making,O
the,O
population,O
of,O
PrP,B-GP
molecules,O
highly,O
heterogeneous,O
with,O
respect,O
to,O
pI,O
and,O
the,O
net,O
charges,O
at,O
physiological,O
pH1718,O
.,O
In,O
PrPSc,O
particles,O
",",O
glycans,O
are,O
believed,O
to,O
be,O
directed,O
outward,O
where,O
the,O
terminal,O
sialic,O
acid,O
residues,O
create,O
a,O
dense,O
negative,O
charge,O
on,O
the,O
PrPSc,O
surface202122,O
.,O
The,O
current,O
study,O
proposed,O
that,O
due,O
to,O
electrostatic,O
repulsion,O
",",O
sialylation,O
of,O
glycans,O
creates,O
structural,O
constraints,O
for,O
PrPSc,O
replication,O
.,O
Several,O
testable,O
predictions,O
were,O
postulated,O
based,O
on,O
this,O
hypothesis,O
.,O
First,O
",",O
to,O
reduce,O
electrostatic,O
repulsion,O
",",O
it,O
is,O
expected,O
that,O
PrPC,O
with,O
a,O
heavy,O
sialylation,O
level,O
is,O
partially,O
excluded,O
from,O
the,O
conversion,O
.,O
This,O
could,O
be,O
achieved,O
via,O
(,O
i,O
),O
selective,O
recruitment,O
of,O
mono,O
-,O
and,O
unglycosylated,O
PrPC,O
at,O
the,O
expense,O
of,O
diglycosylated,O
PrPC,O
and,O
(,O
ii,O
),O
preferential,O
exclusion,O
of,O
hypersialylated,O
diglycosylated,O
PrPC,O
.,O
Depending,O
on,O
the,O
strain,O
-,O
specific,O
alignment,O
of,O
glycan,O
moieties,O
",",O
the,O
extent,O
of,O
this,O
effect,O
is,O
expected,O
to,O
be,O
strain,O
-,O
specific,O
(,O
Fig,O
.,O
6,O
).,O
Second,O
",",O
an,O
increase,O
in,O
the,O
rate,O
of,O
prion,B-GP
amplification,O
is,O
expected,O
when,O
the,O
constraints,O
imposed,O
by,O
sialic,O
acid,O
residues,O
are,O
relieved,O
by,O
employing,O
a,O
substrate,O
with,O
low,O
sialylation,O
levels,O
.,O
In,O
other,O
words,O
",",O
sialylation,O
of,O
PrPC,O
glycans,O
creates,O
a,O
replication,O
barrier,O
that,O
can,O
be,O
reduced,O
by,O
reducing,O
sialylation,O
levels,O
of,O
a,O
substrate,O
.,O
In,O
support,O
of,O
the,O
above,O
hypothesis,O
",",O
the,O
current,O
work,O
showed,O
that,O
the,O
relative,O
population,O
of,O
diglycosylated,O
forms,O
was,O
lower,O
in,O
PrPSc,O
than,O
those,O
in,O
PrPC,O
",",O
and,O
that,O
the,O
negative,O
selection,O
of,O
diglycosylated,O
forms,O
was,O
strain,O
-,O
specific,O
.,O
RML,O
showed,O
the,O
strongest,O
exclusion,O
of,O
diglycosylated,O
forms,O
.,O
The,O
hamster,B-OG
strains,O
(,O
263K,O
",",O
HY,O
",",O
DY,O
",",O
SSLOW,O
),O
had,O
the,O
weakest,O
negative,O
selection,O
",",O
while,O
22L,O
and,O
ME7,O
strains,O
were,O
in,O
the,O
middle,O
.,O
Remarkably,O
",",O
in,O
PrPSc,O
generated,O
from,O
PrPC,O
that,O
was,O
partially,O
desialylated,O
",",O
the,O
relative,O
populations,O
of,O
glycofoms,O
were,O
found,O
to,O
be,O
very,O
similar,O
to,O
those,O
of,O
the,O
substrate,O
.,O
This,O
observation,O
illustrates,O
that,O
the,O
pressure,O
for,O
preferential,O
selection,O
of,O
un,O
-,O
and,O
monoglycosylated,O
forms,O
was,O
released,O
by,O
cleaving,O
sialic,O
acid,O
residues,O
.,O
In,O
addition,O
to,O
the,O
negative,O
selection,O
of,O
diglycosylated,O
forms,O
",",O
strains,O
with,O
the,O
strongest,O
structural,O
constraints,O
also,O
excluded,O
hypersialylated,O
molecules,O
.,O
RML,O
showed,O
the,O
strongest,O
negative,O
selection,O
of,O
diglycosylated,O
and,O
also,O
hypersialylated,O
forms,O
.,O
In,O
fact,O
",",O
a,O
strong,O
correlation,O
between,O
strain,O
-,O
specific,O
percentage,O
of,O
diglycosylated,O
forms,O
and,O
hypersialylated,O
forms,O
presented,O
in,O
Fig,O
.,O
3,O
for,O
brain,O
-,O
derived,O
material,O
suggests,O
that,O
the,O
negative,O
selection,O
of,O
both,O
is,O
attributed,O
to,O
the,O
same,O
structural,O
constrains,O
.,O
The,O
glycoform,O
ratios,O
within,O
PrPSc,O
are,O
believed,O
to,O
be,O
one,O
of,O
the,O
intrinsic,O
characteristics,O
of,O
prion,B-GP
strains,O
or,O
PrPSc,O
subtypes,O
(,O
reviewed,O
in31,O
).,O
In,O
fact,O
",",O
the,O
glycoform,O
ratios,O
have,O
been,O
used,O
for,O
strain,O
typing,O
and,O
classification,O
of,O
CJD,B-DS
type2425,O
.,O
It,O
was,O
not,O
clear,O
why,O
three,O
glycoforms,O
are,O
recruited,O
by,O
prion,B-GP
strains,O
in,O
different,O
proportions,O
even,O
within,O
the,O
same,O
host,O
.,O
The,O
current,O
work,O
demonstrates,O
that,O
the,O
strain,O
-,O
specific,O
ratio,O
of,O
the,O
three,O
glycoforms,O
is,O
a,O
result,O
of,O
negative,O
selection,O
of,O
heavily,O
sialylated,O
PrP,B-GP
molecules,O
.,O
The,O
extent,O
to,O
which,O
heavily,O
sialylated,O
PrP,B-GP
is,O
excluded,O
is,O
presumably,O
controlled,O
by,O
the,O
strain,O
-,O
specific,O
structure,O
of,O
PrPSc,O
and,O
relative,O
position,O
of,O
the,O
two,O
glycans,O
(,O
Fig,O
.,O
6,O
).,O
Remarkably,O
",",O
when,O
exposed,O
to,O
desialylated,O
substrate,O
",",O
prion,B-GP
strains,O
lose,O
strain,O
-,O
specific,O
selectivity,O
toward,O
different,O
glycoforms,O
and,O
the,O
glycoform,O
ratio,O
within,O
PrPSc,O
mirrors,O
that,O
of,O
PrPC,O
.,O
Brain,O
-,O
derived,O
PrPSc,O
of,O
different,O
strains,O
was,O
found,O
to,O
be,O
different,O
with,O
respect,O
to,O
its,O
sialylation,O
status,O
.,O
(,O
Fig,O
.,O
3,O
).,O
In,O
combination,O
with,O
substantial,O
strain,O
-,O
specific,O
differences,O
in,O
glycoform,O
ratios,O
",",O
these,O
differences,O
are,O
likely,O
to,O
produce,O
distinct,O
strain,O
-,O
specific,O
density,O
of,O
sialic,O
acid,O
residues,O
on,O
a,O
surface,O
of,O
PrPSc,O
particles,O
and,O
distinct,O
strain,O
-,O
specific,O
pIs,O
of,O
PrPSc,O
.,O
For,O
instance,O
",",O
at,O
physiological,O
pH,O
",",O
RML,O
PrPSc,O
particles,O
are,O
expected,O
to,O
have,O
net,O
positive,O
charges,O
",",O
whereas,O
PrPSc,O
particles,O
of,O
hamster,B-OG
strains,O
are,O
expected,O
to,O
be,O
charged,O
negatively,O
(,O
Fig,O
.,O
2,O
).,O
Terminal,O
sialic,O
acid,O
residues,O
constitute,O
key,O
elements,O
of,O
diverse,O
functional,O
epitopes,O
that,O
are,O
recognized,O
by,O
dozens,O
of,O
cell,O
receptors,O
including,O
siglecs,B-GP
and,O
selectins3233,B-GP
.,O
Through,O
these,O
functional,O
epitopes,O
",",O
sialylation,O
of,O
glycoproteins,O
mediate,O
their,O
interaction,O
with,O
cells,O
of,O
the,O
innate,O
immune,O
system,O
and,O
microglia34,O
.,O
These,O
interactions,O
define,O
the,O
ultimate,O
fate,O
of,O
mammalian,O
cells,O
",",O
glycoproteins,O
in,O
circulation,O
and,O
microbial,O
pathogens3536,O
.,O
It,O
remains,O
to,O
be,O
established,O
whether,O
strain,O
-,O
specific,O
differences,O
in,O
PrPSc,O
sialylation,O
play,O
any,O
role,O
in,O
defining,O
strain,O
-,O
specific,O
neurotropism,O
and,O
lymphotropism,O
.,O
The,O
current,O
study,O
illustrates,O
that,O
PrPSc,O
glycoform,O
ratio,O
is,O
not,O
only,O
controlled,O
by,O
strain,O
or,O
host,O
",",O
but,O
also,O
by,O
sialylation,O
level,O
of,O
PrPC,O
.,O
As,O
such,O
",",O
experiments,O
on,O
infecting,O
new,O
hosts,O
or,O
cell,O
lines,O
with,O
unknown,O
PrPC,O
sialylation,O
status,O
should,O
be,O
interpreted,O
with,O
great,O
care,O
.,O
In,O
previous,O
studies,O
",",O
shifts,O
in,O
glycoform,O
ratios,O
toward,O
diglycosylated,O
glycoforms,O
were,O
observed,O
in,O
scrapie,B-DS
-,O
infected,O
cells,O
treated,O
with,O
swainsonine,O
",",O
a,O
compound,O
that,O
inhibits,O
complex,O
glycosylation3738,O
.,O
It,O
was,O
concluded,O
that,O
selection,O
of,O
minor,O
strain,O
variants,O
or,O
structural,O
mutants,O
occurred3738,O
.,O
Because,O
treatment,O
with,O
swainsonine,O
blocks,O
complex,O
glycosylation,O
including,O
sialylation,O
",",O
it,O
is,O
expected,O
that,O
the,O
glycoform,O
ratios,O
would,O
change,O
in,O
favor,O
of,O
diglycosylated,O
forms,O
regardless,O
whether,O
selection,O
of,O
a,O
new,O
variants,O
occurs,O
or,O
not,O
.,O
The,O
current,O
work,O
predicts,O
that,O
if,O
the,O
PrPSc,O
glycoform,O
ratio,O
changes,O
upon,O
infecting,O
a,O
new,O
host,O
",",O
this,O
change,O
is,O
indicative,O
of,O
an,O
altered,O
sialylation,O
status,O
of,O
PrPC,O
and,O
",",O
specifically,O
",",O
a,O
shift,O
toward,O
diglycosylated,O
forms,O
would,O
suggest,O
a,O
reduced,O
sialylation,O
level,O
of,O
PrPC,O
.,O
The,O
hypothesis,O
presented,O
in,O
the,O
current,O
work,O
introduces,O
new,O
constraints,O
for,O
establishing,O
PrPSc,O
structure,O
.,O
To,O
account,O
for,O
the,O
negative,O
selection,O
of,O
diglycosylated,O
/,O
hypersialylated,O
PrPC,O
",",O
glycans,O
of,O
the,O
neighboring,O
PrP,B-GP
molecules,O
should,O
be,O
aligned,O
in,O
close,O
proximity,O
to,O
each,O
other,O
within,O
assembled,O
PrPSc,O
particles,O
.,O
The,O
average,O
volume,O
and,O
dimension,O
of,O
glycan,O
moieties,O
should,O
be,O
taken,O
into,O
consideration,O
for,O
estimating,O
the,O
proper,O
folding,O
pattern,O
and,O
the,O
number,O
of,O
intramolecular,O
rings,O
or,O
layers,O
acquired,O
by,O
a,O
single,O
polypeptide,O
chain,O
within,O
intact,O
PrPSc,O
.,O
More,O
substantial,O
clashes,O
between,O
glycans,O
of,O
neighboring,O
diglycosylated,O
forms,O
are,O
expected,O
for,O
strains,O
or,O
PrPSc,O
subtypes,O
with,O
predominantly,O
monoglycosylated,O
forms,O
",",O
such,O
as,O
sporadic,O
CJD,B-DS
",",O
in,O
comparison,O
with,O
the,O
strains,O
where,O
diglycosylated,O
forms,O
are,O
predominant,O
",",O
such,O
as,O
new,O
variant,O
CJD24,O
(,O
Fig,O
.,O
6,O
).,O
For,O
the,O
three,O
mouse,B-OG
strains,O
tested,O
in,O
the,O
current,O
study,O
",",O
partial,O
desialylation,O
of,O
PrPC,O
increased,O
the,O
replication,O
rates,O
by,O
20,O
–,O
50,O
fold,O
(,O
Fig,O
.,O
5,O
).,O
These,O
results,O
suggested,O
that,O
sialylation,O
of,O
PrP,B-GP
glycans,O
contributes,O
to,O
a,O
replication,O
barrier,O
.,O
An,O
alternative,O
explanation,O
is,O
that,O
sialidase,B-GP
treatment,O
of,O
NBH,O
had,O
an,O
effect,O
other,O
than,O
on,O
PrPC,O
.,O
While,O
this,O
seems,O
to,O
be,O
unlikely,O
",",O
this,O
possibility,O
should,O
not,O
be,O
discarded,O
completely,O
.,O
In,O
previous,O
studies,O
",",O
partial,O
desialylation,O
of,O
PrPC,O
was,O
also,O
found,O
to,O
considerably,O
reduce,O
the,O
barrier,O
in,O
cross,O
-,O
seeded,O
PMCAb,O
reactions18,O
.,O
Together,O
",",O
these,O
data,O
suggest,O
that,O
the,O
replication,O
barrier,O
attributable,O
to,O
glycan,O
sialylation,O
is,O
universal,O
",",O
i,O
.,O
e,O
.,O
it,O
might,O
not,O
only,O
control,O
the,O
rate,O
of,O
prion,B-GP
replication,O
within,O
the,O
same,O
host,O
but,O
also,O
the,O
barrier,O
associated,O
with,O
prion,B-GP
transmission,O
between,O
different,O
species,O
.,O
There,O
might,O
be,O
several,O
components,O
that,O
underlie,O
a,O
replication,O
barrier,O
attributable,O
to,O
sialylation,O
.,O
First,O
",",O
electrostatic,O
repulsion,O
between,O
negatively,O
charged,O
sialic,O
acid,O
residues,O
on,O
glycans,O
of,O
PrPSc,O
and,O
PrPC,O
limits,O
the,O
range,O
of,O
PrPC,O
molecules,O
suitable,O
for,O
conversion,O
to,O
those,O
with,O
moderate,O
sialylation,O
levels,O
.,O
Second,O
",",O
even,O
for,O
the,O
PrPC,O
molecules,O
that,O
are,O
suitable,O
for,O
conversion,O
",",O
electrostatic,O
repulsion,O
of,O
surface,O
glycans,O
might,O
slow,O
down,O
the,O
rates,O
of,O
PrPC,O
binding,O
to,O
PrPSc,O
and,O
PrPC,O
conversion,O
.,O
Third,O
",",O
electrostatic,O
repulsion,O
between,O
surface,O
glycans,O
of,O
nascent,O
PrPSc,O
has,O
a,O
negative,O
impact,O
on,O
thermodynamic,O
stability,O
of,O
PrPSc,O
particles,O
",",O
the,O
effect,O
that,O
has,O
to,O
be,O
counteracted,O
by,O
other,O
forces,O
that,O
stabilize,O
packing,O
of,O
polypeptide,O
chains,O
within,O
PrPSc,O
particles,O
.,O
Notably,O
",",O
while,O
thermodynamic,O
stability,O
of,O
PrPSc,O
varies,O
depending,O
on,O
strain,O
-,O
specific,O
structure6293940,O
",",O
the,O
range,O
of,O
strain,O
-,O
specific,O
thermodynamic,O
stabilities,O
of,O
PrPSc,O
is,O
typically,O
lower,O
than,O
those,O
of,O
amyloid,O
fibrils,O
generated,O
in,O
vitro,O
using,O
recombinant,O
PrP4142,O
.,O
In,O
part,O
",",O
this,O
could,O
be,O
due,O
to,O
electrostatic,O
repulsion,O
between,O
sialylated,O
glycans,O
that,O
recombinant,O
PrP,B-GP
lacks,O
.,O
According,O
to,O
the,O
hypothesis,O
introduced,O
here,O
",",O
the,O
same,O
structural,O
constraints,O
account,O
for,O
at,O
least,O
part,O
of,O
the,O
replication,O
barrier,O
and,O
the,O
degree,O
to,O
which,O
diglycosylated,O
forms,O
are,O
excluded,O
.,O
If,O
this,O
is,O
true,O
",",O
there,O
should,O
be,O
a,O
correlation,O
between,O
strain,O
-,O
specific,O
glycoform,O
ratios,O
and,O
the,O
efficiency,O
of,O
prion,B-GP
replication,O
.,O
Indeed,O
",",O
mouse,B-OG
strains,O
have,O
a,O
high,O
proportion,O
of,O
monoglycosylated,O
glycoforms,O
and,O
also,O
slow,O
replication,O
rates,O
in,O
PMCA,O
.,O
Similar,O
correlations,O
between,O
glycoform,O
ratio,O
and,O
the,O
replication,O
efficiency,O
was,O
observed,O
for,O
two,O
forms,O
of,O
CJD,B-DS
.,O
It,O
is,O
known,O
that,O
nvCJD,O
",",O
which,O
is,O
predominantly,O
diglycosylated,O
",",O
replicates,O
in,O
PMCA,O
with,O
a,O
much,O
better,O
efficiency,O
than,O
sCJD,O
",",O
which,O
is,O
predominantly,O
monoglycosylated434445,O
.,O
However,O
",",O
not,O
all,O
strains,O
with,O
predominantly,O
diglycosylated,O
glycoforms,O
display,O
fast,O
replication,O
rates,O
suggesting,O
that,O
factors,O
other,O
than,O
sialylation,O
contribute,O
to,O
the,O
replication,O
barrier,O
.,O
For,O
instance,O
",",O
hamster,B-OG
-,O
adapted,O
strains,O
DY,O
",",O
139H,O
and,O
22AH,O
are,O
predominantly,O
diglycosylated,O
",",O
but,O
replicate,O
very,O
slowly39,O
.,O
Methods,O
Normal,O
and,O
scrapie,B-DS
brain,O
materials,O
Weanling,O
Golden,O
Syrian,B-OG
hamsters,I-OG
or,O
C57BL,B-OG
/,I-OG
6NHsd,I-OG
mice,I-OG
were,O
inoculated,O
intracerebrally,O
under,O
2,O
%,O
O2,O
/,O
4,O
MAC,O
isoflurane,O
anesthesia,O
using,O
scrapie,B-DS
brain,O
homogenates,O
of,O
hamster,B-OG
-,O
or,O
mouse,B-OG
-,O
adapted,O
strains,O
",",O
respectively,O
.,O
For,O
the,O
synthetic,O
strain,O
SSLOW,O
",",O
animals,B-OG
of,O
fourth,O
serial,O
SSLOW,O
passage,O
were,O
used,O
for,O
analysis46,O
.,O
Animals,B-OG
were,O
euthanized,O
at,O
the,O
terminal,O
stage,O
of,O
the,O
disease,O
and,O
brains,O
were,O
collected,O
for,O
subsequent,O
analysis,O
.,O
This,O
study,O
was,O
carried,O
out,O
in,O
strict,O
accordance,O
with,O
the,O
recommendations,O
in,O
the,O
Guide,O
for,O
the,O
Care,O
and,O
Use,O
of,O
Laboratory,O
Animals,B-OG
of,O
the,O
National,O
Institutes,O
of,O
Health,O
.,O
The,O
animal,B-OG
protocol,O
was,O
approved,O
by,O
the,O
Institutional,O
Animal,O
Care,O
and,O
Use,O
Committee,O
of,O
the,O
University,O
of,O
Maryland,O
",",O
Baltimore,O
(,O
Assurance,O
Number,O
A32000,O
-,O
01,O
;,O
Permit,O
Number,O
:,O
0215002,O
).,O
Protein,O
misfolding,O
cyclic,O
amplification,O
with,O
beads,O
(,O
PMCAb,O
),O
and,O
PMCAb,O
in,O
desialylated,O
substrate,O
(,O
dsPMCAb,O
),O
10,O
%,O
normal,O
brain,O
homogenate,O
(,O
NBH,O
),O
from,O
healthy,O
hamsters,B-OG
or,O
mice,B-OG
was,O
prepared,O
as,O
described,O
previously47,O
.,O
To,O
produce,O
desialylated,O
substrates,O
for,O
dsPMCAb,O
",",O
10,O
%,O
NBH,O
was,O
treated,O
with,O
Arthrobacter,B-OG
ureafaciens,I-OG
sialidase,B-GP
(,O
cat,O
#,O
P0722L,O
",",O
New,O
England,O
Biolabs,O
",",O
Ipswich,O
",",O
MA,O
),O
as,O
follows,O
.,O
After,O
preclearance,O
of,O
NBH,O
at,O
500,O
×,O
g,O
for,O
2,O
min,O
and,O
addition,O
of,O
the,O
enzyme,O
buffer,O
supplied,O
with,O
the,O
manufacturer,O
to,O
supernatant,O
200,O
units,O
/,O
mL,O
of,O
sialidase,B-GP
were,O
added,O
to,O
the,O
supernatant,O
",",O
incubated,O
on,O
a,O
rotator,O
at,O
37,O
°,O
C,O
for,O
5,O
h,O
and,O
the,O
resulting,O
material,O
referred,O
to,O
as,O
dsNBH,O
substrate,O
used,O
in,O
dsPMCAb,O
.,O
PMCAb,O
and,O
dsPMCAb,O
reactions,O
were,O
conducted,O
as,O
previously,O
described1848,O
using,O
Misonix,O
S,O
-,O
4000,O
microplate,O
horn,O
(,O
Qsonica,O
LLC,O
",",O
Newtown,O
",",O
CT,O
),O
in,O
the,O
presence,O
of,O
two,O
2,O
/,O
32,O
”,O
Teflon,O
beads,O
in,O
each,O
tube,O
(,O
McMaster,O
-,O
Carr,O
",",O
Elmhurst,O
",",O
IL,O
).,O
One,O
round,O
consisted,O
of,O
20,O
sec,O
sonications,O
delivered,O
at,O
170,O
W,O
energy,O
output,O
applied,O
every,O
20,O
min,O
during,O
a,O
24,O
hour,O
period,O
.,O
For,O
each,O
subsequent,O
round,O
",",O
10,O
μl,O
(,O
for,O
hamster,B-OG
strains,O
),O
or,O
20,O
μl,O
(,O
for,O
mouse,B-OG
strains,O
),O
of,O
the,O
reaction,O
products,O
from,O
the,O
previous,O
round,O
were,O
mixed,O
with,O
90,O
or,O
80,O
μl,O
of,O
fresh,O
substrate,O
",",O
respectively,O
",",O
or,O
as,O
specified,O
for,O
the,O
amplification,O
rate,O
experiment,O
.,O
Western,O
blots,O
10,O
μL,O
of,O
10,O
%,O
brain,O
homogenate,O
or,O
dsPMCAb,O
-,O
derived,O
materials,O
were,O
supplemented,O
with,O
5,O
μL,O
1,O
%,O
SDS,O
and,O
5,O
μL,O
proteinase,B-GP
K,I-GP
(,O
cat,O
.,O
#,O
P8107S,O
",",O
New,O
England,O
Biolabs,O
",",O
Ipswich,O
",",O
MA,O
"),",O
to,O
a,O
final,O
concentration,O
of,O
0,O
.,O
25,O
%,O
SDS,O
and,O
25,O
μg,O
/,O
mL,O
proteinase,B-GP
K,I-GP
",",O
and,O
incubated,O
at,O
37,O
°,O
C,O
for,O
1,O
hour,O
.,O
Then,O
",",O
SDS,O
sample,O
buffer,O
was,O
added,O
",",O
samples,O
were,O
boiled,O
for,O
10,O
minutes,O
and,O
loaded,O
onto,O
NuPage,O
12,O
%,O
BisTris,O
gel,O
(,O
cat,O
.,O
#,O
NP0341BOX,O
",",O
Life,O
Technologies,O
",",O
Carlsbad,O
",",O
CA,O
"),",O
transferred,O
to,O
PVDF,O
membrane,O
",",O
and,O
probed,O
with,O
3F4,O
(,O
cat,O
.,O
#,O
SIG,O
-,O
39600,O
",",O
Covance,O
),O
or,O
Ab3531,O
antibody,B-GP
(,O
Abcam,O
).,O
Preparation,O
of,O
brain,O
-,O
and,O
dsPMCAb,O
-,O
derived,O
materials,O
for,O
2D,O
10,O
%,O
(,O
wt,O
/,O
vol,O
),O
of,O
scrapie,B-DS
brain,O
homogenates,O
were,O
prepared,O
in,O
PBS,O
using,O
glass,O
/,O
Teflon,O
homogenizers,O
attached,O
to,O
a,O
cordless,O
12,O
V,O
compact,O
drill,O
(,O
Ryobi,O
),O
as,O
previously,O
described46,O
.,O
For,O
2D,O
electrophoresis,O
of,O
brain,O
-,O
derived,O
materials,O
",",O
an,O
aliquot,O
of,O
10,O
%,O
(,O
wt,O
/,O
vol,O
),O
homogenate,O
was,O
diluted,O
with,O
nine,O
volumes,O
of,O
1,O
%,O
(,O
vol,O
/,O
vol,O
),O
Triton,O
X,O
-,O
100,O
in,O
PBS,O
",",O
sonicated,O
for,O
30,O
s,O
inside,O
a,O
Misonix,O
S,O
-,O
4000,O
microplate,O
horn,O
(,O
Qsonica,O
LLC,O
",",O
Newtown,O
",",O
CT,O
"),",O
and,O
treated,O
with,O
25,O
μg,O
/,O
mL,O
proteinase,B-GP
K,I-GP
for,O
30,O
min,O
at,O
37,O
°,O
C,O
.,O
dsPMCAb,O
materials,O
were,O
treated,O
with,O
25,O
μg,O
/,O
mL,O
PK,O
in,O
the,O
presence,O
of,O
0,O
.,O
25,O
%,O
SDS,O
for,O
60,O
min,O
at,O
37,O
°,O
C,O
.,O
Resulting,O
brain,O
and,O
dsPMCAb,O
samples,O
were,O
supplemented,O
with,O
4xSDS,O
loading,O
buffer,O
",",O
heated,O
for,O
10,O
min,O
in,O
a,O
boiling,O
water,O
bath,O
and,O
processed,O
for,O
2D,O
electrophoresis,O
as,O
described,O
below,O
.,O
2D,O
electrophoresis,O
Samples,O
of,O
25,O
μL,O
volume,O
prepared,O
in,O
loading,O
buffer,O
as,O
described,O
above,O
were,O
solubilized,O
for,O
1,O
h,O
at,O
room,O
temperature,O
in,O
200,O
μL,O
solubilization,O
buffer,O
(,O
8,O
M,O
Urea,O
",",O
2,O
%,O
(,O
wt,O
/,O
vol,O
),O
CHAPS,O
",",O
5,O
mM,O
TBP,O
",",O
20,O
mM,O
TrisHCl,O
pH,O
8,O
.,O
0,O
"),",O
then,O
alkylated,O
by,O
adding,O
7,O
μL,O
of,O
0,O
.,O
5,O
M,O
iodoacetamide,O
and,O
incubated,O
for,O
1,O
h,O
at,O
room,O
temperature,O
.,O
Then,O
",",O
1150,O
μL,O
of,O
ice,O
-,O
cold,O
methanol,O
was,O
added,O
and,O
samples,O
were,O
incubated,O
for,O
2,O
h,O
at,O
−,O
20,O
°,O
C,O
.,O
After,O
centrifugation,O
at,O
16,O
",",O
000,O
g,O
at,O
4,O
°,O
C,O
",",O
supernatant,O
was,O
discarded,O
and,O
the,O
pellet,O
was,O
re,O
-,O
solubilized,O
in,O
160,O
μL,O
rehydration,O
buffer,O
(,O
7,O
M,O
urea,O
",",O
2,O
M,O
thiourea,O
",",O
1,O
%,O
(,O
wt,O
/,O
vol,O
),O
DTT,O
",",O
1,O
%,O
(,O
wt,O
/,O
vol,O
),O
CHAPS,O
",",O
1,O
%,O
(,O
wt,O
/,O
vol,O
),O
Triton,O
X,O
-,O
100,O
",",O
1,O
%,O
(,O
vol,O
/,O
vol,O
),O
ampholyte,O
",",O
trace,O
amount,O
of,O
Bromophenol,O
Blue,O
).,O
Fixed,O
immobilized,O
pre,O
-,O
cast,O
IPG,O
strips,O
with,O
a,O
non,O
-,O
linear,O
pH,O
gradient,O
3,O
–,O
10,O
used,O
in,O
the,O
previous,O
study18,O
were,O
replaced,O
by,O
fixed,O
immobilized,O
pre,O
-,O
cast,O
IPG,O
strips,O
with,O
a,O
linear,O
pH,O
gradient,O
3,O
–,O
10,O
(,O
cat,O
.,O
#,O
ZM0018,O
",",O
Life,O
Technologies,O
",",O
Carlsbad,O
",",O
CA,O
),O
that,O
provide,O
a,O
better,O
resolution,O
of,O
charge,O
isoforms,O
.,O
Strips,O
were,O
rehydrated,O
in,O
155,O
μL,O
of,O
the,O
resulting,O
mixture,O
overnight,O
at,O
room,O
temperature,O
inside,O
IPG,O
Runner,O
cassettes,O
(,O
cat,O
.,O
#,O
ZM0003,O
",",O
Life,O
Technologies,O
).,O
Isoelectrofocusing,O
(,O
first,O
dimension,O
separation,O
),O
was,O
performed,O
at,O
room,O
temperature,O
with,O
rising,O
voltage,O
(,O
175V,O
for,O
15,O
minutes,O
",",O
then,O
175,O
–,O
2,O
",",O
000V,O
linear,O
gradient,O
for,O
45,O
minutes,O
",",O
then,O
2,O
",",O
000,O
V,O
for,O
30,O
minutes,O
),O
on,O
Life,O
Technologies,O
Zoom,O
Dual,O
Power,O
Supply,O
",",O
using,O
the,O
XCell,O
SureLock,O
Mini,O
-,O
Cell,O
Electrophoresis,O
System,O
(,O
cat,O
.,O
#,O
EI0001,O
",",O
Life,O
Technologies,O
).,O
The,O
IPG,O
strips,O
were,O
then,O
equilibrated,O
for,O
15,O
minutes,O
consecutively,O
in,O
(,O
i,O
),O
6,O
M,O
Urea,O
",",O
20,O
%,O
(,O
vol,O
/,O
vol,O
),O
glycerol,O
",",O
2,O
%,O
SDS,O
",",O
375,O
mM,O
Tris,O
-,O
HCl,O
pH,O
8,O
.,O
8,O
",",O
130,O
mM,O
DTT,O
and,O
(,O
ii,O
),O
6,O
M,O
Urea,O
",",O
20,O
%,O
(,O
vol,O
/,O
vol,O
),O
glycerol,O
",",O
2,O
%,O
SDS,O
",",O
375,O
mM,O
Tris,O
-,O
HCl,O
pH,O
8,O
.,O
8,O
",",O
135,O
mM,O
iodoacetamide,O
",",O
and,O
loaded,O
on,O
4,O
–,O
12,O
%,O
Bis,O
-,O
Tris,O
ZOOM,O
SDS,O
-,O
PAGE,O
pre,O
-,O
cast,O
gels,O
(,O
cat,O
.,O
#,O
NP0330BOX,O
",",O
Life,O
Technologies,O
).,O
For,O
the,O
second,O
dimension,O
",",O
SDS,O
-,O
PAGE,O
was,O
performed,O
for,O
1,O
h,O
at,O
170,O
V,O
.,O
Immunoblotting,O
was,O
performed,O
as,O
described,O
elsewhere,O
",",O
blots,O
were,O
stained,O
using,O
3F4,O
or,O
Ab3531,O
antibody,B-GP
.,O
Western,O
blot,O
densitometry,O
analysis,O
1D,O
or,O
2D,O
western,O
blot,O
signal,O
intensity,O
was,O
digitized,O
for,O
densitometry,O
analysis,O
using,O
AlphaView,O
software,O
(,O
ProteinSimple,O
",",O
San,O
Jose,O
",",O
CA,O
).,O
For,O
densitometry,O
analysis,O
of,O
the,O
glycoform,O
distribution,O
(,O
expressed,O
as,O
a,O
percentage,O
of,O
the,O
diglycosylated,O
form,O
"),",O
target,O
bands,O
were,O
selected,O
using,O
a,O
uniform,O
rectangular,O
sampling,O
area,O
that,O
encompassed,O
the,O
band,O
of,O
interest,O
.,O
Background,O
optical,O
density,O
of,O
an,O
equal,O
area,O
from,O
the,O
same,O
blot,O
was,O
determined,O
and,O
subsequently,O
subtracted,O
from,O
the,O
density,O
of,O
the,O
bands,O
.,O
At,O
least,O
three,O
measurements,O
from,O
independent,O
gel,O
loadings,O
were,O
used,O
for,O
each,O
sample,O
for,O
calculating,O
mean,O
and,O
standard,O
deviations,O
.,O
For,O
analysis,O
of,O
sialylation,O
",",O
2D,O
blots,O
were,O
aligned,O
horizontally,O
and,O
a,O
line,O
drawn,O
at,O
pI,O
7,O
.,O
5,O
was,O
used,O
to,O
arbitrarily,O
separate,O
charge,O
isoforms,O
into,O
hypersialylated,O
and,O
hyposialylated,O
.,O
In,O
the,O
software,O
window,O
",",O
a,O
rectangle,O
was,O
drawn,O
to,O
confine,O
the,O
spots,O
of,O
interest,O
",",O
and,O
the,O
densities,O
measured,O
.,O
The,O
intensity,O
of,O
an,O
equal,O
background,O
area,O
from,O
the,O
same,O
blot,O
was,O
subtracted,O
before,O
calculations,O
were,O
done,O
.,O
The,O
acquired,O
spot,O
ensemble,O
intensities,O
were,O
used,O
to,O
calculate,O
percentage,O
of,O
“,O
hypersialylated,O
”,O
isoforms,O
.,O
Hypersialylated,O
isoforms,O
were,O
defined,O
operationally,O
as,O
all,O
isoforms,O
located,O
to,O
the,O
left,O
of,O
the,O
pI7,O
.,O
5,O
line,O
;,O
the,O
percentage,O
of,O
hypersialylated,O
isoforms,O
was,O
calculated,O
assuming,O
the,O
total,O
intensity,O
of,O
all,O
isoforms,O
as,O
100,O
%.,O
For,O
generating,O
glycoform,O
profiles,O
or,O
sialylation,O
profiles,O
for,O
di,O
-,O
and,O
monoglycosylated,O
glycoforms,O
",",O
densitometry,O
analysis,O
of,O
1D,O
or,O
2D,O
blots,O
",",O
respectively,O
",",O
was,O
performed,O
using,O
the,O
“,O
Lane,O
profile,O
”,O
function,O
in,O
the,O
AlphaView,O
program,O
.,O
For,O
data,O
presented,O
in,O
normalized,O
format,O
(,O
Fig,O
.,O
4,O
"),",O
the,O
highest,O
curve,O
signal,O
value,O
was,O
taken,O
as,O
100,O
%.,O
Additional,O
Information,O
How,O
to,O
cite,O
this,O
article,O
:,O
Katorcha,O
",",O
E,O
.,O
et,O
al,O
.,O
Sialylation,O
of,O
the,O
prion,B-GP
protein,O
glycans,O
controls,O
prion,B-GP
replication,O
rate,O
and,O
glycoform,O
ratio,O
.,O
Sci,O
.,O
Rep,O
.,O
5,O
",",O
16912,O
;,O
doi,O
:,O
10,O
.,O
1038,O
/,O
srep16912,O
(,O
2015,O
).,O
Author,O
Contributions,O
E,O
.,O
K,O
.,O
and,O
I,O
.,O
V,O
.,O
B,O
.,O
conceived,O
the,O
experiments,O
;,O
E,O
.,O
K,O
".,",O
N,O
.,O
M,O
.,O
and,O
R,O
.,O
S,O
.,O
conducted,O
the,O
experiments,O
;,O
E,O
.,O
K,O
.,O
and,O
I,O
.,O
V,O
.,O
B,O
.,O
analyzed,O
the,O
results,O
.,O
E,O
.,O
K,O
.,O
and,O
I,O
.,O
V,O
.,O
B,O
.,O
wrote,O
the,O
manuscript,O
.,O
All,O
authors,O
reviewed,O
the,O
manuscript,O
.,O
Western,O
blots,O
of,O
scrapie,O
brain,O
-,O
derived,O
(,O
SBH,O
),O
and,O
dsPMCAb,O
-,O
derived,O
materials,O
of,O
mouse,O
strains,O
ME7,O
",",O
22L,O
and,O
RML,O
(,O
A,O
),O
or,O
hamster,O
strains,O
263K,O
",",O
HY,O
",",O
DY,O
",",O
SSLOW,O
(,O
B,O
).,O
For,O
producing,O
dsPMCA,O
-,O
derived,O
material,O
",",O
dsPMCAb,O
reactions,O
were,O
seeded,O
with,O
brain,O
material,O
and,O
propagated,O
in,O
serial,O
dsPMCA,O
to,O
the,O
final,O
dilution,O
of,O
brain,O
material,O
108,O
-,O
fold,O
.,O
Mouse,O
or,O
hamster,O
normal,O
brain,O
homogenates,O
(,O
MoNBH,O
or,O
HaNBH,O
",",O
respectively,O
),O
are,O
shown,O
as,O
references,O
.,O
All,O
samples,O
except,O
MoNBH,O
and,O
HaNBH,O
were,O
treated,O
with,O
PK,O
.,O
Mouse,O
and,O
hamster,O
materials,O
were,O
stained,O
with,O
Ab3531,O
or,O
3F4,O
antibodies,O
",",O
respectively,O
.,O
Black,O
triangles,O
",",O
white,O
triangles,O
and,O
arrows,O
mark,O
di,O
"-,",O
mono,O
-,O
and,O
non,O
-,O
glycosylated,O
glycoforms,O
",",O
respectively,O
.,O
Glycoform,O
profiles,O
of,O
mouse,O
PrPC,O
from,O
three,O
independent,O
normal,O
brain,O
materials,O
(,O
C,O
"),",O
scrapie,O
brain,O
-,O
derived,O
material,O
(,O
D,O
),O
or,O
dsPMCAb,O
-,O
derived,O
material,O
(,O
E,O
),O
for,O
ME7,O
(,O
solid,O
lines,O
"),",O
22L,O
(,O
dotted,O
lines,O
),O
and,O
RML,O
(,O
dashed,O
lines,O
).,O
Profiles,O
were,O
built,O
and,O
normalized,O
as,O
described,O
in,O
Materials,O
and,O
Methods,O
using,O
results,O
of,O
1D,O
Western,O
blots,O
.,O
2D,O
analysis,O
of,O
charge,O
distribution,O
of,O
scrapie,O
brain,O
-,O
and,O
dsPMCAb,O
-,O
derived,O
materials,O
for,O
mouse,O
strains,O
RML,O
",",O
22L,O
and,O
ME7,O
(,O
A,O
),O
and,O
hamster,O
strains,O
263K,O
",",O
HY,O
",",O
DY,O
and,O
SSLOW,O
(,O
B,O
).,O
dsPMCAb,O
-,O
derived,O
materials,O
were,O
produced,O
as,O
described,O
in,O
the,O
legend,O
to,O
Fig,O
.,O
1,O
.,O
The,O
dash,O
line,O
shows,O
position,O
of,O
pI,O
7,O
.,O
5,O
and,O
arbitrary,O
divides,O
“,O
hypersialylated,O
”,O
and,O
“,O
hyposialylated,O
”,O
PrP,O
molecules,O
.,O
Appearance,O
of,O
more,O
than,O
one,O
charge,O
isoform,O
for,O
unglycosylated,O
PrP,O
is,O
attributed,O
to,O
structural,O
heterogeneity,O
of,O
the,O
GPI,O
anchor8,O
.,O
Nevertheless,O
",",O
due,O
to,O
sialylation,O
of,O
glycans,O
",",O
monoglycosylated,O
PrPs,O
can,O
carry,O
up,O
to,O
five,O
negatively,O
charged,O
sialic,O
acid,O
residues,O
",",O
while,O
diglycosylated,O
PrPs,O
–,O
up,O
to,O
ten,O
sialic,O
acid,O
residues,O
.,O
As,O
a,O
result,O
",",O
the,O
distribution,O
of,O
charge,O
isoform,O
is,O
shifted,O
toward,O
acidic,O
pH,O
for,O
monoglycosylated,O
PrPs,O
and,O
even,O
more,O
so,O
for,O
diglycosylated,O
PrPs,O
",",O
relative,O
to,O
that,O
of,O
unglycosylated,O
PrPs,O
.,O
All,O
samples,O
were,O
treated,O
with,O
PK,O
.,O
Mouse,O
and,O
hamster,O
materials,O
were,O
stained,O
with,O
Ab3531,O
or,O
3F4,O
antibodies,O
",",O
respectively,O
.,O
Black,O
triangles,O
",",O
white,O
triangles,O
and,O
arrows,O
mark,O
di,O
"-,",O
mono,O
-,O
and,O
non,O
-,O
glycosylated,O
glycoforms,O
",",O
respectively,O
.,O
Percentage,O
of,O
diglycosylated,O
glycoforms,O
plotted,O
as,O
a,O
function,O
of,O
percentage,O
of,O
hypersialylated,O
isoforms,O
for,O
brain,O
-,O
derived,O
(,O
circles,O
),O
and,O
dsPMCAb,O
-,O
derived,O
materials,O
(,O
diamonds,O
),O
for,O
mouse,O
(,O
RML,O
",",O
22L,O
and,O
ME7,O
),O
and,O
hamster,O
(,O
263K,O
",",O
HY,O
",",O
DY,O
and,O
SSLOW,O
),O
strains,O
.,O
Arrows,O
show,O
shifts,O
in,O
glycoform,O
ratio,O
after,O
amplification,O
in,O
dsPMCAb,O
.,O
Percentage,O
of,O
diglycosylated,O
glycoforms,O
and,O
hypersialylated,O
isoforms,O
are,O
calculated,O
as,O
described,O
in,O
Materials,O
and,O
Methods,O
.,O
For,O
each,O
strain,O
",",O
at,O
least,O
three,O
glycoform,O
ratio,O
values,O
were,O
acquired,O
from,O
independent,O
brain,O
materials,O
or,O
dsPMCA,O
reactions,O
;,O
the,O
variations,O
were,O
used,O
to,O
calculate,O
mean,O
and,O
standard,O
deviations,O
.,O
For,O
RML,O
",",O
22L,O
and,O
263K,O
brain,O
materials,O
at,O
least,O
three,O
sialylation,O
ratio,O
values,O
were,O
available,O
",",O
permitting,O
to,O
calculate,O
mean,O
and,O
standard,O
deviations,O
.,O
Black,O
solid,O
line,O
shows,O
the,O
result,O
of,O
linear,O
fitting,O
of,O
the,O
percent,O
of,O
diglycosylated,O
as,O
a,O
function,O
of,O
the,O
percent,O
of,O
hypersialylated,O
for,O
brain,O
-,O
derived,O
PrPSc,O
",",O
R2,O
=,O
0,O
.,O
89,O
.,O
Sialylation,O
profile,O
of,O
di,O
-,O
(,O
solid,O
lines,O
),O
or,O
mono,O
-,O
glycosylated,O
(,O
dashed,O
lines,O
),O
glycofoms,O
of,O
brain,O
-,O
derived,O
materials,O
for,O
263K,O
",",O
22L,O
",",O
ME7,O
and,O
RML,O
.,O
Profiles,O
were,O
built,O
as,O
described,O
in,O
Materials,O
and,O
Methods,O
using,O
results,O
of,O
2D,O
Western,O
blots,O
.,O
Mouse,O
scrapie,O
brain,O
materials,O
were,O
diluted,O
102,O
-,O
fold,O
into,O
10,O
%,O
МоNBH,O
or,O
desialylated,O
МоNBH,O
and,O
subjected,O
to,O
four,O
serial,O
PMCAb,O
or,O
dsPMCAb,O
rounds,O
.,O
The,O
material,O
amplified,O
in,O
each,O
round,O
was,O
diluted,O
to,O
a,O
specified,O
dilution,O
fold,O
for,O
the,O
next,O
round,O
as,O
indicated,O
.,O
Unamplified,O
scrapie,O
seeds,O
diluted,O
into,O
NBH,O
are,O
shown,O
as,O
round,O
0,O
.,O
Samples,O
were,O
treated,O
with,O
PK,O
as,O
indicated,O
.,O
All,O
blots,O
were,O
stained,O
with,O
Аb3531,O
antibody,O
.,O
(,O
A,O
),O
A,O
strain,O
with,O
minor,O
clashes,O
between,O
glycans,O
that,O
belong,O
to,O
neighboring,O
PrP,O
monomers,O
can,O
recruit,O
diglycosylated,O
monomers,O
.,O
This,O
strain,O
is,O
characterized,O
by,O
low,O
electrostatic,O
repulsion,O
between,O
sialylated,O
glycans,O
(,O
schematically,O
marked,O
by,O
lightning,O
bolts,O
).,O
(,O
B,O
),O
A,O
strain,O
with,O
substantial,O
spatial,O
constraints,O
between,O
glycans,O
from,O
neighboring,O
monomers,O
limits,O
percentage,O
of,O
diglycosylated,O
molecules,O
due,O
to,O
high,O
electrostatic,O
repulsion,O
between,O
sialic,O
acids,O
(,O
red,O
circles,O
with,O
negative,O
charge,O
),O
from,O
neighboring,O
N,O
-,O
glycans,O
.,O
Stages,O
of,O
change,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
among,O
a,O
random,O
sample,O
of,O
minority,O
Arab,O
-,O
male,O
smokers,O
in,O
Israel,O
Background,O
Despite,O
advanced,O
smoking,O
prevention,O
and,O
cessation,O
policies,O
in,O
many,O
countries,O
",",O
the,O
prevalence,O
of,O
cigarette,O
smoking,O
among,O
indigenous,O
and,O
some,O
ethnic,O
minorities,O
continues,O
to,O
be,O
high,O
.,O
This,O
study,O
examined,O
the,O
stages,O
of,O
change,O
(,O
SOC,O
),O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
among,O
Arab,O
men,O
in,O
Israel,O
shortly,O
after,O
new,O
regulations,O
of,O
free,O
-,O
of,O
-,O
charge,O
smoking,O
cessation,O
workshops,O
and,O
subsidized,O
medications,O
were,O
introduced,O
through,O
primary,O
health,O
care,O
clinics,O
.,O
Methods,O
We,O
conducted,O
a,O
countrywide,O
study,O
in,O
Israel,O
between,O
2012,O
–,O
2013,O
.,O
Participants,O
",",O
735,O
current,O
smokers,O
;,O
18,O
–,O
64,O
years,O
old,O
;,O
were,O
recruited,O
from,O
a,O
stratified,O
random,O
sample,O
and,O
interviewed,O
face,O
-,O
to,O
-,O
face,O
using,O
a,O
structured,O
questionnaire,O
in,O
Arabic,O
.,O
We,O
used,O
ordered,O
regression,O
to,O
examine,O
the,O
contribution,O
of,O
socio,O
-,O
economic,O
position,O
(,O
SEP,O
"),",O
health,O
status,O
",",O
psychosocial,O
attributes,O
",",O
smoking,O
-,O
related,O
factors,O
",",O
and,O
physician,O
advice,O
to,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
(,O
pre,O
-,O
contemplation,O
",",O
contemplation,O
and,O
preparation,O
).,O
Results,O
Of,O
the,O
current,O
smokers,O
",",O
61,O
.,O
8,O
%,O
were,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
",",O
23,O
.,O
8,O
%,O
were,O
at,O
the,O
contemplation,O
stage,O
",",O
and,O
only,O
14,O
.,O
4,O
%,O
were,O
at,O
the,O
preparation,O
stage,O
.,O
In,O
the,O
multinomial,O
analysis,O
",",O
factors,O
significantly,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
contributing,O
to,O
contemplation,O
stage,O
compared,O
to,O
pre,O
-,O
contemplation,O
stage,O
included,O
[,O
odds,O
ratio,O
(,O
OR,O
"),",O
95,O
%,O
confidence,O
interval,O
(,O
CI,O
)]:,O
chronic,O
morbidity,O
[,O
0,O
.,O
52,O
",",O
(,O
0,O
.,O
31,O
-,O
0,O
.,O
88,O
")],",O
social,O
support,O
[,O
1,O
.,O
35,O
",",O
(,O
1,O
.,O
07,O
-,O
1,O
.,O
70,O
")],",O
duration,O
of,O
smoking,O
for,O
11,O
–,O
21,O
years,O
[,O
1,O
.,O
94,O
",",O
(,O
1,O
.,O
07,O
-,O
3,O
.,O
50,O
")],",O
three,O
or,O
more,O
previous,O
attempts,O
to,O
quit,O
[,O
2,O
.,O
27,O
",",O
(,O
1,O
.,O
26,O
-,O
4,O
.,O
01,O
")],",O
knowledge,O
about,O
smoking,O
hazards,O
[,O
1,O
.,O
75,O
",",O
(,O
1,O
.,O
29,O
-,O
2,O
.,O
35,O
")],",O
positive,O
attitudes,O
toward,O
smoking,O
prevention,O
[,O
1,O
.,O
44,O
",",O
(,O
1,O
.,O
14,O
-,O
1,O
.,O
82,O
")],",O
and,O
physician,O
advice,O
to,O
quit,O
smoking,O
[,O
1,O
.,O
88,O
",",O
(,O
1,O
.,O
19,O
-,O
2,O
.,O
97,O
)].,O
The,O
factors,O
significantly,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
contributing,O
to,O
preparation,O
stage,O
compared,O
to,O
pre,O
-,O
contemplation,O
stage,O
were,O
[,O
OR,O
",",O
(,O
95,O
%,O
CI,O
)]:,O
chronic,O
morbidity,O
[,O
0,O
.,O
36,O
",",O
(,O
0,O
.,O
20,O
-,O
0,O
.,O
67,O
")],",O
anxiety,B-DS
[,O
1,O
.,O
07,O
",",O
(,O
1,O
.,O
01,O
-,O
1,O
.,O
13,O
")],",O
social,O
support,O
[,O
1,O
.,O
34,O
",",O
(,O
1,O
.,O
01,O
-,O
1,O
.,O
78,O
")],",O
duration,O
of,O
smoking,O
5,O
years,O
or,O
less,O
[,O
2,O
.,O
93,O
",",O
(,O
1,O
.,O
14,O
-,O
7,O
.,O
52,O
")],",O
three,O
or,O
more,O
previous,O
attempts,O
to,O
quit,O
[,O
3,O
.,O
16,O
",",O
(,O
1,O
.,O
60,O
-,O
6,O
.,O
26,O
")],",O
knowledge,O
about,O
smoking,O
hazards,O
[,O
1,O
.,O
57,O
",",O
(,O
1,O
.,O
10,O
-,O
2,O
.,O
21,O
")],",O
and,O
positive,O
attitudes,O
toward,O
smoking,O
prevention,O
[,O
1,O
.,O
34,O
",",O
(,O
1,O
.,O
00,O
-,O
1,O
.,O
82,O
)].,O
Conclusions,O
Most,O
Arab,O
men,O
who,O
currently,O
smoke,O
are,O
in,O
the,O
pre,O
-,O
contemplation,O
stage,O
",",O
indicating,O
low,O
readiness,O
to,O
quit,O
smoking,O
.,O
New,O
policies,O
of,O
free,O
-,O
of,O
-,O
charge,O
smoking,O
-,O
cessation,O
group,O
sessions,O
and,O
subsidized,O
medications,O
introduced,O
through,O
primary,O
health,O
care,O
clinics,O
in,O
Israel,O
may,O
be,O
less,O
effective,O
among,O
Arab,O
men,O
.,O
For,O
these,O
policies,O
to,O
promote,O
cessation,O
more,O
successfully,O
",",O
tailored,O
interventions,O
and,O
campaigns,O
may,O
be,O
needed,O
to,O
increase,O
the,O
readiness,O
to,O
quit,O
smoking,O
in,O
this,O
population,O
",",O
especially,O
for,O
those,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
.,O
Background,O
Smoking,O
remains,O
a,O
major,O
global,O
public,O
health,O
concern,O
despite,O
its,O
decreasing,O
prevalence,O
in,O
developed,O
counties,O
[,O
1,O
",",O
2,O
].,O
Smoking,O
is,O
the,O
leading,O
preventable,O
cause,O
of,O
chronic,O
morbidity,O
and,O
mortality,O
[,O
3,O
].,O
On,O
average,O
",",O
the,O
life,O
expectancy,O
of,O
smokers,O
is,O
reduced,O
by,O
almost,O
10,O
years,O
[,O
4,O
].,O
Smoking,O
cessation,O
can,O
decrease,O
the,O
risk,O
of,O
smoking,O
-,O
related,O
diseases,O
and,O
mortality,O
.,O
Smokers,O
who,O
stop,O
smoking,O
before,O
the,O
age,O
of,O
35,O
can,O
enjoy,O
the,O
same,O
life,O
expectancy,O
as,O
non,O
-,O
smokers,O
[,O
3,O
].,O
Smokers,O
who,O
quit,O
at,O
the,O
age,O
of,O
60,O
",",O
50,O
",",O
40,O
and,O
30,O
can,O
increase,O
their,O
life,O
expectancy,O
by,O
3,O
",",O
6,O
",",O
9,O
and,O
10,O
years,O
",",O
respectively,O
[,O
4,O
].,O
For,O
those,O
who,O
quit,O
before,O
the,O
age,O
of,O
50,O
",",O
the,O
risk,O
of,O
myocardial,B-DS
infarction,I-DS
can,O
be,O
reduced,O
by,O
half,O
one,O
year,O
after,O
smoking,O
cessation,O
[,O
5,O
",",O
6,O
].,O
Smoking,O
cessation,O
can,O
also,O
reduce,O
the,O
cost,O
of,O
treating,O
smoking,O
-,O
related,O
diseases,O
[,O
6,O
].,O
However,O
",",O
although,O
many,O
smokers,O
express,O
interest,O
in,O
quitting,O
",",O
only,O
2,O
-,O
5,O
%,O
succeed,O
annually,O
[,O
7,O
].,O
Behavioral,O
and,O
pharmacological,O
interventions,O
have,O
been,O
shown,O
to,O
be,O
effective,O
in,O
smoking,O
cessation,O
[,O
8,O
].,O
The,O
stages,O
of,O
change,O
(,O
SOC,O
),O
theory,O
has,O
been,O
used,O
in,O
many,O
behavioral,O
interventions,O
to,O
facilitate,O
smoking,O
cessation,O
[,O
9,O
",",O
10,O
].,O
The,O
SOC,O
assumes,O
that,O
smoking,O
cessation,O
is,O
a,O
process,O
of,O
movement,O
through,O
five,O
motivational,O
stages,O
[,O
11,O
",",O
12,O
"],",O
each,O
representing,O
a,O
different,O
temporal,O
and,O
motivational,O
aspect,O
of,O
behavioral,O
change,O
[,O
13,O
].,O
The,O
first,O
three,O
out,O
of,O
five,O
stages,O
describe,O
individuals,O
’,O
readiness,O
to,O
quit,O
smoking,O
.,O
These,O
stages,O
include,O
:,O
a,O
.,O
pre,O
-,O
contemplation,O
",",O
when,O
smokers,O
have,O
no,O
intention,O
to,O
quit,O
;,O
b,O
.,O
contemplation,O
",",O
when,O
smokers,O
express,O
an,O
intention,O
to,O
quit,O
smoking,O
within,O
the,O
next,O
6,O
months,O
;,O
and,O
c,O
.,O
preparation,O
",",O
when,O
smokers,O
plan,O
to,O
quit,O
smoking,O
within,O
the,O
next,O
30,O
days,O
.,O
When,O
individuals,O
quit,O
smoking,O
for,O
6,O
months,O
",",O
they,O
are,O
at,O
the,O
action,O
stage,O
.,O
They,O
are,O
considered,O
to,O
be,O
at,O
the,O
maintenance,O
stage,O
if,O
they,O
have,O
been,O
abstinent,O
for,O
6,O
months,O
to,O
5,O
years,O
",",O
and,O
at,O
the,O
termination,O
stage,O
if,O
they,O
have,O
been,O
abstinent,O
for,O
more,O
than,O
5,O
years,O
.,O
A,O
study,O
by,O
DiClemente,O
and,O
colleagues,O
found,O
that,O
stage,O
differences,O
predict,O
attempts,O
to,O
quit,O
smoking,O
and,O
cessation,O
success,O
at,O
1,O
-,O
and,O
6,O
-,O
month,O
follow,O
-,O
up,O
[,O
13,O
].,O
Interventions,O
tailored,O
to,O
an,O
individual,O
’,O
s,O
readiness,O
to,O
quit,O
smoking,O
based,O
on,O
SOC,O
can,O
be,O
more,O
effective,O
in,O
facilitating,O
quitting,O
success,O
[,O
14,O
–,O
17,O
].,O
Prochaska,O
et,O
al,O
.,O
[,O
18,O
].,O
suggested,O
employing,O
different,O
strategies,O
called,O
“,O
process,O
of,O
change,O
”,O
to,O
promote,O
behavioral,O
change,O
across,O
different,O
SOC,O
.,O
Rosen,O
et,O
al,O
.,O
[,O
19,O
].,O
conducted,O
a,O
meta,O
-,O
analysis,O
of,O
studies,O
evaluating,O
the,O
process,O
of,O
change,O
and,O
found,O
that,O
cognitive,O
processes,O
such,O
as,O
“,O
consciousness,O
raising,O
”,O
were,O
more,O
effective,O
among,O
smokers,O
at,O
the,O
pre,O
-,O
contemplation,O
and,O
contemplation,O
stages,O
.,O
Assessing,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
among,O
smokers,O
in,O
health,O
care,O
service,O
settings,O
can,O
help,O
in,O
planning,O
more,O
effective,O
interventions,O
for,O
cessation,O
[,O
11,O
",",O
20,O
].,O
However,O
",",O
smoking,O
cessation,O
policies,O
and,O
interventions,O
do,O
not,O
always,O
consider,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
in,O
program,O
planning,O
.,O
This,O
is,O
particularly,O
important,O
when,O
there,O
are,O
different,O
population,O
groups,O
who,O
might,O
be,O
at,O
different,O
stages,O
in,O
their,O
readiness,O
to,O
quit,O
smoking,O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
policy,O
report,O
on,O
smoking,O
cessation,O
shows,O
that,O
many,O
countries,O
implement,O
the,O
MPOWER,O
plan,O
",",O
which,O
includes,O
monitoring,O
tobacco,B-OG
use,O
",",O
implementing,O
prevention,O
policies,O
",",O
protecting,O
people,O
from,O
tobacco,B-OG
smoke,O
",",O
offering,O
help,O
to,O
quit,O
tobacco,B-OG
use,O
",",O
warning,O
about,O
the,O
dangers,O
of,O
tobacco,B-OG
",",O
enforcing,O
bans,O
on,O
tobacco,B-OG
advertising,O
",",O
promotion,O
and,O
sponsorship,O
",",O
promoting,O
policies,O
to,O
quit,O
smoking,O
",",O
and,O
raising,O
taxes,O
on,O
tobacco,B-OG
[,O
21,O
].,O
However,O
",",O
smoking,O
cessation,O
is,O
a,O
neglected,O
area,O
in,O
the,O
initial,O
period,O
of,O
the,O
Framework,O
Convention,O
on,O
Tobacco,B-OG
Control,O
(,O
FCTC,O
),O
adoption,O
and,O
implementation,O
[,O
22,O
].,O
Despite,O
the,O
availability,O
of,O
nationwide,O
tobacco,B-OG
control,O
programs,O
and,O
policies,O
in,O
many,O
countries,O
[,O
23,O
"],",O
smoking,O
cessation,O
remains,O
a,O
challenge,O
",",O
particularly,O
among,O
some,O
ethnic,O
minorities,O
[,O
24,O
–,O
27,O
].,O
For,O
example,O
",",O
the,O
prevalence,O
of,O
smoking,O
is,O
higher,O
among,O
Aborigine,O
peoples,O
in,O
Australia,O
[,O
28,O
],O
and,O
Canada,O
[,O
29,O
"],",O
racial,O
and,O
ethnic,O
minorities,O
in,O
the,O
UK,O
[,O
30,O
"],",O
and,O
some,O
ethnic,O
minorities,O
in,O
the,O
US,O
[,O
31,O
"],",O
compared,O
to,O
the,O
majority,O
population,O
groups,O
.,O
Generally,O
",",O
few,O
studies,O
have,O
been,O
conducted,O
on,O
smoking,O
cessation,O
in,O
ethnic,O
minority,O
populations,O
[,O
32,O
].,O
Thus,O
",",O
it,O
remains,O
unclear,O
as,O
to,O
why,O
smoking,O
cessation,O
programs,O
are,O
less,O
effective,O
among,O
minority,O
groups,O
[,O
25,O
",",O
26,O
].,O
A,O
study,O
in,O
a,O
health,O
care,O
setting,O
in,O
the,O
US,O
showed,O
that,O
Black,O
and,O
Hispanic,O
individuals,O
were,O
less,O
likely,O
to,O
receive,O
and,O
use,O
smoking,O
cessation,O
interventions,O
[,O
33,O
].,O
Researchers,O
argue,O
that,O
universal,O
policies,O
for,O
smoking,O
cessation,O
can,O
increase,O
inequalities,O
in,O
smoking,O
since,O
such,O
policies,O
are,O
less,O
effective,O
in,O
minority,O
groups,O
[,O
34,O
].,O
Therefore,O
",",O
smoking,O
cessation,O
interventions,O
need,O
to,O
be,O
tailored,O
to,O
different,O
population,O
groups,O
and,O
include,O
assessment,O
of,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
at,O
baseline,O
[,O
27,O
",",O
35,O
].,O
This,O
requires,O
more,O
research,O
on,O
disadvantaged,O
and,O
marginalized,O
subgroups,O
of,O
society,O
[,O
32,O
].,O
In,O
Israel,O
",",O
despite,O
implementation,O
of,O
the,O
WHO,O
MPOWER,O
plan,O
of,O
tobacco,B-OG
control,O
and,O
multiple,O
national,O
programs,O
and,O
interventions,O
",",O
there,O
are,O
persistent,O
inequalities,O
in,O
rates,O
of,O
smoking,O
between,O
population,O
groups,O
.,O
Of,O
special,O
concern,O
is,O
the,O
very,O
high,O
prevalence,O
of,O
smoking,O
among,O
Arab,O
minority,O
men,O
[,O
36,O
].,O
In,O
all,O
age,O
groups,O
",",O
smoking,O
prevalence,O
is,O
1,O
.,O
5,O
-,O
2,O
.,O
2,O
times,O
higher,O
among,O
Arab,O
men,O
compared,O
to,O
Jewish,O
men,O
[,O
36,O
].,O
In,O
2011,O
",",O
smoking,O
prevalence,O
was,O
43,O
.,O
8,O
%,O
among,O
Arab,O
men,O
compared,O
to,O
23,O
.,O
7,O
%,O
among,O
their,O
Jewish,O
counterparts,O
[,O
36,O
].,O
In,O
addition,O
to,O
higher,O
prevalence,O
of,O
smoking,O
",",O
Arab,O
men,O
smoke,O
more,O
frequently,O
than,O
Jewish,O
men,O
.,O
According,O
to,O
the,O
Israeli,O
Ministry,O
of,O
Health,O
report,O
(,O
2011,O
"),",O
among,O
smokers,O
",",O
30,O
.,O
9,O
%,O
of,O
Arab,O
men,O
smoke,O
more,O
than,O
one,O
cigarette,O
pack,O
a,O
day,O
compared,O
to,O
only,O
12,O
.,O
6,O
%,O
of,O
Jewish,O
men,O
[,O
36,O
].,O
Smoking,O
has,O
been,O
attributed,O
to,O
increased,O
incidence,O
of,O
lung,B-DS
cancer,I-DS
among,O
Arab,O
men,O
[,O
37,O
].,O
However,O
",",O
little,O
is,O
known,O
about,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
among,O
Arab,O
men,O
in,O
Israel,O
.,O
Despite,O
a,O
higher,O
prevalence,O
of,O
smoking,O
",",O
few,O
studies,O
have,O
been,O
conducted,O
on,O
smoking,O
cessation,O
and,O
intention,O
to,O
quit,O
among,O
individuals,O
in,O
Arab,O
countries,O
.,O
One,O
study,O
found,O
high,O
rates,O
of,O
smoking,O
in,O
Middle,O
Eastern,O
countries,O
",",O
ranging,O
from,O
30,O
%,O
to,O
60,O
%,O
[,O
38,O
].,O
Between,O
1990,O
and,O
2009,O
",",O
cigarette,O
consumption,O
increased,O
by,O
57,O
%,O
in,O
the,O
Middle,O
East,O
and,O
Africa,O
but,O
dropped,O
by,O
26,O
%,O
in,O
Western,O
Europe,O
[,O
39,O
].,O
High,O
prevalence,O
of,O
smoking,O
in,O
the,O
Mediterranean,O
region,O
had,O
implications,O
for,O
smokers,O
’,O
readiness,O
to,O
quit,O
and,O
might,O
translate,O
into,O
a,O
higher,O
proportion,O
of,O
smokers,O
being,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
.,O
In,O
the,O
current,O
study,O
",",O
we,O
applied,O
the,O
SOC,O
theory,O
to,O
assess,O
the,O
readiness,O
to,O
quit,O
smoking,O
and,O
examined,O
factors,O
that,O
might,O
contribute,O
to,O
pre,O
-,O
contemplation,O
",",O
contemplation,O
",",O
and,O
preparation,O
in,O
a,O
random,O
sample,O
of,O
Arab,O
minority,O
men,O
in,O
Israel,O
.,O
The,O
study,O
was,O
conducted,O
shortly,O
after,O
new,O
regulations,O
of,O
free,O
-,O
of,O
-,O
charge,O
workshops,O
and,O
subsidized,O
medications,O
were,O
introduced,O
in,O
primary,O
health,O
care,O
clinics,O
in,O
2010,O
.,O
Therefore,O
",",O
the,O
current,O
study,O
might,O
provide,O
baseline,O
information,O
needed,O
to,O
assess,O
whether,O
the,O
new,O
health,O
policies,O
of,O
free,O
-,O
of,O
-,O
charge,O
workshops,O
and,O
subsidized,O
medications,O
are,O
effective,O
in,O
changing,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
among,O
Arab,O
male,O
smokers,O
.,O
Methods,O
Sampling,O
We,O
conducted,O
a,O
cross,O
-,O
sectional,O
study,O
between,O
2012,O
and,O
2013,O
.,O
The,O
study,O
included,O
a,O
nationwide,O
stratified,O
random,O
sample,O
of,O
Arab,O
men,O
.,O
Individuals,O
were,O
eligible,O
if,O
they,O
were,O
between,O
18,O
and,O
64,O
years,O
of,O
age,O
",",O
tobacco,B-OG
smokers,O
",",O
Arab,O
citizens,O
in,O
Israel,O
",",O
and,O
living,O
in,O
an,O
Arab,O
town,O
of,O
5,O
",",O
000,O
or,O
more,O
inhabitants,O
.,O
The,O
study,O
participants,O
were,O
randomly,O
selected,O
from,O
the,O
Israeli,O
population,O
registry,O
.,O
The,O
sample,O
design,O
took,O
into,O
account,O
the,O
Arab,O
population,O
distribution,O
according,O
to,O
area,O
of,O
residence,O
",",O
locality,O
size,O
and,O
socio,O
-,O
economic,O
status,O
.,O
Sixty,O
-,O
four,O
Arab,O
towns,O
with,O
5,O
",",O
000,O
or,O
more,O
residents,O
were,O
identified,O
.,O
For,O
the,O
purpose,O
of,O
creating,O
the,O
sample,O
strata,O
",",O
the,O
country,O
was,O
divided,O
into,O
three,O
major,O
regions,O
in,O
Israel,O
:,O
North,O
",",O
Center,O
and,O
South,O
",",O
containing,O
58,O
"%,",O
30,O
%,O
and,O
12,O
%,O
of,O
the,O
Arab,O
population,O
",",O
respectively,O
.,O
Within,O
each,O
region,O
",",O
towns,O
were,O
stratified,O
according,O
to,O
population,O
size,O
(,O
5,O
",",O
000,O
-,O
9,O
",",O
999,O
",",O
10,O
",",O
000,O
-,O
29,O
",",O
999,O
",",O
and,O
30,O
",",O
000,O
or,O
more,O
residents,O
),O
and,O
three,O
ranks,O
of,O
socio,O
-,O
economic,O
score,O
of,O
the,O
locality,O
according,O
to,O
the,O
Central,O
Bureau,O
of,O
Statistics,O
.,O
For,O
each,O
region,O
",",O
one,O
town,O
was,O
sampled,O
from,O
each,O
size,O
and,O
socio,O
-,O
economic,O
specific,O
stratum,O
.,O
The,O
final,O
sample,O
consisted,O
of,O
20,O
towns,O
.,O
The,O
number,O
of,O
persons,O
sampled,O
and,O
interviewed,O
in,O
each,O
locality,O
was,O
proportional,O
to,O
the,O
size,O
of,O
the,O
entire,O
population,O
of,O
the,O
respective,O
stratum,O
.,O
Information,O
that,O
identifies,O
the,O
men,O
sampled,O
from,O
the,O
population,O
registry,O
was,O
received,O
(,O
first,O
name,O
",",O
last,O
name,O
",",O
ID,O
and,O
address,O
),O
from,O
the,O
Ministry,O
of,O
Interior,O
(,O
approximately,O
15,O
",",O
000,O
men,O
).,O
We,O
prepared,O
two,O
random,O
samples,O
of,O
Arab,O
men,O
.,O
The,O
size,O
of,O
each,O
sample,O
was,O
at,O
least,O
three,O
times,O
the,O
number,O
of,O
interviews,O
for,O
replacement,O
of,O
participants,O
",",O
to,O
account,O
for,O
lack,O
of,O
identification,O
or,O
refusal,O
to,O
interview,O
.,O
We,O
used,O
STATA,O
software,O
(,O
version,O
13,O
),O
for,O
power,O
calculation,O
and,O
sample,O
size,O
.,O
This,O
was,O
based,O
on,O
several,O
assumptions,O
:,O
1,O
.,O
The,O
prevalence,O
of,O
Arab,O
men,O
smokers,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
will,O
be,O
50,O
%,O
based,O
on,O
previous,O
reports,O
in,O
this,O
population,O
[,O
36,O
],O
and,O
on,O
results,O
about,O
smokers,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
among,O
Arab,O
immigrants,O
in,O
Australia,O
;,O
[,O
40,O
],O
2,O
.,O
Based,O
on,O
the,O
findings,O
by,O
Wewer,O
et,O
al,O
".,",O
[,O
41,O
],O
there,O
will,O
be,O
approximately,O
a,O
10,O
%,O
difference,O
in,O
the,O
proportion,O
of,O
individuals,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
between,O
the,O
18,O
–,O
24,O
and,O
45,O
–,O
64,O
age,O
groups,O
(,O
58,O
.,O
4,O
%,O
and,O
68,O
.,O
0,O
"%,",O
respectively,O
).,O
The,O
needed,O
sample,O
size,O
is,O
964,O
at,O
a,O
significance,O
level,O
α,O
of,O
5,O
%,O
and,O
80,O
%,O
power,O
.,O
This,O
sample,O
size,O
also,O
took,O
into,O
consideration,O
0,O
.,O
005,O
for,O
Inter,O
Cluster,O
Correlation,O
within,O
towns,O
",",O
as,O
this,O
is,O
a,O
stratified,O
sample,O
[,O
42,O
].,O
Data,O
collection,O
This,O
study,O
was,O
approved,O
by,O
the,O
Ethics,O
Review,O
Board,O
of,O
the,O
Faculty,O
of,O
Health,O
Sciences,O
at,O
Ben,O
-,O
Gurion,O
University,O
of,O
the,O
Negev,O
.,O
Data,O
were,O
collected,O
between,O
September,O
2012,O
and,O
September,O
2013,O
.,O
Men,O
were,O
contacted,O
via,O
telephone,O
calls,O
or,O
home,O
visits,O
and,O
screened,O
for,O
their,O
tobacco,B-OG
smoking,O
status,O
.,O
Men,O
who,O
met,O
the,O
eligibility,O
criteria,O
and,O
agreed,O
to,O
participate,O
in,O
the,O
study,O
signed,O
an,O
informed,O
consent,O
form,O
and,O
were,O
interviewed,O
face,O
-,O
to,O
-,O
face,O
in,O
their,O
home,O
by,O
trained,O
Arab,O
-,O
speaking,O
interviewers,O
using,O
a,O
structured,O
questionnaire,O
in,O
Arabic,O
.,O
Out,O
of,O
1,O
",",O
620,O
men,O
who,O
were,O
approached,O
",",O
1,O
",",O
165,O
men,O
met,O
the,O
eligibility,O
criteria,O
(,O
current,O
or,O
past,O
smokers,O
),O
and,O
964,O
agreed,O
to,O
participate,O
(,O
response,O
rate,O
=,O
83,O
%).,O
Of,O
those,O
",",O
735,O
were,O
current,O
smokers,O
and,O
formed,O
the,O
study,O
population,O
for,O
this,O
paper,O
.,O
Measures,O
The,O
stages,O
of,O
change,O
(,O
SOC,O
),O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
Was,O
measured,O
using,O
the,O
following,O
questions,O
:,O
“,O
Do,O
you,O
smoke,O
?”,O
Participants,O
who,O
replied,O
positively,O
were,O
coded,O
as,O
current,O
smokers,O
.,O
They,O
were,O
then,O
asked,O
if,O
they,O
intend,O
to,O
quit,O
smoking,O
.,O
Response,O
categories,O
were,O
“,O
no,O
",",O
never,O
”,O
(,O
pre,O
-,O
contemplation,O
stage,O
"),",O
“,O
yes,O
",",O
thinking,O
to,O
quit,O
within,O
the,O
next,O
6,O
month,O
”,O
(,O
contemplation,O
stage,O
"),",O
and,O
“,O
yes,O
",",O
thinking,O
to,O
quit,O
within,O
the,O
next,O
month,O
”,O
(,O
preparation,O
stage,O
).,O
Sociodemographic,O
characteristics,O
included,O
age,O
groups,O
according,O
to,O
quintiles,O
(,O
18,O
–,O
25,O
",",O
26,O
–,O
35,O
",",O
36,O
–,O
45,O
and,O
46,O
–,O
64,O
years,O
of,O
age,O
"),",O
and,O
marital,O
status,O
(,O
married,O
or,O
unmarried,O
).,O
Socioeconomic,O
position,O
(,O
SEP,O
),O
was,O
determined,O
by,O
three,O
variables,O
:,O
Education,O
level,O
:,O
The,O
highest,O
educational,O
institution,O
the,O
participant,O
completed,O
(“,O
less,O
than,O
high,O
school,O
",”",O
“,O
high,O
school,O
”,O
and,O
“,O
more,O
than,O
high,O
school,O
”).,O
Primary,O
source,O
of,O
income,O
:,O
The,O
main,O
source,O
of,O
household,O
income,O
(,O
from,O
“,O
work,O
”,O
or,O
“,O
social,O
allowance,O
and,O
other,O
”).,O
Employment,O
status,O
:,O
The,O
participant,O
’,O
s,O
current,O
employment,O
status,O
(“,O
yes,O
",",O
full,O
time,O
employment,O
”,O
and,O
“,O
part,O
-,O
time,O
work,O
or,O
unemployed,O
”).,O
Health,O
status,O
included,O
two,O
variables,O
Chronic,B-DS
disease,I-DS
:,O
A,O
yes,O
/,O
no,O
question,O
;,O
if,O
the,O
participant,O
was,O
ever,O
informed,O
by,O
a,O
physician,O
that,O
he,O
has,O
a,O
chronic,B-DS
disease,I-DS
.,O
Anxiety,B-DS
level,O
was,O
measured,O
by,O
the,O
“,O
State,O
-,O
Trait,O
Anxiety,B-DS
Inventory,O
”,O
(,O
STAI,O
),O
[,O
43,O
",",O
44,O
"],",O
a,O
commonly,O
used,O
measure,O
[,O
45,O
",",O
46,O
].,O
We,O
used,O
ten,O
items,O
from,O
the,O
original,O
scale,O
that,O
assesses,O
trait,O
and,O
state,O
anxiety,B-DS
.,O
Examples,O
of,O
state,O
anxiety,B-DS
items,O
include,O
:,O
“,O
I,O
am,O
tense,O
"”,",O
“,O
I,O
am,O
worried,O
"”,",O
“,O
I,O
feel,O
calm,O
"”,",O
and,O
“,O
I,O
feel,O
secure,O
”.,O
Examples,O
of,O
trait,O
anxiety,B-DS
items,O
include,O
:,O
“,O
I,O
worry,O
too,O
much,O
over,O
something,O
that,O
really,O
doesn,O
’,O
t,O
matter,O
"”,",O
“,O
I,O
am,O
content,O
"”,",O
and,O
“,O
I,O
am,O
a,O
steady,O
person,O
”.,O
Response,O
categories,O
include,O
:,O
1,O
.,O
almost,O
never,O
",",O
2,O
.,O
sometimes,O
",",O
3,O
.,O
often,O
",",O
and,O
4,O
.,O
almost,O
always,O
.,O
The,O
codes,O
of,O
positively,O
worded,O
items,O
were,O
reversed,O
.,O
The,O
ten,O
items,O
were,O
summed,O
to,O
create,O
a,O
total,O
score,O
of,O
anxiety,B-DS
(,O
range,O
1,O
–,O
40,O
).,O
Higher,O
scores,O
indicate,O
greater,O
anxiety,B-DS
levels,O
.,O
Cronbach,O
’,O
s,O
alpha,O
of,O
the,O
scale,O
was,O
0,O
.,O
796,O
",",O
indicating,O
high,O
internal,O
consistency,O
.,O
Psychological,O
factors,O
included,O
two,O
variables,O
Stressful,O
life,O
events,O
measures,O
exposure,O
to,O
nine,O
stressful,O
events,O
during,O
the,O
previous,O
year,O
(,O
e,O
.,O
g,O
".,",O
unemployment,O
",",O
major,O
family,O
problems,O
),O
[,O
47,O
].,O
The,O
list,O
includes,O
a,O
modified,O
version,O
of,O
the,O
recent,O
life,O
events,O
index,O
[,O
48,O
].,O
Respondents,O
were,O
asked,O
:,O
“,O
For,O
each,O
situation,O
",",O
indicate,O
whether,O
it,O
have,O
happened,O
to,O
you,O
or,O
to,O
close,O
family,O
members,O
(,O
i,O
.,O
e,O
".,",O
spouse,O
",",O
children,O
",",O
parents,O
",",O
or,O
close,O
friends,O
),O
in,O
the,O
last,O
year,O
:,O
Did,O
you,O
or,O
someone,O
in,O
your,O
family,O
1,O
),O
Get,O
fired,O
from,O
work,O
?,O
2,O
),O
Had,O
a,O
major,O
financial,O
crisis,O
?,O
3,O
),O
Experienced,O
death,O
of,O
a,O
family,O
member,O
or,O
a,O
close,O
relative,O
?,O
4,O
),O
Get,O
sick,O
or,O
injured,O
?,O
5,O
),O
Experienced,O
a,O
change,O
of,O
job,O
to,O
lower,O
skill,O
one,O
?,O
6,O
),O
Begin,O
receiving,O
income,O
support,O
or,O
go,O
on,O
welfare,O
?,O
and,O
7,O
),O
Experienced,O
any,O
other,O
difficult,O
life,O
events,O
in,O
the,O
last,O
year,O
?”,O
The,O
modified,O
questions,O
include,O
:,O
“,O
During,O
the,O
past,O
four,O
years,O
:,O
8,O
),O
Did,O
you,O
or,O
someone,O
in,O
your,O
family,O
get,O
injured,O
in,O
events,O
related,O
to,O
the,O
Arab,O
-,O
Israeli,O
conflict,O
(,O
e,O
.,O
g,O
".,",O
a,O
terror,O
attack,O
",",O
Nakba,O
day,O
",",O
protests,O
)?,O
and,O
9,O
),O
Did,O
you,O
or,O
someone,O
in,O
your,O
family,O
spend,O
time,O
in,O
prison,O
?”,O
Responses,O
categories,O
were,O
yes,O
\,O
no,O
.,O
We,O
summed,O
the,O
response,O
scores,O
across,O
all,O
items,O
to,O
create,O
a,O
count,O
variable,O
of,O
stressful,O
life,O
events,O
(,O
range,O
0,O
–,O
9,O
).,O
Higher,O
scores,O
indicate,O
higher,O
levels,O
of,O
exposure,O
.,O
Social,O
support,O
was,O
measured,O
by,O
a,O
scale,O
of,O
six,O
items,O
assessing,O
material,O
",",O
emotional,O
and,O
informational,O
support,O
[,O
49,O
].,O
The,O
general,O
question,O
was,O
:,O
“,O
To,O
what,O
extent,O
do,O
you,O
have,O
the,O
following,O
types,O
of,O
support,O
?”;,O
Examples,O
for,O
types,O
of,O
support,O
:,O
1,O
.,O
Someone,O
who,O
provides,O
you,O
with,O
advice,O
during,O
difficult,O
times,O
;,O
2,O
.,O
Someone,O
who,O
helps,O
you,O
materially,O
",",O
such,O
as,O
takes,O
you,O
to,O
the,O
doctor,O
",",O
etc,O
.;,O
and,O
3,O
.,O
Someone,O
you,O
trust,O
and,O
talk,O
to,O
about,O
your,O
daily,O
problems,O
.,O
Response,O
categories,O
were,O
:,O
1,O
.,O
never,O
",",O
2,O
.,O
rarely,O
",",O
3,O
.,O
sometimes,O
",",O
4,O
.,O
frequently,O
",",O
and,O
5,O
.,O
always,O
.,O
We,O
calculated,O
the,O
mean,O
scores,O
for,O
the,O
answers,O
(,O
range,O
1,O
–,O
5,O
).,O
Higher,O
scores,O
indicate,O
a,O
higher,O
level,O
of,O
social,O
support,O
.,O
Internal,O
consistency,O
of,O
the,O
scale,O
was,O
high,O
(,O
Cronbach,O
’,O
s,O
alpha,O
=,O
0,O
.,O
87,O
),O
in,O
prior,O
research,O
among,O
Arab,O
populations,O
in,O
Israel,O
[,O
50,O
].,O
In,O
the,O
current,O
study,O
Cronbach,O
’,O
s,O
alpha,O
was,O
0,O
.,O
91,O
.,O
Smoking,O
-,O
related,O
variables,O
included,O
direct,O
questions,O
regarding,O
Age,O
at,O
initiation,O
of,O
smoking,O
was,O
grouped,O
into,O
three,O
categories,O
:,O
15,O
years,O
or,O
less,O
",",O
16,O
–,O
18,O
years,O
",",O
and,O
19,O
years,O
or,O
more,O
.,O
These,O
categories,O
are,O
closely,O
related,O
to,O
the,O
age,O
quartiles,O
of,O
our,O
study,O
sample,O
.,O
Duration,O
of,O
smoking,O
was,O
classified,O
into,O
four,O
categories,O
:,O
5,O
years,O
or,O
less,O
",",O
6,O
–,O
10,O
years,O
",",O
11,O
–,O
20,O
years,O
",",O
and,O
21,O
years,O
or,O
more,O
.,O
Number,O
of,O
cigarettes,O
smoked,O
per,O
day,O
:,O
Current,O
smokers,O
were,O
asked,O
:,O
“,O
on,O
average,O
",",O
how,O
many,O
cigarettes,O
per,O
day,O
do,O
you,O
smoke,O
?”,O
Response,O
categories,O
were,O
“,O
10,O
cigarettes,O
or,O
less,O
"”,",O
“,O
11,O
-,O
20,O
cigarettes,O
"”,",O
“,O
21,O
-,O
30,O
cigarettes,O
"”,",O
and,O
“,O
31,O
cigarettes,O
or,O
more,O
”.,O
Number,O
of,O
previous,O
attempts,O
to,O
quit,O
was,O
measured,O
by,O
a,O
direct,O
question,O
:,O
“,O
How,O
many,O
times,O
did,O
you,O
try,O
to,O
quit,O
smoking,O
?”,O
Answers,O
were,O
grouped,O
into,O
three,O
categories,O
:,O
never,O
",",O
once,O
or,O
twice,O
",",O
three,O
times,O
or,O
more,O
.,O
Nicotine,B-DS
dependence,I-DS
level,O
was,O
measured,O
by,O
the,O
FrangestÖm,O
Test,O
for,O
Nicotine,B-DS
Dependence,I-DS
(,O
FTND,O
),O
[,O
51,O
].,O
This,O
measure,O
includes,O
six,O
items,O
:,O
three,O
yes,O
/,O
no,O
items,O
are,O
scored,O
0,O
(,O
no,O
),O
and,O
1,O
(,O
yes,O
),O
and,O
three,O
multiple,O
-,O
choice,O
items,O
are,O
scored,O
from,O
0,O
to,O
3,O
.,O
The,O
items,O
were,O
summed,O
to,O
yield,O
a,O
total,O
score,O
of,O
0,O
–,O
10,O
.,O
Classification,O
of,O
dependence,O
is,O
as,O
follows,O
:,O
0,O
–,O
2,O
very,O
low,O
",",O
3,O
–,O
4,O
low,O
",",O
5,O
moderate,O
",",O
6,O
–,O
7,O
high,O
",",O
8,O
–,O
10,O
very,O
high,O
.,O
In,O
the,O
current,O
study,O
this,O
variable,O
was,O
used,O
as,O
continuous,O
variable,O
",",O
with,O
higher,O
scores,O
indicating,O
greater,O
nicotine,B-DS
dependence,I-DS
.,O
Knowledge,O
about,O
smoking,O
hazards,O
included,O
the,O
sum,O
score,O
of,O
three,O
yes,O
/,O
no,O
questions,O
:,O
“,O
Do,O
you,O
think,O
smoking,O
can,O
harm,O
your,O
ability,O
to,O
do,O
activities,O
that,O
you,O
are,O
used,O
to,O
do,O
day,O
by,O
day,O
?”,O
“,O
Do,O
you,O
think,O
that,O
smoking,O
can,O
harm,O
organs,O
within,O
the,O
body,O
?”,O
and,O
“,O
Do,O
you,O
think,O
smoking,O
can,O
cause,O
diseases,O
?”,O
The,O
answers,O
were,O
summed,O
into,O
one,O
score,O
.,O
This,O
was,O
a,O
continuous,O
variable,O
in,O
the,O
current,O
study,O
",",O
with,O
higher,O
scores,O
indicating,O
greater,O
knowledge,O
(,O
range,O
:,O
0,O
–,O
3,O
).,O
Attitudes,O
towards,O
smoking,O
prevention,O
and,O
cessation,O
were,O
measured,O
by,O
the,O
mean,O
score,O
of,O
the,O
level,O
of,O
agreement,O
to,O
three,O
statements,O
:,O
“,O
To,O
what,O
extent,O
do,O
you,O
:,O
1,O
.,O
Support,O
the,O
anti,O
-,O
smoking,O
law,O
in,O
the,O
public,O
places,O
?,O
2,O
.,O
Think,O
that,O
there,O
is,O
a,O
need,O
to,O
enforce,O
smoking,O
prevention,O
and,O
treatment,O
in,O
the,O
Arab,O
society,O
in,O
Israel,O
?,O
3,O
.,O
Think,O
that,O
smoking,O
is,O
a,O
common,O
habit,O
among,O
Arab,O
men,O
?”,O
Response,O
categories,O
were,O
:,O
“,O
strongly,O
agree,O
",”",O
“,O
agree,O
",”",O
“,O
don,O
’,O
t,O
agree,O
",”",O
and,O
“,O
don,O
’,O
t,O
agree,O
at,O
all,O
”.,O
This,O
was,O
a,O
continuous,O
variable,O
in,O
the,O
current,O
study,O
",",O
with,O
higher,O
mean,O
scores,O
indicating,O
greater,O
levels,O
of,O
agreement,O
(,O
range,O
0,O
–,O
3,O
).,O
Smoking,O
social,O
environment,O
included,O
the,O
number,O
of,O
smokers,O
in,O
the,O
participant,O
’,O
s,O
home,O
in,O
addition,O
to,O
himself,O
(,O
none,O
",",O
one,O
",",O
and,O
two,O
or,O
more,O
"),",O
parental,O
smoking,O
(,O
yes,O
/,O
no,O
"),",O
and,O
indoor,O
smoking,O
(,O
yes,O
/,O
no,O
).,O
Physician,O
advice,O
to,O
quit,O
:,O
An,O
answer,O
to,O
a,O
yes,O
/,O
no,O
question,O
assessing,O
if,O
the,O
participant,O
had,O
ever,O
been,O
advised,O
by,O
his,O
family,O
physician,O
to,O
quit,O
smoking,O
.,O
Data,O
analysis,O
Data,O
analysis,O
was,O
conducted,O
using,O
SAS,O
(,O
Version,O
9,O
.,O
3,O
.,O
Cary,O
",",O
NC,O
:,O
SAS,O
Institute,O
Inc,O
.,O
2011,O
).,O
We,O
examined,O
the,O
univariate,O
association,O
between,O
the,O
independent,O
variables,O
and,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
(,O
pre,O
-,O
contemplation,O
",",O
contemplation,O
and,O
preparation,O
"),",O
using,O
Chi,O
-,O
square,O
test,O
for,O
categorical,O
variables,O
",",O
and,O
Kruskel,O
-,O
Wallis,O
for,O
the,O
independent,O
continuous,O
variables,O
.,O
Independent,O
variables,O
that,O
were,O
significantly,O
(,O
p,O
<,O
0,O
.,O
05,O
),O
associated,O
with,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
in,O
the,O
univariate,O
analysis,O
were,O
included,O
in,O
ordered,O
logistic,O
regression,O
analysis,O
after,O
the,O
proportional,O
odds,O
assumption,O
was,O
tested,O
.,O
Pre,O
-,O
contemplation,O
was,O
the,O
reference,O
category,O
for,O
the,O
other,O
two,O
categories,O
(,O
contemplation,O
and,O
preparation,O
).,O
Results,O
The,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
are,O
presented,O
in,O
Fig,O
.,O
1,O
.,O
Of,O
the,O
sample,O
",",O
61,O
.,O
8,O
%,O
were,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
",",O
23,O
.,O
8,O
%,O
were,O
at,O
the,O
contemplation,O
and,O
14,O
.,O
4,O
%,O
were,O
at,O
the,O
preparation,O
stage,O
.,O
Fig,O
.,O
1Stages,O
of,O
change,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
among,O
Arab,O
men,O
smokers,O
in,O
Israel,O
The,O
distribution,O
of,O
the,O
study,O
variables,O
is,O
presented,O
in,O
Table,O
1,O
.,O
The,O
average,O
age,O
of,O
the,O
participants,O
was,O
36,O
.,O
42,O
years,O
(,O
SD,O
=,O
12,O
.,O
88,O
),O
and,O
63,O
.,O
4,O
%,O
were,O
married,O
.,O
Most,O
participants,O
(,O
83,O
.,O
2,O
%),O
had,O
high,O
school,O
education,O
or,O
less,O
.,O
The,O
primary,O
source,O
of,O
income,O
for,O
16,O
.,O
1,O
%,O
of,O
the,O
participants,O
was,O
social,O
allowance,O
",",O
and,O
26,O
.,O
7,O
%,O
were,O
unemployed,O
or,O
had,O
a,O
part,O
time,O
job,O
.,O
About,O
1,O
in,O
3,O
(,O
30,O
.,O
9,O
%),O
men,O
reported,O
having,O
a,O
chronic,B-DS
disease,I-DS
.,O
The,O
average,O
score,O
for,O
anxiety,B-DS
was,O
moderate,O
(,O
mean,O
=,O
16,O
.,O
03,O
",",O
SD,O
=,O
4,O
.,O
35,O
),O
and,O
the,O
average,O
score,O
for,O
stressful,O
events,O
was,O
low,O
(,O
mean,O
=,O
0,O
.,O
79,O
",",O
SD,O
=,O
1,O
.,O
29,O
).,O
The,O
mean,O
social,O
support,O
score,O
was,O
moderate,O
(,O
mean,O
=,O
3,O
.,O
6,O
",",O
SD,O
=,O
0,O
.,O
97,O
).,O
Table,O
1Socio,O
-,O
demographic,O
characteristics,O
of,O
current,O
smokers,O
(,O
N,O
=,O
735,O
),O
Total,O
sampleN,O
%,O
Age,O
18,O
-,O
2520427,O
.,O
83,O
26,O
-,O
3517824,O
.,O
28,O
36,O
-,O
4514920,O
.,O
33,O
46,O
-,O
6420227,O
.,O
56Marital,O
status,O
Unmarried26936,O
.,O
65,O
Married46563,O
.,O
35,O
Socio,O
-,O
economic,O
position,O
Education,O
level,O
Less,O
than,O
high,O
school16322,O
.,O
39,O
High,O
school44360,O
.,O
85,O
More,O
than,O
high,O
school12216,O
.,O
76Primary,O
source,O
of,O
income,O
Social,O
allowances,O
/,O
other11316,O
.,O
14,O
Work58783,O
.,O
86Employment,O
status,O
Unemployed,O
or,O
part,O
time19526,O
.,O
71,O
Full,O
time,O
employment53573,O
.,O
29,O
Health,O
status,O
Chronic,B-DS
disease,I-DS
Yes22730,O
.,O
88,O
No50869,O
.,O
12Anxiety1,O
(,O
mean,O
(,O
SD,O
),O
range,O
),O
73316,O
.,O
03,O
(,O
4,O
.,O
35,O
),O
5,O
-,O
39,O
Psychosocial,O
factors,O
Stressful,O
life,O
events1,O
(,O
mean,O
(,O
SD,O
),O
range,O
),O
7350,O
.,O
79,O
(,O
1,O
.,O
29,O
),O
0,O
-,O
9Social,O
support1,O
(,O
mean,O
(,O
SD,O
),O
range,O
),O
7353,O
.,O
66,O
(,O
0,O
.,O
97,O
),O
1,O
-,O
5,O
Smoking,O
-,O
related,O
variables,O
Age,O
at,O
smoking,O
initiation,O
≤,O
15,O
years,O
old13318,O
.,O
29,O
16,O
-,O
18,O
years36550,O
.,O
21,O
≥,O
19,O
years,O
old22931,O
.,O
50Duration,O
of,O
smoking,O
≥,O
21,O
years23836,O
.,O
56,O
11,O
-,O
20,O
years15523,O
.,O
81,O
6,O
-,O
10,O
years13320,O
.,O
43,O
5,O
years,O
or,O
less12519,O
.,O
20Number,O
of,O
cigarettes,O
per,O
day,O
≥,O
31,O
cigarettes7511,O
.,O
42,O
21,O
-,O
30,O
cigarettes17126,O
.,O
03,O
11,O
-,O
20,O
cigarettes26039,O
.,O
73,O
≤,O
10,O
cigarettes15022,O
.,O
83Number,O
of,O
previous,O
attempts,O
to,O
quit,O
Never43460,O
.,O
78,O
Once,O
or,O
twice15822,O
.,O
13,O
Three,O
times,O
or,O
more12217,O
.,O
09Nicotine,O
dependence,O
score,O
(,O
FTND,O
),O
1,O
(,O
mean,O
(,O
SD,O
),O
and,O
range,O
),O
6724,O
.,O
17,O
(,O
2,O
.,O
61,O
),O
0,O
-,O
10Parents,O
smoking,O
Yes39645,O
.,O
30,O
No32854,O
.,O
70Number,O
of,O
smokers,O
at,O
home,O
Two,O
or,O
more28539,O
.,O
80,O
One23032,O
.,O
12,O
None20128,O
.,O
07Smokes,O
indoors,O
Yes49267,O
.,O
58,O
No23632,O
.,O
42Knowledge,O
about,O
the,O
smoking,O
hazards1,O
(,O
mean,O
(,O
SD,O
),O
range,O
),O
7352,O
.,O
45,O
(,O
0,O
.,O
89,O
),O
0,O
-,O
3Attitudes,O
towards,O
smoking,O
prevention,O
and,O
cessation1,O
(,O
mean,O
(,O
SD,O
),O
range,O
),O
7352,O
.,O
19,O
(,O
1,O
.,O
03,O
),O
0,O
-,O
3Physician,O
advice,O
to,O
quit,O
smoking,O
No44460,O
.,O
57,O
Yes28939,O
.,O
43,O
1For,O
continuous,O
variables,O
",",O
mean,O
",",O
standard,O
deviation,O
and,O
range,O
are,O
presented,O
Half,O
of,O
the,O
participants,O
(,O
50,O
.,O
2,O
%),O
began,O
smoking,O
between,O
16,O
and,O
18,O
years,O
of,O
age,O
.,O
Long,O
-,O
term,O
smoking,O
was,O
evident,O
:,O
36,O
.,O
6,O
%,O
had,O
been,O
smoking,O
for,O
more,O
than,O
21,O
years,O
.,O
About,O
37,O
.,O
5,O
%,O
smoked,O
21,O
cigarettes,O
or,O
more,O
per,O
day,O
.,O
Three,O
fifths,O
(,O
60,O
.,O
8,O
%),O
never,O
attempted,O
to,O
quit,O
smoking,O
.,O
The,O
nicotine,B-DS
dependence,I-DS
score,O
was,O
moderate,O
(,O
mean,O
=,O
4,O
.,O
17,O
",",O
SD,O
=,O
2,O
.,O
61,O
).,O
The,O
prevalence,O
of,O
at,O
least,O
one,O
parent,O
who,O
smoked,O
was,O
high,O
(,O
45,O
.,O
3,O
%).,O
Over,O
two,O
-,O
thirds,O
(,O
71,O
.,O
9,O
%),O
stated,O
that,O
they,O
live,O
with,O
one,O
or,O
more,O
smokers,O
at,O
home,O
and,O
67,O
.,O
6,O
%,O
reported,O
indoor,O
smoking,O
.,O
The,O
participants,O
had,O
a,O
high,O
mean,O
score,O
on,O
the,O
knowledge,O
about,O
smoking,O
hazards,O
(,O
mean,O
=,O
2,O
.,O
45,O
",",O
SD,O
=,O
0,O
.,O
89,O
"),",O
and,O
a,O
high,O
mean,O
score,O
on,O
positive,O
attitudes,O
towards,O
smoking,O
prevention,O
(,O
mean,O
=,O
2,O
.,O
19,O
",",O
SD,O
=,O
1,O
.,O
03,O
).,O
More,O
than,O
half,O
(,O
60,O
.,O
6,O
%),O
stated,O
that,O
their,O
primary,O
care,O
physician,O
did,O
not,O
advise,O
them,O
to,O
quit,O
smoking,O
.,O
Results,O
of,O
the,O
bivariate,O
analysis,O
are,O
presented,O
in,O
Table,O
2,O
.,O
Marital,O
status,O
",",O
education,O
level,O
",",O
presence,O
of,O
a,O
chronic,B-DS
disease,I-DS
",",O
anxiety,B-DS
",",O
and,O
social,O
support,O
were,O
significantly,O
associated,O
with,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
.,O
A,O
high,O
proportion,O
of,O
the,O
participants,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
(,O
Table,O
2,O
),O
were,O
unmarried,O
(,O
65,O
.,O
8,O
%),O
(,O
P,O
=,O
0,O
.,O
039,O
",",O
X2,O
=,O
6,O
.,O
46,O
",",O
df,O
=,O
2,O
),O
and,O
had,O
a,O
high,O
school,O
education,O
(,O
63,O
.,O
7,O
%),O
(,O
P,O
=,O
0,O
.,O
023,O
",",O
X2,O
=,O
11,O
.,O
3,O
",",O
df,O
=,O
4,O
).,O
In,O
addition,O
",",O
they,O
had,O
medium,O
anxiety,B-DS
levels,O
(,O
mean,O
=,O
15,O
.,O
9,O
",",O
SD,O
=,O
4,O
.,O
4,O
),O
(,O
p,O
<,O
0,O
.,O
001,O
",",O
KW,O
=,O
14,O
.,O
17,O
",",O
df,O
=,O
2,O
),O
and,O
a,O
medium,O
social,O
support,O
score,O
(,O
7,O
.,O
04,O
%),O
(,O
P,O
=,O
0,O
.,O
047,O
",",O
KW,O
=,O
1,O
.,O
63,O
",",O
df,O
=,O
2,O
).,O
They,O
were,O
also,O
less,O
likely,O
to,O
have,O
chronic,B-DS
disease,I-DS
(,O
s,O
),O
(,O
66,O
.,O
3,O
%),O
(,O
P,O
<,O
0,O
.,O
001,O
",",O
X2,O
=,O
14,O
.,O
56,O
",",O
df,O
=,O
2,O
).,O
Age,O
",",O
primary,O
source,O
of,O
income,O
",",O
employment,O
status,O
",",O
and,O
stressful,O
life,O
events,O
were,O
not,O
significantly,O
associated,O
with,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
.,O
Table,O
2Bivariate,O
associations,O
:,O
stages,O
of,O
change,O
to,O
quit,O
smoking,O
by,O
socio,O
-,O
demographic,O
characteristics,O
",",O
socio,O
-,O
economic,O
position,O
",",O
health,O
status,O
and,O
psychological,O
wellbeing,O
(,O
N,O
=,O
735,O
),O
Pre,O
-,O
contemplationContemplationPreparationP,O
-,O
value,O
*,O
N,O
=,O
454N,O
=,O
175N,O
=,O
106n,O
%,O
n,O
%,O
n,O
%,O
Age0,O
.,O
058,O
18,O
-,O
2513666,O
.,O
673215,O
.,O
693617,O
.,O
65,O
26,O
-,O
3510760,O
.,O
114726,O
.,O
402413,O
.,O
48,O
X,O
2,O
=,O
12,O
.,O
18,O
36,O
-,O
459362,O
.,O
423724,O
.,O
831912,O
.,O
75,O
DF,O
=,O
6,O
46,O
-,O
6411657,O
.,O
425929,O
.,O
202713,O
.,O
37Marital,O
status0,O
.,O
039,O
Unmarried17765,O
.,O
805018,O
.,O
604215,O
.,O
60,O
X,O
2,O
=,O
6,O
.,O
46,O
Married27659,O
.,O
3612526,O
.,O
886413,O
.,O
76,O
DF,O
=,O
2,O
Socio,O
-,O
economic,O
position,O
Education,O
level0,O
.,O
023,O
Less,O
than,O
high,O
school10161,O
.,O
974426,O
.,O
991811,O
.,O
04,O
X,O
2,O
=,O
11,O
.,O
33,O
High,O
school28263,O
.,O
6610223,O
.,O
025913,O
.,O
32,O
DF,O
=,O
4,O
More,O
than,O
high,O
school6654,O
.,O
102722,O
.,O
132923,O
.,O
77Primary,O
source,O
of,O
income0,O
.,O
263,O
Social,O
allowance,O
/,O
other7768,O
.,O
142522,O
.,O
12119,O
.,O
74,O
X,O
2,O
=,O
2,O
.,O
65,O
Work36061,O
.,O
3313923,O
.,O
688814,O
.,O
99,O
DF,O
=,O
2,O
Employment,O
status0,O
.,O
545,O
Unemployed,O
or,O
part,O
time11458,O
.,O
464925,O
.,O
133216,O
.,O
41,O
X,O
2,O
=,O
1,O
.,O
20,O
Full,O
time,O
employment33562,O
.,O
6212623,O
.,O
557413,O
.,O
83,O
DF,O
=,O
2,O
Health,O
status,O
Chronic,B-DS
disease,I-DS
No33766,O
.,O
34107629,O
.,O
966418,O
.,O
50,O
<,O
0,O
.,O
001,O
Yes11751,O
.,O
54821,O
.,O
064212,O
.,O
60,O
X,O
2,O
=,O
14,O
.,O
56,O
DF,O
=,O
2,O
Anxietya,O
45315,O
.,O
92,O
(,O
4,O
.,O
40,O
),O
17515,O
.,O
56,O
(,O
4,O
.,O
21,O
),O
10517,O
.,O
25,O
(,O
4,O
.,O
21,O
)<,O
0,O
.,O
001b,O
KW,O
=,O
14,O
.,O
17,O
DF,O
=,O
2,O
Psychosocial,O
factors,O
Stressful,O
life,O
eventsa,O
4540,O
.,O
76,O
(,O
1,O
.,O
21,O
),O
1750,O
.,O
81,O
(,O
1,O
.,O
45,O
),O
1060,O
.,O
88,O
(,O
1,O
.,O
23,O
),O
0,O
.,O
440b,O
KW,O
=,O
1,O
.,O
63,O
DF,O
=,O
2,O
Social,O
support,O
a,O
4547,O
.,O
04,O
(,O
4,O
.,O
35,O
),O
1746,O
.,O
65,O
(,O
4,O
.,O
62,O
),O
1067,O
.,O
80,O
(,O
4,O
.,O
15,O
),O
0,O
.,O
047b,O
KW,O
=,O
6,O
.,O
11,O
DF,O
=,O
2,O
*,O
P,O
value,O
indicates,O
the,O
differences,O
in,O
the,O
distribution,O
of,O
the,O
variable,O
of,O
interest,O
across,O
the,O
3,O
levels,O
of,O
the,O
stage,O
of,O
change,O
aFor,O
continuous,O
variables,O
",",O
mean,O
and,O
standard,O
deviation,O
are,O
presented,O
bKruskal,O
Wallis,O
(,O
KW,O
),O
for,O
these,O
associations,O
otherwise,O
X,O
2,O
test,O
We,O
further,O
examined,O
the,O
associations,O
between,O
each,O
of,O
the,O
smoking,O
-,O
related,O
factors,O
and,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
.,O
Table,O
3,O
shows,O
that,O
duration,O
of,O
smoking,O
",",O
previous,O
attempts,O
to,O
quit,O
smoking,O
",",O
number,O
of,O
smokers,O
at,O
home,O
",",O
smoking,O
indoors,O
",",O
knowledge,O
about,O
smoking,O
hazards,O
",",O
attitudes,O
towards,O
smoking,O
prevention,O
and,O
cessations,O
",",O
and,O
receiving,O
physician,O
advice,O
to,O
quit,O
smoking,O
were,O
significantly,O
associated,O
with,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
.,O
A,O
high,O
proportion,O
of,O
participants,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
had,O
long,O
-,O
term,O
(≥,O
21,O
years,O
;,O
67,O
.,O
8,O
%),O
or,O
short,O
-,O
term,O
(≤,O
5,O
years,O
;,O
67,O
.,O
2,O
%),O
duration,O
of,O
smoking,O
(,O
P,O
=,O
0,O
.,O
025,O
",",O
X2,O
=,O
14,O
.,O
5,O
",",O
df,O
=,O
6,O
"),",O
never,O
attempted,O
to,O
quit,O
smoking,O
(,O
71,O
.,O
9,O
%),O
(,O
P,O
<,O
0,O
.,O
001,O
",",O
X2,O
=,O
53,O
.,O
7,O
",",O
df,O
=,O
4,O
"),",O
had,O
two,O
or,O
more,O
smokers,O
at,O
home,O
(,O
66,O
.,O
3,O
%),O
(,O
P,O
=,O
0,O
.,O
032,O
",",O
X2,O
=,O
10,O
.,O
5,O
",",O
df,O
=,O
4,O
"),",O
and,O
had,O
smoked,O
indoors,O
(,O
65,O
.,O
9,O
%),O
(,O
P,O
<,O
0,O
.,O
001,O
",",O
X2,O
=,O
12,O
.,O
6,O
",",O
df,O
=,O
2,O
).,O
In,O
addition,O
",",O
those,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
had,O
low,O
scores,O
on,O
the,O
knowledge,O
about,O
smoking,O
hazards,O
(,O
mean,O
=,O
2,O
.,O
30,O
",",O
SD,O
=,O
0,O
.,O
99,O
"),",O
held,O
less,O
positive,O
attitudes,O
towards,O
smoking,O
prevention,O
and,O
cessation,O
(,O
mean,O
=,O
2,O
.,O
01,O
",",O
SD,O
=,O
1,O
.,O
11,O
"),",O
and,O
were,O
less,O
likely,O
to,O
receive,O
physician,O
advice,O
to,O
quit,O
smoking,O
(,O
68,O
.,O
5,O
%).,O
The,O
age,O
at,O
which,O
individuals,O
began,O
smoking,O
",",O
the,O
number,O
of,O
cigarettes,O
smoked,O
per,O
day,O
",",O
the,O
nicotine,B-DS
dependence,I-DS
scores,O
",",O
and,O
parental,O
smoking,O
were,O
not,O
significantly,O
associated,O
with,O
the,O
SOC,O
.,O
Table,O
3Bivariate,O
associations,O
:,O
Stages,O
of,O
change,O
by,O
smoking,O
-,O
related,O
factors,O
(,O
N,O
=,O
735,O
),O
Pre,O
-,O
contemplationContemplationPreparationP,O
-,O
value,O
*,O
N,O
=,O
454N,O
=,O
175N,O
=,O
106n,O
%,O
n,O
%,O
n,O
%,O
Age,O
at,O
smoking,O
initiation,O
≤,O
15,O
years,O
old8664,O
.,O
662418,O
.,O
052317,O
.,O
290,O
.,O
367,O
16,O
-,O
18,O
years22762,O
.,O
198824,O
.,O
115013,O
.,O
70,O
X,O
2,O
=,O
4,O
.,O
29,O
≥,O
19,O
years,O
old13659,O
.,O
396227,O
.,O
073113,O
.,O
54,O
DF,O
=,O
4,O
Cigarettes,O
per,O
day0,O
.,O
247,O
≥,O
31,O
cigarettes3952,O
.,O
002128,O
.,O
001520,O
.,O
00,O
21,O
-,O
30,O
cigarettes11366,O
.,O
083621,O
.,O
052212,O
.,O
87,O
X,O
2,O
=,O
7,O
.,O
87,O
11,O
-,O
20,O
cigarettes15760,O
.,O
157227,O
.,O
593212,O
.,O
26,O
DF,O
=,O
6,O
≤,O
10,O
cigarettes9664,O
.,O
003120,O
.,O
672315,O
.,O
33Duration,O
of,O
smoking0,O
.,O
025,O
≥,O
21,O
years14767,O
.,O
766226,O
.,O
052912,O
.,O
18,O
11,O
-,O
21,O
years8554,O
.,O
844227,O
.,O
102818,O
.,O
06,O
X,O
2,O
=,O
14,O
.,O
51,O
6,O
-,O
10,O
years8866,O
.,O
163123,O
.,O
311410,O
.,O
53,O
DF,O
=,O
6,O
5,O
years,O
or,O
less8467,O
.,O
201713,O
.,O
602419,O
.,O
20Previous,O
attempts,O
to,O
quit,O
Never31271,O
.,O
898218,O
.,O
89409,O
.,O
22,O
<,O
0,O
.,O
001,O
Once,O
or,O
twice8251,O
.,O
904629,O
.,O
113018,O
.,O
99,O
X,O
2,O
=,O
53,O
.,O
68,O
Three,O
times,O
or,O
more4738,O
.,O
524335,O
.,O
253226,O
.,O
23,O
DF,O
=,O
4,O
Nicotine,B-DS
dependence,I-DS
score,O
(,O
FTND,O
),O
a,O
4144,O
.,O
24,O
(,O
2,O
.,O
66,O
),O
1634,O
.,O
24,O
(,O
2,O
.,O
47,O
),O
953,O
.,O
87,O
(,O
2,O
.,O
60,O
),O
0,O
.,O
421,O
b,O
KW,O
=,O
1,O
.,O
47DF,O
=,O
2Parents,O
smoking,O
Yes24461,O
.,O
628521,O
.,O
466716,O
.,O
910,O
.,O
058,O
No20261,O
.,O
598826,O
.,O
833811,O
.,O
58,O
X,O
2,O
=,O
5,O
.,O
68,O
DF,O
=,O
2,O
Number,O
of,O
smokers,O
at,O
home,O
Two,O
or,O
more18966,O
.,O
326221,O
.,O
753411,O
.,O
930,O
.,O
032,O
One14663,O
.,O
485624,O
.,O
352812,O
.,O
17,O
X,O
2,O
=,O
10,O
.,O
52,O
None10853,O
.,O
735326,O
.,O
374019,O
.,O
90,O
DF,O
=,O
4,O
Smokes,O
indoors,O
No12452,O
.,O
546728,O
.,O
394519,O
.,O
070,O
.,O
001,O
Yes32465,O
.,O
8510821,O
.,O
956012,O
.,O
20,O
X,O
2,O
=,O
12,O
.,O
56,O
DF,O
=,O
2,O
Knowledge,O
about,O
smoking,O
hazardsa,O
4542,O
.,O
30,O
(,O
0,O
.,O
99,O
),O
1752,O
.,O
66,O
(,O
0,O
.,O
64,O
),O
1062,O
.,O
71,O
(,O
0,O
.,O
60,O
)<,O
0,O
.,O
001b,O
KW,O
=,O
25,O
.,O
35,O
DF,O
=,O
2,O
Attitudes,O
towards,O
smoking,O
prevention,O
and,O
cessationa,O
4542,O
.,O
01,O
(,O
1,O
.,O
11,O
),O
1752,O
.,O
49,O
(,O
0,O
.,O
81,O
),O
1062,O
.,O
50,O
(,O
0,O
.,O
60,O
)<,O
0,O
.,O
001,O
b,O
KW,O
=,O
36,O
.,O
94,O
DF,O
=,O
2,O
Physician,O
advice,O
to,O
quit,O
smoking,O
<,O
0,O
.,O
001,O
No30468,O
.,O
478418,O
.,O
925612,O
.,O
61,O
X,O
2,O
=,O
21,O
.,O
39,O
Yes15051,O
.,O
909131,O
.,O
494816,O
.,O
61,O
DF,O
=,O
2,O
*,O
P,O
-,O
value,O
indicates,O
the,O
differences,O
in,O
the,O
distribution,O
of,O
the,O
variable,O
of,O
interest,O
across,O
the,O
3,O
levels,O
of,O
the,O
stage,O
of,O
change,O
aFor,O
continuous,O
variables,O
",",O
mean,O
and,O
standard,O
deviation,O
are,O
presented,O
bKruskel,O
Wallis,O
for,O
these,O
associations,O
otherwise,O
X,O
2,O
test,O
In,O
the,O
ordered,O
multivariable,O
regression,O
results,O
(,O
Table,O
4,O
"),",O
presence,O
of,O
a,O
chronic,B-DS
disease,I-DS
",",O
a,O
higher,O
anxiety,B-DS
score,O
",",O
higher,O
social,O
support,O
score,O
",",O
shorter,O
duration,O
of,O
smoking,O
",",O
higher,O
number,O
of,O
quitting,O
attempts,O
",",O
higher,O
knowledge,O
score,O
about,O
smoking,O
hazards,O
",",O
more,O
positive,O
attitudes,O
towards,O
smoking,O
prevention,O
and,O
cessation,O
",",O
and,O
receiving,O
physician,O
advice,O
to,O
quit,O
smoking,O
were,O
significantly,O
(,O
P,O
<,O
0,O
.,O
05,O
),O
associated,O
with,O
the,O
likelihood,O
of,O
being,O
at,O
a,O
more,O
advanced,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
.,O
Conversely,O
",",O
number,O
of,O
years,O
of,O
education,O
",",O
marital,O
status,O
",",O
and,O
smoking,O
indoors,O
were,O
not,O
significantly,O
associated,O
with,O
the,O
SOC,O
.,O
The,O
odds,O
in,O
favor,O
of,O
being,O
at,O
the,O
contemplation,O
stage,O
versus,O
the,O
pre,O
-,O
contemplation,O
stage,O
for,O
participants,O
without,O
a,O
chronic,B-DS
disease,I-DS
was,O
half,O
that,O
of,O
participants,O
with,O
a,O
chronic,B-DS
disease,I-DS
(,O
OR,O
=,O
0,O
.,O
52,O
",",O
95,O
%,O
CI,O
=,O
0,O
.,O
31,O
-,O
0,O
.,O
88,O
).,O
The,O
same,O
directionality,O
of,O
the,O
OR,O
was,O
found,O
when,O
we,O
compared,O
participants,O
in,O
the,O
preparation,O
stage,O
versus,O
the,O
pre,O
-,O
contemplation,O
stage,O
:,O
the,O
odds,O
of,O
not,O
having,O
a,O
chronic,B-DS
disease,I-DS
were,O
a,O
third,O
of,O
having,O
a,O
chronic,B-DS
disease,I-DS
(,O
OR,O
=,O
0,O
.,O
36,O
",",O
95,O
%,O
CI,O
=,O
0,O
.,O
20,O
-,O
0,O
.,O
67,O
).,O
For,O
a,O
one,O
unit,O
increase,O
in,O
the,O
anxiety,B-DS
score,O
",",O
the,O
odds,O
in,O
favor,O
of,O
being,O
at,O
the,O
contemplation,O
stage,O
versus,O
the,O
pre,O
-,O
contemplation,O
stage,O
were,O
0,O
.,O
97,O
(,O
95,O
%,O
CI,O
=,O
0,O
.,O
92,O
-,O
1,O
.,O
02,O
"),",O
whereas,O
the,O
OR,O
in,O
favor,O
of,O
being,O
in,O
the,O
preparation,O
stage,O
versus,O
the,O
pre,O
-,O
contemplation,O
stage,O
was,O
1,O
.,O
07,O
(,O
95,O
%,O
CI,O
=,O
1,O
.,O
01,O
-,O
1,O
.,O
13,O
).,O
Higher,O
social,O
support,O
was,O
associated,O
with,O
being,O
in,O
a,O
more,O
advanced,O
stage,O
in,O
the,O
readiness,O
to,O
quit,O
smoking,O
.,O
The,O
OR,O
associated,O
with,O
a,O
one,O
unit,O
increment,O
of,O
social,O
support,O
in,O
favor,O
of,O
being,O
in,O
the,O
contemplation,O
stage,O
versus,O
the,O
pre,O
-,O
contemplation,O
stage,O
was,O
1,O
.,O
35,O
(,O
95,O
%,O
CI,O
=,O
1,O
.,O
07,O
-,O
1,O
.,O
70,O
"),",O
and,O
the,O
OR,O
in,O
favor,O
of,O
preparation,O
stage,O
versus,O
pre,O
-,O
contemplation,O
stage,O
was,O
1,O
.,O
34,O
(,O
95,O
%,O
CI,O
=,O
1,O
.,O
01,O
-,O
1,O
.,O
78,O
).,O
Participants,O
who,O
had,O
smoked,O
for,O
less,O
than,O
21,O
years,O
were,O
more,O
likely,O
to,O
be,O
in,O
a,O
more,O
advanced,O
SOC,O
than,O
long,O
-,O
term,O
smokers,O
.,O
Three,O
or,O
more,O
attempts,O
to,O
quit,O
smoking,O
was,O
the,O
strongest,O
contributing,O
factor,O
to,O
being,O
at,O
a,O
more,O
advanced,O
level,O
in,O
the,O
readiness,O
to,O
quit,O
smoking,O
.,O
The,O
odds,O
in,O
favor,O
of,O
being,O
in,O
the,O
contemplation,O
versus,O
the,O
pre,O
-,O
contemplation,O
stage,O
for,O
those,O
who,O
had,O
three,O
or,O
more,O
attempts,O
to,O
quit,O
smoking,O
were,O
2,O
.,O
27,O
(,O
95,O
%,O
CI,O
=,O
1,O
.,O
27,O
-,O
4,O
.,O
10,O
),O
times,O
greater,O
than,O
for,O
those,O
who,O
had,O
never,O
attempted,O
to,O
quit,O
.,O
The,O
same,O
directionality,O
was,O
found,O
among,O
participants,O
in,O
the,O
preparation,O
stage,O
.,O
The,O
odds,O
in,O
favor,O
of,O
being,O
in,O
the,O
preparation,O
versus,O
pre,O
-,O
contemplation,O
stage,O
were,O
3,O
.,O
16,O
(,O
95,O
%,O
CI,O
=,O
1,O
.,O
60,O
-,O
6,O
.,O
26,O
),O
times,O
as,O
great,O
as,O
for,O
those,O
who,O
had,O
never,O
attempted,O
to,O
quit,O
smoking,O
in,O
the,O
past,O
.,O
Higher,O
knowledge,O
about,O
smoking,O
hazards,O
was,O
associated,O
with,O
higher,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
.,O
For,O
a,O
one,O
unit,O
increase,O
in,O
the,O
knowledge,O
about,O
smoking,O
hazards,O
",",O
the,O
OR,O
of,O
advancement,O
to,O
the,O
contemplation,O
from,O
the,O
pre,O
-,O
contemplation,O
stage,O
was,O
1,O
.,O
75,O
(,O
95,O
%,O
CI,O
=,O
1,O
.,O
29,O
-,O
2,O
.,O
35,O
).,O
The,O
same,O
directionality,O
was,O
found,O
in,O
the,O
higher,O
SOC,O
.,O
For,O
a,O
one,O
unit,O
increase,O
in,O
the,O
knowledge,O
about,O
smoking,O
hazards,O
",",O
the,O
OR,O
for,O
being,O
in,O
the,O
preparation,O
versus,O
pre,O
-,O
contemplation,O
stage,O
was,O
1,O
.,O
57,O
(,O
95,O
%,O
CI,O
=,O
1,O
.,O
10,O
-,O
2,O
.,O
21,O
).,O
In,O
addition,O
",",O
more,O
positive,O
attitudes,O
towards,O
smoking,O
prevention,O
and,O
cessation,O
were,O
associated,O
with,O
higher,O
readiness,O
to,O
quit,O
.,O
A,O
one,O
unit,O
increase,O
in,O
positive,O
attitudes,O
toward,O
smoking,O
prevention,O
and,O
cessation,O
increased,O
the,O
OR,O
of,O
being,O
in,O
the,O
contemplation,O
versus,O
pre,O
-,O
contemplation,O
stage,O
by,O
1,O
.,O
44,O
(,O
95,O
%,O
CI,O
=,O
1,O
.,O
14,O
-,O
1,O
.,O
82,O
).,O
The,O
same,O
directionality,O
was,O
found,O
in,O
the,O
higher,O
SOC,O
.,O
A,O
one,O
unit,O
increase,O
in,O
positive,O
attitudes,O
toward,O
smoking,O
prevention,O
and,O
cessation,O
increased,O
the,O
odds,O
of,O
being,O
in,O
the,O
preparation,O
versus,O
pre,O
-,O
contemplation,O
stage,O
by,O
1,O
.,O
34,O
(,O
95,O
%,O
CI,O
=,O
1,O
.,O
00,O
-,O
1,O
.,O
82,O
).,O
Receiving,O
physician,O
advice,O
to,O
quit,O
contributed,O
to,O
participants,O
’,O
advancement,O
from,O
pre,O
-,O
contemplation,O
to,O
contemplation,O
.,O
The,O
OR,O
of,O
being,O
in,O
the,O
contemplation,O
versus,O
pre,O
-,O
contemplation,O
stage,O
among,O
those,O
who,O
received,O
advice,O
from,O
a,O
physician,O
to,O
quit,O
smoking,O
was,O
1,O
.,O
88,O
(,O
95,O
%,O
CI,O
=,O
1,O
.,O
19,O
-,O
2,O
.,O
97,O
),O
compared,O
to,O
participants,O
who,O
did,O
not,O
receive,O
such,O
advice,O
.,O
However,O
",",O
receiving,O
physician,O
advice,O
to,O
quit,O
smoking,O
did,O
not,O
increase,O
the,O
likelihood,O
that,O
participants,O
would,O
be,O
in,O
the,O
preparation,O
stage,O
",",O
as,O
this,O
was,O
not,O
a,O
significant,O
association,O
(,O
OR,O
=,O
1,O
.,O
63,O
",",O
95,O
%,O
CI,O
=,O
0,O
.,O
93,O
-,O
2,O
.,O
77,O
).,O
Table,O
4Ordered,O
logistic,O
regression,O
for,O
factors,O
contributing,O
to,O
the,O
stages,O
of,O
change,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
(,O
N,O
=,O
735,O
),O
Pre,O
-,O
contemplationContemplationPreparationN,O
=,O
454N,O
=,O
175N,O
=,O
106P,O
-,O
valueReference,O
categoriesOdds,O
Ratio,O
(,O
95,O
%,O
CI,O
),O
Odds,O
Ratio,O
(,O
95,O
%,O
CI,O
),O
Education,O
level0,O
.,O
356,O
Less,O
than,O
high,O
school111,O
High,O
school0,O
.,O
97,O
(,O
0,O
.,O
56,O
-,O
1,O
.,O
67,O
),O
1,O
.,O
31,O
(,O
0,O
.,O
63,O
-,O
2,O
.,O
72,O
),O
More,O
than,O
high,O
school0,O
.,O
81,O
(,O
0,O
.,O
41,O
-,O
1,O
.,O
64,O
),O
1,O
.,O
98,O
(,O
0,O
.,O
86,O
-,O
4,O
.,O
57,O
),O
Chronic,B-DS
disease0,I-DS
.,O
002,O
Yes111,O
No0,O
.,O
52,O
(,O
0,O
.,O
31,O
-,O
0,O
.,O
88,O
),O
0,O
.,O
36,O
(,O
0,O
.,O
20,O
-,O
0,O
.,O
67,O
),O
Anxiety10,O
.,O
97,O
(,O
0,O
.,O
92,O
-,O
1,O
.,O
02,O
),O
1,O
.,O
07,O
(,O
1,O
.,O
01,O
-,O
1,O
.,O
13,O
),O
0,O
.,O
016Social,O
support11,O
.,O
35,O
(,O
1,O
.,O
07,O
-,O
1,O
.,O
70,O
),O
1,O
.,O
34,O
(,O
1,O
.,O
01,O
-,O
1,O
.,O
78,O
),O
0,O
.,O
017Marital,O
status0,O
.,O
623,O
Unmarried111,O
Married0,O
.,O
90,O
(,O
0,O
.,O
48,O
-,O
1,O
.,O
67,O
),O
0,O
.,O
70,O
(,O
0,O
.,O
34,O
-,O
1,O
.,O
44,O
),O
Duration,O
of,O
smoking0,O
.,O
025,O
≥,O
21,O
years111,O
11,O
-,O
21,O
years1,O
.,O
94,O
(,O
1,O
.,O
07,O
-,O
3,O
.,O
50,O
),O
2,O
.,O
48,O
(,O
1,O
.,O
18,O
-,O
5,O
.,O
21,O
),O
6,O
-,O
10,O
years1,O
.,O
46,O
(,O
0,O
.,O
71,O
-,O
2,O
.,O
99,O
),O
1,O
.,O
35,O
(,O
0,O
.,O
54,O
-,O
3,O
.,O
40,O
),O
5,O
years,O
or,O
less0,O
.,O
96,O
(,O
0,O
.,O
41,O
-,O
2,O
.,O
27,O
),O
2,O
.,O
93,O
(,O
1,O
.,O
14,O
-,O
7,O
.,O
52,O
),O
Previous,O
attempts,O
to,O
quit0,O
.,O
007,O
Never11,O
Once,O
or,O
twice11,O
.,O
33,O
(,O
0,O
.,O
81,O
-,O
2,O
.,O
20,O
),O
1,O
.,O
76,O
(,O
0,O
.,O
95,O
-,O
3,O
.,O
24,O
),O
Three,O
times,O
or,O
more2,O
.,O
27,O
(,O
1,O
.,O
26,O
-,O
4,O
.,O
01,O
),O
3,O
.,O
16,O
(,O
1,O
.,O
60,O
-,O
6,O
.,O
26,O
),O
Number,O
of,O
smokers,O
at,O
home0,O
.,O
210,O
Two,O
or,O
more111,O
One1,O
.,O
41,O
(,O
0,O
.,O
84,O
-,O
2,O
.,O
38,O
),O
1,O
.,O
30,O
(,O
0,O
.,O
67,O
-,O
2,O
.,O
53,O
),O
None1,O
.,O
41,O
(,O
0,O
.,O
80,O
-,O
2,O
.,O
46,O
),O
2,O
.,O
06,O
(,O
1,O
.,O
05,O
-,O
4,O
.,O
04,O
),O
Knowledge,O
about,O
smoking,O
hazards11,O
.,O
75,O
(,O
1,O
.,O
29,O
-,O
2,O
.,O
35,O
),O
1,O
.,O
57,O
(,O
1,O
.,O
10,O
-,O
2,O
.,O
21,O
)<,O
0,O
.,O
001Positive,O
Attitudes,O
towards,O
smoking,O
prevention,O
and,O
cessation11,O
.,O
44,O
(,O
1,O
.,O
14,O
-,O
1,O
.,O
82,O
),O
1,O
.,O
34,O
(,O
1,O
.,O
00,O
-,O
1,O
.,O
82,O
),O
0,O
.,O
004Smokes,O
indoors0,O
.,O
309,O
Yes11,O
No11,O
.,O
21,O
(,O
0,O
.,O
76,O
-,O
1,O
.,O
94,O
),O
1,O
.,O
52,O
(,O
0,O
.,O
88,O
-,O
2,O
.,O
65,O
),O
Physician,O
advice,O
to,O
quit,O
smoking0,O
.,O
016,O
No111,O
Yes1,O
.,O
88,O
(,O
1,O
.,O
19,O
-,O
2,O
.,O
97,O
),O
1,O
.,O
63,O
(,O
0,O
.,O
93,O
-,O
2,O
.,O
77,O
),O
Discussion,O
The,O
SOC,O
theory,O
has,O
been,O
used,O
extensively,O
to,O
study,O
smoking,O
cessation,O
[,O
9,O
",",O
35,O
",",O
52,O
].,O
However,O
",",O
research,O
on,O
smoking,O
cessation,O
in,O
low,O
-,O
income,O
and,O
marginalized,O
populations,O
is,O
scarce,O
[,O
32,O
].,O
In,O
particular,O
",",O
few,O
studies,O
have,O
used,O
SOC,O
to,O
examine,O
readiness,O
to,O
quit,O
smoking,O
in,O
Mediterranean,O
countries,O
",",O
where,O
smoking,O
prevalence,O
is,O
increasing,O
or,O
has,O
remained,O
consistently,O
high,O
over,O
time,O
[,O
1,O
",",O
39,O
",",O
53,O
].,O
Our,O
findings,O
regarding,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
among,O
Arab,O
minority,O
men,O
in,O
Israel,O
show,O
that,O
62,O
%,O
of,O
the,O
participants,O
were,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
",",O
24,O
%,O
at,O
the,O
contemplation,O
stage,O
",",O
and,O
14,O
%,O
at,O
the,O
preparation,O
stage,O
.,O
These,O
findings,O
indicate,O
lower,O
readiness,O
to,O
quit,O
smoking,O
compared,O
to,O
previous,O
studies,O
in,O
the,O
US,O
and,O
Europe,O
",",O
where,O
40,O
-,O
45,O
%,O
of,O
smokers,O
were,O
at,O
the,O
pre,O
-,O
contemplation,O
",",O
35,O
-,O
40,O
%,O
at,O
the,O
contemplation,O
",",O
and,O
20,O
%,O
at,O
the,O
preparation,O
stage,O
[,O
35,O
].,O
In,O
addition,O
",",O
our,O
result,O
regarding,O
the,O
percentage,O
of,O
individuals,O
at,O
the,O
preparation,O
stage,O
was,O
lower,O
than,O
what,O
has,O
been,O
reported,O
in,O
Turkey,O
(,O
20,O
%),O
[,O
54,O
],O
and,O
Iran,O
(,O
17,O
%),O
[,O
55,O
].,O
Compared,O
to,O
previous,O
findings,O
on,O
minorities,O
in,O
other,O
countries,O
",",O
our,O
study,O
found,O
a,O
higher,O
proportion,O
of,O
smokers,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
.,O
For,O
example,O
",",O
one,O
study,O
of,O
Aboriginal,O
peoples,O
in,O
Canada,O
found,O
that,O
39,O
.,O
6,O
%,O
were,O
at,O
the,O
pre,O
-,O
contemplation,O
and,O
43,O
.,O
4,O
%,O
were,O
at,O
the,O
contemplation,O
stage,O
[,O
27,O
].,O
A,O
study,O
among,O
African,O
Americans,O
in,O
the,O
US,O
found,O
that,O
51,O
"%,",O
28,O
%,O
and,O
17,O
%,O
were,O
in,O
the,O
pre,O
-,O
contemplation,O
",",O
contemplation,O
and,O
preparation,O
stages,O
",",O
respectively,O
[,O
56,O
].,O
Higher,O
prevalence,O
of,O
individuals,O
in,O
the,O
pre,O
-,O
contemplation,O
stage,O
among,O
Arabs,O
in,O
Israel,O
compared,O
to,O
minorities,O
in,O
other,O
countries,O
might,O
relate,O
to,O
the,O
lack,O
of,O
tailored,O
policies,O
and,O
interventions,O
to,O
help,O
these,O
individuals,O
move,O
to,O
a,O
more,O
advanced,O
SOC,O
in,O
the,O
readiness,O
to,O
quit,O
smoking,O
.,O
These,O
findings,O
suggest,O
that,O
Israel,O
’,O
s,O
advanced,O
smoking,O
cessation,O
and,O
prevention,O
policies,O
appear,O
to,O
be,O
less,O
effective,O
among,O
Arabs,O
and,O
highlight,O
the,O
importance,O
of,O
exploring,O
factors,O
that,O
can,O
help,O
Arab,O
men,O
move,O
to,O
a,O
more,O
advanced,O
SOC,O
.,O
Determining,O
the,O
characteristics,O
of,O
smokers,O
in,O
different,O
SOC,O
will,O
provide,O
valuable,O
information,O
that,O
can,O
be,O
used,O
to,O
plan,O
and,O
implement,O
tailored,O
smoking,O
cessation,O
interventions,O
.,O
Previous,O
research,O
has,O
identified,O
different,O
factors,O
that,O
relate,O
to,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
",",O
including,O
demographic,O
and,O
socio,O
-,O
economic,O
characteristics,O
such,O
as,O
age,O
",",O
gender,O
",",O
marital,O
status,O
",",O
SEP,O
",",O
education,O
",",O
and,O
income,O
[,O
31,O
",",O
57,O
].,O
In,O
our,O
study,O
",",O
results,O
from,O
the,O
bivariate,O
analysis,O
showed,O
that,O
among,O
the,O
socio,O
-,O
demographic,O
and,O
socio,O
-,O
economic,O
variables,O
",",O
marital,O
status,O
and,O
education,O
level,O
were,O
significantly,O
associated,O
with,O
the,O
SOC,O
.,O
However,O
",",O
these,O
associations,O
became,O
non,O
-,O
significant,O
in,O
the,O
multivariate,O
analysis,O
.,O
Other,O
variables,O
we,O
examined,O
",",O
such,O
as,O
age,O
",",O
primary,O
source,O
of,O
income,O
and,O
employment,O
status,O
",",O
were,O
not,O
significant,O
in,O
the,O
bivariate,O
analysis,O
.,O
Lack,O
of,O
association,O
between,O
SEP,O
and,O
SOC,O
might,O
be,O
explained,O
by,O
the,O
higher,O
prevalence,O
of,O
smoking,O
among,O
Arab,O
men,O
in,O
Israel,O
regardless,O
of,O
education,O
level,O
or,O
SEP,O
[,O
58,O
].,O
Results,O
from,O
previous,O
studies,O
on,O
the,O
association,O
between,O
demographic,O
and,O
SEP,O
variables,O
and,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
had,O
mixed,O
results,O
",",O
with,O
some,O
finding,O
no,O
association,O
and,O
others,O
finding,O
significant,O
associations,O
[,O
13,O
",",O
59,O
].,O
For,O
example,O
",",O
Vicler,O
et,O
al,O
".,",O
[,O
60,O
],O
found,O
that,O
level,O
of,O
education,O
",",O
ethnicity,O
",",O
and,O
race,O
were,O
important,O
for,O
the,O
SOC,O
",",O
while,O
another,O
study,O
that,O
included,O
results,O
of,O
five,O
studies,O
in,O
the,O
US,O
did,O
not,O
find,O
significant,O
associations,O
with,O
demographic,O
or,O
SEP,O
variables,O
[,O
61,O
].,O
Similar,O
to,O
our,O
results,O
",",O
Choi,O
et,O
al,O
".,",O
[,O
62,O
],O
found,O
that,O
among,O
smokers,O
in,O
Korea,O
",",O
age,O
",",O
education,O
level,O
",",O
and,O
income,O
did,O
not,O
predict,O
the,O
SOC,O
to,O
quit,O
smoking,O
.,O
Gender,O
was,O
the,O
only,O
demographic,O
variable,O
that,O
predicted,O
being,O
at,O
the,O
maintenance,O
stage,O
[,O
62,O
].,O
Our,O
study,O
did,O
not,O
include,O
women,O
since,O
the,O
prevalence,O
of,O
cigarette,O
smoking,O
among,O
Arab,O
women,O
in,O
Israel,O
is,O
very,O
low,O
(,O
about,O
5,O
%),O
[,O
63,O
].,O
A,O
study,O
in,O
the,O
Netherlands,O
compared,O
pre,O
-,O
contemplators,O
with,O
contemplators,O
and,O
preparators,O
and,O
found,O
that,O
the,O
level,O
of,O
education,O
",",O
cultural,O
background,O
",",O
and,O
neighborhood,O
conditions,O
correlated,O
with,O
the,O
intention,O
to,O
quit,O
smoking,O
[,O
64,O
].,O
However,O
",",O
the,O
study,O
compared,O
contemplators,O
and,O
preparators,O
with,O
former,O
smokers,O
[,O
64,O
].,O
In,O
the,O
current,O
study,O
",",O
we,O
were,O
interested,O
in,O
studying,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
among,O
current,O
smokers,O
;,O
therefore,O
",",O
our,O
sample,O
did,O
not,O
include,O
past,O
smokers,O
.,O
Future,O
studies,O
might,O
want,O
to,O
compare,O
the,O
SOC,O
in,O
current,O
and,O
past,O
smokers,O
among,O
Arab,O
men,O
",",O
and,O
longitudinal,O
research,O
is,O
needed,O
to,O
assess,O
the,O
correlates,O
of,O
quitting,O
behavior,O
.,O
Although,O
we,O
did,O
not,O
find,O
associations,O
with,O
demographic,O
and,O
socio,O
-,O
economic,O
variables,O
",",O
our,O
findings,O
indicated,O
significant,O
associations,O
between,O
some,O
smoking,O
-,O
related,O
variables,O
and,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
.,O
We,O
found,O
that,O
a,O
longer,O
duration,O
of,O
smoking,O
",",O
higher,O
number,O
of,O
previous,O
attempts,O
to,O
quit,O
",",O
greater,O
knowledge,O
about,O
smoking,O
hazards,O
",",O
and,O
positive,O
attitudes,O
towards,O
smoking,O
prevention,O
and,O
cessation,O
contributed,O
to,O
advanced,O
SOC,O
(,O
contemplation,O
or,O
preparation,O
stages,O
compared,O
to,O
pre,O
-,O
contemplation,O
stage,O
).,O
These,O
results,O
are,O
consistent,O
with,O
findings,O
of,O
a,O
meta,O
-,O
analysis,O
[,O
61,O
"],",O
and,O
one,O
cohort,O
study,O
on,O
previous,O
attempts,O
to,O
quit,O
smoking,O
[,O
65,O
].,O
Nicotine,B-DS
dependence,I-DS
did,O
not,O
contribute,O
to,O
advanced,O
SOC,O
in,O
our,O
study,O
",",O
perhaps,O
due,O
to,O
the,O
fact,O
that,O
we,O
found,O
unexpectedly,O
low,O
dependence,O
levels,O
.,O
It,O
might,O
be,O
that,O
those,O
with,O
low,O
dependence,O
levels,O
are,O
less,O
likely,O
to,O
attempt,O
to,O
quit,O
",",O
a,O
result,O
that,O
was,O
reported,O
in,O
a,O
longitudinal,O
study,O
of,O
low,O
intensity,O
smokers,O
in,O
Mexico,O
[,O
66,O
"],",O
and,O
in,O
a,O
study,O
in,O
Egypt,O
[,O
67,O
].,O
We,O
did,O
not,O
find,O
evidence,O
that,O
social,O
smoking,O
(,O
parents,O
smoking,O
",",O
indoor,O
smoking,O
and,O
number,O
of,O
smokers,O
in,O
a,O
household,O
),O
contributed,O
to,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
.,O
We,O
assumed,O
that,O
social,O
smoking,O
might,O
be,O
an,O
important,O
factor,O
in,O
the,O
Arab,O
collective,O
society,O
",",O
where,O
cigarettes,O
are,O
distributed,O
during,O
social,O
events,O
such,O
as,O
weddings,O
and,O
funerals,O
.,O
It,O
has,O
previously,O
been,O
suggested,O
that,O
social,O
pressure,O
in,O
Arab,O
societies,O
might,O
contribute,O
to,O
low,O
levels,O
of,O
smoking,O
cessation,O
[,O
68,O
].,O
However,O
",",O
social,O
norms,O
have,O
been,O
identified,O
as,O
an,O
important,O
factor,O
in,O
quitting,O
smoking,O
[,O
64,O
].,O
We,O
found,O
that,O
higher,O
social,O
support,O
contributed,O
to,O
a,O
more,O
advanced,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
.,O
In,O
addition,O
",",O
our,O
finding,O
that,O
higher,O
levels,O
of,O
anxiety,B-DS
contributed,O
to,O
being,O
at,O
the,O
preparation,O
stage,O
",",O
compared,O
to,O
the,O
pre,O
-,O
contemplation,O
",",O
was,O
unexpected,O
but,O
is,O
important,O
and,O
should,O
be,O
investigated,O
in,O
future,O
research,O
.,O
Our,O
finding,O
that,O
having,O
a,O
chronic,B-DS
disease,I-DS
was,O
related,O
to,O
a,O
more,O
advanced,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
is,O
consistent,O
with,O
findings,O
of,O
two,O
previous,O
cohort,O
studies,O
indicating,O
that,O
",",O
in,O
addition,O
to,O
cigarette,O
costs,O
",",O
health,O
status,O
is,O
the,O
most,O
important,O
reason,O
for,O
quitting,O
smoking,O
[,O
65,O
",",O
69,O
].,O
A,O
high,O
proportion,O
of,O
Arab,O
men,O
“,O
wait,O
”,O
until,O
they,O
develop,O
a,O
chronic,B-DS
disease,I-DS
before,O
they,O
are,O
ready,O
to,O
quit,O
smoking,O
",",O
which,O
should,O
set,O
alarms,O
for,O
policy,O
makers,O
and,O
health,O
care,O
providers,O
to,O
intervene,O
before,O
Arab,O
men,O
develop,O
a,O
chronic,B-DS
disease,I-DS
.,O
In,O
the,O
current,O
study,O
",",O
compared,O
to,O
the,O
pre,O
-,O
contemplation,O
stage,O
",",O
physician,O
advice,O
to,O
quit,O
smoking,O
was,O
associated,O
with,O
the,O
contemplation,O
stage,O
",",O
but,O
not,O
with,O
the,O
preparation,O
stage,O
.,O
The,O
OR,O
of,O
being,O
at,O
the,O
contemplation,O
stage,O
for,O
individuals,O
who,O
received,O
physician,O
advice,O
to,O
quit,O
was,O
almost,O
twice,O
as,O
high,O
as,O
compared,O
to,O
those,O
who,O
did,O
not,O
receive,O
such,O
advice,O
",",O
but,O
physician,O
advice,O
did,O
not,O
significantly,O
increase,O
the,O
OR,O
of,O
being,O
at,O
the,O
preparation,O
stage,O
.,O
This,O
is,O
a,O
very,O
important,O
finding,O
since,O
physician,O
advice,O
was,O
previously,O
found,O
to,O
be,O
cost,O
-,O
effective,O
and,O
increased,O
smoking,O
cessation,O
[,O
70,O
].,O
However,O
",",O
60,O
%,O
of,O
participants,O
in,O
our,O
study,O
reported,O
that,O
their,O
family,O
physician,O
did,O
not,O
advise,O
them,O
to,O
quit,O
smoking,O
.,O
This,O
may,O
be,O
related,O
to,O
a,O
previous,O
finding,O
that,O
prevalence,O
of,O
smoking,O
among,O
physicians,O
is,O
similar,O
to,O
the,O
prevalence,O
of,O
smoking,O
in,O
the,O
general,O
population,O
[,O
3,O
].,O
Therefore,O
",",O
more,O
effort,O
should,O
be,O
invested,O
by,O
sick,O
funds,O
to,O
help,O
physicians,O
quit,O
smoking,O
.,O
Longitudinal,O
research,O
is,O
needed,O
to,O
assess,O
the,O
long,O
-,O
term,O
effects,O
of,O
physician,O
interventions,O
and,O
their,O
impact,O
on,O
smoking,O
cessation,O
.,O
The,O
strength,O
of,O
this,O
study,O
is,O
that,O
it,O
is,O
the,O
first,O
study,O
that,O
we,O
know,O
of,O
that,O
examined,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
smoking,O
among,O
Arab,O
men,O
in,O
Israel,O
.,O
The,O
cross,O
-,O
sectional,O
design,O
of,O
the,O
study,O
does,O
not,O
allow,O
for,O
causal,O
inferences,O
of,O
the,O
results,O
",",O
and,O
therefore,O
longitudinal,O
research,O
is,O
recommended,O
.,O
However,O
",",O
the,O
study,O
included,O
",",O
for,O
the,O
first,O
time,O
",",O
a,O
stratified,O
random,O
sample,O
of,O
Arab,O
men,O
who,O
smoke,O
.,O
This,O
enabled,O
us,O
to,O
examine,O
specific,O
factors,O
that,O
relate,O
to,O
the,O
context,O
of,O
these,O
men,O
",",O
who,O
have,O
received,O
less,O
attention,O
in,O
previous,O
research,O
.,O
Conclusions,O
A,O
high,O
proportion,O
of,O
Arab,O
men,O
in,O
Israel,O
who,O
smoke,O
are,O
at,O
the,O
pre,O
-,O
contemplation,O
stage,O
",",O
indicating,O
low,O
readiness,O
to,O
quit,O
smoking,O
.,O
This,O
low,O
readiness,O
might,O
indicate,O
that,O
policies,O
of,O
free,O
-,O
of,O
-,O
charge,O
smoking,O
-,O
cessation,O
technologies,O
in,O
primary,O
health,O
care,O
clinics,O
may,O
be,O
less,O
effective,O
for,O
this,O
minority,O
group,O
.,O
Interventions,O
aimed,O
at,O
increasing,O
smoking,O
cessation,O
among,O
Arab,O
men,O
need,O
to,O
consider,O
the,O
SOC,O
of,O
the,O
readiness,O
to,O
quit,O
and,O
be,O
tailored,O
to,O
fit,O
the,O
needs,O
of,O
Arab,O
men,O
.,O
Generally,O
",",O
statewide,O
smoking,O
cessation,O
programs,O
have,O
been,O
less,O
effective,O
in,O
minority,O
groups,O
.,O
Our,O
study,O
suggests,O
that,O
assessing,O
the,O
SOC,O
might,O
be,O
an,O
important,O
step,O
to,O
designing,O
smoking,O
cessation,O
interventions,O
for,O
ethnic,O
minority,O
groups,O
.,O
Competing,O
interest,O
The,O
authors,O
declare,O
no,O
competing,O
interest,O
.,O
Authors,O
’,O
contributions,O
ND,O
initiated,O
the,O
study,O
",",O
led,O
the,O
all,O
study,O
aspects,O
including,O
the,O
study,O
design,O
",",O
data,O
collection,O
",",O
and,O
analysis,O
",",O
and,O
prepared,O
the,O
first,O
draft,O
of,O
the,O
paper,O
.,O
OK,O
and,O
KA,O
were,O
involved,O
in,O
the,O
study,O
design,O
and,O
preparation,O
of,O
the,O
study,O
sample,O
.,O
ASM,O
coordinated,O
the,O
data,O
collection,O
",",O
data,O
entry,O
and,O
cleaning,O
.,O
SH,O
conducted,O
the,O
data,O
analysis,O
together,O
with,O
ND,O
",",O
AO,O
and,O
ASM,O
.,O
JT,O
",",O
OK,O
",",O
KA,O
",",O
AO,O
",",O
ASM,O
critically,O
reviewed,O
the,O
paper,O
.,O
All,O
the,O
authors,O
participated,O
in,O
the,O
study,O
design,O
",",O
critically,O
reviewed,O
previous,O
versions,O
of,O
the,O
paper,O
",",O
and,O
confirmed,O
the,O
final,O
version,O
.,O
Death,B-GP
receptor,I-GP
6,I-GP
contributes,O
to,O
autoimmunity,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
Expansion,O
of,O
autoreactive,O
follicular,O
helper,O
T,O
(,O
Tfh,O
),O
cells,O
is,O
tightly,O
restricted,O
to,O
prevent,O
induction,O
of,O
autoantibody,O
-,O
dependent,O
immunological,B-DS
diseases,I-DS
",",O
such,O
as,O
systemic,B-DS
lupus,I-DS
erythematosus,I-DS
(,O
SLE,B-DS
).,O
Here,O
we,O
show,O
expression,O
of,O
an,O
orphan,O
immune,O
regulator,O
",",O
death,B-GP
receptor,I-GP
6,I-GP
(,O
DR6,B-GP
/,O
TNFRSF21,B-GP
"),",O
on,O
a,O
population,O
of,O
Tfh,O
cells,O
that,O
are,O
highly,O
expanded,O
in,O
lupus,B-DS
-,O
like,O
disease,O
progression,O
in,O
mice,B-OG
.,O
Genome,O
-,O
wide,O
screening,O
reveals,O
an,O
interaction,O
between,O
syndecan,B-GP
-,I-GP
1,I-GP
and,O
DR6,B-GP
resulting,O
in,O
immunosuppressive,O
functions,O
.,O
Importantly,O
",",O
syndecan,B-GP
-,I-GP
1,I-GP
is,O
expressed,O
specifically,O
on,O
autoreactive,O
germinal,O
centre,O
(,O
GC,O
),O
B,O
cells,O
that,O
are,O
critical,O
for,O
maintenance,O
of,O
Tfh,O
cells,O
.,O
Syndecan,B-GP
-,I-GP
1,I-GP
expression,O
level,O
on,O
GC,O
B,O
cells,O
is,O
associated,O
with,O
Tfh,O
cell,O
expansion,O
and,O
disease,O
progression,O
in,O
lupus,B-DS
-,O
prone,O
mouse,B-OG
strains,O
.,O
In,O
addition,O
",",O
Tfh,O
cell,O
suppression,O
by,O
DR6,B-GP
-,O
specific,O
monoclonal,O
antibody,O
delays,O
disease,O
progression,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
These,O
findings,O
suggest,O
that,O
the,O
DR6,B-GP
/,O
syndecan,B-GP
-,I-GP
1,I-GP
axis,O
regulates,O
aberrant,O
GC,O
reactions,O
and,O
could,O
be,O
a,O
therapeutic,O
target,O
for,O
autoimmune,B-DS
diseases,I-DS
such,O
as,O
SLE,B-DS
.,O
Germinal,O
centre,O
(,O
GC,O
),O
reactions,O
are,O
driven,O
by,O
T,O
follicular,O
helper,O
(,O
Tfh,O
),O
cells,O
and,O
their,O
dysregulation,O
can,O
cause,O
autoimmune,B-DS
disease,I-DS
.,O
Here,O
the,O
authors,O
show,O
that,O
the,O
orphan,O
receptor,O
DR6,B-GP
is,O
a,O
Tfh,O
cell,O
marker,O
that,O
binds,O
syndecan,B-GP
-,I-GP
1,I-GP
on,O
GC,O
B,O
cells,O
driving,O
autoimmunity,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Systemic,B-DS
lupus,I-DS
erythematosus,I-DS
(,O
SLE,B-DS
),O
is,O
a,O
chronic,B-DS
inflammatory,I-DS
disease,I-DS
resulting,O
from,O
autoantibody,O
recognition,O
of,O
self,O
-,O
antigens,O
",",O
with,O
autoantibody,O
production,O
dependent,O
on,O
activation,O
of,O
autoreactive,O
T,O
and,O
B,O
cells1,O
.,O
Although,O
autoreactive,O
T,O
and,O
B,O
cells,O
can,O
be,O
detected,O
in,O
healthy,O
wild,O
-,O
type,O
mice23,B-OG
",",O
the,O
expansion,O
and,O
activation,O
of,O
these,O
cells,O
are,O
tightly,O
controlled,O
by,O
tolerance,O
mechanisms,O
.,O
Defects,O
in,O
genes,O
associated,O
with,O
apoptotic,O
cell,O
clearance,O
cause,O
systemic,B-DS
autoimmune,I-DS
disease,I-DS
in,O
familial,O
SLE,B-DS
patients,O
and,O
C57BL,B-OG
/,I-OG
6,I-OG
(,I-OG
B6,I-OG
),I-OG
mice456,I-OG
.,O
Normally,O
",",O
the,O
activation,O
of,O
autoreactive,O
lymphocytes,O
should,O
be,O
regulated,O
at,O
the,O
stage,O
of,O
initial,O
T,O
/,O
B,O
cell,O
interactions789,O
.,O
The,O
activation,O
and,O
differentiation,O
of,O
peripheral,O
T,O
and,O
B,O
cells,O
requires,O
multiple,O
steps10,O
.,O
Antigen,O
-,O
primed,O
CD4,B-GP
+,O
T,O
cells,O
migrate,O
from,O
the,O
T,O
cell,O
zone,O
to,O
the,O
B,O
cell,O
follicles,O
after,O
expressing,O
CXCR5,B-GP
",",O
which,O
is,O
a,O
chemokine,O
receptor11,O
.,O
In,O
the,O
lymphoid,O
structure,O
termed,O
the,O
germinal,O
centre,O
(,O
GC,O
"),",O
located,O
on,O
the,O
border,O
between,O
the,O
T,O
and,O
B,O
cell,O
zones,O
",",O
the,O
primed,O
CD4,B-GP
+,O
T,O
cells,O
differentiate,O
into,O
follicular,O
helper,O
T,O
(,O
Tfh,O
),O
cells,O
and,O
promote,O
B,O
cell,O
maturation,O
",",O
such,O
as,O
proliferation,O
",",O
somatic,O
hyper,O
maturation,O
and,O
immunoglobulin,B-GP
class,O
switching,O
",",O
through,O
its,O
production,O
of,O
cytokines,B-GP
such,O
as,O
interleukin,B-GP
(,B-GP
IL,I-GP
)-,I-GP
4,I-GP
and,O
IL,B-GP
-,I-GP
21,I-GP
.,O
Tfh,O
cells,O
express,O
the,O
chemokine,B-GP
receptor,I-GP
CXCR4,B-GP
to,O
migrate,O
from,O
the,O
original,O
follicle,O
to,O
a,O
neighboring,O
follicle,O
and,O
induce,O
new,O
GC,O
formation,O
.,O
In,O
these,O
sequential,O
steps,O
",",O
reciprocal,O
signals,O
by,O
antigen,O
-,O
specific,O
GC,O
B,O
cells,O
are,O
important,O
for,O
complete,O
Tfh,O
cell,O
differentiation,O
and,O
maintenance,O
.,O
In,O
promoting,O
complete,O
Tfh,O
cell,O
differentiation,O
",",O
the,O
GC,O
B,O
cells,O
activate,O
T,B-GP
cell,I-GP
receptor,I-GP
(,O
TCR,B-GP
),O
signalling,O
through,O
antigen,O
presentation,O
.,O
The,O
expression,O
of,O
costimulatory,O
ligands,O
such,O
as,O
inducible,B-GP
T,I-GP
cell,I-GP
co,I-GP
-,I-GP
stimulator,I-GP
ligand,I-GP
(,O
ICOSL,B-GP
),O
and,O
programmed,B-GP
cell,I-GP
death,I-GP
-,I-GP
1,I-GP
ligand1,I-GP
/,O
2,O
(,O
PD,B-GP
-,I-GP
L1,I-GP
/,O
2,O
),O
on,O
GC,O
B,O
cells,O
regulates,O
TCR,B-GP
signal,O
activation,O
",",O
both,O
positively,O
and,O
negatively12,O
.,O
Notably,O
",",O
a,O
functional,O
blockade,O
or,O
defect,O
in,O
negative,O
costimulatory,O
molecules,O
",",O
including,O
programmed,B-GP
cell,I-GP
death,I-GP
1,I-GP
(,O
PD1,B-GP
),O
or,O
cytotoxic,B-GP
T,I-GP
-,I-GP
lymphocyte,I-GP
-,I-GP
associated,I-GP
protein,I-GP
4,I-GP
(,O
CTLA4,B-GP
"),",O
induces,O
an,O
aberrant,O
GC,O
reaction,O
and,O
systemic,B-DS
autoimmunological,I-DS
disease13141516,I-DS
.,O
These,O
findings,O
indicate,O
that,O
during,O
T,O
/,O
B,O
cell,O
interactions,O
",",O
costimulatory,O
molecules,O
fine,O
-,O
tune,O
Tfh,O
cell,O
differentiation,O
",",O
thus,O
preventing,O
the,O
induction,O
of,O
systemic,O
autoimmunity,O
.,O
Death,B-GP
receptor,I-GP
6,I-GP
(,O
DR6,B-GP
/,O
CD358,B-GP
),O
is,O
also,O
known,O
as,O
tumour,B-GP
necrosis,I-GP
factor,I-GP
(,I-GP
TNF,I-GP
),I-GP
receptor,I-GP
superfamily,I-GP
member,I-GP
21,I-GP
(,O
TNFRSF21,B-GP
),O
17,O
.,O
The,O
TNFRSF,B-GP
includes,O
costimulatory,O
molecules,O
such,O
as,O
CD40,B-GP
",",O
CD30,B-GP
",",O
Herpes,B-GP
virus,I-GP
entry,I-GP
mediator,I-GP
(,O
HVEM,B-GP
"),",O
4,B-GP
-,I-GP
1BB,I-GP
",",O
OX40,B-GP
",",O
CD27,B-GP
",",O
DR3,B-GP
",",O
and,O
glucocorticoid,B-GP
-,I-GP
induced,I-GP
TNFR,I-GP
-,I-GP
related,I-GP
protein,I-GP
(,O
GITR,B-GP
),O
18,O
.,O
In,O
a,O
previous,O
report,O
",",O
mice,B-OG
with,O
a,O
targeted,O
deletion,O
of,O
the,O
Tnfrsf21,B-GP
gene,O
(,O
encoding,O
DR6,B-GP
),O
exhibited,O
hyper,O
production,O
of,O
immunoglobulins,B-GP
after,O
antigen,O
stimulation19,O
",",O
and,O
DR6,B-GP
deficiency,O
in,O
peripheral,O
T,O
cells,O
enhances,O
the,O
production,O
of,O
cytokines,B-GP
for,O
facilitating,O
B,O
cell,O
activation,O
and,O
differentiation,O
",",O
as,O
well,O
as,O
the,O
antigen,O
-,O
dependent,O
activation,O
of,O
transcriptional,B-GP
factors,I-GP
such,O
as,O
the,O
nuclear,B-GP
factor,I-GP
of,I-GP
activated,I-GP
T,I-GP
cells,I-GP
(,O
NFAT,B-GP
),O
or,O
nuclear,B-GP
factor,I-GP
-,I-GP
kappa,I-GP
B,I-GP
(,O
NFκB,B-GP
),O
20,O
.,O
DR6,B-GP
is,O
associated,O
with,O
the,O
regulations,O
on,O
T,O
cell,O
function,O
in,O
several,O
immunological,B-DS
diseases,I-DS
",",O
including,O
experimental,B-DS
autoimmune,I-DS
encephalomyelitis,I-DS
(,O
EAE,B-DS
"),",O
asthma,B-DS
",",O
and,O
acute,B-DS
graft,I-DS
versus,I-DS
host,I-DS
disease,I-DS
in,O
animal,B-OG
models212223,O
.,O
DR6,B-GP
is,O
weakly,O
expressed,O
on,O
resting,O
peripheral,O
CD4,B-GP
+,O
T,O
cells,O
and,O
upregulated,O
in,O
response,O
to,O
TCR,B-GP
stimulation24,O
.,O
Importantly,O
",",O
the,O
association,O
of,O
TNFRSF21,B-GP
gene,O
induction,O
with,O
disease,O
progression,O
was,O
reported,O
in,O
SLE,B-DS
patients2526,O
.,O
Although,O
the,O
molecular,O
mechanism,O
of,O
action,O
",",O
including,O
its,O
immunological,O
ligand,O
",",O
is,O
unknown,O
",",O
DR6,B-GP
may,O
have,O
a,O
critical,O
role,O
in,O
autoimmune,B-DS
disease,I-DS
progression,O
.,O
Syndecan,B-GP
-,I-GP
1,I-GP
is,O
a,O
glycosylated,B-GP
type,I-GP
-,I-GP
I,I-GP
transmembrane,I-GP
protein,I-GP
.,O
In,O
in,O
vitro,O
experiments,O
",",O
syndecan,B-GP
-,I-GP
1,I-GP
binds,O
to,O
various,O
soluble,O
proteins,O
via,O
its,O
attached,O
oligosaccharide,O
chains,O
.,O
Therefore,O
",",O
syndecan,B-GP
-,I-GP
1,I-GP
may,O
act,O
as,O
a,O
scaffold,O
for,O
soluble,O
factors,O
",",O
inducing,O
the,O
accumulation,O
of,O
inflammatory,O
cells,O
in,O
localized,O
inflammation27,O
.,O
By,O
contrast,O
",",O
several,O
studies,O
suggest,O
that,O
syndecan,B-GP
-,I-GP
1,I-GP
has,O
a,O
suppressive,O
function,O
on,O
the,O
progression,O
of,O
immunological,B-DS
diseases,I-DS
.,O
Similar,O
to,O
DR6,B-GP
deficiency,O
",",O
syndecan,B-GP
-,I-GP
1,I-GP
deficiency,O
increases,O
the,O
severity,O
of,O
disease,O
",",O
lymphocyte,O
activation,O
",",O
as,O
well,O
as,O
production,O
of,O
antigen,O
-,O
specific,O
plasma,O
cells,O
and,O
immunoglobulins,B-GP
in,O
the,O
peripheral,O
lymphoid,O
organs,O
of,O
EAE,B-DS
",",O
immune,O
complex,O
-,O
mediated,O
murine,O
nephritis,B-DS
",",O
and,O
allergic,O
lung,B-DS
inflammation,I-DS
animal,B-OG
models282930,O
.,O
These,O
findings,O
suggest,O
the,O
presence,O
of,O
an,O
undefined,O
regulatory,O
function,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
in,O
peripheral,O
lymphocyte,O
activation27,O
.,O
The,O
amount,O
of,O
syndecan,O
-,O
1shed,O
into,O
the,O
peripheral,O
blood,O
has,O
been,O
shown,O
to,O
correlate,O
with,O
disease,O
severity,O
in,O
SLE,B-DS
patients3132,O
.,O
Although,O
most,O
CD19,B-GP
+,O
B,O
cells,O
do,O
not,O
express,O
syndecan,B-GP
-,I-GP
1,I-GP
",",O
CD19,B-GP
+,O
autoreactive,O
pre,O
-,O
plasma,O
cells,O
express,O
syndecan,B-GP
-,I-GP
1,I-GP
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
and,O
SLE,B-DS
patients3233,O
.,O
These,O
findings,O
suggest,O
that,O
syndecan,B-GP
-,I-GP
1,I-GP
is,O
also,O
engaged,O
in,O
the,O
pathogenesis,O
of,O
autoimmune,B-DS
diseases,I-DS
.,O
However,O
",",O
the,O
details,O
of,O
the,O
suppressive,O
function,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
",",O
particularly,O
on,O
pathogenic,O
lymphocyte,O
maturation,O
and,O
activation,O
",",O
are,O
unclear27,O
.,O
Here,O
we,O
show,O
an,O
increase,O
in,O
DR6,B-GP
expression,O
on,O
Tfh,O
cells,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Importantly,O
",",O
we,O
identify,O
syndecan,B-GP
-,I-GP
1,I-GP
as,O
a,O
binding,O
partner,O
for,O
DR6,B-GP
",",O
and,O
we,O
clarify,O
whether,O
and,O
how,O
this,O
dysregulated,O
DR6,B-GP
/,O
syndecan,B-GP
-,I-GP
1,I-GP
interaction,O
leads,O
to,O
autoimmunity,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Results,O
Induction,O
of,O
DR6,B-GP
+,O
CD4,B-GP
+,O
T,O
cells,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
Recent,O
independent,O
studies,O
have,O
reported,O
that,O
upregulation,O
of,O
the,O
TNFRSF21,B-GP
gene,O
is,O
associated,O
with,O
disease,O
prognosis,O
by,O
genome,O
-,O
wide,O
gene,O
expression,O
analysis,O
using,O
peripheral,O
mononuclear,O
cells,O
obtained,O
from,O
SLE,B-DS
patients2526,O
.,O
To,O
explore,O
the,O
details,O
of,O
the,O
association,O
between,O
DR6,B-GP
and,O
disease,O
",",O
we,O
generated,O
a,O
rat,B-OG
anti,O
-,O
DR6,B-GP
monoclonal,O
antibody,O
(,O
clone,O
25,O
-,O
1,O
",",O
IgG1,B-GP
).,O
The,O
specificity,O
of,O
25,O
-,O
1,O
antibody,O
(,O
25,O
-,O
1,O
Ab,O
),O
is,O
demonstrated,O
in,O
Supplementary,O
Fig,O
.,O
1,O
.,O
Briefly,O
",",O
25,O
-,O
1,O
Ab,O
bound,O
DR6,B-GP
stably,O
expressed,O
on,O
L929,O
cells,O
(,O
L929,O
-,O
mDR6,O
),O
(,O
Supplementary,O
Fig,O
.,O
1a,O
).,O
25,O
-,O
1,O
Abs,O
specifically,O
bound,O
to,O
DR6,B-GP
",",O
but,O
not,O
to,O
other,O
TNFRSF,B-GP
molecules,O
that,O
were,O
expressed,O
on,O
the,O
cell,O
surface,O
(,O
Supplementary,O
Fig,O
.,O
1b,O
).,O
25,O
-,O
1,O
Abs,O
could,O
also,O
bind,O
to,O
endogenous,O
DR6,B-GP
",",O
expressed,O
by,O
murine,O
T,O
cell,O
hybridoma,O
(,O
DO11,O
.,O
10,O
-,O
T,O
),O
cells,O
(,O
Supplementary,O
Fig,O
.,O
1c,O
",",O
left,O
panel,O
"),",O
and,O
this,O
reactivity,O
was,O
lost,O
after,O
Tnfrsf21,B-GP
gene,O
-,O
specific,O
knockout,O
based,O
on,O
the,O
CRISPR,O
-,O
Cas9,B-GP
system,O
(,O
G510,O
-,O
8,O
-,O
7,O
or,O
-,O
10,O
-,O
4,O
),O
(,O
Supplementary,O
Fig,O
.,O
1c,O
",",O
middle,O
and,O
right,O
panels,O
"),",O
indicating,O
that,O
25,O
-,O
1,O
Abs,O
react,O
with,O
endogenous,O
DR6,B-GP
but,O
not,O
the,O
other,O
proteins,O
expressed,O
on,O
the,O
cell,O
(,O
Supplementary,O
Fig,O
.,O
1c,O
",",O
d,O
).,O
We,O
used,O
25,O
-,O
1,O
Abs,O
to,O
detect,O
mouse,B-OG
DR6,B-GP
expression,O
hereafter,O
.,O
Splenocytes,O
were,O
obtained,O
from,O
anti,O
-,O
DNA,O
Ab,O
negative,O
(,O
10,O
weeks,O
of,O
age,O
),O
and,O
positive,O
(,O
24,O
weeks,O
of,O
age,O
),O
female,O
New,O
Zealand,O
Black,O
×,O
New,O
Zealand,O
White,O
F1,O
(,O
BWF1,O
),O
mice,B-OG
and,O
age,O
-,O
and,O
sex,O
matched,O
healthy,O
B6,B-OG
mice,I-OG
.,O
Interestingly,O
",",O
we,O
identified,O
the,O
induction,O
of,O
DR6,B-GP
-,O
expressing,O
cells,O
in,O
splenocytes,O
obtained,O
from,O
BWF1,O
but,O
not,O
B6,B-OG
mice,I-OG
.,O
The,O
majority,O
of,O
DR6,B-GP
+,O
cells,O
were,O
CD3,B-GP
+,O
T,O
cells,O
in,O
all,O
mice,B-OG
that,O
were,O
tested,O
.,O
DR6,B-GP
+,O
cells,O
were,O
increased,O
in,O
an,O
age,O
-,O
dependent,O
fashion,O
in,O
BWF1,B-OG
mice,I-OG
(,O
Fig,O
.,O
1a,O
).,O
Interestingly,O
",",O
a,O
unique,O
CD4,B-GP
+,O
subset,O
expressing,O
DR6,B-GP
was,O
observed,O
in,O
autoreactive,O
Ab,O
positive,O
lupus,B-DS
-,O
prone,O
BWF1,O
(,O
aged,O
24,O
weeks,O
),O
but,O
not,O
in,O
autoreactive,O
Ab,O
negative,O
B6,B-OG
mice,I-OG
(,O
aged,O
10,O
and,O
24,O
weeks,O
;,O
Fig,O
.,O
1b,O
",",O
c,O
).,O
Most,O
of,O
the,O
CD8,B-GP
+,O
T,O
cells,O
also,O
expressed,O
DR6,B-GP
in,O
BWF1,B-OG
mice,I-OG
(,O
Fig,O
.,O
1d,O
",",O
e,O
).,O
While,O
CD4,B-GP
+,O
T,O
cells,O
of,O
BWF1,B-OG
mice,I-OG
markedly,O
expanded,O
with,O
disease,O
progression,O
",",O
CD8,B-GP
+,O
T,O
cells,O
were,O
minimally,O
expanded,O
in,O
the,O
mice,B-OG
(,O
Fig,O
.,O
1f,O
).,O
Therefore,O
",",O
we,O
decided,O
to,O
further,O
define,O
which,O
subpopulation,O
of,O
CD4,B-GP
+,O
T,O
cells,O
expressed,O
DR6,B-GP
.,O
DR6,B-GP
expression,O
on,O
Tfh,O
cells,O
of,O
lupus,B-DS
-,O
prone,O
mice,B-OG
Follicular,O
helper,O
T,O
(,O
Tfh,O
),O
cells,O
expand,O
and,O
promote,O
disease,O
progression,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Therefore,O
",",O
we,O
asked,O
whether,O
DR6,B-GP
expression,O
was,O
associated,O
with,O
Tfh,O
cells,O
in,O
lupus,B-DS
-,O
prone,O
BWF1,B-OG
mice,I-OG
.,O
Thus,O
",",O
we,O
characterized,O
Bcl6,B-GP
expression,O
of,O
DR6,B-GP
+,O
CD4,B-GP
+,O
cells,O
by,O
intracellular,O
staining,O
since,O
Bcl6,B-GP
is,O
a,O
key,O
transcriptional,O
factor,O
for,O
Tfh,O
cells,O
(,O
Fig,O
.,O
2a,O
).,O
Interestingly,O
",",O
we,O
detected,O
anti,O
-,O
Bcl6,B-GP
antibody,O
specific,O
signal,O
in,O
DR6,B-GP
+,O
CD4,B-GP
+,O
splenocytes,O
isolated,O
from,O
24,O
-,O
week,O
-,O
old,O
BWF1,B-OG
mice,I-OG
(,O
Fig,O
.,O
2a,O
).,O
We,O
also,O
analysed,O
DR6,B-GP
expression,O
among,O
Tfh,O
cells,O
that,O
expanded,O
in,O
lupus,B-DS
-,O
prone,O
BWF1,B-OG
mice,I-OG
.,O
The,O
expanded,O
Tfh,O
cells,O
were,O
detected,O
by,O
their,O
expression,O
of,O
CXCR5,B-GP
and,O
PD1,B-GP
among,O
7AAD,O
−,O
(,O
live,O
),O
CD19,B-GP
−,O
CD4,B-GP
+,O
splenocytes,O
of,O
24,O
-,O
week,O
-,O
old,O
female,O
BWF1,B-OG
mice,I-OG
(,O
Fig,O
.,O
2b,O
",",O
upper,O
panel,O
"),",O
but,O
not,O
in,O
age,O
-,O
and,O
sex,O
matched,O
B6,B-OG
mice,I-OG
(,O
Fig,O
.,O
2b,O
",",O
lower,O
panel,O
).,O
By,O
their,O
CXCR5,B-GP
and,O
PD1,B-GP
expression,O
levels,O
",",O
the,O
expanded,O
Tfh,O
cells,O
could,O
also,O
be,O
separated,O
into,O
three,O
populations,O
;,O
CXCR5high,O
/,O
PD1high,O
(,O
mature,O
Tfh,O
cells,O
),O
and,O
CXCR5int,O
/,O
PD1int,O
(,O
pre,O
-,O
Tfh,O
cells,O
),O
or,O
CXCR5,B-GP
−/,O
PD1,B-GP
−,O
(,O
non,O
-,O
Tfh,O
cells,O
).,O
To,O
determine,O
Tnfrsf21,B-GP
gene,O
expression,O
of,O
these,O
three,O
Tfh,O
cell,O
populations,O
",",O
we,O
sorted,O
these,O
cells,O
from,O
splenocytes,O
of,O
24,O
-,O
week,O
-,O
old,O
BWF1,B-OG
mice,I-OG
.,O
We,O
then,O
detected,O
expression,O
of,O
the,O
Tnfrsf21,B-GP
gene,O
in,O
these,O
isolated,O
cells,O
by,O
quantitative,O
PCR,O
(,O
Fig,O
.,O
2c,O
).,O
Tnfrsf21,B-GP
mRNA,O
expression,O
was,O
detected,O
in,O
each,O
cell,O
population,O
isolated,O
from,O
BWF1,B-OG
mice,I-OG
.,O
The,O
expression,O
was,O
highest,O
in,O
Tfh,O
cells,O
;,O
intermediate,O
in,O
pre,O
-,O
Tfh,O
and,O
low,O
in,O
non,O
-,O
Tfh,O
cells,O
.,O
We,O
also,O
analysed,O
the,O
DR6,B-GP
protein,O
expression,O
of,O
these,O
Tfh,O
cell,O
populations,O
.,O
In,O
flow,O
cytometrical,O
assays,O
",",O
DR6,B-GP
expressing,O
cells,O
were,O
observed,O
in,O
each,O
Tfh,O
cell,O
population,O
.,O
The,O
frequency,O
of,O
DR6,B-GP
+,O
cells,O
was,O
highest,O
in,O
Tfh,O
cells,O
",",O
intermediate,O
in,O
pre,O
-,O
Tfh,O
cells,O
and,O
rare,O
in,O
non,O
-,O
Tfh,O
cells,O
(,O
Fig,O
.,O
2d,O
",",O
left,O
panels,O
).,O
The,O
DR6,B-GP
expression,O
on,O
Tfh,O
cells,O
correlated,O
with,O
the,O
expression,O
of,O
another,O
Tfh,O
-,O
associated,O
surface,O
molecule,O
",",O
CXCR4,B-GP
",",O
by,O
the,O
cells,O
(,O
Fig,O
.,O
2d,O
",",O
middle,O
and,O
right,O
panels,O
).,O
These,O
findings,O
indicated,O
that,O
DR6,B-GP
is,O
expressed,O
on,O
Tfh,O
cells,O
that,O
expand,O
in,O
lupus,B-DS
-,O
prone,O
BWF1,B-OG
mice,I-OG
.,O
Identification,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
as,O
a,O
ligand,O
for,O
DR6,B-GP
To,O
understand,O
in,O
detail,O
the,O
function,O
of,O
DR6,B-GP
in,O
immunological,O
events,O
",",O
specific,O
ligand,O
(,O
s,O
),O
for,O
DR6,B-GP
required,O
discovery,O
.,O
To,O
identify,O
the,O
DR6,B-GP
ligand,O
(,O
s,O
"),",O
we,O
generated,O
a,O
soluble,O
fusion,O
protein,O
consisting,O
of,O
an,O
extracellular,O
domain,O
of,O
murine,O
DR6,B-GP
and,O
the,O
Fc,O
portion,O
of,O
human,B-OG
IgG,B-GP
(,O
DR6,B-GP
-,O
Fc,O
).,O
We,O
observed,O
a,O
small,O
portion,O
of,O
the,O
cells,O
bound,O
to,O
DR6,B-GP
-,O
Fc,O
in,O
total,O
splenocytes,O
obtained,O
from,O
B6,B-OG
mice,I-OG
(,O
Fig,O
.,O
3a,O
",",O
red,O
box,O
in,O
left,O
panel,O
).,O
Most,O
of,O
the,O
cells,O
bound,O
to,O
DR6,B-GP
-,O
Fc,O
were,O
detected,O
in,O
the,O
lymphocytes,O
gate,O
on,O
a,O
SSC,O
versus,O
FSC,O
dot,O
plot,O
(,O
Fig,O
.,O
3a,O
",",O
right,O
panels,O
).,O
We,O
also,O
stained,O
total,O
splenocytes,O
with,O
DR6,B-GP
-,O
Fc,O
and,O
a,O
specific,O
antibody,O
against,O
the,O
indicated,O
cell,O
type,O
marker,O
.,O
The,O
cells,O
bound,O
to,O
DR6,B-GP
-,O
Fc,O
were,O
detected,O
with,O
an,O
antibody,O
against,O
a,O
surface,O
marker,O
for,O
B,O
cells,O
",",O
B220,B-GP
",",O
but,O
not,O
for,O
other,O
cell,O
populations,O
tested,O
(,O
Fig,O
.,O
3b,O
",",O
red,O
coloured,O
box,O
).,O
The,O
murine,O
A20,O
B,O
cell,O
line,O
",",O
but,O
not,O
DO11,O
.,O
10,O
-,O
T,O
cell,O
hybridoma,O
",",O
preferentially,O
bound,O
to,O
DR6,B-GP
-,O
Fc,O
(,O
Fig,O
.,O
3c,O
).,O
Thus,O
",",O
we,O
constructed,O
expression,O
plasmids,O
of,O
full,O
-,O
length,O
complementary,O
DNA,O
(,O
cDNA,O
),O
library,O
obtained,O
from,O
DR6,B-GP
-,O
Fc,O
-,O
positive,O
A20,O
cells,O
and,O
retrovirally,O
transfected,O
the,O
plasmids,O
into,O
DR6,B-GP
-,O
Fc,O
-,O
negative,O
DO11,O
.,O
10,O
-,O
T,O
cells,O
.,O
Then,O
",",O
we,O
isolated,O
the,O
transfectants,O
bound,O
to,O
DR6,B-GP
-,O
Fc,O
during,O
four,O
rounds,O
of,O
sorting,O
and,O
culturing,O
expansions,O
(,O
Fig,O
.,O
3d,O
).,O
After,O
the,O
fifth,O
round,O
",",O
we,O
recovered,O
a,O
single,O
library,O
-,O
specific,O
cDNA,O
fragment,O
(,O
approximately,O
3,O
",",O
000,O
bp,O
in,O
length,O
),O
inserted,O
in,O
genomic,O
DNA,O
of,O
the,O
isolated,O
transfectants,O
(,O
Fig,O
.,O
3e,O
).,O
Surprisingly,O
",",O
the,O
fragment,O
encoded,O
the,O
sequence,O
for,O
the,O
full,O
-,O
length,O
mRNA,O
of,O
murine,O
Syndecan,B-GP
-,I-GP
1,I-GP
(,O
Sdc1,B-GP
).,O
The,O
binding,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
to,O
DR6,B-GP
was,O
confirmed,O
by,O
human,B-OG
and,O
mouse,B-OG
syndecan,B-GP
-,I-GP
1,I-GP
ectopically,O
expressed,O
on,O
DO11,O
.,O
10T,O
cells,O
binding,O
to,O
the,O
DR6,B-GP
ectodomain,O
(,O
Fig,O
.,O
3f,O
).,O
We,O
then,O
analysed,O
the,O
molecular,O
specificity,O
of,O
the,O
interaction,O
between,O
syndecan,B-GP
-,I-GP
1,I-GP
and,O
DR6,B-GP
(,O
Supplementary,O
Fig,O
.,O
2,O
).,O
We,O
retrovirally,O
transfected,O
plasmids,O
expressing,O
non,O
-,O
specific,O
(,O
shLuc,O
),O
or,O
Syndecan,B-GP
-,I-GP
1,I-GP
-,O
specific,O
(,O
shmSdc1,O
),O
shRNAs,O
into,O
A20,O
cells,O
.,O
Using,O
flow,O
cytometry,O
",",O
we,O
confirmed,O
the,O
effective,O
knockdown,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
protein,O
expression,O
mediated,O
by,O
shmSdc1,O
",",O
but,O
not,O
shLuc,O
",",O
in,O
A20,O
cells,O
(,O
Supplementary,O
Fig,O
.,O
2a,O
).,O
We,O
also,O
confirmed,O
that,O
shmSdc1,O
treatment,O
did,O
not,O
affect,O
B220,B-GP
expression,O
of,O
the,O
cells,O
(,O
Supplementary,O
Fig,O
.,O
2b,O
).,O
In,O
a,O
further,O
flow,O
cytometrical,O
assay,O
using,O
DR6,B-GP
-,O
Fc,O
",",O
shmSdc1,O
but,O
not,O
shLuc,O
treatment,O
dramatically,O
reduced,O
the,O
binding,O
of,O
DR6,B-GP
-,O
Fc,O
to,O
A20,O
cells,O
(,O
Supplementary,O
Fig,O
.,O
2c,O
).,O
In,O
the,O
same,O
assay,O
using,O
the,O
indicated,O
recombinant,O
Fc,O
proteins,O
",",O
syndecan,B-GP
-,I-GP
1,I-GP
expressed,O
on,O
A20,O
cells,O
preferentially,O
bound,O
to,O
DR6,B-GP
-,O
Fc,O
compared,O
with,O
Fc,O
proteins,O
obtained,O
from,O
the,O
other,O
TNFRSF,B-GP
molecules,O
(,O
Supplementary,O
Fig,O
.,O
2d,O
).,O
This,O
syndecan,B-GP
-,I-GP
1,I-GP
specific,O
interaction,O
of,O
DR6,B-GP
was,O
consistent,O
with,O
the,O
observation,O
that,O
the,O
genome,O
-,O
wide,O
screening,O
identified,O
only,O
syndecan,B-GP
-,I-GP
1,I-GP
as,O
a,O
binding,O
molecule,O
for,O
the,O
DR6,B-GP
-,O
ectodomain,O
(,O
Fig,O
.,O
3e,O
).,O
We,O
also,O
analysed,O
binding,O
specificity,O
within,O
the,O
molecular,O
structures,O
of,O
DR6,B-GP
(,O
Fig,O
.,O
3g,O
).,O
Four,O
cysteine,O
-,O
rich,O
domains,O
(,O
CRDs,O
),O
are,O
conserved,O
in,O
the,O
extracellular,O
region,O
of,O
DR6,B-GP
and,O
are,O
involved,O
in,O
ligand,O
binding17,O
.,O
We,O
generated,O
recombinant,O
Fc,O
proteins,O
fused,O
with,O
DR6,B-GP
-,O
extracellular,O
domain,O
lacking,O
CRD1,O
(,O
ΔCRD1,O
"),",O
CRD2,O
(,O
ΔCRD2,O
"),",O
CRD3,O
(,O
ΔCRD3,O
),O
or,O
CRD4,O
(,O
ΔCRD4,O
).,O
Then,O
",",O
these,O
recombinant,O
proteins,O
were,O
pulled,O
down,O
with,O
syndecan,B-GP
-,I-GP
1,I-GP
endogenously,O
expressed,O
on,O
A20,O
cells,O
.,O
The,O
precipitated,O
syndecan,B-GP
-,I-GP
1,I-GP
was,O
detected,O
with,O
an,O
anti,O
-,O
syndecan,B-GP
-,I-GP
1,I-GP
Ab,O
.,O
Among,O
the,O
tested,O
Fc,O
proteins,O
",",O
the,O
mutants,O
lacking,O
CRD2,O
or,O
CRD3,O
were,O
not,O
capable,O
of,O
precipitating,O
syndecan,B-GP
-,I-GP
1,I-GP
.,O
The,O
observed,O
dependence,O
of,O
the,O
interaction,O
on,O
CRD2,O
and,O
-,O
3,O
is,O
in,O
agreement,O
with,O
the,O
previous,O
observations,O
that,O
both,O
CRD2,O
and,O
-,O
3,O
of,O
DR6,B-GP
are,O
positively,O
charged,O
for,O
its,O
ligand,O
binding34,O
.,O
We,O
further,O
demonstrated,O
a,O
molecular,O
function,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
/,O
DR6,B-GP
interaction,O
in,O
T,O
cell,O
activation,O
(,O
Fig,O
.,O
3h,O
).,O
DO11,O
.,O
10,O
-,O
T,O
cells,O
were,O
electroporated,O
with,O
the,O
indicated,O
transcription,B-GP
factor,I-GP
-,O
dependent,O
reporter,O
plasmids,O
.,O
Then,O
",",O
the,O
cells,O
were,O
stimulated,O
with,O
or,O
without,O
recombinant,O
syndecan,B-GP
-,I-GP
1,I-GP
(,O
recSdc1,O
),O
under,O
activation,O
of,O
TCR,B-GP
signalling,O
mediated,O
by,O
anti,O
-,O
CD3,B-GP
Ab,O
.,O
CD3,B-GP
cross,O
-,O
linking,O
dramatically,O
activated,O
NFAT,B-GP
in,O
the,O
cells,O
(,O
Fig,O
.,O
3h,O
",",O
gray,O
in,O
left,O
columns,O
).,O
Interestingly,O
",",O
the,O
recSdc1,O
stimulation,O
suppressed,O
NFAT,B-GP
activation,O
(,O
Fig,O
.,O
3h,O
",",O
red,O
versus,O
gray,O
in,O
left,O
columns,O
).,O
The,O
suppressive,O
effect,O
of,O
recSdc1,O
was,O
also,O
observed,O
in,O
the,O
reporter,O
assay,O
detecting,O
NFκB,B-GP
activation,O
(,O
Fig,O
.,O
3h,O
",",O
right,O
columns,O
).,O
We,O
also,O
demonstrated,O
the,O
suppressive,O
function,O
of,O
recSdc1,O
by,O
assessing,O
IL,B-GP
-,I-GP
2,I-GP
production,O
",",O
which,O
depends,O
on,O
NFAT,B-GP
and,O
NFκB,B-GP
activation,O
(,O
Fig,O
.,O
3i,O
).,O
Parental,O
DO11,O
.,O
10T,O
cells,O
or,O
their,O
DR6,B-GP
deficient,O
clones,O
(,O
Supplementary,O
Fig,O
.,O
1c,O
",",O
d,O
),O
were,O
stimulated,O
with,O
the,O
indicated,O
combinations,O
of,O
anti,O
-,O
CD3,B-GP
Ab,O
and,O
recSdc1,O
.,O
Parental,O
DO11,O
.,O
10T,O
cells,O
produced,O
IL,B-GP
-,I-GP
2,I-GP
in,O
response,O
to,O
anti,O
-,O
CD3,B-GP
Ab,O
",",O
whereas,O
the,O
cells,O
produced,O
decreased,O
IL,B-GP
-,I-GP
2,I-GP
in,O
the,O
presence,O
of,O
recSdc1,O
(,O
Fig,O
.,O
3i,O
",",O
opened,O
compared,O
with,O
closed,O
column,O
in,O
black,O
coloured,O
columns,O
).,O
Interestingly,O
",",O
DR6,B-GP
deficient,O
DO11,O
.,O
10T,O
cell,O
clones,O
produced,O
IL,B-GP
-,I-GP
2,I-GP
in,O
the,O
presence,O
or,O
absence,O
of,O
recSdc1,O
",",O
indicating,O
that,O
the,O
suppressive,O
effect,O
of,O
recSdc1,O
depends,O
on,O
DR6,B-GP
expression,O
by,O
the,O
cells,O
(,O
Fig,O
.,O
3i,O
",",O
opened,O
compared,O
with,O
closed,O
in,O
red,O
or,O
blue,O
columns,O
).,O
These,O
findings,O
demonstrate,O
that,O
syndecan,B-GP
-,I-GP
1,I-GP
is,O
a,O
specific,O
binding,O
partner,O
for,O
DR6,B-GP
and,O
the,O
interaction,O
negatively,O
regulates,O
NFAT,B-GP
and,O
NFκB,B-GP
activation,O
during,O
TCR,B-GP
activation,O
.,O
Syndecan,B-GP
-,I-GP
1,I-GP
on,O
autoreactive,O
germinal,O
centre,O
B,O
cells,O
We,O
next,O
considered,O
whether,O
syndecan,B-GP
-,I-GP
1,I-GP
was,O
associated,O
with,O
a,O
specific,O
B,O
cell,O
population,O
",",O
germinal,O
centre,O
(,O
GC,O
),O
B,O
cells,O
",",O
because,O
the,O
GC,O
B,O
cell,O
provides,O
critical,O
signals,O
for,O
complete,O
maturation,O
and,O
expansion,O
of,O
Tfh,O
cells,O
in,O
lupus,B-DS
-,O
prone,O
mice9103536,O
.,O
We,O
isolated,O
spleens,O
from,O
non,O
-,O
immunized,O
24,O
-,O
week,O
-,O
old,O
female,O
BWF1,O
and,O
NZB,B-OG
mice,I-OG
.,O
On,O
the,O
splenic,O
cryosections,O
of,O
BWF1,B-OG
mice,I-OG
",",O
anti,O
-,O
GL7,B-GP
Ab,O
stained,O
the,O
GC,O
cells,O
",",O
which,O
were,O
markedly,O
expanded,O
on,O
the,O
border,O
between,O
the,O
T,O
-,O
and,O
B,O
-,O
cell,O
zones,O
(,O
Fig,O
.,O
4a,O
",",O
cyan,O
in,O
left,O
panel,O
).,O
Interestingly,O
",",O
the,O
GL7,B-GP
+,O
GC,O
cells,O
were,O
also,O
stained,O
with,O
anti,O
-,O
syndecan,B-GP
-,I-GP
1,I-GP
Ab,O
(,O
Fig,O
.,O
4a,O
",",O
green,O
in,O
right,O
panel,O
).,O
In,O
another,O
lupus,B-DS
-,O
prone,O
mouse,B-OG
strain,O
",",O
NZB,B-OG
mice,I-OG
",",O
the,O
GC,O
cells,O
(,O
Fig,O
.,O
4b,O
",",O
cyan,O
),O
also,O
expressed,O
syndecan,B-GP
-,I-GP
1,I-GP
(,O
Fig,O
.,O
4b,O
",",O
green,O
).,O
The,O
same,O
results,O
were,O
obtained,O
from,O
other,O
sections,O
(,O
Supplementary,O
Fig,O
.,O
3,O
).,O
Comparing,O
the,O
observations,O
obtained,O
from,O
BWF1,O
(,O
Fig,O
.,O
4a,O
),O
with,O
NZB,B-OG
mice,I-OG
(,O
Fig,O
.,O
4b,O
"),",O
we,O
found,O
some,O
differences,O
;,O
(,O
1,O
),O
the,O
level,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
expression,O
on,O
GC,O
cells,O
was,O
higher,O
in,O
NZB,O
than,O
BWF1,B-OG
mice,I-OG
",",O
and,O
(,O
2,O
),O
the,O
size,O
of,O
expanded,O
GC,O
cells,O
was,O
smaller,O
in,O
NZB,O
than,O
BWF1,B-OG
mice,I-OG
.,O
To,O
confirm,O
the,O
former,O
",",O
we,O
assessed,O
the,O
expression,O
level,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
on,O
GL7,B-GP
+,O
CD19,B-GP
+,O
GC,O
B,O
cells,O
using,O
flow,O
cytometry,O
.,O
As,O
expected,O
",",O
the,O
level,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
expression,O
on,O
GL7,B-GP
+,O
CD19,B-GP
+,O
GC,O
B,O
cells,O
of,O
NZB,B-OG
mice,I-OG
was,O
higher,O
than,O
that,O
of,O
BWF1,B-OG
mice,I-OG
(,O
Fig,O
.,O
4c,O
",",O
upper,O
panel,O
).,O
The,O
levels,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
expression,O
of,O
GL7,B-GP
−,O
CD19,B-GP
+,O
non,O
-,O
GC,O
B,O
cells,O
were,O
low,O
and,O
comparable,O
between,O
lupus,B-DS
-,O
prone,O
and,O
healthy,O
B6,B-OG
mice,I-OG
(,O
Fig,O
.,O
4c,O
",",O
upper,O
panel,O
"),",O
although,O
CD19,B-GP
expression,O
level,O
was,O
comparable,O
among,O
these,O
cells,O
(,O
Fig,O
.,O
4c,O
",",O
lower,O
panel,O
).,O
To,O
confirm,O
the,O
latter,O
",",O
we,O
calculated,O
the,O
numbers,O
and,O
percentages,O
of,O
GC,O
B,O
cells,O
in,O
these,O
mice,B-OG
strains,O
.,O
While,O
GL7,B-GP
+,O
CD19,B-GP
+,O
GC,O
B,O
cells,O
hardly,O
developed,O
in,O
healthy,O
non,O
-,O
immunized,O
B6,B-OG
mice,I-OG
",",O
the,O
cells,O
expanded,O
in,O
lupus,B-DS
-,O
prone,O
NZB,O
and,O
BWF1,B-OG
mice,I-OG
(,O
Fig,O
.,O
4d,O
",",O
upper,O
panel,O
).,O
The,O
number,O
of,O
the,O
GC,O
B,O
cells,O
was,O
significantly,O
lower,O
in,O
the,O
spleen,O
of,O
NZB,B-OG
mice,I-OG
compared,O
with,O
BWF1,B-OG
mice,I-OG
(,O
Fig,O
.,O
4d,O
",",O
upper,O
panel,O
).,O
The,O
percentage,O
of,O
GC,O
B,O
cells,O
was,O
also,O
comparable,O
among,O
these,O
lupus,B-DS
-,O
prone,O
mice,B-OG
strains,O
(,O
Fig,O
.,O
4d,O
",",O
lower,O
panel,O
).,O
Therefore,O
",",O
lupus,B-DS
-,O
specific,O
expansion,O
of,O
GC,O
B,O
cell,O
should,O
be,O
restricted,O
in,O
NZB,O
",",O
although,O
the,O
GC,O
B,O
cells,O
developed,O
in,O
both,O
NZB,O
and,O
BWF1,B-OG
mice,I-OG
.,O
Further,O
analysis,O
also,O
showed,O
the,O
NZB,O
specific,O
restriction,O
of,O
the,O
expansion,O
of,O
both,O
pre,O
-,O
Tfh,O
(,O
Fig,O
.,O
4e,O
",",O
left,O
panels,O
),O
and,O
Tfh,O
cells,O
(,O
Fig,O
.,O
4e,O
",",O
right,O
panels,O
).,O
Therefore,O
",",O
we,O
wondered,O
whether,O
syndecan,B-GP
-,I-GP
1,I-GP
was,O
associated,O
with,O
the,O
regulation,O
of,O
Tfh,O
cells,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
To,O
answer,O
this,O
question,O
",",O
we,O
isolated,O
DR6,B-GP
-,O
expressing,O
Tfh,O
cells,O
from,O
BWF1,B-OG
mice,I-OG
and,O
stimulated,O
the,O
cells,O
with,O
recSdc1,O
in,O
conjunction,O
with,O
TCR,B-GP
activation,O
in,O
vitro,O
.,O
Surprisingly,O
",",O
recSdc1,O
stimulation,O
(,O
at,O
30,O
nM,O
),O
suppressed,O
Il,B-GP
-,I-GP
21,I-GP
production,O
by,O
the,O
Tfh,O
cells,O
during,O
activation,O
(,O
Fig,O
.,O
4f,O
).,O
The,O
recSdc1,O
-,O
mediated,O
suppressive,O
effect,O
was,O
not,O
due,O
to,O
a,O
cytotoxic,O
effect,O
on,O
the,O
Tfh,O
cells,O
because,O
30,O
nM,O
recSdc1,O
did,O
not,O
stimulate,O
cell,O
death,O
induction,O
in,O
DO11,O
.,O
10T,O
cells,O
(,O
Supplementary,O
Fig,O
.,O
4,O
),O
or,O
the,O
Tfh,O
cells,O
(,O
Supplementary,O
Fig,O
.,O
5,O
).,O
These,O
findings,O
indicate,O
that,O
syndecan,B-GP
-,I-GP
1,I-GP
was,O
expressed,O
on,O
GC,O
B,O
cells,O
of,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Suppression,O
of,O
DR6,B-GP
+,O
Tfh,O
cells,O
delays,O
disease,O
progression,O
We,O
found,O
that,O
25,O
-,O
1,O
Ab,O
is,O
capable,O
of,O
DR6,B-GP
cross,O
-,O
linking,O
in,O
in,O
vitro,O
experiments,O
(,O
Supplementary,O
Fig,O
.,O
6,O
",",O
the,O
details,O
are,O
described,O
in,O
the,O
legend,O
).,O
In,O
addition,O
",",O
25,O
-,O
1,O
Ab,O
suppressed,O
Il,B-GP
-,I-GP
21,I-GP
production,O
by,O
DR6,B-GP
-,O
expressing,O
Tfh,O
cells,O
isolated,O
from,O
BWF1,B-OG
mice,I-OG
(,O
Fig,O
.,O
5a,O
).,O
This,O
effect,O
was,O
not,O
due,O
to,O
cytotoxicity,O
because,O
25,O
-,O
1,O
Ab,O
did,O
not,O
affect,O
cell,O
death,O
induction,O
in,O
DO11,O
.,O
10,O
-,O
T,O
(,O
Supplementary,O
Fig,O
.,O
7,O
),O
or,O
isolated,O
DR6,B-GP
-,O
expressing,O
Tfh,O
cells,O
(,O
Supplementary,O
Fig,O
.,O
8,O
).,O
These,O
observations,O
prompted,O
us,O
to,O
test,O
the,O
effect,O
of,O
25,O
-,O
1,O
Ab,O
on,O
disease,O
progression,O
in,O
BWF1,B-OG
mice,I-OG
.,O
We,O
administered,O
25,O
-,O
1,O
Ab,O
(,O
25,O
-,O
1,O
),O
or,O
nonspecific,O
rat,B-OG
IgG,B-GP
as,O
a,O
control,O
(,O
ctrl,O
-,O
IgG,B-GP
),O
to,O
15,O
-,O
week,O
-,O
old,O
BWF1,B-OG
mice,I-OG
.,O
Surprisingly,O
",",O
the,O
25,O
-,O
1,O
Ab,O
administrations,O
significantly,O
reduced,O
serum,O
anti,O
-,O
dsDNA,O
Ab,O
production,O
(,O
Fig,O
.,O
5b,O
"),",O
the,O
percentage,O
of,O
mice,B-OG
with,O
proteinuria,O
(,O
as,O
a,O
marker,O
for,O
kidney,O
dysfunction,O
;,O
Fig,O
.,O
5c,O
"),",O
and,O
improved,O
survival,O
(,O
Fig,O
.,O
5d,O
),O
compared,O
with,O
the,O
ctrl,O
-,O
IgG,B-GP
administration,O
.,O
In,O
addition,O
",",O
25,O
-,O
1,O
Ab,O
administration,O
significantly,O
reduced,O
the,O
induction,O
of,O
DR6,B-GP
+,O
CD4,B-GP
+,O
cells,O
(,O
Fig,O
.,O
5e,O
"),",O
GC,O
B,O
cells,O
(,O
Fig,O
.,O
5f,O
),O
and,O
plasma,O
cells,O
in,O
BWF1,B-OG
mice,I-OG
(,O
Fig,O
.,O
5g,O
).,O
The,O
splenic,O
cryosections,O
also,O
showed,O
25,O
-,O
1,O
Ab,O
-,O
mediated,O
suppressive,O
effects,O
on,O
GC,O
formation,O
(,O
Fig,O
.,O
5h,O
",",O
i,O
",",O
the,O
results,O
obtained,O
from,O
the,O
other,O
sections,O
represented,O
in,O
Supplementary,O
Fig,O
.,O
9,O
).,O
In,O
addition,O
",",O
we,O
did,O
not,O
observe,O
a,O
significant,O
effect,O
of,O
25,O
-,O
1,O
Ab,O
on,O
antibody,O
dependent,O
cellular,O
cytotoxicity,O
(,O
ADCC,O
",",O
Supplementary,O
Fig,O
.,O
10a,O
),O
or,O
complement,O
dependent,O
cytotoxicity,O
(,O
CDC,O
",",O
Supplementary,O
Fig,O
.,O
10b,O
).,O
These,O
findings,O
indicate,O
that,O
regulation,O
of,O
DR6,B-GP
delays,O
disease,O
progression,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Discussion,O
In,O
this,O
current,O
study,O
",",O
we,O
found,O
a,O
disease,O
-,O
specific,O
induction,O
of,O
DR6,B-GP
+,O
T,O
cells,O
in,O
lupus,B-DS
-,O
prone,O
BWF1,B-OG
mice,I-OG
.,O
In,O
particular,O
",",O
the,O
induction,O
of,O
DR6,B-GP
+,O
CD4,B-GP
+,O
T,O
cells,O
correlated,O
with,O
age,O
-,O
and,O
genetic,O
background,O
-,O
dependent,O
disease,O
progression,O
and,O
prognosis,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
A,O
large,O
proportion,O
of,O
CD8,B-GP
+,O
T,O
cells,O
also,O
expressed,O
DR6,B-GP
.,O
However,O
",",O
the,O
expansion,O
of,O
these,O
CD8,B-GP
+,O
T,O
cells,O
was,O
suppressed,O
or,O
not,O
promoted,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Therefore,O
",",O
we,O
further,O
analysed,O
DR6,B-GP
expressing,O
CD4,B-GP
+,O
T,O
cells,O
.,O
DR6,B-GP
+,O
CD4,B-GP
+,O
cells,O
expressed,O
Il,B-GP
-,I-GP
21,I-GP
and,O
Bcl6,B-GP
.,O
The,O
expression,O
levels,O
were,O
lower,O
than,O
those,O
observed,O
in,O
DR6low,O
Tfh,O
cells,O
(,O
Supplementary,O
Fig,O
.,O
11,O
).,O
The,O
up,O
-,O
regulated,O
expression,O
of,O
DR6,B-GP
on,O
the,O
T,O
cell,O
surface,O
-,O
regulated,O
the,O
threshold,O
of,O
DR6,B-GP
activation,O
to,O
suppress,O
activation,O
of,O
TCR,B-GP
signalling,O
in,O
the,O
cells,O
.,O
However,O
",",O
the,O
up,O
-,O
regulated,O
DR6,B-GP
itself,O
is,O
insufficient,O
for,O
complete,O
prevention,O
of,O
Tfh,O
cells,O
in,O
lupus,B-DS
-,O
prone,O
BWF1,B-OG
mice,I-OG
",",O
because,O
of,O
the,O
low,O
amount,O
of,O
DR6,B-GP
ligand,O
on,O
the,O
surface,O
of,O
GC,O
B,O
cells,O
that,O
are,O
the,O
direct,O
counter,O
partners,O
of,O
the,O
Tfh,O
cells,O
.,O
In,O
addition,O
",",O
recent,O
studies,O
have,O
reported,O
that,O
CD4,B-GP
+,O
T,O
cell,O
populations,O
exhibit,O
disease,O
-,O
associated,O
characteristics,O
caused,O
by,O
several,O
SLE,B-DS
-,O
associated,O
genetic,O
mutations,O
on,O
murine,O
chromosomes,O
1,O
",",O
5,O
",",O
6,O
",",O
7,O
and,O
18,O
",",O
leading,O
to,O
high,O
activation,O
and,O
expansion,O
of,O
CD4,B-GP
+,O
T,O
cell,O
populations,O
in,O
lupus,B-DS
-,O
prone,O
mice37383940,O
.,O
Although,O
the,O
murine,O
Tnfrsf21,B-GP
gene,O
(,O
on,O
chromosome,O
17,O
),O
is,O
not,O
in,O
murine,O
SLE,B-DS
-,O
associated,O
loci,O
",",O
the,O
unique,O
characteristics,O
of,O
the,O
lupus,B-DS
CD4,B-GP
+,O
T,O
cell,O
populations,O
emphasize,O
the,O
importance,O
of,O
DR6,B-GP
functions,O
in,O
the,O
regulation,O
of,O
CD4,B-GP
+,O
T,O
cells,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Upregulation,O
of,O
DR6,B-GP
expression,O
was,O
observed,O
in,O
Tfh,O
cell,O
populations,O
of,O
lupus,B-DS
-,O
prone,O
BWF1,B-OG
mice,I-OG
.,O
In,O
contrast,O
to,O
lupus,B-DS
-,O
prone,O
mice,B-OG
",",O
DR6,B-GP
expression,O
was,O
low,O
in,O
Tfh,O
cells,O
of,O
DNP,O
-,O
KLH,O
-,O
immunized,O
mice,B-OG
(,O
Supplementary,O
Fig,O
.,O
12a,O
",",O
b,O
",",O
vertical,O
axes,O
).,O
CXCR4,B-GP
(,O
Supplementary,O
Fig,O
.,O
12b,O
",",O
horizontal,O
axes,O
),O
or,O
Bcl6,B-GP
(,O
Supplementary,O
Fig,O
.,O
12c,O
),O
expression,O
in,O
these,O
cells,O
was,O
also,O
low,O
compared,O
with,O
that,O
in,O
Tfh,O
cells,O
of,O
BWF1,B-OG
mice,I-OG
.,O
Collectively,O
",",O
Tfh,O
cells,O
of,O
lupus,B-DS
-,O
prone,O
mice,B-OG
manifested,O
their,O
pathological,O
characteristics,O
compared,O
with,O
Tfh,O
cells,O
of,O
healthy,O
mice,B-OG
as,O
expected,O
",",O
considering,O
that,O
lupus,B-DS
CD4,B-GP
+,O
T,O
cell,O
populations,O
have,O
a,O
high,O
sensitivity,O
to,O
TCR,B-GP
activation3739,O
.,O
The,O
TCR,B-GP
signal,O
promoted,O
high,O
DR6,B-GP
induction,O
on,O
Tfh,O
cells,O
of,O
lupus,B-DS
-,O
prone,O
mice,B-OG
(,O
Supplementary,O
Fig,O
.,O
13a,O
",",O
b,O
).,O
Recently,O
",",O
these,O
pathological,O
characteristics,O
of,O
lupus,B-DS
CD4,B-GP
+,O
T,O
cells,O
were,O
shown,O
to,O
be,O
caused,O
by,O
aberrant,O
metabolic,O
regulations,O
",",O
and,O
are,O
crucial,O
for,O
spontaneous,O
induction,O
of,O
Tfh,O
cell,O
generation,O
",",O
GC,O
formation,O
",",O
and,O
disease,O
symptoms,O
in,O
lupus,B-DS
-,O
prone,O
mice38,O
.,O
Interestingly,O
",",O
such,O
aberrant,O
regulation,O
of,O
lupus,B-DS
CD4,B-GP
+,O
T,O
cells,O
is,O
not,O
associated,O
with,O
humoral,O
responses,O
against,O
foreign,O
antigens38,O
.,O
Therefore,O
",",O
the,O
pathological,O
cellular,O
characteristics,O
might,O
involve,O
high,O
DR6,B-GP
induction,O
on,O
auto,O
reactive,O
Tfh,O
cells,O
of,O
severe,O
lupus,B-DS
-,O
prone,O
BWF1,B-OG
mice,I-OG
.,O
We,O
characterized,O
syndecan,B-GP
-,I-GP
1,I-GP
as,O
a,O
binding,O
partner,O
for,O
DR6,B-GP
.,O
Recombinant,O
syndecan,B-GP
-,I-GP
1,I-GP
stimulation,O
was,O
not,O
capable,O
of,O
inducing,O
cell,O
death,O
",",O
except,O
when,O
it,O
was,O
highly,O
concentrated,O
(,O
Supplementary,O
Fig,O
.,O
4,O
).,O
This,O
weak,O
apoptotic,O
effect,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
stimulation,O
is,O
consistent,O
with,O
the,O
weak,O
apoptotic,O
capability,O
of,O
DR6,B-GP
compared,O
with,O
that,O
of,O
the,O
other,O
TNFRSF,B-GP
molecules,O
",",O
such,O
as,O
death,B-GP
receptor,I-GP
-,I-GP
4,I-GP
(,O
DR4,B-GP
),O
17,O
and,O
-,O
3,O
(,O
DR3,B-GP
),O
41,O
.,O
This,O
weak,O
apoptotic,O
activity,O
of,O
DR6,B-GP
might,O
depend,O
on,O
its,O
low,O
affinities,O
of,O
binding,O
to,O
Fas,B-GP
-,I-GP
associated,I-GP
protein,I-GP
with,I-GP
death,I-GP
domain,I-GP
(,O
FADD,B-GP
),O
and,O
TNFR,B-GP
-,I-GP
associated,I-GP
death,I-GP
domain,I-GP
protein,I-GP
(,O
TRADD,B-GP
"),",O
which,O
are,O
key,O
components,O
for,O
apoptotic,O
caspase,B-GP
activation17,O
.,O
In,O
addition,O
",",O
DR6,B-GP
receptor,O
cross,O
-,O
linking,O
did,O
not,O
affect,O
caspase,B-GP
activation,O
in,O
the,O
cultured,O
T,O
-,O
cell,O
line,O
(,O
Supplementary,O
Fig,O
.,O
14,O
).,O
Meanwhile,O
",",O
syndecan,B-GP
-,I-GP
1,I-GP
/,O
DR6,B-GP
interaction,O
dramatically,O
suppressed,O
the,O
activation,O
of,O
TCR,B-GP
signalling,O
",",O
which,O
activates,O
NFκB,B-GP
and,O
NFAT,B-GP
in,O
the,O
present,O
study,O
.,O
In,O
addition,O
",",O
DR6,B-GP
gene,O
deficiency,O
in,O
lymphocytes,O
leads,O
to,O
hyper,O
activation,O
of,O
NFκB,B-GP
or,O
NFAT1920,O
.,O
These,O
findings,O
and,O
our,O
data,O
suggest,O
that,O
DR6,B-GP
regulates,O
lymphocyte,O
activation,O
by,O
its,O
negative,O
regulation,O
to,O
NFκB,B-GP
and,O
NFAT,B-GP
signalling,O
rather,O
than,O
apoptotic,O
function,O
.,O
However,O
",",O
the,O
molecular,O
mechanisms,O
of,O
this,O
DR6,B-GP
-,O
mediated,O
suppression,O
have,O
yet,O
to,O
be,O
elucidated,O
.,O
Syndecan,B-GP
-,I-GP
1,I-GP
has,O
multiple,O
functions,O
in,O
immunological,O
events,O
and,O
disease,O
progression27,O
.,O
Syndecan,B-GP
-,I-GP
1,I-GP
can,O
attach,O
to,O
several,O
chemokines,B-GP
",",O
growth,O
factors,O
",",O
and,O
cytokines,B-GP
",",O
suggesting,O
that,O
it,O
has,O
a,O
scaffolding,O
function,O
for,O
the,O
accumulation,O
of,O
inflammatory,O
cells,O
in,O
localized,O
inflammation,O
.,O
Several,O
knockout,O
studies,O
also,O
suggest,O
that,O
syndecan,B-GP
-,I-GP
1,I-GP
regulates,O
antibody,O
production,O
.,O
Syndecan,B-GP
-,I-GP
1,I-GP
deficiency,O
induces,O
pathogenic,O
antigen,O
(,O
myelin,B-GP
oligodendrocyte,I-GP
glycoprotein,I-GP
)-,O
specific,O
plasma,O
cells,O
in,O
an,O
EAE,B-DS
model28,O
.,O
Syndecan,B-GP
-,I-GP
1,I-GP
deficiency,O
also,O
causes,O
high,O
immunoglobulin,B-GP
production,O
in,O
an,O
Ab,O
-,O
dependent,O
nephritis,B-DS
model29,O
.,O
Importantly,O
",",O
DR6,B-GP
is,O
also,O
associated,O
with,O
negative,O
regulation,O
of,O
peripheral,O
lymphocyte,O
activation,O
in,O
syndecan,B-GP
-,I-GP
1,I-GP
-,O
associated,O
immunological,B-DS
disease,I-DS
models,O
such,O
as,O
EAE21,O
",",O
lung,B-DS
inflammation22,I-DS
",",O
and,O
lupus,B-DS
-,O
like,O
disease,O
(,O
the,O
present,O
study,O
).,O
These,O
findings,O
suggest,O
an,O
association,O
of,O
DR6,B-GP
/,O
syndecan,B-GP
-,I-GP
1,I-GP
interaction,O
with,O
the,O
progression,O
of,O
several,O
immunological,B-DS
diseases,I-DS
.,O
The,O
25,O
-,O
1,O
Ab,O
was,O
capable,O
of,O
DR6,B-GP
cross,O
-,O
linking,O
.,O
Recombinant,O
syndecan,B-GP
-,I-GP
1,I-GP
",",O
as,O
well,O
as,O
25,O
-,O
1,O
Ab,O
treatment,O
",",O
suppressed,O
Il,B-GP
-,I-GP
21,I-GP
production,O
by,O
Tfh,O
cells,O
.,O
Therefore,O
",",O
the,O
antibody,O
should,O
mimic,O
the,O
function,O
of,O
syndecan,B-GP
-,I-GP
1,I-GP
that,O
was,O
reduced,O
in,O
BWF1,B-OG
mice,I-OG
.,O
IL,B-GP
-,I-GP
21,I-GP
production,O
by,O
Tfh,O
cells,O
is,O
critical,O
for,O
both,O
maintenance,O
and,O
development,O
of,O
GC,O
B,O
cells42,O
.,O
Although,O
the,O
importance,O
of,O
IL,B-GP
-,I-GP
21,I-GP
production,O
in,O
Tfh,O
cell,O
development,O
is,O
controversial43,O
",",O
GC,O
B,O
/,O
Tfh,O
cell,O
interaction,O
is,O
important,O
for,O
full,O
-,O
maturation,O
and,O
maintenance,O
of,O
Tfh,O
cells,O
and,O
GC,O
formation94445,O
.,O
Therefore,O
",",O
25,O
-,O
1,O
Ab,O
or,O
syndecan,B-GP
-,I-GP
1,I-GP
should,O
fine,O
-,O
tune,O
the,O
outcome,O
of,O
GC,O
B,O
/,O
Tfh,O
cell,O
interactions,O
",",O
to,O
prevent,O
autoantibody,O
production,O
and,O
disease,O
progression,O
in,O
BWF1,B-OG
mice,I-OG
.,O
Moreover,O
",",O
although,O
25,O
-,O
1,O
Ab,O
preferentially,O
bound,O
to,O
CD3,B-GP
+,O
T,O
cells,O
",",O
other,O
cells,O
binding,O
25,O
-,O
1,O
Ab,O
were,O
also,O
observed,O
in,O
total,O
splenocytes,O
obtained,O
from,O
BWF1,B-OG
mice,I-OG
.,O
Several,O
reports,O
have,O
shown,O
DR6,B-GP
expression,O
on,O
B,O
cells,O
",",O
dendritic,O
cells,O
and,O
macrophages194647,O
.,O
In,O
addition,O
",",O
these,O
cells,O
are,O
associated,O
with,O
GC,O
reactions,O
after,O
immunization,O
in,O
healthy,O
mice,B-OG
",",O
as,O
well,O
as,O
the,O
disease,O
progression,O
of,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Therefore,O
",",O
further,O
studies,O
will,O
be,O
needed,O
to,O
investigate,O
the,O
role,O
of,O
DR6,B-GP
/,O
syndecan,B-GP
-,I-GP
1,I-GP
interaction,O
in,O
the,O
regulation,O
of,O
these,O
cells,O
in,O
the,O
immunization,O
as,O
well,O
as,O
the,O
disease,O
progression,O
.,O
Taken,O
together,O
",",O
in,O
the,O
current,O
study,O
",",O
we,O
identified,O
a,O
novel,O
regulatory,O
mechanism,O
that,O
depends,O
on,O
the,O
interaction,O
of,O
DR6,B-GP
with,O
syndecan,B-GP
-,I-GP
1,I-GP
for,O
preventing,O
expansion,O
and,O
activation,O
of,O
Tfh,O
cells,O
and,O
disease,O
progression,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Therefore,O
",",O
the,O
DR6,B-GP
/,O
syndecan,B-GP
-,I-GP
1,I-GP
axis,O
should,O
be,O
a,O
novel,O
therapeutic,O
target,O
in,O
autoimmune,B-DS
disease,I-DS
.,O
Methods,O
Mice,B-OG
Female,O
C57BL,O
/,O
6,O
",",O
New,O
Zealand,O
Black,O
(,O
NZB,O
"),",O
or,O
NZB,O
×,O
New,O
Zealand,O
White,O
F1,O
mice,B-OG
were,O
purchased,O
from,O
SLC,O
Inc,O
.,O
(,O
Shizuoka,O
",",O
Japan,O
).,O
These,O
mice,B-OG
were,O
housed,O
in,O
specific,O
pathogen,O
-,O
free,O
conditions,O
.,O
All,O
mice,B-OG
were,O
assigned,O
randomly,O
to,O
experimental,O
groups,O
.,O
We,O
performed,O
animal,B-OG
care,O
and,O
experiments,O
in,O
accordance,O
with,O
the,O
guidelines,O
and,O
approval,O
of,O
the,O
Animal,B-OG
Care,O
and,O
Use,O
Committee,O
of,O
Hokkaido,O
University,O
.,O
Cells,O
Murine,O
fibrosarcoma,B-DS
L929,O
",",O
human,B-OG
embryonic,O
fibroblast,O
(,O
HEK,O
),O
293T,O
cells,O
",",O
and,O
retrovirus,B-OG
packaging,O
cells,O
(,O
PLAT,O
-,O
E,O
",",O
kindly,O
provided,O
by,O
Dr,O
Kitamura,O
T,O
),O
were,O
maintained,O
in,O
Dulbecco,O
',O
s,O
modified,O
Eagle,O
',O
s,O
medium,O
containing,O
10,O
%,O
fetal,O
calf,O
serum,O
(,O
FCS,O
),O
at,O
37,O
°,O
C,O
in,O
5,O
%,O
CO2,O
.,O
Murine,O
T,O
cell,O
hybridoma,O
DO11,O
.,O
10,O
-,O
T,O
and,O
murine,O
lymphoma,B-DS
A20,O
were,O
also,O
maintained,O
in,O
RPMI,O
-,O
1640,O
medium,O
containing,O
10,O
%,O
FCS,O
.,O
All,O
cell,O
lines,O
were,O
routinely,O
tested,O
for,O
mycoplasma,B-OG
.,O
Generation,O
of,O
recombinant,O
proteins,O
For,O
construction,O
of,O
DR6,B-GP
-,O
Fc,O
",",O
cDNA,O
encoding,O
the,O
extracellular,O
region,O
of,O
DR6,B-GP
(,O
mouse,B-OG
:,O
from,O
+,O
1_,O
+,O
350,O
aa,O
),O
was,O
fused,O
with,O
the,O
Fc,O
region,O
of,O
human,B-OG
IgG,B-GP
",",O
which,O
was,O
mutated,O
at,O
the,O
amino,O
acid,O
position,O
of,O
E233P,O
",",O
L234A,O
",",O
and,O
L235A,O
for,O
preventing,O
binding,O
with,O
mouse,B-OG
Fc,B-GP
receptors,I-GP
",",O
and,O
inserted,O
into,O
pcDNA3,O
(,O
Life,O
Technologies,O
",",O
Carlsbad,O
",",O
CA,O
).,O
The,O
resulted,O
plasmid,O
was,O
transfected,O
into,O
HEK293T,O
cells,O
with,O
lipofectamine,O
2000,O
(,O
Life,O
Technologies,O
).,O
The,O
recombinant,O
protein,O
secreted,O
in,O
the,O
cultured,O
supernatant,O
was,O
purified,O
by,O
protein,B-GP
-,I-GP
A,I-GP
sepharose,O
column48,O
.,O
Biotinylation,O
of,O
the,O
proteins,O
was,O
performed,O
using,O
the,O
EZ,O
-,O
Link,O
NHS,O
-,O
PEO,O
Solid,O
Phase,O
Biotinylation,O
Kit,O
(,O
Life,O
Technologies,O
"),",O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instructions,O
.,O
For,O
the,O
generation,O
of,O
recombinant,O
mouse,B-OG
syndecan,B-GP
-,I-GP
1,I-GP
protein,O
(,O
recSdc1,O
"),",O
the,O
cDNA,O
encoding,O
ectodomain,O
of,O
mouse,B-OG
syndecan,B-GP
-,I-GP
1,I-GP
(+,O
1_,O
+,O
251,O
aa,O
),O
was,O
inserted,O
into,O
pcDNA3,O
.,O
1,O
myc,O
/,O
his,O
ver,O
.,O
B,O
(,O
Life,O
Technologies,O
).,O
The,O
production,O
of,O
recSdc1,O
that,O
was,O
fused,O
with,O
hexamer,O
His,O
tags,O
was,O
achieved,O
in,O
HEK293T,O
cells,O
as,O
described,O
above,O
.,O
RecSdc1,O
in,O
culture,O
medium,O
was,O
purified,O
using,O
Ni,O
-,O
sepharose,O
column,O
(,O
HisTrap,O
HP,O
",",O
GE,O
Healthcare,O
",",O
Piscataway,O
",",O
NJ,O
).,O
Generation,O
of,O
anti,O
-,O
DR6,B-GP
specific,O
monoclonal,O
antibody,O
Hybridomas,O
were,O
generated,O
from,O
splenocytes,O
of,O
Lewis,B-OG
rats,I-OG
immunized,O
with,O
DR6,B-GP
-,O
Fc,O
and,O
L929,O
-,O
mDR6,O
cells,O
.,O
Specificity,O
of,O
the,O
antibody,O
produced,O
in,O
the,O
cells,O
was,O
assessed,O
by,O
enzyme,O
-,O
linked,O
immunosorbent,O
assay,O
(,O
ELISA,O
),O
using,O
DR6,B-GP
-,O
Fc,O
or,O
human,B-OG
IgG,B-GP
as,O
antigen,O
.,O
Flow,O
cytometry,O
Details,O
of,O
antibodies,O
used,O
in,O
the,O
present,O
study,O
are,O
listed,O
in,O
Supplementary,O
Table,O
1,O
.,O
For,O
analysing,O
cell,O
surface,O
molecules,O
",",O
single,O
-,O
cell,O
suspensions,O
were,O
stained,O
with,O
the,O
indicated,O
antibodies,O
(,O
the,O
concentration,O
of,O
antibody,O
is,O
also,O
listed,O
in,O
Supplementary,O
Table,O
1,O
"),",O
after,O
Fc,O
-,O
block,O
with,O
anti,O
-,O
CD16,B-GP
/,O
32,O
(,O
clone,O
2,O
.,O
4G2,O
",",O
20,O
μg,O
ml,O
−,O
l,O
",",O
4,O
°,O
C,O
",",O
15,O
min,O
).,O
After,O
washed,O
twice,O
with,O
ice,O
-,O
cold,O
PBS,O
containing,O
0,O
.,O
5,O
%,O
bovine,O
serum,O
albumin,B-GP
and,O
0,O
.,O
1,O
%,O
NaN3,O
",",O
the,O
cells,O
were,O
further,O
stained,O
with,O
7AAD,O
.,O
Fluorescent,O
intensities,O
of,O
the,O
cells,O
were,O
detected,O
on,O
a,O
LSR,O
Fortessa,O
or,O
Canto,O
(,O
BD,O
Biosciences,O
",",O
San,O
Jose,O
",",O
CA,O
).,O
For,O
identifying,O
lymphocyte,O
cell,O
populations,O
that,O
were,O
indicated,O
in,O
each,O
figure,O
",",O
gate,O
strategies,O
were,O
shown,O
in,O
Supplementary,O
Fig,O
.,O
15,O
.,O
For,O
intracellular,O
Bcl6,B-GP
detection49,O
",",O
Fixable,O
Viability,O
Dye,O
eFluor,O
780,O
(,O
eBioscience,O
",",O
San,O
Diego,O
",",O
CA,O
),O
was,O
used,O
instead,O
of,O
7AAD,O
.,O
Expression,O
screening,O
Expression,O
screening,O
using,O
the,O
retrovirus,B-OG
-,O
based,O
full,O
-,O
length,O
cDNA,O
library,O
was,O
performed,O
as,O
described,O
in,O
our,O
previous,O
report50,O
.,O
Briefly,O
",",O
the,O
full,O
-,O
length,O
cDNA,O
library,O
was,O
constructed,O
using,O
the,O
In,O
-,O
Fusion,O
SMARTer,O
Directional,O
cDNA,O
Library,O
construction,O
kit,O
(,O
Takara,O
Bio,O
",",O
Shiga,O
",",O
Japan,O
),O
and,O
inserted,O
into,O
retrovirus,B-OG
vector,O
",",O
pMXs51,O
.,O
The,O
titer,O
of,O
cDNA,O
library,O
was,O
>,O
1,O
×,O
106,O
plaque,O
forming,O
units,O
per,O
ml,O
",",O
and,O
>,O
90,O
%,O
of,O
individual,O
clones,O
contained,O
different,O
cDNA,O
fragments,O
.,O
pMXs,O
containing,O
cDNA,O
library,O
was,O
retrovirally,O
packaged,O
in,O
PLAT,O
-,O
E,O
cells,O
.,O
DO11,O
.,O
10,O
-,O
T,O
cell,O
hybridoma,O
(,O
2,O
×,O
106,O
cells,O
),O
was,O
infected,O
with,O
the,O
virus,O
particles,O
at,O
a,O
multiplicity,O
of,O
infection,B-DS
=,O
0,O
.,O
1,O
.,O
Two,O
days,O
after,O
the,O
infection,B-DS
",",O
the,O
cells,O
were,O
stained,O
with,O
biotinylated,O
DR6,B-GP
-,O
Fc,O
plus,O
streptavidin,B-GP
-,O
allophycocyanin,B-GP
(,O
APC,B-GP
).,O
After,O
two,O
-,O
washes,O
",",O
APC,B-GP
-,O
positive,O
cells,O
were,O
sorted,O
by,O
MoFlo,O
Astrios,O
(,O
Beckman,O
Coulter,O
",",O
Brea,O
",",O
CA,O
).,O
The,O
sorted,O
cells,O
were,O
then,O
expanded,O
.,O
After,O
five,O
-,O
rounds,O
of,O
sorting,O
and,O
culturing,O
",",O
the,O
provirus,O
in,O
the,O
sorted,O
cells,O
was,O
isolated,O
by,O
PCR,O
using,O
pMXs,O
-,O
specific,O
primer,O
set,O
.,O
Stable,O
gene,O
expression,O
cDNA,O
fragment,O
encoding,O
the,O
indicated,O
gene,O
was,O
cloned,O
into,O
pMXsIG51,O
at,O
multiple,O
cloning,O
sites,O
.,O
The,O
construct,O
was,O
retrovirally,O
transfected,O
into,O
cells,O
.,O
Among,O
the,O
cells,O
",",O
enhanced,O
green,B-GP
fluorescent,I-GP
protein,I-GP
positive,O
cells,O
were,O
sorted,O
by,O
Moflo,O
Astrios,O
.,O
The,O
purity,O
of,O
the,O
cells,O
was,O
confirmed,O
as,O
>,O
90,O
%,O
by,O
flow,O
cytometry,O
.,O
Tnfrsf21,B-GP
knockout,O
single,O
cell,O
clone,O
The,O
23,O
nucleotide,O
guide,O
sequence,O
(,O
5,O
′-,O
CCACGATGGTCGCCGGCTCTCTT,O
-,O
3,O
′,O
),O
targeting,O
on,O
negative,O
strand,O
genomic,O
DNA,O
locating,O
on,O
exon,O
-,O
1,O
of,O
murine,O
Tnfrsf21,B-GP
gene,O
was,O
designed,O
with,O
CRISPR,O
direct,O
software,O
uploaded,O
in,O
http,O
://,O
crispr,O
.,O
dbcls,O
.,O
jp,O
.,O
The,O
DNA,O
fragment,O
was,O
cloned,O
into,O
pSpCas9,O
(,O
BB,O
)-,O
2A,O
-,O
Puro,O
(,O
PX459,O
),O
ver,O
.,O
2,O
(,O
ref,O
.,O
52,O
).,O
The,O
resulted,O
plasmid,O
was,O
electroporated,O
into,O
DO11,O
.,O
10,O
-,O
T,O
cell,O
using,O
Gene,O
Pulser,O
X,O
-,O
cell,O
(,O
Bio,O
-,O
Rad,O
",",O
Hemel,O
Hempstead,O
",",O
UK,O
),O
at,O
280,O
V,O
and,O
950,O
μF,O
.,O
Two,O
days,O
after,O
puromycin,O
selection,O
at,O
3,O
μg,O
ml,O
−,O
1,O
",",O
single,O
cell,O
clones,O
of,O
the,O
cells,O
were,O
isolated,O
by,O
limiting,O
dilution,O
.,O
The,O
single,O
cell,O
clones,O
were,O
selected,O
after,O
their,O
re,O
-,O
exhibition,O
of,O
puromycin,O
sensitivity,O
(,O
for,O
validating,O
plasmid,O
exclusion,O
),O
and,O
sequencing,O
their,O
genomic,O
DNA,O
(,O
for,O
gene,O
editing,O
).,O
Quantitative,O
PCR,O
Quantitative,O
PCR,O
assay,O
was,O
performed,O
using,O
SYBR,O
Premix,O
Ex,O
Taq,O
II,O
(,O
Takara,O
Bio,O
.),O
41,O
.,O
Briefly,O
",",O
cellular,O
total,O
RNAs,O
were,O
isolated,O
by,O
Trizol,O
method,O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instruction,O
(,O
Life,O
Technologies,O
).,O
Reverse,O
-,O
transcription,O
was,O
carried,O
out,O
by,O
using,O
ReverTra,O
Ace,O
(,O
Toyobo,O
CO,O
.,O
Ltd,O
".,",O
Osaka,O
",",O
Japan,O
).,O
Gene,O
-,O
specific,O
primer,O
sets,O
used,O
in,O
the,O
current,O
study,O
are,O
shown,O
in,O
Supplementary,O
Table,O
2,O
.,O
Mean,O
of,O
Actb,B-GP
in,O
each,O
sample,O
was,O
used,O
as,O
internal,O
control,O
.,O
Site,O
-,O
directed,O
mutagenesis,O
For,O
generating,O
region,O
specific,O
deletion,O
mutants,O
of,O
DR6,B-GP
(,O
ΔCRD1,O
;,O
deleted,O
the,O
region,O
from,O
+,O
42,O
to,O
+,O
105,O
aa,O
",",O
ΔCRD2,O
;,O
deleted,O
the,O
region,O
from,O
+,O
106,O
to,O
+,O
145,O
aa,O
",",O
ΔCRD3,O
;,O
deleted,O
the,O
region,O
from,O
+,O
146,O
to,O
+,O
185,O
aa,O
or,O
ΔCRD4,O
;,O
deleted,O
the,O
region,O
from,O
+,O
186,O
to,O
+,O
212,O
aa,O
"),",O
site,O
-,O
directed,O
deletions,O
were,O
introduced,O
into,O
the,O
plasmid,O
encoding,O
DR6,B-GP
-,O
Fc,O
using,O
PrimeSTAR,O
Mutagenesis,O
kit,O
(,O
Takara,O
Bio,O
.),O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instruction,O
.,O
Pull,O
down,O
assay,O
A20,O
cells,O
(,O
2,O
.,O
5,O
×,O
107,O
cells,O
),O
were,O
incubated,O
with,O
the,O
indicated,O
Fc,O
fused,O
protein,O
(,O
10,O
μg,O
ml,O
−,O
1,O
),O
at,O
4,O
°,O
C,O
.,O
Two,O
hours,O
after,O
the,O
incubation,O
",",O
cells,O
were,O
washed,O
three,O
times,O
with,O
ice,O
-,O
cold,O
culture,O
medium,O
and,O
lysed,O
with,O
the,O
lysis,O
buffer,O
containing,O
0,O
.,O
2,O
%,O
NP,O
-,O
40,O
",",O
10,O
%,O
Glycerol,O
",",O
150,O
mM,O
NaCl,O
and,O
20,O
mM,O
Tris,O
-,O
HCl,O
(,O
pH,O
7,O
.,O
4,O
),O
at,O
4,O
°,O
C,O
.,O
After,O
centrifugation,O
(,O
20,O
",",O
000,O
×,O
g,O
",",O
30,O
min,O
",",O
4,O
°,O
C,O
"),",O
the,O
supernatant,O
was,O
precipitated,O
with,O
protein,B-GP
A,I-GP
sepharose,O
beads,O
(,O
GE,O
Healthcare,O
),O
at,O
4,O
°,O
C,O
for,O
2,O
h,O
.,O
The,O
beads,O
were,O
washed,O
three,O
times,O
with,O
the,O
lysis,O
buffer,O
and,O
the,O
eluted,O
materials,O
were,O
analysed,O
by,O
dot,O
blot,O
assay,O
using,O
anti,O
-,O
syndecan,B-GP
-,I-GP
1,I-GP
Ab,O
(,O
clone,O
281,O
-,O
1,O
",",O
1,O
/,O
1,O
",",O
000,O
diluted,O
",",O
Biolegend,O
",",O
San,O
Diego,O
",",O
CA,O
).,O
Reporter,O
gene,O
assay,O
Cells,O
(,O
3,O
×,O
106,O
cells,O
per,O
450,O
μl,O
of,O
Opti,O
-,O
MEM,O
(,O
Life,O
Technologies,O
),O
in,O
a,O
0,O
.,O
4,O
-,O
cm,O
cuvette,O
),O
were,O
electroporated,O
with,O
20,O
μg,O
firefly,B-OG
-,O
luciferase,B-GP
reporter,O
plasmid,O
(,O
pGL4,O
.,O
26,O
",",O
Promega,O
),O
containing,O
binding,O
motif,O
for,O
the,O
indicated,O
transcriptional,O
factor,O
plus,O
5,O
μg,O
reference,O
renilla,B-OG
-,O
luciferase,B-GP
reporter,O
plasmid,O
(,O
phRG,O
-,O
TK,O
",",O
Promega,O
),O
as,O
described,O
above,O
.,O
Twenty,O
-,O
four,O
hours,O
after,O
the,O
electroporation,O
",",O
cells,O
were,O
stimulated,O
with,O
plate,O
-,O
bound,O
anti,O
-,O
CD3,B-GP
Ab,O
(,O
10,O
μg,O
ml,O
−,O
1,O
),O
in,O
the,O
presence,O
or,O
absence,O
of,O
recSdc1,O
(,O
30,O
nM,O
).,O
Six,O
hours,O
after,O
the,O
stimulation,O
",",O
the,O
luciferase,B-GP
activities,O
of,O
the,O
cells,O
were,O
assessed,O
by,O
dual,O
-,O
Glo,O
luciferase,B-GP
assay,O
(,O
Promega,O
).,O
ELISA,O
The,O
amount,O
of,O
mouse,B-OG
IL,B-GP
-,I-GP
2,I-GP
was,O
assessed,O
by,O
mouse,B-OG
IL,B-GP
-,I-GP
2,I-GP
Quantikine,O
ELISA,O
kit,O
",",O
according,O
to,O
the,O
manufacturer,O
',O
s,O
instruction,O
(,O
M2000,O
",",O
R,O
&,O
D,O
systems,O
",",O
Minneapolis,O
",",O
MN,O
).,O
Immunohistochemistry,O
Acetone,O
-,O
fixed,O
cryosections,O
(,O
7,O
μm,O
),O
were,O
blocked,O
by,O
immunoblock,O
(,O
DS,O
Pharma,O
Biomedical,O
",",O
Osaka,O
",",O
Japan,O
),O
and,O
then,O
stained,O
with,O
the,O
indicated,O
Abs,O
.,O
The,O
dilution,O
of,O
each,O
antibody,O
is,O
shown,O
in,O
Supplementary,O
Table,O
1,O
.,O
Fluorescent,O
images,O
of,O
the,O
sections,O
were,O
captured,O
on,O
a,O
confocal,O
laser,O
scanning,O
system,O
(,O
LSM,O
-,O
780,O
",",O
Carl,O
Zeiss,O
Microscopy,O
GmbH,O
",",O
Göttingen,O
",",O
Germany,O
).,O
GL7,B-GP
+,O
area,O
in,O
the,O
field,O
was,O
calculated,O
using,O
ImageJ,O
software,O
.,O
Detection,O
of,O
anti,O
-,O
dsDNA,O
antibody,O
Anti,O
-,O
dsDNA,O
Ab,O
in,O
serum,O
sample,O
was,O
detected,O
by,O
ELISA,O
using,O
double,O
-,O
stranded,O
deoxyribonucleic,O
acid,O
coated,O
plate,O
and,O
horse,B-OG
radish,I-OG
peroxidase,B-GP
conjugated,O
goat,B-OG
anti,O
-,O
mouse,B-OG
IgG,B-GP
(,O
H,O
+,O
L,O
),O
antibody,O
(,O
1,O
/,O
5,O
",",O
000,O
diluted,O
",",O
Jackson,O
Immuno,O
Research,O
",",O
West,O
Grove,O
",",O
PA,O
).,O
Detection,O
of,O
proteinuria,O
Uropaper,O
III,O
strip,O
(,O
Eiken,O
Chemical,O
Co,O
".,",O
Tochigi,O
",",O
Japan,O
),O
was,O
used,O
for,O
urinalysis,O
.,O
Proteinuria,O
was,O
defined,O
as,O
urinary,O
protein,O
excretion,O
exceeding,O
100,O
mg,O
dl,O
−,O
1,O
.,O
Statistical,O
analysis,O
Two,O
sets,O
of,O
data,O
were,O
compared,O
using,O
two,O
-,O
tailed,O
Student,O
',O
s,O
t,O
-,O
test,O
.,O
When,O
variances,O
were,O
not,O
comparable,O
",",O
Welch,O
',O
s,O
correction,O
was,O
applied,O
.,O
Sample,O
sizes,O
were,O
selected,O
based,O
on,O
the,O
number,O
of,O
replicates,O
(,O
up,O
to,O
three,O
).,O
For,O
survival,O
rate,O
or,O
cumulative,O
incidence,O
",",O
statistical,O
analysis,O
was,O
performed,O
by,O
Log,O
-,O
rank,O
test,O
or,O
Grey,O
test,O
with,O
R,O
software,O
(,O
http,O
://,O
www,O
.,O
R,O
-,O
project,O
.,O
org,O
).,O
P,O
values,O
<,O
0,O
.,O
05,O
were,O
considered,O
statistically,O
significant,O
.,O
Asterisk,O
or,O
NS,O
means,O
‘,O
significant,O
',O
or,O
‘,O
not,O
significant,O
"',",O
respectively,O
.,O
Each,O
in,O
vitro,O
experiment,O
was,O
performed,O
at,O
least,O
twice,O
with,O
reproducible,O
results,O
.,O
Data,O
availability,O
The,O
authors,O
declare,O
that,O
the,O
data,O
supporting,O
of,O
the,O
findings,O
of,O
this,O
study,O
are,O
available,O
within,O
the,O
article,O
and,O
its,O
Supplementary,O
Information,O
Files,O
",",O
or,O
from,O
the,O
corresponding,O
authors,O
on,O
reasonable,O
request,O
.,O
Additional,O
information,O
How,O
to,O
cite,O
this,O
article,O
:,O
Fujikura,O
",",O
D,O
.,O
et,O
al,O
.,O
Death,B-GP
receptor,I-GP
6,I-GP
contributes,O
to,O
autoimmunity,O
in,O
lupus,B-DS
-,O
prone,O
mice,B-OG
.,O
Nat,O
.,O
Commun,O
.,O
8,O
",",O
13957,O
doi,O
:,O
10,O
.,O
1038,O
/,O
ncomms13957,O
(,O
2017,O
).,O
Publisher,O
',O
s,O
note,O
:,O
Springer,O
Nature,O
remains,O
neutral,O
with,O
regard,O
to,O
jurisdictional,O
claims,O
in,O
published,O
maps,O
and,O
institutional,O
affiliations,O
.,O
Supplementary,O
Material,O
Supplementary,O
Information,O
Supplementary,O
Figures,O
",",O
Supplementary,O
Tables,O
",",O
Supplementary,O
Methods,O
and,O
Supplementary,O
References,O
D,O
.,O
F,O
.,O
and,O
T,O
.,O
U,O
.,O
have,O
filed,O
an,O
application,O
under,O
the,O
Patent,O
Cooperation,O
Treaty,O
(,O
PCT,O
"),",O
WO2015076282,O
A1,O
",",O
‘,O
Immunosuppressant,O
',O
regarding,O
the,O
studies,O
in,O
the,O
current,O
paper,O
.,O
The,O
remaining,O
authors,O
declare,O
no,O
competing,O
financial,O
interests,O
.,O
Author,O
contributions,O
D,O
.,O
F,O
.,O
and,O
T,O
.,O
U,O
.,O
conceived,O
and,O
designed,O
the,O
experiments,O
.,O
D,O
.,O
F,O
".,",O
M,O
.,O
I,O
".,",O
T,O
.,O
E,O
.,O
and,O
S,O
.,O
C,O
.,O
performed,O
the,O
experiments,O
.,O
D,O
.,O
F,O
.,O
analysed,O
the,O
data,O
.,O
H,O
.,O
H,O
.,O
gave,O
technical,O
advice,O
.,O
D,O
.,O
F,O
.,O
and,O
T,O
.,O
U,O
.,O
wrote,O
the,O
paper,O
.,O
Total,O
splenocytes,O
obtained,O
from,O
the,O
indicated,O
mice,O
were,O
stained,O
with,O
anti,O
-,O
DR6,O
specific,O
monoclonal,O
antibody,O
(,O
clone,O
25,O
-,O
1,O
),O
with,O
anti,O
-,O
CD3,O
",",O
CD8,O
and,O
CD4,O
specific,O
Abs,O
.,O
(,O
a,O
),O
Total,O
splenocytes,O
(,O
gated,O
as,O
live,O
singlet,O
cells,O
shown,O
in,O
Supplementary,O
Fig,O
.,O
15a,O
),O
were,O
analysed,O
on,O
CD3,O
versus,O
DR6,O
dot,O
plot,O
.,O
Numbers,O
in,O
the,O
dot,O
plots,O
indicates,O
percentage,O
of,O
the,O
cells,O
gated,O
.,O
(,O
b,O
),O
CD4,O
+,O
T,O
cells,O
(,O
CD3,O
+,O
CD8,O
−,O
CD4,O
+),O
of,O
the,O
total,O
splenocytes,O
were,O
also,O
analysed,O
on,O
CD4,O
versus,O
DR6,O
dot,O
plots,O
.,O
(,O
c,O
),O
Quantification,O
of,O
the,O
percentage,O
of,O
DR6,O
+,O
cells,O
in,O
the,O
CD4,O
+,O
T,O
cells,O
.,O
Error,O
bars,O
represent,O
standard,O
deviation,O
(,O
s,O
.,O
d,O
.),O
(,O
n,O
=,O
5,O
per,O
group,O
).,O
(,O
d,O
),O
CD8,O
+,O
T,O
cells,O
(,O
CD3,O
+,O
CD8,O
+,O
CD4,O
−),O
of,O
splenocytes,O
of,O
the,O
indicated,O
mice,O
were,O
analysed,O
on,O
CD8,O
versus,O
DR6,O
dot,O
plots,O
.,O
(,O
e,O
),O
DR6,O
expression,O
(,O
median,O
of,O
fluorescent,O
intensity,O
",",O
MFI,O
),O
on,O
CD8,O
+,O
T,O
cells,O
was,O
also,O
quantified,O
.,O
(,O
f,O
),O
Actual,O
numbers,O
of,O
total,O
CD4,O
+,O
T,O
or,O
CD8,O
+,O
T,O
cells,O
(,O
detected,O
as,O
shown,O
in,O
Supplementary,O
Fig,O
.,O
15b,O
),O
were,O
also,O
counted,O
in,O
splenocytes,O
obtained,O
from,O
these,O
mice,O
.,O
Error,O
bar,O
:,O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
5,O
per,O
group,O
).,O
Asterisks,O
indicate,O
statistical,O
significance,O
(,O
P,O
<,O
0,O
.,O
05,O
",",O
Student,O
',O
s,O
t,O
-,O
test,O
).,O
(,O
a,O
),O
DR6,O
+,O
CD4,O
+,O
cells,O
of,O
24,O
-,O
week,O
-,O
old,O
female,O
BWF1,O
mice,O
were,O
stained,O
with,O
PE,O
-,O
conjugated,O
anti,O
-,O
Bcl6,O
or,O
isotype,O
matched,O
control,O
Ab,O
.,O
The,O
antibody,O
specific,O
signals,O
of,O
the,O
cells,O
are,O
shown,O
in,O
histogram,O
.,O
(,O
b,O
),O
7AAD,O
−,O
CD19,O
−,O
CD4,O
+,O
splenocytes,O
obtained,O
from,O
the,O
indicated,O
mice,O
were,O
analysed,O
on,O
CXCR5,O
versus,O
PD1,O
dot,O
plots,O
for,O
recognizing,O
Tfh,O
(,O
PD1high,O
CXCR5high,O
),O
and,O
pre,O
-,O
Tfh,O
(,O
PD1int,O
CXCR5int,O
),O
or,O
non,O
-,O
Tfh,O
(,O
PD1,O
−,O
CXCR5,O
−,O
),O
cells,O
.,O
(,O
c,O
),O
The,O
Tfh,O
cell,O
populations,O
of,O
24,O
-,O
week,O
-,O
old,O
female,O
BWF1,O
mice,O
were,O
sorted,O
and,O
then,O
Tnfrsf21,O
mRNA,O
expression,O
in,O
these,O
fractionated,O
cells,O
was,O
analysed,O
by,O
quantitative,O
PCR,O
(,O
qPCR,O
).,O
Error,O
bar,O
:,O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
5,O
per,O
group,O
).,O
(,O
d,O
),O
Both,O
DR6,O
and,O
CXCR4,O
expressions,O
of,O
the,O
indicated,O
Tfh,O
cell,O
populations,O
that,O
were,O
detected,O
as,O
in,O
b,O
are,O
also,O
shown,O
.,O
For,O
detecting,O
Tfh,O
cell,O
populations,O
",",O
gate,O
strategy,O
that,O
was,O
shown,O
in,O
Supplementary,O
Fig,O
.,O
15c,O
was,O
used,O
in,O
b,O
–,O
d,O
.,O
(,O
a,O
;,O
left,O
panel,O
),O
Total,O
splenocytes,O
of,O
B6,O
mice,O
were,O
stained,O
with,O
biotinylated,O
murine,O
DR6,O
-,O
Fc,O
plus,O
allophycocyanin,O
-,O
conjugated,O
streptavidin,O
.,O
(,O
upper,O
right,O
panel,O
),O
Cells,O
bound,O
to,O
DR6,O
-,O
Fc,O
among,O
live,O
singlet,O
splenocytes,O
were,O
analysed,O
on,O
FSC,O
versus,O
SSC,O
dot,O
plots,O
.,O
(,O
lower,O
right,O
panel,O
),O
The,O
gating,O
shown,O
in,O
the,O
FSC,O
versus,O
SSC,O
dot,O
plot,O
is,O
also,O
schematically,O
explained,O
.,O
(,O
b,O
),O
Total,O
splenocytes,O
were,O
also,O
stained,O
with,O
DR6,O
-,O
Fc,O
and,O
antibody,O
for,O
detecting,O
the,O
indicated,O
cell,O
type,O
.,O
(,O
c,O
),O
A20,O
or,O
DO11,O
.,O
10,O
-,O
T,O
cells,O
were,O
stained,O
with,O
DR6,O
-,O
Fc,O
.,O
DR6,O
-,O
Fc,O
specific,O
fluorescent,O
intensity,O
of,O
these,O
cell,O
lines,O
is,O
shown,O
.,O
(,O
d,O
),O
DO11,O
.,O
10,O
-,O
T,O
cells,O
transfected,O
with,O
a,O
cDNA,O
library,O
derived,O
from,O
A20,O
cells,O
were,O
stained,O
with,O
DR6,O
-,O
Fc,O
.,O
The,O
transfectants,O
bound,O
to,O
DR6,O
-,O
Fc,O
were,O
collected,O
by,O
four,O
rounds,O
of,O
sorting,O
and,O
expansion,O
.,O
(,O
e,O
),O
After,O
the,O
fifth,O
round,O
of,O
sorting,O
",",O
the,O
cDNA,O
library,O
inserted,O
in,O
genomic,O
DNA,O
of,O
the,O
selected,O
transfectants,O
was,O
isolated,O
as,O
a,O
single,O
cDNA,O
fragment,O
(∼,O
3,O
",",O
000,O
bp,O
).,O
(,O
f,O
),O
Intensity,O
of,O
DR6,O
-,O
Fc,O
staining,O
on,O
DO11,O
.,O
10,O
-,O
T,O
cells,O
ectopically,O
expressing,O
Syndecan,O
-,O
1,O
of,O
mouse,O
(,O
mSdc1,O
),O
or,O
human,O
(,O
hSdc1,O
),O
or,O
empty,O
plasmid,O
.,O
(,O
g,O
),O
Endogenous,O
syndecan,O
-,O
1,O
of,O
A20,O
cells,O
was,O
precipitated,O
with,O
the,O
indicated,O
Fc,O
-,O
fusion,O
proteins,O
and,O
detected,O
as,O
described,O
in,O
Methods,O
section,O
.,O
WT,O
means,O
Fc,O
protein,O
fused,O
with,O
the,O
extracellular,O
region,O
of,O
DR6,O
wild,O
type,O
",",O
ΔCRD1,O
means,O
the,O
fusion,O
protein,O
lacking,O
CRD1,O
",",O
ΔCRD2,O
",",O
lacking,O
CRD2,O
",",O
ΔCRD3,O
",",O
lacking,O
CRD3,O
or,O
ΔCRD4,O
",",O
lacking,O
CRD4,O
.,O
(,O
h,O
),O
DO11,O
.,O
10,O
-,O
T,O
cells,O
were,O
transfected,O
with,O
the,O
indicated,O
reporter,O
plasmid,O
with,O
reference,O
plasmid,O
.,O
The,O
cells,O
were,O
then,O
stimulated,O
with,O
the,O
indicated,O
combination,O
of,O
recombinant,O
syndecan,O
-,O
1,O
protein,O
(,O
recSdc1,O
",",O
30,O
nM,O
),O
and,O
anti,O
-,O
CD3,O
Ab,O
(,O
10,O
μg,O
ml,O
−,O
1,O
).,O
Six,O
hours,O
after,O
the,O
stimulation,O
",",O
reporter,O
activities,O
of,O
the,O
cells,O
were,O
assessed,O
.,O
Error,O
bar,O
:,O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
3,O
per,O
group,O
).,O
(,O
i,O
),O
Parental,O
DO11,O
.,O
10,O
-,O
T,O
or,O
its,O
DR6,O
-,O
knockout,O
clone,O
(,O
G510,O
-,O
8,O
-,O
7,O
or,O
G510,O
-,O
10,O
-,O
4,O
),O
was,O
stimulated,O
as,O
described,O
in,O
h,O
.,O
Twelve,O
hours,O
after,O
the,O
stimulation,O
",",O
IL,O
-,O
2,O
production,O
of,O
the,O
cells,O
was,O
assessed,O
as,O
described,O
in,O
Methods,O
section,O
.,O
Error,O
bar,O
:,O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
3,O
per,O
group,O
).,O
Details,O
of,O
the,O
DR6,O
knock,O
out,O
single,O
cell,O
clones,O
is,O
also,O
shown,O
in,O
Supplementary,O
Fig,O
.,O
1c,O
",",O
d,O
.,O
Asterisks,O
or,O
NS,O
in,O
each,O
panel,O
indicate,O
statistical,O
significance,O
(,O
P,O
<,O
0,O
.,O
05,O
",",O
Student,O
',O
s,O
t,O
-,O
test,O
),O
or,O
not,O
significance,O
",",O
respectively,O
.,O
(,O
a,O
–,O
e,O
),O
Spleens,O
were,O
isolated,O
from,O
24,O
-,O
week,O
-,O
old,O
female,O
BWF1,O
",",O
NZB,O
or,O
B6,O
mice,O
.,O
Splenic,O
cryosections,O
obtained,O
from,O
the,O
BWF1,O
(,O
a,O
),O
or,O
NZB,O
(,O
b,O
),O
mice,O
were,O
stained,O
by,O
anti,O
-,O
GL7,O
(,O
left,O
panel,O
),O
and,O
syndecan,O
-,O
1,O
(,O
right,O
panel,O
),O
specific,O
antibodies,O
.,O
Additional,O
anti,O
-,O
CD4,O
Ab,O
staining,O
was,O
also,O
used,O
for,O
identifying,O
the,O
border,O
between,O
B,O
and,O
T,O
cell,O
zone,O
.,O
Representative,O
images,O
of,O
at,O
least,O
3,O
independent,O
fields,O
per,O
slide,O
are,O
shown,O
.,O
B,O
",",O
B,O
cell,O
zone,O
;,O
T,O
",",O
T,O
cell,O
zone,O
.,O
Dashed,O
line,O
indicates,O
the,O
border,O
between,O
each,O
region,O
.,O
Bar,O
=,O
100,O
μm,O
.,O
(,O
c,O
),O
GL7,O
+,O
CD19,O
+,O
and,O
GL7,O
−,O
CD19,O
+,O
B,O
cell,O
populations,O
obtained,O
from,O
the,O
indicated,O
mice,O
were,O
detected,O
by,O
flow,O
cytometry,O
with,O
the,O
gate,O
strategy,O
that,O
is,O
shown,O
in,O
Supplementary,O
Fig,O
.,O
15d,O
.,O
The,O
expression,O
levels,O
of,O
syndecan,O
-,O
1,O
(,O
upper,O
panel,O
),O
and,O
CD19,O
(,O
lower,O
panel,O
),O
on,O
the,O
detected,O
B,O
cell,O
populations,O
were,O
shown,O
.,O
Error,O
bar,O
:,O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
3,O
for,O
B6,O
",",O
5,O
for,O
NZB,O
",",O
5,O
for,O
BWF1,O
per,O
group,O
).,O
(,O
d,O
),O
Mean,O
number,O
(,O
upper,O
panel,O
),O
or,O
percentage,O
(,O
lower,O
),O
of,O
the,O
GL7,O
+,O
CD19,O
+,O
GC,O
B,O
cell,O
in,O
live,O
total,O
splenocytes,O
obtained,O
from,O
the,O
indicated,O
mice,O
.,O
Error,O
bar,O
:,O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
3,O
for,O
B6,O
",",O
5,O
for,O
NZB,O
",",O
5,O
for,O
BWF1,O
per,O
group,O
).,O
(,O
e,O
),O
The,O
number,O
(,O
upper,O
panel,O
),O
or,O
percent,O
(,O
lower,O
),O
of,O
pre,O
-,O
Tfh,O
(,O
left,O
),O
or,O
Tfh,O
cells,O
(,O
right,O
),O
of,O
live,O
total,O
splenocytes,O
from,O
the,O
indicated,O
mice,O
are,O
also,O
analysed,O
with,O
the,O
gate,O
strategy,O
shown,O
in,O
Supplementary,O
Fig,O
.,O
15c,O
.,O
Error,O
bar,O
:,O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
5,O
per,O
group,O
).,O
(,O
f,O
),O
CD3,O
+,O
CD4,O
+,O
PD1high,O
/,O
int,O
CXCR5high,O
/,O
int,O
CXCR4,O
+,O
cells,O
were,O
isolated,O
from,O
24,O
-,O
week,O
-,O
old,O
female,O
BWF1,O
mice,O
.,O
The,O
cells,O
were,O
stimulated,O
with,O
the,O
indicated,O
combinations,O
of,O
recSdc1,O
(,O
30,O
nM,O
"),",O
anti,O
-,O
CD3,O
Ab,O
(,O
10,O
μg,O
ml,O
−,O
1,O
),O
and,O
anti,O
-,O
CD28,O
Ab,O
(,O
10,O
μg,O
ml,O
−,O
1,O
).,O
Seventy,O
-,O
two,O
hours,O
after,O
the,O
indicated,O
stimulations,O
",",O
Il,O
-,O
21,O
mRNA,O
production,O
in,O
the,O
cells,O
was,O
analysed,O
by,O
qPCR,O
.,O
Error,O
bar,O
:,O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
3,O
per,O
group,O
).,O
ND,O
",",O
not,O
detected,O
.,O
Asterisks,O
in,O
each,O
panel,O
indicate,O
statistical,O
significance,O
(,O
P,O
<,O
0,O
.,O
05,O
",",O
Student,O
',O
s,O
t,O
-,O
test,O
).,O
(,O
a,O
),O
Effect,O
of,O
25,O
-,O
1,O
Ab,O
(,O
25,O
-,O
1,O
),O
or,O
nonspecific,O
rat,O
IgG,O
(,O
ctrl,O
-,O
IgG,O
;,O
10,O
μg,O
ml,O
−,O
1,O
),O
administration,O
on,O
Il,O
-,O
21,O
production,O
of,O
CD3,O
+,O
CD4,O
+,O
PD1high,O
/,O
int,O
CXCR5high,O
/,O
int,O
CXCR4,O
+,O
cells,O
was,O
assessed,O
as,O
described,O
in,O
Fig,O
.,O
4f,O
.,O
(,O
b,O
–,O
d,O
),O
15,O
-,O
week,O
-,O
old,O
female,O
BWF1,O
mice,O
were,O
intraperitoneally,O
administered,O
nonspecific,O
control,O
rat,O
IgG,O
(,O
ctrl,O
-,O
IgG,O
),O
or,O
25,O
-,O
1,O
Ab,O
(,O
300,O
μg,O
per,O
mouse,O
every,O
2,O
days,O
",",O
from,O
15,O
to,O
27,O
weeks,O
old,O
;,O
n,O
=,O
8,O
per,O
group,O
).,O
(,O
b,O
),O
anti,O
-,O
dsDNA,O
Ab,O
production,O
in,O
sera,O
of,O
these,O
mice,O
was,O
assessed,O
by,O
ELISA,O
.,O
Error,O
bar,O
:,O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
8,O
per,O
group,O
).,O
(,O
c,O
),O
Percentages,O
of,O
proteinuria,O
positive,O
(>,O
100,O
mg,O
protein,O
per,O
dl,O
),O
mice,O
in,O
each,O
group,O
are,O
shown,O
(,O
P,O
=,O
0,O
.,O
0314,O
by,O
Gray,O
test,O
).,O
(,O
d,O
),O
The,O
survival,O
rate,O
of,O
these,O
groups,O
is,O
also,O
shown,O
(,O
P,O
=,O
0,O
.,O
0251,O
by,O
Log,O
-,O
rank,O
test,O
).,O
(,O
e,O
–,O
i,O
),O
Twenty,O
-,O
four,O
-,O
week,O
-,O
old,O
proteinuria,O
-,O
positive,O
female,O
BWF1,O
mice,O
were,O
treated,O
as,O
described,O
above,O
(,O
until,O
32,O
weeks,O
old,O
),O
(,O
n,O
=,O
4,O
per,O
group,O
).,O
Two,O
days,O
after,O
the,O
last,O
administration,O
",",O
frequency,O
of,O
DR6,O
+,O
cells,O
in,O
CD4,O
+,O
T,O
cells,O
(,O
e,O
"),",O
GL7,O
+,O
GC,O
B,O
cell,O
in,O
B220,O
+,O
B,O
cells,O
(,O
f,O
),O
or,O
syndecan,O
-,O
1high,O
B220,O
−,O
plasma,O
cells,O
in,O
live,O
total,O
splenocytes,O
(,O
g,O
),O
obtained,O
from,O
these,O
mice,O
was,O
assessed,O
by,O
flow,O
cytometry,O
.,O
Gate,O
strategies,O
that,O
were,O
used,O
for,O
identifying,O
each,O
cell,O
population,O
were,O
shown,O
in,O
Supplementary,O
Fig,O
.,O
15a,O
–,O
e,O
.,O
Error,O
bar,O
:,O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
4,O
per,O
group,O
).,O
(,O
h,O
),O
Splenic,O
cryosections,O
obtained,O
from,O
these,O
mice,O
were,O
stained,O
by,O
GL7,O
Ab,O
for,O
detecting,O
GCs,O
(,O
magenta,O
).,O
The,O
sections,O
were,O
also,O
stained,O
by,O
anti,O
-,O
B220,O
Ab,O
(,O
green,O
),O
for,O
detecting,O
B,O
cell,O
area,O
.,O
Bar,O
",",O
100,O
μm,O
.,O
The,O
results,O
obtained,O
from,O
the,O
other,O
sections,O
are,O
also,O
represented,O
in,O
Supplementary,O
Fig,O
.,O
9,O
.,O
(,O
i,O
),O
Area,O
of,O
GL7,O
+,O
in,O
each,O
section,O
was,O
also,O
calculated,O
.,O
Error,O
bar,O
",",O
s,O
.,O
d,O
.,O
(,O
n,O
=,O
4,O
–,O
6,O
per,O
section,O
).,O
Asterisks,O
in,O
each,O
panel,O
indicate,O
statistical,O
significance,O
(,O
P,O
<,O
0,O
.,O
05,O
",",O
Student,O
',O
s,O
t,O
-,O
test,O
).,O
Wnt,B-GP
signalling,O
modulates,O
transcribed,O
-,O
ultraconserved,O
regions,O
in,O
hepatobiliary,B-DS
cancers,I-DS
Part,O
of,O
these,O
data,O
has,O
been,O
presented,O
at,O
the,O
International,O
Liver,B-DS
Cancer,I-DS
Association,O
Annual,O
Meeting,O
2013,O
and,O
2014,O
(,O
available,O
online,O
at,O
http,O
://,O
www,O
.,O
ilca,O
-,O
online,O
.,O
org,O
/,O
annual,O
-,O
conferences,O
"),",O
the,O
2013,O
NCRI,O
Cancer,B-DS
Conference,O
Meeting,O
(,O
available,O
online,O
at,O
http,O
://,O
conference,O
.,O
ncri,O
.,O
org,O
.,O
uk,O
),O
and,O
the,O
EASL,O
Liver,O
Meeting,O
2014,O
(,O
Journal,O
of,O
Hepatology,O
",",O
Vol,O
.,O
60,O
",",O
Issue,O
1,O
",",O
S88,O
),O
and,O
2015,O
(,O
Journal,O
of,O
Hepatology,O
",",O
Vol,O
.,O
62,O
",",O
S413,O
–,O
S414,O
).,O
Transcript,O
profiling,O
:,O
GSE78911,O
(,O
mice,B-OG
lncRNA,O
-,O
T,O
-,O
UCR,O
profiling,O
"),",O
GSE25859,O
(,O
human,B-OG
cell,O
lines,O
lncRNA,O
-,O
T,O
-,O
UCR,O
profiling,O
"),",O
GSE78912,O
(,O
miRNA,O
mice,B-OG
profiling,O
).,O
Objective,O
Transcribed,O
-,O
ultraconserved,O
regions,O
(,O
T,O
-,O
UCR,O
),O
are,O
long,O
non,O
-,O
coding,O
RNAs,O
which,O
are,O
conserved,O
across,O
species,O
and,O
are,O
involved,O
in,O
carcinogenesis,O
.,O
We,O
studied,O
T,O
-,O
UCRs,O
downstream,O
of,O
the,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
in,O
liver,B-DS
cancer,I-DS
.,O
Design,O
Hypomorphic,O
Apc,B-GP
mice,B-OG
(,O
Apcfl,O
/,O
fl,O
),O
and,O
thiocetamide,O
(,O
TAA,O
)-,O
treated,O
rats,B-OG
developed,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
dependent,O
hepatocarcinoma,B-DS
(,O
HCC,B-DS
),O
and,O
cholangiocarcinoma,B-DS
(,O
CCA,B-DS
"),",O
respectively,O
.,O
T,O
-,O
UCR,O
expression,O
was,O
assessed,O
by,O
microarray,O
",",O
real,O
-,O
time,O
PCR,O
and,O
in,O
situ,O
hybridisation,O
.,O
Results,O
Overexpression,O
of,O
the,O
T,O
-,O
UCR,O
uc,O
.,O
158,O
−,O
could,O
differentiate,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
dependent,O
HCC,B-DS
from,O
normal,O
liver,O
and,O
from,O
β,B-GP
-,I-GP
catenin,I-GP
negative,O
diethylnitrosamine,O
(,O
DEN,O
)-,O
induced,O
HCC,B-DS
.,O
uc,O
.,O
158,O
−,O
was,O
overexpressed,O
in,O
human,B-OG
HepG2,O
versus,O
Huh7,O
cells,O
in,O
line,O
with,O
activation,O
of,O
the,O
Wnt,B-GP
pathway,O
.,O
In,O
vitro,O
modulation,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
altered,O
uc,O
.,O
158,O
−,O
expression,O
in,O
human,B-OG
malignant,O
hepatocytes,O
.,O
uc,O
.,O
158,O
−,O
expression,O
was,O
increased,O
in,O
CTNNB1,B-GP
-,O
mutated,O
human,B-OG
HCCs,B-DS
compared,O
with,O
non,O
-,O
mutated,O
human,B-OG
HCCs,B-DS
",",O
and,O
in,O
human,B-OG
HCC,B-DS
with,O
nuclear,O
localisation,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
.,O
uc,O
.,O
158,O
−,O
was,O
increased,O
in,O
TAA,O
rat,B-OG
CCA,B-DS
and,O
reduced,O
after,O
treatment,O
with,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
inhibitors,O
.,O
uc,O
.,O
158,O
−,O
expression,O
was,O
negative,O
in,O
human,B-OG
normal,O
liver,O
and,O
biliary,O
epithelia,O
",",O
while,O
it,O
was,O
increased,O
in,O
human,B-OG
CCA,B-DS
in,O
two,O
different,O
cohorts,O
.,O
Locked,O
nucleic,O
acid,O
-,O
mediated,O
inhibition,O
of,O
uc,O
.,O
158,O
−,O
reduced,O
anchorage,O
cell,O
growth,O
",",O
3D,O
-,O
spheroid,O
formation,O
and,O
spheroid,O
-,O
based,O
cell,O
migration,O
",",O
and,O
increased,O
apoptosis,O
in,O
HepG2,O
and,O
SW1,O
cells,O
.,O
miR,O
-,O
193b,O
was,O
predicted,O
to,O
have,O
binding,O
sites,O
within,O
the,O
uc,O
.,O
158,O
−,O
sequence,O
.,O
Modulation,O
of,O
uc,O
.,O
158,O
−,O
changed,O
miR,O
-,O
193b,O
expression,O
in,O
human,B-OG
malignant,O
hepatocytes,O
.,O
Co,O
-,O
transfection,O
of,O
uc,O
.,O
158,O
−,O
inhibitor,O
and,O
anti,O
-,O
miR,O
-,O
193b,O
rescued,O
the,O
effect,O
of,O
uc,O
.,O
158,O
−,O
inhibition,O
on,O
cell,O
viability,O
.,O
Conclusions,O
We,O
showed,O
that,O
uc,O
.,O
158,O
−,O
is,O
activated,O
by,O
the,O
Wnt,B-GP
pathway,O
in,O
liver,B-DS
cancers,I-DS
and,O
drives,O
their,O
growth,O
.,O
Thus,O
",",O
it,O
may,O
represent,O
a,O
promising,O
target,O
for,O
the,O
development,O
of,O
novel,O
therapeutics,O
.,O
Summary,O
box,O
What,O
is,O
already,O
known,O
on,O
this,O
subject,O
?,O
The,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
is,O
frequently,O
activated,O
in,O
liver,B-DS
cancer,I-DS
.,O
The,O
understanding,O
of,O
the,O
molecular,O
mechanisms,O
of,O
Wnt,B-GP
deregulation,O
is,O
necessary,O
to,O
develop,O
more,O
specific,O
and,O
effective,O
therapeutics,O
.,O
Transcribed,O
-,O
ultraconserved,O
regions,O
(,O
T,O
-,O
UCRs,O
),O
are,O
long,O
non,O
-,O
coding,O
RNAs,O
that,O
harbour,O
ultraconserved,O
elements,O
and,O
are,O
altered,O
in,O
human,B-OG
carcinomas,B-DS
.,O
What,O
are,O
the,O
new,O
findings,O
?,O
We,O
demonstrate,O
that,O
T,O
-,O
UCRs,O
are,O
downstream,O
mediators,O
of,O
the,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
in,O
three,O
different,O
species,O
",",O
and,O
we,O
provide,O
evidence,O
of,O
their,O
role,O
as,O
competing,O
endogeneous,O
long,O
non,O
-,O
coding,O
RNAs,O
.,O
We,O
have,O
identified,O
a,O
mediator,O
that,O
is,O
downstream,O
of,O
the,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
and,O
specific,O
for,O
cancer,B-DS
development,O
",",O
improving,O
the,O
development,O
of,O
effective,O
and,O
selective,O
novel,O
therapeutics,O
.,O
How,O
might,O
it,O
impact,O
on,O
clinical,O
practice,O
in,O
the,O
foreseeable,O
future,O
?,O
We,O
have,O
studied,O
several,O
cohorts,O
of,O
human,B-OG
liver,B-DS
cancers,I-DS
and,O
observed,O
that,O
deregulation,O
of,O
uc,O
.,O
158,O
−,O
is,O
shared,O
between,O
hepatocarcinoma,B-DS
and,O
cholangiocarcinoma,B-DS
",",O
providing,O
interesting,O
insights,O
into,O
the,O
molecular,O
biology,O
of,O
these,O
diseases,O
and,O
the,O
implication,O
for,O
clinical,O
trial,O
design,O
.,O
Background,O
Hepatocellular,B-DS
carcinoma,I-DS
(,O
HCC,B-DS
),O
is,O
the,O
sixth,O
most,O
common,O
malignancy,O
in,O
the,O
world,O
.,O
1,O
Despite,O
the,O
progress,O
of,O
recent,O
decades,O
",",O
the,O
outcome,O
of,O
patients,O
with,O
advanced,O
HCC,B-DS
remains,O
poor,O
",",O
and,O
mortality,O
for,O
liver,B-DS
cancer,I-DS
has,O
increased,O
worldwide,O
.,O
1,O
Sorafenib,O
is,O
the,O
only,O
drug,O
which,O
is,O
effective,O
in,O
advanced,O
HCC,B-DS
with,O
an,O
improvement,O
of,O
about,O
3,O
months,O
in,O
median,O
overall,O
survival,O
.,O
2,O
Novel,O
therapies,O
are,O
urgently,O
needed,O
",",O
but,O
their,O
development,O
is,O
challenged,O
by,O
the,O
limited,O
understanding,O
of,O
the,O
molecular,O
mechanisms,O
underlying,O
HCC,B-DS
progression,O
and,O
the,O
subsequent,O
lack,O
of,O
identified,O
targets,O
that,O
drive,O
liver,O
transformation,O
.,O
The,O
Wnt,B-GP
pathway,O
is,O
frequently,O
activated,O
in,O
HCC,B-DS
.,O
3,O
4,O
Various,O
attempts,O
have,O
been,O
made,O
to,O
develop,O
therapeutics,O
targeting,O
the,O
Wnt,B-GP
pathway,O
components,O
",",O
and,O
some,O
of,O
these,O
are,O
now,O
under,O
clinical,O
evaluation,O
.,O
5,O
However,O
",",O
the,O
challenges,O
faced,O
in,O
the,O
development,O
of,O
Wnt,B-GP
inhibitors,O
",",O
such,O
as,O
specificity,O
and,O
toxicity,O
",",O
demand,O
a,O
better,O
understanding,O
of,O
the,O
molecular,O
mechanisms,O
involved,O
in,O
Wnt,B-GP
deregulation,O
",",O
in,O
order,O
to,O
inform,O
the,O
design,O
of,O
more,O
specific,O
and,O
more,O
effective,O
compounds,O
.,O
The,O
canonical,O
Wnt,B-GP
pathway,O
(,O
or,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
),O
leads,O
to,O
an,O
accumulation,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
in,O
the,O
cytoplasm,O
that,O
can,O
be,O
translocated,O
into,O
the,O
nucleus,O
and,O
activate,O
transcription,B-GP
factors,I-GP
.,O
3,O
A,O
recent,O
analysis,O
of,O
human,B-OG
HCC,B-DS
has,O
shown,O
that,O
the,O
Wnt,B-GP
pathway,O
is,O
activated,O
in,O
49,O
%,O
of,O
HCC,B-DS
and,O
that,O
almost,O
half,O
of,O
these,O
had,O
features,O
consistent,O
with,O
the,O
activation,O
of,O
the,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
.,O
6,O
These,O
data,O
are,O
in,O
line,O
with,O
an,O
integrated,O
analysis,O
of,O
somatic,O
mutations,O
which,O
revealed,O
activating,O
mutations,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
(,O
CTNNB1,B-GP
),O
in,O
33,O
%,O
of,O
human,B-OG
HCC,B-DS
.,O
In,O
addition,O
",",O
mutations,O
of,O
CTNNB1,B-GP
are,O
mutually,O
exclusive,O
with,O
mutations,O
in,O
AXIN1,B-GP
.,O
7,O
Non,O
-,O
coding,O
RNAs,O
(,O
ncRNA,O
),O
are,O
implicated,O
in,O
liver,O
carcinogenesis,O
.,O
8,O
–,O
10,O
We,O
and,O
others,O
have,O
provided,O
data,O
to,O
support,O
the,O
involvement,O
of,O
small,O
ncRNAs,O
",",O
such,O
as,O
microRNAs,O
",",O
in,O
the,O
modulation,O
of,O
liver,O
cell,O
proliferation,O
and,O
apoptosis,O
.,O
10,O
–,O
13,O
Despite,O
several,O
studies,O
linking,O
ncRNA,O
and,O
the,O
Wnt,B-GP
pathway,O
",",O
most,O
of,O
them,O
focused,O
on,O
the,O
modulation,O
of,O
Wnt,B-GP
signalling,O
proteins,O
by,O
microRNAs,O
",",O
little,O
is,O
known,O
about,O
the,O
effect,O
of,O
this,O
pathway,O
on,O
ncRNA,O
.,O
14,O
–,O
17,O
Increasing,O
evidence,O
points,O
to,O
an,O
important,O
regulatory,O
role,O
of,O
long,O
ncRNAs,O
in,O
cellular,O
processes,O
and,O
disease,O
phenotypes,O
.,O
Sequence,O
conservation,O
across,O
species,O
has,O
been,O
postulated,O
to,O
indicate,O
that,O
a,O
given,O
ncRNA,O
may,O
have,O
a,O
cellular,O
function,O
.,O
A,O
genome,O
-,O
wide,O
survey,O
identified,O
481,O
genomic,O
sequences,O
with,O
a,O
size,O
>,O
200,O
bp,O
that,O
showed,O
a,O
remarkable,O
conservation,O
with,O
100,O
%,O
identity,O
across,O
human,B-OG
",",O
mouse,B-OG
and,O
rat,B-OG
genomes,O
.,O
18,O
These,O
ultraconserved,O
regions,O
(,O
UCR,O
),O
were,O
shown,O
to,O
be,O
transcribed,O
as,O
ultraconserved,O
ncRNAs,O
(,O
T,O
-,O
UCR,O
).,O
They,O
exhibit,O
distinct,O
profiles,O
in,O
various,O
human,B-OG
cancers,B-DS
and,O
modulate,O
cellular,O
proliferation,O
and,O
apoptosis,O
.,O
19,O
–,O
25,O
We,O
have,O
previously,O
shown,O
that,O
T,O
-,O
UCRs,O
are,O
aberrantly,O
expressed,O
in,O
HCC,B-DS
and,O
have,O
a,O
role,O
in,O
the,O
malignant,O
growth,O
of,O
human,B-OG
and,O
murine,O
hepatocytes,O
.,O
25,O
In,O
this,O
study,O
",",O
we,O
aim,O
to,O
investigate,O
the,O
effect,O
of,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
signalling,O
on,O
T,O
-,O
UCRs,O
in,O
order,O
to,O
find,O
downstream,O
effectors,O
of,O
this,O
pathway,O
that,O
can,O
be,O
targeted,O
for,O
the,O
development,O
of,O
novel,O
and,O
more,O
specific,O
therapeutics,O
.,O
Methods,O
Animal,B-OG
models,O
All,O
animals,B-OG
were,O
handled,O
in,O
strict,O
accordance,O
with,O
good,O
animal,B-OG
practice,O
as,O
defined,O
by,O
the,O
relevant,O
national,O
and,O
/,O
or,O
local,O
animal,B-OG
welfare,O
bodies,O
",",O
and,O
all,O
animal,B-OG
works,O
were,O
approved,O
by,O
the,O
appropriate,O
committees,O
.,O
Experiments,O
were,O
carried,O
out,O
in,O
compliance,O
with,O
UK,O
Home,O
Office,O
Animal,B-OG
(,O
Scientific,O
Procedures,O
),O
Act,O
1986,O
and,O
the,O
EU,O
Directive,O
2010,O
.,O
Hypomorphic,O
mutant,O
(,O
Apc580s,O
/,O
580s,O
),O
Apcfl,O
/,O
fl,O
mice,B-OG
were,O
used,O
and,O
compared,O
with,O
Apc,B-GP
+/+,O
mice,B-OG
.,O
Model,O
generation,O
and,O
demonstration,O
of,O
the,O
activation,O
of,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
in,O
this,O
HCC,B-DS
model,O
have,O
already,O
been,O
reported,O
.,O
26,O
We,O
extracted,O
RNA,O
from,O
the,O
liver,O
of,O
Apcfl,O
/,O
fl,O
(,O
tumour,B-DS
with,O
activation,O
of,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
),O
and,O
Apc,B-GP
+/+,O
(,O
normal,O
liver,O
).,O
TAA,O
rat,B-OG
tumour,B-DS
model,O
was,O
used,O
as,O
a,O
model,O
of,O
rat,B-OG
cholangiocarcinoma,B-DS
(,O
CCA,B-DS
).,O
Generation,O
of,O
this,O
model,O
and,O
activation,O
of,O
Wnt,B-GP
pathway,O
in,O
this,O
tumour,B-DS
model,O
have,O
already,O
been,O
reported,O
.,O
27,O
ICG,O
-,O
001,O
(,O
5,O
mg,O
/,O
kg,O
),O
(,O
Tocris,O
",",O
Bristol,O
",",O
UK,O
),O
or,O
C,O
-,O
59,O
(,O
20,O
mg,O
/,O
kg,O
),O
(,O
Cellagen,O
Technologies,O
",",O
San,O
Diego,O
",",O
California,O
",",O
USA,O
),O
was,O
given,O
by,O
intraperitoneal,O
injection,O
.,O
The,O
vehicle,O
for,O
this,O
was,O
physiological,O
saline,O
(,O
Sigma,O
-,O
Aldrich,O
",",O
Sigma,O
",",O
St,O
Louis,O
",",O
Missouri,O
",",O
USA,O
).,O
Control,O
animals,B-OG
were,O
given,O
vehicle,O
alone,O
.,O
In,O
all,O
cases,O
",",O
inhibitors,O
and,O
vehicle,O
were,O
given,O
three,O
times,O
per,O
week,O
.,O
27,O
We,O
extracted,O
RNA,O
from,O
the,O
liver,O
of,O
TAA,O
rat,B-OG
(,O
tumour,B-DS
),O
or,O
saline,O
control,O
(,O
normal,O
liver,O
"),",O
as,O
well,O
as,O
from,O
TAA,O
rats,B-OG
treated,O
with,O
ICG,O
-,O
001,O
",",O
C59,O
or,O
saline,O
control,O
.,O
Axin1fl,O
/,O
fl,O
/,O
Cre,B-GP
mouse,B-OG
model,O
was,O
used,O
to,O
investigate,O
the,O
effect,O
of,O
Axin1,B-GP
disruption,O
in,O
the,O
hepatocytes,O
.,O
This,O
model,O
was,O
generated,O
by,O
crossing,O
mice,B-OG
homozygous,O
for,O
the,O
Axin1fl,O
/,O
fl,O
allele,O
with,O
AhCre,O
mice,B-OG
",",O
as,O
previously,O
reported,O
.,O
28,O
We,O
extracted,O
RNA,O
from,O
the,O
liver,O
of,O
Axin1fl,O
/,O
fl,O
/,O
Cre,B-GP
and,O
Axin1,B-GP
+/+/,O
Cre,B-GP
mice,B-OG
.,O
Diethylnitrosamine,O
-,O
induced,O
HCC,B-DS
:,O
C57BL,O
/,O
6,O
",",O
14,O
days,O
old,O
male,O
mice,B-OG
were,O
intraperitoneally,O
injected,O
with,O
diethylnitrosamine,O
(,O
DEN,O
),O
(,O
40,O
μL,O
of,O
a,O
solution,O
containing,O
10,O
mg,O
/,O
mL,O
DEN,O
in,O
PBS,O
:,O
80,O
mg,O
/,O
kg,O
).,O
Mice,B-OG
were,O
sacrificed,O
at,O
36,O
weeks,O
after,O
DEN,O
injection,O
;,O
liver,O
was,O
assessed,O
for,O
macroscopic,O
tumour,B-DS
number,O
and,O
size,O
",",O
and,O
normal,O
liver,O
and,O
tumour,B-DS
samples,O
were,O
placed,O
into,O
RNA,O
later,O
",",O
snap,O
-,O
frozen,O
in,O
liquid,O
nitrogen,O
or,O
fixed,O
in,O
neutral,O
buffered,O
formalin,O
overnight,O
at,O
4,O
°,O
C,O
for,O
the,O
assessment,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
.,O
Rapid,O
Apc,B-GP
inactivation,O
in,O
Apcfl,O
/,O
fl,O
mice,B-OG
To,O
investigate,O
the,O
phenotype,O
of,O
conditional,O
deletion,O
of,O
Apc,B-GP
",",O
AhCre,O
+,O
Apcfl,O
/,O
fl,O
and,O
AhCre,O
+,O
Apc,B-GP
+/+,O
progeny,O
were,O
used,O
as,O
previously,O
described,O
.,O
29,O
Mice,B-OG
were,O
given,O
daily,O
intraperitoneal,O
injections,O
of,O
β,O
-,O
napthoflavone,O
(,O
80,O
mg,O
/,O
kg,O
),O
as,O
previously,O
reported,O
.,O
30,O
After,O
4,O
days,O
",",O
mice,B-OG
were,O
killed,O
and,O
liver,O
removed,O
",",O
weighed,O
and,O
placed,O
into,O
RNA,O
later,O
(,O
Sigma,O
",",O
St,O
Louis,O
",",O
Missouri,O
",",O
USA,O
),O
or,O
fixed,O
in,O
formalin,O
.,O
For,O
BrdU,O
labelling,O
",",O
mice,B-OG
were,O
injected,O
with,O
0,O
.,O
25,O
mL,O
of,O
BrdU,O
(,O
GE,O
Healthcare,O
",",O
Amersham,O
",",O
UK,O
"),",O
2,O
hours,O
prior,O
to,O
sampling,O
",",O
and,O
staining,O
was,O
performed,O
using,O
an,O
anti,O
-,O
BrdU,O
antibody,B-GP
conjugate,O
(#,O
347580,O
",",O
BD,O
Biosciences,O
",",O
San,O
Jose,O
",",O
California,O
",",O
USA,O
;,O
1,O
:,O
150,O
).,O
Staining,O
for,O
mouse,B-OG
β,B-GP
-,I-GP
catenin,I-GP
was,O
performed,O
on,O
sections,O
from,O
tissue,O
samples,O
fixed,O
at,O
4,O
°,O
C,O
for,O
<,O
24,O
hours,O
in,O
10,O
%,O
formalin,O
prior,O
to,O
processing,O
using,O
the,O
antibody,B-GP
(#,O
610154,O
",",O
BD,O
Biosciences,O
;,O
1,O
:,O
50,O
).,O
T,O
-,O
UCR,O
expression,O
profiling,O
in,O
mice,B-OG
RNA,O
from,O
the,O
liver,O
of,O
Apcfl,O
/,O
fl,O
(,O
n,O
:,O
3,O
"),",O
Apc,B-GP
+/+,O
(,O
n,O
:,O
3,O
),O
and,O
DEN,O
-,O
treated,O
mice,B-OG
(,O
n,O
:,O
3,O
),O
were,O
used,O
.,O
mRNA,O
was,O
purified,O
from,O
total,O
RNA,O
after,O
removal,O
of,O
rRNA,O
(,O
mRNA,O
-,O
ONLY,O
Eukaryotic,O
mRNA,O
Isolation,O
Kit,O
",",O
Epicentre,O
",",O
Madison,O
",",O
Wisconsin,O
",",O
USA,O
).,O
Then,O
",",O
each,O
sample,O
was,O
amplified,O
and,O
transcribed,O
into,O
fluorescent,O
cRNA,O
along,O
the,O
entire,O
length,O
of,O
the,O
transcripts,O
without,O
3,O
′,O
bias,O
",",O
using,O
a,O
random,O
priming,O
method,O
.,O
The,O
labelled,O
cRNAs,O
were,O
hybridised,O
onto,O
the,O
mouse,B-OG
LncRNA,O
Array,O
V,O
.,O
2,O
.,O
0,O
(,O
Arraystar,O
",",O
Rockville,O
",",O
Maryland,O
",",O
USA,O
"),",O
which,O
also,O
included,O
probes,O
for,O
protein,O
-,O
coding,O
RNAs,O
.,O
The,O
arrays,O
were,O
scanned,O
by,O
the,O
Agilent,O
Scanner,O
G2505C,O
(,O
Agilent,O
Technologies,O
",",O
Santa,O
Clara,O
",",O
California,O
",",O
USA,O
).,O
Agilent,O
Feature,O
Extraction,O
software,O
(,O
V,O
.,O
11,O
.,O
0,O
.,O
1,O
.,O
1,O
),O
was,O
used,O
to,O
analyse,O
the,O
acquired,O
array,O
images,O
.,O
Quantile,O
normalisation,O
and,O
subsequent,O
data,O
processing,O
were,O
performed,O
using,O
the,O
GeneSpring,O
GX,O
V,O
.,O
11,O
.,O
5,O
.,O
1,O
software,O
package,O
(,O
Agilent,O
Technologies,O
).,O
After,O
quantile,O
normalisation,O
of,O
the,O
raw,O
data,O
",",O
differentially,O
expressed,O
LncRNAs,O
with,O
statistical,O
significance,O
between,O
groups,O
(,O
Apcfl,O
/,O
fl,O
vs,O
Apc,B-GP
+/+;,O
Apcfl,O
/,O
fl,O
vs,O
DEN,O
-,O
HCC,B-DS
),O
were,O
identified,O
through,O
volcano,O
plot,O
filtering,O
",",O
with,O
a,O
threshold,O
fold,O
change,O
≥,O
2,O
.,O
0,O
and,O
p,O
≤,O
0,O
.,O
05,O
.,O
Human,B-OG
tissues,O
The,O
human,B-OG
CCA,B-DS
tissues,O
were,O
collected,O
under,O
approval,O
of,O
the,O
Ethical,O
Committee,O
for,O
Clinical,O
Research,O
of,O
Padua,O
and,O
the,O
University,O
of,O
Edinburgh,O
ethics,O
committee,O
.,O
Healthy,O
liver,O
was,O
provided,O
by,O
the,O
NHS,O
Scotland,O
Research,O
(,O
NRS,O
),O
BioResource,O
",",O
NHS,O
Lothian,O
.,O
All,O
tissues,O
were,O
collected,O
with,O
informed,O
consent,O
.,O
HCC,B-DS
tissues,O
were,O
provided,O
by,O
the,O
University,O
Hospital,O
Basel,O
and,O
University,O
of,O
Ferrara,O
after,O
appropriate,O
ethical,O
approval,O
.,O
For,O
the,O
CCA,B-DS
tissue,O
microarray,O
(,O
TMA,O
"),",O
a,O
retrospective,O
series,O
(,O
1990,O
–,O
2011,O
),O
of,O
102,O
surgically,O
resected,O
primary,O
biliary,B-DS
cancers,I-DS
",",O
including,O
85,O
CCA,B-DS
and,O
17,O
gall,B-DS
bladder,I-DS
carcinoma,I-DS
specimens,O
",",O
were,O
retrieved,O
from,O
the,O
formalin,O
-,O
fixed,O
paraffin,O
-,O
embedded,O
(,O
FFPE,O
),O
archives,O
of,O
the,O
Department,O
of,O
Pathology,O
and,O
Diagnostics,O
and,O
the,O
ARC,O
-,O
NET,O
biobank,O
of,O
the,O
University,O
and,O
Hospital,O
Trust,O
of,O
Verona,O
after,O
appropriate,O
ethical,O
approval,O
.,O
CCAs,O
were,O
classified,O
according,O
to,O
WHO,O
2010,O
as,O
intrahepatic,B-DS
cholangiocarcinoma,I-DS
(,O
ICC,B-DS
",",O
n,O
=,O
54,O
),O
and,O
extrahepatic,B-DS
cholangiocarcinoma,I-DS
(,O
ECC,B-DS
;,O
n,O
=,O
31,O
).,O
Five,O
1,O
mm,O
core,O
TMAs,O
were,O
assembled,O
.,O
Additional,O
14,O
non,O
-,O
neoplastic,O
controls,O
were,O
included,O
in,O
the,O
TMAs,O
.,O
Three,O
tissue,O
cores,O
per,O
case,O
were,O
analysed,O
.,O
Statistical,O
analysis,O
Statistical,O
analyses,O
were,O
performed,O
by,O
GraphPad,O
Prism,O
6,O
(,O
La,O
Jolla,O
",",O
California,O
",",O
USA,O
).,O
Results,O
are,O
expressed,O
as,O
mean,O
±,O
SD,O
",",O
unless,O
indicated,O
otherwise,O
.,O
Groups,O
that,O
were,O
normally,O
distributed,O
were,O
compared,O
with,O
either,O
a,O
two,O
-,O
tailed,O
Student,O
',O
s,O
t,O
-,O
test,O
(,O
for,O
analysis,O
of,O
two,O
groups,O
),O
or,O
using,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
to,O
compare,O
multiple,O
groups,O
.,O
Non,O
-,O
parametric,O
data,O
were,O
analysed,O
using,O
a,O
Wilcoxon,O
-,O
Mann,O
-,O
Whitney,O
U,O
test,O
when,O
comparing,O
two,O
groups,O
.,O
Significance,O
was,O
accepted,O
when,O
p,O
<,O
0,O
.,O
05,O
.,O
*,O
p,O
:,O
0,O
.,O
05,O
–,O
0,O
.,O
01,O
;,O
**,O
p,O
:,O
0,O
.,O
009,O
–,O
0,O
.,O
001,O
;,O
***,O
p,O
<,O
0,O
.,O
001,O
.,O
Additional,O
methods,O
can,O
be,O
found,O
in,O
the,O
online,O
supplementary,O
information,O
",",O
along,O
with,O
the,O
primer,O
sequences,O
(,O
see,O
online,O
supplementary,O
table,O
S1,O
).,O
Results,O
T,O
-,O
UCR,O
profiling,O
in,O
HCC,B-DS
mouse,B-OG
models,O
Hypomorphic,O
Apc,B-GP
mice,B-OG
(,O
Apcfl,O
/,O
fl,O
),O
were,O
previously,O
shown,O
to,O
develop,O
HCC,B-DS
with,O
activation,O
of,O
the,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
(,O
nuclear,O
localisation,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
and,O
activation,O
of,O
Wnt,B-GP
-,O
related,O
genes,O
).,O
26,O
To,O
assess,O
T,O
-,O
UCRs,O
downstream,O
of,O
the,O
Wnt,B-GP
pathway,O
",",O
we,O
profiled,O
ncRNA,O
expression,O
by,O
microarray,O
in,O
the,O
liver,O
of,O
Apcfl,O
/,O
fl,O
and,O
control,O
Apc,B-GP
+/+,O
mice,B-OG
.,O
Twenty,O
-,O
two,O
T,O
-,O
UCRs,O
were,O
aberrantly,O
expressed,O
(,O
figure,O
1A,O
",",O
see,O
online,O
supplementary,O
table,O
S2,O
"),",O
with,O
four,O
upregulated,O
and,O
eighteen,O
downregulated,O
",",O
greater,O
than,O
twofold,O
",",O
in,O
tumour,B-DS
tissues,O
from,O
APCfl,O
/,O
fl,O
compared,O
with,O
normal,O
liver,O
from,O
Apc,B-GP
+/+.,O
To,O
verify,O
if,O
these,O
T,O
-,O
UCRs,O
were,O
specifically,O
altered,O
by,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
or,O
just,O
affected,O
by,O
the,O
malignant,O
transformation,O
",",O
we,O
profiled,O
T,O
-,O
UCR,O
expression,O
in,O
the,O
livers,O
of,O
mice,B-OG
treated,O
with,O
DEN,O
",",O
which,O
developed,O
a,O
median,O
of,O
17,O
(,O
range,O
:,O
13,O
–,O
36,O
),O
tumours,B-DS
per,O
liver,O
with,O
no,O
nuclear,O
activation,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
(,O
see,O
online,O
supplementary,O
figure,O
S1,O
).,O
Interestingly,O
",",O
we,O
found,O
that,O
four,O
T,O
-,O
UCRs,O
could,O
further,O
differentiate,O
Apcfl,O
/,O
fl,O
-,O
HCC,B-DS
from,O
DEN,O
-,O
induced,O
HCC,B-DS
(,O
figure,O
1A,O
",",O
see,O
online,O
supplementary,O
table,O
S3,O
).,O
Expression,O
of,O
uc,O
.,O
158,O
"−,",O
uc,O
.,O
455,O
"+,",O
uc,O
.,O
196,O
+,O
and,O
uc,O
.,O
82,O
−,O
was,O
assessed,O
by,O
real,O
-,O
time,O
PCR,O
in,O
the,O
liver,O
tissues,O
of,O
a,O
second,O
series,O
of,O
Apcfl,O
/,O
fl,O
and,O
control,O
Apc,B-GP
+/+,O
mice,B-OG
(,O
figure,O
1B,O
).,O
uc,O
.,O
158,O
−,O
and,O
uc,O
.,O
455,O
+,O
were,O
confirmed,O
to,O
be,O
significantly,O
upregulated,O
and,O
downregulated,O
",",O
respectively,O
",",O
in,O
Wnt,B-GP
-,O
dependent,O
HCC,B-DS
.,O
uc,O
.,O
158,O
−,O
is,O
an,O
intergenic,O
224,O
nt,O
long,O
UCR,O
located,O
on,O
chromosome,O
13,O
in,O
the,O
mouse,B-OG
and,O
on,O
chromosome,O
5,O
in,O
the,O
human,B-OG
genome,O
.,O
uc,O
.,O
455,O
+,O
is,O
a,O
245,O
nt,O
long,O
UCR,O
located,O
on,O
chromosome,O
2,O
in,O
the,O
mouse,B-OG
and,O
on,O
chromosome,O
20,O
in,O
the,O
human,B-OG
genome,O
",",O
where,O
it,O
overlaps,O
in,O
antisense,O
the,O
RNA,B-GP
-,I-GP
binding,I-GP
protein,I-GP
motif,I-GP
39,I-GP
(,O
RBPM39,B-GP
),O
gene,O
.,O
Given,O
the,O
fact,O
that,O
uc,O
.,O
158,O
−,O
does,O
not,O
overlap,O
protein,O
-,O
coding,O
genes,O
",",O
and,O
that,O
intergenic,O
lncRNAs,O
have,O
been,O
shown,O
to,O
be,O
more,O
stable,O
",",O
31,O
we,O
focused,O
on,O
uc,O
.,O
158,O
−,O
for,O
further,O
studies,O
.,O
Transcribed,O
-,O
ultraconserved,O
regions,O
(,O
T,O
-,O
UCR,O
),O
profiling,O
in,O
an,O
Apc,B-GP
hypomorphic,O
hepatocarcinoma,B-DS
(,O
HCC,B-DS
),O
mouse,B-OG
model,O
.,O
(,O
A,O
),O
T,O
-,O
UCRs,O
aberrantly,O
expressed,O
in,O
Apcfl,O
/,O
fl,O
(,O
n,O
:,O
3,O
),O
versus,O
control,O
Apc,B-GP
+/+,O
(,O
n,O
:,O
3,O
),O
mice,B-OG
livers,O
.,O
Fold,O
change,O
has,O
been,O
plotted,O
against,O
p,O
values,O
",",O
with,O
lowest,O
p,O
values,O
being,O
on,O
the,O
top,O
of,O
the,O
y,O
-,O
axis,O
.,O
T,O
-,O
UCRs,O
highlighted,O
in,O
red,O
are,O
those,O
that,O
were,O
common,O
across,O
the,O
two,O
profiling,O
comparing,O
Apcfl,O
/,O
fl,O
versus,O
Apc,B-GP
+/+,O
and,O
comparing,O
Apcfl,O
/,O
fl,O
versus,O
diethylnitrosamine,O
(,O
DEN,O
)-,O
induced,O
HCC,B-DS
(,O
n,O
:,O
3,O
).,O
(,O
B,O
),O
Validation,O
of,O
T,O
-,O
UCR,O
expression,O
by,O
real,O
-,O
time,O
PCR,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
four,O
samples,O
.,O
Uc,O
.,O
158,O
−,O
expression,O
is,O
downstream,O
of,O
Wnt,B-GP
signalling,O
in,O
human,B-OG
liver,B-DS
cancer,I-DS
cells,O
To,O
understand,O
the,O
human,B-OG
relevance,O
of,O
previous,O
findings,O
",",O
we,O
assessed,O
the,O
expression,O
of,O
uc,O
.,O
158,O
−,O
in,O
human,B-OG
malignant,O
hepatocytes,O
.,O
HepG2,O
cells,O
are,O
known,O
to,O
harbour,O
mutations,O
in,O
exon,O
3,O
of,O
the,O
β,B-GP
-,I-GP
catenin,I-GP
gene,O
(,O
CTNNB1,B-GP
"),",O
while,O
Huh,O
-,O
7,O
cells,O
are,O
known,O
to,O
be,O
wild,O
type,O
(,O
WT,O
),O
for,O
CTNNB1,B-GP
and,O
other,O
genes,O
of,O
the,O
Wnt,B-GP
pathway,O
.,O
6,O
The,O
Wnt,B-GP
pathway,O
is,O
activated,O
in,O
HepG2,O
cell,O
lines,O
",",O
but,O
not,O
in,O
Huh,O
-,O
7,O
",",O
in,O
line,O
with,O
the,O
mutational,O
status,O
of,O
these,O
cells,O
(,O
see,O
online,O
supplementary,O
table,O
S4,O
and,O
figure,O
S2A,O
",",O
B,O
).,O
Global,O
lncRNA,O
expression,O
analysis,O
revealed,O
that,O
uc,O
.,O
158,O
−,O
is,O
increased,O
in,O
malignant,O
hepatocytes,O
in,O
comparison,O
with,O
normal,O
human,B-OG
hepatocytes,O
and,O
that,O
overexpression,O
is,O
greater,O
in,O
HepG2,O
than,O
in,O
Huh,O
-,O
7,O
(,O
see,O
online,O
supplementary,O
figure,O
S2C,O
).,O
We,O
then,O
extended,O
our,O
studies,O
to,O
a,O
panel,O
of,O
malignant,O
hepatocytes,O
.,O
Immunofluorescence,O
showed,O
that,O
β,B-GP
-,I-GP
catenin,I-GP
localises,O
in,O
the,O
nuclei,O
of,O
HepG2,O
cells,O
and,O
Hep,O
-,O
3B,O
",",O
although,O
to,O
a,O
lesser,O
extent,O
(,O
figure,O
2A,O
"),",O
as,O
previously,O
described,O
.,O
32,O
Interestingly,O
",",O
the,O
expression,O
of,O
uc,O
.,O
158,O
−,O
reflects,O
this,O
finding,O
",",O
with,O
the,O
highest,O
expression,O
being,O
in,O
HepG2,O
(,O
figure,O
2B,O
).,O
PLC,O
/,O
PRF,O
-,O
5,O
cells,O
had,O
a,O
very,O
low,O
expression,O
of,O
uc,O
.,O
158,O
−,O
and,O
did,O
not,O
show,O
localisation,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
despite,O
their,O
mutation,O
in,O
AXIN1,B-GP
33,O
(,O
figure,O
2A,O
",",O
B,O
).,O
To,O
further,O
study,O
this,O
finding,O
",",O
we,O
analysed,O
the,O
expression,O
of,O
uc,O
.,O
158,O
−,O
in,O
the,O
liver,O
of,O
mice,B-OG
genetically,O
engineered,O
to,O
harbour,O
deletion,O
of,O
Axin1,B-GP
.,O
These,O
animals,B-OG
(,O
Axin1fl,O
/,O
fl,O
/,O
Cre,B-GP
),O
were,O
shown,O
to,O
develop,O
microscopic,O
foci,O
of,O
HCC,B-DS
in,O
the,O
absence,O
of,O
nuclear,O
localisation,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
.,O
28,O
In,O
line,O
with,O
previous,O
findings,O
",",O
we,O
did,O
not,O
detect,O
any,O
change,O
in,O
the,O
expression,O
of,O
uc,O
.,O
158,O
−,O
in,O
the,O
liver,O
of,O
Axin1fl,O
/,O
fl,O
/,O
Cre,B-GP
in,O
comparison,O
with,O
WT,O
mice,B-OG
(,O
figure,O
2C,O
).,O
uc,O
.,O
158,O
−,O
expression,O
is,O
dependent,O
on,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
in,O
human,B-OG
malignant,O
hepatocytes,O
.,O
(,O
A,O
),O
Immunofluorescence,O
was,O
performed,O
for,O
β,B-GP
-,I-GP
catenin,I-GP
(,O
CTNNB1,B-GP
),O
and,O
Hoechst,O
in,O
a,O
panel,O
of,O
malignant,O
hepatocytes,O
.,O
Scale,O
bar,O
:,O
50,O
μm,O
(,O
B,O
),O
Expression,O
of,O
uc,O
.,O
158,O
−,O
was,O
assessed,O
in,O
the,O
same,O
panel,O
of,O
malignant,O
hepatocytes,O
by,O
real,O
-,O
time,O
PCR,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
three,O
independent,O
samples,O
.,O
(,O
C,O
),O
uc,O
.,O
158,O
−,O
expression,O
was,O
assessed,O
by,O
real,O
-,O
time,O
PCR,O
in,O
the,O
liver,O
of,O
wild,O
-,O
type,O
(,O
WT,O
),O
and,O
Axin1fl,O
/,O
fl,O
/,O
Cre,B-GP
mice,B-OG
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
six,O
samples,O
.,O
p,O
>,O
0,O
.,O
05,O
.,O
(,O
D,O
),O
Huh,O
-,O
7,O
cells,O
were,O
treated,O
with,O
25,O
mM,O
LiCl,O
or,O
diluent,O
control,O
for,O
24,O
hours,O
and,O
cells,O
collected,O
to,O
assess,O
induction,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
protein,O
expression,O
by,O
western,O
blotting,O
",",O
induction,O
of,O
nuclear,O
localisation,O
by,O
immunofluorescence,O
and,O
expression,O
of,O
uc,O
.,O
158,O
−,O
by,O
real,O
-,O
time,O
PCR,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
three,O
experiments,O
.,O
(,O
E,O
),O
HepG2,O
cells,O
were,O
transfected,O
with,O
siRNA,O
against,O
CTNNB1,B-GP
(,O
siCTNNB1,O
),O
or,O
siRNA,O
CTRL,O
(,O
50,O
nM,O
),O
for,O
48,O
hours,O
",",O
and,O
cells,O
collected,O
to,O
assess,O
reduction,O
in,O
expression,O
of,O
CTNNB1,B-GP
mRNA,O
",",O
protein,O
expression,O
and,O
expression,O
of,O
uc,O
.,O
158,O
−,O
by,O
real,O
-,O
time,O
PCR,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
three,O
experiments,O
.,O
(,O
F,O
),O
HepG2,O
cells,O
were,O
treated,O
with,O
50,O
μM,O
ICG,O
-,O
001,O
for,O
24,O
hours,O
",",O
and,O
cells,O
collected,O
to,O
assess,O
downregulation,O
of,O
drug,O
-,O
target,O
mRNAs,O
and,O
expression,O
of,O
uc,O
.,O
158,O
−,O
by,O
real,O
-,O
time,O
PCR,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
three,O
experiments,O
.,O
To,O
further,O
validate,O
the,O
dependency,O
of,O
uc,O
.,O
158,O
−,O
on,O
the,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
",",O
we,O
assessed,O
its,O
expression,O
after,O
modulation,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
in,O
vitro,O
.,O
Treatment,O
of,O
Huh,O
-,O
7,O
cells,O
with,O
LiCl,O
induced,O
activation,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
and,O
an,O
increase,O
in,O
the,O
expression,O
of,O
uc,O
.,O
158,O
−,O
(,O
figure,O
2D,O
).,O
Inhibition,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
by,O
siRNA,O
or,O
by,O
the,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
inhibitor,O
ICG,O
-,O
001,O
induced,O
a,O
decrease,O
in,O
the,O
expression,O
of,O
uc,O
.,O
158,O
−,O
in,O
HepG2,O
cells,O
(,O
figure,O
2E,O
",",O
F,O
).,O
Uc,O
.,O
158,O
−,O
expression,O
in,O
human,B-OG
HCC,B-DS
tissues,O
We,O
have,O
previously,O
shown,O
that,O
T,O
-,O
UCRs,O
are,O
transcribed,O
as,O
independent,O
transcripts,O
which,O
are,O
longer,O
than,O
the,O
UCRs,O
described,O
by,O
Bejerano,O
.,O
25,O
To,O
characterise,O
the,O
5,O
′-,O
end,O
of,O
the,O
transcript,O
including,O
uc,O
.,O
158,O
"−,",O
we,O
performed,O
a,O
rapid,O
amplification,O
of,O
cDNA,O
ends,O
(,O
RACE,O
).,O
We,O
have,O
shown,O
that,O
uc,O
.,O
158,O
−,O
is,O
transcribed,O
in,O
antisense,O
and,O
that,O
the,O
5,O
-,O
end,O
is,O
characterised,O
by,O
additional,O
306,O
nucleotides,O
upstream,O
of,O
the,O
known,O
uc,O
.,O
158,O
−,O
(,O
see,O
online,O
supplementary,O
figure,O
S3,O
).,O
To,O
confirm,O
the,O
transcript,O
is,O
transcribed,O
in,O
antisense,O
",",O
we,O
performed,O
in,O
situ,O
hybridisation,O
in,O
FFPE,O
human,B-OG
liver,O
tissues,O
.,O
We,O
used,O
three,O
different,O
probes,O
:,O
S1,O
which,O
recognised,O
the,O
sense,O
uc,O
.,O
158,O
+,O
and,O
AS1,O
and,O
AS3,O
which,O
both,O
could,O
detect,O
the,O
antisense,O
uc,O
.,O
158,O
−.,O
In,O
line,O
with,O
our,O
RACE,O
experiments,O
",",O
S1,O
did,O
not,O
show,O
any,O
signal,O
",",O
confirming,O
that,O
uc,O
.,O
158,O
−,O
is,O
transcribed,O
in,O
antisense,O
(,O
see,O
online,O
supplementary,O
figure,O
S3,O
).,O
We,O
next,O
analysed,O
a,O
series,O
of,O
human,B-OG
FFPE,O
liver,O
tissues,O
.,O
Cirrhotic,O
tissues,O
were,O
negative,O
for,O
uc,O
.,O
158,O
−,O
expression,O
",",O
while,O
HCC,B-DS
tissues,O
were,O
positive,O
.,O
However,O
",",O
it,O
is,O
of,O
note,O
that,O
HCC,B-DS
with,O
negative,O
or,O
membranous,O
expression,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
by,O
immunohistochemistry,O
(,O
IHC,O
),O
had,O
a,O
weak,O
/,O
moderate,O
cytoplasmic,O
expression,O
",",O
while,O
liver,B-DS
tumours,I-DS
with,O
nuclear,O
β,B-GP
-,I-GP
catenin,I-GP
showed,O
the,O
most,O
intense,O
signal,O
(,O
figure,O
3A,O
",",O
see,O
online,O
supplementary,O
table,O
S5,O
).,O
Next,O
",",O
we,O
studied,O
a,O
second,O
cohort,O
of,O
human,B-OG
frozen,O
HCCs,B-DS
where,O
CTNNB1,B-GP
",",O
APC,B-GP
and,O
AXIN1,B-GP
genes,O
were,O
analysed,O
by,O
sequencing,O
(,O
as,O
previously,O
described34,O
).,O
The,O
median,O
expression,O
of,O
uc,O
.,O
158,O
−,O
was,O
significantly,O
higher,O
in,O
the,O
mutated,O
group,O
(,O
which,O
included,O
six,O
CTNNB1,B-GP
-,O
mutated,O
and,O
one,O
APC,B-GP
-,O
mutated,O
HCC,B-DS
),O
than,O
in,O
WT,O
controls,O
(,O
figure,O
3B,O
).,O
However,O
",",O
isolated,O
WT,O
HCCs,B-DS
showed,O
an,O
increased,O
expression,O
of,O
uc,O
.,O
158,O
"−,",O
suggesting,O
that,O
in,O
rare,O
cases,O
the,O
source,O
of,O
uc,O
.,O
158,O
−,O
may,O
be,O
alternative,O
to,O
the,O
mutations,O
studied,O
.,O
Indeed,O
",",O
hepatitis,B-DS
liver,O
tissues,O
showed,O
negative,O
non,O
-,O
neoplastic,O
hepatocytes,O
and,O
positive,O
lymphocytes,O
(,O
see,O
online,O
supplementary,O
figure,O
S4A,O
"),",O
suggesting,O
that,O
the,O
stroma,O
may,O
represent,O
a,O
source,O
of,O
uc,O
.,O
158,O
−.,O
To,O
understand,O
if,O
uc,O
.,O
158,O
−,O
is,O
specific,O
to,O
malignant,O
cells,O
or,O
can,O
be,O
expressed,O
also,O
in,O
non,O
-,O
tumour,B-DS
hepatocytes,O
",",O
we,O
looked,O
at,O
uc,O
.,O
158,O
−,O
expression,O
in,O
the,O
liver,O
of,O
a,O
mouse,B-OG
model,O
with,O
conditional,O
Apc,B-GP
deletion,O
(,O
AhCre,O
+,O
Apcfl,O
/,O
fl,O
"),",O
which,O
presents,O
an,O
increase,O
in,O
liver,O
weight,O
and,O
proliferation,O
",",O
but,O
not,O
tumours,B-DS
.,O
Indeed,O
",",O
we,O
noticed,O
that,O
uc,O
.,O
158,O
−,O
expression,O
was,O
not,O
changed,O
following,O
activation,O
of,O
the,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
pathway,O
in,O
absence,O
of,O
cancer,B-DS
(,O
figure,O
4,O
).,O
uc,O
.,O
158,O
−,O
expression,O
in,O
human,B-OG
hepatocarcinoma,B-DS
(,O
HCC,B-DS
),O
tissues,O
.,O
(,O
A,O
),O
Formalin,O
-,O
fixed,O
paraffin,O
-,O
embedded,O
human,B-OG
liver,O
tissues,O
have,O
been,O
analysed,O
for,O
the,O
expression,O
of,O
uc,O
.,O
158,O
−,O
by,O
RNA,O
in,O
situ,O
hybridisation,O
and,O
for,O
CTNNB1,B-GP
protein,O
expression,O
by,O
immunohistochemistry,O
.,O
Scale,O
bars,O
:,O
200,O
μM,O
for,O
the,O
top,O
and,O
bottom,O
line,O
",",O
50,O
μM,O
for,O
the,O
second,O
line,O
.,O
(,O
B,O
),O
DNA,O
and,O
RNA,O
were,O
extracted,O
from,O
15,O
frozen,O
HCC,B-DS
tissues,O
and,O
used,O
for,O
uc,O
.,O
158,O
−,O
expression,O
by,O
real,O
-,O
time,O
PCR,O
and,O
sequencing,O
analysis,O
for,O
APC,B-GP
",",O
AXIN1,B-GP
and,O
exon,O
3,O
of,O
CTNNB1,B-GP
.,O
The,O
circled,O
orange,O
dot,O
represents,O
a,O
case,O
with,O
mutation,O
of,O
APC,B-GP
.,O
Bars,O
represent,O
median,O
with,O
IQR,O
.,O
Mann,O
-,O
Whitney,O
test,O
",",O
exact,O
two,O
-,O
tailed,O
p,O
value,O
:,O
0,O
.,O
04,O
.,O
Apc,B-GP
deletion,O
does,O
not,O
induce,O
uc,O
.,O
158,O
−,O
in,O
the,O
absence,O
of,O
tumour,B-DS
.,O
Conditional,O
Apc,B-GP
deletion,O
induced,O
by,O
β,O
-,O
napthoflavone,O
injection,O
in,O
AhCre,O
+,O
Apc,B-GP
+/+,O
and,O
AhCre,O
+,O
Apcfl,O
/,O
fl,O
mice,B-OG
on,O
day,O
1,O
.,O
Mice,B-OG
(,O
n,O
=,O
3,O
for,O
each,O
group,O
),O
were,O
euthanised,O
on,O
day,O
4,O
",",O
and,O
liver,O
weighed,O
and,O
processed,O
for,O
downstream,O
analyses,O
.,O
(,O
A,O
),O
IHC,O
analysis,O
for,O
CTNNB1,B-GP
and,O
BrDU,O
.,O
Scale,O
bar,O
:,O
10,O
μM,O
(,O
B,O
),O
Liver,O
weight,O
is,O
expressed,O
as,O
percentage,O
of,O
the,O
whole,O
body,O
weight,O
(,O
median,O
and,O
range,O
).,O
(,O
C,O
),O
Expression,O
of,O
uc,O
.,O
158,O
−,O
(,O
median,O
and,O
range,O
).,O
Uc,O
.,O
158,O
−,O
in,O
CCA,B-DS
Recent,O
evidence,O
has,O
shown,O
that,O
CCA,B-DS
",",O
another,O
form,O
of,O
primary,B-DS
liver,I-DS
cancer,I-DS
",",O
is,O
dependent,O
on,O
the,O
Wnt,B-GP
pathway,O
despite,O
the,O
lack,O
of,O
CTNNB1,B-GP
mutations,O
in,O
malignant,O
cholangiocytes,O
.,O
27,O
35,O
–,O
37,O
In,O
order,O
to,O
understand,O
if,O
our,O
findings,O
were,O
disease,O
-,O
specific,O
or,O
could,O
be,O
extended,O
also,O
to,O
CCA,B-DS
",",O
we,O
looked,O
at,O
uc,O
.,O
158,O
−,O
expression,O
in,O
an,O
initial,O
cohort,O
of,O
British,O
human,B-OG
intrahepatic,B-DS
CCAs,I-DS
(,O
ICC,B-DS
),O
and,O
found,O
that,O
uc,O
.,O
158,O
−,O
was,O
significantly,O
overexpressed,O
in,O
tumour,B-DS
tissues,O
compared,O
with,O
healthy,O
livers,O
(,O
figure,O
5A,O
).,O
Interestingly,O
",",O
uc,O
.,O
158,O
−,O
was,O
increased,O
in,O
CCA,B-DS
compared,O
with,O
normal,O
tissues,O
in,O
all,O
four,O
cases,O
for,O
which,O
matched,O
adjacent,O
tissues,O
were,O
available,O
(,O
figure,O
5B,O
).,O
These,O
data,O
were,O
confirmed,O
in,O
another,O
series,O
of,O
Italian,O
CCA,B-DS
by,O
in,O
situ,O
hybridisation,O
.,O
We,O
studied,O
the,O
expression,O
of,O
uc,O
.,O
158,O
−,O
using,O
a,O
TMA,O
including,O
54,O
ICC,B-DS
",",O
31,O
extrahepatic,B-DS
CCA,I-DS
(,O
ECC,B-DS
),O
and,O
17,O
gall,B-DS
bladder,I-DS
cancers,I-DS
(,O
GBC,B-DS
"),",O
along,O
with,O
additional,O
8,O
normal,O
biliary,O
ducts,O
and,O
liver,O
parenchyma,O
and,O
6,O
liver,O
tissues,O
adjacent,O
to,O
CCA,B-DS
(,O
see,O
online,O
supplementary,O
table,O
S6,O
).,O
Normal,O
biliary,O
epithelia,O
and,O
liver,O
parenchyma,O
were,O
always,O
uc,O
.,O
158,O
−,O
negative,O
.,O
High,O
uc,O
.,O
158,O
−,O
expression,O
(++/+++),O
was,O
detected,O
in,O
74,O
%,O
of,O
ICC,B-DS
",",O
58,O
%,O
of,O
ECC,B-DS
and,O
24,O
%,O
of,O
GBC,B-DS
(,O
figure,O
5C,O
",",O
see,O
online,O
supplementary,O
table,O
S6,O
).,O
Adequate,O
paired,O
tumoural,O
and,O
adjacent,O
non,O
-,O
tumoural,O
tissues,O
for,O
analysis,O
were,O
available,O
from,O
six,O
cases,O
",",O
and,O
in,O
all,O
of,O
them,O
uc,O
.,O
158,O
−,O
was,O
overexpressed,O
.,O
Interestingly,O
",",O
the,O
perilesional,O
adjacent,O
liver,O
was,O
rarely,O
negative,O
",",O
and,O
most,O
of,O
them,O
showed,O
weak,O
/,O
moderate,O
positivity,O
",",O
suggesting,O
that,O
uc,O
.,O
158,O
−,O
may,O
be,O
involved,O
in,O
the,O
carcinogenic,O
process,O
(,O
see,O
online,O
supplementary,O
figure,O
S5,O
).,O
Stromal,O
cells,O
were,O
strongly,O
positive,O
(,O
see,O
online,O
supplementary,O
figure,O
S4B,O
"),",O
in,O
accordance,O
with,O
data,O
by,O
Boulter,O
et,O
al,O
27,O
showing,O
that,O
the,O
stroma,O
is,O
one,O
of,O
the,O
sources,O
of,O
Wnt,B-GP
in,O
CCA,B-DS
.,O
To,O
further,O
investigate,O
these,O
findings,O
",",O
we,O
studied,O
a,O
rat,B-OG
model,O
of,O
thiocetamide,O
(,O
TAA,O
)-,O
induced,O
CCA,B-DS
",",O
which,O
appropriately,O
models,O
ICC,B-DS
on,O
a,O
background,O
of,O
inflammation,O
and,O
activation,O
of,O
β,B-GP
-,I-GP
catenin,I-GP
",",O
as,O
previously,O
shown,O
.,O
27,O
uc,O
.,O
158,O
−,O
expression,O
was,O
increased,O
in,O
tumour,B-DS
tissues,O
compared,O
with,O
control,O
livers,O
",",O
confirming,O
that,O
uc,O
.,O
158,O
−,O
deregulation,O
is,O
conserved,O
across,O
species,O
along,O
with,O
the,O
sequence,O
(,O
figure,O
5D,O
).,O
To,O
further,O
prove,O
the,O
dependency,O
on,O
the,O
Wnt,B-GP
pathway,O
",",O
we,O
analysed,O
the,O
expression,O
of,O
uc,O
.,O
158,O
−,O
after,O
treatment,O
with,O
two,O
different,O
Wnt,B-GP
inhibitors,O
.,O
ICG,O
-,O
001,O
reduced,O
expression,O
of,O
uc,O
.,O
158,O
−,O
by,O
52,O
"%,",O
while,O
C,O
-,O
59,O
decreased,O
uc,O
.,O
158,O
−,O
expression,O
to,O
almost,O
undetectable,O
levels,O
in,O
rat,B-OG
CCA,B-DS
(,O
figure,O
5E,O
).,O
uc,O
.,O
158,O
−,O
expression,O
in,O
cholangiocarcinoma,B-DS
.,O
(,O
A,O
),O
RNA,O
was,O
extracted,O
from,O
frozen,O
intrahepatic,B-DS
cholangiocarcinoma,I-DS
(,O
CCA,B-DS
),O
(,O
n,O
:,O
5,O
),O
and,O
normal,O
liver,O
(,O
n,O
:,O
8,O
),O
tissues,O
and,O
assessed,O
for,O
uc,O
.,O
158,O
−,O
expression,O
by,O
real,O
-,O
time,O
PCR,O
.,O
Bars,O
represent,O
mean,O
±,O
SE,O
.,O
(,O
B,O
),O
In,O
four,O
cases,O
",",O
CCA,B-DS
and,O
matched,O
adjacent,O
tissues,O
from,O
the,O
same,O
patients,O
were,O
available,O
.,O
Bars,O
represent,O
uc,O
.,O
158,O
−,O
expression,O
in,O
tumour,B-DS
tissue,O
relative,O
to,O
the,O
expression,O
in,O
the,O
adjacent,O
normal,O
tissue,O
.,O
Fold,O
change,O
tumour,B-DS
/,O
normal,O
(,O
T,O
/,O
N,O
),O
is,O
reported,O
for,O
each,O
case,O
on,O
the,O
top,O
of,O
the,O
bars,O
.,O
(,O
C,O
),O
A,O
tissue,O
microarray,O
of,O
formalin,O
-,O
fixed,O
paraffin,O
-,O
embedded,O
human,B-OG
tissues,O
including,O
54,O
intrahepatic,B-DS
cholangiocarcinoma,I-DS
(,O
ICC,B-DS
"),",O
31,O
extrahepatic,B-DS
cholangiocarcinoma,I-DS
(,O
ECC,B-DS
"),",O
17,O
gallbladder,B-DS
cancers,I-DS
(,O
GBC,B-DS
),O
and,O
8,O
normal,O
liver,O
tissues,O
was,O
assessed,O
for,O
expression,O
of,O
uc,O
.,O
158,O
−,O
by,O
RNA,O
in,O
situ,O
hybridisation,O
(,O
ISH,O
),O
with,O
AS3,O
probe,O
.,O
Pictures,O
of,O
representative,O
cases,O
are,O
shown,O
.,O
(,O
D,O
),O
RNA,O
was,O
extracted,O
from,O
the,O
liver,O
of,O
thiocetamide,O
(,O
TAA,O
)-,O
treated,O
(,O
with,O
CCA,B-DS
),O
or,O
vehicle,O
-,O
treated,O
(,O
normal,O
),O
rats,B-OG
for,O
26,O
weeks,O
and,O
analysed,O
for,O
uc,O
.,O
158,O
−,O
expression,O
by,O
real,O
-,O
time,O
PCR,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
three,O
samples,O
.,O
(,O
E,O
),O
Rats,B-OG
with,O
TAA,O
-,O
induced,O
CCA,B-DS
were,O
treated,O
with,O
the,O
CTNNB1,B-GP
-,O
CTBP,B-GP
inhibitor,O
ICG,O
-,O
001,O
(,O
5,O
mg,O
/,O
kg,O
),O
or,O
PORCN,B-GP
inhibitor,O
C,O
-,O
59,O
(,O
20,O
mg,O
/,O
kg,O
),O
or,O
saline,O
vehicle,O
by,O
intraperitoneal,O
injection,O
three,O
times,O
per,O
week,O
",",O
from,O
week,O
21,O
to,O
26,O
.,O
At,O
26,O
weeks,O
",",O
rats,B-OG
were,O
sacrificed,O
",",O
and,O
uc,O
.,O
158,O
−,O
expression,O
assessed,O
by,O
real,O
-,O
time,O
PCR,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
four,O
samples,O
.,O
Biological,O
relevance,O
of,O
uc,O
.,O
158,O
−,O
To,O
gain,O
insights,O
into,O
the,O
biological,O
relevance,O
of,O
uc,O
.,O
158,O
"−,",O
we,O
studied,O
phenotypical,O
changes,O
induced,O
by,O
inhibition,O
of,O
uc,O
.,O
158,O
−,O
in,O
HepG2,O
cells,O
.,O
We,O
tested,O
four,O
different,O
locked,O
nucleic,O
acid,O
probes,O
(,O
GAPMER,O
",",O
GAP1,O
-,O
4,O
),O
specifically,O
designed,O
to,O
interact,O
with,O
the,O
conserved,O
sequence,O
of,O
uc,O
.,O
158,O
−.,O
GAP1,O
and,O
GAP3,O
provided,O
the,O
best,O
inhibition,O
(,O
see,O
online,O
supplementary,O
figure,O
S6,O
),O
and,O
therefore,O
were,O
selected,O
for,O
further,O
experiments,O
.,O
Cell,O
growth,O
was,O
reduced,O
by,O
60,O
%,O
and,O
70,O
%,O
at,O
72,O
hours,O
in,O
HepG2,O
cells,O
transfected,O
with,O
GAP1,O
and,O
GAP3,O
",",O
respectively,O
",",O
compared,O
with,O
the,O
control,O
(,O
CTRL,O
),O
probe,O
(,O
figure,O
6A,O
).,O
To,O
better,O
understand,O
the,O
mechanism,O
through,O
which,O
cell,O
viability,O
is,O
affected,O
",",O
we,O
ran,O
a,O
cell,O
cycle,O
analysis,O
after,O
transfection,O
",",O
and,O
noticed,O
that,O
there,O
were,O
no,O
changes,O
in,O
the,O
progression,O
through,O
the,O
cell,O
cycle,O
phases,O
",",O
but,O
for,O
an,O
increased,O
accumulation,O
of,O
cells,O
in,O
the,O
sub,O
-,O
GO,O
/,O
1,O
phase,O
(,O
potentially,O
apoptotic,O
),O
in,O
cells,O
transfected,O
with,O
GAP1,O
and,O
GAP3,O
(,O
figure,O
6B,O
).,O
Indeed,O
",",O
we,O
observed,O
an,O
increase,O
in,O
the,O
activated,O
caspase,B-GP
3,I-GP
/,O
7,O
by,O
luminescence,O
(,O
figure,O
6C,O
),O
with,O
no,O
increase,O
in,O
necrosis,O
(,O
see,O
online,O
supplementary,O
figure,O
S7,O
).,O
Increase,O
in,O
the,O
expression,O
of,O
caspases,B-GP
and,O
cleaved,O
poly,B-GP
ADP,I-GP
ribose,I-GP
polymerase,I-GP
(,O
PARP,B-GP
),O
was,O
also,O
noted,O
after,O
uc,O
.,O
158,O
−,O
silencing,O
(,O
figure,O
6D,O
",",O
see,O
online,O
supplementary,O
figure,O
S8,O
).,O
uc,O
.,O
158,O
−,O
inhibition,O
reduces,O
cancer,B-DS
cell,O
growth,O
.,O
(,O
A,O
),O
HepG2,O
cells,O
were,O
reverse,O
-,O
transfected,O
with,O
GAPMER,O
probes,O
anti,O
-,O
uc,O
.,O
158,O
−,O
GAP1,O
and,O
GAP3,O
or,O
control,O
-,O
scrambled,O
probe,O
(,O
CTRL,O
),O
in,O
96,O
well,O
plates,O
",",O
and,O
cell,O
viability,O
assessed,O
by,O
CellTiter,O
-,O
Blue,O
after,O
72,O
hours,O
.,O
Non,O
-,O
transfected,O
(,O
untreated,O
),O
cells,O
were,O
added,O
as,O
control,O
for,O
transfection,O
toxicity,O
.,O
Representative,O
pictures,O
and,O
quantification,O
of,O
seven,O
replicates,O
with,O
mean,O
±,O
SD,O
are,O
represented,O
.,O
Scale,O
bar,O
:,O
400,O
μM,O
.,O
(,O
B,O
),O
HepG2,O
cells,O
were,O
transfected,O
",",O
and,O
analysis,O
of,O
cell,O
-,O
cycle,O
distribution,O
was,O
performed,O
by,O
flow,O
cytometry,O
.,O
Quantification,O
of,O
three,O
experiments,O
(,O
mean,O
±,O
SD,O
),O
is,O
shown,O
on,O
the,O
left,O
.,O
The,O
representative,O
picture,O
on,O
the,O
right,O
shows,O
peaks,O
for,O
cells,O
transfected,O
with,O
CTRL,O
",",O
GAP1,O
and,O
GAP3,O
probes,O
.,O
In,O
the,O
red,O
square,O
",",O
representative,O
zoom,O
of,O
the,O
sub,O
-,O
G0,O
/,O
G1,O
peak,O
.,O
(,O
C,O
),O
HepG2,O
cells,O
were,O
reverse,O
-,O
transfected,O
in,O
96,O
well,O
plates,O
",",O
and,O
activation,O
of,O
caspase,B-GP
3,I-GP
/,O
7,O
was,O
assessed,O
by,O
luminescence,O
assay,O
.,O
Staurosporine,O
was,O
added,O
as,O
positive,O
control,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
three,O
replicates,O
.,O
Asterisks,O
indicate,O
p,O
value,O
by,O
t,O
-,O
test,O
analysis,O
.,O
Analysis,O
of,O
variance,O
comparison,O
was,O
performed,O
comparing,O
all,O
the,O
groups,O
",",O
or,O
only,O
the,O
three,O
experimental,O
groups,O
(,O
CTRL,O
",",O
GAP1,O
",",O
GAP3,O
"),",O
with,O
the,O
following,O
results,O
:,O
p,O
:,O
0,O
.,O
0004,O
and,O
p,O
:,O
0,O
.,O
0012,O
",",O
respectively,O
",",O
at,O
6,O
hours,O
;,O
p,O
<,O
0,O
.,O
0001,O
for,O
both,O
comparisons,O
at,O
24,O
hours,O
.,O
(,O
D,O
),O
HepG2,O
cells,O
were,O
transfected,O
with,O
GAPMER,O
probe,O
anti,O
-,O
uc,O
.,O
158,O
−,O
GAP1,O
or,O
CTRL,O
-,O
scrambled,O
probe,O
and,O
then,O
fixed,O
in,O
formalin,O
and,O
embedded,O
in,O
paraffin,O
.,O
Immunohistochemistry,O
was,O
then,O
performed,O
for,O
caspase,B-GP
3,I-GP
.,O
Representative,O
pictures,O
of,O
two,O
independent,O
experiments,O
are,O
shown,O
.,O
(,O
E,O
),O
HepG2,O
cells,O
were,O
reverse,O
-,O
transfected,O
with,O
anti,O
-,O
uc,O
.,O
158,O
−,O
GAP1,O
and,O
GAP3,O
or,O
control,O
probe,O
in,O
100,O
mm,O
dishes,O
and,O
then,O
plated,O
in,O
ultra,O
low,O
attachment,O
(,O
ULA,O
),O
96,O
-,O
well,O
plates,O
to,O
form,O
spheroids,O
.,O
Imaging,O
and,O
quantitation,O
were,O
performed,O
after,O
7,O
days,O
with,O
Celigo,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
six,O
replicates,O
.,O
(,O
F,O
),O
Once,O
the,O
spheroids,O
were,O
formed,O
",",O
they,O
were,O
moved,O
to,O
flat,O
-,O
bottom,O
",",O
gelatin,O
-,O
coated,O
96,O
-,O
well,O
plates,O
",",O
and,O
migration,O
was,O
assessed,O
at,O
different,O
time,O
points,O
through,O
Celigo,O
.,O
Anchorage,O
-,O
independent,O
growth,O
was,O
assessed,O
by,O
tumour,B-DS
3D,O
spheroid,O
assay,O
.,O
The,O
volume,O
of,O
3D,O
spheroid,O
generated,O
from,O
HepG2,O
cells,O
transfected,O
with,O
GAP,O
1,O
and,O
GAP3,O
was,O
reduced,O
to,O
34,O
%,O
and,O
40,O
"%,",O
respectively,O
",",O
in,O
comparison,O
with,O
spheroids,O
generated,O
from,O
cells,O
transfected,O
with,O
GAP,O
CTRL,O
(,O
figure,O
6E,O
).,O
In,O
addition,O
",",O
uc,O
.,O
158,O
−,O
silencing,O
reduced,O
tumour,B-DS
spheroid,O
-,O
based,O
migration,O
in,O
HepG2,O
cells,O
(,O
figure,O
6F,O
).,O
These,O
data,O
were,O
also,O
confirmed,O
in,O
CCA,B-DS
SW1,O
cells,O
whose,O
cell,O
viability,O
was,O
dependent,O
on,O
the,O
Wnt,B-GP
pathway,O
(,O
see,O
online,O
supplementary,O
figure,O
S9,O
).,O
Uc,O
.,O
158,O
−,O
acts,O
as,O
a,O
competing,O
endogenous,O
RNA,O
Recent,O
evidence,O
suggests,O
that,O
T,O
-,O
UCRs,O
may,O
act,O
as,O
endogenous,O
competing,O
RNAs,O
(,O
ceRNA,O
).,O
38,O
Thus,O
",",O
we,O
searched,O
for,O
potential,O
binding,O
sites,O
for,O
miRNAs,O
in,O
the,O
uc,O
.,O
158,O
−,O
conserved,O
sequence,O
.,O
We,O
shortlisted,O
those,O
miRNAs,O
which,O
are,O
conserved,O
across,O
mouse,B-OG
and,O
human,B-OG
and,O
show,O
a,O
binding,O
site,O
with,O
a,O
predicted,O
ddG,O
score,O
<−,O
10,O
(,O
see,O
online,O
supplementary,O
figure,O
S10,O
and,O
table,O
S7,O
).,O
We,O
profiled,O
by,O
NanoString,O
analysis,O
the,O
global,O
expression,O
of,O
miRNAs,O
in,O
the,O
mouse,B-OG
Apcfl,O
/,O
fl,O
HCC,B-DS
model,O
.,O
In,O
the,O
hypothesis,O
that,O
uc,O
.,O
158,O
−,O
acts,O
as,O
ceRNA,O
",",O
we,O
searched,O
for,O
miRNAs,O
that,O
were,O
downregulated,O
in,O
Apcfl,O
/,O
fl,O
versus,O
Apc,B-GP
+/+,O
liver,O
tissues,O
(,O
see,O
online,O
supplementary,O
table,O
S7,O
).,O
Among,O
these,O
nine,O
miRNAs,O
",",O
miR,O
-,O
615,O
",",O
miR,O
-,O
193b,O
and,O
miR,O
-,O
346,O
were,O
upregulated,O
after,O
inhibition,O
of,O
uc,O
.,O
158,O
−,O
in,O
HepG2,O
cells,O
",",O
with,O
miR,O
-,O
193b,O
showing,O
the,O
most,O
significant,O
increase,O
and,O
having,O
higher,O
values,O
of,O
expression,O
(,O
figure,O
7A,O
).,O
Indeed,O
",",O
miR,O
-,O
193b,O
was,O
shown,O
to,O
be,O
downregulated,O
in,O
human,B-OG
HCC,B-DS
.,O
39,O
40,O
We,O
observed,O
downregulation,O
of,O
miR,O
-,O
193b,O
also,O
in,O
human,B-OG
CCA,B-DS
tissues,O
in,O
comparison,O
with,O
matched,O
adjacent,O
non,O
-,O
neoplastic,O
tissues,O
(,O
see,O
online,O
supplementary,O
figure,O
S11,O
).,O
miR,O
-,O
193b,O
was,O
found,O
to,O
be,O
overexpressed,O
in,O
Huh,O
-,O
7,O
versus,O
HepG2,O
cells,O
(,O
in,O
line,O
with,O
uc,O
.,O
158,O
−,O
expression,O
),O
(,O
figure,O
7B,O
).,O
Enforced,O
expression,O
of,O
uc,O
.,O
158,O
−,O
in,O
Huh,O
-,O
7,O
cells,O
induced,O
downregulation,O
of,O
miR,O
-,O
193b,O
(,O
figure,O
7C,O
).,O
Co,O
-,O
transfection,O
of,O
GAP1,O
and,O
anti,O
-,O
miR,O
-,O
193b,O
could,O
rescue,O
the,O
biological,O
effect,O
of,O
uc,O
.,O
158,O
−,O
inhibition,O
on,O
cell,O
viability,O
(,O
figure,O
7D,O
).,O
We,O
then,O
looked,O
at,O
the,O
level,O
of,O
miR,O
-,O
193b,O
in,O
the,O
sera,O
of,O
patients,O
with,O
HCC,B-DS
(,O
n,O
:,O
10,O
),O
who,O
were,O
naive,O
for,O
any,O
treatment,O
.,O
Patients,O
with,O
low,O
circulating,O
miR,O
-,O
193b,O
had,O
mainly,O
alpha,B-GP
-,I-GP
fetoprotein,I-GP
(,O
AFP,B-GP
),O
negative,O
tumours,B-DS
",",O
in,O
line,O
with,O
previous,O
reports,O
of,O
observed,O
lower,O
levels,O
of,O
AFP,B-GP
in,O
CTNNB1,B-GP
-,O
mutated,O
HCC41,O
(,O
figure,O
7E,O
).,O
miR,O
-,O
193b,O
expression,O
is,O
dependent,O
on,O
uc,O
.,O
158,O
−,O
expression,O
.,O
HepG2,O
cells,O
were,O
transfected,O
in,O
100,O
mm,O
dishes,O
for,O
48,O
hours,O
",",O
and,O
RNA,O
extracted,O
to,O
assess,O
microRNA,O
expression,O
by,O
TaqMan,O
assays,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
three,O
experiments,O
.,O
(,O
B,O
),O
miR,O
-,O
193b,O
expression,O
was,O
assessed,O
in,O
Huh,O
-,O
7,O
and,O
HepG2,O
cells,O
.,O
Bars,O
represent,O
logarithmic,O
expression,O
of,O
miR,O
-,O
193b,O
in,O
Huh,O
-,O
7,O
versus,O
HepG2,O
.,O
In,O
three,O
independent,O
experiments,O
",",O
miR,O
-,O
193b,O
expression,O
was,O
higher,O
in,O
Huh,O
-,O
7,O
in,O
comparison,O
with,O
HepG2,O
.,O
(,O
C,O
),O
Huh,O
-,O
7,O
cells,O
were,O
transfected,O
with,O
a,O
vector,O
overexpressing,O
uc,O
.,O
158,O
−,O
or,O
an,O
empty,O
vector,O
for,O
48,O
hours,O
.,O
Expression,O
of,O
uc,O
.,O
158,O
−,O
and,O
miR,O
-,O
193b,O
was,O
assessed,O
by,O
real,O
-,O
time,O
PCR,O
.,O
Bars,O
represent,O
the,O
logarithmic,O
expression,O
of,O
ncRNAs,O
in,O
cells,O
transfected,O
with,O
uc,O
-,O
158,O
−,O
vector,O
compared,O
with,O
empty,O
vector,O
.,O
The,O
downregulation,O
of,O
mR,O
-,O
193,O
is,O
quantitatively,O
comparable,O
with,O
the,O
upregulation,O
achieved,O
in,O
panel,O
A,O
.,O
(,O
D,O
),O
HepG2,O
cells,O
were,O
transfected,O
with,O
GAPMER,O
control,O
or,O
GAP1,O
alone,O
or,O
in,O
association,O
with,O
anti,O
-,O
miR,O
-,O
193b,O
",",O
and,O
cell,O
viability,O
assessed,O
by,O
CellTiter,O
-,O
Blue,O
at,O
48,O
hours,O
.,O
Bars,O
represent,O
mean,O
±,O
SD,O
of,O
six,O
replicates,O
.,O
(,O
E,O
),O
Sera,O
were,O
collected,O
from,O
patients,O
with,O
hepatocarcinoma,B-DS
(,O
HCC,B-DS
),O
naïve,O
for,O
any,O
treatment,O
(,O
n,O
:,O
10,O
"),",O
and,O
microRNA,O
extracted,O
using,O
fixed,O
starting,O
volume,O
.,O
miR,O
-,O
193b,O
was,O
assessed,O
by,O
TaqMan,O
assay,O
.,O
χ2,O
test,O
was,O
used,O
to,O
assess,O
the,O
correlation,O
between,O
miR,O
-,O
193b,O
and,O
alpha,B-GP
-,I-GP
fetoprotein,I-GP
(,O
AFP,B-GP
),O
groups,O
.,O
Discussion,O
It,O
is,O
becoming,O
clear,O
that,O
a,O
large,O
number,O
of,O
lncRNAs,O
have,O
a,O
determining,O
role,O
in,O
regulating,O
normal,O
cell,O
physiology,O
as,O
well,O
as,O
a,O
variety,O
of,O
diseases,O
including,O
cancer,B-DS
.,O
42,O
T,O
-,O
UCRs,O
are,O
long,O
ncRNAs,O
that,O
harbour,O
ultraconserved,O
elements,O
and,O
are,O
altered,O
in,O
human,B-OG
carcinomas,B-DS
.,O
Despite,O
some,O
evidence,O
suggests,O
that,O
DNA,O
methylation,O
and,O
miRNA,O
-,O
mediated,O
regulation,O
may,O
be,O
responsible,O
for,O
their,O
modulation,O
",",O
19,O
20,O
the,O
mechanisms,O
of,O
T,O
-,O
UCR,O
deregulation,O
have,O
been,O
poorly,O
explored,O
.,O
In,O
these,O
studies,O
",",O
we,O
showed,O
that,O
T,O
-,O
UCRs,O
may,O
act,O
downstream,O
of,O
key,O
signalling,O
routes,O
",",O
such,O
as,O
the,O
Wnt,B-GP
pathway,O
",",O
and,O
drive,O
cancer,B-DS
cell,O
growth,O
.,O
Wnt,B-GP
/,O
β,B-GP
-,I-GP
catenin,I-GP
signalling,O
is,O
a,O
key,O
driver,O
in,O
about,O
half,O
of,O
liver,B-DS
cancers,I-DS
",",O
and,O
growing,O
evidence,O
is,O
suggesting,O
that,O
ncRNAs,O
are,O
mediators,O
of,O
this,O
pathway,O
.,O
17,O
43,O
We,O
provide,O
the,O
first,O
evidence,O
that,O
T,O
-,O
UCRs,O
can,O
be,O
dependent,O
on,O
Wnt,B-GP
activation,O
in,O
a,O
species,O
-,O
conserved,O
fashion,O
.,O
In,O
addition,O
",",O
our,O
studies,O
showed,O
that,O
uc,O
.,O
158,O
−,O
is,O
activated,O
only,O
in,O
cancer,B-DS
cells,O
",",O
suggesting,O
it,O
may,O
be,O
specific,O
for,O
Wnt,B-GP
activation,O
that,O
should,O
be,O
targeted,O
for,O
an,O
antitumoural,O
effect,O
.,O
Indeed,O
",",O
Wnt,B-GP
inhibitor,O
exploitation,O
has,O
been,O
limited,O
by,O
toxicity,O
",",O
and,O
activation,O
of,O
the,O
Wnt,B-GP
pathway,O
in,O
cirrhotic,O
liver,O
may,O
preclude,O
the,O
use,O
of,O
these,O
drugs,O
in,O
patients,O
with,O
liver,B-DS
cancer,I-DS
.,O
Conversely,O
",",O
the,O
identification,O
of,O
a,O
cancer,B-DS
-,O
specific,O
mediator,O
of,O
the,O
pathway,O
may,O
improve,O
the,O
potential,O
of,O
designing,O
novel,O
and,O
more,O
selective,O
drugs,O
.,O
Interestingly,O
",",O
we,O
have,O
shown,O
that,O
molecular,O
traits,O
",",O
such,O
as,O
overexpression,O
of,O
uc,O
.,O
158,O
"−,",O
may,O
be,O
present,O
across,O
tumour,B-DS
types,O
independently,O
on,O
site,O
of,O
origin,O
.,O
These,O
findings,O
inform,O
us,O
that,O
T,O
-,O
UCRs,O
may,O
either,O
be,O
used,O
as,O
tissue,O
-,O
specific,O
biomarkers,O
",",O
as,O
in,O
the,O
case,O
of,O
TUC338,O
",",O
25,O
or,O
may,O
be,O
commonly,O
deregulated,O
across,O
tumour,B-DS
types,O
",",O
such,O
as,O
uc,O
.,O
158,O
−.,O
Inclusion,O
criteria,O
with,O
regard,O
to,O
tumour,B-DS
origin,O
(,O
ICC,B-DS
vs,O
ECC,B-DS
),O
are,O
still,O
a,O
debateable,O
question,O
in,O
the,O
design,O
of,O
clinical,O
trials,O
in,O
CCA,B-DS
.,O
However,O
",",O
based,O
on,O
these,O
studies,O
",",O
we,O
may,O
suggest,O
that,O
clinical,O
trials,O
should,O
be,O
designed,O
on,O
the,O
bases,O
of,O
molecular,O
and,O
genomic,O
features,O
instead,O
of,O
tumour,B-DS
site,O
",",O
and,O
may,O
even,O
include,O
ICC,B-DS
and,O
HCC,B-DS
for,O
selective,O
drugs,O
that,O
target,O
commonly,O
deregulated,O
pathways,O
.,O
As,O
per,O
the,O
reason,O
why,O
uc,O
.,O
158,O
−,O
is,O
aberrantly,O
deregulated,O
in,O
malignant,O
hepatocytes,O
and,O
cholangiocytes,O
",",O
we,O
may,O
speculate,O
that,O
uc,O
.,O
158,O
−,O
overexpressing,O
hepatic,B-DS
cancer,I-DS
stem,O
cells,O
may,O
give,O
rise,O
to,O
specific,O
subtypes,O
of,O
HCC,B-DS
and,O
CCA,B-DS
in,O
the,O
presence,O
of,O
Wnt,B-GP
pathway,O
.,O
However,O
",",O
we,O
cannot,O
exclude,O
that,O
the,O
plasticity,O
of,O
mature,O
hepatocytes,O
to,O
differentiate,O
in,O
cholangiocytes,O
may,O
justify,O
some,O
common,O
traits,O
acquired,O
during,O
liver,O
carcinogenesis,O
.,O
44,O
45,O
Another,O
potential,O
explanation,O
relies,O
on,O
the,O
evidence,O
that,O
stroma,O
is,O
an,O
important,O
Wnt,B-GP
activator,O
even,O
in,O
tumours,B-DS
",",O
such,O
as,O
CCA,B-DS
",",O
that,O
lack,O
CTNNB1,B-GP
mutations,O
.,O
27,O
35,O
Thus,O
",",O
further,O
studies,O
are,O
warranted,O
to,O
explore,O
the,O
involvement,O
of,O
the,O
stroma,O
-,O
induced,O
activation,O
of,O
uc,O
.,O
158,O
−,O
driven,O
carcinogenesis,O
.,O
The,O
mechanism,O
of,O
function,O
of,O
T,O
-,O
UCRs,O
is,O
still,O
not,O
clearly,O
elucidated,O
.,O
Previous,O
evidence,O
suggests,O
that,O
they,O
may,O
act,O
as,O
decoy,O
molecules,O
for,O
miRNAs,O
.,O
38,O
We,O
provided,O
data,O
in,O
support,O
of,O
this,O
hypothesis,O
.,O
We,O
have,O
previously,O
shown,O
that,O
miR,O
-,O
193b,O
mediates,O
apoptosis,O
through,O
targeting,O
of,O
mcl,B-GP
-,I-GP
1,I-GP
",",O
12,O
and,O
the,O
overexpression,O
of,O
uc,O
.,O
158,O
−,O
in,O
HCC,B-DS
nicely,O
fits,O
with,O
these,O
data,O
as,O
well,O
as,O
with,O
the,O
previous,O
work,O
that,O
found,O
downregulation,O
of,O
miR,O
-,O
193b,O
in,O
a,O
subgroup,O
of,O
HCCs,B-DS
.,O
39,O
40,O
It,O
is,O
increasingly,O
recognised,O
that,O
cancer,B-DS
cells,O
rely,O
on,O
a,O
complex,O
network,O
of,O
transcripts,O
generated,O
from,O
coding,O
and,O
non,O
-,O
coding,O
genes,O
",",O
and,O
that,O
interplay,O
of,O
different,O
RNA,O
classes,O
drives,O
cancer,B-DS
progression,O
more,O
than,O
a,O
single,O
aberration,O
.,O
46,O
However,O
",",O
identification,O
of,O
a,O
single,O
molecule,O
representing,O
the,O
activation,O
of,O
a,O
network,O
may,O
prove,O
more,O
useful,O
for,O
the,O
identification,O
of,O
therapeutic,O
targets,O
and,O
for,O
the,O
implementation,O
of,O
screening,O
technologies,O
to,O
be,O
adopted,O
for,O
targeted,O
therapy,O
.,O
Ethics,O
approval,O
:,O
Different,O
bodies,O
as,O
specified,O
in,O
the,O
text,O
.,O
Provenance,O
and,O
peer,O
review,O
:,O
Not,O
commissioned,O
;,O
externally,O
peer,O
reviewed,O
.,O
